-DOCSTART- -24532106- O O

The DT N
effect NN N
of IN N
deep JJ i
brain NN i
stimulation NN i
randomized VBN N
by IN N
site NN N
on IN N
balance NN N
in IN N
Parkinson NNP p
's POS p
disease NN p
. . p

BACKGROUND IN N
The DT N
effect NN N
of IN N
the DT N
surgical JJ N
site NN N
of IN N
DBS NNP N
on IN N
balance NN N
and CC N
gait NN N
in IN N
Parkinson NNP p
's POS p
Disease NNP p
( ( p
PD NNP p
) ) p
is VBZ N
uncertain JJ N
. . N

This DT N
is VBZ N
the DT N
first JJ N
double-blind NN N
study NN N
of IN N
subjects NNS p
randomized VBN p
to TO p
either CC p
the DT p
STN NNP i
( ( p
N NNP p
= NNP p
14 CD p
) ) p
or CC p
GPi NNP i
( ( p
N NNP p
= NNP p
14 CD p
) ) p
who WP p
were VBD p
assessed VBN p
on IN p
a DT p
range NN p
of IN p
clinical JJ p
balance NN p
measures NNS p
. . p

METHODS NNP N
Balance NNP N
testing VBG N
occurred VBD N
before IN N
and CC N
6 CD N
months NNS N
postsurgery RB N
. . N

A DT p
control NN i
PD NNP p
group NN p
was VBD p
tested VBN p
over IN p
the DT p
same JJ p
period NN p
without IN p
surgery NN p
( ( p
N NNP p
= NNP p
9 CD p
) ) p
. . p

All DT N
subjects NNS N
were VBD N
tested VBN N
on IN i
and CC i
off IN i
medication NN i
and CC N
DBS NNP N
subjects NNS N
were VBD N
also RB N
tested VBN N
on IN i
and CC i
off IN i
DBS NNP i
. . i

The DT o
Postural NNP o
Instability NNP o
and CC o
Gait NNP o
Disability NNP o
items NNS o
of IN o
the DT o
UPDRS NNP o
and CC o
additional JJ o
functional NN o
tests NNS o
, , o
which WDT o
we PRP o
call VBP o
the DT o
Balance NNP o
and CC o
Gait NNP o
scale NN o
, , N
were VBD N
assessed VBN N
. . N

Activities NNS o
of IN o
Balance NNP o
Confidence NNP o
and CC o
Activities NNP o
of IN o
Daily NNP o
Living NNP o
questionnaires NNS o
were VBD N
also RB N
recorded VBN N
. . N

RESULTS NNP N
Balance NNP N
was VBD N
not RB N
different JJ N
between IN N
the DT N
best-treated JJ N
states NNS N
before IN N
and CC N
after IN N
DBS NNP N
surgery NN N
for IN N
both DT N
sites NNS N
. . N

Switching VBG N
DBS NNP N
on IN N
improved JJ N
balance NN o
scores NNS o
, , N
and CC N
scores VBZ N
further RBR N
improved VBN N
with IN N
medication NN N
, , N
compared VBN N
to TO N
the DT N
off RP N
state NN N
. . N

The DT N
GPi NNP N
group NN N
showed VBD N
improved JJ N
performance NN N
in IN N
the DT N
postsurgery NN N
off IN N
state NN N
and CC N
better JJR N
ratings NNS N
of IN N
balance NN o
confidence NN o
after IN N
surgery NN N
, , N
compared VBN N
to TO N
the DT N
STN NNP N
group NN N
. . N

CONCLUSIONS NNP N
Clinical NNP N
measures NNS N
of IN N
balance NN N
function NN N
for IN N
both DT N
the DT N
STN NNP N
and CC N
GPi NNP N
sites NNS N
showed VBD N
that IN N
balance NN N
did VBD N
not RB N
improve VB N
beyond IN N
the DT N
best JJS N
medically RB N
treated VBN N
state NN N
before IN N
surgery NN N
. . N

Both DT N
clinical JJ N
balance NN N
testing NN N
in IN N
the DT N
off/off NN N
state NN N
and CC N
self-reported JJ N
balance NN N
confidence NN N
after IN N
surgery NN N
showed VBD N
better JJR N
performance NN N
in IN N
the DT N
GPi NNP N
than IN N
the DT N
STN NNP N
group NN N
. . N

-DOCSTART- -16571852- O O

Web-based JJ i
weight NN i
management NN i
programs NNS i
in IN N
an DT N
integrated JJ N
health NN N
care NN N
setting NN N
: : N
a DT N
randomized NN N
, , N
controlled VBN N
trial NN N
. . N

OBJECTIVE UH N
To TO N
assess VB N
the DT N
efficacy NN o
of IN N
a DT N
Web-based JJ i
tailored JJ i
behavioral JJ i
weight JJ i
management NN i
program NN i
compared VBN N
with IN N
Web-based JJ N
information-only JJ N
weight NN N
management NN N
materials NNS N
. . N

RESEARCH NNP N
METHODS NNP N
AND NNP N
PROCEDURES NNP N
Participants NNP N
, , N
2862 CD p
eligible JJ p
overweight NN p
and CC p
obese JJ p
( ( p
BMI NNP p
= VBZ p
27 CD p
to TO p
40 CD p
kg/m2 NNS p
) ) p
members NNS p
from IN p
four CD p
regions NNS p
of IN p
Kaiser NNP p
Permanente NNP p
's POS p
integrated JJ p
health NN p
care NN p
delivery NN p
system NN p
, , N
were VBD N
randomized VBN N
to TO N
receive VB N
either CC N
a DT N
tailored VBN i
expert NN i
system NN i
or CC i
information-only JJ i
Web-based JJ i
weight NN i
management NN i
materials NNS i
. . i

Weight NNP o
change NN o
and CC o
program NN o
satisfaction NN o
were VBD N
assessed VBN N
by IN N
self-report NN N
through IN N
an DT N
Internet-based JJ N
survey NN N
at IN N
3- JJ N
and CC N
6-month JJ N
follow-up JJ N
periods NNS N
. . N

RESULTS NNP N
Significantly NNP N
greater JJR N
weight JJ o
loss NN o
at IN N
follow-up NN N
was VBD N
found VBN N
among IN N
participants NNS p
assigned VBN N
to TO N
the DT N
tailored VBN i
expert NN i
system NN i
than IN N
among IN N
those DT N
assigned VBN N
to TO N
the DT N
information-only JJ N
condition NN N
. . N

Subjects NNS p
in IN p
the DT p
tailored VBN i
expert NN i
system NN i
lost VBD N
a DT N
mean NN N
of IN N
3 CD N
+/- JJ N
0.3 CD N
% NN N
of IN N
their PRP$ N
baseline NN o
weight NN o
, , N
whereas JJ N
subjects NNS p
in IN p
the DT p
information-only JJ p
condition NN p
lost VBD N
a DT N
mean NN N
of IN N
1.2 CD N
+/- JJ N
0.4 CD N
% NN N
( ( N
p JJ N
< NNP N
0.0004 CD N
) ) N
. . N

Participants NNS p
were VBD N
also RB N
more RBR N
likely JJ N
to TO N
report VB N
that IN N
the DT N
tailored VBN i
expert NN i
system NN i
was VBD N
personally RB o
relevant JJ o
, , o
helpful JJ o
, , o
and CC o
easy JJ o
to TO o
understand VB o
. . o

Notably RB N
, , N
36 CD p
% NN p
of IN p
enrollees NNS p
were VBD p
African-American JJ p
, , p
with IN p
enrollment NN p
rates NNS p
higher RBR p
than IN p
the DT p
general JJ p
proportion NN p
of IN p
African JJ p
Americans NNPS p
in IN p
any DT p
of IN p
the DT p
study NN p
regions NNS p
. . p

DISCUSSION NNP N
The DT N
results NNS N
of IN N
this DT N
large JJ N
, , N
randomized VBD N
control NN N
trial NN N
show VBP N
the DT N
potential JJ N
benefit NN N
of IN N
the DT N
Web-based JJ i
tailored VBN i
expert NN i
system NN i
for IN i
weight JJ i
management NN i
compared VBN N
with IN N
a DT N
Web-based JJ i
information-only JJ i
weight JJ i
management NN i
program NN i
. . i

-DOCSTART- -20828635- O O

A DT N
randomized JJ N
trial NN N
of IN N
genetic JJ i
and CC i
environmental JJ i
risk NN i
assessment NN i
( ( i
GERA NNP i
) ) i
for IN N
colorectal JJ N
cancer NN N
risk NN N
in IN N
primary JJ N
care NN N
: : N
trial NN N
design NN N
and CC N
baseline NN N
findings NNS N
. . N

PURPOSE VB N
This DT N
paper NN N
describes VBZ N
an DT N
ongoing JJ N
randomized NN N
controlled VBD N
trial NN N
designed VBN N
to TO N
assess VB N
the DT N
impact NN o
of IN N
genetic JJ i
and CC i
environmental JJ i
risk NN i
assessment NN i
( ( i
GERA NNP i
) ) i
on IN N
colorectal JJ p
cancer NN p
( ( p
CRC NNP p
) ) p
screening NN N
. . N

METHODS NNP N
The DT N
trial NN N
includes VBZ N
asymptomatic JJ p
patients NNS p
who WP p
are VBP p
50-79years NNS p
and CC p
are VBP p
not RB p
up-to-date JJ p
with IN p
CRC NNP p
screening VBG p
guidelines NNS p
. . p

Patients NNS N
who WP N
responded VBD N
to TO N
a DT N
baseline NN N
telephone NN o
survey NN o
are VBP N
randomized VBN N
to TO N
a DT N
GERA NNP i
or CC i
Control NNP i
group NN i
. . i

GERA NNP i
group NN i
participants NNS i
meet VBP i
with IN i
a DT i
nurse NN i
, , i
decide VB i
whether IN i
to TO i
have VB i
a DT i
GERA NNP i
blood NN i
test NN i
( ( i
a DT i
combination NN i
of IN i
genetic JJ i
polymorphism NN i
and CC i
folate NN i
) ) i
, , i
and CC i
, , i
if IN i
tested VBN i
, , i
receive VBP i
GERA NNP i
feedback NN i
. . i

Follow-up NNP i
telephone NN o
surveys NNS o
are VBP i
conducted VBN i
at IN i
1 CD i
and CC i
6months CD i
. . i

A DT i
chart NN o
audit NN o
is VBZ i
performed VBN i
at IN i
6months CD i
. . i

RESULTS NNP N
Of IN p
2,223 CD p
eligible JJ p
patients NNS p
, , p
562 CD p
( ( p
25 CD p
% NN p
) ) p
have VBP p
enrolled VBN p
. . p

Patients NNS p
who WP p
enrolled VBD p
in IN p
the DT p
study NN p
were VBD p
significantly RB p
younger JJR p
than IN p
those DT p
who WP p
did VBD p
not RB p
( ( p
p JJ p
< NNP p
0.001 CD p
) ) p
. . p

Participants NNS p
tended VBD p
to TO p
be VB p
50-59years JJ p
( ( p
64 CD p
% NN p
) ) p
, , p
female JJ p
( ( p
58 CD p
% NN p
) ) p
, , p
white JJ p
( ( p
52 CD p
% NN p
) ) p
, , p
married VBD p
( ( p
51 CD p
% NN p
) ) p
, , p
and CC p
have VBP p
more JJR p
than IN p
a DT p
high JJ p
school NN p
education NN p
( ( p
67 CD p
% NN p
) ) p
. . p

At IN N
baseline NN N
, , N
most JJS N
participants NNS N
had VBD N
some DT N
knowledge NN o
of IN o
CRC NNP o
screening NN o
and CC o
GERA NNP i
, , N
viewed VBD N
CRC NNP N
screening VBG N
favorably RB N
, , N
and CC N
reported VBD N
that IN N
they PRP N
had VBD N
decided VBN N
to TO N
do VB N
screening VBG N
. . N

Almost NNP N
half NN N
had VBD N
worries NNS o
and CC o
concerns NNS o
about IN N
CRC NNP N
. . N

CONCLUSIONS NNP N
One CD p
in IN p
four CD p
eligible JJ p
primary JJ p
care NN p
patients NNS p
enrolled VBN p
in IN p
the DT p
study NN p
. . p

Age NNP N
was VBD N
negatively RB N
associated VBN N
with IN N
enrollment NN N
. . N

Prospective JJ N
analyses NNS N
using VBG N
data NNS N
for IN N
all DT N
participants NNS N
will MD N
provide VB N
more RBR N
definitive JJ N
information NN N
on IN N
GERA NNP i
uptake NN N
and CC N
the DT N
impact NN N
of IN N
GERA NNP i
feedback NN N
. . N

-DOCSTART- -17196973- O O

Do VBP N
readers NNS p
with IN p
autism NN p
make VBP N
bridging VBG N
inferences NNS N
from IN N
world NN N
knowledge NN N
? . N
Individuals NNS p
with IN p
autism NN p
frequently RB N
show VBP N
impairments NNS N
in IN N
text JJ N
reading NN N
comprehension NN N
. . N

This DT N
often RB N
is VBZ N
attributed VBN N
to TO N
poor JJ N
ability NN N
to TO N
draw VB N
inferences NNS N
during IN N
reading NN N
and CC N
to TO N
inadequate VB N
access NN N
to TO N
relevant VB N
knowledge NN N
. . N

The DT N
current JJ N
study NN N
tested VBD N
this DT N
hypothesis NN N
by IN N
measuring VBG N
the DT N
time NN N
taken VBN N
to TO N
read VB i
the DT i
same JJ i
question NN i
, , i
relating VBG i
to TO i
either DT i
physical JJ i
or CC i
social JJ i
world NN i
knowledge NN i
, , i
when WRB i
it PRP i
was VBD i
either CC i
relevant JJ i
or CC i
irrelevant JJ i
to TO i
the DT i
bridging NN i
inference NN i
evoked VBN i
by IN i
a DT i
preceding VBG i
two-sentence NN i
vignette NN i
. . i

In IN N
the DT N
study NN N
, , N
16 CD p
normally RB p
developing VBG p
adolescents NNS p
and CC p
16 CD p
adolescents NNS p
with IN p
autism NN p
were VBD N
matched VBN N
on IN N
word NN N
reading NN N
accuracy NN N
, , N
chronological JJ N
age NN N
, , N
and CC N
vocabulary JJ N
but CC N
differed VBD N
significantly RB N
in IN N
text JJ N
comprehension NN N
. . N

A DT N
strong JJ N
priming NN N
effect NN N
was VBD N
found VBN N
, , N
robust VBZ N
over IN N
participants NNS N
and CC N
over IN N
items NNS N
; : N
participants NNS N
read VBP N
those DT N
questions NNS N
that WDT N
were VBD N
relevant JJ N
to TO N
the DT N
inference NN N
evoked VBN N
by IN N
the DT N
vignette NN N
faster RBR N
than IN N
they PRP N
read VBP N
those DT N
questions NNS N
that WDT N
were VBD N
irrelevant JJ N
, , N
and CC N
no DT N
interaction NN N
with IN N
group NN N
membership NN N
or CC N
type NN N
of IN N
knowledge NN N
was VBD N
found VBN N
. . N

This DT N
indicates VBZ N
that IN N
readers NNS p
with IN p
autism NN p
, , N
just RB N
like IN N
controls NNS N
, , N
were VBD N
activating VBG N
appropriate JJ N
world NN N
knowledge NN N
primed VBN N
by IN N
implicit JJ N
inferences NNS N
while IN N
reading VBG N
the DT N
vignettes NNS N
. . N

Thus RB N
, , N
the DT N
comprehension NN N
problems NNS N
in IN N
these DT N
readers NNS N
can MD N
not RB N
be VB N
attributed VBN N
to TO N
an DT N
inability NN N
to TO N
make VB N
implicit JJ N
inferences NNS N
or CC N
to TO N
draw VB N
on IN N
relevant JJ N
world NN N
knowledge NN N
. . N

Instead RB N
, , N
we PRP N
suggest VBP N
that IN N
these DT N
problems NNS N
must MD N
be VB N
sought VBN N
at IN N
a DT N
higher JJR N
level NN N
of IN N
text JJ N
processing NN N
. . N

-DOCSTART- -11196013- O O

Spatial JJ i
orientation NN i
adjustments NNS i
in IN N
children NNS p
with IN p
autism NN p
in IN p
Hong NNP p
Kong NNP p
. . p

Abnormal NNP N
spatial JJ o
orientation NN o
and CC o
body NN o
postures NNS o
in IN N
children NNS p
with IN p
autism NN p
often RB N
interfere RB N
with IN N
visual JJ N
abilities NNS N
to TO N
attend VB N
tasks NNS N
and CC N
social JJ N
interactions NNS N
. . N

Twenty-four JJ p
children NNS p
diagnosed VBN p
with IN p
autism NN p
from IN p
Kowloon NNP p
, , p
Hong NNP p
Kong NNP p
were VBD N
assessed VBN N
for IN N
spatial JJ o
orientation NN o
and CC N
spatial JJ o
management NN o
abilities NNS N
. . N

Positive JJ o
changes NNS o
in IN N
spatial JJ o
orientation NN o
were VBD N
evident JJ N
when WRB N
the DT N
children NNS N
wore VBD i
ambient JJ i
prism NN i
lenses NNS i
and CC N
included VBD N
changes NNS o
in IN o
posture NN o
from IN N
slanted VBN N
to TO N
erect VB N
. . N

Adjustments NNS N
in IN N
spatial JJ o
management NN o
were VBD N
evident JJ N
in IN N
improved JJ N
ball NN N
catching VBG o
ability NN o
, , N
a DT N
task NN N
requiring VBG N
visual JJ N
tracking NN N
and CC N
eye-hand JJ N
coordination NN N
. . N

The DT N
findings NNS N
suggest VBP N
that IN N
alterations NNS i
to TO i
the DT i
sensory JJ i
systems NNS i
may MD N
lead VB N
to TO N
behavioral JJ N
change NN N
in IN N
some DT N
children NNS N
. . N

-DOCSTART- -11072681- O O

[ JJ i
New NNP i
therapeutic JJ i
approaches NNS i
in IN N
irritable JJ p
bowel NN p
syndrome NN p
] NN p
. . N

-DOCSTART- -24132766- O O

Comparison NNP o
of IN i
three CD i
software NN i
systems NNS i
for IN N
semi-automatic JJ N
volumetry NN o
of IN o
pulmonary JJ o
nodules NNS o
on IN N
baseline NN N
and CC N
follow-up JJ N
CT NNP N
examinations NNS N
. . N

BACKGROUND NNP N
Early JJ N
diagnosis NN N
of IN N
lung NN N
cancer NN N
in IN N
a DT N
treatable JJ N
stage NN N
is VBZ N
the DT N
main JJ N
purpose NN N
of IN N
lung NN p
cancer NN p
screening NN N
by IN N
computed VBN i
tomography NN i
( ( i
CT NNP i
) ) i
. . i

Accurate NNP N
three-dimensional JJ N
size NN N
and CC N
growth NN N
measurements NNS N
are VBP N
essential JJ N
to TO N
assess VB N
the DT N
risk NN N
of IN N
malignancy NN N
. . N

Nodule NNP N
volumes NNS N
can MD N
be VB N
calculated VBN N
by IN N
using VBG N
semi-automated JJ N
volumetric JJ N
software NN N
. . N

Systematic JJ N
differences NNS N
in IN N
volume NN N
measurements NNS N
between IN N
packages NNS N
could MD N
influence VB N
nodule JJ N
categorization NN N
and CC N
management NN N
decisions NNS N
. . N

PURPOSE NNP N
To TO N
compare VB N
volumetric JJ o
measurements NNS o
of IN N
solid JJ N
pulmonary JJ N
nodules NNS N
on IN N
baseline NN N
and CC N
follow-up JJ N
CT NNP i
scans NNS i
as RB N
well RB N
as IN N
the DT N
volume NN o
doubling VBG o
time NN o
( ( o
VDT NNP o
) ) o
for IN N
three CD i
software NN i
packages NNS i
. . i

MATERIAL NNP N
AND CC N
METHODS NNP N
From IN p
a DT p
Lung NNP p
Cancer NNP p
Screening NNP p
study NN p
( ( p
NELSON NNP p
) ) p
, , p
50 CD p
participants NNS p
were VBD p
randomly RB p
selected VBN p
from IN p
the DT p
baseline NN p
round NN p
. . p

The DT N
study NN p
population NN p
comprised VBD p
participants NNS p
with IN p
at IN p
least JJS p
one CD p
pulmonary JJ p
nodule NN p
at IN p
the DT p
baseline NN p
and CC p
consecutive JJ p
CT NNP p
examination NN p
. . p

The DT N
volume NN o
of IN o
each DT o
nodule NN o
was VBD N
determined VBN N
for IN N
both DT N
time NN N
points NNS N
using VBG N
three CD i
semi-automated JJ i
software NN i
packages NNS i
( ( i
P1 NNP i
, , i
P2 NNP i
, , i
and CC i
P3 NNP i
) ) i
. . N

Manual JJ N
modification NN N
was VBD N
performed VBN N
when WRB N
automated JJ N
assessment NN N
was VBD N
visually RB N
inaccurate JJ N
. . N

VDT NNP o
was VBD N
calculated VBN N
to TO N
evaluate VB o
nodule JJ o
growth NN o
. . o

Volume NN o
, , o
VDT NNP o
, , o
and CC o
nodule JJ o
management NN o
were VBD N
compared VBN N
for IN N
the DT N
three CD N
software NN N
packages NNS N
, , N
using VBG N
P1 NNP N
as IN N
the DT N
reference NN N
standard NN N
. . N

RESULTS NNP N
In IN N
25 CD N
participants NNS N
, , N
147 CD N
nodules NNS N
were VBD N
present JJ N
on IN N
both DT N
examinations NNS N
( ( N
volume NN N
: : N
12.0-436.6 JJ N
mm NN N
( ( N
3 CD N
) ) N
) ) N
. . N

Initial JJ o
segmentation NN o
at IN N
baseline NN N
was VBD N
evaluated VBN N
to TO N
be VB N
satisfactory JJ N
in IN N
93.9 CD N
% NN N
of IN N
nodules NNS N
for IN N
P1 NNP N
, , N
84.4 CD N
% NN N
for IN N
P2 NNP N
, , N
and CC N
88.4 CD N
% NN N
for IN N
P3 NNP N
. . N

Significant NNP N
difference NN N
was VBD N
found VBN N
in IN N
measured JJ o
volume NN o
between IN N
P1 NNP N
and CC N
the DT N
other JJ N
two CD N
packages NNS N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

P2 NNP N
overestimated VBD N
the DT N
volume NN o
by IN o
38 CD N
? . N
24 CD N
% NN N
, , N
and CC N
P3 NNP N
by IN N
50 CD N
? . N
22 CD N
% NN N
. . N

At IN N
baseline NN N
, , N
there EX N
was VBD N
consensus NN N
on IN o
nodule JJ o
size NN o
categorization NN o
in IN o
80 CD o
% NN o
for IN o
P1 NNP o
& CC N
P2 NNP N
and CC N
74 CD N
% NN N
for IN N
P1 NNP N
& CC N
P3 NNP N
. . N

At IN N
follow-up JJ N
, , N
consensus NN o
on IN o
VDT NNP o
categorization NN o
was VBD o
present JJ o
in IN o
47 CD N
% NN N
for IN N
P1 NNP N
& CC N
P2 NNP N
and CC N
44 CD N
% NN N
for IN N
P1 NNP N
& CC N
P3 NNP N
. . N

CONCLUSION NNP i
Software NNP i
packages VBZ i
for IN i
lung NN i
nodule NN i
evaluation NN i
yield NN i
significant JJ N
differences NNS N
in IN N
volumetric JJ o
measurements NNS o
and CC o
VDT NNP o
. . o

This DT o
variation NN N
affects VBZ o
the DT o
classification NN o
of IN o
lung NN o
nodules NNS o
, , o
especially RB N
in IN N
follow-up JJ N
examinations NNS N
. . N

-DOCSTART- -10213233- O O

Microbiologic JJ N
yields NNS N
and CC N
complication NN N
rates NNS N
of IN N
vitreous JJ i
needle JJ i
aspiration NN i
versus IN N
mechanized VBN i
vitreous JJ i
biopsy NN i
in IN N
the DT N
Endophthalmitis NNP N
Vitrectomy NNP N
Study NNP N
. . N

PURPOSE NNP N
To TO N
compare VB N
the DT N
microbiologic JJ N
yields NNS N
and CC N
complication NN N
rates NNS N
associated VBN N
with IN N
vitreous JJ i
needle JJ i
tap NN i
and CC N
vitreous JJ i
biopsy NN i
in IN N
the DT N
Endophthalmitis NNP p
Vitrectomy NNP p
Study NNP p
( ( p
EVS NNP p
) ) p
. . p

METHODS NNP N
Of IN N
420 CD p
EVS NNP p
patients NNS p
with IN p
postoperative JJ p
endophthalmitis NN p
, , p
201 CD p
received VBD p
immediate JJ p
vitreous JJ i
tap NN i
or CC i
biopsy NN i
( ( i
without IN i
pars NNS i
plana VBP i
vitrectomy NN i
) ) i
by IN N
random JJ N
assignment NN N
and CC N
193 CD p
completed VBN N
9-12 CD N
months NNS N
of IN N
follow-up NN N
. . N

Vitreous JJ N
specimens NNS N
were VBD N
obtained VBN N
by IN N
biopsy NN N
with IN N
a DT N
20-gauge JJ i
vitrectomy NN i
cutting VBG N
instrument NN N
or CC N
by IN N
needle JJ N
tap NN N
with IN N
a DT N
22-27-gauge JJ N
needle NN N
. . N

If IN N
resistance NN N
to TO N
aspiration NN N
by IN N
needle JJ N
tap NN N
was VBD N
noted VBN N
, , N
a DT N
vitreous JJ N
biopsy NN N
was VBD N
performed VBN N
. . N

RESULTS NNP N
Of IN N
201 CD p
patients NNS p
undergoing JJ p
tap NN p
or CC p
biopsy NN p
, , p
70 CD p
( ( p
35 CD p
% NN p
) ) p
had VBD p
needle JJ p
tap NN p
, , p
127 CD p
( ( p
63 CD p
% NN p
) ) p
had VBD p
mechanized VBN p
biopsy NN p
, , p
and CC p
4 CD p
( ( p
2 CD p
% NN p
) ) p
had VBD p
initial JJ p
needle JJ p
tap NN p
that WDT N
was VBD N
aborted VBN N
to TO N
mechanized VBN N
biopsy NN N
( ( N
abort JJ N
eyes NNS N
) ) N
. . N

Intraoperative JJ o
hyphema NN o
occurred VBD N
in IN N
2 CD N
tap JJ N
eyes NNS N
( ( N
3 CD N
% NN N
) ) N
, , N
3 CD N
biopsy NN N
eyes NNS N
( ( N
2 CD N
% NN N
) ) N
, , N
and CC N
0 CD N
( ( N
0 CD N
% NN N
) ) N
abort NN N
eyes NNS N
. . N

Postoperative JJ o
retinal JJ o
detachment NN o
developed VBD N
in IN N
8 CD N
( ( N
11 CD N
% NN N
) ) N
tap NN N
eyes NNS N
, , N
10 CD N
( ( N
8 CD N
% NN N
) ) N
biopsy NN N
eyes NNS N
, , N
and CC N
0 CD N
( ( N
0 CD N
% NN N
) ) N
abort NN N
eyes NNS N
( ( N
not RB N
significant JJ N
) ) N
. . N

Respective JJ o
rates NNS o
of IN o
culture NN o
and CC o
gram NN o
stain VBP o
positivity NN o
were VBD N
69 CD N
% NN N
and CC N
42 CD N
% NN N
in IN N
tap JJ N
eyes NNS N
and CC N
66 CD N
% NN N
and CC N
41 CD N
% NN N
in IN N
biopsy JJ N
eyes NNS N
( ( N
not RB N
significant JJ N
) ) N
. . N

The DT N
rate NN o
of IN o
severe JJ o
visual JJ o
loss NN o
( ( N
final JJ N
acuity NN N
< NNP N
5/200 CD N
) ) N
was VBD N
significantly RB N
higher JJR N
in IN N
tap JJ N
eyes NNS N
( ( N
16 CD N
eyes NNS N
, , N
24 CD N
% NN N
) ) N
compared VBN N
with IN N
biopsy JJ N
eyes NNS N
( ( N
13 CD N
eyes NNS N
, , N
11 CD N
% NN N
) ) N
and CC N
abort JJ N
eyes NNS N
( ( N
0 CD N
eyes NNS N
, , N
0 CD N
% NN N
; : N
P NNP N
= NNP N
0.043 CD N
) ) N
. . N

The DT N
difference NN N
was VBD N
largely RB N
explained VBN N
by IN N
the DT N
greater JJR N
proportion NN o
of IN o
virulent JJ o
organisms NNS o
in IN o
the DT o
tap JJ o
eyes NNS o
compared VBN N
with IN N
biopsy JJ N
eyes NNS N
. . N

When WRB N
visual JJ o
acuity NN o
outcome NN o
was VBD N
defined VBN N
by IN N
other JJ N
thresholds NNS N
( ( N
20/40 CD N
and CC N
20/100 CD N
) ) N
, , N
the DT N
difference NN N
was VBD N
not RB N
significant JJ N
. . N

CONCLUSIONS VB N
This DT N
study NN N
showed VBD N
no DT N
significant JJ N
differences NNS N
between IN N
mechanized VBN N
vitreous JJ N
biopsy NN N
and CC N
needle JJ N
tap NN N
with IN N
respect NN N
to TO N
microbiologic JJ N
yield NN N
, , N
operative JJ N
complications NNS N
, , N
short-term JJ N
( ( N
9-12 JJ N
months NNS N
) ) N
retinal JJ N
detachment NN N
risk NN N
, , N
or CC N
visual JJ N
outcome NN N
. . N

Choice NNP N
of IN N
vitreous JJ N
sampling VBG N
procedure NN N
must MD N
depend VB N
on IN N
the DT N
clinical JJ N
judgment NN N
of IN N
the DT N
surgeon NN N
. . N

-DOCSTART- -2932908- O O

Chemotherapy NN N
of IN N
large JJ p
bowel NN p
carcinoma NN i
-- : i
fluorouracil NN i
( ( i
FU NNP i
) ) i
+ VBP i
hydroxyurea NN i
( ( i
HU NNP i
) ) i
vs. FW i
methyl-CCNU NN i
, , i
oncovin NN i
, , i
fluorouracil NN i
, , i
and CC i
streptozotocin NN i
( ( i
MOF-Strep NNP i
) ) i
. . i

An DT N
Eastern JJ N
Cooperative NNP N
Oncology NNP N
Group NNP N
study NN N
. . N

In IN N
this DT N
prospective JJ N
randomized NN N
study NN N
of IN N
initial JJ N
chemotherapy NN N
for IN N
advanced JJ p
measurable JJ p
metastatic JJ p
large JJ p
bowel NN o
carcinoma NN o
, , N
the DT N
response NN o
rate NN o
was VBD N
6/32 CD p
( ( p
19 CD p
% NN p
) ) p
for IN p
FU NNP p
+ NNP p
HU NNP p
and CC p
5/32 CD p
( ( p
16 CD p
% NN p
) ) p
for IN p
MOF-Strep NNP p
; : p
the DT N
estimated JJ N
median JJ o
survival NN o
is VBZ N
43 CD N
weeks NNS N
for IN N
both DT N
treatments NNS N
. . N

Patients NNS N
who WP N
received VBD N
MOF-Strep NNP N
experienced VBD N
substantially RB N
greater JJR N
vomiting VBG o
and CC o
hematologic JJ o
toxicity NN o
than IN N
patients NNS p
who WP p
received VBD p
FU NNP N
+ NNP N
HU NNP N
( ( N
p NN N
less JJR N
than IN N
0.001 CD N
) ) N
. . N

-DOCSTART- -18243378- O O

A DT N
field NN N
trial NN N
of IN N
production NN N
and CC N
financial JJ N
consequences NNS N
of IN N
helminthosis NN N
control NN N
in IN N
sheep JJ p
production NN p
in IN p
Ethiopia NNP p
. . p

We PRP N
used VBD N
a DT N
partial-budget JJ N
analysis NN N
to TO N
evaluate VB N
profitability NN o
of IN N
different JJ i
management NN i
strategies NNS i
of IN i
three CD i
genotypes NNS i
of IN i
sheep NN i
in IN p
a DT p
2 CD p
x NN p
2 CD p
x JJ p
3 CD p
factorial JJ p
experiment NN p
conducted VBN p
at IN p
Debre NNP p
Berhan NNP p
research NN p
station NN p
in IN p
the DT p
central JJ p
highlands NNS p
of IN p
Ethiopia NNP p
. . p

This DT N
involved JJ N
two CD i
anthelmintic-treatment JJ i
levels NNS i
( ( i
treated VBN i
vs. IN i
non-treated JJ i
) ) i
, , i
two CD i
supplementary JJ i
nutrition NN i
levels NNS i
( ( i
protein-energy JJ i
supplementation NN i
yes/no NN i
) ) i
and CC i
three CD i
genotypes NNS i
: : i
indigenous JJ i
Menz NNP i
( ( p
n=40 NN p
) ) p
, , p
50 CD p
% NN p
Awassi NNP i
x NNP i
50 CD p
% NN p
Menz NNP i
crosses VBZ i
( ( p
n=38 NN p
) ) p
and CC p
75 CD p
% NN p
Awassi NNP p
x NNP p
25 CD p
% NN p
Menz NNP p
crosses VBZ p
( ( p
n=31 JJ p
) ) p
. . p

All DT N
sheep JJ p
were VBD N
exposed VBN N
to TO N
natural JJ i
sub-clinical JJ i
helminthosis NN i
challenge NN i
. . i

Supplemented VBN N
sheep NN N
were VBD N
offered VBN N
a DT N
concentrate JJ i
mix JJ i
daily RB i
on IN N
an DT N
individual JJ N
basis NN N
. . N

Anthelmintic-treated JJ i
sheep NN i
were VBD i
drenched VBN i
with IN i
fenbendazole NN i
against IN i
nematodes NNS i
and CC i
with IN i
triclabendazole NN i
against IN i
trematodes NNS i
. . i

Data NNS N
were VBD N
collected VBN N
during IN N
the DT N
experimental JJ N
period NN N
( ( N
for IN N
10 CD N
months NNS N
from IN N
approximately RB N
1 CD N
year NN N
of IN N
age NN N
) ) N
on IN N
feed NN o
intake NN o
, , o
live JJ o
weight NN o
, , o
eggs FW o
per IN o
gram NN o
( ( o
EPG NNP o
) ) o
of IN o
faeces NNS o
, , o
packed-cell JJ o
volume NN o
( ( o
PCV NNP o
) ) o
, , o
wool JJ o
weight NN o
, , o
and CC o
adult-worm JJ o
burden NN o
. . o

Actual JJ N
market NN o
input NN o
and CC o
output NN o
prices NNS o
were VBD N
recorded VBN N
. . N

Supplemented VBN N
sheep NN N
had VBD N
significantly RB N
higher JJR N
marginal JJ o
profit NN o
( ( o
MP NNP o
) ) o
per IN N
sheep NN N
than IN N
non-supplemented JJ N
sheep NN N
( ( N
ETB NNP N
33 CD N
vs. IN N
4 CD N
) ) N
. . N

Likewise NNP N
, , N
anthelmintic JJ N
treated VBD N
sheep NN N
performed VBN o
significantly RB N
better RBR N
than IN N
their PRP$ N
non-treated JJ N
contemporaries NNS N
( ( N
MP=ETB NNP N
28 CD N
vs. IN N
8 CD N
) ) N
. . N

The DT N
75 CD N
% NN N
Awassi NNP N
crosses NNS N
were VBD N
least RBS N
profitable JJ o
. . o

-DOCSTART- -2973215- O O

Clinical JJ N
significance NN N
and CC N
prognostic JJ N
importance NN N
of IN N
left JJ N
ventricular JJ N
hypertrophy NN N
in IN N
non-Q-wave JJ p
acute JJ p
myocardial JJ p
infarction NN p
. . p

Left NNP N
ventricular NN N
( ( N
LV NNP N
) ) N
hypertrophy NN N
is VBZ N
known VBN N
to TO N
be VB N
an DT N
independent JJ N
risk NN N
factor NN N
for IN N
cardiac JJ N
death NN N
, , N
but CC N
its PRP$ N
significance NN N
in IN N
non-Q-wave JJ p
acute JJ p
myocardial JJ p
infarction NN p
( ( p
AMI NNP p
) ) p
has VBZ N
not RB N
been VBN N
assessed VBN N
previously RB N
. . N

In IN N
a DT N
randomized JJ N
diltiazem-placebo-controlled JJ i
therapeutic JJ N
trial NN N
of IN N
non-Q-wave JJ p
AMI NNP p
confirmed VBN p
by IN p
creatine NN p
kinase-MB NN p
( ( p
CK-MB NNP p
) ) p
, , N
126 CD N
of IN N
544 CD p
patients NNS p
( ( N
23 CD N
% NN N
) ) N
exhibited VBD N
LV NNP N
hypertrophy NN N
using VBG N
standard JJ N
voltage NN N
criteria NNS N
. . N

Compared VBN N
to TO N
patients NNS N
without IN N
LV NNP N
hypertrophy NN N
, , N
patients NNS p
with IN N
LV NNP N
hypertrophy NN N
were VBD N
significantly RB N
older JJR N
( ( p
65 CD p
vs RB p
60 CD p
years NNS p
, , N
p RB N
less JJR N
than IN N
0.0001 CD N
) ) N
and CC N
had VBD N
smaller JJR N
peak NN N
adjusted VBN N
CK NNP N
levels NNS N
( ( N
490 CD N
+/- JJ N
376 CD N
vs JJ N
666 CD N
+/- JJ N
726 CD N
IU/liter NNP N
, , N
p NN N
less JJR N
than IN N
0.001 CD N
) ) N
than IN N
patients NNS N
without IN N
LV NNP N
hypertrophy NN N
. . N

Patients NNS N
with IN N
and CC N
without IN N
LV NNP N
hypertrophy NN N
did VBD N
not RB N
differ VB N
significantly RB N
in IN N
acute JJ N
mortality NN o
during IN N
hospitalization NN o
, , o
progression NN o
to TO o
Q NNP o
waves NNS o
, , o
reinfarction NN o
by IN o
CK-MB NNP o
criteria NNS o
or CC o
angina NNS o
associated VBN N
with IN N
transient JJ N
electrocardiographic JJ N
changes NNS N
. . N

Compared VBN N
with IN N
patients NNS N
without IN N
LV NNP N
hypertrophy NN N
, , N
those DT N
patients NNS N
with IN N
non-Q-wave JJ N
AMI NNP N
and CC N
LV NNP N
hypertrophy NN N
had VBD N
a DT N
2-fold JJ N
higher JJR N
incidence NN N
of IN N
reinfarction NN o
( ( N
24 CD N
vs RB N
12 CD N
% NN N
, , N
p NN N
less JJR N
than IN N
0.005 CD N
) ) N
and CC N
death NN N
( ( N
19 CD N
vs RB N
9 CD N
% NN N
, , N
p NN N
= NNP N
0.044 CD N
) ) N
during IN N
the DT N
first JJ N
year NN N
of IN N
follow-up NN N
. . N

Multivariate NNP N
regression NN N
analysis NN N
revealed VBD N
that IN N
the DT N
relative JJ N
risk NN o
of IN o
death NN o
and CC o
reinfarction NN o
during IN N
the DT N
initial JJ N
year NN N
after IN N
AMI NNP N
was VBD N
increased VBN N
by IN N
a DT N
factor NN N
of IN N
1.7 CD N
and CC N
2.1 CD N
among IN N
patients NNS N
with IN N
LV NNP N
hypertrophy NN N
, , N
respectively RB N
. . N

It PRP N
was VBD N
therefore RB N
concluded VBD N
that IN N
, , N
although IN N
patients NNS N
with IN N
LV NNP N
hypertrophy NN N
and CC N
non-Q-wave JJ N
AMI NNP N
have VBP N
smaller JJR N
enzymatic JJ N
infarcts NNS N
and CC N
the DT N
same JJ N
short-term JJ N
prognosis NN N
as IN N
do JJ N
patients NNS N
without IN N
LV NNP N
hypertrophy NN N
, , N
their PRP$ N
reinfarction NN N
and CC N
mortality NN N
rates NNS N
are VBP N
significantly RB N
increased VBN N
during IN N
the DT N
first JJ N
year NN N
of IN N
follow-up NN N
. . N

( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
250 CD N
WORDS NNP N
) ) N
-DOCSTART- -1282182- O O

Prevention NN N
of IN N
coronary JJ p
spasm NN p
by IN N
nicorandil NNS i
: : i
comparison NN N
with IN N
nifedipine NN i
. . i

The DT N
efficacy NN N
of IN N
nicorandil NN i
was VBD N
compared VBN N
with IN N
that DT N
of IN N
nifedipine NN i
in IN N
13 CD p
patients NNS p
with IN p
vasospastic JJ p
angina NNS p
enrolled VBN N
in IN N
a DT N
randomized JJ N
, , N
placebo-controlled JJ i
, , N
crossover NN N
study NN N
. . N

All DT p
patients NNS p
had VBD p
a DT p
coronary JJ p
spasm NN p
during IN p
coronary JJ p
arteriography NN p
, , p
either CC p
spontaneously RB p
or CC p
ergometrine-induced JJ p
. . p

During IN N
two CD N
consecutive JJ N
periods NNS N
of IN N
2 CD N
days NNS N
, , N
patients NNS N
received VBD N
active JJ i
drugs NNS i
or CC N
placebo NN i
in IN N
a DT N
randomized JJ N
order NN N
. . N

Each DT N
patient NN N
received VBD N
single JJ N
oral JJ N
doses NNS N
of IN N
30 CD N
mg NN N
nicorandil NN i
, , N
10 CD N
mg NN N
nifedipine NN i
, , N
and CC N
, , N
on IN N
2 CD N
days NNS N
, , N
a DT N
placebo NN i
. . i

One CD N
hour NN N
after IN N
drug NN N
intake NN N
, , N
patients NNS N
underwent VBD N
an DT N
ergometrine JJ N
test NN N
with IN N
increasing VBG N
doses NNS N
of IN N
Methergin NNP i
( ( i
ergometrine NN i
) ) i
( ( N
0.05 CD N
, , N
0.10 CD N
, , N
0.20 CD N
, , N
and CC N
0.40 CD N
mg NN N
every DT N
5 CD N
min NN N
) ) N
. . N

After IN N
placebo NN i
, , N
the DT N
tests NNS N
always RB N
were VBD N
positive JJ N
, , N
and CC N
the DT N
ECG NNP o
changes NNS o
occurred VBD N
at IN N
the DT N
same JJ N
+/- JJ N
1 CD N
dose NN N
of IN N
ergometrine NN i
in IN N
10 CD N
cases NNS N
, , N
showing VBG N
good JJ o
reproducibility NN o
. . o

After IN N
nicorandil NN i
, , N
the DT N
tests NNS N
were VBD N
negative JJ N
in IN N
nine CD N
patients NNS N
and CC N
positive JJ N
for IN N
a DT N
higher JJR N
or CC N
lower JJR N
dose NN N
of IN N
ergometrine NN i
in IN N
three CD N
and CC N
one CD N
patient NN N
, , N
respectively RB N
( ( N
p JJ N
= $ N
0.0034 CD N
vs. FW N
placebo NN i
) ) i
. . N

After IN N
nifedipine NN i
, , N
the DT N
tests NNS N
were VBD N
negative JJ N
in IN N
five CD N
patients NNS N
and CC N
positive JJ N
for IN N
a DT N
higher JJR N
or CC N
the DT N
same JJ N
dose NN N
of IN N
ergometrine NN i
in IN N
four CD N
and CC N
four CD N
patients NNS N
, , N
respectively RB N
( ( N
p JJ N
= $ N
0.0039 CD N
vs. FW N
placebo NN i
) ) i
. . N

Nifedipine NNP i
( ( N
10 CD N
mg NN N
) ) N
and CC N
nicorandil $ N
( ( N
30 CD N
mg NN N
) ) N
were VBD N
equally RB N
effective JJ N
in IN N
eight CD N
patients NNS N
; : N
in IN N
the DT N
remaining VBG N
five CD N
patients NNS N
, , N
nicorandil NNS i
had VBD N
better JJR N
results NNS N
( ( N
p JJ N
= NNP N
0.06 CD N
) ) N
. . N

Nicorandil NNP i
( ( N
30 CD N
mg NN N
) ) N
prevents VBZ N
ergometrine-induced JJ o
coronary JJ o
spasm NN o
. . o

This DT N
compound NN N
may MD N
be VB N
beneficial JJ N
in IN N
patients NNS p
with IN p
vasospastic JJ o
angina NN o
. . o

-DOCSTART- -1849786- O O

Symptomatic JJ i
treatment NN i
versus NN N
combination NN i
chemotherapy NN i
for IN N
patients NNS p
with IN p
extensive JJ p
non-small NN p
cell NN p
lung NN p
cancer NN p
. . p

In IN N
a DT N
randomized JJ N
clinical JJ N
trial NN N
, , N
87 CD p
patients NNS p
with IN p
inoperable JJ p
, , p
extensive JJ p
non-small NN p
cell NN p
lung NN p
cancer NN p
( ( p
NSCLC NNP p
) ) p
were VBD N
randomized VBN N
to TO N
receive VB N
either DT N
combination NN i
chemotherapy NN i
( ( i
cisplatin NN i
at IN N
70 CD N
mg/m2 NN N
intravenously RB N
[ NNP N
i.v NN N
. . N

] VB N
on IN N
day NN N
1 CD N
and CC N
etoposide VB i
at IN N
100 CD N
mg/m2 NN N
i.v NN N
. . N

on IN N
day NN N
1 CD N
and CC N
200 CD N
mg/m2 NNS N
orally RB N
on IN N
days NNS N
2 CD N
and CC N
3 CD N
) ) N
or CC N
symptomatic JJ i
treatment NN i
. . i

No DT N
statistically RB N
significant JJ N
differences NNS N
in IN N
survival JJ o
time NN o
were VBD N
found VBN N
between IN N
the DT N
two CD N
treatment NN N
techniques NNS N
. . N

A DT N
major JJ N
problem NN N
in IN N
the DT N
interpretation NN N
of IN N
the DT N
results NNS N
was VBD N
the DT N
use NN N
of IN N
semicurative JJ N
radiation NN N
therapy NN N
( ( N
3000 CD N
to TO N
4200 CD N
cGy NN N
) ) N
to TO N
the DT N
primary JJ N
tumor NN N
and CC N
mediastinum NN N
, , N
which WDT N
was VBD N
given VBN N
with IN N
symptomatic JJ N
intent NN N
. . N

Three CD o
long-term JJ o
survivors NNS o
were VBD o
seen VBN o
in IN o
the DT o
latter JJ o
group NN o
. . o

-DOCSTART- -9839765- O O

Concurrent JJ N
administration NN N
of IN N
donepezil JJ i
HCl NNP i
and CC i
digoxin NN i
: : i
assessment NN N
of IN N
pharmacokinetic JJ N
changes NNS N
. . N

AIM VBP N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
examine VB N
the DT N
pharmacokinetics NNS N
of IN N
donepezil NN i
HCl NNP i
and CC i
digoxin NN i
separately RB i
, , i
and CC i
in IN i
combination NN i
, , N
following VBG N
administration NN N
of IN N
single JJ N
oral JJ N
doses NNS N
. . N

Changes NNS N
in IN N
cardiac JJ N
conduction NN N
parameters NNS N
following VBG N
drug NN N
administration NN N
were VBD N
also RB N
assessed VBN N
. . N

METHODS NNP N
This DT N
was VBD N
an DT N
open-label JJ N
, , N
randomized VBN N
, , N
three-period JJ N
crossover NN N
study NN N
in IN N
healthy JJ p
male NN p
volunteers NNS p
( ( p
n=12 NN p
) ) p
. . p

During IN N
each DT N
treatment NN N
period NN N
, , N
subjects VBZ p
received VBN p
a DT p
single JJ p
dose NN p
of IN p
either CC p
donepezil JJ i
HCl NNP i
( ( i
5 CD i
mg NN i
) ) i
, , i
digoxin NN i
( ( i
0.25 CD i
mg NN i
) ) i
, , i
or CC i
a DT i
combination NN i
of IN i
both DT i
drugs NNS i
. . i

Each DT N
treatment NN N
period NN N
was VBD N
followed VBN N
by IN N
a DT N
2-week JJ N
, , N
drug-free JJ N
washout NN N
period NN N
. . N

RESULTS NNP N
All DT N
12 CD p
volunteers NNS p
completed VBD N
the DT N
study NN N
without IN N
incident NN N
. . N

No DT N
statistically RB N
significant JJ N
differences NNS N
in IN N
donepezil NN o
pharmacokinetics NNS o
( ( o
Cmax NNP o
, , o
tmax NN o
, , o
AUC NNP o
( ( o
0-120 JJ o
) ) o
, , o
AUC NNP o
( ( o
0-infinity NN o
) ) o
or CC N
t1/2 NN N
) ) N
were VBD N
observed VBN N
when WRB N
donepezil NN i
administered VBD i
alone RB i
was VBD N
compared VBN N
with IN N
donepezil NN i
administered VBN i
in IN i
combination NN i
with IN i
digoxin NN i
. . i

Similarly RB N
, , N
no DT N
statistically RB N
significant JJ N
differences NNS N
in IN N
digoxin NN i
pharmacokinetics NNS N
were VBD N
observed VBN N
when WRB N
digoxin NN i
was VBD N
administered VBN N
alone RB N
or CC N
in IN N
combination NN N
with IN N
donepezil NN i
. . i

No DT N
clinically RB N
relevant JJ N
changes NNS N
in IN N
cardiac JJ o
conduction NN o
( ( N
lead JJ N
II NNP N
ECG NNP N
) ) N
were VBD N
observed VBN N
in IN N
any DT N
subject NN N
during IN N
any DT N
treatment NN N
period NN N
. . N

CONCLUSIONS NNP N
Co-administration NN N
of IN N
single JJ N
doses NNS N
of IN N
donepezil NN i
HCl NNP i
( ( N
5 CD N
mg NN N
) ) N
and CC N
digoxin NN i
( ( N
0.25 CD N
mg NN N
) ) N
produced VBD N
no DT N
changes NNS N
in IN N
the DT N
pharmacokinetic JJ N
profile NN N
of IN N
either DT N
drug NN N
. . N

In IN N
addition NN N
, , N
co-administration NN N
produced VBD N
no DT N
changes NNS N
in IN N
cardiac JJ N
conduction NN N
parameters NNS N
during IN N
the DT N
24 CD N
h NN N
of IN N
telemetry NN N
monitoring NN N
following VBG N
drug NN N
administration NN N
. . N

-DOCSTART- -8561059- O O

Effects NNS N
of IN N
interaction NN N
of IN N
RRR-alpha-tocopheryl NNP i
acetate NN i
and CC i
fish JJ i
oil NN i
on IN N
low-density-lipoprotein JJ N
oxidation NN N
in IN N
postmenopausal JJ p
women NNS p
with IN p
and CC p
without IN p
hormone-replacement JJ i
therapy NN i
. . i

We PRP N
evaluated VBD N
the DT N
effects NNS N
of IN N
RRR-alpha-tocpheryl NNP i
acetate NN i
( ( i
alpha-tocopheryl JJ i
acetate NN i
) ) i
and CC i
hormone-replacement JJ i
therapy NN i
( ( i
HRT NNP i
) ) i
on IN N
the DT N
oxidative JJ N
susceptibility NN N
of IN N
low-density NN N
lipoprotein NN N
( ( N
LDL NNP N
) ) N
in IN N
postmenopausal JJ p
women NNS p
consuming VBG p
a DT p
fish JJ i
oil NN i
supplement NN i
. . i

The DT N
independent JJ N
effect NN o
of IN N
fish JJ N
oil NN N
was VBD N
also RB N
assessed VBN N
. . N

Forty-eight JJ p
women NNS p
, , p
equally RB p
divided VBD p
between IN p
women NNS p
using VBG p
and CC p
not RB p
using VBG p
HRT NNP i
, , N
participated VBD N
in IN N
a DT N
double-blind JJ N
crossover NN N
trial NN N
. . N

Each DT N
of IN N
the DT N
four CD N
periods NNS N
lasted VBD N
5 CD N
wk NN N
and CC N
was VBD N
followed VBN N
by IN N
a DT N
4-wk JJ N
washout NN N
interval NN N
. . N

During IN N
each DT N
period NN N
all DT N
subjects NNS N
were VBD N
given VBN N
a DT N
15-g JJ N
supplement NN N
of IN N
fish JJ N
oil NN N
and CC N
either RB N
0 CD N
( ( i
placebo NN i
) ) i
, , N
100 CD N
, , N
200 CD N
, , N
or CC N
400 CD N
mg JJ N
alpha-tocopheryl JJ i
acetate JJ i
daily JJ N
. . N

LDL NNP o
resistance NN o
to TO o
oxidative VB o
modification NN o
was VBD N
assessed VBN N
by IN N
calculating VBG o
lag NN o
time NN o
, , o
propagation NN o
rate NN o
, , o
and CC o
maximum JJ o
production NN o
of IN o
conjugated JJ o
dienes NNS o
. . o

Supplementation NN N
with IN N
fish JJ N
oil NN N
and CC N
placebo NN i
shortened VBN N
lag JJ o
time NN o
and CC o
slowed VBN o
propagation NN o
rate NN o
in IN N
women NNS N
both DT N
using VBG N
and CC N
not RB N
using VBG N
HRT NNP N
. . N

After IN N
subjects NNS N
consumed VBD N
fish JJ N
oil NN N
, , N
supplementation NN N
with IN N
alpha-tocopheryl JJ N
acetate NN N
increased VBD N
plasma NN o
and CC o
LDL NNP o
alpha-tocopherol NN o
contents NNS o
significantly RB o
and CC o
lengthened VBD o
lag NN o
time NN o
( ( N
at IN N
even RB N
the DT N
lowest JJS N
concentration NN N
) ) N
but CC N
had VBD N
no DT N
significant JJ N
effect NN N
on IN N
propagation NN o
rate NN o
or CC N
maximum JJ o
production NN o
compared VBN N
with IN N
values NNS N
measured VBN N
after IN N
consumption NN N
of IN N
fish JJ N
oil NN N
alone RB N
. . N

Women NNP N
not RB N
using VBG N
HRT NNP N
had VBD N
faster JJR N
propagation NN o
rates NNS o
and CC o
higher JJR o
maximum NN o
production NN o
than IN N
women NNS N
using VBG N
HRT NNP N
; : N
after IN N
supplementation NN N
with IN N
fish JJ N
oil NN N
and CC N
alpha-tocopheryl JJ i
acetate NN N
these DT N
differences NNS N
prevailed VBD N
. . N

Supplements NNS N
as RB N
low JJ N
as IN N
100 CD N
mg JJ N
alpha-tocopheryl JJ N
acetate/d NN N
increase VB N
the DT N
resistance NN o
of IN o
LDL NNP o
to TO o
oxidation VB o
when WRB N
fish JJ N
oil NN N
supplements NNS N
are VBP N
used VBN N
. . N

HRT NNP N
and CC N
fish JJ N
oil NN N
supplements NNS N
may MD N
independently RB N
affect VB N
LDL NNP o
oxidative JJ o
susceptibility NN o
. . o

-DOCSTART- -26725450- O O

Safety NN N
and CC N
immunogenicity NN N
of IN N
a DT N
chimpanzee JJ i
adenovirus-vectored JJ i
Ebola NNP i
vaccine NN i
in IN N
healthy JJ p
adults NNS p
: : p
a DT N
randomised JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
, , N
dose-finding JJ N
, , N
phase VB N
1/2a CD N
study NN N
. . N

BACKGROUND NNP N
The DT N
ongoing JJ N
Ebola NNP N
outbreak NN N
led VBD N
to TO N
accelerated VBN N
efforts NNS N
to TO N
test VB N
vaccine NN N
candidates NNS N
. . N

On IN N
the DT N
basis NN N
of IN N
a DT N
request NN N
by IN N
WHO NNP N
, , N
we PRP N
aimed VBD N
to TO N
assess VB N
the DT N
safety NN N
and CC N
immunogenicity NN N
of IN N
the DT N
monovalent NN i
, , i
recombinant NN i
, , i
chimpanzee JJ i
adenovirus JJ i
type-3 JJ i
vector-based JJ i
Ebola NNP i
Zaire NNP i
vaccine NN i
( ( i
ChAd3-EBO-Z NNP i
) ) i
. . i

METHODS NNP N
We PRP N
did VBD N
this DT N
randomised VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
, , N
dose-finding JJ N
, , N
phase VB N
1/2a CD N
trial NN N
at IN N
the DT N
Centre NNP p
Hospitalier NNP p
Universitaire NNP p
Vaudois NNP p
, , p
Lausanne NNP p
, , p
Switzerland NNP p
. . p

Participants NNS p
( ( p
aged VBN p
18-65 CD p
years NNS p
) ) p
were VBD p
randomly RB p
assigned VBN p
( ( N
2:2:1 CD N
) ) N
, , N
via IN N
two CD N
computer-generated JJ N
randomisation NN N
lists NNS N
for IN N
individuals NNS p
potentially RB p
deployed VBN p
in IN p
endemic JJ p
areas NNS p
and CC p
those DT p
not RB p
deployed VBN p
, , N
to TO N
receive VB N
a DT N
single JJ N
intramuscular NN N
dose NN N
of IN N
high-dose JJ i
vaccine NN i
( ( N
5 CD N
? . N
10 CD N
( ( N
10 CD N
) ) N
viral JJ N
particles NNS i
) ) i
, , i
low-dose JJ i
vaccine NN i
( ( i
2?5 CD i
? . N
10 CD N
( ( N
10 CD N
) ) N
viral JJ N
particles NNS N
) ) N
, , N
or CC i
placebo NN i
. . N

Deployed VBN N
participants NNS N
were VBD N
allocated VBN N
to TO N
only RB N
the DT N
vaccine NN N
groups NNS N
. . N

Group NNP N
allocation NN N
was VBD N
concealed VBN N
from IN N
non-deployed JJ N
participants NNS N
, , N
investigators NNS N
, , N
and CC N
outcome JJ N
assessors NNS N
. . N

The DT N
safety NN N
evaluation NN N
was VBD N
not RB N
masked VBN N
for IN N
potentially RB N
deployed JJ N
participants NNS N
, , N
who WP N
were VBD N
therefore RB N
not RB N
included VBN N
in IN N
the DT N
safety NN N
analysis NN N
for IN N
comparison NN N
between IN N
the DT N
vaccine NN N
doses NNS N
and CC N
placebo NN N
, , N
but CC N
were VBD N
pooled VBN N
with IN N
the DT N
non-deployed JJ N
group NN N
to TO N
compare VB N
immunogenicity NN N
. . N

The DT N
main JJ N
objectives NNS N
were VBD N
safety NN N
and CC N
immunogenicity NN N
of IN N
ChAd3-EBO-Z NNP N
. . N

We PRP N
did VBD N
analysis NN N
by IN N
intention NN N
to TO N
treat VB N
. . N

This DT N
trial NN N
is VBZ N
registered VBN N
with IN N
ClinicalTrials.gov NNP N
, , N
number NN N
NCT02289027 NNP N
. . p

FINDINGS NNP p
Between NNP p
Oct NNP p
24 CD p
, , p
2014 CD p
, , p
and CC p
June NNP p
22 CD p
, , p
2015 CD p
, , p
we PRP p
randomly VBP p
assigned VBN p
120 CD p
participants NNS p
, , p
of IN p
whom WP p
18 CD p
( ( p
15 CD p
% NN p
) ) p
were VBD p
potentially RB p
deployed VBN p
and CC p
102 CD p
( ( p
85 CD p
% NN p
) ) p
were VBD p
non-deployed JJ p
, , p
to TO p
receive VB p
high-dose JJ p
vaccine NN p
( ( p
n=49 JJ p
) ) p
, , p
low-dose JJ p
vaccine NN p
( ( p
n=51 JJ p
) ) p
, , p
or CC p
placebo NN p
( ( p
n=20 JJ p
) ) p
. . p

Participants NNS p
were VBD N
followed VBN N
up RP N
for IN N
6 CD N
months NNS N
. . N

No DT N
vaccine-related JJ o
serious JJ o
adverse JJ o
events NNS o
were VBD o
reported VBN N
. . N

We PRP N
recorded VBD N
local JJ o
adverse JJ o
events NNS o
in IN o
30 CD N
( ( N
75 CD N
% NN N
) ) N
of IN N
40 CD N
participants NNS N
in IN N
the DT N
high-dose JJ N
group NN N
, , N
33 CD N
( ( N
79 CD N
% NN N
) ) N
of IN N
42 CD N
participants NNS N
in IN N
the DT N
low-dose JJ N
group NN N
, , N
and CC N
five CD N
( ( N
25 CD N
% NN N
) ) N
of IN N
20 CD N
participants NNS N
in IN N
the DT N
placebo NN N
group NN o
. . o

Fatigue NNP o
or CC o
malaise NN o
was VBD N
the DT N
most RBS N
common JJ N
systemic JJ N
adverse JJ N
event NN N
, , N
reported VBD N
in IN N
25 CD N
( ( N
62 CD N
% NN N
) ) N
participants NNS N
in IN N
the DT N
high-dose JJ N
group NN N
, , N
25 CD N
( ( N
60 CD N
% NN N
) ) N
participants NNS N
in IN N
the DT N
low-dose JJ N
group NN N
, , N
and CC N
five CD N
( ( N
25 CD N
% NN N
) ) N
participants NNS N
in IN N
the DT N
placebo NN N
group NN N
, , N
followed VBN N
by IN N
headache NN N
, , N
reported VBD N
in IN N
23 CD N
( ( N
57 CD N
% NN N
) ) N
, , N
25 CD N
( ( N
60 CD N
% NN N
) ) N
, , N
and CC N
three CD N
( ( N
15 CD N
% NN N
) ) N
participants NNS N
, , N
respectively RB o
. . o

Fever NNP o
occurred VBD o
24 CD N
h NN N
after IN N
injection NN N
in IN N
12 CD N
( ( N
30 CD N
% NN N
) ) N
participants NNS N
in IN N
the DT N
high-dose JJ N
group NN N
and CC N
11 CD N
( ( N
26 CD N
% NN N
) ) N
participants NNS N
in IN N
the DT N
low-dose JJ N
group NN N
versus IN N
one CD N
( ( N
5 CD N
% NN N
) ) N
participant NN N
in IN N
the DT N
placebo NN N
group NN o
. . o

Geometric NNP o
mean JJ o
concentrations NNS o
of IN o
IgG NNP o
antibodies NNS o
against IN o
Ebola NNP o
glycoprotein NN o
peaked VBD o
on IN o
day NN N
28 CD N
at IN N
51 CD N
?g/mL NN N
( ( N
95 CD N
% NN N
CI NNP N
41?1-63?3 CD N
) ) N
in IN N
the DT N
high-dose JJ N
group NN N
, , N
44?9 CD N
?g/mL NN N
( ( N
25?8-56?3 JJ N
) ) N
in IN N
the DT N
low-dose JJ N
group NN N
, , N
and CC N
5?2 CD N
?g/mL NN N
( ( N
3?5-7?6 JJ N
) ) N
in IN N
the DT N
placebo NN N
group NN N
, , N
with IN N
respective JJ N
response NN N
rates NNS N
of IN N
96 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
85?7-99?5 CD N
) ) N
, , N
96 CD N
% NN N
( ( N
86?5-99?5 JJ N
) ) N
, , N
and CC N
5 CD N
% NN N
( ( N
0?1-24?9 JJ o
) ) o
. . o

Geometric JJ o
mean JJ o
concentrations NNS o
decreased VBN o
by IN N
day NN N
180 CD N
to TO N
25?5 CD N
?g/mL NNS N
( ( N
95 CD N
% NN N
CI NNP N
20?6-31?5 CD N
) ) N
in IN N
the DT N
high-dose JJ N
group NN N
, , N
22?1 CD N
?g/mL NN N
( ( N
19?3-28?6 JJ N
) ) N
in IN N
the DT N
low-dose JJ N
group NN N
, , N
and CC N
3?2 CD N
?g/mL NN N
( ( N
2?4-4?9 JJ N
) ) N
in IN N
the DT N
placebo NN N
group NN N
. . N

28 CD N
( ( N
57 CD N
% NN N
) ) N
participants NNS N
given VBN N
high-dose JJ N
vaccine NN N
and CC N
31 CD N
( ( N
61 CD N
% NN N
) ) N
participants NNS N
given VBN N
low-dose JJ N
vaccine NN N
developed VBD o
glycoprotein-specific JJ o
CD4 NNP o
cell NN o
responses NNS o
, , o
and CC o
33 CD o
( ( o
67 CD o
% NN o
) ) o
and CC o
35 CD o
( ( N
69 CD N
% NN N
) ) N
, , N
respectively RB N
, , N
developed VBD N
CD8 NNP N
responses NNS N
. . N

INTERPRETATION NNP N
ChAd3-EBO-Z NNP N
was VBD o
safe JJ o
and CC o
well RB o
tolerated VBN o
, , N
although IN N
mild NN N
to TO N
moderate VB N
systemic JJ N
adverse JJ N
events NNS N
were VBD N
common JJ N
. . N

A DT N
single JJ N
dose NN N
was VBD N
immunogenic JJ N
in IN N
almost RB N
all DT N
vaccine NN N
recipients NNS N
. . N

Antibody NN N
responses NNS N
were VBD N
still RB N
significantly RB N
present JJ N
at IN N
6 CD N
months NNS N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
doses NNS N
for IN N
safety NN N
and CC N
immunogenicity NN N
outcomes RB N
. . N

This DT N
acceptable JJ N
safety NN N
profile NN N
provides VBZ N
a DT N
reliable JJ N
basis NN N
to TO N
proceed VB N
with IN N
phase NN N
2 CD N
and CC N
phase VB N
3 CD N
efficacy NN N
trials NNS N
in IN N
Africa NNP N
. . N

FUNDING NN N
Swiss JJ N
State NNP N
Secretariat NNP N
for IN N
Education NNP N
, , N
Research NNP N
and CC N
Innovation NNP N
( ( N
SERI NNP N
) ) N
, , N
through IN N
the DT N
EU NNP N
Horizon NNP N
2020 CD N
Research NNP N
and CC N
Innovation NNP N
Programme NNP N
. . N

-DOCSTART- -17950167- O O

Covariation NN N
of IN N
adolescent JJ o
physical JJ o
activity NN o
and CC i
dietary JJ o
behaviors NNS o
over IN N
12 CD N
months NNS N
. . N

PURPOSE VB N
This DT N
study NN N
examined VBD N
covariation NN N
among IN N
changes NNS i
in IN i
dietary JJ i
, , i
physical JJ i
activity NN i
, , i
and CC i
sedentary JJ i
behaviors NNS i
over IN N
12 CD N
months NNS N
among IN N
adolescents NNS p
participating VBG p
in IN p
a DT p
health NN p
behavior NN p
intervention NN p
. . p

Evidence NN N
of IN N
covariation NN N
among IN N
behaviors NNS N
would MD N
suggest VB N
multi-behavior JJ N
interventions NNS N
could MD N
have VB N
synergistic JJ N
effects NNS N
. . N

METHODS NNP N
Prospective JJ N
analyses NNS N
were VBD N
conducted VBN N
with IN N
baseline NN N
and CC N
12-month JJ N
assessments NNS N
from IN N
a DT N
randomized VBN N
controlled VBN N
trial NN N
to TO N
promote VB N
improved JJ N
diet JJ o
, , o
physical JJ o
activity NN o
, , o
and CC o
sedentary JJ o
behaviors NNS o
( ( i
experimental JJ i
condition NN i
) ) i
or CC i
SUN NNP o
protection NN o
behaviors NNS o
( ( N
comparison JJ N
condition NN N
) ) N
. . N

Participants NNS p
were VBD p
adolescent JJ p
girls NNS p
and CC p
boys NNS p
( ( p
N NNP p
= NNP p
878 CD p
) ) p
aged VBN p
11-15 CD p
years NNS p
on IN p
entry NN p
. . p

The DT N
main JJ N
outcomes NNS N
were VBD N
: : N
diet NN o
, , N
based VBN N
on IN N
multiple JJ N
24-hour JJ N
recalls NNS N
( ( N
total JJ N
fat NN N
, , N
grams NNS N
of IN N
fiber NN N
, , N
servings NNS N
of IN N
fruit NN N
and CC N
vegetables NNS N
, , N
total JJ N
calories NNS N
) ) N
; : N
average JJ o
daily JJ o
energy NN o
expenditure NN o
( ( N
kcals/kg NN N
) ) N
based VBN N
on IN N
7-day JJ N
physical JJ N
activity NN N
recall VBP N
interviews NNS N
; : N
daily JJ o
minutes NNS o
of IN o
moderate-vigorous JJ o
physical JJ o
activity NN o
minutes NNS N
from IN N
accelerometery NN N
; : N
and CC N
self-reported JJ o
daily JJ o
hours NNS o
of IN o
sedentary JJ o
behavior NN o
. . o

RESULTS NNP N
Covariation NNP N
was VBD N
found VBN N
between IN N
fat NN o
and CC o
calories NNS o
( ( N
r NN N
= NNP N
.16 NNP N
) ) N
, , N
fiber NN o
and CC o
calories NNS o
( ( N
r NN N
= NNP N
.53 NNP N
) ) N
, , N
fiber NN o
and CC o
fruit/vegetables NNS o
( ( N
r NN N
= NNP N
.53 NNP N
) ) N
, , N
calories NNS o
and CC o
fruit/vegetables NNS o
( ( N
r NN N
= NNP N
.34 NNP N
) ) N
, , N
and CC N
fruit NN o
and CC o
vegetables NNS o
and CC o
sedentary JJ o
behavior NN o
( ( N
r JJ N
= NNP N
-.12 NNP N
) ) N
for IN N
the DT N
total JJ N
sample NN N
( ( N
all DT N
p NN N
values NNS N
< NNP N
.01 NNP N
) ) N
. . N

The DT N
pattern NN N
of IN N
findings NNS N
was VBD N
similar JJ N
for IN N
most JJS N
subgroups NNS N
defined VBN N
by IN N
gender NN N
and CC N
study NN N
condition NN N
. . N

CONCLUSIONS VB N
The DT N
strongest JJS N
covariation NN N
was VBD N
observed VBN N
for IN N
diet JJ o
variables NNS o
that WDT N
are VBP N
inherently RB N
related VBN N
( ( N
calories NNS N
and CC N
fat NN N
, , N
fiber NN N
, , N
and CC N
fruit/vegetables NNS N
) ) N
. . N

Little JJ N
covariation NN N
was VBD N
detected VBN N
within IN N
or CC N
between IN N
other JJ N
diet JJ o
, , o
physical JJ o
activity NN o
and CC o
sedentary JJ o
behavior NN o
domains NNS N
suggesting VBG N
that IN N
interventions NNS N
to TO N
improve VB N
these DT N
behaviors NNS N
in IN N
adolescents NNS p
need VBP N
to TO N
include VB N
specific JJ N
program NN N
components NNS N
for IN N
each DT N
target NN N
behavior NN N
of IN N
interest NN N
. . N

-DOCSTART- -15249792- O O

Effect NN N
of IN N
the DT N
dietary JJ N
approaches NNS N
to TO N
stop VB N
hypertension NN N
diet NN N
and CC N
reduced JJ N
sodium NN N
intake NN N
on IN N
blood NN N
pressure NN N
control NN N
. . N

The DT N
authors NNS N
hypothesized VBD N
that IN N
the DT N
Dietary NNP i
Approaches NNP i
to TO i
Stop VB i
Hypertension NNP i
( ( i
DASH NNP i
) ) i
diet NN i
and CC N
reduced JJ i
sodium NN i
intake NN i
would MD N
control VB N
stage NN N
1 CD N
hypertension NN N
and CC N
reduce VB N
high-normal JJ N
blood NN o
pressure NN o
( ( o
BP NNP o
) ) o
to TO N
optimal JJ N
levels NNS N
. . N

Adults NNS p
with IN p
systolic JJ p
BP NNP p
120-159 JJ p
mm NN p
Hg NNP p
and CC p
diastolic JJ p
BP NNP p
80-95 JJ p
mm NN p
Hg NNP p
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
the DT N
DASH NNP i
diet NN i
or CC i
a DT i
typical JJ i
American NNP i
( ( i
control NN i
) ) i
diet NN i
, , i
consuming VBG i
three CD i
different JJ i
sodium NN i
intakes NNS i
( ( N
higher=142 JJ N
mmol/d NN N
, , N
intermediate=107 NN N
mmol/d NN N
, , N
and CC N
lower=65 JJ N
mmol/d NN N
) ) N
for IN N
30 CD N
days NNS N
each DT N
. . N

BP NNP N
control NN N
was VBD N
defined VBN N
as IN N
systolic JJ o
BP NNP o
< NNP N
140 CD N
mm NN N
Hg NNP N
and CC N
diastolic JJ o
BP NNP o
< NNP N
90 CD N
mm NN N
Hg NNP N
. . N

Among IN N
subjects NNS p
with IN p
hypertension NN p
at IN p
baseline NN p
, , N
at IN N
higher JJR N
sodium NN N
intake VBP N
the DT N
DASH NNP N
diet NN N
increased VBD o
BP NNP o
control NN o
two-fold NN N
over IN N
control NN N
( ( N
63 CD N
% NN N
vs. FW N
32 CD N
% NN N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
1.4-2.9 JJ N
) ) N
. . N

Reducing VBG N
sodium JJ N
intake NN N
in IN N
the DT N
control NN N
diet JJ N
group NN N
increased VBD o
BP NNP o
control NN o
2.3-fold JJ N
( ( N
74 CD N
% NN N
vs. FW N
32 CD N
% NN N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
1.7-3.2 JJ N
) ) N
. . N

The DT N
maximum JJ o
BP NNP o
control NN o
rate NN o
( ( N
84 CD N
% NN N
) ) N
was VBD N
achieved VBN N
with IN N
the DT N
DASH/lower NNP N
sodium NN N
diet NN N
. . N

BP NNP o
became VBD o
normal JJ o
or CC o
optimal JJ o
in IN N
71 CD N
% NN N
of IN N
persons NNS N
consuming VBG N
the DT N
control/lower NN i
sodium NN i
diet NN i
and CC N
77 CD N
% NN N
of IN N
persons NNS N
consuming VBG N
the DT N
DASH/lower NNP i
sodium NN i
diet NN i
. . i

Both CC N
the DT N
DASH NNP N
diet NN N
and CC N
reduced JJ N
sodium NN N
intake NN N
improved VBD N
BP NNP o
control NN o
. . o

-DOCSTART- -6753091- O O

A DT N
randomized JJ N
trial NN N
of IN N
intranasal NN N
beclomethasone NN i
dipropionate NN i
after IN N
polypectomy NN N
. . N

Beneficial JJ N
effects NNS N
of IN N
intranasal NN i
beclomethasone NN i
dipropionate NN i
( ( i
Bdp NNP i
) ) i
in IN N
patients NNS p
with IN p
nasal JJ p
polyposis NN p
have VBP N
been VBN N
reported VBN N
earlier RBR N
. . N

This DT N
study NN N
was VBD N
carried VBN N
out IN N
to TO N
investigate VB N
whether IN N
long-term JJ N
treatment NN N
with IN N
Bdp NNP i
after IN N
polypectomy NN N
could MD N
prevent VB N
formation NN N
of IN N
new JJ N
polyps NNS N
and CC N
reduce VB N
the DT N
number NN N
of IN N
surgical JJ N
removals NNS N
. . N

Forty NNP p
consecutive JJ p
patients NNS p
without IN p
laboratory NN p
or CC p
other JJ p
clinical JJ p
signs NNS p
of IN p
allergy NN p
but CC p
with IN p
severe JJ p
nasal JJ p
polyposis NN p
were VBD p
included VBN p
in IN p
the DT p
study NN p
. . p

Twenty CD p
patients NNS p
were VBD p
treated VBN p
with IN p
intranasal JJ i
Bdp NNP i
and CC p
twenty JJ p
patients NNS p
received VBD p
no DT p
treatment NN p
after IN p
polypectomy NN i
. . i

All DT N
patients NNS p
were VBD p
followed VBN p
for IN p
at IN p
least JJS p
2.5 CD p
years NNS p
. . p

The DT N
size NN o
of IN o
the DT o
polyps NNS o
that WDT o
recurred VBD o
was VBD N
estimated VBN N
at IN N
different JJ N
time-intervals NNS N
by IN N
the DT N
examining VBG N
doctor NN N
. . N

After IN N
six CD N
months NNS N
there RB N
was VBD N
already RB N
a DT N
significant JJ o
difference NN o
in IN N
favour NN N
of IN N
the DT N
group NN N
treated VBD N
with IN N
intranasal JJ N
Bdp NNP i
. . i

Further NNP N
results NNS N
of IN N
the DT N
study NN N
and CC N
the DT N
clinical JJ N
implications NNS N
are VBP N
discussed VBN N
. . N

-DOCSTART- -8094114- O O

Once RB N
versus JJ N
thrice JJ N
daily JJ i
gentamicin NN i
in IN N
patients NNS p
with IN p
serious JJ p
infections NNS p
. . p

Aminoglycosides NNS N
are VBP N
usually RB N
given VBN N
in IN N
two CD N
or CC N
three CD N
divided VBN N
doses NNS N
. . N

A DT N
once-daily JJ N
regimen NN N
might MD N
be VB N
more RBR N
effective JJ N
and CC N
less RBR N
toxic JJ N
. . N

We PRP N
have VBP N
conducted VBN N
a DT N
randomised JJ N
trial NN N
in IN N
consecutive JJ p
patients NNS p
with IN p
serious JJ p
infections NNS p
for IN p
whom WP p
an DT p
aminoglycoside NN i
seemed VBD p
warranted JJ p
. . p

Exclusion NN p
criteria NNS p
were VBD p
neutropenia RB p
or CC p
severely RB p
impaired JJ p
renal JJ p
function NN p
. . p

123 CD p
patients NNS p
were VBD p
enrolled VBN p
. . p

For IN p
efficacy NN p
analysis NN p
only RB p
those DT p
patients NNS p
were VBD p
considered VBN p
in IN p
whom WP p
treatment NN p
with IN p
the DT p
aminoglycoside NN p
was VBD p
not RB p
stopped VBN p
within IN p
72 CD p
h NN p
( ( p
n JJ p
= NNP p
67 CD p
) ) p
; : p
toxicity NN p
was VBD p
analysed VBN p
on IN p
patients NNS p
receiving VBG p
aminoglycosides NNS i
for IN p
more JJR p
than IN p
48 CD p
h NNS p
and CC p
not RB p
using VBG p
other JJ p
nephrotoxic JJ p
medication NN p
( ( p
n JJ p
= NNP p
85 CD p
) ) p
. . p

Gentamicin $ i
4 CD i
mg/kg JJ i
every DT i
day NN i
( ( i
OD NNP i
) ) i
or CC i
gentamicin $ i
1.33 CD i
mg/kg NN i
three CD i
times NNS i
daily RB i
( ( i
MD NNP i
) ) i
( ( i
with IN i
dose-reduction NN i
in IN i
case NN i
of IN i
renal JJ i
dysfunction NN i
) ) i
were VBD N
given VBN N
intravenously RB N
. . N

In IN N
almost RB N
all DT N
patients NNS N
intravenous JJ i
amoxycillin JJ i
1 CD i
g NN i
every DT i
6 CD i
h NN i
was VBD N
also RB N
started VBN N
. . N

Baseline VB p
characteristics NNS p
were VBD p
comparable JJ p
in IN p
both DT p
arms NNS p
. . p

A DT N
good JJ N
clinical JJ N
response NN N
was VBD N
observed VBN N
in IN N
32/35 CD N
( ( N
91 CD N
% NN N
) ) N
of IN N
the DT N
OD NNP i
and CC N
in IN N
25/32 CD N
( ( N
78 CD N
% NN N
) ) N
in IN N
the DT N
MD NNP i
group NN N
( ( N
difference NN N
13 CD N
% NN N
, , N
95 CD N
% NN N
confidence NN N
interval JJ N
-6.4 CD N
% NN N
to TO N
+26.9 VB N
% NN N
) ) N
. . N

2 CD N
patients NNS N
in IN N
each DT N
group NN N
died VBD N
with IN N
uncontrolled JJ N
infection NN N
. . N

An DT N
insufficient JJ N
bacteriological JJ N
response NN N
( ( o
persistent JJ o
positive JJ o
cultures NNS o
, , o
resistance NN o
, , o
or CC o
superinfection NN o
) ) o
was VBD N
observed VBN N
in IN N
2 CD N
patients NNS N
with IN N
OD NNP N
and CC N
3 CD N
patients NNS N
with IN N
MD NNP N
. . N

In IN N
patients NNS N
treated VBN N
for IN N
more JJR N
than IN N
48 CD N
h JJ N
duration NN N
of IN N
therapy NN N
and CC N
mean JJ N
doses NNS N
were VBD N
7.0 CD N
days NNS N
( ( N
1590 CD N
mg NN N
) ) N
and CC N
7.4 CD N
days NNS N
( ( N
1672 CD N
mg NN N
) ) N
in IN N
OD NNP N
and CC N
MD NNP N
respectively RB N
. . N

Mean NNP o
first JJ o
serum NN o
trough/peak NN o
levels NNS o
were VBD N
0.6/10.2 CD N
mg/L NNS N
and CC N
1.4/5.2 CD N
mg/L NN N
. . N

Nephrotoxicity NNP o
( ( o
a DT o
rise NN o
in IN o
serum JJ o
creatinine NN o
of IN o
45 CD o
mumol/L NN o
or CC o
more JJR o
) ) o
developed VBD N
in IN N
2/40 CD N
( ( N
5 CD N
% NN N
) ) N
in IN N
OD NNP i
and CC N
11/45 CD N
( ( N
24 CD N
% NN N
) ) N
in IN N
MD NNP i
( ( N
p JJ N
= NNP N
0.016 CD N
) ) N
. . N

Risk NN N
factors NNS N
for IN N
nephrotoxicity NN o
were VBD N
duration NN N
of IN N
therapy NN N
and CC N
baseline NN N
creatinine JJ o
clearance NN o
rate NN o
. . o

High-tone CD o
audiometry NN o
was VBD N
performed VBN N
when WRB N
possible JJ N
; : N
no DT N
significant JJ N
differences NNS N
were VBD N
found VBN N
in IN N
hearing VBG o
loss NN o
( ( N
3/12 CD N
and CC N
3/11 CD N
) ) N
or CC N
prodromal JJ o
signs NNS o
of IN o
ototoxicity NN o
( ( N
5/12 CD N
and CC N
4/11 CD N
) ) N
. . N

A DT N
once-daily JJ i
dosing VBG i
regimen NNS i
of IN i
gentamicin NN i
is VBZ N
at IN N
least JJS N
as RB N
effective JJ N
as IN N
and CC N
is VBZ N
less RBR N
nephrotoxic JJ N
than IN N
more RBR N
frequent JJ N
dosing NN N
. . N

-DOCSTART- -19948625- O O

Aripiprazole NNP i
in IN N
the DT N
treatment NN N
of IN N
irritability NN o
in IN N
children NNS p
and CC p
adolescents NNS p
with IN p
autistic JJ p
disorder NN p
. . p

OBJECTIVE CC N
The DT N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
short-term JJ o
efficacy NN o
and CC o
safety NN o
of IN N
aripiprazole NN i
in IN N
the DT N
treatment NN N
of IN N
irritability NN o
in IN N
children NNS p
and CC p
adolescents NNS p
with IN p
autistic JJ p
disorder NN p
who WP p
were VBD p
manifesting VBG p
behaviors NNS p
such JJ p
as IN p
tantrums NNS p
, , p
aggression NN p
, , p
self-injurious JJ p
behavior NN p
, , p
or CC p
a DT p
combination NN p
of IN p
these DT p
. . p

METHODS NN N
This DT N
8-week JJ N
, , N
double-blind JJ N
, , N
randomized VBN N
, , N
placebo-controlled JJ N
, , N
parallel-group JJ N
study NN N
was VBD N
conducted VBN N
of IN N
children NNS p
and CC p
adolescents NNS p
( ( p
aged VBN p
6-17 CD p
years NNS p
) ) p
with IN p
autistic JJ p
disorder NN p
. . p

Patients NNS i
were VBD i
randomly RB i
assigned VBN i
( ( i
1:1 CD i
) ) i
to TO i
flexibly RB i
dosed JJ i
aripiprazole NN i
( ( i
target NN i
dosage NN i
: : i
5 CD i
, , i
10 CD i
, , i
or CC i
15 CD i
mg/day NN i
) ) i
or CC i
placebo NN i
. . i

Efficacy NNP N
outcome JJ N
measures NNS N
included VBD N
the DT N
Aberrant NNP o
Behavior NNP o
Checklist NNP o
irritability NN o
subscale NN o
and CC o
the DT o
Clinical JJ o
Global NNP o
Impression-Improvement NN o
score NN o
( ( o
CGI-I NNP o
) ) o
. . o

Safety NN o
and CC o
tolerability NN o
were VBD N
also RB N
assessed VBN N
. . N

RESULTS JJ N
Ninety-eight JJ p
patients NNS p
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
placebo NN i
( ( N
n JJ N
= NNP N
51 CD N
) ) N
or CC N
aripiprazole JJ N
( ( N
n JJ N
= NNP N
47 CD N
) ) N
. . N

Mean JJ N
improvement NN N
in IN N
Aberrant NNP o
Behavior NNP o
Checklist NNP o
irritability NN o
subscale NN o
score NN o
was VBD N
significantly RB N
greater JJR N
with IN N
aripiprazole NN i
than IN N
with IN N
placebo NN i
from IN N
week NN N
1 CD N
through IN N
week NN N
8 CD N
. . N

Aripiprazole NNP N
demonstrated VBD N
significantly RB N
greater JJR N
global JJ N
improvements NNS N
than IN N
placebo NN N
, , N
as IN N
assessed VBN N
by IN N
the DT N
mean JJ N
CGI-I NNP o
score NN o
from IN N
week NN N
1 CD N
through IN N
week NN N
8 CD N
; : N
however RB N
, , N
clinically RB N
significant JJ N
residual JJ o
symptoms NNS o
may MD N
still RB N
persist VB N
for IN N
some DT N
patients NNS N
. . N

Discontinuation NNP o
rates NNS o
as IN N
a DT N
result NN N
of IN N
adverse JJ N
events NNS N
( ( N
AEs NNP N
) ) N
were VBD N
10.6 CD N
% NN N
for IN N
aripiprazole NN i
and CC N
5.9 CD N
% NN N
for IN N
placebo NN i
. . i

Extrapyramidal NNP o
symptom-related JJ o
AE NNP o
rates NNS o
were VBD N
14.9 CD N
% NN N
for IN N
aripiprazole NN i
and CC N
8.0 CD N
% NN N
for IN N
placebo NN i
. . i

No DT N
serious JJ N
AEs NNP N
were VBD N
reported VBN N
. . N

Mean NNP N
weight VBD o
gain NN o
was VBD N
2.0 CD N
kg NN N
on IN N
aripiprazole NN N
and CC N
0.8 CD N
kg NN N
on IN N
placebo NN N
at IN N
week NN N
8 CD N
. . N

CONCLUSIONS NNP N
Aripiprazole NNP i
was VBD N
efficacious JJ N
in IN N
children NNS p
and CC p
adolescents NNS p
with IN p
irritability NN p
associated VBN p
with IN p
autistic JJ p
disorder NN p
and CC N
was VBD N
generally RB N
safe JJ N
and CC N
well RB N
tolerated VBN N
. . N

-DOCSTART- -2184179- O O

Topical JJ i
PUVA NNP i
, , i
etretinate NN i
, , N
and CC N
combined VBN i
PUVA NNP i
and CC i
etretinate VB i
for IN N
palmoplantar JJ N
pustulosis NN N
: : N
comparison NN N
of IN N
therapeutic JJ o
efficacy NN o
and CC N
the DT N
influences NNS N
of IN N
tonsillar JJ o
and CC p
dental JJ p
focal JJ p
infections NNS p
. . p

Twenty CD p
patients NNS p
with IN p
palmoplantar JJ p
pustulosis NN p
( ( p
PPP NNP p
) ) p
were VBD N
treated VBN N
with IN N
topical JJ i
PUVA NNP i
, , i
oral JJ i
etretinate NN i
( ( i
Re NNP i
) ) i
, , N
or CC N
combined VBN i
PUVA NNP i
and CC i
etretinate VB i
( ( i
Re-PUVA NNP i
) ) i
. . N

Re NNP N
and CC N
Re-PUVA NNP N
treated VBD N
sites NNS o
improved VBN o
and/or RB o
cleared VBN o
more RBR N
rapidly RB N
than IN N
PUVA NNP N
treated VBD N
sites NNS N
. . N

Complete JJ o
clearance NN o
was VBD N
observed VBN N
in IN N
six CD N
of IN N
ten NNS N
sites NNS N
treated VBD N
with IN N
Re-PUVA NNP N
, , N
two CD N
of IN N
ten NNS N
with IN N
Re NNP N
, , N
and CC N
one CD N
of IN N
ten NN N
sites NNS N
with IN N
PUVA NNP N
within IN N
12 CD N
weeks NNS N
. . N

UVA-control NNP N
sites VBZ N
failed VBD N
to TO N
be VB N
cleared VBN o
within IN N
12 CD N
weeks NNS N
. . N

Remission NNP o
periods NNS o
after IN N
stopping VBG N
the DT N
treatment NN N
were VBD N
1.5 CD N
+/- JJ N
0.5 CD N
weeks NNS N
( ( N
n JJ N
= NNP N
2 CD N
) ) N
with IN N
Re NNP N
, , N
10.5 CD N
+/- JJ N
11.4 CD N
weeks NNS N
( ( N
n JJ N
= NNP N
6 CD N
) ) N
with IN N
Re-PUVA NNP N
, , N
and CC N
one CD N
year NN N
( ( N
n JJ N
= NNP N
1 CD N
) ) N
with IN N
PUVA NNP N
. . N

These DT N
results NNS N
overall VBP N
suggested VBD N
that IN N
Re-PUVA NNP N
is VBZ N
the DT N
most RBS N
effective JJ N
treatment NN N
for IN N
PPP NNP N
. . N

Tonsillar NNP o
focal JJ o
infection NN o
( ( o
TFI NNP o
) ) o
and CC o
dental JJ o
focal JJ o
infection NN o
( ( o
DFI NNP o
) ) o
were VBD N
found VBN N
in IN N
6/20 CD N
and CC N
17/20 CD N
patients NNS N
, , N
respectively RB N
. . N

However RB N
, , N
the DT N
presence NN N
of IN N
focal JJ o
infection NN o
( ( o
FI NNP o
) ) o
, , o
TFI NNP o
and/or VBZ o
DFI NNP o
, , N
did VBD N
not RB N
appear VB N
to TO N
interfere VB N
with IN N
the DT N
therapeutic JJ N
activities NNS N
of IN N
Re NNP N
and/or NN N
PUVA NNP N
, , N
because IN N
the DT N
complete JJ o
clearance NN o
rates NNS o
and CC o
remission NN o
periods NNS o
in IN N
FI NNP N
( ( N
+ NNP N
) ) N
patients NNS N
were VBD N
comparable JJ N
with IN N
those DT N
in IN N
FI NNP N
( ( N
- : N
) ) N
patients NNS N
. . N

-DOCSTART- -25572620- O O

Efficacy NN o
of IN N
a DT N
tobacco NN i
quitline NN i
among IN N
adult JJ p
cancer NN p
survivors NNS p
. . p

OBJECTIVE IN N
The DT N
purpose NN N
of IN N
the DT N
study NN N
( ( p
conducted VBN p
2010-2013 CD p
) ) p
was VBD N
to TO N
determine VB N
the DT N
efficacy NN N
of IN N
two CD N
common JJ N
types NNS N
of IN N
tobacco NN i
quitlines NNS i
in IN N
adult NN p
cancer NN p
survivors NNS p
who WP p
regularly RB p
smoked VBD p
cigarettes NNS p
. . p

METHOD NNP N
Adult NNP p
onset VBD p
cancer NN p
survivors NNS p
in IN p
Memphis NNP p
, , p
Tennessee NNP p
( ( p
n=427 UH p
, , p
67 CD p
% NN p
female NN p
, , p
60 CD p
% NN p
Caucasian JJ p
) ) p
were VBD N
randomized VBN N
either RB N
to TO N
a DT N
Proactive NNP i
( ( i
i.e. FW i
, , N
counselor-initiated JJ i
calls NNS i
) ) i
or CC N
Reactive NNP i
( ( N
i.e. FW N
, , N
participant-initiated JJ i
calls NNS i
) ) i
quitline NN N
. . N

Both DT N
conditions NNS N
also RB N
received VBD N
nicotine JJ i
replacement NN i
therapy NN i
. . i

The DT N
primary JJ N
outcome NN N
was VBD N
biochemically-verified JJ N
( ( N
i.e. FW N
, , N
salivary JJ N
cotinine NN N
) ) N
smoking NN o
cessation NN o
. . o

RESULTS NNP N
While IN N
12-month JJ N
self-reported JJ N
abstinence NN N
was VBD N
consistent JJ N
with IN N
other JJ N
published VBN N
studies NNS N
of IN N
smoking VBG o
cessation NN o
( ( N
22 CD N
% NN N
and CC N
26 CD N
% NN N
point NN N
prevalence NN N
abstinence NN N
for IN N
Proactive NNP N
and CC N
Reactive NNP N
conditions NNS N
, , N
respectively RB N
) ) N
, , N
48 CD N
% NN N
of IN N
participants NNS N
who WP N
were VBD N
tested VBN N
for IN N
cotinine NN N
failed VBD N
biochemical JJ N
verification NN N
, , N
indicating VBG N
a DT N
considerable JJ N
falsification NN N
of IN N
self-reported JJ o
cessation NN o
. . o

Adjusted VBN o
cessation NN o
rates NNS o
were VBD N
less JJR N
than IN N
5 CD N
% NN N
in IN N
both DT N
intervention NN N
conditions NNS N
. . N

CONCLUSION NNP N
Our PRP$ N
results NNS N
are VBP N
consistent JJ N
with IN N
other JJ N
studies NNS N
indicating VBG N
that IN N
traditional JJ o
smoking NN o
cessation NN o
interventions NNS o
are VBP N
ineffective JJ N
among IN N
cancer NN N
survivors NNS N
. . N

Moreover RB N
, , N
self-reports NNS o
of IN o
cessation NN o
were VBD N
unreliable JJ N
in IN N
cancer NN N
survivors NNS N
participating VBG N
in IN N
a DT N
quitline NN i
intervention NN i
, , N
indicating VBG N
that IN N
future JJ N
studies NNS N
should MD N
include VB N
biochemical JJ N
verification NN N
. . N

Given VBN N
the DT N
importance NN N
of IN N
smoking VBG N
cessation NN N
among IN N
cancer NN p
survivors NNS p
and CC N
low JJ N
cessation NN o
rates NNS o
in IN N
the DT N
current JJ N
study NN N
, , N
it PRP N
may MD N
be VB N
necessary JJ N
to TO N
design VB N
alternative JJ N
interventions NNS N
for IN N
this DT N
population NN N
. . N

ClinicalTrials.gov NNP N
identifier NN N
: : N
NCT00827866 NNP N
. . N

-DOCSTART- -22465904- O O

Evaluation NN N
of IN N
oral JJ i
zinc NN i
sulfate NN i
effect NN N
on IN N
obsessive-compulsive JJ o
disorder NN o
: : o
a DT N
randomized JJ N
placebo-controlled JJ i
clinical JJ N
trial NN N
. . N

OBJECTIVE CC N
Obsessive-compulsive JJ N
disorder NN N
is VBZ N
a DT N
common JJ N
neuropsychiatric JJ N
condition NN N
. . N

Although IN N
various JJ N
pharmaceutical JJ N
agents NNS N
are VBP N
available JJ N
for IN N
the DT N
treatment NN N
of IN N
obsessive-compulsive JJ N
disorder NN N
, , N
psychiatrists NNS N
often RB N
find VBP N
that IN N
many JJ N
patients NNS N
can MD N
not RB N
tolerate VB N
the DT N
side NN o
effects NNS o
of IN N
these DT N
medications NNS N
, , N
the DT N
patients NNS N
do VBP N
not RB N
respond VB N
properly RB N
to TO N
the DT N
treatment NN N
, , N
or CC N
the DT N
medications NNS N
lose VBP N
their PRP$ N
effectiveness NN N
after IN N
a DT N
period NN N
of IN N
treatment NN N
. . N

The DT N
augmentation NN N
with IN N
safe JJ N
supplementation NN N
of IN N
medication NN N
, , N
such JJ N
as IN N
with IN N
trace NN N
elements NNS N
, , N
may MD N
be VB N
a DT N
solution NN N
to TO N
some DT N
of IN N
these DT N
problems NNS N
. . N

METHODS NNP N
This DT N
study NN N
was VBD N
a DT N
prospective JJ N
, , N
double-blinded JJ N
, , N
8-wk JJ N
trial NN N
. . N

Twelve CD p
patients NNS p
were VBD p
given VBN p
fluoxetine NN i
( ( p
20 CD p
mg/d NN p
) ) p
plus CC i
zinc NN i
( ( p
440 CD p
mg/d NN p
) ) p
and CC p
11 CD p
patients NNS p
were VBD p
given VBN p
fluoxetine JJ i
plus CC i
placebo NN i
for IN p
8 CD p
wk NNS p
. . p

RESULTS NNP N
Both NNP N
groups NNS N
showed VBD N
a DT N
decrease NN N
in IN N
the DT o
mean JJ o
Yale-Brown JJ o
Obsessive-Compulsive JJ o
Scale NNP o
score NN o
. . o

Based VBN N
on IN N
t NN N
tests NNS N
, , N
in IN N
weeks NNS N
2 CD N
and CC N
8 CD N
, , N
patients NNS N
treated VBD N
with IN i
fluoxetine JJ i
plus CC i
zinc NN i
had VBD N
significantly RB N
lower JJR o
scores NNS o
than IN N
those DT N
treated VBN N
with IN i
fluoxetine JJ i
plus CC i
placebo NN i
. . i

CONCLUSION VB N
The DT N
results NNS N
show VBP N
that IN i
zinc NN i
, , i
as IN N
adjuvant JJ N
agent NN N
for IN o
obsessive-compulsive JJ o
disorder NN o
, , o
produces VBZ N
improved JJ o
outcomes NNS o
. . o

-DOCSTART- -22585469- O O

Effectiveness NN N
and CC N
safety NN N
of IN N
the DT N
Levitan NNP i
FPS NNP i
Scope? NNP i
for IN i
tracheal JJ p
intubation NN p
under IN p
general JJ p
anesthesia NN p
with IN p
a DT N
simulated JJ p
difficult JJ p
airway NN p
. . p

PURPOSE NNP N
Studies NNP N
show VBP N
that IN N
the DT i
Levitan NNP i
FPS NNP i
( ( i
first JJ i
pass NN i
success NN i
) ) i
Scope? NNP i
( ( i
LFS NNP i
) ) i
is VBZ i
analogous JJ N
to TO N
a DT N
bougie NN N
in IN N
simulated JJ N
difficult JJ N
airways NNS N
with IN N
comparable JJ N
tracheal JJ N
intubation NN N
success NN N
rates NNS N
. . N

In IN N
this DT N
study NN N
, , N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
tracheal JJ N
intubation NN N
with IN N
the DT N
LFS NNP N
was VBD N
compared VBN N
with IN N
that DT N
of IN N
the DT N
Macintosh NNP N
laryngoscope NN N
utilizing VBG N
manual JJ N
in-line JJ N
stabilization NN N
( ( N
MILS NNP N
) ) N
to TO N
simulate VB N
difficult JJ N
airways NNS N
. . N

METHODS NNP p
Ninety-four JJ p
subjects NNS p
successfully RB p
completed VBD p
the DT p
trial NN p
. . p

Manual JJ p
in-line JJ N
stabilization NN N
of IN N
the DT N
cervical JJ N
spine NN N
was VBD N
applied VBN N
and CC N
the DT N
initial JJ i
laryngoscopy NN i
was VBD i
performed VBN N
using VBG N
either CC N
the DT N
Macintosh NNP i
or CC i
the DT i
LFS NNP i
in IN i
conjunction NN i
with IN i
the DT i
Macintosh NNP i
. . i

Following VBG i
the DT N
initial JJ N
grading NN i
, , i
a DT i
second JJ i
laryngoscopy NN i
was VBD i
repeated VBN N
using VBG N
the DT N
second JJ N
randomized JJ N
technique NN o
. . o

Cormack-Lehane NNP o
grades NNS o
, , o
percentage NN o
of IN o
glottic JJ o
opening NN o
( ( o
POGO NNP o
) ) o
scores VBZ o
, , o
time NN o
to TO o
intubate VB o
, , o
number NN o
of IN o
intubation NN o
attempts NNS o
, , o
and CC o
the DT o
use NN o
of IN o
alternate NN o
techniques NNS o
were VBD o
recorded VBN N
. . N

The DT N
anesthesiologist NN N
rated VBD N
the DT N
subjective JJ N
difficulty NN N
in IN N
using VBG N
each DT N
technique NN N
with IN N
a DT o
numeric JJ o
rating NN o
scale NN o
and CC o
a DT o
visual JJ o
rating NN o
scale NN o
. . o

RESULTS NNP o
There EX N
was VBD N
no DT o
significant JJ o
difference NN o
in IN o
the DT N
primary JJ o
outcome NN o
good JJ o
laryngoscopic NN o
views NNS o
( ( o
Cormack-Lehane NNP o
grade VBD o
1 CD o
and CC o
2 CD o
) ) o
compared VBN N
with IN N
poor JJ o
laryngoscopic JJ o
views NNS o
( ( o
Cormack-Lehane NNP o
grade VBD o
3 CD o
and CC o
4 CD o
) ) o
between IN N
the DT N
LFS NNP N
and CC N
the DT N
Macintosh NNP N
. . N

There EX N
were VBD N
higher JJR o
POGO NNP o
scores NNS o
with IN o
the DT N
LFS NNP N
compared VBN N
with IN N
the DT N
Macintosh NNP N
( ( N
80 CD N
% NN N
vs JJ N
20 CD N
% NN N
, , N
respectively RB N
; : N
P NNP N
< NNP N
0.0001 CD N
) ) N
, , N
but CC N
this DT N
did VBD N
not RB N
translate VB N
to TO N
easier JJR N
intubations NNS N
, , N
as IN N
documented VBN N
by IN N
the DT N
need NN N
for IN N
an DT N
alternate JJ N
intubation NN N
technique NN N
or CC N
time NN N
to TO N
intubate VB N
( ( N
< JJ N
30 CD N
and CC N
< $ N
60 CD N
sec NN N
, , N
respectively RB N
) ) N
. . N

The DT N
incidence NN o
of IN o
mucosal NN o
trauma NN o
, , o
sore RB o
throat NN o
, , o
and CC o
hemodynamic JJ o
responses NNS o
did VBD o
not RB o
differ VB o
significantly RB o
between IN N
the DT N
two CD N
techniques NNS N
. . N

CONCLUSION VB N
The DT N
LFS NNP N
in IN N
conjunction NN N
with IN N
the DT N
Macintosh NNP i
laryngoscope NN i
does VBZ i
not RB N
improve VB N
the DT N
efficacy NN N
or CC N
safety NN N
of IN N
tracheal JJ N
intubation NN N
in IN N
a DT N
simulated JJ p
difficult JJ p
airway NN p
. . p

-DOCSTART- -14670288- O O

The DT N
efficacy NN N
of IN N
sublingual JJ i
immunotherapy NN i
for IN N
respiratory NN N
allergy NN N
is VBZ N
not RB N
affected VBN N
by IN N
different JJ N
dosage NN N
regimens NNS N
in IN N
the DT N
induction NN N
phase NN N
. . N

BACKGROUND NNP N
Sublingual NNP i
administration NN i
of IN i
allergens NNS i
is VBZ N
a DT N
safe JJ N
and CC N
effective JJ N
alternative NN N
to TO N
subcutaneous JJ N
immunotherapy NN N
in IN N
patients NNS p
with IN p
respiratory JJ p
allergies NNS p
. . p

A DT N
drawback NN N
to TO N
this DT N
therapeutic JJ N
approach NN N
is VBZ N
the DT N
relatively RB N
long JJ N
and CC N
complex JJ N
management NN N
of IN N
the DT N
induction NN N
phase NN N
. . N

AIM NNP N
OF IN N
THE NNP N
STUDY NNP N
To TO N
determine VB N
whether IN N
different JJ N
induction NN N
regimens NNS N
affect VBP N
the DT N
outcome NN N
of IN N
sublingual JJ i
immunotherapy NN i
. . i

METHODS NNP N
AND CC N
RESULTS NNP N
Adult NNP p
and CC p
pediatric JJ p
patients NNS p
with IN p
allergic JJ p
rhinoconjunctivitis NN p
and/or NN p
asthma NN p
were VBD p
included VBN p
in IN p
the DT p
study NN p
. . p

Ten CD p
subjects VBZ p
served VBN N
as IN N
controls NNS N
and CC N
received VBN N
symptomatic JJ i
treatments NNS i
. . i

Forty-three JJ p
subjects NNS p
were VBD N
allocated VBN N
to TO N
sublingual JJ i
immunotherapy NN i
, , i
with IN i
three CD i
different JJ i
induction NN i
protocols NNS i
( ( i
8- CD i
, , i
15- CD i
and CC i
20-day JJ i
, , i
respectively RB i
) ) i
. . N

Symptom NNP o
and CC o
medication NN o
scores NNS o
, , o
skin JJ o
test NN o
results NNS o
and CC o
( ( o
in IN o
asthmatic JJ o
patients NNS o
) ) o
FEV1 NNP o
values NNS o
were VBD N
monitored VBN N
for IN N
two CD N
years NNS N
. . N

Adverse JJ o
effects NNS o
were VBD N
recorded VBN N
. . N

All DT N
induction NN N
regimens NNS N
produced VBD N
a DT N
significant JJ o
improvement NN o
in IN o
symptom NN o
and CC o
medication NN o
usage NN o
( ( N
p JJ N
< NNP N
0.0001 CD N
) ) N
; : N
skin JJ o
test NN o
scores NNS o
decreased VBN o
( ( N
p JJ N
< NNP N
0.0001 CD N
) ) N
and CC N
FEV1 NNP o
improved VBD o
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

In IN N
contrast NN N
, , N
symptom NN o
and CC o
skin JJ o
test NN o
scores NNS o
did VBD o
not RB o
significantly RB N
change VBP o
in IN N
controls NNS N
. . N

No DT o
relevant JJ N
adverse JJ o
effects NNS o
were VBD N
observed VBN N
with IN N
any DT N
of IN N
the DT N
induction NN N
regimens VBZ N
. . N

CONCLUSIONS NNP N
For IN N
patients NNS p
with IN p
respiratory JJ p
allergies NNS p
, , N
sublingual JJ i
immunotherapy NN i
with IN N
an DT N
8-day JJ N
induction NN N
protocol NN N
is VBZ N
safe JJ N
and CC N
effective JJ N
. . N

Our PRP$ N
results NNS N
encourage VB N
the DT N
usage NN N
of IN N
shorter JJR N
induction NN N
regimens NNS N
, , N
which WDT N
produce VBP N
better JJR N
compliance NN N
with IN N
this DT N
therapy NN N
. . N

-DOCSTART- -15940774- O O

Efficacy NN N
of IN N
rofecoxib NN i
, , i
celecoxib NN i
, , N
and CC N
acetaminophen NN i
in IN N
patients NNS p
with IN p
osteoarthritis NN p
of IN p
the DT p
knee NN p
. . p

A DT N
combined JJ N
analysis NN N
of IN N
the DT N
VACT NNP N
studies NNS N
. . N

OBJECTIVE NNP N
To TO N
compare VB N
efficacy NN N
among IN N
1578 CD p
patients NNS p
with IN p
osteoarthritis JJ p
randomized VBN N
to TO N
take VB N
acetaminophen NN i
4000 CD N
mg NN N
( ( N
n=269 JJ N
) ) N
, , N
celecoxib $ i
200 CD N
mg NN N
( ( N
n=523 JJ N
) ) N
, , N
rofecoxib VBZ i
12.5 CD N
mg NN N
( ( N
n=259 JJ N
) ) N
, , N
or CC N
rofecoxib VB i
25 CD N
mg NN N
( ( N
n=527 JJ N
) ) N
in IN N
a DT N
double JJ N
blind NN N
trial NN N
[ NNP i
Vioxx NNP i
, , i
Acetaminophen NNP i
, , i
Celecoxib NNP i
Trial NNP N
( ( N
VACT2 NNP N
) ) N
] NN N
. . N

Results NNS N
were VBD N
also RB N
pooled VBN N
with IN N
the DT N
similarly RB N
designed VBN N
VACT1 NNP N
trial NN N
. . N

METHODS NNP N
Patients NNPS N
evaluated VBD N
over IN N
Days NNP N
1 CD N
to TO N
6 CD N
and CC N
6 CD N
weeks NNS N
with IN N
Patient NNP o
Global NNP o
Assessment NNP o
of IN o
Response NNP o
to TO o
Therapy NNP o
( ( o
PGART NNP o
) ) o
and CC o
Western JJ o
Ontario NNP o
and CC o
McMaster NNP o
Universities NNP o
( ( o
WOMAC NNP o
) ) o
Osteoarthritis NNP o
Index NNP o
. . o

RESULTS NNP N
For IN N
VACT2 NNP N
, , N
median JJ o
time NN o
to TO o
good JJ o
or CC o
excellent JJ o
PGART NNP o
response NN o
was VBD N
6 CD N
, , N
5 CD N
, , N
4 CD N
, , N
and CC N
3 CD N
days NNS N
for IN N
acetaminophen NN i
, , i
celecoxib NN i
, , i
rofecoxib VBZ i
12.5 CD N
mg NN N
, , N
and CC N
rofecoxib VBZ i
25 CD N
mg NN N
( ( N
COX-2 JJ N
inhibitors NNS N
vs VBP N
acetaminophen NN i
, , N
p NN N
< NNP N
or=0.035 NN N
; : N
rofecoxib CC i
25 CD N
mg NN N
vs NN N
celecoxib NN i
, , N
p=0.01 NN N
) ) N
. . N

WOMAC NNP o
response NN o
over IN N
the DT N
first JJ N
6 CD N
days NNS N
was VBD N
greater JJR N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
with IN N
both DT N
rofecoxib NN i
doses VBZ N
than IN N
acetaminophen NN N
and CC N
celecoxib NN N
. . N

At IN N
Week JJ N
6 CD N
, , N
all DT N
COX-2 NNP N
inhibitors NNS N
provided VBD N
significantly RB N
greater JJR o
efficacy NN o
than IN N
acetaminophen NN N
. . N

Good JJ N
or CC N
excellent JJ N
PGART NNP o
was VBD N
numerically RB N
, , N
but CC N
not RB N
significantly RB N
, , N
greater JJR N
with IN N
rofecoxib NN i
25 CD N
mg NN N
( ( N
55.4 CD N
% NN N
) ) N
than IN N
celecoxib NN i
( ( N
50.6 CD N
% NN N
) ) N
at IN N
Week NNP N
6 CD N
; : N
a DT N
significant JJ N
difference NN N
was VBD N
seen VBN N
at IN N
Weeks NNP N
2 CD N
( ( N
6.9 CD N
, , N
p=0.022 NN N
) ) N
and CC N
4 CD N
( ( N
6.7 CD N
, , N
p=0.027 NN N
) ) N
and CC N
over IN N
6 CD N
weeks NNS N
with IN N
analysis NN N
of IN N
all DT N
5 CD N
PGART NNP o
categories NNS N
of IN N
response NN N
( ( N
p=0.035 NN N
) ) N
. . N

Rofecoxib $ i
25 CD N
mg NN N
provided VBD N
greater JJR N
response NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
than IN N
celecoxib NN i
on IN N
WOMAC NNP o
subscales NNS o
. . o

Pooled VBD N
analysis NN N
of IN N
VACT1/VACT2 NNP N
demonstrated VBD N
greater JJR o
PGART NNP o
( ( N
p=0.023 NN N
) ) N
with IN N
rofecoxib NN i
25 CD N
mg NN N
( ( N
56.1 CD N
% NN N
) ) N
than IN N
celecoxib NN i
( ( N
49.8 CD N
% NN N
) ) N
at IN N
6 CD N
weeks NNS N
and CC N
greater JJR o
response NN o
to TO o
all DT o
other JJ o
PGART NNP o
and CC o
WOMAC NNP o
endpoints NNS o
, , N
and CC N
confirmed VBD N
superiority NN N
of IN N
COX-2 NNP N
inhibitors NNS N
to TO N
acetaminophen VB i
. . i

Overall NNP N
, , N
tolerability NN o
of IN N
the DT N
study NN N
medications NNS N
was VBD N
generally RB N
good JJ o
and CC o
similar JJ o
. . o

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
treatment NN N
groups NNS N
in IN N
the DT N
percentage NN N
of IN N
patients NNS N
who WP N
experienced VBD N
a DT N
clinical JJ o
adverse JJ o
experience NN o
( ( o
AE NNP o
) ) o
. . o

The DT N
incidence NN N
of IN N
discontinuations NNS o
due JJ o
to TO o
an DT o
AE NNP o
was VBD N
significantly RB N
lower JJR N
with IN N
celecoxib NN i
( ( N
2.5 CD N
% NN N
) ) N
compared VBN N
to TO N
rofecoxib VB i
25 CD N
mg NN N
( ( N
6.3 CD N
% NN N
, , N
p=0.004 NN N
) ) N
or CC N
acetaminophen NN i
( ( N
7.8 CD N
% NN N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
, , N
and CC N
did VBD N
not RB N
differ VB N
significantly RB N
from IN N
rofecoxib JJ N
12.5 CD N
mg NN N
( ( N
4.6 CD N
% NN N
) ) N
. . N

Discontinuation NN o
rates NNS o
due JJ N
to TO N
edema VB o
and CC o
hypertension NN o
related VBN o
AE NNP o
were VBD N
similar JJ N
among IN N
all DT N
COX-2 NNP N
inhibitors NNS N
. . N

CONCLUSION NNP N
Rofecoxib NNP i
and CC N
celecoxib NN i
provided VBD N
superior JJ N
efficacy NN o
to TO N
acetaminophen VB i
. . i

There EX N
was VBD N
a DT N
more RBR N
rapid JJ N
and CC N
greater JJR N
response NN o
with IN N
rofecoxib JJ N
25 CD N
mg NN N
than IN N
celecoxib $ i
200 CD N
mg. NN N
Rofecoxib NNP i
12.5 CD N
mg NN N
demonstrated VBD N
greater JJR N
efficacy NN o
than IN N
celecoxib $ i
200 CD N
mg NN N
over IN N
the DT N
first JJ N
6 CD N
days NNS N
, , N
and CC N
was VBD N
similar JJ N
over IN N
6 CD N
weeks NNS N
. . N

All DT N
study NN N
medications NNS N
were VBD N
generally RB N
well RB o
tolerated VBN o
. . o

-DOCSTART- -16772581- O O

Milk NNP o
production NN o
of IN N
dairy NN p
cows NNS p
fed VBP N
wet JJ N
corn NN N
gluten NNS N
feed VBP N
during IN N
the DT N
dry JJ N
period NN N
and CC N
lactation NN N
. . N

An DT N
experiment NN N
was VBD N
conducted VBN N
with IN N
36 CD p
primiparous JJ p
and CC p
40 CD p
multiparous JJ p
Holstein NNP p
cows NNS p
to TO N
examine VB N
the DT N
effects NNS N
of IN N
feeding VBG N
wet JJ i
corn NN i
gluten NNS i
feed VBP i
( ( i
WCGF NNP i
) ) i
on IN N
305-d JJ N
milk NN o
production NN o
, , o
dry JJ o
matter NN o
( ( o
DM NNP o
) ) o
intake NN o
, , o
body NN o
condition NN o
score NN o
( ( o
BCS NNP o
) ) o
, , o
and CC o
health NN o
. . o

The DT N
experimental JJ N
treatments NNS N
included VBD N
: : N
1 CD N
) ) N
control NN i
-- : i
WCGF NNP i
not RB i
fed RB i
( ( i
n JJ i
= NNP i
27 CD i
) ) i
; : i
2 CD i
) ) i
WCGF-L-cows NNP i
received VBD i
diets NNS i
containing VBG i
WCGF NNP i
( ( i
38 CD i
% NN i
DM NNP i
basis NN i
) ) i
during IN i
lactation NN i
( ( i
n JJ i
= NNP i
23 CD i
) ) i
; : i
and CC i
3 CD i
) ) i
WCGF-DL NNP i
-- : i
cows VBZ i
received VBN i
diets NNS i
containing VBG i
WCGF NNP i
( ( i
38 CD i
% NN i
DM NNP i
basis NN i
) ) i
during IN i
the DT i
dry JJ i
period NN i
and CC i
lactation NN i
( ( i
n JJ i
= NNP i
26 CD i
) ) i
. . i

During IN N
the DT N
dry JJ N
period NN N
, , N
cows VBZ p
consuming VBG p
WCGF NNP p
were VBD N
observed VBN N
to TO N
have VB N
a DT N
significant JJ N
gain NN N
in IN N
BCS NNP N
( ( N
0.07 CD N
+/- JJ N
0.06 CD N
) ) N
compared VBN N
with IN N
a DT N
loss NN N
in IN N
BCS NNP N
in IN N
cows NNS N
fed VBP N
the DT N
control NN N
diet JJ N
( ( N
control VB N
= NNP N
-0.11 NNP N
+/- JJ N
0.06 CD N
and CC N
WCGF-L NNP N
= NNP N
-0.04 NNP N
+/- JJ N
0.06 CD N
) ) N
. . N

During IN N
lactation NN N
, , N
there EX N
were VBD N
no DT N
differences NNS N
by IN N
treatment NN N
on IN N
BCS NNP N
. . N

Cows NNP N
consuming VBG p
WCGF NNP p
during IN N
lactation NN N
consumed VBN N
more RBR N
feed JJ o
compared VBN N
with IN N
the DT N
control NN N
: : N
25.4 CD N
, , N
23.8 CD N
, , N
and CC N
21.2 CD N
+/- JJ N
0.76 CD N
kg/d NN N
for IN N
WCGF-L NNP N
, , N
WCGF-DL NNP N
, , N
and CC N
the DT N
control NN N
, , N
respectively RB N
. . N

Milk NNP o
production NN o
was VBD N
higher JJR N
for IN N
cows NNS N
consuming VBG N
WCGF NNP N
: : N
35.0 CD N
, , N
34.7 CD N
, , N
and CC N
31.1 CD N
+/- JJ N
2.1 CD N
kg/d NN N
for IN N
WCGF-L NNP N
, , N
WCGF-DL NNP N
, , N
and CC N
the DT N
control NN N
, , N
respectively RB N
. . N

No UH N
differences NNS N
were VBD N
found VBN N
in IN N
either DT N
DM NNP o
intake NN o
or CC o
actual JJ o
milk NN o
yield NN o
between IN N
the DT N
WCGF-L NNP N
and CC N
WCGF-DL NNP N
treatments NNS N
, , N
indicating VBG N
that IN N
prepartum JJ N
diets NNS N
did VBD N
not RB N
influence VB N
lactational JJ N
performance NN N
. . N

The DT N
WCGF NNP N
diets NNS N
resulted VBD N
in IN N
significant JJ N
reductions NNS N
in IN N
the DT N
concentration NN o
of IN o
milk NN o
fat NN o
( ( N
3.94 CD N
, , N
3.74 CD N
, , N
and CC N
4.15 CD N
+/- JJ N
0.08 CD N
% NN N
for IN N
WCGF-L NNP N
, , N
WCGF-DL NNP N
, , N
and CC N
the DT N
control NN N
, , N
respectively RB N
) ) N
, , N
but CC N
because IN N
total JJ o
milk NN o
yield NN o
was VBD N
increased VBN N
, , N
there EX N
were VBD N
no DT N
differences NNS N
in IN N
total JJ N
milk NN N
fat JJ N
yield NN N
. . N

In IN N
addition NN N
, , N
3.5 CD N
% NN N
of IN N
fat-corrected JJ N
milk NN N
tended VBN N
to TO N
be VB N
affected VBN N
by IN N
diet JJ N
: : N
38.9 CD N
, , N
36.3 CD N
, , N
and CC N
34.7 CD N
+/- JJ N
1.93 CD N
kg/d NN N
for IN N
WCGF-L NNP N
, , N
WCGF-DL NNP N
, , N
and CC N
the DT N
control NN N
, , N
respectively RB N
. . N

The DT N
increasing VBG N
effect NN N
of IN N
DM NNP o
intake NN o
and CC o
milk NN o
yield NN o
in IN N
cows NNS N
consuming VBG N
WCGF NNP N
resulted VBD N
in IN N
a DT N
similar JJ N
efficiency NN N
of IN N
3.5 CD N
% NN N
fat-corrected JJ N
milk NN o
production NN o
for IN N
all DT N
treatments NNS N
, , N
averaging VBG N
1.5 CD N
+/- JJ N
0.09 CD N
. . N

Total JJ o
protein JJ o
yields NNS o
were VBD N
significantly RB N
higher JJR N
for IN N
cows NNS N
consuming VBG N
WCGF NNP N
diets NNS N
during IN N
lactation NN N
: : N
1.15 CD N
, , N
1.10 CD N
, , N
1.00 CD N
+/- JJ N
0.06 CD N
kg/d NN N
for IN N
WCGF-L NNP N
, , N
WCGF-DL NNP N
, , N
and CC N
the DT N
control NN N
, , N
respectively RB N
. . N

These DT N
results NNS N
indicate VBP N
that IN N
diets NNS N
may MD N
be VB N
formulated VBN N
to TO N
contain VB N
as RB N
much JJ N
as IN N
37.5 CD N
% NN N
WCGF NNP N
( ( N
DM NNP N
basis NN N
) ) N
. . N

-DOCSTART- -11143509- O O

[ JJ o
Complication NNP o
rate NN o
after IN N
gastrectomy NN N
and CC N
pouch JJ N
reconstruction NN N
with IN N
Longmire NNP i
interposition NN i
] NNP i
. . N

BACKGROUND/AIMS NNP N
To TO N
determine VB N
whether IN N
a DT N
Longmire-Interposition NN i
with IN N
or CC N
without IN N
a DT N
pouch NN N
used VBN N
for IN N
reconstruction NN N
after IN N
gastrectomy JJ N
influences VBZ N
the DT N
postoperative JJ N
complication NN N
rate NN N
. . N

METHODOLOGY CC N
49 CD p
patients NNS p
who WP p
underwent JJ p
gastrectomy NN i
with IN p
Longmire-Interposition NNP i
with IN p
( ( p
n JJ p
= NNP p
33 CD p
) ) p
or CC p
without IN p
( ( p
n JJ p
= NNP p
16 CD p
) ) p
an DT p
additional JJ p
pouch NN p
and CC p
46 CD p
patients NNS p
with IN p
a DT p
Roux-en-Y-reconstruction NN i
were VBD N
analysed VBN N
retrospectively RB N
. . N

Complication NN o
rate NN o
and CC o
mortality NN o
were VBD N
studied VBN N
. . N

RESULTS VB N
There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
the DT N
reconstruction NN N
groups NNS N
for IN N
postoperative JJ o
complications NNS o
( ( N
Roux-en-Y JJ N
vs. IN N
Longmire-Interposition NNP i
with IN N
and CC N
without IN N
pouch JJ N
: : N
30.4 CD N
% NN N
vs. FW N
28.6 CD N
% NN N
for IN N
the DT N
morbidity NN o
; : o
4.3 CD N
% NN N
vs. FW N
4.1 CD N
% NN N
for IN N
the DT N
mortality NN o
) ) o
. . N

CONCLUSION NNP N
These DT N
findings NNS N
suggest VBP N
that IN N
a DT N
Longmire-Interposition NN i
with IN N
or CC N
without IN N
a DT N
pouch NN N
for IN N
reconstruction NN N
after IN N
total JJ N
gastrectomy NN N
is VBZ N
not RB N
connected VBN N
with IN N
a DT N
higher JJR o
morbidity NN o
or CC o
mortality NN o
in IN N
comparison NN N
to TO N
a DT N
Roux-en-Y-reconstruction NN N
. . N

-DOCSTART- -3516608- O O

Veterans NNS N
Administration NNP N
Cooperative NNP N
Study NNP N
on IN N
antiplatelet NN i
agents NNS i
in IN N
diabetic JJ p
patients NNS p
after IN p
amputation NN p
for IN p
gangrene NN p
: : p
II NNP p
. . p

Effects NNS N
of IN N
aspirin NN i
and CC N
dipyridamole NN i
on IN N
atherosclerotic JJ o
vascular JJ o
disease NN o
rates NNS o
. . o

We PRP N
report VBP N
the DT N
results NNS N
of IN N
a DT N
randomized JJ N
multicenter NN N
clinical JJ N
trial NN N
on IN N
the DT N
effects NNS N
of IN N
aspirin JJ i
plus CC i
dipyridamole JJ i
versus NN i
placebo NN i
on IN N
major JJ N
vascular JJ o
end NN o
points NNS o
in IN N
231 CD p
non-insulin-dependent JJ p
diabetic JJ p
men NNS p
with IN p
either DT p
a DT p
recent JJ p
amputation NN p
for IN p
gangrene NN p
or CC p
active JJ p
gangrene NN p
. . p

Primary JJ N
end NN N
points NNS N
were VBD N
death NN o
from IN o
atherosclerotic JJ o
vascular JJ o
disease NN o
plus CC o
amputation NN o
of IN o
the DT o
opposite JJ o
extremity NN o
for IN o
gangrene NN o
. . o

There EX N
were VBD N
24 CD N
atherosclerotic JJ o
deaths NNS o
in IN N
the DT N
drug NN N
treatment NN N
group NN N
( ( N
21.8 CD N
% NN N
) ) N
and CC N
23 CD N
in IN N
the DT N
placebo NN i
group NN N
( ( N
19.0 CD N
% NN N
) ) N
. . N

There EX N
were VBD N
22 CD N
patients NNS N
in IN N
the DT N
drug NN N
treatment NN N
group NN N
( ( N
20.0 CD N
% NN N
) ) N
and CC N
29 CD N
patients NNS N
in IN N
the DT N
placebo NN N
group NN N
( ( N
24.0 CD N
% NN N
) ) N
with IN N
opposite-side JJ o
amputations NNS o
. . o

Survival NNP N
curve NN N
analyses NNS N
revealed VBD N
little JJ N
difference NN N
between IN N
these DT N
groups NNS N
for IN N
major JJ o
vascular JJ o
end NN o
points NNS o
, , o
total JJ o
mortality NN o
, , o
all DT o
amputations NNS o
, , o
or CC o
myocardial JJ o
infarctions NNS o
. . o

The DT N
most RBS N
noteworthy JJ N
group NN N
difference NN N
was VBD N
observed VBN N
for IN N
cerebrovascular JJ o
end NN o
points NNS o
( ( o
strokes NNS o
and CC o
transient JJ o
ischemic JJ o
attacks NNS o
) ) o
, , N
with IN N
an DT N
incidence NN N
of IN N
8.2 CD N
% NN N
( ( N
9 CD N
patients NNS N
) ) N
in IN N
the DT N
drug NN N
treatment NN N
group NN N
and CC N
19.0 CD N
% NN N
( ( N
23 CD N
patients NNS N
) ) N
in IN N
the DT N
placebo NN N
group NN N
. . N

We PRP N
conclude VBP N
from IN N
this DT N
study NN N
that WDT N
antiplatelet NN N
agents NNS N
have VBP N
no DT N
effect NN N
on IN N
the DT N
primary JJ o
vascular JJ o
end NN o
points NNS o
, , o
vascular JJ o
deaths NNS o
and/or IN o
amputation NN o
of IN o
the DT o
opposite JJ o
extremity NN o
, , N
in IN N
this DT N
population NN N
. . N

Similarly RB N
, , N
no DT N
effects NNS N
were VBD N
seen VBN N
on IN N
secondary JJ o
vascular JJ o
end NN o
points NNS o
, , N
except IN N
for IN N
a DT N
suggestion NN N
of IN N
protection NN o
versus NN o
strokes NNS o
and CC o
transient JJ o
ischemic JJ o
attacks NNS o
. . o

However RB N
, , N
this DT N
finding NN N
must MD N
be VB N
interpreted VBN N
with IN N
caution NN N
, , N
since IN N
it PRP N
is VBZ N
a DT N
secondary JJ N
end NN N
point NN N
and CC N
was VBD N
found VBN N
only RB N
after IN N
multiple JJ N
analyses NNS N
of IN N
the DT N
data NNS N
. . N

-DOCSTART- -6624525- O O

Double JJ N
contrast NN i
arthrography NN i
of IN p
the DT p
knee NN p
. . p

Comparison NNP N
between IN N
three CD N
contrast NN N
media NNS N
. . N

Meglumine NNP i
iothalamate NN i
( ( i
Conray NNP i
Meglumin NNP i
) ) i
, , i
sodium-calcium-meglumine JJ i
metrizoate NN i
( ( i
Isopaque NNP i
Cerebral NNP i
) ) i
and CC i
dimeglumine JJ i
iocarmate NN i
( ( i
Dimerex NNP i
) ) i
, , N
each DT N
containing VBG N
about IN N
280 CD N
mg NNS N
I/ml NNP N
, , N
were VBD N
compared VBN N
in IN N
two CD N
series NN N
of IN N
double JJ p
contrast NN p
knee NN p
arthrography NN p
, , p
190 CD p
and CC p
184 CD p
patients NNS p
each DT p
. . p

With IN N
Dimerex NNP N
the DT N
mixing NN N
of IN N
the DT N
contrast NN N
medium NN N
with IN N
the DT N
synovial JJ o
fluid NN o
was VBD N
slower JJR N
than IN N
with IN N
Conray NNP i
Meglumin NNP i
, , N
and CC N
a DT N
good JJ N
or CC N
fair JJ N
image NN o
quality NN o
, , N
as IN N
evaluated VBN N
subjectively RB N
, , N
lasted VBD N
longer RBR N
. . N

No DT N
difference NN N
was VBD N
observed VBN N
between IN N
Isopaque NNP i
Cerebral NNP i
and CC i
Conray NNP i
Meglumin NNP i
, , N
regardless RB N
of IN N
dosage NN N
. . N

-DOCSTART- -24018545- O O

A DT N
randomized JJ N
, , N
double-blind JJ N
comparison NN N
of IN N
atomoxetine NN i
and CC i
placebo NN i
on IN N
response NN o
inhibition NN o
and CC o
interference NN o
control NN o
in IN N
children NNS p
and CC p
adolescents NNS p
with IN p
autism NN p
spectrum NN p
disorder NN p
and CC p
comorbid VB p
attention-deficit/hyperactivity JJ p
disorder NN p
symptoms NNS p
. . p

-DOCSTART- -24337476- O O

Humour-related JJ N
interventions NNS N
for IN N
people NNS p
with IN p
mental JJ p
illness NN p
: : p
a DT N
randomized VBN N
controlled VBN N
pilot NN N
study NN N
. . N

This DT N
study NN N
explored VBD N
the DT N
feasibility NN N
and CC N
effects NNS N
of IN N
humour-related JJ i
interventions NNS N
for IN N
mentally RB p
ill JJ p
adults NNS p
. . p

Twelve NNP p
, , p
randomly RB p
assigned VBN p
, , p
participated VBN p
in IN N
each DT N
of IN N
3 CD N
arms NNS i
-- : i
stand VBP i
up RP i
comedy NN i
training NN i
( ( i
the DT i
experimental NN i
arm NN i
) ) i
, , i
discussing VBG i
comedy NN i
videos NNS i
( ( i
the DT i
active JJ i
control NN i
arm NN i
) ) i
, , i
and CC i
no DT i
humour-related JJ i
intervention NN i
( ( N
the DT N
passive NN N
control NN N
arm NN N
) ) N
. . N

Quantitative JJ o
and CC o
qualitative JJ o
data NNS o
were VBD N
collected VBN N
at IN N
baseline NN N
, , N
end NN N
of IN N
interventions NNS N
( ( N
3 CD N
months NNS N
) ) N
and CC N
follow VB N
up RP N
( ( N
after IN N
another DT N
3 CD N
months NNS N
) ) N
. . N

Scale JJ o
comparisons NNS o
were VBD N
largely RB N
negative JJ N
, , N
although IN N
self-esteem JJ o
marginally RB N
increased VBN N
in IN N
the DT N
experimental JJ N
arm NN N
. . N

Interview NNP N
responses VBZ N
indicated JJ N
benefits NNS N
for IN N
the DT N
interventions NNS N
, , N
including VBG N
improved VBN o
self-esteem NN o
in IN N
the DT N
experimental JJ N
arm NN N
. . N

These DT N
results NNS N
, , N
though IN N
mixed JJ N
, , N
justify VB N
further JJ N
study NN N
. . N

-DOCSTART- -20694508- O O

Anxiety NN N
disorders NNS N
in IN N
typically RB N
developing VBG N
youth NN N
: : N
autism NN N
spectrum NN N
symptoms NNS N
as IN N
a DT N
predictor NN N
of IN N
cognitive-behavioral JJ i
treatment NN i
. . i

Symptoms NNS N
of IN N
autism NN N
spectrum NN N
disorder NN N
( ( N
ASD NNP N
) ) N
were VBD N
assessed VBN N
( ( N
Social NNP N
Responsiveness NNP N
Scale-Parent NNP N
( ( N
SRS-P NNP N
) ) N
; : N
coded VBN N
in-session NN N
behavior NN N
) ) N
in IN N
typically-developing NN p
, , p
anxiety-disordered JJ p
children NNS p
( ( p
N NNP p
= NNP p
50 CD p
) ) p
treated VBN p
with IN i
cognitive-behavioral JJ i
therapy NN i
( ( i
CBT NNP i
) ) i
. . i

Study $ N
1 CD N
: : N
children NNS p
with IN p
moderate JJ p
autistic JJ p
symptomology NN p
( ( p
per IN N
SRS-P NNP N
) ) N
were VBD N
significantly RB N
more RBR N
likely JJ N
to TO N
improve VB N
from IN i
family NN i
CBT NNP i
( ( i
FCBT NNP i
) ) i
than IN i
individual JJ i
CBT NNP i
( ( i
ICBT NNP i
; : i
OR NNP i
= VBZ N
8.67 CD N
) ) N
. . N

Coded VBN N
behavior NN N
did VBD N
not RB N
predict JJ N
outcome NN N
. . N

Study CC i
2 CD i
: : i
CBT JJ i
components NNS N
were VBD N
compared VBN N
by IN N
treatment NN N
and CC N
ASD NNP N
symptom NN N
status NN o
. . o

At-home JJ o
exposure NN o
completion NN o
was VBD o
greater JJR i
in IN i
FCBT NNP i
and CC i
there EX N
was VBD N
an DT N
interaction NN N
in IN N
child JJ N
involvement NN N
for IN N
treatment NN N
and CC N
ASD NNP N
status NN N
. . N

Though IN N
both DT N
treatments NNS N
reduced VBD o
anxiety NN o
, , o
FCBT NNP o
outperformed VBD i
ICBT NNP i
for IN i
children NNS N
with IN N
moderate JJ N
ASD NNP N
symptoms NNS N
, , N
a DT N
benefit NN N
potentially RB N
linked VBN N
to TO N
more RBR N
at-home JJ N
exposures NNS N
and CC N
greater JJR N
child NN N
involvement NN i
in IN i
FCBT NNP i
. . i

-DOCSTART- -12654143- O O

Effect NN N
of IN N
postural JJ i
supports NNS i
on IN N
neuromotor NN o
function NN o
in IN N
very RB p
preterm JJ p
infants NNS p
to TO p
term NN p
equivalent JJ p
age NN p
. . p

OBJECTIVE UH N
To TO N
determine VB N
the DT N
effect NN N
of IN N
a DT N
postural JJ i
support NN i
nappy JJ i
and/or VBZ i
a DT i
postural JJ i
support NN i
roll NN i
on IN N
neuromotor NN o
function NN o
in IN p
very RB p
preterm JJ p
infants NNS p
when WRB N
nursed VBN N
prone NN N
to TO N
term NN N
equivalent JJ N
age NN N
. . N

METHODS NNP N
A NNP N
randomized VBD N
observer RP N
blind NN N
controlled JJ N
trial NN N
of IN N
123 CD p
very RB p
preterm JJ p
infants NNS p
was VBD p
conducted VBN p
in IN p
the DT p
neonatal JJ p
intensive JJ p
care NN p
unit NN p
of IN p
the DT p
sole JJ p
tertiary JJ p
referral JJ p
centre NN p
in IN p
Western JJ p
Australia NNP p
. . p

Infants NNS p
were VBD p
stratified VBN p
by IN p
gestational JJ p
age NN p
( ( p
< JJ p
29 CD p
weeks NNS p
or CC p
29-30 JJ p
weeks NNS p
) ) p
, , N
then RB N
randomized VBD N
into IN N
one CD N
of IN N
three CD N
intervention NN N
groups NNS N
: : N
postural JJ i
support NN i
nappy JJ i
, , i
postural JJ i
support NN i
nappy JJ i
and CC i
postural JJ i
support NN i
roll NN i
, , i
or CC i
disposable JJ i
nappy JJ i
and CC i
postural JJ i
support NN i
roll NN i
. . i

Interventions NNS N
started VBD N
when WRB N
infants NNS N
were VBD N
stable JJ N
and CC N
ceased VBD N
when WRB N
routine JJ N
side-lying NN N
commenced VBD N
. . N

Measurements NNS N
of IN N
shoulder NN o
and CC o
hip NN o
posture NN o
were VBD N
performed VBN N
pre-intervention NN N
, , N
5 CD N
weeks NNS N
post-intervention NN N
and CC N
term NN N
postmenstrual JJ N
age NN N
. . N

RESULTS JJ N
Infants NNS N
nursed VBN N
with IN N
a DT N
postural JJ i
support NN i
roll NN i
and CC i
a DT i
postural JJ i
support NN i
nappy JJ i
demonstrated VBD N
improved JJ N
hip NN o
posture NN o
to TO N
term NN N
equivalent JJ N
age NN N
compared VBN N
with IN N
infants NNS N
nursed VBN N
with IN N
either CC N
a DT N
postural JJ i
support NN i
roll NN i
only RB N
, , N
or CC N
a DT N
postural JJ i
support NN i
nappy JJ i
only RB N
. . N

Infants NNS N
nursed VBN N
with IN N
a DT N
postural JJ N
support NN N
roll NN N
either RB N
with IN N
or CC N
without IN N
a DT N
postural JJ N
support NN N
nappy JJ N
demonstrated VBD N
improved JJ N
shoulder NN o
posture NN o
to TO N
term NN N
equivalent JJ N
age NN N
. . N

CONCLUSIONS NNP N
Combined NNP N
use NN N
of IN N
a DT N
postural JJ i
support NN i
roll NN i
and CC N
a DT N
postural JJ i
support NN i
nappy JJ i
while IN N
very RB N
preterm JJ N
infants NNS N
are VBP N
nursed VBN N
prone JJ N
improves NNS N
hip NN o
posture NN o
up IN N
to TO N
term NN N
postmenstrual JJ N
age NN N
. . N

Use NNP N
of IN N
a DT N
postural JJ i
support NN i
roll NN i
improves VBZ N
shoulder JJR o
posture NN o
up IN N
to TO N
term NN N
equivalent JJ N
age NN N
. . N

-DOCSTART- -18096070- O O

The DT N
effect NN o
of IN N
oral JJ N
sodium NN i
acetate JJ i
administration NN N
on IN N
plasma JJ o
acetate JJ o
concentration NN o
and CC N
acid-base JJ o
state NN o
in IN N
horses NNS p
. . p

AIM NNP N
Sodium NNP i
acetate NN i
( ( i
NaAcetate NNP i
) ) i
has VBZ N
received VBN N
some DT N
attention NN N
as IN N
an DT N
alkalinizing NN N
agent NN N
and CC N
possible JJ N
alternative JJ N
energy NN N
source NN N
for IN N
the DT N
horse NN N
, , N
however RB N
the DT N
effects NNS N
of IN N
oral JJ N
administration NN N
remain VBP N
largely RB N
unknown JJ N
. . N

The DT N
present JJ N
study NN N
used VBD N
the DT N
physicochemical JJ N
approach NN N
to TO N
characterize VB N
the DT N
changes NNS N
in IN N
acid-base NN o
status NN o
occurring VBG N
after IN N
oral JJ N
NaAcetate/acetic NNP N
acid NN N
( ( N
NAA NNP N
) ) N
administration NN N
in IN N
horses NNS N
. . N

METHODS NNP N
Jugular NNP o
venous JJ o
blood NN o
was VBD N
sampled VBN N
from IN N
9 CD p
exercise-conditioned JJ p
horses NNS p
on IN p
2 CD p
separate JJ p
occasions NNS p
, , N
at IN N
rest NN N
and CC N
for IN N
24 CD N
h NN N
following VBG N
a DT N
competition NN i
exercise NN i
test NN i
( ( N
CET NNP N
) ) N
designed VBN N
to TO N
simulate VB N
the DT N
speed NN N
and CC N
endurance NN N
test NN N
of IN N
3-day JJ N
event NN N
. . N

Immediately RB N
after IN N
the DT N
CETs NNP N
horses NNS N
were VBD N
allowed VBN N
water NN N
ad NN N
libitum NN N
and CC N
either DT N
: : N
1 CD N
) ) N
8 CD N
L NNP N
of IN N
a DT N
hypertonic JJ i
NaAcetate/acetic NNP i
acid NN i
solution NN i
via IN N
nasogastric JJ N
tube NN N
followed VBN N
by IN N
a DT N
typical JJ i
hay/grain NN i
meal NN i
( ( N
NAA NNP N
trial NN N
) ) N
; : N
or CC N
2 CD N
) ) N
a DT i
hay/grain JJ i
meal NN i
alone RB i
( ( N
Control NNP N
trial NN N
) ) N
. . N

RESULTS NNP N
Oral NNP N
NAA NNP N
resulted VBD N
in IN N
a DT N
profound NN o
plasma NN o
alkalosis NN o
marked VBN N
by IN N
decreased JJ N
plasma NN o
[ NNP o
H+ NNP o
] NNP o
and CC N
increased VBD N
plasma NN o
[ NN o
TCO2 NNP o
] NNP o
and CC o
[ NNP o
HCO3- NNP o
] NNP o
compared VBN N
to TO N
Control NNP N
. . N

The DT N
primary JJ N
contributor NN N
to TO N
the DT N
plasma NN o
alkalosis NN o
was VBD N
an DT N
increased VBN N
[ NN o
SID NNP o
] NNP o
, , N
as IN N
a DT N
result NN N
of IN N
increased VBN N
plasma NN N
[ NN N
Na+ NNP N
] NNP N
and CC N
decreased VBD N
plasma NNS N
[ JJ N
Cl- NNP N
] NNP N
. . N

An DT N
increased JJ N
[ NN o
Atot NNP o
] NNP o
, , N
due JJ N
to TO N
increased VBN N
[ NNP o
PP NNP o
] NNP o
and CC N
a DT N
sustained JJ N
increase NN N
in IN N
plasma JJ o
[ JJ o
acetate NN o
] NN o
, , N
contributed VBD N
a DT N
minor JJ N
acidifying NN o
effect NN o
. . N

CONCLUSION VB N
It PRP N
is VBZ N
concluded VBN N
that IN N
oral JJ N
NaAcetate NNP N
could MD N
be VB N
used VBN N
as IN N
both DT N
an DT N
alkalinizing NN N
agent NN N
and CC N
an DT N
alternative JJ N
energy NN N
source NN N
in IN N
the DT N
horse NN p
. . p

-DOCSTART- -10373718- O O

Emerging VBG N
treatment NN o
of IN N
acute JJ o
coronary JJ o
syndromes NNS o
with IN N
platelet NN i
glycoprotein NN i
IIB/IIIA NNP i
inhibitors NNS i
. . i

-DOCSTART- -2087856- O O

[ JJ o
Acute NNP o
cardiovascular NN o
and CC o
metabolic JJ o
changes NNS o
in IN N
interval NN N
and CC N
endurance NN i
training NN i
in IN N
selected VBN p
patients NNS p
following VBG p
aortocoronary JJ p
bypass NN p
operation NN p
] NNP p
. . N

UNLABELLED VB N
This DT N
study NN N
compared VBN N
the DT N
acute NN o
changes NNS o
of IN o
cardiovascular NN o
and CC o
metabolic JJ o
reactions NNS o
during IN N
interval NN i
and CC i
continuous JJ i
training NN i
after IN N
coronary JJ N
bypass NN N
surgery NN N
. . N

Two CD p
groups NNS p
of IN p
9 CD p
male JJ p
patients NNS p
( ( p
age NN p
: : p
59 CD p
+/- JJ p
4 CD p
and CC p
56 CD p
+/- JJ p
6 CD p
years NNS p
, , p
resp NN p
. . p

) ) p
each DT i
trained VBN i
on IN i
bicycle NN i
ergometer JJ i
start NN i
on IN i
post-operative JJ i
days NNS i
24 CD i
and CC i
26 CD i
, , i
resp NN i
. . i

In IN N
both DT N
training NN N
groups NNS N
training VBG o
heart NN o
rate NN o
was VBD N
set VBN N
at IN N
86 CD N
% NN N
of IN N
individual JJ N
maximum JJ N
heart NN N
rate NN N
. . N

In IN i
the DT i
last JJ i
week NN i
of IN i
training VBG i
the DT i
exercise NN i
intensity NN i
in IN i
the DT i
group NN i
of IN i
patients NNS i
who WP i
were VBD i
trained VBN i
by IN i
the DT i
continuous JJ i
method NN i
was VBD i
at IN i
83 CD i
watts NN i
, , i
and CC i
at IN i
20:121 CD i
watts NN i
in IN i
the DT i
group NN i
of IN i
patients NNS i
who WP i
were VBD i
trained VBN i
by IN i
interval JJ i
method NN i
( ( i
rest NN i
: : i
work NN i
each DT i
1:1 CD i
min NN i
) ) i
. . i

At IN N
this DT N
exercise NN N
training NN N
that WDT N
lasted VBD N
for IN N
20 CD N
min PDT N
the DT N
acute JJ o
response NN o
of IN o
heart NN o
rate NN o
, , o
blood NN o
pressure NN o
, , o
rate-pressure JJ o
product NN o
, , o
glucose JJ o
, , o
lactate JJ o
and CC o
catecholamines NNS o
was VBD N
measured VBN N
. . N

RESULTS NNP N
In IN N
both DT N
methods NNS N
there EX N
were VBD N
no DT o
significant JJ o
differences NNS o
in IN o
systolic JJ o
and CC o
diastolic JJ o
pressure NN o
, , o
rate-pressure JJ o
product NN o
, , o
in IN o
glucose NN o
or CC o
catecholamine NN o
levels NNS o
. . o

However RB N
, , N
there EX N
was VBD N
a DT N
significantly RB N
higher JJR N
rate NN o
of IN o
lactate NN o
in IN N
the DT N
second JJ N
10 CD N
min NN N
of IN N
the DT N
interval JJ N
training NN N
. . N

And CC N
, , N
in IN N
spite NN N
of IN N
higher JJR N
peripheral JJ N
exercise NN N
intensity NN N
by IN N
interval JJ N
training NN N
, , N
there EX N
was VBD N
no DT N
higher JJR N
cardiac NN o
work NN o
than IN N
by IN N
the DT N
continuous JJ N
training NN N
. . N

These DT N
findings NNS N
suggest VBP N
that IN N
interval JJ N
training NN N
strains VBZ N
the DT N
oxidative JJ N
capacity NN N
of IN N
the DT N
trained JJ N
muscles NNS N
in IN N
a DT N
more RBR N
intensive JJ N
and CC N
direct JJ N
way NN N
than IN N
does VBZ N
continuous JJ N
training NN N
. . N

-DOCSTART- -25568383- O O

Inclusion NN N
of IN N
anti-phospholipase JJ i
A2 NNP i
antibody NN i
to TO N
backgrounding VBG N
diets NNS N
on IN N
performance NN o
, , o
feed NN o
efficiency NN o
, , o
in IN o
vitro JJ o
fermentation NN o
, , o
and CC o
the DT o
acute-phase JJ o
response NN o
of IN o
growing VBG o
beef NN o
calves NNS o
. . o

In IN N
Exp NNP N
. . N

1 CD N
, , N
individual JJ N
performance NN N
and CC N
daily JJ N
DMI NNP N
was VBD N
measured VBN N
on IN N
70 CD p
crossbred JJ p
weaned VBD p
calves NNS p
during IN p
a DT p
70-d JJ p
period NN p
using VBG p
a DT p
GrowSafe NNP p
system NN p
( ( p
GrowSafe NNP p
Systems NNPS p
Ltd. NNP p
, , N
Airdrie NNP p
, , p
AB NNP p
, , p
Canada NNP p
) ) p
at IN p
the DT p
University NNP p
of IN p
Florida NNP p
North NNP p
Florida NNP p
Research NNP p
and CC p
Education NNP p
Center NNP p
Feed NNP p
Efficiency NNP p
Facility NNP p
( ( p
FEF NNP p
) ) p
. . p

Calves NNS p
were VBD N
fed VBN N
a DT N
low-concentrate NN i
( ( i
LC NNP i
) ) i
growing VBG i
diet JJ i
, , N
blocked VBN N
by IN N
weight NN N
and CC N
sex NN N
, , N
and CC N
then RB N
randomly RB N
assigned VBN N
to TO N
pens NNS N
to TO N
receive VB N
either RB i
no DT i
additional JJ i
supplement NN i
( ( N
CON NNP N
; : N
n CC N
= VB N
35 CD N
) ) N
or CC i
receive VB i
a DT i
supplement NN i
of IN i
anti-phospholipase JJ i
A2 NNP i
antibody NN i
( ( i
aPLA2 NN i
) ) i
at IN N
an DT N
inclusion NN N
rate NN N
of IN N
0.6 CD N
% NN N
of IN N
the DT N
diet JJ N
DM NNP N
( ( N
n JJ N
= NNP N
35 CD N
) ) N
. . N

After IN N
the DT N
70-d JJ N
feed NN N
efficiency NN N
( ( N
FE NNP N
) ) N
trial NN N
( ( N
Phase NNP N
1 CD N
) ) N
, , N
calves NNS N
were VBD N
loaded VBN N
into IN N
a DT N
commercial JJ N
livestock NN N
trailer NN N
and CC N
were VBD N
driven VBN N
for IN N
approximately RB N
1,600 CD N
km NNS N
during IN N
24 CD N
h. NNS N
Upon NNP N
return NN N
to TO N
the DT N
FEF NNP N
( ( N
Phase NNP N
2 CD N
) ) N
, , N
calves NNS N
were VBD N
relocated VBN N
to TO N
the DT N
same JJ N
pens NNS N
and CC N
groups NNS N
and CC N
received VBD N
the DT N
same JJ N
diets NNS N
and CC N
treatments NNS N
for IN N
28 CD N
d. NNS N
Blood NNP N
samples NNS N
from IN N
each DT N
calf NN N
were VBD N
collected VBN N
on IN N
d NN N
0 CD N
, , N
1 CD N
, , N
3 CD N
, , N
5 CD N
, , N
7 CD N
, , N
14 CD N
, , N
21 CD N
, , N
and CC N
28 CD N
relative NN N
to TO N
initiation NN N
of IN N
transportation NN N
and CC N
were VBD N
analyzed VBN N
for IN N
determination NN N
of IN N
concentrations NNS o
of IN o
plasma NN o
ceruloplasmin NN o
and CC o
haptoglobin NN o
. . o

In IN N
Phase NNP N
1 CD N
, , N
initial JJ N
BW NNP o
( ( N
242.0 CD N
? . N
3.7 CD N
kg NN N
; : N
P NNP N
= NNP N
0.92 CD N
) ) N
, , N
BW NNP o
at IN N
d NN N
70 CD N
( ( N
313.0 CD N
? . N
4.1 CD N
kg NN N
; : N
P NNP N
= NNP N
0.79 CD N
) ) N
, , N
and CC o
ADG NNP o
( ( o
1.01 CD N
? . N
0.02 CD N
kg NN N
; : N
P NNP N
= NNP N
0.95 CD N
) ) N
were VBD N
similar JJ N
between IN N
treatments NNS N
. . N

However RB o
, , o
daily JJ o
DMI NNP o
was VBD o
greater JJR N
( ( N
P NNP N
= NNP N
0.01 CD N
) ) N
for IN N
CON NNP N
( ( N
9.18 CD N
? . N
0.15 CD N
kg NN N
) ) N
than IN N
aPLA2 NN N
( ( N
8.53 CD N
? . N
0.15 CD N
kg NN N
) ) N
. . N

In IN N
addition NN o
, , o
residual JJ o
feed NN o
intake NN o
was VBD o
greater JJR N
( ( N
P NNP N
= NNP N
0.002 CD N
) ) N
for IN N
CON NNP N
( ( N
0.389 CD N
? . N
0.110 CD N
kg/d NN N
) ) N
than IN N
aPLA2 NN N
calves NNS N
( ( N
-0.272 VB N
? . N
0.110 CD N
kg/d NN N
) ) N
. . N

In IN N
Phase NNP N
2 CD N
, , N
after IN N
transportation NN N
, , N
there EX N
were VBD N
no DT N
differences NNS N
between IN N
treatments NNS o
on IN o
BW NNP o
loss NN o
due JJ o
to TO o
transportation NN o
shrink VB o
( ( N
26.0 CD N
? . N
0.6 CD N
kg NN N
; : N
P NNP N
= NNP N
0.86 CD N
) ) N
, , N
BW NNP N
at IN N
d NN N
28 CD N
( ( N
339.0 CD N
? . N
4.1 CD N
kg NN N
; : N
P NNP N
= NNP N
0.72 CD N
) ) N
, , N
ADG NNP N
( ( N
1.28 CD N
? . N
0.03 CD N
kg/d NN N
; : N
P NNP N
= NNP N
0.72 CD N
) ) N
, , N
G NNP N
: : N
F NNP N
( ( N
0.164 CD N
? . N
0.004 CD N
; : N
P NNP N
= NNP N
0.83 CD N
) ) N
, , N
and CC N
concentrations NNS N
of IN N
plasma NN N
haptoglobin NN N
( ( N
0.08 CD N
? . N
0.02 CD N
mg/mL NN N
; : N
P NNP N
= NNP N
0.41 CD N
) ) N
. . N

However RB o
, , o
concentrations NNS o
of IN o
plasma NN o
ceruloplasmin NN o
were VBD o
greater JJR o
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
for IN N
CON NNP N
calves NNS N
( ( N
14.3 CD N
? . N
0.3 CD N
mg/dL NN N
) ) N
compared VBN N
to TO N
aPLA2 VB N
calves NNS N
( ( N
13.0 CD N
? . N
0.3 CD N
mg/dL NN N
) ) N
. . N

In IN N
Exp NNP N
. . N

2 CD N
, , N
the DT N
effects NNS N
of IN N
aPLA2 JJ o
inclusion NN o
on IN o
LC NNP o
and CC o
high-concentrate NN o
( ( o
HC NNP o
) ) o
substrates VBZ o
on IN o
in IN o
vitro JJ o
fermentation NN o
parameters NNS o
were VBD o
assessed VBN N
. . N

Addition NN N
of IN N
aPLA2 NN N
had VBD N
no DT N
effects NNS N
on IN N
in IN o
vitro JJ o
fermentation NN o
parameters NNS o
of IN o
LC NNP o
and CC o
HC NNP o
substrates NNS o
. . N

In IN N
conclusion NN N
, , N
supplementation NN i
of IN i
aPLA2 NN i
improved VBN i
FE NNP o
of IN o
growing VBG N
beef NN N
calves NNS N
when WRB N
fed VBN N
LC NNP N
diets NNS N
in IN N
Phase NNP N
1 CD N
and CC N
addition NN N
of IN N
aPLA2 NN N
had VBD N
no DT N
effect NN N
on IN o
fermentation NN o
parameters NNS o
of IN o
LC NNP o
and CC o
HC NNP o
substrates NNS o
. . N

In IN N
addition NN N
, , N
calves NNS N
supplemented VBD N
with IN N
aPLA2 NN N
had VBD N
reduced VBN o
concentrations NNS o
of IN o
plasma NN o
ceruloplasmin NN o
after IN N
24 CD N
h NN N
of IN N
transportation NN N
. . N

-DOCSTART- -15358441- O O

Estradiol NNP i
and CC i
the DT i
addition NN i
of IN i
progesterone NN i
increase NN N
the DT N
sensitivity NN N
to TO N
a DT N
neurosteroid NN N
in IN N
postmenopausal JJ p
women NNS p
. . p

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
pharmacodynamic JJ N
response NN N
to TO N
a DT N
neuroactive JJ i
steroid NN i
, , i
pregnanolone NN i
, , N
before IN N
and CC N
during IN N
different JJ N
hormonal JJ N
settings NNS N
of IN N
postmenopausal NN i
hormone NN i
replacement NN i
therapy NN i
( ( i
HRT NNP i
) ) i
, , N
using VBG N
natural JJ i
progesterone NN i
. . i

A DT N
second JJ N
aim NN N
was VBD N
to TO N
investigate VB N
whether IN N
the DT N
response NN N
to TO N
pregnanolone NN i
was VBD N
associated VBN N
with IN N
cyclicity NN N
in IN N
negative JJ o
mood NN o
symptoms NNS o
during IN N
treatment NN N
. . N

Twenty NNP p
six CD p
postmenopausal JJ p
women NNS p
with IN p
climacteric JJ p
symptoms NNS p
were VBD p
administered VBN N
HRT NNP i
in IN N
a DT N
randomized JJ N
, , N
double JJ N
blinded VBN N
, , N
placebo-controlled JJ N
, , N
crossover NN N
study NN N
. . N

The DT N
women NNS N
received VBD N
2 CD N
mg JJ N
oral JJ i
estradiol NN i
( ( i
E NNP i
( ( i
2 CD i
) ) i
) ) i
continuously RB N
during IN N
two CD N
28-day JJ N
cycles NNS N
and CC N
800 CD N
mg NN N
of IN N
vaginal JJ i
progesterone NN i
or CC i
placebo NN i
sequentially RB N
for IN N
the DT N
last JJ N
14 CD N
days NNS N
of IN N
each DT N
treatment NN N
cycle NN N
. . N

Pharmacodynamic NNP o
response NN o
to TO N
pregnanolone NN i
was VBD N
assessed VBN N
before IN N
treatment NN N
, , N
and CC N
during IN N
the DT N
last JJ N
week NN N
of IN N
each DT N
treatment NN N
cycle NN N
, , N
by IN N
comparing VBG N
the DT N
effects NNS N
of IN N
intravenous JJ N
pregnanolone NN i
( ( i
3alpha-hydroxy-5beta-pregnan-20-one CD i
) ) i
on IN N
saccadic JJ o
eye NN o
velocity NN o
( ( o
SEV NNP o
) ) o
, , o
saccade JJ o
acceleration NN o
, , o
saccade JJ o
latency NN o
and CC o
self-rated JJ o
sedation NN o
. . o

Throughout IN N
the DT N
study NN N
daily JJ o
symptom NN o
rating NN o
scales NNS o
were VBD N
kept VBN N
. . N

According VBG N
to TO N
the DT N
daily JJ o
symptom NN o
rating NN o
scales NNS o
, , N
patients NNS N
were VBD N
divided VBN N
into IN N
two CD p
groups NNS p
; : p
one CD p
group NN p
who WP p
displayed VBD p
a DT p
significant JJ p
variance NN p
in IN p
negative JJ o
mood NN o
symptoms NNS o
during IN p
HRT NNP i
( ( p
cyclicity NN p
) ) p
and CC p
one CD p
group NN p
with IN p
no DT p
cyclical JJ p
changes NNS p
in IN p
negative JJ o
mood NN o
symptoms NNS o
during IN p
treatment NN p
. . p

During IN N
treatment NN N
with IN N
either DT N
E NNP i
( ( i
2 CD i
) ) i
alone RB i
or CC i
E NNP i
( ( i
2 CD i
) ) i
+progesterone CD i
the DT N
response NN N
in IN N
saccadic JJ o
eye NN o
movement NN o
parameters NNS o
and CC N
in IN N
self-rated JJ o
sedation NN o
to TO N
pregnanolone NN N
was VBD N
enhanced VBN N
compared VBN N
to TO N
pretreatment VB N
values NNS N
. . N

The DT N
SEV NNP N
, , N
saccade JJ o
acceleration NN o
and CC o
sedation NN o
responses NNS o
to TO N
pregnanolone NN i
was VBD N
also RB N
increased VBN N
in IN N
women NNS N
expressing VBG N
cyclicity NN N
in IN N
negative JJ o
mood NN o
symptoms NNS o
compared VBN N
to TO N
women NNS N
with IN N
no DT N
cyclical JJ N
changes NNS N
in IN N
negative JJ N
mood NN N
during IN N
HRT NNP i
. . i

In IN N
conclusion NN N
, , N
during IN N
treatment NN N
with IN N
either DT N
E NNP i
( ( i
2 CD i
) ) i
alone RB i
, , i
or CC i
E NNP i
( ( i
2 CD i
) ) i
+progesterone NN i
, , i
pregnanolone NN o
sensitivity NN o
was VBD N
increased VBN N
. . N

Women NNP p
expressing VBG p
cyclicity NN p
in IN p
negative JJ p
mood NN p
symptoms NNS p
were VBD N
more RBR N
sensitive JJ N
to TO N
pregnanolone VB i
than IN N
women NNS N
without IN N
symptom JJ N
cyclicity NN N
during IN N
HRT NNP i
. . i

-DOCSTART- -17208334- O O

Two CD N
randomized JJ N
studies NNS N
demonstrate VBP N
the DT N
efficacy NN o
and CC N
safety NN o
of IN N
dapsone NN i
gel NN i
, , N
5 CD N
% NN N
for IN N
the DT N
treatment NN N
of IN N
acne JJ p
vulgaris NN p
. . p

BACKGROUND VB N
A DT N
new JJ N
aqueous JJ N
gel JJ N
formulation NN N
of IN N
dapsone NN i
has VBZ N
been VBN N
developed VBN N
that IN N
allows VBZ N
clinically-effective JJ N
doses NNS N
of IN N
dapsone NN i
to TO N
be VB N
administered VBN N
topically RB N
with IN N
minimal JJ N
systemic JJ N
absorption NN N
. . N

OBJECTIVES CC N
The DT N
goal NN N
of IN N
these DT N
studies NNS N
was VBD N
to TO N
evaluate VB N
the DT N
efficacy NN o
and CC o
safety NN o
of IN N
dapsone NN i
gel NN i
, , N
5 CD N
% NN N
in IN N
the DT N
treatment NN N
of IN N
acne NN N
. . N

METHODS NNP N
Patients NNPS p
12 CD p
years NNS p
of IN p
age NN p
and CC p
older JJR p
with IN p
acne JJ p
vulgaris NN p
( ( p
N NNP p
= NNP p
3010 CD p
) ) p
participated VBN p
in IN N
two CD N
identically-designed JJ N
12-week JJ N
, , N
randomized VBN N
, , N
double-blind JJ N
studies NNS N
of IN N
twice-daily JJ N
monotherapy NN i
with IN i
dapsone NN i
gel NN i
, , i
5 CD i
% NN i
, , N
versus IN N
a DT N
vehicle NN i
gel NN i
. . i

RESULTS NNP N
Dapsone NNP i
gel-treated JJ i
patients NNS N
achieved VBN N
superior JJ N
results NNS N
in IN N
terms NNS N
of IN N
the DT N
investigator NN o
's POS o
global JJ o
acne NN o
assessment NN o
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
and CC N
the DT N
mean JJ N
percentage NN N
reduction NN o
in IN o
inflammatory NN o
, , o
noninflammatory NN o
, , o
and CC o
total JJ o
lesion NN o
counts NNS o
( ( N
all DT N
, , N
P NNP N
< NNP N
.001 NNP N
) ) N
at IN N
week NN N
12 CD N
. . N

Reductions NNS N
in IN N
inflammatory JJ o
lesion NN o
counts NNS o
favoring VBG N
dapsone NN i
gel NN i
over IN N
vehicle NN N
were VBD N
apparent JJ N
as RB N
early RB N
as IN N
2 CD N
weeks NNS N
and CC N
reached VBD N
statistical JJ N
significance NN N
by IN N
4 CD N
weeks NNS N
. . N

No DT N
clinically RB N
significant JJ N
changes NNS N
in IN N
laboratory NN N
parameters NNS N
, , N
including VBG N
hemoglobin NN o
, , N
even RB N
among IN N
glucose-6-phosphate JJ N
dehydrogenase-deficient JJ N
patients NNS N
, , N
were VBD N
observed VBN N
. . N

Adverse JJ o
events NNS o
were VBD N
comparable JJ N
between IN N
the DT N
treatment NN N
groups NNS N
and CC N
rarely RB N
led VBD N
to TO N
discontinuation NN N
. . N

LIMITATIONS NNP N
Adjunctive NNP N
topical JJ N
treatments NNS N
and CC N
their PRP$ N
impact NN N
on IN N
acne NNS N
were VBD N
not RB N
studied VBN N
in IN N
this DT N
trial NN N
. . N

CONCLUSIONS NNP N
Dapsone NNP i
gel NN i
, , N
5 CD N
% NN N
appears VBZ N
to TO N
be VB N
an DT N
effective JJ N
, , N
safe JJ N
, , N
and CC N
well-tolerated JJ N
treatment NN N
for IN N
acne JJ o
vulgaris NN o
, , N
with IN N
a DT N
rapid JJ N
onset NN N
of IN N
action NN N
. . N

-DOCSTART- -22800470- O O

A DT N
six-month JJ N
crossover NN N
chemoprevention NN N
clinical JJ N
trial NN N
of IN N
tea NN i
in IN N
smokers NNS o
and CC o
non-smokers NNS o
: : o
methodological JJ N
issues NNS N
in IN N
a DT N
feasibility NN N
study NN N
. . N

BACKGROUND NNP N
Chemoprevention NNP N
crossover NN N
trials NNS N
of IN N
tea NN N
can MD N
be VB N
more RBR N
efficient JJ N
than IN N
parallel JJ N
designs NNS N
but CC N
the DT N
attrition NN N
and CC N
compliance NN N
rates NNS N
with IN N
such JJ N
trials NNS N
are VBP N
unknown JJ N
. . N

METHODS NNP N
Attrition NNP N
( ( N
dropouts NNS N
) ) N
and CC N
compliance NN N
with IN N
treatment NN N
were VBD N
assessed VBN N
in IN N
a DT N
25-week JJ N
randomized NN N
, , N
placebo NN N
controlled VBD N
, , N
crossover NN N
, , N
feasibility NN N
clinical JJ N
trial NN N
of IN N
four CD i
tea NN i
treatments NNS i
to TO i
investigate VB i
the DT i
effect NN i
of IN i
tea NN i
on IN i
oral JJ i
cancer NN i
biomarkers NNS i
. . i

Each DT N
treatment NN N
lasted VBD N
4 CD N
weeks NNS N
with IN N
2 CD N
weeks NNS N
of IN N
washout NN N
in IN N
between IN N
. . N

Participants NNS N
were VBD N
32 CD p
smokers NNS p
and CC p
33 CD p
non-smokers NNS p
without IN p
any DT p
evidence NN p
of IN p
premalignant JJ p
oral JJ p
lesions NNS p
. . p

The DT p
interventions NNS N
consisted VBD N
of IN N
packets NNS i
of IN i
green JJ i
tea NN i
, , i
black JJ i
tea NN i
, , i
caffeinated JJ i
water NN i
, , i
or CC i
placebo NN i
. . i

Participants NNS i
were VBD N
assigned VBN N
to TO N
each DT N
treatment NN N
for IN N
four CD N
weeks NNS N
, , N
and CC N
were VBD N
instructed VBN N
to TO N
drink VB N
five CD N
packets NNS N
per IN N
day NN N
while IN N
on IN N
the DT N
treatment NN o
. . o

Dropout IN o
from IN o
the DT o
trial NN o
and CC o
compliance NN o
( ( o
consumption NN o
of IN N
?85 NNP N
% NN N
of IN N
the DT N
prescribed JJ N
treatment NN N
packets NNS N
) ) N
are VBP N
the DT N
main JJ N
outcome NN N
measures NNS N
reported VBN N
. . N

RESULTS NNP N
There EX N
was VBD o
a DT o
high JJ o
rate NN o
of IN o
dropout NN o
( ( N
51 CD N
% NN N
) ) N
from IN N
the DT N
study NN N
, , N
and CC N
the DT N
rates NNS N
were VBD N
significantly RB N
higher JJR N
among IN N
smokers NNS N
( ( N
64 CD N
% NN N
) ) N
than IN N
non-smokers NNS N
( ( N
36 CD N
% NN N
) ) N
. . N

Among IN N
participants NNS N
who WP N
completed VBD N
the DT N
study NN N
the DT N
rate NN N
of IN N
compliance NN N
was VBD N
72 CD N
% NN N
. . N

The DT N
highest JJS N
rates NNS o
of IN o
dropouts NNS o
occurred VBD o
between IN N
the DT N
first JJ N
and CC N
second JJ N
treatment NN N
visits NNS N
in IN N
both DT N
smokers NNS N
( ( N
38 CD N
% NN N
dropout NN N
) ) N
and CC N
non-smokers NNS N
( ( N
18 CD N
% NN N
dropout NN N
) ) N
. . N

Throughout IN N
the DT N
study NN o
smokers NNS o
were VBD N
more RBR N
likely JJ N
to TO o
dropout VB o
than IN N
non-smokers NNS N
. . N

Black NNP N
tea NN N
treatment NN N
was VBD N
associated VBN N
with IN N
the DT N
highest JJS o
rates NNS o
of IN o
dropout NN o
among IN N
smokers NNS N
( ( N
37 CD N
% NN N
) ) N
, , N
but CC N
was VBD N
associated VBN N
with IN N
the DT N
lowest JJS o
rate NN o
of IN o
dropout NN o
among IN N
non-smokers NNS N
( ( N
4 CD N
% NN N
) ) N
. . N

CONCLUSIONS NNP N
In IN N
a DT N
study NN N
conducted VBN N
to TO N
test VB N
the DT N
feasibility NN N
of IN N
a DT N
four-treatment JJ N
crossover NN N
tea NN N
trial NN N
, , N
a DT N
high JJ N
rate NN N
of IN N
dropout NN N
among IN N
smokers NNS N
and CC N
non-smokers NNS N
was VBD N
observed VBN N
. . N

Multi-arm JJ N
crossover NN N
tea NN N
trials NNS N
might MD N
pose VB N
a DT N
higher JJR N
burden NN N
on IN N
participants NNS N
and CC N
research NN N
is VBZ N
needed VBN N
to TO N
improve VB N
adherence NN N
and CC N
treatment NN N
compliance NN N
in IN N
such JJ N
trials NNS N
. . N

TRIAL NNP N
REGISTRATION NNP N
NUMBER NNP N
ISRCTN70410203 NNP N
. . N

-DOCSTART- -7995312- O O

A DT N
comparison NN N
of IN N
lisinopril NN i
and CC i
nifedipine NN i
in IN N
the DT N
treatment NN N
of IN N
mild NN p
to TO p
moderate VB p
hypertension NN p
. . p

A DT N
multicentre NN N
study NN N
. . N

Lisinopril NNP i
has VBZ N
been VBN N
compared VBN N
with IN N
slow-release JJ N
nifedipine NN i
in IN N
a DT N
16-week JJ N
double-blind NN N
, , N
randomized VBN N
, , N
parallel-group JJ N
study NN N
involving VBG N
102 CD p
patients NNS p
with IN p
mild JJ p
to TO p
moderate VB p
hypertension NN p
. . p

Sitting VBG o
systolic JJ o
and CC o
diastolic JJ o
blood NN o
pressures NNS o
were VBD N
reduced VBN N
6 CD N
and CC N
5 CD N
mmHg NNS N
more JJR N
by IN N
lisinopril JJR i
than IN N
by IN N
nifedipine NN i
over IN N
12 CD N
weeks NNS N
monotherapy NN N
. . N

After IN N
12 CD N
weeks NNS N
a DT N
greater JJR N
proportion NN N
of IN N
patients NNS N
taking VBG N
lisinopril NN i
was VBD N
controlled VBN N
( ( N
sitting VBG N
diastolic JJ N
blood NN N
pressure NN N
below IN N
95 CD N
mm NNS N
Hg NNP N
) ) N
than IN N
in IN N
those DT N
taking VBG N
nifedipine JJ i
. . i

As IN N
a DT N
result NN N
, , N
17 CD N
% NN N
of IN N
those DT N
taking VBG N
lisinopril JJ i
and CC N
38 CD N
% NN N
of IN N
those DT N
taking VBG N
nifedipine NN i
required VBN N
additional JJ o
therapy NN o
with IN o
hydrochlorothiazide NN o
. . o

The DT N
addition NN N
of IN N
hydrochlorothiazide NN i
resulted VBD N
in IN N
similar JJ o
response NN o
rates NNS o
in IN N
the DT N
lisinopril NN i
and CC N
nifedipine JJ i
groups NNS N
( ( N
89 CD N
% NN N
and CC N
75 CD N
% NN N
respectively RB N
) ) N
. . N

The DT N
rate NN N
of IN N
reporting NN N
of IN N
adverse JJ o
events NNS o
considered VBN N
to TO N
be VB N
drug-related JJ N
and CC N
the DT N
rate NN o
of IN o
withdrawals NNS o
were VBD N
similar JJ N
for IN N
both DT N
treatments NNS N
. . N

Cough NNP o
was VBD N
more RBR N
often RB N
reported VBN N
with IN N
lisinopril NN i
and CC N
headache NN o
, , o
sweating NN o
, , N
and CC N
hot JJ o
flushes NNS o
with IN N
nifedipine JJ i
. . i

We PRP N
conclude VBP N
that IN N
once-daily RB N
titrated JJ N
doses NNS N
of IN N
lisinopril NN i
produced VBN N
better RBR N
control NN o
of IN o
blood NN o
pressure NN o
than IN N
twice-daily RB N
titrated JJ N
doses NNS N
of IN N
nifedipine NN i
. . i

-DOCSTART- -22923209- O O

Links NNS N
between IN N
multisensory NN o
processing NN o
and CC N
autism NN N
. . N

Autism NNP p
spectrum JJ p
disorder NN p
is VBZ N
typically RB N
associated VBN N
with IN N
social JJ N
deficits NNS N
and CC N
is VBZ N
often RB N
specifically RB N
linked VBN N
to TO N
difficulty VB N
with IN N
processing NN o
faces VBZ o
and CC o
other JJ o
socially RB o
relevant JJ o
stimuli NNS o
. . o

Emerging VBG N
research NN N
has VBZ N
suggested VBN N
that IN N
children NNS p
with IN p
autism NN p
might MD N
also RB N
have VB N
deficits NNS N
in IN N
basic JJ N
perceptual JJ N
abilities NNS N
including VBG N
multisensory NN N
processing NN N
( ( N
e.g. JJ N
, , N
simultaneously RB N
processing VBG N
visual JJ N
and CC N
auditory JJ N
inputs NNS N
) ) N
. . N

The DT N
current JJ N
study NN N
examined VBD N
the DT N
relationship NN o
between IN o
multisensory JJ o
temporal JJ o
processing NN o
( ( N
assessed JJ N
via IN N
a DT N
simultaneity NN i
judgment NN i
task NN i
wherein NN i
participants NNS i
were VBD i
to TO i
report VB i
whether IN i
a DT i
visual JJ i
stimulus NN i
and CC i
an DT i
auditory JJ i
stimulus NN i
occurred VBD i
at IN i
the DT i
same JJ i
time NN i
or CC i
at IN i
different JJ i
times NNS i
) ) i
and CC o
self-reported JJ o
symptoms NNS o
of IN o
autism NN o
( ( N
assessed JJ N
via IN N
the DT N
Autism NNP i
Spectrum NNP i
Quotient NNP i
questionnaire NN i
) ) i
. . N

Data NNS N
from IN N
over IN p
100 CD p
healthy JJ p
adults NNS p
revealed VBD N
a DT N
relationship NN N
between IN N
these DT N
two CD N
factors NNS N
as IN N
multisensory NN o
timing VBG o
perception NN o
correlated VBN o
with IN o
symptoms NNS o
of IN o
autism NN o
. . o

Specifically RB N
, , N
a DT N
stronger JJR N
bias NN o
to TO N
perceive VB N
auditory JJ o
stimuli NNS o
occurring VBG o
before IN N
visual JJ N
stimuli NN N
as IN N
simultaneous JJ N
was VBD N
associated VBN N
with IN N
greater JJR o
levels NNS o
of IN o
autistic JJ o
symptoms NNS o
. . o

Additional NNP N
data NN N
and CC N
analyses NNS N
confirm VBP N
that IN N
this DT N
relationship NN o
is VBZ o
specific JJ o
to TO o
multisensory JJ o
processing NN o
and CC o
symptoms NNS o
of IN o
autism NN o
. . o

These DT N
results NNS N
provide VBP N
insight RB N
into IN N
the DT N
nature NN N
of IN N
multisensory NN N
processing NN N
while IN N
also RB N
revealing VBG N
a DT N
continuum NN N
over IN N
which WDT N
perceptual JJ N
abilities NNS N
correlate VBP N
with IN N
symptoms NNS N
of IN N
autism NN N
and CC N
that IN N
this DT N
continuum NN N
is VBZ N
not RB N
just RB N
specific JJ N
to TO N
clinical JJ N
populations NNS N
but CC N
is VBZ N
present JJ N
within IN N
the DT N
general JJ p
population NN p
. . p

-DOCSTART- -17845737- O O

Expectancies NNS N
, , N
not RB N
aroma RB N
, , N
explain JJ N
impact NN N
of IN N
lavender NN i
aromatherapy NN i
on IN N
psychophysiological JJ N
indices NNS N
of IN N
relaxation NN N
in IN N
young JJ p
healthy JJ p
women NNS p
. . p

OBJECTIVES NNP N
In IN N
aromatherapy NN i
, , i
lavender JJR i
aroma NN i
is VBZ N
reputed VBN N
to TO N
assist VB N
with IN N
relaxation NN N
. . N

However RB N
, , N
while IN N
there EX N
is VBZ N
much JJ N
anecdotal JJ N
evidence NN N
to TO N
that DT N
effect NN N
, , N
the DT N
empirical JJ N
literature NN N
is VBZ N
very RB N
inconsistent JJ N
. . N

Failure NN N
to TO N
employ VB N
adequate JJ N
placebos NNS i
, , N
proper JJ N
blinding NN N
, , N
objective JJ N
measures NNS N
, , N
or CC N
screening NN N
of IN N
prior JJ N
beliefs NNS N
about IN N
aromatherapy NN N
means NNS N
that IN N
many JJ N
previous JJ N
findings NNS N
could MD N
have VB N
been VBN N
influenced VBN N
by IN N
expectancy NN N
biases NNS N
. . N

The DT N
present JJ N
study NN N
sought VBD N
to TO N
establish VB N
whether IN N
lavender NN i
aroma NN i
and/or JJ N
expectancies NNS N
affect VBP N
post-stress JJ N
relaxation NN N
. . N

DESIGN VB N
A DT N
double-blind NN N
, , N
3 CD N
( ( N
aroma NN N
) ) N
x VBZ N
3 CD N
( ( N
instruction NN N
) ) N
x VBZ N
10 CD N
( ( N
time NN N
in IN N
minutes NNS N
) ) N
mixed-factorial JJ i
placebo-controlled JJ i
trial NN N
. . N

METHOD NNP N
In IN N
a DT N
laboratory NN N
, , N
96 CD p
healthy JJ p
undergraduate JJ p
women NNS p
were VBD N
exposed VBN i
to TO i
lavender VB i
, , i
placebo NN i
, , i
or CC i
no DT i
aroma NN i
during IN N
physiologically RB N
assessed VBN N
relaxation NN N
after IN N
an DT N
arousing VBG N
cognitive JJ i
task NN i
. . i

Where WRB N
an DT N
aroma NN N
was VBD N
presented VBN N
, , N
an DT N
instructional JJ N
priming NN N
procedure NN N
was VBD N
used VBN N
to TO N
manipulate VB N
participants NNS N
' POS N
expectancies NNS N
about IN N
the DT N
aroma NN N
's POS N
likely JJ N
impact NN N
on IN N
their PRP$ N
ability NN N
to TO N
relax VB N
. . N

RESULTS NNP N
Results NNP N
showed VBD N
no DT N
effect NN N
of IN N
aroma NN o
on IN o
galvanic JJ o
skin NN o
response NN o
during IN N
relaxation NN N
. . N

However RB N
, , N
the DT N
nature NN N
of IN N
instructional JJ N
prime NN N
was VBD N
associated VBN N
with IN N
relaxation NN o
patterns NNS o
: : o
when WRB N
expecting VBG N
the DT N
aroma NN N
to TO N
inhibit VB N
them PRP N
, , N
participants NNS N
relaxed VBD o
more RBR N
; : N
when WRB N
expecting VBG N
facilitation NN N
, , N
participants NNS N
relaxed VBD o
less RBR N
. . N

The DT N
effect NN N
was VBD N
not RB N
seen VBN N
with IN N
regard NN N
to TO N
self-reported JJ o
relaxation NN o
( ( N
as IN N
represented VBN N
by IN N
changes NNS N
in IN N
state NN N
anxiety NN N
) ) N
and CC N
was VBD N
independent JJ N
of IN N
ratings NNS N
of IN N
attitudes NNS o
towards NNS N
aromatherapy NN N
. . N

CONCLUSIONS VB N
The DT N
findings NNS N
imply VBP N
that IN N
the DT N
previous JJ N
associations NNS N
of IN N
lavender NN i
aroma NN i
with IN N
assisted JJ N
relaxation NN N
may MD N
have VB N
been VBN N
influenced VBN N
by IN N
expectancy NN N
biases NNS N
, , N
and CC N
that IN N
the DT N
relevant JJ N
expectancies NNS N
are VBP N
easily RB N
manipulable JJ N
. . N

-DOCSTART- -10674229- O O

Differential JJ N
effects NNS N
of IN N
amino NN N
acid NN N
and CC N
ketoacid VB N
on IN N
protein NN N
metabolism NN N
in IN N
humans NNS p
. . p

We PRP N
examined VBD N
the DT N
effects NNS N
of IN N
insulin NN N
, , N
amino JJ N
acid NN N
( ( N
AA NNP N
) ) N
, , N
and CC N
branched-chain JJ N
ketoacid NN N
( ( N
KA NNP N
) ) N
availability NN N
on IN N
leucine JJ N
kinetics NNS N
in IN N
eight CD p
healthy JJ p
volunteers NNS p
( ( p
age NN p
= VBZ p
22 CD p
+/- JJ p
2 CD p
y NN p
, , p
body NN p
mass NN p
index NN p
= VBD p
24 CD p
+/- JJ p
1 CD p
kg NN p
) ) p
by IN N
using VBG N
the DT N
euglycemic JJ i
insulin NN i
clamp NN i
and CC i
[ JJ i
1-14C JJ i
] NNP i
leucine NN i
turnover NN i
techniques NNS i
. . i

Four CD N
experimental JJ N
conditions NNS N
were VBD N
studied VBN N
: : N
study NN N
I PRP N
, , N
hyperinsulinemia NN N
; : N
study NN N
II NNP N
, , N
hyperinsulinemia NN N
with IN N
maintenance NN N
of IN N
basal NN N
plasma NN N
AA NNP N
and CC N
branched-chain JJ N
KA NNP N
concentrations NNS N
; : N
study NN N
III NNP N
, , N
hyperinsulinemia NN N
with IN N
hyperaminoacidemia NN N
and CC N
basal NN N
plasma VBP N
branched-chain NN N
KA NNP N
concentrations NNS N
; : N
and CC N
study VB N
IV NNP N
, , N
hyperinsulinemia NN N
plus CC N
basal NN N
plasma VBP N
AA NNP N
concentrations NNS N
and CC N
elevated VBD N
branched-chain NN N
KA NNP N
levels NNS N
. . N

Basal NNP N
endogenous JJ o
leucine NN o
flux NN o
( ( o
ELF NNP o
) ) o
averaged VBD N
1.20 CD N
+/- JJ N
0.05 CD N
( ( N
mumol.kg-1.min-1 NN N
, , N
mean JJ N
+/- JJ N
SE NNP N
) ) N
; : N
basal CC N
leucine JJ o
oxidation NN o
( ( o
LOX NNP o
) ) o
was VBD N
0.25 CD N
+/- JJ N
0.01 CD N
; : N
and CC N
basal VB N
non-oxidative JJ o
leucine NN o
disposal NN o
( ( o
NOLD NNP o
) ) o
was VBD N
0.95 CD N
+/- JJ N
0.04 CD N
. . N

ELF NNP o
significantly RB N
decreased VBD N
in IN N
study NN N
I PRP N
( ( N
0.77 CD N
+/- JJ N
0.06 CD N
mumol.kg-1.min-1 NN N
, , N
P NNP N
< VBZ N
0.01 CD N
versus NN N
basal NN N
) ) N
. . N

When WRB N
plasma NN o
AA NNP o
and CC o
branched-chain JJ o
KA NNP o
were VBD N
either RB N
maintained VBN N
at IN N
their PRP$ N
basal NN N
levels NNS N
( ( N
study VB N
II NNP N
) ) N
or CC N
increased VBN N
above IN N
baseline NN N
values NNS N
( ( N
studies NNS N
III NNP N
and CC N
IV NNP N
) ) N
, , N
ELF NNP N
declined VBD N
further RBR N
( ( N
0.64 CD N
+/- JJ N
0.05 CD N
, , N
0.66 CD N
+/- JJ N
0.02 CD N
, , N
and CC N
0.66 CD N
+/- JJ N
0.03 CD N
mumol.kg-1.min-1 NN N
, , N
respectively RB N
; : N
all DT N
Ps NNP N
< NNP N
0.01 CD N
versus NN N
basal NN N
and CC N
P NNP N
< NNP N
0.01 CD N
versus NN N
study NN N
I PRP N
) ) N
. . N

LOX NNP o
declined VBD N
in IN N
study NN N
I PRP N
( ( N
0.12 CD N
+/- JJ N
0.02 CD N
mumol.kg-1.min-1 NN N
, , N
P NNP N
< VBZ N
0.01 CD N
versus NN N
basal NN N
) ) N
but CC N
increased VBD N
significantly RB N
in IN N
studies NNS N
II NNP N
, , N
III NNP N
, , N
and CC N
IV NNP N
( ( N
0.31 CD N
+/- JJ N
0.04 CD N
, , N
0.37 CD N
+/- JJ N
0.03 CD N
, , N
and CC N
0.40 CD N
+/- JJ N
0.03 CD N
mumol.kg-1.min-1 NN N
, , N
respectively RB N
, , N
all DT N
Ps NNP N
< NNP N
0.01 CD N
versus NN N
basal NN N
, , N
P NNP N
< NNP N
0.05 CD N
study NN N
IV NNP N
versus NN N
study NN N
II NNP N
, , N
and CC N
P NNP N
< NNP N
0.05 CD N
study NN N
III NNP N
versus NN N
study NN N
II NNP N
) ) N
. . N

NOLD NNP o
declined VBD N
in IN N
study NN N
I PRP N
( ( N
0.65 CD N
+/- JJ N
0.05 CD N
mumol/kg.min NN N
, , N
P NNP N
< VBZ N
0.01 CD N
versus NN N
basal NN N
) ) N
, , N
whereas IN N
neither CC N
the DT N
maintenance NN N
of IN N
basal NN o
plasma IN o
AA/branched-chain NNP o
KA NNP o
levels NNS o
( ( N
study NN N
II NNP N
; : N
0.89 CD N
+/- JJ N
0.2 CD N
mumol.kg-1.min-1 NN N
) ) N
nor CC N
the DT N
elevation NN N
of IN N
plasma JJ o
branched-chain JJ o
KA NNP o
concentration NN o
( ( N
study JJ N
IV NNP N
; : N
0.96 CD N
+/- JJ N
0.1 CD N
mumol.kg-1.min-1 NN N
) ) N
increased VBD N
NOLD NNP o
above IN N
baseline NN N
level NN N
. . N

A DT N
stimulation NN N
of IN N
NOLD NNP o
was VBD N
observed VBN N
only RB N
when WRB N
plasma JJ o
AA NNP o
levels NNS o
were VBD N
increased VBN N
( ( N
study NN N
III NNP N
; : N
1.23 CD N
+/- JJ N
0.03 CD N
mumol/kg.min NN N
, , N
P NNP N
< VBZ N
0.01 CD N
versus NN N
basal NN N
) ) N
. . N

In IN N
conclusion NN N
, , N
the DT N
present JJ N
data NNS N
do VBP N
not RB N
support VB N
the DT N
concept NN N
of IN N
a DT N
direct JJ N
anabolic JJ N
action NN N
of IN N
ketoanalogs NNS N
but CC N
do VBP N
provide VB N
additional JJ N
evidence NN N
for IN N
the DT N
pivotal JJ N
role NN N
of IN N
AA NNP N
availability NN N
in IN N
the DT N
stimulation NN N
of IN N
whole-body NN N
protein NN N
synthesis NN N
. . N

-DOCSTART- -7557852- O O

Antipyrine NNP o
clearance NN o
and CC o
response NN o
to TO o
interferon VB o
treatment NN o
in IN N
patients NNS p
with IN p
chronic JJ p
active JJ p
hepatitis NN p
C. NNP p
To TO N
determine VB N
whether IN N
hepatic JJ N
metabolic JJ N
function NN N
affects VBZ N
the DT N
response NN o
to TO o
interferon VB o
treatment NN o
, , N
we PRP N
measured VBD N
antipyrine JJ o
clearance NN o
( ( o
APC NNP o
) ) o
in IN N
85 CD p
patients NNS p
with IN p
chronic JJ p
active JJ p
hepatitis NN p
C NNP p
and CC N
compared VBN N
the DT N
results NNS N
with IN N
treatment NN o
outcome NN o
. . o

Among IN N
55 CD p
patients NNS p
who WP p
responded VBD p
to TO p
interferon VB i
by IN p
normalization NN p
of IN p
alanine JJ p
transaminase NN p
( ( p
ALT NNP p
) ) p
, , p
median JJ p
APC NNP p
before IN p
treatment NN p
was VBD p
0.47 CD p
( ( p
range NN p
, , p
0.12 CD p
to TO p
0.98 CD p
; : p
normal JJ p
range NN p
, , p
0.34 CD p
to TO p
1.02 CD p
mL/min/kg NNS p
body NN p
wt NN p
) ) p
, , p
a DT p
value NN p
that WDT p
was VBD p
significantly RB p
greater JJR p
than IN p
in IN p
30 CD p
nonresponders NNS p
( ( p
0.23 CD p
; : p
0.08 CD p
to TO p
0.67 CD p
mL/min/kg NNS p
body NN p
wt NN p
, , p
P NNP p
< NNP p
.001 NNP p
) ) p
. . N

APC NNP N
was VBD N
closely RB N
associated VBN N
with IN N
response NN o
to TO o
interferon VB o
. . o

The DT N
response NN o
rate NN o
among IN N
cases NNS N
with IN N
values NNS N
> VBP N
0.25 CD N
mL/min/kg NN N
body NN N
weight NN N
was VBD N
79 CD N
% NN N
, , N
the DT N
same JJ N
as IN N
in IN N
cases NNS N
without IN N
cirrhosis NN N
. . N

Cases NNS N
without IN N
cirrhosis NN N
and CC N
with IN N
APC NNP N
of IN N
> NNP N
0.25 CD N
mL/min/kg NN N
body NN N
weight NN N
had VBD N
an DT N
85 CD N
% NN N
chance NN N
of IN N
responding VBG o
to TO o
interferon VB o
; : o
this DT N
was VBD N
unlikely JJ N
a DT N
simple JJ N
reflection NN N
of IN N
histological JJ N
activity NN N
, , N
because IN N
the DT N
correlation NN N
with IN N
Scheuer NNP o
score NN o
was VBD N
poor JJ N
in IN N
this DT N
subgroup NN N
( ( N
r JJ N
= NNP N
-.31 NNP N
, , N
P NNP N
< NNP N
.05 NNP N
) ) N
. . N

A DT p
second JJ p
, , p
independent JJ p
group NN p
of IN p
43 CD p
patients NNS p
was VBD N
used VBN N
to TO N
test VB N
the DT N
predictive JJ o
value NN o
of IN o
APC NNP o
( ( N
using VBG N
0.25 CD N
mL/min/kg NN N
body NN N
wt VBD N
as IN N
a DT N
cut-off NN N
) ) N
for IN N
response NN N
to TO N
interferon VB i
treatment NN N
. . N

In IN N
this DT N
group NN N
, , N
APC NNP N
correctly RB N
predicted VBD N
positive JJ o
response NN o
to TO o
interferon VB o
in IN N
75 CD N
% NN N
of IN N
cases NNS N
. . N

APC NNP N
was VBD N
also RB N
used VBN N
to TO N
measure VB N
the DT N
effects NNS N
of IN N
treatment NN N
on IN N
hepatic JJ o
metabolic JJ o
function NN o
. . o

Regardless NNP N
of IN N
outcome NN N
, , N
there EX N
was VBD N
no DT N
change NN N
in IN N
APC NNP o
at IN N
the DT N
end NN N
of IN N
a DT N
6-month JJ N
course NN N
of IN N
interferon NN i
treatment NN N
. . N

Six CD N
months NNS N
later RB N
, , N
however RB N
, , N
improvement NN N
in IN N
APC NNP N
( ( N
14 CD N
% NN N
; : N
P NNP N
< NNP N
.05 NNP N
) ) N
was VBD N
evident JJ N
among IN N
responders NNS N
but CC N
not RB N
in IN N
those DT N
who WP N
had VBD N
failed VBN N
to TO N
respond VB N
to TO N
interferon VB N
. . N

( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
250 CD N
WORDS NNP N
) ) N
-DOCSTART- -12110494- O O

Use NNP N
of IN N
high-dose JJ N
cytarabine NN i
to TO N
enhance VB N
cisplatin JJ i
cytotoxicity-effects NNS o
on IN N
the DT N
response NN N
and CC N
overall JJ N
survival NN o
rates NNS o
of IN N
advanced JJ p
head NN p
and CC p
neck NN p
cancer NN p
patients NNS p
. . p

UNLABELLED IN N
It PRP N
has VBZ N
been VBN N
reported VBN N
that IN N
cytarabine NN i
, , N
acting VBG N
by IN N
at IN N
least JJS N
two CD N
different JJ N
mechanisms NNS N
, , N
enhances VBZ N
the DT N
cytotoxic JJ N
effect NN N
of IN N
cisplatin NN i
in IN N
in IN N
vitro JJ N
systems NNS N
. . N

The DT N
aim NN N
of IN N
this DT N
open JJ N
, , N
prospective JJ N
, , N
randomised VBD N
study NN N
was VBD N
to TO N
estimate VB N
the DT N
eventual JJ N
benefits NNS N
from IN N
the DT N
inclusion NN N
of IN N
high-dose JJ N
cytarabine NN i
in IN N
the DT N
cisplatin-5-fluorouracil NN i
( ( i
5-FU JJ i
) ) i
regimen NNS N
as IN N
first-line JJ p
treatment NN p
of IN p
patients NNS p
with IN p
advanced JJ p
head NN p
and CC p
neck NN p
cancer NN p
. . p

The DT N
study NN N
recruited VBD N
successive JJ p
patients NNS p
with IN p
unresectable JJ p
grade NN p
I/II NNP p
head NN p
and CC p
neck NN p
cancer NN p
who WP p
were VBD p
not RB p
suitable JJ p
for IN p
irradiation NN i
treatment NN i
( ( p
T NNP p
any DT p
N3 NNP p
or CC p
T4 NNP p
N2C NNP p
) ) p
, , p
metastatic JJ p
or CC p
previously RB p
irradiated VBN p
. . p

All DT N
patients NNS N
gave VBD N
their PRP$ N
informed JJ N
consent NN N
. . N

A DT N
joint JJ N
ear NN N
, , N
nose JJ N
and CC N
throat NN N
( ( N
ENT NNP N
) ) N
oncological JJ N
committee NN N
performed VBD N
the DT N
selection NN N
. . N

A DT p
total NN p
of IN p
170 CD p
patients NNS p
were VBD p
included VBN p
in IN p
the DT p
study NN p
. . p

Patients NNS N
randomised VBD N
to TO N
arm VB N
A NNP N
were VBD N
given VBN N
1000 CD i
mg/m NN i
( ( i
2 CD i
) ) i
cytarabine NN i
on IN N
day NN N
1 CD N
preceding NN N
for IN N
6 CD N
h NN N
cisplatin NN i
infusion NN i
, , N
30 CD N
mg/m NN N
( ( N
2 CD N
) ) N
/24 NN N
h NN N
cisplatin NN i
intravenous JJ N
( ( N
i.v JJ N
. . N

) ) N
bolus JJ N
days NNS N
1-4 CD N
and CC N
1000 CD N
mg/m NN N
( ( N
2 CD N
) ) N
/24 NN N
h JJ N
5-FU JJ N
in IN N
a DT N
4-h JJ N
infusion NN N
on IN N
days NNS N
1-4 JJ N
. . N

Patients NNS N
in IN N
arm NN N
B NNP N
were VBD N
given VBN N
cisplatin NNS i
and CC i
5-FU JJ i
in IN N
the DT N
same JJ N
dosage NN N
and CC N
schedule NN N
as IN N
in IN N
arm NN N
A NNP N
. . N

Additional NNP N
irradiation+/-surgery NN i
was VBD N
performed VBN N
if IN N
and CC N
when WRB N
feasible JJ N
. . N

Patients NNS N
in IN N
both DT N
arms NNS N
were VBD N
well RB N
balanced VBN N
with IN N
regard NN N
to TO N
clinical JJ N
variables NNS N
. . N

The DT N
following JJ N
results NNS N
were VBD N
obtained VBN N
: : N
Arm NN N
A NN N
: : N
84 CD N
patients NNS N
were VBD N
included VBN N
, , N
74 CD N
were VBD N
evaluable JJ N
for IN N
activity NN N
; : N
RESPONSE NNP N
complete JJ o
response NN o
( ( o
CR NNP o
) ) o
8 CD N
( ( N
11 CD N
% NN N
) ) N
, , N
partial JJ o
response NN o
( ( o
PR NNP o
) ) o
40 CD N
( ( N
54 CD N
% NN N
) ) N
, , N
stable JJ o
disease NN o
( ( o
SD NNP o
) ) o
11 CD N
( ( N
15 CD N
% NN N
) ) N
, , N
progressive JJ o
disease NN o
( ( N
PD NNP N
) ) N
15 CD N
( ( N
20 CD N
% NN N
) ) N
. . N

The DT N
overall JJ o
response NN o
rate NN o
( ( o
RR NNP o
) ) o
based VBN N
on IN N
the DT N
evaluable JJ N
patients NNS N
was VBD N
48/74 CD N
( ( N
65 CD N
% NN N
, , N
95 CD N
% NN N
confidence NN N
interval NN N
( ( N
CI NNP N
) ) N
54-75 CD N
% NN N
) ) N
; : N
The DT N
RR NNP o
based VBN o
on IN o
an DT o
intent-to-treat JJ o
analysis NN o
was VBD N
57 CD N
% NN N
, , N
95 CD N
% NN N
CI NNP N
47-67 CD N
% NN N
; : N
Median JJ o
survival NN o
was VBD N
13 CD N
months NNS N
; : N
There EX N
were VBD N
50 CD N
episodes NNS N
of IN N
granulocytopenia NN o
grade NN o
IV NNP o
and CC N
15 CD N
of IN N
febrile JJ o
neutropenia NNS o
per IN N
316 CD N
cycles NNS N
. . N

Arm NN N
B NN N
: : N
86 CD N
patients NNS N
were VBD N
included VBN N
, , N
80 CD N
were VBD N
evaluable JJ N
for IN N
activity NN N
; : N
RESPONSE NNP N
CR NNP o
7 CD N
( ( N
9 CD N
% NN N
) ) N
, , N
PR NNP o
29 CD N
( ( N
36 CD N
% NN N
) ) N
, , N
SD NNP o
10 CD N
( ( N
12.5 CD N
% NN N
) ) N
, , N
PD NNP o
34 CD N
( ( N
42.5 CD N
% NN N
) ) N
; : N
The DT N
overall JJ o
RR NNP o
based VBN N
on IN N
the DT N
evaluable JJ N
patients NNS N
was VBD N
36/80 CD N
( ( N
45 CD N
% NN N
, , N
95 CD N
% NN N
CI NNP N
35-56 CD N
% NN N
) ) N
; : N
The DT N
RR NNP o
based VBN o
on IN o
an DT o
intent-to-treat JJ o
analysis NN o
was VBD N
42 CD N
% NN N
, , N
95 CD N
% NN N
CI NNP N
32-52 CD N
% NN N
; : N
Median JJ o
survival NN o
was VBD N
8 CD N
months NNS N
; : N
There EX N
were VBD N
14 CD N
episodes NNS N
of IN N
granulocytopenia NN N
grade NN N
IV NNP N
and CC N
7 CD N
febrile NN N
neutropenias NNS N
per IN N
324 CD N
cycles NNS N
. . N

The DT N
RR NNP o
was VBD o
significantly RB o
higher JJR o
in IN N
arm NN N
A NNP N
( ( N
P=0.013 NNP N
) ) N
, , N
power NN N
( ( N
one-sided JJ N
) ) N
80 CD N
% NN N
. . N

The DT N
proportion NN N
of IN N
patients NNS N
from IN N
the DT N
appropriate JJ N
subset NN N
who WP N
achieved VBD N
a DT N
clinical JJ o
response NN o
making VBG o
additional JJ o
treatment NN o
feasible NN o
was VBD N
higher RBR o
in IN N
arm NN N
A NNP N
( ( N
P=0.00015 NNP N
) ) N
, , N
as RB N
well RB N
as IN N
the DT N
proportion NN o
of IN o
patients NNS o
with IN o
a DT o
performance NN o
status NN o
2+3 CD o
achieving VBG o
a DT o
response NN o
( ( N
P NNP N
< NNP N
0.0001 CD N
) ) N
. . N

Using VBG N
the DT N
Log-rank JJ N
test NN N
, , N
patients NNS N
from IN N
arm NN N
A NNP N
achieved VBD N
a DT N
significantly RB o
longer RBR o
survival JJ o
( ( N
P=0.009 NNP N
) ) N
, , N
with IN N
the DT N
probability NN N
of IN N
survival NN o
at IN o
12 CD o
months NNS o
of IN N
0.58 CD N
for IN N
patients NNS N
in IN N
arm NN N
A NN N
and CC N
0.28 CD N
for IN N
patients NNS N
in IN N
arm NN N
B. NNP N
Grade NNP o
IV NNP o
granulocytopenia NN o
and CC o
thrombocytopenia NN o
were VBD N
more RBR o
frequent JJ o
in IN N
arm NN N
A NN N
. . N

Due JJ N
to TO N
its PRP$ N
haematological JJ o
side-effects NNS o
, , N
cytarabine NN i
might MD N
not RB N
be VB N
the DT N
ideal JJ N
drug NN N
to TO N
modulate VB N
the DT N
cytotoxicity NN o
of IN N
cisplatin NN i
. . i

However RB N
, , N
other JJ N
modulators NNS N
of IN N
its PRP$ N
activity NN N
could MD N
be VB N
of IN N
interest NN N
for IN N
further JJ N
studies NNS N
in IN N
head NN p
and CC p
neck NN p
cancer NN p
patients NNS p
. . p

-DOCSTART- -25392671- O O

Prospective JJ N
randomized VBN N
comparison NN N
between IN N
transperitoneal JJ i
laparoscopic NN i
pyeloplasty NN i
and CC p
retroperitoneoscopic NN i
pyeloplasty NN i
for IN p
primary JJ p
ureteropelvic JJ p
junction NN p
obstruction NN p
. . p

BACKGROUND NNP N
AND CC N
OBJECTIVES NNP N
To TO N
compare VB N
laparoscopic JJ i
transperitoneal JJ i
versus NN N
retroperitoneoscopic NN i
pyeloplasty NN i
for IN N
primary JJ p
ureteropelvic JJ p
junction NN p
obstruction NN p
in IN N
a DT N
prospective JJ N
randomized JJ N
manner NN N
and CC N
assess NN N
overall JJ N
results NNS N
with IN N
long-term JJ N
follow-up NN N
. . N

METHODS NNP N
In IN N
this DT N
prospective JJ N
study NN N
, , N
from IN p
2008 CD p
to TO p
2012 CD p
, , p
112 CD p
cases NNS p
of IN p
primary JJ p
ureteropelvic JJ p
junction NN p
obstruction NN p
were VBD p
randomized VBN p
in IN p
a DT p
1:1 CD p
ratio NN p
into IN p
2 CD p
groups NNS p
. . p

Group NNP i
I PRP i
included VBD i
patients NNS i
who WP i
underwent VBP i
transperitoneal JJ i
laparoscopic NN i
pyeloplasty NN i
, , i
and CC i
group NN i
II NNP i
consisted VBD i
of IN i
patients NNS i
who WP i
underwent VBP i
retroperitoneoscopic NN i
laparoscopic NN i
pyeloplasty NN i
. . i

Demographic NNP N
and CC N
clinical JJ N
characteristics NNS N
and CC N
postoperative JJ N
and CC N
operative JJ N
data NNS N
were VBD N
collected VBN N
and CC N
analyzed VBN N
. . N

The DT N
statistical JJ N
analysis NN N
was VBD N
performed VBN N
with IN N
the DT N
Fisher NNP N
exact JJ N
test NN N
, , N
?2 JJ N
test NN N
, , N
and CC N
Mann-Whitney NNP N
U NNP N
test NN N
for IN N
independent JJ N
groups NNS N
, , N
and CC N
P NNP N
< NNP N
.05 NNP N
was VBD N
considered VBN N
statistically RB N
significant JJ N
. . N

RESULTS VB N
The DT o
total JJ o
operative JJ o
time NN o
and CC o
intracorporeal VB o
suturing JJ o
time NN o
were VBD N
significantly RB N
higher JJR N
in IN N
group NN N
II NNP N
than IN N
in IN N
group NN N
I PRP N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

The DT o
visual JJ o
analog NN o
scale NN o
score NN o
for IN o
pain NN o
on IN N
postoperative JJ N
day NN N
1 CD N
and CC N
the DT N
requirement NN N
for IN N
tramadol NN N
were VBD N
significantly RB N
higher JJR N
in IN N
group NN N
I PRP N
than IN N
in IN N
group NN N
II NNP N
( ( N
P=.004 NNP N
) ) N
. . N

The DT o
hospital NN o
stay NN o
and CC o
the DT o
rate NN o
of IN o
temporary JJ o
ileus NNS o
were VBD N
significantly RB N
greater JJR N
( ( N
P NNP N
< NNP N
.036 NNP N
and CC N
P NNP N
< NNP N
.02 NNP N
, , N
respectively RB N
) ) N
in IN N
group NN N
I PRP N
than IN N
in IN N
group NN N
II NNP N
. . N

The DT o
success NN o
rate NN o
of IN i
transperitoneal NN i
laparoscopic NN i
pyeloplasty JJ i
versus NN i
retroperitoneoscopic NN i
laparoscopic NN i
pyeloplasty NN i
was VBD N
96.4 CD N
% NN N
versus IN N
96.6 CD N
% NN N
with IN N
a DT N
mean JJ N
follow-up JJ N
period NN N
of IN N
30.75?4.85 CD N
months NNS N
versus IN N
30.99?5.59 CD N
months NNS N
( ( N
P NNP N
< NNP N
.88 NNP N
) ) N
. . N

CONCLUSION NNP i
Transperitoneal NNP i
laparoscopic NN i
pyeloplasty NN i
is VBZ i
associated VBN N
with IN N
significantly RB N
greater JJR N
postoperative JJ N
pain NN N
, , N
a DT N
higher JJR N
tramadol NN N
dose NN N
, , N
a DT N
higher JJR N
rate NN N
of IN N
ileus NN N
, , N
and CC N
a DT N
longer JJR N
hospital JJ N
stay NN N
in IN N
comparison NN N
with IN N
retroperitoneoscopic NN N
laparoscopic NN N
pyeloplasty NN N
. . N

Although IN N
the DT N
operative JJ N
time NN N
for IN N
retroperitoneoscopic NN i
laparoscopic NN i
pyeloplasty NN i
is VBZ i
significantly RB N
longer RBR N
, , N
the DT N
success NN N
rate NN N
remains VBZ N
the DT N
same JJ N
for IN N
both DT N
procedures NNS N
. . N

-DOCSTART- -19915222- O O

Intravenous JJ N
platelet NN N
blockade NN N
with IN N
cangrelor NN i
during IN N
PCI NNP p
. . p

BACKGROUND NNP N
Intravenous NNP N
cangrelor NN i
, , N
a DT N
rapid-acting NN N
, , N
reversible JJ N
adenosine NN N
diphosphate NN N
( ( N
ADP NNP N
) ) N
receptor NN N
antagonist NN N
, , N
might MD N
reduce VB N
ischemic JJ N
events NNS N
during IN N
percutaneous JJ p
coronary JJ p
intervention NN p
( ( p
PCI NNP p
) ) p
. . p

METHODS NNP N
In IN N
this DT N
double-blind NN N
, , N
placebo-controlled JJ N
study NN N
, , N
we PRP N
randomly VBP N
assigned JJ N
5362 CD p
patients NNS p
who WP p
had VBD p
not RB p
been VBN p
treated VBN p
with IN p
clopidogrel NN p
to TO p
receive VB p
either DT p
cangrelor NN i
or CC i
placebo NN i
at IN p
the DT p
time NN p
of IN p
PCI NNP p
, , p
followed VBN p
by IN p
600 CD i
mg NNS i
of IN i
clopidogrel NN i
. . i

The DT N
primary JJ N
end NN N
point NN N
was VBD N
a DT N
composite JJ o
of IN o
death NN o
, , o
myocardial JJ o
infarction NN o
, , o
or CC o
ischemia-driven JJ o
revascularization NN o
at IN o
48 CD o
hours NNS o
. . o

Enrollment NN N
was VBD N
stopped VBN N
when WRB N
an DT N
interim JJ N
analysis NN N
concluded VBD N
that IN N
the DT N
trial NN N
would MD N
be VB N
unlikely JJ N
to TO N
show VB N
superiority NN N
for IN N
the DT N
primary JJ N
end NN N
point NN N
. . N

RESULTS VB N
The DT N
primary JJ o
end NN o
point NN o
occurred VBD p
in IN p
185 CD p
of IN p
2654 CD p
patients NNS p
receiving VBG p
cangrelor NN i
( ( p
7.0 CD p
% NN p
) ) p
and CC p
in IN p
210 CD p
of IN p
2641 CD p
patients NNS p
receiving VBG p
placebo NN i
( ( p
8.0 CD p
% NN p
) ) p
( ( N
odds NNS N
ratio NN N
in IN N
the DT N
cangrelor NN N
group NN N
, , N
0.87 CD N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NNP N
, , N
0.71 CD N
to TO N
1.07 CD N
; : N
P=0.17 NNP N
) ) N
( ( N
modified VBN N
intention-to-treat NN N
population NN N
adjusted VBN N
for IN N
missing VBG N
data NNS N
) ) N
. . N

In IN N
the DT N
cangrelor NN i
group NN N
, , N
as IN N
compared VBN N
with IN N
the DT N
placebo NN N
group NN N
, , N
two CD N
prespecified VBD N
secondary JJ N
end NN N
points NNS N
were VBD N
significantly RB N
reduced VBN N
at IN N
48 CD N
hours NNS N
: : N
the DT N
rate NN o
of IN o
stent JJ o
thrombosis NN o
, , N
from IN N
0.6 CD N
% NN N
to TO N
0.2 CD N
% NN N
( ( N
odds JJ N
ratio NN N
, , N
0.31 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
0.11 CD N
to TO N
0.85 CD N
; : N
P=0.02 NNP N
) ) N
, , N
and CC N
the DT N
rate NN o
of IN o
death NN o
from IN o
any DT o
cause NN o
, , N
from IN N
0.7 CD N
% NN N
to TO N
0.2 CD N
% NN N
( ( N
odds JJ N
ratio NN N
, , N
0.33 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
0.13 CD N
to TO N
0.83 CD N
; : N
P=0.02 NNP N
) ) N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
the DT N
rate NN o
of IN o
blood NN o
transfusion NN o
( ( N
1.0 CD N
% NN N
in IN N
the DT N
cangrelor NN i
group NN N
and CC N
0.6 CD N
% NN N
in IN N
the DT N
placebo NN i
group NN N
, , N
P=0.13 NNP N
) ) N
, , N
though IN N
major JJ o
bleeding VBG o
on IN N
one CD N
scale NN N
was VBD N
increased VBN N
in IN N
the DT N
cangrelor NN N
group NN N
, , N
from IN N
3.5 CD N
% NN N
to TO N
5.5 CD N
% NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
because IN N
of IN N
more JJR N
groin JJ o
hematomas NN o
. . o

CONCLUSIONS VB N
The DT N
use NN N
of IN N
periprocedural JJ N
cangrelor NN i
during IN N
PCI NNP N
was VBD N
not RB N
superior JJ N
to TO N
placebo VB N
in IN N
reducing VBG N
the DT N
primary JJ N
end NN N
point NN N
. . N

The DT N
prespecified JJ N
secondary JJ N
end NN N
points NNS N
of IN N
stent JJ N
thrombosis NN N
and CC N
death NN N
were VBD N
lower JJR N
in IN N
the DT N
cangrelor NN i
group NN N
, , N
with IN N
no DT N
significant JJ N
increase NN N
in IN N
the DT N
rate NN N
of IN N
transfusion NN N
. . N

Further NNP N
study NN N
of IN N
intravenous JJ N
ADP NNP i
blockade NN i
with IN i
cangrelor NN i
may MD N
be VB N
warranted VBN N
. . N

( ( N
ClinicalTrials.gov NNP N
number NN N
, , N
NCT00385138 NNP N
. . N

) ) N
-DOCSTART- -7646610- O O

Paracervical JJ N
anesthesia NN N
for IN N
outpatient JJ o
hysteroscopy NN o
. . o

One CD p
hundred VBD p
seventy-seven JJ p
women NNS p
aged VBD p
41 CD p
+/- JJ p
8 CD p
( ( p
mean JJ p
+/- NNP p
SD NNP p
) ) p
years NNS p
, , p
referred VBD p
for IN p
evaluation NN p
of IN p
excessive JJ p
uterine JJ p
bleeding NN p
, , p
were VBD p
enrolled VBN p
in IN N
an DT N
open-label JJ N
randomized JJ N
trial NN N
to TO N
evaluate VB N
the DT N
efficacy NN N
of IN N
local JJ i
anesthesia NN i
before IN N
hysteroscopy NN o
in IN p
an DT p
outpatient JJ p
population NN p
. . p

The DT N
patients NNS N
underwent JJ N
hysteroscopy NN o
and CC i
endometrial JJ i
biopsy NN i
with IN i
paracervical JJ i
block NN i
by IN i
10 CD i
mL NNS i
of IN i
1 CD i
% NN i
mepivacaine NN i
hydrochloride JJ i
solution NN i
( ( N
n JJ N
= NNP N
87 CD N
) ) N
or CC N
no DT i
local JJ i
anesthesia NN i
( ( N
n JJ N
= NNP N
90 CD N
) ) N
and CC N
assessed VBD N
lower JJR N
abdominal JJ N
and CC N
pelvic JJ N
pain NN N
according VBG N
to TO N
a DT N
10-point JJ N
linear JJ N
analog NN N
scale NN N
. . N

The DT N
mean JJ o
+/- JJ o
SD NNP o
pain NN o
score NN o
was VBD N
4.5 CD N
+/- JJ N
2.0 CD N
at IN N
hysteroscopy NN o
and CC N
5.2 CD N
+/- JJ N
2.1 CD N
at IN N
endometrial JJ N
biopsy NN N
in IN N
the DT N
87 CD N
subjects NNS N
given VBN N
a DT N
paracervical JJ N
block NN N
versus NN N
4.9 CD N
+/- JJ N
2.2 CD N
and CC N
5.7 CD N
+/- JJ N
2.4 CD N
in IN N
the DT N
90 CD N
women NNS N
not RB N
given VBN N
local JJ N
anesthesia NN N
, , N
without IN N
statistically RB N
significant JJ N
differences NNS N
. . N

Paracervical JJ i
anesthesia NN i
for IN N
routine JJ N
outpatient NN o
hysteroscopy NN o
in IN N
premenopausal JJ p
women NNS p
may MD N
be VB N
superfluous JJ N
. . N

-DOCSTART- -22972771- O O

Effects NNS N
of IN N
self-directed JJ i
stress NN i
management NN i
training NN i
and CC i
home-based JJ i
exercise NN i
on IN i
stress NN o
management NN o
skills NNS o
in IN N
cancer NN p
patients NNS p
receiving VBG p
chemotherapy NN p
. . p

Although IN N
exercise NN N
may MD N
be VB N
used VBN N
by IN N
some DT N
to TO N
decrease VB N
distress NN N
, , N
little JJ N
is VBZ N
known VBN N
about IN N
how WRB N
it PRP N
may MD N
contribute VB N
to TO N
stress VB N
management NN N
( ( N
SM NNP N
) ) N
among IN N
patients NNS p
receiving VBG p
chemotherapy NN p
. . p

We PRP N
evaluated VBD N
whether IN N
exercise NN i
separately RB i
or CC i
in IN i
combination NN i
with IN i
SM NNP i
training NN i
is VBZ N
effective JJ N
at IN N
increasing VBG N
perceived JJ N
ability NN N
to TO N
manage VB N
stress NN N
. . N

Patients NNS p
receiving VBG p
chemotherapy NN i
( ( p
N NNP p
= NNP p
391 CD p
) ) p
were VBD p
randomized VBN p
to TO p
receive VB i
usual JJ i
care NN i
only RB i
( ( i
UCO NNP i
) ) i
, , i
SM NNP i
, , i
exercise NN i
( ( i
EX NNP i
) ) i
, , i
or CC i
stress JJ i
management NN i
and CC i
exercise NN i
( ( i
SMEX NNP i
) ) i
. . i

They PRP N
completed VBD N
the DT N
Measure NN N
of IN N
Current NNP N
Status NNP N
prior RB N
to TO N
receiving VBG N
chemotherapy NN N
and CC N
12 CD N
weeks NNS N
after IN N
the DT N
first JJ N
infusion NN N
. . N

We PRP N
hypothesized VBD N
that IN N
participants NNS N
randomized VBN N
to TO N
an DT N
intervention NN N
condition NN N
would MD N
report VB N
improvements NNS N
in IN N
relaxation NN o
, , o
awareness NN o
of IN o
tension NN o
, , o
getting VBG o
needs NNS o
met VBD o
and CC o
coping VBG o
confidence NN o
compared VBN N
with IN N
those DT N
receiving VBG N
UCO NNP N
. . N

Results NNP N
indicated VBD N
significant JJ N
group-by-time JJ N
interactions NNS N
for IN N
the DT N
following NN N
: : N
relaxation NN o
( ( N
UCO NNP N
versus NN N
SM NNP N
, , N
p NN N
= NNP N
0.008 CD N
) ) N
, , N
awareness NN o
of IN o
tension NN o
( ( N
UCO NNP N
versus NN N
SMEX NNP N
, , N
p NN N
= VBD N
0.029 CD N
and CC N
UCO NNP N
versus NN N
EX NNP N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
, , N
getting VBG o
needs NNS o
met VBD o
( ( N
UCO NNP N
versus NN N
SMEX NNP N
, , N
p NN N
= NNP N
0.020 CD N
) ) N
and CC N
Measure NN N
of IN N
Current NNP o
Status NNP o
total NN N
score NN N
( ( N
UCO NNP N
versus NN N
SMEX NNP N
, , N
p NN N
= VBD N
0.007 CD N
and CC N
UCO NNP N
versus NN N
EX NNP N
, , N
p NN N
= NNP N
0.016 CD N
) ) N
. . N

There EX N
were VBD N
no DT N
group-by-time JJ N
interactions NNS N
for IN N
coping VBG o
confidence NN o
( ( N
p-values JJ N
> NNP N
0.05 CD N
) ) N
. . N

This DT N
study NN N
provides VBZ N
support NN N
for IN N
including VBG N
an DT N
exercise NN o
component NN o
in IN N
SM NNP N
interventions NNS N
for IN N
cancer NN p
patients NNS p
receiving VBG p
chemotherapy NN p
( ( N
clinicaltrials.gov JJ N
identifier NN N
: : N
NCT00740038 NNP N
) ) N
. . N

-DOCSTART- -2527542- O O

The DT N
influence NN N
of IN N
prostaglandin NN N
inhibition NN N
by IN N
indomethacin NN i
on IN N
blood NN o
pressure NN o
and CC N
renal JJ o
function NN o
in IN N
hypertensive JJ p
patients NNS p
treated VBN p
with IN p
cilazapril NN i
. . i

1 CD N
. . N

In IN N
a DT N
placebo-controlled JJ i
double-blind JJ N
cross-over NN N
study NN N
lasting VBG N
6 CD N
weeks NNS N
, , N
twenty JJ p
patients NNS p
with IN p
essential JJ p
hypertension NN p
were VBD N
treated VBN N
with IN N
placebo NN i
for IN N
2 CD N
weeks NNS N
followed VBN N
by IN N
oral JJ i
cilazapril NN i
2.5 CD N
mg NN N
once RB N
a DT N
day NN N
or CC N
oral JJ i
indomethacin NN i
50 CD N
mg NN N
twice RB N
daily RB N
for IN N
2 CD N
weeks NNS N
. . N

Afterwards NNS N
they PRP N
received VBD N
the DT N
combination NN N
of IN N
both DT N
drugs NNS N
for IN N
a DT N
further JJ N
2 CD N
weeks NNS N
. . N

2 CD N
. . N

Cilazapril NNP i
significantly RB N
lowered VBD N
systolic JJ o
and CC o
diastolic JJ o
blood NN o
pressure NN o
for IN N
a DT N
period NN N
of IN N
24 CD N
h NNS N
post JJ N
administration NN N
. . N

3 CD N
. . N

Indomethacin NNP i
significantly RB N
attenuated VBD N
the DT N
antihypertensive JJ o
activity NN o
of IN N
cilazapril NN i
. . i

This DT N
was VBD N
more RBR N
pronounced JJ N
in IN N
those DT N
patients NNS N
who WP N
were VBD N
treated VBN N
for IN N
the DT N
initial JJ N
2 CD N
weeks NNS N
with IN N
indomethacin JJ i
plus CC i
placebo NN i
( ( N
and CC N
subsequently RB N
with IN N
cilazapril NN i
in IN N
addition NN N
) ) N
than IN N
in IN N
the DT N
subjects NNS N
who WP N
first RB N
received VBD N
cilazapril JJ i
plus CC i
placebo NN i
and CC N
then RB N
the DT N
combination NN N
. . N

4 CD N
. . N

Correspondingly VB N
the DT N
decrease NN N
of IN N
plasma JJ o
renin NN o
activity NN o
( ( o
PRA NNP o
) ) o
and CC o
urinary JJ o
prostaglandin NN o
excretion NN o
( ( o
PGE2 NNP o
) ) o
was VBD N
more RBR N
pronounced JJ N
in IN N
those DT N
patients NNS N
treated VBD N
initially RB N
with IN N
indomethacin NN i
. . i

5 CD N
. . N

The DT N
effect NN N
of IN N
indomethacin NN i
on IN N
the DT N
antihypertensive JJ N
effect NN N
of IN N
cilazapril NN i
appears VBZ N
to TO N
depend VB N
upon IN N
the DT N
sequence NN N
of IN N
drug NN N
administration NN N
. . N

-DOCSTART- -24961537- O O

Compared VBN N
with IN N
the DT N
intake NN N
of IN N
commercial JJ i
vegetable JJ i
juice NN i
, , N
the DT N
intake NN N
of IN N
fresh JJ i
fruit NN i
and CC i
komatsuna NN i
( ( i
Brassica NNP i
rapa VBZ i
L. NNP i
var NN i
. . i

perviridis NN i
) ) i
juice NN i
mixture NN i
reduces VBZ N
serum JJ p
cholesterol NN p
in IN p
middle-aged JJ p
men NNS p
: : p
a DT N
randomized VBN N
controlled VBN N
pilot NN N
study NN N
. . N

BACKGROUND NNP N
Vegetables NNP N
and CC N
fruits NNS N
are VBP N
rich JJ N
in IN N
vitamins NNS N
, , N
minerals NNS N
and CC N
, , N
dietary JJ N
fiber NN N
and CC N
contribute NN N
to TO N
the DT N
prevention NN N
and CC N
improvement NN N
of IN N
obesity NN N
and CC N
metabolic JJ N
syndrome NN N
. . N

However RB N
, , N
inadequate JJ N
intake NN N
of IN N
vegetable JJ N
and CC N
fruit NN N
is VBZ N
a DT N
concern NN N
in IN N
Japan.We NNP p
therefore RB N
produced VBD N
a DT N
juice NN N
mixture NN N
of IN N
fresh JJ i
fruit NN i
and CC i
komatsuna NN i
( ( i
Brassica NNP i
rapa VBZ i
L. NNP i
var NN i
. . i

perviridis NN i
: : i
B. NNP i
rapa NN i
) ) i
with IN N
the DT N
aim NN N
to TO N
investigate VB N
the DT N
effects NNS N
of IN N
this DT N
juice NN N
mixture NN N
on IN N
anthropometric JJ o
data NNS o
, , o
blood NN o
parameters NNS o
, , N
and CC N
dietary JJ N
intake NN N
differences NNS N
. . N

METHODS NNP N
This DT N
study NN N
was VBD N
performed VBN N
as IN N
a DT N
single JJ N
blind NN N
and CC N
randomized VBD N
controlled VBN N
trial NN N
. . N

Subjects NNS p
were VBD p
16 CD p
men NNS p
( ( p
mean JJ p
age NN p
, , p
46.4 CD p
? . p
7.1 CD p
years NNS p
) ) p
, , p
and CC p
they PRP N
were VBD N
divided VBN N
into IN N
two CD N
groups NNS N
( ( N
control NN N
group NN N
and CC N
intervention NN N
group NN N
) ) N
. . N

The DT N
intervention NN N
group NN N
consumed VBD i
the DT i
juice NN i
mixture NN i
of IN i
fresh JJ i
fruit NN i
and CC i
B. NNP i
rapa NN i
. . i

The DT i
control NN i
group NN i
consumed VBD i
commercial JJ i
vegetable JJ i
juice NN i
. . N

Subjects NNS N
consumed VBD N
juice NN N
twice RB N
a DT N
day NN N
throughout IN N
the DT N
weekday NN N
, , N
for IN N
4 CD N
weeks NNS N
. . N

We PRP N
prepared VBD N
both DT N
juices NNS N
with IN N
an DT N
equivalent JJ N
energy NN N
balance NN N
. . N

RESULTS NNP N
Weight NNP o
and CC o
body NN o
mass NN o
index NN o
( ( o
BMI NNP o
) ) o
of IN N
the DT N
control NN N
group NN N
after IN N
4 CD N
weeks NNS N
were VBD N
significantly RB N
increased VBN N
compared VBN N
with IN N
baseline NN N
values NNS N
. . N

Serum NNP o
total JJ o
cholesterol NN o
( ( o
T-Chol NNP o
) ) o
and CC o
low-density JJ o
lipoprotein NN o
cholesterol NN o
( ( o
LDL-Chol NNP o
) ) o
of IN o
the DT o
intervention NN N
group NN N
after IN N
4 CD N
weeks NNS N
were VBD N
significantly RB N
reduced VBN N
compared VBN N
with IN N
baseline NN N
values NNS N
. . N

Furthermore RB o
, , o
intake NN o
of IN o
total JJ o
vegetables NNS o
and CC o
fruits NNS o
were VBD o
significantly RB N
increased VBN N
compared VBN N
with IN N
baseline NN N
values NNS N
in IN N
both DT N
groups NNS N
. . N

CONCLUSIONS NNP N
Both NNP N
vegetable JJ N
juices NNS N
contributed VBD N
to TO N
improved JJ N
intake NN o
of IN o
total JJ o
vegetables NNS o
and CC o
fruit NN o
. . o

Compared VBN o
with IN N
the DT N
intake NN i
of IN i
commercial JJ i
vegetable JJ i
juice NN i
, , i
the DT i
intake NN N
of IN N
fresh JJ i
fruit NN i
and CC i
B. NNP i
rapa NN i
juice NN i
is VBZ i
highly RB N
effective JJ N
in IN o
reducing VBG o
serum NN o
cholesterol NN o
. . o

Short-term JJ o
intake NN N
of IN N
fresh JJ i
fruit NN i
and CC i
B. NNP i
rapa NN i
juice NN i
was VBD i
shown VBN N
to TO N
enhance VB o
cholesterol NN o
metabolism NN o
. . o

-DOCSTART- -21288666- O O

Effects NNS N
of IN N
maternal JJ N
and CC N
dietary JJ i
selenium NN i
( ( i
Se-enriched NNP i
yeast NN i
) ) i
on IN N
the DT N
expression NN p
of IN p
p34 NN p
( ( p
cdc2 NN p
) ) p
and CC p
CyclinB1 NNP p
of IN p
germ JJ p
cells NNS p
of IN p
their PRP$ p
offspring NN p
in IN p
goats NNS p
. . p

The DT N
aim NN N
of IN N
the DT N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
effect NN N
of IN N
selenium NN i
on IN N
the DT N
expression NN N
of IN N
p34 NN N
( ( N
cdc2 NN N
) ) N
and CC N
CyclinB1 NNP N
( ( N
two CD N
components NNS N
of IN N
MPF NNP N
regulating VBG N
cell NN N
cycle NN N
) ) N
of IN N
germ JJ N
cells NNS N
of IN N
their PRP$ N
offspring NN N
in IN N
goats NNS p
. . p

A DT N
herd NN p
of IN p
119 CD p
Taihang NNP p
Black NNP p
Goats NNP p
, , N
which WDT N
was VBD N
randomly RB N
divided VBN N
into IN N
4 CD N
treatments NNS N
, , N
received VBD N
experimental JJ i
diet JJ i
with IN i
different JJ i
Se NNP i
levels NNS i
( ( N
from IN N
Se-enriched NNP N
yeast NN N
) ) N
for IN N
174d CD N
. . N

The DT N
four CD N
treatments NNS N
, , N
fed VBN N
with IN N
a DT N
basal NN N
diet JJ N
, , N
were VBD N
supplemented VBN N
with IN N
0 CD N
( ( N
control NN N
) ) N
, , N
0.5 CD N
, , N
2 CD N
and CC N
4 CD N
mgkg?? NN N
DM NNP N
Se NNP N
. . N

Testis NN N
samples NNS N
were VBD N
collected VBN N
from IN N
the DT N
young JJ p
male NN p
goats NNS p
of IN p
each DT N
treatment NN N
group NN N
at IN N
the DT N
end NN N
of IN N
the DT N
study NN N
( ( N
30d CD N
after IN N
weaning VBG N
) ) N
for IN N
mRNA NN N
expression NN N
using VBG N
real-time JJ i
PCR NNP i
and CC i
for IN N
protein JJ N
expression NN N
by IN N
immunohistochemistry NN N
assay NN N
. . N

Results NNP N
show VBP N
that IN N
a DT N
significant JJ N
decrease NN N
was VBD N
observed VBN N
in IN N
mRNA JJ o
expression NN o
of IN o
p34 NN o
( ( o
cdc2 NN o
) ) o
and CC o
CyclinB1 NNP o
in IN o
the DT o
testis NN o
of IN o
Se-deficient NNP o
( ( o
Group NNP o
1 CD N
) ) N
and CC N
Se-excess NNP N
( ( N
Group NNP N
4 CD N
) ) N
animals NNS N
compared VBN N
with IN N
that DT N
in IN N
Groups NNP N
2 CD N
and CC N
3 CD N
. . N

However RB N
, , N
no DT N
significant JJ N
changes NNS N
were VBD N
found VBN N
in IN N
mRNA JJ o
expression NN o
of IN o
p34 NN o
( ( o
cdc2 NN o
) ) o
between IN o
Se-deficient NNP N
( ( N
Group NNP N
1 CD N
) ) N
and CC N
Se-excess NNP N
( ( N
Group NNP N
4 CD N
) ) N
. . N

Also RB N
the DT N
immunohistochemistry NN N
assay NN N
detected VBD N
similar JJ N
results NNS N
of IN N
protein JJ o
expression NN o
of IN o
these DT N
two CD N
genes NNS N
. . N

These DT N
results NNS N
suggest VBP N
, , N
that DT N
maternal JJ N
and CC N
dietary JJ N
Se-induced NNP N
oxidative JJ N
stress NN N
can MD N
modulate VB N
the DT N
mRNA NN o
and CC o
protein JJ o
expression NN o
of IN o
the DT N
cell NN N
cycle NN N
related VBN N
genes NNS N
( ( N
p34 NN N
( ( N
cdc2 NN N
) ) N
and CC N
CyclinB1 NNP N
) ) N
in IN N
the DT N
testis NN N
of IN N
their PRP$ N
offspring NN N
. . N

In IN N
addition NN N
, , N
Se NNP N
deficiency NN N
and CC N
Se NNP N
excess NN N
could MD N
prevent VB N
the DT N
completion NN N
of IN N
the DT N
cell NN N
cycle NN N
. . N

-DOCSTART- -2956874- O O

Placebo-controlled JJ N
study NN N
of IN N
oral JJ i
enoximone NN i
in IN N
congestive JJ N
heart NN N
failure NN N
with IN N
initial JJ o
and CC o
final JJ o
intravenous JJ o
hemodynamic JJ o
evaluation NN o
. . o

Seventeen JJ p
patients NNS p
with IN p
stable JJ p
congestive JJ p
heart NN p
failure NN p
( ( p
class NN p
II NNP p
and CC p
III NNP p
New NNP p
York NNP p
Heart NNP p
Association NNP p
) ) p
received VBD N
intravenous JJ N
and CC N
oral JJ N
enoximone NN i
in IN N
a DT N
2-part JJ N
study NN N
. . N

Hemodynamic NNP o
data NNS o
were VBD N
first RB N
obtained VBN N
after IN N
intravenous JJ i
administration NN i
of IN i
0.75 CD i
mg/kg NN i
of IN i
enoximone NN i
; : i
data NNS i
were VBD i
again RB i
obtained VBN i
after IN i
12 CD i
weeks NNS i
of IN i
therapy NN i
with IN i
either DT i
oral JJ i
enoximone NN i
( ( i
150 CD i
mg RB i
3 CD i
times NNS i
daily RB i
) ) i
or CC i
placebo NN i
. . i

The DT N
efficacy NN N
and CC N
safety NN N
of IN N
oral JJ i
enoximone NN i
were VBD N
also RB N
studied VBN N
in IN N
a DT N
12-week JJ N
, , N
double-blind JJ N
randomized JJ N
format NN N
. . N

In IN N
the DT N
intravenous JJ N
study NN N
, , N
enoximone NN i
was VBD i
delivered VBN i
over IN i
5 CD i
minutes NNS i
and CC i
hemodynamic JJ i
data NNS i
were VBD i
measured VBN i
for IN i
up RB i
to TO i
12 CD i
hours NNS i
after IN i
. . i

Cardiac NNP o
index NN o
increased VBD N
2.76 CD N
+/- JJ N
0.63 CD N
to TO N
3.42 CD N
+/- JJ N
0.72 CD N
liters/min/m2 NN N
) ) N
, , N
pulmonary JJ o
wedge NN o
pressure NN o
decreased VBN N
( ( N
19.5 CD N
+/- JJ N
8.8 CD N
to TO N
14.6 CD N
+/- JJ N
8.0 CD N
mm NN N
Hg NNP N
) ) N
as IN N
did VBD N
mean VB o
arterial JJ o
blood NN o
pressure NN o
( ( N
101 CD N
+/- JJ N
14.8 CD N
to TO N
85 CD N
+/- JJ N
13.7 CD N
mm NN N
Hg NNP N
) ) N
and CC N
systemic JJ o
vascular NN o
resistance NN o
( ( N
1,880 CD N
+/- JJ N
573 CD N
to TO N
1,254 CD N
+/- JJ N
383 CD N
dynes NNS N
s RB N
cm-5 NN N
) ) N
. . N

Heart NNP o
rate NN o
increased VBD N
slightly RB N
( ( N
82 CD N
+/- JJ N
17 CD N
to TO N
86 CD N
+/- JJ N
14 CD N
beats/min NN N
) ) N
. . N

All PDT N
these DT N
changes NNS N
were VBD N
maximal JJ N
1 CD N
to TO N
2 CD N
hours NNS N
after IN N
infusion NN N
and CC N
lasted VBD N
8 CD N
hours NNS N
at IN N
least JJS N
. . N

Patients NNS N
were VBD N
then RB N
randomized VBN N
double-blind NN N
to TO N
oral JJ N
treatment NN N
. . N

Baseline NNP N
values VBZ N
showed VBD N
that IN N
the DT N
7 CD N
patients NNS N
who WP N
received VBD N
placebo NN i
had VBD N
more RBR N
severe JJ N
CHF NNP o
. . o

Therefore NNP N
, , N
comparison NN N
might MD N
be VB N
biased VBN N
. . N

Patient NNP N
overall JJ N
assessment NN N
showed VBD N
a DT N
continuous JJ N
benefit NN N
in IN N
both DT N
groups NNS N
. . N

Ejection NNP N
fraction NN N
improved VBD N
from IN N
30.1 CD N
+/- JJ N
6.8 CD N
% NN N
to TO N
33.9 CD N
+/- JJ N
9.9 CD N
% NN N
in IN N
the DT N
enoximone NN N
group NN N
while IN N
it PRP N
remained VBD N
unchanged JJ N
with IN N
placebo NN N
( ( N
23.4 CD N
+/- JJ N
6.5 CD N
% NN N
to TO N
23.4 CD N
+/- JJ N
1.5 CD N
% NN N
) ) N
. . N

( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
250 CD N
WORDS NNP N
) ) N
-DOCSTART- -23778526- O O

Markers NNS N
of IN N
systemic JJ o
inflammation NN o
predict NN N
survival NN N
in IN N
patients NNS p
with IN p
advanced JJ p
renal JJ p
cell NN p
cancer NN p
. . p

BACKGROUND NNP N
The DT N
host NN N
inflammatory NN N
response NN N
has VBZ N
a DT N
vital JJ N
role NN N
in IN N
carcinogenesis NN N
and CC N
tumour JJ N
progression NN N
. . N

We PRP N
examined VBD N
the DT N
prognostic JJ o
value NN o
of IN o
inflammatory JJ o
markers NNS o
( ( o
albumin NN o
, , o
white-cell JJ o
count NN o
and CC o
its PRP$ o
components NNS o
, , o
and CC o
platelets NNS o
) ) o
in IN N
pre-treated JJ p
patients NNS p
with IN p
advanced JJ p
renal JJ p
cell NN p
carcinoma NN p
( ( p
RCC NNP p
) ) p
. . p

METHODS NNP N
Using NNP N
data NNS N
from IN N
a DT N
randomised JJ N
trial NN N
, , N
multivariable JJ N
proportional JJ N
hazards NNS N
models NNS N
were VBD N
generated VBN i
to TO N
examine VB N
the DT N
impact NN o
of IN o
inflammatory JJ o
markers NNS o
and CC N
established VBN N
prognostic JJ o
factors NNS o
( ( N
performance NN N
status NN N
, , N
calcium NN N
, , N
and CC N
haemoglobin NN N
) ) N
on IN N
overall JJ o
survival NN o
( ( N
OS NNP N
) ) N
. . N

We PRP N
evaluated VBD N
a DT N
new JJ N
prognostic JJ i
classification NN i
incorporating VBG N
additional JJ N
information NN N
from IN N
inflammatory NN N
markers NNS N
. . N

RESULTS NNP N
Of IN p
the DT p
416 CD p
patients NNS p
, , p
362 CD p
were VBD p
included VBN p
in IN p
the DT p
analysis NN p
. . p

Elevated VBN o
neutrophil JJ o
counts NNS o
, , o
elevated VBD o
platelet NN o
counts NNS o
, , o
and CC o
a DT o
high JJ o
neutrophil-lymphocyte JJ o
ratio NN o
were VBD N
significant JJ N
independent JJ N
predictors NNS N
for IN N
shorter JJR N
OS NNP N
in IN N
a DT N
model NN N
with IN N
established VBN N
prognostic JJ N
factors NNS N
. . N

The DT N
addition NN N
of IN N
inflammatory JJ N
markers NNS N
improves VBZ N
the DT N
discriminatory JJ N
value NN N
of IN N
the DT N
prognostic JJ N
classification NN N
as IN N
compared VBN N
with IN N
established VBN N
factors NNS N
alone RB N
( ( N
C-statistic JJ N
0.673 CD N
vs NN N
0.654 CD N
, , N
P=0.002 NNP N
for IN N
the DT N
difference NN N
) ) N
, , N
with IN N
25.8 CD N
% NN N
( ( N
P=0.004 NNP N
) ) N
of IN N
patients NNS N
more RBR N
appropriately RB N
classified JJ N
using VBG N
the DT N
new JJ N
classification NN N
. . N

CONCLUSION NNP N
Markers NNP N
of IN N
systemic JJ N
inflammation NN N
contribute NN N
significantly RB N
to TO N
prognostic JJ N
classification NN N
in IN N
addition NN N
to TO N
established VBN N
factors NNS N
for IN N
pre-treated JJ p
patients NNS p
with IN p
advanced JJ p
RCC NNP p
. . p

Upon IN N
validation NN N
of IN N
these DT N
data NNS N
in IN N
independent JJ N
studies NNS N
, , N
stratification NN N
of IN N
patients NNS N
using VBG N
these DT N
markers NNS N
in IN N
future JJ N
clinical JJ N
trials NNS N
is VBZ N
recommended VBN N
. . N

-DOCSTART- -14716650- O O

Transcutaneous JJ i
electrical JJ i
nerve NN i
stimulation NN i
for IN N
postoperative JJ p
pain NN p
relief NN p
after IN p
total JJ p
knee NN p
arthroplasty NN p
. . p

Transcutaneous JJ i
electrical JJ i
nerve NN i
stimulation NN i
( ( i
TENS NNP i
) ) i
has VBZ N
been VBN N
used VBN N
to TO N
treat VB N
chronic JJ N
pain NN N
syndromes NNS N
and CC N
has VBZ N
been VBN N
reported VBN N
to TO N
be VB N
of IN N
some DT N
utility NN N
in IN N
the DT N
treatment NN N
of IN N
postsurgical JJ N
pain NN N
. . N

A DT N
randomized JJ N
, , N
blinded VBD N
, , N
placebo-controlled JJ i
trial NN N
was VBD N
designed VBN N
to TO N
evaluate VB N
the DT N
utility NN N
of IN N
TENS NNP N
after IN N
total JJ p
knee NN p
arthroplasty NN p
. . p

Patients NNS p
were VBD p
randomly RB p
enrolled VBN p
into IN p
patient-controlled JJ i
anesthesia NN i
( ( i
PCA NNP i
) ) i
alone RB i
, , i
PCA NNP i
plus CC i
TENS NNP i
, , i
or CC i
PCA NNP i
plus CC i
sham JJ i
TENS NNP i
. . i

The DT N
cumulative JJ o
dose NN o
of IN o
morphine NN o
by IN N
PCA NNP N
for IN N
each DT N
group NN N
was VBD N
used VBN N
as IN N
the DT N
end-point NN N
of IN N
the DT N
study NN N
. . N

There EX N
was VBD N
no DT o
significant JJ o
reduction NN o
in IN o
the DT o
requirement NN o
for IN o
patient-controlled JJ o
analgesia NN o
with IN N
or CC N
without IN N
TENS NNP N
. . N

We PRP N
conclude VBP N
that IN N
there EX N
is VBZ N
no DT N
utility NN N
for IN N
TENS NNP N
in IN N
the DT N
postoperative JJ N
management NN N
of IN N
pain NN N
after IN N
knee NN N
arthroplasty NN N
. . N

-DOCSTART- -10223244- O O

Allelic JJ o
imbalance NN o
in IN N
the DT N
clonal JJ N
evolution NN N
of IN N
prostate NN p
carcinoma NN p
. . p

BACKGROUND NNP N
To TO N
understand VB N
better JJR N
the DT N
genetic JJ N
basis NN N
of IN N
the DT N
clonal JJ N
evolution NN N
of IN N
prostate NN N
carcinoma NN N
, , N
the DT N
authors NNS N
analyzed VBD N
the DT N
pattern NN N
of IN N
allelic JJ o
loss NN o
in IN N
25 CD p
matched JJ p
primary NN p
and CC p
metastatic JJ p
prostate NN p
tumors NNS p
. . p

METHODS NNP N
Twenty-five JJ p
cases NNS p
were VBD p
selected VBN p
from IN p
the DT p
surgical JJ p
pathology NN p
files NNS p
of IN p
the DT p
Mayo NNP p
Clinic NNP p
from IN p
patients NNS p
who WP p
had VBD p
undergone JJ p
radical JJ i
retropubic NN i
prostatectomy NN i
and CC p
bilateral JJ i
lymphadenectomy NN i
between IN p
1987-1991 JJ p
. . p

All DT p
patients NNS p
had VBD p
regional JJ p
lymph NN p
node NN p
metastases NNS p
at IN p
the DT p
time NN p
of IN p
surgery NN p
. . p

DNA NN N
samples NNS N
for IN N
the DT N
analysis NN N
of IN N
allelic JJ o
loss NN o
pattern NN N
were VBD N
prepared VBN N
from IN N
primary JJ N
tumors NNS N
and CC N
matched VBD N
synchronous JJ N
lymph NN N
node NN N
metastases NNS N
by IN N
tissue NN N
microdissection NN N
. . N

The DT N
oligonucleotide JJ N
primer NN N
pairs NNS N
for IN N
the DT N
microsatellite JJ N
DNA NN N
markers NNS N
were VBD N
D8S133 NNP N
, , N
D8S136 NNP N
, , N
D8S137 NNP N
, , N
ANK1 NNP N
on IN N
chromosome NN N
8p12-21 CD N
, , N
LPLTET NNP N
on IN N
chromosome NN N
8p22 CD N
, , N
and CC N
D17S855 NNP N
( ( N
intragenic JJ N
to TO N
the DT N
BRCA1 NNP N
gene NN N
) ) N
on IN N
chromosome NN N
17q21 CD N
. . N

One CD N
case NN N
was VBD N
not RB N
informative JJ N
at IN N
any DT N
of IN N
the DT N
loci NN N
tested VBD N
and CC N
was VBD N
excluded VBN N
from IN N
further JJ N
analysis NN N
. . N

RESULTS VB N
The DT N
overall JJ o
frequency NN o
of IN o
allelic JJ o
imbalance NN o
was VBD N
79 CD N
% NN N
in IN N
primary JJ N
tumors NNS N
and CC N
88 CD N
% NN N
in IN N
paired JJ N
metastases NNS N
. . N

Of IN N
24 CD p
informative JJ p
cases NNS p
, , N
14 CD N
patients NNS N
( ( N
58 CD N
% NN N
) ) N
showed VBD N
the DT N
same JJ N
pattern NN N
of IN N
allelic JJ o
loss NN o
or CC o
retention NN o
in IN N
matched JJ N
primary NN N
and CC N
metastatic JJ N
tumors NNS N
at IN N
all DT N
marker NN N
locus NN N
; : N
discordant JJ N
allelic JJ o
loss NN o
was VBD N
observed VBN N
in IN N
the DT N
remaining VBG N
10 CD N
patients NNS N
( ( N
42 CD N
% NN N
) ) N
. . N

Four CD N
patients NNS N
showed VBD N
loss NN N
of IN N
the DT N
same JJ N
allele NN o
at IN N
one CD N
or CC N
more JJR N
marker NN N
loci NN N
in IN N
both DT N
primary JJ N
and CC N
metastatic JJ N
tumors NNS N
, , N
but CC N
discordant JJ N
allelic JJ o
loss NN o
was VBD N
observed VBN N
at IN N
other JJ N
marker NN N
loci NN N
. . N

Five CD N
patients NNS N
showed VBD N
allelic JJ o
loss NN o
in IN N
at IN N
least JJS N
one CD N
genetic JJ N
marker NN N
in IN N
the DT N
metastatic JJ N
tumor NN N
but CC N
not RB N
in IN N
its PRP$ N
matched JJ N
primary JJ N
tumor NN N
. . N

Five CD N
patients NNS N
displayed JJ N
loss NN o
of IN o
one CD o
allele NN o
at IN o
one CD o
or CC N
more JJR N
marker NN N
loci NN N
in IN N
a DT N
primary JJ N
tumor NN N
but CC N
not RB N
in IN N
the DT N
matched JJ N
metastases NNS N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
the DT N
frequency NN o
of IN o
allelic JJ o
imbalance NN o
between IN N
primary JJ N
and CC N
metastatic JJ N
tumors NNS N
at IN N
any DT N
marker NN N
analyzed VBN N
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
. . N

CONCLUSIONS NNP N
These DT N
data NNS N
suggest VBP N
that IN N
different JJ N
patterns NNS N
of IN N
allelic JJ o
deletion NN o
may MD N
be VB N
acquired VBN N
during IN N
cancer NN N
progression NN N
to TO N
metastases NNS N
. . N

The DT N
differences NNS N
in IN N
genetic JJ N
composition NN N
between IN N
primary JJ N
prostate NN N
carcinoma NN N
and CC N
its PRP$ N
metastases NNS N
may MD N
be VB N
related VBN N
to TO N
intrinsic JJ N
cancer NN N
heterogeneity NN N
, , N
overall JJ N
genetic JJ N
instability NN N
, , N
and CC N
clonal JJ N
divergence NN N
. . N

-DOCSTART- -11700823- O O

Effect NN N
of IN N
a DT N
specific JJ N
preparation NN N
of IN N
Chinese JJ i
herbs NNS i
( ( N
clear JJ N
the DT N
way NN N
) ) N
on IN N
duration NN o
and CC o
severity NN o
of IN o
the DT o
common JJ o
cold NN o
. . o

-DOCSTART- -23592849- O O

The DT N
role NN N
of IN N
treatment NN i
fidelity NN i
on IN N
outcomes NNS N
during IN N
a DT N
randomized JJ N
field NN N
trial NN N
of IN N
an DT N
autism NN p
intervention NN N
. . N

This DT N
randomized JJ N
field NN N
trial NN N
comparing VBG N
Strategies NNS N
for IN N
Teaching VBG i
based VBN N
on IN N
Autism NNP N
Research NNP N
and CC N
Structured NNP N
Teaching NNP N
enrolled VBD N
educators NNS N
in IN N
33 CD p
kindergarten-through-second-grade JJ p
autism NN p
support NN p
classrooms NNS p
and CC p
119 CD p
students NNS p
, , p
aged VBN p
5-8 CD p
years NNS p
in IN p
the DT p
School NNP p
District NNP p
of IN p
Philadelphia NNP p
. . p

Students NNS p
were VBD N
assessed VBN N
at IN N
the DT N
beginning NN N
and CC N
end NN N
of IN N
the DT N
academic JJ N
year NN N
using VBG N
the DT N
Differential NNP N
Ability NNP N
Scales NNP N
. . N

Program NNP o
fidelity NN o
was VBD N
measured VBN N
through IN N
video NN i
coding NN i
and CC N
use NN N
of IN N
a DT N
checklist NN N
. . N

Outcomes CC N
were VBD N
assessed VBN N
using VBG N
linear JJ N
regression NN N
with IN N
random JJ N
effects NNS N
for IN N
classroom NN N
and CC N
student NN p
. . p

Average JJ o
fidelity NN o
was VBD N
57 CD N
% NN N
in IN N
Strategies NNP N
for IN N
Teaching NNP N
based VBN N
on IN N
Autism NNP N
Research NNP N
classrooms NNS N
and CC N
48 CD N
% NN N
in IN N
Structured NNP N
Teaching NNP N
classrooms NNS N
. . N

There EX N
was VBD N
a DT N
9.2-point JJ N
( ( N
standard JJ N
deviation NN N
= NNP N
9.6 CD N
) ) N
increase NN N
in IN N
Differential NNP o
Ability NNP o
Scales NNP o
score RB o
over IN N
the DT N
8-month JJ N
study NN N
period NN N
, , N
but CC N
no DT N
main JJ N
effect NN N
of IN N
program NN N
. . N

There EX N
was VBD N
a DT N
significant JJ N
interaction NN o
between IN o
fidelity NN o
and CC o
group NN o
. . o

In IN N
classrooms NNS N
with IN N
either DT N
low JJ N
or CC N
high JJ N
program NN N
fidelity NN N
, , N
students NNS p
in IN p
Strategies NNP p
for IN p
Teaching NNP p
based VBN p
on IN p
Autism NNP p
Research NNP p
experienced VBD N
a DT N
greater JJR N
gain NN N
in IN N
Differential NNP o
Ability NNP o
Scales NNP o
score RB o
than IN N
students NNS p
in IN p
Structured NNP p
Teaching NNP p
( ( N
11.2 CD N
vs. RB N
5.5 CD N
points NNS N
and CC N
11.3 CD N
vs. FW N
8.9 CD N
points NNS N
, , N
respectively RB N
) ) N
. . N

In IN N
classrooms NNS N
with IN N
moderate JJ N
fidelity NN o
, , o
students NNS o
in IN o
Structured NNP o
Teaching NNP o
experienced VBD o
a DT N
greater JJR N
gain NN N
than IN N
students NNS p
in IN p
Strategies NNP o
for IN o
Teaching NNP o
based VBN o
on IN o
Autism NNP o
Research NNP o
( ( N
10.1 CD N
vs. RB N
4.4 CD N
points NNS N
) ) N
. . N

The DT N
results NNS N
suggest VBP N
significant JJ N
variability NN N
in IN N
implementation NN N
of IN N
evidence-based JJ N
practices NNS N
, , N
even RB N
with IN N
supports NNS N
, , N
and CC N
also RB N
suggest VBP N
the DT N
need NN N
to TO N
address VB N
challenging VBG N
issues NNS N
related VBN N
to TO N
implementation VB N
measurement NN N
in IN N
community NN N
settings NNS N
. . N

-DOCSTART- -7527107- O O

Double-blind NNP N
comparison NN N
of IN N
the DT N
efficacy NN o
and CC o
safety NN o
of IN N
trandolapril JJ i
2 CD N
mg NN N
and CC N
hydrochlorothiazide VB i
25 CD N
mg NNS N
in IN N
patients NNS p
with IN p
mild-to-moderate JJ p
essential JJ p
hypertension NN p
. . p

Investigator NNP N
Study NNP N
Group NNP N
. . N

This DT N
multicenter NN N
international JJ N
trial NN N
recruited VBD N
205 CD p
patients NNS p
from IN p
16 CD p
investigators NNS p
. . p

After IN N
a DT N
4-week JJ N
, , N
single-blind JJ i
placebo NN i
run-in NN N
, , N
patients NNS N
were VBD N
randomized VBN N
to TO N
receive VB N
16 CD N
weeks NNS N
of IN N
trandolapril JJ i
2 CD N
mg/day NN N
( ( N
68 CD N
patients NNS N
) ) N
, , N
hydrochlorothiazide RB i
( ( i
HCTZ NNP i
) ) i
25 CD N
mg/day NN N
( ( N
68 CD N
patients NNS N
) ) N
, , N
or CC i
the DT i
combination NN i
( ( N
69 CD N
patients NNS N
) ) N
. . N

Morning VBG o
predosing VBG o
supine NN o
diastolic JJ o
blood NN o
pressure NN o
( ( o
DBP NNP o
) ) o
was VBD N
the DT N
primary JJ N
efficacy NN N
measurement NN N
. . N

Intention-to-treat JJ N
analysis NN N
showed VBD N
significant JJ N
decreases NNS N
in IN N
all DT N
three CD N
groups NNS N
in IN N
mean JJ N
( ( N
+/- JJ N
SEM NNP N
) ) N
supine NN o
DBP NNP o
throughout IN N
the DT N
study NN N
, , N
with IN N
no DT N
significant JJ N
differences NNS N
at IN N
week NN N
16 CD N
between IN N
trandolapril NN N
( ( N
-10.6 JJ N
+/- JJ N
1.3 CD N
mm NN N
Hg NNP N
) ) N
and CC N
HCTZ NNP N
( ( N
-10.9 JJ N
+/- JJ N
1.3 CD N
mm NN N
Hg NNP N
) ) N
. . N

The DT N
combination NN N
gave VBD N
a DT N
significantly RB N
greater JJR N
reduction NN N
than IN N
either DT N
drug NN N
alone RB N
( ( N
-15.1 JJ N
+/- JJ N
1.13 CD N
mm NN N
Hg NNP N
) ) N
. . N

Blood NNP o
pressure NN o
was VBD N
normalized VBN N
in IN N
the DT N
combination NN N
group NN N
in IN N
67 CD N
% NN N
of IN N
patients NNS N
, , N
a DT N
significantly RB N
higher JJR N
proportion NN N
than IN N
either DT N
trandolapril NN N
( ( N
63 CD N
% NN N
) ) N
or CC N
HCTZ NNP N
( ( N
60 CD N
% NN N
; : N
p CC N
= VB N
0.04 CD N
) ) N
. . N

Each DT N
treatment NN N
was VBD N
well RB N
tolerated VBN N
. . N

The DT N
incidence NN N
of IN N
adverse JJ o
events NNS o
was VBD N
similar JJ N
in IN N
all DT N
three CD N
groups NNS N
. . N

Trandolapril NNP N
2 CD N
mg NN N
once RB N
daily JJ N
is VBZ N
an DT N
effective JJ N
antihypertensive JJ N
agent NN N
, , N
comparable JJ N
to TO N
HCTZ NNP N
. . N

Furthermore NNP N
, , N
the DT N
combination NN N
of IN N
the DT N
two CD N
drugs NNS N
was VBD N
shown VBN N
to TO N
enhance VB N
the DT N
antihypertensive JJ o
effect NN o
of IN N
the DT N
two CD N
compounds NNS N
alone RB N
. . N

-DOCSTART- -18374024- O O

New NNP i
introducer NN i
PEG NNP i
gastropexy NN i
does VBZ N
not RB N
require VB N
prophylactic JJ N
antibiotics NNS N
: : N
multicenter NN N
prospective JJ N
randomized VBN N
double-blind JJ N
placebo-controlled JJ N
study NN N
. . N

BACKGROUND NNP N
Peristomal NNP N
infections NNS N
are VBP N
the DT N
most RBS N
common JJ N
complications NNS N
of IN N
PEG NNP N
, , N
despite IN N
prophylactic JJ N
antibiotics NNS N
. . N

The DT N
introducer JJ N
PEG-placement NNP N
technique NN N
avoids VBZ N
the DT N
sojourn NN N
of IN N
a DT N
PEG NNP N
catheter NN N
through IN N
the DT N
oropharynx NN N
, , N
and CC N
hence RB N
minimizes VBZ N
the DT N
chances NNS N
of IN N
infectious JJ N
complications NNS N
. . N

Despite IN N
the DT N
obvious JJ N
potential JJ N
advantage NN N
, , N
this DT N
technique NN N
failed VBD N
to TO N
gain VB N
popularity NN N
, , N
mainly RB N
as IN N
a DT N
result NN N
of IN N
other JJ N
associated VBN N
risks NNS N
and CC N
complications NNS N
. . N

Recently RB N
, , N
a DT N
modified JJ N
introducer NN N
endoscopic VBZ N
PEG-gastropexy NNP N
technique NN N
was VBD N
shown VBN N
to TO N
be VB N
quite RB N
safe JJ N
. . N

The DT N
present JJ N
study NN N
is VBZ N
the DT N
first JJ N
study NN N
that WDT N
evaluated VBD N
the DT N
need NN N
of IN N
prophylactic JJ N
antibiotics NNS N
for IN N
introducer NN N
PEG NNP N
. . N

OBJECTIVE NNP N
To TO N
determine VB N
the DT N
incidence NN N
of IN N
peristomal JJ N
wound NN N
infections NNS N
during IN N
the DT N
immediate JJ N
7-day JJ N
postprocedure NN N
follow-up NN N
. . N

DESIGN NNP N
Prospective NNP N
, , N
randomized VBD N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
trial NN N
. . N

SETTINGS NNP N
Multicenter NNP p
; : p
a DT p
university NN p
tertiary-care JJ p
hospital NN p
and CC p
a DT p
private JJ p
practice NN p
endoscopy NN p
clinic NN p
. . p

PATIENTS VB N
A DT p
total NN p
of IN p
633 CD p
patients NNS p
undergoing JJ p
PEG NNP p
were VBD N
assessed VBN N
for IN N
inclusion NN N
. . N

Ninety-seven JJ p
patients NNS p
who WP p
had VBD p
malignant JJ p
stenotic JJ p
oropharyngeal NN p
stricture NN p
were VBD N
randomized VBN N
: : N
group NN N
I PRP N
( ( N
49 CD N
patients NNS N
) ) N
received VBD N
prophylactic JJ i
ceftriaxone NN i
, , i
and CC i
group NN i
II NNP i
( ( i
48 CD i
patients NNS i
) ) i
received VBD i
a DT i
placebo NN i
. . i

Both DT N
groups NNS N
were VBD N
similar JJ N
in IN N
patient JJ N
characteristics NNS N
. . N

INTERVENTIONS NNP N
Introducer NNP N
PEG NNP i
was VBD N
performed VBN N
by IN N
using VBG N
the DT N
Freka NNP N
Pexact-15 NNP N
CH/FR NNP N
, , N
with IN N
the DT N
gastric NN N
wall NN N
nonsurgically RB N
sutured VBD N
to TO N
the DT N
anterior JJ N
abdominal JJ N
wall NN N
by IN N
use NN N
of IN N
an DT N
endoscope NN N
. . N

MAIN NNP N
OUTCOME NNP N
MEASUREMENTS NNP N
The DT o
peristomal JJ o
area NN o
was VBD o
assessed VBN o
daily RB o
for IN o
7 CD o
days NNS o
by IN o
using VBG o
2 CD o
different JJ o
types NNS o
of IN o
infection NN o
scores NNS o
. . o

RESULTS NNP N
Clinically NNP o
significant JJ o
wound VBD o
reaction NN o
was VBD N
observed VBN N
in IN N
1 CD N
patient NN N
in IN N
each DT N
group NN N
. . N

Wound IN o
infection NN o
scores NNS o
were VBD N
marginally RB N
higher JJR N
in IN N
the DT N
placebo NN i
group NN N
, , N
but CC N
the DT N
differences NNS N
in IN N
the DT N
values NNS o
of IN o
infection NN o
scores NNS o
between IN N
both DT N
the DT N
groups NNS N
were VBD N
not RB N
statistically RB N
significant JJ N
during IN N
the DT N
7-day JJ N
post-PEG JJ N
follow-up NN N
. . N

LIMITATIONS VB N
The DT N
introducer NN N
gastropexy JJ N
kit NN N
is VBZ N
5 CD N
times NNS N
more RBR N
expensive JJ N
than IN N
the DT N
pull JJ N
PEG NNP N
. . N

CONCLUSIONS NNP N
The DT i
new JJ i
introducer JJ i
PEG-gastropexy JJ i
technique NN i
can MD N
be VB N
performed VBN N
safely RB N
, , N
without IN N
prophylactic JJ N
antibiotics NNS N
in IN N
patients NNS p
potentially RB p
at IN p
high JJ p
risk NN p
of IN p
peristomal JJ p
infectious JJ p
complications NNS p
( ( p
those DT p
with IN p
advanced JJ p
oropharyngeal JJ p
malignancy NN p
) ) p
( ( N
ClinicalTrials.gov NNP N
identifier RB N
NCT00375414 NNP N
) ) N
. . N

-DOCSTART- -9207711- O O

Effect NN N
of IN N
age NN N
and CC N
activity NN N
on IN N
knee NN o
joint JJ o
proprioception NN o
. . o

Falls NNP N
lead JJ N
to TO N
significant JJ N
morbidity NN o
and CC o
mortality NN o
in IN N
persons NNS p
older JJR p
than IN p
65 CD p
years NNS p
of IN p
age NN p
. . p

Impaired NNP N
proprioception NN N
may MD N
be VB N
a DT N
contributing JJ N
factor NN N
to TO N
falls NNS N
, , N
and CC N
this DT N
may MD N
be VB N
influenced VBN N
by IN N
the DT N
level NN N
of IN N
habitual JJ N
physical JJ N
activity NN N
. . N

The DT N
primary JJ N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
investigate VB N
knee NNS p
joint JJ p
proprioception NN p
among IN p
young JJ p
volunteers NNS p
and CC p
active JJ p
and CC p
sedentary JJ p
elderly JJ p
volunteers NNS p
. . p

Knee NNP o
joint JJ o
proprioception NN o
was VBD N
measured VBN N
through IN N
reproduction NN N
of IN N
static JJ N
knee NN N
angles NNS N
using VBG N
a DT N
Penny NNP i
and CC i
Giles NNP i
electrogoniometer RB i
. . i

The DT N
secondary JJ N
purpose NN N
of IN N
this DT N
investigation NN N
was VBD N
to TO N
test VB N
the DT N
reproducibility NN o
of IN o
the DT o
Penny NNP o
and CC o
Giles NNP o
electrogoniometer RB o
in IN N
measuring VBG o
static JJ o
knee NN o
angles NNS o
. . o

Sixteen NNP p
young JJ p
subjects NNS p
( ( p
age NN p
range NN p
, , p
19-27 JJ p
years NNS p
) ) p
and CC p
24 CD p
elderly JJ p
subjects NNS p
( ( p
age NN p
range NN p
, , p
60-86 JJ p
years NNS p
) ) p
participated VBD p
. . p

Subjects NNS p
were VBD p
given VBN p
a DT p
screening VBG p
history NN p
and CC p
physical JJ p
examination NN p
to TO p
exclude VB p
neuromuscular JJ p
or CC p
vestibular JJ p
disorders NNS p
or CC p
lower JJR p
limb NN p
injuries NNS p
. . p

Knee NNP o
joint JJ o
proprioception NN o
was VBD N
measured VBN N
two CD N
times NNS N
during IN N
one CD N
week NN N
. . N

The DT N
elderly JJ N
group NN N
was VBD N
separated VBN N
into IN N
active JJ N
and CC N
sedentary JJ N
subgroups NNS N
based VBN N
on IN N
their PRP$ N
level NN N
of IN N
activity NN N
during IN N
the DT N
past JJ N
year NN N
. . N

The DT N
electrogoniometer NN N
was VBD N
placed VBN N
laterally RB N
across IN N
the DT N
dominant JJ N
knee NN N
joint NN N
. . N

From IN N
the DT N
prone NN N
position NN N
each DT N
subject NN N
attained VBD N
one CD N
of IN N
ten NN N
randomly NNS N
predetermined VBD N
knee JJ N
joint JJ N
angles NNS N
from IN N
10 CD N
degrees NNS N
to TO N
60 CD N
degrees NNS N
. . N

The DT N
subject NN N
then RB N
returned VBD N
to TO N
the DT N
starting VBG N
position NN N
and CC N
reproduced VBD N
the DT N
test NN N
angle NN N
. . N

The DT N
absolute JJ o
angular JJ o
error NN o
( ( N
the DT N
absolute NN N
difference NN N
between IN N
the DT N
test NN N
angle NN N
and CC N
subject JJ N
perceived VBN N
angle NN N
of IN N
knee JJ N
flexion NN N
) ) N
was VBD N
determined VBN N
. . N

A DT N
positive JJ N
correlation NN N
was VBD N
found VBN N
between IN N
control NN N
visits NNS N
for IN N
all DT N
subjects NNS N
( ( N
r VB N
= RB N
0.88 CD N
) ) N
, , N
and CC N
significant JJ N
differences NNS N
were VBD N
observed VBN N
between IN N
young JJ N
( ( N
mean JJ N
, , N
2.01 CD N
+/- JJ N
0.46 CD N
degrees NNS N
) ) N
and CC N
active-fold JJ N
( ( N
mean JJ N
, , N
3.12 CD N
+/- JJ N
1.12 CD N
degrees NNS N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
young JJ N
and CC N
sedentary-old JJ N
( ( N
mean JJ N
, , N
4.58 CD N
+/- JJ N
1.93 CD N
degrees NNS N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
and CC N
active-old JJ N
and CC N
sedentary-old JJ N
( ( N
P NNP N
< NNP N
0.03 CD N
) ) N
. . N

These DT N
findings NNS N
demonstrate VBP N
that IN N
the DT N
Penny NNP N
and CC N
Giles NNP N
electrogoniometer NN N
is VBZ N
a DT N
reproducible JJ N
device NN N
for IN N
measuring VBG N
knee NN N
joint NN N
angles NNS N
in IN N
both DT N
young JJ N
and CC N
elderly JJ N
subjects NNS N
. . N

Furthermore RB N
, , N
we PRP N
found VBD N
that IN N
proprioception NN o
is VBZ N
diminished VBN N
with IN N
age NN N
and CC N
that IN N
regular JJ N
activity NN N
may MD N
attenuate VB N
this DT N
decline NN N
. . N

One CD N
strategy NN N
to TO N
reduce VB N
the DT N
incidence NN N
of IN N
poor JJ N
proprioception NN o
and CC N
fall NN N
with IN N
ageing NN N
may MD N
be VB N
regular JJ N
exercise NN N
. . N

-DOCSTART- -15606733- O O

5 CD N
% NN N
imiquimod JJ i
cream NN N
and CC N
reflectance-mode JJ i
confocal JJ i
microscopy NN i
as IN N
adjunct JJ N
modalities NNS N
to TO N
Mohs NNP i
micrographic JJ i
surgery NN i
for IN N
treatment NN N
of IN N
basal NN p
cell NN p
carcinoma NN p
. . p

BACKGROUND NNP N
Imiquimod NNP i
is VBZ N
an DT N
immune JJ N
response NN N
modifier NN N
that IN N
up-regulates JJ N
cytokines NNS N
and CC N
has VBZ N
been VBN N
shown VBN N
in IN N
clinical JJ N
studies NNS N
to TO N
reduce VB N
or CC N
clear VB N
basal NN p
cell NN p
carcinoma NN p
tumors NNS N
when WRB N
applied VBN N
topically RB N
. . N

OBJECTIVE CC N
The DT N
objectives NNS N
were VBD N
to TO N
evaluate VB N
the DT N
efficacy NN N
of IN N
5 CD N
% NN N
imiquimod JJ i
cream NN N
in IN N
treating VBG N
basal NN N
cell NN N
carcinoma NN N
preceding VBG N
excision NN N
by IN N
Mohs NNP N
micrographic JJ N
surgery NN N
and CC N
to TO N
determine VB N
if IN N
reflectance-mode JJ i
confocal JJ i
microscopy NN i
is VBZ N
useful JJ N
to TO N
establish VB N
the DT N
need NN N
for IN N
surgical JJ N
intervention NN N
after IN N
imiquimod JJ i
treatment NN N
. . N

METHODS NNP N
Subjects NNP p
applied VBD p
study NN p
cream NN p
to TO p
one CD p
biopsy-confirmed JJ p
basal NN p
cell NN p
carcinoma NN p
tumor NN p
5 CD N
x/week NN N
for IN N
2 CD N
, , N
4 CD N
, , N
or CC N
6 CD N
weeks NNS N
in IN N
this DT N
vehicle-controlled JJ p
, , p
double-blind JJ p
study NN p
. . p

Confocal NNP i
microscopy NN i
was VBD N
used VBN N
for IN N
the DT N
6-week JJ N
treatment NN N
group NN N
to TO N
examine VB N
the DT N
target NN N
tumor NN N
area NN N
at IN N
each DT N
interval JJ N
visit NN N
and CC N
immediately RB N
before IN N
Mohs NNP i
micrographic JJ i
surgery NN i
. . i

After IN N
the DT N
Mohs NNP i
micrographic JJ i
surgery NN i
excision NN i
, , N
the DT N
tissue NN N
was VBD N
evaluated VBN N
histologically RB N
, , N
and CC N
the DT N
excision NN N
area NN N
was VBD N
measured VBN N
. . N

Confocal JJ i
microscopy NN i
readings NNS N
were VBD N
correlated VBN N
to TO N
the DT N
histologic JJ N
diagnosis NN N
. . N

RESULTS NNP N
Tumors NNPS o
cleared VBD o
or CC o
the DT o
target NN o
tumor NN o
area NN o
was VBD N
reduced VBN N
in IN N
subjects NNS N
in IN N
the DT N
4- JJ N
and CC N
6-week JJ N
dosing NN N
regimens NNS N
. . N

Confocal JJ o
microscopy NN o
assessments NNS o
correlated VBN N
well RB N
with IN N
the DT N
histologic JJ N
diagnosis NN N
. . N

CONCLUSION NNP N
Imiquimod NNP i
improved VBD N
excision NN o
results NNS o
relative JJ N
to TO N
vehicle NN N
when WRB N
used VBN N
for IN N
treating VBG N
basal NN p
cell NN p
carcinoma NN p
before IN p
Mohs NNP i
micrographic JJ i
surgery NN i
. . i

Confocal JJ N
microscopy NN N
assessments NNS N
correlated VBN N
well RB N
with IN N
tumor NN N
response NN N
to TO N
therapy VB N
, , N
suggesting VBG N
that IN N
confocal JJ N
microscopy NN N
may MD N
help VB N
determine VB N
the DT N
need NN N
for IN N
surgery NN N
. . N

-DOCSTART- -11362397- O O

Thalidomide NN i
: : i
an DT N
alternative JJ N
therapy NN N
for IN N
treatment NN o
of IN o
apthous JJ o
ulcers NNS o
( ( p
canker NN p
sores NNS p
) ) p
. . p

-DOCSTART- -22118062- O O

Making VBG N
the DT N
connection NN N
: : N
randomized VBN N
controlled VBD N
trial NN N
of IN N
social JJ N
skills NNS N
at IN N
school NN N
for IN N
children NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
. . p

BACKGROUND NNP N
This DT N
study NN N
compared VBN N
two CD N
interventions NNS N
for IN N
improving VBG N
the DT N
social JJ o
skills NNS o
of IN N
high JJ p
functioning VBG p
children NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
in IN p
general JJ p
education NN p
classrooms NNS p
. . p

One CD N
intervention NN N
involved VBN N
a DT N
peer-mediated JJ i
approach NN i
( ( i
PEER NNP i
) ) i
and CC N
the DT N
other JJ N
involved VBD N
a DT N
child-assisted JJ i
approach NN i
( ( i
CHILD NNP i
) ) i
. . i

METHOD PDT N
The DT N
two CD N
interventions NNS N
were VBD N
crossed VBN N
in IN N
a DT N
2 CD N
? . N
2 CD N
factorial JJ N
design NN N
yielding VBG N
control NN i
, , i
PEER NNP i
, , i
CHILD NNP i
, , i
and CC i
both DT N
PEER NNP i
and CC i
CHILD NNP i
conditions NNS i
. . p

Sixty NNP p
children NNS p
participated VBD p
from IN p
56 CD p
classrooms NNS p
in IN p
30 CD p
schools NNS p
. . p

Interventions NNS p
involved VBD N
12 CD N
sessions NNS N
over IN N
6 CD N
weeks NNS N
, , N
with IN N
a DT N
3-month JJ N
follow-up NN N
. . N

Outcome NNP N
measures NNS N
included VBD o
self NN o
, , o
peer NN o
and CC o
teacher JJR o
reports NNS o
of IN o
social JJ o
skills NNS o
and CC o
independent JJ o
weekly JJ o
observations NNS o
of IN o
children NNS o
on IN o
their PRP$ o
school NN o
playground NN o
over IN o
the DT o
course NN o
of IN o
the DT o
intervention NN o
. . o

RESULTS NNP o
Significant JJ N
improvements NNS N
were VBD N
found VBN N
in IN o
social JJ o
network NN o
salience NN o
, , o
number NN o
of IN o
friendship JJ o
nominations NNS o
, , o
teacher JJ o
report NN o
of IN o
social JJ o
skills NNS o
in IN o
the DT o
classroom NN o
, , o
and CC o
decreased JJ o
isolation NN o
on IN o
the DT o
playground NN o
for IN o
children NNS N
who WP N
received VBD i
PEER NNP i
interventions NNS N
. . N

Changes NNS N
obtained VBN N
at IN N
the DT N
end NN N
of IN N
the DT N
treatment NN N
persisted VBD N
to TO N
the DT N
3-month JJ N
follow-up NN N
. . N

CONCLUSIONS NNP N
These DT N
data NNS N
suggest VBP N
that IN N
significant JJ N
improvements NNS N
can MD N
be VB N
made VBN N
in IN o
peer JJ o
social JJ o
connections NNS o
for IN o
children NNS N
with IN N
autism NN p
spectrum NN p
disorders NNS p
in IN p
general JJ p
education NN N
classrooms NNS N
with IN N
a DT N
brief JJ N
intervention NN N
, , N
and CC N
that IN N
these DT N
gains NNS N
persist VBP N
over IN N
time NN N
. . N

-DOCSTART- -2871945- O O

Protective JJ N
effect NN N
of IN N
high-dose JJ i
medroxyprogesterone NN i
acetate NN i
( ( i
HD-MPA NNP i
) ) i
on IN N
hematological JJ o
toxicity NN o
induced VBN N
by IN N
chemotherapy NN i
for IN p
advanced JJ p
solid JJ p
tumors NNS p
: : p
a DT N
multicentric NN N
controlled VBD N
clinical JJ N
trial NN N
. . N

MPA-Hematology NNP N
Italian JJ N
Cooperative NNP N
Group NNP N
. . N

A NNP N
multicenter NN N
, , N
randomized VBN N
, , N
controlled VBD N
trial NN N
was VBD N
conducted VBN N
comparing VBG N
active JJ N
treatment NN N
with IN N
placebo NN i
in IN N
227 CD p
patients NNS p
with IN p
breast NN p
, , p
colorectal NN p
, , p
lung NN p
and CC p
other JJ p
solid JJ p
forms NNS p
of IN p
cancer NN p
. . p

Combination NNP i
therapy NN i
, , i
( ( i
CT NNP i
) ) i
conventionally RB N
employed VBN N
for IN N
the DT N
various JJ N
types NNS N
of IN N
tumor NN N
involved VBN N
, , N
was VBD N
associated VBN N
with IN N
MPA NNP i
( ( p
117 CD p
patients NNS p
) ) p
or CC N
placebo NN i
( ( p
110 CD p
patients NNS p
) ) p
. . p

MPA NNP N
was VBD N
given VBN N
orally RB N
as IN N
tablets NNS N
, , N
as IN N
a DT N
dose NN N
of IN N
500 CD N
mg NN N
b.i.d NN N
. . N

for IN N
6 CD N
months NNS N
. . N

The DT N
results NNS N
were VBD N
, , N
briefly NN N
, , N
as IN N
follows VBZ N
: : N
The DT N
incidence NN o
of IN o
leukopenia NN o
was VBD N
significantly RB N
lower JJR N
in IN N
the DT N
groups NNS N
receiving VBG N
MPA NNP i
in IN N
patients NNS N
with IN N
breast NN N
and CC N
colorectal JJ N
cancer NN N
( ( N
P NNP N
less JJR N
than IN N
0.02 CD N
) ) N
. . N

Tumors NNS o
of IN o
the DT o
lung NN o
and CC o
other JJ o
solid JJ o
forms NNS o
showed VBD N
no DT N
such JJ N
difference NN N
. . N

The DT N
incidence NN o
of IN o
thrombocytopenia NN o
was VBD N
the DT N
same JJ N
in IN N
all DT N
disease NN N
groups NNS N
. . N

Objective JJ o
responses NNS o
( ( o
CR NNP o
+ NNP o
PR NNP o
) ) o
were VBD N
observed VBN N
in IN N
23/46 CD N
( ( N
50 CD N
% NN N
) ) N
of IN N
breast NN N
cancer NN N
patients NNS N
treated VBN N
with IN N
CT NNP i
+ NNP i
MPA NNP i
, , N
and CC N
in IN N
13/47 CD N
( ( N
28 CD N
% NN N
) ) N
of IN N
those DT N
given VBN N
CT NNP i
+ NNP i
placebo NN i
. . i

The DT N
difference NN N
was VBD N
significant JJ N
( ( N
P NNP N
less JJR N
than IN N
0.02 CD N
) ) N
. . N

Subjective JJ o
parameters NNS o
also RB N
showed VBD N
more RBR N
improvement NN N
in IN N
the DT N
MPA NNP i
group NN N
than IN N
in IN N
the DT N
patients NNS N
given VBN N
CT NNP N
alone RB N
. . N

No UH N
significant JJ N
differences NNS N
were VBD N
found VBN N
for IN N
the DT N
other JJ N
types NNS N
of IN N
tumor NN N
, , N
but CC N
the DT N
numbers NNS N
in IN N
this DT N
population NN N
were VBD N
very RB N
limited JJ N
. . N

In IN N
a DT N
group NN N
of IN N
45 CD N
patients NNS N
, , N
antithrombin JJ o
III NNP o
a DT o
( ( o
% NN o
) ) o
, , o
antithrombin JJ o
III NNP o
R NNP o
: : o
Ag NNP o
( ( o
% NN o
) ) o
, , o
plasminogen NN o
( ( o
mg/dl NN o
) ) o
, , o
alpha-2 JJ o
macroglobulin NN o
( ( o
% NN o
) ) o
, , o
factor NN o
VIII NNP o
C NNP o
( ( o
% NN o
) ) o
, , o
factor NN o
VIII NNP o
R NNP o
: : o
Ag NNP o
( ( o
% NN o
) ) o
and CC o
factor NN o
IX NNP o
C NNP o
( ( o
% NN o
) ) o
were VBD N
determined VBN N
. . N

The DT N
most RBS N
interesting JJ N
post-treatment JJ N
findings NNS N
were VBD N
an DT N
increase NN N
in IN N
anti-thrombin JJ o
III NNP o
( ( o
activity NN o
and CC o
antigen NN o
level NN o
) ) o
and CC o
in IN o
plasminogen NN o
. . o

This DT N
suggests VBZ N
that IN N
MPA NNP N
does VBZ N
not RB N
increase VB N
the DT N
risk NN N
of IN N
thrombosis NN N
, , N
and CC N
might MD N
even RB N
, , N
to TO N
some DT N
extent NN N
, , N
impede VB N
tumor-induced JJ N
thrombophilia NN N
. . N

( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
250 CD N
WORDS NNP N
) ) N
-DOCSTART- -12426230- O O

Immunologic NNP N
and CC N
hemodynamic JJ N
effects NNS N
of IN N
low-dose JJ i
hydrocortisone NN i
in IN N
septic JJ p
shock NN p
: : p
a DT N
double-blind NN N
, , N
randomized VBN N
, , N
placebo-controlled JJ i
, , N
crossover NN N
study NN N
. . N

Within IN N
the DT N
last JJ N
few JJ N
years NNS N
, , N
increasing VBG N
evidence NN N
of IN N
relative JJ N
adrenal JJ p
insufficiency NN p
in IN p
septic JJ p
shock NN p
evoked VBD N
a DT N
reassessment NN N
of IN N
hydrocortisone NN i
therapy NN i
. . i

To TO N
evaluate VB N
the DT N
effects NNS N
of IN N
hydrocortisone NN i
on IN N
the DT N
balance NN N
between IN N
proinflammatory NN N
and CC N
antiinflammation NN N
, , N
40 CD p
patients NNS p
with IN p
septic JJ p
shock NN p
were VBD N
randomized VBN N
in IN N
a DT N
double-blind JJ N
crossover NN N
study NN N
to TO N
receive VB N
either CC N
the DT N
first JJ N
100 CD N
mg NN N
of IN N
hydrocortisone NN i
as IN N
a DT N
loading NN N
dose NN N
and CC N
10 CD N
mg NNS N
per IN N
hour NN N
until IN N
Day NNP N
3 CD N
( ( N
n JJ N
= NNP N
20 CD N
) ) N
or CC N
placebo NN i
( ( N
n JJ N
= NNP N
20 CD N
) ) N
, , N
followed VBN N
by IN N
the DT N
opposite JJ N
medication NN N
until IN N
Day NNP N
6 CD N
. . N

Hydrocortisone CD i
infusion NN N
induced VBD N
an DT N
increase NN N
of IN N
mean JJ o
arterial JJ o
pressure NN o
, , o
systemic JJ o
vascular NN o
resistance NN o
, , N
and CC N
a DT N
decline NN N
of IN N
heart NN o
rate NN o
, , o
cardiac JJ o
index NN o
, , o
and CC o
norepinephrine JJ o
requirement NN o
. . o

A DT N
reduction NN N
of IN N
plasma NN o
nitrite/nitrate NN o
indicated VBD N
inhibition NN N
of IN N
nitric JJ o
oxide JJ o
formation NN o
and CC N
correlated VBN N
with IN N
a DT N
reduction NN o
of IN o
vasopressor NN o
support NN o
. . o

The DT N
inflammatory JJ o
response NN o
( ( o
interleukin-6 JJ o
and CC o
interleukin-8 JJ o
) ) o
, , o
endothelial JJ o
( ( o
soluble JJ o
E-selectin NN o
) ) o
and CC o
neutrophil JJ o
activation NN o
( ( o
expression NN o
of IN o
CD11b NNP o
, , o
CD64 NNP o
) ) o
, , o
and CC o
antiinflammatory JJ o
response NN o
( ( o
soluble JJ o
tumor NN o
necrosis NN o
factor NN o
receptors NNS o
I PRP o
and CC o
II NNP o
and CC o
interleukin-10 JJ o
) ) o
were VBD N
attenuated VBN N
. . N

In IN N
peripheral JJ N
blood NN N
monocytes NNS N
, , N
human JJ o
leukocyte VBD o
antigen-DR JJ o
expression NN o
was VBD N
only RB N
slightly RB N
depressed VBN N
, , N
whereas NNS N
in IN o
vitro JJ o
phagocytosis NN o
and CC o
the DT o
monocyte-activating JJ o
cytokine JJ o
interleukin-12 NN o
increased VBD N
. . N

Hydrocortisone NNP i
withdrawal NN N
induced VBD N
hemodynamic JJ o
and CC o
immunologic JJ o
rebound NN o
effects NNS o
. . o

In IN N
conclusion NN N
, , N
hydrocortisone NN i
therapy NN i
restored VBD N
hemodynamic JJ o
stability NN o
and CC N
differentially RB N
modulated VBD N
the DT N
immunologic JJ o
response NN o
to TO o
stress VB o
in IN N
a DT N
way NN N
of IN N
antiinflammation NN N
rather RB N
than IN N
immunosuppression NN N
. . N

-DOCSTART- -3543069- O O

Untoward NNP N
effects NNS N
of IN N
fenfluramine NN i
in IN N
autistic JJ p
children NNS p
. . p

Several JJ N
recent JJ N
studies NNS N
have VBP N
described VBN N
the DT N
benefits NNS N
of IN N
fenfluramine NN i
for IN N
the DT N
symptomatic JJ N
treatment NN N
of IN N
infantile JJ p
autism NN p
. . p

No DT N
large JJ N
surveys NNS N
of IN N
side JJ N
effects NNS N
of IN N
this DT N
drug NN N
have VBP N
been VBN N
reported VBN N
in IN N
autistic JJ p
children NNS p
. . p

To TO N
evaluate VB N
the DT N
untoward JJ N
effects NNS N
of IN N
fenfluramine NN i
in IN N
children NNS p
with IN p
autism NN p
, , p
12 CD p
subjects NNS p
were VBD N
systematically RB N
studied VBN N
. . N

Medication NNP N
was VBD N
administered VBN N
in IN N
a DT N
double-blind JJ N
, , N
placebo-controlled JJ i
cross-over NN N
study NN N
. . N

Parents NNS N
were VBD N
trained VBN N
in IN N
monitoring VBG N
untoward JJ N
effects NNS N
. . N

These DT N
observations NNS N
were VBD N
compiled VBN N
in IN N
detailed JJ N
daily JJ N
notes NNS N
. . N

In IN p
addition NN p
, , p
four CD p
cases NNS p
describing VBG p
unusual JJ p
effects NNS p
found VBN p
in IN p
a DT p
sample NN p
of IN p
170 CD p
patients NNS p
treated VBN p
with IN p
fenfluramine NN i
are VBP p
also RB p
reported VBN p
. . p

In IN N
the DT N
initial JJ N
2 CD N
weeks NNS N
of IN N
active JJ N
drug NN N
listlessness NN N
, , N
food NN o
refusal NN o
, , o
and CC o
stomach NN o
upset NN o
were VBD N
frequently RB N
seen VBN N
. . N

A DT N
different JJ N
pattern NN N
of IN N
untoward JJ o
effects NNS o
was VBD N
seen VBN N
in IN N
the DT N
final JJ N
14 CD N
weeks NNS N
of IN N
treatment NN N
. . N

Irritability NNP o
, , o
agitation NN o
, , o
and CC o
crying VBG o
along RB o
with IN o
continued VBN o
food NN o
refusal NN o
were VBD N
noted VBN N
. . N

The DT N
subjects NNS N
lost VBD N
2.1 CD N
% NN N
of IN N
body NN o
weight NN o
during IN N
active JJ N
drug NN N
phase NN N
, , N
but CC N
there RB N
was VBD N
a DT N
rebound NN o
weight NN o
gain NN o
during IN N
the DT N
subsequent JJ N
placebo NN i
phase NN N
. . N

A DT N
thorough JJ N
understanding NN N
of IN N
fenfluramine NN i
's POS i
side NN N
effects NNS N
and CC N
adverse JJ N
reactions NNS N
is VBZ N
necessary JJ N
so RB N
as IN N
to TO N
differentiate VB N
them PRP N
from IN N
the DT N
multiple NN N
symptoms NNS N
inherent NN N
in IN N
the DT N
syndrome NN N
of IN N
autism NN p
. . p

-DOCSTART- -15746480- O O

The DT N
overt JJ i
aggression NN i
scale NN i
for IN i
rating NN i
aggression NN i
in IN N
outpatient JJ p
youth NN p
with IN p
autistic JJ p
disorder NN p
: : p
preliminary JJ N
findings NNS N
. . N

Aggression NNP N
is VBZ N
a DT N
common JJ N
and CC N
costly JJ N
problem NN N
in IN N
youth NN p
with IN p
developmental JJ p
disabilities NNS p
. . p

Rating VBG N
scales NNS N
that WDT N
accurately RB N
capture NN N
and CC N
measure NN N
subtypes NNS N
of IN N
aggression NN N
phenomenology NN N
, , N
frequency NN N
and CC N
severity NN N
are VBP N
urgently RB N
needed VBN N
, , N
in IN N
both DT N
clinical JJ N
practice NN N
and CC N
research NN N
. . N

The DT N
authors NNS N
studied VBD N
the DT N
Overt NNP o
Aggression NNP o
Scale NNP o
( ( o
OAS NNP o
) ) o
in IN N
a DT N
preliminary JJ N
sample NN N
of IN N
eight CD p
outpatients NNS p
who WP p
participated VBD p
in IN p
an DT p
ongoing JJ p
placebo-controlled JJ i
study NN p
of IN p
valproate NN i
for IN p
aggression NN p
in IN p
autism NN p
. . p

Subjects NNS N
' POS N
OAS NNP o
aggression NN o
scores NNS o
showed VBD N
significant JJ N
correlation NN N
with IN N
the DT N
already RB N
validated VBN N
retrospectively RB N
rated VBN N
Aberrant NNP o
Behavior NNP o
Checklist NNP o
Community NNP o
Scale NNP o
irritability NN o
subscale NN o
. . o

Further NNP N
study NN N
of IN N
the DT N
OAS NNP o
in IN N
outpatients NNS N
with IN N
aggression NN N
and CC N
developmental JJ N
disabilities NNS N
is VBZ N
warranted VBN N
. . N

-DOCSTART- -22709810- O O

Dietary NNP N
patterns NNS N
differ VBP N
between IN N
urban JJ p
and CC p
rural JJ p
older JJR p
, , p
long-term JJ p
survivors NNS p
of IN p
breast NN p
, , p
prostate NN p
, , p
and CC p
colorectal JJ p
cancer NN p
and CC N
are VBP N
associated VBN N
with IN N
body NN N
mass NN N
index NN N
. . N

BACKGROUND NNP N
Older NNP p
adult NN p
cancer NN p
survivors NNS p
are VBP N
at IN N
greater JJR N
risk NN N
of IN N
cancer NN o
recurrence NN o
and CC N
other JJ N
comorbidities NNS o
that WDT N
can MD N
be VB N
prevented VBN N
through IN N
improved VBN N
diet JJ N
and CC N
weight JJ N
management NN N
. . N

The DT N
tertiary JJ N
prevention NN N
needs NNS N
of IN N
rural-dwelling JJ N
survivors NNS N
can MD N
be VB N
even RB N
greater JJR N
, , N
yet RB N
little JJ N
is VBZ N
known VBN N
about IN N
rural JJ N
and CC N
urban JJ N
differences NNS N
in IN N
lifestyle JJ N
factors NNS N
among IN N
this DT N
high-risk JJ N
population NN N
. . N

OBJECTIVES NNP N
To TO N
compare VB i
dietary JJ i
patterns NNS i
of IN N
urban JJ p
and CC p
rural JJ p
cancer NN p
survivors NNS p
and CC N
to TO N
examine VB N
associations NNS N
of IN N
dietary JJ o
patterns NNS o
with IN N
body NN o
mass NN o
index NN o
( ( o
BMI NNP o
) ) o
. . o

DESIGN VB N
A DT N
secondary JJ N
analysis NN N
was VBD N
performed VBN N
of IN N
baseline NN N
data NNS N
from IN N
the DT N
Reach NNP o
Out NNP o
to TO o
Enhance VB o
Wellness NNP o
( ( N
RENEW NNP N
) ) N
trial NN N
, , N
a DT N
diet JJ i
and CC i
exercise JJ i
intervention NN i
among IN N
overweight JJ N
, , N
long-term JJ N
( ( N
?5 CD N
years NNS N
) ) N
, , N
older JJR N
survivors NNS N
of IN N
colorectal NN N
, , N
breast NN N
, , N
and CC N
prostate NN N
cancer NN p
. . p

Survivors NNS p
in IN p
the DT p
present JJ p
analysis NN p
( ( p
n=729 JJ p
) ) p
underwent JJ i
two CD i
45- JJ i
to TO i
60-minute JJ i
telephone NN i
surveys NNS i
, , i
which WDT i
included VBD i
two CD i
24-hour JJ i
dietary JJ i
recalls NNS i
. . i

Principal JJ i
components NNS i
analysis NN i
and CC i
multivariable JJ i
general JJ i
linear JJ i
models NNS i
were VBD i
used VBN N
to TO N
derive VB o
dietary JJ o
patterns NNS o
and CC o
to TO N
evaluate VB N
associations NNS N
between IN o
dietary JJ o
patterns NNS o
and CC o
BMI NNP o
, , o
respectively RB N
. . N

RESULTS VB N
Principal JJ N
components NNS N
analysis NN N
identified VBD N
three CD o
primary JJ o
dietary JJ o
patterns NNS o
among IN o
rural JJ N
dwellers NNS N
( ( N
high JJ N
sweets NNS N
and CC N
starches NNS N
, , N
high JJ N
reduced-fat NN N
dairy NN N
, , N
cereal NN N
, , N
nuts NNS N
, , N
and CC N
fruits NNS N
, , N
and CC N
mixed JJ N
) ) N
and CC N
three CD N
among IN N
urban JJ N
dwellers NNS N
( ( N
high JJ N
fruits NNS N
and CC N
vegetables NNS N
, , N
high JJ N
meat NN N
and CC N
refined VBD N
grains NNS N
, , N
and CC N
high JJ N
sugar-sweetened JJ N
beverages NNS N
) ) N
. . N

Among IN p
rural JJ p
survivors NNS p
, , p
greater JJR N
adherence NN N
to TO N
the DT N
high JJ N
reduced-fat NN N
dairy NN N
, , N
cereal NN N
, , N
nuts NNS N
, , N
and CC N
fruits NNS N
pattern NN N
was VBD N
positively RB N
associated VBN N
with IN N
lower JJR o
BMI NNP o
( ( o
P NNP N
trend NN N
< NNP N
0.05 CD N
) ) N
, , N
whereas IN N
higher JJR N
scores NNS N
on IN N
the DT N
mixed JJ N
pattern NN N
was VBD N
associated VBN N
with IN N
greater JJR o
BMI NNP o
( ( o
P NNP N
trend NN N
< NNP N
0.05 CD N
) ) N
. . N

Greater NNP N
adherence NN N
to TO N
the DT N
high JJ N
fruits NNS N
and CC N
vegetables NNS N
pattern VBP N
among IN N
urban JJ N
survivors NNS N
was VBD N
inversely RB N
associated VBN N
with IN o
BMI NNP o
( ( o
P NNP N
trend NN N
< NNP N
0.05 CD N
) ) N
. . N

CONCLUSIONS NNP N
Urban NNP N
and CC N
rural JJ N
differences NNS N
in IN N
dietary JJ N
intake NN N
behavior NN N
should MD N
be VB N
considered VBN N
in IN N
designing VBG N
public JJ N
health NN N
interventions NNS N
among IN N
the DT o
increasing VBG o
population NN o
of IN o
older JJR N
cancer NN N
survivors NNS N
. . N

In IN N
addition NN N
, , N
targeting VBG N
overall JJ N
dietary JJ N
patterns NNS N
might MD N
be VB N
one CD N
approach NN N
to TO N
help VB N
reduce VB N
the DT N
burden NN N
of IN N
obesity NN N
among IN N
this DT N
population NN N
. . N

-DOCSTART- -7037697- O O

Preliminary JJ N
report NN N
of IN N
the DT N
M.D NNP N
. . N

Anderson NNP p
Hospital NNP p
randomized VBD p
trial NN p
of IN p
neutron NN i
and CC i
photon NN i
irradiation NN i
for IN p
locally RB o
advanced JJ o
carcinoma NN o
of IN o
the DT o
uterine JJ o
cervix NN o
. . p

-DOCSTART- -11920488- O O

The DT N
specific JJ N
role NN N
of IN N
isoflavones NNS i
on IN N
estrogen NN N
metabolism NN N
in IN p
premenopausal JJ p
women NNS p
. . p

BACKGROUND NNP N
There EX N
is VBZ N
increasing VBG N
evidence NN N
that IN N
dietary JJ N
factors NNS N
may MD N
play VB N
a DT N
role NN N
in IN N
the DT N
production NN N
, , N
metabolism NN N
, , N
and CC N
bioavailability NN N
of IN N
sex NN N
hormones NNS N
and CC N
their PRP$ N
impact NN N
on IN N
target NN N
tissues NNS N
. . N

The DT N
specific JJ N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
effectiveness NN N
of IN N
supplementing VBG N
a DT p
group NN p
of IN p
premenopausal JJ p
women NNS p
who WP p
were VBD p
free JJ p
of IN p
breast NN p
carcinoma NN p
with IN N
a DT N
dietary JJ N
supplement NN N
of IN N
isoflavones NNS i
( ( N
40 CD N
mg NNS N
per IN N
day NN N
) ) N
in IN N
producing VBG N
a DT N
change NN N
in IN N
steroid JJ N
hormones NNS N
and CC N
menstrual JJ N
cycle NN N
length NN N
. . N

METHODS NNP N
Sixty-eight NNP p
consecutively RB p
recruited VBD p
, , p
premenopausal NN p
, , p
omnivorous JJ p
women NNS p
of IN p
all DT p
races NNS p
and CC p
ethnicities NNS p
between IN p
the DT p
ages NNS p
of IN p
25 CD p
years NNS p
and CC p
55 CD p
years NNS p
were VBD p
admitted VBN p
to TO p
the DT p
study NN p
and CC N
randomized VBN N
to TO N
an DT N
experimental JJ N
group NN N
supplemented VBD N
with IN N
soy NN i
( ( i
40 CD i
mg NN N
genistein NNS N
per IN N
day NN N
) ) N
or CC N
to TO N
a DT N
control NN N
group NN N
that WDT N
consumed VBD N
a DT N
placebo NN i
for IN N
a DT N
12-week JJ N
period NN N
. . N

Changes NNS N
in IN N
their PRP$ N
anthropometric NN o
, , o
nutritional JJ o
, , o
and CC o
hormonal JJ o
biomarkers NNS o
from IN N
early JJ N
follicular JJ N
phase NN N
were VBD N
analyzed VBN N
at IN N
baseline NN N
and CC N
post-intervention NN N
. . N

RESULTS NNP N
Serum-free JJ o
estradiol NN o
and CC o
estrone NN o
levels NNS o
decreased VBN N
moderately RB N
in IN N
the DT N
experimental JJ N
group NN N
. . N

Serum NNP o
hormone-binding JJ o
globulin NN o
levels NNS o
increased VBN N
in IN N
41.4 CD N
% NN N
of IN N
women NNS N
in IN N
the DT N
experimental JJ N
group NN N
compared VBN N
with IN N
37.5 CD N
% NN N
of IN N
women NNS N
in IN N
the DT N
placebo NN i
group NN N
. . N

Free JJ o
estradiol NN o
decreased VBN N
in IN N
53.85 CD N
% NN N
of IN N
women NNS N
in IN N
the DT N
experimental JJ N
group NN N
compared VBN N
with IN N
37.5 CD N
% NN N
of IN N
women NNS N
in IN N
the DT N
placebo NN i
group NN N
. . N

Estrone CD o
decreased VBD N
in IN N
55.56 CD N
% NN N
of IN N
women NNS N
in IN N
the DT N
experimental JJ N
group NN N
compared VBN N
with IN N
42.86 CD N
% NN N
in IN N
the DT N
placebo NN i
group NN N
. . N

Those DT N
women NNS N
in IN N
the DT N
experimental JJ N
group NN N
who WP N
were VBD N
consuming VBG N
soy NN i
had VBD N
their PRP$ N
mean JJ o
menstrual JJ o
cycle NN o
length NN o
increased VBN N
by IN N
3.52 CD N
days NNS N
compared VBN N
with IN N
a DT N
mean JJ N
decrease NN N
of IN N
0.06 CD N
days NNS N
for IN N
women NNS N
in IN N
the DT N
placebo NN i
group NN N
( ( N
P NNP N
= NNP N
0.04 CD N
) ) N
from IN N
baseline NN N
to TO N
the DT N
third JJ N
menstrual JJ N
cycle NN N
. . N

In IN N
addition NN N
, , N
women NNS N
who WP N
were VBD N
taking VBG N
soy NN i
had VBD N
their PRP$ N
mean JJ o
follicular JJ o
phase NN o
increase NN o
by IN N
1.46 CD N
days NNS N
compared VBN N
with IN N
a DT N
mean JJ N
increase NN N
of IN N
0.14 CD N
days NNS N
for IN N
women NNS N
who WP N
were VBD N
taking VBG N
the DT N
placebo NN i
( ( N
P NNP N
= NNP N
0.08 CD N
) ) N
. . N

CONCLUSIONS NNP N
These DT N
data NNS N
suggest VBP N
that IN N
increased VBD N
isoflavone NN i
intake NN N
affects NNS N
estrogen VBP N
metabolism NN N
by IN N
altering VBG N
the DT N
steroid NN N
hormone NN N
concentrations NNS N
and CC N
menstrual JJ N
cycle NN N
length NN N
, , N
thereby RB N
demonstrating VBG N
a DT N
potential JJ N
to TO N
reduce VB N
the DT N
risk NN N
for IN N
breast NN p
carcinoma NN p
. . p

-DOCSTART- -25066648- O O

Complex NNP i
decongestive JJ i
therapy NN i
and CC i
taping VBG i
for IN N
patients NNS p
with IN p
postmastectomy JJ p
lymphedema NN p
: : p
a DT N
randomized NN N
controlled VBN N
study NN N
. . N

PURPOSE VB N
The DT N
purpose NN N
of IN N
our PRP$ N
study NN N
was VBD N
to TO N
investigate VB N
the DT N
effects NNS N
of IN N
Kinesio NNP i
Taping NNP i
( ( i
? . i
) ) i
Application NN i
with IN i
Complex NNP i
Decongestive NNP i
Therapy NNP i
( ( i
CDT NNP i
) ) i
in IN p
patients NNS p
with IN p
lymphedema NN p
. . p

MATERIALS NNP N
AND NNP N
METHODS NNP p
45 CD p
patients NNS p
were VBD p
randomly RB p
divided VBN p
into IN p
3 CD p
groups NNS p
( ( N
CDT NNP i
including VBG i
Bandage NNP i
, , i
CDT NNP i
including VBG i
Bandage NNP i
+ NNP i
Kinesio NNP i
Tape NNP i
( ( i
? . i
) ) i
, , i
CDT NNP i
including VBG i
Kinesio NNP i
Tape NNP i
( ( i
? . i
) ) i
without IN i
bandage NN i
) ) i
. . i

Assessments NNS i
included VBD N
the DT N
severity NN o
of IN o
the DT o
symptoms NNS o
such JJ o
as IN o
pain NN o
, , o
discomfort NN o
, , o
heaviness NN o
, , o
tension NN o
, , o
stiffness NN o
and CC o
weakness NN o
. . o

Bilateral JJ o
circumference NN o
measurements NNS o
were VBD N
done VBN N
for IN N
evaluation NN N
of IN N
the DT N
edema NN N
. . N

RESULTS NNP N
Symptoms NNP N
were VBD N
decreased VBN N
in IN N
all DT N
three CD N
groups NNS N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

CDT NNP N
was VBD N
found VBN N
effective JJ N
only RB N
during IN N
treatment NN N
in IN N
arm NN o
volume NN o
( ( o
p JJ o
< NNP N
0.05 CD i
) ) i
. . i

Kinesio NNP i
Taping NNP i
( ( i
? . i
) ) i
applied VBD i
with IN N
CDT NNP i
had VBD N
effect NN N
of IN N
decreasing VBG o
edema NN o
after IN o
10 CD N
days NNS N
of IN N
treatment NN N
period NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
and CC N
for IN N
control NN N
period NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

Only RB N
the DT N
application NN i
of IN i
Kinesio NNP i
Taping NNP i
( ( i
? . i
) ) i
group NN i
also RB N
had VBD N
significant JJ N
decrease NN o
at IN o
edema NN o
( ( o
p JJ o
< NNP o
0.05 CD N
) ) N
. . N

CONCLUSION NNP i
Kinesio NNP i
Taping NNP i
( ( i
? . i
) ) i
Application NN i
along IN N
with IN i
CDT NNP i
may MD i
have VB N
a DT N
better JJR N
effect NN N
on IN N
decreasing VBG o
lymphedema NN o
which WDT o
can MD N
stimulate VB N
the DT N
reduction NN o
of IN o
edema NN o
for IN N
long JJ N
term NN N
effects NNS N
. . N

-DOCSTART- -14519754- O O

Selenium NNP i
supplementation NN i
and CC N
secondary JJ o
prevention NN i
of IN N
nonmelanoma JJ p
skin NN p
cancer NN p
in IN N
a DT N
randomized JJ N
trial NN N
. . N

The DT N
Nutritional JJ p
Prevention NN p
of IN p
Cancer NNP p
Trial NNP p
was VBD p
a DT p
double-blind JJ p
, , p
randomized VBN p
, , p
placebo-controlled JJ i
clinical JJ p
trial NN p
designed VBN N
to TO N
test VB N
whether IN N
selenium NN i
as IN i
selenized VBN i
yeast NN i
( ( N
200 CD N
microg NNS N
daily RB N
) ) N
could MD N
prevent VB p
nonmelanoma JJ p
skin JJ p
cancer NN p
among IN p
1312 CD p
patients NNS p
from IN p
the DT p
Eastern NNP p
United NNP p
States NNPS p
who WP p
had VBD p
previously RB p
had VBN p
this DT p
disease NN p
. . p

Results NNS N
from IN N
September NNP N
15 CD N
, , N
1983 CD N
, , N
through IN N
December NNP N
31 CD N
, , N
1993 CD N
, , N
showed VBD N
no DT N
association NN N
between IN N
treatment NN N
and CC N
the DT N
incidence NN N
of IN N
basal NN o
and CC o
squamous JJ o
cell NN o
carcinomas NN o
of IN o
the DT o
skin NN o
. . o

This DT N
report NN N
summarizes VBZ N
the DT N
entire JJ N
blinded VBD N
treatment NN N
period NN N
, , N
which WDT N
ended VBD N
on IN N
January NNP N
31 CD N
, , N
1996 CD N
. . N

The DT N
association NN N
between IN N
treatment NN N
and CC N
time NN o
to TO o
first VB o
nonmelanoma JJ o
skin NN o
cancer NN o
diagnosis NN o
and CC N
between IN N
treatment NN N
and CC N
time NN o
to TO o
multiple VB o
skin JJ o
tumors NNS o
overall JJ N
and CC N
within IN N
subgroups NNS N
, , N
defined VBN N
by IN N
baseline NN N
characteristics NNS N
, , N
was VBD N
evaluated VBN N
. . N

Although IN N
results NNS N
through IN N
the DT N
entire JJ N
blinded VBD N
period NN N
continued VBD N
to TO N
show VB N
that IN N
selenium JJ i
supplementation NN i
was VBD N
not RB N
statistically RB N
significantly RB N
associated VBN N
with IN N
the DT N
risk NN o
of IN o
basal NN o
cell NN o
carcinoma NN o
( ( N
hazard JJ N
ratio NN N
[ NNP N
HR NNP N
] NNP N
= NNP N
1.09 CD N
, , N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NNP N
= VBD N
0.94 CD N
to TO N
1.26 CD N
) ) N
, , N
selenium JJ i
supplementation NN i
was VBD N
associated VBN N
with IN N
statistically RB N
significantly RB N
elevated VBN o
risk NN o
of IN o
squamous JJ o
cell NN o
carcinoma NN o
( ( N
HR NNP N
= NNP N
1.25 CD N
, , N
95 CD N
% NN N
CI NNP N
= VBZ N
1.03 CD N
to TO N
1.51 CD N
) ) N
and CC N
of IN N
total JJ o
nonmelanoma JJ o
skin NN o
cancer NN o
( ( N
HR NNP N
= NNP N
1.17 CD N
, , N
95 CD N
% NN N
CI NNP N
= VBZ N
1.02 CD N
to TO N
1.34 CD N
) ) N
. . N

Results NNS N
from IN N
the DT N
Nutritional NNP N
Prevention NNP N
of IN N
Cancer NNP N
Trial NNP N
conducted VBD N
among IN N
individuals NNS N
at IN N
high JJ N
risk NN N
of IN N
nonmelanoma JJ N
skin NN N
cancer NN N
continue VBP N
to TO N
demonstrate VB N
that IN N
selenium NN i
supplementation NN i
is VBZ N
ineffective JJ N
at IN N
preventing VBG o
basal NN o
cell NN o
carcinoma NN o
and CC N
that IN N
it PRP N
increases VBZ N
the DT N
risk NN o
of IN o
squamous JJ o
cell NN o
carcinoma NN o
and CC o
total JJ o
nonmelanoma NN o
skin NN o
cancer NN o
. . o

-DOCSTART- -4187541- O O

Protective JJ N
effect NN N
of IN N
1-adamantanamine JJ i
hydrochloride NN i
on IN N
influenza NN p
A2 NNP p
infections NNS o
in IN p
the DT p
family NN p
environment NN p
: : p
a DT N
controlled VBN N
double-blind NN N
study NN N
. . N

-DOCSTART- -23838727- O O

The DT N
impact NN N
of IN N
parent-delivered JJ i
intervention NN i
on IN N
parents NNS p
of IN p
very RB p
young JJ p
children NNS p
with IN p
autism NN p
. . p

This DT N
study NN N
investigated VBD N
the DT N
impact NN N
of IN N
a DT N
parent-coaching JJ i
intervention NN i
based VBN N
on IN N
the DT N
Early JJ i
Start NNP i
Denver NNP i
Model NNP i
( ( i
P-ESDM NNP i
) ) i
on IN N
parenting-related JJ o
stress NN o
and CC N
sense NN o
of IN o
competence NN o
. . o

This DT N
was VBD N
part NN N
of IN N
a DT N
multisite NN p
, , N
randomized VBN i
trial NN i
comparing VBG N
P-ESDM NNP i
( ( p
n JJ p
= NNP p
49 CD p
) ) p
with IN i
community NN i
intervention NN i
( ( i
n JJ p
= NNP p
49 CD p
) ) p
for IN p
children NNS p
aged VBN p
12 CD p
and CC p
24 CD p
months NNS p
. . p

The DT p
P-ESDM NNP o
group NN o
reported VBD N
no DT N
increase NN o
in IN o
parenting VBG o
stress NN o
, , o
whereas IN o
the DT N
Community NNP N
group NN N
experienced VBD N
an DT N
increase NN N
over IN N
the DT N
same JJ N
3-month JJ N
period NN o
. . o

Parental JJ o
sense NN o
of IN o
competence NN o
did VBD o
not RB N
differ VB o
. . o

Number NNP o
of IN o
negative JJ o
life NN o
events NNS o
was VBD o
a DT N
significant JJ N
predictor NN N
of IN N
parenting VBG N
stress NN N
and CC N
sense NN N
of IN N
competence NN N
across IN N
both DT N
groups NNS N
. . N

This DT N
suggests VBZ N
that IN N
a DT i
parent-coaching JJ i
intervention NN i
may MD i
help VB N
maintain VB o
parental JJ o
adjustment NN o
directly RB o
after IN N
a DT N
child NN N
is VBZ N
diagnosed VBN N
with IN N
ASD NNP N
. . N

-DOCSTART- -23909380- O O

Low JJ i
protein NN i
provision NN i
during IN N
the DT N
first JJ N
year NN N
of IN N
life NN N
, , N
but CC N
not RB N
during IN N
foetal JJ N
life NN N
, , N
affects VBZ N
metabolic JJ o
traits NNS o
, , o
organ JJ o
mass NN o
development NN o
and CC o
growth NN o
in IN N
male JJ p
mink NN p
( ( p
Neovison NNP p
vison NN p
) ) p
. . p

Low JJ i
protein NN i
provision NN N
in IN N
utero JJ N
and CC N
post-partum JJ N
may MD N
induce VB N
metabolic JJ o
disorders NNS o
in IN N
adulthood NN N
. . N

Studies NNS N
in IN N
mink NN N
have VBP N
mainly RB N
focused VBN N
on IN N
short-term JJ N
consequences NNS N
of IN N
low JJ i
protein NN i
provision NN i
in IN N
utero JJ N
whereas IN N
the DT N
long-term JJ N
responses NNS N
to TO N
low JJ i
protein NN i
( ( i
LP NNP i
) ) i
provision NN i
in IN N
metabolically RB N
programmed VBN N
mink NN N
are VBP N
unknown JJ N
. . N

We PRP N
investigated VBD N
whether IN N
low JJ N
protein NN N
provision NN N
in IN N
utero JJ N
affects NNS N
the DT N
long-term JJ N
response NN N
to TO N
adequate VB N
( ( N
AP NNP N
) ) N
or CC N
LP NNP N
provision NN N
after IN N
weaning VBG N
in IN N
male JJ N
mink NN N
. . N

Eighty-six JJ p
male JJ p
mink NN p
were VBD p
exposed VBN p
to TO p
low VB p
( ( p
19 CD p
% NN p
of IN p
ME NNP p
from IN p
CP NNP p
; : p
crude JJ i
protein NN i
) ) i
or CC p
adequate JJ i
( ( i
31 CD i
% NN i
of IN i
ME NNP i
from IN i
CP NNP i
) ) i
protein NN i
provision NN p
in IN p
utero NN p
, , p
and CC p
to TO p
LP NNP p
( ( p
~20 CD p
% NN p
of IN p
ME NNP p
from IN p
CP NNP p
) ) p
or CC p
AP NNP p
( ( p
30-42 CD p
% NN p
of IN p
ME NNP p
from IN p
CP NNP p
) ) p
provision NN p
post-weaning NN p
. . p

Being NNP N
metabolically RB N
programmed VBN N
by IN N
low JJ i
protein NNS i
provision NN N
in IN N
utero NN N
did VBD N
not RB N
affect VB N
the DT N
response NN N
to TO N
post-weaning JJ o
diets NNS o
. . N

Dietary NNP o
protein NN o
content NN o
in IN N
the DT N
LP NNP N
feed NN N
after IN N
weaning VBG N
was VBD N
below IN N
requirements NNS N
; : N
evidenced VBN N
by IN N
lower JJR N
nitrogen NN o
retention NN o
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
preventing VBG N
LP NNP N
mink NN N
from IN N
attaining VBG N
their PRP$ N
growth NN N
potential NN N
( ( N
p JJ N
< NNP N
0.02 CD N
) ) N
. . N

LP NNP N
mink NN p
had VBD N
a DT N
lower JJR N
liver NN o
, , o
pancreas NNS o
and CC o
kidney NN o
weight NN o
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
as RB N
well RB N
as IN N
lower JJR N
plasma NN o
IGF-1 JJ o
concentrations NNS o
at IN N
8 CD N
and CC N
25 CD N
( ( N
p NN N
< RB N
0.05 CD N
) ) N
weeks NNS N
, , N
and CC N
a DT N
higher JJR N
incidence NN N
of IN N
hepatic JJ o
lipidosis NN o
at IN N
25 CD N
weeks NNS N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

Furthermore UH N
, , N
LP NNP N
mink NN N
had VBD N
a DT N
higher JJR o
body NN o
fat JJ o
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
and CC N
lower JJR o
body NN o
CP NNP o
content NN o
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
at IN N
50 CD N
weeks NNS N
of IN N
age NN N
. . N

It PRP N
is VBZ N
concluded VBN N
that IN N
some DT N
effects NNS N
of IN N
low JJ o
protein NN o
provision NN o
in IN i
utero NN N
can MD N
be VB N
alleviated VBN N
by IN N
an DT N
adequate JJ N
nutrient JJ o
supply NN o
post-partum NN o
. . o

However RB N
, , N
long-term JJ N
exposure NN N
to TO N
low JJ i
protein NN i
provision NN i
in IN N
mink NN N
reduces NNS N
their PRP$ N
growth NN o
potential NN o
and CC o
induces NNS o
transient JJ o
hepatic JJ o
lipidosis NN o
and CC o
modified VBD o
body NN o
composition NN o
. . o

-DOCSTART- -21575130- O O

Safety NN o
and CC o
pharmacokinetics NNS o
of IN N
a DT N
glycoPEGylated JJ i
recombinant NN i
activated VBD i
factor NN i
VII NNP i
derivative NN i
: : i
a DT N
randomized VBN N
first JJ N
human JJ N
dose JJ N
trial NN N
in IN p
healthy JJ p
subjects NNS p
. . p

BACKGROUND NNP N
Extensive NNP N
research NN N
is VBZ N
currently RB N
ongoing VBG N
to TO N
prolong VB N
the DT N
half-life NN N
of IN N
coagulation NN N
factors NNS N
. . N

One CD N
of IN N
these DT N
techniques NNS N
is VBZ i
glycoPEGylation NN i
, , i
which WDT N
has VBZ N
also RB N
been VBN N
applied VBN N
to TO N
recombinant VB N
activated JJ N
factor NN N
VII NNP N
( ( N
rFVIIa NN N
) ) N
, , N
resulting VBG N
in IN N
a DT N
rFVIIa NN i
derivative JJ i
( ( i
N7-GP NNP i
) ) i
with IN N
a DT N
prolonged JJ N
terminal JJ N
half-life NN N
( ( N
t NN N
( ( N
1/2 CD N
) ) N
) ) N
. . N

The DT N
main JJ N
clinical JJ N
purpose NN N
of IN i
N7-GP NNP i
is VBZ N
to TO N
provide VB N
safe JJ N
and CC N
effective JJ N
prophylaxis NN N
to TO p
patients NNS p
with IN p
hemophilia NNS p
and CC p
inhibitors NNS p
. . p

The DT N
prolonged JJ N
t NN N
( ( N
1/2 CD N
) ) N
of IN N
N7-GP NNP N
can MD N
potentially RB N
reduce VB N
the DT N
dosing NN N
frequency NN N
and CC N
thereby RB N
facilitate JJ N
convenience NN N
and CC N
compliance NN N
, , N
which WDT N
are VBP N
two CD N
significant JJ N
barriers NNS N
to TO N
effective JJ N
prophylaxis NN N
. . N

OBJECTIVES UH N
To TO N
determine VB N
the DT o
safety NN o
and CC o
pharmacokinetics NNS o
of IN N
single JJ N
doses NNS N
of IN p
N7-GP NNP p
in IN p
healthy JJ p
men NNS p
. . p

METHODS VB p
A DT p
randomized JJ p
, , p
placebo-controlled JJ p
, , p
dose-escalation JJ p
trial NN p
with IN p
five CD p
cohorts NNS p
( ( p
N7-GP NNP p
dose NN p
of IN p
12.5-100 JJ p
?g NNP p
kg NN p
( ( p
-1 NNP p
) ) p
) ) p
was VBD p
performed VBN p
. . p

In IN p
each DT p
cohort NN p
, , p
eight CD p
subjects NNS p
were VBD p
randomized VBN p
to TO p
receive VB N
N7-GP NNP N
( ( N
n JJ N
= NNP N
6 CD N
) ) N
or CC N
placebo NN i
( ( i
n JJ N
= NNP N
2 CD N
) ) N
. . N

RESULTS VB N
The DT o
mean JJ o
FVIIa NNP o
activity NN o
was VBD o
measurable JJ N
for IN N
up IN N
to TO N
at IN N
least JJS N
72 CD N
h NN N
after IN N
dosing VBG N
, , N
and CC N
the DT N
overall JJ N
mean NN N
t NN N
( ( N
1/2 CD N
) ) N
for IN N
FVIIa NNP N
activity NN N
was VBD N
15 CD N
h. PDT N
The DT o
pharmacokinetics NNS o
of IN o
N7-GP NNP o
appeared VBD o
to TO N
be VB N
dose-proportional JJ N
in IN N
the DT N
dose JJ N
range NN N
investigated VBN o
. . o

No DT o
serious JJ o
adverse JJ o
events NNS o
( ( o
including VBG o
thromboembolic JJ o
events NNS o
) ) o
were VBD o
reported VBN N
. . N

The DT o
frequency NN o
of IN o
adverse JJ o
events NNS o
was VBD o
similar JJ N
in IN N
both DT N
the DT N
placebo NN N
and CC N
N7-GP JJ N
groups NNS N
. . N

No DT N
neutralizing VBG o
antibodies NNS o
against IN o
N7-GP NNP o
were VBD o
detected VBN N
. . N

A DT N
pharmacologic JJ o
effect NN o
was VBD o
apparent JJ N
from IN N
a DT N
dose-dependent JJ N
statistically RB N
significant JJ N
decrease NN N
in IN N
the DT o
mean JJ o
prothrombin NN o
time NN o
in IN o
all DT N
N7-GP JJ N
groups NNS N
as IN N
compared VBN N
with IN N
placebo NN N
. . N

CONCLUSIONS NNP N
N7-GP NNP N
had VBD N
a DT N
plasma JJ N
half-life NN N
of IN N
15 CD N
h NN N
and CC N
a DT N
profile NN N
that WDT N
makes VBZ N
it PRP N
a DT N
potential JJ N
candidate NN N
for IN N
prophylaxis NN N
in IN N
patients NNS p
with IN p
hemophilia NNS p
and CC p
inhibitors NNS p
. . p

-DOCSTART- -7961334- O O

Brief JJ N
report NN N
: : N
a DT N
controlled JJ N
evaluation NN N
of IN N
facilitated JJ p
communication NN p
using VBG p
open-ended JJ i
and CC i
fill-in JJ i
questions NNS i
. . i

-DOCSTART- -4623522- O O

The DT N
effect NN N
of IN N
phenytoin NN i
on IN N
the DT N
absorption NN N
of IN N
synthetic JJ N
folic JJ N
acid NN N
polyglutamate NN N
. . N

The DT N
absorption NN N
of IN N
synthetic JJ N
pteroyltriglutamate NN N
has VBZ N
been VBN N
measured VBN N
in IN N
nine CD p
normal JJ p
students NNS p
with IN p
and CC p
without IN p
the DT p
anticonvulsant JJ p
drug NN p
phenytoin NN i
. . i

It PRP N
has VBZ N
been VBN N
shown VBN N
that IN N
phenytoin NN i
has VBZ N
no DT N
effect NN N
on IN N
the DT N
absorption NN N
of IN N
this DT N
folate JJ o
polyglutamate NN o
. . o

The DT N
reasons NNS N
are VBP N
discussed VBN N
for IN N
the DT N
disparity NN N
between IN N
this DT N
result NN N
and CC N
those DT N
reported VBN N
in IN N
the DT N
literature NN N
when WRB N
folate NN N
polyglutamates NNS N
derived VBN N
from IN N
yeast NN N
were VBD N
used VBN N
. . N

-DOCSTART- -18289310- O O

Effect NN N
of IN N
erythromycin NN i
and CC i
gentamicin NN i
on IN N
abomasal JJ o
emptying VBG o
rate NN o
in IN p
suckling VBG p
calves NNS p
. . p

BACKGROUND NNP N
Commonly NNP N
used VBD N
dosage NN N
protocols NNS N
for IN N
antimicrobial JJ N
agents NNS N
may MD N
alter VB N
the DT N
rate NN N
of IN N
gastric JJ o
emptying VBG o
. . o

HYPOTHESIS NNP N
Parenteral NNP N
administration NN N
of IN N
erythromycin JJ i
increases NNS N
and CC N
gentamicin NN N
decreases VBZ N
the DT N
rate NN N
of IN N
abomasal NN o
emptying VBG o
. . o

ANIMALS NNP N
Five CD p
male JJ p
Holstein-Friesian JJ p
calves NNS p
( ( p
8-15 JJ p
days NNS p
of IN p
age NN p
) ) p
. . p

METHODS NNP N
Calves NNPS N
received VBD N
each DT N
of IN N
the DT N
following VBG N
4 CD N
IM NNP N
treatments NNS N
in IN N
random JJ N
order NN N
: : N
control NN i
, , i
2 CD i
mL NN i
of IN i
0.9 CD i
% NN i
NaCl NNP i
; : i
erythromycin NN i
, , i
8.8 CD i
mg/kg NN i
; : i
low-dose JJ i
gentamicin NN i
, , i
4.4 CD i
mg/kg NN i
; : i
high-dose JJ i
gentamicin NN i
, , i
6.6 CD i
mg/kg NN i
. . i

Abomasal NNP o
emptying VBG o
rate NN N
was VBD N
assessed VBN N
by IN N
acetaminophen NN o
and CC o
glucose JJ o
absorption NN o
. . o

Calves NNS N
were VBD N
fed VBN N
2 CD N
L NNP N
of IN N
cow NN N
's POS N
milk NN N
containing VBG N
acetaminophen NN i
( ( N
50 CD N
mg/kg NN N
body NN N
weight VBD N
) ) N
30 CD N
minutes NNS N
after IN N
each DT N
treatment NN N
was VBD N
administered VBN N
, , N
and CC N
jugular JJ N
venous JJ N
blood NN N
samples NNS N
were VBD N
obtained VBN N
periodically RB N
after IN N
suckling VBG N
. . N

The DT N
maximum JJ N
observed JJ N
plasma NN o
acetaminophen NN o
concentration NN o
( ( N
actual JJ N
C NNP N
( ( N
max NN N
) ) N
) ) N
and CC N
time NN o
of IN o
actual JJ o
C NNP o
( ( o
max NN o
) ) o
( ( o
actual JJ o
T NNP o
( ( o
max NN o
) ) o
) ) o
were VBD N
determined VBN N
, , N
and CC N
pharmacokinetic JJ N
modeling NN N
was VBD N
used VBN N
to TO N
calculate VB N
model NN N
C NNP N
( ( N
max NN N
) ) N
and CC N
model $ N
T NNP N
( ( N
max NN N
) ) N
. . N

RESULTS NNP N
Erythromycin NNP N
increased VBD N
abomasal JJ o
emptying VBG o
rate NN o
, , N
as IN N
indicated VBN N
by IN N
a DT N
shorter JJR N
time NN N
to TO N
actual JJ N
T NNP N
( ( N
max NN N
) ) N
and CC N
model $ N
T NNP N
( ( N
max NN N
) ) N
( ( N
P NNP N
< NNP N
.05 NNP N
) ) N
. . N

Abomasal NNP o
emptying VBG o
rate NN o
after IN N
injection NN N
of IN N
low-dose JJ N
gentamicin NN N
was VBD N
similar JJ N
to TO N
that DT N
of IN N
control NN N
. . N

Administration NNP N
of IN N
high-dose JJ N
gentamicin NN N
resulted VBD N
in IN N
a DT N
longer JJR N
time NN o
to TO o
actual JJ o
T NNP o
( ( o
max NN o
) ) o
( ( N
P= NNP N
.021 NNP N
) ) N
but CC N
did VBD N
not RB N
change VB N
model NN o
T NNP o
( ( o
max NN o
) ) o
( ( N
P= NNP N
.62 NNP N
) ) N
. . N

CONCLUSIONS NNP N
AND NNP N
CLINICAL NNP N
RELEVANCE NNP N
IM NNP N
injection NN N
of IN N
erythromycin NN N
increased VBN N
abomasal JJ o
emptying VBG o
rate NN o
in IN N
dairy NN p
calves NNS p
, , N
whereas IN N
low-dose JJ N
and CC N
high-dose JJ N
gentamicin NN N
did VBD N
not RB N
alter VB N
the DT N
rate NN o
of IN o
abomasal NN o
emptying VBG o
as IN N
measured VBN N
by IN N
acetaminophen NN N
kinetics NNS N
and CC N
glucose JJ N
absorption NN N
. . N

The DT N
clinical JJ N
relevance NN N
of IN N
these DT N
findings NNS N
remains VBZ N
to TO N
be VB N
determined VBN N
. . N

-DOCSTART- -20472253- O O

Effects NNS N
of IN N
fish JJ i
oil NN i
supplementation NN i
on IN N
markers NNS N
of IN N
the DT N
metabolic JJ N
syndrome NN N
. . N

OBJECTIVE UH N
To TO N
investigate VB N
whether IN N
fish JJ i
oil NN i
affects NNS N
cardiovascular JJ o
risk NN o
factors NNS o
during IN N
the DT N
adolescent JJ N
growth NN N
spurt NN N
. . N

STUDY NNP N
DESIGN NNP N
A NNP p
total NN p
of IN p
78 CD p
boys NNS p
age NN p
13-15 CD p
years NNS p
with IN p
a DT p
mean JJ p
body NN p
fat JJ p
percentage NN p
of IN p
30 CD p
% NN p
+/-9 JJ p
% NN p
were VBD N
randomly RB N
assigned VBN N
to TO N
consume VB N
fish JJ i
oil NN i
( ( N
providing VBG N
1.5 CD N
g NN N
of IN N
n-3 JJ N
long-chain NN i
polyunsaturated VBD i
fatty JJ i
acid/day NN i
) ) i
or CC i
vegetable JJ i
oil NN i
( ( i
control NN i
) ) i
for IN N
16 CD N
weeks NNS N
. . N

The DT N
oils NNS N
were VBD N
included VBN N
in IN N
bread NN N
. . N

RESULTS NNP N
After IN N
the DT N
intervention NN N
, , N
the DT N
red JJ o
blood NN o
cell NN o
( ( o
RBC NNP o
) ) o
content NN N
of IN N
eicosapentaenoic JJ o
acid NN o
( ( o
EPA NNP o
) ) o
and CC o
docosahexaenoic JJ o
acid NN o
( ( o
DHA NNP o
) ) o
were VBD N
1.2 CD N
% NN N
+/-0.5 JJ N
% NN N
and CC N
6.7 CD N
% NN N
+/-1.6 JJ N
% NN N
, , N
respectively RB N
, , N
in IN N
the DT N
those DT N
receiving VBG N
fish JJ i
oil NN i
( ( i
FO NNP i
group NN i
) ) i
, , N
compared VBN N
with IN N
0.6 CD N
% NN N
+/-0.3 JJ N
% NN N
and CC N
4.1 CD N
% NN N
+/-0.9 JJ N
% NN N
in IN N
the DT N
control NN i
group NN N
. . N

Systolic NNP o
blood NN o
pressure NN o
( ( o
SBP NNP o
) ) o
was VBD N
3.8+/-1.4 JJ N
mm NN N
Hg NNP N
lower JJR N
( ( N
P NNP N
< NNP N
.006 NNP N
) ) N
and CC N
diastolic JJ N
blood NN N
pressure NN N
( ( N
DBP NNP N
) ) N
was VBD N
2.6+/-1.1 JJ N
mm NN N
Hg NNP N
lower JJR N
( ( N
P NNP N
< NNP N
.01 NNP N
) ) N
in IN N
the DT N
FO NNP N
group NN N
compared VBN N
with IN N
the DT N
control NN N
group NN N
. . N

Plasma NNP o
triacylglycerol NN o
( ( o
TAG NNP o
) ) o
concentration NN o
and CC N
insulin JJ o
sensitivity NN o
were VBD N
unaffected VBN N
by IN N
either DT N
of IN N
the DT N
treatments NNS N
. . N

Plasma NNP o
high-density NN o
lipoprotein NN o
( ( o
HDL NNP o
) ) o
and CC o
non-HDL JJ o
cholesterol NN o
were VBD N
increased VBN N
by IN N
5 CD N
% NN N
and CC N
7 CD N
% NN N
, , N
respectively RB N
, , N
in IN N
the DT N
FO NNP i
group NN N
, , N
and CC N
by IN N
2 CD N
% NN N
and CC N
0 CD N
% NN N
in IN N
the DT N
control NN i
group NN i
( ( N
P NNP N
< NNP N
.01-.02 NN N
) ) N
. . N

The DT N
changes NNS o
in IN o
RBC NNP o
EPA NNP o
content NN o
were VBD N
inversely RB N
correlated VBN N
with IN N
the DT N
changes NNS o
in IN o
SBP NNP o
and CC o
DBP NNP o
and CC N
directly RB N
correlated VBN N
with IN N
the DT N
increases NNS N
in IN N
HDL NNP o
cholesterol NN o
and CC o
non-HDL JJ o
cholesterol NN o
concentrations NNS o
. . o

No DT N
association NN N
was VBD N
seen VBN N
between IN N
RBC NNP o
EPA NNP o
and CC o
plasma VB o
TAG NNP o
concentration NN o
or CC o
insulin JJ o
sensitivity NN o
. . o

CONCLUSION NNP N
Fish NNP i
oil NN i
improves VBZ N
BP NNP o
in IN N
normotensive JJ p
and CC p
normolipidemic JJ p
slightly RB p
overweight JJ p
adolescent NN p
boys NNS p
. . p

-DOCSTART- -15930233- O O

Randomized VBN N
trial NN N
of IN N
liberal JJ i
versus NN i
restrictive JJ i
guidelines NNS i
for IN i
red JJ i
blood NN i
cell NN i
transfusion NN i
in IN N
preterm JJ p
infants NNS p
. . p

OBJECTIVE NNP N
Although IN N
many JJ N
centers NNS N
have VBP N
introduced VBN N
more RBR N
restrictive JJ N
transfusion NN N
policies NNS N
for IN N
preterm JJ p
infants NNS p
in IN N
recent JJ N
years NNS N
, , N
the DT N
benefits NNS N
and CC N
adverse JJ N
consequences NNS N
of IN N
allowing VBG N
lower JJR N
hematocrit NN N
levels NNS N
have VBP N
not RB N
been VBN N
systematically RB N
evaluated VBN N
. . N

The DT N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
if IN N
restrictive JJ i
guidelines NNS i
for IN i
red JJ i
blood NN i
cell NN i
( ( i
RBC NNP i
) ) i
transfusions NNS i
for IN N
preterm JJ N
infants NNS N
can MD N
reduce VB N
the DT N
number NN o
of IN o
transfusions NNS o
without IN N
adverse JJ N
consequences NNS N
. . N

DESIGN NNP N
, , N
SETTING NNP N
, , N
AND NNP N
PATIENTS NNP N
We PRP N
enrolled VBD N
100 CD p
hospitalized JJ p
preterm NN p
infants NNS p
with IN p
birth JJ p
weights NNS p
of IN p
500 CD p
to TO p
1300 CD p
g NN p
into IN N
a DT N
randomized JJ N
clinical JJ N
trial NN N
comparing VBG N
2 CD N
levels NNS N
of IN N
hematocrit NN N
threshold NN N
for IN N
RBC NNP N
transfusion NN N
. . N

INTERVENTION NNP N
The DT N
infants NNS N
were VBD N
assigned VBN N
randomly RB N
to TO N
either VB N
the DT N
liberal- NN i
or CC i
the DT i
restrictive-transfusion NN i
group NN N
. . N

For IN N
each DT N
group NN N
, , N
transfusions NNS N
were VBD N
given VBN N
only RB N
when WRB N
the DT N
hematocrit NN N
level NN N
fell VBD N
below IN N
the DT N
assigned JJ N
value NN N
. . N

In IN N
each DT N
group NN N
, , N
the DT N
transfusion NN N
threshold NN N
levels NNS N
decreased VBN N
with IN N
improving VBG N
clinical JJ N
status NN N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
We PRP N
recorded VBD N
the DT N
number NN o
of IN o
transfusions NNS o
, , o
the DT o
number NN o
of IN o
donor JJ o
exposures NNS o
, , o
and CC o
various JJ o
clinical JJ o
and CC o
physiologic JJ o
outcomes NNS o
. . o

RESULTS JJ N
Infants NNS N
in IN N
the DT N
liberal-transfusion NN N
group NN N
received VBD N
more JJR N
RBC JJ o
transfusions NNS o
( ( N
5.2 CD N
+/- JJ N
4.5 CD N
[ JJ N
mean JJ N
+/- JJ N
SD NNP N
] NNP N
vs VBD N
3.3 CD N
+/- JJ N
2.9 CD N
in IN N
the DT N
restrictive-transfusion NN i
group NN N
) ) N
. . N

However RB N
, , N
the DT N
number NN o
of IN o
donors NNS o
to TO N
whom WP N
the DT N
infants NNS N
were VBD N
exposed VBN N
was VBD N
not RB N
significantly RB N
different JJ N
( ( N
2.8 CD N
+/- JJ N
2.5 CD N
vs JJ N
2.2 CD N
+/- JJ N
2.0 CD N
) ) N
. . N

There EX N
was VBD N
no DT N
difference NN N
between IN N
the DT N
groups NNS N
in IN N
the DT N
percentage NN o
of IN o
infants NNS o
who WP o
avoided VBD o
transfusions NNS o
altogether RB o
( ( N
12 CD N
% NN N
in IN N
the DT N
liberal-transfusion NN N
group NN N
versus VBD N
10 CD N
% NN N
in IN N
the DT N
restrictive-transfusion NN N
group NN N
) ) N
. . N

Infants NNS N
in IN N
the DT N
restrictive-transfusion NN i
group NN N
were VBD N
more RBR N
likely JJ N
to TO N
have VB N
intraparenchymal JJ o
brain NN o
hemorrhage NN o
or CC o
periventricular JJ o
leukomalacia NN o
, , N
and CC N
they PRP N
had VBD N
more RBR o
frequent JJ o
episodes NNS o
of IN o
apnea NN o
, , N
including VBG N
both DT N
mild JJ o
and CC o
severe JJ o
episodes NNS o
. . o

CONCLUSIONS NNP N
Although IN N
both DT N
transfusion NN i
programs NNS N
were VBD N
well RB N
tolerated VBN N
, , N
our PRP$ N
finding NN N
of IN N
more RBR N
frequent JJ N
major JJ o
adverse JJ o
neurologic NN o
events NNS o
in IN N
the DT N
restrictive JJ i
RBC-transfusion NNP i
group NN N
suggests VBZ N
that IN N
the DT N
practice NN N
of IN N
restrictive JJ i
transfusions NNS i
may MD N
be VB N
harmful JJ N
to TO N
preterm VB N
infants NNS N
. . N

-DOCSTART- -10703628- O O

Efficacy NN o
of IN N
a DT N
barrier NN i
cream NN i
and CC i
its PRP$ i
vehicle NN i
as IN N
protective JJ N
measures NNS N
against IN N
occupational JJ o
irritant JJ o
contact NN o
dermatitis NN o
. . o

The DT N
actual JJ N
advantage NN N
of IN N
barrier NN i
creams NNS i
over IN N
bland NN N
emollients NNS N
for IN N
skin NN N
protection NN N
is VBZ N
still RB N
hotly RB N
debated VBN N
. . N

In IN N
a DT N
randomized JJ N
, , N
double-blinded JJ N
study NN N
, , N
a DT N
newly-introduced JJ N
barrier NN i
cream NN i
and CC N
its PRP$ N
moisturizing NN i
vehicle NN i
were VBD N
compared VBN N
regarding VBG N
their PRP$ N
skin NN o
compatibility NN o
, , o
efficacy NN o
and CC o
resulting VBG o
acceptance NN o
. . o

Thus NNP N
, , N
2 CD p
panels NNS p
of IN p
25 CD p
hospital NN p
nurses NNS p
with IN p
mild JJ p
signs NNS p
of IN p
skin JJ p
irritation NN p
were VBD N
asked VBN N
to TO N
use VB N
1 CD N
of IN N
the DT N
test NN N
products NNS N
provided VBN N
( ( i
verum NN i
or CC i
vehicle NN i
) ) i
over IN i
a DT i
period NN i
of IN i
4 CD i
weeks NNS i
. . i

Effects NNS N
of IN N
both DT N
types NNS N
of IN N
preparations NNS N
were VBD N
studied VBN N
weekly JJ N
by IN N
clinical JJ N
examination NN N
and CC N
the DT N
instrumental JJ N
assessment NN N
of IN N
bioengineering VBG N
parameters NNS N
. . N

Results NNS N
showed VBD N
no DT N
significant JJ N
differences NNS N
between IN N
barrier NN i
cream NN i
and CC N
vehicle NN i
. . i

In IN N
both DT N
groups NNS N
, , N
clinical JJ o
skin NN o
status NN o
improved VBN N
and CC N
stratum JJ o
corneum NN o
hydration NN o
increased VBD N
significantly RB N
during IN N
the DT N
study NN N
period NN N
. . N

Both DT N
preparations NNS N
were VBD N
tolerated VBN o
and CC o
accepted VBN o
well RB o
, , N
thus RB N
showing VBG N
both DT N
skin JJ o
protection NN o
and CC o
skin NN o
care NN o
. . o

These DT N
results NNS N
contribute VBP N
to TO N
the DT N
debate NN N
as IN N
to TO N
whether IN N
a DT N
strict JJ N
distinction NN N
between IN N
skin NN N
care NN N
and CC N
skin NN N
protection NN N
products NNS N
is VBZ N
justified JJ N
. . N

The DT N
vehicle NN i
alone RB N
is VBZ N
capable JJ N
of IN N
positively RB N
influencing VBG N
skin NN N
status NN N
. . N

Emphasis NN N
must MD N
be VB N
laid VBN N
on IN N
regular JJ N
, , N
frequent JJ N
, , N
and CC N
correct JJ N
application NN N
of IN N
a DT N
product NN N
for IN N
it PRP N
to TO N
be VB N
effective JJ N
. . N

-DOCSTART- -21379582- O O

Delayed VBN p
perceptual JJ p
awareness NN p
in IN N
rapid JJ p
perceptual JJ p
decisions NNS p
. . p

The DT N
flourishing NN N
of IN N
studies NNS N
on IN N
the DT N
neural JJ N
correlates NNS N
of IN N
decision-making JJ N
calls NNS N
for IN N
an DT N
appraisal NN N
of IN N
the DT N
relation NN N
between IN N
perceptual JJ N
decisions NNS N
and CC N
conscious JJ N
perception NN N
. . N

By IN N
exploiting VBG N
the DT N
long JJ i
integration NN i
time NN i
of IN i
noisy JJ i
motion NN i
stimuli NN i
, , i
and CC i
by IN i
forcing VBG i
human JJ i
observers NNS i
to TO i
make VB i
difficult JJ i
speeded VBN i
decisions NNS i
-- : i
sometimes RB i
a DT i
blind JJ i
guess NN i
-- : i
about IN i
stimulus JJ i
direction NN i
, , N
we PRP N
traced VBD N
the DT N
temporal JJ N
buildup NN N
of IN N
motion NN N
discrimination NN N
capability NN N
and CC N
perceptual JJ N
awareness NN N
, , N
as IN N
assessed VBN N
trial NN N
by IN N
trial NN N
through IN N
direct JJ N
rating NN N
. . N

We PRP N
found VBD N
that IN N
both DT N
increased VBN N
gradually RB N
with IN N
motion NN o
coherence NN o
and CC o
viewing NN o
time NN o
, , N
but CC N
discrimination NN o
was VBD o
systematically RB o
leading JJ o
awareness NN o
, , o
reaching VBG o
a DT o
plateau NN o
much RB o
earlier RBR o
. . o

Sensitivity NNP o
and CC o
criterion NN o
changes NNS o
contributed VBD N
jointly RB N
to TO N
the DT N
slow JJ o
buildup NN o
of IN o
perceptual JJ o
awareness NN o
. . o

It PRP N
made VBD N
no DT o
difference NN o
whether IN N
motion NN o
discrimination NN o
was VBD N
accomplished VBN N
by IN N
saccades NNS o
or CC o
verbal JJ o
responses NNS o
. . o

These DT N
findings NNS N
suggest VBP N
that IN N
perceptual JJ o
awareness NN o
emerges VBZ o
on IN o
the DT o
top NN o
of IN o
a DT o
developing NN o
or CC o
even RB o
mature VBP o
perceptual JJ o
decision NN o
. . o

We PRP N
argue VBP N
that IN N
the DT N
middle JJ N
temporal JJ N
( ( N
MT NNP N
) ) N
cortical JJ N
region NN N
does VBZ N
not RB N
confer VB N
us PRP N
the DT N
full JJ o
phenomenic JJ o
depth NN o
of IN o
motion NN o
perception NN o
, , N
although IN N
it PRP N
may MD N
represent VB N
a DT N
precursor NN o
stage NN o
in IN o
building VBG o
our PRP$ o
subjective JJ o
sense NN o
of IN o
visual JJ o
motion NN o
. . o

-DOCSTART- -21887489- O O

The DT N
relationship NN N
between IN N
physical JJ N
activity NN N
level NN N
, , N
anxiety NN N
, , N
depression NN N
, , N
and CC N
functional JJ o
ability NN o
in IN N
children NNS p
and CC p
adolescents NNS p
with IN p
juvenile JJ p
idiopathic JJ p
arthritis NN p
. . p

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
assess VB N
the DT N
relationships NNS N
between IN N
physical JJ o
activity NN o
level NN o
and CC N
anxiety NN o
, , o
depression NN o
, , N
and CC N
functional JJ o
ability NN o
in IN N
children NNS p
and CC p
adolescents NNS p
with IN p
juvenile JJ p
idiopathic JJ p
arthritis NN p
( ( p
JIA NNP p
) ) p
. . p

Cross-sectional JJ i
study NN i
design NN N
including VBG N
patients NNS p
with IN p
JIA NNP p
aged VBD p
between IN p
8 CD p
and CC p
17 CD p
years NNS p
and CC p
healthy JJ p
controls NNS p
was VBD p
used VBN p
. . p

Sociodemographic NNP o
data NNS o
and CC o
clinical JJ o
features NNS o
were VBD N
assessed VBN N
. . N

Physical JJ o
activity NN o
level NN o
and CC o
energy NN o
expenditure NN o
were VBD N
assessed VBN N
with IN N
a DT N
1-day JJ i
activity NN i
diary NN i
. . i

Anxiety NN o
was VBD N
screened VBN N
by IN o
The DT o
Screen NNP o
for IN o
Child NNP o
Anxiety NNP o
Related NNP o
Emotional NNP o
Disorders NNP o
( ( o
SCARED NNP o
) ) o
questionnaire NN i
. . i

Depressive JJ o
symptoms NNS o
were VBD N
assessed VBN N
by IN N
the DT i
Children NNP i
's POS i
Depression NNP i
Inventory NNP i
( ( i
CDI NNP i
) ) i
. . i

Functional JJ N
ability NN N
was VBD N
assessed VBN N
with IN N
the DT i
Childhood NNP i
Health NNP i
Assessment NNP i
Questionnaire NNP i
( ( N
CHAQ NNP N
) ) N
. . N

Pain NN o
and CC o
overall JJ o
well-being NN o
were VBD N
measured VBN N
using VBG N
a DT N
visual JJ N
analog NN N
scale NN N
( ( N
VAS NNP N
) ) N
. . N

Fifty-two JJ p
patients NNS p
and CC p
48 CD p
controls NNS p
were VBD p
included VBN p
with IN p
a DT p
mean JJ p
age NN p
of IN p
12.13 CD p
? . p
2.92 CD p
and CC p
11.27 CD p
? . p
1.59 CD p
years NNS p
, , p
respectively RB p
. . o

The DT o
mean JJ o
disease NN o
duration NN o
was VBD o
64 CD p
months NNS p
. . p

The DT N
JIA NNP N
group NN N
had VBD N
significantly RB N
less JJR o
time NN o
in IN o
physical JJ o
activity NN o
( ( o
p JJ o
= NNP N
0.000 CD N
) ) N
, , N
decrease NN o
in IN o
energy NN o
expenditure NN o
( ( o
p JJ o
= NNP o
0.04 CD N
) ) N
, , N
and CC N
higher JJR o
CHAQ NNP o
scores NNS o
( ( o
p VB N
= RB N
0.000 CD N
) ) N
compared VBN N
with IN N
the DT N
control NN N
group NN N
. . N

In IN N
the DT N
JIA NNP N
group NN N
, , N
significant JJ N
relationships NNS N
were VBD N
found VBN N
between IN o
the DT o
number NN o
of IN o
active JJ o
joint NN o
and CC o
disease NN o
duration NN o
( ( o
r JJ o
= NN N
0.44 CD N
, , N
p NN N
= NNP N
0.000 CD N
) ) N
and CC N
VAS NNP o
pain NN o
( ( o
r NN o
= VBZ N
0.30 CD N
, , N
p NN N
= NNP N
0.02 CD N
) ) N
, , N
between IN N
SCARED NNP N
and CC N
CDI NNP N
( ( N
r VB N
= RB N
0.54 CD N
, , N
p NN N
= NNP N
0.000 CD N
) ) N
. . N

Significant JJ N
relationships NNS N
were VBD N
found VBN o
between IN o
VAS NNP o
overall JJ o
well-being NN o
and CC o
CDI NNP o
( ( o
r VB o
= RB N
0.29 CD N
, , N
p NN N
= NNP N
0.03 CD N
) ) N
, , N
CHAQ NNP o
( ( o
r VB o
= RB N
0.37 CD N
, , N
p NN N
= NNP N
0.000 CD N
) ) N
, , N
and CC o
VAS NNP o
pain NN o
( ( N
r NN N
= VBZ N
0.41 CD N
, , N
p NN N
= NNP N
0.000 CD N
) ) N
. . N

Correlation NN N
between IN o
CHAQ NNP o
and CC o
CDI NNP o
( ( N
r VB N
= RB N
0.34 CD N
, , N
p NN N
= NNP N
0.01 CD N
) ) N
was VBD N
significant JJ N
. . N

The DT N
result NN N
of IN N
our PRP$ N
study NN N
suggested VBD N
that IN o
only JJ o
depression NN o
was VBD o
related VBN o
to TO o
anxiety NN o
, , o
functional JJ o
ability NN o
, , o
and CC o
well-being NN o
in IN p
children NNS p
and CC p
adolescents NNS p
with IN p
JIA NNP p
. . N

-DOCSTART- -24195864- O O

Iron NNP i
supplementation NN i
improves VBZ N
energetic JJ N
efficiency NN N
in IN N
iron-depleted JJ p
female NN p
rowers NNS p
. . p

PURPOSE NNP N
Studies NNPS N
in IN N
both DT N
animals NNS N
and CC N
humans NNS N
show VBP N
a DT N
relationship NN N
between IN N
iron NN N
depletion NN N
without IN N
anemia NN N
( ( N
IDNA NNP N
) ) N
and CC N
physical JJ N
performance NN N
. . N

Compared VBN N
with IN N
their PRP$ N
sedentary JJ N
counterparts NNS N
, , N
female JJ p
endurance NN p
athletes NNS p
are VBP N
at IN N
greater JJR N
risk NN N
of IN N
IDNA NNP N
, , N
and CC N
consequences NNS N
relevant VBP N
to TO N
endurance VB N
athletes NNS N
include VBP N
reduced JJ N
work NN N
capacity NN N
and CC N
energetic JJ N
efficiency NN N
( ( N
EF NNP N
) ) N
. . N

We PRP N
conducted VBD N
a DT N
randomized JJ N
placebo-controlled JJ i
trial NN N
to TO N
investigate VB N
the DT N
effects NNS N
of IN N
iron NN i
( ( i
Fe NNP i
) ) i
supplementation NN i
on IN N
Fe NNP N
status NN N
and CC N
performance NN N
in IN N
nonanemic JJ p
female NN p
rowers NNS p
during IN p
training NN p
. . p

METHODS NNP N
At IN N
the DT N
beginning NN N
of IN N
a DT N
training NN N
season NN N
, , N
40 CD p
rowers NNS p
were VBD N
randomized VBN N
to TO N
receive VB N
either RB N
100 CD i
mg?d NNS i
FeSO4 NNP i
( ( N
n JJ N
= NNP N
21 CD N
) ) N
or CC i
placebo NN i
( ( N
n JJ N
= NNP N
19 CD N
) ) N
using VBG N
a DT N
double-blind JJ N
design NN N
. . N

Thirty-one NN N
( ( N
n JJ N
= VBZ N
15 CD i
Fe NNP i
, , i
16 CD i
placebo NN i
) ) i
completed VBD N
the DT N
6-wk JJ N
trial NN N
. . N

Fe NNP o
status NN o
( ( o
hemoglobin UH o
, , o
serum JJ o
ferritin NN o
, , o
soluble JJ o
transferrin NN o
receptor NN o
) ) o
, , o
body NN o
composition NN o
, , o
and CC o
laboratory NN o
tests NNS o
of IN o
physical JJ o
performance NN o
( ( o
4-km JJ o
time NN o
trial NN o
, , o
V?O2peak NNP o
, , o
energetic JJ o
EF NNP o
, , o
and CC o
blood NN o
lactate NN o
) ) o
were VBD o
assessed VBN N
at IN N
baseline NN N
and CC N
after IN N
training VBG N
. . N

RESULTS JJ N
Rowers NNPS N
in IN N
both DT N
groups NNS N
increased VBD N
their PRP$ o
fat-free JJ o
mass NN o
( ( o
P NNP N
< NNP N
0.001 CD N
) ) N
and CC o
V?O2peak NNP o
( ( o
P NNP o
< NNP N
0.001 CD N
) ) N
after IN N
training VBG N
. . N

Multiple JJ N
regression NN N
analyses NNS N
revealed VBD N
improvements NNS N
in IN N
Fe NNP o
stores NNS o
( ( o
serum NN o
ferritin NN o
) ) o
in IN o
the DT N
Fe NNP N
treatment NN N
group NN N
after IN N
controlling VBG N
for IN N
baseline NN N
Fe NNP N
stores NNS N
( ( N
P NNP N
= NNP N
0.07 CD N
) ) N
. . N

Rowers NNPS N
in IN N
the DT N
Fe NNP N
group NN N
had VBD N
slower JJR N
lactate JJ N
response NN N
during IN N
the DT N
first JJ N
half NN N
of IN N
the DT N
time NN N
trial NN N
and CC N
after IN N
5 CD N
min NN N
of IN N
recovery NN N
( ( N
P NNP N
= NNP N
0.05 CD N
) ) N
and CC N
showed VBD N
greater JJR N
improvements NNS N
in IN N
energy NN o
expenditure NN o
( ( o
P NNP o
= VBZ N
0.01 CD N
for IN N
group-by JJ N
time NN N
) ) N
and CC N
energetic JJ o
EF NNP o
compared VBN N
with IN N
placebo NN N
( ( N
P NNP N
= VBZ N
0.03 CD N
for IN N
group-by JJ N
time NN N
) ) N
. . N

CONCLUSIONS NNP p
Female NNP p
rowers NNS p
with IN p
depleted JJ p
Fe NNP p
stores NNS N
who WP N
consumed VBD N
supplemental JJ N
Fe NNP N
during IN N
training VBG N
improved VBN N
their PRP$ o
Fe NNP o
status NN o
and CC o
energetic JJ o
EF NNP o
during IN N
endurance NN N
exercise NN N
. . N

These DT N
results NNS N
are VBP N
important JJ N
for IN N
endurance NN p
athletes NNS p
whose WP$ p
dietary JJ N
patterns NNS N
and CC N
physical JJ N
training NN N
increase VB N
their PRP$ N
risk NN N
of IN N
IDNA NNP o
and CC o
suggest VBP N
that IN N
Fe NNP N
supplementation NN N
may MD N
maximize VB N
the DT N
benefits NNS N
of IN N
endurance NN N
training NN N
. . N

-DOCSTART- -19606510- O O

Seven-star NNP i
needle JJ i
stimulation NN i
improves VBZ N
language NN o
and CC o
social JJ o
interaction NN o
of IN N
children NNS p
with IN p
autistic JJ p
spectrum NN p
disorders NNS p
. . p

This DT N
is VBZ N
a DT N
randomized JJ N
controlled VBN N
trial NN N
that WDT N
aimed VBD N
to TO N
evaluate VB N
the DT N
effect NN N
of IN N
the DT N
Seven-star NNP i
Needle NNP i
Stimulation NNP i
treatment NN N
on IN N
children NNS p
with IN p
Autistic NNP p
Spectrum NNP p
Disorders NNP p
( ( p
ASD NNP p
) ) p
. . p

Thirty-two JJ p
children NNS p
with IN p
ASD NNP p
were VBD N
assigned VBN N
randomly RB N
into IN N
the DT N
treatment NN N
and CC N
control NN N
groups NNS N
. . N

Children NNP N
in IN N
the DT N
treatment NN p
group NN p
underwent VBD N
30 CD N
sessions NNS N
of IN N
stimulation NN N
over IN N
6 CD N
weeks NNS N
, , N
while IN N
children NNS N
in IN N
the DT N
control NN p
group NN p
were VBD N
on IN N
a DT N
waiting VBG N
list NN N
and CC N
did VBD N
not RB N
receive VB N
treatment NN N
during IN N
this DT N
period NN N
of IN N
time NN N
. . N

Intervention NNP N
consisted VBD N
of IN N
a DT N
treatment NN N
regime NN N
comprising NN N
of IN N
30 CD i
sessions NNS i
of IN i
Seven-star NNP i
Needle NNP i
Stimulation NNP i
, , N
delivered VBD N
over IN N
6 CD N
weeks NNS N
. . N

Each DT N
session NN N
lasted VBD N
5 CD N
to TO N
10 CD N
min NN N
, , N
children NNS N
in IN N
the DT N
treatment NN N
group NN N
were VBD N
stimulated VBN N
at IN N
the DT N
front NN N
and CC N
back RB N
sides NNS N
of IN N
their PRP$ N
body NN N
and CC N
the DT N
head NN N
by IN N
using VBG N
Seven-star JJ i
Needles NNP i
. . i

The DT N
change NN N
in IN N
the DT N
children NNS o
's POS o
behavior NN o
was VBD N
evaluated VBN N
using VBG N
parents NNS N
' POS N
report NN N
and CC N
neurophysiological JJ N
changes NNS N
were VBD N
measured VBN N
by IN N
quantitative JJ N
EEG NNP N
( ( N
qEEG NN N
) ) N
. . N

Results CC N
showed VBD N
that IN N
the DT N
treatment NN N
group NN N
demonstrated VBD N
significant JJ N
improvement NN N
in IN N
language NN o
and CC o
social JJ o
interaction NN o
, , N
but CC N
not RB N
in IN N
stereotyped JJ o
behavior NN o
or CC o
motor NN o
function NN o
, , N
compared VBN N
to TO N
the DT N
control NN N
group NN N
. . N

qEEG JJ o
spectral JJ o
amplitudes NNS o
in IN N
the DT N
treatment NN N
, , N
but CC N
not RB N
in IN N
the DT N
control NN N
group NN N
, , N
were VBD N
also RB N
reduced VBN N
significantly RB N
. . N

The DT N
results NNS N
suggested VBD N
that IN N
Seven-star NNP i
Needle NNP i
Stimulation NNP i
might MD N
be VB N
an DT N
effective JJ N
intervention NN N
to TO N
improve VB N
language NN o
and CC o
social JJ o
functioning NN o
of IN N
children NNS p
with IN p
ASD NNP p
. . p

-DOCSTART- -10225743- O O

Blood NNP o
purification NN o
for IN N
critical JJ N
care NN N
medicine NN N
: : N
endotoxin NN N
adsorption NN N
. . N

Many JJ N
kinds NNS N
of IN N
blood NN i
purifying VBG i
technologies NNS i
have VBP N
been VBN N
applied VBN N
to TO N
the DT N
treatment NN N
of IN N
critically RB p
ill JJ p
patients NNS p
since IN N
1979 CD N
when WRB N
plasma JJ N
exchange NN N
with IN N
hollow-fiber JJ N
membranes NNS N
was VBD N
developed VBN N
. . N

These DT N
technologies NNS N
have VBP N
been VBN N
applied VBN N
not RB N
only RB N
to TO N
the DT N
removal NN N
of IN N
toxic JJ N
substances NNS N
, , N
but CC N
also RB N
to TO N
the DT N
treatment NN N
of IN N
objective JJ N
diseases NNS N
and CC N
the DT N
removal NN N
of IN N
the DT N
factors NNS N
relating VBG N
to TO N
the DT N
associated VBN N
inflammation NN N
. . N

This DT N
article NN N
summarizes VBZ N
these DT N
methods NNS N
and CC N
their PRP$ N
efficacies NNS N
for IN N
critically RB p
ill JJ p
patients NNS p
, , p
especially RB p
those DT p
with IN p
severe JJ p
sepsis NN p
. . p

Attempts NNS N
have VBP N
been VBN N
made VBN N
to TO N
remove VB N
endotoxin NN N
, , N
the DT N
main JJ N
cause NN N
of IN N
sepsis NN N
, , N
from IN N
the DT N
circulation NN N
using VBG N
polymyxin NN i
B NNP i
immobilized VBD i
fiber NN i
, , i
charcoal NN i
hemoperfusion NN i
, , N
and CC N
plasma NN i
or CC i
whole JJ i
blood NN i
exchange NN i
. . i

Attempts NNS N
have VBP N
also RB N
been VBN N
made VBN N
to TO N
remove VB N
proinflammatory NN N
cytokines NNS N
, , N
eicosanoides NNS N
, , N
and CC N
coagulative JJ N
factors NNS N
from IN N
the DT N
circulation NN N
in IN N
the DT N
human JJ N
body NN N
. . N

Continuous JJ N
hemofiltration NN N
or CC N
hemodiafiltration NN N
is VBZ N
the DT N
representative JJ N
technology NN N
. . N

The DT N
efficacy NN o
of IN N
these DT N
methods NNS N
has VBZ N
been VBN N
established VBN N
, , N
but CC N
several JJ N
issues NNS N
remain VBP N
unresolved JJ N
. . N

All DT N
methods NNS N
of IN N
the DT N
treatment NN N
of IN N
severe JJ N
sepsis NN N
are VBP N
discussed VBN N
with IN N
reference NN N
to TO N
treatment NN N
indications NNS o
, , o
efficacy NN o
, , N
and CC N
outcome JJ o
parameters NNS o
. . o

In IN N
particular JJ N
, , N
the DT N
clinical JJ N
results NNS N
of IN N
endotoxin JJ N
removal NN N
with IN N
polymyxin NN i
B NNP i
immobilized JJ i
fiber NN i
are VBP N
summarized VBN N
in IN N
this DT N
article NN N
. . N

-DOCSTART- -18330493- O O

Allopurinol NNP i
improves VBZ N
endothelial JJ N
function NN N
and CC N
reduces VBZ N
oxidant-inflammatory JJ N
enzyme NN N
of IN N
myeloperoxidase NN N
in IN N
metabolic JJ p
syndrome NN p
. . p

OBJECTIVE NN N
In IN N
this DT N
study NN N
, , N
we PRP N
tested VBD N
in IN N
patients NNS p
with IN p
metabolic JJ p
syndrome VBP p
whether IN N
allopurinol NNS N
through IN N
decreasing VBG N
oxidative JJ N
stress NN N
improves VBZ N
endothelial JJ N
function NN N
, , N
and CC N
ameliorates VBZ N
inflammatory JJ N
state NN N
represented VBN N
by IN N
markers NNS N
of IN N
myeloperoxidase NN N
, , N
C-reactive JJ N
protein NN N
( ( N
CRP NNP N
) ) N
and CC N
fibrinogen NN N
. . N

METHODS NNP N
In IN N
a DT N
randomized JJ N
, , N
double-blind JJ N
fashion NN N
; : N
subjects NNS p
with IN p
metabolic JJ p
syndrome NN p
were VBD p
treated VBN p
with IN p
allopurinol NN i
( ( p
n JJ p
= NNP p
28 CD p
) ) p
or CC p
placebo NN i
( ( p
n JJ p
= NNP p
22 CD p
) ) p
for IN p
one CD p
month NN p
. . p

Before IN N
and CC N
after IN N
treatment NN N
, , N
blood NN i
samples NNS i
were VBD N
collected VBN N
and CC N
the DT N
flow-mediated JJ o
dilation NN o
( ( o
FMD NNP o
) ) o
and CC N
isosorbide JJ o
dinitrate NN o
( ( o
ISDN NNP o
) ) o
-mediated VBD o
dilation NN o
of IN N
the DT N
brachial JJ N
artery NN N
were VBD N
performed VBN N
. . N

RESULTS NNP N
Baseline NNP N
clinical JJ N
characteristics NNS N
of IN N
the DT N
allopurinol NN i
and CC N
placebo NN i
groups NNS N
demonstrated VBD N
no DT N
differences NNS N
in IN N
terms NNS N
of IN N
clinical JJ o
characteristics NNS o
, , o
endothelial JJ o
function NN o
and CC N
inflammatory JJ o
markers NNS o
. . o

After IN N
the DT N
treatment NN N
with IN N
allopurinol NN N
, , N
FMD NNP o
was VBD N
increased VBN N
from IN N
8.0 CD N
+/- JJ N
0.5 CD N
% NN N
to TO N
11.8 CD N
+/- JJ N
0.6 CD N
% NN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
, , N
but CC N
there EX N
were VBD N
no DT N
change NN N
in IN N
the DT N
placebo NN N
group NN N
. . N

In IN N
both DT N
groups NNS N
, , N
ISDN-mediated JJ o
dilation NN o
is VBZ N
unaffected VBN N
by IN N
the DT N
treatment NN N
. . N

As IN N
a DT N
marker NN N
of IN N
oxidative JJ N
stress NN N
, , N
allopurinol VBP N
significantly RB N
reduced VBN o
malondialdehyde NN o
. . o

Moreover RB N
, , N
myeloperoxidase NN o
levels NNS o
were VBD N
reduced VBN N
by IN N
the DT N
treatment NN N
with IN N
allopurinol NN N
( ( N
56.1 CD N
+/- JJ N
3.4 CD N
ng/ml JJ N
vs. FW N
44.4 CD N
+/- JJ N
2.4 CD N
ng/ml NN N
, , N
P NNP N
< NNP N
0.05 CD N
) ) N
but CC N
there EX N
were VBD N
no DT N
change NN N
in IN N
the DT N
placebo NN N
group NN N
. . N

Surprisingly RB N
, , N
neither DT N
CRP NNP o
nor CC o
fibrinogen NN o
levels NNS o
were VBD N
affected VBN N
by IN N
the DT N
treatment NN N
in IN N
both DT N
groups NNS N
. . N

CONCLUSION NNP N
Xanthine NNP N
oxidoreductase NN N
inhibition NN N
by IN N
allopurinol NN N
in IN N
patients NNS p
with IN p
metabolic JJ p
syndrome NN p
reduces NNS N
oxidative JJ o
stress NN o
, , o
improves VBZ o
endothelial JJ o
function NN o
, , o
ameliorates VBZ o
myeloperoxidase NN o
levels NNS o
and CC N
does VBZ N
not RB N
have VB N
any DT N
effect NN N
on IN N
CRP NNP N
and CC N
fibrinogen NN N
levels NNS N
. . N

-DOCSTART- -21798536- O O

Low-dose JJ i
magnesium NN i
sulfate NN i
versus NN i
Pritchard NNP i
regimen NN i
for IN N
the DT N
treatment NN N
of IN N
eclampsia JJ o
imminent JJ o
eclampsia NN o
. . o

-DOCSTART- -2688237- O O

[ NN i
EMLA NNP i
cream NN i
( ( i
lidocaine/prilocaine NN i
) ) i
versus NN i
infiltration NN i
analgesia NN i
with IN i
carbocaine NN i
( ( i
mepivacaine NN i
) ) i
in IN p
vasectomy NN p
] NN p
. . N

The DT N
analgesic JJ o
efficacy NN o
of IN N
EMLA NNP i
cream NN i
was VBD N
compared VBN N
with IN N
infiltration NN i
with IN i
1 CD i
% NN i
carbocaine NN i
in IN N
13 CD p
bilateral JJ p
vasectomies NNS p
. . p

Twelve CD N
patients NNS N
preferred JJ N
infiltration NN N
analgesia NN N
. . N

EMLA NNP i
analgesia NN i
was VBD N
only RB o
effective JJ o
in IN o
the DT o
skin NN o
, , N
and CC N
had VBD o
to TO o
be VB o
supplemented VBN o
as IN N
the DT N
incision NN N
reached VBD N
subcutaneous JJ N
tissue NN N
. . N

-DOCSTART- -20017819- O O

Clinical JJ o
pharmacology NN o
of IN N
methadone NN i
in IN N
dogs NNS p
. . p

OBJECTIVE NNP N
To TO N
investigate VB N
the DT N
pharmacokinetics NNS o
and CC o
effects NNS o
of IN N
methadone NN i
on IN N
behaviour NN o
and CC N
plasma JJ o
concentrations NNS o
of IN o
cortisol NN o
and CC o
vasopressin NN o
in IN N
healthy JJ p
dogs NNS p
. . p

STUDY NNP N
DESIGN NNP N
Randomized NNP N
, , N
cross-over NN N
, , N
experimental JJ N
trial NN N
. . N

ANIMALS NNP N
Nine NNP p
adult NN p
dogs NNS p
( ( p
beagle NN p
and CC p
beagle NN p
cross NN p
breeds NNS p
) ) p
, , p
four CD p
males NNS p
and CC p
five CD p
females NNS p
. . p

METHODS NNP N
Methadone NNP i
hydrochloride NN i
, , N
0.4 CD N
mg NN N
kg NN N
( ( N
-1 NNP N
) ) N
, , N
was VBD N
administered VBN N
intravenously RB N
( ( N
IV NNP N
) ) N
and CC N
subcutaneously RB N
( ( N
SC NNP N
) ) N
with IN N
a DT N
crossover NN N
design NN N
. . N

Drug NNP o
and CC o
hormone NN o
analyses NNS o
in IN o
plasma NN o
were VBD N
performed VBN N
using VBG N
Liquid NNP i
Chromatography-Electrospray NNP i
Ionization-Tandem NNP i
Mass NNP i
Spectrometry NNP i
and CC i
radioimmunoassay VB i
respectively RB N
. . N

Behavioural NNP o
data NNS o
were VBD N
collected VBN N
using VBG N
a DT N
standardized JJ N
protocol NN N
. . N

RESULTS NNP N
After IN N
IV NNP N
administration NN N
, , N
the DT N
plasma JJ o
concentration NN o
of IN o
methadone NN o
at IN N
10 CD N
minutes NNS N
was VBD N
82.1 CD N
+/- JJ N
9.2 CD N
ng JJ N
mL NN N
( ( N
-1 NN N
) ) N
( ( N
mean JJ N
+/- NNP N
SD NNP N
) ) N
, , N
the DT N
terminal JJ o
half-life NN o
was VBD N
3.9 CD N
+/- JJ N
1.0 CD N
hours NNS N
, , N
the DT N
volume NN o
of IN o
distribution NN o
9.2 CD N
+/- JJ N
3.3 CD N
L NNP N
kg NN N
( ( N
-1 NNP N
) ) N
and CC N
plasma JJ o
clearance NN o
27.9 CD N
+/- JJ N
7.6 CD N
mL NNS N
minute NN N
( ( N
-1 NNP N
) ) N
kg NN N
( ( N
-1 NNP N
) ) N
. . N

After IN N
SC NNP N
administration NN N
, , N
time NN o
to TO o
maximal VB o
plasma JJ o
concentration NN o
was VBD N
1.26 CD N
+/- JJ N
1.04 CD N
hours NNS N
and CC N
maximal JJ o
plasma NN o
concentration NN o
of IN o
methadone NN o
was VBD N
23.9 CD N
+/- JJ N
14.4 CD N
ng JJ N
mL NN N
( ( N
-1 NNP N
) ) N
, , N
the DT N
terminal JJ o
half-life NN o
was VBD N
10.7 CD N
+/- JJ N
4.3 CD N
hours NNS N
and CC N
bioavailability NN o
was VBD N
79 CD N
+/- JJ N
22 CD N
% NN N
. . N

Concentrations NNS o
of IN o
both DT o
cortisol NNS o
and CC o
vasopressin NN o
were VBD N
increased VBN N
for IN N
an DT N
hour NN N
following VBG N
IV NNP N
methadone NN i
. . i

The DT N
observed JJ o
behavioural JJ o
effects NNS o
of IN N
methadone NN N
were VBD N
decreased VBN N
licking NN o
and CC o
swallowing NN o
and CC N
an DT N
increase NN N
in IN N
whining VBG o
after IN N
SC NNP N
administration NN N
. . N

The DT N
latter JJ N
finding NN N
is VBZ N
notable JJ N
as IN N
it PRP N
can MD N
be VB N
misinterpreted VBN N
as IN N
pain NN o
when WRB N
methadone NN i
is VBZ N
used VBN N
as IN N
an DT N
analgesic JJ N
. . N

CONCLUSION NNP N
AND NNP N
CLINICAL NNP N
RELEVANCE NNP N
When WRB N
methadone NN i
was VBD N
administered VBN N
by IN N
the DT N
SC NNP N
route NN N
, , N
the DT N
half-life NN o
was VBD N
longer RBR N
, , N
but CC N
the DT N
individual JJ N
variation NN o
in IN o
plasma JJ o
concentrations NNS o
was VBD N
greater JJR N
compared VBN N
with IN N
IV NNP N
administration NN N
. . N

Increased VBD N
frequency NN o
of IN o
whining VBG o
occurred VBN N
after IN N
administration NN N
of IN N
methadone NN i
and CC N
may MD N
be VB N
a DT N
drug NN N
effect NN N
and CC N
not RB N
a DT N
sign NN N
of IN N
pain NN N
. . N

Cortisol NNP o
and CC o
vasopressin JJ o
concentrations NNS o
in IN o
plasma NN o
may MD N
not RB N
be VB N
suitable JJ N
for IN N
evaluating VBG N
analgesia NN o
after IN N
methadone NN i
treatment NN N
. . N

-DOCSTART- -8214547- O O

Analgesia NN o
after IN p
caesarean JJ p
section NN p
with IN N
intramuscular JJ N
ketorolac NN i
or CC N
pethidine NN i
. . i

We PRP N
compared VBN N
, , N
in IN N
a DT N
double-blind NN N
randomised VBN N
study NN N
, , N
intramuscular JJ i
ketorolac NN i
30 CD p
mg NN p
( ( p
n JJ p
= NNP p
49 CD p
) ) p
and CC p
intramuscular JJ i
pethidine NN i
75 CD p
mg NN p
( ( p
n JJ p
= NNP p
51 CD p
) ) p
for IN N
analgesia NN o
after IN p
elective JJ p
caesarean JJ p
section NN p
under IN p
general JJ p
anaesthesia NN p
. . p

Anaesthesia NNP N
was VBD N
induced VBN N
with IN N
thiopentone NN i
and CC i
suxamethonium NN i
and CC i
maintained VBD i
with IN i
atracurium NN i
, , i
nitrous JJ i
oxide NN i
and CC i
isoflurane NN i
. . i

Intravenous JJ i
fentanyl JJ i
100 CD i
micrograms NN i
was VBD i
given VBN i
after IN i
delivery NN i
of IN i
the DT i
neonate NN i
. . i

In IN p
the DT p
recovery NN p
ward NN p
, , p
patients NNS p
who WP p
requested VBD p
analgesia NN p
were VBD p
allocated VBN p
randomly RB p
to TO p
receive VB p
ketorolac NN i
30 CD p
mg NN p
or CC p
pethidine VB p
75 CD p
mg NNS p
intramuscularly RB p
. . p

Analgesia NNP o
was VBD N
assessed VBN N
at IN N
intervals NNS N
up RB N
to TO N
six CD N
hours NNS N
, , N
using VBG N
a DT N
visual JJ N
analogue NN N
scale NN N
and CC N
a DT N
four-point JJ N
verbal JJ N
scale NN N
, , N
while IN N
duration NN N
of IN N
analgesia NN N
was VBD N
taken VBN N
as IN N
the DT N
time NN N
until IN N
the DT N
patient NN N
requested VBD N
additional JJ N
analgesia NN N
. . N

There EX N
was VBD N
no DT N
difference NN N
in IN N
the DT N
duration NN N
of IN N
analgesia NN N
between IN N
groups NNS N
( ( o
Mann-Whitney NNP o
test NN o
P NNP N
= NNP N
0.27 CD N
, , N
Mantel-Haentszel NNP o
test NN N
P NNP N
= NNP N
0.17 CD N
) ) N
. . N

Twenty-six JJ p
patients NNS p
in IN p
the DT p
ketorolac NN p
group NN p
and CC p
17 CD p
patients NNS p
in IN p
the DT p
pethidine NN p
group NN p
requested VBD N
further RBR o
analgesia NN o
by IN N
90 CD N
minutes NNS N
. . N

However RB N
, , N
four CD N
patients NNS N
in IN N
the DT N
ketorolac NN N
group NN N
and CC N
six CD N
patients NNS N
in IN N
the DT N
pethidine NN N
group NN N
requested VBD N
no DT o
further JJ o
analgesia NN o
within IN N
24 CD N
hours NNS N
. . N

Pain NNP o
VAS NNP o
and CC o
overall JJ o
assessment NN o
of IN o
analgesia NN o
was VBD N
similar JJ N
between IN N
groups NNS N
, , N
although IN N
more JJR N
side-effects NNS N
( ( o
nausea NN o
, , o
dizziness NN o
) ) o
were VBD N
noted VBN N
in IN N
the DT N
pethidine NN N
group NN N
. . N

Ketorolac NNP N
30 CD N
mg NN N
and CC N
pethidine NN N
75 CD N
mg NN N
provided VBD N
similar JJ N
but CC N
variable JJ N
quality NN N
of IN N
analgesia NN N
after IN N
caesarean JJ N
section NN N
. . N

-DOCSTART- -11214014- O O

Effect NN N
of IN N
allopurinol NN i
on IN N
myocardial JJ N
oxygen NN o
free JJ o
radical JJ o
production NN o
in IN N
coronary JJ N
bypass NN N
surgery NN N
. . N

OBJECTIVES NNP N
Allopurinol NNP i
protects VBZ N
the DT N
heart NN N
from IN N
reperfusion NN N
injury NN N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
investigate VB N
myocardial JJ o
free JJ o
radical JJ o
production NN o
during IN N
reperfusion NN N
with IN N
and CC N
without IN N
allopurinol JJ N
treatment NN N
in IN N
coronary JJ p
artery NN p
bypass NN p
grafting VBG p
patients NNS p
randomized VBN p
into IN p
allopurinol NN i
( ( p
n JJ p
= NNP p
14 CD p
) ) p
or CC p
placebo NN i
( ( p
n JJ p
= NNP p
13 CD p
) ) p
groups NNS p
. . p

DESIGN NNP N
Allopurinol NNP i
( ( i
1 CD i
g NN i
) ) i
was VBD N
given VBN N
blind RB N
prior JJ N
to TO N
cardiopulmonary JJ N
bypass NN N
and CC N
prior JJ N
to TO N
opening VBG N
the DT N
aorta NN N
. . N

Oxygen NNP o
free JJ o
radicals NNS o
were VBD i
measured VBN i
before IN i
anesthesia NN i
in IN i
arterial JJ i
blood NN i
, , i
before IN i
cross-clamping JJ i
and CC i
1 CD i
and CC i
10 CD i
min NN i
after IN i
reperfusion NN i
in IN i
arterial JJ i
and CC i
coronary JJ i
sinus NN i
blood NN i
. . i

Levels NNS i
were VBD i
measured VBN i
as IN i
relative JJ i
concentrations NNS i
by IN i
the DT i
electron NN i
spin NN i
resonance NN i
method NN i
. . i

RESULTS NNP N
One CD N
minute NN N
after IN N
reperfusion NN N
the DT N
level NN N
of IN N
spin-trapped JJ o
radicals NNS o
in IN o
arterial JJ o
blood NN o
was VBD N
elevated VBN N
significantly RB N
( ( N
p JJ N
= NNP N
0.016 CD N
) ) N
in IN N
the DT N
allopurinol NN N
group NN N
, , N
from IN N
7.7 CD N
( ( N
SE NNP N
: : N
0.8 CD N
) ) N
to TO N
8.6 CD N
( ( N
1.4 CD N
) ) N
and CC N
non-significantly RB N
( ( N
p JJ N
= NNP N
0.074 CD N
) ) N
in IN N
the DT N
placebo NN N
group NN N
, , N
from IN N
7.3 CD N
( ( N
0.7 CD N
) ) N
to TO N
8.3 CD N
( ( N
0.8 CD N
) ) N
. . N

Ten CD N
minutes NNS N
after IN N
reperfusion NN N
the DT N
arterial JJ o
values NNS o
were VBD o
8.6 CD N
( ( N
1.5 CD N
) ) N
in IN N
the DT N
allopurinol NN N
and CC N
7.6 CD N
( ( N
0.7 CD N
) ) N
in IN N
the DT N
placebo NN N
group NN N
, , N
the DT o
sinus NN o
values NNS o
being VBG N
7.6 CD N
( ( N
1.3 CD N
) ) N
and CC N
8.3 CD N
( ( N
0.8 CD N
) ) N
, , N
respectively RB N
. . N

Myocardial NNP o
free JJ o
radical JJ o
production NN o
was VBD N
-0.94 NNP N
( ( N
1.21 CD N
) ) N
in IN N
the DT N
allopurinol NN N
and CC N
+0.79 NNP N
( ( N
0.96 CD N
) ) N
in IN N
the DT N
placebo NN N
group NN N
after IN N
10 CD N
min JJ N
reperfusion NN N
, , N
the DT N
difference NN N
being VBG N
significant JJ N
( ( N
p JJ N
= NNP N
0.043 CD N
) ) N
. . N

CONCLUSIONS NNP N
All DT p
patients NNS p
in IN p
both DT p
groups NNS p
had VBD N
an DT N
increasing VBG N
tendency NN N
to TO N
free JJ N
radical JJ N
production NN N
during IN N
early JJ N
reperfusion NN N
. . N

Patients NNS N
treated VBD N
with IN N
allopurinol NN N
showed VBD N
less RBR N
myocardial JJ o
production NN o
of IN o
free JJ o
radicals NNS o
, , N
indicating VBG N
that IN N
its PRP$ N
protective JJ N
effect NN N
may MD N
be VB N
due JJ N
to TO N
its PRP$ N
antioxidative JJ N
properties NNS N
. . N

-DOCSTART- -19998583- O O

Bioequivalence NNP N
evaluation NN N
of IN N
a DT N
fixed VBN i
dose JJ i
combination NN i
lamivudine NN i
+ NNP i
stavudine NN i
tablet NN N
with IN N
concurrent JJ N
administration NN N
of IN N
lamivudine JJ i
tablet NN N
and CC N
stavudine NN i
capsule NN N
in IN N
healthy JJ p
volunteers NNS p
. . p

The DT N
study NN N
was VBD N
designed VBN N
to TO N
compare VB N
the DT N
rate NN o
and CC o
extent NN o
of IN o
absorption NN o
of IN N
a DT N
fixed VBN N
dose JJ N
combination NN N
tablet NN N
of IN N
lamivudine NN i
( ( i
CAS NNP i
134678-17-4 CD i
) ) i
and CC i
stavudine NN i
( ( i
CAS NNP i
3056-17-5 CD i
) ) i
with IN N
the DT N
concurrent JJ N
administration NN N
of IN N
lamivudine JJ i
tablet NN i
and CC i
stavudine NN i
capsule NN i
in IN N
24 CD p
healthy JJ p
volunteers NNS p
under IN p
fasting VBG p
conditions NNS p
. . p

The DT N
volunteers NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
the DT N
test NN N
or CC N
reference NN N
treatment NN N
, , N
with IN N
the DT N
two CD N
treatment NN N
periods NNS N
separated VBN N
by IN N
a DT N
washout JJ N
period NN N
of IN N
at IN N
least JJS N
7 CD N
days NNS N
. . N

Plasma NNP o
samples NNS o
were VBD N
analyzed VBN N
for IN N
both DT N
analytes NNS N
lamivudine VBP i
and CC N
stavudine VBP i
by IN N
a DT N
validated JJ N
analytical JJ N
method NN N
. . N

Since IN N
the DT N
90 CD N
% NN N
confidence NN N
intervals NNS N
for IN N
the DT N
test/reference NN o
mean JJ N
ratio NN N
of IN N
the DT N
In-transformed NNP N
pharmacokinetic JJ N
variables NNS N
C NNP o
( ( o
max NN o
) ) o
AUC NNP o
( ( o
0-t JJ o
) ) o
and CC o
AUC NNP o
( ( o
0-infinity NN o
) ) o
were VBD N
clearly RB N
within IN N
the DT N
conventional JJ N
bioequivalence NN N
range NN N
of IN N
80 CD N
% NN N
to TO N
125 CD N
% NN N
, , N
the DT N
two CD N
treatments NNS N
were VBD N
considered VBN N
bioequivalent NN N
. . N

The DT N
safety NN o
profiles NNS o
of IN N
both DT N
the DT N
test NN N
and CC N
reference NN N
formulations NNS N
were VBD N
comparable JJ N
. . N

-DOCSTART- -1548248- O O

A DT N
double-blind JJ N
, , N
placebo-controlled JJ i
study NN N
of IN N
the DT N
efficacy NN N
of IN N
transdermal JJ i
clonidine NN i
in IN N
autism NN p
. . p

BACKGROUND NNP N
Autistic JJ p
individuals NNS p
often RB p
exhibit VBP p
hyperarousal JJ p
behaviors NNS p
( ( p
e.g. NN p
, , N
stereotyped VBD p
body NN p
movements NNS p
, , p
self-stimulation NN p
, , p
hypervigilance NN p
, , p
and CC p
hyperactivity NN p
) ) p
. . N

Clonidine NNP i
, , N
an DT N
alpha JJ N
2-adrenergic JJ N
receptor NN N
agonist NN N
, , N
has VBZ N
been VBN N
shown VBN N
to TO N
be VB N
effective JJ N
in IN N
reducing VBG N
impulsivity NN N
, , N
inattention NN N
, , N
and CC N
hyperactivity NN N
associated VBN N
with IN N
attention NN N
deficit NN N
disorder NN N
with IN N
hyperactivity NN N
. . N

This DT N
study NN N
investigated VBD N
the DT N
efficacy NN o
and CC o
safety NN o
of IN N
transdermal JJ N
clonidine NN i
in IN N
reducing VBG N
hyperarousal JJ p
behaviors NNS p
associated VBN p
with IN p
autism NN p
. . p

METHOD VB N
A DT N
double-blind JJ N
, , N
placebo-crossover JJ i
study NN N
with IN N
transdermal JJ N
clonidine NN i
was VBD N
performed VBN N
in IN N
nine CD p
autistic JJ p
males NNS p
( ( p
aged VBN p
5 CD p
to TO p
33 CD p
years NNS p
) ) p
. . p

Subjects VBZ N
received VBN N
either DT N
clonidine NN i
( ( N
approximately RB N
0.005 CD N
mg/kg/day NN N
) ) N
or CC N
placebo VBN i
by IN N
a DT N
weekly JJ N
transdermal NN N
patch NN N
. . N

Each DT N
trial NN N
lasted VBD N
4 CD N
weeks NNS N
with IN N
a DT N
2-week JJ N
washout NN N
period NN N
between IN N
treatment NN N
phases NNS N
. . N

Subjects NNS N
were VBD N
evaluated VBN N
every DT N
2 CD N
weeks NNS N
by IN N
clinician JJ N
raters NNS N
and CC N
weekly JJ N
by IN N
parents NNS N
. . N

RESULTS VB N
The DT N
clonidine NN i
treatment NN N
showed VBD N
a DT N
significant JJ N
difference NN N
from IN N
placebo NN i
treatment NN N
on IN N
three CD N
subscales NNS N
of IN N
the DT N
Ritvo-Freeman NNP o
Real NNP o
Life NNP o
Rating NNP o
Scale NNP o
( ( o
i.e. FW o
, , N
social JJ o
relationship NN o
to TO o
people NNS o
, , o
affectual JJ o
responses NNS o
, , o
and CC o
sensory JJ o
responses NNS o
) ) o
. . o

The DT N
Clinical JJ o
Global NNP o
Impressions NNP o
scale NN o
indicated VBD N
that IN N
clonidine NN i
produced VBD N
a DT N
significant JJ N
improvement NN N
on IN N
severity NN o
of IN o
illness NN o
, , o
global JJ o
improvement NN o
, , o
and CC o
efficacy NN o
index NN o
for IN N
therapeutic JJ N
effect NN N
of IN N
the DT N
drug NN N
. . N

A DT N
patient JJ o
global JJ o
rating NN o
scale NN o
showed VBD N
clonidine JJ i
treatment NN N
resulted VBD N
in IN N
significant JJ N
improvement NN N
in IN N
comparison NN N
with IN N
placebo NN i
. . i

Adverse JJ o
effects NNS o
included VBN o
sedation NN o
and CC o
fatigue NN o
during IN N
the DT N
first JJ N
2 CD N
weeks NNS N
of IN N
clonidine NN i
treatment NN N
. . N

CONCLUSION NNP N
Results NNP N
from IN N
this DT N
preliminary JJ N
study NN N
show NN N
that IN N
clonidine NN i
was VBD N
effective JJ N
in IN N
reducing VBG N
several JJ o
hyperarousal NN o
behaviors NNS o
and CC N
improved VBN N
social JJ o
relationships NNS o
in IN N
some DT p
autistic JJ p
subjects NNS p
. . p

Further JJ N
studies NNS N
are VBP N
needed VBN N
in IN N
a DT N
larger JJR p
autistic JJ p
population NN p
to TO N
determine VB N
the DT N
dose-response JJ N
relationship NN N
of IN N
clonidine NN i
. . i

-DOCSTART- -8123947- O O

Peripheral NNP N
intravenous JJ o
line NN o
survival NN o
and CC N
phlebitis NN o
prevention NN N
in IN N
patients NNS p
receiving VBG p
intravenous JJ p
antibiotics NNS i
: : i
heparin/hydrocortisone NN N
versus IN N
in-line JJ N
filters NNS N
. . N

OBJECTIVE NNP N
To TO N
compare VB N
the DT N
use NN N
of IN N
in-line JJ N
filtration NN N
with IN N
the DT N
addition NN N
of IN N
heparin/hydrocortisone NN i
( ( N
hep/hc NN N
) ) N
to TO N
the DT N
infusate NN N
for IN N
both DT N
phlebitis NN N
prevention NN N
and CC N
intravenous JJ N
( ( N
i.v JJ N
. . N

) ) N
line NN N
survival NN N
in IN N
peripheral JJ N
i.v NN N
. . N

catheters NNS N
. . N

This DT N
study NN N
was VBD N
specific JJ p
for IN p
a DT p
patient NN p
group NN p
receiving VBG p
prolonged JJ p
courses NNS p
of IN p
i.v NN p
. . p

antibiotics NNS p
. . p

Analysis NN N
of IN N
the DT N
two CD N
endpoints NNS N
for IN N
conventional JJ N
short JJ N
i.v NN i
. . i

catheters NNS i
( ( N
short JJ N
lines NNS N
) ) N
versus NN N
long RB N
( ( N
30 CD N
cm NN N
) ) N
i.v NN N
. . N

catheters NNS N
( ( N
long JJ N
lines NNS N
) ) N
was VBD N
also RB N
performed VBN N
. . N

METHODS NNP N
Patients NNPS p
with IN p
cystic JJ p
fibrosis NN p
receiving VBG p
intermittent JJ p
i.v NN p
. . p

antibiotics NNS i
were VBD N
randomly RB N
allocated VBN N
to TO N
receive VB N
their PRP$ N
drugs NNS N
either CC N
through IN N
an DT N
in-line JJ N
filter NN N
using VBG N
a DT N
drug-free JJ N
infusate NN N
or CC N
with IN N
no DT N
filter NN N
and CC N
an DT N
infusate NN N
containing VBG N
heparin JJ i
500 CD N
units NNS N
and CC N
hydrocortisone NN i
10 CD N
mg/L NN N
. . N

Infusion NN N
sites NNS N
were VBD N
assessed VBN N
daily RB N
. . N

RESULTS NNP N
Both NNP N
the DT N
hep/hc NN N
and CC N
filter NN N
groups NNS N
were VBD N
similar JJ N
in IN N
terms NNS N
of IN N
phlebitis NN o
incidence NN o
and CC o
i.v NN o
. . o

line NN o
survival NN o
when WRB N
analyzed VBN N
separately RB N
for IN N
both DT N
short JJ N
and CC N
long JJ N
lines NNS N
. . N

Long NNP N
lines NNS N
displayed VBD N
markedly RB N
prolonged JJ N
survival NN o
times NNS o
and CC N
reduced JJ N
phlebitis NN o
compared VBN N
with IN N
short JJ N
lines NNS N
. . N

CONCLUSIONS VB N
The DT N
effectiveness NN N
of IN N
i.v NN N
. . N

filters NNS N
in IN N
excluding VBG N
the DT N
large JJ N
particle NN N
load NN N
introduced VBN N
by IN N
i.v NN N
. . N

antibiotics NNS N
and CC N
hence NN N
in IN N
reducing VBG N
the DT N
subsequent JJ N
phlebitis NN N
makes VBZ N
them PRP N
a DT N
useful JJ N
alternative NN N
to TO N
the DT N
use NN N
of IN N
hep/hc NN N
. . N

The DT N
use NN N
of IN N
filters NNS N
in IN N
this DT N
patient JJ N
group NN N
may MD N
offer VB N
advantages NNS N
in IN N
terms NNS N
of IN N
ease NN N
of IN N
use NN N
and CC N
a DT N
possible JJ N
decrease NN N
in IN N
hep/hc-related JJ o
problems NNS o
. . N

Long JJ N
lines NNS N
offer VBP N
practical JJ N
advantages NNS N
over IN N
short JJ N
lines NNS N
for IN N
patients NNS p
requiring VBG p
longer JJR p
term NN p
i.v NN p
. . p

access NN p
. . p

-DOCSTART- -8770026- O O

Effects NNS N
of IN N
glucocorticoids NNS i
on IN N
energy NN o
metabolism NN o
and CC N
food NN o
intake NN o
in IN N
humans NNS p
. . p

The DT N
effect NN N
of IN N
glucocorticoid JJ i
administration NN N
on IN N
energy NN o
metabolism NN o
and CC N
food NN o
intake NN o
was VBD N
studied VBN N
in IN N
20 CD p
healthy JJ p
, , p
nondiabetic JJ p
Caucasian NNP p
male NN p
volunteers NNS p
[ VBP p
27 CD p
+/- JJ p
5 CD p
( ( p
SD NNP p
) ) p
yr NN p
, , p
72 CD p
+/- JJ p
9 CD p
kg NN p
, , p
20 CD p
+/- JJ p
7 CD p
% NN p
body NN p
fat JJ p
] NNP p
randomly NN N
and CC N
blindly RB N
assigned VBD N
to TO N
glucocorticoid VB i
( ( i
methylprednisolone NN i
, , i
METH NNP i
; : i
n CC N
= VB N
10 CD N
) ) N
or CC N
placebo NN i
( ( i
PLAC NNP i
; : i
n CC N
= VB N
10 CD N
) ) N
treatment NN N
. . N

Each DT N
subject NN N
was VBD N
studied VBN N
twice RB N
: : N
during IN N
a DT N
weight JJ N
maintenance NN N
diet JJ N
and CC N
during IN N
ad NN N
libitum NN N
food NN N
intake NN N
. . N

Energy NNP o
metabolism NN o
was VBD N
measured VBN N
by IN N
indirect JJ N
calorimetry NN N
and CC N
food NN o
intake NN o
by IN N
an DT N
automated VBN N
food-selection NN N
system NN N
. . N

Twenty-four-hour JJ N
urinary JJ o
norepinephrine NN o
excretion NN o
( ( N
24-h JJ N
NE NNP N
) ) N
was VBD N
used VBN N
as IN N
an DT N
estimate NN N
of IN N
sympathetic JJ o
nervous JJ o
system NN o
activity NN o
. . o

During IN N
weight JJ N
maintenance NN N
, , N
METH NNP N
intravenous JJ N
infusion NN N
( ( N
125 CD N
mg/30 NNS N
min NN N
) ) N
increased VBD N
energy NN o
expenditure NN o
compared VBN N
with IN N
PLAC NNP N
, , N
and CC N
after IN N
4 CD N
days NNS N
of IN N
oral JJ N
therapy NN N
, , N
METH NNP N
( ( N
40 CD N
mg/day NN N
) ) N
decreased VBD N
24-h JJ o
NE NNP o
and CC N
increased VBD N
energy NN o
expenditure NN o
compared VBN N
with IN N
PLAC NNP N
. . N

During IN N
ad NN N
libitum NN N
food NN N
intake NN N
, , N
after IN N
4 CD N
days NNS N
of IN N
METH NNP N
( ( N
40 CD N
mg/day NN N
) ) N
or CC N
PLAC NNP N
oral JJ N
therapy NN N
, , N
both DT N
groups NNS N
increased VBD N
their PRP$ N
energy NN o
intake NN o
over IN N
weight JJ N
maintenance NN N
, , N
but CC N
the DT N
increase NN N
was VBD N
significantly RB N
larger JJR N
in IN N
the DT N
METH NNP N
group NN N
compared VBN N
with IN N
the DT N
PLAC NNP N
group NN N
( ( N
4,554 CD N
+/- JJ N
1,857 CD N
vs. FW N
2,867 CD N
+/- JJ N
846 CD N
kcal/day NN N
; : N
P NNP N
= NNP N
0.04 CD N
) ) N
. . N

Our PRP$ N
data NNS N
suggest VBP N
that IN N
therapeutic JJ N
doses NNS N
of IN N
glucocorticoids NNS N
induce VBP N
obesity NN N
mostly RB N
by IN N
increasing VBG N
energy NN o
intake NN o
, , N
an DT N
effect NN N
which WDT N
may MD N
be VB N
related VBN N
to TO N
the DT N
ability NN N
of IN N
glucocorticoids NNS N
to TO N
act VB N
directly RB N
or CC N
indirectly RB N
on IN N
the DT N
central JJ N
regulation NN N
of IN N
appetite NN N
. . N

-DOCSTART- -9950438- O O

Active NNP i
specific JJ i
immunotherapy NN i
for IN N
stage NN p
II NNP p
and CC p
stage NN p
III NNP p
human JJ p
colon NN p
cancer NN p
: : p
a DT N
randomised JJ N
trial NN N
. . N

BACKGROUND NNP N
Colon NNP N
cancer NN N
is VBZ N
curable JJ N
by IN N
surgery NN N
, , N
but CC N
cure NN N
rate NN N
depends VBZ N
on IN N
the DT N
extent NN N
of IN N
disease NN N
. . N

We PRP N
investigated VBD N
whether IN N
adjuvant JJ N
active JJ i
specific JJ i
immunotherapy NN i
( ( N
ASI NNP N
) ) N
with IN N
an DT N
autologous JJ N
tumour JJ N
cell-BCG JJ N
vaccine NN N
with IN N
surgical JJ N
resection NN N
was VBD N
more RBR N
beneficial JJ N
than IN N
resection NN N
alone RB N
in IN N
stage NN N
II NNP N
and CC N
III NNP N
colon NN N
cancer NN N
. . N

METHODS NNP N
In IN N
a DT N
prospective JJ N
randomised VBN N
trial NN N
, , N
254 CD p
patients NNS p
with IN p
colon NN p
cancer NN p
were VBD p
randomly RB p
assigned VBN p
postoperative JJ i
ASI NNP i
or CC i
no DT i
adjuvant JJ i
treatment NN i
. . i

ASI NNP N
was VBD N
three CD N
weekly JJ N
vaccinations NNS N
starting VBG N
4 CD N
weeks NNS N
after IN N
surgery NN N
, , N
with IN N
a DT N
booster NN N
vaccination NN N
at IN N
6 CD N
months NNS N
with IN N
10 CD N
( ( N
7 CD N
) ) N
irradiated VBN N
autologous JJ i
tumour NN i
cells NNS i
. . i

The DT N
first JJ N
vaccinations NNS N
contained VBN N
10 CD N
( ( N
7 CD N
) ) N
BCG NNP N
organisms UH N
. . N

We PRP N
followed VBD N
up RP N
patients NNS N
for IN N
time NN N
to TO N
recurrence VB N
, , N
and CC N
recurrence-free JJ N
and CC N
overall JJ N
survival NN N
. . N

Analysis NN N
was VBD N
by IN N
intention NN N
to TO N
treat VB N
. . N

FINDINGS NNP N
The DT N
5.3 CD N
year NN N
median JJ N
follow-up NN N
( ( N
range VB N
8 CD N
months NNS N
to TO N
8 CD N
years NNS N
11 CD N
months NNS N
) ) N
showed VBD N
44 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
7-66 CD N
) ) N
risk NN N
reduction NN N
for IN N
recurrence NN N
in IN N
the DT N
recurrence-free JJ N
period NN N
in IN N
all DT N
patients NNS N
receiving VBG N
ASI NNP i
( ( N
p=0.023 NN N
) ) N
. . N

Overall JJ N
, , N
there EX N
were VBD N
40 CD N
recurrences NNS N
in IN N
the DT N
control NN N
group NN N
and CC N
25 CD N
in IN N
the DT N
ASI NNP N
group NN N
. . N

Analysis NN N
by IN N
stage NN N
showed VBD N
no DT N
significant JJ N
benefit NN N
of IN N
ASI NNP o
in IN N
stage NN N
III NNP N
disease NN N
. . N

The DT N
major JJ N
impact NN N
of IN N
ASI NNP N
was VBD N
seen VBN N
in IN N
patients NNS p
with IN p
stage NN p
II NNP p
disease NN p
, , N
with IN N
a DT N
significantly RB N
longer RBR N
recurrence-free JJ o
period NN o
( ( N
p=0.011 NN N
) ) N
and CC N
61 CD N
% NN N
( ( N
18-81 JJ N
) ) N
risk NN o
reduction NN o
for IN o
recurrences NNS o
. . o

Recurrence-free JJ o
survival NN o
was VBD N
significantly RB N
longer RBR N
with IN N
ASI NNP N
( ( N
42 CD N
% NN N
risk NN N
reduction NN N
for IN N
recurrence NN N
or CC N
death NN N
[ JJ N
0-68 JJ N
] NN N
, , N
p=0.032 NN N
) ) N
and CC N
there EX N
was VBD N
a DT N
trend NN N
towards VBZ N
improved VBN N
overall JJ o
survival NN o
. . o

INTERPRETATION NNP N
ASI NNP N
gave VBD N
significant JJ N
clinical JJ N
benefit NN N
in IN N
surgically RB N
resected VBN N
patients NNS N
with IN N
stage NN p
II NNP p
colon NN p
cancer NN p
. . p

ASI NNP N
has VBZ N
minimal JJ N
adverse JJ N
reactions NNS N
and CC N
should MD N
be VB N
considered VBN N
in IN N
the DT N
management NN N
of IN N
stage NN N
II NNP N
colon NN N
cancer NN N
. . N

-DOCSTART- -9553982- O O

Determinants NNS N
of IN N
total JJ N
and CC N
specific JJ N
IgE NNP N
in IN N
infants NNS p
with IN p
atopic JJ p
dermatitis NN p
. . p

ETAC NNP N
Study NNP N
Group NNP N
. . N

Early NNP N
Treatment NNP N
of IN N
the DT N
Atopic NNP p
Child NNP p
. . p

ETAC NNP p
( ( p
Early JJ p
Treatment NN p
of IN p
the DT p
Atopic NNP p
Child NNP p
) ) p
, , p
a DT p
multi-centre JJ p
predominantly RB p
European JJ p
study NN p
to TO p
investigate VB p
the DT p
potential NN p
for IN p
cetirizine NN i
to TO p
prevent VB p
the DT p
development NN p
of IN p
asthma NN p
in IN p
infants NNS p
with IN p
atopic NN p
dermatitis NN p
has VBZ N
completed VBN N
enrollment NN N
: : N
817 CD p
children NNS p
have VBP N
been VBN N
randomised VBN N
to TO N
18 CD N
months NNS N
' POS N
treatment NN N
with IN N
either DT N
active JJ i
or CC N
placebo NN i
and CC N
a DT N
subsequent JJ N
18 CD N
months NNS N
of IN N
post-treatment JJ N
follow-up NN N
. . N

Results NNS N
of IN N
the DT N
therapeutic JJ N
effects NNS N
will MD N
not RB N
be VB N
available JJ N
for IN N
some DT N
time NN N
, , N
but CC N
the DT N
study NN N
has VBZ N
provided VBN N
an DT N
opportunity NN N
to TO N
investigate VB N
influences NNS N
on IN N
sensitization NN o
to TO o
allergens NNS o
in IN N
a DT N
large JJ p
cohort NN p
of IN p
1-2 JJ p
years NNS p
olds VBZ p
with IN p
already RB p
established VBN p
atopic NN p
dermatitis NN p
, , p
resident NN p
in IN p
different JJ p
countries NNS p
and CC p
in IN p
different JJ p
environments NNS p
. . p

The DT N
study NN N
shows VBZ N
that IN N
in IN N
infants NNS p
with IN p
atopic NN p
dermatitis NN p
, , N
raised VBD N
serum JJ o
total NN o
IgE NNP o
has VBZ N
significantly RB N
different JJ N
determinants NNS N
from IN N
that IN N
a DT N
specific JJ o
allergen NN o
sensitization NN o
. . o

In IN N
infancy NN N
, , N
increased VBD N
total JJ o
IgE NNP o
is VBZ N
more RBR N
affected JJ N
by IN N
factors NNS N
increasing VBG N
risk NN N
of IN N
intercurrent JJ N
infection NN N
and CC N
non-specific JJ N
airway NN N
inflammation NN N
, , N
such JJ N
as IN N
environmental JJ N
tobacco NN N
smoke NN N
exposure NN N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
and CC N
the DT N
use NN N
of IN N
gas NN N
cookers NNS N
( ( N
p JJ N
= NNP N
0.02 CD N
) ) N
. . N

Specific JJ N
allergen NN o
sensitization NN o
as IN N
represented VBN N
by IN N
detectable JJ N
IgE NNP o
antibodies NNS o
is VBZ N
influenced VBN N
primarily RB N
by IN N
allergen NN N
exposure NN N
. . N

In IN N
Sweden NNP N
, , N
low JJ N
level NN N
exposure NN N
to TO N
allergens NNS N
is VBZ N
associated VBN N
with IN N
reduced VBN N
specific JJ o
allergen NN o
sensitization NN o
rates NNS N
even RB N
though IN N
the DT N
infants NNS p
already RB N
have VBP N
atopic VBN N
dermatitis NN N
. . N

-DOCSTART- -9793091- O O

The DT N
SPEM NNP N
( ( N
Studio NNP N
Policentrico NNP N
Elettrocateteri NNP N
Membrane NNP N
) ) N
: : N
a DT N
multicenter NN N
study NN N
on IN N
membrane NN p
leads NNS p
. . p

SPEM NNP N
is VBZ N
a DT N
multicenter NN p
randomized VBN N
double-blind NN N
study NN N
performed VBD N
to TO N
test VB N
the DT N
acute NN o
and CC o
chronic JJ o
electrophysiological JJ o
behavior NN o
of IN N
three CD N
different JJ N
ventricular JJ p
leads NNS p
: : p
( ( N
1 CD N
) ) N
an DT i
ion NN i
exchange NN i
membrane NN i
with IN i
30-microgram JJ i
dexamethasone NN i
elution NN i
in IN i
a DT i
contoured JJ i
activated JJ i
carbon NN i
tip NN i
lead NN i
( ( N
Membrane NNP N
1400T CD N
, , N
30 CD N
patients NNS N
) ) N
; : N
( ( N
2 CD N
) ) N
the DT i
same JJ i
lead NN i
design NN i
without IN i
steroid NN i
( ( N
Membrane NNP N
1401T CD N
, , N
24 CD N
patients NNS N
) ) N
; : N
and CC N
( ( N
3 CD N
) ) N
the DT i
same JJ i
lead NN i
design NN i
without IN i
steroid NN i
or CC i
membrane NN i
( ( N
control NN N
group NN N
, , N
27 CD N
patients NNS N
) ) N
. . N

Twenty-three CD p
of IN p
the DT p
81 CD p
patients NNS p
were VBD p
women NNS p
; : p
the DT p
mean JJ p
age NN p
for IN p
all DT p
patients NNS p
was VBD p
74 CD p
+/- JJ p
10 CD p
years NNS p
. . p

Parameters NNS N
are VBP N
calculated VBN N
both DT N
in IN N
uni- JJ N
and CC N
bipolar JJ N
configuration NN N
at IN N
implant JJ N
and CC N
at IN N
follow-up JJ N
after IN N
1 CD N
, , N
5 CD N
, , N
15 CD N
, , N
30 CD N
, , N
90 CD N
, , N
180 CD N
, , N
and CC N
360 CD N
days NNS N
. . N

Implant JJ N
threshold NN N
( ( N
chronaxie JJ N
= $ N
0.413 CD N
+/- JJ N
0.280 CD N
ms NN N
, , N
rheobase VB N
= JJ N
0.264 CD N
+/- JJ N
0.099 CD N
V NNP N
) ) N
, , N
signal JJ N
amplitude NN N
( ( N
13.45 CD N
+/- JJ N
5.87 CD N
mV NN N
) ) N
, , N
and CC N
slew JJ N
rate NN N
( ( N
2.05 CD N
+/- JJ N
1.38 CD N
V/s NNP N
) ) N
reveal VBP N
no DT N
significant JJ N
differences NNS N
. . N

Pacing VBG o
impedance NN o
values NNS o
both DT N
at IN N
implant NN N
( ( N
unipolar JJ N
571 CD N
+/- JJ N
165 CD N
omega NN N
; : N
bipolar JJ N
605 CD N
+/- JJ N
123 CD N
omega NN N
) ) N
and CC N
at IN N
follow-ups NNS N
( ( N
unipolar JJ N
480 CD N
+/- JJ N
72 CD N
omega NN N
; : N
bipolar JJ N
518 CD N
+/- JJ N
75 CD N
omega NN N
) ) N
are VBP N
slightly RB N
lower JJR N
in IN N
the DT N
unipolar JJ N
configuration NN N
. . N

At IN N
15 CD N
and CC N
30-day JJ N
follow-ups NNS N
, , N
control NN N
group NN N
and CC N
nonsteroid JJ N
leads VBZ N
show VB N
a DT N
higher JJR N
threshold JJ o
value NN N
growth NN N
( ( N
in IN N
unipolar NN N
from IN N
0.16 CD N
+/- JJ N
0.11 CD N
to TO N
1.19 CD N
+/- JJ N
0.85 CD N
microJ NN N
; : N
in IN N
bipolar NN N
from IN N
0.18 CD N
+/- JJ N
0.13 CD N
to TO N
1.24 CD N
+/- JJ N
0.88 CD N
microJ NN N
) ) N
than IN N
the DT N
membrane NN N
steroid NN N
leads VBZ N
( ( N
in IN N
unipolar NN N
from IN N
0.13 CD N
+/- JJ N
0.11 CD N
to TO N
0.70 CD N
+/- JJ N
0.39 CD N
microJ NN N
; : N
in IN N
bipolar NN N
from IN N
0.23 CD N
+/- JJ N
0.32 CD N
to TO N
0.76 CD N
+/- JJ N
0.36 CD N
microJ NN N
) ) N
; : N
the DT N
threshold NN o
of IN N
nonsteroid JJ N
leads NNS N
decreases NNS N
after IN N
1-3 JJ N
months NNS N
and CC N
it PRP N
settles VBZ N
at IN N
the DT N
same JJ N
threshold JJ o
level NN N
of IN N
the DT N
leads NNS N
with IN N
membrane NN N
and CC N
steroid NN N
( ( N
in IN N
unipolar JJ N
0.60 CD N
+/- JJ N
0.33 CD N
microJ NN N
; : N
in IN N
bipolar JJ N
0.55 CD N
+/- JJ N
0.26 CD N
microJ NN N
) ) N
, , N
which WDT N
has VBZ N
been VBN N
stable JJ N
since IN N
the DT N
first JJ N
month NN N
. . N

The DT N
ion NN i
exchange NN i
membrane NN i
is VBZ N
effective JJ N
in IN N
reducing VBG N
the DT N
chronic JJ o
pacing NN o
threshold NN o
like IN N
acute JJ N
steroid JJ N
elution NN N
at IN N
low JJ N
doses NNS N
, , N
but CC N
membrane FW N
alone RB N
does VBZ N
not RB N
prevent VB N
an DT N
acute JJ o
pacing NN o
threshold JJ o
increase NN N
through IN N
the DT N
first JJ N
month NN N
postimplant NN N
. . N

-DOCSTART- -2691638- O O

The DT N
Relaxation NNP N
Inventory NN N
: : N
self-report JJ N
scales NNS N
of IN N
relaxation NN i
training NN i
effects NNS i
. . i

The DT N
development NN N
of IN N
a DT N
self-report JJ N
measure NN N
to TO N
assess VB N
the DT N
effects NNS N
of IN N
relaxation NN N
training NN N
was VBD N
examined VBN N
. . N

A DT N
rigorous JJ N
statistical JJ N
method NN N
of IN N
scale JJ N
construction NN N
consisting NN N
of IN N
a DT N
modification NN N
of IN N
the DT N
scale JJ N
discrimination NN N
technique NN N
was VBD N
employed VBN N
, , N
resulting VBG N
in IN N
a DT N
45-item JJ i
questionnaire NN i
representing VBG N
three CD N
orthogonally RB N
derived VBN N
scales NNS N
. . N

The DT N
three CD N
scales NNS N
, , N
Physiological NNP N
Tension NNP N
, , N
Physical NNP N
Assessment NNP N
, , N
and CC N
Cognitive NNP N
Tension NNP N
, , N
demonstrated VBD N
adequate JJ N
internal JJ N
consistency NN N
with IN N
KR20 NNP N
reliability NN N
coefficients NNS N
of IN N
.89 NNP N
, , N
.95 NNP N
, , N
and CC N
.81 NNP N
, , N
respectively RB N
. . N

In IN N
a DT N
second JJ N
study NN N
of IN N
predictive JJ N
validity NN N
, , N
40 CD p
individuals NNS p
were VBD p
randomly RB p
assigned VBN p
to TO N
one CD N
of IN N
four CD N
conditions NNS N
: : N
relaxation NN i
training NN i
, , i
tension NN i
inducement NN i
, , i
pre-postcontrol NN i
, , i
or CC i
postcontrol NN i
. . i

Univariate NNP N
analysis NN N
of IN N
variance NN N
indicated VBN N
significant JJ N
findings NNS N
for IN N
each DT N
of IN N
the DT N
three CD N
dimensions NNS N
of IN N
the DT N
inventory NN N
. . N

The DT N
Physiological JJ N
Tension NNP N
Scale NNP N
detected VBD N
significant JJ N
increases NNS N
in IN N
tension NN o
following VBG N
tension NN N
inducement NN N
, , N
whereas IN N
the DT N
Physical NNP N
Assessment NNP N
Scale NNP N
and CC N
Cognitive NNP N
Tension NNP N
Scale NNP N
detected VBD N
increases NNS N
in IN N
relaxation NN o
following VBG N
relaxation NN i
training NN i
. . i

Recommendations NNS N
were VBD N
made VBN N
for IN N
future JJ N
research NN N
on IN N
the DT N
inventory NN N
. . N

-DOCSTART- -9474454- O O

Twice-a-day JJ N
versus NN N
four-times-a-day JJ N
ofloxacin JJ N
treatment NN N
of IN N
external JJ N
ocular JJ N
infection NN N
. . N

PURPOSE VB N
The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
efficacies NNS o
of IN N
0.3 CD N
% NN N
ofloxacin JJ N
eyedrops NNS N
, , N
when WRB N
given VBN N
twice-a-day JJ N
( ( N
BID NNP N
) ) N
versus IN N
four-times-a-day JJ N
( ( N
QID NNP N
) ) N
, , N
for IN N
the DT N
treatment NN N
of IN N
external JJ N
ocular JJ N
disease NN N
. . N

METHOD NNP N
Fifty NNP p
patients NNS p
with IN p
blepharitis NN p
, , p
conjuctivitis NN p
, , p
or CC p
blepharoconjunctivitis NN p
were VBD N
randomly RB N
assigned VBN N
to TO N
treatment NN i
with IN i
0.3 CD i
% NN i
ofloxacin JJ i
eyedrops NNS i
, , i
BID NNP i
or CC i
QID NNP i
, , i
for IN i
10 CD i
days NNS i
. . i

Signs NNP N
, , N
symptoms NNS N
, , N
and CC N
cultures NNS N
were VBD N
evaluated VBN N
at IN N
the DT N
beginning NN N
and CC N
at IN N
the DT N
end NN N
of IN N
the DT N
study NN N
. . N

RESULTS VB N
The DT N
clinical JJ N
outcome NN N
was VBD N
virtually RB N
identical JJ N
in IN N
the DT N
two CD N
groups NNS N
. . N

There EX N
was VBD N
a DT N
significant JJ N
decrease NN N
in IN N
clinical JJ o
scores NNS o
in IN N
the DT N
BID NNP N
and CC N
QID NNP N
groups NNS N
by IN N
days NNS N
3 CD N
to TO N
5 CD N
( ( N
2.6-3.0 JJ N
points NNS N
) ) N
and CC N
a DT N
further JJ N
decrease NN N
by IN N
day NN N
11 CD N
( ( N
4.3-5.0 JJ N
points NNS N
) ) N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
the DT N
two CD N
groups NNS N
at IN N
any DT N
time NN N
interval NN N
. . N

Microbiologic NNP N
studies NNS N
showed VBD N
a DT N
reduction NN N
in IN N
colony-forming JJ o
units NNS o
in IN N
87 CD N
% NN N
of IN N
the DT N
BID NNP N
group NN N
and CC N
in IN N
80 CD N
% NN N
of IN N
the DT N
QID NNP N
group NN N
. . N

CONCLUSION NNP N
The DT N
treatment NN N
of IN N
external JJ o
ocular JJ o
disease NN o
with IN N
0.3 CD N
% NN N
ofloxacin JJ o
eyedrops NN o
was VBD o
equally RB o
effective JJ o
when WRB o
given VBN o
BID NNP o
or CC o
QID NNP o
. . o

-DOCSTART- -24505318- O O

Addictive JJ o
internet NN o
use NN o
among IN N
Korean JJ p
adolescents NNS p
: : p
a DT N
national JJ N
survey NN N
. . N

BACKGROUND VB N
A DT N
psychological JJ N
disorder NN N
called VBN N
'Internet CD o
addiction NN o
' '' o
has VBZ N
newly RB N
emerged VBN N
along IN N
with IN N
a DT N
dramatic JJ N
increase NN N
of IN N
worldwide JJ N
Internet NNP N
use NN N
. . N

However RB N
, , N
few JJ N
studies NNS N
have VBP N
used VBN N
population-level NN N
samples NNS N
nor CC N
taken VBN N
into IN N
account JJ N
contextual JJ N
factors NNS N
on IN N
Internet NNP N
addiction NN N
. . N

METHODS NNP N
AND CC N
FINDINGS NNP N
We PRP N
identified VBD N
57,857 CD p
middle JJ p
and CC p
high JJ p
school NN p
students NNS p
( ( p
13-18 CD p
year NN p
olds NNS p
) ) p
from IN p
a DT p
Korean NNP p
nationally RB p
representative JJ p
survey NN p
, , p
which WDT p
was VBD p
surveyed VBN p
in IN p
2009 CD p
. . p

To TO N
identify VB N
associated JJ N
factors NNS N
with IN N
addictive JJ o
Internet NNP o
use NN o
, , N
two-level JJ N
multilevel NN N
regression NN N
models NNS N
were VBD N
fitted VBN N
with IN N
individual-level JJ i
responses NNS i
( ( N
1st CD N
level NN N
) ) N
nested VBD N
within IN N
schools NNS N
( ( N
2nd CD N
level NN N
) ) N
to TO N
estimate VB N
associations NNS N
of IN N
individual JJ N
and CC N
school NN N
characteristics NNS N
simultaneously RB N
. . N

Gender NNP N
differences NNS N
of IN N
addictive JJ o
Internet NNP o
use NN o
were VBD N
estimated VBN N
with IN N
the DT N
regression NN N
model NN N
stratified VBN N
by IN N
gender NN N
. . N

Significant JJ N
associations NNS N
were VBD N
found VBN N
between IN N
addictive JJ N
Internet NNP o
use NN o
and CC N
school NN N
grade NN N
, , N
parental JJ N
education NN N
, , N
alcohol NN N
use NN N
, , N
tobacco NN N
use NN N
, , N
and CC N
substance NN N
use NN N
. . N

Female JJ p
students NNS p
in IN p
girls NNS p
' POS p
schools NNS p
were VBD N
more RBR N
likely JJ N
to TO N
use VB o
Internet NNP o
addictively RB o
than IN N
those DT N
in IN N
coeducational JJ N
schools NNS N
. . N

Our PRP$ N
results NNS N
also RB N
revealed VBD N
significant JJ N
gender NN N
differences NNS N
of IN N
addictive JJ o
Internet NNP o
use NN o
in IN N
its PRP$ N
associated VBN N
individual- JJ N
and CC N
school-level JJ N
factors NNS N
. . N

CONCLUSIONS NNP N
Our PRP$ N
results NNS N
suggest VBP N
that IN N
multilevel NN N
risk NN N
factors NNS N
along IN N
with IN N
gender NN N
differences NNS N
should MD N
be VB N
considered VBN N
to TO N
protect VB N
adolescents NNS p
from IN N
addictive JJ o
Internet NNP o
use NN o
. . o

-DOCSTART- -17321529- O O

Misoprostol NNP i
versus NN N
oxytocin NN i
for IN N
the DT N
reduction NN N
of IN N
postpartum NN o
blood NN o
loss NN o
. . o

OBJECTIVE UH N
To TO N
compare VB N
the DT N
effect NN N
of IN N
400 CD N
mug NN N
of IN N
oral JJ i
misoprostol NN i
with IN N
5 CD N
U NNP N
of IN N
intravenous JJ i
oxytocin NNS i
in IN N
the DT N
reduction NN N
of IN N
postpartum NN o
blood NN o
loss NN o
and CC N
prevention NN N
of IN N
postpartum NN N
hemorrhage NN N
. . N

METHODS NNP N
In IN N
a DT N
prospective JJ N
, , N
double-blind JJ N
, , N
randomized VBN N
controlled VBN N
trial NN p
conducted VBN p
in IN p
a DT p
tertiary JJ p
maternity NN p
hospital NN p
622 CD p
women NNS p
received VBD N
either RB N
400 CD N
mug NN N
of IN N
oral JJ i
misoprostol NN i
or CC N
5 CD N
U NNP N
of IN N
intravenous JJ i
oxytocin NNS i
after IN N
delivery NN N
of IN N
the DT N
anterior JJ N
shoulder NN N
or CC N
within IN N
1 CD N
min NNS N
of IN N
delivery NN N
. . N

The DT N
primary JJ N
outcome NN N
was VBD N
a DT N
hematocrit JJ o
drop NN o
of IN o
10 CD o
% NN o
or CC o
greater JJR o
24 CD o
h NN o
postpartum NN o
. . o

The DT N
secondary JJ N
outcomes NNS N
were VBD N
a DT N
hemoglobin JJ o
drop NN o
of IN o
30 CD o
mg/L NN o
or CC o
greater JJR o
, , o
the DT o
use NN o
of IN o
additional JJ o
oxytocin NN o
, , o
an DT o
estimated VBN o
blood NN o
loss NN o
greater JJR o
than IN o
1000 CD o
mL NN o
, , o
manual JJ o
removal NN o
of IN o
the DT o
placenta NN o
, , o
a DT o
blood NN o
transfusion NN o
, , o
and CC o
shivering VBG o
and CC o
fever NN o
( ( o
> JJ o
or=38 NN o
degrees NNS o
C NNP o
) ) o
as IN o
adverse JJ o
effects NNS o
of IN o
misoprostol NN o
. . o

RESULTS NNP N
There EX N
was VBD N
no DT N
difference NN N
between IN N
the DT N
2 CD N
groups NNS N
regarding VBG N
the DT N
primary JJ N
outcome NN N
( ( N
a DT N
> NN N
or=10 NN N
% NN N
hematocrit JJ o
drop NN o
occurred VBD N
in IN N
3.4 CD N
% NN N
and CC N
3.7 CD N
% NN N
of IN N
the DT N
participants NNS N
in IN N
the DT N
oxytocin NN i
and CC N
misoprostol NN i
groups NNS N
, , N
P=0.98 NNP N
) ) N
. . N

The DT N
rate NN N
of IN N
use NN o
of IN o
additional JJ o
oxytocin NN o
was VBD N
higher RBR N
in IN N
the DT N
misoprostol NN i
group NN N
( ( N
51 CD N
% NN N
versus IN N
40.5 CD N
% NN N
, , N
P=0.01 NNP N
) ) N
. . N

Shivering VBG o
was VBD N
confined VBN N
to TO N
the DT N
misoprostol NN i
group NN N
( ( N
6.8 CD N
% NN N
) ) N
, , N
and CC N
fever RB N
occurred VBD N
in IN N
12.5 CD N
% NN N
of IN N
the DT N
women NNS N
in IN N
the DT N
misoprostol NN i
group NN N
and CC N
0.3 CD N
% NN N
of IN N
the DT N
women NNS N
in IN N
the DT N
oxytocin NN i
group NN N
. . N

CONCLUSION NNP N
The DT N
routine JJ N
use NN N
of IN N
400 CD N
microg NN N
of IN N
oral JJ N
misoprostol NN i
was VBD N
no DT N
less RBR N
effective JJ N
than IN N
5 CD N
U NNP N
of IN N
intravenous JJ N
oxytocin NNS i
in IN N
reducing VBG N
blood NN o
loss NN o
after IN N
delivery NN N
, , N
as IN N
assessed VBN N
by IN N
change NN N
in IN N
postpartum NN N
hematocrit NN N
. . N

The DT N
adverse JJ N
effects NNS N
of IN N
misoprostol NN i
were VBD N
mild JJ N
and CC N
self-limiting JJ N
. . N

-DOCSTART- -15446660- O O

Faulty NNP N
Japanese JJ N
sentences NNS N
are VBP N
judged VBN N
more RBR N
grammatical JJ i
when WRB N
punctuation NN N
is VBZ N
used VBN N
: : N
negative JJ N
implications NNS N
for IN N
Chomsky NNP i
's POS i
principle NN i
of IN i
Full NNP i
Interpretation NNP i
. . i

88 CD p
adult JJ p
Japanese JJ p
speakers NNS p
judged VBD N
the DT N
grammaticality NN N
of IN N
isolated JJ N
simple JJ N
bitransitive JJ N
sentences NNS N
involving VBG N
an DT N
uninterpretable JJ i
extra JJ i
argument NN i
in IN N
addition NN N
to TO N
three CD N
legitimate JJ i
arguments NNS i
. . i

The DT N
sentences NNS N
thus RB N
violated VBD N
Chomsky NNP N
's POS N
principle NN N
of IN N
Full NNP N
Interpretation NNP N
which WDT N
prohibits VBZ N
the DT N
structure NN N
building NN N
of IN N
a DT N
sentence NN N
including VBG N
uninterpretable JJ N
elements NNS N
. . N

The DT N
primary JJ N
variable NN N
of IN N
interest NN N
was VBD N
the DT N
presence NN N
or CC N
absence NN N
of IN N
punctuation NN N
, , N
i.e. FW N
, , N
commas NN N
, , N
which WDT N
enclosed VBD N
the DT N
extra JJ N
argument NN N
. . N

Findings NNS N
showed VBD N
that IN N
sentences NNS o
with IN N
punctuation NN N
were VBD N
judged VBN N
more RBR N
grammatical JJ i
than IN N
the DT N
ones NNS N
without IN N
punctuation NN N
, , N
with IN N
an DT N
average JJ N
score NN N
of IN N
judged JJ N
grammaticality NN N
exceeding VBG N
3 CD N
on IN N
a DT N
7-point JJ N
scale NN N
( ( N
1 CD N
=least RB N
grammatical JJ N
; : N
7=most CD N
grammatical NN N
) ) N
. . N

This DT N
score NN N
would MD N
not RB N
be VB N
expected VBN N
if IN N
the DT N
speakers NNS N
possess NN N
and CC N
judge NN N
the DT N
sentences NNS N
in IN N
conformity NN N
with IN N
the DT N
principle NN N
of IN N
Full NNP N
Interpretation NNP N
. . N

-DOCSTART- -1524884- O O

Severe JJ o
complications NNS o
of IN N
5-fluorouracil JJ i
and CC i
cisplatin NN i
with IN i
concomitant JJ i
radiotherapy NN i
in IN N
inoperable JJ p
non-metastatic JJ p
squamous JJ p
cell NN p
oesophageal NN p
cancer NN p
after IN N
intubation NN N
-- : N
early JJ N
termination NN N
of IN N
a DT N
prospective JJ N
randomised VBN N
trial NN N
. . N

-DOCSTART- -23410851- O O

Family RB i
economic JJ i
empowerment NN i
and CC N
mental JJ N
health NN N
among IN N
AIDS-affected JJ p
children NNS p
living VBG p
in IN p
AIDS-impacted JJ p
communities NNS p
: : p
evidence NN N
from IN N
a DT N
randomised JJ N
evaluation NN N
in IN N
southwestern JJ p
Uganda NNP p
. . p

OBJECTIVE CC N
The DT N
authors NNS N
examine VBP N
whether IN N
an DT N
innovative JJ N
family NN i
economic JJ i
empowerment NN i
intervention NN N
addresses VBZ N
mental JJ N
health NN N
functioning NN N
of IN N
AIDS-affected JJ p
children NNS p
in IN p
communities NNS p
heavily RB p
impacted VBN p
by IN p
HIV/AIDS NNP p
in IN p
Uganda NNP p
. . p

METHODS NNP N
A NNP N
cluster NN N
randomised VBD N
controlled VBN N
trial NN N
consisting VBG N
of IN N
two CD N
study NN N
arms NNS N
, , N
a DT p
treatment NN i
condition NN i
( ( p
n=179 JJ p
) ) p
and CC p
a DT p
control NN i
condition NN i
( ( p
n=118 JJ p
) ) p
, , N
was VBD N
used VBN N
to TO N
examine VB N
the DT N
impact NN N
of IN N
the DT N
family NN i
economic JJ i
empowerment NN i
intervention NN i
on IN N
children NNS N
's POS N
levels NNS N
of IN N
hopelessness NN N
and CC N
depression NN N
. . N

The DT N
intervention NN N
comprised VBD N
matched JJ i
children NNS i
savings NNS i
accounts NNS i
, , i
financial JJ i
management NN i
workshops NNS i
and CC i
mentorship NN i
. . i

Data NNS N
were VBD N
collected VBN N
at IN N
baseline NN N
and CC N
12 CD N
months NNS N
post-intervention NN N
. . N

RESULTS NNP N
Using VBG N
multivariate JJ N
analysis NN N
with IN N
several JJ N
socioeconomic JJ N
controls NNS N
, , N
the DT N
authors NNS N
find VBP N
that IN N
children NNS N
in IN N
the DT N
treatment NN N
condition NN N
( ( N
receiving VBG N
the DT N
intervention NN N
) ) N
report NN N
significant JJ N
improvement NN N
in IN N
their PRP$ N
mental JJ o
health NN o
functioning NN o
. . o

Specifically RB N
, , N
the DT N
intervention NN N
reduces VBZ N
hopelessness NN o
and CC o
depression NN o
levels NNS o
. . o

On IN N
the DT N
other JJ N
hand NN N
, , N
children NNS N
in IN N
the DT N
control NN i
condition NN N
( ( N
not RB N
receiving VBG N
the DT N
intervention NN N
) ) N
report NN N
no DT N
changes NNS N
on IN N
both DT N
measures NNS N
. . N

CONCLUSIONS VB N
The DT N
findings NNS N
indicate VBP N
that IN N
children NNS p
with IN p
poor JJ p
mental JJ p
health NN p
functioning VBG p
living NN p
in IN p
communities NNS p
affected VBN p
by IN p
HIV/AIDS NNP p
may MD N
benefit VB N
from IN N
innovative JJ N
family NN N
economic JJ N
empowerment NN N
interventions NNS N
. . N

As IN N
measures NNS N
of IN N
mental JJ N
health NN N
functioning NN N
, , N
both DT N
hopelessness NN o
and CC o
depression NN o
have VBP N
long-term JJ N
negative JJ N
psychosocial NN N
and CC N
developmental JJ N
impacts NNS N
on IN N
children NNS N
. . N

These DT N
findings NNS N
have VBP N
implications NNS N
for IN N
public JJ N
health NN N
programmes NNS N
intended VBN N
for IN N
long-term JJ N
care NN N
and CC N
support NN N
of IN N
children NNS p
living VBG p
in IN p
resource JJ p
poor JJ p
AIDS-impacted JJ p
communities NNS p
. . p

-DOCSTART- -15571443- O O

Abstinence NNP o
incentive NN o
effects NNS o
in IN N
a DT N
short-term JJ N
outpatient JJ N
detoxification NN N
program NN N
. . N

Despite IN N
being VBG N
widely RB N
available JJ N
, , N
outpatient JJ N
detoxification NN N
has VBZ N
limited VBN N
efficacy NN N
as IN N
a DT N
stand-alone JJ N
treatment NN N
. . N

This DT N
study NN N
examined VBD N
whether IN N
abstinence-contingent JJ i
incentives NNS i
would MD N
improve VB N
outcomes NNS N
for IN N
patients NNS p
entering VBG p
outpatient JJ p
opiate JJ o
detoxification NN o
. . o

Participants NNS p
( ( p
N NNP p
= NNP p
211 CD p
) ) p
received VBD N
a DT N
100 CD N
US NNP N
dollars NNS N
voucher RB N
on IN N
the DT N
last JJ N
day NN N
of IN N
detoxification NN i
either CC N
contingent NN N
on IN N
opiate NN N
and CC N
cocaine NN N
abstinence NN N
or CC N
noncontingently RB N
. . N

Urine JJ N
samples NNS N
were VBD N
collected VBN N
at IN N
intake NN N
, , N
on IN N
Wednesday NNP N
, , N
Friday NNP N
( ( N
the DT N
last JJ N
day NN N
of IN N
detoxification NN N
) ) N
, , N
and CC N
the DT N
following JJ N
Monday NNP N
. . N

Among IN N
contingent-voucher JJ i
participants NNS N
, , N
31 CD N
% NN N
were VBD N
drug-free JJ o
on IN N
Friday NNP N
compared VBN N
with IN N
18 CD N
% NN N
of IN N
noncontingent NN N
controls NNS N
( ( N
Z NNP N
= NNP N
2.4 CD N
, , N
p NN N
< NNP N
.05 NNP N
) ) N
. . N

Few JJ N
( ( N
12-13 CD N
% NN N
) ) N
participants NNS N
tested VBN N
negative JJ o
on IN N
Monday NNP N
. . N

Results NNP N
support VBD N
the DT N
ability NN N
of IN N
vouchers NNS N
to TO N
produce VB N
modest JJ o
improvements NNS o
in IN o
abstinence NN o
initiation NN o
rates NNS o
during IN N
brief JJ N
detoxification NN N
but CC N
suggest VBP N
that IN N
additional JJ N
interventions NNS N
are VBP N
needed VBN N
to TO N
sustain VB N
improvements NNS N
. . N

-DOCSTART- -19171500- O O

A DT N
dose-ranging JJ N
study NN N
of IN N
pramipexole NN i
for IN N
the DT N
symptomatic JJ N
treatment NN N
of IN N
restless JJ p
legs JJ p
syndrome NN p
: : p
polysomnographic JJ N
evaluation NN N
of IN N
periodic JJ o
leg NN o
movements NNS o
and CC N
sleep JJ N
disturbance NN N
. . N

OBJECTIVE UH N
To TO N
evaluate VB N
, , N
both DT N
polysomnographically RB N
and CC N
by IN N
subjective JJ N
scales NNS N
, , N
the DT N
efficacy NN o
and CC N
safety NN o
profile NN N
of IN N
pramipexole NN i
for IN N
restless JJ p
legs JJ p
syndrome NN p
( ( p
RLS NNP p
) ) p
via IN N
a DT N
3-week JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
, , N
parallel-group JJ N
, , N
dose-ranging JJ N
study NN N
. . N

METHODS NNP N
At IN N
baseline NN N
and CC N
after IN N
3 CD N
weeks NNS N
, , N
periodic JJ o
limb NN o
movements NNS o
( ( o
PLM NNP o
) ) o
and CC N
sleep JJ o
parameters NNS o
were VBD N
assessed VBN N
by IN N
polysomnography NN o
, , i
and CC i
patients NNS i
self-assessed JJ i
their PRP$ i
sleep JJ o
disturbance NN o
and CC i
overall JJ i
RLS NNP o
severity NN o
using VBG i
the DT i
international JJ i
RLS NNP i
study NN i
group NN i
rating NN i
scale NN i
( ( i
IRLS NNP i
) ) i
. . N

Four CD i
pramipexole NN i
doses NNS i
were VBD i
evaluated VBN i
: : i
0.125 CD i
, , i
0.25 CD i
, , i
0.50 CD i
, , i
and CC i
0.75mg/d CD i
. . i

Data NNS N
from IN N
107 CD p
patients NNS p
were VBD N
included VBN N
in IN N
the DT N
intent-to-treat NN N
( ( N
ITT NNP N
) ) N
analysis NN N
. . N

RESULTS NNP N
For IN N
pramipexole JJ i
recipients NNS N
, , N
the DT N
primary JJ N
outcome NN N
measure NN N
, , N
PLM NNP o
per IN o
hour NN o
in IN o
bed NN o
asleep NN o
or CC o
awake NN o
( ( N
the DT N
PLM NNP N
index NN N
, , N
or CC N
PLMI NNP N
) ) N
, , N
decreased VBN N
by IN N
a DT N
median NN N
of IN N
-26.55 NN N
to TO N
-52.70 VB N
depending VBG N
on IN N
dosage NN N
group NN N
, , N
vs. FW N
-3.00 NN N
for IN N
placebo NN i
( ( N
p JJ N
< VBP N
0.01 CD N
or CC N
0.001 CD N
for IN N
each DT N
group NN N
vs. FW N
placebo NN N
; : N
Wilcoxon-Mann-Whitney NNP N
test NN N
) ) N
. . N

Improvements NNS N
in IN N
the DT N
secondary JJ N
endpoints NNS o
of IN o
PLM NNP o
while IN o
asleep RB o
and CC o
while IN o
awake NN o
were VBD N
also RB N
significantly RB N
superior JJ N
for IN N
pramipexole NN N
. . N

At IN N
3 CD N
weeks NNS N
, , N
all DT N
pramipexole NN i
doses NNS N
reduced VBD N
the DT N
median NN o
for IN o
PLM NNP o
while IN o
asleep RB o
to TO N
levels NNS N
considered VBN N
normal JJ N
( ( N
< JJ N
5PLM/h CD N
) ) N
. . N

Except IN N
for IN N
delta-sleep JJ o
time NN o
and CC o
awakenings/arousals NNS o
, , N
sleep JJ N
parameters NNS N
remained VBD N
unchanged JJ N
or CC N
favored JJ N
pramipexole NN i
. . i

Median JJ o
sleep JJ o
latency NN o
was VBD N
reduced VBN N
by IN N
-5.00 NN N
to TO N
-11.75min VB N
in IN N
the DT N
pramipexole NN N
groups NNS N
, , N
vs. FW N
-2.00 NN N
for IN N
placebo NN i
( ( N
p JJ N
< VBP N
0.05 CD N
for IN N
all DT N
groups NNS N
except IN N
0.25mg/d CD N
) ) N
. . N

Median JJ o
total JJ o
sleep JJ o
time NN o
increased VBN N
by IN N
25.75-66.75min JJ N
, , N
vs. FW N
25.50 CD N
( ( N
p NN N
< VBZ N
0.05 CD N
for IN N
0.50mg/d CD N
) ) N
, , N
and CC N
median JJ N
time NN N
in IN N
stages NNS N
2-4/rapid JJ o
eye NN o
movement NN o
( ( o
REM NNP o
) ) o
sleep NN o
increased VBN N
by IN N
37.00-68.00min JJ N
, , N
vs. FW N
26.75 CD N
( ( N
p NN N
< VBZ N
0.05 CD N
for IN N
0.50mg/d CD N
) ) N
. . N

By IN N
subjective JJ N
IRLS NNP N
ratings NNS N
, , N
all DT N
pramipexole JJ i
doses NNS N
were VBD N
significantly RB N
superior JJ N
to TO N
placebo VB i
. . i

Safety NNP N
analysis NN N
demonstrated VBD N
no DT N
dose-dependent JJ N
increase NN N
in IN N
adverse JJ o
events NNS o
, , N
and CC N
no DT N
drug-related JJ o
increase NN o
in IN o
daytime JJ o
somnolence NN o
was VBD N
observed VBN N
. . N

CONCLUSIONS NNP N
Pramipexole NNP i
is VBZ N
effective JJ o
and CC N
well RB o
tolerated VBN o
in IN N
RLS NNP N
, , N
most RBS N
notably RB N
among IN N
objective JJ N
measures NNS N
, , N
for IN N
reducing VBG o
PLM NNP o
and CC N
decreasing VBG o
sleep JJ o
latency NN o
. . o

Although IN N
other JJ N
sleep JJ N
parameters NNS N
showed VBD N
lesser JJR N
, , N
usually RB N
insignificant JJ N
change NN N
, , N
patients NNS N
' POS N
subjective JJ N
ratings NNS N
of IN N
RLS NNP o
severity NN o
and CC N
sleep JJ o
disturbance NN o
were VBD N
significantly RB N
improved VBN N
( ( N
p0.0023 NN N
) ) N
. . N

-DOCSTART- -25437533- O O

Time NN N
to TO N
onset VB N
of IN N
clinically RB N
meaningful JJ N
improvement NN N
with IN N
tadalafil JJ i
5 CD N
mg NN N
once RB N
daily JJ N
for IN N
lower JJR p
urinary JJ p
tract NN p
symptoms NNS p
secondary JJ p
to TO p
benign VB p
prostatic JJ p
hyperplasia NN p
: : p
analysis NN N
of IN N
data NNS N
pooled VBN N
from IN N
4 CD N
pivotal JJ N
, , N
double-blind JJ N
, , N
placebo NN i
controlled VBD N
studies NNS N
. . N

PURPOSE NNP N
Tadalafil NNP i
once RB N
daily RB N
for IN N
lower JJR N
urinary JJ N
tract NN N
symptoms NNS N
secondary JJ N
to TO N
benign VB N
prostatic JJ N
hyperplasia NN N
consistently RB N
shows VBZ N
statistically RB N
significant JJ N
I-PSS JJ N
improvements NNS N
. . N

However RB N
, , N
physicians NNS N
and CC N
patients NNS N
wish JJ N
to TO N
know VB o
whether IN N
tadalafil JJ i
provides VBZ N
rapid JJ N
, , N
clinically RB N
meaningful JJ N
improvement NN N
in IN N
lower JJR N
urinary JJ N
tract NN N
symptoms NNS N
. . N

In IN N
this DT N
post NN N
hoc NN N
analysis NN N
we PRP N
integrated VBD N
results NNS N
from IN N
4 CD N
placebo NN i
controlled VBN N
studies NNS N
to TO N
determine VB N
the DT N
duration NN N
of IN N
tadalafil NN i
once RB N
daily RB N
required VBN N
to TO N
achieve VB N
clinically RB N
meaningful JJ N
improvement NN N
. . N

MATERIALS NNP N
AND CC N
METHODS NNP N
We PRP N
performed VBD N
post NN N
hoc NN N
analysis NN N
of IN N
data NNS N
integrated VBN N
from IN N
4 CD N
double-blind JJ N
studies NNS N
of IN N
tadalafil NN i
5 CD N
mg NN N
and CC i
placebo NN i
once RB N
daily RB N
in IN N
742 CD p
and CC p
735 CD p
men NNS p
, , p
respectively RB p
, , p
45 CD p
years NNS p
old JJ p
or CC p
older JJR p
with IN p
total JJ p
I-PSS JJ p
13 CD p
or CC p
greater JJR p
. . p

Two CD N
clinically RB N
meaningful JJ N
improvement NN N
categories NNS N
were VBD N
assessed VBN N
, , N
including VBG N
1 CD o
) ) o
3-point CD o
or CC o
greater JJR o
baseline NN o
to TO o
end VB o
point NN o
total JJ o
I-PSS JJ o
improvement NN o
and CC o
2 CD o
) ) o
25 CD o
% NN o
or CC o
greater JJR o
baseline NN o
to TO o
end VB o
point NN o
total JJ o
I-PSS JJ o
improvement NN o
. . o

I-PSS NNP o
was VBD N
assessed VBN N
at IN N
weeks NNS N
4 CD N
, , N
8 CD N
and CC N
12 CD N
in IN N
all DT N
studies NNS N
, , N
week NN N
1 CD N
in IN N
2 CD N
and CC N
week NN N
2 CD N
in IN N
1 CD N
. . N

Results NNS N
in IN N
men NNS N
treated VBN N
with IN N
tadalafil NN i
who WP N
showed VBD N
clinically RB N
meaningful JJ N
improvement NN N
( ( N
responders NNS N
) ) N
were VBD N
further RB N
examined VBN N
to TO N
determine VB N
the DT N
earliest JJS o
time NN o
to TO o
clinically RB o
meaningful JJ o
improvement NN o
. . o

RESULTS NNP N
Of IN N
742 CD N
tadalafil NNS i
treated VBD N
patients NNS N
513 CD N
( ( N
69.1 CD N
% NN N
) ) N
and CC N
444 CD N
( ( N
59.8 CD N
% NN N
) ) N
demonstrated VBD N
category JJ N
1 CD N
and CC N
2 CD N
clinically RB o
meaningful JJ o
improvement NN o
, , N
respectively RB N
, , N
at IN N
the DT N
study NN N
end NN N
point NN N
. . N

Of IN N
234 CD N
category NN N
1 CD N
responders NNS N
with IN N
week NN N
1 CD N
assessments NNS N
140 CD N
( ( N
59.8 CD N
% NN N
) ) N
achieved VBD N
clinically RB o
meaningful JJ o
improvement NN o
by IN N
week NN N
1 CD N
and CC N
407 CD N
of IN N
the DT N
total NN N
of IN N
513 CD N
category NN N
1 CD N
responders NNS N
( ( N
79.3 CD N
% NN N
) ) N
showed VBD N
it PRP N
by IN N
week NN N
4 CD N
. . N

Of IN N
the DT N
205 CD N
category NN N
2 CD N
responders NNS N
with IN N
week NN N
1 CD N
assessments NNS N
103 CD N
( ( N
50.2 CD N
% NN N
) ) N
achieved VBD N
clinically RB o
meaningful JJ o
improvement NN o
by IN N
week NN N
1 CD N
while IN N
322 CD N
of IN N
the DT N
444 CD N
category NN N
2 CD N
responders NNS N
( ( N
72.5 CD N
% NN N
) ) N
did VBD N
so RB N
by IN N
week NN N
4 CD N
. . N

CONCLUSIONS NNP N
Tadalafil NNP i
5 CD N
mg NN N
once RB N
daily RB N
led VBN N
to TO N
clinically RB N
meaningful JJ N
improvement NN N
in IN N
approximately RB N
two-thirds NNS N
of IN N
men NNS N
with IN N
lower JJR p
urinary JJ p
tract NN p
symptoms NNS p
secondary JJ N
to TO N
benign VB N
prostatic JJ N
hyperplasia NN N
. . N

More JJR N
than IN N
half NN N
of IN N
this DT N
group NN N
of IN N
tadalafil NN i
treated VBN N
responders NNS N
achieved VBD N
clinically RB N
meaningful JJ N
improvement NN N
after IN N
1 CD N
week NN N
of IN N
therapy NN N
and CC N
more JJR N
than IN N
70 CD N
% NN N
did VBD N
so RB N
within IN N
4 CD N
weeks NNS N
. . N

-DOCSTART- -19912211- O O

Bipolar JJ i
transurethral JJ i
resection NN i
of IN i
the DT i
prostate NN i
causes VBZ N
less RBR N
bleeding VBG N
than IN N
the DT N
monopolar JJ i
technique NN i
: : i
a DT p
single-centre JJ p
randomized JJ p
trial NN p
of IN p
202 CD p
patients NNS p
. . p

OBJECTIVE NNP N
To TO N
compare VB N
bipolar JJ i
with IN N
the DT N
conventional JJ i
monopolar JJ i
transurethral JJ i
resection NN i
of IN i
the DT i
prostate NN i
( ( i
TURP NNP i
) ) i
for IN N
blood NN N
loss NN N
and CC N
speed NN N
of IN N
resection NN N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
In IN N
all DT N
, , N
202 CD p
consecutive JJ p
patients NNS p
from IN p
the DT p
hospital NN p
waiting VBG p
list NN p
were VBD N
randomized VBN N
to TO N
undergo VB i
TURP NNP i
using VBG i
either CC i
a DT i
bipolar JJ i
system NN i
( ( i
Surgmaster NNP i
TURis NNP i
, , i
Olympus NNP i
, , i
Tokyo NNP i
, , i
Japan NNP i
) ) i
or CC i
a DT i
monopolar JJ i
system NN i
( ( i
24 CD i
F NNP i
, , i
Storz NNP i
, , i
T?bingen NNP i
, , i
Germany NNP i
) ) i
. . i

The DT N
blood NN N
loss NN N
during IN N
and CC N
after IN N
surgery NN N
was VBD N
measured VBN N
using VBG N
a DT N
photometer NN i
. . i

Other JJ N
variables NNS N
compared VBN N
included VBD N
indices NNS N
of IN N
resection NN N
speed NN N
and CC N
transfusion NN N
rate NN N
. . N

RESULTS CC N
There EX N
were VBD N
no DT N
statistically RB N
significant JJ N
differences NNS N
in IN o
operative JJ o
duration NN o
, , o
resection NN o
weight NN o
, , o
resection NN o
speed NN o
or CC o
radicality NN o
of IN o
resection NN o
. . o

However RB N
, , N
the DT o
median JJ o
blood NN o
loss NN o
was VBD N
235 CD N
mL NN N
for IN N
the DT N
bipolar NN N
and CC N
350 CD N
mL NN N
for IN N
monopolar JJ N
TURP NNP N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

The DT N
decrease NN N
in IN o
blood NN o
haemoglobin NN o
concentration NN o
during IN N
the DT N
day NN N
of IN N
surgery NN N
was VBD N
smaller JJR N
in IN N
the DT N
bipolar JJ N
group NN N
( ( N
5.5 CD N
% NN N
vs JJ N
9.6 CD N
% NN N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

Fewer JJR N
patients NNS N
were VBD N
transfused VBN N
with IN N
erythrocytes NNS N
( ( N
4 CD N
% NN N
vs JJ N
11 CD N
% NN N
, , N
P NNP N
< NNP N
0.01 CD N
) ) N
, , N
which WDT N
can MD N
be VB N
explained VBN N
by IN N
the DT N
much RB N
lower JJR N
75th CD N
percentile NN N
for IN o
blood NN o
loss NN o
in IN N
the DT N
bipolar JJ N
group NN N
( ( N
at IN N
472 CD N
vs NN N
855 CD N
mL NN N
, , N
respectively RB N
) ) N
. . N

CONCLUSIONS NNP i
Bipolar NNP i
TURP NNP i
using VBG i
the DT i
TURis NNP i
system NN i
was VBD N
performed VBN N
with IN N
the DT N
same JJ N
speed NN N
as IN i
monopolar JJ i
TURP NNP i
but CC N
caused VBD N
34 CD N
% NN N
less JJR o
bleeding NN o
, , o
the DT N
difference NN N
being VBG N
greatest JJS N
( ( N
81 CD N
% NN N
) ) N
for IN N
the DT N
largest JJS N
blood NN N
losses NNS N
. . N

Bipolar NNP i
TURP NNP i
also RB N
required VBD N
fewer JJR N
erythrocyte NN N
transfusions NNS N
than IN N
the DT N
conventional JJ N
monopolar NN N
technique NN N
. . N

-DOCSTART- -14625812- O O

Twenty-four CD N
vs. IN N
forty-eight JJ N
weeks NNS N
of IN N
re-therapy NN N
with IN N
interferon NN i
alpha NN i
2b CD i
and CC i
ribavirin VB i
in IN N
interferon NN p
alpha NN p
monotherapy NN p
relapsers NNS p
with IN p
chronic JJ p
hepatitis NN p
C. NNP p
BACKGROUND/AIM NNP N
Roughly NNP N
50 CD N
% NN N
of IN N
patients NNS N
with IN N
chronic JJ N
hepatitis NN N
C NNP N
, , N
who WP N
relapsed VBD N
after IN N
a DT N
previous JJ N
monotherapy NN N
with IN N
interferon NN N
alpha NN N
, , N
will MD N
respond VB N
in IN N
a DT N
sustained JJ N
fashion NN N
to TO N
24 CD N
weeks NNS N
of IN N
re-therapy NN N
with IN N
the DT N
combination NN i
of IN i
interferon NN i
alpha NN i
plus CC i
ribavirin NN i
. . i

Whether CC N
prolonging VBG N
treatment NN N
duration NN N
to TO N
48 CD N
weeks NNS N
will MD N
further RB N
increase VB N
sustained JJ N
response NN N
rates NNS N
remains VBZ N
ill JJ N
defined VBN N
. . N

In IN N
this DT N
randomised VBN N
controlled VBD N
pilot JJ N
trial NN N
we PRP N
compared VBN N
the DT N
efficacy NN o
and CC o
tolerability NN o
of IN N
a DT N
24 CD N
week NN N
with IN N
that DT N
of IN N
a DT N
48 CD N
week NN N
course NN N
of IN N
combination NN N
therapy NN N
with IN N
interferon NN N
alpha NN N
and CC N
ribavirin NN N
in IN N
interferon NN p
monotherapy NN p
relapsers NNS p
with IN p
chronic JJ p
hepatitis NN p
C. NNP p
METHODS NNP N
Interferon NNP p
alpha NN p
monotherapy NN p
relapsers NNS p
with IN p
chronic JJ p
hepatitis NN p
C NNP p
were VBD N
randomised VBN N
to TO N
receive VB N
interferon NN i
alpha NN i
2b CD i
( ( N
3 CD N
x RB N
3 CD N
MIU NNP N
sc JJ N
weekly RB N
) ) N
and CC N
oral JJ i
ribavirin NN i
( ( N
1000/1200 CD N
mg NNS N
po JJ N
daily RB N
) ) N
for IN N
either DT N
24 CD N
weeks NNS N
or CC N
48 CD N
weeks NNS N
. . N

Virological JJ N
response NN N
was VBD N
evaluated VBN N
by IN N
HCV NNP N
RNA NNP N
PCR NNP N
at IN N
week NN N
10 CD N
( ( N
initial JJ N
response NN N
) ) N
, , N
at IN N
the DT N
end NN N
of IN N
treatment NN N
( ( N
end JJ N
of- JJ N
treatment NN N
response NN N
) ) N
and CC N
at IN N
the DT N
end NN N
of IN N
24 CD N
weeks NNS N
follow-up JJ N
( ( N
sustained JJ N
response NN N
) ) N
. . N

Only JJ p
patients NNS p
with IN p
negative JJ p
HCV NNP p
RNA NNP p
at IN p
week NN p
10 CD p
continued VBD p
treatment NN p
. . p

Adverse JJ o
events NNS o
were VBD N
recorded VBN N
at IN N
regular JJ N
intervals NNS N
. . N

RESULTS NNP N
Thirty-seven JJ p
patients NNS p
were VBD p
enrolled VBN p
, , p
19 CD p
( ( p
6 CD p
females NNS p
, , p
median JJ p
age NN p
43 CD p
) ) p
in IN p
the DT p
24 CD p
week NN p
and CC p
18 CD p
( ( p
5 CD p
females NNS p
, , p
median JJ p
age NN p
40 CD p
) ) p
in IN p
the DT p
48 CD p
week NN p
treatment NN p
arm NN p
. . p

Baseline JJ p
characteristics NNS p
were VBD p
similar JJ p
in IN p
both DT p
groups NNS p
. . p

At IN N
treatment NN N
week NN N
10 CD N
, , N
12/19 CD N
( ( N
63 CD N
% NN N
) ) N
in IN N
the DT N
24 CD N
week NN N
group NN N
and CC N
14/18 CD N
( ( N
78 CD N
% NN N
) ) N
patients NNS N
in IN N
the DT N
48 CD N
week NN N
group NN N
had VBD N
lost VBN o
HCV NNP o
RNA NNP o
in IN o
serum NN o
( ( N
p JJ N
= NNP N
0.33 CD N
) ) N
. . N

All DT N
initial JJ N
responders NNS N
remained VBD N
HCV NNP o
RNA NNP o
negative JJ o
throughout IN N
the DT N
treatment NN N
period NN N
. . N

Sustained VBN o
response NN o
rates NNS o
were VBD N
10/19 CD N
( ( N
53 CD N
% NN N
) ) N
in IN N
the DT N
24 CD N
week NN N
group NN N
and CC N
13/18 CD N
( ( N
72 CD N
% NN N
) ) N
in IN N
the DT N
48 CD N
week NN N
group NN N
( ( N
p JJ N
= NNP N
0.31 CD N
) ) N
. . N

Three CD p
patients NNS p
discontinued VBN p
treatment NN p
early JJ p
( ( p
two CD p
due JJ p
to TO p
moderate VB o
adverse JJ o
events NNS o
, , p
one CD p
due JJ p
to TO p
non-compliance NN p
) ) p
. . p

Dose JJ N
modifications NNS N
were VBD N
necessary JJ N
in IN N
9 CD N
patients NNS N
, , N
4 CD N
in IN N
the DT N
24 CD N
week NN N
and CC N
5 CD N
in IN N
the DT N
48 CD N
week NN N
group NN N
for IN N
anaemia NN o
, , o
neutropenia NN o
, , o
nausea NN o
and CC o
depression NN o
, , N
respectively RB N
. . N

CONCLUSION NNP N
Prolonging NNP N
interferon NN N
/ NNP N
ribavirin NN N
combination NN N
therapy NN N
in IN N
interferon NN N
alpha NN N
monotherapy NN N
relapsers NNS N
with IN N
chronic JJ N
hepatitis NN N
C NNP N
from IN N
24 CD N
to TO N
48 CD N
weeks NNS N
may MD N
increase VB N
sustained JJ o
response NN o
rates NNS o
. . o

Larger NNP N
controlled VBD N
trials NNS N
using VBG N
pegylated JJ N
interferon NN N
alpha NN N
and CC N
ribavirin NN N
in IN N
relapsers NNS p
with IN p
chronic JJ p
hepatitis NN p
C NNP p
seem VBP N
warranted VBN N
. . N

-DOCSTART- -18051010- O O

Effect NN N
of IN N
a DT N
ferrule NN i
and CC N
increased VBD N
clinical JJ N
crown NN N
length NN N
on IN N
the DT N
in IN N
vitro JJ N
fracture NN N
resistance NN N
of IN N
premolars NNS p
restored VBN p
using VBG p
two CD p
dowel-and-core JJ p
systems NNS p
. . p

This DT N
study NN N
investigated VBD N
the DT N
effect NN N
of IN N
a DT N
crown-lengthening JJ i
ferrule NN i
on IN N
the DT N
fracture NN N
resistance NN N
of IN N
endodontically-treated JJ p
teeth NNS p
restored VBN p
with IN p
two CD p
dowel-core JJ p
systems NNS p
. . p

Thirty-two NNP p
extracted VBD p
mandibular JJ p
first JJ p
premolars NNS p
were VBD N
sectioned VBN N
perpendicular JJ N
to TO N
the DT N
long JJ N
axis NN N
at IN N
a DT N
point NN N
1.0 CD N
mm NN N
occlusal NN N
to TO N
the DT N
buccal JJ N
cementoenamel NN N
junction NN N
. . N

Following VBG N
endodontic JJ N
treatment NN N
, , N
the DT N
teeth NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
four CD N
groups NNS N
: : N
cast VBN i
Ni-Cr JJ i
alloy NN i
dowel-core NN i
with IN i
no DT i
ferrule NN i
( ( i
Group NNP i
A1 NNP i
) ) i
, , i
cast VBD i
Ni-Cr JJ i
alloy NN i
dowel-core NN i
with IN i
2.0 CD i
mm NNS i
ferrule NN i
( ( i
Group NNP i
A2 NNP i
) ) i
, , i
prefabricated VBN i
carbon NN i
fiber-reinforced JJ i
dowel-resin NN i
core NN i
with IN i
no DT i
ferrule NN i
( ( i
Group NNP i
B1 NNP i
) ) i
and CC N
carbon JJ i
fiber-reinforced JJ i
dowel-resin NN i
core NN i
with IN i
2.0 CD i
mm NNS i
ferrule NN i
( ( N
Group NNP N
B2 NNP N
) ) N
. . N

Each DT N
specimen NN N
was VBD N
embedded VBN N
in IN N
a DT N
self-cured JJ N
acrylic JJ N
resin NN N
block NN N
from IN N
2.0 CD N
mm JJ N
apical JJ N
to TO N
the DT N
margins NNS N
of IN N
a DT N
cast JJ N
Ni-Cr JJ N
alloy NN N
crown NN N
, , N
then RB N
loaded VBD N
at IN N
150 CD N
degrees NNS N
from IN N
the DT N
long JJ N
axis NN N
in IN N
a DT N
universal JJ N
testing VBG N
machine NN N
at IN N
a DT N
crosshead JJ N
speed NN N
of IN N
1.0 CD N
mm/minute NN N
until IN N
fracture NN N
. . N

The DT N
data NNS N
were VBD N
recorded VBN N
and CC N
analyzed VBN N
using VBG N
ANOVA NNP o
and CC o
Fisher NNP o
's POS o
exact NN o
tests NNS o
, , N
with IN N
alpha JJ N
= $ N
0.05 CD N
. . N

Mean JJ o
failure NN o
loads NNS o
( ( o
kN NN o
) ) o
for IN N
the DT N
A1 NNP N
, , N
A2 NNP N
, , N
B1 NNP N
and CC N
B2 NNP N
Groups NNP N
were VBD N
: : N
1.46 CD N
( ( N
S.D NNP N
. . N

0.45 CD N
) ) N
, , N
1.07 CD N
( ( N
0.21 CD N
) ) N
, , N
1.13 CD N
( ( N
0.30 CD N
) ) N
and CC N
1.02 CD N
( ( N
0.27 CD N
) ) N
. . N

The DT N
teeth NNS N
restored VBD N
with IN N
cast JJ i
Ni-Cr JJ i
dowel-cores NNS i
and CC i
2.0 CD i
mm NN i
ferrules NNS i
demonstrated VBD N
significantly RB N
lower JJR N
fracture NN o
strengths NNS o
, , N
p VBP N
= JJ N
0.04 CD N
. . N

There EX N
were VBD N
significant JJ N
differences NNS N
in IN N
the DT N
root NN o
fracture NN o
patterns VBZ o
between IN N
the DT N
two CD N
dowel NN N
systems NNS N
, , N
with IN N
the DT N
carbon NN i
fiber-reinforced JJ i
dowel-resin NN i
core NN i
system NN i
, , N
being VBG N
the DT N
less JJS N
severe JJ N
p NN N
< VBD N
0.05 CD N
. . N

Crown NNP i
lengthening VBG i
with IN N
a DT N
2.0 CD i
mm NN i
apical JJ i
extended VBD i
ferrule NN i
resulted VBD N
in IN N
reduced JJ N
fracture NN o
strengths NNS o
for IN N
endodontically-treated JJ N
teeth NNS N
restored VBN N
using VBG N
two CD N
dowel-core JJ N
systems NNS N
and CC N
cast JJ N
metal NN N
crowns NNS N
. . N

The DT N
carbon NN N
fiber-reinforced JJ N
dowel-resin NN N
core NN N
system NN N
reduced VBD N
the DT N
severity NN N
of IN N
the DT N
root NN p
fractures NNS p
. . p

-DOCSTART- -23510581- O O

Effects NNS N
of IN N
intranasal NN i
oxytocin NN i
on IN N
the DT N
neural JJ N
basis NN N
of IN N
face NN N
processing NN N
in IN N
autism NN p
spectrum NN p
disorder NN p
. . p

BACKGROUND NNP N
Autism NNP p
spectrum NN p
disorder NN p
( ( p
ASD NNP p
) ) p
is VBZ N
associated VBN N
with IN N
altered JJ N
face NN N
processing NN N
and CC N
decreased JJ N
activity NN N
in IN N
brain NN N
regions NNS N
involved VBN N
in IN N
face NN N
processing NN N
. . N

The DT N
neuropeptide JJ i
oxytocin NN i
has VBZ N
been VBN N
shown VBN N
to TO N
promote VB N
face NN N
processing NN N
and CC N
modulate NN N
brain NN N
activity NN N
in IN N
healthy JJ p
adults NNS p
. . p

The DT N
present JJ N
study NN N
examined VBD N
the DT N
effects NNS N
of IN N
oxytocin NN i
on IN N
the DT N
neural JJ N
basis NN N
of IN N
face NN N
processing NN N
in IN N
adults NNS p
with IN p
Asperger NNP p
syndrome NN p
( ( p
AS IN p
) ) p
. . p

METHODS NNP N
A NNP N
group NN N
of IN N
14 CD p
individuals NNS p
with IN p
AS NNP p
and CC p
a DT p
group NN p
of IN p
14 CD p
neurotypical JJ p
control NN p
participants NNS p
performed VBD N
a DT N
face-matching JJ N
and CC N
a DT N
house-matching JJ N
task NN N
during IN N
functional JJ N
magnetic JJ N
resonance NN N
imaging NN N
. . N

The DT N
effects NNS N
of IN N
a DT N
single JJ N
dose NN N
of IN N
24 CD N
IU NNP N
intranasally RB N
administered VBD N
oxytocin NNS i
were VBD N
tested VBN N
in IN N
a DT N
randomized JJ N
, , N
placebo-controlled JJ i
, , N
within-subject JJ N
, , N
cross-over JJ N
design NN N
. . N

RESULTS NNP N
Under IN N
placebo NN i
, , N
the DT N
AS NNP N
group NN N
showed VBD N
decreased JJ N
activity NN o
in IN o
the DT o
right JJ o
amygdala NN o
, , o
fusiform NN o
gyrus NN o
, , o
and CC o
inferior JJ o
occipital JJ o
gyrus NN o
compared VBN N
with IN N
the DT N
control NN N
group NN N
during IN N
face NN N
processing NN N
. . N

After IN N
oxytocin JJ N
treatment NN N
, , N
right JJ o
amygdala NN o
activity NN o
to TO o
facial JJ o
stimuli NNS o
increased VBN N
in IN N
the DT N
AS NNP N
group NN N
. . N

CONCLUSIONS NNP N
These DT N
findings NNS N
indicate VBP N
that IN N
oxytocin NN N
increases VBZ N
the DT N
saliency NN N
of IN N
social JJ N
stimuli NNS N
and CC N
in IN N
ASD NNP p
and CC N
suggest VBP N
that IN N
oxytocin NN i
might MD N
promote VB N
face NN N
processing NN N
and CC N
eye NN N
contact NN N
in IN N
individuals NNS N
with IN N
ASD NNP p
as IN N
prerequisites NNS N
for IN N
neurotypical JJ N
social JJ N
interaction NN N
. . N

-DOCSTART- -22370992- O O

Effects NNS N
of IN N
large JJ N
doses NNS N
of IN N
arachidonic JJ i
acid NN i
added VBD N
to TO N
docosahexaenoic VB i
acid NN i
on IN N
social JJ p
impairment NN p
in IN p
individuals NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
: : p
a DT N
double-blind NN N
, , N
placebo-controlled JJ i
, , N
randomized JJ N
trial NN N
. . N

Autism NNP N
spectrum NN N
disorders NNS N
are VBP N
a DT N
neurodevelopmental JJ N
disorders NNS N
with IN N
reduced JJ N
cortical JJ N
functional JJ N
connectivity NN N
relating VBG N
to TO N
social JJ N
cognition NN N
. . N

Polyunsaturated VBN i
fatty JJ i
acids NNS i
arachidonic JJ i
acid NN i
( ( i
ARA NNP i
) ) i
and CC N
docosahexaenoic JJ i
acid NN i
( ( i
DHA NNP i
) ) i
may MD N
have VB N
key JJ N
role NN N
in IN N
brain NN N
network NN N
maturation NN N
. . N

In IN N
particularly RB N
, , N
ARA NNP i
is VBZ N
important JJ N
in IN N
signal JJ N
transduction NN N
related VBN N
to TO N
neuronal JJ N
maturation NN N
. . N

Supplementation NN N
with IN N
larger JJR N
ARA NNP i
doses VBZ i
added VBN i
to TO i
DHA NNP i
may MD N
therefore VB N
mitigate VB N
social JJ N
impairment NN N
. . N

In IN N
a DT N
16-week JJ N
, , N
double-blind JJ N
, , N
randomized VBN N
, , N
placebo-controlled JJ i
trial NN N
, , N
we PRP N
evaluated VBD N
the DT N
efficacy NN N
of IN N
supplementation NN N
with IN N
large JJ N
doses NNS N
of IN N
ARA NNP i
added VBD i
to TO i
DHA NNP i
( ( i
n JJ i
= NNP i
7 CD i
) ) i
or CC p
placebo NN i
( ( i
n JJ i
= NNP i
6 CD i
) ) i
in IN p
13 CD p
participants NNS p
( ( p
mean JJ p
age NN p
, , p
14.6 CD p
[ NN p
SD NNP p
, , p
5.9 CD p
] CD p
years NNS p
) ) p
. . p

To TO N
examine VB N
underlying JJ N
mechanisms NNS N
underlying VBG N
the DT N
effect NN N
of IN N
our PRP$ N
supplementation NN N
regimen NNS N
, , N
we PRP N
examined VBD N
plasma JJ o
levels NNS o
of IN o
antioxidants NNS o
transferrin JJ o
and CC o
superoxide JJ o
dismutase NN o
, , N
which WDT N
are VBP N
useful JJ N
markers NNS N
of IN N
signal JJ N
transduction NN N
. . N

The DT N
outcome NN N
measures NNS N
were VBD N
the DT N
Social NNP o
Responsiveness NNP o
Scale NNP o
and CC o
the DT o
Aberrant NNP o
Behavior NNP o
Checklist-Community NNP o
. . o

Repeated-measures JJ N
analysis NN N
of IN N
variance NN N
revealed VBD N
that IN N
our PRP$ N
supplementation NN N
regimen NNS N
significantly RB N
improved VBN N
Aberrant NNP o
Behavior NNP o
Checklist-Community-measured NNP o
social JJ o
withdrawal NN o
and CC N
Social NNP o
Responsiveness NNP o
Scale-measured JJ o
communication NN o
. . o

Treatment NNP N
effect NN N
sizes NNS N
were VBD N
more RBR N
favorable JJ N
for IN N
the DT N
treatment NN N
group NN N
compared VBN N
with IN N
the DT N
placebo NN i
group NN N
( ( N
communication NN N
: : N
treatment NN N
groups NNS N
, , N
0.87 CD N
vs NN N
, , N
placebo NN i
, , N
0.44 CD N
; : N
social JJ N
withdrawal NN N
: : N
treatment NN N
groups NNS N
, , N
0.88 CD N
, , N
vs NN N
placebo NN i
, , N
0.54 CD N
) ) N
. . N

There EX N
was VBD N
a DT N
significant JJ N
difference NN N
in IN N
the DT N
change NN o
in IN o
plasma NN o
transferrin NN o
levels NNS o
and CC N
a DT N
trend NN N
toward IN N
a DT N
significant JJ N
difference NN N
in IN N
the DT N
change NN N
in IN N
plasma JJ o
superoxide JJ o
dismutase NN o
levels NNS o
between IN N
the DT N
2 CD N
groups NNS N
. . N

This DT N
preliminary JJ N
study NN N
suggests VBZ N
that IN N
supplementation NN N
with IN N
larger JJR N
ARA NNP i
doses VBZ i
added VBN i
to TO i
DHA NNP i
improves NNS N
impaired VBD N
social JJ o
interaction NN o
in IN N
individuals NNS p
with IN p
autism NN p
spectrum NN p
disorder NN p
by IN N
up-regulating JJ N
signal JJ N
transduction NN N
. . N

-DOCSTART- -2540788- O O

Duration NN o
of IN o
chemotherapy NN o
in IN N
small JJ p
cell NN p
lung NN p
cancer NN p
: : p
a DT N
Cancer NNP N
Research NNP N
Campaign NNP N
trial NN N
. . N

A DT N
total NN N
of IN N
610 CD p
patients NNS p
with IN p
small JJ p
cell NN p
lung NN p
cancer NN p
were VBD N
entered VBN N
into IN N
a DT N
randomised JJ N
trial NN N
designed VBN N
to TO N
assess VB N
the DT N
effect NN N
of IN N
duration NN N
of IN N
initial JJ N
chemotherapy NN N
on IN N
survival NN N
. . N

Patients NNS N
were VBD N
randomised VBN N
to TO N
receive VB N
either DT N
four CD N
or CC N
eight CD N
courses NNS N
of IN N
cytotoxic NN i
chemotherapy NN i
with IN i
cyclophosphamide NN i
, , i
vincristine NN i
and CC i
etoposide NN i
and CC N
also RB N
randomised VBD N
to TO N
receive VB N
, , N
on IN N
disease NN N
progression NN N
, , N
either CC N
second JJ i
line NN i
chemotherapy NN i
( ( i
methotrexate NN i
and CC i
doxorubicin NN i
) ) i
or CC i
symptomatic JJ i
treatment NN i
only RB i
. . i

In IN N
the DT N
whole NN N
study NN N
196 CD p
( ( p
32.1 CD p
% NN p
) ) p
had VBD p
limited VBN p
disease NN p
and CC p
414 CD p
( ( p
67.9 CD p
% NN p
) ) p
extensive JJ p
disease NN p
. . p

During IN N
initial JJ N
chemotherapy VBD N
the DT N
response NN o
rate NN o
( ( o
complete JJ o
and CC o
partial JJ o
responses NNS o
) ) o
after IN N
four CD N
courses NNS N
of IN N
treatment NN N
was VBD N
61 CD N
% NN N
with IN N
no DT N
significant JJ N
increase NN N
in IN N
patients NNS N
receiving VBG N
eight CD N
courses NNS N
( ( N
63 CD N
% NN N
) ) N
. . N

In IN N
those DT N
randomised VBN N
to TO N
receive VB N
relapse NN N
chemotherapy VBZ N
the DT N
response NN o
rate NN o
was VBD N
improved VBN N
slightly RB N
for IN N
those DT N
who WP N
had VBD N
originally RB N
received VBN N
four CD N
courses NNS N
of IN N
chemotherapy NN N
( ( N
25.6 CD N
% NN N
) ) N
over IN N
those DT N
receiving VBG N
eight CD N
( ( N
18.7 CD N
% NN N
) ) N
. . N

The DT N
overall JJ N
results NNS N
show VBP N
that IN N
of IN N
the DT N
four CD N
possible JJ N
treatment NN N
randomizations NNS N
, , N
four CD N
courses NNS N
of IN N
chemotherapy NN N
alone NN N
is VBZ N
inferior JJ N
in IN N
terms NNS N
of IN N
overall JJ N
survival NN N
( ( N
30 CD N
weeks NNS N
median JJ N
survival NN N
) ) N
to TO N
the DT N
other JJ N
three CD N
treatment NN N
options NNS N
( ( N
39 CD N
weeks NNS N
median JJ N
survival NN N
, , N
P NNP N
less JJR N
than IN N
0.01 CD N
) ) N
. . N

In IN N
patients NNS N
responding VBG N
to TO N
initial JJ N
chemotherapy NN N
the DT N
disadvantage NN N
of IN N
four CD N
courses NNS N
of IN N
chemotherapy NN N
alone NN N
was VBD N
apparent JJ N
( ( N
median JJ N
survival NN N
of IN N
40 CD N
weeks NNS N
versus RB N
49 CD N
weeks NNS N
, , N
P NNP N
= NNP N
0.003 CD N
) ) N
but CC N
not RB N
if IN N
drug NN N
treatment NN N
was VBD N
given VBN N
on IN N
relapse NN N
. . N

The DT N
study NN N
shows VBZ N
that IN N
limiting VBG N
treatment NN N
to TO N
four CD N
courses NNS N
of IN N
chemotherapy NN N
alone NN N
is VBZ N
associated VBN N
with IN N
inferior JJ N
survival NN N
, , N
but CC N
this DT N
is VBZ N
not RB N
the DT N
case NN N
if IN N
chemotherapy NN N
is VBZ N
given VBN N
at IN N
relapse NN N
. . N

-DOCSTART- -20726255- O O

[ NN N
Study NNP N
on IN N
safety NN N
and CC N
immunogenicity NN N
of IN N
oral JJ i
poliomyelitis NN i
attenuated VBD i
live JJ i
vaccine NN i
( ( N
human JJ N
diploid NN N
cell NN N
) ) N
] NN N
. . N

OBJECTIVE UH N
To TO N
evaluate VB N
the DT N
safety NN o
and CC N
Immunogenicity NNP o
of IN N
the DT N
Poliomyelitis NNP i
vaccine NN i
( ( N
Human NNP N
Diploid NNP N
Cell NNP N
) ) N
in IN N
> NN N
or CC N
=2 VB p
month-old JJ p
children NNS p
. . p

METHODS NNP N
A NNP N
random NN N
, , N
blind NN N
and CC N
control NN N
trial NN N
, , N
1200 CD p
healthy JJ p
children NNS p
of IN p
2-5 JJ p
months NNS p
old JJ p
in IN p
Jiangsu NNP p
province NN p
were VBD p
administered VBN p
OPV NNP i
( ( i
HDC NNP i
) ) i
vaccine NN i
and CC i
control NN i
vaccines NNS i
. . i

The DT N
antibody NN N
was VBD N
tested VBN N
by IN N
neutralization NN N
test NN N
. . N

RESULTS NNP N
After IN N
3 CD N
doses NNS N
of IN N
the DT N
OPV NNP i
( ( i
HDC NNP i
) ) i
vaccine NN i
, , N
the DT N
systemic JJ o
reactions NNS o
were VBD N
mild JJ N
. . N

After IN N
1 CD N
month NN N
of IN N
vaccination NN N
with IN N
3 CD N
doses NNS N
of IN N
the DT N
OPV NNP i
( ( i
HDC NNP i
) ) i
vaccine NN i
, , N
the DT N
immune JJ o
success NN o
rates NNS o
of IN o
I PRP o
, , o
II NNP o
, , o
III NNP o
type NN o
were VBD N
98.28 CD N
% NN N
, , N
99.45 CD N
% NN N
, , N
and CC N
95.71 CD N
% NN N
respectively RB N
, , N
the DT N
GMTs NNP o
of IN o
I PRP o
, , o
II NNP o
, , o
III NNP o
type NN o
in IN N
susceptible JJ N
children NNS N
were VBD N
1:1243.72 CD N
, , N
1:234.38 CD N
and CC N
1:273.10 CD N
respectively RB N
. . N

CONCLUSIONS VB N
The DT N
OPV NNP i
( ( i
HDC NNP i
) ) i
vaccine NN i
was VBD N
safe JJ N
and CC N
immunogenicity NN N
for IN N
the DT p
children NNS p
> VBP p
or CC p
=2 JJ p
months NNS p
old JJ p
. . p

-DOCSTART- -7975860- O O

Correlation NN N
between IN N
in IN N
vivo JJ N
humoral JJ N
and CC N
in IN N
vitro JJ N
cellular JJ N
immune NN N
responses NNS N
following VBG N
immunization NN N
with IN N
hepatitis NN i
B NNP i
surface NN i
antigen NN i
( ( i
HBsAg NNP i
) ) i
vaccines NNS i
. . i

To TO N
study VB N
the DT N
regulation NN N
of IN N
the DT N
human JJ p
immune NN p
response NN p
to TO p
hepatitis VB i
B NNP i
surface NN i
antigen NN i
( ( i
HBsAg NNP i
) ) i
we PRP N
have VBP N
carefully RB N
monitored VBN N
the DT N
in IN N
vivo JJ N
humoral JJ N
and CC N
in IN N
vitro JJ N
cellular JJ N
immune NN N
responses NNS N
to TO N
HBsAg NNP N
in IN N
50 CD p
subjects NNS p
receiving VBG p
four CD p
doses NNS p
of IN p
hepatitis NN i
B NNP i
vaccine NN i
according VBG p
to TO p
a DT p
0 CD p
, , p
1 CD p
, , p
2 CD p
, , p
12 CD p
month NN p
vaccination NN p
scheme NN p
. . p

Twenty-three JJ p
subjects NNS p
were VBD p
given VBN p
a DT p
plasma-derived JJ i
vaccine NN i
( ( i
Hevac NNP i
B NNP i
) ) i
and CC p
27 CD p
received VBD p
a DT p
recombinant JJ i
HBsAg NNP i
vaccine NN i
( ( i
yeast-derived JJ i
; : i
Engerix-B NNP i
) ) i
. . i

The DT N
humoral JJ N
and CC N
cellular JJ N
immune NN N
responses NNS N
were VBD N
measured VBN N
before IN N
vaccination NN N
( ( N
day NN N
0 CD N
) ) N
; : N
6 CD N
days NNS N
after IN N
the DT N
second JJ N
dose NN N
( ( N
day NN N
36 CD N
) ) N
; : N
6 CD N
days NNS N
( ( N
day NN N
66 CD N
) ) N
, , N
2 CD N
months NNS N
( ( N
day NN N
120 CD N
) ) N
and CC N
10 CD N
months NNS N
( ( N
day NN N
365 CD N
) ) N
after IN N
the DT N
third JJ N
dose NN N
and CC N
1 CD N
month NN N
after IN N
the DT N
fourth JJ N
dose NN N
( ( N
day NN N
395 CD N
) ) N
. . N

Based VBN N
on IN N
the DT N
kinetics NNS N
of IN N
the DT N
humoral JJ N
immune NN N
responses NNS N
, , N
the DT N
vaccinees NNS N
could MD N
be VB N
classified VBN N
into IN N
fast NN N
, , N
intermediate JJ N
and CC N
slow/non-responders NNS N
. . N

Based VBN N
on IN N
the DT N
magnitude NN N
of IN N
the DT N
immune JJ N
response NN N
( ( N
anti-HBs JJ N
titre NN N
) ) N
on IN N
day NN N
395 CD N
, , N
the DT N
vaccinees NNS N
could MD N
be VB N
divided VBN N
into IN N
high JJ N
( ( N
> FW N
or CC N
= VB N
2000 CD N
U NNP N
l-1 NN N
) ) N
and CC N
low JJ N
( ( N
< CD N
or CC N
= VB N
2000 CD N
U NNP N
l-1 NN N
) ) N
responders NNS N
. . N

A DT N
close JJ N
correlation NN N
between IN N
the DT N
kinetics NNS N
and CC N
the DT N
magnitude NN N
of IN N
the DT N
humoral JJ o
immune NN o
response NN o
was VBD N
observed VBN N
. . N

The DT N
in IN o
vivo JJ o
anti-HBs JJ o
response NN o
was VBD N
measured VBN N
using VBG N
commercially RB N
available JJ N
immunoradiometric JJ N
assays NNS N
. . N

The DT N
in IN o
vitro NN o
cellular JJ o
immune JJ o
response NN o
was VBD N
measured VBN N
using VBG N
an DT N
HBsAg-specific JJ N
lymphoproliferation NN N
assay NN N
. . N

Because IN N
of IN N
interassay JJ N
variability NN N
the DT N
results NNS N
were VBD N
considered VBN N
as IN N
dichotomous JJ o
variables NNS o
( ( N
proliferation NN N
versus IN N
non-proliferation NN N
) ) N
for IN N
further JJ N
data NNS N
analysis NN N
. . N

A DT N
statistically RB N
significant JJ N
correlation NN N
was VBD N
observed VBN N
between IN N
the DT N
kinetics NNS N
and CC N
magnitude NN N
of IN N
the DT N
humoral JJ N
immune JJ N
response NN N
on IN N
the DT N
one CD N
hand NN N
and CC N
the DT N
in IN N
vitro JJ N
anti-HBs JJ N
response NN N
on IN N
the DT N
other JJ N
hand NN N
. . N

( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
250 CD N
WORDS NNP N
) ) N
-DOCSTART- -9777899- O O

Preventing VBG N
disability NN o
and CC o
managing VBG o
chronic JJ o
illness NN o
in IN N
frail JJ p
older NN p
adults NNS p
: : p
a DT N
randomized JJ N
trial NN N
of IN N
a DT N
community-based JJ N
partnership NN N
with IN N
primary JJ N
care NN N
. . N

BACKGROUND NNP N
Effective NNP N
new JJ N
strategies NNS N
that WDT N
complement VBP N
primary JJ N
care NN N
are VBP N
needed VBN N
to TO N
reduce VB o
disability NN o
risks NNS o
and CC o
improve VB o
self-management NN o
of IN o
chronic JJ o
illness NN o
in IN N
frail JJ p
older JJR p
people NNS p
living VBG p
in IN p
the DT p
community NN p
. . p

OBJECTIVE UH N
To TO N
evaluate VB N
the DT N
impact NN N
of IN N
a DT N
1-year JJ N
, , N
senior JJ N
center-based JJ N
chronic JJ o
illness NN o
self-management NN o
and CC o
disability NN o
prevention NN o
program NN o
on IN o
health NN o
, , o
functioning NN o
, , o
and CC o
healthcare JJ o
utilization NN o
in IN N
frail JJ N
older JJR N
adults NNS N
. . N

DESIGN VB N
A DT N
randomized NN N
controlled VBN N
trial NN N
. . N

SETTING NN N
A DT N
large JJ N
senior JJ N
center NN N
located VBN N
in IN N
a DT N
northeast NN N
Seattle NNP p
suburb NN N
. . N

The DT N
trial NN N
was VBD N
conducted VBN N
in IN N
collaboration NN N
with IN N
primary JJ N
care NN N
providers NNS N
of IN N
two CD N
large JJ N
managed VBD N
care NN N
organizations NNS N
. . N

PARTICIPANTS VB N
A DT N
total NN p
of IN p
201 CD p
chronically RB p
ill JJ p
older JJR p
adults NNS p
seniors NNS p
aged VBD p
70 CD p
and CC p
older JJR p
recruited VBN p
through IN p
medical JJ p
practices NNS p
. . p

INTERVENTION VB N
A NNP i
targeted JJ i
, , i
multi-component JJ i
disability NN i
prevention NN i
and CC i
disease JJ i
self-management JJ i
program NN i
led VBN i
by IN i
a DT i
geriatric JJ i
nurse NN i
practitioner NN i
( ( i
GNP NNP i
) ) i
. . i

MEASUREMENTS NNP N
Self-reported JJ o
Physical NNP o
function NN o
, , o
physical JJ o
performance NN o
tests NNS o
, , o
health NN o
care NN o
utilization NN o
, , o
and CC o
health NN o
behaviors NNS o
. . o

RESULTS NNP N
Each DT N
of IN N
101 CD p
intervention NN p
participants NNS p
met VBD N
with IN N
the DT N
GNP NNP N
from IN N
1 CD N
to TO N
8 CD N
times NNS N
( ( N
median JJ N
= NNP N
3 CD N
) ) N
during IN N
the DT N
study NN N
year NN N
. . N

The DT N
intervention NN N
group NN N
showed VBD N
less JJR o
decline NN o
in IN o
function NN o
, , o
as IN o
measured VBN o
by IN o
disability NN o
days NNS o
and CC N
lower JJR o
scores NNS o
on IN o
the DT o
Health NNP o
Assessment NNP o
Questionnaire NNP o
. . o

Other JJ N
measures NNS N
of IN N
function NN N
, , N
including VBG N
the DT o
SF-36 NNP o
and CC o
a DT o
battery NN o
of IN o
physical JJ o
performance NN o
tests NNS o
, , N
did VBD N
not RB N
change VB N
with IN N
the DT N
intervention NN N
. . N

The DT N
number NN o
of IN o
hospitalized JJ o
participants NNS o
increased VBN N
by IN N
69 CD N
% NN N
among IN N
the DT N
controls NNS N
and CC N
decreased VBN N
by IN N
38 CD N
% NN N
in IN N
the DT N
intervention NN N
group NN N
( ( N
P NNP N
= NNP N
.083 NNP N
) ) N
. . N

The DT N
total JJ o
number NN o
of IN o
inpatient JJ o
hospital NN o
days NNS o
during IN N
the DT N
study NN N
year NN N
was VBD N
significantly RB N
less RBR N
in IN N
the DT N
intervention NN N
group NN N
compared VBN N
with IN N
controls NNS N
( ( N
total JJ N
days NNS N
= VBP N
33 CD N
vs NN N
116 CD N
, , N
P NNP N
= NNP N
.049 NNP N
) ) N
. . N

The DT N
intervention NN N
led VBD N
to TO N
significantly RB N
higher JJR o
levels NNS o
of IN o
physical JJ o
activity NN o
and CC o
senior JJ o
center NN o
participation NN o
and CC o
significant JJ o
reductions NNS o
in IN N
the DT N
use NN o
of IN o
psychoactive JJ o
medications NNS o
. . o

CONCLUSIONS VB N
This DT N
project NN N
provides VBZ N
evidence NN N
that IN N
a DT N
community-based JJ N
collaboration NN N
with IN N
primary JJ N
care NN N
providers NNS N
can MD N
improve VB o
function NN o
and CC o
reduce VB o
inpatient JJ o
utilization NN o
in IN N
chronically RB p
ill JJ p
older JJR p
adults NNS p
. . p

Linking VBG N
organized VBN N
medical JJ N
care NN N
with IN N
complementary JJ N
community-based JJ N
interventions NNS N
may MD N
be VB N
a DT N
promising JJ N
direction NN N
for IN N
research NN N
and CC N
practice NN N
. . N

-DOCSTART- -19833962- O O

Direct JJ N
evidence NN N
for IN N
spinal JJ N
cord NN N
involvement NN N
in IN N
placebo NN N
analgesia NN N
. . N

Placebo NNP N
analgesia NN N
is VBZ N
a DT N
prime JJ N
example NN N
of IN N
the DT N
impact NN N
that WDT N
psychological JJ N
factors NNS N
have VBP N
on IN N
pain NN N
perception NN N
. . N

We PRP N
used VBD N
functional JJ i
magnetic JJ i
resonance NN i
imaging NN i
of IN N
the DT N
human JJ N
spinal JJ N
cord NN N
to TO N
test VB N
the DT N
hypothesis NN N
that WDT N
placebo VBZ N
analgesia JJ N
results NNS N
in IN N
a DT N
reduction NN N
of IN N
nociceptive JJ p
processing NN p
in IN p
the DT p
spinal JJ p
cord NN p
. . p

In IN N
line NN N
with IN N
behavioral JJ N
data NNS N
that WDT N
show VBP N
decreased VBN p
pain NN o
responses NNS o
under IN p
placebo NN p
, , N
pain-related JJ o
activity NN o
in IN N
the DT N
spinal JJ N
cord NN N
is VBZ N
strongly RB N
reduced VBN N
under IN N
placebo NN N
. . N

These DT N
results NNS N
provide VBP N
direct JJ N
evidence NN N
for IN N
spinal JJ N
inhibition NN N
as IN N
one CD N
mechanism NN N
of IN N
placebo NN N
analgesia NN N
and CC N
highlight NN N
that WDT N
psychological JJ N
factors NNS N
can MD N
act VB N
on IN N
the DT N
earliest JJS N
stages NNS N
of IN N
pain NN N
processing NN N
in IN N
the DT N
central JJ N
nervous JJ N
system NN N
. . N

-DOCSTART- -23118244- O O

Effects NNS N
of IN N
a DT N
standardized JJ i
pamphlet NN i
on IN N
insomnia NN o
in IN p
children NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
. . p

OBJECTIVE NNP N
Sleep NNP o
difficulties NNS o
are VBP N
common JJ N
reasons NNS N
why WRB p
parents NNS p
seek VBP p
medical JJ p
intervention NN p
in IN p
children NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
( ( p
ASDs NNP p
) ) p
. . p

We PRP N
determined VBD N
whether IN N
a DT N
pamphlet NN i
alone RB N
could MD N
be VB N
used VBN N
by IN N
parents NNS N
to TO N
help VB N
their PRP$ N
child NN N
's POS N
insomnia NN o
. . o

METHODS NNP N
Thirty-six JJ p
children NNS p
with IN p
ASD NNP p
, , p
ages VBZ p
2 CD p
to TO p
10 CD p
years NNS p
, , p
were VBD p
enrolled VBN p
. . p

All DT p
had VBD p
prolonged VBN p
sleep JJ o
latency NN o
confirmed VBN p
by IN p
actigraphy NN p
showing VBG p
a DT p
mean JJ p
sleep JJ o
latency NN o
of IN p
30 CD p
minutes NNS p
or CC p
more JJR p
. . p

Parents NNS p
were VBD p
randomly RB p
assigned VBN p
to TO p
receive VB p
the DT p
sleep JJ i
education NN i
pamphlet NN i
or CC i
no DT i
intervention NN i
. . i

Children NNP N
wore VBD N
an DT N
actigraphy NN i
device NN i
to TO N
record VB N
baseline NN N
sleep JJ o
parameters NNS o
, , N
with IN N
the DT N
primary JJ N
outcome NN N
variable JJ N
being VBG N
change NN o
in IN o
sleep JJ o
latency NN o
. . o

Actigraphy NNP N
data NNS N
were VBD N
collected VBN N
a DT N
second JJ N
time NN N
2 CD N
weeks NNS N
after IN N
the DT N
parent NN N
received VBD N
the DT N
randomization NN N
assignment NN N
and CC N
analyzed VBN N
by IN N
using VBG N
Student NNP N
's POS N
t JJ N
test NN N
. . N

Parents NNS N
were VBD N
also RB N
asked VBN N
a DT N
series NN N
of IN N
questions NNS N
to TO N
gather VB N
information NN N
about IN N
the DT N
pamphlet NN i
and CC N
its PRP$ N
usefulness NN N
. . N

RESULTS NNP N
Although IN N
participants NNS N
randomized VBN N
to TO N
the DT N
2 CD N
arms NNS N
did VBD N
not RB N
differ VB N
statistically RB N
in IN N
age NN o
, , o
gender NN o
, , o
socioeconomic JJ o
status NN o
, , o
total JJ o
Children NNP o
's POS o
Sleep NNP o
Habits NNP o
Questionnaire NNP o
score NN o
, , o
or CC o
actigraphy NN o
parameters NNS o
, , N
some DT N
differences NNS N
may MD N
be VB N
large JJ N
enough RB N
to TO N
affect VB N
results NNS N
. . N

Mean JJ o
change NN o
in IN o
sleep-onset JJ o
latency NN o
did VBD N
not RB N
differ VB N
between IN N
the DT N
randomized VBN N
groups NNS N
( ( i
pamphlet VB i
versus NN i
no DT i
pamphlet NN i
) ) i
. . i

Parents NNS N
commented VBD N
that IN N
the DT N
pamphlet NN i
contained VBD N
good JJ N
information NN o
, , N
but CC N
indicated VBD N
that IN N
it PRP N
would MD N
have VB N
been VBN N
more RBR N
useful JJ N
to TO N
be VB N
given VBN N
specific JJ N
examples NNS N
of IN N
how WRB N
to TO N
take VB N
the DT N
information NN N
and CC N
put VB N
it PRP N
into IN N
practice NN N
. . N

CONCLUSIONS VB N
A DT N
sleep JJ i
education NN i
pamphlet NN i
did VBD N
not RB N
appear VB N
to TO N
improve VB N
sleep JJ o
latency NN o
in IN p
children NNS p
with IN p
ASDs NNP p
. . p

-DOCSTART- -10826576- O O

Identifying VBG N
the DT N
indications NNS N
for IN N
laparoscopically RB i
assisted VBN i
vaginal JJ i
hysterectomy NN i
: : i
a DT N
prospective JJ N
, , N
randomised VBD N
comparison NN N
with IN N
abdominal JJ i
hysterectomy NN i
in IN p
patients NNS p
with IN p
symptomatic JJ p
uterine JJ p
fibroids NNS p
. . p

OBJECTIVE NNP N
To TO N
compare VB N
laparoscopically RB i
assisted VBN i
vaginal JJ i
hysterectomy NN i
( ( i
LAVH NNP i
) ) i
and CC i
total JJ i
abdominal JJ i
hysterectomy NN i
( ( i
TAH NNP i
) ) i
in IN N
patients NNS p
with IN p
uterine JJ p
fibroids NNS p
. . p

DESIGN VB N
A DT N
prospective JJ N
randomised VBN N
study NN N
. . N

SETTING CC N
The DT p
San NNP p
Paolo NNP p
Hospital NNP p
, , p
Milan NNP p
. . p

POPULATION NNP N
Sixty-two JJ p
patients NNS p
, , p
who WP p
were VBD p
not RB p
suitable JJ p
for IN p
a DT p
vaginal JJ p
hysterectomy NN p
, , p
requiring VBG p
treatment NN p
for IN p
uterine JJ p
fibroids NNS p
. . p

METHODS NNP N
Randomisation NNP N
between IN N
LAVH NNP i
and CC i
TAH NNP i
. . i

Comparison NNP N
of IN N
outcomes NNS N
on IN N
the DT N
whole JJ N
series NN N
, , N
patients NNS N
with IN N
uteri JJ N
< NN N
or CC N
= $ N
500 CD N
g NN N
( ( N
Group NNP N
1 CD N
) ) N
and CC N
patients NNS N
with IN N
uteri JJ N
> $ N
500 CD N
g NN N
( ( N
Group NNP N
2 CD N
) ) N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
To TO N
establish VB N
operating NN o
time NN o
, , o
blood NN o
loss NN o
, , o
complications NNS o
, , o
febrile JJ o
morbidity NN o
, , o
analgesics NNS o
administration NN o
and CC o
hospital JJ o
stay NN o
for IN N
both DT N
treatment NN N
approaches NNS N
. . N

RESULTS NNP N
Median JJ o
uterine JJ o
weight NN o
was VBD N
400 CD N
g NN N
in IN N
both DT N
LAVH NNP i
and CC N
TAH NNP i
group NN N
. . N

Median JJ o
operating NN o
time NN o
was VBD N
longer RBR N
for IN N
LAVH NNP i
( ( N
135 CD N
min NNS N
compared VBN N
with IN N
120 CD N
min NNS N
for IN N
TAH NNP i
; : i
P NNP N
= NNP N
0.001 CD N
) ) N
, , N
but CC N
patients NNS N
undergoing JJ N
LAVH NNP i
had VBD N
less RBR N
analgesics JJ o
administration NN o
( ( N
23 CD N
% NN N
compared VBN N
with IN N
77 CD N
% NN N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
and CC N
a DT N
shorter NN N
median JJ o
hospital NN o
stay NN o
( ( N
3.8 CD N
compared VBN N
with IN N
5.8 CD N
days NNS N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

LAVH NNP i
, , N
when WRB N
compared VBN N
with IN N
TAH NNP i
in IN N
the DT N
two CD N
weight NN N
subgroups NNS N
, , N
required VBD N
a DT N
significantly RB N
longer RBR N
operating VBG o
time NN o
only RB N
in IN N
Group NNP N
2 CD N
, , N
significantly RB N
reduced VBN N
analgesics NNS o
administration NN o
only RB N
in IN N
Group NNP N
1 CD N
, , N
and CC N
significantly RB N
reduced VBN N
hospital NN o
stay NN o
in IN N
both DT N
groups NNS N
. . N

Conversions NNS N
of IN N
LAVH NNP N
to TO N
laparotomy VB N
were VBD N
significantly RB N
more RBR N
frequent JJ N
in IN N
Group NNP N
2 CD N
( ( N
3/11 CD N
) ) N
than IN N
in IN N
Group NNP N
1 CD N
( ( N
0/20 CD N
) ) N
( ( N
P NNP N
= NNP N
0.04 CD N
) ) N
. . N

CONCLUSIONS NNP N
Compared NNP N
with IN N
TAH NNP i
, , i
LAVH NNP i
has VBZ N
advantages NNS o
in IN N
removing VBG N
uteri JJ N
weighing VBG N
< NN N
or CC N
= $ N
500 CD N
g NN N
, , N
with IN N
comparable JJ N
operating NN o
time NN o
, , N
less JJR N
post-operative JJ o
pain NN o
and CC N
shorter JJR N
recovery NN o
. . o

Among IN N
uteri JJ N
weighing VBG N
> JJ N
500 CD N
g NN N
LAVH NNP i
showed VBD N
a DT N
shorter NN N
recovery NN N
, , N
but CC N
longer JJR N
operating NN N
time NN N
than IN N
TAH NNP i
and CC N
a DT N
27 CD N
% NN N
rate NN N
of IN N
conversion NN o
to TO o
laparotomy VB o
. . o

-DOCSTART- -12823122- O O

Evaluation NN N
of IN N
asthma NN N
knowledge NN N
and CC N
quality NN N
of IN N
life NN N
in IN N
Hungarian JJ p
asthmatics NNS p
. . p

BACKGROUND IN N
The DT N
objective NN N
was VBD N
to TO N
develop VB N
an DT N
educational JJ i
instrument NN i
, , N
to TO N
assess VB N
its PRP$ N
impact NN N
as IN N
an DT N
intervention NN i
instrument NN N
and CC N
to TO N
examine VB N
quality NN N
of IN N
life NN N
( ( N
QoL NNP N
) ) N
. . N

METHODS $ N
119 CD p
asthmatics NNS p
were VBD p
randomized VBN p
( ( N
64 CD N
in IN N
the DT N
intervention NN i
and CC N
55 CD N
in IN N
the DT N
reference NN i
group NN N
) ) N
. . N

The DT N
education NN i
instrument NN i
was VBD N
developed VBN N
based VBN N
on IN N
the DT N
EuroPharm-Forum NNP N
Guidelines NNP N
and CC N
its PRP$ N
impact NN N
assessed VBN N
by IN N
a DT N
self-developed JJ N
questionnaire NN N
. . N

Patients NNS N
' POS N
QoL NNP N
, , N
asthma NN N
knowledge NN N
was VBD N
assessed VBN N
twice RB N
, , N
once RB N
before IN N
and CC N
after IN N
the DT N
education NN i
seminar NN i
, , N
education NN N
was VBD N
only RB N
provided VBN N
for IN N
the DT N
intervention NN N
group NN N
. . N

QoL NNP o
was VBD N
measured VBN N
with IN N
the DT N
St NNP o
George NNP o
's POS o
Respiratory NNP o
Questionnaire NNP o
( ( o
SGRQ NNP o
) ) o
and CC N
a DT N
visual JJ o
analogue NN o
scale NN o
( ( o
VAS NNP o
) ) o
. . N

RESULTS NNP N
We PRP N
found VBD N
significant JJ N
differences NNS N
in IN N
answers NNS N
to TO N
the DT N
asthma JJ N
questions NNS N
, , N
by IN N
40 CD N
% NN N
improvement NN N
, , N
but CC N
no DT N
changes NNS N
in IN N
the DT N
control NN N
group NN N
. . N

In IN N
inhaler-use NN N
technique NN N
, , N
we PRP N
could MD N
not RB N
find VB N
significant JJ N
changes NNS N
neither CC N
in IN N
the DT N
intervention NN N
nor CC N
in IN N
the DT N
control NN N
group NN N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
the DT N
results NNS N
of IN N
the DT N
two CD N
visits NNS N
neither CC N
with IN N
the DT N
VAS NNP o
nor CC N
with IN N
the DT N
SGRQ NNP o
on IN N
the DT N
QoL NNP o
data NN o
. . o

CONCLUSION NNP N
The DT N
results NNS N
indicate VBP N
that IN N
asthmatics NNS N
experience VB N
lower JJR N
QoL NNP o
. . o

As IN N
the DT p
subjects NNS p
were VBD p
regularly RB p
controlled VBN p
asthmatics NNS p
they PRP N
had VBD N
better RBR N
general JJ N
knowledge NN N
and CC N
inhaler-use NN N
technique NN N
was VBD N
expected VBN N
. . N

The DT N
results NNS N
suggest VBP N
that IN N
it PRP N
is VBZ N
necessary JJ N
to TO N
regularly VB N
refresh JJ N
asthma NN N
knowledge NN N
, , N
to TO N
assess VB N
patients NNS N
' POS N
self-management JJ N
plans NNS N
to TO N
achieve VB N
long-term JJ N
effectiveness NN N
of IN N
asthma JJ N
management NN N
. . N

-DOCSTART- -18299305- O O

Safety NN o
and CC o
tolerability NN o
of IN N
cold-adapted JJ N
influenza NN i
vaccine NN i
, , i
trivalent NN i
, , N
in IN N
infants NNS p
younger JJR p
than IN p
6 CD p
months NNS p
of IN p
age NN p
. . p

OBJECTIVE NNP N
Young NNP p
children NNS p
are VBP N
at IN N
high JJ N
risk NN N
for IN N
influenza-related JJ N
complications NNS N
. . N

Vaccination NN N
of IN N
close JJ N
household NN N
contacts NNS N
is VBZ N
recommended VBN N
to TO N
provide VB N
indirect JJ N
protection NN N
to TO N
children NNS p
< $ p
6 CD p
months NNS p
of IN p
age NN p
. . p

Studies NNS N
have VBP N
shown VBN N
that IN N
live JJ N
, , N
cold-adapted JJ N
influenza NN i
vaccine NN i
, , N
trivalent NN N
, , N
is VBZ N
efficacious JJ N
in IN N
children NNS p
. . p

To TO N
assess VB N
the DT N
risks NNS N
associated VBN N
with IN N
inadvertent JJ N
exposure NN N
of IN N
infants NNS N
to TO N
vaccine VB N
viruses NNS N
from IN N
vaccinated JJ N
contacts NNS N
, , N
this DT N
study NN N
was VBD N
designed VBN N
to TO N
evaluate VB N
the DT N
safety NN o
and CC o
tolerability NN o
of IN N
cold-adapted JJ N
influenza NN i
vaccine NN i
, , N
trivalent NN N
, , N
administered VBN N
intranasally RB N
to TO N
healthy JJ p
children NNS p
6 CD p
to TO p
< VB p
24 CD p
weeks NNS p
of IN p
age NN p
. . p

METHODS NNP N
Healthy NNP p
infants NNS p
aged VBD p
6 CD p
to TO p
< VB p
16 CD p
weeks NNS p
and CC p
16 CD p
to TO p
< VB p
24 CD p
weeks NNS p
, , N
respectively RB N
, , N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
2 CD i
doses NNS i
of IN i
influenza JJ i
vaccine NN i
, , i
or CC i
placebo VB i
intranasally RB N
35 CD N
+/- JJ N
7 CD N
days NNS N
apart RB N
. . N

Reactogenicity NN N
events NNS N
were VBD N
monitored VBN N
for IN N
11 CD N
days NNS N
after IN N
each DT N
dose NN N
. . N

Other JJ N
adverse JJ N
events NNS N
were VBD N
monitored VBN N
through IN N
28 CD N
to TO N
35 CD N
days NNS N
after IN N
dose JJ N
2 CD N
. . N

RESULTS NN N
Of IN N
the DT N
infants NNS p
aged VBD p
6 CD p
to TO p
< VB p
16 CD p
weeks NNS p
, , N
31 CD N
received VBD N
influenza JJ i
vaccine NN i
and CC N
28 CD N
received VBD N
placebo NN i
, , N
and CC N
of IN N
those DT p
aged VBN p
16 CD p
to TO p
< VB p
24 CD p
weeks NNS p
, , N
30 CD N
received VBD N
influenza JJ i
vaccine NN i
and CC N
31 CD N
received VBD N
placebo NN i
. . i

In IN N
the DT N
6- JJ N
to TO N
< VB N
16-week JJ N
cohort NN N
, , N
more JJR N
influenza JJ N
vaccine NN N
, , N
recipients NNS N
experienced VBD N
irritability NN o
( ( N
66.7 CD N
% NN N
vs JJ N
35.7 CD N
% NN N
) ) N
and CC N
runny JJ o
nose NN o
or CC o
nasal JJ o
congestion NN o
( ( N
63.3 CD N
% NN N
vs JJ N
33.3 CD N
% NN N
) ) N
after IN N
dose JJ N
1 CD N
but CC N
not RB N
dose JJ N
2 CD N
. . N

There EX N
were VBD N
no DT N
significant JJ N
increases NNS N
in IN N
any DT N
other JJ N
reactogenicity NN o
events NNS o
or CC o
adverse JJ o
events NNS o
in IN N
the DT N
vaccine NN N
recipients NNS N
compared VBN N
with IN N
the DT N
placebo NN i
group NN N
. . N

CONCLUSIONS NNP N
Although IN N
there EX N
was VBD N
an DT N
increase NN N
in IN N
mild JJ o
reactogenicity NN o
events NNS o
in IN N
children NNS p
6 CD p
to TO p
< VB p
16 CD p
weeks NNS p
of IN p
age NN p
, , N
cold-adapted JJ N
influenza NN i
vaccine NN i
, , N
trivalent NN N
, , N
was VBD N
generally RB N
well RB N
tolerated VBN N
in IN N
infants NNS p
6 CD p
to TO p
< VB p
24 CD p
weeks NNS p
of IN p
age NN p
. . p

These DT N
findings NNS N
support NN N
further JJ N
evaluation NN N
of IN N
cold-adapted JJ N
influenza NN i
vaccine NN i
, , N
trivalent NN N
, , N
in IN N
infants NNS p
< VBP p
6 CD p
months NNS p
of IN p
age NN p
. . p

-DOCSTART- -18429536- O O

Evaluation NN o
of IN N
a DT N
device NN i
to TO i
facilitate VB i
female JJ i
urethral JJ i
catheterization NN i
. . i

Urethral JJ i
catheterization NN i
is VBZ i
a DT N
skilled JJ N
procedure NN N
that WDT N
nurses VBZ p
in IN p
hospital JJ p
settings NNS p
perform VBP N
routinely RB N
. . N

The DT N
opening NN N
of IN N
the DT N
female JJ N
urethra NN N
is VBZ N
located VBN N
within IN N
the DT N
vulvar NN N
vestibule NN N
, , N
making VBG N
insertion NN N
of IN N
urinary JJ N
catheters NNS N
into IN N
females NNS p
a DT N
greater JJR N
technical JJ N
challenge NN N
than IN N
in IN N
males NNS N
. . N

Researchers NNS N
evaluated VBD N
whether IN N
a DT N
new JJ N
device NN N
might MD N
decrease VB N
the DT N
time NN o
required VBN o
for IN o
catheter NN o
insertion NN o
, , o
increase VB o
the DT o
likelihood NN o
of IN o
inserting VBG o
the DT o
catheter NN o
on IN o
the DT o
first JJ o
attempt NN o
( ( o
improved VBN o
accuracy NN o
) ) o
, , N
and CC N
reduce VB o
patient JJ o
discomfort NN o
. . o

Comments NNS N
about IN N
the DT N
device NN N
from IN N
both DT N
patients NNS N
and CC N
nurses NNS N
also RB N
are VBP N
reported VBN N
. . N

-DOCSTART- -4165041- O O

Beta-cytotrophic JJ o
effects NNS o
of IN N
glucose NN i
, , i
glucagon NN i
, , p
and CC p
tolbutamide NN i
in IN p
man NN p
. . p

-DOCSTART- -7928125- O O

The DT N
effect NN N
of IN N
a DT N
culture-specific JJ i
education NN i
program NN i
to TO i
promote VB i
breastfeeding NN i
among IN p
Vietnamese JJ p
women NNS p
in IN p
Sydney NNP p
. . p

The DT N
rate NN N
of IN N
breastfeeding VBG N
among IN N
immigrant JJ p
Vietnamese JJ p
women NNS p
in IN p
Western JJ p
countries NNS p
is VBZ N
low JJ N
compared VBN N
to TO N
those DT N
in IN N
Vietnam NNP N
. . N

To TO N
counteract VB N
this DT N
trend NN N
, , N
a DT N
language NN i
and CC i
culture NN i
specific JJ i
education NN i
program NN N
was VBD N
developed VBN N
. . N

An DT N
experimental JJ N
design NN N
was VBD N
used VBN N
to TO N
test VB N
the DT N
effectiveness NN N
of IN N
this DT N
program NN N
. . N

The DT p
sample NN p
consisted VBD p
of IN p
182 CD p
prenatal JJ p
Vietnamese JJ p
women NNS p
. . p

Data NNP N
collection NN N
included VBD N
questionnaires NNS N
and CC N
interviews NNS N
. . N

Results NNS N
suggested VBD N
that IN N
the DT N
education NN N
program NN N
had VBD N
significant JJ N
effects NNS N
on IN N
knowledge NN o
, , o
attitudes NNS o
, , o
planned VBD o
and CC o
actual JJ o
behaviour NN o
towards NNS o
breastfeeding VBG o
. . o

However RB N
, , N
the DT N
effect NN N
did VBD N
not RB N
sustain VB N
until IN N
6 CD N
months NNS N
postpartum NN N
. . N

Implications NNS N
for IN N
nursing NN N
practice NN N
and CC N
further JJ N
research NN N
are VBP N
discussed VBN N
. . N

-DOCSTART- -25818246- O O

MDMA-assisted JJ i
therapy NN i
: : i
A DT N
new JJ N
treatment NN N
model NN N
for IN N
social JJ p
anxiety NN p
in IN p
autistic JJ p
adults NNS p
. . p

The DT N
first JJ N
study NN N
of IN N
3,4-methylenedioxymethamphetamine NNP i
( ( i
MDMA NNP i
) ) i
-assisted VBD i
therapy NN i
for IN N
the DT N
treatment NN N
of IN N
social JJ p
anxiety NN p
in IN p
autistic JJ p
adults NNS p
commenced VBD p
in IN p
the DT p
spring NN p
of IN p
2014 CD p
. . p

The DT N
search NN N
for IN N
psychotherapeutic JJ N
options NNS N
for IN N
autistic JJ N
individuals NNS N
is VBZ N
imperative JJ N
considering VBG N
the DT N
lack NN N
of IN N
effective JJ N
conventional JJ N
treatments NNS N
for IN N
mental JJ N
health NN N
diagnoses NNS N
that WDT N
are VBP N
common JJ N
in IN N
this DT N
population NN N
. . N

Serious JJ o
Adverse JJ o
Events NNS o
( ( o
SAEs NNP o
) ) o
involving VBG N
the DT N
administration NN N
of IN N
MDMA NNP i
in IN N
clinical JJ N
trials NNS N
have VBP N
been VBN N
rare JJ N
and CC N
non-life JJ N
threatening NN N
. . N

To TO N
date NN N
, , N
MDMA NNP i
has VBZ p
been VBN p
administered VBN p
to TO p
over IN p
1133 CD p
individuals NNS p
for IN p
research NN p
purposes NNS p
without IN N
the DT N
occurrence NN N
of IN N
unexpected JJ o
drug-related JJ o
SAEs NNP o
that IN N
require VBP N
expedited JJ N
reporting NN N
per IN N
FDA NNP N
regulations NNS N
. . N

Now RB N
that IN N
safety NN N
parameters NNS N
for IN N
limited JJ N
use NN N
of IN N
MDMA NNP i
in IN N
clinical JJ N
settings NNS N
have VBP N
been VBN N
established VBN N
, , N
a DT N
case NN N
can MD N
be VB N
made VBN N
to TO N
further JJ N
develop VB N
MDMA-assisted JJ i
therapeutic JJ i
interventions NNS i
that WDT N
could MD N
support VB N
autistic JJ N
adults NNS N
in IN N
increasing VBG N
social JJ o
adaptability NN o
among IN N
the DT N
typically RB N
developing VBG N
population NN N
. . N

As IN N
in IN N
the DT N
case NN N
with IN N
classic JJ N
hallucinogens NNS N
and CC N
other JJ N
psychedelic JJ N
drugs NNS N
, , N
MDMA NNP i
catalyzes VBZ N
shifts NNS N
toward IN N
openness NN o
and CC o
introspection NN o
that WDT N
do VBP N
not RB N
require VB N
ongoing VBG N
administration NN N
to TO N
achieve VB N
lasting VBG N
benefits NNS N
. . N

This DT N
infrequent JJ N
dosing NN N
mitigates NNS N
adverse JJ o
event NN o
frequency NN o
and CC o
improves VBZ o
the DT o
risk/benefit NN o
ratio NN o
of IN o
MDMA NNP o
, , N
which WDT N
may MD N
provide VB N
a DT N
significant JJ N
advantage NN N
over IN N
medications NNS N
that WDT N
require VBP N
daily JJ N
dosing NN N
. . N

Consequently RB N
, , N
clinicians NNS N
could MD N
employ VB N
new JJ N
treatment NN N
models NNS N
for IN N
social JJ o
anxiety NN o
or CC N
similar JJ N
types NNS N
of IN N
distress NN N
administering VBG N
MDMA NNP i
on IN N
one CD N
to TO N
several JJ N
occasions NNS N
within IN N
the DT N
context NN N
of IN N
a DT N
supportive JJ N
and CC N
integrative JJ N
psychotherapy NN N
protocol NN N
. . N

-DOCSTART- -3830804- O O

[ JJ N
Results NNP N
of IN N
a DT N
cooperative JJ N
prospective JJ N
study NN N
of IN N
treatment NN N
of IN N
primary JJ p
digestive JJ p
localizations NNS p
of IN p
non-Hodgkin NN p
's POS p
lymphoma NN p
] NN p
. . N

We PRP N
report VBP N
the DT N
results NNS N
of IN N
chemotherapy JJ i
treatment NN i
in IN p
82 CD p
patients NNS p
presenting VBG p
with IN p
primary JJ p
digestive JJ p
lymphoma NN p
and CC p
included VBD p
in IN p
a DT p
study NN p
conducted VBN p
between IN p
October NNP p
1977 CD p
and CC p
October NNP p
1985 CD p
. . p

There EX N
were VBD N
31 CD p
gastric JJ p
lymphoma NN p
, , p
18 CD p
small JJ p
intestinal JJ p
lymphomas NN p
, , p
and CC p
19 CD p
with IN p
multiple JJ p
involvement NN p
: : p
63 CD p
patients NNS p
had VBD p
had VBN p
a DT p
surgical JJ p
staging NN p
with IN p
total JJ p
tumor NN p
resection NN p
in IN p
15 CD p
cases NNS p
. . p

Nineteen JJ p
patients NNS p
with IN p
limited JJ p
disease NN p
( ( p
ID NNP p
and CC p
IID NNP p
) ) p
were VBD N
randomly RB N
assigned VBN N
to TO N
either VB N
a DT N
3-week JJ N
chemotherapy NN i
regimen NNS N
associated VBN N
with IN N
whole JJ i
abdominal JJ i
radiotherapy NN i
or CC N
chemotherapy NN i
for IN N
3 CD N
years NNS N
. . N

Twenty-seven JJ p
stage NN p
IIID NNP p
and CC p
thirty-six JJ p
stage NN p
IV NNP p
were VBD N
treated VBN N
with IN N
chemotherapy NN i
alone RB N
for IN N
3 CD N
years NNS N
. . N

Low JJ p
grade NN p
lymphomas NN p
( ( p
16 CD p
patients NNS p
) ) p
received VBD N
a DT N
cyclophosphamide NN i
, , i
vincristine NN i
, , i
prednisone NN i
association NN i
. . i

Intermediate NNP p
( ( p
56 CD p
patients NNS p
) ) p
and CC p
high JJ p
grade NN p
( ( p
10 CD p
patients NNS p
) ) p
lymphomas VBP p
received VBN N
cyclophosphamide NN i
, , i
vincristine NN i
, , i
adriamycin NN i
, , i
prednisone NN i
. . i

The DT N
overall JJ o
complete JJ o
remission NN o
obtained VBN N
was VBD N
63 CD N
p. NN N
100 CD p
( ( p
51 CD p
patients NNS p
) ) p
with IN p
17 CD p
patients NNS p
in IN p
relapse NN o
within IN p
6 CD p
to TO p
40 CD p
months NNS p
. . p

Overall JJ o
survival NN o
was VBD N
46 CD N
p. JJ N
100 CD N
at IN N
5 CD N
years NNS N
. . N

Survival NN o
was VBD N
dependent JJ N
on IN N
abdominal JJ o
extension NN o
, , o
histologic NN o
grade VBD o
according VBG o
to TO o
the DT o
new JJ o
working VBG o
formulation NN o
used VBN o
for IN o
lymph-node JJ o
lymphomas NN o
, , o
initial JJ o
localization NN o
( ( N
gastric JJ N
lymphomas NN N
have VBP N
the DT N
best JJS N
survival NN N
) ) N
and CC N
achievement NN N
of IN N
complete JJ o
remission NN o
. . o

Chemotherapy NNP i
is VBZ N
an DT N
effective JJ N
treatment NN o
for IN N
primary JJ N
digestive JJ N
lymphomas NN N
. . N

The DT N
role NN N
of IN N
surgery NN N
in IN N
the DT N
management NN N
of IN N
lymphomas NN N
has VBZ N
to TO N
be VB N
defined VBN N
by IN N
further JJ N
studies NNS N
. . N

-DOCSTART- -17179098- O O

Dofequidar NNP i
fumarate NN i
( ( N
MS-209 NNP N
) ) N
in IN N
combination NN N
with IN N
cyclophosphamide NN i
, , i
doxorubicin NN i
, , i
and CC i
fluorouracil NN i
for IN N
patients NNS p
with IN p
advanced JJ p
or CC p
recurrent JJ p
breast NN p
cancer NN p
. . p

PURPOSE NNP N
To TO N
evaluate VB N
the DT N
efficacy NN o
and CC o
tolerability NN o
of IN N
dofequidar NN i
plus CC i
cyclophosphamide NN i
, , i
doxorubicin NN i
, , i
and CC i
fluorouracil NN i
( ( i
CAF NNP i
) ) i
therapy NN i
in IN N
comparison NN N
with IN N
CAF NNP i
alone RB i
, , N
in IN N
patients NNS p
with IN p
advanced JJ p
or CC p
recurrent JJ p
breast NN p
cancer NN p
. . p

Dofequidar NNP N
is VBZ N
a DT N
novel NN N
, , N
orally RB N
active JJ N
quinoline NN N
derivative NN N
that WDT N
reverses VBZ N
multidrug JJ N
resistance NN N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
In IN N
this DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
trial NN N
, , N
patients NNS N
were VBD N
treated VBN N
with IN N
six CD N
cycles NNS N
of IN N
CAF NNP i
therapy NN i
: : i
28 CD N
days/cycle NN i
, , i
with IN i
doxorubicin NN i
( ( i
25 CD i
mg/m2 NN i
) ) i
and CC i
fluorouracil NN i
( ( i
500 CD i
mg/m2 NN i
) ) i
administered VBN i
on IN i
days NNS i
1 CD i
and CC i
8 CD i
and CC i
cyclophosphamide NN i
( ( i
100 CD i
mg NN i
orally RB i
[ NNP i
PO NNP i
] NNP i
) ) i
administered VBD i
on IN i
day NN i
1 CD i
through IN i
14 CD i
. . i

Patients NNS N
received VBD N
dofequidar NN i
( ( i
900 CD i
mg RB i
PO NNP i
) ) i
30 CD N
minutes NNS N
before IN N
each DT N
dose NN N
of IN N
doxorubicin NN i
. . i

Primary JJ N
end NN N
point NN N
was VBD N
overall JJ o
response NN o
rate NN o
( ( o
ORR NNP o
; : o
partial JJ o
or CC o
complete JJ o
response NN o
) ) o
. . o

In IN N
total JJ N
, , N
221 CD p
patients NNS p
were VBD p
assessable JJ p
. . p

RESULTS NNP N
ORR NNP o
was VBD N
42.6 CD N
% NN N
for IN N
CAF NNP i
compared VBN N
with IN N
53.1 CD N
% NN N
for IN N
dofequidar NN i
+ NNP i
CAF NNP i
, , N
a DT N
24.6 CD N
% NN N
relative JJ N
improvement NN N
and CC N
10.5 CD N
% NN N
absolute JJ N
increase NN N
( ( N
P NNP N
= NNP N
.077 NNP N
) ) N
. . N

There EX N
was VBD N
a DT N
trend NN N
for IN N
prolonged JJ o
progression-free JJ o
survival NN o
( ( o
PFS NNP o
; : o
median JJ N
241 CD N
days NNS N
for IN N
CAF NNP N
v $ N
366 CD N
days NNS N
for IN N
dofequidar NN N
+ NNP N
CAF NNP N
; : N
P NNP N
= NNP N
.145 NNP N
) ) N
. . N

In IN N
retrospectively RB N
defined VBN N
subgroups NNS N
, , N
significant JJ N
improvement NN N
in IN N
PFS NNP o
in IN N
favor NN N
of IN N
dofequidar NN N
was VBD N
observed VBN N
in IN N
patients NNS p
who WP p
were VBD p
premenopausal NN p
, , p
had VBD p
no DT p
prior JJ p
therapy NN p
, , p
and CC p
were VBD p
stage NN p
IV NNP p
at IN p
diagnosis NN p
with IN p
an DT p
intact JJ p
primary JJ p
tumor NN p
. . p

Except IN N
for IN N
neutropenia NN o
and CC o
leukopenia NN o
, , N
there EX N
was VBD N
no DT N
statistically RB N
significant JJ N
excess NN N
of IN N
grade NN N
3/4 CD N
adverse JJ N
events NNS N
compared VBN N
with IN N
CAF NNP N
. . N

Treatment NN N
with IN N
dofequidar NN i
did VBD N
not RB N
affect VB N
the DT N
plasma JJ o
concentration NN o
of IN o
doxorubicin NN o
. . o

CONCLUSION NNP N
Dofequidar NNP i
+ NNP i
CAF NNP i
was VBD N
well RB N
tolerated VBN N
and CC N
is VBZ N
suggested VBN N
to TO N
have VB N
efficacy NN N
in IN N
patients NNS p
who WP p
had VBD p
not RB p
received VBN p
prior JJ p
therapy NN p
. . p

-DOCSTART- -15223738- O O

Evaluation NN N
of IN N
an DT N
aquatics NNS i
programme NN i
on IN N
fitness NN o
parameters NNS o
of IN N
individuals NNS p
with IN p
a DT p
brain NN p
injury NN p
. . p

The DT N
primary JJ N
objective NN N
was VBD N
to TO N
determine VB N
the DT N
effect NN N
of IN N
an DT N
aquatic JJ i
exercise NN i
programme NN i
on IN N
the DT N
physical JJ o
fitness NN o
of IN N
people NNS p
with IN p
a DT p
brain NN p
injury NN p
. . p

A DT N
pre-test-post-test JJ N
randomized-groups JJ N
design NN N
was VBD N
conducted VBN N
. . N

Sixteen JJ p
outpatients NNS p
with IN p
a DT p
brain NN p
injury NN p
were VBD p
included VBN p
in IN p
the DT p
study NN p
. . p

Eight CD N
participants NNS N
were VBD N
assigned VBN N
to TO N
an DT N
aquatic JJ i
exercise NN i
group NN i
and CC i
eight CD i
to TO i
a DT i
control NN i
group NN i
. . i

The DT N
components NNS N
of IN N
physical JJ N
fitness NN N
measured VBD N
included VBD N
cardiovascular JJ o
endurance NN o
, , o
body NN o
composition NN o
, , o
muscular JJ o
strength NN o
and CC o
endurance NN o
and CC o
flexibility NN o
. . o

Measurements NNS N
were VBD N
taken VBN N
pre- JJ N
and CC N
post-programme JJ N
. . N

Results NNP N
indicated VBD N
an DT N
increase NN N
in IN N
components NNS o
of IN o
physical JJ o
fitness NN o
for IN N
the DT N
experimental JJ N
group NN N
but CC N
not RB N
the DT N
control NN N
group NN N
. . N

Increases VBZ N
in IN N
fitness NN N
were VBD N
reported VBN N
as IN N
having VBG N
a DT N
positive JJ N
impact NN N
on IN N
the DT N
functional JJ o
capacity NN o
of IN N
individuals NNS N
in IN N
the DT N
exercise NN N
group NN N
as RB N
well RB N
as IN N
enhancing VBG N
the DT N
individual NN N
's POS N
ability NN o
to TO o
complete VB o
activities NNS o
of IN o
daily JJ o
living VBG o
successfully RB N
. . N

Results VB N
indicate JJ N
that IN N
aquatic JJ N
exercise NN N
may MD N
positively RB N
impact VB N
the DT N
primary JJ o
and CC o
secondary JJ o
physical JJ o
injuries NNS o
caused VBN N
by IN N
a DT N
brain NN N
injury NN N
. . N

-DOCSTART- -26609668- O O

Socio-demographic JJ N
, , N
anthropometric JJ N
, , N
and CC N
psychosocial JJ N
predictors NNS N
of IN N
attrition NN N
across IN N
behavioral JJ N
weight-loss JJ N
trials NNS N
. . N

Preventing VBG N
attrition NN N
is VBZ N
a DT N
major JJ N
concern NN N
in IN N
behavioral JJ N
weight JJ N
loss NN N
intervention NN N
studies NNS N
. . N

The DT N
purpose NN N
of IN N
this DT N
analysis NN N
was VBD N
to TO N
identify VB N
baseline NN N
and CC N
six-month JJ N
predictors NNS N
associated VBN N
with IN N
participant JJ N
attrition NN N
across IN N
three CD N
independent JJ N
clinical JJ N
trials NNS N
of IN N
behavioral JJ N
weight JJ N
loss NN N
interventions NNS N
( ( i
PREFER NNP i
, , i
SELF NNP i
, , N
and CC N
SMART NNP i
) ) i
that WDT N
were VBD N
conducted VBN N
over IN N
10 CD N
years NNS N
. . N

Baseline NNP i
measures VBZ i
included VBN i
body NN o
mass NN o
index NN o
, , o
Barriers NNP o
to TO o
Healthy NNP o
Eating NNP o
, , o
Beck NNP o
Depression NNP o
Inventory-II NNP o
( ( o
BDI NNP o
) ) o
, , o
Hunger NNP o
Satiety NNP o
Scale NNP o
( ( o
HSS NNP o
) ) o
, , o
Binge NNP o
Eating NNP o
Scale NNP o
( ( o
BES NNP o
) ) o
, , o
Medical NNP o
Outcome NNP o
Study NNP o
Short NNP o
Form NNP o
( ( o
MOS NNP o
SF-36 NNP o
v2 NN o
) ) o
and CC o
Weight NNP o
Efficacy NNP o
Lifestyle NNP o
Questionnaire NNP o
( ( o
WEL NNP o
) ) o
. . o

We PRP N
also RB N
examined VBD N
early JJ o
weight NN o
loss NN o
and CC o
attendance NN o
at IN i
group NN i
sessions NNS i
during IN i
the DT i
first JJ i
6 CD i
months NNS i
. . i

Attrition NNP o
was VBD N
recorded VBN N
at IN N
the DT N
end NN N
of IN N
the DT N
trials NNS N
. . N

Participants NNS p
included VBD p
504 CD p
overweight NN p
and CC p
obese JJ p
adults NNS p
seeking VBG p
weight JJ p
loss NN p
treatment NN p
. . p

The DT N
sample NN p
was VBD p
84.92 CD p
% NN p
female NN p
and CC p
73.61 CD p
% NN p
white JJ p
, , p
with IN p
a DT p
mean NN p
( ( p
? . p
SD NNP p
) ) p
age NN p
of IN p
47.35 CD p
? . p
9.75 CD p
years NNS p
. . p

After IN N
controlling VBG N
for IN N
the DT N
specific JJ N
trial NN N
, , N
for IN N
every DT N
one CD N
unit NN N
increase NN N
in IN N
BMI NNP o
, , o
the DT N
odds NNS N
of IN N
attrition NN N
increased VBN N
by IN N
11 CD N
% NN N
. . N

For IN N
every DT N
year NN o
increase NN o
in IN o
education NN o
, , o
the DT N
odds NNS N
of IN N
attrition NN N
decreased VBN N
by IN N
10 CD N
% NN N
. . N

Additional JJ N
predictors NNS N
of IN N
attrition NN N
included VBD p
previous JJ p
attempts NNS p
to TO p
lose VB p
50-79 JJ p
lbs NN p
, , p
age NN p
, , p
not RB p
possessing VBG o
health NN o
insurance NN o
, , o
and CC o
BES NNP o
, , o
BDI NNP o
, , o
and CC o
HSS NNP o
scores NNS o
. . o

At IN N
6 CD N
months NNS N
, , N
the DT N
odds NNS N
of IN N
attrition NN o
increased VBN o
by IN N
10 CD N
% NN N
with IN N
reduced JJ N
group NN N
session NN N
attendance NN N
. . N

There EX N
was VBD N
also RB N
an DT N
interaction NN N
between IN N
percent NN N
weight NN N
change NN N
and CC N
trial NN N
( ( N
p JJ N
< NNP N
.001 NNP N
) ) N
. . N

Multivariate NNP N
analysis NN N
of IN N
the DT N
three CD N
trials NNS N
showed VBD N
education NN N
, , N
age NN N
, , N
BMI NNP N
, , N
and CC N
BES NNP N
scores NNS N
were VBD N
independently RB N
associated VBN N
with IN N
attrition NN N
( ( N
ps VB N
? . N
.01 NN N
) ) N
. . N

These DT N
findings NNS N
may MD N
inform VB N
the DT N
development NN N
of IN N
more JJR N
robust JJ N
strategies NNS N
for IN N
reducing VBG N
attrition NN N
. . N

-DOCSTART- -24372367- O O

Evaluating VBG N
the DT N
acceptability NN N
and CC N
efficacy NN N
of IN N
a DT N
psycho-educational JJ i
intervention NN i
for IN N
coping VBG N
and CC N
symptom JJ N
management NN N
by IN N
children NNS p
with IN p
cancer NN p
: : p
a DT N
randomized NN N
controlled VBN N
study NN N
. . N

AIMS NNP N
To TO N
evaluate VB N
the DT N
acceptability NN N
and CC N
efficacy NN N
of IN N
a DT N
psycho-educational JJ i
intervention NN i
designed VBN N
to TO N
improve VB N
effective JJ N
coping NN N
and CC N
reduce VB N
symptom JJ N
severity NN N
in IN N
children NNS p
with IN p
cancer NN p
. . p

BACKGROUND NNP N
Cancer NNP N
treatments VBZ N
increase VB N
survival JJ N
rates NNS N
and CC N
also RB N
cause VB N
physical JJ N
and CC N
psychological JJ N
effects NNS N
on IN N
children NNS p
with IN p
cancer NN p
. . p

A DT N
psycho-educational JJ i
intervention NN i
is VBZ N
used VBN N
to TO N
assist VB N
children NNS p
and CC p
adolescents NNS p
with IN p
these DT p
effects NNS p
and CC N
its PRP$ N
efficacy NN N
has VBZ N
been VBN N
described VBN N
in IN N
several JJ N
studies NNS N
. . N

DESIGN VB N
A DT N
randomized NN N
controlled VBN N
trial NN N
. . N

METHODS NNP N
Participants NNPS p
being VBG p
treated VBN p
were VBD p
recruited VBN p
and CC p
randomly RB p
assigned VBN p
to TO p
two CD p
groups NNS p
from IN p
September NNP p
2011-February JJ p
2013 CD p
in IN p
Taiwan NNP p
. . p

The DT N
intervention NN N
group NN N
received VBD N
a DT N
psycho-educational JJ i
intervention NN i
in IN i
addition NN i
to TO i
standard VB i
care NN i
, , i
while IN i
the DT i
control NN i
group NN i
received VBD i
only RB i
standard JJ i
care NN i
. . i

Each DT N
participant NN N
was VBD N
assessed VBN N
using VBG N
a DT N
paediatric JJ N
cancer NN N
coping VBG N
scale NN N
and CC N
perceived VBD N
symptom JJ N
severity NN N
was VBD N
evaluated VBN N
at IN N
three CD N
time NN N
points NNS N
( ( N
baseline NN N
, , N
1 CD N
month NN N
and CC N
3 CD N
months NNS N
) ) N
. . N

A DT N
repeated-measures JJ N
analysis NN N
of IN N
variance NN N
was VBD N
used VBN N
to TO N
estimate VB N
the DT N
effects NNS N
of IN N
intervention NN N
. . N

Qualitative JJ N
findings NNS N
were VBD N
analysed VBN N
using VBG N
content JJ N
analysis NN N
. . N

RESULTS NNP N
No NNP N
significant JJ N
difference NN N
in IN N
coping VBG N
scores NNS N
was VBD N
found VBN N
between IN N
groups NNS N
, , N
but CC N
the DT N
experimental JJ N
group NN N
reported VBD N
significantly RB N
lower JJR N
scores NNS N
in IN N
gastrointestinal JJ o
problems NNS o
and CC o
pain NN o
. . o

Most JJS N
symptoms NNS N
decreased VBN N
significantly RB N
over IN N
time NN N
in IN N
both DT N
groups NNS N
, , N
except IN N
for IN N
gastrointestinal JJ N
problems NNS N
. . N

The DT N
scores NNS N
in IN N
pain NN o
, , o
bone NN o
marrow NN o
suppression NN o
and CC o
body NN o
image NN o
showed VBD N
significant JJ N
interaction NN N
effects NNS N
between IN N
groups NNS N
on IN N
changes NNS N
over IN N
time NN N
. . N

Qualitative JJ N
results NNS N
reported VBD N
that IN N
participants NNS N
evaluated VBD N
the DT N
intervention NN N
positively RB N
, , N
especially RB N
about IN N
receipt NN N
of IN N
psychological JJ N
support NN N
and CC N
learnt NN N
coping VBG N
skills NNS N
. . N

CONCLUSIONS VB N
The DT N
psycho-educational JJ i
intervention NN i
administered VBN N
was VBD N
acceptable JJ N
for IN N
children NNS p
with IN p
cancer NN p
and CC N
was VBD N
found VBN N
to TO N
reduce VB N
gastrointestinal JJ N
problems NNS N
and CC N
pain NN N
. . N

-DOCSTART- -10230191- O O

Naltrexone NN i
and CC N
communication NN N
skills NNS N
in IN N
young JJ p
children NNS p
with IN p
autism NN p
. . p

OBJECTIVE UH N
To TO N
evaluate VB N
the DT N
effect NN N
of IN N
naltrexone NN i
on IN N
communication NN N
skills NNS N
of IN N
young JJ p
children NNS p
with IN p
autism NN p
. . p

METHOD NNP N
Twenty-four JJ p
children NNS p
with IN p
autism NN p
, , p
3.0 CD p
to TO p
8.3 CD p
years NNS p
old JJ p
( ( p
mean JJ p
5.1 CD p
) ) p
who WP p
were VBD p
living VBG p
at IN p
home NN p
and CC p
attending VBG p
appropriate JJ p
school NN p
programs NNS p
, , N
participated VBN N
in IN N
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
, , N
crossover JJ N
trial NN N
. . N

Naltrexone NNP i
, , i
1.0 CD i
mg/kg NN i
, , i
or CC i
placebo NN i
was VBD i
administered VBN i
daily RB i
for IN i
2 CD i
weeks NNS i
. . i

Communication NN N
was VBD N
evaluated VBN N
from IN N
videotaped JJ i
samples NNS i
of IN i
seminaturalistic JJ i
parent-child JJ i
interaction NN i
. . i

Child NN N
and CC N
parent NN N
language NN N
were VBD N
assessed VBN N
using VBG N
similar JJ N
measures NNS N
. . N

RESULTS NNP N
In IN N
this DT N
heterogeneous JJ N
sample NN N
, , N
the DT N
median JJ o
number NN o
of IN o
words NNS o
the DT o
child NN o
produced VBN o
on IN N
placebo NN N
was VBD N
9.5 CD N
( ( N
range VB N
0-124 NN N
) ) N
. . N

The DT N
median JJ o
proportion NN o
of IN o
utterances NNS o
with IN o
echolalia NN o
was VBD N
0.16 CD N
. . N

No DT N
differences NNS N
were VBD N
found VBN N
between IN N
the DT N
naltrexone NN i
and CC N
placebo NN i
conditions NNS N
in IN N
any DT N
of IN N
the DT N
measures NNS N
of IN N
children NNS o
or CC o
parents NNS o
' POS o
communication NN o
. . o

Significant JJ N
correlations NNS N
were VBD N
found VBN N
between IN N
the DT N
child NN o
's POS o
number NN o
of IN o
words NNS o
and CC o
developmental JJ o
quotient NN o
( ( N
Spearman NNP N
rho VBZ N
= JJ N
0.58 CD N
, , N
p NN N
= NNP N
.003 NNP N
) ) N
and CC N
between IN N
the DT N
child NN N
's POS N
and CC N
parent NN N
's POS N
number NN N
of IN N
words NNS N
( ( N
rho VB N
= RB N
0.55 CD N
, , N
p NN N
= NNP N
.005 NNP N
) ) N
. . N

CONCLUSIONS NNP N
Previous NNP N
studies NNS N
showed VBD N
that IN N
naltrexone NN i
was VBD N
associated VBN N
with IN N
modest JJ N
reduction NN N
in IN N
hyperactivity NN N
and CC N
restlessness NN N
in IN N
this DT N
group NN N
of IN N
children NNS N
with IN N
autism NN N
. . N

In IN N
this DT N
short-term JJ N
study NN N
, , N
the DT N
medication NN N
did VBD N
not RB N
lead VB N
to TO N
improvement NN N
in IN N
communication NN N
, , N
a DT N
core NN N
deficit NN N
of IN N
autism NN N
. . N

-DOCSTART- -24982504- O O

Tacrolimus/sirolimus NNP i
vs NN i
tacrolimus/methotrexate NN i
as IN N
GVHD NNP N
prophylaxis NN N
after IN p
matched VBN p
, , N
related VBN N
donor NN p
allogeneic NN p
HCT NNP p
. . p

Grades NNP N
2-4 JJ N
acute JJ N
graft-versus-host JJ N
disease NN N
( ( N
GVHD NNP N
) ) N
occurs VBZ N
in IN N
approximately RB N
35 CD N
% NN N
of IN N
matched VBN p
, , p
related VBN p
donor NN p
( ( p
MRD NNP p
) ) p
allogeneic VBZ p
hematopoietic JJ p
cell NN p
transplantation NN p
( ( p
HCT NNP p
) ) p
recipients NNS p
. . p

We PRP N
sought VBD N
to TO N
determine VB N
if IN N
the DT N
combination NN N
of IN N
tacrolimus NN i
and CC i
sirolimus NN i
( ( i
Tac/Sir NNP i
) ) i
was VBD N
more RBR N
effective JJ N
than IN N
tacrolimus NN i
and CC i
methotrexate NN i
( ( i
Tac/Mtx NNP i
) ) i
in IN N
preventing VBG N
acute JJ N
GVHD NNP N
and CC N
early JJ N
mortality NN N
after IN N
allogeneic JJ N
MRD NNP N
HCT NNP N
in IN N
a DT N
phase NN N
3 CD N
, , N
multicenter JJR N
trial NN N
. . N

The DT N
primary JJ o
end NN o
point NN o
of IN N
the DT N
trial NN N
was VBD N
to TO N
compare VB N
114-day JJ o
grades NNS o
2-4 JJ o
acute JJ o
GVHD-free NNP o
survival NN o
using VBG N
an DT N
intention-to-treat JJ N
analysis NN N
of IN N
304 CD p
randomized JJ p
subjects NNS p
. . p

There EX N
was VBD N
no DT N
difference NN N
in IN N
the DT N
probability NN N
of IN N
day NN N
114 CD N
grades NNS N
2-4 JJ N
acute JJ N
GVHD-free JJ N
survival NN N
( ( N
67 CD N
% NN N
vs JJ N
62 CD N
% NN N
, , N
P NNP N
= NNP N
.38 NNP N
) ) N
. . N

Grades NNP o
2-4 JJ o
GVHD NNP o
was VBD N
similar JJ N
in IN N
the DT N
Tac/Sir NNP N
and CC N
Tac/Mtx NNP N
arms NNS N
( ( N
26 CD N
% NN N
vs JJ N
34 CD N
% NN N
, , N
P NNP N
= NNP N
.48 NNP N
) ) N
. . N

Neutrophil NNP o
and CC o
platelet VB o
engraftment NN o
were VBD N
more RBR N
rapid JJ N
in IN N
the DT N
Tac/Sir NNP N
arm NN N
( ( N
14 CD N
vs RB N
16 CD N
days NNS N
, , N
P NNP N
< NNP N
.001 NNP N
; : N
16 CD N
vs IN N
19 CD N
days NNS N
, , N
P NNP N
= NNP N
.03 NNP N
) ) N
. . N

Oropharyngeal NNP o
mucositis NN o
was VBD N
less RBR N
severe JJ N
in IN N
the DT N
Tac/Sir NNP N
arm NN N
( ( N
peak JJ N
Oral NNP o
Mucositis NNP o
Assessment NNP o
Scale NNP o
score VBD o
0.70 CD N
vs NN N
0.96 CD N
, , N
P NNP N
< NNP N
.001 NNP N
) ) N
, , N
but CC N
otherwise RB N
toxicity NN o
was VBD N
similar JJ N
. . N

Chronic NNP o
GVHD NNP o
, , o
relapse-free JJ o
survival NN o
, , o
and CC o
overall JJ o
survival NN o
at IN o
2 CD o
years NNS o
were VBD N
no DT N
different JJ N
between IN N
study NN N
arms NNS N
( ( N
53 CD N
% NN N
vs JJ N
45 CD N
% NN N
, , N
P NNP N
= NNP N
.06 NNP N
; : N
53 CD N
% NN N
vs JJ N
54 CD N
% NN N
, , N
P NNP N
= NNP N
.77 NNP N
; : N
and CC N
59 CD N
% NN N
vs JJ N
63 CD N
% NN N
, , N
P NNP N
= NNP N
.36 NNP N
) ) N
. . N

Based VBN N
on IN N
similar JJ N
long-term JJ N
outcomes NNS N
, , N
more RBR N
rapid JJ N
engraftment NN N
, , N
and CC N
less JJR N
oropharyngeal JJ N
mucositis NN N
, , N
the DT N
combination NN N
of IN N
Tac/Sir NNP N
is VBZ N
an DT N
acceptable JJ N
alternative NN N
to TO N
Tac/Mtx NNP N
after IN p
MRD NNP p
HCT NNP p
. . p

This DT N
study NN N
was VBD N
funded VBN N
by IN N
the DT N
National NNP N
Heart NNP N
, , N
Lung NNP N
, , N
and CC N
Blood NNP N
Institute NNP N
and CC N
the DT N
National NNP N
Cancer NNP N
Institute NNP N
; : N
and CC N
the DT N
trial NN N
was VBD N
registered VBN N
at IN N
www.clinicaltrials.gov NN N
as IN N
# # N
NCT00406393 NNP N
. . N

-DOCSTART- -20218011- O O

Comparison NNP N
of IN N
the DT N
in IN o
vitro NN o
and CC o
in IN o
vivo JJ o
release NN o
of IN o
digoxin NN o
from IN N
four CD N
different JJ N
soft JJ N
gelatin NN N
capsule NN i
formulations NNS i
. . i

A DT N
blinded JJ N
, , N
four-treatment JJ N
crossover NN N
study NN N
in IN N
16 CD p
normal JJ p
adult NN p
male NN p
volunteers NNS p
compared VBN N
plasma JJ N
concentrations NNS N
and CC N
urinary JJ o
excretion NN o
of IN o
digoxin NN o
, , N
measured VBN N
by IN N
radioimmunoassay NN N
, , N
after IN N
oral JJ N
administration NN N
of IN N
soft JJ i
gelatin NN i
capsule NN i
formulations NNS i
of IN i
digoxin NN i
. . i

Four CD N
0.4-mg JJ N
formulations NNS i
with IN i
different JJ i
in IN i
vitro NN i
burst NN i
times NNS i
and CC N
dissolution NN i
rates NNS i
were VBD N
administered VBN N
, , N
with IN N
2-week JJ N
intervals NNS N
between IN N
treatments NNS N
. . N

The DT N
two CD N
capsules NNS N
with IN N
lowest JJS N
in IN N
vitro NN N
burst NN N
times NNS N
( ( N
2.9 CD N
and CC N
16 CD N
min NN N
) ) N
gave VBD N
comparable JJ N
in IN N
vivo JJ N
results NNS N
. . N

The DT N
other JJ N
two CD N
capsules NNS N
, , N
with IN N
in IN N
vitro NN N
burst NN N
times NNS N
of IN N
62 CD N
and CC N
229 CD N
min NN N
, , N
produced VBD N
significant JJ N
delays NNS N
in IN N
digoxin NN N
absorption NN N
. . N

In IN N
vitro-in JJ N
vivo NN N
correlations NNS N
were VBD N
obtained VBN N
by IN N
comparing VBG N
the DT N
logarithm NN N
of IN N
the DT N
in IN N
vitro JJ N
burst NN N
time NN N
with IN N
time NN N
to TO N
peak VB o
plasma JJ o
level NN o
and CC N
the DT N
time NN N
to TO N
the DT N
first JJ N
measurable JJ N
plasma NN o
level NN o
( ( N
> CD N
or CC N
= VB N
0 CD N
. . N

05 CD N
ng/ml NN N
) ) N
. . N

Also RB N
, , N
the DT N
mean JJ N
time NN N
to TO N
peak VB o
plasma JJ o
level NN o
correlated VBN N
with IN N
the DT N
logarithm NN N
of IN N
the DT N
time NN N
required VBN N
to TO N
release VB N
either RB N
50 CD N
% NN N
or CC N
85 CD N
% NN N
of IN N
the DT N
digoxin NN N
in IN N
vitro NN N
. . N

No DT N
significant JJ N
changes NNS N
were VBD N
found VBN N
in IN N
the DT N
amount NN N
of IN N
digoxin NN i
absorbed VBN N
from IN N
each DT N
capsule NN N
as IN N
determined VBN N
by IN N
urinary JJ N
excretion NN N
or CC N
AUC0-infinity NN N
. . N

-DOCSTART- -15175435- O O

Bevacizumab NNP i
plus CC i
irinotecan JJ i
, , i
fluorouracil NN i
, , i
and CC i
leucovorin NN i
for IN N
metastatic JJ p
colorectal JJ p
cancer NN p
. . p

BACKGROUND NNP N
Bevacizumab NNP i
, , N
a DT N
monoclonal JJ N
antibody NN N
against IN N
vascular JJ N
endothelial JJ N
growth NN N
factor NN N
, , N
has VBZ N
shown VBN N
promising JJ N
preclinical JJ N
and CC N
clinical JJ N
activity NN N
against IN N
metastatic JJ p
colorectal JJ p
cancer NN p
, , N
particularly RB N
in IN N
combination NN N
with IN N
chemotherapy NN N
. . N

METHODS NNP N
Of IN N
813 CD p
patients NNS p
with IN p
previously RB p
untreated VBN p
metastatic JJ p
colorectal NN p
cancer NN p
, , N
we PRP N
randomly VBP N
assigned VBD N
402 CD N
to TO N
receive VB N
irinotecan JJ i
, , i
bolus JJ i
fluorouracil NN i
, , i
and CC i
leucovorin NN i
( ( i
IFL NNP i
) ) i
plus CC i
bevacizumab NN i
( ( N
5 CD N
mg NN N
per IN N
kilogram NN N
of IN N
body NN N
weight JJ N
every DT N
two CD N
weeks NNS N
) ) N
and CC N
411 CD N
to TO N
receive VB N
IFL NNP i
plus CC i
placebo NN i
. . i

The DT N
primary JJ N
end NN N
point NN N
was VBD N
overall JJ o
survival NN o
. . o

Secondary JJ N
end NN N
points NNS N
were VBD N
progression-free JJ o
survival NN o
, , o
the DT o
response NN o
rate NN o
, , o
the DT o
duration NN o
of IN o
the DT o
response NN o
, , o
safety NN o
, , o
and CC o
the DT o
quality NN o
of IN o
life NN o
. . o

RESULTS VB N
The DT N
median JJ o
duration NN o
of IN o
survival NN o
was VBD N
20.3 CD N
months NNS N
in IN N
the DT N
group NN N
given VBN N
IFL NNP i
plus CC i
bevacizumab NN i
, , N
as IN N
compared VBN N
with IN N
15.6 CD N
months NNS N
in IN N
the DT N
group NN N
given VBN N
IFL NNP i
plus CC i
placebo NN i
, , N
corresponding VBG N
to TO N
a DT N
hazard NN N
ratio NN N
for IN N
death NN N
of IN N
0.66 CD N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

The DT N
median JJ o
duration NN o
of IN o
progression-free JJ o
survival NN o
was VBD N
10.6 CD N
months NNS N
in IN N
the DT N
group NN N
given VBN N
IFL NNP i
plus CC i
bevacizumab NN i
, , N
as IN N
compared VBN N
with IN N
6.2 CD N
months NNS N
in IN N
the DT N
group NN N
given VBN N
IFL NNP i
plus CC i
placebo NN i
( ( N
hazard JJ N
ratio NN N
for IN N
disease NN N
progression NN N
, , N
0.54 CD N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
; : N
the DT N
corresponding JJ N
rates NNS N
of IN N
response NN N
were VBD N
44.8 CD N
percent NN N
and CC N
34.8 CD N
percent NN N
( ( N
P=0.004 NNP N
) ) N
. . N

The DT N
median JJ o
duration NN o
of IN o
the DT o
response NN o
was VBD N
10.4 CD N
months NNS N
in IN N
the DT N
group NN N
given VBN N
IFL NNP i
plus CC i
bevacizumab NN i
, , N
as IN N
compared VBN N
with IN N
7.1 CD N
months NNS N
in IN N
the DT N
group NN N
given VBN N
IFL NNP i
plus CC i
placebo NN i
( ( N
hazard JJ N
ratio NN N
for IN N
progression NN N
, , N
0.62 CD N
; : N
P=0.001 NNP N
) ) N
. . N

Grade $ o
3 CD o
hypertension NN o
was VBD N
more RBR N
common JJ N
during IN N
treatment NN N
with IN N
IFL NNP i
plus CC i
bevacizumab NN i
than IN N
with IN N
IFL NNP i
plus CC i
placebo NN i
( ( N
11.0 CD N
percent NN N
vs. FW N
2.3 CD N
percent NN N
) ) N
but CC N
was VBD N
easily RB N
managed VBN N
. . N

CONCLUSIONS VB N
The DT N
addition NN N
of IN N
bevacizumab NN i
to TO N
fluorouracil-based JJ i
combination NN i
chemotherapy NN i
results NNS N
in IN N
statistically RB N
significant JJ N
and CC N
clinically RB N
meaningful JJ N
improvement NN N
in IN N
survival NN o
among IN N
patients NNS p
with IN p
metastatic JJ p
colorectal JJ p
cancer NN p
. . p

-DOCSTART- -25549656- O O

Wrist JJ N
Rehabilitation NNP N
Assisted NNP N
by IN N
an DT N
Electromyography-Driven JJ i
Neuromuscular JJ i
Electrical JJ i
Stimulation NNP i
Robot NNP i
After IN N
Stroke NNP p
. . p

BACKGROUND NNP N
Augmented NNP i
physical JJ i
training NN i
with IN i
assistance NN i
from IN i
robot NN i
and CC i
neuromuscular JJ i
electrical JJ i
stimulation NN i
( ( i
NMES NNP i
) ) i
may MD N
introduce VB N
intensive JJ N
motor NN N
improvement NN N
in IN N
chronic JJ N
stroke NN N
. . N

OBJECTIVE UH N
To TO N
compare VB N
the DT N
rehabilitation NN N
effectiveness NN N
achieved VBN N
by IN N
NMES NNP i
robot-assisted JJ i
wrist NN i
training NN i
and CC N
that IN N
by IN N
robot-assisted JJ i
training NN i
. . i

METHODS NNP N
This DT N
study NN N
was VBD N
a DT N
single-blinded JJ N
randomized NN N
controlled VBD N
trial NN N
with IN N
a DT N
3-month JJ N
follow-up NN N
. . N

Twenty-six JJ p
hemiplegic JJ p
subjects NNS p
with IN p
chronic JJ p
stroke NN p
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
20-session JJ i
wrist NN i
training NN i
with IN i
an DT i
electromyography NN i
( ( i
EMG NNP i
) ) i
-driven RB i
NMES NNP i
robot NN i
( ( N
NMES NNP N
robot NNP N
group NN N
, , N
n RB N
= VBZ N
11 CD N
) ) N
and CC N
with IN N
an DT N
EMG-driven JJ i
robot NN i
( ( N
robot JJ N
group NN N
, , N
n RB N
= VBZ N
15 CD N
) ) N
, , N
completed VBD N
within IN N
7 CD N
consecutive JJ N
weeks NNS N
. . N

Clinical JJ o
scores NNS o
, , o
Fugl-Meyer NNP o
Assessment NNP o
( ( o
FMA NNP o
) ) o
, , o
Modified NNP o
Ashworth NNP o
Score NNP o
( ( o
MAS NNP o
) ) o
, , o
and CC o
Action NNP o
Research NNP o
Arm NNP o
Test NNP o
( ( o
ARAT NNP o
) ) o
were VBD N
used VBN N
to TO N
evaluate VB N
the DT N
training NN N
effects NNS N
before IN N
and CC N
after IN N
the DT N
training NN N
, , N
as RB N
well RB N
as IN N
3 CD N
months NNS N
later RB N
. . N

An DT N
EMG NNP N
parameter NN N
, , N
muscle NN N
co-contraction NN N
index NN N
, , N
was VBD N
also RB N
applied VBN N
to TO N
investigate VB N
the DT N
session-by-session JJ N
variation NN N
in IN N
muscular JJ N
coordination NN N
patterns NNS N
during IN N
the DT N
training NN N
. . N

RESULTS VB N
The DT N
improvement NN o
in IN o
FMA NNP o
( ( o
shoulder/elbow NN o
, , o
wrist/hand NN o
) ) o
obtained VBN N
in IN N
the DT N
NMES NNP i
robot NN i
group NN N
was VBD N
more RBR N
significant JJ N
than IN N
the DT N
robot NN N
group NN N
( ( N
P NNP N
< NNP N
.05 NNP N
) ) N
. . N

Significant JJ N
improvement NN o
in IN o
ARAT NNP o
was VBD N
achieved VBN N
in IN N
the DT N
NMES NNP N
robot NN N
group NN N
( ( N
P NNP N
< NNP N
.05 NNP N
) ) N
but CC N
absent NN N
in IN N
the DT N
robot NN N
group NN N
. . N

NMES NNP N
robot-assisted JJ N
training NN N
showed VBD N
better JJR o
performance NN o
in IN N
releasing VBG o
muscle NN o
co-contraction NN o
than IN N
the DT N
robot-assisted JJ N
across IN N
the DT N
training NN N
sessions NNS N
( ( N
P NNP N
< NNP N
.05 NNP N
) ) N
. . N

CONCLUSIONS VB N
The DT N
NMES NNP i
robot-assisted JJ i
wrist NN i
training NN i
was VBD N
more RBR N
effective JJ N
than IN N
the DT N
pure JJ N
robot NN N
. . N

The DT N
additional JJ N
NMES NNP N
application NN N
in IN N
the DT N
treatment NN N
could MD N
bring VB N
more JJR N
improvements NNS N
in IN N
the DT N
distal JJ N
motor NN N
functions NNS N
and CC N
faster JJR N
rehabilitation NN N
progress NN N
. . N

-DOCSTART- -9207470- O O

Circulating VBG i
blood NN i
B NNP i
cells NNS i
in IN N
multiple JJ p
myeloma NN p
: : p
analysis NN N
and CC N
relationship NN N
to TO N
circulating VBG N
clonal JJ N
cells NNS N
and CC N
clinical JJ N
parameters NNS N
in IN N
a DT N
cohort NN N
of IN N
patients NNS p
entered VBN p
on IN p
the DT p
Eastern NNP p
Cooperative NNP p
Oncology NNP p
Group NNP p
phase VBD p
III NNP p
E9486 NNP p
clinical JJ p
trial NN p
. . p

Recent JJ N
analyses NNS N
of IN N
circulating VBG N
blood NN N
B NNP N
cells NNS N
in IN N
myeloma NN N
have VBP N
generated VBN N
controversy NN N
concerning VBG N
the DT N
exact JJ N
levels NNS N
of IN N
these DT N
cells NNS N
and CC N
whether IN N
they PRP N
may MD N
represent VB N
circulating VBG N
clonal JJ N
tumor NN N
B NNP N
cells NNS N
. . N

Previous JJ N
reports NNS N
suggested VBD N
that IN N
CD19+ NNP o
B NNP o
cells NNS o
are VBP N
markedly RB N
increased VBN N
in IN N
myeloma NN p
patients NNS p
and CC N
that IN N
this DT N
population NN N
shares NNS N
clonotypic VBD N
rearrangements NNS N
with IN N
the DT N
malignant JJ N
plasma NN N
cell NN N
. . N

We PRP N
studied VBD N
the DT N
numbers NNS N
of IN N
CD19+ NNP o
B NNP o
cells NNS o
by IN p
flow JJ p
cytometry NN p
in IN p
previously RB p
untreated JJ p
newly RB p
diagnosed VBN p
myeloma NN p
patients NNS p
in IN p
Eastern NNP p
Cooperative NNP p
Oncology NNP p
Group NNP p
( ( p
ECOG NNP p
) ) p
phase NN p
III NNP p
trial NN p
E9486 NNP p
. . p

There EX p
were VBD p
628 CD p
patients NNS p
who WP p
were VBD p
eligible JJ p
for IN p
the DT p
clinical JJ p
protocol NN p
E9486 NNP p
, , p
but CC p
of IN p
these DT p
521 CD p
were VBD p
also RB p
entered VBN p
on IN p
the DT p
companion NN p
laboratory NN p
study NN p
( ( p
E9487 NNP p
) ) p
and CC p
had VBD p
CD19 NNP p
data NNS p
. . p

In IN N
comparison NN N
with IN N
normal JJ N
controls NNS N
, , N
the DT N
myeloma NN N
patients NNS N
exhibited VBD N
a DT N
marked JJ N
heterogeneity NN N
in IN N
the DT N
number NN N
of IN N
circulating VBG N
CD19+ NNP o
B NNP o
cells NNS o
as IN N
detected VBN N
by IN N
flow JJ i
cytometry NN i
. . i

Approximately RB N
20 CD N
% NN N
of IN N
patients NNS N
had VBD N
significantly RB N
increased VBN N
levels NNS o
of IN o
circulating VBG o
CD19+ NNP o
B NNP o
cells NNS o
. . o

However RB N
, , N
the DT N
total JJ o
CD19+ NNP o
blood NN o
population NN o
from IN N
myeloma NN N
was VBD N
not RB N
significantly RB N
different JJ N
from IN N
the DT N
median NN N
of IN N
age-matched JJ N
, , N
normal JJ N
controls NNS N
. . N

Analysis NN N
of IN N
CD19+ NNP o
blood NN o
cells NNS o
in IN N
relationship NN N
to TO N
circulating VBG N
clonal JJ N
cells NNS N
was VBD N
done VBN N
in IN N
13 CD N
myeloma NN N
patients NNS N
using VBG N
a DT N
clonotypic NN N
, , N
quantitative JJ N
allele-specific JJ N
oligonucleotide-polymerase NN N
chain NN N
reaction NN N
( ( N
PCR NNP N
) ) N
assay VBP N
. . N

No DT N
correlation NN N
was VBD N
found VBN N
between IN N
the DT N
numbers NNS N
of IN N
CD19+ NNP o
B NNP o
cells NNS o
( ( N
range NN N
, , N
5 CD N
% NN N
to TO N
51 CD N
% NN N
) ) N
and CC N
PCR NNP i
estimates NNS N
of IN N
the DT N
number NN N
of IN N
clonal JJ N
cells NNS N
in IN N
the DT N
peripheral JJ N
blood NN N
( ( N
range NN N
, , N
.009 CD N
% NN N
to TO N
3.6 CD N
% NN N
) ) N
. . N

Low JJ N
CD19+ NNP o
B-cell NNP o
level NN o
( ( N
< JJ N
125 CD N
microL NN N
) ) N
was VBD N
associated VBN N
with IN N
clinical JJ o
stage NN o
III NNP o
( ( N
P NNP N
= NNP N
.033 NNP N
) ) N
. . N

A DT N
significant JJ N
relationship NN N
exists VBZ N
between IN N
higher JJR N
levels NNS N
( ( N
> CD N
or CC N
= VB N
125/microL CD N
) ) N
of IN N
CD19 NNP o
cells NNS o
and CC N
longer JJR o
overall JJ o
survival NN o
( ( N
P NNP N
< NNP N
.0001 NNP N
) ) N
. . N

In IN N
addition NN N
, , N
high JJ N
CD19 NNP o
levels NNS o
also RB N
predicted VBD N
a DT N
clinical JJ N
response NN N
and CC N
longer JJR N
event-free JJ o
survival NN o
. . o

There EX N
was VBD N
a DT N
strong JJ N
inverse NN N
association NN N
between IN N
the DT N
level NN N
of IN N
CD19 NNP o
values NNS o
at IN N
diagnosis NN N
and CC N
infections NNS N
within IN N
the DT N
first JJ N
2 CD N
months NNS N
of IN N
diagnosis NN N
. . N

Importantly RB N
, , N
the DT N
number NN o
of IN o
deaths NNS o
related VBN o
to TO o
infections NNS o
was VBD N
significantly RB N
greater JJR N
in IN N
the DT N
low JJ N
versus NN N
high JJ N
CD19 NNP N
group NN N
( ( N
P NNP N
< NNP N
.0202 NNP N
) ) N
. . N

Also RB N
, , N
CD19 NNP N
is VBZ N
an DT N
independent JJ N
prognostic JJ N
factor NN N
in IN N
addition NN N
to TO N
plasma VB N
cell NN N
labeling VBG N
indices NNS N
, , N
beta2-microglobulin NN N
, , N
hemoglobin NN N
, , N
and CC N
plasmablastic JJ N
morphology NN N
. . N

Patients NNS N
with IN N
infections NNS N
were VBD N
more RBR N
likely JJ N
to TO N
have VB N
low JJ N
levels NNS o
of IN o
CD19+ NNP o
cells NNS o
. . o

In IN N
summary JJ N
, , N
higher JJR N
CD19+ NNP o
cell NN o
levels NNS o
are VBP N
a DT N
favorable JJ N
prognostic JJ N
sign NN N
with IN N
no DT N
apparent JJ N
relationship NN N
to TO N
circulating VBG N
tumor NN N
cells NNS N
. . N

In IN N
addition NN N
, , N
this DT N
analysis NN N
strongly RB N
suggests VBZ N
that IN N
low JJ N
peripheral JJ N
blood NN o
levels NNS o
of IN o
CD19+ NNP o
cells NNS N
are VBP N
an DT N
adverse JJ N
prognostic JJ N
sign NN N
in IN N
myeloma NN N
. . N

The DT N
CD19+ NNP o
cell NN o
levels NNS N
in IN N
myeloma NN N
patients NNS p
is VBZ N
an DT N
important JJ N
parameter NN N
in IN N
the DT N
overall JJ N
assessment NN N
of IN N
these DT N
patients NNS p
. . p

-DOCSTART- -19330493- O O

Fixed-dose JJ N
manidipine/delapril NN i
versus NN N
losartan/hydrochlorothiazide NN i
in IN N
hypertensive JJ p
patients NNS p
with IN p
type JJ p
2 CD p
diabetes NNS p
and CC p
microalbuminuria NNS p
. . p

INTRODUCTION NNP N
Patients NNPS p
with IN p
diabetes NNS p
complicated VBN p
by IN p
hypertension NN p
and CC p
microalbuminuria NNS p
have VBP N
elevated VBN N
cardiovascular JJ N
risk NN N
, , N
and CC N
controlling VBG N
blood NN N
pressure NN N
in IN N
these DT N
patients NNS N
is VBZ N
an DT N
urgent JJ N
clinical JJ N
priority NN N
. . N

The DT N
present JJ N
study NN N
aimed VBN N
to TO N
examine VB N
the DT N
effects NNS N
of IN N
a DT N
fixed-dose JJ N
combination NN N
of IN N
antihypertensives NNS N
on IN N
blood NN o
pressure NN o
and CC N
microalbuminuria NN o
. . o

METHODS NNP N
Patients NNPS p
with IN p
type JJ p
2 CD p
diabetes NNS p
, , p
mild-to-moderate JJ p
hypertension NN p
( ( p
diastolic JJ p
blood NN p
pressure NN p
85-105 JJ p
mmHg NN p
, , p
systolic JJ p
blood NN p
pressure NN p
< VBZ p
160 CD p
mmHg NN p
, , p
and CC p
24-hour JJ p
mean JJ p
systolic JJ p
blood NN p
pressure NN p
> VBZ p
130 CD p
mmHg NN p
) ) p
, , p
and CC p
microalbuminuria NNS p
were VBD N
randomized VBN N
to TO N
1 CD N
year NN N
of IN N
doubleblind NN N
treatment NN N
with IN N
fixed-dose JJ i
manidipine/delapril NN i
( ( N
n=54 JJ N
) ) N
or CC N
losartan/hydrochlorothiazide JJ i
( ( i
HCTZ NNP i
) ) i
( ( N
n=56 JJ N
) ) N
. . N

RESULTS NNP N
Blood NNP o
pressure NN o
was VBD N
significantly RB N
reduced VBN N
at IN N
1 CD N
year NN N
in IN N
both DT N
groups NNS N
( ( N
-22.2/-14.6 JJ N
mmHg NN N
and CC N
-19.5/-14.3 NNP N
mmHg NN N
, , N
for IN N
systolic JJ o
and CC o
diastolic JJ o
blood NN o
pressure NN o
respectively RB N
, , N
P NNP N
< VBZ N
0.001 CD N
for IN N
each DT N
) ) N
, , N
with IN N
no DT N
significant JJ N
between-group JJ N
difference NN N
. . N

Reductions NNS N
in IN N
microalbuminuria NN o
occurred VBN N
in IN N
both DT N
groups NNS N
, , N
with IN N
mean JJ N
changes NNS N
at IN N
1 CD N
year NN N
of IN N
-3.9 NNP N
mg/mmol FW N
creatinine NN N
( ( N
95 CD N
% NN N
CI NNP N
-5.3 NNP N
, , N
-2.5 NNP N
) ) N
for IN N
manidipine/delapril NN i
( ( N
P NNP N
< VBZ N
0.001 CD N
vs. FW N
baseline NN N
) ) N
and CC N
-2.7 $ N
mg/mmol FW N
creatinine NN N
( ( N
95 CD N
% NN N
CI NNP N
-4.0 NNP N
, , N
-1.3 NNP N
) ) N
for IN N
losartan/HCTZ NN i
( ( N
P NNP N
< VBZ N
0.001 CD N
vs. NN N
baseline NN N
and CC N
P=0.199 NNP N
between IN N
groups NNS N
) ) N
. . N

Glycemia NNP o
over IN N
the DT N
1-year JJ N
study NN N
was VBD N
largely RB N
unaffected JJ N
; : N
the DT N
blood NN o
glucose JJ o
concentration NN o
was VBD N
reduced VBN N
from IN N
baseline NN N
with IN N
manidipine/delapril NN i
, , N
although IN N
not RB N
statistically RB N
significant JJ N
( ( N
mean JJ N
change NN N
-0.2 NNP N
mmol/L NN N
, , N
P=0.064 NNP N
) ) N
. . N

Both DT N
treatments NNS N
were VBD N
well RB N
tolerated VBN N
, , N
with IN N
discontinuation NN N
for IN N
adverse JJ o
events NNS o
for IN N
one CD N
( ( N
1.9 CD N
% NN N
) ) N
patient NN N
in IN N
the DT N
manidipine/delapril NN i
group NN N
and CC N
two CD N
( ( N
3.6 CD N
% NN N
) ) N
in IN N
the DT N
losartan/HCTZ NN i
group NN N
. . N

CONCLUSIONS VB N
A DT N
fixed-dose JJ N
manidipine/delapril NN i
combination NN N
represents VBZ N
a DT N
useful JJ N
addition NN N
to TO N
the DT N
treatment NN N
options NNS N
available JJ N
to TO N
control VB N
hypertension NN N
complicated VBN N
by IN N
diabetes NNS N
and CC N
microalbuminuria NNS N
. . N

-DOCSTART- -8815984- O O

The DT N
use NN N
of IN N
a DT N
water NN i
extract NN i
from IN i
the DT i
bark NN i
of IN i
Choerospondias NNP i
axillaris NN i
in IN N
the DT N
treatment NN p
of IN p
second JJ p
degree NN p
burns NNS p
. . p

Burns NNS p
are VBP p
common JJ p
in IN p
Vietnam NNP p
, , N
and CC N
because IN N
of IN N
economic JJ N
constraints NNS N
and CC N
limited JJ N
resources NNS N
for IN N
the DT N
import NN N
of IN N
appropriate JJ N
treatments NNS N
, , N
the DT N
health NN N
authorities NNS N
are VBP N
obliged VBN N
to TO N
rely VB N
on IN N
traditional JJ N
herbal JJ N
remedies NNS N
. . N

It PRP N
is VBZ N
therefore RB N
essential JJ N
to TO N
evaluate VB N
current JJ N
drugs NNS N
, , N
one CD N
of IN N
which WDT N
is VBZ N
the DT N
water NN i
extract NN i
of IN i
the DT i
bark NN i
of IN i
the DT i
tree NN i
Choerospondias NNP i
axillaris NN i
. . i

It PRP N
has VBZ N
been VBN N
used VBN N
for IN N
many JJ N
years NNS N
in IN N
the DT N
Vietnam-Sweden JJ p
hospital NN p
at IN p
Uong NNP p
Bi NNP p
in IN p
northern JJ p
Vietnam NNP p
. . p

We PRP N
assessed VBD N
the DT N
efficacy NN o
of IN N
the DT N
remedy NN N
in IN N
an DT N
open JJ N
, , N
randomised VBD N
controlled VBN N
clinical JJ N
trial NN N
, , N
in IN N
which WDT N
20 CD p
patients NNS p
with IN p
second JJ p
degree NN p
burns NNS p
were VBD p
treated VBN p
with IN p
the DT p
extract NN i
of IN i
the DT i
Choerospondias NNP i
axillaris NN i
and CC p
19 CD p
with IN p
saline JJ i
gauze NN i
. . i

The DT N
mean JJ o
healing NN o
time NN o
was VBD N
significantly RB N
shorter JJR N
for IN N
patients NNS N
treated VBN N
with IN N
Choerospondias NNP i
axillaris NN i
( ( N
11 CD N
days NNS N
) ) N
compared VBN N
with IN N
patients NNS N
treated VBN N
with IN N
saline JJ i
gauze NN i
( ( N
17 CD N
days NNS N
) ) N
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
, , N
and CC N
the DT N
number NN o
of IN o
wound JJ o
infections NNS o
was VBD N
significantly RB N
lower JJR N
in IN N
the DT N
Choerospondias NNP i
axillaris NN i
group NN N
( ( N
7/20 CD N
compared VBN N
with IN N
16/19 CD N
, , N
p NN N
= NNP N
0.003 CD N
) ) N
. . N

The DT N
bark NN i
extract NN i
was VBD N
easy JJ N
to TO N
apply VB N
and CC N
additional JJ N
wound NN N
care NN N
was VBD N
not RB N
usually RB N
necessary JJ N
, , N
while IN N
the DT N
treatment NN N
with IN N
saline JJ i
gauze NN i
was VBD N
laborious JJ N
for IN N
both DT N
patients NNS N
and CC N
staff NN N
and CC N
was VBD N
much RB N
more RBR N
expensive JJ o
. . o

The DT N
extract NN i
from IN i
Choerospondias NNP i
axillaris NN i
is VBZ N
a DT N
convenient JJ N
treatment NN N
for IN N
second JJ p
degree NN p
burns NNS p
in IN N
both DT p
children NNS p
and CC p
adults NNS p
. . p

-DOCSTART- -7032811- O O

Effects NNS N
of IN N
a DT N
low-salt JJ i
diet NN i
and CC N
of IN N
acute JJ i
salt NN i
loading VBG i
on IN N
blood NN o
pressure NN o
and CC N
intralymphocytic JJ o
sodium NN o
concentration NN o
in IN N
young JJ p
subjects NNS p
with IN p
borderline JJ p
hypertension NN p
. . p

1 CD N
. . N

Three CD p
groups NNS p
of IN p
young JJ p
patients NNS p
with IN p
borderline JJ p
hypertension NN p
were VBD N
studied VBN N
for IN N
a DT N
12 CD N
months NNS N
period NN N
. . N

The DT N
first JJ N
was VBD N
on IN N
a DT N
free JJ i
sodium NN i
diet NN i
while IN N
the DT N
second JJ N
was VBD N
on IN N
a DT N
low-salt JJ i
diet NN i
. . i

The DT N
third JJ N
group NN N
of IN N
patients NNS N
underwent JJ N
acute JJ i
salt NN i
loading VBG i
. . i

2 CD N
. . N

After IN N
12 CD N
months NNS N
the DT N
group NN N
on IN N
free JJ i
diet NN i
showed VBD N
a DT N
significant JJ N
increase NN N
of IN N
intralymphocytic JJ o
sodium NN o
but CC N
no DT N
change NN N
in IN N
blood NN o
pressure NN o
was VBD N
noted VBN N
. . N

Five CD N
patients NNS N
who WP N
were VBD N
re-checked JJ N
after IN N
24 CD N
months NNS N
also RB N
had VBD N
a DT N
significant JJ N
increase NN N
in IN N
blood NN o
pressure NN o
. . o

3 CD N
. . N

Patients NNS N
treated VBD N
with IN N
a DT N
low-salt JJ i
diet NN i
showed VBD N
a DT N
significant JJ N
decrease NN N
of IN N
both DT N
intralymphocytic JJ o
sodium NN o
concentration NN o
and CC o
blood NN o
pressure NN o
. . o

4 CD N
. . N

After IN N
acute JJ N
salt NN N
loading NN N
, , N
borderline JJ N
subjects NNS N
with IN N
high JJ N
intralymphocytic JJ N
sodium NN N
showed VBD N
a DT N
significant JJ N
greater JJR N
natriuresis NN o
whereas RBR N
intralymphocytic JJ o
sodium NN o
increased VBD N
only RB N
in IN N
those DT N
subjects NNS N
in IN N
whom WP N
it PRP N
was VBD N
initially RB N
normal JJ N
. . N

-DOCSTART- -17595435- O O

Parenteral NNP i
amino NN i
acid NN i
and CC N
metabolic JJ N
acidosis NN N
in IN N
premature JJ p
infants NNS p
. . p

BACKGROUND NNP N
Aggressive NNP i
parenteral JJ i
nutrition NN i
( ( i
PN NNP i
) ) i
including VBG i
amino JJ i
acids NNS i
is VBZ N
recommended VBN N
for IN N
low-birth-weight JJ p
infants NNS p
to TO N
prevent VB N
energy NN N
and CC N
protein NN N
deficit NN N
. . N

Their PRP$ N
impact NN N
on IN N
acid-base JJ N
homeostasis NN N
has VBZ N
not RB N
been VBN N
examined VBN N
. . N

METHODS NNP N
We PRP N
investigated VBD N
the DT N
impact NN N
of IN N
dose NN N
and CC N
duration NN N
of IN N
parenteral JJ i
amino NN i
acids NNS i
, , i
with IN i
cysteine NN i
, , N
on IN N
acid-base JJ N
parameters NNS N
in IN N
122 CD p
low-birth-weight JJ p
infants NNS p
. . p

Premature NN p
infants NNS p
< VBP p
or=32 JJ p
weeks NNS p
, , p
< NNP p
or=1850 MD p
g VB p
, , p
and CC p
receiving VBG p
parenteral JJ i
amino NN i
acids NNS i
at IN p
1.5 CD p
g/kg/d NN p
for IN p
an DT p
extended JJ p
period NN p
( ( p
> JJ p
24 CD p
hours NNS p
) ) p
, , p
or CC p
3 CD p
g/kg/d NN p
for IN p
a DT p
short JJ p
( ( p
5 CD p
hour NN p
) ) p
, , p
extended VBD p
( ( p
24 CD p
hour NN p
) ) p
, , p
or CC p
prolonged VBN p
( ( p
3-5 JJ p
days NNS p
) ) p
duration NN p
were VBD N
included VBN N
in IN N
the DT N
study NN N
. . N

Data NNS N
were VBD N
obtained VBN N
at IN N
age NN N
0-3 JJ N
days NNS N
( ( N
n JJ N
= NNP N
43 CD N
) ) N
or CC N
, , N
when WRB N
clinically RB N
stable JJ N
, , N
age NN N
3-5 JJ N
days NNS N
( ( N
n JJ N
= NNP N
49 CD N
) ) N
. . N

Data NNS N
from IN N
30 CD p
infants NNS p
, , p
matched VBN p
for IN p
birth NN p
weight NN p
and CC p
gestational JJ p
age NN p
, , p
receiving VBG p
PN NNP i
during IN p
the DT p
first JJ p
5 CD p
days NNS p
after IN p
birth NN p
were VBD N
also RB N
obtained VBN N
. . N

Acidosis NNP N
was VBD N
defined VBN N
as IN N
pH NN N
< $ N
7.25 CD N
. . N

RESULTS JJ N
Acidosis NNP o
was VBD N
evident JJ N
in IN N
all DT N
infants NNS N
between IN N
2 CD N
and CC N
5 CD N
days NNS N
after IN N
birth NN N
. . N

Infants NNS p
with IN p
large JJ p
patent NN p
ductus NN p
arteriosus NN p
( ( p
PDA NNP p
) ) p
exhibited VBD N
significantly RB N
( ( N
p JJ N
< NNP N
.05 NNP N
) ) N
lower JJR o
pH NN o
early RB N
, , N
had VBD N
higher JJR N
blood NN o
urea JJ o
nitrogen NN o
levels NNS o
( ( N
26 CD N
+/- JJ N
9 CD N
vs NN N
18 CD N
+ NN N
8 CD N
mg/dL NN N
; : N
p CC N
< NNP N
.05 NNP N
) ) N
, , N
and CC N
had VBD N
greater JJR o
weight JJ o
loss NN o
( ( N
approximately RB N
17 CD N
% NN N
of IN N
birth NN N
weight NN N
) ) N
when WRB N
compared VBN N
with IN N
infants NNS N
without IN N
PDA NNP N
. . N

Gestational NNP o
age NN o
, , o
weight JJ o
loss NN o
, , o
and CC o
patent NN o
ductus NN o
arteriosus NN o
accounted VBD N
for IN N
65 CD N
% NN N
of IN N
variance NN N
in IN N
acidosis NN N
. . N

CONCLUSIONS NNP N
Low-birth-weight JJ p
infants NNS p
develop VB N
metabolic JJ N
acidosis NN N
between IN N
2 CD N
and CC N
5 CD N
days NNS N
after IN N
birth NN N
, , N
irrespective NN N
of IN N
dose NN N
and CC N
duration NN N
of IN N
parenteral JJ i
amino NN i
acid JJ i
administration NN i
. . i

Careful JJ N
management NN N
of IN N
parenteral JJ i
fluids NNS i
and CC N
comorbidities NNS N
may MD N
lower VB N
the DT N
incidence NN N
of IN N
acidosis NN N
and CC N
promote NN N
protein NN N
accretion NN N
. . N

-DOCSTART- -18394874- O O

Benzodiazepine NNP i
and CC N
opioid JJ i
sedation NN i
attenuate IN N
the DT N
sympathetic JJ N
response NN N
to TO N
fiberoptic JJ o
bronchoscopy NN o
. . o

Prophylactic JJ N
labetalol NN N
gave VBD N
no DT N
additional JJ N
benefit NN N
. . N

Results NNS N
of IN N
a DT N
randomized JJ N
double-blind JJ N
placebo-controlled JJ N
study NN N
. . N

BACKGROUND NNP N
Hypertension NNP N
and CC N
tachycardia NN N
are VBP N
common JJ N
during IN N
fiber-optic JJ i
bronchoscopy NN i
( ( i
FOB NNP i
) ) i
, , N
and CC N
this DT N
may MD N
lead VB N
to TO N
cardiac JJ N
ischemia NN N
. . N

The DT N
prophylactic JJ N
addition NN N
of IN N
a DT N
beta-adrenergic JJ i
anatagonist NN i
might MD N
mask VB N
this DT N
response NN N
and CC N
prevent VB N
the DT N
deleterious JJ N
cardiovascular JJ o
effects NNS o
of IN o
FOB NNP o
. . o

METHODS NNP N
We PRP N
performed VBD N
a DT N
randomized JJ N
double-blind JJ N
placebo-controlled JJ N
trial NN N
of IN N
labetalol $ i
10mg CD i
iv NN i
given VBN i
with IN i
midazolam-alfentanil JJ i
sedation NN i
. . i

We PRP N
monitored VBD N
heart NN o
rate NN o
( ( o
HR NNP o
) ) o
and CC o
systolic/diastolic JJ o
blood NN o
pressure NN o
( ( o
SBP/DBP NNP o
) ) o
throughout IN N
the DT N
bronchoscopy NN N
and CC N
calculated VBD N
the DT N
rate-pressure JJ N
product NN N
( ( N
RPP= NNP N
( ( N
HRxSBP NNP N
) ) N
/100 NN N
) ) N
. . N

One-hundred JJ p
twenty NN p
patients NNS p
were VBD p
enrolled VBN p
. . p

RESULTS NNP N
In IN N
the DT N
placebo NN N
group NN N
, , N
there EX N
was VBD N
no DT N
rise NN N
in IN N
HR NNP o
, , o
SBP NNP o
, , o
DBP NNP o
or CC o
RPP NNP o
, , N
and CC N
there EX N
was VBD N
no DT N
difference NN N
between IN N
the DT N
placebo NN N
and CC N
labetalol NN i
groups NNS N
. . N

Adverse JJ o
events NNS o
during IN o
bronchoscopy NN o
were VBD N
similar JJ N
in IN N
both DT N
groups NNS N
. . N

In IN N
a DT N
subgroup NN N
of IN N
patients NNS N
undergoing VBG N
interventional JJ N
bronchoscopy NN N
, , N
there EX N
was VBD N
a DT N
trend NN N
towards NNS N
lower JJR N
SBP NNP o
( ( N
p=0.06 NN N
) ) N
. . N

CONCLUSIONS JJ N
Patients NNPS p
undergoing VBG p
FOB NNP p
under IN N
adequate JJ N
midazolam-alfentanil JJ i
sedation NN i
do VBP N
not RB N
develop VB N
excessive JJ N
sympathetic JJ N
drive NN N
that WDT N
may MD N
lead VB N
to TO N
cardiac JJ N
stress NN N
. . N

The DT N
addition NN N
of IN N
labetalol NN i
did VBD N
not RB N
confer VB N
additional JJ N
benefit NN N
or CC N
risk NN N
to TO N
the DT N
patients NNS N
. . N

( ( N
ClinicalTrials.gov NNP N
number NN N
, , N
NCT00394537 NNP N
) ) N
. . N

-DOCSTART- -24292519- O O

Influence NN N
of IN N
two CD N
different JJ N
doses NNS N
of IN N
antithymocyte JJ i
globulin NN i
in IN N
patients NNS p
with IN p
standard-risk JJ p
disease NN p
following VBG p
haploidentical JJ p
transplantation NN p
: : p
a DT N
randomized JJ N
trial NN N
. . N

To TO N
evaluate VB N
the DT N
effect NN N
of IN N
the DT N
different JJ N
doses NNS N
of IN N
antithymocyte JJ i
globulin NN i
( ( i
ATG NNP i
) ) i
on IN N
the DT N
incidence NN N
of IN N
acute JJ N
GVHD NNP N
among IN N
patients NNS p
receiving VBG p
hematopoietic JJ p
SCT NNP p
without IN p
ex JJ p
vivo FW p
T-cell-depletion NN p
from IN p
haploidentical JJ p
donors NNS p
, , p
224 CD p
patients NNS p
with IN p
standard-risk JJ p
hematological JJ p
malignancy NN p
were VBD N
randomized VBN N
in IN N
this DT N
study NN N
. . N

One CD p
hundred CD p
and CC p
twelve VB p
patients NNS p
received VBD N
6 CD i
mg/kg NN i
ATG NNP i
, , i
whereas IN N
the DT N
remaining VBG N
patients NNS N
received VBD i
10 CD i
mg/kg NN i
ATG NNP i
. . N

This DT N
study NN N
was VBD N
registered VBN N
at IN N
http NN N
: : N
//www.chictr.org NN N
as IN N
No DT N
. . N

ChiCTR-TRC-11001761 NN N
. . N

The DT N
incidence NN o
of IN o
grade JJ o
III-IV NNP o
acute NN o
GVHD NNP o
was VBD o
higher RBR N
in IN N
the DT N
ATG-6 NNP i
group NN i
( ( N
16.1 CD N
% NN N
, , N
95 CD N
% NN N
confidence NN N
interval NN N
( ( N
CI NNP N
) ) N
, , N
9.1-23.1 CD N
% NN N
) ) N
than IN N
in IN N
the DT N
ATG-10 NNP i
group NN i
( ( N
4.5 CD N
% NN N
, , N
CI NNP N
, , N
0.7-8.3 CD N
% NN N
, , N
P=0.005 NNP N
, , N
95 CD N
% NN N
CI NNP N
for IN N
the DT N
difference NN N
, , N
-19.4 CD N
% NN N
to TO N
-3.8 CD N
% NN o
) ) o
. . o

EBV NNP o
reactivation NN o
occurred VBD o
more RBR N
frequently RB N
in IN N
the DT N
ATG-10 NNP i
group NN i
( ( N
25.3 CD N
% NN N
, , N
17.1-33.5 CD N
% NN N
) ) N
than IN N
in IN N
the DT N
ATG-6 NNP i
group NN i
( ( N
9.6 CD N
% NN N
( ( N
4.0-15.2 CD N
% NN N
) ) N
, , N
P=0.001 NNP o
) ) o
. . o

The DT o
1-year JJ o
disease-free JJ o
survival NN o
rates NNS o
were VBD o
84.3 CD N
% NN N
( ( N
77.3-91.3 CD N
% NN N
) ) N
and CC N
86.0 CD N
% NN N
( ( N
79.2-92.8 CD N
% NN N
) ) N
for IN N
the DT N
ATG-6 NNP i
group NN i
and CC N
ATG-10 NNP i
groups NNS i
, , N
respectively RB N
( ( N
P=0.88 NNP N
) ) N
. . N

In IN N
conclusion NN N
, , N
although IN i
6 CD i
mg/kg NNS i
ATG NNP i
applied VBD i
in IN N
haploidentical JJ N
transplantation NN N
decreased VBD o
the DT o
risk NN o
of IN o
EBV NNP o
reactivation NN o
compared VBN o
with IN i
10 CD i
mg/kg NNS i
ATG NNP i
, , i
this DT i
treatment NN N
exposes VBZ N
patients NNS N
to TO N
a DT N
higher JJR N
risk NN o
for IN o
severe JJ o
acute NN o
GVHD NNP o
. . o

-DOCSTART- -20431290- O O

Effects NNS N
of IN N
statins NNS i
on IN N
progression NN N
of IN N
subclinical JJ o
brain NN o
infarct NN o
. . o

BACKGROUND NNP N
Subclinical NNP o
brain NN o
infarct NN o
( ( o
SBI NNP o
) ) o
is VBZ N
associated VBN N
with IN N
subsequent JJ N
stroke NN N
and CC N
cognitive JJ N
decline NN N
. . N

A DT N
longitudinal JJ N
epidemiological JJ N
study NN N
suggests VBZ N
that IN N
statins NNS i
may MD N
prevent VB N
development NN N
of IN N
SBI NNP o
. . o

We PRP N
investigated VBD N
the DT N
effects NNS N
of IN N
statins NNS i
upon IN N
development NN o
of IN o
brain NN o
infarct NN o
by IN N
performing VBG N
a DT N
post-hoc JJ N
analysis NN N
of IN N
the DT N
Regression NNP N
of IN N
Cerebral NNP N
Artery NNP N
Stenosis NNP N
( ( N
ROCAS NNP N
) ) N
study NN N
. . N

METHODS NNP N
The DT N
ROCAS NNP N
study NN N
is VBZ N
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
study NN N
evaluating VBG N
the DT N
effects NNS N
of IN N
simvastatin NN i
20 CD N
mg JJ N
daily JJ N
upon IN N
progression NN N
of IN N
asymptomatic JJ N
middle JJ N
cerebral JJ N
artery NN N
stenosis NN N
among IN N
stroke-free JJ p
individuals NNS p
over IN p
2 CD p
years NNS p
. . p

A DT N
total NN p
of IN p
227 CD p
subjects NNS p
were VBD N
randomized VBN N
to TO N
either DT N
placebo NN i
( ( N
n JJ N
= NNP N
114 CD N
) ) N
or CC N
simvastatin $ i
20 CD N
mg JJ N
daily JJ N
( ( N
n JJ N
= NNP N
113 CD N
) ) N
. . N

The DT N
number NN o
of IN o
brain NN o
infarcts NNS o
as IN N
detected VBN N
by IN N
MRI NNP N
was VBD N
recorded VBN N
at IN N
baseline NN N
and CC N
at IN N
the DT N
end NN N
of IN N
the DT N
study NN N
. . N

The DT N
primary JJ N
outcome NN N
measure NN N
was VBD N
the DT N
number NN o
of IN o
new JJ o
brain NN o
infarcts NNS o
at IN N
the DT N
end NN N
of IN N
the DT N
study NN N
. . N

RESULTS NNP N
Among IN N
the DT N
227 CD p
randomized JJ p
subjects NNS p
, , p
33 CD p
( ( p
14.5 CD p
% NN p
) ) p
had VBD p
SBI VBN p
at IN p
baseline NN p
. . p

At IN N
the DT N
end NN N
of IN N
the DT N
study NN N
, , N
significantly RB N
fewer JJR N
subjects NNS N
in IN N
the DT N
active JJ N
group NN N
( ( N
n JJ N
= NNP N
1 CD N
) ) N
had VBD N
new JJ o
brain NN o
infarcts NNS o
compared VBN N
with IN N
the DT N
placebo NN i
group NN N
( ( N
n JJ N
= VBZ N
8 CD N
; : N
p NN N
= VBZ N
0.018 CD N
) ) N
. . N

The DT N
new JJ N
brain NN o
infarcts NNS o
of IN N
subjects NNS N
in IN N
the DT N
active JJ N
group NN N
were VBD N
subclinical JJ N
. . N

Among IN N
the DT N
placebo NN i
group NN N
, , N
the DT N
new JJ N
brain NN o
infarcts NNS o
of IN N
3 CD N
subjects NNS N
were VBD N
symptomatic JJ N
while IN N
those DT N
of IN N
the DT N
remaining VBG N
5 CD N
subjects NNS N
were VBD N
subclinical JJ N
. . N

Among IN N
putative JJ N
variables NNS N
, , N
multivariate JJ N
regression NN N
analysis NN N
showed VBD N
that IN N
only RB N
the DT N
baseline NN N
number NN N
of IN N
SBIs NNP o
( ( N
OR NNP N
= VBZ N
6.27 CD N
, , N
95 CD N
% NN N
CI NNP N
2.4-16.5 CD N
) ) N
and CC N
simvastatin JJ i
treatment NN N
( ( N
OR NNP N
= VBZ N
0.09 CD N
, , N
95 CD N
% NN N
CI NNP N
0.01-0.82 NN N
) ) N
independently RB N
predicted VBD N
the DT N
development NN N
of IN N
new JJ N
brain NN N
infarcts NNS N
. . N

CONCLUSIONS NNP N
Consistent NNP N
with IN N
findings NNS N
of IN N
the DT N
epidemiological JJ N
study NN N
, , N
our PRP$ N
study NN N
suggests VBZ N
that IN N
statins NNS N
may MD N
prevent VB N
the DT N
development NN N
of IN N
a DT N
new JJ N
brain NN o
infarct NN o
. . o

-DOCSTART- -25292351- O O

Disorder-dissociated JJ N
effects NNS N
of IN N
fluoxetine NN i
on IN N
brain NN N
function NN N
of IN N
working VBG N
memory NN N
in IN N
attention NN p
deficit NN p
hyperactivity NN p
disorder NN p
and CC p
autism NN p
spectrum NN p
disorder NN p
. . p

BACKGROUND NNP N
Attention NNP N
deficit NN N
hyperactivity NN N
disorder NN N
( ( N
ADHD NNP N
) ) N
and CC N
autism NN N
spectrum NN N
disorder NN N
( ( N
ASD NNP N
) ) N
are VBP N
often RB N
co-morbid JJ N
and CC N
share NN N
performance NN N
and CC N
brain NN N
dysfunctions NNS N
during IN N
working VBG N
memory NN N
( ( N
WM NNP N
) ) N
. . N

Serotonin JJ N
agonists NNS N
modulate VBP N
WM NNP N
and CC N
there EX N
is VBZ N
evidence NN N
of IN N
positive JJ N
behavioural JJ N
effects NNS N
in IN N
both DT N
disorders NNS N
. . N

We PRP N
therefore VBP N
used JJ N
functional JJ N
magnetic JJ N
resonance NN N
imaging NN N
( ( N
fMRI NN N
) ) N
to TO N
investigate VB N
shared VBN N
and CC N
disorder-specific JJ N
brain NN N
dysfunctions NNS N
of IN N
WM NNP N
in IN N
these DT N
disorders NNS N
, , N
and CC N
the DT N
effects NNS N
of IN N
a DT N
single JJ N
dose NN N
of IN N
the DT N
selective JJ N
serotonin NN i
reuptake NN i
inhibitor NN i
( ( i
SSRI NNP i
) ) i
fluoxetine NN i
. . i

METHOD NNP N
Age-matched JJ p
boys NNS p
with IN p
ADHD NNP p
( ( p
n JJ p
= NNP p
17 CD p
) ) p
, , p
ASD NNP p
( ( p
n JJ p
= NNP p
17 CD p
) ) p
and CC p
controls NNS p
( ( p
n JJ p
= NNP p
22 CD p
) ) p
were VBD p
compared VBN N
using VBG N
fMRI NN i
during IN N
an DT N
N-back JJ N
WM NNP N
task NN N
. . N

Patients NNS N
were VBD N
scanned VBN N
twice RB N
, , N
under IN N
either DT N
an DT N
acute NN N
dose NN N
of IN i
fluoxetine NN i
or CC i
placebo NN i
in IN i
a DT i
double-blind JJ N
, , N
placebo-controlled JJ N
randomized JJ N
design NN N
. . N

Repeated-measures JJ N
analyses NNS N
within IN N
patients NNS N
assessed JJ N
drug NN N
effects NNS N
on IN N
performance NN N
and CC N
brain NN N
function NN N
. . N

To TO N
test VB N
for IN N
normalization NN N
effects NNS N
of IN N
brain NN N
dysfunctions NNS N
, , N
patients NNS N
under IN N
each DT N
drug NN N
condition NN N
were VBD N
compared VBN N
to TO N
controls NNS N
. . N

RESULTS NNP N
Under IN N
placebo NN i
, , i
relative JJ i
to TO N
controls NNS N
, , N
both DT N
ADHD NNP N
and CC N
ASD NNP N
boys NNS N
shared VBD N
underactivation NN o
in IN o
the DT o
right JJ o
dorsolateral JJ o
prefrontal JJ o
cortex NN o
( ( o
DLPFC NNP o
) ) o
. . o

Fluoxetine NNP o
significantly RB N
normalized VBD o
the DT o
DLPFC NNP o
underactivation NN o
in IN o
ASD NNP o
relative NN N
to TO N
controls NNS N
whereas IN N
it PRP N
increased VBD o
posterior JJ o
cingulate NN o
cortex NN o
( ( o
PCC NNP o
) ) o
deactivation NN o
in IN o
ADHD NNP o
relative JJ N
to TO N
control VB N
boys NNS N
. . N

Within-patient JJ N
analyses NNS N
showed VBD N
inverse JJ N
effects NNS N
of IN N
fluoxetine NN N
on IN N
PCC NNP N
deactivation NN N
, , N
which WDT N
it PRP N
enhanced VBD N
in IN N
ADHD NNP N
and CC N
decreased VBN N
in IN N
ASD NNP N
. . N

CONCLUSIONS NNP N
The DT N
findings NNS N
show VBP N
that IN N
fluoxetine NN N
modulates NNS N
brain NN N
activation NN N
during IN N
WM NNP N
in IN N
a DT N
disorder-specific JJ N
manner NN N
by IN N
normalizing VBG N
task-positive JJ N
DLPFC NNP N
dysfunction NN p
in IN p
ASD NNP p
boys NNS p
and CC N
enhancing VBG N
task-negative JJ N
default NN N
mode NN N
network NN N
( ( N
DMN NNP N
) ) N
deactivation NN N
in IN N
ADHD NNP N
. . N

-DOCSTART- -9055050- O O

Outcome NNP o
assessment NN o
for IN p
clinical JJ p
trials NNS p
: : p
how WRB N
many JJ N
adjudicators NNS p
do VBP N
we PRP N
need VB N
? . N
Canadian JJ N
Lung NNP N
Oncology NNP N
Group NNP N
. . N

Considerable JJ N
effort NN N
is VBZ N
often RB N
expended VBN N
to TO N
adjudicate VB N
outcomes NNS N
in IN N
clinical JJ N
trials NNS N
, , N
but CC N
little JJ N
has VBZ N
been VBN N
written VBN N
on IN N
the DT N
administration NN N
of IN N
the DT N
adjudication NN N
process NN N
and CC N
its PRP$ N
possible JJ N
impact NN N
on IN N
study NN N
results NNS N
. . N

As IN N
a DT N
case NN N
study NN N
, , N
we PRP N
describe VBP N
the DT N
function NN o
and CC o
performance NN o
of IN o
an DT o
adjudication NN o
committee NN o
in IN p
a DT p
large JJ p
randomized JJ p
trial NN p
of IN N
two CD N
diagnostic JJ N
approaches NNS N
to TO N
potentially RB p
operable JJ p
lung NN p
cancer NN p
. . p

Up IN p
to TO p
five CD p
independent JJ p
adjudicators NNS p
independently RB N
determined VBD N
two CD N
primary JJ N
outcomes NNS N
: : N
tumor NN o
status NN o
at IN o
death NN o
or CC o
at IN o
final JJ o
follow-up NN o
and CC o
the DT o
cause NN o
of IN o
death NN o
. . o

Patients NNS p
for IN N
whom WP N
there EX N
was VBD N
any DT N
disagreement NN N
were VBD N
discussed VBN N
in IN N
committee NN N
until IN N
a DT N
consensus NN N
was VBD N
achieved VBN N
. . N

We PRP N
describe VBP N
the DT N
pattern NN N
of IN N
agreement NN N
among IN N
the DT N
adjudicators NNS N
and CC N
with IN N
the DT N
final JJ N
consensus NN N
result NN N
. . N

Additionally RB N
, , N
we PRP N
model VBP N
the DT N
adjudication NN N
process NN N
and CC N
predict VBP N
the DT N
results NNS N
if IN N
a DT N
smaller JJR N
committee NN N
had VBD N
been VBN N
used VBN N
. . N

We PRP N
found VBD N
that IN N
reducing VBG N
the DT N
number NN o
of IN o
adjudicators NNS o
from IN N
five CD N
to TO N
two CD N
or CC N
three CD N
would MD N
probably RB N
have VB N
changed VBN N
the DT N
consensus NN N
outcome NN N
in IN N
less JJR N
than IN N
10 CD N
% NN N
of IN N
cases NNS N
. . N

Correspondingly RB N
, , N
the DT N
effect NN N
on IN N
the DT N
final JJ N
study NN N
results NNS N
( ( N
comparing VBG N
primary JJ N
outcomes NNS N
in IN N
both DT N
randomized JJ N
arms NNS N
) ) N
would MD N
have VB N
been VBN N
altered VBN N
very RB N
little JJ N
. . N

Even RB N
using VBG N
a DT N
single JJ N
adjudicator NN N
would MD N
not RB N
have VB N
affected VBN N
the DT N
results NNS N
substantially RB N
. . N

About IN N
90 CD N
minutes NNS N
of IN N
person-time JJ N
per IN N
patient NN p
was VBD N
required VBN N
for IN N
activities NNS N
directly RB N
related VBN N
to TO N
the DT N
adjudication NN i
process NN i
, , N
or CC N
approximately RB N
6 CD N
months NNS N
of IN N
full JJ N
time NN N
work NN N
for IN N
the DT N
entire JJ N
study NN N
. . N

This DT N
level NN N
of IN N
effort NN N
could MD N
be VB N
substantially RB N
reduced VBN N
by IN N
using VBG N
fewer JJR N
adjudicators NNS N
with IN N
little JJ N
impact NN N
on IN N
the DT N
results NNS N
. . N

Thus RB N
, , N
we PRP N
suggest VBP N
that IN N
when WRB N
high JJ N
observer NN N
agreement NN N
is VBZ N
demonstrated VBN N
or CC N
anticipated VBN N
, , N
adjudication NN N
committees NNS N
should MD N
consist VB N
of IN N
no DT N
more RBR N
than IN N
three CD N
members NNS N
. . N

Further JJ N
work NN N
is VBZ N
needed VBN N
to TO N
evaluate VB N
if IN N
smaller JJR N
committees NNS N
are VBP N
adequate JJ N
to TO N
detect VB N
small JJ N
but CC N
important JJ N
treatment NN N
effects NNS N
or CC N
if IN N
they PRP N
compromise VBP N
validity NN N
when WRB N
the DT N
level NN N
of IN N
adjudicator NN N
agreement NN N
is VBZ N
lower JJR N
. . N

-DOCSTART- -22638779- O O

Propofol NNP i
sedation NN N
with IN N
bispectral JJ N
index NN N
monitoring NN N
is VBZ N
useful JJ N
for IN N
endoscopic NN N
submucosal JJ i
dissection NN N
: : N
a DT N
randomized JJ N
prospective JJ N
phase NN N
II NNP N
clinical JJ N
trial NN N
. . N

BACKGROUND NNP N
AND NNP N
STUDY NNP N
AIMS NNP N
Endoscopic NNP N
submucosal NN N
dissection NN N
( ( N
ESD NNP N
) ) N
has VBZ N
become VBN N
a DT N
standard JJ N
treatment NN N
. . N

However RB N
, , N
the DT N
treatment NN N
time NN N
tends VBZ N
to TO N
be VB N
relatively RB N
long JJ N
and CC N
insufflation NN N
and CC N
manipulation NN N
of IN N
the DT N
endoscope NN N
can MD N
increase VB N
pain NN N
and CC N
discomfort NN N
. . N

We PRP N
aimed VBD N
to TO N
find VB N
an DT N
optimal JJ N
method NN N
for IN N
sedation NN N
during IN N
ESD NNP N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
Patients NNP p
scheduled VBD p
to TO p
undergo VB p
ESD NNP p
for IN p
early JJ p
gastric JJ p
cancer NN p
or CC p
adenoma NN p
were VBD p
randomly RB p
assigned VBN p
to TO p
sedation NN p
with IN p
midazolam NN i
or CC i
propofol NN i
, , p
and CC p
consciousness JJ p
level NN p
was VBD p
evaluated VBN p
by IN p
bispectral JJ p
index NN p
( ( p
BIS NNP p
) ) p
monitoring NN p
. . p

Primary JJ N
end NN N
points NNS N
of IN N
effectiveness NN N
( ( N
three CD N
parameters NNS N
) ) N
and CC N
secondary JJ N
end NN N
points NNS N
of IN N
safety NN N
during IN N
ESD NNP N
and CC N
after IN N
return NN N
to TO N
the DT N
ward NN N
were VBD N
compared VBN N
between IN N
the DT N
groups NNS N
. . N

Study NNP N
registration NN N
was VBD N
in IN N
the DT N
UMIN NNP N
Clinical NNP N
Trial NNP N
Registry NNP N
( ( N
UMIN NNP N
000001497 CD N
) ) N
, , N
and CC N
the DT N
institutional JJ N
trial NN N
number NN N
was VBD N
KDOG NNP N
0801 CD N
. . N

RESULTS VBN N
From IN N
June NNP N
2008 CD N
through IN N
June NNP N
2009 CD N
, , N
we PRP p
enrolled VBD N
178 CD p
patients NNS p
( ( N
90 CD N
midazolam NN N
, , N
88 CD N
propofol NN N
) ) N
. . N

Regarding VBG N
safety NN o
after IN N
ESD NNP N
, , N
recovery NN o
was VBD N
significantly RB N
better RBR N
in IN N
the DT N
propofol NN N
group NN N
immediately RB N
after IN N
and CC N
at IN N
1 CD N
hour NN N
and CC N
2 CD N
hours NNS N
after IN N
return NN N
to TO N
the DT N
ward NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

The DT N
number NN o
of IN o
patients NNS o
who WP o
required VBD o
a DT o
continuous JJ o
supply NN o
of IN o
oxygen NN o
2 CD N
hours NNS N
after IN N
returning VBG N
to TO N
the DT N
ward NN N
was VBD N
significantly RB N
lower JJR N
in IN N
the DT N
propofol NN N
group NN N
( ( N
midazolam JJ N
18 CD N
; : N
propofol CC N
6 CD N
; : N
P NNP N
= NNP N
0.010 CD N
) ) N
. . N

Though IN N
propofol NN N
seemed VBD N
to TO N
be VB N
better JJR N
for IN N
effectiveness NN o
and CC o
safety NN o
, , N
there EX N
were VBD N
no DT N
statistically RB N
significant JJ N
differences NNS N
for IN N
all DT N
three CD N
primary JJ N
end NN N
points NNS N
and CC N
the DT N
safety NN o
parameters NNS o
( ( o
hypotension NN o
, , o
hypoxia NN o
, , o
bradycardia NN o
) ) o
. . N

CONCLUSIONS NNP N
Propofol NNP i
with IN N
BIS NNP N
monitoring VBG N
improved JJ N
recovery NN o
of IN N
patients NNS p
after IN p
ESD NNP p
, , N
though IN N
this DT N
study NN N
was VBD N
underpowered VBN N
to TO N
prove VB N
the DT N
effectiveness NN N
and CC N
safety NN N
of IN N
propofol NN N
. . N

-DOCSTART- -23715475- O O

Yoga JJ N
effects NNS N
on IN N
mood NN o
and CC N
quality NN o
of IN o
life NN o
in IN N
Chinese JJ p
women NNS p
undergoing VBG p
heroin JJ p
detoxification NN p
: : p
a DT N
randomized NN N
controlled VBN N
trial NN N
. . N

BACKGROUND NNP N
Yoga NNP N
, , N
as IN N
a DT N
mind-body NN N
therapy NN N
, , N
is VBZ N
effective JJ N
in IN N
improving VBG N
quality NN o
of IN o
life NN o
for IN N
patients NNS N
with IN N
chronic JJ N
diseases NNS N
, , N
yet RB N
little JJ N
is VBZ N
known VBN N
about IN N
its PRP$ N
effectiveness NN N
in IN N
female JJ N
heroin NN N
addicts NNS N
. . N

OBJECTIVES IN N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
effects NNS o
of IN N
yoga NN i
on IN N
mood NN o
status NN o
and CC o
quality NN o
of IN o
life NN o
among IN N
women NNS N
undergoing VBG N
detoxification NN N
for IN N
heroin NN N
dependence NN N
in IN N
China NNP N
. . N

METHOD NNP N
This DT N
study NN N
was VBD N
a DT N
randomized VBN N
controlled VBN N
trial NN N
. . N

Seventy-five JJ p
women NNS p
aged VBN p
20-37 CD p
years NNS p
undergoing JJ p
detoxification NN p
for IN p
heroin NN p
dependence NN p
at IN p
AnKang NNP p
Hospital NNP p
were VBD N
allocated VBN N
randomly RB N
into IN N
an DT N
intervention NN i
or CC i
a DT i
control NN i
group NN i
. . i

Women NNS p
in IN p
the DT p
intervention NN p
group NN p
received VBD N
a DT N
6-month JJ i
yoga NN i
intervention NN i
in IN N
addition NN N
to TO N
hospital VB N
routine JJ N
care NN N
, , N
and CC N
women NNS N
in IN N
the DT N
control NN N
group NN N
received VBD N
hospital JJ i
routine NN i
care NN i
only RB i
. . i

Mood NNP o
status NN o
and CC o
quality NN o
of IN o
life NN o
were VBD N
assessed VBN N
using VBG N
the DT N
Profile NNP o
of IN o
Mood NNP o
States NNPS o
and CC o
Medical NNP o
Outcomes NNP o
Study NNP o
36-item JJ o
Short-Form NNP o
Health NNP o
Survey NNP o
at IN N
baseline NN N
and CC N
following VBG N
3 CD N
and CC N
6 CD N
months NNS N
of IN N
treatment NN N
. . N

Repeated-measures JJ N
analysis NN N
of IN N
variance NN N
was VBD N
used VBN N
to TO N
evaluate VB N
treatment NN N
and CC N
time NN N
effects NNS N
on IN N
mood NN o
and CC N
quality NN o
of IN o
life NN o
. . o

RESULTS NNP N
Most JJS p
female JJ p
heroin NN p
addicts NNS p
were VBD p
young JJ p
and CC p
single JJ p
, , p
with IN p
a DT p
low JJ p
education NN p
level NN p
. . p

Most JJS p
had VBD p
used VBN p
heroin NN p
by IN p
injection NN p
. . p

Mood NNP o
state NN o
and CC o
quality NN o
of IN o
life NN o
of IN p
female JJ p
heroin NN p
addicts NNS p
were VBD N
poor JJ N
. . N

The DT N
intervention NN N
group NN N
showed VBD N
a DT N
significant JJ N
improvement NN o
in IN N
mood NN o
status NN o
and CC o
quality NN o
of IN o
life NN o
over IN N
time NN N
compared VBN N
with IN N
their PRP$ N
counterparts NNS N
in IN N
the DT N
control NN N
group NN N
. . N

CONCLUSION NNP N
Yoga NNP N
may MD N
improve VB N
mood NN o
status NN o
and CC o
quality NN o
of IN o
life NN o
for IN N
women NNS N
undergoing VBG N
detoxification NN N
for IN N
heroin NN N
dependence NN N
. . N

Yoga CC N
can MD N
be VB N
used VBN N
as IN N
an DT N
auxiliary JJ N
treatment NN N
with IN N
traditional JJ N
hospital NN N
routine NN N
care NN N
for IN N
these DT N
women NNS N
. . N

-DOCSTART- -22067237- O O

Effect NN o
of IN N
motivational JJ i
music NN i
on IN N
lactate NN o
levels NNS o
during IN N
recovery NN N
from IN N
intense JJ N
exercise NN N
. . N

The DT N
effects NNS N
of IN N
music NN N
played VBN N
during IN N
an DT N
exercise NN N
task NN N
on IN N
athletic JJ N
performance NN N
have VBP N
been VBN N
previously RB N
studied VBN N
. . N

Yet CC N
, , N
these DT N
results NNS N
are VBP N
not RB N
applicable JJ N
for IN N
competitive JJ p
athletes NNS p
, , N
who WP N
can MD N
use VB N
music NN N
only RB N
during IN N
warm-up NN N
or CC N
recovery NN N
from IN N
exercise NN N
. . N

Therefore RB N
, , N
the DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
the DT N
effect NN N
of IN N
motivational JJ i
music NN i
( ( i
music NN i
that WDT i
stimulates VBZ i
or CC i
inspires VBZ i
physical JJ i
activity NN i
) ) i
during IN N
recovery NN o
from IN o
intense JJ o
exercise NN o
, , N
on IN N
activity NN o
pattern NN o
, , o
rate NN o
of IN o
perceived VBN o
exertion NN o
( ( o
RPE NNP o
) ) o
, , o
and CC o
blood NN o
lactate NN o
concentration NN o
. . o

Twenty NNP p
young JJ p
, , p
active JJ p
men NNS p
( ( p
mean JJ p
age NN p
26.2 CD p
? . p
2.1 CD p
years NNS p
) ) p
performed VBD N
a DT N
6-minute JJ i
run NN i
at IN i
peak NN i
oxygen NN i
consumption NN i
speed NN i
( ( N
predetermined VBN N
from IN N
the DT N
VO NNP N
( ( N
2 CD N
) ) N
max FW N
test NN N
) ) N
. . N

The DT o
mean JJ o
heart NN o
rate NN o
( ( o
HR NNP o
) ) o
, , o
RPE NNP o
, , o
number NN o
of IN o
steps NNS o
( ( o
determined VBN o
by IN o
step NN o
counter NN o
) ) o
, , o
and CC o
blood NN o
lactate NN o
concentrations NNS o
were VBD N
determined VBN N
at IN N
3 CD N
, , N
6 CD N
, , N
9 CD N
, , N
12 CD N
, , N
and CC N
15 CD N
minutes NNS N
during IN N
the DT N
recovery NN N
from IN N
the DT N
exercise NN N
, , N
with IN N
and CC N
without IN N
motivational JJ N
music NN N
( ( N
2 CD N
separate JJ N
sessions NNS N
, , N
at IN N
random JJ N
order NN N
) ) N
. . N

There EX N
was VBD N
no DT N
difference NN N
in IN N
the DT o
mean JJ o
HR NNP o
during IN N
the DT N
recovery NN N
with IN N
and CC i
without IN i
music NN i
. . i

Listening VBG N
to TO N
motivational JJ N
music NN N
during IN N
the DT N
recovery NN N
was VBD N
associated VBN N
with IN N
increased JJ o
voluntary JJ o
activity NN o
of IN N
the DT N
participants NNS N
, , N
determined VBN N
by IN N
increased JJ o
number NN o
of IN o
steps NNS o
( ( N
499.4 CD N
? . N
220.1 CD N
vs. IN N
413.2 CD N
? . N
150.6 CD N
steps NNS N
, , N
with IN N
and CC N
without IN N
music NN N
, , N
respectively RB N
; : N
p VB N
? . N
0.05 CD N
) ) N
. . N

The DT N
increased JJ N
number NN o
of IN o
steps NNS o
during IN o
the DT N
recovery NN N
was VBD N
accompanied VBN N
by IN N
a DT N
significantly RB N
greater JJR N
decrease NN o
in IN o
blood NN o
lactate NN o
concentration NN o
percentage NN o
( ( N
28.1 CD N
? . N
12.2 CD N
vs. IN N
22.8 CD N
? . N
10.9 CD N
% NN N
, , N
with IN N
and CC N
without IN N
music NN N
, , N
respectively RB N
, , N
p VB N
? . N
0.05 CD N
) ) N
. . N

This DT N
was VBD N
associated VBN N
with IN N
a DT N
greater JJR N
decrease NN N
in IN o
RPE NNP o
( ( o
77.7 CD N
? . N
14.4 CD N
vs. IN N
73.1 CD N
? . N
14.7 CD N
% NN N
with IN N
and CC N
without IN N
music NN N
, , N
respectively RB N
; : N
p VB N
? . N
0.05 CD N
) ) N
. . N

Our PRP$ N
results NNS N
suggest VBP N
that IN N
listening VBG N
to TO N
motivational JJ N
music NN N
during IN N
nonstructured JJ N
recovery NN N
from IN N
intense JJ N
exercise NN N
leads VBZ N
to TO N
increased VBN N
activity NN N
, , N
faster JJR N
lactate JJ N
clearance NN N
, , N
and CC N
reduced VBD N
RPE NNP N
and CC N
therefore RB N
may MD N
be VB N
used VBN N
by IN N
athletes NNS N
in IN N
their PRP$ N
effort NN N
to TO N
enhance VB N
recovery NN N
. . N

-DOCSTART- -26223240- O O

Women NNS p
With IN p
Gestational NNP p
Diabetes NNP p
Mellitus NNP p
Randomized NNP N
to TO N
a DT N
Higher-Complex JJ N
Carbohydrate/Low-Fat NNP N
Diet NNP N
Manifest NNP N
Lower NNP N
Adipose NNP N
Tissue NNP N
Insulin NNP N
Resistance NNP N
, , N
Inflammation NNP N
, , N
Glucose NNP N
, , N
and CC N
Free NNP N
Fatty NNP N
Acids NNP N
: : N
A DT N
Pilot NNP N
Study NNP N
. . N

OBJECTIVE NNP N
Diet NNP N
therapy NN N
in IN N
gestational JJ p
diabetes NNS p
mellitus VBP p
( ( p
GDM NNP p
) ) p
has VBZ N
focused VBN N
on IN N
carbohydrate JJ N
restriction NN N
but CC N
is VBZ N
poorly RB N
substantiated VBN N
. . N

In IN N
this DT N
pilot NN N
randomized VBD N
clinical JJ N
trial NN N
, , N
we PRP N
challenged VBD N
the DT N
conventional JJ i
low-carbohydrate/higher-fat JJ i
( ( i
LC/CONV NNP i
) ) i
diet NN i
, , N
hypothesizing VBG N
that IN N
a DT N
higher-complex JJ i
carbohydrate/lower-fat NN i
( ( i
CHOICE NNP i
) ) i
diet NN i
would MD N
improve VB N
maternal JJ o
insulin NN o
resistance NN o
( ( o
IR NNP o
) ) o
, , o
adipose JJ o
tissue NN o
( ( o
AT NNP o
) ) o
lipolysis NN o
, , o
and CC o
infant JJ o
adiposity NN o
. . o

RESEARCH NNP N
DESIGN NNP N
AND NNP N
METHODS NNP N
At IN N
31 CD p
weeks NNS p
, , p
12 CD p
diet-controlled JJ p
overweight/obese JJ p
women NNS p
with IN p
GDM NNP p
were VBD N
randomized VBN N
to TO N
an DT N
isocaloric JJ N
LC/CONV NNP N
( ( N
40 CD N
% NN N
carbohydrate/45 NN N
% NN N
fat/15 NN N
% NN N
protein NN N
; : N
n CC N
= VB N
6 CD N
) ) N
or CC N
CHOICE NNP i
( ( N
60 CD N
% NN N
/25 CD N
% NN N
/15 CC N
% NN N
; : N
n CC N
= VB N
6 CD N
) ) N
diet NN i
. . i

All DT N
meals NNS i
were VBD N
provided VBN N
. . N

AT NNP N
was VBD N
biopsied VBN N
at IN N
37 CD N
weeks NNS N
. . N

RESULTS NNP N
After IN N
?7 NNP N
weeks NNS o
, , o
fasting VBG o
glucose NN o
( ( o
P NNP N
= NNP N
0.03 CD N
) ) N
and CC o
free JJ o
fatty JJ o
acids NNS o
( ( o
P NNP N
= NNP N
0.06 CD N
) ) N
decreased VBN N
on IN N
CHOICE NNP N
, , N
whereas IN o
fasting VBG o
glucose NN o
increased VBD o
on IN N
LC/CONV NNP N
( ( N
P NNP N
= NNP N
0.03 CD o
) ) o
. . o

Insulin NNP o
suppression NN o
of IN o
AT NNP o
lipolysis NN o
was VBD o
improved VBN N
on IN N
CHOICE NNP N
versus NN N
LC/CONV NNP N
( ( N
56 CD N
vs. FW N
31 CD N
% NN N
, , N
P NNP N
= NNP N
0.005 CD N
) ) N
, , N
consistent JJ N
with IN N
improved JJ N
IR NNP N
. . o

AT NNP o
expression NN o
of IN o
multiple JJ o
proinflammatory NN o
genes NNS o
was VBD o
lower JJR N
on IN N
CHOICE NNP N
( ( N
P NNP N
< NNP N
0.01 CD o
) ) o
. . o

Infant JJ o
adiposity NN o
trended VBD o
lower JJR N
with IN N
CHOICE NNP N
( ( N
10.1 CD N
? . N
1.4 CD N
vs. IN N
12.6 CD N
? . N
2 CD N
% NN N
, , N
respectively RB N
) ) N
. . N

CONCLUSIONS VB N
A DT N
CHOICE NNP N
diet NN N
may MD N
improve VB p
maternal JJ p
IR NNP p
and CC p
infant JJ p
adiposity NN p
, , p
challenging VBG p
recommendations NNS N
for IN N
a DT N
LC/CONV NNP N
diet NN N
. . N

-DOCSTART- -6360773- O O

Effect NN N
of IN N
cicloxilic JJ i
acid NN i
on IN N
bile NN o
lipid JJ o
composition NN o
in IN N
patients NNS p
with IN p
gallstones NNS p
: : p
a DT N
multicenter NN N
trial NN N
. . N

24 CD p
gallstone NN p
patients NNS p
were VBD N
treated VBN N
with IN N
cicloxilic JJ i
acid NN i
, , N
an DT N
agent NN N
endowed VBN N
with IN N
choleretic JJ N
activity NN N
, , N
at IN N
the DT N
dose NN N
of IN N
240 CD N
mg/day NN N
for IN N
1 CD N
month NN N
. . N

24 CD p
comparable JJ p
patients NNS p
on IN p
placebo NN i
treatment NN p
acted VBD N
as IN N
controls NNS N
. . N

Bile NNP o
lipid JJ o
composition NN o
was VBD N
determined VBN N
and CC N
the DT N
saturation NN N
index NN N
calculated VBD N
before IN N
and CC N
after IN N
treatment NN N
, , N
on IN N
samples NNS N
collected VBN N
by IN N
duodenal JJ N
siphonage NN N
after IN N
caerulein JJ N
stimulation NN N
, , N
in IN N
both DT N
groups NNS N
. . N

In IN N
the DT N
cicloxilic JJ N
group NN N
there EX N
was VBD N
little JJ N
or CC N
no DT N
change NN N
in IN N
bile NN o
salts NNS o
and CC o
phospholipids NNS o
, , N
whereas NNS N
biliary VBP o
cholesterol NN o
concentration NN o
was VBD N
significantly RB N
reduced VBN N
( ( N
p NN N
less JJR N
than IN N
0.05 CD N
) ) N
and CC N
consequently RB N
the DT N
lithogenic JJ o
index NN o
lowered VBD N
( ( N
from IN N
1.5 CD N
to TO N
1.2 CD N
, , N
p NN N
less JJR N
than IN N
0.01 CD N
) ) N
. . N

Cicloxilic JJ N
acid NN N
can MD N
have VB N
a DT N
place NN N
in IN N
gallstone NN N
disease NN N
therapy NN N
in IN N
association NN N
with IN N
the DT N
litholytic JJ N
bile NN N
acids NNS N
or CC N
in IN N
the DT N
prevention NN N
of IN N
gallstone NN o
formation NN o
in IN N
high-risk JJ N
populations NNS N
. . N

-DOCSTART- -8332150- O O

A DT N
comparison NN N
of IN N
seven CD p
antiarrhythmic JJ i
drugs NNS i
in IN p
patients NNS p
with IN p
ventricular JJ p
tachyarrhythmias NNS p
. . p

Electrophysiologic NNP N
Study NNP N
versus VBD N
Electrocardiographic NNP N
Monitoring NNP N
Investigators NNP N
. . N

BACKGROUND NNP N
The DT N
relative JJ N
efficacies NNS N
of IN N
various JJ N
antiarrhythmic JJ N
drugs NNS N
in IN N
the DT N
treatment NN N
of IN N
ventricular JJ N
tachyarrhythmias NNS N
are VBP N
not RB N
well RB N
known VBN N
. . N

This DT N
study NN N
examined VBD N
the DT N
effectiveness NN N
of IN N
imipramine NN i
, , i
mexiletine NN i
, , i
pirmenol NN i
, , i
procainamide NN i
, , i
propafenone NN i
, , i
quinidine NN i
, , i
and CC i
sotalol NN i
in IN N
patients NNS p
with IN p
ventricular JJ p
tachyarrhythmias NNS p
who WP N
were VBD N
enrolled VBN N
in IN N
the DT N
Electrophysiologic NNP N
Study NNP N
versus VBD N
Electrocardiographic NNP N
Monitoring NNP N
trial NN N
. . N

METHODS JJ N
Patients NNPS p
were VBD N
randomly RB N
assigned VBN N
to TO N
undergo VB N
serial JJ N
testing NN N
of IN N
the DT N
efficacy NN N
of IN N
the DT N
seven CD N
antiarrhythmic JJ N
drugs NNS N
by IN N
one CD N
of IN N
two CD N
strategies NNS N
: : N
electrophysiologic NN i
study NN i
or CC i
Holter NNP i
monitoring VBG i
together RB i
with IN i
exercise NN i
testing NN i
. . i

The DT N
seven CD N
drugs NNS N
were VBD N
then RB N
tested VBN N
for IN N
efficacy NN N
in IN N
random JJ N
order NN N
in IN N
patients NNS N
who WP N
were VBD N
eligible JJ N
to TO N
receive VB N
them PRP N
. . N

The DT N
frequencies NNS N
of IN N
predictions NNS N
of IN N
drug NN N
efficacy NN N
and CC N
of IN N
adverse JJ N
drug NN N
effects NNS N
during IN N
the DT N
initial JJ N
drug NN N
titration NN N
were VBD N
tabulated VBN N
for IN N
all DT N
486 CD p
randomized VBN p
subjects NNS p
. . p

Patients NNS N
received VBD N
long-term JJ N
treatment NN N
with IN N
the DT N
first JJ N
antiarrhythmic JJ N
drug NN N
that WDT N
was VBD N
predicted VBN N
to TO N
be VB N
effective JJ N
on IN N
the DT N
basis NN N
of IN N
drug NN N
testing NN N
. . N

Recurrences NNS N
of IN N
arrhythmia NN N
, , N
deaths NNS N
, , N
and CC N
adverse JJ N
drug NN N
effects NNS N
during IN N
long-term JJ N
follow-up NNS N
were VBD N
recorded VBN N
for IN N
the DT N
296 CD p
patients NNS p
in IN N
whom WP N
an DT N
antiarrhythmic JJ N
drug NN N
was VBD N
predicted VBN N
to TO N
be VB N
effective JJ N
. . N

RESULTS NNP N
In IN N
the DT N
electrophysiologic-study JJ N
group NN N
, , N
the DT N
percentage NN N
of IN N
patients NNS N
who WP N
had VBD N
predictions NNS N
of IN N
drug NN o
efficacy NN o
was VBD N
higher JJR o
with IN N
sotalol NN N
( ( N
35 CD N
percent NN N
) ) N
than IN N
with IN N
the DT N
other JJ N
drugs NNS N
( ( N
16 CD N
percent NN N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

There EX N
was VBD N
no DT o
significant JJ o
difference NN o
among IN N
the DT N
drugs NNS N
in IN N
the DT N
Holter-monitoring NNP N
group NN N
. . N

The DT N
percentage NN N
of IN N
patients NNS o
with IN o
adverse JJ o
drug NN o
effects NNS o
was VBD N
lowest JJS o
among IN N
those DT N
receiving VBG N
sotalol NN N
. . N

The DT N
actuarial JJ o
probability NN o
of IN o
a DT o
recurrence NN o
of IN o
arrhythmia NN o
after IN N
a DT N
prediction NN N
of IN N
drug NN N
efficacy NN N
by IN N
either DT N
strategy NN N
was VBD N
significantly RB o
lower JJR o
for IN N
patients NNS N
treated VBN N
with IN N
sotalol NN N
than IN N
for IN N
patients NNS N
treated VBN N
with IN N
the DT N
other JJ N
drugs NNS N
( ( N
risk NN N
ratio NN N
, , N
0.43 CD N
; : N
95 CD N
percent NN N
confidence NN N
interval NN N
, , N
0.29 CD N
to TO N
0.62 CD N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

With IN N
sotalol NN N
, , N
as IN N
compared VBN N
with IN N
the DT N
other JJ N
drugs NNS N
combined VBN N
, , N
there EX N
were VBD N
lower JJR o
risks NNS o
of IN o
death NN o
from IN N
any DT N
cause NN N
( ( N
risk NN N
ratio NN N
, , N
0.50 CD N
; : N
95 CD N
percent NN N
confidence NN N
interval NN N
, , N
0.30 CD N
to TO N
0.80 CD N
; : N
P NNP N
= NNP N
0.004 CD N
) ) N
, , N
death NN N
from IN N
cardiac JJ N
causes NNS N
, , N
( ( N
0.50 CD N
; : N
P NNP N
= NNP N
0.02 CD N
) ) N
, , N
and CC N
death NN o
from IN o
arrhythmia NN o
( ( N
0.50 CD N
; : N
P NNP N
= NNP N
0.04 CD N
) ) N
. . N

The DT N
cumulative JJ N
percentage NN N
of IN N
patients NNS N
in IN N
whom WP N
a DT N
drug NN N
was VBD N
predicted VBN N
to TO N
be VB N
effective JJ o
and CC N
in IN N
whom WP N
it PRP N
remained VBD N
effective JJ o
and CC o
tolerated VBD o
was VBD N
higher JJR o
for IN N
sotalol JJR N
than IN N
for IN N
the DT N
other JJ N
drugs NNS N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

CONCLUSIONS NNP N
Sotalol NNP N
was VBD N
more RBR N
effective JJ o
than IN N
the DT N
other JJ N
six CD N
antiarrhythmic JJ N
drugs NNS N
in IN N
preventing VBG o
death NN o
and CC o
recurrences NNS o
of IN o
arrhythmia NN o
. . o

In IN N
patients NNS N
similar JJ N
to TO N
those DT N
in IN N
this DT N
study NN N
, , N
if IN N
antiarrhythmic-drug JJ N
therapy NN N
is VBZ N
to TO N
be VB N
used VBN N
to TO N
prevent VB N
recurrences NNS N
of IN N
ventricular JJ N
tachyarrhythmias NNS N
, , N
treatment NN N
with IN N
sotalol NN N
and CC N
assessment NN N
of IN N
its PRP$ N
potential JJ N
efficacy NN N
by IN N
Holter NNP N
monitoring NN N
are VBP N
a DT N
reasonable JJ N
initial JJ N
strategy NN N
. . N

-DOCSTART- -18443393- O O

A DT N
pilot NN i
group NN i
therapy NN i
for IN N
functional JJ p
memory NN p
disorder NN p
. . p

-DOCSTART- -11077389- O O

Effect NN N
of IN N
systemic JJ i
penicillin NN i
on IN N
pain NN N
in IN N
untreated JJ p
irreversible JJ p
pulpitis NN p
. . p

OBJECTIVE CC N
The DT N
purpose NN N
of IN N
this DT N
prospective JJ N
, , N
randomized VBN N
, , N
double-blind JJ N
study NN N
was VBD N
to TO N
determine VB N
the DT N
effect NN N
of IN N
penicillin NN i
on IN N
pain NN N
in IN N
untreated JJ p
teeth NNS p
diagnosed VBN p
with IN p
irreversible JJ p
pulpitis NN p
. . p

STUDY NNP N
DESIGN NNP N
Forty NNP p
emergency NN p
patients NNS p
participated VBD p
, , p
and CC p
each DT p
had VBD p
a DT p
clinical JJ p
diagnosis NN p
of IN p
an DT p
irreversible JJ p
pulpitis NN p
. . p

Patients NNS N
randomly RB N
received VBD i
a DT i
7-day JJ i
oral JJ i
dose NN i
( ( i
28 CD i
capsules NNS i
, , i
500 CD i
mg NN i
each DT i
, , i
to TO i
be VB i
taken VBN i
every DT i
6 CD i
hours NNS i
) ) i
of IN i
either DT i
penicillin NN i
or CC i
a DT i
placebo NN i
control NN i
in IN i
a DT i
double-blind JJ i
manner NN i
. . i

No CC N
endodontic JJ N
treatment NN N
was VBD N
performed VBN N
. . N

Each DT N
patient NN N
also RB N
received VBD N
ibuprofen NNS i
; : i
acetaminophen VBZ i
with IN i
codeine NN i
( ( i
30 CD i
mg NN i
) ) i
; : i
and CC i
a DT i
7-day JJ o
diary NN o
to TO o
record NN o
pain NN o
, , o
percussion NN o
pain NN o
, , o
and CC o
number NN o
and CC o
type NN o
of IN o
pain NN o
medication NN o
taken VBN o
. . o

RESULTS VB N
The DT N
administration NN N
of IN N
penicillin NN i
did VBD N
not RB N
significantly RB N
( ( N
P NNP N
> NNP N
.05 NNP N
) ) N
reduce VB o
pain NN o
, , o
percussion NN o
pain NN o
, , o
or CC o
the DT o
number NN o
of IN o
analgesic JJ o
medications NNS o
taken VBN N
by IN N
patients NNS N
with IN N
untreated JJ N
irreversible JJ N
pulpitis NN N
. . N

The DT N
majority NN N
of IN N
patients NNS N
with IN N
untreated JJ N
irreversible JJ N
pulpitis NN N
had VBD N
significant JJ o
pain NN o
and CC N
required VBN N
analgesics NNS N
to TO N
manage VB N
this DT N
pain NN N
. . N

CONCLUSION NNP N
Penicillin NNP N
should MD N
not RB N
be VB N
prescribed VBN N
for IN N
untreated JJ N
irreversible JJ N
pulpitis NN N
because IN N
penicillin NN N
is VBZ N
ineffective JJ N
for IN N
pain NN N
relief NN N
. . N

-DOCSTART- -21154265- O O

Effect NN N
of IN N
L-arginine NNP i
or CC i
L-citrulline JJ i
oral JJ i
supplementation NN i
on IN N
blood NN o
pressure NN o
and CC o
right JJ o
ventricular NN o
function NN o
in IN N
heart NN p
failure NN p
patients NNS p
with IN p
preserved JJ p
ejection NN p
fraction NN p
. . p

BACKGROUND IN N
The DT N
effect NN N
of IN N
L-arginine NNP i
and CC i
L-citrulline NNP i
on IN N
blood NN o
pressure NN o
and CC o
right JJ o
ventricular NN o
function NN o
in IN N
heart NN p
failure NN p
patients NNS p
with IN p
preserved JJ p
ejection NN p
fraction NN p
( ( p
HFpEF NNP p
) ) p
is VBZ N
unknown JJ N
. . N

We PRP N
have VBP N
therefore RB N
evaluated VBN N
, , N
in IN N
a DT N
randomized JJ N
clinical JJ N
trial NN N
, , N
the DT N
effect NN N
of IN N
these DT N
aminoacids NNS N
in IN N
chronic JJ p
outstanding JJ p
and CC p
stable JJ p
patients NNS p
with IN p
HFpEF NNP p
. . p

METHODS NNP N
AND CC N
RESULTS NNP N
All NNP p
patients NNS p
underwent VBD p
an DT p
echocardiogram NN i
and CC i
radioisotopic NN i
ventriculography NN i
rest/exercise NN i
, , N
and CC N
were VBD N
randomized VBN N
in IN N
a DT N
consecutive JJ N
manner NN N
to TO N
the DT N
L-arginine NNP i
group NN i
( ( p
n JJ p
= VBZ p
15 CD p
; : p
8 CD p
g/day NN p
) ) p
; : p
and CC p
the DT p
citrulline NN i
malate NN i
group NN i
( ( p
n JJ p
= VBZ p
15 CD p
; : p
3 CD N
g/day NN N
) ) N
. . N

The DT N
duration NN N
of IN N
follow-up NN N
was VBD N
two CD N
months NNS N
. . N

The DT N
principal JJ N
echocardiographic JJ N
finding NN N
was VBD N
a DT N
statistically RB N
significant JJ N
decrease NN N
in IN N
pulmonary JJ o
artery NN o
pressure NN o
in IN N
the DT N
L-arginine NNP i
( ( N
56.3 CD N
? . N
10 CD N
vs NN N
44 CD N
? . N
16.5 CD N
mm NN N
Hg NNP N
, , N
p NN N
< NNP N
0.05 CD N
) ) N
and CC N
the DT i
citrulline NN i
( ( i
56.67 CD N
? . N
7.96 CD N
vs NN N
47.67 CD N
? . N
8.59 CD N
mm NN N
Hg NNP N
, , N
p NN N
< NNP N
0.05 CD N
) ) N
groups NNS o
. . o

Duration NN o
on IN o
treadmill NN o
and CC o
right JJ o
ventricular NN o
ejection NN o
fraction NN o
post NN o
exercise NN o
increased VBD o
, , N
while IN o
diastolic JJ o
and CC o
systolic JJ o
artery NN o
pressure NN o
decreased VBN o
significantly RB N
in IN N
both DT N
groups NNS N
. . N

There EX N
were VBD N
no DT N
other JJ N
statistically RB N
significant JJ N
differences NNS N
between IN N
the DT N
groups NNS N
. . N

CONCLUSIONS NNP N
Administration NNP i
of IN i
L-arginine NNP i
and CC i
citrulline NN i
to TO i
patients NNS p
with IN p
HFpEF NNP p
improved VBD o
right JJ o
ventricular NN o
function NN o
by IN o
increasing VBG N
right JJ N
ventricular NN N
ejection NN N
fraction NN N
, , N
and CC N
probably RB N
decreasing VBG o
systolic JJ o
pulmonary JJ o
artery NN o
pressure NN o
. . o

-DOCSTART- -17979862- O O

Exploring VBG N
effects NNS N
of IN N
different JJ N
treadmill NN i
interventions NNS i
on IN N
walking VBG o
onset NN o
and CC N
gait NN o
patterns NNS o
in IN N
infants NNS p
with IN p
Down NNP p
syndrome NN p
. . p

Two CD N
cohorts NNS N
of IN N
participants NNS N
were VBD N
included VBN N
to TO N
investigate VB N
the DT N
effects NNS N
of IN N
different JJ N
treadmill NN i
interventions NNS i
on IN N
walking VBG o
onset NN o
and CC N
gait NN o
patterns NNS o
in IN N
infants NNS p
with IN p
Down NNP p
syndrome NN p
( ( p
DS NNP p
) ) p
. . p

The DT p
first JJ p
cohort NN p
included VBD p
30 CD p
infants NNS p
with IN p
DS NNP p
( ( p
17 CD p
males NNS p
, , p
13 CD p
females NNS p
; : p
mean JJ p
age NN p
10 CD p
mo NN p
[ NNP p
SD NNP p
1.9 CD p
mo NN p
] NN p
) ) p
who WP N
were VBD N
randomly RB N
assigned VBN N
to TO N
either VB N
a DT N
lower-intensity-generalized JJ i
( ( i
LG NNP i
) ) i
training VBG i
group NN i
, , i
or CC i
a DT i
higher-intensity-individualized JJ i
( ( i
HI NNP i
) ) i
training VBG i
group NN i
. . i

A DT p
control NN i
( ( i
C NNP i
) ) i
group NN p
from IN p
another DT p
study NN p
, , p
who WP p
did VBD p
not RB i
receive VB i
treadmill NN i
training NN i
, , p
served VBD p
as IN p
the DT p
control NN p
( ( p
eight CD p
males NNS p
, , p
seven CD p
females NNS p
; : p
mean JJ p
age NN p
10.4 CD p
mo NN p
[ NNP p
SD NNP p
2.2 CD p
mo NN p
] NN p
) ) p
. . p

Mean JJ o
age NN o
at IN o
walking VBG o
onset NN o
was VBD N
19.2 CD N
, , N
21.4 CD N
, , N
and CC N
23.9 CD N
months NNS N
for IN N
the DT N
HI NNP N
, , N
LG NNP N
, , N
and CC N
C NNP N
groups NNS N
respectively RB N
. . N

At IN N
walking VBG o
onset RP o
the DT N
HI NNP N
group NN N
was VBD N
significantly RB N
younger JJR N
than IN N
the DT N
C NNP N
group NN N
( ( N
p=0.011 NN N
) ) N
. . N

At IN N
the DT N
gait NN N
follow-up NN N
that WDT N
was VBD N
conducted VBN N
between IN N
1 CD N
and CC N
3 CD N
months NNS N
after IN N
walking VBG N
onset NN N
, , N
three CD N
groups NNS N
significantly RB N
different JJ N
in IN N
overall JJ N
gait NN N
patterns NNS N
( ( N
p=0.037 NN N
) ) N
were VBD N
examined VBN N
by IN N
six CD N
basic JJ N
gait NN N
parameters NNS N
including VBG N
average JJ o
velocity NN o
, , o
stride JJ o
length NN o
, , o
step NN o
width NN o
, , o
stride JJ o
time NN o
, , o
stance NN o
time NN o
, , o
and CC o
dynamic JJ o
base NN o
. . o

Post-hoc JJ N
analyses NNS N
demonstrated VBD N
that IN N
stride JJ o
length NN o
was VBD N
the DT N
gait NN N
parameter NN N
largely RB N
contributing VBG N
to TO N
this DT N
overall JJ N
group NN N
difference NN N
( ( N
p=0.033 NN N
) ) N
, , N
and CC N
the DT N
HI NNP N
group NN N
produced VBD N
a DT N
significantly RB N
longer RBR N
stride JJ o
length NN o
than IN N
the DT N
C NNP N
group NN N
( ( N
p=0.030 NN N
) ) N
. . N

In IN N
conclusion NN N
, , N
the DT N
HI NNP N
treadmill NN N
intervention NN N
significantly RB N
promoted VBN N
earlier RBR N
walking JJ o
onset NN o
and CC N
elicited VBD N
more RBR N
advanced JJ N
gait NN o
patterns NNS o
( ( N
particularly RB N
in IN N
stride JJ N
length NN N
) ) N
in IN N
infants NNS p
with IN p
DS NNP p
. . p

-DOCSTART- -17387192- O O

Oral JJ i
sildenafil NN i
to TO N
control VB N
pulmonary JJ o
hypertension NN o
after IN p
congenital JJ p
heart NN p
surgery NN p
. . p

This DT N
study NN N
investigates VBZ N
the DT N
role NN N
of IN N
oral JJ N
sildenafil NN i
in IN N
decreasing VBG N
pulmonary JJ o
pressure NN o
after IN p
congenital JJ i
heart NN i
surgery NN i
. . i

Between NNP p
September NNP p
2002 CD p
and CC p
September NNP p
2004 CD p
, , p
among IN p
a DT p
group NN p
of IN p
postoperative JJ p
children NNS p
with IN p
large JJ p
septal JJ p
defects NNS p
, , p
moderate VBP p
to TO p
severe VB p
pulmonary JJ p
hypertension NN p
[ NNP p
pulmonary JJ p
artery NN p
( ( p
PA NNP p
) ) p
to TO p
aortic JJ p
( ( p
Ao NNP p
) ) p
pressure NN p
ratio NN p
of IN p
0.76 CD p
+/- JJ p
0.17 CD p
] NN p
and CC p
systemic JJ p
desaturation NN p
( ( p
Ao NNP p
Sat NNP p
= VBD p
0.89 CD p
+/- JJ p
0.11 CD p
) ) p
, , p
oral JJ i
sildenafil NN i
( ( p
0.3 CD p
mg NN p
x NN p
kg NN p
( ( p
-1 NNP p
) ) p
, , p
every DT p
3 CD p
hours NNS p
) ) p
was VBD p
administered VBN p
for IN p
a DT p
period NN p
of IN p
24-48 JJ p
hours NNS p
( ( i
sildenafil JJ i
group NN p
) ) p
. . p

These DT N
patients NNS p
were VBD N
compared VBN N
to TO N
a DT N
group NN N
of IN N
22 CD p
children NNS p
with IN p
similar JJ p
pathologies NNS p
who WP p
did VBD p
not RB p
receive VB p
sildenafil NN i
( ( i
control VB i
group NN p
) ) p
. . p

Postoperative JJ o
PA NNP o
pressure NN o
( ( N
28.61 CD N
+/- JJ N
7.80 CD N
vs JJ N
39.40 CD N
+/- JJ N
10.80 CD N
mm NN N
Hg NNP N
) ) N
and CC N
PA/Ao NNP o
pressure NN o
( ( N
0.28 CD N
+/- JJ N
0.08 CD N
vs JJ N
0.41 CD N
+/- JJ N
0.11 CD N
) ) N
were VBD N
significantly RB N
lower JJR N
in IN N
the DT N
sildenafil NN i
group NN N
( ( N
p JJ N
= NN N
0.001 CD N
and CC N
0.001 CD N
respectively RB N
) ) N
. . N

Pulmonary JJ o
hypertensive JJ o
crisis NN o
was VBD N
detected VBN N
in IN N
4 CD N
patients NNS N
in IN N
the DT N
control NN N
group NN N
, , N
but CC N
none NN N
in IN N
the DT N
sildenafil NN i
group NN N
( ( N
p JJ N
= NNP N
0.02 CD N
) ) N
. . N

There EX N
was VBD N
no DT N
significant JJ N
rise NN N
in IN N
PA NNP o
pressure NN o
following VBG N
discontinuation NN N
of IN N
the DT N
drug NN N
( ( N
26.30 CD N
+/- JJ N
6.66 CD N
vs JJ N
28.49 CD N
+/- JJ N
10.93 CD N
mm NN N
Hg NNP N
, , N
p NN N
= NNP N
0.366 CD N
) ) N
. . N

No DT N
significant JJ o
complications NNS o
were VBD N
noticed VBN N
regarding VBG N
sildenafil NN i
use NN N
. . N

Low JJ N
doses NNS N
of IN N
oral JJ N
sildenafil NN i
appear VBP N
to TO N
be VB N
effective JJ N
and CC N
safe JJ N
to TO N
control VB N
postoperative JJ N
PA NNP N
pressure NN N
in IN N
children NNS N
. . N

Absence NN N
of IN N
rebound NN N
pulmonary JJ o
hypertension NN o
, , N
availability NN N
, , N
and CC N
low JJ N
cost NN N
of IN N
the DT N
drug NN N
are VBP N
considered VBN N
as IN N
its PRP$ N
major JJ N
advantages NNS N
. . N

-DOCSTART- -15978926- O O

Endovascular JJ N
aneurysm NN N
repair NN N
and CC N
outcome NN N
in IN N
patients NNS p
unfit JJ p
for IN p
open JJ p
repair NN p
of IN p
abdominal JJ p
aortic JJ p
aneurysm NN p
( ( p
EVAR NNP p
trial NN p
2 CD p
) ) p
: : p
randomised VBN N
controlled JJ N
trial NN N
. . N

BACKGROUND NNP N
Endovascular NNP i
aneurysm NN i
repair NN i
( ( i
EVAR NNP i
) ) i
to TO N
exclude VB N
abdominal JJ N
aortic JJ N
aneurysm NN N
( ( N
AAA NNP N
) ) N
was VBD N
introduced VBN N
for IN N
patients NNS p
of IN p
poor JJ p
health NN p
status NN p
considered VBN p
unfit NN p
for IN p
major JJ p
surgery NN p
. . p

We PRP N
instigated VBD N
EVAR NNP N
trial NN N
2 CD N
to TO N
identify VB N
whether IN N
EVAR NNP N
improves VBZ N
survival JJ o
compared VBN N
with IN N
no DT N
intervention NN N
in IN N
patients NNS p
unfit JJ p
for IN p
open JJ p
repair NN p
of IN p
aortic JJ p
aneurysm NN p
. . p

METHODS NNP N
We PRP N
did VBD N
a DT N
randomised VBN N
controlled VBN N
trial NN N
of IN N
338 CD p
patients NNS p
aged VBN p
60 CD p
years NNS p
or CC p
older JJR p
who WP p
had VBD p
aneurysms NNS p
of IN p
at IN p
least JJS p
5.5 CD p
cm NN p
in IN p
diameter NN p
and CC p
who WP p
had VBD p
been VBN p
referred VBN p
to TO p
one CD p
of IN p
31 CD p
hospitals NNS p
in IN p
the DT p
UK NNP p
. . p

We PRP N
assigned VBD N
patients NNS N
to TO N
receive VB N
either DT N
EVAR NNP i
( ( N
n=166 NN N
) ) N
or CC i
no DT i
intervention NN i
( ( N
n=172 JJ N
) ) N
. . N

Our PRP$ N
primary JJ N
endpoint NN N
was VBD N
all-cause JJ o
mortality NN o
, , N
with IN N
secondary JJ N
endpoints NNS N
of IN N
aneurysm-related JJ o
mortality NN o
, , o
health-related JJ o
quality NN o
of IN o
life NN o
( ( o
HRQL NNP o
) ) o
, , o
postoperative JJ o
complications NNS o
, , o
and CC o
hospital NN o
costs NNS o
. . o

Analyses NNS N
were VBD N
by IN N
intention NN N
to TO N
treat VB N
. . N

FINDINGS NNP N
197 CD p
patients NNS p
underwent JJ N
aneurysm JJ i
repair NN i
( ( N
47 CD N
assigned VBN N
no DT N
intervention NN N
) ) N
and CC N
80 CD N
% NN N
of IN N
patients NNS N
adhered VBN N
to TO N
protocol VB N
. . N

The DT N
30-day JJ o
operative JJ o
mortality NN o
in IN o
the DT o
EVAR NNP o
group NN o
was VBD N
9 CD N
% NN N
( ( N
13 CD N
of IN N
150 CD N
, , N
95 CD N
% NN N
CI NNP N
5-15 CD N
) ) N
and CC N
the DT N
no DT N
intervention NN N
group NN N
had VBD N
a DT N
rupture NN N
rate NN N
of IN N
9.0 CD N
per IN N
100 CD N
person NN N
years NNS N
( ( N
95 CD N
% NN N
CI NNP N
6.0-13.5 CD N
) ) N
. . N

By IN N
end NN N
of IN N
follow JJ N
up IN N
142 CD N
patients NNS N
had VBD N
died VBN o
, , N
42 CD N
of IN N
aneurysm-related JJ N
factors NNS N
; : N
overall JJ o
mortality NN o
after IN N
4 CD N
years NNS N
was VBD N
64 CD N
% NN N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
the DT N
EVAR NNP N
group NN N
and CC N
the DT N
no DT N
intervention NN N
group NN N
for IN N
all-cause JJ o
mortality NN o
( ( N
hazard JJ N
ratio NN N
1.21 CD N
, , N
95 CD N
% NN N
CI NNP N
0.87-1.69 CD N
, , N
p=0.25 NN N
) ) N
. . N

There EX N
was VBD N
no DT N
difference NN N
in IN N
aneurysm-related JJ o
mortality NN o
. . o

The DT N
mean JJ o
hospital NN o
costs NNS o
per IN o
patient NN o
over IN o
4 CD o
years NNS o
were VBD N
UK NNP N
pound NN N
sterling NN N
13,632 CD N
in IN N
the DT N
EVAR NNP N
group NN N
and CC N
pound NN N
sterling NN N
4983 CD N
in IN N
the DT N
no DT N
intervention NN N
group NN N
( ( N
mean JJ N
difference NN N
pound NN N
sterling NN N
8649 CD N
, , N
SE NNP N
1248 CD N
) ) N
, , N
with IN N
no DT N
difference NN N
in IN N
HRQL NNP N
scores NNS N
. . N

INTERPRETATION NNP N
EVAR NNP N
had VBD N
a DT N
considerable JJ N
30-day JJ o
operative JJ o
mortality NN o
in IN N
patients NNS N
already RB N
unfit JJ N
for IN N
open JJ N
repair NN N
of IN N
their PRP$ N
aneurysm NN N
. . N

EVAR NNP i
did VBD N
not RB N
improve VB N
survival NN N
over IN N
no DT N
intervention NN N
and CC N
was VBD N
associated VBN N
with IN N
a DT N
need NN N
for IN N
continued JJ N
surveillance NN N
and CC N
reinterventions NNS N
, , N
at IN N
substantially RB N
increased VBN N
cost NN N
. . N

Ongoing VBG N
follow-up NN N
and CC N
improved JJ N
fitness NN N
of IN N
these DT N
patients NNS N
is VBZ N
a DT N
priority NN N
. . N

-DOCSTART- -14966713- O O

Reliance NN N
on IN N
visual JJ o
information NN o
after IN N
stroke NN N
. . N

Part NNP N
II NNP N
: : N
Effectiveness NN N
of IN N
a DT N
balance NN N
rehabilitation NN i
program NN i
with IN N
visual JJ i
cue NN i
deprivation NN i
after IN p
stroke NN p
: : p
a DT N
randomized NN N
controlled VBN N
trial NN N
. . N

OBJECTIVE UH N
To TO N
test VB N
the DT N
hypothesis NN N
that WDT N
balance NN N
rehabilitation NN i
with IN i
visual JJ i
cue NN i
deprivation NN i
improves VBZ N
balance NN o
more RBR N
effectively RB N
than IN N
rehabilitation NN i
with IN i
free JJ i
vision NN i
. . i

DESIGN NNP N
Single-blind NNP N
, , N
randomized VBD N
controlled VBN N
trial NN N
. . N

SETTING NNP N
Public NNP p
rehabilitation NN p
center NN p
in IN p
France NNP p
. . p

PARTICIPANTS NNP N
Twenty NNP p
patients NNS p
with IN p
hemiplegia NN p
after IN p
a DT p
single-hemisphere JJ p
stroke NN p
that WDT p
occurred VBD p
at IN p
least JJS p
12 CD p
months NNS p
before IN p
the DT p
study NN p
. . p

INTERVENTION NNP N
Patients NNPS i
were VBD i
randomly RB i
assigned VBN i
to TO i
1 CD i
of IN i
2 CD i
balance NN i
rehabilitation NN i
programs-with NN i
and CC i
without IN i
visual JJ i
cue NN i
deprivation NN i
. . i

In IN i
all DT i
other JJ i
respects NNS i
, , i
the DT i
programs NNS i
were VBD i
identical JJ i
. . i

Each DT N
lasted VBD N
for IN N
1 CD N
hour NN N
and CC N
was VBD N
implemented VBN N
5 CD N
days NNS N
a DT N
week NN N
for IN N
4 CD N
weeks NNS N
. . N

All DT p
patients NNS p
completed VBD p
the DT p
program NN p
. . p

Mean NNP N
outcome JJ N
measures NNS N
Balance NNP o
under IN N
6 CD N
sensory JJ N
conditions NNS N
was VBD N
assessed VBN N
by IN N
computerized JJ N
dynamic JJ o
posturography NN o
( ( o
EquiTest NNP o
) ) o
, , o
gait JJ o
velocity NN o
, , o
timed VBD o
stair NN o
climbing NN o
, , o
and CC o
self-assessment NN o
of IN o
ease NN o
of IN o
gait NN o
before IN o
and CC o
after IN o
program NN o
completion NN o
. . o

RESULTS NNP N
After IN N
completing VBG N
the DT N
program NN N
, , N
balance NN o
, , o
gait JJ o
velocity NN o
, , o
and CC o
self-assessment NN o
of IN o
gait NN o
improved VBN N
significantly RB N
in IN N
all DT N
patients NNS N
. . N

The DT N
improvements NNS N
in IN N
gait NN o
velocity NN o
( ( N
P= NNP N
.03 NNP N
) ) N
and CC N
timed VBD o
stair NN o
climbing VBG o
( ( N
P= NNP N
.01 NNP N
) ) N
correlated VBD N
significantly RB N
with IN N
improved JJ N
balance NN N
. . N

Balance NNP o
improved VBD N
more RBR N
in IN N
the DT N
vision-deprived JJ N
group NN N
than IN N
in IN N
the DT N
free-vision NN N
group NN N
. . N

CONCLUSIONS NNP N
Balance NNP o
improved VBD N
more RBR N
after IN N
rehabilitation NN N
with IN N
visual JJ i
deprivation NN i
than IN N
with IN N
free JJ i
vision NN i
. . i

Visual JJ N
overuse NN N
may MD N
be VB N
a DT N
compensatory NN N
strategy NN N
for IN N
coping VBG N
with IN N
initial JJ N
imbalance NN N
exacerbated VBN N
by IN N
traditional JJ N
rehabilitation NN N
. . N

-DOCSTART- -15304592- O O

Minocycline NNP i
safety NN o
and CC o
tolerability NN o
in IN N
Huntington NNP p
disease NN p
. . p

Minocycline NNP i
is VBZ N
an DT N
antibiotic JJ N
with IN N
anti-inflammatory JJ N
and CC N
antiapoptotic JJ N
properties NNS N
that WDT N
prolongs NNS N
survival VBP N
in IN N
a DT N
transgenic JJ N
Huntington NNP p
disease NN p
( ( p
HD NNP p
) ) p
mouse NN N
model NN N
. . N

In IN N
a DT N
double-blind NN N
, , N
randomized VBN N
, , N
placebo-controlled JJ i
study NN N
of IN N
minocycline NN i
in IN N
60 CD p
HD NNP p
patients NNS p
, , N
the DT N
authors NNS N
determined VBD N
that IN N
over IN N
8 CD N
weeks NNS N
, , N
minocycline NN i
at IN i
100 CD i
and CC i
200 CD i
mg/day NN i
was VBD N
well RB o
tolerated VBN o
and CC o
safe JJ o
in IN N
HD NNP p
patients NNS p
. . p

Tolerability NNP o
and CC o
adverse JJ o
event NN o
frequency NN o
were VBD N
similar JJ N
between IN N
treatment NN N
and CC N
placebo NN N
groups NNS N
. . N

-DOCSTART- -25807670- O O

Role NNP N
of IN N
warm JJ i
saline NN i
mouth NN i
rinse NN i
in IN N
prevention NN N
of IN N
alveolar JJ o
osteitis NN o
: : o
a DT N
randomized NN N
controlled VBN N
trial NN N
. . N

BACKGROUND VB N
The DT N
present JJ N
study NN N
was VBD N
aimed VBN N
at IN N
determining VBG N
the DT N
role NN N
warm JJ i
saline NN i
rinse NN i
in IN N
the DT N
prevention NN o
of IN o
alveolar JJ o
osteitis NN o
following VBG N
dental JJ N
extractions NNS N
. . N

MATERIALS NNP N
AND CC N
METHODS NNP N
Apparently NNP N
patients NNS p
aged VBD p
16 CD p
and CC p
above IN p
who WP p
were VBD p
referred VBN p
to TO p
the DT p
Oral NNP p
Surgery NNP p
Clinic NNP p
of IN p
our PRP$ p
institution NN p
, , p
with IN p
an DT p
indication NN p
for IN p
non-surgical JJ p
extraction NN p
of IN p
pathologic JJ p
teeth NNS p
were VBD N
prospectively RB N
and CC N
uniformly RB N
randomized VBN N
into IN N
warm JJ i
saline NN i
group NN i
and CC N
control NN i
. . i

The DT N
experimental JJ p
group NN p
( ( p
n JJ p
= NNP p
80 CD p
) ) p
were VBD N
instructed VBN N
to TO N
gargle VB i
6 CD i
times NNS i
daily RB i
with IN i
warm JJ i
saline NN i
and CC N
no DT i
such JJ i
instructions NNS i
were VBD N
given VBN N
to TO N
the DT N
second JJ p
group NN p
( ( p
n JJ p
= NNP p
80 CD p
) ) p
to TO N
serve VB N
as IN N
controls NNS i
. . i

Information NN N
on IN N
demographic NN o
, , o
indications NNS o
for IN o
extraction NN o
, , o
and CC o
development NN o
of IN o
alveolar JJ o
osteitis NN o
were VBD N
obtained VBN N
and CC N
analyzed VBN N
. . N

Comparative JJ N
statistics NNS N
were VBD N
done VBN N
using VBG N
Pearson NNP N
's POS N
chi NN N
square NN N
or CC N
Fisher NNP N
's POS N
exact JJ N
test NN N
as IN N
appropriate NN N
. . N

A DT N
p JJ N
value NN N
of IN N
less JJR N
than IN N
0.05 CD N
was VBD N
considered VBN N
significant JJ N
. . N

RESULTS VB N
The DT N
demographic JJ o
and CC o
other JJ o
baseline NN o
parameters NNS o
such JJ o
as IN o
indications NNS o
for IN o
extractions NNS o
were VBD N
comparable JJ N
among IN N
the DT N
study NN N
groups NNS N
( ( N
p JJ N
> NNP N
0.05 CD N
) ) N
. . N

The DT N
overall JJ o
prevalence NN o
of IN o
alveolar JJ o
osteitis NN o
was VBD N
13.7 CD N
% NN N
. . N

There EX N
was VBD N
a DT N
statistical JJ N
significant JJ N
difference NN N
between IN N
the DT N
study NN N
groups NNS N
with IN N
respect NN N
to TO N
development NN N
of IN N
alveolar JJ o
osteitis NN o
( ( N
X2 NNP N
= NNP N
15.00 CD N
, , N
df NN N
= VBD N
1 CD N
, , N
p NN N
= NNP N
0.001 CD N
) ) N
.The NN N
risk NN o
of IN o
development NN o
of IN o
alveolar JJ o
osteitis NN o
was VBD N
4 CD N
times NNS N
higher RBR N
in IN N
the DT N
control NN N
group NN N
( ( N
OR NNP N
= VBZ N
4.33 CD N
, , N
P NNP N
= NNP N
0.001 CD N
) ) N
. . N

CONCLUSION NNP N
Warm NNP i
saline NN i
mouth NN i
rinse JJ i
instruction NN N
is VBZ N
beneficial JJ N
in IN N
the DT N
prevention NN N
of IN N
development NN N
of IN N
alveolar JJ o
osteitis NN o
after IN N
dental JJ N
extractions NNS N
. . N

-DOCSTART- -15996057- O O

Longterm NNP o
safety NN o
, , o
efficacy NN o
, , o
and CC o
radiographic JJ o
outcome NN o
with IN N
etanercept JJ i
treatment NN N
in IN N
patients NNS p
with IN p
early JJ p
rheumatoid NN p
arthritis NN p
. . p

OBJECTIVE UH N
To TO N
evaluate VB N
safety NN o
, , o
efficacy NN o
, , o
and CC o
radiographic JJ o
progression NN o
in IN N
patients NNS p
with IN p
early JJ p
rheumatoid NN p
arthritis NN p
( ( p
RA NNP p
) ) p
undergoing VBG p
longterm JJ p
treatment NN p
with IN p
etanercept NN i
. . i

METHODS NNP N
Patients NNPS p
with IN p
early JJ p
RA NNP p
( ( p
disease JJ p
duration NN p
of IN p
3 CD p
years NNS p
or CC p
less JJR p
) ) p
who WP p
had VBD p
completed VBN p
a DT p
2-year JJ p
efficacy NN p
study NN p
comparing VBG p
etanercept NNS i
and CC i
methotrexate NN i
( ( i
MTX NNP i
) ) i
were VBD p
followed VBN p
in IN p
an DT p
extension NN p
where WRB N
they PRP N
received VBD N
25 CD N
mg NNS N
etanercept JJ i
twice RB N
weekly RB N
. . N

Safety NNP o
was VBD N
summarized VBN N
descriptively RB N
and CC N
compared VBN N
with IN N
data NNS N
from IN N
the DT N
efficacy NN N
study NN N
. . N

Efficacy NNP o
and CC o
radiographic JJ o
progression NN o
were VBD N
assessed VBN N
using VBG N
American JJ o
College NNP o
of IN o
Rheumatology NNP o
response NN o
criteria NNS o
, , o
disease NN o
activity NN o
scores VBZ o
, , N
and CC N
Total NNP o
Sharp NNP o
Score NNP o
( ( o
TSS NNP o
) ) o
. . N

RESULTS JJ N
Rates NNS o
of IN o
serious JJ o
adverse JJ o
events NNS o
and CC o
serious JJ o
infections NNS o
did VBD N
not RB N
increase VB N
with IN N
longterm JJ N
exposure NN N
to TO N
etanercept VB N
, , N
and CC N
were VBD N
similar JJ N
to TO N
rates NNS N
reported VBN N
for IN N
the DT N
blinded JJ N
portion NN N
of IN N
the DT N
efficacy NN N
study NN N
. . N

Efficacy NNP o
was VBD N
sustained VBN N
in IN N
patients NNS p
who WP p
completed VBD p
5 CD p
years NNS p
of IN p
etanercept JJ i
treatment NN p
at IN N
the DT N
time NN N
of IN N
this DT N
report NN N
( ( N
N NNP N
= NNP N
201 CD N
) ) N
, , N
even RB N
in IN N
those DT N
who WP N
decreased VBD N
or CC N
discontinued VBN N
use NN N
of IN N
MTX NNP N
or CC N
corticosteroids NNS N
. . N

No DT N
radiographic JJ o
progression NN o
( ( N
change NN N
in IN N
TSS NNP N
< NNP N
or CC N
= VB N
0 CD N
) ) N
was VBD N
seen VBN N
in IN N
55 CD N
% NN N
of IN N
patients NNS N
with IN N
5-year JJ N
radiographs NN N
; : N
negative JJ N
change NN N
( ( N
TSS NNP N
< NNP N
0 CD N
) ) N
was VBD N
seen VBN N
in IN N
11 CD N
% NN N
. . N

CONCLUSION NNP N
Etanercept NNP i
treatment NN N
in IN N
patients NNS p
with IN p
early JJ p
RA NNP p
was VBD N
generally RB N
well RB N
tolerated VBN N
for IN N
up RB N
to TO N
5 CD N
years NNS N
. . N

The DT N
results NNS N
indicate VBP N
sustained VBN N
efficacy NN o
and CC o
decreased JJ o
rate NN o
of IN o
radiographic JJ o
progression NN o
. . o

The DT N
rate NN o
of IN o
radiographic JJ o
progression NN o
was VBD N
low JJ N
compared VBN N
with IN N
other JJ N
studies NNS N
, , N
emphasizing VBG N
the DT N
benefit NN N
gained VBN N
in IN N
patients NNS p
with IN p
early JJ p
aggressive JJ p
RA NNP p
who WP N
undergo VBP N
longterm JJ N
treatment NN N
with IN N
etanercept NN i
. . i

-DOCSTART- -25822242- O O

Randomized VBN N
comparative JJ N
efficacy NN N
study NN N
of IN N
parent-mediated JJ i
interventions NNS i
for IN N
toddlers NNS p
with IN p
autism NN p
. . p

OBJECTIVE CC N
This DT N
study NN N
compared VBN N
effects NNS N
of IN N
two CD p
parent-mediated JJ i
interventions NNS i
on IN N
joint JJ N
engagement NN N
outcomes NNS N
as IN N
augmentations NNS N
of IN N
an DT N
early JJ N
intervention NN N
program NN N
for IN N
toddlers NNS p
with IN p
autism NN p
spectrum NN p
disorder NN p
( ( p
ASD NNP p
) ) p
. . p

METHOD NNP N
Participants NNP N
included VBD N
86 CD p
toddlers NNS p
( ( p
range VB p
22-36 JJ p
months NNS p
) ) p
with IN p
ASD NNP p
and CC p
their PRP$ p
primary JJ p
caregiver NN p
. . p

Caregiver-child JJ p
dyads NNS p
were VBD N
randomized VBN N
to TO N
receive VB N
10 CD N
weeks NNS N
of IN N
hands-on JJ i
parent NN i
training NN i
in IN i
a DT i
naturalistic JJ i
, , i
developmental JJ i
behavioral JJ i
intervention NN i
( ( i
joint JJ i
attention NN i
, , i
symbolic JJ i
play NN i
, , i
engagement NN i
and CC i
regulation-JASPER NN i
) ) i
or CC i
a DT i
parent-only JJ i
psychoeducational JJ i
intervention NN i
( ( i
PEI NNP i
) ) i
. . i

Dose NNP N
was VBD N
controlled VBN N
in IN N
terms NNS N
of IN N
researcher-parent JJ N
contact NN N
and CC N
early JJ N
intervention NN N
services NNS N
received VBN N
by IN N
the DT N
child NN N
. . N

RESULTS JJ N
Results NNP N
yielded VBD N
significant JJ N
effects NNS N
of IN N
the DT N
JASPER NNP i
intervention NN i
on IN N
the DT N
primary JJ N
outcome NN N
of IN N
joint JJ o
engagement NN o
. . o

The DT N
treatment NN N
effect NN N
was VBD N
large JJ N
( ( N
Cohen NNP N
's POS N
f? NN N
= NNP N
.69 NNP N
) ) N
and CC N
maintained VBN N
over IN N
the DT N
6-month JJ N
follow-up NN N
. . N

JASPER NNP i
effects NNS N
were VBD N
also RB N
found VBN N
on IN N
secondary JJ N
outcomes NNS N
of IN o
play NN o
diversity NN o
, , o
highest JJS o
play NN o
level NN o
achieved VBN o
, , o
and CC o
generalization NN o
to TO o
the DT o
child NN o
's POS o
classroom NN o
for IN o
child-initiated JJ o
joint JJ o
engagement NN o
. . o

The DT i
PEI NNP i
intervention NN i
was VBD N
found VBN N
to TO N
be VB N
effective JJ N
in IN N
reducing VBG o
parenting VBG o
stress NN o
associated VBN o
with IN o
child NN o
characteristics NNS o
. . o

All DT N
secondary JJ N
effects NNS N
were VBD N
generally RB N
small JJ N
to TO N
moderate VB N
. . N

CONCLUSIONS NNP N
These DT N
data NNS N
highlight VBD N
the DT N
benefit NN N
of IN N
a DT N
brief NN N
, , N
targeted VBN N
, , N
parent-mediated JJ N
intervention NN N
on IN N
child NN N
outcomes NNS N
. . N

Future JJ N
studies NNS N
may MD N
consider VB N
the DT N
combination NN N
of IN i
JASPER NNP i
and CC i
PEI NNP i
treatments NNS i
for IN N
optimal JJ N
parent NN N
and CC N
child NN N
outcomes NNS N
. . N

Trial JJ N
registry NN N
no DT N
. . N

NCT00999778 NNP N
. . N

-DOCSTART- -23747131- O O

Concomitant NNP N
, , N
sequential JJ N
, , N
and CC N
hybrid JJ N
therapy NN N
for IN N
H. NNP o
pylori JJ o
eradication NN o
: : o
a DT N
pilot NN N
study NN N
. . N

BACKGROUND NNP N
AND NNP N
OBJECTIVE NNP N
Since IN N
the DT N
efficacy NN N
of IN N
the DT N
standard JJ N
triple NN N
therapies NNS N
for IN N
Helicobacter NNP o
pylori NN o
eradication NN o
has VBZ N
decreased VBN N
, , N
novel JJ i
antibiotic JJ i
regimens NNS i
have VBP N
been VBN N
introduced VBN N
, , N
including VBG i
concomitant NN i
, , i
sequential JJ i
, , N
and CC N
hybrid JJ i
therapies NNS i
. . i

We PRP N
aimed VBD N
to TO N
compare VB N
the DT N
cure NN o
rates NNS o
achieved VBN N
by IN N
these DT N
new JJ N
therapy NN N
regimens NNS N
. . N

METHODS NNP N
This DT N
was VBD N
a DT N
multicenter NN p
, , p
open-label JJ p
, , p
pilot NN p
study NN p
enrolling VBG p
consecutive JJ p
non-ulcer JJ p
dyspepsia NN p
patients NNS p
with IN p
H. NNP p
pylori FW p
infection NN p
never RB p
previously RB p
treated VBN p
for IN p
the DT p
infection NN p
. . p

Patients NNS N
were VBD N
randomized VBN N
to TO N
receive VB N
one CD N
of IN N
the DT N
following JJ N
treatments NNS N
: : N
( ( N
a DT N
) ) N
concomitant NN i
therapy NN i
: : i
omeprazole JJ i
20mg CD N
, , N
amoxicillin RB i
1g CD N
, , N
clarithromycin VBD i
500 CD N
mg NN N
, , N
and CC N
tinidazole JJ i
500 CD N
mg NN N
for IN N
5 CD N
days NNS N
; : N
( ( N
b NN N
) ) N
sequential JJ i
therapy NN i
: : i
omeprazole JJ i
20mg CD N
and CC N
amoxicillin $ i
1g CD N
for IN N
5 CD N
days NNS N
followed VBN N
by IN N
omeprazole JJ i
20mg CD N
, , N
clarithromycin VBD i
500 CD N
mg NN N
, , N
and CC N
tinidazole JJ i
500 CD N
mg NN N
for IN N
5 CD N
days NNS N
; : N
( ( N
c NN N
) ) N
hybrid JJ i
therapy NN i
: : i
omeprazole JJ i
20mg CD N
, , N
and CC N
amoxicillin VBZ i
1g CD N
for IN N
7 CD N
days NNS N
followed VBN N
by IN N
omeprazole JJ i
20mg CD N
, , N
amoxicillin RB i
1g CD N
, , N
clarithromycin VBD i
500 CD N
mg NN N
, , N
and CC N
tinidazole JJ i
500 CD N
mg NN N
, , N
for IN N
7 CD N
days NNS N
. . N

All DT N
drugs NNS N
were VBD N
administered VBN N
twice RB N
daily RB N
. . N

Bacterial JJ o
eradication NN o
was VBD N
checked VBN N
6 CD N
weeks NNS N
after IN N
treatment NN N
by IN N
using VBG N
a DT N
( ( i
13 CD i
) ) i
C-urea NNP i
breath NN i
test NN i
. . i

A DT N
10-day JJ N
, , N
second-line JJ i
therapy NN i
with IN N
omeprazole JJ i
20mg CD N
, , N
levofloxacin VBD i
250 CD N
mg NN N
, , N
and CC N
amoxicillin RB i
1g CD N
, , N
all DT N
given VBN N
twice RB N
daily RB N
, , N
was VBD N
offered VBN N
to TO N
the DT N
eradication NN N
failure NN N
patients NNS N
. . N

RESULTS NNP N
Overall NNP N
, , N
270 CD p
patients NNS p
were VBD p
enrolled VBN p
, , p
but CC p
13 CD p
patients NNS p
early RB p
interrupted VBN p
treatment NN p
due JJ N
to TO N
side VB N
effects NNS N
. . N

At IN N
intention-to-treat NN N
( ( N
ITT NNP N
) ) N
and CC N
per-protocol JJ N
analysis NN N
( ( N
PP NNP N
) ) N
, , N
the DT N
eradication NN o
rates NNS o
were VBD N
85.5 CD N
% NN N
and CC N
91.6 CD N
% NN N
with IN N
the DT N
concomitant JJ i
regimen NNS i
, , N
91.1 CD N
% NN N
and CC N
92.1 CD N
% NN N
with IN N
the DT N
sequential JJ i
therapy NN i
, , N
and CC N
80 CD N
% NN N
and CC N
85.7 CD N
% NN N
with IN N
the DT N
hybrid JJ i
regimen NNS i
. . i

Differences NNS N
were VBD N
not RB N
statistically RB N
significant JJ N
. . N

H. NNP o
pylori JJ o
infection NN o
was VBD N
cured VBN o
in IN N
10 CD N
( ( N
55.6 CD N
% NN N
) ) N
patients NNS N
with IN N
the DT N
second-line JJ i
regimen NNS i
. . i

CONCLUSION NN N
In IN N
our PRP$ N
study NN N
, , N
both DT N
concomitant NN i
and CC N
sequential JJ i
therapy NN i
, , N
but CC N
not RB N
hybrid JJ i
therapy NN i
, , N
reached VBN N
high JJ N
eradication NN o
rates NNS o
. . o

The DT N
success NN o
rate NN o
of IN N
second-line JJ N
levofloxacin-based JJ i
triple NN i
therapy NN i
is VBZ N
decreasing VBG N
. . N

-DOCSTART- -19001830- O O

Phosphate NNP i
binder NN i
impact NN N
on IN N
bone NN o
remodeling NN o
and CC o
coronary JJ o
calcification NN o
-- : o
results NNS o
from IN N
the DT N
BRiC NNP N
study NN N
. . N

BACKGROUND NNP N
AND CC N
AIMS NNP N
Calcium-containing NNP i
phosphate NN i
binders NNS i
have VBP N
been VBN N
shown VBN N
to TO N
increase VB N
the DT N
progression NN N
of IN N
vascular JJ o
calcification NN o
in IN N
hemodialysis NN p
patients NNS p
. . p

This DT N
is VBZ N
a DT N
prospective JJ N
study NN N
that WDT N
compares VBZ N
the DT N
effects NNS N
of IN N
calcium NN i
acetate NN i
and CC i
sevelamer NN i
on IN N
coronary JJ o
calcification NN o
( ( N
CAC NNP N
) ) N
and CC N
bone $ o
histology NN o
. . o

METHODS NNP N
101 CD p
hemodialysis NN p
patients NNS p
were VBD p
randomized VBN p
for IN N
each DT N
phosphate NN i
binder NN i
and CC N
submitted VBN N
to TO N
multislice VB i
coronary JJ i
tomographies NNS i
and CC i
bone NN i
biopsies NNS i
at IN N
entry NN N
and CC N
12 CD N
months NNS N
. . N

RESULTS VB N
The DT p
71 CD p
patients NNS p
who WP p
concluded VBD p
the DT p
study NN p
had VBD p
similar JJ p
baseline NN p
characteristics NNS p
. . p

On IN N
follow-up NN N
, , N
the DT N
sevelamer NN N
group NN N
had VBD N
higher JJR N
levels NNS N
of IN N
intact JJ o
parathyroid JJ o
hormone NN o
( ( N
498 CD N
+/- JJ N
352 CD N
vs. FW N
326 CD N
+/- JJ N
236 CD N
pg/ml NN N
, , N
p NN N
= NNP N
0.017 CD N
) ) N
, , N
bone JJ o
alkaline NN o
phosphatase NN o
( ( N
38 CD N
+/- JJ N
24 CD N
vs. FW N
28 CD N
+/- JJ N
15 CD N
U/l NNP N
, , N
p NN N
= NNP N
0.03 CD N
) ) N
and CC N
deoxypyridinoline NN o
( ( N
135 CD N
+/- JJ N
107 CD N
vs. FW N
89 CD N
+/- JJ N
71 CD N
nmol/l NN N
, , N
p NN N
= NNP N
0.03 CD N
) ) N
and CC N
lower JJR o
LDL NNP o
cholesterol NN o
( ( N
74 CD N
+/- JJ N
21 CD N
vs. FW N
91 CD N
+/- JJ N
28 CD N
mg/dl NN N
, , N
p NN N
= NNP N
0.015 CD N
) ) N
. . N

Phosphorus NNP o
( ( N
5.8 CD N
+/- JJ N
1.0 CD N
vs. FW N
6 CD N
+/- JJ N
1.0 CD N
mg/dl NN N
, , N
p NN N
= NNP N
0.47 CD N
) ) N
and CC N
calcium NN o
( ( N
1.27 CD N
+/- JJ N
0.07 CD N
vs. FW N
1.23 CD N
+/- JJ N
0.08 CD N
mmol/l NN N
, , N
p NN N
= NNP N
0.68 CD N
) ) N
levels NNS o
did VBD N
not RB N
differ VB N
between IN N
groups NNS N
. . N

CAC NNP o
progression NN o
( ( N
35 CD N
vs. FW N
24 CD N
% NN N
, , N
p NN N
= NNP N
0.94 CD N
) ) N
and CC N
bone $ o
histological JJ o
diagnosis NN o
at IN N
baseline NN N
and CC N
12 CD N
months NNS N
were VBD N
similar JJ N
in IN N
both DT N
groups NNS N
. . N

Patients NNS N
of IN N
the DT N
sevelamer NN N
group NN N
with IN N
a DT N
high JJ N
turnover NN N
at IN N
baseline NN N
had VBD N
an DT N
increase NN N
in IN N
bone JJ o
resorption NN o
( ( N
eroded JJ N
surface NN N
, , N
ES/BS NNP N
= VBD N
9.0 CD N
+/- JJ N
5.9 CD N
vs. FW N
13.1 CD N
+/- JJ N
9.5 CD N
% NN N
, , N
p NN N
= NNP N
0.05 CD N
) ) N
, , N
whereas JJ N
patients NNS N
of IN N
both DT N
groups NNS N
with IN N
low JJ N
turnover NN N
at IN N
baseline NN N
had VBD N
an DT N
improvement NN N
in IN N
bone NN o
formation NN o
rate NN o
( ( N
BFR/BS NNP N
= VBZ N
0.015 CD N
+/- JJ N
0.016 CD N
vs. FW N
0.062 CD N
+/- JJ N
0.078 CD N
, , N
p NN N
= VBD N
0.003 CD N
for IN N
calcium NN N
and CC N
0.017 CD N
+/- JJ N
0.016 CD N
vs. FW N
0.071 CD N
+/- JJ N
0.084 CD N
microm NN N
( ( N
3 CD N
) ) N
/microm NN N
( ( N
2 CD N
) ) N
/day NN N
, , N
p NN N
= VBD N
0.010 CD N
for IN N
sevelamer NN N
) ) N
. . N

CONCLUSIONS NNP N
There EX N
was VBD N
no DT N
difference NN N
in IN N
CAC NNP o
progression NN o
or CC N
changes NNS N
in IN N
bone NN o
remodeling NN o
between IN N
the DT N
calcium NN N
and CC N
the DT N
sevelamer NN N
groups NNS N
. . N

-DOCSTART- -25675062- O O

A DT N
randomized JJ N
, , N
double-blind JJ N
controlled VBD N
trial NN N
of IN N
lumbar NN N
interlaminar JJ N
epidural JJ N
injections NNS N
in IN N
central JJ p
spinal JJ p
stenosis NN p
: : p
2-year JJ N
follow-up NN N
. . N

BACKGROUND NNP N
While IN N
low JJ N
back RB N
pain NN N
is VBZ N
the DT N
number NN N
one CD N
cause NN N
of IN N
disability NN N
in IN N
the DT N
United NNP N
States NNPS N
, , N
lumbar VBP p
spinal JJ p
stenosis NN p
along IN N
with IN N
intervertebral JJ N
disc NN N
herniation NN N
and CC N
degenerative JJ N
spondylolisthesis NN N
is VBZ N
one CD N
of IN N
the DT N
3 CD N
most JJS N
common JJ N
diagnosis NN N
of IN N
low JJ N
back RB N
and CC N
leg NN N
pain NN N
for IN N
which WDT N
surgery NN N
is VBZ N
performed VBN N
. . N

Numerous JJ N
modalities NNS N
of IN N
treatments NNS N
including VBG N
drug NN N
therapy NN N
and CC N
complex JJ N
surgical JJ N
fusions NNS N
have VBP N
been VBN N
recommended VBN N
for IN N
treatment NN N
of IN N
central JJ N
spinal JJ N
stenosis NN N
. . N

Epidural JJ i
injections NNS i
are VBP N
one CD N
of IN N
the DT N
commonly NN N
performed VBD N
nonsurgical JJ N
interventions NNS N
in IN N
managing VBG N
central JJ N
spinal JJ N
stenosis NN N
; : N
however RB N
, , N
there EX N
has VBZ N
been VBN N
paucity NN N
of IN N
literature NN N
in IN N
reference NN N
to TO N
efficacy NN N
of IN N
epidural JJ i
injections NNS i
in IN N
managing VBG N
central JJ N
spinal JJ N
stenosis NN N
with IN N
lumbar NN i
interlaminar JJ i
epidural JJ i
injections NNS i
. . i

STUDY NNP N
DESIGN NNP N
A NNP N
randomized JJ N
, , N
double-blind JJ N
, , N
active JJ N
controlled VBN N
trial NN N
. . N

SETTING NN N
Private JJ N
interventional JJ N
pain NN N
management NN N
practice NN N
and CC N
specialty NN N
referral JJ N
center NN N
in IN N
the DT N
United NNP p
States NNPS p
. . p

OBJECTIVE NNP N
To TO N
assess VB N
the DT N
effectiveness NN N
of IN N
lumbar NN i
interlaminar JJ i
epidural JJ i
injections NNS i
with IN i
or CC i
without IN i
steroids NNS i
in IN N
providing VBG N
effective JJ N
and CC N
long-lasting JJ N
pain NN N
relief NN N
with IN N
improvement NN N
in IN N
functional JJ N
status NN N
for IN N
the DT N
management NN N
of IN N
chronic NN N
low JJ N
back RB N
and CC N
lower JJR N
extremity NN N
pain NN N
related VBN N
to TO N
lumbar VB N
central JJ N
spinal JJ N
stenosis NN N
. . N

METHODS NNP N
A NNP N
randomized JJ N
, , N
double-blind JJ N
, , N
active-control JJ N
trial NN N
was VBD N
designed VBN N
with IN N
the DT N
inclusion NN N
of IN N
120 CD p
patients NNS p
assigned VBN p
to TO p
2 CD p
groups NNS p
. . p

Group NNP N
I PRP N
patients NNS N
received VBD N
lumbar JJ i
interlaminar JJ i
epidural JJ i
injections NNS i
of IN i
local JJ i
anesthetic JJ i
( ( i
lidocaine JJ i
0.5 CD i
% NN i
) ) i
6 CD i
mL NN i
, , N
whereas WP N
Group NNP i
II NNP i
received VBD i
lumbar JJ i
interlaminar JJ i
epidural JJ i
injections NNS i
with IN i
local JJ i
anesthetic NN i
( ( i
lidocaine JJ i
0.5 CD i
% NN i
) ) i
5 CD i
mL NN i
mixed JJ i
with IN i
1 CD i
mL NNS i
of IN i
steroids NNS i
and CC i
6 CD i
mg NN i
of IN i
betamethasone NN i
. . i

OUTCOMES NNP N
ASSESSMENT NNP N
Outcomes NNP N
were VBD N
assessed VBN N
utilizing VBG N
the DT N
numeric JJ o
pain NN o
rating NN o
scale NN o
( ( o
NRS NNP o
) ) o
and CC o
Oswestry NNP o
Disability NNP o
Index NNP o
( ( o
ODI NNP o
) ) o
at IN N
3 CD N
, , N
6 CD N
, , N
12 CD N
, , N
18 CD N
, , N
and CC N
24 CD N
months NNS N
post VBN N
treatment NN N
. . N

The DT N
primary JJ N
outcome NN N
measure NN N
was VBD N
significant JJ N
improvement NN N
, , N
defined VBD N
as IN N
50 CD o
% NN o
improvement NN o
in IN o
pain NN o
and CC o
disability NN o
scores NNS o
. . o

RESULTS NNP N
Significant JJ o
relief NN o
and CC o
functional JJ o
status NN o
improvement NN o
was VBD N
seen VBN N
in IN N
72 CD N
% NN N
and CC N
73 CD N
% NN N
of IN N
patients NNS N
in IN N
Groups NNP N
I PRP N
and CC N
II NNP N
at IN N
the DT N
end NN N
of IN N
2 CD N
years NNS N
considering VBG N
all DT N
participants NNS N
; : N
however RB N
, , N
this DT N
was VBD N
84 CD N
% NN N
and CC N
85 CD N
% NN N
in IN N
the DT N
successful JJ N
group NN N
. . N

Overall JJ o
significant JJ o
improvement NN o
was VBD N
achieved VBN N
for IN N
65.7 CD N
? . N
37.3 CD N
weeks NNS N
in IN N
Group NNP N
1 CD N
and CC N
68.9 CD N
? . N
37.7 CD N
weeks NNS N
in IN N
Group NNP N
II NNP N
at IN N
the DT N
end NN N
of IN N
2 CD N
years NNS N
when WRB N
all DT N
participants NNS N
were VBD N
considered VBN N
; : N
whereas NNS N
, , N
this DT N
was VBD N
77 CD N
? . N
27.8 CD N
weeks NNS N
and CC N
77.9 CD N
? . N
30.2 CD N
weeks NNS N
when WRB N
they PRP N
were VBD N
separated VBN N
into IN N
successful JJ N
categories NNS N
. . N

The DT N
average JJ o
number NN o
of IN o
procedures NNS o
per IN o
patient NN N
was VBD N
5 CD N
to TO N
6 CD N
in IN N
both DT N
groups NNS N
. . N

LIMITATIONS NNP N
Limitations NNPS N
of IN N
this DT N
trial NN N
include VBP N
lack NN N
of IN N
placebo NN N
control NN N
group NN N
and CC N
treatment NN N
of IN N
patients NNS N
with IN N
multiple JJ N
procedures NNS N
over IN N
a DT N
period NN N
of IN N
2 CD N
years NNS N
. . N

CONCLUSION NNP i
Lumbar NNP i
interlaminar JJ i
epidural JJ i
injections NNS i
of IN i
local JJ i
anesthetic JJ i
with IN i
or CC N
without IN N
steroids NNS N
provide VBP N
relief NN N
in IN N
a DT N
significant JJ N
proportion NN N
of IN N
patients NNS N
with IN N
lumbar JJ p
central JJ p
spinal JJ p
stenosis NN p
. . p

CLINICAL NNP p
TRIAL NNP N
NCT00681447 NNP N
. . N

-DOCSTART- -25241527- O O

[ IN N
The DT N
comparation NN o
of IN o
the DT o
efficacy NN o
of IN o
surgical JJ o
treatment NN o
for IN N
lung NN p
cancer NN p
by IN N
minimally RB i
invasive JJ i
thoracoscopic NN i
and CC N
by IN N
traditional JJ i
thoracotomy NN i
] NNP i
. . N

OBJECTIVE NNP N
To TO N
observe VB N
the DT N
clinical JJ N
effects NNS N
of IN N
lung NN N
cancer NN N
, , N
75 CD p
patients NNS p
with IN p
lung NN p
cancer NN p
were VBD N
randomly RB N
divided VBN N
into IN N
two CD i
groups NNS i
, , i
observation NN i
group NN i
underwent JJ i
minimally RB i
invasive JJ i
thoracic NN i
surgery NN i
38 CD i
cases NNS i
and CC i
the DT i
control NN i
group NN i
underwent JJ i
conventional JJ i
thoracotomy NN i
37 CD i
cases NNS i
. . i

RESULTS NNP N
Observation NNP N
group NN N
was VBD N
significantly RB N
reduced VBN N
compared VBN N
with IN N
the DT N
control NN N
group NN N
in IN N
blood NN o
loss NN o
, , o
postoperative JJ o
pleural JJ o
fluid NN o
drainage NN o
, , o
postoperative JJ o
hospital NN o
stay NN o
, , N
the DT N
difference NN N
was VBD N
statistically RB N
significant JJ N
. . N

While IN N
there EX N
was VBD N
no DT N
statistically RB N
significant JJ N
in IN N
the DT N
number NN N
of IN N
lymph JJ o
node JJ o
dissection NN o
, , o
operative JJ o
time NN o
and CC o
postoperative JJ o
chest NN o
tube NN o
drainage NN o
time NN o
. . o

-DOCSTART- -25264862- O O

PLAY NNP i
Project NNP i
Home NNP i
Consultation NNP i
intervention NN i
program NN i
for IN N
young JJ p
children NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
: : p
a DT N
randomized NN N
controlled VBN N
trial NN N
. . N

OBJECTIVE UH N
To TO N
evaluate VB N
the DT N
effectiveness NN N
of IN N
the DT N
Play NNP i
and CC i
Language NNP i
for IN i
Autistic NNP i
Youngsters NNP i
( ( i
PLAY NNP i
) ) i
Project NNP i
Home NNP i
Consultation NNP i
model NN i
, , i
in IN i
combination NN i
with IN i
usual JJ i
community NN i
services NNS i
( ( i
CS NNP i
) ) i
, , N
to TO N
improve VB N
parent-child JJ N
interaction NN N
, , N
child NN N
development NN N
, , N
and CC N
autism NN N
symptomatology NN N
in IN N
young JJ p
children NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
( ( p
ASDs NNP p
) ) p
compared VBN N
with IN N
CS NNP i
only RB N
. . N

METHODS NNP N
Children NNP p
( ( p
N NNP p
= NNP p
128 CD p
) ) p
with IN p
autism NN p
or CC p
PDD-NOS NNP p
( ( p
DSM-4 NNP p
criteria NNS p
) ) p
aged VBD p
2 CD p
years NNS p
8 CD p
months NNS p
to TO p
5 CD p
years NNS p
11 CD p
months NNS p
and CC p
recruited VBN p
from IN p
5 CD p
disability NN p
agencies NNS p
in IN p
4 CD p
US JJ p
states NNS p
were VBD p
randomized VBN p
in IN N
two CD N
1-year JJ N
cohorts NNS N
. . N

Using VBG N
videotape NN N
and CC N
written VBN N
feedback NN N
within IN N
a DT N
developmental JJ N
framework NN N
, , N
PLAY NNP i
consultants NNS N
coached VBD N
caregivers NNS N
monthly JJ N
for IN N
12 CD N
months NNS N
to TO N
improve VB N
caregiver-child JJ N
interaction NN N
. . N

CS NNP i
included VBD N
speech/language NN i
and CC i
occupational JJ i
therapy NN i
and CC N
public JJ i
education NN i
services NNS i
. . i

Primary JJ N
outcomes NNS N
included VBD N
change NN N
in IN N
parent-child JJ N
interactions NNS N
, , N
language NN N
and CC N
development NN N
, , N
and CC N
autism-related JJ N
diagnostic JJ N
category/symptoms NNS N
. . N

Secondary JJ N
outcomes NNS N
included VBD N
parent NN N
stress NN N
and CC N
depression NN N
and CC N
home NN N
consultant NN N
fidelity NN N
. . N

Data NNS N
were VBD N
collected VBN N
pre- JJ N
and CC N
post-intervention NN N
. . N

RESULTS NNP N
Using VBG N
intent-to-treat JJ i
analysis NN N
( ( N
ITT NNP N
) ) N
, , N
large JJ N
treatment NN N
effects NNS N
were VBD N
evident JJ N
for IN N
parent NN N
and CC N
child JJ N
interactional JJ N
behaviors NNS N
on IN N
the DT N
Maternal NNP N
and CC N
Child NNP N
Behavior NNP N
Rating NNP N
Scales NNP N
. . N

Child NNP N
language NN N
and CC N
developmental JJ N
quotient NN N
did VBD N
not RB N
differ VB N
over IN N
time NN N
by IN N
group NN N
, , N
although IN N
functional JJ N
development NN N
improved VBN N
significantly RB N
. . N

PLAY NNP i
children NNS N
improved VBN N
in IN N
diagnostic JJ N
categories NNS N
on IN N
the DT N
Autism NNP N
Diagnostic NNP N
Observation NNP N
Schedule NNP N
( ( N
ADOS NNP N
) ) N
. . N

PLAY NNP i
caregivers NNS N
' POS N
stress NN N
did VBD N
not RB N
increase VB N
, , N
and CC N
depressive JJ N
symptomatology NN N
decreased VBN N
. . N

Home NNP N
consultants NNS N
administered VBD N
the DT N
intervention NN N
with IN N
fidelity NN N
. . N

CONCLUSIONS NNP N
PLAY NNP o
intervention NN o
demonstrated VBD o
substantial JJ o
changes NNS o
in IN o
parent-child JJ o
interaction NN o
without IN o
increasing VBG o
parents NNS o
' POS o
stress/depression NN o
. . o

ADOS NNP N
findings NNS N
must MD N
be VB N
interpreted VBN N
cautiously RB N
because IN N
results NNS N
do VBP N
not RB N
align VB N
with IN N
clinical JJ N
experience NN N
. . N

PLAY NNP i
offers VBZ N
communities NNS N
a DT N
relatively RB N
inexpensive JJ N
effective JJ N
intervention NN N
for IN N
children NNS p
with IN p
ASD NNP p
and CC p
their PRP$ p
parents NNS p
. . p

-DOCSTART- -10224577- O O

Thrombolysis NN N
is VBZ N
superior JJ N
to TO N
heparin VB N
for IN N
non-obstructive JJ p
mitral JJ p
mechanical JJ p
valve NN p
thrombosis NN p
. . p

BACKGROUND NNP N
AND NNP N
AIM NNP N
OF IN N
THE NNP N
STUDY NNP N
Non-obstructive NNP p
prosthetic JJ p
valve NN p
thrombosis NN p
( ( p
PVT NNP p
) ) p
is VBZ N
a DT N
unique JJ N
subset NN N
that WDT N
features VBZ N
clinical JJ N
presentation NN N
without IN N
heart NN N
failure NN N
, , N
and CC N
may MD N
be VB N
asymptomatic JJ N
. . N

Thrombolysis NN N
has VBZ N
been VBN N
accepted VBN N
for IN N
obstructive JJ N
PVT NNP N
, , N
but CC N
treatment NN N
strategies NNS N
of IN N
non-obstructive JJ N
PVT NNP N
are VBP N
controversial JJ N
. . N

This DT N
study NN N
compared VBN N
the DT N
efficacy NN o
and CC o
safety NN o
of IN N
thrombolysis NN N
and CC N
heparin NN N
treatment NN N
in IN N
these DT N
patients NNS N
. . N

METHODS NNP N
Between NNP N
1993 CD N
and CC N
1998 CD N
, , N
20 CD p
consecutive JJ p
patients NNS p
were VBD p
found VBN p
by IN p
multiplane NN p
transesophageal NN i
echocardiography NN i
( ( p
TEE NNP p
) ) p
to TO p
have VB p
non-obstructive JJ p
PVT NNP p
. . p

TEE NNP N
was VBD N
performed VBN N
for IN N
peripheral JJ N
embolism NN N
in IN N
two CD N
patients NNS N
, , N
stroke VBD N
or CC N
transient JJ N
ischemic JJ N
attack NN N
in IN N
six CD N
, , N
stroke NN N
and CC N
fever NN N
in IN N
two CD N
, , N
fever RB N
in IN N
one CD N
patient NN N
, , N
as IN N
a DT N
routine JJ N
postoperative JJ N
examination NN N
in IN N
two CD N
patients NNS N
, , N
and CC N
for IN N
other JJ N
reasons NNS N
in IN N
seven CD N
. . N

Patients NNS N
were VBD N
allocated VBN N
to TO N
two CD N
groups NNS N
: : N
group NN N
I PRP N
( ( N
n JJ N
= NNP N
8 CD N
) ) N
received VBD N
streptokinase-mediated JJ i
fibrinolysis NN i
; : i
group NN N
II NNP N
( ( N
n JJ N
= NNP N
12 CD N
) ) N
received VBD N
intravenous JJ i
heparin NNS i
by IN i
infusion NN i
. . i

Treatment NN N
was VBD N
monitored VBN N
using VBG N
TEE NNP N
. . N

RESULTS NNP N
There EX N
was VBD N
no DT N
difference NN N
between IN N
patient JJ N
groups NNS N
with IN N
regard NN N
to TO N
sex NN N
, , N
age NN N
, , N
type NN N
of IN N
prosthesis NN N
and CC N
time NN N
since IN N
operation NN N
, , N
though IN N
anticoagulant JJ N
status NN N
was VBD N
more RBR N
often RB N
inadequate JJ N
in IN N
group NN N
II NNP N
. . N

By IN N
TEE NNP N
, , N
valve FW o
motion NN o
was VBD N
normal JJ N
in IN N
all DT N
patients NNS N
. . N

In IN N
group NN N
I PRP N
, , N
all DT N
thrombi NNS o
were VBD N
mobile JJ o
and CC N
5-13 JJ N
mm NN N
in IN N
diameter NN N
; : N
in IN N
group NN N
II NNP N
, , N
all DT N
thrombi NNS N
but CC N
three CD N
were VBD N
mobile JJ o
and CC N
3-18 JJ N
mm NN N
in IN N
diameter NN N
. . N

In IN N
group NN N
I PRP N
, , N
thrombolysis NN N
was VBD N
successful JJ N
in IN N
all DT N
patients NNS N
, , N
without IN N
complications NNS o
, , N
within IN N
6-72 JJ N
h. NN N
In IN N
group NN N
II NNP N
, , N
heparin NN i
treatment NN N
was VBD N
successful JJ N
in IN N
six CD N
patients NNS N
in IN N
3-32 JJ N
days NNS N
. . N

In IN N
one CD N
patient NN N
, , N
seven CD N
days NNS N
' CD N
of IN N
unsuccessful JJ N
heparin NN N
was VBD N
followed VBN N
by IN N
two CD N
months NNS N
' POS N
successful JJ N
coumarin NN N
therapy NN N
. . N

Among IN N
five CD N
unsuccessful JJ N
cases NNS N
, , N
the DT N
thrombus JJ o
size NN o
increased VBD N
in IN N
four CD N
( ( N
three CD N
became VBD N
obstructive JJ N
in IN N
7-35 JJ N
days NNS N
) ) N
; : N
all DT N
four CD N
patients NNS N
were VBD N
switched VBN N
to TO N
fibrinolysis NN N
, , N
which WDT N
was VBD N
successful JJ N
without IN N
complications NNS N
in IN N
12-60 JJ N
h. NN N
The DT N
fifth JJ N
patient NN N
developed VBD N
a DT N
stroke NN o
after IN N
nine CD N
days NNS N
of IN N
heparin JJ N
treatment NN N
and CC N
was VBD N
subsequently RB N
operated VBN N
on IN N
. . N

CONCLUSIONS NNP N
Non-obstructive JJ N
PVT NNP N
may MD N
be VB N
asymptomatic JJ N
in IN N
one-third NN N
of IN N
patients NNS N
. . N

Thrombolysis NNP N
is VBZ N
an DT N
efficient JJ o
and CC o
safe JJ o
treatment NN N
, , N
and CC N
may MD N
be VB N
first-line JJ N
therapy NN N
if IN N
there EX N
is VBZ N
no DT N
contraindication NN N
. . N

Heparin NNP i
treatment NN N
was VBD N
successful JJ N
in IN N
about IN N
one-half NN N
of IN N
our PRP$ N
cases NNS N
in IN N
the DT N
presence NN N
of IN N
sessile NN N
or CC N
small JJ N
thrombi NN N
and CC N
inadequate JJ N
anticoagulant NN N
status NN N
. . N

In IN N
unsuccessful JJ N
cases NNS N
, , N
thrombi NN N
became VBD N
obstructive JJ N
or CC N
caused JJ N
stroke NN o
during IN N
heparin JJ N
therapy NN N
, , N
the DT N
adequate JJ N
duration NN N
of IN N
which WDT N
remains VBZ N
unclear JJ N
. . N

-DOCSTART- -17445928- O O

A DT N
randomised JJ N
trial NN N
of IN N
radiotherapy NN i
compared VBN N
with IN N
cisplatin JJ i
chemo-radiotherapy NN i
in IN N
patients NNS p
with IN p
unresectable JJ p
squamous JJ p
cell NN p
cancer NN p
of IN p
the DT p
esophagus NN p
. . p

BACKGROUND NNP N
AND CC N
PURPOSE NNP N
Following NNP N
our PRP$ N
phase NN N
II NNP N
experience NN N
, , N
a DT N
randomised JJ N
trial NN N
was VBD N
undertaken VBN N
to TO N
evaluate VB N
the DT N
efficacy NN o
of IN N
adding VBG i
chemotherapy NN i
to TO i
radiotherapy VB i
in IN i
patients NNS p
with IN p
unresectable JJ p
squamous JJ p
cell NN p
cancer NN p
of IN p
the DT p
esophagus NN p
. . p

PATIENTS NNP N
AND CC N
METHODS NNP N
Patients NNS N
randomised VBD N
to TO N
the DT N
RT NNP i
group NN i
received VBD i
50 CD i
Gy/25 NNP i
fx/5 JJ i
weeks NNS i
of IN i
teletherapy NN i
followed VBD i
1-2 JJ i
weeks NNS i
later RB i
with IN i
12 CD i
Gy/2 NNP i
fx NN i
of IN i
high-dose-rate JJ i
intra-lumenal JJ i
brachytherapy NN i
spaced VBD i
a DT i
week NN i
apart RB i
. . i

Following VBG N
the DT N
first JJ N
3 CD N
years NNS N
of IN N
recruitment NN N
, , N
due JJ N
to TO N
unexpected JJ N
late JJ N
morbidity NN N
, , N
brachytherapy NN i
was VBD N
excluded VBN N
and CC N
the DT N
protocol NN N
modified VBD N
to TO N
66 CD N
Gy/33 NNP N
fx/6.5 JJ N
weeks NNS N
. . N

The DT N
CRT NNP N
group NN N
received VBD i
identical JJ i
radiotherapy NN i
with IN i
concurrent JJ i
weekly JJ i
cisplatin NN i
at IN i
35 CD i
mg/m NN i
( ( i
2 CD i
) ) i
for IN i
6-7 JJ i
cycles NNS i
. . i

RESULTS NNP N
Between NNP p
April NNP p
1999 CD p
and CC p
December NNP p
2005 CD p
, , p
125 CD p
patients NNS p
were VBD p
randomised VBN p
to TO N
a DT N
RT NNP N
( ( N
n=60 NN N
) ) N
or CC N
CRT NNP N
group NN N
( ( N
n=65 RB N
) ) N
. . N

Radiotherapy NNP N
treatment NN N
was VBD N
completed VBN N
in IN N
78 CD N
% NN N
( ( N
47/60 CD N
) ) N
of IN N
the DT N
RT NNP N
group NN N
and CC N
89 CD N
% NN N
( ( N
58/65 CD N
) ) N
of IN N
the DT N
CRT NNP N
group NN N
( ( N
P=0.10 NNP N
) ) N
. . N

Six CD N
or CC N
more JJR N
cycles NNS N
of IN N
cisplatin NN N
could MD N
be VB N
delivered VBN N
in IN N
63 CD N
% NN N
( ( N
41/65 CD N
) ) N
, , N
which WDT N
resulted VBD N
in IN N
RTOG NNP o
grade VBD o
3 CD o
neutropenia NN o
of IN N
3 CD N
% NN N
. . N

Late JJ o
morbidity NN o
in IN o
the DT o
form NN o
of IN o
ulcers NNS o
( ( N
5 CD N
% NN N
vs. FW N
15 CD N
% NN N
odds NNS N
ratio VBP N
0.29 CD N
, , N
95 CD N
% NN N
CI NNP N
0.08-1.11 CD N
, , N
P=0.08 NNP N
) ) N
and CC N
strictures NNS o
( ( N
13 CD N
% NN N
vs. FW N
28 CD N
% NN N
, , N
odds NNS N
ratio VBP N
0.40 CD N
, , N
95 CD N
% NN N
CI NNP N
0.16-1.01 CD N
, , N
P=0.05 NNP N
) ) N
was VBD N
observed VBN N
in IN N
the DT N
RT NNP N
and CC N
CRT NNP N
groups NNS N
, , N
respectively RB N
. . N

At IN N
a DT N
median NN N
follow VBP N
up IN N
of IN N
23 CD N
months NNS N
of IN N
all DT N
patients NNS N
alive JJ N
( ( N
range JJ N
6-82 JJ N
months NNS N
) ) N
and CC N
with IN N
95/125 CD N
events NNS N
, , N
the DT N
median NN N
, , N
1 CD N
, , N
2 CD N
and CC N
5 CD N
year NN N
projected VBD N
survival NN o
was VBD N
7.1 CD N
months NNS N
, , N
32.3 CD N
% NN N
, , N
22.8 CD N
% NN N
and CC N
13.7 CD N
% NN N
vs. FW N
13.4 CD N
months NNS N
, , N
57.6 CD N
% NN N
, , N
38.9 CD N
% NN N
and CC N
24.8 CD N
% NN N
for IN N
the DT N
RT NNP N
and CC N
CRT NNP N
groups NNS N
, , N
respectively RB N
( ( N
hazard JJ N
ratio NN N
0.65 CD N
, , N
95 CD N
% NN N
CI NNP N
0.44-0.98 CD N
, , N
P=0.038 NNP N
) ) N
. . N

CONCLUSIONS VB N
The DT N
addition NN N
of IN N
concurrent NN N
cisplatin NN i
to TO N
radiotherapy VB i
resulted VBN N
in IN N
a DT N
modest JJ o
improvement NN o
in IN o
survival NN o
and CC N
was VBD N
associated VBN N
with IN N
manageable JJ o
additional JJ o
acute NN o
and CC o
late JJ o
morbidity NN o
. . o

-DOCSTART- -11056593- O O

Efficacy NN o
and CC o
safety NN o
of IN N
recombinant JJ i
human JJ i
nerve NN i
growth NN i
factor NN i
in IN N
patients NNS p
with IN p
diabetic JJ p
polyneuropathy NN p
: : p
A DT N
randomized NN N
controlled VBN N
trial NN N
. . N

rhNGF VB N
Clinical NNP N
Investigator NNP N
Group NNP N
. . N

CONTEXT NNP N
Nerve NNP N
growth NN N
factor NN N
is VBZ N
a DT N
neurotrophic JJ N
factor NN N
that WDT N
promotes VBZ N
the DT N
survival NN N
of IN N
small JJ N
fiber NNP N
sensory JJ N
neurons NNS N
and CC N
sympathetic JJ N
neurons NNS N
in IN N
the DT N
peripheral JJ N
nervous JJ N
system NN N
. . N

Recombinant JJ i
human JJ i
nerve NN i
growth NN i
factor NN i
( ( i
rhNGF NN i
) ) i
has VBZ N
demonstrated VBN N
efficacy NN N
as IN N
treatment NN N
for IN N
peripheral JJ N
neuropathy NN N
in IN N
experimental JJ N
models NNS N
and CC N
phase VB N
2 CD N
clinical JJ N
trials NNS N
. . N

OBJECTIVE NNP N
To TO N
evaluate VB N
the DT N
efficacy NN o
and CC o
safety NN o
of IN N
a DT N
12-month JJ N
regimen NN N
of IN N
rhNGF NN N
in IN N
patients NNS p
with IN p
diabetic JJ p
polyneuropathy NN p
. . p

DESIGN NNP N
Randomized NNP N
, , N
double-blind NN N
, , N
placebo-controlled JJ i
phase NN N
3 CD N
trial NN N
conducted VBN N
from IN N
July NNP N
1997 CD N
through IN N
May NNP N
1999 CD N
. . N

SETTING VB N
Eighty-four JJ p
outpatient NN p
centers NNS p
throughout IN p
the DT p
United NNP p
States NNPS p
. . p

PATIENTS VB N
A DT p
total NN p
of IN p
1019 CD p
men NNS p
and CC p
women NNS p
aged VBD p
18 CD p
to TO p
74 CD p
years NNS p
with IN p
either DT p
type NN p
1 CD p
or CC p
type VB p
2 CD p
diabetes NNS p
and CC p
a DT p
sensory JJ p
polyneuropathy NN p
attributable JJ p
to TO p
diabetes NNS p
. . p

INTERVENTIONS JJ N
Patients NNPS N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
either DT N
rhNGF NN i
, , N
0.1 CD N
microg/kg NN N
( ( N
n JJ N
= NNP N
504 CD N
) ) N
, , N
or CC N
placebo NN i
( ( N
n JJ N
= NNP N
515 CD N
) ) N
by IN N
subcutaneous JJ N
injection NN N
3 CD N
times NNS N
per IN N
week NN N
for IN N
48 CD N
weeks NNS N
. . N

Patients NNS N
were VBD N
assessed VBN N
at IN N
baseline NN N
, , N
12 CD N
weeks NNS N
, , N
24 CD N
weeks NNS N
, , N
and CC N
48 CD N
weeks NNS N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
The DT N
primary JJ N
outcome NN N
measure NN N
was VBD N
a DT N
change NN o
in IN o
neuropathy JJ o
between IN o
baseline NN o
and CC o
week NN o
48 CD o
, , o
demonstrated VBN o
by IN o
the DT o
Neuropathy NNP o
Impairment NNP o
Score NNP o
for IN N
the DT N
Lower NNP N
Limbs NNP N
, , N
compared VBN N
between IN N
the DT N
2 CD N
groups NNS N
. . N

Secondary JJ N
outcome NN N
measures NNS N
included VBD N
quantitative JJ o
sensory NN o
tests NNS o
using VBG o
the DT o
CASE NNP o
IV NNP o
System NNP o
, , o
the DT o
Neuropathy NNP o
Symptom NNP o
and CC o
Change NNP o
questionnaire NN o
, , o
the DT o
Patient NNP o
Benefit NNP o
Questionnaire NNP o
( ( o
PBQ NNP o
) ) o
, , o
and CC o
a DT o
global JJ o
symptom NN o
assessment NN o
, , o
as RB o
well RB o
as IN o
nerve NN o
conduction NN o
studies NNS o
and CC o
occurrence NN o
of IN o
new JJ o
plantar JJ o
foot NN o
ulcers NNS o
. . o

Patients NNS N
also RB N
were VBD N
evaluated VBN N
for IN N
presence NN N
of IN N
adverse JJ o
events NNS o
. . o

RESULTS NNP N
Among IN N
patients NNS N
who WP N
received VBD N
rhNGF NN i
, , N
418 CD N
( ( N
83 CD N
% NN N
) ) N
completed VBD N
the DT N
regimen NNS N
compared VBN N
with IN N
461 CD N
( ( N
90 CD N
% NN N
) ) N
who WP N
received VBD N
placebo NN i
. . i

Administration NNP N
of IN N
rhNGF NN i
was VBD N
safe JJ N
, , N
with IN N
few JJ N
adverse JJ o
events NNS o
attributed VBD N
to TO N
treatment NN N
apart RB N
from IN N
injection NN N
site NN o
pain/hyperalgesia NN o
and CC o
other JJ o
pain NN o
syndromes NNS o
. . o

However RB N
, , N
neither CC N
the DT N
primary JJ N
end NN N
point NN N
( ( N
P NNP N
=.25 NNP N
) ) N
nor CC N
most JJS N
of IN N
the DT N
secondary JJ N
end NN N
points NNS N
demonstrated VBD N
a DT N
significant JJ N
benefit NN N
of IN N
rhNGF NN i
. . i

Exceptions NNS N
were VBD N
the DT N
global JJ o
symptom NN o
assessment NN o
( ( N
P NNP N
=.03 NNP N
) ) N
and CC N
2 CD N
of IN N
32 CD N
comparisons NNS N
within IN N
the DT N
PBQ NNP N
, , N
which WDT N
showed VBD N
a DT N
modest JJ N
but CC N
significant JJ N
benefit NN N
of IN N
rhNGF NN i
( ( N
P NNP N
=.05 NNP N
for IN N
severity NN N
of IN N
pain NN N
in IN N
the DT N
legs NN N
and CC N
P NNP N
=.003 NNP N
for IN N
6-month JJ N
symptoms NNS N
in IN N
the DT N
feet NNS N
and CC N
legs NNS N
) ) N
. . N

CONCLUSION NNP N
Unlike IN N
previous JJ N
phase NN N
2 CD N
trials NNS N
, , N
this DT N
phase NN N
3 CD N
clinical JJ N
trial NN N
failed VBD N
to TO N
demonstrate VB N
a DT N
significant JJ N
beneficial JJ N
effect NN N
of IN N
rhNGF NN N
on IN N
diabetic JJ N
polyneuropathy NN N
. . N

JAMA NNP N
. . N

2000 CD N
; : N
284:2215-2221 JJ N
. . N

-DOCSTART- -2231203- O O

Azathioprine NNP i
and CC N
the DT N
treatment NN N
of IN N
chronic JJ p
inflammatory NN p
bowel NN p
disease NN p
. . p

-DOCSTART- -12121427- O O

Walking VBG N
trials NNS N
in IN N
postmenopausal JJ p
women NNS p
: : p
effect NN N
of IN N
one CD N
vs NN N
two CD N
daily JJ N
bouts NNS N
on IN N
aerobic JJ o
fitness NN o
. . o

We PRP N
compared VBN N
the DT N
effects NNS N
of IN N
one CD i
vs NN i
two CD i
daily JJ i
bouts NNS i
of IN i
walking VBG i
on IN N
aerobic JJ o
fitness NN o
and CC o
body NN o
composition NN o
in IN N
postmenopausal JJ p
women NNS p
. . p

One CD p
hundred CD p
and CC p
thirty-four JJ p
subjects NNS p
were VBD p
randomized VBN p
into IN p
exercise NN p
groups NNS p
or CC p
a DT p
control NN p
group NN p
and CC p
130 CD p
completed VBD p
the DT p
study NN p
. . p

The DT N
subjects NNS N
walked VBD i
5 CD i
d/week NN i
for IN i
15 CD i
weeks NNS i
at IN i
65 CD i
% NN i
of IN i
their PRP$ i
maximal NN i
aerobic JJ i
power NN i
expending VBG i
300 CD i
kcal JJ i
( ( i
1255 CD i
kJ NN i
) ) i
in IN i
exercise NN i
in IN i
one CD i
( ( i
Group NNP i
S1 NNP i
) ) i
or CC i
two CD i
daily JJ i
sessions NNS i
( ( i
Group NNP i
S2 NNP i
) ) i
. . i

VO NNP o
( ( o
2max CD o
) ) o
was VBD i
measured VBN i
in IN i
a DT i
direct JJ i
maximal NN i
treadmill NN i
test NN i
. . i

Body NNP o
mass NN o
index NN o
( ( o
BMI NNP o
) ) o
was VBD i
calculated VBN i
and CC i
the DT i
percentage NN i
of IN i
body NN i
fat NN i
( ( i
fat JJ i
% NN i
) ) i
estimated VBN i
using VBG i
skinfold JJ i
measurements NNS i
. . i

The DT N
net JJ N
change NN N
in IN N
the DT N
VO NNP o
( ( o
2max CD o
) ) o
was VBD N
2.5 CD N
mL NN N
min/kg NN N
( ( N
95 CD N
% NN N
CI NNP N
1.5 CD N
, , N
3.5 CD N
) ) N
( ( N
8.7 CD N
% NN N
) ) N
in IN N
Group NNP N
S1 NNP N
and CC N
2.5 CD N
mL NN N
min/kg NN N
( ( N
95 CD N
% NN N
CI NNP N
1.5 CD N
, , N
3.5 CD N
) ) N
( ( N
8.8 CD N
% NN N
) ) N
in IN N
Group NNP N
S2 NNP N
. . N

The DT N
net JJ o
change NN o
in IN o
body NN o
mass NN o
was VBD N
-1.2 JJ N
kg NN N
( ( N
95 CD N
% NN N
CI-1.9 NNP N
, , N
-0.5 NNP N
) ) N
in IN N
Group NNP N
S1 NNP N
and CC N
-1.1 NNP N
kg NNP N
( ( N
95 CD N
% NN N
CI NNP N
-1.8 NNP N
, , N
-0.4 NNP N
) ) N
in IN N
Group NNP N
S2 NNP N
. . N

The DT N
net JJ o
fat NN o
% NN o
change NN o
was VBD N
-2.1 JJ N
% NN N
( ( N
95 CD N
% NN N
CI-2.7 NNP N
, , N
-1.4 NNP N
) ) N
in IN N
Group NNP N
S1 NNP N
and CC N
-1.7 NNP N
% NN N
( ( N
95 CD N
% NN N
CI-2.3 NNP N
, , N
-1.0 NNP N
) ) N
in IN N
Group NNP N
S2 NNP N
. . N

Exercise NN N
improved VBD N
the DT N
maximal NN N
aerobic JJ N
power NN N
and CC N
body NN N
composition NN N
equally RB N
when WRB N
walking NN i
was VBD N
performed VBN N
in IN N
one CD N
or CC N
two CD N
daily JJ N
bouts NNS N
. . N

-DOCSTART- -1832287- O O

Atrial NNP N
natriuretic JJ N
factor NN N
inhibits NNS N
metoclopramide RB i
stimulated VBD N
aldosterone JJ o
release NN o
in IN N
man NN p
. . p

1 CD N
. . N

Atrial NNP N
natriuretic JJ N
factor NN N
( ( N
ANF NNP N
) ) N
has VBZ N
an DT N
inhibitory JJ N
effect NN N
on IN N
angiotensin NN o
II NNP o
and CC o
ACTH NNP o
stimulated VBD o
aldosterone CD o
secretion NN o
in IN N
man NN N
. . N

The DT N
selectivity NN N
of IN N
this DT N
aldosterone NN N
suppressing VBG N
effect NN N
of IN N
ANF NNP N
is VBZ N
unclear JJ N
in IN N
man NN N
. . N

The DT N
present JJ N
study NN N
investigated VBD N
the DT N
effect NN N
of IN N
ANF NNP N
on IN N
the DT N
increase NN N
in IN N
plasma JJ o
aldosterone NN o
due JJ N
to TO N
metoclopramide VB o
in IN N
man NN p
. . p

2 CD N
. . N

Eight NNP p
normal JJ p
male NN p
volunteers NNS p
were VBD N
studied VBN N
on IN N
three CD N
occasions NNS N
. . N

Metoclopramide NNP i
( ( N
10 CD N
mg RB N
slow JJ N
i.v NN N
. . N

) ) N
was VBD N
given VBN N
on IN N
all DT N
study NN N
days NNS N
and CC N
each DT N
volunteer NN N
was VBD N
randomised VBN N
to TO N
receive VB N
45 CD N
min JJ N
infusion NN N
of IN N
either DT i
5 CD i
% NN i
D-glucose NNP i
( ( i
placebo NN i
) ) i
or CC i
ANF NNP i
( ( N
99-126 CD N
) ) N
3 CD N
or CC N
15 CD N
pmol JJ i
kg-1 JJ N
min-1 NN N
. . N

3 CD N
. . N

Metoclopramide NNP i
increased VBD N
plasma RB o
aldosterone NN o
to TO N
approximately RB N
170 CD N
% NN N
of IN N
baseline NN N
levels NNS N
( ( N
P NNP N
less JJR N
than IN N
0.01 CD N
) ) N
. . N

Concomitant JJ N
infusion NN N
of IN N
ANF NNP i
3 CD i
pmol JJ N
kg-1 JJ N
min-1 NN N
and CC N
15 CD N
pmol JJ N
kg-1 JJ N
min-1 NN N
significantly RB N
attenuated VBD N
this DT N
rise NN o
in IN o
plasma NN o
aldosterone NN o
to TO N
approximately RB N
130 CD N
% NN N
( ( N
P NNP N
less JJR N
than IN N
0.05 CD N
) ) N
and CC N
110 CD N
% NN N
( ( N
P NNP N
less JJR N
than IN N
0.01 CD N
) ) N
of IN N
baseline NN N
values NNS N
respectively RB N
. . N

4 CD N
. . N

It PRP N
is VBZ N
suggested VBN N
, , N
in IN N
the DT N
light NN N
of IN N
previous JJ N
findings NNS N
, , N
that IN N
the DT N
inhibitory JJ N
effect NN N
of IN N
ANF NNP N
represents VBZ N
a DT N
non-selective JJ N
action NN N
of IN N
ANF NNP N
on IN N
aldosterone NN o
release NN o
. . o

-DOCSTART- -24898574- O O

Changes NNS N
in IN N
motor NN N
cortex NN N
excitability NN N
associated VBN N
with IN N
temporal JJ i
repetitive JJ i
transcranial JJ i
magnetic JJ i
stimulation NN i
in IN N
tinnitus NN p
: : p
hints NNS N
for IN N
cross-modal JJ N
plasticity NN N
? . N
BACKGROUND NNP N
Motor NNP N
cortex VBP N
excitability NN N
was VBD N
found VBN N
to TO N
be VB N
changed VBN N
after IN N
repetitive JJ i
transcranial JJ i
magnetic JJ i
stimulation NN i
( ( i
rTMS NN i
) ) i
of IN N
the DT N
temporal JJ N
cortex NN N
highlighting VBG N
the DT N
occurrence NN N
of IN N
cross-modal JJ N
plasticity NN N
in IN N
non-invasive JJ N
brain NN N
stimulation NN N
. . N

Here RB N
, , N
we PRP N
investigated VBD N
the DT N
effects NNS N
of IN N
temporal JJ i
low-frequency NN i
rTMS NN i
on IN N
motor NN N
cortex NN N
plasticity NN N
in IN N
a DT N
large JJ N
sample NN N
of IN N
tinnitus NN p
patients NNS p
. . p

In IN N
116 CD p
patients NNS p
with IN p
chronic JJ p
tinnitus NN p
different JJ N
parameters NNS N
of IN N
cortical JJ N
excitability NN N
were VBD N
assessed VBN N
before IN N
and CC N
after IN N
ten JJ N
rTMS JJ i
treatment NN N
sessions NNS N
. . N

Patients NNS N
received VBD N
one CD N
of IN N
three CD N
different JJ N
protocols NNS N
all DT N
including VBG N
1 CD i
Hz NNP i
rTMS NN i
over IN i
the DT i
left JJ i
temporal JJ i
cortex NN i
. . i

Treatment NNP N
response NN N
was VBD N
defined VBN N
as IN N
improvement NN N
by IN N
at IN N
least JJS N
five CD N
points NNS N
in IN N
the DT N
tinnitus NN N
questionnaire NN N
( ( N
TQ NNP N
) ) N
. . N

Variables NNS N
of IN N
interest NN N
were VBD N
resting VBG o
motor NN o
threshold NN o
( ( o
RMT NNP o
) ) o
, , o
short-interval JJ o
intra-cortical JJ o
inhibition NN o
( ( o
SICI NNP o
) ) o
, , o
intracortical JJ o
facilitation NN o
( ( o
ICF NNP o
) ) o
, , o
and CC o
cortical JJ o
silent JJ o
period NN o
( ( o
CSP NNP o
) ) o
. . o

RESULTS NNP N
After IN N
rTMS JJ i
treatment NN N
RMT NNP o
was VBD o
decreased VBN o
by IN N
about IN N
1 CD N
% NN N
of IN N
stimulator NN N
output NN N
near-significantly RB N
in IN N
the DT N
whole JJ N
group NN N
of IN N
patients NNS N
. . N

SICI NNP o
was VBD N
associated VBN N
with IN N
significant JJ N
changes NNS N
with IN N
respect NN N
to TO N
treatment NN N
response NN N
. . N

The DT N
group NN N
of IN N
treatment NN N
responders NNS N
showed VBD N
a DT N
decrease NN o
of IN o
SICI NNP o
over IN N
the DT N
course NN N
of IN N
treatment NN N
, , N
the DT N
group NN N
of IN N
non-responders NNS N
the DT N
reverse NN N
pattern NN N
. . N

CONCLUSIONS NNP N
Minor NNP o
RMT NNP o
changes NNS o
during IN N
rTMS NN i
treatment NN N
do VBP N
not RB N
necessarily RB N
suggest VB N
the DT N
need NN N
for IN N
systematic JJ N
re-examination NN N
of IN N
the DT N
RMT NNP N
for IN N
safety NN N
and CC N
efficacy NN N
issues NNS N
. . N

Treatment NNP N
response NN N
to TO N
rTMS VB i
was VBD N
shown VBN N
to TO N
be VB N
related VBN N
to TO N
changes NNS N
in IN N
SICI NNP N
that WDT N
might MD N
reflect VB N
modulation NN N
of IN N
GABAergic NNP N
mechanisms FW N
directly RB N
or CC N
indirectly RB N
related VBN N
to TO N
rTMS VB N
treatment NN N
effects NNS N
. . N

-DOCSTART- -7007454- O O

Effects NNS N
of IN N
topical JJ i
and CC i
systemic JJ i
folic JJ i
acid NN i
supplementation NN N
on IN N
gingivitis NN o
in IN o
pregnancy NN o
. . o

A DT N
double-blind JJ N
study NN N
evaluated VBD N
the DT N
effects NNS N
of IN N
systemic JJ i
and CC i
topical JJ i
folate NN i
on IN N
gingival JJ o
inflammation NN o
during IN o
the DT o
fourth JJ o
and CC o
eighth JJ o
months NNS o
of IN o
pregnancy NN o
. . o

Thirty JJ p
women NNS p
were VBD N
randomly RB N
divided VBN N
into IN N
three CD N
groups NNS N
. . N

Group NNP N
A NNP N
received VBD N
placebo JJ i
mouthwash NN i
and CC i
tablets NNS i
; : i
Group NNP N
B NNP N
; : N
placebo NN i
mouthwash NN i
and CC i
5 CD i
mg NN i
folate JJ i
tablets NNS i
; : i
Group NNP N
C NNP N
: : N
folate NN i
mouthwash NN i
and CC i
placebo NN i
tablets NNS i
. . i

Supplementation NNP N
lasted VBD N
for IN N
14 CD N
days NNS N
during IN N
months NNS N
4 CD N
and CC N
8 CD N
. . N

Subjects NNS N
took VBD N
one CD N
tablet NN N
daily NN N
and CC N
rinsed JJ N
twice RB N
daily RB N
for IN N
1 CD N
min NN N
with IN N
the DT N
mouthwash NN N
. . N

At IN N
the DT N
start NN N
and CC N
finish NN N
of IN N
each DT N
14-day JJ N
period NN N
, , N
fasting VBG o
serum NN o
and CC o
red JJ o
cell NN o
folate NN o
levels NNS o
were VBD N
estimated VBN N
and CC N
oral JJ o
status NN o
assessed VBN N
by IN N
a DT N
plaque NN o
index NN o
( ( o
P1I NNP o
) ) o
, , o
a DT o
gingival JJ o
index NN o
( ( o
GI NNP o
) ) o
, , o
and CC o
gingival JJ o
exudate NN o
flow NN o
meter NN o
( ( o
GEF NNP o
) ) o
. . o

Subjects NNS N
completed VBD N
1-week JJ N
diet JJ N
sheets NNS N
which WDT N
were VBD N
analysed VBN N
for IN N
dietary JJ o
folate NN o
. . o

All DT N
groups NNS N
were VBD N
similar JJ N
in IN N
each DT N
parameter NN N
at IN N
the DT N
start NN N
. . N

Correlation NN N
was VBD N
demonstrated VBN N
between IN N
GI NNP o
and CC o
P1I NNP o
, , N
and CC N
between IN N
GI NNP o
and CC o
GEF NNP o
. . o

GI NNP o
tended VBD N
to TO N
increase VB N
throughout IN N
pregnancy NN N
in IN N
all DT N
groups NNS N
except IN N
Group NNP N
C NNP N
, , N
when WRB N
in IN N
the DT N
eighth JJ N
month NN N
there EX N
was VBD N
a DT N
highly RB N
significant JJ N
improvement NN N
( ( N
0.001 CD N
less JJR N
than IN N
P NNP N
0.01 CD N
) ) N
despite IN N
no DT N
significant JJ N
change NN N
in IN N
P1I NNP N
. . N

Although IN N
dietary JJ N
intake NN N
of IN N
folate NN N
was VBD N
significantly RB N
higher JJR N
during IN N
the DT N
eighth JJ N
month NN N
in IN N
Group NNP N
C NNP N
as IN N
compared VBN N
with IN N
Groups NNP N
A NNP N
and CC N
B NNP N
, , N
( ( N
0.001 CD N
less JJR N
than IN N
P NNP N
less JJR N
than IN N
0.01 CD N
) ) N
, , N
the DT N
folate NN N
mouthwash NN N
produced VBD N
highly RB N
significantly RB N
improvement NN N
in IN N
gingival JJ o
health NN o
in IN p
pregnancy NN p
. . p

-DOCSTART- -22278094- O O

Effects NNS p
of IN p
a DT p
common JJ p
variant NN p
in IN p
the DT p
CD38 NNP p
gene NN p
on IN p
social JJ o
processing NN o
in IN N
an DT N
oxytocin NN i
challenge NN N
study NN N
: : N
possible JJ N
links NNS N
to TO N
autism NN N
. . N

The DT N
intranasal JJ N
application NN N
of IN N
oxytocin NN i
( ( i
OT NNP i
) ) i
has VBZ N
been VBN N
shown VBN N
to TO N
influence VB N
behavioral JJ o
and CC o
neural JJ o
correlates NNS o
of IN o
social JJ o
processing NN o
. . o

These DT N
effects NNS N
are VBP N
probably RB N
mediated VBN N
by IN N
genetic JJ N
variations NNS N
within IN N
the DT N
OT NNP N
system NN N
. . N

One CD p
potential JJ p
candidate NN p
could MD p
be VB p
the DT p
CD38 NNP p
gene NN p
, , N
which WDT N
codes VBZ N
for IN N
a DT N
transmembrane NN N
protein NN N
engaged VBD N
in IN N
OT NNP N
secretion NN N
processes VBZ N
. . N

A DT N
common JJ N
variation NN N
in IN N
this DT N
gene NN N
( ( N
rs3796863 NN N
) ) N
was VBD N
recently RB N
found VBN N
to TO N
be VB N
associated VBN N
with IN N
autism NN p
spectrum NN p
disorders NNS p
( ( p
ASD NNP p
) ) p
. . p

Using VBG N
an DT N
imaging NN N
genetics NNS N
approach NN N
, , N
we PRP N
studied VBD N
differential JJ N
effects NNS N
of IN N
an DT N
intranasal NN N
OT NNP i
application NN i
on IN N
neural JJ o
processing NN o
of IN o
social JJ o
stimuli NNS o
in IN N
55 CD p
healthy JJ p
young JJ p
men NNS p
depending VBG p
on IN p
their PRP$ p
CD38 NNP p
gene NN p
variant NN p
in IN N
a DT N
double-blind JJ N
placebo-controlled JJ i
crossover NN N
design NN N
. . N

Genotype NNP N
had VBD N
a DT N
significant JJ N
influence NN N
on IN N
both DT N
behavioral JJ o
and CC o
neuronal JJ o
measures NNS o
of IN o
social JJ o
processing NN o
. . o

Homozygotic JJ p
risk NN p
allele NN p
carriers NNS p
showed VBD N
slower JJR o
reaction NN o
times NNS o
( ( o
RT NNP o
) ) o
and CC N
higher JJR o
activation NN o
of IN o
left JJ o
fusiform NN o
gyrus NN o
during IN N
visual JJ N
processing NN N
of IN N
social JJ o
stimuli NNS o
. . o

Under IN N
OT NNP N
activation NN o
differences NNS o
between IN N
genotypes NNS N
were VBD N
more RBR N
evident JJ N
( ( N
though IN N
not RB N
statistically RB N
significantly RB N
increased VBN N
) ) N
and CC N
RT NNP o
were VBD N
accelerated VBN N
in IN N
homozygotic JJ p
risk NN p
allele NN p
carriers NNS p
. . p

According VBG N
to TO N
our PRP$ N
data NNS N
, , N
rs3796863 NN o
mainly RB o
influences VBZ o
fusiform NN o
gyrus NN o
activation NN o
, , N
an DT N
area NN N
which WDT N
has VBZ N
been VBN N
widely RB N
discussed VBN N
in IN N
ASD NNP N
research NN N
. . N

OT CC N
seems VBZ N
to TO N
modulate VB N
this DT N
effect NN N
by IN N
enhancing VBG N
activation NN o
differences NNS o
between IN N
allele JJ p
groups NNS p
, , N
which WDT N
suggests VBZ N
an DT N
interaction NN N
between IN N
genetic JJ o
makeup NN o
and CC N
OT NNP o
availability NN o
on IN N
fusiform NN o
gyrus NN o
activation NN o
. . o

These DT N
results NNS N
support VBP N
recent JJ N
approaches NNS N
to TO N
apply VB N
OT NNP i
as IN N
a DT N
pharmacological JJ i
treatment NN i
of IN N
ASD NNP N
symptoms NNS N
. . N

-DOCSTART- -6762195- O O

Immunotherapy NNP i
maintenance NN N
in IN N
acute JJ p
non-lymphocytic JJ p
leukaemia NN p
. . p

Between NNP p
January NNP p
1975 CD p
and CC p
December NNP p
1977 CD p
, , p
264 CD p
adult NN p
patients NNS p
with IN p
acute JJ p
non-lymphocytic JJ p
leukaemia NN p
entered VBD p
the DT p
Australian JJ p
National NNP p
Leukaemia NNP p
Trial NNP p
. . p

Of IN N
251 CD p
evaluable JJ p
patients NNS p
, , N
three CD N
induction NN N
regimens VBZ N
achieved VBN N
similar JJ N
complete JJ o
response NN o
( ( o
CR NNP o
) ) o
rates NNS o
. . o

CROP NNP i
( ( i
cytosine JJ i
arabinoside NN i
, , i
daunorubicin NN i
, , i
vincristine NN i
, , i
prednisolone NN i
) ) i
produced VBD N
CR NNP N
in IN N
41 CD N
% NN N
of IN N
patients NNS N
, , N
7 CD N
and CC N
3 CD N
( ( i
cytosine NN i
arabinoside RB i
, , i
daunorubicin NN i
) ) i
in IN N
42 CD N
% NN N
and CC N
7 CD N
and CC N
3 CD N
plus CC i
hydroxyurea NN i
in IN N
52 CD N
% NN N
. . N

Remission NNP o
duration NN o
and CC o
survival NN o
were VBD N
similar JJ N
when WRB N
induction NN N
regimens NNS N
were VBD N
compared VBN N
. . N

Forty-five JJ N
patients NNS N
reaching VBG N
maintenance NN i
therapy NN i
were VBD N
randomised VBN N
to TO N
either DT N
chemo-immunotherapy NN i
( ( i
BCG NNP i
plus CC i
intradermal JJ i
leukaemic JJ i
blast NN i
cells NNS i
) ) i
or CC i
chemotherapy VB i
alone RB i
. . i

The DT N
duration NN o
of IN o
CR NNP o
in IN N
these DT N
two CD N
groups NNS N
was VBD N
almost RB N
identical JJ N
, , N
though IN N
patients NNS N
receiving VBG N
chemotherapy NN i
alone RB N
had VBD N
prolonged VBN N
survival NN o
( ( N
median JJ N
161 CD N
weeks NNS N
) ) N
when WRB N
compared VBN N
to TO N
the DT N
chemo-immunotherapy JJ i
group NN N
( ( N
84 CD N
weeks NNS N
, , N
p VBP N
= JJ N
0 CD N
. . N

07 CD N
) ) N
. . N

Institutions NNS N
with IN N
less JJR N
developed JJ N
supportive NN N
facilities NNS N
reported VBD N
lower JJR N
CR NNP N
rates NNS N
( ( N
p VB N
= RB N
0 CD N
. . N

04 CD N
) ) N
. . N

Leucocytosis NNP o
( ( N
greater JJR N
than IN N
100 CD N
X JJ N
10 CD N
( ( N
9 CD N
) ) N
/1 NN N
) ) N
and CC N
older JJR N
age NN N
( ( N
greater JJR N
than IN N
50 CD N
years NNS N
) ) N
were VBD N
associated VBN N
with IN N
shortened JJ N
survival NN N
. . N

The DT N
Trial NNP N
has VBZ N
failed VBN N
to TO N
show VB N
any DT N
advantage NN N
for IN N
this DT N
form NN N
of IN N
immunotherapy NN i
. . i

-DOCSTART- -26052790- O O

Environmental JJ i
enrichment NN i
as IN N
a DT N
therapy NN N
for IN N
autism NN p
: : p
A DT N
clinical JJ N
trial NN N
replication NN N
and CC N
extension NN N
. . N

Based VBN N
on IN N
work NN N
done VBN N
in IN N
animal NN N
models NNS N
showing VBG N
that IN N
autism-like JJ N
symptoms NNS N
are VBP N
ameliorated VBN N
following JJ N
exposure NN N
to TO N
an DT N
enriched JJ i
sensorimotor NN i
environment NN i
, , N
we PRP N
attempted VBD N
to TO N
develop VB N
a DT N
comparable JJ N
therapy NN N
for IN N
children NNS p
with IN p
autism NN p
. . p

In IN N
an DT N
initial JJ N
randomized NN N
controlled VBD N
trial NN N
, , N
children NNS p
with IN p
autism NN p
who WP p
received VBD p
sensorimotor NN i
enrichment NN i
at IN i
home NN i
for IN p
6 CD p
months NNS p
had VBD p
significant JJ p
improvements NNS p
in IN p
both DT p
their PRP$ p
cognitive NN p
ability NN p
and CC p
the DT p
severity NN p
of IN p
their PRP$ p
autism NN p
symptoms NNS p
( ( N
Woo NNP N
& CC N
Leon NNP N
, , N
2013 CD N
) ) N
. . N

We PRP N
now RB N
report VBP N
the DT N
outcomes NNS N
of IN N
a DT N
similar JJ N
randomized NN N
controlled VBD N
trial NN N
in IN N
which WDT N
children NNS p
with IN p
autism NN p
, , p
3 CD p
to TO p
6 CD p
years NNS p
old JJ p
, , p
were VBD p
randomly RB p
assigned VBN p
to TO N
groups NNS i
that WDT i
received VBD i
either DT i
daily JJ i
sensorimotor NN i
enrichment NN i
, , i
administered VBN i
by IN i
their PRP$ i
parents NNS i
, , i
along IN i
with IN i
standard JJ i
care NN i
, , i
or CC i
they PRP i
received VBD i
standard JJ i
care NN i
alone RB i
. . i

After IN N
6 CD N
months NNS N
, , N
enriched VBD N
children NNS N
showed VBD N
statistically RB N
significant JJ N
gains NNS N
in IN N
their PRP$ N
IQ NNP o
scores NNS o
, , N
a DT N
decline NN N
in IN N
their PRP$ N
atypical JJ o
sensory NN o
responses NNS o
, , N
and CC N
an DT N
improvement NN N
in IN N
their PRP$ N
receptive JJ o
language NN o
performance NN o
, , N
compared VBN N
to TO N
controls NNS N
. . N

Furthermore NNP N
, , N
after IN N
6 CD N
months NNS N
of IN N
enrichment JJ N
therapy NN N
, , N
21 CD N
% NN N
of IN N
the DT N
children NNS N
who WP N
initially RB N
had VBD N
been VBN N
given VBN N
an DT N
autism NN N
classification NN N
, , N
using VBG N
the DT N
Autism NNP N
Diagnostic NNP N
Observation NNP N
Schedule NNP N
, , N
improved VBN N
to TO N
the DT N
point NN N
that IN N
, , N
although IN N
they PRP N
remained VBD N
on IN N
the DT N
autism NN N
spectrum NN N
, , N
they PRP N
no RB N
longer RBR N
met VBD N
the DT N
criteria NNS N
for IN N
classic JJ N
autism NN N
. . N

None NN N
of IN N
the DT N
standard NN N
care NN N
controls VBZ N
reached VBD N
an DT N
equivalent JJ N
level NN N
of IN N
improvement NN N
. . N

Finally RB N
, , N
the DT N
outcome NN o
measures NNS o
for IN N
children NNS N
who WP N
received VBD N
only RB N
a DT N
subset NN N
of IN N
sensory JJ N
stimuli NNS N
were VBD N
similar JJ N
to TO N
those DT N
receiving VBG N
the DT N
full JJ N
complement NN N
of IN N
enrichment NN N
exercises NNS N
. . N

Sensorimotor NNP N
enrichment JJ N
therapy NN N
therefore RB N
appears VBZ N
to TO N
be VB N
a DT N
cost-effective JJ o
means NNS N
of IN N
treating VBG N
a DT N
range NN N
of IN N
symptoms NNS N
for IN N
children NNS N
with IN N
autism NN N
. . N

-DOCSTART- -8394956- O O

The DT N
relative JJ N
contributions NNS N
of IN N
medication NN i
adherence NN i
and CC i
AA NNP i
meeting NN i
attendance NN i
to TO N
abstinent VB N
outcome NN N
for IN N
chronic JJ p
alcoholics NNS p
. . p

Our PRP$ N
preliminary JJ N
studies NNS N
of IN N
the DT N
efficacy NN N
of IN N
lithium NN i
carbonate NN i
therapy NN i
for IN N
alcoholism NN N
under IN N
double-blind NN N
, , N
placebo-controlled JJ N
conditions NNS N
demonstrated VBD N
that IN N
alcoholics NNS p
who WP p
took VBD p
their PRP$ p
assigned JJ p
medication NN p
( ( i
lithium NN i
or CC i
placebo NN i
) ) i
for IN p
the DT p
first JJ p
6 CD p
months NNS p
after IN p
discharge NN p
from IN p
an DT p
inpatient JJ p
rehabilitation NN p
program NN p
were VBD N
more RBR N
likely JJ N
to TO N
abstain VB N
from IN N
any DT N
alcohol NN N
use NN N
for IN N
18 CD N
months NNS N
following VBG N
discharge NN N
than IN N
were VBD N
alcoholics NNS p
who WP p
took VBD p
their PRP$ p
medication NN p
erratically RB p
or CC p
not RB p
at IN p
all DT p
. . p

Attendance NN p
at IN p
Alcoholics NNP p
Anonymous NNP p
( ( p
AA NNP p
) ) p
meetings NNS p
was VBD N
also RB N
associated VBN N
with IN N
medication NN N
adherence NN N
. . N

We PRP N
applied VBD N
a DT N
structural JJ N
equation NN N
model NN N
to TO N
data NNS N
on IN N
the DT N
relationships NNS N
between IN N
medication NN N
adherence NN N
, , N
AA NNP N
meeting NN N
attendance NN N
and CC N
abstinent JJ o
outcome NN o
to TO N
clarify VB N
whether IN N
medication NN N
adherence NN N
or CC N
AA NNP N
meeting NN N
attendance NN N
better RBR N
explains VBZ N
the DT N
positive-outcome JJ N
adherence NN o
effect NN N
we PRP N
observed VBD N
. . N

Both DT N
medication NN N
adherence NN N
and CC N
AA NNP N
meeting NN N
attendance NN N
evidenced VBD N
direct JJ N
and CC N
independent JJ N
influences NNS N
on IN N
abstinent JJ N
outcome NN N
: : N
medication NN N
adherence NN N
showed VBD N
a DT N
small JJ N
direct JJ N
influence NN N
, , N
and CC N
AA NNP N
meeting NN N
attendance NN N
showed VBD N
a DT N
much RB N
larger JJR N
, , N
independent JJ N
influence NN N
. . N

-DOCSTART- -10568568- O O

Effect NN N
of IN N
nitric-oxide-generating JJ i
system NN i
on IN N
microcirculatory NN o
blood NN o
flow NN o
in IN N
skin NN N
of IN N
patients NNS p
with IN p
severe JJ p
Raynaud NNP p
's POS p
syndrome NN p
: : p
a DT N
randomised JJ N
trial NN N
. . N

BACKGROUND NNP N
Patients NNPS p
with IN p
Raynaud NNP p
's POS p
syndrome NN p
have VBP N
abnormal JJ N
digital JJ N
vasoconstriction NN N
, , N
which WDT N
may MD N
be VB N
secondary JJ N
to TO N
impaired JJ N
synthesis NN N
of IN N
, , N
or CC N
impaired JJ N
sensitivity NN N
to TO N
, , N
nitric JJ N
oxide NN N
. . N

We PRP N
studied VBD N
the DT N
effect NN N
on IN N
microcirculation NN N
of IN N
a DT N
nitric-oxide-generating JJ i
system NN i
applied VBN N
topically RB N
to TO N
the DT N
finger NN N
and CC N
forearm NN N
of IN N
healthy JJ p
volunteers NNS p
and CC p
patients NNS p
with IN p
primary JJ p
Raynaud NNP p
's POS p
syndrome NN p
. . p

METHODS NNP N
We PRP N
did VBD N
a DT N
single-blind NN N
, , N
randomised VBN N
, , N
placebo NN N
controlled VBD N
, , N
cross-over NN N
study NN N
of IN N
the DT N
microcirculatory NN o
response NN o
to TO N
topical JJ N
application NN N
of IN N
a DT N
nitric-oxidegenerating JJ i
gel NN i
in IN N
20 CD p
patients NNS p
with IN p
severe JJ p
Raynaud NNP p
's POS p
syndrome NN p
, , p
and CC p
ten RB p
healthy JJ p
volunteers NNS p
. . p

We PRP i
prepared VBD i
the DT i
nitric-oxide-generating JJ i
system NN i
by IN i
mixing VBG i
a DT i
solution NN i
of IN i
KY NNP i
jelly RB i
and CC i
sodium JJ i
nitrite NN i
( ( i
5 CD i
% NN i
weight/volume NN i
) ) i
, , i
with IN i
a DT i
solution NN i
of IN i
KY NNP i
jelly RB i
and CC i
ascorbic JJ i
acid NN i
( ( i
5 CD i
% NN i
weight/volume NN i
) ) i
. . N

About IN i
0.5 CD i
mL NNS i
of IN i
each DT i
solution NN i
was VBD i
separately RB i
applied VBN i
to TO i
the DT i
skin NN i
of IN i
the DT i
forearm NN i
( ( i
3 CD i
cm2 NN i
) ) i
, , i
and CC i
then RB i
mixed JJ i
with IN i
a DT i
sterile JJ i
cotton NN i
bud NN i
. . i

A DT i
similar JJ i
procedure NN i
was VBD i
done VBN i
simultaneously RB i
on IN i
the DT i
other JJ i
arm NN i
with IN i
KY NNP i
jelly RB i
only RB i
( ( i
placebo NN i
) ) i
. . N

The DT N
procedure NN N
was VBD N
then RB N
repeated VBN N
on IN N
the DT N
finger NN N
pulps VBZ N
. . N

Changes NNS o
in IN o
skin JJ o
microcirculatory NN o
volume NN o
and CC o
flux NN o
were VBD N
measured VBN N
bilaterally RB N
by IN N
infrared JJ N
photoplethysmography NN N
and CC N
laser NN N
doppler NN N
fluxmetry NN N
, , N
respectively RB N
. . N

FINDINGS NNP N
In IN N
the DT N
forearm NN N
, , N
blood NN o
flow NN o
increased VBD N
significantly RB N
after IN N
application NN N
of IN N
the DT N
active JJ N
gel NN N
both DT N
in IN N
patients NNS N
with IN N
Raynaud NNP N
's POS N
syndrome NN N
( ( N
microcirculatory JJ N
volume NN N
from IN N
mean JJ N
area NN N
under IN N
the DT N
curve NN N
98 CD N
[ NNP N
SE NNP N
14 CD N
] NN N
to TO N
1024 CD N
[ NN N
130 CD N
] NN N
; : N
microcirculatory JJ N
flux NN N
from IN N
5060 CD N
[ $ N
462 CD N
] NN N
to TO N
74,800 CD N
[ NN N
3940 CD N
] NN N
) ) N
and CC N
in IN N
healthy JJ N
controls NNS N
( ( N
volume NN N
from IN N
85 CD N
[ $ N
19 CD N
] NN N
to TO N
1020 CD N
[ NN N
60 CD N
] NN N
; : N
flux NN N
from IN N
4420 CD N
[ $ N
435 CD N
] NN N
to TO N
84,500 CD N
[ NN N
7000 CD N
] NN N
) ) N
. . N

In IN N
the DT N
fingers NNS N
, , N
although IN N
baseline NN o
blood NN o
flow NN o
was VBD N
lower JJR N
in IN N
patients NNS N
than IN N
in IN N
controls NNS N
, , N
both DT N
groups NNS N
showed VBD N
increases NNS N
with IN N
application NN N
of IN N
active JJ N
gel NN N
( ( N
volume NN N
from IN N
1100 CD N
[ $ N
194 CD N
] NN N
to TO N
3280 CD N
[ NN N
672 CD N
] NN N
and CC N
2380 CD N
[ NN N
441 CD N
] NN N
to TO N
6160 CD N
[ NN N
1160 CD N
] NN N
, , N
respectively RB N
; : N
flux NN o
from IN N
33,400 CD N
[ JJ N
4200 CD N
] NN N
to TO N
108,000 CD N
[ NNS N
13,600 CD N
] NNS N
and CC N
52,000 CD N
[ NN N
8950 CD N
] NN N
to TO N
185,000 CD N
[ NNS N
19,500 CD N
] NN N
) ) N
. . N

Increases VBZ N
in IN N
blood NN o
flow NN o
with IN N
placebo JJ N
gel NNS N
were VBD N
not RB N
significant JJ N
. . N

No DT N
adverse JJ N
effects NNS N
were VBD N
reported VBN N
. . N

INTERPRETATION NNP N
In IN N
primary JJ p
Raynaud NNP p
's POS p
syndrome NN p
, , N
topical JJ N
application NN N
of IN N
a DT N
nitric-oxide-generating JJ i
system NN i
can MD N
stimulate VB N
an DT N
increase NN N
in IN N
both DT N
microcirculatory JJ o
volume NN o
and CC o
flux NN o
. . o

-DOCSTART- -8964729- O O

Effects NNS N
of IN N
fenoterol NN i
on IN N
inspiratory JJ N
effort NN N
sensation NN N
and CC N
fatigue NN N
during IN N
inspiratory JJ N
threshold JJ N
loading NN N
. . N

We PRP N
studied VBD N
the DT N
effects NNS N
of IN N
a DT N
single JJ N
dose NN N
of IN N
fenoterol NN i
on IN N
the DT N
relationship NN N
between IN N
inspiratory NN N
effort NN N
sensation NN N
( ( N
IES NNP N
) ) N
and CC N
inspiratory JJ N
muscle NN N
fatigue NN N
induced VBN N
by IN N
inspiratory NN N
threshold NN N
loading NN N
in IN N
healthy JJ p
subjects NNS p
. . p

The DT N
magnitude NN N
of IN N
the DT N
threshold NN N
was VBD N
60 CD N
% NN N
of IN N
maximal JJ N
static JJ N
inspiratory NN N
mouth NN N
pressure NN N
( ( N
PI NNP N
, , N
mmax NN N
) ) N
at IN N
functional JJ N
residual JJ N
capacity NN N
, , N
and CC N
the DT N
duty NN N
cycle NN N
was VBD N
0.5 CD N
. . N

Subjects NNS p
continued VBD N
the DT N
threshold NN N
loaded VBD N
breathing NN N
until IN N
the DT N
target NN N
mouth NN N
pressure NN N
could MD N
no RB N
longer RB N
be VB N
maintained VBN N
( ( N
endurance JJ N
time NN N
) ) N
. . N

The DT N
intensity NN N
of IN N
the DT N
IES NNP N
was VBD N
scored VBN N
with IN N
a DT N
modified JJ N
Borg NNP N
scale NN N
. . N

Either CC N
fenoterol NN i
( ( i
5 CD i
mg NN i
) ) i
or CC i
a DT i
placebo NN i
was VBD N
given VBN N
orally RB N
2 CD N
h NN N
before IN N
loading VBG N
in IN N
a DT N
randomized JJ N
double-blind NN N
crossover NN N
protocol NN N
. . N

The DT N
endurance NN o
time NN o
with IN N
fenoterol NN N
( ( N
34.4 CD N
+/- JJ N
8.6 CD N
min NN N
) ) N
was VBD N
longer JJR N
than IN N
that DT N
with IN N
the DT N
placebo NN N
( ( N
22.2 CD N
+/- JJ N
7.1 CD N
min NN N
; : N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

The DT N
ratio NN o
of IN o
high- JJ o
to TO o
low-frequency JJ o
power NN o
of IN o
the DT o
diaphragmatic JJ o
electromyogram NN o
( ( o
EMGdi NNP o
) ) o
decreased VBD N
during IN N
loading NN N
; : N
the DT N
decrease NN N
was VBD N
less RBR N
with IN N
fenoterol NN i
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

The DT N
EMGdi NNP o
also RB N
decreased VBD N
with IN N
loading NN N
; : N
the DT N
decrease NN N
was VBD N
greater JJR N
on IN N
fenoterol NN N
treatment NN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

The DT N
PI NNP o
, , o
mmax NN o
and CC o
maximal JJ o
transdiaphragmatic JJ o
pressure NN o
( ( o
Pdi NNP o
) ) o
were VBD N
similarly RB N
decreased VBN N
after IN N
loading VBG N
on IN N
either DT N
treatment NN N
. . N

The DT N
intensity NN o
of IN o
the DT o
IES NNP o
rose VBD o
with IN o
time NN o
during IN N
loading VBG N
in IN N
both DT N
groups NNS N
but CC N
was VBD N
lower JJR N
with IN N
fenoterol NN i
than IN N
with IN N
the DT N
placebo NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

The DT N
ratio NN o
of IN o
Pdi NNP o
to TO N
integrated JJ N
activity NN N
of IN N
the DT N
EMGdi NNP N
increased VBD N
with IN N
fenoterol NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

Fenoterol NNP N
treatment NN N
increased VBD N
both DT N
superimposed VBN o
Pdi NNP o
twitch NN o
and CC o
Pdi NNP o
twitch NN o
of IN o
relaxed JJ o
diaphragm NN o
and CC N
decreased VBD N
the DT N
value NN o
of IN o
( ( o
1-superimposed JJ o
Pdi NNP o
twitch/Pdi NN o
twitch NN o
of IN o
relaxed JJ o
diaphragm NN o
) ) o
. . o

Thus IN N
we PRP N
conclude VBP N
that IN N
in IN N
normal JJ p
subjects NNS p
fenoterol JJ N
reduces NNS N
diaphragmatic JJ N
fatigue NN N
and CC N
decreases VBZ N
the DT N
motor NN N
command NN N
to TO N
the DT N
diaphragm NN N
, , N
resulting VBG N
in IN N
a DT N
decrease NN N
in IN N
IES NNP N
during IN N
inspiratory JJ N
threshold JJ N
loading NN N
and CC N
a DT N
prolongation NN N
of IN N
endurance NN N
. . N

-DOCSTART- -18566882- O O

LEGO NNP i
therapy NN i
and CC N
the DT N
social JJ i
use NN i
of IN i
language NN i
programme NN i
: : i
an DT N
evaluation NN N
of IN N
two CD N
social JJ o
skills NNS o
interventions NNS N
for IN N
children NNS p
with IN p
high JJ p
functioning VBG p
autism NN p
and CC p
Asperger NNP p
Syndrome NNP p
. . p

LEGO NNP i
therapy NN i
and CC N
the DT N
Social NNP i
Use NNP i
of IN i
Language NNP i
Programme NNP i
( ( i
SULP NNP i
) ) i
were VBD N
evaluated VBN N
as IN N
social JJ i
skills NNS i
interventions NNS i
for IN p
6-11 JJ p
year NN p
olds NNS p
with IN p
high JJ p
functioning VBG p
autism NN p
and CC p
Asperger NNP p
Syndrome NNP p
. . p

Children NNP p
were VBD N
matched VBN N
on IN N
CA NNP N
, , N
IQ NNP N
, , N
and CC N
autistic JJ N
symptoms NNS N
before IN N
being VBG N
randomly RB N
assigned VBN N
to TO N
LEGO NNP i
or CC N
SULP NNP i
. . i

Therapy NNP N
occurred VBD N
for IN N
1 CD p
h/week NN p
over IN p
18 CD p
weeks NNS p
. . p

A DT N
no-intervention JJ i
control NN i
group NN i
was VBD N
also RB N
assessed VBN N
. . N

Results NNS N
showed VBD N
that IN N
the DT N
LEGO NNP i
therapy NN N
group NN N
improved VBD N
more JJR N
than IN N
the DT N
other JJ p
groups NNS p
on IN p
autism-specific JJ o
social JJ o
interaction NN o
scores NNS o
( ( o
Gilliam NNP o
Autism NNP o
Rating NNP o
Scale NNP o
) ) o
. . N

Maladaptive JJ o
behaviour NN o
decreased VBD N
significantly RB N
more RBR N
in IN N
the DT N
LEGO NNP i
and CC p
SULP NNP i
groups NNS p
compared VBN p
to TO p
the DT p
control NN p
group NN p
. . p

There EX N
was VBD N
a DT N
non-significant JJ N
trend NN N
for IN N
SULP NNP i
and CC p
LEGO NNP i
groups NNS p
to TO N
improve VB N
more JJR N
than IN N
the DT N
no-intervention JJ i
group NN N
in IN N
communication NN o
and CC o
socialisation NN o
skills NNS o
. . o

-DOCSTART- -24490842- O O

Examining VBG N
the DT N
effectiveness NN N
of IN N
psychological JJ i
strategies NNS i
on IN N
physiologic JJ N
markers NNS N
: : N
evidence-based JJ N
suggestions NNS N
for IN N
holistic JJ N
care NN N
of IN N
the DT p
athlete NN p
. . p

CONTEXT NNP N
Current NNP N
holistic JJ i
rehabilitation NN i
blends VBZ N
both DT N
physical JJ N
and CC N
psychological JJ N
techniques NNS N
. . N

However RB N
, , N
validation NN N
of IN N
the DT N
usefulness NN N
of IN N
psychological JJ i
strategies NNS i
is VBZ N
limited VBN N
in IN N
the DT N
literature NN N
. . N

OBJECTIVE UH N
To TO N
quantify VB N
the DT N
effects NNS N
of IN N
psychological JJ N
strategies NNS N
on IN N
both DT N
physiologic NN N
( ( N
salivary JJ N
cortisol NN N
) ) N
and CC N
subjective JJ N
assessments NNS N
of IN N
stress NN N
. . N

DESIGN NNP N
Randomized NNP N
controlled VBD N
clinical JJ N
trial NN N
. . N

SETTING NN N
Laboratory NNP N
. . N

PATIENTS NNP N
OR NNP N
OTHER NNP N
PARTICIPANTS VBD N
A DT p
total NN p
of IN p
97 CD p
college-aged JJ p
students NNS p
( ( p
age NN p
= VBZ p
20.65 CD p
? . p
4.38 CD p
years NNS p
) ) p
, , p
most JJS p
with IN p
little JJ p
to TO p
no DT p
experience NN p
with IN p
psychological JJ p
strategies NNS p
. . p

INTERVENTION NNP N
( ( N
S NNP N
) ) N
A DT N
15-minute JJ i
script NN i
via IN i
an DT i
iPod NN i
led VBD N
the DT N
participant NN N
through IN i
visual JJ i
imagery NN i
( ( i
cognitive JJ i
relaxation NN i
) ) i
or CC i
deep JJ i
breathing NN i
exercises NNS i
( ( i
somatic JJ i
relaxation NN i
) ) i
cues NNS N
. . N

The DT N
control NN N
group NN N
listened VBD N
to TO N
15 CD N
minutes NNS N
of IN i
ambient JJ i
nature NN i
sounds VBZ i
. . i

MAIN NNP N
OUTCOME NNP N
MEASURE NNP N
( ( N
S NNP N
) ) N
Two CD N
samples NNS N
( ( N
pretest JJS N
, , N
posttest JJS N
) ) N
of IN o
salivary JJ o
cortisol NNS o
were VBD N
analyzed VBN N
using VBG N
an DT N
enzyme JJ N
immunoassay JJ N
kit NN N
; : N
the DT N
average NN N
was VBD N
used VBN N
for IN N
statistical JJ N
analysis NN N
. . N

Descriptive JJ N
statistics NNS N
and CC N
correlations NNS N
were VBD N
conducted VBN N
to TO N
examine VB N
group NN N
differences NNS N
in IN o
time NN o
of IN o
day NN o
, , o
salivary JJ o
cortisol NN o
, , o
sex NN o
, , o
Stress-O-Meter NNP o
values NNS o
, , o
and CC o
Perceived NNP o
Stress NNP o
Scale NNP o
scores NNS o
. . o

RESULTS NNP o
Salivary NNP o
cortisol NN o
levels NNS o
were VBD N
lower JJR N
in IN N
the DT i
treatment NN i
group NN i
than IN N
the DT i
control NN i
group NN i
( ( N
F2,97 NNP N
= NNP N
15.62 CD N
, , N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

Females NNS N
had VBD N
higher JJR N
scores NNS N
on IN N
both DT N
the DT N
pretest JJS o
Stress-O-Meter NN o
( ( N
5.15 CD N
? . N
1.796 CD N
) ) N
and CC N
the DT o
Perceived NNP o
Stress NNP o
Scale NNP o
( ( o
18.31 CD N
? . N
5.833 CD N
) ) N
than IN N
males NNS N
( ( N
4.25 CD N
? . N
1.741 CD N
and CC N
15.272 CD N
? . N
5.390 CD N
, , N
respectively RB N
) ) N
. . N

CONCLUSIONS NNP N
Both NNP N
cognitive JJ i
and CC i
somatic JJ i
relaxation NN i
strategies NNS i
reduced VBD o
cortisol JJ o
levels NNS o
. . o

Participants NNS o
who WP N
received VBD N
verbal JJ N
guidance NN N
achieved VBD N
a DT N
larger JJR o
cortisol JJ o
reduction NN o
. . o

However RB o
, , N
the DT N
change NN N
in IN N
cortisol JJ N
level NN N
was VBD N
uncorrelated VBN N
with IN N
the DT N
change NN N
in IN N
report NN N
of IN N
acute JJ N
stress NN N
; : N
females NNS N
reported VBD N
higher JJR N
levels NNS N
of IN N
stress NN N
. . N

Clinical JJ N
implications NNS N
include VBP N
attention NN N
to TO N
sex NN N
when WRB N
assessing VBG N
stress NN N
and CC N
providing VBG N
coping VBG N
skills NNS N
during IN N
the DT N
rehabilitation NN N
process NN N
. . N

-DOCSTART- -21204103- O O

Interleukin-6 NNP N
receptor NN N
inhibition NN N
with IN N
tocilizumab NN i
and CC N
attainment NN N
of IN N
disease NN N
remission NN N
in IN N
rheumatoid JJ p
arthritis NN p
: : p
the DT N
role NN N
of IN N
acute-phase JJ N
reactants NNS N
. . N

OBJECTIVE NN N
To TO N
determine VB N
the DT N
effects NNS N
of IN N
tocilizumab NN i
on IN N
rheumatoid NN p
arthritis NN p
( ( p
RA NNP p
) ) p
disease NN o
activity NN o
and CC N
remission NN o
assessment NN o
, , N
using VBG N
measures NNS N
that WDT N
do VBP N
or CC N
do VB N
not RB N
comprise VB N
acute-phase JJ N
reactants NNS N
. . N

METHODS NNP N
Simplified NNP o
Disease NNP o
Activity NNP o
Index NNP o
( ( o
SDAI NNP o
) ) o
scores VBZ o
, , o
Clinical JJ o
Disease NNP o
Activity NNP o
Index NNP o
( ( o
CDAI NNP o
) ) o
scores VBZ o
, , o
and CC o
the DT o
Disease NNP o
Activity NNP o
Score NNP o
in IN o
28 CD o
joints NNS o
( ( o
DAS28 NNP o
) ) o
were VBD N
calculated VBN N
using VBG N
data NNS N
from IN N
tocilizumab JJ i
trials NNS N
in IN N
patients NNS p
with IN p
RA NNP p
in IN p
whom WP p
disease NN p
had VBD p
remained VBN p
active JJ p
despite IN p
treatment NN p
with IN p
disease-modifying JJ i
antirheumatic JJ i
drugs NNS i
. . i

The DT N
CDAI NNP N
does VBZ N
not RB N
contain VB N
an DT N
acute-phase JJ N
reactant NN N
component NN N
. . N

Disease NNP o
activity NN o
states NNS o
, , o
including VBG o
remission NN o
, , N
were VBD N
defined VBN N
using VBG N
established VBN N
cut NN N
points NNS N
; : N
for IN N
the DT N
DAS28 NNP N
, , N
an DT N
alternative JJ N
cut NN N
point NN N
of IN N
< $ N
2.4 CD N
was VBD N
also RB N
used VBN N
. . N

RESULTS JJ N
Changes NNS o
in IN o
the DT o
DAS28 NNP o
, , o
the DT o
SDAI NNP o
score NN o
, , o
and CC o
the DT o
CDAI NNP o
score NN o
among IN N
patients NNS N
receiving VBG N
tocilizumab NN i
were VBD N
significantly RB N
higher JJR N
than IN N
those DT N
among IN N
patients NNS N
receiving VBG N
placebo NN i
, , N
and CC N
the DT N
magnitude NN N
of IN N
these DT N
changes NNS N
was VBD N
similar JJ N
for IN N
the DT N
SDAI NNP o
and CC N
the DT N
CDAI NNP o
. . o

Among IN N
patients NNS N
who WP N
achieved VBD N
50 CD N
% NN N
improvement NN o
in IN o
disease NN o
activity NN o
according VBG N
to TO N
the DT N
American NNP N
College NNP N
of IN N
Rheumatology NNP N
criteria NNS N
, , N
only RB N
?20 VBZ N
% NN N
required VBN N
a DT N
reduction NN N
in IN N
acute-phase JJ N
reactant NN N
values NNS N
in IN N
order NN N
to TO N
fulfill VB N
the DT N
criteria NNS N
. . N

However RB o
, , o
DAS28 NNP o
remission NN o
rates NNS o
were VBD o
higher JJR N
( ( N
even RB N
when WRB N
using VBG N
the DT N
lower JJR N
cut NN N
point NN N
) ) N
than IN N
the DT o
SDAI NNP o
and CC o
CDAI NNP o
remission NN o
rates NNS o
. . o

Only RB N
a DT N
minority NN N
of IN N
tocilizumab-treated JJ i
patients NNS i
with IN o
DAS28 NNP o
remission NN o
also RB o
had VBD o
disease NN o
remission NN o
according VBG o
to TO N
the DT N
SDAI NNP N
( ( N
26 CD N
% NN N
) ) N
or CC N
CDAI NNP N
( ( N
?21 NNP N
% NN N
) ) N
. . N

With IN N
infliximab JJ i
treatment NN o
, , o
SDAI NNP o
and CC o
CDAI NNP o
remission NN o
rates NNS o
were VBD o
of IN N
the DT N
same JJ N
magnitude NN N
as IN N
those DT N
observed VBN N
with IN N
tocilizumab JJ i
treatment NN i
, , N
and CC N
DAS28 NNP o
remission NN o
rates NNS o
were VBD o
lower JJR i
. . i

Tocilizumab-treated JJ i
patients NNS i
with IN N
DAS28 NNP o
remission NN o
but CC o
without IN o
CDAI NNP o
remission NN o
had VBD o
significantly RB N
higher JJR o
swollen JJ o
joint JJ o
counts NNS o
but CC o
lower JJR o
erythrocyte NN o
sedimentation NN o
rates NNS o
( ( o
ESRs NNP o
) ) o
compared VBN o
with IN N
patients NNS N
with IN N
SDAI NNP N
or CC N
CDAI NNP N
remission NN N
. . N

CONCLUSION NNP o
Disease NNP o
activity NN o
in IN o
RA NNP N
is VBZ N
reduced VBN i
by IN i
tocilizumab NN i
treatment NN i
, , N
irrespective NN N
of IN N
the DT N
type NN N
of IN N
composite JJ N
measure NN N
used VBN N
to TO N
evaluate VB N
disease NN N
activity NN o
. . o

Remission NN o
rates NNS o
were VBD o
much RB N
higher JJR N
using VBG N
the DT N
DAS28 NNP N
compared VBN N
with IN N
the DT N
SDAI NNP N
and CC N
CDAI NNP N
, , N
due JJ N
to TO N
the DT N
high JJ N
weight NN N
of IN N
the DT N
ESR NNP N
in IN N
the DT N
DAS28 NNP N
and CC N
the DT N
effect NN N
of IN N
tocilizumab NN N
on IN N
the DT N
ESR NNP N
. . N

Using VBG N
the DT N
stringent NN N
SDAI NNP N
and CC N
CDAI NNP N
criteria NNS N
, , N
however RB N
, , N
remission NN N
rates NNS N
in IN N
patients NNS N
treated VBN N
with IN N
tocilizumab NNS i
were VBD i
in IN N
the DT N
same JJ N
range NN N
as IN N
those DT N
seen VBN N
in IN N
patients NNS N
treated VBN N
with IN N
tumor NN N
necrosis NN N
factor NN N
inhibitors NNS N
. . N

-DOCSTART- -22853706- O O

Virtual JJ i
patients NNS i
design NN i
and CC N
its PRP$ N
effect NN N
on IN N
clinical JJ o
reasoning NN o
and CC N
student NN o
experience NN o
: : o
a DT N
protocol NN N
for IN N
a DT N
randomised JJ N
factorial JJ N
multi-centre NN N
study NN N
. . N

BACKGROUND NNP N
Virtual JJ i
Patients NNP i
( ( i
VPs NNP i
) ) i
are VBP N
web-based JJ N
representations NNS N
of IN N
realistic JJ N
clinical JJ N
cases NNS N
. . N

They PRP N
are VBP N
proposed VBN N
as IN N
being VBG N
an DT N
optimal JJ N
method NN N
for IN N
teaching VBG N
clinical JJ N
reasoning NN N
skills NNS N
. . N

International NNP N
standards NNS N
exist VBP N
which WDT N
define VBP N
precisely RB N
what WP N
constitutes VBZ N
a DT N
VP NNP i
. . i

There EX N
are VBP N
multiple JJ N
design NN N
possibilities NNS N
for IN N
VPs NNP N
, , N
however RB N
there EX N
is VBZ N
little JJ N
formal JJ N
evidence NN N
to TO N
support VB N
individual JJ N
design NN N
features NNS N
. . N

The DT N
purpose NN N
of IN N
this DT N
trial NN N
is VBZ N
to TO N
explore VB N
the DT N
effect NN N
of IN N
two CD N
different JJ N
potentially RB N
important JJ N
design NN N
features NNS N
on IN N
clinical JJ o
reasoning NN o
skills NNS o
and CC o
the DT o
student NN o
experience NN o
. . o

These DT N
are VBP N
the DT N
branching VBG N
case NN N
pathways NNS N
( ( N
present JJ N
or CC N
absent NN N
) ) N
and CC N
structured JJ N
clinical JJ N
reasoning VBG N
feedback NN N
( ( N
present JJ N
or CC N
absent NN N
) ) N
. . N

METHODS/DESIGN NNP N
This DT N
is VBZ N
a DT N
multi-centre JJ N
randomised JJ N
2 CD N
x JJ N
2 CD N
factorial JJ N
design NN N
study NN N
evaluating VBG N
two CD N
independent JJ N
variables NNS N
of IN N
VP NNP i
design NN i
, , i
branching NN i
( ( i
present JJ i
or CC i
absent NN i
) ) i
, , N
and CC N
structured VBD i
clinical JJ i
reasoning NN i
feedback NN i
( ( i
present JJ i
or CC i
absent NN i
) ) i
.The NN i
study NN N
will MD N
be VB N
carried VBN N
out RP N
in IN N
medical JJ p
student NN p
volunteers NNS p
in IN p
one CD p
year NN p
group NN p
from IN p
three CD p
university NN p
medical JJ p
schools NNS p
in IN p
the DT p
United NNP p
Kingdom NNP p
, , p
Warwick NNP p
, , p
Keele NNP p
and CC p
Birmingham NNP p
. . p

There EX N
are VBP N
four CD N
core NN N
musculoskeletal NN N
topics NNS N
. . N

Each DT N
case NN N
can MD N
be VB N
designed VBN N
in IN N
four CD N
different JJ N
ways NNS N
, , N
equating VBG N
to TO N
16 CD N
VPs NNP N
required VBN N
for IN N
the DT N
research NN N
. . N

Students NNS p
will MD N
be VB N
randomised VBN N
to TO N
four CD N
groups NNS N
, , N
completing VBG N
the DT N
four CD N
VP NNP i
topics NNS N
in IN N
the DT N
same JJ N
order NN N
, , N
but CC N
with IN N
each DT N
group NN N
exposed VBD N
to TO N
a DT N
different JJ N
VP NNP i
design NN N
sequentially RB N
. . N

All DT N
students NNS p
will MD N
be VB N
exposed VBN N
to TO N
the DT N
four CD N
designs NNS N
. . N

Primary JJ N
outcomes NNS N
are VBP N
performance NN o
for IN o
each DT o
case NN o
design NN o
in IN o
a DT o
standardized JJ o
fifteen JJ o
item NN o
clinical JJ o
reasoning NN o
assessment NN o
, , o
integrated VBN o
into IN o
each DT o
VP NNP o
, , o
which WDT o
is VBZ o
identical JJ o
for IN o
each DT o
topic NN o
. . o

Additionally RB N
a DT N
15-item JJ o
self-reported JJ o
evaluation NN o
is VBZ N
completed VBN N
for IN N
each DT N
VP NNP i
, , N
based VBN N
on IN N
a DT N
widely RB N
used VBN N
EViP NNP N
tool NN N
. . N

Student NN p
patterns NNS N
of IN N
use NN N
of IN N
the DT N
VPs NNP N
will MD N
be VB N
recorded.In JJ N
one CD N
centre NN N
, , N
formative JJ N
clinical JJ N
and CC N
examination NN N
performance NN N
will MD N
be VB N
recorded VBN N
, , N
along IN N
with IN N
a DT N
self NN N
reported VBN N
pre JJ N
and CC N
post-intervention NN N
reasoning NN N
score NN N
, , N
the DT N
DTI NNP N
. . N

Our PRP$ N
power NN N
calculations NNS N
indicate VBP N
a DT p
sample JJ p
size NN p
of IN p
112 CD p
is VBZ p
required VBN p
for IN N
both DT N
primary JJ N
outcomes NNS N
. . N

DISCUSSION NNP N
This DT N
trial NN N
will MD N
provide VB N
robust JJ N
evidence NN N
to TO N
support VB N
the DT N
effectiveness NN N
of IN N
different JJ N
designs NNS N
of IN N
virtual JJ N
patients NNS N
, , N
based VBN N
on IN N
student NN o
performance NN o
and CC o
evaluation NN o
. . o

The DT N
cases NNS N
and CC N
all DT N
learning JJ N
materials NNS N
will MD N
be VB N
open JJ N
access NN N
and CC N
available JJ N
on IN N
a DT N
Creative JJ N
Commons NNP N
Attribution-Share-Alike NNP N
license NN N
. . N

-DOCSTART- -7871820- O O

Effect NN N
of IN N
omega JJ i
3 CD i
fatty JJ i
acids NNS i
and CC i
vitamin NN i
E NNP i
supplements NNS i
on IN N
lipid JJ o
peroxidation NN o
measured VBN N
by IN N
breath NN i
ethane NN i
and CC N
pentane NN i
output NN i
: : i
a DT p
randomized NN p
controlled VBN p
trial NN p
. . p

-DOCSTART- -7673658- O O

Cyproheptadine NNP N
augmentation NN N
of IN N
haloperidol NN i
in IN N
chronic JJ p
schizophrenic JJ p
patients NNS p
: : p
a DT N
double-blind JJ N
placebo-controlled JJ N
study NN N
. . N

A DT N
6 CD N
week NN N
double-blind JJ N
placebo-controlled JJ i
trial NN N
of IN N
cyproheptadine JJ i
augmentation NN i
of IN p
ongoing VBG p
haloperidol NN i
treatment NN p
was VBD N
conducted VBN N
in IN N
40 CD p
chronic JJ p
schizophrenic JJ p
in-patients NNS p
. . p

Cyproheptadine NNP N
augmentation NN N
, , N
compared VBN N
to TO N
administration NN N
of IN N
haloperidol NN i
with IN i
placebo NN i
, , N
did VBD N
not RB N
produce VB N
a DT N
statistically RB N
significant JJ N
improvement NN N
in IN N
psychotic JJ o
symptoms NNS o
. . o

Cyproheptadine NNP N
augmentation NN N
caused VBD N
significant JJ N
reduction NN N
in IN N
the DT N
extrapyramidal NN o
symptoms NNS o
, , N
which WDT N
supports VBZ N
the DT N
atypical JJ N
profile NN N
of IN N
antipsychotics NNS N
. . N

As IN N
to TO N
the DT N
neuroendocrinological JJ o
effect NN o
, , N
cyproheptadine JJ N
augmentation NN N
did VBD N
not RB N
reduce VB N
the DT N
plasma NN o
prolactin NN o
level NN o
but CC N
did VBD N
induce VB N
a DT N
decrease NN N
in IN N
the DT N
plasma NN o
cortisol NN o
level NN o
. . o

Although IN N
long-term JJ N
follow-up JJ N
studies NNS N
are VBP N
needed VBN N
to TO N
confirm VB N
the DT N
results NNS N
, , N
this DT N
study NN N
suggests VBZ N
that IN N
cyproheptadine NN N
augmentation NN N
may MD N
be VB N
effective JJ N
in IN N
treating VBG N
chronic JJ o
schizophrenic JJ o
patients NNS o
who WP p
are VBP p
intolerant JJ p
of IN p
extrapyramidal JJ o
side NN o
effects NNS o
of IN p
conventional JJ p
antipsychotics NNS p
. . p

-DOCSTART- -15738536- O O

Zoledronic JJ i
acid NN i
significantly RB N
reduces VBZ N
skeletal JJ N
complications NNS N
compared VBN N
with IN N
placebo NN i
in IN N
Japanese JJ p
women NNS p
with IN p
bone NN p
metastases NNS p
from IN p
breast NN p
cancer NN p
: : p
a DT N
randomized JJ N
, , N
placebo-controlled JJ N
trial NN N
. . N

PURPOSE NNP N
To TO N
investigate VB N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
zoledronic JJ i
acid NN i
for IN N
the DT N
treatment NN N
of IN N
bone NN N
metastases NNS N
from IN N
breast NN N
cancer NN N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
Women NNP p
with IN p
bone NN p
metastases NNS p
( ( p
N NNP p
= NNP p
228 CD p
) ) p
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
4 CD i
mg NN i
zoledronic JJ i
acid NN i
( ( N
n JJ N
= NNP N
114 CD N
) ) N
or CC N
placebo NN i
( ( N
n JJ N
= NNP N
114 CD N
) ) N
via IN N
15-minute JJ N
infusions NNS N
every DT N
4 CD N
weeks NNS N
for IN N
1 CD N
year NN N
. . N

The DT N
primary JJ N
efficacy JJ N
end NN N
point NN N
was VBD N
the DT N
skeletal-related JJ N
event NN N
( ( N
SRE NNP N
) ) N
rate NN N
ratio NN N
between IN N
treatment NN N
groups NNS N
. . N

An DT N
SRE NNP N
was VBD N
defined VBN N
as IN N
pathologic JJ N
fracture NN N
, , N
spinal JJ N
cord NN N
compression NN N
, , N
and CC N
radiation NN N
or CC N
surgery NN N
to TO N
bone VB N
. . N

Secondary JJ N
end NN N
points NNS N
included VBD N
percentage NN N
of IN N
patients NNS N
with IN N
at IN N
least JJS N
one CD N
SRE NNP N
, , N
time-to-first JJ N
SRE NNP N
, , N
and CC N
Andersen-Gill NNP N
multiple-event JJ N
analysis NN N
. . N

RESULTS VB N
The DT N
SRE NNP o
rate NN o
ratio NN o
at IN N
1 CD N
year NN N
( ( N
excluding VBG N
HCM NNP N
and CC N
adjusted VBN N
for IN N
prior JJ N
fracture NN N
) ) N
was VBD N
0.61 CD N
( ( N
permutation NN N
test NN N
; : N
P NNP N
= NNP N
.027 NNP N
) ) N
, , N
indicating VBG N
that IN N
zoledronic JJ i
acid NN i
reduced VBD N
the DT N
rate NN o
of IN o
SRE NNP o
by IN N
39 CD N
% NN N
compared VBN N
with IN N
placebo NN i
. . i

The DT N
percentage NN o
of IN o
patients NNS o
with IN o
at IN o
least JJS o
one CD o
SRE NNP o
( ( o
excluding VBG o
HCM NNP o
) ) o
was VBD o
significantly RB o
reduced VBN o
by IN N
20 CD N
% NN N
by IN N
zoledronic JJ N
acid NN N
( ( N
29.8 CD N
% NN N
v JJ N
49.6 CD N
% NN N
for IN N
placebo NN N
; : N
P NNP N
= NNP N
.003 NNP N
) ) N
. . N

Zoledronic JJ i
acid NN i
significantly RB o
delayed VBN o
time-to-first JJ o
SRE NNP o
( ( N
median JJ N
not RB N
reached VBN N
v RB N
364 CD N
days NNS N
; : N
Cox NNP N
regression NN N
; : N
P NNP N
= NNP N
.007 NNP N
) ) N
and CC N
reduced VBD o
the DT o
risk NN o
of IN o
SREs NNP o
by IN N
41 CD N
% NN N
in IN N
multiple JJ N
event NN N
analysis NN N
( ( N
risk NN N
ratio NN N
= NNP N
0.59 CD N
; : N
P NNP N
= NNP N
.019 NNP N
) ) N
compared VBN N
with IN N
placebo NN i
. . i

Zoledronic JJ i
acid NN i
was VBD N
well RB N
tolerated VBN o
with IN N
a DT N
safety NN N
profile NN N
similar JJ N
to TO N
placebo VB N
. . N

No DT N
patient NN N
treated VBD N
with IN N
zoledronic JJ N
acid NN N
had VBD N
grade VBN N
3 CD N
or CC N
4 CD N
serum JJ N
creatinine NN N
increase NN N
. . N

CONCLUSION NNP N
Zoledronic NNP i
acid NN i
significantly RB N
reduced VBD N
skeletal JJ N
complications NNS N
compared VBN N
with IN N
placebo NN i
across IN N
multiple JJ N
end NN N
points NNS N
in IN N
Japanese JJ p
women NNS p
with IN p
bone NN p
metastases NNS p
from IN p
breast NN p
cancer NN p
. . p

-DOCSTART- -20209171- O O

Effect NN N
of IN N
enamel JJ i
pretreatment NN i
on IN N
shear JJ o
bond NN o
strength NN o
of IN N
brackets NNS p
bonded VBN p
with IN p
resin-modified JJ p
glass-ionomer JJ p
cement NN p
. . p

AIM NNP N
To TO N
evaluate VB N
the DT N
shear JJ o
bond NN o
strength NN o
of IN N
brackets NNS N
bonded VBN N
with IN N
resin-modified JJ i
glass-ionomer JJ i
cement NN i
( ( i
RMGIC NNP i
) ) i
using VBG N
various JJ N
methods NNS N
of IN N
enamel JJ i
conditioning NN N
. . N

METHODS NNP N
Forty-five JJ p
human JJ p
premolars NNS p
were VBD p
randomly RB p
divided VBN p
into IN p
five CD p
groups NNS p
. . p

The DT N
roots NNS N
of IN N
these DT N
teeth NNS N
were VBD N
fixed VBN N
in IN N
acrylic JJ N
resin NN N
cylinders NNS N
, , N
and CC N
brackets NNS N
were VBD N
bonded VBN N
to TO N
the DT N
teeth NN N
's POS N
crowns NNS N
using VBG N
the DT N
following JJ N
material NN N
combinations NNS N
: : N
RMGIC NNP i
only RB N
; : N
RMGIC NNP N
and CC N
corresponding VBG N
primer NN i
; : i
RMGIC NNP N
, , N
acid NN i
etching NN i
, , N
and CC N
Scotchbond NNP i
Multipurpose NNP N
; : N
RMGIC NNP N
and CC N
two-step JJ N
self-etching JJ N
primer NN N
; : N
and CC N
RMGIC NNP i
and CC N
one-step JJ N
primer NN N
. . N

All DT N
specimens NNS N
were VBD N
submitted VBN N
to TO N
pH VB N
cycling NN N
for IN N
14 CD N
days NNS N
before IN N
shear JJ N
bond NN o
strength NN o
was VBD N
assessed VBN N
in IN N
a DT N
universal JJ N
test NN N
machine NN N
. . N

RESULTS VB N
The DT N
medians NNS N
and CC N
standard JJ N
deviations NNS N
( ( N
in IN N
MPa NNP N
) ) N
were VBD N
RMGIC NNP i
only RB N
= VBZ N
8.34 CD N
? . N
1.11 CD N
; : N
RMGIC NNP N
and CC N
corresponding VBG N
primer NN N
= $ N
7.05 CD N
? . N
2.24 CD N
; : N
RMGIC NNP N
, , N
acid NN N
etching NN N
, , N
and CC N
Scotchbond NNP N
Multipurpose NNP N
= VBD N
7.00 CD N
? . N
4.79 CD N
; : N
RMGIC NNP N
and CC N
two-step JJ N
self-etching JJ N
primer NN N
= NN N
0.54 CD N
? . N
0.30 CD N
; : N
and CC N
RMGIC NNP N
and CC N
one-step JJ N
primer NN N
= NN N
10.61 CD N
? . N
4.58 CD N
. . N

The DT N
value NN o
for IN o
RMGIC NNP i
and CC i
two-step JJ N
self-etching JJ N
primer NN o
was VBD o
significantly RB N
lower JJR N
than IN N
all DT N
other JJ N
values NNS N
. . N

CONCLUSION VB N
It PRP N
can MD N
be VB N
concluded VBN N
that IN N
the DT N
tested JJ N
RMGIC NNP N
is VBZ N
suitable JJ N
for IN N
bonding VBG N
orthodontic JJ N
brackets NNS N
, , N
even RB N
when WRB N
used VBN N
by IN N
itself PRP N
. . N

Different NNP N
enamel JJ N
preparations NNS N
do VBP N
not RB N
improve VB N
its PRP$ N
performance NN N
. . N

However RB N
, , N
they PRP N
can MD N
worsen VB N
its PRP$ N
bonding VBG N
capacity NN N
as IN N
the DT N
combination NN N
with IN N
the DT N
two-step JJ N
primer NN N
system NN N
clearly RB N
shows VBZ N
. . N

-DOCSTART- -20460711- O O

Vinegar NNP i
intake NN N
enhances NNS N
flow-mediated JJ p
vasodilatation NN p
via IN N
upregulation NN N
of IN N
endothelial JJ N
nitric JJ N
oxide JJ N
synthase NN N
activity NN N
. . N

This DT N
study NN N
examined VBD N
the DT N
effect NN N
of IN N
acetate NN i
on IN N
endothelial JJ N
nitric JJ N
oxide NN N
synthase NN N
( ( N
eNOS NN N
) ) N
in IN N
human JJ N
umbilical JJ N
vein NN N
endothelial JJ N
cells NNS N
( ( N
HUVECs NNP N
) ) N
by IN N
immunoblotting VBG N
assay NN N
and CC N
the DT N
ability NN N
of IN N
acetic JJ N
acid NN N
to TO N
upregulate VB N
flow-mediated JJ p
vasodilatation NN p
in IN p
humans NNS p
. . p

In IN N
HUVECs NNP N
, , N
acetate NN N
induced VBD N
a DT N
biphasic JJ N
increase NN N
in IN N
the DT N
phosphorylated JJ N
form NN N
of IN N
eNOS NN N
. . N

The DT N
amount NN N
of IN N
phosphorylated JJ N
eNOS NN N
was VBD N
significantly RB N
increased VBN N
by IN N
exposure NN N
to TO N
200 CD i
mumol/l NNS i
acetate VBP i
for IN i
20 CD i
min NN i
( ( i
early JJ i
phase NN i
) ) i
and CC i
for IN i
4 CD i
h NNS i
( ( i
late JJ i
phase NN i
) ) i
. . N

The DT N
inhibitors NNS N
of IN N
cAMP-dependent JJ N
protein NN N
kinase NN N
( ( N
PKA NNP N
) ) N
and CC N
AMP-activated JJ N
protein NN N
kinase NN N
( ( N
AMPK NNP N
) ) N
blocked VBD N
acetate-induced JJ N
eNOS JJ N
phosphorylation NN N
in IN N
the DT N
early JJ N
and CC N
the DT N
late JJ N
phase NN N
respectively RB N
. . N

Furthermore NNP N
, , N
in IN N
postmenopausal JJ p
women NNS p
, , N
maximum JJ o
forearm NN o
blood NN o
flow NN o
( ( o
FBF NNP o
) ) o
in IN N
response NN N
to TO N
shear VB N
stress NN N
increased VBN N
in IN N
the DT N
vinegar NN p
( ( i
acetic JJ i
acid NN i
) ) i
administered VBD p
group NN p
compared VBN N
to TO N
the DT N
placebo NN N
group NN N
. . N

These DT N
results NNS N
suggest VBP N
that IN N
acetic JJ N
acid-induced JJ N
eNOS NN N
phosphorylation NN N
contributes VBZ N
to TO N
upregulation NN N
of IN N
flow-mediated JJ N
vasodilatation NN N
in IN N
humans NNS N
. . N

-DOCSTART- -11265037- O O

RAB-plate JJ i
versus NN N
sliding VBG i
hip NN i
screw NN i
for IN N
unstable JJ p
trochanteric JJ p
hip NN p
fractures NNS p
: : p
stability NN N
of IN N
the DT N
fixation NN N
and CC N
modes NNS o
of IN o
failure NN o
-- : o
radiographic JJ o
analysis NN p
of IN p
218 CD p
fractures NNS p
. . p

BACKGROUND IN N
The DT N
sliding VBG i
hip NN i
screw NN i
has VBZ N
gained VBN N
considerable JJ N
acceptance NN N
in IN N
the DT N
treatment NN N
of IN N
unstable JJ N
trochanteric JJ N
fractures NNS N
. . N

However RB N
, , N
the DT N
new JJ N
type NN N
of IN N
120 CD i
degrees NNS i
fixed VBN i
angle JJ i
blade-plate NN i
with IN i
a DT i
buttress NN i
rod NN i
( ( N
RAB-plate NNP N
) ) N
showed VBD N
encouraging JJ N
clinical JJ N
results NNS N
. . N

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
assess JJ N
stability NN o
of IN o
fixation NN o
and CC N
analyze JJ N
modes NNS o
of IN o
failure NN o
in IN N
unstable JJ N
trochanteric JJ N
hip NN N
fractures NNS N
treated VBN N
with IN N
these DT N
devices NNS N
. . N

METHODS NNP N
A NNP N
retrospective JJ p
radiographic JJ p
review NN p
of IN p
218 CD p
unstable JJ p
fractures NNS p
was VBD N
performed VBN N
. . N

Linear JJ o
and CC o
angular JJ o
displacements NNS o
of IN N
the DT N
major JJ N
fragments NNS N
and CC N
implant JJ o
migration NN o
into IN o
the DT o
femoral JJ o
head NN o
during IN N
healing VBG N
were VBD N
assessed VBN N
. . N

Additionally RB N
, , N
adequacy NN o
of IN o
the DT o
reduction NN o
and CC o
the DT o
location NN o
of IN o
the DT o
implant NN o
within IN N
the DT N
femoral JJ N
head NN N
as IN N
predictors NNS N
of IN N
fixation NN o
failure NN o
were VBD N
evaluated VBN N
. . N

RESULTS VB N
The DT N
postreduction NN N
neck-shaft JJ o
angle NN o
was VBD N
maintained VBN N
in IN N
the DT N
majority NN N
of IN N
the DT N
fractures NNS N
in IN N
both DT N
groups NNS N
. . N

However RB N
, , N
there EX N
was VBD N
a DT N
significantly RB N
higher JJR N
incidence NN o
of IN o
varus NN o
angulation NN o
by IN o
10 CD o
degrees NNS o
or CC o
more JJR o
by IN N
the DT N
completion NN N
of IN N
healing VBG N
among IN N
fractures NNS N
treated VBN N
with IN N
the DT N
sliding VBG i
hip NN i
screw NN i
( ( N
p JJ N
= NNP N
0.04 CD N
) ) N
. . N

There EX N
was VBD N
no DT N
statistically RB N
significant JJ N
difference NN N
in IN N
vertical JJ o
migration NN o
of IN o
the DT o
device NN o
into IN o
the DT o
femoral JJ o
head NN o
between IN N
the DT N
implants NNS N
used VBN N
( ( N
p JJ N
= NNP N
0.3 CD N
) ) N
. . N

There EX N
was VBD N
a DT N
significant JJ N
relationship NN N
between IN N
failure NN o
of IN o
the DT o
fixation NN o
and CC o
varus NN o
reduction NN o
( ( N
p JJ N
= NNP N
0.04 CD N
) ) N
as RB N
well RB N
as IN N
screw/neck NN o
angle NN o
deviation NN o
more JJR N
than IN N
20 CD N
degrees NNS N
in IN N
the DT N
lateral JJ N
projection NN N
( ( N
p JJ N
= NNP N
0.005 CD N
) ) N
or CC N
if IN N
the DT N
implant NN N
was VBD N
in IN N
a DT N
superior JJ N
or CC N
posterior JJ N
position NN N
( ( N
p JJ N
= NNP N
0.02 CD N
) ) N
. . N

CONCLUSION VB N
The DT N
RAB-plate NNP i
provided VBD N
a DT N
more RBR N
stable JJ N
fixation NN N
, , N
especially RB N
with IN N
regard NN N
to TO N
maintained VBN N
postoperative JJ N
alignment NN N
. . N

However RB N
, , N
positive JJ N
predictors NNS N
for IN N
fixation NN o
failure NN o
were VBD N
identical JJ N
for IN N
both DT N
devices NNS N
. . N

Here RB N
, , N
the DT N
screw/neck NN o
angle NN o
deviation NN o
has VBZ N
had VBN N
the DT N
strongest JJS N
significance NN N
for IN N
prediction NN N
of IN N
fixation NN o
failure NN o
. . o

-DOCSTART- -20004739- O O

A DT N
multi-center NN N
, , N
randomized VBN N
, , N
controlled VBD N
trial NN N
of IN N
parenteral JJ i
nutrition NN i
titrated VBD N
to TO N
resting VBG N
energy NN N
expenditure NN N
in IN N
children NNS p
undergoing VBG p
hematopoietic JJ p
stem NN p
cell NN p
transplantation NN p
( ( p
PNTREE NNP p
) ) p
: : p
rationale NN N
and CC N
design NN N
. . N

BACKGROUND NNP N
Children NNP p
undergoing VBG p
hematopoietic JJ p
stem NN p
cell NN p
transplantation NN p
( ( p
HSCT NNP p
) ) p
frequently RB N
require VBP N
prolonged JJ N
courses NNS N
of IN N
parenteral JJ i
nutrition NN i
( ( i
PN NNP i
) ) i
as IN N
a DT N
consequence NN N
of IN N
gastrointestinal JJ N
dysfunction NN N
related VBN N
to TO N
preparative JJ N
chemotherapy NN N
and CC N
radiation NN N
. . N

PN NNP N
has VBZ N
been VBN N
associated VBN N
with IN N
shorter JJR N
engraftment NN N
time NN N
and CC N
decreased JJ N
mortality NN N
during IN N
HSCT NNP N
, , N
however RB N
, , N
it PRP N
is VBZ N
also RB N
linked VBN N
with IN N
complications NNS N
, , N
including VBG N
infections NNS o
, , o
liver RB o
disease NN o
, , o
and CC o
metabolic JJ o
disturbances NNS o
. . o

Some DT N
of IN N
these DT N
complications NNS N
may MD N
be VB N
a DT N
result NN N
of IN N
providing VBG N
PN NNP N
in IN N
excess NN N
of IN N
nutrient JJ N
requirements NNS N
. . N

We PRP N
previously RB N
described VBD N
significant JJ N
reductions NNS N
in IN N
resting VBG N
energy NN N
expenditure NN N
( ( N
REE NNP N
) ) N
, , N
as IN N
measured VBN N
by IN N
indirect JJ N
calorimetry NN N
, , N
over IN N
the DT N
course NN N
of IN N
HSCT NNP N
. . N

We PRP N
also RB N
documented VBD N
a DT N
decline NN N
in IN N
mid-arm JJ N
muscle NN N
area NN N
, , N
suggesting VBG N
depletion NN N
of IN N
muscle NN N
mass NN N
, , N
while IN N
triceps NNS N
skinfold RB N
, , N
a DT N
marker NN N
of IN N
fat JJ N
stores NNS N
, , N
was VBD N
unchanged JJ N
. . N

These DT N
results NNS N
suggested VBD N
the DT N
need NN N
for IN N
further JJ N
study NN N
of IN N
energy NN N
expenditure NN N
, , N
body NN N
composition NN N
and CC N
nutritional JJ N
intake NN N
in IN N
this DT N
group NN N
of IN N
high JJ N
risk NN N
patients NNS N
. . N

DESIGN NNP N
AND CC N
HYPOTHESIS NNP N
We PRP N
hypothesize VBP N
that IN N
changes NNS N
in IN N
body NN N
composition NN N
affect JJ N
REE NNP N
during IN N
HSCT NNP N
, , N
and CC N
that IN N
standard JJ N
nutritional JJ N
support NN N
may MD N
lead VB N
to TO N
overfeeding VBG N
. . N

We PRP N
are VBP N
performing VBG N
a DT N
randomized VBN N
controlled JJ N
trial NN N
of IN N
parenteral JJ i
nutrition NN i
among IN N
children NNS p
undergoing VBG p
allogeneic NN p
HSCT NNP p
. . p

Subjects NNS N
are VBP N
randomized VBN N
to TO N
receive VB i
PN NNP i
designed VBN i
to TO i
provide VB i
100 CD i
% NN i
of IN i
measured JJ i
REE NNP i
, , i
or CC i
standard JJ i
PN NNP i
, , i
i.e. NN i
, , N
140 CD i
% NN i
of IN i
estimated VBN i
energy NN i
expenditure NN i
. . i

The DT N
primary JJ N
outcome NN N
variable NN N
is VBZ N
change VBN o
in IN o
percent NN o
body NN o
fat JJ o
. . o

Secondary JJ N
outcomes NNS N
include VBP N
glycemic JJ o
control NN o
and CC o
frequency NN o
of IN o
infections NNS o
, , o
changes NNS o
in IN o
REE NNP o
and CC o
body NN o
composition NN o
. . o

CONCLUSION NNP N
This DT N
study NN N
will MD N
provide VB N
unique JJ N
and CC N
comprehensive JJ N
nutritional JJ N
data NNS N
and CC N
its PRP$ N
results NNS N
will MD N
guide VB N
nutritional JJ N
therapy NN N
for IN N
children NNS p
undergoing VBG p
HSCT NNP p
and CC N
possibly RB N
other JJ N
catabolic JJ N
patients NNS N
. . N

-DOCSTART- -17047022- O O

Prevention NN N
of IN N
bone NN N
loss NN N
in IN N
survivors NNS p
of IN p
breast NN p
cancer NN p
: : p
A DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
clinical JJ N
trial NN N
. . N

BACKGROUND NNP N
Few NNP N
data NNS N
are VBP N
available JJ N
on IN N
the DT N
safety NN N
and CC N
efficacy NN N
of IN N
once-weekly JJ N
oral JJ N
bisphosphonate NN i
therapy NN i
in IN N
breast NN p
cancer NN p
survivors NNS p
. . p

OBJECTIVE NNP N
Our PRP$ N
objective NN N
was VBD N
to TO N
determine VB N
whether IN N
risedronate NN i
, , N
35 CD N
mg JJ N
weekly JJ N
, , N
is VBZ N
efficacious JJ N
and CC N
safe JJ N
in IN N
preventing VBG N
bone NN N
loss NN N
associated VBN N
with IN N
chemotherapy-induced JJ N
menopause NN N
. . N

DESIGN VB N
The DT N
study NN N
was VBD N
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
clinical JJ N
trial NN N
over IN N
12 CD N
months NNS N
. . N

SETTING NN N
AND CC N
PARTICIPANTS NNP N
Participants NNP p
included VBD p
87 CD p
newly RB p
postmenopausal JJ p
women NNS p
with IN p
status NN p
post NN p
chemotherapy NN p
, , p
recruited VBN p
from IN p
a DT p
breast NN p
cancer NN p
clinic NN p
in IN p
an DT p
academic JJ p
medical JJ p
center NN p
. . p

INTERVENTION JJ N
Participants NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
risedronate NN i
35 CD N
mg/wk NN N
or CC N
placebo NN i
. . i

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
The DT N
primary JJ N
outcomes NNS N
were VBD N
the DT N
12-month JJ o
changes NNS o
in IN o
spine NN o
and CC o
hip NN o
bone NN o
mineral JJ o
density NN o
. . o

Secondary JJ N
outcomes NNS N
included VBD N
changes NNS o
in IN o
markers NNS o
of IN o
bone NN o
resorption NN o
( ( o
urine JJ o
N-telopeptide NNP o
cross-linked JJ o
collagen NN o
type NN o
I PRP o
) ) o
and CC o
formation NN o
( ( o
osteocalcin JJ o
, , o
N-terminal JJ o
propeptide NN o
of IN o
type NN o
I PRP o
procollagen VBP o
, , o
and CC o
bone-specific JJ o
alkaline NN o
phosphatase NN o
) ) o
. . N

RESULTS NNP N
After IN N
12 CD N
months NNS N
, , N
bone JJ o
mineral JJ o
density NN o
increased VBN N
by IN N
1.2 CD N
% NN N
at IN N
the DT N
spine NN N
and CC N
1.3 CD N
% NN N
at IN N
the DT N
hip NN N
in IN N
women NNS N
on IN N
risedronate NN i
vs. FW N
significant JJ N
decreases NNS N
for IN N
women NNS N
in IN N
the DT N
placebo NN N
group NN N
of IN N
0.9 CD N
% NN N
at IN N
the DT N
spine NN N
and CC N
0.8 CD N
% NN N
at IN N
the DT N
hip NN N
( ( N
P NNP N
< NNP N
0.01 CD N
, , N
difference NN N
between IN N
groups NNS N
) ) N
. . N

N-telopeptide JJ o
cross-linked JJ o
collagen NN o
type NN o
I PRP o
, , N
a DT N
marker NN N
of IN N
bone NN N
resorption NN N
, , N
decreased VBN N
by IN N
19.3 CD N
% NN N
, , N
and CC N
N-terminal JJ N
propeptide NN N
of IN N
type NN N
I PRP N
procollagen VBP N
, , N
a DT N
marker NN N
of IN N
bone NN N
formation NN N
, , N
decreased VBN N
by IN N
26.6 CD N
% NN N
in IN N
participants NNS N
on IN N
active JJ N
therapy NN N
compared VBN N
with IN N
increases NNS N
in IN N
the DT N
control NN N
group NN N
. . N

Risedronate NNP i
was VBD N
well RB N
tolerated VBN o
, , N
and CC N
the DT N
retention NN o
rate NN o
was VBD N
95 CD N
% NN N
at IN N
1 CD N
yr NN N
. . N

CONCLUSIONS NNP N
Risedronate NNP i
once RB N
weekly RB N
prevented VBD N
bone JJ N
loss NN N
and CC N
reduced JJ N
bone NN N
turnover NN N
in IN N
women NNS p
with IN p
breast NN p
cancer NN p
treated VBN p
with IN p
chemotherapy NN p
. . p

Early JJ N
measures NNS N
to TO N
prevent VB N
bone JJ N
loss NN N
should MD N
be VB N
considered VBN N
in IN N
this DT N
cohort NN N
of IN N
breast NN p
cancer NN p
survivors NNS p
. . p

-DOCSTART- -8892490- O O

The DT N
evolving VBG N
clinical JJ N
status NN N
of IN N
patients NNS p
after IN p
a DT p
myocardial JJ p
infarction NN p
: : p
the DT N
importance NN N
of IN N
post-hospital JJ i
data NNS i
for IN N
mortality NN N
prediction NN N
. . N

Studies NNPS N
predicting VBG N
mortality NN N
after IN N
myocardial JJ p
infarction NN p
( ( p
MI NNP p
) ) p
usually RB N
rely VBP N
on IN N
in-hospital JJ i
data NNS i
, , N
and CC N
combine NN N
patients NNS p
admitted VBN p
for IN p
the DT p
first JJ p
MI NNP p
with IN p
recurrent JJ p
MI NNP p
patients NNS p
. . p

Since IN N
treatment NN N
decisions NNS N
are VBP N
often RB N
made VBN N
or CC N
modified VBN N
at IN N
the DT N
first JJ N
outpatient NN N
clinic JJ N
visit NN N
, , N
this DT N
study NN N
was VBD N
designed VBN N
to TO N
evaluate VB N
the DT N
importance NN N
of IN N
post-hospital JJ i
data NNS i
on IN N
mortality NN N
prediction NN N
after IN N
a DT N
first JJ N
myocardial JJ N
infarction NN N
( ( N
MI NNP N
) ) N
. . N

An DT p
inception NN p
cohort NN p
of IN p
patients NNS p
enrolled VBN p
in IN p
the DT p
Beta-Blocker NNP p
in IN p
Heart NNP p
Attack NNP p
Trial NNP p
( ( p
n JJ p
= NN p
2830 CD p
) ) p
was VBD p
included VBN p
. . p

Forty-three JJ o
variables NNS o
( ( N
including VBG N
in-hospital JJ i
and CC i
post-hospital JJ i
data NNS i
) ) i
were VBD N
evaluated VBN N
using VBG N
stepwise NN N
logistic JJ N
regression NN N
. . N

Ten CD N
variables NNS N
were VBD N
independently RB N
associated VBN N
with IN N
1-year JJ N
mortality NN N
: : N
five CD N
used VBN N
in-hospital JJ N
data NNS N
( ( o
history NN o
of IN o
hypertension NN o
, , o
hypercholesterolemia NN o
, , o
congestive JJ o
heart NN o
failure NN o
[ NNP o
CHF NNP o
] NNP o
, , o
ventricular JJ o
tachycardia NN o
, , o
and CC o
age NN o
) ) o
; : o
and CC N
five CD N
variables NNS N
depended VBN N
on IN N
post-hospital JJ i
data NNS i
collected VBN N
at IN N
the DT N
first JJ N
outpatient JJ N
visit NN N
( ( o
CHF NNP o
after IN o
discharge NN o
, , o
New NNP o
York NNP o
Heart NNP o
Association NNP o
functional JJ o
class NN o
, , o
heart NN o
rate NN o
, , o
pulmonary JJ o
rates NNS o
, , o
and CC o
smoking NN o
) ) o
. . N

Two CD N
predictive JJ N
systems NNS N
were VBD N
developed VBN N
that IN N
partitioned JJ N
patients NNS N
into IN N
one CD N
of IN N
four CD N
classes NNS N
with IN N
distinct JJ N
mortality NN N
risks NNS N
: : N
a DT N
composite JJ N
system NN N
using VBG N
the DT N
10 CD N
in- JJ N
and CC N
post-hospital JJ N
variables NNS N
, , N
and CC N
a DT N
system NN N
using VBG N
only RB N
the DT N
5 CD N
in-hospital JJ N
variables NNS N
. . N

Mortality NNP o
risk NN o
for IN N
the DT N
composite JJ N
system NN N
classes NNS N
ranged VBD N
from IN N
0.6 CD N
to TO N
20.0 CD N
% NN N
( ( N
I PRP N
[ VBP N
n JJ N
= $ N
861 CD N
] NNP N
, , N
0.6 CD N
% NN N
; : N
II NNP N
[ NNP N
n RB N
= VBZ N
1151 CD N
] NN N
, , N
2.3 CD N
% NN N
; : N
III NNP N
[ NNP N
n MD N
=698 VB N
] NNP N
, , N
4.3 CD N
% NN N
; : N
IV NNP N
[ NNP N
n VBD N
= $ N
120 CD N
] NNP N
, , N
20.0 CD N
% NN N
) ) N
. . N

In IN N
contrast NN N
, , N
the DT N
range NN o
of IN o
mortality NN o
risk NN N
using VBG N
the DT N
in-hospital JJ i
data NNS i
only RB N
system NN N
was VBD N
less JJR N
( ( N
1 CD N
to TO N
8.3 CD N
% NN N
) ) N
. . N

Most JJS N
importantly RB N
, , N
a DT N
distinct JJ N
gradient NN N
within IN N
each DT N
class NN N
of IN N
the DT N
in-hospital JJ i
data NNS i
only RB N
system NN N
was VBD N
created VBN N
by IN N
the DT N
addition NN N
of IN N
the DT N
post-hospital JJ i
data NN i
. . i

This DT N
study NN N
demonstrates VBZ N
that IN N
risk NN N
stratification NN N
after IN N
an DT N
acute NN N
first RB N
MI NNP N
is VBZ N
improved VBN N
by IN N
the DT N
addition NN N
of IN N
post-hospital JJ i
data NNS i
. . i

-DOCSTART- -19644033- O O

Isometric JJ i
contractions NNS i
reduce VB N
plantar NN o
flexor NN o
moment NN o
, , o
Achilles NNP o
tendon VBZ o
stiffness NN o
, , o
and CC o
neuromuscular JJ o
activity NN o
but CC N
remove VB N
the DT N
subsequent JJ N
effects NNS N
of IN N
stretch NN N
. . N

The DT N
effects NNS N
of IN N
isometric JJ i
contractions NNS i
and CC N
passive JJ i
stretching NN i
on IN i
muscle-tendon JJ i
mechanics NNS i
and CC i
muscle NN i
activity NN i
were VBD N
studied VBN N
in IN N
16 CD p
healthy JJ p
human JJ p
volunteers NNS p
. . p

First NNP N
, , N
peak NN i
concentric NN i
and CC i
passive JJ i
ankle NN i
joint JJ i
moment NN i
data NNS i
were VBD i
recorded VBN i
on IN i
an DT i
isokinetic JJ i
dynamometer NN i
with IN i
electromyographic JJ i
monitoring NN i
of IN i
the DT i
triceps NNS i
surae VBP i
; : i
real-time JJ i
motion NN i
analysis NN i
of IN i
the DT i
lower JJR i
leg NN i
and CC i
ultrasound JJ i
imaging NN i
of IN i
the DT i
Achilles-medial JJ i
gastrocnemius NN i
muscle-tendon JJ i
junction NN i
were VBD i
simultaneously RB i
conducted VBN i
. . i

Second NNP N
, , N
the DT N
subjects NNS N
performed VBD N
six CD i
8-s JJ i
maximal JJ i
voluntary JJ i
isometric JJ i
contractions NNS i
( ( i
MVICs NNP i
) ) i
before IN i
repeating VBG i
the DT i
passive NN i
and CC i
active JJ i
trials NNS i
. . i

Although IN N
there EX N
was VBD N
no DT N
decrease NN N
in IN N
isometric JJ o
joint JJ o
moment NN o
after IN N
MVICs NNP N
, , N
peak NN o
concentric JJ o
moment NN o
was VBD N
significantly RB N
reduced VBN N
( ( N
11.5 CD N
% NN N
, , N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

This DT N
was VBD N
accompanied VBN N
by IN N
, , N
and CC N
correlated VBN N
with IN N
( ( N
r NN N
= VBZ N
0.90 CD N
, , N
P NNP N
< NNP N
0.01 CD N
) ) N
, , N
significant JJ N
reductions NNS N
in IN N
peak JJ o
triceps NNS o
surae VBP o
electromyographic JJ o
amplitude NN o
( ( N
21.0 CD N
% NN N
, , N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

Achilles NNP o
tendon VBZ o
stiffness NN o
( ( N
10.9 CD N
% NN N
, , N
P NNP N
< NNP N
0.01 CD N
) ) N
and CC N
passive JJ o
joint NN o
moment NN o
( ( N
4.9 CD N
% NN N
, , N
P NNP N
< NNP N
0.01 CD N
) ) N
were VBD N
also RB N
significantly RB N
reduced VBN N
. . N

Third NNP N
, , N
the DT N
subjects NNS N
performed VBD N
three CD N
60-s JJ N
static JJ i
plantar NN i
flexor NN i
stretches NNS i
before IN N
being VBG N
retested VBN N
2 CD N
and CC N
30 CD N
min NN N
after IN N
stretch NN N
. . N

The DT N
stretch NN N
protocol NN N
caused VBD N
no DT N
significant JJ N
change NN N
in IN N
any DT N
measure NN N
. . N

At IN N
30 CD N
min NN N
after IN N
stretching VBG N
, , N
significant JJ N
recovery NN N
in IN N
concentric JJ o
moment NN o
and CC o
muscle NN o
activity NN o
was VBD N
detected VBN N
at IN N
dorsiflexed JJ N
joint JJ N
angles NNS N
, , N
while IN N
Achilles NNP o
tendon CC o
stiffness NN o
and CC o
passive JJ o
joint JJ o
moment NN o
remained VBD N
significantly RB N
reduced VBN N
. . N

These DT N
data NNS N
show VBP N
that IN N
the DT N
performance NN N
of IN N
MVICs NNP N
interrupts VBP N
the DT N
normal JJ N
stretch-induced JJ N
losses NNS N
in IN N
active JJ N
and CC N
passive JJ N
plantar NN N
flexor NN N
joint JJ N
moment NN N
and CC N
neuromuscular JJ N
activity NN N
, , N
largely RB N
because IN N
concentric JJ N
strength NN N
and CC N
tendon NN N
properties NNS N
were VBD N
already RB N
affected VBN N
. . N

Importantly RB N
, , N
the DT N
decrease NN N
in IN N
Achilles NNP o
tendon NN o
stiffness NN o
remained VBD N
30 CD N
min NN N
later RB N
, , N
which WDT N
may MD N
be VB N
an DT N
important JJ N
etiological JJ N
factor NN N
for IN N
muscle-tendon JJ N
strain NN N
injury NN N
risk NN N
. . N

-DOCSTART- -20936417- O O

The DT N
use NN N
of IN N
vitamin NN i
E NNP i
for IN N
the DT N
prevention NN N
of IN N
chemotherapy-induced JJ N
peripheral JJ N
neuropathy NNS N
: : N
results NNS N
of IN N
a DT N
randomized JJ N
phase NN N
III NNP N
clinical JJ N
trial NN N
. . N

BACKGROUND NNP N
Chemotherapy-induced JJ N
peripheral JJ N
neuropathy NN N
( ( N
CIPN NNP N
) ) N
continues VBZ N
to TO N
be VB N
a DT N
substantial JJ N
problem NN N
for IN N
many JJ N
cancer NN p
patients NNS p
. . p

Pursuant NNP N
to TO N
promising VBG N
appearing VBG N
pilot NN N
data NNS N
, , N
the DT N
current JJ N
study NN N
evaluated VBD N
the DT N
use NN N
of IN N
vitamin NN i
E NNP i
for IN N
the DT N
prevention NN N
of IN N
CIPN NNP N
. . N

METHODS NNP N
A DT N
phase NN N
III NNP N
, , N
randomized VBD N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
study NN N
was VBD N
conducted VBN N
in IN N
patients NNS p
undergoing VBG p
therapy NN p
with IN p
neurotoxic JJ p
chemotherapy NN p
, , N
utilizing JJ N
twice RB i
daily JJ i
dosing NN i
of IN i
vitamin NN i
E NNP i
( ( i
400 CD i
mg NN i
) ) i
/placebo NN i
. . i

The DT N
primary JJ N
endpoint NN N
was VBD N
the DT N
incidence NN o
of IN o
grade NN o
2+ CD o
sensory NN o
neuropathy NN o
( ( o
SN NNP o
) ) o
toxicity NN o
( ( o
CTCAE NNP o
v RB o
3.0 CD o
) ) o
in IN N
each DT N
treatment NN N
arm NN N
, , N
analyzed VBN N
by IN N
chi-square JJ N
testing NN N
. . N

Planned VBN N
sample NN N
size NN N
was VBD N
100 CD p
patients NNS p
per IN p
arm NN p
to TO N
provide VB N
80 CD N
% NN N
power NN N
to TO N
detect VB N
a DT N
difference NN N
in IN N
incidence NN N
of IN N
grade NN o
2+ CD o
SN NNP o
toxicity NN o
from IN N
25 CD N
% NN N
in IN N
the DT N
placebo NN N
group NN N
to TO N
10 CD N
% NN N
in IN N
the DT N
vitamin NN N
E NNP N
group NN N
. . N

RESULTS NNP N
Two-hundred JJ p
seven CD p
patients NNS p
were VBD p
enrolled VBN p
between IN p
December NNP p
1 CD p
, , p
2006 CD p
and CC p
December NNP p
14 CD p
, , p
2007 CD p
, , p
producing VBG p
189 CD p
evaluable JJ p
cases NNS p
for IN p
analysis NN p
. . p

Cytotoxic JJ N
agents NNS N
included VBN N
taxanes NNS N
( ( N
109 CD N
) ) N
, , N
cisplatin NN N
( ( N
8 CD N
) ) N
, , N
carboplatin NN N
( ( N
2 CD N
) ) N
, , N
oxaliplatin FW N
( ( N
50 CD N
) ) N
, , N
or CC N
combination NN N
( ( N
20 CD N
) ) N
. . N

There EX N
was VBD N
no DT N
difference NN N
in IN N
the DT N
incidence NN N
of IN N
grade NN o
2+ CD o
SN NNP o
between IN N
the DT N
two CD N
arms NNS N
( ( i
34 CD i
% NN i
-vitamin NNP i
E NNP i
, , N
29 CD N
% NN N
-placebo NN N
; : N
P NNP N
= NNP N
0.43 CD N
) ) N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
treatment NN N
arms NNS N
for IN N
time NN o
to TO o
onset VB o
of IN o
neuropathy JJ o
( ( o
P NNP o
= NNP N
0.58 CD N
) ) N
, , N
for IN N
chemotherapy NN N
dose NN N
reductions NNS N
due JJ N
to TO N
neuropathy JJ N
( ( N
P NNP N
= NNP N
0.21 CD N
) ) N
, , N
or CC N
for IN N
secondary JJ N
endpoints NNS N
derived VBN N
from IN N
patient-reported JJ N
neuropathy JJ N
symptom NN N
assessments NNS N
. . N

The DT N
treatment NN N
was VBD o
well RB o
tolerated VBN o
overall JJ o
. . N

CONCLUSIONS NNP N
Vitamin NNP i
E NNP i
did VBD i
not RB N
appear VB N
to TO N
reduce VB N
the DT N
incidence NN N
of IN N
sensory JJ o
neuropathy NN o
in IN N
the DT N
studied JJ N
group NN p
of IN p
patients NNS p
receiving VBG p
neurotoxic JJ p
chemotherapy NN p
. . p

-DOCSTART- -16220085- O O

Efficacy NN o
, , o
tolerability NN o
and CC o
pharmacokinetics NNS o
of IN N
two CD N
nelfinavir-based JJ i
regimens NNS N
in IN N
human JJ p
immunodeficiency NN p
virus-infected JJ p
children NNS p
and CC p
adolescents NNS p
: : p
pediatric JJ N
AIDS NNP N
clinical JJ N
trials NNS N
group NN N
protocol VBZ N
403 CD N
. . N

INTRODUCTION NNP N
Few JJ N
combinations NNS N
of IN N
highly RB N
active JJ N
antiretrovirals NNS i
have VBP N
been VBN N
studied VBN N
in IN N
nucleoside JJ p
reverse NN p
transcription NN p
inhibitor NN p
( ( p
NRTI NNP p
) ) p
-experienced VBD p
, , p
human JJ p
immunodeficiency NN p
virus NN p
( ( p
HIV NNP p
) ) p
-infected VBD p
children NNS p
. . p

We PRP N
tested VBD N
the DT N
efficacy NN N
, , N
tolerability NN N
and CC N
pharmacokinetics NNS N
of IN N
2 CD N
combination NN N
therapies NNS N
containing VBG N
an DT N
NRTI NNP i
, , i
protease NN i
inhibitors NNS i
+/- VBP i
a DT i
nonnucleoside JJ i
reverse NN i
transcription NN i
inhibitor NN i
( ( i
NNRTI NNP i
) ) i
. . i

METHODS NNP N
This DT N
was VBD N
a DT N
phase NN N
II NNP N
, , N
randomized VBD N
, , N
multicenter NN N
study NN N
. . N

Forty-one CD p
children NNS p
and CC p
youths NNS p
between IN p
5 CD p
months NNS p
and CC p
21 CD p
years NNS p
with IN p
prior JJ p
NRTI NNP p
and CC p
no DT p
prior JJ p
NNRTI NNP p
or CC p
protease VB p
inhibitor NN p
experience NN p
received VBD N
either CC N
nelfinavir JJ i
( ( i
NFV NNP i
) ) i
30 CD i
mg/kg JJ i
twice RB i
daily RB i
( ( i
bid NN i
) ) i
, , i
ritonavir FW i
( ( i
RTV NNP i
) ) i
400 CD i
mg/m JJ i
bid NN i
and CC i
buffered VBN i
didanosine NN i
( ( i
ddI NN i
) ) i
240 CD i
mg/m JJ i
daily JJ i
( ( i
arm IN i
A NNP i
) ) i
or CC N
NFV NNP i
50-55 JJ i
mg/kg NN i
bid NN i
, , i
nevirapine NN i
( ( i
NVP NNP i
) ) i
120 CD i
mg/m JJ i
bid NN i
and CC i
stavudine NN i
( ( i
d4T NN i
) ) i
1 CD i
mg/kg JJ i
bid NN i
( ( i
arm NN i
B NNP i
) ) i
. . N

Patients NNS N
were VBD N
evaluated VBN N
clinically RB N
for IN N
48 CD N
weeks NNS N
after IN N
initiation NN N
of IN N
therapy NN N
. . N

Intensive JJ N
pharmacokinetic JJ N
sampling NN N
occurred VBD N
after IN N
4 CD N
weeks NNS N
of IN N
therapy NN N
. . N

RESULTS NN N
: : N
The DT N
proportion NN N
of IN N
children NNS N
with IN N
HIV-1 NNP N
RNA NNP N
< NNP N
or CC N
=400 NNP N
copies/mL NN N
and CC N
on IN N
randomized JJ N
treatment NN N
at IN N
48 CD N
weeks NNS N
was VBD N
65 CD N
% NN N
among IN N
children NNS N
assigned VBN N
NFV NNP N
+ NNP N
RTV NNP N
+ NNP N
ddI VBD N
versus JJ N
28 CD N
% NN N
among IN N
those DT N
assigned VBN N
NFV NNP N
+ NNP N
NVP NNP N
+ NNP N
d4T NN N
( ( N
P NNP N
= NNP N
0.039 CD N
) ) N
. . N

No DT N
significant JJ N
difference NN N
in IN N
median JJ o
CD4 NNP o
% NN o
change NN o
from IN N
baseline NN N
to TO N
week NN N
48 CD N
was VBD N
found VBN N
( ( N
3 CD N
% NN N
versus IN N
1 CD N
% NN N
) ) N
. . N

No DT N
significant JJ N
differences NNS N
in IN N
safety NN o
or CC o
tolerability NN o
between IN N
children NNS N
randomized VBN N
to TO N
NFV NNP i
+ NNP i
RTV NNP i
+ NNP i
ddI VBZ i
versus NN N
NFV NNP i
+ NNP i
NVP NNP i
+ NNP i
d4T NN i
were VBD N
identified VBN N
. . N

However RB N
, , N
a DT N
trend NN N
toward IN N
a DT N
higher JJR N
rate NN N
of IN N
permanent JJ o
discontinuation NN o
of IN o
study NN o
treatment NN o
was VBD N
noted VBN N
among IN N
children NNS N
assigned VBN N
to TO N
NFV NNP N
+ NNP N
NVP NNP N
+ NNP N
d4T NN N
compared VBN N
with IN N
NFV NNP N
+ NNP N
RTV NNP N
+ NNP N
ddI VBD N
[ JJ N
7 CD N
of IN N
20 CD N
( ( N
35 CD N
% NN N
) ) N
versus NN N
2 CD N
of IN N
21 CD N
( ( N
10 CD N
% NN N
) ) N
; : N
P NNP N
= VBD N
0.12 CD N
] NN N
. . N

NFV NNP o
pharmacokinetic JJ o
measurements NNS o
were VBD N
not RB N
statistically RB N
different JJ N
between IN N
the DT N
treatment NN N
groups NNS N
, , N
yet RB N
exposure NN N
to TO N
the DT N
NFV NNP N
metabolite NN N
, , N
M8 NNP N
, , N
was VBD N
significantly RB N
higher JJR N
in IN N
subjects NNS N
receiving VBG N
RTV NNP N
. . N

The DT N
pharmacokinetics NNS o
for IN o
NVP NNP o
, , o
RTV NNP o
and CC o
d4T NN o
were VBD N
similar JJ N
to TO N
those DT N
of IN N
previously RB N
reported VBN N
data NN N
. . N

CONCLUSION NN N
: : N
Combination NN N
therapy NN N
containing VBG N
NFV NNP N
+ NNP N
RTV NNP N
+ NNP N
ddI NN N
appears VBZ N
more RBR N
efficacious JJ N
in IN N
NRTI-experienced NNP N
children NNS N
than IN N
a DT N
regimen JJ N
containing VBG N
NFV NNP N
+ NNP N
NVP NNP N
+ NNP N
d4T NN N
. . N

Differences NNS N
in IN N
tolerability NN o
between IN N
the DT N
2 CD N
treatment NN N
groups NNS N
were VBD N
not RB N
identified VBN N
. . N

Systemic JJ N
exposure NN N
of IN N
these DT N
drugs NNS N
was VBD N
similar JJ N
to TO N
that DT N
reported VBN N
in IN N
other JJ N
HIV-infected JJ p
children NNS p
and CC p
adults NNS p
. . p

-DOCSTART- -3630589- O O

Gastric JJ o
contents NNS o
and CC N
pH NN N
after IN N
oral JJ N
premedication NN i
. . i

Forty NNP p
women NNS p
, , p
aged VBN p
26-40 CD p
years NNS p
, , N
were VBD N
investigated VBN N
with IN N
regard NN N
to TO N
gastric JJ p
contents NNS p
and CC p
pH NN p
before IN p
general JJ p
anaesthesia NN i
. . i

The DT N
patients NNS N
were VBD N
divided VBN N
into IN N
two CD N
groups NNS N
( ( N
20 CD N
in IN N
each DT N
) ) N
. . N

Group NNP N
100 CD N
received VBD N
0.3 CD N
mg JJ N
kg-1 JJ N
diazepam NN i
orally RB N
with IN N
100 CD N
ml NNS N
of IN N
water NN i
2 CD N
h NN N
before IN N
surgery NN N
. . N

Group NNP N
50 CD N
received VBD N
0.3 CD N
mg JJ N
kg-1 JJ N
diazepam NN i
with IN i
50 CD N
ml NNS N
of IN N
water NN i
2 CD N
h NN N
before IN N
surgery NN N
. . N

The DT N
amount NN o
of IN o
gastric JJ o
content NN o
was VBD N
significantly RB N
greater JJR N
in IN N
Group NNP N
100 CD N
than IN N
in IN N
Group NNP N
50 CD N
( ( N
P NNP N
less JJR N
than IN N
0.05 CD N
) ) N
. . N

There EX N
was VBD N
no DT N
statistical JJ N
difference NN N
in IN N
pH NN o
values NNS o
between IN N
the DT N
groups NNS N
. . N

The DT N
number NN N
of IN N
patients NNS N
with IN N
both DT N
gastric JJ o
pH NN o
less JJR N
than IN N
2.5 CD N
and CC N
gastric JJ o
volume NN o
greater JJR N
than IN N
25 CD N
ml NN N
was VBD N
significantly RB N
higher JJR N
in IN N
Group NNP N
100 CD N
compared VBN N
to TO N
Group NNP N
50 CD N
( ( N
P NNP N
less JJR N
than IN N
0.05 CD N
) ) N
. . N

We PRP N
can MD N
not RB N
recommend VB N
the DT N
use NN N
of IN N
oral JJ N
premedication NN i
using VBG N
these DT N
amounts NNS N
of IN N
water NN N
, , N
considering VBG N
the DT N
increased VBN N
risk NN N
of IN N
aspiration NN N
of IN N
gastric JJ N
contents NNS N
. . N

-DOCSTART- -15154956- O O

ROMEO NN N
: : N
rethink NN N
organization NN N
to TO N
improve VB N
education NN N
and CC N
outcomes NNS N
. . N

AIMS NNP N
Scarcity NNP N
of IN N
resources NNS N
, , N
expertise NN N
and CC N
evidence-based JJ N
models NNS N
have VBP N
so RB N
far RB N
limited JJ N
delivery NN N
of IN N
patient-centred JJ N
diabetes NNS N
education NN N
. . N

We PRP N
have VBP N
developed VBN N
and CC N
validated VBD N
a DT N
group NN N
care NN N
approach NN N
that WDT N
is VBZ N
applicable JJ N
to TO N
everyday VB N
clinical JJ N
practice NN N
and CC N
cost-effective JJ N
in IN N
improving VBG N
metabolic JJ o
control NN o
, , o
knowledge NN o
of IN o
diabetes NNS o
, , o
health NN o
behaviours NNS o
, , N
and CC N
quality NN o
of IN o
life NN o
in IN N
Type NNP N
2 CD N
diabetes NNS N
. . N

A DT N
clinical JJ N
trial NN N
( ( N
ROMEO NNP N
) ) N
was VBD N
planned VBN N
to TO N
evaluate VB N
applicability NN N
and CC N
reproducibility NN N
of IN N
group NN N
care NN N
in IN N
other JJ N
outpatients NNS N
facilities NNS N
and CC N
assess VB N
its PRP$ N
impact NN N
on IN N
a DT N
larger JJR p
patient JJ p
population NN p
. . p

METHODS NNP N
Multicentre NNP N
, , N
randomized VBD N
, , N
controlled VBD N
clinical JJ N
trial NN N
of IN N
group NN i
vs. FW i
individual JJ i
care NN i
in IN N
the DT N
routine JJ N
management NN N
of IN N
Type NNP N
2 CD N
diabetes NNS N
. . N

Nine NNP p
hundred VBD p
patient JJ p
aged VBN p
< NN p
80 CD p
, , p
with IN p
diabetes NNS p
of IN p
> NN p
or CC p
=1 JJ p
year NN p
known VBN p
duration NN p
, , p
treated VBN p
by IN p
either DT p
diet JJ i
alone NN i
or CC i
diet JJ i
and CC i
oral JJ i
agents NNS i
, , p
will MD p
be VB p
recruited VBN p
in IN p
15 CD p
centres NNS p
and CC p
followed VBD p
for IN p
4 CD p
years NNS p
. . p

Training NN i
of IN i
physicians NNS i
, , i
nurses NNS i
and CC i
dietitians NNS i
included VBD i
preparation NN i
of IN i
operating VBG i
manual JJ i
and CC i
videos NNS i
, , i
interactive JJ i
sessions NNS i
, , i
and CC i
evaluation NN i
of IN i
local JJ i
facilities NNS i
and CC i
resources NNS i
. . i

RESULTS NNP N
PRIMARY NNP N
MEASUREMENTS NNP N
3-monthly JJ o
HbA1c NNP o
, , o
fasting VBG o
blood NN o
glucose NN o
, , o
body NN o
weight VBD o
, , o
waist-hip JJ o
ratio NN o
, , o
yearly RB o
blood NN o
lipids NNS o
, , o
and CC o
bi-yearly JJ o
assessment NN o
of IN o
knowledge NN o
of IN o
diabetes NNS o
, , o
health NN o
behaviours NNS o
and CC o
quality NN o
of IN o
life NN o
. . o

SECONDARY NNP N
OUTCOMES NNP N
systolic JJ o
and CC o
diastolic JJ o
blood NN o
pressure NN o
, , o
evaluation NN o
of IN o
ECG NNP o
for IN o
ischaemia NN o
and CC o
QT NNP o
interval NN o
, , o
hypoglycaemic JJ o
and CC o
anti-hypertensive JJ o
medication NN o
and CC o
cardiovascular JJ o
events NNS o
. . o

Analysis NN N
will MD N
be VB N
by IN N
intention-to-treat JJ N
. . N

DISCUSSION NNP N
If IN N
ROMEO NNP N
confirms VBZ N
that IN N
group NN N
care NN N
can MD N
be VB N
successfully RB N
implemented VBN N
in IN N
different JJ N
clinics NNS N
, , N
a DT N
novel JJ N
clinico-pedagogic JJ N
tool NN N
will MD N
have VB N
been VBN N
acquired VBN N
to TO N
support VB N
patient-centred JJ N
education NN N
, , N
improve VB o
lifestyle NN o
and CC N
outcomes NNS o
, , o
support NN o
team NN o
work NN o
, , o
enhance NN o
providers NNS o
' POS o
attitudes NNS o
and CC N
competencies NNS o
and CC N
ameliorate VB N
diabetes NNS N
care JJ N
organization NN N
. . N

-DOCSTART- -19852789- O O

Safety NN o
and CC o
efficacy NN o
of IN N
oral JJ N
DMSA NNP i
therapy NN i
for IN N
children NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
: : p
Part VB N
A DT N
-- : N
medical JJ N
results NNS N
. . N

BACKGROUND NNP N
This DT N
study NN N
investigated VBD N
the DT N
effect NN N
of IN N
oral JJ i
dimercapto NN i
succinic JJ i
acid NN i
( ( i
DMSA NNP i
) ) i
therapy NN i
for IN N
children NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
ages VBZ p
3-8 CD p
years NNS p
. . p

METHODS NNP N
Phase NNP p
1 CD p
involved VBD p
65 CD p
children NNS p
who WP p
received VBD p
one CD p
round NN p
of IN p
DMSA NNP i
( ( p
3 CD p
days NNS p
) ) p
. . p

Participants NNS p
who WP p
had VBD p
high JJ p
urinary JJ p
excretion NN p
of IN p
toxic JJ p
metals NNS p
were VBD N
selected VBN N
to TO N
continue VB N
on IN N
to TO N
phase VB N
2 CD N
. . N

In IN N
phase NN p
2 CD p
, , p
49 CD p
participants NNS p
were VBD N
randomly RB N
assigned VBN N
in IN N
a DT N
double-blind JJ N
design NN N
to TO N
receive VB N
an DT N
additional JJ N
6 CD N
rounds NNS N
of IN N
either DT N
DMSA NNP i
or CC i
placebo NN i
. . i

RESULTS NNP N
DMSA NNP N
greatly RB N
increased VBD N
the DT N
excretion NN o
of IN o
lead NN o
, , N
substantially RB N
increased VBN N
excretion NN o
of IN o
tin NN o
and CC o
bismuth NN o
, , N
and CC N
somewhat RB N
increased VBD N
the DT N
excretion NN o
of IN o
thallium NN o
, , o
mercury NN o
, , o
antimony NN o
, , o
and CC o
tungsten RB o
. . o

There EX N
was VBD N
some DT N
increase NN N
in IN N
urinary JJ o
excretion NN o
of IN o
essential JJ o
minerals NNS o
, , N
especially RB N
potassium JJ N
and CC N
chromium NN N
. . N

The DT N
Phase NNP N
1 CD N
single JJ N
round NN N
of IN N
DMSA NNP i
led VBD N
to TO N
a DT N
dramatic JJ N
normalization NN o
of IN o
RBC NNP o
glutathione NN o
in IN N
almost RB N
all DT N
cases NNS N
, , N
and CC N
greatly RB N
improved VBN N
abnormal JJ o
platelet NN o
counts NNS o
, , N
suggesting VBG N
a DT N
significant JJ N
decrease NN N
in IN N
inflammation NN o
. . o

CONCLUSION NNP N
Overall NNP N
, , N
DMSA NNP i
therapy NN N
seems VBZ N
to TO N
be VB N
reasonably RB N
safe JJ o
, , o
effective JJ o
in IN N
removing VBG N
several JJ N
toxic JJ o
metals NNS o
( ( N
especially RB N
lead VBP N
) ) N
, , N
dramatically RB N
effective JJ N
in IN N
normalizing VBG o
RBC NNP o
glutathione NN o
, , N
and CC N
effective JJ N
in IN N
normalizing VBG o
platelet NN o
counts NNS o
. . o

Only RB N
1 CD N
round NN N
( ( N
3 CD N
days NNS N
) ) N
was VBD N
sufficient JJ N
to TO N
improve VB N
glutathione NN o
and CC o
platelets NNS o
. . o

Additional JJ N
rounds NNS N
increased VBD N
excretion NN o
of IN o
toxic JJ o
metals NNS o
. . o

-DOCSTART- -12956656- O O

Investigation NN N
of IN N
erosion NN o
and CC o
abrasion NN o
on IN o
enamel NN o
and CC o
dentine NN o
: : o
a DT N
model NN N
in IN N
situ JJ N
using VBG N
toothpastes NNS i
of IN N
different JJ N
abrasivity NN i
. . i

BACKGROUND NNP N
Studies NNPS N
in IN N
vitro JJ N
suggest VBP N
that IN N
abrasion NN o
and CC o
erosion NN o
may MD N
act VB N
synergistically RB N
to TO N
produce VB N
wear NN o
of IN o
enamel NN o
and CC o
dentine NN o
. . o

Methods NNS N
in IN N
situ NN N
are VBP N
recently RB N
available JJ N
to TO N
study VB N
separately RB N
erosion NN o
and CC o
abrasion NN o
of IN o
dental JJ o
tissues NNS o
. . o

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
combine VB N
two CD N
in IN N
situ NN N
protocols NNS N
to TO N
study VB N
the DT N
interplay NN N
between IN N
erosion NN o
and CC o
abrasion NN o
of IN o
enamel NN o
and CC o
dentine NN o
. . o

METHOD NNP N
The DT N
study NN N
was VBD N
a DT N
single-blind JJ N
, , N
randomised JJ N
, , N
five-treatment JJ i
cross-over NN i
design NN i
involving VBG N
15 CD p
healthy JJ p
volunteers NNS p
. . p

During IN N
each DT N
10-day JJ N
study NN N
period NN N
, , N
subjects NNS p
wore VBP p
from IN p
0900 CD p
to TO p
1700 CD p
h NN p
an DT p
upper JJ i
removable JJ i
acrylic JJ i
appliance NN i
holding VBG i
one CD i
polished JJ i
enamel NN i
and CC i
one CD i
polished VBN i
dentine NN i
specimen NNS i
. . i

The DT N
specimen JJ N
treatment NN N
regimens NNS N
were VBD N
: : N
1 CD N
. . N

Drinking NN i
water NN i
and CC N
brushing NN i
with IN N
toothpaste NN i
A NNP N
. . N

2 CD N
. . N

Drinking NN N
water NN N
and CC N
brushing NN N
with IN N
toothpaste NN N
B NNP N
. . N

3 CD N
. . N

Drinking VBG i
orange NN i
juice NN i
. . i

4 CD N
. . N

Drinking VBG N
orange NN i
juice NN i
and CC i
brushing VBG i
with IN i
toothpaste NN i
A NNP N
. . N

5 CD N
. . N

Drinking VBG N
orange NN N
juice NN N
and CC N
brushing VBG N
with IN N
toothpaste NN N
B NNP N
. . N

Drinking NN N
and CC N
brushing VBG N
times NNS N
were VBD N
around IN N
0900 CD N
, , N
1100 CD N
, , N
1300 CD N
and CC N
1500 CD N
h. NN N
Drinks NNP N
were VBD N
consumed VBN N
as IN N
250 CD N
ml NN N
over IN N
10 CD N
min NNS N
and CC N
brushing VBG N
ex JJ N
vivo NN N
for IN N
1 CD N
min NNS N
to TO N
each DT N
specimen NNS N
. . N

Measurement NN N
of IN N
tissue NN o
loss NN o
was VBD N
made VBN N
on IN N
days NNS N
5 CD N
and CC N
10 CD N
of IN N
each DT N
period NN N
using VBG N
a DT N
profilometer NN N
. . N

RESULTS NNP N
All NNP N
treatments NNS N
produced VBD N
increasing VBG N
tissue NN o
loss NN o
over IN o
time NN o
, , N
which WDT N
was VBD N
considerably RB N
greater JJR N
for IN N
dentine NN N
than IN N
enamel NN N
. . N

For IN N
enamel NN N
, , N
the DT N
data NNS N
at IN N
days NNS N
5 CD N
and CC N
10 CD N
showed VBD N
a DT N
significant JJ N
effect NN N
for IN N
erosion NN o
( ( N
i.e NN N
. . N

orange NN N
juice NN N
was VBD N
significantly RB N
more RBR N
erosive JJ N
than IN N
water NN N
) ) N
, , N
but CC N
no DT N
significant JJ N
effect NN N
for IN N
abrasion NN o
( ( N
i.e NN N
. . N

no DT N
significant JJ N
difference NN N
between IN N
the DT N
two CD N
toothpaste NN N
treatments NNS N
) ) N
. . N

The DT N
combined JJ N
orange NN N
juice NN N
and CC N
toothpaste NN N
effects NNS N
were VBD N
directional JJ N
for IN N
synergy NN N
but CC N
did VBD N
not RB N
reach VB N
significance NN N
. . N

For IN N
dentine NN N
at IN N
day NN N
10 CD N
, , N
many JJ N
specimens NNS N
exceeded VBD N
the DT N
50 CD N
microm NN N
set VBN N
limit NN N
of IN N
the DT N
profilometer NN N
and CC N
only RB N
day NN N
5 CD N
data NNS N
were VBD N
considered VBN N
. . N

There EX N
were VBD N
significant JJ N
effects NNS N
for IN N
erosion NN o
( ( N
orange JJ N
juice NN N
produced VBD N
significantly RB N
more JJR N
erosion NN N
than IN N
water NN N
) ) N
and CC N
for IN N
abrasion NN o
( ( N
paste NN N
A DT N
was VBD N
significantly RB N
more RBR N
abrasive JJ N
to TO N
dentine VB N
than IN N
paste NN N
B NNP N
) ) N
. . N

The DT N
synergy JJ o
effect NN o
could MD N
not RB N
be VB N
examined VBN N
for IN N
dentine NN N
due JJ N
to TO N
the DT N
truncation NN N
effect NN N
as IN N
the DT N
set NN N
limit NN N
of IN N
the DT N
profilometer NN N
was VBD N
exceeded VBN N
. . N

CONCLUSIONS NNP N
Erosion NNP N
increases VBZ N
the DT N
susceptibility NN o
of IN o
enamel NN o
to TO N
toothpaste VB o
abrasion NN o
. . o

Dentine NNP N
is VBZ N
considerably RB N
more RBR N
susceptible JJ N
than IN N
enamel NN N
to TO N
erosion NN o
and CC o
abrasion NN o
alone RB N
or CC N
combined VBN N
. . N

Dentine NNP o
loss NN o
appears VBZ N
to TO N
correlate VB N
with IN N
toothpaste NN N
abrasivity NN N
( ( N
RDA NNP N
value NN N
) ) N
. . N

-DOCSTART- -2036277- O O

Double-blind JJ N
placebo-controlled JJ i
comparison NN N
of IN N
the DT N
analgesic JJ o
effects NNS o
of IN N
single JJ N
doses NNS N
of IN N
lornoxicam NN i
and CC i
aspirin NN i
in IN N
patients NNS p
with IN p
postoperative JJ p
dental NN p
pain NN p
. . p

The DT N
pain NN N
experienced VBD N
after IN N
third JJ N
molar JJ N
surgery NN N
was VBD N
used VBN N
as IN N
a DT N
model NN N
to TO N
evaluate VB N
the DT N
analgesic JJ o
efficacy NN o
of IN N
a DT N
new JJ N
non-steroidal JJ N
anti-inflammatory JJ N
drug NN N
, , N
lornoxicam NN i
, , N
in IN N
a DT N
Phase NNP N
II NNP N
study NN N
. . N

One CD p
hundred CD p
and CC p
fifty JJ p
fit NN p
, , p
young JJ p
adults NNS p
participated VBD p
in IN N
this DT N
randomised VBN N
, , N
single JJ N
dose NN N
, , N
double-blind NN N
, , N
parallel JJ N
group NN N
clinical JJ N
study NN N
. . N

Three CD N
doses NNS N
of IN N
lornoxicam NN i
( ( N
2 CD N
mg NN N
, , N
4 CD N
mg NN N
, , N
and CC N
8 CD N
mg NN N
) ) N
were VBD N
compared VBN N
with IN N
aspirin JJ i
650 CD i
mg NN N
and CC N
placebo NN i
. . i

Patients NNS p
suffering VBG p
from IN p
moderate JJ p
to TO p
severe VB p
pain NN p
following VBG p
surgery NN p
were VBD p
monitored VBN p
for IN p
up RB p
to TO p
8 CD p
hours NNS p
. . p

All DT N
indices NNS N
of IN N
efficacy NN o
showed VBD N
similar JJ N
results NNS N
, , N
all DT N
active JJ N
treatments NNS N
being VBG N
associated VBN N
with IN N
highly RB N
significant JJ N
( ( N
P NNP N
less JJR N
than IN N
0.0001 CD N
) ) N
reductions NNS o
in IN o
pain NN o
during IN N
the DT N
study NN N
period NN N
. . N

Lornoxicam NNP i
8 CD N
mg NN N
demonstrated VBD N
significant JJ N
analgesic JJ o
efficacy NN o
as IN N
compared VBN N
with IN N
placebo NN N
. . N

The DT N
two CD N
lower JJR N
doses NNS N
of IN N
lornoxicam NN i
and CC N
aspirin VB i
all DT N
showed VBD N
apparent JJ N
degrees NNS N
of IN N
efficacy NN o
intermediate NN N
between IN N
that DT N
of IN N
placebo NN N
and CC N
lornoxicam $ N
8 CD N
mg NN N
, , N
although IN N
the DT N
trial NN N
proved VBD N
to TO N
have VB N
inadequate JJ N
power NN N
to TO N
show VB N
significant JJ N
differences NNS N
between IN N
these DT N
three CD N
treatments NNS N
. . N

Lornoxicam NNP N
was VBD N
very RB N
well RB o
tolerated VBN o
at IN N
all DT N
three CD N
doses NNS N
studied VBN N
, , N
with IN N
no DT N
adverse JJ o
events NNS o
definitely RB N
attributable JJ N
to TO N
its PRP$ N
administration NN N
. . N

-DOCSTART- -15985559- O O

Long JJ N
term NN N
follow VBP N
up IN N
of IN N
patients NNS p
treated VBN p
for IN p
Helicobacter NNP o
pylori JJ o
infection NN o
. . o

BACKGROUND NNP N
Helicobacter NNP N
pylori POS N
infection NN N
induces NNS N
progressive JJ N
inflammatory JJ o
changes NNS o
in IN N
the DT N
gastric JJ N
mucosa NN N
that WDT N
may MD N
lead VB N
to TO N
gastric JJ N
cancer NN N
. . N

Understanding VBG N
long JJ N
term NN N
effects NNS N
resulting VBG N
from IN N
the DT N
cure NN N
of IN N
this DT N
infection NN N
is VBZ N
needed VBN N
to TO N
design VB N
cancer NN N
prevention NN N
strategies NNS N
. . N

METHODS NNP N
A NNP N
cohort NN N
of IN N
795 CD p
adults NNS p
with IN p
preneoplastic JJ p
gastric JJ p
lesions NNS p
was VBD p
randomised VBN p
to TO p
receive VB i
anti-H JJ i
pylori NN i
treatment NN i
and/or JJ i
antioxidants NNS i
. . i

At IN N
the DT N
end NN N
of IN N
six CD N
years NNS N
of IN N
intervention NN N
, , N
those DT N
who WP N
did VBD N
not RB N
receive VB N
anti-H JJ N
pylori NN N
treatment NN N
were VBD N
offered VBN N
it PRP N
. . N

Gastric JJ N
biopsies NNS N
were VBD N
obtained VBN N
at IN N
baseline NN N
, , N
and CC N
at IN N
3 CD N
, , N
6 CD N
, , N
and CC N
12 CD N
years NNS N
. . N

A DT N
histopathology NN o
score NN o
was VBD N
utilised VBN N
to TO N
document VB N
changes NNS N
in IN N
gastric JJ o
lesions NNS o
. . o

Non-linear JJ N
mixed JJ N
models NNS N
were VBD N
used VBN N
to TO N
estimate VB N
the DT N
cumulative JJ N
effect NN N
of IN N
H NNP N
pylori JJ N
clearance NN N
on IN N
histopathology NN o
scores NNS o
adjusted VBN N
for IN N
follow VB N
up RP N
time NN N
, , N
interventions NNS N
, , N
and CC N
confounders NNS N
. . N

RESULTS NNP N
Ninety NNP p
seven CD p
per IN p
cent NN p
of IN p
subjects NNS p
were VBD p
H NNP o
pylori JJ o
positive JJ p
at IN p
baseline NN p
, , p
and CC p
53 CD p
% NN p
were VBD p
positive JJ p
at IN p
12 CD p
years NNS p
. . p

Subjects NNS N
accumulated JJ N
1703 CD N
person NN N
years NNS N
free JJ o
of IN o
infection NN o
. . o

A DT N
multivariate NN N
model NN N
showed VBD N
a DT N
significant JJ N
regression NN o
in IN o
histopathology NN o
score NN o
as IN N
a DT N
function NN N
of IN N
the DT N
square NN N
of IN N
H NNP o
pylori FW o
negative JJ o
time NN o
. . o

Subjects NNS N
who WP N
were VBD N
H NNP o
pylori JJ o
negative JJ N
had VBD N
14.8 CD N
% NN N
more JJR N
regression NN o
and CC N
13.7 CD N
% NN N
less JJR N
progression NN o
than IN N
patients NNS N
who WP N
were VBD N
positive JJ N
at IN N
12 CD N
years NNS N
( ( N
p JJ N
= NNP N
0.001 CD N
) ) N
. . N

The DT N
rate NN o
of IN o
healing NN o
of IN o
gastric JJ o
lesions NNS o
occurred VBD N
more RBR N
rapidly RB N
as IN N
years NNS o
free JJ o
of IN o
infection NN o
accumulated VBN N
, , N
and CC N
was VBD N
more RBR N
pronounced JJ N
in IN N
less RBR N
advanced JJ N
lesions NNS N
. . N

CONCLUSIONS NNP N
Preneoplastic NNP o
gastric JJ o
lesions NNS o
regress NN N
at IN N
a DT N
rate NN N
equal JJ N
to TO N
the DT N
square NN N
of IN N
time NN N
in IN N
patients NNS N
rendered JJ N
free JJ N
of IN N
H NNP N
pylori JJ N
infection NN N
. . N

Our PRP$ N
findings NNS N
suggest VBP N
that IN N
patients NNS p
with IN p
preneoplastic JJ p
gastric JJ p
lesions NNS p
should MD N
be VB N
treated VBN N
and CC N
cured VBN N
of IN N
their PRP$ N
H NNP o
pylori NN o
infection NN o
. . o

-DOCSTART- -26037035- O O

Intradermal NNP N
insulin NN i
infusion NN i
achieves VBZ N
faster JJR N
insulin NN N
action NN N
than IN N
subcutaneous JJ N
infusion NN N
for IN N
3-day JJ N
wear NN N
. . N

Rapid JJ N
uptake JJ N
previously RB N
demonstrated VBN N
by IN N
intradermal JJ i
( ( i
ID NNP i
) ) i
drug NN N
administration NN N
indicates VBZ N
compound JJ N
delivery NN N
within IN N
the DT N
dermis NN N
may MD N
have VB N
clinical JJ N
and CC N
pharmacological JJ N
advantages NNS N
for IN N
certain JJ N
drug NN N
therapies NNS N
. . N

This DT N
study NN N
is VBZ N
the DT N
first JJ N
clinical JJ N
trial NN N
to TO N
evaluate VB N
continuous JJ i
microneedle-based JJ i
drug NN i
infusion NN i
, , N
device NN N
wearability NN N
, , N
and CC N
intradermal JJ N
microneedle JJ N
insulin NN N
kinetics NNS N
over IN N
a DT N
multi-day JJ N
( ( N
72 CD N
h NN N
) ) N
wear NN N
period NN N
. . N

This DT N
was VBD N
a DT N
single JJ N
center NN N
, , N
open-label JJ N
, , N
two-period JJ N
crossover NN N
study NN N
in IN p
T1DM NNP p
patients NNS p
on IN p
continuous JJ p
subcutaneous JJ i
insulin NN i
infusion NN p
( ( p
CSII NNP p
) ) p
. . p

Patients NNPS N
received VBD N
treatment NN N
during IN N
interventional JJ N
visits NNS N
: : N
one CD i
SC NNP i
and CC N
one CD i
ID NNP i
basal/bolus CC N
infusion NN N
of IN i
insulin JJ i
aspart NN i
( ( i
NovoRapid? NNP i
U-100 NNP i
) ) i
administered VBD i
over IN N
3 CD N
days NNS N
in IN N
a DT N
randomized JJ N
order NN p
. . p

Twenty-eight JJ p
patients NNS p
were VBD p
randomized VBN p
and CC p
exposed VBN N
to TO N
trial NN N
product NN N
, , N
and CC N
23 CD p
completed VBD p
the DT p
study NN i
. . i

Bolus NNP i
insulin JJ i
infusions NNS i
were VBD i
given VBN N
prior RB N
to TO N
standardized VBN N
breakfast NN N
and CC N
lunch JJ N
test NN N
meals NNS N
on IN N
each DT N
of IN N
the DT N
three CD N
treatment NN N
days NNS N
. . N

Blood NN N
samples NNS N
were VBD N
drawn VBN N
at IN N
predefined JJ N
time NN N
points NNS N
for IN N
measurements NNS N
of IN N
insulin JJ o
aspart NN o
and CC o
blood NN o
glucose NN o
in IN o
serum NN o
. . o

The DT o
primary JJ N
endpoint NN o
insulin NN o
Tmax NNP o
demonstrated VBD o
that IN N
ID NNP N
bolus CC N
infusion NN N
was VBD N
associated VBN N
with IN N
a DT N
significantly RB o
shorter JJR o
Tmax NNP o
with IN o
statistically RB N
significantly RB N
smaller JJR o
intra-subject JJ o
variability NN o
, , o
compared VBN o
to TO N
SC NNP N
infusion NN N
, , N
and CC N
this DT N
difference NN N
was VBD N
maintained VBN N
over IN N
three CD N
treatment NN N
days NNS N
. . N

Analyses NNS N
of IN N
secondary JJ o
PK NNP o
endpoints NNS o
corresponded VBD o
with IN N
the DT N
primary JJ N
endpoint NN N
findings NNS o
. . o

Postprandial JJ o
glycemic JJ o
response NN o
was VBD o
significantly RB N
less JJR N
pronounced JJ N
after IN N
ID NNP N
bolus NN N
: : N
For IN N
most JJS N
endpoints NNS N
ID NNP N
vs. IN N
SC NNP N
, , N
differences NNS N
were VBD N
statistically RB N
significant JJ N
within IN N
the DT N
0-1.5 JJ N
or CC N
0-2 JJ N
h JJ N
time NN N
period NN N
. . N

Intradermal JJ N
delivery NN i
of IN i
insulin NN i
is VBZ i
a DT N
viable JJ N
delivery NN N
route NN N
alternative NN N
providing VBG N
reduced JJ o
time NN o
for IN o
insulin JJ o
absorption NN o
with IN o
less JJR N
intra-subject JJ o
variability NN o
and CC o
lower JJR o
glycemic JJ o
response NN o
. . o

-DOCSTART- -9701205- O O

Pelvic JJ N
lymphocysts NNS N
following VBG N
retroperitoneal JJ N
lymphadenectomy NN N
: : N
retroperitoneal JJ i
partial JJ i
no-closure NN i
for IN N
ovarian JJ N
and CC N
endometrial JJ N
cancers NNS N
. . N

BACKGROUND NNP N
AND NNP N
OBJECTIVES NNP N
Pelvic NNP N
lymphocysts NNS N
have VBP N
been VBN N
reported VBN N
mainly RB N
following VBG N
pelvic JJ N
lymphadenectomy NN N
for IN N
cervical JJ N
cancer NN N
. . N

We PRP N
attempted VBD N
to TO N
assess VB N
whether IN N
retroperitoneal JJ i
partial JJ i
no-closure NN i
reduces VBZ N
the DT N
incidence NN N
of IN N
lymphocyst JJ o
formation NN o
following VBG N
retroperitoneal JJ N
lymphadenectomy NN N
. . N

METHODS NNP N
Sixty-one JJ p
patients NNS p
with IN p
ovarian JJ p
cancer NN p
or CC p
endometrial JJ p
cancer NN p
who WP p
underwent JJ p
retroperitoneal NN p
lymph NN p
node JJ p
resection NN p
were VBD N
assigned VBN N
at IN N
random NN N
to TO N
a DT N
retroperitoneal JJ i
partial JJ i
no-closure JJ i
group NN i
or CC i
a DT i
closure NN i
group NN i
. . i

The DT N
incidence NN N
of IN N
lymphocysts NNS o
in IN N
the DT N
two CD N
groups NNS N
as IN N
determined JJ N
using VBG N
ultrasonography NN N
was VBD N
compared VBN N
. . N

RESULTS JJ N
Lymphocysts NNS o
appeared VBD N
in IN N
23/61 CD N
patients NNS N
( ( N
38 CD N
% NN N
) ) N
in IN N
total JJ N
. . N

In IN N
the DT N
closure NN N
group NN N
, , N
the DT N
incidence NN N
was VBD N
52 CD N
% NN N
( ( N
16/31 CD N
) ) N
, , N
but CC N
in IN N
the DT N
no-closure JJ N
group NN N
it PRP N
was VBD N
only RB N
23 CD N
% NN N
( ( N
7/30 CD N
) ) N
; : N
the DT N
incidence NN N
in IN N
the DT N
no-closure JJ N
group NN N
was VBD N
significantly RB N
lower JJR N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

The DT N
incidence NN N
of IN N
postoperative JJ o
fever NN o
was VBD N
17 CD N
% NN N
( ( N
5/30 CD N
) ) N
in IN N
the DT N
no-closure JJ N
group NN N
, , N
which WDT N
was VBD N
lower JJR N
than IN N
that DT N
in IN N
the DT N
closure NN N
group NN N
( ( N
42 CD N
% NN N
, , N
13/31 CD N
) ) N
, , N
but CC N
not RB N
significantly RB N
so RB N
( ( N
P NNP N
< NNP N
0.1 CD N
) ) N
. . N

No DT N
patients NNS N
in IN N
the DT N
no-closure JJ N
group NN N
required VBD N
surgical JJ N
procedures NNS N
such JJ N
as IN N
needle JJ N
aspiration NN N
or CC N
cyst NN N
drainage NN N
. . N

CONCLUSIONS NNP N
Retroperitoneal NNP i
partial JJ i
no-closure NN i
appears VBZ N
to TO N
be VB N
a DT N
useful JJ N
procedure NN N
for IN N
reducing VBG N
the DT N
incidence NN N
of IN N
pelvic JJ o
lymphocysts NNS o
associated VBN N
with IN N
retroperitoneal JJ i
lymphadenectomy NN i
. . i

-DOCSTART- -4752239- O O

Mebendazole NNP i
in IN N
enterobiasis NN o
: : o
a DT N
placebo NN i
-- : i
controlled VBD i
trial NN N
in IN N
a DT N
paediatric JJ p
community NN p
. . p

-DOCSTART- -26628383- O O

Body NNP N
Mass NNP N
Index NNP N
and CC N
Adverse NNP N
Outcomes NNP N
in IN N
Elderly JJ p
Patients NNS p
With IN p
Atrial JJ p
Fibrillation NN p
: : p
The DT N
AMADEUS NNP N
Trial NNP N
. . N

BACKGROUND NNP N
AND CC N
PURPOSE NNP N
Obesity NNP N
has VBZ N
been VBN N
associated VBN N
with IN N
increased JJ N
cardiovascular NN N
risk NN N
in IN N
atrial JJ N
fibrillation NN N
, , N
but CC N
little JJ N
is VBZ N
known VBN N
in IN N
elderly JJ p
patients NNS p
with IN p
atrial JJ p
fibrillation NN p
. . p

METHODS NNP N
Post NNP N
hoc NN N
analysis NN N
of IN N
data NNS N
from IN N
the DT N
AMADEUS NNP N
( ( N
Evaluating VBG N
the DT N
Use NNP N
of IN N
SR34006 NNP N
Compared NNP N
to TO N
Warfarin NNP i
or CC i
Acenocoumarol NNP i
in IN N
Patients NNP p
With IN p
Atrial NNP p
Fibrillation NNP p
) ) p
trial NN N
. . N

RESULTS NNP N
We PRP N
studied VBD N
1588 CD p
elderly JJ p
patients NNS p
, , p
who WP p
were VBD p
categorized VBN p
as IN p
normal JJ p
body NN p
mass NN p
index NN p
( ( p
BMI NNP p
, , p
18.5-25 JJ p
kg/m NN p
( ( p
2 CD p
) ) p
; : p
n=515 CC p
[ VB p
32.4 CD p
% NN p
] NN p
) ) p
, , p
overweight JJ p
( ( p
BMI NNP p
, , p
25-30 JJ p
kg/m NN p
( ( p
2 CD p
) ) p
; : p
n=711 CC p
[ VB p
44.8 CD p
% NN p
] NN p
) ) p
, , p
and CC p
obese JJ p
( ( p
BMI?30 NNP p
kg/m NNP p
( ( p
2 CD p
) ) p
; : p
n=362 CC p
[ VB p
22.8 CD p
% NN p
] NN p
) ) p
. . p

There EX N
was VBD N
a DT N
significant JJ N
reduction NN N
in IN N
the DT N
composite JJ N
outcome NN N
of IN N
cardiovascular JJ o
death NN o
and CC o
stroke/systemic JJ o
embolism NN o
with IN o
increasing VBG N
BMI NNP N
category NN N
, , N
being VBG N
5.0 CD N
% NN N
, , N
3.2 CD N
% NN N
, , N
and CC N
1.5 CD N
% NN N
per IN N
100 CD N
patient-years NNS N
, , N
respectively RB N
( ( N
P NNP N
for IN N
trend=0.01 NN N
) ) N
. . N

Cox NNP N
proportional JJ N
hazards NNS N
analysis NN N
found VBD N
obesity NN N
to TO N
be VB N
associated VBN N
with IN N
a DT N
lower JJR N
risk NN N
of IN N
the DT N
primary JJ N
composite JJ N
outcome NN N
( ( N
hazard JJ N
ratio NN N
, , N
0.29 CD N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
0.11-0.77 JJ N
; : N
P=0.01 NNP N
) ) N
. . N

In IN N
the DT i
warfarin NN i
arm NN i
( ( N
n=814 NN N
) ) N
, , N
multivariate JJ N
logistic JJ N
regression NN N
analysis NN N
demonstrated VBD N
that IN N
obesity NN N
was VBD N
independently RB N
related VBN N
to TO N
higher JJR N
odds NNS N
of IN N
time NN N
in IN N
therapeutic JJ N
range NN N
?60 CD N
% NN N
( ( N
odds JJ N
ratio NN N
, , N
1.84 CD N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
1.21-2.80 JJ N
; : N
P=0.004 NNP N
) ) N
. . N

CONCLUSION NNP N
Obesity NNP N
was VBD N
associated VBN N
with IN N
a DT o
lower JJR o
stroke NN o
and CC o
mortality NN o
rate NN o
in IN o
elderly JJ p
anticoagulated VBN p
atrial JJ p
fibrillation NN p
patients NNS p
. . p

Obesity NNP p
was VBD N
related VBN N
to TO N
good JJ N
quality NN N
anticoagulation NN N
control NN N
. . N

-DOCSTART- -17901383- O O

Transcutaneous JJ i
electrical JJ i
nerve NN i
stimulation NN i
combined VBN i
with IN i
task-related JJ i
training NN i
improves NNS N
lower JJR o
limb NN o
functions NNS o
in IN N
subjects NNS p
with IN p
chronic JJ p
stroke NN p
. . p

BACKGROUND NNP N
AND NNP N
PURPOSE NNP N
Previous NNP N
studies NNS N
have VBP N
shown VBN N
that IN N
repeated VBD N
sensory JJ N
inputs NNS N
could MD N
enhance VB N
brain NN o
plasticity NN o
and CC o
cortical JJ o
motor NN o
output NN o
. . o

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
investigate VB N
whether IN N
combining VBG N
electrically RB N
induced JJ N
sensory NN N
inputs NNS N
through IN N
transcutaneous JJ i
electrical JJ i
nerve NN i
stimulation NN i
( ( i
TENS NNP i
) ) i
with IN i
task-related JJ i
training NN i
( ( i
TRT NNP i
) ) i
in IN N
a DT N
home-based JJ N
program NN N
would MD N
augment VB N
voluntary JJ o
motor NN o
output NN o
in IN N
chronic JJ p
stroke NN p
survivors NNS p
better RBR N
than IN N
either DT N
treatment NN N
alone RB N
or CC N
no DT N
treatment NN N
. . N

METHODS NNP N
Eighty-eight JJ p
patients NNS p
with IN p
stroke NN p
were VBD N
assigned VBN N
randomly RB N
to TO N
receive VB N
a DT N
home-based JJ N
program NN N
of IN N
( ( N
1 CD N
) ) N
TENS NN i
, , i
( ( i
2 CD i
) ) i
TENS+TRT NN i
, , i
( ( i
3 CD i
) ) i
placebo NN i
TENS+TRT NNP i
, , i
or CC i
( ( i
4 CD i
) ) i
no DT i
treatment NN i
( ( i
control NN i
) ) i
5 CD N
days NNS N
a DT N
week NN N
for IN N
4 CD N
weeks NNS N
. . N

Outcome NN N
measurements NNS N
included VBD N
Composite NNP o
Spasticity NNP o
Scale NNP o
, , o
peak NN o
torques NNS o
generated VBD o
during IN o
maximum JJ o
isometric JJ o
voluntary JJ o
contraction NN o
of IN o
ankle JJ o
dorsiflexors NNS o
and CC o
plantarflexors NNS o
, , o
and CC o
gait VBP o
velocity NN o
recorded VBN N
at IN N
baseline NN N
, , N
after IN N
2 CD N
and CC N
4 CD N
weeks NNS N
of IN N
treatment NN N
, , N
and CC N
4 CD N
weeks NNS N
after IN N
treatment NN N
ended VBN N
. . N

RESULTS VB N
When WRB N
compared VBN N
with IN N
TENS NNP i
, , N
the DT N
combined JJ N
TENS+TRT NNP i
group NN N
showed VBD N
significantly RB N
greater JJR N
improvement NN N
in IN N
ankle JJ o
dorsiflexion NN o
torque NN o
at IN N
follow-up JJ N
and CC N
in IN N
ankle JJ o
plantarflexion NN o
torque NN o
at IN N
week NN N
2 CD N
and CC N
follow-up JJ N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

When WRB N
compared VBN N
with IN N
placebo+TRT NN i
, , N
the DT N
TENS+TRT NNP i
group NN N
produced VBD N
earlier JJR N
and CC N
greater JJR N
reduction NN N
of IN N
plantarflexor NN o
spasticity NN o
and CC N
improvement NN o
in IN o
ankle JJ o
dorsiflexion NN o
torque NN o
at IN N
week NN N
2 CD N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

When WRB N
compared VBN N
with IN N
all DT N
3 CD N
groups NNS N
, , N
the DT N
TENS+TRT NNP i
group NN N
showed VBD N
significantly RB N
greater JJR N
improvement NN N
in IN N
gait NN o
velocity NN o
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

CONCLUSIONS NNP N
In IN N
patients NNS p
with IN p
chronic JJ p
stroke NN p
, , N
20 CD N
sessions NNS N
of IN N
a DT N
combined JJ i
TENS+TRT NNP i
home-based JJ i
program NN N
decreased VBN o
plantarflexor JJ o
spasticity NN o
, , o
improved VBN o
dorsiflexor NN o
and CC o
plantarflexor NN o
strength NN o
, , o
and CC o
increased VBD o
gait NN o
velocity NN o
significantly RB N
more RBR N
than IN N
TENS NNP i
alone RB N
, , N
placebo+TRT NN N
, , N
or CC N
no DT N
treatment NN N
. . N

Such JJ N
improvements NNS N
can MD N
even RB N
be VB N
maintained VBN N
4 CD N
weeks NNS N
after IN N
treatment NN N
ended VBD N
. . N

-DOCSTART- -21042763- O O

An DT N
explorative JJ N
study NN N
on IN N
the DT N
clinical JJ N
utility NN N
of IN N
baseline NN N
and CC N
serial JJ N
serum NN N
tumour NN N
marker NN N
measurements NNS N
in IN N
advanced JJ p
upper JJ p
gastrointestinal JJ p
cancer NN p
. . p

The DT N
value NN N
of IN N
early JJ N
tumour NN N
marker NN N
changes NNS N
during IN N
palliative JJ N
chemotherapy NN N
in IN N
patients NNS p
with IN p
upper JJ p
gastrointestinal JJ p
adenocarcinoma NN p
( ( p
UGIA NNP p
) ) p
is VBZ N
unclear JJ N
. . N

Seventy-three JJ p
patients NNS p
with IN p
advanced JJ p
UGIA NNP p
were VBD p
randomised VBN p
to TO N
receive VB N
45 CD i
mg/m2 NN i
docetaxel NN i
or CC i
180 CD i
mg/m2 NNS i
irinotecan JJ i
with IN i
5-FU/leucovorin JJ i
. . i

After IN N
every DT N
2nd CD i
course NN i
the DT i
patients NNS i
were VBD i
crossed VBN i
over IN i
to TO i
the DT i
other JJ i
regimen NNS i
. . i

Serum NNP o
was VBD N
sampled VBN N
before IN N
start NN N
of IN N
chemotherapy NN N
and CC N
every DT N
2nd CD N
week NN N
during IN N
8 CD N
weeks NNS N
for IN N
CEA NNP N
, , N
TPA NNP N
, , N
TPS NNP N
, , N
CA72-4 NNP N
, , N
CA19-9 NNP N
and CC N
CA242 NNP N
measurements NNS N
. . N

Eighteen JJ N
patients NNS N
( ( N
25 CD N
% NN N
) ) N
had VBD N
partial JJ N
response NN N
( ( N
PR NNP N
) ) N
and CC N
21 CD N
patients NNS N
had VBD N
stable JJ N
disease NN N
for IN N
at IN N
least JJS N
4 CD N
months NNS N
( ( N
SD4 NNP N
) ) N
. . N

All DT N
baseline NN N
marker NN N
levels NNS N
, , N
except IN N
CA72-4 NNP N
, , N
correlated VBN N
with IN N
time NN o
to TO o
progression NN o
and CC N
survival NN o
. . o

Patients NNS p
with IN p
normal JJ p
levels NNS p
, , p
except IN p
CA72-4 NNP p
, , N
also RB N
had VBD N
more RBR N
clinical JJ N
responses NNS N
( ( N
PR+SD4 NNP N
) ) N
than IN N
patients NNS N
with IN N
elevated JJ N
values NNS N
. . N

Tumour CD o
marker NN o
changes NNS o
early RB N
during IN N
treatment NN N
provided VBN N
modest JJ N
predictive JJ N
information NN N
for IN N
tumour NN N
response NN N
and CC N
survival NN N
. . N

A DT N
model NN N
combining VBG N
baseline JJ N
level NN N
, , N
the DT N
change NN N
and CC N
the DT N
interaction NN N
between IN N
them PRP N
gave VBD N
the DT N
best JJS N
prediction NN N
of IN N
outcome NN N
, , N
however RB N
, , N
insignificantly RB N
better JJR N
than IN N
baseline JJ N
level NN N
for IN N
all DT N
markers NNS N
except IN N
CA242 NNP N
. . N

Baseline NNP o
tumour JJ o
marker NN o
levels NNS N
provide VBP N
prognostic JJ N
information NN N
for IN N
patients NNS p
with IN p
UGIA NNP p
on IN p
palliative JJ p
chemotherapy NN p
. . p

Early JJ N
changes NNS N
generally RB N
failed VBD N
to TO N
provide VB N
accurate JJ N
information NN N
for IN N
tumour NN N
response NN N
and CC N
survival NN N
. . N

-DOCSTART- -23611569- O O

Vilazodone NN i
lacks VBZ N
proarrhythmogenic JJ N
potential NN N
in IN N
healthy JJ p
participants NNS p
: : p
a DT N
thorough JJ N
ECG NNP N
study NN N
. . N

OBJECTIVE NNP N
Vilazodone NNP i
is VBZ N
a DT N
potent JJ N
serotonin NN N
reuptake NN N
inhibitor NN N
and CC N
5-HT1A JJ N
receptor NN N
partial JJ N
agonist NN N
approved VBD N
for IN N
the DT N
treatment NN N
of IN N
major JJ p
depressive JJ p
disorder NN p
( ( p
MDD NNP p
) ) p
in IN p
adults NNS p
. . p

The DT N
effect NN N
of IN N
clinical JJ N
and CC N
supratherapeutic JJ N
doses NNS N
of IN N
vilazodone NN i
on IN N
cardiac JJ N
repolarization NN N
was VBD N
determined VBN N
in IN N
healthy JJ p
volunteers NNS p
. . p

METHODS NNP N
In IN N
this DT N
Phase NNP N
1 CD N
, , N
randomized VBN N
, , N
doubleblind VB N
, , N
placebo- JJ i
and CC N
active-controlled JJ N
, , N
3-arm JJ N
, , N
parallel JJ N
, , N
single-center JJ N
study NN N
, , N
healthy JJ p
subjects NNS p
received VBD N
placebo NN i
; : i
moxifloxacin CC i
400 CD i
mg NN i
; : i
or CC i
vilazodone NN i
( ( N
sequentially RB N
escalated VBN N
every DT N
3 CD N
days NNS N
) ) N
10 CD N
, , N
20 CD N
, , N
40 CD N
, , N
60 CD N
, , N
and CC N
80 CD N
mg/day NN N
. . N

The DT N
primary JJ N
endpoint NN N
was VBD N
the DT N
time-matched JJ N
change NN N
from IN N
baseline NN N
in IN N
the DT N
QT NNP o
interval NN o
corrected VBD o
for IN o
heart NN o
rate NN o
( ( o
QTc NNP o
) ) o
using VBG N
an DT N
individual JJ N
correction NN N
method NN N
( ( N
QTcI NNP N
) ) N
. . N

RESULTS JJ N
Placebo-corrected JJ i
time-matched JJ N
analysis NN N
of IN N
the DT N
QTcI NNP o
duration NN o
for IN N
the DT N
vilazodone NN i
treatment NN N
effect NN N
indicated VBD N
that IN N
no DT N
vilazodone NN i
dose NN N
had VBD N
an DT N
upper JJ N
bound NN N
that IN N
approached VBD N
or CC N
exceeded VBD N
10 CD N
ms NN N
, , N
demonstrating VBG N
no DT N
signal NN N
for IN N
a DT N
significant JJ N
vilazodone NN i
effect NN N
on IN N
cardiac JJ o
repolarization NN o
. . o

Vilazodone NNP i
had VBD N
no DT N
significant JJ N
effect NN N
on IN N
heart NN o
rate NN o
, , o
PR NNP o
, , o
or CC o
QRS NNP o
interval JJ o
duration NN o
. . o

The DT N
pharmacokinetic/pharmacodynamic JJ N
model NN N
showed VBD N
that IN N
the DT N
QTcI NNP o
slope NN N
for IN N
vilazodone NN i
was VBD N
not RB N
different JJ N
from IN N
0.0 CD N
and CC N
that IN N
the DT N
predicted JJ N
increase NN N
from IN N
baseline NN N
in IN N
the DT N
QTc NNP o
at IN o
Cmax NNP o
for IN N
the DT N
highest JJS N
therapeutic JJ N
dose NN N
( ( N
156 CD N
ng/ml RB N
after IN N
40 CD N
mg/day NN N
) ) N
was VBD N
< JJ N
1 CD N
ms NN N
. . N

The DT N
incidence NN N
of IN N
adverse JJ o
events NNS o
( ( o
AEs NNP o
) ) o
was VBD N
higher RBR N
in IN N
the DT N
vilazodone NN i
group NN N
( ( N
57.6 CD N
% NN N
) ) N
than IN N
in IN N
the DT N
moxifloxacin NN i
( ( N
37.0 CD N
% NN N
) ) N
and CC N
placebo NN i
( ( N
35.6 CD N
% NN N
) ) N
groups NNS N
, , N
though IN N
AEs NNP o
were VBD N
generally RB N
mild VBN N
to TO N
moderate VB N
in IN N
severity NN N
and CC N
resulted VBD N
in IN N
few JJ N
discontinuations NNS N
. . N

CONCLUSIONS NNP N
Vilazodone NNP i
had VBD N
no DT N
significant JJ N
effect NN N
on IN N
cardiac JJ o
repolarization NN o
, , o
heart NN o
rate NN o
, , o
PR NNP o
or CC o
QRS NNP o
interval JJ o
duration NN o
, , o
or CC o
ECG NNP o
morphology NN o
in IN N
healthy JJ p
adult NN p
participants NNS p
. . p

-DOCSTART- -22845070- O O

Development NNP N
, , N
awareness NN N
and CC N
inductive JJ N
selectivity NN N
. . N

Two CD N
studies NNS N
examined VBD N
whether IN N
adults NNS p
and CC p
children NNS p
could MD N
learn VB N
to TO N
make VB N
context-dependent JJ N
inferences NNS N
about IN N
novel JJ N
stimuli NNS N
and CC N
the DT N
role NN N
of IN N
awareness NN N
of IN N
context NN N
cues NNS N
in IN N
such JJ N
learning NN N
. . N

Participants NNS p
were VBD N
trained VBN i
to TO i
match VB i
probes NNS i
to TO i
targets NNS i
on IN N
the DT N
basis NN N
of IN N
shape NN N
or CC N
color NN N
with IN N
the DT N
relevant JJ N
dimension NN N
shifting VBG N
according VBG N
to TO N
item NN N
context NN N
. . N

A DT N
selective JJ N
induction NN i
test NN i
then RB N
examined VBD N
context-dependent JJ N
responding NN N
in IN N
a DT N
more RBR N
complex JJ N
matching NN N
task NN N
. . N

Awareness NNP N
of IN N
the DT N
role NN N
of IN N
context NN N
was VBD N
assessed VBN N
using VBG N
a DT N
behavioral JJ i
task NN i
and CC N
explicit JJ i
questions NNS i
. . i

Experiment JJ N
1 CD N
showed VBD N
that IN N
after IN N
training VBG i
with IN N
the DT N
procedure NN N
described VBN N
by IN N
Sloutsky NNP N
and CC N
Fisher NNP N
( ( N
2008 CD N
) ) N
, , N
only RB N
a DT N
minority NN N
of IN N
adults NNS p
showed VBD N
evidence NN N
of IN N
context-dependent JJ N
responding NN N
in IN N
the DT N
selective JJ N
induction NN N
test NN N
. . N

Experiment NN N
2 CD N
used VBD N
a DT N
modified JJ i
training NN i
protocol NN i
that WDT N
promoted VBD N
attention NN N
to TO N
context VB N
cues NNS N
. . N

This DT N
led VBD N
to TO N
reliable VB N
selective JJ N
induction NN N
in IN N
a DT N
majority NN p
of IN p
adults NNS p
and CC p
a DT p
sizeable JJ p
proportion NN p
of IN p
4- JJ p
to TO p
6-year-olds NNS p
. . p

Crucially NNP N
, , N
in IN N
both DT p
age NN p
groups NNS p
, , N
selective JJ o
induction NN o
was VBD N
dependent JJ N
on IN N
awareness NN N
of IN N
context NN N
. . N

Hence NNP N
, , N
children NNS p
as RB p
young JJ p
as IN p
4 CD p
can MD N
learn VB N
to TO N
make VB N
selective JJ N
inferences NNS N
about IN N
novel JJ N
stimuli NNS N
, , N
but CC N
only RB N
when WRB N
they PRP N
are VBP N
aware JJ N
of IN N
the DT N
relevant JJ N
context NN N
cues NNS N
. . N

These DT N
results NNS N
challenge VBP N
previous JJ N
claims NNS N
that WDT N
selective JJ o
induction NN o
in IN N
children NNS p
is VBZ N
the DT N
product NN N
of IN N
implicit JJ N
learning NN N
. . N

-DOCSTART- -12834936- O O

Pethidine NNP i
versus NN i
tramadol NN i
for IN N
pain NN o
relief NN o
during IN p
labor NN p
. . p

OBJECTIVE UH N
To TO N
evaluate VB N
and CC N
compare VB N
the DT N
analgesic JJ o
efficacy NN o
and CC N
adverse JJ o
effects NNS o
of IN N
tramadol NN i
and CC N
pethidine NN i
in IN N
labor NN N
. . N

METHOD NNP N
Fifty-nine NNP p
full JJ p
term NN p
parturients NNS p
were VBD p
randomly RB p
assigned VBN p
to TO p
one CD p
of IN p
two CD p
groups NNS p
in IN p
active JJ p
labor NN p
. . p

Group NNP N
1 CD N
received VBD N
100 CD N
mg NNS N
pethidine VBP i
; : i
group NN N
2 CD N
, , N
100 CD N
mg NN N
tramadol NN i
, , N
intramuscularly RB N
. . N

Analgesic JJ o
efficacy NN o
, , o
maternal JJ o
side NN o
effects NNS o
, , o
changes NNS o
in IN o
the DT o
blood NN o
pressure NN o
, , o
heart NN o
rate NN o
, , o
and CC o
duration NN o
of IN o
labor NN o
were VBD N
assessed VBN N
. . N

RESULT NNP N
At IN N
30 CD N
and CC N
60 CD N
min NNS N
after IN N
drug NN N
administration NN N
, , N
pain VBP o
relief NN o
was VBD N
greater JJR N
in IN N
the DT N
pethidine NN i
group NN N
than IN N
in IN N
tramadol JJ i
group NN N
. . N

The DT N
incidence NN N
of IN N
nausea NN o
and CC o
fatigue NN o
was VBD N
higher RBR N
in IN N
the DT N
tramadol NN i
group NN N
. . N

Following VBG N
drug NN N
administration NN N
the DT N
decrease NN o
in IN o
systolic JJ o
and CC o
diastolic JJ o
blood NN o
pressure NN o
and CC N
the DT N
increase NN o
in IN o
heart NN o
rate NN o
were VBD N
statistically RB N
significant JJ N
in IN N
both DT N
groups NNS N
. . N

No DT N
significant JJ N
difference NN N
was VBD N
found VBN N
between IN N
the DT N
groups NNS N
when WRB N
compared VBN N
for IN N
duration NN o
of IN o
labor NN o
and CC o
Apgar NNP o
scores NNS o
. . o

None NN N
of IN N
the DT N
neonates NNS N
developed VBD N
respiratory JJ o
depression NN o
. . o

CONCLUSION NNP N
Pethidine NNP i
seems VBZ N
to TO N
be VB N
a DT N
better RBR N
alternative JJ N
than IN N
tramadol NN i
in IN N
obstetric JJ N
analgesia NN N
because IN N
of IN N
its PRP$ N
superiority NN N
in IN N
analgesic JJ o
efficacy NN o
and CC N
low JJ N
incidence NN N
of IN N
maternal JJ o
side NN o
effects NNS o
. . o

-DOCSTART- -19880586- O O

Effects NNS N
of IN N
walnut NN i
consumption NN i
on IN N
endothelial JJ o
function NN o
in IN N
type NN p
2 CD p
diabetic JJ p
subjects NNS p
: : p
a DT N
randomized VBN N
controlled VBN N
crossover RB N
trial NN N
. . N

OBJECTIVE NN N
To TO N
determine VB N
the DT N
effects NNS N
of IN N
daily JJ N
walnut NN i
consumption NN i
on IN N
endothelial JJ o
function NN o
, , o
cardiovascular JJ o
biomarkers NNS o
, , o
and CC o
anthropometric JJ o
measures NNS o
in IN N
type NN p
2 CD p
diabetic JJ p
individuals NNS p
. . p

RESEARCH NNP N
DESIGN NNP N
AND NNP N
METHODS NNP N
This DT N
study NN N
was VBD N
a DT N
randomized JJ N
, , N
controlled VBN N
, , N
single-blind NN N
, , N
crossover JJ N
trial NN N
. . N

Twenty-four JJ p
participants NNS p
with IN p
type NN p
2 CD p
diabetes NNS p
( ( p
mean JJ p
age NN p
58 CD p
years NNS p
; : p
14 CD p
women NNS p
and CC p
10 CD p
men NNS p
) ) p
were VBD N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
the DT N
two CD N
possible JJ N
sequence NN N
permutations NNS N
to TO N
receive VB N
an DT N
ad NN i
libitum NN i
diet JJ i
enriched VBD i
with IN i
56 CD i
g NNS i
( ( i
366 CD i
kcal NN i
) ) i
walnuts/day NN i
and CC i
an DT i
ad NN i
libitum NN i
diet NN i
without IN i
walnuts NNS i
for IN i
8 CD i
weeks NNS i
. . i

Subjects NNS N
underwent JJ N
endothelial JJ i
function NN i
testing VBG i
( ( N
measured VBN N
as IN N
flow-mediated JJ N
dilatation NN N
[ NNP N
FMD NNP N
] NNP N
) ) N
and CC N
assessment NN N
of IN N
cardiovascular JJ N
biomarkers NNS N
before IN N
and CC N
after IN N
each DT N
8-week JJ N
treatment NN N
phase NN N
. . N

The DT N
primary JJ N
outcome NN N
measure NN N
was VBD N
the DT N
change NN o
in IN o
FMD NNP o
after IN N
8 CD N
weeks NNS N
. . N

Secondary JJ N
outcome NN N
measures NNS N
included VBD N
changes NNS o
in IN o
plasma NN o
lipids NNS o
, , o
A1C NNP o
, , o
fasting VBG o
glucose NN o
, , o
insulin NN o
sensitivity NN o
, , o
and CC o
anthropometric JJ o
measures NNS o
. . o

RESULTS NNP N
Endothelial NNP o
function NN o
significantly RB N
improved VBN N
after IN N
consumption NN N
of IN N
a DT N
walnut-enriched JJ N
ad NN N
libitum NN N
diet JJ N
compared VBN N
with IN N
that DT N
after IN N
consumption NN N
of IN N
an DT N
ad NN N
libitum NN N
diet NN N
without IN N
walnuts NNS N
( ( N
2.2 CD N
+/- JJ N
1.7 CD N
vs. FW N
1.2 CD N
+/- JJ N
1.6 CD N
% NN N
; : N
P NNP N
= NNP N
0.04 CD N
) ) N
. . N

The DT N
walnut-enriched JJ N
diet NN N
increased VBD N
fasting VBG o
serum NN o
glucose NN o
and CC o
lowered VBD o
serum NN o
total JJ o
cholesterol NN o
and CC o
LDL NNP o
cholesterol NN o
from IN N
baseline NN N
( ( N
10.0 CD N
+/- JJ N
20.5 CD N
mg/dl NN N
, , N
P NNP N
= NNP N
0.04 CD N
; : N
-9.7 JJ N
+/- JJ N
14.5 CD N
mg/dl NN N
, , N
P NNP N
< NNP N
0.01 CD N
; : N
and CC N
-7.7 VB N
+/- JJ N
10 CD N
mg/dl NN N
, , N
P NNP N
< NNP N
0.01 CD N
, , N
respectively RB N
) ) N
, , N
although IN N
these DT N
changes NNS N
were VBD N
not RB N
significant JJ N
compared VBN N
with IN N
those DT N
for IN N
an DT N
ad NN N
libitum NN N
diet NN N
without IN N
walnuts NNS N
. . N

There EX N
were VBD N
no DT N
significant JJ N
changes NNS N
in IN N
anthropometric JJ o
measures NNS o
, , o
plasma NN o
A1C NNP o
, , o
and CC o
insulin JJ o
sensitivity NN o
. . o

CONCLUSIONS VB N
A DT N
walnut-enriched JJ N
ad NN N
libitum NN N
diet JJ N
improves VBZ N
endothelium-dependent JJ N
vasodilatation NN N
in IN N
type NN N
2 CD N
diabetic JJ N
individuals NNS N
, , N
suggesting VBG N
a DT N
potential JJ N
reduction NN N
in IN N
overall JJ N
cardiac JJ o
risk NN o
. . o

-DOCSTART- -21639907- O O

Infliximab NNP i
in IN N
ankylosing VBG N
spondylitis NN p
: : p
alone RB N
or CC N
in IN N
combination NN N
with IN N
methotrexate NN i
? . N
A NNP N
pharmacokinetic JJ N
comparative NN N
study NN N
. . N

INTRODUCTION NNP N
Methotrexate NNP i
( ( i
MTX NNP i
) ) i
has VBZ N
been VBN N
shown VBN N
to TO N
modify VB N
infliximab JJ i
pharmacokinetics NNS N
in IN N
rheumatoid JJ N
arthritis NN N
. . N

However RB N
, , N
its PRP$ N
combination NN N
with IN N
infliximab NN i
in IN N
the DT N
treatment NN N
of IN N
ankylosing VBG N
spondylitis NN N
( ( N
AS IN N
) ) N
is VBZ N
not RB N
recommended VBN N
. . N

The DT N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
examine VB N
the DT N
influence NN N
of IN N
MTX NNP i
on IN i
infliximab NN i
exposure NN N
in IN N
patients NNS p
with IN p
AS NNP p
. . p

METHODS NNP N
Patients NNPS p
with IN p
AS NNP p
patients NNS p
who WP p
had VBD p
predominantly RB p
axial JJ p
symptoms NNS p
were VBD N
randomised VBN N
to TO N
receive VB N
infliximab NN i
alone RB i
( ( N
infusions NNS N
of IN N
5 CD N
mg/kg NNS N
at IN N
weeks NNS N
0 CD N
, , N
2 CD N
, , N
6 CD N
, , N
12 CD N
and CC N
18 CD N
) ) N
or CC i
infliximab JJ i
combined VBN i
with IN i
MTX NNP i
( ( N
10 CD N
mg/week NN N
) ) N
. . N

Infliximab JJ o
concentrations NNS o
were VBD N
measured VBN N
before IN N
and CC N
2 CD N
hours NNS N
after IN N
each DT N
infusion NN N
and CC N
at IN N
1 CD N
, , N
3 CD N
, , N
4 CD N
, , N
5 CD N
, , N
8 CD N
, , N
10 CD N
, , N
14 CD N
and CC N
18 CD N
weeks NNS N
. . N

We PRP N
estimated VBD N
individual JJ o
cumulative JJ o
area NN o
under IN o
the DT o
concentration NN o
versus NN o
time NN o
curves NNS o
( ( o
AUC NNP o
) ) o
for IN N
infliximab JJ o
concentration NN o
between IN N
baseline NN N
and CC N
week NN N
18 CD N
( ( N
AUC NNP N
( ( N
0-18 NNP N
) ) N
) ) N
. . N

Clinical JJ N
and CC N
laboratory JJ N
evaluations NNS N
were VBD N
performed VBN N
at IN N
each DT N
visit NN N
. . N

The DT N
Bath NNP o
Ankylosing NNP o
Spondylitis NNP o
Disease NNP o
Activity NNP o
Index NNP o
( ( o
BASDAI NNP o
) ) o
score NN o
was VBD N
the DT N
primary JJ N
end NN N
point NN N
for IN N
clinical JJ N
response NN N
. . N

RESULTS NNP N
Twenty-six JJ p
patients NNS p
were VBD p
included VBN p
( ( N
infliximab JJ N
group NN N
: : N
n JJ N
= NN N
12 CD N
, , N
infliximab NN i
+ NNP i
MTX NNP i
group NN N
: : N
n JJ N
= NNP N
14 CD N
) ) N
, , N
and CC N
507 CD N
serum NN N
samples NNS N
were VBD N
available JJ N
for IN N
measurement NN N
of IN N
infliximab JJ o
concentration NN o
. . o

The DT N
two CD N
groups NNS N
did VBD N
not RB N
differ VB N
with IN N
regard NN N
to TO N
AUC NNP o
( ( o
0-18 CD o
) ) o
or CC N
evolution NN N
of IN N
BASDAI NNP o
scores NNS o
and CC N
biomarkers NNS N
of IN N
inflammation NN N
. . N

CONCLUSIONS VB N
The DT N
combination NN N
of IN N
MTX NNP i
and CC i
infliximab NN i
does VBZ N
not RB N
increase VB N
the DT N
exposure NN N
to TO N
infliximab VB N
over RP N
infliximab JJ i
alone RB N
in IN N
patients NNS p
with IN p
AS NNP p
. . p

TRIAL NNP N
REGISTRATION NNP N
ClinicalTrials.gov NNP N
: : N
NCT00507403 NN N
. . N

-DOCSTART- -6938012- O O

Cardiovascular JJ N
complications NNS N
to TO N
treatment NN N
of IN N
prostate NN p
cancer NN p
with IN N
estramustine JJ i
phosphate NN i
( ( i
Estracyt NNP i
) ) i
or CC i
conventional JJ i
estrogen NN i
. . i

A DT N
follow-up NN p
of IN p
212 CD p
randomized JJ p
patients NNS p
. . p

Two CD p
hundred VBD p
and CC p
twelve JJ p
patients NNS p
treated VBN p
for IN p
prostatic JJ p
cancer NN p
grade NN p
I PRP p
or CC p
II NNP p
were VBD p
investigated VBN N
for IN N
cardiovascular JJ N
complications NNS N
. . N

The DT p
patients NNS p
were VBD p
part NN p
of IN p
a DT p
multicentre NN p
study NN p
in IN p
the DT p
Stockholm NNP p
area NN p
and CC p
had VBD p
been VBN p
randomized VBN p
to TO p
treatment NN p
with IN p
either DT p
estramustine JJ i
phosphate NN i
( ( i
Estracyt NNP i
) ) i
or CC i
polyestradiol JJ i
phosphate NN i
and CC i
ethinyl JJ i
estradiol NN i
. . i

Cardiovascular JJ N
complications NNS N
categorized VBN N
as IN N
impaired JJ N
arterial JJ N
circulation NN N
including VBG N
ischemic JJ o
heart NN o
disease NN o
, , o
venous JJ o
thromboembolism NN o
, , o
cardiac JJ o
incompensation NN o
and CC o
cerebral JJ o
depression NN o
were VBD N
found VBN N
to TO N
be VB N
equally RB N
frequent JJ N
following VBG N
the DT N
two CD N
different JJ N
forms NNS N
of IN N
treatment NN N
. . N

Among IN N
the DT N
patients NNS N
getting VBG N
cardiovascular JJ N
complications NNS N
, , N
these DT N
occurred VBD N
within IN N
two CD N
months NNS N
after IN N
the DT N
start NN N
of IN N
treatment NN N
in IN N
50 CD N
% NN N
and CC N
within IN N
one CD N
year NN N
in IN N
85 CD N
% NN N
of IN N
them PRP N
. . N

There EX N
was VBD N
a DT N
statistically RB N
significant JJ N
correlation NN N
between IN N
the DT N
incidence NN o
of IN o
cardiovascular JJ o
complications NNS o
and CC o
a DT o
history NN o
of IN o
previous JJ o
cardiovascular JJ o
disease NN o
. . o

This DT N
criterion NN N
was VBD N
however RB N
in IN N
retrospect NN N
found VBN N
to TO N
predict VB N
cardiovascular JJ o
complications NNS o
in IN N
only RB N
67 CD N
of IN N
the DT N
126 CD N
patients NNS N
getting VBG N
one CD N
or CC N
several JJ N
of IN N
these DT N
complications NNS N
. . N

-DOCSTART- -23873901- O O

A DT N
randomised VBN N
controlled VBN N
trial NN N
of IN N
ranibizumab NN i
with IN i
and CC i
without IN i
ketorolac NN i
eyedrops NNS i
for IN N
exudative JJ o
age-related JJ o
macular JJ o
degeneration NN o
. . o

AIMS NNP N
To TO N
evaluate VB N
whether IN N
ketorolac NN i
eyedrops NNS i
and CC N
ranibizumab VB i
intravitreal JJ i
injections NNS i
would MD N
provide VB N
additional JJ N
benefit NN N
over IN N
ranibizumab NN i
alone RB N
in IN N
the DT N
treatment NN N
of IN N
choroidal JJ p
neovascularisation NN p
( ( p
CNV NNP p
) ) p
. . p

METHODS NNP N
This DT N
was VBD N
a DT N
pilot NN N
study NN N
of IN N
eyes NNS p
with IN p
new-onset JJ p
CNV NNP p
. . p

A NNP N
total NN p
of IN p
56 CD p
patients NNS p
were VBD p
enrolled VBN p
consecutively RB N
and CC N
randomised VBN N
in IN N
a DT N
1:1 CD N
ratio NN N
to TO N
receive VB N
combination NN N
treatment NN N
with IN N
intravitreal JJ i
ranibizumab NN i
and CC i
topical JJ i
ketorolac NN i
( ( N
group NN N
1 CD N
) ) N
or CC N
ranibizumab VB i
alone RB i
( ( N
group NN N
2 CD N
) ) N
. . N

All DT N
patients NNS N
received VBN N
monthly JJ N
0.5-mg JJ N
ranibizumab NN i
intravitreal NN i
injections NNS i
for IN N
3 CD N
months NNS N
, , N
after IN N
which WDT N
monthly JJ N
injections NNS N
were VBD N
administered VBN N
in IN N
accordance NN N
with IN N
the DT N
standard NN N
of IN N
care NN N
. . N

Group NNP N
1 CD N
patients NNS N
also RB N
self-administered JJ N
one CD N
drop NN N
of IN N
ketorolac NN i
three CD N
times NNS N
a DT N
day NN N
for IN N
6 CD N
months NNS N
. . N

All DT N
patients NNS N
were VBD N
followed VBN N
up RP N
for IN N
6 CD N
months NNS N
. . N

RESULTS NNP N
At IN N
6 CD N
months NNS N
, , N
both DT N
groups NNS N
showed VBD N
a DT N
significant JJ N
improvement NN N
in IN N
best-corrected JJ o
visual JJ o
acuity NN o
( ( N
both DT N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
. . N

The DT N
two CD N
treatments NNS N
did VBD N
not RB N
show VB N
significant JJ N
differences NNS N
in IN N
terms NNS N
of IN N
the DT N
number NN o
of IN o
ranibizumab JJ o
injections NNS o
required VBN o
. . o

However RB N
, , N
the DT N
mean JJ N
6-month JJ o
change NN o
in IN o
central JJ o
macular JJ o
thickness NN o
( ( o
CMT NNP o
) ) o
in IN N
the DT N
combination NN N
group NN N
was VBD N
-124 VBN N
?m NNP N
( ( N
-29.7 CD N
% NN N
; : N
p CC N
< VB N
0.001 CD N
) ) N
, , N
while IN N
in IN N
the DT i
ranibizumab-only JJ i
group NN N
, , N
the DT N
change NN N
was VBD N
-86.9 JJ N
?m NNP N
( ( N
-19.5 CD N
% NN N
; : N
p=0.001 CC N
) ) N
; : N
thus RB N
, , N
the DT i
combination NN i
treatment NN i
resulted VBD i
in IN N
a DT N
greater JJR N
reduction NN N
( ( N
p=0.003 NN N
) ) N
. . N

The DT i
combination NN i
treatment NN i
had VBD i
no DT N
adverse JJ o
effects NNS o
. . o

CONCLUSIONS VB N
This DT N
pilot NN N
study NN N
is VBZ N
the DT N
first JJ N
to TO N
prospectively RB N
investigate VB N
the DT o
efficacy NN o
and CC o
safety NN o
of IN o
a DT N
combination NN N
of IN N
0.45 CD i
% NN i
ketorolac NN i
eyedrops VBZ i
three CD i
times NNS N
a DT N
day NN N
and CC i
intravitreal VB i
ranibizumab JJ i
injections NNS i
in IN i
patients NNS p
with IN p
CNV NNP p
, , p
and CC N
suggests VBZ N
that DT N
topical JJ i
ketorolac NN i
supplements VBZ i
the DT N
activity NN N
of IN N
intravitreal NN i
ranibizumab NN i
in IN i
reducing VBG o
CMT NNP o
in IN o
CNV NNP N
. . N

-DOCSTART- -8015776- O O

Laser-aided JJ i
external JJ i
drainage NN i
of IN p
subretinal JJ p
fluid NN p
: : p
prospective JJ N
randomized VBN N
comparison NN N
with IN N
needle JJ N
drainage NN N
. . N

In IN N
a DT N
prospective JJ N
randomized VBN N
study NN N
of IN N
50 CD p
consecutive JJ p
eyes NNS p
, , N
we PRP N
compared VBN N
the DT N
safety NN o
and CC o
efficacy NN o
of IN N
draining VBG N
subretinal JJ i
fluid NN i
transchoroidally RB i
in IN N
primary JJ N
scleral JJ N
buckling NN N
for IN N
rhegmatogenous JJ N
retinal JJ N
detachment NN N
using VBG N
a DT N
needle JJ i
, , N
with IN N
the DT N
safety NN o
and CC o
efficacy NN o
of IN N
the DT N
same JJ N
procedure NN N
using VBG N
an DT N
angulated VBN i
endolaser NN i
probe NN i
set VBN N
at IN N
1 CD N
W NNP N
for IN N
0.2 CD N
seconds NNS N
, , N
using VBG N
an DT N
average NN N
of IN N
2.4 CD N
laser NN N
burns NNS N
. . N

There EX N
were VBD N
no DT N
significant JJ N
complications NNS o
associated VBN N
with IN N
the DT N
laser-aided JJ i
drainage NN i
procedures NNS N
( ( N
25 CD N
eyes NNS N
) ) N
. . N

In IN N
the DT N
transchoroidal NN i
needle JJ i
drainage NN i
procedures NNS N
( ( N
25 CD N
eyes NNS N
) ) N
, , N
subretinal JJ o
hemorrhage NN o
occurred VBD N
in IN N
three CD N
eyes NNS N
and CC N
retinal JJ N
incarceration NN N
in IN N
one CD N
. . N

Thus VB N
, , N
though IN N
our PRP$ N
numbers NNS N
are VBP N
small JJ N
, , N
there EX N
appears VBZ N
to TO N
be VB N
some DT N
advantage NN N
of IN N
laser-assisted JJ N
drainage NN N
in IN N
terms NNS N
of IN N
a DT N
lower JJR N
incidence NN o
of IN o
complications NNS o
. . o

-DOCSTART- -20538165- O O

A DT N
first-in-man JJ N
, , N
randomized VBN N
, , N
placebo-controlled JJ i
study NN N
to TO N
evaluate VB N
the DT N
safety NN o
and CC o
feasibility NN o
of IN N
autologous JJ i
delipidated VBN i
high-density NN i
lipoprotein NN i
plasma NN i
infusions NNS i
in IN N
patients NNS p
with IN p
acute JJ p
coronary JJ p
syndrome NN p
. . p

OBJECTIVES CC N
This DT N
study NN N
aimed VBD N
to TO N
determine VB N
whether IN N
serial JJ i
autologous JJ i
infusions NNS i
of IN i
selective JJ i
high-density NN i
lipoprotein NN i
( ( i
HDL NNP i
) ) i
delipidated VBD i
plasma NN i
are VBP N
feasible JJ o
and CC N
well RB N
tolerated VBN o
in IN N
patients NNS p
with IN p
acute JJ p
coronary JJ p
syndrome NN p
( ( p
ACS NNP p
) ) p
. . p

BACKGROUND NNP N
Low NNP N
HDL NNP N
is VBZ N
associated VBN N
with IN N
increased JJ N
risk NN N
of IN N
cardiovascular JJ N
disease NN N
. . N

Plasma NNP N
selective JJ N
delipidation NN N
converts NNS N
alphaHDL VBP N
to TO N
prebeta-like JJ N
HDL NNP N
, , N
the DT N
most RBS N
effective JJ N
form NN N
of IN N
HDL NNP N
for IN N
lipid JJ N
removal NN N
from IN N
arterial JJ N
plaques NNS N
. . N

METHODS NNP N
ACS NNP p
patients NNS p
undergoing VBG p
cardiac JJ p
catheterization NN p
with IN p
> NNP p
or=1 VBP p
nonobstructive JJ p
native JJ p
coronary JJ p
artery NN p
atheroma NN p
were VBD N
randomized VBN N
to TO N
either DT N
7 CD N
weekly JJ N
HDL NNP i
selective NN i
delipidated VBD i
or CC i
control VB i
plasma JJ i
apheresis/reinfusions NNS i
. . i

Patients NNS N
underwent JJ N
intravascular JJ o
ultrasound NN o
( ( o
IVUS NNP o
) ) o
evaluation NN o
of IN N
the DT N
target NN N
vessel NN N
during IN N
the DT N
catheterization NN N
for IN N
ACS NNP N
and CC N
up RB N
to TO N
14 CD N
days NNS N
following VBG N
the DT N
final JJ N
apheresis/reinfusion NN i
session NN N
. . N

2-D JJ N
gel JJ N
electrophoresis NN N
of IN N
delipidated JJ N
plasmas NN N
established VBN N
successful JJ N
conversion NN N
of IN N
alphaHDL NN N
to TO N
prebeta-like JJ N
HDL NNP N
. . N

The DT N
trial NN N
was VBD N
complete JJ N
with IN N
28 CD p
patients NNS p
randomized VBN N
. . N

RESULTS NNP N
All DT N
reinfusion NN N
sessions NNS N
were VBD N
tolerated VBN o
well RB N
by IN N
all DT N
patients NNS N
. . N

The DT N
levels NNS o
of IN o
prebeta-like JJ o
HDL NNP o
and CC o
alphaHDL NN o
in IN N
the DT N
delipidated JJ N
plasma NN N
converted VBD N
from IN N
5.6 CD N
% NN N
to TO N
79.1 CD N
% NN N
and CC N
92.8 CD N
% NN N
to TO N
20.9 CD N
% NN N
, , N
respectively RB N
. . N

The DT N
IVUS NNP N
data NNS N
demonstrated VBD N
a DT N
numeric JJ N
trend NN N
toward IN N
regression NN N
in IN N
the DT N
total JJ N
atheroma NN o
volume NN o
of IN N
-12.18 JJ N
+/- JJ N
36.75 CD N
mm NN N
( ( N
3 CD N
) ) N
in IN N
the DT N
delipidated JJ N
group NN N
versus VBD N
an DT N
increase NN N
of IN N
total JJ o
atheroma JJ o
volume NN o
of IN N
2.80 CD N
+/- JJ N
21.25 CD N
mm NN N
( ( N
3 CD N
) ) N
in IN N
the DT N
control NN N
group NN N
( ( N
p JJ N
= NNP N
0.268 CD N
) ) N
. . N

CONCLUSIONS NNP N
In IN p
ACS NNP p
patients NNS p
, , N
serial JJ N
autologous JJ N
infusions NNS N
of IN N
selective JJ i
HDL NNP i
delipidated VBD i
plasma NNS i
are VBP N
clinically RB o
feasible JJ o
and CC N
well RB N
tolerated VBN o
. . o

This DT N
therapy NN N
may MD N
offer VB N
a DT N
novel JJ N
adjunct JJ N
treatment NN N
for IN N
patients NNS p
presenting VBG p
with IN p
ACS NNP p
. . p

Further NNP N
study NN N
will MD N
be VB N
needed VBN N
to TO N
determine VB N
its PRP$ N
ability NN N
to TO N
reduce VB N
clinical JJ o
cardiovascular JJ o
events NNS o
. . o

-DOCSTART- -24919961- O O

Video-feedback JJ i
Intervention NNP i
to TO N
promote VB N
Positive NNP N
Parenting NNP N
adapted VBD N
to TO N
Autism NNP N
( ( N
VIPP-AUTI NNP N
) ) N
: : N
A DT N
randomized NN N
controlled VBN N
trial NN N
. . N

In IN N
a DT N
randomized NN N
controlled VBN N
trial NN N
, , N
we PRP N
evaluated VBD N
the DT N
early JJ N
intervention NN N
program NN N
Video-feedback NNP i
Intervention NNP i
to TO N
promote VB N
Positive NNP p
Parenting NNP p
adapted VBD p
to TO p
Autism NNP p
( ( p
VIPP-AUTI NNP p
) ) p
with IN p
78 CD p
primary JJ p
caregivers NNS p
and CC p
their PRP$ p
child NN p
( ( p
16-61 JJ p
months NNS p
) ) p
with IN p
Autism NNP p
Spectrum NNP p
Disorder NNP p
. . p

VIPP-AUTI NNP i
is VBZ N
a DT N
brief JJ N
attachment-based JJ i
intervention NN i
program NN i
, , N
focusing VBG N
on IN N
improving VBG N
parent-child JJ o
interaction NN o
and CC N
reducing VBG N
the DT N
child NN o
's POS o
individual JJ o
Autism NNP o
Spectrum NNP o
Disorder-related NNP o
symptomatology NN o
in IN N
five CD N
home NN N
visits NNS N
. . N

VIPP-AUTI NNP i
, , N
as IN N
compared VBN N
with IN N
usual JJ N
care NN N
, , N
demonstrated VBD N
efficacy NN o
in IN N
reducing VBG N
parental JJ N
intrusiveness NN N
. . N

Moreover RB N
, , N
parents NNS N
who WP N
received VBD N
VIPP-AUTI NNP i
showed VBD N
increased JJ o
feelings NNS o
of IN o
self-efficacy NN o
in IN N
child NN N
rearing NN N
. . N

No DT o
significant JJ N
group NN N
differences NNS N
were VBD N
found VBN N
on IN N
other JJ N
aspects NNS N
of IN N
parent-child JJ o
interaction NN o
or CC o
on IN o
child JJ o
play NN o
behavior NN o
. . o

At IN N
3-months JJ N
follow-up NN N
, , N
intervention NN N
effects NNS N
were VBD N
found VBN N
on IN N
child-initiated JJ o
joint JJ o
attention NN o
skills NNS o
, , N
not RB N
mediated VBN N
by IN N
intervention NN N
effects NNS N
on IN N
parenting VBG N
. . N

Implementation NN N
of IN N
VIPP-AUTI NNP i
in IN N
clinical JJ N
practice NN N
is VBZ N
facilitated VBN N
by IN N
the DT N
use NN N
of IN N
a DT N
detailed JJ N
manual NN N
and CC N
a DT N
relatively RB N
brief JJ N
training NN N
of IN N
interveners NNS N
. . N

-DOCSTART- -3900301- O O

Chemotherapy NN i
with IN i
cyclophosphamide NN i
, , i
doxorubicin NN i
, , i
vincristine NN i
, , i
and CC i
prednisone VB i
alone RB i
or CC i
with IN i
levamisole JJ i
or CC i
with IN i
levamisole JJ i
plus CC i
BCG NNP i
for IN i
malignant JJ N
lymphoma NN N
: : N
a DT N
Southwest NNP N
Oncology NNP N
Group NNP N
Study NNP N
. . N

Between NNP N
1977 CD N
and CC N
1983 CD N
the DT N
Southwest NNP N
Oncology NNP N
Group NNP N
( ( N
SWOG NNP N
) ) N
evaluated VBD N
chemotherapy NN i
alone RB i
( ( i
cyclophosphamide JJ i
, , i
doxorubicin NN i
, , i
vincristine NN i
, , i
prednisone NN i
; : i
CHOP NNP i
) ) i
or CC N
chemoimmunotherapy NN i
( ( i
CHOP-levamisole JJ i
or CC i
CHOP-levamisole-BCG JJ i
) ) i
in IN N
a DT N
randomized JJ N
prospective JJ N
clinical JJ N
trial NN N
involving VBG N
715 CD p
eligible JJ p
patients NNS p
with IN p
all DT p
types NNS p
of IN p
malignant JJ p
lymphoma NN p
( ( p
ML NNP p
) ) p
. . p

Of IN N
281 CD p
evaluable JJ p
patients NNS p
with IN p
favorable JJ p
histologic JJ p
types NNS p
of IN p
ML NNP p
, , N
171 CD N
( ( N
61 CD N
% NN N
) ) N
achieved VBD N
complete JJ o
remission NN o
( ( o
CR NNP o
) ) o
and CC N
there EX N
was VBD N
no DT N
difference NN N
in IN N
CR NNP o
rate NN o
, , o
CR NNP o
duration NN o
, , o
or CC o
survival NN o
according VBG N
to TO N
the DT N
type NN N
of IN N
initial JJ N
treatment NN N
. . N

Of IN N
388 CD p
evaluable JJ p
patients NNS p
with IN p
unfavorable JJ p
histologic JJ p
types NNS p
of IN p
ML NNP p
, , N
194 CD N
( ( N
50 CD N
% NN N
) ) N
achieved VBD N
CR NNP o
. . o

Levamisole NNP i
appeared VBD N
to TO N
adversely RB N
affect VB N
CR NNP o
rates NNS o
in IN N
nodular JJ N
mixed JJ N
and CC N
nodular JJ N
large-cell NN N
lymphoma NN N
and CC N
CR NNP o
duration NN o
in IN N
patients NNS N
with IN N
unfavorable JJ N
histology NN N
ML NNP N
. . N

Chemoimmunotherapy NNP i
with IN i
levamisole JJ i
or CC i
levamisole-BCG JJ i
offers NNS N
no DT N
advantage NN N
in IN N
terms NNS N
of IN N
CR NNP o
rates NNS o
, , o
CR NNP o
duration NN o
, , o
or CC o
survival NN o
compared VBN N
to TO N
CHOP NNP i
chemotherapy NN i
alone RB N
, , N
and CC N
levamisole NN i
may MD N
have VB N
had VBD N
an DT N
adverse JJ N
impact NN N
on IN N
outcome NN N
in IN N
certain JJ N
subtypes NNS N
of IN N
ML NNP N
. . N

-DOCSTART- -24213956- O O

Combining VBG N
afferent JJ i
stimulation NN i
and CC i
mirror NN i
therapy NN i
for IN N
rehabilitating VBG N
motor NN o
function NN o
, , o
motor NN o
control NN o
, , o
ambulation NN o
, , o
and CC o
daily JJ o
functions NNS o
after IN o
stroke NN o
. . o

BACKGROUND NNP N
Mirror NNP i
therapy NN i
( ( i
MT NNP i
) ) i
and CC i
mesh JJ i
glove NN i
( ( i
MG NNP i
) ) i
afferent NN i
stimulation NN i
may MD N
be VB N
effective JJ N
in IN N
reducing VBG N
motor NN N
impairment NN N
after IN N
stroke NN N
. . N

A DT N
hybrid JJ N
intervention NN N
of IN N
MT NNP i
combined VBD i
with IN i
MG NNP i
( ( i
MT NNP i
+ NNP i
MG NNP i
) ) i
may MD N
broaden VB N
aspects NNS N
of IN N
treatment NN N
benefits NNS N
. . N

OBJECTIVE NNP N
To TO N
demonstrate VB N
the DT N
comparative JJ N
effects NNS N
of IN N
MG NNP i
+ NNP i
MT NNP i
, , i
MT NNP i
, , N
and CC N
a DT N
control NN i
treatment NN i
( ( i
CT NNP i
) ) i
on IN N
the DT N
outcomes NNS N
of IN N
motor NN N
impairments NNS N
, , N
manual JJ N
dexterity NN N
, , N
ambulation NN N
function NN N
, , N
motor NN N
control NN N
, , N
and CC N
daily JJ N
function NN N
. . N

METHODS NNP N
Forty-three JJ p
chronic JJ p
stroke NN p
patients NNS p
with IN p
mild JJ p
to TO p
moderate VB p
upper JJ p
extremity NN p
impairment NN p
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
MT NNP i
+ NNP i
MG NNP i
, , i
MT NNP i
, , N
or CC N
CT NNP i
for IN N
1.5 CD N
hours/day NN N
, , N
5 CD N
days/week NN N
for IN N
4 CD N
weeks NNS N
. . N

Outcome NNP N
measures NNS N
were VBD N
the DT N
Fugl-Meyer NNP o
Assessment NNP o
( ( o
FMA NNP o
) ) o
and CC o
muscle NN o
tone NN o
measured VBN o
by IN o
Myoton-3 NNP o
for IN o
motor NN o
impairment NN o
and CC N
the DT N
Box NNP o
and CC o
Block NNP o
Test NNP o
( ( o
BBT NNP o
) ) o
and CC N
10-Meter JJ o
Walk NNP o
Test NNP o
( ( o
10 CD o
MWT NNP o
) ) o
for IN N
motor NN N
function NN N
. . N

Secondary JJ N
outcomes NNS N
included VBD N
kinematic JJ o
parameters NNS o
for IN o
motor NN o
control NN o
and CC N
the DT N
Motor NNP o
Activity NNP o
Log NNP o
and CC N
ABILHAND NNP o
Questionnaire NNP o
for IN o
daily JJ o
function NN o
. . o

RESULTS NNP N
FMA NNP o
total JJ o
scores NNS o
were VBD N
significantly RB N
higher JJR N
and CC N
synergistic JJ o
shoulder NN o
abduction NN o
during IN o
reach NN o
was VBD N
less RBR N
in IN N
the DT N
MT NNP i
+ NNP i
MG NNP i
and CC N
MT NNP i
groups NNS N
compared VBN N
with IN N
the DT N
CT NNP i
group NN N
. . N

Performance NN N
on IN N
the DT N
BBT NNP o
and CC N
the DT N
10 CD o
MWT NNP o
( ( N
velocity NN N
and CC N
stride JJ N
length NN N
in IN N
self-paced JJ N
task NN N
and CC N
velocity NN N
in IN N
as-quickly-as-possible JJ N
task NN N
) ) N
were VBD N
improved VBN N
after IN N
MT NNP i
+ NNP i
MG NNP i
compared VBN N
with IN N
MT NNP i
. . i

CONCLUSIONS NNP N
MT NNP i
+ NNP i
MG NNP i
improved VBD N
manual JJ o
dexterity NN o
and CC o
ambulation NN o
. . o

MT NNP i
+ NNP i
MG NNP i
and CC N
MT NNP i
reduced VBD N
motor NN o
impairment NN o
and CC o
synergistic JJ o
shoulder NN o
abduction NN o
more JJR N
than IN N
CT. NNP i
Future NNP N
studies NNS N
may MD N
integrate VB N
functional JJ N
task NN N
practice NN N
into IN N
treatments NNS N
to TO N
enhance VB N
functional JJ N
outcomes NNS N
in IN N
patients NNS N
with IN N
various JJ N
levels NNS N
of IN N
motor NN N
severity NN N
. . N

The DT N
long-term JJ N
effects NNS N
of IN N
MG NNP i
+ NNP i
MT NNP i
remain VBP N
to TO N
be VB N
evaluated VBN N
. . N

-DOCSTART- -19910194- O O

Conservative JJ N
surgery NN N
with IN N
and CC N
without IN N
radiotherapy NN N
in IN N
elderly JJ p
patients NNS p
with IN p
early-stage JJ p
breast NN p
cancer NN p
: : p
a DT N
prospective JJ N
randomised VBN N
multicentre JJ N
trial NN N
. . N

Breast NNP i
conserving VBG i
therapy NN i
( ( i
BCT NNP i
) ) i
including VBG N
postoperative JJ N
irradiation NN N
of IN N
the DT N
remaining VBG N
breast NN N
tissue NN N
is VBZ N
generally RB N
accepted VBN N
as IN N
the DT N
best JJS N
treatment NN N
for IN N
the DT N
majority NN N
of IN N
patients NNS p
with IN p
early-stage JJ p
breast NN p
cancer NN p
. . p

The DT N
question NN N
is VBZ N
whether IN N
there EX N
is VBZ N
a DT N
necessity NN N
for IN N
irradiating VBG N
all DT N
patients NNS N
. . N

Between JJ p
2001 CD p
and CC p
2005 CD p
, , p
749 CD p
women NNS p
aged VBN p
55-75 JJ p
years NNS p
with IN p
infiltrating VBG p
breast NN p
carcinoma NN p
were VBD N
randomly RB N
assigned VBN N
to TO N
breast VB i
conservative JJ i
surgery NN i
, , i
with IN i
or CC i
without IN i
radiotherapy NN i
( ( N
RT NNP N
) ) N
, , N
to TO N
evaluate VB N
the DT N
incidence NN o
of IN o
in-breast JJ o
recurrence NN o
( ( o
IBR NNP o
) ) o
. . o

After IN N
5 CD N
years NNS N
of IN N
median JJ N
follow-up NN N
, , N
the DT N
cumulative JJ o
incidence NN o
of IN o
IBR NNP o
was VBD N
2.5 CD N
% NN N
in IN N
the DT N
surgery-only JJ N
arm NN N
and CC N
0.7 CD N
% NN N
in IN N
the DT N
surgery NN N
plus CC N
RT NNP N
arm NN N
. . N

There EX N
are VBP N
no DT o
differences NNS o
in IN N
terms NNS N
of IN N
overall JJ o
survival NN o
and CC o
distant JJ o
disease-free JJ o
survival NN o
. . o

The DT N
preliminary JJ N
evaluation NN N
suggests VBZ N
that IN N
breast NN N
irradiation NN N
after IN N
conservative JJ N
surgery NN N
can MD N
be VB N
avoided VBN N
without IN N
exposing VBG N
these DT N
patients NNS N
to TO N
an DT N
increased VBN N
risk NN o
of IN o
distant-disease JJ o
recurrence NN o
. . o

Prolonged VBN N
follow-up NN N
will MD N
further RBR N
clarify VB N
the DT N
possible JJ N
risks NNS N
and CC N
late JJ N
sequelae NN N
potentially RB N
induced VBN N
by IN N
breast NN N
RT NNP N
. . N

-DOCSTART- -18420953- O O

Effect NN N
of IN N
prophylactic JJ i
transluminal JJ i
balloon NN i
angioplasty NN i
on IN N
cerebral JJ o
vasospasm NN o
and CC N
outcome NN N
in IN N
patients NNS p
with IN p
Fisher NNP p
grade NN p
III NNP p
subarachnoid JJ p
hemorrhage NN p
: : p
results NNS N
of IN N
a DT N
phase NN N
II NNP N
multicenter NN N
, , N
randomized VBN N
, , N
clinical JJ N
trial NN N
. . N

BACKGROUND NNP N
AND CC N
PURPOSE NNP N
Cerebral NNP N
vasospasm NN N
continues VBZ N
to TO N
be VB N
a DT N
major JJ N
cause NN N
of IN N
poor JJ N
outcome NN N
in IN N
patients NNS p
with IN p
ruptured JJ p
aneurysms NNS p
. . p

Prophylactic JJ i
Transluminal NNP i
Balloon NNP i
Angioplasty NNP i
( ( i
pTBA NN i
) ) i
appeared VBD N
to TO N
prevent VB N
delayed JJ o
ischemic JJ o
neurological JJ o
deficit NN o
in IN N
a DT N
pilot NN N
study NN N
. . N

A DT N
phase NN N
II NNP N
multicenter NN N
randomized VBD N
clinical JJ N
trial NN N
was VBD N
subsequently RB N
designed VBN N
. . N

METHODS NNP N
One CD p
hundred CD p
and CC p
seventy JJ p
patients NNS p
with IN p
Fisher NNP p
Grade NNP p
III NNP p
subarachnoid JJ p
hemorrhage NN p
were VBD p
enrolled VBN p
in IN p
the DT p
study NN p
. . p

Of IN N
these DT N
, , N
85 CD N
patients NNS N
were VBD N
randomized VBN N
to TO N
the DT N
treatment NN N
group NN N
and CC N
underwent JJ N
pTBA NN i
within IN N
96 CD N
hours NNS N
after IN N
subarachnoid JJ N
hemorrhage NN N
. . N

Main NNP N
end NN N
points NNS N
of IN N
the DT N
study NN N
included VBD N
the DT N
3-month JJ o
dichotomized JJ o
Glasgow NNP o
Outcome NNP o
Score NNP o
( ( o
GOS NNP o
) ) o
, , o
development NN o
of IN o
delayed JJ o
ischemic JJ o
neurological JJ o
deficit NN o
( ( o
DIND NNP o
) ) o
, , o
occurrence NN o
of IN o
Transcranial NNP o
Doppler NNP o
( ( o
TCD NNP o
) ) o
vasospasm NN o
, , o
and CC o
length NN o
of IN o
stay NN o
in IN o
the DT o
ICU NNP o
and CC N
hospital NN N
. . N

RESULTS VB N
The DT N
incidence NN o
of IN o
DIND NNP o
was VBD N
lower RBR N
in IN N
the DT N
pTBA NN i
group NN N
( ( N
P=0.30 NNP N
) ) N
and CC N
fewer JJR N
patients NNS N
required VBN N
therapeutic JJ N
angioplasty NN i
to TO N
treat VB N
DIND NNP N
( ( N
P=0.03 NNP N
) ) N
. . N

Overall JJ N
pTBA NN o
resulted VBD N
in IN N
an DT N
absolute NN N
risk NN o
reduction NN o
of IN N
5.9 CD N
% NN N
and CC N
a DT N
relative JJ o
risk NN o
reduction NN o
of IN N
10.4 CD N
% NN N
unfavorable JJ N
outcome NN N
( ( N
P=0.54 NNP N
) ) N
. . N

Good JJ N
grade NN N
patients NNS N
had VBD N
absolute JJ o
and CC o
relative JJ o
risk NN o
reductions NNS o
of IN N
respectively RB N
9.5 CD N
and CC N
29.4 CD N
% NN N
( ( N
P=0.73 NNP N
) ) N
. . N

Length NNP o
of IN o
stay NN o
in IN o
ICU NNP o
and CC N
hospital NN N
was VBD N
similar JJ N
in IN N
both DT N
groups NNS N
. . N

Four CD N
patients NNS N
had VBD N
a DT N
procedure-related JJ o
vessel NN o
perforation NN o
, , N
of IN N
which WDT N
three CD N
patients NNS N
died VBD N
. . N

CONCLUSIONS NNP N
While IN N
the DT N
trial NN N
is VBZ N
unsuccessful JJ N
as IN N
defined VBN N
by IN N
the DT N
primary JJ N
end NN N
point NN N
( ( N
GOS NNP N
) ) N
, , N
proof NN N
of IN N
concept NN N
is VBZ N
confirmed VBN N
by IN N
these DT N
results NNS N
. . N

Fewer JJR N
patients NNS N
tend VBP N
to TO N
develop VB N
vasospasm NN o
after IN N
treatment NN N
with IN N
pTBA NN i
and CC N
there EX N
is VBZ N
a DT N
statistically RB N
significantly RB N
decreased VBN N
need NN o
for IN o
therapeutic JJ o
angioplasty NN o
. . o

pTBA NN i
does VBZ N
not RB N
improve VB N
the DT N
poor JJ N
outcome NN N
of IN N
patients NNS p
with IN p
Fisher NNP p
grade NN p
III NNP p
subarachnoid NN p
hemorrhage NN p
. . p

-DOCSTART- -3710012- O O

Acute NNP i
reduction NN i
of IN i
arterial JJ i
blood NN i
pressure NN i
reduces VBZ N
urinary JJ o
albumin NN o
excretion NN o
in IN N
type NN p
1 CD p
( ( p
insulin-dependent NN p
) ) p
diabetic JJ p
patients NNS p
with IN p
incipient JJ p
nephropathy NN p
. . p

The DT N
effect NN N
of IN N
an DT N
acute JJ i
reduction NN i
in IN i
arterial JJ i
blood NN i
pressure NN i
upon IN N
kidney NN o
function NN o
was VBD N
studied VBN N
in IN N
12 CD p
patients NNS p
with IN p
Type NNP p
1 CD p
( ( p
insulin-dependent NN p
) ) p
diabetes VBZ p
and CC p
incipient JJ p
nephropathy NN p
( ( p
persistent JJ p
microalbuminuria NN p
) ) p
. . p

Renal JJ o
function NN o
was VBD N
assessed VBN N
by IN N
measurement NN N
of IN N
the DT N
glomerular JJ o
filtration NN o
rate NN o
( ( N
single JJ N
bolus IN N
51Cr-EDTA JJ N
technique NN N
) ) N
and CC N
by IN N
the DT N
urinary JJ o
albumin JJ o
excretion NN o
rate NN o
( ( o
radioimmunoassay NN o
) ) o
. . o

The DT N
study NN N
was VBD N
performed VBN N
twice RB N
within IN N
2 CD N
weeks NNS N
, , N
with IN N
the DT N
patients NNS N
receiving VBG N
a DT N
slow JJ i
intravenous JJ i
injection NN i
of IN N
either DT N
clonidine NN i
( ( N
225 CD N
micrograms NNS N
) ) N
or CC N
saline NN i
( ( N
154 CD N
mmol/l NN N
) ) N
in IN N
random NN N
order NN N
. . N

Clonidine NNP i
reduced VBD N
arterial JJ o
blood NN o
pressure NN o
from IN N
125/79 CD N
+/- JJ N
13/8 CD N
to TO N
104/68 CD N
+/- JJ N
9/7 CD N
mmHg NN N
( ( N
p NN N
less JJR N
than IN N
0.01 CD N
) ) N
, , N
urinary JJ o
albumin JJ o
excretion NN o
rate NN o
from IN N
68 CD N
( ( N
31-369 JJ N
) ) N
to TO N
46 CD N
( ( N
6-200 CD N
) ) N
micrograms/min NN N
( ( N
median JJ N
and CC N
range NN N
) ) N
( ( N
p NN N
less JJR N
than IN N
0.01 CD N
) ) N
, , N
and CC N
fractional JJ o
clearance NN o
of IN o
albumin NN o
in IN N
all DT N
patients NNS N
( ( N
median JJ N
29 CD N
% NN N
) ) N
( ( N
p NN N
less JJR N
than IN N
0.01 CD N
) ) N
. . N

Glomerular JJ o
filtration NN o
rate NN o
was VBD N
110 CD N
+/- JJ N
11 CD N
before IN N
and CC N
106 CD N
+/- JJ N
13 CD N
ml/min/1.73 NN N
m2 NN N
after IN N
clonidine JJ i
injection NN N
. . N

The DT N
blood NN o
glucose JJ o
concentration NN o
was VBD N
15 CD N
+/- JJ N
4 CD N
mmol/l NN N
before IN N
and CC N
14 CD N
+/- JJ N
5 CD N
mmol/l NN N
after IN N
clonidine JJ i
injection NN N
. . N

In IN N
agreement NN N
with IN N
findings NNS N
in IN N
animal JJ N
studies NNS N
, , N
our PRP$ N
results NNS N
suggest VBP N
that IN N
microalbuminuria NN N
is VBZ N
to TO N
a DT N
large JJ N
extent NN N
pressure-dependent NN N
, , N
probably RB N
because IN N
of IN N
glomerular JJ N
hypertension NN N
, , N
and CC N
that DT N
autoregulation NN N
of IN N
glomerular JJ o
filtration NN o
rate NN o
is VBZ N
normal JJ N
in IN N
most JJS N
patients NNS p
with IN p
incipient JJ p
diabetic JJ p
nephropathy NN p
. . p

-DOCSTART- -16399263- O O

Playing VBG N
on IN N
the DT N
typewriter NN N
, , N
typing VBG N
on IN N
the DT N
piano NN N
: : N
manipulation NN N
knowledge NN N
of IN N
objects NNS N
. . N

Two CD N
experiments NNS N
investigated VBD N
sensory/motor-based JJ o
functional JJ o
knowledge NN o
of IN p
man-made JJ p
objects NNS p
: : p
manipulation NN N
features NNS N
associated VBN N
with IN N
the DT N
actual JJ N
usage NN N
of IN N
objects NNS N
. . N

In IN N
Experiment JJ N
1 CD N
, , N
a DT N
series NN N
of IN N
prime-target JJ N
pairs NNS N
was VBD N
presented VBN N
auditorily RB N
, , N
and CC N
participants NNS p
were VBD N
asked VBN N
to TO N
make VB N
a DT N
lexical JJ i
decision NN i
on IN N
the DT N
target NN N
word NN N
. . N

Participants NNS p
made VBD N
a DT N
significantly RB N
faster JJR N
decision NN o
about IN N
the DT N
target NN i
word NN i
( ( N
e.g NN N
. . N

'typewriter CC N
' POS N
) ) N
following VBG N
a DT N
related JJ N
prime NN N
that WDT N
shared VBD N
manipulation NN N
features NNS N
with IN N
the DT N
target NN N
( ( N
e.g JJ N
. . N

'piano CC N
' POS N
) ) N
than IN N
an DT N
unrelated JJ N
prime NN N
( ( N
e.g NN N
. . N

'blanket CC N
' POS N
) ) N
. . N

In IN N
Experiment JJ N
2 CD N
, , N
participants NNS p
' POS p
eye NN N
movements NNS N
were VBD N
monitored VBN N
when WRB N
they PRP N
viewed VBD N
a DT N
visual JJ i
display NN i
on IN i
a DT i
computer NN i
screen NN i
while IN i
listening VBG i
to TO i
a DT i
concurrent JJ i
auditory NN i
input NN i
. . i

Participants NNS p
were VBD N
instructed VBN N
to TO N
simply RB N
identify VB N
the DT N
auditory NN N
input NN N
and CC N
touch VB N
the DT N
corresponding JJ N
object NN N
on IN N
the DT N
computer NN N
display NN N
. . N

Participants NNS p
fixated VBD o
an DT N
object JJ N
picture NN N
( ( N
e.g JJ N
. . N

typewriter NN N
) ) N
related VBN N
to TO N
a DT N
target NN N
word NN N
( ( N
e.g NN N
. . N

'piano CC N
' POS N
) ) N
significantly RB N
more RBR N
often RB N
than IN N
an DT N
unrelated JJ N
object JJ N
picture NN N
( ( N
e.g JJ N
. . N

bucket NN N
) ) N
as RB N
well RB N
as IN N
a DT N
visually RB N
matched VBN N
control NN N
( ( N
e.g JJ N
. . N

couch NN N
) ) N
. . N

Results NNS N
of IN N
the DT N
two CD N
experiments NNS N
suggest VBP N
that IN N
manipulation NN o
knowledge NN o
of IN o
words NNS o
is VBZ N
retrieved VBN N
without IN N
conscious JJ N
effort NN N
and CC N
that DT N
manipulation NN o
knowledge NN o
constitutes VBZ N
a DT N
part NN N
of IN N
the DT N
lexical-semantic JJ N
representation NN N
of IN N
objects NNS N
. . N

-DOCSTART- -8512622- O O

Ethanol-induced JJ N
alterations NNS N
in IN N
electroencephalographic JJ o
activity NN o
in IN N
adult NN p
males NNS p
. . p

The DT N
present JJ N
investigation NN N
examined VBD N
the DT N
effects NNS N
of IN N
placebo NN i
( ( i
P NNP i
) ) i
, , N
low-dose JJ N
( ( N
LD NNP N
) ) N
, , N
and CC N
high-dose JJ N
( ( N
HD NNP N
) ) N
ethanol VBP i
on IN N
electroencephalographic JJ o
( ( o
EEG NNP o
) ) o
activity NN p
in IN p
21 CD p
healthy JJ p
, , p
adult JJ p
males NNS p
( ( p
X NNP p
= VBZ p
22.7 CD p
years NNS p
) ) p
. . p

Only RB N
one CD N
condition NN N
( ( N
P NNP N
, , N
LD NNP N
, , N
or CC N
HD NNP N
) ) N
was VBD N
presented VBN N
per IN N
day NN N
and CC N
the DT N
condition NN N
order NN N
was VBD N
randomized VBN N
. . N

For IN N
each DT N
subject NN N
, , N
blood-alcohol NN N
levels NNS N
measured VBN N
via IN N
breathalyzer NN N
and CC N
EEG NNP o
activity NN o
, , N
using VBG N
the DT N
entire JJ N
10/20 CD N
International NNP N
System NNP N
, , N
were VBD N
recorded VBN N
both DT N
prior JJ N
to TO N
and CC N
at IN N
intervals NNS N
of IN N
35 CD N
, , N
70 CD N
, , N
105 CD N
, , N
and CC N
140 CD N
minutes NNS N
after IN N
P NNP N
, , N
LD NNP N
, , N
or CC N
HD NNP N
administration NN N
. . N

The DT N
Fast NNP N
Fourier NNP N
Transform NNP N
was VBD N
used VBN N
to TO N
calculate VB N
power NN N
spectral JJ N
densities NNS N
for IN N
each DT N
EEG NNP N
recording NN N
. . N

Measures NNS N
of IN N
the DT N
relative JJ N
areas NNS N
under IN N
the DT N
power NN N
spectral JJ N
curve NN N
were VBD N
made VBN N
for IN N
each DT N
of IN N
the DT N
following JJ N
frequency NN N
bands NNS N
: : N
slow VB N
alpha NN N
( ( N
7.5 CD N
to TO N
10 CD N
Hz NNP N
) ) N
; : N
fast VBN N
alpha NN N
( ( N
10.5 CD N
to TO N
13.0 CD N
Hz NNP N
) ) N
; : N
slow JJ N
beta NN N
( ( N
13.5 CD N
to TO N
19.5 CD N
Hz NNP N
) ) N
; : N
and CC N
fast VB N
beta NN N
( ( N
20 CD N
to TO N
26 CD N
Hz NNP N
) ) N
at IN N
electrodes NNS N
F3 NNP N
, , N
F4 NNP N
, , N
C3 NNP N
, , N
C4 NNP N
, , N
P3 NNP N
, , N
P4 NNP N
, , N
O1 NNP N
, , N
and CC N
O2 NNP N
. . N

Repeated-measures NNS N
multivariate JJ N
analysis NN N
of IN N
variance NN N
performed VBN N
on IN N
normalized JJ N
relative JJ N
area NN N
values NNS N
revealed VBD N
that IN N
ethanol NN N
had VBD N
significant JJ N
effects NNS N
on IN N
EEG NNP o
activity NN o
at IN o
anterior JJ o
sites NNS o
: : o
frontal NN N
( ( N
F3 NNP N
, , N
F4 NNP N
) ) N
and CC N
central JJ N
( ( N
C3 NNP N
, , N
C4 NNP N
) ) N
that WDT N
presented VBD N
as IN N
increased JJ N
activity NN N
in IN N
the DT N
slow JJ N
alpha NN N
frequency NN N
band NN N
. . N

These DT N
results NNS N
suggest VBP N
a DT N
differential JJ N
responsivity NN N
of IN N
both DT N
cortical JJ o
region NN o
and CC o
EEG NNP o
frequency NN o
band NN o
to TO N
the DT N
effects NNS N
of IN N
ethanol JJ N
ingestion NN N
. . N

-DOCSTART- -12199005- O O

Mandibular JJ i
advancement NN i
splint NN i
improves VBZ N
indices NNS N
of IN N
obstructive JJ p
sleep NN p
apnoea NN p
and CC p
snoring VBG p
but CC N
side JJ N
effects NNS N
are VBP N
common JJ N
. . N

AIM NNP N
To TO N
assess VB N
the DT N
efficacy NN N
of IN N
a DT N
mandibular JJ i
advancement NN i
splint NN i
( ( i
MAS NNP i
) ) i
in IN N
the DT N
treatment NN N
of IN N
obstructive JJ o
sleep JJ o
apnoea NN o
syndrome NN o
( ( o
OSAS NNP o
) ) o
. . o

METHODS NNP N
Nineteen NNP p
patients NNS p
using VBG p
a DT p
MAS NNP i
for IN p
symptomatic JJ p
OSAS NNP p
underwent NN p
polysomnography NN i
, , p
with IN p
MAS NNP i
use NN p
randomised VBD p
to TO p
one CD p
half NN p
of IN p
the DT p
night NN p
. . p

Indices NNS o
of IN o
snoring VBG o
and CC o
OSAS NNP o
were VBD N
compared VBN N
. . N

Side NNP o
effects NNS o
, , o
compliance NN o
and CC o
treatment NN o
response NN o
were VBD N
evaluated VBN N
by IN N
questionnaire NN N
. . N

RESULTS NNP N
Use NNP N
of IN N
the DT N
MAS NNP i
improved VBD N
total JJ o
respiratory NN o
disturbance NN o
index NN o
( ( o
RDI NNP o
) ) o
from IN N
22.2 CD N
+/- JJ N
19.8 CD N
( ( N
SD NNP N
) ) N
events NNS o
per IN o
hour NN o
to TO N
16.5 CD N
+/- JJ N
21.4/hr CD N
( ( N
p NN N
= RB N
0.03 CD N
) ) N
, , N
supine JJ o
RDI NNP o
( ( N
30.8 CD N
+/- JJ N
23.8/hr CD N
to TO N
18.8 CD N
+/- JJ N
22.1/hr CD N
, , N
p NN N
= NNP N
0.01 CD N
) ) N
, , N
arousal JJ o
index NN o
( ( N
25.2 CD N
+/- JJ N
18.9/hr CD N
to TO N
19.3 CD N
+/- JJ N
14.2/hr CD N
, , N
p NN N
= NNP N
0.01 CD N
) ) N
and CC N
snoring VBG o
intensity NN o
( ( N
52.7 CD N
+/- JJ N
4.1 CD N
to TO N
50.7 CD N
+/- JJ N
2.7 CD N
dB NN N
, , N
p NN N
= NNP N
0.02 CD N
) ) N
but CC N
not RB N
total JJ o
snore NN o
frequency NN o
( ( N
p JJ N
> NNP N
0.05 CD N
) ) N
. . N

Using VBG N
polysomnographic JJ N
criteria NNS N
, , N
MAS NNP i
treatment NN N
was VBD N
completely RB o
successful JJ o
in IN N
four CD N
( ( N
21 CD N
% NN N
) ) N
patients NNS N
, , N
partially RB o
successful JJ o
in IN N
ten NN N
( ( N
52.6 CD N
% NN N
) ) N
and CC N
a DT N
failure NN o
in IN N
five CD N
( ( N
26.3 CD N
% NN N
) ) N
. . N

Treatment NN N
over IN N
a DT N
median NN N
of IN N
6.5 CD N
weeks NNS N
( ( N
range VB N
2-48 CD N
) ) N
was VBD N
perceived VBN N
as IN N
beneficial JJ N
by IN N
ten NN N
of IN N
eleven JJ N
partners NNS N
. . N

Fifteen JJ p
patients NNS p
( ( p
79 CD p
% NN p
) ) p
reported VBD N
side JJ o
effects NNS o
, , N
9 CD N
( ( N
46 CD N
% NN N
) ) N
did VBD N
not RB N
use VB N
the DT N
device NN N
every DT N
night NN N
and CC N
four CD N
( ( N
21 CD N
% NN N
) ) N
used VBD N
the DT N
device NN N
less JJR N
than IN N
three CD N
nights NNS N
per IN N
week NN N
. . N

CONCLUSION NNP N
The DT N
use NN N
of IN N
the DT N
MAS NNP i
resulted VBD N
in IN N
significant JJ N
reductions NNS N
in IN N
indices NNS N
of IN N
OSAS NNP o
and CC o
snoring VBG o
. . o

However RB N
, , N
a DT N
significant JJ N
number NN N
of IN N
patients NNS N
had VBD N
difficulty NN N
tolerating NN N
and CC N
regularly RB N
using VBG N
the DT N
device NN N
. . N

-DOCSTART- -15730346- O O

Efficacy NN o
screening VBG N
trials NNS N
of IN N
paroxetine NN i
, , i
pentoxifylline NN i
, , i
riluzole NN i
, , i
pramipexole NN i
and CC i
venlafaxine NN i
in IN N
cocaine NN p
dependence NN p
. . p

AIMS CC N
The DT N
two CD N
studies NNS N
presented VBN N
here RB N
were VBD N
conducted VBN N
to TO N
assess VB N
the DT N
efficacy NN o
of IN N
paroxetine NN i
, , i
pentoxifylline NN i
, , i
riluzole NN i
, , i
venlafaxine NN i
and CC i
pramipexole NN i
as IN N
medications NNS N
for IN N
the DT N
treatment NN N
of IN N
cocaine NN N
dependence NN N
. . N

DESIGN VB N
A DT N
multi-arm NN N
, , N
modified VBN N
blinded VBD N
, , N
placebo-controlled JJ i
design NN N
was VBD N
used VBN N
. . N

SETTING VBG N
The DT N
studies NNS p
were VBD p
conducted VBN p
at IN p
the DT p
Boston NNP p
VA NNP p
Healthcare NNP p
System NNP p
and CC p
the DT p
Boston NNP p
University NNP p
School NNP p
of IN p
Medicine NNP p
Medication NNP p
Development NNP p
Research NNP p
Unit NNP p
( ( p
MDRU NNP p
) ) p
. . p

PARTICIPANTS JJ N
Participants NNS p
met VBD p
criteria NNS p
for IN p
cocaine NN p
dependence NN p
during IN p
a DT p
2-week JJ p
screening NN p
period NN p
. . p

INTERVENTION NNP N
Following VBG N
random JJ N
assignment NN N
to TO N
one CD N
of IN N
the DT N
treatment NN N
groups NNS N
, , N
subjects NNS N
received VBD N
active JJ i
medication NN i
or CC N
placebo NN i
for IN N
8 CD N
weeks NNS N
in IN N
combination NN N
with IN N
cognitive JJ i
behavioral JJ i
counseling NN i
. . i

In IN N
the DT N
first JJ N
study NN N
the DT N
efficacy NN o
of IN N
the DT N
antidepressant JJ i
paroxetine NN i
( ( N
20 CD N
mg NNS N
daily RB N
) ) N
, , N
the DT N
phosphodiesterase NN i
inhibitor NN i
pentoxifylline NN i
( ( N
1200 CD N
mg FW N
daily RB N
) ) N
and CC N
the DT N
glutamate NN i
release NN i
inhibitor NN i
riluzole NN i
( ( N
100 CD N
mg NNS N
daily RB N
) ) N
was VBD N
assessed VBN N
. . N

The DT N
antidepressant JJ i
venlafaxine NN i
( ( N
150 CD N
mg NNS N
daily RB N
) ) N
and CC N
the DT N
dopamine JJ i
agonist NN i
pramipexole NN i
( ( N
1.5 CD N
mg NNS N
daily RB N
) ) N
were VBD N
evaluated VBN N
in IN N
the DT N
second JJ N
study NN N
. . N

MEASUREMENTS NNP N
Urine NNP o
benzoylecgonine NN o
( ( o
BE NNP o
) ) o
concentrations NNS o
, , o
self-report NN o
of IN o
cocaine NN o
use NN o
and CC o
global JJ o
impression NN o
scores NNS o
served VBD N
as IN N
primary JJ N
outcome NN N
measures NNS N
. . N

Secondary JJ N
measures NNS N
included VBD N
assessments NNS o
of IN o
cocaine NN o
craving NN o
and CC o
psychiatric JJ o
functioning NN o
. . o

Adverse JJ o
events NNS o
were VBD N
monitored VBN N
during IN N
the DT N
treatment NN N
period NN N
. . N

FINDINGS NNP N
None NN N
of IN N
the DT N
active JJ N
medications NNS N
produced VBD N
greater JJR N
reductions NNS N
in IN N
urine JJ o
BE NNP o
concentrations NNS o
over IN N
the DT N
treatment NN N
period NN N
than IN N
did VBD N
placebo NN i
. . i

There EX N
were VBD N
trends NNS N
for IN N
BE NNP o
levels NNS o
to TO N
become VB N
reduced VBN N
in IN N
the DT N
pentoxifylline NN i
group NN N
during IN N
the DT N
first JJ N
4 CD N
weeks NNS N
of IN N
treatment NN N
and CC N
for IN N
Addiction NNP o
Severity NNP o
Index NNP o
( ( o
ASI NNP o
) ) o
drug NN N
composite JJ N
scores NNS N
to TO N
be VB N
lower JJR N
in IN N
the DT N
pentoxyfylline NN i
group NN N
at IN N
end-point NN N
compared VBN N
to TO N
the DT N
placebo NN N
group NN N
. . N

Significant JJ N
within-group JJ N
reductions NNS N
in IN N
reported JJ N
cocaine NN o
use NN o
and CC o
craving NN o
were VBD N
found VBN N
for IN N
all DT N
treatment NN N
groups NNS N
, , N
but CC N
none NN N
of IN N
the DT N
active JJ N
medications NNS N
were VBD N
superior JJ N
to TO N
placebo VB i
on IN N
these DT N
measures NNS N
. . N

The DT N
accuracy NN N
of IN N
self-reported JJ o
cocaine NN o
use NN o
declined VBD N
over IN N
the DT N
study NN N
period NN N
. . N

Overall JJ N
, , N
the DT N
active JJ N
medications NNS N
were VBD N
well RB N
tolerated VBN o
. . o

CONCLUSIONS VB N
This DT N
study NN N
does VBZ N
not RB N
support VB N
the DT N
use NN N
of IN N
paroxetine NN i
, , i
pentoxifylline NN i
, , i
riluzole NN i
, , i
venlafaxine NN i
or CC i
pramipexole NN i
for IN N
the DT N
treatment NN N
of IN N
cocaine NN N
dependence NN N
. . N

However RB N
, , N
these DT N
results NNS N
need VBP N
to TO N
be VB N
interpreted VBN N
with IN N
caution NN N
because IN N
of IN N
the DT N
small JJ N
size NN N
and CC N
lack NN N
of IN N
homogeneity NN N
of IN N
the DT N
experimental JJ N
groups NNS N
. . N

-DOCSTART- -19797985- O O

A DT N
placebo-controlled JJ i
, , N
fixed-dose JJ N
study NN N
of IN N
aripiprazole NN i
in IN N
children NNS p
and CC p
adolescents NNS p
with IN p
irritability NN p
associated VBN p
with IN p
autistic JJ p
disorder NN p
. . p

OBJECTIVE UH N
To TO N
evaluate VB N
the DT N
short-term JJ N
efficacy NN o
and CC N
safety NN o
of IN N
aripiprazole NN i
in IN N
the DT N
treatment NN N
of IN N
irritability NN N
in IN N
children NNS p
and CC p
adolescents NNS p
with IN p
autistic JJ p
disorder NN p
. . p

METHOD NNP N
Two CD p
hundred VBD p
eighteen JJ p
children NNS p
and CC p
adolescents NNS p
( ( p
aged VBN p
6-17 CD p
years NNS p
) ) p
with IN p
a DT p
diagnosis NN p
of IN p
autistic JJ p
disorder NN p
, , p
and CC p
with IN p
behaviors NNS p
such JJ p
as IN p
tantrums NNS p
, , p
aggression NN p
, , p
self-injurious JJ p
behavior NN p
, , p
or CC p
a DT p
combination NN p
of IN p
these DT p
symptoms NNS p
, , N
were VBD N
randomized VBN N
1:1:1:1 CD N
to TO N
aripiprazole VB i
( ( i
5 CD i
, , i
10 CD i
, , i
or CC i
15 CD i
mg/day NN i
) ) i
or CC i
placebo NN i
in IN N
this DT N
8-week JJ N
double-blind NN N
, , N
randomized VBN N
, , N
placebo-controlled JJ N
, , N
parallel-group JJ N
study NN N
. . N

Efficacy NNP o
was VBD N
evaluated VBN N
using VBG N
the DT N
caregiver-rated JJ N
Aberrant NNP o
Behavior NNP o
Checklist NNP o
Irritability NNP o
subscale NN o
( ( o
primary JJ o
efficacy NN o
measure NN o
) ) o
and CC o
the DT o
clinician-rated JJ o
Clinical JJ o
Global NNP o
Impressions-Improvement NNP o
score NN o
. . o

Safety NNP o
and CC o
tolerability NN o
were VBD N
also RB N
assessed VBN N
. . N

RESULTS NNP N
At IN N
week NN N
8 CD N
, , N
all DT N
aripiprazole JJ i
doses NNS N
produced VBN N
significantly RB N
greater JJR N
improvement NN o
than IN N
placebo NN N
in IN N
mean JJ N
Aberrant NNP o
Behavior NNP o
Checklist NNP o
Irritability NNP o
subscale NN o
scores NNS o
( ( N
5 CD N
mg/day NN N
, , N
-12.4 NNP N
; : N
10 CD N
mg/day NN N
, , N
-13.2 NNP N
; : N
15 CD N
mg/day NN N
, , N
-14.4 NNP N
; : N
versus NN N
placebo NN N
, , N
-8.4 NNP N
; : N
all DT N
p VBP N
< NNP N
.05 NNP N
) ) N
. . N

All DT N
aripiprazole JJ i
doses NNS N
demonstrated VBN N
significantly RB N
greater JJR N
improvements NNS o
in IN o
mean JJ o
Clinical JJ o
Global NNP o
Impressions-Improvement NNP o
score NN o
than IN N
placebo NN i
at IN N
week NN N
8 CD N
. . N

Discontinuation NN N
rates NNS N
due JJ N
to TO N
adverse JJ o
events NNS o
were VBD N
as IN N
follows VBZ N
: : N
placebo VB N
7.7 CD N
% NN N
, , N
aripiprazole JJ N
5 CD N
mg/day JJ N
9.4 CD N
% NN N
, , N
10 CD N
mg/day JJ N
13.6 CD N
% NN N
, , N
and CC N
15 CD N
mg/day JJ N
7.4 CD N
% NN N
. . N

The DT N
most RBS N
common JJ N
adverse JJ o
event NN o
leading VBG N
to TO N
discontinuation NN N
was VBD N
sedation NN o
. . o

There EX N
were VBD N
two CD N
serious JJ o
adverse JJ o
events NNS o
: : o
presyncope NN o
( ( N
5 CD N
mg/day NN N
) ) N
and CC N
aggression NN o
( ( N
10 CD N
mg/day NN N
) ) N
. . N

At IN N
week NN N
8 CD N
, , N
mean JJ N
weight NN o
change NN o
( ( N
last JJ N
observation NN N
carried VBD N
forward RB N
) ) N
was VBD N
as IN N
follows VBZ N
: : N
placebo NN N
+0.3 NNP N
kg NN N
, , N
aripiprazole JJ i
5 CD N
mg/day JJ N
+1.3 NNP N
kg NN N
, , N
10 CD N
mg/day NN N
+1.3 NNP N
kg NN N
, , N
and CC N
15 CD N
mg/day NN N
+1.5 NNP N
kg NN N
; : N
all DT N
p VBP N
< JJ N
.05 NNP N
versus NN N
placebo NN i
. . i

CONCLUSIONS NNP N
Aripiprazole NNP i
was VBD N
efficacious JJ o
and CC N
generally RB N
safe JJ o
and CC N
well RB o
tolerated VBN o
in IN N
the DT N
treatment NN N
of IN N
children NNS p
and CC p
adolescents NNS p
with IN p
irritability NN p
associated VBN p
with IN p
autistic JJ p
disorder NN p
. . p

-DOCSTART- -18246895- O O

Cryotherapy NN N
does VBZ N
not RB N
affect VB N
peroneal JJ N
reaction NN N
following VBG N
sudden JJ N
inversion NN N
. . N

CONTEXT NNP N
If IN N
ankle JJ N
joint NN N
cryotherapy NN N
impairs VBZ N
the DT N
ability NN N
of IN N
the DT N
ankle JJ N
musculature NN N
to TO N
counteract VB N
potentially RB N
injurious JJ N
forces NNS N
, , N
the DT N
ankle NN N
is VBZ N
left VBN N
vulnerable JJ N
to TO N
injury VB N
. . N

OBJECTIVE NNP N
To TO N
compare VB N
peroneal JJ N
reaction NN N
to TO N
sudden JJ N
inversion NN N
following VBG N
ankle JJ N
joint JJ N
cryotherapy NN N
. . N

DESIGN NNP N
Repeated VBD N
measures NNS N
design NN N
with IN N
independent JJ N
variables NNS N
, , N
treatment NN N
( ( i
cryotherapy NN i
and CC i
control NN i
) ) i
, , N
and CC N
time NN N
( ( N
baseline NN N
, , N
immediately RB N
post NN N
treatment NN N
, , N
15 CD N
minutes NNS N
post RB N
treatment NN N
, , N
and CC N
30 CD N
minutes NNS N
post RB N
treatment NN N
) ) N
. . N

SETTING NNP N
University NNP p
research NN p
laboratory NN p
. . p

PATIENTS CC N
OR CC N
OTHER NNP N
PARTICIPANTS NNP N
Twenty-seven NNP p
healthy JJ p
volunteers NNS p
. . p

INTERVENTION NNP N
( ( N
S NNP N
) ) N
An DT N
ice NN N
bag NN N
was VBD N
secured VBN N
to TO N
the DT N
lateral JJ N
ankle NN N
joint NN N
for IN N
20 CD N
minutes NNS N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
The DT N
onset NN o
and CC o
average JJ o
root NN o
mean JJ o
square JJ o
amplitude NN o
of IN o
EMG NNP o
activity NN o
in IN o
the DT o
peroneal NN o
muscles NNS o
was VBD o
calculated VBN o
following VBG o
the DT o
release NN o
of IN o
a DT o
trap NN o
door NN o
mechanism NN o
causing VBG o
inversion NN o
. . o

RESULTS NNP N
There EX N
was VBD N
no DT N
statistically RB N
significant JJ N
change NN N
from IN N
baseline NN N
for IN N
peroneal JJ o
reaction NN o
time NN o
or CC o
average JJ o
peroneal JJ o
muscle NN o
activity NN o
at IN N
any DT N
post NN N
treatment NN N
time NN N
. . N

CONCLUSIONS NNP N
Cryotherapy NNP N
does VBZ N
not RB N
affect VB N
peroneal JJ N
muscle NN N
reaction NN N
following VBG N
sudden JJ N
inversion NN N
perturbation NN N
. . N

-DOCSTART- -21694630- O O

A DT N
pilot NN N
study NN N
to TO N
improve VB N
venipuncture NN o
compliance NN o
in IN N
children NNS p
and CC p
adolescents NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
. . p

OBJECTIVE NNP N
Medical NNP N
procedures NNS N
, , N
particularly RB N
venipuncture NN N
( ( N
the DT N
puncture NN N
of IN N
a DT N
vein NN N
especially RB N
for IN N
the DT N
withdrawal NN N
of IN N
blood NN N
) ) N
, , N
can MD N
cause VB N
serious JJ o
distress NN o
and CC N
behavior JJ o
disturbance NN o
for IN N
many JJ N
children NNS N
. . N

Noncompliance NN N
to TO N
blood VB N
draws NNS N
can MD N
have VB N
significant JJ N
ramifications NNS N
in IN N
both DT N
research NN N
and CC N
clinical JJ N
settings NNS N
. . N

The DT N
negative JJ o
reactions NNS o
may MD N
be VB N
exacerbated VBN N
in IN N
individuals NNS N
with IN N
autism NN N
spectrum NN N
disorders NNS N
. . N

Even RB N
so RB N
, , N
there EX N
has VBZ N
been VBN N
little JJ N
research NN N
into IN N
the DT N
prevalence NN N
of IN N
the DT N
problem NN N
or CC N
effective JJ N
intervention NN N
procedures NNS N
. . N

In IN N
response NN N
to TO N
these DT N
concerns NNS N
, , N
we PRP N
developed VBD N
and CC N
evaluated VBD N
the DT N
Blood NNP i
Draw NNP i
Intervention NNP i
Program NNP i
. . i

The DT N
program NN N
was VBD N
designed VBN N
to TO N
be VB N
easy JJ N
to TO N
use VB N
, , N
require VB N
little JJ N
provider NN N
or CC N
family NN N
time NN N
, , N
effectively RB N
reduce VB N
negative JJ o
behaviors NNS o
, , N
and CC N
increase VB o
blood NN o
draw JJ o
compliance NN o
. . o

METHOD NNP N
In IN N
a DT N
quasi-randomized JJ N
trial NN N
over IN N
the DT N
course NN N
of IN N
? . N
18 CD N
months NNS p
, , p
58 CD p
of IN p
210 CD p
families NNS p
with IN p
children NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
participating VBG p
in IN p
a DT p
larger JJR p
study NN p
of IN p
phenotypic NN p
and CC p
genotypic NN p
factors NNS p
reported VBD p
significant JJ p
concerns NNS p
about IN p
blood NN p
draws NNS p
and CC p
elected VBN p
to TO p
use VB p
the DT p
Blood NNP p
Draw NNP p
Intervention NNP p
Program NNP p
. . p

RESULTS NNP N
Completion NNP N
of IN N
the DT N
program NN N
increased VBD o
blood NN o
draw NN o
compliance NN o
rates NNS o
from IN o
85.4 CD N
% NN N
to TO N
96.6 CD N
% NN N
( ( N
odds NNS N
ratio VBP N
= JJ N
4.80 CD N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
= VBD N
1.12 CD N
, , N
20.59 CD N
; : N
p NN N
= NNP N
.03 NNP N
) ) N
. . N

CONCLUSION NNP N
Results NNP N
indicate VBP N
the DT N
efficacy NN N
of IN N
the DT N
program NN N
in IN N
a DT N
research NN N
setting NN N
and CC N
suggest VB N
a DT N
potential JJ N
clinical JJ N
application NN N
. . N

The DT N
current JJ N
intervention NN N
, , N
unlike IN N
many JJ N
others NNS N
for IN N
the DT N
same JJ N
or CC N
similar JJ N
difficulties NNS N
proposed VBN N
in IN N
the DT N
past NN N
, , N
was VBD N
successful JJ N
without IN N
requiring VBG N
extensive JJ N
time NN N
, , N
training NN N
, , N
or CC N
effort NN N
on IN N
the DT N
part NN N
of IN N
providers NNS N
and CC N
parents NNS N
or CC N
their PRP$ N
children NNS N
, , N
nor CC N
did VBD N
it PRP N
require VB N
large-scale JJ N
institutional JJ N
changes NNS N
. . N

-DOCSTART- -8521712- O O

Differential JJ N
effects NNS N
on IN N
bone NN o
density NN o
of IN N
progestogen-only JJ i
methods NNS N
for IN N
contraception NN N
in IN N
premenopausal JJ p
women NNS p
. . p

The DT N
question NN N
of IN N
differential JJ N
effects NNS N
on IN N
bone NN N
density NN N
by IN N
two CD N
different JJ N
types NNS N
of IN N
progestogen-only JJ i
methods NNS N
for IN N
contraception NN N
in IN N
premenopausal JJ p
women NNS p
was VBD N
addressed VBN N
. . N

Data NNS N
from IN N
a DT N
prospective JJ N
randomized VBN N
clinical JJ N
trial NN N
among IN N
22 CD p
premenopausal JJ p
women NNS p
, , p
age NN p
32.6 CD p
( ( p
range JJ p
20-45 CD p
years NNS p
) ) p
, , N
who WP N
were VBD N
randomly RB N
assigned VBN N
to TO N
either DT N
of IN N
two CD N
treatments NNS N
with IN N
continuous JJ i
progestogens NNS i
for IN i
contraception NN i
were VBD N
analyzed VBN N
; : N
depot-medroxyprogesterone JJ i
acetate NN i
( ( i
DMPA NNP i
) ) i
or CC N
continuous JJ i
levonorgestrel NN i
treatment NN i
with IN i
subdermal JJ i
implants NNS i
( ( N
Norplant NNP N
) ) N
, , N
respectively RB N
. . N

Forearm NNP o
bone NN o
density NN o
( ( o
BMDprox NNP o
) ) o
increased VBD N
with IN N
2.94 CD N
% NN N
( ( N
p JJ N
= NNP N
0.006 CD N
) ) N
in IN N
women NNS N
who WP N
were VBD N
prescribed VBN N
levonorgestrel NN N
, , N
which WDT N
was VBD N
in IN N
contrast NN N
to TO N
stable JJ N
values NNS N
in IN N
those DT N
prescribed JJ N
depot-medroxy-progesterone JJ i
acetate NN i
; : i
group NN N
difference NN N
at IN N
6 CD N
months NNS N
for IN N
BMDprox NNP o
3.4 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
1.3 CD N
, , N
5.5 CD N
; : N
p NN N
= VBZ N
0.025 CD N
) ) N
and CC N
BMDdist $ o
4.1 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
- : N
1.3 CD N
, , N
9.6 CD N
; : N
p NN N
= VBZ N
0.077 CD N
) ) N
. . N

The DT N
changes NNS o
in IN o
bone NN o
density NN o
were VBD N
consistent JJ N
with IN N
the DT N
changes NNS N
in IN N
biochemical JJ o
indices NNS o
for IN o
bone NN o
metabolism NN o
; : o
DMPA NNP i
users NNS N
showed VBD N
signs NNS N
of IN N
increased VBN N
bone NN o
turnover NN o
and CC N
users NNS N
of IN N
levonorgestrel NN N
showed VBD N
increased JJ o
bone NN o
formation NN o
with IN N
increased JJ N
levels NNS N
of IN N
both DT N
alkaline JJ N
phosphatase NN N
( ( N
p JJ N
= NNP N
0.004 CD N
) ) N
and CC N
osteocalcin $ N
( ( N
p JJ N
= NNP N
0.007 CD N
) ) N
. . N

The DT N
findings NNS N
suggest VBP N
an DT N
increase NN N
in IN N
bone JJ o
density NN o
during IN N
treatment NN N
with IN N
levonorgestrel NN i
and CC N
stable JJ N
values NNS N
during IN N
short-term JJ N
administration NN N
of IN N
DMPA NNP i
, , N
in IN N
standard JJ N
clinical JJ N
doses NNS N
for IN N
contraception NN N
. . N

-DOCSTART- -1862788- O O

Comparison NNP N
of IN N
amantadine NN i
and CC i
desipramine NN i
combined VBN N
with IN N
psychotherapy NN i
for IN N
treatment NN N
of IN N
cocaine NN p
dependence NN p
. . p

We PRP N
conducted VBD N
a DT N
single-blind NN N
, , N
random JJ N
assignment NN N
, , N
placebo-controlled JJ i
, , N
12-week JJ N
comparison NN N
of IN N
desipramine JJ i
hydrochloride NN i
and CC i
amantadine JJ i
hydrochloride NN i
as IN N
adjunctive JJ N
treatments NNS N
to TO N
counseling VBG N
for IN N
cocaine NN N
dependence NN N
. . N

Subjects NNS p
were VBD p
54 CD p
outpatients NNS p
who WP p
met VBD p
DSM NNP p
III-R NNP p
criteria NNS p
for IN p
active JJ p
cocaine NN p
dependence NN p
and CC p
who WP p
completed VBD p
a DT p
minimum NN p
of IN p
2 CD p
weeks NNS p
of IN p
treatment NN p
. . p

Subjects NNS N
treated VBD N
with IN N
fixed JJ N
doses NNS N
of IN N
200 CD N
mg/day JJ N
desipramine NN i
( ( N
N NNP N
= NNP N
17 CD N
) ) N
, , N
400 CD N
mg/day JJ N
amantadine-placebo JJ i
( ( N
N NNP N
= NNP N
16 CD N
) ) N
, , N
and CC N
placebo NN i
( ( N
N NNP N
= NNP N
21 CD N
) ) N
did VBD p
not RB p
differ VB p
for IN p
lifetime NN p
cocaine NN p
use NN p
, , p
lifetime JJ p
histories NNS p
of IN p
psychopathology NN p
, , p
admission NN p
scores NNS p
on IN p
psychometric JJ p
assessments NNS p
, , p
and CC p
sociodemographics NNS p
. . p

All DT N
treatment NN N
groups NNS N
demonstrated VBD N
dramatic JJ o
and CC o
persistent JJ o
decreases NNS o
in IN N
cocaine NN o
use NN o
, , o
craving VBG o
for IN o
cocaine NN o
, , o
and CC o
psychiatric JJ o
symptoms NNS o
consequent NN N
to TO N
treatment NN N
. . N

Although IN N
there EX N
was VBD N
a DT N
trend NN N
for IN N
more JJR N
dropouts NNS o
by IN N
subjects NNS N
taking VBG N
desipramine NN i
, , N
there EX N
were VBD N
no DT N
significant JJ N
differences NNS N
among IN N
treatment NN N
groups NNS N
regarding VBG N
retention NN o
in IN o
treatment NN o
, , o
craving VBG o
for IN o
cocaine NN o
, , o
and CC o
decreased VBD o
cocaine NN o
use NN o
confirmed VBN N
by IN N
urine JJ o
toxicology NN o
. . o

There EX N
was VBD N
a DT N
trend NN N
for IN N
subjects NNS N
treated VBN N
with IN N
desipramine NN i
to TO N
maintain VB N
longer JJR N
periods NNS N
of IN N
cocaine NN o
abstinence NN o
. . o

Mean NNP o
plasma JJ o
concentration NN o
of IN o
desipramine NN o
in IN N
a DT N
subsample NN N
of IN N
our PRP$ N
subjects NNS N
was VBD N
less JJR N
than IN N
that DT N
recommended VBD N
for IN N
treatment NN N
of IN N
depression NN N
, , N
thus RB N
the DT N
dosage NN N
of IN N
desipramine NN i
may MD N
have VB N
been VBN N
subtherapeutic JJ N
. . N

-DOCSTART- -19620953- O O

Enhancing VBG N
the DT N
working VBG o
memory NN o
of IN N
stroke NN p
patients NNS p
using VBG N
tDCS NN i
. . i

OBJECTIVES IN N
We PRP N
investigated VBD N
whether IN N
anodal JJ i
transcranial JJ i
direct JJ i
current JJ i
stimulation NN i
over IN N
the DT N
left JJ N
dorsolateral JJ N
prefrontal JJ N
cortex NN N
affected VBD N
the DT N
working JJ o
memory NN o
performance NN o
of IN N
patients NNS p
after IN p
a DT p
stroke NN p
. . p

DESIGN NNP N
Ten CD p
patients NNS p
( ( p
mean JJ p
age NN p
47.7 CD p
yrs NN p
) ) p
with IN p
cognitive JJ p
deficits NNS p
after IN p
a DT p
first-ever JJ p
stroke NN p
participated VBD p
in IN N
this DT N
single-blind NN N
, , N
crossover NN N
, , N
and CC N
sham-controlled JJ i
experiment NN N
. . N

Each DT N
patient NN N
was VBD N
randomly RB N
assigned VBN N
to TO N
undergo VB N
two CD N
transcranial JJ i
direct JJ i
current JJ i
stimulation NN i
sessions NNS i
: : i
anodal JJ i
dorsolateral JJ i
prefrontal NN i
cortex NN i
and CC i
sham JJ i
stimulation NN i
within IN N
48 CD N
hrs NN N
of IN N
a DT N
washout NN N
period NN N
. . N

All DT N
participants NNS N
performed VBD N
a DT N
two-back JJ o
working JJ o
memory NN o
task NN o
before IN i
and CC i
after IN i
the DT N
administration NN N
of IN N
the DT N
transcranial JJ N
direct JJ N
current JJ N
stimulation NN N
. . N

Accuracy NNP o
( ( o
correction NN o
rate NN o
) ) o
, , o
recognition NN o
accuracy NN o
( ( o
correction NN o
rate-commission NN o
error NN o
rate NN o
) ) o
, , o
and CC o
response NN o
time NN o
were VBD N
measured VBN N
during IN N
each DT N
experiment NN N
. . N

RESULTS NNP N
Repeated-measures JJ N
analysis NN N
of IN N
variance NN N
indicated VBD N
a DT N
significant JJ N
interaction NN N
effect NN N
of IN N
transcranial JJ N
direct JJ N
current JJ N
stimulation NN N
type NN N
and CC N
time NN N
on IN N
the DT N
recognition NN o
accuracy NN o
. . o

Post NNP N
hoc NN N
analyses NNS N
revealed VBD N
a DT N
significant JJ N
difference NN N
between IN N
prestimulation NN N
and CC N
poststimulation NN N
in IN N
the DT N
anodal JJ i
stimulation NN i
group NN N
but CC N
not RB N
in IN N
the DT N
sham JJ N
stimulation NN N
group NN N
. . N

Regarding VBG N
the DT N
accuracy NN o
, , N
the DT N
paired JJ N
t JJ N
test NN N
indicated VBD N
significant JJ N
improvement NN N
only RB N
after IN N
anodal JJ i
transcranial JJ i
direct JJ i
current JJ i
stimulation NN i
without IN N
a DT N
significant JJ N
interaction NN N
effect NN N
between IN N
the DT N
two CD N
transcranial JJ N
direct JJ N
current JJ N
stimulation NN N
types NNS N
. . N

The DT N
response NN o
time NN o
was VBD N
not RB N
significantly RB N
different JJ N
in IN N
the DT N
anodal NN N
and CC N
sham JJ N
stimulation NN N
groups NNS N
. . N

CONCLUSION NNP N
Our PRP$ N
results NNS N
demonstrated VBD N
that IN N
anodal JJ i
transcranial JJ i
direct JJ i
current JJ i
stimulation NN i
over IN N
the DT N
left JJ N
dorsolateral JJ N
prefrontal NN N
cortex NN N
was VBD N
associated VBN N
with IN N
enhanced JJ N
working VBG o
memory NN o
performance NN o
as IN N
indexed VBN N
by IN N
the DT N
recognition NN N
accuracy NN N
in IN N
patients NNS p
after IN p
a DT p
stroke NN p
. . p

-DOCSTART- -15039684- O O

A DT N
randomized JJ N
, , N
double-blinded JJ N
, , N
placebo-controlled JJ N
trial NN N
of IN N
phenytoin NN i
for IN N
the DT N
prevention NN N
of IN N
early JJ N
posttraumatic JJ N
seizures NNS N
in IN N
children NNS N
with IN N
moderate JJ N
to TO N
severe VB N
blunt NN N
head JJ N
injury NN N
. . N

STUDY NNP N
OBJECTIVE NNP N
We PRP N
determine VBP N
the DT N
efficacy NN N
of IN N
prophylactic JJ N
phenytoin NN i
in IN N
preventing VBG N
early JJ N
posttraumatic JJ N
seizures NNS N
in IN N
children NNS N
with IN N
moderate JJ N
to TO N
severe VB N
blunt NN N
head JJ N
injury NN N
. . N

METHODS NNP N
Children NNP p
younger JJR p
than IN p
16 CD p
years NNS p
and CC p
experiencing VBG p
moderate JJ p
to TO p
severe VB p
blunt NN p
head JJ p
injury NN p
were VBD N
randomized VBN N
to TO N
receive VB N
phenytoin NN i
or CC i
placebo NN i
within IN N
60 CD N
minutes NNS N
of IN N
presentation NN N
at IN N
3 CD N
pediatric JJ N
trauma NN N
centers NNS N
. . N

The DT N
primary JJ N
endpoint NN N
was VBD N
posttraumatic JJ o
seizures NNS o
within IN N
48 CD N
hours NNS N
; : N
secondary JJ N
endpoints NNS N
were VBD N
survival JJ N
and CC N
neurologic JJ N
outcome NN N
30 CD N
days NNS N
after IN N
injury NN N
. . N

A DT N
Bayesian JJ N
decision-theoretic JJ N
clinical JJ N
trial NN N
design NN N
was VBD N
used VBN N
to TO N
determine VB N
the DT N
probability NN N
of IN N
remaining VBG N
posttraumatic JJ N
seizure NN N
free JJ N
for IN N
each DT N
treatment NN N
group NN p
. . p

RESULTS NNP N
One CD p
hundred VBD p
two CD p
patients NNS p
were VBD p
enrolled VBN p
, , p
with IN p
a DT p
median JJ p
age NN p
of IN p
6.1 CD p
years NNS p
. . p

Sixty-eight JJ p
percent NN p
were VBD p
boys NNS p
. . p

The DT N
2 CD p
treatment NN p
groups NNS p
were VBD N
well RB N
matched VBN N
. . N

During IN N
the DT N
48-hour JJ N
observation NN N
period NN N
, , N
3 CD p
( ( p
7 CD p
% NN p
) ) p
of IN p
46 CD p
patients NNS p
given VBN N
phenytoin NNS i
and CC N
3 CD p
( ( p
5 CD p
% NN p
) ) p
of IN p
56 CD p
patients NNS p
given VBN N
placebo NNS i
experienced VBD N
a DT N
posttraumatic JJ o
seizure NN o
. . o

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
the DT N
treatment NN N
groups NNS p
in IN N
survival NN o
or CC o
neurologic JJ o
outcome NN o
after IN N
30 CD N
days NNS N
. . N

According VBG N
to TO N
these DT N
results NNS N
, , N
the DT N
probability NN N
that WDT N
phenytoin NN i
has VBZ N
the DT N
originally RB N
hypothesized VBN N
effect NN N
of IN N
reducing VBG N
the DT N
rate NN o
of IN o
early JJ o
posttraumatic JJ o
seizures NNS o
by IN N
12.5 CD N
% NN N
is VBZ N
0.0053 CD N
. . N

The DT N
probability NN N
that WDT N
phenytoin NN i
has VBZ N
any DT N
prophylactic JJ o
efficacy NN o
is VBZ N
0.383 CD N
. . N

The DT N
median JJ N
effect NN N
size NN N
in IN N
this DT N
trial NN N
was VBD N
-0.015 NNP N
( ( p
seizure JJ p
rate NN p
increased VBN p
by IN p
1.5 CD p
% NN p
in IN p
the DT p
phenytoin NN i
group NN p
) ) p
, , N
95 CD N
% NN N
probability NN N
interval NN N
-0.127 NN N
to TO N
0.091 CD N
( ( N
12.7 CD N
% NN N
higher JJR N
rate NN N
of IN N
posttraumatic JJ o
seizures NNS o
to TO N
a DT N
9.1 CD N
% NN N
lower JJR N
rate NN N
of IN N
posttraumatic JJ N
seizures NNS N
with IN N
phenytoin NN i
) ) i
. . N

CONCLUSION VB N
The DT N
rate NN N
of IN N
early JJ N
posttraumatic JJ N
seizures NNS N
in IN N
children NNS p
may MD p
be VB p
much RB p
lower JJR N
than IN N
previously RB N
reported VBN N
. . N

Phenytoin VB i
did VBD N
not RB N
substantially RB N
reduce VB N
that DT N
rate NN N
. . N

-DOCSTART- -19672771- O O

Randomized VBN N
trial NN N
of IN N
daily JJ N
versus FW N
weekly JJ N
administration NN N
of IN N
2-chlorodeoxyadenosine JJ i
in IN N
patients NNS p
with IN p
hairy JJ p
cell NN p
leukemia NN p
: : p
a DT p
multicenter NN p
phase NN p
III NNP p
trial NN p
( ( p
SAKK NNP p
32/98 CD p
) ) p
. . p

Daily JJ N
administration NN N
of IN N
2-chlorodeoxyadenosine JJ i
( ( i
Cladribine NNP i
, , i
CDA NNP i
) ) i
is VBZ N
a DT N
standard JJ N
treatment NN N
for IN N
hairy NN N
cell NN N
leukemia NN N
, , N
but CC N
may MD N
cause VB N
severe JJ N
neutropenia NN o
and CC o
neutropenic JJ o
fever NN o
. . o

This DT N
trial NN N
compared VBN N
toxicity NN N
and CC N
efficacy NN N
of IN N
weekly JJ N
versus NN N
daily RB N
CDA NNP i
administration NN N
. . N

One CD p
hundred VBD p
patients NNS p
were VBD N
randomized VBN N
to TO N
receive VB N
standard NN N
( ( i
CDA NNP i
0.14 CD N
mg/kg/day JJ N
day NN N
1-5 JJ N
[ NNP N
Arm NNP N
A NNP N
] NN N
) ) N
or CC N
experimental JJ N
treatment NN N
( ( i
CDA NNP i
0.14 CD N
mg/kg/day NN N
once RB N
weekly JJ N
for IN N
5 CD N
weeks NNS N
[ JJ N
Arm NNP N
B NNP N
] NN N
) ) N
. . N

The DT N
primary JJ N
endpoint NN N
was VBD N
average JJ o
leukocyte JJ o
count NN o
within IN N
6 CD N
weeks NNS N
from IN N
randomization NN N
. . N

Secondary JJ N
endpoints NNS N
included VBD N
response NN o
rates NNS o
, , o
other JJ o
acute JJ o
hematotoxicity NN o
, , o
acute JJ o
infection NN o
rate NN o
, , o
hospital NN o
admission NN o
, , o
remission NN o
duration NN o
, , o
event-free JJ o
, , o
and CC o
overall JJ o
survival NN o
. . o

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
average JJ o
leukocyte JJ o
count NN o
. . o

Response JJ o
rate NN o
( ( N
complete JJ N
+ NNP N
partial JJ N
remission NN N
) ) N
at IN N
week NN N
10 CD N
was VBD N
78 CD N
% NN N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
( ( N
CI NNP N
) ) N
64-88 CD N
% NN N
) ) N
in IN N
Arm NNP N
A NNP N
and CC N
68 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
54-80 CD N
% NN N
) ) N
in IN N
Arm NNP N
B NNP N
( ( N
p JJ N
= NNP N
0.13 CD N
) ) N
. . N

Best JJS N
response NN o
rates NNS o
during IN N
follow-up JJ N
were VBD N
identical JJ N
( ( N
86 CD N
% NN N
) ) N
in IN N
both DT N
arms NNS N
. . N

No DT N
significant JJ N
difference NN N
was VBD N
found VBN N
in IN N
the DT N
rate NN N
of IN N
grade NN o
3+4 CD o
leukocytopenia NN o
( ( N
94 CD N
% NN N
vs NN N
. . N

84 CD N
% NN N
) ) N
, , N
grade VBD o
3+4 CD o
neutropenia NN o
( ( N
90 CD N
% NN N
vs NN N
. . N

80 CD N
% NN N
) ) N
, , N
acute JJ o
infection NN o
( ( N
44 CD N
% NN N
vs NN N
. . N

40 CD N
% NN N
) ) N
, , N
hospitalization NN o
( ( N
38 CD N
% NN N
vs NN N
. . N

34 CD N
% NN N
) ) N
, , N
and CC N
erythrocyte JJ o
support NN o
( ( N
22 CD N
% NN N
vs NN N
. . N

30 CD N
% NN N
) ) N
within IN N
10 CD N
weeks NNS N
. . N

Overall JJ N
, , N
these DT N
findings NNS N
indicate VBP N
that IN N
there EX N
are VBP N
no DT N
apparent JJ N
advantages NNS N
in IN N
toxicity NN o
and CC o
efficacy NN o
by IN N
giving VBG N
CDA NNP i
weekly RB N
rather RB N
than IN N
daily RB N
. . N

-DOCSTART- -22987458- O O

Hyperbaric NNP i
oxygen NN i
in IN N
the DT N
treatment NN N
of IN N
childhood NN p
autism NN p
: : p
a DT N
randomised JJ N
controlled VBN N
trial NN N
. . N

BACKGROUND NNP N
Promising NNP N
results NNS N
with IN N
hyperbaric JJ i
therapy NN i
for IN N
children NNS p
with IN p
autism NN p
have VBP N
been VBN N
reported VBN N
, , N
but CC N
most JJS N
involved VBD N
the DT N
use NN N
of IN N
only RB N
mild JJ N
pressure NN N
with IN N
oxygen NN N
supplementation NN N
. . N

To TO N
date NN N
, , N
there EX N
has VBZ N
been VBN N
no DT N
randomised VBN N
, , N
blinded VBD N
trial NN N
of IN N
100 CD N
% NN N
oxygen NN N
administered VBN N
at IN N
hyperbaric JJ N
pressure NN N
. . N

This DT N
study NN N
evaluated VBD N
the DT N
efficacy NN o
of IN N
hyperbaric JJ N
oxygen NN N
therapy NN N
( ( N
HBOT NNP N
) ) N
. . N

METHODS NNP N
Sixty NNP p
Thai NNP p
children NNS p
with IN p
autism NN p
, , p
aged VBD p
three CD p
to TO p
nine CD p
years NNS p
, , N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
20 CD N
one-hour JJ i
sessions NNS i
of IN i
either DT i
HBOT NNP i
at IN i
153 CD i
kPa NN i
( ( N
1.5 CD N
ATA NNP N
) ) N
or CC N
sham JJ i
air NN i
at IN i
116 CD i
kPa NN i
( ( N
1.15 CD N
ATA NNP N
) ) N
. . N

Effects NNS o
on IN o
behaviour NNS o
were VBD N
measured VBN N
using VBG N
the DT N
Autism NNP o
Treatment NNP o
Evaluation NNP o
Checklist NNP o
score NN o
( ( o
ATEC NNP o
) ) o
and CC N
clinical JJ o
improvement NN o
was VBD N
measured VBN N
with IN N
the DT N
Clinical NNP o
Global NNP o
Impression NNP o
( ( o
CGI NNP o
) ) o
system NN o
; : o
in IN N
particular JJ N
the DT N
clinical JJ o
change NN o
( ( o
CGIC NNP o
) ) o
and CC o
severity NN o
( ( o
CGIS NNP o
) ) o
sub-scores NNS o
. . o

These DT N
were VBD N
evaluated VBN N
by IN N
parents NNS N
and CC N
clinicians NNS N
, , N
both DT N
of IN N
whom WP N
were VBD N
blinded VBN N
to TO N
the DT N
actual JJ N
exposure NN N
. . N

RESULTS VB N
The DT N
mean JJ o
total JJ o
ATEC NNP o
scores NNS o
by IN N
both DT N
parents NNS N
and CC N
clinicians NNS N
were VBD N
significantly RB N
improved VBN N
after IN N
intervention NN N
in IN N
both DT N
arms NNS N
of IN N
the DT N
study NN N
compared VBN N
to TO N
the DT N
score NN N
before IN N
intervention NN N
( ( N
P NNP N
< VBZ N
0.001 CD N
in IN N
both DT N
groups NNS N
by IN N
parents NNS N
, , N
P NNP N
= VBZ N
0.015 CD N
in IN N
HBOT NNP N
group NN N
and CC N
P NNP N
= NNP N
0.004 CD N
in IN N
sham NN N
group NN N
by IN N
clinician NN N
) ) N
. . N

There EX N
were VBD N
no DT N
statistically RB N
significant JJ N
differences NNS N
in IN N
average JJ N
percentage NN N
changes NNS N
of IN N
total JJ o
ATEC NNP o
score NN o
and CC N
all DT N
subscales NNS N
scores NNS N
when WRB N
comparing VBG N
the DT N
HBOT NNP N
and CC N
sham NNP N
air NN N
groups NNS N
, , N
either RB N
by IN N
parents NNS N
or CC N
clinicians NNS N
. . N

Changes NNS N
in IN N
the DT N
CGI NNP o
scores NNS o
following VBG N
intervention NN N
were VBD N
inconsistent JJ N
between IN N
parents NNS N
and CC N
clinicians NNS N
. . N

For IN N
severity NN o
scores NNS o
( ( o
CGIS NNP o
) ) o
, , N
parents NNS N
rated VBD N
their PRP$ N
children NNS N
as IN N
more JJR N
improved JJ N
following NN N
HBOT NNP N
( ( N
P NNP N
= NNP N
0.005 CD N
) ) N
, , N
while IN N
the DT N
clinicians NNS N
found VBD N
no DT N
significant JJ N
differences NNS N
( ( N
P NNP N
= NNP N
0.10 CD N
) ) N
. . N

On IN N
the DT N
other JJ N
hand NN N
, , N
for IN N
change NN o
scores NNS o
( ( o
CGIC NNP o
) ) o
the DT N
clinicians NNS N
indicated VBD N
greater JJR N
improvement NN N
following VBG N
HBOT NNP N
( ( N
P NNP N
= NNP N
0.03 CD N
) ) N
, , N
but CC N
the DT N
parents NNS N
found VBD N
no DT N
such JJ N
difference NN N
( ( N
P NNP N
= NNP N
0.28 CD N
) ) N
. . N

CONCLUSIONS NNP N
Children NNP p
with IN p
autism NN p
who WP N
received VBD N
20 CD N
sessions NNS N
of IN N
either DT N
HBOT NNP i
or CC N
a DT N
sham JJ N
air NN N
exposure NN N
had VBD N
significant JJ N
improvements NNS N
in IN N
overall JJ o
behaviour NN o
but CC N
there EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
improvement NN N
between IN N
groups NNS N
. . N

The DT N
inconsistent JJ N
changes NNS N
on IN N
CGI NNP o
sub-scores NNS o
between IN N
parents NNS N
and CC N
clinicians NNS N
are VBP N
difficult JJ N
to TO N
interpret VB N
, , N
but CC N
no DT N
overall JJ N
clinically RB N
significant JJ N
benefit NN N
from IN N
HBOT NNP N
could MD N
be VB N
shown VBN N
. . N

Both DT N
interventions NNS N
were VBD N
safe JJ o
and CC o
well RB o
tolerated VBN o
with IN N
minimal JJ o
side NN o
effect NN o
from IN N
middle JJ N
ear JJ N
barotraumas NN N
. . N

-DOCSTART- -23766737- O O

Prospective JJ N
, , N
blinded VBD N
exploratory JJ N
evaluation NN N
of IN N
the DT N
PlayWisely NNP i
program NN i
in IN N
children NNS p
with IN p
autism NN p
spectrum NN p
disorder NN p
. . p

The DT N
purpose NN N
of IN N
the DT N
study NN N
was VBD N
to TO N
explore VB N
a DT N
low-cost JJ i
intervention NN i
that WDT N
targets VBZ N
an DT N
increasingly RB N
common JJ N
developmental JJ N
disorder NN N
. . N

The DT N
study NN N
was VBD N
a DT N
blinded JJ N
, , N
exploratory JJ N
evaluation NN N
of IN N
the DT N
PlayWisely NNP i
program NN i
on IN N
autism NN o
symptoms NNS o
and CC o
essential JJ o
learning NN o
foundation NN o
skills NNS o
( ( o
attention NN o
, , o
recognition NN o
, , o
and CC o
memory NN o
skills NNS o
) ) o
in IN N
children NNS p
with IN p
a DT p
diagnosis NN p
of IN p
autism NN p
, , p
autism NN p
spectrum NN p
disorder NN p
( ( p
ASD NNP p
) ) p
, , p
pervasive JJ p
developmental NN p
disorder NN p
- : p
not RB p
otherwise RB p
specified VBN p
( ( p
PDD-NOS NNP p
) ) p
, , p
and CC p
Asperger NNP p
syndrome VBP p
( ( p
AS IN p
) ) p
. . p

Eighteen JJ p
children NNS p
, , p
1 CD p
to TO p
10 CD p
years NNS p
of IN p
age NN p
, , N
were VBD N
evaluated VBN N
using VBG N
the DT N
Childhood NNP N
Autism NNP N
Rating NNP N
Scale NNP N
, , N
Second NNP N
Edition NNP N
( ( N
CARS2 NNP N
) ) N
; : N
the DT N
PlayWisely NNP N
Interactive NNP N
Test NNP N
of IN N
Attention NNP N
, , N
Recognition NNP N
, , N
and CC N
Memory NNP N
Skills NNP N
; : N
Autism NNP N
Treatment NNP N
Evaluation NNP N
Checklist NNP N
( ( N
ATEC NNP N
) ) N
, , N
and CC N
the DT N
Modified NNP N
Checklist NNP N
for IN N
Autism NNP N
in IN N
Toddlers NNP N
( ( N
M-CHAT NNP N
) ) N
. . N

There EX N
were VBD N
significant JJ N
treatment NN N
effects NNS o
for IN N
the DT N
PlayWisely NNP N
measure NN N
on IN N
the DT N
Yellow NNP N
Sets NNPS N
that WDT N
examine VBP N
recognition NN o
; : o
Purple NNP N
Sets VBZ N
that IN N
examine NN N
brain NN o
region NN o
agility NN o
and CC o
early JJ o
memory NN o
skills NNS o
; : o
Blue NNP N
Sets NNPS N
that WDT N
examine VBP N
phonemic JJ o
awareness NN o
and CC o
recognition NN o
; : o
and CC N
for IN N
the DT N
Total NNP N
Sets NNP N
, , N
with IN N
a DT N
similar JJ N
trend NN N
toward IN N
improvement NN N
in IN N
the DT N
Green JJ N
Sets NNS N
that WDT N
examine VBP N
perception NN N
and CC N
Red NNP N
Sets NNP N
that IN N
examine JJ N
attention NN o
. . o

No DT N
other JJ N
measures NNS N
reached VBD N
statistical JJ N
significance NN N
. . N

The DT N
results NNS N
suggest VBP N
that IN N
PlayWisely RB N
can MD N
improve VB N
recognition NN o
, , o
brain NN o
region NN o
agility NN o
, , o
phonemic JJ o
awareness NN o
, , o
letter NN o
recognition NN o
, , o
and CC o
early JJ o
memory NN o
skills NNS o
in IN N
ASD NNP N
. . N

It PRP N
was VBD N
observed VBN N
by IN N
the DT N
parents NNS N
, , N
coaches NNS N
, , N
and CC N
study NN N
investigators NNS N
that IN N
the DT N
children NNS N
who WP N
were VBD N
less JJR N
than IN N
3 CD N
years NNS N
of IN N
age NN N
showed VBD N
improvements NNS N
in IN N
autism NN o
symptoms NNS o
; : o
however RB N
, , N
the DT N
group NN N
was VBD N
too RB N
small JJ N
to TO N
reach VB N
statistical JJ N
significance NN N
. . N

Future JJ N
studies NNS N
are VBP N
needed VBN N
to TO N
see VB N
if IN N
this DT N
intervention NN N
can MD N
mitigate VB N
autism NN o
symptoms NNS o
in IN N
very RB N
young JJ N
children NNS N
with IN N
ASD NNP N
. . N

-DOCSTART- -18235151- O O

Reduced VBN N
albuminuria NNS N
with IN N
sarpogrelate NN i
is VBZ N
accompanied VBN N
by IN N
a DT N
decrease NN N
in IN N
monocyte JJ N
chemoattractant JJ N
protein-1 NN N
levels NNS N
in IN N
type NN p
2 CD p
diabetes NNS p
. . p

BACKGROUND NNP N
AND NNP N
OBJECTIVES NNP N
Sarpogrelate NNP i
has VBZ N
been VBN N
shown VBN N
to TO N
reduce VB N
albuminuria NNS N
in IN N
diabetic JJ N
nephropathy NN N
. . N

For IN N
examination NN N
of IN N
whether IN N
this DT N
is VBZ N
based VBN N
on IN N
the DT N
same JJ N
mechanisms NN N
as IN N
angiotensin NN N
II NNP N
receptor NN N
blockers NNS N
or CC N
thiazolidinedione NN i
, , N
effects NNS N
of IN N
sarpogrelate NN i
on IN N
atherosclerotic JJ N
inflammatory NN N
molecules NNS N
and CC N
their PRP$ N
relations NNS N
to TO N
albuminuria NNS N
in IN N
patients NNS p
who WP p
had VBD p
diabetes NNS p
and CC p
had VBD p
already RB p
been VBN p
treated VBN p
with IN p
angiotensin NN i
II NNP i
receptor NN i
blockers NNS i
and CC p
with IN p
or CC p
without IN p
thiazolidinedione NN i
were VBD N
examined VBN N
. . N

DESIGN NNP N
, , N
SETTING NNP N
, , N
PARTICIPANTS NNP N
, , N
& CC N
MEASUREMENTS NNP N
Forty NNP p
patients NNS p
who WP p
had VBD p
diabetes NNS p
with IN p
nephropathy JJ p
and CC p
arteriosclerosis NN p
obliterans NNS p
and CC p
had VBD p
already RB p
been VBN p
treated VBN p
with IN p
angiotensin NN i
II NNP i
receptor NN i
blocker NN i
( ( p
n JJ p
= NNP p
40 CD p
) ) p
were VBD N
randomly RB N
assigned VBN N
to TO N
sarpogrelate VB i
( ( N
300 CD N
mg/d NN N
; : N
n CC N
= VB N
20 CD N
) ) N
or CC N
aspirin JJ i
group NN i
( ( N
100 CD N
mg/d NN N
; : N
n CC N
= VB N
20 CD N
) ) N
. . N

Plasma NNP o
monocyte JJ o
chemoattractant JJ o
protein-1 NN o
and CC o
urinary JJ o
albumin-to-creatinine JJ o
ratio NN o
and CC o
monocyte NN o
chemoattractant JJ o
protein-1 NN o
were VBD N
measured VBN N
at IN N
baseline NN N
and CC N
16 CD N
wk NN N
after IN N
administration NN N
. . N

RESULTS NNP N
Only RB N
the DT N
sarpogrelate NN i
group NN N
showed VBD N
increases NNS N
in IN N
plasma NN o
adiponectin NN o
and CC N
decreases NNS N
in IN N
both DT N
plasma NN o
and CC o
urinary JJ o
monocyte NN o
chemoattractant JJ o
protein-1 JJ o
and CC o
albumin-to-creatinine JJ o
ratio NN o
levels NNS o
. . o

Moreover RB N
, , N
percentage NN o
change NN o
of IN o
monocyte NN o
chemoattractant JJ o
protein-1 JJ o
level NN o
correlated VBD N
positively RB N
to TO N
that DT N
of IN N
albumin-to-creatinine JJ N
ratio NN N
. . N

Even RB N
when WRB N
the DT N
sarpogrelate NN i
group NN N
was VBD N
further RB N
divided VBN N
into IN N
two CD N
groups NNS N
with IN N
( ( N
n JJ N
= NNP N
9 CD N
) ) N
or CC N
without IN N
thiazolidinedione NN i
( ( N
n JJ N
= NNP N
11 CD N
) ) N
, , N
changes NNS N
in IN N
monocyte NN o
chemoattractant JJ o
protein-1 JJ o
or CC o
albumin-to-creatinine JJ o
ratio NN o
did VBD N
not RB N
differ VB N
. . N

CONCLUSIONS NNP N
Sarpogrelate NNP i
can MD N
reduce VB N
albuminuria NNS N
and CC N
plasma NN N
and CC N
urinary JJ N
monocyte NN N
chemoattractant JJ N
protein-1 JJ N
levels NNS N
while IN N
increasing VBG N
plasma NN N
adiponectin NN N
in IN N
diabetic JJ N
nephropathy NN N
. . N

These DT N
effects NNS N
seem VBP N
to TO N
be VB N
mediated VBN N
via IN N
mechanisms NNS N
that WDT N
are VBP N
different JJ N
from IN N
those DT N
of IN N
angiotensin JJ i
II NNP i
receptor NN i
blocker NN i
or CC N
thiazolidinedione NN i
. . i

-DOCSTART- -14627879- O O

Parent-defined JJ N
target NN N
symptoms NNS N
respond NN N
to TO N
risperidone VB i
in IN N
RUPP NNP p
autism NN p
study NN p
: : p
customer NN N
approach NN N
to TO N
clinical JJ N
trials NNS N
. . N

OBJECTIVE VB N
A DT N
consumer-oriented JJ N
efficacy NN N
assessment NN N
in IN N
clinical JJ N
trials NNS N
should MD N
measure VB N
changes NNS N
in IN N
chief NN N
complaint NN N
and CC N
consumer NN N
request NN N
( ( N
symptoms NNS N
of IN N
most JJS N
concern NN N
to TO N
patient/caregiver NN N
) ) N
, , N
which WDT N
may MD N
be VB N
diluted VBN N
in IN N
change NN N
scores NNS N
of IN N
multisymptom NN N
scales NNS N
. . N

METHOD NNP N
In IN N
the DT N
Research NNP p
Units NNP p
on IN p
Pediatric NNP p
Psychopharmacology NNP p
( ( p
RUPP NNP p
) ) p
Autism NNP p
Network NNP p
8-week JJ N
double-blind JJ N
trial NN N
of IN N
risperidone NN i
versus NN i
placebo NN i
, , N
the DT N
chief JJ N
concerns NNS N
of IN N
parents NNS p
were VBD N
collected VBN N
at IN N
0 CD N
, , N
4 CD N
, , N
and CC N
8 CD N
weeks NNS N
( ( N
endpoint NN N
) ) N
, , N
in IN N
addition NN N
to TO N
standardized JJ N
primary JJ N
measures NNS N
. . N

Blinded NNP N
clinical JJ N
judges NNS N
rated VBN N
change NN N
from IN N
baseline NN N
to TO N
4 CD N
and CC N
8 CD N
weeks NNS N
on IN N
a DT N
9-point JJ N
scale NN N
( ( N
1 CD N
= NNP N
normalized VBD N
, , N
5 CD N
= NN N
unchanged JJ N
, , N
9 CD N
= NNP N
disastrous JJ N
) ) N
; : N
94 CD p
participants NNS p
had VBD p
usable JJ p
data NNS p
. . p

RESULTS VB N
The DT N
most RBS N
common JJ N
symptoms NNS N
identified VBN N
by IN N
parents NNS N
were VBD N
tantrums NNS o
, , o
aggression NN o
, , o
and CC o
hyperactivity NN o
. . o

Interrater NNP o
reliability NN o
was VBD N
excellent JJ N
. . N

Mean JJ o
ratings NNS o
at IN o
endpoint NN o
were VBD N
2.8 CD N
+/- JJ N
1.2 CD N
on IN N
risperidone NN i
and CC N
4.5 CD N
+/- JJ N
1.3 CD N
on IN N
placebo NN i
( ( N
p JJ N
< NNP N
.001 NNP N
) ) N
. . N

Ratings NNS N
were VBD N
collinear JJ N
with IN N
Clinical JJ o
Global NNP o
Impression-Improvement NN o
and CC N
Aberrant NNP o
Behavior NNP o
Checklist NNP o
Irritability NNP o
subscale NN N
( ( N
primary JJ N
dimensional JJ N
measure NN N
) ) N
. . N

Effect JJ o
size NN o
d NN o
was VBD N
1.4 CD N
, , N
compared VBN N
to TO N
1.2 CD N
on IN N
the DT N
Aberrant NNP o
Behavior NNP o
Checklist NNP o
Irritability NNP N
subscale NN N
. . N

Effect NNP o
sizes VBZ o
varied VBN N
twofold JJ N
by IN N
symptom JJ N
category NN N
, , N
largest JJS N
for IN N
self-injury NN N
( ( N
2.11 CD N
) ) N
and CC N
tantrums NNS N
( ( N
1.95 CD N
) ) N
. . N

CONCLUSIONS NNP N
Risperidone NNP i
was VBD N
superior JJ N
to TO N
placebo VB i
in IN N
reducing VBG N
symptoms NNS o
of IN N
most JJS N
concern NN N
to TO N
parents NNS p
of IN p
autistic JJ p
children NNS p
with IN p
irritable JJ o
behavior NN o
. . o

Rating VBG N
individualized JJ N
participant-chosen JJ N
target NN N
symptoms NNS N
seems VBZ N
a DT N
reliable JJ N
, , N
sensitive JJ N
, , N
efficient JJ N
, , N
and CC N
consumer-friendly JJ N
way NN N
to TO N
assess VB N
treatment NN N
effect NN N
and CC N
might MD N
have VB N
clinical JJ N
application NN N
. . N

-DOCSTART- -12457629- O O

Pharmacokinetics NNS p
of IN p
azithromycin NN i
in IN p
lung NN p
tissue NN p
, , p
bronchial JJ p
washing NN p
, , p
and CC p
plasma NN p
in IN p
patients NNS p
given VBN p
multiple JJ p
oral JJ p
doses NNS p
of IN p
500 CD p
and CC p
1000 CD p
mg JJ p
daily RB p
. . p

The DT N
present JJ N
study NN N
compares VBZ N
the DT N
pharmacokinetics NNS p
of IN p
azithromycin NN i
in IN N
plasma NN N
, , N
lung NN N
tissue NN N
, , N
and CC N
bronchial JJ N
washing NN N
after IN N
oral JJ N
administration NN N
of IN N
500 CD N
mg NNS N
( ( N
standard JJ N
dose NN N
) ) N
versus NN N
1000 CD N
mg JJ N
daily JJ N
for IN N
3 CD N
days NNS N
. . N

Samples NNS N
were VBD N
taken VBN N
during IN N
surgery NN N
for IN N
lung NN N
resection NN N
at IN N
various JJ N
time NN N
points NNS N
up RB N
to TO N
204 CD N
h NN N
after IN N
the DT N
last JJ N
drug NN N
dose NN N
, , N
and CC N
azithromycin NN i
levels NNS N
were VBD N
analyzed VBN N
by IN N
HPLC NNP N
method NN N
. . N

Azithromycin NNP i
was VBD N
widely RB N
distributed VBN N
within IN N
the DT N
lower JJR N
respiratory NN N
tract NN N
; : N
sustained VBN o
concentrations NNS o
of IN o
the DT o
drug NN o
were VBD N
detectable JJ N
at IN N
the DT N
last JJ N
sampling JJ N
time NN N
( ( N
204 CD N
h NN N
) ) N
in IN N
lung NN N
tissue NN N
and CC N
bronchial JJ N
washing NN N
, , N
with IN N
long JJ N
terminal JJ N
half-lives NNS N
of IN N
132.86 CD N
and CC N
74.32 CD N
h NN N
at IN N
500 CD N
mg JJ N
daily JJ N
and CC N
133.32 CD N
and CC N
70.5 CD N
h NN N
at IN N
1000 CD N
mg JJ N
daily RB N
, , N
respectively RB N
. . N

Doubling VBG N
the DT N
drug NN N
dose NN N
resulted VBD N
in IN N
a DT N
remarkable JJ N
increase NN N
in IN N
lung JJ o
area NN o
under IN o
the DT o
curve NN o
( ( N
AUC NNP N
, , N
1318 CD N
hx NN N
microg NN N
g NN N
( ( N
-1 NNP N
) ) N
vs NN N
2502 CD N
hx NN N
microg NN N
g NN N
( ( N
-1 NNP N
) ) N
) ) N
and CC N
peak JJ N
tissue NN N
concentration NN N
( ( N
9.13+/-0.53 JJ N
microg NN N
g NN N
( ( N
-1 NNP N
) ) N
vs VBD N
17.85+/-2.4 JJ N
microg NN N
g NN N
( ( N
-1 NNP N
) ) N
) ) N
. . N

In IN N
addition NN N
to TO N
this DT N
, , N
enhanced VBD N
azithromycin JJ i
penetration NN N
from IN N
plasma NN N
into IN N
bronchial JJ N
secretion NN N
and CC N
lung NN N
tissue NN N
was VBD N
evidenced VBN N
by IN N
the DT N
increase NN N
in IN N
the DT N
ratio NN o
of IN o
AUC NNP o
( ( o
bronchial JJ o
washing NN o
) ) o
versus NN o
AUC NNP o
( ( o
plasma NN o
) ) o
( ( N
2.96 CD N
vs RB N
5.27 CD N
at IN N
500 CD N
and CC N
1000 CD N
mg NN N
, , N
respectively RB N
) ) N
and CC N
AUC NNP o
( ( o
lung NN o
) ) o
versus NN o
AUC NNP o
( ( o
plasma NN o
) ) o
( ( N
64.35 CD N
vs RB N
97.73 CD N
at IN N
500 CD N
and CC N
1000 CD N
mg NN N
, , N
respectively RB N
) ) N
. . N

In IN N
conclusion NN N
, , N
the DT N
exposure NN N
of IN N
lung NN N
and CC N
bronchial JJ N
washing NN N
to TO N
azithromycin VB i
is VBZ N
increased VBN N
by IN N
doubling VBG N
the DT N
dose NN N
, , N
which WDT N
results NNS N
in IN N
favorable JJ N
pharmacokinetic JJ o
profile NN o
of IN N
the DT N
drug NN N
in IN N
the DT N
lower JJR N
respiratory NN N
tract NN N
. . N

-DOCSTART- -16879519- O O

Pharmacokinetic-pharmacodynamic JJ N
relationship NN N
of IN N
rocuronium NN i
under IN p
stable JJ p
nitrous JJ i
oxide-fentanyl JJ i
or CC p
nitrous JJ i
oxide-sevoflurane JJ i
anesthesia NN i
in IN p
children NNS p
. . p

BACKGROUND IN N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
pharmacokinetics NNS N
and CC N
pharmacokinetic-pharmacodynamic JJ N
( ( N
PK-PD NNP N
) ) N
relationship NN N
of IN N
rocuronium NN i
in IN N
children NNS p
anesthetized VBN p
with IN p
nitrous JJ i
oxide NN i
( ( i
N2O NNP i
) ) i
and CC i
fentanyl $ i
or CC p
with IN p
N2O NNP i
and CC i
sevoflurane NN i
. . i

METHODS NNP N
Twenty-four JJ p
children NNS p
( ( p
3-11 CD p
years NNS p
old JJ p
, , p
ASA NNP p
PS NNP p
I PRP p
or CC p
II NNP p
) ) p
were VBD p
randomized VBN p
to TO N
receive VB N
N2O/O2-fentanyl NNP i
or CC i
N2O/O2-sevoflurane NNP i
( ( i
one CD i
MAC NNP i
) ) i
anesthesia NN i
. . i

Neuromuscular JJ N
transmission NN N
was VBD N
monitored VBN N
electromyographically RB i
. . i

Initial JJ N
bolus NN N
dose NN N
of IN N
rocuronium NN i
, , N
0.6 CD N
mg NN N
x NN N
kg NN N
( ( N
-1 NNP N
) ) N
was VBD N
followed VBN N
by IN N
continuous JJ N
infusion NN N
, , N
targeting VBG N
at IN N
steady-state JJ N
95 CD N
% NN N
T1 NNP N
depression NN N
. . N

Neuromuscular JJ N
transmission NN N
was VBD N
allowed VBN N
to TO N
recover VB N
spontaneously RB N
. . N

Plasma NNP N
samples NNS N
were VBD N
collected VBN N
at IN N
the DT N
moment NN N
of IN N
discontinuation NN N
of IN N
infusion NN N
, , N
and CC N
10 CD N
, , N
20 CD N
, , N
30 CD N
, , N
50 CD N
, , N
60 CD N
and CC N
75 CD N
min NN N
afterwards NNS N
. . N

Concentrations NNS N
of IN N
rocuronium NN N
were VBD N
measured VBN N
using VBG N
high-performance NN N
liquid NN N
chromatography NN N
with IN N
electrochemical JJ N
detection NN N
( ( N
HPLC-EC NNP N
) ) N
. . N

Rocuronium NNP N
PK NNP N
was VBD N
described VBN N
by IN N
a DT N
two-compartment JJ N
model NN N
and CC N
PD NNP N
parameters NNS N
were VBD N
estimated VBN N
using VBG N
effect NN N
compartment NN N
and CC N
sigmoidal JJ N
E NNP N
( ( N
max NN N
) ) N
models NNS N
. . N

RESULTS NNP N
No NNP N
differences NNS N
in IN N
rocuronium NN o
PK NNP o
parameters NNS o
were VBD N
observed VBN N
between IN N
study NN N
groups NNS N
. . N

Clearance NNP o
was VBD N
3.91 CD N
+/- JJ N
2.07 CD N
and CC N
3.62 CD N
+/- JJ N
0.80 CD N
ml NN N
x NN N
min NN N
( ( N
-1 NNP N
) ) N
x VBP N
kg NN N
( ( N
-1 NN N
) ) N
in IN N
sevoflurane NN N
and CC N
fentanyl NN N
groups NNS N
, , N
respectively RB N
( ( N
P NNP N
< NNP N
0.65 CD N
) ) N
. . N

Effect JJ o
compartment JJ o
concentrations NNS o
corresponding VBG o
to TO o
50 CD o
% NN o
inhibition NN o
of IN o
T1 NNP o
( ( N
EC50 NNP N
) ) N
were VBD N
1.41 CD N
+/- JJ N
0.45 CD N
and CC N
2.32 CD N
+/- JJ N
1.00 CD N
microg NN N
x NN N
ml NN N
( ( N
-1 NN N
) ) N
( ( N
P NNP N
< NNP N
0.02 CD N
) ) N
, , N
and CC N
rate NN o
constants NNS o
for IN o
equilibration NN o
between IN o
plasma NN o
and CC o
effect NN o
compartment NN o
( ( o
k NN o
( ( o
e0 NN o
) ) o
) ) o
values NNS N
were VBD N
0.10 CD N
+/- JJ N
0.04 CD N
and CC N
0.24 CD N
+/- JJ N
0.14 CD N
min NN N
( ( N
-1 NN N
) ) N
( ( N
P NNP N
< NNP N
0.009 CD N
) ) N
in IN N
sevoflurane NN N
and CC N
fentanyl NN N
groups NNS N
, , N
respectively RB N
. . N

CONCLUSIONS NNP N
Disposition NNP o
of IN o
rocuronium NN o
was VBD N
similar JJ N
under IN N
stable JJ N
N2O-fentanyl JJ N
and CC N
N2O-sevoflurane JJ N
anesthesia NN N
. . N

Sevoflurane NNP N
reduced VBD N
rocuronium NN o
requirements NNS o
as RB N
well RB N
as IN N
decreased VBN N
EC50 NNP o
relevant JJ o
to TO o
inhibition NN o
of IN o
T1 NNP o
and CC N
rocuronium NN o
transfer NN o
to TO o
effect NN o
compartment NN o
. . o

Therefore RB N
, , N
the DT N
potentiating VBG N
effect NN N
of IN N
sevoflurane NN N
seems VBZ N
to TO N
be VB N
mainly RB N
of IN N
PD NNP N
origin NN N
, , N
probably RB N
due JJ N
to TO N
an DT N
increased VBN N
sensitivity NN N
of IN N
the DT N
neuromuscular JJ N
junction NN N
. . N

-DOCSTART- -12049860- O O

Postoperative JJ i
fondaparinux NN i
versus NN i
postoperative JJ i
enoxaparin NN i
for IN N
prevention NN N
of IN N
venous JJ o
thromboembolism NN o
after IN p
elective JJ p
hip-replacement JJ p
surgery NN p
: : p
a DT N
randomised JJ N
double-blind JJ N
trial NN N
. . N

BACKGROUND NNP N
Elective NNP N
hip-replacement NN N
surgery NN N
carries VBZ N
significant JJ N
risk NN N
of IN N
venous JJ o
thromboembolism NN o
, , N
despite IN N
use NN N
of IN N
thromboprophylaxis NN i
. . i

We PRP N
aimed VBD N
to TO N
see VB N
whether IN N
the DT N
pentasaccharide NN i
fondaparinux NN i
, , N
the DT N
first JJ N
drug NN N
of IN N
a DT N
new JJ N
class NN N
of IN N
synthetic JJ i
antithrombotic JJ i
agents NNS i
, , N
could MD N
reduce VB N
this DT N
risk NN N
to TO N
a DT N
greater JJR N
extent NN N
than IN N
other JJ N
available JJ N
treatments NNS N
. . N

METHODS NNP N
In IN N
a DT N
double-blind NN N
study NN N
, , N
we PRP p
randomly VBP p
assigned JJ p
2275 CD p
consecutive JJ p
patients NNS p
aged VBN p
18 CD p
years NNS p
or CC p
older JJR p
who WP p
were VBD p
undergoing VBG p
elective JJ p
hip-replacement JJ p
surgery NN p
to TO p
receive VB p
postoperative JJ p
subcutaneous JJ p
injections NNS p
of IN p
either DT p
2.5 CD i
mg NN i
fondaparinux NN i
once RB i
daily JJ i
or CC i
30 CD i
mg NNS i
enoxaparin JJ i
twice RB p
daily RB p
. . p

The DT N
primary JJ N
efficacy NN N
outcome NN N
was VBD N
venous JJ o
thromboembolism NN o
to TO N
day NN N
11 CD N
. . N

The DT N
main JJ N
safety NN N
outcomes NNS N
were VBD N
bleeding VBG o
and CC o
death NN o
. . o

Patients NNS N
were VBD N
followed VBN N
up RP N
for IN N
6 CD N
weeks NNS N
. . N

FINDINGS IN N
We PRP N
assessed VBD N
venous JJ o
thromboembolism NN o
to TO N
day NN N
11 CD N
in IN N
1584 CD N
( ( N
70 CD N
% NN N
) ) N
of IN N
2275 CD N
patients NNS N
. . N

By IN N
day NN N
11 CD N
, , N
venous JJ o
thromboembolisms NNS o
were VBD N
recorded VBN N
in IN N
48 CD N
( ( N
6 CD N
% NN N
) ) N
of IN N
787 CD N
patients NNS N
on IN N
fondaparinux NN i
and CC N
in IN N
66 CD N
( ( N
8 CD N
% NN N
) ) N
of IN N
797 CD N
patients NNS N
on IN N
enoxaparin NN i
. . i

The DT N
relative JJ N
reduction NN N
in IN N
risk NN o
was VBD N
26.3 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
-10.8 NNP N
to TO N
52.8 CD N
, , N
p=0.099 NN N
) ) N
. . N

The DT N
two CD N
groups NNS N
did VBD N
not RB N
differ VB N
in IN N
the DT N
number NN N
of IN N
patients NNS o
who WP o
died VBD o
or CC N
in IN N
the DT N
number NN N
who WP N
had VBD N
clinically RB o
relevant JJ o
bleeding NN o
. . o

INTERPRETATION NNP N
In IN N
patients NNS N
undergoing VBG N
elective JJ N
hip-replacement JJ N
surgery NN N
, , N
2.5 CD N
mg NN N
fondaparinux NN i
once RB N
daily RB N
was VBD N
not RB N
significantly RB N
more RBR N
effective JJ N
than IN N
30 CD N
mg JJ N
enoxaparin JJ i
twice RB N
daily RB N
in IN N
reducing VBG N
risk NN N
of IN N
venous JJ o
thromboembolism NN o
. . o

However RB N
, , N
the DT N
lower JJR N
risk NN N
recorded VBN N
with IN N
fondaparinux NN i
than IN N
enoxaparin NN i
was VBD N
clinically RB N
important JJ N
, , N
with IN N
no DT N
increase NN N
in IN N
clinically RB o
relevant JJ o
bleeding NN o
. . o

-DOCSTART- -26138912- O O

Predicting VBG N
Overall JJ o
Survival NNP o
After IN o
Stereotactic NNP o
Ablative NNP o
Radiation NNP o
Therapy NNP o
in IN N
Early-Stage NNP N
Lung NNP N
Cancer NNP N
: : N
Development NNP N
and CC N
External NNP N
Validation NNP N
of IN N
the DT N
Amsterdam NNP N
Prognostic NNP N
Model NNP N
. . N

PURPOSE VB N
A NNP N
prognostic JJ N
model NN N
for IN N
5-year JJ N
overall JJ N
survival NN N
( ( N
OS NNP N
) ) N
, , N
consisting VBG N
of IN N
recursive JJ N
partitioning NN N
analysis NN N
( ( N
RPA NNP N
) ) N
and CC N
a DT N
nomogram NN N
, , N
was VBD N
developed VBN N
for IN N
patients NNS p
with IN p
early-stage JJ p
non-small JJ p
cell NN p
lung NN p
cancer NN p
( ( p
ES-NSCLC NNP p
) ) p
treated VBD p
with IN p
stereotactic JJ i
ablative JJ i
radiation NN i
therapy NN i
( ( i
SABR NNP i
) ) i
. . i

METHODS NNP N
AND NNP N
MATERIALS NNP N
A NNP p
primary JJ p
dataset NN p
of IN p
703 CD p
ES-NSCLC JJ p
SABR NNP i
patients NNS p
was VBD N
randomly RB N
divided VBN N
into IN N
a DT N
training NN N
( ( N
67 CD N
% NN N
) ) N
and CC N
an DT N
internal JJ N
validation NN N
( ( N
33 CD N
% NN N
) ) N
dataset NN N
. . N

In IN N
the DT N
former JJ N
group NN N
, , N
21 CD N
unique JJ N
parameters NNS N
consisting VBG N
of IN N
patient NN o
, , o
treatment NN o
, , o
and CC o
tumor NN o
factors NNS o
were VBD N
entered VBN N
into IN N
an DT N
RPA NNP N
model NN N
to TO N
predict VB N
OS NNP N
. . N

Univariate NNP N
and CC N
multivariate NN N
models NNS N
were VBD N
constructed VBN N
for IN N
RPA-selected JJ N
factors NNS N
to TO N
evaluate VB N
their PRP$ N
relationship NN N
with IN N
OS NNP N
. . N

A DT N
nomogram NN N
for IN N
OS NNP N
was VBD N
constructed VBN N
based VBN N
on IN N
factors NNS N
significant JJ N
in IN N
multivariate NN N
modeling NN N
and CC N
validated VBN N
with IN N
calibration NN N
plots NNS N
. . N

Both CC N
the DT N
RPA NNP N
and CC N
the DT N
nomogram NN N
were VBD N
externally RB N
validated VBN N
in IN N
independent JJ N
surgical JJ N
( ( N
n JJ N
= NNP N
193 CD N
) ) N
and CC N
SABR NNP N
( ( N
n JJ N
= NNP N
543 CD N
) ) N
datasets NNS N
. . N

RESULTS NNP N
RPA NNP o
identified VBD o
2 CD o
distinct JJ o
risk NN o
classes NNS o
based VBN o
on IN o
tumor NN o
diameter NN o
, , o
age NN o
, , o
World NNP o
Health NNP o
Organization NNP o
performance NN o
status NN o
( ( o
PS NNP o
) ) o
and CC o
Charlson NNP o
comorbidity NN o
index NN o
. . o

This DT N
RPA NNP N
had VBD N
moderate JJ N
discrimination NN N
in IN N
SABR NNP N
datasets NNS N
( ( N
c-index NN N
range NN N
: : N
0.52-0.60 JJ N
) ) N
but CC N
was VBD N
of IN N
limited JJ N
value NN N
in IN N
the DT N
surgical JJ N
validation NN N
cohort NN N
. . N

The DT N
nomogram JJ N
predicting NN N
OS NNP N
included VBD N
smoking VBG N
history NN N
in IN N
addition NN N
to TO N
RPA-identified JJ N
factors NNS N
. . N

In IN N
contrast NN N
to TO N
RPA NNP N
, , N
validation NN N
of IN N
the DT N
nomogram NN N
performed VBN N
well RB N
in IN N
internal JJ N
validation NN N
( ( N
r NN N
( ( N
2 CD N
) ) N
= FW N
0.97 CD N
) ) N
and CC N
external JJ N
SABR NNP N
( ( N
r NN N
( ( N
2 CD N
) ) N
= FW N
0.79 CD N
) ) N
and CC N
surgical JJ N
cohorts NNS N
( ( N
r NN N
( ( N
2 CD N
) ) N
= FW N
0.91 CD N
) ) N
. . N

CONCLUSIONS VB N
The DT N
Amsterdam NNP o
prognostic JJ o
model NN o
is VBZ N
the DT N
first JJ N
externally RB N
validated VBN N
prognostication NN N
tool NN N
for IN N
OS NNP N
in IN N
ES-NSCLC NNP N
treated VBD N
with IN N
SABR NNP N
available JJ N
to TO N
individualize VB N
patient JJ N
decision NN N
making NN N
. . N

The DT N
nomogram NN N
retained VBD N
strong JJ N
performance NN N
across IN N
surgical JJ N
and CC N
SABR NNP N
external JJ N
validation NN N
datasets NNS N
. . N

RPA NNP o
performance NN o
was VBD N
poor JJ N
in IN N
surgical JJ N
patients NNS N
, , N
suggesting VBG N
that IN N
2 CD N
different JJ N
distinct JJ N
patient NN N
populations NNS N
are VBP N
being VBG N
treated VBN N
with IN N
these DT N
2 CD N
effective JJ N
modalities NNS N
. . N

-DOCSTART- -26449739- O O

Rituximab NNP i
maintenance NN N
improves VBZ N
survival NN N
in IN N
male JJ p
patients NNS p
with IN p
diffuse JJ p
large JJ p
B-cell NNP p
lymphoma NN p
. . p

Results NNS N
of IN N
the DT N
HD2002 NNP N
prospective JJ N
multicentre NN p
randomized VBD N
phase NN N
III NNP N
trial NN N
. . N

In IN N
the DT N
multicentre NN N
prospective JJ N
randomized VBN N
HD2002 NNP N
trial NN N
, , N
rituximab JJ i
maintenance NN i
therapy NN i
( ( N
375 CD N
mg/m NN N
( ( N
2 CD N
) ) N
every DT N
3 CD N
months NNS N
for IN N
2 CD N
years NNS N
) ) N
versus VBP N
observation NN i
was VBD N
evaluated VBN N
for IN N
CD20 NNP N
( ( N
+ NNP N
) ) N
B-cell NNP N
lymphoma NN N
. . N

Out IN N
of IN N
321 CD p
patients NNS p
[ JJ p
161 CD p
randomized VBN p
to TO p
the DT p
treatment NN p
group NN p
( ( p
TG NNP p
) ) p
, , p
160 CD p
to TO p
the DT p
observation NN p
group NN p
( ( p
OG NNP p
) ) p
] NN p
, , p
295 CD p
data NNS p
sets NNS p
were VBD N
evaluable JJ N
for IN N
statistical JJ N
analysis NN N
. . N

Estimated VBN N
5-year JJ o
relapse-free JJ o
survival NN o
( ( o
RFS NNP o
) ) o
was VBD N
81 CD N
% NN N
in IN N
the DT N
TG NNP N
and CC N
70 CD N
% NN N
in IN N
the DT N
OG NNP N
( ( N
logrank JJ N
test NN N
, , N
P NNP N
= NNP N
0?047 CD N
) ) N
. . N

In IN N
the DT N
diffuse NN N
large JJ N
B-cell NNP N
lymphoma NN N
( ( N
DLBCL NNP p
) ) p
subgroup NN p
( ( N
n JJ N
= NNP N
152 CD N
) ) N
, , N
5-year JJ o
RFS NNP o
was VBD N
excellent JJ N
, , N
at IN N
87 CD N
% NN N
in IN N
the DT N
TG NNP N
and CC N
84 CD N
% NN N
in IN N
the DT N
OG NNP N
( ( N
logrank JJ N
test NN N
, , N
P NNP N
= NNP N
0?35 CD N
) ) N
. . N

Of IN N
note NN N
, , N
only RB N
in IN N
male JJ p
patients NNS p
of IN p
the DT p
DLBCL NNP p
subgroup NN p
was VBD o
RFS NNP o
significantly RB o
superior VBZ N
in IN N
the DT N
TG NNP N
in IN N
comparison NN N
to TO N
the DT N
OG NNP N
( ( N
5-year JJ N
RFS NNP N
: : N
88 CD N
% NN N
vs. FW N
74 CD N
% NN N
; : N
logrank JJ N
test NN N
, , N
P NNP N
= NNP N
0?05 CD N
) ) N
. . N

Cox NNP N
regression NN N
analysis NN N
showed VBD N
a DT N
significant JJ N
interaction NN N
between IN N
treatment NN N
and CC N
gender NN N
regarding VBG o
overall JJ o
survival NN o
( ( o
OS NNP o
) ) o
( ( o
P NNP o
= NNP N
0?006 CD N
) ) N
and CC N
RFS NNP o
( ( N
P NNP N
= NNP N
0?02 CD N
) ) N
, , N
with IN N
a DT N
lower JJR N
hazard NN N
in IN N
females NNS N
than IN N
males NNS N
in IN N
the DT o
OG NNP o
[ NNP o
OS NNP o
: : o
hazard NN o
ratio NN o
( ( o
HR NNP o
) ) o
( ( N
female JJ N
: : N
male NN N
) ) N
= VBZ N
0?11 CD N
; : N
95 CD o
% NN o
confidence NN o
interval NN o
( ( o
CI NNP o
) ) o
= VBZ N
0?00-1?03 JJ o
; : o
RFS NNP o
: : o
HR NNP o
( ( N
female JJ N
: : N
male NN N
) ) N
= VBZ N
0?27 CD N
; : N
95 CD N
% NN N
CI NNP N
= NNP N
0?05-0?97 JJ N
] NNP N
, , N
and CC N
no DT N
significant JJ N
differences NNS N
between IN N
males NNS N
and CC N
females NNS N
in IN N
the DT N
TG NNP N
. . N

We PRP N
conclude VBP N
that IN i
Rituximab NNP i
maintenance NN i
therapy NN i
improves VBZ i
survival NN N
in IN N
male JJ p
patients NNS p
with IN p
DLBCL NNP p
. . N

-DOCSTART- -17603862- O O

Effects NNS N
of IN N
low-level JJ i
laser NN i
and CC i
plyometric JJ i
exercises NNS i
in IN N
the DT N
treatment NN N
of IN N
lateral JJ p
epicondylitis NN p
. . p

OBJECTIVE CC N
This DT N
study NN N
was VBD N
undertaken VBN N
to TO N
compare VB N
the DT N
effectiveness NN N
of IN N
a DT N
protocol NN N
of IN N
combination NN N
of IN N
laser NN i
with IN i
plyometric JJ i
exercises NNS i
and CC N
a DT N
protocol NN N
of IN N
placebo NN i
laser NN i
with IN i
the DT i
same JJ i
program NN i
, , N
in IN N
the DT N
treatment NN N
of IN N
tennis NN p
elbow NN p
. . p

BACKGROUND NNP N
DATA NNP N
The DT N
use NN N
of IN N
low-level JJ i
laser NN i
has VBZ N
been VBN N
recommended VBN N
for IN N
the DT N
management NN N
of IN N
tennis NN p
elbow NN p
with IN N
contradictory JJ N
results NNS N
. . N

Also RB N
, , N
plyometric JJ i
exercises NNS i
was VBD N
recommended VBN N
for IN N
the DT N
treatment NN N
of IN N
the DT N
tendinopathy NN N
. . N

METHODS NNP N
Fifty NNP p
patients NNS p
who WP p
had VBD p
tennis NN p
elbow NN p
participated VBD p
in IN p
the DT p
study NN p
and CC N
were VBD N
randomised VBN N
into IN N
two CD N
groups NNS N
. . N

Group NNP N
A NNP N
( ( N
n JJ N
= NNP N
25 CD N
) ) N
was VBD N
treated VBN N
with IN N
a DT N
904 CD i
Ga-As NNP i
laser NN i
CW NNP i
, , N
frequency NN N
50 CD N
Hz NNP N
, , N
intensity NN N
40 CD N
mW NN N
and CC N
energy NN N
density NN N
2.4 CD N
J/cm NNP N
( ( N
2 CD N
) ) N
, , N
plus CC i
plyometric JJ i
exercises NNS i
and CC N
group NN N
B NNP N
( ( N
n JJ N
= NNP N
25 CD N
) ) N
that WDT N
received VBD N
placebo NNS i
laser RBR i
plus CC i
the DT i
same JJ i
plyometric JJ i
exercises NNS i
. . i

During IN N
eight CD N
weeks NNS N
of IN N
treatment NN N
, , N
the DT N
patients NNS N
of IN N
the DT N
two CD N
groups NNS N
received VBD N
12 CD N
sessions NNS N
of IN N
laser NN i
or CC i
placebo NN i
, , N
two CD N
sessions NNS N
per IN N
week NN N
( ( N
weeks NNS N
1-4 RB N
) ) N
and CC N
one CD N
session NN N
per IN N
week NN N
( ( N
weeks NNS N
5-8 RB N
) ) N
. . N

Pain NN o
at IN o
rest NN o
, , o
at IN o
palpation NN o
on IN o
the DT o
lateral JJ o
epicondyle NN o
, , o
during IN o
resisted VBN o
wrist JJ o
extension NN o
, , o
middle JJ o
finger NN o
test NN o
, , N
and CC N
strength NN o
testing NN o
was VBD N
evaluated VBN N
using VBG N
Visual NNP o
Analogue NNP o
Scales NNP o
. . o

Also RB N
it PRP N
was VBD N
evaluated VBN N
the DT N
grip NN o
strength NN o
, , N
the DT N
range NN o
of IN o
motion NN o
and CC N
weight JJ o
test NN o
. . o

Parameters NNS N
were VBD N
determined VBN N
before IN N
the DT N
treatment NN N
, , N
at IN N
the DT N
end NN N
of IN N
the DT N
eighth JJ N
week NN N
course NN N
of IN N
treatment NN N
( ( N
week NN N
8 CD N
) ) N
, , N
and CC N
eighth RB N
( ( N
week NN N
8 CD N
) ) N
after IN N
the DT N
end NN N
of IN N
treatment NN N
. . N

RESULTS NNP N
Relative NNP N
to TO N
the DT N
group NN N
B NNP N
, , N
the DT N
group NN N
A NNP N
had VBD N
( ( N
1 CD N
) ) N
a DT N
significant JJ N
decrease NN o
of IN o
pain NN o
at IN o
rest NN o
at IN N
the DT N
end NN N
of IN N
8 CD N
weeks NNS N
of IN N
the DT N
treatment NN N
( ( N
p JJ N
< NNP N
0.005 CD N
) ) N
and CC N
at IN N
the DT N
end NN N
of IN N
following VBG N
up RP N
period NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
, , N
( ( N
2 CD N
) ) N
a DT N
significant JJ N
decrease NN o
in IN o
pain NN o
at IN o
palpation NN o
and CC o
pain NN o
on IN o
isometric JJ o
testing VBG o
at IN N
8 CD N
weeks NNS N
of IN N
treatment NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
, , N
and CC N
at IN N
8 CD N
weeks NNS N
follow-up JJ N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
, , N
( ( N
3 CD N
) ) N
a DT N
significant JJ N
decrease NN N
in IN N
pain NN o
during IN o
middle JJ o
finger NN o
test NN o
at IN N
the DT N
end NN N
of IN N
8 CD N
weeks NNS N
of IN N
treatment NN N
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
, , N
and CC N
at IN N
the DT N
end NN N
of IN N
the DT N
follow-up JJ N
period NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
, , N
( ( N
4 CD N
) ) N
a DT N
significant JJ N
decrease NN o
of IN o
pain NN o
during IN o
grip NN o
strength NN o
testing VBG o
at IN N
8 CD N
weeks NNS N
of IN N
treatment NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
, , N
and CC N
at IN N
8 CD N
weeks NNS N
follow-up JJ N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
, , N
( ( N
5 CD N
) ) N
a DT N
significant JJ N
increase NN o
in IN o
the DT o
wrist NN o
range NN o
of IN o
motion NN o
at IN N
8 CD N
weeks NNS N
follow-up JJ N
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
, , N
( ( N
6 CD N
) ) N
an DT N
increase NN o
in IN o
grip JJ o
strength NN o
at IN N
8 CD N
weeks NNS N
of IN N
treatment NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
and CC N
at IN N
8 CD N
weeks NNS N
follow-up JJ N
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
, , N
and CC N
( ( N
7 CD N
) ) N
a DT N
significant JJ N
increase NN o
in IN o
weight-test JJ o
at IN N
8 CD N
weeks NNS N
of IN N
treatment NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
and CC N
at IN N
8 CD N
weeks NNS N
follow-up JJ N
( ( N
p JJ N
< NNP N
0.005 CD N
) ) N
. . N

CONCLUSION VB N
The DT N
results NNS N
suggested VBD N
that IN N
the DT N
combination NN i
of IN i
laser NN i
with IN i
plyometric JJ i
exercises NNS i
was VBD N
more RBR N
effective JJ N
treatment NN N
than IN N
placebo FW i
laser NN i
with IN i
the DT i
same JJ i
plyometric JJ i
exercises NNS i
at IN N
the DT N
end NN N
of IN N
the DT N
treatment NN N
as RB N
well RB N
as IN N
at IN N
the DT N
follow-up NN N
. . N

Future JJ N
studies NNS N
are VBP N
needed VBN N
to TO N
establish VB N
the DT N
relative JJ N
and CC N
absolute JJ N
effectiveness NN N
of IN N
the DT N
above JJ N
protocol NN N
. . N

-DOCSTART- -18165484- O O

The DT N
cost-effectiveness NN o
of IN N
parasitologic JJ N
diagnosis NN N
for IN N
malaria-suspected JJ p
patients NNS p
in IN N
an DT N
era NN N
of IN N
combination NN N
therapy NN N
. . N

The DT N
introduction NN N
of IN N
artemisinin-based JJ i
combination NN i
therapy NN i
in IN N
sub-Saharan NN p
Africa NNP p
has VBZ N
prompted VBN N
calls NNS N
for IN N
increased VBN N
use NN N
of IN N
parasitologic JJ N
diagnosis NN N
for IN N
malaria NN N
. . N

We PRP N
evaluated VBD N
the DT N
cost-effectiveness NN o
of IN N
rapid JJ i
diagnostic JJ i
tests NNS i
( ( i
RDTs NNP i
) ) i
in IN N
comparison NN N
to TO N
microscopy VB i
in IN N
guiding VBG N
treatment NN N
of IN N
non-severe JJ N
febrile JJ N
illness NN N
at IN N
varying VBG N
levels NNS N
of IN N
malaria NN N
endemicity NN N
using VBG N
data NNS N
on IN N
test NN N
accuracy NN N
and CC N
costs NNS o
collected VBN N
as IN N
part NN N
of IN N
a DT N
Tanzanian JJ p
trial NN p
. . p

If IN N
prescribers NNS N
complied VBD N
with IN N
current JJ N
guidelines NNS N
, , N
microscopy NN N
would MD N
give VB N
rise NN N
to TO N
lower JJR N
average NN N
costs NNS o
per IN N
patient NN N
correctly RB N
treated VBD N
than IN N
RDTs NNP i
in IN N
areas NNS N
of IN N
both DT N
high JJ N
and CC N
low JJ N
transmission NN N
. . N

RDT NNP N
introduction NN N
would MD N
result VB N
in IN N
an DT N
additional JJ N
2.3 CD N
% NN N
and CC N
9.4 CD o
% NN o
of IN o
patients NNS o
correctly RB o
treated VBN o
, , N
at IN N
an DT N
incremental JJ o
cost NN o
of IN N
$ $ N
25 CD N
and CC N
$ $ N
7 CD N
in IN N
the DT N
low JJ N
and CC N
high JJ N
transmission NN N
settings NNS N
, , N
respectively RB N
. . N

Cost-effectiveness NNP o
would MD N
be VB N
worse JJR N
if IN N
prescribers NNS N
do VBP N
not RB N
comply VB N
with IN N
test NN N
results NNS N
. . N

The DT N
cost NN N
of IN N
this DT N
additional JJ N
benefit NN N
may MD N
be VB N
higher JJR N
than IN N
many JJ N
countries NNS N
can MD N
afford VB N
without IN N
external JJ N
assistance NN N
or CC N
lower JJR N
RDT NNP N
prices NNS N
. . N

-DOCSTART- -21270510- O O

Prevalence NN o
of IN o
metabolic JJ o
syndrome NN o
in IN N
rural JJ p
and CC p
urban JJ p
Chinese JJ p
population NN p
in IN p
Qingdao NNP p
. . p

AIMS NNP N
To TO N
investigate VB N
the DT N
prevalence NN o
of IN o
metabolic JJ o
syndrome NN o
and CC N
its PRP$ N
components NNS N
in IN N
both DT N
rural JJ p
and CC p
urban JJ p
Chinese JJ p
population NN p
. . p

SUBJECTS NNP N
AND NNP N
METHODS NNP N
A NNP N
population-based JJ i
crosssectional JJ i
survey NN i
was VBD N
conducted VBN N
in IN N
Qingdao NNP p
, , p
China NNP p
in IN p
2006 CD p
with IN p
6100 CD p
Chinese JJ p
aged VBN p
35-74 JJ p
yr NN p
invited VBN p
and CC p
5355 CD p
who WP p
attended VBD p
; : p
3357 CD p
subjects NNS p
, , p
1562 CD p
urban NN p
( ( p
46.5 CD p
% NN p
) ) p
and CC p
1795 CD p
rural JJ p
residents NNS p
( ( p
53.5 CD p
% NN p
) ) p
met VBD p
the DT p
inclusion NN p
criteria NNS p
for IN p
the DT p
current JJ p
data NN p
analysis NN p
. . p

The DT N
metabolic JJ N
syndrome JJ N
definitions NNS N
of IN N
National NNP N
Cholesterol NNP N
Education NNP N
Program NNP N
Adult NNP N
Treatment NNP N
Expert NNP N
Panel NNP N
III NNP N
( ( N
NCEPATPIII NNP N
) ) N
2004 CD N
, , N
NCEP NNP N
2005 CD N
and CC N
International NNP N
Diabetes NNP N
Federation NNP N
( ( N
IDF NNP N
) ) N
were VBD N
used VBN N
. . N

RESULTS VB N
The DT N
age-standardized JJ o
prevalences NNS o
of IN o
metabolic JJ o
syndrome NN o
were VBD N
16.2 CD N
% NN N
, , N
32.2 CD N
% NN N
, , N
and CC N
28.3 CD N
% NN N
in IN N
men NNS N
and CC N
26.8 CD N
% NN N
, , N
37.2 CD N
% NN N
, , N
and CC N
34.6 CD N
% NN N
in IN N
women NNS N
, , N
according VBG N
to TO N
the DT N
definitions NNS N
of IN N
the DT N
NCEP NNP N
2004 CD N
, , N
NCEP NNP N
2005 CD N
, , N
and CC N
IDF NNP N
, , N
respectively RB N
. . N

Urban JJ N
men NNS N
have VBP N
more JJR N
risk NN o
factors NNS o
and CC o
higher JJR o
prevalence NN o
of IN o
the DT o
metabolic JJ o
syndrome NN o
than IN N
rural JJ N
men NNS N
, , N
but CC N
the DT N
differences NNS N
in IN N
women NNS N
were VBD N
not RB N
that IN N
striking VBG N
. . N

Elevated VBN o
blood NN o
pressure NN o
( ( N
62.6 CD N
% NN N
) ) N
was VBD N
, , N
among IN N
risk NN N
factors NNS N
, , N
most JJS N
common JJ N
in IN N
the DT N
study NN N
population NN N
, , N
followed VBN N
by IN N
central JJ o
obesity NN o
( ( N
53.4 CD N
% NN N
) ) N
, , N
and CC N
hyperglycemia NN o
( ( N
52.2 CD N
% NN N
) ) N
defined VBD N
using VBG N
the DT N
NCEP NNP N
2005 CD N
criteria NN N
. . N

CONCLUSIONS NNP N
Metabolic NNP N
disorders NNS N
were VBD N
common JJ N
among IN N
adult JJ p
Chinese NNPS p
in IN p
both DT p
rural JJ p
and CC p
urban JJ p
areas NNS p
in IN p
Qingdao NNP p
. . p

-DOCSTART- -8275152- O O

Comparison NNP N
of IN N
tidal JJ N
volumes NNS N
obtained VBN N
by IN N
one-handed JJ i
and CC i
two-handed JJ i
ventilation NN i
techniques NNS i
. . i

OBJECTIVES NNP N
To TO N
compare VB N
tidal JJ N
volumes NNS N
delivered VBN N
by IN N
one- JJ i
vs JJ i
two-handed JJ i
compressions NNS i
of IN i
a DT i
manual JJ i
resuscitation NN i
bag NN i
and CC N
assess VB N
the DT N
effects NNS N
of IN N
subject JJ N
characteristics NNS N
on IN N
those DT N
tidal JJ N
volumes NNS N
. . N

DESIGN NNP N
Subjects NNP p
( ( p
108 CD p
healthcare NN p
providers NNS p
from IN p
a DT p
500-bed JJ p
teaching NN p
hospital NN p
) ) p
were VBD N
assigned VBN N
randomly RB N
to TO N
one CD N
of IN N
two CD N
procedures NNS N
: : N
one- JJ i
followed VBN i
by IN i
two-handed JJ i
compression NN i
or CC i
two- NN i
followed VBN i
by IN i
one-handed JJ i
compression NN i
. . i

A DT N
1-liter JJ N
resuscitation NN N
bag NN N
, , N
lung NN N
performance NN N
analyzer NN N
and CC N
Wright NNP N
spirometer NN N
were VBD N
used VBN N
to TO N
measure VB N
tidal JJ N
volume NN N
. . N

Data NNP N
collection NN N
occurred VBD N
in IN N
a DT p
simulated JJ p
situation NN p
. . p

RESULTS NNP N
There EX N
was VBD N
a DT N
significant JJ N
difference NN N
in IN N
tidal JJ o
volume NN o
delivered VBN N
by IN N
one-handed JJ i
( ( N
mean JJ N
= VBP N
694 CD N
mL NN N
, , N
SD NNP N
= NNP N
111 CD N
) ) N
vs NN N
two-handed JJ i
compressions NNS i
( ( N
mean JJ N
= VBP N
827 CD N
mL NN N
, , N
SD NNP N
= NNP N
113 CD N
) ) N
. . N

Hand NNP N
size NN N
, , N
grip NN N
strength NN N
, , N
height NN N
and CC N
weight NN N
were VBD N
correlated VBN N
with IN N
tidal JJ o
volumes NNS o
generated VBN N
by IN N
one-handed JJ i
and CC N
two-handed JJ i
procedures NNS N
. . N

No DT N
other JJ N
subject JJ N
characteristics NNS N
were VBD N
correlated VBN N
with IN N
tidal JJ o
volumes NNS o
. . o

CONCLUSIONS NNP N
Tidal NNP o
volumes NNS o
delivered VBN N
by IN N
healthcare NN N
providers NNS N
using VBG N
one- JJ i
vs JJ i
two-handed JJ i
compressions NNS i
were VBD N
found VBN N
to TO N
be VB N
significantly RB N
different JJ N
, , N
with IN N
those DT N
delivered VBN N
by IN N
two CD i
hands NNS i
significantly RB N
greater JJR N
than IN N
those DT N
delivered VBN N
by IN N
one CD i
hand NN i
. . i

Strength NN N
of IN N
hand NN N
grip NN N
was VBD N
the DT N
best JJS N
predictor NN N
of IN N
volume NN N
delivered VBN N
and CC N
was VBD N
more RBR N
strongly RB N
correlated VBN N
with IN N
volumes NNS N
delivered VBN N
by IN N
one CD i
rather RB N
than IN N
two CD i
hands NNS i
. . i

-DOCSTART- -24662027- O O

Pegylated VBN i
feline JJ i
granulocyte NN i
colony-stimulating JJ i
factor NN i
increases NNS N
neutrophil JJ N
levels NNS N
in IN N
cats NNS p
. . p

Neutropenia NNP N
can MD N
often RB N
be VB N
corrected VBN N
by IN N
treatment NN N
with IN N
granulocyte-colony JJ i
stimulating VBG i
factor NN i
( ( i
G-CSF NNP i
) ) i
and CC N
off-label JJ i
use NN i
of IN i
commercial JJ i
human JJ i
G-CSF NNP i
( ( i
HuG-CSF NNP i
) ) i
is VBZ N
a DT N
commonly RB N
used VBN N
treatment NN N
for IN N
neutropenic JJ p
animals NNS p
. . p

However RB N
, , N
long-term JJ N
HuG-CSF NNP i
treatment NN i
can MD N
be VB N
associated VBN N
with IN N
adverse JJ o
effects NNS o
, , N
including VBG N
neutropenia NN o
. . o

Here RB N
, , N
feline NN N
( ( N
Fe NNP N
) ) N
G-CSF NNP N
was VBD N
produced VBN N
in IN N
Pichia NNP N
pastoris NN N
, , N
pegylated VBN N
( ( N
Peg NNP N
) ) N
FeG-CSF NNP N
and CC N
tested VBN N
in IN N
cats NNS N
. . N

A DT N
randomized JJ N
controlled JJ N
clinical JJ N
trial NN N
was VBD N
conducted VBN N
to TO N
evaluate VB N
the DT N
efficacy NN o
of IN N
PegFeG-CSF NNP i
compared VBN N
to TO N
FeG-CSF NNP i
or CC i
HuG-CSF NNP i
in IN N
FIV-infected NNP p
( ( p
n=14 NN p
) ) p
, , p
FIV-uninfected JJ p
healthy JJ p
cats NNS p
( ( p
n=19 NN p
) ) p
, , p
and CC p
in IN p
HuG-CSF-induced NNP p
neutropenic JJ p
cats NNS p
( ( p
n=4 NN p
) ) p
. . p

Daily JJ N
FeG-CSF NNP i
doses NNS N
induced VBD N
higher JJR o
neutrophil NN o
production NN o
than IN N
HuG-CSF NNP i
after IN N
the DT N
second JJ N
week NN N
of IN N
treatment NN N
( ( N
P NNP N
? . N
0.002 CD N
) ) N
. . N

Weekly JJ N
doses NNS N
of IN N
PegFeG-CSF NNP o
induced VBD o
higher JJR o
neutrophil JJ o
counts NNS o
and CC o
showed VBD o
greater JJR o
sustained VBN o
activity NN o
than IN o
weekly JJ N
doses NNS N
of IN N
FeG-CSF NNP i
. . i

PegFeG-CSF NNP i
provided VBD i
the DT N
most RBS N
therapeutic JJ N
and CC N
sustainable JJ o
neutrophil JJ o
production NN o
( ( o
P NNP N
< NNP N
0.001 CD N
) ) N
in IN N
both DT p
FIV-uninfected JJ p
and CC p
FIV-infected JJ p
cats NNS p
, , p
without IN N
the DT N
development NN N
of IN N
neutralizing VBG o
antibodies NNS o
. . o

Conversely RB N
, , N
all DT i
HuG-CSF-treated JJ i
cats NNS i
developed VBD o
neutralizing VBG o
antibodies NNS o
, , o
suggesting VBG N
cross-reactive JJ N
antibodies NNS N
to TO N
endogenous JJ N
G-CSF NNP N
in IN N
a DT N
majority NN N
of IN N
the DT N
cases NNS N
with IN N
severe JJ N
neutropenia NN N
. . N

Strikingly RB N
, , N
when WRB i
PegFeG-CSF NNP i
was VBD i
used VBN N
to TO N
rescue VB N
cats NNS N
with IN i
HuG-CSF-induced NNP o
neutropenia NN o
, , o
clinically RB N
normal JJ o
neutrophil JJ o
numbers NNS o
returned VBN o
. . N

Thus RB i
, , i
PegFeG-CSF NNP i
appears VBZ i
to TO N
be VB N
a DT N
superior JJ N
treatment NN N
for IN N
neutropenia NN N
in IN N
feline JJ p
patients NNS p
. . p

-DOCSTART- -17934678- O O

An DT N
exploratory NN N
, , N
pragmatic JJ N
, , N
cluster NN N
randomised VBD N
trial NN N
of IN N
practice NN i
nurse JJ i
training NN i
in IN p
the DT p
use NN p
of IN p
asthma JJ p
action NN p
plans NNS p
. . p

INTRODUCTION NNP N
To TO N
investigate VB N
the DT N
feasibility NN o
of IN N
improving VBG N
asthma JJ N
management NN N
- : N
in IN N
particular JJ N
, , N
the DT N
implementation NN N
of IN N
individualised JJ i
asthma JJ i
action NN i
plans NNS i
( ( i
AAPs NNP i
) ) i
for IN N
poorly-controlled JJ p
adult NN p
asthma NN p
patients NNS p
- : N
by IN N
providing VBG N
training NN N
in IN N
asthma-focused JJ N
clinical JJ N
and CC N
communication NN N
skills NNS N
for IN N
practice NN N
nurses NNS p
who WP p
deliver VBP p
asthma JJ p
clinics NNS p
. . p

METHODS NNP N
A NNP N
pragmatic JJ N
, , N
cluster NN N
randomised VBD N
trial NN N
with IN N
an DT N
intervention NN N
( ( N
an DT N
interactive JJ N
seminar NN N
) ) N
delivered VBD N
at IN N
practice NN N
level NN N
( ( p
n=13 JJ p
practices NNS p
; : p
6=intervention CD p
, , p
7=control CD p
) ) p
. . N

The DT N
impact NN N
of IN N
the DT N
intervention NN N
was VBD N
assessed VBN N
against IN N
patient JJ o
outcomes NNS o
: : o
routinely RB o
available JJ o
asthma JJ o
outcome NN o
measures NNS o
( ( o
beta2-agonist JJ o
prescription NN o
rate NN o
and CC o
number NN o
of IN o
oral JJ o
steroid NN o
courses NNS o
) ) o
for IN N
asthma NN p
patients NNS p
identified VBN p
as IN p
being VBG p
poorly-controlled JJ p
from IN p
practice NN p
records NNS p
; : p
and CC N
questionnaire VB o
data NNS o
- : o
Mini NNP o
Asthma NNP o
Quality NNP o
of IN o
Life NNP o
Questionnaire NNP o
( ( o
AQLQ NNP o
) ) o
and CC o
the DT o
Asthma NNP o
Control NNP o
Questionnaire NNP o
( ( o
ACQ NNP o
) ) o
- : N
from IN N
a DT N
subset NN N
of IN N
consenting VBG N
patients NNS N
. . N

Data NNP N
was VBD N
collected VBN N
at IN N
baseline NN N
and CC N
at IN N
6-month JJ N
follow-up NN N
. . N

ANALYSISs NN N
: : N
Routine NNP N
data NN N
was VBD N
analysed VBN N
for IN N
629 CD p
patients NNS p
. . p

236 CD p
( ( p
37 CD p
% NN p
) ) p
of IN p
these DT p
patients NNS p
consented VBD p
to TO p
provide VB p
questionnaire NN p
data NNS p
at IN N
baseline NN N
, , N
with IN N
75 CD N
% NN N
returning VBG N
questionnaires NNS N
at IN N
follow-up NN N
. . N

After IN N
adjustment NN N
for IN N
baseline NN N
and CC N
practice NN N
, , N
there EX N
was VBD N
a DT N
significant JJ N
difference NN N
at IN N
followup NN N
between IN N
intervention NN N
and CC N
control NN N
practices NNS N
on IN N
the DT N
Mini NNP o
AQLQ NNP o
only RB N
( ( N
p=0.03 NN N
) ) N
. . N

Estimates NNS N
for IN N
subsequent JJ N
sample NN N
sizes NNS N
to TO N
inform VB N
future JJ N
trials NNS N
of IN N
asthma JJ N
training NN N
were VBD N
identified VBN N
. . N

CONCLUSION NNP N
Training NNP N
designed VBD N
to TO N
support VB N
practice NN p
nurses NNS p
in IN N
implementing VBG N
individualised JJ N
AAPs NNP N
impacted VBD N
on IN N
one CD N
patient NN N
outcome NN N
only RB N
. . N

This DT N
disappointing JJ N
outcome NN N
may MD N
have VB N
been VBN N
due JJ N
to TO N
many JJ N
different JJ N
factors NNS N
such JJ N
as IN N
outcome JJ N
measure NN N
limitations NNS N
, , N
data NNS N
collection NN N
problems NNS N
, , N
and CC N
underestimating VBG N
the DT N
complexity NN N
of IN N
supporting VBG N
practice NN p
nurses NNS p
in IN N
behaviour JJ N
change NN N
. . N

-DOCSTART- -9607867- O O

Humoral NNP o
immune JJ o
response NN o
to TO N
tetanus-diphtheria JJ i
vaccine NN i
given VBN N
during IN N
extended VBN N
use NN N
of IN N
chloroquine NN i
or CC i
primaquine NN i
malaria NNS i
chemoprophylaxis NN i
. . i

Immune NNP o
suppression NN o
resulting VBG N
from IN N
prolonged VBN N
chemoprophylaxis NN N
and CC N
potential JJ N
drug-vaccine JJ N
interaction NN N
were VBD N
investigated VBN N
within IN N
the DT N
context NN N
of IN N
a DT N
randomized JJ N
placebo-controlled JJ i
trial NN N
that WDT N
compared VBN N
daily RB N
primaquine NN i
or CC N
weekly JJ N
chloroquine NN i
administration NN N
for IN N
malaria JJ N
prevention NN N
. . N

After IN N
11 CD N
months NNS N
of IN N
prophylaxis NN N
, , N
adult VB p
male JJ p
subjects NNS p
received VBD N
a DT N
tetanus-diphtheria NN i
( ( i
Td NNP i
) ) i
vaccination NN i
. . i

Prophylaxis NNP N
continued VBD N
4 CD N
weeks NNS N
longer RBR N
. . N

Anti-tetanus JJ o
and CC o
anti-diphtheria JJ o
antibody NN o
levels NNS o
were VBD o
measured VBN o
by IN o
ELISA NNP o
at IN N
baseline NN N
and CC N
at IN N
1 CD N
, , N
3 CD N
, , N
7 CD N
, , N
and CC N
14 CD N
months NNS N
after IN N
Td NNP N
vaccination NN N
. . N

All DT N
groups NNS N
were VBD N
comparable JJ N
at IN N
baseline NN N
. . N

Immunization NN N
triggered VBD N
significant JJ N
increases NNS N
in IN N
anti-tetanus JJ o
and CC o
anti-diphtheria JJ o
IgG NNP o
levels NNS o
over IN N
each DT N
group NN N
's POS N
pre-Td JJ N
baseline NN N
levels NNS N
and CC N
those DT N
of IN N
an DT N
unvaccinated JJ N
control NN N
group NN N
. . N

Geometric JJ o
mean JJ o
anti-tetanus JJ o
titers NNS o
( ( o
GMTs NNP o
) ) o
in IN N
the DT N
primaquine NN N
group NN N
were VBD N
significantly RB N
higher JJR N
than IN N
those DT N
of IN N
the DT N
placebo NN i
group NN N
at IN N
1 CD N
, , N
3 CD N
, , N
and CC N
14 CD N
months NNS N
. . N

Anti-tetanus NNP o
GMTs NNP o
in IN N
placebo NN i
and CC N
chloroquine NN i
groups NNS N
declined VBD N
over IN N
14 CD N
months NNS N
to TO N
levels NNS N
comparable JJ N
to TO N
those DT N
of IN N
unvaccinated JJ N
controls NNS N
, , N
but CC N
levels NNS N
in IN N
the DT N
primaquine NN N
group NN N
remained VBD N
significantly RB N
higher JJR N
than IN N
in IN N
controls NNS N
. . N

-DOCSTART- -25253808- O O

Effect NN N
of IN N
dietary JJ i
zinc NN i
oxide NN i
on IN N
jejunal JJ N
morphological JJ N
and CC N
immunological JJ N
characteristics NNS N
in IN N
weaned JJ p
piglets NNS p
. . p

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
age-related JJ N
changes NNS N
and CC N
the DT N
effect NN N
of IN N
dietary JJ N
Zn NNP N
concentration NN N
on IN N
morphological JJ N
and CC N
immunological JJ N
characteristics NNS N
in IN N
the DT N
gastrointestinal JJ p
tract NN p
of IN p
piglets NNS p
. . p

A DT p
total NN p
of IN p
96 CD p
purebred JJ p
Landrace NNP p
piglets NNS p
were VBD p
weaned VBN p
at IN p
the DT p
age NN p
of IN p
26 CD p
? . p
1 CD p
d NN p
, , p
and CC N
randomly RB N
allocated VBD N
into IN N
3 CD N
treatment NN N
groups NNS N
fed VBP N
with IN i
low JJ i
( ( i
57 CD i
mg RB i
Zn/kg NNP i
) ) i
, , i
medium NN i
( ( i
164 CD i
mg RB i
Zn/kg NNP i
) ) i
, , i
and CC i
high JJ i
( ( i
2425 CD i
mg NN i
Zn/kg NNP i
) ) i
dietary JJ i
Zn NNP i
( ( i
ZnO NNP i
) ) i
. . i

Piglets NNS p
( ( p
4 CD p
males NNS p
and CC p
4 CD p
females NNS p
per IN p
treatment NN p
group NN p
) ) p
were VBD N
killed VBN N
at IN N
33 CD N
? . N
1 CD N
, , N
40 CD N
? . N
1 CD N
, , N
47 CD N
? . N
1 CD N
, , N
and CC N
54 CD N
? . N
1 CD N
d NN N
of IN N
age NN N
. . N

In IN N
the DT N
jejunum NN N
, , N
villus JJ N
height NN N
, , N
crypt NN N
depth NN N
, , N
and CC N
the DT N
number NN N
of IN N
goblet NN N
cells NNS N
producing VBG N
neutral JJ N
, , N
acidic JJ N
, , N
sulfated VBN N
, , N
and CC N
sialylated VBD N
mucins NNS N
were VBD N
measured VBN N
. . N

Intraepithelial JJ N
lymphocytes NNS N
were VBD N
characterized VBN N
by IN N
flow JJ N
cytometry NN N
and CC N
the DT N
gene NN N
expression NN N
of IN N
mucin NN N
2 CD N
( ( N
MUC2 NNP N
) ) N
, , N
mucin $ N
20 CD N
( ( N
MUC20 NNP N
) ) N
, , N
?-defensin JJ N
3 CD N
, , N
and CC N
trefoil NN N
factor NN N
3 CD N
( ( N
TFF3 NNP N
) ) N
was VBD N
determined VBN N
by IN N
reverse JJ N
transcription NN N
quantitative JJ N
PCR NNP N
. . N

Villus CC N
height JJ N
and CC N
crypt JJ N
depth NN N
in IN N
the DT N
jejunum NN N
showed VBD N
age NN N
related VBN N
differences NNS N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
, , N
whereas IN N
the DT N
dietary JJ N
concentrations NNS N
of IN N
Zn NNP N
had VBD N
no DT N
effect NN N
. . N

The DT N
mucin NN N
types NNS N
were VBD N
modified VBN N
mainly RB N
by IN N
age NN N
, , N
and CC N
dietary JJ N
Zn NNP N
had VBD N
no DT N
effect NN N
in IN N
the DT N
proximal JJ N
jejunum NN N
. . N

In IN N
the DT N
distal JJ N
jejunum NN N
, , N
age NN N
and CC N
Zn NNP N
had VBD N
effects NNS N
on IN N
the DT N
mucin NN N
types NNS N
. . N

The DT N
abundance NN o
of IN o
sulfomucins NNS o
decreased VBN o
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
and CC o
sialomucins NNS o
increased VBD o
with IN N
age NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
while IN N
high JJ N
dietary JJ N
ZnO NNP N
reduced VBD N
the DT N
sulfomucins NNS N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
and CC N
increased VBD N
the DT N
sialomucins NNS N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
in IN N
the DT N
crypts NNS N
. . N

The DT N
phenotypes NNS N
of IN N
lymphocytes NNS N
in IN N
the DT N
epithelium NN N
of IN N
the DT N
proximal JJ N
jejunum NN N
showed VBD N
relatively RB N
constant JJ o
percentages NNS o
of IN o
T-cells NNP o
, , o
as RB o
well RB o
as IN N
natural JJ N
killer NN N
cells NNS N
. . N

High NNP o
dietary JJ o
Zn NNP o
treatment NN o
led VBD o
to TO o
a DT N
reduced JJ N
abundance NN o
of IN o
CD8 NNP o
( ( o
+ NNP o
) ) o
?? VBZ o
T-cells NNP o
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

The DT N
apportionment NN N
of IN N
different JJ o
cytotoxic JJ o
T-cell NNP o
was VBD N
age NN N
dependent NN N
. . N

Although IN N
the DT N
percentage NN o
of IN o
CD4 NNP o
( ( o
- : o
) ) o
CD8? NNP o
( ( o
+ NNP o
) ) o
increased VBD o
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
, , N
the DT o
relative JJ o
amount NN o
of IN o
CD4 NNP o
( ( o
+ NNP o
) ) o
CD8? NNP o
( ( o
+ NNP o
) ) o
decreased VBD o
with IN N
age NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

The DT N
expression NN N
of IN N
MUC2 NNP N
and CC N
MUC20 NNP N
was VBD N
not RB N
influenced VBN N
by IN N
age NN N
or CC N
dietary JJ N
Zn NNP N
concentration NN i
. . i

High JJ i
Zn NNP i
intakes NNS N
resulted VBD N
in IN N
a DT N
reduced JJ N
gene NN N
expression NN N
of IN o
?-defensin JJ o
3 CD o
( ( o
P NNP o
< NNP o
0.05 CD o
) ) N
, , N
but CC N
did VBD N
not RB N
affect VB N
the DT N
expression NN N
of IN N
TFF3 NNP N
. . N

It PRP N
is VBZ N
concluded VBN N
that IN N
Zn NNP N
in IN N
the DT N
form NN N
of IN N
ZnO NNP N
appears VBZ N
to TO N
have VB N
specific JJ N
effects NNS N
on IN N
the DT N
innate NN N
and CC N
adaptive JJ N
gut NN N
associated VBN N
immune JJ N
system NN p
of IN p
piglets NNS p
. . N

These DT N
might MD N
contribute VB N
to TO N
the DT N
positive JJ N
effects NNS N
of IN N
Zn NNP N
on IN N
the DT N
prevention NN N
of IN N
postweaning VBG N
diarrhea NN N
. . N

-DOCSTART- -2141092- O O

Should MD N
angioplasty VB N
be VB N
deferred VBN N
after IN N
infarction NN N
? . N
-DOCSTART- -24925924- O O

COPD NNP p
detected VBD p
with IN p
screening NN p
: : p
impact NN N
on IN N
patient JJ o
management NN o
and CC o
prognosis NN o
. . o

It PRP N
is VBZ N
uncertain JJ N
whether IN N
screening VBG N
of IN N
older JJR p
persons NNS p
for IN p
chronic JJ p
obstructive JJ p
pulmonary JJ p
disease NN p
( ( p
COPD NNP p
) ) p
is VBZ N
worthwhile JJ N
because IN N
the DT N
effects NNS N
on IN N
patient JJ o
management NN o
and CC o
prognosis NN o
are VBP N
unknown JJ N
. . N

We PRP N
aimed VBD N
to TO N
assess VB N
the DT N
short-term JJ o
consequences NNS o
of IN N
detecting VBG N
COPD NNP p
in IN p
frail JJ p
elderly JJ p
subjects NNS p
with IN p
dyspnoea NN p
, , N
considering VBG N
pulmonary JJ o
drug NN o
use NN o
, , o
hospitalisations NNS o
and CC o
all-cause JJ o
mortality NN o
. . o

Community-dwelling JJ p
frail JJ p
elderly JJ p
subjects NNS p
, , p
aged VBD p
65 CD p
years NNS p
and CC p
older JJR p
, , p
with IN p
dyspnoea NN p
, , p
participating VBG p
in IN p
a DT p
screening NN p
study NN p
on IN p
COPD NNP p
and CC p
heart NN p
failure NN p
were VBD p
included VBN p
. . p

Final JJ N
diagnoses NNS N
were VBD N
assigned VBN N
by IN N
an DT N
expert JJ N
panel NN N
based VBN N
on IN N
all DT N
data NNS N
from IN N
the DT N
screening NN N
strategy NN N
, , N
including VBG N
spirometry NN i
. . i

Follow-up NNP N
data NNS N
were VBD N
collected VBN N
from IN N
the DT N
general JJ N
practitioners NNS N
. . N

Of IN N
the DT N
386 CD p
patients NNS p
, , N
84 CD N
( ( N
21.8 CD N
% NN N
) ) N
were VBD N
received VBN N
a DT N
new JJ N
diagnosis NN N
of IN N
COPD NNP N
. . N

Overall NNP N
, , N
changes NNS o
in IN o
pulmonary JJ o
drug NN o
prescription NN o
during IN N
6 CD N
months NNS N
of IN N
follow-up NN N
were VBD N
infrequent JJ N
( ( N
n JJ N
= NN N
53 CD N
, , N
13.7 CD N
% NN N
; : N
among IN N
new JJ N
cases NNS N
of IN N
COPD NNP N
, , N
15 CD N
( ( N
17.9 CD N
% NN N
) ) N
out IN N
of IN N
84 CD N
) ) N
. . N

Of IN N
all DT N
participants NNS N
, , N
25.9 CD N
% NN N
were VBD N
hospitalised VBN o
in IN N
the DT N
first JJ N
year NN N
of IN N
follow-up NN N
, , N
with IN N
the DT N
highest JJS N
rate NN N
in IN N
patients NNS N
with IN N
newly RB N
detected VBN N
COPD NNP N
( ( N
32.1 CD N
% NN N
) ) N
. . N

Many JJ N
new JJ N
cases NNS N
of IN N
COPD NNP p
could MD N
be VB N
detected VBN N
by IN N
screening VBG p
frail JJ p
elderly JJ p
subjects NNS p
with IN p
dyspnoea NN o
, , N
but CC N
the DT N
impact NN N
on IN N
patient JJ o
management NN o
seems VBZ N
limited VBN N
. . N

Our PRP$ N
study NN N
underlines VBZ N
the DT N
importance NN N
of IN N
obtaining VBG N
follow-up JJ N
data NNS N
to TO N
assess VB N
the DT N
true JJ o
impact NN o
of IN N
a DT N
( ( N
screen-detected JJ N
) ) N
diagnosis NN N
of IN N
COPD NNP N
on IN N
patient JJ o
management NN o
and CC o
outcome NN o
. . o

-DOCSTART- -7829176- O O

Effect NN N
of IN N
flurbiprofen JJ i
sodium NN i
on IN N
pupillary JJ o
dilatation NN o
during IN N
scleral JJ p
buckling NN p
surgery NN p
. . p

Maintenance NN N
of IN N
pupillary JJ o
dilatation NN o
is VBZ N
necessary JJ N
for IN N
success NN N
of IN N
scleral JJ p
buckling NN p
procedures NNS p
. . p

The DT N
efficacy NN N
of IN N
0.03 CD i
% NN i
flurbiprofen NN i
in IN N
preventing VBG N
intraoperative JJ N
miosis NN N
was VBD N
evaluated VBN N
by IN N
a DT N
prospective JJ N
randomized VBN N
, , N
double-masked JJ N
controlled VBD N
trial NN N
of IN N
60 CD p
patients NNS p
. . p

Thirty JJ p
patients NNS p
received VBD N
0.03 CD N
% NN N
flurbiprofen NN i
6 CD N
times NNS N
at IN N
15 CD N
minute NN N
intervals NNS N
90 CD N
minutes NNS N
preoperatively RB N
in IN N
addition NN N
to TO N
the DT N
routine JJ N
dilation NN N
regimen NNS N
. . N

The DT N
treated JJ N
group NN N
had VBD N
a DT N
mean JJ o
pupillary JJ o
decrease NN o
of IN N
1.88 CD N
mm NNS N
and CC N
the DT N
control NN N
group NN N
had VBD N
a DT N
decrease NN N
of IN N
1.57 CD N
mm NN N
( ( N
p JJ N
> NNP N
0.05 CD N
) ) N
. . N

Flurbiprofen NNP i
did VBD N
not RB N
affect VB N
the DT N
pupillary JJ o
size NN o
at IN N
any DT N
step NN N
of IN N
the DT N
surgery NN N
. . N

Factors NNS N
such JJ N
as IN N
age NN o
of IN o
the DT o
patient NN o
, , o
lens VBZ o
status NN o
, , o
number NN o
of IN o
cryo NN o
applications NNS o
, , o
duration NN o
of IN o
surgery NN o
, , o
and CC o
the DT o
size NN o
and CC o
extent NN o
of IN o
buckle NN o
were VBD N
assessed VBN N
. . N

The DT N
use NN N
of IN N
flurbiprofen NN i
did VBD N
not RB N
affect VB N
the DT N
mean JJ o
pupillary JJ o
change NN o
for IN N
any DT N
of IN N
these DT N
groups NNS N
. . N

Preoperative NNP N
use NN N
of IN N
flurbiprofen NN i
does VBZ N
not RB N
significantly RB N
decrease VB N
intraoperative JJ o
miosis NN o
during IN o
scleral JJ o
buckling NN o
procedures NNS o
. . o

-DOCSTART- -19590523- O O

Excimer NNP i
laser NN i
trabeculotomy NN i
vs NN N
180 CD i
degrees NNS i
selective JJ i
laser NN i
trabeculoplasty NN i
in IN N
primary JJ N
open-angle JJ N
glaucoma NN N
. . N

A DT N
2-year JJ N
randomized NN N
, , N
controlled VBN N
trial NN N
. . N

PURPOSE NNP N
To TO N
compare VB N
the DT N
effectiveness NN o
and CC o
safety NN o
of IN N
excimer FW i
laser NN i
trabeculotomy NN i
( ( i
ELT NNP i
) ) i
ab VBP N
interno JJ N
vs NN N
selective JJ i
laser NN i
trabeculoplasty NN i
( ( i
SLT NNP i
) ) i
over IN N
24 CD N
months NNS N
of IN N
follow-up NN N
in IN N
patients NNS p
with IN p
primary JJ p
open-angle JJ p
glaucoma NN p
( ( p
POAG NNP p
) ) p
refractory NN p
to TO p
medical JJ p
therapy NN p
. . p

PATIENTS NNP N
AND CC N
METHODS NNP N
This DT N
prospective JJ N
, , N
randomized VBN N
study NN N
included VBD N
30 CD p
consecutive JJ p
eyes NNS p
assigned VBD N
randomly RB N
to TO N
either DT N
ELT NNP i
or CC N
SLT NNP i
group NN N
. . N

ELT NNP i
was VBD i
carried VBN i
out RP i
using VBG i
a DT i
XeCl JJ i
Excimer NNP i
Laser NNP i
with IN i
an DT i
emission NN i
wavelength NN i
of IN i
308 CD i
nm NN i
. . i

Eight JJ i
spots NNS i
were VBD i
equally RB i
distributed VBN i
at IN i
a DT i
distance NN i
of IN i
500 CD i
microm NN i
from IN i
one CD i
another DT i
over IN i
the DT i
anterior JJ i
trabeculum NN i
. . i

The DT N
SLT JJ N
patients NNS N
were VBD N
treated VBN i
with IN i
a DT i
frequency-doubled JJ i
q-switched JJ i
neodymium NN i
: : i
yytrium-aluminum-garnet JJ i
laser NN i
( ( i
wavelength JJ i
532 CD i
nm NN i
) ) i
. . i

Approximately RB i
50 CD i
adjacent JJ i
, , i
but CC i
not RB i
overlapping JJ i
, , i
laser JJ i
spots NNS i
were VBD i
distributed VBN i
over IN i
180 CD i
degrees NNS i
of IN i
the DT i
trabecular JJ i
meshwork NN i
, , i
using VBG i
an DT i
energy NN i
level NN i
ranging VBG i
from IN i
0.7 CD i
to TO i
1.0 CD i
mJ NNS i
per IN i
pulse NN i
. . i

The DT N
main JJ N
outcome NN N
measure NN N
was VBD N
intraocular JJ o
pressure NN o
( ( o
IOP NNP o
) ) o
lowering NN o
after IN o
ELT NNP o
and CC o
SLT NNP o
. . o

Success NNP N
was VBD N
defined VBN N
as IN N
> JJ N
or=20 CD N
% NN N
reduction NN o
in IN o
IOP NNP o
without IN N
further JJ N
glaucoma NN N
intervention NN N
. . N

RESULTS NNP N
At IN N
24 CD N
months NNS N
, , N
complete JJ N
success NN o
rates NNS o
were VBD N
53.3 CD N
% NN N
for IN N
the DT N
ELT NNP N
group NN N
and CC N
40 CD N
% NN N
for IN N
the DT N
SLT NNP N
group NN N
( ( N
P=0.35 NNP N
, , N
Fisher NNP N
's POS N
exact JJ N
test NN N
) ) N
; : N
qualified VBN o
success NN o
rates NNS o
were VBD N
33.3 CD N
% NN N
for IN N
the DT N
ELT NNP N
and CC N
26.6 CD N
% NN N
for IN N
the DT N
SLT NNP N
group NN N
( ( N
P=0.5 NNP N
, , N
Fisher NNP N
's POS N
exact JJ N
test NN o
) ) o
.Mean VBP o
IOP NNP o
decreased VBD o
from IN N
25.0+/-1.9 JJ N
to TO N
17.6+/-2.2 JJ N
mmHg NN N
( ( N
-29.6 CD N
% NN N
; : N
P NNP N
< NNP N
0.0001 CD N
) ) N
in IN N
the DT N
ELT NNP N
group NN N
and CC N
from IN N
23.9+/-0.9 JJ N
to TO N
19.1+/-1.8 JJ N
mmHg NN N
( ( N
-21 CD N
% NN N
; : N
P NNP N
< NNP N
0.0001 CD N
) ) N
in IN N
the DT N
SLT NNP N
group NN N
. . N

CONCLUSIONS NNP N
Both NNP N
ELT NNP N
and CC N
SLT NNP N
proved VBD N
to TO N
be VB N
effective JJ N
techniques NNS N
in IN N
the DT N
treatment NN N
of IN N
POAG NNP N
refractory NN N
to TO N
medical JJ N
therapy NN N
. . N

-DOCSTART- -8921775- O O

Effect NN N
of IN N
supplementary JJ i
antioxidant JJ i
vitamin NNS i
intake VBP N
on IN N
carotid NNS o
arterial JJ o
wall JJ o
intima-media JJ o
thickness NN o
in IN N
a DT N
controlled JJ N
clinical JJ N
trial NN N
of IN N
cholesterol NN N
lowering VBG N
. . N

BACKGROUND NNP N
There EX N
is VBZ N
accumulating VBG N
experimental JJ N
, , N
epidemiological JJ N
, , N
and CC N
clinical JJ N
evidence NN N
of IN N
an DT N
association NN N
between IN N
anti-oxidant JJ i
vitamin NNS i
intake NN N
and CC N
reduced JJ N
risk NN N
of IN N
coronary JJ N
heart NN N
disease NN N
. . N

Using VBG N
data NNS N
from IN N
the DT N
Cholesterol NNP N
Lowering NNP N
Atherosclerosis NNP N
Study NNP N
( ( N
CLAS NNP N
) ) N
, , N
we PRP N
explored VBD N
the DT N
association NN N
of IN N
self-selected JJ N
supplementary JJ N
antioxidant NN i
vitamin NNS i
intake VBP N
on IN N
the DT N
rate NN N
of IN N
progression NN N
of IN N
early JJ p
preintrusive JJ p
atherosclerosis NN p
. . p

METHODS NNP N
AND CC N
RESULTS NNP N
CLAS NNP N
was VBD N
an DT N
arterial JJ N
imaging NN N
trial NN N
in IN N
which WDT N
nonsmoking VBG p
40- JJ p
to TO p
59-year-old JJ p
men NNS p
with IN p
previous JJ p
coronary JJ p
artery NN p
bypass NN p
graft NN p
surgery NN p
were VBD N
randomized VBN N
to TO N
colestipol/niacin VB i
plus JJ i
diet JJ i
or CC N
placebo JJ i
plus CC i
diet JJ i
. . i

The DT N
rate NN o
of IN o
progression NN o
of IN o
early JJ o
preintrusive JJ o
atherosclerosis NN o
was VBD N
determined VBN N
in IN N
146 CD p
subjects NNS p
using VBG N
high-resolution JJ N
B-mode NNP N
ultrasound JJ N
quantification NN N
of IN N
the DT N
distal JJ N
common JJ N
carotid NN N
artery NN N
far RB N
wall JJ N
intima-media JJ N
thickness NN N
( ( N
IMT NNP N
) ) N
. . N

From IN N
the DT N
nutritional JJ N
supplement NN N
database NN N
, , N
22 CD N
subjects NNS N
had VBD N
an DT N
on-trial JJ N
average JJ N
supplementary JJ N
vitamin NN i
E NNP i
intake NN N
of IN N
> NN N
or CC N
= $ N
100 CD N
IU NNP N
per IN N
day NN N
( ( N
high JJ N
users NNS N
) ) N
and CC N
29 CD N
subjects NNS N
had VBD N
an DT N
average JJ N
on-trial JJ N
supplementary JJ N
vitamin NN i
C NNP i
intake NN N
of IN N
> NN N
or CC N
= $ N
250 CD N
mg JJ N
per IN N
day NN N
( ( N
high JJ N
users NNS N
) ) N
. . N

Within IN N
the DT N
placebo NN i
group NN N
, , N
less JJR o
carotid JJ o
IMT NNP o
progression NN o
was VBD N
found VBN N
for IN N
high JJ N
supplementary JJ N
vitamin NN i
E NNP i
users NNS N
when WRB N
compared VBN N
with IN N
low JJ N
vitamin NNS i
E NN i
users NNS N
( ( N
0.008 CD N
versus NN N
0.023 CD N
mm/y NN N
, , N
P NNP N
= NNP N
.03 NNP N
) ) N
. . N

No DT N
effect NN N
of IN N
vitamin NN o
E NNP i
within IN N
the DT N
drug NN N
group NN N
was VBD N
found VBN N
. . N

No DT N
effect NN N
of IN N
vitamin NN i
C NNP i
within IN N
the DT N
drug NN N
or CC N
placebo NN i
group NN N
was VBD N
found VBN N
. . N

CONCLUSIONS NNP N
Supplementary NNP i
vitamin NN i
E NNP i
intake NN N
appears VBZ N
to TO N
be VB N
effective JJ N
in IN N
reducing VBG o
the DT N
progression NN o
of IN o
atherosclerosis NN o
in IN N
subjects NNS p
not RB p
treated VBN p
with IN p
lipid-lowering JJ i
drugs NNS i
while IN N
the DT N
process NN N
is VBZ N
still RB N
confined VBN N
to TO N
the DT N
arterial JJ N
wall NN N
( ( N
early JJ N
preintrusive JJ N
atherosclerosis NN N
) ) N
. . N

-DOCSTART- -16076379- O O

Prospective JJ N
randomized VBN N
multicenter RBR N
trial NN N
of IN N
sevelamer NN i
hydrochloride NN i
and CC i
calcium NN i
carbonate NN i
for IN N
the DT N
treatment NN N
of IN N
hyperphosphatemia NN o
in IN p
hemodialysis NN p
patients NNS p
in IN p
Japan NNP p
. . p

A NNP N
prospective JJ N
, , N
randomized JJ N
open-label JJ N
trial NN N
of IN N
sevelamer JJ i
hydrochloride NN i
with IN i
or CC i
without IN i
calcium JJ i
carbonate NN i
( ( i
CC NNP i
) ) i
involved VBD N
86 CD p
hemodialysis NN p
patients NNS p
in IN p
Japan NNP p
. . p

The DT N
dosage NN N
of IN N
CC NNP N
was VBD N
fixed VBN N
at IN N
3.0 CD N
g/day NN N
for IN N
the DT N
12-week JJ N
study NN N
. . N

After IN N
the DT N
first JJ N
4 CD N
weeks NNS N
all DT N
subjects NNS N
were VBD N
changed VBN N
from IN N
CC NNP i
to TO i
sevelamer VB i
3.0 CD N
g/day NN N
for IN N
another DT N
4 CD N
weeks NNS N
, , N
then RB N
allocated VBD N
randomly RB N
to TO N
three CD N
groups NNS N
for IN N
the DT N
final JJ N
4 CD N
weeks NNS N
: : N
group NN i
A NNP i
, , i
sevelamer NN i
6.0 CD i
g/day NN i
; : i
group NN i
B NNP i
, , i
sevelamer VBD i
3.0 CD i
g/day NN i
and CC i
CC NNP i
3.0 CD i
g/day NN i
; : i
group NN i
C NNP i
, , i
CC NNP i
3.0 CD i
g/day NN i
. . i

The DT N
target NN o
serum NN o
phosphorous JJ o
concentration NN o
( ( N
P NNP N
) ) N
=5.5 VBP N
mg/dL NN N
and CC N
the DT N
corrected JJ o
calcium NN o
concentration NN o
( ( o
Ca NNP o
) ) o
was VBD N
9.0-10.0 JJ N
mg/dL NN N
. . N

Of IN p
the DT p
86 CD p
patients NNS p
, , p
62 CD p
finished VBD p
the DT p
study NN p
without IN p
a DT p
change NN p
of IN p
dosage NN p
and CC p
their PRP$ p
data NNS p
were VBD p
analyzed VBN p
( ( p
group NN p
A NNP p
, , p
N=16 NNP p
; : p
group NN p
B NNP p
, , p
N=26 NNP p
; : p
group NN p
C NNP p
, , p
N=20 NNP p
) ) p
. . p

At IN N
week NN N
8 CD N
compared VBN N
with IN N
week NN N
4 CD N
, , N
the DT N
concentration NN o
of IN o
P NNP o
increased VBD N
from IN N
5.7+/-1.4 JJ N
to TO N
6.4+/-1.7 JJ N
mg/dL NN N
in IN N
group NN N
A NNP N
, , N
and CC N
decreased VBD N
significantly RB N
in IN N
groups NNS N
B NNP N
and CC N
C NNP N
, , N
and CC N
in IN N
group NN N
B NNP N
compared VBN N
with IN N
groups NNS N
A NNP N
and CC N
C NNP N
; : N
groups NNS N
A DT N
and CC N
C NNP N
had VBD N
similar JJ N
concentrations NNS N
at IN N
week NN N
8 CD N
. . N

The DT N
Ca NNP o
concentration NN o
decreased VBD N
significantly RB N
from IN N
9.7+/-1.0 CD N
to TO N
9.1+/-0.7 CD N
mg/dL NNS N
after IN N
the DT N
change NN N
to TO N
sevelamer VB i
. . i

At IN N
week NN N
8 CD N
Ca NNP o
was VBD N
not RB N
significantly RB N
changed VBN N
in IN N
group NN N
A NNP N
, , N
whereas IN N
a DT N
significant JJ N
increase NN N
occurred VBD N
in IN N
groups NNS N
B NNP N
and CC N
C. NNP N
Side-effects NNP o
with IN N
sevelamer JJ i
administration NN N
occurred VBD N
in IN N
34 CD N
of IN N
the DT N
86 CD N
patients NNS N
and CC N
24 CD N
dropped VBD N
out IN N
of IN N
the DT N
study NN N
, , N
with IN N
a DT N
high JJ N
frequency NN N
in IN N
group NN N
A NNP N
( ( N
13/29 CD N
; : N
44.8 CD N
% NN N
) ) N
. . N

In IN N
conclusion NN N
, , N
there EX N
was VBD N
an DT N
additive JJ o
effect NN o
of IN N
sevelamer NN N
for IN N
the DT N
treatment NN N
of IN N
hyperphosphatemia NN N
with IN N
CC NNP N
. . N

The DT N
combination NN N
therapy NN N
was VBD N
better RBR N
tolerated VBN o
and CC N
showed VBD N
higher JJR N
patient NN o
compliance NN o
than IN N
CC NNP N
or CC N
sevelamer JJR N
monotherapy NN N
. . N

-DOCSTART- -20189663- O O

Differential JJ N
response NN N
to TO N
resistance VB i
training NN i
in IN N
CHF NNP N
according VBG N
to TO N
ACE NNP N
genotype NN N
. . N

BACKGROUND IN N
The DT N
Angiotensin NNP N
Converting NNP N
Enzyme NNP N
( ( N
ACE NNP N
) ) N
gene NN N
may MD N
influence VB N
the DT N
risk NN N
of IN N
heart NN N
disease NN N
and CC N
the DT N
response NN N
to TO N
various JJ N
forms NNS N
of IN N
exercise NN N
training NN N
may MD N
be VB N
at IN N
least JJS N
partly RB N
dependent JJ N
on IN N
the DT N
ACE NNP N
genotype NN N
. . N

We PRP N
aimed VBD N
to TO N
determine VB N
the DT N
effect NN N
of IN N
ACE NNP N
genotype NN N
on IN N
the DT N
response NN N
to TO N
moderate VB N
intensity NN N
circuit NN N
resistance NN i
training NN i
in IN N
chronic JJ p
heart NN p
failure NN p
( ( p
CHF NNP p
) ) p
patients NNS p
. . p

METHODS NNP N
The DT N
relationship NN N
between IN N
ACE NNP N
genotype NN N
and CC N
the DT N
response NN N
to TO N
11weeks CD i
of IN i
resistance NN i
exercise NN i
training NN i
was VBD N
determined VBN N
in IN N
37 CD p
CHF JJ p
patients NNS p
( ( p
New NNP p
York NNP p
Heart NNP p
Association NNP p
Functional NNP p
Class=2.3?0.5 NNP p
; : p
left VBD p
ventricular JJ p
ejection NN p
fraction NN p
28?7 CD p
% NN p
; : p
age NN p
64?12years CD p
; : p
32:5 CD p
male NN p
: : p
female NN p
) ) p
who WP p
were VBD p
randomised VBN p
to TO p
either DT i
resistance NN i
exercise NN i
( ( i
n=19 JJ i
) ) N
or CC N
inactive JJ i
control NN i
group NN i
( ( i
n=18 RB i
) ) N
. . N

Outcome NNP N
measures NNS N
included VBD o
V?O NNP o
( ( o
2peak CD o
) ) o
, , o
peak JJ o
power NN o
output NN o
and CC o
muscle NN o
strength NN o
and CC o
endurance NN o
. . o

ACE NNP o
genotype NN N
was VBD N
determined VBN N
using VBG N
standard JJ N
methods NNS N
. . N

RESULTS NNP N
At IN N
baseline NN N
, , N
patients NNS N
who WP N
were VBD N
homozygous JJ N
for IN N
the DT N
I PRP N
allele VBP N
had VBD N
higher JJR o
V?O NNP o
( ( o
2peak CD o
) ) o
( ( o
p=0.02 NN o
) ) o
and CC o
peak JJ o
power NN o
( ( o
p=0.003 NN o
) ) N
compared VBN N
to TO N
patients NNS N
who WP N
were VBD N
homozygous JJ N
for IN N
the DT N
D NNP N
allele NN N
. . N

Patients NNS N
with IN N
the DT N
D NNP N
allele NN N
, , N
who WP N
were VBD N
randomised VBN i
to TO i
resistance VB i
training NN i
, , i
compared VBN i
to TO i
non-exercising JJ i
controls NNS i
, , N
had VBD N
greater JJR N
peak JJ N
power NN N
increases NNS N
( ( N
ID NNP N
p VBZ N
< JJ N
0.001 CD N
; : N
DD NNP N
p VBP N
< NNP N
0.001 CD N
) ) N
when WRB N
compared VBN N
with IN N
patients NNS N
homozygous JJ N
for IN N
the DT N
I PRP N
allele VBP N
, , N
who WP N
did VBD N
not RB N
improve VB N
. . N

No DT N
significant JJ N
genotype-dependent JJ N
changes NNS N
were VBD N
observed VBN o
in IN o
V?O NNP o
( ( o
2peak CD o
) ) o
, , o
muscle NN o
strength NN o
, , o
muscle NN o
endurance NN o
or CC o
lactate NN o
threshold NN o
. . o

CONCLUSION NNP o
ACE NNP N
genotype NN N
may MD N
have VB N
a DT N
role NN N
in IN N
exercise NN N
tolerance NN N
in IN N
CHF NNP N
and CC N
could MD N
also RB N
influence VB N
the DT N
effectiveness NN N
of IN N
resistance NN N
training NN N
in IN N
this DT N
condition NN N
. . N

-DOCSTART- -11073017- O O

Calcium NN i
and CC i
fibre JJ i
supplementation NN i
in IN N
prevention NN N
of IN N
colorectal JJ o
adenoma JJ o
recurrence NN o
: : o
a DT N
randomised JJ N
intervention NN N
trial NN N
. . N

European JJ N
Cancer NNP N
Prevention NNP N
Organisation NNP N
Study NNP N
Group NNP N
. . N

BACKGROUND NNP N
Some DT N
epidemiological JJ N
studies NNS N
have VBP N
suggested VBN N
that IN N
high JJ N
dietary JJ N
intake NN N
of IN N
calcium NN i
and CC N
fibre JJ i
reduces NNS N
colorectal JJ N
carcinogenesis NN N
. . N

Available JJ N
data NNS N
are VBP N
not RB N
sufficient JJ N
to TO N
serve VB N
as IN N
a DT N
basis NN N
for IN N
firm NN N
dietary JJ N
advice NN N
. . N

We PRP N
undertook VBD N
a DT N
multicentre NN N
randomised VBN N
trial NN N
to TO N
test VB N
the DT N
effect NN N
of IN N
diet JJ i
supplementation NN i
with IN i
calcium NN i
and CC i
fibre NN i
on IN N
adenoma NN N
recurrence NN N
. . N

METHODS NNP N
We PRP N
randomly VBP N
assigned VBD N
665 CD p
patients NNS p
with IN p
a DT p
history NN p
of IN p
colorectal JJ p
adenomas NN p
to TO p
three CD p
treatment NN p
groups NNS p
, , N
in IN N
a DT N
parallel JJ N
design NN N
: : N
calcium NN i
gluconolactate NN i
and CC i
carbonate NN i
( ( i
2 CD i
g NN i
elemental JJ i
calcium NN i
daily RB i
) ) i
, , i
fibre JJ i
( ( i
3.5 CD i
g NN i
ispaghula NN i
husk NN i
) ) i
, , i
or CC i
placebo NN i
. . i

Participants NNS N
had VBD N
colonoscopy NN N
after IN N
3 CD N
years NNS N
of IN N
follow-up NN N
. . N

The DT N
primary JJ N
endpoint NN N
was VBD N
adenoma JJ N
recurrence NN N
. . N

Analyses NNS N
were VBD N
by IN N
intention NN N
to TO N
treat VB N
. . N

FINDINGS NNP N
23 CD p
patients NNS p
died VBD p
, , p
15 CD p
were VBD p
lost VBN p
to TO p
follow-up NN p
, , p
45 CD p
refused VBD p
repeat NN p
colonoscopy NN p
, , p
and CC p
five CD p
developed NNS p
severe JJ o
contraindications NNS o
to TO o
colonoscopy VB o
. . o

Among IN N
the DT N
552 CD p
participants NNS p
who WP p
completed VBD p
the DT p
follow-up JJ p
examination NN p
, , p
94 CD p
stopped VBD p
treatment NN p
early RB p
. . p

At IN N
least JJS N
one CD N
adenoma NN o
developed VBD N
in IN N
28 CD p
( ( p
15.9 CD p
% NN p
) ) p
of IN p
176 CD p
patients NNS p
in IN N
the DT N
calcium NN i
group NN N
, , N
58 CD p
( ( p
29.3 CD p
% NN p
) ) p
of IN p
198 CD p
in IN N
the DT N
fibre NN N
group NN N
, , N
and CC N
36 CD p
( ( p
20.2 CD p
% NN p
) ) p
of IN p
178 CD p
in IN p
the DT p
placebo NN p
group NN p
. . p

The DT N
adjusted JJ o
odds NNS o
ratio NN o
for IN o
recurrence NN o
was VBD N
0.66 CD N
( ( N
95 CD N
% NN N
CI NNP N
0.38-1.17 CD N
; : N
p=0.16 NN N
) ) N
for IN N
calcium NN i
treatment NN N
and CC N
1.67 CD N
( ( N
1.01-2.76 CD N
, , N
p=0.042 NN N
) ) N
for IN N
the DT N
fibre JJ i
treatment NN N
. . N

The DT N
odds NNS o
ratio NN o
associated VBN o
with IN o
the DT o
fibre NN o
treatment NN o
was VBD N
significantly RB N
higher JJR N
in IN N
participants NNS N
with IN N
baseline NN N
dietary JJ N
calcium NN i
intake NN N
above IN N
the DT N
median JJ N
than IN N
in IN N
those DT N
with IN N
intake JJ N
below IN N
the DT N
median NN N
( ( N
interaction JJ N
test NN N
, , N
p=0.028 NN N
) ) N
INTERPRETATION NNP N
Supplementation NNP N
with IN N
fibre NN i
as IN N
ispaghula JJ N
husk NN N
may MD N
have VB N
adverse JJ o
effects NNS o
on IN o
colorectal JJ o
adenoma NN o
recurrence NN o
, , N
especially RB N
in IN N
patients NNS p
with IN p
high JJ p
dietary JJ p
calcium NN p
intake NN p
. . p

Calcium NNP N
supplementation NN N
was VBD N
associated VBN N
with IN N
a DT N
modest JJ N
but CC N
not RB N
significant JJ N
reduction NN N
in IN N
the DT N
risk NN N
of IN N
adenoma JJ o
recurrence NN o
. . o

-DOCSTART- -10509459- O O

Tactile NNP o
feedback NN o
is VBZ N
present JJ N
during IN N
minimally RB i
invasive JJ i
surgery NN i
. . i

BACKGROUND IN N
The DT N
applications NNS N
of IN N
minimally RB i
invasive JJ i
surgery NN i
( ( i
MIS NNP i
) ) i
and CC N
laparoscopy $ i
are VBP N
rapidly RB N
expanding VBG N
. . N

Despite IN N
this DT N
expansion NN N
, , N
our PRP$ N
understanding NN N
of IN N
the DT N
importance NN N
of IN N
haptic JJ N
feedback NN N
during IN N
laparoscopic NN i
surgery NN i
is VBZ N
incomplete JJ N
. . N

Although IN N
many JJ N
surgeons NNS N
believe VBP N
that IN N
the DT N
use NN N
of IN N
minimally RB i
invasive JJ i
techniques NNS i
eliminates VBZ N
force VBP o
feedback NN o
and CC o
tactile JJ o
sensation NN o
( ( o
haptics NNS o
) ) o
, , N
the DT N
importance NN N
of IN N
haptics NNS N
in IN N
MIS NNP N
has VBZ N
not RB N
been VBN N
fully RB N
evaluated VBN N
. . N

There EX N
is VBZ N
considerable JJ N
interest NN N
in IN N
the DT N
development NN N
of IN N
simulators NNS N
for IN N
MIS NNP N
even RB N
though IN N
the DT N
importance NN N
of IN N
force NN o
feedback NN o
remains VBZ N
poorly RB N
understood JJ N
. . N

This DT N
study NN N
was VBD N
designed VBN N
to TO N
determine VB N
the DT N
ability NN N
of IN N
experienced JJ p
surgeons NNS p
to TO N
interpret VB N
haptic JJ o
feedback NN o
with IN N
respect NN N
to TO N
texture NN o
, , o
shape NN o
, , o
and CC o
consistency NN o
of IN o
an DT o
object NN o
. . o

STUDY NNP N
DESIGN NNP N
A NNP N
randomized JJ N
, , N
single-blinded JJ N
study NN N
was VBD N
designed VBN N
. . N

Twenty CD p
surgeons NNS p
were VBD p
presented VBN p
objects NNS p
in IN p
a DT p
random NN p
order NN p
, , p
with IN p
participants NNS p
blinded VBN p
as IN p
to TO p
their PRP$ p
identity NN p
. . p

Inspection NN o
by IN o
direct JJ o
palpation NN o
, , o
conventional JJ o
instruments NNS o
, , o
and CC o
laparoscopic JJ o
instruments NNS o
was VBD N
performed VBN N
on IN N
all DT N
objects NNS N
. . N

Statistic JJ N
analysis NN N
of IN N
the DT N
data NN N
was VBD N
performed VBN N
using VBG N
chi-square JJ N
analysis NN N
and CC N
, , N
when WRB N
appropriate NN N
, , N
a DT N
Fischer NNP N
exact JJ N
probability NN N
test NN N
. . N

RESULTS NNP N
Direct NNP o
palpation NN o
was VBD N
associated VBN N
with IN N
the DT N
highest JJS N
accuracy NN N
for IN N
shape NN N
identification NN N
and CC N
was VBD N
superior VBN N
to TO N
both DT N
conventional JJ N
instruments NNS N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
and CC N
laparoscopic JJ N
instruments NNS N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
. . N

Fine JJ N
texture NN N
analysis NN N
with IN N
either CC N
a DT N
conventional JJ i
instrument NN i
or CC N
a DT N
laparoscopic JJ i
instrument NN i
was VBD N
superior JJ N
to TO N
direct JJ N
palpation NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

Finally RB N
, , N
the DT N
three CD N
methods NNS N
of IN N
analysis NN N
were VBD N
comparable JJ N
for IN N
consistency NN N
analysis NN N
. . N

CONCLUSIONS NNP N
These DT N
data NNS N
indicate VBP N
that IN N
laparoscopic NN N
instruments NNS N
do VBP N
, , N
in IN N
fact NN N
, , N
provide VB N
surgeons NNS p
with IN N
haptic JJ o
feedback NN o
. . o

Interpretation NN N
of IN N
the DT N
texture NN N
, , N
shape NN N
, , N
and CC N
consistency NN N
of IN N
objects NNS N
can MD N
be VB N
performed VBN N
. . N

In IN N
some DT N
situations NNS N
, , N
laparoscopic JJ i
instruments NNS i
appear VBP N
to TO N
amplify VB N
the DT N
haptic JJ N
information NN N
available JJ N
. . N

Our PRP$ N
ongoing JJ N
work NN N
is VBZ N
directed VBN N
at IN N
further JJ N
defining VBG N
force NN N
interactions NNS N
. . N

-DOCSTART- -1553169- O O

Use NNP N
of IN N
Interceed NNP i
( ( i
TC7 NNP i
) ) i
absorbable JJ i
adhesion NN i
barrier NN i
to TO N
reduce VB N
postoperative JJ o
adhesion NN o
reformation NN o
in IN N
infertility NN p
and CC p
endometriosis NN p
surgery NN p
. . p

The DT N
Obstetrics NNPS N
and CC N
Gynecology NNP N
Adhesion NNP N
Prevention NNP N
Committee NNP N
. . N

Interceed NNP i
( ( i
TC7 NNP i
) ) i
is VBZ N
a DT N
fabric NN N
composed VBN N
of IN N
oxidized JJ N
, , N
regenerated VBD N
cellulose NN N
that WDT N
was VBD N
designed VBN N
to TO N
reduce VB N
the DT N
formation NN N
of IN N
postsurgical JJ N
adhesions NNS N
. . N

We PRP N
evaluated VBD N
Interceed NNP i
( ( i
TC7 NNP i
) ) i
in IN N
a DT N
randomized JJ N
, , N
multicenter RB N
clinical JJ N
study NN N
. . N

Sixty-three JJ p
infertility NN p
patients NNS p
had VBD N
bilateral JJ N
pelvic JJ N
sidewall NN N
adhesions NNS N
removed VBD N
at IN N
laparotomy NN N
. . N

One CD N
pelvic NN N
sidewall NN N
was VBD N
covered VBN N
by IN N
Interceed NNP i
( ( i
TC7 NNP i
) ) i
and CC N
the DT N
other JJ i
was VBD i
left VBN i
uncovered JJ i
. . i

The DT N
deperitonealized JJ N
areas NNS N
( ( N
N NNP N
= NNP N
205 CD N
) ) N
of IN N
all DT N
sidewalls NNS N
were VBD N
divided VBN N
into IN N
three CD N
groups NNS N
: : N
less JJR N
than IN N
100 CD N
mm2 NN N
, , N
N NNP N
= NNP N
72 CD N
; : N
100-1000 CD N
mm2 NN N
, , N
N NNP N
= NNP N
95 CD N
; : N
and CC N
more JJR N
than IN N
1000 CD N
mm2 NN N
, , N
N NNP N
= VBZ N
38 CD N
. . N

The DT N
effectiveness NN o
of IN o
Interceed NNP o
( ( o
TC7 NNP o
) ) o
was VBD N
evaluated VBN N
at IN N
laparoscopy JJ N
10-98 JJ N
days NNS N
after IN N
laparotomy NN i
. . i

Significantly RB N
more JJR N
adhesions NNS o
were VBD N
observed VBN N
at IN N
laparoscopy NN N
on IN N
the DT N
control NN N
pelvic JJ N
sidewalls NNS N
( ( N
48 CD N
of IN N
63 CD N
, , N
76 CD N
% NN N
) ) N
than IN N
on IN N
the DT N
treated VBN N
sides NNS N
( ( N
26 CD N
of IN N
63 CD N
, , N
41 CD N
% NN N
) ) N
( ( N
P NNP N
less JJR N
than IN N
.0001 NN N
) ) N
. . N

The DT N
Interceed NNP o
( ( o
TC7 NNP o
) ) o
-treated VBD o
sidewalls NNS N
also RB N
had VBD N
significantly RB N
less RBR N
area NN o
involved VBN o
with IN o
adhesions NNS o
at IN N
laparoscopy NN N
( ( N
P NNP N
less JJR N
than IN N
.05 NN N
, , N
P NNP N
less JJR N
than IN N
.001 NN N
, , N
and CC N
P NNP N
less JJR N
than IN N
.001 NN N
in IN N
the DT N
three CD N
groups NNS N
, , N
respectively RB N
) ) N
. . N

Twenty-eight JJ N
women NNS N
with IN N
severe JJ N
endometriosis NN N
also RB N
had VBD N
significantly RB N
more JJR N
adhesions NNS o
on IN N
the DT N
control NN N
side NN N
( ( N
23 CD N
of IN N
28 CD N
, , N
82 CD N
% NN N
) ) N
than IN N
on IN N
the DT N
treated JJ N
side NN N
( ( N
14 CD N
of IN N
28 CD N
, , N
50 CD N
% NN N
) ) N
( ( N
P NNP N
less JJR N
than IN N
.05 NN N
) ) N
. . N

We PRP N
conclude VBP N
that DT N
Interceed NNP i
( ( i
TC7 NNP i
) ) i
effectively RB N
reduced VBD N
the DT N
incidence NN N
and CC N
extent NN N
of IN N
postoperative JJ o
adhesions NNS o
, , N
even RB N
in IN N
patients NNS N
with IN N
severe JJ N
endometriosis NN N
. . N

-DOCSTART- -1451242- O O

A DT N
prospective JJ N
, , N
placebo-controlled JJ i
, , N
randomized JJ N
trial NN N
of IN N
intravenous JJ N
streptokinase NN i
and CC N
angioplasty JJ i
versus NN i
lone NN i
angioplasty JJ i
therapy NN i
of IN N
acute JJ N
myocardial JJ N
infarction NN N
. . N

BACKGROUND IN N
The DT N
value NN N
of IN N
routine JJ N
administration NN N
of IN N
intravenous JJ N
thrombolytic JJ i
agents NNS i
during IN N
percutaneous JJ i
transluminal JJ i
coronary NN i
angioplasty NN i
( ( i
PTCA NNP i
) ) i
therapy NN i
of IN N
acute JJ N
myocardial JJ N
infarction NN N
( ( N
MI NNP N
) ) N
has VBZ N
not RB N
been VBN N
determined VBN N
. . N

Therefore RB N
, , N
we PRP N
prospectively RB N
randomized VBD N
122 CD p
patients NNS p
with IN p
evolving VBG p
MI NNP p
to TO p
PTCA NNP i
therapy NN i
with IN p
or CC p
without IN p
adjunctive JJ p
intravenous JJ i
streptokinase NN i
therapy NN i
. . i

METHODS NNP N
AND CC N
RESULTS NNP N
Patients NNP p
with IN p
ECG NNP p
ST NNP p
segment NN p
elevation NN p
who WP p
presented VBD p
within IN p
4 CD p
hours NNS p
of IN p
symptom JJ p
onset NN p
, , p
had VBD p
no DT p
contraindication NN p
to TO p
thrombolytic JJ i
therapy NN i
, , p
and CC p
were VBD p
not RB p
in IN p
cardiogenic JJ p
shock NN p
were VBD p
enrolled VBN p
. . p

They PRP N
were VBD N
treated VBN N
immediately RB N
with IN N
intravenous JJ i
heparin NNS i
( ( N
10,000 CD N
units NNS N
) ) N
and CC N
oral JJ i
aspirin NN i
( ( N
325 CD N
mg NN N
) ) N
and CC N
randomized VBN N
to TO N
treatment NN N
with IN N
placebo NN i
or CC i
streptokinase NN i
( ( N
1.5 CD N
M NNP N
units NNS N
) ) N
administered VBD N
intravenously RB N
over IN N
30 CD N
minutes NNS N
. . N

Patients NNS N
then RB N
were VBD N
taken VBN N
immediately RB N
to TO N
the DT N
catheterization NN N
laboratory NN N
, , N
and CC N
those DT N
with IN N
suitable JJ N
coronary JJ N
anatomy NN N
underwent JJ N
immediate JJ N
PTCA NNP i
. . i

Subsequent NNP N
clinical JJ N
course NN N
, , N
serial JJ N
radionuclide NN N
ventriculography NN N
, , N
and CC N
6-month JJ N
repeat NN N
angiography NN N
were VBD N
analyzed VBN N
. . N

A DT N
total NN N
of IN N
106 CD p
patients NNS p
were VBD p
treated VBN p
with IN p
PTCA NNP i
. . i

Use NNP N
of IN N
PTCA NNP i
was VBD N
similar JJ N
for IN N
placebo NN i
( ( N
92 CD N
% NN N
) ) N
and CC N
streptokinase NNP i
( ( N
83 CD N
% NN N
) ) N
groups NNS N
. . N

Angioplasty NNP i
was VBD N
successful JJ N
in IN N
95 CD N
% NN N
of IN N
patients NNS N
, , N
with IN N
no DT N
difference NN N
in IN N
placebo NN i
( ( N
93 CD N
% NN N
) ) N
and CC N
streptokinase NNP i
( ( N
98 CD N
% NN N
) ) N
groups NNS N
. . N

Serial JJ N
radionuclide NN N
ventriculography NN N
demonstrated VBD N
no DT N
difference NN N
in IN N
24-hour JJ N
( ( N
52 CD N
+/- JJ N
12 CD N
% NN N
versus NN N
50 CD N
+/- JJ N
12 CD N
% NN N
) ) N
or CC N
6-week JJ N
( ( N
51 CD N
+/- JJ N
12 CD N
% NN N
versus NN N
51 CD N
+/- JJ N
13 CD N
% NN N
) ) N
ejection NN o
fraction NN o
values NNS o
for IN N
placebo NN i
and CC i
streptokinase NN i
groups NNS N
, , N
respectively RB N
. . N

Contrast NNP o
ventriculography NN o
demonstrated VBD N
improvement NN N
in IN N
immediate NN N
( ( N
54 CD N
+/- JJ N
12 CD N
% NN N
) ) N
versus NN N
6-month JJ N
( ( N
60 CD N
+/- JJ N
15 CD N
% NN N
, , N
p NN N
< NNP N
0.05 CD N
) ) N
values NNS N
for IN N
the DT N
overall JJ N
group NN N
. . N

No DT N
differences NNS N
in IN N
6-month JJ o
values NNS o
were VBD N
present JJ N
( ( N
58 CD N
+/- JJ N
15 CD N
% NN N
versus NN N
62 CD N
+/- JJ N
15 CD N
% NN N
, , N
p NN N
= NNP N
NS NNP N
) ) N
for IN N
placebo NN i
and CC i
streptokinase NN i
groups NNS N
, , N
respectively RB N
. . N

Coronary JJ o
angiography NN o
was VBD N
performed VBN N
in IN N
75 CD N
% NN N
of IN N
the DT N
90 CD N
patients NNS N
eligible JJ N
for IN N
restudy NN N
. . N

Arterial JJ o
patency NN o
was VBD N
87 CD N
% NN N
at IN N
6 CD N
months NNS N
, , N
and CC N
coronary JJ o
restenosis NN o
was VBD N
present JJ N
in IN N
38 CD N
% NN N
of IN N
patients NNS N
. . N

No DT N
differences NNS N
in IN N
chronic JJ o
patency NN o
or CC o
restenosis NN o
were VBD N
detected VBN N
for IN N
the DT N
two CD N
treatment NN N
groups NNS N
. . N

Although IN N
adjunctive JJ N
intravenous JJ N
streptokinase NN i
therapy NN N
did VBD N
not RB N
improve VB N
outcome NN N
, , N
it PRP N
did VBD N
complicate VB N
the DT N
hospital NN N
course NN N
. . N

Hospitalization NNP o
was VBD N
longer JJR N
( ( N
9.3 CD N
+/- JJ N
5.0 CD N
versus NN N
7.7 CD N
+/- JJ N
4.4 CD N
days NNS N
, , N
p VBP N
= RB N
0.046 CD N
) ) N
and CC N
more RBR N
costly JJ o
( ( N
$ $ N
25,191 CD N
+/- JJ N
15,368 CD N
versus IN N
$ $ N
19,643 CD N
+/- JJ N
7,250 CD N
, , N
p NN N
< NNP N
0.02 CD N
) ) N
. . N

Transfusion NN o
rate NN o
was VBD N
higher JJR N
( ( N
39 CD N
% NN N
versus IN N
8 CD N
% NN N
, , N
p NN N
= NNP N
0.0001 CD N
) ) N
and CC N
need VBP N
for IN N
emergency NN N
coronary JJ N
bypass NN N
surgery NN N
was VBD N
greater JJR N
( ( N
10.3 CD N
% NN N
versus IN N
1.6 CD N
% NN N
, , N
p NN N
= NNP N
0.03 CD N
) ) N
for IN N
the DT N
streptokinase-treated JJ N
patients NNS N
. . N

CONCLUSIONS NNP N
Adjunctive NNP N
intravenous JJ N
streptokinase NN i
therapy NN i
does VBZ N
not RB N
enhance VB N
early JJ N
preservation NN N
of IN N
ventricular JJ o
function NN o
, , N
improve VB N
arterial JJ o
patency NN o
rates NNS o
, , N
or CC N
lower JJR N
restenosis NN o
rates NNS o
after IN N
PTCA NNP i
therapy NN i
of IN N
acute JJ N
MI NNP N
. . N

Hospital NNP N
course NN N
is VBZ N
longer JJR N
, , N
more RBR N
expensive JJ N
, , N
and CC N
more RBR N
complicated JJ N
. . N

For IN N
these DT N
reasons NNS N
, , N
PTCA NNP i
therapy NN i
of IN N
acute JJ N
MI NNP N
should MD N
not RB N
be VB N
routinely RB N
performed VBN N
with IN N
adjunctive JJ N
intravenous JJ N
streptokinase NN i
therapy NN i
. . i

-DOCSTART- -19574500- O O

Impact NN N
of IN N
preinduced JJ p
quadriceps NNS p
fatigue VBP p
on IN N
exercise NN N
response NN N
in IN N
chronic JJ p
obstructive JJ p
pulmonary JJ p
disease NN p
and CC p
healthy JJ p
subjects NNS p
. . p

Exercise NN N
intolerance NN N
in IN N
chronic JJ p
obstructive JJ p
pulmonary JJ p
disease NN p
( ( p
COPD NNP p
) ) p
results NNS N
from IN N
a DT N
complex JJ N
interaction NN N
between IN N
central JJ N
( ( N
ventilatory NN N
) ) N
and CC N
peripheral JJ N
( ( N
limb JJ N
muscles NNS N
) ) N
components NNS N
of IN N
exercise NN N
limitation NN N
. . N

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
influence NN N
of IN N
quadriceps NNS N
muscle VBP N
fatigue NN N
on IN N
exercise NN N
tolerance NN N
and CC N
ventilatory JJ N
response NN N
during IN N
constant-workrate JJ i
cycling NN i
exercise NN i
testing NN i
( ( i
CWT NNP i
) ) i
in IN N
patients NNS p
with IN p
COPD NNP p
and CC p
healthy JJ p
subjects NNS p
. . p

Fifteen JJ p
patients NNS p
with IN p
COPD NNP p
and CC p
nine CD p
age-matched JJ p
healthy JJ p
subjects NNS p
performed VBN N
, , N
7 CD N
days NNS N
apart RB N
, , N
two CD N
CWTs NNP i
up RB N
to TO N
exhaustion NN N
at IN N
80 CD N
% NN N
of IN N
their PRP$ N
predetermined VBN N
maximal JJ N
work NN N
capacity NN N
. . N

In IN N
a DT N
randomized JJ N
order NN N
, , N
one CD N
test NN N
was VBD N
performed VBN N
with IN N
preinduced JJ N
quadriceps NNS N
fatigue NN N
and CC N
the DT N
other JJ N
in IN N
a DT N
fresh JJ N
state NN N
. . N

Quadriceps NNP N
fatigue NN N
was VBD N
produced VBN N
by IN N
electrostimulation-induced JJ N
contractions NNS N
and CC N
quantified VBN N
by IN N
maximal JJ o
voluntary JJ o
contraction NN o
and CC N
potentiated VBD o
twitch NN o
force NN o
( ( o
TwQ NNP o
( ( o
pot NN o
) ) o
) ) o
. . N

Endurance NN o
time NN o
and CC o
ventilatory JJ o
response NN o
during IN N
CWT NNP N
were VBD N
compared VBN N
between IN N
fatigued VBN N
and CC N
fresh JJ N
state NN N
. . N

Endurance NN o
time NN o
significantly RB N
decreased VBN N
in IN N
the DT N
fatigued JJ N
state NN N
compared VBN N
with IN N
the DT N
fresh JJ N
condition NN N
in IN N
COPD NNP N
( ( N
356 CD N
+/- JJ N
69 CD N
s NN N
vs. FW N
294 CD N
+/- JJ N
45 CD N
s NN N
, , N
P NNP N
< NNP N
0.05 CD N
) ) N
and CC N
controls NNS N
( ( N
450 CD N
+/- JJ N
74 CD N
s NN N
vs. FW N
340 CD N
+/- JJ N
45 CD N
s NN N
, , N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

Controls NNP N
showed VBD N
significantly RB N
higher JJR N
ventilation NN o
and CC o
end-exercise JJ o
dyspnea NN o
scores NNS o
in IN N
the DT N
fatigued JJ N
condition NN N
, , N
whereas NNS N
, , N
in IN N
COPD NNP N
, , N
fatigue NN N
did VBD N
not RB N
influence VB N
ventilation NN N
or CC N
dyspnea NN N
during IN N
exercise NN N
. . N

The DT N
degree NN N
of IN N
ventilatory NN o
limitation NN o
, , N
as IN N
expressed VBN N
by IN N
the DT N
Ve/maximum NNP o
voluntary JJ o
ventilation NN o
ratio NN o
, , N
was VBD N
similar JJ N
in IN N
both DT N
conditions NNS N
in IN N
patients NNS p
with IN p
COPD NNP p
. . p

We PRP N
conclude VBP N
that IN N
it PRP N
is VBZ N
possible JJ N
to TO N
induce VB N
quadriceps NNS N
fatigue VBN N
by IN N
local JJ N
electrostimulation-induced JJ N
contractions NNS N
. . N

Our PRP$ N
findings NNS N
demonstrate VBP N
that IN N
peripheral JJ p
muscle NN p
fatigue NN p
is VBZ N
an DT N
additional JJ N
important JJ N
factor NN N
, , N
besides IN N
intense JJ N
dyspnea NN N
, , N
that IN N
limits NNS N
exercise VBP N
tolerance NN N
in IN N
COPD NNP N
. . N

-DOCSTART- -22402015- O O

Development NNP N
of IN N
an DT N
adaptive JJ i
low-pass NN i
filtered VBD i
speech JJ i
test NN i
for IN N
the DT N
identification NN N
of IN N
auditory NN o
processing NN o
disorders NNS o
. . o

OBJECTIVE CC N
One CD N
type NN N
of IN N
test NN N
commonly RB N
used VBD N
to TO N
examine VB N
auditory JJ p
processing NN p
disorders NNS p
( ( p
APD NNP p
) ) p
is VBZ N
the DT N
low-pass NN i
filtered VBD i
speech JJ i
test NN i
( ( N
LPFST NNP N
) ) N
, , N
of IN N
which WDT N
there EX N
are VBP N
various JJ N
versions NNS N
. . N

In IN N
LPFSTs NNP N
, , N
a DT N
monaural JJ N
, , N
low-redundancy JJ N
speech NN N
sample NN N
is VBZ N
distorted VBN N
by IN N
using VBG N
filtering VBG N
to TO N
modify VB N
its PRP$ N
frequency NN N
content NN N
. . N

Due JJ N
to TO N
the DT N
richness NN N
of IN N
the DT N
neural JJ N
pathways NNS N
in IN N
the DT N
auditory NN N
system NN N
and CC N
the DT N
redundancy NN N
of IN N
acoustic JJ N
information NN N
in IN N
spoken JJ N
language NN N
, , N
a DT N
normal JJ N
listener NN N
is VBZ N
able JJ N
to TO N
recognize VB N
speech NN N
even RB N
when WRB N
parts NNS N
of IN N
the DT N
signal NN N
are VBP N
missing VBG N
, , N
whereas IN N
this DT N
ability NN N
is VBZ N
often RB N
impaired VBN N
in IN N
listeners NNS p
with IN p
APD NNP p
. . p

One CD N
limitation NN N
of IN N
the DT N
various JJ N
versions NNS N
of IN N
the DT N
LPFST NNP i
is VBZ N
that IN N
they PRP N
are VBP N
carried VBN N
out IN N
using VBG N
a DT N
constant JJ N
level NN N
of IN N
low-pass JJ N
filtering NN N
( ( N
e.g NN N
. . N

a DT N
fixed JJ N
1kHz CD N
corner NN N
frequency NN N
) ) N
which WDT N
makes VBZ N
them PRP N
prone VB N
to TO N
ceiling NN N
and CC N
floor NN N
effects NNS N
. . N

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
counter VB N
these DT N
effects NNS N
by IN N
modifying VBG N
the DT N
LPFST NNP N
using VBG N
a DT N
computer-based JJ N
adaptive JJ N
procedure NN N
, , N
and CC N
to TO N
evaluate VB N
the DT N
performance NN N
of IN N
normal-hearing JJ p
participants NNS p
of IN p
varying VBG p
ages NNS p
on IN N
the DT N
test NN N
. . N

METHODS NNP N
In IN N
this DT N
preliminary JJ N
study NN N
, , N
33 CD p
adults NNS p
and CC p
30 CD p
children NNS p
( ( p
aged VBN p
8-11 CD p
years NNS p
) ) p
with IN p
no DT p
known JJ p
history NN p
of IN p
listening VBG p
difficulties NNS p
were VBD N
tested VBN N
. . N

The DT i
University NNP i
of IN i
Canterbury NNP i
Adaptive NNP i
Speech NNP i
Test NNP i
( ( i
UCAST NNP i
) ) i
platform NN i
was VBD i
used VBN i
to TO i
administer VB i
a DT i
four-alternative JJ i
forced-choice JJ i
adaptive JJ i
test NN i
that WDT i
altered VBD i
a DT i
low-pass JJ i
filter NN i
( ( i
LPF NNP i
) ) i
to TO i
track VB i
the DT i
corner NN i
frequency NN i
at IN i
which WDT i
participants NNS i
correctly RB i
identified VBN i
a DT i
certain JJ i
percentage NN i
of IN i
the DT i
word NN i
stimuli NN i
. . i

RESULTS NNP N
Findings NNP N
on IN N
the DT N
University NNP o
of IN o
Canterbury NNP o
Adaptive NNP o
Speech NNP o
Test-Filtered NNP o
Words NNP o
( ( o
UCAST-FW NNP o
) ) o
indicated VBD N
a DT N
significant JJ o
maturational JJ o
effect NN o
. . o

Adult NN p
participants NNS p
performed VBD N
significantly RB N
better RBR N
on IN N
the DT N
UCAST-FW NNP o
in IN N
comparison NN N
to TO N
the DT N
child NN p
participants NNS p
. . p

The DT N
UCAST-FW JJ i
test NN N
was VBD N
reliable JJ N
over IN N
repeated JJ N
administrations NNS N
. . N

CONCLUSIONS NNP N
An DT N
adaptive JJ N
low-pass NN N
filtered VBD N
speech JJ N
test NN N
such JJ N
as IN N
the DT N
UCAST-FW NNP o
is VBZ N
sensitive JJ N
to TO N
maturational JJ o
changes NNS o
in IN o
auditory NN o
processing NN o
ability NN o
. . o

-DOCSTART- -15162076- O O

A DT N
description NN N
of IN N
the DT N
clinical JJ N
characteristics NNS N
at IN N
baseline NN N
of IN N
patients NNS p
recruited VBN p
into IN p
the DT p
Carvedilol NNP i
or CC i
Metoprolol NNP i
European JJ i
Trial NNP i
( ( i
COMET NNP i
) ) i
. . i

BACKGROUND NNP N
& CC N
AIMS NNP N
The DT N
COMET NNP i
trial NN N
was VBD N
a DT N
prospective JJ N
, , N
double-blind JJ N
, , N
randomised JJ N
trial NN N
comparing VBG N
carvedilol NN i
, , N
a DT N
comprehensive JJ N
adrenergic NN N
receptor NN N
antagonist NN i
, , N
with IN N
metoprolol NN i
, , i
a DT i
beta-1-selective JJ i
agent NN i
in IN N
patients NNS p
with IN p
heart NN p
failure NN p
and CC p
left VBD p
ventricular JJ p
systolic JJ p
dysfunction NN p
. . p

The DT N
trial NN N
showed VBD N
a DT N
reduction NN N
in IN N
mortality NN o
with IN N
carvedilol NN i
that WDT N
was VBD N
consistent JJ N
across IN N
subgroups NNS N
. . N

The DT N
purpose NN N
of IN N
this DT N
report NN N
is VBZ N
to TO N
describe VB N
in IN N
greater JJR N
detail NN N
the DT N
heterogeneity NN N
of IN N
this DT N
population NN N
at IN N
baseline NN N
with IN N
particular JJ N
reference NN N
to TO N
the DT N
impact NN N
of IN N
symptomatic JJ N
severity NN N
, , N
age NN N
and CC N
gender NN N
on IN N
patient JJ N
characteristics NNS N
. . N

METHODS NNP N
A NNP N
descriptive JJ N
report NN N
using VBG N
data NNS N
entered VBN N
in IN N
the DT N
COMET NNP i
study NN N
data-base NN N
. . N

RESULTS VB N
The DT N
characteristics NNS N
of IN N
the DT N
population NN N
studied VBN N
were VBD N
similar JJ N
to TO N
those DT N
reported VBN N
in IN N
previous JJ N
trials NNS N
of IN N
beta-blockers NNS N
. . N

Almost NNP p
all DT p
patients NNS p
were VBD p
receiving VBG p
diuretics NNS i
and CC p
ACE NNP i
inhibitors NNS i
with IN p
few JJ p
patients NNS p
taking VBG p
angiotensin JJ i
receptor NN i
blockers NNS i
. . i

As IN N
expected VBN N
, , N
older JJR N
patients NNS N
had VBD N
more RBR N
co-morbidity JJ o
. . o

Older JJR N
patients NNS N
and CC N
women NNS N
reported VBD N
worse JJR N
symptoms NNS o
and CC o
poorer JJR o
well-being JJ o
despite IN N
similar JJ N
ventricular JJ o
dimensions NNS o
and CC o
systolic JJ o
dysfunction NN o
. . o

NT-proBNP NNP o
was VBD N
higher RBR N
in IN N
patients NNS N
with IN N
more RBR N
severe JJ o
symptoms NNS o
and CC N
older JJR N
patients NNS N
but CC N
not RB N
in IN N
women NNS N
, , N
although IN N
differences NNS N
in IN N
NT-proBNP NNP N
may MD N
have VB N
been VBN N
confounded VBN N
by IN N
differences NNS N
in IN N
renal JJ o
function NN o
. . o

CONCLUSION NNP N
Age NNP N
and CC N
gender NN N
, , N
as RB N
well RB N
as IN N
the DT N
severity NN N
of IN N
cardiac JJ N
dysfunction NN N
, , N
appear VBP N
to TO N
have VB N
an DT N
important JJ N
effect NN N
on IN N
the DT N
severity NN N
of IN N
heart NN o
failure NN o
symptoms NNS o
and CC N
patient JJ o
'well-being NN o
' POS o
. . o

This DT N
could MD N
have VB N
important JJ N
implications NNS N
for IN N
the DT N
relationship NN N
between IN N
symptoms NNS N
and CC N
prognosis NN N
and CC N
therefore RB N
the DT N
way NN N
in IN N
which WDT N
patients NNS N
are VBP N
selected VBN N
for IN N
clinical JJ N
trials NNS N
and CC N
the DT N
goals NNS N
of IN N
treatment NN N
. . N

This DT N
will MD N
be VB N
the DT N
subject NN N
of IN N
further JJ N
analyses NNS N
. . N

-DOCSTART- -21785368- O O

A DT N
web-based JJ i
approach NN i
to TO N
address VB N
cardiovascular JJ o
risks NNS o
in IN p
managers NNS p
: : p
results NNS N
of IN N
a DT N
randomized JJ N
trial NN N
. . N

OBJECTIVES UH N
To TO N
examine VB N
whether IN N
a DT N
Web-based JJ i
health NN i
and CC i
leadership NN i
development NN i
program NN i
-- : i
designed VBN i
specifically RB N
for IN N
managers NNS p
-- : p
was VBD p
associated VBN N
with IN N
changes NNS N
in IN N
self-reported JJ o
and CC o
biometric JJ o
indicators NNS o
of IN o
cardiovascular JJ o
disease NN o
within IN N
the DT N
context NN N
of IN N
a DT N
randomized VBN N
control NN N
trial NN N
. . N

METHODS VB N
A DT N
total NN N
of IN N
145 CD p
managers NNS p
from IN p
8 CD p
organizations NNS p
participated VBN N
in IN N
a DT N
6-month JJ i
Internet-based JJ i
program NN i
or CC i
a DT i
control JJ i
condition NN i
. . i

They PRP N
completed VBD N
pre- NN N
and CC N
posttest NN N
assessments NNS N
that WDT N
included VBD N
both DT N
self-reported JJ o
attitudes NNS o
( ( o
on IN o
diet NN o
, , o
exercise NN o
, , o
and CC o
mental JJ o
health NN o
) ) o
and CC N
biometric JJ o
measures NNS o
( ( o
eg NN o
, , o
body NN o
weight NN o
, , o
waist JJ o
circumference NN o
) ) o
. . o

RESULTS VB N
The DT N
intervention NN i
was VBD N
associated VBN N
with IN N
improvements NNS N
in IN N
dietary JJ o
attitudes NNS o
, , o
dietary JJ o
self-efficacy NN o
, , o
and CC o
exercise NN o
, , o
and CC o
reductions NNS o
in IN o
distress NN o
symptoms NNS o
. . o

Women NNS N
in IN N
the DT N
program NN N
reduced VBD N
their PRP$ N
waist NN o
circumference NN o
significantly RB N
more RBR N
than IN N
controls NNS N
. . N

CONCLUSIONS VB N
The DT N
program NN N
showed VBD N
promise NN N
for IN N
reducing VBG N
cardiovascular JJ o
disease NN o
risk NN o
factors NNS o
. . o

Similar JJ N
results NNS N
across IN N
diverse JJ N
organizations NNS N
suggest VBP N
the DT N
program NN N
may MD N
be VB N
useful JJ N
across IN N
industry NN N
types NNS N
. . N

-DOCSTART- -20952020- O O

Cardiovascular JJ N
safety NN N
of IN N
degarelix NN i
: : i
results NNS N
from IN N
a DT N
12-month JJ N
, , N
comparative JJ N
, , N
randomized VBN N
, , N
open JJ N
label NN N
, , N
parallel JJ N
group NN N
phase NN N
III NNP N
trial NN N
in IN N
patients NNS p
with IN p
prostate JJ p
cancer NN p
. . p

PURPOSE NNP N
We PRP N
assessed VBD N
the DT N
cardiovascular JJ N
safety NN N
profile NN N
of IN N
degarelix NN i
, , N
a DT N
new JJ N
gonadotropin-releasing JJ i
hormone NN i
antagonist NN i
. . i

MATERIALS NNP N
AND CC N
METHODS NNP N
This DT N
is VBZ N
the DT N
first JJ N
report NN N
to TO N
our PRP$ N
knowledge NN N
on IN N
cardiovascular JJ N
safety NN N
data NNS N
from IN N
a DT N
completed VBN N
1-year JJ N
randomized NNS N
controlled VBD N
trial NN N
of IN N
leuprolide JJ i
acetate NN i
vs NN i
degarelix NN i
. . i

Outcomes CC N
considered VBN N
in IN N
these DT N
analyses NNS N
included VBD N
the DT N
QT NNP o
interval NN o
by IN o
central JJ o
reading NN o
and CC o
analysis NN o
, , o
and CC o
cardiovascular JJ o
adverse JJ o
events NNS o
. . o

On IN N
multivariate NN N
analyses NNS N
relationships VBP N
between IN N
selected VBN N
baseline NN N
factors NNS N
and CC N
cardiovascular JJ o
events NNS o
were VBD N
evaluated VBN N
. . N

RESULTS VB N
There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
treatment NN N
groups NNS N
for IN N
mean JJ N
change NN N
in IN N
Fridericia NNP N
's POS N
correction NN N
of IN N
QT NNP N
during IN N
the DT N
trial NN N
. . N

Markedly RB o
abnormal JJ o
Fridericia NNP o
's POS o
correction NN o
of IN o
QT NNP o
values NNS o
( ( N
500 CD N
milliseconds NNS N
or CC N
greater JJR N
) ) N
were VBD N
observed VBN N
in IN N
only RB N
a DT N
small JJ N
number NN N
of IN N
subjects NNS N
by IN N
treatment NN N
group NN N
, , N
that WDT N
is VBZ N
2 CD N
( ( N
less JJR N
than IN N
1 CD N
% NN N
) ) N
in IN N
the DT N
pooled JJ N
degarelix NN i
group NN N
and CC N
2 CD N
( ( N
1 CD N
% NN N
) ) N
in IN N
the DT N
leuprolide NN i
group NN N
. . N

Supraventricular JJ o
arrhythmias NN o
were VBD N
the DT N
most RBS N
common JJ N
type NN N
of IN N
arrhythmias NN N
, , N
affecting VBG N
2 CD N
% NN N
of IN N
subjects NNS N
in IN N
the DT N
pooled JJ N
degarelix NN i
group NN N
and CC N
4 CD N
% NN N
in IN N
the DT N
leuprolide NN i
group NN N
. . N

Other JJ o
arrhythmias JJ o
occurred VBN N
in IN N
1 CD N
% NN N
or CC N
less JJR N
of IN N
subjects NNS N
by IN N
treatment NN N
group NN N
. . N

The DT N
most RBS N
frequently RB N
reported VBD N
cardiac JJ N
disorder NN N
was VBD N
ischemic JJ o
heart NN o
disease NN o
, , N
which WDT N
occurred VBD N
in IN N
4 CD N
% NN N
of IN N
subjects NNS N
treated VBN N
with IN N
degarelix NN i
and CC N
10 CD N
% NN N
of IN N
those DT N
on IN N
leuprolide NN i
. . i

Cox NNP N
proportional JJ N
hazard NN N
ratio NN N
estimates NNS N
for IN N
selected VBN N
baseline NN N
covariates NNS N
showed VBD N
a DT N
significantly RB N
increased VBN N
risk NN N
of IN N
cardiovascular JJ N
events NNS N
by IN N
age NN N
( ( N
p=0.0459 NN N
) ) N
and CC N
systolic JJ N
blood NN N
pressure NN N
( ( N
p=0.0061 NN N
) ) N
. . N

CONCLUSIONS NNP N
In IN N
men NNS p
with IN p
prostate NN p
cancer NN p
degarelix NN i
and CC N
leuprolide NN i
have VBP N
similar JJ N
cardiovascular JJ N
safety NN N
profiles NNS N
. . N

These DT N
observations NNS N
suggest VBP N
that IN N
the DT N
cardiovascular JJ N
events NNS N
associated VBN N
with IN N
both DT N
agents NNS N
result VBP N
from IN N
hypogonadism NN N
rather RB N
than IN N
a DT N
direct JJ N
drug NN N
effect NN N
. . N

-DOCSTART- -21989146- O O

A DT N
randomized VBN N
study NN N
comparing VBG N
levofloxacin NN i
, , i
omeprazole NN i
, , i
nitazoxanide RB i
, , N
and CC N
doxycycline VB i
versus NN N
triple JJ i
therapy NN i
for IN N
the DT N
eradication NN N
of IN N
Helicobacter NNP o
pylori NN o
. . o

OBJECTIVES NNP N
Resistance NNP N
to TO N
standard VB N
Helicobacter NNP p
pylori NN p
( ( p
HP NNP p
) ) p
treatment NN N
regimens VBZ N
has VBZ N
led VBN N
to TO N
unsatisfactory JJ N
cure NN N
rates NNS N
in IN N
HP-infected JJ p
patients NNS p
. . p

This DT N
study NN N
was VBD N
designed VBN N
to TO N
evaluate VB N
a DT N
novel JJ N
four-drug JJ i
regimen NNS i
( ( N
three CD N
antibiotics NNS N
and CC N
a DT N
proton NN N
pump NN N
inhibitor NN N
( ( N
PPI NNP N
) ) N
) ) N
for IN N
eradication NN N
of IN N
HP NNP N
infection NN N
in IN N
treatment-naive JJ p
patients NNS p
. . p

METHODS NNP N
Patients NNPS p
with IN p
a DT p
diagnosis NN p
of IN p
HP NNP p
gastritis NN p
or CC p
peptic JJ p
ulcer JJ p
disease NN p
confirmed VBD p
using VBG p
endoscopy NN p
and CC p
stool NN p
antigen NN p
testing VBG p
were VBD p
eligible JJ p
for IN p
inclusion NN p
in IN p
this DT p
study NN p
. . p

All DT N
patients NNS p
underwent VBD N
a DT N
washout JJ N
period NN N
of IN N
6 CD N
weeks NNS N
from IN N
any DT N
prior JJ N
antibiotic JJ N
or CC N
PPI JJ N
usage NN N
. . N

Patients NNS p
were VBD N
then RB N
randomized VBN N
to TO N
either DT N
levofloxacin NN i
, , i
omeprazole NN i
, , i
nitazoxanide RB i
, , i
and CC i
doxycycline NN i
( ( i
LOAD NNP i
) ) i
therapy NN N
for IN N
7 CD N
days NNS N
( ( N
LOAD-7 NNP N
) ) N
or CC N
10 CD N
days NNS N
( ( N
LOAD-10 NNP N
) ) N
, , N
including VBG N
levofloxacin JJ i
250 CD i
mg NN i
with IN i
breakfast NN i
, , i
omeprazole JJ i
40 CD i
mg NN i
before IN i
breakfast NN i
, , i
nitazoxanide RB i
( ( i
Alina NNP i
) ) i
500 CD i
mg JJ i
twice RB i
daily RB i
with IN i
meals NNS i
and CC i
doxycycline VB i
100 CD i
mg NN i
at IN i
dinner NN i
, , i
or CC i
lansoprozole NN i
, , i
amoxicillin NN i
, , i
and CC i
clarithromycin NN i
( ( i
LAC NNP i
) ) i
therapy NN i
for IN N
10 CD N
days NNS N
, , N
which WDT N
included VBD N
lansoprozole JJ i
30 CD i
mg NN i
, , i
amoxicillin VBZ i
1 CD i
g NN i
with IN i
breakfast NN i
and CC i
dinner NN i
, , i
and CC i
clarithromycin VBZ i
500 CD i
mg NN i
with IN i
breakfast NN i
and CC i
dinner NN i
. . i

HP NNP N
eradication NN N
was VBD N
confirmed VBN N
by IN N
stool NN o
antigen NN o
testing VBG o
at IN N
least JJS N
4 CD N
weeks NNS N
after IN N
cessation NN N
of IN N
therapy NN N
. . N

RESULTS NNP N
Intention-to-treat JJ o
analysis NN o
revealed VBD N
significant JJ N
differences NNS N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
in IN N
the DT N
respective JJ N
eradication NN o
rates NNS o
of IN o
the DT o
LOAD NNP o
therapies NNS o
( ( N
88.9 CD N
% NN N
( ( N
80/90 CD N
) ) N
LOAD-10 NNP N
, , N
90 CD N
% NN N
( ( N
81/90 CD N
) ) N
LOAD-7 NNP N
, , N
89.4 CD N
% NN N
( ( N
161/180 CD N
) ) N
for IN N
combined VBN N
LOAD NNP N
) ) N
compared VBN N
with IN N
those DT N
receiving VBG N
LAC NNP o
, , N
73.3 CD N
% NN N
( ( N
66/90 CD N
) ) N
. . N

There EX N
were VBD N
no DT N
differences NNS N
in IN N
adverse JJ o
effects NNS o
between IN N
the DT N
groups NNS N
. . N

CONCLUSIONS VB N
This DT N
open-label JJ N
, , N
prospective JJ N
trial NN N
demonstrates VBZ N
that IN N
LOAD NNP o
is VBZ N
a DT N
highly RB N
active JJ N
regimen NNS N
for IN N
the DT N
treatment NN N
of IN N
HP NNP p
in IN p
treatment-naive JJ p
patients NNS p
. . p

A DT N
large JJ N
randomized VBN N
controlled JJ N
trial NN N
is VBZ N
warranted VBN N
to TO N
further RBR N
evaluate VB N
the DT N
efficacy NN N
of IN N
this DT N
regimen NNS N
. . N

-DOCSTART- -11053333- O O

Effect NN N
of IN N
systemic JJ N
nitric JJ i
oxide IN i
synthase JJ i
inhibition NN N
on IN N
postexercise NN p
hypotension NN p
in IN p
humans NNS p
. . p

An DT N
acute JJ N
bout NN N
of IN N
aerobic JJ N
exercise NN N
results NNS N
in IN N
a DT N
reduced JJ N
blood NN o
pressure NN o
that WDT N
lasts VBZ N
several JJ N
hours NNS N
. . N

Animal NNP N
studies NNS N
suggest VBP N
this DT N
response NN N
is VBZ N
mediated VBN N
by IN N
increased JJ N
production NN N
of IN N
nitric JJ N
oxide NN N
. . N

We PRP N
tested VBD N
the DT N
extent NN N
to TO N
which WDT N
systemic JJ N
nitric JJ N
oxide IN N
synthase JJ N
inhibition NN N
[ NNP N
N NNP N
( ( N
G NNP N
) ) N
-monomethyl-L-arginine NN N
( ( N
L-NMMA NNP N
) ) N
] NN N
can MD N
reverse VB N
the DT N
drop NN N
in IN N
blood NN o
pressure NN o
that WDT p
occurs VBZ p
after IN p
exercise NN p
in IN p
humans NNS p
. . p

Eight NNP p
healthy JJ p
subjects NNS p
underwent JJ N
parallel JJ N
experiments NNS N
on IN N
2 CD N
separate JJ N
days NNS N
. . N

The DT N
order NN N
of IN N
the DT N
experiments NNS N
was VBD N
randomized VBN N
between IN N
sham NN N
( ( i
60 CD i
min NN i
of IN i
seated JJ i
upright JJ i
rest NN i
) ) i
and CC N
exercise NN N
( ( i
60 CD i
min NN i
of IN i
upright JJ i
cycling NN i
at IN i
60 CD i
% NN i
peak NN i
aerobic JJ i
capacity NN i
) ) i
. . N

After IN N
both DT N
sham NN N
and CC N
exercise NN N
, , N
subjects VBZ N
received VBN N
, , N
in IN N
sequence NN N
, , N
systemic JJ N
alpha-adrenergic JJ N
blockade NN N
( ( N
phentolamine NN N
) ) N
and CC N
L-NMMA NNP N
. . N

Phentolamine NNP N
was VBD N
given VBN N
first RB N
to TO N
isolate VB N
the DT N
contribution NN N
of IN N
nitric JJ N
oxide NN N
to TO N
postexercise VB N
hypotension NN N
by IN N
preventing VBG N
reflex JJ N
changes NNS N
in IN N
sympathetic JJ N
tone NN N
that WDT N
result NN N
from IN N
systemic JJ N
nitric JJ N
oxide IN N
synthase JJ N
inhibition NN N
and CC N
to TO N
control VB N
for IN N
alterations NNS N
in IN N
resting VBG N
sympathetic JJ N
activity NN N
after IN N
exercise NN N
. . N

During IN N
each DT N
condition NN N
, , N
systemic JJ o
and CC o
regional JJ o
hemodynamics NNS o
were VBD N
measured VBN N
. . N

Throughout IN N
the DT N
study NN N
, , N
arterial JJ o
pressure NN o
and CC o
vascular JJ o
resistances NNS o
remained VBD N
lower JJR N
postexercise NN N
vs. FW N
postsham NN N
despite IN N
nitric JJ o
oxide JJ o
synthase NN o
inhibition NN N
( ( N
e.g. JJ N
, , N
mean JJ o
arterial JJ o
pressure NN o
after IN o
L-NMMA NNP o
was VBD N
108.0+/-2.4 JJ N
mmHg NN N
postsham NN N
vs. FW N
102.1+/-3.3 JJ N
mmHg NN N
postexercise NN N
; : N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

Thus VB N
it PRP N
does VBZ N
not RB N
appear VB N
that IN N
postexercise NN o
hypotension NN o
is VBZ N
dependent JJ N
on IN N
increased JJ N
production NN o
of IN o
nitric JJ o
oxide NN o
in IN N
humans NNS p
. . p

-DOCSTART- -24266796- O O

Stimulus JJ o
over-selectivity NN o
in IN N
temporal JJ p
brain NN p
injury NN p
: : p
mindfulness NN i
as IN i
a DT i
potential JJ i
intervention NN i
. . i

OBJECTIVE IN N
The DT N
current JJ N
study NN N
aimed VBD N
to TO N
investigate VB N
the DT N
impact NN N
of IN N
brief JJ N
mindfulness JJ i
training NN i
on IN N
the DT N
performance NN N
of IN N
a DT N
sample NN N
of IN N
patients NNS p
with IN p
TBI NNP p
in IN p
an DT p
over-selectivity JJ o
task NN p
. . p

PARTICIPANTS VB N
Twenty-four JJ p
patients NNS p
who WP p
had VBD p
suffered VBN p
TBI NNP p
and CC p
reported VBD p
problems NNS p
with IN p
focused JJ p
or CC p
sustained JJ p
attention NN p
. . p

METHOD NNP N
The DT N
study NN N
was VBD N
a DT N
between-subjects JJ N
design NN N
( ( i
mindfulness JJ i
intervention NN i
vs NNS N
control NN i
) ) i
with IN N
difference NN N
between IN N
number NN N
of IN N
most JJS N
and CC N
least JJS N
chosen JJ N
stimulus JJ N
selections NNS N
on IN N
an DT N
over-selectivity JJ N
task NN N
as IN N
the DT N
dependent JJ N
measure NN N
. . N

RESULTS VB N
The DT N
results NNS N
of IN N
this DT N
study NN N
indicated VBD N
that IN N
stimulus JJ o
over-selectivity NN o
was VBD N
present JJ N
in IN N
a DT N
group NN N
of IN N
patients NNS N
with IN N
TBI NNP N
. . N

However RB N
, , N
the DT N
level NN o
of IN o
emergent JJ o
over-selectivity NN o
was VBD N
significantly RB N
reduced VBN N
by IN N
a DT N
mindfulness NN N
induction NN N
when WRB N
compared VBN N
to TO N
a DT N
no- JJ N
intervention NN N
control NN i
group NN N
. . N

CONCLUSIONS VB N
The DT N
findings NNS N
are VBP N
discussed VBN N
in IN N
terms NNS N
of IN N
the DT N
efficacy NN o
of IN N
mindfulness NN i
training NN i
in IN N
reducing VBG N
TBI-related JJ o
cognitive JJ o
deficits NNS o
. . o

-DOCSTART- -20159310- O O

A DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
, , N
phase NN N
I PRP N
study VBP N
of IN N
MEDI-545 NNP i
, , N
an DT N
anti-interferon-alfa JJ N
monoclonal NN N
antibody NN N
, , N
in IN N
subjects NNS p
with IN p
chronic JJ p
psoriasis NN p
. . p

BACKGROUND NNP N
Interferon-alfa NNP N
( ( N
IFN-alpha NNP N
) ) N
has VBZ N
been VBN N
implicated VBN N
in IN N
the DT N
pathogenesis NN N
of IN N
psoriasis NN N
. . N

OBJECTIVE UH N
To TO N
evaluate VB N
the DT N
safety NN N
profile NN N
of IN N
MEDI-545 NNP i
, , N
a DT N
fully RB N
human JJ N
anti-IFN-alpha JJ N
monoclonal NN N
antibody NN N
and CC N
to TO N
explore VB N
its PRP$ N
effect NN N
on IN N
the DT N
involvement NN N
of IN N
type NN N
I PRP N
IFN-alpha VBP N
activity NN N
in IN N
the DT N
maintenance NN N
of IN N
established VBN N
plaque NN N
psoriasis NN N
. . N

METHODS NNP N
We PRP N
conducted VBD N
an DT N
18-week JJ N
, , N
randomized VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
, , N
dose-escalating JJ N
study NN N
in IN N
36 CD p
subjects NNS p
with IN p
chronic JJ p
plaque NN p
psoriasis NN p
. . p

Subjects VBZ N
received VBD N
one CD N
intravenous JJ N
dose NN N
of IN N
MEDI-545 NNP i
( ( i
0.3-30.0 JJ i
mg/kg NN i
) ) i
or CC i
placebo NN i
. . i

Study NNP N
outcomes NNS N
were VBD N
safety NN o
profile NN o
, , o
pharmacokinetics NNS o
, , o
immunogenicity NN o
, , o
and CC o
clinical JJ o
effects NNS o
. . o

RESULTS NNP N
There EX N
was VBD N
no DT N
difference NN N
in IN N
adverse JJ o
events NNS o
between IN N
MEDI-545 NNP i
and CC i
placebo NN i
. . i

Two CD N
serious JJ N
adverse JJ N
events NNS N
were VBD N
reported VBN N
; : N
one CD N
drug-related JJ o
hypotensive JJ o
infusion NN o
reaction NN o
occurred VBD N
in IN N
one CD N
subject NN N
in IN N
the DT N
30.0 CD N
mg/kg JJ N
MEDI-545 NNP i
dose NN N
group NN N
, , N
causing VBG N
discontinuation NN N
of IN N
study JJ N
drug NN N
in IN N
that DT N
subject NN N
and CC N
study NN N
dismissal NN N
of IN N
the DT N
other JJ N
subjects NNS N
in IN N
the DT N
same JJ N
cohort NN N
; : N
and CC N
a DT N
myocardial JJ o
infarction NN o
occurred VBD N
in IN N
one CD N
subject NN N
in IN N
the DT N
10 CD N
mg/kg JJ N
MEDI-545 NNP i
dose NN N
group NN N
, , N
which WDT N
was VBD N
considered VBN N
to TO N
be VB N
unrelated JJ N
to TO N
treatment NN N
. . N

MEDI-545 NNP i
was VBD N
nonimmunogenic JJ N
, , N
had VBD N
a DT N
half-life NN o
of IN N
21 CD N
days NNS N
, , N
showed VBD N
no DT N
significant JJ N
inhibition NN N
of IN N
the DT N
type NN N
I PRP N
IFN NNP N
gene NN N
signature NN N
, , N
and CC N
had VBD N
no DT N
clinical JJ o
activity NN o
. . o

LIMITATIONS VB N
The DT N
study NN N
addressed VBD N
only RB N
IFN-alpha NNP N
and CC N
chronic JJ N
psoriatic JJ N
lesions NNS N
. . N

CONCLUSION VB N
The DT N
safety NN N
profile NN N
of IN N
MEDI-545 NNP i
supports NNS N
further RBR N
clinical JJ N
development NN N
. . N

IFN-alpha NN N
does VBZ N
not RB N
appear VB N
to TO N
be VB N
significantly RB N
involved VBN N
in IN N
the DT N
maintenance NN N
of IN N
established VBN N
plaque NN N
psoriasis NN N
. . N

-DOCSTART- -25623276- O O

The DT N
effects NNS N
of IN N
stimulation NN N
of IN N
the DT N
autonomic JJ N
nervous JJ N
system NN N
via IN N
perioperative JJ i
nutrition NN i
on IN N
postoperative JJ o
ileus NN o
and CC o
anastomotic JJ o
leakage NN o
following VBG N
colorectal JJ N
surgery NN N
( ( N
SANICS NNP N
II NNP N
trial NN N
) ) N
: : N
a DT N
study NN N
protocol NN N
for IN N
a DT N
double-blind JJ N
randomized NN N
controlled VBD N
trial NN N
. . N

BACKGROUND NNP N
Postoperative NNP N
ileus NN N
and CC N
anastomotic JJ N
leakage NN N
are VBP N
important JJ N
complications NNS N
following VBG N
colorectal JJ N
surgery NN N
associated VBN N
with IN N
short-term JJ N
morbidity NN N
and CC N
mortality NN N
. . N

Previous JJ N
experimental JJ N
and CC N
preclinical JJ N
studies NNS N
have VBP N
shown VBN N
that IN N
a DT N
short JJ N
intervention NN N
with IN N
enriched JJ N
enteral JJ N
nutrition NN N
dampens VBZ N
inflammation NN N
via IN N
stimulation NN N
of IN N
the DT N
autonomic JJ N
nervous JJ N
system NN N
and CC N
thereby RB N
reduces NNS N
postoperative JJ N
ileus NN N
. . N

Furthermore RB N
, , N
early JJ N
administration NN N
of IN N
enteral JJ N
nutrition NN N
reduced VBD N
anastomotic JJ o
leakage NN o
. . o

This DT N
study NN N
will MD N
investigate VB N
the DT N
effect NN N
of IN N
nutritional JJ N
stimulation NN N
of IN N
the DT N
autonomic JJ N
nervous JJ N
system NN N
just RB N
before RB N
, , N
during IN N
and CC N
early RB N
after IN N
colorectal JJ N
surgery NN N
on IN N
inflammation NN N
, , N
postoperative JJ N
ileus NN N
and CC N
anastomotic JJ N
leakage NN N
. . N

METHODS/DESIGN NNP N
This DT N
multicenter NN N
, , N
prospective JJ N
, , N
double-blind JJ N
, , N
randomized VBN N
controlled VBN N
trial NN N
will MD N
include VB N
280 CD p
patients NNS p
undergoing JJ p
colorectal JJ p
surgery NN p
. . p

All DT N
patients NNS p
will MD N
receive VB N
a DT N
selfmigrating JJ i
nasojejunal JJ i
tube NN i
that WDT N
will MD N
be VB N
connected VBN N
to TO N
a DT N
specially RB N
designed VBN N
blinded VBN N
tubing NN N
system NN N
. . N

Patients NNS p
will MD N
be VB N
allocated VBN N
either DT N
to TO N
the DT N
intervention NN N
group NN N
, , N
receiving VBG i
perioperative JJ i
nutrition NN i
, , N
or CC N
to TO N
the DT N
control NN N
group NN N
, , N
receiving VBG i
no DT i
nutrition NN i
. . i

The DT N
primary JJ N
endpoint NN N
is VBZ N
postoperative JJ o
ileus NN o
. . o

Secondary JJ N
endpoints NNS N
include VBP N
anastomotic JJ o
leakage NN o
, , o
local JJ o
and CC o
systemic JJ o
inflammation NN o
, , o
( ( o
aspiration NN o
) ) o
pneumonia NN o
, , o
surgical JJ o
complications NNS o
classified VBD o
according VBG o
to TO o
Clavien-Dindo NNP o
, , o
quality NN o
of IN o
life NN o
, , o
gut FW o
barrier JJR o
integrity NN o
and CC o
time NN o
until IN o
functional JJ o
recovery NN o
. . o

Furthermore NNP N
, , N
a DT N
cost-effectiveness JJ N
analysis NN N
will MD N
be VB N
performed VBN N
. . N

DISCUSSION NNP N
Activation NNP N
of IN N
the DT N
autonomic JJ N
nervous JJ N
system NN N
via IN N
perioperative JJ N
enteral JJ N
feeding NN N
is VBZ N
expected VBN N
to TO N
dampen VB N
the DT N
local JJ o
and CC o
systemic JJ o
inflammatory NN o
response NN o
. . o

Consequently RB N
, , N
postoperative JJ o
ileus NN o
will MD N
be VB N
reduced VBN N
as RB N
well RB N
as IN N
anastomotic JJ o
leakage NN o
. . o

The DT N
present JJ N
study NN N
is VBZ N
the DT N
first JJ N
to TO N
investigate VB N
the DT N
effects NNS N
of IN N
enriched JJ N
nutrition NN N
given VBN N
shortly RB N
before RB N
, , N
during IN N
and CC N
after IN N
surgery NN N
in IN N
a DT N
clinical JJ N
setting NN N
. . N

TRIAL NNP N
REGISTRATION NNP N
ClinicalTrials.gov NNP N
: : N
NCT02175979 NNP N
- : N
date NN N
of IN N
registration NN N
: : N
25 CD N
June NNP N
2014 CD N
. . N

Dutch VB N
Trial JJ N
Registry NN N
: : N
NTR4670 NNP N
- : N
date NN N
of IN N
registration NN N
: : N
1 CD N
August NNP N
2014 CD N
. . N

-DOCSTART- -11013775- O O

[ JJ N
Effectiveness NNP N
of IN N
morphine NN i
by IN N
periarticular JJ N
injections NNS N
after IN N
shoulder NN p
arthroscopy NN p
] NNP p
. . N

Peripheral NNP N
opioid JJ N
receptors NNS N
have VBP N
been VBN N
found VBN N
in IN N
inflamed JJ N
synovia NN N
and CC N
the DT N
analgesic JJ N
effect NN N
of IN N
intra-articularly JJ N
administered JJ N
morphine NN i
after IN N
arthroscopic NN N
knee NN N
surgery NN N
has VBZ N
been VBN N
proven RB N
. . N

There EX N
is VBZ N
controversy NN N
about IN N
efficacy NN N
of IN N
intraarticular JJ N
morphine NN i
after IN N
shoulder NN N
arthroscopy NN N
. . N

Thirty-two JJ p
patients NNS p
with IN p
impingement JJ p
syndrome JJ p
underwent JJ p
subacromial JJ p
decompression NN p
in IN p
the DT p
course NN p
of IN p
arthroscopic JJ i
shoulder NN i
surgery NN i
. . i

At IN N
the DT N
end NN N
of IN N
the DT N
operation NN i
morphine NN i
( ( i
5 CD i
mg NN i
) ) i
or CC i
saline NN i
was VBD N
injected VBN N
periarticularly RB N
. . N

Pain NNP o
intensity NN o
( ( o
rest NN o
and CC o
passive JJ o
mobilisation NN o
) ) o
was VBD N
recorded VBN N
after IN N
recovery NN N
and CC N
after IN N
1,2,4 CD N
, , N
and CC N
24 CD N
hours NNS N
( ( N
Numeric NNP N
Rating NNP N
Scale NNP N
) ) N
; : N
the DT N
use NN o
of IN o
rescue NN o
medication NN o
( ( o
piritramide JJ o
by IN o
patient NN o
controlled VBN o
analgesia NN o
) ) o
was VBD N
noted VBN N
. . N

No DT N
relevant JJ N
pain NN o
reduction NN o
was VBD N
apparent JJ N
in IN N
the DT N
morphine NN N
group NN N
. . N

Piritramide NNP o
consumption NN o
was VBD N
identical JJ N
in IN N
both DT N
groups NNS N
( ( N
19.7 CD N
+/- JJ N
16 CD N
mg NN N
vs. FW N
19.8 CD N
+/- JJ N
19 CD N
mg NN N
) ) N
. . N

We PRP N
conclude VBP N
that IN N
periarticularly RB N
administered VBN N
morphine NN i
in IN N
arthroscopic JJ N
subacromial JJ N
decompression NN N
in IN N
the DT N
dosage NN N
applied VBN N
in IN N
this DT N
study NN N
does VBZ N
exert VB N
no DT N
relevant JJ N
analgesic JJ o
effect NN o
. . o

This DT N
is VBZ N
possibly RB N
due JJ N
to TO N
the DT N
fact NN N
that IN N
either DT N
subacromial JJ N
tissue NN N
, , N
despite IN N
of IN N
chronic JJ N
inflammation NN N
, , N
does VBZ N
not RB N
show VB N
the DT N
same JJ N
reagibility NN N
as IN N
synovia NN N
or CC N
it PRP N
is VBZ N
a DT N
problem NN N
of IN N
the DT N
nearly RB N
complete JJ N
resection NN N
of IN N
the DT N
subacromial JJ N
bursa NN N
. . N

-DOCSTART- -25074072- O O

A DT N
comparison NN N
of IN N
multiphasic JJ i
oral JJ i
contraceptives NNS i
containing VBG i
norgestimate NN i
or CC i
desogestrel NN i
in IN N
acne JJ o
treatment NN N
: : N
a DT N
randomized JJ N
trial NN N
. . N

OBJECTIVE VB N
This DT N
study NN N
aimed VBD N
to TO N
compare VB N
the DT N
effectiveness NN N
and CC N
safety NN N
of IN N
triphasic JJ i
combined JJ i
oral JJ i
contraceptives NNS i
( ( i
OCs NNP i
) ) i
containing VBG i
ethinyl JJ i
estradiol NN i
( ( i
EE NNP i
) ) i
and CC i
norgestimate JJ i
( ( i
NGM NNP i
) ) i
and CC N
biphasic JJ i
combined VBN i
OCs NNP i
containing VBG i
EE NNP i
and CC i
desogestrel NN i
( ( i
DSG NNP i
) ) i
in IN N
the DT N
treatment NN N
of IN N
mild NN p
to TO p
moderate VB p
acne NN p
. . p

STUDY NNP N
DESIGN NNP N
This DT N
was VBD N
an DT N
investigator-blinded JJ N
, , N
randomized VBN N
, , N
parallel JJ N
group NN N
trial NN N
conducted VBD N
at IN N
3 CD p
centers NNS p
in IN p
Thailand NNP p
. . p

Female NNP p
subjects VBZ p
18-45 CD p
years NNS p
old JJ p
were VBD N
assigned VBN N
to TO N
one CD N
or CC N
the DT N
other JJ N
OCs NNP N
and CC N
evaluated VBN N
for IN N
efficacy NN N
and CC N
safety NN N
parameters NNS N
at IN N
the DT N
baseline NN N
visit NN N
and CC N
after IN N
1 CD N
, , N
3 CD N
and CC N
6 CD N
months NNS N
of IN N
treatment NN N
. . N

RESULTS NNP N
Among IN N
201 CD p
randomized JJ p
subjects NNS p
, , N
data NNS N
from IN N
93 CD N
subjects NNS N
in IN N
the DT N
EE/NGM NNP i
group NN N
and CC N
95 CD N
subjects NNS N
in IN N
the DT N
EE/DSG NNP i
group NN N
were VBD N
analyzed VBN N
. . N

After IN N
6 CD N
months NNS N
of IN N
treatment NN N
with IN N
EE/NGM NNP i
and CC i
EE/DSG NNP i
, , N
no DT N
differences NNS N
between IN N
formulations NNS N
were VBD N
found VBN N
for IN N
the DT N
decrease NN o
in IN o
total JJ o
acne JJ o
lesion NN o
counts NNS o
( ( N
74.4 CD N
% NN N
vs. FW N
65.1 CD N
% NN N
, , N
respectively RB N
, , N
p=.070 NN N
) ) N
or CC N
facial JJ o
improvement NN o
score NN o
. . o

More JJR N
women NNS N
using VBG N
EE/NGM NNP i
showed VBD N
a DT N
decrease NN N
in IN N
severity NN o
of IN o
facial JJ o
seborrhea NN o
than IN N
those DT N
using VBG N
EE/DSG NNP i
( ( N
p=.005 NN N
) ) N
. . N

No DT N
changes NNS o
in IN o
weight NN o
were VBD N
noted VBN N
in IN N
either DT N
group NN N
as IN N
compared VBN N
to TO N
baseline VB N
. . N

CONCLUSION NNP N
Multiphasic NNP N
OCs NNP i
containing VBG N
EE/NGM NNP i
and CC i
EE/DSG NNP i
provided VBD N
comparable JJ N
efficacy NN o
and CC o
tolerability NN o
in IN N
the DT N
treatment NN N
of IN N
acne NN N
. . N

However RB N
, , N
EE/NGM NNP i
had VBD N
a DT N
more RBR N
beneficial JJ N
effect NN N
on IN N
facial JJ o
seborrhea NN o
reduction NN N
than IN N
EE/DSG NNP i
. . i

IMPLICATIONS NNP N
EE/NGM NNP i
and CC i
EE/DSG NNP i
are VBP N
multiphasic JJ i
OCs NNP i
, , N
which WDT N
were VBD N
shown VBN N
to TO N
be VB N
clinically RB N
equally RB N
effective JJ N
for IN N
mild NN N
to TO N
moderate VB N
facial JJ N
acne NN N
, , N
and CC N
the DT N
multiphasic JJ N
combined JJ N
OC NNP N
with IN N
NGM NNP N
was VBD N
more RBR N
effective JJ N
for IN N
women NNS N
with IN N
facial JJ N
seborrhea NN N
. . N

Clinicians NNPS N
may MD N
apply VB N
the DT N
results NNS N
of IN N
this DT N
study NN N
when WRB N
considering VBG N
treatment NN N
options NNS N
for IN N
facial JJ p
acne NN p
and CC p
seborrhea NN p
. . p

-DOCSTART- -20102495- O O

Efficacy NN N
of IN N
omeprazole JJ i
versus NN N
high-dose JJ i
famotidine NN i
for IN N
prevention NN N
of IN N
exercise-induced JJ o
gastritis NN o
in IN N
racing VBG p
Alaskan NNP p
sled VBD p
dogs NNS p
. . p

BACKGROUND NNP N
Omeprazole NNP i
and CC N
famotidine VB i
both DT N
reduce VB N
severity NN N
of IN N
exercise-induced JJ o
gastritis NN o
, , N
but CC N
administering VBG N
famotidine NN N
is VBZ N
easier JJR N
than IN N
administering VBG N
omeprazole JJ N
during IN N
racing VBG N
competition NN N
. . N

HYPOTHESIS NNP N
Famotidine NNP N
is VBZ N
more RBR N
efficacious JJ N
than IN N
no DT N
treatment NN N
in IN N
reducing VBG N
severity NN N
of IN N
exercise-induced JJ N
gastritis NN N
; : N
and CC N
high-dose JJ N
famotidine NN N
is VBZ N
more RBR N
efficacious JJ N
than IN N
omeprazole NN N
in IN N
reducing VBG N
severity NN N
of IN N
exercise-induced JJ N
gastritis NN N
. . N

ANIMALS NNP N
Experiment VBD N
1 CD N
: : N
Randomized VBN p
placebo-controlled JJ p
study NN p
, , p
36 CD p
sled VBD p
dogs NNS p
( ( p
3-8 CD p
years NNS p
) ) p
; : p
Experiment JJ N
2 CD N
: : N
Randomized VBN p
positive-control NN p
study NN p
, , p
52 CD p
sled VBD p
dogs NNS p
( ( p
2-8 CD p
years NNS p
) ) p
. . p

METHODS NNP N
Experiment JJ N
1 CD N
: : N
Equal JJ N
numbers NNS N
of IN N
dogs NNS p
randomly RB N
assigned VBN N
to TO N
famotidine VB i
( ( N
20 CD N
mg RB N
q24h NN N
) ) N
or CC N
no DT i
treatment NN i
groups NNS N
. . N

Gastroscopy NNP N
was VBD N
performed VBN N
24 CD N
hours NNS N
after IN N
the DT N
dogs NNS N
ran VBD N
330 CD N
miles NNS N
. . N

Mucosal NNP o
appearance NN o
was VBD N
blindly RB N
scored VBN N
by IN N
previously RB N
described VBN N
scoring VBG N
system NN N
. . N

Experiment JJ N
2 CD N
: : N
Equal JJ N
numbers NNS N
of IN N
dogs NNS N
randomly RB N
assigned VBN N
to TO N
omeprazole VB i
( ( N
20 CD N
mg RB N
q24h NN N
) ) N
or CC N
high-dose JJ N
famotidine NN i
( ( N
40 CD N
mg RB N
q12h NN N
) ) N
groups NNS N
. . N

Gastroscopy NNP N
was VBD N
performed VBN N
48 CD N
hours NNS N
before IN N
and CC N
24 CD N
hours NNS N
after IN N
the DT N
dogs NNS N
ran VBD N
300 CD N
miles NNS N
. . N

Mucosal NNP o
appearance NN o
was VBD N
blindly RB N
scored VBN N
by IN N
previously RB N
described VBN N
scoring VBG N
system NN N
. . N

RESULTS NNP N
Famotidine NNP i
reduced VBD N
the DT N
prevalence NN N
of IN N
clinically RB o
relevant JJ o
, , o
exercise-induced JJ o
gastric JJ o
lesions NNS o
compared VBN N
with IN N
no DT N
treatment NN N
( ( N
7/16 CD N
versus NN N
11/16 CD N
, , N
P NNP N
= NNP N
.031 NNP N
) ) N
. . N

Compared VBN N
with IN N
high-dose JJ N
famotidine NN i
, , i
omeprazole VBP i
significantly RB N
decreased VBN N
the DT N
severity NN o
( ( N
0.4 CD N
versus NN N
1.2 CD N
, , N
P NNP N
= NNP N
.0002 NNP N
) ) N
and CC N
prevalence NN o
( ( N
2/23 CD N
versus NN N
7/21 CD N
, , N
P NNP N
= NNP N
.049 NNP N
) ) N
of IN N
gastric JJ o
lesions NNS o
. . o

CONCLUSIONS NNP N
AND NNP N
CLINICAL NNP N
RELEVANCE NNP N
Although IN N
famotidine NN N
provides VBZ N
some DT N
benefit NN N
in IN N
the DT N
prevention NN N
of IN N
exercise-induced JJ o
gastric JJ o
lesions NNS o
, , N
omeprazole NN N
is VBZ N
superior JJ N
to TO N
famotidine VB N
in IN N
preventing VBG N
gastritis NN o
in IN N
dogs NNS p
running VBG N
300 CD N
miles NNS N
. . N

Routine NNP N
administration NN N
of IN N
omeprazole NN i
is VBZ N
recommended VBN N
to TO N
prevent VB N
stress-associated JJ o
gastric JJ o
disease NN o
in IN N
exercising VBG p
and CC p
racing VBG p
Alaskan NNP p
sled VBD p
dogs NNS p
. . p

-DOCSTART- -3168620- O O

The DT N
influence NN N
of IN N
adult NN i
intervention NN i
on IN N
infants NNS o
' POS o
level NN o
of IN o
attention NN o
. . o

The DT N
effects NNS N
of IN N
adult NN i
intervention NN i
on IN N
infants NNS N
' POS N
level NN o
of IN o
attention NN o
to TO N
objects NNS N
were VBD N
studied VBN N
with IN N
10-month-old JJ p
infants NNS p
. . p

After IN N
a DT N
baseline JJ N
measure NN N
of IN N
spontaneous JJ N
attention NN N
was VBD N
obtained VBN N
, , N
infants NNS p
were VBD N
randomly RB N
assigned VBN N
to TO N
1 CD N
of IN N
4 CD N
conditions NNS N
( ( i
low JJ i
, , i
medium NN i
, , i
high JJ i
intervention NN i
, , i
or CC i
no-intervention JJ i
control NN i
) ) i
. . N

Level NN N
of IN N
intervention NN N
was VBD N
controlled VBN N
by IN N
systematically RB i
varying VBG i
the DT i
manner NN i
and CC i
frequency NN i
with IN i
which WDT i
objects NNS i
were VBD i
presented VBN i
, , i
the DT i
extent NN i
to TO i
which WDT i
the DT i
experimenter NN i
talked VBD i
to TO i
the DT i
infant NN i
, , i
and CC i
physical JJ i
proximity NN i
. . i

Infant JJ N
attention NN N
was VBD N
defined VBN N
as IN N
duration NN o
of IN o
time NN o
spent VBN o
examining VBG o
objects NNS o
. . o

The DT N
overall JJ o
duration NN o
of IN o
infant JJ o
attention NN o
increased VBD N
during IN N
medium NN N
intervention NN N
when WRB N
compared VBN N
to TO N
the DT N
control NN N
group NN N
. . N

Baseline NNP N
attention NN N
was VBD N
then RB N
used VBN N
to TO N
separate VB N
low JJ N
and CC N
high JJ N
attenders NNS N
. . N

Low JJ N
attending VBG N
infants NNS N
attended VBD o
more RBR N
in IN N
medium NN N
and CC N
high JJ N
intervention NN N
than IN N
in IN N
the DT N
low JJ N
condition NN N
, , N
while IN N
high JJ N
attending VBG N
infants NNS N
were VBD N
unaffected VBN N
by IN N
intervention NN N
. . N

The DT N
results NNS N
show VBP N
that IN N
level NN N
of IN N
intervention NN i
interacts NNS N
with IN N
the DT N
child NN o
's POS o
spontaneous JJ o
tendency NN o
to TO o
focus VB o
attention NN o
on IN N
objects NNS N
. . N

-DOCSTART- -17224353- O O

Dynamic NNP N
surface NN o
electromyographic JJ o
responses NNS o
in IN N
chronic JJ p
low JJ p
back RB p
pain NN p
treated VBN N
by IN N
traditional JJ i
bone NN i
setting NN i
and CC i
conventional JJ i
physical JJ i
therapy NN i
. . i

OBJECTIVE CC N
This DT N
study NN N
compared VBN N
the DT N
dynamic JJ o
surface NN o
electromyographic JJ o
( ( o
EMG NNP o
) ) o
activities NNS o
of IN N
back JJ N
muscles NNS N
and CC N
pain NN N
before IN N
and CC N
after IN N
traditional JJ i
bone NN i
setting NN i
and CC i
physical JJ i
therapy NN i
. . i

METHODS NNP N
This DT N
study NN N
was VBD N
a DT N
prospective JJ N
clinical JJ N
trial NN N
that WDT N
compared VBN N
surface NN o
EMG NNP o
dynamic JJ o
activities NNS o
after IN N
traditional JJ i
bone NN i
setting NN i
and CC i
physical JJ i
therapy NN i
. . i

Sixty-one CD p
patients NNS p
( ( p
mean JJ p
age NN p
, , p
41 CD p
years NNS p
) ) p
with IN p
nonspecific JJ p
low JJ p
back RB p
pain NN p
were VBD p
randomized VBN p
into IN N
two CD N
subgroups NNS N
by IN N
treatment NN N
. . N

The DT N
patients NNS N
underwent VBD N
a DT N
dynamic JJ o
EMG NNP o
evaluation NN o
for IN N
which WDT N
they PRP N
were VBD N
asked VBN N
to TO N
stand VB N
and CC N
then RB N
bend VB N
forward RB N
as RB N
far RB N
as IN N
possible JJ N
, , N
stay VB N
fully RB N
flexed VBN N
, , N
and CC N
return NN N
to TO N
standing VBG N
. . N

A DT N
flexion-relaxation JJ o
ratio NN o
was VBD N
calculated VBN N
by IN N
comparing VBG N
maximal JJ o
EMG NNP o
activity NN o
while IN N
flexing VBG N
with IN N
the DT N
average JJ N
EMG NNP N
activity NN N
in IN N
full JJ N
flexion NN N
. . N

Concentric NNP o
( ( o
maximal JJ o
EMG NNP o
activity NN o
during IN o
extension NN o
) ) o
and CC o
eccentric JJ o
( ( o
maximal JJ o
EMG NNP o
activity NN o
during IN o
flexion NN o
) ) o
ratios NNS o
were VBD N
also RB N
used VBN N
in IN N
the DT N
analyses NNS N
. . N

RESULTS NNP N
Disability NNP o
, , o
depression NN o
, , o
and CC o
visual JJ o
analog NN o
scale NN o
scores NNS o
decreased VBN N
significantly RB N
after IN N
both DT N
treatments NNS N
. . N

The DT N
concentric JJ o
ratio NN o
increased VBD N
statistically RB N
in IN N
both DT N
groups NNS N
after IN N
the DT N
treatments NNS N
. . N

The DT N
study NN N
failed VBD N
to TO N
show VB N
a DT N
significant JJ N
association NN N
between IN N
experienced VBN N
back RB N
pain NN N
and CC N
EMG NNP o
parameters NNS o
. . o

CONCLUSIONS NNP N
Both NNP N
treatments NNS N
seem VBP N
to TO N
have VB N
a DT N
positive JJ N
influence NN N
on IN N
back JJ N
muscle NN N
function NN N
by IN N
improving VBG N
muscle NN o
symmetry NN o
; : o
however RB N
, , N
the DT N
treatments NNS N
had VBD N
no DT N
effect NN N
on IN N
the DT N
flexion-relaxation NN o
phenomenon NN o
after IN N
1 CD N
month NN N
. . N

Active NNP i
back RB i
exercise NN i
at IN i
home NN i
together RB N
with IN N
rehabilitation NN N
treatments NNS i
might MD N
be VB N
effective JJ N
and CC N
improve VB N
function NN N
for IN N
patients NNS p
with IN p
chronic JJ p
low JJ p
back RB p
pain NN p
. . p

-DOCSTART- -9788422- O O

Preoperative JJ N
irradiation NN N
versus IN N
the DT N
use NN N
of IN N
nonsteroidal JJ N
anti-inflammatory JJ N
drugs NNS N
for IN N
prevention NN N
of IN N
heterotopic JJ o
ossification NN o
following VBG p
total JJ p
hip JJ p
replacement NN p
: : p
the DT N
results NNS N
of IN N
a DT N
randomized JJ N
trial NN N
. . N

PURPOSE NNP N
Previous JJ N
studies NNS N
showed VBD N
the DT N
effectiveness NN N
of IN N
early JJ N
preoperative NN N
( ( N
4 CD N
h NN N
before IN N
operation NN N
) ) N
irradiation NN N
for IN N
prevention NN N
of IN N
heterotopic NN o
ossification NN o
( ( o
HO NNP o
) ) o
after IN N
total JJ N
hip NN N
replacement NN N
. . N

This DT N
procedure NN N
can MD N
result VB N
in IN N
logistic JJ N
problems NNS N
, , N
if IN N
there EX N
is VBZ N
a DT N
great JJ N
distance NN N
between IN N
the DT N
department NN N
of IN N
radiotherapy NN N
and CC N
the DT N
orthopedic JJ N
clinic NN N
. . N

To TO N
avoid VB N
these DT N
organizational JJ N
problems NNS N
a DT N
prospective JJ N
study NN N
was VBD N
undertaken VBN N
to TO N
analyze VB N
the DT N
effectiveness NN o
of IN o
preoperative JJ o
irradiation NN o
on IN N
the DT N
day NN N
preceding VBG N
surgery NN N
( ( N
16-20 JJ N
h NN N
before IN N
operation NN N
) ) N
. . N

METHODS NNP N
AND CC N
MATERIALS NNP N
Between NNP p
1995 CD p
and CC p
1996 CD p
, , p
100 CD p
patients NNS p
were VBD p
randomized VBN i
to TO p
receive VB p
a DT p
prophylactic JJ p
therapy NN p
for IN p
prevention NN p
of IN p
heterotopic NN p
ossification NN p
. . p

Forty-six JJ N
patients NNS N
were VBD N
irradiated VBN i
with IN i
7 CD i
Gy NNP i
single JJ i
dose NN i
within IN i
16-20 JJ i
h NN i
before IN i
operation NN i
. . i

Fifty-four CD N
patients NNS N
were VBD N
treated VBN i
with IN i
nonsteroidal JJ i
anti-inflammatory JJ i
drugs NNS i
( ( i
NSAID NNP i
) ) i
( ( i
Voltaren NNP i
resinat VBZ i
2 CD i
x NN i
75 CD i
mg/day NN i
for IN i
2 CD i
weeks NNS i
) ) i
. . i

Heterotopic NNP o
ossification NN o
was VBD o
scored VBN o
according VBG o
to TO o
the DT o
Brooker NNP o
Grading NNP o
system NN o
. . o

One CD p
hundred VBD p
patients NNS p
receiving VBG p
no DT p
prophylactic JJ p
therapy NN p
after IN p
total JJ p
hip NN p
arthroplasty NN p
between IN p
1988 CD p
and CC p
1992 CD p
were VBD p
analyzed VBN p
and CC p
defined VBN p
as IN p
the DT p
historical JJ p
control NN p
group NN p
. . p

RESULTS NNP N
Incidence NNP N
of IN N
heterotopic NN o
ossification NN o
was VBD N
47.8 CD N
% NN N
in IN N
the DT N
7 CD N
Gy NNP N
preoperative JJ N
group NN N
( ( o
Brooker NNP o
Score NNP o
I PRP o
: : o
36.9 CD N
% NN N
; : N
II NNP N
: : N
8.7 CD N
% NN N
; : N
III NNP N
: : N
2.2 CD N
% NN N
; : N
IV NNP N
: : N
0 CD N
% NN N
) ) N
and CC N
11.1 CD N
% NN N
in IN N
the DT N
NSAID NNP N
group NN N
( ( o
Brooker NNP o
Score NNP o
I PRP o
: : o
9.3 CD N
% NN N
; : N
II NNP N
: : N
1.8 CD N
% NN N
; : N
III NNP N
: : N
0 CD N
% NN N
; : N
IV NNP N
: : N
0 CD N
% NN N
) ) N
. . N

Regarding VBG N
overall JJ N
heterotopic NN o
ossification NN o
there EX N
was VBD N
a DT N
significant JJ N
difference NN N
between IN N
the DT N
NSAID NNP N
group NN N
and CC N
the DT N
7 CD N
Gy NNP N
group NN N
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
. . N

Analyzing VBG N
the DT N
clinically RB N
significant JJ N
heterotopic NN o
ossification NN o
( ( o
Brooker NNP o
Score NNP o
III NNP o
and CC o
IV NNP o
) ) o
there EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
the DT N
two CD N
treatment NN N
arms NNS N
( ( N
p JJ N
> NNP N
0.05 CD N
) ) N
. . N

In IN N
the DT N
untreated JJ N
historical JJ N
control NN N
group NN N
the DT N
incidence NN N
of IN N
heterotopic NN o
ossification NN o
was VBD N
65 CD N
% NN N
( ( o
Brooker NNP o
Score NNP o
I PRP N
: : N
26 CD N
% NN N
; : N
II NNP N
: : N
15 CD N
% NN N
; : N
III NNP N
: : N
19 CD N
% NN N
; : N
IV NNP N
: : N
5 CD N
% NN N
) ) N
. . N

Referring VBG N
to TO N
overall JJ N
and CC N
to TO N
clinically RB N
relevant JJ N
heterotopic NN o
ossification NN o
the DT N
incidence NN N
of IN N
HO NNP o
was VBD N
greater JJR N
in IN N
the DT N
control NN N
group NN N
than IN N
in IN N
the DT N
prophylactically RB N
treated VBN N
groups NNS N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

CONCLUSION NNP N
Irradiation NNP N
within IN N
16-20 JJ N
h NN N
before IN N
operation NN N
and CC N
use NN N
of IN N
NSAID NNP N
( ( N
Voltaren NNP N
resinat NN N
) ) N
can MD N
reduce VB N
the DT N
incidence NN N
of IN N
clinically RB N
relevant JJ N
heterotopic NN o
ossification NN o
after IN N
total JJ N
hip NN N
replacement NN N
. . N

-DOCSTART- -11199239- O O

Is VBZ N
hands-on JJ N
experience NN N
more RBR N
effective JJ N
than IN N
didactic JJ N
workshops NNS N
in IN N
postgraduate NN p
cancer NN p
pain NN p
education NN p
? . N
BACKGROUND NNP N
This DT N
study NN N
examined VBD N
the DT N
nurse JJ o
outcomes NNS o
of IN N
a DT N
cancer NN p
pain NN p
education NN p
program NN p
for IN p
nurses NNS p
of IN p
patients NNS p
from IN p
11 CD p
different JJ p
ethnic JJ p
groups NNS p
. . p

METHODS NNP N
Four CD p
hundred VBD p
ninety NN p
six CD p
home NN p
, , p
hospital NN p
, , p
and CC p
hospice NN p
nurses NNS p
participated VBD p
in IN p
a DT p
one-day JJ i
workshop NN i
or CC i
two CD i
half-day JJ i
workshops NNS i
on IN i
cancer NN i
pain NN i
assessment NN i
and CC i
management NN i
. . i

Of IN N
these DT N
, , N
116 CD N
were VBD N
randomized VBN N
to TO N
participate VB N
in IN N
a DT N
bedside-precepted JJ i
visit NN i
with IN i
an DT i
oncology NN i
nurse JJ i
specialist NN i
with IN i
pain NN i
specialization NN i
and CC i
a DT i
focus NN i
group NN i
to TO i
discuss VB i
attitudinal JJ i
issues NNS i
. . i

Eighty-six JJ i
nurses NNS i
served VBD i
as IN i
controls NNS i
. . p

Pre- NNP N
, , N
post- JJ N
and CC N
one-year JJ N
follow-up JJ N
tests NNS N
were VBD N
administered VBN N
. . N

RESULTS NNP N
Attitudes NNP o
, , o
knowledge NN o
, , o
and CC o
application NN o
skills NNS o
significantly RB N
improved VBN N
for IN N
workshop-only JJ N
and CC N
enriched-model JJ N
nurses NNS N
relative VBP N
to TO N
controls NNS N
. . N

CONCLUSION NNP N
For IN N
postgraduate NN p
nurses NNS p
, , N
daylong JJ N
cancer NN N
pain NN N
education NN N
workshops NNS N
were VBD N
, , N
in IN N
the DT N
group NN N
studied VBD N
, , N
as RB N
effective JJ N
as IN N
hands-on JJ N
experience NN N
in IN N
improving VBG N
cancer NN o
pain NN o
knowledge NN o
and CC o
changing VBG o
attitudes NNS o
. . o

Both DT N
the DT N
workshop-only JJ N
and CC N
the DT N
enriched-model JJ N
nurses NNS N
relative VBP N
to TO N
controls NNS N
had VBD N
significantly RB N
improved VBN N
knowledge NN N
and CC N
changed VBD N
attitudes NNS N
towards IN N
optimal JJ N
pain NN N
management NN N
. . N

-DOCSTART- -24467617- O O

Deslorelin NNP i
implants NNS i
in IN N
pre-pubertal JJ p
female JJ p
dogs NNS p
: : p
short- JJ o
and CC o
long-term JJ o
effects NNS o
on IN o
the DT o
genital JJ o
tract NN o
. . o

Deslorelin NNP i
acetate NN i
is VBZ N
a DT N
GnRH NNP N
agonist NN N
used VBN N
for IN N
contraception NN N
in IN N
dogs NNS N
. . N

This DT N
study NN N
aimed VBD N
to TO N
evaluate VB N
the DT N
treatment NN N
of IN N
pre-pubertal JJ p
female JJ p
dogs NNS p
with IN p
deslorelin JJ i
acetate NN i
implants NNS i
, , N
to TO N
better RBR N
investigate VB N
the DT N
primary JJ o
stimulatory JJ o
effect NN o
of IN N
the DT N
drug NN N
and CC N
the DT N
long-term JJ o
effects NNS o
on IN N
the DT N
genital JJ N
tract NN N
, , N
throughout IN N
repeated VBN N
treatments NNS N
. . N

Sicilian JJ p
hound NN p
female JJ p
dogs NNS p
( ( p
24 CD p
) ) p
were VBD N
randomly RB N
assigned VBN N
to TO N
treated VBN N
group NN N
, , N
control NN N
group NN N
1 CD N
and CC N
control VB N
group NN N
2 CD N
. . N

First NNP N
group NN N
bitches NNS N
were VBD N
implanted VBN N
at IN N
4.5 CD N
, , N
9.0 CD N
and CC N
13.5 CD N
months NNS N
and CC N
monitored VBD N
clinically RB N
, , N
ultrasonographically RB N
and CC N
endocrinologically RB N
, , N
throughout IN N
the DT N
study NN N
period NN N
( ( N
13.5 CD N
months NNS N
) ) N
. . N

Control NNP N
group NN N
1 CD N
bitches NNS N
were VBD N
not RB i
implanted VBN i
and CC N
clinically RB N
monitored VBD N
for IN N
the DT N
same JJ N
period NN N
. . N

At IN N
18 CD N
months NNS N
, , N
the DT N
animals NNS N
underwent JJ N
ovariohysterectomy JJ i
, , N
thus RB N
allowing VBG N
evaluation NN o
of IN o
the DT o
internal JJ o
genitalia NN o
. . o

Control NNP N
group NN N
2 CD N
bitches NNS N
were VBD N
ovariohysterectomized VBN N
at IN N
the DT N
age NN N
of IN N
4.5 CD N
months NNS N
. . N

The DT N
suppression NN o
of IN o
oestrus NN o
was VBD N
obtained VBN N
in IN N
the DT N
treated JJ N
group NN N
despite IN N
the DT N
fact NN N
that IN N
the DT N
first JJ N
implant NN N
caused VBD N
a DT N
modest JJ N
increase NN N
in IN N
plasmatic JJ o
levels NNS o
of IN o
17-beta JJ o
estradiol NN o
and CC N
an DT N
evident JJ N
cornification NN o
of IN o
the DT o
vaginal JJ o
mucosa NN o
cells NNS o
( ( N
50-80 CD N
% NN N
) ) N
. . N

Estradiol NNP o
and CC o
progesterone NN o
were VBD N
at IN N
baseline NN N
levels NNS N
for IN N
the DT N
remaining VBG N
study NN N
period NN N
, , N
in IN N
which WDT N
no DT o
other JJ o
oestrous JJ o
manifestations NNS o
were VBD o
observed VBN o
. . o

The DT N
external JJ o
genitalia NN o
maintained VBD o
a DT o
juvenile JJ o
appearance NN o
. . o

The DT N
ovaries NNS o
, , o
ultrasonographically RB o
, , o
showed VBD o
no DT o
follicular JJ o
structures NNS o
and CC N
stayed VBD o
the DT o
same JJ o
size NN o
. . o

At IN N
18 CD N
months NNS N
, , N
the DT N
genital JJ o
tract NN o
was VBD o
still RB o
juvenile JJ o
with IN o
inactive JJ o
small JJ o
ovaries NNS o
and CC o
a DT o
thin JJ o
filiform NN o
uterus NN o
. . o

Deslorelin NNP N
suppressed VBD o
ovarian JJ o
activity NN o
in IN N
pre-pubertal JJ N
bitches NNS N
, , N
and CC N
oestrous JJ o
induction NN o
was VBD o
not RB o
observed VBN o
despite IN N
the DT N
presence NN N
of IN N
the DT N
primary JJ N
stimulatory JJ N
effect NN N
of IN N
the DT N
drug NN N
. . N

Juvenile NNP o
genitalia NN o
were VBD N
an DT N
expected JJ N
side NN N
effect NN N
of IN N
the DT N
treatment NN N
. . N

-DOCSTART- -10594396- O O

Standard-dose JJ i
lansoprazole NN i
is VBZ N
more RBR N
effective JJ N
than IN N
high-dose JJ i
ranitidine NN i
in IN N
achieving VBG N
endoscopic NN N
healing NN N
and CC N
symptom JJ N
relief NN N
in IN N
patients NNS p
with IN p
moderately RB p
severe JJ p
reflux NN p
oesophagitis NN p
. . p

The DT N
Dutch JJ N
Lansoprazole NNP i
Study NNP N
Group NNP N
. . N

BACKGROUND NNP N
In IN N
the DT N
treatment NN N
of IN N
reflux NN N
oesophagitis NN N
, , N
H2-receptor NNP N
antagonists NNS N
are VBP N
still RB N
widely RB N
used VBN N
in IN N
spite NN N
of IN N
the DT N
apparent JJ N
higher JJR N
efficacy NN N
of IN N
proton NN N
pump NN N
inhibitors NNS N
. . N

In IN N
an DT N
attempt NN N
to TO N
compensate VB N
for IN N
the DT N
lower JJR N
efficacy NN N
, , N
H2-receptor NNP N
antagonists NNS N
are VBP N
now RB N
increasingly RB N
being VBG N
used VBN N
at IN N
a DT N
higher JJR N
dose NN N
. . N

OBJECTIVE UH N
To TO N
assess VB N
whether IN N
or CC N
not RB N
standard-dose JJ i
lansoprazole NN i
( ( N
30 CD N
mg NN N
o.d NN N
. . N

) ) N
is VBZ N
more RBR N
effective JJ N
than IN N
high-dose JJ i
ranitidine NN i
( ( N
300 CD N
mg NN N
b.d NN N
. . N

) ) N
in IN N
moderately RB N
severe JJ N
reflux NN N
oesophagitis NN N
( ( N
grades JJ N
II-III NNP N
) ) N
. . N

METHODS NNP N
Lansoprazole NNP i
or CC N
ranitidine NN i
was VBD N
given VBN N
to TO N
133 CD p
patients NNS p
for IN N
4-8 JJ N
weeks NNS N
in IN N
a DT N
double-blind NN N
, , N
randomized VBN N
, , N
parallel JJ N
group NN N
, , N
multicentre VBZ N
trial NN N
. . N

RESULTS VB N
The DT N
percentage NN o
of IN o
patients NNS o
with IN o
endoscopically-verified JJ o
healing NN o
was VBD N
significantly RB N
higher JJR N
on IN N
lansoprazole JJR i
than IN N
on IN N
ranitidine NN i
both DT N
after IN N
4 CD N
weeks NNS N
( ( N
79 CD N
% NN N
vs. FW N
42 CD N
% NN N
) ) N
and CC N
8 CD N
weeks NNS N
( ( N
91 CD N
% NN N
vs. FW N
66 CD N
% NN N
) ) N
, , N
though IN N
smoking NN N
had VBD N
a DT N
negative JJ N
impact NN N
on IN N
oesophagitis NN N
healing VBG N
with IN N
lansoprazole JJ i
. . i

Heartburn NNP o
, , o
retrosternal JJ o
pain NN o
and CC o
belching NN o
improved VBN N
significantly RB N
better RBR N
with IN N
lansoprazole JJ i
than IN N
with IN N
ranitidine NN i
, , N
as IN N
did VBD N
the DT N
patient-rated JJ N
overall JJ N
symptom NN N
severity NN N
. . N

Relief NN o
of IN o
heartburn NN o
appeared VBD N
somewhat RB N
faster RBR N
with IN N
ranitidine NN i
, , N
but CC N
was VBD N
more RBR N
pronounced JJ N
with IN N
lansoprazole NN i
. . i

The DT N
number NN o
of IN o
patients NNS o
with IN o
adverse JJ o
events NNS o
was VBD N
similar JJ N
in IN N
both DT N
treatment NN N
groups NNS N
. . N

CONCLUSION NNP N
Standard-dose JJ i
lansoprazole NN i
is VBZ N
better JJR N
than IN N
high-dose JJ i
ranitidine NN i
in IN N
moderately RB N
severe JJ N
reflux NN N
oesophagitis NN N
. . N

-DOCSTART- -11932879- O O

Step-down JJ N
approach NN N
using VBG N
either CC N
cyclosporin VB i
A DT i
or CC i
methotrexate NN i
as IN N
maintenance NN N
therapy NN N
in IN N
early JJ p
rheumatoid NN p
arthritis NN p
. . p

OBJECTIVE UH N
To TO N
evaluate VB N
the DT N
feasibility NN o
and CC o
outcome NN o
of IN N
the DT N
step-down JJ N
approach NN N
using VBG N
either CC N
cyclosporin VB i
A NNP i
( ( i
CSA NNP i
) ) i
or CC N
methotrexate NN i
( ( i
MTX NNP i
) ) i
as IN N
maintenance NN N
therapy NN N
following VBG N
6 CD N
months NNS N
treatment NN N
with IN N
these DT N
2 CD N
agents NNS N
in IN N
combination NN N
in IN N
early JJ N
, , N
nonerosive JJ N
rheumatoid NN N
arthritis NN N
( ( N
RA NNP N
) ) N
. . N

METHODS NNP N
Fifty-seven JJ p
patients NNS p
younger JJR p
than IN p
65 CD p
years NNS p
with IN p
early JJ p
, , p
nonerosive JJ p
RA NNP p
were VBD N
first RB N
treated VBN N
with IN N
CSA NNP i
and CC i
MTX NNP i
in IN i
combination NN i
for IN N
6 CD N
months NNS N
. . N

They PRP N
were VBD N
then RB N
randomly RB N
stepped VBD N
down RB N
to TO N
single-agent JJ i
maintenance NN N
treatment NN N
for IN N
another DT N
18 CD N
months NNS N
. . N

Safety NNP o
, , o
clinical JJ o
efficacy NN o
, , o
survival NN o
on IN o
treatment NN o
, , o
and CC o
radiographic JJ o
progression NN o
were VBD N
evaluated VBN N
. . N

RESULTS VB N
When WRB N
being VBG N
treated VBN N
with IN N
combination NN N
therapy NN N
, , N
7 CD p
of IN p
the DT p
57 CD p
patients NNS p
( ( p
12.3 CD p
% NN p
) ) p
withdrew NN p
because IN N
of IN N
adverse JJ o
events NNS o
. . o

Of IN N
the DT N
remaining VBG N
50 CD N
patients NNS N
, , N
42 CD N
( ( N
84.0 CD N
% NN N
) ) N
were VBD N
American JJ N
College NNP N
of IN N
Rheumatology NNP N
( ( N
ACR NNP N
) ) N
20 CD N
% NN N
responders NNS N
, , N
30 CD N
( ( N
60.0 CD N
% NN N
) ) N
were VBD N
ACR NNP N
50 CD N
% NN N
responders NNS N
, , N
and CC N
23 CD N
( ( N
46.0 CD N
% NN N
) ) N
were VBD N
ACR NNP N
70 CD N
% NN N
responders NNS N
. . N

At IN N
month NN N
6 CD N
, , N
22 CD N
patients NNS N
were VBD N
randomized VBN N
to TO N
CSA NNP i
and CC N
27 CD N
to TO N
MTX NNP i
. . i

During IN N
this DT N
trial NN N
period NN N
, , N
the DT N
treatment NN N
was VBD N
discontinued VBN N
by IN N
16 CD N
patients NNS N
taking VBG N
CSA NNP i
( ( N
mainly RB N
because IN N
of IN N
loss NN N
of IN N
efficacy NN o
) ) o
and CC N
by IN N
4 CD N
taking VBG N
MTX NNP i
. . i

At IN N
month NN N
24 CD N
, , N
the DT N
probability NN N
( ( N
+/- JJ N
SEM NNP N
) ) N
of IN N
survival NN o
on IN N
treatment NN N
was VBD N
0.273 CD N
+/- JJ N
0.09 CD N
for IN N
CSA NNP i
and CC N
0.852 CD N
+/- JJ N
0.07 CD N
for IN N
MTX NNP i
. . i

Of IN N
the DT N
6 CD N
CSA NNP N
patients NNS N
who WP N
completed VBD N
the DT N
trial NN N
, , N
4 CD N
( ( N
66.7 CD N
% NN N
) ) N
were VBD N
ACR NNP N
20 CD N
% NN N
responders NNS N
, , N
and CC N
3 CD N
( ( N
50 CD N
% NN N
) ) N
were VBD N
both DT N
ACR NNP N
50 CD N
% NN N
and CC N
ACR NNP N
70 CD N
% NN N
responders NNS N
. . N

Of IN N
the DT N
23 CD N
completers NNS N
in IN N
the DT N
MTX NNP i
arm NN N
, , N
21 CD N
( ( N
91.3 CD N
% NN N
) ) N
were VBD N
ACR NNP N
20 CD N
% NN N
responders NNS N
, , N
18 CD N
( ( N
78.3 CD N
% NN N
) ) N
were VBD N
ACR NNP N
50 CD N
% NN N
, , N
and CC N
10 CD N
( ( N
43.5 CD N
% NN N
) ) N
were VBD N
ACR NNP N
70 CD N
% NN N
responders NNS N
. . N

The DT N
treatment NN N
was VBD N
not RB N
responsible JJ N
for IN N
severe JJ N
adverse JJ o
events NNS o
. . o

Radiography NNP N
showed VBD N
a DT N
slow JJ N
progression NN N
in IN N
the DT N
damage NN o
score NN o
and CC o
number NN o
of IN o
eroded JJ o
joints NNS o
in IN N
both DT N
treatment NN N
groups NNS N
. . N

CONCLUSION NNP N
Stepping VBG N
down RP N
to TO N
single JJ N
agent JJ N
maintenance NN N
therapy NN N
following VBG N
6 CD N
months NNS N
of IN N
combination NN N
treatment NN N
with IN N
CSA NNP i
and CC N
MTX NNP i
in IN N
early JJ N
RA NNP N
was VBD N
only RB N
successful JJ N
with IN N
MTX NNP i
. . i

Because IN N
this DT N
treatment NN N
did VBD N
not RB N
prevent VB N
some DT N
radiographic JJ o
progression NN o
, , N
other JJ N
approaches NNS N
( ( N
e.g. NN N
, , N
step-up JJ N
approach NN N
) ) N
may MD N
be VB N
more JJR N
appropriate JJ N
in IN N
early JJ p
RA NNP p
. . p

-DOCSTART- -17165495- O O

[ JJ N
Observation NNP N
on IN N
therapeutic JJ N
effect NN N
of IN N
picking VBG N
therapy NN N
on IN N
Graves NNP p
' POS p
disease NN p
] NNP p
. . N

OBJECTIVE NNP N
To TO N
observe VB N
therapeutic JJ N
effect NN N
of IN N
picking VBG N
therapy NN N
on IN N
Graves NNP p
' POS p
disease NN p
( ( p
GD NNP p
) ) p
and CC N
its PRP$ N
effects NNS N
on IN N
thyroid JJ N
function NN N
. . N

METHODS NNP N
Sixty NNP p
cases NNS p
of IN p
GD NNP p
were VBD p
randomly RB p
divided VBN p
into IN N
a DT N
treatment NN i
group NN i
( ( i
pricking VBG i
therapy NN i
group NN i
) ) i
and CC i
a DT i
control NN i
group NN i
( ( i
medication NN i
group NN i
) ) i
. . i

They PRP N
were VBD N
treated VBN N
respectively RB N
with IN N
pricking VBG i
thyroid JJ i
gland NN i
high JJ i
point NN i
or CC i
oral JJ i
administration NN i
of IN i
tapazole NN i
. . i

And CC N
changes NNS N
of IN N
total JJ o
triiodothyronine NN o
( ( o
TT3 NNP o
) ) o
, , o
total JJ o
thyroxine NN o
( ( o
TT4 NNP o
) ) o
, , o
free JJ o
T3 NNP o
( ( o
FT3 NNP o
) ) o
, , o
free JJ o
T4 NNP o
( ( o
FT4 NNP o
) ) o
, , o
thyroxine JJ o
receptor NN o
antibody NN o
( ( o
TRAb NNP o
) ) o
, , o
supersensitive JJ o
thyrotropin NN o
( ( o
S-TSH NNP o
) ) o
after IN N
treatment NN N
were VBD N
investigated VBN N
. . N

RESULTS VB N
The DT N
total JJ N
effective JJ N
rate NN N
was VBD N
93.33 CD N
% NN N
in IN N
the DT N
treatment NN N
group NN N
and CC N
76.67 CD N
% NN N
in IN N
the DT N
control NN N
group NN N
with IN N
a DT N
significant JJ N
difference NN N
between IN N
the DT N
two CD N
groups NNS N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

After IN N
treatment NN N
, , N
serum NN o
TT3 NNP o
, , o
TT4 NNP o
, , o
FT3 NNP o
, , o
FT4 NNP o
and CC o
S-TSH NNP o
contents NNS o
had VBD N
very RB N
significant JJ N
change NN N
in IN N
the DT N
two CD N
groups NNS N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
, , N
TRAb NNP N
had VBD N
very RB N
significant JJ N
change NN N
in IN N
the DT N
treatment NN N
group NN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
and CC N
no DT N
significant JJ N
change NN N
in IN N
the DT N
control NN N
group NN N
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
there EX N
were VBD N
significant JJ N
differences NNS N
in IN N
decrease NN N
of IN N
TT3 NNP o
, , o
FT3 NNP o
, , o
TRAb NNP o
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
and CC N
no DT N
significant JJ N
difference NN N
in IN N
decrease NN N
of IN N
TT4 NNP o
, , o
FT4 NNP o
and CC o
increase NN o
of IN o
S-TSH NNP o
between IN N
the DT N
two CD N
groups NNS N
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
. . N

CONCLUSION NNP N
Pricking VBG N
therapy NN N
has VBZ N
a DT N
definite JJ N
therapeutic JJ N
effect NN N
on IN N
Graves NNP p
' POS p
disease NN p
, , N
which WDT N
is VBZ N
carried VBN N
out RP N
through IN N
regulating VBG N
thyroid JJ N
function NN N
. . N

-DOCSTART- -11701672- O O

Acute NNP N
effect NN N
of IN N
pegvisomant NN i
on IN N
cardiovascular JJ N
risk NN N
markers NNS N
in IN N
healthy JJ p
men NNS p
: : p
implications NNS N
for IN N
the DT N
pathogenesis NN N
of IN N
atherosclerosis NN N
in IN N
GH NNP N
deficiency NN N
. . N

Cardiovascular JJ N
risk NN N
is VBZ N
increased VBN N
in IN N
GH NNP N
deficiency NN N
( ( N
GHD NNP N
) ) N
. . N

GHD NNP p
adults NNS p
are VBP N
frequently RB N
abdominally RB N
obese JJ N
and CC N
display JJ N
features NNS N
of IN N
the DT N
metabolic JJ N
syndrome NN N
. . N

Otherwise NNP N
healthy JJ N
abdominally RB N
obese JJ N
subjects NNS N
have VBP N
low JJ N
GH NNP N
levels NNS N
and CC N
show NN N
features NNS N
of IN N
the DT N
metabolic JJ N
syndrome NN N
as RB N
well RB N
. . N

We PRP N
investigated VBD N
in IN N
healthy JJ p
nonobese JJ p
males NNS p
the DT N
effect NN N
of IN N
the DT N
GH NNP N
receptor NN N
antagonist NN N
pegvisomant NN i
in IN N
different JJ N
metabolic JJ N
conditions NNS N
. . N

This DT N
is VBZ N
a DT N
model NN N
for IN N
acute JJ N
GHD NNP N
without IN N
the DT N
alterations NNS N
in IN N
body NN N
composition NN N
associated VBN N
with IN N
GHD NNP N
. . N

We PRP N
compared VBN N
the DT N
effect NN N
of IN N
pegvisomant NN i
with IN N
that DT N
of IN N
placebo NN i
before IN N
and CC N
after IN N
3 CD N
d NN N
of IN N
fasting VBG N
. . N

In IN N
addition NN N
, , N
we PRP N
investigated VBD N
the DT N
effect NN N
of IN N
pegvisomant JJ i
under IN N
normal JJ N
, , N
i.e JJ N
. . N

fed VBN N
, , N
conditions NNS N
. . N

Three CD N
days NNS N
of IN N
fasting NN N
as RB N
well RB N
as IN N
pegvisomant JJ N
alone NN N
decreased VBD N
serum JJ o
free JJ o
IGF-I NN o
levels NNS o
( ( N
1.0 CD N
+/- JJ N
0.15 CD N
vs. FW N
0.31 CD N
+/- JJ N
0.05 CD N
ng/ml NN N
and CC N
0.86 CD N
+/- JJ N
0.23 CD N
vs. FW N
0.46 CD N
+/- JJ N
0.23 CD N
ng/ml NN N
, , N
respectively RB N
) ) N
. . N

Fasting VBG N
in IN N
combination NN N
with IN N
pegvisomant NN N
also RB N
decreased VBD N
serum JJ o
free JJ o
IGF-I NN o
levels NNS o
( ( N
1.0 CD N
+/- JJ N
0.15 CD N
vs. FW N
0.31 CD N
+/- JJ N
0.07 CD N
ng/ml NN N
) ) N
. . N

Treatment NN N
with IN N
pegvisomant NN i
had VBD N
no DT N
additional JJ N
influence NN N
on IN N
the DT N
decline NN N
of IN N
free JJ o
IGF-I NNP o
induced VBN N
by IN N
fasting VBG N
. . N

Pegvisomant VB N
alone RB N
had VBD N
no DT N
influence NN N
on IN N
insulin NN o
sensitivity NN o
. . o

The DT N
increase NN N
in IN N
insulin JJ o
sensitivity NN o
induced VBN N
by IN N
fasting VBG N
was VBD N
comparable JJ N
to TO N
the DT N
increase NN N
in IN N
insulin JJ o
sensitivity NN o
induced VBN N
by IN N
fasting VBG N
combined VBN N
with IN N
pegvisomant JJ N
. . N

Among IN N
serum JJ o
lipid JJ o
concentrations NNS o
, , N
only RB N
serum JJ o
triglycerides NNS o
increased VBD N
significantly RB N
as IN N
a DT N
result NN N
of IN N
pegvisomant NN N
alone NN N
( ( N
1.0 CD N
+/- JJ N
0.2 CD N
vs. FW N
1.6 CD N
+/- JJ N
0.4 CD N
mmol/liter NN N
) ) N
. . N

The DT N
changes NNS o
in IN o
lipid JJ o
concentrations NNS o
induced VBN N
by IN N
fasting VBG N
alone RB N
or CC N
pegvisomant VB N
were VBD N
not RB N
different JJ N
from IN N
those DT N
induced VBN N
by IN N
pegvisomant JJ N
alone NN N
. . N

von JJ o
Willebrand NNP o
factor NN o
antigen NN o
levels NNS o
declined VBD N
significantly RB N
under IN N
the DT N
influence NN N
of IN N
pegvisomant NN N
alone NN N
( ( N
1.1 CD N
+/- JJ N
0.07 CD N
vs. FW N
0.8 CD N
+/- JJ N
0.06 CD N
U/ml NNP N
) ) N
. . N

In IN N
conclusion NN N
, , N
in IN N
different JJ N
metabolic JJ N
conditions NNS N
the DT N
GH NNP N
receptor NN N
antagonist NN N
pegvisomant NN N
induces VBZ N
no DT N
significant JJ N
acute NN N
changes NNS N
in IN N
the DT N
major JJ N
risk NN o
markers NNS o
for IN o
cardiovascular JJ o
disease NN o
. . o

These DT N
data NNS N
suggest VBP N
that IN N
the DT N
secondary JJ N
metabolic NN N
changes NNS N
, , N
e.g NN N
. . N

abdominal JJ o
obesity NN o
or CC o
inflammatory JJ o
factors NNS o
, , N
that WDT N
develop VBZ N
as IN N
a DT N
result NN N
of IN N
long-standing JJ N
GHD NNP N
are VBP N
of IN N
primary JJ N
importance NN N
in IN N
the DT N
pathogenesis NN N
of IN N
atherosclerosis NN N
in IN N
patients NNS N
with IN N
GHD NNP N
. . N

-DOCSTART- -8210831- O O

How WRB N
to TO N
establish VB N
equivalence NN N
when WRB N
data NNS N
are VBP N
censored VBN N
: : N
a DT N
randomized JJ p
trial NN p
of IN p
treatments NNS p
for IN p
B NNP p
non-Hodgkin JJ p
lymphoma NN p
. . p

Interest NN N
in IN N
equivalence NN N
trials NNS N
has VBZ N
been VBN N
increasing VBG N
for IN N
many JJ N
years NNS N
, , N
though IN N
the DT N
methodology NN N
which WDT N
has VBZ N
been VBN N
developed VBN N
for IN N
such JJ N
trials NNS N
is VBZ N
mainly RB N
for IN N
uncensored JJ N
data NNS N
. . N

In IN N
cancer NN N
research NN N
we PRP N
are VBP N
more RBR N
often RB N
concerned VBN N
with IN N
survival NN o
. . o

In IN N
an DT N
efficacy NN N
trial NN N
, , N
the DT N
null JJ N
hypothesis NN N
specifies NNS N
equality NN N
of IN N
the DT N
two CD N
survival JJ N
distributions NNS N
, , N
but CC N
in IN N
an DT N
equivalence NN N
trial NN N
, , N
a DT N
null JJ N
hypothesis NN N
of IN N
inequivalence NN N
H0 NNP N
has VBZ N
to TO N
be VB N
tested VBN N
. . N

The DT N
usual JJ N
logrank NN i
test NN i
has VBZ N
to TO N
be VB N
modified VBN N
to TO N
test VB N
whether IN N
the DT N
true JJ N
value NN N
r NN N
of IN N
the DT N
ratio NN N
of IN N
hazard NN N
rates NNS N
in IN N
two CD N
treatment NN N
groups NNS N
is VBZ N
at IN N
least JJS N
equal JJ N
to TO N
a DT N
limit NN N
value NN N
r0 NN N
. . N

If IN N
prognostic JJ N
factors NNS N
have VBP N
to TO N
be VB N
taken VBN N
into IN N
account NN N
, , N
the DT N
Cox NNP N
model NN N
provides VBZ N
tests NNS N
of IN N
Ho NNP N
, , N
and CC N
a DT N
useful JJ N
confidence NN N
interval NN N
for IN N
the DT N
adjusted JJ N
relative JJ N
derived VBN N
from IN N
the DT N
regression NN N
parameter NN N
for IN N
the DT N
treatment NN N
indicator NN N
. . N

An DT N
equivalence NN N
trial NN N
of IN N
maintenance NN i
therapy NN i
was VBD N
carried VBN N
out RP N
in IN N
children NNS p
with IN p
B NNP p
non-Hodgkin JJ p
lymphoma NN p
, , N
and CC N
serves VBZ N
as IN N
an DT N
illustration NN N
. . N

-DOCSTART- -21859314- O O

Effect NN N
of IN N
ozone NN i
application NN i
on IN N
the DT N
resin-dentin JJ o
microtensile NN o
bond NN o
strength NN o
. . o

When WRB N
ozone NN N
is VBZ N
used VBN N
during IN N
caries NNS N
treatment NN N
, , N
bond NN N
strength NN N
can MD N
be VB N
compromised VBN N
by IN N
the DT N
release NN N
of IN N
oxygen NN N
. . N

The DT N
use NN N
of IN N
antioxidant JJ N
agents NNS N
neutralizes VBZ N
the DT N
free JJ N
oxygen NN N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
effects NNS N
of IN N
ozone NN i
and CC i
sodium NN i
ascorbate NN i
on IN N
resin-dentin JJ o
microtensile NN o
bond NN o
strength NN o
( ( o
?TBS NN o
) ) o
. . o

Forty NNP p
human JJ p
third JJ p
molars NNS p
were VBD N
divided VBN N
into IN N
four CD N
groups NNS N
: : N
Group NNP N
1 CD N
, , N
not RB i
treated VBN i
with IN i
ozone NN i
; : i
Group NNP N
2 CD N
, , N
ozone NN i
application NN i
followed VBN i
by IN i
acid NN i
etching NN i
; : i
Group NNP N
3 CD N
, , N
acid NN i
etching VBG i
followed VBN i
by IN i
ozone NN i
application NN i
; : i
and CC N
Group NNP N
4 CD N
, , N
ozone NN i
and CC i
application NN i
of IN i
sodium NN i
ascorbate NN i
. . i

Bonded VBN N
beams NN N
( ( N
1.0 CD N
mm NN N
( ( N
2 CD N
) ) N
) ) N
were VBD N
tested VBN N
under IN N
tension NN N
( ( N
0.5 CD N
mm NN N
min NN N
( ( N
-1 NNP N
) ) N
) ) N
. . N

The DT o
?TBS JJ o
values NNS o
were VBD N
analyzed VBN N
using VBG N
one-way JJ N
analysis NN N
of IN N
variance NN N
( ( N
ANOVA NNP N
) ) N
and CC N
the DT N
Tukey NNP N
test NN N
( ( N
p=0.05 NN N
) ) N
. . N

All DT N
beams NNS N
that WDT N
fractured VBD N
were VBD N
analyzed VBN N
under IN N
stereomicroscopy NN N
( ( N
40? CD N
) ) N
. . N

Group NNP N
1 CD N
had VBD N
significantly RB N
higher JJR o
?TBS NN o
values NNS o
than IN o
Group NNP N
2 CD N
or CC N
3 CD N
. . N

The DT N
?TBS JJ o
values NNS o
of IN o
Groups NNP o
1 CD N
and CC N
4 CD N
were VBD N
similar JJ N
and CC N
higher JJR N
than IN N
those DT N
of IN N
Group NNP N
2 CD N
. . N

The DT N
use NN N
of IN N
ozone NN N
in IN N
Group NNP N
2 CD N
resulted VBD N
in IN N
lower JJR N
values NNS o
of IN o
?TBS NN o
in IN N
all DT N
conditions NNS N
evaluated VBN N
. . N

The DT N
predominant JJ o
failure NN o
mode NN o
was VBD N
adhesive JJ N
. . N

The DT N
application NN N
of IN N
ozone NN N
decreased VBD o
the DT o
?TBS NN o
of IN o
the DT o
dentin-composite JJ o
resin NN o
interface NN o
. . o

These DT o
values NNS N
were VBD N
reversed VBN N
when WRB N
compared VBN N
with IN N
Groups NNP N
1 CD N
and CC N
2 CD N
when WRB N
sodium NN N
ascorbate NN N
was VBD N
used VBN N
. . N

-DOCSTART- -21355149- O O

[ JJ N
Clinical NNP N
observation NN N
on IN N
acupuncture NN i
for IN N
treatment NN N
of IN N
male JJ p
osteoporosis NN p
] NNP p
. . N

OBJECTIVE NNP N
To TO N
compare VB N
the DT N
therapeutic JJ N
effects NNS N
of IN N
acupuncture NN i
combined VBN N
with IN N
drug NN N
and CC N
simple JJ N
drug NN N
for IN N
treatment NN N
of IN N
male JJ p
osteoporosis NN p
. . p

METHODS NNP N
Fifty-five JJ p
cases NNS p
were VBD N
divided VBN N
into IN N
an DT N
observation NN N
group NN N
( ( N
25 CD N
cases NNS N
) ) N
and CC N
a DT N
control NN N
group NN N
( ( N
30 CD N
cases NNS N
) ) N
randomly RB N
. . N

The DT N
observation NN N
group NN N
was VBD N
treated VBN N
with IN N
acupuncture NN i
and CC i
moxibustion NN i
at IN i
Pishu NNP i
( ( N
BL NNP N
20 CD N
) ) N
, , N
Shenshu NNP i
( ( N
BL NNP N
23 CD N
) ) N
, , N
Mingmen NNP i
( ( N
GV NNP N
4 CD N
) ) N
, , N
Shenque NNP i
( ( N
CV NNP N
8 CD N
) ) N
and CC N
so RB N
on IN N
combined VBN N
with IN N
taking VBG N
Alendronate NNP i
, , N
while IN N
the DT N
control NN N
group NN N
was VBD N
treated VBN N
with IN N
taking VBG N
Alendronate NNP i
simply RB i
. . i

The DT N
improvement NN N
of IN N
both DT N
Integral NNP o
of IN o
Clinical NNP o
Symptoms NNP o
( ( o
ICS NNP o
) ) o
and CC N
Bone NNP o
Mineral NNP o
Density NNP o
( ( o
BMD NNP o
) ) o
of IN N
two CD N
groups NNS N
was VBD N
observed VBN N
after IN N
6 CD N
months NNS N
treatment NN N
. . N

RESULTS VB N
The DT N
ICS NNP N
of IN N
two CD N
groups NNS N
after IN N
treatment NN N
both DT N
decreased VBN N
significantly RB N
( ( N
both DT N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
and CC N
the DT N
decreasing VBG N
degree NN N
in IN N
observation NN N
group NN N
was VBD N
more RBR N
significant JJ N
than IN N
that DT N
in IN N
control NN N
group NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

The DT N
BMD NNP o
of IN o
lumbar NN o
vertebrae NN o
and CC N
femur NN o
in IN N
observation NN N
group NN N
increased VBD N
obviously RB N
than IN N
that DT N
before IN N
treatment NN N
( ( N
P NNP N
< NNP N
0.01 CD N
, , N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

The DT N
increasing VBG N
degree NN N
of IN N
BMD NNP o
of IN o
lumbar NN o
vertebrae NN o
in IN N
observation NN N
group NN N
after IN N
treatment NN N
was VBD N
more RBR N
obvious JJ N
than IN N
that DT N
in IN N
control NN N
group NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

There EX N
were VBD N
abdominal JJ o
pain NN o
, , o
diarrhea NN o
, , o
nausea NN o
, , o
vomiting VBG o
, , o
dyspepsia NN o
and CC o
other JJ o
adverse JJ o
reaction NN o
in IN N
control NN N
group NN N
, , N
while IN N
the DT N
degree NN o
and CC o
occurrence NN o
rate NN o
of IN N
those DT N
in IN N
observation NN N
group NN N
alleviated VBD N
and CC N
decreased VBD N
obviously RB N
. . N

CONCLUSION VB N
The DT N
effect NN N
of IN N
acupuncture NN i
combined VBN N
with IN N
drug NN N
for IN N
treatment NN N
of IN N
male JJ p
osteoporosis NN p
is VBZ N
good JJ N
with IN N
little JJ N
adverse JJ N
reaction NN N
. . N

This DT N
method NN N
is VBZ N
better JJR N
than IN N
taking VBG N
Alendronate NNP N
. . N

-DOCSTART- -23135337- O O

The DT N
paroxetine NN i
352 CD i
bipolar JJ p
trial NN N
: : N
A DT N
study NN N
in IN N
medical JJ N
ghostwriting NN N
. . N

BACKGROUND IN N
The DT N
problem NN N
of IN N
ghostwriting VBG N
in IN N
corporate-sponsored JJ N
clinical JJ N
trials NNS N
is VBZ N
of IN N
concern NN N
to TO N
medicine VB N
, , N
bioethics NNS N
, , N
and CC N
government NN N
agencies NNS N
. . N

We PRP N
present VBD N
a DT N
study NN N
of IN N
the DT N
ghostwritten JJ N
archival JJ N
report NN N
of IN N
an DT N
industry-sponsored JJ N
trial NN N
comparing VBG N
antidepressant JJ N
treatments NNS N
for IN N
bipolar JJ o
depression NN o
: : o
GlaxoSmithKline NNP N
( ( N
GSK NNP N
) ) N
paroxetine NN i
study NN p
352 CD p
. . p

This DT N
analysis NN N
is VBZ N
based VBN N
upon IN N
publicly RB N
available JJ N
evidence NN N
presented VBN N
in IN N
a DT N
complaint NN N
of IN N
research NN N
misconduct NN N
filed VBN N
with IN N
the DT N
Office NNP N
of IN N
Research NNP N
Integrity NNP N
of IN N
the DT N
Department NNP N
of IN N
Health NNP N
and CC N
Human NNP N
Services NNPS N
. . N

OBJECTIVES IN N
We PRP N
performed VBD N
a DT N
deconstruction NN N
of IN N
the DT N
published VBN N
study NN N
to TO N
show VB N
how WRB N
primary JJ o
and CC o
secondary JJ o
outcome NN o
analyses NNS N
were VBD N
conflated VBN N
, , N
turning VBG N
a DT N
'negative JJ N
' POS N
clinical JJ N
trial NN N
into IN N
a DT N
'positive JJ N
' POS N
study NN N
- : N
with IN N
conclusions NNS N
and CC N
recommendations NNS N
that WDT N
could MD N
adversely RB N
affect VB N
patient JJ N
health NN N
. . N

METHODS NNP N
The DT N
paroxetine NN i
352 CD N
study NN N
was VBD N
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
, , N
19-site JJ N
trial NN N
comparing VBG N
paroxetine NN i
and CC i
imipramine NN i
in IN N
117 CD p
patients NNS p
with IN p
bipolar JJ o
type NN o
I PRP o
major JJ o
depressive JJ o
episode NN o
which WDT p
was VBD p
unresponsive JJ p
to TO p
prior VB p
lithium NN p
carbonate NN p
therapy NN p
. . p

RESULTS NNP N
Analysis NNP N
of IN N
the DT N
primary JJ o
outcome NN o
measures NNS o
found VBD N
no DT N
statistically RB N
significant JJ N
difference NN N
between IN N
paroxetine NN i
or CC i
imipramine VB i
versus NN i
placebo NN i
. . i

However RB N
, , N
the DT N
published VBN N
article NN N
concluded VBD N
that IN N
both DT N
drugs NNS N
were VBD N
efficacious JJ o
versus NN N
placebo NN N
for IN N
a DT N
post NN N
hoc NN N
subgroup NN N
of IN N
patients NNS N
. . N

CONCLUSIONS NNP N
Few JJ N
industry-sponsored JJ N
studies NNS N
gain VBP N
public JJ N
scrutiny NN N
. . N

It PRP N
is VBZ N
important JJ N
to TO N
make VB N
these DT N
articles NNS N
transparent NN N
to TO N
the DT N
scientific JJ N
and CC N
medical JJ N
community NN N
. . N

-DOCSTART- -21545527- O O

Physical JJ N
activity NN N
for IN N
patients NNS p
undergoing VBG p
an DT p
allogeneic JJ p
hematopoietic JJ p
stem NN p
cell NN p
transplantation NN p
: : p
benefits NNS N
of IN N
a DT N
moderate JJ i
exercise NN i
intervention NN i
. . i

UNLABELLED IN N
An DT N
allogeneic JJ i
hematopoietic JJ i
stem NN i
cell NN i
transplantation NN i
( ( N
HSCT NNP N
) ) N
can MD N
have VB N
profound VBN N
and CC N
lasting JJ N
adverse JJ N
effects NNS N
on IN N
a DT N
patient NN N
's POS N
physical JJ N
and CC N
psychological JJ N
well-being NN N
. . N

So RB N
far RB N
, , N
only RB N
few JJ N
studies NNS N
have VBP N
investigated VBN N
the DT N
effectiveness NN o
of IN N
physical JJ N
activity NN N
over IN N
the DT N
entire JJ N
inpatient NN N
phase NN N
of IN N
an DT N
allogeneic JJ N
HSCT NNP N
. . N

PURPOSE NNP N
We PRP N
performed VBD N
a DT N
randomized VBN N
controlled VBN N
study NN N
to TO N
examine VB N
the DT N
influence NN N
of IN N
a DT N
controlled JJ N
moderate JJ i
exercise NN i
program NN i
starting VBG N
parallel JJ N
to TO N
chemotherapeutic JJ N
conditioning NN N
and CC N
total JJ N
body NN N
irradiation NN N
on IN N
the DT N
patient NN N
's POS N
physical JJ N
and CC N
psychological JJ N
constitution NN N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
Forty-seven NNP p
patients NNS p
undergoing VBG p
an DT p
allogeneic JJ p
HSCT NNP p
were VBD N
randomly RB N
assigned VBN N
to TO N
an DT N
exercise NN i
group NN i
( ( i
EG NNP i
) ) i
or CC N
a DT N
control NN i
group NN i
( ( i
CG NNP i
) ) i
. . N

While IN N
the DT N
EG NNP N
took VBD N
part NN N
in IN N
an DT N
endurance NN N
and CC N
activity NN N
of IN N
daily JJ N
living-training JJ N
twice NN N
a DT N
day NN N
, , N
the DT N
CG NNP N
received VBD N
the DT N
clinic NN N
's POS N
standard JJ N
physiotherapy NN N
program NN N
once RB N
a DT N
day NN N
. . N

RESULTS NNP N
Significant NNP o
differences VBZ o
and/or JJ N
trends NNS N
in IN N
favor NN N
of IN N
the DT N
EG NNP N
were VBD N
observed VBN N
regarding VBG N
the DT N
primary JJ N
endpoint NN N
endurance NN o
performance NN o
( ( N
P=0.002 NNP N
) ) N
, , N
muscular JJ o
strength NN o
( ( N
P=0.022 NNP N
) ) N
, , N
fatigue NN o
( ( N
P=0.046 NNP N
) ) N
, , N
and CC N
emotional JJ o
state NN o
( ( N
P=0.028 NNP N
) ) N
without IN N
posing VBG N
an DT N
additional JJ N
risk NN N
for IN N
the DT N
individual NN N
. . N

CONCLUSION VB N
The DT N
results NNS N
show VBP N
that IN N
the DT N
training NN N
program NN N
is VBZ N
feasible JJ N
and CC N
seems VBZ N
to TO N
have VB N
positive JJ N
influences NNS N
on IN N
physical JJ o
performance NN o
and CC o
quality NN o
of IN o
life NN o
in IN N
patients NNS p
undergoing VBG p
an DT p
allogeneic JJ p
HSCT NNP p
. . p

However RB N
, , N
further JJ N
studies NNS N
are VBP N
necessary JJ N
to TO N
confirm VB N
these DT N
results NNS N
. . N

-DOCSTART- -18635304- O O

Placebo-controlled JJ i
trial NN N
evaluating VBG N
safety NN N
with IN N
12-months JJ N
continuous JJ N
use NN N
of IN N
6 CD i
% NN i
hydrogen NN i
peroxide IN i
whitening VBG i
strips NNS i
. . i

OBJECTIVE NNP N
To TO N
assess VB N
the DT N
safety NN N
and CC N
tolerability NN N
of IN N
6 CD i
% NN i
hydrogen NN i
peroxide IN i
whitening VBG i
strips NNS i
over IN N
12 CD N
months NNS N
. . N

METHODS NNP N
80 CD p
adults NNS p
were VBD p
randomly RB p
assigned VBN p
equally RB N
to TO N
one CD N
of IN N
two CD N
treatments NNS N
: : N
6 CD i
% NN i
hydrogen NN i
peroxide JJ i
strips NNS i
or CC i
placebo VB i
strips NNS i
. . i

Strips NNS N
were VBD N
worn JJ N
5 CD N
min JJ N
daily RB N
for IN N
12 CD N
months NNS N
. . N

Safety NNP N
and CC N
tolerability NN N
were VBD N
assessed VBN N
via IN N
oral JJ N
status NN N
interviews NNS N
and CC N
oral JJ N
examinations NNS N
at IN N
baseline NN N
and CC N
after IN N
1 CD N
, , N
2 CD N
, , N
3 CD N
, , N
6 CD N
, , N
9 CD N
, , N
and CC N
12 CD N
months NNS N
of IN N
use NN N
. . N

RESULTS NNP N
Tooth NNP N
sensitivity NN N
and CC N
oral JJ N
irritation NN N
were VBD N
the DT N
two CD N
most JJS N
common JJ N
adverse JJ N
events NNS N
. . N

After IN N
12 CD N
months NNS N
use RB N
, , N
tooth DT N
sensitivity NN N
was VBD N
reported VBN N
by IN N
10 CD N
% NN N
of IN N
subjects NNS N
in IN N
the DT N
6 CD i
% NN i
strip NN i
group NN N
with IN N
a DT N
95 CD N
% NN N
confidence NN N
interval NN N
( ( N
CI NNP N
) ) N
of IN N
( ( N
2.8 CD N
% NN N
, , N
23.7 CD N
% NN N
) ) N
and CC N
5 CD N
% NN N
of IN N
subjects NNS N
in IN N
the DT N
placebo NN i
group NN N
with IN N
a DT N
95 CD N
% NN N
CI NNP N
of IN N
( ( N
0.6 CD N
% NN N
, , N
16.9 CD N
% NN N
) ) N
. . N

The DT N
occurrence NN N
of IN N
reported VBN N
oral JJ N
irritation NN N
was VBD N
0 CD N
% NN N
in IN N
the DT N
6 CD i
% NN i
strip NN i
group NN N
with IN N
a DT N
95 CD N
% NN N
CI NNP N
of IN N
( ( N
0 CD N
% NN N
, , N
8.8 CD N
% NN N
) ) N
and CC N
2.5 CD N
% NN N
in IN N
the DT N
placebo NN i
strip NN i
group NN N
with IN N
a DT N
95 CD N
% NN N
CI NNP N
of IN N
( ( N
0.1 CD N
% NN N
, , N
13.2 CD N
% NN N
) ) N
. . N

The DT N
occurrence NN N
of IN N
observed JJ N
oral JJ N
irritation NN N
was VBD N
also RB N
similar JJ N
between IN N
groups NNS N
. . N

The DT N
groups NNS N
did VBD N
not RB N
differ VB N
significantly RB N
( ( N
p JJ N
> NNP N
0.67 CD N
) ) N
for IN N
the DT N
percent NN N
of IN N
subjects NNS N
with IN N
each DT N
type NN N
of IN N
adverse JJ N
event NN N
. . N

In IN N
the DT N
6 CD i
% NN i
strip NN i
group NN N
, , N
two CD N
subjects NNS N
discontinued VBN N
product NN N
use NN N
due JJ N
to TO N
an DT N
adverse JJ N
event NN N
( ( N
tooth JJ N
sensitivity NN N
) ) N
compared VBN N
to TO N
no DT N
subjects NNS N
in IN N
the DT N
placebo NN i
group NN N
. . N

Groups NNP N
did VBD N
not RB N
differ VB N
significantly RB N
( ( N
p JJ N
> NNP N
0.49 CD N
) ) N
with IN N
respect NN N
to TO N
this DT N
outcome NN N
. . N

CONCLUSION NNP N
Use NNP N
of IN N
6 CD i
% NN i
hydrogen NN i
peroxide IN i
whitening VBG i
strips NNS i
over IN N
12 CD N
months NNS N
resulted VBN N
in IN N
a DT N
safety NN N
profile NN N
similar JJ N
to TO N
that DT N
seen VBN N
with IN N
placebo JJ i
strips NNS i
. . i

-DOCSTART- -15814479- O O

Development NNP N
of IN N
the DT N
WAIS-III NNP N
general JJ N
ability NN N
index NN N
estimate NN N
( ( N
GAI-E NNP N
) ) N
. . N

The DT N
WAIS-III JJ N
General NNP N
Ability NNP N
Index NNP N
( ( N
GAI NNP N
; : N
Tulsky NNP N
, , N
Saklofske NNP N
, , N
Wilkins NNP N
, , N
& CC N
Weiss NNP N
, , N
2001 CD N
) ) N
is VBZ N
a DT N
recently RB N
developed VBN N
, , N
6-subtest JJ N
measure NN N
of IN N
global JJ N
intellectual JJ N
functioning NN N
. . N

However RB N
, , N
clinical JJ N
use NN N
of IN N
the DT N
GAI NNP N
is VBZ N
currently RB N
limited VBN N
by IN N
the DT N
absence NN N
of IN N
a DT N
method NN N
to TO N
estimate VB N
premorbid NN N
functioning VBG N
as IN N
measured VBN N
by IN N
this DT N
index NN N
. . N

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
develop VB N
regression NN N
equations NNS N
to TO N
estimate VB N
GAI NNP o
scores NNS o
from IN N
demographic JJ N
variables NNS N
and CC N
WAIS-III JJ o
subtest NN o
performance NN o
. . o

Participants NNS p
consisted VBD p
of IN p
those DT p
subjects NNS p
in IN p
the DT p
WAIS-III JJ p
standardization NN p
sample NN p
that WDT p
has VBZ p
complete JJ p
demographic JJ p
data NNS p
( ( p
N=2,401 NNP p
) ) p
and CC p
were VBD p
randomly RB p
divided VBN p
into IN p
two CD p
groups NNS p
. . p

The DT N
first JJ N
group NN N
( ( N
n=1,200 RB N
) ) N
was VBD N
used VBN N
to TO N
develop VB i
the DT i
formulas NN i
( ( N
i.e. FW N
, , N
Development NNP N
group NN N
) ) N
and CC N
the DT N
second JJ N
( ( N
n=1,201 JJ N
) ) N
group NN N
was VBD N
used VBN N
to TO N
validate VB i
the DT i
prediction NN i
algorithms NN i
( ( N
i.e. FW N
, , N
Validation NNP N
group NN N
) ) N
. . N

Demographic JJ o
variables NNS o
included VBD o
age NN o
, , o
education NN o
, , o
ethnicity NN o
, , o
gender NN o
and CC o
region NN o
of IN o
country NN o
. . o

Subtest NNP N
variables NNS N
included VBD N
vocabulary JJ o
, , o
information NN o
, , o
picture NN o
completion NN o
, , o
and CC o
matrix NN o
reasoning VBG o
raw JJ o
scores NNS o
. . o

Ten CD N
regression NN N
algorithms NNS N
were VBD N
generated VBN N
designed VBN N
to TO N
estimate VB N
GAI NNP o
. . o

The DT N
GAI-Estimate NNP o
( ( o
GAI-E NNP o
) ) o
algorithms NN o
accounted VBD N
for IN N
58 CD N
% NN N
to TO N
82 CD N
% NN N
of IN N
the DT N
variance NN N
. . N

The DT N
standard JJ o
error NN o
of IN N
estimate NN N
ranged VBN N
from IN N
6.44 CD N
to TO N
9.57 CD N
. . N

The DT N
correlations NNS N
between IN N
actual JJ N
and CC N
estimated JJ N
GAI NNP N
ranged VBD N
from IN N
r=.76 NN N
to TO N
r=.90 VB N
. . N

These DT N
algorithms NNS N
provided VBD N
accurate JJ N
estimates NNS N
of IN N
GAI NNP N
in IN N
the DT N
WAIS-III JJ N
standardization NN N
sample NN N
. . N

Implications NNS N
for IN N
estimating VBG N
GAI NNP N
in IN N
patients NNS p
with IN p
known VBN p
or CC p
suspected VBN p
neurological JJ p
dysfunction NN p
is VBZ N
discussed VBN N
and CC N
future JJ N
research NN N
is VBZ N
proposed VBN N
. . N

-DOCSTART- -15603203- O O

Histamine NNP p
intolerance-like NN p
symptoms NNS p
in IN p
healthy JJ p
volunteers NNS p
after IN N
oral JJ N
provocation NN N
with IN N
liquid JJ N
histamine NN N
. . N

Histamine NNP N
in IN N
food NN N
at IN N
non-toxic JJ N
doses NNS N
has VBZ N
been VBN N
proposed VBN N
to TO N
be VB N
a DT N
major JJ N
cause NN N
of IN N
food NN N
intolerance NN N
causing NN N
symptoms NNS N
like IN N
diarrhea NN N
, , N
hypotension NN N
, , N
headache NN N
, , N
pruritus NN N
and CC N
flush NN N
( ( N
histamine JJ N
intolerance NN N
) ) N
. . N

Histamine-rich JJ N
foods NNS N
such JJ N
as IN N
cheese NN N
, , N
sausages NNS N
, , N
sauerkraut NN N
, , N
tuna NN N
, , N
tomatoes NNS N
, , N
and CC N
alcoholic JJ N
beverages NNS N
may MD N
contain VB N
histamine VB N
up IN N
to TO N
500 CD N
mg/kg NNS N
. . N

We PRP N
conducted VBD N
a DT N
randomized VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
cross-over NN N
study NN N
in IN N
10 CD p
healthy JJ p
females NNS p
( ( p
age NN p
range NN p
22-36 CD p
years NNS p
, , p
mean JJ p
29.1 CD p
+/- JJ p
5.4 CD p
) ) p
who WP p
were VBD p
hospitalized VBN p
and CC p
challenged VBN p
on IN p
two CD p
consecutive JJ p
days NNS p
with IN p
placebo NN i
( ( i
peppermint JJ i
tea NN i
) ) i
or CC i
75 CD i
mg NN i
of IN i
pure JJ i
histamine NN i
( ( p
equaling VBG p
124 CD p
mg JJ p
histamine NN p
dihydrochloride NN p
, , p
dissolved VBN p
in IN p
peppermint NN p
tea NN p
) ) p
. . p

Objective JJ N
parameters NNS N
( ( N
heart NN N
rate NN N
, , N
blood NN N
pressure NN N
, , N
skin JJ N
temperature NN N
, , N
peak VB N
flow NN N
) ) N
as RB N
well RB N
as IN N
a DT N
total JJ N
clinical JJ N
symptom NN N
score NN N
using VBG N
a DT N
standardized VBN N
protocol NN N
were VBD N
recorded VBN N
at IN N
baseline NN N
, , N
10 CD N
, , N
20 CD N
, , N
40 CD N
, , N
80 CD N
minutes NNS N
, , N
and CC N
24 CD N
hours NNS N
. . N

The DT N
subjects NNS N
received VBD N
a DT N
histamine-free JJ i
diet NN i
also RB N
low JJ N
in IN N
allergen NN N
24 CD N
hours NNS N
before IN N
hospitalization NN N
and CC N
over IN N
the DT N
whole JJ N
observation NN N
period NN N
. . N

Blood NN N
samples NNS N
were VBD N
drawn VBN N
at IN N
baseline NN N
, , N
10 CD N
, , N
20 CD N
, , N
40 CD N
, , N
and CC N
80 CD N
minutes NNS N
, , N
and CC N
histamine NN N
and CC N
the DT N
histamine-degrading JJ N
enzyme NN N
diamine NN N
oxidase NN N
( ( N
DAO NNP N
) ) N
were VBD N
determined VBN N
. . N

After IN N
histamine JJ N
challenge NN N
, , N
5 CD N
of IN N
10 CD N
subjects NNS N
showed VBD N
no DT o
reaction NN o
. . o

One CD N
individual NN N
experienced VBD N
tachycardia NN o
, , o
mild JJ o
hypotension NN o
after IN o
20 CD o
minutes NNS o
, , o
sneezing VBG o
, , o
itching NN o
of IN o
the DT o
nose NN o
, , o
and CC o
rhinorrhea NN o
after IN o
60 CD o
minutes NNS o
. . o

Four CD N
subjects NNS N
experienced VBD N
delayed JJ N
symptoms NNS N
like IN N
diarrhea NN o
( ( o
4x CD o
) ) o
, , o
flatulence NN o
( ( o
3x CD o
) ) o
, , o
headache NN o
( ( o
3x CD o
) ) o
, , o
pruritus NN o
( ( o
2x CD o
) ) o
and CC o
ocular JJ o
symptoms NNS o
( ( N
1x CD N
) ) N
starting VBG N
3 CD N
to TO N
24 CD N
hours NNS N
after IN N
provocation NN N
. . N

No DT N
subject NN N
reacted VBD N
to TO N
placebo VB N
. . N

No DT N
changes NNS N
were VBD N
observed VBN N
in IN N
histamine NN o
and CC o
DAO NNP o
levels NNS o
within IN N
the DT N
first JJ N
80 CD N
minutes NNS N
in IN N
non-reactors NNS N
as RB N
well RB N
as IN N
reactors NNS N
. . N

There EX N
was VBD N
no DT N
difference NN N
in IN N
challenge NN N
with IN N
histamine JJ N
versus NN N
challenge NN N
with IN N
placebo NN N
. . N

We PRP N
conclude VBP N
that IN N
75 CD N
mg NN N
of IN N
pure NN N
liquid JJ N
oral JJ N
histamine NN N
-- : N
a DT N
dose JJ N
found VBN N
in IN N
normal JJ N
meals NNS N
-- : N
can MD N
provoke VB N
immediate JJ N
as RB N
well RB N
as IN N
delayed VBN N
symptoms NNS N
in IN N
50 CD N
% NN N
of IN N
healthy JJ p
females NNS p
without IN p
a DT p
history NN p
of IN p
food NN p
intolerance NN p
. . p

-DOCSTART- -23880333- O O

A DT N
cognitive-behavioral JJ i
intervention NN i
for IN N
emotion NN N
regulation NN N
in IN N
adults NNS p
with IN p
high-functioning JJ p
autism NN p
spectrum NN p
disorders NNS p
: : p
study NN N
protocol NN N
for IN N
a DT N
randomized VBN N
controlled VBN N
trial NN N
. . N

BACKGROUND NNP N
Adults NNP p
with IN p
high-functioning JJ p
autism NN p
spectrum NN p
disorders NNS p
( ( p
ASD NNP p
) ) p
have VBP p
difficulties NNS p
in IN p
social JJ p
communication NN p
; : p
thus RB N
, , N
these DT N
individuals NNS N
have VBP N
trouble NN N
understanding VBG N
the DT N
mental JJ N
states NNS N
of IN N
others NNS N
. . N

Recent JJ N
research NN N
also RB N
suggests VBZ N
that IN N
adults NNS p
with IN p
ASD NNP p
are VBP N
unable JJ N
to TO N
understand VB N
their PRP$ N
own JJ N
mental JJ N
states NNS N
, , N
which WDT N
could MD N
lead VB N
to TO N
difficulties NNS N
in IN N
emotion-regulation NN N
. . N

Some DT N
studies NNS N
have VBP N
reported VBN N
the DT N
efficacy NN N
of IN N
cognitive-behavioral JJ i
therapy NN i
( ( i
CBT NNP i
) ) i
in IN N
improving VBG N
emotion-regulation NN N
among IN N
children NNS p
with IN p
ASD NNP p
. . p

The DT N
current JJ N
study NN N
will MD N
investigate VB N
the DT N
efficacy NN N
of IN N
group-based JJ N
CBT NNP N
for IN N
adults NNS p
with IN p
ASD NNP p
. . p

METHODS/DESIGN NNP N
The DT N
study NN N
is VBZ N
a DT N
randomized JJ N
, , N
waitlist NN N
controlled VBD N
, , N
single-blinded JJ N
trial NN N
. . N

The DT p
participants NNS p
will MD p
be VB p
60 CD p
adults NNS p
with IN p
ASD NNP p
; : p
30 CD p
will MD p
be VB p
assigned VBN p
to TO p
a DT p
CBT NNP i
group NN p
and CC p
30 CD p
to TO p
a DT p
waitlist NN i
control NN i
group NN i
. . i

Primary NNP N
outcome JJ N
measures NNS N
are VBP N
the DT N
20-item JJ o
Toronto NNP o
Alexithymia NNP o
Scale NNP o
, , o
the DT o
Coping NNP o
Inventory NNP o
for IN o
Stressful NNP o
Situations NNP o
, , o
the DT o
Motion NNP o
Picture NNP o
Mind-Reading NNP o
task NN o
, , o
and CC o
an DT o
ASD NNP o
questionnaire NN o
. . o

The DT N
secondary JJ N
outcome NN N
measures NNS N
are VBP N
the DT N
Center NNP o
for IN o
Epidemiological NNP o
Studies NNPS o
Depression NNP o
Scale NNP o
, , o
the DT o
World NNP o
Health NNP o
Organization NNP o
Quality NNP o
of IN o
Life NNP o
Scale NNP o
26-item JJ o
version NN o
, , o
the DT o
Global NNP o
Assessment NNP o
of IN o
Functioning NNP o
, , o
State-trait NNP o
Anxiety NNP o
Inventory NNP o
, , o
Social NNP o
Phobia NNP o
and CC o
Anxiety NNP o
Inventory NNP o
, , o
and CC o
Liebowitz NNP o
Social NNP o
Anxiety NNP o
Scale NNP o
. . o

All DT N
will MD N
be VB N
administered VBN N
during IN N
the DT N
pre- JJ N
and CC N
post-intervention NN N
, , N
and CC N
12 CD N
week NN N
follow-up JJ N
periods NNS N
. . N

The DT N
CBT NNP N
group NN N
will MD N
receive VB N
group NN N
therapy NN N
over IN N
an DT N
8 CD N
week NN N
period NN N
( ( N
one CD N
session NN N
per IN N
week NN N
) ) N
with IN N
each DT N
session NN N
lasting VBG N
approximately RB N
100 CD N
minutes NNS N
. . N

Group NNP N
therapy NN N
will MD N
consist VB N
of IN N
four CD N
or CC N
five CD N
adults NNS N
with IN N
ASD NNP N
and CC N
two CD N
psychologists NNS N
. . N

We PRP N
will MD N
be VB N
using VBG N
visual JJ N
materials NNS N
for IN N
this DT N
program NN N
, , N
mainly RB N
the DT N
Cognitive NNP N
Affective NNP N
Training NNP N
kit NN N
. . N

DISCUSSION NNP N
This DT N
trial NN N
will MD N
hopefully RB N
indicate VB N
the DT N
efficacy NN N
of IN N
group-based JJ N
CBT NNP N
for IN N
adults NNS N
with IN N
high- JJ N
functioning NN N
ASD NNP N
. . N

TRIAL NNP N
REGISTRATION NNP N
This DT N
trial NN N
was VBD N
registered VBN N
in IN N
The DT N
University NNP N
Hospital NNP N
Medical NNP N
Information NNP N
Network NNP N
Clinical NNP N
Trials NNP N
Registry NNP N
No NNP N
. . N

UMIN000006236 NNP N
. . N

-DOCSTART- -20216293- O O

Comparison NNP N
of IN N
laser NN i
photocoagulation NN i
for IN N
diabetic JJ N
retinopathy NN N
using VBG N
532-nm JJ N
standard NN N
laser NN N
versus NN N
multispot NN N
pattern JJ N
scan JJ N
laser NN N
. . N

PURPOSE VB N
The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
efficacy NN N
, , N
collateral JJ N
damage NN N
, , N
and CC N
convenience NN N
of IN N
panretinal JJ N
photocoagulation NN N
for IN N
proliferative JJ p
diabetic JJ p
retinopathy NN p
or CC p
severe JJ p
nonproliferative JJ p
diabetic JJ p
retinopathy NN p
using VBG N
a DT N
532-nm JJ N
solid-state NN i
green JJ i
laser NN i
( ( i
GLX NNP i
) ) i
versus VBP N
a DT N
multispot NN i
532-nm JJ i
pattern JJ i
scan JJ i
laser NN i
( ( N
PASCAL NNP N
) ) N
. . N

METHODS NNP N
This DT N
study NN N
was VBD N
a DT N
prospective JJ N
randomized VBN N
clinical JJ N
trial NN N
. . N

Sixty JJ p
patients NNS p
with IN p
bilaterally RB p
symmetrical JJ p
proliferative JJ p
diabetic JJ p
retinopathy NN p
or CC p
severe JJ p
nonproliferative JJ p
diabetic JJ p
retinopathy NN p
participated VBD N
. . N

Each DT N
patient JJ N
underwent JJ N
panretinal JJ N
photocoagulation NN N
: : N
one CD i
eye NN i
with IN i
GLX NNP i
and CC N
the DT N
other JJ N
with IN N
PASCAL NNP i
, , N
two CD N
sittings NNS N
per IN N
eye NN N
. . N

Grade $ N
3 CD N
burns NNS N
with IN N
a DT N
200-mum JJ N
spot NN N
size NN N
were VBD N
placed VBN N
with IN N
both DT N
modalities NNS N
. . N

The DT N
fluence NN o
, , o
pain NN o
using VBG o
the DT o
visual JJ o
analog NN o
scale NN o
, , o
time NN o
, , o
laser NN o
spot NN o
spread NN o
with IN N
infrared JJ N
images NNS N
, , N
and CC N
retinal JJ o
sensitivity NN o
were VBD N
compared VBN N
. . N

RESULTS NNP N
Pattern NNP N
scan JJ N
laser NN N
and CC N
GLX NNP N
required VBD N
an DT N
average JJ o
fluence NN o
of IN N
40.33 CD N
vs NNS N
191 CD N
J/cm NNP N
( ( N
2 CD N
) ) N
, , N
respectively RB N
. . N

Average JJ o
time NN o
required VBN o
per IN o
sitting VBG o
was VBD N
1.43 CD N
minutes NNS N
with IN N
PASCAL NNP N
and CC N
4.53 CD N
minutes NNS N
with IN N
GLX NNP N
. . N

Average NNP o
visual JJ o
analog NN o
scale NN o
reading NN o
for IN N
GLX NNP N
was VBD N
4.6 CD N
, , N
whereas NNS N
that IN N
for IN N
PASCAL NNP N
was VBD N
0.33 CD N
. . N

Heidelberg NNP N
retinal JJ N
angiography NN N
images NNS N
showed VBD N
the DT N
spot NN o
spread NN o
as IN N
being VBG N
430 CD N
versus NN N
310 CD N
microm NN N
at IN N
3 CD N
months NNS N
with IN N
GLX NNP N
and CC N
PASCAL NNP N
. . N

The DT N
eyes NNS N
treated VBN N
with IN N
PASCAL NNP N
showed VBD N
higher JJR N
average JJ o
retinal JJ o
sensitivity NN o
in IN N
the DT N
central JJ N
15 CD N
degrees NNS N
and CC N
15 CD N
degrees NNS N
to TO N
30 CD N
degrees NNS N
zones NNS N
( ( N
25.08 CD N
and CC N
22.08 CD N
dB NN N
, , N
respectively RB N
) ) N
than IN N
the DT N
eyes NNS N
treated VBN N
with IN N
GLX NNP N
( ( N
23.16 CD N
and CC N
17.14 CD N
dB NN N
) ) N
, , N
respectively RB N
. . N

CONCLUSION NNP N
Pattern NNP N
scan JJ N
laser NN N
showed VBD N
lesser JJR N
collateral JJ N
damage NN N
and CC N
similar JJ N
regression NN o
of IN o
retinopathy JJ o
compared VBN N
with IN N
GLX NNP N
. . N

Pattern NNP N
scan JJ N
laser NN N
treatment NN N
was VBD N
less JJR N
time NN N
consuming VBG N
and CC N
less RBR N
painful JJ N
for IN N
the DT N
patient NN N
compared VBN N
with IN N
GLX NNP N
. . N

-DOCSTART- -19817753- O O

The DT N
effect NN N
of IN N
oral JJ N
steroids NNS i
with IN i
and CC i
without IN i
vitamin JJ i
D3 NNP i
on IN N
early JJ N
efficacy NN N
of IN N
immunotherapy NN N
in IN N
asthmatic JJ p
children NNS p
. . p

BACKGROUND NNP N
The DT N
possibility NN N
of IN N
additional JJ N
strategies NNS N
to TO N
enhance VB N
the DT N
effectiveness NN N
of IN N
specific JJ N
immunotherapy NN N
( ( N
SIT NNP N
) ) N
is VBZ N
highly RB N
attractive JJ N
. . N

AIM IN N
The DT N
aim NN N
of IN N
our PRP$ N
study NN N
was VBD N
to TO N
assess VB N
the DT N
influence NN N
of IN N
oral JJ N
corticosteroids NNS i
and CC N
oral JJ i
corticosteroids NNS i
combined VBN i
with IN i
vitamin NN i
D NNP i
( ( i
3 CD i
) ) i
on IN N
the DT N
early JJ N
clinical JJ N
and CC N
immunological JJ N
effects NNS N
of IN N
SIT NNP N
. . N

METHODS NNP N
It PRP N
was VBD N
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
trial NN N
conducted VBN N
in IN N
54 CD p
asthmatic JJ p
children NNS p
allergic VBP p
to TO p
house NN p
dust NN p
mites NNS p
. . p

Intervention NN N
was VBD N
based VBN N
on IN N
receiving VBG N
a DT N
single JJ i
dose NN i
of IN i
oral JJ i
steroid NN i
, , i
with IN i
or CC i
without IN i
vitamin JJ i
D NNP i
( ( i
3 CD i
) ) i
, , N
or CC N
placebo VBZ i
only RB N
on IN N
the DT N
day NN N
of IN N
the DT N
build-up JJ N
phase NN N
of IN N
SIT NNP N
. . N

RESULTS NNP N
After IN N
12 CD N
months NNS N
of IN N
SIT NNP N
, , N
the DT N
median JJ o
daily JJ o
inhaled VBN o
corticosteroid NN o
( ( o
ICS NNP o
) ) o
dose NN o
, , N
which WDT N
controls VBZ N
the DT N
symptoms NNS N
of IN N
asthma NN N
, , N
was VBD N
reduced VBN N
by IN N
25 CD N
% NN N
in IN N
the DT N
steroid NN i
group NN p
. . p

However RB N
, , N
a DT N
50 CD N
% NN N
reduction NN N
of IN N
the DT N
median JJ o
daily JJ o
ICS NNP o
dose NN o
was VBD N
observed VBN N
in IN N
the DT N
control NN p
group NN p
. . p

The DT N
clinical JJ N
effects NNS N
of IN N
SIT NNP N
were VBD N
not RB N
affected VBN N
in IN N
the DT N
steroid+D NN p
( ( p
3 CD p
) ) p
group NN p
. . p

Concomitantly RB N
, , N
we PRP N
found VBD N
that IN N
intervention NN N
with IN N
prednisone NN N
significantly RB N
impaired VBD N
the DT N
induction NN o
of IN o
T NNP o
regulatory JJ o
lymphocytes NNS o
. . o

Importantly RB N
, , N
the DT N
clinical JJ N
and CC N
immunological JJ N
effects NNS N
of IN N
SIT NNP N
were VBD N
not RB N
affected VBN N
by IN N
intervention NN N
with IN N
steroids NNS N
administered VBN N
with IN N
vitamin NN N
D NNP N
( ( N
3 CD N
) ) N
. . N

CONCLUSIONS NNP N
Our PRP$ N
study NN N
failed VBD N
to TO N
show VB N
a DT N
beneficial JJ N
effect NN N
of IN N
oral JJ N
corticosteroids NNS N
on IN N
allergen-specific JJ N
immunotherapy NN N
. . N

We PRP N
observed VBD N
that IN N
the DT N
combined JJ i
administration NN i
of IN i
a DT i
corticosteroid JJ i
drug NN i
and CC i
allergen NN i
extract NN N
suppressed VBD N
the DT N
early JJ N
clinical JJ N
and CC N
immunological JJ N
effects NNS N
of IN N
SIT NNP N
and CC N
that IN N
vitamin NN N
D NNP N
( ( N
3 CD N
) ) N
prevented VBD N
this DT N
'adverse NN N
' '' N
influence NN N
of IN N
steroids NNS N
. . N

-DOCSTART- -11454840- O O

Uncomplicated VBN N
moderate JJ N
coronary JJ p
artery NN p
dissections NNS p
after IN N
balloon NN N
angioplasty NN N
: : N
good JJ N
outcome NN N
without IN N
stenting VBG i
. . i

OBJECTIVE NNP N
To TO N
study VB N
the DT N
relation NN N
between IN N
moderate JJ N
coronary JJ N
dissections NNS N
, , N
coronary JJ N
flow NN N
velocity NN N
reserve NN N
( ( N
CFVR NNP N
) ) N
, , N
and CC N
long JJ N
term NN N
outcome NN N
. . N

METHODS NNP N
523 CD p
patients NNS p
undergoing JJ p
balloon NN i
angioplasty NN i
and CC p
sequential JJ p
intracoronary JJ p
Doppler NN p
measurements NNS p
were VBD N
examined VBN N
as IN N
part NN N
of IN N
the DT N
DEBATE NNP N
II NNP N
trial NN N
( ( N
Doppler NNP N
endpoints VBZ N
balloon NN N
angioplasty JJ N
trial NN N
Europe NNP N
) ) N
. . N

After IN p
successful JJ p
balloon NN i
angioplasty NN i
, , N
patients NNS N
were VBD N
randomised VBN N
to TO N
stenting VBG i
or CC i
no DT i
further JJ i
treatment NN i
. . i

Dissections NNS N
were VBD N
graded VBN N
at IN N
the DT N
core NN N
laboratory NN N
by IN N
two CD N
observers NNS N
and CC N
divided VBD N
into IN N
four CD N
categories NNS N
: : N
none NN N
, , N
mild NN N
( ( N
type JJ N
A-B NNP N
) ) N
, , N
moderate JJ N
( ( N
type JJ N
C NNP N
) ) N
, , N
severe JJ N
( ( N
types NNS N
D NNP N
to TO N
F NNP N
) ) N
. . N

Patients NNS p
with IN p
severe JJ p
dissections NNS p
( ( p
n JJ p
= NNP p
128 CD p
) ) p
or CC p
without IN p
available JJ p
reference NN p
vessel NN p
CFVR NNP p
( ( p
n JJ p
= NNP p
139 CD p
) ) p
were VBD p
excluded VBN p
. . p

The DT N
remaining VBG p
256 CD p
patients NNS p
were VBD N
divided VBN N
into IN N
two CD N
groups NNS N
according VBG N
to TO N
the DT N
presence NN N
( ( N
group NN N
A NNP N
, , N
n JJ N
= NNP N
45 CD N
) ) N
or CC N
absence NN N
( ( N
group NN N
B NNP N
, , N
n JJ N
= NNP N
211 CD N
) ) N
of IN N
moderate JJ N
dissection NN N
. . N

RESULTS NNP N
Following VBG N
balloon NN N
angioplasty RB N
, , N
there EX N
was VBD N
no DT N
difference NN N
in IN N
CFVR NNP o
between IN N
the DT N
two CD N
groups NNS N
. . N

At IN N
12 CD N
months NNS N
follow VBP N
up RP N
, , N
a DT N
higher JJR N
rate NN N
of IN N
major JJ o
adverse JJ o
cardiac NN o
events NNS o
was VBD N
observed VBN N
overall JJ N
in IN N
group NN N
A NNP N
than IN N
in IN N
group NN N
B NNP N
( ( N
10 CD N
( ( N
22 CD N
% NN N
) ) N
v NN N
23 CD N
( ( N
11 CD N
% NN N
) ) N
, , N
p JJ N
= NNP N
0.041 CD N
) ) N
. . N

However RB N
, , N
the DT N
risk NN o
of IN o
major JJ o
adverse JJ o
events NNS o
was VBD N
similar JJ N
in IN N
the DT N
subgroups NNS N
receiving VBG N
balloon NN N
angioplasty NN N
( ( N
group NN N
A NNP N
, , N
6 CD N
( ( N
19 CD N
% NN N
) ) N
v NN N
group NN N
B NNP N
, , N
16 CD N
( ( N
16 CD N
% NN N
) ) N
, , N
NS NNP N
) ) N
. . N

Among IN N
group NN N
A NNP N
patients NNS N
, , N
the DT N
adverse JJ o
events NNS o
risk NN o
was VBD N
greater JJR N
in IN N
those DT N
randomised VBN N
to TO N
stenting VBG N
( ( N
odds JJ N
ratios NNS N
6.603 CD N
v NN N
1.197 CD N
, , N
p NN N
= NNP N
0.046 CD N
) ) N
, , N
whereas IN N
there EX N
was VBD N
no DT N
difference NN N
in IN N
risk NN N
if IN N
the DT N
group NN N
was VBD N
analysed VBN N
according VBG N
to TO N
whether IN N
the DT N
CFVR NNP N
was VBD N
< JJ N
2.5 CD N
or CC N
> VB N
/= CD N
2.5 CD N
after IN N
balloon NN N
angioplasty NN N
. . N

CONCLUSIONS NNP N
Moderate NNP N
dissections NNS N
left VBD N
untreated JJ N
result NN N
in IN N
no DT N
increased VBN N
risk NN o
of IN o
major JJ o
adverse JJ o
cardiac NN o
events NNS o
. . o

Additional JJ N
stenting NN N
does VBZ N
not RB N
improve VB N
the DT N
long JJ N
term NN N
outcome NN N
. . N

-DOCSTART- -19217236- O O

Using VBG N
a DT N
laryngeal JJ i
tube NN i
suction-device NN i
( ( i
LTS-D NNP i
) ) i
reduces VBZ N
the DT N
no DT o
flow JJ o
time NN o
in IN N
a DT N
single JJ N
rescuer NN N
manikin NN N
study NN N
. . N

BACKGROUND NNP N
In IN N
2005 CD N
, , N
the DT N
European JJ N
Resuscitation NNP N
Council NNP N
and CC N
the DT N
American NNP N
Heart NNP N
Association NNP N
published VBD N
new JJ N
guidelines NNS N
for IN N
Advanced NNP N
Life NNP N
Support NNP N
. . N

One CD N
of IN N
the DT N
points NNS N
was VBD N
to TO N
reduce VB N
the DT N
time NN o
without IN o
chest JJS o
compressions NNS o
in IN N
the DT N
first JJ N
phase NN N
of IN N
cardiac JJ N
arrest NN N
. . N

OBJECTIVE IN N
We PRP N
evaluated VBD N
in IN N
a DT N
manikin JJ N
model NN N
whether IN N
using VBG N
the DT N
single-use JJ i
laryngeal NN i
tube NN i
with IN i
suction NN i
option NN i
( ( i
LTS-D NNP i
) ) i
instead RB i
of IN N
endotracheal JJ i
intubation NN i
( ( i
ET NNP i
) ) i
and CC i
bag-mask-valve JJ i
ventilation NN i
( ( i
BMV NNP i
) ) i
for IN i
emergency NN i
airway NN i
management NN i
could MD i
reduce VB N
the DT N
no-flow JJ o
time NN o
( ( o
NFT NNP o
) ) o
. . N

The DT N
NFT NNP N
is VBZ N
defined VBN N
as IN N
the DT N
time NN N
during IN N
resuscitation NN N
when WRB N
no DT N
chest NN N
compressions NNS N
take VBP N
place NN N
. . N

METHODS CC N
A DT N
randomized JJ p
, , p
prospective JJ p
study NN p
was VBD p
undertaken VBN p
with IN p
150 CD p
volunteers NNS p
who WP p
performed VBD p
management NN p
of IN p
a DT p
standardized JJ p
simulated JJ p
cardiac NN p
arrest NN p
in IN p
a DT p
manikin NN p
. . p

Every DT N
participant NN N
was VBD N
randomized VBN N
to TO N
one CD N
of IN N
three CD N
different JJ N
airway RB N
management NN N
groups NNS N
( ( N
LTS-D JJ N
vs NN N
. . N

ET NNP N
vs. IN N
BMV NNP N
) ) N
. . N

RESULTS VB N
The DT N
LTS-D NNP i
was VBD N
inserted VBN N
significantly RB N
faster RBR N
than IN N
the DT N
ET NNP N
tube NN N
( ( N
15 CD N
s NN N
vs. FW N
44 CD N
s NN N
, , N
respectively RB N
, , N
p JJ N
< NNP N
0.01 CD N
) ) N
. . N

During IN N
the DT N
cardiac JJ N
arrest NN N
simulation NN N
, , N
establishing VBG o
and CC o
performing VBG o
ventilation NN o
took VBD N
an DT N
average NN N
of IN N
57 CD N
s NN N
with IN N
the DT N
LTS-D NNP i
compared VBN N
to TO N
116 CD N
s NN N
with IN N
ET NNP i
and CC N
111 CD N
s NN N
with IN N
the DT N
BMV NNP i
. . i

Using VBG N
the DT N
LTS-D NNP i
significantly RB N
reduced VBD N
NFT NNP o
compared VBN N
to TO N
ET NNP i
and CC N
the DT N
BMV NNP i
( ( N
125 CD N
s NN N
vs. FW N
207 CD N
s NN N
vs. FW N
160 CD N
s NN N
; : N
p CC N
< VB N
0.01 CD N
) ) N
. . N

CONCLUSIONS NN N
In IN N
our PRP$ N
manikin NN N
study NN N
, , N
NFT NNP o
was VBD N
reduced VBN N
significantly RB N
when WRB N
the DT N
LTS-D NNP i
was VBD N
used VBN N
when WRB N
compared VBN N
to TO N
ET NNP i
and CC i
BMV NNP i
. . i

The DT N
results NNS N
of IN N
our PRP$ N
manikin NN N
study NN N
suggest VBP N
that IN N
for IN N
personnel NNS N
not RB N
experienced VBN N
in IN N
tracheal JJ N
intubation NN N
, , N
the DT N
LTS-D NNP i
offers VBZ N
a DT N
good JJ N
alternative NN N
to TO N
ET NNP i
and CC N
BMV NNP i
to TO N
manage VB N
the DT N
airway NN N
during IN N
resuscitation NN N
, , N
and CC N
to TO N
avoid VB N
the DT N
failure NN N
to TO N
achieve VB N
tracheal JJ N
intubation NN N
with IN N
the DT N
ET NNP i
, , N
and CC N
the DT N
failure NN N
to TO N
achieve VB N
adequate JJ N
ventilation NN N
with IN N
the DT N
BMV NNP i
. . i

-DOCSTART- -12238830- O O

Combination NN N
of IN N
sotalol NN i
and CC i
magnesium NN i
prevents NNS N
atrial JJ p
fibrillation NN p
after IN p
coronary JJ p
artery NN p
bypass NN p
grafting NN p
. . N

BACKGROUND NNP N
Atrial NNP N
fibrillation NN N
( ( N
AF NNP N
) ) N
is VBZ N
a DT N
common JJ N
complication NN N
reported VBD N
in IN N
20 CD N
% NN N
to TO N
40 CD N
% NN N
of IN N
patients NNS p
after IN p
coronary JJ p
operations NNS p
. . p

Sotalol NNP i
alone RB i
and CC N
magnesium VB i
alone RB i
have VBP N
been VBN N
shown VBN N
to TO N
partially RB N
decrease VB N
the DT N
incidence NN N
of IN N
AF NNP N
. . N

The DT N
goal NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
efficacy NN N
of IN N
these DT N
two CD N
pharmacological JJ N
agents NNS N
, , N
used VBD N
alone RB i
or CC i
in IN i
combination NN i
, , N
to TO N
reduce VB N
postoperative JJ o
AF NNP o
. . o

METHODS NNP N
Two CD p
hundred VBD p
seven CD p
consecutive JJ p
coronary JJ p
artery NN p
bypass NN p
patients NNS p
( ( p
mean JJ p
age NN p
62 CD p
+/- JJ p
11 CD p
years NNS p
) ) p
were VBD N
randomized VBN N
to TO N
receive VB N
sotalol NN i
alone RB i
( ( N
80 CD N
mg NN N
twice RB N
daily RB N
for IN N
5 CD N
days NNS N
starting VBG N
from IN N
the DT N
morning NN N
of IN N
the DT N
first JJ N
postoperative JJ N
day NN N
) ) N
( ( N
group NN N
S NNP N
) ) N
, , N
magnesium NN i
alone RB i
( ( N
1.5 CD N
g NNS N
daily RB N
for IN N
6 CD N
days NNS N
starting VBG N
in IN N
the DT N
operating NN N
room NN N
just RB N
before IN N
cardiopulmonary JJ N
bypass NN N
) ) N
( ( N
group NN N
M NNP N
) ) N
, , N
both DT i
pharmacologic JJ i
agents NNS i
at IN i
the DT i
same JJ i
dosages NNS i
( ( N
group NN N
S+M NNP N
) ) N
, , N
or CC i
no DT i
antiarrhythmic JJ i
agents NNS i
( ( N
group NN N
CTR NNP N
) ) N
. . N

All DT p
patients NNS p
with IN p
an DT p
ejection NN p
fraction NN p
less JJR p
than IN p
0.40 CD p
were VBD p
excluded VBN p
. . p

RESULTS VB N
The DT N
incidence NN o
of IN o
postoperative JJ o
AF NNP o
was VBD N
11.8 CD N
% NN N
( ( N
6/51 CD N
) ) N
in IN N
the DT N
S NNP N
group NN N
, , N
14.8 CD N
% NN N
( ( N
8/54 CD N
) ) N
in IN N
the DT N
M NNP N
group NN N
, , N
1.9 CD N
% NN N
( ( N
1/52 CD N
) ) N
in IN N
the DT N
S+M NNP N
group NN N
, , N
and CC N
38 CD N
% NN N
( ( N
19/50 CD N
) ) N
in IN N
the DT N
CTR NNP N
group NN N
. . N

The DT N
following JJ N
differences NNS N
were VBD N
significant JJ N
: : N
group NN N
CTR NNP N
versus NN N
groups NNS N
S NNP N
, , N
M NNP N
, , N
and CC N
S+M NNP N
with IN N
values NNS N
of IN N
p NN N
= NN N
0.002 CD N
, , N
p NN N
= VBD N
0.007 CD N
and CC N
p VB N
< JJ N
0.0001 CD N
, , N
respectively RB N
; : N
and CC N
group NN N
S+M NNP N
versus NN N
groups NNS N
S NNP N
and CC N
M NNP N
with IN N
p JJ N
= $ N
0.04 CD N
and CC N
p VB N
= JJ N
0.01 CD N
, , N
respectively RB N
. . N

CONCLUSIONS NNP N
Incidence NNP o
of IN o
AF NNP o
after IN N
coronary JJ N
operation NN N
was VBD N
significantly RB N
reduced VBN N
by IN N
the DT N
administration NN N
of IN N
sotalol JJ i
alone NN N
and CC N
magnesium NN i
alone RB N
; : N
more RBR N
importantly RB N
, , N
the DT N
incidence NN N
was VBD N
further RBR N
reduced VBN N
by IN N
combining VBG N
these DT N
agents NNS N
. . N

-DOCSTART- -23045537- O O

Patient JJ i
navigation NN i
improves VBZ N
cancer NN N
diagnostic JJ N
resolution NN N
: : N
an DT N
individually RB N
randomized JJ N
clinical JJ N
trial NN N
in IN N
an DT N
underserved JJ p
population NN p
. . p

BACKGROUND NNP N
Barriers NNPS N
to TO N
timely JJ N
resolution NN N
of IN N
abnormal JJ N
cancer NN N
screening VBG N
tests NNS N
add VBP N
to TO N
cancer NN N
health NN N
disparities NNS N
among IN N
low-income JJ p
, , p
uninsured JJ p
, , p
and CC p
minority NN p
populations NNS p
. . p

We PRP N
conducted VBD N
a DT N
randomized JJ N
trial NN N
to TO N
evaluate VB N
the DT N
impact NN N
of IN N
lay NN i
patient NN i
navigators NNS i
on IN N
time NN N
to TO N
resolution NN N
and CC N
completion NN N
of IN N
follow-up JJ N
testing NN N
among IN N
patients NNS p
with IN p
abnormal JJ p
screening VBG p
tests NNS p
in IN p
a DT p
medically RB p
underserved JJ p
patient JJ p
population NN p
. . p

METHODS NNP N
Denver NNP p
Health NNP p
, , p
the DT p
safety-net JJ p
health NN p
care NN p
system NN p
serving VBG p
Denver NNP p
, , p
is VBZ p
one CD p
of IN p
10 CD p
performance NN p
sites NNS p
participating VBG p
in IN p
the DT p
Patient NNP p
Navigation NNP p
Research NNP p
Program NNP p
. . p

Of IN N
993 CD p
eligible JJ p
subjects NNS p
with IN p
abnormal JJ p
screening VBG p
tests NNS p
randomized VBD p
to TO p
navigation NN i
and CC i
no-navigation NN i
( ( i
control NN i
) ) i
arms NNS p
and CC p
analyzed VBD p
, , p
628 CD p
had VBD p
abnormal JJ p
breast NN p
screens NNS p
( ( p
66 CD p
abnormal RB p
clinical JJ p
breast NN p
examinations NNS p
, , p
304 CD p
BIRADS NNP p
0 CD p
, , p
200 CD p
BIRADS NNP p
3 CD p
, , p
58 CD p
BIRADS NNP p
4 CD p
or CC p
5 CD p
) ) p
whereas VBD p
235 CD p
had VBD p
abnormal JJ p
colorectal NN p
and CC p
130 CD p
had VBD p
abnormal JJ p
prostate NN p
screens NNS p
. . p

RESULTS JJ N
Time NNP o
to TO o
resolution NN o
was VBD N
significantly RB N
shorter JJR N
in IN N
the DT N
navigated JJ N
group NN N
( ( N
stratified VBN N
log NN N
rank NN N
test NN N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

Patient JJ i
navigation NN i
improved VBD N
diagnostic JJ o
resolution NN o
for IN N
patients NNS N
presenting VBG N
with IN N
mammographic JJ N
BIRADS NNP N
3 CD N
( ( N
P NNP N
= NNP N
0.0003 CD N
) ) N
and CC N
BIRADS $ N
0 CD N
( ( N
P NNP N
= NNP N
0.09 CD N
) ) N
, , N
but CC N
not RB N
BIRADS NNP N
4/5 CD N
or CC N
abnormal JJ N
breast NN N
examinations NNS N
. . N

Navigation NNP N
shortened VBD N
the DT N
time NN N
for IN N
both DT N
colorectal JJ o
( ( N
P NNP N
= NNP N
0.0017 CD N
) ) N
and CC N
prostate VB o
screening VBG o
resolution NN o
( ( N
P NNP N
= NNP N
0.06 CD N
) ) N
. . N

Participant JJ p
demographics NNS p
included VBD p
72 CD p
% NN p
minority NN p
, , p
49 CD p
% NN p
with IN p
annual JJ p
household JJ p
income NN p
less JJR p
than IN p
$ $ p
10,000 CD p
, , p
and CC p
36 CD p
% NN p
uninsured JJ p
. . p

CONCLUSIONS NNP N
Patient NNP i
navigation NN i
positively RB N
impacts VBZ N
time NN N
to TO N
resolution NN o
of IN N
abnormal JJ N
screening NN N
tests NNS N
for IN N
breast NN N
, , N
colorectal NN N
, , N
and CC N
prostate NN N
cancers NNS N
in IN N
a DT N
medically RB p
underserved JJ p
population NN p
. . p

IMPACT NNP N
By IN N
shortening VBG N
the DT N
time NN N
to TO N
and CC N
increasing VBG N
the DT N
proportion NN N
of IN N
patients NNS N
with IN N
diagnostic JJ N
resolution NN N
patient NN N
navigation NN N
could MD N
reduce VB N
disparities NNS N
in IN N
stage NN N
at IN N
diagnosis NN N
and CC N
improve VB N
cancer NN N
outcomes NNS N
. . N

-DOCSTART- -16212446- O O

Intensive JJ i
behavioral JJ i
treatment NN i
for IN N
children NNS p
with IN p
autism NN o
: : o
four-year JJ N
outcome NN N
and CC N
predictors NNS N
. . N

Twenty-four JJ p
children NNS p
with IN p
autism NN p
were VBD N
randomly RB N
assigned VBN p
to TO p
a DT p
clinic-directed JJ i
group NN i
, , N
replicating VBG N
the DT N
parameters NNS N
of IN N
the DT N
early JJ i
intensive JJ i
behavioral JJ i
treatment NN i
developed VBD i
at IN i
UCLA NNP i
, , i
or CC i
to TO i
a DT i
parent-directed JJ i
group NN i
that WDT i
received VBD i
intensive JJ i
hours NNS i
but CC i
less JJR i
supervision NN i
by IN i
equally RB i
well-trained JJ i
supervisors NNS i
. . i

Outcome NNP N
after IN N
4 CD N
years NNS N
of IN N
treatment NN N
, , N
including VBG N
cognitive JJ o
, , o
language NN o
, , o
adaptive JJ o
, , o
social JJ o
, , o
and CC o
academic JJ o
measures NNS o
, , N
was VBD N
similar JJ N
for IN N
both DT N
groups NNS N
. . N

After IN N
combining VBG N
groups NNS N
, , N
we PRP N
found VBD N
that IN N
48 CD N
% NN N
of IN N
all DT N
children NNS N
showed VBD N
rapid JJ o
learning NN o
, , N
achieved VBN N
average JJ o
posttreatment JJ o
scores NNS o
, , N
and CC N
at IN N
age NN N
7 CD N
, , N
were VBD N
succeeding VBG N
in IN N
regular JJ N
education NN N
classrooms NNS N
. . N

Treatment NNP N
outcome NN N
was VBD N
best RB N
predicted VBN N
by IN N
pretreatment JJ o
imitation NN o
, , o
language NN o
, , o
and CC o
social JJ o
responsiveness NN o
. . o

These DT N
results NNS N
are VBP N
consistent JJ N
with IN N
those DT N
reported VBN N
by IN N
Lovaas NNP N
and CC N
colleagues NNS N
( ( N
Lovaas NNP N
, , N
1987 CD N
; : N
McEachin NNP N
, , N
Smith NNP N
, , N
& CC N
Lovaas NNP N
, , N
1993 CD N
) ) N
. . N

-DOCSTART- -8748041- O O

Risperidone NN i
in IN N
the DT N
treatment NN N
of IN N
negative JJ o
symptoms NNS o
of IN N
schizophrenia NN p
: : p
a DT N
meta-analysis NN N
. . N

Risperidone NN i
has VBZ N
antiserotonergic VBN N
and CC N
antidopaminergic JJ N
properties NNS N
that WDT N
may MD N
make VB N
it PRP N
more RBR N
effective JJ N
than IN N
conventional JJ N
antipsychotic JJ N
agents NNS N
in IN N
the DT N
treatment NN N
of IN N
the DT N
negative JJ o
symptoms NNS o
of IN N
schizophrenia NN p
. . p

Clinical JJ N
trials NNS N
in IN N
chronic JJ p
schizophrenic JJ p
patients NNS p
have VBP N
shown VBN N
trends NNS N
in IN N
favor NN N
of IN N
risperidone NN i
in IN N
the DT N
control NN N
of IN N
negative JJ o
symptoms NNS o
compared VBN N
with IN N
haloperidol NN i
, , i
perphenazine NN i
or CC i
zuclopenthixol NN i
, , N
but CC N
the DT N
differences NNS N
were VBD N
not RB N
consistently RB N
statistically RB N
significant JJ N
. . N

A DT N
meta-analysis NN N
of IN N
the DT N
pooled JJ N
results NNS N
from IN N
six CD p
double-blind JJ p
trials NNS p
showed VBD N
that IN N
risperidone NN i
at IN N
doses NNS N
ranging VBG N
from IN N
4 CD N
to TO N
8 CD N
mg/day NN N
had VBD N
a DT N
significantly RB N
( ( N
p JJ N
< NNP N
0.004 CD N
) ) N
higher JJR N
negative JJ o
symptom JJ o
response NN o
rate NN o
, , N
defined VBN N
as IN N
the DT N
percentage NN N
of IN N
patients NNS N
with IN N
a DT N
20 CD N
% NN N
or CC N
more JJR o
reduction NN o
in IN o
scores NNS o
on IN o
the DT o
negative JJ o
subscale NN o
of IN o
the DT o
Positive NNP o
and CC o
Negative NNP o
Syndrome NNP o
Scale NNP o
, , N
than IN N
patients NNS N
receiving VBG N
active JJ N
controls NNS N
. . N

The DT N
combined JJ p
patient JJ p
population NN p
treated VBN N
with IN N
4-8 JJ N
mg/day NN N
of IN N
risperidone NN i
was VBD N
1.43 CD N
times NNS N
more RBR N
likely JJ N
to TO N
have VB N
had VBN N
a DT N
clinical JJ o
response NN o
on IN o
the DT o
negative JJ o
symptom NN o
subscale NN o
than IN N
the DT N
combined JJ N
population NN N
treated VBN N
with IN N
haloperidol NN i
, , i
perphenazine NN i
or CC i
zuclopenthixol NN i
. . i

-DOCSTART- -8018108- O O

Endurance NNP i
physical JJ i
activity NN i
, , i
diet JJ i
and CC N
fibrinolysis NN N
. . N

The DT N
impact NN N
of IN N
long-term JJ i
, , i
heavy JJ i
exercise NN i
on IN N
recently RB N
established VBN N
cardiovascular/thromboembolic JJ N
risk NN N
factors NNS N
of IN N
the DT N
fibrinolytic JJ N
system NN N
, , N
tissue NN N
plasminogen NN N
activator NN N
( ( N
tPA NN N
) ) N
and CC N
plasminogen NN N
activator NN N
inhibitor NN N
( ( N
PAI-1 NNP N
) ) N
in IN N
relation NN N
to TO N
food NN N
composition NN N
was VBD N
studied VBN N
. . N

Twenty NNP p
healthy JJ p
men NNS p
, , p
aged VBN p
18-55 CD p
years NNS p
participated VBN N
in IN N
a DT N
14-day JJ i
skiing NN i
tour NN i
through IN i
the DT i
Swedish JJ i
mountains NNS i
, , i
carrying VBG i
a DT i
pack NN i
load NN i
of IN i
30 CD i
kg NNS i
, , i
and CC i
spending VBG i
each DT i
night NN i
in IN i
self-dug JJ i
igloos NN i
( ( i
ambient JJ i
temp NN i
-10 NN i
degrees NNS i
to TO i
-25 VB i
degrees NNS i
C NNP i
) ) i
, , i
and CC i
were VBD i
randomized VBN i
to TO i
2 CD i
food NN i
regimens NNS i
having VBG i
30 CD i
or CC i
40 CD i
energy NN i
percent NN i
of IN i
fat NN i
. . i

Individual JJ i
records NNS i
were VBD i
kept VBN i
of IN i
all DT i
consumed VBN i
food NN i
. . i

Citrated VBD o
plasma NN o
was VBD i
obtained VBN i
before IN i
and CC i
after IN i
1 CD i
and CC i
2 CD i
weeks NNS i
of IN i
exercise NN i
: : i
tPA NN o
release NN o
was VBD i
assessed VBN i
by IN i
a DT i
10 CD i
min NN i
venous JJ i
occlusion NN i
( ( i
VO NNP i
) ) i
test NN i
. . i

At IN N
baseline NN N
, , N
daily JJ o
dietary JJ o
fiber NN o
intake NN o
correlated VBD N
negatively RB N
with IN N
PAI-1 NNP N
activity NN N
. . N

Already RB N
after IN N
the DT N
first JJ N
week NN N
of IN N
the DT N
skiing VBG N
tour NN N
there EX N
were VBD N
significant JJ N
drops NNS N
in IN N
PAI-1 NNP o
activities NNS o
, , o
cholesterol NN o
and CC o
triglycerides NNS o
. . o

The DT N
tPA JJ o
mass NN o
concentrations NNS o
also RB N
dropped VBD N
, , N
both DT N
before IN N
and CC N
after IN N
VO NNP N
, , N
but CC N
tPA JJ o
activities NNS o
were VBD N
unchanged JJ N
, , N
as IN N
were VBD N
von JJ o
Willebrand NNP o
factor NN o
( ( o
vWF NN o
) ) o
levels NNS o
. . o

These DT N
changes NNS N
were VBD N
related VBN N
mainly RB N
to TO N
the DT N
expenditure NN N
of IN N
energy NN N
, , N
calculated VBN N
from IN N
the DT N
food NN N
consumption NN N
, , N
and CC N
appeared VBD N
to TO N
be VB N
mediated VBN N
through IN N
changed VBN N
insulin NN N
sensitivity NN N
and CC N
decreased VBD N
body NN N
fat JJ N
mass NN N
. . N

The DT N
energy NN N
percent NN N
of IN N
fat NN N
in IN N
the DT N
food NN N
had VBD N
no DT N
differential JJ N
impact NN N
. . N

The DT N
effects NNS N
receded VBD N
a DT N
few JJ N
weeks NNS N
after IN N
cessation NN N
of IN N
the DT N
endurance NN N
exercise NN N
. . N

Thus RB N
, , N
endurance JJ i
physical JJ i
activity NN i
improves VBZ N
the DT N
fibrinolytic JJ N
risk NN N
factor NN N
profile NN N
by IN N
reducing VBG N
PAI-1 NNP N
while IN N
leaving VBG N
tPA JJ o
activity NN N
unaffected VBD N
, , N
independently RB N
of IN N
food NN N
composition NN N
. . N

A DT N
low JJ N
dietary JJ N
fiber NN N
intake NN N
appears VBZ N
to TO N
be VB N
associated VBN N
with IN N
higher JJR N
PAI-1 NN o
activities NNS o
at IN N
baseline NN N
. . N

-DOCSTART- -1833682- O O

Desogestrel NNP N
and CC N
gestodene NN N
in IN N
oral JJ N
contraceptives NNS N
: : N
12 CD N
months NNS N
' POS N
assessment NN N
of IN N
carbohydrate NN o
and CC o
lipoprotein JJ o
metabolism NN o
. . o

We PRP N
examined VBD N
the DT N
influence NN N
on IN N
carbohydrate NN N
and CC N
lipoprotein JJ N
metabolism NN N
of IN N
oral JJ i
contraceptives NNS i
( ( i
OCs NNP i
) ) i
containing VBG N
two CD N
new JJ N
third-generation NN N
progestogens NNS i
, , i
desogestrel NN i
and CC i
gestodene NN i
. . N

This DT N
was VBD N
a DT N
prospective JJ N
randomized NN N
study NN N
in IN N
which WDT N
monophasic JJ N
combinations NNS N
of IN N
20 CD i
micrograms NNS i
ethinyl VBP i
estradiol NN i
( ( i
E2 NNP i
) ) i
and CC N
150 CD i
micrograms NNS i
desogestrel VBD i
or CC N
30 CD N
micrograms NNS N
ethinyl VBP i
E2 NNP i
plus CC i
75 CD i
micrograms NNS i
gestodene VBP i
were VBD N
administered VBN N
to TO N
15 CD p
and CC p
19 CD p
healthy JJ p
women NNS p
, , p
respectively RB p
. . p

An DT N
oral JJ o
glucose NN o
tolerance NN o
test NN o
including VBG N
measurement NN N
of IN N
insulin NN N
response NN N
was VBD N
performed VBN N
before IN N
treatment NN N
and CC N
after IN N
3 CD N
, , N
6 CD N
, , N
and CC N
12 CD N
months NNS N
of IN N
treatment NN N
. . N

We PRP N
also RB N
determined VBD N
fasting VBG o
plasma JJ o
concentrations NNS o
of IN o
total JJ o
cholesterol NN o
; : o
high-density JJ o
lipoprotein NN o
cholesterol NN o
, , o
including VBG o
the DT o
subfractions NNS o
high-density NN o
lipoprotein2 NN o
cholesterol NN o
and CC o
high-density NN o
lipoprotein3 NN o
cholesterol NN o
; : o
low-density JJ o
lipoprotein NN o
cholesterol NN o
; : o
very RB o
low-density NN o
lipoprotein NN o
cholesterol NN o
; : o
and CC o
triglycerides NNS o
. . o

A DT N
transient JJ o
deterioration NN o
of IN o
glucose JJ o
tolerance NN o
was VBD N
observed VBN N
despite IN N
unchanged JJ N
levels NNS N
of IN N
insulin NN o
after IN N
treatment NN N
with IN N
both DT N
compounds NNS N
for IN N
3 CD N
months NNS N
. . N

In IN N
both DT N
groups NNS N
plasma VBP o
levels NNS o
of IN o
triglycerides NNS o
, , o
very RB o
low-density JJ o
lipoprotein NN o
cholesterol NN o
, , o
and CC o
high-density NN o
lipoprotein NN o
cholesterol NN o
increased VBD o
significantly RB N
after IN N
3 CD N
months NNS N
. . N

After IN N
12 CD N
months NNS N
, , N
a DT N
significant JJ N
increase NN N
in IN N
the DT N
high-density NN o
lipoprotein NN o
cholesterol/total JJ o
cholesterol NN o
ratio NN o
was VBD N
observed VBN N
in IN N
the DT N
ethinyl JJ N
E2-desogestrel NNP N
group NN N
, , N
and CC N
no DT N
persistent JJ N
changes NNS N
in IN N
low-density NN o
lipoprotein NN o
cholesterol NN o
could MD N
be VB N
demonstrated VBN N
in IN N
any DT N
of IN N
the DT N
groups NNS N
. . N

Our PRP$ N
results NNS N
indicate VBP N
that IN N
treatment NN N
with IN N
either DT N
compound NN N
for IN N
12 CD N
months NNS N
has VBZ N
no DT N
effect NN N
on IN N
carbohydrate NN o
or CC o
lipoprotein JJ o
metabolism NN o
known VBN N
to TO N
increase VB N
the DT N
risk NN N
of IN N
cardiovascular JJ N
disease NN N
. . N

-DOCSTART- -22374696- O O

The DT N
FLT3ITD NNP i
mRNA NN i
level NN i
has VBZ N
a DT N
high JJ N
prognostic JJ N
impact NN N
in IN N
NPM1 NNP p
mutated VBD p
, , p
but CC p
not RB p
in IN p
NPM1 NNP p
unmutated VBD p
, , p
AML NNP p
with IN p
a DT p
normal JJ p
karyotype NN p
. . p

The DT N
impact NN N
of IN N
a DT N
FLT3-internal JJ N
tandem NN N
duplication NN N
( ( N
FLT3ITD NNP N
) ) N
on IN N
prognosis NN N
of IN N
patients NNS p
with IN p
acute JJ p
myeloid NN p
leukemia NN p
( ( p
AML NNP p
) ) p
is VBZ N
dependent JJ N
on IN N
the DT N
ratio NN N
of IN N
mutated VBN N
to TO N
wild-type JJ N
allele NN N
. . N

In IN N
648 CD p
normal JJ p
karyotype NN p
( ( p
NK NNP p
) ) p
AML NNP p
patients NNS p
, , N
we PRP N
found VBD N
a DT N
significant JJ N
independent JJ N
effect NN N
of IN N
the DT N
quantitative JJ o
FLT3ITD NNP o
mRNA NN o
level NN o
-- : o
measured VBN o
as IN N
( ( i
FLT3ITD/wtFLT3 NNP i
) ) i
/ NN i
( ( i
FLT3ITD/wtFLT3+1 NNP i
) ) i
-- : i
on IN i
outcome NN N
. . N

Moreover RB N
, , N
this DT N
effect NN N
was VBD N
clearly RB N
seen VBN N
in IN N
329 CD p
patients NNS p
with IN p
a DT p
mutated VBN p
NPM1 NNP p
gene NN p
( ( p
NPM1+ NNP p
) ) p
, , N
but CC N
not RB N
in IN N
319 CD p
patients NNS p
without IN p
a DT p
NPM1 NNP p
mutation NN p
( ( p
wtNPM1 NN p
) ) p
. . p

In IN N
a DT N
multivariate NN N
Cox NNP N
regression NN N
model NN N
, , N
the DT N
quantitative JJ N
FLT3ITD NNP i
mRNA NN N
level NN N
showed VBD N
an DT N
independent JJ N
prognostic JJ N
impact NN N
on IN N
overall JJ o
survival NN o
( ( N
OS NNP N
) ) N
and CC N
relapse-free JJ o
survival NN o
( ( N
RFS NNP N
) ) N
only RB N
in IN N
the DT N
NPM1+ NNP p
subgroup NN p
( ( N
OS NNP N
: : N
hazard NN N
ratio NN N
, , N
5.9 CD N
; : N
[ CC N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NN N
: : N
3.1-11.2 JJ N
] NN N
; : N
RFS NNP N
: : N
hazard NN N
ratio NN N
, , N
7.5 CD N
[ JJ N
95 CD N
% NN N
CI NNP N
: : N
3.4-16.5 JJ N
] NN N
) ) N
. . N

The DT N
FLT3ITD NNP i
mRNA MD N
level VB N
contributes NNS N
to TO N
relapse VB N
risk NN N
stratification NN N
and CC N
might MD N
help VB N
to TO N
guide VB N
postremission NN N
therapy NN N
in IN N
NPM1-mutated JJ p
AML NNP p
. . p

-DOCSTART- -18581595- O O

Effects NNS N
of IN N
supervised JJ i
exercise NN i
therapy NN i
in IN N
patients NNS p
receiving VBG p
radiotherapy NN i
for IN p
breast NN p
cancer NN p
. . p

PURPOSE NNP N
Postoperative NNP p
radiotherapy NN i
for IN p
breast NN p
cancer NN p
has VBZ N
a DT N
number NN N
of IN N
associated JJ N
complications NNS N
. . N

This DT N
study NN N
examined VBD N
whether IN N
supervised VBN N
moderate-intensity NN i
exercise NN i
could MD N
mitigate VB N
the DT N
complications NNS N
that WDT N
occur VBP N
during IN N
radiotherapy NN i
. . i

PATIENTS NNP N
AND CC N
METHODS NNP N
Forty NNP p
women NNS p
were VBD p
randomized VBN p
before IN p
radiotherapy NN i
after IN N
various JJ N
operations NNS N
for IN N
breast NN N
cancer NN N
. . N

Seventeen JJ p
patients NNS p
who WP N
were VBD N
assigned VBN N
to TO N
the DT N
exercise NN i
group NN i
performed VBD N
supervised VBN i
moderate-intensity NN i
exercise NN i
therapy NN i
for IN N
50 CD N
min NN N
3 CD N
times NNS N
per IN N
week NN N
for IN N
5 CD N
weeks NNS N
. . N

Twenty-three JJ p
patients NNS p
in IN N
the DT N
control NN i
group NN i
were VBD N
asked VBN N
to TO N
perform VB i
self-shoulder JJ i
stretching VBG i
exercise NN i
. . i

The DT N
World NNP o
Health NNP o
Organization NNP o
Quality NNP o
of IN o
Life-BREF NNP o
( ( o
WHOQOL-BREF NNP o
) ) o
, , o
brief JJ o
fatigue JJ o
inventory NN o
( ( o
BFI NNP o
) ) o
, , o
range NN o
of IN o
motion NN o
( ( o
ROM NNP o
) ) o
of IN o
the DT o
shoulder NN o
, , o
and CC o
pain NN o
score NN o
were VBD N
assessed VBN N
before IN N
and CC N
after IN N
radiotherapy NN i
. . i

RESULTS CC N
There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
noted VBD N
at IN N
baseline NN N
between IN N
groups NNS N
. . N

In IN N
the DT N
exercise NN p
group NN p
, , N
there EX N
was VBD N
an DT N
increase NN N
in IN N
the DT N
WHOQOL-BREF NNP o
and CC o
shoulder NN o
ROM NNP o
and CC N
decrease NN o
in IN o
BFI NNP o
and CC o
pain NN o
score NN o
after IN N
radiotherapy NN i
. . i

On IN N
the DT N
other JJ N
hand NN N
, , N
patients NNS p
in IN N
the DT N
control NN i
group NN p
showed VBD N
decrease NN N
in IN N
the DT N
WHOQOL-BREF NNP o
and CC o
shoulder NN o
ROM NNP o
and CC N
increase VB o
in IN o
BFI NNP o
and CC o
pain NN o
score NN o
after IN N
radiotherapy NN i
. . i

There EX N
were VBD N
statistically RB N
significant JJ N
differences NNS N
in IN N
the DT N
changes NNS N
in IN N
the DT N
WHOQOL NNP o
, , o
BFI NNP o
, , o
shoulder NN o
ROM NNP o
, , o
and CC o
pain VB o
score NN o
between IN N
the DT N
groups NNS p
. . p

CONCLUSION NNP N
Patients NNPS p
receiving VBG p
radiotherapy NN i
for IN p
breast NN p
cancer NN p
may MD N
benefit VB N
in IN N
physical JJ N
and CC N
psychological JJ N
aspects NNS N
from IN N
supervised VBN i
moderate-intensity NN i
exercise NN i
therapy NN i
. . i

-DOCSTART- -1530836- O O

A DT N
comparison NN N
of IN N
the DT N
effects NNS N
of IN N
anticholinergic NN i
and CC i
beta VB i
2-agonist JJ i
and CC i
combination NN i
therapy NN i
on IN N
respiratory NN N
impedance NN N
in IN N
COPD NNP p
. . p

The DT N
effects NNS N
of IN N
three CD N
different JJ N
regimens NNS N
of IN N
inhaled JJ i
bronchodilators NNS i
on IN N
spirometry NN N
and CC N
respiratory JJ N
impedance NN N
as IN N
measured VBN N
with IN N
the DT N
technique NN N
of IN N
forced JJ N
oscillations NNS N
were VBD N
compared VBN N
in IN N
a DT N
double-blind JJ N
crossover NN N
study NN N
in IN N
22 CD p
patients NNS p
with IN p
stable JJ p
chronic JJ p
obstructive JJ p
pulmonary JJ p
disease NN p
( ( p
FEV1 NNP p
less JJR p
than IN p
70 CD p
percent NN p
predicted VBN p
) ) p
. . p

On IN N
three CD N
trial NN N
days NNS N
, , N
patients NNS N
inhaled VBD N
, , N
in IN N
random JJ N
order NN N
, , N
40 CD N
micrograms NNS N
ipratropium JJ i
bromide NN i
, , N
200 CD N
micrograms NNS N
fenoterol JJ i
hydrobromide NN i
, , N
or CC N
a DT i
combination NN i
of IN i
40 CD i
micrograms NNS i
ipratropium NN i
and CC i
100 CD i
micrograms NNS i
fenoterol VBP i
from IN N
a DT N
powder NN N
inhaler NN N
, , N
followed VBN N
by IN N
a DT N
second JJ N
dose NN N
of IN N
the DT N
same JJ N
drug NN N
after IN N
60 CD N
min NN N
. . N

The DT N
effects NNS N
were VBD N
measured VBN N
at IN N
baseline NN N
and CC N
20 CD N
, , N
40 CD N
, , N
60 CD N
, , N
and CC N
120 CD N
min NN N
after IN N
the DT N
first JJ N
inhalation NN N
. . N

No DT o
significant JJ o
decrease NN o
in IN o
total JJ o
respiratory NN o
resistance NN o
at IN o
8 CD o
Hz NNP o
( ( o
Rrs NNP o
[ VBZ o
8 CD o
] NN o
) ) o
was VBD o
observed VBN o
after IN o
ipratropium NN o
, , o
whereas JJ o
Rrs NNP o
( ( o
8 CD o
) ) o
decreased VBD o
significantly RB o
20 CD o
min NNS o
after IN o
fenoterol NN o
and CC o
40 CD o
min NN o
after IN o
the DT o
combination NN o
regimen NNS o
( ( o
p NN o
less JJR o
than IN o
0.05 CD o
) ) o
. . o

All DT o
three CD o
studied VBD o
drugs NNS o
resulted VBD o
in IN o
a DT o
significant JJ o
increase NN o
in IN o
the DT o
reactance NN o
( ( o
p NN o
less JJR o
than IN o
0.01 CD o
) ) o
and CC o
decrease NN o
in IN o
resonant JJ o
frequency NN o
. . o

Both DT o
fenoterol NN o
( ( o
delta JJ o
FEV1 NNP o
34 CD o
percent NN o
, , o
p NN o
less JJR o
than IN o
0.0001 CD o
) ) o
and CC o
the DT o
combination NN o
regimen NNS o
( ( o
delta JJ o
FEV1 NNP o
38 CD o
percent NN o
, , o
p NN o
less JJR o
than IN o
0.0001 CD o
) ) o
resulted VBD o
in IN o
a DT o
significantly RB o
larger JJR o
increase NN o
in IN o
FEV1 NNP o
than IN o
ipratropium NN o
alone RB o
( ( o
delta JJ o
FEV1 NNP o
17 CD o
percent NN o
, , o
p NN o
less JJR o
than IN o
0.0001 CD o
) ) o
. . o

A DT o
second JJ o
dose NN o
of IN o
fenoterol NN o
and CC o
of IN o
the DT o
combination NN o
regimen NNS o
resulted VBD o
in IN o
a DT o
further JJ o
significant JJ o
increase NN o
in IN o
FEV1 NNP o
after IN o
120 CD o
min NN o
( ( o
p NN o
less JJR o
than IN o
0.05 CD o
) ) o
. . o

A DT o
second JJ o
dose NN o
of IN o
ipratropium NN o
did VBD o
not RB o
result VB o
in IN o
a DT o
further JJ o
significant JJ o
increase NN o
in IN o
FEV1 NNP o
. . o

The DT N
changes NNS o
in IN o
respiratory NN o
impedance NN o
were VBD o
qualitatively RB o
similar JJ o
for IN o
all DT o
three CD o
drug NN o
regimens NNS o
, , o
but CC o
larger JJR o
in IN o
absolute NN o
terms NNS o
after IN o
fenoterol NN o
and CC o
the DT o
combination NN o
regimen NNS o
than IN o
after IN o
ipratropium NN o
. . o

The DT o
similar JJ o
effect NN o
of IN o
these DT o
drugs NNS o
on IN o
the DT o
reactance NN o
can MD o
be VB o
explained VBN o
by IN o
an DT o
increase NN o
in IN o
the DT o
capacitance NN o
of IN o
the DT o
respiratory NN o
system NN o
, , o
and CC o
in IN o
combination NN o
with IN o
a DT o
decrease NN o
in IN o
frequency NN o
dependence NN o
of IN o
resistance NN o
, , o
by IN o
assuming VBG o
a DT o
decrease NN o
in IN o
peripheral JJ o
airway NN o
resistance NN o
. . o

-DOCSTART- -7670096- O O

Results NNS N
of IN N
a DT N
phase NN N
I/II NNP N
trial NN N
of IN N
recombinant JJ i
human JJ i
granulocyte-macrophage NN i
colony-stimulating NN i
factor NN i
in IN N
very RB p
low JJ p
birthweight NN p
neonates NNS p
: : p
significant JJ N
induction NN N
of IN N
circulatory NN N
neutrophils NNS N
, , N
monocytes NNS N
, , N
platelets NNS N
, , N
and CC N
bone NN N
marrow NN N
neutrophils NNS N
. . N

Neonates NNS N
, , N
especially RB N
those DT p
of IN p
very RB p
low JJ p
birthweight NN p
( ( p
VLBW NNP p
) ) p
, , N
have VBP N
an DT N
increased VBN N
risk NN N
of IN N
nosocomial JJ N
infections NNS N
secondary JJ N
to TO N
deficiencies NNS N
in IN N
development NN N
. . N

We PRP N
previously RB N
demonstrated VBD N
that IN N
granulocyte-macrophage JJ N
colony-stimulating JJ N
factor NN N
( ( N
GM-CSF NNP N
) ) N
production NN N
and CC N
mRNA JJ N
expression NN N
from IN N
stimulated VBN N
neonatal JJ N
mononuclear JJ N
cells NNS N
are VBP N
significantly RB N
less JJR N
than IN N
that DT N
from IN N
adult NN N
cells NNS N
. . N

Recombinant JJ i
murine JJ i
GM-CSF NNP i
administration NN i
to TO N
neonatal JJ N
rats NNS N
has VBZ N
resulted VBN N
in IN N
neutrophilia JJ N
, , N
increased JJ N
neutrophil NN N
production NN N
, , N
and CC N
increased VBD N
survival NN N
of IN N
pups NNS N
during IN N
experimental JJ N
Staphylococcus NNP N
aureus NN N
sepsis NN N
. . N

In IN N
the DT N
present JJ N
study NN N
, , N
we PRP N
sought VBD N
to TO N
determine VB N
the DT N
safety NN N
and CC N
biologic JJ N
response NN N
of IN N
recombinant JJ i
human JJ i
( ( i
rhu NN i
) ) i
GM-CSF NNP i
in IN N
VLBW NNP N
neonates NNS N
. . N

Twenty NNP p
VLBW NNP p
neonates NNS p
( ( p
500 CD p
to TO p
1,500 CD p
g NN p
) ) p
, , p
aged VBD p
< JJ p
72 CD p
hours NNS p
, , p
were VBD p
randomized VBN p
to TO N
receive VB N
either DT N
placebo NN i
( ( N
n JJ N
= NNP N
5 CD N
) ) N
or CC N
rhuGM-CSF NN i
at IN N
5.0 CD N
micrograms/kg NN N
once RB N
per IN N
day NN N
( ( N
n JJ N
= NNP N
5 CD N
) ) N
, , N
5.0 CD N
micrograms/kg NN N
twice RB N
per IN N
day NN N
( ( N
n JJ N
= NNP N
5 CD N
) ) N
, , N
or CC N
10 CD N
micrograms/kg NN N
once RB N
per IN N
day NN N
( ( N
n JJ N
= NNP N
5 CD N
) ) N
given VBN N
via IN N
2-hour JJ N
intravenous JJ N
infusion NN N
for IN N
7 CD N
days NNS N
. . N

Complete JJ N
blood NN N
counts NNS N
, , N
differential NN N
, , N
and CC N
platelet NN N
counts NNS N
were VBD N
obtained VBN N
, , N
and CC N
tibial JJ N
bone NN N
marrow NN N
aspirate NN N
was VBD N
performed VBN N
on IN N
day NN N
8 CD N
. . N

Neutrophil NNP N
C3bi NNP N
receptor NN N
expression NN N
was VBD N
measured VBN N
at IN N
0 CD N
and CC N
24 CD N
hours NNS N
. . N

GM-CSF JJ o
levels NNS o
were VBD N
measured VBN N
by IN N
a DT N
sandwich JJ N
enzyme-linked JJ N
immunosorbent NN N
assay NN N
at IN N
2 CD N
, , N
4 CD N
, , N
6 CD N
, , N
12 CD N
, , N
and CC N
24 CD N
hours NNS N
after IN N
the DT N
first JJ N
dose NN N
of IN N
rhuGM-CSF NN i
. . i

At IN N
all DT N
doses NNS N
, , N
rhuGM-CSF NN i
was VBD N
well RB N
tolerated VBN N
, , N
and CC N
there EX N
was VBD N
no DT N
evidence NN N
of IN N
grade NN o
III NNP o
or CC o
IV NNP o
toxicity NN o
. . o

Within IN N
48 CD N
hours NNS N
of IN N
administration NN N
, , N
there EX N
was VBD N
a DT N
significant JJ N
increase NN N
in IN N
the DT N
circulating VBG o
absolute JJ o
neutrophil NN o
count NN o
( ( o
ANC NNP o
) ) o
at IN N
5.0 CD N
micrograms/kg NN N
twice RB N
per IN N
day NN N
and CC N
10.0 CD N
micrograms/kg NN N
once RB N
per IN N
day NN N
, , N
which WDT N
continued VBD N
for IN N
at IN N
least JJS N
24 CD N
hours NNS N
after IN N
discontinuation NN N
of IN N
rhuGM-CSF NN i
. . i

When WRB N
the DT N
ANC NNP N
was VBD N
normalized VBN N
for IN N
each DT N
patient NN N
's POS N
first JJ N
ANC NNP N
, , N
there EX N
was VBD N
a DT N
significant JJ N
increase NN N
in IN N
the DT N
ANC NNP o
on IN N
days NNS N
6 CD N
and CC N
7 CD N
at IN N
each DT N
dose JJ N
level NN N
. . N

By IN N
day NN N
7 CD N
, , N
all DT N
tested JJ N
doses NNS N
of IN N
rhuGM-CSF NN i
resulted VBD N
in IN N
an DT N
increase NN N
in IN N
the DT N
absolute NN o
monocyte NN o
count NN o
( ( o
AMC NNP o
) ) o
compared VBN N
with IN N
placebo-treated JJ N
neonates NNS N
. . N

In IN N
those DT N
receiving VBG N
rhuGM-CSF JJ i
5.0 CD N
micrograms/kg NN N
twice RB N
per IN N
day NN N
, , N
there EX N
was VBD N
additionally RB N
a DT N
significant JJ N
increase NN N
in IN N
the DT N
day NN o
7 CD o
and CC o
8 CD o
platelet NN o
count NN o
. . o

Tibial NNP N
bone NN N
marrow NN N
aspirates VBZ N
demonstrated VBD N
a DT N
significant JJ N
increase NN N
in IN N
the DT N
bone NN o
marrow NN o
neutrophil JJ o
storage NN o
pool NN o
( ( o
BM NNP o
NSP NNP o
) ) o
at IN N
5.0 CD N
micrograms/kg NN N
twice RB N
per IN N
day NN N
and CC N
10.0 CD N
micrograms/kg NN N
once RB N
per IN N
day NN N
. . N

Neutrophil NNP o
C3bi NNP o
receptor NN o
expression NN o
was VBD N
significantly RB N
increased VBN N
24 CD N
hours NNS N
after IN N
the DT N
first JJ N
dose NN N
of IN N
rhuGM-CSF NN i
at IN N
5.0 CD N
micrograms/kg NN N
once RB N
per IN N
day NN N
. . N

The DT N
elimination NN N
half-life NN N
( ( N
T1/2 NNP N
) ) N
of IN N
rhuGM-CSF NN N
was VBD N
1.4 CD N
+/- JJ N
0.8 CD N
to TO N
3.9 CD N
+/- JJ N
2.8 CD N
hours NNS N
. . N

( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
400 CD N
WORDS NNP N
) ) N
-DOCSTART- -24338168- O O

Low-dose JJ N
versus NN N
standard-dose JJ N
gemcitabine NN i
infusion NN i
and CC N
cisplatin NN i
for IN N
patients NNS p
with IN p
advanced JJ p
bladder NN p
cancer NN p
: : p
a DT N
randomized JJ N
phase NN N
II NNP N
trial-an NN N
update NN N
. . N

Prolonged JJ N
infusion NN N
of IN N
low-dose JJ N
gemcitabine NN i
and CC i
cisplatin NN i
( ( i
GC NNP i
) ) i
proved VBD N
to TO N
be VB N
an DT N
effective JJ N
treatment NN N
for IN N
patients NNS p
with IN p
advanced JJ p
bladder NN p
cancer NN p
. . p

One CD p
hundred CD p
and CC p
twenty RB p
untreated JJ p
patients NNS p
with IN p
stage NN p
III/IV NNP p
bladder NN p
cancer NN p
were VBD N
randomized VBN N
to TO N
receive VB N
either DT N
gemcitabine NN i
( ( N
250 CD N
mg/m NN N
( ( N
2 CD N
) ) N
) ) N
6-h JJ N
infusion NN N
on IN N
days NNS N
1 CD N
and CC N
8 CD N
, , N
and CC i
cisplatin NN i
( ( N
70 CD N
mg/m NN N
( ( N
2 CD N
) ) N
) ) N
on IN N
day NN N
2 CD N
every DT N
21-day JJ N
cycle NN N
( ( N
arm JJ N
1 CD N
) ) N
or CC N
gemcitabine NN i
( ( N
1,250 CD N
mg/m NN N
( ( N
2 CD N
) ) N
) ) N
30-min JJ N
infusion NN N
on IN N
days NNS N
1 CD N
and CC N
8 CD N
, , N
with IN N
the DT N
same JJ N
dose NN N
of IN N
cisplatin NN i
( ( N
arm JJ N
2 CD N
) ) N
. . N

The DT N
92 CD p
males NNS p
and CC p
28 CD p
females NNS p
included VBN p
in IN p
the DT p
study NN p
had VBD p
a DT p
median JJ p
age NN p
of IN p
62 CD p
years NNS p
( ( p
range VB p
40-85 CD p
years NNS p
) ) p
. . p

Among IN N
the DT N
120 CD N
patient NN N
, , N
complete JJ N
response NN N
was VBD N
achieved VBN N
in IN N
11.7 CD N
% NN N
( ( N
7/60 CD N
patients NNS N
of IN N
arm JJ N
1 CD N
) ) N
and CC N
5 CD N
% NN N
( ( N
3/60 CD N
patients NNS N
of IN N
arm JJ N
2 CD N
) ) N
. . N

Eighteen JJ N
patients NNS N
in IN N
arm JJ N
1 CD N
( ( N
30 CD N
% NN N
) ) N
and CC N
17 CD N
patients NNS N
( ( N
28.3 CD N
% NN N
) ) N
in IN N
arm NN N
2 CD N
had VBD N
partial JJ N
response NN N
on IN N
therapy NN N
. . N

Thus RB N
, , N
the DT N
overall JJ o
response NN o
rate NN o
of IN N
patients NNS N
in IN N
arm JJ N
1 CD N
and CC N
arm VBD N
2 CD N
was VBD N
41.7 CD N
% NN N
( ( N
25/60 CD N
patients NNS N
) ) N
and CC N
33.3 CD N
% NN N
( ( N
20/60 CD N
patients NNS N
) ) N
, , N
respectively RB N
( ( N
p JJ N
= NNP N
0.37 CD N
) ) N
. . N

No DT N
significant JJ N
difference NN N
in IN N
median JJ o
time NN o
to TO o
disease VB o
progression NN o
( ( N
26 CD N
vs. FW N
24 CD N
months NNS N
, , N
p VBP N
= RB N
0.4 CD N
) ) N
, , N
median JJ o
survival NN o
( ( N
12 CD N
vs. FW N
16 CD N
months NNS N
, , N
p VBP N
= RB N
0.8 CD N
) ) N
, , N
and CC N
1-year JJ o
survival NN o
( ( N
49.9 CD N
vs. FW N
54.7 CD N
% NN N
, , N
p NN N
= NNP N
0.8 CD N
) ) N
was VBD N
detected VBN N
between IN N
arms NNS N
1 CD N
and CC N
2 CD N
, , N
respectively RB N
. . N

Main NNP o
toxicities NNS o
were VBD N
similar JJ N
in IN N
both DT N
arms NNS N
with IN N
no DT N
statistically RB N
significant JJ N
differences NNS N
. . N

Low-dose JJ N
, , N
prolonged JJ N
infusion NN N
gemcitabine NN i
in IN i
combination NN i
with IN i
cisplatin NN i
is VBZ N
not RB N
inferior JJ N
to TO N
the DT N
standard JJ i
GC NNP i
regimen NNS i
with IN N
favorable JJ N
toxicity NN o
profile NN o
and CC N
less RBR N
financial JJ o
costs NNS o
. . o

-DOCSTART- -6352035- O O

A DT N
comparative JJ N
study NN N
of IN N
netilmicin-cefoxitin JJ i
and CC N
gentamicin-cefoxitin JJ i
in IN N
surgical JJ p
patients NNS p
with IN p
serious JJ p
systemic JJ p
infection NN p
. . p

A DT N
double-blind NN N
, , N
randomized VBN N
study NN N
of IN N
gentamicin NN i
and CC N
netilmicin NN i
, , N
each DT N
in IN N
combination NN N
with IN N
cefoxitin NN i
, , N
was VBD N
done VBN N
to TO N
compare VB N
their PRP$ N
respective JJ N
efficacy NN o
and CC o
toxicity NN o
in IN N
patients NNS p
with IN p
serious JJ p
systemic JJ p
infection NN p
. . p

Thirty-seven JJ p
surgical JJ p
patients NNS p
were VBD p
evaluated VBN p
for IN p
efficacy NN o
and CC p
46 CD p
patients NNS p
were VBD p
evaluated VBN p
for IN p
toxicity NN p
. . p

The DT N
most RBS N
frequently RB N
cultured VBN N
organisms NNS N
were VBD N
Escherichia NNP N
coli NNS N
( ( N
15 CD N
) ) N
, , N
Klebsiella NNP N
sp NN N
( ( N
9 CD N
) ) N
, , N
Proteus NNP N
sp NN N
( ( N
6 CD N
) ) N
, , N
and CC N
Bacteroides NNP N
sp NN N
( ( N
4 CD N
) ) N
. . N

For IN N
23 CD N
patients NNS N
treated VBN N
with IN N
gentamicin-cefoxitin JJ i
( ( N
G-C NNP N
) ) N
, , N
the DT N
clinical JJ o
response NN o
was VBD N
favorable JJ N
in IN N
20/21 CD N
( ( N
95.2 CD N
% NN N
) ) N
evaluable JJ N
cases NNS N
, , N
and CC N
elimination NN N
or CC N
marked VBN N
reduction NN N
of IN N
33/34 CD N
( ( N
97.1 CD N
% NN N
) ) N
organisms NN N
was VBD N
achieved VBN N
. . N

For IN N
14 CD N
patients NNS N
treated VBN N
with IN N
netilmicin-cefoxitin JJ i
( ( N
N-C NNP N
) ) N
, , N
the DT N
clinical JJ o
response NN o
was VBD N
favorable JJ N
in IN N
13/13 CD N
( ( N
100 CD N
% NN N
) ) N
evaluable JJ N
cases NNS N
, , N
and CC N
19/20 CD N
( ( N
95 CD N
% NN N
) ) N
organisms WDT N
were VBD N
eliminated VBN N
or CC N
markedly RB N
reduced VBN N
. . N

Nephrotoxicity NNP o
was VBD N
defined VBN N
as IN N
an DT N
increase NN N
in IN N
serum JJ o
creatinine NN o
to TO N
greater JJR N
than IN N
25 CD N
% NN N
over IN N
baseline NN N
with IN N
an DT N
absolute JJ N
rise NN N
of IN N
at IN N
least JJS N
0.5 CD N
mg/100 JJ N
ml NN N
to TO N
a DT N
value NN N
greater JJR N
than IN N
or CC N
equal JJ N
to TO N
1.3 CD N
mg/100 NN N
ml NN N
. . N

Based VBN N
on IN N
these DT N
criteria NNS N
, , N
nephrotoxicity NN o
was VBD N
seen VBN N
in IN N
2/27 CD N
( ( N
7.4 CD N
% NN N
) ) N
patients NNS N
treated VBN N
with IN N
G-C NNP N
and CC N
in IN N
3/19 CD N
( ( N
15.8 CD N
% NN N
) ) N
patients NNS N
treated VBN N
with IN N
N-C. NNP N
Ototoxicity NNP o
was VBD N
defined VBN N
as IN N
a DT N
greater JJR N
than IN N
20 CD N
dB JJ N
loss NN N
at IN N
any DT N
frequency NN N
. . N

Based VBN N
on IN N
these DT N
criteria NNS N
, , N
ototoxicity NN o
was VBD N
seen VBN N
in IN N
5/27 CD N
( ( N
18.5 CD N
% NN N
) ) N
patients NNS N
treated VBN N
with IN N
G-C NNP N
and CC N
2/19 CD N
( ( N
10.5 CD N
% NN N
) ) N
patients NNS N
treated VBN N
with IN N
N-C NNP N
. . N

The DT N
data NN N
show NN N
no DT N
significant JJ N
difference NN N
in IN N
toxicity NN o
and CC N
suggest VBP N
that IN N
netilmicin NN N
and CC N
gentamicin NN N
are VBP N
both DT N
highly RB N
effective JJ N
in IN N
combination NN N
with IN N
cefoxitin NN N
in IN N
patients NNS p
who WP p
have VBP p
serious JJ p
infections NNS p
after IN p
surgery NN p
. . p

-DOCSTART- -16740812- O O

A DT N
randomized JJ N
clinical JJ N
trial NN N
of IN N
clinician JJ i
feedback NN i
to TO N
improve VB N
quality NN N
of IN N
care NN N
for IN N
inner-city JJ p
children NNS p
with IN p
asthma NN p
. . p

CONTEXT NNP N
Barriers NNP N
impede VBP N
translating VBG N
recommendations NNS N
for IN N
asthma JJ N
treatment NN N
into IN N
practice NN N
, , N
particularly RB N
in IN N
inner NN N
cities NNS N
where WRB N
asthma JJ N
morbidity NN N
is VBZ N
highest JJS N
. . N

METHODS VB N
The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
test VB N
the DT N
effectiveness NN N
of IN N
timely JJ N
patient JJ i
feedback NN i
in IN N
the DT N
form NN N
of IN N
a DT i
letter NN i
providing VBG N
recent JJ N
patient-specific JJ N
symptoms NNS N
, , N
medication NN N
, , N
and CC N
health NN N
service NN N
use NN N
combined VBN N
with IN N
guideline-based JJ N
recommendations NNS N
for IN N
changes NNS N
in IN N
therapy NN N
on IN N
improving VBG N
the DT N
quality NN N
of IN N
asthma NN N
care NN N
by IN N
inner-city NN N
primary NN N
care NN N
providers NNS N
and CC N
on IN N
resultant JJ N
asthma JJ N
morbidity NN N
. . N

This DT N
was VBD N
a DT N
randomized JJ N
, , N
controlled VBD N
clinical JJ N
trial NN N
in IN N
5- JJ p
to TO p
11-year-old JJ p
children NNS p
( ( p
n JJ p
= NNP p
937 CD p
) ) p
with IN p
moderate JJ p
to TO p
severe VB p
asthma RB p
receiving VBG p
health NN p
care NN p
in IN p
hospital- JJ p
and CC p
community-based JJ p
clinics NNS p
and CC p
private JJ p
practices NNS p
in IN p
7 CD p
inner-city JJ p
urban JJ p
areas NNS p
. . p

The DT N
caretaker NN p
of IN p
each DT p
child NN p
received VBD N
a DT N
bimonthly JJ i
telephone NN i
call NN i
to TO i
collect VB i
clinical JJ i
information NN i
about IN i
the DT i
child NN i
's POS i
asthma NN i
. . i

For IN N
a DT N
full JJ N
year NN N
, , N
the DT N
providers NNS N
of IN N
intervention NN N
group NN N
children NNS N
received VBD N
bimonthly RB i
computer-generated JJ i
letters NNS i
based VBN N
on IN N
these DT N
calls NNS N
summarizing VBG N
the DT N
child NN N
's POS N
asthma NN N
symptoms NNS N
, , N
health NN N
service NN N
use NN N
, , N
and CC N
medication NN N
use NN N
with IN N
a DT N
corresponding JJ N
recommendation NN N
to TO N
step VB N
up RP N
or CC N
step VB N
down RP N
medications NNS N
. . N

We PRP N
measured VBD N
the DT N
number NN N
and CC N
proportion NN N
of IN N
scheduled JJ N
visits NNS N
resulting VBG N
in IN N
stepping VBG N
up IN N
of IN N
medications NNS N
, , N
asthma NN N
symptoms NNS N
( ( N
2-week JJ N
recall NN N
) ) N
, , N
and CC N
health NN N
care NN N
use NN N
( ( N
2-month JJ N
recall NN N
) ) N
. . N

RESULTS VBN N
In IN N
this DT N
population NN N
, , N
only RB N
a DT N
modest JJ N
proportion NN N
of IN N
children NNS N
whose WP$ N
symptoms NNS N
warranted VBD N
a DT N
medication NN N
increase NN N
actually RB N
had VBD N
a DT N
scheduled JJ o
visit NN o
to TO N
reevaluate VB N
their PRP$ N
asthma JJ N
treatment NN N
. . N

However RB N
, , N
in IN N
the DT N
2-month JJ N
interval NN N
after IN N
receipt NN N
of IN N
a DT N
step-up JJ N
letter NN N
, , N
17.1 CD N
% NN N
of IN N
the DT N
letters NNS N
were VBD N
followed VBN N
by IN N
scheduled JJ N
visits NNS N
in IN N
the DT N
intervention NN N
group NN N
compared VBN N
with IN N
scheduled JJ N
visits NNS N
12.3 CD N
% NN N
of IN N
the DT N
time NN N
by IN N
the DT N
control NN N
children NNS N
with IN N
comparable JJ N
clinical JJ N
symptoms NNS N
. . N

Asthma NNP i
medications NNS i
were VBD N
stepped VBN N
up RP N
when WRB N
indicated VBN N
after IN N
46.0 CD N
% NN N
of IN N
these DT N
visits NNS N
in IN N
the DT N
intervention NN N
group NN N
compared VBN N
with IN N
35.6 CD N
% NN N
in IN N
the DT N
control NN i
group NN N
, , N
and CC N
when WRB N
asthma NN N
symptoms NNS N
warranted VBD N
a DT N
step NN N
up RB N
in IN N
therapy NN N
, , N
medication NN N
changes NNS N
occurred VBD N
earlier RBR N
among IN N
the DT N
intervention NN N
children NNS N
. . N

Among IN N
children NNS N
whose WP$ N
medications NNS N
were VBD N
stepped VBN N
up RP N
at IN N
any DT N
time NN N
during IN N
the DT N
12-month JJ N
study NN N
period NN N
, , N
those DT N
in IN N
the DT N
intervention NN N
group NN N
experienced VBD N
22.1 CD N
% NN N
fewer JJR N
symptom JJ N
days NNS N
and CC N
37.9 CD N
% NN N
fewer JJR N
school NN N
days NNS N
missed VBN N
. . N

The DT N
intention-to-treat JJ N
analysis NN N
showed VBD N
no DT N
difference NN N
over IN N
the DT N
intervention NN N
year NN N
in IN N
the DT N
number NN o
of IN o
symptom JJ o
days NNS o
, , N
yet RB N
there EX N
was VBD N
a DT N
trend NN N
toward IN N
fewer JJR N
days NNS N
of IN N
limited JJ N
activity NN N
and CC N
a DT N
significant JJ N
decrease NN N
in IN N
emergency NN o
department NN o
visits NNS o
by IN N
the DT N
intervention NN N
group NN N
compared VBN N
with IN N
controls NNS N
. . N

This DT N
24 CD N
% NN N
drop NN N
in IN N
emergency NN o
department NN o
visits NNS o
resulted VBD N
in IN N
an DT N
intervention NN N
that WDT N
was VBD N
cost VBN N
saving NN N
in IN N
its PRP$ N
first JJ N
year NN N
. . N

CONCLUSIONS NNP N
Patient-specific JJ i
feedback NN i
to TO N
inner-city JJ N
providers NNS N
increased VBD N
scheduled VBN N
asthma RB N
visits NNS N
, , N
increased VBD N
asthma JJ N
visits NNS N
in IN N
which WDT N
medications NNS N
were VBD N
stepped VBN N
up RP N
when WRB N
clinically RB N
indicated VBN N
, , N
and CC N
reduced JJ N
emergency NN N
department NN N
visits NNS N
. . N

-DOCSTART- -23647761- O O

Palliative JJ i
brachytherapy NN i
with IN i
or CC i
without IN i
primary JJ i
stent JJ i
placement NN i
in IN N
patients NNS p
with IN p
oesophageal JJ p
cancer NN p
, , N
a DT N
randomised JJ N
phase NN N
III NNP N
trial NN N
. . N

PURPOSE NNP N
To TO N
investigate VB N
whether IN N
a DT N
combination NN i
of IN i
self-expanding JJ i
metal NN i
stent NN i
( ( i
SEMS NNP i
) ) i
and CC i
brachytherapy NN i
provided VBD N
more RBR N
rapid JJ N
and CC N
prolonged JJ N
effect NN N
on IN N
dysphagia NN N
without IN N
increased VBN N
pain NN N
compared VBN N
to TO N
brachytherapy VB N
alone RB N
in IN N
patients NNS p
with IN p
incurable JJ p
oesophageal JJ p
cancer NN p
. . p

METHODS NNP N
41 CD p
Patients NNPS p
were VBD N
randomised VBN N
to TO N
SEMS NNP i
followed VBN i
by IN i
brachytherapy NN i
, , i
8 CD i
Gy?3 NNP i
( ( i
n=21 NN i
) ) i
or CC i
brachytherapy VB i
alone RB i
, , i
8 CD i
Gy?3 NNP i
( ( i
n=20 NN o
) ) o
. . o

Change NN o
in IN o
dysphagia NN o
and CC o
pain NN o
three CD o
and CC N
seven CD N
weeks NNS N
after IN N
randomisation NN N
( ( N
FU1 NNP N
and CC N
FU2 NNP N
) ) N
was VBD N
assessed VBN N
by IN N
patient-reported JJ N
outcome NN o
. . o

Dysphagia NNP o
, , o
other JJ N
symptoms NNS N
and CC N
health-related JJ N
quality NN N
of IN N
life NN N
were VBD N
assessed VBN N
every DT N
four CD N
weeks NNS N
thereafter RB N
. . N

The DT N
study NN N
was VBD N
closed VBN N
before IN N
the DT N
estimated VBN N
patient-number NN N
was VBD N
reached VBN N
due JJ N
to TO N
slow VB N
recruitment NN N
. . N

RESULTS JJ N
Patients NNPS N
receiving VBG i
SEMS NNP i
followed VBN i
by IN i
brachytherapy NN i
had VBD i
significantly RB N
improved VBN o
dysphagia NN o
at IN o
FU1 NNP N
compared VBN N
to TO N
patients NNS N
receiving VBG i
brachytherapy NN i
alone RB i
( ( i
n=35 JJ N
) ) N
. . N

Difference NN N
in IN N
pain NN o
was VBD o
not RB N
observed VBN N
. . N

At IN N
FU2 NNP N
, , N
patients NNS N
in IN N
both DT N
arms NNS N
( ( N
n=21 NN N
) ) N
had VBD N
less JJR o
dysphagia JJ o
. . o

Four CD N
patients NNS N
in IN N
the DT N
combined JJ N
treatment NN N
arm NN N
experienced VBD o
manageable JJ o
complications NNS o
, , o
no DT o
complications NNS o
occurred VBD o
after IN N
brachytherapy NN N
alone RB N
. . N

CONCLUSION NNP N
For IN N
the DT N
relief NN N
of IN N
dysphagia NN i
, , i
SEMS NNP i
followed VBN i
by IN N
brachytherapy NN i
is VBZ i
preferable JJ N
and CC N
safe JJ N
for IN N
patients NNS N
in IN N
need NN N
of IN N
immediate JJ N
alleviation NN N
, , N
while IN i
brachytherapy NN i
with IN i
or CC i
without IN i
preceding VBG i
SEMS NNP i
provides VBZ i
relief NN N
within IN N
a DT N
few JJ N
weeks NNS N
after IN N
treatment NN N
. . N

-DOCSTART- -16562630- O O

The DT N
effect NN N
of IN N
random JJ i
modulation NN i
of IN i
functional JJ i
electrical JJ i
stimulation NN i
parameters NNS i
on IN N
muscle NN p
fatigue NN p
. . p

Muscle NNP N
contractions NNS N
induced VBN N
by IN N
functional JJ i
electrical JJ i
stimulation NN i
( ( N
FES NNP N
) ) N
tend VBP N
to TO N
result VB N
in IN N
rapid JJ o
muscle NN o
fatigue NN o
, , N
which WDT N
greatly RB N
limits VBZ N
activities NNS N
such JJ N
as IN N
FES-assisted JJ N
standing NN N
and CC N
walking NN N
. . N

It PRP N
was VBD N
hypothesized VBN N
that IN N
muscle NN o
fatigue NN o
caused VBN N
by IN N
FES NNP N
could MD N
be VB N
reduced VBN N
by IN N
randomly RB N
modulating VBG N
parameters NNS N
of IN N
the DT N
electrical JJ N
stimulus NN N
. . N

Seven NNP p
paraplegic JJ p
subjects NNS p
participated VBN p
in IN N
this DT N
study NN N
. . N

While IN N
subjects NNS N
were VBD N
seated VBN N
, , N
FES NNP N
was VBD N
applied VBN N
to TO N
quadriceps NNS N
and CC N
tibialis JJ N
anterior JJ N
muscles NNS N
bilaterally RB N
using VBG N
surface NN N
electrodes NNS N
. . N

The DT N
isometric JJ o
force NN o
was VBD N
measured VBN N
, , N
and CC N
the DT N
time NN N
for IN N
the DT N
force NN N
to TO N
drop VB N
by IN N
3 CD N
dB NN N
( ( N
fatigue JJ N
time NN N
) ) N
and CC N
the DT N
normalized JJ N
force-time JJ o
integral JJ o
( ( o
FTI NNP o
) ) o
were VBD N
determined VBN N
. . N

Four CD N
different JJ N
modes NNS N
of IN N
FES NNP N
were VBD N
applied VBN N
in IN N
random JJ N
order NN N
: : N
constant JJ N
stimulation NN N
, , N
randomized VBN N
frequency NN N
( ( N
mean JJ N
40 CD N
Hz NNP N
) ) N
, , N
randomized VBN N
current JJ N
amplitude NN N
, , N
and CC N
randomized VBD N
pulsewidth NN N
( ( N
mean JJ N
250 CD N
micros NN N
) ) N
. . N

In IN N
randomized JJ N
trials NNS N
, , N
stimulation NN N
parameters NNS N
were VBD N
stochastically RB N
modulated VBN N
every DT N
100 CD N
ms NN N
in IN N
a DT N
range NN N
of IN N
+/-15 NNP N
% NN N
using VBG N
a DT N
uniform JJ N
probability NN N
distribution NN N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
the DT N
fatigue NN o
time NN o
measurements NNS o
for IN N
the DT N
four CD N
modes NNS N
of IN N
stimulation NN N
. . N

There EX N
was VBD N
also RB N
no DT N
significant JJ N
difference NN N
in IN N
the DT N
FTI NNP o
measurements NNS o
. . o

Therefore RB N
, , N
our PRP$ N
particular JJ N
method NN N
of IN N
stochastic JJ N
modulation NN N
of IN N
the DT N
stimulation NN N
parameters NNS N
, , N
which WDT N
involved VBD N
moderate JJ N
( ( N
15 CD N
% NN N
) ) N
variations NNS N
updated VBN N
every DT N
100 CD N
ms NN N
and CC N
centered VBD N
around IN N
40 CD N
Hz NNP N
, , N
appeared VBD N
to TO N
have VB N
no DT N
effect NN N
on IN N
muscle NN o
fatigue NN o
. . o

There EX N
was VBD N
a DT N
strong JJ N
correlation NN N
between IN N
maximum JJ N
force NN N
measurements NNS N
and CC N
stimulation NN N
order NN N
, , N
which WDT N
was VBD N
not RB N
apparent JJ N
in IN N
the DT N
fatigue JJ o
time NN o
or CC o
FTI NNP o
measurements NNS o
. . o

It PRP N
was VBD N
concluded VBN N
that IN N
a DT N
10-min JJ N
rest NN N
period NN N
between IN N
stimulation NN N
trials NNS N
was VBD N
insufficient JJ N
to TO N
allow VB N
full JJ N
recovery NN o
of IN o
muscle NN o
strength NN o
. . o

-DOCSTART- -7235205- O O

Theophylline NNP o
concentrations NNS o
in IN N
serum NN N
and CC N
saliva NN N
after IN N
oral JJ N
microcrystalline NN i
and CC N
sustained-release JJ i
preparations NNS i
in IN N
asthmatics NNS p
. . p

Theophylline NNP o
concentrations NNS o
in IN N
saliva NN N
have VBP N
been VBN N
compared VBN N
with IN N
those DT N
in IN N
serum NN N
in IN N
13 CD p
asthmatic JJ p
patients NNS p
after IN p
single JJ p
and CC p
multiple JJ p
oral JJ p
dosage NN p
of IN p
a DT p
microcrystalline JJ i
theophylline NN i
tablet NN i
( ( p
Nuelin NNP p
) ) p
and CC p
a DT p
sustained-release JJ i
preparation NN i
( ( p
Nuelin NNP p
Retard NNP p
) ) p
. . N

There EX N
was VBD N
wide JJ N
individual JJ N
variation NN N
in IN N
the DT N
ratio NN o
of IN o
serum NN o
to TO o
saliva VB o
concentrations NNS o
indicating VBG N
that IN N
, , N
even RB N
when WRB N
individual JJ N
serum NN N
to TO N
saliva VB N
ratios NNS N
have VBP N
been VBN N
established VBN N
, , N
the DT N
use NN N
of IN N
saliva JJ N
theophylline NN i
measurements NNS N
alone RB N
is VBZ N
unreliable JJ N
for IN N
the DT N
routine JJ N
monitoring NN N
of IN N
theophylline JJ i
therapy NN i
. . i

Both DT N
preparations NNS N
produced VBD N
mean JJ o
serum NN o
theophylline NN o
concentrations NNS o
within IN N
the DT N
10 CD N
-- : N
20 CD N
mcg/ml NN N
range NN N
, , N
the DT N
sustained-release JJ N
tablet NN N
giving VBG N
higher JJR N
monitoring NN N
through IN N
values NNS N
and CC N
smaller JJR N
through IN N
to TO N
peak VB o
variation NN o
. . o

The DT N
preparations NNS N
were VBD N
equally RB N
and CC N
highly RB N
bioavailable JJ N
. . N

Side JJ o
effects NNS o
were VBD N
reported VBN N
by IN N
three CD N
patients NNS N
, , N
which WDT N
were VBD N
the DT N
patients NNS N
with IN N
the DT N
highest JJS N
AUC NN N
. . N

The DT N
Nuelin NNP i
Retard NNP i
preparation NN N
appears VBZ N
to TO N
provide VB N
smooth RB N
, , N
sustained VBD N
serum JJ o
theophylline NN o
concentrations NNS o
within IN N
the DT N
therapeutic JJ N
range NN N
and CC N
the DT N
simple JJ N
, , N
twice-daily JJ N
dosage NN N
should MD N
result VB N
in IN N
improved JJ N
patient NN N
compliance NN N
. . N

-DOCSTART- -15689088- O O

Immunogenicity NN o
and CC o
reactogenicity NN o
of IN N
two CD N
regimens NNS N
of IN N
diphtheria-tetanus-acellular JJ N
pertussis-hepatitis JJ N
B-inactivated JJ N
polio NN N
and CC N
Haemophilus NNP N
influenzae VBP N
type NN i
b NN i
vaccines NNS i
administered VBN i
to TO N
infants NNS p
primed VBN p
at IN p
birth NN p
with IN p
hepatitis NN p
B NNP p
vaccine NN p
. . p

An DT N
open JJ N
, , N
randomized VBN N
study NN N
evaluated VBD N
the DT N
immune JJ o
response NN o
and CC o
safety NN o
of IN N
two CD N
different JJ N
regimens NNS N
of IN N
diphtheria-tetanus-acellular JJ o
pertussis-hepatitis JJ o
B-inactivated JJ o
poliovirus-Haemophilus JJ o
influenzae NN o
type NN o
b NN o
( ( o
DTPa-HBV-IPV-Hib NNP o
) ) o
immunization NN N
in IN N
infants NNS p
primed VBN p
at IN p
birth NN p
with IN p
hepatitis NN p
B NNP p
vaccine NN p
. . p

One-half NN N
of IN N
the DT N
150 CD p
healthy JJ p
, , p
full-term JJ p
infants NNS p
received VBD i
a DT i
DTPa NNP i
HBV-IPV-Hib NNP i
vaccine NN i
at IN i
1 CD i
1/2 CD i
, , i
3 CD i
and CC i
5 CD i
months NNS i
of IN i
age NN i
; : i
the DT i
other JJ i
received VBD i
a DT i
DTPa-IPV-Hib JJ i
vaccine NN i
at IN i
1 CD i
1/2 CD i
, , i
3 CD i
and CC i
5 CD i
months NNS i
of IN i
age NN i
with IN i
separate JJ i
HBV NNP i
vaccine NN i
at IN i
1 CD i
and CC i
5 CD i
months NNS i
of IN i
age NN i
. . i

Immune NNP N
response NN N
was VBD N
similar JJ N
following VBG N
the DT N
two CD N
regimens NNS N
with IN N
100 CD N
% NN N
of IN N
the DT N
vaccinees NNS N
seroprotected VBD N
for IN N
HBV NNP N
, , N
diphtheria NN N
, , N
tetanus NN N
, , N
Hib NNP N
and CC N
poliovirus VB N
types NNS N
2 CD N
and CC N
3 CD N
diseases NNS N
after IN N
the DT N
full JJ N
vaccination NN N
course NN N
. . N

One CD N
vaccinee NN N
in IN N
the DT N
DTPa NNP N
HBV-HPV- NNP N
Hib NNP N
group NN N
failed VBD N
to TO N
respond VB N
to TO N
the DT N
poliovirus NN N
type NN N
1 CD N
antigen NN N
. . N

Response NN o
to TO N
the DT N
three CD N
pertussis NN N
antigens NNS N
ranged VBD N
from IN N
92-97 CD N
% NN N
in IN N
the DT N
DTPa-IPV-Hib NNP N
plus CC N
separate JJ N
HBV NNP N
group NN N
and CC N
100 CD N
% NN N
in IN N
the DT N
DTPa NNP N
HBV-IPV-Hib NNP N
group NN N
. . N

The DT N
most RBS N
frequently RB N
reported VBD N
post-vaccination NN N
symptoms NNS N
were VBD N
irritability NN o
in IN N
the DT N
DTPa-IPV-Hib NNP N
plus CC N
separate JJ N
HBV NNP N
group NN N
( ( N
49 CD N
% NN N
of IN N
vaccinees NNS N
) ) N
and CC N
fever NN o
, , N
defined VBD N
as IN N
axillary JJ N
temperature NN N
> NN N
or CC N
=37.5 NN N
degrees NNS N
C NNP N
, , N
in IN N
the DT N
DTPa NNP N
HBV- NNP N
IPV-Hib NNP N
group NN N
( ( N
50 CD N
% NN N
of IN N
vaccinees NNS N
) ) N
. . N

-DOCSTART- -16229958- O O

Over IN N
time NN N
relationships NNS N
between IN N
early JJ p
adolescent NN p
and CC p
peer NN o
substance NN o
use NN N
. . N

Peer NNP N
and CC N
adolescent JJ N
substance NN N
use NN N
are VBP N
highly RB N
correlated VBN N
, , N
but CC N
this DT N
relationship NN N
is VBZ N
not RB N
fully RB N
understood JJ N
. . N

In IN N
particular JJ N
, , N
the DT N
relative JJ N
contributions NNS N
of IN N
selection NN N
and CC N
socialization NN N
to TO N
substance VB N
use NN N
progression NN N
have VBP N
not RB N
been VBN N
established VBN N
. . N

Students NNS p
( ( p
n=2453 NN p
) ) p
in IN p
the DT p
seven CD p
middle JJ p
schools NNS p
in IN p
one CD p
school NN p
district NN p
were VBD p
assessed VBN p
at IN p
school NN p
at IN p
the DT p
beginning NN p
and CC p
end NN p
of IN p
the DT p
sixth JJ p
, , p
seventh JJ p
, , p
eighth JJ p
grade NN p
and CC p
beginning NN p
of IN p
the DT p
9th CD p
grade NN p
. . p

Self-reported JJ o
smoking NN o
and CC o
drinking NN o
and CC p
the DT p
number NN p
of IN p
substance NN p
using VBG p
friends NNS p
were VBD p
assessed VBN p
5 CD p
times NNS p
over IN p
3 CD p
years NNS p
. . p

The DT N
relationship NN i
between IN i
peer NN o
and CC o
adolescent NN o
substance NN o
use NN o
were VBD i
assessed VBN i
in IN i
parallel JJ i
processes NNS i
as IN i
part NN i
of IN i
an DT i
autoregressive JJ i
latent NN i
trajectory NN i
model NN i
. . i

Substance NNP o
use NN o
and CC N
the DT o
number NN o
of IN o
substance NN o
using VBG N
friends NNS N
increased VBN N
in IN N
linear JJ N
fashion NN N
from IN N
T1 NNP N
to TO N
T5 NNP N
. . N

Initial NNP N
substance NN N
use NN N
predicted VBD N
an DT N
increase NN N
in IN N
the DT N
number NN o
of IN o
substance NN o
using VBG o
friends NNS o
over IN o
time NN o
, , N
indicating VBG N
an DT N
effect NN N
of IN N
selection NN N
, , N
and CC N
the DT N
initial JJ N
number NN N
of IN N
substance NN N
using VBG N
friends NNS N
predicted VBD N
substance NN o
use NN o
progression NN N
, , N
providing VBG N
evidence NN N
of IN N
socialization NN N
. . N

The DT N
magnitudes NNS N
of IN N
these DT N
relationships NNS N
were VBD N
similar JJ N
. . N

Bivariate NNP N
, , N
lagged VBD N
autoregressive JJ N
analyses NNS N
of IN N
the DT N
successive JJ N
relationships NNS N
from IN N
one CD N
assessment NN N
to TO N
the DT N
next JJ N
showed JJ N
consistent NN N
, , N
significant JJ N
associations NNS N
from IN N
peer NN o
use NN o
to TO o
adolescent VB o
substance NN o
use NN o
. . o

The DT N
association NN N
from IN N
adolescent NN o
to TO o
peer VB o
use NN o
was VBD N
significant JJ N
only RB N
from IN N
7th CD N
to TO N
8th CD N
grade NN N
. . N

The DT N
findings NNS N
provide VBP N
evidence NN N
of IN N
reciprocal JJ N
influences NNS N
, , N
but CC N
socialization NN N
was VBD N
a DT N
more RBR N
consistent JJ N
influence NN N
than IN N
selection NN N
. . N

-DOCSTART- -7923916- O O

Decreased VBN o
sensitivity NN o
to TO o
dexamethasone VB o
in IN N
lymphocytes NNS N
from IN N
patients NNS p
with IN p
Alzheimer NNP p
's POS p
disease NN p
. . p

Cortisol NNP o
levels NNS o
in IN N
patients NNS p
with IN p
Alzheimer NNP p
's POS p
disease NN p
( ( p
AD NNP p
) ) p
are VBP N
relatively RB N
unaffected JJ N
by IN N
a DT N
challenge NN N
with IN N
dexamethasone NN i
( ( i
DEX NNP i
) ) i
in IN N
vivo NN N
. . N

The DT N
present JJ N
study NN N
demonstrates VBZ N
that IN N
DEX NNP i
is VBZ N
less RBR o
inhibitory JJ o
for IN o
phytohemagglutinin NN o
( ( o
PHA NNP o
) ) o
-induced VBD o
T NNP o
cell NN o
proliferation NN o
in IN o
AD NNP o
patients NNS o
as IN p
compared VBN p
to TO p
age-matched JJ p
controls NNS p
. . p

Since IN N
no DT N
significant JJ N
differences NNS N
were VBD N
found VBN N
between IN N
AD NNP p
patients NNS p
and CC N
age-matched JJ N
controls NNS N
with IN N
regard NN N
to TO N
the DT N
fraction NN o
of IN o
CD45RA+ NNP o
or CC o
CD45RO+ NNP o
CD4+ NNP o
T NNP o
cells NNS o
nor CC N
the DT N
ability NN o
of IN o
peripheral JJ o
blood NN o
mononuclear NN o
cells NNS o
to TO o
produce VB o
IL-2 NNP o
or CC o
IL-4 NNP o
, , N
it PRP N
is VBZ N
unlikely JJ N
that IN N
the DT N
difference NN N
in IN N
DEX NNP i
sensitivity NN N
is VBZ N
due JJ N
to TO N
a DT N
changed VBN N
lymphokine NN N
profile NN N
or CC N
a DT N
changed JJ N
composition NN N
of IN N
the DT N
CD4+ NNP N
T NNP N
cell NN N
population NN N
. . N

Sensitivity NNP N
to TO N
DEX NNP i
was VBD N
negatively RB N
correlated VBN N
with IN N
the DT N
ability NN o
to TO o
produce VB o
IL-2 NNP o
and CC o
IL-4 NNP o
in IN N
the DT N
controls NNS N
but CC N
not RB N
in IN N
AD NNP p
patients NNS p
. . p

This DT N
suggests VBZ N
that IN N
IL-2 NNP o
and CC o
IL-4 NNP o
synthesis NN o
in IN o
AD NNP o
patients NNS o
is VBZ N
less RBR N
sensitive JJ N
to TO N
regulation NN N
by IN N
glucocorticoids NNS i
. . i

-DOCSTART- -10971538- O O

Uvulopalatopharyngoplasty NNP i
versus NN N
laser NN i
assisted VBD i
uvulopalatoplasty JJ i
for IN N
the DT N
treatment NN N
of IN N
snoring NN p
: : p
an DT N
objective NN N
randomised VBD N
clinical JJ N
trial NN N
. . N

This DT N
study NN N
was VBD N
designed VBN N
to TO N
evaluate VB N
objectively RB N
the DT N
clinical JJ N
effectiveness NN N
of IN N
surgery NN N
for IN N
snoring VBG N
and CC N
to TO N
compare VB N
the DT N
results NNS N
of IN N
conventional JJ i
uvulopalatopharyngoplasty JJ i
( ( i
UPPP NNP i
) ) i
and CC N
laser $ i
assisted VBN i
uvulopalatoplasty JJ i
( ( i
LAUP NNP i
) ) i
in IN N
the DT N
treatment NN N
of IN N
snoring VBG N
. . N

Patients NNS p
who WP p
had VBD p
been VBN p
referred VBN p
for IN p
investigation NN p
and CC p
treatment NN p
of IN p
their PRP$ p
snoring NN p
were VBD p
randomly RB p
allocated VBN p
to TO p
receive VB p
either DT p
UPPP NNP i
or CC i
LAUP NNP i
. . i

Forty-seven JJ p
patients NNS p
with IN p
confirmed JJ p
palatal JJ p
flutter NN p
had VBD p
surgery NN p
and CC p
all DT p
of IN p
them PRP p
had VBD p
a DT p
preoperative JJ p
and CC p
postoperative JJ p
objective JJ p
assessment NN p
of IN p
their PRP$ p
snoring NN o
loudness NN o
and CC o
duration NN o
in IN o
the DT o
home NN o
. . o

The DT N
recording NN N
device NN N
( ( N
Snore NNP N
Box NNP N
) ) N
is VBZ N
simple JJ N
for IN N
the DT N
patient NN N
to TO N
operate VB N
, , N
portable JJ N
with IN N
a DT N
built VBN N
in IN N
microphone NN N
, , N
and CC N
able JJ N
to TO N
produce VB N
objective JJ N
results NNS N
, , N
which WDT N
can MD N
be VB N
automatically RB N
analysed VBN N
. . N

Of IN N
the DT N
38 CD N
patients NNS N
, , N
who WP N
had VBD N
technically RB N
valid JJ N
recordings NNS N
, , N
22 CD N
underwent JJ N
LAUP NNP i
and CC N
16 CD N
UPPP NNP i
. . i

Overall VB N
the DT N
mean NN o
postoperative NN o
Snore NNP o
Index NNP o
( ( o
SI NNP o
) ) o
was VBD N
less JJR N
than IN N
the DT N
preoperative JJ N
SI NNP o
( ( N
P NNP N
< NNP N
0.0001 CD N
) ) N
, , N
the DT N
average JJ N
difference NN N
being VBG N
78.2 CD N
snores/h NN N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
the DT N
LAUP NNP i
and CC N
UPPP NNP i
regarding VBG N
the DT N
fall NN o
in IN o
the DT o
SI NNP o
. . o

This DT N
study NN N
is VBZ N
the DT N
first JJ N
objective JJ N
comparative NN N
study NN N
to TO N
demonstrate VB N
the DT N
effectiveness NN o
of IN o
snoring VBG o
surgery NN o
. . o

-DOCSTART- -20337981- O O

Effects NNS N
of IN N
early JJ i
enteral JJ i
feeding NN i
on IN N
fecal JJ o
elastase NN o
1 CD o
and CC o
plasma JJ o
secretin NN o
. . o

BACKGROUND NNP N
Enteral NNP i
feeding NN i
is VBZ N
known VBN N
to TO N
be VB N
effective JJ N
on IN N
the DT N
development NN N
of IN N
gut NN N
hormone NN N
secretion NN N
and CC N
pancreatic JJ N
exocrine NN N
function NN N
. . N

The DT N
aim NN N
of IN N
the DT N
present JJ N
study NN N
was VBD N
to TO N
examine VB N
the DT N
effects NNS N
of IN N
extremely RB N
early JJ i
enteral JJ i
feedings NNS i
on IN N
the DT N
development NN N
in IN N
very RB o
low-birthweight JJ o
( ( o
VLBW NNP o
) ) o
infants NNS o
. . o

METHODS NNP N
Fecal NNP o
elastase VBD o
1 CD o
and CC o
plasma VB o
secretin JJ o
concentrations NNS o
were VBD N
measured VBN N
at IN N
four CD N
different JJ N
periods NNS N
during IN N
the DT N
first JJ N
28 CD N
days NNS N
of IN N
life NN N
in IN N
VLBW NNP p
infants NNS p
, , N
with IN N
extremely RB N
early JJ N
enteral JJ N
feeding NN N
starting VBG N
within IN N
24 CD N
h NN N
of IN N
birth NN N
, , N
as RB N
well RB N
as IN N
in IN N
control NN N
infants NNS N
. . N

RESULTS NNP N
Fecal JJ o
concentrations NNS o
of IN o
elastase NN o
1 CD o
at IN N
7 CD N
, , N
14 CD N
and CC N
28 CD N
days NNS N
after IN N
birth NN N
were VBD N
significantly RB N
higher JJR N
than IN N
those DT N
at IN N
1 CD N
or CC N
2 CD N
days NNS N
in IN N
both DT N
the DT N
early JJ N
feeding NN N
and CC N
control NN N
groups NNS N
. . N

Fecal JJ o
elastase NN o
1 CD o
levels NNS o
in IN N
the DT N
early JJ N
feeding NN N
group NN N
were VBD N
significantly RB N
higher JJR N
than IN N
those DT N
in IN N
the DT N
control NN N
group NN N
at IN N
7 CD N
and CC N
14 CD N
days NNS N
after IN N
birth NN N
. . N

The DT N
plasma JJ o
concentration NN o
of IN o
secretin NN o
at IN N
14 CD N
days NNS N
after IN N
birth NN N
was VBD N
significantly RB N
higher JJR N
than IN N
that DT N
at IN N
1 CD N
or CC N
2 CD N
days NNS N
and CC N
7 CD N
days NNS N
after IN N
birth NN N
in IN N
the DT N
early JJ N
feeding NN N
group NN N
. . N

No DT N
significant JJ N
differences NNS N
in IN N
plasma NN o
secretin NN o
levels NNS o
were VBD N
detected VBN N
between IN N
the DT N
early JJ N
feeding NN N
and CC N
control NN N
groups NNS N
at IN N
1 CD N
or CC N
2 CD N
days NNS N
, , N
7 CD N
days NNS N
and CC N
28 CD N
days NNS N
after IN N
birth NN N
, , N
but CC N
a DT N
significant JJ N
difference NN N
in IN N
secretin JJ o
level NN o
was VBD N
observed VBN N
between IN N
the DT N
two CD N
groups NNS N
at IN N
14 CD N
days NNS N
after IN N
birth NN N
. . N

CONCLUSIONS NNP N
Extremely RB i
early JJ i
enteral JJ i
feedings NNS i
may MD N
play VB N
an DT N
important JJ N
role NN N
in IN N
the DT N
development NN N
of IN N
pancreatic JJ o
exocrine NN o
function NN o
and CC o
secretin JJ o
secretion NN o
in IN N
the DT N
early JJ N
period NN N
of IN N
life NN N
in IN N
VLBW NNP p
infants NNS p
. . p

-DOCSTART- -12895217- O O

Pre-medication NN N
with IN N
pronase NN i
reduces NNS N
artefacts VBZ o
during IN N
endoscopic NN N
ultrasonography NN i
. . i

BACKGROUND NNP N
Gastric NNP N
mucus NN N
usually RB N
induces VBZ N
artefacts NNS o
during IN N
endoscopic JJ N
ultrasonography NN N
. . N

AIM NNP N
To TO N
investigate VB N
the DT N
effectiveness NN N
of IN N
pre-medication NN N
with IN N
the DT N
proteolytic JJ i
enzyme NN i
, , i
pronase NN i
, , N
before IN N
endoscopic JJ i
ultrasonography NN i
. . i

METHODS NNP N
Out-patients NNS p
scheduled VBN p
for IN p
endoscopic NN p
ultrasonography NN p
were VBD p
randomly RB p
assigned VBN p
to TO p
oral JJ p
pre-medication NN i
with IN i
the DT i
anti-foam JJ i
agent NN i
, , i
dimethylpolysiloxane NN i
, , i
alone RB i
( ( i
treatment NN i
A NNP i
; : i
n JJ i
= NNP i
29 CD i
) ) i
, , i
with IN i
dimethylpolysiloxane JJ i
plus CC i
sodium JJ i
bicarbonate NN i
( ( i
treatment NN i
B NNP i
; : i
n CC i
= VB i
29 CD i
) ) i
or CC i
with IN i
dimethylpolysiloxane NN i
, , i
sodium NN i
bicarbonate NN i
and CC i
pronase NN i
( ( i
treatment NN i
C NNP i
; : i
n CC p
= VB p
29 CD p
) ) p
. . p

All DT N
drinks NNS N
were VBD N
given VBN N
about IN N
10 CD N
min NN N
before IN N
the DT N
start NN N
of IN N
the DT N
procedure NN N
. . N

After IN N
insertion NN N
of IN N
the DT N
endoscope NN N
, , N
endoscopists VBZ N
recorded JJ N
visibility NN N
scores NNS N
before IN N
the DT N
procedure NN N
, , N
imaging VBG N
scores NNS N
at IN N
endoscopic NN N
ultrasonography NN N
and CC N
the DT N
numbers NNS N
of IN N
high-echo JJ N
spots NNS N
in IN N
the DT N
gastric JJ N
cavity NN N
and CC N
on IN N
the DT N
gastric NN N
wall NN N
surface NN N
after IN N
the DT N
procedure NN N
. . N

RESULTS VB N
Pre-medication JJ N
with IN N
pronase NN i
( ( N
treatment NN N
C NNP i
) ) i
significantly RB N
reduced VBN N
( ( N
both DT N
at IN N
P NNP N
< NNP N
0.05 CD N
) ) N
the DT N
visibility NN o
score NN o
( ( N
score RB N
4 CD N
, , N
46 CD N
% NN N
) ) N
in IN N
comparison NN N
with IN N
that DT N
obtained VBN N
for IN N
pre-medication NN N
without IN N
pronase NN i
( ( N
10 CD N
% NN N
for IN N
both DT N
treatments NNS i
A DT i
and CC i
B NNP i
) ) i
. . N

Treatment NN N
with IN N
pronase NN i
significantly RB N
reduced VBN N
( ( N
both DT N
at IN N
P NNP N
< NNP N
0.05 CD N
) ) N
the DT o
endoscopic NN o
ultrasonography NN o
score NN o
in IN N
the DT N
gastric JJ N
cavity NN N
( ( N
score RB N
4 CD N
, , N
34 CD N
% NN N
) ) N
in IN N
comparison NN N
with IN N
that DT N
found NN N
for IN N
treatments NNS N
A NNP N
( ( N
7 CD N
% NN N
) ) N
and CC N
B NNP N
( ( N
0 CD N
% NN N
) ) N
. . N

It PRP N
also RB N
significantly RB N
reduced VBN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
the DT N
endoscopic NN o
ultrasonography NN o
score NN o
on IN N
the DT N
gastric NN N
wall NN N
surface NN N
( ( N
score RB N
4 CD N
, , N
14 CD N
% NN N
) ) N
in IN N
comparison NN N
with IN N
that DT N
observed VBD N
for IN N
treatment NN N
A NNP N
( ( N
3 CD N
% NN N
) ) N
. . N

The DT o
numbers NNS o
of IN o
high-echo JJ o
spots NNS o
in IN o
the DT o
gastric JJ o
cavity NN o
and CC o
on IN o
the DT o
gastric NN o
wall NN o
surface NN o
were VBD N
significantly RB N
less JJR N
( ( N
both DT N
at IN N
P NNP N
< NNP N
0.001 CD N
) ) N
for IN N
pre-medication NN N
with IN N
pronase NN i
( ( i
treatment NN i
C NNP i
) ) i
than IN N
for IN N
pre-medication NN N
with IN N
treatments NNS i
A NNP i
and CC i
B NNP i
. . i

There EX N
were VBD N
no DT o
complications NNS o
associated VBN N
with IN N
the DT N
solutions NNS N
. . N

CONCLUSIONS NNP N
Pre-treatment JJ N
with IN N
pronase NN i
reduced VBD N
the DT N
artefacts NNS o
during IN N
endoscopic JJ N
ultrasonography NN N
. . N

-DOCSTART- -18339525- O O

Pentoxifylline NN i
to TO N
treat VB N
radiation NN p
proctitis NN p
: : p
a DT N
small JJ N
and CC N
inconclusive JJ N
randomised VBN N
trial NN N
. . N

This DT N
prospective JJ N
randomised VBN N
controlled VBN N
study NN p
of IN p
40 CD p
patients NNS p
could MD N
not RB N
show VB N
a DT N
statistically RB N
significant JJ N
advantage NN N
with IN N
6 CD N
months NNS N
of IN N
pentoxifylline NN i
compared VBN N
with IN N
standard JJ i
measures NNS i
for IN N
late JJ o
radiation-induced JJ o
rectal NN o
bleeding NN o
. . o

However RB N
, , N
a DT N
modest JJ N
benefit NN N
can MD N
not RB N
be VB N
excluded VBN N
and CC N
larger JJR N
randomised VBD N
placebo-controlled JJ i
trials NNS N
with IN N
longer JJR N
durations NNS o
of IN o
pentoxifylline JJ o
treatment NN o
may MD N
be VB N
justified VBN N
. . N

-DOCSTART- -26173631- O O

Eltrombopag NNP N
dose JJ N
predictors NNS N
in IN N
thrombocytopenic JJ p
subjects NNS p
with IN p
hepatitis NN p
C NNP p
virus NN p
infection NN p
. . p

This DT N
study NN N
aims VBZ N
to TO N
identify VB N
patient JJ N
characteristics NNS N
that WDT N
predict VBP N
effective JJ N
eltrombopag NN N
dosage NN N
for IN N
the DT N
treatment NN N
of IN N
Hepatitis NNP N
C NNP N
virus NN N
( ( N
HCV NNP N
) ) N
-related VBD N
thrombocytopenia NN N
. . N

Demographic NNP N
, , N
clinical JJ N
and CC N
genetic JJ N
data NNS N
collected VBN N
from IN N
thrombocytopenic JJ p
patients NNS p
( ( p
n JJ p
= NN p
1463 CD p
, , p
age NN p
? . p
18 CD p
years NNS p
) ) p
with IN p
chronic JJ p
HCV NNP p
infection NN p
who WP p
were VBD p
able JJ p
to TO p
achieve VB p
a DT p
target NN p
platelet NN p
count NN p
of IN p
> $ p
90 CD p
? . p
10 CD p
( ( p
9 CD p
) ) p
/L NN p
following VBG i
eltrombopag JJ i
treatment NN i
. . p

Patients NNS p
were VBD N
categorized VBN N
into IN N
four CD N
groups NNS N
( ( N
25 CD N
, , N
50 CD N
, , N
75 CD N
, , N
and CC N
100 CD N
mg NN N
) ) N
based VBN N
on IN N
the DT N
eltrombopag NN i
dose NN i
needed VBN N
to TO N
achieve VB N
the DT N
target NN N
platelet NN N
count NN i
. . i

Eltrombopag NNP i
dose JJ i
predictors NNS N
were VBD N
identified VBN N
using VBG N
a DT N
two CD N
stage NN N
approach NN N
. . N

First NNP N
, , N
bivariate NN N
analysis NN N
, , N
using VBG N
anova NN N
for IN N
continuous JJ N
variables NNS N
and CC N
Chi-square NNP N
test NN N
for IN N
categorical JJ N
variables NNS N
, , N
was VBD N
performed VBN N
to TO N
identify VB N
possible JJ N
predictors NNS N
of IN N
eltrombopag NN N
dose NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

Second JJ N
, , N
ordinal JJ N
logistic JJ N
regression NN N
with IN N
stepwise NN N
addition NN N
followed VBN N
by IN N
backward NN N
deletion NN N
was VBD N
then RB N
performed VBN N
using VBG N
predictors NNS N
identified VBN N
in IN N
bivariate NN N
analysis NN N
step NN N
to TO N
produce VB N
final JJ N
model NN N
containing VBG N
independent JJ N
predictors NNS N
at IN N
P NNP N
< NNP N
0.05 CD N
. . N

Ordinal NNP N
logistic JJ N
model NN N
identified VBD N
several JJ N
predictors NNS N
of IN N
eltrombopag NN N
dose NN N
. . N

Predictors NNS N
of IN N
higher JJR N
eltrombopag NN N
dose JJ N
include NN o
: : o
having VBG o
a DT o
HCV NNP o
genotype NN o
2 CD o
or CC o
3 CD o
, , o
being VBG o
Central/South NNP o
Asian NNP o
, , o
being VBG o
White NNP o
( ( o
Caucasian JJ o
or CC o
European JJ o
heritage NN o
) ) o
, , o
increased VBD o
weight NN o
, , o
and CC o
increased VBD o
spleen JJ o
length NN o
. . o

Predictors NNS o
of IN N
lower JJR N
eltrombopag NN N
dose JJ N
include NN o
: : o
female JJ o
gender NN o
, , o
increased VBN o
age NN o
, , o
having VBG o
a DT o
higher JJR o
ALP NNP o
plasma JJ o
concentration NN o
, , o
increased VBD o
creatinine JJ o
clearance NN o
, , o
increased VBD o
baseline NN o
lymphocytes NNS o
count NN o
, , o
and CC o
increased VBD o
baseline NN o
platelet NN o
count NN o
. . o

In IN o
conclusion NN N
, , N
this DT N
study NN N
identified VBD N
patient JJ N
characteristics NNS N
that WDT N
predict VBP N
effective JJ N
eltrombopag NN N
dose NN N
for IN N
the DT N
treatment NN N
of IN N
HCV-related NNP N
thrombocytopenia NN N
. . N

Early JJ N
selection NN N
of IN N
the DT N
optimal JJ N
eltrombopag NN N
dose NN N
expedites VBZ N
the DT N
initiation NN N
of IN N
antiviral JJ N
therapy NN N
. . N

This DT N
is VBZ N
expected VBN N
to TO N
improve VB N
the DT N
antiviral JJ N
therapy NN N
outcome NN N
before IN N
the DT N
patient NN N
progress NN N
into IN N
liver JJ N
decompensation NN N
. . N

-DOCSTART- -18953651- O O

Is VBZ N
adjuvant JJ i
chemotherapy NN i
of IN N
benefit NN N
for IN N
postmenopausal JJ p
women NNS p
who WP p
receive VBP p
endocrine NN p
treatment NN p
for IN p
highly RB p
endocrine-responsive JJ p
, , p
node-positive JJ p
breast NN p
cancer NN p
? . N
International NNP N
Breast NNP p
Cancer NNP p
Study NNP p
Group NNP p
Trials NNP N
VII NNP N
and CC N
12-93 JJ N
. . N

To TO N
compare VB N
the DT N
efficacy NN o
of IN N
chemoendocrine NN i
treatment NN i
with IN i
that DT i
of IN i
endocrine NN i
treatment NN i
( ( i
ET NNP i
) ) i
alone RB i
for IN N
postmenopausal JJ p
women NNS p
with IN p
highly RB p
endocrine JJ p
responsive JJ p
breast NN p
cancer NN p
. . p

In IN N
the DT N
International NNP N
Breast NNP N
Cancer NNP N
Study NNP N
Group NNP N
( ( N
IBCSG NNP N
) ) N
Trials NNP N
VII NNP N
and CC N
12-93 JJ p
, , p
postmenopausal JJ p
women NNS p
with IN p
node-positive JJ p
, , p
estrogen JJ p
receptor NN p
( ( p
ER NNP p
) ) p
-positive CD p
or CC p
ER-negative JJ p
, , p
operable JJ p
breast NN p
cancer NN p
were VBD N
randomized VBN N
to TO N
receive VB N
either DT N
chemotherapy NN i
or CC i
endocrine JJ i
therapy NN i
or CC i
combined VBN i
chemoendocrine JJ i
treatment NN i
. . i

Results NNS N
were VBD N
analyzed JJ N
overall JJ N
in IN N
the DT N
cohort NN N
of IN N
893 CD p
patients NNS p
with IN p
endocrine-responsive JJ p
disease NN p
, , p
and CC p
according VBG p
to TO p
prospectively RB p
defined JJ p
categories NNS p
of IN p
ER NNP p
, , p
age NN p
and CC p
nodal JJ p
status NN p
. . p

STEPP NNP o
analyses VBZ o
assessed JJ o
chemotherapy NN o
effect NN o
. . o

The DT N
median JJ N
follow-up NN N
was VBD N
13 CD N
years NNS N
. . N

Adding VBG N
chemotherapy NN i
reduced VBD N
the DT N
relative JJ o
risk NN o
of IN o
a DT o
disease-free JJ o
survival NN o
event NN o
by IN N
19 CD N
% NN N
( ( N
P NNP N
= NNP N
0.02 CD N
) ) N
compared VBN N
with IN N
ET NNP i
alone RB N
. . N

STEPP NNP N
analyses VBZ N
showed VBD N
little JJ N
effect NN N
of IN N
chemotherapy NN N
for IN N
tumors NNS N
with IN N
high JJ N
levels NNS o
of IN o
ER NNP o
expression NN o
( ( N
P NNP N
= NNP N
0.07 CD N
) ) N
, , N
or CC N
for IN N
the DT N
cohort NN N
with IN N
one CD N
positive JJ N
node NN N
( ( N
P NNP N
= NNP N
0.03 CD N
) ) N
. . N

Chemotherapy NNP i
significantly RB N
improves VBZ N
disease-free JJ o
survival NN o
for IN o
postmenopausal JJ p
women NNS p
with IN p
endocrine-responsive JJ p
breast NN p
cancer NN p
, , N
but CC N
the DT N
magnitude NN N
of IN N
the DT N
effect NN N
is VBZ N
substantially RB N
attenuated VBN N
if IN N
ER NNP N
levels NNS N
are VBP N
high JJ N
. . N

-DOCSTART- -25854713- O O

Visual JJ i
Assessment NNP i
of IN i
Relative NNP i
Apical NNP i
Sparing NNP i
Pattern NNP i
Is VBZ N
More RBR N
Useful JJ N
Than NNP N
Quantitative NNP N
Assessment NNP N
for IN N
Diagnosing NNP N
Cardiac NNP N
Amyloidosis NNP N
in IN N
Borderline NNP p
or CC p
Mildly RB p
Increased VBD p
Left NNP p
Ventricular NNP p
Wall NNP p
Thickness NNP p
. . p

BACKGROUND NNP N
Relative NNP i
apical JJ i
sparing VBG i
pattern NN i
of IN i
longitudinal JJ i
strain NN i
( ( i
RapSP-LS NNP i
) ) i
was VBD N
suggested VBN N
in IN N
advanced JJ N
cardiac JJ N
amyloidosis NN N
( ( N
CA NNP N
) ) N
. . N

It PRP N
is VBZ N
unclear JJ N
whether IN N
it PRP N
is VBZ N
present JJ N
in IN N
less RBR N
advanced JJ p
CA NNP p
. . p

METHODS NNP N
AND CC N
RESULTS NNP N
Patients NNP p
with IN p
presumptive JJ p
diagnosis NN p
of IN p
CA NNP p
and CC p
mean VB p
left JJR p
ventricular NN p
wall NN p
thickness NN p
( ( p
LVWT NNP p
) ) p
?14 VBP p
mm NNS p
were VBD p
recruited VBN p
. . p

Apart RB N
from IN i
RapSP-LS NNP i
visually RB i
identified VBD i
, , i
relative JJ i
apical JJ i
longitudinal NN i
strain NN i
index NN i
( ( i
RapLSI NNP i
) ) i
was VBD i
defined VBN N
as IN N
[ JJ N
average JJ N
apical JJ N
LS/ NNP N
( ( N
average JJ N
basal NN N
LS+average NNP N
mid-ventricle NN N
LS NNP N
) ) p
] NN p
. . p

Among IN p
119 CD p
patients NNS p
included VBD p
, , p
47 CD p
were VBD p
finally RB p
diagnosed VBN p
with IN p
CA NNP p
. . o

RapLSI NNP o
was VBD o
higher RBR N
in IN N
the DT N
CA NNP N
group NN N
compared VBN N
to TO N
other JJ N
causes NNS N
of IN N
increased JJ o
mean NN o
LVWT NNP o
( ( o
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
but CC N
with IN N
a DT N
significant JJ N
range NN N
of IN N
overlap NN N
noted VBN N
. . N

In IN N
contrast NN i
, , i
RapSP-LS NNP i
visually RB i
assessed VBD N
was VBD N
noted VBN N
in IN N
most JJS N
CA JJ N
patients NNS N
( ( N
31/47 CD N
, , N
66.0 CD N
% NN N
) ) N
except IN N
in IN N
those DT N
with IN N
preserved JJ N
LV NNP N
ejection NN N
fraction NN N
, , N
normal JJ N
LVWT NNP N
, , N
and CC N
mildly RB N
decreased VBD N
global JJ N
LS NNP N
, , N
suggesting VBG N
least JJS N
advanced JJ N
CA NNP N
. . N

On IN N
multivariate JJ N
analysis NN N
of IN N
the DT N
added JJ N
diagnostic JJ N
role NN N
of IN N
RapSP-LS NNP i
or CC i
RapLSI NNP i
on IN i
top NN N
of IN N
clinical JJ N
, , N
electrocardiographic JJ N
, , N
and CC N
conventional JJ N
echocardiographic JJ N
parameters NNS N
, , N
addition NN N
of IN N
RapLSI NNP i
produced VBD i
only RB N
borderline JJ N
increase NN N
in IN N
area NN N
under IN N
the DT N
curve NN N
of IN N
the DT N
multivariate NN N
model NN N
( ( N
P=0.05 NNP N
) ) N
, , N
whereas JJ N
addition NN N
of IN N
RapSP-LS NNP i
significantly RB i
increased VBD N
it PRP N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

CONCLUSIONS NNP N
Visual NNP N
identification NN N
of IN N
RapSP-LS NNP i
is VBZ i
useful JJ N
in IN N
terms NNS N
of IN N
added VBN o
diagnostic JJ o
value NN o
compared VBN o
with IN N
quantitative JJ N
calculation NN N
of IN N
RapLSI NNP i
. . i

Its PRP$ N
clinical JJ N
application NN N
, , N
however RB N
, , N
should MD N
be VB N
used VBN N
with IN N
caution NN N
in IN N
patients NNS p
with IN p
less JJR p
advanced JJ p
CA NNP p
. . p

-DOCSTART- -9267377- O O

Cranberry NNP i
concentrate NN i
: : i
UTI NNP p
prophylaxis NN N
. . N

-DOCSTART- -25526101- O O

TRANSCONJUNCTIVAL NNP i
NONVITRECTOMIZING NNP i
VITREOUS NNP i
SURGERY NNP i
VERSUS NNP i
25-GAUGE JJ i
VITRECTOMY NNP i
IN NNP N
PATIENTS NNP p
WITH NNP p
EPIRETINAL NNP p
MEMBRANE NNP p
: : p
A DT N
Prospective NNP N
Randomized NNP N
Study NNP N
. . N

PURPOSE NNP N
To TO N
compare VB N
the DT N
clinical JJ N
outcomes NNS N
and CC N
the DT N
rate NN N
of IN N
complications NNS N
of IN N
27-gauge JJ i
transconjunctival NN i
nonvitrectomizing VBG i
vitreous JJ i
surgery NN i
( ( i
NVS NNP i
) ) i
and CC N
of IN N
25-gauge JJ i
transconjunctival NN i
sutureless NN i
vitrectomy NN i
surgery NN i
for IN p
idiopathic JJ p
epiretinal JJ p
membrane NN p
removal NN p
. . p

METHODS NNP N
In IN N
this DT N
prospective JJ N
randomized NN N
study NN N
, , N
83 CD p
phakic JJ p
eyes NNS p
of IN p
83 CD p
consecutive JJ p
patients NNS p
with IN p
an DT p
idiopathic JJ p
epiretinal JJ p
membrane NN p
were VBD p
randomized VBN p
to TO p
receive VB p
27-gauge JJ i
NVS NNP i
( ( i
NVS-group NNP i
) ) i
or CC p
25-gauge JJ i
vitrectomy NN i
( ( p
Standard-group NNP p
) ) p
. . N

Main NNP N
outcome JJ N
measures NNS N
were VBD N
best-corrected JJ N
visual JJ N
acuity NN N
, , N
central JJ N
retinal JJ N
thickness NN N
, , N
nuclear JJ N
density NN N
units NNS N
' POS N
changes NNS N
, , N
and CC N
rate NN N
of IN N
complications NNS N
. . N

RESULTS NNP N
Thirty-nine JJ p
eyes NNS p
of IN p
the DT p
Standard-group NNP p
and CC p
40 CD p
of IN p
the DT p
NVS-group NNP p
were VBD p
considered VBN p
in IN p
final JJ p
analysis NN p
. . p

Mean JJ o
best-corrected JJ o
visual JJ o
acuity NN o
improved VBN N
significantly RB N
in IN N
both DT N
groups NNS N
, , N
with IN N
a DT N
significant JJ N
better RBR N
result NN N
at IN N
12 CD N
months NNS N
in IN N
NVS-group NNP i
( ( N
P NNP N
= NNP N
0.039 CD N
; : N
t-test JJ N
) ) N
. . N

Central JJ o
retinal JJ o
thickness NN o
decreased VBN N
significantly RB N
in IN N
both DT N
groups NNS N
( ( N
P NNP N
< NNP N
0.001 CD N
, , N
Tukey NNP N
test NN N
) ) N
, , N
without IN N
significant JJ N
difference NN N
between IN N
the DT N
two CD N
groups NNS N
at IN N
any DT N
time NN N
point NN N
. . N

At IN N
12 CD N
months NNS N
, , N
nuclear JJ o
density NN o
increased VBD N
significantly RB N
in IN N
the DT N
Standard-group NNP N
( ( N
analysis NN N
of IN N
variance NN N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
and CC N
it PRP N
did VBD N
not RB N
change VB N
in IN N
the DT N
NVS-group NNP N
( ( N
analysis NN N
of IN N
variance NN N
, , N
P NNP N
= NNP N
0.537 CD N
) ) N
. . N

Epiretinal NNP o
membrane NN o
recurred VBD N
in IN N
5.1 CD N
% NN N
of IN N
eyes NNS N
in IN N
the DT N
Standard-group NNP N
and CC N
in IN N
7.5 CD N
% NN N
of IN N
eyes NNS N
in IN N
the DT N
NVS-group NNP N
( ( N
Fisher NNP N
's POS N
exact JJ N
test NN N
, , N
P NNP N
= NNP N
1.000 CD N
) ) N
. . N

CONCLUSION VB N
The DT N
27-gauge JJ i
NVS NNP i
is VBZ N
an DT N
effective JJ N
surgical JJ N
procedure NN N
in IN N
eyes NNS N
with IN N
epiretinal JJ N
membrane NN N
and CC N
it PRP N
induces VBZ N
less JJR N
progression NN N
of IN N
nuclear JJ N
sclerosis NN N
than IN N
25-gauge JJ i
vitrectomy NN i
. . i

-DOCSTART- -3617996- O O

[ JJ i
Intra-arterial JJ i
chemotherapy NN i
in IN N
advanced JJ N
ovarian JJ N
cancers NNS N
. . N

2 CD N
. . N

Therapeutic JJ N
results NNS N
in IN N
relation NN N
to TO N
prognostic JJ N
factors NNS N
] VBP N
. . N

85 CD p
patients NNS p
with IN p
advanced JJ p
ovarian JJ p
carcinomas NN p
were VBD N
treated VBN N
either RB N
intra-arterially RB i
with IN i
MTX NNP i
and CC i
5-FU CD i
, , N
later RB N
systemically RB i
with IN i
the DT i
CMFV-combination NNP i
( ( N
therapy NN N
arm NN N
A NNP N
) ) N
or CC N
only RB i
systemically RB i
( ( N
therapy NN N
arm NN N
B NNP N
) ) N
after IN N
randomization NN N
. . N

The DT N
achieved JJ N
rates NNS o
of IN o
remission NN o
and CC o
survival JJ o
time NN o
showed VBD N
an DT N
obvious JJ N
dependence NN N
on IN N
the DT N
histological JJ N
type NN N
of IN N
tumor NN N
and CC N
on IN N
the DT N
degree NN N
of IN N
differentiation NN N
. . N

Whereas IN N
the DT N
results NNS N
of IN N
the DT N
treatment NN N
were VBD N
nearly RB N
identical JJ N
in IN N
both DT N
groups NNS N
of IN N
treatment NN N
with IN N
badly RB N
differentiated VBN N
carcinomas NN N
, , N
a DT N
significant JJ N
improvement NN N
could MD N
be VB N
achieved VBN N
by IN N
the DT N
initial JJ N
local JJ N
treatment NN N
of IN N
well RB N
and CC N
moderately RB N
differentiated JJ N
malignancies NNS N
. . N

More JJR N
than IN N
one CD N
third NN N
of IN N
the DT N
cases NNS p
of IN p
advanced JJ p
tumors NNS p
were VBD N
operable JJ N
by IN N
local JJ N
chemotherapy NN N
. . N

Thus VB N
the DT N
survival JJ o
time NN o
could MD N
be VB N
extended VBN N
. . N

The DT N
intra-arterial JJ i
chemotherapy NN i
represents VBZ N
an DT N
expensive JJ N
, , N
but CC N
effective JJ N
method NN N
of IN N
treatment NN N
of IN N
advanced JJ N
ovarian JJ N
carcinomas NN N
. . N

-DOCSTART- -1722167- O O

5 CD N
alpha-metabolism NN N
in IN N
finasteride-treated JJ i
subjects NNS p
and CC p
male JJ p
pseudohermaphrodites NNS p
with IN p
inherited JJ p
5 CD p
alpha-reductase JJ p
deficiency NN p
. . p

A DT N
review NN N
. . N

Male JJ p
pseudohermaphrodites NNS p
( ( p
MPHs NNP p
) ) p
with IN p
inherited JJ p
5 CD p
alpha-reductase JJ p
deficiency NN p
and CC p
decreased VBD p
dihydrotestosterone NN p
production NN p
have VBP N
a DT N
global JJ N
defect NN N
in IN N
5 CD N
alpha-metabolism NN N
affecting VBG N
both DT N
C19 NNP N
androgen NN N
metabolism NN N
and CC N
C21 NNP N
steroid VBP N
metabolism NN N
. . N

However RB N
, , N
the DT N
decreased JJ N
5 CD N
alpha-reduction NN N
of IN N
testosterone NN N
to TO N
dihydrotestosterone NN N
is VBZ N
the DT N
only RB N
impaired JJ N
steroid JJ N
conversion NN N
to TO N
have VB N
clinical JJ N
consequences NNS N
, , N
e.g. NN N
, , N
ambiguous JJ o
genitalia NN o
, , o
impaired JJ o
prostate NN o
differentiation NN o
and CC o
development NN o
, , N
and CC N
decreased VBD o
facial JJ o
and CC o
body JJ o
hair NN o
. . o

The DT p
5 CD o
alpha-steroid JJ o
metabolite NN o
profile NN o
in IN p
the DT p
MPHs NNP p
was VBD p
compared VBN p
with IN p
that DT p
of IN p
men NNS p
with IN p
benign JJ p
prostatic JJ p
hyperplasia NN p
who WP N
were VBD N
administered VBN N
varying VBG N
doses NNS N
of IN N
the DT N
5 CD i
alpha-reductase JJ i
inhibitor NN i
finasteride NN i
. . i

Finasteride NNP i
was VBD N
found VBN N
to TO N
be VB N
a DT N
potent JJ N
inhibitor NN N
of IN N
both DT N
C19 NNP o
androgen NN o
and CC o
C21 NNP o
5 CD o
alpha-steroid JJ o
metabolism NN o
affecting VBG N
both DT N
hepatic JJ o
and CC o
peripheral JJ o
5 CD o
alpha-metabolism NN o
. . o

The DT N
5 CD N
alpha-steroid JJ o
metabolite NN o
profile NN o
was VBD N
strikingly RB N
similar JJ N
to TO N
that DT N
of IN N
MPHs NNP N
with IN N
inherited JJ N
5 CD N
alpha-reductase JJ N
deficiency NN N
. . N

The DT N
data NN N
suggest NN N
that IN N
a DT N
5 CD N
alpha-reductase JJ N
gene NN N
codes NNS N
for IN N
an DT N
enzyme NN N
with IN N
affinity NN o
for IN o
multiple JJ o
steroid JJ o
substrates NNS o
. . o

-DOCSTART- -7564450- O O

Hemostatic JJ o
function NN o
of IN N
aspirin-treated JJ i
platelets NNS N
vulnerable JJ N
to TO N
cardiopulmonary JJ N
bypass NN N
. . N

Altered NNP N
shear-induced JJ N
pathway NN N
. . N

The DT N
impaired JJ N
hemostasis NN N
of IN N
aspirin-treated JJ i
patients NNS p
is VBZ N
an DT N
annoying VBG N
problem NN N
during IN p
and CC p
after IN p
cardiopulmonary JJ p
bypass NN p
. . p

The DT N
hemostatic JJ o
function NN o
of IN N
platelets NNS N
comprises NNS N
two CD N
mechanisms NNS N
: : N
the DT N
shear-induced JJ N
and CC N
the DT N
cyclooxygenase NN N
pathways NNS N
. . N

Because IN N
the DT N
latter NN N
is VBZ N
inhibited VBN N
in IN N
aspirin-treated JJ i
patients NNS p
, , N
the DT N
hemostatic JJ N
function NN N
depends VBZ N
mainly RB N
on IN N
the DT N
former JJ N
pathway NN N
. . N

To TO N
investigate VB N
the DT N
effect NN N
of IN N
cardiopulmonary JJ N
bypass NN N
on IN N
the DT N
shear-induced JJ N
pathway NN N
, , N
a DT N
double-blind JJ N
study NN N
of IN N
preoperative JJ N
aspirin NN i
treatment NN N
( ( N
325 CD N
mg NN N
) ) N
and CC N
placebo NN i
was VBD N
conducted VBN N
in IN N
40 CD p
patients NNS p
undergoing JJ p
coronary JJ i
artery NN i
bypass NN i
grafting NN i
. . i

Postoperative JJ o
blood NN o
loss NN o
was VBD N
higher RBR N
in IN N
the DT N
aspirin-treated JJ i
patients NNS p
than IN N
in IN N
the DT N
placebo-treated JJ N
patients NNS N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

The DT N
shear-induced JJ o
hemostasis NN o
was VBD N
monitored VBN N
by IN N
the DT N
in IN N
vitro NN N
bleeding VBG N
test NN N
( ( N
Thrombostat NNP N
) ) N
, , N
which WDT N
mimics VBD N
bleeding VBG N
through IN N
an DT N
injured JJ N
arteriole NN N
. . N

The DT N
shear-induced JJ o
pathway NN o
of IN o
aspirin-treated JJ o
platelets NNS o
was VBD N
not RB N
affected VBN N
before IN N
cardiopulmonary JJ N
bypass NN N
, , N
but CC N
it PRP N
was VBD N
impaired VBN N
more RBR N
during IN N
the DT N
operation NN N
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
and CC N
remained VBD N
worse JJR N
afterward NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
, , N
compared VBN N
with IN N
that DT N
of IN N
placebo-treated JJ i
platelets NNS N
. . N

The DT N
inhibitory JJ N
effects NNS N
of IN N
aspirin NN i
on IN N
thromboxane NN o
production NN o
and CC o
on IN o
collagen-induced JJ o
platelet NN o
aggregation NN o
remained VBD N
throughout IN N
the DT N
operation NN N
. . N

In IN N
aspirin-treated JJ i
platelets NNS N
, , N
the DT N
aggregation NN o
capacity NN o
induced VBN N
by IN N
adenosine JJ N
diphosphate NN N
was VBD N
inhibited VBN N
before IN N
the DT N
operation NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
and CC N
showed VBD N
substantial JJ N
recovery NN N
during IN N
the DT N
operation NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

These DT N
results NNS N
suggest VBP N
that IN N
the DT N
shear-induced JJ N
pathway NN N
of IN N
aspirin-treated JJ i
platelets NNS N
is VBZ N
more RBR N
vulnerable JJ N
to TO N
cardiopulmonary JJ N
bypass NN N
than IN N
the DT N
pathway NN N
in IN N
normal JJ N
platelets NNS N
and CC N
causes NNS N
severe JJ N
impairment NN N
of IN N
hemostasis NN N
afterward NN N
. . N

-DOCSTART- -6686808- O O

Effect NN o
of IN N
antacids NNS i
on IN p
intragastric JJ o
pH NN o
in IN p
healthy JJ p
subjects NNS p
and CC p
duodenal JJ p
ulcer NN p
patients NNS p
. . p

Influence NN N
of IN N
the DT N
size NN N
of IN N
the DT N
antacid NN i
dose NN i
and CC N
of IN N
anticholinergics NNS i
. . i

Different JJ i
doses NNS i
of IN i
two CD i
liquid JJ i
antacids NNS i
, , i
alone RB i
and CC i
combined VBN i
with IN i
an DT i
anticholinergic JJ i
agent NN i
, , N
were VBD N
studied VBN N
with IN N
respect NN N
to TO N
the DT N
duration NN o
of IN o
antacid JJ o
action NN o
. . o

The DT N
studies NNS N
were VBD N
performed VBN N
in IN p
healthy JJ p
subjects NNS p
with IN p
MAO NNP p
less JJR p
than IN p
30 CD p
mmol/h NN p
and CC p
in IN p
duodenal JJ p
ulcer NN p
patients NNS p
with IN p
MAO NNP p
greater JJR p
than IN p
35 CD p
mmol/h NN p
. . p

Gastric NNP o
pH NN o
was VBD o
recorded VBN o
using VBG o
radiotelemetric JJ o
technique NN o
( ( o
Heidelberg NNP o
capsule NN o
) ) o
. . o

In IN N
the DT N
healthy JJ p
subjects NNS p
, , N
there EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
the DT N
duration NN o
of IN o
action NN o
with IN N
the DT N
different JJ N
doses NNS N
but CC N
in IN N
duodenal JJ p
ulcer NN p
patients NNS p
a DT N
tenfold JJ N
increase NN N
of IN N
the DT N
antacid NN i
dose NN N
resulted VBD N
in IN N
a DT N
doubling NN N
of IN N
the DT N
duration NN o
of IN o
action NN o
. . o

Combined VBN N
treatment NN N
with IN N
an DT N
anticholinergic NN i
and CC N
antacids NNS i
enhanced VBD N
the DT N
antacid NN o
effects NNS o
in IN N
both DT N
groups NNS N
. . N

It PRP N
is VBZ N
concluded VBN N
that IN N
an DT N
antacid NN N
dose NN N
should MD N
be VB N
so RB N
great JJ N
that IN N
it PRP N
binds VBZ N
secreted JJ N
acid NN N
before IN N
the DT N
dose NN N
leaves VBZ N
the DT N
stomach NN N
. . N

Further JJ N
increase NN N
of IN N
the DT N
dose NN N
will MD N
not RB N
increase VB N
the DT N
duration NN o
. . o

Concomitant NNP N
use NN N
of IN N
an DT N
anticholinergic JJ i
agent NN i
increases VBZ N
the DT N
duration NN o
of IN o
antacid JJ o
action NN o
. . o

-DOCSTART- -11922398- O O

Parenteral NNP N
troxerutin NN i
and CC i
carbazochrome JJ i
combination NN i
in IN N
the DT N
treatment NN N
of IN N
post-hemorrhoidectomy JJ p
status NN p
: : p
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
, , N
phase NN N
IV NNP N
study NN N
. . N

Flavonoids NNP N
, , N
such JJ N
as IN N
troxerutin NN i
, , N
have VBP N
been VBN N
shown VBN N
to TO N
be VB N
safe JJ N
and CC N
effective JJ N
agents NNS N
for IN N
the DT N
treatment NN N
of IN N
chronic JJ p
venous JJ p
insufficiency NN p
. . p

The DT N
fixed JJ N
combination NN N
between IN N
troxerutin $ i
150 CD N
mg NN N
and CC N
carbazochrome VB i
1.5 CD N
mg NN N
( ( N
Fleboside NNP N
ampoules NNS N
) ) N
was VBD N
previously RB N
shown VBN N
to TO N
have VB N
a DT N
good JJ N
efficacy NN N
and CC N
safety NN N
profile NN N
in IN N
non-surgical JJ p
patients NNS p
with IN p
acute JJ p
uncomplicated JJ p
hemorrhoids NNS p
. . p

The DT N
purpose NN N
of IN N
this DT N
randomized VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
study NN N
was VBD N
to TO N
investigate VB N
the DT N
efficacy NN N
and CC N
tolerability NN N
of IN N
the DT N
active JJ N
combination NN N
in IN N
the DT N
treatment NN N
of IN N
post-hemorrhoidectomy JJ p
patients NNS p
. . p

30 CD p
patients NNS p
were VBD p
randomized VBN p
to TO N
receive VB N
one CD N
of IN N
two CD N
treatments NNS N
: : N
troxerutin NN i
150 CD i
mg NN i
and CC i
carbazochrome VB i
1.5 CD i
mg NN i
, , N
or CC N
placebo NN i
, , N
i.m NN N
. . N

3 CD N
ml JJ N
ampoules NNS N
twice RB N
a DT N
day NN N
for IN N
five CD N
consecutive JJ N
days NNS N
after IN N
the DT N
surgical JJ N
procedure NN N
, , N
starting VBG N
from IN N
the DT N
day NN N
of IN N
surgery NN N
. . N

Efficacy NN o
parameters NNS N
were VBD N
assessed VBN N
as IN N
follows VBZ N
: : N
at IN N
baseline NN N
( ( N
T1 NNP N
) ) N
, , N
after IN N
the DT N
first JJ N
administration NN N
( ( N
T2 NNP N
; : N
day NN N
of IN N
surgery NN N
) ) N
, , N
the DT N
second JJ N
day NN N
after IN N
the DT N
surgical JJ N
procedure NN N
( ( N
T3 NNP N
) ) N
, , N
and CC N
the DT N
fifth JJ N
day NN N
after IN N
the DT N
surgical JJ N
procedure NN N
( ( N
T4 NNP N
) ) N
; : N
hemorrhoidal PRP$ o
symptoms NNS o
based VBN o
on IN o
a DT o
visual JJ o
analogue NN o
scale NN o
( ( o
VAS NNP o
) ) o
: : o
pain NN o
, , o
discharge NN o
, , o
bleeding NN o
, , o
inflammation NN o
, , o
and CC o
pruritus NN o
; : o
analgesic JJ o
intake NN o
, , o
if IN o
any DT o
; : o
time NN o
to TO o
restore VB o
a DT o
physiological JJ o
defecation NN o
; : o
edema CC o
evaluation NN o
( ( o
based VBN o
on IN o
a DT o
four-point JJ o
scale NN o
: : o
0 CD N
= JJ N
absent NN N
; : N
1 CD N
= NNP N
mild NN N
; : N
2 CD N
= NN N
moderate NN N
; : N
3 CD N
= NNP N
severe RB N
) ) N
; : N
camera NN o
pictures VBZ o
taken VBN o
at IN o
T1 NNP o
and CC o
T4 NNP o
( ( N
in IN N
selected VBN N
patients NNS N
) ) N
; : N
and CC N
blood NN o
coagulation NN o
tests NNS o
. . o

Analysis NN N
between IN N
treatment NN N
groups NNS N
revealed VBD N
a DT N
highly RB N
significant JJ o
difference NN o
at IN N
T3 NNP N
and CC N
T4 NNP N
for IN N
the DT N
total JJ o
VAS NNP o
score NN o
( ( N
p JJ N
= NN N
0.007 CD N
and CC N
p VB N
= JJ N
0.001 CD N
, , N
respectively RB N
) ) N
in IN N
favor NN N
of IN N
the DT N
active JJ N
combination NN N
treatment NN N
. . N

A DT N
statistically RB N
significant JJ N
difference NN N
was VBD N
also RB N
observed VBN N
for IN N
bleeding NN o
and CC o
pruritus NN o
at IN N
T3 NNP N
and CC N
for IN N
these DT N
two CD N
parameters NNS N
and CC N
both DT N
inflammation NN o
and CC o
edema NN o
at IN N
T4 NNP N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
in IN N
favor NN N
of IN N
the DT N
active JJ N
combination NN N
group NN N
. . N

No DT o
adverse JJ o
events NNS o
were VBD N
reported VBN N
. . N

Neither CC N
the DT N
active JJ N
combination NN N
nor CC N
placebo NN N
affected VBD N
blood NN o
coagulation NN o
tests NNS N
. . N

We PRP N
conclude VBP N
that IN N
intramuscular JJ N
administration NN N
of IN N
the DT N
fixed JJ N
combination NN i
of IN i
troxerutin $ i
150 CD N
mg NN N
and CC i
carbazochrome VB i
1.5 CD N
mg NN N
is VBZ N
effective JJ N
, , N
well RB N
tolerated VBN N
and CC N
superior JJ N
to TO N
placebo VB i
in IN N
improving VBG N
hemorrhoidal NN N
and CC N
post-surgical JJ N
symptoms NNS N
during IN N
the DT N
five CD N
days NNS N
following VBG N
surgery NN N
. . N

-DOCSTART- -7706148- O O

Teaching VBG i
children NNS i
with IN i
autism NN i
to TO i
seek VB i
information NN i
: : i
acquisition NN N
of IN N
novel JJ N
information NN N
and CC N
generalization NN N
of IN N
responding VBG N
. . N

A DT i
time NN i
delay NN i
procedure NN i
was VBD i
used VBN i
to TO i
teach VB i
3 CD i
children NNS i
with IN i
autism NN i
to TO i
ask VB i
the DT i
question NN i
What WP i
's VBZ i
that DT i
? . i
when WRB i
novel JJ i
stimuli NNS i
were VBD i
presented VBN i
during IN i
an DT i
instructional JJ i
task NN i
. . i

Once IN N
the DT N
ability NN N
to TO N
ask VB N
the DT N
question NN N
was VBD N
acquired VBN N
, , N
the DT N
children NNS N
's POS N
ability NN N
to TO N
learn VB N
novel JJ N
information NN N
by IN N
asking VBG N
the DT N
question NN N
was VBD N
assessed VBN N
. . N

The DT N
children NNS N
were VBD N
then RB N
taught VBN N
to TO N
ask VB N
the DT N
question NN N
within IN N
a DT N
less RBR N
structured JJ N
context NN N
. . N

All DT N
three CD N
studies NNS N
used VBD N
a DT N
multiple JJ N
baseline NN N
across IN N
participants NNS N
. . N

Generalization NN N
was VBD N
assessed VBN N
in IN N
a DT N
different JJ N
room NN N
, , N
to TO N
a DT N
new JJ N
person NN N
, , N
and CC N
to TO N
novel VB N
stimuli NNS N
. . N

All DT N
of IN N
the DT N
children NNS p
learned VBD N
to TO N
ask VB N
the DT N
question NN N
within IN N
the DT N
instructional JJ N
context NN N
, , N
while IN N
on IN N
a DT N
walk NN N
in IN N
the DT N
school NN N
building NN N
, , N
and CC N
to TO N
request VB N
information NN N
about IN N
three-dimensional JJ N
objects NNS N
. . N

The DT N
acquisition NN o
of IN o
novel JJ o
information NN o
was VBD N
consistent JJ N
for IN N
receptive JJ N
and CC N
expressive JJ N
tests NNS N
for IN N
2 CD N
of IN N
the DT N
children NNS N
, , N
with IN N
varied JJ N
results NNS N
for IN N
the DT N
3rd CD N
. . N

These DT N
studies NNS N
indicate VBP N
that IN N
children NNS p
with IN p
autism NN p
can MD N
be VB N
taught VBN N
to TO N
ask VB N
questions NNS N
that WDT N
lead VBP N
to TO N
the DT N
acquisition NN N
of IN N
new JJ N
information NN N
. . N

-DOCSTART- -7881024- O O

Gastric JJ p
ulcer NN p
treatment NN p
with IN N
intravenous JJ N
human JJ i
epidermal JJ i
growth NN i
factor NN i
: : i
a DT N
double-blind NN N
controlled VBN N
clinical JJ N
study NN N
. . N

We PRP N
introduced VBD N
a DT N
double-blind NN N
controlled VBN N
clinical JJ N
study NN N
to TO N
compare VB N
intravenous JJ i
human JJ i
epidermal JJ i
growth NN i
factor NN i
( ( i
hEGF NN i
) ) i
to TO N
cetraxate VB i
hydrochloride NN i
( ( i
CH NNP i
) ) i
, , N
an DT N
antiulcer JJ N
drug NN N
, , N
for IN N
their PRP$ N
healing NN N
effect NN N
on IN N
gastric JJ o
ulcers NNS o
. . o

We PRP N
also RB N
prospected VBD N
an DT N
oral JJ N
use NN N
of IN N
EGF NNP i
on IN N
the DT N
basis NN N
of IN N
our PRP$ N
experimental JJ N
evidence NN N
. . N

In IN N
the DT N
clinical JJ N
trial NN N
, , N
the DT N
rate NN o
of IN o
ulcer NN o
healing VBG o
within IN N
8 CD N
weeks NNS N
was VBD N
77.9 CD N
% NN N
( ( p
67/86 CD p
) ) p
in IN N
patients NNS p
receiving VBG p
6 CD p
micrograms NNS p
EGF NNP i
intravenously RB p
twice RB p
a DT p
week NN p
, , N
being VBG N
significantly RB N
greater JJR N
than IN N
51.7 CD N
% NN N
( ( N
45/87 CD N
) ) N
in IN N
those DT N
given VBN N
CH NNP i
. . i

Taking VBG N
together RB N
all DT N
aspects NNS N
assessed VBD N
including VBG N
the DT N
healing NN o
rate NN o
, , o
pain NN o
relief NN o
, , o
blood NN o
examination NN o
and CC o
adverse JJ o
reactions NNS o
, , N
we PRP N
judged VBD N
the DT N
hEGF NN i
to TO N
be VB N
a DT N
useful JJ N
and CC N
safe JJ N
anticuler NN N
drug NN N
. . N

In IN N
rats NNS N
, , N
50 CD N
micrograms/kg NN N
mouse NN N
EGF NNP N
( ( N
mEGF NN N
) ) N
and CC N
2 CD N
% NN N
hydroxypropyl NN i
cellulose NN i
( ( N
HPC NNP N
) ) N
or CC N
1.0 CD N
g/kg JJ N
sucralfate NN N
given VBN N
by IN N
gastric JJ N
intubation NN N
significantly RB N
raised VBD N
the DT N
residual JJ o
mEGF NN o
levels NNS o
in IN N
both DT N
gastric JJ N
luminal JJ N
content NN N
( ( N
HPC NNP N
: : N
x JJ N
30 CD N
; : N
sucralfate NN N
: : N
x RB N
300 CD N
as RB N
high JJ N
as IN N
those DT N
in IN N
EGF NNP N
alone RB N
) ) N
and CC N
tissue NN N
( ( N
HPC NNP N
: : N
x JJ N
60 CD N
; : N
sucralfate NN N
: : N
x JJ N
100 CD N
) ) N
. . N

In IN N
addition NN N
, , N
the DT N
combined JJ N
treatments NNS N
significantly RB N
promoted VBD N
healing NN o
of IN o
rat NN o
gastric JJ o
ulcers NNS o
whereas VBP N
each DT N
agent NN N
alone RB N
had VBD N
no DT N
significant JJ N
effect NN N
as IN N
compared VBN N
with IN N
control NN N
( ( N
saline NN N
) ) N
. . N

This DT N
indicated VBD N
the DT N
beneficial JJ N
effect NN N
on IN N
ulcers NNS N
of IN N
oral JJ N
administration NN N
of IN N
EGF NNP i
with IN N
agents NNS N
allowing VBG N
it PRP N
to TO N
remain VB N
at IN N
high JJ N
levels NNS N
in IN N
the DT N
stomach NN N
, , N
whereas IN N
most JJS N
reports NNS N
suggested VBD N
less RBR N
effect NN N
of IN N
oral JJ N
EGF NNP N
on IN N
healing NN N
of IN N
gastroduodenal JJ N
ulcers NNS N
. . N

Subsequent JJ N
to TO N
the DT N
clinical JJ N
study NN N
, , N
evaluation NN N
of IN N
oral JJ N
use NN N
of IN N
EGF NNP i
may MD N
be VB N
expected VBN N
as IN N
the DT N
next JJ N
step NN N
in IN N
the DT N
treatment NN N
of IN N
ulcers NNS N
. . N

The DT N
experimental JJ N
evidence NN N
above IN N
would MD N
possibly RB N
be VB N
a DT N
guide NN N
for IN N
such JJ N
trial NN N
. . N

-DOCSTART- -6751144- O O

Epidural JJ i
morphine NN i
in IN N
the DT p
elderly JJ p
. . p

A DT N
controlled JJ N
trial NN N
after IN p
upper JJ p
abdominal JJ p
surgery NN p
. . p

The DT N
effectiveness NN N
of IN N
epidurally RB i
administered VBN i
morphine NN i
in IN N
the DT N
relief NN o
of IN o
pain NN o
after IN N
upper JJ N
abdominal JJ N
surgery NN N
was VBD N
assessed VBN N
in IN N
a DT N
controlled VBN N
study NN N
involving VBG N
20 CD p
patients NNS p
aged VBD p
61 CD p
to TO p
78 CD p
years NNS p
. . p

Analgesia NNP o
provided VBN N
by IN N
epidural JJ i
morphine NN i
was VBD N
comparable JJ N
to TO N
that DT N
obtained VBN N
in IN N
matched JJ N
patients NNS N
given VBN N
an DT N
intramuscular JJ i
regime NN i
. . i

The DT N
total JJ N
dose NN N
required VBN N
by IN N
the DT N
epidural JJ N
route NN N
was VBD N
less JJR N
than IN N
one-fifth JJ N
that IN N
required VBD N
intramuscularly RB N
, , N
and CC N
sedation NN N
was VBD N
correspondingly RB N
reduced VBN N
. . N

Postoperative JJ o
respiratory NN o
mechanics NNS o
, , N
however RB N
, , N
were VBD N
not RB N
significantly RB N
improved VBN N
and CC N
delayed VBN o
respiratory NN o
depression NN o
was VBD N
observed VBN N
in IN N
one CD N
patient NN N
. . N

It PRP N
is VBZ N
concluded VBN N
that IN N
in IN N
elderly JJ p
patients NNS p
undergoing VBG p
upper JJ p
abdominal JJ p
surgery NN p
the DT N
risks NNS N
related VBN N
to TO N
the DT N
use NN N
of IN N
morphine NN i
by IN N
the DT N
epidural JJ N
route NN N
outweigh VBP N
the DT N
marginal JJ N
advantages NNS N
it PRP N
may MD N
offer VB N
over IN N
conventional JJ N
analgesic JJ N
techniques NNS N
. . N

-DOCSTART- -10790473- O O

Language NN N
, , N
speech NN N
sound NN N
production NN N
, , N
and CC N
cognition NN N
in IN N
three-year-old JJ p
children NNS p
in IN p
relation NN p
to TO p
otitis VB p
media NNS p
in IN p
their PRP$ p
first JJ p
three CD p
years NNS p
of IN p
life NN p
. . p

OBJECTIVE CC N
As IN N
part NN N
of IN N
a DT N
prospective JJ N
study NN N
of IN N
possible JJ N
effects NNS N
of IN N
early-life JJ N
otitis NN N
media NNS N
on IN N
speech NN N
, , N
language NN N
, , N
cognitive JJ N
, , N
and CC N
psychosocial JJ N
development NN N
, , N
we PRP N
tested VBD N
relationships NNS N
between IN N
children NNS N
's POS N
cumulative JJ N
duration NN N
of IN N
middle JJ N
ear JJ N
effusion NN N
( ( N
MEE NNP N
) ) N
in IN N
their PRP$ N
first JJ N
3 CD N
years NNS N
of IN N
life NN N
and CC N
their PRP$ N
scores NNS N
on IN N
measures NNS o
of IN o
language NN o
, , o
speech NN o
sound NN o
production NN o
, , o
and CC o
cognition NN o
at IN N
3 CD N
years NNS N
of IN N
age NN N
. . N

METHODS NNP N
We PRP p
enrolled VBD p
6350 CD p
healthy JJ p
infants NNS p
by IN p
2 CD p
months NNS p
of IN p
age NN p
who WP p
presented VBD p
for IN p
primary JJ p
care NN p
at IN p
1 CD p
of IN p
2 CD p
urban JJ p
hospitals NNS p
or CC p
1 CD p
of IN p
2 CD p
small JJ p
town/rural JJ p
and CC p
4 CD p
suburban JJ p
private JJ p
pediatric JJ p
practices NNS p
. . p

We PRP N
intensively RB N
monitored VBD N
the DT N
children NNS N
's POS N
middle JJ N
ear NN N
status NN N
by IN N
pneumatic JJ i
otoscopy NN i
, , i
supplemented VBN i
by IN i
tympanometry NN i
, , N
throughout IN N
their PRP$ N
first JJ N
3 CD N
years NNS N
of IN N
life NN N
; : N
we PRP N
monitored VBD N
the DT N
validity NN N
of IN N
the DT N
otoscopic JJ N
observations NNS N
on IN N
an DT N
ongoing JJ N
basis NN N
; : N
and CC N
we PRP i
treated VBD i
children NNS i
for IN i
otitis NN i
media NNS i
according VBG i
to TO i
specified VBN i
guidelines NNS i
. . i

Children NNP p
who WP p
met VBD p
specified VBN p
minimum JJ p
criteria NNS p
regarding VBG p
the DT p
persistence NN p
of IN p
MEE NNP p
became VBD p
eligible JJ p
for IN p
a DT p
clinical JJ p
trial NN p
in IN N
which WDT N
they PRP N
were VBD N
assigned VBN N
randomly RB N
to TO N
undergo VB N
tympanostomy JJ i
tube NN i
placement NN i
either CC N
promptly RB N
or CC N
after IN N
a DT N
defined JJ N
extended JJ N
period NN N
if IN N
MEE NNP N
remained VBD N
present JJ N
. . N

From IN p
among IN p
those DT p
remaining VBG p
, , p
we PRP p
selected VBD p
randomly RB p
, , p
within IN p
sociodemographic JJ p
strata NNS p
, , p
a DT p
sample NN p
of IN p
241 CD p
children NNS p
who WP p
represented VBD p
a DT p
spectrum NN p
of IN p
MEE NNP p
experience NN p
from IN p
having VBG p
no DT p
MEE NNP p
to TO p
having VBG p
MEE NNP p
whose WP$ p
cumulative JJ p
duration NN p
fell VBD p
just RB p
short RB p
of IN p
meeting VBG p
randomization NN p
criteria NNS p
. . p

In IN p
subjects NNS p
so RB p
selected VBN p
, , p
the DT p
estimated JJ p
duration NN p
of IN p
MEE NNP p
ranged VBD p
from IN p
none NN p
to TO p
65.6 CD p
% NN p
of IN p
the DT p
first JJ p
year NN p
of IN p
life NN p
and CC p
44.8 CD p
% NN p
of IN p
the DT p
first JJ p
3 CD p
years NNS p
of IN p
life NN p
. . p

In IN N
these DT N
241 CD p
children NNS p
we PRP N
assessed VBD N
language NN o
development NN o
, , o
speech NN o
sound NN o
production NN o
, , o
and CC o
cognition NN o
at IN N
3 CD N
years NNS N
of IN N
age NN N
, , N
using VBG N
both DT N
formal JJ N
tests NNS N
and CC N
conversational JJ N
samples NNS N
. . N

RESULTS NNP N
We PRP N
found VBD N
weak JJ N
to TO N
moderate VB N
, , N
statistically RB N
significant JJ N
negative JJ N
correlations NNS N
between IN N
children NNS N
's POS N
cumulative JJ N
durations NNS N
of IN N
MEE NNP N
in IN N
their PRP$ N
first JJ N
year NN N
of IN N
life NN N
or CC N
in IN N
age NN N
periods NNS N
that WDT N
included VBD N
their PRP$ N
first JJ N
year NN N
of IN N
life NN N
, , N
and CC N
their PRP$ N
scores NNS o
on IN o
formal JJ o
tests NNS o
of IN o
receptive JJ o
vocabulary NN o
and CC o
verbal JJ o
aspects NNS o
of IN o
cognition NN o
at IN N
3 CD N
years NNS N
of IN N
age NN N
. . N

However RB N
, , N
the DT N
percent NN N
of IN N
variance NN N
in IN N
these DT N
scores NNS N
explained VBN N
by IN N
time NN N
with IN N
MEE NNP N
in IN N
the DT N
first JJ N
year NN N
of IN N
life NN N
beyond IN N
that DT N
explained VBN N
by IN N
sociodemographic JJ N
variables NNS N
ranged VBD N
only RB N
from IN N
1.2 CD N
% NN N
to TO N
2.9 CD N
% NN N
, , N
and CC N
the DT N
negative JJ N
correlations NNS N
were VBD N
concentrated VBN N
in IN N
the DT N
subgroup NN N
of IN N
children NNS N
whose WP$ N
families NNS N
had VBD N
private JJ N
health NN N
insurance NN N
( ( N
rather RB N
than IN N
Medicaid NNP N
) ) N
. . N

We PRP N
found VBD N
no DT N
significant JJ N
correlations NNS N
in IN N
the DT N
study NN N
population NN N
as IN N
a DT N
whole NN N
or CC N
in IN N
any DT N
subgroup NN N
between IN N
time NN N
with IN N
MEE NNP N
during IN N
antecedent JJ N
periods NNS N
and CC N
children NNS N
's POS N
scores NNS N
on IN N
measures NNS N
of IN N
spontaneous JJ o
expressive JJ o
language NN o
, , o
speech NN o
sound NN o
production NN o
, , o
or CC o
other JJ o
measured JJ o
aspects NNS o
of IN o
cognition NN o
. . o

In IN N
contrast NN N
, , N
by IN N
wide JJ N
margins NNS N
, , N
scores NNS o
on IN o
all DT o
measures NNS o
were VBD N
consistently RB N
highest JJS N
among IN N
the DT N
most RBS N
socioeconomically RB N
advantaged JJ N
children NNS N
and CC N
lowest JJS N
among IN N
the DT N
most RBS N
socioeconomically RB N
disadvantaged JJ N
children NNS N
. . N

CONCLUSIONS NNP N
Our PRP$ N
findings NNS N
suggest VBP N
either RB N
that DT N
persistent JJ p
early-life JJ p
MEE NNP p
actually RB N
causes VBZ N
later RB N
small JJ N
, , N
circumscribed JJ N
impairments NNS N
of IN N
receptive JJ N
language NN N
and CC N
verbal JJ N
aspects NNS N
of IN N
cognition NN N
in IN N
certain JJ N
groups NNS N
of IN N
children NNS N
or CC N
that DT N
unidentified JJ N
, , N
confounding VBG N
factors NNS N
predispose JJ N
children NNS N
both DT N
to TO N
early-life NN N
otitis NN N
media NNS N
and CC N
to TO N
certain JJ N
types NNS N
of IN N
developmental JJ o
impairment NN o
. . o

Findings NNS N
in IN N
the DT N
randomized JJ N
clinical JJ N
trial NN N
component NN N
of IN N
the DT N
larger JJR N
study NN N
should MD N
help VB N
distinguish VB N
between IN N
causality NN N
and CC N
confounding NN N
as IN N
explanations NNS N
for IN N
our PRP$ N
findings.language NN o
, , o
speech NN o
, , o
cognition NN o
, , N
development NN N
, , N
otitis NN N
media NNS N
, , N
middle JJ N
ear JJ N
effusion NN N
. . N

-DOCSTART- -24926950- O O

36-month JJ N
treatment NN N
experience NN N
of IN N
two CD N
doses NNS N
of IN N
leuprolide JJ i
acetate JJ i
3-month JJ i
depot NN i
for IN N
children NNS p
with IN p
central JJ p
precocious JJ p
puberty NN p
. . p

CONTEXT NNP N
We PRP N
have VBP N
recently RB N
demonstrated VBN N
short-term JJ N
( ( N
6-month JJ N
) ) N
efficacy NN N
and CC N
safety NN N
of IN N
leuprolide JJ i
acetate JJ i
3-month JJ i
depot NN i
11.25 CD N
and CC N
30 CD N
mg NN N
in IN N
children NNS p
with IN p
central JJ p
precocious JJ p
puberty NN p
( ( p
CPP NNP p
) ) p
. . p

OBJECTIVE UH N
To TO N
assess VB N
long-term JJ o
( ( N
36-month JJ N
) ) N
hypothalamic-pituitary-gonadal JJ o
axis JJ o
suppression NN o
and CC o
safety NN o
of IN N
leuprolide JJ i
acetate JJ i
3-month JJ i
depot NN i
11.25 CD N
and CC N
30 CD N
mg NN N
in IN N
children NNS p
with IN p
CPP NNP p
. . p

DESIGN NNP N
Open-label NNP N
, , N
36-month JJ N
extension NN N
. . N

SETTING NNP N
Twenty NNP p
pediatric JJ p
endocrine NN p
centers NNS p
. . p

PATIENTS VB N
Seventy-two JJ p
children NNS p
( ( p
mean JJ p
age NN p
, , p
8.5 CD p
? . p
1.6 CD p
y NN p
; : p
65 CD p
females NNS p
) ) p
with IN p
CPP NNP p
completed VBD p
and CC p
showed VBD o
maintenance NN o
of IN o
LH NNP o
suppression NN o
after IN p
a DT p
6-month JJ p
lead-in NN p
study NN p
. . p

INTERVENTION NNP i
Leuprolide NNP i
acetate NN i
depot NN i
( ( N
11.25 CD N
or CC N
30 CD N
mg NN N
) ) N
administered VBD N
im JJ N
every DT N
3 CD N
months NNS N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP o
Peak-stimulated NNP o
LH NNP o
, , o
estradiol NN o
, , o
T NNP o
, , o
growth NN o
rate NN o
, , o
pubertal JJ o
progression NN o
, , o
and CC o
adverse JJ o
events NNS o
( ( o
AEs NNP o
) ) o
. . o

RESULTS JJ N
Twenty-nine NNP N
of IN N
34 CD N
subjects NNS N
in IN N
the DT N
11.25-mg JJ N
group NN N
and CC N
36 CD N
of IN N
38 CD N
subjects NNS N
in IN N
the DT N
30-mg JJ N
group NN N
had VBD o
LH NNP o
values NNS o
< VBP N
4 CD N
mIU/mL NNS N
after IN N
day NN N
1 CD N
at IN N
all DT N
time NN N
points NNS N
. . N

All DT N
seven CD N
subjects NNS N
who WP N
escaped VBD o
LH NNP o
suppression NN o
at IN N
any DT N
time NN N
still RB N
maintained VBD o
sex NN o
steroid NN o
concentrations NNS o
at IN N
prepubertal JJ N
levels NNS N
and CC N
showed VBD N
no DT N
signs NNS N
of IN o
pubertal JJ o
progression NN o
. . o

AEs NNP o
were VBD N
comparable JJ N
between IN N
groups NNS N
, , N
with IN o
injection NN o
site NN o
pain NN o
being VBG N
the DT N
most RBS N
common JJ N
( ( N
26.4 CD N
% NN N
overall JJ N
) ) N
. . N

No DT o
AE NNP o
led VBD N
to TO N
discontinuation NN N
of IN N
study JJ N
drug NN N
. . N

The DT o
safety NN o
profile NN o
over IN N
36 CD N
months NNS N
was VBD N
comparable JJ N
to TO N
that DT N
observed VBD N
during IN N
the DT N
6-month JJ N
pivotal NN N
study NN N
. . N

CONCLUSIONS VB N
The DT N
two CD N
doses NNS N
of IN i
leuprolide JJ i
acetate JJ i
3-month JJ i
depot NN N
were VBD N
associated VBN N
with IN N
an DT o
acceptable JJ o
safety NN o
profile NN o
and CC N
provided VBD o
maintenance NN o
of IN o
LH NNP o
suppression NN o
in IN N
the DT N
majority NN N
of IN N
children NNS N
with IN N
CPP NNP N
during IN N
the DT N
36 CD N
months NNS N
of IN N
the DT N
study NN N
or CC N
until IN N
readiness NN N
for IN N
puberty NN N
. . N

-DOCSTART- -23760519- O O

Ultrasonography-guided JJ i
bilateral JJ i
rectus NN i
sheath NN i
block NN i
vs NN i
local JJ i
anesthetic JJ i
infiltration NN i
after IN N
pediatric JJ N
umbilical JJ N
hernia NN N
repair NN N
: : N
a DT N
prospective JJ N
randomized VBN N
clinical JJ N
trial NN N
. . N

IMPORTANCE NNP N
Regional NNP i
anesthetic JJ i
techniques NNS i
can MD N
be VB N
used VBN N
to TO N
alleviate VB N
postoperative JJ N
pain NN N
in IN N
children NNS N
undergoing VBG N
pediatric JJ N
surgical JJ N
procedures NNS N
. . N

Use NNP N
of IN N
ultrasonographic JJ N
guidance NN N
for IN N
bilateral JJ N
rectus NN N
sheath NN N
block NN N
( ( N
BRSB NNP N
) ) N
has VBZ N
been VBN N
shown VBN N
to TO N
improve VB N
immediate JJ N
pain NN N
scores NNS N
and CC N
reduce VB N
use NN N
of IN N
postoperative JJ N
analgesia NN N
in IN N
the DT N
postanesthesia NN N
care NN N
unit NN N
( ( N
PACU NNP N
) ) N
. . N

OBJECTIVE UH N
To TO N
compare VB N
efficacy NN N
of IN N
ultrasonography-guided JJ N
BRSB NNP N
and CC N
local JJ N
anesthetic JJ N
infiltration NN N
( ( N
LAI NNP N
) ) N
in IN N
providing VBG N
postoperative JJ N
analgesia NN N
after IN p
pediatric JJ p
umbilical JJ p
hernia NN p
repair NN p
. . p

DESIGN NNP N
Prospective NNP N
, , N
observer-blinded JJ N
, , N
randomized JJ N
clinical JJ N
trial NN N
. . N

SETTING CC N
Tertiary-referral JJ p
urban JJ p
children NNS p
's POS p
hospital NN p
. . p

PARTICIPANTS NNP N
Eligible JJ p
children NNS p
3 CD p
to TO p
12 CD p
years NNS p
of IN p
age NN p
undergoing JJ p
elective JJ p
umbilical JJ p
hernia NN p
repair NN p
from IN p
November NNP p
16 CD p
, , p
2009 CD p
, , p
through IN p
May NNP p
31 CD p
, , p
2011 CD p
. . p

INTERVENTIONS NNP N
Ropivacaine NNP i
hydrochloride NN i
administered VBD i
at IN i
the DT i
conclusion NN i
of IN i
surgery NN i
as IN i
LAI NNP i
by IN i
the DT i
surgeon NN i
( ( N
n JJ N
= NNP N
25 CD N
) ) N
or CC N
as IN i
ultrasonography-guided JJ i
BRSB NNP i
by IN i
the DT i
anesthesiologist NN i
( ( i
n JJ i
= NNP N
27 CD N
) ) N
. . N

MAIN NNP N
OUTCOMES NNP N
AND NNP N
MEASURES NNP N
Scores NNP o
on IN o
the DT o
FACES NNP o
Pain NNP o
Rating NNP o
Scale NNP o
measured VBD o
at IN o
10-minute JJ o
intervals NNS o
and CC o
all DT o
use NN o
of IN o
analgesic JJ o
medications NNS o
in IN o
the DT o
PACU NNP o
. . o

RESULTS NNP o
Median JJ o
FACES NNP o
scores NNS o
in IN N
the DT N
PACU NNP N
were VBD N
lower JJR N
in IN N
the DT N
BRSB NNP N
group NN N
compared VBN N
with IN N
the DT N
LAI NNP N
group NN N
at IN N
10 CD N
minutes NNS N
( ( N
0 CD N
vs RB N
1 CD N
; : N
P NNP N
= NNP N
.04 NNP N
) ) N
, , N
30 CD N
minutes NNS N
( ( N
0 CD N
vs RB N
1 CD N
; : N
P NNP N
= NNP N
.01 NNP N
) ) N
, , N
and CC N
40 CD N
minutes NNS N
or CC N
later RB N
( ( N
0 CD N
vs RB N
1 CD N
; : N
P NNP N
= NNP N
.03 NNP N
) ) N
. . N

Fewer JJR N
doses NNS o
of IN o
opioid NN o
and CC o
nonopioid JJ o
medications NNS o
were VBD o
given VBN o
to TO N
the DT N
BRSB NNP N
group NN N
compared VBN N
with IN N
the DT N
LAI NNP N
group NN N
( ( N
5 CD N
vs RB N
11 CD N
doses NNS N
for IN N
opioids NNS N
; : N
5 CD N
vs NN N
10 CD N
for IN N
nonopioids NNS N
) ) N
. . N

CONCLUSIONS NNP N
AND CC N
RELEVANCE NNP N
In IN N
the DT N
PACU NNP N
, , N
ultrasonography-guided JJ N
BRSB NNP N
after IN N
umbilical JJ N
hernia NN N
repair NN N
in IN N
children NNS N
is VBZ N
associated VBN N
with IN N
lower JJR N
median JJ N
FACES NNP N
scores NNS N
and CC N
decreased VBN N
use NN N
of IN N
opioid NN N
and CC N
nonopioid JJ N
medications NNS N
compared VBN N
with IN N
LAI NNP N
. . N

Future NNP N
studies NNS N
could MD N
examine VB N
the DT N
use NN N
of IN N
longer-acting JJ N
anesthetic JJ N
agents NNS N
with IN N
ultrasonography-guided JJ N
BRSB NNP N
. . N

TRIAL NNP N
REGISTRATION NNP N
clinicaltrials.gov NN N
Identifier NNP N
: : N
NCT01015053 NN N
. . N

-DOCSTART- -15678729- O O

Postoperative JJ p
magnesium NN i
sulphate NN i
infusion NN i
reduces NNS N
analgesic JJ N
requirements NNS N
in IN N
spinal JJ N
anaesthesia NN N
. . N

BACKGROUND NNP N
AND NNP N
OBJECTIVES NNP N
Magnesium NNP i
sulphate NN i
infusion NN N
during IN N
general JJ N
anaesthesia NN N
reduces NNS N
anaesthetic JJ o
consumption NN o
and CC N
analgesic JJ o
requirements NNS o
. . o

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
assess VB N
the DT N
effects NNS N
of IN N
postoperative JJ N
magnesium NN i
infusion NN N
on IN N
duration NN o
of IN o
block NN o
, , o
sedation NN o
and CC o
analgesic JJ o
consumption NN o
after IN N
spinal JJ N
anaesthesia NN N
. . N

METHODS NNP N
Fifty NNP p
ASA NNP p
I-II JJ p
patients NNS p
were VBD N
included VBN N
in IN N
the DT N
randomized JJ N
double JJ N
blind NN N
study NN N
. . N

Spinal NNP i
anaesthesia NN i
was VBD i
performed VBN i
at IN i
L3-4 NNP i
or CC i
L4-5 NNP i
interspace NN i
with IN i
12.5 CD i
mg NNS i
0.5 CD i
% NN i
heavy JJ i
bupivacaine NN i
, , i
using VBG i
a DT i
25 CD i
G NNP i
Quincke NNP i
needle NN i
. . i

Patients NNS i
received VBD i
a DT i
5 CD i
mg NN i
kg NN i
( ( i
-1 NNP i
) ) i
bolus NN i
of IN i
magnesium NN i
sulphate NN i
followed VBN i
by IN i
a DT i
500 CD i
mg NN i
h NN i
( ( i
-1 NNP i
) ) i
infusion NN i
or CC i
saline NN i
in IN N
the DT N
same JJ N
volumes NNS N
for IN N
24 CD N
h. JJ N
Time NNP o
to TO o
first VB o
pain NN o
, , o
analgesic JJ o
request NN o
, , o
return NN o
of IN o
motor NN o
function NN o
, , o
visual JJ o
analogue NN o
pain NN o
and CC o
sedation NN o
scores NNS o
were VBD N
evaluated VBN N
every DT N
4 CD N
h NN N
during IN N
the DT N
24 CD N
h JJ N
postoperative JJ N
period NN N
. . N

The DT N
t- JJ N
and CC N
U-tests NNS N
were VBD N
used VBN N
for IN N
statistical JJ N
analyses NNS N
. . N

Data NNS N
were VBD N
expressed VBN N
as IN N
mean JJ N
+/- JJ N
SD NNP N
, , N
with IN N
P NNP N
< $ N
0.05 CD N
being VBG N
considered VBN N
significant JJ N
. . N

RESULTS NNP N
Vital JJ o
signs NNS o
were VBD N
stable JJ N
during IN N
spinal JJ N
anaesthesia NN N
and CC N
postoperative JJ N
period NN N
. . N

When WRB N
compared VBN N
to TO N
the DT N
control NN N
group NN N
, , N
time NN o
to TO o
analgesic VB o
need NN o
was VBD N
increased VBN N
and CC N
total JJ o
analgesic JJ o
consumption NN o
was VBD N
reduced VBN N
in IN N
the DT N
magnesium NN N
group NN N
( ( N
meperidine JJ N
consumption NN N
60.0 CD N
+/- JJ N
73.1 CD N
mg NNS N
control NN N
group NN N
, , N
31.8 CD N
+/- JJ N
30.7 CD N
mg JJ N
magnesium NN N
group NN N
, , N
P NNP N
= NNP N
0.02 CD N
) ) N
. . N

CONCLUSIONS NNP N
Magnesium NNP i
sulphate JJ i
infusion NN N
may MD N
be VB N
used VBN N
as IN N
an DT N
adjunct NN N
for IN N
reducing VBG N
analgesic JJ o
consumption NN o
after IN p
spinal JJ p
anaesthesia NN p
. . p

-DOCSTART- -24656872- O O

Factors NNS N
associated VBN N
with IN N
low JJ o
consumption NN o
of IN o
fruits NNS o
and CC o
vegetables NNS o
by IN N
preschoolers NNS p
of IN p
low JJ p
socio-economic JJ p
level NN p
. . p

OBJECTIVE UH N
To TO N
evaluate VB N
factors NNS N
associated VBN N
with IN N
low JJ N
consumption NN o
of IN o
fruits NNS o
and CC o
vegetables NNS o
among IN N
preschoolers NNS p
from IN p
families NNS p
treated VBN p
at IN p
basic JJ p
health NN p
centers NNS p
in IN p
Porto NNP p
Alegre NNP p
, , p
RS NNP p
, , p
Brazil NNP p
. . p

METHODS NNP N
This DT N
was VBD N
a DT N
cohort NN N
study NN N
nested VBN N
in IN N
a DT N
randomized JJ N
field NN N
trial NN N
. . N

Data NNP N
collection NN N
was VBD N
performed VBN N
through IN N
structured JJ i
questionnaires NNS i
to TO N
obtain VB N
demographic JJ N
and CC N
dietary JJ N
data NNS N
, , N
combined VBN N
with IN N
two CD N
24-hour JJ N
recalls NNS N
in IN p
the DT p
age NN p
groups NNS p
12-16 JJ p
months NNS p
and CC p
again RB p
at IN p
2-3 CD p
years NNS p
of IN p
age NN p
. . p

Data NNS N
on IN N
the DT N
consumption NN o
of IN o
one CD o
daily JJ o
serving NN o
of IN o
fruits NNS o
( ( o
80 CD o
g NN o
) ) o
and CC o
vegetables NNS o
( ( o
60 CD o
g NN o
) ) o
were VBD N
evaluated VBN N
, , N
as RB N
well RB N
as IN N
consumption NN N
of IN N
non-recommended JJ o
foods NNS o
such JJ N
as IN N
candy NN i
, , i
chocolate NN i
, , i
and CC i
soft JJ i
drinks NNS i
. . i

Statistical JJ N
analyses NNS N
were VBD N
performed VBN N
using VBG N
Poisson NNP N
regression NN N
with IN N
robust JJ N
estimation NN N
. . N

RESULTS VB N
A DT p
total NN p
of IN p
388 CD p
children NNS p
aged VBN p
2-3 CD p
years NNS p
were VBD p
evaluated VBN p
; : p
of IN N
these DT N
, , N
58 CD N
% NN N
and CC N
87.4 CD N
% NN N
did VBD N
not RB N
consume VB N
one CD N
daily JJ N
serving NN N
of IN N
fruits NNS i
and CC i
vegetables NNS i
, , N
respectively RB N
. . N

The DT N
following JJ N
factors NNS N
were VBD N
negatively RB N
associated VBN N
with IN N
fruit NN o
consumption NN o
: : o
family NN o
income NN o
higher JJR o
than IN o
four CD o
minimum NN o
wages NNS o
, , N
( ( N
p=0.024 NN N
) ) N
, , N
lower JJR o
paternal JJ o
educational JJ o
level NN o
( ( N
p=0.03 NN N
) ) N
, , N
and CC N
lower JJR o
fruit NN o
consumption NN o
at IN o
12-16 JJ o
months NNS o
( ( N
p=0.002 NN N
) ) N
. . N

Factors NNS N
negatively RB N
associated VBN N
with IN N
the DT N
consumption NN o
of IN o
vegetables NNS o
were VBD N
low JJ o
paternal JJ o
educational JJ o
level NN o
( ( N
p=0.033 NN N
) ) N
and CC N
consumption NN o
of IN o
high-sugar JJ o
content NN o
beverages NNS o
at IN o
12-16 JJ o
months NNS o
( ( N
p=0.014 NN N
) ) N
. . N

CONCLUSION VB N
This DT N
study NN N
demonstrated VBD N
a DT N
high JJ N
prevalence NN N
of IN N
children NNS N
who WP N
consumed VBD N
less JJR N
than IN N
one CD N
daily JJ N
serving NN N
of IN N
fruit NN i
and CC i
vegetables NNS i
; : i
early JJ o
feeding NN o
practices NNS o
, , o
parental JJ o
education NN o
, , N
and CC N
family NN o
income NN o
were VBD N
associated VBN N
with IN N
this DT N
process NN N
. . N

-DOCSTART- -12538120- O O

Direct JJ i
aortic JJ i
cannulation NN i
in IN N
minimally RB p
invasive JJ p
mitral-valve JJ p
operations NNS p
. . p

The DT N
minimally RB i
invasive JJ i
Port-Access NNP i
( ( N
Heartport NNP N
, , N
Redwood NNP N
City NNP N
, , N
CA NNP N
) ) N
approach NN N
in IN N
mitral-valve JJ N
operations NNS N
originally RB N
required VBN N
femoral JJ i
arterial JJ i
cannulation NN i
, , N
which WDT N
is VBZ N
considered VBN N
a DT N
disadvantage NN N
, , N
especially RB N
in IN N
patients NNS p
with IN p
peripheral JJ p
vessel NN p
disease NN p
. . p

In IN N
this DT N
study NN N
20 CD p
patients NNS p
were VBD p
prospectively RB p
randomized VBN p
into IN p
2 CD p
groups NNS p
, , p
to TO p
undergo VB p
either RB p
standard JJ i
femoral NN i
( ( i
group NN i
A NNP i
) ) i
or CC i
direct JJ i
aortic JJ i
cannulation NN i
( ( p
group NN p
B NNP p
) ) p
. . p

Pre- JJ N
and CC N
postoperative JJ N
data NNS N
as RB N
well RB N
as IN N
markers NNS N
for IN N
myocardial JJ N
damage NN N
were VBD N
assessed VBN N
. . N

Postoperatively RB N
, , N
patients NNS N
of IN N
group NN N
B NNP N
showed VBD N
lower JJR N
levels NNS o
of IN o
damage NN o
, , N
indicating VBG N
that IN N
direct JJ i
aortic JJ i
cannulation NN i
might MD N
provide VB N
better JJR N
myocardial JJ N
protection NN N
. . N

Furthermore NNP N
, , N
the DT N
direct JJ i
aortic JJ i
cannulation NN i
technique NN N
may MD N
eliminate VB N
complications NNS o
associated VBN N
with IN N
the DT N
standard JJ i
femoral JJ i
artery NN i
cannulation NN i
. . i

-DOCSTART- -23303244- O O

Accuracy NN N
of IN N
noninvasive JJ o
haemoglobin NN o
measurement NN o
by IN N
pulse JJ i
oximetry NN i
depends VBZ N
on IN N
the DT N
type NN N
of IN N
infusion NN N
fluid NN N
. . N

CONTEXT NNP N
Measurement NNP N
of IN N
blood NN N
haemoglobin NN o
concentration NN N
by IN N
pulse JJ i
oximetry NN i
could MD N
be VB N
of IN N
value NN N
in IN N
determining VBG N
when WRB N
erythrocytes NNS N
should MD N
be VB N
transfused VBN N
during IN N
surgery NN N
, , N
but CC N
the DT N
effect NN N
of IN N
infusion NN N
fluids NNS N
on IN N
the DT N
results NNS N
is VBZ N
unclear JJ N
. . N

OBJECTIVE NNP N
To TO N
study VB N
the DT N
effect NN N
of IN N
crystalloid NN N
and CC N
colloid JJ N
fluid NN N
on IN N
the DT N
accuracy NN N
( ( N
bias NN N
) ) N
and CC N
precision NN N
of IN N
pulse JJ N
oximetry NN N
haemoglobin NN o
estimation NN N
to TO N
indicate VB N
the DT N
venous JJ N
haemoglobin NN N
concentration NN N
in IN N
volunteers NNS p
. . p

DESIGN NNP N
Open NNP N
interventional JJ N
crossover NN N
study NN N
. . N

SETTING NNP N
Single NNP p
university NN p
hospital NN p
. . p

PARTICIPANTS NNP N
Ten CD p
male NN p
volunteers NNS p
aged VBN p
18-28 JJ p
( ( p
mean JJ p
22 CD p
) ) p
years NNS p
. . p

INTERVENTIONS NNP N
Each DT N
volunteer NN N
underwent JJ N
three CD N
infusion NN i
experiments NNS i
on IN N
separate JJ N
days NNS N
and CC N
in IN N
random JJ N
order NN N
. . N

The DT N
infusions NNS N
were VBD N
Ringer NNP i
's POS i
acetate NN i
( ( i
20 CD i
ml RB i
kg NN i
) ) i
, , i
hydroxyethyl VBD i
starch NN i
130/0.4 CD i
( ( i
10 CD i
ml RB i
kg NN i
) ) i
and CC i
a DT i
combination NN i
of IN i
both DT i
. . N

RESULTS NN N
At IN N
the DT N
end NN N
of IN N
the DT N
infusions NNS i
of IN i
Ringer NNP i
's POS i
acetate NN i
, , N
pulse JJ o
oximetry NN o
haemoglobin NN o
concentration NN o
had VBD N
decreased VBN N
more RBR N
than IN N
the DT N
true JJ N
haemoglobin NN N
concentration NN N
( ( N
15 CD N
vs. FW N
8 CD N
% NN N
; : N
P NNP N
< VBZ N
0.005 CD N
; : N
n CC N
= VB N
10 CD N
) ) N
whereas IN N
starch NN N
solution NN N
decreased VBD o
pulse JJ o
oximetry NN o
haemoglobin NN o
concentration NN o
less JJR o
than IN N
true JJ N
haemoglobin JJ N
concentration NN N
( ( N
7 CD N
vs. FW N
11 CD N
% NN N
; : N
P NNP N
< VBZ N
0.02 CD N
; : N
n CC N
= VB N
20 CD N
) ) N
. . N

The DT N
same JJ N
differences NNS N
were VBD N
seen VBN N
when WRB N
the DT N
fluids NNS N
were VBD N
infused VBN N
separately RB N
and CC N
when WRB N
they PRP N
were VBD N
combined VBN N
. . N

The DT N
overall JJ N
difference NN N
between IN N
all DT N
956 CD N
pairs NNS N
of IN N
pulse JJ o
oximetry NN o
haemoglobin NN o
concentration NN o
and CC o
true JJ o
haemoglobin NN o
concentrations NNS o
( ( o
the DT o
bias NN o
) ) N
averaged VBD N
only RB N
-0.7 JJ N
g NN N
l NN N
whereas IN N
the DT N
95 CD N
% NN N
prediction NN N
interval NN N
was VBD N
wide JJ N
, , N
ranging VBG N
from IN N
-24.9 NN N
to TO N
23.7 CD N
g NNS N
l. RBR N
In IN N
addition NN N
to TO N
the DT N
choice NN N
of IN N
infusion NN N
fluid NN N
, , N
the DT N
bias NN N
was VBD N
strongly RB N
dependent JJ N
on IN N
the DT N
volunteer NN N
( ( N
each DT N
factor NN N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

CONCLUSION VB N
The DT N
bias NN N
of IN N
measuring VBG N
haemoglobin JJ N
concentration NN N
by IN i
pulse JJ i
oximetry NN i
is VBZ i
dependent JJ N
on IN N
whether IN N
a DT N
crystalloid NN N
or CC N
a DT N
colloid JJ N
fluid NN N
is VBZ N
infused VBN N
. . N

TRIAL NNP N
REGISTRATION NNP N
ClinicalTrials NNP N
identifier NN N
: : N
NCT01195025 NNP N
. . N

-DOCSTART- -11788219- O O

Quantitative JJ N
angiographic JJ N
methods NNS N
for IN N
appropriate JJ N
end-point JJ o
analysis NN o
, , o
edge-effect JJ o
evaluation NN o
, , N
and CC N
prediction NN o
of IN o
recurrent NN o
restenosis NN o
after IN N
coronary JJ i
brachytherapy NN i
with IN p
gamma JJ p
irradiation NN p
. . p

OBJECTIVES CC N
The DT N
study NN N
was VBD N
done VBN N
to TO N
investigate VB N
the DT N
relationship NN N
between IN N
clinical JJ N
restenosis NN N
and CC N
the DT N
relative JJ N
angiographic JJ N
location NN N
of IN N
the DT N
recurrent NN N
restenotic JJ N
lesion NN N
, , N
after IN N
treatment NN N
of IN N
in-stent JJ p
restenosis NN p
with IN N
vascular JJ i
brachytherapy NN i
in IN N
the DT N
Washington NNP p
Radiation NNP p
for IN p
In-Stent NNP p
Restenosis NNP p
Trial NNP p
( ( p
WRIST NNP p
) ) p
. . p

BACKGROUND NNP N
Intracoronary NNP i
radiation NN i
therapy NN i
reduces VBZ N
recurrence NN N
of IN N
in-stent JJ N
restenosis NN N
. . N

We PRP N
investigated VBD N
the DT N
above JJ N
objective NN N
in IN N
patients NNS p
enrolled VBN p
in IN p
WRIST NNP p
. . p

METHODS NNP N
The DT N
WRIST NNP N
study NN N
randomized VBD p
130 CD p
patients NNS p
to TO p
double-blinded JJ i
therapy NN i
with IN i
gamma JJ i
irradiation NN i
( ( i
iridium-192 JJ i
[ NNP i
( ( i
192 CD i
) ) i
Ir NNP i
] NNP i
) ) i
versus NN i
placebo NN i
after IN p
interventional JJ i
treatment NN i
of IN i
diffuse NN i
in-stent JJ i
restenosis NN i
. . i

After IN N
the DT N
intervention NN N
and CC N
at IN N
follow-up NN N
, , N
three CD N
vessel NN N
segments NNS N
were VBD N
individually RB N
analyzed VBN N
with IN N
quantitative JJ N
coronary JJ N
angiography NN N
: : N
1 CD N
) ) N
the DT N
stent NN N
, , N
2 CD N
) ) N
the DT N
radiation NN N
ribbon NN N
, , N
and CC N
3 CD N
) ) N
the DT N
ribbon+margin NN N
segment NN N
( ( N
including VBG N
5 CD N
mm NN N
on IN N
either DT N
end NN N
of IN N
the DT N
injured JJ N
or CC N
radiation-ribbon JJ N
segment NN N
) ) N
. . N

Receiver NNP N
operator NN N
curves NNS N
( ( N
ROC NNP N
) ) N
were VBD N
used VBN N
to TO N
assess VB N
the DT N
value NN N
of IN N
the DT N
follow-up JJ N
percent NN N
diameter NN N
stenosis NN N
( ( N
DS NNP N
) ) N
for IN N
each DT N
of IN N
the DT N
three CD N
analyzed VBD N
segments NNS N
in IN N
predicting VBG N
target NN N
vessel NN N
revascularization NN N
( ( N
TVR NNP N
) ) N
. . N

RESULTS NNP N
( ( N
192 CD N
) ) N
Ir NNP N
reduced VBD N
recurrent JJ o
restenosis NN o
( ( N
23.7 CD N
% NN N
vs. FW N
60.7 CD N
% NN N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
and CC N
the DT N
length NN o
of IN o
recurrent JJ o
restenosis NN o
( ( N
8.99 CD N
+/- JJ N
4.34 CD N
mm NN N
vs. FW N
17.54 CD N
+/- JJ N
10.48 CD N
mm NN N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
at IN N
follow-up JJ N
compared VBN N
to TO N
placebo VB N
. . N

Isolated NNP o
stent NN o
edge NN o
( ( N
3.4 CD N
% NN N
) ) N
and CC N
ribbon NN o
edge NN o
( ( N
1.7 CD N
% NN N
) ) N
restenoses VBZ o
were VBD N
infrequent NN N
in IN N
both DT N
groups NNS N
. . N

The DT N
best JJS N
angiographic JJ N
surrogate NN N
of IN N
TVR NNP N
was VBD N
the DT N
50 CD N
% NN N
follow-up JJ N
DS NNP N
obtained VBD N
from IN N
the DT N
ribbon+margin NN N
analysis NN N
( ( N
ROC NNP N
area NN N
0.806 CD N
) ) N
. . N

CONCLUSIONS NNP N
In IN N
WRIST NNP N
, , N
not RB N
only RB N
was VBD N
( ( i
192 CD i
) ) i
Ir NNP i
therapy NN i
effective JJ N
in IN N
reducing VBG N
restenosis NN N
, , N
but CC N
it PRP N
also RB N
reduced VBD N
the DT N
lesion NN N
length NN N
of IN N
treatment NN N
failures NNS N
by IN N
50 CD N
% NN N
, , N
and CC N
it PRP N
was VBD N
not RB N
associated VBN N
with IN N
edge NN N
proliferation NN N
. . N

The DT N
restenosis NN N
rate NN N
obtained VBN N
from IN N
the DT N
vessel NN N
segment NN N
inclusive NN N
of IN N
the DT N
dose JJ N
fall-off JJ N
zones NNS N
was VBD N
the DT N
best JJS N
correlate NN N
of IN N
TVR NNP N
and CC N
should MD N
become VB N
a DT N
standard JJ N
analysis NN N
site NN N
in IN N
all DT N
vascular JJ N
brachytherapy NN N
trials NNS N
. . N

-DOCSTART- -11550726- O O

Is VBZ N
psychotherapy VBN i
more RBR N
effective JJ N
when WRB N
therapists NNS p
disclose VB N
information NN N
about IN N
themselves PRP N
? . N
Theorists NNS N
have VBP N
long RB N
debated VBN N
the DT N
wisdom NN N
of IN N
therapists NNS p
disclosing VBG o
personal JJ o
information NN o
during IN p
psychotherapy NN i
. . i

Some DT N
observers NNS N
have VBP N
argued VBN N
that IN N
such JJ N
therapist JJ N
self-disclosure NN N
impedes NNS N
treatment NN N
, , N
whereas IN N
others NNS N
have VBP N
suggested VBN N
that IN N
it PRP N
enhances VBZ N
the DT N
effectiveness NN o
of IN o
therapy NN o
. . o

To TO N
test VB N
these DT N
competing VBG N
positions NNS N
, , N
therapists NNS p
at IN p
a DT p
university NN p
counseling NN p
center NN p
were VBD N
instructed VBN N
to TO N
increase VB i
the DT i
number NN i
of IN i
self-disclosures NNS i
they PRP N
made VBD N
during IN N
treatment NN i
of IN N
one CD p
client NN p
and CC N
refrain NN i
from IN i
making VBG i
self-disclosures NNS i
during IN i
treatment NN i
of IN N
another DT p
client NN p
. . p

Analyses NNS N
revealed VBD N
that IN N
clients NNS N
receiving VBG N
psychotherapy NN i
under IN N
conditions NNS N
of IN N
heightened VBN N
therapist NN i
disclosure NN i
not RB N
only RB N
reported VBD N
lower JJR o
levels NNS o
of IN o
symptom NN o
distress NN o
but CC N
also RB N
liked VBD o
their PRP$ o
therapist NN o
more RBR o
. . o

Such JJ N
findings NNS N
suggest VBP N
that IN N
self-disclosure NN N
by IN N
the DT N
therapist NN N
may MD N
improve VB N
both PDT N
the DT N
quality NN o
of IN o
the DT o
therapeutic JJ o
relationship NN o
and CC o
the DT o
outcome NN o
of IN o
treatment NN o
. . o

-DOCSTART- -25552279- O O

Concentrated JJ N
parenteral JJ i
nutrition NN i
solutions NNS N
and CC N
central JJ o
venous JJ o
catheter NN o
complications NNS o
in IN p
preterm JJ p
infants NNS p
. . p

UNLABELLED NNP N
Standardised VBD N
, , N
concentrated VBD i
neonatal JJ i
parenteral JJ i
nutrition NN i
( ( i
PN NNP i
) ) i
regimens VBZ i
can MD N
overcome VB N
early JJ N
nutritional JJ N
deficits NNS N
in IN N
very RB p
preterm JJ p
infants NNS p
. . p

A DT N
PN JJ N
regimen NN N
with IN N
increased JJ N
macronutrient NN N
content NN N
( ( i
standardised VBN i
, , i
concentrated VBN i
, , i
added VBD i
macronutrients NNS i
parenteral JJ i
( ( i
SCAMP NNP i
) ) i
) ) i
has VBZ N
been VBN N
shown VBN N
to TO N
improve VB N
early JJ N
head NN N
growth NN N
in IN N
a DT N
randomised JJ N
controlled VBN N
trial NN N
. . N

Line JJ o
complications NNS o
including VBG N
late JJ o
onset VBN o
sepsis NN o
were VBD N
secondary JJ N
outcomes NNS N
of IN N
this DT N
study NN N
. . N

Infants NNS N
were VBD N
started VBN N
on IN N
standardised VBN N
, , N
concentrated VBD i
PN NNP i
at IN N
birth NN N
and CC N
randomised VBN N
at IN N
2-5 JJ N
days NNS N
to TO N
either DT N
switch NN N
to TO N
SCAMP NNP i
or CC N
remain VB i
on IN i
control NN i
PN NNP i
. . i

Central NNP o
venous JJ o
catheter NN o
( ( o
CVC NNP o
) ) o
, , o
blood JJ o
culture NN o
( ( o
BC NNP o
) ) o
and CC o
inflammatory JJ o
marker NN o
data NNS o
were VBD N
collected VBN N
for IN N
the DT N
28-day JJ N
intervention NN N
period NN N
. . N

150 CD p
infants NNS p
were VBD p
randomised VBN p
with IN p
mean NN p
( ( p
SD NNP p
) ) p
birth NN o
weight NN o
( ( p
g NN p
) ) p
of IN p
900 CD p
( ( p
158 CD p
) ) p
versus NN p
884 CD p
( ( p
183 CD p
) ) p
in IN p
SCAMP NNP p
( ( p
n=74 NN p
) ) p
and CC p
control NN p
( ( p
n=76 JJ p
) ) p
groups NNS p
, , N
respectively RB N
. . N

There EX N
were VBD N
no DT N
differences NNS N
in IN N
CVC NNP o
use/type NN o
or CC o
duration NN o
or CC o
in IN o
positive/negative JJ o
BC NNP o
with/without NN o
associated VBN o
C NNP o
reactive JJ o
protein NN o
rise NN o
in IN N
SCAMP NNP i
versus NN N
control NN N
groups NNS N
. . N

Increasing VBG N
the DT N
macronutrient NN N
content NN N
of IN N
a DT N
standardised JJ N
, , N
concentrated JJ N
neonatal JJ N
PN NNP i
regimen NN N
does VBZ N
not RB N
increase VB N
CVC NNP o
complication NN o
rates NNS o
. . o

TRIAL NNP N
REGISTRATION NNP N
NUMBER NNP N
ISRCTN NNP N
76597892 CD N
. . N

-DOCSTART- -23888359- O O

Nasal NNP N
oxytocin MD i
for IN N
social JJ N
deficits NNS N
in IN N
childhood NN p
autism NN p
: : p
a DT N
randomized NN N
controlled VBN N
trial NN N
. . N

The DT N
last JJ N
two CD N
decades NNS N
have VBP N
witnessed VBN N
a DT N
surge NN N
in IN N
research NN N
investigating VBG N
the DT N
application NN N
of IN N
oxytocin NN N
as IN N
a DT N
method NN N
of IN N
enhancing VBG N
social JJ N
behaviour NN N
in IN N
humans NNS N
. . N

Preliminary JJ N
evidence NN N
suggests VBZ N
oxytocin NN N
may MD N
have VB N
potential NN N
as IN N
an DT N
intervention NN N
for IN N
autism NN N
. . N

We PRP N
evaluated VBD N
a DT N
5-day JJ N
'live-in NN N
' POS N
intervention NN N
using VBG N
a DT N
double-blind JJ N
randomized VBN N
control NN N
trial NN N
. . N

38 CD p
male JJ p
youths NNS p
( ( p
7-16 CD p
years NNS p
old JJ p
) ) p
with IN p
autism NN p
spectrum NN p
disorders NNS p
were VBD N
administered VBN N
24 CD i
or CC i
12 CD i
international JJ i
units NNS i
( ( i
depending VBG i
on IN i
weight NN i
) ) i
intranasal NN i
placebo NN i
or CC i
oxytocin JJ i
once RB N
daily RB N
over IN N
four CD N
consecutive JJ N
days NNS N
. . N

The DT N
oxytocin NN N
or CC N
placebo NN N
was VBD N
administered VBN N
during IN N
parent-child JJ N
interaction NN N
training NN N
sessions NNS N
. . N

Parent NN N
and CC N
child NN N
behaviours NNS N
were VBD N
assessed VBN N
using VBG N
parent NN o
reports NNS o
, , o
clinician JJ o
ratings NNS o
, , o
and CC o
independent JJ o
observations NNS o
, , N
at IN N
multiple JJ N
time NN N
points NNS N
to TO N
measure VB o
side-effects NNS o
; : o
social JJ o
interaction NN o
skills NNS o
; : o
repetitive JJ o
behaviours NNS o
; : o
emotion NN o
recognition NN o
and CC o
diagnostic JJ o
status NN o
. . o

Compared VBN N
to TO N
placebo VB N
, , N
intranasal VB N
oxytocin RB N
did VBD N
not RB N
significantly RB N
improve VB N
emotion NN o
recognition NN o
, , o
social JJ o
interaction NN o
skills NNS o
, , o
or CC o
general JJ o
behavioral JJ o
adjustment NN o
in IN N
male JJ N
youths NNS N
with IN N
autism NN N
spectrum NN N
disorders NNS N
. . N

The DT N
results NNS N
show VBP N
that IN N
the DT N
benefits NNS N
of IN N
nasal JJ N
oxytocin NN N
for IN N
young JJ p
individuals NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
may MD N
be VB N
more JJR N
circumscribed JJ N
than IN N
suggested VBN N
by IN N
previous JJ N
studies NNS N
, , N
and CC N
suggest JJS N
caution NN N
in IN N
recommending VBG N
it PRP N
as IN N
an DT N
intervention NN N
that WDT N
is VBZ N
broadly RB N
effective JJ N
. . N

-DOCSTART- -19169289- O O

Pegfilgrastim NN i
for IN N
peripheral JJ N
CD34+ NNP N
mobilization NN N
in IN N
patients NNS p
with IN p
solid JJ o
tumours NNS o
. . o

The DT N
efficacy NN o
of IN N
pegfilgrastim+/-chemotherapy NN i
for IN N
mobilizing VBG N
stem NN N
cells NNS N
in IN N
patients NNS p
with IN p
solid JJ o
tumours NN o
was VBD N
assessed VBN N
. . N

In IN N
cycle NN N
0 CD N
, , N
a DT N
14-day JJ N
prechemotherapy NN N
cycle NN N
, , N
patients NNS p
( ( p
N=61 NNP p
) ) p
were VBD N
randomized VBN N
open-label NN N
to TO N
single JJ N
doses NNS N
of IN N
pegfilgrastim NN i
( ( N
6 CD N
, , N
12 CD N
or CC N
18 CD N
mg NN N
) ) N
on IN N
day NN N
1 CD N
, , N
or CC N
daily RB N
filgrastim NNS i
( ( N
10 CD N
microg/kg NN N
) ) N
for IN N
< NN N
or CC N
=7 JJ N
days NNS N
. . N

Mean JJ o
peak JJ o
peripheral JJ o
CD34+ NNP o
cell NN o
counts NNS o
increased VBD o
with IN N
pegfilgrastim NN i
dose NN N
, , N
but CC N
were VBD N
significantly RB o
higher JJR o
than IN N
filgrastim JJR i
only RB N
at IN N
the DT N
18 CD N
mg NN N
dose NN N
( ( N
10.17 CD N
vs RB N
4.96 CD N
x JJ N
10 CD N
( ( N
4 CD N
) ) N
/ml NN N
; : N
P=0.014 NNP N
) ) N
. . N

In IN N
the DT N
clinically NN N
relevant JJ N
period NN N
of IN N
days NNS N
3-7 CD N
, , N
both DT N
12 CD N
and CC N
18 CD N
mg NN N
pegfilgrastim NN i
doses NNS N
produced VBD N
significantly RB o
higher JJR o
peak NN o
CD34+ NNP o
counts VBZ o
( ( N
8.18 CD N
and CC N
9.96 CD N
vs NN N
4.51 CD N
x NN N
10 CD N
( ( N
4 CD N
) ) N
/ml NN N
for IN N
filgrastim NN i
; : i
P=0.034 NNP N
and CC N
0.006 CD N
) ) N
. . N

In IN N
cycle NN N
1 CD N
, , N
patients NNS N
received VBD N
carboplatin/paclitaxel NNS i
on IN N
day NN N
1 CD N
, , N
followed VBD N
from IN N
day NN N
2 CD N
by IN N
pegfilgrastim JJ i
6-18 JJ N
mg NN N
or CC N
daily JJ N
filgrastim NN i
( ( N
5 CD N
microg/kg/day NN N
for IN N
< NN N
or CC N
=14 NNP N
days NNS N
) ) N
as IN N
per IN N
randomization NN N
in IN N
cycle NN N
0 CD N
. . N

There EX N
were VBD N
no DT o
significant JJ o
differences NNS o
in IN N
mean JJ o
peak NN o
CD34+ NNP o
count NN o
between IN N
pegfilgrastim NN i
and CC N
filgrastim NN i
, , N
but CC N
there EX N
was VBD N
an DT N
advantage NN N
for IN N
pegfilgrastim NN i
18 CD N
mg NN N
in IN N
the DT N
relevant JJ N
period NN N
of IN N
days NNS N
7-12 NNP N
( ( N
3.14 CD N
vs RB N
1.19 CD N
x JJ N
10 CD N
( ( N
4 CD N
) ) N
/ml NN N
; : N
P=0.043 NNP N
) ) N
. . N

A DT N
single JJ N
pegfilgrastim NN i
dose NN N
( ( N
> CD N
or CC N
=6 VB N
mg NN N
) ) N
could MD N
be VB N
substituted VBN N
for IN N
daily JJ N
filgrastim NN i
in IN N
cytokine-only JJ o
peripheral JJ o
CD34+ NNP o
cell NN o
mobilization NN o
. . o

-DOCSTART- -14984440- O O

Delayed VBN N
genomic JJ N
and CC N
acute JJ N
nongenomic JJ N
action NN N
of IN N
glucocorticosteroids NNS i
in IN N
seasonal JJ p
allergic JJ p
rhinitis NN p
. . p

BACKGROUND NNP N
Glucocorticosteroids NNP i
are VBP N
effective JJ N
in IN N
the DT N
treatment NN N
of IN N
allergic JJ p
rhinitis NN p
, , N
a DT N
disease NN N
characterized VBN N
by IN N
a DT N
variety NN N
of IN N
symptoms NNS N
, , N
e.g NN N
. . N

rhinorrhea NN N
and CC N
itching NN N
. . N

The DT N
time NN N
course NN N
of IN N
symptomatic JJ N
relief NN N
for IN N
allergic JJ N
rhinitis NN N
by IN N
steroids NNS N
has VBZ N
not RB N
been VBN N
examined VBN N
in IN N
detail NN N
to TO N
date NN N
, , N
although IN N
the DT N
onset NN N
of IN N
steroid JJ N
action NN N
is VBZ N
one CD N
of IN N
the DT N
main JJ N
discriminations NNS N
between IN N
genomic JJ N
and CC N
nongenomic JJ N
actions NNS N
of IN N
steroids NNS N
. . N

We PRP N
therefore RB N
investigated VBD N
the DT N
time NN N
course NN N
of IN N
subjective JJ N
and CC N
objective JJ N
measures NNS N
of IN N
nasal JJ o
affection NN o
after IN N
steroid JJ N
administration NN N
in IN N
patients NNS p
with IN p
allergic JJ p
rhinitis NN p
following VBG N
specific JJ N
allergen NN N
challenge NN N
. . N

METHODS NNP N
Six NNP p
female NN p
and CC p
18 CD p
male NN p
volunteers NNS p
( ( p
median JJ p
age NN p
26 CD p
years NNS p
) ) p
with IN p
a DT p
history NN p
of IN p
allergic JJ p
rhinitis NN p
but CC p
currently RB p
free JJ p
of IN p
symptoms NNS p
were VBD p
included VBN p
in IN N
this DT N
randomized JJ N
, , N
placebo-controlled JJ i
, , N
double-blind JJ N
, , N
three-period JJ N
crossover NN N
study NN N
. . N

A DT N
single JJ N
dose NN N
of IN N
either CC N
betamethasone NN i
( ( i
60 CD i
mg NN i
) ) i
, , i
methylprednisolone NN i
( ( i
400 CD i
mg NN i
) ) i
or CC i
placebo NN i
was VBD N
given VBN N
intravenously RB N
, , N
5 CD N
min NN N
after IN N
intranasal JJ N
allergen JJ N
provocation NN N
. . N

After IN N
10 CD N
, , N
20 CD N
, , N
60 CD N
, , N
150 CD N
and CC N
240 CD N
min NN N
, , N
nasal JJ o
itching NN o
and CC o
nasal JJ o
obstruction NN o
were VBD N
assessed VBN N
using VBG N
a DT N
standardized JJ o
visual JJ o
analogue NN o
scale NN o
. . o

In IN N
addition NN N
, , N
nasal RB o
airflow NN o
was VBD N
measured VBN N
by IN N
anterior JJ o
rhinomanometry NN o
. . o

RESULTS NNP N
Nasal NNP o
itching NN o
was VBD N
markedly RB N
reduced VBN N
following VBG N
either NN N
of IN N
the DT N
two CD N
steroids NNS N
within IN N
10 CD N
min NNS N
after IN N
administration NN N
of IN N
study JJ N
drug NN N
. . N

Itching NNP o
was VBD N
depressed VBN N
by IN N
38 CD N
% NN N
following VBG N
betamethasone NN i
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
and CC N
by IN N
18 CD N
% NN N
following VBG N
methylprednisolone NN i
( ( N
P=0.07 NNP N
) ) N
compared VBN N
with IN N
placebo NN i
. . i

Nasal NNP o
airflow JJ o
and CC o
nasal JJ o
obstruction NN o
were VBD N
not RB N
significantly RB N
altered VBN N
by IN N
steroids NNS N
during IN N
the DT N
first JJ N
2 CD N
h NN N
of IN N
the DT N
study NN N
. . N

However RB N
, , N
after IN N
150 CD N
min NN N
, , N
nasal RB o
airflow NN o
was VBD N
21 CD N
% NN N
rsp NN N
. . N

19 CD N
% NN N
higher JJR N
after IN N
methylprednisolone NN i
and CC N
betamethasone NN i
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
compared VBN N
with IN N
placebo NN i
. . i

After IN N
240 CD N
min NN N
, , N
nasal RB o
airflow JJ o
was VBD N
increased VBN N
by IN N
20 CD N
% NN N
following VBG N
betamethasone NN i
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
and CC N
by IN N
19 CD N
% NN N
following VBG N
methylprednisolone NN i
. . i

Nasal NNP o
obstruction NN o
was VBD N
also RB N
beneficially RB N
affected VBN N
by IN N
both DT N
steroids NNS N
150 CD N
and CC N
240 CD N
min NN N
after IN N
administration NN N
compared VBN N
with IN N
placebo NN i
( ( N
P NNP N
< VBZ N
0.05 CD N
for IN N
both DT N
time NN N
points NNS N
following VBG N
betamethasone NN N
) ) N
. . N

CONCLUSION VB N
This DT N
study NN N
for IN N
the DT N
first JJ N
time NN N
shows NNS N
rapid VBP N
in IN N
vivo JJ N
effects NNS N
of IN N
external JJ N
glucocorticosteroids NNS i
in IN N
humans NNS p
. . p

Itching NNP o
, , N
a DT N
pathophysiologically RB N
complex JJ N
sensation NN N
, , N
is VBZ N
favourably RB N
influenced VBN N
by IN N
steroids NNS N
within IN N
10 CD N
min NNS N
, , N
therefore RB N
presumably RB N
via IN N
nongenomic JJ N
mechanisms NN N
. . N

Though IN N
no DT N
detailed JJ N
mechanisms NNS N
can MD N
be VB N
derived VBN N
from IN N
this DT N
study NN N
, , N
steroid JJ N
interaction NN N
with IN N
receptors NNS N
in IN N
the DT N
central JJ N
nervous JJ N
system NN N
may MD N
play VB N
an DT N
important JJ N
role NN N
in IN N
mediating VBG N
this DT N
effect NN N
. . N

-DOCSTART- -15960148- O O

Lanthanum NNP i
carbonate NN i
( ( i
Fosrenol NNP i
) ) i
efficacy NN o
and CC o
tolerability NN o
in IN N
the DT N
treatment NN N
of IN N
hyperphosphatemic JJ p
patients NNS p
with IN p
end-stage JJ p
renal JJ p
disease NN p
. . p

AIMS NNP N
High NNP N
serum NN N
phosphorus NN N
levels NNS N
are VBP N
a DT N
common JJ N
problem NN N
in IN N
patients NNS p
receiving VBG p
long-term JJ p
dialysis NN p
treatment NN p
. . p

Lanthanum NNP i
carbonate NN i
( ( i
Fosrenol NNP i
) ) i
is VBZ N
a DT N
new JJ N
non-aluminum JJ N
, , N
non-calcium JJ N
phosphate NN N
binder NN N
developed VBD N
for IN N
the DT N
treatment NN N
of IN N
hyperphosphatemia NN N
in IN N
patients NNS p
with IN p
end-stage JJ p
renal JJ p
disease NN p
( ( p
ESRD NNP p
) ) p
. . p

We PRP N
report VBP N
data NNS N
from IN N
a DT N
recent JJ N
trial NN N
, , N
which WDT N
, , N
for IN N
the DT N
first JJ N
time NN N
, , N
assessed VBD N
the DT N
efficacy NN o
and CC N
tolerability NN o
of IN N
lanthanum JJ i
carbonate NN i
treatment NN i
, , N
compared VBN N
with IN N
placebo NN i
, , N
in IN N
Chinese JJ p
patients NNS p
with IN p
ESRD NNP p
. . p

PATIENTS NNP N
AND CC N
METHODS NNP N
Following VBG N
a DT N
one- JJ N
to TO N
three-week JJ N
washout NN N
phase NN N
and CC N
a DT N
four-week JJ N
, , N
open-label JJ N
lanthanum NN i
carbonate NN i
dose-titration NN N
phase NN N
, , N
male NN p
and CC p
female JJ p
hemodialysis NN p
patients NNS p
were VBD N
randomized VBN N
( ( N
1:1 CD N
) ) N
to TO N
receive VB N
either DT N
lanthanum NN i
carbonate NN i
or CC i
placebo NN i
for IN N
four CD N
weeks NNS N
. . N

The DT N
primary JJ N
efficacy NN N
parameter NN N
of IN N
the DT N
study NN N
was VBD N
the DT N
control NN N
of IN N
serum JJ o
phosphorus NN o
levels NNS o
( ( N
< CD N
or CC N
=1.8 VB N
mmol/l JJ N
[ NNP N
< NN N
or CC N
= $ N
5.6 CD N
mg/dl NN N
] NN N
) ) N
. . N

Secondary JJ N
endpoints NNS N
included VBD N
the DT o
profile NN o
of IN o
serum JJ o
phosphorus NN o
during IN o
titration NN o
and CC o
parathyroid NN o
hormone NN o
, , o
calcium NN o
, , o
and CC o
calcium NN o
x NN o
phosphorus NN o
( ( o
Ca NNP o
x NNP o
P NNP o
) ) o
product NN o
levels NNS o
. . o

The DT N
safety NN o
and CC o
tolerability NN o
of IN o
lanthanum NN o
carbonate NN o
were VBD N
assessed VBN N
by IN N
monitoring VBG N
adverse JJ o
events NNS o
throughout IN N
the DT N
study NN N
. . N

RESULTS NNP N
Mean NNP o
serum VBZ o
phosphorus JJ o
level NN o
at IN N
the DT N
end NN N
of IN N
washout NN N
was VBD N
2.5 CD N
+/- JJ N
0.5 CD N
mmol/l NN N
( ( N
7.7 CD N
+/- JJ N
1.5 CD N
mg/dl NN N
; : N
n=73 CC p
) ) p
, , N
and CC N
there EX N
was VBD N
no DT N
evidence NN N
of IN N
a DT N
difference NN N
in IN N
levels NNS N
between IN N
the DT N
treatment NN N
groups NNS N
pre-randomization NN N
. . N

At IN N
the DT N
end NN N
of IN N
the DT N
study NN N
, , N
lanthanum JJ i
carbonate-treated JJ i
patients NNS N
had VBD N
significantly RB N
lower JJR N
phosphorus NN o
levels NNS o
( ( N
1.6 CD N
+/- JJ N
0.5 CD N
mmol/l NN N
[ VBD N
5.1 CD N
+/- JJ N
1.5 CD N
mg/dl NN N
] NN N
; : N
n=30 CC p
) ) p
than IN N
those DT N
receiving VBG N
placebo NN N
( ( N
2.3 CD N
+/- JJ N
0.4 CD N
mmol/l NN N
[ VBD N
7.2 CD N
+/- JJ N
1.3 CD N
mg/dl NN N
] NN N
; : N
n=31 CC p
; : p
p CC N
< VB N
0.001 CD N
) ) N
. . N

In IN N
addition NN N
, , N
a DT N
significantly RB N
higher JJR N
proportion NN N
of IN N
patients NNS N
receiving VBG N
lanthanum JJ i
carbonate NN i
had VBD N
controlled VBN N
serum JJ o
phosphorus NN o
levels NNS o
( ( N
60 CD N
% NN N
) ) N
compared VBN N
with IN N
the DT N
placebo NN N
group NN N
( ( N
10 CD N
% NN N
; : N
p CC N
< VB N
0.001 CD N
) ) N
. . N

Ca NNP o
x JJ o
P NNP o
product NN o
levels NNS o
were VBD N
also RB N
significantly RB N
lower JJR N
in IN N
the DT N
lanthanum NN i
carbonate NN i
group NN N
at IN N
the DT N
end NN N
of IN N
randomized JJ N
treatment NN N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
. . N

Lanthanum NNP i
carbonate NN i
was VBD N
well RB N
tolerated VBN o
; : o
only RB N
one CD N
serious JJ o
adverse JJ o
event NN o
was VBD N
reported VBN N
, , N
which WDT N
was VBD N
unrelated JJ N
to TO N
treatment NN N
. . N

CONCLUSIONS NNP N
Lanthanum NNP i
carbonate NN i
was VBD N
shown VBN N
to TO N
be VB N
an DT N
effective JJ o
and CC N
well-tolerated JJ o
phosphate NN N
binder NN N
for IN N
the DT N
treatment NN N
of IN N
hyperphosphatemia NN N
in IN N
Chinese JJ p
patients NNS p
with IN p
ESRD NNP p
. . p

This DT N
finding NN N
supports VBZ N
the DT N
results NNS N
of IN N
previous JJ N
US NNP N
and CC N
European JJ N
studies NNS N
, , N
which WDT N
have VBP N
also RB N
shown VBN N
that IN N
lanthanum NN i
carbonate NN i
treatment NN N
effectively RB N
controls VBZ N
serum JJ o
phosphorus NN o
levels NNS o
. . o

-DOCSTART- -22808053- O O

Promoting VBG i
physical JJ N
activity NN N
in IN N
patients NNS p
with IN p
colon NN p
adenomas NN p
: : p
a DT N
randomized JJ N
pilot NN N
intervention NN N
trial NN N
. . N

BACKGROUND NNP N
Physical NNP N
activity NN N
decreases VBZ N
risk NN N
of IN N
colon NN N
polyps NNS N
and CC N
colon NN N
cancer NN N
and CC N
might MD N
reduce VB N
risk NN N
of IN N
colon NN N
cancer NN N
recurrence NN N
. . N

Focusing VBG N
on IN N
recent JJ N
calls NNS N
for IN N
translation NN N
of IN N
epidemiologic JJ N
evidence NN N
into IN N
clinical JJ N
care NN N
, , N
our PRP$ N
pilot NN N
study NN N
delivered VBD N
an DT N
evidence-based JJ i
physical JJ i
activity NN i
intervention NN i
in IN N
adults NNS p
with IN p
polyps NNS p
, , N
who WP N
are VBP N
thus RB N
at IN N
elevated VBN N
risk NN N
of IN N
developing VBG N
colon NN N
cancer NN N
. . N

The DT N
objective NN N
was VBD N
to TO N
evaluate VB N
change NN N
in IN N
physical JJ N
activity NN N
, , N
measured VBN N
by IN N
steps NNS N
per IN N
day NN N
and CC N
minutes NNS N
of IN N
moderate/vigorous JJ o
physical JJ N
activity NN N
. . N

METHODS NNP N
Sixteen NNP p
adults NNS p
with IN p
adenomas NN p
detected VBN p
and CC p
removed VBN p
at IN p
screening VBG i
colonoscopy NN i
were VBD N
recruited VBN N
to TO N
a DT N
12-week JJ N
physical JJ i
activity NN i
intervention NN i
. . i

Participants NNS N
were VBD N
randomized VBN N
to TO N
receive VB N
a DT N
standard NN i
( ( i
30 CD i
minutes/day NN i
) ) i
or CC i
high JJ i
( ( i
60 CD i
minutes/day NN i
) ) i
walking VBG i
program NN i
. . i

Physical JJ i
activity NN i
was VBD N
measured VBN N
via IN N
blinded VBN i
pedometer NN i
and CC i
accelerometer NN i
at IN i
baseline NN i
and CC i
follow-up NN i
. . i

Intervention NN N
messages NNS N
focused VBD N
on IN N
self-monitoring JJ N
using VBG N
pedometers NNS N
and CC N
overcoming VBG N
barriers NNS N
to TO N
engaging VBG N
in IN N
physical JJ N
activity NN N
. . N

RESULTS JJ N
Participants NNS N
in IN N
both DT N
arms NNS N
significantly RB N
increased VBD N
objectively RB N
measured VBN o
minutes NNS o
of IN o
moderate/vigorous JJ o
physical JJ o
activity NN o
over IN N
the DT N
course NN N
of IN N
the DT N
intervention NN N
. . N

Both DT N
arms NNS N
exceeded VBD N
the DT N
intervention NN N
goal NN N
, , N
but CC N
there RB N
was VBD N
not RB N
a DT N
significant JJ N
difference NN N
between IN N
arms NNS N
at IN N
follow-up JJ N
. . N

Results NNS N
were VBD N
similar JJ N
for IN N
pedometer NN o
measured VBN o
physical JJ o
activity NN o
, , N
with IN N
a DT N
significant JJ N
overall JJ N
increase NN o
in IN o
steps/day JJ o
from IN N
baseline NN N
to TO N
follow-up NN N
, , N
but CC N
no DT N
between IN N
arm NN N
difference NN N
in IN N
change NN N
. . N

CONCLUSION NNP N
Simple NNP N
interventions NNS N
of IN N
minimal JJ N
contact NN N
time NN N
focusing VBG N
on IN N
walking NN N
can MD N
significantly RB N
increase VB N
physical JJ N
activity NN N
in IN N
individuals NNS N
at IN N
increased VBN N
risk NN N
of IN N
developing VBG N
colon NN N
cancer NN N
. . N

TRIAL NNP N
REGISTRATION NNP N
ClinicalTrials.gov NNP N
NCT01476631 NNP N
. . N

-DOCSTART- -698606- O O

Ambulation NN i
in IN N
labour NN N
. . N

In IN N
a DT N
randomised JJ N
prospective JJ N
study NN N
of IN N
68 CD p
women NNS p
in IN p
spontaneous JJ p
labour JJ p
half NN N
were VBD N
allocated VBN N
to TO N
an DT i
ambulant JJ i
group NN i
and CC i
half NN i
to TO i
a DT i
recumbent NN i
group NN i
. . i

The DT N
duration NN o
of IN o
labour NN o
was VBD N
significantly RB N
shorter JJR N
, , N
the DT N
need NN o
for IN o
analgesia NN o
significantly RB N
less RBR N
, , N
and CC N
the DT N
incidence NN o
of IN o
fetal JJ o
heart NN o
abnormalities NNS o
significantly RB N
smaller JJR N
in IN N
the DT N
ambulant NN N
group NN N
than IN N
in IN N
the DT N
recumbent NN N
group NN N
. . N

Apgar NNP o
scores VBZ o
at IN N
one CD N
and CC N
five CD N
minutes NNS N
were VBD N
also RB N
significantly RB N
greater JJR N
in IN N
the DT N
ambulant JJ N
group NN N
. . N

More JJR N
patients NNS N
in IN N
the DT N
recumbent NN N
group NN N
required VBD N
augmentations NNS o
with IN o
oxytocic JJ o
drugs NNS o
. . o

There EX N
was VBD N
no DT N
statistically RB N
significant JJ N
difference NN N
in IN N
the DT N
third JJ o
stage NN o
loss NN o
in IN N
the DT N
two CD N
groups NNS N
. . N

Ambulation NNP i
in IN N
labour NN N
should MD N
be VB N
encouraged VBN N
: : N
it PRP N
may MD N
bring VB N
human JJ N
benefits NNS N
while IN N
allowing VBG N
the DT N
advantages NNS N
of IN N
hospital JJ N
supervision NN N
. . N

-DOCSTART- -14616872- O O

Presentation NN N
of IN N
allergen NN N
in IN N
different JJ N
food NN N
preparations NNS N
affects VBZ N
the DT N
nature NN N
of IN N
the DT N
allergic JJ p
reaction NN p
-- : p
a DT p
case NN p
series NN p
. . p

BACKGROUND NNP N
Characterization NNP N
of IN N
fatal JJ N
and CC N
non-fatal JJ N
reactions NNS N
to TO N
food NN N
indicates NNS N
that IN N
the DT N
majority NN N
of IN N
reactions NNS N
are VBP N
due JJ N
to TO N
the DT N
ingestion NN N
of IN N
prepared JJ N
foods NNS N
rather RB N
than IN N
the DT N
non-processed JJ N
allergen NN N
. . N

In IN N
an DT N
ongoing JJ N
study NN N
that WDT N
used VBD N
a DT N
double-blind JJ N
placebo-controlled JJ i
food NN N
challenge NN N
to TO N
investigate VB N
peanut NN N
allergy NN N
and CC N
clinical JJ N
symptoms NNS N
, , N
the DT N
observed JJ N
reaction NN N
severity NN N
in IN N
four CD N
of IN N
the DT N
first JJ p
six CD p
subjects NNS p
was VBD N
greater JJR N
than IN N
anticipated VBN N
. . N

We PRP N
hypothesized VBD N
that IN N
this DT N
was VBD N
due JJ N
to TO N
differences NNS N
in IN N
the DT N
composition NN N
of IN N
the DT N
challenge NN N
vehicle NN N
. . N

OBJECTIVE CC N
The DT N
aim NN N
was VBD N
to TO N
investigate VB N
whether IN N
the DT N
severity NN N
of IN N
observed JJ N
challenge NN N
reactions NNS N
would MD N
be VB N
repeated VBN N
on IN N
re-challenge NN N
with IN N
a DT N
lower JJR i
fat JJ i
challenge NN i
vehicle NN i
. . i

METHODS NNP N
Peanut-allergic JJ p
subjects NNS p
were VBD N
re-challenged JJ N
with IN N
a DT N
lower JJR i
fat NN i
recipe NN i
after IN N
reacting VBG N
more RBR N
severely RB N
than IN N
was VBD N
anticipated VBN N
to TO N
an DT N
initial JJ N
peanut NN i
challenge NN N
. . N

Similar JJ N
challenge NN N
vehicle NN N
recipes NNS N
were VBD N
used VBN N
, , N
the DT N
only JJ N
difference NN N
being VBG N
the DT N
lower JJR N
fat JJ N
content NN N
( ( N
22.9 CD N
% NN N
compared VBN N
with IN N
31.5 CD N
% NN N
) ) N
. . N

The DT N
peanut NN N
content NN N
of IN N
the DT N
two CD N
recipes NNS N
was VBD N
analysed VBN N
using VBG N
RAST NNP N
inhibition NN N
studies NNS N
and CC N
ELISA NNP N
tests NNS N
. . N

RESULTS NNP N
Three CD N
of IN N
four CD N
subjects NNS N
reacted VBD N
to TO N
much JJ N
smaller JJR N
doses NNS o
of IN o
peanut NN o
protein NN o
on IN o
re-challenge NN o
( ( N
mean JJ N
dose NN N
equivalence NN N
- : N
23 CD N
times NNS N
less RBR N
peanut NN N
) ) N
with IN N
the DT N
lower JJR N
fat JJ N
recipe NN N
. . N

RAST NNP o
inhibition NN o
showed VBD N
that IN N
neither CC N
recipe VB N
altered VBN N
epitope DT o
recognition NN o
. . o

The DT N
higher JJR N
fat JJ N
recipe NN N
required VBN N
twice RB N
as RB N
much JJ N
peanut NN N
to TO N
cause VB N
50 CD o
% NN o
inhibition NN o
. . o

ELISA NNP N
detected VBD N
far RB N
lower JJR N
levels NNS N
of IN N
peanut NN N
in IN N
the DT N
higher JJR N
fat JJ N
recipe NN N
( ( N
220 CD N
000 CD N
parts NNS N
per IN N
million CD N
( ( N
p.p.m NN N
. . N

) ) N
) ) N
than IN N
in IN N
the DT N
lower JJR N
fat NN N
recipe NN N
( ( N
990 CD N
000 CD N
p.p.m. NN N
) ) N
. . N

CONCLUSION VB N
The DT N
fat JJ N
content NN N
of IN N
a DT N
challenge NN N
vehicle NN N
has VBZ N
a DT N
profound JJ N
effect NN N
on IN N
the DT N
reaction NN N
experienced VBD N
after IN N
allergen NN N
ingestion NN N
. . N

This DT N
is VBZ N
another DT N
factor NN N
to TO N
be VB N
considered VBN N
in IN N
assessing VBG N
the DT N
risk NN N
of IN N
certain JJ N
foods NNS N
to TO N
food-allergic JJ p
consumers NNS p
and CC N
adds VBZ N
another DT N
dimension NN N
to TO N
clinical JJ N
, , N
research NN N
and CC N
regulatory JJ N
practice NN N
. . N

-DOCSTART- -6807568- O O

Treatment NN N
of IN N
stable JJ p
angina NN p
of IN p
effort NN p
with IN N
verapamil NN i
: : i
a DT N
double-blind NN N
, , N
placebo-controlled JJ i
randomized VBN N
crossover NN N
study NN N
. . N

The DT N
effects NNS N
of IN N
verapamil NN i
were VBD N
assessed VBN N
in IN N
26 CD p
patients NNS p
with IN p
stable JJ p
exertional JJ p
angina NN p
pectoris NN p
in IN N
a DT N
double-blind JJ N
, , N
placebo-controlled JJ N
, , N
randomized VBN N
crossover NN N
protocol NN N
using VBG N
serial JJ N
treadmill NN N
tests NNS N
. . N

Verapamil NNP i
, , N
480 CD N
mg/day NN N
, , N
reduced VBD N
anginal JJ o
frequency NN o
from IN N
5.6 CD N
+/- JJ N
7.3 CD N
to TO N
2.2 CD N
+/- JJ N
3.9 CD N
attacks NNS N
per IN N
week NN N
( ( N
p NN N
less JJR N
than IN N
0.001 CD N
) ) N
and CC N
nitroglycerin JJ o
consumption NN o
from IN N
3.4 CD N
+/- JJ N
4.9 CD N
to TO N
1.2 CD N
+/- JJ N
2.5 CD N
tablets NNS N
per IN N
week NN N
( ( N
p NN N
less JJR N
than IN N
0.05 CD N
) ) N
compared VBN N
with IN N
placebo NN i
. . i

Treadmill NNP o
time NN o
increased VBD N
from IN N
6.4 CD N
+/- JJ N
2.1 CD N
minutes NNS N
during IN N
the DT N
placebo NN i
phase NN N
to TO N
7.5 CD N
+/- JJ N
1.8 CD N
minutes NNS N
during IN N
the DT N
verapamil JJ i
phase NN N
( ( N
p NN N
less JJR N
than IN N
0.001 CD N
) ) N
. . N

Verapamil NNP i
's POS i
beneficial JJ N
effect NN N
appeared VBD N
to TO N
be VB N
related VBN N
, , N
in IN N
part NN N
, , N
to TO N
a DT N
10 CD N
% NN N
reduction NN N
of IN N
the DT N
rate-pressure JJ o
product NN o
at IN N
rest NN N
( ( N
p IN N
less JJR N
than IN N
0.05 CD N
) ) N
and CC N
a DT N
12 CD N
% NN N
reduction NN N
during IN N
submaximal JJ N
exercise NN N
( ( N
p NN N
less JJR N
than IN N
0.001 CD N
) ) N
. . N

Verapamil NNP i
also RB N
caused VBD N
less JJR N
marked JJ N
ST-segment JJ o
depressions NNS o
at IN o
peak NN o
exercise NN o
( ( N
p NN N
less JJR N
than IN N
0.05 CD N
) ) N
at IN N
a DT N
similar JJ N
rate-pressure NN N
product NN N
, , N
suggesting VBG N
a DT N
favorable JJ N
redistribution NN N
of IN N
coronary JJ o
blood NN o
flow NN o
to TO N
the DT N
ischemic JJ N
zone NN N
. . N

Side JJ N
effects NNS N
from IN N
verapamil NN i
were VBD N
minimal JJ N
, , N
consisting VBG N
mainly RB N
of IN N
constipation NN o
( ( N
six CD N
patients NNS N
) ) N
. . N

Verapamil NNP i
appears VBZ N
to TO N
be VB N
a DT N
safe JJ o
and CC o
effective JJ o
drug NN N
for IN N
treating VBG N
angina NN p
of IN N
effort NN N
. . N

-DOCSTART- -7011331- O O

Preventive JJ N
treatment NN N
of IN N
serotonin-migraine JJ p
with IN N
1,3,4,14b-tetrahydro-2,7-dimethyl-2H-dibenzo JJ i
( ( i
b NN i
, , i
f NN i
) ) i
pyrazino- NN i
( ( i
1,2 CD i
-- : i
d NN i
) ) i
- : i
( ( i
1,4 CD i
) ) i
-oxazepine NN i
hydrogen NN i
maleate NN i
( ( i
Org NNP i
GC NNP i
94 CD i
) ) i
. . i

A DT N
double-blind JJ N
study NN N
. . N

1,3,4,14b-Tetrahydro-2,7-dimethyl-2H-dibenzo JJ i
( ( i
b NN i
, , i
f NN i
) ) i
pyrazino- NN i
( ( i
1,2-d CD i
) ) i
- : i
( ( i
1,4 CD i
) ) i
-oxazepine NN i
hydrogen NN i
maleate NN i
( ( i
Org NNP i
GC NNP i
94 CD i
) ) i
is VBZ N
an DT N
oral JJ N
antamine NN N
preparation NN N
with IN N
anti-serotoninergic JJ N
and CC N
anti-histaminic JJ N
effects NNS N
. . N

Its PRP$ N
lack NN N
of IN N
unpleasant JJ N
side-effects NNS N
permits NNS N
protracted VBN N
use NN N
for IN N
the DT N
preventive JJ N
treatment NN N
of IN N
serotonin-migraine NN N
. . N

Its PRP$ N
chemical NN N
structure NN N
-- : N
tetracyclic JJ N
ring NN N
, , N
C-beta NNP N
, , N
C-alpha NNP N
, , N
amine NN N
in IN N
a DT N
secondary JJ N
position NN N
-- : N
allows VBZ N
block NN N
of IN N
the DT N
receptors NNS N
for IN N
serotonin NN N
and CC N
histamine NN N
. . N

Preventive JJ N
treatment NN N
with IN N
3 CD N
x NNS N
5 CD N
mg/day NN N
of IN N
Org NNP i
GC NNP i
94 CD i
for IN N
a DT N
period NN N
of IN N
3 CD N
months NNS N
can MD N
almost RB N
completely RB N
eliminate JJ N
migraine NN o
attacks NNS N
. . N

21 CD N
out IN N
of IN N
30 CD p
patients NNS p
( ( N
70 CD N
% NN N
) ) N
profited VBN N
from IN N
such JJ N
a DT N
treatment NN N
, , N
showing VBG N
a DT N
drop NN N
from IN N
5 CD N
-- : N
30 CD N
attacks NNS N
to TO N
0 CD N
-- : N
1 CD N
attack NN o
per IN o
month NN o
and CC o
normalization NN o
of IN o
high JJ o
urinary JJ o
serotonin NN o
, , o
5-HIAA JJ o
or CC o
histamine JJ o
levels NNS o
. . o

However RB N
, , N
30 CD p
patients NNS p
receiving VBG p
3 CD p
x JJ p
0.5 CD p
mg NN p
or CC p
placebo JJ i
daily RB p
reacted VBD N
only RB N
rarely RB N
. . N

The DT N
typical JJ N
side-effects NNS N
of IN N
anti-serotonin JJ o
drugs NNS o
, , N
especially RB N
sedation NN o
or CC o
dizziness NN o
and CC o
hyperorexia NN o
were VBD N
hardly RB N
observed VBN N
. . N

Randomization NN N
of IN N
the DT N
serotonin-migraine JJ N
cases NNS N
and CC N
double-blind JJ N
methodology NN N
were VBD N
applied VBN N
throughout IN N
the DT N
trial NN N
. . N

-DOCSTART- -1697914- O O

Use NNP N
of IN N
an DT N
alpha JJ i
1-blocker NN i
, , i
YM617 NNP i
, , N
in IN N
the DT N
treatment NN N
of IN N
benign JJ p
prostatic JJ p
hypertrophy NN p
. . p

YM617 NNP N
Clinical NNP N
Study NNP N
Group NNP N
. . N

A DT N
recently RB N
synthesized VBN N
alpha JJ i
1-blocker CD i
, , i
( ( i
R NNP i
) ) i
( ( i
- : i
) ) i
-5- VBP i
[ JJ i
2- JJ i
[ NN i
[ CD i
2- JJ i
( ( i
o-ethoxyphenoxy JJ i
) ) i
ethyl FW i
] NNP i
amino NN i
] NNP i
propyl NN i
] NNP i
-2- NNP i
methoxybenzenesulfonamide NN i
hydrochloride NN i
( ( i
YM617 NNP i
) ) i
, , N
was VBD N
evaluated VBN N
in IN N
270 CD p
patients NNS p
with IN p
benign JJ p
prostatic JJ p
hypertrophy NN p
in IN N
a DT N
double-blind NN N
study NN N
. . N

After IN N
2 CD N
weeks NNS N
on IN N
placebo IN i
the DT N
patients NNS N
were VBD N
assigned VBN N
at IN N
random NN N
to TO N
4 CD N
groups NNS N
: : N
group NN N
P NNP i
-- : i
placebo NN i
, , N
group NN N
L NNP N
-- : N
0.1 CD N
mg. NN N
, , N
group NN N
M NNP N
-- : N
0.2 CD N
mg. NN N
and CC N
group NN N
H NNP N
-- : N
0.4 CD N
mg. NN N
of IN N
YM617 NNP i
. . i

Comparing VBG N
the DT N
placebo NN i
to TO N
the DT N
treatment NN N
period NN N
, , N
subjective JJ N
symptoms NNS N
, , N
such JJ N
as IN N
nocturia NNS o
and CC o
urgency NN o
, , N
were VBD N
significantly RB N
decreased VBN N
in IN N
group NN N
H NNP N
( ( N
p NN N
less JJR N
than IN N
0.01 CD N
) ) N
. . N

The DT N
sensation NN o
of IN o
incomplete JJ o
voiding NN o
was VBD N
significantly RB N
improved VBN N
in IN N
groups NNS N
M NNP N
and CC N
H NNP N
( ( N
p NN N
less JJR N
than IN N
0.01 CD N
) ) N
. . N

However RB N
, , N
the DT N
differences NNS N
among IN N
the DT N
groups NNS N
were VBD N
statistically RB N
insignificant JJ N
. . N

Residual JJ o
urine JJ o
volume NN o
was VBD N
significantly RB N
decreased VBN N
in IN N
groups NNS N
L NNP N
, , N
M NNP N
and CC N
H NNP N
after IN N
instillation NN N
of IN N
saline NN N
into IN N
the DT N
bladder NN N
( ( N
p NN N
less JJR N
than IN N
0.01 CD N
) ) N
but CC N
not RB N
in IN N
group NN N
P. NNP N
The DT N
maximum NN o
and CC o
average JJ o
flow JJ o
rates NNS o
were VBD N
significantly RB N
increased VBN N
in IN N
groups NNS N
L NNP N
, , N
M NNP N
and CC N
H NNP N
( ( N
p NN N
less JJR N
than IN N
0.01 CD N
) ) N
but CC N
not RB N
in IN N
group NN N
P. NNP N
Average NNP o
flow JJ o
rate NN o
showed VBD N
significant JJ N
differences NNS N
between IN N
groups NNS N
M NNP N
or CC N
H NNP N
versus NN N
group NN N
P. NNP N
Neither NNP N
orthostatic JJ o
hypotension NN o
nor CC N
a DT N
decrease NN N
in IN N
blood NN o
pressure NN o
was VBD N
noted VBN N
. . N

Adverse JJ N
side NN N
effects NNS N
and CC N
changes NNS N
in IN N
laboratory NN N
data NNS N
were VBD N
all DT N
slight JJ N
and CC N
disappeared VBD N
when WRB N
the DT N
second JJ N
tests NNS N
were VBD N
performed VBN N
. . N

In IN N
summary JJ N
, , N
the DT N
irritative JJ o
and CC o
obstructive JJ o
symptoms NNS o
caused VBN N
by IN N
benign JJ o
prostatic JJ o
hypertrophy NN o
were VBD N
decreased VBN N
and CC N
urodynamic JJ o
studies NNS o
were VBD N
markedly RB N
improved VBN N
by IN N
the DT N
alpha JJ i
1-blocker NN i
, , i
YM617 NNP i
. . i

The DT N
drug NN N
seems VBZ N
to TO N
be VB N
useful JJ N
in IN N
the DT N
treatment NN N
of IN N
patients NNS p
with IN p
benign JJ p
prostatic JJ p
hypertrophy NN p
. . p

-DOCSTART- -7118776- O O

The DT N
pharmacokinetics NNS o
of IN N
metronidazole NN i
and CC i
tinidazole NN i
in IN N
patients NNS p
with IN p
mixed JJ p
aerobic NNS p
-- : p
anaerobic JJ p
infections NNS p
. . p

-DOCSTART- -15642753- O O

A DT N
home NN i
visiting NN i
asthma JJ i
education NN i
program NN i
: : i
challenges NNS N
to TO N
program NN N
implementation NN N
. . N

This DT N
study NN N
describes VBZ N
the DT N
implementation NN N
of IN N
a DT N
nurse JJ i
home NN i
visiting NN i
asthma JJ i
education NN i
program NN i
for IN N
low-income JJ p
African JJ p
American JJ p
families NNS p
of IN p
young JJ p
children NNS p
with IN p
asthma NN p
. . p

Of IN p
55 CD p
families NNS p
, , p
71 CD p
% NN p
completed VBD p
the DT p
program NN p
consisting NN N
of IN N
eight CD N
lessons NNS N
. . N

The DT N
achievement NN o
of IN o
learning VBG o
objectives NNS o
was VBD N
predicted VBN N
by IN N
caregiver NN o
factors NNS o
, , o
such JJ o
as IN o
education NN o
, , o
presence NN o
of IN o
father NN o
or CC o
surrogate VB o
father NN o
in IN o
the DT o
household NN o
, , o
and CC o
safety NN o
of IN o
the DT o
neighborhood NN o
, , N
but CC N
not RB N
by IN N
child JJ o
factors NNS o
, , o
such JJ o
as IN o
age NN o
or CC o
severity NN o
of IN o
asthma NN o
as IN N
implied VBN N
by IN N
the DT N
prescribed JJ N
asthma JJ N
medication NN N
regimen NNS N
. . N

Incompatibility NN N
between IN N
the DT N
scheduling VBG N
needs NNS N
of IN N
the DT N
families NNS N
and CC N
the DT N
nurse JJ N
home NN N
visitors NNS N
was VBD N
a DT N
major JJ N
obstacle NN N
in IN N
delivering VBG N
the DT N
program NN N
on IN N
time NN N
, , N
despite IN N
the DT N
flexibility NN N
of IN N
the DT N
nurse JJ N
home NN N
visitors NNS N
. . N

The DT N
authors NNS N
suggest VBP N
that IN N
future JJ N
home-based JJ i
asthma NN i
education NN i
programs NNS i
contain VBP N
a DT N
more RBR N
limited JJ N
number NN o
of IN o
home NN o
visits NNS o
but CC N
add VBP N
telephone NN N
follow-ups NNS N
and CC N
address VB N
the DT N
broader JJR N
needs NNS N
of IN N
low-income JJ p
families NNS p
that IN N
most JJS N
likely JJ N
function NN N
as IN N
barriers NNS N
to TO N
program NN N
success NN N
. . N

-DOCSTART- -21220480- O O

Gefitinib NNP i
or CC i
placebo NN i
in IN N
combination NN N
with IN N
tamoxifen NN N
in IN N
patients NNS p
with IN p
hormone JJ o
receptor-positive JJ o
metastatic JJ o
breast NN o
cancer NN o
: : o
a DT N
randomized JJ N
phase NN N
II NNP N
study NN N
. . N

PURPOSE NNP N
Increased VBD N
growth NN N
factor NN N
signaling VBG N
may MD N
contribute VB N
to TO N
tamoxifen VB N
resistance NN N
. . N

This DT N
randomized JJ N
phase NN N
II NNP N
trial NN N
assessed VBD N
tamoxifen JJ i
plus CC i
placebo NN i
or CC N
the DT N
epidermal JJ N
growth NN N
factor NN N
receptor NN N
inhibitor NN N
gefitinib NN N
in IN N
estrogen NN N
receptor NN N
( ( N
ER NNP N
) ) N
-positive VBP N
metastatic JJ N
breast NN N
cancer NN N
. . N

EXPERIMENTAL NNP N
DESIGN NNP N
Patients NNPS p
with IN p
newly RB p
metastatic JJ p
disease NN p
or CC p
recurred VBN p
after IN p
adjuvant JJ p
tamoxifen NN i
( ( p
stratum JJ p
1 CD p
) ) p
, , p
or CC p
recurred VBD p
during/after NN p
adjuvant JJ p
aromatase NN p
inhibitor NN p
( ( p
AI NNP p
) ) p
or CC p
after IN p
failed VBN p
first-line NN p
AI NNP p
( ( p
stratum JJ p
2 CD p
) ) p
, , p
were VBD p
eligible JJ p
. . p

Primary JJ N
variables NNS N
were VBD N
progression-free JJ o
survival NN o
( ( N
PFS NNP N
; : N
stratum VBZ N
1 CD N
) ) N
and CC N
clinical JJ o
benefit NN o
rate NN o
( ( N
CBR NNP N
; : N
stratum VBZ N
2 CD N
) ) N
. . N

A DT N
5 CD N
% NN N
or CC N
more JJR N
improvement NN N
in IN N
response NN N
variables NNS N
with IN N
gefitinib NN i
was VBD N
considered VBN N
to TO N
warrant VB N
further JJ N
investigation NN N
. . N

Outcome NNP N
was VBD N
correlated VBN N
with IN N
biomarkers NNS N
measured VBN N
on IN N
the DT N
primary JJ N
tumor NN N
. . N

RESULTS NNP N
In IN N
stratum JJ N
1 CD N
( ( N
n JJ N
= NNP N
206 CD N
) ) N
, , N
the DT N
PFS NNP o
HR NNP o
( ( i
gefitinib NN i
: : i
placebo NN i
) ) i
was VBD N
0.84 CD N
( ( N
95 CD N
% NN N
CI NNP N
, , N
0.59-1.18 NNP N
; : N
median JJ o
PFS NNP o
10.9 CD N
versus NN N
8.8 CD N
months NNS N
) ) N
. . N

In IN N
the DT N
stratum NN N
1 CD N
endocrine JJ N
therapy-na?ve JJ N
subset NN N
( ( N
n JJ N
= NNP N
158 CD N
) ) N
the DT o
HR NNP o
was VBD N
0.78 CD N
( ( N
95 CD N
% NN N
CI NNP N
, , N
0.52-1.15 NNP N
) ) N
, , N
and CC N
the DT N
prior JJ N
endocrine-treated JJ N
subgroup NN N
( ( N
n JJ N
= NNP N
48 CD N
) ) N
1.47 CD N
( ( N
95 CD N
% NN N
CI NNP N
, , N
0.63-3.45 NN N
) ) N
. . N

In IN N
stratum NN N
1 CD N
, , N
CBRs NNP o
were VBD N
50.5 CD N
% NN N
with IN i
gefitinib NN i
and CC N
45.5 CD N
% NN N
with IN i
placebo NN i
. . i

In IN N
stratum NN N
2 CD N
( ( N
n JJ N
= NNP N
84 CD N
) ) N
, , N
CBRs NNP o
were VBD N
29.2 CD N
% NN N
with IN i
gefitinib NN i
and CC N
31.4 CD N
% NN N
with IN i
placebo NN i
. . i

Biomarker NNP N
analysis NN N
suggested VBD N
that IN N
in IN N
stratum NN N
1 CD N
there EX N
was VBD N
greater JJR N
benefit NN N
with IN N
gefitinib NN N
in IN N
patients NNS N
who WP N
were VBD N
ER-negative JJ N
or CC N
had VBD N
lower JJR N
levels NNS N
of IN N
ER NNP N
protein NN N
. . N

CONCLUSIONS NNP N
In IN N
stratum NN N
1 CD N
, , N
the DT N
improved JJ N
PFS NNP N
with IN i
gefitinib JJ i
plus CC i
tamoxifen JJ i
met VBD N
the DT N
protocol NN N
criteria NNS N
to TO N
warrant VB N
further JJ N
investigation NN N
of IN N
this DT N
strategy NN N
. . N

In IN N
stratum NN N
2 CD N
, , N
there EX N
was VBD N
a DT N
numerical JJ N
disadvantage NN N
for IN i
gefitinib NN i
; : i
additional JJ N
investigation NN N
after IN N
AI NNP N
therapy NN N
is VBZ N
not RB N
warranted VBN N
. . N

Studies NNS N
of IN N
predictive JJ N
biomarkers NNS N
are VBP N
needed VBN N
to TO N
subset VB p
appropriate JJ p
patients NNS p
. . p

-DOCSTART- -11691515- O O

Potentiation NN N
of IN N
bradykinin-induced JJ N
tissue NN N
plasminogen NN N
activator NN N
release NN N
by IN N
angiotensin-converting JJ N
enzyme JJ N
inhibition NN N
. . N

OBJECTIVES CC N
The DT N
aim NN N
of IN N
the DT N
present JJ N
study NN N
was VBD N
to TO N
determine VB N
the DT N
effect NN N
of IN N
angiotensin-converting JJ N
enzyme NN N
( ( N
ACE NNP N
) ) N
inhibition NN N
on IN N
the DT N
local JJ N
stimulated VBD N
release NN N
of IN N
tissue NN N
plasminogen NN N
activator NN N
( ( N
t-PA JJ N
) ) N
from IN N
the DT N
endothelium NN N
. . N

BACKGROUND NNP N
Angiotensin-converting NNP i
enzyme NN i
inhibitor NN i
therapy NN i
may MD N
exert VB N
a DT N
beneficial JJ N
effect NN N
on IN N
the DT N
endogenous JJ N
fibrinolytic JJ N
balance NN N
. . N

METHODS NNP N
Blood NNP o
flow NN o
and CC o
plasma JJ o
fibrinolytic JJ o
factors NNS o
were VBD N
measured VBN N
in IN N
both DT p
forearms NNS p
of IN p
eight CD p
healthy JJ p
males NNS p
who WP p
received VBD p
unilateral JJ p
brachial JJ p
artery NN p
infusions NNS p
of IN p
the DT p
endothelium-dependent JJ i
vasodilators NNS i
substance NN i
P NNP i
( ( p
2 CD p
to TO p
8 CD p
pmol/min NN p
) ) p
and CC p
bradykinin NN i
( ( p
100 CD p
to TO p
1,000 CD p
pmol/min NN p
) ) p
, , p
and CC p
the DT p
endothelium-independent JJ i
vasodilator NN i
sodium NN i
nitroprusside NN i
( ( p
2 CD p
to TO p
8 CD p
microg/min NN p
) ) p
. . p

These DT N
measurements NNS N
were VBD N
performed VBN N
on IN N
each DT N
of IN N
three CD N
occasions NNS N
following VBG N
one CD N
week NN N
of IN N
matched JJ N
placebo NN i
, , i
quinapril RB i
40 CD N
mg NN N
or CC N
losartan JJ i
50 CD N
mg JJ N
daily RB N
administered VBN N
in IN N
a DT N
double-blind JJ N
randomized JJ N
crossover NN N
design NN N
. . N

RESULTS NNP N
Sodium NNP N
nitroprusside RB N
, , N
substance NN N
P NNP N
and CC N
bradykinin NN N
produced VBD N
dose-dependent JJ N
increases NNS o
in IN o
the DT o
blood NN o
flow NN o
of IN N
infused JJ N
forearm NN N
( ( N
analysis NN N
of IN N
variance NN N
[ NNP N
ANOVA NNP N
] NNP N
, , N
p NN N
< VBD N
0.001 CD N
for IN N
all DT N
) ) N
. . N

Although IN N
sodium JJ N
nitroprusside RB N
did VBD N
not RB N
affect VB N
plasma JJ o
t-PA JJ o
concentrations NNS o
, , N
they PRP N
were VBD N
increased VBN N
dose-dependently RB N
in IN N
the DT N
infused JJ N
forearm NN N
by IN N
substance NN N
P NNP N
and CC N
bradykinin JJ N
infusion NN N
( ( N
ANOVA NNP N
, , N
p NN N
< VBD N
0.001 CD N
for IN N
both DT N
) ) N
. . N

Bradykinin-induced JJ N
release NN o
of IN o
active JJ o
t-PA NN o
was VBD N
more RBR N
than IN N
doubled VBD N
during IN N
treatment NN N
with IN N
quinapril NN i
in IN N
comparison NN N
to TO N
placebo VB i
or CC N
losartan VB i
( ( N
two-way JJ N
ANOVA NNP N
: : N
p NN N
< VBZ N
0.003 CD N
for IN N
treatment NN N
group NN N
, , N
p VBP N
< $ N
0.001 CD N
for IN N
t-PA JJ N
response NN N
and CC N
p NN N
= NNP N
ns NN N
for IN N
interaction NN N
) ) N
, , N
whereas IN N
the DT N
substance NN o
P NNP o
response NN o
was VBD o
unaffected JJ o
. . o

CONCLUSIONS NN N
We PRP N
have VBP N
shown VBN N
a DT N
selective JJ N
and CC N
marked JJ N
augmentation NN N
of IN N
bradykinin-induced JJ N
t-PA JJ N
release NN N
during IN N
ACE NNP N
inhibition NN N
. . N

These DT N
findings NNS N
suggest VBP N
that IN N
the DT N
beneficial JJ N
clinical JJ N
and CC N
vascular JJ N
effects NNS N
of IN N
ACE NNP N
inhibition NN N
may MD N
, , N
in IN N
part NN N
, , N
be VB N
mediated VBN N
through IN N
local JJ N
augmentation NN N
of IN N
bradykinin-induced JJ N
t-PA JJ N
release NN N
. . N

-DOCSTART- -16731878- O O

Outcomes NNS o
in IN N
a DT N
nursing NN N
home NN N
transition NN N
case-management JJ N
program NN N
targeting VBG N
new JJ p
admissions NNS p
. . p

PURPOSE VB N
The DT N
Providing VBG i
Assistance NNP i
to TO i
Caregivers NNPS i
in IN i
Transition NNP i
( ( i
PACT NNP i
) ) i
program NN i
offers NNS N
nursing VBG N
home NN N
discharge NN N
planning NN N
and CC N
case NN N
management NN N
for IN N
individuals NNS p
in IN p
the DT p
transitional JJ p
period NN p
following VBG p
a DT p
return NN p
to TO p
the DT p
community NN p
. . p

The DT N
PACT NNP i
program NN i
targeted VBN N
individuals NNS p
newly RB p
admitted VBN p
to TO p
nursing VBG p
homes NNS p
and CC p
worked VBD p
with IN p
a DT p
family NN p
caregiver NN p
to TO p
develop VB p
and CC p
implement VB p
a DT p
nursing NN p
home NN p
discharge NN p
plan NN p
. . p

DESIGN NNP N
AND CC N
METHOD NNP N
Reported NNP N
are VBP N
the DT N
results NNS N
of IN N
a DT N
randomized JJ N
control NN N
design NN N
evaluating VBG N
the DT N
program NN N
's POS N
effectiveness NN o
. . o

Those DT N
individuals NNS N
randomly RB N
assigned VBN N
to TO N
the DT N
intervention NN p
group NN p
( ( p
n JJ p
= NNP p
33 CD p
) ) p
received VBN N
PACT NNP i
case NN i
management NN i
in IN i
addition NN i
to TO i
their PRP$ i
usual JJ i
medical JJ i
and CC i
nursing NN i
home NN i
care NN i
. . i

The DT N
individuals NNS N
in IN N
the DT N
control NN p
group NN p
( ( p
n JJ p
= NNP p
29 CD p
) ) p
continued VBD N
their PRP$ N
usual JJ i
care NN i
. . i

RESULT CC N
There EX N
were VBD N
no DT N
statistical JJ N
differences NNS o
in IN o
the DT o
discharge NN o
rate NN o
( ( N
84 CD N
% NN N
treatment NN N
vs RB N
76 CD N
% NN N
controls NNS N
) ) N
or CC o
in IN o
the DT o
median JJ o
length NN o
of IN o
stay NN o
( ( N
42 CD N
days NNS N
vs RB N
55 CD N
days NNS N
) ) N
between IN N
the DT N
two CD N
groups NNS N
of IN N
individuals NNS N
. . N

IMPLICATIONS NNP N
Replications NNPS N
or CC N
extensions NNS N
of IN N
a DT N
PACT-type JJ i
intervention NN i
might MD N
consider VB N
a DT N
broader JJR N
mix NN N
of IN N
nursing NN N
homes NNS N
, , N
working VBG N
directly RB N
with IN N
the DT N
nursing NN N
home NN N
's POS N
admission NN N
Minimum NNP N
Data NNP N
Set NNP N
coordinator NN N
in IN N
patient JJ N
selection NN N
, , N
or CC N
working VBG N
with IN N
Medicare NNP N
or CC N
Medicaid NNP N
HMO NNP N
plans VBZ N
. . N

-DOCSTART- -2486557- O O

The DT N
Randomised JJ N
Intervention NNP N
Treatment NNP N
of IN N
Angina NNP N
( ( N
RITA NNP N
) ) N
Trial NNP N
protocol NN N
: : N
a DT N
long JJ N
term NN N
study NN N
of IN N
coronary JJ i
angioplasty NN i
and CC i
coronary JJ i
artery NN i
bypass NN i
surgery NN i
in IN p
patients NNS p
with IN p
angina NN p
. . p

The DT N
Randomised JJ N
Intervention NNP N
Treatment NNP N
of IN N
Angina NNP N
( ( N
RITA NNP N
) ) N
Trial NNP N
is VBZ N
a DT N
prospective JJ N
, , N
randomised VBD N
study NN N
to TO N
compare VB N
the DT N
short JJ N
term NN N
and CC N
long JJ N
term NN N
effects NNS N
of IN N
percutaneous JJ i
transluminal JJ i
coronary NN i
angioplasty NN i
and CC i
coronary JJ i
artery NN i
bypass NN i
surgery NN i
. . i

During IN N
the DT N
study NN N
a DT N
register NN N
of IN N
patients NNS p
undergoing VBG p
coronary JJ i
arteriography NN i
at IN p
the DT p
fourteen JJ p
participating VBG p
centres NNS p
is VBZ N
being VBG N
maintained VBN N
to TO N
assess VB N
the DT N
overall JJ N
context NN N
of IN N
patient JJ N
recruitment NN N
. . N

Patients NNS p
with IN p
arteriographically RB p
proven JJ p
coronary JJ p
artery NN p
disease NN p
are VBP p
considered VBN p
for IN p
the DT p
trial NN p
if IN N
the DT N
participating VBG N
cardiologist NN N
and CC N
surgeon NN N
agree VBP N
that IN N
equivalent JJ N
revascularisation NN N
could MD N
be VB N
achieved VBN N
by IN N
either DT N
treatment NN N
method NN N
. . N

Patients NNS N
who WP N
satisfy VBP N
the DT N
trial NN N
entry NN N
criteria NNS N
are VBP N
randomised VBN N
to TO N
treatment NN N
by IN N
coronary JJ i
angioplasty NN i
or CC i
coronary JJ i
artery NN i
bypass NN i
surgery NN i
, , N
with IN N
prospective JJ N
stratification NN N
into IN N
groups NNS N
with IN N
one CD N
, , N
two CD N
, , N
or CC N
three CD N
treatment NN N
vessels NNS N
. . N

Randomisation NNP N
implies VBZ N
an DT N
intention NN N
to TO N
treat VB N
the DT N
patient NN N
by IN N
the DT N
assigned JJ N
procedure NN N
and CC N
the DT N
analysis NN N
of IN N
long JJ N
term NN N
results NNS N
will MD N
include VB N
all DT N
randomised JJ N
cases NNS N
. . N

The DT p
trial NN p
will MD p
recruit VB p
at IN p
least JJS p
1000 CD p
patients NNS p
who WP p
will MD p
be VB p
followed VBN p
for IN p
five CD p
years NNS p
. . p

The DT N
major JJ N
trial NN N
end NN N
points NNS N
include VBP N
death NN o
, , o
new JJ o
myocardial JJ o
infarction NN o
, , o
and CC o
new JJ o
coronary JJ o
angioplasty NN o
or CC o
coronary JJ o
artery NN o
bypass NN o
procedures NNS o
. . o

Other JJ N
outcome JJ N
measures NNS N
include VBP N
symptom NN o
and CC o
employment NN o
status NN o
, , o
quality NN o
of IN o
life NN o
, , o
exercise NN o
tolerance NN o
, , o
and CC o
left VBD o
ventricular JJ o
function NN o
. . o

-DOCSTART- -16146466- O O

Hyperbaric NNP i
oxygen NN i
attenuation NN N
of IN N
lipopolysaccharide-induced JJ p
acute NN p
lung NN p
injury NN p
involves VBZ N
heme JJ N
oxygenase-1 NN N
. . N

BACKGROUND NNP N
Hyperbaric NNP i
oxygen NN i
( ( i
HBO NNP i
) ) i
attenuates VBZ N
lipopolysaccharide JJ N
( ( N
LPS NNP N
) ) N
-induced VBD N
acute JJ p
lung NN p
injury NN p
. . p

This DT N
beneficial JJ N
effect NN N
of IN N
HBO NNP N
involves VBZ N
inhibition NN N
of IN N
inducible JJ N
nitric JJ N
oxide NN N
synthase NN N
( ( N
iNOS NN N
) ) N
expression NN N
and CC N
subsequent JJ N
nitric JJ N
oxide NN N
( ( N
NO NNP N
) ) N
biosynthesis NN N
. . N

We PRP N
sought VBD N
to TO N
investigate VB N
the DT N
role NN N
of IN N
heme JJ N
oxygenase-1 JJ N
( ( N
HO-1 NNP N
) ) N
on IN N
this DT N
HBO NNP N
inhibition NN N
of IN N
iNOS JJ N
induction NN N
and CC N
acute NN N
lung NN N
injury NN N
in IN N
septic JJ N
rat NN p
lungs NNS N
. . N

METHODS NNP N
Before IN N
the DT N
experiment NN N
, , N
72 CD p
rats NNS p
were VBD p
randomly RB p
allocated VBN p
to TO p
receive VB p
HBO NNP i
or CC i
air NN i
treatment NN i
. . i

With IN N
or CC N
without IN N
HBO NNP i
pre-treatment NN N
, , N
the DT N
rats NNS p
were VBD N
further RB N
divided VBN N
into IN N
the DT N
following JJ N
subgroups NNS N
( ( N
n JJ N
= NNP N
6 CD N
) ) N
: : N
( ( N
i NN N
) ) N
LPS NNP i
injection NN i
, , i
( ( i
ii NN i
) ) i
normal JJ i
saline NN i
( ( i
N/S NNP i
) ) i
injection NN i
, , i
( ( i
iii NN i
) ) i
hemin NN i
( ( i
a DT i
HO-1 NNP i
inducer NN i
) ) i
plus CC i
LPS NNP i
, , i
( ( i
iv NN i
) ) i
hemin NN i
alone RB i
, , i
( ( i
v NN i
) ) i
tin NN i
protoporphyrin NN i
( ( i
SnPP NNP i
; : i
a DT i
HO-1 NNP i
inhibitor NN i
) ) i
plus CC i
LPS NNP i
, , i
and CC i
( ( i
vi NN i
) ) i
SnPP NNP i
alone RB i
. . i

All DT N
rats NNS p
were VBD N
maintained VBN N
for IN N
6 CD N
h NN N
and CC N
then RB N
sacrificed VBD N
with IN N
a DT N
high-dose JJ i
pentobarbital JJ i
injection NN i
. . i

Lung NNP N
injuries NNS N
and CC N
relevant JJ N
enzymes NNS N
expression NN N
were VBD N
thus RB N
assayed VBN N
. . N

RESULTS NNP N
Histological NNP o
analysis NN o
, , o
PMNs/alveoli NNP o
ratio NN o
, , o
and CC o
wet/dry JJ o
weight NN o
ratio NN o
measurements NNS o
demonstrated VBD N
that IN N
LPS NNP N
caused VBD N
significant JJ N
lung JJ N
injury NN N
and CC N
HBO NNP N
and/or VBP N
hemin NN N
significantly RB N
attenuated VBD N
this DT N
LPS-induced JJ N
lung NN N
injury NN N
. . N

Increased VBD N
pulmonary JJ N
iNOS NN o
expression NN o
and CC o
NO DT o
production NN o
were VBD N
associated VBN N
with IN N
lung JJ N
injury NN N
. . N

Induction NN N
of IN N
HO-1 NNP N
, , N
by IN N
HBO NNP N
and/or NN N
hemin NN N
, , N
significantly RB N
attenuated VBD N
this DT N
LPS-induced JJ N
iNOS NN N
expression NN N
and CC N
acute NN N
lung NN N
injury NN N
. . N

SnPP NNP N
, , N
on IN N
the DT N
contrary JJ N
, , N
offset VB N
the DT N
effects NNS N
of IN N
HBO NNP i
and CC N
worsened VBD N
the DT N
LPS-induced NNP N
lung NN N
injury NN N
. . N

CONCLUSIONS NNP N
HBO NNP i
may MD N
act VB N
through IN N
inhibiting VBG N
pulmonary JJ N
iNOS NN N
expression NN N
to TO N
attenuate VB N
LPS-induced NNP N
acute NN N
lung NN N
injury NN N
in IN N
septic JJ p
rats NNS p
. . p

Furthermore RB N
, , N
this DT N
HBO NNP i
attenuation NN N
of IN N
iNOS JJ N
expression NN N
involves VBZ N
HO-1 NNP N
induction NN N
. . N

-DOCSTART- -4157501- O O

Potassium NN i
, , i
glucose NN i
, , i
and CC i
insulin NN i
in IN N
treatment NN o
of IN N
myocardial JJ o
infarction NN o
. . o

-DOCSTART- -11701101- O O

The DT N
role NN N
of IN N
radiography NN i
in IN N
primary JJ p
care NN p
patients NNS p
with IN p
low JJ p
back RB p
pain NN p
of IN p
at IN p
least JJS p
6 CD p
weeks NNS p
duration NN p
: : p
a DT N
randomised JJ N
( ( N
unblinded JJ N
) ) N
controlled VBD N
trial NN N
. . N

OBJECTIVES UH N
To TO N
test VB N
the DT N
hypotheses NNS N
that WDT N
: : N
( ( N
1 CD N
) ) N
Lumbar NNP N
spine NN N
radiography NN N
in IN N
primary JJ p
care NN p
patients NNS p
with IN p
low JJ p
back RB p
pain NN p
is VBZ N
not RB N
associated VBN N
with IN N
improved JJ N
patient NN N
outcomes NNS N
, , N
including VBG N
pain NN o
, , o
disability NN o
, , o
health NN o
status NN o
, , o
sickness NN o
absence NN o
, , o
reassurance NN o
, , N
and CC N
patient JJ N
satisfaction NN o
or CC N
belief NN o
in IN N
the DT N
value NN N
of IN N
radiography NN N
. . N

( ( N
2 CD N
) ) N
Lumbar NNP i
spine NN i
radiography NN i
in IN N
primary JJ p
care NN p
patients NNS p
with IN p
low JJ p
back RB p
pain NN p
is VBZ N
not RB N
associated VBN N
with IN N
changes NNS N
in IN N
patient JJ N
management NN N
, , N
including VBG N
medication NN N
use NN N
, , N
and CC N
the DT N
use NN N
of IN N
primary JJ N
and CC N
secondary JJ N
care NN N
services NNS N
, , N
physical JJ N
therapies NNS N
and CC N
complementary JJ N
therapies NNS N
. . N

( ( N
3 CD N
) ) N
Participants NNS N
choosing VBG N
their PRP$ N
treatment NN N
group NN N
( ( N
i.e NN N
. . N

radiography NN i
or CC N
no DT i
radiography NN i
) ) i
do VBP N
not RB N
have VB N
better JJR N
outcomes NNS N
than IN N
those DT N
randomised VBN N
to TO N
a DT N
treatment NN N
group NN N
. . N

( ( N
4 CD N
) ) N
Lumbar NNP N
spine NN N
radiography NN N
is VBZ N
not RB N
cost-effective JJ N
compared VBN N
with IN N
usual JJ N
care NN N
without IN N
lumbar NN N
spine NN N
radiography NN N
. . N

DESIGN VB N
A DT N
randomised JJ N
unblinded JJ N
controlled VBN N
trial NN N
. . N

SETTING CC N
Seventy-three JJ p
general JJ p
practices NNS p
in IN p
Nottingham NNP p
, , p
North NNP p
Nottinghamshire NNP p
, , p
Southern NNP p
Derbyshire NNP p
, , p
North NNP p
Lincolnshire NNP p
and CC p
North NNP p
Leicestershire NNP p
. . p

Fifty-two NNP p
practices NNS p
recruited VBD p
participants NNS p
to TO p
the DT p
trial NN p
. . p

SUBJECTS NNP N
Randomised VBD N
arm NN N
: : N
421 CD p
participants NNS p
with IN p
low JJ p
back RB p
pain NN p
, , p
with IN p
median JJ p
duration NN p
of IN p
10 CD p
weeks NNS p
. . p

Patient JJ N
preference NN N
arm NN N
: : N
55 CD p
participants NNS p
with IN p
low JJ p
back RB p
pain NN p
, , p
with IN p
median JJ p
duration NN p
of IN p
11 CD p
weeks NNS p
. . p

INTERVENTION NNP N
Lumbar NNP i
spine NN i
radiography NN i
and CC i
usual JJ i
care NN i
versus NN i
usual JJ i
care NN i
without IN i
radiography NN i
. . i

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Roland NNP o
adaptation NN o
of IN o
the DT o
Sickness NNP o
Impact NNP o
Profile NNP o
, , o
visual JJ o
analogue NN o
pain NN o
scale NN o
, , o
health NN o
status NN o
scale NN o
, , o
EuroQol NNP o
, , o
use NN o
of IN o
primary JJ o
and CC o
secondary JJ o
care NN o
services NNS o
, , o
and CC o
physical JJ o
and CC o
complementary JJ o
therapies NNS o
, , o
sickness JJ o
absence NN o
, , o
medication NN o
use NN o
, , o
patient JJ o
satisfaction NN o
, , o
reassurance NN o
and CC o
belief NN o
in IN o
value NN o
of IN o
radiography NN o
at IN N
3 CD N
and CC N
9 CD N
months NNS N
post-randomisation NN N
. . N

RESULTS JJ N
Participants NNS N
randomised VBD N
to TO N
receive VB N
an DT N
X-ray NN N
were VBD N
more RBR N
likely JJ N
to TO N
report VB N
low JJ o
back RB o
pain NN o
at IN N
3 CD N
months NNS N
( ( N
odds NNS N
ratio NN N
( ( N
OR NNP N
) ) N
= VBZ N
1.56 CD N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
( ( N
CI NNP N
) ) N
, , N
1.02 CD N
to TO N
2.40 CD N
) ) N
and CC N
had VBD N
a DT N
lower JJR N
overall JJ N
health NN o
status NN o
score NN N
( ( N
p JJ N
= NNP N
0.02 CD N
) ) N
. . N

There EX N
were VBD N
no DT N
differences NNS N
in IN N
health NN o
or CC N
functional JJ o
status NN o
at IN N
9 CD N
months NNS N
. . N

A DT N
higher JJR N
proportion NN N
of IN N
participants NNS N
consulted VBN o
the DT o
general JJ o
practitioner NN o
( ( o
GP NNP o
) ) o
in IN N
the DT N
3 CD N
months NNS N
following VBG N
an DT N
X-ray JJ N
( ( N
OR NNP N
= VBZ N
2.72 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
1.80 CD N
to TO N
4.10 CD N
) ) N
. . N

There EX N
were VBD N
no DT N
differences NNS N
in IN N
use NN N
of IN N
any DT o
other JJ o
services NNS o
, , o
medication NN o
use NN o
or CC N
sickness NN o
absence NN o
at IN N
3 CD N
or CC N
9 CD N
months NNS N
. . N

No DT N
serious JJ o
spinal JJ o
pathology NN o
was VBD N
identified VBN N
in IN N
either DT N
group NN N
. . N

The DT N
commonest JJS N
X-ray JJ N
reports NNS N
were VBD N
of IN N
discovertebral JJ o
degeneration NN o
and CC N
normal JJ o
findings NNS o
. . o

Many JJ N
patients NNS N
did VBD N
not RB N
perceive VB N
their PRP$ N
information NN N
needs NNS N
were VBD N
met VBN N
within IN N
the DT N
consultation NN N
. . N

Satisfaction NN o
with IN N
care NN N
was VBD N
greater JJR N
in IN N
the DT N
group NN N
receiving VBG N
radiography NN N
at IN N
9 CD N
months NNS N
. . N

Participants NNS N
randomised VBD N
to TO N
receive VB N
an DT N
X-ray NN i
were VBD N
not RB N
less RBR N
worried JJ o
, , N
or CC N
more JJR N
reassured JJ o
about IN N
serious JJ N
disease NN N
causing VBG N
their PRP$ N
low JJ N
back RB N
pain NN N
. . N

Satisfaction NN N
was VBD N
associated VBN N
with IN N
meeting NN N
participants NNS N
' POS N
information NN N
needs NNS N
and CC N
reduced JJ N
belief NN N
in IN N
the DT N
necessity NN N
for IN N
investigations NNS N
for IN N
low JJ N
back RB N
pain NN N
, , N
including VBG N
X-rays NNS N
and CC N
blood NN N
tests NNS N
. . N

In IN N
both DT N
groups NNS N
, , N
at IN N
3 CD N
and CC N
9 CD N
months NNS N
80 CD N
% NN N
of IN N
participants NNS N
would MD N
choose VB N
to TO N
have VB N
an DT N
X-ray JJ N
if IN N
the DT N
choice NN N
was VBD N
available JJ N
. . N

Participants NNS N
in IN N
the DT N
patient JJ N
preference NN N
group NN N
achieved VBD N
marginally RB N
better JJR N
outcomes NNS o
than IN N
those DT N
randomised VBN N
to TO N
a DT N
treatment NN N
group NN N
, , N
but CC N
the DT N
clinical JJ N
significance NN N
of IN N
these DT N
differences NNS N
is VBZ N
unclear JJ N
. . N

Lumbar NNP N
spine NN N
radiography NN N
was VBD N
associated VBN N
with IN N
a DT N
net JJ N
economic JJ o
loss NN o
at IN N
3 CD N
and CC N
9 CD N
months NNS N
. . N

CONCLUSIONS NNP N
Lumbar NNP N
spine NN N
radiography NN N
in IN N
primary JJ N
care NN N
patients NNS N
with IN N
low JJ N
back RB N
pain NN N
of IN N
at IN N
least JJS N
6 CD N
weeks NNS N
duration NN N
is VBZ N
not RB N
associated VBN N
with IN N
improved JJ N
functioning NN o
, , o
severity NN o
of IN o
pain NN o
or CC N
overall JJ o
health NN o
status NN o
, , N
and CC N
is VBZ N
associated VBN N
with IN N
an DT N
increase NN N
in IN N
GP NNP o
workload NN o
. . o

Participants NNS N
receiving VBG N
X-rays NNS N
are VBP N
more RBR N
satisfied JJ N
with IN N
their PRP$ N
care NN N
, , N
but CC N
are VBP N
not RB N
less RBR N
worried JJ N
or CC N
more RBR N
reassured JJ N
about IN N
serious JJ N
disease NN N
causing VBG N
their PRP$ N
low JJ N
back RB N
pain NN N
. . N

CONCLUSIONS NNP N
- : N
RECOMMENDATIONS NN N
FOR IN N
FURTHER JJ N
RESEARCH NN N
: : N
Further JJ N
work NN N
is VBZ N
required VBN N
to TO N
develop VB N
and CC N
test VB N
an DT N
educational JJ N
package NN N
that WDT N
educates VBZ N
patients NNS N
and CC N
GPs NNP N
about IN N
the DT N
utility NN N
of IN N
radiography NN N
and CC N
provides VBZ N
strategies NNS N
for IN N
identifying VBG N
and CC N
meeting VBG N
the DT N
information NN N
needs NNS N
of IN N
patients NNS N
, , N
and CC N
the DT N
needs NNS N
of IN N
patients NNS N
and CC N
GPs NNP N
to TO N
be VB N
reassured VBN N
about IN N
missing VBG N
serious JJ N
disease NN N
. . N

Guidelines NNS N
on IN N
the DT N
management NN N
of IN N
low JJ N
back RB N
pain NN N
in IN N
primary JJ N
care NN N
should MD N
be VB N
consistent JJ N
about IN N
not RB N
recommending VBG N
lumbar NN i
spine NN i
radiography NN i
in IN N
patients NNS N
with IN N
low JJ N
back RB N
pain NN N
in IN N
the DT N
absence NN N
of IN N
red JJ N
flags NNS N
for IN N
serious JJ N
spinal JJ N
pathology NN N
, , N
even RB N
if IN N
the DT N
pain NN N
has VBZ N
persisted VBN N
for IN N
at IN N
least JJS N
6 CD N
weeks NNS N
. . N

-DOCSTART- -2204661- O O

Long-term JJ i
oral JJ i
branched-chain NN i
amino NN i
acid NN i
treatment NN i
in IN N
chronic JJ p
hepatic JJ p
encephalopathy NN p
. . p

A DT N
randomized JJ N
double-blind JJ N
casein-controlled JJ N
trial NN N
. . N

The DT p
Italian JJ p
Multicenter NNP p
Study NNP p
Group NNP p
. . p

In IN N
a DT N
double JJ N
blind NN N
randomized VBN N
study NN N
, , N
branched-chain JJ i
amino NN i
acids NNS i
and CC N
placebo NN i
( ( i
casein NN i
) ) i
were VBD N
compared VBN N
as IN N
a DT N
treatment NN N
for IN N
chronic JJ p
hepatic JJ p
encephalopathy NN p
in IN p
cirrhosis NN p
. . p

After IN N
a DT N
15-day JJ N
run-in JJ N
period NN N
with IN N
controlled JJ N
diet JJ N
( ( N
45-65 JJ N
g NN N
protein NN N
) ) N
, , N
the DT N
patients NNS p
were VBD p
administered VBN p
, , p
in IN p
addition NN p
to TO p
their PRP$ p
diet JJ p
, , p
branched-chain JJ i
amino NN i
acids NNS i
( ( p
0.24 CD p
g/kg NN p
, , p
30 CD p
patients NNS p
) ) p
or CC p
an DT p
equinitrogenous JJ i
amount NN i
of IN i
casein NN i
( ( p
34 CD p
patients NNS p
) ) p
. . p

One CD N
patient NN N
on IN N
branched-chain NN N
amino NN N
acids NNS N
and CC N
two CD N
on IN N
casein NNS N
were VBD N
lost VBN N
to TO N
the DT N
study NN N
. . N

After IN N
3 CD N
months NNS N
, , N
the DT N
index NN o
of IN o
portal-systemic JJ o
encephalopathy NN o
significantly RB N
improved VBN N
in IN N
patients NNS N
on IN N
active JJ i
treatment NN i
( ( N
from IN N
40 CD N
[ JJ N
S.D NNP N
. . N

14 CD N
] CD N
% NN N
to TO N
21 CD N
[ NNS N
17 CD N
] NN N
) ) N
, , N
but CC N
was VBD N
not RB N
in IN N
subjects NNS N
receiving VBG N
casein NN i
( ( N
from IN N
37 CD N
[ $ N
13 CD N
] NNP N
% NN N
to TO N
36 CD N
[ NNS N
12 CD N
] NN N
) ) N
. . N

Two CD N
or CC N
more JJR N
parameters NNS N
of IN N
the DT N
index NN N
improved VBD N
in IN N
24 CD N
patients NNS N
treated VBN N
with IN N
amino JJ i
acids NNS i
( ( N
80 CD N
% NN N
; : N
confidence NN N
limits NNS N
, , N
61-92 CD N
% NN N
) ) N
, , N
and CC N
only RB N
in IN N
12 CD N
receiving VBG N
casein NN i
( ( N
35 CD N
% NN N
; : N
confidence NN N
limits NNS N
, , N
20-54 JJ N
% NN N
; : N
p CC N
less JJR N
than IN N
0.001 CD N
) ) N
. . N

Patients NNS N
who WP N
did VBD N
not RB N
improve VB N
were VBD N
given VBN N
an DT N
alternative JJ i
treatment NN i
for IN N
3 CD N
more JJR N
months NNS N
. . N

Casein-treated JJ o
patients NNS o
given VBN o
branched-chain JJ o
amino NN o
acids NNS o
rapidly RB N
improved VBN o
. . o

The DT N
changes NNS N
in IN N
neuropsychologic JJ N
function NN N
were VBD N
associated VBN N
with IN N
an DT N
improvement NN N
in IN N
semiquantitative JJ o
nitrogen NN o
balance NN o
, , N
which WDT N
became VBD N
consistently RB N
positive JJ N
in IN N
amino JJ i
acid-treated JJ i
subjects NNS N
; : N
there EX N
was VBD N
also RB N
a DT N
mild JJ N
improvement NN N
in IN N
nutritional JJ o
parameters NNS o
and CC N
in IN N
liver JJ o
function NN o
tests NNS N
. . N

The DT N
supplementation NN N
of IN N
oral JJ i
branched-chain NN i
amino NN i
acids NNS i
to TO N
the DT N
diet NN N
is VBZ N
superior JJ N
to TO N
casein VB i
as IN N
a DT N
treatment NN N
for IN N
providing VBG N
adequate JJ N
nitrogen JJ o
supply NN o
and CC N
improving VBG N
the DT N
mental JJ o
state NN o
of IN N
cirrhotic JJ p
patients NNS p
with IN p
chronic JJ p
encephalopathy NN p
. . p

-DOCSTART- -18073312- O O

Short-term JJ i
aerobic JJ i
exercise NN i
training NN i
in IN N
obese JJ p
humans NNS p
with IN p
type JJ p
2 CD p
diabetes NNS p
mellitus JJ p
improves VBZ N
whole-body JJ N
insulin NN N
sensitivity NN N
through IN N
gains NNS N
in IN N
peripheral JJ N
, , N
not RB N
hepatic JJ N
insulin NN N
sensitivity NN N
. . N

CONTEXT NNP N
Short-term JJ i
aerobic JJ i
exercise NN i
training NN i
can MD N
improve VB N
whole-body JJ o
insulin NN o
sensitivity NN o
in IN N
humans NNS p
with IN p
type JJ p
2 CD p
diabetes NNS p
mellitus VBP p
; : p
however RB N
, , N
the DT N
contributions NNS N
of IN N
peripheral JJ N
and CC N
hepatic JJ N
tissues NNS N
to TO N
these DT N
improvements NNS N
are VBP N
not RB N
known VBN N
. . N

OBJECTIVE VB N
Our PRP$ N
objective NN N
was VBD N
to TO N
determine VB N
the DT N
effect NN N
of IN N
7-d JJ N
aerobic JJ i
exercise NN i
training NN N
on IN N
peripheral JJ N
and CC N
hepatic JJ N
insulin NN N
sensitivity NN N
during IN N
isoglycemic/hyperinsulinemic JJ N
clamp NN N
conditions NNS N
. . N

DESIGN NNP N
Subjects NNPS N
were VBD N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
two CD N
groups NNS N
. . N

The DT N
energy NN i
balance NN i
group NN N
consumed VBD N
an DT i
isocaloric JJ i
diet JJ i
consisting NN i
of IN i
50 CD i
% NN i
carbohydrate NN i
, , i
30 CD i
% NN i
fat NN i
, , i
and CC i
20 CD i
% NN i
protein NN i
for IN i
15 CD i
d. NN i
The DT N
energy NN i
balance NN i
plus CC i
exercise NN i
group NN N
consumed VBD N
a DT N
similar JJ i
diet NN i
over IN i
the DT i
15 CD i
d NN i
and CC i
performed VBD i
50-min CD i
of IN i
treadmill NN i
walking VBG i
at IN i
70 CD i
% NN i
of IN i
maximum JJ i
oxygen NN i
consumption NN i
maximum NN i
during IN i
the DT i
second JJ i
7 CD i
d NN i
of IN i
the DT i
15-d JJ i
study NN i
period NN i
. . i

Each DT N
subject NN N
underwent VBD N
an DT N
initial JJ N
isoglycemic/hyperinsulinemic JJ i
clamp NN i
after IN N
1-wk JJ N
dietary JJ N
control NN N
and CC N
a DT N
second JJ N
clamp NN N
after IN N
completing VBG N
the DT N
study NN N
. . N

SETTING CC N
The DT p
study NN p
was VBD p
performed VBN p
at IN p
Ohio NNP p
State NNP p
University NNP p
's POS p
General NNP p
Clinical NNP p
Research NNP p
Center NNP p
. . p

PARTICIPANTS CC N
There EX p
were VBD p
18 CD p
obese JJ p
, , p
mildly RB p
diabetic JJ p
humans NNS p
included VBD p
in IN p
the DT p
study NN p
. . p

INTERVENTION NNP N
Aerobic NNP i
exercise NN i
training NN i
was VBD N
performed VBN N
for IN N
7 CD N
d. NN N
MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Whole-body NNP o
, , o
peripheral JJ o
, , o
and CC o
hepatic JJ o
insulin NN o
sensitivity NN o
were VBD N
measured VBN N
. . N

RESULTS NNP N
Exercise NNP i
training NN i
did VBD N
not RB N
have VB N
an DT N
impact NN N
on IN N
peripheral JJ o
glucose JJ o
uptake NN o
or CC o
endogenous JJ o
glucose JJ o
production NN o
during IN N
the DT N
basal NN N
state NN N
or CC N
low-dose JJ N
insulin NN N
. . N

Likewise NNP N
, , N
it PRP N
did VBD N
not RB N
alter RB N
endogenous JJ o
glucose JJ o
production NN o
during IN N
high-dose JJ N
insulin NN N
. . N

However RB N
, , N
1-wk CD N
of IN N
exercise NN i
training NN i
increased VBD N
both DT N
whole-body NN o
( ( o
P NNP o
< NNP o
0.05 CD o
) ) o
and CC o
peripheral JJ o
insulin NN o
sensitivity NN o
( ( N
P NNP N
< NNP N
0.0001 CD N
) ) N
during IN N
high-dose JJ N
insulin NN N
. . N

CONCLUSION NNP N
Improvements NNPS N
to TO N
whole VB N
body NN N
insulin JJ N
sensitivity NN N
after IN N
short-term JJ i
aerobic JJ i
exercise NN i
training NN N
are VBP N
due JJ N
to TO N
gains NNS N
in IN N
peripheral JJ N
, , N
not RB N
heptic JJ N
insulin NN N
sensitivity NN N
. . N

-DOCSTART- -20008622- O O

Phase NNP N
III NNP N
, , N
randomized VBD N
, , N
open-label JJ N
study NN N
of IN N
daily JJ N
imatinib NN i
mesylate NN i
400 CD N
mg NN N
versus NN N
800 CD N
mg NN N
in IN N
patients NNS p
with IN p
newly RB p
diagnosed VBN p
, , p
previously RB p
untreated VBN p
chronic JJ p
myeloid NN p
leukemia NN p
in IN p
chronic JJ p
phase NN p
using VBG N
molecular JJ N
end NN N
points NNS N
: : N
tyrosine NN N
kinase NN N
inhibitor NN N
optimization NN N
and CC N
selectivity NN N
study NN N
. . N

PURPOSE NNP N
To TO N
evaluate VB N
the DT N
safety NN N
and CC N
efficacy NN N
of IN N
initial JJ N
treatment NN N
with IN N
imatinib JJ i
mesylate NN i
800 CD N
mg/d NN N
( ( N
400 CD N
mg NN N
twice RB N
daily RB N
) ) N
versus NN N
400 CD N
mg/d NN N
in IN N
patients NNS p
with IN p
newly RB p
diagnosed VBN p
chronic JJ p
myeloid NN p
leukemia NN p
in IN p
chronic JJ p
phase NN p
. . p

PATIENTS NNP N
AND CC N
METHODS NNP N
A NNP p
total NN p
of IN p
476 CD p
patients NNS p
were VBD p
randomly RB p
assigned VBN p
2:1 CD N
to TO N
imatinib VB i
800 CD i
mg NN i
( ( N
n JJ N
= NNP N
319 CD N
) ) N
or CC i
400 CD i
mg NN i
( ( N
n JJ N
= NNP N
157 CD N
) ) N
daily RB N
. . N

The DT N
primary JJ N
end NN N
point NN N
was VBD N
the DT N
major JJ o
molecular JJ o
response NN o
( ( o
MMR NNP o
) ) o
rate NN o
at IN N
12 CD N
months NNS N
. . N

RESULTS NNP N
At IN N
12 CD N
months NNS N
, , N
differences NNS N
in IN N
MMR NNP o
and CC o
complete JJ o
cytogenetic JJ o
response NN o
( ( o
CCyR NNP o
) ) o
rates NNS o
were VBD N
not RB N
statistically RB N
significant JJ N
( ( N
MMR NNP N
, , N
46 CD N
% NN N
v JJ N
40 CD N
% NN N
; : N
P NNP N
= NNP N
.2035 NNP N
; : N
CCyR NNP N
, , N
70 CD N
% NN N
v JJ N
66 CD N
% NN N
; : N
P NNP N
= NNP N
.3470 NNP N
) ) N
. . N

However RB N
, , N
MMR NNP o
occurred VBD N
faster RBR N
among IN N
patients NNS N
randomly RB N
assigned VBN N
to TO N
imatinib VB i
800 CD N
mg/d NNS N
, , N
who WP N
had VBD N
higher JJR N
rates NNS N
of IN N
MMR NNP o
at IN N
3 CD N
and CC N
6 CD N
months NNS N
compared VBN N
with IN N
those DT N
in IN N
the DT N
imatinib JJ N
400-mg/d JJ N
arm NN N
( ( N
P NNP N
= NNP N
.0035 NNP N
by IN N
log-rank JJ N
test NN N
) ) N
. . N

CCyR NNP o
also RB N
occurred VBD N
faster RBR N
in IN N
the DT N
800-mg/d JJ N
arm NN N
( ( N
CCyR NNP N
at IN N
6 CD N
months NNS N
, , N
57 CD N
% NN N
v JJ N
45 CD N
% NN N
; : N
P NNP N
= NNP N
.0146 NNP N
) ) N
. . N

The DT N
most RBS N
common JJ N
adverse JJ N
events NNS N
were VBD N
edema RB o
, , o
gastrointestinal JJ o
problems NNS o
, , o
and CC o
rash NN o
, , N
and CC N
all DT N
were VBD N
more JJR N
common JJ N
in IN N
patients NNS N
in IN N
the DT N
800-mg/d JJ N
arm NN N
. . N

Grades VBZ o
3 CD o
to TO o
4 CD o
hematologic NN o
toxicity NN o
also RB N
occurred VBD N
more RBR N
frequently RB N
in IN N
patients NNS N
receiving VBG N
imatinib JJ N
800 CD N
mg/d NN N
. . N

CONCLUSION NNP N
MMR NNP N
rates NNS N
at IN N
1 CD N
year NN N
were VBD N
similar JJ N
with IN N
imatinib JJ N
800 CD N
mg/d NN N
and CC N
400 CD N
mg/d NN N
, , N
but CC N
MMR NNP o
and CC o
CCyR NNP o
occurred VBD N
earlier RBR N
in IN N
patients NNS N
treated VBN N
with IN N
800 CD N
mg/d NN N
. . N

Continued VBN N
follow-up NN N
is VBZ N
needed VBN N
to TO N
determine VB N
the DT N
clinical JJ N
significance NN N
of IN N
earlier JJR N
responses NNS N
on IN N
high-dose JJ N
imatinib NN i
. . i

-DOCSTART- -25492271- O O

Effect NN N
of IN N
L-type NNP N
calcium NN N
channel NN N
blocker NN N
( ( i
amlodipine NN i
) ) i
on IN N
myocardial JJ o
iron NN o
deposition NN o
in IN N
patients NNS p
with IN p
thalassaemia NN p
with IN p
moderate-to-severe JJ p
myocardial JJ o
iron NN o
deposition NN o
: : o
protocol NN N
for IN N
a DT N
randomised JJ N
, , N
controlled JJ N
trial NN N
. . N

INTRODUCTION NNP N
Sideroblastic NNP N
cardiomyopathy NN N
secondary JJ N
to TO N
repeated VB o
blood NN o
transfusions NNS o
is VBZ N
a DT N
feared JJ N
complication NN N
in IN N
thalassaemia NN N
. . N

Control NNP N
of IN N
myocardial JJ o
iron NN o
is VBZ N
thus RB N
becoming VBG N
the DT N
cornerstone NN N
of IN N
thalassaemia JJ N
management NN N
. . N

Recent JJ N
evidence NN N
suggests VBZ N
a DT N
role NN N
for IN N
L-type NNP N
Ca NNP N
( ( N
2+ CD N
) ) N
channels NNS N
in IN N
mediating VBG N
iron NN N
uptake NN N
by IN N
the DT N
heart NN N
. . N

Blocking VBG N
the DT N
cellular JJ N
iron NN N
uptake VBP N
through IN N
these DT N
channels NNS N
may MD N
add VB N
to TO N
the DT N
benefit NN N
of IN N
therapy NN N
to TO N
standard VB N
chelation NN N
in IN N
reducing VBG N
myocardial JJ o
iron NN o
. . o

We PRP N
aim VBP N
to TO N
determine VB N
the DT N
efficacy NN N
of IN N
amlodipine NN i
( ( N
a DT N
calcium NN N
channel NN N
blocker NN N
) ) N
as IN N
an DT N
adjunct NN N
to TO N
standard VB N
aggressive JJ N
chelation NN N
in IN N
retarding VBG N
myocardial JJ o
iron NN o
deposition NN o
in IN N
thalassaemics NNS N
with IN N
or CC N
without IN N
cardiomyopathy JJ N
. . N

OUTCOMES IN N
The DT N
primary JJ N
outcome NN N
is VBZ N
to TO N
compare VB o
the DT o
efficacy NN o
of IN o
amlodipine+chelation NN o
( ( o
intervention NN o
) ) o
versus FW o
standard JJ o
chelation NN o
( ( o
control NN o
) ) o
in IN o
retarding VBG o
myocardial JJ o
iron NN o
deposition NN o
. . o

Secondary JJ N
outcomes NNS N
include VBP N
the DT N
effect NN o
of IN o
amlodipine NN o
therapy NN o
on IN o
systolic JJ o
and CC o
diastolic JJ o
function NN o
, , o
strain NN o
and CC o
strain NN o
rate NN o
and CC o
liver NN o
iron NN o
content NN o
. . o

METHODS NNP N
AND CC N
ANALYSIS NNP N
This DT N
is VBZ N
a DT N
single-centre JJ N
, , N
parallel-group JJ N
, , N
prospective JJ N
randomised VBN N
control NN N
trial NN N
. . N

Twenty CD p
patients NNS p
will MD N
be VB N
randomised VBN N
in IN N
a DT N
1:1 CD N
allocation NN N
ratio NN N
into IN N
the DT N
intervention NN N
and CC N
control NN N
arms NNS N
. . N

In IN N
addition NN N
to TO N
conventional JJ N
echocardiography NN N
, , N
MRI NNP N
T2* NNP N
values NNS N
for IN N
assessment NN N
of IN N
cardiac NN o
and CC o
liver NN o
iron NN o
load NN o
will MD N
be VB N
obtained VBN N
at IN N
baseline NN N
and CC N
at IN N
6 CD N
and CC N
12 CD N
months NNS N
. . N

Cardiac NNP N
T2* NNP N
will MD N
be VB N
reported VBN N
as IN N
the DT N
geometric JJ N
mean NN N
and CC N
per IN N
cent NN N
coefficient NN N
of IN N
variation NN N
, , N
and CC N
an DT N
increase NN N
in IN N
cardiac JJ N
T2* NNP N
values NNS N
from IN N
baseline NN N
will MD N
be VB N
used VBN N
as IN N
an DT N
end NN N
point NN N
to TO N
compare VB N
the DT N
efficacy NN N
of IN N
therapy NN N
. . N

A DT N
p JJ N
Value NNP N
of IN N
< NNP N
0.05 CD N
will MD N
be VB N
considered VBN N
significant JJ N
. . N

STUDY NNP N
SETTING NNP N
Department NNP p
of IN p
Pediatric NNP p
and CC p
Child NNP p
Health NNP p
, , p
Aga NNP p
Khan NNP p
University NNP p
Hospital NNP p
, , p
Karachi NNP p
, , p
Pakistan NNP p
. . p

ETHICS NNP N
AND CC N
DISSEMINATION NNP N
This DT N
study NN N
has VBZ N
been VBN N
approved VBN N
by IN N
the DT N
Ethics NNP N
Review NNP N
Committee NNP N
and CC N
Clinical NNP N
Trials NNP N
Unit NNP N
at IN N
The DT p
Aga NNP p
Khan NNP p
University NNP p
with IN N
respect NN N
to TO N
scientific JJ N
content NN N
and CC N
compliance NN N
with IN N
applicable JJ N
research NN N
and CC N
human JJ N
subjects NNS N
regulations NNS N
. . N

Findings NNS N
will MD N
be VB N
reported VBN N
through IN N
scientific JJ N
publications NNS N
and CC N
research NN N
conferences NNS N
and CC N
project NN N
summary JJ N
papers NNS N
for IN N
participants NNS N
. . N

TRIAL NNP N
REGISTRATION NNP N
NUMBER NNP N
ClinicalTrials.Gov NNP N
. . N

Registration NNP N
no DT N
: : N
NCT02065492 NN N
. . N

-DOCSTART- -8607589- O O

Prevention NN N
of IN N
venous JJ N
thromboembolism NN N
after IN N
knee NN p
arthroplasty NN p
. . p

A DT N
randomized JJ N
, , N
double-blind JJ N
trial NN N
comparing VBG N
enoxaparin NN i
with IN N
warfarin NN i
. . i

OBJECTIVE UH N
To TO N
compare VB N
the DT N
effectiveness NN o
and CC o
safety NN o
of IN N
fixed-dose JJ i
enoxaparin NN i
and CC N
adjusted VBD i
dose JJ i
warfarin NN i
in IN N
preventing VBG N
venous JJ N
thromboembolism NN N
after IN p
knee NN p
arthroplasty NN p
. . p

DESIGN VB N
A DT N
randomized JJ N
, , N
double-blind JJ N
controlled VBN N
trial NN N
. . N

SETTING NN N
8 CD p
university NN p
hospitals NNS p
. . p

PATIENTS VB N
670 CD p
consecutive JJ p
patients NNS p
who WP p
had VBD p
knee VBN p
arthroplasty RB p
. . p

INTERVENTION NN N
Patients NNPS N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
enoxaparin NN i
( ( i
30 CD i
mg NN i
subcutaneously RB i
every DT i
12 CD i
hours NNS i
) ) i
or CC i
adjusted-dose JJ i
warfarin NN i
( ( i
international JJ i
normalized VBN i
ratio NN i
, , i
2.0 CD i
to TO i
3.0 CD i
) ) i
. . N

Both DT N
regimens NNS N
were VBD N
started VBN N
after IN N
surgery NN N
. . N

MEASUREMENTS PDT N
The DT N
primary JJ N
end NN N
point NN N
was VBD N
the DT N
incidence NN o
of IN o
deep JJ o
venous JJ o
thrombosis NN o
in IN N
patients NNS p
with IN p
adequate JJ p
bilateral JJ p
venograms NNS p
; : p
the DT N
secondary JJ N
end NN N
point NN N
was VBD N
hemorrhage NN o
. . o

RESULTS NNP N
Among IN N
the DT N
417 CD p
patients NNS p
with IN p
adequate JJ p
venograms NNS p
, , N
109 CD N
of IN N
211 CD N
warfarin NN i
recipients NNS N
( ( N
51.7 CD N
% NN N
) ) N
had VBD N
deep JJ o
venous JJ o
thrombosis NN o
compared VBN N
with IN N
76 CD N
of IN N
206 CD N
enoxaparin NN i
recipients NNS N
( ( N
36.9 CD N
% NN N
) ) N
( ( N
P NNP N
= NNP N
0.003 CD N
) ) N
. . N

The DT N
absolute NN o
risk NN o
difference NN o
was VBD N
14.8 CD N
% NN N
in IN N
favor NN N
of IN N
enoxaparin NN i
( ( N
95 CD N
% NN N
Cl NNP N
, , N
5.3 CD N
% NN N
to TO N
24.1 CD N
% NN N
) ) N
Twenty-two NNP N
warfarin NN i
recipients NNS N
( ( N
10.4 CD N
% NN N
) ) N
and CC N
24 CD N
enoxaparin NN i
recipients NNS N
( ( N
11.7 CD N
% NN N
) ) N
had VBD N
proximal JJ N
venous JJ N
thrombosis NN N
( ( N
P NNP N
> NNP N
0.2 CD N
) ) N
. . N

The DT N
absolute NN o
risk NN o
difference NN o
was VBD N
1.2 CD N
% NN N
in IN N
favor NN N
of IN N
warfarin NN i
( ( N
Cl NNP N
, , N
-7.2 NNP N
% NN N
to TO N
4.8 CD N
% NN N
) ) N
. . N

The DT N
incidence NN N
of IN N
major JJ o
bleeding NN o
was VBD N
1.8 CD N
% NN N
( ( N
6 CD N
of IN N
334 CD N
patients NNS N
) ) N
in IN N
the DT N
warfarin NN N
group NN N
and CC N
2.1 CD N
% NN N
( ( N
7 CD N
of IN N
336 CD N
patients NNS N
) ) N
in IN N
the DT N
enoxaparin NN N
group NN N
( ( N
P NNP N
> NNP N
0.2 CD N
) ) N
. . N

The DT N
absolute NN o
risk NN o
difference NN o
was VBD N
0.3 CD N
% NN N
in IN N
favor NN N
of IN N
warfarin NN N
( ( N
Cl NNP N
, , N
-2.4 NNP N
% NN N
to TO N
1.8 CD N
% NN N
) ) N
. . N

CONCLUSIONS VB N
A DT N
postoperative JJ N
, , N
fixed-dose JJ N
enoxaparin NN i
regimen NNS N
is VBZ N
more RBR N
effective JJ N
than IN N
adjusted-dose JJ N
warfarin NN i
in IN N
preventing VBG N
deep JJ N
venous JJ N
thrombosis NN N
after IN p
knee NN p
arthroplasty NN p
. . p

No DT N
differences NNS N
were VBD N
seen VBN N
in IN N
the DT N
incidence NN N
of IN N
proximal JJ N
venous JJ N
thrombosis NN N
or CC N
clinically RB N
overt JJ N
hemorrhage NN N
. . N

-DOCSTART- -3081148- O O

Combined VBN N
use NN N
of IN N
vasopressin NN i
and CC N
synthetic JJ i
hypothalamic JJ i
releasing NN i
factors NNS i
as IN N
a DT N
new JJ N
test NN N
of IN N
anterior JJ N
pituitary JJ N
function NN N
. . N

Nine NNP p
normal JJ p
volunteers NNS p
and CC p
15 CD p
patients NNS p
with IN p
pituitary JJ p
disorders NNS p
were VBD N
given VBN N
a DT N
combined JJ N
test NN N
of IN N
anterior JJ N
pituitary JJ N
function NN N
using VBG N
four CD N
hypothalamic JJ N
releasing VBG N
factors NNS N
and CC N
arginine JJ i
vasopressin NN i
. . i

Rapid JJ N
sequential JJ N
intravenous JJ N
infusions NNS N
of IN N
human JJ i
corticotrophin NN i
releasing VBG N
factor NN N
100 CD N
micrograms NNS N
, , N
growth NN i
hormone NN i
releasing VBG N
factor NN N
100 CD N
micrograms NNS N
, , N
luteinising VBG i
hormone NN i
releasing VBG N
hormone NN N
100 CD N
micrograms NNS N
, , N
and CC N
thyrotrophin IN i
releasing VBG N
hormone NN N
200 CD N
micrograms NNS N
were VBD N
administered VBN N
. . N

Arginine NNP i
vasopressin NN i
( ( N
10 CD N
pressor NN N
units NNS N
) ) N
was VBD N
given VBN N
intramuscularly RB N
at IN N
the DT N
same JJ N
time NN N
. . N

Plasma NNP N
or CC N
serum NN N
samples NNS N
were VBD N
assayed VBN N
for IN N
concentrations NNS N
of IN N
cortisol NN N
, , N
growth NN N
hormone NN N
, , N
luteinising VBG N
hormone NN N
, , N
follicle NN N
stimulating VBG N
hormone NN N
, , N
prolactin NN N
, , N
and CC N
thyroid JJ N
stimulating VBG N
hormone NN N
at IN N
multiple JJ N
times NNS N
for IN N
120 CD N
minutes NNS N
. . N

No DT N
troublesome JJ N
side NN o
effects NNS o
occurred VBD N
. . N

The DT N
results NNS N
of IN N
the DT N
releasing VBG N
factor NN N
combined VBD N
test NN N
with IN N
arginine JJ N
vasopressin NN N
were VBD N
compared VBN N
in IN N
the DT N
same JJ N
subjects NNS N
with IN N
a DT N
conventional JJ N
combined JJ N
test NN N
using VBG N
insulin NN N
together RB N
with IN N
thyrotrophin JJ N
releasing VBG N
hormone NN N
and CC N
luteinising VBG N
hormone NN N
releasing VBG N
hormone NN N
. . N

No DT N
difference NN N
was VBD N
observed VBN N
in IN N
the DT N
basal NN o
and CC o
peak JJ o
concentrations NNS o
of IN o
luteinising VBG o
hormone NN o
, , o
follicle NN o
stimulating VBG o
hormone NN o
, , o
thyroid JJ o
stimulating VBG o
hormone NN o
, , o
and CC o
prolactin NN o
. . o

Both DT N
cortisol NN o
and CC o
growth NN o
hormone NN o
responses VBZ o
to TO N
the DT N
releasing VBG N
factors NNS N
with IN N
arginine JJ N
vasopressin NN N
were VBD N
much RB N
greater JJR N
than IN N
those DT N
seen VBN N
with IN N
insulin NN N
induced VBN N
hypoglycaemia NN N
or CC N
the DT N
combined JJ N
releasing NN N
factors NNS N
without IN N
arginine JJ N
vasopressin NN N
. . N

Patients NNS N
with IN N
pituitary JJ o
hypo-function NN o
were VBD N
similarly RB N
recognised VBN N
in IN N
both DT N
studies NNS N
. . N

There EX N
was VBD N
a DT N
rapid JJ N
increase NN N
in IN N
all DT N
hormone NN o
values NNS o
with IN N
a DT N
peak NN N
usually RB N
by IN N
60 CD N
minutes NNS N
. . N

In IN N
most JJS N
people NNS N
adequate VBP N
assessment NN N
of IN N
individual JJ N
hormone NN N
reserves NNS N
may MD N
be VB N
achieved VBN N
using VBG N
basal NN N
, , N
30 CD N
minute NN N
, , N
and CC N
60 CD N
minute NN N
samples NNS N
. . N

This DT N
new JJ N
combined JJ N
releasing NN N
factor NN N
test NN N
appears VBZ N
to TO N
be VB N
a DT N
safe JJ N
, , N
rapid JJ N
, , N
and CC N
useful JJ N
test NN N
of IN N
anterior JJ N
pituitary JJ N
function NN N
. . N

-DOCSTART- -24021291- O O

Novel NNP N
population NN N
pharmacokinetic JJ N
method NN N
compared VBN N
to TO N
the DT N
standard JJ N
noncompartmental JJ N
approach NN N
to TO N
assess VB N
bioequivalence NN N
of IN N
iron NN N
gluconate NN N
formulations NNS N
. . N

PURPOSE NNP N
Iron-containing JJ N
products NNS N
are VBP N
atypical JJ N
in IN N
terms NNS N
of IN N
their PRP$ N
pharmacokinetic JJ N
properties NNS N
because IN N
iron NN N
is VBZ N
only RB N
removed VBN N
by IN N
plasma NN N
sampling NN N
and CC N
is VBZ N
non-linear JJ N
. . N

This DT N
study NN N
aims VBZ N
to TO N
present VB N
a DT N
novel JJ N
way NN N
of IN N
assessing VBG N
the DT N
relative JJ N
bioavailability NN N
of IN N
two CD N
sodium NN i
ferric JJ i
gluconate NN i
complex NN i
( ( i
SFGC NNP i
) ) i
formulations NNS N
and CC N
compare VB N
this DT N
approach NN N
to TO N
a DT N
standard NN N
previously RB N
published VBN N
noncompartmental JJ N
approach NN N
. . N

METHODS NNP N
Data NNP N
were VBD N
from IN N
open-label JJ N
, , N
randomized VBN N
, , N
single-dose JJ N
studies NNS N
( ( N
Study NNP N
1 CD N
was VBD N
parallel JJ N
whereas NNS N
Study VBP N
2 CD N
was VBD N
crossover NN N
) ) N
. . N

Subjects NNS p
with IN p
low JJ p
but CC p
normal JJ p
iron NN p
levels NNS p
were VBD N
infused VBN N
IV NNP i
SFGC NNP i
in IN i
sucrose JJ i
by IN N
GeneraMedix NNP N
Inc. NNP N
and/or VBD N
Ferrlecit NNP i
? . i
Injection NNP i
( ( N
Watson NNP N
Laboratories NNP N
Inc. NNP N
) ) N
. . N

In IN p
Study NNP p
1 CD p
( ( p
n=240 NN p
) ) p
, , p
125 CD p
mg NN p
was VBD p
infused VBN p
over IN p
10 CD p
minutes NNS p
. . p

In IN p
Study NNP p
2 CD p
( ( p
n=29 NN p
) ) p
, , p
62.5 CD p
mg NN p
was VBD p
infused VBN p
over IN p
30 CD p
minutes NNS p
. . p

Samples NNS N
were VBD N
assayed VBN N
for IN N
total JJ N
iron NN N
( ( N
TI NNP N
) ) N
and CC N
transferrin-bound JJ N
iron NN N
( ( N
TBI NNP N
) ) N
over IN N
36 CD N
hours NNS N
( ( N
Study NNP N
1 CD N
) ) N
or CC N
72 CD N
hours NNS N
( ( N
Study NNP N
2 CD N
) ) N
post-dose NN N
. . N

Studies VBZ N
1 CD N
and CC N
2 CD N
used JJ N
standard NN N
noncompartmental JJ N
analysis NN N
. . N

Study NNP N
2 CD N
also RB N
used VBN N
population NN N
PK NNP N
( ( N
PPK NNP N
) ) N
analyses VBZ N
with IN N
ADAPT NNP N
5? CD N
. . N

The DT N
final JJ N
model NN N
predicted VBD N
SFGC NNP N
area-under-the-curve NN N
( ( N
AUCpred NNP N
) ) N
and CC N
maximal JJ N
concentration NN N
( ( N
Cmaxpred NNP N
) ) N
. . N

Analyses NNS N
of IN N
variance NN N
was VBD N
conducted VBN N
on IN N
ln-transformed JJ N
PK NNP N
parameters NNS N
. . N

Ratios NNP N
of IN N
means NNS N
and CC N
90 CD N
% NN N
confidence NN N
intervals NNS N
( ( N
CIs NNP N
) ) N
were VBD N
estimated VBN N
. . N

Bioequivalence NNP N
was VBD N
demonstrated VBN N
if IN N
values NNS N
were VBD N
within IN N
80-125 JJ N
% NN N
. . N

RESULTS NNP N
For IN N
Study NNP N
1 CD N
, , N
ratios NNS N
and CC N
90 CD N
% NN N
CIs NNP N
for IN N
TI NNP N
baseline-corrected JJ N
Cmax NNP N
and CC N
AUC0-36 NNP N
were VBD N
100.4 CD N
( ( N
96.5 CD N
- : N
104.5 CD N
) ) N
and CC N
99.7 CD N
( ( N
94.2 CD N
- : N
105.5 CD N
) ) N
. . N

For IN N
TBI NNP N
, , N
results NNS N
for IN N
TI NNP N
baseline-corrected JJ N
Cmax NNP N
and CC N
AUC0-36 NNP N
were VBD N
86.8 CD N
( ( N
82.7 CD N
- : N
91.1 CD N
) ) N
and CC N
92.4 CD N
( ( N
85.6 CD N
- : N
99.7 CD N
) ) N
. . N

For IN N
Study NNP N
2 CD N
, , N
a DT N
multi-compartmental JJ N
model NN N
simultaneously RB N
described VBD N
the DT N
PK NNP N
of IN N
TI NNP N
, , N
TBI NNP N
and CC N
SFGC NNP N
. . N

Ratios NNP N
and CC N
90 CD N
% NN N
CIs NNP N
for IN N
SFGC NNP N
Cmaxpred NNP N
and CC N
AUCpred NNP N
were VBD N
89.9 CD N
( ( N
85.9 CD N
- : N
94.0 CD N
) ) N
and CC N
89.7 CD N
( ( N
85.7 CD N
- : N
93.9 CD N
) ) N
, , N
while IN N
ratios NNS N
and CC N
90 CD N
% NN N
CI NNP N
obtained VBN N
from IN N
the DT N
noncompartmental JJ N
analysis NN N
of IN N
Study NNP N
2 CD N
did VBD N
not RB N
meet VB N
BE NNP N
criteria NNS N
because IN N
of IN N
low JJ N
power NN N
. . N

CONCLUSIONS NNP N
Both NNP N
the DT N
standard NN N
and CC N
PPK NNP N
modeling VBG N
approach NN N
suggested VBD N
bioequivalence NN N
between IN N
the DT N
iron NN N
products NNS N
. . N

However RB N
, , N
with IN N
the DT N
PPK NNP N
method NN N
, , N
less JJR N
subjects NNS N
were VBD N
required VBN N
to TO N
meet VB N
study NN N
objectives NNS N
compared VBN N
to TO N
the DT N
standard JJ N
noncompartmental NN N
approach NN N
which WDT N
required VBD N
considerably RB N
more RBR N
subjects NNS N
( ( N
29 CD N
vs RB N
240 CD N
) ) N
. . N

-DOCSTART- -24915013- O O

Mechanical JJ N
sensitivity NN N
of IN N
the DT N
human JJ p
conjunctiva NN p
. . p

PURPOSE VB N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
map VB N
the DT N
sensitivity NN N
of IN N
the DT N
marginal JJ N
and CC N
other JJ N
conjunctival NN N
regions NNS N
and CC N
to TO N
investigate VB N
changes NNS N
in IN N
the DT N
sensitivity NN N
of IN N
these DT N
regions NNS N
when WRB N
determined VBN N
in IN N
the DT N
morning NN N
and CC N
evening NN N
. . N

METHODS NNP N
Thirty-five JJ p
healthy JJ p
, , p
noncontact JJ p
lens VBZ p
wearers NNS p
( ( p
20 CD p
female NN p
, , p
15 CD p
male NN p
; : p
age NN p
27.7 CD p
? . p
7.3 CD p
years NNS p
) ) p
were VBD p
enrolled VBN p
. . p

Mechanical JJ i
sensitivity NN i
was VBD i
measured VBN i
at IN i
8 CD i
locations NNS i
on IN i
the DT i
ocular JJ i
surface NN i
and CC i
adnexa NN i
( ( i
cornea NN i
, , i
marginal JJ i
, , i
bulbar NN i
, , i
and CC i
tarsal VB i
conjunctiva NN i
) ) i
using VBG i
a DT i
Cochet-Bonnet JJ i
esthesiometer NN i
( ( i
0.12-mm JJ i
diameter NN i
filament NN i
) ) i
. . i

A DT N
subgroup NN N
of IN N
11 CD N
subjects NNS N
( ( N
6 CD N
female NN N
, , N
5 CD N
male NN N
; : N
age NN N
28.9 CD N
? . N
9.9 CD N
years NNS N
) ) N
returned VBD N
after IN N
12 CD N
hours NNS N
when WRB N
this DT N
protocol NN N
was VBD N
repeated VBN N
. . N

RESULTS VB N
The DT N
cornea NN N
was VBD N
found VBN N
to TO N
be VB N
the DT o
most RBS o
sensitive JJ o
region NN o
( ( N
all DT N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

The DT o
marginal JJ o
conjunctiva NN o
showed VBD o
greater JJR o
sensitivity NN o
than IN o
did VBD N
the DT N
bulbar NN N
and CC N
tarsal NN N
conjunctiva NN N
( ( N
all DT N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

The DT o
temporal JJ o
marginal JJ o
conjunctiva NN o
was VBD o
more RBR o
sensitive JJ o
than IN o
the DT N
central JJ N
marginal JJ N
conjunctiva NN N
( ( N
all DT N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

No DT N
difference NN N
in IN N
marginal JJ o
conjunctival NN o
sensitivity NN o
was VBD o
found VBN N
between IN N
upper JJ N
and CC N
lower JJR N
eyelids NNS N
( ( N
all DT N
P NNP N
> NNP N
0.05 CD N
) ) N
. . N

The DT o
upper JJ o
tarsal NN o
conjunctiva NN o
was VBD o
more RBR o
sensitive JJ o
than IN o
the DT N
lower JJR N
tarsal NN N
conjunctiva NN N
( ( N
P NNP N
= NNP N
0.04 CD N
) ) N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
the DT o
sensitivity NN o
determined VBN o
in IN N
the DT N
morning NN N
and CC N
the DT N
evening NN N
for IN N
any DT N
of IN N
the DT N
locations NNS N
investigated VBN N
( ( N
Bonferroni NNP N
adjusted VBN N
, , N
P NNP N
> NNP N
0.006 CD N
) ) N
. . N

CONCLUSIONS VB N
This DT N
work NN N
has VBZ N
demonstrated VBN N
that IN N
the DT o
marginal JJ o
conjunctiva NN o
was VBD o
the DT o
most RBS o
sensitive JJ o
of IN o
all PDT N
the DT N
conjunctival NN N
regions NNS N
and CC N
that IN N
this DT N
does VBZ N
not RB N
alter VB N
over IN N
the DT N
course NN N
of IN N
the DT N
day NN N
. . N

-DOCSTART- -10337083- O O

Getting VBG N
a DT N
high JJ N
response NN N
rate NN N
of IN N
sexual JJ N
behavior JJ N
survey NN N
among IN N
the DT N
general JJ p
population NN p
in IN p
Japan NNP p
: : p
three CD N
different JJ N
methods NNS N
of IN N
survey NN N
on IN N
sexual JJ N
behavior NN N
. . N

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
specify VB N
the DT N
most RBS N
accurate JJ N
, , N
reliable JJ N
and CC N
valid JJ N
technique NN N
for IN N
a DT N
general JJ p
sexual JJ p
behavioral JJ p
survey NN p
in IN p
Japan NNP p
. . p

This DT N
pilot NN N
study NN N
was VBD N
conducted VBN N
to TO N
assure VB N
a DT N
high JJ N
response NN N
rate NN N
and CC N
to TO N
keep VB N
respondents NNS N
' POS N
privacy NN N
confidential NN N
by IN N
using VBG N
an DT N
anonymous JJ N
questionnaire NN N
survey NN N
technique NN N
. . N

The DT p
sample NN p
( ( p
360 CD p
potential JJ p
respondents NNS p
) ) p
was VBD p
selected VBN p
randomly RB p
from IN p
basic JJ p
resident NN p
registers NNS p
in IN N
two CD p
geographically RB p
different JJ p
areas NNS p
. . p

From IN N
the DT N
registries NNS N
, , N
90 CD p
residents NNS p
, , p
aged VBD p
20 CD p
to TO p
49 CD p
years NNS p
old JJ p
, , N
were VBD N
randomly RB N
selected VBN N
to TO N
represent VB N
each DT N
sex NN N
from IN N
each DT N
area NN N
. . N

The DT N
subjects NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
three CD N
groups NNS N
each DT N
having VBG N
a DT N
different JJ N
procedure NN N
of IN N
requesting VBG N
the DT N
completion NN N
of IN N
the DT N
survey NN N
and CC N
providing VBG N
the DT N
questionnaires NNS N
: : N
( ( N
1 CD N
) ) N
Postal NNP i
Group NNP i
, , i
( ( i
2 CD i
) ) i
Telephone CD i
Group NNP i
, , i
and CC i
( ( i
3 CD i
) ) i
Face-to-face NN i
Group NNP i
. . i

The DT N
survey NN N
was VBD N
carried VBN N
out RP N
from IN N
October NNP p
1995 CD p
to TO p
February NNP p
1996 CD p
. . p

Effective JJ o
response NN o
rates NNS o
for IN N
the DT N
above NN N
mentioned VBD N
three CD N
groups NNS N
were VBD N
69.2 CD N
% NN N
, , N
69.2 CD N
% NN N
and CC N
55.8 CD N
% NN N
, , N
respectively RB N
. . N

It PRP N
is VBZ N
difficult JJ N
to TO N
determine VB N
the DT N
best JJS N
method NN N
when WRB N
only RB N
considering VBG N
the DT N
effective JJ o
response NN o
rates NNS o
. . o

However RB N
, , N
judging VBG N
from IN N
our PRP$ N
effort NN N
and CC N
expense NN N
, , N
the DT N
mail NN i
survey NN i
is VBZ N
the DT N
best JJS N
possible JJ N
procedure NN N
and CC N
would MD N
be VB N
a DT N
reasonable JJ N
method NN N
for IN N
a DT N
national JJ N
sexual JJ N
behavior NN N
survey NN N
. . N

-DOCSTART- -16541481- O O

Etanercept NNP i
treatment NN N
in IN N
adults NNS p
with IN p
established VBN p
rheumatoid NN p
arthritis NN p
: : p
7 CD N
years NNS N
of IN N
clinical JJ N
experience NN N
. . N

OBJECTIVE UH N
To TO N
evaluate VB N
safety NN o
and CC o
efficacy NN o
of IN N
longterm JJ N
etanercept FW i
treatment NN N
in IN N
patients NNS p
with IN p
disease NN p
modifying VBG p
antirheumatic JJ p
drug NN p
( ( p
DMARD NNP p
) ) p
refractory NN p
rheumatoid JJ p
arthritis NN p
( ( p
RA NNP p
) ) p
. . p

METHODS NNP N
Safety NNP N
results NNS N
are VBP N
reported VBN N
for IN N
714 CD p
patients NNS p
who WP p
received VBD p
etanercept RB i
in IN p
one CD p
of IN p
7 CD p
initial JJ p
trials NNS p
or CC p
a DT p
longterm JJ p
extension NN p
. . p

Efficacy NN N
results NNS N
are VBP N
reported VBN N
for IN N
581 CD p
patients NNS p
who WP p
enrolled VBD p
in IN p
the DT p
extension NN p
. . p

RESULTS NNP N
Of IN N
the DT N
714 CD p
patients NNS p
enrolled VBN p
in IN p
the DT p
initial JJ p
trials NNS p
, , p
581 CD p
( ( p
81 CD p
% NN p
) ) p
enrolled VBN p
in IN p
the DT p
extension NN p
, , p
and CC p
388 CD p
( ( p
54 CD p
% NN p
) ) p
patients NNS p
are VBP p
continuing VBG p
to TO p
receive VB p
etanercept JJ i
therapy NN i
. . i

The DT N
longest JJS N
individual JJ N
treatment NN N
was VBD N
8.2 CD N
years NNS N
, , N
with IN N
3139 CD N
total JJ N
patient-years NNS N
of IN N
etanercept JJ N
exposure NN N
. . N

Rates NNS o
of IN o
serious JJ o
adverse JJ o
events NNS o
( ( N
overall JJ N
rate=14.8 NN N
events/100 IN N
patient-yrs NN N
) ) N
, , N
serious JJ o
infections NNS o
( ( N
overall JJ N
rate=4.2 NN N
events/100 IN N
patient-yrs NN N
) ) N
, , N
cancer NN o
( ( N
overall JJ N
rate=1.0 NN N
events/100 IN N
patient-yrs NN N
) ) N
, , N
and CC o
deaths NNS o
( ( N
overall JJ N
rate=0.7 NN N
events/100 IN N
patient-yrs NN N
) ) N
were VBD N
stable JJ N
each DT N
year NN N
, , N
through IN N
8 CD N
years NNS N
of IN N
etanercept JJ N
exposure NN N
. . N

For IN N
356 CD p
patients NNS p
who WP p
completed VBD p
6 CD p
years NNS p
of IN p
etanercept JJ p
treatment NN p
, , N
response NN o
rates NNS o
were VBD N
ACR20=73 NNP N
% NN N
, , N
ACR50=52 NNP N
% NN N
, , N
ACR70=27 NNP N
% NN N
, , N
DAS28 NNP N
CRP NNP N
good JJ N
response=52 NN N
% NN N
, , N
and CC N
DAS28 NNP N
CRP NNP N
remission=37 VBZ N
% NN N
of IN N
patients NNS N
. . N

Similar JJ N
responses NNS N
occurred VBD N
in IN N
167 CD p
patients NNS p
who WP p
completed VBD p
Year NNP p
7 CD p
. . p

Doses NNS o
of IN N
concomitant JJ N
methotrexate NN N
or CC N
corticosteroids NNS N
were VBD N
reduced VBN N
in IN N
many JJ N
patients NNS N
who WP N
maintained VBD N
clinical JJ N
responses NNS N
. . N

CONCLUSION VB N
The DT N
safety NN o
profile NN o
of IN N
etanercept NN i
was VBD N
consistent JJ N
over IN N
time NN N
, , N
with IN N
rates NNS o
of IN o
adverse JJ o
events NNS o
similar JJ N
to TO N
those DT N
reported VBN N
for IN N
patients NNS p
with IN p
RA NNP p
in IN p
general JJ p
. . p

Durable JJ N
clinical JJ N
responses NNS N
were VBD N
observed VBN N
in IN N
some DT N
patients NNS N
for IN N
7 CD N
years NNS N
or CC N
more JJR N
. . N

The DT N
benefit-to-risk JJ N
ratio NN N
for IN N
longterm JJ N
etanercept JJ i
treatment NN N
remains VBZ N
highly RB N
favorable JJ N
. . N

-DOCSTART- -10361648- O O

Effects NNS N
of IN N
a DT N
videotape NN i
information NN i
intervention NN i
at IN N
discharge NN N
on IN N
diet JJ N
and CC N
exercise NN N
compliance NN N
after IN N
coronary JJ N
bypass NN N
surgery NN N
. . N

BACKGROUND NNP N
This DT N
study NN N
evaluated VBD N
the DT N
relative JJ N
effects NNS N
on IN N
compliance NN N
with IN N
recommended JJ N
lifestyle JJ N
changes NNS N
of IN N
two CD N
experimental JJ i
videotapes NNS i
that WDT N
involved VBD N
different JJ N
approaches NNS N
for IN N
preparing VBG N
coronary JJ p
artery NN p
bypass NN p
graft NN p
( ( p
CABG NNP p
) ) p
patients NNS p
for IN N
the DT N
posthospital JJ N
recovery NN N
period NN N
. . N

The DT N
tapes NNS N
differed VBN N
in IN N
the DT N
extent NN N
to TO N
which WDT N
they PRP N
portrayed VBD N
the DT N
recovery NN N
period NN N
as IN N
a DT N
steady JJ N
, , N
forward JJ N
progression NN N
versus IN N
a DT N
series NN N
of IN N
ups NNS N
and CC N
downs NNS N
. . N

METHODS NNP N
Two CD p
hundred VBD p
sixteen JJ p
male NN p
and CC p
female JJ p
CABG NNP p
patients NNS p
were VBD N
assigned VBN N
randomly RB N
either DT N
to TO N
view VB N
one CD i
of IN i
the DT i
two CD i
videotapes NNS i
before IN i
discharge NN i
from IN i
the DT i
hospital NN i
or CC i
to TO i
receive VB i
only RB i
the DT i
standard JJ i
discharge NN i
preparation NN i
provided VBN N
by IN N
the DT N
hospital NN N
. . N

All DT N
patients NNS N
completed VBN N
measures NNS o
of IN o
anxiety NN o
and CC o
self-efficacy NN o
at IN N
discharge NN N
, , N
1 CD N
month NN N
and CC N
3 CD N
months NNS N
after IN N
discharge NN N
from IN N
the DT N
hospital NN N
. . N

Patients NNS N
also RB N
completed VBD N
measures NNS N
of IN N
dietary JJ o
fat JJ o
consumption NN o
and CC N
activity NN o
level NN o
1 CD o
and CC o
3 CD o
months NNS N
after IN N
discharge NN N
. . N

RESULTS NNP N
Relative NNP N
to TO N
controls NNS N
, , N
patients NNS N
who WP N
viewed VBD N
either DT N
of IN N
the DT N
videotapes NNS i
before IN N
hospital NN N
release NN N
reported VBD N
higher JJR N
self-efficacy NN o
for IN o
adhering VBG o
to TO o
the DT o
recommended VBN o
low-fat NN o
diet JJ o
both DT N
at IN N
discharge NN N
and CC N
1 CD N
month NN N
after IN N
surgery NN N
. . N

Viewing VBG N
either DT N
of IN N
the DT N
videotapes NNS N
also RB N
resulted VBD N
in IN N
significantly RB o
less JJR o
dietary JJ o
fat NN o
intake NN o
1 CD o
month NN o
after IN o
hospital NN o
release NN o
compared VBN N
with IN N
controls NNS N
. . N

Patients NNS N
who WP N
viewed VBD N
the DT N
tape NN N
that WDT N
portrayed VBD N
the DT N
recovery NN N
period NN N
as IN N
consisting NN N
of IN N
ups NNS N
and CC N
downs NNS N
also RB N
reported VBD N
significantly RB N
more RBR N
frequent JJ N
moderate JJ o
exercise NN o
at IN o
1 CD o
month NN o
and CC N
more RBR N
frequent JJ N
strenuous JJ o
exercise NN o
3 CD N
months NNS N
after IN N
discharge NN N
. . N

CONCLUSIONS VB N
The DT N
experimental JJ N
videotapes NNS i
proved VBD N
to TO N
be VB N
an DT N
effective JJ N
method NN N
for IN N
increasing VBG N
dietary JJ o
and CC o
exercise NN o
compliance NN o
during IN N
the DT N
first JJ N
3 CD N
months NNS N
after IN N
CABG NNP N
. . N

-DOCSTART- -21418794- O O

[ JJ N
Protective NNP N
effect NN N
of IN N
ischemia NN i
postconditioning VBG i
on IN N
reperfusion NN N
injury NN N
in IN N
patients NNS p
with IN p
ST-segment JJ p
elevation NN p
acute IN p
myocardial JJ p
infarction NN p
] NNP p
. . N

OBJECTIVE NNP N
To TO N
observe VB N
the DT N
effect NN N
of IN N
ischemia NN i
postconditioning VBG i
during IN N
the DT N
first JJ N
minutes NNS N
of IN N
reperfusion NN N
for IN N
the DT N
myocardial JJ N
reperfusion NN N
injury NN N
in IN N
ST-segment JJ p
elevation NN p
acute IN p
myocardial JJ p
infarction NN p
( ( p
STEMI NNP p
) ) p
patients NNS p
undergoing VBG p
emergency NN i
percutaneous JJ i
coronary JJ i
intervention NN i
( ( i
PCI NNP i
) ) i
. . i

METHODS NNP N
STEMI NNP p
patients NNS p
undergoing VBG p
emergency NN i
PCI NNP i
in IN p
affiliated JJ p
hospital NN p
of IN p
Beihua NNP p
University NNP p
between IN p
October NNP p
2006 CD p
and CC p
January NNP p
2009 CD p
were VBD N
randomly RB N
divided VBN N
into IN N
two CD N
groups NNS N
: : N
the DT p
control NN i
group NN i
( ( p
n JJ p
= NNP p
34 CD p
) ) p
without IN i
any DT i
intervention NN i
after IN i
PTCA NNP i
, , N
and CC N
the DT N
postconditioning NN i
group NN i
( ( p
n JJ p
= NNP p
30 CD p
) ) p
with IN i
ischemia NN i
postconditioning VBG i
within IN N
first JJ N
minutes NNS N
of IN N
reflow NN N
by IN N
3 CD N
episodes NNS N
of IN N
30-second JJ N
inflation NN N
and CC N
30-second JJ N
deflation NN N
with IN N
the DT N
angioplasty JJ i
balloon NN i
. . i

Reperfusion NN o
arrhythmias NN o
, , o
CK NNP o
and CC o
CKMB NNP o
, , o
corrected VBD o
TIMI NNP o
frame NN o
count NN o
( ( o
CTFC NNP o
) ) o
, , o
wall JJ o
motion NN o
score NN o
index NN o
( ( o
WMSI NNP o
) ) o
and CC o
left VBD o
ventricular JJ o
ejection NN o
fraction NN o
( ( o
LVEF NNP o
) ) o
by IN N
echocardiography NN N
were VBD N
compared VBN N
between IN N
the DT N
two CD N
groups NNS N
. . N

MI NNP N
areas NNS N
were VBD N
evaluated VBN N
with IN N
the DT N
ECG-54 NNP N
criteria/32 NN N
system NN N
and CC N
myocardial JJ o
blush NN o
grade NN o
( ( o
MBG NNP o
) ) o
was VBD N
measured VBN N
. . N

RESULTS VB N
The DT N
incidence NN o
of IN o
reperfusion NN o
arrhythmias-frequent JJ o
ventricular JJ o
premature NN o
( ( N
26.7 CD N
% NN N
vs. FW N
52.9 CD N
% NN N
) ) N
and CC N
short JJ o
array NN o
ventricular JJ o
tachycardia NN o
beat NN o
( ( N
23.3 CD N
% NN N
vs. FW N
58.8 CD N
% NN N
) ) N
as RB N
well RB N
as IN N
values NNS N
of IN N
peaks NNS o
CK NNP o
[ NNP N
( ( N
1162 CD N
? . N
548 CD N
) ) N
U/L NNP N
vs. FW N
( ( N
1732 CD N
? . N
480 CD N
) ) N
U/L NNP N
, , N
P NNP N
< VBZ N
0.01 CD N
] NN N
, , N
CKMB NNP N
[ NNP N
( ( N
165 CD N
? . N
70 CD N
) ) N
U/L NNP N
vs. FW N
( ( N
280 CD N
? . N
99 CD N
) ) N
U/L NNP N
, , N
P NNP N
< VBZ N
0.01 CD N
] NN N
, , N
CTFC NNP N
( ( N
22.23 CD N
? . N
3.81 CD N
vs. IN N
26.97 CD N
? . N
3.42 CD N
) ) N
, , N
WMSI NNP N
( ( N
1.27 CD N
? . N
0.52 CD N
vs. IN N
1.82 CD N
? . N
0.83 CD N
) ) N
, , N
and CC o
infarction NN o
areas NNS o
determined VBN o
by IN o
ECG NNP o
methods NNS N
( ( N
10.60 CD N
% NN N
? . N
4.97 CD N
% NN N
vs.14.65 NN N
% NN N
? . N
6.88 CD N
% NN N
, , N
all DT N
P NNP N
< NNP N
0.05 CD N
) ) N
were VBD N
all DT o
significantly RB o
lower JJR o
in IN o
the DT N
postconditioning VBG N
group NN N
than IN N
in IN N
control NN N
group NN N
while IN N
LVEF NNP N
( ( N
0.55 CD N
? . N
0.08 CD N
vs. IN N
0.47 CD N
? . N
0.10 CD N
) ) N
and CC N
MBG NNP N
( ( N
2.27 CD N
? . N
0.64 CD N
vs. IN N
1.47 CD N
? . N
0.61 CD N
, , N
all DT N
P NNP N
< NNP N
0.05 CD N
) ) N
were VBD N
significantly RB o
higher JJR o
in IN o
the DT o
postconditioning VBG N
group NN N
than IN N
in IN N
control NN N
group NN N
. . N

CONCLUSIONS NNP i
Ischemia NNP i
postconditioning NN i
can MD i
significantly RB i
reduce VB N
myocardial JJ N
reperfusion NN N
injury NN p
in IN p
patients NNS p
with IN p
STEMI NNP p
. . p

-DOCSTART- -25861158- O O

The DT N
short-term JJ N
effects NNS N
of IN N
transcranial JJ i
direct JJ i
current JJ i
stimulation NN i
on IN N
electroencephalography NN N
in IN N
children NNS p
with IN p
autism NN p
: : p
a DT N
randomized VBN N
crossover NN N
controlled VBN N
trial NN N
. . N

Abnormal NNP N
synaptic JJ N
maturation NN N
and CC N
connectivity NN N
are VBP N
possible JJ N
etiologies NNS N
of IN N
autism NN N
. . N

Previous JJ N
studies NNS N
showed VBD N
significantly RB N
less JJR N
alpha JJ N
activity NN N
in IN N
autism NN p
than IN N
normal JJ N
children NNS N
. . N

Therefore RB N
, , N
we PRP N
studied VBD N
the DT N
effects NNS N
of IN N
anodal JJ i
tDCS NN i
on IN N
peak NN N
alpha NN N
frequency NN N
( ( N
PAF NNP N
) ) N
related VBD N
to TO N
autism VB N
treatment NN N
evaluation NN N
checklist NN N
( ( N
ATEC NNP N
) ) N
. . N

Twenty NNP p
male JJ p
children NNS p
with IN p
autism NN p
were VBD p
randomly RB p
assigned VBN p
in IN N
a DT N
crossover NN N
design NN N
to TO N
receive VB N
a DT N
single JJ N
session NN N
of IN N
both DT N
active JJ i
and CC i
sham JJ i
tDCS NN i
stimulation NN i
( ( N
11 CD N
mA NN N
) ) N
over IN N
F3 NNP N
( ( N
left JJ N
dorsolateral JJ N
prefrontal JJ N
cortex NN N
) ) N
. . N

Pre- JJ N
to TO N
postsession NN N
changes NNS o
in IN o
a DT o
measure NN o
of IN o
cortical JJ o
activity NN o
impacted VBN N
by IN N
tDCS NN o
( ( o
PAF NNP o
) ) o
and CC N
ATEC NNP o
were VBD N
compared VBN N
between IN N
groups NNS N
. . N

We PRP N
also RB N
examined VBD N
the DT N
associations NNS N
between IN N
pre- NN N
and CC N
postsession NN N
changes NNS N
in IN N
the DT N
PAF NNP o
and CC N
ATEC NNP o
. . o

The DT N
results NNS o
show VBP o
significant JJ o
pre- JJ o
to TO o
postsession NN o
improvements NNS o
in IN N
two CD o
domains NNS o
of IN o
ATEC NNP o
( ( o
social JJ o
and CC o
health/behavior JJ o
domains NNS o
) ) o
following VBG N
active JJ N
tDCS NN o
, , N
relative JJ N
to TO N
sham VB N
treatment NN N
. . N

PAF NNP o
also RB N
significantly RB N
increased VBN o
at IN N
the DT N
stimulation NN N
site NN N
, , N
and CC N
an DT N
increase NN o
in IN o
PAF NNP o
was VBD N
significantly RB N
associated VBN N
with IN N
improvements NNS N
in IN N
the DT N
two CD N
domains NNS N
of IN N
ATEC NNP o
impacted VBN N
by IN N
tDCS NN N
. . N

The DT N
findings NNS N
suggest VBP N
that IN N
a DT N
single JJ N
session NN N
of IN N
anodal JJ i
tDCS NN i
over IN N
the DT N
F3 NNP N
may MD N
have VB N
clinical JJ o
benefits NNS o
in IN N
children NNS N
with IN N
autism NN N
and CC N
that IN N
those DT N
benefits NNS N
may MD N
be VB N
related VBN N
to TO N
an DT N
increase NN N
in IN N
PAF NNP o
. . o

-DOCSTART- -11060324- O O

Commentary NNP N
on IN N
cytoreduction NN i
nephrectomy NN i
in IN p
metastatic JJ p
renal JJ p
cancer NN p
: : p
the DT N
results NNS N
of IN N
Southwest NNP p
Oncology NNP p
Group NNP p
Trial NNP p
8949 CD p
. . N

-DOCSTART- -21598839- O O

The DT N
effects NNS N
of IN N
encoding VBG N
in IN N
hypnosis NN N
and CC N
post-hypnotic JJ N
suggestion NN N
on IN N
academic JJ N
performance NN N
. . N

This DT N
study NN N
examined VBD N
the DT N
relationship NN N
between IN N
proactive JJ p
learning NN p
in IN p
hypnosis NN i
, , i
post-hypnotic JJ i
suggestion NN i
, , p
and CC p
academic JJ p
performance NN p
. . p

Participants NNS p
( ( p
N NNP p
= NNP p
56 CD p
) ) p
were VBD N
randomly RB N
assigned VBN N
to TO N
a DT N
control NN i
group NN p
or CC N
a DT N
treatment NN i
group NN p
. . p

The DT N
treatment NN N
group NN N
was VBD N
hypnotized VBN i
and CC i
read VB i
a DT i
passage NN i
while IN i
in IN i
hypnosis NN i
. . i

Concurrently RB N
, , N
they PRP N
were VBD N
given VBN N
a DT N
post-hypnotic JJ i
suggestion NN i
, , N
which WDT N
attempted VBD N
to TO N
aid VB N
recognition NN N
and CC N
performance NN N
on IN N
a DT N
test NN N
immediately RB N
following VBG N
the DT N
hypnosis NN N
session NN N
. . N

Both DT N
groups NNS N
completed VBD N
a DT N
multiple-choice JJ N
test NN N
based VBN N
on IN N
the DT N
aforementioned JJ N
passage NN N
. . N

An DT N
analysis NN N
of IN N
covariance NN N
discerned VBD N
the DT N
effect NN o
of IN o
proactive JJ o
learning NN o
and CC N
post-hypnotic JJ o
suggestion NN o
on IN N
test NN o
performance NN o
, , N
while IN N
controlling VBG N
for IN N
the DT N
variance NN N
introduced VBN N
by IN N
scholastic JJ o
aptitude NN o
as IN N
measured VBN N
by IN N
the DT N
ACT NNP N
. . N

Results NNP N
indicated VBD N
that IN N
the DT N
hypnosis NN i
sessions NNS N
predicted VBD N
significantly RB N
impaired JJ o
test NN o
performance NN o
. . o

-DOCSTART- -10960380- O O

The DT N
anesthetic JJ N
and CC N
recovery NN N
profile NN N
of IN N
two CD N
doses NNS N
( ( N
60 CD N
and CC N
80 CD N
mg NN N
) ) N
of IN N
plain NN i
mepivacaine NN i
for IN N
ambulatory JJ N
spinal JJ p
anesthesia NN p
. . p

UNLABELLED JJ N
Reports NNS N
of IN N
transient JJ N
neurological JJ N
symptoms NNS N
with IN N
the DT N
use NN N
of IN N
subarachnoid JJ i
lidocaine NN i
has VBZ N
generated VBN N
interest NN N
in IN N
alternate JJ N
local JJ N
anesthetics NNS N
of IN N
intermediate JJ N
duration NN N
, , N
such JJ N
as IN N
mepivacaine NN i
. . i

This DT N
prospective JJ N
randomized NN N
, , N
double-blinded JJ N
, , N
dose-response JJ N
study NN N
examined VBD N
the DT N
anesthetic JJ N
and CC N
recovery NN N
profiles NNS N
of IN N
60- JJ N
and CC N
80-mg JJ N
doses NNS N
of IN N
preservative-free JJ i
plain NN i
mepivacaine NN i
for IN N
ambulatory JJ N
spinal JJ N
anesthesia NN N
. . N

Sixty CD p
patients NNS p
undergoing JJ p
ambulatory JJ p
anterior JJ p
cruciate NN p
ligament NN p
repair NN p
of IN p
the DT p
knee NN p
under IN p
spinal JJ p
anesthesia NN p
were VBD p
randomized VBN p
into IN p
two CD p
groups NNS p
; : p
Group NNP p
1 CD p
( ( N
29 CD N
patients NNS N
) ) N
received VBD N
4 CD N
mL NN N
of IN N
1.5 CD N
% NN N
( ( N
60-mg JJ N
dose NN N
) ) N
and CC N
Group NNP p
2 CD p
( ( N
31 CD N
patients NNS N
) ) N
received VBD N
4 CD N
mL NN N
of IN N
2 CD N
% NN N
( ( N
80-mg CD N
dose NN N
) ) N
of IN N
plain NN i
mepivacaine NN i
. . i

All DT N
patients NNS N
received VBD N
a DT N
combined JJ N
spinal-epidural JJ i
anesthetic JJ i
technique NN i
. . i

The DT N
epidural JJ N
catheter NN N
was VBD N
used VBN N
only RB N
in IN N
the DT N
event NN N
the DT N
surgery NN N
outlasted VBD N
the DT N
duration NN N
of IN N
surgical JJ N
anesthesia NN N
with IN N
subarachnoid JJ i
mepivacaine NN i
. . i

Epidural JJ N
supplementation NN N
was VBD N
administered VBN N
in IN N
three CD N
patients NNS N
( ( N
12 CD N
% NN N
) ) N
in IN N
Group NNP N
1 CD N
and CC N
one CD N
patient NN N
( ( N
3 CD N
% NN N
) ) N
in IN N
Group NNP N
2 CD N
when WRB N
the DT N
sensory JJ N
block NN N
regressed VBD N
to TO N
L-1 NNP N
with IN N
surgery NN N
expected VBN N
to TO N
last JJ N
longer JJR N
than IN N
15 CD N
min NN N
. . N

The DT N
cephalad JJ o
dermatome JJ o
level NN o
of IN o
the DT o
block NN o
and CC o
degree NN o
of IN o
motor NN o
block NN o
was VBD N
comparable JJ N
in IN N
the DT N
two CD N
groups NNS N
. . N

Times NNS o
to TO o
two-segment JJ o
and CC N
T-10 JJ o
regression NN o
were VBD N
comparable JJ N
in IN N
the DT N
two CD N
groups NNS N
( ( N
112 CD N
+/- JJ N
26 CD N
min NN N
in IN N
Group NNP N
1 CD N
versus NN N
122 CD N
+/- JJ N
28 CD N
min NN N
in IN N
Group NNP N
2 CD N
) ) N
. . N

Time NN o
to TO o
L-1 NNP o
regression NN o
was VBD N
significantly RB N
longer RBR N
in IN N
Group NNP N
2 CD N
( ( N
146 CD N
+/- JJ N
28 CD N
min NN N
in IN N
Group NNP N
1 CD N
versus NN N
159 CD N
+/- JJ N
19 CD N
min NN N
in IN N
Group NNP N
2 CD N
) ) N
. . N

All DT N
of IN N
the DT N
ambulatory JJ N
milestones NNS N
were VBD N
significantly RB N
faster RBR N
in IN N
Group NNP N
1 CD N
. . N

Side NN N
effects NNS N
, , N
such JJ N
as IN N
hypotension NN o
and CC o
emesis NN o
were VBD N
negligible JJ N
, , N
severe JJ N
bradycardia NN o
and CC o
urinary JJ o
retention NN o
did VBD N
not RB N
occur VB N
, , N
and CC N
none NN N
of IN N
the DT N
patients NNS N
in IN N
the DT N
two CD N
groups NNS N
reported VBD N
transient JJ o
neurological JJ o
symptoms NNS o
over IN N
24 CD N
h. NNS N
In IN N
conclusion NN N
, , N
plain VBP N
mepivacaine NN i
in IN N
a DT N
60- JJ N
or CC N
80-mg JJ N
dose NN N
is VBZ N
a DT N
suitable JJ N
local JJ N
anesthetic JJ N
choice NN N
for IN N
ambulatory JJ N
spinal JJ N
anesthesia NN N
with IN N
respect NN N
to TO N
anesthetic JJ N
, , N
as RB N
well RB N
as IN N
recovery NN N
profiles NNS N
. . N

IMPLICATIONS NNP N
We PRP N
evaluated VBD N
the DT N
anesthetic JJ N
and CC N
recovery NN N
profiles NNS N
of IN N
60- JJ N
and CC N
80-mg JJ N
doses NNS N
of IN N
plain NN N
mepivacaine NN N
for IN N
ambulatory JJ N
spinal JJ N
anesthesia NN N
. . N

Both DT N
doses NNS N
produced VBD N
comparable JJ N
sensory NN N
and CC N
motor NN N
block NN N
. . N

Sensory NNP o
and CC o
motor NN o
regression NN o
and CC N
ambulatory JJ N
milestones NNS N
were VBD N
20-30 JJ N
min NN N
longer RBR N
with IN N
the DT N
80-mg JJ N
dose NN N
. . N

Side JJ o
effects NNS o
were VBD N
negligible JJ N
and CC N
transient JJ o
neurological JJ o
symptoms NNS o
were VBD N
not RB N
reported VBN N
during IN N
a DT N
24-h JJ N
follow-up NN N
. . N

-DOCSTART- -17453398- O O

Similar JJ N
effects NNS N
of IN N
rofecoxib NN i
and CC N
indomethacin NN i
on IN N
the DT N
incidence NN N
of IN N
heterotopic NN N
ossification NN N
after IN p
hip NN p
arthroplasty NN p
. . p

BACKGROUND NNP N
Although IN N
indomethacin NN i
is VBZ N
effective JJ N
in IN N
preventing VBG N
heterotopic NN o
ossification NN o
( ( o
HO NNP o
) ) o
after IN N
primary JJ p
total JJ p
hip NN p
arthroplasty NN p
, , N
side NN o
effects NNS o
are VBP N
frequently RB N
observed VBN N
. . N

In IN N
the DT N
last JJ N
decade NN N
a DT N
new JJ N
class NN N
of IN N
drugs NNS N
-- : N
the DT N
COX-2 NNP i
selective JJ i
nonsteroidal JJ i
anti-inflammatory JJ i
drugs NNS i
-- : i
has VBZ i
been VBN N
developed VBN N
. . N

To TO N
investigate VB N
the DT N
effect NN N
of IN N
these DT N
COX-2 NNP i
selective NN i
NSAIDs NNP o
on IN o
heterotopic NN o
ossification NN o
( ( o
HO NNP o
) ) o
after IN N
primary JJ N
total JJ N
hip NN N
arthroplasty NN N
( ( N
THA NNP N
) ) N
, , N
we PRP N
conducted VBD N
a DT N
randomized VBN N
controlled VBN N
trial NN N
using VBG N
either CC N
indomethacin NN i
or CC N
rofecoxib NN i
for IN N
7 CD N
days NNS N
. . N

METHODS NNP N
186 CD p
patients NNS p
received VBD p
either RB p
indomethacin JJ i
3 CD p
times NNS p
daily RB p
, , p
or CC p
rofecoxib VB i
twice RB p
, , p
and CC p
1 CD p
placebo NN i
, , p
daily RB p
for IN p
7 CD p
days NNS p
. . p

HO NNP o
was VBD o
graded VBN o
according VBG N
to TO N
the DT N
1-year JJ N
postoperative NN N
radiographs NN N
according VBG N
to TO N
the DT N
Brooker NNP N
classification NN N
. . N

RESULTS NNP N
12 CD p
of IN p
the DT p
186 CD p
patients NNS p
included VBD p
discontinued VBN o
their PRP$ p
medication NN p
before IN p
the DT p
end NN p
of IN p
the DT p
trial NN p
due JJ p
to TO p
side VB o
effects NNS o
. . o

The DT p
remaining VBG p
174 CD p
patients NNS p
were VBD p
included VBN p
in IN p
the DT p
analysis NN p
. . p

In IN p
the DT p
indomethacin NN i
group NN p
( ( p
n JJ p
= NNP p
89 CD p
) ) p
, , p
77 CD p
patients NNS p
( ( p
87 CD p
% NN p
) ) p
showed VBD o
no DT o
HO NNP o
, , p
9 CD p
showed VBD o
HO NNP o
of IN o
grade NN o
1 CD o
and CC p
3 CD p
showed VBD o
HO NNP o
of IN o
grade NN o
2 CD o
according VBG p
to TO p
the DT p
Brooker NNP p
classification NN p
. . p

In IN p
the DT p
rofecoxib NN i
group NN p
( ( p
n JJ p
= NNP p
85 CD p
) ) p
73 CD p
patients NNS p
( ( p
86 CD p
% NN p
) ) p
showed VBD o
no DT o
ossification NN o
, , p
9 CD p
showed VBD o
grade NN o
1 CD o
, , p
and CC p
3 CD p
showed VBD o
grade JJ o
2 CD o
. . o

INTERPRETATION VB N
The DT N
prophylactic JJ N
effect NN N
of IN N
rofecoxib NN i
for IN N
7 CD N
days NNS N
in IN N
preventing VBG N
heterotopic NN N
ossification NN N
after IN N
primary JJ N
total JJ N
hip NN N
arthroplasty NN N
is VBZ N
comparable JJ N
to TO N
the DT N
effect NN N
of IN N
indomethacin NN i
given VBN N
for IN N
7 CD N
days NNS N
. . N

These DT N
results NNS N
indicate VBP N
that IN N
the DT N
development NN N
of IN N
HO NNP N
follows VBZ N
a DT N
COX-2 JJ N
pathway NN N
. . N

-DOCSTART- -9735623- O O

Conservative JJ i
treatment NN i
of IN N
plantar NN p
fasciitis NN p
. . p

A DT N
prospective JJ N
study NN N
. . N

A DT N
randomized JJ N
, , N
prospective JJ N
study NN N
was VBD N
conducted VBN N
to TO N
compare VB N
the DT N
individual JJ o
effectiveness NN o
of IN N
three CD N
types NNS N
of IN N
conservative JJ i
therapy NN i
in IN N
the DT N
treatment NN N
of IN N
plantar NN N
fasciitis NN N
. . N

One CD p
hundred VBD p
three CD p
subjects NNS p
were VBD p
randomly RB p
assigned VBN p
to TO p
one CD p
of IN p
three CD p
treatment NN p
categories NNS p
: : p
anti-inflammatory NN i
, , i
accommodative JJ i
, , i
or CC i
mechanical JJ i
. . i

Subjects NNS p
were VBD N
treated VBN N
for IN N
3 CD N
months NNS N
, , N
with IN N
follow-up JJ N
visits NNS N
at IN N
2 CD N
, , N
4 CD N
, , N
6 CD N
, , N
and CC N
12 CD N
weeks NNS N
. . N

For IN N
the DT N
85 CD p
patients NNS p
who WP p
completed VBD p
the DT p
study NN p
, , N
a DT N
statistically RB N
significant JJ N
difference NN N
was VBD N
noted VBN N
between IN N
groups NNS N
, , N
with IN N
mechanical JJ i
treatment NN i
with IN i
taping VBG i
and CC i
orthoses NNS i
proving VBG N
to TO N
be VB N
more RBR N
effective JJ N
than IN N
either DT N
anti-inflammatory JJ i
or CC N
accommodative JJ i
modalities NNS i
. . i

-DOCSTART- -11547366- O O

Matched-pair JJ N
analysis NN i
of IN N
all-polyethylene JJ i
versus NN i
metal-backed JJ i
tibial JJ i
components NNS i
. . i

Forty-eight NNP p
matched VBD p
pairs NNS p
of IN p
osteoarthritic JJ p
knees NNS p
from IN p
patients NNS p
who WP p
underwent VBP p
primary JJ p
total JJ p
knee NN p
arthroplasty NN p
with IN p
a DT p
round-on-round NN p
, , p
Apollo NNP p
Knee NNP p
System NNP p
were VBD N
studied VBN N
to TO N
evaluate VB N
the DT N
outcome NN N
between IN N
all-polyethylene JJ i
and CC i
metal-backed JJ i
tibial JJ i
components NNS i
. . i

Patients NNS p
were VBD p
matched VBN p
for IN p
patient JJ p
factors NNS p
, , p
preoperative JJ p
deformities NNS p
, , p
cruciate JJ p
salvage NN p
or CC p
sacrifice NN p
, , p
and CC p
surgical JJ p
technique NN p
. . p

At IN N
the DT N
last JJ N
follow-up JJ N
( ( N
average JJ N
, , N
38.4 CD N
months NNS N
) ) N
, , N
there EX N
was VBD N
no DT N
statistically RB N
significant JJ N
difference NN N
in IN N
terms NNS N
of IN N
knee NN o
scores NNS o
, , o
patient JJ o
self-assessment NN o
, , o
and CC o
radiographic JJ o
outcomes NNS o
. . o

No DT N
component NN N
required VBN N
revision NN N
, , N
and CC N
no DT N
revisions NNS N
were VBD N
pending VBG N
. . N

Maintenance NN N
of IN N
these DT N
results NNS N
over IN N
time NN N
would MD N
project VB N
into IN N
better JJR N
long-term JJ N
success NN N
for IN N
all-polyethylene JJ i
tibial JJ i
components NNS i
because IN N
of IN N
the DT N
amount NN N
of IN N
wear NN N
and CC N
osteolysis NN N
with IN N
current JJ N
modular JJ N
metal-backed JJ i
tibial JJ i
components NNS i
. . i

We PRP N
advocate VBP N
the DT N
use NN N
of IN N
a DT N
more RBR N
cost-effective JJ N
all-polyethylene JJ i
tibial JJ i
component NN i
in IN N
elderly JJ p
patients NNS p
( ( p
> JJ p
70 CD p
years NNS p
old JJ p
) ) p
who WP N
are VBP N
not RB N
likely JJ N
to TO N
need VB N
the DT N
versatility NN N
of IN N
exchange NN N
of IN N
a DT N
modular JJ N
polyethylene NN N
insert NN N
because IN N
of IN N
wear NN N
. . N

-DOCSTART- -23773886- O O

An DT N
Exploratory NNP N
, , N
Open-Label NNP N
, , N
Randomized NNP N
Trial NNP N
Comparing NNP N
Risperidone NNP i
Long-Acting NNP i
Injectable NNP i
with IN N
Oral NNP i
Antipsychotic NNP i
Medication NNP i
in IN N
the DT N
Treatment NNP N
of IN N
Early NNP p
Psychosis NNP p
. . p

Few JJ N
studies NNS N
have VBP N
examined VBN N
effectiveness NN N
and CC N
tolerability NN N
of IN N
risperidone NN i
long-acting JJ i
injections NNS i
( ( i
RLAI NNP i
) ) i
in IN N
the DT N
early JJ p
phase NN p
of IN p
a DT p
schizophrenia NN p
spectrum NN p
( ( p
SS NNP p
) ) p
disorder NN p
using VBG N
a DT N
randomized VBN N
controlled VBN N
trial NN N
( ( N
RCT NNP N
) ) N
design NN N
. . N

Eighty-five JJ p
patients NNS p
in IN p
early JJ p
phase NN p
of IN p
an DT p
SS NNP p
disorder NN p
were VBD N
randomized VBN N
to TO N
receive VB N
either DT N
oral JJ i
second-generation NN i
antipsychotics NNS i
( ( i
SGAs NNP i
; : i
n=41 CC N
) ) N
or CC N
RLAI NNP i
( ( N
n=44 NN N
) ) N
over IN N
two CD N
years NNS N
. . N

Analyses NNS N
were VBD N
conducted VBN N
on IN N
eligible JJ p
participants NNS p
( ( p
n=77 NN p
) ) p
for IN N
the DT N
stabilization NN N
( ( N
maximum JJ N
18 CD N
weeks NNS N
) ) N
and CC N
maintenance NN N
phases NNS N
( ( N
up RB N
to TO N
Week NNP N
104 CD N
) ) N
on IN N
primary JJ N
outcome JJ N
measures NNS N
of IN N
time NN o
to TO o
stabilization NN o
and CC N
relapse NN o
, , o
change NN o
in IN o
symptoms NNS o
and CC o
safety NN o
, , N
and CC N
comparisons NNS o
made VBN N
across IN N
the DT N
two CD N
groups NNS N
. . N

Both DT N
groups NNS N
showed VBD N
improvement NN N
on IN N
Positive NNP o
and CC o
Negative NNP o
Syndrome NNP o
Scale NNP o
( ( o
PANSS NNP o
) ) o
scores NNS o
and CC o
Clinical NNP o
Global NNP o
Impression-Severity NNP o
( ( o
CGI-S NNP o
) ) o
scores VBZ o
. . o

There EX N
were VBD N
no DT N
time NN N
X NNP N
group NN N
interactions NNS N
on IN N
any DT N
of IN N
the DT N
primary JJ N
outcome NN N
measures NNS N
. . N

Post NNP N
hoc JJ N
examination NN N
revealed VBD N
that IN N
the DT N
RLAI NNP N
group NN N
showed VBD N
greater JJR N
change NN N
on IN N
CGI-S NNP o
and CC o
PANSS NNP o
negative JJ o
symptom NN o
scores NNS o
during IN N
the DT N
stabilization NN N
phase NN N
, , N
while IN N
the DT N
oral JJ N
group NN N
reached VBD N
the DT N
same JJ N
level NN N
of IN N
improvement NN N
during IN N
the DT N
maintenance NN N
phase NN N
. . N

The DT N
current JJ N
exploratory NN N
study NN N
suggests VBZ N
that-within VBP N
an DT N
RCT NNP N
design-RLAI NN N
and CC N
oral JJ N
SGAs NNP N
are VBP N
equally RB N
effective JJ o
and CC N
have VBP N
similar JJ o
safety NN o
profiles NNS o
in IN N
patients NNS p
in IN N
the DT N
early JJ N
phase NN N
of IN N
SS NNP N
disorders NNS N
. . N

Thus RB N
, , N
RLAI NNP N
offers VBZ N
no DT N
advantage NN N
to TO N
patients NNS N
in IN N
early JJ N
phase NN N
of IN N
SS NNP N
disorders NNS N
, , N
but CC N
is VBZ N
likely JJ N
to TO N
be VB N
effective JJ o
and CC N
safe JJ o
for IN N
those DT N
who WP N
may MD N
have VB N
problems NNS N
with IN N
adherence NN N
and CC N
may MD N
either RB N
choose VB N
to TO N
take VB N
it PRP N
or CC N
be VB N
prescribed VBN N
under IN N
conditions NNS N
of IN N
external JJ N
control NN N
such JJ N
as IN N
community NN N
treatment NN N
orders NNS N
. . N

-DOCSTART- -11056245- O O

Depressive JJ N
mood NN N
symptoms NNS N
associated VBN N
with IN N
ovarian JJ N
suppression NN N
. . N

OBJECTIVE UH N
To TO N
determine VB N
if IN N
sertraline NN i
is VBZ N
helpful JJ N
in IN N
the DT N
management NN N
of IN N
depressive NN N
symptoms NNS N
associated VBN N
with IN N
ovarian JJ N
suppression NN N
during IN N
GnRH NNP i
agonist JJ i
therapy NN i
as IN N
compared VBN N
with IN N
a DT N
placebo-controlled JJ i
group NN N
. . N

DESIGN NNP N
Double-blind JJ N
placebo-controlled JJ i
prospective JJ N
study NN N
design NN N
. . N

SETTING NN N
An DT N
obstetrics/gynecological JJ N
office NN N
specializing VBG N
in IN N
infertility NN N
in IN N
an DT N
academic JJ N
environment NN N
. . N

PATIENT NNP N
( ( N
S NNP N
) ) N
Premenstrual NNP p
women NNS p
with IN p
laparoscopically RB p
diagnosed VBN p
endometriosis NN p
who WP p
required VBD p
GnRH NNP i
agonist JJ i
therapy NN i
for IN p
treatment NN p
and CC p
did VBD p
not RB p
have VB p
significant JJ p
depressive JJ p
or CC p
premenstrual JJ p
mood NN p
symptoms NNS p
at IN p
baseline NN p
. . p

INTERVENTION NNP N
( ( N
S NNP N
) ) N
Participants NNPS p
were VBD p
randomly RB p
assigned VBN p
to TO p
either CC p
the DT p
sertraline JJ i
treatment NN i
group NN p
or CC p
to TO p
the DT p
placebo NN i
group NN p
for IN p
the DT p
3-month JJ p
duration NN p
of IN p
the DT p
GnRH NNP i
agonist NN i
therapy NN i
. . i

MAIN NNP N
OUTCOME NNP N
MEASURE NNP N
( ( N
S NNP N
) ) N
The DT o
21-item JJ o
Hamilton NNP o
Rating NNP o
Scale NNP o
for IN o
Depression NNP o
( ( o
HRSD NNP o
) ) o
, , N
which WDT N
is VBZ N
an DT N
instrument NN N
designed VBN N
to TO N
assess VB N
depressive JJ N
symptomatology NN N
. . N

RESULT NNP N
( ( N
S NNP N
) ) N
A NNP N
Hotellings NNP N
T NNP N
( ( N
2 CD N
) ) N
test NN N
for IN N
repeated VBN N
measure NN N
analysis NN N
indicated VBD N
a DT N
statistically RB N
significant JJ N
( ( N
P NNP N
< NNP N
.05 NNP N
) ) N
between-group NN N
difference NN N
across IN N
time NN N
for IN N
the DT N
HRSD NNP o
( ( N
T NNP N
( ( N
2 CD N
) ) N
= NN N
13.3 CD N
; : N
F NNP N
[ VBZ N
3 CD N
, , N
28 CD N
] NN N
= NN N
4.1 CD N
; : N
P=.02 NNP N
) ) N
with IN N
the DT N
sertraline NN i
treatment NN N
group NN N
manifesting VBG N
significantly RB N
fewer JJR N
depressive NN o
symptoms NNS o
than IN N
the DT N
control NN N
group NN N
. . N

CONCLUSION NNP N
( ( N
S NNP N
) ) N
The DT N
results NNS N
indicate VBP N
that DT N
sertraline NN i
is VBZ N
an DT N
effective JJ N
option NN N
in IN N
the DT N
management NN N
of IN N
depressive JJ N
mood NN N
symptoms NNS N
associated VBN N
with IN N
ovarian JJ N
suppression NN N
during IN N
GnRH NNP i
agonist JJ i
therapy NN i
. . i

-DOCSTART- -23130813- O O

Emotional JJ o
reactivity NN o
to TO N
social JJ N
rejection NN N
and CC N
negative JJ N
evaluation NN N
among IN N
persons NNS p
with IN p
borderline JJ p
personality NN p
features NNS p
. . p

The DT N
present JJ N
study NN N
examined VBD N
the DT N
emotional JJ o
reactivity NN o
of IN N
persons NNS p
with IN p
heightened JJ p
borderline NN p
personality NN p
( ( p
BP NNP p
) ) p
features VBZ p
to TO N
social JJ N
rejection NN N
and CC N
negative JJ N
evaluation NN N
in IN N
the DT N
laboratory NN N
. . N

Individuals NNS p
with IN p
high JJ p
levels NNS p
of IN p
BP NNP p
features NNS p
( ( p
n JJ p
= NNP p
30 CD p
) ) p
and CC p
controls NNS p
with IN p
low JJ p
levels NNS p
of IN p
BP NNP p
features NNS p
( ( p
n JJ p
= NNP p
44 CD p
) ) p
were VBD N
randomly RB N
assigned VBN N
to TO N
a DT N
condition NN i
involving VBG i
negative JJ i
evaluation NN i
based VBN i
on IN i
writing NN o
( ( i
negative JJ i
evaluation/academic NN i
) ) i
, , i
or CC i
a DT i
condition NN i
involving VBG i
negative JJ i
evaluation NN i
based VBN i
on IN i
personal JJ o
characteristics NNS o
as RB i
well RB i
as IN i
social JJ o
rejection NN o
( ( o
negative JJ o
evaluation/social JJ o
rejection NN o
) ) o
. . o

Hypothesis $ N
1 CD N
was VBD N
that IN N
high-BP JJ p
individuals NNS p
, , N
but CC N
not RB N
low-BP JJ p
controls NNS p
, , N
would MD N
show VB N
greater JJR N
emotional JJ o
reactivity NN o
to TO N
the DT N
negative JJ i
evaluation/social JJ i
rejection NN i
stressor NN i
, , N
compared VBN N
with IN N
the DT N
negative JJ i
evaluation/academic JJ i
( ( i
writing VBG i
) ) i
stressor NN i
. . i

Hypothesis $ N
2 CD N
was VBD N
that IN N
high-BP JJ p
individuals NNS p
would MD N
specifically RB N
show VB N
greater JJR N
reactivity NN o
of IN o
shame- JJ o
and CC o
anger-related JJ o
emotions NNS o
to TO N
the DT N
negative JJ i
evaluation/social JJ i
rejection NN i
stressor NN i
compared VBN N
with IN N
the DT N
negative JJ i
evaluation/academic JJ i
stressor NN i
. . i

Findings NNS N
indicated VBD N
that IN N
high-BP JJ p
individuals NNS p
showed VBD N
heightened VBN o
emotional JJ o
reactivity NN o
to TO N
the DT N
social JJ i
rejection NN i
stressor NN i
but CC N
not RB N
to TO N
the DT N
negative JJ i
evaluation NN i
stressor NN i
, , N
but CC N
the DT N
opposite JJ N
pattern NN N
occurred VBD N
for IN N
controls NNS N
. . N

In IN N
addition NN N
, , N
there EX N
was VBD N
evidence NN N
for IN N
heightened JJ o
reactivity NN o
of IN o
irritability NN o
, , o
distress NN o
, , o
and CC o
shame NN o
for IN N
the DT N
high-BP JJ N
group NN N
, , N
specifically RB N
in IN N
the DT N
social JJ N
rejection NN N
condition NN N
. . N

-DOCSTART- -22628369- O O

Enhancing VBG N
HIV NNP N
medication NN N
adherence NN o
in IN N
India NNP N
. . N

BACKGROUND NNP N
This DT N
pilot NN N
study NN N
evaluated VBD N
an DT N
intervention NN N
designed VBN N
to TO N
enhance VB N
adherence NN N
among IN N
those DT N
new JJ N
to TO N
antiretroviral JJ N
therapy NN N
. . N

METHODS NNP p
Participants NNP p
( ( p
n JJ p
= NNP p
80 CD p
) ) p
were VBD p
recruited VBN p
from IN p
a DT p
hospital NN p
clinic NN p
in IN p
Chandigarh NNP p
, , p
India NNP p
, , p
and CC p
randomized VBD p
to TO p
a DT p
3-month JJ i
group NN i
intervention NN i
or CC i
individual JJ i
enhanced JJ i
standard NN i
of IN i
care NN i
followed VBN i
by IN i
crossover NN i
of IN i
condition NN i
and CC i
assessed VBD i
over IN i
6 CD i
months NNS i
. . i

Adherence NNP N
was VBD N
measured VBN N
by IN N
prescription NN o
refill NN o
, , o
pill NN o
count NN o
, , o
and CC o
self-report NN o
. . o

RESULTS NNP N
At IN N
baseline NN N
, , N
56 CD N
% NN N
of IN N
group NN N
condition NN N
( ( N
immediate JJ N
intervention NN N
) ) N
and CC N
54 CD N
% NN N
of IN N
individual JJ N
condition NN N
( ( N
delayed VBN N
intervention NN N
) ) N
participants NNS N
were VBD N
nonadherent JJ N
by IN N
pill NN o
count NN o
and CC N
23 CD N
% NN N
of IN N
group NN N
and CC N
26 CD N
% NN N
of IN N
individual JJ N
condition NN N
participants NNS N
self-reported JJ o
skipping JJ o
medication NN o
at IN N
least JJS N
once RB N
over IN N
the DT N
last JJ N
3 CD N
months NNS N
. . N

From IN N
the DT N
postintervention NN N
to TO N
long-term JJ N
follow-up NN N
, , N
adherence NN N
in IN N
the DT N
group NN N
condition NN N
( ( N
immediate JJ N
intervention NN N
) ) N
improved VBN N
in IN N
comparison NN N
with IN N
adherence NN N
in IN N
the DT N
individual JJ N
condition NN N
( ( N
delayed VBN N
intervention NN N
; : N
? . N
( ( N
2 CD N
) ) N
= NN N
5.67 CD N
, , N
P NNP N
= NNP N
.02 NNP N
) ) N
. . N

CONCLUSIONS JJ N
Results NNP N
support NN N
the DT N
use NN N
of IN N
interventions NNS N
early RB N
in IN N
treatment NN N
to TO N
provide VB N
information NN N
and CC N
social JJ N
support NN N
to TO N
establish VB N
long-term JJ N
healthy JJ o
adherence NN o
behaviors NNS N
. . N

-DOCSTART- -24716680- O O

Spironolactone NN i
for IN N
heart NN N
failure NN N
with IN N
preserved JJ N
ejection NN o
fraction NN o
. . o

BACKGROUND NNP N
Mineralocorticoid-receptor NNP N
antagonists NNS N
improve VBP N
the DT N
prognosis NN N
for IN N
patients NNS p
with IN p
heart NN p
failure NN p
and CC N
a DT N
reduced JJ N
left NN N
ventricular JJ N
ejection NN N
fraction NN N
. . N

We PRP N
evaluated VBD N
the DT N
effects NNS o
of IN N
spironolactone NN i
in IN N
patients NNS p
with IN p
heart NN p
failure NN p
and CC p
a DT p
preserved JJ p
left NN p
ventricular JJ p
ejection NN p
fraction NN p
. . p

METHODS NNP N
In IN N
this DT N
randomized JJ N
, , N
double-blind JJ N
trial NN N
, , N
we PRP N
assigned VBD N
3445 CD p
patients NNS p
with IN p
symptomatic JJ p
heart NN p
failure NN p
and CC p
a DT p
left JJ p
ventricular JJ p
ejection NN p
fraction NN p
of IN p
45 CD p
% NN p
or CC p
more JJR p
to TO N
receive VB i
either DT i
spironolactone NN i
( ( i
15 CD i
to TO i
45 CD i
mg NNS i
daily RB i
) ) i
or CC i
placebo NN i
. . i

The DT N
primary JJ N
outcome NN N
was VBD N
a DT N
composite JJ o
of IN o
death NN o
from IN o
cardiovascular JJ o
causes NNS o
, , o
aborted VBD o
cardiac JJ o
arrest NN o
, , o
or CC o
hospitalization NN o
for IN o
the DT o
management NN o
of IN o
heart NN o
failure NN o
. . o

RESULTS NN N
With IN N
a DT N
mean JJ N
follow-up NN N
of IN N
3.3 CD N
years NNS N
, , N
the DT N
primary JJ N
outcome NN N
occurred VBD N
in IN N
320 CD N
of IN N
1722 CD N
patients NNS N
in IN N
the DT N
spironolactone NN i
group NN N
( ( N
18.6 CD N
% NN N
) ) N
and CC N
351 CD N
of IN N
1723 CD N
patients NNS N
in IN N
the DT N
placebo NN i
group NN N
( ( N
20.4 CD N
% NN N
) ) N
( ( N
hazard JJ N
ratio NN N
, , N
0.89 CD N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NNP N
, , N
0.77 CD N
to TO N
1.04 CD N
; : N
P=0.14 NNP N
) ) N
. . N

Of IN N
the DT N
components NNS N
of IN N
the DT N
primary JJ N
outcome NN N
, , N
only RB N
hospitalization NN o
for IN o
heart NN o
failure NN o
had VBD N
a DT N
significantly RB N
lower JJR N
incidence NN N
in IN N
the DT N
spironolactone NN i
group NN N
than IN N
in IN N
the DT N
placebo NN i
group NN N
( ( N
206 CD N
patients NNS N
[ JJ N
12.0 CD N
% NN N
] NNP N
vs. IN N
245 CD N
patients NNS N
[ JJ N
14.2 CD N
% NN N
] NN N
; : N
hazard CC N
ratio NN N
, , N
0.83 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
0.69 CD N
to TO N
0.99 CD N
, , N
P=0.04 NNP N
) ) N
. . N

Neither CC N
total JJ o
deaths NNS o
nor CC N
hospitalizations NNS o
for IN N
any DT N
reason NN N
were VBD N
significantly RB N
reduced VBN N
by IN N
spironolactone NN i
. . i

Treatment NN N
with IN N
spironolactone NN i
was VBD N
associated VBN N
with IN N
increased JJ N
serum NN o
creatinine NN o
levels NNS o
and CC N
a DT N
doubling NN N
of IN N
the DT N
rate NN o
of IN o
hyperkalemia NN o
( ( N
18.7 CD N
% NN N
, , N
vs. FW N
9.1 CD N
% NN N
in IN N
the DT N
placebo NN N
group NN N
) ) N
but CC N
reduced JJ N
hypokalemia NN N
. . N

With IN N
frequent JJ N
monitoring NN N
, , N
there EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
the DT N
incidence NN N
of IN N
serious JJ N
adverse JJ N
events NNS N
, , N
a DT N
serum JJ o
creatinine NN o
level NN o
of IN N
3.0 CD N
mg NNS N
per IN N
deciliter NN N
( ( N
265 CD N
?mol NN N
per IN N
liter NN N
) ) N
or CC N
higher JJR N
, , N
or CC N
dialysis NN N
. . N

CONCLUSIONS NNP N
In IN p
patients NNS p
with IN p
heart NN p
failure NN p
and CC p
a DT p
preserved JJ p
ejection NN p
fraction NN p
, , p
treatment NN N
with IN i
spironolactone NN i
did VBD N
not RB N
significantly RB N
reduce VB N
the DT o
incidence NN o
of IN o
the DT o
primary JJ o
composite JJ o
outcome NN o
of IN o
death NN o
from IN o
cardiovascular JJ o
causes NNS o
, , o
aborted VBD o
cardiac JJ o
arrest NN o
, , o
or CC o
hospitalization NN o
for IN o
the DT o
management NN o
of IN o
heart NN o
failure NN o
. . o

( ( N
Funded VBN N
by IN N
the DT N
National NNP N
Heart NNP N
, , N
Lung NNP N
, , N
and CC N
Blood NNP N
Institute NNP N
; : N
TOPCAT NNP N
ClinicalTrials.gov NNP N
number NN N
, , N
NCT00094302 NNP N
. . N

) ) N
. . N

-DOCSTART- -12612897- O O

Gastrointestinal NNP o
safety NN o
of IN N
NO-aspirin NNP i
( ( i
NCX-4016 NNP i
) ) i
in IN N
healthy JJ p
human JJ p
volunteers NNS p
: : p
a DT N
proof NN N
of IN N
concept NN N
endoscopic NN N
study NN N
. . N

BACKGROUND NNP N
AND CC N
AIMS NNP N
NCX-4016 NNP i
is VBZ N
a DT N
nitric JJ N
oxide-releasing JJ N
derivative NN N
of IN N
aspirin NN N
with IN N
antiplatelet NN o
activity NN o
. . o

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
investigate VB N
the DT N
effect NN N
of IN N
NCX-4016 NNP i
on IN N
gastrointestinal JJ N
mucosa NN N
and CC N
platelet NN o
functions NNS o
in IN N
healthy JJ p
human JJ p
volunteers NNS p
. . p

METHODS NNP N
This DT N
was VBD N
a DT N
parallel-group JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
study NN N
. . N

Forty NNP p
healthy JJ p
subjects NNS p
were VBD N
randomly RB N
allocated VBN N
to TO N
receive VB N
7 CD N
days NNS N
of IN N
treatment NN N
with IN N
NCX-4016 NNP i
( ( i
400 CD i
and CC i
800 CD i
mg NN i
twice RB i
daily RB i
) ) i
, , i
equimolar JJ i
doses NNS i
of IN i
aspirin NN i
( ( i
200 CD i
and CC i
420 CD i
mg NN i
twice RB i
daily RB i
) ) i
, , i
or CC i
placebo NN i
. . i

Upper IN N
endoscopies NNS N
were VBD N
performed VBN N
before RB N
and CC N
at IN N
the DT N
end NN N
of IN N
the DT N
treatment NN N
period NN N
, , N
and CC N
gastroduodenal JJ o
lesions NNS o
were VBD N
graded VBN N
using VBG N
a DT N
predefined VBN o
scoring NN o
system NN o
. . o

Basal NNP o
and CC o
posttreatment JJ o
platelet NN o
aggregation NN o
in IN N
response NN N
to TO N
arachidonic JJ N
acid NN N
( ( N
AA NNP N
) ) N
and CC N
serum JJ N
thromboxane NN N
( ( N
TX NNP N
) ) N
B NNP N
( ( N
2 CD N
) ) N
and CC N
AA-stimulated JJ N
platelet NN N
TXB NNP N
( ( N
2 CD N
) ) N
production NN N
were VBD N
investigated VBN N
. . N

RESULTS NNP N
Mucosal NNP o
endoscopic JJ o
injury NN o
score NN o
on IN N
day NN N
7 CD N
was VBD N
0.63 CD N
+/- JJ N
0.16 CD N
in IN N
the DT N
placebo NN N
group NN N
and CC N
11.0 CD N
+/- JJ N
3.0 CD N
and CC N
16.1 CD N
+/- JJ N
1.6 CD N
in IN N
healthy JJ p
volunteers NNS p
treated VBD N
with IN N
200 CD N
and CC N
420 CD N
mg NN N
aspirin JJ N
twice RB N
daily RB N
( ( N
P NNP N
< VBZ N
0.0001 CD N
vs. FW N
placebo NN N
) ) N
. . N

NCX-4016 NN N
was VBD N
virtually RB N
devoid JJ N
of IN N
gastric JJ o
and CC o
duodenal JJ o
toxicity NN o
, , N
resulting VBG N
in IN N
a DT N
total JJ o
gastric NN o
and CC o
duodenal JJ o
endoscopic NN o
score NN o
of IN N
1.38 CD N
+/- JJ N
0.3 CD N
and CC N
1.25 CD N
+/- JJ N
0.5 CD N
( ( N
P NNP N
< VBZ N
0.0001 CD N
vs. NN N
aspirin NN N
, , N
not RB N
significant JJ N
vs. FW N
placebo NN N
) ) N
. . N

NCX-4016 JJ N
inhibited JJ N
AA-induced JJ o
platelet NN o
aggregation NN o
as RB N
well RB N
as IN N
serum NN o
TXB NNP o
( ( o
2 CD o
) ) o
and CC N
platelet NN o
TXB NNP o
( ( o
2 CD o
) ) o
generation NN o
induced VBN N
by IN N
AA NNP N
to TO N
the DT N
same JJ N
extent NN N
as IN N
aspirin NN i
( ( N
not RB N
significant JJ N
vs. FW N
aspirin NN N
) ) N
. . N

CONCLUSIONS NNP N
In IN N
this DT N
study NN N
, , N
we PRP N
have VBP N
proven VBN N
the DT N
concept NN N
that IN N
addition NN N
of IN N
an DT N
NO-donating JJ N
moiety NN N
to TO N
aspirin VB N
results NNS N
in IN N
a DT N
new JJ N
chemical NN N
entity NN N
that WDT N
maintains VBZ N
cyclooxygenase-1 NN N
and CC N
platelet VB N
inhibitory JJ N
activity NN N
while IN N
nearly RB N
avoiding VBG N
gastrointestinal JJ o
damage NN o
. . o

-DOCSTART- -18806616- O O

Monitoring NN N
of IN N
the DT N
central JJ o
pulse JJ o
pressure NN o
is VBZ N
useful JJ N
for IN N
detecting VBG N
cardiac JJ N
overload NN N
during IN N
antiadrenergic JJ N
treatment NN N
: : N
the DT p
Japan NNP p
Morning NNP p
Surge NNP p
1 CD p
study NN p
. . p

OBJECTIVE NNP N
Lowering NNP N
of IN N
the DT N
central JJ o
pulse JJ o
pressure NN o
( ( N
PP NNP N
) ) N
has VBZ N
been VBN N
shown VBN N
to TO N
contribute VB N
to TO N
an DT N
improvement NN N
of IN N
the DT N
cardiac JJ N
damage NN N
beyond IN N
that DT N
of IN N
lowering VBG N
the DT N
brachial JJ N
PP NNP N
. . N

We PRP N
assessed VBD N
the DT N
hypothesis NN N
that IN N
the DT N
change NN N
in IN N
the DT N
central JJ N
PP NNP N
is VBZ N
more RBR N
useful JJ N
than IN N
that DT N
in IN N
the DT N
brachial JJ N
PP NNP N
in IN N
the DT N
assessment NN N
of IN N
the DT N
change NN N
in IN N
cardiac JJ N
load NN N
. . N

METHODS NNP N
We PRP N
studied VBD N
434 CD p
treated JJ p
hypertensive JJ p
patients NNS p
whose WP$ p
home NN p
systolic NN p
blood NN p
pressure NN p
was VBD p
135 CD p
mmHg NN p
or CC p
higher JJR p
. . p

They PRP p
were VBD N
followed VBN N
for IN N
6 CD N
months NNS N
after IN N
allocation NN N
to TO N
either VB N
a DT N
control NN i
group NN i
or CC i
an DT i
added JJ i
treatment NN i
group NN i
( ( i
doxazosin JJ i
1-4 JJ i
mg NN i
and CC i
atenolol NN i
when WRB i
needed VBN i
) ) i
. . i

We PRP N
measured VBD N
the DT N
brachial NN N
and CC N
central JJ N
( ( N
carotid NN N
) ) N
blood NN N
pressure NN N
simultaneously RB N
using VBG N
a DT N
validated JJ N
device NN N
, , N
and CC N
the DT N
B-type NNP N
natriuretic JJ N
peptide NN N
at IN N
baseline NN N
and CC N
at IN N
the DT N
sixth JJ N
month NN N
of IN N
treatment NN N
. . N

RESULTS NNP N
In IN N
the DT N
added JJ N
treatment NN N
group NN N
, , N
the DT N
brachial JJ o
systolic JJ o
blood NN o
pressure NN o
was VBD N
successfully RB N
reduced VBN N
, , N
but CC N
the DT N
central JJ o
PP NNP o
increased VBD N
significantly RB N
, , N
whereas IN N
the DT N
other JJ N
blood NN N
pressure NN N
parameters NNS N
did VBD N
not RB N
change NN N
from IN N
the DT N
baseline NN N
. . N

In IN N
the DT N
added JJ N
treatment NN N
group NN N
, , N
the DT N
change NN N
in IN N
the DT N
B-type NNP N
natriuretic JJ N
peptide NN N
was VBD N
significantly RB N
correlated VBN N
with IN N
the DT N
change NN N
in IN N
the DT N
brachial JJ o
PP NNP o
( ( N
r VB N
= RB N
0.18 CD N
) ) N
, , N
central JJ o
systolic JJ o
blood NN o
pressure NN o
( ( N
r JJ N
= NNP N
0.18 CD N
) ) N
, , N
central JJ o
PP NNP o
( ( N
r VB N
= RB N
0.26 CD N
) ) N
, , N
and CC N
PP NNP o
amplification NN o
( ( N
r JJ N
= NNP N
-0.22 NNP N
) ) N
even RB N
after IN N
adjusting VBG N
for IN N
the DT N
confounding NN N
factors NNS N
. . N

The DT N
correlation NN N
with IN N
the DT N
central JJ N
PP NNP N
was VBD N
stronger JJR N
than IN N
with IN N
the DT N
brachial JJ o
PP NNP o
( ( N
P NNP N
= NNP N
0.018 CD N
) ) N
or CC N
central JJ o
systolic JJ o
blood NN o
pressure NN o
( ( N
P NNP N
= NNP N
0.002 CD N
) ) N
, , N
and CC N
these DT N
relationships NNS N
were VBD N
essentially RB N
the DT N
same JJ N
even RB N
after IN N
adjustment NN N
for IN N
the DT N
use NN N
of IN N
atenolol NN i
or CC N
the DT N
change NN N
in IN N
heart NN N
rate NN N
. . N

CONCLUSION NNP N
This DT N
study NN N
showed VBD N
that IN N
the DT N
central JJ o
PP NNP o
measurement NN o
may MD N
be VB N
more RBR N
important JJ N
to TO N
assess VB N
cardiac JJ N
load NN N
than IN N
the DT N
brachial JJ N
PP NNP N
during IN N
antiadrenergic JJ i
treatment NN i
. . i

-DOCSTART- -15965311- O O

Safety NN o
, , o
tolerability NN o
, , o
and CC o
changes NNS o
in IN o
amyloid JJ o
beta NN o
concentrations NNS o
after IN N
administration NN N
of IN N
a DT N
gamma-secretase JJ i
inhibitor NN i
in IN N
volunteers NNS p
. . p

Amyloid NNP N
beta NN N
( ( N
Abeta NNP N
) ) N
may MD N
play VB N
a DT N
central JJ N
role NN N
in IN N
the DT N
pathogenesis NN N
of IN N
Alzheimer NNP N
disease NN N
. . N

A DT N
functional JJ N
gamma-secretase NN N
inhibitor NN N
, , N
LY450139 NNP i
, , N
was VBD N
developed VBN N
that IN N
inhibits NNS N
Abeta NNP N
formation NN N
in IN N
whole JJ N
cell NN N
assays NNS N
, , N
transgenic JJ N
mice NN N
, , N
and CC N
beagle JJ N
dogs NNS N
. . N

The DT N
authors NNS N
wished VBD N
to TO N
determine VB N
the DT N
safety NN N
and CC N
tolerability NN N
of IN N
this DT N
drug NN N
, , N
and CC N
the DT N
reduction NN N
of IN N
Abeta NNP o
in IN o
plasma NN o
and CC o
cerebrospinal JJ o
fluid NN o
( ( o
CSF NNP o
) ) o
after IN N
multiple JJ N
doses NNS N
. . N

Volunteer NNP p
subjects NNS p
( ( p
N NNP p
= NNP p
37 CD p
) ) p
were VBD N
studied VBN N
using VBG i
doses NNS i
from IN i
5 CD i
to TO i
50 CD i
mg/day NN i
given VBN i
for IN i
14 CD i
days NNS i
. . i

Plasma NNP o
and CC o
CSF NNP o
concentrations NNS o
of IN o
LY450139 NNP o
, , o
Abeta NNP o
( ( o
1-40 JJ o
) ) o
and CC i
Abeta NNP o
( ( o
1-X JJ o
) ) o
( ( o
Abeta NNP o
( ( o
total JJ o
) ) o
) ) o
were VBD N
determined VBN N
, , N
and CC N
safety NN N
and CC N
tolerability NN N
were VBD N
assessed VBN N
. . N

The DT N
plasma JJ N
half-life NN N
of IN N
LY450139 NNP N
was VBD N
approximately RB N
2.5 CD N
hours NNS N
. . N

Pharmacokinetic JJ N
analyses NNS N
showed VBD N
a DT N
linear JJ N
relationship NN N
between IN N
dose NN N
and CC N
plasma JJ N
concentrations NNS N
, , N
with IN N
a DT N
Cmax NNP N
of IN N
828 CD N
+/- JJ N
19.2 CD N
ng/mL NN N
after IN N
a DT N
50-mg JJ N
dose NN N
. . N

Plasma NNP o
Abeta NNP o
concentrations NNS o
decreased VBD N
in IN N
a DT N
dose-dependent JJ N
manner NN N
over IN N
a DT N
6-hour JJ N
interval NN N
following VBG N
drug NN N
administration NN N
, , N
with IN N
a DT N
maximum JJ N
decrease NN N
of IN N
approximately RB N
40 CD N
% NN N
relative JJ N
to TO N
baseline VB N
. . N

After IN N
returning VBG N
to TO N
baseline VB N
, , N
Abeta NNP o
concentrations NNS o
were VBD N
transiently RB N
increased VBN N
. . N

CSF NNP o
Abeta NNP o
concentrations NNS o
were VBD N
unchanged JJ N
. . N

Adverse JJ o
events NNS o
reported VBN N
by IN N
subjects NNS N
taking VBG N
5-mg JJ N
, , N
20-mg JJ N
, , N
or CC N
40-mg JJ N
doses NNS N
were VBD N
similar JJ N
to TO N
those DT N
reported VBN N
by IN N
subjects NNS p
taking VBG p
placebo NN p
. . p

Two CD N
of IN N
7 CD N
subjects NNS N
taking VBG N
50 CD N
mg/day NN N
experienced VBD N
adverse JJ N
events NNS N
that WDT N
may MD N
have VB N
been VBN N
drug NN N
related VBN N
. . N

In IN N
this DT N
phase NN N
1 CD N
volunteer NN N
study NN N
, , N
reported VBD N
adverse JJ N
events NNS N
after IN N
taking VBG N
LY450139 NNP i
were VBD N
manageable JJ N
. . N

A DT N
dose-dependent JJ N
reduction NN N
in IN N
plasma NN o
Abeta NNP o
was VBD N
demonstrated VBN N
, , N
and CC N
changes NNS N
in IN N
plasma NN o
Abeta NNP o
concentrations NNS N
were VBD N
temporally RB N
related VBN N
to TO N
the DT N
pharmacokinetic JJ N
characteristics NNS N
of IN N
LY450139 NNP N
. . N

-DOCSTART- -22273828- O O

Comparison NNP N
of IN N
the DT N
antiemetic JJ N
effect NN N
of IN N
ramosetron NN i
and CC N
combined VBN i
ramosetron NN i
and CC i
midazolam NN i
in IN N
children NNS p
: : p
a DT N
double-blind NN N
, , N
randomised VBD N
clinical JJ N
trial NN N
. . N

CONTEXT NNP N
Postoperative NNP N
nausea NN N
and CC N
vomiting NN N
remains VBZ N
a DT N
clinically RB N
important JJ N
problem NN N
after IN N
strabismus NN p
surgery NN p
in IN p
children NNS p
. . p

OBJECTIVE NN N
To TO N
study VB N
the DT N
benefit NN N
of IN N
adding VBG N
midazolam NN i
to TO i
ramosetron VB i
on IN N
the DT N
incidence NN N
of IN N
postoperative JJ N
nausea NN N
, , N
retching VBG N
or CC N
vomiting VBG N
and CC N
on IN N
the DT N
incidence NN N
of IN N
postoperative JJ N
agitation NN N
. . N

DESIGN VB N
A DT N
randomised JJ N
, , N
double-blind JJ N
comparison NN N
. . N

SETTING CC N
The DT p
operating NN p
theatre NN p
suite NN p
and CC p
day NN p
care NN p
unit NN p
of IN p
Seoul NNP p
National NNP p
University NNP p
Hospital NNP p
. . p

The DT N
study NN N
period NN N
was VBD N
January NNP N
to TO N
December NNP N
2010 CD N
. . N

PATIENTS VB N
In IN N
total JJ N
, , N
405 CD p
paediatric JJ p
patients NNS p
( ( p
aged VBN p
4-12 CD p
years NNS p
) ) p
undergoing VBG p
strabismus JJ i
surgery NN i
were VBD N
enrolled VBN N
and CC N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
two CD N
groups NNS N
, , N
ramosetron NN i
or CC i
ramosetron NN i
with IN i
midazolam NN i
. . i

INTERVENTION NN N
Patients NNPS N
received VBD N
either DT N
ramosetron NN i
6 CD i
?g JJ i
kg NN i
or CC i
ramosetron VB i
6 CD i
?g NNP i
kg NN i
and CC i
midazolam $ i
0.1 CD i
mg NN N
kg NN N
prior RB N
to TO N
induction NN N
of IN N
anaesthesia NN N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
The DT N
incidences NNS N
of IN N
nausea NN N
, , N
retching VBG N
or CC N
vomiting VBG N
in IN N
the DT N
first JJ N
48 CD N
h NN N
after IN N
surgery NN N
, , N
and CC N
the DT N
incidence NN N
of IN N
emergence NN N
agitation NN N
in IN N
the DT N
post-anaesthetic JJ N
care NN N
unit NN N
. . N

RESULT VB N
The DT N
incidences NNS N
of IN N
nausea NN N
, , N
retching VBG N
or CC N
vomiting VBG N
during IN N
the DT N
first JJ N
and CC N
second JJ N
24-h JJ N
periods NNS N
after IN N
surgery NN N
were VBD N
similar JJ N
in IN N
the DT N
two CD N
groups NNS N
. . N

There EX N
was VBD N
a DT N
small JJ N
, , N
clinically RB N
insignificant JJ N
reduction NN N
in IN N
delirium NN N
scores NNS N
in IN N
the DT i
ramosetron NN i
with IN i
midazolam JJ i
group NN i
. . i

CONCLUSION NNP N
Adding NNP i
midazolam NN i
to TO i
ramosetron VB i
had VBD i
no DT N
advantages NNS N
over IN i
ramosetron NN i
alone RB i
in IN N
reducing VBG N
the DT N
incidence NN N
of IN N
postoperative JJ N
nausea NN N
and CC N
vomiting NN N
in IN N
children NNS N
undergoing VBG i
strabismus NN i
surgery NN i
. . i

-DOCSTART- -21419391- O O

Evaluation NN N
of IN N
a DT N
preventive JJ i
intervention NN i
for IN N
child JJ p
anxiety NN p
in IN N
two CD N
randomized JJ N
attention-control JJ N
school NN N
trials NNS N
. . N

The DT N
present JJ N
research NN N
examined VBD N
the DT N
effectiveness NN N
of IN N
a DT N
cognitive-behavioral JJ o
therapy NN o
( ( i
CBT NNP i
) ) i
based VBN i
intervention NN i
program NN i
, , i
FRIENDS NNP i
, , N
for IN p
children NNS p
from IN p
grades NNS p
4 CD p
to TO p
6 CD p
, , p
using VBG p
random JJ p
assignment NN p
at IN p
the DT p
school-level NN p
and CC N
an DT N
attention-control JJ N
design NN N
in IN N
two CD N
longitudinal JJ N
studies NNS N
. . N

The DT N
first JJ N
study NN N
targeted VBD N
children NNS p
with IN p
anxiety NN o
symptoms NNS o
( ( p
N=191 NNP p
, , p
mean JJ p
age=10.1 NN p
) ) p
as IN p
screened VBN p
with IN p
self NN p
, , p
parent NN p
, , p
and CC p
teacher-reports NNS p
; : p
the DT p
second JJ p
study NN p
took VBD p
a DT p
universal JJ p
approach NN p
with IN p
full JJ p
classrooms NNS p
of IN p
children NNS p
participating VBG p
( ( p
N=253 NNP p
, , p
mean JJ p
age=9.8 NN p
) ) p
. . p

The DT N
results NNS N
showed VBD N
no DT N
intervention NN N
effect NN N
in IN N
both DT N
studies NNS N
, , N
with IN o
children NNS o
's POS o
anxiety NN o
symptoms NNS o
decreasing VBG N
over IN N
time NN N
regardless NN N
of IN N
whether IN N
they PRP N
were VBD N
in IN N
the DT i
story-reading NN i
( ( N
attention NN N
control NN N
) ) N
or CC i
FRIENDS JJ i
condition NN N
. . N

The DT N
findings NNS N
also RB N
indicated VBD N
that IN N
girls NNS N
reported VBD N
a DT N
higher JJR o
level NN o
of IN o
anxiety NN o
than IN N
boys NNS N
and CC N
children NNS N
in IN N
higher JJR N
grades NNS N
reported VBD N
lower JJR o
anxiety NN o
relative NN N
to TO N
younger JJR N
children NNS N
in IN N
both DT N
studies NNS N
. . N

In IN N
addition NN N
, , N
similar JJ N
patterns NNS N
were VBD N
found VBN N
using VBG N
a DT N
subgroup NN N
of IN p
children NNS p
with IN o
high-anxiety NN o
symptoms NNS o
from IN N
both DT N
studies NNS N
. . N

-DOCSTART- -22682024- O O

Effectiveness NN N
and CC N
durability NN N
of IN N
Interceptor? NNP i
long-lasting JJ i
insecticidal JJ i
nets NNS i
in IN p
a DT p
malaria NN p
endemic JJ p
area NN p
of IN p
central JJ p
India NNP p
. . p

BACKGROUND NNP N
In IN N
the DT N
present JJ N
study NN N
, , N
Interceptor? NNP i
, , i
long-lasting JJ i
polyester NN i
net NN i
, , i
75 CD i
denier NN i
and CC i
bursting VBG i
strength NN i
of IN i
minimum JJ i
250 CD i
kPa NN i
coated VBN i
with IN i
alpha-cypermethrin JJ i
@ NNS i
200 CD i
mg/m? NN i
was VBD i
evaluated VBN N
for IN N
its PRP$ N
efficacy NN N
in IN N
reducing VBG N
the DT N
mosquito NN N
density NN N
, , N
blood NN N
feeding NN N
inhibition NN N
and CC N
malaria NN o
incidence NN o
in IN p
a DT p
tribal NN p
dominated VBN p
malaria NNS p
endemic JJ p
area NN p
in IN p
Chhattisgarh NNP p
state NN p
, , p
central JJ p
India NNP p
. . p

Its PRP$ p
durability NN N
, , N
washing VBG N
practices NNS N
and CC N
usage JJ N
pattern NN N
by IN N
the DT N
community NN p
was VBD p
also RB N
assessed VBN N
up RP N
to TO N
a DT N
period NN N
of IN N
three CD N
years NNS N
. . N

METHODS PDT N
The DT N
study NN N
was VBD N
carried VBN N
out RP N
in IN N
two CD N
phases NNS N
. . N

In IN N
the DT N
first JJ N
phase NN p
( ( p
September NNP p
2006 CD p
to TO p
August NNP p
2007 CD p
) ) p
, , p
16 CD p
malaria NNS p
endemic JJ p
villages NNS p
in IN p
district NN p
Kanker NNP p
were VBD p
randomized VBN N
into IN N
three CD N
groups NNS N
, , N
viz NN N
. . i

Interceptor JJ i
net JJ i
( ( i
LN NNP i
) ) i
, , i
untreated JJ i
polyester NN i
net NN i
( ( i
100 CD i
denier NN i
) ) i
and CC i
without IN i
net NN i
. . i

Malaria NNP i
cases NNS N
were VBD N
detected VBN N
by IN N
undertaking VBG N
fortnightly RB N
surveillance VBN N
by IN N
home NN N
visits NNS N
and CC N
treated VBD N
as IN N
per IN N
the DT N
national JJ N
drug NN N
policy NN N
. . N

Mosquito NNP N
collections NNS N
were VBD N
made VBN N
by IN N
hand NN N
catch NN N
and CC N
pyrethrum JJ N
space NN N
spray NN N
methods NNS N
from IN N
human JJ N
dwellings NNS N
once RB N
every DT N
month NN N
. . N

Slide NNP N
positivity NN N
rate NN N
( ( N
SPR NNP N
) ) N
and CC N
malaria $ N
incidence NN N
per IN N
1000 CD N
population NN N
( ( N
PI NNP N
) ) N
were VBD N
compared VBN N
between IN N
the DT N
three CD N
study NN N
arms NNS N
to TO N
assess VB N
the DT N
impact NN N
of IN N
use NN N
of IN N
Interceptor NNP N
nets NNS N
. . N

Simultaneously RB N
, , N
wash JJ N
resistance NN N
studies NNS N
were VBD N
carried VBN N
out RP N
in IN N
the DT N
laboratory NN N
by IN N
doing VBG N
cone NN N
bioassays NNS N
on IN N
Interceptor NNP i
LNs NNP i
washed VBD i
up RB N
to TO N
20 CD N
times NNS N
. . N

Activities NNS N
undertaken VBP N
in IN N
second JJ N
Phase NNP N
( ( N
April NNP N
2008 CD N
to TO N
October NNP N
2009 CD N
) ) N
after IN N
an DT N
interval NN N
of IN N
about IN N
18 CD N
months NNS N
post-net JJ N
distribution NN N
included VBD N
questionnaire NN N
based VBN N
surveys NNS N
at IN N
every DT N
six CD N
months NNS N
, , N
i.e NN N
. . N

18 CD N
, , N
24 CD N
, , N
30 CD N
and CC N
36 CD N
months NNS N
to TO N
observe VB N
durability NN N
, , N
usage JJ N
pattern NN N
of IN N
LNs NNP N
and CC N
washing VBG N
practices NNS N
by IN N
the DT N
community NN p
. . p

After IN p
36 CD N
months NNS N
of IN N
field NN N
use NN N
, , N
30 CD N
nets NNS N
were VBD N
retrieved VBN N
and CC N
sampled VBN N
destructively RB N
for IN N
chemical NN N
analysis NN N
. . N

RESULTS NNP i
Interceptor NNP i
nets NNS i
were VBD i
found VBN o
effective JJ o
in IN o
reducing VBG N
the DT N
density NN o
, , o
parity NN o
rate NN o
and CC o
blood NN o
feeding NN o
success NN o
rate NN o
of IN o
main JJ o
malaria NNS o
vector NN o
Anopheles NNP o
culicifacies NNS o
as IN o
compared VBN N
to TO N
that DT N
in IN N
untreated JJ i
net NN i
and CC i
no DT i
net JJ i
villages NNS o
. . o

SPR NNP o
in IN o
LN NNP N
villages NNS N
was VBD N
3.7 CD N
% NN N
as IN N
compared VBN N
to TO N
6.5 CD N
% NN N
in IN N
untreated JJ N
and CC N
11 CD N
% NN N
in IN N
no DT N
net JJ N
villages NNS o
. . o

PI NNP o
in IN N
LN NNP N
villages NNS N
was VBD N
16.4 CD N
in IN N
comparison NN N
to TO N
24.8 CD N
and CC N
44.2 CD N
in IN N
untreated JJ N
polyester NN N
net NN N
and CC N
no DT N
net JJ N
villages NNS N
respectively RB N
. . N

In IN N
surveys NNS N
carried VBD N
out RP N
after IN N
three CD N
years NNS N
of IN N
initial JJ N
distribution NN N
, , N
78.7 CD N
% NN N
( ( N
737/936 CD N
) ) N
nets NNS N
were VBD N
still RB N
in IN N
possession NN N
with IN N
the DT N
households NNS N
, , N
of IN N
which WDT N
68 CD N
% NN N
were VBD N
used VBN N
every DT N
night NN N
. . N

An DT N
. . N

culicifacies NNS o
mortality NN o
was VBD o
> JJ N
80 CD N
% NN N
in IN N
cone NN N
bioassays NNS N
done VBN N
on IN N
LNs NNP N
washed VBD N
up RB N
to TO N
20 CD N
times NNS N
in IN N
laboratory NN o
. . o

Mean JJ o
alpha-cypermethrin JJ o
content NN o
was VBD o
43.5 CD N
? . N
31.7 CD N
mg/m? NN N
on IN N
Interceptor NNP N
LNs NNP N
withdrawn NN N
after IN N
three CD N
years NNS N
of IN N
household NN N
use NN N
against IN N
the DT N
baseline JJ N
specification NN N
of IN N
200 CD N
mg/m? NN N
. . N

A DT N
gradual JJ N
increase NN N
in IN N
the DT N
proportion NN o
of IN o
holed JJ o
nets NNS o
was VBD N
observed VBN N
with IN N
the DT N
increased JJ N
period NN N
of IN N
usage NN N
. . N

CONCLUSION NNP i
Interceptor NNP i
nets NNS i
were VBD N
highly RB N
effective JJ o
in IN o
reducing VBG o
vector NN N
densities NNS N
as RB N
well RB N
as IN N
malaria NNS N
incidence NN N
in IN N
the DT N
study NN p
villages NNS p
. . p

Availability NNP p
of IN N
78 CD N
% NN N
nets NNS N
with IN N
the DT N
households NNS N
in IN N
usable JJ N
condition NN N
clearly RB N
indicated JJ N
durability NN N
of IN N
Interceptor NNP N
LNs NNP N
up RB N
to TO N
three CD N
years NNS N
in IN N
the DT N
rural JJ N
setting NN p
of IN p
India NNP p
. . N

The DT N
nets NNS N
were VBD N
found VBN N
to TO N
contain VB o
an DT o
effective JJ o
concentration NN o
of IN N
alpha-cypermethrin JJ N
against IN N
malaria NNS N
vector NN N
after IN N
three CD N
years NNS N
of IN N
household NN N
use NN N
. . N

-DOCSTART- -7742155- O O

The DT N
effect NN N
of IN N
fasting VBG i
on IN N
total JJ o
serum NN o
bilirubin NN o
concentrations NNS o
. . o

Thirty-seven NNP p
healthy JJ p
volunteers NNS p
, , p
19 CD p
of IN p
whom WP p
had VBD p
consistently RB p
elevated VBN p
total JJ o
serum NN o
bilirubin NN o
( ( o
TSB NNP o
) ) o
concentrations NNS o
, , p
took VBD p
part NN p
in IN N
an DT N
open JJ N
, , N
randomised VBD N
cross-over NN N
study NN N
to TO N
determine VB N
the DT N
effect NN N
of IN N
fasting VBG i
on IN N
TSB NNP N
concentrations NNS N
. . N

The DT N
study NN N
comprised VBD N
of IN N
two CD N
treatments NNS N
. . N

During IN N
one CD N
treatment NN N
period NN N
volunteers NNS p
ate VBP i
a DT i
standard JJ i
supper NN i
but CC i
fasted VBD i
for IN i
24 CD i
h NN i
thereafter RB i
. . i

During IN N
the DT N
other JJ N
treatment NN N
period NN N
volunteers NNS p
ate VBP N
a DT N
standard JJ i
supper NN i
, , i
snacks NNS i
, , i
breakfast NN i
and CC i
lunch NN i
. . i

TSB NNP o
concentrations NNS o
were VBD N
measured VBN N
at IN N
regular JJ N
intervals NNS N
. . N

In IN N
both DT N
the DT N
normal JJ N
and CC N
high JJ N
bilirubin NN N
groups NNS N
, , N
minimum JJ o
TSB NNP o
values NNS o
were VBD N
recorded VBN N
4 CD N
h NN N
after IN N
the DT N
supper NN N
. . N

A DT N
24 CD N
h NN N
fast RB N
more RBR o
than IN o
doubled VBD o
TSB NNP o
concentration NN o
from IN N
baseline NN N
values NNS N
in IN N
both DT N
the DT N
normal JJ N
and CC N
high JJ N
bilirubin NN N
groups NNS N
. . N

A DT N
clinically RB N
relevant JJ N
rise NN o
in IN o
TSB NNP o
took VBD N
place NN N
after IN N
12 CD N
h NN N
into IN N
the DT N
fasting JJ N
period NN N
( ( N
TSB NNP N
of IN N
17.3 CD N
mumol JJ N
l-1 NN N
in IN N
the DT N
fasted JJ N
group NN N
vs VBD N
14.0 CD N
mumol JJ N
l-1 NN N
in IN N
the DT N
non-fasted JJ N
group NN N
) ) N
. . N

When WRB N
designing VBG N
a DT N
clinical JJ N
trial NN N
, , N
selecting VBG N
volunteers NNS p
, , N
or CC N
judging VBG N
the DT N
tolerance NN N
of IN N
a DT N
new JJ N
drug NN N
, , N
the DT N
rise NN N
in IN N
TSB NNP o
caused VBN N
by IN N
fasting VBG N
must MD N
therefore RB N
be VB N
taken VBN N
into IN N
account NN N
, , N
particularly RB N
in IN N
trials NNS N
where WRB N
volunteers NNS p
or CC N
patients NNS N
fast JJ N
before IN N
entering VBG N
the DT N
study NN N
. . N

-DOCSTART- -23400613- O O

Disparities NNS N
in IN N
transition NN i
planning NN i
for IN N
youth NN p
with IN p
autism NN p
spectrum NN p
disorder NN p
. . p

OBJECTIVE NNP N
Little NNP N
is VBZ N
known VBN N
about IN N
accessibility NN N
to TO N
health NN i
care NN i
transition NN i
( ( i
HCT NNP i
) ) i
services NNS N
for IN N
youth NN p
with IN p
autism NN p
spectrum NN p
disorder NN p
( ( p
ASD NNP p
) ) p
. . p

This DT N
study NN N
expands VBZ N
our PRP$ N
understanding JJ N
by IN N
examining VBG N
the DT N
receipt NN N
of IN N
HCT NNP N
services NNS N
in IN N
youth NN p
with IN p
ASD NNP p
compared VBN p
with IN p
youth NN p
with IN p
other JJ p
special JJ p
health NN p
care NN p
needs NNS p
( ( p
OSHCN NNP p
) ) p
. . p

METHODS NNP N
We PRP p
used VBD p
the DT p
2005-2006 JJ p
National NNP p
Survey NNP p
of IN p
Children NNP p
with IN p
Special NNP p
Health NNP p
Care NNP p
Needs NNP p
to TO p
examine VB p
receipt NN p
of IN p
HCT NNP i
services NNS i
for IN p
youth NN p
( ( p
aged VBN p
12-17 CD p
years NNS p
) ) p
with IN p
ASD NNP p
and CC p
youth NN p
with IN p
OSHCN NNP p
. . p

Logistic JJ N
regression NN N
analyses NNS N
explored VBD N
whether IN N
individual JJ N
, , N
family NN N
, , N
or CC N
health NN N
system NN N
factors NNS N
were VBD N
associated VBN N
with IN N
receipt NN N
of IN N
HCT NNP N
services NNS N
for IN N
youth NN N
with IN N
ASD NNP N
. . N

RESULTS NNP N
Whereas NNP N
half NN N
of IN N
youth NN N
with IN N
OSHCN NNP N
received VBD N
HCT NNP o
services NNS o
, , N
less JJR N
than IN N
a DT N
quarter NN N
of IN N
youth NN N
with IN N
ASD NNP N
did VBD N
. . N

Only RB N
14 CD N
% NN N
of IN N
youth NN N
with IN N
ASD NNP N
had VBD N
a DT N
discussion NN N
with IN N
their PRP$ N
pediatrician JJ N
about IN N
transitioning VBG N
to TO N
an DT N
adult NN N
provider NN N
, , N
less JJR N
than IN N
a DT N
quarter NN N
had VBD N
a DT N
discussion NN N
about IN N
health NN o
insurance NN o
retention NN o
, , N
and CC N
just RB N
under IN N
half NN N
discussed VBN N
adult NN o
health NN o
care NN o
needs NNS o
or CC o
were VBD o
encouraged VBN o
to TO o
take VB o
on IN o
appropriate JJ o
responsibility NN o
. . o

Logistic JJ N
regression NN N
analyses NNS N
indicated VBD N
that IN N
having VBG N
a DT N
developmental JJ N
disability NN N
or CC N
multiple JJ N
health NN N
conditions NNS N
in IN N
addition NN N
to TO N
ASD NNP N
and CC N
quality NN N
of IN N
health NN N
care NN N
were VBD N
strong JJ N
predictors NNS N
of IN N
HCT NNP o
, , N
whereas JJ N
demographic JJ N
and CC N
family NN N
variables NNS N
accounted VBD N
for IN N
little JJ N
variance NN N
. . N

CONCLUSIONS NNP N
Youth NNP p
with IN p
ASD NNP p
experience NN N
disparities NNS N
in IN N
access NN N
to TO N
HCT NNP i
services NNS N
. . N

Youth NN p
with IN p
comorbid JJ p
conditions NNS p
are VBP N
at IN N
greatest JJS N
risk NN N
for IN N
poor JJ N
access NN N
to TO N
HCT NNP i
services NNS N
and CC N
increased JJ N
quality NN N
of IN N
care NN N
has VBZ N
a DT N
positive JJ N
effect NN N
. . N

Research NNP N
is VBZ N
needed VBN N
to TO N
understand VB N
barriers NNS N
to TO N
care VB N
and CC N
develop VB N
policy NN N
and CC N
practice NN N
guidelines NNS N
tailored VBD N
for IN N
youth NN p
with IN p
ASD NNP p
. . p

-DOCSTART- -11196396- O O

Comparison NNP N
of IN N
the DT N
efficacy NN N
of IN N
fluoxetine NN i
alone RB i
vs. FW i
fluoxetine JJ i
plus CC i
local JJ i
lidocaine NN i
ointment NN i
in IN N
the DT N
treatment NN N
of IN N
premature JJ p
ejaculation NN p
. . p

OBJECTIVE CC N
The DT N
present JJ N
study NN N
compares VBZ N
the DT N
efficacy NN N
and CC N
side JJ N
effects NNS N
of IN N
fluoxetine NN i
alone RB i
vs. FW i
fluoxetine JJ i
plus CC i
local JJ i
lidocaine NN i
ointment NN i
in IN N
the DT N
treatment NN N
of IN N
premature JJ p
ejaculation NN p
. . p

METHODS NNP N
Forty-three JJ p
patients NNS p
suffering VBG p
from IN p
premature JJ p
ejaculation NN p
were VBD N
studied VBN N
. . N

The DT p
exclusion NN p
criteria NNS p
were VBD p
erectile JJ p
dysfunction NN p
, , p
loss NN p
of IN p
libido NN p
, , p
alcohol NN p
and CC p
substance NN p
abuse NN p
, , p
mental JJ p
retardation NN p
, , p
diabetes VBZ p
mellitus NN p
, , p
thyroid JJ p
disease NN p
, , p
hypotension NN p
, , p
previous JJ p
use NN p
of IN p
these DT p
drugs NNS p
and CC p
urogenital JJ p
infections NNS p
. . p

The DT p
patients NNS p
' POS p
ages NNS p
ranged VBD p
from IN p
19 CD p
to TO p
48 CD p
years NNS p
( ( p
mean JJ p
age NN p
28 CD p
+/- JJ p
1.6 CD p
) ) p
. . p

They PRP p
had VBD p
regular JJ p
sexual JJ p
lives NNS p
. . p

They PRP p
had VBD p
normal JJ p
psychiatric JJ p
consultation NN p
and CC p
the DT p
Glombock NNP o
Rast NNP o
Sexual NNP o
Satisfactory NNP o
Test NNP o
( ( o
GRISS NNP o
) ) o
psychiatric JJ o
test NN o
were VBD p
in IN p
accordance NN p
with IN p
premature JJ p
ejaculation NN p
. . p

RESULTS VB N
The DT N
patients NNS N
were VBD N
assigned VBN N
to TO N
two CD N
groups NNS N
. . N

Twenty-six JJ N
patients NNS N
, , N
aged VBD N
21 CD N
to TO N
36 CD N
years NNS N
( ( N
mean JJ N
age NN N
27 CD N
) ) N
, , N
received VBD N
only RB N
fluoxetine JJ i
20 CD N
mg/day NN N
( ( N
1 CD N
capsule NN N
) ) N
for IN N
a DT N
week NN N
which WDT N
was VBD N
later RBR N
increased VBN N
to TO N
40 CD N
mg/day NN N
( ( N
2 CD N
capsules NNS N
) ) N
. . N

Seventeen JJ N
patients NNS N
, , N
aged VBD N
19 CD N
to TO N
48 CD N
years NNS N
( ( N
mean JJ N
age NN N
31 CD N
) ) N
, , N
were VBD N
given VBN N
fluoxetine JJ i
20 CD N
mg/day JJ N
plus CC N
local JJ N
application NN N
of IN N
lidocaine JJ i
ointment NN i
. . i

The DT N
patients NNS N
and CC N
partners NNS N
were VBD N
re-evaluated JJ N
8 CD N
weeks NNS N
after IN N
the DT N
treatment NN N
. . N

The DT N
results NNS N
were VBD N
classified VBN N
as IN N
unsuccessful JJ o
, , o
improvement NN o
and CC o
cure NN o
. . o

The DT N
chi-square JJ o
test NN o
was VBD N
used VBN N
for IN N
statistical JJ N
analysis NN N
. . N

In IN N
the DT N
fluoxetine NN N
group NN N
, , N
8 CD N
( ( N
30.8 CD N
% NN N
) ) N
patients NNS N
cured VBD o
, , N
11 CD N
( ( N
42.2 CD N
% NN N
) ) N
showed VBD N
improvement NN o
and CC N
there EX N
were VBD N
7 CD N
failures NNS o
( ( N
26.9 CD N
% NN N
) ) N
. . N

In IN N
the DT N
combination NN N
treatment NN N
group NN N
, , N
9 CD N
( ( N
52.9 CD N
% NN N
) ) N
patients NNS N
cured VBN N
, , N
improvement NN o
was VBD N
observed VBN N
in IN N
5 CD N
( ( N
29.4 CD N
% NN N
) ) N
and CC N
failure NN N
in IN N
3 CD N
( ( N
17.6 CD N
% NN N
) ) N
. . N

Side JJ N
effects NNS N
in IN N
group NN N
I PRP N
were VBD N
observed VBN N
in IN N
6 CD N
patients NNS N
( ( N
23 CD N
% NN N
) ) N
and CC N
in IN N
5 CD N
( ( N
29.4 CD N
% NN N
) ) N
in IN N
group NN N
II NNP N
. . N

There EX N
were VBD N
no DT N
statistical JJ N
differences NNS N
between IN N
the DT N
two CD N
groups NNS N
according VBG N
to TO N
the DT N
side NN N
effects NNS N
( ( N
p JJ N
> NNP N
0.01 CD N
) ) N
. . N

No UH p
patients NNS p
were VBD p
excluded VBN p
from IN p
the DT p
study NN p
due JJ p
to TO p
side VB p
effects NNS p
. . p

CONCLUSION VB N
The DT N
combination NN N
of IN N
fluoxetine JJ i
plus CC N
local JJ N
application NN N
of IN N
lidocaine JJ i
ointment NN N
was VBD N
found VBN N
to TO N
be VB N
more RBR N
effective JJ N
than IN N
fluoxetine VB i
alone RB N
in IN N
the DT N
treatment NN N
of IN N
premature JJ p
ejaculation NN p
. . p

However RB N
, , N
the DT N
results NNS N
should MD N
be VB N
confirmed VBN N
in IN N
further JJ N
studies NNS N
with IN N
a DT N
placebo NN N
group NN N
to TO N
rule VB N
out IN N
the DT N
placebo NN N
effect NN N
. . N

-DOCSTART- -22512510- O O

The DT N
Social NNP N
Communication NNP N
Intervention NNP N
Project NNP N
: : N
a DT N
randomized NN N
controlled VBN N
trial NN N
of IN N
the DT N
effectiveness NN N
of IN N
speech NN N
and CC N
language NN N
therapy NN N
for IN N
school-age JJ p
children NNS p
who WP p
have VBP p
pragmatic JJ p
and CC p
social JJ p
communication NN p
problems NNS p
with IN p
or CC p
without IN p
autism NN p
spectrum NN p
disorder NN p
. . p

BACKGROUND NNP N
Children NNPS p
who WP p
show VBP p
disproportionate JJ p
difficulty NN p
with IN p
the DT p
pragmatic JJ p
as IN p
compared VBN p
with IN p
the DT p
structural JJ p
aspects NNS p
of IN p
language NN p
are VBP p
described VBN p
as IN p
having VBG p
pragmatic JJ p
language NN p
impairment NN p
( ( p
PLI NNP p
) ) p
or CC p
social JJ p
communication NN p
disorder NN p
( ( p
SCD NNP p
) ) p
. . p

Some DT N
children NNS N
who WP N
have VBP N
PLI NNP N
also RB N
show VBP N
mild JJ N
social JJ N
impairments NNS N
associated VBN N
with IN N
high-functioning JJ N
autism NN N
or CC N
autism NN N
spectrum JJ N
disorder NN N
( ( N
ASD NNP N
) ) N
. . N

There EX N
is VBZ N
little JJ N
robust JJ N
evidence NN N
of IN N
effectiveness NN N
of IN N
speech-language NN N
interventions NNS N
which WDT N
target VBP N
the DT N
language NN N
, , N
pragmatic JJ N
or CC N
social JJ N
communication NN N
needs NNS N
of IN N
these DT N
children NNS N
. . N

AIMS NNP N
To TO N
evaluate VB N
the DT N
effectiveness NN N
of IN N
an DT N
intensive JJ i
manualized VBN i
social JJ i
communication NN i
intervention NN i
( ( i
SCIP NNP i
) ) i
for IN N
children NNS p
who WP p
have VBP p
PLI VBN p
with IN p
or CC p
without IN p
features NNS p
of IN p
ASD NNP p
. . p

METHODS NNP N
& CC N
PROCEDURES NNP N
In IN N
a DT N
single-blind JJ N
RCT NNP N
design NN N
, , N
88 CD p
children NNS p
with IN p
pragmatic JJ p
and CC p
social JJ p
communication NN p
needs NNS p
aged VBD p
5 CD p
; : p
11-10 JJ p
; : p
8 CD p
, , p
recruited VBN p
from IN p
UK NNP p
speech NN p
and CC p
language NN p
therapy NN p
services NNS p
, , N
were VBD N
randomly RB N
assigned VBN N
in IN N
a DT N
2:1 CD N
ratio NN N
to TO N
SCIP NNP i
or CC N
to TO N
treatment-as-usual JJ i
. . i

Children NNP p
in IN p
the DT p
SCIP NNP i
condition NN p
received VBD N
up RB N
to TO N
20 CD i
sessions NNS i
of IN i
direct JJ i
intervention NN i
from IN i
a DT i
specialist JJ i
research NN i
speech NN i
and CC i
language NN i
therapist NN i
working VBG i
with IN i
supervised JJ i
assistants NNS i
. . i

All DT N
therapy NN N
content NN N
and CC N
methodology NN N
was VBD N
derived VBN N
from IN N
an DT N
intervention NN N
manual NN N
. . N

A DT N
primary JJ N
outcome JJ N
measure NN N
of IN N
structural JJ o
language NN o
and CC N
secondary JJ N
outcome NN N
measures NNS N
of IN N
narrative JJ o
, , o
parent-reported JJ o
pragmatic JJ o
functioning NN o
and CC o
social JJ o
communication NN o
, , o
blind-rated JJ o
perceptions NNS o
of IN o
conversational JJ o
competence NN o
and CC o
teacher-reported JJ o
ratings NNS o
of IN o
classroom NN o
learning VBG o
skills NNS o
were VBD N
taken VBN N
pre-intervention NN N
, , N
immediately RB N
post-intervention NN N
and CC N
at IN N
6-month JJ N
follow-up NN N
. . N

Analysis NN N
was VBD N
by IN N
intention NN N
to TO N
treat VB N
. . N

OUTCOMES NNP N
& CC N
RESULTS NNP N
No NNP N
significant JJ N
treatment NN N
effect NN N
was VBD N
found VBN N
for IN N
the DT N
primary JJ N
outcome JJ N
measure NN N
of IN N
structural JJ o
language NN o
ability NN o
or CC o
for IN o
a DT o
measure NN o
of IN o
narrative JJ o
ability NN o
. . o

Significant JJ N
treatment NN N
effects NNS N
were VBD N
found VBN N
for IN N
blind-rated JJ o
perceptions NNS o
of IN o
conversational JJ o
competence NN o
, , o
for IN o
parent-reported JJ o
measures NNS o
of IN o
pragmatic JJ o
functioning NN o
and CC o
social JJ o
communication NN o
, , o
and CC o
for IN o
teacher-reported JJ o
ratings NNS o
of IN o
classroom NN o
learning NN o
skills NNS o
. . o

CONCLUSIONS NNP N
& CC N
IMPLICATIONS NNP N
There EX N
is VBZ N
some DT N
evidence NN N
of IN N
an DT N
intervention NN N
effect NN N
on IN N
blind NN N
and CC N
parent/teacher-reported JJ N
communication NN N
outcomes NNS N
, , N
but CC N
not RB N
standardized JJ N
language NN N
assessment NN N
outcomes NNS N
, , N
for IN N
6-11-year-old JJ p
children NNS p
who WP p
have VBP p
pragmatic JJ p
and CC p
social JJ p
communication NN p
needs NNS p
. . p

These DT N
findings NNS N
are VBP N
discussed VBN N
in IN N
the DT N
context NN N
of IN N
the DT N
increasingly RB N
central JJ N
role NN N
of IN N
service NN N
user NN N
outcomes NNS N
in IN N
providing VBG N
evidence NN N
for IN N
an DT N
intervention NN N
. . N

The DT N
substantial JJ N
overlap NN N
between IN N
the DT N
presence NN N
of IN N
PLI NNP N
and CC N
ASD NNP N
( ( N
75 CD N
% NN N
) ) N
across IN N
the DT N
whole JJ N
cohort NN N
suggests VBZ N
that IN N
the DT N
intervention NN N
may MD N
also RB N
be VB N
applicable JJ N
to TO N
some DT N
verbally RB N
able JJ N
children NNS N
with IN N
ASD NNP N
who WP N
have VBP N
pragmatic JJ N
communication NN N
needs NNS N
. . N

-DOCSTART- -24069775- O O

A DT N
shortened JJ N
versus NN N
standard NN N
matched VBD N
postpartum JJ i
magnesium NN i
sulphate NN i
regimen NNS i
in IN N
the DT N
treatment NN N
of IN N
eclampsia NN p
: : p
a DT N
randomised JJ N
controlled VBN N
trial NN N
. . N

Magnesium NN i
sulphate NN i
is VBZ N
currently RB N
the DT N
most RBS N
ideal JJ N
drug NN N
for IN N
the DT N
treatment NN N
of IN N
eclampsia NN N
but CC N
its PRP$ N
use NN N
in IN N
Nigeria NNP N
is VBZ N
still RB N
limited JJ N
due JJ N
its PRP$ N
cost NN N
and CC N
clinicians NNS N
inexperience NN N
with IN N
the DT N
drug NN N
. . N

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
whether IN N
a DT N
shortened JJ N
postpartum NN N
course NN N
of IN N
magnesium NN i
sulphate NN i
is VBZ N
as RB N
effective JJ N
as IN N
the DT N
standard JJ N
Pritchard NNP N
regimen NN N
in IN N
controlling VBG N
fits NNS N
in IN N
eclampsia NN N
Between NNP p
January NNP p
and CC p
June NNP p
2011 CD p
, , p
98 CD p
eclamptic JJ p
mothers NNS p
presenting VBG p
at IN p
the DT p
labour JJ p
ward NN p
of IN p
the DT p
University NNP p
of IN p
Maiduguri NNP p
Teaching NNP p
Hospital NNP p
were VBD N
randomised VBN N
to TO N
receive VB N
either RB N
the DT N
standard JJ i
Pritchard NNP i
regimen NN i
of IN i
magnesium NN i
sulphate NN i
or CC N
a DT N
shortened JJ i
postpartum NN i
course NN i
in IN N
which WDT N
only RB N
two CD N
doses NNS N
of IN N
intramuscular JJ i
magnesium NN i
sulphate NN i
is VBZ N
given VBN N
four CD N
hours NNS N
apart RB N
. . N

The DT N
maternal JJ N
and CC N
fetal JJ N
outcomes NNS N
were VBD N
compared VBN N
. . N

The DT N
primary JJ N
outcome NN N
measure NN N
was VBD N
recurrence NN o
of IN o
fits NNS o
. . o

The DT N
recurrence NN o
of IN o
fits NNS o
and CC N
other JJ o
maternal JJ o
complications NNS o
were VBD N
similar JJ o
in IN N
the DT N
two CD N
groups NNS N
. . N

The DT N
total JJ o
dosage NN o
of IN o
magnesium NN o
sulphate NN o
in IN N
the DT N
shortened JJ N
group NN N
was VBD N
reduced VBN o
by IN N
40 CD N
% NN N
in IN N
66 CD N
% NN N
of IN N
patients NNS N
. . N

The DT N
shortened JJ N
postpartum NN N
course NN N
of IN N
magnesium NN i
sulphate NN o
is VBZ N
as RB N
effective JJ o
as IN N
the DT N
standard JJ N
Pritchard NNP N
regimen NN N
in IN N
the DT N
management NN o
of IN o
eclampsia NN o
. . o

-DOCSTART- -20203546- O O

Attenuation NN N
of IN N
hemodynamic JJ N
responses NNS N
to TO N
laryngoscopy VB N
and CC N
tracheal VB N
intubation NN N
during IN N
rapid JJ N
sequence NN N
induction NN N
: : N
remifentanil NN i
vs. FW N
lidocaine NN i
with IN i
esmolol NN i
. . i

AIM NNP N
This DT N
study NN N
was VBD N
designed VBN N
to TO N
compare VB N
the DT N
effectiveness NN N
of IN N
remifentanil NN i
vs. FW N
a DT N
lidocaine-esmolol JJ i
combination NN N
in IN N
blunting VBG N
the DT N
hemodynamic JJ o
response NN o
to TO N
laryngoscopy VB N
and CC N
intubation NN N
during IN N
rapid JJ N
sequence NN N
induction NN N
using VBG N
thiopental JJ N
and CC N
rocuronium NN N
in IN N
normotensive JJ p
patients NNS p
. . p

METHODS NNP N
Sixty-six JJ p
patients NNS p
with IN p
American JJ p
Society NNP p
of IN p
Anesthesiologists NNP p
( ( p
ASA NNP p
) ) p
physical JJ p
status NN p
class NN p
I PRP p
who WP p
required VBD p
tracheal JJ p
intubation NN p
for IN p
elective JJ p
surgery NN p
were VBD N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
two CD N
groups NNS N
. . N

Group NNP N
R NNP N
received VBD N
0.9 CD i
% NN i
saline NN i
10 CD i
ml NN i
and CC i
remifentanil VB i
1 CD i
microg/kg NN i
. . i

Group NNP N
LE NNP N
received VBD N
lidocaine JJ i
1.5 CD i
mg/kg NN i
and CC i
esmolol $ i
1.0 CD i
mg/kg NN i
. . i

Anesthesia NNP N
was VBD N
induced VBN N
with IN N
thiopental JJ i
sodium NN i
5 CD N
mg/kg NN N
, , N
followed VBN N
by IN N
rocuronium NN i
1.0 CD N
mg/kg NN N
. . N

Mean NNP o
arterial JJ o
pressure NN o
and CC o
heart NN o
rate NN o
were VBD N
recorded VBN N
at IN N
baseline NN N
, , N
after IN N
induction NN N
, , N
immediately RB N
after IN N
intubation NN N
and CC N
every DT N
minute NN N
for IN N
five CD N
minutes NNS N
after IN N
intubation NN N
. . N

RESULTS NNP N
Changes NNP N
in IN N
mean JJ o
arterial JJ o
pressure NN o
over IN o
time NN o
between IN N
the DT N
two CD N
groups NNS N
were VBD N
significantly RB N
different JJ N
( ( N
P NNP N
< NNP N
0.0001 CD N
) ) N
. . N

The DT N
maximum JJ o
pressor NN o
response NN o
was VBD N
observed VBN N
immediately RB N
after IN N
intubation NN N
, , N
at IN N
which WDT N
time NN N
the DT N
mean JJ o
arterial JJ o
pressure NN o
change NN o
from IN N
baseline NN N
in IN N
group NN N
LE NNP N
( ( N
29.7 CD N
% NN N
) ) N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NN N
: : N
116.1 CD N
, , N
121.9 CD N
) ) N
was VBD N
higher JJR N
than IN N
that DT N
in IN N
group NN N
R NNP N
( ( N
4.4 CD N
% NN N
) ) N
( ( N
95 CD N
% NN N
CI NNP N
: : N
92.9 CD N
, , N
98.5 CD N
) ) N
( ( N
P NNP N
< NNP N
0.0001 CD N
) ) N
. . N

Two CD N
patients NNS N
in IN N
group NN N
R NNP N
and CC N
15 CD N
patients NNS N
in IN N
group NN N
LE NNP N
developed VBD N
hypertension NN o
( ( N
odds NNS N
ratio VBP N
[ CD N
OR NNP N
] NN N
: : N
0.064 CD N
) ) N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

Changes NNS N
in IN N
heart NN o
rate NN o
over IN o
time NN o
between IN N
the DT N
two CD N
groups NNS N
were VBD N
not RB N
significantly RB N
different JJ N
( ( N
P=0.465 NNP N
) ) N
. . N

CONCLUSION VB N
The DT N
results NNS N
of IN N
this DT N
study NN N
show NN N
that IN N
remifentanil VBZ i
1 CD N
mg/kg NN N
is VBZ N
more RBR N
effective JJ N
than IN N
the DT N
combination NN N
of IN N
lidocaine JJ i
1.5 CD N
mg/kg NN N
and CC N
esmolol $ i
1 CD N
mg/kg NN N
for IN N
attenuating VBG N
the DT N
hemodynamic JJ o
responses NNS o
to TO N
rapid JJ N
sequence NN N
intubation NN N
. . N

-DOCSTART- -20164800- O O

Relief NN N
of IN N
periorbital JJ N
pain NN N
after IN N
acute JJ N
angle JJ N
closure NN N
glaucoma NN N
attack NN N
by IN N
botulinum NN i
toxin NN i
type NN i
A NNP i
. . i

PURPOSE NNP N
To TO N
assess VB N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
botulinum NN i
toxin NN i
type NN i
A NNP i
( ( i
BoNT-A NNP i
) ) i
injection NN N
in IN N
patients NNS p
suffering VBG p
from IN p
intractable JJ p
periorbital NN p
pain NN p
after IN p
acute JJ p
angle JJ p
closure NN p
glaucoma NN p
( ( p
AACG NNP p
) ) p
. . p

PATIENTS NNP N
AND CC N
METHODS NNP N
In IN N
this DT N
prospective JJ N
randomized VBN N
intervention NN N
study NN N
, , N
19 CD p
patients NNS p
suffering VBG p
from IN p
periorbital JJ p
pain NN p
after IN p
an DT p
AACG NNP p
attack NN p
were VBD N
injected VBN i
with IN i
BoNT-A NNP i
or CC i
placebo NN i
for IN N
pain NN N
relief NN N
. . N

Patients NNS N
were VBD N
assessed VBN N
on IN N
days NNS N
1 CD N
, , N
2 CD N
, , N
7 CD N
, , N
14 CD N
, , N
30 CD N
, , N
60 CD N
, , N
and CC N
90 CD N
. . N

The DT N
main JJ N
outcomes NNS N
were VBD N
mean JJ N
change NN N
of IN N
visual JJ N
analog NN N
rating NN N
scale NN N
( ( N
VARS NNP N
) ) N
and CC N
index NN N
scores NNS N
measured VBN N
through IN N
a DT N
quality-of-life JJ N
questionnaire NN N
( ( N
EQ-5D NNP N
) ) N
, , N
and CC N
changes NNS N
in IN N
the DT N
visual JJ o
analog NN o
scale NN o
( ( N
VAS NNP N
) ) N
, , N
all DT N
of IN N
which WDT N
were VBD N
assessed VBN N
at IN N
each DT N
visit NN N
. . N

A DT N
secondary JJ N
outcome NN N
was VBD N
the DT N
frequency NN N
and CC N
nature NN N
of IN N
adverse JJ N
events NNS N
and CC N
the DT N
number NN N
of IN N
patients NNS N
who WP N
withdrew VBP N
from IN N
the DT N
study NN N
as IN N
a DT N
result NN N
. . N

RESULTS NN N
In IN N
the DT N
treatment NN N
group NN N
( ( N
n=10 NN N
) ) N
, , N
the DT N
mean JJ o
index NN o
score NN o
of IN o
EQ-5D NNP o
and CC o
VAS NNP o
changed VBD N
significantly RB N
from IN N
the DT N
placebo NN i
group NN N
( ( N
by IN N
0.299 CD N
and CC N
2.61 CD N
, , N
respectively RB N
) ) N
from IN N
day NN N
2 CD N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

The DT N
VARS NNP o
of IN o
EQ-5D NNP o
also RB N
disclosed VBD N
significant JJ N
changes NNS N
from IN N
day NN N
2 CD N
( ( N
17 CD N
, , N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

In IN N
addition NN N
, , N
efficacy NN o
was VBD N
maintained VBN N
mainly RB N
between IN N
days NNS N
2 CD N
and CC N
60 CD N
but CC N
declined VBD N
slightly RB N
by IN N
day NN N
90 CD N
. . N

The DT N
most RBS N
frequently RB N
reported VBD N
treatment-related JJ N
adverse JJ N
events NNS N
in IN N
the DT N
treatment NN N
and CC N
placebo NN N
groups NNS N
were VBD N
local JJ o
tenderness NN o
( ( N
21 CD N
% NN N
) ) N
, , N
subcutaneous JJ o
hemorrhage NN o
( ( N
10.5 CD N
% NN N
) ) N
, , N
and CC N
conjunctivitis NN o
( ( N
10.5 CD N
% NN N
) ) N
. . N

No UH N
severe JJ o
adverse JJ o
events NNS o
were VBD N
reported VBN N
during IN N
the DT N
study NN N
or CC N
follow-up JJ N
period NN N
. . N

CONCLUSIONS NNP N
BoNT-A NNP i
is VBZ N
effective JJ N
and CC N
well RB N
tolerated VBN N
for IN N
the DT N
treatment NN N
of IN N
periorbital JJ N
pain NN N
after IN N
an DT N
AACG NNP N
attack NN N
. . N

Its PRP$ N
effects NNS N
may MD N
be VB N
maintained VBN N
for IN N
3 CD N
months NNS N
. . N

-DOCSTART- -16495253- O O

Pharmacokinetic JJ N
and CC N
safety NN N
evaluation NN N
of IN N
high-dose JJ N
combinations NNS N
of IN N
fosamprenavir NN N
and CC N
ritonavir NN N
. . N

High-dose JJ N
combinations NNS N
of IN N
fosamprenavir NN i
( ( i
FPV NNP i
) ) i
and CC i
ritonavir NN i
( ( i
RTV NNP i
) ) i
were VBD N
evaluated VBN N
in IN N
healthy JJ p
adult NN p
subjects NNS p
in IN N
order NN N
to TO N
select VB N
doses NNS N
for IN N
further JJ N
study NN N
in IN N
multiple JJ p
protease NN p
inhibitor NN p
( ( p
PI NNP p
) ) p
-experienced VBD p
patients NNS p
infected VBN p
with IN p
human JJ p
immunodeficiency NN p
virus NN p
type NN p
1 CD p
. . p

Two CD N
high-dose JJ N
regimens NNS N
, , N
FPV NNP i
1,400 CD N
mg NN N
twice RB N
a DT N
day NN N
( ( N
BID NNP N
) ) N
plus CC N
RTV $ i
100 CD N
mg NN N
BID NNP N
and CC N
FPV NNP i
1,400 CD N
mg NN N
BID NNP N
plus CC N
RTV NNP i
200 CD N
mg NN N
BID NNP N
, , N
were VBD N
planned VBN N
to TO N
be VB N
compared VBN N
to TO N
the DT N
approved JJ N
regimen NNS N
, , N
FPV NNP i
700 CD N
mg NN N
BID NNP N
plus CC N
RTV NNP i
100 CD N
mg NN N
BID NNP N
, , N
in IN N
a DT N
randomized JJ N
three-period NN N
crossover NN N
study NN N
. . N

Forty-two NNP p
healthy JJ p
adult NN p
subjects NNS p
were VBD p
enrolled VBN p
, , N
and CC N
39 CD N
subjects NNS N
completed VBN N
period NN N
1 CD N
. . N

Due JJ N
to TO N
marked VB N
hepatic JJ N
transaminase NN N
elevations NNS N
, , N
predominantly RB N
with IN N
FPV NNP i
1,400 CD N
mg NN N
BID NNP N
plus CC N
RTV NNP i
200 CD N
mg NN N
BID NNP N
, , N
the DT N
study NN N
was VBD N
terminated VBN N
prematurely RB N
. . N

For IN N
FPV NNP i
1,400 CD N
mg NN N
BID NNP N
plus CC N
RTV NNP i
100 CD N
mg NN N
BID NNP N
, , N
the DT N
values NNS o
for IN o
plasma NN o
amprenavir NN o
( ( o
APV NNP o
) ) o
area NN o
under IN o
the DT o
concentration-time JJ o
profile NN o
over IN o
the DT o
dosing VBG o
interval NN o
( ( o
tau NN o
) ) o
at IN o
steady JJ o
state NN o
[ NNS N
AUC NNP N
( ( N
0-tau JJ N
) ) N
] NN N
, , N
maximum JJ o
concentration NN o
of IN o
drug NN o
in IN o
plasma NN o
( ( o
C NNP o
( ( o
max NN o
) ) o
) ) o
, , o
and CC o
plasma JJ o
concentration NN o
at IN o
the DT o
end NN o
of IN o
tau NN o
at IN o
steady JJ o
state NN o
( ( o
C NNP o
( ( o
tau NN o
) ) o
) ) o
were VBD N
54 CD N
, , N
81 CD N
, , N
and CC N
26 CD N
% NN N
higher JJR N
, , N
respectively RB N
, , N
and CC N
the DT N
values NNS o
for IN o
plasma NN o
RTV NNP o
AUC NNP o
( ( o
0-tau JJ o
) ) o
, , o
C NNP o
( ( o
max NN o
) ) o
, , o
and CC o
C NNP o
( ( o
tau NN o
) ) o
were VBD N
49 CD N
% NN N
higher JJR N
, , N
71 CD N
% NN N
higher JJR N
, , N
and CC N
11 CD N
% NN N
lower JJR N
, , N
respectively RB N
, , N
than IN N
those DT N
for IN N
FPV NNP i
700 CD N
mg NN N
BID NNP N
plus CC N
RTV NNP N
100 CD N
mg NN N
BID NNP N
. . N

For IN N
FPV NNP i
1,400 CD N
mg NN N
BID NNP N
plus CC N
RTV NNP N
200 CD N
mg NN N
BID NNP N
, , N
the DT N
values NNS o
for IN o
plasma NN o
APV NNP o
AUC NNP o
( ( o
0-tau JJ o
) ) o
, , o
C NNP o
( ( o
max NN o
) ) o
, , o
and CC o
C NNP o
( ( o
tau NN o
) ) o
were VBD N
26 CD N
, , N
48 CD N
, , N
and CC N
32 CD N
% NN N
higher JJR N
, , N
respectively RB N
, , N
and CC N
the DT N
values NNS N
for IN N
plasma NN o
RTV NNP o
AUC NNP o
( ( o
0-tau JJ o
) ) o
, , o
C NNP o
( ( o
max NN o
) ) o
, , o
and CC o
C NNP o
( ( o
tau NN o
) ) o
increased VBD N
4.15-fold JJ N
, , N
4.17-fold JJ N
, , N
and CC N
3.99-fold JJ N
, , N
respectively RB N
, , N
compared VBN N
to TO N
those DT N
for IN N
FPV NNP i
700 CD N
mg NN N
BID NNP N
plus CC N
RTV NNP i
100 CD N
mg NN N
BID NNP N
. . N

FPV NNP i
1,400 CD N
mg NN N
BID NNP N
plus CC N
RTV NNP i
200 CD N
mg NN N
BID NNP N
is VBZ N
not RB N
recommended VBN N
due JJ N
to TO N
an DT N
increased VBN N
rate NN o
of IN o
marked VBN o
hepatic JJ o
transaminase NN o
elevations NNS o
and CC N
lack NN o
of IN o
pharmacokinetic JJ o
advantage NN o
. . o

FPV NNP i
1,400 CD N
mg NN N
BID NNP N
plus CC N
RTV NNP i
100 CD N
mg NN N
BID NNP N
is VBZ N
currently RB N
under IN N
clinical JJ N
evaluation NN N
in IN N
multiple JJ N
PI-experienced JJ N
patients NNS N
. . N

-DOCSTART- -18678578- O O

Local JJ N
delivery NN N
of IN N
a DT N
recombinant NN i
adenoassociated VBN i
vector NN i
containing VBG i
a DT i
tumour JJ i
necrosis NN i
factor NN i
alpha IN i
antagonist JJ i
gene NN i
in IN N
inflammatory JJ N
arthritis NN N
: : N
a DT N
phase NN N
1 CD N
dose-escalation NN N
safety NN o
and CC o
tolerability NN o
study NN N
. . N

OBJECTIVE NNP N
To TO N
examine VB N
the DT N
safety NN o
and CC o
tolerability NN o
of IN N
a DT N
single JJ N
intra-articular JJ N
injection NN N
of IN N
rAAV2-TNFR NN i
: : i
Fc NNP i
, , i
an DT i
adenoassociated JJ i
virus NN i
serotype NN i
2 CD i
vector NN i
containing VBG i
the DT i
cDNA NN i
for IN N
the DT N
human JJ N
tumour JJ N
necrosis NN N
factor-immunoglobulin JJ N
Fc NNP N
fusion NN N
gene NN N
( ( N
tgAAC94 NN N
) ) N
, , N
in IN N
subjects NNS p
with IN p
inflammatory JJ p
arthritis NN p
. . p

METHODS NNP N
In IN N
a DT N
double-blind JJ N
, , N
placebo-controlled JJ i
, , N
phase JJ N
1 CD N
, , N
dose-escalation NN N
study NN N
, , N
15 CD p
subjects NNS p
with IN p
inflammatory JJ p
arthritis NN p
( ( p
14 CD p
with IN p
rheumatoid JJ p
arthritis NN p
and CC p
1 CD p
with IN p
ankylosing VBG p
spondylitis NN p
) ) p
not RB p
receiving VBG p
tumour JJ p
necrosis NN p
factor NN p
alpha NN p
( ( p
TNFalpha NNP p
) ) p
inhibitors NNS p
with IN p
persistent JJ p
moderate NN p
( ( p
grade JJ p
2 CD p
) ) p
or CC p
severe JJ p
( ( p
grade JJ p
3 CD p
) ) p
swelling NN p
in IN p
a DT p
target NN p
joint NN p
due JJ p
to TO p
inflammatory JJ p
arthritis NN p
received VBD N
a DT N
single JJ N
intra-articular JJ N
injection NN N
of IN N
rAAV2-TNFR NN i
: : i
Fc NN i
at IN N
1 CD N
x JJ N
10 CD N
( ( N
10 CD N
) ) N
( ( N
n JJ N
= NNP N
5 CD N
) ) N
or CC N
1 CD N
x JJ N
10 CD N
( ( N
11 CD N
) ) N
( ( N
n JJ N
= NNP N
6 CD N
) ) N
DNase NNP N
resistant JJ N
particles NNS N
per IN N
ml NN N
joint NN N
volume NN N
or CC i
placebo NN i
( ( N
n JJ N
= NNP N
4 CD N
) ) N
into IN N
a DT N
knee NN N
( ( N
n JJ N
= NNP N
14 CD N
) ) N
or CC N
ankle NN N
( ( N
n JJ N
= NNP N
1 CD N
) ) N
. . N

Safety NN o
was VBD N
assessed VBN N
through IN N
adverse JJ N
event NN N
monitoring NN N
. . N

As IN N
a DT N
secondary JJ N
objective NN N
, , N
changes NNS o
in IN o
injected JJ o
joint NN o
tenderness NN o
and CC o
swelling VBG o
scores NNS o
, , N
each DT N
measured VBN N
on IN N
a DT N
four-point JJ N
scale NN N
, , N
were VBD N
evaluated VBN N
. . N

RESULTS NNP N
Intra-articular JJ N
injections NNS N
of IN N
rAAV2-TNFR NN N
: : N
Fc NN N
were VBD N
well RB N
tolerated VBN N
with IN N
no DT N
major JJ N
safety NN N
issues NNS N
. . N

One CD N
event NN N
, , N
mild JJ N
knee NN N
pruritus NN N
, , N
was VBD N
considered VBN N
probably RB N
related VBN N
. . N

Synovial JJ o
fluid NN o
TNFR NNP o
: : o
Fc NNP o
protein NN o
was VBD N
not RB N
detected VBN N
( ( N
nor CC N
expected VBN N
) ) N
at IN N
the DT N
doses NNS N
used VBN N
. . N

At IN N
12 CD N
weeks NNS N
after IN N
injection NN N
, , N
a DT N
two-point JJ N
decrease NN o
in IN o
swelling VBG o
was VBD N
noted VBN N
in IN N
2/11 CD N
and CC N
2/4 CD N
subjects NNS N
injected VBN N
with IN N
rAAV2-TNFR NN N
: : N
Fc NNP N
and CC N
placebo NN N
, , N
respectively RB N
. . N

CONCLUSION VB N
A DT N
single JJ N
dose NN N
of IN N
intra-articular JJ N
rAAV2-TNFR NN N
: : N
Fc CD N
appears VBZ N
to TO N
be VB N
safe JJ N
and CC N
well RB N
tolerated VBN N
in IN N
subjects NNS N
without IN N
concurrent JJ N
systemic JJ N
TNFalpha NNP N
antagonist NN N
use NN N
. . N

It PRP N
is VBZ N
thus RB N
feasible JJ N
to TO N
proceed VB N
with IN N
larger JJR N
trials NNS N
to TO N
further JJ N
test NN N
the DT N
safety NN o
and CC o
efficacy NN o
of IN N
local JJ N
TNFR NNP N
: : N
Fc NNP N
gene NN N
transfer NN N
as IN N
a DT N
therapeutic JJ N
modality NN N
for IN N
patients NNS p
with IN p
inflammatory JJ p
arthritis NN p
. . p

-DOCSTART- -19365716- O O

Social NNP i
competence NN i
and CC i
social JJ i
skills NNS i
training VBG i
and CC i
intervention NN i
for IN N
children NNS p
with IN p
Autism NNP p
Spectrum NNP p
Disorders NNP p
. . p

This DT N
study NN N
examined VBD N
the DT N
effectiveness NN N
of IN N
a DT N
30 CD N
week NN N
social JJ i
competence NN i
and CC i
social JJ i
skills NNS i
group NN i
intervention NN i
program NN i
with IN N
children NNS p
, , p
ages VBZ p
7-11 CD p
, , p
diagnosed VBN p
with IN p
Autism NNP p
Spectrum NNP p
Disorders NNP p
( ( p
ASD NNP p
) ) p
. . p

Eighteen JJ p
children NNS p
with IN p
ASD NNP p
were VBD N
assessed VBN N
with IN N
pretreatment NN N
and CC N
posttreatment NN N
measures NNS N
on IN N
the DT N
Walker-McConnell NNP o
Scale NNP o
( ( o
WMS NNP o
) ) o
and CC o
the DT o
MGH NNP o
YouthCare NNP o
Social NNP o
Competence NNP o
Development NNP o
Scale NNP o
. . o

Each DT N
received VBD N
the DT N
30-week JJ N
intervention NN N
program NN N
. . N

For IN N
comparison NN N
, , N
a DT N
matched JJ N
sample NN N
of IN N
ten JJ p
non-ASD JJ p
children NNS p
was VBD N
also RB N
assessed VBN N
, , N
but CC N
received VBD N
no DT N
treatment NN N
. . N

The DT N
findings NNS N
indicated VBD N
that IN N
each DT N
ASD NNP N
intervention NN N
group NN N
demonstrated VBD N
significant JJ N
gains NNS N
on IN N
the DT N
WMS NNP o
and CC N
significant JJ N
improvement NN N
in IN N
the DT N
areas NNS N
of IN N
anxiety NN o
management NN o
, , o
joint JJ o
attention NN o
, , o
and CC o
flexibility/transitions NNS o
. . o

Results VB N
suggest JJS N
that IN N
this DT N
approach NN N
can MD N
be VB N
effective JJ N
in IN N
improving VBG N
core NN N
social JJ o
deficits NNS o
in IN N
individuals NNS p
with IN p
ASD NNP p
. . p

-DOCSTART- -11219757- O O

Simplified NNP i
subjective JJ i
workload NN i
assessment NN i
technique NN i
. . i

Although IN N
the DT N
subjective JJ o
workload NN o
assessment NN o
technique NN o
( ( i
SWAT NNP i
) ) i
has VBZ N
been VBN N
widely RB N
used VBN N
, , N
it PRP N
has VBZ N
two CD N
main JJ N
problems NNS N
: : N
it PRP N
is VBZ N
not RB N
very RB N
sensitive JJ N
for IN N
low JJ N
mental JJ N
workloads NNS N
and CC N
it PRP N
requires VBZ N
a DT N
time-consuming JJ N
card NN N
sorting VBG N
pretask JJ N
procedure NN N
. . N

In IN N
this DT N
study NN N
are VBP N
presented VBN N
five CD i
variations NNS i
of IN i
SWAT NNP i
in IN N
an DT N
effort NN N
to TO N
overcome VB N
the DT N
limitations NNS N
. . N

Four CD N
of IN N
the DT N
variants NNS N
used VBD N
the DT N
continuous JJ i
SWAT NNP i
subscales NNS i
while IN N
one CD N
used VBD N
the DT N
discrete JJ i
SWAT NNP i
subscale NN i
. . i

Fifteen JJ p
subjects NNS p
participated VBN p
in IN p
the DT p
experiment NN p
. . p

The DT N
scales NNS N
were VBD N
compared VBN N
with IN N
the DT N
original JJ N
SWAT NNP i
scale NN N
in IN N
terms NNS N
of IN N
sensitivity NN o
and CC N
pretask NN N
procedure NN N
completion NN N
time NN N
when WRB N
performing VBG N
arithmetic JJ N
tasks NNS N
. . N

The DT N
results NNS N
show VBP N
that IN N
all DT N
four CD N
variants NNS N
are VBP N
more RBR N
sensitive JJ o
than IN N
the DT N
conventional JJ o
SWAT NNP o
scale NN o
and CC N
that IN N
the DT N
pairwise NN N
comparison NN N
procedure NN N
takes VBZ N
significantly RB N
less JJR N
pretask JJ o
completion NN o
time NN o
compared VBN N
with IN N
the DT N
original JJ i
SWAT NNP i
scale NN i
. . i

Thus RB N
, , N
the DT N
conventional JJ i
pretask JJ i
procedure NN i
can MD N
be VB N
replaced VBN N
by IN N
a DT N
simple JJ N
unweighted JJ N
averaging VBG N
to TO N
yield VB N
a DT N
scale NN N
of IN N
high JJ N
sensitivity NN N
. . N

-DOCSTART- -19159477- O O

An DT N
emergency NN N
clinical JJ N
pathway NN N
for IN N
stroke NN p
patients NNS p
-- : p
results NNS p
of IN N
a DT N
cluster NN N
randomised VBN N
trial NN N
( ( N
isrctn41456865 NN N
) ) N
. . N

BACKGROUND NNP N
Emergency NNP i
Clinical NNP i
Pathways NNP i
( ( i
ECP NNP i
) ) i
for IN N
stroke NN N
have VBP N
never RB N
been VBN N
tested VBN N
in IN N
randomized VBN N
controlled JJ N
trials NNS N
( ( N
RCTs NNP N
) ) N
. . N

OBJECTIVE UH N
To TO N
evaluate VB N
the DT N
effectiveness NN o
of IN N
an DT N
ECP NNP i
for IN N
stroke NN p
patients NNS p
in IN p
Latium NNP p
( ( p
Italy NNP p
) ) p
emergency NN p
system NN p
. . p

METHODS NNP N
cluster-RCT NN i
designed VBN N
to TO N
compare VB N
stroke JJ p
patient JJ p
referrals NNS p
by IN p
Emergency NNP i
Medical NNP i
Service NNP i
( ( i
EMS NNP i
) ) i
and CC p
Emergency NNP p
Room NNP p
( ( p
ER NNP p
) ) p
health NN p
professionals NNS p
trained VBN p
in IN p
the DT p
ECP NNP i
, , p
with IN p
those DT p
of IN p
non-trained JJ p
EMS NNP p
and CC p
ER NNP p
controls NNS p
. . p

Primary NNP N
outcome JJ N
measure NN N
was VBD N
the DT N
proportion NN o
of IN o
eligible JJ o
( ( o
aged VBN o
< NNP o
/= $ o
80 CD o
and CC o
symptom JJ o
onset NN o
< NNP o
/= VBZ o
6 CD o
hours NNS o
) ) o
stroke VBD o
patients NNS o
referred VBN o
to TO o
a DT o
stroke NN o
unit NN o
( ( o
SU NNP o
) ) o
. . o

Intention NN o
to TO o
treat VB o
( ( o
ITT NNP o
) ) o
and CC o
per-protocol JJ o
( ( o
PP NNP o
) ) o
analyses NNS o
were VBD N
performed VBN N
, , N
and CC N
risk NN o
ratios NNS o
( ( o
RR NNP o
) ) o
adjusted VBN N
by IN N
age NN N
, , N
gender NN N
and CC N
area NN N
, , N
were VBD N
calculated VBN N
. . N

RESULTS JJ N
2656 CD p
patients NNS p
in IN p
the DT p
intervention NN p
arm NN p
and CC p
2239 CD p
in IN p
the DT p
control NN p
arm NN p
required VBN N
assistance NN o
; : o
78.3 CD N
% NN N
of IN N
the DT N
former JJ N
and CC N
80.6 CD N
% NN N
of IN N
the DT N
latter NN N
were VBD N
admitted VBN o
to TO o
hospitals NNS o
, , N
and CC N
respectively RB N
74.8 CD N
% NN N
and CC N
78.3 CD N
% NN N
were VBD N
confirmed VBN o
strokes NNS o
. . o

Of IN N
the DT N
eligible JJ N
confirmed JJ o
strokes NNS o
, , N
106/434 CD N
( ( N
24.4 CD N
% NN N
) ) N
in IN N
the DT N
intervention NN N
arm NN N
and CC N
43/328 CD N
( ( N
13.1 CD N
% NN N
) ) N
in IN N
the DT N
control NN N
arm NN N
were VBD N
referred VBN N
to TO N
the DT N
SU NNP o
in IN N
the DT N
ITT NNP N
analysis NN N
( ( N
RR NNP N
= NNP N
2.01 CD N
; : N
95 CD N
% NN N
CI NNP N
: : N
0.79-4.00 NN N
) ) N
, , N
and CC N
respectively RB N
105/243 CD N
( ( N
43.2 CD N
% NN N
) ) N
and CC N
43/311 CD N
( ( N
13.8 CD N
% NN N
) ) N
in IN N
the DT N
PP NNP N
analysis NN N
( ( N
RR NNP N
= NNP N
3.21 CD N
; : N
95 CD N
% NN N
CI NNP N
: : N
1.62-4.98 JJ N
) ) N
. . N

Of IN N
patients NNS N
suitable JJ N
for IN N
i.v NN N
. . N

thrombolysis NN N
, , N
15/175 CD N
( ( N
8.6 CD N
% NN N
) ) N
in IN N
the DT N
intervention NN N
arm NN N
and CC N
2/115 CD N
( ( N
1.7 CD N
% NN N
) ) N
in IN N
the DT N
control NN N
arm NN N
received VBN N
thrombolysis NN N
( ( N
p JJ N
= NNP N
0.02 CD N
) ) N
in IN N
the DT N
ITT NNP N
analysis NN N
, , N
and CC N
respectively RB N
15/99 CD N
( ( N
15.1 CD N
% NN N
) ) N
and CC N
2/107 CD N
( ( N
1.9 CD N
% NN N
) ) N
( ( N
p JJ N
= NNP N
0.001 CD N
) ) N
in IN N
the DT N
PP NNP N
analysis NN N
. . N

CONCLUSION NNP N
Our PRP$ N
data NNS N
suggest VBP N
potenti JJ N
efficiency NN o
and CC o
feasibility NN o
of IN N
an DT N
ECP NNP N
. . N

The DT N
integration NN N
of IN N
EMS NNP N
and CC N
ERs NNP N
with IN N
SU NNP N
networks NNS N
for IN N
organised JJ N
acute NN N
stroke NN N
care NN N
is VBZ N
feasible JJ N
and CC N
may MD N
ameliorate VB N
the DT N
quality NN o
of IN o
care NN o
for IN N
stroke NN p
patients NNS p
. . p

TRIAL NNP N
REGISTRATION NNP N
Current NNP N
Controlled NNP N
Trials NNP N
( ( N
ISRCTN41456865 NNP N
) ) N
. . N

-DOCSTART- -21788433- O O

Effect NN N
of IN N
shearing VBG i
on IN N
water NN o
turnover NN o
and CC o
thermobiological JJ o
variables NNS o
in IN N
German JJ p
Blackhead NNP p
mutton NN p
sheep NN p
. . p

Current JJ N
equations NNS N
for IN N
estimating VBG N
water NN N
requirements NNS N
in IN N
sheep JJ N
do VBP N
not RB N
differentiate VB N
between IN N
shorn JJ p
and CC p
unshorn JJ p
sheep NN p
. . p

Furthermore RB N
, , N
the DT N
effect NN N
of IN N
shearing VBG N
on IN N
thermoregulative JJ o
responses NNS o
in IN N
sheep NN N
has VBZ N
not RB N
been VBN N
adequately RB N
studied VBN N
under IN N
temperate JJ p
environmental JJ p
conditions NNS p
. . p

Therefore RB N
, , N
the DT N
present JJ N
study NN N
was VBD N
conducted VBN N
to TO N
investigate VB N
the DT N
effect NN N
of IN N
wool NN N
coverage NN N
on IN N
water NN o
turnover NN o
in IN N
relation NN N
to TO N
thermoregulation NN N
in IN N
sheep NN N
by IN N
using VBG N
the DT N
deuterium NN N
dilution NN N
technique NN N
to TO N
predict VB N
total JJ N
water NN N
intake NN N
before IN N
and CC N
after IN N
shearing VBG i
. . i

Physiological JJ N
responses NNS N
, , N
such JJ N
as IN N
water NN o
turnover NN o
, , o
surface NN o
temperature NN o
, , o
and CC o
rectal JJ o
temperature NN o
, , o
as RB o
well RB o
as IN o
drinking VBG o
behavior NN o
of IN o
sheep NN o
were VBD N
also RB N
evaluated VBN N
. . N

Fourteen NNP p
nonlactating JJ p
German JJ p
Blackhead NNP p
mutton NN p
ewes NN p
were VBD N
randomly RB N
allocated VBN N
into IN N
2 CD N
groups NNS N
: : N
a DT i
control NN i
group NN i
( ( N
n JJ N
= NNP N
7 CD N
) ) N
that WDT N
was VBD N
already RB i
shorn VBN i
, , i
and CC i
a DT i
treatment NN i
group NN i
( ( N
n JJ N
= NNP N
7 CD N
) ) N
that WDT N
was VBD N
left VBN i
unshorn JJ i
( ( N
wool JJ N
length NN N
: : N
10.6 CD N
? . N
1.2 CD N
cm NN N
) ) N
. . N

Individual NNP o
feed NN o
and CC o
water NN o
intakes NNS o
were VBD N
recorded VBN N
throughout IN N
the DT N
experiment NN N
( ( N
d JJ N
1 CD N
to TO N
71 CD N
) ) N
. . N

Two CD N
weeks NNS N
after IN N
measurements NNS N
commenced VBD N
( ( N
d JJ N
15 CD N
) ) N
, , N
treatment NN N
sheep NN N
were VBD N
shorn VBN N
. . N

Water NNP o
intake NN o
was VBD N
estimated VBN N
twice RB N
for IN N
2 CD N
consecutive JJ N
weeks NNS N
by IN N
using VBG N
deuterium JJ N
dilution NN N
techniques NNS N
( ( N
d VB N
1 CD N
to TO N
15 CD N
and CC N
d VB N
57 CD N
to TO N
71 CD N
) ) N
. . N

Ambient JJ o
temperature NN o
( ( o
T NNP o
( ( o
a DT o
) ) o
) ) o
, , o
relative JJ o
humidity NN o
, , o
and CC o
respiratory JJ o
rate NN o
were VBD N
measured VBN N
daily RB N
, , N
whereas JJ o
BW NNP o
, , o
rectal NN o
and CC o
animal JJ o
surface NN o
temperatures NNS o
( ( N
using VBG N
infrared VBN N
thermography NN N
) ) N
, , N
and CC o
wool JJ o
length NN o
were VBD N
measured VBN N
weekly RB N
. . N

In IN N
the DT N
first JJ N
2 CD N
wk NN N
, , N
when WRB N
treatment NN N
sheep NN N
were VBD N
unshorn JJ N
, , N
treatment NN N
and CC N
control NN N
ewes NN N
differed VBN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
in IN o
DMI NNP o
( ( N
52 CD N
? . N
4 CD N
vs. IN N
59 CD N
? . N
4 CD N
g?kg NN o
( ( o
-0.75 NNP o
) ) o
?d NN o
( ( o
-1 NNP o
) ) o
) ) o
, , o
water NN o
intake NN o
( ( o
165 CD o
? . N
17 CD N
vs. IN N
134 CD N
? . N
18 CD N
g?kg NN N
( ( N
-0.75 NNP o
) ) o
?d NN o
( ( o
-1 NNP o
) ) o
) ) o
, , o
respiratory JJ o
rate NN o
( ( o
66 CD o
? . N
5 CD N
vs. IN N
31 CD N
? . N
4 CD N
breath/min NN N
) ) N
, , o
rectal JJ o
temperature NN o
( ( o
39.3 CD o
? . o
0.2 CD o
vs. IN N
38.8 CD N
? . N
0.1?C CD N
) ) N
, , N
and CC o
surface NN o
temperatures NNS o
( ( N
body JJ N
side NN N
: : N
19.3 CD N
? . N
0.3 CD N
vs. IN N
24.5 CD N
? . N
0.6?C CD N
; : N
leg NN N
: : N
25.8 CD N
? . N
2.4 CD N
vs. IN N
27.4 CD N
? . N
1.6?C CD N
) ) N
. . N

However RB N
, , N
after IN N
shearing VBG N
, , N
these DT N
differences NNS N
partly RB N
disappeared VBD N
. . N

The DT N
same JJ o
trend NN o
in IN o
water NN o
intake NN o
between IN o
groups NNS N
was VBD N
confirmed VBN N
using VBG N
the DT N
isotope NN N
dilution NN N
technique NN N
. . N

We PRP N
found VBD N
a DT N
significant JJ N
relationship NN N
between IN N
T NNP o
( ( o
a DT o
) ) o
and CC o
water NN o
intake NN o
, , o
respiratory NN o
rate NN o
, , o
and CC o
body NN o
surface NN o
temperatures NNS o
. . o

Even RB o
under IN N
temperate NN N
conditions NNS N
( ( N
T NNP N
( ( N
a DT N
) ) N
< $ N
28?C CD N
) ) N
, , N
shearing VBG N
significantly RB N
reduced VBN N
core NN o
body NN o
temperature NN o
, , o
water NN o
intake NN o
, , o
and CC o
respiratory NN o
rate NN o
in IN p
German JJ p
Blackhead NNP p
mutton NN p
sheep NN p
, , p
thus RB p
indicating VBG o
heat NN o
stress NN o
in IN o
fleeced JJ o
animals NNS p
, , p
which WDT N
should MD N
be VB N
considered VBN N
when WRB N
determining VBG N
the DT N
optimal JJ N
shearing NN N
time NN N
in IN N
sheep NN N
as RB N
well RB N
as IN N
when WRB N
estimating VBG N
water NN N
requirements NNS N
. . N

-DOCSTART- -8893393- O O

Intrathecal JJ o
immunoactivation NN o
in IN N
patients NNS p
with IN p
HIV-1 NNP p
infection NN p
is VBZ N
reduced VBN N
by IN N
zidovudine NN i
but CC N
not RB N
by IN N
didanosine NN i
. . i

The DT N
effect NN N
of IN N
zidovudine NN i
and CC i
didanosine NN i
on IN N
the DT N
cerebrospinal JJ N
fluid NN N
( ( N
CSF NNP N
) ) N
concentrations NNS N
of IN N
neopterin NN N
was VBD N
studied VBN N
in IN p
12 CD p
patients NNS p
with IN p
human JJ p
immunodeficiency NN p
virus NN p
type-1 NN p
( ( p
HIV-1 NNP p
) ) p
infection NN p
3-12 JJ p
months NNS p
after IN p
initiation NN p
of IN p
antiretroviral JJ i
therapy NN i
. . i

Ten CD N
treatment NN N
periods NNS N
on IN N
zidovudine NN i
and CC N
7 CD N
on IN N
didanosine NN i
were VBD N
analysed VBN N
. . N

The DT N
CSF NNP o
concentrations NNS o
of IN o
neopterin NNS o
decreased VBN N
by IN N
63 CD N
% NN N
( ( N
from IN N
29.6 CD N
to TO N
12.9 CD N
nmol/l NNS N
, , N
p VBP N
< RB N
0.01 CD N
) ) N
during IN N
zidovudine NN i
but CC N
increased VBN N
by IN N
15 CD N
% NN N
( ( N
from IN N
22.6 CD N
to TO N
25.9 CD N
nmol/l NNS N
, , N
not RB N
significant JJ N
during IN N
didanosine JJ i
treatment NN N
. . N

The DT N
CSF NNP o
monocytic JJ o
cell NN o
count NN o
decreased VBD N
during IN N
zidovudine NN i
but CC N
increased VBD N
during IN N
didanosine JJ i
treatment NN N
. . N

The DT N
results NNS N
suggest VBP N
that IN N
zidovudine NN i
but CC N
not RB N
didanosine JJ i
reduces NNS N
intrathecal JJ o
immunoactivation NN o
during IN o
HIV-1 NNP o
infection NN o
. . o

-DOCSTART- -17414940- O O

Neurophysiological JJ N
double-blind JJ N
trial NN N
of IN N
a DT N
botulinum NN i
neurotoxin NN i
type IN i
a DT i
free JJ N
of IN N
complexing VBG N
proteins NNS N
. . N

OBJECTIVE NNP N
Safety NNP o
and CC o
efficacy NN o
of IN N
botulinum NN i
neurotoxin NN i
type NN i
A DT i
preparation NN i
NT NNP i
201 CD i
( ( N
Xeomin NNP N
, , N
Merz NNP N
Pharmaceuticals NNP N
GmbH NNP N
, , N
Frankfurt NNP N
am VBP N
Main NNP N
, , N
Germany NNP N
) ) N
were VBD N
investigated VBN N
over IN N
52 CD N
weeks NNS N
in IN N
a DT N
double-blind NN N
, , N
randomized VBN p
trial NN p
with IN p
32 CD p
male JJ p
volunteers NNS p
. . p

METHODS NNP N
Electroneurographic JJ o
assessments NNS o
with IN o
surface NN o
electrodes NNS o
were VBD N
performed VBN N
after IN N
single JJ i
injections NNS i
of IN i
NT NNP i
201 CD i
( ( N
2 CD N
, , N
4 CD N
, , N
16 CD N
, , N
or CC N
32 CD N
units NNS N
) ) N
into IN N
the DT N
extensor NN i
digitorum NN i
brevis NN i
( ( N
EDB NNP N
) ) N
muscle NN N
and CC N
the DT N
same JJ i
dose NN i
( ( N
Botox NNP N
; : N
Allergan NNP N
Pharmaceuticals NNP N
( ( N
Ireland NNP N
) ) N
Ltd. NNP N
Westport NNP N
, , N
Ireland NNP N
) ) N
into IN i
the DT i
contralateral JJ i
EDB NNP i
. . i

RESULTS NNP N
All NNP N
NT NNP i
201 CD i
and CC i
BTXCo NNP i
doses VBZ N
achieved VBD N
a DT N
statistically RB N
significant JJ N
reduction NN o
of IN o
the DT o
compound NN o
muscle NN o
action NN o
potential JJ o
M-wave NNP o
amplitude NN o
in IN N
the DT o
EDB NNP o
muscle NN o
. . o

At IN N
week NN N
4 CD N
, , N
the DT N
highest JJS N
dose NN N
was VBD N
statistically RB N
significantly RB N
more RBR N
effective JJ o
than IN N
the DT N
lowest JJS N
dose NN N
( ( N
NT NNP N
201 CD N
, , N
P NNP N
= NNP N
0.019 CD N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
0.195-1.370 JJ N
; : N
and CC N
BTXCo NNP N
, , N
P NNP N
= NNP N
0.002 CD N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
0.309-1.167 JJ N
) ) N
. . N

Duration NN o
of IN o
effect NN o
was VBD N
dose JJ N
dependent NN N
. . N

The DT N
mean JJ o
values NNS o
of IN o
compound NN o
muscle NN o
action NN o
potential JJ o
M-wave NNP o
amplitudes NNS o
in IN o
the DT o
adjacent JJ o
muscles NNS o
( ( N
abductor NN N
digiti NN N
quinti NN N
and CC N
abductor NN N
hallucis NN N
) ) N
were VBD N
above IN N
the DT N
predefined JJ N
threshold NN N
of IN N
effect NN N
, , N
indicating VBG N
that IN N
there EX N
was VBD N
no DT N
relevant JJ N
diffusion-induced JJ N
reduction NN N
of IN N
muscle NN o
activity NN o
. . o

NT CC i
201 CD i
and CC N
BTXCo NNP i
were VBD N
well RB N
tolerated VBN o
. . o

CONCLUSIONS NNP N
NT NNP i
201 CD i
is VBZ N
effective JJ N
and CC N
safe JJ N
in IN N
inducing VBG N
the DT N
desired VBN N
paretic JJ N
effect NN N
. . N

-DOCSTART- -19968217- O O

Evaluation NN N
of IN N
reducing VBG N
postoperative JJ o
hip NN o
precautions NNS o
in IN N
total JJ p
hip JJ p
replacement NN p
: : p
a DT p
randomized JJ p
prospective JJ p
study NN p
. . p

Currently NNP N
, , N
many JJ N
rehabilitation NN N
protocols NNS N
for IN N
total JJ N
hip NN N
replacements NNS N
( ( N
THRs NNP N
) ) N
include VBP N
activity NN N
restrictions NNS N
to TO N
prevent VB N
postoperative JJ N
dislocation NN N
. . N

There EX N
is VBZ N
increasing VBG N
demand NN N
for IN N
more RBR N
efficient JJ N
and CC N
safe JJ N
rehabilitation NN N
protocols NNS N
. . N

This DT N
randomized JJ N
prospective JJ N
study NN N
evaluates VBZ N
the DT N
need NN N
for IN N
hip NN N
restrictions NNS N
following VBG N
a DT N
modified JJ N
anterolateral JJ N
procedure NN N
. . N

From IN p
2004 CD p
to TO p
2008 CD p
, , p
81 CD p
patients NNS p
seeking VBG p
elective JJ p
THRs NNP p
were VBD p
randomly RB p
assigned VBN p
into IN p
a DT p
standard JJ p
rehabilitation NN p
group NN p
or CC p
an DT p
early JJ p
rehabilitation NN p
group NN p
. . p

The DT N
standard JJ p
group NN p
included VBD p
restrictions NNS i
to TO i
avoid VB i
hip NN i
flexion NN i
> VBD i
90 CD i
degrees NNS i
and CC i
avoidance NN i
of IN i
riding VBG i
in IN i
a DT i
car NN i
for IN i
the DT i
first JJ i
postoperative JJ i
month NN i
. . i

The DT p
early JJ p
group NN p
had VBD p
no DT i
flexion NN i
or CC i
car NN i
riding NN i
restrictions NNS i
. . i

Forty-three JJ p
patients NNS p
were VBD p
in IN p
the DT p
standard JJ p
group NN p
and CC p
38 CD p
patients NNS p
were VBD p
in IN p
the DT p
early JJ p
group NN p
. . p

There EX N
were VBD N
no DT p
significant JJ p
demographic JJ p
differences NNS p
between IN p
the DT p
2 CD p
groups NNS p
. . p

All DT N
patients NNS N
completed VBD N
the DT N
Short JJ N
Form NNP N
12-question JJ N
Health NNP N
Survey NNP N
and CC N
Harris NNP N
Hip NNP N
Score NNP N
preoperatively RB N
and CC N
at IN N
4 CD N
weeks NNS N
, , N
1 CD N
month NN N
, , N
3 CD N
months NNS N
, , N
and CC N
1 CD N
year NN N
postoperatively RB N
. . N

The DT N
time-points NNS o
at IN o
which WDT o
the DT o
patient NN o
first RB o
drove VBD o
and CC o
ambulated VBD o
with IN N
a DT N
cane NN N
, , N
without IN N
a DT N
cane NN N
, , N
and CC N
without IN N
a DT N
limp NN N
were VBD N
also RB N
collected VBN N
. . N

No DT N
incidents NNS N
of IN N
dislocation NN o
occurred VBD N
. . N

Patients NNS N
in IN N
the DT N
early JJ N
group NN N
were VBD N
faster JJR N
to TO N
ambulate VB o
with IN o
only RB o
a DT o
cane NN o
( ( N
P=.03 NNP N
) ) N
, , N
without IN o
a DT o
cane NN o
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
, , N
and CC N
without IN o
a DT o
limp NN o
( ( N
P=.003 NNP N
) ) N
. . N

They PRP N
also RB N
drove VBD o
earlier RBR N
( ( N
P=.02 NNP N
) ) N
. . N

Pace NN o
of IN o
recovery NN o
was VBD N
the DT N
only JJ N
significant JJ N
difference NN N
between IN N
the DT N
2 CD N
groups NNS N
. . N

The DT N
early JJ i
rehabilitation NN i
protocol NN i
increases VBZ N
the DT N
pace NN o
of IN o
recovery NN o
compared VBN N
to TO N
a DT N
pathway NN N
with IN N
hip NN N
precautions NNS N
without IN N
increasing VBG o
complications NNS o
. . o

-DOCSTART- -11839712- O O

Effects NNS N
of IN N
glucagon-like JJ i
peptide-1 JJ i
( ( i
7-36 JJ i
) ) i
amide NN i
on IN N
motility NN o
and CC o
sensation NN o
of IN o
the DT o
proximal JJ o
stomach NN o
in IN p
humans NNS p
. . p

BACKGROUND NNP N
Glucagon-like JJ i
peptide-1 NN i
( ( i
7-36 JJ i
) ) i
amide NN i
( ( i
GLP-1 NNP i
) ) i
retards NNS N
gastric JJ o
emptying NN o
, , o
reduces NNS o
food NN o
intake NN o
, , o
and CC o
inhibits VBZ o
antroduodenal JJ o
and CC o
stimulates VBZ o
pyloric JJ o
motility NN o
. . o

AIMS NNP N
To TO N
assess VB N
the DT N
effects NNS N
of IN N
synthetic JJ i
GLP-1 NNP i
on IN N
fundus NN o
tone NN o
and CC o
volume NN o
waves NNS o
, , o
gastric JJ o
compliance NN o
, , o
and CC o
perception NN o
of IN o
gastric JJ o
distension NN o
. . o

SUBJECTS NNP N
Eleven NNP p
healthy JJ p
male NN p
volunteers NNS p
. . p

METHODS NNP N
Background NNP N
infusions NNS N
were VBD N
saline JJ i
, , i
or CC i
GLP-1 NNP i
at IN N
0.3 CD N
or CC N
0.9 CD N
pmol/ JJ N
kg/min NN N
on IN N
separate JJ N
days NNS N
in IN N
random JJ N
order NN N
. . N

Interdigestive JJ o
fundus NN o
motility NN o
was VBD N
recorded VBN N
by IN N
barostat NN N
( ( N
maximum JJ N
capacity NN N
of IN N
intragastric JJ N
bag NN N
1200 CD N
ml NN N
) ) N
during IN N
basal NN N
and CC N
peptide JJ N
periods NNS N
of IN N
60 CD N
minutes NNS N
each DT N
. . N

Thereafter RB N
stepwise JJ N
isobaric JJ N
distensions NNS N
were VBD N
performed VBN N
with IN N
ongoing JJ N
peptide NN N
infusion NN N
, , N
and CC N
gastric JJ o
sensation NN o
was VBD N
scored VBN N
. . N

RESULTS NNP N
Low NNP N
and CC N
high JJ N
loads NNS N
of IN N
GLP-1 NNP i
induced JJ N
physiological JJ o
and CC o
supraphysiological JJ o
plasma NN o
immunoreactivities NNS o
, , N
respectively RB N
. . N

GLP-1 NNP i
dose NN N
dependently RB N
diminished VBD N
fundus JJ o
tone NN o
( ( N
162.9 CD N
( ( N
15.0 CD N
) ) N
and CC N
259.5 CD N
( ( N
17.2 CD N
) ) N
v NN N
121.1 CD N
( ( N
6.0 CD N
) ) N
ml NN N
with IN N
saline NN N
; : N
p CC N
< VB N
0.0001 CD N
) ) N
. . N

It PRP N
greatly RB N
reduced VBD N
volume NN o
waves NNS o
and CC o
total JJ o
volume NN o
displaced VBN o
by IN N
these DT N
events NNS N
( ( N
p JJ N
< NNP N
0.0001 CD N
) ) N
. . N

Gastric NNP o
compliance NN o
derived VBD N
from IN N
isobaric JJ N
distension NN N
rose VBD N
in IN N
a DT N
dose NN N
related JJ N
manner NN N
( ( N
42.6 CD N
( ( N
5.5 CD N
) ) N
and CC N
63.6 CD N
( ( N
7.7 CD N
) ) N
v NN N
27.0 CD N
( ( N
3.5 CD N
) ) N
ml/mm NN N
Hg NNP N
; : N
p=0.0004 NN N
) ) N
with IN N
a DT N
concomitant JJ N
reduction NN N
of IN N
the DT N
pressure NN o
at IN N
half JJ N
maximum JJ N
bag NN N
volume NN N
( ( N
6.4 CD N
( ( N
0.4 CD N
) ) N
and CC N
5.5 CD N
( ( N
0.4 CD N
) ) N
v NN N
7.2 CD N
( ( N
0.1 CD N
) ) N
mm NN N
Hg NNP N
; : N
p VBZ N
< $ N
0.0001 CD N
) ) N
. . N

GLP-1 NNP i
did VBD N
not RB N
change VB N
perception NN N
of IN N
isobaric JJ o
distension NN o
but CC N
reduced VBD N
the DT N
perception NN o
score RB o
related VBN N
to TO N
corresponding VBG N
bag NN N
volume NN N
( ( N
p JJ N
< NNP N
0.0001 CD N
) ) N
. . N

CONCLUSIONS NNP N
GLP-1 NNP i
is VBZ N
a DT N
candidate JJ N
physiological JJ N
inhibitory NN N
regulator NN N
of IN N
fundus JJ o
motility NN o
. . o

It PRP N
allows VBZ N
the DT N
stomach NN N
to TO N
afford VB N
a DT N
larger JJR N
volume NN N
without IN N
increase NN o
in IN o
sensation NN o
. . o

-DOCSTART- -9066329- O O

Comparison NNP N
of IN N
cuffed NN i
and CC i
uncuffed JJ i
endotracheal NN i
tubes NNS i
in IN N
young JJ p
children NNS p
during IN p
general JJ p
anesthesia NN p
. . p

BACKGROUND NNP N
Uncuffed NNP i
endotracheal NN i
tubes NNS i
are VBP N
routinely RB N
used VBN N
in IN N
young JJ p
children NNS p
. . p

This DT N
study NN N
tests VBZ N
a DT N
formula NN N
for IN N
selecting VBG N
appropriately RB N
sized VBN N
cuffed NN N
endotracheal NN N
tubes NNS N
and CC N
compares VBZ N
the DT N
use NN N
of IN N
cuffed NN i
versus NN i
uncuffed JJ i
endotracheal NN i
tubes NNS i
for IN N
patients NNS p
whose WP$ N
lungs NNS N
are VBP N
mechanically RB N
ventilated VBN N
during IN N
anesthesia NN N
. . N

METHODS NNP N
Full-term NNP p
newborns NNS p
and CC p
children NNS p
( ( p
n JJ p
= NNP p
488 CD p
) ) p
through IN p
8 CD p
yr NN p
of IN p
age NN p
who WP p
required VBD p
general JJ p
anesthesia NN p
and CC p
tracheal JJ p
intubation NN p
were VBD N
assigned VBN N
randomly RB N
to TO N
receive VB N
either CC N
a DT N
cuffed NN i
tube NN i
sized VBN i
by IN i
a DT i
new JJ i
formula NN i
[ NN N
size NN N
( ( N
mm JJ N
internal JJ N
diameter NN N
) ) N
= NN N
( ( N
age/4 NN N
) ) N
+ VBZ N
3 CD N
] NN N
, , N
or CC N
an DT N
uncuffed JJ i
tube NN i
sized VBN i
by IN i
the DT i
modified JJ i
Cole NNP i
's POS i
formula NN i
[ NN N
size NN N
( ( N
mm JJ N
internal JJ N
diameter NN N
) ) N
= NN N
( ( N
age/4 NN N
) ) N
+ VBZ N
4 CD N
] NN N
. . N

The DT N
number NN o
of IN o
intubations NNS o
required VBN o
to TO o
achieve VB o
an DT o
appropriately RB o
sized JJ o
tube NN o
, , N
the DT N
need NN o
to TO o
use VB o
more JJR o
than IN o
21.min-1 JJ o
fresh JJ o
gas NN o
flow NN o
, , N
the DT N
concentration NN o
of IN o
nitrous JJ o
oxide NN o
in IN o
the DT o
operating NN o
room NN o
, , N
and CC N
the DT N
incidence NN o
of IN o
croup NN o
were VBD N
compared VBN N
. . N

RESULTS NNP N
Cuffed NNP i
tubes RB i
selected VBN N
by IN N
our PRP$ N
formula NN N
were VBD N
appropriate JJ o
for IN N
99 CD N
% NN N
of IN N
patients NNS N
. . N

Uncuffed NNP i
tubes RB i
selected VBN N
by IN N
Cole NNP N
's POS N
formula NN N
were VBD N
appropriate JJ o
for IN N
77 CD N
% NN N
of IN N
patients NNS N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

The DT N
lungs NNS o
of IN o
patients NNS o
with IN N
cuffed JJ N
tubes NNS N
were VBD N
adequately RB o
ventilated VBN o
with IN N
2 CD N
1.min-1 JJ N
fresh JJ N
gas NN N
flow NN N
, , N
whereas RB N
11 CD N
% NN N
of IN N
those DT N
with IN N
uncuffed JJ N
tubes NNS N
needed VBN N
greater JJR N
fresh JJ N
gas NN N
flow NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

Ambient NNP o
nitrous JJ o
oxide IN o
concentration NN o
exceeded VBD N
25 CD N
parts NNS N
per IN N
million CD N
in IN N
37 CD N
% NN N
of IN N
cases NNS N
with IN N
uncuffed JJ N
tubes NNS N
and CC N
in IN N
0 CD N
% NN N
of IN N
cases NNS N
with IN N
cuffed JJ N
tubes NNS N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

Three CD N
patients NNS N
in IN N
each DT N
group NN N
were VBD N
treated VBN N
for IN N
croup NN o
symptoms NNS o
( ( N
1.2 CD N
% NN N
cuffed NN N
; : N
1.3 CD N
% NN N
uncuffed NN N
) ) N
. . N

CONCLUSIONS VB N
Our PRP$ N
formula NN N
for IN N
cuffed NN N
tube NN N
selection NN N
is VBZ N
appropriate JJ o
for IN N
young JJ o
children NNS o
. . o

Advantages NNS o
of IN N
cuffed JJ i
endotracheal JJ i
tubes NNS i
include VBP N
avoidance NN o
of IN o
repeated VBN o
laryngoscopy NN o
, , o
use NN o
of IN o
low JJ o
fresh JJ o
gas NN o
flow NN o
, , N
and CC N
reduction NN o
of IN o
the DT o
concentration NN o
of IN o
anesthetics NNS o
detectable JJ o
in IN o
the DT o
operating NN o
room NN o
. . o

We PRP N
conclude VBP N
that IN N
cuffed NN i
endotracheal VBP i
tubes NNS i
may MD N
be VB N
used VBN N
routinely RB N
during IN N
controlled VBN N
ventilation NN N
in IN N
full-term JJ p
newborns NNS p
and CC p
children NNS p
during IN p
anesthesia NN p
. . p

-DOCSTART- -20674829- O O

Double-blind NNP N
, , N
placebo-controlled JJ N
study NN N
of IN N
azelastine NN i
and CC i
fluticasone NN i
in IN N
a DT N
single JJ N
nasal NN N
spray NN N
delivery NN N
device NN N
. . N

BACKGROUND VB N
A DT N
proof-of-concept JJ N
study NN N
suggested VBD N
that IN N
combination NN N
therapy NN N
with IN N
commercial JJ N
azelastine NN i
hydrochloride NN i
nasal NN N
spray NN N
and CC N
fluticasone NN i
propionate NN i
nasal NN N
spray NN N
significantly RB N
improved VBN N
nasal JJ o
symptoms NNS o
of IN o
seasonal JJ o
allergic JJ o
rhinitis NN o
compared VBN N
with IN N
either DT N
agent NN N
alone RB N
. . N

OBJECTIVE UH N
To TO N
compare VB N
an DT N
azelastine-fluticasone JJ i
combination NN N
nasal NN N
spray NN N
administered VBN N
in IN N
a DT N
single-delivery JJ N
device NN N
with IN N
a DT N
commercially RB N
available JJ N
azelastine NN N
nasal NN N
spray NN N
and CC N
fluticasone NN N
nasal NN N
spray NN N
. . N

METHODS NNP N
This DT N
14-day JJ N
, , N
multicenter NN N
, , N
randomized VBN N
, , N
double-blind JJ N
study NN N
was VBD N
conducted VBN N
during IN N
the DT N
Texas NNP N
mountain NN N
cedar NN N
season NN N
. . N

After IN N
a DT N
5-day JJ N
placebo NN i
lead-in NN N
, , N
610 CD p
patients NNS p
with IN p
moderate-to-severe JJ p
nasal NN p
symptoms NNS p
were VBD N
randomized VBN N
to TO N
treatment NN N
with IN N
( ( i
1 CD i
) ) i
azelastine NN i
nasal NN i
spray NN i
, , i
( ( i
2 CD i
) ) i
fluticasone NN i
nasal NN i
spray NN i
, , i
( ( i
3 CD i
) ) i
combination NN i
azelastine NN i
and CC i
fluticasone NN i
nasal NN i
spray NN i
, , i
or CC i
( ( i
4 CD i
) ) i
placebo NN i
nasal JJ i
spray NN i
. . i

All DT N
treatments NNS N
were VBD N
given VBN N
as IN N
1 CD i
spray NN i
per IN i
nostril JJ i
twice JJ i
daily RB i
. . i

The DT N
primary JJ N
efficacy NN N
variable NN N
was VBD N
the DT N
change NN N
from IN N
baseline NN N
in IN N
the DT N
total JJ o
nasal JJ o
symptom NN o
score NN o
( ( o
TNSS NNP o
) ) o
, , o
consisting VBG o
of IN o
nasal JJ o
congestion NN o
, , o
runny NN o
nose RB o
, , o
itchy NN o
nose NN o
, , o
and CC o
sneezing VBG o
. . o

RESULTS NNP N
All DT N
3 CD N
active JJ N
groups NNS N
were VBD N
statistically RB N
superior JJ N
( ( N
P NNP N
< NNP N
or= NNP N
.02 NNP N
) ) N
to TO N
placebo VB N
, , N
and CC N
the DT N
combination NN N
was VBD N
statistically RB N
superior JJ N
( ( N
P NNP N
< NNP N
or= NNP N
.003 NNP N
) ) N
to TO N
either DT N
agent NN N
alone RB N
. . N

The DT N
TNSS NNP o
improved VBN N
by IN N
28.4 CD N
% NN N
with IN N
combination NN N
azelastine-fluticasone NN i
, , N
20.4 CD N
% NN N
with IN N
fluticasone NN i
, , N
16.4 CD N
% NN N
with IN N
azelastine NN i
, , N
and CC N
11.2 CD N
% NN N
with IN N
placebo NN i
. . i

All DT N
3 CD N
treatments NNS N
were VBD N
well RB N
tolerated VBN N
. . N

CONCLUSIONS VB N
The DT N
combination NN N
azelastine-fluticasone NN i
nasal NN N
spray NN N
provided VBD N
statistically RB N
significant JJ N
improvement NN N
in IN N
the DT N
TNSS NNP o
and CC N
additive JJ N
clinical JJ N
benefit NN N
compared VBN N
with IN N
either DT N
agent NN N
alone RB N
in IN N
patients NNS p
with IN p
moderate-to-severe JJ p
seasonal JJ p
allergic JJ p
rhinitis NN p
. . p

TRIAL NNP N
REGISTRATION NNP N
clinicaltrials.gov NN N
Identifier NNP N
: : N
NCT00660517 NN N
. . N

-DOCSTART- -15916851- O O

Association NNP N
between IN N
platelet NN N
activation NN N
and CC N
fibrinolysis NN N
in IN N
acute JJ p
stroke NN p
patients NNS p
. . p

We PRP N
aimed VBD N
to TO N
evaluate VB N
platelet NN N
activation NN N
and CC N
fibrinolyis NN N
in IN N
acute JJ p
atherosclerotic JJ p
ischemic JJ p
stroke NN p
patients NNS p
to TO N
clarify VB N
the DT N
relationship NN N
between IN N
them PRP N
. . N

Plasma VB o
P-selectin NNP o
antigen NN o
, , o
tissue NN o
plasminogen NN o
activator NN o
( ( o
tPA NN o
) ) o
antigen NN o
and CC o
activity NN o
, , o
and CC o
plasminogen NN o
activator NN o
inhibitor-1 JJ o
( ( o
PAI-1 NNP o
) ) o
activity NN o
were VBD N
determined VBN N
in IN N
60 CD p
acute JJ p
atherosclerotic JJ p
stroke NN p
patients NNS p
and CC p
matched VBN p
control NN p
subjects NNS p
. . p

All DT p
patients NNS p
were VBD p
examined VBN p
within IN p
72 CD p
h NN p
after IN p
stroke NN p
onset NN p
. . p

The DT N
levels NNS o
of IN o
P-selectin NNP o
, , o
tPA NN o
antigen NN o
, , o
and CC o
PAI-1 JJ o
activity NN o
were VBD N
all DT N
significantly RB o
higher JJR o
in IN N
stroke NN N
patients NNS N
compared VBN N
with IN N
controls NNS N
( ( N
all DT N
p VBP N
< $ N
0.0001 CD N
) ) N
; : N
the DT N
level NN o
of IN o
tPA JJ o
activity NN o
was VBD N
significantly RB N
lower JJR N
in IN N
patients NNS N
than IN N
that DT N
in IN N
controls NNS N
( ( N
p VB N
< RB N
0.0001 CD N
) ) N
. . N

These DT N
markers NNS N
did VBD N
not RB N
change VB N
much RB N
at IN N
different JJ N
time NN N
points NNS N
within IN N
72 CD N
h. NN N
In IN N
stroke NN N
group NN N
, , N
P-selectin NNP o
concentration NN o
was VBD N
highly RB N
correlated VBN N
to TO N
PAI-1 NNP o
activity NN o
( ( N
r NN N
= VBZ N
0.8433 CD N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
, , N
but CC N
not RB N
to TO N
tPA VB o
antigen NN o
( ( N
r JJ N
= NNP N
-0.1752 NNP N
, , N
p NN N
> NNP N
0.05 CD N
) ) N
, , N
and CC N
tPA NN o
activity NN o
( ( N
r NN N
= VBZ N
0.2465 CD N
, , N
p NN N
> NNP N
0.05 CD N
) ) N
, , N
which WDT N
was VBD N
further RBR N
confirmed VBN N
in IN N
the DT N
multiple JJ N
linear JJ N
regression NN N
analysis NN N
( ( N
F NNP N
= NNP N
47.052 CD N
, , N
p NN N
< NNP N
0.0001 CD N
) ) N
. . N

Our PRP$ N
results NNS N
indicate VBP N
increased JJ o
platelet NN o
activation NN o
and CC N
decreased JJ o
fibrinolysis NN o
in IN N
patients NNS p
with IN p
acute JJ p
atherosclerotic JJ p
ischemic JJ p
stroke NN p
. . p

Increased VBN N
platelet NN o
activation NN o
may MD N
be VB N
correlated VBN N
with IN N
decreased JJ N
fibrinolysis NN N
. . N

-DOCSTART- -8852235- O O

An DT N
occupation NN i
based VBN i
physical JJ i
activity NN i
intervention NN i
program NN i
: : i
improving NN o
fitness NN o
and CC o
decreasing VBG o
obesity NN o
. . o

The DT N
purpose NN N
of IN N
this DT N
quasi-experimental JJ N
study NN N
was VBD N
to TO N
determine VB N
the DT N
effectiveness NN N
of IN N
an DT N
occupation NN i
based VBN i
health NN i
and CC i
fitness NN i
program NN i
. . i

Subjects NNS p
were VBD p
1,504 CD p
police NNS p
trainees NNS p
( ( p
85 CD p
% NN p
male NN p
, , p
15 CD p
% NN p
female NN p
) ) p
with IN p
an DT p
ethnic JJ p
distribution NN p
of IN p
82 CD p
% NN p
white JJ p
, , p
16 CD p
% NN p
African JJ p
American NNP p
, , p
and CC p
2 CD p
% NN p
other JJ p
. . p

Data NNS p
were VBD p
collected VBN p
at IN p
25 CD p
sites NNS p
across IN p
the DT p
state NN p
of IN p
North NNP p
Carolina NNP p
. . p

The DT N
sites NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
either CC N
the DT N
experimental JJ N
group NN N
( ( i
implemented VBN i
the DT i
intervention NN i
) ) i
or CC N
the DT N
control NN N
group NN N
( ( i
continued VBN i
usual JJ i
training NN i
) ) i
. . N

As IN N
compared VBN N
with IN N
controls NNS N
, , N
subjects NNS N
at IN N
the DT N
experimental JJ N
sites NNS N
improved VBN N
significantly RB N
in IN N
cardiovascular JJ o
fitness NN o
( ( o
aerobic JJ o
power NN o
) ) o
, , o
general JJ o
muscular JJ o
strength NN o
( ( o
number NN o
of IN o
sit NN o
ups NNS o
per IN o
minute NN o
) ) o
, , o
and CC o
flexibility NN o
, , o
and CC o
lowered VBD o
their PRP$ o
body NN o
fat NN o
. . o

The DT N
intervention NN N
required VBN N
minimal JJ N
equipment NN N
and CC N
was VBD N
taught VBN N
primarily RB N
by IN N
peers NNS N
who WP N
received VBD N
a DT N
1 CD N
week NN N
training NN N
program NN N
. . N

This DT N
occupational JJ i
approach NN i
to TO N
improving VBG N
health NN N
could MD N
be VB N
particularly RB N
useful JJ N
in IN N
occupations NNS N
with IN N
many JJ N
workers NNS N
who WP N
seldom VBP N
engage VB N
in IN N
leisure NN N
time NN N
physical JJ N
activity NN N
. . N

-DOCSTART- -10726430- O O

Evaluating VBG N
a DT N
test NN N
protocol NN N
for IN N
predicting VBG N
maximum JJ o
lactate NN o
steady JJ o
state NN o
. . o

BACKGROUND NNP N
Maximum NNP N
lactate NN N
steady JJ N
state NN N
( ( N
MLSS NNP N
) ) N
is VBZ N
defined VBN N
as IN N
the DT N
highest JJS N
steady JJ N
state NN N
exercise NN N
level NN N
one CD N
can MD N
maintain VB N
while IN N
also RB N
maintaining VBG N
an DT N
equilibrium NN N
between IN N
the DT N
elimination NN N
of IN N
blood NN N
lactate NN N
and CC N
the DT N
diffusion NN N
of IN N
lactate NN N
into IN N
the DT N
blood NN N
. . N

MLSS NNP N
is VBZ N
an DT N
excellent JJ N
tool NN N
for IN N
assessing VBG N
fitness JJ N
level NN N
, , N
predicting VBG N
endurance NN N
performance NN N
, , N
and CC N
designing VBG N
training NN N
programs NNS N
. . N

METHODS NNP N
This DT N
investigation NN N
assesses VBZ N
the DT N
validity NN N
of IN N
the DT N
Lactate NNP i
Minimum NNP i
Test NNP i
( ( i
LMT NNP i
) ) i
, , N
which WDT N
consists VBZ N
of IN N
inducing VBG N
lactic JJ N
acidosis NN N
through IN N
a DT N
VO2peak NNP N
test NN N
, , N
followed VBN N
by IN N
an DT N
eight-minute JJ N
walking NN N
recovery NN N
and CC N
an DT N
incremental JJ N
exercise NN N
test NN N
, , N
to TO N
determine VB N
if IN N
the DT N
running VBG N
velocity NN N
associated VBN N
with IN N
the DT N
minimum JJ N
lactate NN N
value NN N
predicts VBZ N
the DT N
MLSS NNP N
velocity NN N
. . N

Following VBG N
this DT N
LMT NNP N
, , N
two CD N
constant JJ N
velocity NN N
28-minute JJ N
runs NNS N
were VBD N
performed VBN N
, , N
one CD N
at IN N
the DT N
predicted JJ N
MLSS NNP N
velocity NN N
( ( N
trial NN N
1 CD N
) ) N
and CC N
the DT N
other JJ N
0.13 CD N
m JJ N
sec-1 JJ N
( ( N
4-8 CD N
% NN N
) ) N
above IN N
the DT N
predicted JJ N
MLSS NNP N
velocity NN N
( ( N
trial NN N
2 CD N
) ) N
. . N

Ten CD p
active JJ p
female JJ p
subjects NNS p
participated VBD p
( ( p
32 CD p
+/- JJ p
7 CD p
yrs NN p
( ( p
mean JJ p
+/- NNP p
SD NNP p
) ) p
; : p
65.7 CD p
+/- JJ p
16.4 CD p
kg NN p
; : p
VO2peak NNP p
40.0 CD p
+/- JJ p
7.5 CD p
ml.kg-1.min-1 NN p
) ) p
. . p

RESULTS NNP N
During IN N
trial NN N
1 CD N
, , N
there EX N
was VBD N
a DT N
-0.6 JJ N
+/- JJ N
0.3 CD N
mmol JJ N
l-1 NN N
( ( N
mean JJ N
+/- NNP N
SE NNP N
) ) N
change NN o
in IN o
lactate NN o
. . o

Based VBN N
on IN N
a DT N
definition NN N
of IN N
lactate NN o
steady JJ o
state NN o
( ( o
LSS NNP o
) ) o
as IN N
less JJR N
than IN N
a DT N
0.5 CD N
mmol.l-1 JJ N
increase NN N
, , N
this DT N
value NN N
signified VBD N
LSS NNP N
. . N

A DT N
similar JJ N
comparison NN N
during IN N
trial NN N
2 CD N
revealed VBD N
a DT N
1.8 CD N
+/- JJ N
0.3 CD N
mmol.l-1 JJ N
increase NN N
in IN N
lactate NN o
, , N
signifying VBG N
a DT N
workload NN N
above IN N
LSS NNP N
and CC N
therefore RB N
confirming VBG N
trial NN N
1 CD N
as IN N
the DT N
maximum JJ N
LSS NNP N
( ( N
MLSS NNP N
) ) N
. . N

CONCLUSIONS NNP N
These DT N
results NNS N
suggest VBP N
that IN N
the DT N
test NN N
protocol NN N
accurately RB N
predicted VBD N
the DT N
MLSS NNP o
velocity NN o
. . o

-DOCSTART- -16296713- O O

An DT N
open JJ N
multicenter NN N
efficacy NN o
and CC o
safety NN o
evaluation NN o
of IN N
amlodipine NN i
in IN N
the DT N
treatment NN N
of IN N
symptomatic JJ p
myocardial JJ p
ischemia NN p
. . p

The DT N
efficacy NN o
and CC o
safety NN o
of IN N
amlodipine NN i
( ( N
5-10 JJ N
mg NN N
) ) N
once RB N
daily JJ N
were VBD N
studied VBN N
in IN N
an DT p
open JJ p
study NN p
in IN p
patients NNS p
with IN p
symptomatic JJ p
myocardial JJ p
ischemia NN p
. . p

The DT N
study NN N
is VBZ N
ongoing VBG N
and CC N
this DT N
report NN N
is VBZ N
based VBN N
on IN N
an DT N
interim JJ N
analysis NN N
of IN N
data NNS p
from IN p
78 CD p
patients NNS p
. . p

A DT N
2-week JJ N
baseline NN N
period NN N
in IN N
which WDT N
patients NNS N
maintained VBD N
their PRP$ N
current JJ i
antianginal JJ i
therapy NN i
was VBD N
followed VBN N
by IN N
a DT N
10-week JJ N
treatment NN N
period NN N
with IN N
5-10 JJ N
mg NN N
of IN N
amlodipine/day NN i
. . N

Both CC N
the DT N
median JJ o
number NN o
of IN o
angina JJ o
attacks NNS o
per IN o
week NN o
and CC o
the DT o
median JJ o
number NN o
of IN o
nitroglycerin NN o
( ( o
NTG NNP o
) ) o
tablets NNS o
consumed/week VBP o
were VBD N
significantly RB N
reduced VBN N
after IN N
amlodipine NN i
( ( N
mean JJ N
daily RB N
dose NN N
of IN N
8.6 CD N
mg NNS N
) ) N
when WRB N
compared VBN N
with IN N
baseline NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

A DT N
total NN N
of IN N
98.4 CD N
% NN N
of IN N
patients NNS N
( ( N
63/64 CD N
) ) N
experienced VBD N
a DT N
reduction NN N
in IN N
the DT N
frequency NN o
of IN o
angina JJ o
attacks/week NN o
and CC N
91 CD N
% NN N
of IN N
patients NNS N
( ( N
58/64 CD N
) ) N
had VBD N
angina VBN o
attacks NNS o
reduced VBD N
to TO N
< VB N
or CC N
= VB N
2/week CD N
. . N

In IN N
self-assessments NNS o
, , N
95 CD N
% NN N
of IN N
patients NNS N
( ( N
55/58 CD N
) ) N
reported VBD N
improved JJ N
angina NNS o
control NN o
and CC N
91 CD N
% NN N
( ( N
53/58 CD N
) ) N
felt VBD N
their PRP$ N
ability NN o
to TO o
perform VB o
usual JJ o
activities NNS o
had VBD N
improved VBN N
. . N

Twenty-seven JJ N
patients NNS N
experienced JJ N
adverse JJ o
events NNS o
reported VBN N
as IN N
drug NN N
related VBN N
. . N

The DT N
most RBS N
common JJ N
adverse JJ o
event NN o
noted VBD N
was VBD N
edema RB o
. . o

Amlodipine NNP i
once RB N
daily RB N
significantly RB N
reduced VBN N
the DT N
incidence NN o
of IN o
angina NN o
attacks NNS o
and CC N
the DT N
concomitant JJ N
need NN o
of IN o
nitroglycerin NN o
for IN N
relief NN N
of IN N
symptoms NNS N
and CC N
thus RB N
improved VBN N
the DT N
patients NNS N
' POS N
ability NN N
to TO N
perform VB N
daily JJ N
activities NNS N
. . N

Most JJS N
adverse JJ N
events NNS N
reported VBN N
were VBD N
mild JJ N
or CC N
moderate JJ N
and CC N
the DT N
incidence NN N
is VBZ N
as RB N
would MD N
be VB N
expected VBN N
in IN N
this DT N
patient JJ N
population NN N
. . N

-DOCSTART- -23905378- O O

[ NN N
Treating VBG N
rheumatoid JJ p
arthritis NN p
patients NNS p
of IN p
Shen NNP p
deficiency NN p
and CC p
cold JJ p
invading NN p
syndrome NN p
by IN p
bushen NN i
quhan NN i
zhiwang CD i
decoction NN i
combined VBN i
methotrexate NN i
: : i
an DT N
evaluation NN N
of IN N
clinical JJ N
efficacy NN N
and CC N
safety NN N
] NN N
. . N

OBJECTIVE UH N
To TO N
evaluate VB N
the DT N
clinical JJ N
efficacy NN N
and CC N
safety NN N
of IN N
bushen NN i
quhan NN i
zhiwang CD i
decoction NN i
( ( i
BQZD NNP i
) ) i
combined VBN i
methotrexate NN i
( ( i
MTX NNP i
) ) i
in IN N
treating VBG N
rheumatoid NN N
arthritis NN N
( ( N
RA NNP N
) ) N
. . N

METHODS CC N
A DT N
prospective JJ N
, , N
randomized VBN N
controlled VBD N
study NN N
was VBD N
carried VBN N
out RP N
. . N

RA NNP p
patients NNS p
of IN p
Shen NNP p
deficiency NN p
and CC p
cold JJ p
invading NN p
syndrome NN p
in IN p
the DT p
treatment NN p
group NN p
( ( p
120 CD p
cases NNS p
) ) p
were VBD p
treated VBN p
with IN p
BQZD NNP i
and CC i
MTX NNP i
( ( i
10 CD i
mg/week NN i
) ) i
, , N
while IN N
those DT N
in IN N
the DT N
control NN p
group NN p
( ( p
120 CD p
cases NNS p
) ) p
were VBD p
treated VBN i
with IN i
MTX NNP i
( ( i
10 CD i
mg/week NN i
) ) i
alone RB i
. . i

The DT N
therapeutic JJ N
course NN N
for IN N
all DT N
was VBD N
24 CD N
weeks NNS N
. . N

The DT N
efficacy NN N
and CC N
safety NN N
indices NNS N
were VBD N
evaluated VBN N
at IN N
the DT N
baseline NN N
and CC N
24 CD N
weeks NNS N
after IN N
treatment NN N
, , N
including VBG N
clinical JJ o
signs NNS o
and CC o
symptoms NNS o
, , o
condition NN o
assessment NN o
, , o
Health NNP o
Assessment NNP o
Questionnaire NNP o
( ( o
HAQ NNP o
) ) o
, , o
disease NN o
activity NN o
index NN o
28 CD o
( ( o
DAS28 NNP o
) ) o
, , o
laboratory JJ o
parameters NNS o
of IN o
erythrocyte JJ o
sedimentation NN o
rate NN o
( ( o
ESR NNP o
) ) o
and CC o
C-reactive JJ o
protein NN o
( ( o
CRP NNP o
) ) o
, , o
safety NN o
indicators NNS o
, , o
and CC o
Chinese NNP o
medical JJ o
syndrome NN o
integrals NNS o
. . o

RESULTS VB N
The DT N
total JJ N
effective JJ N
rate NN N
was VBD N
80 CD N
. . N

0 CD N
% NN N
in IN N
the DT N
treatment NN N
group NN N
, , N
better JJR N
than IN N
that DT N
of IN N
the DT N
control NN N
group NN N
( ( N
66.7 CD N
% NN N
) ) N
, , N
showing VBG N
statistical JJ N
difference NN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

In IN N
the DT N
two CD N
groups NNS N
significant JJ N
improvement NN N
of IN N
clinical JJ o
signs NNS o
and CC o
symptoms NNS o
, , o
ESR NNP o
, , o
CRP NNP o
, , o
visual JJ o
analogue NN o
scale NN o
( ( o
VAS NNP o
) ) o
by IN N
both DT N
physicians NNS N
and CC N
patients NNS N
, , N
HAQ NNP o
, , o
DAS28 NNP o
, , N
and CC N
Chinese NNP N
medical JJ N
syndrome NN N
integrals NNS N
after IN N
treatment NN N
were VBD N
shown VBN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

Better JJR N
effects NNS N
were VBD N
obtained VBN N
in IN N
the DT N
treatment NN N
group NN N
in IN N
lessening VBG N
tender NN o
joint NN o
numbers NNS o
and CC o
swollen JJ o
joint NN o
numbers NNS o
, , N
VAS NNP N
by IN N
both DT N
physicians NNS N
and CC N
patients NNS N
, , N
DAS28 NNP N
, , N
and CC N
Chinese NNP N
medical JJ N
syndrome NN N
integrals NNS N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

Besides NNP N
, , N
adverse JJ N
reactions NNS N
occurred VBD N
less RBR N
in IN N
the DT N
treatment NN N
group NN N
than IN N
in IN N
the DT N
control NN N
group NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

CONCLUSIONS NNP N
BQZD NNP i
had VBD N
roles NNS N
in IN N
relieving VBG N
symptoms NNS N
, , N
improving VBG N
joint JJ N
functions NNS N
, , N
signs NNS N
, , N
ESR NNP N
, , N
and CC N
CRP NNP N
. . N

It PRP N
was VBD N
an DT N
effective JJ N
herb NN N
for IN N
RA NNP p
patients NNS p
of IN p
Shen NNP p
deficiency NN p
and CC p
cold JJ p
invading NN p
syndrome NN p
. . p

It PRP N
could MD N
enhance VB N
the DT N
efficacy NN N
and CC N
reduce VB N
adverse JJ N
reactions NNS N
of IN N
MTX NNP N
through IN N
synergistic JJ N
effects NNS N
with IN N
MTX NNP N
. . N

-DOCSTART- -23379651- O O

Pretreatment NN N
and CC N
co-administration NN N
of IN N
oral JJ i
anti-diabetic JJ i
agent NN i
with IN N
clomiphene JJ i
citrate NN i
or CC N
rFSH NN i
for IN N
ovulation NN N
induction NN N
in IN N
clomiphene-citrate-resistant JJ p
polycystic JJ p
ovary JJ p
syndrome NN p
. . p

AIM IN N
The DT N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
explore VB N
the DT N
result NN N
of IN N
pretreatment NN N
and CC N
concomitant NN N
use NN N
of IN N
metformin NN i
with IN N
clomiphene JJ i
citrate NN i
( ( i
CC NNP i
) ) i
and CC N
rFSH NN i
for IN N
ovulation NN N
induction NN N
in IN N
clomiphene-citrate-resistant JJ p
polycystic JJ p
ovary JJ p
syndrome NN p
( ( p
PCOS NNP p
) ) p
. . p

MATERIAL NNP N
AND CC N
METHODS NNP N
This DT N
randomized VBD N
controlled JJ N
trial NN N
was VBD N
done VBN N
in IN N
the DT N
Dhaka NNP p
Medical NNP p
College NNP p
and CC p
Hospital NNP p
and CC p
the DT p
Infertility NNP p
Care NNP p
and CC p
Research NNP p
Centre NNP p
, , p
Dhaka NNP p
, , p
Bangladesh NNP p
. . p

A NNP N
total NN N
of IN N
165 CD p
infertile JJ p
patients NNS p
with IN p
CC-resistant JJ p
PCOS NNP p
who WP p
attended VBD p
for IN p
treatment NN p
were VBD p
the DT p
target NN p
population NN p
for IN p
this DT p
study NN p
. . p

Patients NNS N
were VBD N
divided VBN N
into IN N
three CD N
groups NNS N
: : N
groups NNS N
A DT N
and CC N
B NNP N
were VBD N
given VBN N
metformin NNS i
and CC N
group NN N
C NNP N
was VBD N
the DT N
control NN i
. . i

Along IN N
with IN N
metformin NN i
, , N
group NN N
A NNP N
received VBD N
CC NNP i
and CC N
group NN N
B NNP N
received VBD N
rFSH NN i
. . i

Group NNP N
C NNP N
was VBD N
treated VBN N
with IN N
only RB N
rFSH NN i
. . i

Metformin NNP i
was VBD N
given VBN N
1500 CD N
mg JJ N
daily JJ N
for IN N
4 CD N
weeks NNS N
. . N

Afterwards NNS i
CC NNP i
or CC i
rFSH VB i
were VBD i
added VBN N
for IN N
induction NN N
of IN N
ovulation NN N
along IN N
with IN i
metformin NN i
. . i

Six NNP N
ovulatory JJ N
cycles NNS N
were VBD N
assessed VBN N
. . N

Treatment NNP N
was VBD N
terminated VBN N
when WRB N
there EX N
was VBD N
no DT N
response NN N
with IN N
maximum JJ N
dose NN N
of IN N
CC NNP i
and CC i
rFSH NN i
or CC i
after IN N
six CD N
ovulatory JJ N
cycles NNS N
without IN N
pregnancy NN N
or CC N
after IN N
achieving VBG N
pregnancy NN N
. . N

A DT N
P-value NNP N
of IN N
< NNP N
0.5 CD N
was VBD N
considered VBN N
as IN N
significant JJ N
. . N

RESULTS NNP o
Ovulation NNP o
( ( o
89.09 CD N
% NN N
) ) N
and CC o
pregnancy NN o
( ( o
54.55 CD N
% NN N
) ) N
rates NNS N
were VBD N
higher JJR N
in IN N
group NN N
B. NNP N
Ovulation NNP o
( ( o
74.55 CD N
% NN N
) ) N
and CC o
pregnancy NN o
( ( o
29.09 CD N
% NN N
) ) N
rates NNS N
were VBD N
also RB N
satisfactory JJ N
in IN N
group NN N
C NNP N
but CC N
a DT N
dose NN N
of IN N
rFSH JJ i
requirement NN i
was VBD N
significantly RB N
higher JJR N
( ( N
P NNP N
= NNP N
0.000 CD N
) ) N
. . N

In IN N
group NN N
A NNP N
, , N
both DT N
ovulation NN o
and CC o
pregnancy NN o
rate NN o
were VBD N
much RB N
lower JJR N
than IN N
the DT N
other JJ N
two CD N
groups NNS N
( ( N
27.27 CD N
% NN N
and CC N
12.73 CD N
% NN N
, , N
respectively RB N
) ) N
. . N

CONCLUSIONS NNP N
Use NNP N
of IN N
metformin NN i
increases VBZ i
the DT N
response NN N
of IN N
ovulation-inducing JJ N
agents NNS N
and CC N
can MD N
be VB N
used VBN N
safely RB N
in IN p
PCOS NNP p
. . p

-DOCSTART- -10374155- O O

Primary JJ i
capsulectomy NN i
, , i
anterior JJ i
vitrectomy NN i
, , i
lensectomy NN i
, , i
and CC i
posterior JJ i
chamber NN i
lens NNS i
implantation NN i
in IN p
children NNS p
: : p
limbal JJ N
versus NN N
pars NNS N
plana VBP N
. . N

PURPOSE NNP N
To TO N
compare VB N
the DT N
results NNS N
of IN N
a DT N
limbal JJ i
versus NN N
a DT N
pars NNS i
plana VBP i
approach NN i
for IN N
primary JJ i
posterior JJ i
capsulectomy NN i
and CC i
anterior JJ i
vitrectomy NN i
in IN N
the DT N
management NN N
of IN N
childhood NN o
cataract NN o
. . o

SETTING NNP N
Department NNP N
of IN N
Ophthalmology NNP N
, , N
Labbafinejad NNP N
Medical NNP N
Center NNP N
, , N
Tehran NNP N
, , N
Iran NNP N
. . N

METHODS NNP N
A NNP N
randomized NN N
, , N
controlled VBN N
, , N
double-masked JJ N
clinical JJ N
trial NN N
of IN N
45 CD p
eyes NNS p
was VBD N
conducted VBN N
. . N

After IN N
being VBG N
matched VBN N
, , N
38 CD p
eyes NNS p
were VBD p
included VBN p
in IN N
the DT N
study NN N
and CC N
were VBD N
divided VBN N
into IN N
2 CD N
equal JJ N
groups NNS N
for IN N
data NNS N
analysis NN N
. . N

All DT p
eyes NNS p
had VBD p
lensectomy NN i
and CC i
posterior JJ i
chamber NN i
intraocular JJ i
lens NNS i
( ( i
PC NNP i
IOL NNP i
) ) i
implantation NN i
. . i

Primary JJ i
posterior JJ i
capsulectomy NN i
and CC i
anterior JJ i
vitrectomy NN i
were VBD N
performed VBN N
through IN N
the DT N
limbus NN N
in IN N
half NN N
of IN N
the DT N
eyes NNS N
and CC N
the DT N
pars NNS N
plana VBP N
in IN N
the DT N
other JJ N
half NN N
. . N

Main NNP N
outcome NN N
measures NNS N
included VBD N
visual JJ o
acuity NN o
, , o
estimated VBN o
red JJ o
reflex NN o
, , o
postsurgical JJ o
inflammatory NN o
reaction NN o
, , o
corneal JJ o
clarity NN o
, , o
posterior JJ o
synechias NN o
, , o
iris JJ o
capture NN o
, , o
IOL NNP o
position NN o
, , o
capsulectomy JJ o
size NN o
, , o
glaucoma NN o
, , o
cystoid JJ o
macular NN o
edema NN o
, , o
retinal JJ o
tear NN o
, , o
and CC o
postoperative JJ o
refraction NN o
. . o

RESULTS NNP N
No NNP N
statistically RB N
significant JJ N
differences NNS N
were VBD N
found VBN N
between IN N
the DT N
2 CD N
approaches NNS N
in IN N
the DT N
outcome NN N
measures NNS N
. . N

CONCLUSION NNP N
The DT N
anatomic JJ N
and CC N
visual JJ N
results NNS N
were VBD N
encouraging VBG N
when WRB N
posterior JJ i
capsulectomy NN i
and CC i
anterior JJ i
vitrectomy NN i
, , N
using VBG N
a DT N
limbal NN N
or CC N
pars NNS N
plana IN N
approach NN N
, , N
were VBD N
combined VBN N
with IN N
lensectomy NN i
and CC i
PC NN i
IOL NNP i
implantation NN i
in IN N
children NNS p
. . p

The DT N
application NN N
of IN N
these DT N
techniques NNS N
depends VBZ N
on IN N
surgeon JJ N
experience NN N
and CC N
skill NN N
. . N

-DOCSTART- -22904179- O O

Adult NNP p
height NN p
in IN p
short JJ p
children NNS p
born VBN p
SGA NNP p
treated VBD p
with IN p
growth NN i
hormone NN i
and CC i
gonadotropin NN i
releasing VBG i
hormone NN i
analog NN i
: : i
results NNS N
of IN N
a DT N
randomized JJ N
, , N
dose-response JJ N
GH NNP i
trial NN N
. . N

CONTEXT NNP N
GH NNP i
treatment NN i
is VBZ N
effective JJ N
in IN N
improving VBG N
height NN N
in IN N
short JJ p
children NNS p
born VBP p
small JJ p
for IN p
gestational JJ p
age NN p
( ( p
SGA NNP p
) ) p
. . p

GH NNP i
is VBZ N
thought VBN N
to TO N
have VB N
limited VBN N
effect NN N
when WRB N
started VBD N
during IN N
adolescence NN N
. . N

OBJECTIVE CC N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
investigate VB N
GH NNP i
treatment NN i
efficacy NN o
in IN N
short JJ N
SGA NNP N
children NNS N
when WRB N
treatment NN N
was VBD N
started VBN N
during IN N
adolescence NN N
; : N
to TO N
assess VB N
whether IN N
GH NNP i
2 CD i
mg/m NN i
( ( i
2 CD i
) ) i
? . N
d NN N
during IN N
puberty JJ N
improves NNS o
adult VBP o
height NN o
( ( o
AH NNP o
) ) o
compared VBN N
with IN N
1 CD N
mg/m NNS N
( ( N
2 CD N
) ) N
? . N
d NN N
; : N
and CC N
to TO N
assess VB N
whether IN N
an DT N
additional JJ N
2-yr JJ N
postponement NN N
of IN N
puberty NN N
by IN N
GnRH NNP i
analog NN i
( ( i
GnRHa NNP i
) ) i
improves VBZ i
AH NNP N
in IN N
children NNS N
who WP N
are VBP N
short JJ N
at IN N
the DT N
start NN N
of IN N
puberty NN N
( ( N
< JJ N
140 CD N
cm NN N
) ) N
, , N
with IN N
a DT N
poor JJ N
AH NNP N
expectation NN p
. . p

PATIENTS NNP N
AND CC N
DESIGN NNP N
In IN N
this DT N
longitudinal JJ N
, , N
randomized VBN N
, , N
dose-response JJ N
GH NNP N
trial NN N
, , N
we PRP N
included VBD p
121 CD p
short JJ p
SGA NNP p
children NNS p
( ( p
60 CD p
boys NNS p
) ) p
at IN p
least JJS p
8 CD p
yr NN p
of IN p
age NN p
. . p

We PRP N
performed VBD p
intention-to-treat JJ p
analyses NNS p
on IN p
all DT p
children NNS p
and CC p
uncensored JJ p
case NN p
analyses VBZ p
on IN p
84 CD p
children NNS p
who WP p
reached VBD p
AH NNP p
. . p

Besides NNP N
, , N
we PRP N
evaluated VBD o
growth NN o
during IN o
2 CD N
yr NNS N
of IN N
combined JJ i
GH/GnRHa NNP i
and CC i
subsequent JJ i
GH NNP i
treatment NN i
until IN i
AH NNP N
in IN N
a DT N
subgroup NN N
of IN N
40 CD N
pubertal JJ N
children NNS N
with IN N
a DT N
height NN N
of IN N
less JJR N
than IN N
140 CD N
cm NN N
at IN N
the DT N
start NN N
. . N

RESULTS NNP p
Short NNP p
SGA NNP p
children NNS p
started VBD p
treatment NN N
at IN N
a DT N
median JJ N
age NN N
of IN N
11.2 CD N
yr NNS N
, , N
when WRB N
46 CD N
% NN N
had VBD N
already RB N
started VBN N
puberty NN o
. . o

Median JJ o
height NN o
increased VBD o
from IN N
-2.9 NN N
at IN N
start NN N
to TO N
-1.7 VB N
sd NN N
score NN N
( ( N
SDS NNP N
) ) N
at IN N
AH NNP N
( ( N
P NNP N
< NNP N
0.001 CD i
) ) i
. . i

Treatment NN i
with IN i
GH NNP i
2 CD i
vs. FW N
1 CD N
mg/m NN N
( ( N
2 CD N
) ) N
? . N
d NN N
during IN N
puberty NN N
resulted VBD N
in IN N
significantly RB N
better JJR o
AH NNP o
( ( N
P NNP N
= NNP N
0.001 CD N
) ) N
, , N
also RB N
after IN N
correction NN N
for IN N
gender NN N
, , N
age NN N
at IN N
start NN N
, , N
height VBD N
SDS NNP N
at IN N
start NN N
, , N
treatment NN N
years NNS N
before IN N
puberty NN N
, , N
and CC N
target VB N
height JJ N
SDS NNP N
. . o

AH NNP o
was VBD N
similar JJ N
in IN N
children NNS N
who WP N
started VBD N
puberty NN N
at IN N
less JJR N
than IN N
140 CD N
cm NN N
and CC N
received VBD i
GH/GnRHa NNP i
, , i
compared VBN i
with IN N
children NNS N
who WP N
started VBD N
puberty NN N
greater JJR N
than IN N
140 CD N
cm NN N
and CC N
received VBD i
GH NNP i
only RB i
( ( i
P NNP i
= NNP N
0.795 CD N
) ) N
. . N

CONCLUSION NN N
When WRB N
started VBN N
in IN N
adolescence NN i
, , i
GH NNP i
treatment NN i
significantly RB i
improves VBZ o
AH NNP o
in IN N
short JJ p
SGA NNP p
children NNS p
, , p
particularly RB p
with IN i
GH NNP i
2 CD p
mg/m NN p
( ( p
2 CD p
) ) p
? . p
d NN p
during IN p
puberty NN p
. . p

When WRB p
SGA NNP N
children NNS N
are VBP N
short JJ N
at IN N
the DT N
start NN N
of IN N
puberty NN N
, , N
they PRP N
can MD N
benefit VB N
from IN N
combined JJ i
GH/GnRHa NNP i
treatment NN i
. . i

-DOCSTART- -11570966- O O

Benefit NN N
of IN N
FSH NNP i
priming NN i
of IN N
women NNS p
with IN p
PCOS NNP p
to TO N
the DT N
in IN N
vitro JJ N
maturation NN N
procedure NN N
and CC N
the DT N
outcome NN N
: : N
a DT N
randomized JJ N
prospective JJ N
study NN N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
whether IN N
the DT N
rates NNS o
of IN o
in IN o
vitro JJ o
oocyte JJ o
maturation NN o
, , o
fertilization NN o
and CC o
cleavage NN o
, , N
as RB N
well RB N
as IN N
implantation NN o
rate NN o
and CC o
pregnancy NN o
rate NN o
, , N
could MD N
be VB N
improved VBN N
by IN N
low-dose JJ N
priming NN N
with IN N
FSH NNP i
in IN N
vivo NN N
before IN N
retrieval NN N
of IN N
immature NN N
oocytes NNS N
in IN N
patients NNS p
with IN p
polycystic JJ p
ovary JJ p
syndrome NN p
( ( p
PCOS NNP p
) ) p
. . p

From IN p
March NNP p
1998 CD p
to TO p
June NNP p
2000 CD p
, , p
a DT p
total NN p
of IN p
28 CD p
women NNS p
underwent JJ p
36 CD p
completed VBN p
treatment NN p
cycles NNS p
, , N
randomized VBN N
sequentially RB N
in IN N
one CD N
of IN N
two CD N
groups NNS N
. . N

Women NNP N
in IN N
group NN N
1 CD N
( ( N
n JJ N
= $ N
12 CD N
cycles NNS N
) ) N
received VBD N
no DT i
stimulation NN i
and CC N
women NNS N
in IN N
group NN N
2 CD N
( ( N
n JJ N
= $ N
24 CD N
cycles NNS N
) ) N
received VBD N
150 CD N
iu NN N
recombinant JJ i
FSH NNP i
day NN N
( ( N
-1 NNP N
) ) N
for IN N
3 CD N
days NNS N
, , N
initiated VBN N
on IN N
day NN N
3 CD N
after IN N
menstruation NN N
. . N

Aspiration NN N
was VBD N
performed VBN N
transvaginally RB N
between IN N
day NN N
9 CD N
and CC N
day NN N
17 CD N
in IN N
the DT N
unstimulated JJ N
group NN N
and CC N
on IN N
day NN N
8 CD N
or CC N
day NN N
9 CD N
in IN N
the DT N
FSH-primed NNP N
group NN N
after IN N
FSH NNP N
deprivation NN N
for IN N
2 CD N
or CC N
3 CD N
days NNS N
. . N

All DT N
cumulus-enclosed JJ N
oocytes NNS N
of IN N
healthy JJ N
appearance NN N
were VBD N
matured VBN N
in IN N
culture NN N
medium NN N
( ( N
TCM-199 NNP N
) ) N
in IN N
vitro NN N
for IN N
28-36 JJ N
h NN N
before IN N
intracytoplasmic JJ N
sperm NN N
injection NN N
( ( N
ICSI NNP N
) ) N
. . N

After IN N
oocyte JJ N
retrieval NN N
the DT N
women NNS N
were VBD N
given VBN N
oestradiol NNS N
( ( N
6 CD N
mg NNS N
day NN N
( ( N
-1 NNP N
) ) N
) ) N
and CC N
progesterone JJ N
administration NN N
( ( N
300 CD N
mg NNS N
day NN N
( ( N
-1 NNP N
) ) N
) ) N
was VBD N
initiated VBN N
2 CD N
days NNS N
later RB N
. . N

Suitable JJ N
embryos NN N
( ( N
maximum JJ N
two CD N
embryos NN N
) ) N
were VBD N
transferred VBN N
on IN N
day NN N
3 CD N
after IN N
ICSI NNP N
. . N

The DT N
percentage NN o
of IN o
oocytes NNS o
reaching VBG o
metaphase NN o
II NNP o
was VBD N
significantly RB N
higher JJR N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
in IN N
the DT N
FSH-primed NNP N
group NN N
( ( N
59 CD N
% NN N
, , N
92/156 CD N
) ) N
compared VBN N
with IN N
the DT N
non-primed JJ N
group NN N
( ( N
44 CD N
% NN N
, , N
36/81 CD N
) ) N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
the DT N
rates NNS o
of IN o
oocyte JJ o
fertilization NN o
and CC o
cleavage NN o
between IN N
these DT N
groups NNS N
. . N

No DT N
pregnancies NNS o
were VBD N
obtained VBN N
in IN N
group NN N
1 CD N
( ( N
0 CD N
% NN N
, , N
0/12 CD N
) ) N
, , N
whereas JJ N
seven CD N
clinical JJ o
pregnancies NNS o
were VBD N
obtained VBN N
in IN N
group NN N
2 CD N
( ( N
29 CD N
% NN N
, , N
7/24 CD N
) ) N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

In IN N
group NN N
2 CD N
, , N
37 CD N
embryo NN N
transfers NNS N
resulted VBD N
in IN N
eight CD N
implantations NNS o
( ( N
21.6 CD N
% NN N
) ) N
. . N

Three CD N
healthy JJ o
singleton NN o
children NNS o
have VBP N
been VBN N
born VBN o
at IN N
term NN N
; : N
the DT N
remaining VBG N
pregnancies NNS N
ended VBN N
with IN N
spontaneous JJ o
abortions NNS o
in IN N
the DT N
first JJ N
trimester NN N
. . N

These DT N
results NNS N
indicate VBP N
that IN N
priming VBG N
with IN N
recombinant JJ N
FSH NNP N
before IN N
harvesting NN N
of IN N
immature NN N
oocytes NNS N
from IN N
patients NNS p
with IN p
PCOS NNP p
may MD N
improve VB N
the DT N
maturational JJ o
potential NN o
of IN o
the DT o
oocytes NNS o
and CC o
the DT o
implantation NN o
rate NN o
of IN o
the DT o
cleaved JJ o
embryos NN o
. . o

-DOCSTART- -20447774- O O

Acute NNP o
and CC o
late JJ o
toxicity NN o
in IN N
a DT N
randomized JJ N
trial NN N
of IN N
conventional JJ i
versus NN N
hypofractionated VBD i
three-dimensional JJ i
conformal JJ i
radiotherapy NN i
for IN N
prostate NN p
cancer NN p
. . p

PURPOSE NNP N
To TO N
compare VB N
the DT N
toxicity NN N
between IN N
hypofractionation NN i
vs. FW i
conventional JJ i
fractionation NN i
schedules NNS N
in IN N
patients NNS p
with IN p
high-risk JJ p
prostate NN p
cancer NN p
. . p

METHODS NNP N
AND CC N
MATERIALS NNP N
Between NNP p
January NNP p
2003 CD p
and CC p
December NNP p
2007 CD p
, , p
168 CD p
patients NNS p
were VBD N
randomized VBN N
to TO N
receive VB N
either RB N
hypofractionated VBN i
( ( N
62 CD N
Gy NNP N
in IN N
20 CD N
fractions NNS N
within IN N
5 CD N
weeks NNS N
, , N
4 CD N
fractions/wk NN N
) ) N
or CC i
conventionally RB i
fractionated VBN i
( ( N
80 CD N
Gy NNP N
in IN N
40 CD N
fractions NNS N
within IN N
8 CD N
weeks NNS N
) ) N
three-dimensional JJ i
conformal JJ i
radiotherapy NN i
to TO N
the DT N
prostate NN N
and CC N
seminal JJ N
vesicles NNS N
. . N

All DT p
patients NNS p
had VBD p
undergone RP p
a DT p
9-month JJ p
course NN p
of IN p
total JJ p
androgen NN p
deprivation NN p
, , p
with IN p
radiotherapy NN p
starting VBG p
2 CD p
months NNS p
after IN p
initiation NN p
of IN p
the DT p
total JJ p
androgen NN p
deprivation NN p
. . p

RESULTS VB N
The DT N
median JJ N
follow-up NN N
was VBD N
32 CD N
and CC N
35 CD N
months NNS N
in IN N
the DT N
hypofractionation NN N
and CC N
conventional JJ N
fractionation NN N
arms NNS N
, , N
respectively RB N
. . N

For IN N
the DT N
patients NNS N
developing VBG N
acute JJ N
toxicity NN N
, , N
no DT N
difference NN N
between IN N
the DT N
two CD N
fractionation NN N
groups NNS N
was VBD N
found VBN N
in IN N
either DT N
severity NN o
or CC o
duration NN o
of IN o
gastrointestinal JJ o
or CC o
genitourinary JJ o
toxicity NN o
. . o

Also RB N
, , N
no DT N
difference NN N
was VBD N
found VBN N
in IN N
the DT N
incidence NN N
and CC N
severity NN o
of IN o
late JJ o
gastrointestinal NN o
and CC o
genitourinary JJ o
toxicity NN o
between IN N
the DT N
two CD N
treatment NN N
schedules NNS N
, , N
with IN N
a DT N
3-year JJ N
rate NN N
of IN N
Grade NNP N
2 CD N
or CC N
greater JJR N
toxicity NN N
of IN N
17 CD N
% NN N
and CC N
16 CD N
% NN N
for IN N
the DT N
hypofractionation NN N
arm NN N
and CC N
14 CD N
% NN N
and CC N
11 CD N
% NN N
for IN N
the DT N
conventional JJ N
fractionation NN N
arm NN N
, , N
respectively RB N
. . N

A DT N
statistically RB N
significant JJ N
correlation NN N
between IN N
acute NN o
and CC o
late JJ o
gastrointestinal JJ o
toxicity NN o
was VBD N
found VBN N
only RB N
in IN N
the DT N
conventional JJ N
fractionation NN N
group NN N
. . N

CONCLUSION NNP N
Our PRP$ N
findings NNS N
suggest VBP N
that IN N
the DT N
hypofractionation NN i
regimen NNS N
used VBN N
in IN N
our PRP$ N
study NN N
is VBZ N
safe JJ N
, , N
with IN N
only RB N
a DT N
slight NN N
, , N
nonsignificant JJ N
increase NN N
in IN N
tolerable JJ o
and CC o
temporary JJ o
acute NN o
toxicity NN o
compared VBN N
with IN N
the DT N
conventional JJ N
fractionation NN N
schedule NN N
. . N

The DT N
severity NN N
and CC N
frequency NN N
of IN N
late JJ N
complications NNS N
was VBD N
equivalent JJ N
between IN N
the DT N
two CD N
treatment NN N
groups NNS N
. . N

-DOCSTART- -2788816- O O

A DT N
comparison NN N
of IN N
sclerotherapy NN i
with IN N
staple JJ i
transection NN i
of IN i
the DT i
esophagus NN i
for IN N
the DT N
emergency NN N
control NN o
of IN o
bleeding VBG o
from IN p
esophageal JJ p
varices NNS p
. . p

We PRP N
compared VBN N
two CD N
procedures NNS N
for IN N
the DT N
emergency NN N
treatment NN N
of IN N
bleeding VBG o
esophageal JJ p
varices NNS p
in IN p
patients NNS p
who WP p
did VBD p
not RB p
respond VB p
to TO p
blood VB p
transfusion NN p
and CC p
vasoactive JJ p
drugs NNS p
. . p

We PRP N
randomly VBP N
assigned VBD N
101 CD p
patients NNS p
with IN p
cirrhosis NN p
of IN p
the DT p
liver NN p
and CC p
bleeding VBG p
esophageal JJ p
varices NNS p
to TO N
undergo VB i
either DT i
emergency NN i
sclerotherapy NN i
( ( i
n JJ i
= NNP i
50 CD i
) ) i
or CC i
staple JJ i
transection NN i
of IN i
the DT i
esophagus NN i
( ( i
n JJ i
= NNP i
51 CD i
) ) i
. . N

Four CD N
patients NNS N
assigned VBN N
to TO N
sclerotherapy VB i
and CC N
12 CD N
assigned VBN N
to TO N
staple VB N
transection NN N
did VBD N
not RB N
actually RB N
undergo VBP N
those DT N
procedures NNS N
, , N
but CC N
all DT N
analyses NNS N
were VBD N
made VBN N
on IN N
an DT N
intention-to-treat JJ N
basis NN N
. . N

Total JJ o
mortality NN o
did VBD N
not RB N
differ VB N
significantly RB N
between IN N
the DT N
two CD N
groups NNS N
; : N
the DT N
relative JJ o
risk NN o
of IN o
death NN o
for IN N
staple JJ N
transection NN N
as IN N
compared VBN N
with IN N
sclerotherapy NN N
was VBD N
0.88 CD N
( ( N
95 CD N
percent NN N
confidence NN N
interval NN N
, , N
0.51 CD N
to TO N
1.54 CD N
) ) N
. . N

Mortality NN o
at IN N
six CD N
weeks NNS N
was VBD N
44 CD N
percent NN N
among IN N
those DT N
assigned VBN N
to TO N
sclerotherapy VB i
and CC N
35 CD N
percent NN N
among IN N
those DT N
assigned VBN N
to TO N
staple VB N
transection NN N
. . N

Complication NN o
rates NNS o
were VBD N
similar JJ N
for IN N
the DT N
two CD N
groups NNS N
. . N

An DT N
interval NN o
of IN o
five CD o
days NNS o
without IN o
bleeding NN o
was VBD N
achieved VBN N
in IN N
88 CD N
percent NN N
of IN N
those DT N
assigned VBN N
to TO N
staple VB N
transection NN N
and CC N
in IN N
62 CD N
percent NN N
of IN N
those DT N
assigned VBN N
to TO N
sclerotherapy VB i
after IN N
a DT N
single JJ N
injection NN N
( ( N
P NNP N
less JJR N
than IN N
0.01 CD N
) ) N
and CC N
82 CD N
percent NN N
after IN N
three CD N
injections NNS N
. . N

In IN N
only RB N
2 CD N
of IN N
the DT N
11 CD N
patients NNS N
who WP N
received VBD N
a DT N
third JJ N
sclerotherapy NN i
injection NN N
was VBD N
bleeding VBG o
controlled VBN o
for IN N
more JJR N
than IN N
five CD N
days NNS N
, , N
and CC N
9 CD N
died VBD N
. . N

We PRP N
conclude VBP N
that IN N
staple JJ N
transection NN N
of IN N
the DT N
esophagus NN N
is VBZ N
as RB o
safe JJ o
as IN o
sclerotherapy NN o
for IN N
the DT N
emergency NN o
treatment NN o
of IN o
bleeding VBG o
esophageal JJ N
varices NNS N
and CC N
that IN N
it PRP N
is VBZ N
more RBR N
effective JJ N
than IN N
a DT N
single JJ N
sclerotherapy NN i
procedure NN N
. . N

We PRP N
currently RB N
recommend VBP N
surgery NN N
after IN N
two CD N
injection NN N
treatments NNS N
have VBP N
failed VBN N
. . N

-DOCSTART- -17477785- O O

Can MD N
a DT N
home-visit JJ i
invitation NN i
increase NN p
Pap NNP p
smear JJ p
screening NN p
in IN p
Samliem NNP p
, , p
Khon NNP p
Kaen NNP p
, , p
Thailand NNP p
? . N
Our PRP$ N
objective NN N
was VBD N
to TO N
assess VB N
the DT N
efficiency NN N
of IN N
a DT N
home-visit JJ i
invitation NN i
aimed VBN N
to TO N
increase VB N
uptake NN N
of IN N
cervical JJ p
cancer NN p
screening VBG p
in IN p
women NNS p
between IN p
35 CD p
and CC p
60 CD p
years NNS p
of IN p
age NN p
. . p

From NN N
May NNP N
, , N
2006 CD N
, , N
we PRP N
conducted VBD N
a DT N
quasi-randomized JJ N
trial NN N
to TO N
determine VB N
if IN N
an DT N
in-home JJ i
education NN i
and CC i
invitation NN i
intervention NN i
would MD N
increase VB N
uptake NN N
of IN N
cervical JJ N
cancer NN N
screening VBG N
. . N

We PRP N
randomly RB p
recruited VBD p
304 CD p
women NNS p
from IN p
the DT p
Samliem NNP p
inner-city NN p
community NN p
, , p
Khon NNP p
Kaen NNP p
, , p
Northeast NNP p
Thailand NNP p
, , p
and CC p
assigned VBD p
participants NNS p
to TO N
either VB N
the DT N
intervention NN i
or CC N
control VB i
zone NN i
. . i

Baseline NNP N
screening VBG N
coverage NN N
interviews NNS N
were VBD N
then RB N
performed VBN N
: : N
58 CD p
of IN p
158 CD p
women NNS p
in IN p
the DT p
intervention NN p
zone NN p
and CC p
46 CD p
of IN p
146 CD p
in IN p
the DT p
control NN p
zone NN p
were VBD p
excluded VBN p
from IN p
the DT p
study NN p
because IN p
of IN p
having VBG p
had VBD p
a DT p
Pap NNP p
smear NN p
within IN p
5 CD p
years NNS p
, , p
but CC p
these DT p
were VBD p
included VBN p
in IN p
the DT p
final JJ p
analysis NN p
. . p

First NNP N
, , N
100 CD p
women NNS p
in IN p
the DT p
intervention NN p
group NN p
were VBD N
visited VBN i
in IN i
their PRP$ i
homes NNS i
by IN i
one CD i
of IN i
the DT i
researchers NNS i
, , i
who WP i
provided VBD i
culturally-sensitive JJ i
health NN i
education NN i
that WDT i
emphasized VBD i
the DT i
need NN i
for IN i
screening VBG i
. . i

Four CD N
months NNS N
later RB N
, , N
post-intervention NN N
, , N
screening-coverage JJ i
interviews NNS i
were VBD N
again RB N
performed VBN N
in IN N
both DT N
groups NNS N
, , N
in IN N
combination NN N
with IN N
the DT N
same JJ N
health NN N
education NN N
for IN N
100 CD p
women NNS p
in IN p
the DT p
control NN i
group NN p
for IN N
a DT N
comparison NN N
. . N

There EX N
was VBD N
no DT N
difference NN N
in IN N
the DT N
baseline NN o
Pap NNP o
smear JJ o
screening-coverage NN o
rate NN o
in IN N
the DT N
intervention NN N
vs. FW N
control NN N
zones NNS N
( ( N
36.7 CD N
vs. FW N
31.5 CD N
% NN N
, , N
p=0.339 NN N
) ) N
. . N

One CD N
hundred JJ N
women NNS N
in IN N
the DT N
intervention NN N
group NN N
completed VBD N
the DT N
intervention NN N
interviews NNS N
and CC N
after IN N
four CD N
months NNS N
, , N
100 CD N
women NNS N
in IN N
the DT N
intervention NN N
group NN N
and CC N
100 CD N
in IN N
the DT N
control NN N
group NN N
also RB N
completed VBD N
the DT N
post-intervention NN N
interviews NNS N
. . N

The DT N
increased JJ N
screening-coverage NN o
rate NN o
in IN N
the DT N
intervention NN N
zone NN N
was VBD N
similar JJ N
to TO N
that DT N
of IN N
the DT N
control NN N
zone NN N
( ( N
43.6 CD N
vs. FW N
34.9 CD N
% NN N
, , N
p=0.119 NN N
) ) N
; : N
however RB N
, , N
there EX N
was VBD N
a DT N
borderline NN N
significant JJ N
increase NN N
in IN N
the DT N
intervention NN N
zone NN N
compared VBN N
with IN N
baseline NN N
( ( N
36.7 CD N
to TO N
43.6 CD N
% NN N
, , N
p=0.070 NN N
) ) N
. . N

Therefore NNP N
, , N
home NN i
visit NN i
education NN i
and CC i
invitation NN i
intervention NN i
produced VBD N
only RB N
a DT N
nominal JJ N
effect NN N
on IN N
increasing VBG N
Pap NNP N
smear JJ N
coverage NN N
within IN N
a DT N
4-month JJ N
study NN N
period NN N
. . N

-DOCSTART- -23000125- O O

The DT N
role NN N
of IN N
nasal JJ i
IgA NNP i
in IN N
children NNS p
vaccinated VBN p
with IN p
live JJ p
attenuated VBN p
influenza JJ p
vaccine NN p
. . p

BACKGROUND NNP N
Immunoglobulin NNP i
A NNP i
( ( i
IgA NNP i
) ) i
is VBZ N
the DT N
predominant JJ N
antibody NN N
produced VBN N
in IN N
response NN N
to TO N
mucosal VB N
infections NNS N
. . N

The DT N
role NN N
of IN N
IgA NNP i
in IN N
providing VBG N
protection NN N
against IN N
influenza NN N
in IN N
children NNS p
vaccinated VBN p
with IN p
live JJ i
attenuated VBN i
influenza JJ i
vaccine NN i
( ( i
LAIV NNP i
) ) i
has VBZ N
not RB N
been VBN N
well RB N
described VBN N
. . N

METHODS NNP N
Nasal NNP N
IgA NNP N
responses NNS N
were VBD N
assessed VBN N
using VBG N
data NNS N
from IN N
3 CD N
prospective JJ N
, , N
2-year JJ N
, , N
randomized JJ N
studies NNS N
comparing VBG N
LAIV NNP i
with IN N
placebo NN i
in IN N
children NNS p
6-36 JJ p
months NNS p
of IN p
age NN p
. . p

In IN N
each DT N
study NN N
, , N
samples NNS N
were VBD N
collected VBN N
in IN N
a DT N
subset NN N
of IN N
patients NNS N
; : N
a DT N
new JJ N
cohort NN N
was VBD N
enrolled VBN N
each DT N
year NN N
. . N

Ratios NNP N
of IN N
strain-specific JJ N
nasal JJ i
IgA NNP i
to TO N
total VB N
nasal JJ N
IgA NNP N
were VBD N
calculated VBN N
and CC N
prevaccination NN N
to TO N
postvaccination NN N
geometric JJ o
mean JJ o
fold-rises NNS o
( ( o
GMFRs NNP o
) ) o
were VBD N
evaluated VBN N
. . N

Mean JJ o
postvaccination NN o
IgA NNP o
ratios NNS o
were VBD N
compared VBN N
for IN N
subjects NNS N
with IN N
and CC N
without IN N
confirmed VBN N
influenza NN N
illness NN N
by IN N
study NN N
and CC N
in IN N
pooled JJ N
analyses NNS N
. . N

RESULTS NNP N
Across NNP N
studies NNS N
, , N
a DT N
higher JJR N
percentage NN N
of IN N
children NNS N
receiving VBG N
LAIV NNP i
had VBD N
a DT N
? . o
2-fold JJ o
increase NN o
in IN o
strain-specific JJ o
IgA NNP o
ratio NN o
compared VBN o
with IN N
placebo NN N
recipients NNS o
. . o

GMFRs NNP o
after IN o
LAIV NNP i
in IN i
years NNS N
1 CD N
and CC N
2 CD N
ranged VBD N
from IN N
1.2 CD N
to TO N
6.2 CD N
, , N
compared VBN N
with IN N
0.5-2.2 JJ N
among IN N
placebo JJ N
recipients NNS N
. . N

Similar JJ N
responses NNS N
were VBD N
observed VBN N
in IN N
subjects NNS N
who WP N
were VBD N
baseline JJ N
seronegative JJ N
and CC N
seropositive JJ N
based VBN N
on IN N
serum JJ N
hemagglutination NN N
inhibition NN N
antibody NN N
titers NNS N
. . N

In IN N
years NNS N
1 CD N
and CC N
2 CD N
, , N
the DT o
mean JJ o
postvaccination NN o
strain-specific NN o
to TO o
total JJ o
IgA NNP o
ratio NN o
was VBD o
3.1-fold JJ N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
and CC N
2.0-fold JJ N
( ( N
P NNP N
< NNP N
0.03 CD N
) ) N
higher JJR N
among IN N
LAIV JJ N
recipients NNS N
with IN N
no DT N
evidence NN N
of IN N
culture-confirmed JJ N
influenza NN N
illness NN N
compared VBN N
with IN N
LAIV NNP N
recipients NNS N
who WP N
developed VBD N
culture-confirmed JJ N
influenza NN N
illness NN N
; : N
a DT N
similar JJ N
and CC N
consistent JJ N
trend NN N
was VBD N
observed VBN N
for IN N
each DT N
individual NN N
study NN N
and CC N
type/subtype NN N
. . N

CONCLUSIONS VB N
The DT N
current JJ N
analysis NN N
demonstrates VBZ N
that IN N
nasal JJ N
IgA NNP N
contributes VBZ N
to TO N
the DT N
efficacy NN N
of IN N
LAIV NNP i
and CC i
can MD N
provide VB N
evidence NN N
of IN N
vaccine-induced JJ N
immunity NN N
. . N

However RB N
, , N
the DT N
inherent JJ N
heterogeneity NN N
in IN N
nasal JJ N
antibody NN N
levels NNS N
and CC N
variability NN N
in IN N
nasal JJ N
specimen NNS N
collection NN N
hinders VBZ N
the DT N
precise JJ N
evaluation NN N
of IN N
mucosal NN N
antibody NN N
responses NNS N
. . N

Other JJ N
studies NNS N
have VBP N
demonstrated VBN N
that IN i
LAIV-induced NNP i
immunity NN i
is VBZ N
also RB N
partially RB N
explained VBN N
by IN N
T-cell NNP N
immunity NN N
, , N
serum NN N
antibody NN N
responses NNS N
, , N
and CC N
innate JJ N
immunity NN N
, , N
consistent JJ N
with IN N
the DT N
multi-faceted JJ N
nature NN N
of IN N
immunity NN N
induced VBN N
by IN N
wild-type JJ N
influenza JJ N
infection NN N
and CC N
other JJ N
live JJ N
virus NN N
vaccines NNS N
. . N

-DOCSTART- -3548803- O O

A DT N
randomized JJ N
study NN N
of IN N
fetal JJ N
abdominal JJ N
diameter NN N
and CC N
fetal JJ N
weight NN N
estimation NN N
for IN N
detection NN N
of IN N
light-for-gestation NN p
infants NNS p
in IN p
low-risk JJ p
pregnancies NNS p
. . p

A DT N
total NN N
of IN N
2771 CD p
pregnant JJ p
women NNS p
with IN p
gestational JJ p
age NN p
estimated VBN p
by IN p
ultrasound JJ p
measurement NN p
of IN p
the DT p
fetal JJ p
biparietal JJ p
diameter NN p
( ( p
BPD NNP p
) ) p
before IN p
the DT p
22nd CD p
week NN p
of IN p
gestation NN p
were VBD N
re-examined VBN N
by IN N
ultrasound NN i
in IN p
the DT p
32nd CD p
and CC p
37th CD p
week NN p
of IN p
pregnancy NN p
at IN N
which WDT N
time NN N
the DT N
fetal JJ N
BPD NNP N
and CC N
abdominal JJ N
diameter NN N
( ( N
AD NNP N
) ) N
were VBD N
measured VBN N
. . N

An DT N
additional JJ N
examination NN N
was VBD N
performed VBN N
at IN N
34 CD N
weeks NNS N
if IN N
the DT N
fetal JJ N
weight NN N
in IN N
the DT N
32nd CD N
week NN N
was VBD N
estimated VBN N
to TO N
be VB N
less JJR N
than IN N
95 CD N
% NN N
of IN N
the DT N
expected JJ N
mean JJ N
weight NN N
. . N

Light-for-gestational JJ o
age NN o
( ( o
LGA NNP o
) ) o
was VBD N
suspected VBN N
if IN N
the DT N
estimated VBN N
birth-weight NN N
was VBD N
less JJR N
than IN N
85 CD N
% NN N
of IN N
the DT N
expected JJ N
mean NN N
birthweight NN N
. . N

This DT N
applied VBD N
to TO N
186 CD p
uncomplicated JJ p
pregnancies NNS p
in IN p
which WDT p
there EX p
was VBD p
no DT p
clinical JJ p
suspicion NN p
of IN p
poor JJ o
intrauterine JJ o
growth NN o
. . o

These DT N
pregnancies NNS N
were VBD N
randomly RB N
allocated VBN N
to TO N
a DT N
treatment NN N
group NN N
( ( N
AD NNP N
and CC N
estimated VBN N
weight NN N
reported VBN N
) ) N
or CC N
to TO N
a DT N
control NN N
group NN N
( ( N
AD NNP N
and CC N
estimated VBN N
weight JJ N
withheld NN N
) ) N
. . N

Induction NN o
of IN o
labour NN o
was VBD N
significantly RB N
more JJR N
common JJ N
in IN N
the DT N
treatment NN N
group NN N
( ( N
41 CD N
% NN N
) ) N
than IN N
in IN N
the DT N
control NN N
group NN N
( ( N
15 CD N
% NN N
) ) N
. . N

No DT N
statistically RB N
significant JJ N
difference NN N
was VBD N
found VBN N
in IN N
the DT N
use NN o
of IN o
instrumental JJ o
vaginal JJ o
delivery NN o
or CC o
caesarean JJ o
section NN o
. . o

There EX N
was VBD N
a DT N
suggestion NN N
of IN N
marginal JJ N
benefit NN N
in IN N
terms NNS N
of IN N
neonatal JJ o
morbidity NN o
but CC N
this DT N
was VBD N
not RB N
statistically RB N
significant JJ N
. . N

-DOCSTART- -6516935- O O

Rational-emotive JJ i
therapy NN i
and CC N
the DT N
reduction NN N
of IN N
interpersonal JJ o
anxiety NN o
in IN N
junior JJ p
high JJ p
school NN p
students NNS p
. . p

This DT N
study NN N
evaluated VBD N
the DT N
effectiveness NN N
of IN N
rational-emotive JJ i
therapy NN i
and CC i
rational-emotive JJ i
imagery NN i
. . i

Fifty-nine JJ p
junior JJ p
high JJ p
school NN p
students NNS p
who WP p
volunteered VBD p
to TO p
participate VB p
in IN p
treatment NN p
for IN p
interpersonal JJ o
anxiety NN o
were VBD N
randomly RB N
assigned VBN N
to TO N
rational-emotive JJ i
therapy NN i
without IN i
imagery NN i
( ( i
RET NNP i
) ) i
, , i
rational-emotive JJ i
therapy NN i
with IN i
imagery NN i
( ( i
REI NNP i
) ) i
, , i
relationship-oriented JJ i
counseling NN i
( ( i
ROC NNP i
) ) i
, , i
and CC i
waiting-list JJ i
control NN i
( ( i
WLC NNP i
) ) i
groups NNS i
. . i

Groups NNP N
met VBD N
for IN N
seven CD N
50-minute JJ N
treatment NN N
sessions NNS N
during IN N
a DT N
three-week JJ N
period NN N
. . N

Assessments NNS N
were VBD N
conducted VBN N
at IN N
pretreatment NN N
, , N
posttreatment NN N
, , N
and CC N
three-week JJ N
follow-up NN N
. . N

Both DT N
self-report JJ o
and CC o
sociometric JJ o
measures NNS o
were VBD N
used VBN N
to TO N
evaluate VB N
treatment NN N
outcome NN N
. . N

At IN N
postassessment NN N
, , N
both CC N
the DT N
RET NNP N
and CC N
REI NNP N
groups NNS N
were VBD N
rated VBN N
on IN N
sociometric JJ o
measures NNS o
as IN N
significantly RB o
less RBR o
interpersonally RB o
anxious JJ o
than IN N
the DT N
WLC NNP N
group NN N
. . N

Mean NNP o
scores VBZ o
favored VBD N
the DT N
RET NNP N
and CC N
REI NNP N
groups NNS N
, , N
but CC N
no DT N
significant JJ N
differences NNS N
between IN N
these DT N
groups NNS N
and CC N
the DT N
ROC NNP N
group NN N
were VBD N
obtained VBN N
. . N

The DT N
self-report JJ o
measure NN o
did VBD N
not RB N
significantly RB N
differentiate VBP N
between IN N
groups NNS N
, , N
but CC N
the DT N
REI NNP N
group NN N
demonstrated VBD N
significant JJ N
pre- JJ N
to TO N
follow-up JJ N
changes NNS N
. . N

Both CC N
the DT N
RET NNP N
and CC N
REI NNP N
groups NNS N
yielded VBD N
greater JJR N
reductions NNS o
in IN o
irrational JJ o
thinking NN o
than IN N
did VBD N
the DT N
ROC NNP N
and CC N
WLC NNP N
groups NNS N
. . N

In IN N
addition NN N
, , N
the DT N
pattern NN N
of IN N
the DT N
results NNS N
supported VBD N
the DT N
use NN N
of IN N
rational-emotive JJ i
imagery NN i
as IN N
a DT N
component NN N
of IN N
rational-emotive JJ i
therapy NN i
. . i

The DT N
practical JJ N
implications NNS N
of IN N
these DT N
findings NNS N
are VBP N
discussed VBN N
. . N

-DOCSTART- -12668582- O O

Pharmacokinetics NNS o
and CC o
tolerance NN o
of IN N
single- JJ N
and CC N
multiple-dose JJ N
oral JJ N
or CC N
intravenous JJ N
linezolid NNS i
, , N
an DT N
oxazolidinone NN N
antibiotic JJ N
, , N
in IN N
healthy JJ p
volunteers NNS p
. . p

AIMS NNP N
To TO N
determine VB N
the DT N
pharmacokinetics NNS N
and CC N
tolerance NN o
of IN N
oral JJ N
and CC N
intravenous JJ N
linezolid NN i
, , N
an DT N
oxazolidinone NN N
antibiotic JJ N
, , N
in IN N
healthy JJ p
volunteers NNS p
following VBG N
single- JJ N
and CC N
multiple-dose JJ N
administration NN N
. . N

METHODS NNP N
In IN N
two CD N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
, , N
dose-escalating JJ N
trials NNS N
, , N
subjects NNS p
were VBD N
exposed VBN N
either RB N
to TO N
oral JJ N
( ( N
375 CD N
, , N
500 CD N
or CC N
625 CD N
mg NN N
) ) N
or CC N
intravenous JJ N
( ( N
500 CD N
or CC N
625 CD N
mg NN N
) ) N
linezolid VBD i
or CC i
placebo VB i
twice JJ N
daily RB N
. . N

Serial JJ o
blood NN o
and CC o
urine JJ o
samples NNS o
were VBD N
obtained VBN N
after IN N
the DT N
first- JJ N
and CC N
multiple-dose JJ N
administrations NNS N
for IN N
up IN N
to TO N
18 CD N
days NNS N
. . N

Non-compartmental JJ N
pharmacokinetic JJ o
analyses NNS o
were VBD N
used VBN N
to TO N
describe VB N
the DT N
disposition NN N
of IN N
linezolid JJ i
. . i

RESULTS NNP N
Plasma NNP o
linezolid JJ o
concentrations NNS o
and CC o
area NN o
under IN o
the DT o
concentration-time JJ o
curves NNS o
increased VBD N
proportionally RB N
with IN N
dose JJ N
irrespective NN N
of IN N
the DT N
route NN N
of IN N
administration NN N
. . N

Plasma NNP o
linezolid JJ o
concentrations NNS o
remained VBN N
above IN N
the DT N
MIC90 NNP N
for IN N
susceptible JJ N
target NN N
pathogens NNS N
( ( N
4.0 CD N
mg/L NN N
) ) N
for IN N
the DT N
majority NN N
of IN N
the DT N
12 CD N
h NN N
dosing VBG N
interval NN N
. . N

Mean JJ o
clearance NN o
, , o
half-life JJ o
and CC o
volume NN o
of IN o
distribution NN o
were VBD N
similar JJ N
irrespective NN N
of IN N
dose NN N
for IN N
both DT N
the DT N
oral JJ N
and CC N
intravenous JJ N
routes NNS N
. . N

Linezolid NNP i
was VBD N
well RB N
tolerated VBN o
and CC N
the DT N
frequency NN o
of IN o
drug-related JJ o
adverse JJ o
events NNS o
was VBD N
similar JJ N
between IN N
the DT N
linezolid JJ i
and CC N
placebo JJ N
groups NNS N
. . N

CONCLUSIONS NNP N
Oral NNP N
and CC N
intravenous JJ N
linezolid JJ i
exhibit NN N
linear JJ o
pharmacokinetics NNS o
, , N
with IN N
concentrations NNS N
remaining VBG N
above IN N
the DT N
target NN o
MIC90 NNP o
for IN N
most JJS N
of IN N
the DT N
dosing NN N
interval NN N
. . N

These DT N
results NNS N
support VBD N
a DT N
twice-daily JJ N
schedule NN N
for IN N
linezolid JJ N
and CC N
demonstrate VB N
the DT N
feasibility NN N
of IN N
converting VBG N
from IN N
intravenous JJ N
to TO N
oral JJ N
dosing NN N
without IN N
a DT N
dose JJ N
adjustment NN N
. . N

-DOCSTART- -24127304- O O

Increasing VBG N
participation NN N
in IN N
cervical JJ o
cancer NN o
screening NN N
: : N
offering NN N
a DT N
HPV NNP N
self-test NN N
to TO N
long-term JJ N
non-attendees NNS N
as IN N
part NN N
of IN N
RACOMIP NNP N
, , N
a DT N
Swedish JJ N
randomized VBN N
controlled JJ N
trial NN N
. . N

RACOMIP NNP N
is VBZ N
a DT N
population-based JJ N
, , N
randomized JJ N
trial NN N
of IN N
the DT N
effectiveness NN o
and CC o
cost-effectiveness NN o
of IN N
different JJ N
interventions NNS N
aimed VBN N
at IN N
increasing VBG N
participation NN N
in IN N
a DT N
well-run JJ N
cervical JJ N
cancer NN N
screening VBG N
program NN N
in IN N
western JJ p
Sweden NNP p
. . p

In IN N
this DT N
article NN N
, , N
we PRP N
report VBP N
results NNS N
from IN N
one CD N
intervention NN N
, , N
offering VBG N
non-attendees NNS N
a DT N
high-risk JJ N
human JJ N
papillomavirus NN N
( ( N
HPV NNP N
) ) N
self-test NN N
. . N

Comparison NNP N
was VBD N
made VBN N
with IN N
standard JJ N
screening VBG N
invitation NN N
routine NN N
or CC N
standard JJ N
routine JJ N
plus CC N
a DT N
telephone NN N
call NN N
. . N

Women NNP p
( ( p
8,800 CD p
) ) p
, , p
aged VBD p
30-62 CD p
, , p
were VBD p
randomly RB p
selected VBN p
among IN p
women NNS p
without IN p
a DT p
registered JJ p
Pap NNP p
smear NN p
in IN p
the DT p
two CD p
latest JJS p
screening VBG p
rounds NNS p
. . p

These DT N
women NNS N
were VBD N
randomized VBN N
1:5:5 CD N
to TO N
one CD N
of IN N
three CD N
arms NNS N
: : N
800 CD p
were VBD p
offered VBN p
a DT p
high-risk JJ i
HPV NNP i
self-test NN i
, , p
4,000 CD p
were VBD p
randomized VBN p
to TO p
a DT p
telephone NN i
call NN i
( ( p
reported VBN p
previously RB p
) ) p
and CC p
4,000 CD p
constituted VBD p
a DT p
control NN i
group NN p
( ( i
standard JJ i
screening VBG i
invitation NN i
routine NN i
) ) i
. . p

Results NNS N
were VBD N
based VBN N
on IN N
intention NN N
to TO N
treat VB N
analysis NN N
and CC N
cost-effectiveness NN N
was VBD N
calculated VBN N
as IN N
marginal JJ N
cost NN N
per IN N
cancer NN N
case NN N
prevented VBN N
. . N

The DT N
endpoint NN N
was VBD N
the DT N
frequency NN o
of IN o
testing VBG o
. . o

The DT N
total JJ o
response NN o
rate NN o
in IN N
the DT N
self-testing JJ N
arm NN N
was VBD N
24.5 CD N
% NN N
, , N
significantly RB N
higher JJR N
than IN N
in IN N
the DT N
telephone NN N
arm NN N
( ( N
18 CD N
% NN N
, , N
RR NNP N
1.36 CD N
, , N
95 CD N
% NN N
CI NNP N
1.19-1.57 CD N
) ) N
and CC N
the DT N
control NN N
group NN N
( ( N
10.6 CD N
% NN N
, , N
RR NNP N
2.33 CD N
, , N
95 CD N
% NN N
CI NNP N
2.00-2.71 CD N
) ) N
. . N

All DT N
nine CD N
women NNS N
who WP N
tested VBD N
positive JJ N
for IN N
high-risk JJ N
HPV NNP N
attended VBD N
for IN N
a DT N
cervical JJ N
smear NN N
and CC N
colposcopy NN N
. . N

From IN N
the DT N
health-care NN N
sector NN N
perspective NN N
, , N
the DT N
intervention NN N
will MD N
most VB N
likely JJ N
lead NN N
to TO N
no DT o
additional JJ o
cost NN o
. . o

Offering VBG N
a DT N
self-test NN N
for IN N
HPV NNP N
as IN N
an DT N
alternative NN N
to TO N
Pap NNP N
smears NNS N
increases VBZ N
participation NN o
among IN N
long-term JJ N
non-attendees NNS N
. . N

Offering VBG N
various JJ N
screening VBG N
options NNS N
can MD N
be VB N
a DT N
successful JJ N
method NN N
for IN N
increasing VBG N
participation NN o
in IN N
this DT N
group NN N
. . N

-DOCSTART- -2577555- O O

[ JJ N
European JJ N
topic NN N
: : N
liver NN i
surgery NN i
II NNP i
-- : i
regional JJ i
chemotherapy NN i
] NN i
. . N

The DT N
most RBS N
important JJ N
methods NNS N
of IN N
regional JJ i
chemotherapy NN i
are VBP N
exemplified VBN N
by IN N
657 CD p
cases NNS p
of IN p
primary JJ p
and CC p
secondary JJ p
liver NN p
only RB p
malignancies VBZ p
. . p

I PRP N
. . N

Adjuvant JJ i
portal JJ i
therapy NN i
of IN i
the DT i
liver NN i
with IN i
resection NN i
of IN i
the DT i
colorectal JJ i
primary JJ i
malignancy NN i
seems VBZ N
to TO N
be VB N
advantageous JJ N
for IN N
advanced JJ N
tumors NNS N
. . N

II NNP N
. . N

It PRP N
is VBZ N
still RB N
unresolved JJ N
whether IN N
survival NN o
is VBZ N
prolonged VBN N
by IN N
adjuvant JJ N
treatment NN N
of IN N
the DT N
liver NN N
following VBG N
curative JJ i
resection NN i
of IN i
colorectal JJ i
liver NN i
metastases NNS i
. . i

III NNP N
. . N

The DT N
median JJ o
survival NN o
time NN o
( ( o
FUDR NNP o
, , o
pump NN o
) ) o
is VBZ N
17 CD N
months NNS N
for IN N
palliative JJ i
local JJ i
chemotherapy NN i
of IN N
unresectable JJ p
colorectal JJ p
liver NN p
metastases NNS p
. . p

IV NNP N
. . N

Primary NNP N
non-resectable JJ N
liver NN N
malignancies NNS N
show VBP N
the DT N
best JJS N
results NNS N
after IN N
chemoembolisation NN N
( ( N
Frankfurt NNP N
method NN N
) ) N
. . N

-DOCSTART- -22777592- O O

Effectiveness NN N
of IN N
vaginal JJ i
tablets NNS i
containing VBG N
lactobacilli JJ i
versus NN N
pH NN i
tablets NNS i
on IN N
vaginal JJ o
health NN o
and CC o
inflammatory JJ o
cytokines NNS o
: : o
a DT N
randomized JJ N
, , N
double-blind JJ N
study NN N
. . N

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
effectiveness NN N
of IN N
lactobacilli NN i
on IN N
vaginal JJ o
health NN o
and CC o
proinflammatory NN o
cytokines NNS o
. . o

Sixty-seven JJ p
patients NNS p
with IN p
bacterial JJ p
vaginosis NN p
( ( p
BV NNP p
) ) p
, , p
50 CD p
with IN p
intermediate JJ p
flora NNS p
and CC p
42 CD p
with IN p
normal JJ p
vaginal JJ p
flora NNS p
were VBD p
enrolled VBN p
in IN N
this DT N
double-blind NN N
study NN N
. . N

The DT N
subjects NNS N
were VBD N
randomized VBN N
to TO N
receive VB i
probiotic JJ i
lactobacilli JJ i
vaginal JJ i
tablets NNS i
( ( i
L. NNP i
brevis NN i
CD2 NNP i
, , i
L. NNP i
salivarius NN i
subsp NN i
. . i

salicinius NN i
, , i
L. NNP i
plantarum NN i
) ) i
or CC i
the DT i
vaginal JJ i
pH NN i
tablet NN i
( ( i
active JJ i
comparator NN i
) ) i
. . i

Cervico-vaginal JJ N
lavage NN N
was VBD N
collected VBN N
to TO N
measure VB N
the DT N
concentrations NNS N
of IN N
IL-1? NNP N
, , N
TNF? NNP N
and CC N
IL-6 NNP N
by IN N
ELISA NNP N
. . N

Neutral JJ N
sphingomyelinase NN N
activity NN N
was VBD N
also RB N
quantified VBN N
in IN N
both DT N
arms NNS N
before IN N
and CC N
after IN N
treatment NN N
. . N

The DT N
probiotic JJ N
vaginal JJ N
tablet NN N
was VBD N
well RB o
tolerated VBN o
and CC o
no DT N
side NN o
effects NNS o
were VBD o
reported VBN N
. . N

The DT N
study NN N
demonstrated VBD N
a DT N
cure NN o
rate NN o
of IN N
nearly RB N
80 CD N
% NN N
; : N
i.e. NN N
, , N
32 CD N
% NN N
of IN N
the DT N
women NNS N
could MD N
restore VB N
normal JJ N
vaginal JJ N
flora NNS N
and CC N
47 CD N
% NN N
had VBD o
improved VBN o
Nugent NNP o
score NN o
, , o
whereas RB o
20 CD N
% NN N
of IN N
the DT N
subjects NNS N
did VBD N
not RB N
clear JJ N
BV NNP N
in IN N
the DT N
first JJ N
follow-up NN N
( ( N
after IN N
8 CD N
days NNS N
treatment NN N
) ) N
. . N

The DT N
pH JJ N
tablet NN N
containing VBG N
pH NN N
lowering VBG N
compounds NNS N
induced JJ N
resolution NN o
of IN o
BV NNP o
and CC o
restoration NN o
of IN o
normal JJ o
vaginal JJ o
flora NN o
in IN N
74 CD N
% NN N
and CC N
26 CD N
% NN N
, , N
respectively RB N
. . N

The DT N
lactobacilli JJ N
tablet NN N
was VBD N
found VBN N
to TO N
be VB N
better JJR N
than IN N
the DT N
pH JJ N
tablet NN N
in IN N
preventing VBG o
BV NNP o
in IN o
healthy JJ o
subjects NNS N
. . N

A DT N
significant JJ N
reduction NN o
in IN o
IL-1? NNP o
and CC o
IL-6 NNP o
vaginal JJ o
cytokines NNS o
was VBD o
observed VBN o
after IN N
treatment NN N
with IN N
lactobacilli NN N
, , N
while IN N
the DT N
active JJ N
comparator NN N
did VBD N
not RB N
have VB N
any DT N
effect NN N
on IN N
local JJ N
proinflammatory NN N
cytokines NNS N
. . o

Vaginal JJ o
neutral JJ o
sphingomyelinase NN o
activity NN o
was VBD N
not RB N
modified VBN N
in IN N
either DT N
group NN N
. . N

Vaginal NNP N
tablets NNS N
containing VBG N
lactobacilli NN N
can MD N
cure VB N
BV NNP o
and CC o
reduce VB o
vaginal JJ o
inflammatory NN o
response NN o
. . N

-DOCSTART- -10489959- O O

Assessment NN p
of IN p
the DT p
pain NN p
of IN p
blood-sugar JJ p
testing NN p
: : p
a DT p
randomised JJ p
controlled VBN p
trial NN p
. . p

Lancet NNP i
puncture NN i
to TO i
the DT i
side NN i
of IN i
the DT i
thumb NN i
resulted VBD N
in IN N
less JJR o
pain NN o
than IN N
lancet JJ i
puncture NN i
to TO i
the DT i
finger NN i
or CC i
venepuncture NN i
at IN i
the DT i
elbow NN i
. . i

Success JJ N
rates NNS N
were VBD N
the DT N
same JJ N
. . N

-DOCSTART- -1751266- O O

Propofol NNP i
and CC i
midazolam NNP i
act NN N
synergistically RB N
in IN N
combination NN N
. . N

We PRP N
have VBP N
studied VBN N
interactions NNS N
between IN N
i.v NN i
. . i

propofol NN i
and CC i
midazolam NN i
for IN N
induction NN p
of IN p
anaesthesia NN p
in IN p
200 CD p
unpremedicated JJ p
female NN p
patients NNS p
undergoing VBG p
elective JJ p
gynaecological JJ p
surgery NN p
. . p

Using VBG N
end-points NNS N
of IN N
hypnosis NN o
( ( o
loss NN o
of IN o
response NN o
to TO o
verbal JJ o
command NN o
) ) o
and CC N
anaesthesia $ o
( ( o
loss NN o
of IN o
response NN o
to TO o
a DT o
5-s JJ o
transcutaneous JJ o
tetanic JJ o
stimulus NN o
) ) o
, , N
we PRP N
determined VBD N
dose-response JJ N
curves NNS N
for IN N
propofol NN i
and CC i
midazolam VB i
alone RB i
and CC i
in IN i
combination NN i
. . i

For IN N
hypnosis NN o
, , o
synergistic JJ o
interaction NN o
was VBD N
found VBN N
( ( N
P NNP N
less JJR N
than IN N
0.01 CD N
) ) N
, , N
the DT N
combination NN N
having VBG N
1.44 CD N
times NNS N
the DT N
potency NN N
of IN N
the DT N
individual JJ N
agents NNS N
. . N

Although IN N
midazolam NN i
failed VBD N
to TO N
produce VB N
anaesthesia NN o
in IN N
the DT N
dose NN N
range NN N
used VBN N
, , N
the DT N
dose NN N
of IN N
propofol NN i
required VBN o
to TO o
produce VB o
anaesthesia NN o
was VBD N
reduced VBN N
by IN N
52 CD N
% NN N
in IN N
the DT N
presence NN N
of IN N
midazolam NN i
( ( N
P NNP N
less JJR N
than IN N
0.01 CD N
) ) N
. . N

The DT N
reduction NN N
in IN N
arterial JJ o
pressure NN o
at IN o
induction NN o
was VBD N
the DT N
same JJ N
for IN N
the DT N
combination NN N
as IN N
for IN N
the DT N
individual JJ N
agents NNS N
. . N

The DT N
cause NN N
of IN N
the DT N
synergism NN N
was VBD N
not RB N
clear JJ N
, , N
but CC N
may MD N
have VB N
been VBN N
interaction NN N
at IN N
CNS NNP N
GABAA NNP N
receptors NNS N
. . N

-DOCSTART- -1410028- O O

The DT N
radial JJ N
forearm NN N
flap NN N
: : N
a DT N
biomechanical JJ N
study NN N
of IN N
donor-site JJ N
morbidity NN N
utilizing VBG N
sheep JJ N
tibia NN N
. . N

The DT N
use NN N
of IN N
vascularized JJ i
bone NN i
grafts NNS i
to TO N
reconstruct VB N
extremity NN N
and CC N
mandibular JJ N
defects NNS N
is VBZ N
now RB N
commonplace NN N
in IN N
reconstructive JJ N
surgery NN N
. . N

Fibula NNP N
, , N
scapula NN N
, , N
iliac JJ N
crest NN N
, , N
rib NN N
, , N
and CC N
metatarsal NN N
as RB N
well RB N
as IN N
the DT N
radial JJ N
forearm NN N
osseocutaneous JJ N
flaps NNS N
have VBP N
all DT N
been VBN N
utilized VBN N
for IN N
this DT N
purpose NN N
. . N

Troublesome NNP N
spiral JJ N
fractures NNS N
of IN N
the DT N
distal JJ N
radius NN N
are VBP N
the DT N
most RBS N
common JJ N
fractures NNS N
associated VBN N
with IN N
the DT N
use NN N
of IN N
the DT N
distal JJ N
radius NN N
as IN N
a DT N
vascularized JJ N
bone-graft NN N
donor NN N
site NN N
. . N

This DT N
study NN N
was VBD N
proposed VBN N
to TO N
investigate VB N
the DT N
effect NN N
of IN N
donor-site JJ N
bone NN N
loss NN N
on IN N
the DT N
strength NN p
of IN p
the DT p
radius NN p
under IN N
torsional JJ N
( ( N
rotational JJ N
) ) N
loading NN N
. . N

Previous JJ N
clinical JJ N
series NN N
and CC N
experimental JJ N
studies NNS N
have VBP N
not RB N
examined VBN N
this DT N
aspect NN N
of IN N
distal JJ N
radius NN N
loading NN N
after IN N
harvesting VBG N
the DT N
bone NN N
graft NN N
. . N

Fifty NNP p
pairs NN p
of IN p
sheep JJ p
tibiae NN p
were VBD p
utilized VBN p
in IN N
the DT N
experiment NN N
. . N

Five CD p
pairs NNS p
were VBD p
used VBN p
in IN p
a DT p
pilot NN p
study NN p
and CC p
45 CD p
pairs NNS p
were VBD p
used VBN p
in IN p
the DT p
main JJ p
experiment NN p
. . p

Five CD p
pairs NNS p
of IN p
human JJ p
radii NN p
were VBD p
used VBN p
for IN p
the DT p
control NN p
in IN p
the DT p
pilot NN p
study NN p
. . p

The DT N
pilot NN N
study NN N
attempted VBD N
to TO N
make VB N
a DT N
comparison NN N
between IN N
the DT N
human JJ N
radius NN N
and CC N
the DT N
sheep JJ N
tibia NN N
for IN N
experimental JJ N
purposes NNS N
. . N

For IN N
the DT N
biomechanical JJ N
study NN N
of IN N
donor-site JJ N
defects NNS N
, , N
four CD N
study NN N
groups NNS N
were VBD N
examined VBN N
with IN N
random JJ N
assignment NN N
and CC N
matched JJ N
pairs NNS N
. . N

The DT N
control NN p
group NN p
( ( p
group NN p
1 CD p
) ) p
had VBD p
no DT i
alteration NN i
to TO i
the DT i
bone NN i
. . i

Each DT N
test NN N
condition NN N
included VBD N
five CD N
matched VBN N
pairs NNS N
of IN N
sheep JJ N
tibiae NN N
. . N

Experiment JJ N
1 CD N
compared VBN N
the DT N
difference NN N
in IN N
the DT N
depth NN N
of IN N
the DT N
osteotomy NN o
defect NN o
. . o

In IN N
doing VBG N
this DT N
, , N
one-third NN i
of IN i
the DT i
total JJ i
length NN i
of IN i
the DT i
bone NN i
was VBD i
removed VBN i
in IN N
each DT N
of IN N
the DT N
following VBG N
specimens NNS N
to TO N
include VB N
( ( N
1a CD N
) ) N
30 CD N
percent NN N
of IN N
the DT N
cross-sectional JJ N
area NN N
of IN N
the DT N
total JJ N
bone NN N
, , N
( ( N
1b CD N
) ) N
37 CD N
percent NN N
of IN N
the DT N
cross-sectional JJ N
area NN N
of IN N
the DT N
total JJ N
bone NN N
, , N
and CC N
( ( N
1c CD N
) ) N
50 CD N
percent NN N
of IN N
the DT N
cross-sectional JJ N
area NN N
of IN N
the DT N
total JJ N
bone NN N
. . N

In IN N
experiment JJ N
2 CD N
, , N
the DT N
osteotomy JJ o
shape NN o
was VBD N
varied VBN N
. . N

Instead RB N
of IN N
the DT N
ends NNS N
of IN N
the DT N
cuts NNS N
being VBG N
squared VBN N
, , N
the DT N
ends NNS N
were VBD N
beveled VBN N
or CC N
rounded VBN N
. . N

Experiment JJ N
3 CD N
compared VBN N
different JJ N
lengths NNS N
of IN N
bone NN N
removed VBN N
in IN N
the DT N
osteotomy NN N
defect NN N
and CC N
included VBD N
the DT N
following NN N
: : N
In IN N
experiment NN N
3a CD N
the DT N
diameter NN N
of IN N
the DT N
sheep JJ N
tibia NN N
was VBD N
measured VBN N
at IN N
the DT N
incisura NN N
fibularis NN N
. . N

This DT N
dimension NN N
was VBD N
one CD N
diameter NN N
of IN N
bone NN N
, , N
and CC N
a DT N
one-diameter JJ N
length NN N
of IN N
bone NN N
was VBD N
removed VBN N
. . N

In IN N
experiment JJ N
3b CD N
, , N
a DT N
two-diameter JJ N
length NN N
of IN N
bone NN N
was VBD N
removed VBN N
. . N

In IN N
experiment JJ N
3c CD N
, , N
a DT N
three-diameter JJ N
length NN N
of IN N
bone NN N
was VBD N
removed VBN N
. . N

In IN N
experiment JJ N
3d CD N
, , N
a DT N
four-diameter JJ N
length NN N
of IN N
bone NN N
was VBD N
removed VBN N
. . N

( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
400 CD N
WORDS NNP N
) ) N
-DOCSTART- -2374275- O O

Nicotinic JJ i
acid NN i
as IN N
therapy NN N
for IN N
dyslipidemia NN N
in IN N
non-insulin-dependent JJ p
diabetes NNS p
mellitus NN p
. . p

Recently RB N
, , N
nicotinic JJ i
acid NN i
has VBZ N
been VBN N
recommended VBN N
as IN N
a DT N
first-line JJ N
hypolipidemic JJ N
drug NN N
. . N

To TO N
determine VB N
the DT N
effectiveness NN N
of IN N
nicotinic JJ N
acid NN N
in IN N
dyslipidemic JJ p
patients NNS p
with IN p
non-insulin-dependent JJ p
diabetes NNS p
mellitus VBP p
, , p
13 CD p
patients NNS p
were VBD p
treated VBN p
in IN p
a DT p
randomized JJ p
crossover NN p
trial NN p
. . p

Patients NNS N
received VBD N
either RB N
nicotinic JJ i
acid NN i
( ( N
1.5 CD N
g NN N
three CD N
times NNS N
daily RB N
) ) N
or CC N
no DT i
therapy NN i
( ( N
control JJ N
period NN N
) ) N
for IN N
8 CD N
weeks NNS N
each DT N
. . N

Compared VBN N
with IN N
the DT N
control NN N
period NN N
, , N
nicotinic JJ i
acid NN i
therapy NN N
reduced VBD N
the DT N
plasma NN o
total JJ o
cholesterol NN o
level NN o
by IN N
24 CD N
% NN N
, , N
plasma JJ o
triglyceride IN o
level NN o
by IN N
45 CD N
% NN N
, , N
very-low-density NN o
lipoprotein NN o
cholesterol NN o
level NN o
by IN N
58 CD N
% NN N
, , N
and CC N
low-density NN o
lipoprotein NN o
cholesterol NN o
level NN o
by IN N
15 CD N
% NN N
, , N
and CC N
it PRP N
increased VBD N
the DT N
high-density NN o
lipoprotein NN o
cholesterol NN o
level NN o
by IN N
34 CD N
% NN N
. . N

However RB N
, , N
nicotinic JJ i
acid NN i
therapy NN N
resulted VBD N
in IN N
the DT N
deterioration NN o
of IN o
glycemic JJ o
control NN o
, , N
as IN N
evidenced VBN N
by IN N
a DT N
16 CD N
% NN N
increase NN N
in IN N
mean JJ o
plasma NN o
glucose JJ o
concentrations NNS o
, , N
a DT N
21 CD N
% NN N
increase NN N
in IN N
glycosylated JJ o
hemoglobin NN o
levels NNS o
, , N
and CC N
the DT N
induction NN N
of IN N
marked JJ o
glycosuria NN o
in IN N
some DT N
patients NNS N
. . N

Furthermore NNP N
, , N
a DT N
consistent JJ N
increase NN N
in IN N
plasma JJ o
uric JJ o
acid NN o
levels NNS o
was VBD N
observed VBN N
. . N

Therefore RB N
, , N
despite IN N
improvement NN N
in IN N
lipid JJ o
and CC o
lipoprotein JJ o
concentrations NNS o
, , N
because IN N
of IN N
worsening VBG N
hyperglycemia NN o
and CC N
the DT N
development NN N
of IN N
hyperuricemia NN o
, , N
nicotinic JJ N
acid NN N
must MD N
be VB N
used VBN N
with IN N
caution NN N
in IN N
patients NNS p
with IN N
non-insulin-dependent JJ N
diabetes NNS N
mellitus VBP N
with IN N
dyslipidemia NN N
. . N

We PRP N
suggest VBP N
that IN N
the DT N
drug NN N
not RB N
be VB N
used VBN N
as IN N
a DT N
first-line JJ N
hypolipidemic JJ N
drug NN N
in IN N
patients NNS p
with IN p
non-insulin-dependent JJ p
diabetes NNS p
mellitus NN p
. . p

-DOCSTART- -20456192- O O

Capsaicin NNP i
jelly RB i
against IN N
migraine NN o
pain NN o
. . o

OBJECTIVE NNP N
Recent NNP N
studies NNS N
support VBP N
the DT N
role NN N
of IN N
extracranial JJ N
perivascular JJ N
afferents NNS N
in IN N
a DT N
substantial JJ N
percentage NN N
of IN N
migraineurs NNS p
. . p

Perivascular JJ N
afferent JJ N
fibres NNS N
of IN N
the DT N
superficial JJ N
temporal JJ N
artery NN N
contain NN N
peptides NNS N
, , N
like IN N
calcitonin JJ N
gene-related JJ N
peptide NN N
( ( N
CGRP NNP N
) ) N
and CC N
substance NN N
P NNP N
( ( N
SP NNP N
) ) N
. . N

CGRP NNP N
and CC N
SP NNP N
are VBP N
considered VBN N
relevant JJ N
in IN N
the DT N
genesis NN N
of IN N
migraine NN N
pain NN N
. . N

Capsaicin NNP i
is VBZ N
an DT N
agonist NN N
of IN N
the DT N
transient NN N
receptor NN N
potential JJ N
vanilloid NN N
type NN N
1 CD N
. . N

It PRP N
causes VBZ N
membrane JJ N
depolarisation NN N
of IN N
sensory JJ N
neurons NNS N
, , N
which WDT N
release VBP N
CGRP NNP N
, , N
SP NNP N
and CC N
other JJ N
pain NN N
peptides NNS N
; : N
excitation NN N
is VBZ N
followed VBN N
by IN N
a DT N
refractory NN N
state NN N
, , N
causing VBG N
inactivation NN N
. . N

Topical JJ i
capsaicin NN i
has VBZ N
been VBN N
found VBN N
to TO N
be VB N
efficacious JJ N
in IN N
several JJ N
types NNS N
of IN N
neuropathic JJ o
pain NN o
. . o

We PRP N
attempted VBD N
to TO N
verify VB N
whether IN N
topical JJ i
periarterial JJ i
capsaicin NN i
could MD N
ameliorate VB N
pain NN o
in IN o
absence NN o
of IN o
and CC o
during IN o
a DT o
migraine JJ o
attack NN o
. . o

METHODS NNP N
On IN N
23 CD p
migraineurs NNS p
showing VBG p
pain NN p
at IN p
pressure NN p
on IN p
scalp NN p
arteries NNS p
, , N
we PRP N
administered VBD N
topical JJ i
capsaicin NN i
0.1 CD i
% NN i
or CC i
vaseline NN i
jelly RB i
on IN N
painful JJ N
arteries NNS N
in IN N
absence NN N
of IN N
migraine JJ N
attack NN N
. . N

In IN N
those DT N
having VBG N
pain NN N
reduction NN N
> VBD N
50 CD N
% NN N
, , N
we PRP N
made VBD N
the DT N
same JJ N
comparison NN N
during IN N
a DT N
migraine JJ N
attack NN N
. . N

RESULTS NNP N
Topical NNP i
capsaicin NN i
caused VBD N
> JJ N
50 CD N
% NN N
reduction NN N
of IN N
arterial JJ o
pain NN o
in IN N
absence NN N
of IN N
attack NN N
in IN N
17/23 CD N
patients NNS N
, , N
as IN N
opposed VBN N
to TO N
two CD N
with IN N
vaseline NN N
. . N

During IN N
attacks NNS N
of IN N
mild- NN N
to TO N
moderate-intensity NN N
, , N
> VB N
50 CD N
% NN N
improvement NN N
was VBD N
obtained VBN N
in IN N
11/17 CD N
with IN N
capsaicin NN i
and CC N
in IN N
one CD N
with IN N
vaseline NN i
. . i

CONCLUSIONS NNP N
Although IN N
referring VBG N
to TO N
a DT N
small JJ N
number NN N
of IN N
patients NNS N
, , N
our PRP$ N
data NNS N
show VBP N
that IN N
topical JJ i
capsaicin NN i
may MD N
relieve VB N
arterial JJ o
pain NN o
in IN N
absence NN N
of IN N
and CC N
during IN N
a DT N
migraine JJ N
attack NN N
in IN N
a DT N
substantial JJ N
number NN N
of IN N
patients NNS p
experiencing VBG p
scalp JJ p
arterial JJ p
tenderness NN p
. . p

More RBR N
active JJ N
capsacinoids NNS i
might MD N
be VB N
tried VBN N
in IN N
the DT N
future NN N
and CC N
could MD N
provide VB N
a DT N
new JJ N
method NN N
for IN N
treating VBG N
migraine NN N
attacks NNS N
. . N

-DOCSTART- -17450704- O O

Women NNP p
's POS p
responses NNS p
to TO p
information NN p
on IN p
mammographic JJ p
breast NN p
density NN p
. . p

The DT N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
the DT N
negative JJ N
and CC N
positive JJ N
outcomes NNS N
of IN N
providing VBG N
mammographic JJ N
breast NN N
density NN N
( ( N
MBD NNP N
) ) N
information NN N
to TO N
participants NNS p
of IN p
a DT p
screening JJ i
program NN i
. . i

A DT N
randomized JJ N
experiment NN N
was VBD N
conducted VBN N
with IN N
a DT N
sample NN p
of IN p
618 CD p
women NNS p
50 CD p
years NNS p
or CC p
older JJR p
with IN p
MBD NNP p
greater JJR p
than IN p
50 CD p
% NN p
of IN p
breast NN p
volume NN p
. . p

The DT N
intervention NN N
consisted VBD N
of IN N
reporting VBG i
the DT i
presence NN i
of IN i
MBD NNP i
in IN i
the DT i
screening NN i
mammography NN i
results NNS i
letter NN i
that WDT i
was VBD i
sent VBN i
along IN i
with IN i
an DT i
information NN i
pamphlet NN i
. . i

Compared VBN N
to TO N
the DT N
controls NNS i
, , N
more JJR N
women NNS N
in IN N
the DT N
intervention NN N
group NN N
described VBD N
the DT N
term NN N
breast NN o
density NN o
correctly RB N
and CC N
recognized VBD N
it PRP N
as IN N
a DT N
risk NN N
factor NN N
for IN N
breast NN N
cancer NN N
. . N

Although IN N
at IN N
the DT N
4-week JJ N
follow-up NN N
the DT N
intervention NN N
group NN N
indicated VBD N
that IN N
they PRP N
were VBD N
very RB N
likely JJ N
to TO N
have VB N
an DT N
annual JJ i
clinical JJ i
breast NN i
examination NN i
more RBR N
frequently RB N
than IN N
controls NNS N
, , N
no DT N
differences NNS N
were VBD N
detected VBN N
at IN N
6 CD N
months NNS N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
on IN N
other JJ N
behavioural JJ o
or CC o
psychological JJ o
measures NNS o
, , N
although IN N
at IN N
the DT N
4-week JJ N
follow-up JJ N
the DT N
control NN N
group NN N
perceived VBD N
their PRP$ N
risk NN N
for IN N
breast NN N
cancer NN N
, , N
relative VBP N
to TO N
other JJ N
women NNS N
their PRP$ N
age NN N
, , N
as IN N
a DT N
lot NN N
lower JJR N
than IN N
did VBD N
women NNS N
in IN N
the DT N
intervention NN N
group NN N
. . N

The DT N
results NNS N
demonstrate VBP N
a DT N
feasible JJ N
and CC N
non-threatening JJ N
way NN N
to TO N
provide VB N
women NNS N
with IN N
important JJ N
personalized VBN N
information NN N
about IN N
breast NN o
cancer NN o
risk NN o
. . o

-DOCSTART- -15492789- O O

Single NNP i
nucleotide JJ i
polymorphism NN i
in IN N
the DT N
hypoxia-inducible JJ N
factor-1alpha JJ N
gene NN N
in IN N
colorectal JJ N
carcinoma NN N
. . N

Colorectal JJ p
carcinoma NN p
is VBZ N
one CD N
of IN N
the DT N
most RBS N
common JJ N
malignancies NNS N
in IN N
the DT N
world NN N
, , N
and CC N
its PRP$ N
incidence NN N
has VBZ N
increased VBN N
in IN N
recent JJ N
years NNS N
. . N

We PRP N
have VBP N
reported VBN N
that IN N
expression NN N
of IN N
hypoxia-inducible JJ N
factor NN N
( ( N
HIF NNP N
) ) N
-1alpha VBZ N
correlates NNS N
with IN N
expression NN N
of IN N
vascular JJ N
endothelial JJ N
growth NN N
factor NN N
( ( N
VEGF NNP N
) ) N
, , N
tumor NN N
stage NN N
, , N
lymphatic JJ N
invasion NN N
, , N
venous JJ N
invasion NN N
, , N
and CC N
liver RB N
metastasis NN N
. . N

It PRP N
has VBZ N
also RB N
been VBN N
reported VBN N
that IN N
a DT N
single JJ i
nucleotide NN i
polymorphism NN i
( ( i
SNP NNP i
) ) i
in IN N
exon $ N
12 CD N
of IN N
HIF-1alpha NNP N
gene NN N
is VBZ N
present JJ N
in IN N
renal JJ N
cell NN N
carcinoma NN N
and CC N
head NN N
and CC N
neck NN N
squamous JJ N
cell NN N
carcinoma NN N
patients NNS N
. . N

We PRP N
investigated VBD N
the DT N
C1772T NNP i
polymorphism NN i
in IN N
colorectal JJ p
cancer NN p
patients NNS p
and CC p
healthy JJ p
control NN p
subjects VBZ p
to TO N
clarify VB N
the DT N
mechanism NN N
of IN N
HIF-1alpha NNP i
activation NN i
in IN N
colorectal JJ N
carcinoma NN N
. . N

The DT N
exon JJ N
12 CD N
genotype NN N
was VBD N
not RB N
associated VBN N
with IN N
sex NN N
or CC N
age NN N
. . N

The DT N
distribution NN N
of IN N
HIF-1alpha NNP o
genotypes NNS o
in IN N
controls NNS N
was VBD N
89 CD N
C/C NNP N
( ( N
89 CD N
% NN N
) ) N
, , N
11 CD N
C/T NNP N
( ( N
11 CD N
% NN N
) ) N
, , N
and CC N
0 CD N
T/T NNP N
( ( N
0 CD N
% NN N
) ) N
. . N

The DT N
distribution NN N
of IN N
HIF-1alpha NNP o
genotypes NNS o
in IN N
colorectal JJ p
cancer NN p
patients NNS p
was VBD N
100 CD N
C/C NNP N
( ( N
100 CD N
% NN N
) ) N
, , N
0 CD N
C/T NNP N
( ( N
0 CD N
% NN N
) ) N
, , N
and CC N
0 CD N
T/T NNP N
( ( N
0 CD N
% NN N
) ) N
. . N

The DT N
difference NN N
in IN N
genotype JJ N
distribution NN N
between IN N
patients NNS N
and CC N
control NN i
subjects NNS N
was VBD N
significant JJ N
( ( N
p JJ N
< NNP N
0.0005 CD N
) ) N
. . N

These DT N
results NNS N
suggest VBP N
that IN N
the DT N
C1772T NNP o
polymorphism NN o
in IN N
HIF-1alpha NNP N
is VBZ N
not RB N
involved VBN N
in IN N
progression NN N
or CC N
metastasis NN N
of IN N
colorectal JJ N
carcinoma NN N
. . N

-DOCSTART- -12850861- O O

Alendronate NNP i
daily RB N
, , N
weekly JJ N
in IN N
conventional JJ N
tablets NNS N
and CC N
weekly JJ N
in IN N
enteric JJ N
tablets NNS N
: : N
preliminary JJ N
study NN N
on IN N
the DT N
effects NNS N
in IN N
bone NN o
turnover NN o
markers NNS o
and CC N
incidence NN o
of IN o
side NN o
effects NNS o
. . o

Bisphosphonates NNS i
are VBP N
now RB N
in IN N
the DT N
vanguard NN N
of IN N
osteoporosis NN N
treatment NN N
. . N

Frequently RB N
, , N
gastro-oesophageal JJ N
symptoms NNS N
are VBP N
associated VBN N
with IN N
these DT N
drugs NNS N
. . N

The DT N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
side JJ N
effects NNS N
and CC N
bone NN N
turnover NN N
markers NNS N
in IN N
postmenopausal JJ p
women NNS p
who WP p
had VBD p
received VBN p
alendronate JJ i
daily JJ p
or CC p
weekly JJ p
in IN p
tablets NNS p
with IN p
or CC p
without IN p
enteric JJ p
coating NN p
. . p

We PRP N
conducted VBD N
a DT N
randomised JJ N
, , N
double-blind JJ N
, , N
3-month JJ N
trial NN N
. . N

The DT N
trial NN N
involved VBD N
75 CD p
volunteers NNS p
, , p
aged VBD p
45-58 JJ p
with IN p
moderate JJ p
to TO p
severe VB p
osteopenia NN p
( ( p
T-score NNP p
lower JJR p
than IN p
-2 JJR p
SD NNP p
) ) p
assessed VBN p
by IN p
quantitative JJ p
ultrasound NN p
. . p

Women NNS N
were VBD N
assigned VBN N
randomly RB N
to TO N
receive VB N
: : N
( ( N
a DT N
) ) N
alendronate NN i
10mg/day CD i
: : i
( ( N
b NN N
) ) N
alendronate NN i
70 CD i
mg NN i
once RB i
a DT i
week NN i
: : i
or CC N
( ( N
c NN N
) ) N
enteric JJ i
alendronate NN i
70 CD i
mg NN i
per IN i
week NN i
. . i

We PRP N
recorded VBD N
side JJ o
effects NNS o
, , o
C-telopeptide NNP o
, , o
osteocalcin NN o
and CC o
urine JJ o
hydroxyproline NN o
at IN N
the DT N
start NN N
of IN N
the DT N
study NN N
and CC N
at IN N
3 CD N
months NNS N
. . N

After IN N
3 CD N
months NNS N
, , N
pyrosis NN o
( ( o
heartburn NN o
) ) o
was VBD N
noted VBN N
by IN N
seven CD N
women NNS N
in IN N
group NN N
A NNP N
( ( N
28 CD N
% NN N
) ) N
, , N
three CD N
in IN N
group NN N
B NNP N
( ( N
12 CD N
% NN N
) ) N
and CC N
two CD N
in IN N
group NN N
C NNP N
( ( N
8 CD N
% NN N
) ) N
; : N
nausea NN o
: : o
by IN N
one CD N
woman NN N
in IN N
group NN N
B NNP N
; : N
and CC N
headache NN o
by IN N
one CD N
patient NN N
in IN N
each DT N
group NN N
. . N

C-telopeptide NNP o
( ( N
A DT N
: : N
40.7 CD N
% NN N
; : N
B NNP N
: : N
34.1 CD N
% NN N
and CC N
C NNP N
: : N
38.5 CD N
% NN N
) ) N
; : N
hydroxyproline NN o
( ( N
A DT N
: : N
31.1 CD N
% NN N
; : N
B NNP N
: : N
25.3 CD N
% NN N
and CC N
C NNP N
: : N
31.5 CD N
% NN N
) ) N
and CC N
osteocalcin $ o
( ( N
A DT N
: : N
27.0 CD N
% NN N
; : N
B NNP N
: : N
25.4 CD N
% NN N
and CC N
C NNP N
: : N
25.1 CD N
% NN N
) ) N
decreased VBD N
similarly RB N
in IN N
the DT N
three CD N
groups NNS N
. . N

Weekly JJ N
intake NN N
of IN N
alendronate NN i
, , N
whether IN N
conventional JJ N
or CC N
enteric-coated JJ N
; : N
is VBZ N
associated VBN N
with IN N
less JJR N
heartburn NN o
and CC o
nausea NN o
. . o

Enteric JJ i
alendronate NN i
has VBZ N
a DT N
similar JJ N
action NN N
to TO N
the DT N
conventional JJ N
tablets NNS N
on IN N
biochemical JJ o
markers NNS o
. . o

-DOCSTART- -862429- O O

Comparison NNP p
of IN p
synemol JJ i
cream NN i
and CC p
other JJ i
topical JJ i
corticosteroid NN i
creams NNS i
using VBG p
the DT p
vasoconstrictor NN p
bioassay NN p
. . p

The DT N
human JJ p
vasoconstrictor NN p
bioassay NN p
was VBD N
used VBN N
to TO N
assess VB N
the DT N
potency NN N
of IN N
open JJ p
applications NNS p
of IN p
Synemol NNP i
cream NN i
( ( p
0.025 CD p
% NN p
) ) p
, , p
Diprosone NNP i
cream NN i
( ( i
0.05 CD i
% NN i
) ) i
, , i
Aristocort-A NNP i
cream NN i
( ( p
0.5 CD p
% NN p
) ) p
, , p
and CC p
Valisone NNP i
cream NN i
( ( i
0.1 CD i
% NN i
) ) i
. . p

Intensity NN N
of IN N
vasoconstriction NN p
was VBD N
determined VBN N
eight CD N
, , N
twenty-four NN N
, , N
and CC N
thirty-two JJ N
hours NNS N
after IN N
application NN N
. . N

Results NNS N
obtained VBD N
from IN N
the DT N
average JJ N
intensity NN o
scores NNS o
of IN N
the DT N
three CD N
determinations NNS N
indicated VBD N
that IN N
Synemol NNP i
cream NN i
( ( N
0.025 CD N
% NN N
) ) N
is VBZ N
actually RB N
a DT N
more RBR N
active JJ N
compound NN N
than IN N
are VBP N
Diprosone NNP i
cream NN i
( ( N
0.05 CD N
% NN N
) ) N
, , N
Aristocort-A NNP i
cream NN i
( ( N
0.5 CD N
% NN N
) ) N
, , N
and CC N
Valisone NNP i
cream NN i
( ( N
0.1 CD N
% NN N
) ) N
, , N
and CC N
that IN N
its PRP$ N
activity NN N
is VBZ N
longer RBR N
acting VBG N
. . N

-DOCSTART- -352099- O O

A DT N
prospective JJ N
study NN N
of IN N
streptokinase NN i
and CC N
heparin NN i
in IN N
the DT N
treatment NN N
of IN N
deep JJ o
vein NN o
thrombosis NN o
. . o

In IN N
a DT N
prospective JJ N
trial NN N
, , N
42 CD p
medical JJ p
patients NNS p
with IN p
a DT p
history NN p
of IN p
deep JJ p
vein NN p
thrombosis NN p
of IN p
less JJR p
than IN p
five CD p
days NNS p
were VBD N
allocated VBN N
at IN N
random NN N
to TO N
treatment NN N
with IN N
streptokinase NN i
or CC N
heparin NN i
. . i

Only JJ p
patients NNS p
with IN p
extensive JJ p
thromboses NNS p
were VBD p
included VBN p
. . p

Streptokinase NNP i
was VBD N
given VBN N
in IN N
a DT N
loading NN N
dose NN N
of IN N
250 CD N
000 CD N
IU NNP N
and CC N
a DT N
maintenance NN N
dose NN N
of IN N
100 CD N
000 CD N
IU/hour NNP N
for IN N
4 CD N
days NNS N
as IN N
a DT N
mean NN N
. . N

Heparin NNP i
was VBD N
given VBN N
in IN N
a DT N
loading NN N
dose NN N
of IN N
15 CD N
000 CD N
IU NNP N
and CC N
a DT N
maintenance NN N
dose NN N
of IN N
20 CD N
000-50 JJ N
000 CD N
IU/day NNP N
. . N

The DT N
therapeutic JJ N
results NNS N
were VBD N
evaluated VBN N
by IN N
phlebography NN N
. . N

Significant JJ o
thrombolysis NN o
occurred VBD p
in IN p
71.4 CD p
% NN p
of IN p
21 CD p
patients NNS p
treated VBN p
with IN p
streptokinase NN i
and CC N
in IN N
23.8 CD N
% NN N
of IN N
the DT N
21 CD p
heparin-treated JJ i
patients NNS p
. . p

Using VBG N
the DT N
chi2-test NN N
for IN N
overall JJ N
association NN N
, , N
this DT N
difference NN N
was VBD N
statistically RB N
highly RB N
significant JJ N
( ( N
p JJ N
= NNP N
0.002 CD N
) ) N
. . N

Three CD N
patients NNS N
in IN N
each DT N
treatment NN N
group NN N
experienced VBD N
major JJ o
bleeding NN o
, , N
two CD N
in IN N
each DT N
group NN N
requiring VBG N
blood NN o
transfusions NNS o
. . o

Minor NNP o
bleeding NN o
and CC o
slight JJ o
rise NN o
in IN o
temperature NN o
were VBD N
encountered VBN N
more RBR N
often RB N
in IN N
the DT N
streptokinase NN i
than IN N
in IN N
the DT N
heparin NN i
group NN N
. . N

It PRP N
is VBZ N
concluded VBN N
that IN N
patients NNS p
with IN p
acute JJ p
deep JJ p
vein NN p
thrombosis NN p
with IN p
proximal JJ p
extension NN p
of IN p
the DT p
thrombus NN p
beyond IN p
the DT p
calf NN p
veins NNS p
should MD N
be VB N
offered VBN N
a DT N
therapeutic JJ N
trial NN N
with IN N
streptokinase NN i
. . i

-DOCSTART- -12839657- O O

[ RB N
Long NNP N
term NN N
observation NN N
in IN N
effects NNS N
of IN N
potassium NN i
and CC i
calcium NN i
supplementation NN i
on IN N
arterial JJ o
blood NN o
pressure NN o
and CC o
sodium NN o
metabolism NN o
in IN N
adolescents NNS p
with IN p
higher JJR p
blood NN p
pressure NN p
] NNP p
. . N

OBJECTIVE NNP N
To TO N
investigate VB N
the DT N
effects NNS N
of IN N
potassium NN i
and CC i
calcium NN i
supplementation NN i
in IN N
table JJ N
salt NN N
on IN N
reduction NN N
of IN N
arterial JJ o
blood NN o
pressure NN o
and CC o
sodium NN o
metabolism NN o
in IN N
adolescents NNS p
with IN p
higher JJR p
blood NN p
pressure NN p
. . p

METHODS CC N
A DT N
single JJ N
blind NN N
placebo-controlled JJ i
trial NN N
was VBD N
carried VBN N
out RP N
for IN N
two CD N
years NNS N
in IN N
220 CD p
adolescents NNS p
with IN p
higher JJR p
blood NN p
pressure NN p
, , p
aged VBD p
18 CD p
- : p
22 CD p
years NNS p
, , p
who WP p
were VBD p
randomly RB p
divided VBN p
into IN p
supplementary JJ p
group NN p
( ( p
n JJ p
= NNP p
110 CD p
) ) p
and CC p
control NN p
group NN p
( ( p
n JJ p
= NNP p
110 CD p
) ) p
. . p

Each DT p
of IN p
the DT p
subjects NNS p
in IN p
the DT p
supplementary JJ p
group NN p
and CC p
their PRP$ p
family NN p
members NNS p
was VBD N
given VBN N
10 CD i
mmol NN i
of IN i
potassium NN i
and CC i
10 CD i
mmol NN i
of IN i
calcium NN i
mixed VBN i
in IN i
their PRP$ i
table JJ i
salt JJ i
daily RB N
for IN N
24 CD N
months NNS N
. . N

RESULTS NNP N
Night NNP o
urinary JJ o
sodium NN o
and CC o
potassium JJ o
excretion NN o
increased VBD N
( ( N
urinary JJ N
Na NNP N
( ( N
+ NNP N
) ) N
, , N
P NNP N
< NNP N
0.05 CD N
; : N
urinary JJ N
K NNP N
( ( N
+ NNP N
) ) N
, , N
P NNP N
< NNP N
0.01 CD N
) ) N
and CC N
blood NN o
pressure NN o
lowered VBN o
by IN N
5.3 CD N
mm NNS N
Hg/1.8 NNP N
mm NN N
Hg NNP N
in IN N
average NN N
from IN N
the DT N
baseline NN N
in IN N
the DT N
supplementary JJ N
group NN N
two CD N
years NNS N
after IN N
potassium NN i
and CC i
calcium NN i
supplementation NN i
, , N
as IN N
compared VBN N
with IN N
that DT N
in IN N
the DT N
control NN N
group NN N
increased VBN N
by IN N
( ( N
1.3/1.7 CD N
) ) N
mm NN N
Hg NNP N
. . N

CONCLUSIONS NNP N
Adequate NNP N
supplement NN i
of IN i
potassium NN i
and CC i
calcium NN i
in IN N
daily JJ N
table JJ N
salt NN N
intake NN N
was VBD N
an DT N
effective JJ N
way NN N
to TO N
prevent VB N
form NN o
hypertension NN o
and CC N
could MD N
promote VB N
their PRP$ N
urinary JJ o
sodium NN o
excretion NN o
and CC o
reduction NN o
of IN o
arterial JJ o
blood NN o
pressure NN o
in IN N
adolescents NNS p
with IN p
higher JJR p
blood NN p
pressure NN p
. . p

-DOCSTART- -17544361- O O

A DT N
comparison NN N
of IN N
acceptance- JJ N
and CC N
control-based JJ N
strategies NNS N
for IN N
coping VBG N
with IN N
food NN N
cravings NNS N
: : N
an DT N
analog NN N
study NN N
. . N

The DT N
present JJ N
study NN N
utilized VBD N
an DT N
analog NN o
paradigm NN o
to TO N
investigate VB N
the DT N
effectiveness NN o
of IN N
two CD N
strategies NNS N
for IN N
coping VBG N
with IN N
food NN N
cravings NNS N
, , N
which WDT N
was VBD N
theorized VBN N
to TO N
be VB N
critical JJ N
to TO N
the DT N
maintenance NN N
of IN N
weight JJ N
loss NN N
. . N

Ninety-eight JJ p
undergraduate JJ p
students NNS p
were VBD p
given VBN i
transparent JJ i
boxes NNS i
of IN i
chocolate NN i
Hershey NNP i
's POS i
Kisses NNP i
and CC i
instructed VBN i
to TO i
keep VB i
the DT i
chocolates NNS i
with IN i
them PRP i
, , N
but CC N
not RB N
to TO N
eat VB N
them PRP N
, , N
for IN N
48 CD N
h. NN N
Before IN N
receiving VBG N
the DT N
Kisses NNP N
, , N
participants NNS N
were VBD N
randomized VBN N
to TO N
receive VB N
either RB i
( ( i
a DT i
) ) i
no DT i
intervention NN i
, , i
( ( i
b NN i
) ) i
instruction NN i
in IN i
control-based JJ i
coping VBG i
strategies NNS i
such JJ i
as IN i
distraction NN i
and CC i
cognitive JJ i
restructuring NN i
, , i
or CC i
( ( i
c NN i
) ) i
instruction NN i
in IN i
acceptance-based JJ i
strategies NNS i
such JJ i
as IN i
experiential JJ i
acceptance NN i
and CC i
defusion NN i
techniques NNS i
. . i

Measures NNS N
included VBD N
the DT N
Power NNP o
of IN o
Food NNP o
Scale NNP o
( ( o
PFS NNP o
; : o
a DT o
measure NN o
of IN o
psychological JJ o
sensitivity NN o
to TO o
the DT o
food NN o
environment NN o
) ) o
, , o
self-report JJ o
ratings NNS o
of IN o
chocolate NN o
cravings NNS o
and CC o
surreptitiously RB o
recorded VBN o
chocolate NN o
consumption NN o
. . o

Results NNS N
suggested VBD N
that IN N
the DT N
effect NN o
of IN N
the DT N
intervention NN N
depended VBD N
on IN N
baseline NN o
PFS NNP o
levels NNS o
, , N
such JJ N
that IN N
acceptance-based JJ N
strategies NNS N
were VBD N
associated VBN N
with IN N
better JJR N
outcomes NNS N
( ( o
cravings NNS o
, , o
consumption NN o
) ) o
among IN N
those DT N
reporting VBG N
the DT N
highest JJS N
susceptibility NN N
to TO N
the DT N
presence NN N
of IN N
food NN N
, , N
but CC N
greater JJR N
cravings NNS N
among IN N
those DT N
who WP N
scored VBD N
lowest JJS N
on IN N
the DT N
PFS NNP N
. . N

It PRP N
was VBD N
observed VBN N
that IN N
craving VBG o
self-report JJ o
measures NNS o
predicted VBN N
chocolate NN o
consumption NN o
, , N
and CC N
baseline VB N
PFS NNP o
levels NNS o
predicted VBD N
both DT N
cravings NNS N
and CC N
consumption NN N
. . N

Results NNS N
are VBP N
discussed VBN N
in IN N
terms NNS N
of IN N
the DT N
implications NNS N
for IN N
weight JJ N
loss NN N
maintenance NN N
strategies NNS N
. . N

-DOCSTART- -22721929- O O

Effect NN N
of IN N
chelation NN i
therapy NN i
on IN N
progressive JJ N
diabetic JJ N
nephropathy NN N
in IN N
patients NNS p
with IN p
type JJ p
2 CD p
diabetes NNS p
and CC p
high-normal JJ p
body NN p
lead JJ p
burdens NNS p
. . p

BACKGROUND VB N
A DT N
previous JJ N
study NN N
in IN N
type NN p
2 CD p
diabetic JJ p
patients NNS p
with IN N
high-normal JJ N
body NN N
lead NN N
burdens VBZ N
showed VBD N
that IN N
EDTA NNP i
chelation NN i
therapy NN i
for IN N
3 CD N
months NNS N
slows VBZ N
progressive JJ N
diabetic JJ N
nephropathy NN N
during IN N
a DT N
12-month JJ N
follow-up NN N
. . N

The DT N
effect NN N
of IN N
a DT N
longer JJR N
course NN N
of IN N
therapy NN N
on IN N
kidney NN N
function NN N
decrease NN N
over IN N
a DT N
longer JJR N
follow-up NN N
is VBZ N
not RB N
known VBN N
. . N

STUDY NNP N
DESIGN NNP N
A NNP N
12-month JJ N
run-in JJ N
phase NN N
, , N
then RB N
a DT N
randomized VBN N
single-blind NN N
study NN N
with IN N
a DT N
27-month JJ N
intervention NN N
. . N

SETTING NNP N
& CC N
PARTICIPANTS NNP N
University NNP p
medical JJ p
center NN p
; : p
50 CD p
patients NNS p
( ( p
serum JJ p
creatinine NN p
, , p
1.5-3.9 JJ p
mg/dL NN p
) ) p
with IN p
high-normal JJ p
body NN p
lead JJ p
burden NN p
( ( p
?80- JJ p
< NN p
600 CD p
?g NN p
) ) p
were VBD p
randomly RB N
assigned VBN N
to TO N
the DT N
treatment NN i
and CC i
control NN i
groups NNS i
. . i

INTERVENTION NNP i
The DT N
treatment NN N
group NN N
received VBD N
weekly JJ i
chelation NN i
therapy NN i
for IN i
3 CD N
months NNS N
to TO N
reduce VB N
their PRP$ N
body NN N
lead JJ N
burden NN N
to TO N
< VB N
60 CD N
?g NNS N
and CC N
then RB N
as IN N
needed VBN N
for IN N
24 CD N
months NNS N
to TO N
maintain VB N
this DT N
level NN N
. . N

The DT N
control NN N
group NN N
received VBD i
placebo NN i
for IN i
3 CD N
months NNS N
and CC N
then RB N
weekly VB N
for IN N
5 CD N
weeks NNS N
at IN N
6-month JJ N
intervals NNS N
for IN N
24 CD N
months NNS N
. . N

OUTCOMES IN o
The DT o
primary JJ o
end NN o
point NN o
was VBD o
change NN o
in IN o
estimated VBN o
glomerular JJ o
filtration NN o
rate NN o
( ( o
eGFR NN o
) ) o
over IN o
time NN o
. . o

A DT o
secondary JJ N
end NN N
point NN N
was VBD N
a DT o
2-fold JJ o
increase NN o
in IN o
baseline JJ o
serum NN o
creatinine NN o
level NN o
or CC o
the DT o
requirement NN o
for IN o
renal JJ o
replacement NN o
therapy NN o
. . o

MEASUREMENTS NNP o
Body NNP N
lead JJ N
burdens NNS N
were VBD N
assessed VBN N
by IN N
EDTA NNP N
mobilization NN N
tests NNS N
and CC N
eGFR NN N
was VBD N
calculated VBN N
using VBG N
the DT N
equation NN N
for IN N
Chinese JJ p
patients NNS p
with IN p
type JJ p
2 CD p
diabetes NNS p
. . p

RESULTS NNP o
Mean NNP o
baseline NN o
eGFRs NN o
in IN o
the DT N
treatment NN N
and CC N
control NN N
groups NNS N
were VBD N
similar JJ N
. . N

After IN N
3 CD N
months NNS N
of IN N
chelation NN N
therapy NN N
, , N
the DT N
change NN o
in IN o
eGFR NN o
in IN o
the DT N
treatment NN N
group NN N
( ( N
+1.0 NNP N
? . N
4.8 CD N
mL/min/1.73 NN N
m NN N
( ( N
2 CD N
) ) N
) ) N
differed VBN N
significantly RB N
from IN N
that DT N
in IN N
the DT N
control NN N
group NN N
( ( N
-1.5 NNP N
? . N
4.8 CD N
mL/min/1.73 NN N
m NN N
( ( N
2 CD N
) ) N
; : N
P NNP N
= NNP N
0.04 CD N
) ) N
. . N

In IN N
the DT N
subsequent JJ N
24-month JJ N
intervention NN N
, , N
the DT N
yearly JJ N
rate NN o
of IN o
decrease NN o
in IN o
eGFR NN o
( ( N
5.6 CD N
? . N
5.0 CD N
mL/min/1.73 NN N
m NN N
( ( N
2 CD N
) ) N
per IN N
year NN N
) ) N
in IN N
the DT N
treatment NN N
group NN N
was VBD N
slower JJR N
than IN N
that DT N
( ( N
9.2 CD N
? . N
3.6 CD N
mL/min/1.73 NN N
m NN N
( ( N
2 CD N
) ) N
per IN N
year NN N
; : N
P NNP N
= NNP N
0.04 CD N
) ) N
in IN N
the DT N
control NN N
group NN p
. . p

17 CD p
( ( p
68 CD p
% NN p
) ) N
control-group NN p
patients NNS p
and CC p
9 CD p
( ( p
36 CD p
% NN p
) ) p
treatment-group NN p
patients NNS p
achieved VBD p
the DT N
secondary JJ N
end NN N
point NN N
. . N

LIMITATIONS NNP N
Small NNP N
sample NN N
size NN N
, , N
not RB N
double JJ N
blind NN N
. . N

CONCLUSIONS VB N
A DT N
27-month JJ N
course NN N
of IN N
EDTA NNP N
chelation NN N
therapy NN N
retards VBZ N
the DT N
progression NN N
of IN N
diabetic JJ N
nephropathy NN p
in IN p
type NN p
2 CD p
diabetic JJ p
patients NNS p
with IN p
high-normal JJ p
body NN p
lead JJ p
burdens NNS p
. . N

-DOCSTART- -21487259- O O

Effect NN N
of IN N
propranolol NN i
on IN N
word NN N
fluency NN N
in IN N
autism NN p
. . p

OBJECTIVE NNP N
AND CC N
BACKGROUND NNP N
Autism NNP N
is VBZ N
characterized VBN N
by IN N
repetitive JJ N
behaviors NNS N
and CC N
impaired JJ N
socialization NN N
and CC N
communication NN N
. . N

Preliminary JJ N
evidence NN N
showed VBD N
possible JJ N
language NN N
benefits NNS N
in IN N
autism NN N
from IN N
the DT N
?-adrenergic JJ i
antagonist NN i
propranolol NN i
. . i

Earlier JJR N
studies NNS N
in IN N
other JJ N
populations NNS N
suggested VBD i
propranolol NN i
might MD N
benefit VB N
performance NN N
on IN N
tasks NNS N
involving VBG N
a DT N
search NN N
of IN N
semantic JJ N
and CC N
associative JJ N
networks NNS N
under IN N
certain JJ N
conditions NNS N
. . N

Therefore RB N
, , N
we PRP N
wished VBD N
to TO N
determine VB N
whether IN N
this DT N
benefit NN N
of IN i
propranolol NN i
includes VBZ N
an DT N
effect NN N
on IN N
semantic JJ N
fluency NN N
in IN N
autism NN N
. . N

METHODS NNP p
A NNP p
sample NN p
of IN p
14 CD p
high-functioning JJ p
adolescent NN p
and CC p
adult NN p
participants NNS p
with IN p
autism NN p
and CC p
14 CD p
matched VBN p
controls NNS p
were VBD N
given VBN N
letter NN N
and CC N
category NN N
word NN N
fluency NN N
tasks NNS N
on IN N
2 CD N
separate JJ N
testing NN N
sessions NNS N
; : N
1 CD N
test NN N
was VBD N
given VBN N
60 CD N
minutes NNS N
after IN N
the DT N
administration NN N
of IN N
40 CD N
mg NNS i
propranolol JJ i
orally RB N
, , N
and CC N
1 CD N
test NN N
was VBD N
given VBN N
after IN i
placebo NN i
, , i
administered VBN N
in IN N
a DT N
double-blinded JJ N
, , N
counterbalanced JJ N
manner NN N
. . N

RESULTS JJ p
Participants NNS p
with IN p
autism NN p
were VBD N
significantly RB N
impaired VBN N
compared VBN N
with IN N
controls NNS N
on IN N
both DT o
fluency NN o
tasks NNS o
. . o

Propranolol NNP i
significantly RB N
improved VBD o
performance NN o
on IN o
category NN o
fluency NN o
, , o
but CC N
not RB o
letter NN o
fluency NN o
among IN N
autism NN p
participants NNS p
. . p

No DT o
drug NN o
effect NN o
was VBD N
observed VBN N
among IN N
controls NNS N
. . N

Expected VBN N
drug NN N
effects NNS N
on IN o
heart NN o
rate NN o
and CC o
blood NN o
pressure NN o
were VBD N
observed VBN N
in IN N
both CC N
the DT N
groups NNS N
. . N

CONCLUSIONS NNP N
Results NNP N
are VBP N
consistent JJ N
with IN N
a DT N
selective JJ N
beneficial JJ N
effect NN N
of IN i
propranolol NN i
on IN N
flexibility NN N
of IN N
access NN N
to TO N
semantic JJ N
and CC N
associative JJ N
networks NNS N
in IN N
autism NN N
, , N
with IN N
no DT N
observed JJ N
effect NN N
on IN N
phonological JJ N
networks NNS N
. . N

Further NNP N
study NN N
will MD N
be VB N
necessary JJ N
to TO N
understand VB N
potential JJ N
clinical JJ N
implications NNS N
of IN N
this DT N
finding NN N
. . N

-DOCSTART- -25342184- O O

Administration NN N
of IN N
subcutaneous JJ N
buffered VBN N
lidocaine JJ i
prior RB N
to TO N
breast VB p
lymphoscintigraphy NN p
reduces NNS N
pain VBP o
without IN N
decreasing VBG N
lymph NN N
node DT N
visualization NN N
. . N

UNLABELLED NNP N
Breast NNP N
lymphoscintigraphy NN N
using VBG N
( ( N
99m CD N
) ) N
Tc-sulfur CD N
colloid NN N
( ( N
( ( N
99m CD N
) ) N
Tc-SC NN N
) ) N
is VBZ N
well RB N
established VBN N
in IN N
clinical JJ N
practice NN N
for IN N
staging VBG N
patients NNS p
with IN p
breast JJ p
carcinoma NN p
. . p

Nearly RB N
all DT N
patients NNS N
report VBP N
having VBG N
pain NN o
during IN N
the DT N
procedure NN N
. . N

However RB N
, , N
techniques NNS N
used VBN N
to TO N
minimize VB N
pain NN o
during IN N
breast NN p
lymphoscintigraphy NN i
are VBP N
highly RB N
variable JJ N
across IN N
institutions NNS N
. . N

Our PRP$ N
study NN N
was VBD N
to TO N
determine VB N
whether IN N
anesthetizing VBG N
the DT N
skin NN N
with IN N
sodium JJ i
bicarbonatehether-buffered JJ i
lidocaine NN i
before IN N
performing VBG N
breast NN N
lymphoscintigraphy NN N
reduced VBD N
the DT N
pain NN o
experienced VBN N
by IN N
the DT N
patients NNS N
. . N

The DT N
second JJ N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
whether IN N
anesthetizing VBG N
the DT N
skin NN N
with IN N
buffered JJ N
lidocaine NN N
changed VBN N
visualization NN o
of IN o
lymph NN o
nodes NNS o
. . o

METHODS NNP N
This DT N
prospective JJ N
, , N
patient-masked JJ N
and CC N
randomized JJ N
study NN N
involved VBN N
performing VBG N
breast NN i
lymphoscintigraphy NN i
in IN N
a DT N
control NN p
group NN p
and CC p
experimental JJ p
group NN p
of IN p
female JJ p
breast NN p
cancer NN p
patients NNS p
. . p

The DT N
control NN N
group NN N
did VBD N
not RB N
receive VB N
skin NN N
anesthetic JJ N
before IN N
( ( N
99m CD N
) ) N
Tc-SC CD N
injections NNS N
, , N
whereas IN N
the DT N
experimental JJ N
group NN N
first JJ N
underwent JJ N
skin NN N
anesthesia NN N
with IN N
an DT N
injection NN N
of IN N
2 CD i
% NN i
sodium JJ i
bicarbonate-buffered JJ i
lidocaine NN i
. . i

All DT N
patients NNS N
were VBD N
asked VBN N
to TO N
rate NN o
their PRP$ o
pain NN o
levels NNS o
, , o
using VBG o
the DT o
National NNP o
Institutes NNPS o
of IN o
Health NNP o
pain NN o
scale NN o
, , N
before IN N
the DT N
procedure NN N
and CC N
immediately RB N
after IN N
the DT N
injections NNS N
. . N

The DT N
change NN o
in IN o
pain NN o
from IN o
baseline NN o
was VBD N
compared VBN N
between IN N
the DT N
2 CD N
groups NNS N
. . N

After IN N
the DT N
injections NNS N
, , N
scintigraphic JJ N
imaging NN N
of IN N
the DT N
axilla NN N
was VBD N
performed VBN N
, , N
and CC N
the DT N
number NN o
of IN o
axillary JJ o
lymph NN o
nodes NNS o
visualized VBN o
was VBD N
recorded VBN N
. . N

RESULTS NNP N
No NNP N
significant JJ N
difference NN N
was VBD N
found VBN N
in IN N
preprocedural JJ N
baseline NN o
pain NN o
from IN N
the DT N
control NN N
group NN N
, , N
compared VBN N
with IN N
the DT N
experimental JJ N
group NN N
. . N

There EX N
was VBD N
a DT N
statistically RB N
significant JJ N
difference NN N
in IN N
the DT N
increase NN o
in IN o
pain NN o
experienced VBD N
during IN N
the DT N
procedure NN N
between IN N
the DT N
control NN N
group NN N
and CC N
the DT N
experimental JJ N
group NN N
( ( N
P NNP N
= NNP N
0.009 CD N
) ) N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
the DT N
detection NN o
of IN o
lymph NN o
nodes NNS o
between IN N
the DT N
control NN N
and CC N
experimental JJ N
groups NNS N
( ( N
P NNP N
= NNP N
0.56 CD N
) ) N
. . N

CONCLUSION VB N
The DT N
results NNS N
from IN N
our PRP$ N
study NN N
indicate VBP N
that IN N
injecting VBG N
subcutaneous JJ N
buffered VBN N
lidocaine NN i
before IN N
intradermal JJ N
injection NN N
of IN N
( ( N
99m CD N
) ) N
Tc-SC NN N
for IN N
breast NN N
lymphoscintigraphy NN N
significantly RB N
decreases VBZ N
patient JJ o
pain NN o
without IN N
interfering VBG N
with IN N
lymph JJ o
node JJ o
visualization NN o
. . o

-DOCSTART- -21090563- O O

Blockade NN N
of IN N
cytotoxic JJ N
T-lymphocyte JJ N
antigen-4 NN N
by IN N
ipilimumab JJ i
results NNS N
in IN N
dysregulation NN N
of IN N
gastrointestinal JJ N
immunity NN N
in IN N
patients NNS p
with IN p
advanced JJ p
melanoma NN p
. . p

Blockade NNP N
of IN N
cytotoxic JJ N
T-lymphocyte JJ N
antigen-4 NN N
( ( N
CTLA-4 NNP N
) ) N
by IN N
ipilimumab NN N
leads NNS N
to TO N
immune-mediated JJ N
tumor NN N
regression NN N
and CC N
immune-related JJ N
adverse JJ N
events NNS N
( ( N
irAEs NN N
) ) N
, , N
including VBG N
diarrhea NN N
and CC N
colitis NN N
. . N

The DT N
current JJ N
analyses NNS N
were VBD N
undertaken JJ N
to TO N
promote VB N
an DT N
understanding NN N
of IN N
the DT N
underlying VBG N
mechanism NN N
of IN N
action NN N
and CC N
to TO N
identify VB N
potential JJ N
biomarkers NNS N
that WDT N
could MD N
help VB N
in IN N
the DT N
prediction NN N
and CC N
management NN N
of IN N
ipilimumab-induced JJ N
gastrointestinal JJ N
irAEs NN N
. . N

Treatment-na?ve CD p
or CC p
previously RB p
treated VBN p
patients NNS p
with IN p
unresectable JJ p
stage NN p
III/IV NNP p
melanoma NN p
( ( p
n JJ p
= NNP p
115 CD p
) ) p
received VBD i
open-label JJ i
ipilimumab NN i
( ( i
10 CD i
mg/kg NN i
every DT i
3 CD i
weeks NNS i
for IN i
four CD i
doses NNS i
) ) i
and CC i
were VBD i
randomized VBN i
to TO i
receive VB i
concomitant NN i
blinded VBN i
prophylactic JJ i
oral JJ i
budesonide NN i
( ( i
9 CD i
mg/d NN i
with IN i
gradual JJ i
taper NN i
through IN i
week NN i
16 CD i
) ) i
or CC i
placebo NN i
. . i

Outcome NNP i
measures NNS N
included VBD o
histologic JJ o
assessment NN o
of IN o
bowel NN o
biopsies NNS o
and CC o
assessment NN o
of IN o
serologic JJ o
markers NNS o
of IN o
inflammatory JJ o
bowel NN o
disease NN o
( ( o
IBD NNP o
) ) o
, , o
fecal JJ o
calprotectin NN o
levels NNS o
, , o
and CC o
polymorphisms NNS o
in IN o
immune-related JJ o
genes NNS o
. . o

Ipilimumab NNP o
resulted VBD i
in IN N
dysregulation NN N
of IN N
gastrointestinal JJ N
mucosal NN N
immunity NN N
as IN N
evidenced VBN N
by IN N
altered JJ N
antibody NN N
levels NNS o
to TO o
enteric VB o
flora NNS o
, , o
inflammatory NN o
cell NN o
infiltration NN o
into IN o
gastrointestinal JJ o
mucosa NN o
, , o
and CC o
increased VBD o
fecal JJ o
calprotectin NN o
associated VBN o
with IN o
diarrhea NN o
and CC o
clinical JJ o
evidence NN o
of IN o
colitis NN o
. . o

The DT o
pattern NN N
of IN N
ipilimumab-induced JJ N
antibody NN N
titers NNS N
to TO N
microbial JJ N
flora NN N
and CC N
the DT N
histologic NN N
features NNS N
and CC N
location NN N
of IN N
the DT N
inflammation NN N
were VBD N
distinct JJ N
from IN N
classic JJ N
IBD NNP N
. . N

Prophylactic NNP i
budesonide NN i
did VBD i
not RB N
prevent VB o
ipilimumab-induced JJ o
bowel NN o
inflammation NN o
. . o

Despite IN o
an DT N
observed JJ N
association NN N
between IN N
colonic JJ N
inflammation NN N
and CC N
grade VB N
2 CD N
or CC N
higher JJR N
diarrhea NN o
, , o
no DT o
baseline NN N
biomarkers NNS N
could MD N
reliably RB N
predict VB N
development NN N
of IN N
gastrointestinal JJ N
toxicity NN N
. . N

Although IN N
classic JJ N
IBD NNP N
and CC N
ipilimumab-related JJ N
gastrointestinal JJ N
toxicity NN N
are VBP N
both DT N
immune JJ N
mediated VBN N
, , N
the DT N
observed JJ N
pattern NN N
of IN N
biomarkers NNS N
suggests VBZ N
ipilimumab-related JJ N
gastrointestinal JJ N
toxicity NN N
may MD N
be VB N
a DT N
distinct JJ N
clinicopathologic NN N
entity NN N
. . N

-DOCSTART- -175669- O O

Comparison NNP N
of IN N
split-course JJ i
radiation NN i
therapy NN i
and CC N
continuous JJ i
radiation NN i
therapy NN i
for IN N
unresectable JJ p
bronchogenic JJ p
carcinoma NN p
: : p
5 CD N
year NN N
results NNS N
. . N

One CD p
hundred CD p
and CC p
eighty-eight JJ p
patients NNS p
with IN p
inoperable JJ p
or CC p
unresectable JJ p
bronchogenic JJ p
carcinoma NN p
were VBD N
stratified VBN N
by IN N
cell NN N
type NN N
, , N
TNM NNP N
staging NN N
, , N
and CC N
prior RB N
surgery NN N
and CC N
then RB N
randomized VBN N
into IN N
two CD N
treatment NN N
groups NNS N
: : N
continuous JJ i
radiation NN i
therapy NN i
and CC i
split-course JJ i
radiation NN i
therapy NN i
. . i

There EX N
was VBD N
no DT N
difference NN N
in IN N
clinical JJ N
or CC N
objective JJ N
improvement NN N
in IN N
the DT N
two CD N
groups NNS N
. . N

Survival JJ o
rates NNS o
for IN N
cases NNS N
of IN N
squamous JJ N
cell NN N
carcinoma NN N
, , N
small JJ N
cell NN N
carcinoma NN N
, , N
and CC N
adrenocarcinoma NN N
were VBD N
the DT N
same JJ N
after IN N
both DT N
regimens NNS N
of IN N
therapy NN N
. . N

Split-course JJ o
therapy NN o
resulted VBD N
in IN N
a DT N
significantly RB N
better JJR N
survival NN N
rate NN N
in IN N
cases NNS N
of IN N
large JJ N
cell NN N
carcinoma NN N
but CC N
the DT N
number NN N
of IN N
cases NNS N
was VBD N
small JJ N
. . N

We PRP N
doubt VBP N
that IN N
the DT N
difference NN N
is VBZ N
clinically RB N
significant JJ N
. . N

Objective JJ o
roentgenographic JJ o
response NN o
was VBD N
accompanied VBN N
by IN N
improved JJ o
survival NN o
in IN N
squamous JJ N
cell NN N
carcinoma NN N
, , N
but CC N
not RB N
in IN N
the DT N
other JJ N
three CD N
cell NN N
types NNS N
. . N

Split-course JJ N
radiation NN N
therapy NN N
is VBZ N
superior JJ N
to TO N
continuous JJ N
radiation NN N
therapy NN N
because IN N
it PRP N
is VBZ N
better RBR o
tolerated VBN o
by IN N
the DT N
patient NN N
and CC N
because IN N
re-examination NN N
of IN N
the DT N
patient NN N
prior RB N
to TO N
the DT N
second JJ N
half NN N
of IN N
split-course JJ N
therapy NN N
permits VBZ N
the DT N
detection NN N
of IN N
new JJ N
metastatic JJ N
disease NN N
that WDT N
has VBZ N
become VBN N
manifest JJS N
during IN N
the DT N
rest NN N
period NN N
and CC N
spares VBZ N
the DT N
patient NN N
the DT N
futile JJ N
second JJ N
half NN N
of IN N
radiation NN N
therapy NN N
. . N

-DOCSTART- -11439748- O O

Brief JJ N
report NN N
: : N
case NN N
reports NNS N
on IN N
naltrexone NN i
use NN N
in IN N
children NNS p
with IN p
autism NN p
: : p
controlled VBN N
observations NNS N
regarding VBG N
benefits NNS o
and CC N
practical JJ o
issues NNS o
of IN N
medication NN N
management NN N
. . N

-DOCSTART- -15741753- O O

Phase NNP N
III NNP N
trial NN N
of IN N
satraplatin NN i
, , N
an DT N
oral JJ N
platinum NN i
plus CC i
prednisone NN i
vs. FW i
prednisone NN i
alone RB i
in IN N
patients NNS p
with IN p
hormone-refractory JJ p
prostate NN p
cancer NN p
. . p

Satraplatin NNP i
is VBZ N
a DT N
novel JJ N
oral JJ N
platinum NN i
( ( N
IV NNP N
) ) N
complex VBP N
that DT N
shows VBZ N
activity NN N
against IN N
hormone-refractory JJ p
prostate NN p
cancer NN p
( ( p
HRPC NNP p
) ) p
in IN N
cisplatin-resistant JJ i
human JJ N
tumor NN N
lines NNS N
in IN N
phase NN N
I PRP N
and CC N
phase VB N
II NNP N
trials NNS N
. . N

A DT N
randomized JJ N
multicenter NN N
phase NN N
III NNP N
trial NN N
with IN N
a DT N
target NN N
sample JJ N
size NN N
of IN N
380 CD p
patients NNS p
was VBD p
initiated VBN p
in IN p
men NNS p
with IN p
HRPC NNP p
. . p

After IN N
50 CD p
randomized JJ p
patients NNS p
, , N
the DT N
trial NN N
was VBD N
closed VBN N
to TO N
further RBR N
accrual JJ N
by IN N
the DT N
sponsoring VBG N
company NN N
. . N

An DT N
ad NN N
hoc NN N
analysis NN N
of IN N
all DT N
available JJ N
data NNS N
is VBZ N
reported VBN N
here RB N
. . N

Eligibility NNP N
criteria NNS N
included VBD N
pathological JJ N
proof NN N
of IN N
prostate NN p
cancer NN p
, , N
documented VBN N
progression NN N
despite IN N
prior JJ N
hormonal JJ N
manipulation NN N
, , N
WHO WP N
PS NNP N
0-2 NN N
, , N
and CC N
no DT N
daily JJ N
intake NN N
of IN N
narcotic JJ i
analgesics NNS i
. . i

Patients NNS N
were VBD N
randomized VBN N
between IN N
satraplatin NN i
100 CD N
mg/m NN N
( ( N
2 CD N
) ) N
for IN N
5 CD N
days NNS N
plus CC N
prednisone JJ i
10 CD N
mg NNS N
orally RB N
BID NNP N
or CC N
prednisone VB i
alone RB N
. . N

Compliance NN N
was VBD N
excellent JJ N
. . N

48/50 CD N
patients NNS N
have VBP N
progressed VBN o
and CC N
42 CD N
have VBP N
died VBN o
, , N
mostly RB N
due JJ N
to TO N
prostate VB N
cancer NN N
. . N

Median JJ o
overall JJ o
survival NN o
was VBD N
14.9 CD N
months NNS N
( ( N
95 CD N
% NN N
CI NNP N
: : N
13.7-28.4 JJ N
) ) N
on IN N
the DT N
satraplatin NN i
plus CC N
prednisone NN i
arm NN N
and CC N
11.9 CD N
months NNS N
( ( N
95 CD N
% NN N
CI NNP N
: : N
8.4-23.1 JJ N
) ) N
on IN N
prednisone NN i
alone RB N
( ( N
hazard JJ N
ratio NN N
, , N
HR NNP N
= NNP N
0.84 CD N
, , N
95 CD N
% NN N
CI NNP N
: : N
0.46-1.55 NN N
) ) N
. . N

A DT N
> JJ N
50 CD N
% NN N
decrease NN N
in IN N
prostrate NN o
specific JJ o
antigen NN o
( ( N
PSA NNP N
) ) N
was VBD N
seen VBN N
in IN N
9/27 CD N
( ( N
33.3 CD N
% NN N
) ) N
in IN N
the DT N
satraplatin NN i
plus CC i
prednisone NN i
arm NN N
vs. FW N
2/23 CD N
( ( N
8.7 CD N
% NN N
) ) N
on IN N
the DT N
prednisone NN i
alone RB N
arm NN N
. . N

Progression-free JJ o
survival NN o
was VBD N
5.2 CD N
months NNS N
( ( N
95 CD N
% NN N
CI NNP N
: : N
2.8-13.7 JJ N
) ) N
on IN N
the DT N
satraplatin NN i
plus CC N
prednisone NN i
arm NN N
as IN N
compared VBN N
to TO N
2.5 CD N
months NNS N
( ( N
95 CD N
% NN N
CI NNP N
: : N
2.1- JJ N
4.7 CD N
) ) N
on IN N
the DT N
prednisone NN i
alone RB N
arm NN N
( ( N
HR NNP N
= NNP N
0.50 CD N
, , N
95 CD N
% NN N
CI NNP N
: : N
0.28-0.92 NN N
) ) N
. . N

This DT N
difference NN N
is VBZ N
statistically RB N
significant JJ N
( ( N
p JJ N
= NNP N
0.023 CD N
) ) N
. . N

Toxicity NN o
was VBD N
generally RB N
minimal JJ N
in IN N
both DT N
arms NNS N
. . N

This DT N
randomized JJ N
comparison NN N
of IN N
a DT N
combination NN N
of IN N
satraplatin NN i
and CC i
prednisone NN i
versus NN N
prednisone NN N
alone RB N
supports VBZ N
the DT N
antitumor NN N
activity NN N
of IN N
the DT N
combination NN N
. . N

Its PRP$ N
role NN N
in IN N
the DT N
treatment NN N
of IN N
HPRC NNP N
remains VBZ N
to TO N
be VB N
elucidated VBN N
in IN N
an DT N
appropriate JJ N
phase NN N
III NNP N
setting NN N
. . N

-DOCSTART- -8936541- O O

Durability NN o
of IN N
central JJ i
venous JJ i
catheters NNS i
. . i

A DT N
randomized JJ N
trial NN N
in IN N
children NNS p
with IN p
malignant JJ p
diseases NNS p
. . p

In IN N
a DT N
prospective JJ N
randomized NN N
study VBD N
the DT N
durability NN o
of IN N
tunnelled JJ i
and CC i
non-tunnelled JJ i
central JJ i
venous JJ i
catheters NNS i
was VBD N
investigated VBN N
in IN N
children NNS p
with IN p
malignant JJ p
diseases NNS p
. . p

Twenty CD p
children NNS p
were VBD p
included VBN p
in IN p
the DT p
study NN p
but CC p
four CD p
( ( p
two CD p
in IN p
each DT p
group NN p
) ) p
had VBD p
to TO p
be VB p
excluded VBN p
; : p
three CD p
because IN p
the DT p
entry NN p
criteria NNS p
turned VBD p
out RP p
not RB p
to TO p
be VB p
fulfilled VBN p
and CC p
one CD p
because NN p
of IN p
lack NN p
of IN p
data NNS p
. . p

The DT N
median JJ o
duration NN o
of IN N
the DT N
tunnelled JJ i
catheters NNS i
was VBD N
224 CD N
days NNS N
with IN N
a DT N
range NN N
of IN N
25-846 JJ N
days NNS N
which WDT N
was VBD N
significantly RB o
longer JJR o
than IN N
that DT N
of IN N
conventional JJ i
catheters NNS i
( ( N
39.5 CD N
days NNS N
, , N
range VBP N
9-228 JJ N
days NNS N
) ) N
. . N

In IN N
addition NN N
six CD N
of IN N
eight CD N
conventional JJ N
catheters NNS N
were VBD N
accidentally RB N
removed VBN N
whereas IN N
all DT N
catheters NNS N
in IN N
the DT N
tunnelled JJ N
group NN N
had VBD N
to TO N
be VB N
removed VBN N
via IN N
a DT N
small JJ N
incision NN N
. . N

Three CD N
cases NNS N
of IN N
catheter NN o
related VBN o
sepsis NN o
, , N
two CD N
in IN N
the DT N
tunnelled JJ N
group NN N
and CC N
one CD N
in IN N
the DT N
conventional JJ N
group NN N
, , N
were VBD N
registered VBN N
. . N

The DT N
corresponding JJ N
number NN o
of IN o
infections NNS o
per IN o
catheter NN o
days NNS o
were VBD N
1 CD N
in IN N
1189 CD N
days NNS N
and CC N
1 CD N
in IN N
522 CD N
days NNS N
, , N
respectively RB N
. . N

In IN N
conclusion NN N
cuffed NN i
, , i
tunnelled JJ i
central JJ i
venous JJ i
catheters NNS i
are VBP N
less RBR N
prone JJ N
to TO N
displacement VB o
than IN N
traditional JJ i
percutaneous JJ i
central JJ i
venous JJ i
catheters NNS i
when WRB N
used VBN N
in IN N
children NNS p
with IN p
malignant JJ p
diseases NNS p
. . p

-DOCSTART- -7936339- O O

[ JJ N
Effect NNP N
of IN N
dopexamine NN i
in IN N
splanchnic JJ N
perfusion NN N
during IN N
surgery NN p
of IN p
the DT p
abdominal JJ p
aorta NN p
] NNP p
. . N

Abdominal NNP N
aortic JJ N
surgery NN N
has VBZ N
significant JJ N
effects NNS N
on IN N
cardiac NN N
and CC N
splanchnic JJ N
perfusion NN N
. . N

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
examine VB N
the DT N
effects NNS N
of IN N
dopexamine NN N
, , N
an DT N
inodilator JJ N
drug NN N
, , N
on IN N
hemodynamic JJ N
and CC N
splanchnic JJ N
perfusion NN N
with IN N
measurement NN N
of IN N
gastric JJ N
intramucosal NN N
pH NN N
, , N
by IN N
the DT N
method NN N
of IN N
gastric JJ N
tonometry NN N
, , N
during IN N
abdominal JJ N
aneurysm JJ N
resection NN N
. . N

Twenty-five JJ p
patients NNS p
undergoing VBG p
excision NN p
of IN p
an DT p
aortic JJ p
abdominal JJ p
aneurysm NN p
were VBD N
randomly RB N
divided VBN N
into IN N
two CD N
groups NNS N
. . N

During IN N
aortic JJ N
cross-clamping JJ N
Group NNP N
II NNP N
patients NNS N
received VBD N
dopexamine JJ i
infusion NN N
, , N
at IN N
a DT N
dose NN N
of IN N
1 CD N
microgram/kg/m NN N
, , N
and CC N
at IN N
a DT N
dose NN N
of IN N
0.5 CD N
micrograms/kg/m NN N
from IN N
declamping VBG N
to TO N
the DT N
end NN N
of IN N
the DT N
surgery NN N
. . N

Whereas NNP N
Group NNP N
I PRP N
patients NNS N
did VBD i
not RB i
receive VB i
a DT i
dopexamine JJ i
infusion NN i
. . i

During IN N
aortic JJ N
cross-clamping VBG N
the DT N
intramucosal NN o
pH VBZ o
value NN o
decreased VBN N
in IN N
Group NNP N
I PRP N
patients NNS N
, , N
but CC N
did VBD N
not RB N
change VB N
in IN N
Group NNP N
II NNP N
patients NNS N
. . N

Heart NNP o
rate NN o
, , o
cardiac JJ o
index NN o
, , o
and CC o
mixed JJ o
venous JJ o
oxygen NN o
saturation NN o
increased VBD N
significantly RB N
during IN N
dopexamine JJ N
infusion NN N
, , N
whereas JJ N
systemic JJ o
vascular NN o
resistance NN o
was VBD N
reduced VBN N
. . N

During IN N
aortic JJ N
cross-clamping JJ N
dopexamine NN i
was VBD N
a DT N
useful JJ N
agent NN N
in IN N
improving VBG N
splanchnic JJ o
blood NN o
flow NN o
, , o
cardiac JJ o
index NN o
venous JJ o
saturation NN o
. . o

Also RB N
, , N
since IN N
the DT N
drug NN N
produces VBZ N
dose RB N
related JJ N
hemodynamic JJ N
changes NNS N
of IN N
rapid JJ N
onset NN N
and CC N
reversibility NN N
, , N
it PRP N
is VBZ N
possible JJ N
to TO N
interrupt VB N
the DT N
infusion NN N
before IN N
aortic JJ N
declamping NN N
to TO N
avoid VB N
the DT N
decrease NN N
in IN N
the DT N
intramucosal NN N
pH VBZ N
value NN N
. . N

-DOCSTART- -2474103- O O

Moderate NNP i
sodium NN i
restriction NN i
, , i
angiotensin NN i
converting VBG i
enzyme JJ i
inhibition NN i
, , i
and CC i
thiazide RB i
diuretic JJ i
in IN i
the DT N
management NN N
of IN N
essential JJ N
hypertension NN N
. . N

Dietary NNP i
sodium JJ i
restriction NN i
alone RB N
is VBZ N
effective JJ N
in IN N
lowering VBG N
blood NN o
pressure NN o
in IN N
some DT N
, , N
but CC N
not RB N
all DT N
, , N
patients NNS p
with IN p
essential JJ p
hypertension NN p
. . p

Homeostatic JJ N
mechanisms NNS N
, , N
including VBG N
activation NN N
of IN N
the DT N
renin-aldosterone NN N
system NN N
, , N
may MD N
counteract VB N
the DT N
effects NNS N
of IN N
sodium JJ i
restriction NN N
. . N

Angiotensin NNP i
converting VBG i
enzyme NN i
( ( i
ACE NNP i
) ) i
inhibitors NNS i
are VBP N
also RB N
effective JJ o
as IN N
sole JJ N
therapy NN N
in IN N
many JJ N
patients NNS p
with IN p
essential JJ p
hypertension NN p
, , N
but CC N
may MD N
be VB N
less RBR N
effective JJ N
in IN N
those DT N
with IN N
low-renin JJ N
hypertension NN N
. . N

The DT i
combination NN i
of IN i
dietary JJ i
sodium NN i
restriction NN i
with IN i
blockade NN i
of IN i
the DT i
renin NN i
system NN i
by IN i
an DT i
ACE NNP i
inhibitor NN i
is VBZ N
a DT N
particularly RB N
effective JJ N
way NN N
to TO N
improve VB N
blood NN o
pressure NN o
control NN o
. . o

Addition NNP N
of IN N
a DT N
thiazide JJ i
diuretic NN i
will MD N
reduce VB N
pressure NN o
further RBR N
. . N

-DOCSTART- -10690138- O O

Comparison NNP N
of IN N
0.25 CD N
% NN N
S NNP N
( ( N
- : N
) ) N
-bupivacaine VBP N
with IN N
0.25 CD N
% NN N
RS-bupivacaine NNP N
for IN N
epidural JJ N
analgesia NN o
in IN p
labour NN p
. . p

We PRP N
have VBP N
compared VBN N
the DT N
efficacy NN N
of IN N
0.25 CD N
% NN N
S NNP i
( ( i
- : i
) ) i
-bupivacaine VBP i
with IN N
0.25 CD N
% NN N
RS-bupivacaine NNP i
in IN N
providing VBG N
epidural JJ o
analgesia NN o
for IN N
labour NN N
in IN N
a DT N
randomized JJ N
, , N
multicentre JJ N
, , N
double-blind JJ N
study NN N
. . N

Analgesia NNP i
was VBD i
initiated VBN i
with IN i
10 CD i
ml NN i
of IN i
the DT i
study NN i
solution NN i
and CC i
maintained VBN i
with IN i
10-ml JJ i
top-ups NNS i
. . i

We PRP N
studied VBD N
137 CD p
women NNS p
and CC N
treatments NNS N
were VBD N
found VBN N
to TO N
be VB N
equivalent JJ N
for IN N
onset NN N
, , N
duration NN N
and CC N
quality NN N
of IN N
block NN N
. . N

Median JJ o
onset NN o
of IN o
pain NN o
relief NN o
was VBD N
12 CD N
min NN N
for IN N
both DT N
drugs NNS N
and CC N
median JJ N
duration NN N
was VBD N
49 CD N
( ( N
range VB N
3-129 NNP N
) ) N
min NN N
and CC N
51 CD N
( ( N
7-157 CD N
) ) N
min NN N
for IN N
S NNP N
( ( N
- : N
) ) N
-bupivacaine NN N
and CC N
RS NNP N
bupivacaine NN N
, , N
respectively RB N
. . N

The DT N
estimated JJ N
treatment NN N
difference NN N
for IN N
duration NN o
of IN o
pain NN o
relief NN o
was VBD N
-4 NNP N
( ( N
90 CD N
% NN N
CI NNP N
-13 NNP N
, , N
6 CD N
) ) N
min NN N
. . N

Thirty NNP N
patients NNS N
failed VBD N
to TO N
achieve VB o
pain NN o
relief NN o
after IN N
the DT N
first JJ N
injection NN N
( ( N
20 CD N
patients NNS N
after IN N
S NNP N
( ( N
- : N
) ) N
-bupivacaine NN N
and CC N
10 CD N
after IN N
RS-bupivacaine NNP N
; : N
P NNP N
= NNP N
0.039 CD N
) ) N
. . N

However RB N
, , N
median JJ o
duration NN o
of IN o
pain NN o
relief NN o
from IN N
the DT N
first JJ N
top-up NN N
was VBD N
82 CD N
( ( N
range VB N
3-164 NNP N
) ) N
min NN N
for IN N
S NNP N
( ( N
- : N
) ) N
-bupivacaine NN N
and CC N
76 CD N
( ( N
22-221 JJ N
) ) N
min NN N
for IN N
RS-bupivacaine NNP N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
the DT N
quality NN o
of IN o
analgesia NN o
, , N
as IN N
assessed VBN N
by IN N
the DT N
investigators NNS N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
the DT N
extent NN N
of IN N
sensory JJ o
block NN o
, , o
percentage NN o
of IN o
patients NNS o
with IN o
motor NN o
block NN o
or CC o
incidence NN o
of IN o
adverse JJ o
events NNS o
. . o

-DOCSTART- -7390376- O O

[ JJ p
Obstetrical NNP p
analgesia NN p
with IN N
tramadol JJ i
] NN i
. . N

Parenteral JJ N
analgesia NN N
with IN N
Tramal NNP i
was VBD N
performed VBN N
in IN N
23 CD p
normal JJ p
deliveries NNS p
. . p

The DT N
results NNS N
were VBD N
compared VBN N
with IN N
a DT N
group NN p
of IN p
normal JJ p
deliveries NNS p
in IN p
which WDT p
analgesia NN o
was VBD p
achieved VBN p
with IN p
pethidine NN i
. . i

Both DT N
medicaments NNS N
excerted VBD N
an DT N
identical JJ o
analgetic JJ o
efficiency NN o
. . o

No DT N
adverse JJ o
side NN o
effects NNS o
were VBD N
observed VBN N
with IN N
Tramal NNP i
concerning VBG N
the DT N
follow-up NN N
of IN N
labour NN N
or CC N
the DT N
newborn JJ N
. . N

Tramal JJ i
can MD N
be VB N
recommended VBN N
for IN N
obstetrical JJ o
analgesia NN o
since IN N
it PRP N
does VBZ N
not RB N
excert VB N
inhibitory JJ o
effects NNS o
upon IN N
the DT N
respiratory NN N
center NN N
. . N

-DOCSTART- -25915138- O O

Indicators NNS N
for IN N
Cervical JJ N
Length NNP N
in IN N
Twin NNP p
Pregnancies NNP p
. . p

OBJECTIVE NNP N
Cervical NNP o
length NN o
( ( o
CL NNP o
) ) o
is VBZ N
associated VBN N
with IN N
the DT N
risk NN N
of IN N
preterm JJ N
birth NN N
( ( N
PTB NNP N
) ) N
in IN N
multiple JJ N
pregnancies NNS N
. . N

However RB N
, , N
the DT N
position NN N
of IN N
CL NNP N
within IN N
the DT N
pathophysiological JJ N
pathway NN N
of IN N
PTB NNP N
is VBZ N
unclear JJ N
, , N
and CC N
it PRP N
is VBZ N
unknown JJ N
which WDT N
factors NNS N
are VBP N
predictive JJ N
for IN N
CL NNP o
. . o

This DT N
study NN N
aims VBZ N
to TO N
investigate VB N
whether IN N
in IN N
twin JJ N
pregnancies NNS N
baseline VBP N
maternal JJ N
and CC N
obstetrical JJ N
characteristics NNS N
are VBP N
potential JJ N
indicators NNS N
for IN N
CL NNP o
, , N
to TO N
improve VB N
insight NN N
in IN N
the DT N
pathophysiological JJ N
pathway NN N
of IN N
PTB NNP N
. . N

STUDY NNP N
DESIGN NNP N
Secondary NNP N
analysis NN o
of IN o
data NNS o
on IN o
twin NN o
pregnancies NNS o
and CC p
CL NNP o
measurement NN o
between IN p
16 CD p
and CC p
22 CD p
weeks NNS p
. . p

A DT N
set NN N
of IN N
10 CD N
potential JJ N
indicators NNS N
, , N
known VBN N
to TO N
be VB N
associated VBN N
with IN N
an DT N
increased VBN N
risk NN N
of IN N
PTB NNP N
and/or NN N
which WDT N
have VBP N
a DT N
plausible JJ N
mechanism NN N
resulting VBG N
in IN N
a DT o
change NN o
of IN o
CL NNP o
were VBD N
selected VBN N
. . N

We PRP N
used VBD N
multivariable JJ N
linear JJ N
regression NN N
with IN N
backward JJ N
selection NN N
to TO N
identify VB N
independent JJ N
indicators NNS o
for IN o
CL NNP o
. . o

RESULTS VB N
A DT p
total NN p
of IN p
1,447 CD p
women NNS p
with IN p
twin JJ p
pregnancies NNS p
were VBD p
included VBN p
. . p

Mean NNP o
CL NNP o
was VBD N
43.7 CD N
( ( N
?8.9 NN N
) ) N
mm NN N
. . N

In IN N
multivariable JJ N
analysis NN N
, , N
age NN N
( ( N
0.27 CD N
mm/y NN N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] VBD N
0.16 CD N
to TO N
0.39 CD N
) ) N
, , N
use NN N
of IN N
assisted JJ N
reproductive JJ N
technologies NNS N
( ( N
ART NNP N
) ) N
( ( N
-1.42 JJ N
mm NN N
, , N
95 CD N
% NN N
CI NNP N
-2.6 NNP N
to TO N
-0.25 VB N
) ) N
, , N
and CC N
having VBG N
delivered VBN N
at IN N
term NN N
in IN N
a DT N
previous JJ N
pregnancy NN N
( ( N
1.32 CD N
mm NN N
, , N
95 CD N
% NN N
CI NNP N
0.25 CD N
to TO N
2.39 CD N
) ) N
were VBD N
significantly RB N
associated VBN N
with IN N
CL NNP o
. . o

CONCLUSION NNP N
This DT N
study NN N
shows VBZ N
that IN N
in IN p
twin NN p
pregnancies NNS p
, , p
age NN p
, , N
use NN N
of IN N
ART NNP N
and CC N
having VBG N
delivered VBN N
term NN N
in IN N
a DT N
previous JJ N
pregnancy NN N
has VBZ N
an DT N
association NN N
with IN N
CL NNP o
. . o

-DOCSTART- -1715416- O O

[ VB N
A DT N
randomized JJ N
trial NN N
of IN N
PVB NNP i
, , i
VAB-6 NNP i
, , i
BVP NNP i
regimen VBP i
versus NN i
PEB NNP i
chemotherapy NN i
in IN N
patients NNS p
with IN p
disseminated JJ p
testicular JJ p
tumors NNS p
] VBP p
. . N

During IN N
2 CD N
years NNS N
and CC N
7 CD N
months NNS N
from IN N
June NNP N
, , N
1985 CD N
to TO N
December NNP N
, , N
1987 CD N
, , N
a DT N
randomized JJ N
multi-center JJ N
trial NN N
of IN N
PVB NNP i
, , i
VAB-6 NNP i
, , i
BVP NNP i
regimen NNS i
( ( N
group NN N
A DT N
) ) N
without IN i
etoposide JJ i
versus NN i
PEB NNP i
chemotherapy NN i
( ( i
bleomycin NN i
, , i
etoposide RB i
and CC i
cisplatinum NN i
) ) i
( ( N
group NN N
B NNP N
) ) N
was VBD N
given VBN N
to TO N
patients NNS p
with IN p
disseminated JJ p
testicular JJ p
tumors NNS p
. . p

Of IN p
34 CD p
patients NNS p
registered VBD p
, , p
10 CD p
patients NNS p
were VBD p
with IN p
minimal JJ p
disease NN p
in IN p
stages NNS p
IIA NNP p
, , p
IIIO NNP p
and CC p
IIIA NNP p
and CC p
24 CD p
with IN p
extensive JJ p
disease NN p
in IN p
IIB NNP p
, , p
IIIB2 NNP p
and CC p
IIIC NNP p
. . p

Seminomas NNP p
were VBD p
found VBN p
in IN p
10 CD p
patients NNS p
, , p
while IN p
non-seminomatous JJ p
tumors NNS p
in IN p
24 CD p
. . p

Among IN N
groups NNS N
A NNP N
and CC N
B NNP N
, , N
there EX N
was VBD N
no DT N
statistical JJ N
difference NN N
in IN N
clinicopathological JJ N
profiles NNS N
. . N

A DT N
group NN N
patients NNS N
were VBD N
given VBN N
either RB N
PVB NNP N
, , N
VAB-6 NNP N
or CC N
BVP NNP N
according VBG N
to TO N
the DT N
physician NN N
's POS N
discretion NN N
. . N

In IN N
groups NNS N
A NNP N
and CC N
B NNP N
, , N
35 CD N
% NN N
and CC N
43 CD N
% NN N
of IN N
the DT N
patients NNS N
achieved VBD N
complete JJ o
response NN o
, , N
and CC N
45 CD N
% NN N
and CC N
50 CD N
% NN N
achieved VBN N
partial JJ o
response NN o
, , N
respectively RB N
. . N

The DT N
difference NN N
in IN N
CR NNP o
rates NNS o
among IN N
both DT N
groups NNS N
was VBD N
not RB N
statistically RB N
significant JJ N
even RB N
when WRB N
calculated VBN N
according VBG N
to TO N
the DT N
stage NN N
or CC N
histologic JJ N
grouping NN N
. . N

Salvage NN N
treatments NNS N
mainly RB N
with IN N
surgical JJ N
resection NN N
of IN N
residual JJ N
tumors NNS N
after IN N
the DT N
chemotherapy NN N
, , N
however RB N
, , N
were VBD N
more RBR N
successful JJ N
in IN N
group NN N
B NNP N
( ( N
88 CD N
% NN N
) ) N
than IN N
group NN N
A NNP N
( ( N
61 CD N
% NN N
) ) N
. . N

It PRP N
appears VBZ N
likely JJ N
that IN N
the DT N
higher JJR N
response NN N
of IN N
induction NN N
chemotherapy NN i
in IN N
patients NNS N
with IN N
extensive JJ N
disease NN N
made VBD N
the DT N
salvage NN N
surgery NN i
more RBR N
successful JJ N
in IN N
group NN N
B NNP N
than IN N
in IN N
group NN N
A NNP N
. . N

The DT N
3 CD o
year NN o
survival NN o
rate NN o
was VBD N
100 CD N
% NN N
in IN N
group NN N
B NNP N
, , N
whereas IN N
it PRP N
was VBD N
76 CD N
% NN N
in IN N
group NN N
A NNP N
. . N

Although IN N
the DT N
incidence NN o
of IN o
myelosuppression NN o
and CC o
alopecia NN o
was VBD N
significantly RB N
higher JJR N
in IN N
group NN N
B NNP N
, , N
neuropathy NN o
was VBD N
significantly RB N
more RBR N
frequent JJ N
in IN N
group NN N
A NNP N
. . N

From IN N
the DT N
above JJ N
results NNS N
, , N
PEB NNP N
seems VBZ N
to TO N
be VB N
a DT N
better JJR N
induction NN N
chemotherapy NN N
than IN N
the DT N
conventional JJ N
one NN N
for IN N
advanced JJ N
testicular JJ N
tumors NNS N
. . N

-DOCSTART- -18957616- O O

Hyperinsulinemia NNP N
fails VBZ N
to TO N
augment VB N
ET-1 JJ N
action NN N
in IN N
the DT N
skeletal JJ N
muscle NN N
vascular JJ N
bed NN N
in IN N
vivo NN p
in IN p
humans NNS p
. . p

Endogenous JJ N
endothelin JJ N
action NN N
is VBZ N
augmented VBN N
in IN N
human JJ N
obesity NN N
and CC N
type NN N
2 CD N
diabetes NNS N
and CC N
contributes NNS N
to TO N
endothelial JJ N
dysfunction NN N
and CC N
impairs VB N
insulin-mediated JJ N
vasodilation NN N
in IN N
humans NNS p
. . p

We PRP N
hypothesized VBD N
that IN N
insulin JJ N
resistance-associated JJ N
hyperinsulinemia NN N
could MD N
preferentially RB N
drive VB N
endothelin-mediated JJ o
vasoconstriction NN o
. . o

We PRP N
applied VBD N
hyperinsulinemic-euglycemic JJ i
clamps NNS i
with IN N
higher JJR p
insulin NN i
dosing VBG p
in IN p
obese JJ p
subjects NNS p
than IN p
lean JJ p
subjects NNS p
( ( p
30 CD p
vs. FW p
10 CD p
mU.m NN p
( ( p
-2 NNP p
) ) p
.min NNP p
( ( p
-1 NNP p
) ) p
, , p
respectively RB p
) ) p
, , N
with IN N
the DT N
goal NN N
of IN N
matching VBG N
insulin NN N
's POS N
nitric JJ N
oxide NN N
( ( N
NO NNP N
) ) N
-mediated VBD N
vascular JJ N
effects NNS N
. . N

We PRP N
predicted VBD N
that IN N
, , N
under IN N
these DT N
circumstances NNS N
, , N
insulin-stimulated JJ N
endothelin-1 JJ N
( ( N
ET-1 NNP N
) ) N
action NN N
( ( N
assessed VBN N
with IN N
the DT N
type NN N
A NNP N
endothelin NN N
receptor NN N
antagonist IN N
BQ-123 NNP N
) ) N
would MD N
be VB N
augmented VBN N
in IN N
proportion NN N
to TO N
hyperinsulinemia VB N
. . N

NO DT o
bioactivity NN o
was VBD N
assessed VBN N
using VBG N
the DT N
nitric JJ N
oxide JJ N
synthase NN N
inhibitor NN N
N NNP N
( ( N
G NNP N
) ) N
-monomethyl-l-arginine NN N
. . N

Insulin-mediated JJ o
vasodilation NN o
and CC o
insulin-stimulated JJ o
NO NNP o
bioavailability NN o
were VBD N
well RB N
matched VBN N
across IN N
groups NNS N
by IN N
this DT N
approach NN N
. . N

As IN N
expected VBN N
, , N
steady-state JJ o
insulin NN o
levels NNS o
were VBD N
approximately RB N
threefold JJ N
higher JJR N
in IN N
obese JJ N
than IN N
lean JJ N
subjects NNS N
( ( N
109.2 CD N
+/- JJ N
10.2 CD N
pmol/l NN N
vs. FW N
518.4 CD N
+/- JJ N
84.0 CD N
, , N
P NNP N
= NNP N
0.03 CD N
) ) N
. . N

Despite IN N
this DT N
, , N
the DT N
augmentation NN N
of IN N
insulin-mediated JJ o
vasodilation NN o
by IN N
BQ-123 NNP N
was VBD N
not RB N
different JJ N
between IN N
groups NNS N
. . N

ET-1 JJ o
flux NN o
across IN N
the DT N
leg NN N
was VBD N
not RB N
augmented VBN N
by IN N
insulin NN N
alone RB N
but CC N
was VBD N
increased VBN N
with IN N
the DT N
addition NN N
of IN N
BQ-123 NNP N
to TO N
insulin VB N
( ( N
P NNP N
= VBZ N
0.01 CD N
BQ-123 JJ N
effect NN N
, , N
P NNP N
= NNP N
not RB N
significant JJ N
comparing VBG N
groups NNS N
) ) N
. . N

Endothelin NNP N
antagonism NN N
augmented VBD N
insulin-stimulated JJ o
NO NNP o
bioavailability NN o
and CC o
NOx NNP o
flux NN o
, , N
but CC N
not RB N
differently RB N
between IN N
groups NNS N
and CC N
not RB N
proportional JJ N
to TO N
hyperinsulinemia VB N
. . N

These DT N
findings NNS N
do VBP N
not RB N
support VB N
the DT N
hypothesis NN N
that WDT N
insulin VBZ N
resistance-associated JJ N
hyperinsulinemia NN N
preferentially RB N
drives VBZ N
endothelin-mediated JJ o
vasoconstriction NN o
. . o

-DOCSTART- -22940159- O O

Psychological JJ i
adjustment NN i
and CC i
levels NNS i
of IN i
self NN i
esteem NN i
in IN N
children NNS p
with IN p
visual-motor JJ p
integration NN p
difficulties NNS p
influences VBZ N
the DT N
results NNS N
of IN N
a DT N
randomized VBN N
intervention NN N
trial NN N
. . N

This DT N
study NN N
evaluates VBZ N
how WRB N
much JJ N
the DT N
effects NNS N
of IN N
intervention NN N
programs NNS N
are VBP N
influenced VBN N
by IN N
pre-existing JJ p
psychological JJ p
adjustment NN p
and CC p
self-esteem JJ p
levels NNS p
in IN p
kindergarten NN p
and CC p
first JJ p
grade NN p
children NNS p
with IN p
poor JJ p
visual-motor JJ p
integration NN p
skills NNS p
, , p
from IN p
low JJ p
socioeconomic JJ p
backgrounds NNS p
. . p

One CD p
hundred CD p
and CC p
sixteen JJ p
mainstream NN p
kindergarten NN p
and CC p
first-grade JJ p
children NNS p
, , p
from IN p
low JJ p
socioeconomic JJ p
backgrounds NNS p
, , p
scoring VBG p
below IN p
the DT p
25th CD p
percentile NN p
on IN p
a DT p
measure NN p
of IN p
visual-motor NN p
integration NN p
( ( p
VMI NNP p
) ) p
were VBD p
recruited VBN p
and CC N
randomly RB N
divided VBN N
into IN N
two CD N
parallel JJ N
intervention NN N
groups NNS N
. . N

One CD N
intervention NN N
group NN N
received VBD N
directive JJ i
visual-motor NN i
intervention NN i
( ( i
DVMI NNP i
) ) i
, , N
while IN N
the DT N
second JJ N
intervention NN N
group NN N
received VBD N
a DT N
non-directive JJ i
supportive JJ i
intervention NN i
( ( i
NDSI NNP i
) ) i
. . i

Tests NNS N
were VBD N
administered VBN N
to TO N
evaluate VB N
visual-motor JJ N
integration NN N
skills VBZ N
outcome NN N
. . N

Children NNP N
with IN N
higher JJR N
baseline NN N
measures NNS N
of IN N
psychological JJ N
adjustment NN N
and CC N
self-esteem NN N
responded VBD N
better RBR N
in IN N
NDSI NNP i
while IN N
children NNS N
with IN N
lower JJR N
baseline NN N
performance NN N
on IN N
psychological JJ N
adjustment NN N
and CC N
self-esteem NN N
responded VBD N
better RBR N
in IN N
DVMI NNP i
. . i

This DT N
study NN N
suggests VBZ N
that IN N
children NNS N
from IN N
low JJ N
socioeconomic JJ N
backgrounds NNS N
with IN N
low JJ N
VMI NNP N
performance NN N
scores NNS N
will MD N
benefit VB N
more RBR N
from IN N
intervention NN N
programs NNS N
if IN N
clinicians NNS N
choose VBP N
the DT N
type NN N
of IN N
intervention NN N
according VBG N
to TO N
baseline VB N
psychological JJ N
adjustment NN N
and CC N
self-esteem JJ N
measures NNS N
. . N

-DOCSTART- -21262119- O O

Dark-phase NNP N
light JJ N
contamination NN N
disrupts NNS N
circadian JJ N
rhythms NN N
in IN N
plasma JJ o
measures NNS N
of IN N
endocrine NN p
physiology NN o
and CC p
metabolism NN o
in IN p
rats NNS p
. . p

Dark-phase NNP i
light JJ i
contamination NN i
can MD N
significantly RB N
disrupt VB N
chronobiologic JJ o
rhythms NN o
, , N
thereby RB N
potentially RB N
altering VBG N
the DT N
endocrine NN N
physiology NN N
and CC N
metabolism NN N
of IN N
experimental JJ p
animals NNS p
and CC N
influencing VBG N
the DT N
outcome NN N
of IN N
scientific JJ N
investigations NNS N
. . N

We PRP N
sought VBD N
to TO N
determine VB N
whether IN N
exposure NN N
to TO N
low-level JJ N
light JJ N
contamination NN N
during IN N
the DT N
dark JJ N
phase NN N
influenced VBD N
the DT N
normally RB N
entrained JJ N
circadian JJ N
rhythms NN N
of IN N
various JJ N
substances NNS N
in IN N
plasma NN N
. . N

Male JJ p
Sprague-Dawley JJ p
rats NNS p
( ( p
n JJ p
= $ p
6 CD p
per IN p
group NN p
) ) p
were VBD N
housed VBN N
in IN N
photobiologic JJ i
light-exposure JJ i
chambers NNS i
configured VBD N
to TO N
create VB N
1 CD N
) ) N
a DT N
12:12-h JJ N
light NN i
: : i
dark JJ i
cycle NN i
without IN i
dark-phase JJ i
light JJ i
contamination NN i
( ( N
control JJ N
condition NN N
; : N
123 CD N
?W/cm NN N
( ( N
2 CD N
) ) N
, , N
lights NNS N
on IN N
at IN N
0600 CD N
) ) N
, , N
2 CD N
) ) N
experimental NN N
exposure NN N
to TO N
a DT N
low JJ i
level NN i
of IN i
light NN i
during IN N
the DT N
12-h JJ N
dark NN N
phase NN N
( ( N
with IN N
0.02 CD N
, , N
0.05 CD N
, , N
0.06 CD N
, , N
or CC N
0.08 CD N
?W/cm NNS N
( ( N
2 CD N
) ) N
light NN N
at IN N
night NN N
) ) N
, , N
or CC N
3 CD N
) ) N
constant JJ i
bright JJ i
light NN i
( ( i
123 CD N
?W/cm NNP N
( ( N
2 CD N
) ) N
) ) N
. . N

Dietary NNP N
and CC N
water NN N
intakes NNS N
were VBD N
recorded VBN N
daily RB N
. . N

After IN N
2 CD N
wk NN N
, , N
rats VB N
underwent JJ N
6 CD N
low-volume JJ N
blood NN N
draws NNS N
at IN N
4-h JJ N
intervals NNS N
( ( N
beginning VBG N
at IN N
0400 CD N
) ) N
during IN N
both DT N
the DT N
light NN N
and CC N
dark JJ N
phases NNS o
. . o

Circadian JJ o
rhythms NN o
in IN o
dietary JJ o
and CC o
water NN o
intake NN o
and CC o
levels NNS o
of IN o
plasma NN o
total JJ o
fatty JJ o
acids NNS o
and CC o
lipid JJ o
fractions NNS o
remained VBD o
entrained JJ N
during IN N
exposure NN N
to TO N
either DT N
control NN N
conditions NNS N
or CC N
low-intensity NN N
light NN N
during IN N
the DT N
dark JJ N
phase NN N
. . N

However RB N
, , N
these DT N
patterns NNS N
were VBD N
disrupted VBN N
in IN N
rats NNS N
exposed VBN N
to TO N
constant VB i
bright JJ i
light NN o
. . o

Circadian JJ o
patterns NNS o
of IN o
plasma NN o
melatonin NN o
, , o
glucose NN o
, , o
lactic JJ o
acid NN o
, , o
and CC o
corticosterone NN o
were VBD o
maintained VBN N
in IN N
all DT N
rats NNS N
except IN N
those DT N
exposed VBN N
to TO N
constant VB i
bright JJ i
light NN i
or CC i
the DT N
highest JJS N
level NN N
of IN N
light NN N
during IN N
the DT N
dark JJ N
phase NN N
. . N

Therefore RB N
even RB N
minimal JJ N
light JJ N
contamination NN N
during IN N
the DT N
dark JJ N
phase NN N
can MD N
disrupt VB N
normal JJ o
circadian JJ o
rhythms NN o
of IN o
endocrine JJ N
metabolism NN N
and CC N
physiology NN N
and CC N
may MD N
alter VB N
the DT N
outcome NN N
of IN N
scientific JJ N
investigations NNS N
. . N

-DOCSTART- -6341410- O O

Comparison NNP N
of IN N
hypnotherapy NN i
with IN N
systematic JJ i
relaxation NN i
in IN N
the DT N
treatment NN N
of IN N
cigarette NN N
habituation NN N
. . N

Because IN N
of IN N
the DT N
methodological JJ N
deficiencies NNS N
in IN N
this DT N
area NN N
of IN N
research NN N
, , N
it PRP N
is VBZ N
impossible JJ N
to TO N
make VB N
any DT N
valid JJ N
conclusions NNS N
about IN N
whether IN N
hypnosis NN N
itself PRP N
is VBZ N
effective JJ N
in IN N
the DT N
treatment NN N
of IN N
cigarette NN N
habituation NN N
. . N

In IN N
this DT N
study NN N
, , N
87 CD p
volunteers NNS p
who WP p
wanted VBD p
to TO p
quit VB p
cigarette NN p
smoking NN p
were VBD N
assigned VBN N
randomly RB N
to TO N
the DT N
experimental JJ i
hypnosis NN i
group NN i
, , i
the DT i
comparison NN i
relaxation NN i
group NN i
, , i
and CC i
the DT i
waiting VBG i
list NN i
control NN i
group NN i
. . i

Ss NNP N
in IN N
the DT N
treatment NN N
groups NNS N
had VBD N
four CD N
weekly JJ N
50-minute NN N
, , N
individual JJ N
sessions NNS N
. . N

Four CD N
months NNS N
after IN N
the DT N
completion NN N
of IN N
treatment NN N
, , N
Ss NNP N
were VBD N
administered VBN N
a DT N
questionnaire NN o
and CC o
a DT o
hypnotic JJ o
susceptibility NN o
scale NN o
. . o

Ss NNP N
in IN N
the DT N
hypnosis NN i
group NN N
who WP N
were VBD N
in IN N
the DT N
upper JJ N
two-thirds NNS N
of IN N
the DT N
group NN N
in IN N
terms NNS N
of IN N
hypnotic JJ N
susceptibility NN N
reduced VBD N
their PRP$ N
cigarette NN o
consumption NN o
substantially RB N
more JJR N
than IN N
Ss NNP N
in IN N
the DT N
relaxation NN N
group NN N
who WP N
were VBD N
in IN N
the DT N
upper JJ N
two-thirds NNS N
of IN N
the DT N
group NN N
in IN N
terms NNS N
of IN N
hypnotic JJ o
susceptibility NN o
. . o

Therefore RB N
, , N
the DT N
hypnotic JJ N
state NN N
appears VBZ N
to TO N
be VB N
therapeutic JJ N
for IN N
individuals NNS p
who WP N
can MD N
enter VB N
medium NN N
or CC N
deep JJ N
states NNS N
of IN N
hypnosis NN N
. . N

-DOCSTART- -8722072- O O

Resource NNP N
utilization NN N
and CC N
costs NNS o
of IN o
care NN o
in IN N
the DT N
diabetes NNS N
control NN N
and CC N
complications NNS N
trial NN N
. . N

OBJECTIVE UH N
To TO N
describe VB N
in IN N
detail NN N
the DT N
resources NNS o
used VBN N
and CC N
costs NNS o
incurred VBN o
in IN N
the DT N
clinical JJ N
management NN N
of IN N
patients NNS p
with IN p
insulin-dependent JJ i
diabetes NNS p
mellitus FW p
( ( p
IDDM NNP p
) ) p
in IN p
the DT p
Diabetes NNP p
Control NNP p
and CC p
Complications NNP p
Trial NNP p
( ( p
DCCT NNP p
) ) p
. . p

RESEARCH NNP N
DESIGN NNP N
AND NNP N
METHODS NNP N
The DT N
resources NNS i
used VBN i
for IN i
intensive JJ i
and CC i
conventional JJ i
therapy NN i
and CC i
to TO i
deal VB i
with IN i
the DT i
side NN i
effects NNS i
of IN i
therapy NN i
were VBD i
assessed VBN i
at IN i
each DT i
of IN i
the DT i
29 CD i
DCCT NNP i
clinics NNS i
and CC i
summarized VBN i
. . i

Unit NN i
costs NNS i
were VBD i
derived VBN i
from IN i
the DT i
DCCT NNP i
, , i
manufacturers NNS i
, , i
and CC i
Medicare NNP i
and CC N
chosen VBN N
to TO N
reflect VB N
what WP N
an DT N
item NN N
would MD N
cost VB N
to TO N
a DT N
single-payer JJ N
national JJ N
health NN N
system NN N
. . N

Costs NNS o
were VBD N
calculated VBN N
as IN N
the DT N
product NN N
of IN N
resources NNS N
used VBN N
and CC N
unit NN N
costs NNS N
. . N

The DT N
costs NNS o
of IN N
the DT N
research NN N
component NN N
of IN N
the DT N
DCCT NNP i
were VBD N
not RB N
included VBN N
. . N

RESULTS NNP N
In IN N
the DT N
DCCT NNP i
, , N
the DT N
annual JJ o
cost NN o
of IN o
intensive JJ o
therapy NN o
( ( N
$ $ N
4,000 CD N
and CC N
$ $ N
5,800/year CD N
for IN N
multiple JJ N
daily JJ N
injections NNS N
and CC N
continuous JJ N
subcutaneous JJ N
insulin NN N
infusion NN N
, , N
respectively RB N
) ) N
was VBD N
approximately RB N
three CD N
times NNS N
the DT N
cost NN o
of IN o
conventional JJ o
therapy NN o
( ( o
$ $ o
1,700/year CD o
) ) N
. . N

A DT N
large JJ N
portion NN N
of IN N
the DT N
difference NN N
in IN N
cost NN o
was VBD N
related VBN N
to TO N
the DT N
greater JJR N
frequency NN o
of IN o
outpatient JJ o
visits NNS o
and CC N
the DT N
greater JJR N
resources NNS o
used VBN o
in IN o
self-care NN o
. . o

CONCLUSIONS NNP N
DCCT NNP i
intensive JJ i
therapy NN i
is VBZ N
more RBR N
expensive JJ N
than IN N
conventional JJ N
therapy NN N
, , N
but CC N
it PRP N
offers VBZ N
the DT N
hope NN N
of IN N
cost NN N
savings NNS N
as IN N
a DT N
result NN N
of IN N
averted JJ N
complications NNS N
. . N

-DOCSTART- -21458811- O O

Specific JJ i
exercises VBZ i
to TO N
treat VB N
pregnancy-related JJ N
low JJ N
back RB N
pain NN N
in IN N
a DT N
South JJ p
African JJ p
population NN p
. . p

OBJECTIVE UH N
To TO N
investigate VB N
the DT N
effect NN N
of IN N
an DT N
exercise NN i
program NN i
, , i
including VBG i
specific JJ i
stabilizing NN i
exercises NNS i
, , N
on IN N
pain NN N
intensity NN N
and CC N
functional JJ N
ability NN N
in IN N
women NNS p
with IN p
pregnancy-related JJ p
low JJ p
back RB p
pain NN p
. . p

METHODS NNP N
Fifty NNP p
women NNS p
between IN p
16 CD p
and CC p
24 CD p
weeks NNS p
of IN p
pregnancy NN p
were VBD p
recruited VBN p
at IN p
Tygerberg NNP p
and CC p
Paarl NNP p
Hospitals NNP p
, , p
Western NNP p
Cape NNP p
, , p
South NNP p
Africa NNP p
. . p

Twenty-six JJ p
women NNS p
were VBD p
randomized VBN p
to TO p
a DT p
10-week JJ i
exercise NN i
program NN i
and CC i
24 CD p
were VBD p
randomized VBN p
as IN p
controls NNS i
. . i

RESULTS NNP N
Overall NNP N
, , N
the DT N
most RBS N
frequent JJ N
type NN N
of IN N
back RB N
pain NN N
experienced VBD N
was VBD N
lumbar JJ o
pain NN o
( ( N
36 CD N
[ RB N
72.0 CD N
% NN N
] NN N
) ) N
. . N

Pain NNP o
intensity NN o
( ( N
P=0.76 NNP N
) ) N
and CC N
functional JJ o
ability NN o
( ( N
P=0.29 NNP N
) ) N
were VBD N
comparable JJ N
between IN N
the DT N
groups NNS N
on IN N
study NN N
entry NN N
. . N

In IN N
the DT N
study NN N
group NN N
, , N
there EX N
was VBD N
a DT N
significant JJ N
improvement NN N
in IN N
pain NN o
intensity NN o
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
and CC N
an DT N
improvement NN N
in IN N
functional JJ o
ability NN o
( ( N
P=0.06 NNP N
) ) N
at IN N
the DT N
end NN N
of IN N
the DT N
study NN N
. . N

In IN N
the DT N
control NN N
group NN N
, , N
there EX N
were VBD N
no DT N
significant JJ N
changes NNS N
in IN N
pain NN o
intensity NN o
( ( N
P=0.89 NNP N
) ) N
or CC N
functional JJ o
ability NN o
( ( N
P=0.70 NNP N
) ) N
at IN N
the DT N
end NN N
of IN N
the DT N
study NN N
. . N

CONCLUSION VB N
A DT N
specific JJ i
exercise NN i
program NN i
decreased VBN N
back RB N
pain JJ N
intensity NN N
and CC N
increased VBD N
functional JJ N
ability NN N
during IN N
pregnancy NN p
in IN p
South JJ p
African JJ p
women NNS p
with IN p
lumbar NN p
and CC p
pelvic JJ p
girdle NN p
pain NN p
. . p

-DOCSTART- -23753523- O O

Effect NN p
of IN p
resistance NN i
exercise NN i
contraction NN i
mode NN i
and CC p
protein JJ i
supplementation NN i
on IN p
members NNS p
of IN p
the DT p
STARS NNP p
signalling VBG p
pathway RB p
. . p

The DT N
striated JJ N
muscle NN N
activator NN N
of IN N
Rho NNP N
signalling VBG N
( ( N
STARS NNP N
) ) N
pathway NN N
is VBZ N
suggested VBN N
to TO N
provide VB N
a DT N
link NN N
between IN N
external JJ N
stress NN N
responses NNS N
and CC N
transcriptional JJ N
regulation NN N
in IN N
muscle NN N
. . N

However RB N
, , N
the DT N
sensitivity NN N
of IN N
STARS NNP N
signalling VBG N
to TO N
different JJ N
mechanical JJ N
stresses NNS N
has VBZ N
not RB N
been VBN N
investigated VBN N
. . N

In IN N
a DT N
comparative JJ N
study NN N
, , N
we PRP N
examined VBD N
the DT N
regulation NN N
of IN N
the DT N
STARS NNP N
signalling VBG N
pathway RB N
in IN N
response NN N
to TO N
unilateral JJ N
resistance NN i
exercise NN i
performed VBN N
as IN N
either DT N
eccentric JJ i
( ( i
ECC NNP i
) ) i
or CC i
concentric JJ i
( ( i
CONC NNP i
) ) i
contractions NNS i
as RB N
well RB N
as IN N
prolonged JJ i
training NN i
; : i
with IN p
and CC p
without IN p
whey JJ i
protein NN i
supplementation NN i
. . i

Skeletal JJ N
muscle NN N
STARS NNP N
, , N
myocardian-related JJ N
transcription NN N
factor-A NN N
( ( N
MRTF-A NNP N
) ) N
and CC N
serum JJ N
response NN N
factor NN N
( ( N
SRF NNP N
) ) N
mRNA NN N
and CC N
protein NN N
, , N
as RB N
well RB N
as IN N
muscle NN N
cross-sectional JJ N
area NN N
and CC N
maximal JJ N
voluntary JJ N
contraction NN N
, , N
were VBD N
measured VBN N
. . N

A DT N
single-bout NN N
of IN N
exercise NN i
produced VBN N
increases NNS N
in IN N
STARS NNP o
and CC o
SRF NNP o
mRNA NN o
and CC o
decreases NNS o
in IN o
MRTF-A NNP o
mRNA NN o
with IN o
both DT o
ECC NNP o
and CC o
CONC NNP o
exercise NN o
, , N
but CC N
with IN N
an DT N
enhanced JJ N
response NN N
occurring VBG N
following VBG N
ECC NNP i
exercise NN i
. . i

A DT N
31 CD N
% NN N
increase NN N
in IN N
STARS NNP o
protein NN o
was VBD N
observed VBN N
exclusively RB N
after IN N
CONC NNP i
exercise NN i
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
while IN N
pSRF JJ o
protein NN N
levels NNS N
increased VBD N
similarly RB N
by IN N
48 CD N
% NN N
with IN N
both DT N
CONC NNP N
and CC N
ECC NNP N
exercise NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

Prolonged VBN N
ECC NNP N
and CC N
CONC NNP N
training VBG N
equally RB N
stimulated VBN N
muscle NN N
hypertrophy NN N
and CC N
produced VBD N
increases NNS N
in IN N
MRTF-A NNP o
protein NN o
of IN N
125 CD N
% NN N
and CC N
99 CD N
% NN N
, , N
respectively RB N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

No UH N
changes NNS N
occurred VBD N
for IN N
total JJ o
SRF NNP o
protein NN o
. . o

There EX N
was VBD N
no DT N
effect NN N
of IN N
whey NN o
protein NN o
supplementation NN o
. . o

These DT N
results NNS N
show VBP N
that IN N
resistance NN N
exercise NN N
provides VBZ N
an DT N
acute JJ o
stimulation NN o
of IN o
the DT o
STARS NNP o
pathway NN o
that WDT N
is VBZ N
contraction JJ N
mode NN N
dependent NN N
. . N

The DT N
responses NNS N
to TO N
acute VB i
exercise NN i
were VBD N
more RBR N
pronounced JJ N
than IN N
responses NNS N
to TO N
accumulated JJ i
training NN i
, , N
suggesting VBG N
that IN N
STARS NNP N
signalling VBG N
is VBZ N
primarily RB N
involved VBN N
in IN N
the DT N
initial JJ N
phase NN N
of IN N
exercise-induced JJ N
muscle NN N
adaptations NNS N
. . N

-DOCSTART- -15088136- O O

Bisphosphonate JJ i
infusions NNS i
: : i
patient NN o
preference NN o
, , o
safety NN o
and CC o
clinic JJ o
use NN o
. . o

GOALS NNP N
OF NNP N
WORK NNP N
We PRP N
set VBD N
out RP N
to TO N
assess VB N
the DT N
preference NN N
of IN N
patients NNS p
with IN p
common JJ p
cancers NNS p
involving VBG p
bone NN p
receiving VBG p
intravenous JJ p
bisphosphonate NN i
therapy NN i
for IN N
either DT N
pamidronate NN i
( ( i
P NNP i
) ) i
or CC i
zoledronic JJ i
acid NN i
( ( i
Z NNP i
) ) i
and CC N
their PRP$ N
preference NN N
for IN N
the DT N
location NN N
of IN N
the DT N
infusion NN N
( ( N
clinic JJ N
or CC N
home NN N
) ) N
. . N

We PRP N
also RB N
aimed VBD N
to TO N
monitor VB N
these DT N
patients NNS N
' POS N
renal JJ o
safety NN o
, , N
and CC N
to TO N
compare VB N
their PRP$ N
time NN N
in IN N
clinic NN N
to TO N
receive VB N
P NNP i
and CC i
Z NNP i
infusions NNS i
. . i

PATIENTS NNP N
AND CC N
METHODS NNP N
Enrolled NNP p
in IN p
the DT p
study NN p
were VBD p
184 CD p
patients NNS p
, , N
and CC N
all DT N
received VBD N
initial JJ N
infusions NNS i
of IN i
Z NNP i
( ( N
so RB N
any DT N
first JJ N
infusion NN N
reactions NNS N
did VBD N
not RB N
confound VB N
preferences NNS N
for IN N
P NNP N
) ) N
. . N

For IN N
their PRP$ N
second JJ N
and CC N
third JJ N
infusions NNS N
, , N
patients NNS N
were VBD N
randomized VBN N
to TO N
receive VB N
Z NNP i
then RB i
P NNP i
or CC i
P NNP i
then RB i
Z NNP i
, , N
and CC N
questioned VBD N
on IN N
their PRP$ N
preferences NNS N
. . N

For IN N
up IN N
to TO N
1 CD N
year NN N
they PRP N
continued VBD N
on IN N
Z NNP i
infusions NNS i
every DT N
3-4 JJ N
weeks NNS N
, , N
while IN N
their PRP$ N
renal JJ N
safety NN N
was VBD N
monitored VBN N
. . N

Where NNP N
practical JJ N
, , N
later JJ N
infusions NNS N
were VBD N
given VBN N
at IN N
home NN N
( ( N
rather RB N
than IN N
in IN N
the DT N
clinic NN N
) ) N
and CC N
patients NNS N
questioned VBN N
on IN N
their PRP$ N
preferred JJ N
infusion NN N
location NN N
. . N

In IN N
a DT N
convenience NN N
subset NN N
of IN N
43 CD N
patients NNS N
, , N
clinic JJ N
use NN N
for IN N
Z NNP i
and CC i
P NNP i
infusions NNS i
was VBD N
also RB N
measured VBN N
by IN N
timing VBG N
infusions NNS N
and CC N
other JJ N
procedures NNS N
. . N

MAIN NNP N
RESULTS NNP N
Of IN N
144 CD N
patients NNS N
who WP N
received VBD N
a DT N
third JJ N
infusion NN N
, , N
138 CD N
responded VBD N
to TO N
questions NNS N
on IN N
bisphosphonate NN N
preference NN N
, , N
and CC N
of IN N
these DT N
138 CD N
, , N
92 CD N
% NN N
( ( N
127 CD N
) ) N
preferred VBD N
Z NNP i
to TO i
P VB i
, , N
because IN N
shorter JJR N
infusions NNS N
caused VBD N
less JJR N
disruption NN o
to TO o
their PRP$ o
day NN o
. . o

Only RB N
12 CD p
% NN p
of IN p
eligible JJ p
patients NNS p
( ( p
16/138 CD p
) ) p
received VBD N
home NN N
infusions NNS N
, , N
but CC N
13/14 CD N
questioned VBD N
preferred VBN N
this DT N
location NN N
. . N

Among IN N
184 CD N
patients NNS N
, , N
19 CD N
episodes NNS N
of IN N
renal JJ o
impairment NN o
were VBD N
noted VBN N
, , N
mostly RB N
owing VBG N
to TO N
disease VB o
progression NN o
( ( N
e.g JJ N
. . N

obstructive JJ N
uropathy JJ N
) ) N
, , N
with IN N
none NN N
linked VBN N
to TO N
Z NNP N
therapy NN N
. . N

The DT N
mean JJ o
clinic JJ o
time NN o
taken VBN o
to TO o
receive VB o
Z NNP o
and CC o
any DT o
concomitant JJ o
therapy NN o
was VBD N
about IN N
half PDT N
that DT N
for IN N
P NNP N
( ( N
78 CD N
vs RB N
161 CD N
min NN N
) ) N
. . N

CONCLUSIONS NNP N
Cancer NNP p
patients NNS p
prefer VBP N
shorter JJR N
bisphosphonate JJ o
infusions-and NN o
at IN N
home NN N
, , N
where WRB N
practical JJ N
. . N

Regular JJ N
Z NNP i
4 CD i
mg NN i
infusions NNS i
appear VBP N
to TO N
be VB N
safe JJ o
in IN N
these DT N
patients NNS N
, , N
with IN N
routine JJ N
monitoring NN N
of IN N
serum JJ N
creatinine NN N
. . N

Using VBG N
Z NNP i
rather RB i
than IN i
P NNP i
could MD N
save VB N
busy JJ N
cancer NN N
centres NNS N
time NN N
and CC N
improve VB N
patient JJ o
satisfaction NN o
. . o

-DOCSTART- -26068449- O O

Self-management JJ N
education NN N
for IN N
adults NNS p
with IN p
poorly RB p
controlled VBN p
epilepsy NN p
( ( p
SMILE NNP p
( ( p
UK NNP p
) ) p
) ) p
: : p
statistical JJ N
, , N
economic JJ N
and CC N
qualitative JJ N
analysis NN N
plan NN N
for IN N
a DT N
randomised JJ N
controlled VBN N
trial NN N
. . N

BACKGROUND NNP N
There EX N
is VBZ N
a DT N
need NN N
to TO N
test VB N
the DT o
effectiveness NN o
of IN o
new JJ o
educational JJ o
interventions NNS o
for IN N
people NNS N
with IN N
poorly RB N
controlled VBN N
epilepsy NN N
. . N

The DT N
SMILE NNP p
( ( p
self-management JJ p
education NN p
for IN p
adults NNS p
with IN p
poorly RB p
controlled VBN p
epilepsy NN p
) ) p
trial NN p
evaluates VBZ N
a DT N
complex JJ N
service NN N
intervention NN N
that WDT N
involves VBZ N
a DT N
2-day JJ N
self-management JJ N
course NN N
with IN N
the DT N
aim NN N
of IN N
improving VBG o
quality NN o
of IN o
life NN o
and CC o
clinical JJ o
outcomes NNS o
. . o

This DT N
article NN N
describes VBZ N
the DT N
statistical JJ N
, , N
economic JJ N
, , N
and CC N
qualitative JJ N
analysis NN N
plan NN N
for IN N
the DT N
trial NN N
. . N

METHODS NNP N
AND CC N
DESIGN NNP N
SMILE NNP p
is VBZ p
a DT p
pragmatic JJ p
, , p
parallel JJ p
design NN p
, , p
two-arm JJ p
, , p
multi-centre JJ p
randomised VBD p
controlled JJ p
superiority NN p
trial NN p
of IN p
a DT i
group-based JJ i
interactive JJ i
course NN i
compared VBN i
with IN i
treatment NN i
as IN i
usual JJ i
for IN p
people NNS p
who WP p
have VBP p
experienced VBN p
two CD p
or CC p
more JJR p
seizures NNS p
in IN p
the DT p
past JJ p
12 CD p
months NNS p
. . p

RESULTS VB N
A DT N
summary NN N
of IN N
the DT N
objectives NNS N
and CC N
design NN N
of IN N
the DT N
trial NN N
are VBP N
reported VBN N
as RB N
well RB N
as IN N
the DT N
manner NN N
in IN N
which WDT N
the DT N
data NN N
will MD N
be VB N
summarised VBN N
and CC N
inferentially RB N
analysed VBN N
. . N

This DT N
includes VBZ N
the DT N
type NN N
of IN N
modelling VBG N
that DT N
will MD N
be VB N
employed VBN N
for IN N
each DT N
of IN N
the DT N
primary JJ N
and CC N
secondary JJ N
outcomes NNS N
and CC N
the DT N
methods NNS N
by IN N
which WDT N
the DT N
assumptions NNS N
of IN N
these DT N
models NNS N
will MD N
be VB N
checked VBN N
. . N

Strategies NNS N
are VBP N
described VBN N
for IN N
handling VBG N
clustering NN N
of IN N
outcome NN N
data NNS N
, , N
missing VBG N
observations NNS N
, , N
and CC N
treatment NN N
non-compliance NN N
. . N

CONCLUSION VB N
This DT N
update NN N
to TO N
the DT N
previously RB N
published VBN N
trial NN N
protocol NN N
provides VBZ N
a DT N
description NN N
of IN N
the DT N
trial NN N
analysis NN N
which WDT N
is VBZ N
transparent JJ N
and CC N
specified VBN N
before IN N
any DT N
outcome NN N
data NNS N
are VBP N
available JJ N
. . N

It PRP N
also RB N
provides VBZ N
guidance NN N
to TO N
those DT N
planning VBG N
the DT N
analysis NN N
of IN N
similar JJ N
trials NNS N
. . N

TRIAL NNP N
REGISTRATION NNP N
Current NNP N
Controlled NNP N
Trials NNP N
ISRCTN57937389 NNP N
; : N
date NN N
assigned VBD N
: : N
27 CD N
March NNP N
2013 CD N
. . N

-DOCSTART- -12065558- O O

Superior JJ N
survival NN o
with IN N
capecitabine JJ i
plus CC i
docetaxel JJ i
combination NN i
therapy NN i
in IN N
anthracycline-pretreated JJ p
patients NNS p
with IN p
advanced JJ p
breast NN p
cancer NN p
: : p
phase NN N
III NNP N
trial NN N
results NNS N
. . N

PURPOSE NNP N
Docetaxel NNP i
and CC i
capecitabine NN i
, , N
a DT N
tumor-activated JJ N
oral JJ N
fluoropyrimidine NN N
, , N
show VBP N
high JJ N
single-agent JJ N
efficacy NN N
in IN N
metastatic JJ p
breast NN p
cancer NN p
( ( N
MBC NNP N
) ) N
and CC N
synergy NN N
in IN N
preclinical JJ N
studies NNS N
. . N

This DT N
international JJ N
phase NN N
III NNP N
trial NN N
compared VBN N
efficacy NN o
and CC o
tolerability NN o
of IN N
capecitabine/docetaxel JJ i
therapy NN i
with IN N
single-agent JJ i
docetaxel NN i
in IN N
anthracycline-pretreated JJ p
patients NNS p
with IN p
MBC NNP p
. . p

PATIENTS NNP N
AND CC N
METHODS NNP N
Patients NNPS N
were VBD N
randomized VBN N
to TO N
21-day JJ N
cycles NNS N
of IN N
oral JJ N
capecitabine NN i
1,250 CD N
mg/m NN N
( ( N
2 CD N
) ) N
twice RB N
daily RB N
on IN N
days NNS N
1 CD N
to TO N
14 CD N
plus CC N
docetaxel JJ i
75 CD N
mg/m NN N
( ( N
2 CD N
) ) N
on IN N
day NN N
1 CD N
( ( N
n JJ N
= NNP N
255 CD N
) ) N
or CC N
to TO N
docetaxel VB i
100 CD N
mg/m NN N
( ( N
2 CD N
) ) N
on IN N
day NN N
1 CD N
( ( N
n JJ N
= NNP N
256 CD N
) ) N
. . N

RESULTS NNP N
Capecitabine/docetaxel NNP i
resulted VBD N
in IN N
significantly RB N
superior JJ N
efficacy NN o
in IN N
time NN o
to TO o
disease VB o
progression NN o
( ( o
TTP NNP o
) ) o
( ( N
hazard JJ N
ratio NN N
, , N
0.652 CD N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NNP N
, , N
0.545 CD N
to TO N
0.780 CD N
; : N
P NNP N
=.0001 NNP N
; : N
median JJ N
, , N
6.1 CD N
v NN N
4.2 CD N
months NNS N
) ) N
, , N
overall JJ o
survival NN o
( ( N
hazard JJ N
ratio NN N
, , N
0.775 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
0.634 CD N
to TO N
0.947 CD N
; : N
P NNP N
=.0126 NNP N
; : N
median JJ N
, , N
14.5 CD N
v NN N
11.5 CD N
months NNS N
) ) N
, , N
and CC N
objective JJ o
tumor NN o
response NN o
rate NN o
( ( N
42 CD N
% NN N
v JJ N
30 CD N
% NN N
, , N
P NNP N
=.006 NNP N
) ) N
compared VBN N
with IN N
docetaxel NN i
. . i

Gastrointestinal JJ o
side NN o
effects NNS o
and CC o
hand-foot JJ o
syndrome NN o
were VBD N
more JJR N
common JJ N
with IN N
combination NN i
therapy NN i
, , N
whereas JJ N
myalgia NN o
, , o
arthralgia NN o
, , N
and CC N
neutropenic JJ o
fever/sepsis NN o
were VBD N
more JJR N
common JJ N
with IN N
single-agent JJ i
docetaxel NN i
. . i

More JJR N
grade JJ o
3 CD o
adverse JJ o
events NNS o
occurred VBD N
with IN N
combination NN i
therapy NN i
( ( N
71 CD N
% NN N
v JJ N
49 CD N
% NN N
, , N
respectively RB N
) ) N
, , N
whereas JJ N
grade VBP o
4 CD o
events NNS o
were VBD N
slightly RB N
more RBR N
common JJ N
with IN N
docetaxel NN i
( ( N
31 CD N
% NN N
v JJ N
25 CD N
% NN N
with IN N
combination NN N
) ) N
. . N

CONCLUSION VB N
The DT N
significantly RB N
superior JJ N
TTP NNP o
and CC o
survival NN o
achieved VBN N
with IN N
the DT N
addition NN i
of IN i
capecitabine NN i
to TO i
docetaxel VB i
75 CD N
mg/m NN N
( ( N
2 CD N
) ) N
, , N
with IN N
the DT N
manageable JJ N
toxicity NN o
profile NN o
, , N
indicate VBP N
that IN N
this DT N
combination NN i
provides VBZ N
clear JJ N
benefits NNS N
over IN N
single-agent JJ i
docetaxel NN i
100 CD N
mg/m NN N
( ( N
2 CD N
) ) N
. . N

Docetaxel/capecitabine NNP i
therapy NN i
is VBZ N
an DT N
important JJ N
treatment NN N
option NN N
for IN N
women NNS p
with IN p
anthracycline-pretreated JJ p
MBC NNP p
. . p

-DOCSTART- -1920171- O O

Cardiac JJ N
failure NN N
: : N
symptoms NNS N
and CC N
functional JJ N
status NN N
. . N

The DT N
associations NNS N
between IN N
exercise NN N
capacity NN N
, , N
symptoms NNS N
and CC N
specific JJ N
aspects NNS N
of IN N
quality NN N
of IN N
life NN N
were VBD N
examined VBN N
in IN N
subjects NNS p
participating VBG p
in IN p
a DT p
trial NN p
of IN p
the DT p
treatment NN i
of IN i
heart NN i
failure NN i
. . i

Patients NNS i
were VBD i
assessed VBN i
on IN p
entry NN p
and CC p
after IN p
three CD p
months NNS p
treatment NN i
. . i

The DT N
principle NN N
symptoms NNS N
were VBD N
fatigue JJ p
, , p
breathlessness NN p
and CC p
chest NN p
pain NN p
. . p

These DT N
limited VBD N
the DT N
extent NN N
and CC N
speed NN N
of IN N
physical JJ N
activities NNS N
, , N
restricted VBN N
social JJ N
, , N
leisure NN N
and CC N
family NN N
life NN N
and CC N
were VBD N
associated VBN N
with IN N
emotional JJ N
distress NN N
. . N

There EX N
were VBD N
associations NNS N
between IN N
baseline NN o
exercise NN o
capacity NN o
and CC o
measures NNS o
of IN o
quality NN o
of IN o
life NN o
. . o

Change NNP N
in IN N
exercise NN N
capacity NN N
during IN N
three CD N
months NNS N
treatment NN i
was VBD N
correlated VBN N
with IN N
changes NNS N
in IN N
measures NNS o
of IN o
symptoms NNS o
, , o
limitation NN o
of IN o
activity NN o
and CC o
quality NN o
of IN o
life NN o
. . o

The DT N
findings NNS N
confirm VBP N
the DT N
value NN N
of IN N
change NN N
in IN N
exercise NN o
capacity NN o
as IN N
a DT N
measure NN N
of IN N
functional JJ N
status NN N
and CC N
suggest VBP N
that IN N
it PRP N
should MD N
be VB N
supported VBN N
by IN N
a DT N
limited JJ N
number NN N
of IN N
specific JJ N
measures NNS N
of IN N
quality NN o
of IN o
life NN o
. . o

-DOCSTART- -8792262- O O

The DT N
influence NN N
of IN N
nonhandicapped JJ i
peers NNS i
on IN N
the DT N
social JJ o
interactions NNS o
of IN N
children NNS p
with IN p
a DT p
pervasive JJ p
development NN p
disorder NN p
. . p

This DT N
study NN N
investigated VBD N
whether IN N
or CC N
not RB N
children NNS p
with IN p
autism NN p
or CC p
a DT p
related JJ p
pervasive JJ p
developmental NN p
disorder NN p
( ( p
PDD NNP p
) ) p
can MD N
benefit VB o
from IN N
regular JJ i
opportunities NNS i
to TO i
interact VB i
with IN i
a DT i
normally RB i
developing VBG i
peer NN i
, , N
matched VBD N
as IN N
to TO N
sex NN N
and CC N
age NN N
. . N

An DT N
experimental JJ N
design NN N
with IN N
random JJ N
assignment NN N
of IN N
subjects NNS N
to TO N
treatment NN N
and CC N
control NN N
groups NNS N
was VBD N
used VBN N
to TO N
demonstrate VB N
the DT N
impact NN o
of IN N
this DT N
peer-mediated JJ i
intervention NN i
. . i

In IN N
the DT N
treatment NN N
group NN N
, , N
we PRP N
found VBD N
significant JJ N
improvements NNS N
in IN N
the DT N
social JJ o
behavior NN o
of IN N
the DT N
children NNS N
with IN N
PDD NNP N
. . N

Several JJ N
gains NNS o
were VBD N
also RB N
generalized VBN N
to TO N
interactions NNS o
with IN o
an DT o
unfamiliar JJ o
nonhandicapped JJ o
peer NN o
, , N
to TO N
interactions NNS o
with IN o
another DT o
child NN o
with IN o
PDD NNP o
, , o
and CC o
to TO o
the DT o
large JJ o
school NN o
setting VBG o
. . o

In IN N
the DT N
untreated JJ N
control NN N
group NN N
, , N
no DT N
positive JJ o
changes NNS o
were VBD N
observed VBN N
. . N

Results VB N
suggest JJS N
that IN N
children NNS p
with IN p
PDD NNP p
can MD N
develop VB N
peer JJ o
relations NNS o
if IN N
appropriate JJ N
social JJ N
contexts NN N
are VBP N
made VBN N
available JJ N
for IN N
them PRP N
. . N

-DOCSTART- -14520769- O O

Analgesic JJ N
efficacy NN N
of IN N
low-dose JJ N
diclofenac NN i
versus NN i
paracetamol NN i
and CC i
placebo NN i
in IN N
postoperative JJ p
dental NN p
pain NN p
. . p

AIMS NNP N
To TO N
compare VB N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
diclofenac-K NN i
( ( N
12.5 CD N
mg NN N
) ) N
vs NN N
paracetamol NN i
( ( N
500 CD N
mg NN N
) ) N
and CC N
placebo VB i
given VBN N
in IN N
a DT N
flexible JJ N
dosage NN N
regimen NNS N
to TO N
treat VB N
pain NN p
resulting VBG p
from IN p
extraction NN p
of IN p
impacted JJ p
third JJ p
molar JJ p
teeth NN p
. . p

METHODS NNP N
This DT N
was VBD N
a DT N
2-day JJ N
, , N
double-blind JJ N
, , N
double-dummy JJ N
, , N
randomized VBN N
, , N
parallel-group JJ N
, , N
placebo-controlled JJ i
study NN N
of IN N
diclofenac-K NN i
( ( i
12.5 CD i
mg NN i
) ) i
tablets VBZ i
vs JJ i
paracetamol NN i
( ( N
500 CD N
mg NN N
) ) N
tablets NNS N
and CC N
placebo NN i
in IN N
patients NNS p
with IN p
moderate JJ p
or CC p
severe JJ p
pain NN p
within IN p
8 CD p
hours NNS p
of IN p
extraction NN p
of IN p
impacted JJ p
third JJ p
molars NNS p
. . p

RESULTS NNP N
After IN N
the DT N
first JJ N
2-tablet JJ N
dose NN N
, , N
patients NNS N
took VBD N
on IN N
average JJ N
2.5 CD N
additional JJ N
tablets NNS N
of IN N
diclofenac-K NN i
or CC N
2.4 CD N
tablets NNS N
of IN N
paracetamol NN i
, , N
almost RB N
all DT N
as IN N
1-tablet JJ N
doses NNS N
. . N

Most JJS N
placebo JJ i
patients NNS N
discontinued VBN N
by IN N
taking VBG N
rescue JJ o
medication NN o
( ( N
ibuprofen JJ N
200 CD N
mg NN N
) ) N
on IN N
the DT N
first JJ N
day NN N
. . N

Pain NNP o
relief NN o
after IN N
the DT N
initial JJ N
dose NN N
of IN N
diclofenac-K NN i
( ( N
2 CD N
x RB N
12.5 CD N
mg NN N
) ) N
was VBD N
superior JJ N
to TO N
placebo VB i
( ( N
P NNP N
< NNP N
.01 NNP N
for IN N
all DT N
efficacy NN N
outcomes NNS N
) ) N
and CC N
comparable JJ N
to TO N
paracetamol VB i
( ( N
2 CD N
x RB N
500 CD N
mg NN N
) ) N
. . N

About IN N
30 CD N
% NN N
of IN N
patients NNS N
in IN N
each DT N
active JJ N
treatment NN N
group NN N
took VBD N
rescue NN o
medication NN o
during IN N
the DT N
study NN N
, , N
compared VBN N
to TO N
78 CD N
% NN N
on IN N
placebo NN i
. . i

About IN N
70 CD N
% NN N
in IN N
each DT N
active JJ N
treatment NN N
group NN N
considered VBD N
the DT N
overall JJ o
pain NN o
relief NN o
to TO N
be VB N
some DT N
, , N
a DT N
lot NN N
, , N
or CC N
complete JJ N
compared VBN N
to TO N
only RB N
15 CD N
% NN N
on IN N
placebo NN i
. . i

The DT N
incidence NN o
of IN o
adverse JJ o
events NNS o
in IN N
each DT N
active JJ N
treatment NN N
group NN N
was VBD N
low JJ N
and CC N
comparable JJ N
between IN N
the DT N
treatments NNS N
. . N

CONCLUSION NNP N
An DT N
initial JJ N
double-dose NN N
of IN N
diclofenac-K NN i
( ( N
2 CD N
x RB N
12.5 CD N
mg NN N
) ) N
or CC N
paracetamol NN i
( ( N
2 CD N
x RB N
500 CD N
mg NNS N
) ) N
adequately RB N
relieved VBD N
the DT N
most RBS N
intense JJ N
postoperative NN o
pain NN o
, , N
and CC N
the DT N
flexible JJ N
multiple NN N
dose JJ N
regimen NNS N
( ( N
1 CD N
or CC N
2 CD N
tablets NNS N
) ) N
maintained VBD N
adequate JJ N
pain NN o
relief NN o
thereafter RB N
. . N

Most JJS N
patients NNS N
needed VBN N
only RB N
1-tablet JJ N
doses NNS N
following VBG N
the DT N
initial JJ N
2-tablet JJ N
dose NN N
. . N

-DOCSTART- -12418582- O O

Evaluation NN N
of IN N
different JJ N
inhaled JJ i
combination NN i
therapies NNS i
( ( i
EDICT NNP i
) ) i
: : i
a DT N
randomised JJ N
, , N
double-blind JJ N
comparison NN N
of IN N
Seretide NNP i
( ( N
50/250 CD N
microg NN N
bd NN N
Diskus NNP i
vs. FW i
formoterol NN i
( ( N
12 CD N
microg RB N
bd NN N
) ) N
and CC N
budesonide NN i
( ( N
800 CD N
microg RB N
bd NN N
) ) N
given VBN N
concurrently RB N
( ( N
both DT N
via IN N
Turbuhaler NNP N
) ) N
in IN N
patients NNS p
with IN p
moderate-to-severe JJ p
asthma NN p
. . p

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
efficacy NN o
safety NN o
and CC o
cost NN o
of IN N
Seretide NNP i
( ( i
salmeterol/fluticasone NN i
propionate NN i
( ( i
Salm/FP NNP i
) ) i
, , N
50/250 CD N
microg NN N
bd NN N
) ) N
via IN N
Diskus NNP i
with IN i
formoterol NN i
( ( N
Form NNP N
; : N
12 CD N
microg NN N
bd NN N
) ) N
and CC N
budesonide NN i
( ( N
Bud NNP N
; : N
800 CD N
microg NN N
bd NN N
) ) N
given VBN N
concurrently RB N
( ( N
Form+Bud NNP N
) ) N
via IN N
Turbuhaler NNP N
in IN N
patients NNS p
with IN p
moderate-to-severe JJ p
asthma NNS p
who WP N
were VBD N
uncontrolled VBN N
on IN N
existing VBG N
corticosteroid JJ N
therapy NN N
. . N

The DT N
study NN N
used VBD N
a DT N
randomised JJ N
, , N
double-blind JJ N
, , N
double-dummy JJ N
, , N
parallel-group JJ N
design NN N
, , N
consisting VBG N
of IN N
a DT N
2-week JJ N
run-in JJ N
period NN N
on IN N
current JJ i
corticosteroid NN i
therapy NN i
( ( N
1000-1600 JJ N
microg/day NN N
of IN N
BDP NNP N
or CC N
equivalent NN N
) ) N
and CC N
a DT N
12-week JJ N
treatment NN N
period NN N
. . N

Symptomatic JJ p
patients NNS p
( ( p
n JJ p
= NNP p
428 CD p
) ) p
with IN p
FEV1 NNP p
of IN p
50-85 CD p
% NN p
predicted JJ p
and CC p
increased JJ p
symptom NN o
scores NNS o
or CC p
reliever NN p
use NN p
during IN p
run-in NN p
were VBD N
randomly RB N
allocated VBN N
to TO N
receive VB N
either DT N
Salm/FP NNP N
( ( N
50/250 CD N
microg RB N
bd NN N
) ) N
via IN N
a DT N
single JJ N
Diskus NNP N
inhaleror NN N
Form+Bud NNP N
( ( N
12+800 CD N
microg RB N
bd NN N
) ) N
via IN N
separate JJ N
Turbuhalers NNPS N
. . N

Clinic NNP N
, , N
diary JJ N
card NN N
and CC N
asthma-related JJ N
health-care JJ N
resource NN N
utilisation NN N
data NNS N
were VBD N
collected VBN N
. . N

Improvement NN N
in IN N
mean JJ N
morning NN N
peak NN N
expiratory NN N
flow NN N
( ( N
PEFam NNP N
was VBD N
similar JJ N
in IN N
the DT N
Salm/FP NNP N
and CC N
Form+Bud NNP N
groups NNS N
. . N

Both DT N
PEFam NNP o
and CC N
mean JJ o
evening NN o
PEF NNP o
( ( o
PEFpm NNP o
) ) o
increased VBN N
by IN N
a DT N
clinically RB N
significant JJ N
amount NN N
( ( N
> JJ N
20 CD N
L/min NNP N
) ) N
from IN N
baseline NN N
in IN N
both DT N
treatment NN N
groups NNS N
. . N

The DT N
mean JJ o
rate NN o
of IN o
exacerbations NNS o
( ( N
mild NN N
, , N
moderate JJ N
or CC N
severe JJ N
) ) N
was VBD N
significantly RB N
lower JJR N
in IN N
the DT N
Salm/FP NNP N
group NN N
( ( N
0.472 CD N
) ) N
compared VBN N
with IN N
the DT N
Form+Bud NNP N
group NN N
( ( N
0.735 CD N
) ) N
( ( N
ratio JJ N
= VBZ N
0.64 CD N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
despite IN N
the DT N
three-fold JJ N
lower JJR N
microgram NN N
inhaled VBN N
corticosteroid NN N
dose NN N
in IN N
the DT N
Salm/FP NNP N
group NN N
. . N

Patients NNS N
in IN N
the DT N
Salm/FP NNP N
group NN N
also RB N
experienced VBD N
significantly RB N
fewer JJR o
nocturnal JJ o
symptoms NNS o
, , N
with IN N
a DT N
higher JJR N
median JJ N
percentage NN N
of IN N
symptom-free JJ o
nights NNS o
( ( N
P NNP N
= NNP N
0.04 CD N
) ) N
, , N
nights NNS o
with IN o
a DT o
symptom NN o
score NN o
< $ N
2 CD N
( ( N
P NNP N
= NNP N
0.03 CD N
) ) N
, , N
and CC N
nights NNS o
with IN o
no DT o
awakenings NNS o
( ( N
P NNP N
= NNP N
0.02 CD N
) ) N
. . N

Total JJ o
asthma-related JJ o
health-care NN o
costs NNS o
were VBD N
significantly RB N
lower JJR N
in IN N
the DT N
Salm/FP NNP N
group NN N
than IN N
the DT N
Form+Bud NNP N
group NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

Both DT N
treatments NNS N
were VBD N
well RB o
tolerated VBN o
, , N
with IN N
a DT N
similar JJ o
low JJ o
incidence NN o
of IN N
adverse JJ o
events NNS o
. . o

This DT N
study NN N
showed VBD N
that IN N
in IN N
symptomatic JJ N
patients NNS N
with IN N
moderate-to-severe JJ N
asthma NN N
, , N
Salm/FP NNP i
( ( N
50/250 CD N
microg RB N
bd NN N
) ) N
, , N
administered VBN N
in IN N
a DT N
single JJ N
convenient NN N
device NN N
( ( N
Diskus NNP N
) ) N
, , N
was VBD N
at IN N
least JJS N
as RB N
effective JJ N
as IN N
an DT N
approximately RB N
three-fold JJ N
higher JJR N
microgram NN N
corticosteroid VBP i
dose NN i
of IN i
Bud NNP i
( ( i
800 CD i
microg RB N
bd NN N
) ) N
given VBN N
concurrently RB N
with IN N
Form NNP i
( ( N
12 CD N
microg RB N
bd NN N
) ) N
in IN N
terms NNS N
of IN N
improvement NN N
in IN N
PEFam NNP N
, , N
and CC N
superior JJ N
at IN N
reducing VBG o
exacerbations NNS o
and CC o
nights NNS o
with IN o
symptoms NNS o
or CC o
night-time JJ o
awakenings NNS o
. . o

Salm/FP NNP i
was VBD N
also RB N
the DT N
less RBR o
costly JJ o
treatment NN N
due JJ N
primarily RB N
to TO N
lower JJR o
hospitalisation NN o
and CC o
drug NN o
costs NNS o
. . o

-DOCSTART- -25555877- O O

Effects NNS N
of IN N
stellate NN i
ganglionic JJ i
block NN i
on IN N
hemodynamic JJ o
changes NNS o
and CC o
intrapulmonary JJ o
shunt NN o
in IN N
perioperative JJ p
patients NNS p
with IN p
esophageal JJ p
cancer NN p
. . p

OBJECTIVE CC N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
observe VB N
the DT N
effects NNS N
of IN i
stellate JJ i
ganglion NN i
block NN i
( ( i
SGB NNP i
) ) i
on IN o
hemodynamic JJ o
changes NNS o
and CC o
intrapulmonary JJ o
shunt NN o
during IN N
one-lung JJ N
ventilation NN N
( ( N
OLV NNP N
) ) N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP p
Thirty NNP p
ASA NNP p
class NN p
I-II NNP p
patients NNS p
undergoing VBG p
elective JJ p
esophageal NN p
surgery NN p
were VBD N
randomly RB N
divided VBN N
into IN N
two CD N
groups NNS i
: : i
general JJ i
anesthesia NN i
group NN i
( ( i
group NN i
N NNP i
, , i
n=15 NN i
) ) i
and CC i
general JJ i
anesthesia NN i
combined VBD i
SGB NNP i
group NN i
( ( i
group NN i
S NNP i
, , i
n=15 NN i
) ) i
, , i
patients NNS i
in IN i
group NN i
S NNP i
were VBD i
received VBN i
left JJ i
SGB NNP i
before IN i
induction NN i
. . i

Radial JJ i
artery NN i
was VBD i
cannulated VBN i
for IN o
arterial JJ o
blood NN o
pressure NN o
( ( o
ABP NNP o
) ) o
monitoring NN o
and CC o
blood NN o
sampling NN i
and CC i
Swan-Ganz NNP i
catheter NN i
was VBD i
position NN i
in IN i
the DT i
pulmonary JJ i
artery NN i
via IN i
right JJ i
internal JJ i
jugular NN i
vein NN i
under IN i
local JJ i
anesthesia NN i
. . i

ECG NNP o
, , o
MAP NNP o
, , o
HR NNP o
, , o
CVP NNP o
, , o
continuous JJ o
cardiac NN o
output NN o
( ( o
CCO NNP o
) ) o
index NN o
and CC o
BIS NNP o
were VBD N
continuously RB N
monitored VBN N
during IN N
anesthesia NN N
. . N

General NNP N
anesthesia NN N
was VBD N
induced VBN N
with IN N
propofol JJ N
1.5-2.0 JJ N
mg/kg NN N
, , N
sufentanil VBD N
0.4 CD N
?g/kg NN N
, , N
and CC N
Rocuronium NNP N
0.6-0.9 JJ N
mg/kg NN N
. . N

Endobronchial JJ N
occluder NN N
was VBD N
placed VBN N
blindly RB N
after IN N
tracheal JJ N
indubation NN N
and CC N
the DT N
correct JJ N
position NN N
was VBD N
verified VBN N
by IN N
auscultation NN N
and CC N
fiberoptic JJ N
bronchoscopy NN N
. . N

The DT N
patients NNS N
were VBD N
mechanically RB N
ventilated VBN N
. . N

The DT N
ventilation NN N
conditions NNS N
were VBD N
Fio2=100 NNP N
% NN N
, , N
VT NNP N
= NNP N
8-10 JJ N
ml/kg NN N
, , N
I PRP N
: : N
E NN N
= VBZ N
1:2 CD N
and CC N
respiratory JJ N
rate NN N
was VBD N
adjusted VBN N
to TO N
maintained VBN N
PETCO2 NNP N
at IN N
35-45 JJ N
mmHg NN N
during IN N
both DT N
two-lung JJ N
ventilation NN N
( ( N
TLV NNP N
) ) N
and CC N
OLV NNP N
. . N

Anesthesia NNP N
was VBD N
maintained VBN N
with IN N
continuous JJ N
infusion NN N
of IN N
propofol JJ N
4-10 JJ N
mg/kg?h NN N
, , N
sufentanil VBD N
0.2 CD N
?g/kg?h NN N
, , N
vecuronium NN N
o.1 NN N
mg/kg?h NN N
, , N
BIS NNP N
was VBD N
maintained VBN N
at IN N
45-55 JJ N
. . N

Blood NN N
samples NNS N
were VBD N
taken VBN N
from IN N
radial JJ N
artery NN N
and CC N
S-G NNP N
catheter NN N
for IN N
blood NN N
gas NN N
analysis NN N
at IN N
following VBG N
intervals NNS N
: : N
during IN N
spontaneous JJ N
breathing VBG N
when WRB N
the DT N
patient NN N
was VBD N
awake JJ N
( ( N
T0 NNP N
) ) N
, , N
1 CD N
min NN N
after IN N
tracheal JJ N
indubation NN N
( ( N
T1 NNP N
) ) N
, , N
1 CD N
min NN N
after IN N
patient NN N
was VBD N
placed VBN N
in IN N
lateral JJ N
position NN N
( ( N
T2 NNP N
) ) N
and CC N
15 CD N
min NN N
after IN N
it PRP N
( ( N
T3 NNP N
) ) N
, , N
1 CD N
min NN N
after IN N
ribs NN N
was VBD N
braced VBN N
( ( N
T4 NNP N
) ) N
, , N
30 CD N
, , N
60 CD N
, , N
120 CD N
min NN N
during IN N
the DT N
course NN N
of IN N
OLV NNP N
( ( N
T5 NNP N
, , N
T6 NNP N
, , N
T7 NNP N
) ) N
, , N
the DT N
two CD N
lungs NNS N
were VBD N
ventilated VBN N
again RB N
for IN N
30 CD N
min NN N
( ( N
T8 NNP N
) ) N
and CC o
Qs/Qt NNP o
was VBD N
calculated VBN N
. . N

RESULTS NNP o
SVRI NNP o
, , o
MAP NNP o
, , o
HR NNP o
in IN o
group NN o
N NNP o
increased VBD o
significantly RB N
at IN N
T1 NNP N
, , N
T2 NNP N
, , N
T4 NNP N
compared VBN N
with IN N
group NN N
S NNP N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

Qs/Qt NNP o
was VBD N
significantly RB N
increased VBN N
after IN N
patient NN N
was VBD N
placed VBN N
in IN N
lateral JJ N
position NN N
and CC N
increased VBD N
further RBR N
during IN N
OLV NNP N
; : N
the DT N
calculated JJ o
Qs/Qt NNP o
values NNS N
were VBD N
highest JJS N
at IN N
T5? NNP N
PaO2 NNP o
was VBD o
significantly RB N
lower JJR N
after IN N
OLV NNP N
was VBD N
started VBN N
and CC N
reached VBN N
the DT N
lowest JJS N
level NN N
at IN N
T6 NNP N
then RB N
was VBD N
gradually RB N
increasing VBG N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN o
in IN o
Qs/Qt NNP o
and CC o
PaO2 NNP o
at IN o
all DT N
time NN N
points NNS N
between IN N
two CD N
groups NNS N
. . N

CONCLUSIONS NNP i
SGB NNP i
before IN i
induction NN N
effectively RB N
suppress VBD N
the DT N
stress NN N
response NN N
work NN N
as IN N
stable JJ N
blood NN N
dynamics NNS N
and CC N
does VBZ N
not RB N
affect VB N
Qs/Qt NNP o
and CC N
arterial JJ N
oxygenation NN N
during IN N
OLV NNP N
, , N
SGB NNP N
is VBZ N
a DT N
safe JJ N
technique NN N
of IN N
anesthesia NN N
for IN N
general JJ N
thoracic NN N
surgery NN N
. . N

-DOCSTART- -18686184- O O

Smoking VBG o
cessation NN o
with IN N
smokeless JJ i
tobacco NN i
and CC N
group NN i
therapy NN i
: : i
an DT N
open JJ N
, , N
randomized VBN N
, , N
controlled VBN N
trial NN N
. . N

Smokeless NNP i
tobacco NN i
might MD N
be VB N
effective JJ N
as IN N
an DT N
adjunct NN N
for IN N
smoking VBG o
cessation NN o
. . o

We PRP N
evaluated VBD N
the DT N
efficacy NN N
of IN N
smokeless NN i
tobacco NN i
and CC N
group NN i
support NN i
for IN N
smoking VBG o
cessation NN o
in IN N
an DT N
open JJ N
, , N
randomized VBN N
study NN N
that WDT N
compared VBN N
smokeless NN i
tobacco NN i
plus CC i
group NN i
support NN i
versus NN i
group NN i
support NN i
only RB i
. . i

The DT N
study NN p
enrolled VBD p
263 CD p
healthy JJ p
smokers NNS p
( ( p
M NNP p
( ( p
age NN p
) ) p
= VBZ p
49 CD p
years NNS p
) ) p
who WP p
smoked VBD p
a DT p
mean NN p
of IN p
24 CD p
cigarettes/day NN p
, , p
with IN p
a DT p
mean NN p
of IN p
31 CD p
pack-years NNS p
. . p

Smokeless NNP i
tobacco NN i
was VBD N
provided VBN N
for IN N
7 CD N
weeks NNS N
( ( N
or CC N
up RB N
to TO N
12 CD N
) ) N
, , N
combined VBN N
with IN N
eight CD N
group NN i
support NN i
visits NNS i
provided VBN i
by IN i
nurses NNS i
. . i

The DT N
control NN i
group NN i
received VBD N
group NN i
support NN i
only RB i
. . i

Smoking VBG o
cessation NN o
rates NNS o
were VBD N
statistically RB N
significantly RB N
better RBR N
in IN N
the DT N
smokeless NN N
tobacco NN N
group NN N
than IN N
in IN N
the DT N
control NN N
group NN N
during IN N
the DT N
first JJ N
7 CD N
weeks NNS N
. . N

Point-prevalence NN o
abstinence NN o
rates NNS o
at IN N
7 CD N
weeks NNS N
were VBD N
36.4 CD N
% NN N
versus IN N
20.8 CD N
% NN N
( ( N
OR NNP N
= VBZ N
2.52 CD N
, , N
p NN N
= NNP N
.001 NNP N
) ) N
, , N
respectively RB N
; : N
and CC N
continuous JJ o
abstinence NN o
rates NNS o
from IN N
weeks NNS N
4 CD N
to TO N
7 CD N
were VBD N
31.5 CD N
% NN N
versus IN N
19.2 CD N
% NN N
( ( N
OR NNP N
= VBZ N
1.94 CD N
, , N
p NN N
= NNP N
.023 NNP N
) ) N
, , N
respectively RB N
. . N

The DT N
primary JJ N
outcomes NNS N
( ( N
i.e. JJ N
, , N
6-month JJ o
point NN o
prevalence NN o
) ) o
were VBD N
23.1 CD N
% NN N
versus IN N
20.8 CD N
% NN N
, , N
respectively RB N
( ( N
OR NNP N
= VBZ N
1.31 CD N
, , N
ns NN N
) ) N
. . N

Smokeless NNP i
tobacco NN i
was VBD N
relatively RB N
well RB N
tolerated VBN o
, , N
although IN N
15 CD N
subjects NNS N
( ( N
11.2 CD N
% NN N
) ) N
stopped VBD N
use NN N
due JJ N
to TO N
adverse JJ o
events NNS o
. . o

A DT N
total NN N
of IN N
25 CD N
subjects NNS N
( ( N
17.5 CD N
% NN N
) ) N
were VBD N
still RB N
using VBG N
smokeless JJ N
tobacco NN N
after IN N
6 CD N
months NNS N
. . N

This DT N
trial NN N
demonstrated VBD N
short-term JJ o
efficacy NN o
of IN o
smokeless JJ o
tobacco NN o
in IN N
combination NN N
with IN N
group NN N
support NN N
for IN N
smoking VBG N
cessation NN N
but CC N
no DT N
long-term JJ o
efficacy NN o
. . o

-DOCSTART- -11965204- O O

Diet NNP i
and CC N
tobacco NN N
use NN N
: : N
analysis NN N
of IN N
data NNS N
from IN N
the DT N
diabetic JJ N
control NN N
and CC N
complications NNS N
trial NN N
, , N
a DT N
randomized VBN N
study NN N
. . N

CONTEXT NNP N
The DT N
Diabetic NNP N
Control NNP N
and CC N
Complications NNP N
Trial NNP N
( ( N
DCCT NNP N
) ) N
researchers NNS N
kept VBD N
careful JJ N
records NNS N
of IN N
the DT N
food NN N
consumption NN N
and CC N
tobacco NN N
using VBG N
habits NNS N
of IN p
type NN p
1 CD p
diabetic JJ p
subjects NNS p
. . p

However RB N
, , N
they PRP N
did VBD N
not RB N
report VB N
the DT N
relationship NN N
of IN N
tobacco NN o
using VBG o
habits NNS o
with IN N
dietary JJ o
intake NN o
. . o

OBJECTIVE NNP N
Analyze NNP N
the DT N
relationship NN o
between IN o
tobacco NN o
smoking NN o
and CC o
intake NN o
of IN o
macro NN o
and CC o
micronutrients NNS o
. . o

DESIGN NNP N
Randomized NNP N
controlled VBD N
trial NN N
. . N

SETTING NNP N
Referral JJ p
clinics NNS p
in IN p
27 CD p
academic JJ p
centers NNS p
. . p

PATIENTS NNP p
Type NNP p
1 CD p
diabetics NNS p
. . p

INTERVENTION NNP N
Using VBG N
the DT N
data NNS i
sets NNS i
of IN i
the DT i
DCCT NNP i
, , N
this DT N
study NN N
analyzed VBD N
the DT N
strengths NNS N
of IN N
the DT N
associations NNS o
between IN o
smoking NN o
and CC o
macronutrient NN o
consumption NN o
, , o
hemoglobin NN o
A1c NNP o
( ( o
HbA1c NNP o
) ) o
, , o
body JJ o
mass NN o
index NN o
( ( o
BMI NNP o
) ) o
, , o
and CC o
serum VB o
lipid JJ o
levels NNS o
at IN N
the DT N
study NN N
baseline NN N
, , N
2 CD N
years NNS N
, , N
and CC N
4 CD N
years NNS N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Statistically NNP o
significant JJ o
correlations NNS o
between IN o
smoking NN o
and CC o
nutrient JJ o
intake NN o
, , o
HbA1c NNP o
, , o
and CC o
serum VB o
lipid JJ o
levels NNS o
. . o

RESULTS NNP N
Cigarette NNP o
, , o
cigar NN o
, , o
or CC o
pipe NN o
use NN o
at IN N
each DT N
time NN N
interval NN N
correlated VBD N
with IN N
significantly RB N
increased VBN N
caloric JJ o
intake NN o
in IN N
males NNS N
but CC N
not RB N
in IN N
females NNS N
. . N

In IN N
both DT N
males NNS p
and CC p
females NNS p
, , p
tobacco NN o
users NNS o
consumed VBD o
more RBR o
fat JJ o
, , o
cholesterol NN o
, , o
and CC o
alcohol NN o
. . o

Female JJ p
smokers NNS p
had VBD N
higher JJR N
serum JJ o
low-density NN o
lipoprotein NN o
( ( o
LDL NNP o
) ) o
/high-density NN o
lipoprotein NN o
( ( o
HDL NNP o
) ) o
ratios NNS o
and CC o
triglycerides NNS o
. . o

Serum NNP o
cholesterols NNS o
, , o
LDL/HDL NNP o
ratios NNS o
, , o
LDL NNP o
cholesterols VBZ o
, , o
and CC o
triglyceride JJ o
determinations NNS o
in IN N
male JJ p
tobacco NN p
users NNS p
significantly RB N
exceeded VBD N
those DT N
in IN N
nonsmoking JJ N
males NNS N
. . N

HDL NNP o
cholesterols NNS o
were VBD N
lower JJR N
in IN N
both DT N
female JJ p
and CC p
male JJ p
tobacco NN p
users NNS p
. . p

Nutrient NNP o
intake NN o
of IN N
former JJ p
tobacco NN p
users NNS p
resembled VBD N
that IN N
of IN N
nonusers NNS N
rather RB N
than IN N
current JJ N
users NNS N
. . N

CONCLUSIONS VB N
A NNP N
significant JJ N
association NN N
exists NNS N
between IN N
smoking NN N
and CC N
a DT N
diet JJ o
with IN o
higher JJR o
risks NNS o
of IN o
atherosclerosis NN o
, , o
cancer NN o
, , o
and CC o
other JJ o
degenerative JJ o
diseases NNS o
. . o

The DT N
strong JJ N
association NN N
of IN N
tobacco NN N
with IN N
heart NN N
disease NN N
, , N
stroke NN N
, , N
vasculopathies NNS N
, , N
and CC N
various JJ N
malignancies NNS N
may MD N
be VB N
in IN N
part NN N
due JJ N
to TO N
its PRP$ N
association NN N
with IN N
a DT N
higher JJR N
fat JJ o
diet NN N
. . N

The DT N
higher JJR N
fat JJ N
diet NNS N
of IN N
tobacco NN N
users NNS N
probably RB N
accounts NNS N
in IN N
part NN N
for IN N
their PRP$ N
higher JJR N
risk NN N
of IN N
developing VBG N
type JJ N
2 CD N
diabetes NNS N
and CC N
hyperlipidemia NN N
. . N

Tobacco NN N
users NNS N
should MD N
be VB N
informed VBN N
about IN N
the DT N
diet JJ o
and CC o
tobacco NN o
use NN o
association NN N
. . N

-DOCSTART- -11363044- O O

Peptide NNP o
T NNP o
: : o
negative JJ o
trial NN o
result NN o
. . o

-DOCSTART- -16437191- O O

Does VBZ N
an DT N
educational JJ i
leaflet NN i
improve VB N
self-reported JJ N
adherence NN o
to TO N
therapy VB N
in IN N
osteoporosis NN p
? . N
The DT N
OPTIMA NNP N
study NN N
. . N

INTRODUCTION NNP N
Adherence NNP o
to TO N
treatment NN N
in IN N
osteoporosis NN N
remains VBZ N
poor JJ N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
effects NNS N
of IN N
an DT N
educational JJ i
leaflet NN i
on IN N
adherence NN o
to TO N
medication NN N
and CC N
to TO N
assess VB N
the DT N
association NN N
between IN N
adherence NN o
and CC N
health-related JJ o
quality NN o
of IN o
life NN o
( ( o
HRQOL NNP o
) ) o
. . N

METHODS CC N
A NNP N
naturalistic JJ N
, , N
observational JJ N
, , N
multi-center JJ p
, , N
prospective JJ N
study NN N
of IN N
12 CD N
months NNS N
' POS N
follow-up NN N
was VBD N
performed VBN N
. . N

Consecutive JJ p
post-menopausal JJ p
women NNS p
aged VBN p
50 CD p
years NNS p
to TO p
86 CD p
years NNS p
starting VBG p
treatment NN p
with IN p
raloxifene NN i
according VBG p
to TO p
daily JJ p
practice NN p
were VBD p
enrolled VBN p
from IN p
126 CD p
primary JJ p
care NN p
offices NNS p
in IN p
Spain NNP p
. . p

The DT N
women NNS p
were VBD N
assigned VBN N
to TO N
two CD N
study NN N
groups NNS N
. . N

Group NNP N
A NNP N
received VBD N
an DT N
educational JJ i
leaflet NN i
with IN i
general JJ i
information NN i
about IN i
osteoporosis NN i
; : i
group NN N
B NNP N
followed VBD N
current JJ i
practice NN i
. . i

To TO N
assess VB N
adherence NN o
to TO o
medication NN o
and CC o
HRQOL NNP o
, , o
the DT o
Morisky NNP o
test NN o
and CC o
the DT o
EuroQoL NNP o
questionnaire NN o
were VBD N
administered VBN N
. . N

A DT p
total NN p
of IN p
745 CD p
post-menopausal JJ p
women NNS p
( ( p
group NN p
A NNP p
, , p
n=366 RB p
; : p
group NN p
B NNP p
n=379 NN p
) ) p
, , p
with IN p
a DT p
mean JJ p
age NN p
of IN p
62 CD p
years NNS p
, , N
were VBD N
included VBN N
. . N

RESULTS NNP N
Most JJS N
patients NNS N
in IN N
both DT N
study NN N
groups NNS N
showed VBD N
high JJ N
adherence NN o
to TO N
raloxifene VB i
at IN N
the DT N
3-month JJ N
visit NN N
: : N
56.3 CD N
% NN N
vs JJ N
62.7 CD N
% NN N
for IN N
groups NNS N
A NNP N
and CC N
B NNP N
, , N
respectively RB N
; : N
this DT N
proportion NN N
at IN N
the DT N
12-month JJ N
visit NN N
was VBD N
47.4 CD N
% NN N
( ( N
P=0.15 NNP N
) ) N
and CC N
52.5 CD N
% NN N
( ( N
P=0.02 NNP N
) ) N
, , N
respectively RB N
. . N

At IN N
baseline NN N
, , N
pain/discomfort NN o
was VBD N
the DT N
dimension NN N
showing VBG N
the DT N
highest JJS N
percentage NN N
of IN N
women NNS N
reporting VBG N
problems NNS N
: : N
86.4 CD N
% NN N
vs JJ N
83.2 CD N
% NN N
in IN N
groups NNS N
A NNP N
and CC N
B NNP N
, , N
respectively RB N
( ( N
P=0.22 NNP N
) ) N
. . N

HRQOL NNP o
improved VBN N
in IN N
both DT N
groups NNS N
throughout IN N
the DT N
study NN N
, , N
with IN N
an DT N
overall JJ N
mean JJ N
increment NN N
in IN N
the DT N
EuroQoL NNP o
visual JJ o
analog NN o
scale NN o
( ( o
EQ NNP o
VAS NNP o
) ) o
of IN N
9.2 CD N
at IN N
12 CD N
months NNS N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

Correlations NNS N
between IN N
adherence NN o
and CC o
HRQOL NNP o
were VBD N
weak JJ N
. . N

After IN N
receiving VBG N
an DT N
educational JJ i
leaflet NN i
, , N
young JJ p
post-menopausal JJ p
women NNS p
suffering VBG p
osteoporosis NN p
did VBD N
not RB N
show VB N
improvement NN N
in IN N
adherence NN o
to TO o
therapy VB o
. . o

HRQOL NNP o
improved VBD N
at IN N
12-month JJ N
follow-up JJ N
under IN N
treatment NN N
. . N

CONCLUSION NNP N
No NNP N
consistent JJ N
correlation NN N
between IN N
adherence NN o
and CC o
HRQOL NNP o
was VBD N
found VBN N
. . N

-DOCSTART- -15233698- O O

Six-month JJ N
trial NN N
of IN N
on-demand JJ N
rabeprazole NN i
10 CD N
mg NN N
maintains NNS N
symptom JJ o
relief NN o
in IN N
patients NNS p
with IN p
non-erosive JJ p
reflux NN o
disease NN o
. . o

BACKGROUND NNP N
Compliance NNP N
studies NNS N
have VBP N
shown VBN N
that IN N
patients NNS p
with IN p
reflux NN p
symptoms NNS p
generally RB N
take VBP N
their PRP$ N
medication NN N
only RB N
when WRB N
experiencing VBG N
these DT N
symptoms NNS N
. . N

AIM NNP N
To TO N
evaluate VB N
the DT N
efficacy NN o
of IN N
on-demand JJ N
rabeprazole JJ i
maintenance NN N
therapy NN N
in IN N
patients NNS p
with IN p
non-erosive JJ p
reflux NN p
disease NN p
. . p

METHODS NNP N
This DT N
multicentre NN p
, , N
randomized VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
, , N
withdrawal NN N
study NN N
compared VBN N
6 CD N
months NNS N
of IN N
on-demand JJ N
treatment NN N
with IN N
rabeprazole JJ i
10 CD N
mg NN N
vs. FW N
placebo NN i
. . i

Adults NNS p
with IN p
a DT p
history NN p
of IN p
reflux NN p
symptoms NNS p
, , p
a DT p
negative JJ p
endoscopy NN p
, , p
and CC p
> NNP p
or CC p
= VB p
3 CD p
days NNS p
of IN p
moderate JJ p
to TO p
very RB p
severe JJ p
heartburn NN p
in IN p
the DT p
7 CD p
days NNS p
before IN p
enrollment NN p
( ( p
N NNP p
= NNP p
535 CD p
) ) p
entered VBD N
4 CD N
weeks NNS N
of IN N
open-label NN N
, , N
acute JJ N
treatment NN N
with IN N
rabeprazole JJ i
10 CD N
mg NN N
once RB N
daily JJ N
. . N

Patients NNS p
with IN p
complete JJ p
symptom NN o
relief NN o
then RB p
entered VBD p
the DT p
on-demand JJ p
phase NN p
. . p

The DT N
primary JJ N
end-point NN N
was VBD N
discontinuation NN o
due JJ o
to TO o
lack VB o
of IN o
heartburn NN o
control NN o
during IN o
the DT o
on-demand JJ o
phase NN o
. . o

RESULTS NNP N
Eighty-three JJ N
percent NN N
( ( N
432 CD N
of IN N
523 CD N
) ) N
of IN N
patients NNS N
reported VBD N
complete JJ N
symptom NN o
relief NN o
at IN N
the DT N
end NN N
of IN N
the DT N
acute JJ N
phase NN N
. . N

During IN N
on-demand JJ N
treatment NN N
, , N
rates NNS o
of IN o
discontinuation NN o
because IN o
of IN o
inadequate JJ o
heartburn NN o
control NN o
were VBD N
20 CD N
% NN N
( ( N
28 CD N
of IN N
139 CD N
) ) N
for IN N
placebo NN i
vs. FW N
6 CD N
% NN N
( ( N
16 CD N
of IN N
279 CD N
) ) N
for IN N
rabeprazole NN i
( ( N
P NNP N
< NNP N
0.00001 CD N
) ) N
. . N

Antacid NNP o
use NN o
was VBD N
twofold JJ N
higher JJR N
in IN N
the DT N
placebo NN i
group NN N
vs. FW N
the DT N
rabeprazole NN i
group NN N
( ( N
P NNP N
= NNP N
0.0009 CD N
) ) N
. . N

CONCLUSIONS NNP N
Rabeprazole NNP i
10 CD N
mg NN N
once RB N
daily JJ N
is VBZ N
highly RB N
effective JJ o
in IN N
acute JJ o
symptom NN o
relief NN o
and CC N
as IN N
on-demand JJ N
long-term JJ N
maintenance NN N
therapy NN N
in IN N
non-erosive JJ p
reflux NN p
disease NN p
patients NNS p
. . p

-DOCSTART- -6206796- O O

[ JJ N
Local NNP N
application NN N
of IN N
anti-cancer JJ i
drugs NNS i
for IN N
the DT N
treatment NN N
of IN N
malignant JJ p
pleural JJ p
and CC p
pericardial JJ p
effusion NN p
] NNP p
. . N

Pleural NNP N
effusion NN N
is VBZ N
a DT N
common JJ N
complication NN N
in IN N
patients NNS p
with IN p
malignant JJ p
neoplasm NN p
. . p

A DT N
randomized VBN N
controlled VBN N
study NN N
of IN N
intrapleural JJ N
instillation NN N
of IN N
Adriamycin NNP i
( ( p
control NN p
group NN p
, , p
30 CD p
patients NNS p
) ) p
and CC N
Adriamycin NNP i
Nocardia NNP i
rubra NN i
cell NN i
wall NN i
skeleton NN i
( ( p
N-CWS NNP p
group NN p
, , p
26 CD p
patients NNS p
) ) p
with IN N
tube NN i
thoracostomy NN i
was VBD N
performed VBN N
in IN p
55 CD p
patients NNS p
with IN p
malignant JJ p
pleural JJ p
effusion NN p
due JJ p
to TO p
primary JJ p
lung NN p
cancer NN p
. . p

The DT N
response NN N
rates NNS N
for IN N
control NN o
of IN o
pleural JJ o
effusion NN o
were VBD N
73.4 CD N
% NN N
in IN N
the DT N
N-CWS NNP i
group NN i
and CC N
46.1 CD N
% NN N
in IN N
the DT N
N-CWS NNP i
group NN i
. . i

These DT N
results NNS N
suggest VBP N
that IN N
intrapleural JJ N
instillation NN N
using VBG N
a DT N
combination NN N
of IN N
anti-cancer JJ i
agent NN i
and CC i
immunopotentiator NN i
is VBZ N
an DT N
effective JJ N
treatment NN N
for IN N
malignant JJ N
pleurisy NN N
. . N

Cardiac NNP N
tamponade VBD N
secondary JJ N
to TO N
cancer NN N
is VBZ N
a DT N
life-threatening JJ N
complication NN N
requiring VBG N
immediate JJ N
treatment NN N
. . N

Twenty-four JJ p
patients NNS p
with IN p
malignant JJ p
pericardial JJ p
effusion NN p
were VBD N
treated VBN N
by IN N
intrapericardial JJ N
instillation NN N
of IN N
anti-cancer JJ i
drugs NNS i
, , N
such JJ N
as IN N
Carbazilquinone NNP i
, , i
Mitomycin-C NNP i
or CC N
ACNU NNP i
, , N
with IN N
pericardial JJ i
drainage NN i
. . i

The DT N
range NN o
of IN o
survival JJ o
time NN o
from IN N
the DT N
instillation NN N
of IN N
anti-cancer JJ i
drug NN i
was VBD N
3-365 JJ N
days NNS N
( ( N
average JJ N
days NNS N
) ) N
. . N

In IN N
only RB N
4 CD N
patients NNS N
, , N
reaccumulation NN o
of IN o
pericardial JJ o
effusion NN o
was VBD N
recognized VBN N
. . N

There EX N
were VBD N
no DT N
serious JJ N
complications NNS N
with IN N
this DT N
procedure NN N
. . N

It PRP N
was VBD N
considered VBN N
that IN N
local JJ N
instillation NN N
of IN N
anti-cancer JJ i
agents NNS i
with IN N
pericardial JJ i
drainage NN i
was VBD N
a DT N
useful JJ N
therapeutic JJ N
modality NN N
for IN N
malignant JJ N
pericarditis NN N
. . N

-DOCSTART- -12183788- O O

[ JJ p
Local NNP p
treatment NN p
of IN p
periarthropathies NNS p
with IN N
the DT N
5-HT3-receptor-antagonist JJ i
tropisetron NN i
] NN i
. . N

All DT N
substances NNS N
used VBN N
in IN N
the DT N
local JJ p
treatment NN p
for IN p
periarthropathies NNS p
, , N
such JJ N
as IN N
local JJ i
anesthetics NNS i
, , i
corticosteroids NNS i
or CC i
botulinum NN i
toxin NN i
A NNP i
, , N
possess NN N
certain JJ N
disadvantages NNS N
. . N

Finding VBG N
alternatives NNS N
to TO N
these DT N
agents NNS N
in IN N
the DT N
local JJ N
treatment NN N
of IN N
the DT N
disease NN N
therefore RB N
seems VBZ N
desirable JJ N
. . N

Comparative JJ N
studies NNS N
proved VBD N
a DT N
local JJ o
injection NN o
of IN o
the DT o
5-HT3 JJ o
receptor NN o
antagonist NN o
, , o
tropisetron NN o
( ( o
Navoban NNP o
( ( o
R NNP o
) ) o
) ) o
, , N
to TO N
be VB N
more RBR N
effective JJ o
than IN N
an DT N
injection NN N
of IN N
the DT N
local JJ i
anesthetic JJ i
prilocaine NN i
in IN N
treating VBG N
periarthropathies NNS p
of IN p
different JJ p
localizations NNS p
. . p

A DT N
comparison NN N
between IN N
the DT N
local JJ N
injection NN N
of IN N
10 CD N
mg NN N
of IN N
depot NN i
dexamethasone NN i
combined VBN N
with IN N
60 CD N
mg NNS N
of IN N
lidocaine NN i
and CC N
5 CD N
mg NN N
of IN N
tropisetron NN i
showed VBD N
that IN N
the DT N
two CD N
regimens NNS N
had VBD N
the DT N
same JJ N
effect NN N
. . N

These DT N
findings NNS N
demonstrate VBP N
that IN N
a DT N
local JJ o
injection NN o
of IN o
5 CD o
mg NNS o
tropisetron NN o
does VBZ N
represent VB N
an DT N
alternative NN N
to TO N
the DT N
local JJ N
treatment NN N
with IN N
corticosteriods NNS i
plus CC i
local JJ i
anesthetics NNS i
. . i

However RB N
, , N
these DT N
results NNS N
should MD N
be VB N
corroborated VBN N
by IN N
additional JJ N
studies NNS N
. . N

-DOCSTART- -23524942- O O

Clinical JJ N
benefits NNS N
of IN N
concurrent JJ N
capecitabine NN i
and CC i
cisplatin NN i
versus NN N
concurrent NN i
cisplatin NN i
and CC i
5-flurouracil JJ i
in IN N
locally RB p
advanced JJ p
squamous JJ p
cell NN p
head NN p
and CC p
neck NN p
cancer NN p
. . p

We PRP N
aimed VBD N
to TO N
assess VB N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
concurrent JJ N
capecitabine NN i
and CC i
cisplatin NN i
over IN N
concurrent JJ i
cisplatin NN i
and CC i
5-flurouracil JJ i
( ( i
5-FU JJ i
) ) i
in IN N
locally RB p
advanced JJ p
squamous JJ p
cell NN p
carcinoma NN p
of IN p
the DT p
head NN p
and CC p
neck NN p
. . p

One CD p
hundred CD p
and CC p
fifty-three JJ p
patients NNS p
( ( p
all DT p
of IN p
whom WP p
had VBD p
stage NN p
III NNP p
or CC p
IV NNP p
unresectable JJ p
disease NN p
with IN p
no DT p
distant JJ p
metastases NNS p
and CC p
who WP p
had VBD p
received VBN p
two CD p
cycles NNS p
of IN p
taxol NN i
and CC i
cisplatin NN i
chemotherapy NN i
) ) i
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
either DT N
concurrent NN i
cisplatin NN i
( ( N
75 CD N
mg/m NN N
( ( N
2 CD N
) ) N
in IN N
day NN N
1 CD N
and CC N
2 CD N
) ) N
and CC i
5-FU JJ i
( ( N
750 CD N
mg/m NN N
( ( N
2 CD N
) ) N
in IN N
day NN N
1 CD N
, , N
2 CD N
, , N
and CC N
3 CD N
) ) N
from IN N
the DT N
first JJ N
day NN N
of IN N
radiotherapy NN N
at IN N
an DT N
interval NN N
of IN N
3 CD N
weeks NNS N
( ( N
Arm NNP N
I PRP N
) ) N
or CC N
cisplatin NN i
( ( N
75 CD N
mg/m NN N
( ( N
2 CD N
) ) N
in IN N
day NN N
1 CD N
and CC N
2 CD N
) ) N
and CC N
capecitabine NN i
( ( N
750 CD N
mg/m NN N
( ( N
2 CD N
) ) N
in IN N
two CD N
divided JJ N
doses NNS N
from IN N
day NN N
1-14 CD N
) ) N
from IN N
the DT N
first JJ N
day NN N
of IN N
radiotherapy NN N
at IN N
a DT N
3-week JJ N
interval NN N
( ( N
Arm NNP N
II NNP N
) ) N
. . N

Results CC N
showed VBD N
that IN N
patients NNS N
in IN N
Arm NNP N
II NNP N
had VBD N
a DT N
significantly RB N
better RBR o
rate NN o
of IN o
complete JJ o
response NN o
, , o
fewer JJR o
nodes NNS o
, , o
and CC o
better JJR o
overall JJ o
response NN o
compared VBN N
to TO N
those DT N
in IN N
Arm NNP N
I PRP N
. . N

The DT N
two CD N
groups NNS N
had VBD N
a DT N
similar JJ N
3-year JJ o
disease-free JJ o
survival NN o
, , o
progression NN o
free JJ o
survival NN o
, , o
and CC o
overall JJ o
survival NN o
, , N
i.e NN N
. . N

they PRP N
did VBD N
not RB N
differ VB N
significantly RB N
. . N

Variables NNS N
indicating VBG N
the DT N
quality NN o
of IN o
life NN o
of IN N
the DT N
two CD N
groups NNS N
were VBD N
compared VBN N
. . N

Patients NNS N
in IN N
Arm NNP N
II NNP N
had VBD N
a DT N
significantly RB N
higher JJR N
quality NN o
of IN o
life NN o
compared VBN N
to TO N
those DT N
in IN N
Arm NNP N
I PRP N
. . N

The DT N
two CD N
groups NNS N
had VBD N
similar JJ N
treatment-related JJ N
acute NN o
and CC o
late JJ o
toxicity NN o
, , N
i.e NN N
. . N

they PRP N
did VBD N
not RB N
differ VB N
significantly RB N
. . N

These DT N
results NNS N
have VBP N
thoroughly RB N
substantiated VBN N
the DT N
contention NN N
that WDT N
concurrent JJ N
chemoradiation NN N
with IN N
capecitabine NN i
and CC i
cisplatin NN i
may MD N
be VB N
regarded VBN N
as IN N
an DT N
effective JJ N
and CC N
well-tolerated JJ N
regimen NNS N
in IN N
the DT N
treatment NN N
of IN N
the DT N
patients NNS p
with IN p
locally RB p
advanced VBN p
head NN p
and CC p
neck NN p
cancer NN p
. . p

-DOCSTART- -19948568- O O

Randomized VBN N
, , N
controlled VBD N
trial NN N
of IN N
an DT N
intervention NN i
for IN N
toddlers NNS p
with IN p
autism NN p
: : p
the DT N
Early JJ N
Start NNP N
Denver NNP N
Model NNP N
. . N

OBJECTIVE NNP N
To TO N
conduct VB N
a DT N
randomized NN N
, , N
controlled VBD N
trial NN N
to TO N
evaluate VB N
the DT N
efficacy NN o
of IN N
the DT N
Early JJ i
Start NNP i
Denver NNP i
Model NNP i
( ( i
ESDM NNP i
) ) i
, , N
a DT N
comprehensive JJ N
developmental JJ N
behavioral JJ N
intervention NN N
, , N
for IN N
improving VBG N
outcomes NNS N
of IN N
toddlers NNS p
diagnosed VBN p
with IN p
autism NN p
spectrum NN p
disorder NN p
( ( p
ASD NNP p
) ) p
. . p

METHODS NNP N
Forty-eight JJ p
children NNS p
diagnosed VBN p
with IN p
ASD NNP p
between IN p
18 CD p
and CC p
30 CD p
months NNS p
of IN p
age NN p
were VBD N
randomly RB N
assigned VBN N
to TO N
1 CD N
of IN N
2 CD N
groups NNS N
: : N
( ( N
1 CD N
) ) N
ESDM NNP i
intervention NN i
, , N
which WDT N
is VBZ N
based VBN N
on IN N
developmental JJ N
and CC N
applied JJ N
behavioral JJ N
analytic JJ N
principles NNS N
and CC N
delivered VBN N
by IN N
trained JJ N
therapists NNS N
and CC N
parents NNS N
for IN N
2 CD N
years NNS N
; : N
or CC N
( ( N
2 CD N
) ) N
referral NN i
to TO i
community NN i
providers NNS i
for IN i
intervention NN i
commonly RB i
available JJ i
in IN i
the DT i
community NN i
. . i

RESULTS NNP N
Compared VBD N
with IN N
children NNS N
who WP N
received VBD N
community-intervention NN N
, , N
children NNS N
who WP N
received VBD N
ESDM NNP N
showed VBD N
significant JJ N
improvements NNS N
in IN N
IQ NNP o
, , o
adaptive JJ o
behavior NN o
, , o
and CC o
autism NN o
diagnosis NN o
. . o

Two CD N
years NNS N
after IN N
entering VBG N
intervention NN N
, , N
the DT N
ESDM NNP N
group NN N
on IN N
average NN N
improved VBD N
17.6 CD N
standard NN N
score NN N
points NNS N
( ( N
1 CD N
SD NNP N
: : N
15 CD N
points NNS N
) ) N
compared VBN N
with IN N
7.0 CD N
points NNS N
in IN N
the DT N
comparison NN N
group NN N
relative VBP N
to TO N
baseline VB N
scores NNS N
. . N

The DT N
ESDM NNP N
group NN N
maintained VBD N
its PRP$ N
rate NN o
of IN o
growth NN o
in IN o
adaptive JJ o
behavior NN o
compared VBN N
with IN N
a DT N
normative JJ N
sample NN N
of IN N
typically RB N
developing VBG N
children NNS N
. . N

In IN N
contrast NN N
, , N
over IN N
the DT N
2-year JJ N
span NN N
, , N
the DT N
comparison NN N
group NN N
showed VBD N
greater JJR N
delays NNS N
in IN N
adaptive JJ o
behavior NN o
. . o

Children NNP N
who WP N
received VBD N
ESDM NNP i
also RB N
were VBD N
more RBR N
likely JJ N
to TO N
experience VB N
a DT N
change NN o
in IN o
diagnosis NN o
from IN N
autism NN N
to TO N
pervasive VB N
developmental JJ N
disorder NN N
, , N
not RB N
otherwise RB N
specified VBN N
, , N
than IN N
the DT N
comparison NN N
group NN N
. . N

CONCLUSIONS NNP N
This DT N
is VBZ N
the DT N
first JJ N
randomized VBN N
, , N
controlled VBN N
trial NN N
to TO N
demonstrate VB N
the DT N
efficacy NN N
of IN N
a DT N
comprehensive JJ N
developmental JJ N
behavioral JJ N
intervention NN N
for IN N
toddlers NNS p
with IN p
ASD NNP p
for IN N
improving VBG N
cognitive JJ o
and CC o
adaptive JJ o
behavior NN o
and CC N
reducing VBG N
severity NN o
of IN o
ASD NNP o
diagnosis NN o
. . o

Results NNS N
of IN N
this DT N
study NN N
underscore VBD N
the DT N
importance NN N
of IN N
early JJ N
detection NN N
of IN N
and CC N
intervention NN N
in IN N
autism NN N
. . N

-DOCSTART- -21334545- O O

Augmented VBN i
soft JJ i
tissue NN i
mobilization NN i
vs IN N
natural JJ i
history NN i
in IN N
the DT N
treatment NN N
of IN N
lateral JJ N
epicondylitis NN N
: : N
a DT N
pilot NN N
study NN N
. . N

OBJECTIVE CC N
The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
effect NN N
of IN N
augmented JJ i
soft JJ i
tissue NN i
mobilization NN i
( ( N
ASTM NNP N
) ) N
on IN N
the DT N
treatment NN N
of IN N
lateral JJ N
epicondylitis NN N
. . N

METHODS NNP N
This DT N
randomized VBD N
clinical JJ N
study NN N
assessed VBD N
27 CD p
subjects NNS p
( ( p
12 CD p
men NNS p
and CC p
15 CD p
women NNS p
) ) p
with IN p
lateral JJ p
epicondylitis NN p
and CC N
were VBD N
divided VBN N
randomly RB N
into IN N
2 CD p
groups NNS p
. . p

The DT i
experimental JJ i
group NN i
( ( i
n JJ i
= NNP i
15 CD i
) ) i
received VBD i
ASTM NNP i
twice RB i
a DT i
week NN i
for IN i
5 CD i
weeks NNS i
. . i

The DT i
subjects NNS i
of IN i
the DT i
control NN i
group NN i
( ( i
n JJ i
= NNP i
12 CD i
) ) i
received VBN i
advice NN i
on IN i
the DT i
natural JJ i
evolution NN i
of IN i
lateral JJ i
epicondylitis NN i
, , i
computer NN i
ergonomics NNS i
, , i
and CC i
stretching VBG i
exercises NNS i
. . i

Patient-rated JJ i
outcome NN i
was VBD i
assessed VBN i
at IN i
baseline NN i
and CC i
after IN i
6 CD i
weeks NNS i
and CC i
3 CD i
months NNS i
using VBG i
a DT i
visual JJ i
analog NN i
scale NN i
and CC i
the DT i
Patient-Rated JJ i
Tennis NNP i
Elbow NNP i
Evaluation NNP i
. . i

The DT N
function NN N
was VBD N
assessed VBN N
using VBG N
the DT N
pain-free JJ o
grip NN o
strength NN o
at IN N
baseline NN N
and CC N
after IN N
6 CD N
weeks NNS N
. . N

RESULTS NNP N
Both NNP N
groups NNS N
showed VBD N
improvements NNS o
in IN o
pain-free JJ o
grip NN o
strength NN o
, , o
visual JJ o
analog NN o
scale NN o
, , o
and CC o
Patient-Rated JJ o
Tennis NNP o
Elbow NNP o
Evaluation NNP o
. . o

Sample NNP N
size NN N
for IN N
larger JJR N
future NN N
randomized VBD N
clinical JJ N
trial NN N
was VBD N
116 CD N
participants NNS N
. . N

CONCLUSION VB N
A NNP N
larger JJR N
study NN N
investigating VBG N
the DT N
same JJ N
hypothesis NN N
is VBZ N
warranted VBN N
to TO N
detect VB N
difference NN N
in IN N
the DT N
effects NNS N
of IN N
these DT N
treatments NNS N
strategies NNS N
. . N

The DT N
study NN N
design NN N
is VBZ N
feasible JJ N
, , N
and CC N
minor JJ N
improvements NNS N
will MD N
help VB N
to TO N
minimize VB N
the DT N
potential JJ N
bias NN N
. . N

-DOCSTART- -23414585- O O

Ganitumab NNP i
with IN N
either DT N
exemestane NN i
or CC N
fulvestrant NN i
for IN N
postmenopausal JJ p
women NNS p
with IN p
advanced JJ p
, , p
hormone-receptor-positive JJ p
breast NN p
cancer NN p
: : p
a DT N
randomised JJ N
, , N
controlled VBN N
, , N
double-blind NN N
, , N
phase NN N
2 CD N
trial NN N
. . N

BACKGROUND NNP N
Insulin-like JJ N
growth NN N
factors NNS N
( ( N
IGF-1 JJ N
and CC N
IGF-2 NNP N
) ) N
bind NN N
to TO N
the DT N
IGF-1 NNP N
receptor NN N
( ( N
IGF-1R NNP N
) ) N
, , N
increasing VBG N
cell NN o
proliferation NN o
and CC N
survival NN o
. . o

Ganitumab NNP i
is VBZ N
a DT N
monoclonal JJ N
IgG1 NNP N
antibody NN N
that WDT N
blocks VBZ N
IGF-1R NNP N
. . N

We PRP N
tested VBD N
the DT N
efficacy NN o
and CC N
safety NN o
of IN N
adding VBG N
ganitumab NN N
to TO N
endocrine VB N
treatment NN N
for IN N
patients NNS p
with IN p
hormone-receptor-positive JJ p
breast NN p
cancer NN p
. . p

METHODS NNP N
We PRP N
did VBD N
this DT N
phase NN N
2 CD N
trial NN N
in IN N
outpatient JJ p
clinics NNS p
and CC p
hospitals NNS p
. . p

We PRP p
enrolled VBD p
postmenopausal JJ p
women NNS p
with IN p
hormone-receptor-positive JJ p
, , p
locally RB p
advanced VBD p
or CC p
metastatic JJ p
breast NN p
cancer NN p
previously RB p
treated VBN p
with IN p
endocrine JJ p
treatment NN p
. . p

They PRP N
were VBD N
randomly RB N
assigned VBN N
( ( N
2:1 CD N
) ) N
with IN N
a DT N
central JJ N
randomisation NN N
schedule NN N
to TO N
receive VB N
intravenous JJ i
ganitumab NNS i
12 CD i
mg NNS i
per IN i
kg NN i
bodyweight NN i
or CC i
placebo NN i
in IN i
combination NN i
with IN i
open-label JJ i
intramuscular JJ i
fulvestrant NN i
( ( i
500 CD i
mg NN i
on IN i
day NN i
1 CD i
, , i
then RB i
250 CD i
mg NNS i
on IN i
days NNS i
15 CD i
, , i
29 CD i
, , i
and CC i
every DT i
28 CD i
days NNS i
) ) i
or CC i
oral JJ i
exemestane NN i
( ( i
25 CD i
mg NN i
once RB i
daily RB i
) ) i
on IN i
a DT i
28-day JJ i
cycle NN i
. . i

Patients NNS N
, , N
investigators NNS N
, , N
study NN N
monitors NNS N
, , N
and CC N
the DT N
sponsor JJ N
staff NN N
were VBD N
masked VBN N
to TO N
treatment NN N
allocation NN N
. . N

Response NNP i
was VBD i
assessed VBN i
every DT i
8 CD i
weeks NNS i
. . i

The DT N
primary JJ N
endpoint NN N
was VBD N
median JJ o
progression-free JJ o
survival NN o
in IN N
the DT N
intention-to-treat JJ N
population NN N
. . N

We PRP N
analysed VBD N
overall JJ o
survival NN o
as IN N
one CD N
of IN N
our PRP$ N
secondary JJ N
endpoints NNS N
. . N

The DT N
study NN N
is VBZ N
registered VBN N
at IN N
ClinicalTrials.gov NNP N
, , N
number NN N
NCT00626106 NNP N
. . N

FINDINGS NNP N
We PRP p
screened VBD p
189 CD p
patients NNS p
and CC p
enrolled VBD p
156 CD p
( ( p
106 CD p
in IN p
the DT p
ganitumab NN i
group NN p
and CC p
50 CD p
in IN p
the DT p
placebo NN p
group NN p
) ) p
. . p

Median JJ o
progression-free JJ o
survival NN o
did VBD N
not RB N
differ VB N
significantly RB N
between IN N
the DT N
ganitumab NN i
and CC N
placebo NN N
groups NNS N
( ( N
3?9 CD N
months NNS N
, , N
80 CD N
% NN N
CI NNP N
3?6-5?3 CD N
vs NN N
5?7 CD N
months NNS N
, , N
4?4-7?4 JJ N
; : N
hazard PRP$ N
ratio NN N
[ NNP N
HR NNP N
] NNP N
1?17 CD N
, , N
80 CD N
% NN N
CI NNP N
0?91-1?50 CD N
; : N
p=0?44 NN N
) ) N
. . N

However RB N
, , N
overall JJ o
survival NN o
was VBD N
worse RBR N
in IN N
the DT N
the DT N
ganitumab NN i
group NN N
than IN N
in IN N
the DT N
placebo NN N
group NN N
( ( N
HR NNP N
1?78 CD N
, , N
80 CD N
% NN N
CI NNP N
1?27-2?50 CD N
; : N
p=0?025 NN N
) ) N
. . N

With IN N
the DT N
exception NN N
of IN N
hyperglycaemia NN N
, , N
adverse JJ N
events NNS N
were VBD N
generally RB N
similar JJ N
between IN N
groups NNS N
. . N

The DT N
most RBS N
common JJ N
grade NN N
3 CD N
or CC N
higher JJR o
adverse JJ o
event NN o
was VBD o
neutropenia-reported JJ o
by IN N
six CD N
of IN N
106 CD N
( ( N
6 CD N
% NN N
) ) N
patients NNS N
in IN N
the DT i
ganitumab NN i
group NN N
and CC N
one CD N
of IN N
49 CD N
( ( N
2 CD N
% NN N
) ) N
in IN N
the DT N
placebo NN N
group NN N
. . N

Hyperglycaemia NNP o
was VBD o
reported VBN o
by IN N
12 CD N
of IN N
106 CD N
( ( N
11 CD N
% NN N
) ) N
patients NNS N
in IN N
the DT N
ganitumab NN N
group NN N
( ( N
with IN N
six CD N
patients NNS N
having VBG N
grade JJ N
3 CD N
or CC N
4 CD N
hyperglycaemia NN N
) ) N
and CC N
none NN N
of IN N
49 CD N
in IN N
the DT N
placebo NN N
group NN N
. . N

Serious JJ o
adverse JJ o
events NNS o
were VBD o
reported VBN o
by IN N
27 CD N
of IN N
106 CD N
( ( N
25 CD N
% NN N
) ) N
patients NNS N
in IN N
the DT N
ganitumab NN N
group NN N
and CC N
nine CD N
of IN N
49 CD N
( ( N
18 CD N
% NN N
) ) N
patients NNS N
in IN N
the DT N
placebo NN N
group NN N
. . N

INTERPRETATION NNP N
Addition NNP i
of IN i
ganitumab NN i
to TO N
endocrine VB N
treatment NN p
in IN p
women NNS p
with IN p
previously RB p
treated VBN p
hormone-receptor-positive JJ p
locally RB p
advanced VBD p
or CC p
metastatic JJ p
breast NN p
cancer NN p
did VBD N
not RB N
improve VB o
outcomes RB o
. . o

Our PRP$ o
results NNS N
do VBP N
not RB N
support VB N
further RBR N
study NN N
of IN N
ganitumab NN N
in IN N
this DT N
subgroup NN N
of IN N
patients NNS N
. . N

FUNDING NN N
Amgen NNP N
. . N

-DOCSTART- -8428787- O O

Effect NN o
of IN N
reduced JJ N
alcohol NN N
consumption NN N
on IN N
blood NN o
pressure NN o
in IN N
untreated JJ p
hypertensive JJ p
men NNS p
. . p

Fifty-four CD p
untreated JJ p
, , p
mildly RB p
hypertensive JJ p
men NNS p
whose WP$ p
daily JJ p
alcohol NN p
consumption NN p
was VBD p
> JJ p
or CC p
= JJ p
28 CD p
ml NN p
ethanol NN p
and CC p
who WP p
drank VBP p
at IN p
least JJS p
4 CD p
times NNS p
per IN p
week NN p
took VBD N
part NN N
in IN N
a DT N
randomized NN N
, , N
controlled VBD N
crossover RB N
trial NN N
. . N

The DT N
purpose NN N
of IN N
the DT N
trial NN N
was VBD N
to TO N
test VB N
the DT N
effects NNS o
of IN N
alcohol NN N
reduction NN N
on IN N
blood NN o
pressure NN o
. . o

After IN i
a DT i
2-week JJ i
familiarization NN i
period NN i
, , i
the DT i
participants NNS i
were VBD i
assigned VBN i
to TO i
either CC i
a DT i
reduced JJ i
alcohol NN i
drinking NN i
group NN i
or CC i
a DT i
usual JJ i
drinking NN i
group NN i
for IN i
3 CD i
weeks NNS i
( ( i
experimental JJ i
period NN i
1 CD i
) ) i
. . i

The DT i
situation NN i
was VBD i
then RB i
reversed VBN i
for IN i
the DT i
next JJ i
3 CD i
weeks NNS i
( ( i
experimental JJ i
period NN i
2 CD i
) ) i
. . i

The DT i
participants NNS i
were VBD i
requested VBN i
to TO i
limit VB i
their PRP$ i
daily JJ i
alcohol NN i
consumption NN i
to TO i
zero CD i
or CC i
reduce VB i
it PRP i
as RB i
much RB i
as IN i
possible JJ i
for IN i
the DT i
reduced JJ i
alcohol NN i
consumption NN i
period NN i
. . i

The DT N
self-reported JJ o
alcohol NN o
consumption NN o
was VBD N
56.1 CD N
+/- JJ N
3.6 CD N
( ( N
SEM NNP N
) ) N
ml/day NN N
during IN N
the DT N
usual JJ N
alcohol NN N
drinking NN N
period NN N
and CC N
26.1 CD N
+/- JJ N
3.0 CD N
ml/day NN N
during IN N
the DT N
period NN N
of IN N
reduced JJ N
alcohol NN N
consumption NN N
. . N

Systolic NNP o
and CC o
diastolic JJ o
blood NN o
pressures NNS o
in IN N
the DT N
intervention NN N
group NN N
were VBD N
found VBN N
by IN N
analysis NN N
of IN N
variance NN N
to TO N
be VB N
significantly RB N
lower JJR N
( ( N
2.6-4.8 JJ N
and CC N
2.2-3.0 JJ N
mm NN N
Hg NNP N
, , N
respectively RB N
) ) N
than IN N
those DT N
in IN N
the DT N
control NN N
group NN N
during IN N
experimental JJ N
period NN N
2 CD N
for IN N
systolic JJ o
blood NN o
pressure NN o
and CC N
experimental JJ N
period NN N
1 CD N
for IN N
diastolic JJ o
blood NN o
pressure NN o
. . o

Significant NNP N
( ( N
3.6 CD N
mm RB N
Hg NNP N
) ) N
and CC N
nonsignificant JJ N
( ( N
1.9 CD N
mm RB N
Hg NNP N
) ) N
decreases VBZ N
in IN N
systolic JJ o
and CC o
diastolic JJ o
blood NN o
pressure NN o
, , N
respectively RB N
, , N
were VBD N
observed VBN N
. . N

The DT N
method NN N
of IN N
Hills NNP N
and CC N
Armitage NNP N
was VBD N
used VBN N
, , N
reducing VBG N
ethanol NNS N
in IN N
daily JJ N
alcohol NN N
consumption NN N
by IN N
28 CD N
ml NN N
. . N

The DT N
lowering VBG N
effect NN N
of IN N
reduced JJ N
alcohol NN N
consumption NN N
on IN N
blood NN N
pressure NN N
was VBD N
independent JJ N
of IN N
changes NNS N
in IN N
salt NN N
consumption NN N
, , N
which WDT N
were VBD N
estimated VBN N
by IN N
24-hour JJ N
urine JJ N
collection NN N
and CC N
body NN N
weight NN N
. . N

( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
250 CD N
WORDS NNP N
) ) N
-DOCSTART- -10742359- O O

Impact NN N
of IN N
an DT N
encounter-based JJ i
prompting NN i
system NN i
on IN N
resident JJ o
vaccine JJ o
administration NN o
performance NN o
and CC o
immunization NN o
knowledge NN o
. . o

OBJECTIVES NNP N
To TO N
evaluate VB N
an DT N
encounter-based JJ i
immunization NN i
prompting VBG i
system NN i
on IN N
resident JJ p
performance NN N
in IN N
administering VBG N
vaccines NNS N
and CC N
knowledge NN N
of IN N
immunization NN N
guidelines NNS N
. . N

DESIGN/METHODS NNP N
Prospective NNP N
randomized VBD N
, , N
controlled VBD N
trial NN N
. . N

Subjects NNS p
were VBD p
first- JJ p
and CC p
second-year JJ p
pediatric JJ p
residents NNS p
in IN p
a DT p
hospital-based JJ p
continuity NN p
clinic NN p
. . p

The DT N
intervention NN N
group NN N
received VBD N
manual JJ i
prompts NNS i
of IN i
immunizations NNS i
due JJ i
. . i

Postclinic NNP N
chart NN N
review NN N
compared VBN N
immunizations NNS N
due JJ N
with IN N
those DT N
administered VBN N
. . N

Acceptable JJ N
and CC N
unacceptable JJ N
reasons NNS N
for IN N
not RB N
administering VBG N
vaccines NNS N
were VBD N
assigned VBN N
. . N

Resident NNP o
knowledge NN o
was VBD N
measured VBN N
by IN N
a DT N
70-item JJ N
examination NN N
. . N

RESULTS VB N
The DT N
intervention NN N
group NN N
had VBD N
significantly RB o
less RBR o
missed JJ o
opportunities/vaccine JJ o
administration NN o
errors NNS o
( ( N
11.4 CD N
% NN N
vs JJ N
21.6 CD N
% NN N
) ) N
. . N

The DT N
most RBS N
common JJ N
reason NN N
for IN N
unacceptable JJ N
errors NNS N
in IN N
the DT N
intervention NN N
group NN N
: : N
vaccine NN N
was VBD N
given VBN N
too RB N
early JJ N
; : N
in IN N
the DT N
control NN N
group NN N
: : N
vaccine NN N
was VBD N
postponed VBN N
to TO N
next JJ N
visit NN N
. . N

Pre- NNP N
and CC N
postintervention NN o
knowledge NN o
scores NNS o
were VBD N
similar JJ N
: : N
intervention NN N
group NN N
( ( N
75.5 CD N
% NN N
vs JJ N
80.7 CD N
% NN N
, , N
control NN N
group NN N
; : N
76.5 CD N
% NN N
vs JJ N
81.3 CD N
% NN N
) ) N
. . N

CONCLUSION NNP N
An DT N
immunization NN N
prompting VBG N
system NN N
in IN N
a DT N
hospital-based JJ N
pediatric JJ p
resident NN p
continuity NN N
clinic NN N
reduced VBD o
missed JJ o
opportunities/vaccine JJ o
administration NN o
errors NNS o
without IN N
significantly RB N
impacting VBG N
resident JJ N
knowledge NN N
of IN N
immunization NN N
guidelines.immunization NN N
schedule NN N
, , N
vaccination NN N
, , N
immunization NN N
, , N
prompting VBG N
systems NNS N
, , N
resident JJ N
education NN N
. . N

-DOCSTART- -15119720- O O

Bitewing NNP p
film NN p
quality NN p
: : p
a DT N
clinical JJ N
comparison NN N
of IN N
the DT N
loop NN i
vs. FW i
holder NN i
techniques NNS i
. . i

OBJECTIVE NNP N
To TO N
compare VB N
in IN N
vivo JJ N
bitewing NN N
film NN N
quality NN N
using VBG N
the DT N
holder NN i
versus IN i
the DT i
paper NN i
loop NN i
technique NN i
. . i

METHOD NNP N
AND CC N
MATERIALS NNP N
Four NNP p
bitewing VBG p
films NNS p
were VBD N
taken VBN N
from IN N
the DT N
right NN p
and CC p
left VBD p
premolar JJ p
and CC p
molar JJ p
regions NNS p
of IN p
45 CD p
dental JJ p
students NNS p
using VBG N
both DT N
the DT N
bitewing NN i
holder NN i
and CC i
paper NN i
loop NN i
techniques NNS i
. . i

A DT N
total NN N
of IN N
360 CD p
films NNS p
were VBD N
taken VBN N
and CC N
assessed VBN N
by IN N
an DT N
experienced JJ N
practitioner NN N
not RB N
apprised VBN N
of IN N
the DT N
bitewing NN i
technique NN i
used VBN N
. . N

Of IN N
interest NN N
were VBD N
: : N
( ( N
1 CD N
) ) N
the DT N
number NN N
of IN N
overlaps NNS N
and CC N
the DT N
percentage NN N
of IN N
teeth NNS N
showing VBG N
the DT N
alveolar JJ N
crest NN N
; : N
( ( N
2 CD N
) ) N
proper NN N
film NN N
positioning NN N
; : N
and CC N
( ( N
3 CD N
) ) N
the DT N
percentage NN N
of IN N
cone NN N
cutting NN N
. . N

A DT N
Poisson NNP N
regression NN N
using VBG N
generalized VBN N
estimating VBG N
equations NNS N
( ( N
GEEs NNP N
) ) N
was VBD N
used VBN N
to TO N
estimate VB N
the DT N
difference NN N
in IN N
overlap NN N
between IN N
the DT N
two CD N
techniques NNS N
. . N

For IN N
proper JJ N
positioning NN N
and CC N
cone NN N
cutting NN N
, , N
logistic JJ N
regressions NNS N
using VBG N
GEEs NNP N
were VBD N
used VBN N
. . N

RESULTS VB N
The DT N
average JJ o
number NN o
of IN o
horizontal JJ o
overlaps NNS o
for IN o
the DT o
loop NN o
and CC o
holder NN o
techniques NNS o
at IN N
the DT N
right JJ N
premolar NN N
, , N
right JJ N
molar NN N
, , N
left VBD N
premolar JJ N
, , N
and CC N
left VBD N
molar NN N
were VBD N
1.64 CD N
, , N
2.11 CD N
, , N
2.16 CD N
, , N
2.78 CD N
, , N
and CC N
1.64 CD N
, , N
2.00 CD N
, , N
2.00 CD N
, , N
2.18 CD N
, , N
respectively RB N
. . N

The DT N
loop NN i
technique NN i
was VBD N
1.11 CD N
times NNS N
more RBR N
likely JJ N
to TO N
cause VB N
overlapping VBG o
than IN N
the DT N
holder NN i
technique NN i
. . i

The DT N
highest JJS o
percentage NN o
of IN o
teeth NNS o
showing VBG o
the DT o
alveolar JJ o
crest NN o
by IN o
the DT o
loop NN o
technique NN o
was VBD N
97.8 CD N
% NN N
in IN N
the DT N
mandibular JJ N
second JJ N
premolar NN N
and CC N
first JJ N
molar NN N
. . N

With IN N
respect NN N
to TO N
film NN N
positioning NN N
, , N
the DT N
loop NN i
technique NN i
was VBD N
1.12 CD N
times NNS N
more RBR N
likely JJ N
to TO N
cause VB N
improper JJ o
positioning NN o
than IN N
the DT N
holder NN i
technique NN i
. . i

Both DT N
techniques NNS N
demonstrated VBN N
minimal JJ o
cone NN o
cutting NN o
( ( N
1 CD N
in IN N
the DT N
loop NN N
versus NN N
0 CD N
in IN N
the DT N
holder NN N
) ) N
. . N

CONCLUSION VB N
The DT N
quality NN N
of IN N
bitewing VBG N
films NNS N
taken VBN N
by IN N
the DT N
loop NN i
and CC i
holder NN i
techniques NNS i
was VBD N
not RB N
significantly RB N
different JJ N
. . N

-DOCSTART- -24502859- O O

A DT N
randomized VBN N
controlled VBN N
trial NN N
investigating VBG N
the DT N
safety NN o
and CC o
efficacy NN o
of IN N
aripiprazole NN i
in IN N
the DT N
long-term JJ N
maintenance NN N
treatment NN N
of IN N
pediatric JJ p
patients NNS p
with IN p
irritability NN p
associated VBN p
with IN p
autistic JJ p
disorder NN p
. . p

OBJECTIVE UH N
To TO N
evaluate VB N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
aripiprazole JJ i
versus NN N
placebo NN i
in IN N
preventing VBG N
relapse NN N
of IN N
irritability NN o
symptoms NNS o
associated VBN N
with IN N
autistic JJ p
disorder NN p
in IN p
pediatric JJ p
patients NNS p
. . p

METHOD NNP N
This DT N
multicenter NN N
, , N
double-blind NN N
, , N
randomized VBN N
, , N
placebo-controlled JJ i
, , N
relapse-prevention JJ N
trial NN N
enrolled VBD N
patients NNS p
( ( p
6-17 CD p
years NNS p
) ) p
who WP p
met VBD p
the DT p
current JJ p
Diagnostic NNP p
and CC p
Statistical NNP p
Manual NNP p
of IN p
Mental NNP p
Disorders NNP p
, , p
Fourth NNP p
Edition NNP p
, , p
Text NNP p
Revision NNP p
( ( p
DMS-IV-TR NNP p
) ) p
criteria NN p
for IN p
autistic JJ p
disorder NN p
and CC p
who WP p
also RB p
had VBD p
serious JJ p
behavioral JJ p
problems NNS p
( ( p
ie VB p
, , p
tantrums NNS p
, , p
aggression NN p
, , p
self-injurious JJ p
behavior NN p
, , p
or CC p
a DT p
combination NN p
of IN p
these DT p
behavioral JJ p
problems NNS p
) ) p
between IN p
March NNP p
2011 CD p
and CC p
June NNP p
2012 CD p
. . p

In IN N
phase NN N
1 CD N
, , N
single-blind JJ N
aripiprazole NN i
was VBD N
flexibly RB N
dosed VBN N
( ( N
2-15 JJ N
mg/d NN N
) ) N
for IN N
13-26 JJ N
weeks NNS N
. . N

Patients NNS p
with IN p
a DT p
stable JJ p
response NN p
( ( p
? . p
25 CD p
% NN p
decrease NN p
in IN p
Aberrant NNP o
Behavior NNP o
Checklist-irritability NNP o
subscale NN o
score NN o
and CC o
a DT p
rating NN p
of IN p
much JJ p
improved VBN p
or CC p
very RB p
much JJ p
improved VBN p
on IN p
the DT o
Clinical JJ o
Global NNP o
Impressions-Improvement NNP o
scale NN o
) ) o
for IN o
12 CD p
consecutive JJ p
weeks NNS p
were VBD p
randomized VBN N
into IN N
phase NN N
2 CD N
to TO N
continue VB i
aripiprazole NN i
or CC i
switch VB i
to TO i
placebo VB i
. . i

Treatment NN N
was VBD N
continued VBN N
until IN N
relapse NN N
or CC N
up RB N
to TO N
16 CD N
weeks NNS N
. . N

The DT N
primary JJ N
end NN N
point NN N
was VBD N
time NN N
from IN N
randomization NN N
to TO N
relapse VB N
. . N

RESULTS NNP p
Eighty-five JJ p
patients NNS p
were VBD p
randomized VBN p
in IN p
phase NN p
2 CD p
. . N

The DT N
difference NN N
in IN N
time NN o
to TO o
relapse VB o
between IN o
aripiprazole NN i
and CC i
placebo NN i
was VBD i
not RB N
statistically RB N
significant JJ N
( ( N
P NNP N
= NNP N
.097 NNP o
) ) o
. . o

Kaplan-Meier NNP o
relapse NN o
rates NNS o
at IN o
week NN N
16 CD N
were VBD N
35 CD N
% NN N
for IN N
aripiprazole NN N
and CC N
52 CD N
% NN N
for IN i
placebo NN i
( ( i
hazard JJ N
ratio NN N
[ NNP N
HR NNP N
] NNP N
= NNP N
0.57 CD N
; : N
number NN N
needed VBN N
to TO N
treat VB N
[ JJ N
NNT NNP N
] NNP N
= NNP N
6 CD N
) ) N
. . N

The DT N
most RBS N
common JJ o
adverse JJ o
events NNS o
during IN o
phase NN N
1 CD N
were VBD o
weight JJ o
increase NN o
( ( o
25.2 CD o
% NN o
) ) o
, , o
somnolence NN o
( ( o
14.8 CD N
% NN N
) ) N
, , N
and CC o
vomiting VBG o
( ( o
14.2 CD N
% NN N
) ) N
; : N
and CC N
, , N
during IN N
phase NN N
2 CD N
( ( N
aripiprazole JJ N
vs NN N
placebo NN N
) ) N
, , N
they PRP N
were VBD o
upper JJ o
respiratory NN o
tract NN o
infection NN o
( ( o
10.3 CD N
% NN N
vs JJ N
2.3 CD o
% NN o
) ) o
, , o
constipation NN o
( ( o
5.1 CD N
% NN N
vs JJ N
0 CD N
% NN N
) ) N
, , N
and CC o
movement NN o
disorder NN o
( ( o
5.1 CD N
% NN N
vs JJ N
0 CD N
% NN N
) ) N
. . N

CONCLUSIONS NNP N
In IN N
this DT N
study NN N
, , N
there EX N
was VBD N
no DT N
statistically RB N
significant JJ N
difference NN N
between IN i
aripiprazole NN i
and CC i
placebo NN i
in IN i
time NN o
to TO o
relapse VB o
during IN o
maintenance NN N
therapy NN N
. . N

However RB N
, , N
the DT N
HR NNP N
and CC N
NNT NNP N
suggest VBP N
some DT N
patients NNS N
will MD N
benefit VB N
from IN N
maintenance NN N
treatment NN N
. . N

Patients NNS N
receiving VBG N
aripiprazole NN N
should MD N
be VB N
periodically RB N
reassessed VBN N
to TO N
determine VB N
the DT N
continued JJ N
need NN N
for IN N
treatment NN N
. . N

TRIAL NNP N
REGISTRATION NNP N
ClinicalTrials.gov NNP N
identifier NN N
: : N
NCT01227668 NNP N
. . N

-DOCSTART- -7608801- O O

A DT N
randomized VBN N
, , N
controlled VBD N
trial NN N
of IN N
the DT N
efficacy NN o
of IN N
a DT N
heparin NN i
and CC i
vancomycin JJ i
solution NN i
in IN N
preventing VBG N
central JJ o
venous JJ o
catheter NN o
infections NNS o
in IN p
children NNS p
. . p

OBJECTIVE NN N
To TO N
determine VB N
whether IN N
adding VBG N
vancomycin NN i
to TO i
central JJ i
venous JJ i
catheter NN i
( ( i
CVC NNP i
) ) i
flush NN i
solution NN N
would MD N
significantly RB N
reduce VB N
the DT N
incidence NN N
of IN N
bacteremia NN N
attributable JJ N
to TO N
luminal JJ N
colonization NN N
with IN N
vancomycin-susceptible JJ N
organisms NNS N
. . N

STUDY NNP N
DESIGN NNP N
Fifty-five JJ p
children NNS p
with IN p
cancer NN p
and CC p
eight CD p
children NNS p
given VBN p
total JJ p
parenteral JJ p
nutrition NN p
by IN p
the DT p
surgery NN p
or CC p
nutrition NN p
support NN p
services NNS p
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
a DT N
heparin NN i
CVC NNP i
flush JJ i
solution NN i
( ( N
n JJ N
= NNP N
31 CD N
) ) N
or CC N
a DT N
heparin-vancomycin JJ i
CVC NNP i
flush NN i
solution NN i
( ( N
n JJ N
= NNP N
32 CD N
) ) N
. . N

RESULTS NNP N
During IN N
9158 CD N
catheter NN N
days NNS N
, , N
6.5 CD N
% NN N
of IN N
the DT N
patients NNS N
in IN N
the DT N
heparin NN N
group NN N
and CC N
15.6 CD N
% NN N
of IN N
the DT N
patients NNS N
in IN N
the DT N
heparin-vancomycin JJ N
group NN N
had VBD N
bacteremia VBN N
attributable JJ N
to TO N
luminal JJ N
colonization NN N
with IN N
vancomycin-susceptible JJ N
organisms NNS N
( ( N
p JJ N
= NNP N
0.43 CD N
) ) N
. . N

The DT N
mean JJ o
rates NNS o
of IN o
bacteremia NN o
attributable JJ N
to TO N
luminal JJ N
colonization NN N
with IN N
vancomycin-susceptible JJ N
organisms NNS N
were VBD N
0.6/1000 CD N
catheter NN N
days NNS N
in IN N
the DT N
heparin NN N
group NN N
and CC N
1.4/1000 CD N
catheter NN N
days NNS N
in IN N
the DT N
heparin-vancomycin JJ N
group NN N
( ( N
p JJ N
= NNP N
0.25 CD N
) ) N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
the DT N
groups NNS N
when WRB N
the DT N
time NN o
to TO o
the DT o
first JJ o
episode NN o
of IN o
bacteremia NN o
attributable JJ N
to TO N
luminal JJ N
colonization NN N
with IN N
a DT N
vancomycin-susceptible JJ N
organism NN N
was VBD N
compared VBN N
by IN N
means NNS N
of IN N
Kaplan-Meier NNP N
survival NN N
estimates NNS N
. . N

Streptococcus NNP o
viridans NNPS o
infection NN o
was VBD N
not RB N
attributable JJ N
to TO N
luminal JJ N
colonization NN N
. . N

CONCLUSION VB N
The DT N
addition NN N
of IN N
vancomycin NN N
to TO N
heparin VB N
CVC NNP N
flush JJ N
solution NN N
did VBD N
not RB N
reduce VB N
bacteremia NN o
with IN N
vancomycin-susceptible JJ N
organisms NNS N
. . N

Bacteremia NNP o
with IN N
Streptococcus NNP N
viridans NNS N
was VBD N
not RB N
related VBN N
to TO N
the DT N
use NN N
of IN N
a DT N
CVC NNP N
. . N

-DOCSTART- -22634446- O O

A DT N
randomized JJ N
trial NN N
of IN N
immunotherapy NN i
for IN N
persistent JJ p
genital JJ p
warts NNS p
. . p

AIM NNP N
To TO N
determine VB N
whether IN N
immunotherapy NN N
with IN N
HPV6 NNP i
L1 NNP i
virus NN i
like IN i
particles NNS i
( ( i
VLPs NNP i
) ) i
without IN i
adjuvant NN i
( ( i
VLP NNP i
immunotherapy NN i
) ) i
reduces VBZ N
recurrence NN N
of IN N
genital JJ o
warts NNS o
following VBG N
destructive JJ N
therapy NN N
. . N

TRIAL NNP N
DESIGN NNP N
A NNP N
randomized JJ N
placebo NN i
controlled VBD N
blinded VBD N
study NN N
of IN N
treatment NN N
of IN N
recurrent JJ p
genital JJ p
warts NNS p
amenable JJ N
to TO N
destructive JJ N
therapy NN N
, , N
conducted VBN p
independently RB p
in IN p
Australia NNP p
and CC p
China NNP p
. . p

METHODS NNP N
Patients NNPS N
received VBD N
conventional JJ i
destructive JJ i
therapy NN i
of IN N
all DT N
evident JJ N
warts NNS N
together RB N
with IN N
intramuscular JJ i
administration NN i
of IN i
1 CD i
?g NNS i
, , i
5 CD i
?g NN i
or CC i
25 CD i
?g NN i
of IN i
VLP NNP i
immunotherapy NN i
, , i
or CC i
of IN i
placebo JJ i
immunotherapy NN i
( ( i
0.9 CD i
% NN i
NaCl NNP i
) ) i
, , i
as IN i
immunotherapy NN i
at IN i
week NN N
0 CD N
and CC N
week NN N
4 CD N
. . N

Primary JJ N
outcome NN N
, , N
assessed VBN N
at IN N
week NN N
8 CD N
, , N
was VBD N
recurrence NN N
of IN N
visible JJ N
warts NNS N
. . N

RESULTS NNP N
Of IN N
33 CD p
protocol NN p
compliant NN p
Brisbane NNP p
recipients NNS p
of IN p
placebo NN p
immunotherapy NN p
, , p
11 CD p
were VBD N
disease JJ N
free JJ N
at IN N
two CD N
months NNS N
, , N
and CC N
a DT N
further JJ N
9 CD N
demonstrated JJ N
reduction NN N
of IN N
> $ N
50 CD N
% NN N
in IN N
total JJ o
wart JJ o
area NN o
. . o

Wart NNP o
area NN o
reduction NN o
following VBG o
destructive JJ N
treatment NN N
correlated VBN N
with IN N
prior JJ N
duration NN N
of IN N
disease NN N
. . N

Among IN p
102 CD p
protocol NN p
compliant NN p
Brisbane NNP p
recipients NNS p
of IN p
VLP NNP p
immunotherapy NN o
, , o
disease NN o
reduction NN o
was VBD o
significantly RB N
greater JJR N
than IN N
among IN N
the DT N
placebo NN N
immunotherapy NN N
( ( N
50 CD N
% NN N
? . N
s.e.m NN N
. . N

7 CD N
% NN N
) ) N
recipients NNS N
for IN N
subjects NNS N
receiving VBG N
5 CD N
?g NN N
or CC N
25 CD N
?g NN N
of IN N
VLP NNP N
immunotherapy/dose NN N
( ( N
71 CD N
% NN N
? . N
s.e.m NN N
. . N

7 CD N
% NN N
) ) N
but CC N
not RB N
for IN N
those DT N
receiving VBG N
1 CD N
?g JJ N
VLP NNP N
immunotherapy/dose NN N
( ( N
42 CD N
% NN N
? . N
7 CD N
% NN N
) ) N
. . N

Of IN p
52 CD p
protocol NN p
compliant NN p
placebo NN p
immunotherapy NN p
recipients NNS p
in IN p
Wenzhou NNP p
, , p
37 CD N
were VBD N
disease JJ N
free JJ N
at IN N
two CD N
months NNS N
, , N
and CC N
a DT N
further JJ N
8 CD N
had VBD N
> VBN N
50 CD N
% NN N
disease NN o
reduction NN o
. . o

Prior NNP o
disease NN o
duration NN o
was VBD N
much JJ N
shorter JJR N
in IN N
Wenzhou NNP N
subject NN N
( ( N
8.1 CD N
? . N
1.1 CD N
mo NN N
) ) N
than IN N
in IN N
Brisbane NNP N
subjects NNS N
( ( N
53.7 CD N
? . N
5.5 CD N
mo NN N
) ) N
. . N

No DT N
significant JJ N
reduction NN N
in IN o
mean JJ o
wart JJ o
area NN o
was VBD N
observed VBN N
for IN p
the DT p
168 CD p
Wenzhou NNP p
protocol NN p
compliant JJ p
subjects NNS p
who WP p
also RB p
received VBD p
VLP NNP p
immunotherapy NN p
. . p

CONCLUSIONS VB p
This DT N
study NN N
confirms VBZ N
the DT N
findings NNS N
in IN N
a DT N
previous JJ N
open JJ N
label NN N
trial NN N
that IN N
administration NN N
of IN N
VLP NNP N
immunotherapy NN N
may MD N
assist VB N
in IN N
clearance NN N
of IN N
recurrent JJ o
genital JJ o
warts NNS o
in IN o
patients NNS o
for IN p
whom WP p
destructive JJ p
therapy NN p
is VBZ p
unsuccessful JJ p
and CC p
that DT p
unsuccessful JJ p
destructive JJ N
therapy NN N
is VBZ N
more RBR N
common JJ N
with IN N
increasing VBG N
prior JJ N
disease NN N
duration NN N
. . N

-DOCSTART- -389265- O O

Immunotherapy NNP i
using VBG N
BCG NNP i
during IN N
remission NN N
induction NN N
and CC N
as IN N
the DT N
sole JJ N
form NN N
of IN N
maintenance NN N
in IN N
acute JJ p
myeloid NN p
leukaemia NN p
. . p

Thirty-two JJ p
adults NNS p
with IN p
acute JJ p
myeloid NN p
leukaemia NN p
( ( p
AML NNP p
) ) p
were VBD N
randomized VBN N
to TO N
receive VB N
, , N
from IN N
the DT N
time NN N
of IN N
diagnosis NN N
, , N
either CC N
chemotherapy NN i
alone RB i
( ( N
C NNP N
group NN N
) ) N
or CC N
chemotherapy JJ i
plus CC i
Bacille NNP i
Calmette-Gu?rin NNP i
vaccine NN i
( ( i
BCG NNP i
) ) i
( ( N
C+I NNP N
group NN N
) ) N
. . N

After IN N
remission NN N
induction NN N
and CC N
consolidation NN N
, , N
chemotherapy NN N
was VBD N
stopped VBN N
in IN N
both DT N
groups NNS N
but CC N
BCG NNP N
was VBD N
continued VBN N
in IN N
the DT N
C+I NNP N
group NN N
. . N

The DT o
overall JJ o
survival NN o
of IN N
the DT N
C+I NNP N
group NN N
was VBD N
significantly RB N
increased VBN N
( ( N
P NNP N
less JJR N
than IN N
0.05 CD N
) ) N
. . N

There EX N
was VBD N
no DT N
significant JJ o
increase NN o
in IN o
the DT o
duration NN o
of IN o
first JJ o
remission NN o
in IN N
the DT N
C+I NNP N
group NN N
( ( N
0.05 CD N
less JJR N
than IN N
P NNP N
less JJR N
than IN N
0.1 CD N
) ) N
nor CC N
in IN N
the DT N
time NN N
from IN N
first JJ o
relapse NN o
to TO o
death NN o
( ( N
0.05 CD N
less JJR N
than IN N
P NNP N
less JJR N
than IN N
0.1 CD N
) ) N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
the DT o
incidence NN o
of IN o
first JJ o
or CC o
second JJ o
remissions NNS o
, , o
and CC N
the DT o
time NN o
taken VBN o
to TO o
enter VB o
remission NN o
did VBD N
not RB N
differ VB N
significantly RB N
between IN N
the DT N
two CD N
groups NNS N
. . N

Comparison NNP N
with IN N
the DT N
results NNS N
of IN N
other JJ N
trials NNS N
suggests VBZ N
that IN N
the DT N
use NN N
of IN N
maintenance NN N
chemotherapy NN N
in IN N
addition NN N
to TO N
immunotherapy VB N
produces NNS N
longer JJR o
remissions NNS o
. . o

Five CD N
patients NNS N
in IN N
the DT N
C NNP N
group NN N
developed VBD o
leukaemic JJ o
central-nervous-system NN o
( ( o
CSN NNP o
) ) o
involvement NN o
, , o
in IN N
comparison NN N
with IN N
none NN N
in IN N
the DT N
C+I NNP N
group NN N
. . N

CNS NNP N
relapse NN N
did VBD N
not RB N
produce VB N
a DT N
significant JJ N
decrease NN N
in IN o
remission NN o
length NN o
( ( N
P NNP N
greater JJR N
than IN N
0.1 CD N
) ) N
but CC N
reduction NN N
in IN o
survival NN o
after IN o
CNS NNP o
relapse NN o
was VBD N
highly RB N
significant JJ N
( ( N
P NNP N
= NNP N
0.001 CD N
) ) N
. . N

These DT N
results NNS N
suggest VBP N
that IN N
administration NN N
of IN i
BCG NNP i
from IN N
an DT N
early JJ N
stage NN N
in IN N
the DT N
treatment NN N
of IN N
AML NNP N
may MD o
protect VB o
the DT o
CNS NNP o
against IN o
leukaemic JJ o
infiltration NN o
and CC N
therefore RB N
serve VBP N
as IN N
a DT N
simple NN N
, , N
innocuous JJ N
form NN N
of IN o
CNS NNP o
prophylaxis NN o
. . o

-DOCSTART- -9003876- O O

Topical JJ N
beta-blockade NN N
with IN N
intrinsic JJ N
sympathomimetic JJ N
activity NN N
offers VBZ N
no DT N
advantage NN N
for IN N
the DT N
respiratory NN N
and CC N
cardiovascular JJ N
function NN N
of IN N
elderly JJ p
people NNS p
. . p

Topical JJ i
therapy NN i
with IN i
beta-antagonists NNS i
, , N
such JJ N
as IN N
timolol NNS i
, , N
may MD N
cause VB N
unrecognized JJ N
impairment NN N
of IN N
respiratory NN N
and CC N
cardiovascular JJ N
function NN N
in IN N
elderly JJ p
people NNS p
. . p

Beta-antagonists NNS N
with IN N
intrinsic JJ N
sympathomimetic JJ N
or CC N
cardioselective JJ N
properties NNS N
, , N
such JJ N
as IN N
carteolol NN i
or CC N
betaxolol NN i
, , N
may MD N
cause VB N
less JJR N
impairment NN N
. . N

In IN N
a DT N
randomized JJ N
, , N
double-masked JJ N
study NN N
of IN N
glaucoma NN p
patients NNS p
, , p
over IN p
60 CD p
years NNS p
of IN p
age NN p
, , p
without IN p
history NN p
of IN p
bronchospasm NN p
and CC p
who WP p
were VBD p
using VBG p
timolol NN i
( ( p
0.5 CD p
% NN p
) ) p
, , p
60 CD p
patients NNS p
were VBD N
allocated VBN N
to TO N
betaxolol VB i
( ( N
0.5 CD N
% NN N
) ) N
or CC N
carteolol NN i
( ( N
2 CD N
% NN N
) ) N
or CC N
continued VBN N
timolol NNS i
( ( N
0.5 CD N
% NN N
) ) N
treatment NN N
. . N

Spirometry NNP o
, , o
pulse NN o
and CC o
blood NN o
pressure NN o
were VBD N
measured VBN N
on IN N
enrollment NN N
and CC N
after IN N
4 CD N
weeks NNS N
. . N

In IN N
the DT N
timolol NN N
and CC N
carteolol NN N
groups NNS N
there EX N
were VBD N
no DT N
significant JJ N
changes NNS N
in IN N
mean JJ o
spirometric JJ o
values NNS o
. . o

Changing VBG N
to TO N
betaxolol VB N
improved JJ N
mean JJ o
peak NN o
flow NN o
( ( o
PF NNP o
) ) o
by IN N
9.1 CD N
% NN N
, , N
from IN N
310 CD N
to TO N
3411/min CD N
( ( N
p NN N
< RB N
0.05 CD N
) ) N
and CC N
forced JJ o
expiratory NN o
volume NN o
in IN N
1 CD N
second JJ N
( ( N
FEV1 NNP N
) ) N
by IN N
9.4 CD N
% NN N
, , N
from IN N
1.74 CD N
to TO N
1.861 CD N
( ( N
p NN N
< RB N
0.05 CD N
) ) N
. . N

Differences NNS N
in IN N
the DT N
changes NNS o
in IN o
PF NNP o
and CC o
FEV1 NNP o
between IN N
betaxolol NN N
and CC N
timolol NN N
as RB N
well RB N
as IN N
betaxolol NN N
and CC N
carteolol NN N
groups NNS N
were VBD N
statistically RB N
significant JJ N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

Twenty-one CD N
per IN N
cent NN N
of IN N
those DT N
allocated VBN N
to TO N
betaxolol VB N
showed VBN N
clinically RB N
significant JJ N
improvement NN N
in IN N
FEV1 NNP o
. . o

There EX N
was VBD N
no DT N
change NN N
in IN N
pulse NN o
or CC o
blood NN o
pressure NN o
when WRB N
carteolol NN N
was VBD N
substituted VBN N
for IN N
timolol NN N
but CC N
an DT N
increase NN N
of IN N
10 CD N
beats NNS N
per IN N
minute NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
in IN N
mean NN o
resting VBG o
pulse NN o
in IN N
the DT N
betaxolol NN N
group NN N
. . N

Therapy NN N
with IN N
cardioselective JJ N
beta-blockade NN N
may MD N
offer VB N
significant JJ N
advantages NNS N
in IN N
respiratory NN N
function NN N
for IN N
elderly JJ p
people NNS p
with IN p
glaucoma NN p
over IN N
non-selective JJ N
drugs NNS N
, , N
even RB N
if IN N
they PRP N
have VBP N
sympathomimetic JJ N
activity NN N
. . N

-DOCSTART- -19154562- O O

Randomized VBN N
prospective JJ N
study NN N
to TO N
evaluate VB N
child NN p
abuse NN o
documentation NN p
in IN p
the DT p
emergency NN p
department NN p
. . p

OBJECTIVES IN N
The DT N
objective NN N
was VBD N
to TO N
determine VB N
whether IN N
an DT N
educational JJ i
intervention NN i
for IN i
health NN i
care NN i
providers NNS i
would MD N
result VB N
in IN N
improved JJ N
documentation NN o
of IN N
cases NNS N
of IN N
possible JJ N
physical JJ p
child NN p
abuse NN p
in IN p
children NNS p
< VBP p
36 CD p
months NNS p
old JJ p
treated VBN p
in IN p
the DT p
emergency NN p
department NN p
( ( p
ED NNP p
) ) p
setting NN p
. . p

METHODS NNP N
This DT N
study NN N
had VBD N
a DT N
statewide JJ N
group-randomized JJ N
prospective JJ N
trial NN N
design NN N
. . N

Participating VBG N
EDs NNP p
were VBD N
randomized VBN N
to TO N
one CD N
of IN N
three CD N
intervention NN N
groups NNS N
: : N
no DT i
intervention NN i
, , i
partial JJ i
intervention NN i
, , N
or CC N
full JJ i
intervention NN i
. . i

Medical JJ p
records NNS p
for IN p
children NNS p
< $ p
36 CD p
months NNS p
of IN p
age NN p
were VBD N
abstracted VBN N
before RB N
, , N
during IN N
, , N
and CC N
after IN N
the DT N
intervention NN N
periods NNS N
for IN N
specific JJ N
documentation NN N
elements NNS N
. . N

The DT N
main JJ N
outcome NN N
measure NN N
was VBD N
the DT N
change NN N
in IN N
documentation NN N
from IN N
baseline NN N
. . N

Generalized VBN N
estimating VBG N
equations NNS N
( ( N
GEEs NNP N
) ) N
were VBD N
used VBN N
to TO N
test VB N
for IN N
intervention NN N
effect NN N
. . N

RESULTS VB N
A DT p
total NN p
of IN p
1,575 CD p
charts NNS p
from IN p
14 CD p
hospitals NNS p
EDs NNP p
were VBD p
abstracted VBN p
. . p

Hospital NNP N
and CC N
demographic JJ N
characteristics NNS N
were VBD N
similar JJ N
across IN N
intervention NN N
groups NNS N
. . N

There EX N
were VBD N
922 CD N
( ( N
59 CD N
% NN N
) ) N
injury NN N
visits NNS N
and CC N
653 CD N
( ( N
41 CD N
% NN N
) ) N
noninjury NN N
visits NNS N
. . N

For IN N
each DT N
specific JJ N
documentation NN N
element NN N
, , N
a DT N
GEE NNP N
model NN N
gave VBD N
p-values NNS N
of IN N
> JJ N
0.2 CD N
in IN N
independent JJ N
tests NNS N
, , N
indicating VBG N
no DT N
evidence NN N
of IN N
significant JJ N
change NN N
in IN N
documentation NN N
after IN N
the DT N
intervention NN N
. . N

Even RB N
among IN N
the DT N
26 CD N
charts NNS N
in IN N
which WDT N
the DT N
possibility NN N
of IN N
physical JJ N
abuse NN N
was VBD N
noted VBN N
, , N
documentation NN N
remained VBD N
variable JJ N
. . N

CONCLUSIONS VB N
The DT N
educational JJ i
interventions NNS i
studied VBD N
did VBD N
not RB N
improve VB N
ED NNP o
documentation NN o
of IN N
cases NNS N
of IN N
possible JJ N
physical JJ N
child NN N
abuse NN N
. . N

The DT N
need NN N
for IN N
improved JJ N
health NN N
care NN N
provider NN N
education NN N
in IN N
child NN N
abuse NN N
identification NN N
and CC N
documentation NN N
remains NNS N
. . N

Future NNP N
innovative JJ N
educational JJ N
studies NNS N
to TO N
improve VB N
recognition NN o
of IN o
abuse NN o
are VBP N
warranted VBN N
. . N

-DOCSTART- -22079088- O O

Safety NN N
and CC N
efficacy NN N
of IN N
sitaxsentan JJ i
50 CD N
and CC N
100 CD N
mg NNS N
in IN p
patients NNS p
with IN p
pulmonary JJ p
arterial JJ p
hypertension NN p
. . p

OBJECTIVE UH N
To TO N
assess VB N
safety NN N
and CC N
efficacy NN N
of IN i
sitaxsentan JJ i
50 CD N
and CC N
100 CD N
mg NNS N
in IN N
patients NNS p
with IN p
pulmonary JJ p
arterial JJ p
hypertension NN p
( ( p
PAH NNP p
) ) p
. . p

BACKGROUND NNP i
Sitaxsentan NNP i
is VBZ i
a DT N
highly RB N
selective JJ N
endothelin-A JJ N
receptor NN N
antagonist NN N
that WDT N
was VBD N
recently RB N
withdrawn VBN N
by IN N
the DT N
manufacturer NN N
because IN N
of IN N
a DT N
pattern NN N
of IN N
idiosyncratic JJ N
liver JJ N
injury NN N
. . N

METHODS NNP N
Before IN i
sitaxsentan NN i
withdrawal NN i
, , N
this DT N
18-week JJ N
double-blind NN N
, , N
placebo-controlled JJ N
study NN N
randomized VBD p
patients NNS p
with IN p
PAH NNP p
to TO p
receive VB i
placebo NN i
or CC i
sitaxsentan VB i
50 CD i
or CC p
100 CD p
mg NNS p
once RB p
daily RB p
. . p

The DT p
primary JJ N
efficacy NN N
endpoint NN N
was VBD N
change NN N
from IN N
baseline NN N
in IN N
6-min JJ N
walk NN N
distance NN N
( ( N
6MWD CD N
) ) N
at IN N
week NN N
18 CD N
. . N

Changes NNS N
in IN N
World NNP N
Health NNP N
Organization NNP N
( ( N
WHO NNP N
) ) N
functional JJ N
class NN N
and CC N
time NN N
to TO N
clinical JJ N
worsening NN N
( ( N
TTCW NNP N
) ) N
were VBD N
secondary JJ N
endpoints NNS N
. . N

The DT N
primary JJ N
efficacy NN N
analysis NN N
was VBD N
powered VBN N
for IN N
sitaxsentan JJ i
100 CD i
mg NN N
versus NN i
placebo NN i
. . i

RESULTS NNP i
Of IN p
98 CD p
randomized JJ p
patients NNS p
, , p
61 CD p
% NN p
were VBD p
WHO NNP p
functional JJ p
class NN p
II NNP p
at IN p
baseline NN p
. . p

Improvement NN p
from IN N
baseline NN o
to TO o
week NN o
18 CD o
in IN o
6MWD CD o
occurred VBD o
with IN N
sitaxsentan JJ i
100 CD i
but CC N
not RB N
50 CD N
mg NNS N
; : N
a DT N
strong JJ i
placebo NN i
effect NN i
was VBD N
observed VBN N
. . N

At IN N
week NN N
18 CD o
, , o
WHO NNP o
functional VBP o
class NN o
was VBD o
improved VBN N
or CC N
maintained VBN N
in IN N
more RBR N
patients NNS N
receiving VBG i
sitaxsentan JJ i
100 CD i
mg NN i
than IN i
placebo NN i
( ( i
P NNP i
= NNP i
0.038 CD N
) ) N
; : N
0 CD N
% NN N
versus IN N
12 CD N
% NN N
of IN N
patients NNS N
deteriorated VBN N
, , N
respectively RB o
. . o

TTCW NNP o
was VBD o
not RB N
significantly RB N
different JJ N
for IN N
100-mg JJ i
sitaxsentan NN i
patients NNS i
than IN i
placebo NN i
( ( N
P NNP N
= NNP N
0.090 CD o
) ) o
. . o

Adverse JJ o
events NNS o
( ( o
AEs NNP o
) ) o
occurring VBG o
more RBR N
frequently RB N
with IN i
sitaxsentan NN i
( ( i
50 CD i
or CC i
100 CD i
mg NN N
) ) N
included VBD o
headache NN o
, , o
peripheral JJ o
edema NN o
, , o
dizziness NN o
, , o
nausea NN o
, , o
extremity NN o
pain NN o
, , o
and CC o
fatigue NN o
; : o
most JJS o
AEs NNP N
were VBD N
of IN N
mild NN N
or CC N
moderate JJ N
severity NN N
. . N

CONCLUSION NNP N
Sitaxsentan NNP i
100 CD i
mg NN i
improved VBD o
functional JJ o
class NN o
but CC o
not RB o
6MWD CD o
in IN o
PAH NNP p
patients NNS p
who WP p
were VBD p
mostly RB p
WHO NNP p
functional JJ p
class NN p
II NNP p
at IN p
baseline NN p
. . p

No DT p
patient NN N
receiving VBG i
sitaxsentan JJ i
100 CD N
mg NN N
experienced VBD N
clinical JJ N
worsening NN i
; : i
sitaxsentan NN i
was VBD N
well RB N
tolerated VBN N
. . N

-DOCSTART- -17160228- O O

[ JJ o
Sentinel NNP o
lymph NN o
node NN o
detection NN o
in IN N
colorectal JJ N
cancer NN N
: : N
importance NN N
, , N
techniques NNS N
and CC N
results NNS N
] NNP N
. . N

BACKGROUND NNP N
AND NNP N
AIM NNP N
Considering NNP N
that IN N
lymph VBD N
node DT N
status NN N
is VBZ N
a DT N
key JJ N
factor NN N
in IN N
colorectal JJ N
cancer NN N
staging NN N
, , N
and CC N
the DT N
main JJ N
determinant NN N
for IN N
adjuvant JJ i
therapy NN i
of IN N
colorectal JJ N
cancer NN N
being VBG N
this DT N
therapy NN N
, , N
responsible JJ N
for IN N
a DT N
significant JJ N
increase NN N
in IN N
colorectal JJ N
cancer NN N
patients NNS N
survival JJ N
, , N
the DT N
staging VBG N
methods NNS N
should MD N
be VB N
the DT N
most RBS N
accurate JJ N
possible JJ N
in IN N
order NN N
to TO N
offer VB N
this DT N
individuals NNS N
the DT N
opportunity NN N
to TO N
be VB N
adequate JJ N
treated VBN N
in IN N
order NN N
to TO N
achieve VB N
the DT N
best JJS N
survival NN N
possible JJ N
. . N

Sentinel NNP N
lymph NN N
node NN N
study NN N
is VBZ N
progressively RB N
being VBG N
popularized VBN N
as IN N
a DT N
method NN N
that WDT N
increases VBZ N
sensibility NN o
in IN o
detect JJ o
positive JJ o
nodes NNS o
to TO N
reveal VB N
a DT N
more RBR N
accurate JJ N
stage NN o
and CC o
prognosis NN o
in IN N
colorectal JJ N
cancer NN N
patients NNS N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
Thirty NNP p
one CD p
colorectal NN p
cancer NN p
patients NNS p
were VBD N
prospectively RB N
studied VBN N
and CC N
sentinel JJ N
lymph NN N
node NN N
was VBD N
identified VBN N
in IN N
100 CD N
% NN N
of IN N
the DT N
cases NNS N
utilizing VBG i
either CC i
patent JJ i
blue NN i
alone RB i
, , i
or CC i
in IN i
association NN i
with IN i
radiotracer NN i
based VBN i
on IN i
technetium NN i
99m CD i
colloid JJ i
solution NN i
in IN i
a DT i
randomized JJ i
fashion NN i
. . i

RESULTS VB N
The DT N
mean JJ o
number NN o
of IN o
sentinel NNS o
nodes NNS o
per IN o
patient NN o
was VBD N
1.96 CD N
ranging VBG N
from IN N
1 CD N
to TO N
3 CD N
nodes NNS N
. . N

With IN N
the DT N
addition NN N
of IN N
transoperative JJ o
lympho-scintigraphy NN o
five CD N
extra JJ o
sentinel NN o
nodes NNS o
, , N
not RB N
identified VBN N
by IN N
the DT N
blue JJ N
dye NN N
alone RB N
, , N
were VBD N
identified VBN N
and CC N
considered VBN N
for IN N
histopathology NN N
study NN N
. . N

In IN N
four CD N
cases NNS N
( ( N
12.9 CD N
% NN N
) ) N
the DT N
sentinel NN N
lymph NN N
node NN N
was VBD N
the DT N
only JJ N
site NN N
of IN N
metastasis NN N
, , N
all DT N
of IN N
them PRP N
being VBG N
detected VBN N
by IN N
association NN o
of IN o
hematoxylin NN o
and CC o
eosin NN o
and CC o
immunohistochemical JJ o
examination NN o
. . o

CONCLUSION NNP N
Sentinel NNP N
lymph NN N
node NN N
detection NN N
and CC N
analysis NN N
is VBZ N
feasible JJ o
, , N
technique NN N
is VBZ N
relatively RB N
simple JJ o
and CC N
is VBZ N
able JJ N
to TO N
produce VB o
upstage NN o
in IN N
colorectal JJ N
cancer NN N
. . N

Blue NNP i
staining VBG i
and CC i
radio NN i
guided VBN i
techniques NNS i
are VBP N
both DT N
safe JJ o
and CC N
their PRP$ N
superposition NN N
has VBZ N
shown VBN N
good JJ N
results NNS N
in IN N
terms NNS N
of IN N
increase NN N
accuracy NN o
in IN N
our PRP$ N
experience NN N
. . N

There EX N
was VBD N
no DT N
aberrant JJ N
lymph NN o
drainage NN o
that WDT N
would MD N
alter VB N
resection NN N
margins NNS N
in IN N
patients NNS N
studied VBN N
. . N

Upstaging VBG o
rate NN o
, , N
identifying VBG N
potential JJ N
candidates NNS N
for IN N
adjuvant JJ i
therapy NN i
was VBD N
12.9 CD N
% NN N
( ( N
4/31 CD N
) ) N
. . N

To TO N
this DT N
individuals NNS N
chemotherapy NN i
could MD N
be VB N
a DT N
chance NN N
to TO N
increase VB N
their PRP$ N
global JJ N
survival NN N
. . N

-DOCSTART- -22238957- O O

[ JJ N
Pharmacological NNP N
correction NN N
of IN N
free JJ o
radical JJ o
disturbances NNS o
and CC o
endotoxicosis NN o
in IN N
patients NNS p
with IN p
diffuse NN p
peritonitis NN p
at IN p
the DT p
postoperative JJ p
period NN p
] NNP p
. . N

The DT N
examination NN N
and CC N
treatment NN N
of IN N
64 CD p
patients NNS p
have VBP N
shown VBN N
that IN p
inclusion NN p
of IN p
complex JJ i
antioxidant NN i
cytoflavin NN i
in IN p
intensive JJ p
therapy NN p
at IN p
the DT p
postoperative JJ p
period NN p
of IN p
diffuse NN p
peritonitis NN p
allows VBZ N
the DT N
hypoxia NN N
degree NN N
to TO N
be VB N
decreased VBN N
that IN N
in IN N
its PRP$ N
turn NN N
results NNS N
in IN N
quicker JJ N
recovery NN o
of IN o
the DT o
antioxidant JJ o
system NN o
and CC o
decreased JJ o
activity NN o
of IN o
peroxidation NN o
and CC o
endotoxicosis NN o
level NN o
. . o

The DT N
clinical JJ N
course NN N
of IN N
the DT N
postoperative JJ N
period NN N
of IN N
diffuse NN N
peritonitis NN N
with IN N
cytoflavin NN i
included VBN N
in IN N
intensive JJ N
therapy NN N
is VBZ N
characterized VBN N
by IN N
shorter JJR N
terms NNS N
of IN N
artificial JJ o
lung NN o
ventilation NN o
, , N
shorter JJR N
time NN N
of IN N
staying VBG o
in IN o
critical JJ o
condition NN o
, , N
more RBR N
favorable JJ N
course NN o
of IN o
complications NNS o
. . o

-DOCSTART- -4198313- O O

A DT N
multicenter NN N
investigation NN N
of IN N
lorazepam NN i
in IN p
anxiety NN o
neurosis NN o
. . o

-DOCSTART- -17958625- O O

Oral NNP N
amoxicillin NN i
vs. FW N
oral JJ N
erythromycin NN i
in IN N
the DT N
treatment NN o
of IN o
pyoderma NN o
in IN p
Bamako NNP p
, , p
Mali NNP p
: : p
an DT N
open JJ N
randomized VBN N
trial NN N
. . N

BACKGROUND NNP N
Pyoderma NNP p
( ( p
bacterial JJ p
superficial NN p
skin NN p
infection NN p
) ) p
is VBZ N
an DT N
extremely RB N
common JJ N
disorder NN N
in IN N
tropical JJ p
developing VBG p
countries NNS p
. . p

In IN N
these DT N
settings NNS N
, , N
Streptococcus NNP N
pyogenes NNS N
is VBZ N
considered VBN N
to TO N
be VB N
the DT N
main JJ N
etiological JJ N
agent NN N
. . N

Apart RB N
from IN N
epidemics NNS N
of IN N
poststreptococcal JJ N
glomerulonephritis NN N
where WRB N
mass NN N
treatment NN N
with IN N
intramuscular JJ N
benzathine-penicillin NN i
is VBZ N
recommended VBN N
, , N
no DT N
recommendation NN N
exists VBZ N
for IN N
the DT N
treatment NN N
of IN N
pyoderma NN N
in IN N
this DT N
setting NN N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
efficacy NN N
of IN N
oral JJ N
amoxicillin NN i
in IN N
the DT N
treatment NN N
of IN N
pyoderma NN N
in IN N
Mali NNP N
, , N
by IN N
comparison NN N
with IN N
oral JJ N
erythromycin NN i
. . i

METHODS NNP N
In IN p
Bamako NNP p
, , p
132 CD p
patients NNS p
with IN p
pyoderma NN p
, , p
diagnosed VBN p
and CC p
graded VBN p
as IN p
severe JJ p
on IN p
clinical JJ p
grounds NNS p
, , N
were VBD N
randomly RB N
assigned VBN N
to TO N
an DT N
oral JJ N
treatment NN N
by IN N
either DT N
amoxicillin NN i
( ( N
50 CD N
mg/kg NNS N
per IN N
day NN N
) ) N
or CC N
erythromycin $ i
; : i
infections NNS N
of IN N
the DT N
follicular JJ N
appendage NN N
were VBD N
excluded VBN N
. . N

Both DT N
drugs NNS N
were VBD N
associated VBN N
with IN N
the DT N
topical JJ N
application NN N
of IN N
povidone NN N
iodine NN N
. . N

The DT N
patients NNS N
were VBD N
evaluated VBN N
openly RB N
at IN N
the DT N
seventh JJ N
day NN N
of IN N
treatment NN N
for IN N
cure NN N
or CC N
marked JJ N
improvement NN N
of IN N
the DT N
clinical JJ o
features NNS o
, , N
indicating VBG N
successful JJ o
treatment NN o
. . o

RESULTS NNP N
Three CD N
patients NNS N
were VBD N
lost VBN N
to TO N
follow-up JJ N
. . N

Treatment NN o
was VBD o
successful JJ o
in IN N
57 CD N
of IN N
64 CD N
patients NNS N
treated VBN N
with IN N
amoxicillin NN N
vs. FW N
58 CD N
of IN N
65 CD N
patients NNS N
treated VBN N
with IN N
erythromycin NN N
( ( N
P NNP N
= NNP N
0.00 CD N
) ) N
. . N

CONCLUSIONS NNP N
Amoxicillin NNP o
was VBD o
as RB o
efficacious JJ o
as IN N
erythromycin NN N
in IN N
the DT N
treatment NN o
of IN o
severe JJ o
pyoderma NN o
in IN p
Mali NNP p
. . p

Owing VBG N
to TO N
its PRP$ N
efficacy NN N
, , N
added VBD N
to TO N
high JJ N
availability NN N
and CC N
low JJ N
cost NN N
, , N
this DT N
compound NN N
should MD N
be VB N
considered VBN N
a DT N
first-line JJ N
treatment NN N
of IN N
this DT N
disorder NN N
in IN N
this DT N
country NN N
, , N
and CC N
perhaps RB N
in IN N
other JJ N
countries NNS N
where WRB N
this DT N
condition NN N
presents VBZ N
in IN N
a DT N
similar JJ N
way NN N
. . N

-DOCSTART- -6124226- O O

Neuroleptics NNS i
and CC p
depression NN o
. . o

-DOCSTART- -26148018- O O

Gluten NNP i
and CC i
casein JJ i
supplementation NN i
does VBZ N
not RB N
increase VB N
symptoms NNS N
in IN N
children NNS p
with IN p
autism NN p
spectrum NN p
disorder NN p
. . p

AIM VB N
A DT N
gluten- JJ i
and CC i
casein-free JJ i
diet NN i
is VBZ N
often RB N
given VBN N
to TO N
children NNS N
with IN N
autism NN N
spectrum NN N
disorder NN N
( ( N
ASD NNP N
) ) N
. . N

We PRP N
aimed VBD N
to TO N
determine VB N
the DT N
effect NN N
of IN N
gluten NN N
and CC N
casein JJ N
supplementation NN N
on IN N
maladaptive JJ N
behaviour NN N
, , N
gastrointestinal JJ N
symptom NN N
severity NN N
and CC N
intestinal JJ N
fatty JJ N
acids NNS N
binding VBG N
protein NN N
( ( N
I-FABP NNP N
) ) N
excretion NN N
in IN N
children NNS N
with IN N
ASD NNP N
. . N

METHODS NNP N
A DT N
randomised VBN N
, , N
controlled VBN N
, , N
double-blind JJ N
trial NN N
was VBD N
performed VBN N
on IN N
74 CD p
children NNS p
with IN p
ASD NNP p
with IN p
severe JJ p
maladaptive JJ p
behaviour NN p
and CC p
increased VBD p
urinary JJ p
I-FABP NNP p
. . p

Subjects NNS p
were VBD p
randomised VBN p
to TO p
receive VB p
gluten-casein NN i
or CC i
a DT i
placebo NN i
for IN p
seven CD p
days NNS p
. . p

We PRP N
evaluated VBD N
maladaptive JJ o
behaviour NN o
before IN N
and CC N
after IN N
supplementation NN N
, , N
using VBG N
I-FABP JJ N
excretion NN N
, , N
the DT N
approach NN N
withdrawal NN N
problem NN N
composite JJ N
subtest NN N
of IN N
the DT N
Pervasive NNP o
Developmental NNP o
Disorder NNP o
Behavior NNP o
Inventory NNP o
and CC o
the DT o
Gastrointestinal NNP o
Symptom NNP o
Severity NNP o
Index NNP o
. . o

RESULTS VB N
The DT N
mean JJ o
approach NN o
withdrawal NN o
problem NN o
composite JJ o
score NN o
was VBD N
significantly RB N
higher JJR N
before IN N
supplementation NN N
than IN N
after IN N
, , N
both DT N
in IN N
the DT N
placebo NN N
and CC N
in IN N
the DT N
gluten-casein JJ i
group NN N
. . N

However RB N
, , N
the DT N
mean JJ o
difference NN o
was VBD N
not RB N
significant JJ N
and CC N
may MD N
have VB N
been VBN N
caused VBN N
by IN N
additional JJ N
therapy NN N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
gastrointestinal JJ o
symptoms NNS o
and CC o
urinary JJ o
I-FABP NNP o
excretion NN o
. . o

CONCLUSION NNP N
Administrating VBG N
gluten-casein NN i
to TO N
children NNS N
with IN N
ASD NNP N
for IN N
one CD N
week NN N
did VBD N
not RB N
increase VB N
maladaptive JJ N
behaviour NN N
, , N
gastrointestinal JJ N
symptom NN N
severity NN N
or CC N
urinary JJ N
I-FABP JJ N
excretion NN N
. . N

The DT N
effect NN N
of IN N
prolonged JJ N
administration NN N
or CC N
other JJ N
mechanisms NNS N
of IN N
enterocyte JJ N
damage NN N
in IN N
ASD NNP N
should MD N
be VB N
explored VBN N
. . N

-DOCSTART- -11207836- O O

The DT N
effect NN N
of IN N
aging VBG N
on IN N
circulating VBG o
levels NNS o
of IN o
proinflammatory NN o
cytokines NNS o
during IN N
septic JJ p
shock NN p
. . p

Norasept NNP i
II NNP i
Study NNP N
Investigators NNP N
. . N

BACKGROUND NNP N
As IN N
the DT N
proportion NN N
of IN N
the DT N
population NN N
that WDT N
is VBZ N
older JJR N
continues VBZ N
to TO N
rise VB N
, , N
infection NN N
in IN N
older JJR p
people NNS p
has VBZ N
become VBN N
an DT N
important JJ N
healthcare NN N
problem NN N
. . N

Although IN N
aging VBG N
is VBZ N
associated VBN N
with IN N
multiple JJ N
abnormalities NNS N
in IN N
immune JJ N
function NN N
, , N
the DT N
effect NN N
of IN N
aging VBG N
on IN N
the DT N
production NN N
of IN N
proinflammatory NN o
cytokines NNS N
has VBZ N
not RB N
been VBN N
well RB N
studied VBN N
under IN N
conditions NNS N
of IN N
clinical JJ N
stress NN N
. . N

OBJECTIVES CC N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
examine VB N
the DT N
effect NN N
of IN N
aging VBG N
on IN N
circulating VBG o
levels NNS o
of IN o
the DT o
proinflammatory NN o
cytokines NNS o
in IN N
a DT N
large JJ N
cohort NN N
of IN N
septic JJ p
shock NN p
patients NNS p
. . p

We PRP N
hypothesized VBD N
that IN N
aging VBG N
would MD N
be VB N
associated VBN N
with IN N
a DT N
diminished JJ N
proinflammatory NN N
cytokine NN N
response NN N
to TO N
sepsis NN N
. . N

DESIGN NNP N
Patients NNPS p
with IN p
septic JJ p
shock NN p
who WP p
were VBD p
enrolled VBN p
in IN p
the DT p
placebo NN i
limb NN p
of IN p
the DT p
North JJ i
American JJ i
Sepsis NNP i
Trial NNP i
( ( i
NORASEPT NNP i
II NNP i
) ) i
study NN N
were VBD N
analyzed VBN N
. . N

SETTING VBG N
The DT N
intensive JJ N
care NN N
units NNS N
of IN N
105 CD N
hospitals NNS N
in IN N
the DT N
United NNP N
States NNPS N
and CC N
Canada NNP N
. . N

PARTICIPANTS NNP N
Nine NNP p
hundred VBD p
and CC p
thirty JJ p
patients NNS p
presenting VBG p
to TO p
hospital VB p
within IN p
12 CD p
hours NNS p
of IN p
the DT p
onset NN p
of IN p
septic JJ p
shock NN p
. . p

MEASUREMENTS NNP N
Interleukin-6 NNP o
( ( o
IL-6 NNP o
) ) o
, , o
tumor JJ o
necrosis NN o
factor-alpha NN o
( ( o
TNF-alpha NNP o
) ) o
, , o
soluble JJ o
tumor NN o
necrosis NN o
factor-receptor-55 JJ o
( ( o
sTNF-R55 JJ o
) ) o
, , o
and CC o
soluble JJ o
tumor NN o
necrosis NN o
factor-receptor-75 JJ o
( ( o
sTNF-R75 JJ o
) ) o
concentrations NNS o
were VBD N
measured VBN N
at IN N
enrollment NN N
. . N

The DT N
study NN N
population NN p
was VBD p
broken VBN p
down RP p
into IN p
five CD p
age NN p
groups NNS p
as IN p
follows VBZ p
: : p
less JJR p
than IN p
50 CD p
years NNS p
( ( p
group NN p
one CD p
) ) p
, , p
50 CD p
to TO p
64 CD p
years NNS p
( ( p
group NN p
two CD p
) ) p
, , p
65 CD p
to TO p
74 CD p
years NNS p
( ( p
group NN p
three CD p
) ) p
, , p
75 CD p
to TO p
84 CD p
years NNS p
( ( p
group NN p
four CD p
) ) p
, , p
and CC p
85 CD p
or CC p
older JJR p
( ( p
group NN p
five CD p
) ) p
. . p

Clinical JJ o
, , o
demographic JJ o
, , o
and CC o
cytokine NN o
data NNS o
were VBD N
extracted VBN N
to TO N
describe VB N
each DT N
age NN N
group NN N
. . N

RESULTS NNP N
Data NNP N
were VBD N
available JJ N
for IN N
930 CD p
patients NNS p
. . p

The DT N
patients NNS p
' POS p
mean JJ p
age NN p
( ( p
+/- JJ p
SD NNP p
) ) p
was VBD p
59 CD p
+/- JJ p
17 CD p
years NNS p
( ( p
range NN p
, , p
18 CD p
to TO p
102 CD p
) ) p
. . p

There EX N
were VBD N
280 CD p
patients NNS p
in IN p
group NN p
one CD p
, , p
242 CD p
in IN p
group NN p
two CD p
, , p
210 CD p
in IN p
group NN p
three CD p
, , p
150 CD p
in IN p
group NN p
four CD p
, , p
and CC p
48 CD p
in IN p
group NN p
five CD p
. . p

The DT N
primary JJ o
diagnoses NNS o
; : o
clinical JJ o
characteristics NNS o
; : o
and CC o
IL-6 NNP o
, , o
sTNF-R55 NN o
, , o
and CC o
sTNF-R75 JJ o
levels NNS o
were VBD N
similar JJ N
among IN N
the DT N
five CD N
age NN N
groups NNS N
. . N

The DT N
TNF-alpha JJ o
levels NNS o
were VBD N
significantly RB N
higher JJR N
, , N
however RB N
, , N
in IN N
the DT N
oldest JJS N
group NN N
of IN N
patients NNS N
( ( N
group NN N
five CD N
) ) N
. . N

The DT N
28-day JJ o
survival NN o
was VBD N
49 CD N
% NN N
in IN N
patients NNS N
over IN N
the DT N
age NN N
of IN N
75 CD N
and CC N
58 CD N
% NN N
in IN N
those DT N
under IN N
75 CD N
years NNS N
( ( N
P NNP N
= NNP N
.03 NNP N
) ) N
. . N

There EX N
was VBD N
no DT N
gender NN o
difference NN o
in IN N
survival NN o
or CC o
cytokine NN o
levels NNS o
. . o

CONCLUSIONS NNP N
Contrary NNP N
to TO N
our PRP$ N
expectations NNS N
, , N
we PRP N
found VBD N
that IN N
aging VBG N
was VBD N
not RB N
associated VBN N
with IN N
a DT N
decline NN N
in IN N
the DT N
circulating NN N
levels NNS N
of IN N
proinflammatory NN N
cytokines NNS N
. . N

-DOCSTART- -20149953- O O

Helping VBG N
women NNS N
make VBP N
choices NNS N
about IN N
mammography NN N
screening NN N
: : N
an DT N
online NN N
randomized VBN N
trial NN N
of IN N
a DT N
decision NN N
aid NN N
for IN N
40-year-old JJ p
women NNS p
. . p

OBJECTIVE NNP N
To TO N
evaluate VB N
the DT N
effect NN N
of IN N
a DT N
decision NN i
aid NN i
( ( i
DA NNP i
) ) i
on IN N
women NNS N
's POS N
knowledge NN N
of IN N
the DT N
benefits NNS N
and CC N
harms NNS N
of IN N
screening VBG N
and CC N
on IN N
their PRP$ N
ability NN N
to TO N
make VB N
an DT N
informed JJ N
decision NN N
. . N

METHODS NNP N
An DT N
online NN N
randomized VBN N
controlled VBN N
trial NN N
among IN N
321 CD p
women NNS p
aged VBN p
38-45 CD p
years NNS p
was VBD p
conducted VBN p
. . p

Participants NNS N
were VBD N
randomized VBN N
to TO N
either DT N
immediate JJ i
or CC i
delayed JJ i
access NN i
to TO i
the DT i
online NN i
DA NNP i
which WDT N
( ( N
i NN N
) ) N
explained VBD N
the DT N
benefits NNS N
and CC N
harms NNS N
, , N
( ( N
ii NN N
) ) N
included VBD N
a DT N
values NNS N
clarification NN N
exercise NN N
and CC N
a DT N
worksheet NN N
to TO N
support VB N
decision NN N
making NN N
. . N

The DT N
primary JJ N
outcome NN N
, , N
knowledge NN o
of IN o
benefits NNS o
and CC o
harms NNS o
of IN o
screening NN o
, , o
and CC o
secondary JJ o
outcomes NNS o
, , o
informed VBN o
choice NN o
( ( o
composite JJ o
of IN o
knowledge NN o
, , o
values NNS o
and CC o
intention NN o
) ) o
, , o
anxiety NN o
and CC o
acceptability NN o
of IN o
the DT o
DA NNP o
were VBD N
measured VBN N
using VBG N
online JJ N
questionnaires NNS N
. . N

RESULTS NNP N
Women NNP p
in IN p
the DT p
intervention NN p
group NN p
were VBD N
more RBR N
knowledgeable JJ o
( ( N
mean VB N
score NN N
out IN N
of IN N
10 CD N
, , N
7.35 CD N
vs NN N
6.27 CD N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
and CC N
were VBD N
more RBR N
likely JJ N
to TO N
have VB N
made VBN o
a DT o
decision NN o
( ( N
82 CD N
% NN N
vs JJ N
61 CD N
% NN N
p NN N
< NNP N
0.001 CD N
) ) N
. . N

Of IN N
those DT N
who WP N
made VBD N
a DT N
decision NN N
, , N
women NNS N
in IN N
the DT N
intervention NN N
group NN N
were VBD N
less RBR N
likely JJ N
to TO N
start VB o
screening VBG o
now RB o
( ( N
52 CD N
% NN N
vs JJ N
65 CD N
% NN N
p=0.05 NN N
) ) N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
the DT N
proportion NN o
of IN o
women NNS o
who WP o
made VBD o
an DT o
informed JJ o
choice NN o
( ( N
71 CD N
% NN N
intervention NN N
group NN N
vs VBD N
64 CD N
% NN N
control NN i
group NN N
, , N
p=0.24 NN N
) ) N
. . N

The DT N
DA NNP N
was VBD N
helpful JJ N
, , N
balanced JJ N
and CC N
clear JJ N
, , N
and CC N
did VBD N
not RB N
make VB N
women NNS N
anxious JJ o
. . o

CONCLUSIONS VB N
The DT N
DA NNP N
increased VBD N
knowledge NN o
and CC N
reduced JJ N
indecision NN o
, , N
without IN N
increasing VBG N
feelings NNS o
of IN o
anxiety NN o
. . o

PRACTICE NNP N
IMPLICATIONS NNP N
This DT N
decision NN N
aid NN N
is VBZ N
easy JJ N
to TO N
access NN N
online NN N
and CC N
could MD N
be VB N
an DT N
inexpensive JJ N
way NN N
of IN N
supporting VBG N
women NNS N
aged VBN N
40 CD N
who WP N
are VBP N
considering VBG N
whether IN N
to TO N
start VB N
screening VBG N
now RB N
, , N
or CC N
wait VBP N
until IN N
they PRP N
are VBP N
50 CD N
. . N

The DT N
results NNS N
of IN N
this DT N
study NN N
demonstrate VB N
the DT N
potential NN N
of IN N
DAs NNP N
to TO N
help VB N
inform VB N
women NNS N
about IN N
both DT N
the DT N
benefits NNS N
and CC N
risks NNS N
of IN N
screening VBG N
at IN N
this DT N
age NN N
and CC N
to TO N
support VB N
women NNS N
and CC N
clinicians NNS N
in IN N
this DT N
decision NN N
making VBG N
process NN N
. . N

-DOCSTART- -17912634- O O

Letrozole NNP i
in IN N
the DT N
neoadjuvant JJ N
setting NN N
: : N
the DT N
P024 NNP N
trial NN N
. . N

Neoadjuvant JJ i
chemotherapy NN i
trials NNS N
have VBP N
consistently RB N
reported VBN N
lower JJR N
response NN o
rates NNS o
in IN N
hormone NN N
receptor-positive JJ N
( ( N
HR+ NNP N
) ) N
breast NN N
cancer NN N
when WRB N
compared VBN N
with IN N
HR- NNP N
cases NNS N
. . N

Preoperative JJ i
endocrine NN i
therapy NN i
has VBZ N
therefore RB N
become VBN N
a DT N
logical JJ N
alternative NN N
and CC N
has VBZ N
gained VBN N
considerable JJ N
momentum NN N
from IN N
the DT N
finding NN N
that WDT N
aromatase NN i
inhibitors NNS i
( ( N
AIs NNP N
) ) N
are VBP N
more RBR N
effective JJ N
than IN N
tamoxifen NN i
for IN N
HR+ NNP N
breast NN N
cancer NN N
in IN N
both CC N
the DT N
neoadjuvant NN N
and CC N
adjuvant JJ N
settings NNS N
. . N

The DT N
most RBS N
convincing JJ N
neoadjuvant JJ N
trial NN N
to TO N
demonstrate VB N
the DT N
superiority NN N
of IN N
an DT N
AI NNP i
versus NN N
tamoxifen NN i
was VBD N
the DT N
P024 NNP N
study NN N
, , N
a DT N
large JJ N
multinational JJ p
double-blind JJ N
trial NN N
in IN N
postmenopausal JJ p
women NNS p
with IN p
HR+ NNP p
breast NN p
cancer NN p
ineligible JJ p
for IN p
breast-conserving JJ i
surgery NN i
. . i

The DT N
overall JJ o
response NN o
rate NN o
( ( o
ORR NNP o
) ) o
was VBD N
55 CD N
% NN N
for IN N
letrozole NN i
and CC N
36 CD N
% NN N
for IN N
tamoxifen NN i
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

Significantly RB N
more RBR N
letrozole-treated JJ N
patients NNS N
underwent JJ o
breast-conserving JJ o
surgery NN o
( ( N
45 CD N
vs. FW N
35 CD N
% NN N
, , N
respectively RB N
; : N
P=0.022 NNP N
) ) N
. . N

In IN N
addition NN N
, , N
ORR NNP o
was VBD N
significantly RB N
higher JJR N
with IN N
letrozole JJR N
than IN N
tamoxifen NN i
in IN N
the DT N
human JJ N
epidermal JJ N
growth NN N
factor NN N
receptor NN N
HER1/HER2+ NNP N
subgroup NN N
( ( N
P=0.0004 NNP N
) ) N
. . N

The DT N
clinical JJ o
efficacy NN o
of IN N
letrozole NN i
in IN N
HER2+ NNP N
breast NN N
cancer NN N
was VBD N
confirmed VBN N
by IN N
fluorescent NN N
in IN N
situ JJ N
hybridization NN N
analysis NN N
and CC N
was VBD N
found VBN N
to TO N
be VB N
comparable JJ N
to TO N
that DT N
of IN N
HER2- NNP N
cases NNS N
( ( N
ORR NNP N
71 CD N
% NN N
in IN N
both DT N
subsets NNS N
) ) N
. . N

Biomarker NNP o
studies NNS o
confirmed VBD N
the DT N
superiority NN N
of IN N
letrozole NN i
in IN N
centrally RB N
assessed VBN N
estrogen NN N
receptor-positive JJ N
( ( N
ER+ NNP N
) ) N
tumors NNS N
and CC N
found VBD N
a DT N
strong JJ N
relationship NN N
with IN N
the DT N
degree NN o
of IN o
ER NNP o
positivity NN o
for IN N
both DT N
agents NNS N
. . N

Interestingly RB N
, , N
letrozole NN i
was VBD N
effective JJ N
even RB N
in IN N
marginally RB N
ER+ NNP N
tumors NNS N
and CC N
, , N
unlike IN N
tamoxifen NN N
, , N
consistently RB N
reduced VBD N
the DT N
expression NN o
from IN o
estrogen-regulated JJ o
genes NNS o
( ( N
progesterone NN N
receptor NN N
and CC N
trefoil NN N
factor NN N
1 CD N
) ) N
. . N

Furthermore RB N
, , N
when WRB N
analyzed VBN N
by IN N
Ki67 NNP N
immunohistochemistry NN N
, , N
letrozole NN N
was VBD N
significantly RB N
more RBR N
effective JJ N
than IN N
tamoxifen NN N
in IN N
reducing VBG N
tumor NN o
proliferation NN o
( ( N
P=0.0009 NNP N
) ) N
. . N

Thus RB N
, , N
neoadjuvant JJ N
letrozole NN i
is VBZ N
safe JJ N
and CC N
superior JJ N
to TO N
tamoxifen VB i
in IN N
the DT N
treatment NN N
of IN N
postmenopausal JJ p
women NNS p
with IN p
HR+ NNP p
locally RB p
advanced VBD p
breast NN p
cancer NN p
. . p

-DOCSTART- -9553664- O O

The DT N
role NN N
of IN N
pneumatic JJ i
compression NN i
in IN N
the DT N
treatment NN N
of IN N
postmastectomy NN p
lymphedema NN p
. . p

A DT N
randomized JJ N
phase NN N
III NNP N
study NN N
. . N

BACKGROUND NNP N
Pneumatic NNP i
compression NN i
is VBZ N
a DT N
frequently RB N
prescribed VBN N
physical JJ N
therapy NN N
for IN N
patients NNS p
affected VBN p
by IN p
postmastectomy JJ p
lymphedema NN p
but CC N
, , N
despite IN N
its PRP$ N
wide JJ N
use NN N
, , N
its PRP$ N
efficacy NN N
has VBZ N
not RB N
been VBN N
demonstrated VBN N
in IN N
phase NN N
III NNP N
studies NNS N
. . N

We PRP N
performed VBD N
a DT N
randomized VBN N
study NN N
comparing VBG N
pneumatic JJ i
compression NN i
versus IN N
no DT N
treatment NN N
in IN N
patients NNS p
with IN p
postmastectomy JJ p
lymphedema NN p
. . p

PATIENTS NNP N
AND CC N
METHODS NNP N
Patients NNPS p
with IN p
monolateral JJ p
postmastectomy NN p
lymphedema NN p
were VBD N
randomized VBN N
to TO N
receive VB N
two CD N
cycles NNS N
of IN N
intermittent JJ N
pneumatic JJ i
compression NN i
( ( N
PC NNP N
group NN N
) ) N
, , N
i.e. FW N
, , N
five CD N
two-hour JJ N
sessions NNS N
per IN N
week NN N
for IN N
two CD N
weeks NNS N
, , N
to TO N
be VB N
repeated VBN N
after IN N
a DT N
five-week JJ N
interval NN N
, , N
or CC N
to TO N
no DT i
treatment NN i
( ( N
control VB N
group NN N
) ) N
. . N

The DT N
patients NNS N
in IN N
both DT N
groups NNS N
were VBD N
instructed VBN N
as IN N
to TO N
the DT N
prophylactic JJ N
hygienic NN N
care NN N
of IN N
the DT N
limb NN N
. . N

Lymphedema NNP o
was VBD N
assessed VBN N
by IN N
the DT N
sum NN N
of IN N
differences NNS N
in IN N
circumference NN o
measurements NNS o
between IN o
affected JJ o
and CC o
normal JJ o
limbs NNS o
( ( o
'delta NNP o
' POS o
) ) o
. . o

Response NNP N
was VBD N
defined VBN N
as IN N
a DT N
> NN N
or CC N
= VB N
25 CD N
% NN N
reduction NN N
in IN N
delta JJ N
value NN N
. . N

RESULTS NNP N
Eighty NNP p
patients NNS p
entered VBD N
the DT N
study NN N
. . N

No DT N
statistically RB N
significant JJ N
differences NNS N
in IN N
response NN o
rates NNS o
between IN N
the DT N
two CD N
groups NNS N
were VBD N
observed VBN N
: : N
20 CD N
% NN N
in IN N
the DT N
control NN N
group NN N
( ( N
95 CD N
% NN N
CI NNP N
: : N
9 CD N
% NN N
-36 NNP N
% NN N
) ) N
, , N
25 CD N
% NN N
in IN N
the DT N
PC NN N
group NN N
( ( N
95 CD N
% NN N
CI NNP N
: : N
13 CD N
% NN N
-41 CD N
% NN N
, , N
P NNP N
= NNP N
0.59 CD N
) ) N
. . N

The DT N
absolute JJ N
mean NN N
decrease NN o
in IN o
delta JJ o
value NN o
was VBD N
1.9 CD N
+/- JJ N
3.7 CD N
cm NN N
in IN N
the DT N
PC NN N
group NN N
and CC N
0.5 CD N
+/- JJ N
3.3 CD N
cm NN N
in IN N
the DT N
control NN N
group NN N
. . N

CONCLUSIONS NNP N
We PRP N
demonstrated VBD N
that IN N
intermittent JJ i
pneumatic JJ i
compression NN i
has VBZ N
a DT N
limited JJ N
clinical JJ N
role NN N
in IN N
the DT N
treatment NN N
of IN N
postmastectomy NN N
lymphedema NN N
. . N

Efforts NNS N
to TO N
prevent VB N
this DT N
complication NN N
should MD N
be VB N
undertaken VBN N
. . N

-DOCSTART- -2855516- O O

Strategies NNS N
for IN N
dietary JJ N
and CC N
anti-smoking JJ N
advice NN N
. . N

Practical JJ N
experiences NNS N
from IN N
the DT N
Oslo NNP N
Study NNP N
. . N

One CD N
of IN N
the DT N
2 CD N
controlled VBD N
preventive JJ N
trials NNS N
within IN N
the DT N
Oslo NNP N
Study NNP N
was VBD N
a DT N
non-drug JJ N
trial NN N
on IN N
the DT N
effect NN o
of IN o
diet NN o
and CC o
smoking VBG o
intervention NN o
on IN N
coronary JJ N
heart NN N
disease NN N
in IN N
1232 CD p
middleaged VBD p
, , p
normotensive JJ p
, , p
healthy JJ p
men NNS p
. . p

All DT N
had VBD N
elevated VBN N
serum NN N
cholesterol NN N
and CC N
4 CD N
out IN N
of IN N
5 CD N
smoked JJ N
every DT N
day NN N
. . N

The DT N
participants NNS N
in IN N
the DT N
intervention NN N
group NN N
met VBD N
every DT N
6 CD N
months NNS N
during IN N
the DT N
5-year JJ N
study NN N
for IN N
clinical JJ N
examination NN N
and CC N
for IN N
dietary JJ o
and CC o
smoking VBG o
counselling NN o
. . o

The DT N
effect NN o
on IN o
serum NN o
cholesterol NN o
was VBD N
a DT N
13 CD N
% NN N
lowering NN N
( ( N
i.e NN N
. . N

10 CD N
% NN N
net JJ N
reduction NN N
compared VBN N
with IN N
control NN N
group NN N
) ) N
, , N
and CC N
about IN N
a DT N
50 CD N
% NN N
reduction NN N
in IN N
cigarette NN o
consumption NN o
. . o

The DT N
effect NN o
on IN o
coronary JJ o
heart NN o
disease NN o
( ( o
fatal JJ o
and CC o
non-fatal JJ o
myocardial JJ o
infarction NN o
or CC o
sudden JJ o
death NN o
) ) o
was VBD N
a DT N
47 CD N
% NN N
lowering NN N
of IN N
the DT N
5-year JJ N
incidence NN N
in IN N
the DT N
intervention NN N
group NN N
compared VBN N
with IN N
the DT N
control NN N
group NN N
( ( N
p JJ N
= NN N
0.02 CD N
, , N
2-sided JJ N
) ) N
. . N

The DT N
main JJ N
intervention NN N
strategies NNS N
were VBD N
: : N
information NN N
about IN N
the DT N
risk NN N
factor NN N
concept NN N
to TO N
participant VB N
and CC N
spouse VB N
( ( N
in IN N
groups NNS N
) ) N
individual VBP i
diet JJ i
and CC i
anti-smoking JJ i
counselling NN i
after IN N
finishing VBG N
an DT N
extensive JJ N
clinical JJ N
and CC N
electrocardiographic JJ N
examination NN N
, , N
including VBG N
exercise-ECG JJ N
basis NN N
and CC N
background NN N
for IN N
the DT N
counselling NN N
strategy NN N
: : N
the DT N
total JJ N
situation NN N
of IN N
the DT N
participant NN N
. . N

Some DT N
of IN N
the DT N
most RBS N
important JJ N
items NNS N
: : N
personality NN N
, , N
motivation NN N
, , N
diet JJ N
history NN N
, , N
bodyweight NN N
, , N
blood NN N
lipids NNS N
and CC N
blood NN N
sugar NN N
anti-smoking JJ N
advice NN N
given VBN N
individually RB N
to TO N
all DT N
smokers NNS N
in IN N
the DT N
intervention NN N
group NN N
advice NN N
that IN N
smoking VBG N
cessation NN N
was VBD N
expected VBN N
to TO N
be VB N
of IN N
special JJ N
importance NN N
for IN N
those DT N
with IN N
elevated JJ N
blood NN N
lipids NNS N
. . N

-DOCSTART- -1497159- O O

Rapid-sequence JJ i
intubation NN i
of IN N
head NN p
trauma NN p
patients NNS p
: : p
prevention NN N
of IN N
fasciculations NNS o
with IN N
pancuronium NN i
versus NN N
minidose JJ i
succinylcholine NN i
. . i

INTRODUCTION NNP N
Fasciculations NNP o
during IN N
rapid-sequence JJ N
intubation NN N
may MD N
lead VB N
to TO N
increased VBN N
intracranial JJ N
pressure NN N
and CC N
emesis NN o
with IN N
aspiration NN N
. . N

Standard NNP N
rapid-sequence NN N
intubation NN N
requires VBZ N
a DT N
nondepolarizing JJ N
blocking NN N
agent NN N
before IN N
succinylcholine JJ i
administration NN i
. . i

HYPOTHESIS NNP N
Prevention NNP N
of IN N
fasciculations NNS o
during IN N
rapid-sequence JJ N
intubation NN N
of IN N
head NN p
trauma IN p
patients NNS p
can MD N
be VB N
accomplished VBN N
as IN N
safely RB N
and CC N
effectively RB N
with IN N
minidose JJ N
succinylcholine NN i
as IN N
with IN N
a DT N
defasciculating VBG N
dose NN N
of IN N
pancuronium NN N
. . N

DESIGN VB N
A DT N
prospective JJ N
, , N
randomized VBN N
, , N
double-blind JJ N
study NN N
. . N

SETTING VBG N
An DT N
inner-city JJ p
county NN p
trauma NN p
center NN p
with IN p
70,000 CD p
patient JJ p
visits NNS p
per IN p
year NN p
. . p

PARTICIPANTS NNP N
Sequential NNP p
adult NN p
head NN p
trauma NN p
patients NNS p
requiring VBG p
rapid-sequence JJ p
intubation NN p
who WP p
had VBD p
no DT p
contraindications NNS p
to TO p
succinylcholine VB i
or CC p
pancuronium VB i
. . i

INTERVENTIONS NNP N
Each DT N
head NN p
trauma NN p
patient JJ p
requiring VBG N
rapid-sequence NN N
intubation NN N
who WP N
met VBD N
the DT N
inclusion NN N
criteria NNS N
received VBD N
standard JJ N
rapid-sequence NN i
intubation NN i
maneuvers NNS i
and CC N
lidocaine NN i
( ( N
1 CD N
mg/kg NN N
) ) N
IV NNP N
. . N

Patients NNS N
were VBD N
randomized VBN N
to TO N
receive VB N
either RB N
minidose JJ i
succinylcholine NN i
( ( i
0.1 CD i
mg/kg NN i
) ) i
or CC i
pancuronium NN i
( ( N
0.03 CD N
mg/kg NN N
) ) N
IV NNP N
one CD N
minute NN N
prior RB N
to TO N
the DT N
full JJ i
paralytic JJ i
dose NN i
of IN i
succinylcholine NN i
( ( N
1.5 CD N
mg/kg NN N
) ) N
IV NNP N
. . N

Fasciculations NNS o
were VBD N
recorded VBN N
using VBG N
a DT N
graded JJ o
visual JJ o
scale NN o
. . o

RESULTS NNP N
Of IN N
46 CD p
patients NNS p
, , N
eight CD N
of IN N
19 CD N
( ( N
42 CD N
% NN N
) ) N
in IN N
the DT N
pancuronium NN i
group NN N
and CC N
six CD N
of IN N
27 CD N
( ( N
22 CD N
% NN N
) ) N
in IN N
the DT N
succinylcholine NN i
group NN N
experienced VBD N
fasciculations NNS o
. . o

No DT N
statistically RB N
significant JJ N
difference NN N
in IN N
fasciculations NNS o
was VBD N
detected VBN N
between IN N
the DT N
two CD N
groups NNS N
using VBG N
chi JJ N
2 CD N
analysis NN N
. . N

Complete JJ o
relaxation NN o
of IN o
the DT o
cords NNS o
was VBD N
present JJ N
in IN N
all DT N
but CC N
two CD N
patients NNS N
, , N
one CD N
in IN N
each DT N
group NN N
. . N

No DT N
patient NN N
in IN N
either DT N
group NN N
experienced VBD N
emesis NN o
or CC o
significant JJ o
dysrhythmias NN o
. . o

CONCLUSION NNP N
Pretreatment NNP N
with IN N
minidose JJ N
succinylcholine JJ i
causes VBZ N
no DT N
greater JJR N
incidence NN N
of IN N
fasciculations NNS o
than IN N
pancuronium NN i
in IN N
rapid-sequence JJ N
intubation NN N
of IN N
head NN p
trauma NN p
patients NNS p
in IN p
an DT p
ED NNP p
setting NN p
. . p

Thus NNP N
succinylcholine NN i
may MD N
be VB N
used VBN N
as IN N
the DT N
sole JJ N
paralytic JJ N
agent NN N
in IN N
rapid-sequence JJ N
intubation NN N
of IN N
head NN N
trauma NN N
patients NNS N
. . N

-DOCSTART- -6752752- O O

[ JJ i
Treatment NNP i
of IN i
the DT i
hyperkinetic JJ i
response NN i
to TO i
exercise NN i
after IN p
myocardial JJ p
infarct NN p
. . p

Results NNS N
of IN N
a DT N
randomized JJ N
ergometric NN N
study NN N
] NNP N
. . N

-DOCSTART- -17917935- O O

A DT N
randomized JJ N
parallel NN N
study NN N
to TO N
assess VB N
the DT N
safety NN o
and CC o
efficacy NN o
of IN N
two CD N
different JJ N
dosing VBG N
regimens NNS N
of IN N
5 CD N
% NN N
imiquimod NN i
in IN N
the DT N
treatment NN N
of IN N
superficial JJ p
basal NN p
cell NN p
carcinoma NN p
. . p

OBJECTIVES CC N
This DT N
study NN N
was VBD N
designed VBN N
to TO N
compare VB N
the DT N
safety NN o
and CC o
efficacy NN o
of IN N
two CD N
cycled VBD N
dosing VBG N
regimens NNS N
of IN N
imiquimod JJ i
5 CD N
% NN N
cream NN N
for IN N
treatment NN N
of IN N
superficial JJ p
basal NN p
cell NN p
carcinoma NN p
( ( p
sBCC NN p
) ) p
. . p

METHODS JJ N
Patients NNPS p
( ( p
n JJ p
= NNP p
32 CD p
) ) p
were VBD N
randomized VBN N
to TO N
receive VB N
one CD N
of IN N
two CD N
treatment NN N
regimens NNS N
: : N
8 CD i
weeks NNS i
of IN i
treatment NN i
with IN i
once-daily JJ i
dosing VBG i
for IN i
alternate JJ i
weeks NNS i
( ( i
R1 NNP i
) ) i
and CC i
5 CD i
weeks NNS i
of IN i
once-daily JJ i
dosing NN i
with IN i
a DT i
1-week JJ i
interval NN i
in IN i
the DT i
middle NN i
of IN i
the DT i
course NN i
( ( N
R2 NNP N
) ) N
. . N

Efficacy NN N
measures NNS N
were VBD N
tumour JJ o
clearance NN o
at IN N
weeks NNS N
19 CD N
and CC N
52 CD N
and CC N
measures NNS o
of IN o
patients NNS o
' POS o
acceptability NN o
. . o

RESULTS NNP N
Data NNP N
from IN N
30 CD p
patients NNS p
( ( p
13 CD p
females NNS p
) ) p
, , p
14 CD p
on IN p
R1 NNP p
and CC p
16 CD p
on IN p
R2 NNP p
, , N
were VBD N
analysed VBN N
. . N

The DT N
results NNS N
revealed VBD N
an DT N
initial JJ N
clearance NN o
rate NN o
of IN N
64 CD N
% NN N
at IN N
week NN N
19 CD N
for IN N
R1 NNP N
and CC N
81 CD N
% NN N
for IN N
R2 NNP N
( ( N
95 CD N
% NN N
CI NNP N
for IN N
difference NN N
: : N
-14 NN N
% NN N
to TO N
45 CD N
% NN N
, , N
p NN N
= NNP N
0.21 CD N
) ) N
. . N

However RB N
, , N
clearance NN o
rates NNS o
at IN N
week NN N
52 CD N
were VBD N
significantly RB N
different JJ N
: : N
43 CD N
% NN N
for IN N
R1 NNP N
and CC N
88 CD N
% NN N
for IN N
R2 NNP N
( ( N
95 CD N
% NN N
CI NNP N
for IN N
difference NN N
: : N
11 CD N
% NN N
to TO N
68 CD N
% NN N
, , N
p NN N
= NNP N
0.02 CD N
) ) N
. . N

There EX N
was VBD N
no DT N
difference NN N
in IN N
acceptability NN o
of IN o
treatment NN o
as IN N
measured VBN N
by IN N
composite JJ N
median JJ N
visual JJ N
analogue NN N
scores NNS N
at IN N
week NN N
8 CD N
. . N

CONCLUSION NNP N
Five NNP N
weeks NNS N
of IN N
5 CD N
% NN N
imiquimod JJ i
cream NN N
once RB N
daily JJ N
with IN N
a DT N
1-week JJ N
interval NN N
was VBD N
more RBR N
effective JJ o
but CC N
as RB N
well RB o
tolerated VBN o
as IN N
the DT N
8-week JJ N
alternate NN N
week NN N
regimen NNS N
for IN N
sBCC NN p
. . p

-DOCSTART- -21915543- O O

Functional JJ N
outcome NN N
following VBG N
intramedullary JJ i
nailing NN i
of IN i
the DT i
femur NN i
: : i
a DT N
prospective JJ N
randomized VBN N
comparison NN N
of IN N
piriformis NN N
fossa NN N
and CC N
greater JJR N
trochanteric JJ N
entry NN N
portals NNS N
. . N

BACKGROUND IN N
The DT N
purpose NN N
of IN N
the DT N
study NN N
was VBD N
to TO N
prospectively RB N
compare VB N
the DT N
functional JJ N
outcome NN N
of IN N
intramedullary JJ i
nailing NN i
of IN i
the DT i
femur NN i
performed VBD N
with IN N
use NN N
of IN N
a DT N
trochanteric NN N
and CC N
a DT N
piriformis NN N
fossa NN N
entry NN N
portal NN N
. . N

METHODS NNP N
One CD p
hundred CD p
and CC p
ten JJ p
patients NNS p
with IN p
a DT p
femoral JJ p
shaft NN p
fracture NN p
were VBD p
enrolled VBN p
in IN p
a DT p
prospective JJ p
, , p
randomized VBN p
study NN p
. . p

Fifty-four CD p
patients NNS p
were VBD N
randomized VBN N
to TO N
Group NNP N
A NNP N
( ( i
piriformis JJ i
fossa NN i
portal NN i
) ) i
and CC N
fifty-six JJ p
to TO N
Group NNP N
B NNP N
( ( i
trochanteric JJ i
portal NN i
) ) i
. . N

Outcome NNP N
measures NNS N
included VBD N
the DT N
Western NNP N
Ontario NNP N
and CC N
McMaster NNP N
Universities NNP N
( ( N
WOMAC NNP N
) ) N
Osteoarthritis NNP N
Index NNP N
hip NN N
function NN N
score NN N
, , N
pain NN N
, , N
and CC N
blinded VBD N
functional JJ N
evaluation NN N
by IN N
a DT N
physical JJ N
therapist NN N
. . N

RESULTS NNP N
Most JJS N
measures NNS N
of IN N
hip NN N
function NN N
did VBD N
not RB N
differ VB N
between IN N
the DT N
two CD N
groups NNS N
. . N

The DT N
WOMAC NNP o
score NN o
at IN N
three CD N
, , N
six CD N
, , N
and CC N
twelve JJ N
months NNS N
did VBD N
not RB N
differ VB N
significantly RB N
between IN N
the DT N
piriformis NN N
fossa NN N
and CC N
trochanteric JJ N
nailing NN N
groups NNS N
. . N

Functional JJ N
tests NNS N
included VBD N
the DT N
chair NN N
stand VBP N
test NN N
and CC N
the DT N
timed VBN N
up RP N
and CC N
go VB N
test NN N
. . N

Patients NNS N
in IN N
Group NNP N
B NNP N
had VBD N
significantly RB N
better JJR N
scores NNS N
on IN N
the DT N
chair NN o
stand VBP o
test NN o
( ( N
13.3 CD N
compared VBN N
with IN N
11.1 CD N
in IN N
Group NNP N
A NNP N
, , N
p NN N
= NNP N
0.04 CD N
) ) N
at IN N
six CD N
months NNS N
postoperatively RB N
, , N
but CC N
there EX N
was VBD N
no DT N
difference NN N
at IN N
twelve JJ N
months NNS N
( ( N
14.0 CD N
compared VBN N
with IN N
13.6 CD N
) ) N
. . N

The DT N
two CD N
groups NNS N
did VBD N
not RB N
differ VB N
significantly RB N
on IN N
the DT N
timed VBN N
up RP N
and CC N
go VB N
test NN N
at IN N
either DT N
six CD N
or CC N
twelve VB N
months NNS N
. . N

The DT N
two CD N
groups NNS N
also RB N
did VBD N
not RB N
differ VB N
on IN N
the DT N
muscle NN o
strength NN o
testing VBG o
. . o

Intraoperative JJ N
parameters NNS N
differed VBD N
significantly RB N
between IN N
the DT N
groups NNS N
with IN N
respect NN o
to TO o
operative JJ o
time NN o
, , o
fluoroscopy JJ o
time NN o
, , o
and CC o
incision NN o
length NN o
, , N
with IN N
the DT N
difference NN N
favoring VBG N
Group NNP N
B NNP N
for IN N
each DT N
parameter NN N
. . N

Analog NNP N
pain VBP o
scale JJ o
values NNS o
were VBD N
similar JJ N
in IN N
Group NNP N
A NNP N
( ( N
2.49 CD N
) ) N
and CC N
Group NNP N
B NNP N
( ( N
2.15 CD N
) ) N
at IN N
twelve JJ N
months NNS N
postoperatively RB N
. . N

CONCLUSIONS JJ N
Patients NNPS N
in IN N
our PRP$ N
prospective JJ N
randomized VBN N
study NN N
who WP N
were VBD N
treated VBN N
with IN N
trochanteric JJ N
nailing VBG N
did VBD N
not RB N
differ VB N
in IN N
hip NN o
function NN o
at IN N
one CD N
year NN N
postoperatively RB N
compared VBN N
with IN N
patients NNS N
treated VBN N
with IN N
intramedullary JJ i
nailing VBG i
through IN N
the DT N
piriformis NN N
fossa NN N
. . N

The DT N
values NNS o
of IN o
several JJ o
intraoperative JJ o
parameters NNS o
were VBD N
significantly RB N
better RBR N
in IN N
the DT N
trochanteric JJ N
nailing NN N
group NN N
. . N

Our PRP$ N
data NNS N
indicate VBP N
that IN N
the DT N
functional JJ N
hip NN N
outcome NN N
of IN N
femoral JJ N
intramedullary JJ N
nailing NN N
performed VBN N
through IN N
the DT N
greater JJR N
trochanter NN N
is VBZ N
equal JJ N
to TO N
that DT N
of IN N
intramedullary JJ i
nailing NN i
performed VBN N
through IN N
the DT N
piriformis NN N
fossa NN N
. . N

-DOCSTART- -2224810- O O

Recombinant JJ i
human JJ i
erythropoietin NN i
. . i

-DOCSTART- -16044227- O O

Investigation NN p
of IN p
maxillary JJ o
tooth NN o
sizes NNS o
in IN p
patients NNS p
with IN p
palatal JJ p
canine NN p
displacement NN p
. . p

AIM IN N
The DT N
aim NN N
of IN N
this DT N
retrospective JJ N
trial NN N
was VBD N
to TO N
investigate VB N
differences NNS N
in IN N
mesiodistal JJ N
and CC N
vestibulo-oral JJ N
crown NN N
sizes NNS N
of IN N
naturally RB N
, , N
fully-erupted JJ N
permanent JJ N
maxillary JJ N
teeth NNS N
between IN N
patients NNS p
with IN p
and CC p
without IN p
palatal JJ p
canine NN p
displacement NN p
. . p

PATIENTS NNP N
AND CC N
METHOD NNP N
115 CD p
patients NNS p
( ( p
mean JJ p
age NN p
: : p
14 CD p
years NNS p
10 CD p
months NNS p
; : p
females NNS p
: : p
77 CD p
males NNS p
: : p
38 CD p
) ) p
treated VBN p
in IN p
the DT p
Department NNP p
of IN p
Orthodontics NNP p
, , p
University NNP p
of IN p
Munich NNP p
were VBD p
included VBN p
in IN p
the DT p
study NN p
. . p

65 CD p
of IN p
the DT p
patients NNS p
showed VBD p
at IN p
least JJS p
one CD p
palatally-displaced JJ p
canine NN p
. . p

Diagnosis NN p
and CC p
the DT p
location NN p
of IN p
the DT p
displacement NN p
were VBD p
determined VBN p
on IN p
the DT p
basis NN p
of IN p
standardized JJ i
radiographs NN i
and CC p
confirmed VBN p
by IN p
surgical JJ p
documentation NN p
. . p

Each DT p
maxillary JJ p
tooth NN p
's POS p
mesiodistal JJ p
and CC p
vestibulo-oral JJ p
width NN p
was VBD p
measured VBN p
using VBG p
a DT p
dial JJ i
caliper NN i
on IN p
each DT p
dental JJ p
cast NN p
. . p

Excluded VBN p
were VBD p
partially-erupted JJ p
teeth NNS p
and CC p
surfaces NNS p
with IN p
caries NNS p
or CC p
restorations NNS p
that WDT p
had VBD p
to TO p
be VB p
measured VBN p
. . p

An DT N
analysis NN N
of IN N
available JJ N
space NN N
was VBD N
made VBN N
by IN N
evaluating VBG N
the DT N
pre-treatment JJ N
dental JJ N
casts NNS N
of IN N
all DT N
patients NNS N
included VBN N
in IN N
the DT N
study NN N
. . N

RESULTS NNP N
Comparing VBG N
the DT N
tooth JJ o
widths NNS o
of IN N
patients NNS N
with IN N
unilateral JJ N
canine NN N
displacement NN N
with IN N
the DT N
corresponding JJ N
contralateral JJ N
quadrants NNS N
, , N
we PRP N
noted VBD N
a DT N
statistically RB N
significant JJ N
difference NN N
, , N
namely RB N
that IN N
the DT N
central JJ N
and CC N
lateral JJ N
incisors NNS N
and CC N
the DT N
canines NNS N
of IN N
the DT N
affected JJ N
side NN N
were VBD N
narrower JJR N
than IN N
those DT N
of IN N
the DT N
non-affected JJ N
side NN N
in IN N
the DT N
same JJ N
patient NN N
. . N

Moreover RB N
, , N
the DT N
displaced JJ N
upper JJ N
canines NNS N
showed VBD N
an DT N
increase NN N
in IN N
vestibulo-oral JJ o
dimension NN o
. . o

Overall JJ o
tooth JJ o
width NN o
( ( N
including VBG N
all DT N
tooth DT N
groups NNS N
) ) N
in IN N
patients NNS N
with IN N
palatally-displaced JJ N
canines NNS N
was VBD N
significantly RB N
less JJR N
than IN N
that DT N
in IN N
the DT N
control NN N
group NN N
. . N

However RB N
, , N
when WRB N
comparing VBG N
the DT N
crown JJ o
diameters NNS o
of IN N
unilaterally- JJ N
and CC N
bilaterally-affected JJ N
patients NNS N
, , N
no DT N
differences NNS N
in IN N
tooth-size NN o
were VBD N
observed VBN N
. . N

The DT N
space-analysis NN N
showed VBD N
excessive JJ N
dental-arch JJ o
space NN o
in IN N
patients NNS N
with IN N
a DT N
palatally-displaced JJ N
canine NN N
. . N

CONCLUSION NNP N
Patients NNPS N
affected VBN N
by IN N
palatal JJ N
canine NN N
displacement NN N
showed VBD N
significantly RB N
smaller JJR N
maxillary JJ N
tooth DT N
size NN N
. . N

-DOCSTART- -17880325- O O

Timing NN o
of IN o
death NN o
and CC o
myocardial JJ o
infarction NN o
in IN p
patients NNS p
with IN p
non-ST JJ p
elevation NN p
acute NN p
coronary JJ p
syndromes NNS p
: : p
insights NNS N
from IN N
randomized VBN N
clinical JJ N
trials NNS N
. . N

BACKGROUND NNP N
Adverse NNP N
events NNS N
occur VBP N
following VBG N
non-ST JJ p
elevation NN p
acute NN p
coronary JJ p
syndromes NNS p
( ( p
NSTE NNP p
ACS NNP p
) ) p
. . p

However RB N
, , N
the DT N
timing NN N
of IN N
these DT N
events NNS N
in IN N
relation NN N
to TO N
index NN N
event NN N
is VBZ N
less RBR N
clear JJ N
. . N

METHODS NNP N
Accordingly RB N
, , N
we PRP p
evaluated VBD p
26,466 CD p
NSTE NNP p
ACS NNP p
patients NNS p
from IN p
the DT p
Global NNP p
Use NNP p
of IN p
Strategies NNPS p
to TO p
Open VB p
Occluded NNP p
Arteries NNPS p
in IN p
Acute NNP p
Coronary NNP p
Syndromes NNP p
( ( p
GUSTO-IIb NNP p
) ) p
, , p
Platelet NNP i
Glycoprotein NNP i
IIb/IIIa NNP i
in IN p
Unstable JJ p
Angina NNP p
: : p
Receptor NNP i
Suppression NNP i
Using NNP i
Integrilin NNP i
Therapy NNP i
( ( N
PURSUIT NNP N
) ) N
, , N
and CC N
Platelet NNP i
IIb/IIIa NNP i
Antagonism NNP i
for IN N
the DT N
Reduction NNP N
of IN N
Acute NNP N
Coronary NNP N
Syndrome NNP N
Events NNP N
in IN N
a DT N
Global NNP N
Organization NNP N
Network NNP N
( ( N
PARAGON NNP N
) ) N
A NNP N
and CC N
B NNP N
trials NNS N
to TO N
ascertain VB N
the DT N
timing NN N
of IN N
adverse JJ N
events NNS N
. . N

Outcomes NNS N
of IN N
interest NN N
were VBD N
death NN o
, , o
myocardial JJ o
infarction NN o
( ( o
MI NNP o
) ) o
, , o
and CC o
death NN o
or CC o
MI NNP o
at IN o
180 CD o
days NNS o
. . o

Logistic JJ i
regression NN i
modeling VBG i
for IN N
death NN N
was VBD N
used VBN N
to TO N
categorize VB N
patients NNS N
into IN N
low- JJ N
, , N
medium- JJ N
, , N
and CC N
high-risk JJ N
groups NNS N
. . N

RESULTS NNP N
At IN N
6 CD N
months NNS N
, , N
6.2 CD N
% NN N
of IN N
patients NNS N
died VBD o
, , N
12.1 CD N
% NN N
had VBD N
MI NNP o
, , N
and CC N
15.7 CD N
% NN N
suffered VBD N
death NN o
or CC o
MI NNP o
. . o

From IN N
15 CD N
% NN N
to TO N
40 CD N
% NN N
of IN N
these DT N
events NNS N
occurred VBD N
beyond IN N
30 CD N
days NNS N
. . N

At IN N
6 CD N
months NNS N
, , N
3 CD N
% NN N
, , N
4 CD N
% NN N
, , N
and CC N
13 CD N
% NN N
of IN N
patients NNS N
died VBN N
in IN N
low- JJ N
, , N
medium- JJ N
, , N
and CC N
high-risk JJ N
groups NNS N
, , N
respectively RB N
. . N

However RB N
, , N
the DT N
proportion NN o
of IN o
patients NNS o
dying VBG o
beyond IN N
30 CD N
days NNS N
was VBD N
similar JJ N
in IN N
the DT N
three CD N
groups NNS N
( ( N
44 CD N
% NN N
, , N
43 CD N
% NN N
, , N
and CC N
41 CD N
% NN N
of IN N
death NN N
, , N
respectively RB N
) ) N
. . N

Similarly RB N
, , N
whereas JJ N
death NN o
or CC o
MI NNP o
increased VBD N
with IN N
higher JJR N
risk NN N
( ( N
11 CD N
% NN N
, , N
14 CD N
% NN N
, , N
and CC N
23 CD N
% NN N
, , N
respectively RB N
) ) N
, , N
the DT N
proportion NN o
of IN o
patients NNS o
with IN N
this DT N
event NN N
beyond IN N
30 CD N
days NNS N
did VBD N
not RB N
differ VB N
in IN N
the DT N
three CD N
strata NNS N
( ( N
22 CD N
% NN N
, , N
20 CD N
% NN N
, , N
and CC N
25 CD N
% NN N
, , N
respectively RB N
) ) N
. . N

CONCLUSIONS NNP N
Our PRP$ N
study NN N
provides VBZ N
important JJ N
insights NNS N
into IN N
the DT N
timing NN N
of IN N
adverse JJ N
events NNS N
and CC N
suggests VBZ N
that IN N
the DT N
substantial JJ N
proportion NN N
of IN N
patients NNS N
suffer VBP N
subsequent JJ N
adverse JJ N
events NNS N
after IN N
their PRP$ N
index NN N
NSTE NNP N
ACS NNP N
. . N

Thus RB N
, , N
these DT N
data NNS N
call NN N
for IN N
continuous JJ N
surveillance NN N
for IN N
these DT N
events NNS N
and CC N
efforts NNS N
beyond IN N
the DT N
acute JJ N
phase NN N
at IN N
increasing VBG N
adherence NN N
to TO N
evidence-based JJ N
therapies NNS N
to TO N
improve VB N
the DT N
outcomes NNS N
of IN N
these DT N
patients NNS N
. . N

-DOCSTART- -1488874- O O

Oscillatory NN p
potentials NNS p
, , p
retinopathy NN p
, , p
and CC p
long-term JJ p
glucose NN p
control NN p
in IN p
insulin-dependent JJ p
diabetes NNS p
. . p

The DT N
main JJ N
objective NN N
of IN N
the DT N
study NN N
was VBD N
to TO N
assess JJ N
effects NNS N
of IN N
long-term JJ i
lowering NN i
of IN i
glucosylated JJ o
hemoglobin NN o
( ( i
HbA1 NNP i
% NN i
) ) i
on IN N
neurosensory JJ N
function NN N
in IN N
insulin-dependent JJ p
diabetes NNS p
. . p

Individual NNP i
( ( i
OP-1 NNP i
, , i
OP-2 NNP i
, , i
OP-3 NNP i
) ) i
and CC i
summed VBN i
( ( i
OP-sum NNP i
) ) i
amplitudes NNS i
of IN i
oscillatory JJ i
potentials NNS i
( ( i
OPs NNP i
) ) i
of IN i
electroretinography NN i
were VBD i
recorded VBN i
at IN N
study JJ N
start NN N
and CC N
7-years NNS N
later RB N
in IN N
45 CD p
patients NNS p
( ( N
the DT N
Oslo NNP p
study NN N
) ) N
. . N

As IN N
an DT N
overall JJ N
7-year JJ N
change NN N
, , N
amplitudes NNS o
of IN o
OP-2 NNP o
, , o
OP-3 NNP o
and CC o
OP-sum NNP o
were VBD o
reduced VBN o
( ( N
p JJ N
< NNP N
0.0001-0.01 NN N
) ) N
, , N
retinopathy JJ o
worsened VBD o
( ( N
p JJ N
= NNP N
0.005 CD N
) ) N
, , N
intraocular JJ o
pressure NN o
decreased VBN o
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
, , N
systolic JJ o
blood NN o
pressure NN o
increased VBD o
( ( N
p JJ N
< NNP N
0.0002 CD N
) ) N
, , N
and CC N
glycemic JJ o
control NN o
improved VBN N
from IN N
HbA1 NNP N
of IN N
11.2 CD N
+/- JJ N
2.2 CD N
% NN N
at IN N
study JJ N
start NN N
to TO N
a DT N
7-year JJ N
cumulative JJ N
mean NN N
of IN N
9.5 CD N
+/- JJ N
1.5 CD N
% NN N
( ( N
p JJ N
< NNP N
0.0001 CD N
) ) N
. . N

Multiple JJ N
regression NN N
analysis NN N
did VBD N
not RB N
identify VB N
any DT N
independent JJ N
relations NNS N
between IN N
change NN N
in IN N
OP-1 NNP o
, , o
OP-2 NNP o
, , o
OP-3 NNP o
, , o
OP-sum NNP o
and CC N
change NN o
in IN o
glycemic JJ o
control NN o
or CC o
background NN o
variables NNS o
, , N
including VBG N
change NN N
in IN N
age NN N
and CC N
duration NN N
of IN N
diabetes NNS N
. . N

However RB N
, , N
cross-sectional JJ N
observations NNS N
at IN N
7 CD N
years NNS N
showed VBD N
negative JJ N
correlations NNS N
between IN N
all DT N
OPs NNP o
and CC N
age NN N
( ( N
p JJ N
< NNP N
0.0001-0.003 NN N
) ) N
, , N
and CC N
between IN N
OP-3 NNP o
and CC o
duration NN o
( ( N
p JJ N
= NNP N
0.003 CD N
) ) N
and CC N
counts NNS o
of IN o
microaneurysms NNS o
( ( N
p JJ N
= NNP N
0.02 CD N
) ) N
. . N

The DT N
data NN N
suggest NN N
that IN N
various JJ N
clinical JJ N
background NN N
variables NNS N
may MD N
influence VB N
individual JJ N
and CC N
summed VBD N
amplitudes NNS N
of IN N
OPs NNP N
differently RB N
. . N

Reduced NNP o
neurosensory JJ o
retinal JJ o
function NN o
( ( o
OPs NNP o
) ) o
seemed VBD N
to TO N
appear VB N
after IN N
7-years NNS N
, , N
independently RB N
of IN N
vascular JJ o
defects NNS o
of IN o
retinopathy JJ o
and CC N
long-term JJ o
improvement NN o
in IN o
glucose JJ o
control NN o
. . o

-DOCSTART- -15278032- O O

[ JJ N
Tension-free NNP N
laparoscopic NN N
versus NN N
open JJ i
inguinal JJ i
hernia NN i
repair NN i
] NNP i
. . N

AIM NNP N
During IN N
the DT N
last JJ N
decade NN N
laparoscopic NN N
techniques NNS N
have VBP N
been VBN N
applied VBN N
to TO N
the DT N
treatment NN N
of IN N
inguinal JJ o
hernia NN o
to TO N
combine VB N
tension-free JJ N
technique NN N
, , N
esthetic JJ N
, , N
and CC N
functional JJ N
benefits NNS N
of IN N
mini-invasive JJ N
surgery NN N
. . N

Anyway NNP N
controversy NN N
persists VBZ N
regarding VBG N
the DT N
most RBS N
effective JJ o
inguinal JJ N
hernia NN N
repair NN N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
is VBZ N
to TO N
compare VB N
the DT N
open JJ N
technique NN N
and CC N
the DT N
laparoscopic NN N
approach NN N
concerning NN N
: : N
complications NNS o
, , o
recurrences NNS o
, , o
recovery NN o
time NN o
and CC o
return NN o
to TO o
usual JJ o
activity NN o
. . o

METHODS CC N
A DT N
randomized JJ p
prospective JJ p
analysis NN p
of IN p
121 CD p
consecutive JJ p
inguinal JJ i
hernia NN i
repairs NNS i
was VBD p
performed VBN p
over IN p
a DT p
12-month JJ p
period NN p
. . p

Male JJ p
well-informed JJ p
patients NNS p
with IN p
primary JJ p
monolateral JJ p
inguinal JJ p
hernia NN p
( ( p
ASA NNP p
I-II NNP p
) ) p
were VBD N
divided VBN N
into IN N
2 CD p
groups NNS p
and CC N
consecutively RB N
treated VBD N
; : N
group NN p
A DT p
was VBD N
treated VBN N
with IN N
laparoscopic JJ i
transabdominal JJ i
preperitoneal NN i
approach NN i
( ( p
TAPP NNP p
) ) p
( ( p
median JJ p
age NN p
47+/-7 JJ p
years NNS p
, , p
57 CD p
patients NNS p
) ) p
, , p
group NN p
B NNP p
with IN N
open JJ i
mesh NN i
herniorrhaphy NN i
( ( p
45+/-6 JJ p
years NNS p
, , p
64 CD p
patients NNS p
) ) p
. . p

RESULTS JJ N
Complication NNP o
rate NN o
was VBD N
5.26 CD N
% NN N
for IN N
group NN N
A NNP N
( ( N
none NN N
needed VBN N
conversion NN N
) ) N
and CC N
4.68 CD N
% NN N
for IN N
group NN N
B NNP N
. . N

All DT N
complications NNS o
were VBD N
considered VBN N
minor JJ N
. . N

No DT N
recurrences NNS o
were VBD N
observed VBN N
over IN N
a DT N
12-month JJ N
follow-up NN N
in IN N
both DT N
groups NNS N
. . N

Post-operative JJ o
hospital NN o
stay NN o
and CC o
return NN o
to TO o
activity NN o
show VB N
statistically RB N
significant JJ N
differences NNS N
. . N

Median JJ o
post-hospital JJ o
stay NN o
was VBD N
1.7 CD N
days NNS N
for IN N
group NN N
A NNP N
while IN N
it PRP N
was VBD N
longer RB N
( ( N
2.9 CD N
days NNS N
) ) N
for IN N
group NN N
B NNP N
. . N

Significant NNP N
difference NN N
was VBD N
observed VBN N
in IN N
the DT N
duration NN o
of IN o
convalescence NN o
too RB N
( ( N
group NN N
A DT N
9.3+/-7.2 JJ N
days NNS N
; : N
group NN N
B NNP N
12.1+/-7 NN N
. . N

1 CD N
days NNS N
) ) N
. . N

CONCLUSION NN N
On IN N
the DT N
basis NN N
of IN N
our PRP$ N
experience NN N
, , N
even RB N
if IN N
a DT N
longer JJR N
follow-up NN N
is VBZ N
needed VBN N
, , N
the DT N
validity NN N
of IN N
laparoscopic JJ i
approach NN i
to TO i
inguinal JJ i
hernia NN i
is VBZ N
confirmed VBN N
. . N

General NNP N
anesthesia NN N
and CC N
higher JJR N
costs NNS N
are VBP N
reasonable JJ N
compromises NNS N
for IN N
a DT N
shorter JJR N
period NN o
of IN o
discomfort NN o
in IN N
patients NNS p
with IN p
a DT p
low JJ p
ASA NNP p
index NN p
and CC p
busy JJ p
job/sport NN p
activity NN p
. . p

-DOCSTART- -9594153- O O

[ JJ N
Treatment NNP N
of IN N
irresectable JJ p
hepatocellular JJ p
carcinoma NN p
with IN N
repeated JJ i
transient JJ i
dearterialization NN i
] NNP i
. . N

A DT N
joint JJ N
clinical JJ N
prospective NN N
study NN N
between IN N
SUMS NNP p
and CC p
Lund NNP p
university NN p
was VBD N
reported VBN N
. . N

40 CD p
patients NNS p
with IN p
the DT p
irresectable JJ p
hepatocellular JJ p
carcinoma NN p
( ( p
HCC NNP p
) ) p
admitted VBD p
to TO p
the DT p
department NN p
of IN p
HPB NNP p
surgery NN p
in IN p
the DT p
First NNP p
Affiliated NNP p
Hospital NNP p
of IN p
SUMS NNP p
were VBD p
randomized VBN p
into IN p
two CD p
groups NNS p
: : p
( ( p
20 CD p
each DT p
) ) p
from IN p
Feb. NNP p
1994 CD p
to TO p
April NNP p
, , p
1995 CD p
. . p

The DT N
patients NNS N
were VBD N
treated VBN N
with IN N
hepatic JJ i
artery NN i
ligation NN i
( ( i
HAL NNP i
) ) i
and CC i
repeated VBN i
transient JJ i
dearterialization NN i
( ( i
RTD NNP i
) ) i
respectively RB N
. . N

Postoperative JJ N
response NN N
to TO N
treatment NN N
, , N
liver JJ o
function NN o
change NN o
( ( o
ALT NNP o
) ) o
, , o
AFP NNP o
, , o
imaging VBG o
examination NN o
of IN o
the DT o
tumor NN o
, , o
patient NN o
's POS o
survival NN o
were VBD N
evaluated VBN N
. . N

It PRP N
has VBZ N
been VBN N
shown VBN N
that IN N
RTD NNP i
is VBZ N
superior JJ N
to TO N
HAL NNP N
in IN N
terms NNS N
of IN N
the DT N
objective JJ N
response NN N
to TO N
the DT N
therapy NN o
, , o
reduction NN o
of IN o
tumor NN o
size NN o
, , o
patient NN o
's POS o
symptom JJ o
relief NN o
, , o
liver CC o
function NN o
and CC o
AFP NNP o
changes NNS o
and CC o
patient NN o
's POS o
survival NN o
. . o

In IN N
the DT N
RTD NNP i
group NN N
, , N
the DT N
effective JJ o
rate NN o
was VBD N
70 CD N
% NN N
, , N
the DT N
mean JJ o
survival NN o
time NN o
was VBD N
8.2 CD N
months NNS N
, , N
and CC N
the DT N
6-month JJ N
survival NN o
rate NN o
was VBD N
79.7 CD N
% NN N
. . N

In IN N
HAL NNP N
group NN N
, , N
the DT N
effective JJ o
rate NN o
was VBD N
only RB N
5 CD N
% NN N
, , N
the DT N
mean JJ o
survival NN o
time NN o
was VBD N
5.1 CD N
months NNS N
, , N
6 CD N
months NNS N
survival JJ o
rate NN o
was VBD N
35.8 CD N
% NN N
. . N

It PRP N
has VBZ N
been VBN N
postulated VBN N
that IN N
RTD NNP i
may MD N
prevent VB N
the DT N
rapid JJ N
development NN N
of IN N
collateral JJ N
circulation NN N
and CC N
increase VB N
the DT N
production NN o
of IN o
oxygen-derived JJ o
free JJ o
radicals NNS o
, , N
which WDT N
may MD N
be VB N
the DT N
responsible JJ N
factors NNS N
for IN N
the DT N
ischemic JJ N
treatment NN N
of IN N
hepatic JJ N
tumours NNS N
. . N

We PRP N
consider VBP N
that DT N
RTD NNP i
would MD N
be VB N
a DT N
promising JJ N
polliative JJ N
method NN N
for IN N
HCC NNP N
. . N

-DOCSTART- -17608965- O O

A DT N
comparison NN N
of IN N
the DT N
laryngeal JJ i
tube-S JJ i
and CC N
Proseal NNP i
laryngeal JJ i
mask NN i
during IN N
outpatient JJ p
surgical JJ p
procedures NNS p
. . p

BACKGROUND NNP N
AND CC N
OBJECTIVE NNP N
The DT N
Laryngeal NNP i
Tube NNP i
Sonda NNP i
( ( i
LTS NNP i
) ) i
and CC N
the DT N
ProSeal NNP i
Laryngeal NNP i
Mask NNP i
Airway NNP i
( ( i
PLMA NNP i
) ) i
are VBP N
two CD N
new JJ N
devices NNS N
introduced VBN N
for IN N
maintaining VBG N
the DT N
airway NN N
during IN N
controlled VBN N
ventilation NN N
under IN p
general JJ p
anaesthesia NN p
. . p

The DT N
present JJ N
investigation NN N
compared VBN N
their PRP$ N
performance NN N
in IN N
a DT N
randomized NN N
controlled VBN N
study NN N
. . N

METHODS NNP N
One CD p
hundred VBD p
ASA NNP p
I-II NNP p
patients NNS p
, , p
aged VBN p
18-60 JJ p
yr NN p
undergoing VBG p
elective JJ p
minor JJ p
surgery NN p
, , N
were VBD N
randomized VBN N
to TO N
receive VB N
either DT N
an DT N
LTS NNP i
( ( N
n JJ N
= NNP N
50 CD N
) ) N
or CC N
PLMA NNP i
( ( N
n JJ N
= NNP N
50 CD N
) ) N
for IN N
airway JJ N
management NN N
. . N

After IN N
induction NN N
of IN N
general JJ N
anaesthesia NN N
, , N
the DT N
devices NNS N
were VBD N
inserted VBN N
, , N
its PRP$ N
correct JJ N
placement NN N
was VBD N
verified VBN N
and CC N
airway RB N
leak JJ N
pressure NN N
was VBD N
measured VBN N
. . N

Ease NNP o
of IN o
insertion NN o
, , o
quality NN o
of IN o
airway NN o
seal NN o
, , o
fibre-optic JJ o
view NN o
and CC o
postoperative JJ o
pharyngeal NN o
morbidity NN o
were VBD N
examined VBN N
. . N

RESULTS VB N
There EX N
were VBD N
no DT N
differences NNS N
in IN N
patient JJ N
characteristics NNS N
for IN N
both DT N
groups NNS N
. . N

First-time JJ o
and CC o
second-time JJ o
success NN o
rates NNS o
were VBD N
comparable JJ N
for IN N
both DT N
groups NNS N
( ( N
86 CD N
vs. FW N
88 CD N
% NN N
and CC N
96 CD N
vs. FW N
98 CD N
% NN N
in IN N
LTS NNP N
and CC N
PLMA NNP N
groups NNS N
, , N
respectively RB N
) ) N
. . N

The DT N
airway NN o
of IN N
one CD N
patient NN N
in IN N
each DT N
group NN N
could MD N
not RB N
be VB N
managed VBN N
with IN N
these DT N
devices NNS N
after IN N
three CD N
attempts NNS N
. . N

Time NNP o
until IN o
delivery NN o
of IN o
first JJ o
tidal JJ o
volume NN o
for IN N
LTS NNP N
and CC N
PLMA NNP N
was VBD N
24.5 CD N
+/- JJ N
6.9 CD N
and CC N
28.8 CD N
+/- JJ N
10.3 CD N
s. JJ N
Fixation NNP o
and CC o
manipulation NN o
time NN o
was VBD N
54.9 CD N
+/- JJ N
15.2 CD N
and CC N
73.2 CD N
+/- JJ N
25 CD N
s NN N
, , N
respectively RB N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

Airway NNP o
seal JJ o
pressure NN o
( ( N
cm JJ N
H NNP N
( ( N
2 CD N
) ) N
O NNP N
) ) N
for IN N
LTS NNP N
and CC N
PLMA NNP N
was VBD N
20 CD N
+/- JJ N
8.6 CD N
and CC N
24.1 CD N
+/- JJ N
10.8 CD N
, , N
respectively RB N
( ( N
P NNP N
= NNP N
0.04 CD N
) ) N
. . N

Patients NNS N
were VBD N
questioned VBN N
on IN N
a DT N
variety NN N
of IN N
postoperative JJ o
pharyngeal NN o
morbidities NNS o
. . o

Only RB N
hoarseness NN o
was VBD N
more RBR N
frequent JJ N
in IN N
the DT N
LTS NNP N
group NN N
. . N

CONCLUSIONS NNP N
Both NNP N
devices NNS N
provide VBP N
a DT N
secure NN N
airway NN N
, , N
are VBP N
similar JJ N
in IN N
clinical JJ N
utility NN N
and CC N
are VBP N
easy JJ N
to TO N
insert VB N
. . N

Better NNP N
airway RB o
seal NN o
was VBD N
detected VBN N
in IN N
the DT N
PLMA NNP N
group NN N
. . N

-DOCSTART- -21084429- O O

Phase NNP N
III NNP N
trial NN N
of IN N
gemcitabine NN i
plus CC i
docetaxel JJ i
versus NN N
capecitabine NN i
plus CC i
docetaxel NN i
with IN N
planned VBN N
crossover NN N
to TO N
the DT N
alternate NN N
single JJ N
agent NN N
in IN N
metastatic JJ p
breast NN p
cancer NN p
. . p

BACKGROUND NNP N
Safety NNP o
and CC o
efficacy NN o
of IN N
gemcitabine JJ i
plus CC i
docetaxel JJ i
( ( i
GD NNP i
) ) i
and CC N
capecitabine JJ i
plus CC i
docetaxel JJ i
( ( i
CD NN i
) ) i
were VBD N
compared VBN N
in IN N
patients NNS p
with IN p
metastatic JJ p
breast NN p
cancer NN p
, , p
where WRB p
the DT p
alternate NN p
crossover NN p
monotherapy NN i
( ( i
GD?C NNP i
or CC i
CD?G NNP i
) ) i
was VBD i
predetermined VBN p
. . p

PATIENTS NNP p
AND CC N
METHODS NNP N
Patients NNPS N
were VBD N
randomly RB N
assigned VBN N
to TO N
3-week JJ N
cycles NNS N
of IN N
either DT i
gemcitabine NN i
1000 CD i
mg/m NN N
( ( N
2 CD N
) ) N
on IN N
days NNS N
1 CD N
and CC N
8 CD N
plus CC N
docetaxel JJ i
75 CD i
mg/m NN N
( ( N
2 CD N
) ) N
on IN N
day NN N
1 CD N
or CC N
capecitabine VB i
1000 CD i
mg/m NN N
( ( N
2 CD N
) ) N
twice RB N
daily RB N
on IN N
days NNS N
1-14 JJ N
plus JJ i
docetaxel NN i
75 CD i
mg/m NN N
( ( N
2 CD N
) ) N
day NN N
1 CD N
. . N

Upon IN N
progression NN N
, , N
patients NNS N
received VBD i
crossover JJ i
monotherapy NN i
. . i

Primary JJ i
end NN N
point NN N
was VBD N
time NN o
to TO o
progression NN o
( ( o
TtP NNP o
) ) o
. . o

Secondary JJ o
end NN N
points NNS N
evaluated VBD o
overall JJ o
response NN o
rate NN o
( ( o
ORR NNP o
) ) o
, , o
overall JJ o
survival NN o
( ( o
OS NNP o
) ) o
, , o
and CC o
adverse JJ o
events NNS o
( ( o
AEs NNP o
) ) o
. . o

RESULTS NNP o
Despite IN p
over-accrual JJ p
of IN p
475 CD p
patients NNS p
, , p
the DT p
trial NN p
matured VBD p
with IN p
only RB p
324 CD p
of IN p
385 CD p
planned JJ p
TtP NNP p
events NNS p
due JJ p
to TO p
patient JJ p
discontinuations NNS p
. . p

Human NNP p
epidermal JJ N
growth NN N
factor NN N
receptor NN N
2 CD N
status NN N
was VBD N
not RB N
captured VBN N
in IN N
this DT N
study NN N
. . N

More JJR N
CD NN i
patients NNS N
( ( N
28 CD N
% NN N
) ) N
discontinued VBD N
due JJ N
to TO N
AEs NNP N
than IN N
GD NNP i
patients NNS N
( ( N
18.0 CD N
% NN N
, , N
P NNP N
= NNP N
0.009 CD o
) ) o
. . o

TtP NNP o
[ NNP N
hazard NN N
ratio NN N
( ( N
HR NNP N
) ) N
= VBD N
1.101 CD N
, , N
95 CD N
% NN N
confidence NN N
interval NN N
( ( N
CI NNP N
) ) N
0.885-1.370 NN N
, , N
P NNP N
= VBZ N
0.387 CD N
] NN N
and CC N
OS NNP o
( ( N
HR NNP N
= NNP N
1.031 CD N
, , N
95 CD N
% NN N
CI NNP N
0.830-1.280 NN N
, , N
P NNP N
= NNP N
0.785 CD N
) ) N
were VBD N
not RB N
significantly RB N
different JJ N
comparing VBG i
GD NNP i
and CC N
CD NNP i
. . i

ORR NNP o
was VBD N
not RB N
statistically RB N
different JJ N
( ( N
P NNP N
= NNP N
0.239 CD N
) ) N
comparing VBG N
GD NNP N
( ( N
72 CD N
of IN N
207 CD N
, , N
34.8 CD N
% NN N
) ) N
and CC N
CD NNP N
( ( N
78 CD N
of IN N
191 CD N
, , N
40.8 CD N
% NN o
) ) o
. . o

TtP NNP o
, , N
OS NNP o
, , o
and CC o
ORR NNP o
were VBD N
not RB N
significantly RB N
different JJ N
comparing VBG N
crossover NN N
groups NNS i
. . i

GD NNP i
caused VBD N
greater JJR o
fatigue NN o
, , o
hepatotoxicity NN o
, , o
neutropenia NN o
, , o
and CC o
thrombocytopenia NNS o
but CC o
not RB o
febrile JJ o
neutropenia NN o
; : o
CD NN o
caused VBD N
more JJR N
hand-foot JJ o
syndrome NN o
, , o
gastrointestinal JJ o
toxicity NN o
, , o
and CC o
mucositis NN o
. . o

CONCLUSIONS NNP o
GD NNP i
and CC N
CD NNP i
produced VBD N
similar JJ o
efficacy NN o
and CC o
toxicity NN o
profiles NNS o
consistent JJ N
with IN N
prior JJ N
clinical JJ N
experience NN N
. . N

-DOCSTART- -23484763- O O

Efficacy NN N
of IN N
bepotastine NN i
besilate NN i
ophthalmic JJ i
solution NN i
1.5 CD N
% NN N
for IN N
seasonal JJ o
allergic JJ o
conjunctivitis NN o
: : o
a DT N
randomized JJ N
, , N
placebo-controlled JJ i
, , N
natural JJ N
exposure NN N
, , N
clinical JJ N
trial NN N
. . N

Allergic NNP N
conjunctivitis NN N
( ( N
AC NNP N
) ) N
affects VBZ N
an DT N
estimated JJ N
20 CD N
% NN N
of IN N
the DT N
population NN N
in IN N
the DT N
Western JJ N
world NN N
, , N
with IN N
a DT N
large JJ N
fraction NN N
suffering VBG N
due JJ N
to TO N
seasonal JJ N
or CC N
perennial JJ N
allergen NN N
exposures NNS N
. . N

Bepotastine NNP i
besilate NN i
ophthalmic JJ i
solution NN i
( ( i
BBOS NNP i
) ) i
1.5 CD N
% NN N
, , N
a DT N
dual-acting JJ i
histamine NN i
( ( N
H NNP N
( ( N
1 CD N
) ) N
) ) N
receptor NN N
antagonist NN N
and CC N
mast NN N
cell NN N
stabilizer NN N
, , N
is VBZ N
indicated VBN N
for IN N
itching VBG N
associated VBN N
with IN N
AC NNP N
. . N

This DT N
study NN N
was VBD N
designed VBN N
to TO N
evaluate VB N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
BBOS NNP N
1.5 CD N
% NN N
for IN N
reducing VBG N
ocular JJ p
itching NN p
associated VBN p
with IN p
AC NNP p
in IN p
subjects NNS p
enrolled VBN p
in IN p
a DT p
natural JJ p
exposure NN p
trial NN p
. . p

Eligible JJ p
subjects NNS p
in IN N
a DT N
multicenter NN N
, , N
double-masked JJ N
, , N
randomized VBN N
, , N
parallel-group JJ N
, , N
placebo-controlled JJ i
, , N
natural JJ N
exposure NN N
clinical JJ N
trial NN N
were VBD N
randomly RB N
assigned VBN N
to TO N
either DT N
BBOS NNP i
1.5 CD N
% NN N
or CC i
placebo NN i
eyedrops NNS i
on IN N
a DT N
1:1 CD N
basis NN N
and CC N
instilled VBD N
1 CD N
drop NN N
of IN N
the DT N
test NN N
agent NN N
into IN N
both DT N
eyes NNS N
twice RB N
daily RB N
for IN N
2 CD N
weeks NNS N
. . N

The DT N
mean JJ N
change NN N
from IN N
baseline NN N
in IN N
instantaneous JJ N
and CC N
reflective JJ o
ocular JJ o
itching NN o
scores NNS o
at IN N
the DT N
end NN N
of IN N
2 CD N
weeks NNS N
of IN N
treatment NN N
were VBD N
evaluated VBN N
based VBN N
on IN N
subject-assessed JJ N
severity NN N
of IN N
instantaneous JJ N
and CC N
reflective JJ N
itching NN N
. . N

Subject-reported JJ o
adverse JJ o
events NNS o
( ( o
AEs NNP o
) ) o
were VBD N
also RB N
recorded VBN N
for IN N
safety NN N
. . N

Treatment NN N
with IN N
BBOS NNP N
1.5 CD N
% NN N
significantly RB N
reduced VBN N
instantaneous JJ o
and CC o
reflective JJ o
ocular JJ o
itching NN o
scores NNS o
from IN N
baseline NN N
compared VBN N
with IN N
placebo NN N
over IN N
the DT N
2-week JJ N
study NN N
period NN N
( ( N
p JJ N
= NN N
0.007 CD N
and CC N
p VB N
= JJ N
0.005 CD N
, , N
respectively RB N
) ) N
. . N

BBOS $ N
1.5 CD N
% NN N
was VBD N
well RB N
tolerated VBN o
, , o
and CC o
AEs NNP o
were VBD N
generally RB N
transient JJ N
and CC N
mild JJ N
. . N

This DT N
clinical JJ N
study NN N
indicates VBZ N
BBOS NNP N
1.5 CD N
% NN N
effectively RB o
and CC o
safely RB o
treated VBD o
ocular JJ o
itching NN o
in IN N
a DT N
natural JJ N
exposure NN N
allergy NN N
study NN N
and CC N
is VBZ N
a DT N
useful JJ N
treatment NN N
option NN N
for IN N
the DT N
management NN N
of IN N
ocular JJ N
itching NN N
associated VBN N
with IN N
AC NNP N
. . N

( ( N
ClinicalTrials.gov NNP N
identifier VBZ N
number NN N
: : N
NCT01174823 NNP N
. . N

) ) N
-DOCSTART- -1894676- O O

Need VB N
the DT N
thumb NN i
be VB i
immobilised VBN i
in IN N
scaphoid NN p
fractures NNS p
? . N
A DT N
randomised JJ N
prospective JJ N
trial NN N
. . N

Immobilisation NN i
of IN i
the DT i
thumb NN i
is VBZ N
widely RB N
believed VBN N
to TO N
be VB N
important JJ N
in IN N
the DT N
management NN N
of IN N
fractures NNS p
of IN p
the DT p
carpal JJ p
scaphoid NN p
. . p

To TO N
assess VB N
the DT N
need NN N
for IN N
this DT N
, , N
we PRP N
randomly RB N
allocated VBD N
392 CD p
fresh JJ p
fractures NNS p
for IN N
treatment NN N
by IN N
either CC N
a DT N
forearm JJ i
gauntlet NN i
( ( i
Colles NNP i
' POS i
) ) i
cast NN i
, , N
leaving VBG N
the DT N
thumb JJ N
free JJ N
, , N
or CC N
by IN N
a DT N
conventional JJ i
'scaphoid NN i
' '' i
plaster NN i
incorporating VBG i
the DT i
thumb NN i
as RB i
far RB i
as IN i
its PRP$ i
interphalangeal NN i
joint NN i
. . i

In IN N
the DT N
292 CD p
fractures NNS p
which WDT N
were VBD N
followed VBN N
for IN N
six CD N
months NNS N
, , N
the DT N
incidence NN o
of IN o
nonunion NN o
was VBD N
independent JJ N
of IN N
the DT N
type NN N
of IN N
cast NN N
used VBN N
. . N

-DOCSTART- -19232615- O O

Intensive JJ i
insulin NN i
therapy NN i
on IN N
infection NN N
rate NN N
, , N
days NNS N
in IN N
NICU NNP N
, , N
in-hospital JJ o
mortality NN o
and CC o
neurological JJ o
outcome NN o
in IN N
severe JJ p
traumatic JJ p
brain NN p
injury NN p
patients NNS p
: : p
a DT N
randomized NN N
controlled VBN N
trial NN N
. . N

OBJECTIVES NNP N
Evaluate NNP N
the DT N
impact NN N
of IN N
an DT N
intensive JJ i
insulin NN i
therapy NN i
and CC N
conventional JJ i
glucose NN i
control NN i
protocol NN i
during IN N
staying VBG N
in IN N
neurological JJ N
intensive JJ N
care NN N
unit NN N
( ( N
NICU NNP N
) ) N
on IN N
infection NN o
rate NN o
, , o
days NNS o
in IN o
NICU NNP o
, , o
in-hospital JJ o
mortality NN o
and CC o
long-term JJ o
neurological JJ o
outcome NN o
in IN N
severe JJ p
traumatic JJ p
brain NN p
injury NN p
( ( p
TBI NNP p
) ) p
patients NNS p
. . p

METHODS NNP N
A NNP N
total NN N
of IN N
240 CD p
patients NNS p
with IN p
severe JJ p
TBI NNP p
( ( p
GCS NNP p
score RB p
3-8 JJ p
) ) p
admitted VBD p
to TO p
NICU NNP p
were VBD N
prospectively RB N
enrolled VBN N
and CC N
randomly RB N
assigned VBD N
either DT N
to TO N
conventional JJ i
insulin NN i
therapy NN i
or CC N
to TO N
intensive JJ i
insulin NN i
therapy NN i
. . i

Patients NNS N
in IN N
intensive JJ i
glucose NNS i
control NN i
group NN i
( ( N
n=121 NN N
) ) N
received VBD N
continuous JJ i
insulin NN i
infusion NN i
to TO N
maintain VB N
glucose JJ N
levels NNS N
between IN N
4.4 CD N
m NNS N
mol/l NN N
( ( N
80 CD N
mg/dl NN N
) ) N
and CC N
6.1 CD N
m NN N
mol/l NN N
( ( N
110 CD N
mg/dl NN N
) ) N
. . N

Patients NNS N
in IN N
the DT N
conventional JJ i
treatment NN i
group NN i
( ( N
n=119 RB N
) ) N
were VBD N
not RB N
given VBN N
insulin NN i
unless IN N
glucose JJ o
levels NNS o
were VBD N
greater JJR N
than IN N
11.1 CD N
m JJ N
mol/l NN N
( ( N
200mg/dl CD N
) ) N
. . N

Both DT N
groups NNS N
were VBD N
treated VBN N
with IN N
insulin JJ i
infusion NN N
to TO N
maintain VB N
normoglycemia RB N
after IN N
leaving VBG N
NICU NNP N
. . N

Comparison NNP N
was VBD N
made VBN N
against IN N
conventional JJ i
insulin NN i
therapy NN i
using VBG N
a DT N
randomized JJ N
trial NN N
design NN N
. . N

The DT N
primary JJ N
outcomes NNS N
is VBZ N
the DT N
mortality NN o
rate NN o
at IN N
6 CD N
months NNS N
follow-up RB N
. . N

The DT N
second JJ N
outcomes NNS N
including VBG N
ICU NNP o
infection NN o
rate NN o
, , o
duration NN o
of IN o
ICU NNP o
stay NN o
, , o
in-hospital JJ o
mortality NN o
rate NN o
and CC o
neurologic JJ o
outcome NN o
at IN N
6 CD N
months NNS N
follow-up RB N
. . N

RESULTS NNP N
There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
gender NN p
( ( p
66 CD p
% NN p
vs. FW p
67 CD p
% NN p
male NN p
) ) p
, , p
age NN p
( ( p
46+/-11 CD p
years NNS p
vs. IN p
45+/-10 CD p
years NNS p
) ) p
, , p
APACHE NNP p
II NNP p
score NN p
( ( p
30 CD p
vs. FW p
29 CD p
) ) p
, , p
TISS-28 NNP o
score NN o
( ( p
47 CD p
vs. FW p
46 CD p
) ) p
, , p
and CC p
Glasgow NNP o
Coma NNP o
Score NNP o
( ( p
GCS NNP p
, , p
5.3 CD p
vs. FW p
5.3 CD p
) ) p
between IN N
the DT N
two CD N
groups NNS N
. . N

Overall JJ o
mortality NN o
rates NNS o
at IN N
6 CD N
months NNS N
follow-up JJ N
were VBD N
similar JJ N
in IN N
the DT N
2 CD N
groups NNS N
( ( N
61 CD N
of IN N
117 CD N
, , N
52.1 CD N
% NN N
vs. FW N
62 CD N
of IN N
116 CD N
, , N
53.4 CD N
% NN N
; : N
P=0.8 NNP N
) ) N
. . N

The DT N
infection NN o
rate NN o
during IN N
the DT N
study NN N
was VBD N
significantly RB N
higher JJR N
in IN N
patients NNS N
who WP N
received VBD N
conventional JJ i
insulin NN i
therapy NN i
than IN N
that DT N
in IN N
patients NNS N
who WP N
received VBD N
intensive JJ i
insulin NN i
therapy NN i
( ( N
46.2 CD N
% NN N
vs. FW N
31.4 CD N
% NN N
; : N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

The DT N
days NNS o
stay VBP o
in IN o
NICU NNP o
was VBD N
shorter RBR N
in IN N
intensive JJ i
insulin NN i
control NN i
group NN i
than IN N
that DT N
in IN N
conventional JJ i
therapy NN i
group NN i
[ VBD N
4.2 CD N
days NNS N
vs. FW N
5.6 CD N
days NNS N
( ( N
medians NNS N
) ) N
P NNP N
< $ N
0.05 CD N
] NNP N
. . N

The DT N
in-hospital JJ o
mortality NN o
during IN N
the DT N
study NN N
was VBD N
similar JJ N
in IN N
conventional JJ i
and CC i
intensive JJ i
therapy NN i
groups NNS i
( ( N
34 CD N
of IN N
119 CD N
, , N
28.6 CD N
% NN N
vs. FW N
35 CD N
of IN N
121 CD N
, , N
28.9 CD N
% NN N
in IN N
the DT N
conventional JJ i
and CC i
intensive JJ i
insulin NN i
therapy NN i
groups NNS N
; : N
P=0.85 NNP N
) ) N
. . N

The DT N
neurologic JJ o
outcome NN o
according VBG N
to TO N
Glasgow NNP o
Outcome NNP o
Score NNP o
( ( o
GOS NNP o
) ) o
at IN N
6 CD N
months NNS N
( ( N
GOS NNP N
5 CD N
and CC N
4 CD N
) ) N
was VBD N
better RBR N
in IN N
the DT N
intensive JJ i
insulin NN i
therapy NN i
group NN N
( ( N
34 CD N
of IN N
117 CD N
, , N
29.1 CD N
% NN N
) ) N
than IN N
that DT N
in IN N
the DT N
conventional JJ i
therapy NN i
group NN N
( ( N
26 CD N
of IN N
116 CD N
, , N
22.4 CD N
% NN N
, , N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

CONCLUSIONS NNP N
Mortality NNP o
rates NNS o
at IN N
6 CD N
months NNS N
follow-up NNS N
are VBP N
not RB N
affected VBN N
by IN N
intensive JJ N
glucose NNS N
control NN N
in IN N
patients NNS p
with IN p
severe JJ p
TBI NNP p
. . p

Intensive JJ i
insulin NN i
therapy NN i
decreases VBZ N
infection NN o
rate NN o
and CC o
days NNS o
in IN o
NICU NNP o
and CC N
improves VBZ o
the DT o
neurological JJ o
outcome NN o
at IN N
6 CD N
months NNS N
follow-up RB N
, , N
while IN N
has VBZ N
no DT N
obvious JJ N
influence NN N
on IN N
in-hospital JJ o
mortality NN o
of IN N
severe JJ p
TBI NNP p
patients NNS p
. . p

-DOCSTART- -7208897- O O

Breast NNP p
cancer NN p
screening VBG i
in IN N
Sweden NNP p
. . p

The DT N
single JJ N
modality NN N
approach NN N
. . N

Four CD p
population-based JJ p
breast NN p
cancer NN p
screening VBG p
projects NNS p
are VBP p
in IN p
progress NN p
in IN p
Sweden NNP p
, , N
three CD N
of IN N
which WDT N
are VBP N
randomized VBN N
studies NNS N
. . N

Mammography NNP i
is VBZ N
the DT N
only JJ N
screening NN N
method NN N
. . N

51 CD N
% NN N
of IN N
all DT N
carcinomas NN N
detected VBN N
at IN N
the DT N
first JJ N
screening NN N
were VBD N
either RB N
in IN N
situ NN N
or CC N
invasive JJ N
with IN N
a DT N
diameter NN N
of IN N
10 CD N
mm NN N
or CC N
less JJR N
. . N

Axillary JJ o
metastases NNS o
were VBD N
found VBN N
in IN N
16 CD N
% NN N
of IN N
the DT N
patients NNS N
. . N

Sensitivity NNP o
was VBD N
over RB N
90 CD N
% NN N
in IN N
all DT N
projects NNS N
. . N

The DT o
ultimate JJ o
aim NN o
of IN o
the DT o
randomized JJ o
projects NNS o
is VBZ o
to TO o
demonstrate VB o
the DT o
effect NN o
of IN o
screening VBG o
on IN o
breast NN o
cancer NN o
mortality NN o
. . o

It PRP N
is VBZ N
estimated VBN N
that IN N
mortality NN o
statistics NNS o
will MD N
reach VB N
significant JJ N
levels NNS N
in IN N
1983. CD N
, , N
-DOCSTART- -23104718- O O

ARIX NN N
: : N
a DT N
randomised JJ N
trial NN N
of IN N
acupuncture NN i
v FW N
oral JJ i
care NN i
sessions NNS i
in IN N
patients NNS p
with IN p
chronic JJ p
xerostomia NN p
following VBG p
treatment NN p
of IN p
head NN p
and CC p
neck NN p
cancer NN p
. . p

BACKGROUND NNP N
Radiation NNP N
treatment NN N
of IN N
head NN p
and CC p
neck NN p
cancer NN p
can MD N
cause VB N
chronic JJ p
xerostomia NN p
which WDT N
impairs VBZ N
patients NNS N
' POS N
quality NN N
of IN N
life NN N
. . N

The DT N
study NN N
reported VBD N
here RB N
examined VBN N
the DT N
efficacy NN o
of IN N
acupuncture NN i
in IN N
alleviating VBG N
xerostomia NN N
symptoms NNS N
especially RB N
dry JJ N
mouth NN N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
A NNP N
total NN p
of IN p
145 CD p
patients NNS p
with IN p
chronic JJ p
radiation-induced JJ p
xerostomia NN p
> $ p
18 CD p
months NNS p
after IN p
treatments NNS p
were VBD p
recruited VBN p
from IN p
seven CD p
UK NNP p
cancer NN p
centres NNS p
. . p

The DT N
study NN N
employed VBD N
a DT N
randomised JJ N
crossover NN N
design NN N
with IN N
participants NNS N
receiving VBG N
two CD N
group NN N
sessions NNS N
of IN N
oral JJ i
care NN i
education NN i
and CC N
eight CD N
of IN N
acupuncture NN i
using VBG i
standardised VBN i
methods NNS i
. . i

Patient-reported JJ o
outcome NN o
( ( o
PROs NNP o
) ) o
measures NNS o
were VBD N
completed VBN N
at IN N
baseline NN N
and CC N
weeks NNS N
5 CD N
, , N
9 CD N
, , N
13 CD N
, , N
17 CD N
, , N
and CC N
21 CD N
. . N

The DT N
primary JJ N
outcome NN N
was VBD N
improvement NN o
in IN o
dry JJ o
mouth NN o
. . o

OBJECTIVE NNP N
saliva NN o
measurements NNS o
were VBD N
also RB N
carried VBN N
out RP N
. . N

RESULTS JJ N
Acupuncture NNP i
compared VBN N
with IN N
oral JJ N
care NN N
, , N
produced VBD N
significant JJ N
reductions NNS N
in IN N
patient JJ N
reports NNS N
of IN N
severe JJ o
dry JJ o
mouth NN o
( ( N
OR NNP N
= VBZ N
2.01 CD N
, , N
P NNP N
= NNP N
0.031 CD N
) ) N
sticky NN o
saliva NN o
( ( N
OR NNP N
= VBZ N
1.67 CD N
, , N
P NNP N
= NNP N
0.048 CD N
) ) N
, , N
needing VBG o
to TO o
sip VB o
fluids NNS o
to TO o
swallow VB o
food NN o
( ( N
OR NNP N
= VBZ N
2.08 CD N
, , N
P NNP N
= NNP N
0.011 CD N
) ) N
and CC N
in IN N
waking VBG o
up RP o
at IN o
night NN o
to TO o
drink VB o
( ( N
OR NNP N
= VBZ N
1.71 CD N
, , N
P NNP N
= NNP N
0.013 CD N
) ) N
. . N

There EX N
were VBD N
no DT N
significant JJ N
changes NNS N
in IN N
either DT N
stimulated VBD o
or CC o
unstimulated JJ o
saliva NN o
measurements NNS o
over IN N
time NN N
. . N

CONCLUSION NNP N
Eight NNP N
sessions NNS N
of IN N
weekly JJ N
group NN N
acupuncture NN i
compared VBN N
with IN N
group NN N
oral JJ N
care NN N
education NN N
provide VBP N
significantly RB N
better JJR N
relief NN N
of IN N
symptoms NNS N
in IN N
patients NNS p
suffering VBG p
from IN p
chronic JJ p
radiation-induced JJ p
xerostomia NN p
. . p

-DOCSTART- -19235039- O O

Effect NN N
of IN N
broccoli NNS i
intake VBP i
on IN N
markers NNS o
related VBN o
to TO o
oxidative JJ o
stress NN o
and CC o
cancer NN o
risk NN o
in IN N
healthy JJ p
smokers NNS p
and CC p
nonsmokers NNS p
. . p

Cruciferous JJ i
vegetables NNS i
( ( i
CVs NNP i
) ) i
have VBP N
been VBN N
widely RB N
studied VBN N
for IN N
their PRP$ N
anticarcinogenic JJ N
properties NNS N
. . N

The DT N
aim NN N
of IN N
the DT N
present JJ N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
protective JJ N
effect NN N
of IN N
broccoli NNS i
intake VBP N
in IN N
smokers NNS p
and CC p
nonsmokers NNS p
. . p

Twenty NNP p
young JJ p
healthy JJ p
males NNS p
( ( p
10 CD p
smokers NNS p
and CC p
10 CD p
nonsmokers NNS p
) ) p
were VBD N
randomized VBN N
in IN N
a DT N
cross-over JJ N
design NN N
and CC N
received VBD N
a DT N
portion NN N
of IN N
broccoli NN i
( ( N
200 CD N
g NN N
) ) N
or CC N
maintained VBD i
a DT i
controlled VBN i
diet NN i
for IN N
10 CD N
days NNS N
each DT N
. . N

The DT N
two CD N
periods NNS N
were VBD N
separated VBN N
by IN N
a DT N
wash-out JJ N
period NN N
( ( N
20 CD N
days NNS N
) ) N
. . N

Blood NN N
samples NNS N
were VBD N
collected VBN N
at IN N
0 CD N
, , N
10 CD N
, , N
30 CD N
, , N
and CC N
40 CD N
days NNS N
and CC N
used VBN N
for IN N
the DT N
evaluation NN N
of IN N
DNA NNP o
damage NN o
, , o
insulin-like JJ o
growth NN o
factor-I JJ o
( ( o
IGF-I NNP o
) ) o
and CC o
histone JJ o
deacetylase NN o
( ( o
HDAC NNP o
) ) o
. . o

Ex NNP o
vivo JJ o
protection NN o
from IN o
H NNP o
( ( o
2 CD o
) ) o
O NNP o
( ( o
2 CD o
) ) o
-induced VBD o
DNA NNP o
damage NN o
and CC o
endogenous JJ o
DNA NNP o
damage NN o
were VBD o
evaluated VBN o
in IN N
lymphocytes NNS N
by IN N
means NNS N
of IN N
the DT N
comet NN o
assay NN o
. . o

Strand NNP o
breaks NNS o
decreased VBD N
significantly RB N
after IN N
the DT N
broccoli NN N
diet NN N
in IN N
smokers NNS N
as RB N
well RB N
as IN N
in IN N
nonsmokers NNS N
( ( N
-22.2 CD N
% NN N
; : N
P NNP N
< NNP N
0.0001 CD N
) ) N
, , N
whereas JJ N
oxidized VBN o
purines NNS o
decreased VBD N
significantly RB N
only RB N
in IN N
smokers NNS N
( ( N
-51.0 CD N
% NN N
; : N
P NNP N
< NNP N
0.0001 CD N
) ) N
. . N

Broccoli NNP i
intake NN N
did VBD N
not RB N
modify VB N
HDAC NNP o
activity NN o
and CC o
IGF-I NNP o
serum NN o
levels NNS o
. . o

Our PRP$ N
results NNS N
strengthen VBP N
the DT N
importance NN N
of IN N
consuming VBG N
CVs NNP N
to TO N
increase VB o
cell NN o
protection NN o
against IN o
DNA NNP o
damage NN o
. . o

Future JJ N
investigation NN N
, , N
with IN N
different JJ N
amount NN N
of IN N
broccoli JJ i
and/or JJ N
different JJ N
time NN N
of IN N
exposure NN N
, , N
is VBZ N
needed VBN N
to TO N
understand VB N
the DT N
lack NN N
of IN N
effect NN N
on IN N
HDAC NNP o
activity NN o
and CC o
IGF-I JJ o
levels NNS o
. . o

-DOCSTART- -17046466- O O

Toxicity NN o
and CC o
efficacy NN o
of IN N
6-thioguanine JJ i
versus NN i
6-mercaptopurine JJ i
in IN N
childhood NN p
lymphoblastic JJ p
leukaemia NN p
: : p
a DT N
randomised JJ N
trial NN N
. . N

BACKGROUND NNP N
6-mercaptopurine JJ i
has VBZ N
been VBN N
a DT N
standard JJ N
component NN N
of IN N
long-term JJ N
continuing VBG N
treatment NN N
for IN N
childhood NN p
lymphoblastic JJ p
leukaemia NN p
, , N
whereas JJ N
6-thioguanine NN i
has VBZ N
been VBN N
mainly RB N
used VBN N
for IN N
intensification NN N
courses NNS N
. . N

Since IN N
preliminary JJ N
data NNS N
have VBP N
shown VBN N
that IN N
6-thioguanine JJ i
is VBZ N
more RBR N
effective JJ N
than IN N
6-mercaptopurine JJ i
, , N
we PRP N
compared VBN N
the DT N
efficacy NN o
and CC o
toxicity NN o
of IN N
the DT N
two CD N
drugs NNS N
for IN N
childhood NN p
lymphoblastic JJ p
leukaemia NN p
. . p

METHODS NNP N
Consecutive JJ p
children NNS p
with IN p
lymphoblastic JJ p
leukaemia NN p
diagnosed VBN p
in IN p
the DT p
UK NNP p
and CC p
Ireland NNP p
between IN p
April NNP p
, , p
1997 CD p
, , p
and CC p
June NNP p
, , p
2002 CD p
, , N
were VBD N
randomly RB N
assigned VBN N
either CC N
6-thioguanine JJ i
( ( i
750 CD i
patients NNS N
) ) N
or CC N
6-mercaptopurine JJ i
( ( N
748 CD N
patients NNS N
) ) N
during IN N
interim JJ N
maintenance NN N
and CC N
continuing VBG N
therapy NN N
. . N

All DT N
patients NNS N
received VBD N
6-thioguanine JJ i
during IN N
intensification NN N
courses NNS N
. . N

We PRP N
analysed VBD N
event-free JJ o
and CC o
overall JJ o
survival NN o
on IN N
an DT N
intention-to-treat JJ N
basis NN N
. . N

We PRP N
obtained VBD N
toxicity NN o
data NNS N
using VBG N
an DT N
adverse-event JJ N
reporting NN N
system NN N
, , N
with IN N
follow-up JJ N
questionnaires NNS N
to TO N
seek VB N
detailed JJ N
information NN N
for IN N
specific JJ N
toxicities NNS N
. . N

This DT N
trial NN N
is VBZ N
registered VBN N
with IN N
the DT N
International NNP N
Standard NNP N
Randomised VBD N
Controlled NNP N
Number NNP N
26727615 CD N
with IN N
the DT N
name NN N
ALL97 NNP N
. . N

FINDINGS NNP N
After IN N
a DT N
median JJ N
follow NN N
up IN N
of IN N
6 CD N
years NNS N
, , N
there EX N
was VBD N
no DT N
difference NN N
in IN N
event-free JJ o
or CC o
overall JJ o
survival NN o
between IN N
the DT N
two CD N
treatment NN N
groups NNS N
. . N

Although IN N
6-thioguanine JJ i
conferred VBD N
a DT N
significantly RB N
lower JJR N
risk NN N
of IN N
isolated JJ N
CNS NNP o
relapse NN o
than IN N
did VBD N
6-mercaptopurine JJ i
( ( N
odds NNS N
ratio VBP N
[ CD N
OR NNP N
] $ N
0.53 CD N
, , N
95 CD N
% NN N
CI NNP N
0.30-0.92 CD N
, , N
p=0.02 NN N
) ) N
, , N
the DT N
benefit NN N
was VBD N
offset VBN N
by IN N
an DT N
increased VBN N
risk NN o
of IN o
death NN o
in IN N
remission NN N
( ( N
2.22 CD N
, , N
1.20-4.14 CD N
, , N
p=0.01 NN N
) ) N
, , N
mainly RB N
due JJ N
to TO N
infections NNS N
during IN N
continuing VBG N
therapy NN N
. . N

Additionally RB N
, , N
95 CD N
patients NNS N
developed VBD N
veno-occlusive JJ o
disease NN o
of IN o
the DT o
liver NN o
. . o

Of IN N
these DT N
, , N
82 CD N
were VBD N
randomly RB N
assigned VBN N
6-thioguanine JJ i
, , N
representing VBG N
11 CD N
% NN N
of IN N
all DT N
6-thioguanine JJ i
recipients NNS N
. . N

On IN N
long-term JJ N
follow-up NN N
, , N
about RB N
5 CD N
% NN N
of IN N
6-thioguanine JJ i
recipients NNS N
have VBP N
evidence NN N
of IN N
non-cirrhotic JJ o
portal JJ o
hypertension NN o
due JJ N
to TO N
periportal JJ N
liver JJ N
fibrosis NN N
or CC N
nodular JJ N
regenerative JJ N
hyperplasia NN N
. . N

INTERPRETATION NNP N
Compared VBD N
with IN N
6-mercaptopurine JJ i
, , i
6-thioguanine JJ i
causes NNS N
excess JJ N
toxicity NN o
without IN N
an DT N
overall JJ o
benefit NN o
. . o

6-mercaptopurine JJ i
should MD N
remain VB N
the DT N
thiopurine NN N
of IN N
choice NN N
for IN N
continuing VBG N
therapy NN N
of IN N
childhood NN N
lymphoblastic JJ N
leukaemia NN N
. . N

-DOCSTART- -2382949- O O

Comparison NNP N
of IN N
enflurane NN i
and CC N
halothane NN i
in IN N
hypotensive JJ p
eye NN p
surgery NN p
. . p

Thirty NN p
patients NNS p
undergoing VBG p
elective JJ p
eye NN p
surgery NN p
had VBD N
anaesthesia NNS N
induced VBN N
with IN N
sodium NN i
thiopentone NN i
, , i
suxamethonium NN i
and CC i
d-tubocurarine JJ i
chloride NN i
. . i

Patients NNS N
were VBD N
ventilated VBN N
with IN N
nitrous JJ i
oxide NN i
, , i
oxygen NN i
and CC i
either DT i
halothane NN i
or CC i
enflurane NN i
. . i

The DT N
volatile JJ N
agents NNS N
were VBD N
used VBN N
to TO N
decrease VB N
the DT N
systolic JJ o
blood NN o
pressure NN o
to TO N
80 CD N
mmHg NN N
. . N

The DT N
volatile JJ o
agent NN o
concentration NN o
in IN o
the DT o
blood NN o
was VBD N
measured VBN N
at IN N
30 CD N
min NN N
intervals NNS N
. . N

Both DT N
agents NNS N
were VBD N
effective JJ N
in IN N
producing VBG N
hypotension NN o
, , N
but CC N
enflurane NN N
was VBD N
the DT N
more RBR N
potent JJ N
hypotensive JJ N
agent NN N
in IN N
terms NNS N
of IN N
MAC NNP N
equivalents NNS N
. . N

There EX N
was VBD N
no DT N
significant JJ N
differences NNS N
between IN N
the DT N
agents NNS N
with IN N
respect NN N
to TO N
speed NN o
of IN o
recovery NN o
. . o

-DOCSTART- -21287255- O O

Avatar NNP N
assistant NN N
: : N
improving VBG N
social JJ o
skills NNS o
in IN N
students NNS p
with IN p
an DT p
ASD NNP p
through IN N
a DT N
computer-based JJ i
intervention NN i
. . i

This DT N
study NN N
assessed VBD N
the DT N
efficacy NN o
of IN N
FaceSay NNP i
, , i
a DT i
computer-based JJ i
social JJ o
skills NNS o
training VBG i
program NN i
for IN N
children NNS p
with IN p
Autism NNP p
Spectrum NNP p
Disorders NNP p
( ( p
ASD NNP p
) ) p
. . p

This DT N
randomized VBD N
controlled VBN N
study NN p
( ( p
N NNP p
= NNP p
49 CD p
) ) p
indicates VBZ p
that IN N
providing VBG p
children NNS p
with IN p
low-functioning JJ p
autism NN p
( ( p
LFA NNP p
) ) p
and CC p
high JJ p
functioning NN p
autism NN p
( ( p
HFA NNP p
) ) p
opportunities VBZ p
to TO N
practice NN N
attending VBG N
to TO N
eye NN N
gaze NN N
, , N
discriminating VBG N
facial JJ N
expressions NNS N
and CC N
recognizing VBG N
faces VBZ N
and CC N
emotions NNS N
in IN N
FaceSay NNP N
's POS N
structured JJ N
environment NN N
with IN N
interactive JJ N
, , N
realistic JJ N
avatar NN N
assistants NNS N
improved VBD N
their PRP$ o
social JJ o
skills NNS o
abilities NNS o
. . o

The DT N
children NNS N
with IN N
LFA NNP N
demonstrated VBD N
improvements NNS N
in IN N
two CD N
areas NNS N
of IN N
the DT N
intervention NN o
: : o
emotion NN o
recognition NN o
and CC o
social JJ o
interactions NNS o
. . o

The DT N
children NNS N
with IN N
HFA NNP N
demonstrated VBD N
improvements NNS N
in IN N
all DT N
three CD N
areas NNS o
: : o
facial JJ o
recognition NN o
, , o
emotion NN o
recognition NN o
, , o
and CC o
social JJ o
interactions NNS o
. . o

These DT N
findings NNS N
, , N
particularly RB N
the DT N
measured JJ N
improvements NNS N
to TO N
social JJ o
interactions NNS o
in IN o
a DT N
natural JJ N
environment NN N
, , N
are VBP N
encouraging VBG N
. . N

-DOCSTART- -7562882- O O

Lisinopril NNP i
administration NN N
improves VBZ N
insulin JJ o
action NN o
in IN N
aged JJ p
patients NNS p
with IN p
hypertension NN p
. . p

Thirty NNP p
elderly JJ p
, , p
mildly RB p
hypertensive JJ p
patients NNS p
were VBD N
enrolled VBN N
for IN N
a DT N
single-blind NN N
, , N
randomised VBD N
cross-over NN N
placebo NN i
controlled VBD N
trial NN N
in IN N
which WDT N
placebo NN i
and CC i
lisinopril NN i
( ( N
20 CD N
mg/day NN N
before IN N
breakfast NN N
) ) N
were VBD N
given VBN N
for IN N
4 CD N
and CC N
8 CD N
weeks NNS N
, , N
respectively RB N
. . N

A DT N
wash-out JJ N
period NN N
of IN N
3 CD N
weeks NNS N
between IN N
placebo NN i
and CC i
lisinopril NN i
was VBD N
observed VBN N
. . N

In IN N
each DT N
patient NN N
a DT N
euglycaemic JJ N
glucose NN N
clamp NN N
with IN N
simultaneous JJ N
indirect JJ N
calorimetry NN N
allowed VBD N
us PRP N
to TO N
determine VB N
whole JJ o
body NN o
glucose JJ o
disposal NN o
and CC N
substrate JJ o
oxidation NN o
. . o

Changes NNS o
in IN N
morning NN o
SBP NNP o
and CC o
DBP NNP o
were VBD N
also RB N
determined VBN N
. . N

Lisinopril NNP i
vs. IN i
placebo NN i
significantly RB N
improved VBN N
whole JJ o
body NN o
glucose JJ o
disposal NN o
( ( N
40.4 CD N
+/- JJ N
0.4 CD N
vs. FW N
30.3 CD N
+/- JJ N
0.4 CD N
mumol/kg NN N
LBM NNP N
x NNP N
min NN N
; : N
P NNP N
< NNP N
0.01 CD N
) ) N
, , N
non-oxidative JJ o
glucose JJ o
metabolism NN o
( ( N
18.1 CD N
+/- JJ N
0.7 CD N
vs. FW N
10.9 CD N
+/- JJ N
0.6 CD N
mumol/kg NN N
LBM NNP N
x NNP N
min NN N
; : N
P NNP N
< NNP N
0.01 CD N
) ) N
and CC N
fasting VBG o
plasma JJ o
potassium NN o
levels NNS o
( ( N
4.8 CD N
+/- JJ N
3 CD N
vs. FW N
4.4 CD N
+/- JJ N
0.4 CD N
mmol/l NN N
; : N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

SBP NNP o
( ( N
175 CD N
+/- JJ N
3.3 CD N
vs. FW N
160 CD N
+/- JJ N
3.0 CD N
mm NN N
Hg NNP N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
and CC N
DBP NNP o
( ( N
106 CD N
+/- JJ N
2.3 CD N
vs. FW N
95 CD N
+/- JJ N
2.0 CD N
mm NN N
Hg NNP N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
were VBD N
significantly RB N
reduced VBN N
by IN N
lisinopril JJ i
administration NN N
. . N

After IN N
ACE NNP N
inhibition NN N
, , N
fasting VBG o
plasma JJ o
potassium NN o
levels NNS o
correlated VBN N
with IN N
the DT N
decline NN o
in IN o
mean JJ o
arterial JJ o
BP NNP o
( ( N
r NN N
= NNP N
-0.71 NNP N
; : N
P NNP N
< NNP N
0.006 CD N
) ) N
. . N

In IN N
conclusion NN N
, , N
lisinopril JJ i
administration NN N
reduces VBZ N
arterial JJ o
BP NNP o
and CC N
improves VBZ o
insulin JJ o
sensitivity NN o
in IN N
elderly JJ p
hypertensive JJ p
patients NNS p
. . p

-DOCSTART- -23019005- O O

Sensitivity NN p
to TO p
musical JJ p
structure NN p
in IN p
the DT p
human JJ p
brain NN p
. . p

Evidence NN N
from IN N
brain-damaged JJ p
patients NNS p
suggests VBZ N
that IN N
regions NNS N
in IN N
the DT N
temporal JJ N
lobes NNS N
, , N
distinct NN N
from IN N
those DT N
engaged VBN N
in IN N
lower-level JJ N
auditory NN N
analysis NN N
, , N
process NN N
the DT N
pitch NN N
and CC N
rhythmic JJ N
structure NN N
in IN N
music NN N
. . N

In IN N
contrast NN N
, , N
neuroimaging VBG N
studies NNS N
targeting VBG N
the DT N
representation NN N
of IN N
music NN N
structure NN N
have VBP N
primarily RB N
implicated VBN N
regions NNS N
in IN N
the DT N
inferior JJ N
frontal JJ N
cortices NNS N
. . N

Combining VBG N
individual-subject JJ i
fMRI NN i
analyses NNS i
with IN N
a DT N
scrambling VBG N
method NN N
that WDT N
manipulated VBD N
musical JJ N
structure NN N
, , N
we PRP N
provide VBP N
evidence NN N
of IN N
brain NN o
regions NNS o
sensitive VBP o
to TO o
musical JJ o
structure NN o
bilaterally RB N
in IN N
the DT N
temporal JJ N
lobes NNS N
, , N
thus RB N
reconciling VBG N
the DT N
neuroimaging NN N
and CC N
patient JJ N
findings NNS N
. . N

We PRP N
further VBP N
show VB N
that IN N
these DT N
regions NNS N
are VBP N
sensitive JJ N
to TO N
the DT N
scrambling NN o
of IN o
both DT o
pitch NN o
and CC o
rhythmic JJ o
structure NN o
but CC N
are VBP N
insensitive JJ N
to TO N
high-level JJ o
linguistic JJ o
structure NN o
. . o

Our PRP$ N
results NNS N
suggest VBP N
the DT N
existence NN N
of IN N
brain NN N
regions NNS N
with IN N
representations NNS o
of IN o
musical JJ o
structure NN o
that WDT N
are VBP N
distinct JJ N
from IN N
high-level JJ N
linguistic JJ N
representations NNS N
and CC N
lower-level JJ N
acoustic JJ N
representations NNS N
. . N

These DT N
regions NNS N
provide VBP N
targets NNS N
for IN N
future JJ N
research NN N
investigating VBG N
possible JJ N
neural JJ N
specialization NN N
for IN N
music NN N
or CC N
its PRP$ N
associated JJ N
mental JJ N
processes NNS N
. . N

-DOCSTART- -11392343- O O

Double-blind NNP N
, , N
placebo-controlled JJ i
study NN N
of IN N
amantadine JJ i
hydrochloride NN i
in IN N
the DT N
treatment NN N
of IN N
children NNS p
with IN p
autistic JJ p
disorder NN p
. . p

OBJECTIVE UH N
To TO N
test VB N
the DT N
hypothesis NN N
that WDT N
amantadine JJ i
hydrochloride NN N
is VBZ N
a DT N
safe JJ N
and CC N
effective JJ N
treatment NN N
for IN N
behavioral JJ o
disturbances NNS o
-- : o
for IN o
example NN N
, , N
hyperactivity NN o
and CC o
irritability NN o
-- : o
in IN o
children NNS p
with IN p
autism NN p
. . p

METHOD NNP N
Thirty-nine JJ p
subjects NNS p
( ( p
intent NN p
to TO p
treat VB p
; : p
5-19 CD p
years NNS p
old JJ p
; : p
IQ NNP p
> NNP p
35 CD p
) ) p
had VBD p
autism NN p
diagnosed VBN p
according VBG p
to TO p
DSM-IV NNP p
and CC p
ICD-10 NNP p
criteria NNS p
using VBG p
the DT p
Autism NNP p
Diagnostic NNP p
Interview-Revised JJ p
and CC p
the DT p
Autism NNP p
Diagnostic NNP p
Observation NNP p
Schedule-Generic NNP p
. . p

The DT N
Aberrant JJ o
Behavior NNP o
Checklist-Community NNP o
Version NNP o
( ( o
ABC-CV NNP o
) ) o
and CC o
Clinical JJ o
Global NNP o
Impressions NNP o
( ( o
CGI NNP o
) ) o
scale NN N
were VBD N
used VBN N
as IN N
outcome JJ N
variables NNS N
. . N

After IN N
a DT N
1-week JJ N
, , N
single-blind JJ N
placebo NN N
run-in NN N
, , N
patients NNS N
received VBD N
a DT N
single JJ i
daily JJ i
dose NN i
of IN i
amantadine NN i
( ( i
2.5 CD i
mg/kg NNS i
per IN i
day NN i
) ) i
or CC i
placebo NN i
for IN i
the DT i
next JJ i
week NN i
, , i
and CC i
then RB i
bid VB i
dosing VBG i
( ( i
5.0 CD i
mg/kg NNS i
per IN i
day NN i
) ) i
for IN i
the DT i
subsequent JJ i
3 CD i
weeks NNS i
. . i

RESULTS VB N
When WRB N
assessed VBN N
on IN N
the DT N
basis NN N
of IN N
parent-rated JJ o
ABC-CV NNP o
ratings NNS o
of IN o
irritability NN o
and CC o
hyperactivity NN o
, , N
the DT N
mean JJ N
placebo NN N
response NN N
rate NN N
was VBD N
37 CD N
% NN N
versus NN N
amantadine NN N
at IN N
47 CD N
% NN N
( ( N
not RB N
significant JJ N
) ) N
. . N

However RB N
, , N
in IN N
the DT N
amantadine-treated JJ i
group NN N
there EX N
were VBD N
statistically RB N
significant JJ N
improvements NNS N
in IN N
absolute JJ N
changes NNS N
in IN N
clinician-rated JJ N
ABC-CVs NNP o
for IN o
hyperactivity NN o
( ( N
amantadine JJ N
-6.4 NNP N
versus NN N
placebo NN N
-2.1 NNP N
; : N
p CC N
= NNP N
.046 NNP N
) ) N
and CC N
inappropriate JJ o
speech NN o
( ( N
-1.9 JJ N
versus NN N
0.4 CD N
; : N
p NN N
= NNP N
.008 NNP N
) ) N
. . N

CGI NNP o
scale JJ o
ratings NNS o
were VBD N
higher JJR N
in IN N
the DT N
amantadine NN N
group NN N
: : N
53 CD N
% NN N
improved JJ N
versus NN N
25 CD N
% NN N
( ( N
p JJ N
= NNP N
.076 NNP N
) ) N
. . N

Amantadine NNP i
was VBD N
well RB N
tolerated VBN N
. . N

CONCLUSIONS NNP N
Parents NNPS N
did VBD N
not RB N
report VB N
statistically RB N
significant JJ N
behavioral JJ o
change NN o
with IN N
amantadine NN N
. . N

However RB N
, , N
clinician-rated JJ o
improvements NNS o
in IN o
behavioral JJ o
ratings NNS o
following VBG N
treatment NN N
with IN N
amantadine JJ i
suggest VBP N
that IN N
further JJ N
studies NNS N
with IN N
this DT N
or CC N
other JJ N
drugs NNS N
acting VBG N
on IN N
the DT N
glutamatergic NN N
system NN N
are VBP N
warranted VBN N
. . N

The DT N
design NN N
of IN N
these DT N
and CC N
similar JJ N
drug NN N
trials NNS N
in IN N
children NNS p
with IN p
autistic JJ p
disorder NN p
must MD N
take VB N
into IN N
account NN N
the DT N
possibility NN N
of IN N
a DT N
large JJ N
placebo NN N
response NN N
. . N

-DOCSTART- -10448447- O O

Befriending NNP i
as IN N
an DT N
intervention NN N
for IN N
chronic JJ p
depression NN p
among IN p
women NNS p
in IN p
an DT p
inner JJ p
city NN p
. . p

2 CD N
: : N
Role NN N
of IN N
fresh-start JJ N
experiences NNS N
and CC N
baseline JJ N
psychosocial JJ N
factors NNS N
in IN N
remission NN p
from IN p
depression NN p
. . p

BACKGROUND NNP N
Volunteer NNP i
befriending NN i
promoted VBD N
remission NN p
of IN p
chronic JJ p
depression NN p
when WRB N
clinical JJ N
and CC N
other JJ N
treatment NN N
variables NNS N
were VBD N
controlled VBN N
. . N

AIMS NNP N
To TO N
examine VB N
the DT N
role NN N
of IN N
other JJ N
psychosocial JJ N
factors NNS N
relevant VBP N
for IN N
outcome NN N
. . N

METHOD NNP N
Factors NNPS N
measured VBD N
at IN N
baseline NN N
interview NN N
were VBD N
examined VBN N
in IN N
multivariate NN N
analyses NNS N
along IN N
with IN N
psychosocial JJ N
factors NNS N
occurring VBG N
during IN N
follow-up JJ N
, , N
such JJ N
as IN N
'fresh-start JJ o
' POS o
experiences NNS o
and CC N
new JJ o
severe JJ o
events NNS o
and CC o
difficulties NNS o
. . o

RESULTS NNP N
Fresh-start JJ o
experiences NNS o
and CC N
a DT N
standard JJ o
attachment NN o
style NN o
were VBD N
found VBN N
to TO N
enhance VB N
chances NNS N
of IN N
remission NN o
, , N
with IN N
new JJ N
severe JJ N
stressors NNS N
and CC N
markedly RB N
poor JJ N
coping VBG N
strategies NNS N
liable JJ N
to TO N
prevent VB N
it PRP N
, , N
with IN N
volunteer NN N
befriending VBG i
continuing VBG N
to TO N
play VB N
a DT N
role NN N
. . N

CONCLUSIONS VB N
The DT N
positive JJ N
result NN N
reported VBN N
in IN N
the DT N
preceding JJ N
paper NN N
is VBZ N
unlikely JJ N
to TO N
be VB N
an DT N
artefact NN N
. . N

However RB N
, , N
fresh-start JJ N
experiences NNS N
, , N
absence NN N
of IN N
new JJ N
severe JJ N
stressors NNS N
and CC N
standard JJ N
attachment NN N
style NN N
were VBD N
more RBR N
important JJ N
predictors NNS N
of IN N
remission NN N
. . N

This DT N
knowledge NN N
might MD N
profitably RB N
be VB N
incorporated VBN N
into IN N
the DT N
evaluation NN N
of IN N
existing VBG N
treatments NNS N
. . N

-DOCSTART- -21618513- O O

Dietary NNP i
lignan NN i
and CC i
proanthocyanidin NN i
consumption NN i
and CC N
colorectal JJ o
adenoma NN o
recurrence NN o
in IN N
the DT N
Polyp NNP N
Prevention NNP N
Trial NNP N
. . N

Lignans NNPS N
and CC N
proanthocyanidins NNS N
are VBP N
plant NN N
polyphenols NNS i
that WDT N
have VBP N
shown VBN N
protective JJ N
properties NNS N
against IN N
colorectal JJ o
neoplasms NNS o
in IN p
some DT p
human JJ p
studies NNS p
. . p

Using VBG N
logistic JJ N
regression NN N
, , N
we PRP N
estimated VBD N
odds NNS N
ratios NNS N
( ( N
ORs NNP N
) ) N
and CC N
95 CD N
% NN N
confidence NN N
intervals NNS N
( ( N
CIs NNP N
) ) N
to TO N
prospectively RB N
evaluate VB N
the DT N
association NN N
between IN N
lignan NN i
and CC i
proanthocyanidin JJ i
intake NN i
, , N
estimated VBN N
from IN N
databases NNS N
linked VBN N
to TO N
a DT N
food NN N
frequency NN N
questionnaire NN N
, , N
and CC N
adenoma JJ o
recurrence NN o
in IN N
1,859 CD p
participants NNS p
of IN p
the DT p
Polyp NNP p
Prevention NNP p
Trial NNP p
. . p

Overall NNP N
, , N
individual NN N
or CC N
total JJ N
lignans NNS N
or CC N
proanthocyanidins NNS N
were VBD N
not RB N
associated VBN N
with IN N
colorectal JJ o
adenoma NN o
recurrence NN o
. . o

However RB N
, , N
in IN N
sex-specific JJ N
analyses NNS N
, , N
total JJ N
lignan JJ N
intake NN N
was VBD N
positively RB N
associated VBN N
with IN N
any DT N
adenoma JJ o
recurrence NN o
in IN N
women NNS N
( ( N
highest JJS N
vs. NN N
lowest JJS N
lignan JJ N
intake NN N
quartile NN N
OR NNP N
= VBZ N
2.07 CD N
, , N
95 CD N
% NN N
CI NNP N
: : N
1.22-3.52 JJ N
, , N
p JJ N
trend NN N
= VBZ N
0.004 CD N
) ) N
but CC N
not RB N
in IN N
men NNS N
( ( N
p JJ N
interaction NN N
= NNP N
0.04 CD N
) ) N
. . N

To TO N
conclude VB N
, , N
dietary JJ N
lignan NN N
and CC N
proanthocyanidin NN N
consumption NN N
were VBD N
not RB N
generally RB N
related VBN N
to TO N
colorectal JJ o
adenoma JJ o
recurrence NN o
; : o
however RB N
, , N
high JJ N
lignan NNS N
intake VBP N
may MD N
increase VB N
the DT N
risk NN o
of IN o
adenoma JJ o
recurrence NN o
in IN p
women NNS p
. . p

-DOCSTART- -19691092- O O

A DT N
randomized JJ N
trial NN N
of IN N
external JJ i
beam NN i
radiotherapy NN i
versus NN N
cryoablation NN i
in IN N
patients NNS p
with IN p
localized JJ p
prostate NN p
cancer NN p
: : p
quality NN N
of IN N
life NN N
outcomes NNS N
. . N

BACKGROUND VB N
A DT N
recent JJ N
randomized JJ N
trial NN N
to TO N
compare VB N
external JJ i
beam NN i
radiation NN i
therapy NN i
( ( i
EBRT NNP i
) ) i
to TO N
cryoablation NN N
for IN N
localized JJ N
disease NN N
showed VBD N
cryoablation NN N
to TO N
be VB N
noninferior JJ N
to TO N
external JJ i
beam NN i
EBRT NNP i
in IN N
disease NN N
progression NN N
and CC N
overall JJ N
and CC N
disease-specific JJ N
survival NN N
. . N

We PRP N
report VBP N
on IN N
the DT N
quality NN o
of IN o
life NN o
( ( o
QOL NNP o
) ) o
outcomes VBZ N
for IN N
this DT N
trial NN N
. . N

METHODS NN N
From IN p
December NNP p
1997 CD p
through IN p
February NNP p
2003 CD p
, , p
244 CD p
men NNS p
with IN p
newly RB p
diagnosed VBN p
localized JJ p
prostate NN p
cancer NN p
were VBD N
randomly RB N
assigned VBN N
to TO N
cryoablation NN i
or CC i
EBRT NNP i
( ( N
median JJ N
dose NN N
68 CD N
Gy NNP N
) ) N
. . N

All DT N
patients NNS N
received VBD N
neoadjuvant JJ i
antiandrogen NN i
therapy NN N
. . N

Patients NNS N
completed VBD N
the DT N
EORTC NNP N
QLQ NNP N
C30 NNP N
and CC N
the DT N
Prostate NNP N
Cancer NNP N
Index NNP N
( ( N
PCI NNP N
) ) N
before IN N
treatment NN N
and CC N
at IN N
1.5 CD N
, , N
3 CD N
, , N
6 CD N
, , N
12 CD N
, , N
18 CD N
, , N
24 CD N
, , N
and CC N
36 CD N
months NNS N
post-treatment JJ N
. . N

RESULTS NNP N
Regardless NNP N
of IN N
treatment NN N
arm NN N
, , N
participants NNS N
reported VBD N
high JJ N
levels NNS N
of IN N
QOL NNP o
with IN N
few JJ N
exceptions NNS N
. . N

cryoablation NN o
was VBD N
associated VBN N
with IN N
more RBR N
acute JJ o
urinary JJ o
dysfunction NN o
( ( N
mean JJ N
PCI NNP N
urinary JJ N
function NN N
cryoablation=69.4 NN N
; : N
mean JJ N
EBRT=90.7 NNP N
; : N
P NNP N
< NNP N
.001 NNP N
) ) N
, , N
which WDT N
resolved VBD N
over IN N
time NN N
. . N

No DT o
late JJ o
arising NN o
QOL NNP o
issues NNS o
were VBD N
observed VBN N
. . N

Both DT N
EBRT NNP i
and CC N
cryoablation NN i
participants NNS N
reported VBD N
decreases NNS o
in IN o
sexual JJ o
function NN o
at IN N
3 CD N
months NNS N
with IN N
the DT N
cryoablation NN N
patients NNS N
reporting VBG N
poorer NN N
functioning NN N
( ( N
mean JJ N
cryoablation=7.2 NN N
: : N
mean JJ N
EBRT=32.9 NNP N
; : N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

Mean JJ o
sexual JJ o
function NN o
score NN o
was VBD N
15 CD N
points NNS N
lower JJR N
at IN N
3 CD N
years NNS N
for IN N
the DT N
cryoablation NN i
group NN N
and CC N
13 CD N
% NN N
more JJR N
of IN N
the DT N
cryoablation NN i
men NNS N
said VBD N
that IN N
sexuality NN N
was VBD N
a DT N
moderate JJ N
or CC N
big JJ N
problem NN N
. . N

CONCLUSIONS NNP N
In IN N
this DT N
randomized JJ N
trial NN N
, , N
no DT N
long-term JJ N
QOL NNP o
advantage NN N
for IN N
either DT N
treatment NN N
was VBD N
apparent JJ N
with IN N
the DT N
exception NN N
of IN N
poorer JJR N
sexual JJ o
function NN o
reported VBN N
by IN N
those DT N
treated VBN N
with IN N
cryoablation NN i
. . i

Men NN N
who WP N
wish VBZ N
to TO N
increase VB N
their PRP$ N
odds NNS N
of IN N
retaining VBG N
sexual JJ o
function NN o
might MD N
be VB N
counseled VBN N
to TO N
choose VB N
EBRT NNP i
over IN N
cryoablation NN i
. . i

-DOCSTART- -22843280- O O

Adjunctive JJ N
perampanel NN i
for IN N
refractory JJ N
partial-onset JJ N
seizures NNS N
: : N
randomized VBN N
phase NN N
III NNP N
study NN N
304 CD N
. . N

OBJECTIVE NN N
To TO N
assess VB N
efficacy NN N
and CC N
safety NN N
of IN N
once-daily JJ N
8 CD N
or CC N
12 CD N
mg JJ N
perampanel NN i
, , N
a DT N
noncompetitive JJ N
?-amino-3-hydroxy-5-methyl-4-isoxazole-propionic JJ N
acid NN N
( ( N
AMPA NNP N
) ) N
receptor NN N
antagonist NN N
, , N
when WRB N
added VBN N
to TO N
concomitant VB N
antiepileptic JJ N
drugs NNS N
( ( N
AEDs NNP N
) ) N
in IN N
the DT N
treatment NN N
of IN N
drug-resistant JJ N
partial-onset JJ N
seizures NNS N
. . N

METHODS NNP N
This DT N
was VBD N
a DT N
multicenter NN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
trial NN N
( ( N
ClinicalTrials.gov NNP N
identifier NN N
: : N
NCT00699972 NNP N
) ) N
. . N

Patients NNS p
( ( p
?12 CD p
years NNS p
, , p
with IN p
ongoing JJ p
seizures NNS p
despite IN p
1-3 JJ p
AEDs NNP p
) ) p
were VBD p
randomized VBN N
( ( N
1:1:1 CD N
) ) N
to TO N
once-daily JJ i
perampanel NN i
8 CD i
mg NN i
, , i
12 CD i
mg NN i
, , i
or CC i
placebo NN i
. . i

Following VBG i
baseline NN N
( ( N
6 CD N
weeks NNS N
) ) N
, , N
patients NNS N
entered VBD N
a DT N
19-week JJ N
double-blind JJ N
phase NN i
: : i
6-week JJ i
titration NN i
( ( i
2 CD i
mg/week NN i
increments NNS i
to TO i
target VB i
dose NN i
) ) i
followed VBN i
by IN i
a DT i
13-week JJ i
maintenance NN i
period NN i
. . i

Percent JJ i
change NN N
in IN N
seizure NN N
frequency NN N
was VBD N
the DT N
primary JJ N
endpoint NN N
; : N
50 CD N
% NN N
responder NN N
rate NN N
was VBD N
the DT N
primary JJ N
endpoint NN N
for IN N
EU NNP N
registration NN N
. . N

RESULTS NNP p
Of IN p
388 CD p
patients NNS p
randomized VBN p
and CC p
treated VBN p
, , p
387 CD p
provided VBD p
seizure NN p
frequency NN p
data NNS p
. . p

Using VBG p
this DT N
intent-to-treat JJ N
population NN N
over IN N
the DT N
double-blind JJ N
phase NN N
, , N
the DT N
median JJ o
percent NN o
change NN o
in IN o
seizure NN o
frequency NN o
was VBD o
-21.0 JJ N
% NN N
, , N
-26.3 CD N
% NN N
, , N
and CC N
-34.5 CD N
% NN N
for IN N
placebo NN i
and CC i
perampanel NN i
8 CD i
and CC N
12 CD N
mg NN N
, , N
respectively RB N
( ( N
p JJ N
= NN N
0.0261 CD N
and CC N
p VB N
= $ N
0.0158 CD N
for IN N
8 CD N
and CC N
12 CD N
mg NN N
vs NN N
placebo NN N
, , N
respectively RB N
) ) N
. . N

Fifty NNP N
percent NN N
responder NN N
rates NNS N
during IN N
the DT N
maintenance NN N
period NN N
were VBD N
26.4 CD N
% NN N
, , N
37.6 CD N
% NN N
, , N
and CC N
36.1 CD N
% NN N
, , N
respectively RB N
, , N
for IN N
placebo NN i
, , i
perampanel VBP i
8 CD i
mg NN N
, , N
and CC N
perampanel $ i
12 CD i
mg NN N
; : N
these DT N
differences NNS N
were VBD N
not RB N
statistically RB N
significant JJ N
for IN N
8 CD N
mg NN N
( ( N
p JJ N
= NNP N
0.0760 CD N
) ) N
or CC N
12 CD N
mg NN N
( ( N
p JJ N
= NNP N
0.0914 CD p
) ) p
. . p

Sixty-eight NNP p
( ( p
17.5 CD p
% NN p
) ) p
patients NNS p
discontinued VBN p
, , p
including VBG p
40 CD p
( ( p
10.3 CD p
% NN p
) ) p
for IN p
adverse JJ p
events NNS p
. . p

Most JJS p
frequent JJ N
treatment-emergent JJ N
adverse JJ N
events NNS N
were VBD o
dizziness RB o
, , o
somnolence NN o
, , o
irritability NN o
, , o
headache NN o
, , o
fall NN o
, , o
and CC o
ataxia RB o
. . o

CONCLUSIONS VB o
This DT N
trial NN N
demonstrated VBD N
that IN N
once-daily RB N
, , N
adjunctive JJ i
perampanel NN i
at IN i
doses NNS N
of IN N
8 CD N
or CC N
12 CD N
mg NNS N
improved JJ o
seizure NN o
control NN o
in IN o
patients NNS p
with IN p
uncontrolled JJ p
partial-onset NN p
seizures NNS p
. . p

Doses NNS p
of IN N
perampanel NN N
8 CD N
and CC N
12 CD N
mg NNS N
were VBD N
safe JJ N
, , N
and CC N
tolerability NN N
was VBD N
acceptable JJ N
. . N

CLASSIFICATION NNP N
OF IN N
EVIDENCE NNP N
This DT N
study NN N
provides VBZ N
Class NNP N
I PRP N
evidence NN N
that IN N
once-daily JJ N
8 CD N
and CC N
12 CD N
mg NN N
doses NNS N
of IN N
adjunctive JJ i
perampanel NNS i
are VBP i
effective JJ N
in IN N
patients NNS N
with IN N
uncontrolled JJ N
partial-onset NN N
seizures NNS N
. . N

-DOCSTART- -16911649- O O

Topical JJ N
adrenaline NN i
in IN N
the DT N
control NN N
of IN N
intraoperative JJ o
bleeding NN o
in IN N
adenoidectomy NN p
: : p
a DT N
randomised JJ N
, , N
controlled JJ N
trial NN N
. . N

OBJECTIVES UH N
To TO N
evaluate VB N
the DT N
efficacy NN N
of IN N
topical JJ N
racemic JJ i
adrenaline NN i
( ( i
RA NNP i
) ) i
( ( N
Micronefrin NNP N
; : N
Bird NNP N
Products NNPS N
, , N
Palm NNP N
Springs NNP N
, , N
CA NNP N
, , N
USA NNP N
) ) N
in IN N
the DT N
control NN N
of IN N
intraoperative JJ o
bleeding NN o
and CC o
the DT o
prevention NN o
of IN o
postoperative JJ o
bleeding NN o
, , o
laryngeal JJ o
spasm NN o
and CC o
postoperative JJ o
pain NN o
in IN N
adenoidectomy NN p
among IN p
children NNS p
< VBP p
6 CD p
years NNS p
of IN p
age NN p
. . p

DESIGN NNP N
Prospective NNP N
, , N
randomised VBD N
, , N
blinded VBD N
and CC N
placebo-controlled JJ N
trial NN N
. . N

SETTING CC N
Kanta-Hame JJ p
Central NNP p
Hospital NNP p
, , p
a DT p
district NN p
referral NN p
center NN p
in IN p
Finland NNP p
. . p

PATIENTS VB N
A DT N
consecutive JJ N
sample NN N
of IN N
93 CD p
children NNS p
undergoing JJ p
outpatient JJ p
adenoidectomy NN p
. . p

INTERVENTION NN N
Patients NNPS N
were VBD N
randomised VBN N
to TO N
receive VB N
topical JJ i
gauze NN i
sponges NNS i
soaked VBN i
in IN i
either DT i
1:500 CD i
RA NNP i
or CC i
0.9 CD i
% NN i
sodium NN i
chloride NN i
( ( i
physiological JJ i
saline NN i
) ) i
for IN i
3 CD i
min NN i
after IN i
adenoidectomy NN i
. . i

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Amount NNP N
of IN N
intraoperative JJ o
bleeding NN o
( ( N
surgeons NNS N
' POS N
subjective JJ N
estimate NN N
) ) N
, , N
need VBP o
for IN o
additional JJ o
packings NNS o
, , o
need VBP o
for IN o
electrocautery NN o
, , o
laryngeal JJ o
spasm NN o
, , o
postoperative JJ o
bleeding NN o
and CC o
pain NN o
, , o
duration NN o
of IN o
procedure NN o
and CC o
duration NN o
of IN o
patients NNS o
' POS o
stay NN o
in IN o
the DT o
operation NN o
room NN o
( ( o
OR NNP o
) ) o
. . o

RESULTS NNP N
Adrenaline NNP i
significantly RB N
decreased VBD N
surgeons NNS N
' POS N
subjective JJ N
estimate NN N
of IN N
the DT N
amount NN o
of IN o
intraoperative JJ o
bleeding NN o
( ( N
proportion NN N
of IN N
patients NNS N
with IN N
significant JJ N
decrease NN N
67 CD N
versus NN N
21 CD N
% NN N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
reduced VBD N
the DT N
mean JJ N
number NN o
of IN o
packings NNS o
needed VBN o
( ( N
0.6 CD N
versus NN N
1.2 CD N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
and CC N
use NN o
of IN o
electrocautery NN o
( ( N
22 CD N
versus RB N
45 CD N
% NN N
, , N
P NNP N
= NNP N
0.015 CD N
) ) N
, , N
and CC N
shortened VBD N
the DT N
mean JJ N
duration NN o
of IN o
the DT o
procedure NN o
( ( N
13 CD N
versus NN N
18 CD N
min NN N
, , N
P NNP N
= NNP N
0.043 CD N
) ) N
and CC N
the DT N
mean JJ N
stay NN o
in IN o
the DT o
OR NNP o
( ( N
31 CD N
versus NN N
35 CD N
min NN N
, , N
P NNP N
= NNP N
0.058 CD N
) ) N
. . N

The DT N
impact NN N
of IN N
adrenaline NN i
was VBD N
even RB N
more RBR N
pronounced JJ N
among IN N
patients NNS p
with IN p
extensive JJ p
adenoids NNS o
and/or VBP p
profuse RB p
intraoperative JJ o
bleeding NN o
. . o

A DT N
slight JJ N
elevation NN o
of IN o
heart NN o
rate NN o
was VBD N
observed VBN N
more RBR N
often RB N
in IN N
the DT N
adrenaline NN i
group NN N
( ( N
P NNP N
= NNP N
0.043 CD N
) ) N
. . N

CONCLUSIONS NNP N
Use NNP N
of IN N
topical JJ N
adrenaline NN i
can MD N
be VB N
recommended VBN N
in IN N
adenoidectomy NN p
among IN p
children NNS p
. . p

It PRP N
helps VBZ N
control VB N
the DT N
intraoperative JJ o
bleeding NN o
, , N
reduces VBZ N
the DT N
use NN N
of IN N
electrocautery NN o
and CC N
shortens VBZ N
the DT N
durations NNS N
of IN N
procedure NN o
and CC o
stay VB o
in IN o
the DT o
OR NNP o
. . o

-DOCSTART- -20124059- O O

Minimally RB N
invasive JJ N
compared VBN N
with IN N
traditional JJ N
transgluteal NN N
approach NN N
for IN N
total JJ p
hip NN p
arthroplasty NN p
: : p
a DT N
comparative JJ N
gait NN N
analysis NN N
. . N

BACKGROUND NNP N
Minimally NNP p
invasive JJ p
total NN p
hip NN p
arthroplasty NN p
is VBZ N
purported VBN N
to TO N
allow VB N
an DT N
improved JJ N
and CC N
faster JJ N
rehabilitation NN o
in IN N
the DT N
immediate JJ N
postoperative JJ N
period NN N
because IN N
of IN N
reduced JJ N
soft-tissue JJ N
damage NN N
compared VBN N
with IN N
total JJ N
hip NN N
arthroplasty NN N
performed VBD N
with IN N
use NN N
of IN N
a DT N
standard JJ N
approach NN N
. . N

In IN N
the DT N
present JJ N
study NN N
, , N
a DT N
minimally RB N
invasive JJ N
approach NN N
was VBD N
compared VBN N
with IN N
a DT N
traditional JJ N
standard NN N
approach NN N
in IN N
terms NNS N
of IN N
the DT N
effect NN N
on IN N
gait NN o
kinematics NNS o
as IN N
demonstrated VBN N
with IN N
gait NN N
analysis NN N
and CC N
electromyography NN N
. . N

METHODS NNP N
Twenty NNP p
randomized VBD p
patients NNS p
who WP p
underwent VBP p
a DT p
primary JJ i
total JJ i
hip NN i
replacement NN i
with IN i
use NN i
of IN i
a DT i
minimally RB i
invasive JJ i
modified VBN i
Watson-Jones JJ i
approach NN i
( ( i
minimally RB i
invasive JJ i
group NN i
) ) i
were VBD p
compared VBN p
with IN p
a DT p
group NN p
of IN p
twenty NN p
patients NNS p
who WP p
underwent VBD p
a DT p
total JJ i
hip NN i
arthroplasty NN i
with IN i
use NN i
of IN i
a DT i
standard JJ i
transgluteal NN i
Hardinge NNP i
approach NN i
( ( i
standard JJ i
group NN i
) ) i
. . i

All DT N
patients NNS N
received VBD N
the DT N
same JJ N
cementless NN i
implant NN i
, , N
inserted VBN N
with IN N
use NN N
of IN N
standard JJ N
instruments NNS N
, , N
and CC N
all DT N
operations NNS N
were VBD N
performed VBN N
by IN N
a DT N
single JJ N
, , N
experienced JJ N
surgeon NN N
. . N

The DT N
patients NNS N
were VBD N
evaluated VBN N
with IN N
use NN N
of IN N
three-dimensional JJ N
gait NN o
analysis NN N
and CC N
dynamic JJ N
electromyograms NNS N
at IN N
three CD N
time NN N
points NNS N
: : N
preoperatively RB N
, , N
ten JJ N
days NNS N
postoperatively RB N
, , N
and CC N
twelve VB N
weeks NNS N
postoperatively RB N
. . N

Temporospatial JJ N
and CC N
joint-kinematic JJ N
parameters NNS N
were VBD N
evaluated VBN N
. . N

RESULTS VB N
There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
the DT N
two CD N
groups NNS N
with IN N
regard NN N
to TO N
the DT N
temporospatial JJ N
variables NNS N
of IN N
velocity NN o
, , o
cadence NN o
, , o
step NN o
length NN o
, , o
and CC o
stride JJ o
length NN o
at IN N
any DT N
tested JJ N
time NN N
point NN N
. . N

With IN N
regard NN N
to TO N
the DT N
range NN o
of IN o
motion NN o
of IN N
the DT N
operatively RB N
treated JJ N
hip NN N
, , N
the DT N
minimally RB N
invasive JJ N
group NN N
had VBD N
a DT N
smaller JJR N
decrease NN N
at IN N
the DT N
ten-day JJ N
time NN N
point NN N
in IN N
comparison NN N
with IN N
the DT N
standard JJ N
group NN N
. . N

However RB N
, , N
this DT N
finding NN N
was VBD N
not RB N
significant JJ N
. . N

The DT N
reduction NN N
in IN N
the DT N
range NN o
of IN o
motion NN o
was VBD N
mainly RB N
caused VBN N
by IN N
reduced JJ N
hip NN N
extension NN N
. . N

A DT N
compensatory JJ N
increase NN N
in IN N
the DT N
pelvic JJ o
tilt NN o
was VBD N
observed VBN N
in IN N
both DT N
groups NNS N
. . N

One CD N
patient NN N
in IN N
the DT N
standard NN N
group NN N
showed VBD N
a DT N
positive JJ N
Trendelenburg NNP o
gait NN o
ten NN N
days NNS N
postoperatively RB N
; : N
it PRP N
had VBD N
disappeared VBN N
completely RB N
at IN N
the DT N
twelve-week JJ N
time NN N
point NN N
. . N

CONCLUSIONS NNP N
With IN N
regard NN N
to TO N
gait VB N
kinematics NNS N
in IN N
the DT N
early JJ N
postoperative JJ N
period NN N
( ( N
three CD N
months NNS N
) ) N
, , N
the DT N
present JJ N
study NN N
showed VBD N
no DT N
significant JJ N
benefit NN N
for IN N
patients NNS p
who WP p
underwent VBD p
a DT p
total JJ p
hip NN p
arthroplasty NN p
through IN p
a DT p
minimally RB p
invasive JJ p
Watson-Jones NNS p
approach NN p
in IN N
comparison NN N
with IN N
those DT N
who WP N
were VBD N
managed VBN N
with IN N
a DT N
standard JJ p
transgluteal NN p
approach NN p
. . p

-DOCSTART- -7616334- O O

Primary JJ N
care-based JJ N
ambulatory NN o
opioid JJ o
detoxification NN o
: : o
the DT N
results NNS N
of IN N
a DT N
clinical JJ N
trial NN N
. . N

OBJECTIVE NN N
To TO N
determine VB N
the DT N
feasibility NN o
of IN N
primary JJ o
care-based JJ o
ambulatory NN o
opioid JJ o
detoxification NN o
( ( o
AOD NNP o
) ) o
using VBG N
two CD N
protocols NNS N
: : N
clonidine NN i
and CC i
clonidine NN i
plus CC i
naltrexone NN i
. . i

SETTING CC N
The DT p
Central NNP p
Medical NNP p
Unit NNP p
( ( p
CMU NNP p
) ) p
-- : p
a DT p
freestanding JJ p
primary NN p
care NN p
medical JJ p
clinic NN p
staffed VBN p
by IN p
physicians NNS p
and CC p
nurse JJ p
practitioners NNS p
. . p

PATIENTS NNP N
Injection NNP p
drug NN p
users NNS p
( ( p
IDUs NNP p
) ) p
seeking VBG p
substance NN p
abuse NN p
treatment NN p
between IN p
the DT p
ages NNS p
of IN p
18 CD p
and CC p
50 CD p
years NNS p
who WP p
were VBD p
addicted VBN p
to TO p
opioids NNS p
( ( p
e.g. NN p
, , N
heroin NN p
) ) p
and CC p
not RB p
currently RB p
in IN p
drug NN p
treatment NN p
. . p

INTERVENTIONS NNP N
In IN N
the DT N
clonidine NN N
protocol NN N
, , N
clonidine NN i
was VBD N
administered VBN N
every DT N
4 CD N
hours NNS N
as IN N
needed VBN N
for IN N
up RB N
to TO N
12 CD N
days NNS N
. . N

In IN N
the DT N
clonidine NN i
plus CC i
naltrexone NN i
protocol NN N
, , N
clonidine NN N
was VBD N
administered VBN N
and CC N
naltrexone NN i
was VBD N
administered VBN N
in IN N
increasing VBG N
doses NNS N
over IN N
five CD N
days NNS N
. . N

Both DT N
protocols NNS N
included VBD N
adjuvant JJ N
medications NNS N
for IN N
muscle NN N
cramps NNS N
, , N
insomnia NN N
, , N
and CC N
vomiting VBG N
. . N

Successfully RB N
detoxified JJ N
patients NNS N
were VBD N
referred VBN N
to TO N
ongoing VBG N
drug NN N
treatment NN N
. . N

DESIGN VB N
A DT N
prospective JJ N
nonrandomized JJ N
clinical JJ N
trial NN N
. . N

MEASUREMENTS NNP N
AND CC N
MAIN NNP N
RESULTS NNP N
One CD p
hundred VBD p
forty JJ p
opioid-addicted JJ p
IDUs NNP p
were VBD p
referred VBN p
to TO p
the DT p
medical JJ p
clinic NN p
for IN p
AOD NNP p
. . p

Among IN p
the DT p
125 CD p
patients NNS p
who WP p
enrolled VBD p
in IN p
the DT p
study NN p
, , p
57 CD p
selected VBN p
clonidine NN p
and CC p
68 CD p
selected VBN p
clonidine/naltrexone NN p
. . p

The DT N
treatment NN N
groups NNS N
( ( N
clonidine JJ N
vs IN N
clonidine/naltrexone NN N
) ) N
were VBD N
similar JJ N
at IN N
baseline NN N
with IN N
respect NN N
to TO N
: : N
age NN N
at IN N
first JJ N
heroin NN N
use NN N
( ( N
21 CD N
years NNS N
vs RB N
23 CD N
years NNS N
) ) N
, , N
mean JJ o
admission NN o
opioid IN o
craving VBG o
score NN o
( ( N
45/100 CD N
vs RB N
49/100 CD N
) ) N
, , N
and CC N
withdrawal NN o
symptom NN o
score NN o
( ( N
19/72 CD N
vs RB N
18/72 CD N
) ) N
. . N

Overall JJ N
, , N
70 CD N
% NN N
( ( N
88/125 CD N
) ) N
of IN N
the DT N
AODs NNP o
were VBD N
successful JJ N
, , N
including VBG N
42 CD N
% NN N
( ( N
24/57 CD N
) ) N
for IN N
clonidine NN N
and CC N
94 CD N
% NN N
( ( N
64/68 CD N
) ) N
for IN N
clonidine/naltrexone NN N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
. . N

CONCLUSIONS VB N
This DT N
study NN N
suggests VBZ N
that IN N
primary JJ N
care-based JJ N
AOD NNP N
can MD N
be VB N
safely RB N
and CC N
effectively RB N
carried VBN N
out RP N
by IN N
primary JJ N
care NN N
providers NNS N
and CC N
that IN N
clonidine/naltrexone NN N
may MD N
be VB N
more RBR N
effective JJ N
in IN N
this DT N
setting NN N
than IN N
is VBZ N
clonidine JJ N
alone RB N
. . N

Ambulatory NNP N
opioid JJ N
detoxification NN N
can MD N
give VB N
internists NNS N
a DT N
larger JJR N
role NN N
in IN N
initiating VBG N
drug NN N
treatment NN N
for IN N
IDUs NNP p
who WP p
are VBP p
addicted VBN p
to TO p
opioids NNS p
. . p

-DOCSTART- -17967671- O O

Mode NNP i
of IN i
ventilation NN i
during IN i
cardiopulmonary JJ i
bypass NN i
does VBZ N
not RB N
affect VB N
immediate JJ N
postbypass NN N
oxygenation NN N
in IN N
pediatric JJ p
cardiac JJ p
patients NNS p
. . p

STUDY NNP N
OBJECTIVE NNP N
To TO N
investigate VB N
the DT N
impact NN o
of IN N
different JJ N
modes NNS i
of IN i
ventilation NN i
during IN i
cardiopulmonary JJ i
bypass NN i
( ( i
CPB NNP i
) ) i
on IN N
immediate JJ N
postbypass NN N
oxygenation NN N
in IN N
pediatric JJ p
cardiac JJ p
surgery NN p
. . p

DESIGN NNP N
Prospective NNP N
, , N
randomized VBD N
clinical JJ N
trial NN N
. . N

SETTING NN N
University NNP N
hospital NN N
. . N

PATIENTS CC N
50 CD p
pediatric JJ p
patients NNS p
( ( p
18 CD p
girls NNS p
, , p
32 CD p
boys NNS p
) ) p
, , p
aged VBD p
4 CD p
months NNS p
to TO p
15 CD p
years NNS p
, , p
undergoing VBG p
elective JJ p
repair NN p
of IN p
congenital JJ p
heart NN p
disease NN p
. . p

INTERVENTIONS JJ N
Patients NNPS N
were VBD N
randomized VBN N
to TO N
receive VB N
one CD i
of IN i
5 CD i
modes NNS i
of IN i
ventilation NN i
during IN i
bypass NN i
. . i

Groups NNP N
1 CD N
and CC N
2 CD N
received VBD N
high-frequency/low-volume JJ i
ventilation NN i
with IN i
100 CD i
% NN i
( ( N
group NN N
1 CD N
) ) N
or CC N
21 CD i
% NN i
oxygen NN i
( ( N
group NN N
2 CD N
) ) N
. . N

Groups $ N
3 CD N
and CC N
4 CD N
received VBD N
continuous JJ i
positive JJ i
airway NN i
pressure NN i
of IN i
5 CD i
cm NN i
H NNP i
( ( i
2 CD i
) ) i
O NN i
with IN i
100 CD i
% NN i
( ( N
group NN N
3 CD N
) ) N
or CC N
21 CD i
% NN i
oxygen NN i
( ( N
group NN N
4 CD N
) ) N
; : N
and CC N
in IN N
group NN N
5 CD N
, , N
each DT i
patient NN i
's POS i
airway NN i
was VBD i
disconnected VBN i
from IN i
the DT i
ventilator NN i
( ( i
passive JJ i
deflation NN i
) ) i
. . N

MEASUREMENTS NNP N
Blood NNP o
gas NN o
analysis NN o
and CC o
spirometry NN o
data NNS o
were VBD N
recorded VBN N
5 CD N
minutes NNS N
before IN N
chest NN N
opening NN N
, , N
5 CD N
minutes NNS N
before IN N
inducing VBG N
bypass NN N
, , N
5 CD N
minutes NNS N
after IN N
weaning VBG N
from IN N
bypass NN N
, , N
and CC N
5 CD N
minutes NNS N
after IN N
chest JJ N
closure NN N
. . N

MAIN NNP N
RESULTS NNP N
There EX N
were VBD N
no DT N
differences NNS N
in IN N
Pao NNP o
( ( o
2 CD o
) ) o
values NNS o
among IN N
the DT N
5 CD N
groups NNS N
studied VBN N
and CC N
at IN N
the DT N
different JJ N
time NN N
points NNS N
. . N

Lung NNP o
compliance NN o
was VBD N
higher JJR N
5 CD N
minutes NNS N
before IN N
bypass NN N
in IN N
group NN N
1 CD N
versus NN N
group NN N
5 CD N
( ( N
34 CD N
+/- JJ N
13 CD N
mL/cm NN N
H NNP N
( ( N
2 CD N
) ) N
O NNP N
vs $ N
20 CD N
+/- JJ N
9 CD N
mL/cm NN N
H NNP N
( ( N
2 CD N
) ) N
O NNP N
; : N
P NNP N
= NNP N
0.048 CD N
) ) N
. . N

CONCLUSIONS NNP N
Mode NNP i
of IN i
ventilation NN i
during IN N
CPB NNP N
did VBD N
not RB N
affect VB N
immediate JJ N
postbypass NN N
oxygenation NN N
. . N

-DOCSTART- -9427455- O O

Safety NN N
and CC N
immunogenicity NN N
of IN N
a DT N
combined JJ N
pentavalent NN i
diphtheria NN i
, , i
tetanus NN i
, , i
acellular JJ i
pertussis NN i
, , i
inactivated VBN i
poliovirus NN i
and CC i
Haemophilus NNP i
influenzae VBP i
type JJ i
b-tetanus JJ i
conjugate NN i
vaccine NN i
in IN N
infants NNS p
, , N
compared VBN N
with IN N
a DT N
whole JJ i
cell NN i
pertussis NN i
pentavalent NN i
vaccine NN i
. . i

BACKGROUND IN N
We PRP N
compared VBN N
the DT N
safety NN N
and CC N
immunogenicity NN N
of IN N
two CD N
combined JJ i
diphtheria-tetanus-pertussis-inactivated JJ i
poliovirus NN i
vaccines NNS i
containing VBG i
either CC i
acellular JJ i
( ( i
Pa NNP i
, , i
SmithKline NNP i
Beecham NNP i
Biologicals NNP i
) ) i
or CC i
whole JJ i
cell NN i
( ( i
Pw NNP i
, , i
Pasteur NNP i
Merieux NNP i
Connaught NNP i
) ) i
pertussis NN i
components NNS i
, , i
mixed JJ i
with IN i
a DT i
Haemophilus NNP i
influenzae NN i
type NN i
b NN i
polysaccharide NN i
polyribosylribitol IN i
phosphate-tetanus JJ i
conjugate NN i
vaccine NN i
in IN N
an DT N
open JJ N
, , N
randomized VBN N
study NN N
in IN N
healthy JJ p
infants NNS p
. . p

DESIGN VB N
The DT N
combined JJ N
vaccines NNS N
were VBD N
given VBN N
at IN N
2 CD N
, , N
4 CD N
, , N
6 CD N
and CC N
12 CD N
months NNS N
of IN N
age NN N
, , N
and CC N
serum NN N
samples NNS N
were VBD N
obtained VBN N
at IN N
ages NNS N
2 CD N
, , N
6 CD N
, , N
7 CD N
, , N
12 CD N
and CC N
13 CD N
months NNS N
. . N

Adverse JJ N
events NNS N
were VBD N
obtained VBN N
by IN N
diary JJ N
cards NNS N
. . N

RESULTS VB N
The DT p
Pa NNP p
group NN p
( ( p
n JJ p
= NNP p
101 CD p
) ) p
had VBD p
a DT p
clearly RB p
lower JJR o
incidence NN o
of IN o
both DT o
local JJ o
and CC o
systemic JJ o
adverse JJ o
events NNS o
than IN p
the DT p
Pw NNP p
group NN p
( ( p
n JJ p
= NNP p
100 CD p
) ) p
. . p

Immunogenicity NNP o
was VBD N
comparable JJ N
for IN N
the DT N
diphtheria NN N
and CC N
tetanus NN N
components NNS N
, , N
but CC N
significantly RB N
superior JJ N
for IN N
pertussis NN o
toxin NN o
, , o
filamentous JJ o
hemagglutinin NN o
, , o
pertactin NN o
and CC o
polioviruses VBZ o
1 CD o
, , o
2 CD o
and CC o
3 CD o
in IN o
the DT o
Pa NNP o
group NN o
. . o

Both DT N
groups NNS N
had VBD N
an DT N
appropriate JJ N
response NN N
with IN N
regard NN N
to TO N
H. NNP N
influenzae NN N
type NN N
b NN N
polysaccharide NN N
polyribosylribitol NN N
phosphate NN N
, , N
but CC N
the DT N
dynamics NNS N
of IN N
the DT N
response NN N
were VBD N
significantly RB N
different JJ N
: : N
geometric JJ o
mean NN o
concentrations NNS o
( ( N
micrograms NNS N
per IN N
ml NN N
) ) N
after IN N
the DT N
second JJ N
, , N
third JJ N
and CC N
booster JJ N
doses NNS N
were VBD N
1.27 CD N
, , N
5.06 CD N
and CC N
23.12 CD N
in IN N
the DT N
Pa NNP N
group NN N
and CC N
2.72 CD N
, , N
6.66 CD N
and CC N
13.59 CD N
in IN N
the DT N
Pw NNP N
group NN N
, , N
respectively RB N
( ( N
P NNP N
= NNP N
0.0002 CD N
after IN N
second JJ N
dose NN N
; : N
P NNP N
= VBD N
0.0005 CD N
after IN N
booster NN N
) ) N
. . N

CONCLUSION VB N
The DT N
presently RB N
studied VBN N
diphtheria NN N
, , N
tetanus NN N
, , N
acellular JJ N
pertussis-H. NN N
influenzae NN N
b NN N
vaccine NN N
conjugated VBN N
to TO N
tetanus VB i
toxoid JJ i
combination NN i
was VBD N
at IN N
least JJS N
as RB N
immunogenic JJ N
as IN N
the DT N
diphtheria NN i
, , i
tetanus NN i
, , i
whole JJ i
cell NN i
pertussis-H. JJ i
influenzae NN i
b NN i
vaccine NN i
conjugated VBN i
to TO i
tetanus VB i
toxoid JJ i
combination NN i
, , N
with IN N
a DT N
significantly RB N
better JJR N
safety NN N
profile NN N
. . N

This DT N
is VBZ N
of IN N
obvious JJ N
importance NN N
in IN N
countries NNS N
where WRB N
inactivated JJ N
poliovirus NN N
vaccine NN N
is VBZ N
part NN N
of IN N
the DT N
routine JJ N
infant NN N
immunization NN N
programs NNS N
. . N

-DOCSTART- -3313023- O O

[ JJ N
Prevention NNP N
of IN N
migraine NN o
with IN N
flunarizine NN i
and CC N
acetylsalicylic JJ i
acid NN i
. . i

A DT N
double-blind JJ N
study NN N
] NNP N
. . N

UNLABELLED CC N
30 CD p
children NNS p
between IN p
7 CD p
and CC p
17 CD p
years NNS p
suffering VBG p
from IN p
at IN p
least JJS p
2 CD p
attacks/month NN p
of IN p
common JJ p
or CC p
classical JJ p
migraine NN p
since IN p
more JJR p
than IN p
1 CD p
year NN p
were VBD N
studied VBN N
. . N

After IN N
clinical JJ N
exclusion NN N
of IN N
symptomatic JJ N
headache NN N
4 CD N
weeks NNS N
were VBD N
documented VBN N
by IN N
means NNS N
of IN N
a DT N
migraine NN N
diary NN N
. . N

Prophylaxis NNP N
with IN N
Calcium NNP N
entry NN N
blocker NN i
Flunarizine NNP i
( ( i
Sibelium NNP i
) ) i
or CC N
Thromboxane VB N
A DT N
inhibitor NN N
Acetylsalicylic NNP i
acid NN i
( ( i
ASS NNP i
) ) i
was VBD N
carried VBN N
out RP N
in IN N
a DT N
double JJ N
blind NN N
design NN N
for IN N
3 CD N
months NNS N
. . N

Medication NNP N
was VBD N
given VBN N
as IN N
one CD N
dosage NN N
in IN N
the DT N
evening NN N
: : N
2-5 JJ N
mg/kg NN N
KG NNP N
ASS NNP i
or CC N
5-10 JJ N
mg NN N
Flunarizine NNP i
. . i

Documented NNP N
attack NN o
frequency NN o
and CC o
duration NN o
were VBD N
controlled VBN N
at IN N
monthly JJ N
physical JJ N
examinations NNS N
. . N

Final JJ N
results NNS N
showed VBD N
no DT N
differences NNS N
in IN N
significant JJ N
reduction NN o
of IN o
attack NN o
frequency NN o
or CC o
symptoms NNS o
between IN N
both DT N
different JJ N
therapeutic JJ N
principals NNS N
. . N

72.4 CD N
% NN N
( ( N
ASS NNP N
73.3 CD N
% NN N
; : N
Flunarizine NNP i
71.4 CD N
% NN N
) ) N
of IN N
patients NNS N
were VBD N
attack-free JJ N
or CC N
had VBD N
at IN N
least JJS N
a DT N
50 CD N
% NN N
reduction NN N
. . N

Migraine NNP o
frequency NN o
of IN N
initially RB N
7-8 NNP N
was VBD N
reduced VBN N
to TO N
1-2 JJ N
attacks/month NN N
. . N

Duration NN o
remained VBD N
constant JJ N
in IN N
both DT N
groups NNS N
( ( N
1-3 JJ N
h NN N
) ) N
. . N

Side JJ N
effects NNS N
were VBD N
slight JJ o
body NN o
weight VBD o
gain NN o
or CC N
abdominal JJ o
pain NN o
after IN N
intake NN N
, , N
prophylaxis NN N
had VBD N
not RB N
to TO N
be VB N
interrupted VBN N
therefore RB N
. . N

Longtime JJ N
prognosis NN N
is VBZ N
not RB N
yet RB N
possible JJ N
because IN N
the DT N
time NN N
of IN N
observation NN N
is VBZ N
too RB N
short JJ N
so RB N
far RB N
. . N

CONCLUSION NNP N
Both NNP N
substances NNS N
are VBP N
definitely RB N
useful JJ N
and CC N
have VBP N
few JJ N
side NN N
effects NNS N
in IN N
childhood NN p
migraine NN p
. . p

If IN N
the DT N
response NN N
to TO N
one CD N
is VBZ N
insufficient JJ N
the DT N
other JJ N
substance NN N
should MD N
be VB N
tried VBN N
. . N

-DOCSTART- -16313112- O O

[ RB N
Clinical NNP N
study NN N
of IN N
feiyanqing VBG i
rectum NN i
condensed VBD i
liquid NN i
in IN N
treating VBG N
36 CD N
cases NNS N
of IN N
children NNS N
syncytial JJ N
viral JJ N
pneumonia NN N
] NNP N
. . N

OBJECTIVE NNP N
To TO N
evaluate VB N
the DT N
clinical JJ N
efficacy NN N
and CC N
mechanism NN N
of IN N
Feiyangqin NNP i
Rectum NNP i
Condensed VBD i
Liquid NNP i
( ( i
FRCL NNP i
) ) i
in IN N
treating VBG N
children NNS p
syncytial JJ p
viral JJ p
pneumonia NN p
. . p

Methods NNS N
Seventy-two JJ p
patients NNS p
were VBD p
randomly RB p
divided VBN p
into IN p
two CD p
groups NNS p
, , p
the DT p
36 CD p
patients NNS p
in IN p
the DT p
treated JJ p
group NN p
were VBD p
treated VBN p
with IN p
FRCL NNP i
, , p
and CC p
the DT p
other JJ p
36 CD p
patients NNS p
in IN p
the DT p
control NN p
group NN p
simply RB p
treated VBD p
with IN p
Western JJ i
medicine NN i
. . i

Efficacy NN o
of IN N
treatment NN N
on IN N
clinical JJ N
condition NN N
and CC N
some DT N
immune JJ o
function NN o
( ( o
IgA NNP o
, , o
IgG NNP o
, , o
CD3 NNP o
, , o
CD4 NNP o
) ) o
were VBD N
observed VBN N
. . N

RESULTS NNP N
In IN N
the DT N
treated JJ N
group NN N
, , N
28 CD N
patients NNS N
were VBD N
cured VBN o
( ( N
77.8 CD N
% NN N
) ) N
, , N
treatment NN N
was VBD N
markedly RB N
effective JJ N
in IN N
4 CD N
patients NNS N
( ( N
11.1 CD N
% NN N
) ) N
, , N
effective JJ N
in IN N
2 CD N
( ( N
5.5 CD N
% NN N
) ) N
and CC N
ineffective JJ N
in IN N
2 CD N
( ( N
5.6 CD N
% NN N
) ) N
, , N
with IN N
the DT N
total JJ o
effective JJ o
rate NN o
of IN N
94.4 CD N
% NN N
. . N

The DT N
corresponding JJ N
number NN N
in IN N
the DT N
control NN N
group NN N
was VBD N
20 CD N
( ( N
55.6 CD N
% NN N
) ) N
, , N
7 CD N
( ( N
19.4 CD N
% NN N
) ) N
, , N
6 CD N
( ( N
16.7 CD N
% NN N
) ) N
, , N
3 CD N
( ( N
8.3 CD N
% NN N
) ) N
and CC N
91.7 CD N
% NN N
, , N
respectively RB N
. . N

The DT N
cure NN o
rate NN o
in IN N
the DT N
treated JJ N
group NN N
was VBD N
obviously RB N
superior JJ N
to TO N
that DT N
in IN N
the DT N
control NN N
group NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

FRCL NNP i
could MD N
improve VB N
serum NN o
IgA NNP o
, , o
IgG NNP o
, , o
CD3 NNP o
, , o
CD4 NNP o
, , o
and CC o
CD4/CD8 NNP o
, , o
lower JJR o
serum NN o
IgE NNP o
, , N
these DT N
indexes NNS N
in IN N
the DT N
treated JJ N
group NN N
were VBD N
significantly RB N
different JJ N
to TO N
those DT N
in IN N
the DT N
control NN N
group NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

CONCLUSION NNP N
FRCL NNP i
had VBD N
the DT N
action NN N
in IN N
treating VBG N
children NNS N
syncytial JJ N
viral JJ N
pneumonia NN N
without IN N
any DT N
adverse JJ N
reaction NN N
, , N
one CD N
of IN N
its PRP$ N
mechanisms NNS N
might MD N
be VB N
related VBN N
to TO N
its PRP$ N
regulation NN N
on IN N
immune JJ N
function NN N
. . N

-DOCSTART- -20203165- O O

Effect NN o
of IN N
membrane NN N
permeability NN N
on IN N
inflammation NN N
and CC N
arterial JJ N
stiffness NN N
: : N
a DT N
randomized JJ N
trial NN N
. . N

BACKGROUND NNP N
AND CC N
OBJECTIVES NNP N
Both NNP N
larger JJR N
molecule NN N
removal NN N
and CC N
dialyzer NN N
biocompatibility NN N
have VBP N
been VBN N
implicated VBN N
in IN N
the DT N
high-flux JJ i
hemodialysis NN i
( ( N
HD NNP N
) ) N
-associated VBD N
favorable JJ N
outcome NN N
. . N

In IN N
an DT N
attempt NN N
to TO N
delineate VB N
the DT N
effect NN N
of IN N
membrane NN N
permeability NN N
, , N
we PRP N
performed VBD N
a DT N
randomized VBN N
, , N
crossover NN N
study NN N
to TO N
compare VB N
the DT N
inflammatory JJ N
biomarkers NNS N
, , N
lipid JJ N
profile NN N
, , N
and CC N
aortic JJ N
pulse NN N
wave NN N
velocity NN N
( ( N
PWV NNP N
) ) N
of IN N
two CD N
dialyzers NNS N
that WDT N
are VBP N
composed VBN N
of IN N
identical JJ N
membranes NNS N
but CC N
with IN N
different JJ N
flux NN N
characteristics NNS N
. . N

DESIGN NNP N
, , N
SETTING NNP N
, , N
PARTICIPANTS NNP N
, , N
& CC N
MEASUREMENTS NNP N
Stable JJ p
patients NNS p
who WP p
had VBD p
anuria NNS p
and CC p
were VBD p
on IN p
low-flux JJ p
polysulfone NN p
membrane NN p
were VBD N
randomly RB N
allocated VBN N
either RB N
to TO N
HD NNP i
with IN i
high-flux JJ i
polyamide NN i
membrane NN i
( ( N
group NN N
A NNP N
; : N
22 CD N
patients NNS N
) ) N
or CC N
to TO N
HD NNP i
with IN i
low-flux JJ i
polyamide NN i
membrane NN i
( ( N
group NN N
B NNP N
; : N
24 CD N
patients NNS N
) ) N
for IN N
24 CD N
weeks NNS N
, , N
then RB N
they PRP N
were VBD N
started VBN N
on IN N
24 CD N
weeks NNS N
of IN N
the DT N
alternative JJ i
HD NNP i
treatment NN i
. . i

Apart RB N
from IN N
the DT N
dialyzer NN N
, , N
the DT N
dialysis NN N
prescription NN N
remained VBD N
unchanged JJ N
. . N

RESULTS NNP N
Nineteen JJ p
patients NNS p
from IN p
group NN p
A NNP p
and CC p
23 CD p
patients NNS p
from IN p
group NN p
B NNP p
completed VBD p
the DT p
study NN p
. . p

Predialysis NNP o
beta NN o
( ( o
2 CD o
) ) o
-microglobulin NN o
levels NNS o
decreased VBN N
significantly RB N
when WRB N
using VBG N
the DT N
high-flux JJ i
polyamide NN i
membrane NN i
. . i

No DT N
difference NN N
between IN N
membranes NNS N
was VBD N
observed VBN N
for IN N
serum NN o
albumin NN o
, , o
high-sensitivity JJ o
C-reactive JJ o
protein NN o
, , o
fibrinogen NN o
, , o
IL-6 NNP o
, , o
triglycerides NNS o
, , o
HDL NNP o
cholesterol NN o
, , o
LDL NNP o
cholesterol NN o
, , o
and CC o
lipoprotein NN o
( ( o
a DT o
) ) o
during IN N
the DT N
study NN N
. . N

A DT N
significant JJ N
increase NN N
in IN N
aortic JJ o
PWV NNP o
, , o
a DT o
marker NN o
of IN o
aortic JJ o
stiffness NN o
, , N
was VBD N
noted VBN N
after IN N
patients NNS N
switched VBD N
from IN N
high-flux NN i
to TO N
low-flux JJ i
polyamide NN i
membranes NNS i
. . i

Similarly RB N
, , N
the DT N
rate NN o
of IN o
change NN o
in IN o
aortic JJ o
PWV NNP o
was VBD N
significantly RB N
decreased VBN N
with IN N
the DT N
use NN N
of IN N
the DT N
high-flux JJ i
polyamide NN i
membrane NN i
. . i

CONCLUSIONS NNP N
Our PRP$ N
findings NNS N
suggest VBP N
that IN N
dialysis NN N
with IN N
polyamide JJ i
membranes NNS i
with IN N
different JJ N
flux NN N
characteristics NNS N
did VBD N
not RB N
modify VB N
the DT N
inflammatory NN N
indices NNS N
and CC N
lipid JJ N
profile NN N
in IN N
stable JJ p
HD NNP p
patients NNS p
; : p
however RB N
, , N
a DT N
seemingly RB N
beneficial JJ N
effect NN N
on IN N
aortic JJ N
stiffness NN N
was VBD N
noted VBN N
for IN N
patients NNS p
who WP p
were VBD p
maintained VBN p
on IN p
high-flux JJ i
polyamide NN i
membrane NN i
. . i

-DOCSTART- -17393618- O O

Effects NNS N
of IN N
electro-acupuncture NN i
on IN N
T NNP o
cell NN o
subpopulations NNS o
, , o
NK NNP o
activity NN o
, , o
humoral JJ o
immunity NN o
and CC o
leukocyte NN o
count NN o
in IN p
patients NNS p
undergoing JJ p
chemotherapy NN p
. . p

OBJECTIVE UH N
To TO N
observe VB N
the DT N
effects NNS N
of IN N
electro-acupuncture NN i
on IN N
T NNP o
cell NN o
subpopulations NNS o
, , o
natural JJ o
killer NN o
cell NN o
( ( o
NK NNP o
) ) o
activity NN o
, , o
humoral JJ o
immunity NN o
and CC o
leukocyte NN o
count NN o
in IN N
patients NNS p
undergoing JJ p
chemotherapy NN i
. . i

METHODS NNP N
Electro-acupuncture NN i
was VBD N
added VBN N
for IN N
patients NNS p
undergoing JJ p
chemotherapy NN i
. . i

Tests NNS N
were VBD N
done VBN N
on IN N
T NNP o
cell NN o
subpopulations NNS o
, , o
NK NNP o
activity NN o
, , o
humoral JJ o
immunity NN o
and CC o
leukocyte JJ o
count NN o
before IN N
treatment NN N
and CC N
after IN N
4 CD N
courses NNS N
of IN N
treatment NN N
. . N

RESULTS NNP N
After IN N
4 CD N
courses NNS N
of IN N
treatment NN N
with IN N
chemotherapy NN i
and CC N
electro-acupuncture NN i
, , N
no DT N
obvious JJ N
changes NNS o
were VBD N
found VBN N
in IN N
T NNP o
cell NN o
subpopulations NNS o
, , o
NK NNP o
activity NN o
, , o
humoral JJ o
immunity NN o
and CC o
leukocyte NN o
count NN o
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
as IN N
compared VBN N
with IN N
those DT N
before IN N
treatment NN N
. . N

Patients NNS N
undergoing VBG N
chemotherapy NN i
combined VBN N
with IN N
electro-acupuncture NN i
showed VBD N
obviously RB N
higher JJR N
leukocyte NN o
count NN o
than IN N
that DT N
of IN N
the DT N
control NN N
group NN N
given VBN N
no DT N
leukogenic JJ N
drugs NNS N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

CONCLUSION NNP N
Electro-acupuncture NN i
may MD N
reduce VB N
immunologic JJ o
damage NN o
caused VBN N
by IN N
chemotherapy NN i
, , N
thus RB N
it PRP N
can MD N
be VB N
used VBN N
as IN N
the DT N
auxiliary JJ N
therapy NN N
for IN N
patients NNS p
undergoing JJ p
chemotherapy NN i
. . i

-DOCSTART- -18678836- O O

Concurrent NNP i
doxorubicin NN i
plus CC i
docetaxel NN i
is VBZ N
not RB N
more RBR N
effective JJ N
than IN N
concurrent NN i
doxorubicin NN i
plus CC i
cyclophosphamide NN i
in IN N
operable JJ p
breast NN o
cancer NN o
with IN p
0 CD p
to TO p
3 CD p
positive JJ p
axillary JJ p
nodes NNS p
: : p
North JJ N
American JJ N
Breast NNP N
Cancer NNP N
Intergroup NNP N
Trial NNP N
E NNP N
2197 CD N
. . N

PURPOSE VB N
The DT N
combination NN N
of IN N
doxorubicin NN i
and CC i
cyclophosphamide NN i
( ( i
AC NNP i
) ) i
is VBZ N
a DT N
standard JJ N
adjuvant JJ N
regimen NNS N
. . N

Doxorubicin NNP i
and CC i
docetaxel NN i
( ( i
AT NNP i
) ) i
is VBZ N
one CD N
of IN N
the DT N
most RBS N
active JJ N
cytotoxic NN N
regimens NNS N
for IN N
metastatic JJ o
breast NN o
cancer NN o
. . o

The DT N
purpose NN N
of IN N
this DT N
trial NN N
was VBD N
to TO N
determine VB N
whether IN N
adjuvant NN N
AT NNP N
improved VBD N
disease-free JJ N
survival NN N
compared VBN N
with IN N
AC NNP N
in IN N
operable JJ p
breast NN o
cancer NN o
. . o

PATIENTS NNP N
AND CC N
METHODS NNP N
Women NNP p
with IN p
invasive JJ p
breast NN p
cancer NN p
were VBD p
eligible JJ p
if IN p
there EX p
were VBD p
one CD p
to TO p
three CD p
positive JJ p
lymph NN p
nodes NNS p
or CC p
if IN p
the DT p
node-negative JJ p
tumor NN p
was VBD p
greater JJR p
than IN p
1 CD p
cm NN p
. . p

Patients NNS p
were VBD p
randomly RB p
assigned VBN p
after IN p
surgery NN p
to TO N
receive VB N
doxorubicin NN i
( ( N
60 CD N
mg/m NN N
( ( N
2 CD N
) ) N
) ) N
plus CC i
either DT i
cyclophosphamide NN i
( ( N
600 CD N
mg/m NN N
( ( N
2 CD N
) ) N
; : N
AC NNP N
) ) N
or CC i
docetaxel NN i
( ( N
60 CD N
mg/m NN N
( ( N
2 CD N
) ) N
; : N
AT NNP N
) ) N
given VBN N
every DT N
3 CD N
weeks NNS N
for IN N
four CD N
cycles NNS N
, , N
followed VBN N
by IN N
hormone NN N
therapy NN N
for IN N
patients NNS p
with IN p
estrogen JJ p
receptor NN p
( ( p
ER NNP p
) ) p
and/or VBP p
progesterone NN p
receptor NN p
( ( p
PR NNP p
) ) p
-positive JJ p
tumors NNS p
. . p

RESULTS VB N
There EX N
were VBD N
2,882 CD p
eligible JJ p
patients NNS p
enrolled VBN p
. . p

After IN N
a DT N
median JJ N
follow-up NN N
of IN N
79.5 CD N
months NNS N
, , N
there EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
disease-free JJ o
survival NN o
( ( N
DFS NNP N
; : N
85 CD N
% NN N
in IN N
both DT N
arms NNS N
) ) N
or CC N
overall JJ o
survival NN o
( ( N
91 CD N
% NN N
v JJ N
92 CD N
% NN N
) ) N
at IN N
5 CD N
years NNS N
. . N

The DT N
hazard NN o
ratio NN o
for IN N
AC NNP i
versus NN N
AT NNP N
was VBD N
1.02 CD N
( ( N
95 CD N
% NN N
CI NNP N
for IN N
DFS NNP N
, , N
0.86 CD N
to TO N
1.22 CD N
; : N
P NNP N
= NNP N
.78 NNP N
) ) N
. . N

In IN N
an DT N
exploratory JJ N
analysis NN N
of IN N
prespecified JJ N
stratification NN N
factors NNS N
by IN N
ER NNP N
and CC N
PR NNP N
expression NN N
there EX N
were VBD N
trends NNS N
toward IN N
improved JJ o
DFS NNP o
for IN N
AT NNP N
in IN N
ER/PR-negative JJ N
disease NN N
. . N

Grade VB o
3 CD o
neutropenia RB o
associated VBN o
with IN o
fever NN o
or CC o
infection NN o
occurred VBD N
more RBR N
often RB N
with IN N
AT NNP N
( ( N
26 CD N
% NN N
v JJ N
10 CD N
% NN N
; : N
P NNP N
< NNP N
.05 NNP N
) ) N
. . N

CONCLUSION NN N
AT NNP i
did VBD N
not RB N
improve VB N
DFS NNP o
or CC o
overall JJ o
survival NN o
in IN N
this DT N
population NN N
, , N
and CC N
was VBD N
associated VBN N
with IN N
more JJR N
toxicity NN o
. . o

-DOCSTART- -11471578- O O

A DT N
comparison NN N
of IN N
acupuncture NN i
with IN N
advice NN i
and CC i
exercises NNS i
on IN N
the DT N
symptomatic JJ o
treatment NN o
of IN N
osteoarthritis NN p
of IN p
the DT p
hip NN p
-- : p
a DT p
randomised JJ N
controlled VBN N
trial NN N
. . N

Acupuncture NN i
is VBZ N
becoming VBG N
a DT N
common JJ N
technique NN N
within IN N
the DT N
physiotherapy NN N
profession NN N
as IN N
a DT N
treatment NN N
modality NN N
for IN N
pain NN o
relief NN o
; : o
however RB N
, , N
few JJ N
randomised VBD N
controlled VBN N
trials NNS N
have VBP N
been VBN N
undertaken VBN N
to TO N
assess VB N
the DT N
effectiveness NN N
of IN N
acupuncture NN i
, , N
particularly RB N
in IN N
the DT N
treatment NN N
of IN N
osteoarthritis NN p
( ( p
OA NNP p
) ) p
of IN p
the DT p
hip NN p
. . p

Therefore RB N
, , N
a DT N
randomised JJ N
trial NN N
to TO N
compare VB N
the DT N
effectiveness NN N
of IN N
acupuncture NN i
with IN N
advice NN N
and CC N
exercises NNS i
on IN N
the DT N
symptomatic JJ N
treatment NN N
of IN N
OA NNP p
of IN p
the DT p
hip NN p
was VBD N
carried VBN N
out RP N
. . N

Thirty-two JJ p
patients NNS p
awaiting VBG p
a DT p
total JJ p
hip NN p
arthroplasty NN p
were VBD N
randomly RB N
allocated VBN N
to TO N
either CC N
the DT N
experimental JJ N
group NN N
, , N
( ( N
A DT N
) ) N
, , N
to TO N
have VB N
six CD i
sessions NNS i
of IN i
acupuncture NN i
each DT N
lasting VBG N
up RP N
to TO N
25 CD N
minutes NNS N
, , N
or CC N
the DT N
control NN N
group NN N
, , N
( ( N
B NNP N
) ) N
, , N
to TO N
be VB N
given VBN N
advice NN i
and CC i
exercises NNS i
for IN N
their PRP$ N
hip NN N
over IN N
a DT N
six CD N
week NN N
period NN N
. . N

Group NNP p
A NNP p
consisted VBD p
of IN p
three CD p
men NNS p
and CC p
13 CD p
women NNS p
, , p
and CC p
group NN p
B NNP p
consisted VBD p
of IN p
four CD p
men NNS p
and CC p
eight CD p
women NNS p
. . p

The DT N
average JJ p
age NN p
in IN p
group NN p
A NNP p
was VBD p
66 CD p
years NNS p
and CC p
in IN p
group NN p
B NNP p
it PRP p
was VBD p
68 CD p
years NNS p
. . p

Patients NNS N
were VBD N
assessed VBN N
for IN N
pain NN N
and CC N
functional JJ N
ability NN N
, , N
using VBG N
a DT N
modified JJ N
version NN N
of IN N
the DT N
WOMAC NNP o
questionnaire NN o
, , N
pre-treatment JJ N
, , N
immediately RB N
post-treatment JJ N
and CC N
at IN N
eight CD N
weeks NNS N
post-treatment JJ N
. . N

The DT N
pre-treatment JJ N
WOMAC NNP o
scores NNS o
in IN N
the DT N
two CD N
groups NNS N
were VBD N
similar JJ N
( ( N
p=0.85 NN N
) ) N
. . N

There EX N
was VBD N
a DT N
significant JJ N
improvement NN N
in IN N
group NN N
A NNP N
( ( N
decrease NN N
in IN N
WOMAC NNP o
score NN o
) ) o
immediately RB N
post-treatment JJ N
( ( N
p=0.002 NN N
) ) N
and CC N
this DT N
was VBD N
maintained VBN N
at IN N
the DT N
eight-week JJ N
follow-up NN N
( ( N
p=0.03 NN N
) ) N
. . N

There EX N
were VBD N
no DT N
significant JJ N
changes NNS N
in IN N
group NN N
B NNP N
. . N

When WRB N
the DT N
changes NNS N
in IN N
WOMAC NNP o
scores NNS o
were VBD N
compared VBN N
between IN N
groups NNS N
, , N
a DT N
significantly RB N
greater JJR N
improvement NN N
was VBD N
found VBN N
between IN N
pre-treatment JJ N
and CC N
immediately RB N
post-treatment JJ N
in IN N
group NN N
A NNP N
, , N
compared VBN N
with IN N
group NN N
B NNP N
( ( N
p=0.02 NN N
) ) N
. . N

The DT N
changes NNS N
between IN N
pre-treatment NN N
and CC N
the DT N
eight-week JJ N
follow-up NN N
also RB N
showed VBD N
a DT N
significant JJ N
improvement NN N
in IN N
group NN N
A NNP N
compared VBN N
with IN N
group NN N
B NNP N
( ( N
p=0.03 NN N
) ) N
. . N

In IN N
conclusion NN N
, , N
this DT N
trial NN N
supports VBZ N
the DT N
hypothesis NN N
that IN N
acupuncture NN i
is VBZ N
more RBR N
effective JJ o
than IN N
advice NN N
and CC N
exercises NNS N
in IN N
the DT N
symptomatic JJ N
treatment NN N
of IN N
OA NNP N
of IN N
the DT N
hip NN N
. . N

-DOCSTART- -21849168- O O

Effect NN N
of IN N
gravity NN N
on IN N
robot-assisted JJ i
motor NN i
training NN i
after IN p
chronic JJ o
stroke NN o
: : o
a DT N
randomized JJ N
trial NN N
. . N

OBJECTIVES UH N
To TO N
determine VB N
the DT N
efficacy NN N
of IN N
2 CD N
distinct JJ N
6-week JJ N
robot-assisted JJ i
reaching NN i
programs NNS i
compared VBN N
with IN N
an DT N
intensive JJ N
conventional JJ i
arm NN i
exercise NN i
program NN i
( ( N
ICAE NNP N
) ) N
for IN N
chronic NN o
, , o
stroke-related JJ o
upper-extremity NN o
( ( o
UE NNP o
) ) o
impairment NN N
. . N

To TO N
examine VB N
whether IN N
the DT N
addition NN N
of IN N
robot-assisted JJ i
training VBG i
out IN p
of IN p
the DT p
horizontal JJ p
plane NN p
leads VBZ N
to TO N
improved VBN N
outcomes NNS N
. . N

DESIGN NNP N
Randomized NNP N
controlled VBD N
trial NN N
, , N
single-blinded JJ N
, , N
with IN N
12-week JJ N
follow-up NN N
. . N

SETTING NNP N
Research NNP N
setting VBG N
in IN N
a DT N
large JJ N
medical JJ N
center NN N
. . N

PARTICIPANTS NNP N
Adults NNP p
( ( p
N=62 NNP p
) ) p
with IN p
chronic JJ p
, , p
stroke-related JJ p
arm NN p
weakness NN p
stratified VBN p
by IN p
impairment JJ p
severity NN p
using VBG p
baseline JJ p
UE NNP p
motor NN p
assessments NNS p
. . p

INTERVENTIONS NNP N
Sixty NNP N
minutes NNS N
, , N
3 CD N
times NNS N
a DT N
week NN N
for IN N
6 CD N
weeks NNS N
of IN N
robot-assisted JJ i
planar NN i
reaching NN i
( ( i
gravity NN i
compensated VBN i
) ) i
, , i
combined VBN i
planar NN i
with IN i
vertical JJ i
robot-assisted JJ i
reaching NN i
, , N
or CC N
intensive JJ i
conventional JJ i
arm NN i
exercise NN i
program NN i
. . i

MAIN NNP N
OUTCOME NNP N
MEASURE NNP N
UE NNP o
Fugl-Meyer NNP o
Assessment NNP o
( ( o
FMA NNP o
) ) o
mean VBP o
change NN o
from IN N
baseline NN N
to TO N
final JJ N
training NN N
. . N

RESULTS NNP N
All DT N
groups NNS N
showed VBD N
modest JJ o
gains NNS o
in IN o
the DT o
FMA NNP o
from IN N
baseline NN N
to TO N
final JJ N
with IN N
no DT N
significant JJ N
between IN N
group NN N
differences NNS N
. . N

Most JJS N
change NN N
occurred VBD N
in IN N
the DT N
planar NN N
robot NN N
group NN N
( ( N
mean JJ N
change NN N
? . N
SD NNP N
, , N
2.94 CD N
? . N
0.77 CD N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NNP N
, , N
1.40-4.47 JJ p
) ) p
. . p

Participants NNS p
with IN p
greater JJR o
motor NN o
impairment NN o
( ( o
n=41 JJ p
) ) p
demonstrated VBD p
a DT N
larger JJR N
difference NN N
in IN N
response NN o
( ( o
mean JJ N
change NN N
? . N
SD NNP N
, , N
2.29 CD N
? . N
0.72 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
0.85-3.72 NNP N
) ) N
for IN N
planar JJ N
robot-assisted JJ N
exercise NN N
compared VBN N
with IN N
the DT N
intensive JJ N
conventional JJ N
arm NN N
exercise NN N
program NN N
( ( N
mean JJ N
change NN N
? . N
SD NNP N
, , N
0.43 CD N
? . N
0.72 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
-1.00 NNP N
to TO N
1.86 CD N
) ) N
. . N

CONCLUSIONS NNP o
Chronic NNP o
UE NNP o
deficits NNS o
because IN N
of IN N
stroke NN N
are VBP o
responsive JJ o
to TO N
intensive JJ N
motor NN N
task NN N
training NN N
. . N

However RB N
, , N
training VBG N
outside IN N
the DT N
horizontal JJ N
plane NN N
in IN N
a DT N
gravity NN N
present JJ N
environment NN N
using VBG N
a DT N
combination NN N
of IN N
vertical JJ N
with IN N
planar JJ N
robots NNS N
was VBD o
not RB o
superior JJ o
to TO o
training VBG o
with IN N
the DT N
planar NN N
robot NN N
alone RB N
. . N

-DOCSTART- -22882961- O O

Who WP N
is VBZ N
at IN N
low JJ N
risk NN N
for IN N
cardiovascular JJ N
disease NN N
? . N
An DT N
assessment NN N
of IN N
different JJ N
definitions NNS N
. . N

BACKGROUND NNP N
There EX N
is VBZ N
little JJ N
information NN N
regarding VBG N
the DT N
determinants NNS N
and CC N
trends NNS N
of IN N
the DT N
prevalence NN N
of IN N
low JJ o
cardiovascular JJ o
risk NN o
factor NN o
( ( N
RF NNP N
) ) N
profile NN N
in IN N
the DT N
general JJ p
population NN p
. . p

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
assess VB N
the DT N
prevalence NN o
and CC o
trends NNS o
of IN o
low JJ o
RF NNP o
profile NN o
in IN N
the DT N
Swiss JJ p
population NN p
according VBG N
to TO N
different JJ N
definitions NNS N
. . N

METHODS NNP N
Population-based JJ i
cross-sectional JJ i
studies NNS i
conducted VBN p
in IN p
1984-1986 JJ p
( ( p
N=3300 NNP p
) ) p
, , p
1988-1989 JJ p
( ( p
N=3331 NNP p
) ) p
, , p
1992-1993 JJ p
( ( p
N=3133 NNP p
) ) p
and CC p
2003-2006 JJ p
( ( p
N=6170 NNP p
) ) p
and CC p
restricted VBN p
to TO p
age NN p
group NN p
35-75 CD p
years NNS p
. . p

Seven RB i
different JJ i
definitions NNS i
of IN i
low JJ i
RF NNP i
profile NN i
were VBD N
used VBN N
to TO N
assess VB N
determinants NNS N
, , N
while IN N
two CD N
definitions NNS N
were VBD N
used VBN N
to TO N
assess VB N
trends NNS N
. . N

RESULTS NNP N
Prevalence NNP N
of IN N
low JJ o
RF NNP o
profile NN o
varied VBD N
between IN N
6.5 CD N
% NN N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
: : N
5.9-7.1 JJ N
) ) N
and CC N
9.7 CD N
% NN N
( ( N
9.0-10.5 CD N
) ) N
depending VBG N
on IN N
the DT N
definition NN N
used VBN N
. . N

This DT N
prevalence NN N
was VBD N
higher JJR N
than IN N
in IN N
other JJ N
countries NNS N
. . N

Irrespective NNP N
of IN N
the DT N
definition NN N
used VBN N
, , N
the DT N
prevalence NN N
of IN N
low JJ o
RF NNP o
profile NN o
was VBD N
higher RBR N
in IN N
women NNS N
and CC N
in IN N
physically RB N
active JJ N
participants NNS N
, , N
and CC N
decreased VBD N
with IN N
increasing VBG N
age NN N
or CC N
in IN N
the DT N
presence NN N
of IN N
a DT N
family NN N
history NN N
of IN N
cardiovascular JJ N
disease NN N
. . N

Using VBG N
one CD N
definition NN N
, , N
the DT N
prevalence NN N
of IN N
low JJ N
RF NNP o
profile NN o
increased VBD N
from IN N
3.8 CD N
% NN N
( ( N
3.1-4.5 JJ N
) ) N
in IN N
1984-1986 JJ N
to TO N
6.7 CD N
% NN N
( ( N
6.1-7.3 JJ N
) ) N
in IN N
2003-2006 JJ N
; : N
using VBG N
another DT N
definition NN N
, , N
the DT N
results NNS N
were VBD N
5.9 CD N
% NN N
( ( N
5.1-6.8 JJ N
) ) N
and CC N
9.7 CD N
% NN N
( ( N
9.0-10.5 CD N
) ) N
, , N
respectively RB N
. . N

CONCLUSION NNP N
Switzerland NNP N
is VBZ N
characterized VBN N
by IN N
a DT N
high JJ N
and CC N
increasing VBG N
prevalence NN N
of IN N
low JJ N
RF NNP N
profile NN N
within IN N
the DT N
age NN p
group NN p
35 CD p
to TO p
75 CD p
, , N
irrespective NN N
of IN N
the DT N
criteria NNS N
used VBN N
. . N

This DT N
high JJ N
prevalence NN N
might MD N
partly RB N
explain VB N
the DT N
low JJ N
and CC N
decreasing VBG o
trend NN o
in IN o
cardiovascular JJ o
mortality NN o
rates NNS o
. . o

-DOCSTART- -10437192- O O

Clinical JJ N
observation NN N
on IN N
treatment NN N
of IN N
obstinate JJ p
heart NN p
failure NN p
by IN N
supplementing VBG i
qi NN i
and CC i
activating VBG i
blood NN i
flow NN i
. . i

-DOCSTART- -24217336- O O

Improving VBG N
maternal JJ o
mental JJ o
health NN o
after IN p
a DT p
child NN p
's POS p
diagnosis NN p
of IN p
autism NN p
spectrum JJ p
disorder NN p
: : p
results NNS N
from IN N
a DT N
randomized JJ N
clinical JJ N
trial NN N
. . N

IMPORTANCE VBZ N
The DT N
prevalence NN N
of IN N
psychological JJ N
distress NN N
among IN N
mothers NNS p
of IN p
children NNS p
with IN p
autism NN p
spectrum NN p
disorder NN p
( ( p
ASD NNP p
) ) p
suggests VBZ N
a DT N
need NN N
for IN N
interventions NNS N
that WDT N
address VBP N
parental JJ o
mental JJ o
health NN o
during IN N
the DT N
critical JJ N
period NN N
after IN N
the DT N
child NN N
's POS N
autism NN N
diagnosis NN N
when WRB N
parents NNS N
are VBP N
learning VBG N
to TO N
navigate VB N
the DT N
complex JJ N
system NN N
of IN N
autism NN N
services NNS N
. . N

OBJECTIVE NNP N
To TO N
investigate VB N
whether IN N
a DT N
brief JJ N
cognitive JJ N
behavioral JJ N
intervention NN N
, , N
problem-solving JJ i
education NN i
( ( i
PSE NNP i
) ) i
, , N
decreases VBZ N
parenting VBG o
stress NN o
and CC o
maternal JJ o
depressive NN o
symptoms NNS o
during IN N
the DT N
period NN N
immediately RB N
following VBG N
a DT N
child NN N
's POS N
diagnosis NN N
of IN N
ASD NNP N
. . N

DESIGN NNP N
, , N
SETTING NNP N
, , N
AND NNP N
PARTICIPANTS NNP N
A NNP N
randomized VBD N
clinical JJ N
trial NN N
compared VBN N
6 CD N
sessions NNS N
of IN N
PSE NNP i
with IN N
usual JJ i
care NN i
. . i

Settings NNP N
included VBD N
an DT N
autism NN p
clinic NN p
and CC p
6 CD p
community-based JJ p
early JJ p
intervention NN p
programs NNS p
that WDT p
primarily RB p
serve VBP p
low-income JJ p
families NNS p
. . p

Participants NNS p
were VBD p
mothers NNS p
of IN p
122 CD p
young JJ p
children NNS p
( ( p
mean JJ p
age NN p
, , p
34 CD p
months NNS p
) ) p
who WP p
recently RB p
received VBD p
a DT p
diagnosis NN p
of IN p
ASD NNP p
. . p

Among IN N
mothers NNS N
assessed VBN N
for IN N
eligibility NN N
, , N
17.0 CD N
% NN N
declined VBD N
participation NN N
. . N

We PRP N
report VBP N
outcomes NNS N
after IN N
3 CD N
months NNS N
of IN N
follow-up NN N
( ( N
immediate JJ N
postdiagnosis NN N
period NN N
) ) N
. . N

INTERVENTIONS NNP N
Problem-solving JJ i
education NN i
is VBZ N
a DT N
brief JJ N
, , N
cognitive JJ N
intervention NN N
delivered VBN N
in IN N
six CD N
30-minute JJ i
individualized VBN i
sessions NNS i
by IN i
existing VBG i
staff NN i
( ( N
early JJ N
intervention NN N
programs NNS N
) ) N
or CC N
research NN i
staff NN i
without IN i
formal JJ i
mental JJ i
health NN i
training NN i
( ( N
autism NN N
clinic NN N
) ) N
. . N

MAIN NNP N
OUTCOMES NNP N
AND NNP N
MEASURES NNP N
Primary NNP N
outcomes NNS N
were VBD N
parental JJ o
stress NN o
and CC o
maternal JJ o
depressive NN o
symptoms NNS o
. . o

RESULTS NNP N
Fifty-nine JJ p
mothers NNS p
were VBD N
randomized VBN N
to TO N
receive VB N
PSE NNP i
and CC N
63 CD N
to TO N
receive VB N
usual JJ i
care NN i
. . i

The DT N
follow-up JJ N
rate NN N
was VBD N
91.0 CD N
% NN N
. . N

Most JJS N
intervention NN N
mothers NNS N
( ( N
78.0 CD N
% NN N
) ) N
received VBD N
the DT N
full JJ N
PSE NNP i
course NN N
. . N

At IN N
the DT N
3-month JJ N
follow-up JJ N
assessment NN N
, , N
PSE NNP i
mothers NNS N
were VBD N
significantly RB N
less RBR N
likely JJ N
than IN N
those DT N
serving VBG N
as RB N
controls NNS N
to TO N
have VB N
clinically RB N
significant JJ N
parental JJ o
stress NN o
( ( N
3.8 CD N
% NN N
vs JJ N
29.3 CD N
% NN N
; : N
adjusted VBN N
relative JJ N
risk NN N
[ NNP N
aRR NN N
] NNP N
, , N
0.17 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
0.04 CD N
to TO N
0.65 CD N
) ) N
. . N

For IN N
depressive JJ o
symptoms NNS o
, , N
the DT N
risk NN N
reduction NN N
in IN N
clinically RB N
significant JJ N
symptoms NNS N
did VBD N
not RB N
reach VB N
statistical JJ N
significance NN N
( ( N
5.7 CD N
% NN N
vs JJ N
22.4 CD N
% NN N
; : N
aRR CC N
, , N
0.33 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
0.10 CD N
to TO N
1.08 CD N
) ) N
; : N
however RB N
, , N
the DT N
reduction NN N
in IN N
mean JJ N
depressive NN o
symptoms NNS o
was VBD N
statistically RB N
significant JJ N
( ( N
Quick NNP N
Inventory NNP N
of IN N
Depressive NNP N
Symptomatology NNP N
score NN N
, , N
4.6 CD N
with IN N
PSE NNP N
vs FW N
6.9 CD N
with IN N
usual JJ N
care NN N
; : N
adjusted VBN N
mean NN N
difference NN N
, , N
-1.67 NNP N
; : N
95 CD N
% NN N
CI NNP N
, , N
-3.17 NNP N
to TO N
-0.18 VB N
) ) N
. . N

CONCLUSIONS NNP N
AND CC N
RELEVANCE NNP N
The DT N
positive JJ N
effects NNS N
of IN N
PSE NNP i
in IN N
reducing VBG N
parenting VBG o
stress NN o
and CC N
depressive JJ o
symptoms NNS o
during IN N
the DT N
critical JJ N
postdiagnosis NN N
period NN N
, , N
when WRB N
parents NNS N
are VBP N
asked VBN N
to TO N
navigate VB N
a DT N
complex JJ N
service NN N
delivery NN N
system NN N
, , N
suggest VBP N
that IN N
it PRP N
may MD N
have VB N
a DT N
place NN N
in IN N
clinical JJ N
practice NN N
. . N

Further NNP N
work NN N
will MD N
monitor VB N
these DT N
families NNS N
for IN N
a DT N
total NN N
of IN N
9 CD N
months NNS N
to TO N
determine VB N
the DT N
trajectory NN N
of IN N
outcomes NNS N
. . N

TRIAL NNP N
REGISTRATION NNP N
clinicaltrials.gov NN N
Identifier NNP N
: : N
NCT01021384 NN N
. . N

-DOCSTART- -15713151- O O

Reducing VBG N
blood NN o
loss NN o
at IN N
open JJ i
myomectomy NN i
using VBG N
triple JJ i
tourniquets NNS i
: : i
a DT N
randomised JJ N
controlled VBN N
trial NN N
. . N

OBJECTIVES UH N
To TO N
evaluate VB N
triple JJ i
tourniquets NNS i
in IN N
controlled JJ N
conditions NNS N
and CC N
for IN N
the DT N
first JJ N
time NN N
to TO N
investigate VB N
the DT N
hypothesis NN N
that IN N
leaving VBG N
a DT N
semi-permanent JJ N
tourniquet NN N
around IN N
the DT N
uterine JJ N
artery NN N
reduces VBZ N
post-operative JJ N
bleeding NN N
from IN N
the DT N
uterine JJ N
incisions NNS N
. . N

DESIGN VB N
A DT N
randomised JJ N
controlled VBN N
trial NN N
. . N

SETTING NN N
Two CD p
University NNP p
teaching NN p
hospitals NNS p
. . p

POPULATION NNP N
Twenty-eight JJ p
patients NNS p
with IN p
symptomatic JJ p
fibroids NNS p
and CC p
uterine JJ p
sizes NNS p
ranging VBG p
from IN p
14 CD p
to TO p
24 CD p
weeks NNS p
of IN p
gestation NN p
undergoing VBG p
open JJ p
myomectomy NN i
. . i

METHODS NNP N
A NNP N
number NN i
1 CD i
polyglactin JJ i
suture NN i
was VBD i
tied VBN i
around IN i
the DT i
cervix NN i
to TO i
occlude VB i
the DT i
uterine JJ i
arteries NNS i
, , N
and CC N
polythene JJ i
tourniquets NNS i
were VBD i
tied VBN i
around IN i
the DT i
infundibulopelvic JJ i
ligament NN i
to TO i
obstruct VB i
the DT i
ovarian JJ i
vessels NNS i
. . i

At IN N
the DT N
end NN N
of IN N
the DT N
procedure NN N
, , N
the DT N
ovarian JJ N
ties NNS N
were VBD N
released VBN N
but CC N
the DT N
uterine JJ N
artery NN N
suture NN N
remained VBD N
in IN N
situ NN N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Intra-operative JJ o
blood NN o
loss NN o
, , o
post-operative JJ o
blood NN o
loss NN o
, , o
blood NN o
transfusion NN o
rates NNS o
, , o
operative JJ o
morbidity NN o
, , o
uterine JJ o
blood NN o
flow NN o
and CC o
ovarian JJ o
function NN o
. . o

RESULTS NNP N
There EX N
was VBD N
significantly RB N
less JJR o
blood NN o
lost VBN o
in IN N
the DT N
tourniquet NN N
group NN N
than IN N
in IN N
the DT N
control NN N
group NN N
( ( N
difference NN N
between IN N
means NNS N
1870 CD N
mL NN N
, , N
95 CD N
% NN N
CI NNP N
1159-2580 CD N
mL NN N
, , N
P NNP N
< NNP N
0.0001 CD N
; : N
transfusion NN N
rates NNS N
of IN N
7 CD N
% NN N
and CC N
79 CD N
% NN N
, , N
P= NNP N
0.0003 CD N
) ) N
. . N

The DT N
volume NN o
in IN o
the DT o
pelvic JJ o
drain NN o
20 CD N
min NN N
post-operatively RB N
and CC N
after IN N
48 CD N
hours NNS N
failed VBD N
to TO N
reach VB N
statistical JJ N
significance NN N
between IN N
the DT N
two CD N
groups NNS N
( ( N
P= NNP N
0.10 CD N
and CC N
P= NNP N
0.165 CD N
) ) N
. . N

There EX N
were VBD N
no DT o
differences NNS o
in IN N
uterine JJ o
artery NN o
Doppler NNP o
resistance NN o
indices NNS o
at IN N
five CD N
days NNS N
( ( N
P= NNP N
0.54 CD N
) ) N
, , N
six CD N
weeks NNS N
( ( N
P= NNP N
0.47 CD N
) ) N
, , N
three CD N
months NNS N
( ( N
P= NNP N
0.49 CD N
) ) N
and CC N
at IN N
six CD N
months NNS N
( ( N
P= NNP N
0.18 CD N
) ) N
. . N

Day NNP N
two CD N
serum NN o
FSH NNP o
concentrations NNS o
after IN N
surgery NN N
were VBD N
unchanged JJ o
( ( N
P= NNP N
0.45 CD N
) ) N
, , N
compared VBN N
with IN N
baseline NN N
values NNS N
. . N

CONCLUSIONS NNP N
Triple NNP i
tourniquets NNS i
are VBP N
effective JJ N
in IN N
reducing VBG N
bleeding NN o
and CC o
transfusion NN o
rates NNS o
. . o

There EX N
appears VBZ N
no DT N
obvious JJ N
adverse JJ N
effect NN N
on IN N
uterine JJ o
perfusion NN o
or CC o
ovarian JJ o
function NN o
. . o

-DOCSTART- -21042930- O O

Intensive JJ i
case NN i
management NN i
before IN N
and CC N
after IN N
prison NN N
release NN N
is VBZ N
no DT N
more RBR N
effective JJ N
than IN N
comprehensive JJ i
pre-release JJ i
discharge NN i
planning NN i
in IN N
linking VBG N
HIV-infected JJ p
prisoners NNS p
to TO N
care VB N
: : N
a DT N
randomized JJ N
trial NN N
. . N

Imprisonment NNP N
provides VBZ N
opportunities NNS N
for IN N
the DT N
diagnosis NN N
and CC N
successful JJ N
treatment NN N
of IN N
HIV NNP N
, , N
however RB N
, , N
the DT N
benefits NNS N
of IN N
antiretroviral JJ i
therapy NN i
are VBP N
frequently RB N
lost VBN N
following VBG N
release NN N
due JJ N
to TO N
suboptimal JJ N
access NN N
and CC N
utilization NN N
of IN N
health NN N
care NN N
and CC N
services NNS N
. . N

In IN N
response NN N
, , N
some DT N
have VBP N
advocated VBN N
for IN N
development NN N
of IN N
intensive JJ N
case-management JJ N
interventions NNS N
spanning VBG N
incarceration NN N
and CC N
release NN N
to TO N
support VB N
treatment NN N
adherence NN N
and CC N
community NN N
re-entry NN N
for IN N
HIV-infected JJ p
releasees NNS p
. . p

We PRP N
conducted VBD N
a DT N
randomized VBN N
controlled JJ N
trial NN N
of IN N
a DT N
motivational JJ i
Strengths NNP i
Model NNP i
bridging VBG i
case NN i
management NN i
intervention NN i
( ( i
BCM NNP i
) ) i
beginning VBG N
approximately RB N
3 CD N
months NNS N
prior RB N
to TO N
and CC N
continuing VBG N
6 CD N
months NNS N
after IN N
release NN N
versus IN N
a DT N
standard NN i
of IN i
care NN i
prison-administered JJ i
discharge NN i
planning VBG i
program NN i
( ( i
SOC NNP i
) ) i
for IN i
HIV-infected JJ p
state NN p
prison NN p
inmates NNS p
. . p

The DT N
primary JJ N
outcome NN N
variable NN N
was VBD o
self-reported JJ o
access NN o
to TO o
post-release VB o
medical JJ o
care NN o
. . o

Of IN N
the DT p
104 CD p
inmates NNS p
enrolled VBD p
, , p
89 CD p
had VBD p
at IN p
least JJS p
1 CD p
post-release JJ p
study NN p
visit NN p
. . p

Of IN N
these DT N
, , N
65.1 CD N
% NN N
of IN N
BCM NNP N
and CC N
54.4 CD N
% NN N
of IN N
SOC NNP i
assigned VBD i
participants NNS N
attended VBD N
a DT N
routine JJ o
medical JJ o
appointment NN o
within IN o
4 CD N
weeks NNS N
of IN N
release NN N
( ( N
P NNP N
> NNP N
0.3 CD N
) ) N
. . N

By IN N
week NN N
12 CD N
post-release NN N
, , N
88.4 CD N
% NN N
of IN N
the DT i
BCM NNP i
arm NN N
and CC N
78.3 CD N
% NN N
of IN N
the DT N
SOC NNP N
arm NN N
had VBD N
at IN N
attended VBN N
at IN N
least JJS N
one CD o
medical JJ o
appointment NN o
( ( o
P NNP o
= NNP o
0.2 CD N
) ) N
, , N
increasing VBG N
in IN N
both DT N
arms NNS N
at IN N
week NN N
24-90.7 CD N
% NN N
with IN N
BCM NNP N
and CC N
89.1 CD N
% NN N
with IN N
SOC NNP N
( ( N
P NNP N
> NNP N
0.5 CD N
) ) N
. . N

No DT N
participant NN N
without IN N
a DT N
routine JJ N
medical JJ N
visit NN N
by IN N
week NN N
24 CD N
attended VBD N
an DT o
appointment NN o
from IN o
weeks NNS o
24 CD N
to TO N
48 CD N
. . N

The DT o
mean JJ o
number NN o
of IN o
clinic JJ o
visits NNS o
during IN o
the DT N
48 CD N
weeks NNS N
post NN N
release NN N
was VBD N
5.23 CD N
( ( N
SD NNP N
= NNP N
3.14 CD N
) ) N
for IN N
BCM NNP N
and CC N
4.07 CD N
( ( N
SD NNP N
= NNP N
3.20 CD N
) ) N
for IN N
SOC NNP N
( ( N
P NNP N
> NNP N
0.5 CD N
) ) N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
arms NNS N
in IN N
social JJ o
service NN o
utilization NN o
and CC o
re-incarceration NN o
rates NNS o
were VBD o
also RB o
similar JJ N
. . N

We PRP N
found VBD N
that IN N
a DT N
case NN i
management NN i
intervention NN i
bridging VBG i
incarceration NN i
and CC i
release NN N
was VBD N
no DT N
more RBR N
effective JJ N
than IN N
a DT N
less RBR N
intensive JJ N
pre-release JJ i
discharge NN i
planning VBG i
program NN i
in IN i
supporting VBG i
health NN N
and CC N
social JJ N
service NN N
utilization NN N
for IN N
HIV-infected JJ p
individuals NNS p
released VBN p
from IN p
prison NN p
. . p

-DOCSTART- -12918532- O O

A DT N
comparison NN N
of IN N
magnesium NN i
sulfate NN i
and CC i
nimodipine NN i
for IN N
the DT N
prevention NN o
of IN o
eclampsia NN o
. . o

-DOCSTART- -17505452- O O

[ JJ i
Laparoscopic NNP i
lymphadenectomy NN i
as IN N
treatment NN N
of IN N
endometrial JJ p
cancer NN p
] NNP p
. . N

AIM NNP N
This DT N
study NN N
compares VBZ N
the DT N
effects NNS o
of IN N
laparoscopic JJ N
lymphadenectomy JJ i
versus IN N
those DT N
of IN N
abdominal JJ N
lymphadenectomy NN i
in IN N
patients NNS p
with IN p
endometrial JJ p
cancer NN p
. . p

METHODS NNP N
A NNP N
prospective JJ N
randomized NN N
study NN N
was VBD N
performed VBN N
among IN N
80 CD p
patients NNS p
randomly RB p
assigned VBN p
to TO p
laparoscopic VB i
lymphadenectomy NN i
and CC p
to TO p
abdominal JJ i
lymphadenectomy NN i
in IN p
the DT p
treatment NN p
of IN p
endometrial JJ p
cancer NN p
. . p

Clinical JJ N
outcomes NNS o
and CC N
complications NNS o
were VBD N
compared VBN N
for IN N
1 CD N
year NN N
of IN N
follow-up NN N
. . N

RESULTS NNP N
Forty NNP p
patients NNS p
were VBD N
assigned VBN N
to TO N
laparoscopic VB N
lymphadenectomy NN i
and CC N
40 CD N
patients NNS N
to TO N
abdominal JJ N
lymphadenectomy NN i
. . i

The DT N
laparoscopic NN N
approach NN N
was VBD N
associated VBN N
with IN N
a DT N
longer RBR o
operative JJ o
time NN o
( ( N
234.1 CD N
min NN N
vs NN N
137.3 CD N
min NN N
) ) N
but CC N
was VBD N
less JJR o
painful JJ o
( ( N
VAS NNP N
5.3 CD N
vs NN N
7.9 CD N
; : N
P NNP N
< NNP N
0.000 CD N
) ) N
and CC N
resulted VBN N
in IN N
a DT N
shorter JJR o
hospital NN o
stay NN o
( ( N
4.4+/-1 JJ N
vs NN N
7.9+/-1.2 JJ N
days NNS N
; : N
P NNP N
< NNP N
0.000 CD N
) ) N
. . N

At IN N
6 CD N
weeks NNS N
the DT N
quality NN o
of IN o
life NN o
was VBD N
better RBR N
in IN N
patients NNS N
who WP N
had VBD N
laparoscopic VBN N
lymphadenectomy JJ i
( ( N
SF-12 NNP N
) ) N
. . N

CONCLUSION NNP N
Laparoscopic NNP N
lymphadenectomy NN i
was VBD N
associated VBN N
with IN N
a DT N
significantly RB N
lower JJR N
rate NN o
of IN o
major JJ o
and CC o
minor JJ o
postoperative JJ o
complications NNS o
and CC N
a DT N
better JJR N
short JJ N
term NN N
quality NN o
of IN o
life NN o
. . o

-DOCSTART- -12900807- O O

Effects NNS N
of IN N
pentoxifylline JJ i
administration NN N
on IN N
urinary JJ N
N-acetyl-beta-glucosaminidase JJ N
excretion NN N
in IN N
type NN p
2 CD p
diabetic JJ p
patients NNS p
: : p
a DT N
short-term JJ N
, , N
prospective JJ N
, , N
randomized VBN N
study NN N
. . N

BACKGROUND NNP N
Tubulointerstitial NNP N
injury NN N
is VBZ N
a DT N
major JJ N
feature NN N
of IN N
diabetic JJ N
nephropathy NN N
and CC N
an DT N
important JJ N
predictor NN N
of IN N
renal JJ N
dysfunction NN N
. . N

In IN N
45 CD p
patients NNS p
with IN p
type JJ p
2 CD p
diabetes NNS p
mellitus FW p
( ( p
DM NNP p
) ) p
, , N
we PRP N
prospectively RB N
analyzed VBD N
urinary JJ N
excretion NN N
of IN N
N-acetyl-beta-glucosaminidase NNP N
( ( N
NAG NNP N
) ) N
, , N
a DT N
marker NN N
of IN N
tubular JJ N
renal JJ N
damage NN N
; : N
the DT N
potential JJ N
relationship NN N
with IN N
urinary JJ N
protein NN N
excretion NN N
; : N
and CC N
effects NNS N
of IN N
pentoxifylline NN i
( ( i
PTF NNP i
) ) i
administration NN N
. . N

METHODS NNP N
Forty-five JJ p
patients NNS p
with IN p
type JJ p
2 CD p
DM NNP p
initially RB p
were VBD p
compared VBN p
with IN p
15 CD p
healthy JJ p
controls NNS p
matched VBN p
for IN p
age NN p
and CC p
sex NN p
. . p

After IN N
randomization NN N
, , N
PTF NNP i
( ( N
1,200 CD N
mg/d NN N
) ) N
was VBD N
administered VBN N
for IN N
4 CD N
months NNS N
to TO N
30 CD N
patients NNS N
and CC N
results NNS N
were VBD N
compared VBN N
with IN N
data NNS N
from IN N
a DT N
control NN N
group NN N
( ( N
n JJ N
= NNP N
15 CD N
) ) N
. . N

RESULTS NNP N
Proteinuria NNP o
and CC o
urinary JJ o
NAG NNP o
excretion NN o
were VBD N
significantly RB N
greater JJR N
in IN N
patients NNS N
with IN N
DM NNP N
with IN N
respect NN N
to TO N
healthy JJ N
controls NNS N
. . N

Before IN N
PTF NNP N
administration NN N
, , N
baseline JJ N
parameters NNS N
were VBD N
similar JJ N
in IN N
both DT N
groups NNS N
of IN N
patients NNS N
with IN N
DM NNP N
. . N

At IN N
the DT N
end NN N
of IN N
the DT N
study NN N
, , N
urinary JJ o
protein NN o
excretion NN o
and CC o
NAG-creatinine JJ o
ratios NNS o
decreased VBN N
in IN N
the DT N
active JJ N
group NN N
from IN N
920 CD N
+/- JJ N
522 CD N
mg/d NN N
and CC N
14.3 CD N
+/- JJ N
16.9 CD N
U/g NNP N
to TO N
803 CD N
+/- JJ N
523 CD N
mg/d NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
and CC N
10.5 CD N
+/- JJ N
9.3 CD N
U/g NNP N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
, , N
respectively RB N
. . N

Conversely RB N
, , N
proteinuria NNS o
and CC o
urinary JJ o
NAG NNP o
excretion NN o
did VBD N
not RB N
change VB N
in IN N
the DT N
control NN i
group NN N
. . N

Regression NN N
analysis NN N
showed VBD N
that IN N
urinary JJ o
NAG NNP o
excretion NN o
was VBD N
significantly RB N
associated VBN N
with IN N
duration NN o
of IN o
DM NNP o
( ( N
r VB N
= RB N
0.61 CD N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
and CC N
proteinuria NN o
( ( N
r JJ N
= VBZ N
0.51 CD N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

CONCLUSION NNP N
Urinary NNP o
NAG NNP o
excretion NN o
is VBZ N
elevated VBN N
in IN N
patients NNS N
with IN N
type JJ p
2 CD p
DM NNP p
compared VBN N
with IN N
healthy JJ p
individuals NNS p
and CC N
increases NNS N
as IN N
nephropathy JJ N
progresses NNS N
. . N

PTF NNP i
administration NN N
is VBZ N
effective JJ N
in IN N
reducing VBG N
proteinuria NN o
and CC o
urinary JJ o
NAG NNP o
excretion NN o
in IN N
these DT N
patients NNS N
. . N

These DT N
findings NNS N
suggest VBP N
that IN N
PTF NNP i
may MD N
have VB N
beneficial JJ N
effects NNS N
on IN N
tubulointerstitial JJ N
damage NN N
in IN N
diabetic JJ N
kidney NN N
disease NN N
. . N

-DOCSTART- -22385102- O O

Combination NN i
peel NN i
with IN i
incorporated JJ i
fractional JJ i
prickle NN i
coral JJ i
calcium NN i
for IN N
the DT N
treatment NN N
of IN N
keratosis NN p
pilaris NN p
: : p
a DT N
pilot NN N
study NN N
. . N

BACKGROUND NNP N
Keratosis NNP p
pilaris NN p
( ( N
KP NNP N
) ) N
is VBZ N
a DT N
common JJ N
condition NN N
of IN N
follicular JJ N
plugging VBG N
with IN N
variable JJ N
erythema NN N
. . N

There EX N
is VBZ N
a DT N
lack NN N
of IN N
reliable JJ N
response NN N
to TO N
the DT N
treatment NN N
of IN N
KP NNP N
. . N

OBJECTIVE NNP N
We PRP N
evaluated VBD N
the DT N
effect NN N
and CC N
safety NN N
of IN N
combination NN N
peel NN N
with IN N
fractional JJ i
prickle JJ i
coral JJ i
calcium NN i
( ( i
FCR? NNP i
) ) i
in IN i
the DT N
treatment NN N
of IN N
KP NNP N
. . N

MATERIALS NNP N
AND CC N
METHODS NNP p
Sixteen NNP p
Korean JJ p
patients NNS p
were VBD p
treated VBN p
with IN p
FCR? NNP p
on IN p
both DT p
upper JJ p
arms NNS p
for IN p
five CD p
sessions NNS p
at IN p
2-week JJ p
intervals NNS o
. . o

Clinical JJ o
evaluations NNS o
, , o
mexameter NN o
measurements NNS o
, , o
and CC o
assessment NN o
of IN o
patients NNS o
' POS o
satisfaction NN o
and CC o
adverse JJ o
events NNS o
were VBD o
performed VBN N
at IN N
baseline NN N
and CC N
every DT N
visit NN N
. . N

RESULTS NNP N
After IN N
treatments NNS N
, , N
statistically RB N
significant JJ N
improvements NNS N
in IN N
the DT N
baseline NN o
KP NNP o
were VBD N
observed VBN N
in IN N
erythema NN N
and CC N
melanin NN N
index NN N
of IN N
mexameter NN N
on IN N
treated JJ N
upper JJ N
arms NNS N
. . N

Both CC N
the DT N
physicians NNS N
' POS N
and CC N
patients NNS N
' POS N
assessments NNS N
correlate VBP N
with IN N
the DT N
results NNS N
of IN N
mexameter NN N
scores NNS N
. . N

CONCLUSION NNP N
Our PRP$ N
results NNS N
suggest VBP N
FCR? NNP N
should MD N
be VB N
considered VBN N
as IN N
an DT N
effective JJ o
and CC o
safe JJ o
treatment NN N
option NN N
for IN N
the DT N
patients NNS p
with IN p
KP NNP p
. . p

-DOCSTART- -24576886- O O

Collagen NNP i
cross-linking NN i
with IN i
photoactivated JJ i
riboflavin NN i
( ( i
PACK-CXL NNP i
) ) i
for IN N
the DT N
treatment NN N
of IN N
advanced JJ p
infectious JJ p
keratitis NN p
with IN p
corneal JJ p
melting NN p
. . p

PURPOSE NNP N
To TO N
investigate VB N
the DT N
efficacy NN o
and CC o
safety NN o
of IN N
corneal JJ i
collagen NN i
cross-linking NN i
( ( i
CXL NNP i
) ) i
with IN N
photoactivated VBN i
riboflavin NN i
( ( i
photoactivated VBN i
chromophore NN i
for IN i
infectious JJ i
keratitis NN i
[ NNP i
PACK NNP i
] NNP i
-CXL NNP i
) ) i
in IN N
the DT N
management NN N
of IN N
infectious JJ N
keratitis NN N
with IN N
corneal JJ N
melting VBG N
. . N

DESIGN NNP N
Prospective NNP N
clinical JJ N
trial NN N
. . N

PARTICIPANTS NNP N
Forty NNP p
eyes NNS p
from IN p
40 CD p
patients NNS p
with IN p
advanced JJ p
infectious JJ p
keratitis NN p
and CC p
coexisting VBG p
corneal NN p
melting NN p
. . p

METHODS NNP N
Twenty-one CD p
patients NNS p
( ( p
21 CD p
eyes NNS p
) ) p
underwent JJ p
PACK-CXL JJ i
treatment NN i
in IN i
addition NN i
to TO i
antimicrobial JJ i
therapy NN i
. . i

The DT p
control NN p
group NN p
consisted VBD p
of IN p
19 CD p
patients NNS p
( ( p
19 CD p
eyes NNS p
) ) p
who WP N
received VBD N
only RB i
antimicrobial JJ i
therapy NN i
. . i

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
The DT N
slit-lamp JJ o
characteristics NNS o
of IN o
the DT o
corneal NN o
ulceration NN o
, , o
corrected VBN o
distance NN o
visual JJ o
acuity NN o
, , o
duration NN o
until IN o
healing VBG o
, , o
and CC o
complications NNS o
were VBD N
documented VBN N
in IN N
each DT N
group NN N
. . N

The DT N
Mann-Whitney NNP N
U NNP N
test NN N
was VBD N
used VBN N
for IN N
statistical JJ N
analysis NN N
. . N

P NNP N
values VBZ N
less JJR N
than IN N
0.05 CD N
were VBD N
considered VBN N
statistically RB N
significant JJ N
. . N

RESULTS VB N
The DT N
average JJ N
time NN o
until IN o
healing VBG o
was VBD N
39.76 CD N
? . N
18.22 CD N
days NNS N
in IN N
the DT i
PACK-CXL NNP i
group NN N
and CC N
46.05 CD N
? . N
27.44 CD N
days NNS N
in IN N
the DT N
control NN N
group NN N
( ( N
P NNP N
= NNP N
0.68 CD N
) ) N
. . N

After IN N
treatment NN N
and CC N
healing NN o
, , o
corrected VBN o
distance NN o
visual JJ o
acuity NN o
was VBD o
1.64 CD N
? . N
0.62 CD N
in IN N
the DT N
PACK-CXL NNP i
group NN i
and CC N
1.67 CD N
? . N
0.48 CD N
in IN N
the DT N
control NN N
group NN N
( ( N
P NNP N
= NNP N
0.68 CD N
) ) N
. . N

The DT N
corneal JJ o
ulceration NN o
's POS o
width NN o
and CC o
length NN o
was VBD o
significantly RB N
bigger JJR N
in IN N
the DT N
PACK-CXL NNP i
group NN i
( ( N
P NNP N
= NNP N
0.004 CD N
and CC N
P NNP N
= NNP N
0.007 CD N
) ) N
. . N

Three CD N
patients NNS N
in IN N
the DT N
control NN N
group NN N
demonstrated VBD o
corneal JJ o
perforation NN o
; : o
infection NN o
recurred VBD N
in IN N
1 CD N
of IN N
them PRP N
. . N

No DT N
serious JJ N
complications NNS N
occurred VBD N
in IN N
the DT N
PACK-CXL NNP i
group NN i
. . N

CONCLUSIONS NNP i
Corneal NNP i
CXL NNP i
with IN i
photoactivated JJ i
riboflavin NN i
did VBD i
not RB N
shorten VB N
the DT N
time NN o
to TO o
corneal VB o
healing NN o
; : o
however RB o
, , N
the DT N
complication NN N
rate NN N
was VBD N
21 CD N
% NN N
in IN N
the DT N
control NN N
group NN N
, , N
whereas IN N
there EX N
was VBD N
no DT N
incidence NN N
of IN N
corneal JJ N
perforation NN o
or CC o
recurrence NN o
of IN o
the DT o
infection NN o
in IN o
the DT N
PACK-CXL NNP N
group NN N
. . N

These DT N
results NNS N
indicate VBP N
that IN N
PACK-CXL NNP i
may MD i
be VB N
an DT N
effective JJ N
adjuvant NN N
therapy NN N
in IN N
the DT N
management NN N
of IN N
severe JJ N
infectious JJ N
keratitis NN N
associated VBN N
with IN N
corneal NN N
melting NN N
. . N

-DOCSTART- -25304947- O O

Secondary JJ N
analysis NN N
of IN N
RTOG NNP N
9508 CD N
, , N
a DT N
phase NN N
3 CD N
randomized JJ N
trial NN N
of IN N
whole-brain JJ i
radiation NN i
therapy NN i
versus NN i
WBRT NNP i
plus CC i
stereotactic JJ i
radiosurgery NN i
in IN N
patients NNS p
with IN p
1-3 JJ p
brain NN p
metastases NNS p
; : p
poststratified VBN p
by IN p
the DT p
graded JJ p
prognostic JJ p
assessment NN p
( ( p
GPA NNP p
) ) p
. . p

PURPOSE NNP N
Radiation NNP i
Therapy NNP i
Oncology NNP i
Group NNP i
( ( i
RTOG NNP i
) ) i
9508 CD i
showed VBD N
a DT N
survival JJ N
advantage NN N
for IN N
patients NNS p
with IN p
1 CD p
but CC p
not RB p
2 CD p
or CC p
3 CD p
brain NN p
metastasis NN p
( ( p
BM NNP p
) ) p
treated VBD N
with IN N
whole-brain JJ i
radiation NN i
therapy NN i
( ( i
WBRT NNP i
) ) i
and CC i
stereotactic JJ i
radiosurgery NN i
( ( i
SRS NNP i
) ) i
versus NN i
WBRT NNP i
alone RB i
. . i

An DT N
improved JJ N
prognostic JJ N
index NN N
, , N
the DT N
graded JJ N
prognostic JJ N
assessment NN N
( ( N
GPA NNP N
) ) N
has VBZ N
been VBN N
developed VBN N
. . N

Our PRP$ N
hypothesis NN N
was VBD N
that IN N
if IN N
the DT N
data NN N
from IN N
RTOG JJ i
9508 CD i
were VBD N
poststratified VBN N
by IN N
the DT N
GPA NNP N
, , N
the DT N
conclusions NNS N
may MD N
vary VB N
. . N

METHODS NNP N
AND CC N
MATERIALS NNP N
In IN N
this DT N
analysis NN N
, , N
252 CD p
of IN p
the DT p
331 CD p
patients NNS p
were VBD p
evaluable JJ p
by IN p
GPA NNP p
. . p

Of IN p
those DT p
, , p
211 CD p
had VBD p
lung NN p
cancer NN p
. . p

Breast NNP p
cancer NN p
patients NNS p
were VBD p
excluded VBN p
because IN N
the DT N
components NNS N
of IN N
the DT N
breast NN N
GPA NNP N
are VBP N
not RB N
in IN N
the DT N
RTOG NNP N
database NN N
. . N

Multiple NNP N
Cox NNP N
regression NN N
was VBD N
used VBN N
to TO N
compare VB N
survival NN N
between IN N
treatment NN p
groups NNS p
, , N
adjusting VBG N
for IN N
GPA NNP N
. . N

Treatment NNP N
comparisons NNS N
within IN N
subgroups NNS N
were VBD N
performed VBN N
with IN N
the DT N
log-rank JJ N
test NN N
. . N

A DT N
free JJ N
online NN N
tool NN N
( ( N
brainmetgpa.com NN N
) ) N
simplified VBD N
GPA NNP N
use NN N
. . N

RESULTS VB N
The DT N
fundamental JJ N
conclusions NNS N
of IN N
the DT N
primary JJ N
analysis NN N
were VBD N
confirmed VBN N
in IN N
that DT N
there EX N
was VBD N
no DT N
survival JJ o
benefit NN o
overall JJ N
for IN N
patients NNS N
with IN N
1 CD N
to TO N
3 CD N
metastases NNS N
; : N
however RB N
, , N
there EX N
was VBD N
a DT N
benefit NN N
for IN N
the DT N
subset NN N
of IN N
patients NNS N
with IN N
GPA NNP N
3.5 CD N
to TO N
4.0 CD N
( ( N
median JJ N
survival NN N
time NN N
[ NNP N
MST NNP N
] NNP N
for IN N
WBRT NNP i
+ NNP i
SRS NNP i
vs FW N
WBRT NNP N
alone RB N
was VBD N
21.0 CD N
versus NN N
10.3 CD N
months NNS N
, , N
P=.05 NNP N
) ) N
regardless NN N
of IN N
the DT N
number NN N
of IN N
metastases NNS N
. . N

Among IN N
patients NNS N
with IN N
GPA NNP N
3.5 CD N
to TO N
4.0 CD N
treated VBN N
with IN N
WBRT NNP i
and CC i
SRS NNP i
, , N
the DT N
MST NNP o
for IN N
patients NNS N
with IN N
1 CD N
versus NN N
2 CD N
to TO N
3 CD N
metastases NNS N
was VBD N
21 CD N
and CC N
14.1 CD N
months NNS N
, , N
respectively RB N
. . N

CONCLUSIONS VB N
This DT N
secondary JJ N
analysis NN N
of IN N
predominantly RB N
lung JJ p
cancer NN p
patients NNS p
, , N
consistent JJ N
with IN N
the DT N
original JJ N
analysis NN N
, , N
shows VBZ N
no DT N
survival JJ o
advantage NN o
for IN N
the DT N
group NN N
overall JJ N
when WRB N
treated VBN N
with IN N
WBRT NNP N
and CC N
SRS NNP N
; : N
however RB N
, , N
in IN N
patients NNS p
with IN p
high JJ p
GPA NNP p
( ( N
3.5-4 JJ N
) ) N
, , N
there EX N
is VBZ N
a DT N
survival JJ N
advantage NN N
regardless NN N
of IN N
whether IN N
they PRP N
have VBP N
1 CD N
, , N
2 CD N
, , N
or CC N
3 CD N
BM NNPS N
. . N

This DT N
benefit NN N
did VBD N
not RB N
extend VB N
to TO N
patients NNS N
with IN N
lower JJR N
GPA NNP N
. . N

Prospective JJ N
validation NN N
of IN N
this DT N
survival JJ N
benefit NN N
for IN N
patients NNS p
with IN p
multiple JJ p
BM NNP p
and CC p
high JJ p
GPA NNP p
when WRB p
treated VBN p
with IN p
WBRT NNP i
and CC i
SRS NNP i
is VBZ N
warranted VBN N
. . N

-DOCSTART- -23716409- O O

The DT N
effectiveness NN N
of IN N
educational JJ i
interventions NNS i
to TO N
enhance VB N
the DT N
adoption NN o
of IN o
fee-based JJ o
arsenic JJ o
testing NN o
in IN p
Bangladesh NNP p
: : p
a DT N
cluster NN N
randomized VBN N
controlled VBN N
trial NN N
. . N

Arsenic NNP N
( ( N
As IN N
) ) N
testing NN N
could MD N
help VB N
22 CD N
million CD N
people NNS N
, , N
using VBG N
drinking NN N
water NN N
sources NNS N
that WDT N
exceed VBP N
the DT N
Bangladesh NNP N
As NNP N
standard NN N
, , N
to TO N
identify VB N
safe JJ N
sources NNS N
. . N

A DT N
cluster NN N
randomized VBN N
controlled VBD N
trial NN N
was VBD N
conducted VBN N
to TO N
evaluate VB N
the DT N
effectiveness NN o
of IN o
household NN o
education NN o
and CC o
local JJ o
media NNS o
in IN N
the DT N
increasing VBG N
demand NN N
for IN N
fee-based JJ N
As IN N
testing VBG N
. . N

Randomly RB p
selected VBN p
households NNS p
( ( p
N NNP p
= NNP p
452 CD p
) ) p
were VBD N
divided VBN N
into IN N
three CD i
interventions NNS i
implemented VBN i
by IN i
community NN i
workers NNS i
: : i
1 CD i
) ) i
fee-based JJ i
As IN i
testing VBG i
with IN i
household NN i
education NN i
( ( i
HE NNP i
) ) i
; : i
2 CD i
) ) i
fee-based JJ i
As IN i
testing VBG i
with IN i
household NN i
education NN i
and CC i
a DT i
local JJ i
media NNS i
campaign NN i
( ( i
HELM NNP i
) ) i
; : i
and CC i
3 CD i
) ) i
fee-based JJ i
As IN i
testing VBG i
alone RB i
( ( i
Control NNP i
) ) i
. . i

The DT N
fee NN N
for IN N
the DT N
As NNP N
test NN N
was VBD N
US NNP N
$ $ N
0.28 CD N
, , N
higher JJR N
than IN N
the DT N
cost NN N
of IN N
the DT N
test NN N
( ( N
US NNP N
$ $ N
0.16 CD N
) ) N
. . N

Of IN N
households NNS N
with IN N
untested JJ N
wells NNS N
, , N
93 CD N
% NN N
in IN N
both DT N
intervention NN N
groups NNS N
HE NNP o
and CC o
HELM NNP o
purchased VBD o
an DT o
As IN o
test NN o
, , N
whereas IN N
only RB N
53 CD N
% NN N
in IN N
the DT N
control NN N
group NN N
. . N

In IN N
conclusion NN N
, , N
fee-based JJ o
As IN o
testing VBG o
with IN i
household NN o
education NN o
is VBZ o
effective JJ o
in IN o
the DT o
increasing VBG o
demand NN o
for IN o
As IN o
testing VBG o
in IN p
rural JJ p
Bangladesh NNP p
. . p

-DOCSTART- -6366124- O O

Histologic NNP o
conversion NN o
in IN N
the DT N
non-Hodgkin NN p
's POS p
lymphomas NN p
. . p

Between NNP p
July NNP p
1 CD p
, , p
1971 CD p
and CC p
December NNP p
31 CD p
, , p
1978 CD p
, , p
150 CD p
patients NNS p
with IN p
favorable JJ p
subtypes NNS p
of IN p
non-Hodgkin NN p
's POS p
lymphoma NN p
[ NNP p
nodular JJ p
poorly RB p
differentiated VBN p
lymphocytic JJ p
( ( p
NLPD NNP p
) ) p
, , p
nodular JJ p
mixed JJ p
, , p
or CC p
diffuse RB p
well RB p
differentiated VBN p
lymphocytic JJ p
] NNS p
were VBD N
entered VBN N
into IN N
prospective JJ N
randomized VBN N
clinical JJ p
trials NNS p
at IN p
Stanford NNP p
University NNP p
. . p

Treatments NNS N
included VBD N
involved JJ N
field NN i
, , i
total JJ i
lymphoid NN i
, , i
or CC i
whole JJ i
body NN i
irradiation NN i
, , i
single JJ i
alkylating VBG i
agent NN i
chemotherapy NN i
, , i
combination NN i
chemotherapy NN i
with IN i
cyclophosphamide NN i
, , i
vincristine NN i
and CC i
prednisone NN i
( ( i
CVP NNP i
) ) i
or CC i
with IN i
cyclophosphamide NN i
, , i
vincristine NN i
, , i
procarbazine NN i
, , i
and CC i
prednisone NN i
( ( i
C-MOPP NNP i
) ) i
, , i
or CC i
various JJ i
combinations NNS i
of IN i
chemotherapy NN i
and CC i
irradiation NN i
. . i

The DT N
initial JJ N
complete JJ o
response NN o
rate NN o
( ( o
CR NNP o
) ) o
was VBD N
79 CD N
% NN N
. . N

Among IN N
patients NNS N
who WP N
achieved VBD o
a DT o
CR NNP o
, , N
31 CD N
% NN N
later RB N
relapsed VBN o
. . o

There EX N
were VBD N
78 CD N
patients NNS N
who WP N
either RB N
failed VBD N
to TO N
achieve VB o
a DT o
CR NNP o
or CC N
achieved VBD o
a DT o
CR NNP o
and CC N
later RB N
relapsed VBN o
. . o

Histologic NNP o
conversion NN o
( ( N
change NN N
from IN N
initially RB N
favorable JJ N
to TO N
an DT N
unfavorable JJ N
subtype NN N
of IN N
non-Hodgkin NN N
's POS N
lymphoma NN N
) ) N
was VBD N
documented VBN N
in IN N
22/78 CD N
patients NNS N
( ( N
28 CD N
% NN N
) ) N
. . N

However RB N
, , N
the DT N
actuarial JJ o
risk NN o
for IN o
conversion NN o
was VBD N
actually RB N
much JJ N
greater JJR o
( ( N
60 CD N
% NN N
at IN N
8 CD N
yr NN N
) ) N
. . N

The DT N
median JJ o
time NN o
to TO o
documentation NN o
of IN o
conversion NN o
was VBD N
51 CD N
mo NN N
. . N

The DT N
most RBS o
common JJ o
type NN N
of IN N
histologic JJ o
conversion NN o
was VBD N
from IN N
NLPD NNP N
to TO N
diffuse VB N
histiocytic JJ o
lymphoma NN o
. . o

Documented VBN N
histologic JJ o
conversion NN o
was VBD N
often RB N
associated VBN N
with IN N
a DT N
more RBR N
aggressive JJ o
clinical JJ o
behavior NN o
of IN N
the DT N
lymphoma NN N
, , N
and CC N
the DT N
median JJ o
survival NN o
after IN N
conversion NN o
was VBD N
less JJR N
than IN N
1 CD N
yr NN N
. . N

However RB N
, , N
those DT N
patients NNS N
who WP N
achieved VBD o
a DT o
CR NNP o
after IN N
conversion NN o
had VBD N
a DT N
more RBR N
favorable JJ o
outcome NN o
( ( o
actuarial JJ o
survival NN o
75 CD N
% NN N
at IN N
5 CD N
yr NN N
) ) N
. . N

No DT N
specific JJ N
risk NN o
factors NNS o
predictive VBP N
of IN N
histologic JJ o
conversion NN o
could MD N
be VB N
identified VBN N
. . N

-DOCSTART- -24852722- O O

Causes NNS N
of IN N
variation NN N
in IN N
BCG NNP i
vaccine NN i
efficacy NN o
: : o
examining VBG N
evidence NN N
from IN N
the DT N
BCG NNP N
REVAC NNP N
cluster NN N
randomized VBD N
trial NN N
to TO N
explore VB N
the DT N
masking NN N
and CC N
the DT N
blocking NN N
hypotheses NNS N
. . N

BCG NNP N
protection NN N
varies NNS N
and CC N
in IN N
some DT N
places NNS N
( ( N
nearest JJS N
the DT N
equator NN N
) ) N
is VBZ N
low JJ N
or CC N
absent NN N
. . N

Understanding VBG N
this DT N
variation NN N
can MD N
inform VB N
the DT N
efforts NNS N
to TO N
develop VB N
new JJ N
vaccines NNS N
against IN N
tuberculosis NN N
. . N

Two CD N
main JJ N
hypotheses NNS N
are VBP N
used VBN N
to TO N
explain VB N
this DT N
variation NN N
: : N
under IN N
masking VBG N
, , N
new JJ N
vaccines NNS N
are VBP N
unlikely JJ N
to TO N
increase VB N
protection NN o
; : o
under IN N
blocking VBG N
new JJ N
vaccines NNS N
have VBP N
a DT N
greater JJR N
potential JJ N
to TO N
be VB N
effective JJ N
when WRB N
BCG NNP N
is VBZ N
not RB N
. . N

We PRP N
conducted VBD N
a DT N
cluster NN N
randomized VBN N
trial NN N
to TO N
explored VB N
the DT N
masking NN N
and CC N
blocking VBG N
hypotheses NNS N
by IN N
studying VBG N
BCG NNP i
vaccine NN i
efficacy NN N
of IN N
neonatal JJ N
vaccination NN N
and CC N
when WRB N
administered VBN N
for IN N
the DT N
first JJ N
or CC N
a DT N
second JJ N
( ( N
revaccination NN N
) ) N
time NN N
at IN N
school NN p
age NN p
in IN p
two CD p
sites NNS p
( ( p
Manaus NNP p
close RB p
and CC p
Salvador NNP p
further RB p
south RB p
from IN p
the DT p
equator NN p
) ) p
. . p

Seven VBN p
hundred CD p
and CC p
sixty VBD p
three CD p
state NN p
schools NNS p
were VBD p
matched VBN p
on IN p
socio JJ p
economic JJ p
characteristics NNS p
of IN p
the DT p
neighborhood NN p
and CC p
239,934 CD p
children NNS p
were VBD p
randomized VBN p
to TO N
vaccine VB N
( ( i
BCG NNP i
vaccination NN i
at IN N
school NN N
age NN N
) ) N
or CC N
control VB i
group NN i
. . i

Protection NN o
by IN o
first JJ o
BCG NNP o
vaccination NN o
at IN N
school NN N
age NN N
was VBD N
high JJ N
in IN N
Salvador NNP p
( ( N
34 CD N
% NN N
, , N
95 CD N
% NN N
CI NNP N
7-53 CD N
% NN N
, , N
p=0.017 NN N
) ) N
but CC N
low JJ N
in IN N
Manaus NNP p
( ( N
8 CD N
% NN N
, , N
95 CD N
% NN N
CI NNP N
t0 VBZ N
39-40 CD N
% NN N
, , N
p=0.686 NN N
) ) N
. . N

For IN N
revaccination NN o
at IN o
school NN o
age NN o
, , N
protection NN N
was VBD N
modest JJ N
in IN N
Salvador NNP N
( ( N
19 CD N
% NN N
, , N
95 CD N
% NN N
CI NNP N
3-33 CD N
% NN N
, , N
p=0.022 NN N
) ) N
and CC N
absent NN N
in IN N
Manaus NNP N
( ( N
1 CD N
% NN N
, , N
95 CD N
% NN N
CI NNP N
to TO N
27-23 CD N
% NN N
, , N
p=0.932 NN N
) ) N
. . N

Vaccine NNP o
efficacy NN o
for IN N
neonatal JJ N
vaccination NN N
was VBD N
similar JJ N
in IN N
Salvador NNP N
( ( N
40 CD N
% NN N
, , N
95 CD N
% NN N
CI NNP N
22-54 CD N
% NN N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
and CC N
Manaus NNP N
( ( N
36 CD N
% NN N
, , N
95 CD N
% NN N
CI NNP N
11-53 CD N
% NN N
, , N
p=0.008 NN N
) ) N
. . N

Variation NN o
in IN o
BCG NNP o
efficacy NN o
was VBD N
marked VBN N
when WRB N
vaccine NN N
was VBD N
given VBN N
at IN N
school NN N
age NN N
but CC N
absent NN N
at IN N
birth NN N
, , N
which WDT N
points VBZ N
towards NNS N
blocking VBG N
as IN N
the DT N
dominant JJ N
mechanism NN N
. . N

New NNP N
tuberculosis NN N
vaccines NNS N
that WDT N
overcome VBP N
or CC N
by IN N
pass NN N
this DT N
blocking VBG N
effect NN N
could MD N
confer VB N
protection NN N
in IN N
situations NNS N
where WRB N
BCG NNP N
is VBZ N
not RB N
protective JJ N
. . N

-DOCSTART- -9308064- O O

Postoperative JJ N
analgesia NN N
with IN N
preoperative JJ N
oral JJ N
ibuprofen NN i
or CC N
acetaminophen NN i
in IN N
children NNS p
undergoing VBG p
myringotomy NN p
. . p

Previous JJ N
studies NNS N
have VBP N
shown VBN N
over IN N
70 CD p
% NN p
of IN p
children NNS p
require VBP N
analgesics NNS i
following VBG N
bilateral JJ p
myringotomy NNS p
and CC p
tube VB p
placement NN p
( ( p
BM NNP p
& CC p
T NNP p
) ) p
. . p

This DT N
double-blind JJ N
, , N
placebo-controlled JJ N
study NN N
compared VBN N
the DT N
postoperative JJ N
analgesic JJ N
effects NNS N
of IN N
preoperatively RB N
administered VBN N
oral JJ N
acetaminophen NN i
or CC i
ibuprofen NN i
. . i

Forty NNP p
three CD p
ASA NNP p
I PRP p
or CC p
II NNP p
children NNS p
age NN p
six CD p
months NNS p
or CC p
older JJR p
scheduled VBN p
for IN p
elective JJ p
BM NNP p
& CC p
T NNP p
were VBD N
randomized VBN N
to TO N
receive VB N
acetaminophen NN i
( ( i
paracetamol NN i
) ) i
15 CD i
mg.kg-1 JJ i
, , i
ibuprofen JJ i
10 CD i
mg.kg-1 NN i
, , i
or CC i
placebo NN i
. . i

Postoperative JJ N
pain NN N
was VBD N
assessed VBN N
using VBG N
the DT N
Children NNP o
's POS o
Hospital NNP o
of IN o
Eastern NNP o
Ontario NNP o
Pain NNP o
Scale NNP o
( ( o
CHEOPS NNP o
) ) o
upon IN N
arrival NN N
to TO N
the DT N
PACU NNP N
and CC N
at IN N
5 CD N
, , N
10 CD N
, , N
15 CD N
, , N
30 CD N
, , N
45 CD N
, , N
and CC N
60 CD N
min NN N
. . N

CHEOP NNP N
scores NNS N
did VBD N
not RB N
differ VB N
between IN N
the DT N
groups NNS N
at IN N
any DT N
time NN N
. . N

There EX N
was VBD N
no DT N
difference NN N
in IN N
the DT N
number NN N
of IN N
children NNS p
receiving VBG p
rescue NN o
analgesia NN o
. . o

This DT N
study NN N
showed VBD N
no DT N
benefit NN N
of IN N
preoperatively RB N
administered VBN N
oral JJ N
ibuprofen NN i
10 CD N
mg.kg-1 NN N
or CC N
acetaminophen VB i
15 CD N
mg.kg-1 NN N
over IN N
placebo NN N
for IN N
the DT N
relief NN N
of IN N
postoperative JJ N
pain NN N
in IN N
children NNS p
undergoing VBG p
BM NNP p
& CC p
T NNP p
. . p

-DOCSTART- -1857525- O O

The DT N
effect NN N
of IN N
cyclosporin NN i
administered VBN N
during IN N
a DT N
third-party JJ p
blood NN p
transfusion NN p
protocol NN p
on IN N
humoral JJ N
immune JJ N
responses NNS N
. . N

Antigen NNP i
pre-treatment NN i
in IN p
animals NNS p
undoubtedly RB N
prolongs NNS N
graft NN o
survival NN o
. . o

In IN N
man NN N
, , N
however RB N
, , N
routine JJ N
pre-transplantation NN p
blood NN p
transfusions NNS p
have VBP N
recently RB N
become VBN N
controversial JJ N
, , N
principally RB N
because IN N
of IN N
the DT N
adverse JJ N
effect NN N
of IN N
transfusion-induced JJ N
sensitisation NN N
on IN N
graft NN o
survival NN o
rates NNS o
. . o

We PRP N
have VBP N
monitored VBN N
the DT N
effect NN N
of IN N
cyclosporin NN i
administered VBN N
during IN N
a DT N
planned JJ p
programme NN p
of IN p
third-party JJ p
blood NN p
transfusions NNS p
on IN N
the DT N
development NN N
of IN N
both DT o
cytotoxic JJ o
and CC o
anti-idiotypic JJ o
antibodies NNS o
. . o

A DT N
total NN N
of IN N
24 CD p
patients NNS p
were VBD p
recruited VBN p
to TO p
the DT p
study NN p
; : p
ten CC p
received VBD p
cyclosporin NNS i
with IN i
blood NN i
transfusions NNS i
( ( i
BT NNP i
) ) i
( ( p
group NN p
1 CD p
) ) p
, , p
14 CD p
received VBD p
BT NNP i
alone RB i
( ( p
group NN p
2 CD p
) ) p
. . N

Anti-HLA JJ o
antibodies NNS o
developed VBN N
in IN N
3 CD N
of IN N
9 CD N
patients NNS N
in IN N
group NN N
1 CD N
and CC N
8 CD N
of IN N
12 CD N
patients NNS N
in IN N
group NN N
2 CD N
( ( N
P NNP N
less JJR N
than IN N
0.05 CD N
) ) N
. . N

Anti-idiotypic JJ o
antibody NN o
activity NN o
was VBD N
detectable JJ N
in IN N
9 CD N
of IN N
9 CD N
patients NNS N
in IN N
group NN N
1 CD N
and CC N
7 CD N
of IN N
12 CD N
patients NNS N
in IN N
group NN N
2 CD N
( ( N
P NNP N
less JJR N
than IN N
0.006 CD N
) ) N
. . N

The DT N
mechanism NN N
by IN N
which WDT N
cyclosporin NN N
can MD N
prevent VB N
an DT N
anti-HLA JJ o
antibody NN o
response NN o
and CC N
promote VB o
an DT o
anti-idiotypic JJ o
response NN o
is VBZ N
unclear JJ N
. . N

-DOCSTART- -16684856- O O

Endurance NN N
training NN N
has VBZ N
little JJ N
effect NN N
on IN N
active JJ N
muscle NN N
free JJ o
fatty NN o
acid NN o
, , o
lipoprotein FW o
cholesterol NN o
, , o
or CC o
triglyceride JJ o
net JJ N
balances NNS N
. . N

We PRP N
evaluated VBD N
the DT N
hypothesis NN N
that WDT N
net JJ o
leg NN o
total JJ o
FFA NNP o
, , o
LDL-C NNP o
, , o
and CC o
TG NNP o
uptake JJ o
and CC o
HDL-C JJ o
release NN o
during IN N
moderate-intensity NN N
cycling NN N
exercise NN N
would MD N
be VB N
increased VBN N
following VBG N
endurance NN N
training NN N
. . N

Eight NNP p
sedentary JJ p
men NNS p
( ( p
26 CD p
+/- JJ p
1 CD p
yr NN p
, , p
77.4 CD p
+/- JJ p
3.7 CD p
kg NN p
) ) p
were VBD p
studied VBN p
in IN N
the DT N
postprandial JJ N
state NN N
during IN N
90 CD i
min NNS i
of IN i
rest NN i
and CC i
60 CD i
min NN i
of IN i
exercise NN i
twice NN i
before IN N
( ( N
45 CD N
% NN N
and CC N
65 CD N
% NN N
V NNP N
( ( N
O2 NNP N
peak NN N
) ) N
) ) N
and CC N
twice RB N
after IN N
9 CD i
wk NN i
of IN i
endurance NN i
training NN i
( ( N
55 CD N
% NN N
and CC N
65 CD N
% NN N
posttraining VBG N
V NNP N
( ( N
O2 NNP N
peak NN N
) ) N
) ) N
. . N

Measurements NNS N
across IN N
an DT N
exercising VBG N
leg NN N
were VBD N
taken VBN N
to TO N
be VB N
a DT N
surrogate NN N
for IN N
active JJ N
skeletal JJ N
muscle NN N
. . N

To TO N
determine VB N
limb NN o
lipid JJ o
exchange NN o
, , N
femoral JJ N
arterial NN N
and CC N
venous JJ N
blood NN N
samples NNS N
drawn VBP N
simultaneously RB N
at IN N
rest NN N
and CC N
during IN N
exercise NN N
were VBD N
analyzed VBN N
for IN N
total JJ N
and CC N
individual JJ N
FFA NNP N
( ( N
e.g. NN N
, , N
palmitate NN N
, , N
oleate NN N
) ) N
, , N
LDL-C NNP o
, , o
HDL-C NNP o
, , o
and CC o
TG NNP o
concentrations NNS o
, , o
and CC o
limb NN o
blood NN o
flow NN o
was VBD N
determined VBN N
by IN N
thermodilution NN N
. . N

The DT N
transition NN N
from IN N
rest NN N
to TO N
exercise VB N
resulted VBN N
in IN N
a DT N
shift NN N
from IN N
net JJ N
leg NN N
total JJ o
FFA NNP o
release NN o
( ( N
-44 JJ N
+/- JJ N
16 CD N
micromol/min NN N
) ) N
to TO N
uptake VB N
( ( N
193 CD N
+/- JJ N
49 CD N
micromol/min NN N
) ) N
that WDT N
was VBD N
unaffected VBN N
by IN N
either DT N
exercise NN N
intensity NN N
or CC N
endurance NN N
training NN N
. . N

The DT N
relative JJ N
net NN N
leg NN N
release NN N
and CC N
uptake NN N
of IN N
individual JJ N
FFA NNP N
closely RB N
resembled VBD N
their PRP$ N
relative JJ N
abundances NNS N
in IN N
the DT N
plasma NN N
with IN N
approximately RB N
21 CD N
and CC N
41 CD N
% NN N
of IN N
net JJ N
leg NN N
total JJ N
FFA NNP N
uptake NN N
during IN N
exercise NN N
accounted VBN N
for IN N
by IN N
palmitate NN N
and CC N
oleate NN N
, , N
respectively RB N
. . N

Endurance NNP i
training NN i
resulted VBD N
in IN N
significant JJ N
changes NNS N
in IN N
arterial JJ o
concentrations NNS o
of IN o
HDL-C NNP o
( ( N
49 CD N
+/- JJ N
5 CD N
vs. FW N
52 CD N
+/- JJ N
5 CD N
mg/dl NN N
, , N
pre NN N
vs. FW N
post NN N
) ) N
and CC N
LDL-C NNP o
( ( N
82 CD N
+/- JJ N
9 CD N
vs. FW N
76 CD N
+/- JJ N
9 CD N
mg/dl NN N
, , N
pre NN N
vs. FW N
post NN N
) ) N
, , N
but CC N
there EX N
was VBD N
no DT N
net JJ o
TG NN o
or CC o
LDL-C JJ o
uptake NN o
or CC o
HDL-C JJ o
release NN o
across IN N
the DT N
resting NN N
or CC N
active JJ N
leg NN N
before IN N
or CC N
after IN N
endurance JJ N
training NN N
. . N

In IN N
conclusion NN N
, , N
endurance NN N
training NN N
favorably RB N
affects VBZ N
blood NN o
lipoprotein NN o
profiles NNS o
, , N
even RB N
in IN p
young JJ p
, , p
healthy JJ p
normolipidemic JJ p
men NNS p
, , N
but CC N
muscle NN N
contractions NNS N
per IN N
se NN N
have VBP N
little JJ N
effect NN N
on IN N
net JJ N
leg NN o
LDL-C NNP o
, , o
or CC o
TG NNP o
uptake VBP o
or CC o
HDL-C JJ o
release NN o
during IN N
moderate-intensity NN N
cycling NN N
exercise NN N
. . N

Therefore RB N
, , N
the DT N
favorable JJ N
effects NNS N
of IN N
physical JJ N
activity NN N
on IN N
the DT N
lipid JJ N
profiles NNS N
of IN N
young JJ p
, , p
healthy JJ p
normolipidemic JJ p
men NNS p
in IN p
the DT p
postprandial JJ p
state NN p
are VBP N
not RB N
attributable JJ N
to TO N
changes NNS N
in IN N
HDL-C NNP o
or CC o
LDL-C NNP o
exchange NN N
across IN N
active JJ N
skeletal JJ N
muscle NN N
. . N

-DOCSTART- -16882628- O O

Effects NNS N
of IN N
sensory-level JJ N
high-volt NN N
pulsed VBD N
electrical JJ N
current JJ N
ondelayed-onset JJ o
muscle NN o
soreness NN o
. . o

Ten CD p
healthy JJ p
males NNS p
and CC p
ten VB p
healthy JJ p
females NNS p
aged VBD p
21.5 CD p
+/- JJ p
3.2 CD p
years NNS p
( ( p
mean JJ p
+/- NNP p
s NN p
) ) p
participated VBD p
in IN p
the DT p
study NN p
, , N
which WDT N
was VBD N
designed VBN N
to TO N
evaluate VB N
the DT N
effectiveness NN N
of IN N
sensory JJ i
level-high JJ i
volt NN i
pulsed VBD i
electrical JJ i
current JJ i
( ( i
HVPC NNP i
) ) i
on IN N
delayed-onset JJ o
muscle NN o
soreness NN o
( ( o
DOMS NNP o
) ) o
. . o

Arm NNP N
discomfort NN N
, , N
elbow JJ N
extension NN N
range NN N
of IN N
motion NN N
and CC N
isometric JJ N
elbow NN N
flexion NN N
strength NN N
were VBD N
obtained VBN N
as IN N
baseline NN N
measurements NNS N
. . N

Delayed-onset NNP o
muscle NN o
soreness NN o
was VBD N
induced VBN N
in IN N
the DT N
participants NNS N
' POS N
dominant NN N
or CC N
non-dominant JJ N
arm NN N
using VBG N
two CD N
sets NNS N
of IN N
20 CD N
maximal JJ N
eccentric JJ N
elbow NN N
flexion NN N
contractions NNS N
. . N

After IN N
the DT N
induction NN N
of IN N
DOMS NNP o
, , N
the DT N
participants NNS N
were VBD N
randomly RB N
divided VBN N
into IN N
an DT N
experimental JJ i
condition NN i
( ( i
HVPC NNP i
) ) i
or CC N
a DT N
placebo JJ i
condition NN N
. . N

The DT N
experimental JJ N
condition NN N
consisted VBD N
of IN N
20 CD N
min NN N
of IN N
HVPC NNP i
immediately RB N
after IN N
the DT N
induction NN N
of IN N
DOMS NNP o
, , N
and CC N
20 CD N
min NN N
every DT N
24 CD N
h NN N
for IN N
three CD N
consecutive JJ N
days NNS N
thereafter RB N
. . N

The DT N
participants NNS N
in IN N
the DT N
placebo NN i
condition NN N
received VBD N
an DT N
intervention NN N
similar JJ N
in IN N
design NN N
; : N
however RB N
, , N
no DT N
electrical JJ N
current JJ N
was VBD N
administered VBN N
. . N

Baseline JJ o
measurements NNS o
were VBD N
reevaluated VBN N
at IN N
24 CD N
, , N
48 CD N
, , N
72 CD N
and CC N
96 CD N
h NN N
after IN N
the DT N
induction NN N
of IN N
DOMS NNP o
. . o

Three CD N
weeks NNS N
later RB N
, , N
the DT N
participants NNS N
returned VBD N
and CC N
the DT N
protocol NN N
was VBD N
repeated VBN N
on IN N
the DT N
contralateral JJ N
limb NN N
, , N
using VBG N
the DT N
opposite JJ N
intervention NN N
( ( i
HVPC NNP i
or CC i
placebo NN i
) ) i
. . N

Repeated-measures JJ N
analysis NN N
of IN N
variance NN N
revealed VBD N
a DT N
significant JJ N
increase NN N
in IN N
overall JJ o
arm NN o
discomfort NN o
, , N
decrease NN N
in IN N
elbow JJ o
extension NN o
and CC N
decrease NN N
in IN N
isometric JJ o
strength NN o
for IN N
both DT o
conditions NNS o
over IN N
time NN N
. . N

No DT o
significant JJ o
main JJ o
effect NN o
of IN o
treatment NN o
, , o
or CC o
time-by-treatment JJ o
interaction NN o
, , N
was VBD N
found VBN N
for IN N
the DT N
HVPC NNP i
condition NN N
when WRB N
compared VBN N
with IN N
the DT N
placebo NN i
condition NN N
for IN N
any DT N
variable JJ N
. . N

Sensory-level JJ N
HVPC NNP N
, , N
as IN N
utilized VBN N
in IN N
our PRP$ N
application NN N
, , N
was VBD N
ineffective JJ N
in IN N
reducing VBG N
the DT N
measured JJ N
variables NNS N
associated VBN N
with IN N
DOMS NNP o
. . o

-DOCSTART- -1326734- O O

Randomized VBN N
phase NN N
II NNP N
trial NN N
of IN N
high-dose JJ N
4'-epi-doxorubicin JJ i
+ NNP N
cyclophosphamide NN i
versus IN N
high-dose JJ N
4'-epi-doxorubicin JJ i
+ NN i
cisplatin NN i
in IN N
previously RB p
untreated JJ p
patients NNS p
with IN p
extensive JJ p
small JJ p
cell NN p
lung NN p
cancer NN p
. . p

One CD p
hundred CD p
and CC p
eleven RB p
previously RB p
untreated JJ p
patients NNS p
with IN p
extensive JJ p
small JJ p
cell NN p
lung NN p
cancer NN p
were VBD N
included VBN N
in IN N
a DT N
prospective JJ N
randomized VBN N
study NN N
with IN N
the DT N
aim NN N
to TO N
assess VB N
the DT N
efficacy NN o
and CC N
tolerance NN o
of IN N
high-dose JJ i
epirubicin NN i
( ( N
120 CD N
mg/m2 NN N
) ) N
in IN N
combination NN N
with IN N
either DT N
cyclophosphamide NN i
( ( N
800 CD N
mg/m2 NN N
; : N
arm CC N
1 CD N
) ) N
or CC N
cisplatin NN i
( ( N
60 CD N
mg/m2 NN N
; : N
arm CC N
2 CD N
) ) N
. . N

Ninety-six JJ p
patients NNS p
were VBD p
evaluable JJ p
for IN p
response NN o
and CC o
toxicity NN o
and CC p
additional JJ p
12 CD p
patients NNS p
for IN p
toxicity NN o
only RB p
. . p

The DT N
overall JJ o
response NN o
rate NN o
( ( o
CR+PR NNP o
) ) o
in IN N
arm NN N
1 CD N
and CC N
2 CD N
were VBD N
61.4 CD N
( ( N
27/44 CD N
) ) N
and CC N
67.3 CD N
% NN N
( ( N
35/52 CD N
) ) N
, , N
respectively RB N
. . N

The DT N
mean JJ o
duration NN o
of IN o
remission NN o
was VBD N
4.4 CD N
months NNS N
( ( N
arm JJ N
1 CD N
) ) N
and CC N
4.9 CD N
months NNS N
( ( N
arm JJ N
2 CD N
) ) N
. . N

The DT N
mean JJ o
survival NN o
time NN o
was VBD N
6.6 CD N
months NNS N
in IN N
arm NN N
1 CD N
and CC N
7.7 CD N
months NNS N
in IN N
arm NN N
2. CD N
WHO NNP o
grade VBD o
4 CD o
toxicity NN o
was VBD N
encountered VBN N
in IN N
25.5 CD N
and CC N
15.8 CD N
% NN N
of IN N
patients NNS N
in IN N
arm JJ N
1 CD N
and CC N
2 CD N
, , N
respectively RB N
. . N

One CD N
case NN N
of IN N
cardiotoxicity NN o
resulting VBG N
in IN N
the DT N
patient NN N
's POS N
death NN o
was VBD N
observed VBN N
in IN N
arm NN N
1 CD N
. . N

Both DT N
combinations NNS N
showed VBD N
considerable JJ N
antitumor NN o
activity NN o
. . o

Toxicity NN o
was VBD N
acceptable JJ N
. . N

-DOCSTART- -12093332- O O

Bovine NNP i
pericardium NN i
vs NN i
dacron NN i
for IN N
patch NN N
angioplasty NN N
after IN p
carotid JJ p
endarterectomy NN p
: : p
a DT N
prospective JJ N
randomized NN N
study NN N
. . N

HYPOTHESIS NNP N
Bovine NNP i
pericardium NN i
( ( i
BP NNP i
) ) i
demonstrates VBZ N
improved JJ N
intraoperative JJ N
hemostasis NN N
and CC N
equivalent JJ N
perioperative JJ N
morbidity NN N
compared VBN N
with IN N
Dacron NNP i
when WRB N
used VBN N
as IN N
patch JJ N
material NN N
for IN N
angioplasty NN N
following VBG N
carotid JJ i
endarterectomy NN i
. . i

OBJECTIVE UH N
To TO N
prospectively RB N
compare VB N
BP NNP i
and CC i
Dacron NNP i
patch NN i
angioplasty NN i
after IN N
carotid JJ N
endarterectomy NN N
in IN N
a DT N
randomized JJ N
fashion NN N
. . N

METHODS NNP N
Ninety-five JJ p
consecutive JJ p
primary JJ p
carotid NN p
endarterectomies NNS p
were VBD p
performed VBN p
in IN p
a DT p
prospective JJ p
randomized VBN p
fashion NN p
in IN p
92 CD p
patients NNS p
. . p

Fifty-one CD p
procedures NNS p
were VBD N
performed VBN N
using VBG N
BP NNP i
and CC N
44 CD N
using VBG N
Dacron NNP i
. . i

Intraoperative JJ N
suture NN N
line NN N
bleeding NN N
was VBD N
subjectively RB N
evaluated VBN N
by IN N
observing VBG N
bleeding VBG N
at IN N
3 CD N
and CC N
4 CD N
minutes NNS N
following VBG N
carotid JJ i
cross-clamp JJ i
removal NN i
and CC N
then RB N
objectively RB N
weighing VBG N
the DT N
sponge NN N
used VBN N
to TO N
tamponade VB N
bleeding VBG N
during IN N
these DT N
time NN N
intervals NNS N
. . N

Perioperative JJ o
morbidity NN o
, , o
including VBG o
cervical JJ o
wound NN o
hematoma NN o
, , o
transient JJ o
ischemic JJ o
attack NN o
, , o
and CC o
stroke NN o
, , o
and CC o
perioperative JJ o
mortality NN o
were VBD N
recorded VBN N
. . N

Statistical JJ N
analysis NN N
was VBD N
performed VBN N
using VBG N
paired JJ N
t NN N
tests NNS N
, , N
chi NN N
( ( N
2 CD N
) ) N
analysis NN N
, , N
Fisher NNP N
exact JJ N
test NN N
, , N
or CC N
multiple JJ N
linear JJ N
regression NN N
as IN N
appropriate JJ N
. . N

RESULTS JJ N
Suture NNP o
line NN o
bleeding VBG o
at IN o
3 CD o
minutes NNS o
was VBD N
present JJ N
in IN N
7 CD N
( ( N
14 CD N
% NN N
) ) N
of IN N
51 CD N
patients NNS N
in IN N
the DT N
BP NNP i
group NN N
and CC N
24 CD N
( ( N
55 CD N
% NN N
) ) N
of IN N
44 CD N
patients NNS N
in IN N
the DT N
Dacron NNP i
group NN N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

Suture JJ o
line NN o
bleeding NN o
evaluated VBD o
at IN o
4 CD o
minutes NNS o
was VBD N
present JJ N
in IN N
2 CD N
( ( N
4 CD N
% NN N
) ) N
of IN N
51 CD N
patients NNS N
in IN N
the DT N
BP NNP i
group NN N
and CC N
13 CD N
( ( N
30 CD N
% NN N
) ) N
of IN N
44 CD N
patients NNS N
in IN N
the DT N
Dacron NNP i
group NN N
( ( N
P NNP N
=.001 NNP N
) ) N
. . N

Net JJ o
+/- JJ o
SEM NNP o
sponge NN o
weight NN o
( ( o
total JJ o
intraoperative JJ o
suture NN o
line NN o
bleeding VBG o
) ) o
was VBD N
6.25 CD N
+/- JJ N
0.55 CD N
g NN N
in IN N
the DT N
BP NNP i
group NN N
and CC N
16.34 CD N
+/- JJ N
1.85 CD N
g NN N
in IN N
the DT N
Dacron NNP i
group NN N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

Total JJ o
suture NN o
line NN o
bleeding NN o
was VBD N
significantly RB N
affected VBN N
by IN N
activated JJ N
clotting NN N
time NN N
; : N
however RB N
, , N
multivariate JJ N
analysis NN N
demonstrated VBD N
that IN N
bleeding NN o
was VBD N
significantly RB N
less JJR N
with IN N
BP NNP i
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
even RB N
after IN N
adjusting VBG N
for IN N
differences NNS N
in IN N
activated JJ N
clotting NN N
time NN N
. . N

CONCLUSIONS NNP N
Bovine NNP i
pericardium NN i
demonstrated VBD N
a DT N
statistically RB N
significant JJ N
decrease NN N
in IN N
intraoperative JJ N
suture NN N
line NN N
bleeding VBG N
compared VBN N
with IN N
Dacron NNP i
. . i

Handling VBG N
characteristics NNS N
were VBD N
judged VBN N
by IN N
the DT N
surgeons NNS N
to TO N
be VB N
superior JJ N
for IN N
BP NNP i
. . i

Therefore RB N
, , N
we PRP N
believe VBP N
BP NNP i
may MD N
be VB N
an DT N
alternative JJ N
to TO N
Dacron NNP i
when WRB N
performing VBG N
patch NN N
angioplasty NN N
of IN N
the DT N
carotid NN N
artery NN N
after IN N
endarterectomy NN N
. . N

-DOCSTART- -18609155- O O

Central JJ N
neuronal JJ N
mechanisms NNS N
of IN N
gastric JJ i
electrical JJ i
stimulation NN i
in IN N
diabetic JJ p
gastroparesis NN p
. . p

OBJECTIVE CC N
The DT N
mechanisms NNS N
underlying VBG N
symptom JJ N
improvement NN N
in IN N
gastric JJ i
electrical JJ i
stimulation NN i
( ( i
GES NNP i
) ) i
are VBP N
not RB N
fully RB N
understood JJ N
. . N

Modulation NN N
of IN N
the DT N
central JJ N
nervous JJ N
system NN N
excitability NN N
may MD N
be VB N
involved VBN N
. . N

The DT N
objective NN N
of IN N
the DT N
study NN N
was VBD N
to TO N
investigate VB N
the DT N
central JJ N
effects NNS N
of IN N
GES NNP i
, , N
including VBG N
the DT N
possible JJ N
modulation NN N
of IN N
the DT N
visceral JJ N
sensory NN N
nervous JJ N
system NN N
. . N

MATERIAL NNP N
AND NNP N
METHODS NNP N
A NNP N
gastric JJ i
electrical JJ i
stimulator NN i
was VBD N
implanted VBN N
in IN N
seven CD p
diabetic JJ p
patients NNS p
with IN p
medically RB p
refractory JJ p
gastroparesis NN i
. . i

A DT N
double-blinded JJ N
protocol NN N
was VBD N
used VBN N
to TO N
investigate VB N
the DT N
patients NNS N
at IN N
baseline NN N
and CC N
one CD N
month NN N
after IN N
recovery NN N
with IN N
the DT N
stimulator NN N
turned VBD N
on IN N
and CC N
off IN N
( ( N
1-month JJ N
periods NNS N
) ) N
. . N

The DT N
following JJ N
assessments NNS N
were VBD N
carried VBN N
out IN N
: : N
mechanical JJ N
, , N
thermal JJ N
and CC N
electrical JJ N
stimulations NNS N
with IN N
sensory JJ N
recordings NNS N
in IN N
the DT N
esophagus NN N
and CC N
duodenum NN N
, , N
and CC N
standardized VBD N
, , N
self-administered JJ N
, , N
daily JJ N
symptom NN N
questionnaires NNS N
. . N

RESULTS NNP N
No NNP N
difference NN N
was VBD N
found VBN N
between IN N
baseline NN N
and CC N
the DT N
on- JJ N
and CC N
off RP N
periods NNS N
in IN N
overall JJ o
gut NN o
pain NN o
thresholds NNS N
across IN N
all DT N
stimulus NN N
modalities NNS N
in IN N
the DT N
esophagus NN N
( ( N
p=0.63 NN N
) ) N
, , N
duodenum NN N
( ( N
p=0.19 NN N
) ) N
or CC N
esophagus JJ N
and CC N
duodenum NN N
combined VBN N
( ( N
p=0.76 NN N
) ) N
. . N

No DT N
difference NN N
in IN N
the DT N
sensory JJ o
response NN o
to TO o
mechanical JJ o
stimulation NN o
was VBD N
found VBN N
in IN N
the DT N
esophagus NN N
before IN N
( ( N
all DT N
p VBP N
> $ N
0.31 CD N
) ) N
and CC N
after IN N
( ( N
all DT N
p VBP N
> $ N
0.43 CD N
) ) N
smooth FW N
muscle NN N
relaxation NN N
with IN N
butylscopolamine NN i
. . i

Similar JJ N
findings NNS N
were VBD N
observed VBN N
in IN N
the DT N
duodenum NN N
. . N

No DT N
differences NNS N
were VBD N
found VBN N
in IN N
thermal JJ o
sensitivity NN o
( ( N
esophagus JJ N
( ( N
p=0.67 NN N
) ) N
and CC N
duodenum NN o
( ( N
p=0.17 NN N
) ) N
) ) N
, , N
sensory JJ o
response NN o
to TO o
electrical JJ o
stimulation NN o
( ( N
esophagus JJ N
( ( N
p=0.57 NN N
) ) N
and CC N
duodenum NN o
( ( N
p=0.52 NN N
) ) N
) ) N
or CC N
induced VBN o
somatic JJ o
referred VBD o
pain NN o
areas NNS o
( ( N
esophagus NN N
( ( N
p=0.75 NN N
) ) N
and CC N
duodenum NN N
( ( N
p=0.51 NN N
) ) N
) ) N
. . N

No DT N
difference NN N
was VBD N
seen VBN N
in IN N
the DT N
induced JJ N
somatic JJ o
referred VBD o
pain JJ o
areas NNS o
or CC o
self-reported JJ o
symptoms NNS o
. . o

CONCLUSIONS NNP N
No NNP N
evidence NN N
was VBD N
found VBN N
for IN N
GES-induced NNP i
modulation NN N
of IN N
the DT N
visceral JJ N
sensory NN N
system NN N
and CC N
central JJ N
excitability NN N
. . N

However RB N
, , N
GES NNP i
has VBZ N
been VBN N
proven VBN N
to TO N
modulate VB N
the DT N
central JJ N
nervous JJ N
system NN N
in IN N
animal JJ N
studies NNS N
, , N
necessitating VBG N
further JJ N
human JJ N
experiments NNS N
in IN N
order NN N
unambiguously RB N
to TO N
establish VB N
the DT N
possible JJ N
central JJ N
effects NNS N
of IN N
GES NNP i
. . i

-DOCSTART- -1286738- O O

A DT N
comparative JJ N
study NN N
of IN N
a DT N
new JJ N
food NN N
supplement NN N
, , N
ViviScal NNP i
, , i
with IN i
fish JJ i
extract NN i
for IN N
the DT N
treatment NN N
of IN N
hereditary JJ p
androgenic JJ p
alopecia NN p
in IN p
young JJ p
males NNS p
. . p

A DT N
controlled JJ N
, , N
randomized VBN N
, , N
double-blind JJ N
, , N
parallel-group JJ N
study NN N
compared VBN N
the DT N
effects NNS N
of IN N
ViviScal NNP i
( ( i
a DT i
new JJ i
food NN i
supplement NN i
incorporating VBG i
special JJ i
marine JJ i
extracts NNS i
and CC i
a DT i
silica JJ i
compound NN i
) ) i
with IN i
those DT i
of IN i
a DT i
fish JJ i
extract NN i
in IN N
the DT N
treatment NN N
of IN N
young JJ p
males NNS p
with IN p
hereditary JJ p
androgenic JJ p
alopecia NN p
. . p

The DT N
pretreatment JJ N
histological JJ N
diagnosis NN N
was VBD N
alopecia VBN p
with IN p
a DT p
mild NN p
to TO p
moderate VB p
perifollicular JJ p
inflammation NN p
zone NN p
. . p

The DT N
study NN N
consisted VBD N
of IN N
20 CD p
subjects NNS p
who WP p
received VBD p
two CD i
tablets NNS i
of IN i
ViviScal NNP i
once RB i
daily RB i
and CC i
20 CD i
who WP i
received VBD i
two CD i
tablets NNS i
of IN i
fish JJ i
extract NN i
once RB i
daily JJ i
for IN i
6 CD i
months NNS i
. . i

The DT p
mean JJ p
patient NN p
age NN p
and CC p
mean JJ p
duration NN p
and CC p
severity NN p
of IN p
baldness NN p
compared VBN N
well RB N
between IN N
the DT N
two CD N
groups NNS N
. . N

Most JJS p
patients NNS p
had VBD p
been VBN p
treated VBN p
with IN p
long-term JJ p
topical JJ p
2 CD p
% NN p
minoxidil NN i
for IN p
1 CD p
year NN p
or CC p
more JJR p
prior JJ N
to TO N
the DT N
study NN N
. . N

At IN N
baseline NN N
and CC N
after IN N
6 CD N
months NNS N
' POS N
treatment NN N
, , N
a DT N
biopsy NN N
was VBD N
taken VBN N
for IN N
histological JJ N
examination NN N
. . N

A DT N
non-vellus JJ o
hair NN o
count NN o
was VBD N
performed VBN N
at IN N
baseline NN N
and CC N
after IN N
2 CD N
, , N
4 CD N
and CC N
6 CD N
months NNS N
. . N

In IN N
the DT N
fish JJ i
extract NN i
treatment NN N
group NN N
three CD p
patients NNS p
withdrew VBD p
from IN p
the DT p
study NN p
before IN p
the DT p
fourth JJ p
month NN p
due JJ p
to TO p
lack VB o
of IN o
therapeutic JJ o
effect NN o
. . o

After IN N
6 CD N
months NNS N
' POS N
treatment NN N
, , N
patients NNS N
receiving VBG N
ViviScal NNP i
showed VBD N
a DT N
mean JJ o
increase NN o
in IN o
non-vellus JJ o
hair NN o
of IN N
38 CD N
% NN N
compared VBN N
with IN N
a DT N
2 CD N
% NN N
increase NN N
in IN N
the DT N
fish JJ i
extract NN i
treatment NN N
group NN N
( ( N
P NNP N
< NNP N
0.0001 CD N
) ) N
. . N

In IN N
the DT N
ViviScal NNP i
group NN N
, , N
19 CD N
( ( N
95 CD N
% NN N
) ) N
subjects VBZ N
showed VBN N
both DT o
clinical JJ o
and CC o
histological JJ o
cure NN o
, , N
whereas IN N
none NN N
treated VBN N
with IN N
fish JJ N
extract NN N
showed VBD N
any DT N
clinical JJ N
or CC N
histological JJ N
difference NN N
after IN N
6 CD N
months NNS N
' POS N
treatment NN N
( ( N
P NNP N
< NNP N
0.0001 CD N
) ) N
. . N

In IN N
both DT N
groups NNS N
, , N
a DT N
minimal JJ N
decrease NN N
in IN N
the DT N
erythemal JJ o
index NN o
was VBD N
observed VBN N
. . N

In IN N
conclusion NN N
, , N
ViviScal JJ i
appears VBZ N
to TO N
be VB N
the DT N
first JJ N
highly RB N
active JJ N
treatment NN N
for IN N
androgenic JJ N
alopecia NN N
in IN N
young JJ N
males NNS N
. . N

-DOCSTART- -1721246- O O

Bradykinin-induced JJ N
cough NN N
reflex NN N
markedly RB N
increases VBZ N
in IN N
patients NNS p
with IN p
cough NN p
associated VBN p
with IN p
captopril NN p
and CC p
enalapril NN p
. . p

We PRP N
studied VBD N
the DT N
effects NNS N
of IN N
angiotensin NN i
converting VBG i
enzyme NN i
( ( i
ACE NNP i
) ) i
inhibitors NNS i
on IN N
cough NN o
responses NNS o
to TO i
bradykinin VB i
( ( i
BK NNP i
) ) i
, , i
substance NN i
P NNP i
( ( i
SP NNP i
) ) i
and CC i
citric JJ i
acid NN i
in IN N
a DT N
double JJ N
blind NN N
, , N
random NN N
study NN N
on IN N
10 CD p
hypertensive JJ p
patients NNS p
receiving VBG p
ACE NNP i
inhibitors NNS i
. . i

Of IN p
these DT p
patients NNS p
, , p
five CD p
had VBD p
reported VBN p
cough NN p
with IN p
ACE NNP i
inhibitors NNS i
. . i

Cough NNP N
responses VBZ N
to TO N
citric VB N
acid NN N
were VBD N
similar JJ N
between IN N
patients NNS N
with IN N
and CC N
without IN N
cough NN N
, , N
and CC N
SP NNP N
up RB N
to TO N
10 CD N
( ( N
-5 NN N
) ) N
M NNP N
did VBD N
not RB N
cause VB N
cough NN N
in IN N
any DT N
of IN N
the DT N
subjects NNS N
. . N

BK NNP i
caused VBD p
cough NN o
at IN p
13.4 CD p
+/- JJ p
1.2 CD p
( ( p
-log NNP p
M NNP p
) ) p
in IN p
5 CD p
patients NNS p
with IN p
cough NN p
associated VBN p
with IN p
ACE NNP i
inhibitors NNS i
, , p
but CC p
it PRP p
did VBD p
not RB p
cause VB p
cough NN o
at IN p
concentrations NNS p
up RB p
to TO p
10 CD p
( ( p
-5 NN p
) ) p
M NNP p
in IN p
other JJ p
5 CD p
patients NNS p
. . p

One CD N
month NN N
after IN N
the DT N
withdrawal NN N
of IN N
ACE NNP N
inhibitors NNS N
, , N
5 CD p
patients NNS p
were VBD p
free JJ p
from IN p
cough NN o
symptoms NNS o
, , p
and CC p
BK NNP p
did VBD p
not RB p
cause VB p
cough NN o
up RB p
to TO p
10 CD p
( ( p
-5 NN p
) ) p
M NNP p
in IN p
these DT p
patients NNS p
, , p
except IN p
for IN p
one CD p
who WP p
coughed VBD p
at IN p
10 CD p
( ( p
-9 NN p
) ) p
M NNP p
, , N
without IN N
changes NNS N
in IN N
responses NNS N
to TO N
citric VB N
acid NN N
. . N

BK NNP N
caused VBD N
cough NN o
at IN N
14.3 CD N
+/- JJ N
0.7 CD N
( ( N
-log NNP N
M NNP N
) ) N
although IN N
BK1-7 NNP N
, , N
a DT N
major JJ N
metabolite NN N
of IN N
BK NNP N
by IN N
ACE NNP N
, , N
caused VBD N
cough NN o
at IN N
5.7 CD N
+/- JJ N
0.7 CD N
( ( N
-log NNP N
M NNP N
) ) N
in IN N
another DT N
3 CD N
patients NNS N
with IN N
cough NN N
associated VBN N
with IN N
ACE NNP N
inhibitor NN N
. . N

These DT N
results NNS N
suggest VBP N
that IN N
impaired JJ N
metabolism NN N
of IN N
BK NNP N
induced VBN N
by IN N
ACE NNP N
inhibitors NNS N
may MD N
relate VB N
to TO N
the DT N
manifestation NN N
of IN N
cough NN N
in IN N
hypertensive JJ p
patients NNS p
receiving VBG p
ACE NNP p
inhibitors NNS p
. . p

-DOCSTART- -12233993- O O

Examining VBG N
possible JJ N
gender NN N
differences NNS N
among IN N
cocaine-dependent JJ p
outpatients NNS p
. . p

Potential JJ N
differences NNS N
in IN N
sociodemographics NNS N
, , N
drug NN N
use NN N
, , N
and CC N
measures NNS N
of IN N
treatment NN N
outcome NN N
were VBD N
examined VBN N
among IN N
137 CD p
male NN p
and CC p
51 CD p
female JJ p
cocaine-dependent JJ p
outpatients NNS p
. . p

More JJR p
women NNS p
than IN p
men NNS p
were VBD p
unemployed JJ p
, , p
received VBD p
public JJ p
assistance NN p
, , p
and CC p
were VBD p
living VBG p
with IN p
their PRP$ p
children NNS p
. . p

Women NNP N
reported VBD N
fewer JJR N
years NNS N
of IN N
regular JJ N
cocaine NN N
use NN N
, , N
spending NN N
less JJR N
money NN N
per IN N
week NN N
on IN N
cocaine NN N
, , N
less JJR N
prior JJ N
treatment NN N
for IN N
cocaine NN N
abuse NN N
, , N
and CC N
were VBD N
more RBR N
likely JJ N
than IN N
men NNS N
to TO N
test VB N
positive JJ N
for IN N
cocaine NN N
at IN N
intake NN N
. . N

With IN N
respect NN N
to TO N
other JJ N
drug NN N
use NN N
, , N
fewer JJR N
women NNS N
than IN N
men NNS N
reported VBN N
using VBG o
sedatives NNS o
and CC N
tested VBD N
positive JJ N
for IN N
sedatives NNS o
at IN o
intake NN o
. . o

Women NNP N
reported VBD N
a DT N
lower JJR N
frequency NN o
of IN o
alcohol NN o
use NN o
before IN o
intake NN o
, , N
and CC N
fewer JJR N
women NNS N
than IN N
men NNS N
met VBD N
criteria NNS N
for IN N
cannabis NN N
dependence NN N
. . N

Men NNP N
and CC N
women NNS N
experienced VBD N
comparable JJ N
improvement NN N
during IN N
the DT N
course NN N
of IN N
treatment NN N
and CC N
follow-up NN N
. . N

-DOCSTART- -15564950- O O

Intranasal NNP N
nicotine NN i
for IN N
postoperative JJ p
pain NN p
treatment NN p
. . p

BACKGROUND NNP N
Despite IN N
pharmacological JJ N
treatment NN N
, , N
70-80 CD N
% NN N
of IN N
patients NNS N
report NN N
moderate VBP N
to TO N
severe VB N
pain NN N
after IN N
surgery NN N
. . N

Because IN N
nicotine NN N
has VBZ N
been VBN N
reported VBN N
to TO N
have VB N
analgesic JJ N
properties NNS N
in IN N
animal NN N
and CC N
human JJ N
volunteer NN N
studies NNS N
, , N
the DT N
authors NNS N
assessed VBD N
the DT N
analgesic JJ N
efficacy NN N
of IN N
a DT N
single JJ N
3 CD N
mg NN N
dose NN N
of IN N
nicotine JJ i
nasal NN N
spray NN N
administered VBD N
before IN N
emergence NN N
from IN N
general JJ N
anesthesia NN N
. . N

METHODS NNP N
The DT N
authors NNS N
conducted VBD N
a DT N
randomized VBN N
, , N
double JJ N
blind NN N
, , N
placebo NN i
controlled VBD N
trial NN N
of IN N
20 CD p
healthy JJ p
women NNS p
( ( p
mean JJ p
age NN p
45 CD p
( ( p
SD NNP p
8 CD p
) ) p
yr NN p
) ) p
who WP p
were VBD p
to TO p
undergo VB p
uterine JJ i
surgery NN i
through IN p
a DT p
low JJ i
transverse NN i
incision NN i
. . i

After IN N
the DT N
conclusion NN N
of IN N
surgery NN N
but CC N
before IN N
emergence NN N
from IN N
general JJ N
anesthesia NN N
, , N
the DT N
anesthesiologist NN N
administered VBD N
either CC N
nicotine JJ i
nasal NN i
spray NN i
or CC i
a DT i
placebo NN i
. . i

Numerical JJ N
analog NN N
pain NN N
score NN N
and CC N
morphine JJ N
utilization NN N
and CC N
hemodynamic JJ N
values NNS N
were VBD N
measured VBN N
for IN N
24 CD N
h. NN N
RESULTS NNP N
The DT N
patients NNS N
treated VBN N
with IN N
nicotine NN N
reported VBN N
lower JJR o
pain NN o
scores NNS o
during IN N
the DT N
first JJ N
hour NN N
after IN N
surgery NN N
( ( N
peak JJ N
numerical JJ N
analog NN N
score NN N
, , N
7.6 CD N
( ( N
SD NNP N
1.4 CD N
) ) N
versus NN N
5.3 CD N
( ( N
SD NNP N
1.6 CD N
) ) N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
and CC N
used VBN N
half PDT N
the DT N
amount NN o
of IN o
morphine NN o
as IN N
the DT N
control NN N
group NN N
( ( N
12 CD N
( ( N
SD NNP N
6 CD N
) ) N
versus NN N
6 CD N
( ( N
SD NNP N
5 CD N
) ) N
mg NN N
; : N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

Patients NNPS N
who WP N
received VBD N
nicotine NN N
still RB N
reported VBD o
less RBR o
pain NN o
than IN N
those DT N
in IN N
the DT N
control NN N
group NN N
24 CD N
h NN N
after IN N
surgery NN N
( ( N
1.5 CD N
( ( N
SD NNP N
0.5 CD N
) ) N
versus NN N
4.9 CD N
( ( N
SD NNP N
1.4 CD N
) ) N
; : N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

Systolic JJ o
blood NN o
pressure NN o
was VBD o
lower JJR o
in IN N
the DT N
group NN N
that WDT N
received VBD N
nicotine JJ N
( ( N
105 CD N
( ( N
SD NNP N
3 CD N
) ) N
versus NN N
122 CD N
( ( N
SD NNP N
3 CD N
) ) N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
but CC N
there EX N
was VBD N
no DT o
difference NN o
in IN o
diastolic JJ o
blood NN o
pressure NN o
or CC o
heart NN o
rate NN o
. . o

CONCLUSIONS NNP N
Treatment NNP N
with IN N
a DT N
single JJ N
dose NN N
of IN N
nicotine JJ N
immediately RB N
before IN N
emergence NN N
from IN N
anesthesia NN N
was VBD N
associated VBN N
with IN N
significantly RB N
lower JJR N
reported VBD N
pain JJ o
scores NNS o
during IN N
the DT N
first JJ N
day NN N
after IN N
surgery NN N
. . N

The DT N
decreased JJ N
pain NN o
was VBD N
associated VBN N
with IN N
a DT N
reduction NN N
in IN N
morphine JJ N
utilization NN N
and CC N
the DT N
analgesic JJ N
effect NN N
of IN N
nicotine NN N
was VBD N
not RB N
associated VBN N
with IN N
hypertension NN N
or CC N
tachycardia NN N
. . N

-DOCSTART- -18606053- O O

Dexamethasone NN i
phosphate NN i
in IN i
antibiotic JJ i
ear NN i
drops NNS i
for IN N
the DT N
treatment NN N
of IN N
acute JJ p
bacterial JJ p
otitis NN p
externa NN p
. . p

OBJECTIVES NNP N
To TO N
compare VB N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
polymyxin NN i
sulfate NN i
7500 CD i
IU/neomycin NNP i
sulfate NN i
3500 CD i
IU/dexamethasone NNP i
phosphate VB i
0.1 CD i
% NN i
( ( i
PN+Dx NNP i
) ) i
otic JJ i
solution NN i
with IN i
polymyxin NN i
sulfate NN i
7500 CD i
IU/neomycin NNP i
sulfate NN i
3500 CD i
IU NNP i
( ( i
PN-Dx NNP i
) ) i
in IN N
patients NNS p
with IN p
acute JJ p
bacterial JJ p
otitis NN p
externa NN p
( ( p
AOE NNP p
) ) p
, , N
in IN N
order NN N
to TO N
determine VB N
the DT N
possible JJ N
benefit NN N
of IN N
the DT N
addition NN N
of IN N
dexamethasone NN N
. . N

RESEARCH NNP N
DESIGN NNP N
AND NNP N
METHODS NNP N
Active NNP N
controlled VBD N
, , N
double-blind NN N
, , N
randomized VBN N
, , N
parallel JJ N
group NN N
, , N
multi-center JJ p
clinical JJ p
trial NN p
in IN p
ear NN p
, , p
nose RB p
, , p
and CC p
throat NN p
( ( p
ENT NNP p
) ) p
specialist NN p
practices NNS p
with IN N
a DT N
planned VBN N
interim NN N
analysis NN N
for IN N
sample JJ N
size NN N
adaptation NN N
. . N

In IN N
total JJ N
, , N
338 CD p
patients NNS p
aged VBN p
18-76 NNS p
who WP p
had VBD p
a DT p
previous JJ p
episode NN p
of IN p
otitis NN p
externa NN p
within IN p
the DT p
last JJ p
year NN p
were VBD N
randomized VBN N
to TO N
receive VB N
10 CD N
+/- JJ N
2 CD N
days NNS N
of IN N
treatment NN N
with IN N
two CD i
drops NNS i
, , i
three CD i
times NNS i
daily RB i
, , i
of IN i
either DT i
PN+Dx NNP i
or CC i
PN-Dx NNP i
. . i

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Change NNP o
in IN o
the DT o
clinical JJ o
symptom NN o
score NN o
( ( o
consisting VBG o
of IN o
the DT o
subscores NNS o
redness NN o
, , o
swelling VBG o
, , o
pain NN o
, , o
and CC o
secretion NN o
) ) o
and CC N
of IN N
the DT N
visual JJ o
analogue NN o
scale NN o
( ( o
VAS NNP o
) ) o
rating NN o
for IN o
pain NN o
from IN N
Visit NNP N
1 CD N
( ( N
Day NNP N
1 CD N
) ) N
to TO N
Visit VB N
2 CD N
( ( N
Day NNP N
4 CD N
+/- JJ N
1 CD N
) ) N
, , N
patient NN o
's POS o
assessment NN o
of IN o
efficacy NN o
at IN N
Visit NNP N
3 CD N
( ( N
Day NNP N
10 CD N
+/- JJ N
2 CD N
) ) N
, , N
and CC N
the DT N
frequency NN o
and CC o
type NN o
of IN o
adverse JJ o
events NNS o
. . o

RESULTS NNP N
There EX N
was VBD N
a DT N
significantly RB N
greater JJR N
reduction NN N
of IN N
swelling VBG o
from IN N
Visit NNP N
1 CD N
to TO N
Visit VB N
2 CD N
with IN N
PN+Dx NNP N
, , N
and CC N
more JJR N
patients NNS N
rated VBD N
the DT N
efficacy NN o
of IN N
PN+Dx NNP N
as IN N
'very RB N
good JJ N
' '' N
or CC N
'good POS N
' '' N
at IN N
Visit NNP N
3 CD N
( ( N
p NN N
= RB N
0.03 CD N
) ) N
. . N

There EX N
was VBD N
also RB N
a DT N
significantly RB N
greater JJR N
decrease NN N
in IN N
the DT N
clinical JJ o
symptom NN o
score NN o
from IN N
Visit NNP N
1 CD N
to TO N
Visit VB N
2 CD N
in IN N
the DT N
PN+Dx NNP N
group NN N
in IN N
patients NNS N
who WP N
had VBD N
at IN N
least JJS N
a DT N
moderately RB N
severe JJ o
symptom NN o
score NN o
with IN N
more JJR N
than IN N
seven CD N
points NNS N
at IN N
Visit NNP N
1 CD N
( ( N
p NN N
= RB N
0.01 CD N
) ) N
and CC N
in IN N
patients NNS N
suffering VBG N
from IN N
their PRP$ N
current JJ N
episode NN N
of IN N
otitis NN N
externa NN N
for IN N
more JJR N
than IN N
2 CD N
days NNS N
( ( N
p JJ N
= NNP N
0.02 CD N
) ) N
. . N

In IN N
total JJ N
, , N
14 CD N
adverse JJ N
events NNS N
were VBD N
reported VBN N
during IN N
the DT N
study NN N
period NN N
with IN N
no DT N
related JJ N
adverse JJ o
drug NN o
reactions NNS o
for IN N
PN+Dx NNP N
. . N

CONCLUSIONS NNP N
The DT N
addition NN i
of IN i
dexamethasone NN i
phosphate NN i
to TO i
polymyxin VB i
B/neomycin NNP i
significantly RB N
reduces VBZ N
swelling VBG N
in IN N
patients NNS p
with IN p
AOE NNP p
and CC N
leads VBZ N
to TO N
significantly RB N
higher JJR N
patient NN N
's POS N
ratings NNS N
of IN N
treatment NN N
efficacy NN N
. . N

It PRP N
especially RB N
leads VBZ N
to TO N
an DT N
overall JJ N
reduction NN N
of IN N
symptoms NNS N
in IN N
cases NNS N
of IN N
moderately RB N
or CC N
more JJR N
severe JJ N
otitis NN N
externa NN N
and CC N
cases NNS N
lasting VBG N
for IN N
more JJR N
than IN N
2 CD N
days NNS N
. . N

-DOCSTART- -20646286- O O

Predictors NNS N
of IN N
stable JJ i
return-to-work NN i
in IN N
non-acute JJ N
, , N
non-specific JJ N
spinal JJ N
pain NN N
: : N
low JJ N
total JJ N
prior JJ N
sick-listing NN N
, , N
high JJ N
self NN N
prediction NN N
and CC N
young JJ N
age NN N
. . N

A DT N
two-year JJ N
prospective JJ N
cohort NN N
study NN N
. . N

BACKGROUND NNP N
Non-specific JJ p
spinal JJ p
pain NN p
( ( p
NSP NNP p
) ) p
, , p
comprising VBG p
back RP p
and/or JJ p
neck NN p
pain NN p
, , N
is VBZ N
one CD N
of IN N
the DT N
leading VBG N
disorders NNS N
in IN N
long-term JJ N
sick-listing NN N
. . N

During IN N
2000-2004 JJ N
, , N
125 CD p
Swedish JJ p
primary-care JJ p
patients NNS p
with IN p
non-acute JJ p
NSP NNP p
, , p
full-time JJ p
sick-listed JJ p
6 CD p
weeks-2 JJ p
years NNS p
, , N
were VBD N
included VBN N
in IN N
a DT N
randomized NN N
controlled VBN N
trial NN N
to TO N
compare VB N
a DT N
cognitive-behavioural JJ i
programme NN i
with IN i
traditional JJ i
primary JJ i
care NN i
. . i

This DT N
prospective JJ N
cohort NN N
study NN N
is VBZ N
a DT N
re-assessment NN N
of IN N
the DT N
data NN N
from IN N
the DT N
randomized VBN N
trial NN N
with IN N
the DT N
2 CD p
treatment NN p
groups NNS p
considered VBN p
as IN p
a DT p
single JJ p
cohort NN p
. . p

The DT N
aim NN N
was VBD N
to TO N
investigate VB N
which WDT N
baseline NN N
variables NNS N
predict VBP N
a DT N
stable JJ N
return-to-work NN N
during IN N
a DT N
2-year JJ N
period NN N
after IN N
baseline NN N
: : N
objective JJ N
variables NNS N
from IN N
function NN N
tests NNS N
, , N
socioeconomic JJ N
, , N
subjective JJ N
and/or NN N
treatment NN N
variables NNS N
. . N

Stable JJ N
return-to-work NN N
was VBD N
a DT N
return-to-work JJ N
lasting NN N
for IN N
at IN N
least JJS N
1 CD N
month NN N
from IN N
the DT N
start NN N
of IN N
follow-up NN N
. . N

METHODS NNP N
Stable JJ N
return-to-work NN N
was VBD N
the DT N
outcome NN N
variable NN N
, , N
the DT N
above-mentioned JJ N
factors NNS N
were VBD N
the DT N
predictive JJ N
variables NNS N
in IN N
multiple-logistic JJ N
regression NN N
models NNS N
, , N
one CD N
per IN N
follow-up NN N
at IN N
6 CD N
, , N
12 CD N
, , N
18 CD N
and CC N
24 CD N
months NNS N
after IN N
baseline NN N
. . N

The DT N
factors NNS N
from IN N
univariate JJ N
analyzes NNS N
with IN N
a DT N
p-value NN N
of IN N
at IN N
most JJS N
.10 NNS N
were VBD N
included VBN N
. . N

The DT N
non-significant JJ N
variables NNS N
were VBD N
excluded VBN N
stepwise NN N
to TO N
yield VB N
models NNS N
comprising VBG N
only RB N
significant JJ N
factors NNS N
( ( N
p JJ N
< NNP N
.05 NNP N
) ) N
. . N

As IN N
the DT N
comparatively RB N
few JJ N
cases NNS N
made VBD N
it PRP N
risky JJ N
to TO N
associate VB N
certain JJ N
predictors NNS N
with IN N
certain JJ N
time-points NNS N
, , N
we PRP N
finally RB N
considered VBD N
the DT N
predictors NNS N
which WDT N
were VBD N
represented VBN N
in IN N
at IN N
least JJS N
3 CD N
follow-ups NNS N
. . N

They PRP N
are VBP N
presented VBN N
with IN N
odds NNS N
ratios NNS N
( ( N
OR NNP N
) ) N
and CC N
95 CD N
% NN N
confidence NN N
intervals NNS N
. . N

RESULTS NNP N
Three CD N
variables NNS N
qualified VBN N
, , N
all DT N
of IN N
them PRP N
represented VBN N
in IN N
3 CD N
follow-ups NNS N
: : N
Low NNP o
total JJ o
prior RB o
sick-listing NN o
( ( o
including VBG o
all DT o
diagnoses NNS o
) ) o
was VBD N
the DT N
strongest JJS o
predictor NN o
in IN N
2 CD N
follow-ups NNS N
, , N
18 CD N
and CC N
24 CD N
months NNS N
, , N
OR NNP N
4.8 CD N
[ JJ N
1.9-12.3 JJ N
] NN N
and CC N
3.8 CD N
[ JJ N
1.6-8.7 JJ N
] NN N
respectively RB N
, , N
High NNP o
self NN o
prediction NN o
( ( N
the DT N
patients NNS N
' POS N
own JJ N
belief NN N
in IN N
return-to-work NN N
) ) N
was VBD N
the DT N
strongest JJS N
at IN N
12 CD N
months NNS N
, , N
OR NNP N
5.2 CD N
[ JJ N
1.5-17.5 JJ N
] NN N
and CC N
Young NNP o
age NN o
( ( N
max JJ N
44 CD N
years NNS N
) ) N
the DT N
second JJ N
strongest NN N
at IN N
18 CD N
months NNS N
, , N
OR NNP N
3.5 CD N
[ JJ N
1.3-9.1 JJ N
] NN N
. . N

CONCLUSIONS NNP N
In IN N
primary-care JJ p
patients NNS p
with IN p
non-acute JJ p
NSP NNP p
, , N
the DT N
strong JJ N
predictors NNS N
of IN N
stable JJ i
return-to-work NN i
were VBD N
2 CD N
socioeconomic JJ N
variables NNS N
, , N
Low NNP N
total JJ N
prior JJ N
sick-listing NN N
and CC N
Young NNP N
age NN N
, , N
and CC N
1 CD N
subjective JJ N
variable NN N
, , N
High NNP N
self-prediction NN N
. . N

Objective JJ N
variables NNS N
from IN N
function NN N
tests NNS N
and CC N
treatment NN N
variables NNS N
were VBD N
non-predictors NNS N
. . N

Except IN N
for IN N
Young NNP N
age NN N
, , N
the DT N
predictors NNS N
have VBP N
previously RB N
been VBN N
insufficiently RB N
studied VBN N
, , N
and CC N
so RB N
our PRP$ N
study NN N
should MD N
widen VB N
knowledge NN N
within IN N
clinical JJ N
practice NN N
. . N

-DOCSTART- -19148734- O O

A DT N
double-blind JJ N
, , N
placebo-controlled JJ i
trial NN N
of IN N
oral JJ i
human JJ i
immunoglobulin NN i
for IN N
gastrointestinal JJ p
dysfunction NN p
in IN p
children NNS p
with IN p
autistic JJ p
disorder NN p
. . p

Controversy NNP N
exists VBZ N
regarding VBG N
the DT N
extent NN N
and CC N
possible JJ N
causal NN N
relationship NN N
between IN N
gastrointestinal JJ N
symptoms NNS N
and CC N
autism NN N
. . N

A DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
, , N
parallel JJ N
groups NNS N
, , N
dose-ranging JJ N
study NN N
of IN N
oral JJ i
, , i
human JJ i
immunoglobulin NN i
( ( i
IGOH NNP i
140 CD N
, , N
420 CD N
, , N
or CC N
840 CD N
mg/day NN N
) ) N
was VBD N
utilized VBN N
with IN N
125 CD p
children NNS p
( ( p
ages VBZ p
2-17 CD p
years NNS p
) ) p
with IN p
autism NN p
and CC p
persistent JJ p
GI NNP p
symptoms NNS p
. . p

Endpoint NNP N
analysis NN N
revealed VBD N
no DT N
significant JJ N
differences NNS N
across IN N
treatment NN N
groups NNS N
on IN N
a DT N
modified JJ N
global JJ o
improvement NN o
scale NN o
( ( N
validated VBN N
in IN N
irritable JJ o
bowel NN o
syndrome JJ o
studies NNS o
) ) o
, , o
number NN o
of IN o
daily JJ o
bowel NN o
movements NNS o
, , o
days NNS o
of IN o
constipation NN o
, , o
or CC o
severity NN o
of IN o
problem NN o
behaviors NNS o
. . o

IGOH NNP i
was VBD N
well-tolerated JJ o
; : o
there EX N
were VBD N
no DT N
serious JJ o
adverse JJ o
events NNS o
. . o

This DT N
study NN N
demonstrates VBZ N
the DT N
importance NN N
of IN N
conducting VBG N
rigorous JJ N
trials NNS N
in IN N
children NNS p
with IN p
autism NN p
and CC N
casts VBZ N
doubt NN N
on IN N
one CD N
GI NNP N
mechanism NN N
presumed VBD N
to TO N
exert VB N
etiological JJ N
and/or NN N
symptomatic JJ N
effects NNS N
in IN N
this DT N
population NN N
. . N

-DOCSTART- -20526599- O O

Alvimopan NNP i
for IN N
the DT N
management NN N
of IN N
postoperative JJ N
ileus NN N
after IN N
bowel JJ N
resection NN N
: : N
characterization NN N
of IN N
clinical JJ N
benefit NN N
by IN N
pooled JJ N
responder NN N
analysis NN N
. . N

BACKGROUND VB N
A NNP N
pooled JJ N
post NN N
hoc NN N
responder NN N
analysis NN N
was VBD N
performed VBN N
to TO N
assess VB N
the DT N
clinical JJ N
benefit NN N
of IN N
alvimopan NN i
, , N
a DT N
peripherally RB N
acting VBG N
mu-opioid JJ N
receptor NN N
( ( N
PAM-OR NNP N
) ) N
antagonist NN N
, , N
for IN N
the DT N
management NN N
of IN N
postoperative JJ N
ileus NN N
after IN N
bowel NN N
resection NN N
. . N

METHODS NNP N
Adult NNP p
patients NNS p
who WP p
underwent VBP p
laparotomy NN i
for IN p
bowel NN p
resection NN p
scheduled VBN p
for IN p
opioid-based JJ i
intravenous JJ i
patient-controlled JJ i
analgesia NN i
received VBD i
oral JJ i
alvimopan NN i
or CC i
placebo NN i
preoperatively RB p
and CC p
twice RB p
daily RB p
postoperatively RB p
until IN p
hospital JJ p
discharge NN p
or CC p
for IN p
7 CD p
postoperative JJ p
days NNS p
. . p

The DT N
proportion NN N
of IN N
responders NNS N
and CC N
numbers NNS N
needed VBN N
to TO N
treat VB N
( ( N
NNT NNP N
) ) N
were VBD N
examined VBN N
on IN N
postoperative JJ N
days NNS N
( ( N
POD NNP N
) ) N
3-8 CD N
for IN N
GI-2 JJ N
recovery NN N
( ( N
first JJ N
bowel NN N
movement NN N
, , N
toleration NN N
of IN N
solid JJ N
food NN N
) ) N
and CC N
hospital JJ N
discharge NN N
order NN N
( ( N
DCO NNP N
) ) N
written VBN N
. . N

RESULTS NNP N
Alvimopan NNP i
significantly RB N
increased VBD N
the DT N
proportion NN o
of IN o
patients NNS o
with IN o
GI-2 NNP o
recovery NN o
and CC o
DCO NNP o
written VBN o
by IN o
each DT o
POD NNP o
( ( N
P NNP N
< VBZ N
0.001 CD N
for IN N
all DT N
) ) N
. . N

More JJR N
patients NNS N
who WP N
received VBD N
alvimopan RB i
achieved VBN N
GI-2 JJ o
recovery NN o
on IN o
or CC o
before IN o
POD NNP o
5 CD o
( ( i
alvimopan NN i
, , N
80 CD N
% NN N
; : N
placebo NN i
, , N
66 CD N
% NN N
) ) N
and CC N
DCO NNP N
written VBN N
before IN N
POD NNP N
7 CD N
( ( i
alvimopan NN i
, , N
87 CD N
% NN N
; : N
placebo NN i
, , N
72 CD N
% NN N
) ) N
, , N
with IN N
corresponding JJ N
NNTs NNP N
equal JJ N
to TO N
7 CD N
. . N

CONCLUSIONS VB N
On IN N
each DT N
POD NNP N
analyzed VBD N
, , N
alvimopan VBZ N
significantly RB N
increased VBN N
the DT N
proportion NN N
of IN N
patients NNS N
who WP N
achieved VBD N
GI-2 NNP o
recovery NN o
and CC N
DCO NNP N
written VBN N
versus NN N
placebo NN N
and CC N
was VBD N
associated VBN N
with IN N
relatively RB N
low JJ N
NNTs NNP N
. . N

The DT N
results NNS N
of IN N
these DT N
analyses NNS N
provide VBP N
additional JJ N
characterization NN N
and CC N
support NN N
for IN N
the DT N
overall JJ N
clinical JJ N
benefit NN N
of IN N
alvimopan NN N
in IN N
patients NNS p
undergoing VBG p
bowel JJ p
resection NN p
. . p

-DOCSTART- -16792607- O O

Paraesthesia NN N
during IN N
the DT N
needle-through-needle JJ i
and CC N
the DT N
double JJ i
segment NN i
technique NN i
for IN N
combined JJ p
spinal JJ p
epidural JJ p
anaesthesia NN p
. . p

Paraesthesia NNP N
during IN N
regional JJ N
anaesthesia NN N
is VBZ N
an DT N
unpleasant JJ N
sensation NN N
for IN N
patients NNS N
and CC N
, , N
more RBR N
importantly RB N
, , N
in IN N
some DT N
cases NNS N
it PRP N
is VBZ N
related VBN N
to TO N
neurological JJ N
injury NN N
. . N

Relatively RB N
few JJ N
studies NNS N
have VBP N
been VBN N
conducted VBN N
on IN N
the DT N
frequency NN N
of IN N
paraesthesia NN N
during IN N
combined JJ N
spinal JJ N
epidural JJ N
anaesthesia NN N
. . N

We PRP N
compared VBN N
two CD N
combined JJ N
spinal JJ i
epidural JJ i
anaesthesia NN i
techniques NNS N
: : N
the DT i
needle-through-needle JJ i
technique NN i
and CC i
the DT i
double JJ i
segment NN i
technique NN i
in IN N
this DT N
respect NN N
. . N

We PRP N
randomly RB N
allocated VBD N
116 CD p
parturients NNS p
undergoing JJ p
elective JJ p
Caesarean JJ p
section NN p
to TO p
receive VB p
anaesthesia NN i
using VBG p
one CD p
of IN p
these DT p
techniques NNS p
. . p

Both DT N
techniques NNS N
were VBD N
performed VBN N
using VBG N
a DT N
27G CD i
pencil NN i
point NN i
needle NN i
, , i
an DT i
18G CD i
Tuohy NNP i
needle NN i
, , i
and CC i
a DT i
20G CD i
multiport NN i
epidural JJ i
catheter NN i
from IN N
the DT N
same JJ N
manufacturer NN N
. . N

The DT N
overall JJ o
frequency NN o
of IN o
paraesthesia NN o
was VBD N
higher RBR N
in IN N
the DT N
needle-through-needle JJ i
technique NN i
group NN N
( ( N
56.9 CD N
% NN N
vs. FW N
31.6 CD N
% NN N
, , N
p NN N
= NNP N
0.011 CD N
) ) N
. . N

The DT N
frequency NN o
of IN o
paraesthesia NN o
at IN N
spinal JJ N
needle JJ N
insertion NN N
was VBD N
20.7 CD N
% NN N
in IN N
the DT N
needle-through-needle JJ i
technique NN N
group NN N
and CC N
8.8 CD N
% NN N
in IN N
the DT N
double JJ i
segment NN i
technique NN N
group NN N
; : N
whereas VBZ N
the DT N
frequency NN o
of IN o
paraesthesia NN o
at IN N
epidural JJ N
catheter NN N
insertion NN N
was VBD N
46.6 CD N
% NN N
in IN N
the DT N
needle-through-needle JJ i
technique NN i
group NN N
and CC N
24.6 CD N
% NN N
in IN N
the DT N
double JJ i
segment NN i
technique NN N
group NN N
. . N

-DOCSTART- -17286730- O O

The DT N
patient JJ p
experience NN p
of IN N
community NN i
hospital NN i
-- : i
the DT i
process NN i
of IN i
care NN i
as IN N
a DT N
determinant NN N
of IN N
satisfaction NN N
. . N

AIMS NNP N
AND CC N
OBJECTIVES NNP N
We PRP N
report VBP N
findings NNS N
from IN N
a DT N
qualitative JJ N
study NN N
to TO N
identify VB N
patient JJ p
views NNS p
of IN p
community NN i
hospital NN i
care NN i
. . i

We PRP N
consider VBP N
how WRB N
far RB N
these DT N
were VBD N
in IN N
accord NN N
with IN N
the DT N
hospital NN N
staffs NNS N
' POS N
views NNS N
. . N

This DT N
constituted JJ N
part NN N
of IN N
a DT N
wider NN N
randomized VBN N
controlled VBN N
trial NN N
( ( N
RCT NNP N
) ) N
. . N

The DT N
methodological JJ N
challenges NNS N
in IN N
seeking VBG N
to TO N
identify VB N
patient JJ N
satisfaction NN o
and CC N
in IN N
linking VBG N
qualitative JJ o
findings NNS o
with IN N
trial NN N
results NNS N
are VBP N
explored JJ N
. . N

DESIGN VB N
A DT p
sample NN p
of IN p
13 CD p
patients NNS p
randomized VBN p
to TO p
the DT p
community NN p
hospital NN p
arm NN p
of IN p
the DT p
RCT NNP p
joined VBD p
the DT p
qualitative JJ i
study NN i
. . i

Official JJ N
documentation NN N
from IN N
the DT N
hospital NN N
were VBD N
accessed VBN N
and CC N
six CD N
staff NN N
interviewed VBN N
to TO N
identify VB N
assumptions NNS N
underlying VBG N
practice NN N
. . N

RESULTS NNP N
Analysis NNP N
of IN N
interviews NNS i
identified VBN N
a DT N
complex JJ N
picture NN N
concerning VBG N
expectations NNS N
These DT N
could MD N
be VB N
classified VBN N
as IN N
ideal NN N
, , N
realistic JJ N
, , N
normative JJ N
and CC N
unformed JJ N
. . N

The DT N
hospital NN N
philosophy NN N
and CC N
staff NN o
views NNS o
about IN N
service NN N
delivery NN N
were VBD N
closely RB N
in IN N
harmony NN N
, , N
they PRP N
delivered VBD N
rehabilitation NN N
in IN N
a DT N
home-based JJ N
atmosphere NN N
. . N

The DT N
formal JJ o
, , o
or CC o
'hard POS o
' '' o
, , o
process NN o
of IN o
rehabilitation NN o
was VBD N
not RB N
well RB N
understood JJ N
by IN N
patients NNS N
. . N

They PRP N
were VBD N
primarily RB N
concerned VBN N
with IN N
'soft NNP N
' POS N
or CC N
process NN N
issues NNS N
-- : N
where WRB N
and CC N
how WRB N
care NN N
was VBD N
delivered VBN N
. . N

CONCLUSIONS NNP N
We PRP N
identify VBP N
a DT N
model NN N
of IN N
community NN N
hospital NN N
care NN N
that WDT N
incorporates VBZ N
technical JJ N
aspects NNS N
of IN N
rehabilitation NN N
within IN N
a DT N
human JJ N
approach NN N
that WDT N
is VBZ N
welcomed VBN N
by IN N
patients NNS p
. . p

If IN N
patients NNS p
are VBP N
to TO N
be VB N
able JJ N
to TO N
participate VB N
in IN N
making VBG N
informed JJ N
decisions NNS N
about IN N
care NN N
, , N
the DT N
rationale NN N
for IN N
the DT N
activities NNS N
of IN N
staff NN N
need NN N
to TO N
be VB N
more JJR N
clearly RB N
explained VBN N
. . N

Recommendations NNS N
are VBP N
made VBN N
about IN N
the DT N
appropriate JJ N
scope NN N
of IN N
qualitative JJ N
findings NNS N
in IN N
the DT N
context NN N
of IN N
trials NNS N
and CC N
about RB N
techniques NNS N
to TO N
access NN N
patient JJ p
views NNS N
in IN N
areas NNS N
where WRB N
they PRP N
have VBP N
difficulty NN N
in IN N
expressing VBG N
critical JJ N
impressions NNS N
. . N

-DOCSTART- -7672876- O O

Efficacy NN N
of IN N
Contractubex NNP N
gel NN N
in IN N
the DT N
treatment NN N
of IN N
fresh JJ p
scars NNS p
after IN p
thoracic NN p
surgery NN p
in IN p
children NNS p
and CC p
adolescents NNS p
. . p

Scar NNP N
development NN N
was VBD N
investigated VBN N
in IN N
45 CD p
young JJ p
patients NNS p
who WP p
had VBD p
undergone JJ p
thoracic NN p
surgery NN p
. . p

Patients NNS N
were VBD N
randomly RB N
assigned VBN N
either RB N
to TO N
a DT N
group NN N
which WDT N
was VBD N
treated VBN i
topically RB i
with IN i
Contractubex NNP i
gel NN i
( ( i
Merz NNP i
+ NNP i
Co. NNP i
, , N
D-Frankfurt/Main NNP i
) ) i
, , i
containing VBG i
10 CD i
% NN i
onion NN i
extract NN i
, , i
50/U CD i
of IN i
sodium NN i
heparin NN i
per IN i
one CD i
g NN i
of IN i
gel NN i
and CC i
1 CD i
% NN i
allantoin NN i
, , i
or CC i
to TO i
a DT i
group NN i
receiving VBG i
no DT i
treatment NN i
. . i

The DT N
treatment NN N
began VBD N
on IN N
average JJ i
26 CD i
days NNS i
after IN i
the DT i
operation NN i
and CC i
was VBD i
continued VBN i
for IN i
one CD i
year NN i
. . i

The DT N
scars NNS N
of IN N
all DT N
treated VBN N
and CC N
untreated JJ N
patients NNS N
were VBD N
evaluated VBN N
at IN N
monthly JJ N
intervals NNS N
. . N

The DT N
appearance NN o
of IN o
the DT o
scar NN o
, , o
including VBG o
scar NN o
type NN o
and CC o
scar NN o
size NN o
as RB o
well RB o
as IN o
scar NN o
colour NN o
, , N
was VBD N
assessed VBN N
by IN N
the DT N
physician NN N
. . N

A DT N
reduction NN N
of IN N
the DT N
increase NN N
of IN N
scar NN o
width NN N
was VBD N
seen VBN N
in IN N
the DT N
Contractubex-treated JJ N
group NN N
as IN N
compared VBN N
with IN N
the DT N
untreated JJ N
group NN N
. . N

Further NNP N
, , N
physiological JJ o
scars NNS o
and CC o
skin-coloured JJ o
scars NNS o
were VBD N
more RBR N
frequent JJ N
in IN N
the DT N
treated JJ N
group NN N
than IN N
in IN N
the DT N
untreated JJ N
group NN N
. . N

Hypertrophic NNP o
or CC o
keloidal VB o
scars NNS o
were VBD N
less RBR N
frequent JJ N
in IN N
the DT N
treated JJ N
group NN N
. . N

No DT N
differences NNS N
in IN N
scar NN o
length NN o
and CC o
scar NN o
height NN o
were VBD N
seen VBN N
. . N

At IN N
the DT N
end NN N
of IN N
the DT N
observation NN N
period NN N
, , N
the DT N
clinical JJ N
course NN N
of IN N
scar NN o
development NN o
was VBD N
rated VBN N
as IN N
very RB N
good JJ N
or CC N
good JJ N
in IN N
more JJR N
than IN N
90 CD N
% NN N
of IN N
the DT N
treated JJ N
patients NNS N
, , N
good JJ N
in IN N
less JJR N
than IN N
40 CD N
% NN N
and CC N
moderate JJ N
or CC N
bad JJ N
in IN N
more JJR N
than IN N
60 CD N
% NN N
of IN N
the DT N
untreated JJ N
cases NNS N
. . N

The DT N
tolerability NN N
of IN N
the DT N
drug NN N
was VBD N
good JJ N
or CC N
very RB N
good JJ N
in IN N
all DT N
cases NNS N
. . N

In IN N
conclusion NN N
, , N
Contractubex NNP N
gel NN N
is VBZ N
useful JJ N
in IN N
scar NN p
treatment NN p
after IN p
thoracic NN p
surgery NN p
. . p

-DOCSTART- -11981150- O O

Effects NNS N
of IN N
clonidine NN i
on IN N
postoperative JJ N
nausea NN N
and CC N
vomiting NN N
in IN N
breast NN p
cancer NN p
surgery NN p
. . p

BACKGROUND NNP N
Postoperative NNP N
nausea NN N
and CC N
vomiting NN N
( ( N
PONV NNP N
) ) N
is VBZ N
still RB N
common JJ N
, , N
especially RB N
among IN N
female JJ p
patients NNS p
. . p

Our PRP$ N
hypothesis NN N
is VBZ N
that IN N
coinduction NN N
with IN N
clonidine NN i
reduces VBZ N
the DT N
incidence NN N
of IN N
PONV NNP N
in IN N
adult NN p
patients NNS p
undergoing VBG p
breast NN p
cancer NN p
surgery NN p
. . p

METHODS NNP N
Sixty-eight JJ p
women NNS p
premedicated VBN p
with IN p
midazolam NNS p
were VBD N
randomly RB N
allocated VBN N
to TO N
coinduction NN N
with IN N
intravenous JJ N
clonidine NN i
( ( N
group NN N
C NNP N
) ) N
or CC N
placebo NN i
( ( N
group NN N
P NNP N
) ) N
in IN N
this DT N
prospective JJ N
, , N
double-blind JJ N
study NN N
. . N

Anesthesia NNP N
was VBD N
standardized VBN N
( ( i
laryngeal JJ i
mask NN i
airway NN i
, , i
fentanyl NN i
, , i
propofol NN i
, , i
sevoflurane NN i
, , i
nitrous JJ i
oxide NN i
, , i
and CC i
oxygen NN i
) ) i
. . N

Hemodynamic JJ N
parameters NNS N
and CC N
the DT N
requirements NNS N
for IN N
propofol NN N
, , N
sevoflurane NN N
, , N
and CC N
the DT N
postoperative JJ N
need NN N
for IN N
ketobemidone NN N
were VBD N
noted VBN N
. . N

The DT N
primary JJ N
endpoints NNS N
studied VBN N
were VBD N
the DT N
number NN o
of IN o
PONV-free JJ o
patients NNS o
and CC o
patient JJ o
satisfaction NN o
with IN o
respect NN o
to TO o
PONV NNP o
. . o

RESULTS NNP N
Patients NNPS N
in IN N
group NN N
C NNP N
had VBD N
a DT N
significantly RB N
reduced VBN o
need NN o
for IN o
propofol NN o
( ( N
P NNP N
< NNP N
0.04 CD N
) ) N
and CC N
sevoflurane NN o
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
and CC N
a DT N
reduced VBN N
early JJ o
need NN o
for IN o
ketobemidone NN o
( ( N
P NNP N
< NNP N
0.04 CD N
) ) N
. . N

There EX N
were VBD N
significantly RB N
more RBR N
PONV-free JJ o
patients NNS o
in IN N
group NN N
C NNP N
compared VBN N
with IN N
group NN N
P NNP N
( ( N
20 CD N
and CC N
11 CD N
of IN N
30 CD N
, , N
respectively RB N
; : N
P NNP N
< NNP N
0.04 CD N
) ) N
. . N

The DT N
number NN N
needed VBN N
to TO N
treat VB N
was VBD N
3.3 CD N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
1.8 CD N
, , N
16.9 CD N
) ) N
. . N

Intraoperative JJ o
blood NN o
pressure NN o
, , o
postoperative JJ o
heart NN o
rate NN o
, , o
and CC o
postoperative JJ o
blood NN o
pressure NN o
were VBD N
all DT N
significantly RB N
lower JJR N
in IN N
group NN N
C NNP N
compared VBN N
with IN N
group NN N
P NNP N
, , N
but CC N
were VBD N
not RB N
considered VBN N
to TO N
be VB N
of IN N
clinical JJ N
importance NN N
. . N

No DT N
negative JJ N
side NN o
effects NNS o
were VBD N
recorded VBN N
. . N

CONCLUSION NNP N
Coinduction NNP N
with IN N
clonidine NN i
significantly RB N
increased VBD N
the DT N
number NN N
of IN N
PONV-free JJ o
patients NNS o
after IN p
breast NN p
cancer NN p
surgery NN p
with IN p
general JJ p
anesthesia NN p
. . p

-DOCSTART- -12096292- O O

Pain NN o
and CC o
fatigue JJ o
management NN o
: : o
results NNS N
of IN N
a DT N
nursing NN N
randomized VBN N
clinical JJ N
trial NN N
. . N

PURPOSE/OBJECTIVES NNP N
Through IN N
a DT N
randomized JJ N
clinical JJ N
trial NN N
, , N
to TO N
compare VB N
patients NNS p
undergoing VBG p
an DT p
initial JJ p
course NN p
of IN p
chemotherapy NN i
who WP p
report VBP p
pain NN o
and CC o
fatigue NN o
at IN p
baseline NN p
and CC p
who WP p
are VBP p
receiving VBG p
conventional JJ i
care NN i
alone RB i
with IN p
those DT p
receiving VBG p
conventional JJ i
care NN i
plus CC i
a DT i
nursing NN i
intervention NN i
on IN N
outcomes NNS N
reported VBN N
at IN N
20 CD N
weeks NNS N
. . N

SETTING NN N
Chemotherapy NNP p
clinics NNS p
of IN p
two CD p
comprehensive JJ p
and CC p
two CD p
community NN p
cancer NN p
centers NNS p
. . p

METHODS NNP N
Interviews NNP N
were VBD N
conducted VBN N
at IN N
baseline NN N
and CC N
10 CD N
and CC N
20 CD N
weeks NNS N
. . N

An DT N
18-week JJ N
, , N
10-contact JJ N
nursing NN i
intervention NN i
utilizing VBG i
problem-solving JJ i
approaches NNS i
to TO i
symptom VB i
management NN i
and CC i
improving VBG i
physical JJ o
functioning NN o
and CC o
emotional JJ o
health NN o
was VBD N
implemented VBN N
. . N

SAMPLE VB N
The DT N
sample NN N
consisted VBD N
of IN N
53 CD p
patients NNS p
in IN p
the DT p
experimental JJ p
arm NN p
and CC p
60 CD p
in IN p
the DT p
control NN p
arm NN p
who WP p
reported VBD p
pain NN o
and CC o
fatigue NN o
at IN p
baseline NN p
. . p

VARIABLES NNP N
Pain NNP o
and CC o
fatigue NN o
, , o
numbers NNS o
of IN o
other JJ o
symptoms NNS o
, , o
and CC o
physical JJ o
role NN o
impact NN o
and CC o
social-functioning JJ o
subscales NNS o
from IN N
the DT N
Medical NNP N
Outcomes NNP N
Study NNP N
36 CD N
Short NNP N
Form NNP N
. . N

FINDINGS NNP N
Patients NNPS N
who WP N
received VBD N
the DT N
intervention NN i
reported VBD N
a DT N
significant JJ N
reduction NN N
in IN N
the DT N
number NN o
of IN o
symptoms NNS o
experienced VBN o
and CC N
improved VBN N
physical JJ o
and CC o
social JJ o
functioning NN o
. . o

Fewer JJR N
patients NNS N
in IN N
the DT N
experimental JJ N
arm NN N
reported VBD N
both DT N
pain NN o
and CC o
fatigue NN o
at IN N
20 CD N
weeks NNS N
. . N

CONCLUSIONS NNP N
Behavioral NNP i
interventions NNS i
targeted VBD N
to TO N
patients NNS N
with IN N
pain NN o
and CC o
fatigue NN o
can MD N
reduce VB N
symptom JJ o
burden NN o
, , N
improve VB N
the DT N
quality NN o
of IN o
the DT o
daily JJ o
life NN o
of IN N
patients NNS N
, , N
and CC N
demonstrate VB N
the DT N
value-added JJ N
role NN N
of IN N
nursing VBG i
care NN i
for IN N
patients NNS N
undergoing JJ N
chemotherapy NN N
. . N

IMPLICATIONS NNP N
FOR IN N
NURSING NNP N
These DT N
data NNS N
support VBD N
the DT N
value-added JJ N
role NN N
of IN N
nursing NN i
interventions NNS i
for IN N
symptom JJ N
management NN N
and CC N
improved JJ o
quality NN o
of IN o
life NN o
during IN N
the DT N
course NN N
of IN N
cancer NN N
treatment NN N
. . N

-DOCSTART- -3385217- O O

Actions NNS N
of IN N
platelet NN i
activating VBG i
factor NN i
( ( i
PAF NNP i
) ) i
homologues NNS i
and CC N
their PRP$ N
combinations NNS N
on IN N
neutrophil JJ p
chemokinesis NN p
and CC p
cutaneous JJ p
inflammatory NN p
responses NNS p
in IN p
man NN p
. . p

The DT N
inflammatory JJ N
actions NNS N
of IN N
synthetic JJ i
C16:0 NNP i
and CC i
C18:0 NNP i
platelet NN i
activating VBG i
factor NN i
( ( i
PAF NNP i
) ) i
homologues NNS i
, , N
both DT N
alone RB N
and CC N
in IN N
combination NN N
, , N
have VBP N
been VBN N
compared VBN N
in IN N
an DT N
in IN p
vitro JJ p
human JJ p
neutrophil JJ p
chemokinesis NN p
assay NN p
and CC p
by IN p
intradermal JJ p
injection NN p
in IN p
human JJ p
skin NN p
. . p

In IN N
the DT N
chemokinesis NN N
assay NN N
, , N
the DT N
maximum JJ o
distance NN o
moved VBN o
by IN o
neutrophils NNS o
in IN N
the DT N
presence NN N
of IN N
C18:0 NNP i
PAF NNP i
was VBD N
significantly RB N
greater JJR N
than IN N
that DT N
seen VBN N
with IN N
the DT N
C16:0 NNP i
compound NN i
. . i

A DT N
mixture NN N
of IN N
C16:0 NNP i
and CC N
C18:0 NNP i
PAFs NNP i
in IN N
a DT N
ratio NN N
of IN N
1:9 CD N
appeared VBD N
to TO N
be VB N
more RBR N
active JJ N
than IN N
in IN N
a DT N
ratio NN N
of IN N
3:1 CD N
. . N

Intradermal JJ N
injection NN N
of IN N
the DT N
C16:0 NNP i
and CC i
C18:0 NNP i
PAF NNP i
homologues NNS i
induced VBD N
dose-dependent JJ N
increases NNS N
in IN N
weal JJ o
volume NN o
and CC o
flare JJ o
area NN o
responses NNS o
which WDT N
were VBD N
not RB N
significantly RB N
different JJ N
. . N

Combination NN N
of IN N
these DT N
phospholipids NNS N
in IN N
a DT N
ratio NN N
of IN N
3:1 CD N
or CC N
1:9 CD N
of IN N
C16:0 NN N
: : N
C18:0 NN N
did VBD N
not RB N
significantly RB N
alter VB N
the DT N
dose JJ N
response NN N
curves NNS N
. . N

Thus RB N
, , N
changes NNS N
in IN N
the DT N
chain NN N
length NN N
of IN N
the DT N
alkyl JJ N
substituent NN N
of IN N
synthetic JJ N
PAF NNP i
homologues NNS i
and CC N
combination NN N
of IN N
these DT N
homologues NNS N
, , N
in IN N
ratios NNS N
found VBN N
in IN N
vivo NN N
or CC N
formed VBN N
by IN N
leukocytes NNS p
in IN p
vitro NN p
, , N
did VBD N
not RB N
alter VB N
the DT N
cutaneous JJ p
inflammatory NN o
responses NNS o
to TO o
PAF NNP o
in IN p
man NN p
. . p

The DT N
C18:0 NNP i
homologue NN i
was VBD N
, , N
however RB N
, , N
more RBR N
active JJ N
as IN N
a DT N
human JJ N
neutrophil NN N
chemoattractant NN N
in IN N
vitro NN N
. . N

-DOCSTART- -24317552- O O

Activation NN N
and CC N
intermuscular JJ N
coherence NN N
of IN N
distal JJ N
arm NN N
muscles NNS N
during IN N
proximal JJ N
muscle NN N
contraction NN N
. . N

In IN N
the DT N
human JJ N
upper JJ N
extremity NN N
( ( N
UE NNP N
) ) N
, , N
unintended JJ N
effects NNS N
of IN N
proximal JJ N
muscle NN N
activation NN N
on IN N
muscles NNS N
controlling VBG N
the DT N
hand NN N
could MD N
be VB N
an DT N
important JJ N
aspect NN N
of IN N
motor NN N
control NN N
due JJ N
to TO N
the DT N
necessary JJ N
coordination NN N
of IN N
distal NN N
and CC N
proximal JJ N
segments NNS N
during IN N
functional JJ N
activities NNS N
. . N

This DT N
study NN N
aimed VBD N
to TO N
elucidate VB N
the DT N
effects NNS N
of IN N
concurrent JJ N
activation NN N
of IN N
elbow NN N
muscles NNS N
on IN N
the DT N
coordination NN N
between IN N
hand NN N
muscles NNS N
performing VBG N
a DT N
grip NN N
task NN N
. . N

Eleven NNP p
healthy JJ p
subjects NNS p
performed VBN N
precision NN i
grip NN i
tasks NNS i
while IN i
a DT i
constant JJ i
extension NN i
or CC i
flexion NN i
moment NN i
was VBD i
applied VBN i
to TO i
their PRP$ i
elbow NN i
joints NNS i
, , N
inducing VBG N
a DT N
sustained VBN N
submaximal JJ N
contraction NN N
of IN N
elbow NN N
muscles NNS N
to TO N
counter VB N
the DT N
applied JJ N
torque NN N
. . N

Activation NNP N
of IN N
four CD N
hand NN N
muscles NNS N
was VBD N
measured VBN N
during IN N
each DT N
task NN N
condition NN N
using VBG N
surface NN i
electromyography NN i
( ( i
EMG NNP i
) ) i
. . i

When WRB N
concurrent JJ N
activation NN N
of IN N
elbow NN N
muscles NNS N
was VBD N
induced VBN N
, , N
significant JJ N
changes NNS N
in IN N
the DT N
activation NN o
levels NNS o
of IN o
the DT o
hand NN o
muscles NNS o
were VBD N
observed VBN N
, , N
with IN N
greater JJR N
effects NNS N
on IN N
the DT N
extrinsic JJ N
finger NN N
extensor NN N
( ( N
23.2 CD N
% NN N
increase NN N
under IN N
30 CD N
% NN N
elbow NN N
extensor NN N
activation NN N
; : N
p CC N
= VB N
0.003 CD N
) ) N
than IN N
extrinsic JJ N
finger NN N
flexor NN N
( ( N
14.2 CD N
% NN N
increase NN N
under IN N
30 CD N
% NN N
elbow NN N
flexor JJ N
activation NN N
; : N
p CC N
= VB N
0.130 CD N
) ) N
. . N

Elbow NNP o
muscle NN o
activation NN o
also RB N
induced VBD N
involuntary JJ N
changes NNS N
in IN N
the DT N
intrinsic JJ o
thumb NN o
flexor NN o
activation NN o
( ( N
44.6 CD N
% NN N
increase NN N
under IN N
30 CD N
% NN N
elbow NN N
extensor NN N
activation NN N
; : N
p CC N
= VB N
0.005 CD N
) ) N
. . N

EMG-EMG JJ N
coherence NN N
analyses NNS N
revealed VBD N
that IN N
elbow JJ o
muscle NN o
activation NN o
significantly RB N
reduced VBD N
intermuscular JJ o
coherence NN o
between IN o
distal JJ o
muscle NN o
pairs NNS o
, , N
with IN N
its PRP$ N
greatest JJS N
effects NNS N
on IN N
coherence NN N
in IN N
the DT N
?-band NN N
( ( N
13-25 JJ N
Hz NNP N
) ) N
( ( N
average NN N
of IN N
17 CD N
% NN N
decrease NN N
under IN N
30 CD N
% NN N
elbow NN N
flexor JJ N
activation NN N
) ) N
. . N

The DT N
results NNS N
of IN N
this DT N
study NN N
provide VBP N
evidence NN N
for IN N
involuntary JJ N
, , N
muscle-specific JJ N
interactions NNS N
between IN N
distal NN N
and CC N
proximal JJ N
UE NNP N
muscles NNS N
, , N
which WDT N
may MD N
contribute VB N
to TO N
UE NNP N
motor NN N
performance NN N
in IN N
health NN N
and CC N
disease NN N
. . N

-DOCSTART- -9834207- O O

Marginal JJ N
benefit/disadvantage NN o
of IN N
granulocyte JJ i
colony-stimulating JJ i
factor NN i
therapy NN i
after IN p
autologous JJ p
blood NN p
stem NN p
cell NN p
transplantation NN p
in IN p
children NNS p
: : p
results NNS N
of IN N
a DT N
prospective JJ N
randomized VBN N
trial NN N
. . N

The DT N
Japanese JJ p
Cooperative NNP p
Study NNP p
Group NNP p
of IN p
PBSCT NNP p
. . p

In IN N
this DT N
prospective JJ N
trial NN N
, , N
a DT N
total NN N
of IN N
74 CD p
children NNS p
who WP p
were VBD p
scheduled VBN p
to TO p
undergo VB p
high-dose JJ i
chemotherapy NN i
followed VBN p
by IN p
autologous JJ i
peripheral JJ i
blood NN i
stem NN i
cell NN i
transplantation NN i
( ( p
PBSCT NNP p
) ) p
were VBD N
prospectively RB N
randomized VBN N
at IN N
diagnosis NN N
to TO N
evaluate VB N
the DT N
effectiveness NN o
of IN N
exogenous JJ N
granulocyte JJ i
colony-stimulating JJ i
factor NN i
( ( N
G-CSF NNP N
) ) N
treatment NN N
in IN N
accelerating VBG N
hematopoietic JJ o
recovery NN o
after IN N
PBSCT NNP N
. . N

The DT p
diagnosis NN p
included VBD p
acute JJ p
lymphoblastic JJ p
leukemia NN p
( ( p
ALL DT p
) ) p
( ( p
n JJ p
= NNP p
27 CD p
) ) p
, , p
neuroblastoma FW p
( ( p
n JJ p
= NNP p
29 CD p
) ) p
, , p
and CC p
miscellaneous JJ p
solid JJ p
tumors NNS p
( ( p
n JJ p
= NNP p
18 CD p
) ) p
. . p

Eligibility NNP p
criteria NNS p
included VBD p
( ( p
1 CD p
) ) p
primary NN i
PBSCT NNP i
, , p
( ( p
2 CD p
) ) p
chemotherapy-responsive JJ p
disease NN p
, , p
and CC p
( ( p
3 CD p
) ) p
collected VBN p
cell NN p
number NN p
> $ p
1 CD p
x $ p
10 CD p
( ( p
5 CD p
) ) p
colony-forming NN p
unit-granulocyte-macrophage JJ p
( ( p
CFU-GM NNP p
) ) p
/kg NN p
and CC p
> $ p
1 CD p
x $ p
10 CD p
( ( p
6 CD p
) ) p
CD34 NNP p
( ( p
+ NNP p
) ) p
cells/kg VBP p
patient NN p
's POS p
body NN p
weight NN p
. . p

After IN N
applying VBG N
the DT N
above NN N
criteria NN N
, , N
11 CD p
patients NNS p
were VBD p
excluded VBN p
due JJ p
to TO p
disease VB p
progression NN p
before IN p
PBSCT NNP i
( ( p
n JJ p
= NNP p
6 CD p
) ) p
or CC p
a DT p
low JJ p
number NN p
of IN p
harvested JJ p
cells NNS p
( ( p
n JJ p
= NNP p
5 CD p
) ) p
, , p
leaving VBG p
63 CD p
patients NNS p
for IN p
analysis NN p
; : p
32 CD p
patients NNS p
in IN N
the DT N
treatment NN N
group NN N
( ( N
300 CD N
microg/m2 NN N
of IN N
G-CSF NNP i
intravenously RB N
over IN N
1 CD N
hour NN N
from IN N
day NN N
1 CD N
of IN N
PBSCT NNP i
) ) i
and CC N
31 CD N
in IN N
the DT N
control NN i
group NN i
without IN N
treatment NN N
. . N

Two CD N
distinct JJ N
disease-oriented JJ N
high-dose JJ i
regimens NNS i
without IN i
total JJ i
body NN i
irradiation NN i
consisted VBD i
of IN i
the DT i
MCVAC NNP i
regimen NNS i
using VBG i
ranimustine NN i
( ( i
MCNU NNP i
, , i
450 CD i
mg/m2 NN i
) ) i
, , i
cytosine JJ i
arabinoside NN i
( ( i
16 CD i
g/m2 NN i
) ) i
, , i
etoposide RB i
( ( i
1.6 CD i
g/m2 NN i
) ) i
, , i
and CC i
cyclophosphamide NN i
( ( N
100 CD N
mg/kg NN N
) ) N
for IN N
patients NNS N
with IN N
ALL NNP N
, , N
and CC N
the DT N
Hi-MEC NNP i
regimen NNS i
using VBG i
melphalan NN i
( ( N
180 CD N
mg/m2 NN N
) ) N
, , N
etoposide RB i
( ( N
1.6 CD N
g/m2 NN N
) ) N
, , N
and CC N
carboplatinum NN i
( ( N
1.6 CD N
g/m2 NN N
) ) N
for IN N
those DT N
with IN N
solid JJ N
tumors NNS N
. . N

Five CD p
patients NNS p
( ( p
two CD p
in IN p
the DT p
treatment NN p
group NN p
and CC p
three CD p
in IN p
the DT p
control NN p
group NN p
) ) p
were VBD p
subsequently RB p
removed VBN p
due JJ p
to TO p
protocol VB p
violations NNS p
. . p

All DT N
patients NNS N
survived VBD o
PBSCT NNP p
. . p

The DT N
median JJ o
numbers NNS o
of IN o
transfused JJ o
mononuclear JJ o
cells NNS o
( ( o
MNC NNP o
) ) o
, , o
CD34 NNP o
( ( o
+ NNP o
) ) o
cells NNS o
, , o
and CC o
CFU-GM NNP o
were VBD N
, , N
respectively RB N
, , N
4.5 CD N
( ( N
range NN N
, , N
1 CD N
to TO N
19 CD N
) ) N
x NN N
10 CD N
( ( N
8 CD N
) ) N
/kg NN N
, , N
8.0 CD N
( ( N
1.1 CD N
to TO N
25 CD N
) ) N
x NN N
10 CD N
( ( N
6 CD N
) ) N
/kg NN N
, , N
and CC N
3.7 CD N
( ( N
1.2 CD N
to TO N
23 CD N
) ) N
x NN N
10 CD N
( ( N
5 CD N
) ) N
/kg NN N
in IN N
the DT N
treatment NN N
group NN N
( ( N
n JJ N
= NNP N
30 CD N
) ) N
and CC N
2.9 CD N
( ( N
0.8 CD N
to TO N
21 CD N
) ) N
x NN N
10 CD N
( ( N
8 CD N
) ) N
/kg NN N
, , N
6.3 CD N
( ( N
1.1 CD N
to TO N
34 CD N
) ) N
x NN N
10 CD N
( ( N
6 CD N
) ) N
/kg NN N
, , N
and CC N
5.5 CD N
( ( N
1.3 CD N
to TO N
37 CD N
) ) N
x NN N
10 CD N
( ( N
5 CD N
) ) N
/kg NN N
, , N
respectively RB N
, , N
in IN N
the DT N
control NN N
group NN N
( ( N
n JJ N
= NNP N
28 CD N
) ) N
, , N
with IN N
no DT N
significant JJ N
difference NN N
. . N

After IN N
PBSCT NNP N
, , N
the DT N
time NN o
to TO o
achieve VB o
an DT o
absolute JJ o
neutrophil NN o
count NN o
( ( o
ANC NNP o
) ) o
of IN o
> $ o
0.5 CD o
x $ o
10 CD o
( ( o
9 CD o
) ) o
/L NN o
in IN N
the DT N
treatment NN N
group NN N
was VBD N
less JJR N
than IN N
that DT N
in IN N
the DT N
control NN N
group NN N
( ( N
median JJ N
, , N
11 CD N
v NN N
12 CD N
days NNS N
; : N
the DT N
log-rank JJ N
test NN N
, , N
P NNP N
=.046 NNP N
) ) N
, , N
although IN N
the DT N
last JJ N
day NN N
of IN N
red JJ N
blood NN N
cell NN N
( ( N
RBC NNP N
) ) N
transfusion NN N
( ( N
day NN N
11 CD N
v NN N
day NN N
10 CD N
) ) N
and CC N
the DT N
duration NN o
of IN o
febrile JJ o
days NNS o
( ( N
> JJ N
38 CD N
degrees NNS N
C NNP N
) ) N
after IN N
PBSCT NNP N
( ( N
4 CD N
v RB N
4 CD N
days NNS N
) ) N
were VBD N
identical JJ N
in IN N
both DT N
groups NNS N
. . N

However RB N
, , N
platelet JJ o
recovery NN o
to TO o
> VB o
20 CD o
x JJ o
10 CD o
( ( o
9 CD o
) ) o
/L NN o
was VBD N
significantly RB N
longer RBR N
in IN N
treatment NN N
group NN N
than IN N
control NN N
group NN N
( ( N
26 CD N
v RB N
16 CD N
days NNS N
; : N
P NNP N
=.009 NNP N
) ) N
and CC N
> $ N
50 CD N
x $ N
10 CD N
( ( N
9 CD N
) ) N
/L NN N
tended VBD N
to TO N
take VB N
longer JJR N
in IN N
the DT N
treatment NN N
group NN N
( ( N
29 CD N
v RB N
26 CD N
days NNS N
; : N
P NNP N
=.126 NNP N
) ) N
, , N
with IN N
significantly RB N
more JJR N
platelet JJ o
transfusion-dependent JJ o
days NNS o
( ( N
27 CD N
v RB N
13 CD N
days NNS N
; : N
t-test JJ N
, , N
P NNP N
=.037 NNP N
) ) N
. . N

When WRB N
patients NNS N
were VBD N
divided VBN N
into IN N
two CD N
different JJ N
disease NN N
cohorts NNS N
, , N
ALL DT N
patients NNS N
showed VBD N
no DT N
difference NN N
in IN N
engraftment JJ o
kinetics NNS o
between IN N
the DT N
G-CSF NNP N
treatment NN N
and CC N
control NN N
groups NNS N
, , N
while IN N
differences NNS N
were VBD N
seen VBN N
in IN N
those DT N
with IN N
solid JJ N
tumors NNS N
. . N

We PRP N
concluded VBD N
that IN N
the DT N
marginal JJ N
clinical JJ N
benefit NN N
of IN N
1 CD N
day NN N
earlier RBR N
recovery NN o
of IN o
granulocytes NNS o
could MD N
be VB N
offset VBN N
by IN N
the DT N
delayed JJ N
recovery NN o
of IN o
platelets NNS o
. . o

We PRP N
recommend VBP N
that IN N
the DT N
routine JJ N
application NN N
of IN N
costly JJ N
G-CSF NNP p
therapy NN p
in IN p
children NNS p
undergoing VBG p
PBSCT NNP p
should MD N
be VB N
seriously RB N
reconsidered VBN N
. . N

-DOCSTART- -22892323- O O

Long-term JJ N
effects NNS N
of IN N
ezetimibe-plus-statin JJ i
therapy NN i
on IN N
low-density NN o
lipoprotein NN o
cholesterol NN o
levels NNS o
as IN N
compared VBN N
with IN N
double-dose JJ i
statin NN i
therapy NN i
in IN N
patients NNS p
with IN p
coronary JJ p
artery NN p
disease NN p
. . p

OBJECTIVE UH N
To TO N
assess VB N
the DT N
mechanism NN N
of IN N
long-term JJ N
LDL-C-lowering JJ N
effect NN N
of IN N
ezetimibe-plus-statin NN i
. . i

METHODS NNP N
Coronary NNP p
artery NN p
disease NN p
patients NNS p
whose WP$ p
LDL-C NNP p
? . p
70 CD p
mg/dL NN p
after IN p
treatment NN p
with IN i
atorvastatin JJ i
10 CD i
mg/day NN i
or CC i
rosuvastatin VB i
2.5 CD i
mg/day NN i
were VBD i
randomly RB N
assigned VBN N
to TO N
receive VB i
ezetimibe NN i
10 CD i
mg/day NN i
+ NNP i
statin NN i
( ( i
n JJ N
= NNP N
78 CD N
) ) N
or CC N
double-dose JJ i
statin NN i
( ( i
n JJ N
= NNP N
72 CD N
) ) N
for IN N
52 CD N
weeks NNS N
. . N

RESULTS NNP N
Greater NNP o
LDL-C NNP o
reduction NN o
was VBD o
observed VBN N
and CC N
maintained VBN N
until IN N
52 CD N
weeks NNS N
in IN N
ezetimibe-plus-statin JJ i
, , i
while IN o
LDL-C JJ o
levels NNS o
re-increased VBN o
after IN N
12 CD N
weeks NNS N
in IN N
double-dose JJ N
statin NN N
. . N

Although IN o
lathosterol/TC NN o
increased VBD o
, , o
campesterol/TC NN o
decreased VBD o
more RBR N
in IN N
ezetimibe-plus-statin NN i
. . i

In IN N
contrast NN o
, , o
lathosterol/TC CC o
unchanged JJ o
and CC o
campesterol/TC NN o
increased VBD o
, , N
increasing VBG o
campesterol/lathosterol NN o
ratio NN o
for IN o
52 CD N
weeks NNS N
in IN N
double-dose JJ i
statin NN o
. . o

Plasma NNP o
PCSK9 NNP o
levels NNS o
were VBD o
higher JJR N
in IN N
double-dose JJ i
statin NN i
than IN i
in IN N
ezetimibe-plus-statin NN i
at IN i
12 CD N
weeks NNS N
, , N
but CC N
similar JJ N
at IN N
52 CD N
weeks NNS N
. . N

CONCLUSION NNP N
Although IN N
the DT N
difference NN N
in IN N
PCSK9 NNP N
between IN N
2 CD N
groups NNS N
was VBD N
transient JJ N
, , N
that IN N
in IN N
both DT N
campesterol NN N
and CC N
lathosterol NN N
persisted VBN N
until IN N
52 CD N
weeks NNS N
. . N

These DT N
results NNS N
demonstrated VBD N
simultaneous JJ N
inhibition NN N
of IN N
cholesterol NN N
absorption NN N
and CC N
synthesis NN N
provides VBZ N
stable JJ N
and CC N
greater JJR N
decrease NN N
in IN N
LDL-C NNP o
levels NNS o
. . o

-DOCSTART- -22080631- O O

Cognitive JJ o
and CC o
physical JJ o
rehabilitation NN o
of IN N
intensive JJ p
care NN p
unit NN p
survivors NNS p
: : p
results NNS N
of IN N
the DT N
RETURN NNP N
randomized VBD N
controlled VBN N
pilot NN N
investigation NN N
. . N

BACKGROUND NNP N
Millions NNP N
of IN N
patients NNS p
who WP p
survive VBP p
medical JJ p
and CC p
surgical JJ p
general JJ p
intensive JJ p
care NN p
unit NN p
care NN p
every DT N
year NN N
experience NN N
newly RB N
acquired VBN N
long-term JJ N
cognitive JJ N
impairment NN N
and CC N
profound JJ N
physical JJ N
and CC N
functional JJ N
disabilities NNS N
. . N

To TO N
overcome VB N
the DT N
current JJ N
reality NN N
in IN N
which WDT N
patients NNS N
receive VBP N
inadequate JJ N
rehabilitation NN N
, , N
we PRP N
devised VBD N
a DT N
multifaceted VBN N
, , N
in-home JJ N
, , N
telerehabilitation JJ N
program NN N
implemented VBN N
using VBG N
social JJ N
workers NNS N
and CC N
psychology NN N
technicians NNS N
with IN N
the DT N
goal NN N
of IN N
improving VBG N
cognitive JJ N
and CC N
functional JJ N
outcomes NNS N
. . N

METHODS NNP N
This DT N
was VBD N
a DT N
single-site JJ N
, , N
feasibility NN N
, , N
pilot NN N
, , N
randomized VBN N
trial NN N
of IN N
21 CD p
general JJ p
medical/surgical JJ p
intensive JJ p
care NN p
unit NN p
survivors NNS p
( ( p
8 CD p
controls NNS p
and CC p
13 CD p
intervention NN p
patients NNS p
) ) p
with IN p
either DT p
cognitive NN p
or CC p
functional JJ p
impairment NN p
at IN p
hospital JJ p
discharge NN p
. . p

After IN N
discharge NN N
, , N
study NN N
controls NNS N
received VBD N
usual JJ i
care NN i
( ( i
sporadic JJ i
rehabilitation NN i
) ) i
, , N
whereas JJ N
intervention NN N
patients NNS N
received VBD N
a DT N
combination NN N
of IN N
in-home JJ i
cognitive NN i
, , i
physical JJ i
, , i
and CC i
functional JJ i
rehabilitation NN i
over IN N
a DT N
3-month JJ N
period NN N
via IN N
a DT N
social JJ N
worker NN N
or CC N
master NN N
's POS N
level NN N
psychology NN N
technician JJ N
utilizing JJ N
telemedicine NN N
to TO N
allow VB N
specialized JJ N
multidisciplinary JJ N
treatment NN N
. . N

Interventions NNS N
over IN N
12 CD N
wks NNS N
included VBD N
six CD N
in-person JJ N
visits NNS N
for IN N
cognitive JJ i
rehabilitation NN i
and CC N
six CD N
televisits NNS N
for IN N
physical/functional JJ i
rehabilitation NN i
. . i

Outcomes CC N
were VBD N
measured VBN N
at IN N
the DT N
completion NN N
of IN N
the DT N
rehabilitation NN N
program NN N
( ( N
i.e. FW N
, , N
at IN N
3 CD N
months NNS N
) ) N
, , N
with IN N
cognitive JJ o
functioning NN o
as IN N
the DT N
primary JJ N
outcome NN N
. . N

Analyses NNS N
were VBD N
conducted VBN N
using VBG N
linear JJ N
regression NN N
to TO N
examine VB N
differences NNS N
in IN N
3-month JJ N
outcomes NNS N
between IN N
treatment NN N
groups NNS N
while IN N
adjusting VBG N
for IN N
baseline NN N
scores NNS N
. . N

RESULTS NNP N
Patients NNPS p
tolerated VBD o
the DT p
program NN p
with IN p
only RB p
one CD p
adverse JJ p
event NN p
reported VBD p
. . p

At IN N
baseline JJ N
both DT N
groups NNS N
were VBD N
well-matched JJ N
. . N

At IN N
3-month JJ N
follow-up NN N
, , N
intervention NN N
group NN N
patients NNS N
demonstrated VBD N
significantly RB N
improved VBN o
cognitive JJ o
executive NN o
functioning NN o
on IN N
the DT N
widely RB N
used VBN N
and CC N
well-normed JJ N
Tower NNP N
test NN N
( ( N
for IN N
planning NN o
and CC o
strategic JJ o
thinking NN o
) ) o
vs. NN N
controls NNS N
( ( N
median JJ N
[ NN N
interquartile NN N
range NN N
] NNP N
, , N
13.0 CD N
[ JJ N
11.5-14.0 JJ N
] NNP N
vs. FW N
7.5 CD N
[ JJ N
4.0-8.5 JJ N
] NN N
; : N
adjusted VBN N
p NN N
< NNP N
.01 NNP N
) ) N
. . N

Intervention NNP N
group NN N
patients NNS N
also RB N
reported VBD N
better JJR N
performance NN o
( ( N
i.e. FW N
, , N
lower JJR N
score NN N
) ) N
on IN N
one CD N
of IN N
the DT N
most RBS N
frequently RB N
used JJ N
measures NNS N
of IN N
functional JJ N
status NN N
( ( o
Functional NNP o
Activities NNP o
Questionnaire NNP o
at IN N
3 CD N
months NNS N
vs. FW N
controls NNS N
, , N
1.0 CD N
[ NN N
0.0 CD N
-3.0 NN N
] NNP N
vs. IN N
8.0 CD N
[ JJ N
6.0-11.8 JJ N
] NN N
, , N
adjusted VBN N
p NN N
= NNP N
.04 NNP N
) ) N
. . N

CONCLUSIONS VB N
A DT N
multicomponent JJ N
rehabilitation NN i
program NN N
for IN N
intensive JJ p
care NN p
unit NN p
survivors NNS p
combining VBG N
cognitive JJ N
, , N
physical JJ N
, , N
and CC N
functional JJ N
training NN N
appears VBZ N
feasible JJ o
and CC o
possibly RB o
effective JJ o
in IN o
improving VBG o
cognitive JJ o
performance NN o
and CC o
functional JJ o
outcomes NNS o
in IN N
just RB N
3 CD N
months NNS N
. . N

Future JJ N
investigations NNS N
with IN N
a DT N
larger JJR N
sample JJ N
size NN N
should MD N
be VB N
conducted VBN N
to TO N
build VB N
on IN N
this DT N
pilot JJ N
feasibility NN N
program NN N
and CC N
to TO N
confirm VB N
these DT N
results NNS N
, , N
as RB N
well RB N
as IN N
to TO N
elucidate VB N
the DT N
elements NNS N
of IN N
rehabilitation NN N
contributing VBG N
most JJS N
to TO N
improved VBN N
outcomes NNS N
. . N

-DOCSTART- -22825926- O O

A DT N
parent-mediated JJ i
intervention NN i
to TO N
increase VB N
responsive JJ o
parental JJ o
behaviors NNS o
and CC o
child JJ o
communication NN o
in IN N
children NNS p
with IN p
ASD NNP p
: : p
a DT N
randomized JJ N
clinical JJ N
trial NN N
. . N

Longitudinal NNP N
research NN N
has VBZ N
demonstrated VBN N
that IN N
responsive JJ o
parental JJ o
behaviors NNS o
reliably RB N
predict VBP N
subsequent JJ N
language NN o
gains NNS o
in IN N
children NNS p
with IN p
autism NN p
spectrum NN p
disorder NN p
. . p

To TO N
investigate VB N
the DT N
underlying JJ N
causal NN N
mechanisms NNS N
, , N
we PRP N
conducted VBD N
a DT N
randomized JJ N
clinical JJ N
trial NN N
of IN N
an DT N
experimental JJ i
intervention NN i
( ( i
Focused JJ i
Playtime NNP i
Intervention NNP i
, , i
FPI NNP i
) ) i
that WDT N
aims VBZ N
to TO N
enhance VB N
responsive JJ o
parental JJ o
communication NN o
( ( p
N NNP p
= NNP p
70 CD p
) ) p
. . N

Results $ N
showed VBD N
a DT N
significant JJ N
treatment NN N
effect NN N
of IN N
FPI NNP i
on IN N
responsive JJ o
parental JJ o
behaviors NNS o
. . o

Findings NNS N
also RB N
revealed VBD N
a DT N
conditional JJ N
effect NN N
of IN N
FPI NNP i
on IN N
children NNS o
's POS o
expressive JJ o
language NN o
outcomes NNS o
at IN N
12-month JJ N
follow VBP N
up RP N
, , N
suggesting VBG N
that IN N
children NNS N
with IN N
baseline NN N
language NN N
skills NNS N
below IN N
12 CD N
months NNS N
( ( N
n JJ N
= NNP N
24 CD N
) ) N
are VBP N
most RBS N
likely JJ N
to TO N
benefit VB N
from IN N
FPI NNP i
. . i

Parents NNS p
of IN p
children NNS p
with IN p
more RBR p
advanced JJ p
language NN o
skills NNS o
may MD N
require VB N
intervention NN N
strategies NNS N
that WDT N
go VBP N
beyond IN N
FPI NNP N
's POS N
focus NN N
on IN N
responsive JJ o
communication NN o
. . o

-DOCSTART- -9296510- O O

Comparison NNP N
of IN N
hand-sewn NN i
and CC N
stapled VBD i
esophagogastric JJ i
anastomosis NN i
after IN N
esophageal JJ N
resection NN N
for IN N
cancer NN N
: : N
a DT N
prospective JJ N
randomized NN N
controlled VBD N
trial NN N
. . N

OBJECTIVE CC N
The DT N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
hand-sewn JJ i
and CC N
stapled JJ i
methods NNS N
in IN N
esophagogastric JJ i
anastomosis NN i
. . i

SUMMARY NNP N
BACKGROUND NNP N
DATA NNP N
After IN N
esophageal JJ N
resection NN N
for IN N
cancer NN N
, , N
the DT N
relative JJ N
merits NNS N
of IN N
the DT N
hand-sewn NN N
and CC N
the DT N
stapled JJ N
methods NNS N
of IN N
esophagogastric JJ N
anastomosis NN N
, , N
especially RB N
regarding VBG N
leakage NN o
and CC o
stricture NN o
rates NNS o
, , N
have VBP N
not RB N
adequately RB N
been VBN N
studied VBN N
. . N

METHODS VB N
A DT N
prospective JJ N
randomized NN N
controlled VBD N
trial NN N
was VBD N
undertaken VBN N
in IN N
122 CD p
patients NNS p
with IN p
squamous JJ p
cell NN p
cancer NN p
of IN p
the DT p
thoracic NN p
esophagus NN p
who WP p
underwent VBD p
a DT p
Lewis-Tanner JJ i
esophagectomy NN i
. . i

Patients NNS p
were VBD p
stratified VBN N
according VBG p
to TO p
esophageal VB p
size NN p
, , p
based VBN p
on IN p
the DT p
diameter NN p
of IN p
the DT p
divided VBN p
esophagus NN p
( ( N
< CD N
or CC N
> VB N
or CC N
= VB N
30 CD N
mm NN N
) ) N
and CC N
then RB N
were VBD N
randomized VBN N
to TO N
have VB N
either CC N
a DT N
hand-sewn NN i
or CC i
a DT i
stapled JJ i
anastomosis NN i
. . i

RESULTS VB N
The DT N
mean JJ o
total NN o
operating VBG o
times NNS o
( ( N
standard JJ N
error NN N
of IN N
the DT N
mean NN N
) ) N
when WRB N
the DT N
hand-sewn NN N
and CC N
the DT N
stapled JJ N
methods NNS N
were VBD N
used VBN N
were VBD N
214 CD N
( ( N
4 CD N
) ) N
minutes NNS N
and CC N
217 CD N
( ( N
3.4 CD N
) ) N
minutes NNS N
, , N
respectively RB N
( ( N
p JJ N
= NNP N
not RB N
significant JJ N
[ NNP N
NS NNP N
] NNP N
) ) N
. . N

The DT N
respective NN N
in IN N
vivo NN o
proximal JJ o
resection NN o
margins NNS o
( ( N
standard JJ N
error NN N
of IN N
the DT N
mean NN N
) ) N
were VBD N
8 CD N
( ( N
0.4 CD N
) ) N
cm NN N
and CC N
7.6 CD N
( ( N
0.4 CD N
) ) N
cm NN N
( ( N
p JJ N
= NNP N
NS NNP N
) ) N
. . N

Leakage VB o
rates NNS o
were VBD N
1.6 CD N
% NN N
and CC N
4.9 CD N
% NN N
( ( N
p JJ N
= NNP N
NS NNP N
) ) N
. . N

Excluding VBG N
hospital JJ o
deaths NNS o
, , N
patients NNS N
with IN N
leakage NN o
or CC o
anastomotic JJ o
recurrence NN o
, , N
and CC N
those DT N
who WP N
received VBD N
radiation NN N
therapy NN N
to TO N
histologically RB N
infiltrated JJ N
resection NN N
margin NN N
, , N
anastomotic JJ o
stricture NN o
was VBD N
found VBN N
in IN N
5 CD N
( ( N
9.1 CD N
% NN N
) ) N
of IN N
55 CD N
patients NNS N
in IN N
the DT N
hand-sewn JJ N
group NN N
and CC N
20 CD N
( ( N
40 CD N
% NN N
) ) N
of IN N
50 CD N
in IN N
the DT N
stapler NN N
group NN N
( ( N
p JJ N
= NNP N
0.0003 CD N
) ) N
. . N

The DT N
difference NN o
in IN o
stricture NN o
rates NNS o
was VBD N
significant JJ N
in IN N
small JJ N
as RB N
well RB N
as IN N
large JJ N
esophagi NN N
. . N

Anastomotic JJ o
recurrence NN o
developed VBD N
in IN N
only RB N
one CD N
patient NN N
in IN N
each DT N
group NN N
. . N

CONCLUSIONS VB N
The DT N
authors NNS N
conclude VBP N
that IN N
both DT N
methods NNS N
were VBD N
safe JJ o
, , N
but CC N
the DT N
stapled JJ N
technique NN N
resulted VBD N
in IN N
more RBR N
stricture JJ o
formation NN o
. . o

-DOCSTART- -23838275- O O

Contrast NNP N
, , N
motion NN N
, , N
perceptual JJ N
integration NN N
, , N
and CC N
neurocognition NN N
in IN N
schizophrenia NN N
: : N
the DT N
role NN N
of IN N
fragile-X JJ N
related JJ N
mechanisms NN N
. . N

Recent JJ N
studies NNS N
demonstrated VBD N
a DT N
reduced JJ N
expression NN N
of IN N
Fragile NNP N
X NNP N
Mental NNP N
Retardation NNP N
Protein NNP N
( ( N
FMRP NNP N
) ) N
, , N
an DT N
RNA NNP N
binding NN N
protein NN N
and CC N
translation NN N
regulator NN N
, , N
in IN N
the DT N
brain NN N
and CC N
peripheral JJ N
lymphocytes NNS N
of IN N
patients NNS p
with IN p
schizophrenia NN p
. . p

Low JJ N
FMRP NNP N
levels NNS N
may MD N
be VB N
related VBN N
to TO N
impaired JJ N
neurodevelopmental JJ N
processes NNS N
and CC N
synaptic JJ N
plasticity NN N
. . N

Here RB N
, , N
we PRP N
studied VBD N
the DT N
relationship NN N
between IN N
peripheral JJ N
FMRP NNP N
level NN N
, , N
visual JJ o
perception NN o
( ( o
contrast JJ o
sensitivity NN o
, , o
perceptual JJ o
integration NN o
, , o
motion/form VB o
perception NN o
) ) o
, , o
and CC o
neuropsychological JJ o
functions NNS o
in IN N
schizophrenia NN N
as IN N
measured VBN i
with IN i
the DT i
Repeatable JJ i
Battery NN i
for IN i
the DT i
Assessment NNP i
of IN i
Neuropsychological NNP i
Status NNP i
( ( i
RBANS NNP i
) ) i
. . N

Results NNP N
revealed VBD N
that IN N
patients NNS p
with IN p
schizophrenia JJ p
displayed NNS p
lower JJR p
FMRP NNP o
levels NNS o
in IN p
peripheral JJ p
lymphocytes NNS p
as IN N
compared VBN N
to TO N
control VB p
individuals NNS p
. . p

We PRP N
found VBD N
significant JJ N
correlations NNS N
between IN N
FMRP NNP o
levels NNS o
and CC N
contrast NN N
sensitivity NN N
at IN N
low JJ N
spatial NN N
and CC N
high JJ N
temporal JJ N
frequencies NNS N
, , N
perceptual JJ N
integration NN N
, , N
and CC N
motion NN N
perception NN N
. . N

The DT N
relationship NN N
between IN N
FMRP NNP o
level NN o
and CC o
neuropsychological JJ o
functions NNS o
was VBD N
less RBR N
pronounced JJ N
than IN N
that DT N
seen VBN N
in IN N
the DT N
case NN N
of IN N
visual JJ N
perception NN N
, , N
with IN N
the DT N
greatest JJS N
effect NN N
for IN N
RBANS NNP N
attention NN N
. . N

FMRP NNP o
level NN o
was VBD N
not RB N
related VBN N
to TO N
contrast VB N
sensitivity NN N
at IN N
high JJ N
spatial JJ N
and CC N
low JJ N
temporal JJ N
frequencies NNS N
and CC N
form JJ N
perception NN N
. . N

This DT N
pattern NN N
of IN N
data NNS N
is VBZ N
reminiscent JJ N
to TO N
that DT N
observed VBN N
in IN N
patients NNS p
with IN N
Fragile NNP N
X NNP N
Syndrome NNP N
( ( N
FXS NNP N
) ) N
. . N

These DT N
results NNS N
suggest VBP N
that IN N
FMRP NNP N
may MD N
be VB N
implicated VBN N
in IN N
the DT N
pathogenesis NN N
of IN N
schizophrenia NN N
, , N
possibly RB N
via IN N
the DT N
regulation NN N
of IN N
neurodevelopment NN o
, , o
plasticity NN o
, , o
GABA-ergic NNP o
, , o
and CC o
glutamatergic JJ o
neurotransmission NN o
. . o

-DOCSTART- -22728026- O O

Phase NNP N
II NNP N
trial NN N
of IN N
nab-paclitaxel JJ N
compared VBN N
with IN N
docetaxel NN i
as IN N
first-line JJ N
chemotherapy NN N
in IN N
patients NNS p
with IN p
metastatic JJ p
breast NN p
cancer NN p
: : p
final JJ N
analysis NN N
of IN N
overall JJ N
survival NN N
. . N

BACKGROUND VB N
A DT N
randomized JJ N
phase NN N
II NNP N
study NN N
in IN N
first-line JJ N
MBC NNP N
demonstrated VBD N
superior JJ N
efficacy NN o
and CC N
safety NN o
of IN N
weekly JJ N
nab-paclitaxel NNS N
compared VBN N
with IN N
docetaxel NN i
. . i

Final NNP N
survival NN o
analyses NNS o
and CC N
updated JJ N
safety NN o
results NNS N
are VBP N
reported VBN N
. . N

PATIENTS NNS N
AND CC N
METHODS NNP N
Three NNP p
hundred VBD p
two CD p
patients NNS p
with IN p
no DT p
previous JJ p
chemotherapy NN p
for IN p
MBC NNP p
were VBD N
randomized VBN i
to TO i
receive VB i
nab-paclitaxel JJ i
300 CD i
mg/m NN i
( ( i
2 CD i
) ) i
q3w NN i
, , i
nab-paclitaxel JJ i
100 CD i
mg/m NN i
( ( i
2 CD i
) ) i
or CC i
150 CD i
mg/m NN i
( ( i
2 CD i
) ) i
the DT i
first JJ i
3 CD i
of IN i
4 CD i
weeks NNS i
( ( i
qw VB i
3/4 CD i
) ) i
, , i
or CC i
docetaxel VB i
100 CD i
mg/m NN i
( ( i
2 CD i
) ) i
q3w NN i
. . i

The DT N
trial NN N
was VBD N
powered VBN N
for IN N
analyses NNS N
of IN N
antitumor NN o
activity NN o
and CC N
safety NN o
. . o

RESULTS NNP N
Treatment NNP N
with IN N
nab-paclitaxel JJ N
150 CD N
mg/m NN N
( ( N
2 CD N
) ) N
qw NN N
3/4 CD N
resulted VBD N
in IN N
a DT N
median JJ N
overall JJ N
survival NN o
( ( N
OS NNP N
) ) N
of IN N
33.8 CD N
months NNS N
compared VBN N
with IN N
22.2 CD N
, , N
27.7 CD N
, , N
and CC N
26.6 CD N
months NNS N
for IN N
nab-paclitaxel JJ N
100 CD N
mg/m NN N
( ( N
2 CD N
) ) N
qw NN N
3/4 CD N
, , N
nab-paclitaxel JJ N
300 CD N
mg/m NN N
( ( N
2 CD N
) ) N
q3w NN N
, , N
and CC N
docetaxel NN i
, , N
respectively RB N
( ( N
overall JJ N
P NNP N
= NNP N
.047 NNP N
) ) N
. . N

Patients NNPS N
receiving VBG N
150 CD N
mg/m NN N
( ( N
2 CD N
) ) N
nab-paclitaxel NN N
had VBD N
prolonged VBN N
median JJ o
OS NNP o
compared VBN N
with IN N
those DT N
in IN N
the DT N
100 CD N
mg/m NN N
( ( N
2 CD N
) ) N
nab-paclitaxel JJ N
arm NN N
( ( N
hazard JJ N
ratio NN N
, , N
0.575 CD N
; : N
P NNP N
= NNP N
.008 NNP N
) ) N
. . N

A DT N
trend NN N
toward IN N
a DT N
longer JJR N
OS NNP o
was VBD N
noted VBN N
in IN N
the DT N
150 CD N
mg/m NN N
( ( N
2 CD N
) ) N
nab-paclitaxel JJ N
arm NN N
versus NN N
docetaxel NN i
arm NN N
( ( N
hazard JJ N
ratio NN N
, , N
0.688 CD N
) ) N
. . N

Grade $ o
3 CD o
or CC o
4 CD o
fatigue NN o
, , o
neutropenia NN o
, , o
and CC o
febrile JJ o
neutropenia NN o
were VBD N
less JJR N
frequent JJ N
in IN N
all DT N
nab-paclitaxel JJ N
arms NNS N
compared VBN N
with IN N
docetaxel NN i
. . i

CONCLUSIONS NNP N
Consistent NNP N
with IN N
previously RB N
published VBN N
efficacy NN N
results NNS N
, , N
these DT N
data NNS N
suggest VBP N
that IN N
150 CD N
mg/m NN N
( ( N
2 CD N
) ) N
qw NN N
3/4 CD N
may MD N
represent VB N
the DT N
most RBS N
clinically RB N
efficacious JJ N
nab-paclitaxel JJ N
dosing VBG N
regimen NNS N
for IN N
patients NNS p
with IN p
no DT p
previous JJ p
chemotherapy NN p
for IN p
MBC NNP p
. . p

A DT N
phase NN N
III NNP N
trial NN N
confirming VBG N
these DT N
results NNS N
would MD N
be VB N
necessary JJ N
and CC N
prudent JJ N
before RB N
widespread JJ N
adoption NN N
of IN N
the DT N
150 CD N
mg/m NN N
( ( N
2 CD N
) ) N
dose NN N
in IN N
clinical JJ N
practice NN N
. . N

-DOCSTART- -7820060- O O

Interferon NNP i
treatment NN i
for IN N
hairy NN o
cell NN o
leukemia NN o
. . o

An DT N
update NN N
on IN N
a DT N
cohort NN p
of IN p
69 CD p
patients NNS p
treated VBN p
from IN p
1983 CD p
to TO p
1986 CD p
. . p

We PRP N
report VBP N
follow-up JJ N
information NN N
on IN N
69 CD p
hairy NN o
cell NN o
leukemia NN o
( ( o
HCL NNP o
) ) o
patients NNS p
treated VBN p
with IN p
interferon JJ i
alfa-2b NN i
( ( i
IFN NNP i
) ) i
as IN p
primary JJ p
treatment NN p
from IN p
1983 CD p
to TO p
1986 CD p
. . p

Follow-up NNP N
through IN N
April NNP N
, , N
1993 CD N
shows VBZ N
that IN N
only RB N
14 CD N
patients NNS N
have VBP N
expired VBN N
. . N

Forty-seven CD N
of IN N
the DT N
61 CD N
patients NNS N
completing VBG N
the DT N
intended JJ N
12 CD N
or CC N
more JJR N
months NNS N
of IN N
initial JJ N
IFN NNP i
treatment NN N
were VBD N
eventually RB N
considered VBN N
IFN NNP i
failures NNS N
. . N

Forty-three CD N
required JJ N
re-treatment NN N
( ( N
41 CD N
received VBD N
a DT N
second JJ N
course NN N
of IN N
IFN NNP i
and CC N
2 CD N
received VBD N
pentostatin NN i
) ) i
. . N

Four CD N
patients NNS N
died VBD N
without IN N
further JJ N
therapy NN N
for IN N
HCL NNP o
. . o

The DT N
median JJ N
time NN N
to TO N
interferon VB i
failure NN N
was VBD N
31.3 CD N
months NNS N
. . N

Fourteen JJ N
patients NNS N
are VBP N
alive JJ N
and CC N
have VBP N
not RB N
required VBN N
further RBR N
treatment NN N
after IN N
completing VBG N
their PRP$ N
initial JJ N
12 CD N
or CC N
more JJR N
months NNS N
of IN N
interferon NN i
. . i

Fifteen JJ N
patients NNS N
underwent VBD N
a DT N
third JJ N
course NN N
of IN N
interferon NN i
therapy NN N
at IN N
a DT N
median JJ N
time NN N
after IN N
completion NN N
of IN N
a DT N
second JJ N
course NN N
of IN N
IFN NNP i
of IN N
1.0 CD N
year NN N
. . N

Eighteen JJ N
patients NNS N
were VBD N
eventually RB N
treated VBN N
with IN N
pentostatin NN i
and CC N
ten VB N
with IN N
2-chlorodeoxyadenosine JJ i
( ( i
2-CdA JJ i
) ) i
. . i

Thirteen JJ N
patients NNS N
developed VBD N
a DT N
second JJ o
malignancy NN o
; : o
six CD N
of IN N
these DT N
patients NNS N
developed VBD N
a DT N
hematologic JJ o
malignancy NN o
between IN N
44.6 CD N
months NNS N
and CC N
99.1 CD N
months NNS N
after IN N
initiation NN N
of IN N
interferon NN i
therapy NN N
. . N

We PRP N
conclude VBP N
that IN N
although IN N
interferon NN i
provides VBZ N
excellent JJ o
palliation NN o
, , N
that IN N
most JJS N
patients NNS N
will MD N
eventually RB N
require VB N
further JJ N
treatment NN N
with IN N
interferon NN o
or CC N
chemotherapy NN o
. . o

Future JJ N
trials NNS N
in IN N
HCL NNP N
must MD N
be VB N
aware JJ N
of IN N
the DT N
risk NN N
of IN N
second JJ o
malignancies NNS o
. . o

-DOCSTART- -7148967- O O

A DT N
comparison NN N
of IN N
dorsal NN i
and CC i
volar JJ i
resting NN i
hand NN i
splints NNS i
in IN N
the DT N
reduction NN N
of IN N
hypertonus NN p
. . p

Ten CD p
adults NNS p
with IN p
hypertonic JJ p
wrist NN p
flexors NNS p
volunteered VBD p
as IN p
subjects NNS p
in IN N
an DT N
experiment NN N
comparing VBG N
the DT N
effectiveness NN N
of IN N
dorsal NN i
and CC i
volar JJ i
resting NN i
hand NN i
splints NNS i
in IN N
the DT N
reduction NN N
of IN N
abnormal JJ o
muscle NN o
tone NN o
. . o

Subjects NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
two CD N
groups NNS N
of IN N
five CD N
each DT N
. . N

Individuals NNS N
in IN N
one CD N
group NN N
were VBD N
fitted VBN N
with IN N
dorsal NN i
splints NNS i
, , N
and CC N
individuals NNS N
in IN N
a DT N
second JJ N
group NN N
with IN N
volar JJ i
splints NNS i
. . i

Measurements NNS N
by IN N
spring-weighted JJ N
scales NNS N
were VBD N
taken VBN N
to TO N
assess VB N
the DT N
efficiency NN N
of IN N
each DT N
splint NN N
design NN N
in IN N
the DT N
reduction NN N
of IN N
hypertonus NN o
. . o

Results NNP N
demonstrated VBD N
no DT o
significant JJ o
differences NNS o
between IN N
the DT N
volar NN i
and CC i
dorsal NN i
splints NNS i
in IN N
reducing VBG N
hypertonus NN o
. . o

However RB N
, , N
the DT N
age NN N
of IN N
the DT N
subjects NNS N
was VBD N
found VBN N
to TO N
be VB N
an DT N
intervening VBG N
variable NN N
: : N
The DT N
older JJR p
subjects NNS p
of IN N
both DT N
groups NNS N
demonstrated VBD N
a DT N
gradual JJ N
but CC N
not RB N
significant JJ N
decline NN N
in IN N
hypertonus NN N
, , N
whereas IN N
the DT N
younger JJR p
adults NNS p
demonstrated VBD N
a DT N
significant JJ N
decline NN N
in IN N
hypertonus NN N
over IN N
a DT N
6-week JJ N
period NN N
. . N

-DOCSTART- -1857873- O O

Influence NN N
of IN N
infusion NN p
time NN p
on IN N
the DT N
acute JJ o
toxicity NN o
of IN o
amphotericin NN o
B NNP o
: : o
results NNS N
of IN N
a DT N
randomized JJ N
double-blind NN N
study NN N
. . N

-DOCSTART- -22488107- O O

A DT N
potent JJ N
oral JJ N
P-selectin NNP i
blocking NN i
agent NN i
improves VBZ N
microcirculatory JJ o
blood NN o
flow NN o
and CC N
a DT N
marker NN o
of IN o
endothelial JJ o
cell NN o
injury NN o
in IN N
patients NNS p
with IN p
sickle JJ p
cell NN p
disease NN p
. . p

Abnormal JJ o
blood NN o
flow NN o
accounts NNS N
for IN N
most JJS N
of IN N
the DT N
clinical JJ N
morbidity NN N
of IN N
sickle NN N
cell NN N
disease NN N
( ( N
SCD NNP N
) ) N
[ VBD N
1,2 CD N
] NNP N
. . N

Most JJS N
notably RB N
, , N
occlusion NN N
of IN N
flow NN N
in IN N
the DT N
microvasculature NN N
causes VBZ N
the DT N
acute NN N
pain NN N
crises NNS N
[ VBP N
3 CD N
] NN N
that WDT N
are VBP N
the DT N
commonest NN N
cause NN N
for IN N
patients NNS p
with IN p
SCD NNP p
to TO p
seek VB N
medical JJ N
attention NN N
[ VBD N
4 CD N
] NN N
and CC N
major JJ N
determinants NNS N
of IN N
their PRP$ N
quality NN p
of IN p
life NN p
[ $ N
5 CD N
] NNP N
. . N

Based VBN N
on IN N
evidence NN N
that IN N
endothelial JJ N
P-selectin NNP N
is VBZ N
central JJ N
to TO N
the DT N
abnormal JJ o
blood NN o
flow NN o
in IN o
SCD NNP o
we PRP N
provide VBP N
results NNS N
from IN N
four CD N
of IN N
our PRP$ N
studies NNS N
that WDT N
are VBP N
germane VBN N
to TO N
microvascular VB N
blood NN N
flow NN N
in IN N
SCD NNP N
. . N

A DT N
proof-of-principle JJ N
study NN N
established VBD N
that IN N
doses NNS N
of IN N
heparin NN i
lower JJR N
than IN N
what WP N
are VBP N
used VBN N
for IN N
anticoagulation NN N
but CC N
sufficient JJ N
to TO N
block VB N
P-selectin NNP N
improved JJ N
microvascular JJ o
blood NN o
flow NN o
inpatients NNS p
with IN p
SCD NNP p
. . p

An DT N
in IN N
vitro NN N
study NN N
showed VBD N
that IN N
Pentosan NNP i
Polysulfate NNP i
Sodium NNP i
( ( i
PPS NNP i
) ) i
had VBD N
greater JJR N
P-selectin JJ N
blocking NN N
activity NN N
than IN N
heparin NN N
. . N

A DT N
Phase NN N
I PRP N
clinical VBP N
study NN N
demonstrated VBD N
that IN N
a DT N
single JJ N
oral JJ N
dose NN N
of IN N
PPS NNP i
increased VBD N
microvascular JJ o
blood NN o
flow NN o
in IN N
patients NNS N
with IN N
SCD NNP N
. . N

A NNP N
Phase NNP N
II NNP N
clinical JJ N
study NN N
that WDT N
was VBD N
not RB N
completed VBN N
documented VBD N
that IN N
daily JJ N
oral JJ N
doses NNS N
of IN N
PPS NNP i
administered VBD N
for IN N
8 CD N
weeks NNS N
lowered VBD N
plasma JJ o
levels NNS o
of IN o
sVCAM-1 NN o
and CC N
tended VBD N
to TO N
improve VB N
microvascular JJ o
blood NN o
flow NN o
in IN N
patients NNS N
with IN N
SCD NNP N
. . N

These DT N
data NNS N
support NN N
the DT N
concept NN N
that IN N
P-selectin NNP N
on IN N
the DT N
microvascular JJ N
endothelium NN N
is VBZ N
critical JJ N
to TO N
both DT N
acute JJ o
vascular NN o
occlusion NN o
and CC o
chronically RB o
impaired JJ o
microvascular JJ o
blood NN o
flow NN o
in IN o
SCD NNP o
. . o

They PRP N
also RB N
demonstrate VBP N
that IN N
oral JJ N
PPS NNP N
is VBZ N
beneficial JJ N
to TO N
microvascular VB N
sickle NN N
cell NN N
blood NN o
flow NN o
and CC N
has VBZ N
potential JJ N
as IN N
an DT N
efficacious JJ N
agent NN N
for IN N
long-term JJ N
prophylactic JJ N
therapy NN N
of IN N
SCD NNP N
. . N

-DOCSTART- -16647616- O O

A DT N
comparison NN N
of IN N
home NN i
measurement NN i
and CC N
ambulatory JJ i
monitoring NN i
of IN N
blood NN N
pressure NN N
in IN N
the DT N
adjustment NN N
of IN N
antihypertensive JJ p
treatment NN p
. . p

BACKGROUND IN N
The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
home NN N
and CC N
ambulatory JJ N
blood NN N
pressure NN N
( ( N
BP NNP N
) ) N
in IN N
the DT N
adjustment NN N
of IN N
antihypertensive JJ N
treatment NN N
. . N

METHODS NNP N
After IN N
a DT N
4-week JJ N
washout NN N
period NN N
, , N
patients NNS p
whose WP$ p
untreated JJ p
daytime JJ p
diastolic JJ p
ambulatory NN p
BP NNP p
averaged VBD p
> NNP p
or CC p
= $ p
85 CD p
mm NN p
Hg NNP p
were VBD N
randomized VBN N
to TO N
be VB N
treated VBN N
according VBG N
to TO N
their PRP$ N
ambulatory NN i
or CC i
home NN i
BP NNP i
. . i

Antihypertensive NNP i
treatment NN i
was VBD i
adjusted VBN i
at IN N
6-week JJ N
intervals NNS N
according VBG N
to TO N
the DT N
mean JJ N
daytime JJ o
ambulatory NN o
diastolic JJ o
BP NNP o
or CC N
the DT N
mean JJ N
home NN o
diastolic NN o
BP NNP o
, , N
depending VBG N
on IN N
the DT N
patient NN N
's POS N
randomization NN N
group NN N
. . N

If IN N
the DT N
diastolic JJ N
BP NNP N
stayed VBD N
above IN N
80 CD N
mm NN N
Hg NNP N
, , N
the DT N
physician NN N
blinded VBD N
to TO N
randomization VB N
intensified JJ i
hypertensive JJ i
treatment NN i
. . i

RESULTS NNP N
Ninety-eight JJ p
patients NNS p
completed VBD p
the DT p
study NN p
. . p

During IN N
the DT N
24-week JJ N
follow-up JJ N
period NN N
both DT N
systolic JJ o
and CC o
diastolic JJ o
BP NNP o
decreased VBD N
significantly RB N
within IN N
both DT N
groups NNS N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

At IN N
the DT N
end NN N
of IN N
the DT N
study NN N
, , N
the DT N
systolic/diastolic JJ o
differences NNS o
between IN o
ambulatory NN o
( ( N
n JJ N
= NNP N
46 CD N
) ) N
and CC N
home NN N
( ( N
n JJ N
= NNP N
52 CD N
) ) N
BP NNP o
groups NNS N
in IN N
home NN o
, , o
daytime JJ o
ambulatory NN o
, , o
night-time JJ o
ambulatory NN o
, , o
and CC o
24-h JJ o
ambulatory NN o
BP NNP o
changes NNS o
averaged VBD N
2.6/2.6 CD N
mm NN N
Hg NNP N
, , N
0.6/1.7 CD N
mm NN N
Hg NNP N
, , N
1.0/1.4 CD N
mm NN N
Hg NNP N
, , N
and CC N
0.6/1.5 CD N
mm NN N
Hg NNP N
, , N
respectively RB N
( ( N
P NNP N
range VBP N
.06 NNP N
to TO N
.75 VB N
) ) N
A DT N
nonsignificant JJ N
trend NN N
to TO N
more RBR N
intensive JJ N
drug NN N
therapy NN N
in IN N
the DT N
ambulatory JJ o
BP NNP o
group NN N
and CC N
a DT N
nonsignificant JJ N
trend NN N
to TO N
larger JJR N
share NN N
of IN N
patients NNS N
reaching VBG N
( ( N
57.7 CD N
% NN N
v JJ N
43.5 CD N
% NN N
, , N
P NNP N
= NNP N
.16 NNP N
) ) N
the DT N
target NN N
pressure NN N
in IN N
the DT N
home NN N
BP NNP N
group NN N
was VBD N
observed VBN N
due JJ N
to TO N
the DT N
3.8 CD N
mm NN N
Hg NNP N
difference NN N
in IN N
ambulatory NN o
and CC o
home NN o
diastolic NN o
BP NNP o
at IN N
randomization NN N
. . N

CONCLUSIONS VB N
The DT N
adjustment NN N
of IN N
antihypertensive JJ i
treatment NN i
based VBN N
on IN N
either DT N
ambulatory NN i
or CC i
home NN i
BP NNP i
measurement NN i
led VBD N
to TO N
good JJ N
BP NNP N
control NN N
. . N

No DT N
significant JJ N
between-group JJ N
differences NNS N
in IN N
BP NNP o
changes NNS N
were VBD N
seen VBN N
at IN N
the DT N
end NN N
of IN N
the DT N
study NN N
. . N

Additional NNP N
research NN N
is VBZ N
needed VBN N
to TO N
provide VB N
more JJR N
conclusive JJ N
results NNS N
. . N

-DOCSTART- -17175376- O O

No DT N
association NN o
between IN o
dinucleotide JJ o
repeat NN o
polymorphism NN o
in IN o
intron NN o
1 CD o
of IN o
the DT o
epidermal JJ o
growth NN o
factor NN o
receptor NN o
gene NN o
EGFR NNP o
and CC o
risk NN o
of IN o
lung NN o
cancer NN o
. . o

The DT N
tyrosine JJ N
kinase NN N
receptor NN N
EGFR NNP N
pathway NN N
is VBZ N
one CD N
of IN N
the DT N
oncogenic JJ N
signaling NN N
cascades NNS N
involved VBN N
in IN N
lung NN N
cancer NN N
, , N
mediating VBG N
the DT N
epidermal JJ N
growth NN N
factor NN N
receptor NN N
gene NN N
EGFR NNP N
. . N

First-intron NNP i
polymorphisms NN i
with IN N
greater JJR N
numbers NNS N
of IN N
CA NNP N
dinucleotide NN N
repeats NNS N
tend VBP N
to TO N
downregulate VB N
EGFR NNP N
expression NN N
, , N
which WDT N
suggests VBZ N
that IN N
this DT N
polymorphism NN i
may MD N
modulate VB N
susceptibility NN p
to TO p
lung NN p
cancer NN p
. . p

The DT N
present JJ N
hospital-based JJ i
case-control NN i
study NN i
evaluated VBD i
the DT i
possible JJ i
association NN o
of IN o
CA NNP o
repeat NN o
polymorphism NN o
in IN o
the DT o
EGFR NNP o
gene NN o
with IN o
risk NN o
of IN o
lung NN o
cancer NN o
in IN p
a DT p
Korean JJ p
population NN p
. . p

A DT N
bimodal JJ N
pattern NN N
appeared VBD N
, , N
with IN N
a DT N
frequency NN N
of IN N
57.1 CD N
% NN N
for IN N
20 CD N
CA NNP N
repeats NNS N
and CC N
18.6 CD N
% NN N
for IN N
16 CD N
CA NNP N
repeats NNS N
. . N

There EX N
was VBD N
, , N
however RB N
, , N
no DT N
significant JJ N
difference NN N
in IN N
distribution NN o
of IN o
allele JJ o
genotypes NNS o
between IN o
all DT o
lung NN o
cancer NN o
cases NNS o
and CC o
the DT o
controls NNS o
, , N
nor CC N
among IN N
histological JJ N
types NNS N
for IN N
the DT N
cases NNS N
. . N

-DOCSTART- -20513659- O O

Magnocellular JJ i
visual JJ i
evoked VBN N
potential JJ N
delay NN N
with IN N
high JJ p
autism NN p
spectrum JJ p
quotient NN p
yields NNS N
a DT N
neural JJ N
mechanism NN N
for IN N
altered JJ o
perception NN o
. . o

Everyone NN N
has VBZ N
autistic JJ N
characteristics NNS N
to TO N
a DT N
greater JJR N
or CC N
lesser JJR N
degree NN N
, , N
encapsulated VBN N
in IN N
the DT N
Autism NNP o
Spectrum NNP o
Quotient NNP o
, , N
a DT N
scale NN N
that WDT N
measures VBZ N
the DT N
degree NN N
to TO N
which WDT N
an DT N
adult NN p
of IN p
normal JJ p
intelligence NN p
displays NNS N
traits NNS N
associated VBN N
with IN N
autism NN N
spectrum NN N
disorders NNS N
. . N

Recent JJ N
psychophysical JJ N
analyses NNS N
of IN N
autism NN N
spectrum NN N
disorders NNS N
point VBP N
to TO N
superior VB N
local JJ N
processing NN N
, , N
and CC N
impaired VBD N
or CC N
ignored VBN N
global JJ N
and CC N
contextual JJ N
processing NN N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
test VB N
whether IN N
low- JJ i
and CC p
high-scoring JJ i
individuals NNS i
on IN i
the DT i
Autism NNP i
Spectrum NNP i
Quotient NNP i
differ NN N
on IN N
a DT N
measure NN N
of IN N
local JJ o
and CC o
global JJ o
processing NN o
, , i
motion NN i
processing NN i
and CC i
visual JJ i
pathway NN i
integrity NN i
. . i

Fifteen NNP p
low-scoring JJ p
individuals NNS p
and CC p
14 CD p
high-scoring JJ p
individuals NNS p
derived VBN p
from IN p
a DT p
normal JJ p
population NN p
participated VBD p
in IN p
the DT p
study NN p
. . p

The DT N
results NNS N
indicate VBP N
that IN N
the DT N
initial JJ N
cortical JJ o
response NN o
to TO N
the DT N
magnocellular JJ N
afferents NNS N
is VBZ N
weaker JJR N
at IN N
low JJ N
contrast NN N
in IN N
the DT N
high JJ N
autistic JJ N
tendency NN N
group NN N
and CC N
that IN N
a DT N
second-order JJ N
response NN N
, , N
reflecting VBG N
magnocellular JJ N
activity NN N
, , N
demonstrated VBD N
a DT o
delay NN o
for IN N
high JJ N
versus NN N
low JJ N
scorers NNS N
when WRB N
the DT N
parvocellular JJ N
pathway NN N
was VBD N
also RB N
active JJ N
in IN N
response NN N
to TO N
a DT N
high JJ N
contrast NN N
stimulus NN N
. . N

High-scoring JJ N
individuals NNS N
also RB N
demonstrated VBD N
difficulty NN N
in IN N
identifying VBG o
the DT o
global JJ o
components NNS o
of IN N
locally RB N
salient JJ N
hierarchical JJ N
Navon NNP N
figures NNS N
. . N

Furthermore RB N
, , N
cross-validated JJ N
discriminant NN N
analysis NN N
, , N
using VBG N
four CD N
physiologically RB N
and CC N
three CD N
psychophysically RB N
derived JJ N
parameters NNS N
, , N
correctly RB N
classified VBD N
83 CD N
% NN N
of IN N
individuals NNS N
who WP N
scored VBD N
either CC N
high JJ N
or CC N
low JJ N
on IN N
the DT N
Autism NNP N
Spectrum NNP N
Quotient NNP N
. . N

These DT N
findings NNS N
in IN N
the DT N
group NN N
scoring VBG N
high JJ N
on IN N
the DT N
Autism NNP p
Spectrum NNP p
Quotient NNP p
indicate VBP N
that IN N
a DT N
delay NN N
in IN N
primary JJ N
visual/prestriate JJ N
cortical JJ N
processing NN N
of IN N
magnocellular JJ N
input NN N
diminishes VBZ N
the DT N
advantage NN N
of IN N
its PRP$ N
early JJ N
arrival NN N
to TO N
primary JJ N
visual JJ N
cortex NN N
. . N

This DT N
appears VBZ N
to TO N
be VB N
associated VBN N
with IN N
impaired JJ o
global JJ o
visual JJ o
perception NN o
, , N
predicting VBG N
with IN N
high JJ N
accuracy NN N
behavioural JJ o
tendencies NNS o
associated VBN N
with IN N
autism NN N
spectrum NN N
disorders NNS N
. . N

It PRP N
has VBZ N
been VBN N
proposed VBN N
that IN N
perceptual JJ N
impairment NN N
in IN N
autism NN N
may MD N
be VB N
attributed VBN N
to TO N
a DT N
dysfunction NN N
of IN N
horizontal JJ N
connections NNS N
within IN N
early JJ N
visual JJ N
areas NNS N
, , N
presumably RB N
parvocellular JJ N
in IN N
nature NN N
. . N

However RB N
, , N
the DT N
timing NN N
of IN N
such JJ N
form NN N
processing NN N
aberrations NNS N
is VBZ N
much RB N
later RBR N
than IN N
the DT N
timing NN N
of IN N
abnormal JJ N
magnocellular JJ N
visual JJ N
processing NN N
measured VBN N
directly RB N
here RB N
. . N

Thus VB N
it PRP N
is VBZ N
proposed VBN N
that IN N
a DT N
magnocellular JJ N
processing NN N
delay NN N
decreases VBZ N
the DT N
ability NN N
of IN N
autistic JJ p
individuals NNS p
to TO N
benefit VB N
perceptually RB N
from IN N
feedback NN N
normally RB N
associated VBN N
with IN N
the DT N
magnocellular JJ N
advantage NN N
. . N

-DOCSTART- -26529471- O O

Reducing VBG N
Sitting VBG N
Time NNP N
After IN N
Stroke NNP N
: : N
A DT N
Phase NNP N
II NNP N
Safety NNP N
and CC N
Feasibility NNP N
Randomized NNP N
Controlled NNP N
Trial NNP N
. . N

OBJECTIVE NNP N
To TO N
test VB N
the DT N
safety NN N
, , N
feasibility NN N
, , N
and CC N
effectiveness NN N
of IN N
reducing VBG i
sitting VBG i
time NN i
in IN i
stroke NN i
survivors NNS i
. . i

DESIGN NNP N
Randomized NNP N
controlled VBD N
trial NN N
with IN N
attention-matched JJ N
controls NNS N
and CC N
blinded VBD N
assessments NNS N
. . N

SETTING NNP N
Community NNP N
. . N

PARTICIPANTS NNP N
Stroke NNP p
survivors NNS p
( ( p
N=35 NNP p
; : p
22 CD p
men NNS p
; : p
mean JJ p
age NN p
, , p
66.9?12.7y CD p
) ) p
. . p

INTERVENTIONS NNP i
Four CD i
counseling NN i
sessions NNS i
over IN N
7 CD N
weeks NNS N
with IN N
a DT N
message NN N
of IN i
sit NN i
less CC i
and CC i
move VB i
more JJR i
( ( i
intervention NN i
group NN i
) ) i
or CC i
calcium NN i
for IN i
bone NN i
health NN i
( ( N
attention-matched JJ N
control NN N
group NN N
) ) N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Measures NNP N
included VBD o
safety NN o
( ( o
adverse JJ o
events NNS o
, , o
increases NNS o
in IN o
pain NN o
, , o
spasticity NN o
, , o
or CC o
fatigue NN o
) ) o
and CC o
feasibility NN o
( ( o
adherence NN o
to TO o
trial NN o
protocol NN o
) ) o
. . o

Secondary JJ N
measures NNS N
included VBD o
time NN o
spent VBN o
sitting VBG o
( ( o
including VBG o
in IN o
prolonged JJ o
bouts NNS o
?30min NN o
) ) o
, , o
standing VBG o
, , o
and CC o
stepping VBG o
as IN o
measured VBN o
by IN o
the DT o
thigh-worn JJ o
inclinometer NN o
( ( o
7d CD o
, , N
24h/d CD N
protocol NN N
) ) N
and CC N
time NN o
spent VBN o
in IN o
physical JJ o
activity NN o
of IN o
at IN N
least JJS N
moderate JJ N
intensity NN N
as IN N
measured VBN N
by IN N
a DT N
triaxial JJ N
accelerometer NN N
. . N

The DT N
Multimedia NNP o
Activity NNP o
Recall NNP o
for IN o
Children NNP o
and CC o
Adults NNP o
was VBD o
used VBN N
to TO N
describe VB N
changes NNS N
in IN N
use NN N
of IN N
time NN N
. . N

RESULTS VB p
Thirty-three JJ p
participants NNS p
completed VBD p
the DT p
full JJ N
protocol NN N
. . N

Four CD N
participants NNS N
reported VBD o
falls NNS o
during IN o
the DT N
intervention NN N
period NN N
with IN N
no DT N
other JJ o
adverse JJ o
events NNS o
. . o

From IN o
a DT N
baseline JJ N
average NN N
of IN N
640.7?99.6min/d CD o
, , o
daily RB o
sitting VBG o
time NN o
reduced VBN o
on IN N
average NN N
by IN N
30?50.6min/d CD N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NNP N
, , N
5.8-54.6 JJ N
) ) N
in IN N
the DT N
intervention NN N
group NN N
and CC N
40.4?92.5min/d CD N
in IN N
the DT N
control NN i
group NN i
( ( N
95 CD N
% NN N
CI NNP N
, , N
13.0-93.8 JJ N
) ) N
. . N

Participants NNS N
in IN N
both DT N
groups NNS N
also RB N
reduced VBD N
their PRP$ N
time NN o
spent VBN o
in IN o
prolonged JJ o
sitting NN o
bouts NNS o
( ( N
?30min NN N
) ) N
and CC N
increased JJ o
time NN o
spent VBN o
standing NN o
and CC o
stepping NN o
. . o

CONCLUSIONS NNP o
Our PRP$ N
protocol NN N
was VBD N
both DT N
safe JJ N
and CC N
feasible JJ N
. . N

Participants NNS N
in IN N
both DT N
groups NNS N
spent VBD N
less JJR N
time NN N
sitting VBG N
and CC N
more JJR N
time NN N
standing NN N
and CC N
stepping VBG N
postintervention NN N
, , N
but CC N
outcomes NNS N
were VBD N
not RB N
superior JJ N
for IN N
intervention NN p
participants NNS p
. . p

Attention NN p
matching NN N
is VBZ N
desirable JJ N
in IN N
clinical JJ N
trials NNS N
and CC N
may MD N
have VB N
contributed VBN N
to TO N
the DT N
positive JJ N
outcomes NNS N
for IN N
control NN N
participants NNS p
. . p

-DOCSTART- -22850220- O O

Errors NNS N
during IN N
the DT N
preparation NN N
of IN N
drug NN N
infusions NNS N
: : N
a DT N
randomized NN N
controlled VBN N
trial NN N
. . N

BACKGROUND IN N
We PRP N
investigated VBD N
the DT N
extent NN N
and CC N
frequency NN N
of IN N
dose JJ N
errors NNS N
and CC N
treatment NN N
delays NNS N
made VBN N
as IN N
a DT N
consequence NN N
of IN N
preparing VBG N
drug NN i
infusions NNS i
at IN i
the DT i
bedside NN i
, , N
rather RB N
than IN N
using VBG N
pre-filled JJ i
syringes NNS i
. . i

METHODS NNP N
Forty-eight JJ p
nurses NNS p
with IN p
critical JJ p
care NN p
experience NN p
volunteered VBD p
to TO p
take VB p
part NN p
in IN p
this DT p
randomized VBN p
, , p
blinded VBD p
, , p
controlled VBD p
study NN p
conducted VBN p
in IN p
the DT p
simulation NN p
centre NN p
of IN p
an DT p
urban JJ p
hospital NN p
. . p

They PRP N
assisted VBD N
in IN N
the DT N
management NN N
of IN N
a DT N
simulated JJ p
patient NN p
with IN p
septic JJ p
shock NN p
. . p

Vasopressor NNP i
infusions NNS i
were VBD N
prepared VBN N
either RB N
by IN N
diluting VBG i
concentrated VBN i
drugs NNS i
from IN i
ampoules NNS i
or CC N
were VBD N
provided VBN N
in IN N
syringes NNS i
pre-filled JJ i
beforehand NN N
by IN N
an DT N
intensive JJ N
care NN N
unit NN N
resident NN N
. . N

RESULTS VB N
The DT N
time NN N
taken VBN N
for IN N
the DT N
infusion NN N
to TO N
be VB N
started VBN N
and CC N
the DT N
final JJ o
concentration NN o
of IN o
the DT o
drugs NNS o
were VBD o
measured VBN o
. . o

We PRP N
also RB N
measured VBD N
the DT N
concentration NN o
of IN o
infusions NNS o
prepared VBN N
by IN N
a DT N
pharmacist NN N
and CC N
a DT N
pharmaceutical JJ N
company NN N
. . N

Nurses NNS N
took VBD N
156 CD N
s NN N
to TO N
start VB N
infusions NNS N
when WRB N
using VBG N
pre-filled JJ i
syringes NNS i
compared VBN N
with IN N
276 CD N
s NNS N
when WRB N
preparing VBG N
them PRP N
de FW N
novo FW N
, , N
a DT N
mean JJ N
delay NN N
of IN N
106 CD N
s NNS N
[ RB N
95 CD N
% NN N
confidence NN N
interval NN N
( ( N
CI NNP N
) ) N
73-140 CD N
s NN N
, , N
P NNP N
< VBZ N
0.0001 CD N
] NN N
. . N

One CD N
infusion NN N
prepared VBN N
from IN N
ampoules NNS N
contained VBN N
one-fifth CD N
of IN N
the DT N
expected JJ N
concentration NN N
of IN N
epinephrine NN i
; : i
another DT N
contained VBD N
none NN N
at IN N
all DT N
. . N

Medication NNP o
errors NNS o
were VBD N
17.0 CD N
times NNS N
less RBR N
likely JJ N
when WRB N
pre-filled JJ i
syringes NNS i
were VBD N
used VBN N
( ( N
95 CD N
% NN N
CI NNP N
5.2-55.5 CD N
) ) N
, , N
and CC N
infusions NNS i
prepared VBN N
by IN N
pharmacy NN N
and CC N
industry NN N
were VBD N
significantly RB N
more RBR N
likely JJ N
to TO N
contain VB N
the DT N
expected JJ N
concentration NN N
( ( N
P NNP N
< VBZ N
0.001 CD N
for IN N
norepinephrine NN i
and CC N
P=0.001 NNP N
for IN N
epinephrine NN i
) ) i
. . N

CONCLUSIONS NNP N
Providing VBG N
drug NN i
infusions NNS i
in IN N
syringes NNS N
pre-filled VBN i
by IN N
pharmacists NNS N
or CC N
pharmaceutical JJ N
companies NNS N
would MD N
reduce VB N
medication NN o
errors NNS o
and CC o
treatment NN o
delays NNS o
, , N
and CC N
improve VB N
patient NN o
safety NN o
. . o

However RB N
, , N
this DT N
approach NN N
would MD N
have VB N
substantial JJ N
financial JJ N
implications NNS N
for IN N
healthcare NN N
providers NNS N
, , N
especially RB N
in IN N
less JJR N
developed JJ N
countries NNS N
. . N

-DOCSTART- -6740101- O O

A DT N
comparison NN N
of IN N
the DT N
serologic JJ N
responses NNS N
to TO N
oral JJ N
and CC N
injectable JJ N
trivalent NN i
poliovirus NN i
vaccines NNS i
. . i

United NNP p
States NNPS p
children NNS p
two CD p
months NNS p
of IN p
age NN p
were VBD N
randomly RB N
assigned VBN N
to TO N
two CD N
groups NNS N
that WDT N
received VBD N
either RB N
the DT N
commercially RB N
available JJ N
oral JJ i
trivalent NN i
poliovirus NN i
vaccine NN i
( ( i
OPV NNP i
) ) i
or CC N
an DT N
injectable JJ i
( ( i
inactivated VBN i
) ) i
trivalent NN i
poliovirus NN i
vaccine NN i
( ( i
IPV NNP i
) ) i
with IN N
a DT N
confirmed JJ N
minimum JJ N
D-antigen NNP N
content NN N
of IN N
27 CD N
, , N
3.5 CD N
, , N
and CC N
29 CD N
units NNS N
for IN N
poliovirus NN N
types NNS N
1 CD N
, , N
2 CD N
, , N
and CC N
3 CD N
, , N
respectively RB N
. . N

Vaccine NNP N
was VBD N
given VBN N
at IN N
two CD N
, , N
four CD N
, , N
and CC N
18 CD N
months NNS N
of IN N
age NN N
. . N

Sera NN N
obtained VBN N
from IN N
439 CD p
children NNS p
at IN p
two CD p
, , p
four CD p
, , p
and CC p
six CD p
months NNS p
of IN p
age NN p
and CC p
from IN p
85 CD p
children NNS p
at IN p
18 CD p
and CC p
20 CD p
months NNS p
of IN p
age NN p
were VBD N
examined VBN N
for IN N
neutralizing VBG o
antibodies NNS o
. . o

The DT N
percentage NN o
of IN o
children NNS o
with IN o
detectable JJ o
antibodies NNS o
and CC o
the DT o
reciprocal JJ o
geometric JJ o
mean NN o
titers NNS o
were VBD N
similar JJ N
for IN N
both DT N
groups NNS N
at IN N
two CD N
months NNS N
of IN N
age NN N
for IN N
antibodies NNS o
to TO o
all DT o
three CD o
poliovirus NN o
types NNS o
. . o

At IN N
20 CD N
months NNS N
of IN N
age NN N
, , N
all DT N
children NNS N
but CC N
one CD N
had VBD N
detectable JJ o
antibodies NNS N
to TO N
all DT N
three CD N
poliovirus NN N
types NNS N
. . N

Significantly RB N
higher JJR N
geometric JJ o
mean NN o
titers NNS o
against IN o
types NNS o
2 CD o
and CC o
3 CD o
were VBD N
noted VBN N
at IN N
20 CD N
months NNS N
of IN N
age NN N
for IN N
the DT N
IPV NNP i
group NN N
. . N

-DOCSTART- -17621027- O O

Observer NNP N
variation NN N
in IN N
the DT N
assessment NN o
of IN o
outcome NN o
in IN N
traumatic JJ N
brain NN N
injury NN N
: : N
experience NN N
from IN N
a DT N
multicenter NN N
, , N
international JJ N
randomized VBD N
clinical JJ N
trial NN N
. . N

OBJECTIVE NNP N
Accurate NNP N
and CC N
consistent JJ N
outcome NN o
assessment NN o
is VBZ N
essential JJ N
to TO N
randomized VB N
clinical JJ N
trials NNS N
. . N

We PRP N
aimed VBD N
to TO N
explore VB N
observer JJ N
variation NN N
in IN N
the DT N
assessment NN o
of IN o
outcome NN o
in IN N
a DT N
recently RB N
completed VBN N
trial NN N
of IN N
dexanabinol NN i
in IN N
head JJ p
injury NN p
and CC N
to TO N
consider VB N
steps NNS N
to TO N
reduce VB N
such JJ N
variation NN N
. . N

METHODS NNP N
Eight NNP p
hundred VBD p
sixty-one JJ p
patients NNS p
with IN p
severe JJ p
traumatic JJ p
brain NN p
injury NN p
who WP p
were VBD p
admitted VBN p
to TO p
86 CD p
centers NNS p
were VBD N
included VBN N
in IN N
a DT N
multicenter NN N
, , N
placebo-controlled JJ i
, , N
Phase NNP N
III NNP N
trial NN N
. . N

Outcome NNP N
was VBD N
assessed VBN N
at IN N
3 CD N
and CC N
6 CD N
months NNS N
postinjury NN N
using VBG N
the DT N
extended JJ o
Glasgow NNP o
Outcome NNP o
Scale NNP o
; : o
standardized VBD N
assessment NN N
was VBD N
facilitated VBN N
by IN N
the DT N
use NN N
of IN N
a DT N
structured JJ N
interview NN N
. . N

Before IN N
initiation NN N
of IN N
trial NN N
centers NNS N
, , N
outcome JJ o
ratings NNS o
were VBD N
obtained VBN N
for IN N
sample JJ N
cases NNS N
to TO N
establish VB N
initial JJ N
levels NNS N
of IN N
agreement NN N
. . N

Training NN N
sessions NNS N
in IN N
outcome JJ N
assessment NN N
were VBD N
held VBN N
, , N
and CC N
problems NNS N
in IN N
assigning VBG N
outcome NN N
were VBD N
investigated VBN N
. . N

During IN N
the DT N
trial NN N
, , N
a DT N
process NN N
of IN N
central JJ N
review NN N
was VBD N
established VBN N
to TO N
monitor VB N
performance NN N
. . N

Interobserver NNP N
variation NN N
was VBD N
analyzed VBN N
using VBG N
the DT N
kappa NN N
statistic JJ N
. . N

RESULTS NNP N
Substantial NNP o
observer JJ o
variation NN o
was VBD N
found VBN N
in IN N
the DT N
rating NN N
of IN N
sample JJ N
cases NNS N
( ( N
weighted JJ N
kappa NN N
, , N
0.72 CD N
; : N
confidence NN N
interval NN N
, , N
0.68-0.75 JJ N
) ) N
and CC N
in IN N
assigning VBG N
outcome NN o
based VBN N
on IN N
completed VBN N
structured JJ N
interviews NNS N
( ( N
weighted JJ N
kappa NN N
, , N
0.61 CD N
; : N
confidence NN N
interval NN N
, , N
0.57-0.64 JJ N
) ) N
. . N

In IN N
the DT N
early JJ N
stages NNS N
of IN N
the DT N
trial NN N
, , N
a DT N
relatively RB N
large JJ N
number NN N
of IN N
discrepancies NNS o
( ( N
29-37 CD N
% NN N
) ) N
were VBD N
identified VBN N
on IN N
central JJ N
review NN N
. . N

This DT N
number NN N
declined VBD N
as IN N
the DT N
trial NN N
progressed VBD N
and CC N
coincided VBD N
with IN N
investigator NN N
training NN N
and CC N
feedback NN N
from IN N
central JJ N
review NN N
. . N

Centers NNS N
with IN N
higher JJR N
enrollment NN N
rates NNS N
showed VBD N
better JJR N
performance NN N
. . N

CONCLUSION NNP N
Observer NNP o
variation NN o
in IN N
outcome JJ o
assessment NN o
is VBZ N
a DT N
significant JJ N
problem NN N
for IN N
head NN N
injury NN N
trials NNS N
. . N

Consistency NN o
can MD N
be VB N
improved VBN N
by IN N
standardizing VBG N
procedures NNS N
, , N
training VBG N
assessors NNS N
, , N
and CC N
monitoring VBG N
the DT N
quality NN N
of IN N
assessments NNS N
and CC N
providing VBG N
feedback NN N
to TO N
interviewers NNS N
. . N

-DOCSTART- -17404138- O O

Comparison NNP N
of IN N
indicators NNS N
for IN N
a DT N
primary JJ N
care NN N
medical JJ N
home NN N
between IN N
children NNS p
with IN p
autism NN p
or CC p
asthma NN p
and CC p
other JJ p
special JJ p
health NN p
care NN p
needs NNS p
: : p
National NNP N
Survey NNP N
of IN N
Children NNP N
's POS N
Health NNP N
. . N

OBJECTIVE NNP N
To TO N
assess VB N
the DT N
extent NN N
to TO N
which WDT N
parents NNS i
of IN i
children NNS i
with IN i
autism NN i
compared VBN i
with IN i
parents NNS i
of IN i
children NNS i
with IN i
asthma NN i
or CC i
other JJ i
special JJ i
health NN i
care NN i
needs VBZ i
report NN N
receiving VBG N
primary JJ N
care NN N
for IN N
their PRP$ N
child NN N
consistent NN N
with IN N
the DT N
American JJ N
Academy NNP N
of IN N
Pediatrics NNP N
medical JJ N
home NN N
model NN N
. . N

DESIGN NNP N
Population-based JJ N
cross-sectional JJ N
study NN N
. . N

SETTING NNP N
National NNP i
Survey NNP i
for IN i
Children NNP i
's POS i
Health NNP i
2003-2004 CD i
telephone NN i
interview NN i
. . i

PARTICIPANTS NNP N
Parents NNPS p
of IN p
495 CD p
children NNS p
with IN p
autism NN p
, , p
parents NNS p
of IN p
6716 CD p
children NNS p
with IN p
asthma NN p
, , p
and CC p
parents NNS p
of IN p
11,403 CD p
children NNS p
with IN p
other JJ p
special JJ p
health NN p
care NN p
needs VBZ p
without IN p
asthma NN p
. . p

Main NNP N
Exposures NNPS N
Autism NNP N
and CC N
other JJ N
special JJ N
health NN N
care NN N
needs VBZ N
including VBG N
asthma NN N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Medical NNP N
home NN N
score NN N
and CC N
components NNS N
of IN N
care NN N
, , N
as IN N
follows VBZ N
: : N
personal JJ N
provider NN N
and CC N
preventive NN N
; : N
family-centered JJ N
, , N
compassionate NN N
, , N
and CC N
culturally RB N
appropriate JJ N
; : N
accessible JJ N
; : N
comprehensive JJ N
; : N
and CC N
coordinated VBD N
. . N

RESULTS VB N
The DT N
odds NNS o
of IN o
parents NNS o
reporting VBG o
care NN o
consistent JJ o
with IN o
that DT o
in IN o
a DT o
medical JJ o
home NN o
were VBD N
less RBR o
likely JJ o
for IN o
children NNS o
with IN o
autism NN o
( ( N
odds NNS N
ratio NN N
, , N
0.45 CD N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
0.30-0.66 JJ N
) ) N
and CC N
more RBR N
likely JJ N
for IN N
children NNS N
with IN N
asthma NN N
( ( N
odds NNS N
ratio NN N
, , N
1.17 CD N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
1.06-1.30 JJ N
) ) N
compared VBN N
with IN N
children NNS N
with IN N
other JJ N
special JJ N
health NN N
care NN N
needs NNS N
( ( N
1 CD N
[ NN N
reference NN N
] NN N
) ) N
. . N

These DT N
differences NNS N
persisted VBD N
even RB N
after IN N
controlling VBG N
for IN N
condition NN N
severity NN N
, , N
personal JJ N
characteristics NNS N
, , N
and CC N
insurance NN N
status NN N
. . N

Specific JJ N
components NNS N
of IN N
a DT N
medical JJ N
home NN N
less RBR N
prevalent JJ N
among IN N
children NNS N
with IN N
autism NN N
than IN N
among IN N
children NNS N
with IN N
other JJ N
special JJ N
health NN N
care NN N
needs VBZ N
included VBN N
family-centered JJ N
, , N
comprehensive JJ N
, , N
and CC N
coordinated VBD N
care NN N
. . N

CONCLUSION NNP N
Although IN N
we PRP N
could MD N
not RB N
evaluate VB N
the DT N
reasons NNS N
why WRB N
, , N
a DT N
large JJ N
percentage NN N
of IN N
children NNS N
with IN N
autism NN N
do VBP N
not RB N
receive VB N
primary JJ o
care NN o
consistent JJ o
with IN o
that DT o
in IN o
a DT o
medical JJ o
home NN o
. . o

-DOCSTART- -19608530- O O

A DT N
double-blind JJ N
placebo-controlled JJ i
study NN N
to TO N
evaluate VB N
valacyclovir NN i
alone RB i
and CC N
with IN N
aspirin NN i
for IN N
asymptomatic JJ N
HSV-1 NNP N
DNA NNP N
shedding VBG N
in IN N
human JJ p
tears NNS p
and CC p
saliva NN p
. . p

PURPOSE NNP N
To TO N
test VB N
the DT N
effect NN N
of IN N
valacyclovir NN i
alone RB i
and CC N
with IN N
aspirin NN i
on IN N
the DT N
asymptomatic JJ N
shedding NN N
of IN N
HSV-1 NNP N
DNA NNP N
in IN N
tears NNS p
and CC p
saliva NN p
of IN p
healthy JJ p
individuals NNS p
. . p

METHOD NNP N
. . N

The DT p
subjects NNS p
( ( p
n JJ p
= NNP p
45 CD p
) ) p
were VBD N
randomized VBN N
into IN N
three CD N
groups NNS N
without IN N
regard NN N
to TO N
age NN N
, , N
sex NN N
, , N
or CC N
race NN N
. . N

Group NNP N
1 CD N
( ( N
n JJ N
= NNP N
14 CD N
) ) N
received VBD N
the DT N
placebo NN i
, , N
group NN N
2 CD N
( ( N
n JJ N
= NNP N
15 CD N
) ) N
received VBD N
a DT N
dose NN N
of IN N
500 CD i
mg NNS i
valacyclovir JJ i
once RB i
daily JJ i
, , N
and CC N
group NN N
3 CD N
( ( N
n JJ N
= NNP N
16 CD N
) ) N
received VBD N
a DT N
dose NN N
of IN N
500 CD i
mg NNS i
valacyclovir JJ i
once RB i
daily JJ i
and CC i
350 CD i
mg NN i
aspirin JJ i
twice RB N
daily RB N
for IN N
30 CD N
days NNS N
. . N

Ocular JJ N
and CC N
oral JJ N
swabs NNS N
were VBD N
collected VBN N
twice RB N
daily RB N
for IN N
30 CD N
days NNS N
. . N

DNA NN N
was VBD N
extracted VBN N
from IN N
all DT N
swabs NNS N
and CC N
HSV-1 NNP N
DNA NNP N
copy NN N
numbers NNS N
were VBD N
determined VBN N
. . N

Statistical JJ N
analysis NN N
was VBD N
performed VBN N
to TO N
compare VB N
the DT N
DNA NNP N
copy NN N
numbers NNS N
of IN N
the DT N
three CD N
groups NNS N
. . N

RESULTS NNP N
There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
the DT N
HSV-1 NNP o
DNA NNP o
copy NN o
numbers NNS o
in IN o
the DT o
tears NNS o
or CC o
saliva NN o
among IN N
any DT N
of IN N
the DT N
three CD N
treatment NN i
groups NNS N
. . N

The DT N
mean JJ o
copy NN o
numbers NNS o
+/- JJ o
SE NNP o
of IN o
mean NN o
( ( o
SEM NNP o
) ) o
of IN o
HSV-1 NNP o
DNA NNP o
in IN N
tears NNS N
were VBD N
340 CD N
+/- JJ N
35 CD N
, , N
1074 CD N
+/- JJ N
320 CD N
, , N
and CC N
630 CD N
+/- JJ N
51 CD N
for IN N
groups NNS N
1 CD N
, , N
2 CD N
, , N
and CC N
3 CD N
, , N
and CC N
in IN N
saliva NN N
were VBD N
238 CD N
+/- JJ N
35 CD N
, , N
963 CD N
+/- JJ N
462 CD N
, , N
and CC N
493 CD N
+/- JJ N
25 CD N
, , N
respectively RB N
, , N
for IN N
groups NNS N
1 CD N
, , N
2 CD N
, , N
and CC N
3 CD N
. . N

CONCLUSIONS NNP N
No NNP N
correlation NN N
was VBD N
found VBN N
between IN N
HSV-1 NNP o
shedding VBG o
and CC N
valacyclovir NNS i
and CC N
valacyclovir NN i
with IN i
aspirin JJ i
treatment NN N
. . N

The DT N
HSV-1 NNP N
DNA NNP N
copy NN N
number NN N
was VBD N
not RB N
reduced VBN N
by IN N
treatment NN N
with IN N
500 CD N
mg NNS N
of IN N
valacyclovir JJ i
daily JJ N
or CC N
with IN N
a DT N
combination NN N
of IN N
daily JJ N
valacyclovir NN i
( ( N
500 CD N
mg NN N
) ) N
plus CC N
twice-daily JJ N
doses NNS N
of IN N
aspirin NN i
( ( N
350 CD N
mg NN N
) ) N
over IN N
30 CD N
days NNS N
. . N

-DOCSTART- -20486905- O O

Early JJ N
withdrawal NN N
of IN N
calcineurin NN i
inhibitors NNS i
and CC i
everolimus JJ i
monotherapy NN i
in IN N
de FW p
novo FW p
liver NN p
transplant NN p
recipients VBZ p
preserves VBZ N
renal JJ N
function NN N
. . N

We PRP N
designed VBD N
a DT N
randomized JJ N
trial NN N
to TO N
assess VB N
whether IN N
the DT N
early JJ i
withdrawal NN i
of IN i
cyclosporine NN i
( ( i
CsA NNP i
) ) i
followed VBN i
by IN i
the DT i
initiation NN i
of IN i
everolimus NN i
( ( i
Evr NNP i
) ) i
monotherapy NN i
in IN N
de FW p
novo FW p
liver FW p
transplantation NN p
( ( p
LT NNP p
) ) p
patients NNS p
would MD N
result VB N
in IN N
superior JJ N
renal JJ N
function NN N
compared VBN N
to TO N
a DT N
CsA-based JJ N
immunosuppression NN N
protocol NN N
. . N

All DT N
patients NNS N
were VBD N
treated VBN N
with IN N
CsA NNP i
for IN N
the DT N
first JJ N
10 CD N
days NNS N
and CC N
then RB N
randomized VBN N
to TO N
receive VB N
Evr NNP i
in IN i
combination NN i
with IN i
CsA NNP i
up RB N
to TO N
day NN N
30 CD N
, , N
then RB N
either DT N
continued VBN N
on IN N
Evr NNP i
monotherapy NN i
( ( i
Evr NNP i
group NN i
) ) i
or CC N
maintained VBN N
on IN N
CsA NNP i
with/without NN i
mycophenolate NN i
mofetil NN i
( ( i
CsA NNP i
group NN i
) ) i
in IN N
case NN N
of IN N
chronic JJ N
kidney NN N
disease NN N
( ( N
CKD NNP N
) ) N
. . N

Seventy-eight JJ p
patients NNS p
were VBD p
randomized VBN p
( ( i
Evr NNP i
n RB N
= VBZ N
52 CD N
; : N
CsA NNP i
n VBD N
= NNP N
26 CD N
) ) N
. . N

The DT N
1-year JJ o
freedom NN o
from IN o
efficacy NN o
failure NN o
in IN N
Evr NNP i
group NN N
was VBD N
75 CD N
% NN N
versus IN N
69.2 CD N
% NN N
in IN N
CsA NNP i
group NN N
, , N
p VBP N
= JJ N
0.36 CD N
. . N

There EX N
was VBD N
no DT N
statistically RB N
significant JJ N
difference NN N
in IN N
patient JJ o
survival NN o
between IN N
the DT N
two CD N
groups NNS N
. . N

Mean NNP o
modification NN o
of IN o
diet NN o
in IN o
renal JJ o
disease NN o
( ( o
MDRD NNP o
) ) o
was VBD N
significantly RB N
better RBR N
in IN N
the DT N
Evr NNP i
group NN N
at IN N
12 CD N
months NNS N
( ( N
87.7 CD N
? . N
26.1 CD N
vs. IN N
59.9 CD N
? . N
12.6 CD N
mL/min NN N
; : N
p CC N
< VB N
0.001 CD N
) ) N
. . N

The DT o
incidence NN o
of IN o
CKD NNP o
stage NN o
? . o
3 CD o
( ( o
estimated VBN N
glomerular JJ N
filtration NN N
rate NN N
< $ N
60 CD N
mL/min NN N
) ) N
was VBD N
higher RBR N
in IN N
the DT N
CsA NNP i
group NN N
at IN N
1 CD N
year NN N
( ( N
52.2 CD N
% NN N
vs. FW N
15.4 CD N
% NN N
, , N
p NN N
= NNP N
0.005 CD N
) ) N
. . N

The DT N
results NNS N
indicate VBP N
that IN N
early JJ N
withdrawal NN i
of IN i
CsA NNP i
followed VBN i
by IN i
Evr NNP i
monotherapy NN i
in IN i
de FW p
novo FW p
LT NNP p
patients NNS p
is VBZ p
associated VBN N
with IN N
an DT N
improvement NN N
in IN N
renal JJ N
function NN N
, , N
with IN N
a DT N
similar JJ N
incidence NN N
of IN N
rejection NN N
and CC N
major JJ N
complications NNS N
. . N

-DOCSTART- -17977295- O O

Effect NN N
of IN N
a DT N
dental JJ N
cream NN N
containing VBG N
amorphous JJ i
cream NN i
phosphate NN i
complexes NNS i
on IN N
white JJ N
spot NN N
lesion NN N
regression NN N
assessed VBN N
by IN N
laser NN N
fluorescence NN N
. . N

PURPOSE NNP N
To TO N
investigate VB N
and CC N
compare VB N
the DT N
effects NNS N
of IN N
a DT N
dental JJ N
cream NN N
containing VBG N
complexes NNS N
of IN N
casein JJ i
phosphoprotein-amorphous JJ i
calcium NN i
phosphate NN i
( ( N
CPP-ACP NNP N
) ) N
and CC N
fluoride JJ i
mouthwashes NNS N
on IN N
the DT N
regression NN N
of IN N
white JJ p
spot NN p
lesions NNS p
( ( p
WSL NNP p
) ) p
. . p

MATERIALS NNP N
AND CC N
METHODS NNP N
The DT N
study NN N
group NN N
consisted VBD N
of IN N
26 CD p
healthy JJ p
adolescents NNS p
( ( p
mean JJ p
age NN p
14.6 CD p
years NNS p
) ) p
exhibiting VBG p
60 CD p
teeth NNS p
with IN p
152 CD p
visible JJ p
WSL NNP p
sites NNS p
on IN p
incisors NNS p
and CC p
canines NNS p
immediately RB p
after IN p
debonding VBG p
of IN p
fixed VBN p
orthodontic JJ p
appliances NNS p
. . p

After IN N
bracket NN i
removal NN i
, , i
professional JJ i
tooth NN i
cleaning NN i
and CC i
drying NN i
, , i
a DT i
visual JJ i
scoring NN i
( ( i
0-4 JJ i
) ) i
and CC i
laser JJR i
fluorescence NN i
( ( i
LF NNP i
) ) i
readings NNS i
were VBD N
carried VBN N
out RP N
. . N

The DT N
patients NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
two CD N
different JJ N
treatment NN N
protocols NNS N
with IN N
the DT N
aim NN N
of IN N
remineralising VBG N
the DT N
lesions NNS N
: : N
A DT N
) ) N
daily RB i
topical JJ i
applications NNS i
of IN i
a DT i
dental JJ i
cream NN i
containing VBG i
CPP-ACP NNP i
( ( i
Topacal NNP i
) ) i
for IN i
3 CD i
months NNS i
followed VBN i
by IN i
a DT i
3-month JJ i
period NN i
of IN i
daily JJ i
toothbrushing VBG i
with IN i
fluoridated JJ i
dentifrice NN i
, , i
or CC i
B NNP i
) ) i
daily RB i
0.05 CD i
% NN i
sodium NN i
fluoride NN i
mouthwash NN i
combined VBN i
with IN i
fluoridated JJ i
dentifrice NN i
for IN i
6 CD i
months NNS i
. . i

The DT N
registrations NNS N
were VBD N
repeated VBN N
after IN N
1 CD N
, , N
3 CD N
, , N
6 CD N
and CC N
12 CD N
months NNS N
and CC N
follow-up JJ N
data NNS N
were VBD N
compared VBN N
with IN N
baseline NN N
with IN N
aid NN N
of IN N
chi-square NN N
and CC N
paired VBD N
t-tests NNS N
. . N

RESULTS VB N
A DT N
significant JJ N
improvement NN N
of IN N
the DT N
clinical JJ o
WSL-scores NNS o
was VBD N
found VBN N
over IN N
time NN N
in IN N
both DT N
groups NNS N
, , N
but CC N
there RB N
was VBD N
a DT N
statistically RB N
significant JJ N
difference NN N
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
concerning VBG N
the DT N
number NN o
of IN o
sites NNS o
that WDT o
totally RB o
disappeared VBD o
after IN N
12 CD N
months NNS N
in IN N
favour NN N
of IN N
the DT N
CPP-ACP NNP N
regime NN N
, , N
63 CD N
% NN N
compared VBN N
with IN N
25 CD N
% NN N
respectively RB N
. . N

The DT N
clinical JJ N
registrations NNS N
were VBD N
mirrored VBN N
by IN N
a DT N
statistically RB N
significant JJ N
decrease NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
in IN N
the DT N
LF NNP o
readings NNS o
at IN N
the DT N
6- JJ N
and CC N
12-month JJ N
follow-ups NNS N
compared VBN N
with IN N
baseline NN N
. . N

No DT N
significant JJ N
differences NNS N
were VBD N
displayed VBN N
between IN N
the DT N
groups NNS N
. . N

CONCLUSIONS NNP N
Clinical NNP N
scoring NN N
and CC N
LF NNP N
assessment NN N
suggested VBD N
that IN N
both DT N
regimens NNS N
could MD N
promote VB N
regression NN N
of IN N
WSL NNP N
after IN N
debonding VBG N
of IN N
fixed VBN N
orthodontic JJ N
appliances NNS N
. . N

The DT N
visual JJ N
evaluation NN N
suggested VBD N
an DT N
aesthetically RB N
more RBR N
favourable JJ N
outcome NN N
of IN N
the DT N
amorphous JJ i
calcium NN i
phosphate NN i
treatments NNS i
. . N

-DOCSTART- -3539897- O O

An DT N
analysis NN N
of IN N
the DT N
radiation NN N
related VBN N
morbidity NN o
observed VBN N
in IN N
a DT N
randomized JJ N
trial NN N
of IN N
neutron NN i
therapy NN i
for IN N
bladder NN p
cancer NN p
. . p

This DT N
report NN N
is VBZ N
an DT N
analysis NN N
of IN N
the DT N
morbidity NN o
in IN p
the DT p
bladder NN p
and CC N
bowel NN N
observed VBN N
in IN N
a DT N
randomized JJ N
trial NN N
of IN N
d NN i
( ( i
15 CD i
) ) i
+Be NN i
neutrons NNS i
versus VBP N
megavoltage NN i
photons NNS i
in IN N
the DT N
treatment NN N
of IN N
bladder NN N
cancer NN N
. . N

Acute JJ o
reactions NNS o
in IN N
the DT N
bladder NN N
and CC N
bowel NN N
were VBD N
significantly RB N
worse JJR N
after IN N
photon NN i
therapy NN i
. . i

Of IN N
the DT N
patients NNS p
treated VBN p
with IN p
photons NNS i
45.7 CD N
% NN N
had VBD N
severe JJ N
reactions NNS o
in IN o
the DT o
bladder NN o
compared VBN N
with IN N
10.6 CD N
% NN N
after IN N
neutron JJ i
therapy NN i
( ( N
p NN N
less JJR N
than IN N
0.001 CD N
) ) N
. . N

Severe NNP o
acute JJ o
bowel NN o
reactions NNS o
were VBD N
observed VBN N
in IN N
8.5 CD N
% NN N
of IN N
the DT N
patients NNS N
after IN N
photon NN i
therapy NN i
compared VBN N
with IN N
3.8 CD N
% NN N
after IN N
neutron JJ i
therapy NN i
( ( N
p NN N
less JJR N
than IN N
0.05 CD N
) ) N
. . N

Late JJ o
reactions NNS o
were VBD N
significantly RB N
worse JJR N
after IN N
neutrons NNS i
. . i

Severe NNP o
late JJ o
reactions NNS o
in IN o
the DT o
bladder NN o
were VBD N
seen VBN N
in IN N
58.5 CD N
% NN N
of IN N
patients NNS N
after IN N
neutron JJ i
therapy NN i
and CC N
in IN N
40.5 CD N
% NN N
after IN N
photon NN i
therapy NN i
( ( N
p NN N
less JJR N
than IN N
0.05 CD N
) ) N
. . N

In IN N
the DT N
bowel NN N
they PRP N
were VBD N
observed VBN N
in IN N
53.3 CD N
% NN N
of IN N
patients NNS N
after IN N
neutron JJ i
therapy NN i
compared VBN N
with IN N
8 CD N
% NN N
after IN N
photon NN i
therapy NN i
( ( N
p NN N
less JJR N
than IN N
0.0001 CD N
) ) N
. . N

The DT N
disparity NN o
in IN o
the DT o
degree NN o
of IN o
early JJ o
and CC o
late JJ o
complications NNS o
makes VBZ N
assessment NN N
of IN N
RBE NNP o
values NNS o
difficult JJ N
. . N

It PRP N
is VBZ N
estimated VBN N
that IN N
for IN N
bladder NN o
morbidity NN o
the DT N
RBE NNP o
value NN o
, , N
for IN N
photon NN N
dose JJ N
fractions NNS N
of IN N
2.75 CD N
Gy NNP N
, , N
is VBZ N
less JJR N
than IN N
3.3 CD N
for IN N
early JJ N
reactions NNS N
and CC N
equal JJ N
to TO N
3.4 CD N
for IN N
late JJ N
effects NNS N
. . N

The DT N
respective JJ N
RBE NNP o
values NNS o
for IN N
early RB N
and CC N
late JJ N
effects NNS N
in IN N
the DT N
bowel NN N
are VBP N
less JJR N
than IN N
3.4 CD N
and CC N
3.8 CD N
. . N

-DOCSTART- -16087911- O O

A DT N
single JJ N
dose NN N
of IN N
gabapentin NN i
reduces NNS N
acute VBP o
pain NN o
and CC N
allodynia NN o
in IN N
patients NNS p
with IN p
herpes NNS p
zoster NN p
. . p

This DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
crossover NN N
study NN N
measured VBD N
the DT N
effect NN N
of IN N
a DT N
single JJ N
dose NN N
of IN N
oral JJ i
gabapentin NN i
( ( N
900 CD N
mg NN N
) ) N
on IN N
pain NN o
and CC o
allodynia NN o
associated VBN o
with IN o
herpes NNS o
zoster NN o
. . o

Pain NNP o
severity NN o
decreased VBN N
by IN N
66 CD N
% NN N
with IN N
gabapentin NN i
compared VBN N
to TO N
33 CD N
% NN N
with IN N
placebo NN i
. . i

Reductions NNS N
in IN N
allodynia JJ o
area NN o
and CC o
severity NN o
, , o
and CC o
overall JJ o
pain NN o
relief NN o
, , N
were VBD N
also RB N
greater JJR N
with IN N
gabapentin NN i
. . i

-DOCSTART- -23621350- O O

Double-blind NNP N
, , N
placebo-controlled JJ i
, , N
dose-ranging JJ N
study NN N
of IN N
new JJ N
recombinant JJ i
hypoallergenic JJ i
Bet NNP i
v NN i
1 CD i
in IN N
an DT N
environmental JJ N
exposure NN N
chamber NN N
. . N

BACKGROUND NNP N
Recombinant NNP N
allergens VBZ N
offer VBP N
a DT N
tool NN N
for IN N
improving VBG N
specific JJ N
immunotherapy NN N
( ( N
SIT NNP N
) ) N
. . N

OBJECTIVE UH N
To TO N
find VB N
the DT N
optimal JJ N
dose NN N
of IN N
a DT N
new JJ N
hypoallergenic JJ N
folding NN N
variant NN N
of IN N
recombinant JJ i
Bet NNP i
v NN i
1 CD i
( ( i
rBet JJ i
v IN i
1-FV JJ i
) ) i
as IN N
SIT NNP N
for IN N
patients NNS p
with IN p
birch NN p
pollen NN p
allergy NN p
. . p

METHODS NNP N
Before IN N
SIT NNP N
, , N
thirty-seven JJ p
adult NN p
patients NNS p
were VBD p
exposed VBN p
for IN p
eight CD p
hours NNS p
in IN p
an DT p
environmental JJ i
exposure NN i
chamber NN i
( ( p
EEC NNP p
) ) p
to TO p
birch VB p
pollen NN p
at IN p
an DT p
average JJ p
concentration NN p
of IN p
3500 CD p
? . p
500 CD p
grains/m NN p
( ( p
3 CD p
) ) p
, , N
then RB N
randomized VBD N
to TO N
four CD N
maintenance NN N
dose NN N
groups NNS N
of IN i
rBet JJ i
v JJ i
1-FV JJ i
and CC N
one CD i
placebo NN i
group NN N
: : N
20 CD N
?g NN N
( ( N
n JJ N
= NNP N
7 CD N
) ) N
, , N
80 CD N
?g NN N
( ( N
n JJ N
= NNP N
8 CD N
) ) N
, , N
160 CD N
?g NN N
( ( N
n JJ N
= NNP N
7 CD N
) ) N
, , N
320 CD N
?g NN N
( ( N
n JJ N
= NNP N
8 CD N
) ) N
, , N
and CC N
placebo NN i
( ( i
n JJ i
= NNP i
7 CD N
) ) N
. . N

Patients NNS N
were VBD N
treated VBN N
for IN N
10 CD N
weeks NNS N
with IN N
weekly JJ N
injections NNS N
and CC N
then RB N
re-exposed JJ N
in IN N
the DT N
EEC NNP N
. . N

The DT N
optimal JJ N
dose NN N
for IN N
SIT NNP N
was VBD N
assessed VBN N
using VBG N
efficacy NN o
results NNS o
from IN o
the DT o
EEC NNP o
, , o
IgG NNP o
responses VBZ o
, , o
and CC o
tolerability NN o
. . o

RESULTS NNP o
Thirty-six JJ p
patients NNS p
were VBD p
evaluable JJ N
for IN N
efficacy NN N
assessment NN N
. . N

The DT N
total JJ o
symptom NN o
score NN o
significantly RB o
decreased VBN N
in IN N
all DT N
active JJ N
groups NNS N
compared VBN N
with IN N
placebo NN i
( ( i
-18.8 CD i
% NN N
for IN N
placebo NN N
patients NNS N
; : N
-71.9 CD N
% NN N
, , N
P NNP N
= VBZ N
0.0022 CD N
for IN N
20 CD N
?g NN N
; : N
-75.6 CD N
% NN N
, , N
P NNP N
= VBZ N
0.0007 CD N
for IN N
80 CD N
?g NN N
; : N
-81.8 CD N
% NN N
, , N
P NNP N
= VBZ N
0.0009 CD N
for IN N
160 CD N
?g NN N
; : N
-78.3 CD N
% NN N
, , N
P NNP N
= VBZ N
0.0003 CD N
for IN N
320 CD N
?g NN N
) ) N
. . N

IgG1 NNP o
increased VBD o
significantly RB N
in IN N
all DT N
active JJ N
groups NNS N
compared VBN N
to TO N
placebo VB N
. . N

All DT N
four CD N
active JJ N
doses NNS N
were VBD N
well RB N
tolerated VBN o
, , o
no DT o
serious JJ o
adverse JJ o
event NN o
occurred VBD o
; : N
two CD o
Grade NNP o
II NNP o
reactions NNS o
, , o
according VBG o
to TO N
EAACI NNP N
classification NN N
, , N
were VBD N
observed VBN N
, , N
one CD N
in IN N
each DT N
of IN N
the DT N
160- JJ N
and CC N
320-?g JJ N
groups NNS N
. . N

CONCLUSIONS NNP N
Considering NNP N
efficacy NN N
, , N
immunological JJ N
response NN N
, , N
and CC N
tolerability NN N
, , N
a DT N
maintenance NN N
dose NN N
of IN N
80 CD N
?g NN N
of IN i
rBet JJ i
v JJ i
1-FV JJ i
appears VBZ i
to TO N
be VB N
the DT N
ideal NN N
dose NN N
for IN N
allergen NN N
immunotherapy NN p
in IN p
birch NN p
pollen NN p
allergic JJ p
patients NNS p
. . p

-DOCSTART- -8392359- O O

Effect NN N
of IN N
extradural JJ i
analgesia NN i
on IN N
stress NN o
responses NNS o
to TO N
abdominal JJ N
surgery NN N
in IN N
infants NNS p
. . p

We PRP N
studied VBD N
40 CD p
children NNS p
younger JJR p
than IN p
4 CD p
yr NNS p
having VBG p
elective JJ p
abdominal JJ p
surgery NN p
under IN p
general JJ i
anaesthesia NN i
supplemented VBN p
with IN p
either DT p
systemic JJ i
opioids NNS i
or CC i
extradural JJ i
bupivacaine NN i
. . i

Venous JJ o
blood NN o
samples NNS o
were VBD N
obtained VBN N
before IN N
tracheal JJ N
intubation NN N
to TO N
measure VB N
baseline JJ N
concentrations NNS o
of IN o
adrenaline NN o
, , o
noradrenaline NN o
, , o
glucose NN o
, , o
ACTH NNP o
and CC o
cortisol NN o
. . o

Additional JJ N
samples NNS N
were VBD N
obtained VBN N
45 CD N
min NNS N
after IN N
the DT N
start NN N
of IN N
surgery NN N
, , N
at IN N
the DT N
end NN N
of IN N
surgery NN N
, , N
1 CD N
h NN N
and CC N
24 CD N
h NN N
after IN N
the DT N
end NN N
of IN N
surgery NN N
. . N

Plasma NNP o
concentrations NNS o
of IN o
bupivacaine NN o
were VBD N
measured VBN N
also RB N
in IN N
the DT N
extradural JJ N
group NN N
at IN N
each DT N
sampling VBG N
time NN N
. . N

Both DT N
techniques NNS N
provided VBN N
acceptable JJ N
analgesia NN N
, , N
but CC N
the DT N
perioperative JJ o
increases NNS o
in IN o
adrenaline NN o
, , o
glucose NN o
and CC o
ACTH NNP o
were VBD N
significantly RB N
greater JJR N
in IN N
the DT N
opioid JJ N
group NN N
. . N

Noradrenaline NNP o
concentrations NNS o
decreased VBD N
to TO N
less JJR N
than IN N
baseline NN N
values NNS N
in IN N
the DT N
extradural JJ N
group NN N
and CC N
were VBD N
significantly RB N
less JJR N
than IN N
in IN N
the DT N
opioid JJ N
group NN N
. . N

The DT N
perioperative JJ o
increase NN o
in IN o
cortisol NN o
was VBD N
similar JJ N
in IN N
the DT N
two CD N
groups NNS N
, , N
despite IN N
the DT N
differences NNS N
in IN N
ACTH NNP N
responses NNS N
. . N

Most JJS N
responses NNS N
returned VBN N
to TO N
the DT N
baseline NN N
values NNS N
within IN N
24 CD N
h. NN N
Plasma NNP o
bupivacaine NN o
concentrations NNS o
remained VBD N
within IN N
safe JJ N
limits NNS N
during IN N
the DT N
study NN N
, , N
but CC N
systemic JJ o
concentrations NNS o
increased VBD N
in IN N
some DT N
of IN N
the DT N
patients NNS N
during IN N
postoperative JJ N
infusion NN N
with IN N
0.125 CD N
% NN N
bupivacaine NN N
. . N

-DOCSTART- -1751081- O O

Is VBZ N
Na+ NNP i
modeling VBG i
necessary JJ N
in IN N
high JJ N
flux NN N
dialysis NN N
? . N
One CD N
important JJ N
pathogenic JJ N
factor NN N
in IN N
dialysis NN N
hypotension NN N
is VBZ N
the DT N
drop NN N
in IN N
plasma JJ N
osmolality NN N
. . N

Increasing VBG N
the DT N
dialysate NN N
Na+ NNP i
concentration NN N
decreases VBZ N
hypotensive JJ N
episodes NNS N
. . N

The DT N
authors NNS N
studied VBD N
39 CD p
patients NNS p
being VBG p
treated VBN p
with IN p
high JJ i
flux JJ i
dialysis NN i
. . i

During IN N
a DT N
9 CD N
week NN N
period NN N
, , N
the DT N
patients NNS N
were VBD N
on IN N
a DT N
standard JJ i
Na+ NNP i
dialysate NN i
( ( N
Na+ NNP N
= VBZ N
140 CD N
meq/L NN N
) ) N
basal NN N
period NN N
( ( N
B NNP N
) ) N
; : N
9 CD N
% NN N
( ( N
Na+ NNP N
= VBZ N
149 CD N
meq/L NN N
) ) N
linear NN i
( ( N
L NNP N
) ) N
; : N
step VBN N
drop NN N
( ( N
S NNP N
) ) N
; : N
and CC N
exponential JJ N
drop NN N
( ( N
E NNP N
) ) N
. . N

The DT N
Na+ NNP i
program NN i
was VBD N
changed VBN N
weekly RB N
at IN N
random NN N
. . N

The DT N
results NNS N
obtained VBD N
with IN N
the DT N
three CD N
Na+ NNP i
modeling VBG i
programs NNS N
were VBD N
similar JJ N
. . N

We PRP N
compared VBN N
the DT N
periods NNS N
with IN N
and CC N
without IN N
Na+ NNP i
modeling NN i
: : i
no DT N
differences NNS N
were VBD N
found VBN N
in IN N
weight NN o
gained VBN o
interdialysis NN o
, , o
mean JJ o
blood NN o
pressure NN o
predialysis NN o
and CC o
postdialysis NN o
, , o
and CC o
hemoconcentration NN o
. . o

Serum NNP o
Na+ NNP o
levels NNS o
were VBD N
significantly RB N
higher JJR N
predialysis NN N
and CC N
postdialysis NN N
for IN N
those DT N
patients NNS N
on IN N
Na+ NNP i
modeling VBG i
. . i

Hypotensive NNP o
episodes NNS o
and CC o
cramps NNS o
decreased VBD N
50 CD N
% NN N
with IN N
Na+ NNP i
modeling VBG i
. . i

The DT N
amount NN o
of IN o
hypertonic JJ o
and CC o
normal JJ o
saline NN o
given VBN N
during IN N
dialysis NN N
was VBD N
markedly RB N
reduced VBN N
. . N

Na+ NNP i
modeling VBG i
should MD N
always RB N
be VB N
used VBN N
in IN N
patients NNS p
being VBG p
maintained VBN p
on IN p
high JJ i
flux JJ i
dialysis NN i
. . i

-DOCSTART- -21445888- O O

Microbial JJ N
protein NN N
synthesis NN N
, , N
nitrogen JJ N
capture NN N
efficiency NN N
and CC N
nutrient JJ N
utilisation NN N
in IN N
sheep JJ p
fed NN p
on IN p
finger NN i
millet NN i
straw NN i
( ( i
Eleucine NNP i
coracana NN i
) ) i
-based VBD i
diet JJ p
with IN N
different JJ N
rumen-degradable JJ N
nitrogen NN N
levels NNS N
. . N

BACKGROUND NNP N
Microbial NNP N
protein NN N
synthesised VBD N
in IN N
the DT N
rumen NNS N
is VBZ N
a DT N
very RB N
important JJ N
protein NN N
source NN N
for IN N
ruminants NNS N
. . N

It PRP N
is VBZ N
essential JJ N
to TO N
provide VB N
an DT N
adequate JJ N
amount NN N
of IN N
rumen-degradable JJ N
nitrogen NN N
( ( N
RDN NNP N
) ) N
for IN N
optimum JJ N
microbial JJ N
protein NN N
synthesis NN N
in IN N
the DT N
rumen NNS N
on IN N
straw-based JJ N
diets NNS N
. . N

The DT N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
the DT N
RDN NNP N
requirement NN N
for IN N
optimum JJ N
microbial JJ N
protein NN N
synthesis NN N
( ( N
MPS NNP N
) ) N
, , N
nitrogen JJ N
capture NN N
efficiency NN N
( ( N
NCE NNP N
) ) N
and CC N
nutrient JJ N
utilisation NN N
in IN N
Nellore NNP p
rams NNS p
fed VBP p
on IN p
a DT p
finger NN i
millet NN i
straw NN i
( ( i
FMS NNP i
) ) i
-based VBD i
diet JJ i
. . i

RESULTS VB N
Thirty-six JJ p
Nellore NNP p
sheep NN p
were VBD N
randomly RB N
divided VBN N
into IN N
four CD N
groups NNS N
of IN N
nine CD N
animals NNS N
each DT N
using VBG N
a DT N
balanced VBN N
, , N
completely RB N
randomised JJ N
design NN N
. . N

The DT N
animals NNS N
in IN N
group NN N
1 CD N
( ( N
RDN0 NNP N
) ) N
were VBD N
fed VBN N
with IN N
ad NN i
libitum NN i
FMS NNP i
. . i

Those DT N
in IN N
groups NNS N
2 CD N
, , N
3 CD N
and CC N
4 CD N
( ( N
RDN1 NNP N
, , N
RDN2 NNP N
and CC N
RDN3 NNP N
) ) N
were VBD N
supplemented VBN N
with IN N
groundnut NNS i
cake VBP i
to TO N
provide VB N
RDN NNP o
levels NNS o
of IN N
14 CD N
, , N
18 CD N
and CC N
23 CD N
g NN N
RDN NNP N
kg?? NNP N
digestible JJ N
organic JJ N
matter NN N
intake NN N
( ( N
DOMI NNP N
) ) N
or CC N
21 CD N
, , N
27 CD N
and CC N
35 CD N
g NN N
RDN NNP N
kg?? NNP N
digestible JJ N
organic JJ N
matter NN N
apparently RB N
digested VBN N
in IN N
the DT N
rumen NNS N
( ( N
DOMR NNP N
) ) N
respectively RB N
along IN N
with IN i
FMS NNP o
. . o

The DT o
digestibility NN o
coefficients NNS o
of IN o
all DT o
nutrients NNS o
and CC o
MPS NNP o
increased VBD o
( ( o
P NNP o
< NNP o
0.05 CD N
) ) N
quadratically RB N
with IN N
increasing VBG o
level NN o
of IN o
RDN NNP o
supplementation NN o
. . o

NCE NNP o
decreased VBD o
linearly RB o
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
as IN N
the DT N
level NN N
of IN o
RDN NNP o
increased VBD o
. . o

CONCLUSION NNP o
The DT N
results NNS N
suggest VBP N
that IN N
12 CD N
g NNS N
RDN NNP N
kg?? VBP N
DOMI NNP N
or CC N
19 CD N
g NNS N
RDN NNP N
kg?? VBD N
DOMR NNP N
may MD N
be VB N
adequate JJ N
for IN N
optimum JJ N
MPS NNP N
, , N
NCE NNP N
and CC N
digestibility NN N
of IN N
nutrients NNS N
in IN N
sheep JJ p
fed NN p
on IN p
an DT i
FMS-based JJ i
diet NN i
. . i

-DOCSTART- -9419170- O O

The DT N
effect NN N
of IN N
valaciclovir NN i
on IN N
cytomegalovirus NN o
viremia NN o
and CC N
viruria NN N
detected VBN N
by IN N
polymerase NN N
chain NN N
reaction NN N
in IN N
patients NNS p
with IN p
advanced JJ p
human JJ p
immunodeficiency NN p
virus NN p
disease NN p
. . p

AIDS NNP N
Clinical JJ N
Trials NNP N
Group NNP N
Protocol NNP N
204/Glaxo CD N
Wellcome NNP N
123-014 JJ N
International NNP N
CMV NNP N
Prophylaxis NNP N
Study NNP N
Group NNP N
. . N

Samples NNP N
of IN N
blood NN N
and CC N
urine NN N
were VBD N
collected VBN N
at IN N
baseline NN N
, , N
week NN N
4 CD N
, , N
and CC N
week NN N
8 CD N
and CC N
then RB N
every DT N
8 CD N
weeks NNS N
from IN N
310 CD p
patients NNS p
entering VBG p
a DT p
controlled JJ p
trial NN p
of IN p
prophylaxis NN i
with IN p
valaciclovir JJ i
versus NN i
acyclovir NN i
. . i

Samples NNS N
were VBD N
tested VBN N
under IN N
code NN N
by IN N
polymerase NN i
chain NN i
reaction NN i
( ( N
PCR NNP N
) ) N
in IN N
one CD N
laboratory NN N
. . N

The DT N
median JJ N
number NN o
of IN o
samples NNS o
collected VBN N
from IN N
each DT N
patient NN N
was VBD N
5 CD N
for IN N
blood NN N
( ( N
range NN N
, , N
0-15 NN N
) ) N
and CC N
5 CD N
for IN N
urine NN N
( ( N
range NN N
, , N
0-15 NN N
) ) N
. . N

Both DT N
baseline JJ N
PCR NNP o
viremia NN o
and CC o
PCR NNP o
viruria NNS o
were VBD N
significantly RB N
associated VBN N
with IN N
future JJ N
cytomegalovirus NN N
( ( N
CMV NNP N
) ) N
disease NN N
( ( N
P NNP N
= NNP N
.002 NNP N
and CC N
P NNP N
= NNP N
.02 NNP N
, , N
respectively RB N
) ) N
. . N

The DT N
greatest JJS N
effect NN N
of IN N
valaciclovir NN i
on IN N
CMV NNP o
disease NN N
was VBD N
seen VBN N
in IN N
patients NNS N
who WP N
were VBD N
PCR-positive NNP N
in IN N
blood NN N
at IN N
baseline NN N
( ( N
P NNP N
= NNP N
.002 NNP N
) ) N
, , N
although IN N
a DT N
significant JJ N
effect NN N
was VBD N
also RB N
seen VBN N
in IN N
those DT N
who WP N
were VBD N
PCR-negative NNP N
in IN N
urine NN N
( ( N
P NNP N
= NNP N
.02 NNP N
) ) N
. . N

Thus RB N
, , N
PCR NNP o
viremia NNP o
provides VBZ N
prognostic JJ N
information NN N
about IN N
CMV NNP N
disease NN N
in IN N
AIDS NNP N
patients NNS N
, , N
and CC N
valaciclovir NN i
showed VBD N
activity NN N
as IN N
both DT N
a DT N
preemptive NN N
and CC N
prophylactic JJ N
agent NN N
. . N

-DOCSTART- -22485232- O O

Procalcitonin NNP i
is VBZ N
a DT N
good JJ N
tool NN N
to TO N
guide VB N
duration NN N
of IN N
antibiotic JJ i
therapy NN i
in IN N
patients NNS p
with IN p
severe JJ p
acute NN p
pancreatitis NN p
. . p

A DT N
randomized JJ N
prospective JJ N
single-center NN N
controlled VBN N
trial NN N
. . N

OBJECTIVE UH N
To TO N
investigate VB N
the DT N
clinical JJ N
usefulness NN N
of IN N
procalcitonin NN i
( ( N
PCT NNP N
) ) N
for IN N
guiding VBG N
duration NN N
of IN N
antibiotic JJ i
therapy NN i
in IN N
patients NNS p
with IN p
severe JJ p
acute NN p
pancreatitis NN p
( ( p
SAP NNP p
) ) p
. . p

METHODS CC N
A DT N
total NN N
of IN N
71 CD p
patients NNS p
with IN p
confirmed VBN p
severe JJ p
acute NN p
pancreatitis NN p
from IN p
March NNP p
2009 CD p
to TO p
September NNP p
2011 CD p
in IN p
the DT p
Department NNP p
of IN p
Critical NNP p
Care NNP p
Medicine NNP p
of IN p
Huizhou NNP p
Municipal NNP p
Central NNP p
Hospital NNP p
, , p
Guangdong NNP p
, , p
China NNP p
were VBD N
enrolled VBN N
in IN N
this DT N
study NN N
. . N

Procalcitonin NNP i
was VBD i
measured VBN i
daily RB i
by IN i
a DT i
semi-quantitative JJ i
immunoassay NN i
in IN i
the DT i
study NN i
group NN i
. . i

Patients NNS N
were VBD N
randomly RB N
assigned VBN N
into IN N
2 CD i
groups NNS i
including VBG i
a DT i
PCT-guided JJ i
group NN i
( ( i
study VB i
group NN i
) ) i
and CC i
a DT i
prophylactic JJ i
antibiotic JJ i
therapy NN i
( ( i
control VB i
group NN i
) ) i
. . N

Antibiotic JJ i
therapy NN i
in IN i
the DT i
study NN i
group NN i
was VBD i
not RB i
applied VBN i
until IN i
clinical JJ i
signs NNS i
and CC i
symptoms NNS i
of IN i
infection NN i
appeared VBN i
( ( i
PCT NNP i
value NN i
was VBD i
> JJ i
0.5ng/ml CD i
) ) i
. . N

We PRP N
discontinued VBD N
the DT N
antibiotic JJ N
therapy NN N
if IN N
clinical JJ N
signs NNS N
and CC N
symptoms NNS N
of IN N
infection NN N
improved VBN N
and CC N
PCT NNP N
was VBD N
< JJ N
0.5ng/ml CD N
over IN N
3 CD N
days NNS N
. . N

In IN N
the DT N
control NN N
group NN N
, , N
antibiotic JJ N
therapy NN N
was VBD N
administrated VBN N
for IN N
2 CD N
weeks NNS N
, , N
or CC N
antibiotic JJ i
therapy NN i
was VBD N
continued VBN N
because IN N
of IN N
confirmed JJ N
infection NN N
until IN N
clinical JJ N
signs NNS N
and CC N
symptoms NNS N
of IN N
infection NN N
disappeared VBD N
over IN N
3 CD N
days NNS N
. . N

RESULTS NNP N
In IN N
the DT N
study NN N
group NN N
( ( N
35 CD N
patients NNS N
) ) N
, , N
the DT N
duration NN o
of IN o
antibiotic JJ o
therapy NN o
and CC o
hospitalization NN o
was VBD N
significantly RB N
shorter JJR N
than IN N
the DT N
control NN N
group NN N
( ( N
36 CD N
patients NNS N
) ) N
( ( N
10.89+/-2.85 JJ N
versus NN N
16.06+/-2.48 JJ N
days NNS N
, , N
p VBP N
< JJ N
0.001 CD N
, , N
and CC N
16.66+/-4.02 JJ N
days NNS N
versus IN N
23.81+/-7.56 JJ N
days NNS N
, , N
p VBP N
< RB N
0.001 CD N
) ) N
without IN N
negative JJ o
clinical JJ o
effects NNS o
and CC N
the DT N
cost NN o
of IN o
hospitalization NN o
was VBD N
significantly RB N
lower JJR N
. . N

CONCLUSION NNP N
Procalcitonin NNP i
is VBZ N
a DT N
helpful JJ N
and CC N
safe JJ N
tool NN N
for IN N
guiding VBG N
duration NN N
of IN N
antibiotic JJ N
treatment NN N
in IN N
patients NNS p
with IN p
severe JJ p
acute NN p
pancreatitis NN p
. . p

-DOCSTART- -22917554- O O

Effectiveness NN N
and CC N
safety NN N
of IN N
inhaled JJ N
treprostinil NN i
for IN N
the DT N
treatment NN N
of IN N
pulmonary JJ p
arterial JJ p
hypertension NN p
in IN p
children NNS p
. . p

The DT N
introduction NN N
of IN N
prostanoid NN i
therapy NN i
has VBZ N
revolutionized VBN N
the DT N
treatment NN N
of IN N
pulmonary JJ N
arterial JJ N
hypertension NN N
( ( N
PAH NNP N
) ) N
. . N

However RB N
, , N
continuous JJ N
intravenous JJ N
prostacyclin NN i
infusion NN N
poses VBZ N
significant JJ N
risks NNS N
and CC N
challenges NNS N
, , N
particularly RB N
in IN N
children NNS p
. . p

Inhaled VBN N
treprostinil NN i
has VBZ N
been VBN N
shown VBN N
to TO N
be VB N
safe JJ N
and CC N
efficacious JJ N
in IN N
adults NNS N
. . N

This DT N
study NN N
describes VBZ N
the DT N
safety NN N
and CC N
efficacy NN N
of IN N
inhaled JJ N
treprostinil NN i
in IN N
children NNS p
with IN p
PAH NNP p
. . p

A NNP N
retrospective JJ N
analysis NN N
of IN N
29 CD p
children NNS p
treated VBN p
with IN p
inhaled JJ p
treprostinil NN i
for IN p
?6 JJ p
weeks NNS p
was VBD p
performed VBN p
. . p

Effects NNS N
of IN N
inhaled JJ i
treprostinil NN i
on IN i
exercise NN N
capacity NN N
, , N
functional JJ N
class NN N
, , N
and CC N
echocardiographic JJ N
and CC N
hemodynamic JJ N
data NNS N
were VBD N
evaluated VBN N
. . N

Adverse JJ N
events NNS N
were VBD N
documented VBN N
. . N

Patients NNS N
received VBD N
3 CD N
to TO N
9 CD N
breaths NNS N
( ( N
6 CD N
?g/breath NN N
) ) N
of IN N
inhaled VBN i
treprostinil NN i
4 CD i
times/day NN N
. . N

All DT N
were VBD N
receiving VBG i
background NN i
PAH NNP i
therapy NN i
; : i
12 CD i
had VBD N
previously RB N
received VBN N
parenteral JJ N
prostanoid NN N
. . N

Inhaled VBD i
treprostinil NN i
was VBD i
discontinued VBN N
in IN N
4 CD p
patients NNS p
because IN p
of IN N
symptoms NNS N
including VBG o
cough NN o
and CC o
bronchospasm NN o
( ( o
n JJ o
= NNP N
3 CD N
) ) N
and CC N
progression NN o
of IN o
PAH NNP o
( ( o
n JJ o
= NNP N
1 CD N
) ) N
. . N

Mild JJ o
side JJ o
effects NNS o
including VBG o
cough NN o
( ( o
n JJ o
= NNP N
9 CD N
) ) N
and CC N
sore $ o
throat NN o
( ( o
n JJ o
= NNP N
6 CD N
) ) N
did VBD N
not RB N
require VB N
discontinuation NN N
of IN N
therapy NN o
. . o

World NNP o
Health NNP o
Organization NNP o
functional JJ o
class NN o
improved VBN o
in IN N
19 CD N
and CC N
was VBD N
unchanged JJ N
in IN N
10 CD N
; : N
exercise NN o
capacity NN o
significantly RB o
improved VBN N
with IN N
the DT N
6-minute JJ N
walk NN N
distance NN N
, , N
improving VBG N
on IN N
follow-up NN N
from IN N
455.7 CD N
? . N
71.5 CD N
to TO N
498 CD N
? . N
70 CD N
m NN N
( ( N
p JJ N
= NNP N
0.01 CD N
) ) N
and CC o
peak JJ o
oxygen NN o
consumption NN o
increasing VBG o
from IN N
25.5 CD N
? . N
10.2 CD N
to TO N
27.4 CD N
? . N
10 CD N
( ( N
p NN N
= RB N
0.04 CD N
) ) N
. . N

In IN N
conclusion NN N
, , N
inhaled VBD N
treprostinil NN N
was VBD N
associated VBN N
with IN N
improvement NN o
in IN o
exercise NN o
capacity NN o
and CC o
World NNP o
Health NNP o
Organization NNP o
functional JJ o
class NN o
when WRB N
added VBD N
to TO N
background VB N
targeted JJ p
PAH NNP p
therapy NN p
in IN p
children NNS p
and CC p
had VBD p
an DT N
acceptable JJ N
safety NN N
profile NN N
. . N

Based VBN N
on IN N
these DT N
early JJ N
data NNS N
, , N
further JJ N
study NN N
of IN N
inhaled JJ N
treprostinil NN i
appears VBZ i
warranted VBN p
in IN p
pediatric JJ p
patients NNS p
with IN p
PAH NNP p
. . p

-DOCSTART- -16522696- O O

Efficacy NN o
and CC o
safety NN o
of IN N
oral JJ i
conivaptan NN i
: : i
a DT N
V1A/V2 NNP i
vasopressin NN i
receptor NN i
antagonist NN i
, , N
assessed VBN N
in IN N
a DT N
randomized JJ N
, , N
placebo-controlled JJ i
trial NN N
in IN N
patients NNS p
with IN p
euvolemic JJ p
or CC p
hypervolemic JJ p
hyponatremia NN p
. . p

CONTEXT NNP N
Hyponatremia NNP N
[ NNP N
serum NN N
sodium NN N
concentration NN N
( ( N
[ JJ N
Na NNP N
( ( N
+ NNP N
) ) N
] NN N
) ) N
, , N
< $ N
135 CD N
mEq/liter NN N
] NN N
is VBZ N
the DT N
most RBS N
common JJ N
fluid NN N
and CC N
electrolyte JJ N
abnormality NN p
among IN p
hospitalized JJ p
patients NNS p
. . p

It PRP N
is VBZ N
frequently RB N
caused VBN N
by IN N
the DT N
inappropriate JJ N
release NN N
of IN N
arginine JJ N
vasopressin NN N
. . N

OBJECTIVE CC N
The DT N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
efficacy NN o
and CC o
safety NN o
of IN N
oral JJ i
conivaptan NN i
, , i
a DT i
vasopressin NN i
V NNP i
( ( i
1A CD i
) ) i
/V NN i
( ( i
2 CD i
) ) i
receptor NN i
antagonist NN i
, , N
in IN N
patients NNS p
with IN p
euvolemic JJ p
or CC p
hypervolemic JJ p
hyponatremia NN p
. . p

DESIGN VB N
The DT N
study NN N
design NN N
was VBD N
a DT N
5-d JJ N
placebo-controlled JJ i
, , N
randomized VBN N
, , N
double-blind JJ N
study NN N
. . N

SETTING CC N
The DT N
study NN N
was VBD N
performed VBN N
at IN p
a DT p
hospital NN p
. . p

INTERVENTION NNP N
Oral NNP i
conivaptan NN i
( ( N
40 CD N
or CC N
80 CD N
mg/d NN N
) ) N
or CC N
placebo NN i
was VBD N
given VBN N
in IN N
two CD N
divided JJ N
doses NNS N
. . N

PATIENTS VB N
Seventy-four JJ p
patients NNS p
( ( p
average JJ p
baseline NN p
serum NN p
[ NNP p
Na NNP p
( ( p
+ NNP p
) ) p
] NN p
, , p
115 CD p
to TO p
< VB p
130 CD p
mEq/liter NN p
) ) p
were VBD p
studied VBN p
. . p

MAIN NNP N
OUTCOME NNP N
MEASURE NNP N
The DT N
main JJ N
outcome NN N
measure NN N
was VBD o
the DT o
change NN o
from IN o
baseline NN o
in IN o
serum NN o
[ NN o
Na NNP o
( ( o
+ NNP o
) ) o
] VBP o
area NN o
under IN o
the DT o
curve NN o
. . o

RESULTS VB N
The DT N
least-squares JJ N
mean JJ o
change NN N
from IN N
baseline NN N
in IN N
the DT N
serum NN N
[ NNP N
Na NNP N
( ( N
+ NNP N
) ) N
] VBP N
area NN N
under IN N
the DT N
curve NN N
with IN N
conivaptan NN i
( ( N
40 CD N
and CC N
80 CD N
mg/d NN N
) ) N
was VBD N
2.0-fold JJ N
( ( N
P NNP N
= NNP N
0.03 CD N
) ) N
and CC N
2.5-fold JJ N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
greater JJR N
, , N
respectively RB N
, , N
than IN N
that DT N
with IN N
placebo NN i
. . i

The DT N
median JJ N
time NN N
to TO N
achieve VB N
a DT N
confirmed JJ N
increase NN N
in IN N
serum JJ o
[ NNP N
Na NNP N
( ( N
+ NNP N
) ) N
] NN N
of IN N
4 CD N
mEq/liter NN N
or CC N
more JJR N
from IN N
baseline NN N
was VBD N
71.7 CD N
h NN N
for IN N
placebo NN i
, , N
27.5 CD N
h NN N
for IN N
40 CD N
mg/d NNS N
conivaptan NN i
( ( N
P NNP N
= NNP N
0.044 CD N
) ) N
, , N
and CC N
12.1 CD N
h NN N
for IN N
80 CD N
mg/d NNS N
conivaptan NN i
( ( N
P NNP N
= NNP N
0.002 CD N
) ) N
. . N

The DT N
mean JJ N
total JJ N
times NNS N
during IN N
which WDT N
patients NNS N
had VBD N
a DT N
serum NN o
[ NN o
Na NNP o
( ( o
+ NNP o
) ) o
] VBP o
level NN N
of IN N
4 CD N
mEq/liter NN N
or CC N
more JJR N
above IN N
baseline NN N
were VBD N
46.5 CD N
, , N
69.8 CD N
, , N
and CC N
88.8 CD N
h NN N
( ( N
P NNP N
= NNP N
0.001 CD N
) ) N
, , N
respectively RB N
. . N

The DT N
least-squares JJ N
mean NN o
change NN o
in IN o
serum NN o
[ NN o
Na NNP o
( ( o
+ NNP o
) ) o
] VBP o
from IN N
baseline NN N
to TO N
end VB N
of IN N
treatment NN N
was VBD N
3.4 CD N
mEq/liter NN N
for IN N
placebo NN i
, , N
6.4 CD N
mEq/liter NN N
for IN N
40 CD N
mg/d NN N
conivaptan NN i
, , N
and CC N
8.2 CD N
mEq/liter NN N
for IN N
80 CD N
mg/d NNS N
conivaptan NN i
( ( N
P NNP N
= NNP N
0.002 CD N
) ) N
. . N

A DT N
confirmed JJ N
normal JJ o
serum NN o
[ NNP o
Na NNP o
( ( o
+ NNP o
) ) o
] NN o
( ( N
> JJ N
/=135 NNP N
mEq/liter NN N
) ) N
or CC N
increase NN N
of IN N
6 CD N
mEq/liter NN N
or CC N
more JJR N
was VBD N
observed VBN N
in IN N
48 CD N
% NN N
of IN N
patients NNS N
given VBN N
placebo NNS i
, , N
71 CD N
% NN N
given VBN N
40 CD N
mg/d JJ N
conivaptan NN i
, , N
and CC N
82 CD N
% NN N
given VBN N
80 CD N
mg/d JJ N
conivaptan NN i
( ( N
P NNP N
= NNP N
0.014 CD N
) ) N
. . N

Headache NNP o
, , o
hypotension NN o
, , o
nausea NN o
, , o
constipation NN o
, , o
and CC o
postural JJ o
hypotension NN o
were VBD N
the DT N
most RBS N
common JJ N
adverse JJ N
events NNS N
. . N

CONCLUSION NNP N
Oral NNP i
conivaptan NN i
( ( N
40 CD N
and CC N
80 CD N
mg/d NN N
) ) N
was VBD N
well RB N
tolerated VBN N
and CC N
efficacious JJ N
in IN N
correcting VBG N
serum NN N
[ NNP N
Na NNP N
( ( N
+ NNP N
) ) N
] NN N
in IN N
hyponatremia NN N
. . N

-DOCSTART- -6753858- O O

Comparative JJ o
efficacy NN o
and CC o
safety NN o
of IN N
lofexidine NN i
and CC i
clonidine VB i
given VBN N
alone RB N
or CC N
concomitantly RB N
with IN N
hydrochlorothiazide NN i
in IN N
hypertensive JJ p
outpatients NNS p
. . p

-DOCSTART- -3931144- O O

Drug NN N
preference NN N
in IN N
normal JJ p
volunteers NNS p
: : p
effects NNS N
of IN N
age NN N
and CC N
time NN N
of IN N
day NN N
. . N

These DT N
experiments NNS N
assessed VBD N
the DT N
influence NN N
of IN N
two CD N
variables NNS N
, , N
age NN N
of IN N
subjects NNS N
and CC N
time NN N
of IN N
drug NN N
administration NN N
, , N
on IN N
the DT N
reinforcing VBG N
properties NNS N
of IN N
amphetamine NN i
and CC N
of IN N
diazepam NN i
in IN N
normal JJ N
volunteers NNS N
. . N

Three CD p
groups NNS p
of IN p
subjects NNS p
were VBD p
tested VBN p
: : p
i NN p
) ) p
a DT p
group NN p
of IN p
40-55-year-old JJ p
subjects NNS p
( ( p
AGE NNP p
group NN p
; : p
N NNP p
= NNP p
11 CD p
) ) p
who WP p
were VBD p
tested VBN p
in IN p
the DT p
morning NN p
, , p
ii NN p
) ) p
a DT p
group NN p
of IN p
21-35-year-old JJ p
subjects NNS p
( ( p
CTL NNP p
group NN p
; : p
N NNP p
= NNP p
12 CD p
) ) p
who WP p
were VBD p
also RB p
tested VBN p
in IN p
the DT p
morning NN p
, , p
and CC p
iii NN p
) ) p
a DT p
group NN p
of IN p
21-35-year-olds NNS p
who WP p
were VBD p
tested VBN p
in IN p
the DT p
late JJ p
afternoon NN p
( ( p
AFT NNP p
group NN p
; : p
N NNP p
= NNP p
13 CD p
) ) p
. . p

All DT N
subjects NNS N
participated VBN N
in IN N
three CD N
separate JJ N
experiments NNS N
comparing VBG N
one CD N
drug NN N
( ( N
5 CD N
mg NN N
d NN i
, , i
l-amphetamine JJ i
, , N
5 CD N
mg NN N
diazepam NN i
or CC N
10 CD N
mg NNS N
diazepam RB i
) ) i
to TO N
placebo VB i
. . i

Each DT N
experiment NN N
consisted VBN N
of IN N
nine CD N
sessions NNS N
: : N
On IN N
the DT N
first JJ N
four CD N
sessions NNS N
subjects NNS N
sampled VBD N
two CD N
color-coded JJ N
capsules NNS N
on IN N
alternate JJ N
sessions NNS N
and CC N
on IN N
the DT N
following JJ N
five CD N
sessions NNS N
they PRP N
chose VBD N
and CC N
ingested VBD N
the DT N
capsule NN N
they PRP N
preferred VBD N
. . N

Subjective JJ N
effects NNS N
of IN N
the DT N
drugs NNS N
were VBD N
monitored VBN N
using VBG N
the DT N
Profile NNP o
of IN o
Mood NNP o
States NNPS o
( ( o
POMS NNP o
) ) o
and CC o
a DT o
shortened JJ o
version NN o
of IN o
the DT o
Addiction NNP o
Research NNP o
Center NNP o
Inventory NNP o
( ( o
ARCI NNP o
) ) o
. . o

Subjects NNS N
in IN N
all DT N
three CD N
groups NNS N
chose VBD N
5 CD N
mg NN N
diazepam NN i
as RB N
often RB N
as IN N
placebo NNS N
but CC N
preferred JJ N
placebo NN i
to TO N
10 CD N
mg NN N
diazepam NN i
. . i

In IN N
contrast NN N
, , N
they PRP N
chose VBD N
amphetamine NN i
either CC N
as RB N
often RB N
as IN N
or CC N
more RBR N
often RB N
than IN N
placebo NNS i
. . i

The DT N
subjective JJ N
effects NNS N
of IN N
diazepam NN i
( ( N
i.e JJ N
. . N

sedation NN N
) ) N
were VBD N
similar JJ N
across IN N
all DT N
three CD N
groups NNS N
, , N
but CC N
after IN N
amphetamine VBP N
the DT N
AGE NNP N
group NN N
showed VBD N
greater JJR N
stimulant JJ N
effects NNS N
. . N

In IN N
addition NN N
, , N
the DT N
AFT NNP N
group NN N
showed VBD N
fewer JJR N
positive JJ N
mood NN N
effects NNS N
after IN N
amphetamine NN N
than IN N
the DT N
CTL NNP N
group NN N
. . N

( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
250 CD N
WORDS NNP N
) ) N
-DOCSTART- -10338217- O O

Oral NNP N
and CC N
parenteral JJ N
glutamine NN i
in IN N
bone NN N
marrow NN N
transplantation NN N
: : N
a DT N
randomized JJ N
, , N
double-blind JJ N
study NN N
. . N

BACKGROUND NNP N
Total NNP i
parenteral JJ i
nutrition NN i
( ( i
TPN NNP i
) ) i
supplemented VBD i
with IN i
glutamine NN i
( ( i
GLN NNP i
) ) i
has VBZ N
been VBN N
reported VBN N
to TO N
be VB N
effective JJ N
for IN N
patients NNS p
with IN p
bone NN p
marrow NN p
transplantation NN p
( ( p
BMT NNP p
) ) p
. . p

Our PRP$ N
aim NN N
was VBD N
to TO N
evaluate VB N
enteral JJ N
and CC N
parenteral JJ N
glutamine NN N
in IN N
patients NNS p
undergoing JJ p
BMT NNP p
. . p

METHODS NNP N
For IN N
evaluation NN N
of IN N
GLN NNP N
in IN N
BMT NNP N
, , N
66 CD p
patients NNS p
with IN p
43 CD p
hematologic NNS p
and CC p
23 CD p
solid JJ p
malignancies NNS p
( ( p
21 CD p
breast NN p
carcinomas NN p
) ) p
, , N
were VBD N
randomized VBN N
, , N
double-blinded JJ N
, , N
to TO N
either DT N
oral JJ i
GLN NNP i
( ( N
n JJ N
= NNP N
35 CD N
) ) N
or CC N
glycine-control NN i
( ( N
GLY NNP N
) ) N
( ( N
n JJ N
= NNP N
31 CD N
) ) N
, , N
10 CD N
g NN N
three CD N
times NNS N
daily RB N
. . N

When WRB N
TPN NNP i
became VBD N
necessary JJ N
, , N
patients NNS N
who WP N
received VBD N
GLN NNP i
orally RB N
were VBD N
given VBN N
TPN NNP i
with IN i
GLN NNP i
( ( N
0.57 CD N
g/kg NN N
) ) N
. . N

Those DT N
who WP N
received VBD N
GLY NNP N
received VBD N
standard JJ N
TPN NNP i
, , N
isocaloric JJ N
and CC N
isonitrogenous JJ N
. . N

Patients NNS p
with IN p
hematologic JJ p
malignancies NNS p
received VBD N
high-dose JJ i
chemotherapy NN i
, , i
total JJ i
body NN i
irradiation NN i
, , i
and CC i
either DT i
allogeneic NN i
( ( i
ALLO NNP i
) ) i
BMT NNP i
( ( N
n JJ N
= NNP N
18 CD N
) ) N
or CC N
autologous JJ i
( ( i
AUTO NNP i
) ) i
stem NN i
cell NN i
transplantation NN i
( ( N
n JJ N
= NNP N
25 CD N
) ) N
. . N

Patients NNS p
with IN p
solid JJ p
malignancies NNS p
( ( p
n JJ p
= NNP p
23 CD p
) ) p
received VBD N
AUTO NNP i
. . i

RESULTS NNP N
There EX N
were VBD N
14 CD p
in-hospital JJ p
deaths NNS p
without IN p
relationship NN p
to TO p
GLN NNP p
administration NN p
. . p

For IN N
respective JJ N
comparisons NNS N
of IN N
ALLO NNP N
and CC N
AUTO NNP N
transplants NNS N
in IN N
the DT N
GLN NNP N
and CC N
GLY NNP N
hematologic VBP N
groups NNS N
and CC N
AUTO NNP N
in IN N
the DT N
solid JJ N
tumor NN N
groups NNS N
, , N
there EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
hospital NN o
stay NN o
, , o
duration NN o
of IN o
stay NN o
after IN o
BMT NNP o
, , o
TPN NNP o
days NNS o
, , o
neutrophil JJ o
recovery NN o
> NN o
500/mm3 CD o
, , o
incidence NN o
of IN o
positive JJ o
blood NN o
cultures NNS o
, , o
sepsis NN o
, , o
mucositis NN o
, , o
and CC o
diarrhea NN o
. . o

Acute NNP o
graft VBD o
us PRP o
host VB o
disease NN o
occurred VBD N
in IN N
1 CD p
of IN p
10 CD p
hematologic JJ p
patients NNS p
receiving VBG p
GLN NNP p
and CC N
in IN N
3 CD N
of IN N
8 CD N
patients NNS N
receiving VBG N
GLY NNP N
placebo NN N
( ( N
p JJ N
> NNP N
.05 NNP N
) ) N
. . N

Possible JJ N
reduction NN o
in IN o
need NN o
for IN o
TPN NNP o
and CC N
a DT N
suggestion NN N
of IN N
improved JJ o
long-term JJ o
survival NN o
were VBD N
associated VBN N
with IN N
GLN NNP N
. . N

CONCLUSIONS NNP N
Oral NNP N
and CC N
parenteral JJ N
GLN NNP i
seemed VBD N
to TO N
be VB N
of IN N
limited JJ N
benefit NN N
for IN N
patients NNS N
having VBG N
AUTO NNP N
or CC N
ALLO NNP N
BMT NNP N
for IN N
hematologic NN N
or CC N
solid JJ N
malignancies NNS N
. . N

Further NNP N
study NN N
of IN N
long-term JJ N
effects NNS N
of IN N
GLN NNP N
in IN N
BMT NNP N
seems VBZ N
warranted VBN N
. . N

-DOCSTART- -21430242- O O

Fecal JJ o
butyrate NN o
levels NNS o
vary VBP N
widely RB N
among IN N
individuals NNS N
but CC N
are VBP N
usually RB N
increased VBN N
by IN N
a DT N
diet JJ i
high JJ i
in IN i
resistant JJ i
starch NN i
. . i

Butyrate NNP N
and CC N
other JJ N
SCFA NNP N
produced VBN N
by IN N
bacterial JJ N
fermentation NN N
of IN N
resistant JJ i
starch NN i
( ( i
RS NNP i
) ) i
or CC N
nonstarch JJ i
polysaccharides NNS i
( ( i
NSP NNP i
) ) i
promote VBP N
human JJ o
colonic JJ o
health NN o
. . o

To TO N
examine VB N
variation NN N
in IN N
fecal JJ o
variables NNS o
, , N
especially RB N
butyrate JJ o
, , N
among IN N
individuals NNS N
and CC N
the DT N
response NN N
to TO N
these DT N
fibers NNS N
, , N
a DT N
randomized VBN N
cross-over NN N
study NN N
was VBD N
conducted VBN N
that IN N
compared VBN N
the DT N
effects NNS N
of IN N
foods NNS i
supplying VBG i
25 CD i
g NN i
of IN i
NSP NNP i
or CC i
25 CD i
g NN i
of IN i
NSP NNP i
plus CC i
22 CD i
g NN i
of IN i
RS/d NNP i
over IN N
4 CD N
wk NNS N
in IN N
46 CD p
healthy JJ p
adults NNS p
( ( p
16 CD p
males NNS p
, , p
30 CD p
females NNS p
; : p
age NN p
31-66 JJ p
y NN p
) ) p
. . p

Fecal JJ o
SCFA NNP o
levels NNS o
varied VBD p
widely RB p
among IN p
participants NNS p
at IN p
entry NN p
( ( p
butyrate JJ p
concentrations NNS p
: : p
3.5-32.6 JJ p
mmol/kg NN p
; : p
butyrate JJ p
excretions NNS p
: : p
0.3-18.2 JJ p
mmol/48 NN p
h NN p
) ) p
. . p

BMI NNP N
explained VBD N
27 CD N
% NN N
of IN N
inter-individual JJ N
butyrate NN N
variation NN N
, , N
whereas JJ N
protein NN N
, , N
starch NN N
, , N
carbohydrate NN N
, , N
fiber NN N
, , N
and CC N
fat JJ N
intake NN N
explained VBD N
up RB N
to TO N
16 CD N
, , N
6 CD N
, , N
2 CD N
, , N
4 CD N
, , N
and CC N
2 CD N
% NN N
of IN N
butyrate NN N
variation NN N
, , N
respectively RB N
. . N

Overall JJ N
, , N
acetate NN o
, , o
butyrate NN o
, , o
and CC o
total JJ o
SCFA NNP o
concentrations NNS o
were VBD N
higher JJR N
when WRB N
participants NNS N
consumed VBD N
RS NNP N
compared VBN N
with IN N
entry NN N
and CC N
NSP NNP i
diets NNS N
, , N
but CC N
individual JJ N
responses NNS N
varied VBD N
. . N

Individual NNP o
and CC o
total JJ o
fecal JJ o
SCFA NNP o
excretion NN o
, , o
weight NN o
, , o
and CC o
moisture NN o
were VBD N
higher JJR N
than IN N
those DT N
for IN N
habitual JJ N
diets NNS N
when WRB N
either DT N
fiber NN N
diet NN N
was VBD N
consumed VBN N
. . N

SCFA NNP o
concentrations NNS o
( ( o
except IN o
butyrate NN o
) ) o
and CC o
excretions NNS o
were VBD N
higher JJR N
for IN N
males NNS N
than IN N
for IN N
females NNS N
. . N

Butyrate NNP o
levels NNS o
increased VBD N
in IN N
response NN N
to TO N
RS NNP N
in IN N
most JJS N
individuals NNS N
but CC N
often RB N
decreased VBD N
when WRB N
entry NN N
levels NNS N
were VBD N
high JJ N
. . N

Fecal JJ o
butyrate NN o
and CC o
ammonia JJ o
excretions NNS o
were VBD N
positively RB N
associated VBN N
( ( N
( ( N
2 CD N
) ) N
= NN N
0.76 CD N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

In IN N
conclusion NN N
, , N
fecal JJ o
butyrate NN o
levels NNS o
vary VBP N
widely RB N
among IN N
individuals NNS N
but CC N
consuming VBG N
a DT N
diet JJ N
high JJ N
in IN N
RS NNP i
usually RB N
increases VBZ N
levels NNS N
and CC N
may MD N
help VB N
maintain VB N
colorectal JJ o
health NN o
. . o

-DOCSTART- -23754339- O O

Parent-based JJ i
sleep JJ i
education NN i
for IN N
children NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
. . p

This DT N
study NN N
provided VBD N
sleep JJ i
education NN i
to TO i
parents NNS i
of IN p
children NNS p
with IN p
autism NN p
spectrum NN p
disorder NN p
( ( p
ASD NNP p
) ) p
to TO N
determine VB N
whether IN N
an DT N
individual NN i
or CC N
group NN i
format NN i
was VBD N
more RBR N
effective JJ N
in IN N
improving VBG N
sleep NN o
and CC N
aspects NNS N
of IN N
daytime JJ o
behavior NN o
and CC N
family NN o
functioning NN o
. . o

Eighty NNP p
children NNS p
, , p
ages VBZ p
2-10 CD p
years NNS p
, , p
with IN p
ASD NNP p
and CC p
sleep JJ p
onset NN p
delay NN p
completed VBD p
the DT p
study NN p
. . p

Actigraphy NN N
and CC N
parent NN N
questionnaires NNS N
were VBD N
collected VBN N
at IN N
baseline NN N
and CC N
1 CD N
month NN N
after IN N
treatment NN N
. . N

Mode NNP N
of IN N
education NN N
did VBD N
not RB N
affect VB N
outcomes NNS o
. . o

Sleep NNP o
latency NN o
, , o
insomnia NN o
subscales NNS o
on IN o
the DT o
Children NNP o
's POS o
Sleep NNP o
Habits NNP o
Questionnaire NNP o
, , o
and CC N
other JJ o
outcomes NNS o
related VBN o
to TO o
child VB o
and CC o
family NN o
functioning VBG o
improved VBN o
with IN N
treatment NN N
. . N

Parent-based JJ N
sleep JJ N
education NN N
, , N
delivered VBN N
in IN N
relatively RB N
few JJ N
sessions NNS N
, , N
was VBD N
associated VBN N
with IN N
improved JJ o
sleep JJ o
onset NN o
delay NN o
in IN o
children NNS N
with IN N
ASD NNP p
. . p

Group NNP N
versus VBD N
individualized JJ N
education NN N
did VBD N
not RB N
affect VB N
outcome NN N
. . N

-DOCSTART- -17998493- O O

Short-course JJ N
nitrofurantoin NN i
for IN N
the DT N
treatment NN N
of IN N
acute NN p
uncomplicated JJ p
cystitis NN p
in IN p
women NNS p
. . p

BACKGROUND NNP N
There EX N
is VBZ N
a DT N
paucity NN N
of IN N
data NNS N
on IN N
the DT N
efficacy NN N
of IN N
nitrofurantoin NN i
for IN N
the DT N
treatment NN N
of IN N
acute NN N
uncomplicated JJ N
cystitis NN N
in IN N
regimens NNS N
shorter JJR N
than IN N
7 CD N
days NNS N
. . N

Evidence-based JJ N
use NN N
of IN N
this DT N
drug NN N
is VBZ N
increasingly RB N
important JJ N
as IN N
trimethoprim-sulfamethoxazole JJ i
resistance NN N
among IN N
uropathogens JJ N
increases NNS N
. . N

METHODS NNP N
To TO N
assess VB N
the DT N
efficacy NN N
of IN N
nitrofurantoin JJ i
vs JJ N
trimethoprim-sulfamethoxazole NN i
, , N
338 CD p
women NNS p
aged VBD p
18 CD p
to TO p
45 CD p
years NNS p
with IN p
acute NN p
uncomplicated JJ p
cystitis NN p
were VBD N
randomized VBN N
to TO N
open-label JJ N
treatment NN N
with IN N
either DT N
trimethoprim-sulfamethoxazole JJ i
, , i
1 CD i
double-strength JJ i
tablet NN i
twice RB i
daily RB i
for IN i
3 CD i
days NNS i
, , i
or CC i
nitrofurantoin RB i
, , i
100 CD i
mg NN i
twice RB i
daily RB i
for IN i
5 CD i
days NNS i
. . i

Clinical JJ o
cure NN o
30 CD o
days NNS o
after IN o
therapy NN o
was VBD N
the DT N
main JJ N
outcome NN N
measure NN N
. . N

Secondary JJ N
outcomes NNS N
included VBD N
clinical JJ o
and CC o
microbiological JJ o
cure NN o
rates NNS o
5 CD N
to TO N
9 CD N
days NNS N
after IN N
therapy NN N
and CC N
, , N
for IN N
trimethoprim-sulfamethoxazole-treated JJ i
women NNS N
, , N
clinical JJ o
cure NN o
stratified VBN N
by IN N
the DT N
trimethoprim-sulfamethoxazole JJ i
susceptibility NN N
of IN N
the DT N
uropathogen NN N
. . N

RESULTS NNP N
Clinical JJ o
cure NN o
was VBD N
achieved VBN N
in IN N
79 CD N
% NN N
of IN N
the DT N
trimethoprim-sulfamethoxazole JJ N
group NN N
and CC N
in IN N
84 CD N
% NN N
of IN N
the DT N
nitrofurantoin NN N
group NN N
, , N
for IN N
a DT N
difference NN N
of IN N
-5 NN N
% NN N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
-13 CD N
% NN N
to TO N
4 CD N
% NN N
) ) N
. . N

Clinical JJ o
and CC o
microbiological JJ o
cure NN o
rates NNS o
at IN N
the DT N
first JJ N
follow-up JJ N
visit NN N
were VBD N
also RB N
equivalent JJ N
between IN N
the DT N
2 CD N
groups NNS N
. . N

In IN N
the DT N
trimethoprim-sulfamethoxazole JJ i
arm NN N
, , N
7 CD N
of IN N
17 CD N
women NNS N
( ( N
41 CD N
% NN N
) ) N
with IN N
a DT N
trimethoprim-sulfamethoxazole-nonsusceptible JJ N
isolate NN N
had VBD N
a DT N
clinical JJ o
cure NN o
compared VBN N
with IN N
84 CD N
% NN N
of IN N
women NNS N
with IN N
a DT N
trimethoprim-sulfamethoxazole-susceptible JJ N
isolate NN N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

CONCLUSION VB N
A DT N
5-day JJ N
course NN N
of IN N
nitrofurantoin NN N
is VBZ N
equivalent JJ N
clinically RB N
and CC N
microbiologically RB N
to TO N
a DT N
3-day JJ N
course NN N
of IN N
trimethoprim-sulfamethoxazole JJ N
and CC N
should MD N
be VB N
considered VBN N
an DT N
effective JJ N
fluoroquinolone-sparing JJ N
alternative NN N
for IN N
the DT N
treatment NN N
of IN N
acute JJ p
cystitis NN p
in IN p
women NNS p
. . p

-DOCSTART- -18248651- O O

The DT N
impact NN N
of IN N
fasting VBG i
and CC i
treatment NN i
omission NN i
on IN N
susceptibility NN o
to TO o
hypoglycaemia VB o
in IN N
children NNS p
and CC p
adolescents NNS p
with IN p
GH NNP p
and CC p
cortisol JJ p
insufficiency NN p
. . p

OBJECTIVE NNP N
Hypoglycaemia NNP N
may MD N
be VB N
a DT N
frequent JJ N
occurrence NN N
in IN N
young JJ p
GH NNP p
deficient NN p
patients NNS p
and CC N
so RB N
we PRP N
studied VBD N
the DT N
response NN N
to TO N
fasting VBG N
in IN N
children NNS p
and CC p
adolescents NNS p
with IN p
GH NNP p
and/or VBP p
cortisol JJ p
deficiency NN p
. . p

METHODS NNP N
A NNP p
total NN p
of IN p
20 CD p
patients NNS p
( ( p
2-18 CD p
years NNS p
) ) p
fasted VBD i
for IN p
14 CD p
h NN p
( ( p
22.00-12.00 JJ p
h NN p
) ) p
on IN p
two CD p
occasions NNS p
as IN N
part NN N
of IN N
a DT N
randomized JJ N
cross-over NN N
study NN N
. . N

Fourteen NNP p
had VBD p
pituitary JJ p
hormone NN p
deficiency NN p
( ( p
PHD NNP p
) ) p
including VBG p
GH NNP p
deficiency NN p
( ( p
GHD NNP p
) ) p
. . p

Of IN p
the DT p
14 CD p
patients NNS p
, , p
seven CD p
were VBD p
ACTH NNP p
sufficient NN p
( ( p
PHDC+ NNP p
) ) p
and CC p
seven CD p
ACTH NNP p
deficient NN p
( ( p
PHDC- NNP p
) ) p
. . p

Six NNP p
had VBD p
primary JJ p
adrenal JJ p
failure NN p
( ( p
PAF NNP p
) ) p
. . p

Subjects NNPS N
administered VBD N
or CC N
omitted VBD i
their PRP$ N
normal JJ i
dose NN i
of IN i
evening VBG i
GH NNP i
and/or NN i
morning NN i
hydrocortisone NN i
. . i

Glucose NNP o
, , o
insulin NN o
, , o
GH NNP o
, , o
cortisol NN o
, , o
ketones NNS o
and CC o
catecholamines NNS o
were VBD N
measured VBN N
at IN N
04.00 CD N
h NN N
and CC N
regularly RB N
from IN N
07.00 CD N
to TO N
12.00 CD N
h. NNS N
Insulin NNP o
sensitivity NN o
was VBD N
assessed VBN N
by IN N
HOMA NNP o
and CC N
hypoglycaemia NN o
defined VBN N
as IN N
a DT N
blood NN o
glucose NN o
( ( N
BG NNP N
) ) N
< VBD N
/= $ N
3.3 CD N
mmol/l NN N
. . N

RESULTS NNP N
BG NNP N
was VBD N
related VBN N
to TO N
age NN o
and CC o
body NN o
mass NN o
index NN o
on IN N
treatment NN N
but CC N
no DT N
subject NN N
became VBD N
hypoglycaemic JJ N
on IN N
or CC N
off IN N
therapy NN N
prior RB N
to TO N
07.00 CD N
h. NN N
Five CD N
children NNS N
( ( N
aged VBN N
3 CD N
, , N
4 CD N
, , N
7 CD N
, , N
8 CD N
and CC N
11 CD N
years NNS N
) ) N
were VBD N
hypoglycaemic JJ o
between IN N
07.00 CD N
and CC N
12.00 CD N
h NNS N
off IN N
treatment NN N
. . N

There EX N
was VBD N
a DT N
positive JJ N
relationship NN N
between IN N
GH NNP o
AUC NNP o
and CC o
minimum JJ o
BG NNP o
in IN N
patients NNS N
with IN N
PHD NNP N
on IN N
treatment NN N
( ( N
r NN N
( ( N
2 CD N
) ) N
= NN N
0.45 CD N
, , N
P NNP N
= NNP N
0.012 CD N
) ) N
with IN N
increased VBN N
insulin NN o
sensitivity NN o
off IN N
treatment NN N
. . N

Increased VBN o
cortisol NN o
levels NNS o
were VBD N
seen VBN N
in IN N
PHDC+ NNP N
patients NNS N
off RP N
GH NNP N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

A DT N
negative JJ N
relationship NN N
was VBD N
observed VBN N
between IN N
minimum JJ N
BG NNP o
and CC o
adrenaline NN o
( ( N
r NN N
( ( N
2 CD N
) ) N
= NN N
0.37 CD N
, , N
P NNP N
= NNP N
0.01 CD N
) ) N
, , N
ketone JJ o
bodies NNS o
( ( N
r NN N
( ( N
2 CD N
) ) N
= NN N
-0.20 NN N
, , N
P NNP N
= NNP N
0.05 CD N
) ) N
and CC N
NEFA NNP o
( ( N
r NN N
( ( N
2 CD N
) ) N
= NN N
-0.35 NN N
, , N
P NNP N
= NNP N
0.02 CD N
) ) N
. . N

Noradrenaline JJ o
levels NNS o
were VBD N
reduced VBN N
in IN N
patients NNS p
with IN p
PHDC- NNP p
. . p

Low NNP N
BMI NNP o
( ( N
on IN N
treatment NN N
) ) N
and CC N
young JJ N
age NN N
( ( N
off IN N
treatment NN N
) ) N
were VBD N
determinants NNS N
of IN N
low JJ o
BG NNP o
levels NNS o
in IN N
a DT N
multiple JJ N
regression NN N
model NN N
. . N

CONCLUSIONS NNP N
Unrecognized NNP N
overnight VBD N
hypoglycaemia NN N
in IN N
children NNS p
and CC p
adolescents NNS p
on IN N
pituitary JJ N
hormone NN N
replacement NN N
is VBZ N
uncommon JJ N
but CC N
BG NNP o
levels NNS o
quickly RB N
become VBP N
abnormal JJ N
when WRB N
treatment NN N
and CC N
meals NNS N
are VBP N
omitted VBN i
. . i

The DT N
insulin NN o
antagonistic JJ o
actions NNS o
of IN o
GH NNP o
are VBP N
important JJ N
in IN N
preventing VBG N
hypoglycaemia NN N
. . N

Patients NNS p
with IN p
PHD NNP p
have VBP N
altered VBN N
sympathetic JJ o
nerve NN o
activity NN o
. . o

-DOCSTART- -1575174- O O

Effectiveness NN o
of IN N
once-daily JJ i
monotherapy NN i
with IN N
a DT N
new JJ N
nifedipine NN N
sustained VBN N
release NN N
calcium NN N
antagonist NN N
. . N

Data NNS N
from IN N
2 CD p
separate JJ p
multicenter NN p
, , N
double-blind JJ N
clinical JJ N
studies NNS N
following VBG N
the DT N
same JJ N
protocol NN N
, , N
except IN N
for IN N
the DT N
selection NN N
of IN N
doses NNS N
, , N
were VBD N
pooled VBN N
to TO N
evaluate VB N
the DT N
efficacy NN o
and CC o
tolerability NN o
of IN N
fixed JJ N
doses NNS N
of IN N
a DT N
new JJ i
sustained-release NN i
( ( i
SR NNP i
) ) i
formulation NN i
of IN i
nifedipine JJ i
compared VBN N
with IN N
placebo NN i
in IN N
388 CD p
patients NNS p
with IN p
mild JJ p
to TO p
moderate VB p
uncomplicated JJ p
essential JJ p
hypertension NN p
. . p

After IN N
a DT N
3-6 JJ N
week NN N
placebo NN N
washout IN N
period NN N
, , N
the DT N
patients NNS N
were VBD N
randomized VBN N
to TO N
receive VB N
either DT N
placebo NN i
or CC i
nifedipine JJ i
SR-20 JJ N
mg NN N
( ( N
study NN N
I PRP N
only RB N
) ) N
, , N
50 CD N
mg NN N
, , N
100 CD N
mg NN N
, , N
or CC N
150 CD N
mg NN N
( ( N
study VB N
II NNP N
only RB N
) ) N
. . N

Among IN N
the DT N
278 CD N
patients NNS N
who WP N
completed VBD N
6 CD N
weeks NNS N
of IN N
active JJ N
therapy NN N
, , N
mean JJ o
supine VBP o
diastolic JJ o
blood NN o
pressure NN o
reductions NNS o
from IN N
pretreatment JJ N
baseline NN N
were VBD N
5.9 CD N
, , N
9.3 CD N
, , N
9.2 CD N
, , N
11.1 CD N
, , N
and CC N
13.2 CD N
mm NN N
Hg NNP N
in IN N
the DT N
placebo NN N
, , N
20- JJ N
, , N
50- JJ N
, , N
100- JJ N
, , N
and CC N
150-mg JJ N
groups NNS N
, , N
respectively RB N
. . N

The DT N
reductions NNS N
achieved VBN N
in IN N
each DT N
of IN N
the DT N
nifedipine JJ i
SR NNP N
groups NNS N
were VBD N
statistically RB N
significant JJ N
versus NN N
baseline NN N
values NNS N
( ( N
p NN N
less JJR N
than IN N
0.001 CD N
) ) N
. . N

All DT N
nifedipine-SR JJ N
doses NNS N
reduced VBN o
supine JJ o
systolic JJ o
blood NN o
pressure NN o
significantly RB N
more RBR N
than IN N
placebo NN i
( ( N
p NN N
less JJR N
than IN N
0.001 CD N
) ) N
. . N

In IN N
addition NN N
, , N
there EX N
was VBD N
a DT N
significant JJ N
linear JJ N
relationship NN N
between IN N
the DT N
log NN o
of IN o
the DT o
dose NN o
and CC N
the DT N
blood NN o
pressure NN o
reduction NN o
( ( N
p NN N
less JJR N
than IN N
0.05 CD N
) ) N
. . N

Automated VBN o
ambulatory JJ o
blood NN o
pressure NN o
recordings NNS o
performed VBN N
in IN N
221 CD N
of IN N
the DT N
patients NNS N
showed VBD N
that IN N
the DT N
blood NN o
pressure NN o
was VBD o
lowered VBN o
evenly RB N
through IN N
the DT N
entire JJ N
24-hour JJ N
dosing NN N
period NN N
. . N

The DT N
doses NNS N
that WDT N
were VBD N
effective JJ N
and CC N
associated VBN N
with IN N
the DT N
fewest JJS N
adverse JJ N
reactions NNS N
were VBD N
20 CD N
mg NNS N
and CC N
50 CD N
mg NN N
once RB N
daily RB N
. . N

-DOCSTART- -20332358- O O

The DT N
role NN N
of IN N
adjunctive JJ i
exenatide NN i
therapy NN i
in IN N
pediatric JJ p
type NN p
1 CD p
diabetes NNS p
. . p

OBJECTIVE NNP N
Exenatide NNP i
improves VBZ N
postprandial JJ N
glycemic JJ o
excursions NNS o
in IN N
type NN N
2 CD N
diabetes NNS N
. . N

Exenatide NNP i
could MD N
benefit VB N
type JJ N
1 CD N
diabetes NNS N
as RB N
well RB N
. . N

We PRP N
aimed VBD N
to TO N
determine VB N
an DT N
effective JJ N
and CC N
safe JJ N
glucose-lowering NN o
adjuvant JJ N
exenatide NN N
dose NN N
in IN N
adolescents NNS p
with IN p
type JJ p
1 CD p
diabetes NNS p
. . p

RESEARCH NNP N
DESIGN NNP N
AND NNP N
METHODS NNP N
Eight NNP p
subjects NNS p
completed VBD N
a DT N
three-part JJ N
double-blinded JJ N
randomized VBN N
controlled VBN N
study NN N
of IN N
premeal JJ N
exenatide NN i
. . i

Two CD i
doses NNS i
of IN i
exenatide NN i
( ( i
1.25 CD i
and CC i
2.5 CD i
microg NN i
) ) i
were VBD i
compared VBN i
with IN i
insulin NN i
monotherapy NN i
. . i

Prandial JJ N
insulin NN i
dose NN N
was VBD N
reduced VBN N
by IN N
20 CD N
% NN N
. . N

Gastric NNP N
emptying VBG N
and CC N
hormones NNS N
were VBD N
analyzed VBN N
for IN N
300 CD N
min JJ N
postmeal NN N
. . N

RESULTS NNP N
Treatment NNP N
with IN N
both DT N
doses NNS N
of IN N
exenatide JJ i
versus NN N
insulin NN i
monotherapy NN i
significantly RB N
reduced VBD o
glucose JJ o
excursions NNS o
over IN N
300 CD N
min NNS N
( ( N
P NNP N
< NNP N
0.0001 CD N
) ) N
. . N

Exenatide NNP i
administration NN N
failed VBD o
to TO o
suppress VB o
glucagon NN o
but CC o
delayed VBD o
gastric JJ o
emptying NN o
( ( N
P NNP N
< NNP N
0.004 CD N
) ) N
. . N

CONCLUSIONS NNP N
Adjunctive NNP N
exenatide NN i
therapy NN N
reduces VBZ o
postprandial JJ o
hyperglycemia NN o
in IN N
adolescents NNS p
with IN p
type JJ p
1 CD p
diabetes NNS p
. . p

This DT N
reduction NN N
in IN N
glucose JJ o
excursion NN o
occurs VBZ N
despite IN N
reduction NN N
in IN N
insulin NN N
dose NN N
. . N

We PRP N
suggest VBP N
that DT N
exenatide NN i
has VBZ N
therapeutic JJ N
potential NN N
as IN N
adjunctive JJ N
therapy NN N
in IN N
type NN N
1 CD N
diabetes NNS N
. . N

-DOCSTART- -1300984- O O

T NNP N
lymphocyte JJ N
subsets NNS N
and CC N
NK NNP N
cell VBP N
cytotoxicity NN N
in IN N
chronic JJ p
hemodialysis NN p
patients NNS p
. . p

The DT N
effect NN N
of IN N
recombinant JJ i
human JJ i
erythropoietin NN i
( ( i
rHu-EPO JJ i
) ) i
treatment NN i
. . i

We PRP N
investigated VBD N
subpopulations NNS N
of IN N
T NNP o
lymphocytes NNS o
, , o
NK NNP o
cell NN o
number NN o
and CC o
cytotoxic JJ o
activity NN o
in IN N
14 CD p
chronic JJ p
uremic JJ p
patients NNS p
on IN p
regular JJ i
hemodialysis NN i
treatment NN i
. . i

We PRP N
observed VBD N
a DT N
significantly RB N
decreased VBN N
absolute NN o
lymphocyte NN o
number NN o
and CC o
percentage NN o
of IN o
CD3 NNP o
cells NNS o
. . o

Relative JJ N
numbers NNS N
of IN N
CD16 NNP o
cells NNS o
were VBD N
significantly RB N
elevated VBN N
, , N
but CC N
NK NNP o
cell VBP o
cytotoxic JJ o
activity NN o
was VBD N
within IN N
a DT N
normal JJ N
range NN N
. . N

Nine JJ p
patients NNS p
with IN p
chronic JJ p
renal JJ p
anemia NN p
on IN p
maintenance NN p
hemodialysis NN p
were VBD N
enrolled VBN N
in IN N
rHu-EPO JJ i
treatment NN N
trial NN N
. . N

The DT N
treatment NN N
was VBD N
continued VBN N
till IN N
the DT N
hematocrit NN o
level NN o
reached VBD N
30 CD N
% NN N
. . N

Each DT N
of IN N
the DT N
patients NNS p
had VBD p
corrected VBN N
anemia NN o
and CC N
well-being NN N
. . N

After IN N
12 CD N
weeks NNS N
of IN N
the DT N
treatment NN N
we PRP N
observed VBD N
in IN N
these DT N
patients NNS N
decreases NNS N
in IN N
CD3 NNP o
, , o
CD4 NNP o
, , o
CD8 NNP o
and CC o
CD16 NNP o
cell NN o
numbers NNS o
and CC N
elevation NN N
of IN N
CD4/CD8 NNP o
ratio NN o
. . o

Cytotoxic NNP o
activity NN o
of IN o
NK NNP o
cells NNS o
did VBD N
not RB N
change VB N
significantly RB N
. . N

Presented VBN N
results NNS N
indicate VBP N
that IN N
chronic JJ p
hemodialysis NN p
patients NNS p
have VBP N
significantly RB N
diminished VBN N
lymphocyte JJ o
number NN o
. . o

rHu JJ i
EPO NNP i
treatment NN N
affects VBZ N
the DT N
T NNP N
lymphocyte NN N
subsets NNS N
inducing VBG N
a DT N
deep JJ N
decrease NN N
of IN N
CD8 NNP o
and CC o
CD16 NNP o
cell NN o
percentage NN o
leading VBG N
to TO N
normalisation NN N
of IN N
the DT N
CD4/CD8 NNP o
ratio NN o
. . o

-DOCSTART- -8911127- O O

The DT N
impact NN N
of IN N
a DT N
psychological JJ i
intervention NN i
on IN N
quality NN o
of IN o
life NN o
in IN N
non-metastatic JJ p
breast NN p
cancer NN p
. . p

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
whether IN N
psychological JJ i
intervention NN i
had VBD N
a DT N
beneficial JJ N
effect NN N
on IN N
the DT N
quality NN o
of IN o
life NN o
and CC o
behaviour NN o
of IN N
women NNS p
diagnosed VBN p
with IN p
breast NN p
cancer NN p
. . p

36 CD p
consecutive JJ p
patients NNS p
with IN p
non-metastatic JJ p
breast NN p
cancer NN p
assigned VBD p
to TO p
surgery VB p
and CC p
systemic VB p
chemotherapy NN p
were VBD N
randomised VBN N
to TO N
receive VB N
either DT N
psychological JJ i
intervention NN i
( ( i
weekly JJ i
cognitive VBP i
individual JJ i
psychotherapy NN i
and CC i
bimonthly JJ i
family NN i
counselling VBG i
) ) i
or CC N
standard JJ i
follow-up NN i
. . i

Personality NNP o
( ( o
16-PF JJ o
and CC o
IIQ NNP o
) ) o
, , o
quality NN o
of IN o
life NN o
( ( o
FLIC NNP o
) ) o
, , o
and CC o
depression NN o
( ( o
BDI NNP o
) ) o
scores NNS o
were VBD N
the DT N
endpoints NNS N
for IN N
this DT N
study NN N
, , N
and CC N
the DT N
questionnaires NNS N
were VBD N
completed VBN N
by IN N
the DT N
patients NNS N
at IN N
diagnosis NN N
, , N
and CC N
up RB N
to TO N
9 CD N
months NNS N
after IN N
diagnosis NN N
. . N

Cognitive JJ N
psychotherapy NN N
and CC N
family NN N
counselling NN N
improved VBD N
both DT N
depression NN o
and CC o
quality NN o
of IN o
life NN o
indexes NNS o
compared VBN N
with IN N
the DT N
control NN N
group NN N
. . N

Better NNP N
emotional JJ o
coping NN o
behaviours NNS o
were VBD N
also RB N
revealed VBN N
by IN N
some DT N
changes NNS N
in IN N
personality NN N
traits NNS N
in IN N
the DT N
intervention NN N
group NN N
. . N

-DOCSTART- -19127179- O O

Effects NNS N
of IN N
static JJ i
stretching VBG i
on IN N
repeated VBN o
sprint NN o
and CC o
change NN o
of IN o
direction NN o
performance NN o
. . o

PURPOSE NNP N
To TO N
examine VB N
the DT N
effects NNS N
of IN N
static JJ i
stretching VBG i
during IN N
the DT N
recovery NN N
periods NNS N
of IN N
field-based JJ N
team NN N
sports NNS N
on IN N
subsequent NN N
repeated VBN o
sprint JJ o
ability NN o
( ( o
RSA NNP o
) ) o
and CC o
change NN o
of IN o
direction NN o
speed NN o
( ( o
CODS NNP o
) ) o
performance NN o
. . o

METHODS NNP N
On IN N
four CD N
separate JJ N
occasions NNS N
, , N
12 CD p
male JJ p
team-sport NN p
players NNS p
performed VBD N
a DT N
standardized JJ N
warm-up NN N
, , N
followed VBN N
by IN N
a DT N
test NN N
of IN N
either DT N
RSA NNP o
or CC N
CODS NNP i
( ( N
on IN N
two CD N
occasions NNS N
each DT N
) ) N
in IN N
a DT N
counterbalanced JJ N
design NN N
. . N

Both DT N
tests NNS N
involved VBD N
three CD N
sets NNS N
of IN N
six CD i
maximal JJ i
sprint NN i
repetitions NNS i
, , i
with IN i
a DT i
4-min JJ i
recovery NN i
between IN i
sets NNS i
. . i

During IN N
the DT N
break NN N
between IN N
sets NNS N
, , N
the DT N
participants NNS p
either CC N
rested VBN i
( ( i
control VB i
[ NNP i
CON NNP i
] NNP i
) ) i
or CC N
completed VBN N
a DT N
static JJ i
stretching NN i
protocol NN i
( ( i
static JJ i
stretch NN i
[ NNP i
SS NNP i
] NNP i
) ) i
. . N

The DT N
RSA NNP i
test NN N
involved VBN N
straight-line JJ i
sprints NNS i
, , N
whereas IN N
the DT N
CODS NNP i
test NN N
required VBD N
a DT N
change NN N
of IN N
direction NN N
( ( N
100 CD N
degrees NNS N
) ) N
every DT N
4 CD N
m NN N
( ( N
total JJ N
of IN N
four CD N
) ) N
. . N

Mean NNP o
, , o
total NN o
( ( o
sum NN o
of IN o
six CD o
sprints NNS o
) ) o
, , o
first RB o
, , o
and CC o
best JJS o
sprint NN o
times NNS o
( ( o
MST NNP o
, , o
TST NNP o
, , o
FST NNP o
, , o
and CC o
BST NNP o
, , o
respectively RB o
) ) o
were VBD N
recorded VBN N
for IN N
each DT N
set NN N
. . N

RESULTS NNP N
There EX N
was VBD N
a DT N
consistent JJ N
tendency NN N
for IN N
RSA NNP o
times NNS o
to TO N
be VB N
slower JJR N
after IN N
the DT N
static JJ i
stretching NN i
intervention NN i
, , N
which WDT N
was VBD N
supported VBN N
by IN N
statistical JJ N
significance NN N
for IN N
three CD N
performance NN N
variables NNS N
( ( N
MST NNP N
0-5 NNP N
m NN N
set NN N
2 CD N
, , N
MST NNP N
0-20 NNP N
m NN N
set NN N
2 CD N
, , N
and CC N
TST NNP N
set VBD N
2 CD N
; : N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

This DT N
tendency NN N
was VBD N
also RB N
supported VBN N
by IN N
moderate JJ N
effect NN N
sizes NNS N
and CC N
qualitative JJ N
indications NNS N
of IN N
likely JJ N
harmful NN N
or CC N
detrimental JJ N
effects NNS N
associated VBN N
with IN N
RSA-SS NNP i
. . i

Further NNP N
, , N
sprint NN o
times NNS o
again RB N
tended VBD N
to TO N
be VB N
slower JJR N
in IN N
the DT N
CODS-SS NNP i
trial NN N
compared VBN N
with IN N
the DT N
CODS-CON NNP i
across IN N
all DT N
sprint NN N
variables NNS N
, , N
with IN N
a DT N
significantly RB N
slower JJR N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
BST NNP N
recorded VBD N
for IN N
set NN N
3 CD N
after IN N
static JJ N
stretching NN N
. . N

CONCLUSION NNP N
These DT N
results NNS N
suggest VBP N
that IN N
an DT N
acute NN N
bout NN N
( ( N
4 CD N
min NN N
) ) N
of IN N
static JJ i
stretching NN i
of IN N
the DT N
lower JJR N
limbs NN N
during IN N
recovery NN N
periods NNS N
between IN N
efforts NNS N
may MD N
compromise VB N
RSA NNP o
performance NN o
but CC N
has VBZ N
less JJR N
effect NN N
on IN N
CODS NNP o
performance NN o
. . o

-DOCSTART- -11377310- O O

Effects NNS N
of IN N
irrigation NN N
fluid NN N
temperature NN N
on IN N
core NN N
body NN N
temperature NN N
during IN N
transurethral JJ i
resection NN i
of IN N
the DT N
prostate NN N
. . N

OBJECTIVES UH N
To TO N
determine VB N
the DT N
effect NN N
irrigation NN N
fluid NN N
temperature NN N
has VBZ N
on IN N
core NN N
body NN N
temperature NN N
changes NNS N
in IN N
patients NNS p
undergoing JJ p
transurethral JJ i
resection NN i
of IN i
the DT i
prostate NN i
( ( i
TURP NNP i
) ) i
. . p

METHODS NNP N
Fifty-six NNP p
male NN p
patients NNS p
( ( p
mean JJ p
age NN p
71.2 CD p
+/- JJ p
8.2 CD p
years NNS p
) ) p
scheduled VBD p
for IN p
TURP NNP p
were VBD p
enrolled VBN p
in IN p
the DT p
study NN p
. . p

Patients NNS N
were VBD N
randomized VBN N
to TO N
one CD N
of IN N
two CD N
groups NNS N
. . N

Group NNP N
1 CD N
consisted VBD N
of IN N
27 CD p
patients NNS p
who WP N
received VBD N
room NN i
temperature NN i
irrigation NN i
fluid NN i
( ( i
70 CD i
degrees NNS i
F NNP i
) ) i
throughout IN i
TURP NNP i
; : i
group NN N
2 CD N
consisted VBD N
of IN N
29 CD p
patients NNS p
whose WP$ N
procedure NN N
was VBD N
performed VBN N
with IN N
warmed JJ i
irrigation NN i
fluid NN i
( ( N
91.5 CD N
degrees NNS N
F NNP N
) ) N
. . N

The DT N
irrigation NN N
fluid NN N
used VBN N
for IN N
both DT N
groups NNS N
was VBD N
glycine NN N
. . N

The DT N
baseline NN N
temperature NN N
, , N
final JJ N
temperature NN N
, , N
total JJ N
time NN N
in IN N
the DT N
operating NN N
room NN N
, , N
and CC N
amount NN N
of IN N
irrigation NN N
fluid NN N
used VBN N
during IN N
the DT N
procedure NN N
were VBD N
recorded VBN N
for IN N
each DT N
patient NN N
. . N

RESULTS NNP N
No NNP N
significant JJ N
difference NN N
in IN N
the DT N
average JJ o
time NN o
spent VBN o
in IN o
the DT o
operating NN o
room NN o
or CC o
in IN o
the DT o
total JJ o
irrigation NN o
fluid NN o
used VBN N
between IN N
the DT N
two CD N
groups NNS N
was VBD N
observed VBN N
. . N

Of IN N
the DT N
27 CD N
patients NNS N
who WP N
received VBD N
room NN o
temperature NN o
irrigation NN o
fluid NN o
, , N
15 CD N
( ( N
55.6 CD N
% NN N
) ) N
had VBD N
a DT N
decrease NN N
in IN N
body NN o
temperature NN o
. . o

A DT N
decrease NN N
in IN N
temperature NN o
was VBD N
observed VBN N
in IN N
21 CD N
( ( N
72.4 CD N
% NN N
) ) N
of IN N
the DT N
29 CD N
patients NNS N
who WP N
received VBD N
warm JJ i
irrigation NN o
fluid NN o
. . o

Groups NNP N
1 CD N
and CC N
2 CD N
had VBD N
12 CD N
( ( N
44.4 CD N
% NN N
) ) N
of IN N
27 CD N
and CC N
8 CD N
( ( N
27.6 CD N
% NN N
) ) N
of IN N
29 CD N
patients NNS N
, , N
respectively RB N
, , N
who WP N
demonstrated VBD N
an DT N
elevation NN o
in IN N
their PRP$ N
core NN o
body NN o
temperature NN o
. . o

CONCLUSIONS VB N
The DT N
results NNS N
of IN N
our PRP$ N
study NN N
suggest VBP N
that IN N
irrigation NN N
fluid NN N
temperature NN N
is VBZ N
not RB N
a DT N
factor NN N
responsible JJ N
for IN N
altering VBG N
the DT N
core NN N
body NN o
temperature NN o
in IN N
patients NNS N
undergoing JJ N
TURP NNP N
. . N

-DOCSTART- -1426893- O O

Interferon NNP i
alfa NN i
in IN N
acute JJ p
posttransfusion NN p
hepatitis NN p
C NNP p
: : p
a DT N
randomized NN N
, , N
controlled VBN N
trial NN N
. . N

-DOCSTART- -25223836- O O

Safety NN o
, , o
pharmacokinetics NNS o
, , o
pharmacogenomics NNS o
and CC o
QT NNP o
concentration-effect JJ o
modelling NN o
of IN N
the DT N
SirT1 NNP i
inhibitor NN i
selisistat NN i
in IN N
healthy JJ p
volunteers NNS p
. . p

AIM NNP N
Selisistat NNP i
( ( i
SEN0014196 NNP i
) ) i
, , i
a DT i
first-in-class JJ i
SirT1 NNP i
inhibitor NN i
, , N
is VBZ N
being VBG N
developed VBN N
as IN N
a DT N
disease-modifying JJ N
therapy NN N
for IN N
Huntington NNP p
's POS p
disease NN p
. . p

This DT N
first-in-human JJ N
study NN N
investigated VBD N
the DT N
safety NN N
, , N
pharmacokinetics NNS N
and CC N
pharmacogenomics NNS N
of IN N
single JJ N
and CC N
multiple JJ N
doses NNS N
of IN N
selisistat NN i
in IN N
healthy JJ p
male NN p
and CC p
female JJ p
subjects NNS p
. . p

METHOD NNP N
In IN N
this DT N
double-blind NN N
, , N
randomized VBN N
, , N
placebo-controlled JJ i
study NN N
, , N
seven CD p
cohorts NNS p
of IN p
eight CD p
subjects NNS p
received VBD N
a DT N
single JJ N
dose NN N
of IN N
selisistat NN i
at IN N
dose JJ N
levels NNS N
of IN N
5 CD N
, , N
25 CD N
, , N
75 CD N
, , N
150 CD N
, , N
300 CD N
and CC N
600 CD N
mg NNS N
and CC N
four CD p
cohorts NNS p
of IN p
eight CD p
subjects NNS p
were VBD N
administered VBN N
100 CD N
, , N
200 CD N
and CC N
300 CD N
mg NN N
once RB N
daily JJ N
for IN N
7 CD N
days NNS N
. . N

Blood NNP N
sampling NN N
and CC N
safety NN o
assessments NNS o
were VBD N
conducted VBN N
throughout IN N
the DT N
study NN N
. . N

RESULTS NNP N
Selisistat NNP i
was VBD N
rapidly RB N
absorbed VBN N
and CC N
systemic JJ N
exposure NN N
increased VBN N
in IN N
proportion NN N
to TO N
dose VB N
in IN N
the DT N
5-300 JJ N
mg NN N
range NN N
. . N

Steady-state JJ o
plasma JJ o
concentrations NNS o
were VBD N
achieved VBN N
within IN N
4 CD N
days NNS N
of IN N
repeated JJ N
dosing NN N
. . N

The DT N
incidence NN N
of IN N
drug NN N
related VBN N
adverse JJ o
events NNS o
showed VBD N
no DT N
correlation NN N
with IN N
dose JJ N
level NN N
or CC N
number NN N
of IN N
doses NNS N
received VBN N
and CC N
was VBD N
comparable JJ N
with IN N
the DT N
placebo NN i
group NN N
. . N

No DT N
serious JJ N
adverse JJ o
events NNS o
were VBD N
reported VBN N
and CC N
no DT N
subjects NNS N
were VBD N
withdrawn VBN N
due JJ N
to TO N
adverse JJ N
events NNS N
. . N

There EX N
were VBD N
no DT N
trends NNS N
in IN N
clinical JJ N
laboratory NN N
parameters NNS N
or CC N
vital JJ N
signs NNS N
. . N

No DT N
trends NNS N
in IN N
heart NN o
rate NN o
or CC o
ECG NNP o
parameters NNS o
, , o
including VBG o
the DT o
QTc NNP o
interval NN o
and CC o
T-wave NNP o
morphology NN o
, , N
were VBD N
observed VBN N
. . N

There EX N
were VBD N
no DT N
findings NNS N
in IN N
physical JJ N
or CC N
neurological JJ N
examinations NNS N
or CC N
postural JJ N
control NN N
. . N

Transcriptional JJ N
alteration NN N
was VBD N
observed VBN N
in IN N
peripheral JJ N
blood NN N
. . N

CONCLUSION NNP N
Selisistat NNP i
was VBD N
safe JJ N
and CC N
well RB N
tolerated VBN N
by IN N
healthy JJ p
male NN p
and CC p
female JJ p
subjects NNS p
after IN N
single JJ N
doses VBZ N
up IN N
to TO N
600 CD N
mg NNS N
and CC N
multiple NN N
doses VBZ N
up IN N
to TO N
300 CD N
mg NNS N
day NN N
( ( N
-1 NN N
) ) N
. . N

-DOCSTART- -12447025- O O

Lofexidine NNP i
in IN N
hyperactive JJ p
and CC p
impulsive JJ p
children NNS p
with IN p
autistic JJ p
disorder NN p
. . p

-DOCSTART- -9808499- O O

Oral JJ i
ganciclovir NN i
dosing VBG N
in IN N
transplant NN p
recipients NNS p
and CC p
dialysis NN p
patients NNS p
based VBN N
on IN N
renal JJ N
function NN N
. . N

BACKGROUND NNP N
An DT N
oral JJ i
formulation NN i
of IN i
ganciclovir NN i
( ( i
GCV NNP i
) ) i
was VBD N
recently RB N
approved VBN N
for IN N
the DT N
prevention NN N
of IN N
cytomegalovirus NN N
disease NN N
in IN N
solid JJ N
organ NN N
transplant JJ N
recipients NNS N
. . N

This DT N
study NN N
was VBD N
designed VBN N
to TO N
determine VB N
the DT N
bioavailability NN N
of IN N
GCV NNP i
and CC N
to TO N
test VB N
a DT N
dosing NN N
algorithm NN N
in IN N
transplant NN p
and CC p
dialysis NN p
patients NNS p
with IN p
different JJ p
levels NNS p
of IN p
renal JJ p
function NN p
. . p

METHODS NNP N
Pharmacokinetic JJ N
studies NNS N
were VBD N
carried VBN N
out IN N
in IN N
23 CD p
patients NNS p
who WP p
were VBD p
either CC p
a DT p
recipient NN p
of IN p
an DT p
organ JJ p
transplant NN p
or CC p
on IN p
hemodialysis NN p
. . p

Drug NNP N
dosing NN N
was VBD N
established VBN N
by IN N
the DT N
following VBG N
algorithm NN N
based VBN N
on IN N
calculated JJ N
creatinine NN N
clearance NN N
( ( N
CrCl NNP N
) ) N
: : N
CrCl NNP N
= NNP N
[ NNP N
( ( N
140-age JJ N
) ) N
x FW N
body NN N
weight VBD N
] JJ N
/ NNP N
( ( N
72 CD N
x NNP N
Cr NNP N
) ) N
x VBZ N
0.85 CD N
for IN N
women NNS N
that WDT N
is VBZ N
, , N
CrCl NNP N
> VBZ N
50 CD N
ml/min NN N
, , N
1000 CD N
mg NN N
every DT N
8 CD N
hr NN N
; : N
CrCl NNP N
of IN N
25-50 JJ N
ml/min NN N
, , N
1000 CD N
mg NN N
every DT N
24 CD N
hr NN N
; : N
CrCl NNP N
of IN N
10-24 JJ N
ml/ NN N
min NN N
, , N
500 CD N
mg NN N
every DT N
day NN N
; : N
CrCl NNP N
< VBD N
10 CD N
ml/min NN N
( ( N
or CC N
on IN N
dialysis NN N
) ) N
, , N
500 CD N
mg NN N
every DT N
other JJ N
day NN N
after IN N
dialysis NN N
. . N

GCV NNP i
was VBD i
taken VBN i
within IN i
30 CD i
min NNS i
after IN i
a DT i
meal NN i
. . i

The DT N
patients NNS N
received VBD N
oral JJ i
GCV NNP i
for IN N
between IN N
12 CD N
days NNS N
and CC N
14 CD N
weeks NNS N
. . N

Serum NNP o
specimens VBZ o
( ( o
or CC o
plasma NN o
from IN o
patients NNS o
on IN o
hemodialysis NN o
) ) o
obtained VBD N
at IN N
steady JJ N
state NN N
were VBD N
analyzed VBN N
for IN N
GCV NNP N
concentrations NNS N
by IN N
high-performance NN N
liquid NN N
chromatography NN N
. . N

In IN N
nine CD N
of IN N
the DT N
transplant NN N
recipients NNS N
, , N
absolute JJ o
bioavailability NN o
was VBD N
determined VBN N
by IN N
comparing VBG N
GCV NNP o
levels NNS o
after IN N
single JJ N
oral JJ N
and CC N
intravenous JJ N
doses NNS N
of IN N
GCV NNP N
. . N

RESULTS VB N
The DT N
following JJ N
GCV NNP o
concentrations NNS o
( ( N
mean JJ N
+/-SD NN N
) ) N
were VBD N
determined VBN N
: : N
with IN N
CrCl NNP N
of IN N
> NNP N
or CC N
=70 NNP N
ml/min NN N
, , N
the DT N
minimum JJ N
steady-state JJ N
concentration NN N
( ( N
Cmin NNP N
) ) N
and CC N
maximum JJ N
concentration NN N
( ( N
Cmax NNP N
) ) N
were VBD N
0.78+/-0.46 JJ N
microg/ml NN N
and CC N
1.42+/-0.37 JJ N
microg/ml NN N
, , N
respectively RB N
, , N
with IN N
a DT N
24-hr JJ N
area NN N
under IN N
the DT N
concentration NN N
time NN N
curve NN N
( ( N
AUC0-24 NNP N
) ) N
of IN N
24.7+/-7.8 JJ N
microg NN N
x NNP N
hr/ml NN N
; : N
with IN N
CrCl NNP N
of IN N
50-69 JJ N
ml/min NN N
, , N
the DT N
Cmin NNP N
and CC N
Cmax NNP N
were VBD N
1.93+/-0.48 JJ N
and CC N
2.57+/-0.39 JJ N
microg/ml NN N
, , N
respectively RB N
, , N
with IN N
an DT N
AUC0-24 NNP N
of IN N
52.1+/-10.1 JJ N
microg NN N
x NNP N
hr/ml NN N
; : N
with IN N
CrCl NNP N
of IN N
25-50 JJ N
ml/min NN N
, , N
the DT N
Cmin NNP N
and CC N
Cmax NNP N
were VBD N
0.41+/-0.27 JJ N
and CC N
1.17+/-0.32 JJ N
microg/ml NN N
, , N
respectively RB N
, , N
with IN N
an DT N
AUC0-24 NNP N
of IN N
14.6+/-7.4 JJ N
microg NN N
x NNP N
hr/ml NN N
. . N

For IN N
one CD N
patient NN N
with IN N
a DT N
CrCl NNP N
of IN N
23.8 CD N
ml/min NN N
, , N
the DT N
Cmin NNP N
and CC N
Cmax NNP N
were VBD N
0.32 CD N
and CC N
0.7 CD N
microg/ml NN N
, , N
respectively RB N
, , N
with IN N
an DT N
AUC0-24 NNP N
of IN N
10.7 CD N
microg NNS N
x JJ N
hr/ml NN N
. . N

With IN N
CrCl NNP N
of IN N
< NNP N
10 CD N
ml/min NN N
, , N
the DT N
mean JJ N
Cmin NNP N
and CC N
Cmax NNP N
were VBD N
0.75+/-0.42 JJ N
and CC N
1.59+/-0.55 JJ N
microg/ml NN N
, , N
respectively RB N
, , N
with IN N
a DT N
mean JJ N
AUC0-24 NNP N
of IN N
64.6+/-18.8 JJ N
microg NN N
x NNP N
hr/ml NN N
. . N

Absolute NNP o
bioavailability NN o
, , N
for IN N
the DT N
nine CD N
patients NNS N
so RB N
analyzed JJ N
, , N
was VBD N
7.2+/-2.4 JJ N
% NN N
. . N

For IN N
those DT N
patients NNS p
with IN p
end-stage JJ p
renal JJ p
failure NN p
, , N
GCV NNP o
concentrations NNS o
fell VBD N
during IN N
dialysis NN N
from IN N
a DT N
mean NN N
of IN N
1.47+/-0.48 JJ N
microg/ml NN N
before IN N
dialysis NN N
to TO N
0.69+/-0.38 JJ N
microg/ml NN N
after IN N
dialysis NN N
. . N

CONCLUSIONS VB N
The DT N
bioavailability NN N
of IN N
oral JJ i
GCV NNP i
in IN N
transplant JJ p
patients NNS p
was VBD N
similar JJ N
to TO N
that DT N
observed VBN N
in IN N
human JJ p
immunodeficiency NN p
virus-infected JJ p
patients NNS p
. . p

However RB N
, , N
levels NNS N
between IN N
0.5 CD N
and CC N
1 CD N
microg/ml NN N
( ( N
within IN N
the DT N
IC50 NNP N
of IN N
most JJS N
cytomegalovirus JJ N
isolates NNS N
) ) N
could MD N
be VB N
achieved VBN N
with IN N
tolerable JJ N
oral JJ N
doses NNS N
. . N

The DT N
proposed VBN N
dosing NN N
algorithm NN N
resulted VBD N
in IN N
adequate JJ N
levels NNS N
for IN N
patients NNS N
with IN N
CrCl NNP N
greater JJR N
than IN N
50 CD N
ml/min NNS N
and CC N
for IN N
patients NNS N
on IN N
dialysis NN N
. . N

For IN N
patients NNS N
with IN N
CrCl NNP N
between IN N
10 CD N
and CC N
50 CD N
ml/min NN N
, , N
the DT N
levels NNS N
achieved VBN N
were VBD N
low JJ N
and CC N
these DT N
patients NNS N
would MD N
likely RB N
benefit VB N
from IN N
increased JJ N
doses NNS N
. . N

-DOCSTART- -2187009- O O

Event-related JJ N
potentials NNS N
and CC N
monoamines NNS N
in IN N
autistic JJ p
children NNS p
on IN N
a DT N
clinical JJ N
trial NN N
of IN N
fenfluramine NN i
. . i

In IN N
a DT N
double JJ N
blind NN N
, , N
crossover NN N
study NN N
of IN N
the DT N
response NN N
of IN N
autistic JJ p
subjects NNS p
to TO N
fenfluramine VB i
, , i
event-related JJ i
potentials NNS i
( ( i
ERPs NNP i
) ) i
were VBD N
recorded VBN N
from IN N
7 CD p
subjects NNS p
on IN N
an DT N
attention-demanding JJ N
auditory NN N
choice NN N
reaction NN N
time NN N
task NN N
( ( N
ACRT NNP N
) ) N
. . N

ACRT NNP N
, , N
IQ NNP N
and CC N
biochemical JJ N
measures NNS N
were VBD N
taken VBN N
after IN N
5 CD N
months NNS N
placebo NN i
and CC N
5 CD N
months NNS N
fenfluramine JJ i
treatment NN i
. . i

After IN N
fenfluramine JJ N
treatment NN N
blood NN N
serotonin NN N
levels NNS N
fell VBD N
, , N
urinary JJ N
catecholamine NN N
levels NNS N
fell VBD N
and CC N
the DT N
HVA/DA NNP N
ratio NN N
rose VBD N
. . N

IQ NNP o
and CC o
ACRT NNP o
performance NN o
improved VBD N
. . N

On IN N
the DT N
ACRT NNP o
subjects NNS N
were VBD N
asked VBN N
to TO N
press VB N
a DT N
button NN N
to TO N
a DT N
rare JJ N
target NN N
( ( N
500 CD N
Hz NNP N
, , N
P NNP N
= NNP N
0.14 CD N
) ) N
and CC N
to TO N
ignore VB N
higher JJR N
pitched VBN N
rare JJ N
( ( N
2,000 CD N
Hz NNP N
, , N
P NNP N
= NNP N
0.14 CD N
) ) N
and CC N
frequent JJ N
non-targets NNS N
( ( N
1,000 CD N
Hz NNP N
) ) N
. . N

After IN N
fenfluramine JJ i
treatment NN N
N1 NNP o
latencies NNS o
increased VBD N
. . N

The DT N
scalp JJ o
distribution NN o
of IN o
ERP NNP o
maxima NNP N
changes NNS N
slightly RB N
with IN N
treatment NN N
. . N

P3 NNP o
maxima NN o
elicited VBN N
by IN N
rare JJ N
non-targets NNS N
were VBD N
recorded VBN N
more RBR N
rostrally RB N
after IN N
fenfluramine JJ i
treatment NN N
. . N

After IN N
rare JJ N
non-targets NNS N
N1 NNP o
amplitudes NNS o
at IN o
Fz NNP o
decreased VBD N
but CC N
P3 NNP o
amplitudes NNS o
at IN o
Pz NNP o
increased VBD N
. . N

Early JJ N
negativity NN N
after IN N
the DT N
rare JJ N
non-target JJ N
( ( N
particularly RB N
on IN N
the DT N
right JJ N
side NN N
) ) N
was VBD N
negatively RB N
correlated VBN N
with IN N
the DT N
HVA/DA NNP N
ratio NN N
. . N

Subtraction NN N
of IN N
the DT N
P3 NNP N
component NN N
elicited VBN N
in IN N
a DT N
passive JJ N
condition NN N
where WRB N
no DT N
response NN N
was VBD N
required VBN N
from IN N
the DT N
active JJ N
condition NN N
showed VBD N
that IN N
P3 NNP o
positivity NN o
to TO N
targets NNS N
was VBD N
halved VBN N
with IN N
treatment NN N
. . N

( ( N
In IN N
contrast NN N
Nd NNP N
increased VBD N
on IN N
fenfluramine JJ N
treatment NN N
) ) N
. . N

Overall JJ N
, , N
N1 NNP N
and CC N
P3 NNP N
components NNS N
showed VBD N
greatest JJS N
responsiveness NN N
to TO N
rare VB N
non-targets NNS N
on IN N
fenfluramine NN N
. . N

N1 NNP N
but CC N
not RB N
P3 NNP N
changes NNS N
may MD N
represent VB N
slight JJ N
improvement NN N
of IN N
attention-related JJ N
function NN N
with IN N
treatment NN N
. . N

Small JJ N
changes NNS N
in IN N
ERP NNP o
latency NN o
and CC o
distribution NN o
, , N
associated VBN N
with IN N
the DT N
neuroleptic JJ N
action NN N
of IN N
fenfluramine NN i
may MD N
be VB N
partly RB N
responsible JJ N
for IN N
a DT N
mild JJ N
improvement NN N
of IN N
IQ NNP N
and CC N
ACRT NNP N
performance NN N
on IN N
medication NN N
. . N

-DOCSTART- -26129831- O O

The DT N
effect NN N
of IN N
the DT N
video NN i
game NN i
Mindlight NNP i
on IN N
anxiety NN o
symptoms NNS o
in IN N
children NNS p
with IN p
an DT p
Autism NNP p
Spectrum NNP p
Disorder NNP p
. . p

BACKGROUND NNP N
In IN N
the DT N
clinical JJ N
setting NN N
, , N
a DT N
large JJ N
proportion NN N
of IN N
children NNS p
with IN p
an DT p
autism NN p
spectrum NN p
disorder NN p
( ( p
ASD NNP p
) ) p
experience NN p
anxiety NN o
symptoms NNS o
. . o

Because IN N
anxiety NN N
is VBZ N
an DT N
important JJ N
cause NN N
of IN N
impairment NN N
for IN N
children NNS p
with IN p
an DT p
ASD NNP p
, , N
it PRP N
is VBZ N
necessary JJ N
that IN N
effective JJ N
anxiety NN N
interventions NNS N
are VBP N
implemented VBN N
for IN N
these DT N
children NNS N
. . N

Recently RB N
, , N
a DT N
serious JJ N
game NN i
called VBN i
Mindlight NNP i
has VBZ N
been VBN N
developed VBN N
that DT N
is VBZ N
focused VBN N
on IN N
decreasing VBG N
anxiety NN N
in IN N
children NNS N
. . N

This DT N
approach NN N
is VBZ N
based VBN N
on IN N
recent JJ N
research NN N
suggesting VBG N
that IN N
video JJ i
games NNS i
might MD N
be VB N
suitable JJ N
as IN N
an DT N
intervention NN N
vehicle NN N
to TO N
enhance VB N
mental JJ N
health NN N
in IN N
children NNS N
. . N

In IN N
the DT N
present JJ N
study NN N
it PRP N
will MD N
be VB N
investigated VBN N
whether IN N
Mindlight NNP i
is VBZ N
effective JJ N
in IN N
decreasing VBG N
( ( N
sub NN N
) ) N
clinical JJ o
anxiety NN o
symptoms NNS o
in IN N
children NNS p
who WP p
are VBP p
diagnosed VBN p
with IN p
an DT p
ASD NNP p
. . p

METHODS/DESIGN NNP N
The DT N
present JJ N
study NN N
involves VBZ N
a DT N
randomized NN N
controlled VBN N
trial NN N
( ( N
RCT NNP N
) ) N
with IN N
two CD N
conditions NNS N
( ( N
experimental JJ N
versus NN N
control NN N
) ) N
, , N
in IN N
which WDT N
it PRP N
is VBZ N
investigated VBN N
whether IN N
Mindlight NNP i
is VBZ N
effective JJ N
in IN N
decreasing VBG N
( ( N
sub NN N
) ) N
clinical JJ N
anxiety NN o
symptoms NNS o
in IN N
children NNS N
with IN N
an DT N
ASD NNP N
. . N

For IN N
this DT N
study NN N
, , N
children NNS p
of IN p
8-16 CD p
years NNS p
old JJ p
with IN p
a DT p
diagnosis NN p
of IN p
an DT p
ASD NNP p
and CC p
( ( p
sub NN p
) ) p
clinical JJ p
anxiety NN o
symptoms NNS o
will MD p
be VB p
randomly RB p
assigned VBN p
to TO p
the DT p
experimental NN p
( ( p
N NNP p
= NNP p
60 CD p
) ) p
or CC p
the DT p
control NN p
( ( p
N NNP p
= NNP p
60 CD p
) ) p
condition NN p
. . p

Children NNP N
in IN N
the DT N
experimental JJ N
condition NN N
will MD N
play VB i
Mindlight NNP i
for IN N
one CD N
hour NN N
per IN N
week NN N
, , N
for IN N
six CD N
consecutive JJ N
weeks NNS N
. . N

Children NNP N
in IN N
the DT N
control NN N
condition NN N
will MD N
play VB N
the DT N
puzzle NN i
game NN i
Triple NNP i
Town NNP i
, , N
also RB N
for IN N
one CD N
hour NN N
per IN N
week NN N
and CC N
for IN N
six CD N
consecutive JJ N
weeks NNS N
. . N

All DT N
children NNS N
will MD N
complete VB N
assessments NNS N
at IN N
baseline NN N
, , N
post-intervention NN N
and CC N
3-months JJ N
follow-up NN N
. . N

Furthermore NNP N
, , N
parents NNS N
and CC N
teachers NNS N
will MD N
also RB N
complete JJ N
assessments NNS N
at IN N
the DT N
same JJ N
time NN N
points NNS N
. . N

The DT N
primary JJ N
outcome NN N
will MD N
be VB N
child JJ o
report NN o
of IN o
anxiety NN o
symptoms NNS o
. . o

Secondary JJ N
outcomes NNS N
will MD N
be VB N
parent JJ o
report NN o
of IN o
child JJ o
anxiety NN o
, , o
child/parent JJ o
report NN o
of IN o
depressive JJ o
symptoms NNS o
, , o
and CC o
parent/teacher JJ o
report NN o
of IN o
social JJ o
functioning NN o
and CC o
behavior NN o
problems NNS o
. . o

DISCUSSION NNP N
This DT N
paper NN N
aims VBZ N
to TO N
describe VB N
a DT N
study NN N
that WDT N
will MD N
examine VB N
the DT N
effect NN N
of IN N
the DT N
serious JJ N
game NN N
Mindlight NNP N
on IN N
( ( N
sub NN N
) ) N
clinical JJ N
anxiety NN N
symptoms NNS N
of IN N
children NNS N
with IN N
an DT N
ASD NNP o
in IN o
the DT o
age NN o
of IN o
8-16 CD o
years NNS o
old JJ o
. . o

It PRP N
is VBZ N
expected VBN N
that IN N
children NNS N
in IN N
the DT N
experimental JJ N
condition NN N
will MD N
show VB N
lower JJR N
levels NNS N
of IN N
anxiety NN o
symptoms NNS o
at IN N
3-months JJ N
follow-up NN N
, , N
compared VBN N
to TO N
children NNS N
in IN N
the DT N
control NN N
condition NN N
. . N

If IN N
Mindlight NNP i
turns VBZ N
out RP N
to TO N
be VB N
effective JJ N
, , N
it PRP N
could MD N
be VB N
an DT N
important JJ N
contribution NN N
to TO N
the DT N
already RB N
existing JJ N
interventions NNS N
for IN N
anxiety NN N
in IN N
children NNS N
with IN N
an DT N
ASD NNP N
. . N

Mindlight NNP i
could MD N
then RB N
be VB N
implemented VBN N
as IN N
an DT N
evidence-based JJ N
treatment NN N
for IN N
anxiety NN o
symptoms NNS o
in IN N
children NNS p
with IN p
an DT p
ASD NNP p
in IN N
mental JJ N
health NN N
institutes NNS N
and CC N
special JJ N
education NN N
schools NNS N
. . N

TRIAL NNP N
REGISTRATION NNP N
Dutch NNP N
Trial NNP N
Register NNP N
NTR5069 NNP N
. . N

Registered VBD N
20 CD N
April NNP N
2015 CD N
. . N

-DOCSTART- -8971536- O O

Treatment NN N
of IN N
men NNS p
with IN p
flat JJ p
( ( p
FC NNP p
) ) p
or CC p
acuminata NN p
( ( p
CA NNP p
) ) p
condylomata NN p
with IN p
interferon JJ i
alpha-2a NN i
. . i

This DT N
study NN N
was VBD N
undertaken VBN N
to TO N
assess VB N
the DT N
effect NN N
of IN N
CO2 NNP i
laser NN i
vaporization NN i
, , i
5-fluorouracil JJ i
5 CD i
% NN i
( ( i
5-FU JJ i
) ) i
topical JJ i
application NN i
and CC i
Interferon NNP i
alpha-2a NN i
( ( i
IFA NNP i
alpha-2a NN i
) ) i
in IN N
the DT N
treatment NN N
of IN N
C.A NNP p
. . p

or CC p
F.C NNP p
. . p

of IN p
the DT p
male JJ p
genital JJ p
tract NN p
. . p

From IN p
March NNP p
1986 CD p
to TO p
September NNP p
1991 CD p
, , p
1372 CD p
men NNS p
, , p
sexual JJ p
partners NNS p
of IN p
women NNS p
with IN p
F.C NNP p
. . p

or CC p
C.A NNP p
. . p

or CC p
cervical JJ p
intraepithelial JJ p
neoplasia NN p
, , p
were VBD p
submitted VBN p
to TO p
peoscopy VB i
. . i

One CD p
thousand NN p
and CC p
nineteen JJ p
( ( p
74.27 CD p
% NN p
) ) p
men NNS p
presented VBN p
with IN p
various JJ p
penile JJ p
lesions NNS p
caused VBN p
by IN p
HPV NNP p
( ( p
histologically RB p
confirmed VBN p
) ) p
; : p
of IN N
these DT N
505 CD p
were VBD p
treated VBN p
for IN p
C.A NNP p
. . p

or CC p
F.C NNP p
. . p

or CC p
a DT p
combination NN p
of IN p
F.C NNP p
. . p

and CC p
C.A NNP p
. . p

The DT N
best JJS N
treatment NN N
modalities NNS N
, , N
irrespective NN N
of IN N
the DT N
kind NN N
of IN N
lesion NN N
, , N
were VBD N
found VBN N
to TO N
be VB N
the DT N
combination NN N
of IN N
5-FU JJ i
plus JJ i
IFN NNP i
alpha-2a NN i
( ( N
high JJ N
dose NN N
) ) N
( ( N
98.27 CD N
% NN N
) ) N
, , N
the DT N
combination NN N
of IN N
CO2 NNP i
laser NN i
vaporization NN i
plus CC i
5-FU JJ i
plus JJ i
IFN NNP i
alpha-2a NN i
( ( i
high JJ i
dose NN i
) ) i
( ( i
93.93 CD i
% NN i
) ) i
and CC N
the DT N
combination NN i
of IN i
CO2 NNP i
laser NN i
vaporization NN i
plus CC i
5-FU JJ i
( ( N
87.23 CD N
% NN N
) ) N
. . N

In IN N
conclusion NN N
we PRP N
believe VBP N
that IN N
IFN NNP i
alpha-2a NN i
can MD N
be VB N
used VBN N
with IN N
excellent JJ N
results NNS N
as IN N
first JJ N
line NN N
treatment NN N
in IN N
combination NN N
with IN N
CO2 NNP i
laser NN i
vaporization NN i
or/plus IN i
5-FU JJ i
in IN N
patients NNS N
with IN N
C.A NNP p
. . p

or CC p
F.C NNP p
. . p

or CC p
combined VBN p
condylomata NNS p
. . N

-DOCSTART- -17178532- O O

Dietary JJ N
status NN N
and CC N
impact NN N
of IN N
risperidone NN i
on IN N
nutritional JJ o
balance NN o
in IN N
children NNS p
with IN p
autism NN p
: : p
a DT N
pilot NN N
study NN N
. . N

BACKGROUND NNP N
Risperidone NNP i
may MD N
be VB N
effective JJ N
in IN N
improving VBG N
tantrums NNS o
, , o
aggression NN o
, , o
or CC o
self-injurious JJ o
behaviour NN o
in IN N
children NNS p
with IN p
autism NN p
, , N
but CC N
often RB N
leads VBZ N
to TO N
weight VB o
gain NN o
. . o

METHOD NNP N
Using VBG N
a DT N
quantitative JJ N
Food NNP o
Frequency NNP o
Questionnaire NNP o
( ( o
FFQ NNP o
) ) o
, , N
we PRP N
prospectively RB N
examined VBD N
the DT N
nutritional JJ N
intake NN N
of IN N
20 CD p
children NNS p
with IN p
autism NN p
participating VBG p
in IN p
a DT p
randomised JJ p
placebo-controlled JJ i
trial NN p
of IN p
risperidone NN i
for IN p
disruptive JJ p
behaviours NNS p
. . p

RESULTS NNP N
At IN N
baseline NN N
, , N
the DT N
mean NN o
intakes NNS o
for IN o
macronutrients NNS o
, , o
vitamins NNS o
and CC o
minerals NNS o
exceeded VBD N
Dietary NNP N
Reference NNP N
Intakes NNP N
( ( N
DRIs NNP N
) ) N
. . N

However RB N
there EX N
was VBD N
substantial JJ N
inter-participant JJ N
variability NN N
, , N
with IN N
individual JJ o
deficiencies NNS o
( ( N
< VB N
80 CD N
% NN N
of IN N
DRI NNP N
) ) N
in IN N
the DT N
intake NN o
of IN o
calcium NN o
( ( N
9 CD N
of IN N
20 CD N
participants NNS N
) ) N
, , N
pantothenic JJ o
acid NN o
( ( N
6 CD N
of IN N
20 CD N
) ) N
, , N
vitamin FW o
D NNP o
( ( N
5 CD N
of IN N
20 CD N
) ) N
and CC N
vitamin $ N
K NNP N
( ( N
8 CD N
of IN N
20 CD N
) ) N
. . N

For IN N
the DT N
participants NNS N
for IN N
whom WP N
FFQs NNP N
were VBD N
available JJ N
, , N
there EX N
was VBD N
an DT N
increase NN o
in IN o
weight NN o
and CC N
an DT N
increase NN o
in IN o
vitamin JJ o
K NNP o
intake NN o
after IN N
2 CD N
months NNS N
of IN N
risperidone NN i
treatment NN N
( ( N
n JJ N
= NNP N
9 CD N
) ) N
compared VBN N
to TO N
placebo VB i
( ( N
n JJ N
= NNP N
8 CD N
) ) N
. . N

An DT N
additional JJ N
4 CD N
months NNS N
of IN N
risperidone NN i
treatment NN N
( ( N
n JJ N
= NNP N
8 CD N
) ) N
did VBD N
not RB N
result VB N
in IN N
significant JJ N
changes NNS N
in IN N
reported JJ N
nutritional JJ o
balance NN o
. . o

CONCLUSION NNP N
These DT N
pilot NN N
data NNS N
suggest VBP N
that IN N
treatment NN N
with IN N
risperidone NN i
did VBD N
not RB N
significantly RB o
affect VBP o
the DT N
nutritional JJ o
balance NN o
of IN N
this DT N
small JJ N
group NN N
of IN N
children NNS N
. . N

-DOCSTART- -8780837- O O

The DT N
effects NNS N
of IN N
chronic JJ N
naltrexone NN i
treatment NN i
in IN N
young JJ p
autistic JJ p
children NNS p
: : p
a DT N
double-blind JJ N
placebo-controlled JJ N
crossover NN N
study NN N
. . N

In IN N
a DT N
double-blind JJ N
placebo-controlled JJ N
crossover NN N
trial NN N
23 CD p
autistic JJ p
children NNS p
, , p
aged VBN p
3-7 CD p
years NNS p
, , N
were VBD N
treated VBN N
with IN i
a DT i
mean JJ i
daily JJ i
dosage NN i
of IN i
1 CD i
mg/kg NNS i
naltrexone RB i
for IN i
4 CD i
weeks NNS i
. . i

Drug JJ N
effects NNS N
were VBD N
monitored VBN N
with IN i
behavior JJ i
checklists NNS i
rated VBN i
by IN i
parents NNS i
and CC i
teachers NNS i
, , i
and CC i
ethological JJ i
playroom NN i
observations NNS i
. . i

On IN N
average NN N
, , N
parents NNS N
' POS N
checklists NNS N
and CC N
playroom NN N
data NNS N
could MD N
not RB N
differentiate VB N
between IN N
naltrexone JJ N
treatment NN N
and CC N
placebo NN N
treatment NN N
; : N
however RB N
, , N
teachers NNS N
significantly RB N
favored VBD N
naltrexone JJ i
treatment NN N
. . N

They PRP N
reported VBD N
a DT N
decrease NN N
in IN N
hyperactivity NN o
and CC o
irritability NN o
. . o

No DT N
effects NNS N
of IN N
naltrexone NN N
on IN N
social JJ N
and CC N
stereotypic JJ N
behavior NN N
could MD N
be VB N
demonstrated VBN N
. . N

-DOCSTART- -23416308- O O

Safety NN N
, , N
pharmacokinetics NNS N
and CC N
pharmacodynamics NNS N
of IN N
GS-9620 NNP i
, , N
an DT N
oral JJ N
Toll-like NNP N
receptor NN N
7 CD N
agonist NN N
. . N

BACKGROUND NNP N
GS-9620 NNP i
is VBZ N
a DT N
novel JJ N
oral JJ N
agonist NN N
of IN N
Toll-like NNP N
receptor NN N
7 CD N
( ( N
TLR7 NNP N
) ) N
in IN N
development NN N
for IN N
the DT N
treatment NN N
of IN N
chronic JJ N
viral JJ N
hepatitis NN N
. . N

TLR7 NNP N
is VBZ N
a DT N
highly RB N
conserved JJ N
innate NN N
immune NN N
receptor NN N
expressed VBD N
primarily RB N
on IN N
plasmacytoid JJ N
dendritic JJ N
cells NNS N
and CC N
B NNP N
lymphocytes NNS N
. . N

The DT N
aim NN N
of IN N
this DT N
double-blind JJ N
, , N
placebo-controlled JJ i
, , N
single JJ N
ascending-dose JJ N
study NN N
was VBD N
to TO N
investigate VB N
the DT N
safety NN o
, , o
tolerability NN o
, , o
pharmacokinetics NNS o
and CC o
pharmacodynamics NNS o
of IN N
GS-9620 NNP i
in IN N
healthy JJ p
volunteers NNS p
. . p

METHODS NNP N
In IN N
total JJ N
, , N
75 CD p
healthy JJ p
volunteers NNS p
( ( p
8 CD p
subjects NNS p
in IN p
each DT p
of IN p
the DT p
10 CD p
cohorts NNS p
; : p
5 CD p
subjects NNS p
participated VBN p
in IN p
two CD p
cohorts NNS p
) ) p
were VBD p
randomized VBN p
( ( p
6:2 CD p
) ) p
to TO N
receive VB N
a DT N
single JJ i
dose NN i
of IN i
GS-9620 NNP i
( ( i
0.3 CD i
, , i
1 CD i
, , i
2 CD i
, , i
4 CD i
, , i
6 CD i
, , i
8 CD i
or CC i
12 CD i
mg NN i
) ) i
or CC i
placebo NN i
. . i

RESULTS NNP N
GS-9620 NNP i
was VBD N
well-absorbed JJ o
and CC o
well-tolerated JJ o
in IN N
oral JJ N
doses NNS N
up RB N
to TO N
12 CD N
mg NN N
. . N

Minimal JJ o
treatment-related JJ o
adverse JJ o
events NNS o
were VBD N
seen VBN N
at IN N
doses NNS N
up RB N
to TO N
8 CD N
mg. NNS N
Serum NNP o
interferon NN o
( ( o
IFN NNP o
) ) o
-? NN o
was VBD N
only RB N
detected VBN N
in IN N
subjects NNS N
who WP N
received VBD N
8 CD N
or CC N
12 CD N
mg NN N
doses NNS N
, , N
and CC N
the DT N
adverse JJ N
event NN N
profile NN N
at IN N
8 CD N
and CC N
12 CD N
mg NN N
doses NNS N
was VBD N
generally RB N
consistent JJ N
with IN N
that DT N
associated VBN N
with IN N
IFN-? NNP N
exposure NN N
( ( N
flu-like JJ N
symptoms NNS N
) ) N
, , N
consistent JJ N
with IN N
the DT N
mechanism NN N
of IN N
TLR7 NNP N
agonism NN N
. . N

All DT N
adverse JJ N
events NNS N
resolved VBD N
within IN N
72 CD N
h. JJ N
Induction NNP o
of IN o
chemokines/cytokines NNS o
and CC o
IFN-stimulated JJ o
genes NNS o
were VBD o
seen VBN N
at IN N
GS-9620 NNP i
doses NNS i
? . N
2 CD N
mg NN N
, , N
well RB N
below IN N
doses NNS N
that WDT N
induced VBD N
serum JJ N
IFN-? NNP N
or CC N
led VBN N
to TO N
clinical JJ N
adverse JJ N
events NNS N
. . N

CONCLUSIONS NNP i
GS-9620 NNP i
demonstrates VBZ o
safety NN o
and CC o
pharmacodynamic JJ o
activity NN o
at IN o
doses VBZ o
up RB N
to TO N
12 CD N
mg. NNS N
Pharmacodynamic NNP N
activity NN N
is VBZ N
seen VBN N
before IN N
adverse JJ N
events NNS N
, , N
suggesting VBG N
the DT N
potential NN N
for IN N
induction NN N
of IN N
an DT N
antiviral JJ N
response NN N
without IN N
systemic JJ N
adverse JJ N
events NNS N
in IN N
subjects NNS N
with IN N
chronic JJ N
viral JJ N
hepatitis NN N
. . N

-DOCSTART- -16806442- O O

Pelvic NNP i
lymphadenectomy NN i
for IN N
cervical JJ p
carcinoma NN p
: : p
laparotomy JJ i
extraperitoneal NN i
, , i
transperitoneal NN i
or CC i
laparoscopic NN i
approach NN N
? . N
A DT N
randomized JJ N
study NN N
. . N

OBJECTIVE NNP N
To TO N
compare VB N
transperitoneal NN i
, , i
extraperitoneal NN i
and CC i
laparoscopic NN i
pelvic JJ i
lymphadenectomy NN i
in IN N
terms NNS N
of IN N
feasibility NN o
and CC o
morbidity NN o
in IN N
patients NNS p
affected VBN p
by IN p
cervical JJ p
cancer NN p
undergoing VBG p
radical JJ i
hysterectomy NN i
. . i

METHODS NNP N
Consecutive JJ p
patients NNS p
affected VBN p
by IN p
stage NN p
IB-IIB JJ p
cervical JJ p
carcinoma NN p
scheduled VBN p
for IN p
radical JJ i
surgery NN i
entered VBD N
the DT N
study NN N
. . N

Patients NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
transperitoneal VB i
( ( i
TPL NNP i
) ) i
, , i
extraperitoneal FW i
( ( i
EPL NNP i
) ) i
or CC i
laparoscopic JJ i
pelvic JJ i
lymphadenectomy NN i
( ( i
LPL NNP i
) ) i
. . i

All DT p
patients NNS p
underwent JJ p
classical JJ i
radical JJ i
hysterectomy NN i
. . i

Perioperative JJ N
data NNS N
were VBD N
recorded VBN N
. . N

Follow VB N
up RP N
examinations NNS o
were VBD N
performed VBN N
at IN N
the DT N
15th CD N
, , N
30th CD N
and CC N
60th CD N
day NN N
after IN N
surgery NN N
. . N

RESULTS CC N
168 CD p
patients NNS p
entered VBD p
the DT p
study NN p
. . p

The DT N
mean JJ o
operative JJ o
times NNS o
were VBD N
: : N
63+/-7.6 JJ N
, , N
54+/-6.7 JJ N
and CC N
75+/-8.4 JJ N
min NN N
( ( i
TPL NNP i
vs RB N
EPL NNP i
P NNP N
< NNP N
0.001 CD N
; : N
EPL NNP N
vs FW N
LPL NNP N
P NNP N
< NNP N
0.001 CD N
; : N
TPL NNP i
vs FW N
LPL NNP i
P NNP N
< NNP N
0.001 CD N
) ) N
for IN N
TPL NNP i
, , i
EPL NNP i
and CC N
LPL NNP i
respectively RB N
. . N

The DT N
feasibility NN o
of IN o
the DT o
procedures NNS o
, , N
analyzed VBN N
on IN N
an DT N
intention-to-treat JJ N
basis NN N
, , N
was VBD N
96 CD N
% NN N
, , N
93 CD N
% NN N
and CC N
95 CD N
% NN N
for IN N
TPL NNP i
, , i
EPL NNP i
and CC i
LPL NNP i
group NN i
respectively RB N
( ( N
P=ns NNP N
) ) N
. . N

The DT N
average JJ o
hospitalizations NNS o
were VBD N
: : N
5.6+/-0.9 JJ N
, , N
3.2+/-0.4 JJ N
and CC N
3.1+/-0.3 JJ N
days NNS N
( ( i
TPL NNP i
vs RB N
EPL NNP i
P NNP N
< NNP N
0.001 CD N
; : N
TPL NNP i
vs FW N
LPL NNP i
P NNP N
< NNP N
0.001 CD N
) ) N
for IN N
TPL NNP i
, , i
EPL NNP i
and CC N
LPL NNP i
respectively RB N
. . N

CONCLUSIONS NNP N
EPL NNP i
and CC N
LPL NNP i
are VBP N
as IN N
feasible JJ o
and CC N
effective JJ o
as IN N
TPL NNP i
and CC N
can MD N
be VB N
adequately RB N
performed VBN N
with IN N
a DT N
reasonable JJ N
complication NN N
rate NN N
. . N

LPL NNP i
showed VBD N
a DT N
statistically RB N
significant JJ N
longer RBR N
operative JJ o
time NN o
. . o

However RB N
, , N
both DT N
EPL NNP i
and CC N
LPL NNP i
can MD N
minimize VB N
some DT N
postoperative JJ N
complications NNS N
reducing VBG N
length NN o
of IN o
stay NN o
. . o

-DOCSTART- -9842079- O O

[ RB N
Clinical JJ N
trial NN N
of IN N
2 CD N
tobacco NN N
use NN N
cessation NN i
interventions NNS i
in IN N
primary JJ N
care NN N
] NNP N
. . N

OBJECTIVE NNP N
To TO N
study VB N
the DT N
efficacy NN N
of IN N
two CD N
types NNS N
of IN N
intervention NN N
to TO N
stop VB N
tobacco NN o
dependency NN o
. . o

DESIGN NNP N
Randomised VBD N
clinical JJ N
trial NN N
. . N

SETTING NN N
Primary NNP N
care NN N
centre NN N
. . N

PATIENTS NNP N
AND CC N
OTHER NNP N
PARTICIPANTS NNP N
Smokers NNP p
recruited VBD p
from IN p
among IN p
the DT p
health NN p
centre NN p
users NNS p
through IN p
the DT p
preventive JJ p
activities NNS p
and CC p
health NN p
promotion NN p
programme NN p
. . p

INTERVENTIONS NNP N
INDEPENDENT NNP i
VARIABLE NNP i
type NN i
of IN i
intervention NN i
. . i

General JJ N
variables NNS N
: : N
age NN N
, , N
sex NN N
, , N
marital JJ N
status NN N
, , N
educational JJ N
level NN N
, , N
work NN N
situation NN N
, , N
cohabitation NN N
with IN N
children NNS N
, , N
smokers NNS N
at IN N
home NN N
, , N
number NN N
of IN N
years NNS N
smoking VBG N
, , N
type NN N
of IN N
tobacco NN N
. . N

There EX N
were VBD N
two CD N
types NNS N
of IN N
intervention NN N
: : N
a DT N
) ) N
Minimal NNP i
Intervention NNP i
( ( N
MI NNP N
) ) N
. . N

b NN N
) ) N
Advanced NNP i
Intervention NNP i
( ( N
AI NNP N
) ) N
. . N

54 CD p
patients NNS p
were VBD p
included VBN p
, , p
with IN p
6 CD p
losses NNS p
. . p

21 CD p
were VBD N
assigned VBN N
at IN N
random NN N
to TO N
the DT N
MI NNP i
group NN p
and CC N
27 CD p
to TO N
the DT N
AI NNP i
group NN p
. . p

Progress NNP N
was VBD N
measured VBN N
at IN N
15 CD N
days NNS N
, , N
1 CD N
month NN N
, , N
3 CD N
months NNS N
, , N
6 CD N
months NNS N
and CC N
a DT N
year NN N
. . N

RESULTS NNP N
In IN N
the DT N
MI NNP N
, , N
23.8 CD N
% NN N
were VBD N
abstinent JJ o
at IN N
15 CD N
days NNS N
; : N
the DT N
same JJ N
percentage NN N
at IN N
one CD N
month NN N
and CC N
3 CD N
months NNS N
; : N
19 CD N
% NN N
at IN N
6 CD N
months NNS N
; : N
and CC N
14.3 CD N
% NN N
remained VBD N
abstinent JJ o
after IN o
a DT o
year NN o
. . o

In IN N
the DT N
AI NNP N
, , N
51.9 CD N
% NN N
were VBD N
abstinent JJ o
at IN N
15 CD N
days NNS N
; : N
48.1 CD N
% NN N
at IN N
both DT N
one CD N
and CC N
3 CD N
months NNS N
; : N
25.9 CD N
% NN N
at IN N
6 CD N
months NNS N
; : N
and CC N
22.2 CD N
% NN N
were VBD N
still RB N
not RB o
smoking VBG o
after IN o
a DT o
year NN o
. . o

No DT N
significant JJ N
differences NNS N
between IN N
the DT N
two CD N
interventions NNS N
were VBD N
found VBN N
in IN N
any DT N
of IN N
the DT N
observations NNS N
. . N

CONCLUSIONS NNP N
These DT N
data NNS N
do VBP N
not RB N
show VB N
that IN N
one CD N
intervention NN N
is VBZ N
better RBR N
than IN N
the DT N
other JJ N
. . N

With IN N
the DT N
passage NN N
of IN N
time NN N
the DT N
effect NN N
of IN N
the DT N
intervention NN N
decreased VBN N
in IN N
both DT N
groups NNS N
. . N

-DOCSTART- -18590393- O O

Effect NN N
of IN N
preoperative JJ N
skull NN N
block NN N
on IN N
pediatric JJ p
moyamoya NN p
disease NN p
. . p

OBJECT NNP N
Stable JJ N
hemodynamics NNS N
, , N
normocapnia NN N
, , N
and CC N
adequate JJ N
pain NN N
relief NN N
are VBP N
considered VBN N
important JJ N
factors NNS N
in IN N
the DT N
reduction NN N
of IN N
neurological JJ N
complications NNS N
in IN N
pediatric JJ p
patients NNS p
undergoing JJ p
encephaloduroarteriomyosynangiosis NN i
( ( i
EDAMS NNP i
) ) i
operations NNS p
for IN p
the DT p
treatment NN p
of IN p
moyamoya JJ p
disease NN p
. . p

A DT N
preoperative JJ N
skull NN N
block NN N
may MD N
reduce VB N
hemodynamic JJ o
fluctuations NNS o
and CC o
hypo- NN o
or CC o
hyperventilation NN o
due JJ N
to TO N
emergence VB N
delirium NN N
or CC N
oversedation NN N
and CC N
provide VB N
adequate JJ N
pain NN N
relief NN N
, , N
thereby RB N
reducing VBG N
postoperative JJ o
morbidity NN o
. . o

METHODS NNP N
Pediatric NNP p
patients NNS p
( ( p
age NN p
3-13 CD p
years NNS p
) ) p
undergoing VBG p
EDAMS NNP i
surgery NN i
for IN p
moyamoya JJ p
disease NN p
were VBD p
randomly RB p
divided VBN p
into IN p
a DT p
nerve NN p
block NN p
( ( p
NB NNP p
) ) p
group NN p
( ( p
18 CD p
cases NNS p
) ) p
or CC p
control VB p
group NN p
( ( p
21 CD p
cases NNS p
) ) p
. . N

The DT N
treatment NN N
group NN N
patients NNS N
received VBD N
a DT N
preoperative JJ N
NB NNP i
( ( N
0.25 CD N
% NN N
5-8 JJ N
ml NN N
bupivacaine NN i
mixed JJ N
with IN N
20-40 JJ N
mg NNS N
methylprednisolone NN i
) ) i
targeting VBG N
the DT N
supraorbital NN N
, , N
supratrochlear JJ N
, , N
auriculotemporal JJ N
, , N
and CC N
posterior JJ N
auricular JJ N
nerves NNS N
. . N

Patients NNS N
in IN N
the DT N
control NN N
group NN N
did VBD N
not RB N
receive VB N
NB NNP N
. . N

General NNP N
anesthesia NN N
with IN N
sevoflurane NN i
was VBD N
induced VBN N
in IN N
both DT N
groups NNS N
. . N

RESULTS NNP N
In IN N
the DT N
NB NNP N
group NN N
, , N
stable JJ o
hemodynamic JJ o
parameters NNS o
were VBD N
obtained VBN N
with IN N
a DT N
lower JJR N
sevoflurane NN N
concentration NN N
than IN N
in IN N
the DT N
control NN N
group NN N
. . N

For IN N
delirious JJ o
awakening NN o
, , N
the DT N
odds NNS N
ratio NN N
in IN N
the DT N
control NN N
group NN N
was VBD N
4.9 CD N
compared VBN N
with IN N
the DT N
NB NNP N
group NN N
. . N

Pain NNP o
and CC o
analgesic JJ o
requirement NN o
were VBD N
higher JJR N
in IN N
the DT N
control NN N
patients NNS N
than IN N
in IN N
the DT N
NB-treated JJ N
patients NNS N
during IN N
the DT N
postanesthesia NN N
care NN N
unit NN N
stay NN N
. . N

However RB N
, , N
the DT N
arterial JJ o
CO NNP o
( ( o
2 CD o
) ) o
tension NN o
in IN o
the DT o
postanesthesia NN o
care NN o
unit NN o
did VBD N
not RB N
differ VB N
between IN N
the DT N
2 CD N
groups NNS N
. . N

The DT N
odds NNS o
ratio NN o
in IN N
the DT N
control NN N
group NN N
for IN N
the DT N
rate NN o
of IN o
morbidity NN o
( ( o
cerebral JJ o
infarction NN o
and CC o
reversible JJ o
ischemic JJ o
neurological JJ o
deficits NNS o
) ) o
during IN N
the DT N
first JJ N
24 CD N
hours NNS N
following VBG N
the DT N
operation NN N
was VBD N
3.2 CD N
compared VBN N
with IN N
the DT N
NB NNP N
group NN N
. . N

CONCLUSIONS NNP N
The DT N
use NN N
of IN N
skull JJ N
block NN N
during IN N
EDAMS NNP N
surgery NN N
provided VBD N
easy JJ N
hemodynamic JJ o
control NN o
, , o
calm JJ o
awakening NN o
, , o
and CC o
better JJR o
pain NN o
relief NN o
and CC N
may MD N
be VB N
related VBN N
to TO N
the DT N
reduced VBN N
postoperative JJ o
morbidity NN o
. . o

-DOCSTART- -24336330- O O

TGF-beta JJ N
receptor NN N
type-2 JJ N
expression NN N
in IN N
cancer-associated JJ N
fibroblasts NNS N
regulates VBZ N
breast JJ N
cancer NN N
cell NN N
growth NN N
and CC N
survival NN N
and CC N
is VBZ N
a DT N
prognostic JJ N
marker NN N
in IN N
pre-menopausal JJ N
breast NN N
cancer NN N
. . N

Transforming VBG N
growth NN N
factor-beta JJ N
( ( i
TGF-? NNP i
) ) i
is VBZ N
a DT N
pleiotropic JJ N
cytokine NN N
with IN N
the DT N
capability NN N
to TO N
act VB N
as IN N
tumour JJ N
suppressor NN N
or CC N
tumour NN N
promoter NN N
depending VBG N
on IN N
the DT N
cellular JJ N
context NN N
. . N

TGF-beta JJ i
receptor NN i
type-2 NN i
( ( i
TGFBR2 NNP i
) ) i
is VBZ N
the DT N
ligand-binding JJ N
receptor NN N
for IN N
all DT N
members NNS N
of IN N
the DT N
TGF-? NNP N
family NN N
. . N

Data NNS N
from IN p
mouse NN p
model NN p
experiments NNS p
demonstrated VBD p
that IN N
loss NN N
of IN N
Tgfbr2 NNP N
expression NN N
in IN N
mammary JJ N
fibroblasts NNS N
was VBD N
linked VBN N
to TO N
tumour VB N
initiation NN N
and CC N
metastasis NN N
. . N

Using VBG p
a DT p
randomised JJ i
tamoxifen NN i
trial NN i
cohort NN p
including VBG p
in IN p
total JJ p
564 CD p
invasive JJ p
breast NN p
carcinomas NN p
, , p
we PRP N
examined VBD i
TGFBR2 NNP i
expression NN i
( ( N
n=252 JJ N
) ) N
and CC N
phosphorylation JJ N
level NN N
of IN N
downstream NN N
target NN i
SMAD2 NNP i
( ( i
pSMAD2 NN i
) ) i
( ( i
n=319 JJ N
) ) N
in IN N
cancer-associated JJ i
fibroblasts NNS i
( ( i
CAFs NNP i
) ) i
and CC i
assessed JJ N
links NNS N
to TO N
clinicopathological JJ N
markers NNS N
, , N
prognostic JJ N
and CC N
treatment-predictive JJ N
values NNS N
. . N

The DT N
study NN N
revealed VBD N
that IN N
CAF-specific NNP N
TGFBR2 NNP N
expression NN N
correlated VBD N
with IN N
improved JJ N
recurrence-free JJ N
survival NN N
. . N

Multivariate NNP N
analysis NN N
confirmed VBD N
CAF-TGFBR2 NNP N
to TO N
be VB N
an DT N
independent JJ N
prognostic JJ N
marker NN N
( ( N
multivariate JJ N
Cox NNP N
regression NN N
, , N
hazard NN N
ratio NN N
: : N
0.534 CD N
, , N
95 CD N
% NN N
( ( N
CI NNP N
) ) N
: : N
0.360-0.793 JJ N
, , N
P=0.002 NNP o
) ) o
. . o

CAF-specific JJ o
pSMAD2 NN o
levels NNS o
, , o
however RB N
, , N
did VBD N
not RB N
associate VB N
with IN N
survival JJ N
outcome NN N
. . N

Experimentally RB o
, , o
TGF-? NNP o
signalling NN o
in IN o
fibroblasts NNS o
was VBD o
modulated VBN N
using VBG N
a DT N
TGF-? JJ N
ligand NN N
and CC N
inhibitor NN N
or CC N
through IN N
lentiviral JJ N
short JJ N
hairpin NN N
RNA-mediated JJ N
TGFBR2-specific JJ N
knockdown NN N
. . N

To TO N
determine VB N
the DT N
role NN N
of IN N
fibroblastic JJ N
TGF-? NNP N
pathway NN N
on IN N
breast NN N
cancer NN N
cells NNS N
, , N
we PRP N
used VBD N
cell NN N
contact-dependent NN N
cell NN N
growth NN N
and CC N
clonogenicity NN N
assays NNS N
, , N
which WDT N
showed VBD N
that IN N
knockdown NN N
of IN N
TGFBR2 NNP N
in IN N
CAFs NNP N
resulted VBD N
in IN N
increased VBN o
cell NN o
growth NN o
, , o
proliferation NN o
and CC o
clonogenic JJ o
survival NN o
. . o

Further NNP o
, , p
in IN p
a DT p
mouse NN p
model NN p
transfected VBD i
CAFs NNP i
were VBD N
co-injected JJ N
with IN N
MCF7 NNP i
and CC o
tumour VB o
weight NN o
and CC o
proportion NN o
was VBD o
monitored VBN N
. . N

We PRP N
found VBD N
that IN N
mouse NN p
xenograft NN p
tumours NNS N
comprising VBG N
TGFBR2 NNP N
knockdown JJ N
fibroblasts NNS N
were VBD N
slightly RB N
bigger JJR N
and CC N
displayed VBD N
increased VBN N
tumour NN N
cell NN N
capacity NN N
. . N

Overall UH N
, , N
our PRP$ N
data NNS N
demonstrate NN N
that IN N
fibroblast-related JJ N
biomarkers NNS N
possess VBP N
clinically RB N
relevant JJ N
information NN N
and CC N
that IN N
fibroblasts NNS N
confer VBP N
effects NNS N
on IN N
breast NN N
cancer NN N
cell NN N
growth NN N
and CC N
survival NN N
. . N

Regulation NN N
of IN N
tumour-stromal JJ N
cross-talk NN N
through IN N
fibroblastic JJ N
TGF-? NNP N
pathway NN N
may MD N
depend VB N
on IN N
fibroblast NN N
phenotype NN N
, , N
emphasising VBG N
the DT N
importance NN N
to TO N
characterise VB N
tumour JJ N
microenvironment NN N
subtypes NNS N
. . N

-DOCSTART- -2885887- O O

Noradrenergic NNP p
mechanisms NNS p
in IN p
akathisia NN p
: : p
treatment NN p
with IN p
propranolol NN i
and CC i
clonidine NN i
. . i

-DOCSTART- -27025129- O O

[ JJ N
PLACE NNP N
REMAXOL NNP i
AS IN N
A NNP N
HEPATOPROTECTOR NNP N
IN NNP N
INTENSIVE NNP N
THERAPY NNP N
OF NNP N
PERVASIVE NNP p
PERITONITIS NNP p
] NNP p
. . N

UNLABELLED NNP N
PERPOSE NNP N
OF NNP N
RESEARCH NNP N
: : N
to TO N
evaluate VB N
the DT N
effectiveness NN N
of IN N
Remaxol NNP i
in IN N
patients NNS p
with IN p
pervasive JJ p
peritonitis NN p
. . p

MATERIALS NNP N
AND CC N
METHODS NNP N
assessed VBD N
the DT N
effectiveness NN N
of IN N
a DT N
balanced JJ N
infusion NN N
of IN N
the DT N
drug NN i
( ( i
Remaxol NNP i
) ) i
in IN N
the DT N
treatment NN N
of IN N
44 CD p
patients NNS p
agedfrom RB p
18 CD p
to TO p
50 CD p
years NNS p
. . p

Patients NNS N
were VBD N
devided VBN N
into IN N
2 CD N
groups NNS N
by IN N
the DT N
method NN N
of IN N
envelopes NNS N
. . N

All DT N
patients NNS N
received VBD N
a DT N
comprehensive JJ N
differential JJ N
therapy NN N
: : N
21 CD p
patient NN p
1 CD p
group NN p
consisting VBG N
of IN N
infusion NN i
therapy NN i
in IN N
the DT N
postoperative JJ N
period NN N
received VBD N
Remaxol NNP i
at IN i
a DT i
dose NN i
of IN i
800 CD i
mg/day NN i
for IN N
7 CD N
days NNS N
. . N

RESULTS VB N
the DT N
comporative JJ N
assessment NN N
of IN N
indicators NNS o
of IN o
systemic JJ o
hemodinamics NNS o
, , o
oxygen NN o
transport NN o
, , o
asid JJ o
base NN o
status NN o
, , o
glucose RB o
, , o
lactose JJ o
and CC o
free JJ o
radical JJ o
oxydation NN o
. . o

Patients NNS N
on IN N
the DT N
first JJ N
background NN N
was VBD N
used VBN N
Remaxol NNP i
have VBP N
experiensed VBN N
a DT N
more RBR N
rapid JJ o
relief NN o
of IN o
metabolic JJ o
disorders NNS o
, , o
endotoxemia NN o
and CC o
hepatic JJ o
dysfunction NN o
compared VBN o
with IN N
the DT N
indices NNS N
of IN N
the DT N
2 CD N
group NN N
patients NNS N
. . N

Noted VBN N
earlier JJR N
stabilization NN N
of IN N
rudicators NNS N
of IN N
systemic JJ o
hemodynamics NNS o
and CC o
oxygen NN o
transport NN o
. . o

This DT N
has VBZ N
reduced VBN N
the DT N
duration NN o
of IN o
respiratory NN o
and CC o
vasopressor NN o
suppot NN o
, , N
early JJ N
start NN N
ofparenteral JJ N
intreduction NN N
in IN N
case NN N
the DT N
power NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

CONCLUSIONS VB N
this DT N
study NN N
shows VBZ N
that IN N
use NN N
of IN N
the DT N
drug NN N
for IN N
the DT N
purpose NN N
of IN N
relief NN N
Remaxol NNP i
hepatic JJ N
dysfunction NN N
and CC N
prevention NN N
of IN N
drug NN N
liver NN N
toxicity NN N
in IN N
conditions NNS N
ofperitonitis VBP N
, , N
after IN N
48 CD N
hours NNS N
of IN N
operation NN N
, , N
provides VBZ N
a DT N
positive JJ N
dynamics NNS N
and CC N
stabilization NN N
ofparameters NNS N
of IN N
central JJ N
hemodynamics NNS N
, , N
contributing VBG N
to TO N
the DT N
abolition NN N
of IN N
vasopressor NN N
support NN N
, , N
and CC N
contributes VBZ N
to TO N
the DT N
effective JJ N
utilization NN N
of IN N
oxygen NN N
, , N
while IN N
providing VBG N
antioxidant JJ N
effect NN N
. . N

-DOCSTART- -11234566- O O

Phase-dependent JJ o
modulation NN o
of IN N
the DT N
soleus JJ o
H-reflex NNP o
during IN N
rhythmical JJ i
arm NN o
swing NN o
in IN p
humans NNS p
. . p

The DT N
purpose NN N
of IN N
this DT N
study NN N
is VBZ N
to TO N
investigate VB N
modulation NN o
of IN o
the DT o
soleus JJ o
H-reflex NNP o
during IN N
rhythmic JJ i
arm NN i
swing NN i
in IN p
humans NNS p
. . p

Significant JJ N
depression NN N
of IN N
the DT N
soleus JJ N
H-reflex NNP o
was VBD N
observed VBN N
when WRB N
subjects NNS p
swung VBP p
their PRP$ p
ipsilateral JJ p
arms NNS p
or CC p
both DT p
arms NNS p
reciprocally RB p
during IN p
testing VBG p
. . p

The DT N
degree NN N
of IN N
soleus JJ o
H-reflex NNP o
depression NN o
appeared VBD N
directly RB N
proportional JJ N
to TO N
the DT N
speed NN N
of IN N
the DT N
arm NN N
swing NN N
. . N

This DT N
depression NN o
was VBD N
observed VBN N
in IN N
the DT N
conditioning-testing JJ N
intervals NNS N
of IN N
400 CD N
, , N
500 CD N
, , N
and CC N
600 CD N
msec NN N
during IN N
the DT N
ipsilateral JJ i
backward NN i
arm NN i
swing NN i
and CC N
at IN N
the DT N
onset NN N
of IN N
the DT N
ipsilateral JJ i
arm NN i
forward NN i
swing NN i
. . i

This DT N
phase NN N
of IN N
depression NN o
partially RB N
overlapped VBD N
the DT N
phase NN N
of IN N
depression NN N
of IN N
the DT N
soleus JJ N
H-reflex NNP N
during IN N
walking VBG N
. . N

However RB N
, , N
the DT N
pattern NN N
of IN N
modulation NN N
during IN N
arm NN N
swing NN N
was VBD N
not RB N
exactly RB N
the DT N
same JJ N
as IN N
that DT N
during IN N
walking VBG N
. . N

Therefore RB N
, , N
we PRP N
concluded VBD N
that IN N
the DT N
ipsilateral JJ o
arm NN o
swing NN o
may MD N
partially RB N
affect VB N
the DT N
depression NN o
of IN o
the DT o
soleus JJ o
H-reflex NNP o
during IN N
the DT N
arm NN N
swing NN N
phase NN N
of IN N
walking VBG N
but CC N
is VBZ N
not RB N
responsible JJ N
for IN N
depression NN o
of IN o
the DT o
soleus NN o
H-reflex NNP o
throughout IN N
the DT N
entire JJ N
walking NN N
cycle NN N
. . N

-DOCSTART- -12198659- O O

Endoscopic NNP i
ligation NN i
compared VBN N
with IN N
sclerotherapy NN i
for IN N
bleeding VBG o
esophageal JJ o
varices NNS o
in IN N
children NNS p
with IN p
extrahepatic JJ p
portal NN p
venous JJ p
obstruction NN p
. . p

Endoscopic NNP i
sclerotherapy NN i
is VBZ N
an DT N
effective JJ N
treatment NN N
for IN N
bleeding VBG o
esophageal JJ o
varices NNS o
, , N
but CC N
it PRP N
is VBZ N
associated VBN N
with IN N
significant JJ o
complications NNS o
. . o

Endoscopic NNP i
ligation NN i
, , N
a DT N
new JJ N
form NN N
of IN N
endoscopic NN N
treatment NN N
for IN N
bleeding VBG o
varices NNS o
, , N
has VBZ N
been VBN N
shown VBN N
to TO N
be VB N
superior JJ N
to TO N
sclerotherapy VB N
in IN N
adult NN p
patients NNS p
with IN p
cirrhosis NN p
. . p

To TO N
determine VB N
the DT N
efficacy NN o
and CC o
safety NN o
of IN N
endoscopic JJ N
sclerotherapy NN N
and CC N
ligation NN N
, , N
the DT N
2 CD N
methods NNS N
were VBD N
compared VBN N
in IN N
a DT N
randomized JJ N
control NN N
trial NN N
in IN N
49 CD p
children NNS p
with IN p
extrahepatic JJ p
portal NN p
venous JJ p
obstruction NN p
who WP p
had VBD p
proven VBN p
bleeding VBG p
from IN p
esophageal JJ p
varices NNS p
. . p

Twenty-four CD p
patients NNS p
were VBD p
treated VBN p
with IN p
sclerotherapy NN i
and CC p
25 CD p
with IN p
band NN i
ligation NN i
. . i

No DT N
significant JJ N
differences NNS N
were VBD N
found VBN N
between IN N
the DT N
sclerotherapy NN N
and CC N
ligation NN N
groups NNS N
in IN N
arresting VBG o
active JJ o
index NN o
bleeding NN o
( ( N
100 CD N
% NN N
each DT N
) ) N
and CC N
achieving VBG o
variceal JJ o
eradication NN o
( ( N
91.7 CD N
% NN N
vs. FW N
96 CD N
% NN N
, , N
P NNP N
=.61 NNP N
) ) N
. . N

Band NNP N
ligation NN N
eradicated VBD N
varices NNS o
in IN N
fewer JJR N
endoscopic NN o
sessions NNS o
than IN N
did VBD N
sclerotherapy VB N
( ( N
3.9 CD N
+/- JJ N
1.1 CD N
vs. FW N
6.1 CD N
+/- JJ N
1.7 CD N
, , N
respectively RB N
, , N
P NNP N
< NNP N
.0001 NNP N
) ) N
. . N

The DT N
rebleeding VBG o
rate NN o
was VBD N
significantly RB N
higher JJR N
in IN N
the DT N
sclerotherapy NN N
group NN N
( ( N
25 CD N
% NN N
vs. FW N
4 CD N
% NN N
, , N
P NNP N
=.049 NNP N
) ) N
, , N
as IN N
was VBD N
the DT N
rate NN o
of IN o
major JJ o
complications NNS o
( ( N
25 CD N
% NN N
vs. FW N
4 CD N
% NN N
, , N
P NNP N
=.049 NNP N
) ) N
. . N

After IN N
eradication NN N
, , N
esophageal JJ o
variceal NN o
recurrence NN o
was VBD N
not RB N
significantly RB N
different JJ N
in IN N
patients NNS N
treated VBN N
by IN N
ligation NN N
than IN N
by IN N
sclerotherapy NN N
( ( N
17.4 CD N
% NN N
vs. FW N
10 CD N
% NN N
, , N
P NNP N
=.67 NNP N
) ) N
. . N

In IN N
conclusion NN N
, , N
variceal JJ i
band NN i
ligation NN i
in IN N
children NNS p
is VBZ N
a DT N
safe JJ o
and CC o
effective JJ o
technique NN N
that WDT N
achieves VBZ N
variceal JJ o
eradication NN o
more RBR N
quickly RB N
, , N
with IN N
a DT N
lower JJR N
rebleeding NN o
rate NN o
and CC N
fewer JJR N
complications NNS o
compared VBN N
with IN N
sclerotherapy NN N
. . N

-DOCSTART- -12090782- O O

Onset NNP N
of IN N
action NN N
following VBG N
formoterol NN i
Turbuhaler NNP N
and CC N
salbutamol JJ i
pMDI NN N
in IN N
reversible JJ p
chronic JJ p
airway NN p
obstruction NN p
. . p

Short-acting JJ N
beta NN N
( ( N
2 CD N
) ) N
-agonists NNS N
are VBP N
currently RB N
recommended VBN N
for IN N
symptom JJ N
relief NN N
in IN N
asthma NN N
and CC N
the DT N
treatment NN N
of IN N
mild NN N
, , N
acute JJ N
exacerbations NNS N
in IN N
COPD NNP N
. . N

However RB N
, , N
formoterol NN i
has VBZ N
as IN N
fast RB N
an DT N
onset NN N
of IN N
action NN N
as IN N
salbutamol NN i
with IN N
the DT N
additional JJ N
benefit NN N
of IN N
longer-lasting JJ N
bronchodilation NN N
( ( N
approximately RB N
12 CD N
h NN N
) ) N
. . N

Furthermore UH N
, , N
systemic JJ N
side NN N
effects NNS N
observed VBN N
with IN N
formoterol NN i
are VBP N
of IN N
a DT N
similar JJ N
duration NN N
but CC N
less JJR N
pronounced VBD N
than IN N
with IN N
short-acting JJ N
beta NN N
( ( N
2 CD N
) ) N
-agonists NNS N
. . N

In IN N
this DT N
double-blind NN N
, , N
randomized VBN N
, , N
cross-over JJ N
study NN N
, , N
20 CD p
adult NN p
patients NNS p
with IN p
reversible JJ p
chronic JJ p
airway NN p
obstruction NN p
( ( p
intrinsic JJ p
asthma NN p
or CC p
COPD NNP p
) ) p
inhaled VBD N
single JJ N
doses NNS N
of IN N
formoterol NN i
9 CD i
microg NN i
or CC i
salbutamol VB i
100 CD i
microg NN i
( ( i
group NN i
A NNP i
) ) i
or CC i
formoterol $ i
18 CD i
microg NN i
or CC i
salbutamol VB i
200 CD i
microg NN i
( ( i
group NN i
B NNP i
) ) i
. . i

FEV NNP o
( ( o
1 CD o
) ) o
was VBD N
measured VBN N
prior RB N
to TO N
and CC N
5 CD N
, , N
10 CD N
, , N
15 CD N
, , N
20 CD N
, , N
25 CD N
and CC N
30 CD N
min NN N
following VBG N
inhalation NN N
of IN N
study JJ N
drug NN N
. . N

No DT N
significant JJ N
differences NNS N
in IN N
FEV NNP o
( ( o
1 CD o
) ) o
values NNS o
were VBD N
observed VBN N
between IN N
group NN N
A NNP N
( ( N
P=0.704 NNP N
) ) N
or CC N
group NN N
B NNP N
( ( N
P=0.270 NNP N
) ) N
at IN N
baseline NN N
, , N
or CC N
at IN N
5 CD N
( ( N
Group NNP N
A NNP N
: : N
P=0.340 NNP N
; : N
Group NNP N
B NNP N
: : N
P=0.559 NN N
) ) N
and CC N
15 CD N
min NN N
( ( N
Group NNP N
A NNP N
: : N
P=0.526 NNP N
; : N
Group NNP N
B NNP N
: : N
P=0.818 NNP N
) ) N
post NN N
dose NN N
. . N

No DT N
adverse JJ o
events NNS o
were VBD N
reported VBN N
during IN N
the DT N
study NN N
. . N

Formoterol NNP i
Turbuhaler NNP N
has VBZ N
as RB N
rapid JJ N
an DT N
onset NN N
of IN N
action NN N
as IN N
salbutamol NN i
pMDI NN N
when WRB N
given VBN N
at IN N
the DT N
recommended JJ N
doses NNS N
. . N

-DOCSTART- -16335132- O O

Phytase NNP i
and CC i
1alpha-hydroxycholecalciferol JJ i
supplementation NN i
of IN N
broiler NN p
chickens NNS p
during IN p
the DT p
starting NN p
and CC p
growing/finishing NN p
phases NNS p
. . p

Supplemental JJ N
1alpha-hydroxycholecalciferol JJ N
( ( N
1alpha-OHD3 JJ N
) ) N
has VBZ N
been VBN N
shown VBN N
to TO N
have VB N
qualitatively RB N
similar JJ N
and CC N
quantitatively RB N
additive JJ N
effects NNS N
to TO N
exogenous JJ N
phytase NN N
. . N

Two CD N
experiments NNS N
were VBD N
conducted VBN N
from IN N
0 CD N
to TO N
35 CD N
d NN N
in IN N
floor NN N
pens NNS N
to TO N
determine VB N
the DT N
additive JJ N
effect NN N
of IN N
phytase NN i
and CC i
1alpha-OHD3 JJ i
when WRB N
supplemented VBN N
to TO N
Ca- NNP i
and CC i
P-deficient NNP i
diets NNS i
. . i

In IN N
both DT N
experiments NNS N
, , N
at IN p
least JJS p
4 CD p
replicates NNS p
per IN p
treatment NN p
( ( p
50 CD p
chicks NNS p
per IN p
replicate NN p
) ) p
were VBD p
used VBN p
. . p

Corn-soybean-meal-and JJ i
soybean-oil-based JJ i
diets NNS i
were VBD i
fed VBN i
and CC i
birds NNS i
were VBD i
raised VBN i
in IN i
a DT i
house NN i
impervious JJ i
to TO i
ultraviolet VB i
light NN i
. . i

During IN N
the DT N
starter JJ N
phase NN N
( ( N
ST NNP N
) ) N
, , N
from IN N
0 CD N
to TO N
18 CD N
d NN N
, , N
chicks NNS N
were VBD N
fed VBN N
a DT N
23 CD N
% NN N
CP NNP N
diet JJ N
containing VBG N
0.60 CD N
% NN N
Ca NNP N
and CC N
0.47 CD N
% NN N
total JJ N
P NNP N
( ( N
tP NN N
) ) N
. . N

During IN N
the DT N
grower/finisher NN N
phase NN N
( ( N
GF NNP N
) ) N
, , N
from IN N
19 CD N
to TO N
35 CD N
d NN N
, , N
birds NNS N
were VBD N
fed VBN N
a DT N
19 CD N
% NN N
CP NNP N
diet JJ N
containing VBG N
0.30 CD N
% NN N
Ca NNP N
and CC N
0.37 CD N
% NN N
tP NN N
. . N

A DT N
combination NN N
of IN N
1,000 CD N
phytase NN N
units/kg NN N
of IN N
Natuphos NNP N
phytase NN N
and CC N
5 CD N
microg/kg NN N
of IN N
1alpha-OHD3 JJ N
( ( N
P+1A NNP N
) ) N
was VBD N
supplemented VBN N
to TO N
some DT N
of IN N
the DT N
feed NN N
during IN N
the DT N
ST NNP N
and CC N
GF NNP N
. . N

Diets NNS N
containing VBG N
adequate NN N
Ca NNP N
and CC N
P NNP N
were VBD N
also RB N
fed VBN N
during IN N
the DT N
ST NNP N
( ( N
0.90 CD N
% NN N
Ca NNP N
, , N
0.68 CD N
% NN N
tP NN N
) ) N
and CC N
GF NNP N
( ( N
0.80 CD N
% NN N
Ca NNP N
, , N
0.67 CD N
% NN N
tP NN N
) ) N
. . N

Performance NN o
characteristics NNS o
and CC N
the DT N
incidence NN o
of IN o
rickets NNS o
and CC o
tibial JJ o
dyschondroplasia NN o
were VBD N
measured VBN N
at IN N
18 CD N
and CC N
35 CD N
d. NN N
In IN N
experiment JJ N
1 CD N
, , N
unsupplemented JJ N
chicks NNS N
performed VBN N
well RB N
but CC N
had VBD N
considerable JJ N
leg JJ o
problems NNS o
. . o

Chicks NNP N
fed VBD N
P+1A NNP N
during IN N
the DT N
ST NNP N
or CC N
GF NNP N
did VBD N
not RB N
perform VB N
as RB N
well RB N
as IN N
birds NNS N
fed VBN N
P+1A NNP N
throughout IN N
. . N

Birds NNS N
fed VBD N
P+1A NNP N
throughout IN N
performed VBN N
as IN N
well RB N
birds NNS N
fed VBD N
the DT N
adequate JJ N
diets NNS N
without IN N
any DT N
indication NN N
of IN N
leg NN N
problems NNS N
. . N

In IN N
experiment JJ N
2 CD N
, , N
unsupplemented JJ N
birds NNS N
performed VBD N
similarly RB N
to TO N
unsupplemented JJ N
birds NNS p
in IN p
experiment JJ p
1 CD p
. . p

However RB N
, , N
chicks NNS N
fed VBP N
the DT N
supplements NNS N
or CC N
the DT N
control JJ N
diets NNS N
did VBD N
not RB N
perform VB N
as RB N
well RB N
or CC N
accumulate VB o
as IN o
much JJ o
bone NN o
ash NN o
as IN N
birds NNS p
in IN p
experiment JJ p
1 CD p
, , N
although IN N
the DT N
diets NNS N
were VBD N
formulated VBN N
identically RB N
in IN N
both DT N
experiments NNS N
. . N

Diets NNS N
with IN N
as RB N
little JJ N
as IN N
0.30 CD N
% NN N
Ca NNP N
and CC N
0.37 CD N
% NN N
tP NN N
appear VBP N
to TO N
be VB N
adequate JJ N
for IN N
broilers NNS N
older JJR N
than IN N
18 CD N
d NN N
if IN N
supplemented VBN N
with IN N
the DT N
correct JJ N
amounts NNS N
of IN N
phytase NN N
and CC N
1alpha-OHD3 JJ N
. . N

However RB N
, , N
there EX N
are VBP N
unknown JJ N
variables NNS N
that WDT N
may MD N
limit VB N
the DT N
potential NN N
of IN N
broilers NNS N
in IN N
terms NNS N
of IN N
bone NN o
mineralization NN o
and CC o
bone NN o
pathology NN o
, , N
even RB N
when WRB N
adequate JJ N
diets NNS N
are VBP N
fed VBN N
. . N

-DOCSTART- -1645768- O O

Application NN N
of IN N
ambulatory JJ N
blood NN N
pressure NN N
monitoring NN N
to TO N
clinical JJ N
therapeutic JJ N
decisions NNS N
in IN N
hypertension NN p
. . p

The DT N
antihypertensive JJ o
efficacies NNS N
of IN N
lisinopril NN i
and CC N
captopril NN i
were VBD N
compared VBN N
using VBG N
office NN N
sphygmomanometry NN N
and CC N
24-h JJ N
ambulatory NN N
blood NN N
pressure NN N
monitoring NN N
. . N

In IN N
a DT N
double-blind NN N
, , N
prospective JJ N
, , N
randomly RB N
allocated VBN N
trial NN N
, , N
the DT p
patients NNS p
were VBD N
given VBN N
increasing VBG N
doses NNS N
of IN N
captopril NN i
at IN N
25-100 JJ N
mg NN N
twice RB N
a DT N
day NN N
or CC N
lisinopril NN i
at IN N
10-40 JJ N
mg NN N
once IN N
a DT N
day NN N
until IN N
a DT N
clinical JJ o
response NN o
was VBD N
achieved VBN N
or CC N
the DT N
highest JJS N
dose NN N
was VBD N
reached VBN N
. . N

A DT N
response NN N
was VBD N
defined VBN N
as IN N
a DT N
reduction NN o
in IN o
diastolic JJ o
pressure NN o
below IN o
90 CD o
mmHg NN o
or CC o
a DT o
fall NN o
of IN o
at IN o
least JJS o
10 CD o
mmHg NN o
from IN o
baseline NN o
. . o

The DT N
ambulatory NN N
monitoring NN N
showed VBD N
that IN N
lisinopril NN N
reduced VBD N
blood NN o
pressure NN o
from IN N
baseline NN N
to TO N
the DT N
final JJ N
value NN N
and CC N
maintained VBD o
the DT o
reduction NN o
to TO N
a DT N
greater JJR N
degree NN N
than IN N
captopril NN i
throughout IN N
24-h JJ N
periods NNS N
of IN N
observation NN N
. . N

The DT N
office NN o
measurements NNS o
showed VBD N
a DT N
similar JJ N
trend NN N
, , N
but CC N
the DT N
intertreatment JJ N
differences NNS N
did VBD N
not RB N
reach VB N
statistical JJ N
significance NN N
. . N

No DT N
first-dose JJ o
side NN o
effects NNS N
were VBD N
observed VBN N
with IN N
either DT N
drug NN N
. . N

Once IN N
a DT N
day NN N
lisinopril NN i
appeared VBD N
to TO N
be VB N
a DT N
more RBR N
effective JJ o
antihypertensive JJ i
regimen NNS i
than IN N
twice RB N
a DT N
day NN N
captopril NN N
. . N

-DOCSTART- -23405154- O O

Is VBZ N
altered JJ N
central JJ N
pain NN N
processing NN N
related VBN N
to TO N
disease VB N
stage NN N
in IN N
chronic JJ p
pancreatitis NN p
patients NNS p
with IN p
pain NN p
? . N
An DT N
exploratory NN N
study NN N
. . N

BACKGROUND NNP N
The DT N
most RBS N
dominant JJ N
feature NN N
in IN N
chronic JJ N
pancreatitis NN N
is VBZ N
intense JJ N
abdominal JJ N
pain NN N
. . N

Changes NNS N
in IN N
spinal JJ N
and/or JJ N
supraspinal JJ N
central JJ N
nervous JJ N
system NN N
pain NN N
processing NN N
due JJ N
to TO N
visceral JJ N
nociceptive JJ N
input NN N
play VBP N
an DT N
important JJ N
role NN N
in IN N
this DT N
pain NN N
. . N

How WRB N
altered JJ i
pain NN i
processing NN i
is VBZ N
related VBN N
to TO N
disease VB N
stage NN N
still RB N
needs VBZ N
study NN N
. . N

METHODOLOGY/PRINCIPAL NNP N
FINDINGS NNP N
Sixty NNP p
chronic JJ p
pancreatitis NN p
patients NNS p
were VBD p
compared VBN p
to TO p
15 CD p
healthy JJ p
controls NNS p
. . p

Two CD N
subgroups NNS N
of IN N
pancreatitis NN N
patients NNS N
were VBD N
defined VBN N
based VBN N
on IN N
the DT N
M-ANNHEIM NNP N
severity NN N
index NN N
of IN N
chronic JJ N
pancreatitis NN N
; : N
i.e NN N
. . N

moderate JJ N
and CC N
severe JJ N
. . N

Pain VB o
detection NN o
and CC o
tolerance NN o
thresholds NNS o
for IN o
pressure NN o
and CC o
electric JJ o
stimuli NNS o
were VBD N
measured VBN N
in IN N
six CD N
selected VBN N
dermatomes NNS N
( ( N
C5 NNP N
, , N
T4 NNP N
, , N
T10 NNP N
, , N
L1 NNP N
, , N
L4 NNP N
and CC N
T10BACK NNP N
) ) N
. . N

In IN N
addition NN N
, , N
the DT N
conditioned VBN N
pain NN i
modulation NN i
response NN i
to TO N
cold VB i
pressor NN i
task NN i
was VBD N
determined VBN N
. . N

These DT N
measures NNS N
were VBD N
compared VBN N
between IN N
the DT N
healthy JJ N
controls NNS N
and CC N
chronic JJ N
pancreatitis NN N
patients NNS N
. . N

Severe NNP N
pancreatitis NN N
patients NNS N
showed VBD N
lower JJR N
pain NN o
thresholds NNS o
than IN N
moderate JJ N
pancreatitis NN N
patients NNS p
or CC N
healthy JJ N
volunteers NNS N
. . N

Healthy NNP N
controls VBZ N
showed VBD N
a DT N
significantly RB N
larger JJR N
conditioned VBN N
pain NN o
modulation NN o
response NN N
compared VBN N
to TO N
all DT N
chronic JJ N
pancreatitis NN N
patients NNS p
taken VBN N
together RB N
. . N

CONCLUSIONS/SIGNIFICANCE VB N
The DT N
present JJ N
study NN N
confirms VBZ N
that IN N
chronic JJ N
pancreatitis NN N
patients NNS N
show VBP N
signs NNS N
of IN N
altered JJ i
central JJ i
processing NN i
of IN N
nociception NN N
compared VBN N
to TO N
healthy JJ N
controls NNS N
. . N

The DT N
study NN N
further JJ N
suggests VBZ N
that IN N
these DT N
changes NNS N
, , N
i.e NN N
. . N

central JJ N
sensitization NN N
, , N
may MD N
be VB N
influenced VBN N
by IN N
disease NN N
stage NN N
. . N

These DT N
findings NNS N
underline VBP N
the DT N
need NN N
to TO N
take VB N
altered JJ N
central JJ N
pain NN N
processing NN N
into IN N
account NN N
when WRB N
managing VBG N
the DT N
pain NN N
of IN N
chronic JJ N
pancreatitis NN N
. . N

-DOCSTART- -12463729- O O

Pharmacokinetic JJ o
and CC o
safety NN o
assessments NNS o
of IN N
galantamine NN i
and CC i
risperidone NN i
after IN N
the DT N
two CD N
drugs NNS N
are VBP N
administered VBN N
alone RB N
and CC N
together RB N
. . N

To TO N
explore VB N
the DT N
steady-state JJ N
pharmacokinetic JJ N
profile NN N
after IN N
coadministration NN N
of IN N
galantamine NN i
and CC i
risperidone NN i
, , N
an DT N
open-label JJ N
, , N
randomized VBN N
, , N
single-center JJ N
, , N
two-way JJ N
crossover NN N
drug-drug JJ N
interaction NN N
study NN N
was VBD N
conducted VBN N
in IN N
16 CD p
healthy JJ p
elderly JJ p
subjects NNS p
, , p
ages VBZ p
60 CD p
years NNS p
and CC p
older JJR p
. . p

The DT N
results NNS N
showed VBD N
that IN N
risperidone NN i
, , N
when WRB N
administered VBN N
with IN N
galantamine NN i
, , N
did VBD N
not RB N
change VB N
the DT N
bioavailability NN o
of IN N
galantamine NN i
at IN N
steady JJ N
state NN N
. . N

In IN N
addition NN N
, , N
systemic JJ N
exposure NN N
of IN N
risperidone NN i
active JJ N
moiety NN N
( ( i
risperidone JJ i
plus CC i
9-hydroxyrisperidone CD i
) ) i
, , N
the DT N
most RBS N
clinically RB N
relevant JJ N
component NN N
of IN N
risperidone NN i
treatment NN N
, , N
was VBD N
not RB N
affected VBN N
by IN N
galantamine JJ i
coadministration NN N
, , N
while IN N
systemic JJ o
exposure NN o
was VBD N
increased VBN N
by IN N
approximately RB N
10 CD N
% NN N
for IN N
risperidone NN i
and CC N
decreased VBN N
by IN N
about IN N
10 CD N
% NN N
for IN N
9-hydroxyrisperidone CD i
( ( N
active JJ N
metabolite NN N
of IN N
risperidone NN i
) ) i
. . N

Galantamine NNP i
and CC i
risperidone NN i
were VBD N
both DT N
safe JJ o
and CC o
well RB o
tolerated VBN o
administered VBN N
either CC N
alone RB N
or CC N
together RB N
. . N

Thus NNP N
, , N
no DT N
dose JJ N
adjustment NN N
for IN N
either DT N
risperidone NN i
orgalantamine NN i
is VBZ N
necessary JJ N
when WRB N
these DT N
two CD N
drugs NNS N
are VBP N
administered VBN N
together RB N
in IN N
the DT N
dose JJ N
range NN N
evaluated VBD N
. . N

-DOCSTART- -24817216- O O

Reliable JJ N
LC-MS/MS JJ i
assay NN i
for IN N
the DT N
estimation NN o
of IN o
rilpivirine NN o
in IN p
human JJ p
plasma NN p
: : p
application NN N
to TO N
a DT N
bioequivalence NN N
study NN N
and CC N
incurred JJ N
sample NN N
reanalysis NN N
. . N

A DT N
simple JJ N
, , N
precise JJ N
, , N
and CC N
rapid JJ N
stable JJ N
isotope NN N
dilution NN N
liquid VBD N
chromatography-tandem JJ N
mass NN N
spectrometry NN N
method NN N
has VBZ N
been VBN N
developed VBN N
and CC N
validated VBN N
for IN N
the DT N
quantification NN N
of IN N
rilpivirine NN p
, , N
a DT N
non-nucleoside JJ N
reverse NN N
transcriptase NN N
inhibitor NN N
in IN N
human JJ p
plasma NN p
. . p

Rilpivirine NNP N
and CC N
its PRP$ N
deuterated JJ N
analogue NN N
, , N
rilpivirine-d6 NN i
, , N
used VBD N
as IN N
an DT N
internal JJ N
standard NN N
( ( N
IS NNP N
) ) N
were VBD N
quantitatively RB N
extracted VBN N
by IN N
liquid-liquid JJ N
extraction NN N
with IN N
methyl-tert-butyl JJ N
ether NN N
and CC N
diethyl NN N
ether RB N
solvent JJ N
mixture NN N
from IN N
50 CD N
?L JJ N
plasma NN N
. . N

The DT N
chromatography NN N
was VBD N
achieved VBN N
on IN N
Gemini NNP N
C18 NNP N
( ( N
150 CD N
? . N
4.6 CD N
mm NN N
, , N
5 CD N
?m NN N
) ) N
analytical JJ N
column NN N
in IN N
a DT N
run JJ N
time NN N
of IN N
2.2 CD N
min NN N
. . N

The DT N
precursor NN N
? . N
product NN N
ion NN N
transitions NNS N
for IN N
rilpivirine NN N
( ( N
m/z $ N
367.1 CD N
? . N
128.0 CD N
) ) N
and CC N
IS NNP N
( ( N
m/z $ N
373.2 CD N
? . N
134.2 CD N
) ) N
were VBD N
monitored VBN N
on IN N
a DT N
triple JJ N
quadrupole JJ N
mass NN N
spectrometer NN N
in IN N
the DT N
positive JJ N
ionization NN N
mode NN N
. . N

The DT N
linearity NN N
of IN N
the DT N
method NN N
was VBD N
established VBN N
in IN N
the DT N
concentration NN N
range NN N
of IN N
0.5-200 JJ N
ng/mL NN N
. . N

The DT o
mean JJ o
extraction NN o
recovery NN o
for IN N
rilpivirine NN N
( ( N
94.9 CD N
% NN N
) ) N
and CC N
IS NNP N
( ( N
99.9 CD N
% NN N
) ) N
from IN N
spiked VBN N
plasma NN N
samples NNS N
was VBD N
consistent JJ N
and CC N
reproducible JJ o
. . o

The DT o
IS-normalized JJ o
matrix NN o
factors NNS o
for IN o
rilpivirine NN o
ranged VBN N
from IN N
0.98 CD N
to TO N
1.02 CD N
across IN N
three CD N
quality NN N
controls NNS o
. . o

Bench NNP o
top JJ o
, , o
freeze-thaw JJ o
, , o
wet JJ o
extract NN o
, , o
and CC o
long-term JJ o
stability NN o
of IN N
rilpivirine NN N
was VBD N
examined VBN N
in IN N
spiked JJ N
plasma NN N
samples NNS N
. . N

The DT N
application NN N
of IN N
the DT N
method NN N
was VBD N
demonstrated VBN N
by IN N
a DT N
bioequivalence NN N
study NN N
with IN N
25 CD i
mg NNS i
rilpivirine JJ i
tablet NN i
formulation NN p
in IN p
40 CD p
healthy JJ p
subjects NNS p
. . p

The DT N
assay JJ N
reproducibility NN N
was VBD N
shown VBN N
by IN N
reanalysis NN N
of IN p
200 CD p
study NN p
samples NNS p
and CC p
the DT N
% NN N
change NN N
in IN N
the DT N
concentration NN N
of IN N
repeat NN N
values NNS N
from IN N
the DT N
original JJ N
values NNS N
was VBD N
within IN N
?15 NNP N
% NN N
. . N

-DOCSTART- -25001543- O O

A DT N
further JJ N
investigation NN N
of IN N
goal-directed JJ o
intention NN o
understanding NN o
in IN N
young JJ p
children NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
. . p

Findings NNS N
from IN N
research NN N
investigating VBG N
goal-directed JJ o
intention NN o
understanding NN o
in IN N
children NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
( ( p
ASD NNP p
) ) p
have VBP N
been VBN N
equivocal JJ N
, , N
in IN N
part NN N
because IN N
of IN N
the DT N
varying NN N
methodologies NNS N
used VBN N
across IN N
studies NNS N
. . N

This DT N
study NN N
compares VBZ N
both DT N
object-oriented JJ i
and CC i
social-communicatively JJ i
cued VBN i
goal-directed JJ i
intention NN i
understanding NN i
in IN N
children NNS p
with IN p
ASD NNP p
and CC p
typically-developing JJ p
children NNS p
. . p

Relative JJ N
to TO N
matched VB N
controls NNS N
, , N
children NNS N
with IN N
ASD NNP N
did VBD N
not RB N
exhibit VB N
deficits NNS N
in IN N
object-oriented JJ o
intention NN o
understanding NN o
. . o

While IN N
children NNS p
with IN p
ASD NNP p
also RB N
demonstrated VBD N
the DT N
ability NN N
to TO N
understand VB N
intention NN N
when WRB N
cued VBN N
by IN N
social-communication NN N
indicators NNS N
, , N
typically-developing JJ N
children NNS N
differentiated VBD N
between IN N
intentional JJ N
and CC N
unintentional JJ N
acts NNS N
at IN N
a DT N
significantly RB N
greater JJR N
level NN N
. . N

Group NNP N
differences VBZ N
in IN N
performance NN N
were VBD N
eliminated VBN N
if IN N
only JJ N
trials NNS N
in IN N
which WDT N
children NNS N
attended VBD N
to TO N
the DT N
experimenter NN N
's POS N
face NN N
were VBD N
considered VBN N
. . N

Results VB N
suggest JJS N
that IN N
children NNS p
with IN p
ASD NNP p
have VBP N
intact JJ N
object-oriented JJ o
intention NN o
understanding VBG o
abilities NNS N
, , N
and CC N
are VBP N
able JJ N
to TO N
use VB N
social-communicative JJ N
cues NNS N
to TO N
understand VB N
intention NN N
. . N

However RB N
, , N
their PRP$ N
ability NN N
to TO N
demonstrate VB N
social-communicatively JJ o
cued VBN o
intention NN o
understanding NN i
is VBZ N
limited VBN N
by IN N
a DT N
lack NN N
of IN N
attention NN N
to TO N
relevant VB N
social-communicative JJ N
information NN N
. . N

-DOCSTART- -25920470- O O

Effect NN N
of IN N
motor NN i
training NN i
involving VBG N
the DT N
less-affected JJ N
side NN N
( ( N
MTLA NNP N
) ) N
in IN N
post-stroke JJ p
subjects NNS p
: : p
a DT N
pilot NN N
randomized VBN N
controlled VBN N
trial NN N
. . N

INTRODUCTION NNP N
Poststroke NNP N
, , N
less-severe JJ N
motor NN N
impairment NN N
occurs VBZ N
on IN N
the DT N
ipsilesional JJ N
side NN N
of IN N
body NN N
. . N

The DT N
objective NN N
of IN N
the DT N
present JJ N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
effectiveness NN N
of IN N
the DT N
motor NN i
training NN i
involving VBG N
the DT N
less-affected JJ N
side NN N
( ( N
MTLA NNP N
) ) N
in IN N
stroke NN N
. . N

METHODS NNP N
This DT N
was VBD N
a DT N
randomized JJ N
, , N
controlled VBN N
, , N
double-blinded JJ N
pilot NN N
study NN N
conducted VBN p
in IN p
the DT p
occupational JJ p
therapy NN p
unit NN p
of IN p
a DT p
rehabilitation NN p
Institute NNP p
. . p

A DT p
convenience NN p
sample NN p
of IN p
35 CD p
stroke NN p
subjects NNS p
( ( p
mean JJ p
poststroke NN p
duration NN p
, , p
28.76 CD p
weeks NNS p
) ) p
was VBD N
randomized VBN N
into IN N
two CD N
groups NNS N
( ( N
the DT N
experimental NN N
group NN N
: : N
17 CD N
and CC N
control VB N
group NN N
: : N
18 CD N
) ) N
. . N

Thirty-two JJ p
participants NNS p
completed VBD p
the DT p
entire JJ p
study NN p
protocol NN p
. . p

The DT N
experimental JJ N
group NN N
and CC N
control NN N
group NN N
were VBD N
provided VBN N
MTLA NNP i
and CC i
neurophysiological-based JJ i
conventional JJ i
therapy NN i
respectively RB i
. . i

Both CC N
the DT N
groups NNS N
received VBD N
24 CD N
treatment NN N
sessions NNS N
( ( N
60 CD N
minutes NNS N
each DT N
) ) N
over IN N
the DT N
period NN N
of IN N
two CD N
months NNS N
. . N

The DT N
Affected JJ N
side NN N
was VBD N
assessed VBN N
using VBG N
Brunnstrom NNP o
recovery NN o
stage NN o
( ( o
BRS NNP o
) ) o
and CC o
Fugl-Meyer NNP o
assessment NN o
( ( o
FMA NNP o
) ) o
whereas VBD N
the DT N
less-affected JJ N
side NN N
was VBD N
evaluated VBN N
by IN N
Minnesota NNP o
manual JJ o
dexterity NN o
test NN o
( ( o
MMDT NNP o
) ) o
, , o
Purdue NNP o
peg NNP o
board NN o
test NN o
( ( o
PPBT NNP o
) ) o
and CC o
Manual JJ o
Muscle NNP o
Testing NNP o
( ( o
MMT NNP o
) ) o
. . o

RESULTS NNP N
Postintervention NNP N
, , N
the DT N
less-affected JJ N
side NN N
of IN N
experimental JJ N
group NN N
demonstrated VBD N
significant JJ N
improvement NN o
for IN o
MMDT NNP o
( ( N
P NNP N
= NNP N
0.003 CD N
) ) N
, , N
PPBT NNP o
( ( N
P NNP N
= NNP N
0.01 CD N
) ) N
and CC N
MMT NNP o
( ( N
P NNP N
< VBZ N
0.001 CD N
to TO N
0.043 CD N
) ) N
in IN N
comparison NN N
to TO N
the DT N
control NN N
group NN N
. . N

Further RB N
, , N
as IN N
compared VBN N
to TO N
the DT N
control NN N
group NN N
, , N
the DT N
experimental JJ N
group NN N
exhibited VBD N
positive JJ N
significant JJ N
change NN N
for IN N
the DT N
measure NN o
of IN o
affected JJ o
side NN o
[ NNP o
BRS NNP o
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
and CC o
FMA NNP o
( ( o
P NNP N
< VBZ N
0.001 CD N
to TO N
0.03 CD N
) ) N
] NN N
at IN N
post NN N
assessment NN N
. . N

CONCLUSION NNP o
MTLA NNP o
enhanced VBD o
the DT N
muscle NN N
strength NN N
, , N
dexterity NN N
and CC N
coordination NN N
of IN N
the DT N
less-affected JJ N
side NN N
as RB N
well RB N
as IN N
the DT N
motor NN N
recovery NN N
of IN N
the DT N
affected JJ N
side NN N
in IN N
poststroke NN p
hemiparetic JJ p
subjects NNS p
. . p

-DOCSTART- -21207788- O O

Controlled VBN N
, , N
prospective JJ N
, , N
randomized VBN N
, , N
clinical JJ N
evaluation NN N
of IN N
partial JJ i
ceramic JJ i
crowns NNS i
inserted VBN N
with IN N
RelyX NNP i
Unicem NNP i
with IN i
or CC i
without IN i
selective JJ i
enamel NN i
etching VBG i
. . i

1-year JJ N
results NNS N
. . N

PURPOSE NNP N
To TO N
compare VB N
the DT N
performance NN N
of IN N
partial JJ o
ceramic JJ o
crowns NNS o
( ( o
PCCs NNP o
) ) o
inserted VBD i
with IN i
RelyX NNP i
Unicem NNP i
( ( i
RXU NNP i
) ) i
either CC i
with IN i
( ( i
RXU+E NNP i
) ) i
or CC i
without IN i
( ( i
RXU NNP i
) ) i
selective VBP i
enamel JJ i
etching NN i
. . i

METHODS NNP N
34 CD p
patients NNS p
( ( p
15 CD p
male NN p
, , p
19 CD p
female NN p
) ) p
participated VBD p
in IN p
the DT p
investigation NN p
, , p
with IN p
a DT p
total NN p
of IN p
68 CD p
PCC NNP p
restorations NNS p
. . p

In IN N
each DT N
patient NN N
, , N
one CD N
PCC NNP i
was VBD N
randomly RB N
assigned VBN N
to TO N
insertion NN N
with IN N
RXU NNP i
, , N
the DT N
second JJ N
PCC NNP i
was VBD N
assigned VBN N
to TO N
insertion NN N
with IN N
RXU+E NNP i
. . i

The DT N
PCCs NNPS N
were VBD N
CAD/CAM NNP N
fabricated VBD N
using VBG N
the DT N
Cerec NNP i
3 CD i
system NN i
. . i

RXU NN i
: : i
25 CD N
PCCs NNP N
were VBD N
placed VBN N
in IN N
molars NNS N
, , N
nine CD N
in IN N
premolars NNS N
. . N

RXU+E NN i
: : i
26 CD N
PCCs NNP N
were VBD N
placed VBN N
in IN N
molars NNS N
, , N
eight CD N
in IN N
premolars NNS N
. . N

The DT N
restorations NNS N
were VBD N
clinically RB N
rated VBN N
using VBG N
modified VBN N
United NNP N
States NNPS N
Public NNP N
Health NNP N
Service NNP N
( ( N
USPHS NNP N
) ) N
criteria NNS N
at IN N
baseline NN N
, , N
6 CD N
and CC N
12 CD N
months NNS N
after IN N
placement NN N
. . N

The DT N
median JJ p
patient NN p
age NN p
was VBD p
41 CD p
years NNS p
( ( p
24-59 CD p
years NNS p
) ) p
. . p

The DT N
median JJ N
( ( N
25-75 CD N
% NN N
) ) N
PBI NNP N
was VBD N
6 CD N
% NN N
( ( N
3-9 CD N
% NN N
) ) N
. . N

RESULTS NNP N
All DT p
patients NNS p
were VBD p
available JJ p
for IN p
the DT p
three CD p
recall NN p
appointments NNS p
. . p

One CD N
PCC NNP N
( ( i
RXU NNP i
) ) i
debonded VBD o
after IN N
11 CD N
months NNS N
in IN N
situ NN N
, , N
one CD N
PCC NNP N
( ( i
RXU+E NNP i
) ) i
fractured VBD o
after IN N
12 CD N
months NNS N
in IN N
situ NN N
. . N

Both DT N
restorations NNS o
had VBD N
to TO N
be VB N
replaced VBN o
. . o

At IN N
the DT N
12 CD N
months NNS N
recall RB N
, , N
66 CD N
of IN N
68 CD N
controlled JJ N
restorations NNS N
were VBD N
functional JJ o
without IN N
need NN N
of IN N
replacement NN N
. . N

The DT N
evaluation NN N
using VBG N
USHPS NNP N
criteria NNS N
revealed VBD N
a DT N
significant JJ N
decrease NN N
of IN N
alfa JJ o
ratings NNS o
over IN o
time NN o
with IN o
respect NN o
to TO o
criteria VB o
marginal JJ o
adaptation NN o
and CC o
marginal JJ o
discoloration NN o
. . o

No DT N
statistically RB N
significant JJ N
differences NNS N
between IN N
the DT N
two CD N
luting VBG N
techniques NNS N
, , N
RXU NNP i
and CC i
RXU+E NNP i
, , N
we PRP N
reobserved VBD N
during IN N
the DT N
observation NN N
period NN N
of IN N
1 CD N
year NN N
. . N

Within IN N
the DT N
limitations NNS N
of IN N
the DT N
present JJ N
study NN N
, , N
adhesive JJ N
luting NN N
with IN N
RXU NNP i
with IN N
or CC N
without IN N
selective JJ N
enamel NN N
etching NN N
can MD N
be VB N
recommended VBN N
. . N

-DOCSTART- -9042119- O O

Dexamethasone NN i
in IN N
salbutamol-treated JJ p
inpatients NNS p
with IN p
acute JJ p
bronchiolitis NN p
: : p
a DT N
randomized NN N
, , N
controlled VBN N
trial NN N
. . N

OBJECTIVE NN N
To TO N
determine VB N
the DT N
clinical JJ o
benefit NN o
of IN N
oral JJ N
dexamethasone NN N
in IN N
children NNS p
admitted VBN p
to TO p
the DT p
hospital NN p
with IN p
bronchiolitis NN p
treated VBN p
with IN p
nebulized JJ p
salbutamol NN p
. . p

METHODS NNP N
Randomized NNP N
, , N
double-blind NN N
, , N
placebo-controlled JJ N
trial NN N
in IN N
the DT N
inpatient JJ N
wards NNS N
of IN N
a DT N
pediatric JJ N
tertiary NN N
care NN N
hospital NN N
. . N

The DT N
participants NNS p
, , p
children NNS p
aged VBD p
6 CD p
weeks NNS p
to TO p
15 CD p
months NNS p
, , p
admitted VBN p
with IN p
first-time JJ p
wheezing NN p
, , p
were VBD p
eligible JJ p
if IN p
their PRP$ p
oxygen NN p
saturation NN p
was VBD p
less JJR p
than IN p
95 CD p
% NN p
on IN p
admission NN p
to TO p
the DT p
hospital NN p
and CC p
their PRP$ p
Respiratory NNP o
Distress NNP o
Assessment NNP o
Instrument NNP o
( ( o
RDAI NNP o
) ) o
score NN o
was VBD p
greater JJR p
than IN p
6 CD p
. . p

Patients NNS p
were VBD p
excluded VBN p
if IN p
they PRP p
had VBD p
any DT p
one CD p
of IN p
the DT p
following NN p
: : p
an DT p
underlying JJ p
disease NN p
that WDT p
might MD p
affect VB p
cardiopulmonary JJ p
status NN p
, , p
asthma NN p
, , p
recent JJ p
treatment NN p
with IN p
steroids NNS p
( ( p
within IN p
2 CD p
weeks NNS p
) ) p
, , p
or CC p
any DT p
history NN p
of IN p
adverse JJ p
reaction NN p
to TO p
steroids NNS p
. . p

Patients NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
either DT N
orally RB N
administered VBN N
dexamethasone NN i
with IN i
0.5 CD i
mg/kg NNS i
as IN N
the DT N
first JJ N
dose NN N
and CC N
0.3 CD N
mg/kg NN N
for IN N
the DT N
next JJ N
2 CD N
mornings NNS N
, , N
or CC N
an DT N
equal JJ N
volume NN N
of IN N
an DT N
orally RB N
administered VBN N
placebo NN i
with IN N
an DT N
identical JJ N
appearance NN N
. . N

All DT N
patients NNS N
received VBD N
nebulized JJ N
salbutamol NN i
at IN N
0.15 CD N
mg/kg NN N
every DT N
4 CD N
hours NNS N
for IN N
the DT N
first JJ N
24 CD N
hours NNS N
. . N

The DT N
primary JJ N
outcome NN N
measure NN N
was VBD N
the DT N
change NN N
from IN N
baseline NN N
in IN N
the DT N
RDAI NNP o
score NN o
at IN N
24 CD N
hours NNS N
. . N

Secondary JJ N
outcome NN N
measures NNS N
were VBD N
oxygen JJ o
saturation NN o
, , o
respiratory NN o
rate NN o
, , o
RDAI NNP o
measurement NN o
twice RB o
daily RB o
for IN N
the DT N
first JJ N
4 CD N
days NNS N
, , N
and CC N
the DT N
length NN o
of IN o
hospitalization NN o
. . o

RESULTS NNP N
At IN N
24 CD N
hours NNS N
the DT N
mean JJ o
change NN o
( ( o
SD NNP o
) ) o
from IN N
baseline NN N
in IN N
the DT N
RDAI NNP o
score NN o
was VBD N
1.6 CD N
( ( N
2.3 CD N
) ) N
in IN N
the DT N
placebo NN N
group NN N
( ( N
n JJ N
= NNP N
28 CD N
) ) N
and CC N
1.4 CD N
( ( N
2.0 CD N
) ) N
in IN N
the DT N
dexamethasone NN N
group NN N
( ( N
n JJ N
= VBZ N
33 CD N
; : N
p NN N
= VBZ N
0.74 CD N
) ) N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
the DT N
two CD N
groups NNS N
in IN N
change NN N
in IN N
oxygen NN o
saturation NN o
, , o
respiratory NN o
rate NN o
, , o
and CC o
RDAI NNP o
score NN o
at IN N
any DT N
assessment JJ N
period NN N
. . N

The DT N
median JJ o
length NN o
of IN o
stay NN o
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
) ) N
for IN N
the DT N
placebo NN N
group NN N
was VBD N
48 CD N
( ( N
42 CD N
, , N
54 CD N
) ) N
hours NNS N
compared VBN N
with IN N
57 CD N
( ( N
38 CD N
, , N
76 CD N
) ) N
hours NNS N
in IN N
the DT N
dexamethasone NN N
group NN N
( ( N
p JJ N
= NNP N
0.19 CD N
) ) N
. . N

CONCLUSIONS NNP N
Oral NNP N
dexamethasone NN N
therapy NN N
does VBZ N
not RB N
affect VB N
the DT N
clinical JJ o
course NN o
of IN N
children NNS p
hospitalized VBN p
with IN p
bronchiolitis NN p
and CC N
therefore RB N
can MD N
not RB N
be VB N
recommended VBN N
in IN N
this DT N
clinical JJ N
situation NN N
. . N

-DOCSTART- -21224870- O O

Efficient JJ N
tetanus NN i
toxoid JJ i
immunization NN i
on IN N
vitamin NN o
D NNP o
supplementation NN p
. . p

BACKGROUND/OBJECTIVES NNP N
Vitamin NNP p
D NNP p
mediates VBZ N
immunomodulatory JJ N
functions NNS N
, , N
and CC N
its PRP$ N
deficiency NN p
has VBZ N
been VBN N
associated VBN N
with IN N
an DT N
increased JJ N
prevalence NN N
of IN N
immunological JJ N
diseases NNS N
. . N

The DT N
supplementation NN N
of IN N
vitamin NN i
D NNP i
might MD N
be VB N
therapeutically RB N
beneficial JJ N
, , N
for IN N
example NN N
, , N
in IN p
lupus JJ p
erythematosus NN p
patients NNS p
. . p

However RB N
, , N
its PRP$ N
affect NN N
on IN N
established VBN N
recall NN N
immune NN N
responses NNS N
is VBZ N
undefined JJ N
. . N

SUBJECTS/METHODS NNP N
In IN p
all DT p
, , p
32 CD p
individuals NNS p
were VBD p
randomized VBN p
in IN p
a DT p
placebo NN i
controlled VBN p
, , p
double-blind JJ p
setting NN p
, , N
and CC N
received VBD N
vitamin NNS i
D NNP i
( ( N
daily JJ N
2000 CD N
IU NNP N
) ) N
for IN N
10 CD N
weeks NNS N
followed VBN N
by IN N
tetanus NN i
toxoid NN i
( ( i
TT NNP i
) ) i
booster NN i
immunization NN i
. . i

RESULTS NNP N
During IN N
vitamin JJ N
D NNP N
supplementation NN N
the DT N
median JJ o
25-hydroxyvitamin JJ o
D NNP o
serum NN o
concentration NN o
increased VBD N
to TO N
80.3 CD N
nM NNS N
, , N
which WDT N
as IN N
expected VBN N
decreased VBN N
in IN N
the DT N
placebo NN N
group NN N
to TO N
29.1 CD N
nM NNS N
during IN N
the DT N
ultraviolet-deprived JJ N
winter NN N
months NNS N
. . N

The DT N
TT-specific JJ o
immunoglobulin NN o
G NNP o
( ( o
IgG NNP o
) ) o
boost VBD o
efficiency NN o
was VBD N
marginal JJ N
higher JJR N
in IN N
the DT N
vitamin NN N
D NNP N
group NN N
( ( N
P NNP N
= NNP N
0.04 CD N
) ) N
. . N

The DT N
increase NN N
of IN N
the DT N
25-hydroxyvitamin JJ o
D NNP o
levels NNS o
correlated VBN N
with IN N
the DT N
increase NN N
of IN N
TT-IgG NNP o
serum NN o
concentrations NNS o
. . o

The DT N
induction NN N
of IN N
specific JJ N
serum NN o
IgA NNP o
and CC N
specific JJ N
antibody NN N
secreting VBG N
cells NNS N
was VBD N
comparable JJ N
between IN N
both DT N
groups NNS N
. . N

Accordingly RB N
, , N
the DT N
TT-specific NNP o
and CC o
polyclonally RB o
triggered VBD o
T-cell NNP o
cytokine NN o
profiles NNS o
were VBD N
stable JJ N
as RB N
well RB N
. . N

CONCLUSIONS NNP N
Vitamin NNP N
D NNP N
supplementation NN N
was VBD N
successful JJ N
and CC N
booster JJ N
immunization NN N
induced VBD N
efficiently RB N
specific JJ N
antibodies NNS N
titers NNS N
. . N

-DOCSTART- -15591756- O O

Dual-task-related JJ N
gait NN N
changes NNS N
in IN N
transitionally RB p
frail JJ p
older JJR p
adults NNS p
: : p
the DT N
type NN N
of IN N
the DT N
walking-associated JJ i
cognitive JJ i
task NN i
matters NNS N
. . N

BACKGROUND NNP N
Changes NNP N
in IN N
gait NN N
patterns NNS N
due JJ N
to TO N
a DT N
simultaneously RB i
performed VBN i
cognitive JJ i
task NN i
have VBP N
been VBN N
reported VBN N
previously RB N
and CC N
associated VBN N
with IN N
an DT N
increased VBN N
falling VBG p
risk NN p
among IN p
older JJR p
adults NNS p
. . p

Little NNP N
is VBZ N
known VBN N
whether IN N
the DT N
type NN N
of IN N
cognitive JJ i
task NN i
performed VBN N
while IN N
walking VBG N
is VBZ N
important JJ N
concerning VBG N
possible JJ N
gait NN N
interference NN N
in IN N
older JJR p
fall-prone NN p
individuals NNS p
. . p

OBJECTIVE NN N
To TO N
quantify VB N
and CC N
compare VB N
the DT N
effects NNS N
of IN N
two CD N
different JJ N
cognitive JJ N
tasks NNS N
on IN N
gait NN N
in IN N
transitionally RB p
frail JJ p
older JJR p
adults NNS p
. . p

MEASUREMENTS NNP N
Gait NNP N
was VBD N
tested VBN N
in IN N
30 CD p
transitionally RB p
frail JJ p
older JJR p
adults NNS p
( ( p
mean JJ p
age NN p
82.6 CD p
+/- JJ p
7.1 CD p
years NNS p
, , p
90 CD p
% NN p
female NN p
) ) p
while IN N
either CC N
walking VBG o
alone RB o
, , o
performing VBG o
a DT o
simple JJ o
arithmetic JJ o
task NN o
, , i
or CC i
performing VBG i
a DT i
task NN i
of IN i
verbal JJ i
fluency NN i
. . i

Walking JJ o
time NN o
in IN o
seconds NNS o
, , o
number NN o
of IN o
steps NNS o
, , o
frequency NN o
of IN o
lateral JJ o
line NN o
stepping-over NN o
, , o
and CC o
stops NNS o
were VBD N
recorded VBN N
. . N

Health NNP o
status NN o
was VBD N
assessed VBN N
using VBG N
standard JJ N
instruments NNS N
of IN N
geriatric JJ N
assessment NN N
. . N

The DT N
classification NN N
of IN N
Speechley NNP N
and CC N
Tinetti NNP N
was VBD N
used VBN N
to TO N
define VB N
the DT N
participants NNS N
' POS N
degree NN N
of IN N
frailty NN N
. . N

RESULTS NNP N
Walking JJ o
time NN o
and CC o
number NN o
of IN o
steps NNS o
increased VBN N
significantly RB N
under IN N
both DT N
dual-task JJ N
conditions NNS N
compared VBN N
to TO N
walking VBG N
alone RB N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
without IN N
reaching VBG N
a DT N
significant JJ N
difference NN N
between IN N
the DT N
two CD N
dual-task JJ N
conditions NNS N
( ( N
respectively RB N
, , N
p JJ N
= NN N
0.131 CD N
and CC N
p VB N
= NNP N
0.407 CD N
) ) N
, , N
whereas JJ N
lateral JJ o
gait NN o
instability NN o
( ( N
frequency NN N
of IN N
lateral JJ N
line NN N
stepping-over NN N
) ) N
increased VBD N
significantly RB N
in IN N
association NN N
with IN N
counting VBG N
backward NN N
( ( N
p JJ N
= NNP N
0.006 CD N
) ) N
but CC N
not RB N
with IN N
the DT N
verbal JJ N
fluency NN N
task NN N
( ( N
p JJ N
= NNP N
1 CD N
) ) N
. . N

CONCLUSION NNP N
Among IN N
the DT N
studied JJ N
sample NN N
of IN N
transitional JJ p
older NN p
adults NNS p
, , N
a DT N
walking- JJ o
associated VBN o
arithmetic JJ o
task NN o
significantly RB N
interfered VBN N
with IN N
lateral JJ o
gait NN o
stability NN o
, , N
whereas IN N
no DT N
lateral JJ N
gait NN N
deviations NNS N
were VBD N
seen VBN N
in IN N
association NN N
with IN N
a DT N
verbal JJ o
fluency NN o
task NN o
. . o

We PRP N
, , N
therefore RB N
, , N
suggest VBP N
that IN N
the DT N
choice NN N
of IN N
the DT N
attention-splitting JJ N
task NN N
in IN N
dual-task JJ N
gait JJ N
assessment NN N
among IN N
older JJR p
adults NNS p
must MD N
be VB N
made VBN N
carefully RB N
. . N

-DOCSTART- -19531038- O O

Quick JJ i
change NN i
versus NN i
double JJ i
pump NN i
while IN N
changing VBG N
the DT N
infusion NN N
of IN N
inotropes NNS N
: : N
an DT N
experimental JJ N
study NN N
. . N

BACKGROUND NNP N
Quick NNP i
change NN i
( ( i
QC NNP i
) ) i
and CC i
double JJ i
pumping NN i
( ( i
DP NNP i
) ) i
are VBP N
common JJ N
methods NNS N
of IN N
substituting VBG N
the DT N
infusion NN N
of IN N
inotropes NNS N
given VBN N
through IN N
intravenous JJ N
pump NN N
. . N

AIMS IN N
The DT N
aim NN N
of IN N
the DT N
study NN N
was VBD N
to TO N
compare VB N
two CD N
methods NNS N
in IN N
respect NN N
with IN N
the DT N
variation NN N
in IN N
mean JJ o
arterial JJ o
pressure NN o
( ( o
MAP NNP o
) ) o
. . o

The DT N
hypothesis NN N
was VBD N
that IN N
the DT N
DP NNP i
method NN N
could MD N
be VB N
the DT N
most RBS N
effective JJ N
in IN N
achieving VBG N
haemodynamic JJ o
stability NN o
. . o

DESIGN VB N
The DT N
study NN N
is VBZ N
a DT N
randomized JJ N
research NN N
in IN N
an DT N
open JJ N
randomized JJ N
clinical JJ N
trial NN N
. . N

METHODS NNP N
The DT N
study NN N
took VBD N
place NN N
at IN N
the DT N
Paediatric NNP p
Intensive NNP p
Care NNP p
Unit NNP p
of IN p
Padua NNP p
Hospital NNP p
. . p

It PRP p
considered VBD p
patients NNS p
of IN p
0-36 JJ p
months NNS p
, , p
not RB p
premature NN p
, , p
treated VBN p
with IN p
inotropic JJ i
infusion NN i
with IN p
monitoring NN p
of IN p
blood NN o
pressure NN o
. . o

The DT N
research NN N
obtained VBD N
the DT N
approval NN N
of IN N
the DT N
Hospital NNP p
Research NNP p
Ethics NNP p
committee NN p
and CC N
parents NNS p
signed VBD N
informed JJ N
consent NN N
. . N

Comparison NNP N
of IN N
the DT N
two CD N
groups NNS N
made VBN N
use NN N
of IN N
the DT N
Wilcoxon NNP N
test NN N
for IN N
the DT N
continuous JJ N
variables NNS N
and CC N
the DT N
Fisher NNP N
's POS N
exact JJ N
test NN N
for IN N
the DT N
comparison NN N
of IN N
frequencies NNS N
, , N
at IN N
significance NN N
value NN N
of IN N
5 CD N
% NN N
. . N

The DT N
data NNS N
were VBD N
registered VBN N
in IN N
an DT N
Excel NNP N
spreadsheet NN N
and CC N
analysed VBN N
with IN N
SAS NNP N
. . N

RESULTS VB N
The DT p
sample NN p
comprised VBD p
30 CD p
patients NNS p
of IN p
age NN p
between IN p
1 CD p
and CC p
27 CD p
months NNS p
, , p
of IN p
whom WP p
13 CD p
( ( p
43 CD p
% NN p
) ) p
were VBD p
male JJ p
. . p

They PRP p
were VBD p
all DT p
affected VBN p
by IN p
cardiac NN p
, , p
respiratory NN p
or CC p
infective JJ p
pathology NN p
, , p
all DT p
of IN p
them PRP p
intubated VBN p
and CC p
on IN p
artificial JJ p
respiratory NN p
support NN p
, , p
sedated VBN p
and CC p
infused VBN p
with IN p
dopamine NN p
. . p

The DT N
characteristics NNS N
of IN N
the DT N
patients NNS N
of IN N
the DT N
two CD N
groups NNS N
did VBD N
not RB N
differ VB N
significantly RB N
. . N

The DT N
percentage NN N
variation NN N
of IN N
the DT N
baseline NN N
value NN N
of IN N
MAP NNP o
after IN N
30 CD N
min NN N
from IN N
starting VBG N
the DT N
treatment NN N
between IN N
the DT N
two CD N
methods NNS N
was VBD N
not RB N
statistically RB N
significant JJ N
( ( N
p JJ N
= NNP N
0.85 CD N
) ) N
. . N

The DT N
95 CD N
% NN N
confidence NN N
interval NN N
for IN N
the DT N
difference NN N
in IN N
the DT N
percentage NN N
variation NN N
of IN N
MAP NNP o
between IN N
the DT N
two CD N
groups NNS N
was VBD N
( ( N
-3.1 JJ N
, , N
+3.7 NNP N
) ) N
. . N

From IN N
a DT N
clinical JJ N
perspective NN N
, , N
the DT N
methods NNS N
are VBP N
to TO N
be VB N
considered VBN N
equivalent JJ N
. . N

CONCLUSIONS VB N
The DT p
study NN p
was VBD p
conducted VBN p
on IN p
a DT p
limited JJ p
sample NN p
; : p
no DT N
statistically RB N
significant JJ N
differences NNS N
were VBD N
detected VBN N
; : N
QC NNP i
is VBZ N
the DT N
quickest JJS o
and CC o
more JJR o
cost-effective JJ o
method NN N
. . N

-DOCSTART- -17634259- O O

Protein NNP i
ingestion NN i
further RBR N
augments NNS N
S6K1 NNP N
phosphorylation NN N
in IN N
skeletal JJ N
muscle NN N
following VBG N
resistance NN p
type NN p
exercise NN p
in IN p
males NNS p
. . p

Our PRP$ N
objective NN N
was VBD N
to TO N
determine VB N
the DT N
impact NN N
of IN N
carbohydrate NN i
and/or NN i
protein NN i
ingestion NN i
before IN N
and CC N
after IN N
exercise NN i
on IN N
ribosomal JJ N
protein NN N
S6 NNP N
kinase NN N
( ( N
S6K1 NNP N
) ) N
and CC N
S6 NNP N
phosphorylation NN N
status NN N
in IN N
human JJ p
skeletal JJ N
muscle NN N
tissue NN N
. . N

Seven NNP p
healthy JJ p
, , p
untrained JJ p
men NNS p
( ( p
22.5 CD p
+/- JJ p
0.9 CD p
y NN p
) ) p
were VBD N
randomly RB N
assigned VBN N
to TO N
2 CD N
cross-over JJ N
experiments NNS N
. . N

Before IN N
, , N
immediately RB N
after IN N
, , N
and CC N
1 CD N
h NN N
after IN N
a DT N
single JJ N
bout NN N
of IN N
resistance NN i
exercise NN i
, , N
subjects NNS N
consumed VBD N
0.3 CD N
g NN N
x NN N
kg NN N
( ( N
-1 NNP N
) ) N
carbohydrate NN i
with IN i
or CC i
without IN i
0.3 CD i
g NN i
x NN i
kg NN i
( ( i
-1 NNP i
) ) i
protein NN i
hydrolysate NN i
( ( i
CHO+PRO NNP i
and CC i
CHO NNP i
, , i
respectively RB i
) ) i
. . i

Muscle NN i
biopsies NNS i
were VBD N
taken VBN N
before RB N
and CC N
immediately RB N
after IN N
exercise NN N
and CC N
after IN N
1 CD N
and CC N
4 CD N
h NN N
of IN N
postexercise NN N
recovery NN N
to TO N
determine VB N
4E-BP1 JJ N
, , N
S6K1 NNP N
( ( N
both DT N
T NNP N
( ( N
421 CD N
) ) N
/S NN N
( ( N
424 CD N
) ) N
and CC N
T NNP N
( ( N
389 CD N
) ) N
) ) N
, , N
and CC N
S6 NNP N
phosphorylation NN N
status NN N
. . N

Following VBG o
resistance NN o
exercise NN o
, , o
4E-BP1 JJ o
phosphorylation NN o
was VBD o
reduced VBN o
to TO o
a DT o
greater JJR o
extent NN o
in IN o
the DT o
CHO NNP o
treatment NN o
( ( o
-48 JJ o
+/- JJ o
7 CD o
% NN o
) ) o
than IN o
in IN o
the DT o
CHO+PRO NNP o
treatment NN o
( ( o
-15 JJ o
+/- JJ o
14 CD o
% NN o
, , o
P NNP o
< NNP o
0.01 CD o
) ) o
. . o

During IN o
recovery NN o
, , o
4E-BP1 JJ o
phosphorylation NN o
increased VBN o
in IN o
both DT o
experiments NNS o
( ( o
P NNP o
< NNP o
0.01 CD o
) ) o
, , o
and CC o
tended VBD o
to TO o
be VB o
higher JJR o
in IN o
the DT o
CHO+PRO NNP o
test NN o
( ( o
P NNP o
= NNP o
0.08 CD o
) ) o
. . o

S6K1 JJ o
phosphorylation NN o
at IN o
T NNP o
( ( o
421 CD o
) ) o
/S NN o
( ( o
424 CD o
) ) o
substantially RB o
increased VBD o
following VBG o
exercise NN o
and CC o
remained VBD o
elevated VBN o
during IN o
recovery NN o
with IN o
no DT o
differences NNS o
between IN o
treatments NNS o
. . o

In IN o
contrast NN o
to TO o
the DT o
CHO NNP o
treatment NN o
( ( o
-4 JJ o
+/- JJ o
2 CD o
% NN o
) ) o
, , o
S6K1 NNP o
phosphorylation NN o
at IN o
T NNP o
( ( o
389 CD o
) ) o
was VBD o
higher JJR o
following VBG o
exercise NN o
in IN o
the DT o
CHO+PRO NNP o
treatment NN o
only RB o
( ( o
+78 JJ o
+/- JJ o
2 CD o
% NN o
, , o
P NNP o
< NNP o
0.01 CD o
) ) o
. . o

During IN o
recovery NN o
, , o
S6K1 NNP o
phosphorylation NN o
at IN o
T NNP o
( ( o
389 CD o
) ) o
remained VBD o
higher RBR o
in IN o
CHO+PRO NNP o
than IN o
in IN o
CHO NNP o
( ( o
P NNP o
< NNP o
0.05 CD o
) ) o
. . o

S6 NNP o
phosphorylation NN o
was VBD o
substantially RB o
higher JJR o
following VBG o
exercise NN o
in IN o
the DT o
CHO+PRO NNP o
( ( o
1.69 CD o
+/- JJ o
0.35 CD o
) ) o
than IN o
in IN o
the DT o
CHO NNP o
experiment NN o
( ( o
0.45 CD o
+/- JJ o
0.07 CD o
, , o
P NNP o
< NNP o
0.01 CD o
) ) o
and CC o
remained VBD o
elevated VBN o
during IN o
recovery NN o
( ( o
P NNP o
< NNP o
0.05 CD o
) ) o
. . o

We PRP N
conclude VBP N
that IN N
the DT N
availability NN N
of IN N
dietary JJ N
protein NN N
further RBR N
enhances NNS N
phosphorylation NN N
of IN N
S6K1 NNP N
during IN N
recovery NN N
from IN N
resistance NN N
type NN N
exercise NN N
. . N

-DOCSTART- -25888263- O O

Effect NN N
of IN N
enzalutamide NN i
on IN N
health-related JJ o
quality NN o
of IN o
life NN o
, , o
pain NN o
, , o
and CC o
skeletal-related JJ o
events NNS o
in IN N
asymptomatic JJ p
and CC p
minimally RB p
symptomatic JJ p
, , p
chemotherapy-naive JJ p
patients NNS p
with IN p
metastatic JJ p
castration-resistant JJ p
prostate NN p
cancer NN p
( ( p
PREVAIL NNP p
) ) p
: : p
results NNS N
from IN N
a DT N
randomised VBN N
, , N
phase VB N
3 CD N
trial NN N
. . N

BACKGROUND NNP N
Enzalutamide NNP i
significantly RB N
increased VBD N
overall JJ o
survival NN o
and CC N
radiographic JJ o
progression-free JJ o
survival NN o
compared VBN N
with IN N
placebo NN i
in IN N
the DT N
PREVAIL NNP N
trial NN N
of IN N
asymptomatic JJ p
and CC p
minimally RB p
symptomatic JJ p
, , p
chemotherapy-naive JJ p
patients NNS p
with IN p
metastatic JJ p
castration-resistant JJ p
prostate NN p
cancer NN p
. . p

We PRP N
report VBP N
the DT N
effect NN N
of IN N
enzalutamide NN i
on IN N
health-related JJ o
quality NN o
of IN o
life NN o
( ( o
HRQoL NNP o
) ) o
, , o
pain NN o
, , o
and CC o
skeletal-related JJ o
events NNS o
observed VBD N
during IN N
this DT N
trial NN N
. . N

METHODS NNP N
In IN N
this DT N
phase NN N
3 CD N
, , N
double-blind JJ N
trial NN N
, , N
patients NNS p
were VBD p
randomly RB p
assigned VBN p
( ( p
1:1 CD p
) ) p
to TO p
receive VB p
enzalutamide RB i
160 CD i
mg/day NN i
( ( p
n=872 JJ p
) ) p
or CC i
placebo NN i
( ( p
n=845 JJ p
) ) p
orally RB p
. . p

HRQoL NNP o
was VBD N
assessed VBN N
at IN N
baseline NN N
and CC N
during IN N
treatment NN N
using VBG N
the DT N
Functional NNP N
Assessment NNP N
of IN N
Cancer NNP N
Therapy-Prostate NNP N
( ( N
FACT-P NNP N
) ) N
and CC N
EQ-5D JJ N
questionnaires NNS N
. . N

Pain NN o
status NN o
was VBD N
assessed VBN N
at IN N
screening NN N
, , N
baseline NN N
, , N
week NN N
13 CD N
, , N
and CC N
week NN N
25 CD N
with IN N
the DT N
Brief NNP o
Pain NNP o
Inventory NNP o
Short NNP o
Form NNP o
( ( o
BPI-SF NNP o
) ) o
. . o

The DT N
primary JJ o
analysis NN o
of IN o
HRQoL NNP o
data NNS o
used VBD N
a DT N
mixed-effects NNS N
model NN N
to TO N
test VB N
the DT N
difference NN N
between IN N
least JJS N
square JJ N
means NNS N
change VBP N
from IN N
baseline NN N
at IN N
week NN N
61 CD N
. . N

We PRP N
assessed VBD N
change NN o
from IN o
baseline NN o
, , o
percentage NN o
improvement NN o
, , o
and CC o
time NN o
to TO o
deterioration NN o
in IN o
HRQoL NNP o
and CC o
pain NN o
, , N
the DT N
proportion NN o
of IN o
patients NNS o
with IN o
a DT o
skeletal-related JJ o
event NN o
, , N
and CC N
time NN o
to TO o
first VB o
skeletal-related JJ o
event NN o
. . o

Analysis NN N
was VBD N
done VBN N
on IN N
the DT N
intention-to-treat JJ N
population NN N
. . N

This DT N
study NN N
is VBZ N
registered VBN N
with IN N
ClinicalTrials.gov NNP N
, , N
number NN N
NCT01212991 NNP N
. . N

FINDINGS NNP N
Median NNP o
treatment NN o
duration NN o
was VBD N
16?6 CD N
months NNS N
( ( N
IQR NNP N
10?1-21?1 CD N
) ) N
in IN N
the DT N
enzalutamide NN i
group NN i
and CC N
4?6 CD N
months NNS N
( ( N
2?8-9?7 JJ N
) ) N
in IN N
the DT N
placebo NN i
group NN i
. . N

The DT N
mixed-effects NNS N
model NN N
analyses VBZ N
showed VBD N
significant JJ o
treatment NN o
differences NNS o
in IN o
change NN o
from IN N
baseline NN N
to TO N
week NN N
61 CD N
with IN i
enzalutamide JJ i
compared VBN i
with IN i
placebo NN i
for IN i
most JJS i
FACT-P JJ N
endpoints NNS o
and CC o
EQ-5D NNP o
visual JJ o
analogue NN o
scale NN o
. . o

Median JJ o
time NN o
to TO o
deterioration VB o
in IN o
FACT-P NNP o
total JJ o
score NN o
was VBD N
11?3 CD N
months NNS N
( ( N
95 CD N
% NN N
CI NNP N
11?1-13?9 CD i
) ) i
in IN i
the DT i
enzalutamide NN i
group NN i
and CC i
5?6 CD N
months NNS N
( ( N
5?5-5?6 JJ N
) ) N
in IN i
the DT i
placebo NN i
groups NNS N
( ( N
hazard JJ N
ratio NN N
[ NNP N
HR NNP N
] VBD N
0?62 CD N
[ JJ N
95 CD N
% NN N
CI NNP N
0?54-0?72 CD N
] NNP N
; : N
p VBZ N
< $ N
0?0001 CD N
) ) N
. . N

A DT N
significantly RB N
greater JJR N
proportion NN N
of IN N
patients NNS N
in IN N
the DT N
enzalutamide NN i
group NN i
than IN N
in IN N
the DT i
placebo NN i
group NN N
reported VBD N
clinically RB N
meaningful JJ N
improvements NNS N
in IN N
FACT-P NNP o
total JJ o
score NN o
( ( o
327 CD o
[ RB N
40 CD N
% NN N
] NN N
of IN N
826 CD N
vs NNS N
181 CD N
[ JJ N
23 CD N
% NN N
] NN N
of IN N
790 CD N
) ) N
, , N
in IN o
EQ-5D NNP o
utility NN o
index NN o
( ( o
224 CD N
[ RB N
28 CD N
% NN N
] NN N
of IN N
812 CD N
vs NNS N
99 CD N
[ JJ N
16 CD N
% NN N
] NN N
of IN N
623 CD N
) ) N
, , N
and CC o
visual JJ o
analogue NN o
scale NN o
( ( N
218 CD N
[ RB N
27 CD N
% NN N
] NN N
of IN N
803 CD N
vs JJ N
106 CD N
of IN N
[ JJ N
18 CD N
% NN N
] JJ N
603 CD N
; : N
all DT N
p VBP N
< $ N
0?0001 CD o
) ) o
. . o

Median JJ o
time NN o
to TO o
progression NN o
in IN o
BPI-SF NNP o
pain NN o
at IN o
its PRP$ N
worst JJS N
was VBD N
5?7 CD N
months NNS N
( ( N
95 CD N
% NN N
CI NNP N
5?6-5?7 CD N
) ) N
in IN N
the DT N
enzalutamide NN i
group NN N
and CC N
5?6 CD N
months NNS N
( ( N
5?4-5?6 JJ N
) ) N
in IN N
the DT i
placebo NN i
group NN i
( ( i
HR NNP N
0?62 CD N
[ VBD N
95 CD N
% NN N
CI NNP N
0?53-0?74 CD N
] NNP N
; : N
p VBZ N
< $ N
0?0001 CD N
) ) N
. . o

Progression NN o
of IN o
pain NN o
at IN o
its PRP$ o
worst JJS N
was VBD N
less JJR N
common JJ N
in IN N
the DT N
enzalutamide NN N
group NN N
than IN N
in IN N
the DT i
placebo NN i
group NN N
at IN N
week NN N
13 CD N
( ( N
220 CD N
[ RB N
29 CD N
% NN N
] NN N
of IN N
769 CD N
vs NNS N
257 CD N
[ JJ N
42 CD N
% NN N
] NN N
of IN N
610 CD N
; : N
p NN N
< VBZ N
0?0001 CD N
) ) N
, , N
but CC N
not RB N
at IN N
week NN N
25 CD N
( ( N
225 CD N
[ RB N
32 CD N
% NN N
] NN N
of IN N
705 CD N
vs NNS N
135 CD N
[ JJ N
38 CD N
% NN N
] NN N
of IN N
360 CD N
; : N
p=0?068 NN N
) ) N
. . N

278 CD N
( ( N
32 CD N
% NN N
) ) N
of IN N
872 CD N
patients NNS N
in IN N
the DT N
enzalutamide NN i
group NN N
and CC N
309 CD N
( ( N
37 CD N
% NN N
) ) N
of IN N
845 CD N
patients NNS N
in IN N
the DT N
placebo NN i
group NN N
had VBD N
experienced VBN N
a DT o
skeletal-related JJ o
event NN o
by IN o
data NNS o
cutoff NN o
. . o

Median JJ o
time NN o
to TO o
first VB o
skeletal-related JJ o
events NNS o
in IN o
the DT o
enzalutamide NN i
group NN i
was VBD N
31?1 CD N
months NNS N
( ( N
95 CD N
% NN N
CI NNP N
29?5-not CD N
reached VBD N
) ) N
and CC N
31?3 CD N
months NNS N
( ( N
95 CD N
% NN N
CI NNP N
23?9-not CD N
reached VBD N
) ) N
in IN N
the DT N
placebo NN i
group NN i
( ( i
HR NNP i
0?72 CD N
[ VBD N
95 CD N
% NN N
CI NNP N
0?61-0?84 CD N
] NNP N
; : N
p VBZ N
< $ N
0?0001 CD N
) ) N
. . N

INTERPRETATION NNP N
In IN N
addition NN N
to TO N
improving VBG o
overall JJ o
survival JJ o
relative NN o
to TO i
placebo VB i
, , i
enzalutamide VB i
significantly RB i
improves VBZ N
patient-related JJ o
outcomes NNS o
and CC o
delays NNS o
occurrence NN o
of IN o
first JJ o
skeletal-related JJ o
event NN o
in IN o
chemotherapy-naive JJ o
men NNS p
with IN p
metastatic JJ p
castration-resistant JJ p
prostate NN p
cancer NN p
. . N

FUNDING NNP N
Astellas NNP N
Pharma NNP N
and CC N
Medivation NNP N
. . N

-DOCSTART- -6448998- O O

The DT N
treatment NN N
of IN N
acne JJ p
vulgaris NN p
in IN N
general JJ p
practice NN p
. . p

A DT N
double-blind JJ N
assessment NN N
of IN N
co-trimoxazole JJ i
and CC i
tetracycline NN i
. . i

-DOCSTART- -10755175- O O

Auditory NNP i
integration NN i
training NN i
for IN N
children NNS p
with IN p
autism NN o
: : o
no DT N
behavioral JJ N
benefits NNS N
detected VBN N
. . N

Auditory NNP i
integration NN i
training NN i
and CC i
a DT i
control NN i
treatment NN i
were VBD N
provided VBN N
for IN N
16 CD p
children NNS p
with IN p
autism NN o
in IN N
a DT N
crossover NN N
experimental JJ N
design NN N
. . N

Measures NNS N
, , N
blind NN N
to TO N
treatment NN N
order NN N
, , N
included VBD N
parent NN o
and CC o
teacher JJ o
ratings NNS o
of IN o
behavior NN o
, , o
direct JJ o
observational JJ o
recordings NNS o
, , o
IQ NNP o
, , o
language NN o
, , o
and CC o
social/adaptive JJ o
tests NNS o
. . o

Significant JJ o
differences NNS o
tended VBD N
to TO N
show VB N
that IN N
the DT N
control NN N
condition NN N
was VBD N
superior JJ o
on IN o
parent-rated JJ o
measures NNS o
of IN o
hyperactivity NN o
and CC o
on IN o
direct JJ o
observational JJ o
measures NNS o
of IN o
ear-occlusion NN o
. . o

No DT o
differences NNS o
were VBD N
detected VBN N
on IN N
teacher-rated JJ o
measures NNS o
. . o

Children NNP o
's POS o
IQs NNP o
and CC o
language NN o
comprehension NN o
did VBD o
not RB o
increase VB o
, , N
but CC N
adaptive/social JJ o
behavior NN o
scores NNS o
and CC o
expressive JJ o
language NN o
quotients NNS o
decreased VBN o
. . o

The DT N
majority NN N
of IN N
parents NNS p
( ( N
56 CD N
% NN N
) ) N
were VBD N
unable JJ o
to TO o
report VB o
in IN o
retrospect NN o
when WRB N
their PRP$ N
child NN N
had VBD N
received VBN N
auditory JJ i
integration NN i
training NN i
. . i

No DT o
individual JJ N
child NN p
was VBD N
identified VBN N
as IN N
benefiting VBG o
clinically RB o
or CC o
educationally RB o
from IN N
the DT N
treatment NN N
. . N

-DOCSTART- -22617366- O O

A DT N
comparison NN N
of IN N
a DT N
short JJ i
nurse-based JJ i
and CC i
a DT i
long JJ i
multidisciplinary JJ i
version NN i
of IN i
structured JJ i
patient JJ i
education NN i
in IN N
irritable JJ p
bowel NN p
syndrome NN p
. . p

OBJECTIVE CC N
Structured NNP i
multidisciplinary JJ i
patient NN i
group NN i
education NN i
has VBZ N
positive JJ N
effects NNS N
on IN N
symptoms NNS N
, , N
health-related JJ N
quality NN N
of IN N
life NN N
, , N
and CC N
disease-related JJ N
knowledge NN N
in IN N
patients NNS p
with IN p
irritable JJ p
bowel NN p
syndrome NN p
( ( p
IBS NNP p
) ) p
, , N
but CC N
few JJ N
studies NNS N
comparing VBG N
different JJ N
forms NNS N
of IN N
educational JJ N
interventions NNS N
are VBP N
available JJ N
. . N

Our PRP$ N
aim NN N
was VBD N
to TO N
compare VB N
the DT N
effects NNS N
of IN N
long JJ i
multidisciplinary JJ i
group NN i
education NN i
with IN N
a DT N
short JJ i
nurse-based JJ i
group NN i
education NN i
with IN N
regard NN N
to TO N
symptoms NNS N
, , N
knowledge NN N
, , N
quality NN N
of IN N
life NN N
, , N
and CC N
satisfaction NN N
with IN N
the DT N
intervention NN N
in IN N
IBS NNP p
patients NNS p
. . p

METHODS NNP N
Patients NNPS p
with IN p
IBS NNP p
according VBG p
to TO p
the DT p
Rome NNP p
II NNP p
criteria NNS p
were VBD N
randomized VBN N
to TO N
either DT N
short JJ i
nurse-based JJ i
or CC i
a DT i
long JJ i
multidisciplinary-based JJ i
education NN i
. . i

The DT N
effects NNS N
were VBD N
evaluated VBN N
by IN N
self-administered JJ i
questionnaires NNS i
at IN N
3 CD N
, , N
6 CD N
, , N
and CC N
12 CD N
months NNS N
after IN N
baseline NN N
, , N
and CC N
compared VBN N
between IN N
the DT N
groups NNS N
. . N

RESULTS NNP N
No NNP N
differences NNS N
in IN N
effects NNS N
were VBD N
detected VBN N
in IN N
the DT N
between-group JJ N
comparisons NNS N
at IN N
any DT N
of IN N
the DT N
follow-up JJ N
assessments NNS N
. . N

However RB N
, , N
positive JJ N
effects NNS N
on IN N
symptoms NNS o
, , o
knowledge NN o
, , o
quality NN o
of IN o
life NN o
, , o
and CC o
satisfaction NN o
with IN N
the DT N
intervention NN N
were VBD N
found VBN N
in IN N
both CC N
the DT N
short JJ N
and CC N
the DT N
long JJ N
version NN N
. . N

CONCLUSION VB N
A DT N
short JJ i
, , i
nurse-based JJ i
educational JJ i
intervention NN i
seems VBZ N
to TO N
be VB N
as RB N
efficacious JJ N
as IN N
a DT N
longer RBR i
multidisciplinary JJ i
version NN N
. . N

In IN N
both DT N
groups NNS N
, , N
positive JJ N
effects NNS N
on IN N
patients NNS N
' POS N
well-being NN N
were VBD N
found VBN N
to TO N
a DT N
similar JJ N
extent NN N
. . N

This DT N
is VBZ N
an DT N
important JJ N
finding NN N
that IN N
, , N
from IN N
a DT N
cost-effective JJ N
perspective NN N
, , N
could MD N
contribute VB N
toward IN N
an DT N
optimized JJ N
management NN N
of IN N
patients NNS N
with IN N
IBS NNP N
. . N

-DOCSTART- -2295911- O O

The DT N
prognostic JJ N
value NN N
of IN N
testicular JJ i
biopsy NN i
in IN N
childhood NN p
acute NN p
lymphoblastic JJ p
leukemia NN p
: : p
a DT N
report NN N
from IN N
the DT N
Childrens NNP N
Cancer NNP N
Study NNP N
Group NNP N
. . N

One CD N
of IN N
the DT N
objectives NNS N
of IN N
Childrens NNP N
Cancer NNP N
Study NNP N
Group NNP N
( ( N
CCSG NNP N
) ) N
study NN N
141 CD N
( ( N
CCG-141 NNP N
) ) N
was VBD N
to TO N
determine VB N
the DT N
frequency NN o
of IN N
occult NN o
testicular JJ o
leukemia NN o
( ( o
TL NNP o
) ) o
after IN N
3 CD N
years NNS N
of IN N
disease-free JJ o
survival NN o
( ( o
DFS NNP o
) ) o
and CC N
to TO N
retreat VB N
boys NNS p
with IN p
occult NN p
TL NNP p
to TO N
prolong VB N
their PRP$ N
subsequent JJ N
DFS NNP N
. . N

Of IN N
the DT N
494 CD p
boys NNS p
entered VBD p
on IN p
study NN p
, , N
255 CD N
( ( N
51.6 CD N
% NN N
) ) N
were VBD N
in IN N
complete JJ N
continuous JJ N
remission NN N
( ( N
CCR NNP N
) ) N
3 CD N
years NNS N
after IN N
entering VBG N
remission NN N
and CC N
an DT N
additional JJ N
eight CD N
were VBD N
in IN N
CCR NNP N
3 CD N
years NNS N
after IN N
localized JJ N
extramedullary JJ N
relapse NN N
and CC N
retreatment NN N
; : N
263 CD p
boys NNS p
were VBD p
eligible JJ p
for IN p
testicular JJ i
biopsy NN i
. . i

Elective JJ p
testicular JJ i
biopsy NN i
was VBD p
performed VBN p
on IN p
235 CD p
( ( p
89.4 CD p
% NN p
) ) p
boys VBZ p
. . p

Of IN N
the DT N
204 CD N
( ( N
86.8 CD N
% NN N
) ) N
boys VBZ N
with IN N
negative JJ N
biopsies NNS N
, , N
175 CD N
( ( N
85.8 CD N
% NN N
) ) N
remained VBD N
in IN N
CCR NNP N
10 CD N
to TO N
12 CD N
years NNS N
after IN N
diagnosis NN N
and CC N
25 CD N
( ( N
12.3 CD N
% NN N
) ) N
relapsed VBD N
, , N
11 CD N
( ( N
44 CD N
% NN N
) ) N
of IN N
whom WP N
died VBD N
. . N

Isolated NNP N
overt JJ N
TL NNP N
occurred VBD N
in IN N
four CD N
( ( N
2.0 CD N
% NN N
) ) N
and CC N
all DT N
remained VBN N
in IN N
CCR NNP N
22+ CD N
to TO N
60+ CD N
months NNS N
after IN N
re-treatment JJ N
. . N

Of IN N
the DT N
26 CD N
boys NNS N
with IN N
occult NN N
TL NNP N
, , N
16 CD N
( ( N
62 CD N
% NN N
) ) N
remained VBD N
in IN N
CCR NNP N
. . N

Ten NNP N
( ( N
38 CD N
% NN N
) ) N
relapsed VBD o
despite IN N
local JJ i
testicular JJ i
irradiation NN i
and CC N
systemic JJ i
re-treatment NN i
; : i
six CD N
of IN N
the DT N
10 CD N
died VBD o
. . o

Of IN N
the DT N
26 CD N
boys NNS N
who WP N
did VBD N
not RB N
undergo JJ N
biopsy NN i
, , N
21 CD N
( ( N
80.8 CD N
% NN N
) ) N
remained VBD N
in IN N
CCR NNP N
; : N
two CD N
( ( N
7.7 CD N
% NN N
) ) N
developed VBD o
isolated JJ o
overt JJ o
TL NNP o
. . o

DFS NNP o
after IN o
testicular JJ o
biopsy NN o
was VBD N
significantly RB o
better RBR o
in IN N
boys NNS N
without IN N
occult NN N
TL NNP N
( ( N
P NNP N
= NNP N
.001 NNP N
) ) N
. . N

Occult NNP N
TL NNP N
after IN N
3 CD N
years NNS N
of IN N
CCR NNP N
represents VBZ N
aggressive JJ N
minimal-residual JJ N
disease NN N
and CC N
carries VBZ N
a DT N
worse JJR N
prognosis NN N
than IN N
absence NN N
of IN N
TL NNP N
. . N

Initial NNP N
treatment NN N
should MD N
be VB N
directed VBN N
at IN N
obviating VBG N
occult NN N
and CC N
overt JJ N
testicular JJ N
relapse NN N
. . N

Conventional JJ N
therapy NN N
as IN N
used VBN N
in IN N
this DT N
study NN N
was VBD N
suboptimal JJ N
in IN N
preventing VBG N
subsequent JJ o
bone NN o
marrow NN o
( ( o
BM NNP o
) ) o
relapse NN o
and CC o
death NN o
. . o

If IN N
occult JJ N
TR NNP N
is VBZ N
identified VBN N
during IN N
or CC N
at IN N
the DT N
end NN N
of IN N
planned JJ N
therapy NN N
, , N
a DT N
higher JJR o
salvage NN o
rate NN o
may MD N
require VB N
intensified JJ N
alternate JJ N
therapy NN N
. . N

As IN N
such JJ N
, , N
testicular JJ i
biopsies NNS i
may MD N
be VB N
clinically RB N
useful JJ N
. . N

Further JJ N
investigation NN N
is VBZ N
limited VBN N
by IN N
the DT N
relative JJ N
rarity NN N
of IN N
, , N
and CC N
the DT N
lack NN N
of IN N
identifying VBG N
features NNS N
in IN N
boys NNS N
with IN N
occult NN N
TL NNP N
. . N

-DOCSTART- -11429349- O O

The DT N
clinical JJ N
and CC N
biochemical JJ N
effects NNS N
of IN N
propofol JJ i
infusion NN N
with IN i
and CC i
without IN i
EDTA NNP i
for IN N
maintenance NN N
anesthesia NN N
in IN N
healthy JJ p
children NNS p
undergoing VBG p
ambulatory NN p
surgery NN p
. . p

UNLABELLED IN N
We PRP N
conducted VBD N
this DT N
randomized VBN N
, , N
double-blinded JJ N
, , N
comparative JJ N
, , N
parallel-group JJ N
study NN N
to TO N
determine VB N
whether IN N
adding VBG N
EDTA NNP i
to TO i
propofol VB i
would MD N
affect VB N
the DT N
clinical JJ N
profile NN N
, , N
calcium NN N
and CC N
magnesium NN N
homeostasis NN N
, , N
or CC N
renal JJ N
function NN N
in IN N
healthy JJ p
children NNS p
. . p

After IN N
the DT N
induction NN i
of IN i
anesthesia NN i
with IN i
halothane NN i
, , N
69 CD p
ambulatory JJ p
surgical JJ p
patients NNS p
( ( p
1 CD p
mo NN p
to TO p
< VB p
17 CD p
yr NNP p
old JJ p
) ) p
, , N
received VBD i
propofol NN i
without IN i
EDTA NNP i
( ( i
n JJ i
= NNP i
33 CD i
) ) i
or CC i
propofol NN i
with IN i
EDTA NNP i
( ( N
n JJ N
= NNP N
36 CD N
) ) N
. . N

Blood NN o
samples NNS o
were VBD N
obtained VBN N
for IN N
the DT N
measurement NN o
of IN o
ionized JJ o
calcium NN o
, , o
ionized JJ o
magnesium NN o
, , o
and CC o
laboratory JJ o
indicators NNS o
of IN o
renal JJ o
function NN o
. . o

Hemodynamic NNP o
measurements NNS o
, , o
recovery NN o
, , N
and CC N
adverse JJ o
events NNS o
were VBD N
recorded VBN N
. . N

Propofol NNP i
with IN i
EDTA NNP i
produced VBD N
no DT N
significant JJ N
effects NNS N
on IN N
clinical JJ o
efficacy NN o
or CC o
renal JJ o
function NN o
. . o

Propofol NNP i
and CC i
propofol JJ i
EDTA NNP i
produced VBD N
a DT N
statistically RB N
significant JJ N
decrease NN o
from IN o
baseline NN o
in IN o
serum JJ o
concentrations NNS o
of IN o
ionized JJ o
calcium NN o
and CC o
magnesium NN o
during IN o
infusion NN o
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
, , N
but CC N
with IN N
no DT N
apparent JJ N
clinical JJ N
effect NN N
. . N

Hemodynamic NNP o
measurements NNS o
generally RB N
remained VBD N
stable JJ N
and CC N
were VBD N
similar JJ N
for IN N
both DT N
groups NNS N
. . N

Statistically NNP N
significant JJ N
changes NNS N
in IN N
systolic JJ o
blood NN o
pressure NN o
, , o
mean JJ o
arterial JJ o
pressure NN o
, , o
and CC o
heart NN o
rate NN o
were VBD N
not RB N
considered VBN N
clinically RB N
significant JJ N
. . N

Adverse JJ N
events NNS N
were VBD N
mild JJ N
or CC N
moderate JJ N
. . N

The DT N
addition NN N
of IN N
EDTA NNP i
does VBZ N
not RB N
alter VB N
the DT N
clinical JJ N
profile NN N
of IN N
propofol NN N
in IN N
pediatric JJ p
ambulatory JJ p
surgical JJ p
patients NNS p
. . p

With IN N
or CC N
without IN N
EDTA NNP i
, , i
propofol NN i
is VBZ N
associated VBN N
with IN N
a DT N
decrease NN N
in IN N
ionized JJ o
calcium NN o
with IN N
no DT N
apparent JJ N
clinical JJ N
effect NN N
. . N

IMPLICATIONS VBZ N
The DT N
addition NN N
of IN N
EDTA NNP N
does VBZ N
not RB N
alter VB N
the DT N
clinical JJ N
profile NN N
of IN N
propofol NN N
in IN N
pediatric JJ p
ambulatory JJ p
surgical JJ p
patients NNS p
. . p

With IN N
or CC N
without IN N
EDTA NNP N
, , N
propofol NN N
is VBZ N
associated VBN N
with IN N
a DT N
decrease NN N
in IN N
ionized JJ o
calcium NN o
with IN N
no DT N
apparent JJ N
clinical JJ N
effect NN N
. . N

-DOCSTART- -21410033- O O

Hepatobiliary JJ o
response NN o
in IN N
postoperative JJ N
lipid JJ i
therapy NN i
in IN N
gastrointestinal JJ p
surgery NN p
. . p

BACKGROUND/AIMS NNP N
Intravenous NNP N
lipid JJ i
emulsions NNS i
may MD N
contribute VB N
to TO N
the DT N
development NN N
of IN N
total JJ N
parenteral JJ N
nutrition NN N
( ( N
TPN NNP N
) ) N
-- : N
induced VBD N
hepatobiliary JJ N
complications NNS N
. . N

METHODS NNP N
In IN N
a DT N
prospective JJ N
, , N
randomised VBD N
setting VBG N
the DT N
authors NNS N
compared VBN N
the DT N
short-term JJ N
hepatic JJ N
effects NNS N
of IN N
medium-chain JJ i
triglycerides/short-chain JJ i
triglycerides NNS i
( ( i
MCT/LCT NNP i
) ) i
physical JJ i
mixture NN i
with IN i
a DT i
four-component JJ i
intravenous JJ i
( ( i
i.v JJ i
. . i

) ) i
lipid JJ i
emulsion NN i
( ( i
LCT NNP i
, , i
MCT NNP i
, , i
Olive-oil NNP i
and CC i
Fish-oil NNP i
) ) i
in IN N
patients NNS p
undergoing VBG p
elective JJ p
gastrointestial JJ p
surgery NN p
during IN p
the DT p
early JJ p
postoperative JJ p
period NN p
. . p

RESULTS VB N
The DT N
authors NNS N
demonstrated VBD N
that IN N
total JJ o
and CC o
conjugated VBD o
bilirubin NN o
, , o
alkaline JJ o
phosphatase NN o
, , o
alanine JJ o
aminotransferase NN o
, , o
aspartate VBP o
amino JJ o
transferase NN o
and CC o
cholinesterase NN o
did VBD N
not RB N
change VB N
significantly RB N
during IN N
the DT N
5-days JJ N
observation NN N
period NN N
. . N

In IN N
contrast NN N
to TO N
this DT N
, , N
gamma-glutamyl JJ o
transferase NN o
( ( o
GGT NNP o
) ) o
activity NN o
increased VBN N
by IN N
2,4 CD N
times NNS N
during IN N
5-days JJ N
therapy NN i
with IN i
the DT i
lipid JJ i
emulsions NNS i
mentioned VBN N
above IN N
( ( N
SMOF NNP N
lipid VBZ N
: : N
21,9 CD N
to TO N
52,9 CD N
U/L NNP N
, , N
Lipofundin NNP N
: : N
from IN N
32,5 CD N
to TO N
79,6 CD N
U/L NNP N
) ) N
. . N

CONCLUSION NNP N
during IN N
a DT N
4-days JJ N
administration NN N
hepatic JJ N
effect NN N
of IN N
the DT N
intravenous JJ N
lipid JJ i
emulsions NNS i
did VBD N
not RB N
differ VB N
significantly RB N
. . N

The DT N
changes NNS o
in IN o
enzyme NN o
levels NNS o
confirm VBP N
the DT N
cholestatic JJ N
type NN N
of IN N
hepatobiliary JJ N
deviations NNS N
without IN N
clinical JJ N
impact NN N
on IN N
short-term JJ N
TPN NNP i
therapy NN i
. . i

-DOCSTART- -23652826- O O

The DT N
effects NNS N
of IN N
ezetimibe/simvastatin JJ i
versus NN i
simvastatin NN i
monotherapy NN i
on IN N
platelet NN o
and CC o
inflammatory JJ o
biomarkers NNS o
in IN N
patients NNS p
with IN p
metabolic JJ p
syndrome NN p
. . p

In IN N
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
crossover NN N
study NN N
of IN N
15 CD p
aspirin-naive JJ i
patients NNS p
( ( p
mean JJ p
age NN p
48.8 CD p
? . p
10.2 CD p
years NNS p
) ) p
with IN p
the DT p
metabolic JJ p
syndrome NN p
, , p
statin NN i
monotherapy NN i
( ( i
simvastatin JJ i
40 CD N
mg JJ N
daily RB N
) ) N
was VBD N
compared VBN N
to TO i
combination VB i
therapy NN i
( ( i
simvastatin JJ i
40 CD N
mg NN i
and CC i
ezetimibe $ i
10 CD N
mg JJ N
daily RB N
) ) N
on IN N
biomarkers NNS N
of IN o
inflammation NN o
and CC o
platelet NN o
activity NN o
. . o

The DT N
addition NN N
of IN i
ezetimibe NN i
to TO i
simvastatin VB i
over RP N
a DT N
4-week JJ N
period NN N
was VBD N
associated VBN N
with IN N
reduced JJ o
expression NN o
of IN o
CD141 NNP o
( ( N
thrombomodulin NN N
; : N
p CC N
= VB N
0.02 CD N
) ) N
, , N
platelet VBP o
endothelial JJ o
cell NN o
adhesion NN o
molecule NN o
( ( N
p JJ N
< NNP N
0.0001 CD N
) ) N
and CC o
CD51/61 NNP o
( ( N
vitronectin JJ N
receptor NN N
; : N
p CC N
= VB N
0.048 CD N
) ) N
compared VBN N
to TO i
statin VB i
monotherapy NN i
. . i

Ezetimibe NNP i
added VBD N
to TO N
simvastatin VB N
improves NNS o
several JJ o
indices NNS o
of IN o
platelet NN o
reactivity NN o
beyond IN i
statin JJ i
monotherapy NN i
. . i

However RB N
, , N
the DT N
clinical JJ N
relevance NN N
of IN N
these DT N
findings NNS N
await VBP N
results NNS N
of IN N
the DT N
IMPROVE-IT NNP N
trial NN N
( ( N
Improved NNP N
Reduction NNP N
of IN N
Outcomes NNP N
: : N
Vytorin NNP N
Efficacy NNP N
International NNP N
Trial NNP N
) ) N
. . N

-DOCSTART- -8367775- O O

Early RB i
versus NN i
late JJ i
replacement NN i
of IN i
autotransfused JJ i
blood NN i
in IN N
elective JJ p
spinal JJ i
surgery NN i
. . i

A DT N
prospective JJ N
randomized NN N
study NN N
. . N

The DT N
use NN N
of IN N
autologous JJ i
blood NN i
is VBZ N
a DT N
well RB N
established VBN N
and CC N
extremely RB N
popular JJ N
technique NN N
to TO N
decrease VB N
the DT N
necessity NN N
for IN N
homologous JJ N
transfusions NNS N
and CC N
the DT N
attendant JJ N
risks NNS N
of IN N
hepatitis NN N
, , N
HIV NNP N
, , N
and CC N
HTLV NNP N
-- : N
I/II NNP N
infections NNS N
. . N

The DT N
most RBS N
beneficial JJ N
timing NN N
for IN N
autologous JJ i
reinfusion NN N
of IN N
predonated JJ N
blood NN N
remains VBZ N
unknown JJ N
. . N

The DT N
present JJ N
study NN N
was VBD N
undertaken VBN N
to TO N
determine VB N
the DT N
optimal JJ N
timing NN N
of IN N
autologous JJ i
blood NN i
reinfusion NN i
in IN i
elective JJ i
spinal JJ i
surgery NN i
. . i

Fifty-seven JJ p
patients NNS p
were VBD N
prospectively RB N
individually RB N
randomly RB N
allocated VBN N
into IN N
early JJ i
versus NN i
delayed VBN i
reinfusion NN i
groups NNS i
prior RB N
to TO N
undergoing VBG p
elective JJ i
spinal JJ i
surgery NN i
by IN N
a DT N
single JJ N
surgeon NN N
. . N

Three CD N
surgical JJ N
subgroups NNS N
were VBD N
entered VBN N
into IN N
the DT N
study NN N
: : N
anterior/posterior NN p
( ( p
A/P NNP p
) ) p
spinal JJ p
fusion NN p
patients NNS p
, , p
posterior JJ p
thoracolumbar NN p
scoliosis NN p
fusion NN p
patients NNS p
( ( p
PSF NNP p
) ) p
, , p
and CC p
degenerative JJ p
posterior JJ p
lumbar NN p
fusion NN p
patients NNS p
( ( p
LF NNP p
) ) p
. . N

Randomization NN N
was VBD N
successful JJ N
in IN N
that DT N
three CD N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
male NN N
to TO N
female VB N
ratio NN N
, , N
age NN N
, , N
preoperative JJ N
hemoglobin NN N
, , N
or CC N
number NN N
of IN N
units NNS N
predonated VBN N
between IN N
the DT N
early JJ i
and CC i
delayed JJ i
reinfusion NN i
groups NNS i
. . i

Likewise NNP N
, , N
there EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
the DT N
details NNS N
of IN N
the DT N
operative JJ N
procedure NN N
when WRB N
compared VBN N
as IN N
a DT N
group NN N
for IN N
the DT N
early JJ N
versus NN N
delayed VBN N
reinfusion NN N
groups NNS N
. . N

A DT N
significant JJ N
increase NN N
in IN N
the DT N
postoperative JJ N
day NN o
# # o
1 CD o
, , o
2 CD o
and CC o
3 CD o
hemoglobin NN o
was VBD N
seen VBN N
in IN N
the DT N
early JJ i
reinfusion NN i
group NN i
, , N
while IN N
there EX N
was VBD N
no DT N
significant JJ N
difference NN N
seen VBN N
in IN N
the DT N
postoperative JJ N
day NN N
# # N
7 CD N
hemoglobin NN N
between IN N
the DT N
early JJ i
versus NN i
delayed VBN i
reinfusion NN i
group NN N
. . N

There EX N
was VBD N
no DT N
effect NN N
of IN N
surgical JJ N
grouping NN N
on IN N
these DT N
significant JJ N
comparisons NNS N
. . N

Earlier RBR N
patient JJ o
mobilization NN o
was VBD N
also RB N
seen VBN N
in IN N
the DT N
early JJ i
reinfusion NN i
groups NNS N
for IN N
the DT N
A/P NNP N
and CC N
PSF NNP N
groups NNS N
. . N

There EX N
was VBD N
no DT N
difference NN N
in IN N
patients NNS N
' POS N
subjective JJ N
evaluation NN N
of IN N
satisfaction NN N
and CC N
discomfort NN N
between IN N
the DT N
early JJ N
or CC N
delayed VBN N
reinfusion NN N
groups NNS N
as IN N
determined VBN N
by IN N
blinded VBN N
interview NN N
on IN N
days NNS N
1 CD N
, , N
3 CD N
, , N
5 CD N
, , N
and CC N
7 CD N
postoperatively RB N
. . N

( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
250 CD N
WORDS NNP N
) ) N
-DOCSTART- -15305197- O O

A DT N
randomised JJ N
comparison NN N
of IN N
UK NNP i
genetic JJ i
risk NN i
counselling NN i
services NNS i
for IN p
familial JJ p
cancer NN p
: : p
psychosocial JJ o
outcomes NNS o
. . o

The DT N
aim NN N
of IN N
the DT N
study NN N
was VBD N
to TO N
compare VB N
psychosocial JJ o
outcomes NNS o
for IN N
50 CD p
new JJ p
clinic JJ p
attendees NNS p
, , p
referred VBD p
for IN p
cancer NN i
genetic JJ i
counselling NN i
to TO p
five CD p
UK NNP p
centres NNS p
. . p

The DT p
centres NNS p
represented VBD p
England NNP p
, , p
Scotland NNP p
and CC p
Wales NNP p
, , p
and CC p
were VBD p
randomly RB p
selected VBN p
from IN p
groups NNS p
ranked VBN p
by IN p
different JJ p
levels NNS p
of IN p
clinical JJ p
activity NN p
in IN p
cancer NN p
genetics NNS p
practice NN p
. . p

Questionnaires NNS N
assessed VBD N
demographic JJ o
data NNS o
, , o
risk NN o
perception NN o
, , o
mental JJ o
health NN o
and CC o
use NN o
of IN o
health NN o
services NNS o
pre-consultation NN o
and CC N
at IN N
1 CD N
and CC N
12 CD N
months NNS N
follow-up RB N
. . N

Satisfaction NN o
was VBD N
measured VBN N
for IN N
attendees NNS N
and CC N
referring VBG N
doctors NNS N
at IN N
follow-up NN N
. . N

A DT p
total NN p
of IN p
256 CD p
unaffected JJ p
adults NNS p
fulfilled VBD p
the DT p
study NN p
criteria NNS p
. . p

The DT N
five CD N
centres NNS N
varied VBD N
widely RB N
with IN N
respect NN N
to TO N
service NN N
organisation NN N
and CC N
activity NN N
, , N
but CC N
all DT N
had VBD N
a DT N
greater JJR N
proportion NN N
of IN N
unaffected JJ N
attendees NNS N
with IN N
a DT N
breast NN N
cancer NN N
risk NN N
( ( N
61-91 CD N
% NN N
) ) N
than IN N
either CC N
a DT N
bowel NN N
cancer NN N
risk NN N
( ( N
0-33 CD N
% NN N
) ) N
or CC N
ovarian JJ N
cancer NN N
risk NN N
( ( N
3-25 CD N
% NN N
) ) N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
the DT N
psychosocial JJ o
data NN o
between IN N
centres NNS N
pre-counselling VBG i
. . i

No DT N
significant JJ N
change NN N
over IN N
time NN N
occurred VBN N
for IN N
any DT N
of IN N
the DT N
centres NNS N
for IN N
risk NN o
perception NN o
or CC o
general JJ o
psychological JJ o
distress NN o
. . o

There EX N
were VBD N
significant JJ N
differences NNS N
between IN N
centres NNS N
in IN N
reduction NN N
of IN N
cancer NN o
worry NN N
from IN N
baseline NN N
to TO N
12 CD N
months NNS N
and CC N
with IN N
the DT N
number NN N
of IN N
women NNS N
who WP N
were VBD N
recommended VBN N
to TO N
have VB N
mammographic JJ N
surveillance NN N
who WP N
had VBD N
not RB N
received VBN N
this DT N
. . N

Overall JJ N
, , N
one-third JJ N
of IN N
women NNS N
for IN N
whom WP N
mammography NN N
had VBD N
been VBN N
recommended VBN N
had VBD N
not RB N
been VBN N
screened VBN N
within IN N
1 CD N
year NN N
of IN N
follow-up NN N
. . N

Subsequent JJ N
attendance NN N
at IN N
the DT N
GP NNP N
, , N
but CC N
not RB N
at IN N
a DT N
hospital NN N
, , N
was VBD N
associated VBN N
with IN N
risk NN N
level NN N
, , N
but CC N
differences NNS N
between IN N
centres NNS N
could MD N
not RB N
be VB N
analysed VBN N
. . N

Satisfaction NN o
differed VBD N
significantly RB N
between IN N
centres NNS N
for IN N
4 CD N
: : N
14 CD N
aspects NNS N
of IN N
service NN N
provision NN N
and CC N
with IN N
3 CD N
: : N
17 CD N
items NNS N
concerning VBG N
communication NN N
; : N
satisfaction NN N
was VBD N
high JJ N
overall JJ N
. . N

Over IN N
90 CD N
% NN N
of IN N
referring VBG N
doctors NNS N
were VBD N
moderately/very RB N
satisfied VBN N
with IN N
the DT N
service NN N
, , N
but CC N
23 CD N
% NN N
were VBD N
dissatisfied VBN N
with IN N
waiting VBG N
times NNS N
and CC N
19 CD N
% NN N
with IN N
access NN N
to TO N
preventive VB N
treatment NN N
. . N

Results NNS N
differed VBD N
significantly RB N
between IN N
centres NNS N
for IN N
doctor NN N
's POS N
satisfaction NN N
with IN N
the DT N
provision NN N
of IN N
referral JJ N
criteria NNS N
and CC N
prescribing VBG N
information NN N
. . N

In IN N
conclusion NN N
, , N
there EX N
were VBD N
relatively RB N
few JJ N
significant JJ N
differences NNS N
in IN N
psychosocial JJ o
outcomes NNS o
between IN N
centres NNS N
, , N
considering VBG N
the DT N
wide JJ N
variation NN N
in IN N
service NN N
organisation NN N
and CC N
activity NN N
. . N

These DT N
significant JJ N
differences NNS N
were VBD N
not RB N
consistent JJ N
across IN N
the DT N
centres NNS N
, , N
therefore RB N
, , N
differences NNS N
could MD N
not RB N
be VB N
linked VBN N
to TO N
specific JJ N
aspects NNS N
of IN N
service NN N
provision NN N
. . N

-DOCSTART- -22101219- O O

Challenges NNS N
and CC N
potential JJ N
solutions NNS N
to TO N
meeting VBG N
accrual JJ N
goals NNS N
in IN N
a DT N
Phase NNP N
II NNP N
chemoprevention NN N
trial NN N
for IN N
prostate NN p
cancer NN p
. . p

OBJECTIVE CC N
The DT N
goal NN N
of IN N
this DT N
report NN N
is VBZ N
to TO N
describe VB N
the DT N
on IN N
going VBG N
strategies NNS N
, , N
successes NNS N
, , N
challenges NNS N
and CC N
solutions NNS N
for IN N
recruitment NN N
in IN N
this DT N
multi-center NN N
, , N
phase NN N
II NNP N
chemoprevention NN N
trial NN N
targeting VBG N
men NNS p
at IN p
high JJ p
risk NN p
for IN p
prostate NN p
cancer NN p
. . p

METHODS NNP N
We PRP N
developed VBD N
and CC N
implemented VBD N
a DT N
multi-center JJ N
clinical JJ N
trial NN N
in IN N
institutions NNS N
with IN N
supportive JJ N
infrastructure NN N
, , N
lead NN N
by IN N
a DT N
recruitment NN N
team NN N
of IN N
experienced JJ N
and CC N
committed JJ N
physicians NNS N
and CC N
clinical JJ N
trial NN N
staff NN N
, , N
implementing VBG N
multi-media NN i
and CC i
community NN i
outreach VBP i
strategies NNS N
to TO N
meet VB N
recruitment JJ N
goals NNS N
. . N

Screening VBG i
logs NNS i
were VBD N
reviewed VBN N
to TO N
identify VB N
trends NNS N
as RB N
well RB N
as IN N
patient NN N
, , N
protocol NN N
and CC N
infrastructure NN N
-related VBD N
barriers NNS N
impacting VBG N
accrual JJ N
and CC N
revisions NNS N
to TO N
protocol VB N
implemented VBN N
. . N

RESULTS NNP N
Between NNP p
January NNP p
2008 CD p
and CC p
February NNP p
2011 CD p
a DT p
total NN p
of IN p
3547 CD p
individuals NNS p
were VBD p
prescreened VBN p
with IN p
94 CD p
% NN p
( ( p
n=3092 JJ p
) ) p
determined VBD p
to TO p
be VB p
ineligible JJ p
based VBN p
on IN p
diagnosis NN p
of IN p
cancer NN p
or CC p
benign JJ p
biopsy NN p
results NNS p
. . p

Of IN N
these DT N
, , N
216 CD p
were VBD p
considered VBN p
eligible JJ p
for IN p
further JJ p
screening NN p
with IN p
52 CD p
% NN p
( ( p
n=113 JJ p
) ) p
declining VBG p
to TO p
participate VB p
due JJ p
to TO p
patient VB p
related JJ p
factors NNS p
and CC p
14 CD p
% NN p
( ( p
n=29 JJ p
) ) p
eliminated VBD p
due JJ p
to TO p
protocol-related JJ p
criteria NNS p
for IN p
exclusion NN p
. . p

Ninety-four NNP p
( ( p
94 CD p
) ) p
subjects NNS p
consented VBN p
to TO p
participate VB p
with IN p
34 CD p
% NN p
of IN p
these DT p
subjects NNS p
( ( p
n=74 NN p
) ) p
meeting VBG p
all DT p
eligibility NN p
criteria NNS p
to TO N
be VB N
randomized VBN N
to TO N
receive VB N
study NN N
agent NN N
or CC N
placebo NN N
. . N

Across IN N
all DT N
sites NNS N
, , N
99 CD N
% NN N
of IN N
the DT N
recruitment NN N
of IN N
subjects NNS N
in IN N
this DT N
clinical JJ N
trial NN N
is VBZ N
via IN N
physician JJ N
recruitment NN N
and CC N
referral JJ N
with IN N
less JJR N
than IN N
1 CD N
% NN N
responding VBG N
to TO N
other JJ N
recruitment NN N
strategies NNS N
. . N

CONCLUSION VB N
A DT N
contemporary JJ N
approach NN N
to TO N
subject VB N
recruitment NN N
and CC N
frequent JJ N
evaluation NN N
is VBZ N
needed VBN N
to TO N
assure VB N
responsiveness NN N
to TO N
emerging VBG N
challenges NNS N
to TO N
accrual JJ N
and CC N
the DT N
evolving VBG N
scientific JJ N
literature NN N
. . N

A DT N
focus NN N
on IN N
investing VBG N
on IN N
improving VBG N
systems NNS N
for IN N
physician JJ N
recruitment NN N
may MD N
be VB N
key JJ N
to TO N
meeting VBG N
recruitment JJ N
target NN N
in IN N
chemoprevention NN N
trials NNS N
. . N

-DOCSTART- -15319704- O O

Ropinirole NNP i
as IN N
a DT N
treatment NN N
of IN N
restless JJ p
legs JJ p
syndrome NN p
in IN p
patients NNS p
on IN p
chronic JJ p
hemodialysis NN p
: : p
an DT N
open JJ N
randomized VBN N
crossover NN N
trial NN N
versus NN N
levodopa NN i
sustained VBD i
release NN i
. . i

OBJECTIVE NNP N
Restless NNP N
legs VBZ N
syndrome NN N
( ( N
RLS NNP N
) ) N
is VBZ N
a DT N
common JJ N
neurologic JJ N
condition NN N
characterized VBN N
by IN N
uncomfortable JJ N
and CC N
unpleasant JJ N
sensations NNS N
in IN N
the DT N
legs NN N
, , N
occurring VBG N
primarily RB N
at IN N
rest NN N
, , N
which WDT N
are VBP N
usually RB N
worse JJR N
in IN N
the DT N
evening NN N
and CC N
are VBP N
alleviated VBN N
by IN N
movement NN N
. . N

RLS NNP N
is VBZ N
present JJ N
in IN N
20-40 JJ N
% NN N
of IN N
patients NNS p
with IN p
renal JJ p
failure NN p
. . p

This DT N
study NN N
was VBD N
a DT N
14-week JJ N
open JJ N
, , N
randomized VBN N
, , N
crossover JJ N
trial NN N
of IN N
ropinirole NN i
vs. FW i
levodopa NN i
sustained VBN i
release NN i
( ( i
SR NNP i
) ) i
in IN N
11 CD p
patients NNS p
with IN p
RLS NNP p
on IN p
chronic JJ p
hemodialysis NN p
. . p

METHODS NNP N
Eleven NNP p
patients NNS p
( ( p
7 CD p
men NNS p
, , p
4 CD p
women NNS p
) ) p
were VBD p
enrolled VBN p
in IN p
the DT p
study NN p
. . p

They PRP N
received VBD N
either CC N
levodopa JJ i
SR NNP i
or CC i
ropinirole VB i
for IN N
6 CD N
weeks NNS N
, , N
followed VBN N
by IN N
a DT N
washout NN N
week NN N
, , N
then RB i
the DT i
alternate NN i
treatment NN i
for IN N
6 CD N
weeks NNS N
. . N

Patients NNS N
rated VBD N
the DT N
severity NN o
of IN o
RLS NNP o
by IN N
means NNS N
of IN N
a DT N
6-item JJ N
questionnaire NN N
developed VBN N
by IN N
the DT N
International NNP N
Restless NNP N
Legs NNP N
Study NNP N
Group NNP N
( ( N
6-item JJ N
IRLS NNP N
) ) N
, , N
by IN N
the DT N
Clinical NNP N
Global NNP N
Impression NNP N
( ( N
CGI NNP N
) ) N
scale NN N
, , N
and CC N
by IN N
sleep JJ N
diaries NNS N
. . N

RESULTS NNP N
Under IN N
treatment NN N
with IN N
levodopa JJ N
SR NNP N
, , N
1 CD N
patient NN N
presented VBN N
severe JJ o
vomiting NN o
, , N
leading VBG N
to TO N
study VB N
discontinuation NN N
. . N

The DT p
10 CD p
patients NNS p
who WP p
completed VBD p
the DT p
study NN p
reported VBD N
a DT N
33.5 CD N
% NN N
improvement NN N
( ( N
from IN N
16.7 CD N
+/- JJ N
3.2 CD N
to TO N
11.1 CD N
+/- JJ N
4 CD N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
of IN N
the DT N
6-item JJ N
IRLS NNP N
scores NNS N
during IN N
levodopa JJ N
SR NNP N
treatment NN N
and CC N
a DT N
73.5 CD N
% NN N
improvement NN N
( ( N
from IN N
16.6 CD N
+/- JJ N
2.8 CD N
to TO N
4.4 CD N
+/- JJ N
3.8 CD N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
during IN N
ropinirole JJ N
treatment NN N
. . N

By IN N
the DT N
end NN N
of IN N
the DT N
study NN N
the DT N
mean JJ N
levodopa NN N
SR NNP N
dosage NN N
was VBD N
190 CD N
mg/d NN N
and CC N
the DT N
mean JJ N
ropinirole NN N
dosage NN N
was VBD N
1.45 CD N
mg/d NN N
. . N

Ropinirole NNP i
was VBD N
superior JJ N
to TO N
levodopa VB i
SR NNP i
in IN N
reducing VBG N
6-item JJ N
IRLS NNP N
scores NNS N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
and CC N
in IN N
increasing VBG N
sleep JJ o
time NN o
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

The DT N
patient NN N
CGI NNP o
scale NN o
showed VBD N
a DT N
significant JJ N
difference NN N
favoring VBG N
ropinirole NN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

There EX N
was VBD N
no DT N
significant JJ N
carryover NN o
or CC o
period NN o
effect NN o
for IN N
any DT N
outcome JJ N
measure NN N
. . N

Four CD N
patients NNS N
reported VBD N
a DT N
complete JJ N
reversion NN N
of IN N
RLS NNP o
symptoms NNS o
during IN N
ropinirole JJ N
treatment NN N
at IN N
doses NNS N
ranging VBG N
from IN N
0.25-2 JJ N
mg/d NN N
. . N

CONCLUSIONS NNP N
These DT N
results NNS N
suggest VBP N
that IN N
ropinirole NN N
is VBZ N
more RBR N
effective JJ N
than IN N
levodopa JJS N
SR NNP N
in IN N
the DT N
treatment NN N
of IN N
RLS NNP N
in IN N
patients NNS p
on IN p
chronic JJ p
hemodialysis NN p
. . p

-DOCSTART- -9411221- O O

A DT N
comparison NN N
of IN N
antiarrhythmic-drug JJ i
therapy NN i
with IN i
implantable JJ i
defibrillators NNS i
in IN N
patients NNS p
resuscitated VBN p
from IN p
near-fatal JJ p
ventricular JJ p
arrhythmias NN p
. . p

The DT N
Antiarrhythmics NNPS i
versus NN N
Implantable JJ i
Defibrillators NNS i
( ( N
AVID NNP N
) ) N
Investigators NNPS N
. . N

BACKGROUND NNP N
Patients NNPS N
who WP N
survive VBP N
life-threatening JJ N
ventricular JJ N
arrhythmias NNS N
are VBP N
at IN N
risk NN N
for IN N
recurrent NN N
arrhythmias NN N
. . N

They PRP N
can MD N
be VB N
treated VBN N
with IN N
either DT N
an DT N
implantable JJ i
cardioverter-defibrillator NN i
or CC N
antiarrhythmic JJ i
drugs NNS i
, , N
but CC N
the DT N
relative JJ N
efficacy NN N
of IN N
these DT N
two CD N
treatment NN N
strategies NNS N
is VBZ N
unknown JJ N
. . N

METHODS NNP N
To TO N
address VB N
this DT N
issue NN N
, , N
we PRP N
conducted VBD N
a DT N
randomized JJ N
comparison NN N
of IN N
these DT N
two CD N
treatment NN N
strategies NNS N
in IN N
patients NNS p
who WP p
had VBD p
been VBN p
resuscitated VBN p
from IN p
near-fatal JJ p
ventricular JJ p
fibrillation NN p
or CC p
who WP p
had VBD p
undergone JJ p
cardioversion NN p
from IN p
sustained VBN p
ventricular JJ p
tachycardia NN p
. . p

Patients NNS p
with IN p
ventricular JJ p
tachycardia NN p
also RB p
had VBD p
either CC p
syncope NN p
or CC p
other JJ p
serious JJ p
cardiac NN p
symptoms NNS p
, , p
along IN p
with IN p
a DT p
left JJ p
ventricular JJ p
ejection NN p
fraction NN p
of IN p
0.40 CD p
or CC p
less JJR p
. . p

One CD N
group NN N
of IN N
patients NNS N
was VBD N
treated VBN N
with IN N
implantation NN i
of IN i
a DT i
cardioverter-defibrillator NN i
; : i
the DT N
other JJ N
received JJ N
class NN i
III NNP i
antiarrhythmic JJ i
drugs NNS i
, , i
primarily RB i
amiodarone NN i
at IN N
empirically RB N
determined VBN N
doses NNS N
. . N

Fifty-six NNP N
clinical JJ N
centers NNS N
screened VBD N
all DT N
patients NNS N
who WP N
presented VBD N
with IN N
ventricular JJ N
tachycardia NN N
or CC N
ventricular JJ N
fibrillation NN N
during IN N
a DT N
period NN N
of IN N
nearly RB N
four CD N
years NNS N
. . N

Of IN p
1016 CD p
patients NNS p
( ( p
45 CD p
percent NN p
of IN p
whom WP p
had VBD p
ventricular JJ p
fibrillation NN p
, , p
and CC p
55 CD p
percent NN p
ventricular JJ p
tachycardia NN p
) ) p
, , p
507 CD p
were VBD p
randomly RB p
assigned VBN p
to TO p
treatment NN p
with IN p
implantable JJ i
cardioverter-defibrillators NNS i
and CC p
509 CD p
to TO p
antiarrhythmic-drug JJ i
therapy NN i
. . i

The DT N
primary JJ N
end NN N
point NN N
was VBD N
overall JJ o
mortality NN o
. . o

RESULTS NNP N
Follow-up NNP N
was VBD N
complete JJ N
for IN N
1013 CD N
patients NNS N
( ( N
99.7 CD N
percent NN N
) ) N
. . N

Overall JJ N
survival NN o
was VBD N
greater JJR N
with IN N
the DT N
implantable JJ i
defibrillator NN i
, , N
with IN N
unadjusted JJ N
estimates NNS N
of IN N
89.3 CD N
percent NN N
, , N
as IN N
compared VBN N
with IN N
82.3 CD N
percent NN N
in IN N
the DT N
antiarrhythmic-drug JJ i
group NN N
at IN N
one CD N
year NN N
, , N
81.6 CD N
percent NN N
versus NN N
74.7 CD N
percent NN N
at IN N
two CD N
years NNS N
, , N
and CC N
75.4 CD N
percent NN N
versus NN N
64.1 CD N
percent NN N
at IN N
three CD N
years NNS N
( ( N
P NNP N
< NNP N
0.02 CD N
) ) N
. . N

The DT N
corresponding JJ N
reductions NNS N
in IN N
mortality NN o
( ( N
with IN N
95 CD N
percent NN N
confidence NN N
limits NNS N
) ) N
with IN N
the DT N
implantable JJ i
defibrillator NN i
were VBD N
39+/-20 JJ N
percent NN N
, , N
27+/-21 JJ N
percent NN N
, , N
and CC N
31+/-21 JJ N
percent NN N
CONCLUSIONS NNP N
Among IN N
survivors NNS p
of IN p
ventricular JJ p
fibrillation NN p
or CC p
sustained VBN p
ventricular JJ p
tachycardia NN p
causing VBG p
severe JJ p
symptoms NNS p
, , N
the DT N
implantable JJ i
cardioverter-defibrillator NN i
is VBZ N
superior JJ N
to TO N
antiarrhythmic VB i
drugs NNS i
for IN N
increasing VBG N
overall JJ N
survival NN N
. . N

-DOCSTART- -19702485- O O

Randomized VBN N
, , N
placebo-controlled JJ i
, , N
crossover NN N
study NN N
of IN N
methylphenidate NN i
for IN N
attention-deficit/hyperactivity NN N
disorder NN N
symptoms NNS N
in IN p
preschoolers NNS p
with IN p
developmental JJ p
disorders NNS p
. . p

OBJECTIVE IN N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
investigate VB N
the DT N
short-term JJ N
efficacy NN o
and CC N
safety NN N
of IN N
methylphenidate NN i
( ( i
MPH NNP i
) ) i
to TO N
treat VB N
attention-deficit/hyperactivity JJ N
disorder NN N
( ( N
ADHD NNP N
) ) N
symptoms NNS N
in IN N
an DT N
understudied JJ p
population NN p
of IN p
preschoolers NNS p
with IN p
pervasive JJ p
developmental JJ p
disorder NN p
( ( p
PDD NNP p
) ) p
or CC p
intellectual JJ p
disability NN p
( ( p
ID NNP p
) ) p
. . p

METHODS NNP N
Fourteen NNP p
preschoolers NNS p
with IN p
developmental JJ p
disorders NNS p
( ( p
DD NNP p
, , p
n JJ p
= VBP p
14 CD p
; : p
PDD NNP p
, , p
n JJ p
= VBP p
12 CD p
; : p
ID NNP p
, , p
n JJ p
= NNP p
2 CD p
) ) p
underwent NN N
MPH NNP i
titration NN i
in IN N
a DT N
single-blind JJ N
manner NN N
followed VBN N
by IN N
a DT N
4-week JJ N
double-blind NN N
crossover NN N
phase NN N
. . N

Each DT N
child NN N
was VBD N
administered VBN N
placebo NN i
for IN N
2 CD N
weeks NNS N
and CC N
optimal JJ i
dose NN i
for IN N
2 CD N
weeks NNS N
. . N

The DT N
primary JJ N
outcome NN N
measure NN N
was VBD N
the DT N
Diagnostic NNP o
and CC o
Statistical NNP o
Manual NNP o
of IN o
Mental NNP o
Disorders NNP o
, , o
4 CD o
( ( o
th NN o
) ) o
edition NN o
( ( o
DSM-IV NNP o
) ) o
ADHD NNP o
subscale NN o
of IN o
the DT o
Conners NNP o
' POS o
Parent NN o
Rating VBG o
Scale-Revised JJ o
( ( N
CPRS-R-DSM-IV-ADHD NNP N
) ) N
. . N

RESULTS NNP N
MPH NNP i
improved VBD N
parent-rated JJ o
ADHD NNP o
symptoms NNS o
of IN N
the DT N
preschoolers NNS N
; : N
50 CD N
% NN N
were VBD N
rated VBN N
as IN N
responders NNS N
. . N

The DT N
CPRS-R-DSM-IV-ADHD JJ o
subscale NN o
was VBD N
significant JJ N
for IN N
the DT N
PDD NNP p
subgroup NN p
( ( N
p JJ N
= NN N
0.005 CD N
, , N
Cohen NNP N
d VBZ N
= NNP N
0.97 CD N
) ) N
and CC N
marginally RB N
significant JJ N
for IN N
the DT N
entire JJ N
DD NNP N
sample NN N
( ( N
p JJ N
= NN N
0.08 CD N
, , N
Cohen NNP N
d VBZ N
= NNP N
0.50 CD N
) ) N
. . N

Half NN N
of IN N
the DT N
preschoolers NNS p
experienced VBD N
side JJ o
effects NNS o
with IN N
MPH NNP i
, , N
including VBG N
reports NNS N
of IN N
increased VBN N
stereotypic NN o
behavior NN o
, , o
upset JJ o
stomach NN o
, , o
sleep-related JJ o
difficulties NNS o
, , o
and CC o
emotional JJ o
lability NN o
. . o

One CD N
child NN N
discontinued VBN N
during IN N
titration NN N
due JJ N
to TO N
side VB N
effects NNS N
. . N

CONCLUSION VB N
The DT N
predominant JJ N
direction NN N
of IN N
response NN N
in IN N
these DT N
preschoolers NNS p
with IN p
both DT p
ADHD NNP p
and CC p
PDD/ID NNP p
favored VBD N
MPH NNP i
, , N
even RB N
though IN N
the DT N
response NN N
was VBD N
more RBR N
subtle JJ N
and CC N
variable JJ N
than IN N
in IN N
older JJR N
and CC N
typically RB N
developing VBG N
children NNS N
. . N

Due NNP N
to TO N
high JJ N
rates NNS N
of IN N
adverse JJ N
effects NNS N
, , N
preschoolers NNS N
should MD N
be VB N
monitored VBN N
closely RB N
. . N

-DOCSTART- -8549538- O O

The DT N
effect NN N
of IN N
liquid NN i
fibre NN i
on IN N
feeding VBG o
behaviour NN o
. . o

-DOCSTART- -11453509- O O

Ipratropium NNP i
bromide NN i
nasal NN i
spray NN i
for IN N
treatment NN N
of IN N
rhinorrhea NN p
in IN p
the DT p
laryngectomized JJ p
patient NN p
: : p
a DT N
pilot NN N
study NN N
. . N

Many NNP N
who WP N
have VBP N
had VBD N
a DT N
total JJ N
laryngectomy NN N
complain NN N
of IN N
unrelenting VBG N
rhinorrhea NN N
that WDT N
is VBZ N
often RB N
very RB N
difficult JJ N
to TO N
control VB N
. . N

This DT N
study NN N
was VBD N
undertaken VBN N
to TO N
evaluate VB N
the DT N
effect NN N
of IN N
ipratropium NN i
bromide NN i
( ( i
IB NNP i
) ) i
, , N
an DT N
anticholinergic JJ N
nasal NN N
spray NN N
, , N
on IN N
rhinorrhea NN N
in IN N
these DT N
patients NNS N
. . N

This DT N
was VBD N
designed VBN N
as IN N
a DT N
prospective JJ N
, , N
randomized VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
, , N
crossover NN N
pilot NN N
study NN N
. . N

Participants NNS p
were VBD p
selected VBN p
if IN p
they PRP p
had VBD p
a DT p
total JJ p
laryngectomy NN p
and CC p
complained VBD p
of IN p
rhinorrhea NN p
. . p

They PRP N
were VBD N
asked VBN N
to TO N
rate NN N
the DT N
severity NN o
and CC N
duration NN o
of IN o
their PRP$ o
rhinorrhea JJ o
each DT N
day NN N
throughout IN N
the DT N
study NN N
on IN N
a DT N
scale NN N
from IN N
zero CD N
to TO N
six CD N
. . N

Each DT N
participant NN N
was VBD N
initially RB N
given VBN N
a DT N
saline NN i
nasal NN i
spray NN i
for IN N
one CD N
week NN N
. . N

They PRP N
were VBD N
then RB N
randomized VBN N
to TO N
use VB N
either DT N
IB NNP i
or CC i
saline NN i
for IN N
the DT N
double-blinded JJ N
portion NN N
of IN N
the DT N
study NN N
. . N

Two CD N
sprays NNS N
of IN N
IB NNP i
at IN N
a DT N
dose NN N
of IN N
42 CD N
micrograms/spray NN N
( ( N
0.06 CD N
% NN N
) ) N
, , N
or CC N
saline NN i
, , N
were VBD N
administered VBN N
intranasally RB N
twice JJ N
daily RB N
for IN N
two CD N
weeks NNS N
, , N
after IN N
which WDT N
time NN N
the DT N
participants NNS N
were VBD N
given VBN N
another DT N
nasal NN N
spray NN N
( ( N
either CC N
IB NNP i
or CC i
saline NN i
) ) i
for IN N
the DT N
crossover NN N
portion NN N
of IN N
the DT N
study NN N
. . N

Six CD p
patients NNS p
entered VBD p
and CC p
completed VBD p
the DT p
study NN p
. . p

Those DT N
patients NNS N
using VBG N
the DT N
IB NNP N
recorded VBD N
a DT N
mean JJ N
55 CD N
% NN N
decline NN o
in IN o
severity NN o
and CC N
a DT N
mean JJ N
51 CD N
% NN N
decline NN o
in IN o
duration NN o
of IN o
the DT o
rhinorrhea NN o
as IN N
compared VBN N
to TO N
placebo VB N
. . N

The DT N
relief NN o
in IN o
both DT o
severity NN o
and CC o
duration NN o
of IN o
rhinorrhea NN o
obtained VBN N
by IN N
patients NNS N
was VBD N
analyzed VBN N
using VBG N
the DT N
Wilcoxon NNP o
signed-rank JJ o
test NN o
and CC N
found VBN N
to TO N
be VB N
highly RB o
significant JJ o
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
. . N

Despite IN N
the DT N
limitations NNS N
of IN N
a DT N
small JJ N
sample NN N
size NN N
in IN N
this DT N
study NN N
, , N
ipratropium NN N
bromide NN N
nasal NN N
spray NN N
significantly RB N
reduced VBD N
both DT N
the DT N
severity NN o
and CC o
duration NN o
of IN o
rhinorrhea NN o
in IN N
laryngectomized JJ N
patients NNS N
. . N

We PRP N
suggest VBP N
ipratropium JJ N
nasal NN N
spray NN N
as IN N
a DT N
safe JJ N
, , N
effective JJ N
way NN N
to TO N
treat VB N
chronic JJ N
rhinorrhea NN N
in IN N
laryngectomized JJ N
patients NNS N
, , N
improving VBG N
their PRP$ N
quality NN o
of IN o
life NN o
. . o

-DOCSTART- -15509022- O O

Total JJ N
anthelmintic JJ N
failure NN N
to TO N
control VB N
nematode JJ p
parasites NNS p
of IN p
small JJ p
ruminants NNS p
on IN p
government NN p
breeding NN p
farms NNS p
in IN p
Sabah NNP p
, , p
East NNP p
Malaysia NNP p
. . p

Government-owned JJ p
small-ruminant JJ p
breeding NN p
farms NNS p
in IN N
Malaysia NNP N
provide VBP N
the DT N
source NN N
of IN N
sheep NN N
and CC N
goats NNS N
to TO N
smallholder VB N
farmers NNS N
in IN N
the DT N
country NN N
. . N

In IN N
the DT N
eastern JJ p
Malaysian JJ p
state NN p
of IN p
Sabah NNP p
, , N
high-level JJ N
stock NN N
losses NNS N
have VBP N
been VBN N
recorded VBN N
on IN N
these DT N
farms NNS N
for IN N
several JJ N
years NNS N
, , N
frequently RB N
accompanied VBN N
by IN N
clinical JJ N
signs NNS N
indicating VBG N
pathogenic JJ N
levels NNS N
of IN N
infections NNS N
with IN N
the DT N
nematode JJ p
parasite NN p
Haemonchus NNP p
contortus NN p
. . p

This DT N
suggests VBZ N
that IN N
their PRP$ N
dependence NN N
on IN N
chemotherapy NN i
to TO N
control VB N
parasite JJ N
infections NNS N
had VBD N
failed VBN N
. . N

Accordingly RB N
, , N
tests NNS N
for IN N
anthelmintic JJ o
efficacy NN o
using VBG N
the DT N
faecal JJ o
egg NN o
count NN o
reduction NN o
test NN o
( ( o
FECRT NNP o
) ) o
on IN N
the DT N
range NN N
of IN N
drugs NNS N
used VBN N
to TO N
control VB N
nematode JJ N
parasites NNS N
were VBD N
carried VBN N
out RP N
on IN N
the DT N
five CD N
government NN N
small-ruminant JJ N
breeding NN N
farms NNS N
in IN N
Sabah NNP N
. . N

These DT N
tests NNS N
showed VBD N
a DT N
total JJ N
failure NN o
of IN o
the DT o
benzimidazole NN o
, , o
imidothiazole NN o
, , o
macrocyclic JJ o
lactone NN o
and CC o
salicylanilide JJ o
groups NNS o
of IN o
anthelmintics NNS o
to TO N
control VB o
H. NNP o
contortus JJ o
infections NNS o
of IN N
sheep NN p
and CC p
goats NNS p
on IN p
all DT p
farms NNS p
. . p

Drastic JJ N
changes NNS N
in IN N
animal JJ N
management NN N
need NN N
to TO N
be VB N
made VBN N
in IN N
an DT N
attempt NN N
to TO N
deal VB N
with IN N
this DT N
situation NN N
, , N
for IN N
which WDT N
suggestions NNS N
are VBP N
made VBN N
. . N

-DOCSTART- -9819368- O O

Yohimbine NN i
in IN N
neurally RB p
mediated VBN p
syncope NN p
. . p

Pathophysiological JJ N
implications NNS N
. . N

In IN N
this DT N
study NN N
, , N
we PRP N
evaluated VBD N
if IN N
increased VBN N
sympathetic JJ N
stimulation NN N
is VBZ N
an DT N
essential JJ N
requirement NN N
for IN N
the DT N
development NN N
of IN N
neurally RB N
mediated VBN N
syncope NN N
( ( N
NMS NNP N
) ) N
by IN N
manipulating VBG N
overall JJ N
sympathetic JJ N
outflow NN N
in IN N
subjects NNS p
susceptible JJ p
to TO p
tilt-induced JJ p
syncope NN p
. . p

Eight NNP p
previously RB p
characterized VBD p
patients NNS p
with IN p
recurrent JJ p
NMS NNP p
( ( p
five CD p
females NNS p
and CC p
three CD p
males NNS p
; : p
34+/-2 JJ p
yr NN p
) ) p
were VBD p
recruited VBN p
from IN p
the DT p
Vanderbilt NNP p
Syncope NNP p
Unit NNP p
and CC N
eight CD p
age-matched JJ p
controls NNS p
underwent JJ N
initial JJ N
administration NN N
of IN N
clonidine NN i
( ( i
CLO NNP i
) ) i
or CC i
yohimbine NN i
( ( N
YHO NNP N
) ) N
. . N

This DT N
was VBD N
done VBN N
, , N
prospectively RB N
, , N
to TO N
determine VB N
doses NNS N
of IN N
these DT N
agents NNS N
that WDT N
would MD N
increase VB N
or CC N
decrease VB N
plasma JJ o
norepinephrine NN o
levels NNS o
by IN N
> NNP N
/= NNP N
30 CD N
% NN N
. . N

On IN N
a DT N
different JJ N
day NN N
, , N
in IN N
all DT N
subjects NNS N
we PRP N
determined VBD N
intraarterial JJ o
blood NN o
pressure NN o
, , o
EKG NNP o
and CC o
muscle NN o
sympathetic JJ o
nerve NN o
activity NN o
( ( o
MSNA NNP o
) ) o
both DT N
supine JJ N
and CC N
during IN N
upright JJ N
tilt NN N
. . N

After IN N
this DT N
, , N
subjects VBZ N
randomly RB N
received VBN N
either CC N
CLO NNP i
or CC N
YHO NNP i
, , N
and CC N
3 CD N
h NN N
later RB N
another DT N
tilt NN N
was VBD N
performed VBN N
. . N

After IN N
1 CD N
wk NN N
, , N
a DT N
similar JJ N
procedure NN N
with IN N
the DT N
other JJ N
drug NN N
was VBD N
performed VBN N
. . N

During IN N
the DT N
two CD N
basal NN N
tilts NNS N
, , N
all PDT N
the DT N
control NN N
subjects VBZ N
completed VBN N
the DT N
study NN N
, , N
whereas IN N
all PDT N
the DT N
NMS NNP N
patients NNS N
developed VBD N
syncope NN N
. . N

Reduction NN o
in IN o
sympathetic JJ o
tone NN o
by IN N
CLO NNP i
resulted VBD N
in IN N
a DT N
decreased JJ N
tolerance NN o
to TO o
tilt VB o
in IN N
three CD N
out IN N
of IN N
eight CD N
controls NNS N
and CC N
in IN N
all PDT N
the DT N
NMS NNP p
patients NNS p
. . p

In IN N
contrast NN N
, , N
YHO NNP N
not RB N
only RB N
increased VBD N
basal NN o
plasma NN o
NorEpi NNP o
levels NNS o
and CC o
MSNA NNP o
, , N
but CC N
also RB N
prevented VBD N
syncope NN o
in IN N
seven CD N
out IN N
of IN N
eight CD N
patients NNS N
. . N

In IN N
a DT N
selected JJ N
population NN N
of IN N
patients NNS N
, , N
increased VBD N
sympathetic JJ o
activity NN o
is VBZ N
not RB N
a DT N
prerequisite NN N
for IN N
the DT N
development NN N
of IN N
syncope NN N
. . N

Yohimbine-induced JJ N
enhancement NN N
of IN N
sympathetic JJ N
tone NN N
in IN N
patients NNS p
with IN p
NMS NNP p
improves VBZ N
orthostatic JJ N
tolerance NN N
and CC N
raises VBZ N
the DT N
possibility NN N
that IN N
this DT N
drug NN N
may MD N
be VB N
a DT N
useful JJ N
agent NN N
in IN N
the DT N
treatment NN N
of IN N
NMS NNP N
. . N

-DOCSTART- -8069156- O O

Bronchodilator NNP i
treatment NN i
in IN N
asthma NN p
and CC p
bronchitis NN p
. . p

-DOCSTART- -22585532- O O

Immunologic NNP o
response NN o
after IN N
laparoscopic NN p
colon NN p
cancer NN p
operation NN p
within IN N
an DT N
enhanced JJ N
recovery NN N
program NN N
. . N

OBJECTIVE NN N
It PRP N
has VBZ N
been VBN N
demonstrated VBN N
that IN N
colon NN N
operation NN N
combined VBN N
with IN N
fast-track NN N
( ( N
FT NNP N
) ) N
surgery NN N
and CC N
laparoscopic NN N
technique NN N
can MD N
shorten VB N
the DT N
length NN o
of IN o
hospital NN o
stay NN o
, , o
accelerate JJ o
recovery NN o
of IN o
intestinal JJ o
function NN o
, , o
and CC o
reduce VB o
the DT o
occurrence NN o
of IN o
post-operative JJ o
complications NNS o
. . o

However RB N
, , N
there EX N
are VBP N
no DT N
reports NNS N
regarding VBG N
the DT N
combined JJ N
effects NNS N
of IN N
FT NNP N
colon NN N
operation NN N
and CC N
laparoscopic NN N
technique NN N
on IN N
humoral JJ o
inflammatory NN o
cellular JJ o
immunity NN o
. . o

METHODS NNP N
This DT N
was VBD N
a DT N
prospective JJ N
, , N
controlled VBD N
study NN N
. . N

One CD p
hundred VBD p
sixty-three JJ p
colon NN p
cancer NN p
patients NNS p
underwent VBD p
the DT p
traditional JJ i
protocol NN i
and CC i
open JJ i
operation NN i
( ( p
traditional JJ p
open JJ p
group NN p
, , p
n=42 RB p
) ) p
, , p
the DT p
traditional JJ i
protocol NN i
and CC i
laparoscopic NN i
operation NN i
( ( p
traditional JJ p
laparoscopic NN p
group NN p
, , p
n=40 RB p
) ) p
, , p
the DT p
FT NNP i
protocol NN i
and CC i
open JJ i
operation NN i
( ( p
FT NNP p
open JJ p
group NN p
, , p
n=41 RB p
) ) p
, , p
or CC p
the DT p
FT NNP i
protocol NN i
and CC i
laparoscopic NN i
operation NN i
( ( p
FT NNP p
laparoscopic NN p
group NN p
, , p
n=40 RB p
) ) p
. . p

Blood NN N
samples NNS N
were VBD N
taken VBN N
prior RB N
to TO N
operation NN N
as RB N
well RB N
as IN N
on IN N
days NNS N
1 CD N
, , N
3 CD N
, , N
and CC N
5 CD N
after IN N
operation NN N
. . N

The DT N
number NN o
of IN o
lymphocyte JJ o
subpopulations NNS o
was VBD N
determined VBN N
by IN N
flow JJ N
cytometry NN N
, , N
and CC N
serum VB o
interleukin-6 JJ o
and CC o
C-reactive JJ o
protein NN o
levels NNS o
were VBD N
measured VBN N
. . N

Post-operative JJ o
hospital NN o
stay NN o
, , o
post-operative JJ o
morbidity NN o
, , o
readmission NN o
rate NN o
, , o
and CC o
in-hospital JJ o
mortality NN o
were VBD N
recorded VBN N
. . N

RESULTS NNP N
Compared VBD N
with IN N
open JJ N
operation NN N
, , N
laparoscopic JJ N
colon NN N
operation NN N
effectively RB N
inhibited VBD N
the DT N
release NN N
of IN N
post-operative JJ o
inflammatory JJ o
factors NNS o
and CC N
yielded VBD N
good JJ N
protection NN N
via IN N
post-operative JJ N
cell NN N
immunity NN N
. . N

FT NNP N
surgery NN N
had VBD N
a DT N
better RBR N
protective JJ N
role NN N
with IN N
respect NN N
to TO N
the DT N
post-operative JJ N
immune NN N
system NN N
compared VBN N
with IN N
traditional JJ N
peri-operative JJ N
care NN N
. . N

Inflammatory JJ o
reactions NNS o
, , o
based VBN o
on IN o
interleukin-6 JJ o
and CC o
C-reactive JJ o
protein NN o
levels NNS o
, , N
were VBD N
less JJR N
intense JJ N
following VBG N
FT NNP N
laparoscopic NN N
operation NN N
compared VBN N
to TO N
FT NNP N
open JJ N
operation NN N
; : N
however RB N
, , N
there EX N
were VBD N
no DT N
differences NNS N
in IN N
specific JJ o
immunity NN o
( ( o
CD3+ NNP o
and CC o
CD4+ NNP o
counts NNS o
, , o
and CC o
the DT o
CD4+/CD8+ NNP o
ratio NN o
) ) o
during IN N
these DT N
two CD N
types NNS N
of IN N
surgical JJ N
procedures NNS N
. . N

Post-operative JJ o
hospital NN o
stay NN o
in IN N
patients NNS N
randomized VBN N
to TO N
the DT N
FT NNP N
laparoscopic NN N
group NN N
was VBD N
significantly RB N
shorter JJR N
than IN N
in IN N
the DT N
other JJ N
three CD N
treatment NN N
groups NNS N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

Post-operative JJ o
complications NNS o
in IN N
patients NNS N
who WP N
underwent VBP N
FT NNP N
laparoscopic NN N
treatment NN N
were VBD N
less JJR N
than IN N
in IN N
the DT N
other JJ N
three CD N
treatment NN N
groups NNS N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
the DT N
four CD N
treatment NN N
groups NNS N
regarding VBG N
readmission NN o
rate NN o
and CC o
in-hospital JJ o
mortality NN o
. . o

CONCLUSIONS VB N
The DT N
laparoscopic NN N
technique NN N
and CC N
FT NNP N
surgery NN N
rehabilitation NN N
program NN N
effectively RB N
inhibited VBD N
release NN N
of IN N
post-operative JJ o
inflammatory JJ o
factors NNS o
with IN o
a DT o
reduction NN o
in IN o
peri-operative JJ o
trauma NN o
and CC o
stress NN o
, , N
which WDT N
together RB N
played VBD N
a DT N
protective JJ N
role NN N
on IN N
the DT N
post-operative JJ N
immune NN N
system NN N
. . N

Combining VBG N
two CD N
treatment NN N
measures NNS N
during IN N
colon NN N
operation NN N
produced VBD N
better RBR N
protective JJ o
effects NNS o
via IN o
the DT o
immune JJ o
system NN o
. . o

The DT N
beneficial JJ N
clinical JJ N
effects NNS N
support NN N
that IN N
the DT N
better-preserved JJ N
post-operative JJ N
immune NN N
system NN N
may MD N
also RB N
contribute VB N
to TO N
the DT N
improvement NN o
of IN o
post-operative JJ o
results NNS o
in IN N
FT NNP p
laparoscopic NN p
patients NNS p
. . p

-DOCSTART- -12653895- O O

Randomized VBN N
controlled VBD N
trial NN N
to TO N
compare VB N
the DT N
dose NN N
of IN N
adjuvant JJ i
chemotherapy NN i
after IN N
curative JJ i
resection NN i
of IN N
hepatocellular JJ p
carcinoma NN p
. . p

BACKGROUND NNP N
AND NNP N
AIM NNP N
Adjuvant NNP i
locoregional JJ i
chemotherapy NN i
has VBZ N
been VBN N
shown VBN N
to TO N
be VB N
useful JJ N
to TO N
prevent VB N
recurrence NN N
after IN N
curative JJ N
resection NN N
of IN N
hepatocellular JJ N
carcinoma NN N
( ( N
HCC NNP N
) ) N
in IN N
some DT N
retrospective JJ N
studies NNS N
. . N

Our PRP$ N
aim NN N
was VBD N
to TO N
compare VB N
the DT N
dose JJ N
effect NN N
in IN N
the DT N
prevention NN N
of IN N
tumor NN N
recurrence NN N
. . N

METHODS NNP N
A NNP N
prospective JJ N
randomized VBN N
controlled JJ N
trial NN N
was VBD N
conducted VBN N
in IN N
patients NNS p
with IN p
curative JJ p
resection NN p
of IN p
HCC NNP p
; : p
they PRP N
were VBD N
given VBN N
either DT N
one CD N
intra-arterial JJ N
dose NN N
of IN N
cisplatin/lipiodol NN i
, , N
or CC N
received VBD N
four CD N
doses NNS N
, , N
once RB N
every DT N
3 CD N
months NNS N
. . N

The DT N
rates NNS o
of IN o
recurrence NN o
, , o
disease-free JJ o
and CC o
overall JJ o
survival NN o
were VBD N
compared VBN N
. . N

RESULTS NNP N
During IN N
a DT N
median JJ N
follow NN N
up IN N
of IN N
818 CD p
days NNS p
, , p
21 CD p
patients NNS p
received VBD p
one CD p
dose NN p
and CC p
19 CD p
received VBD p
four CD p
doses NNS p
, , p
with IN p
10 CD p
( ( p
47.6 CD p
% NN p
) ) p
and CC p
eight CD p
( ( p
42.1 CD p
% NN p
) ) p
recurrences NNS p
, , p
respectively RB p
. . p

The DT N
1-year JJ o
, , o
2-year JJ o
and CC o
3-year JJ o
disease-free JJ o
survival NN o
rates NNS o
were VBD N
71 CD N
% NN N
, , N
54 CD N
% NN N
and CC N
44 CD N
% NN N
for IN N
the DT N
one-dose JJ N
group NN N
and CC N
74 CD N
% NN N
, , N
60 CD N
% NN N
and CC N
40 CD N
% NN N
for IN N
the DT N
four-dose JJ N
group NN N
( ( N
P NNP N
= NNP N
0.78 CD N
) ) N
. . N

The DT N
respective JJ o
overall JJ o
survival NN o
rates NNS o
were VBD N
85 CD N
% NN N
, , N
74 CD N
% NN N
, , N
55 CD N
% NN N
and CC N
84 CD N
% NN N
, , N
71 CD N
% NN N
, , N
40 CD N
% NN N
( ( N
P NNP N
= NNP N
0.64 CD N
) ) N
. . N

The DT N
only JJ N
prognostic JJ N
factor NN N
was VBD N
presence NN o
of IN o
vascular JJ o
permeation NN o
. . o

The DT N
side-effects NNS o
were VBD N
mild JJ o
and CC o
tolerable JJ o
. . o

CONCLUSIONS NNP N
There EX N
is VBZ N
no DT N
significant JJ N
difference NN N
in IN N
the DT N
survival NN o
rates NNS o
between IN N
the DT N
two CD p
groups NNS p
. . p

Adjuvant NNP i
chemotherapy NN i
may MD N
not RB N
be VB N
useful JJ N
. . N

-DOCSTART- -16413892- O O

Comparison NNP N
of IN N
remifentanil NN i
with IN N
fentanyl NN i
for IN N
deep JJ o
sedation NN o
in IN N
oral JJ N
surgery NN N
. . N

PURPOSE VB N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
recovery NN N
for IN N
oral JJ p
surgery NN p
patients NNS p
given VBN N
a DT N
deep JJ N
sedation NN N
regimen NNS N
of IN N
midazolam NN i
, , i
propofol NN i
, , N
and CC N
remifentanil NN i
with IN N
a DT N
standard JJ N
control NN N
of IN N
fentanyl NN N
in IN N
place NN N
of IN N
remifentanil NN N
. . N

MATERIALS NNP N
AND CC N
METHODS NNP N
This DT N
investigation NN N
was VBD N
designed VBN N
as IN N
a DT N
randomized NN N
, , N
prospective JJ N
, , N
single-blinded JJ N
controlled VBD N
study NN N
. . N

Group NNP N
1 CD N
, , N
the DT N
control NN N
, , N
received VBD N
midazolam JJ i
0.03 CD i
mg/kg NN i
, , i
fentanyl VBP i
1 CD i
microg/kg NN i
, , i
and CC i
propofol VB i
initially RB i
at IN i
140 CD i
microg/kg/min NN i
. . i

Group NNP N
2 CD N
received VBD N
midazolam RB i
0.03 CD i
mg/kg NN i
, , i
remifentanil NN i
: : i
propofol NN i
( ( i
1:500 CD i
) ) i
given VBN i
at IN i
an DT i
initial JJ i
propofol JJ i
infusion NN i
rate NN i
of IN i
40 CD i
microg/kg/min NN i
. . i

Outcome NNP N
measures NNS N
included VBD N
time NN o
to TO o
response NN o
to TO o
verbal JJ o
command NN o
, , o
Aldrete NNP o
score VBD o
= JJ o
9 CD o
, , o
Postanesthesia NNP o
Discharge NNP o
Scoring NNP o
System NNP o
= VBD o
7 CD o
, , o
and CC o
assessment NN o
by IN o
the DT o
Digit NNP o
Symbol NNP o
Substitution NNP o
Test NNP o
. . o

RESULTS NNP N
Forty-seven JJ p
subjects NNS p
were VBD p
entered VBN p
in IN p
the DT p
study NN p
. . p

Baseline NNP N
findings NNS N
were VBD N
homogenous JJ N
between IN N
the DT N
2 CD N
groups NNS N
. . N

Subjects NNS N
in IN N
group NN N
2 CD N
recovered VBN N
earlier JJR N
( ( N
P NNP N
< NNP N
.005 NNP N
) ) N
and CC N
required VBN N
less JJR N
propofol NN i
for IN N
both DT N
the DT N
induction NN o
( ( N
0.8 CD N
+/- JJ N
0.4 CD N
versus NN N
1.2 CD N
+/- JJ N
0.6 CD N
mg/kg NN N
; : N
mean JJ N
+/- JJ N
SD NNP N
, , N
P NNP N
< NNP N
.01 NNP N
) ) N
and CC N
maintenance NN o
of IN o
deep JJ o
sedation NN o
( ( N
46 CD N
+/- JJ N
9 CD N
versus NN N
131 CD N
+/- JJ N
17 CD N
microg/kg/min NN N
; : N
P NNP N
< NNP N
.005 NNP N
) ) N
. . N

There EX N
were VBD N
minor JJ N
differences NNS N
in IN N
vital JJ N
signs NNS N
. . N

CONCLUSIONS VB N
This DT N
study NN N
demonstrated VBD N
that IN N
this DT N
remifentanil JJ N
regimen NNS N
provided VBD N
significantly RB N
more RBR N
rapid JJ o
recovery NN o
and CC N
used VBD N
significantly RB N
less JJR N
propofol JJ i
compared VBN N
with IN N
the DT N
fentanyl JJ i
regimen NNS N
. . N

-DOCSTART- -23381483- O O

Practice NNP N
makes VBZ N
improvement NN N
: : N
how WRB N
adults NNS p
with IN p
autism NN p
out-perform JJ N
others NNS N
in IN N
a DT N
naturalistic JJ N
visual JJ N
search NN N
task NN N
. . N

People NNS p
with IN p
autism NN p
spectrum NN p
disorder NN p
( ( p
ASD NNP p
) ) p
often RB N
exhibit JJ N
superior JJ N
performance NN N
in IN N
visual JJ N
search NN N
compared VBN N
to TO N
others NNS N
. . N

However RB N
, , N
most JJS N
studies NNS N
demonstrating VBG N
this DT N
advantage NN N
have VBP N
employed VBN N
simple JJ N
, , N
uncluttered JJ N
images NNS N
with IN N
fully RB N
visible JJ N
targets NNS N
. . N

We PRP N
compare VBP N
the DT N
performance NN N
of IN N
high-functioning JJ p
adults NNS p
with IN p
ASD NNP p
and CC N
matched VBN p
controls NNS p
on IN N
a DT N
naturalistic JJ i
luggage NN i
screening VBG i
task NN i
. . i

Although IN N
the DT N
two CD N
groups NNS N
were VBD N
equally RB N
accurate JJ N
in IN N
detecting VBG N
targets NNS N
, , N
the DT N
ASD NNP p
adults NNS p
improve VBP N
in IN N
their PRP$ N
correct JJ o
elimination NN o
of IN o
target-absent NN o
bags NNS N
faster RBR N
than IN N
controls NNS N
. . N

This DT N
feature NN N
of IN N
their PRP$ N
behavior NN N
is VBZ N
extremely RB N
important JJ N
for IN N
many JJ N
real-world JJ N
monitoring NN N
tasks NNS N
that WDT N
require VBP N
sustained JJ N
attention NN N
for IN N
long JJ N
time NN N
periods NNS N
. . N

Further JJ N
analyses NNS N
suggest VBP N
that IN N
this DT N
improvement NN N
is VBZ N
attributable JJ N
neither RB N
to TO N
the DT N
motor NN N
speed NN N
nor CC N
to TO N
the DT N
level NN N
of IN N
intelligence NN N
of IN N
the DT N
adults NNS p
with IN p
ASD NNP p
. . p

These DT N
findings NNS N
may MD N
have VB N
possible JJ N
implications NNS N
for IN N
employment NN N
opportunities NNS N
of IN N
adult NN p
individuals NNS p
with IN p
ASD NNP p
. . p

-DOCSTART- -25319807- O O

Benefit NN N
of IN N
adjuvant JJ i
interferon NN i
alfa-2b NN i
( ( i
IFN-? NNP i
) ) i
therapy NN i
in IN p
melanoma NN p
patients NNS p
with IN p
high JJ p
serum NN p
MMP-8 NNP p
levels NNS p
. . p

Matrix NNP N
metalloproteinases NNS N
( ( N
MMPs NNP N
) ) N
are VBP N
important JJ N
enzymes NNS N
in IN N
tissue NN N
turnover NN N
and CC N
various JJ N
inflammatory JJ N
processes NNS N
. . N

In IN N
this DT N
study NN N
, , N
it PRP N
was VBD N
evaluated VBN N
whether IN N
serum JJ N
MMP-8 NNP N
can MD N
predict VB N
the DT N
response NN N
to TO i
adjuvant VB i
interferon JJ i
alfa-2b JJ i
( ( i
IFN-? NNP i
) ) i
therapy NN i
in IN i
patients NNS N
with IN N
operated JJ N
high-risk JJ N
cutaneous JJ N
melanoma NN p
. . p

Pre-treatment JJ N
sera NN N
from IN p
460 CD p
patients NNS p
with IN p
stage JJ p
IIB-IIIC JJ p
melanoma NN p
were VBD p
analyzed VBN p
for IN p
MMP-8 NNP p
. . p

The DT N
patients NNS N
were VBD N
randomized VBN N
after IN i
surgery NN i
to TO i
adjuvant VB i
IFN-? NNP i
for IN i
12 CD N
or CC N
24 CD N
months NNS N
( ( N
n JJ N
= NNP N
313 CD N
) ) N
or CC N
observation NN i
only RB i
( ( i
n JJ i
= NNP N
147 CD N
) ) N
. . N

The DT N
median JJ o
serum NN o
MMP-8 NNP o
level NN o
was VBD o
used VBN N
to TO N
classify VB N
the DT N
patients NNS N
into IN N
a DT N
low JJ N
MMP-8 NNP N
( ( N
n JJ N
= NNP N
232 CD N
) ) N
and CC N
a DT N
high JJ N
MMP-8 NNP N
( ( N
n JJ N
= NNP N
228 CD N
) ) N
group NN N
. . N

In IN N
the DT N
high JJ N
MMP-8 NNP N
subgroup NN o
, , o
IFN-? NNP o
therapy NN o
significantly RB o
improved VBN o
relapse-free JJ o
survival NN o
( ( o
RFS NNP o
) ) o
. . o

RFS NNP o
was VBD N
36.8 CD N
months NNS p
in IN p
patients NNS p
with IN p
high JJ p
MMP-8 JJ o
levels NNS o
receiving VBG o
IFN-? NNP i
therapy NN i
, , i
whereas WP o
RFS NNP o
for IN N
those DT N
with IN N
high JJ N
MMP-8 JJ o
levels NNS o
with IN o
observation NN N
only RB N
was VBD N
10.6 CD N
months NNS N
( ( N
P NNP N
= NNP N
0.027 CD N
) ) o
. . o

Median JJ o
overall JJ o
survival NN o
for IN o
patients NNS p
with IN p
high JJ p
MMP-8 NNP o
and CC o
observation NN N
only RB N
was VBD N
36.7 CD N
versus NN N
71.7 CD N
months NNS N
in IN N
those DT N
receiving VBG N
IFN-? NNP N
( ( N
P NNP N
= NNP N
0.13 CD N
) ) N
. . N

In IN N
a DT N
multivariate NN N
model NN N
, , N
IFN-? NNP o
therapy NN o
was VBD o
a DT o
significant JJ N
predictor NN N
of IN N
favorable JJ o
RFS NNP o
( ( o
HR NNP o
0.74 CD N
; : N
95 CD N
% NN N
CI NNP N
0.55-0.99 CD N
; : N
P NNP N
= NNP N
0.048 CD N
) ) N
, , N
after IN N
adjustment NN N
for IN N
pre-treatment JJ N
MMP-8 NNP N
( ( N
HR NNP N
1.17 CD N
; : N
95 CD N
% NN N
CI NNP N
0.88-1.55 CD N
; : N
P NNP N
= NNP N
0.28 CD N
) ) N
, , N
gender FW N
( ( N
HR NNP N
1.16 CD N
; : N
95 CD N
% NN N
CI NNP N
0.86-1.56 CD N
; : N
P NNP N
= NNP N
0.32 CD N
) ) N
, , N
age NN N
( ( N
HR NNP N
1.00 CD N
; : N
95 CD N
% NN N
CI NNP N
1.00-1.02 CD N
; : N
P NNP N
= NNP N
0.12 CD N
) ) N
, , N
ulceration NN N
( ( N
HR NNP N
1.09 CD N
; : N
95 CD N
% NN N
CI NNP N
0.81-1.46 CD N
; : N
P NNP N
= NNP N
0.58 CD N
) ) N
, , N
and CC N
the DT N
presence NN N
of IN N
node JJ N
metastases NNS N
( ( N
HR NNP N
1.36 CD N
; : N
95 CD N
% NN N
CI NNP N
1.17-1.58 CD N
; : N
P NNP N
< NNP N
0.0001 CD N
) ) N
. . N

In IN N
conclusion NN N
, , N
patients NNS N
with IN N
high JJ o
serum NN o
MMP-8 NNP o
levels NNS o
may MD N
benefit VB N
from IN i
adjuvant JJ i
IFN-? NNP i
therapy NN i
, , N
but CC N
this DT N
observation NN N
should MD N
be VB N
further RB N
investigated VBN N
. . N

-DOCSTART- -18391640- O O

The DT N
effects NNS N
of IN N
strength NN i
training NN i
on IN N
central JJ o
arterial JJ o
compliance NN o
in IN N
middle-aged JJ p
and CC p
older JJR p
adults NNS p
. . p

BACKGROUND NNP N
Contrary NNP N
to TO N
aerobic VB N
exercise NN N
, , N
strength NN i
training NN i
( ( i
ST NNP i
) ) i
is VBZ N
associated VBN N
with IN N
decreased JJ p
central JJ o
arterial JJ o
compliance NN o
in IN p
young JJ p
men NNS p
. . p

It PRP N
is VBZ N
unknown JJ N
whether IN N
ST NNP i
, , N
with IN N
or CC N
without IN N
concurrent JJ N
endurance NN N
training NN N
, , N
would MD N
have VB N
a DT N
similar JJ N
effect NN N
in IN N
older JJR p
adults NNS p
with IN p
reduced JJ p
baseline NN p
arterial JJ o
compliance NN o
. . o

OBJECTIVE CC N
The DT N
primary JJ N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
the DT N
effect NN N
of IN N
a DT N
ST NNP i
program NN N
on IN N
central JJ o
arterial JJ o
compliance NN o
in IN N
middle-aged JJ p
and CC p
older JJR p
adults NNS p
. . p

DESIGN NNP N
Randomized NNP N
, , N
controlled VBD N
intervention NN N
study NN N
in IN N
which WDT N
37 CD p
healthy JJ p
, , p
sedentary JJ p
men NNS p
and CC p
women NNS p
( ( p
52+/-2 JJ p
years NNS p
) ) p
performed VBD p
13 CD p
weeks NNS p
of IN p
ST NNP p
( ( p
n=13 NN p
) ) p
, , p
ST+aerobic NNP i
exercise NN i
( ( p
n=12 JJ p
) ) p
or CC i
stretching VBG i
exercises NNS i
as IN i
a DT i
control NN i
group NN i
( ( N
n=12 RB N
) ) N
. . N

METHODS JJ N
Participants NNS p
were VBD p
rigorously RB p
screened VBN p
for IN p
cardiovascular JJ p
disease NN p
and CC p
underwent JJ p
pre-post JJ p
testing NN p
for IN p
carotid JJ o
arterial JJ o
compliance NN o
( ( o
via IN o
simultaneous JJ o
ultrasound NN o
and CC o
applanation NN o
tonometry NN o
) ) o
, , o
carotid-femoral JJ o
pulse NN o
wave NN o
velocity NN o
, , o
plasma JJ o
endothelin-1 NN o
and CC o
angiotensin NN o
II NNP o
concentrations NNS o
and CC o
carotid JJ o
artery NN o
vasoreactivity NN o
( ( o
cold JJ o
pressor NN o
test NN o
) ) o
. . o

RESULTS NNP N
ST NNP N
performed VBD N
alone RB N
, , N
or CC N
in IN N
conjunction NN N
with IN N
aerobic JJ i
exercise NN i
, , N
improved VBN N
maximal JJ o
muscle NN o
strength NN o
and CC o
increased VBD o
total JJ o
lean JJ o
body NN o
mass NN o
( ( N
both DT N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

No DT N
significant JJ N
changes NNS N
were VBD N
observed VBN N
in IN N
carotid NN o
artery NN o
compliance NN o
or CC o
carotid-femoral JJ o
pulse JJ o
wave NN o
velocity NN o
following VBG o
ST NNP o
or CC o
ST+aerobic NNP o
exercise NN o
. . o

Carotid NNP o
artery JJ o
compliance NN o
increased VBD N
significantly RB N
( ( N
23 CD N
% NN N
) ) N
following VBG N
stretching VBG N
which WDT N
may MD N
be VB N
attributed VBN N
to TO N
a DT N
reduction NN N
in IN N
carotid NN N
pulse JJ N
pressure NN N
. . N

No DT N
significant JJ N
changes NNS N
were VBD N
observed VBN N
in IN N
plasma JJ o
vasoconstrictor NN o
hormones NNS o
or CC o
carotid VB o
artery JJ o
vasoreactivity NN o
following VBG N
the DT N
interventions NNS N
. . N

CONCLUSION NNP N
Thirteen NNP N
weeks NNS N
of IN N
moderate JJ N
ST NNP i
two CD N
or CC N
three CD N
times NNS N
per IN N
week NN N
does VBZ N
not RB N
reduce VB N
central JJ o
arterial JJ o
compliance NN o
in IN N
middle-aged JJ p
and CC p
older JJR p
adults NNS p
. . p

-DOCSTART- -2975949- O O

Lack NN N
of IN N
effect NN N
of IN N
warfarin NN i
on IN N
the DT N
restenosis NN o
rate NN o
or CC N
on IN p
clinical JJ p
outcome NN p
after IN p
balloon NN p
coronary JJ p
angioplasty NN p
. . p

Between NNP p
September NNP p
1985 CD p
and CC p
April NNP p
1987 CD p
, , p
110 CD p
consecutive JJ p
patients NNS p
who WP p
had VBD p
successful JJ p
coronary JJ p
angioplasty NN p
were VBD N
included VBN N
in IN N
a DT N
randomised JJ N
prospective NN N
controlled VBN N
evaluation NN N
of IN N
the DT N
effects NNS N
of IN N
warfarin NN i
on IN N
restenosis NN N
. . N

The DT N
warfarin NN i
( ( N
n JJ N
= NNP N
56 CD N
) ) N
and CC N
the DT N
control NN i
( ( N
n JJ N
= NNP N
54 CD N
) ) N
groups NNS N
were VBD N
not RB N
different JJ N
in IN N
terms NNS N
of IN N
age NN N
, , N
sex NN N
, , N
previous JJ N
coronary JJ N
bypass NN N
surgery NN N
or CC N
coronary JJ N
balloon NN N
angioplasty NN N
, , N
severity NN N
of IN N
symptoms NNS N
, , N
and CC N
frequency NN N
of IN N
multivessel JJ N
disease NN N
or CC N
of IN N
total JJ N
coronary JJ N
occlusions NNS N
. . N

Warfarin NNP i
was VBD N
started VBN N
on IN N
the DT N
day NN N
of IN N
the DT N
procedure NN N
and CC N
the DT N
dosage NN N
was VBD N
adjusted VBN N
to TO N
maintain VB N
the DT N
thromboplastin JJ N
international JJ N
normalised VBN N
ratio NN N
greater JJR N
than IN N
or CC N
equal JJ N
to TO N
2.5 CD N
. . N

One CD N
hundred CD N
and CC N
five CD N
( ( N
96 CD N
% NN N
) ) N
of IN N
the DT N
patients NNS N
were VBD N
given VBN N
verapamil NNS i
and CC N
other JJ i
antianginal JJ i
drugs NNS i
were VBD N
prescribed VBN N
as IN N
needed VBN N
. . N

Low JJ i
molecular JJ i
weight NN i
dextran NN i
and CC i
heparin NN i
were VBD N
given VBN N
during IN N
the DT N
procedure NN N
and CC N
heparin NN i
was VBD N
continued VBN N
for IN N
24 CD N
hours NNS N
in IN N
all DT N
patients NNS N
. . N

One CD p
hundred CD p
and CC p
eight CD p
( ( p
98 CD p
% NN p
) ) p
of IN p
patients NNS p
were VBD p
followed VBN p
up RP p
clinically RB p
after IN p
a DT p
median NN p
of IN p
five CD p
months NNS p
( ( p
range VB p
1-20 CD p
) ) p
. . p

Eighty NNP p
five CD p
( ( p
77 CD p
% NN p
) ) p
had VBD p
follow VBN p
up RP p
angiography NN p
at IN p
five CD p
months NNS p
. . p

In IN N
the DT N
warfarin NN i
group NN N
symptoms NNS o
improved VBN o
in IN N
46 CD N
( ( N
85 CD N
% NN N
) ) N
patients NNS N
by IN N
at IN N
least JJS N
1 CD N
angina JJ N
class NN N
and CC N
31 CD N
( ( N
57 CD N
% NN N
) ) N
were VBD N
symptom JJ o
free JJ o
; : o
the DT N
exercise NN N
test NN N
remained VBD N
positive JJ N
in IN N
20 CD N
( ( N
36 CD N
% NN N
) ) N
patients NNS N
and CC N
the DT N
angiographic JJ o
restenosis NN o
rate NN o
was VBD N
25 CD N
% NN N
per IN N
lesion NN N
and CC N
29 CD N
% NN N
per IN N
patient NN N
. . N

There EX N
were VBD N
no DT N
major JJ o
bleeding NN o
complications NNS o
. . o

In IN N
the DT N
control NN i
group NN N
46 CD N
( ( N
85 CD N
% NN N
) ) N
patients NNS N
were VBD N
improved VBN N
by IN N
at IN N
least JJS N
1 CD N
angina JJ N
class NN N
and CC N
31 CD N
( ( N
57 CD N
% NN N
) ) N
were VBD N
symptom JJ N
free JJ N
; : N
the DT N
exercise NN o
test NN o
was VBD N
positive JJ N
in IN N
11 CD N
( ( N
21 CD N
% NN N
) ) N
patients NNS N
and CC N
the DT N
angiographic JJ o
restenosis NN o
rate NN o
was VBD N
33 CD N
% NN N
per IN N
lesion NN N
and CC N
37 CD N
% NN N
per IN N
patient NN N
. . N

Although IN N
the DT N
incidence NN N
of IN N
angiographic JJ N
restenosis NN N
tended VBD N
to TO N
be VB N
lower JJR N
with IN N
warfarin NN i
, , N
none NN N
of IN N
these DT N
differences NNS N
was VBD N
significant JJ N
. . N

These DT N
data NNS N
suggest VBP N
that IN N
the DT N
combination NN N
of IN N
verapamil NN i
and CC N
warfarin NN i
, , N
in IN N
the DT N
absence NN N
of IN N
aspirin NN i
, , N
is VBZ N
not RB N
significantly RB N
better JJR N
than IN N
verapamil NN N
alone RB N
in IN N
preventing VBG N
symptom JJ N
recurrence NN N
or CC N
angiographic JJ o
restenosis NN o
after IN N
coronary JJ N
angioplasty NN N
. . N

-DOCSTART- -7010528- O O

The DT N
influence NN N
of IN N
amiloride NN i
on IN N
the DT N
therapeutic JJ N
and CC N
metabolic JJ N
effects NNS N
of IN N
carbenoxolone NN i
in IN N
patients NNS p
with IN p
gastric JJ p
ulcer NN p
. . p

A DT N
double-blind NN N
controlled VBN N
trial NN N
. . N

Patients NNS p
with IN p
benign JJ p
gastric JJ p
ulcer NN p
were VBD N
treated VBN N
for IN N
four CD N
weeks NNS N
with IN N
carbenoxolone NN i
sodium NN i
as IN i
Biogastrone NNP i
tablets VBZ i
100 CD i
mg NN i
three CD i
times NNS i
a DT i
day NN i
, , N
and CC N
if IN N
the DT N
ulcers NNS N
were VBD N
not RB N
healed VBN N
at IN N
4 CD N
weeks NNS N
treatment NN N
was VBD N
continued VBN N
for IN N
a DT N
further JJ N
4 CD N
weeks NNS N
. . N

Fifty NNP p
two CD p
patients NNS p
entered VBD p
the DT p
trial NN p
, , p
and CC p
12 CD p
were VBD p
withdrawn VBN p
. . p

In IN N
17 CD N
patients NNS N
who WP N
were VBD N
randomly RB N
allotted VBN N
double-blind JJ N
additional JJ N
dummy NN i
tablets NNS i
16 CD N
of IN N
their PRP$ N
ulcer NN N
healed VBD N
completely RB N
endoscopically RB N
, , N
whereas NNS N
of IN N
the DT N
23 CD N
patients NNS N
given VBN N
additional JJ N
amiloride NN i
5 CD N
mg NN N
three CD N
times NNS N
a DT N
day NN N
only RB N
14 CD N
ulcers NNS N
healed VBD N
, , N
a DT N
significant JJ N
reduction NN N
in IN N
ulcer JJ N
healing NN N
. . N

The DT N
clinical JJ N
( ( o
weight JJ o
gain NN o
and CC o
oedema NN o
) ) o
and CC N
metabolic JJ N
( ( o
hypertension NN o
, , o
hypokalaemia NN o
and CC o
hypernatraemia NN o
) ) o
side-effects NNS N
were VBD N
reduced VBN N
by IN N
the DT N
active JJ N
amiloride NN i
therapy NN N
, , N
but CC N
serum VBP o
carbenoxolone NN o
levels NNS o
were VBD N
not RB N
affected VBN N
. . N

Thus VB N
the DT N
potassium-retaining JJ N
diuretic JJ N
amiloride NN i
, , N
like IN N
the DT N
aldosterone NN N
antagonist NN N
spironolactone NN i
, , N
markedly RB N
reduces VBZ N
both CC N
the DT N
ulcer-healing JJ o
and CC N
the DT N
metabolic JJ o
side-effects NNS o
of IN N
carbenoxolone NN N
sodium NN N
, , N
and CC N
should MD N
not RB N
be VB N
used VBN N
together RB N
with IN N
it PRP N
in IN N
the DT N
treatment NN N
of IN N
peptic JJ p
ulcer NN p
. . p

-DOCSTART- -21621992- O O

Lung NNP N
function NN N
and CC N
respiratory NN N
symptoms NNS N
in IN N
a DT N
1-year JJ N
randomized JJ N
smoking NN N
cessation NN N
trial NN N
of IN N
varenicline NN i
in IN N
COPD NNP p
patients NNS p
. . p

UNLABELLED IN N
There EX N
are VBP N
few JJ N
data NNS N
concerning VBG N
changes NNS N
in IN N
lung NN N
function NN N
and CC N
respiratory NN N
symptoms NNS N
in IN N
smokers NNS p
with IN p
chronic JJ p
obstructive JJ p
pulmonary JJ p
disease NN p
( ( p
COPD NNP p
) ) p
weeks NNS p
to TO p
months NNS p
after IN p
quitting VBG p
smoking NN p
. . p

We PRP N
examined VBD N
serial JJ N
changes NNS N
in IN N
spirometry NN N
and CC N
Clinical NNP N
COPD NNP N
Questionnaire NNP N
( ( N
CCQ NNP N
) ) N
scores VBZ N
( ( N
measuring VBG N
respiratory NN N
symptoms NNS N
and CC N
health-related JJ N
quality NN N
of IN N
life NN N
) ) N
in IN N
COPD NNP p
participants NNS p
by IN p
smoking VBG p
status NN p
during IN N
a DT N
smoking NN N
cessation NN N
trial NN N
. . N

In IN N
this DT N
randomized JJ N
, , N
double-blind JJ N
trial NN N
, , N
smokers NNS p
with IN p
mild-to-moderate JJ p
COPD NNP p
were VBD N
treated VBN N
with IN N
varenicline JJ i
1 CD i
mg NN i
b.i.d NN i
. . i

or CC i
placebo NN i
for IN N
12 CD N
weeks NNS N
and CC N
followed VBD N
to TO N
Week VB N
52 CD N
. . N

Primary JJ N
endpoints NNS N
of IN N
abstinence NN o
were VBD N
previously RB N
reported VBN N
. . N

Secondary JJ N
endpoints NNS N
were VBD N
mean JJ o
changes NNS o
from IN o
baseline NN o
in IN N
post-bronchodilator NN o
forced VBN o
expired JJ o
volume NN o
in IN o
1 CD o
s NN o
( ( o
FEV NNP o
( ( o
1 CD o
) ) o
) ) o
and CC o
CCQ NNP o
scores NNS o
. . o

Change NN o
from IN o
baseline NN o
in IN N
post-bronchodilator NN N
FEV NNP o
( ( o
1 CD o
) ) o
was VBD N
significantly RB N
improved VBN N
in IN N
continuous JJ N
abstainers NNS N
( ( N
121.8 CD N
mL NN N
) ) N
vs. FW N
continuous JJ N
smokers NNS N
( ( N
37.9 CD N
mL NN N
) ) N
at IN N
Week $ N
12 CD N
( ( N
P NNP N
= NNP N
0.0069 CD N
) ) N
, , N
but CC N
not RB N
at IN N
Weeks NNP N
24 CD N
or CC N
52 CD N
. . N

Mean JJ o
change NN o
from IN o
baseline NN o
at IN o
Week NNP o
12 CD o
in IN o
CCQ NNP o
Total NNP o
Score NNP o
was VBD N
significantly RB N
better RBR N
in IN N
continuous JJ N
abstainers NNS N
( ( N
-1.04 NN N
) ) N
vs. FW N
continuous JJ N
smokers NNS N
( ( N
-0.53 NN N
; : N
P NNP N
< NNP N
0.0001 CD N
) ) N
: : N
this DT N
improvement NN N
was VBD N
sustained VBN N
at IN N
Weeks NNP N
24 CD N
and CC N
52 CD N
. . N

In IN N
a DT N
1-year JJ N
cessation NN N
trial NN N
of IN N
smokers NNS p
with IN p
COPD NNP p
, , N
continuous JJ o
abstinence NN o
compared VBN N
with IN N
continuous JJ N
smoking VBG N
significantly RB N
improved VBN N
post-bronchodilator NN o
FEV NNP N
( ( N
1 CD N
) ) N
at IN N
Week $ N
12 CD N
( ( N
although IN N
the DT N
difference NN N
narrowed VBD N
subsequently RB N
) ) N
and CC N
CCQ NNP o
Total NNP o
Scores NNP o
at IN N
Week NNP N
12 CD N
, , N
with IN N
sustained JJ N
improvement NN N
thereafter RB N
. . N

( ( N
TRIAL NNP N
REGISTRY NNP N
http NN N
: : N
//www.clinicaltrials.gov NN N
; : N
trial NN N
identifier NN N
: : N
NCT00285012 NNP N
) ) N
. . N

-DOCSTART- -16824559- O O

Analysis NN N
of IN N
face NN i
gaze NN i
in IN N
autism NN p
using VBG N
Bubbles NNP N
. . N

One CD N
of IN N
the DT N
components NNS N
of IN N
abnormal JJ N
social JJ N
functioning NN N
in IN N
autism NN p
is VBZ N
an DT N
impaired JJ N
ability NN N
to TO N
direct VB N
eye NN N
gaze NN N
onto IN N
other JJ N
people NNS N
's POS N
faces VBZ N
in IN N
social JJ N
situations NNS N
. . N

Here RB N
, , N
we PRP N
investigated VBD N
the DT N
relationship NN N
between IN N
gaze NN o
onto IN o
the DT o
eye NN o
and CC o
mouth JJ o
regions NNS o
of IN o
faces VBZ o
, , N
and CC N
the DT N
visual JJ N
information NN N
that WDT N
was VBD N
present JJ N
within IN N
those DT N
regions NNS N
. . N

We PRP N
used VBD N
the DT N
Bubbles NNP i
method NN i
to TO N
vary VB N
the DT N
facial JJ N
information NN N
available JJ N
on IN N
any DT N
given VBN N
trial NN N
by IN N
revealing VBG N
only RB N
small JJ N
parts NNS N
of IN N
the DT N
face NN N
, , N
and CC N
measured VBD N
the DT N
eye NN o
movements NNS o
made VBN N
as IN N
participants NNS N
viewed IN N
these DT N
stimuli NNS N
. . N

Compared VBN p
to TO p
ten VB p
IQ- NNP p
and CC p
age-matched JJ p
healthy JJ p
controls NNS p
, , p
eight CD p
participants NNS p
with IN p
autism NN p
showed VBD N
less JJR N
fixation JJ o
specificity NN o
to TO N
the DT N
eyes NNS N
and CC N
mouth NN N
, , N
a DT N
greater JJR N
tendency NN N
to TO N
saccade VB N
away RB N
from IN N
the DT N
eyes NNS N
when WRB N
information NN N
was VBD N
present JJ N
in IN N
those DT N
regions NNS N
, , N
and CC N
abnormal JJ N
directionality NN N
of IN N
saccades NNS N
. . N

The DT N
findings NNS N
provide VBP N
novel JJ N
detail NN N
to TO N
the DT N
abnormal JJ N
way NN N
in IN N
which WDT N
people NNS N
with IN N
autism NN N
look NN N
at IN N
faces VBZ N
, , N
an DT N
impairment NN N
that WDT N
likely JJ N
influences VBZ N
all DT N
subsequent JJ N
face NN N
processing NN N
. . N

-DOCSTART- -1449552- O O

Oestrogen NNP o
replacement NN o
after IN p
oophorectomy NN p
: : p
comparison NN N
of IN N
patches NNS i
and CC N
implants NNS i
. . i

-DOCSTART- -19430389- O O

Topical JJ N
administration NN N
of IN N
diclofenac NN i
( ( N
1 CD N
% NN N
) ) N
in IN N
the DT N
prevention NN N
of IN N
miosis NN o
during IN p
vitrectomy NN p
. . p

PURPOSE VB N
A NNP N
prospective JJ N
, , N
randomized JJ N
clinical JJ N
trial NN N
was VBD N
conducted VBN N
to TO N
assess VB N
the DT N
usefulness NN N
of IN N
preoperative JJ N
diclofenac NN i
eye NN N
drops NNS N
in IN N
maintaining VBG N
mydriasis NN o
during IN N
vitrectomy NN N
and CC N
in IN N
reducing VBG N
postoperative JJ o
inflammation NN o
. . o

METHODS NNP N
Fifty NNP p
consecutive JJ p
patients NNS p
undergoing VBG p
vitrectomy NN p
were VBD N
randomly RB N
assigned VBN N
to TO N
diclofenac VB i
( ( N
n JJ N
= NNP N
24 CD N
) ) N
or CC N
control NN i
( ( N
n JJ N
= NNP N
26 CD N
) ) N
groups NNS N
. . N

All DT N
patients NNS N
received VBD N
a DT N
standard JJ N
preoperative JJ N
regimen NNS N
of IN N
cyclopentolate NN i
( ( N
2 CD N
% NN N
) ) N
and CC N
phenylephrine JJ i
hydrochloride NN i
( ( N
2.5 CD N
% NN N
) ) N
. . N

The DT N
diclofenac NN i
group NN N
also RB N
received VBD N
diclofenac NNS i
( ( N
1 CD N
% NN N
) ) N
preoperatively RB N
. . N

Pupillary JJ o
diameter NN o
was VBD N
recorded VBN N
at IN N
four CD N
time NN N
points NNS N
during IN N
surgery NN N
. . N

Inflammatory JJ o
indices NNS o
were VBD N
measured VBN N
postoperatively RB N
using VBG N
slit-lamp JJ N
examination NN N
. . N

RESULTS NNP N
After IN N
induction NN N
of IN N
anesthesia NN N
, , N
the DT N
decrease NN o
in IN o
pupil JJ o
size NN o
was VBD N
not RB N
significantly RB N
different JJ N
between IN N
the DT N
two CD N
groups NNS N
( ( N
P NNP N
= NNP N
0.112 CD N
) ) N
, , N
but CC N
for IN N
the DT N
next JJ N
two CD N
stages NNS N
, , N
it PRP N
was VBD N
significantly RB N
less RBR N
in IN N
the DT N
diclofenac NN i
group NN N
( ( N
P NNP N
= NNP N
0.012 CD N
and CC N
P NNP N
= NNP N
0.003 CD N
, , N
respectively RB N
) ) N
. . N

No DT N
significant JJ N
differences NNS N
were VBD N
found VBN N
between IN N
the DT N
two CD N
groups NNS N
for IN N
anterior JJ o
chamber NN o
cells NNS o
and CC N
redness NN o
in IN o
the DT o
eye NN o
postoperatively RB N
( ( N
P NNP N
= NNP N
0.609 CD N
and CC N
P NNP N
= NNP N
0.123 CD N
, , N
respectively RB N
) ) N
. . N

However RB N
, , N
anterior JJ o
chamber NN o
flare NN o
was VBD N
significantly RB N
greater JJR N
in IN N
the DT N
control NN N
group NN N
( ( N
P NNP N
= NNP N
0.035 CD N
) ) N
, , N
and CC N
patients NNS N
felt VBD N
significantly RB N
more RBR N
pain NN o
in IN N
this DT N
group NN N
( ( N
P NNP N
= NNP N
0.001 CD N
) ) N
. . N

CONCLUSIONS NNP N
Topical NNP N
administration NN N
of IN N
diclofenac NN i
was VBD N
effective JJ N
in IN N
maintaining VBG o
mydriasis NN o
during IN N
vitrectomy NN N
and CC N
in IN N
reducing VBG N
postoperative JJ o
pain NN o
and CC N
anterior JJ o
chamber NN o
flare NN o
as IN N
determined VBN N
by IN N
slit-lamp JJ N
evaluations NNS N
. . N

-DOCSTART- -8097925- O O

Modest NNP N
antihypertensive JJ N
effect NN N
of IN N
epanolol NN i
, , N
a DT N
beta NN N
1-selective JJ N
receptor NN N
blocker NN N
with IN N
beta NN N
1 CD N
agonist NN N
activity NN N
: : N
an DT N
acute NN N
and CC N
long-term JJ N
hemodynamic NN N
study NN N
at IN N
rest NN N
and CC N
during IN N
exercise NN N
and CC N
double JJ N
crossover NN N
comparison NN N
with IN N
atenolol NN N
on IN N
ambulatory JJ N
blood NN N
pressure NN N
. . N

Beta-blockers NNS N
with IN N
less JJR N
cardiodepressive JJ N
effect NN N
than IN N
traditional JJ N
nonselective JJ N
beta NN N
( ( N
1+2 CD N
) ) N
-blocking VBG N
agents NNS N
could MD N
be VB N
useful JJ N
in IN N
the DT N
treatment NN N
of IN N
hypertension NN N
, , N
provided VBD N
the DT N
reduction NN N
in IN N
blood NN N
pressure NN N
was VBD N
satisfactory JJ N
. . N

Epanolol NNP i
, , N
a DT N
selective JJ N
beta NN N
1-receptor JJ N
blocker NN N
with IN N
intrinsic JJ N
sympathomimetic JJ N
activity NN N
, , N
induced VBD N
a DT N
fall NN N
in IN N
intraarterial JJ o
pressure NN o
of IN N
8 CD N
% NN N
at IN N
rest NN N
sitting VBG N
and CC N
11 CD N
% NN N
during IN N
100 CD N
W NNP N
bicycle NN N
exercise NN N
after IN N
the DT N
first JJ N
dose NN N
of IN N
200 CD N
mg NNS N
in IN N
12 CD p
patients NNS p
with IN p
essential JJ p
hypertension NN p
. . p

Heart NNP o
rate NN o
, , o
stroke VBD o
index NN o
, , o
and CC o
cardiac JJ o
index NN o
initially RB N
fell VBD N
by IN N
14 CD N
% NN N
, , N
11 CD N
% NN N
, , N
and CC N
23 CD N
% NN N
, , N
respectively RB N
. . N

The DT N
total JJ o
peripheral JJ o
resistance NN o
index NN o
increased VBD N
by IN N
21 CD N
% NN N
after IN N
2 CD N
hours NNS N
, , N
and CC N
then RB N
reverted VBD N
towards IN N
the DT N
pretreatment NN N
level NN N
. . N

After IN N
10 CD N
months NNS N
of IN N
epanolol JJ i
treatment NN N
( ( N
mean JJ N
300 CD N
mg/day NN N
) ) N
, , N
the DT N
reduction NN o
in IN N
arterial JJ o
pressure NN o
was VBD N
5 CD N
% NN N
at IN N
rest NN N
and CC N
10 CD N
% NN N
during IN N
exercise NN N
. . N

Cardiac NNP o
index NN o
and CC o
heart NN o
rate NN o
were VBD N
still RB N
reduced VBN N
14-21 CD N
% NN N
, , N
while IN N
total JJ o
peripheral JJ o
resistance NN o
was VBD N
unchanged JJ N
or CC N
slightly RB N
increased VBN N
( ( N
2-10 CD N
% NN N
) ) N
. . N

Twenty-four JJ o
hour NN o
ambulatory NN o
blood NN o
pressure NN o
was VBD N
higher JJR N
on IN N
epanolol NN i
( ( N
300 CD N
mg/day NN N
) ) N
than IN N
on IN N
atenolol NN i
( ( N
150 CD N
mg/day NN N
) ) N
treatment NN N
( ( N
137/97 CD N
vs. FW N
128/91 CD N
mmHg NN N
) ) N
. . N

Thus RB N
, , N
the DT N
achieved VBN o
blood NN o
pressure NN o
reduction NN o
induced VBN N
by IN N
epanolol NN i
was VBD N
moderate JJ N
, , N
while IN N
other JJ N
characteristics NNS N
of IN N
beta-receptor NN N
blockade NN N
, , N
in IN N
particular JJ N
, , N
the DT N
reduction NN o
of IN o
heart NN o
rate NN o
and CC o
cardiac JJ o
output NN o
, , N
were VBD N
maintained VBN N
. . N

This DT N
suggests VBZ N
that IN N
the DT N
compound NN N
may MD N
be VB N
useful JJ N
for IN N
other JJ N
cardiovascular JJ p
disorders NNS p
, , N
e.g. NN N
, , N
angina JJ p
pectoris NN p
in IN p
patients NNS p
without IN p
hypertension NN p
or CC p
cardiac JJ p
arrhythmia NN p
. . p

-DOCSTART- -12743142- O O

Phase NNP N
III NNP N
trial NN N
comparing VBG N
whole-pelvic JJ N
versus NN N
prostate-only JJ N
radiotherapy NN i
and CC N
neoadjuvant JJ i
versus NN i
adjuvant NN i
combined VBN i
androgen JJ i
suppression NN i
: : i
Radiation NN i
Therapy NNP i
Oncology NNP N
Group NNP N
9413 CD N
. . N

PURPOSE VB N
This DT N
trial NN N
tested VBD N
the DT N
hypothesis NN N
that WDT N
combined VBD N
androgen DT i
suppression NN i
( ( i
CAS NNP i
) ) i
and CC i
whole-pelvic JJ i
( ( i
WP NNP i
) ) i
radiotherapy NN i
( ( i
RT NNP i
) ) i
followed VBN N
by IN N
a DT N
boost NN N
to TO N
the DT N
prostate NN N
improves VBZ N
progression-free JJ o
survival NN o
( ( o
PFS NNP o
) ) o
by IN N
10 CD N
% NN N
compared VBN N
with IN N
CAS NNP N
and CC N
prostate-only RB N
( ( N
PO NNP N
) ) N
RT NNP N
. . N

This DT N
trial NN N
also RB N
tested VBD N
the DT N
hypothesis NN N
that WDT N
neoadjuvant JJ i
and CC i
concurrent JJ i
hormonal JJ i
therapy NN i
( ( i
NCHT NNP i
) ) i
improves VBZ N
PFS NNP N
compared VBN N
with IN N
adjuvant JJ i
hormonal JJ i
therapy NN i
( ( i
AHT NNP i
) ) i
by IN N
10 CD N
% NN N
. . N

MATERIALS NNP N
AND CC N
METHODS NNP N
Eligibility NNP p
included VBD p
localized JJ p
prostate NN p
cancer NN p
with IN p
an DT p
elevated JJ p
prostate-specific JJ p
antigen NN p
( ( p
PSA NNP p
) ) p
< VBD p
or CC p
= $ p
100 CD p
ng/mL NN p
and CC p
an DT p
estimated VBN p
risk NN p
of IN p
lymph JJ p
node NN p
( ( p
LN NNP p
) ) p
involvement NN p
of IN p
15 CD p
% NN p
. . p

Between NNP p
April NNP p
1 CD p
, , p
1995 CD p
, , p
and CC p
June NNP p
1 CD p
, , p
1999 CD p
, , p
1,323 CD p
patients NNS p
were VBD p
accrued VBN p
. . p

Patients NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
WP NNP N
+ NNP N
NCHT NNP N
, , N
PO NNP N
+ NNP N
NCHT NNP N
, , N
WP NNP N
+ NNP N
AHT NNP N
, , N
or CC N
PO NNP N
+ NNP N
AHT NNP N
. . N

Failure NN o
for IN o
PFS NNP o
was VBD N
defined VBN N
as IN N
the DT N
first JJ N
occurrence NN N
of IN N
local JJ o
, , o
regional JJ o
, , o
or CC o
distant JJ o
disease NN o
; : o
PSA NNP o
failure NN o
; : o
or CC N
death NN o
for IN N
any DT N
cause NN N
. . N

RESULTS NNP N
With IN N
a DT N
median JJ N
follow-up NN N
of IN N
59.5 CD N
months NNS N
, , N
WP NNP N
RT NNP N
was VBD N
associated VBN N
with IN N
a DT N
4-year JJ o
PFS NNP o
of IN N
54 CD N
% NN N
compared VBN N
with IN N
47 CD N
% NN N
in IN N
patients NNS N
treated VBN N
with IN N
PO NNP N
RT NNP N
( ( N
P NNP N
=.022 NNP N
) ) N
. . N

Patients NNS N
treated VBD N
with IN N
NCHT NNP i
experienced VBD N
a DT N
4-year JJ o
PFS NNP o
of IN N
52 CD N
% NN N
versus IN N
49 CD N
% NN N
for IN N
AHT NNP i
( ( N
P NNP N
=.56 NNP N
) ) N
. . N

When WRB N
comparing VBG N
all DT N
four CD N
arms NNS N
, , N
there EX N
was VBD N
a DT N
progression-free JJ o
difference NN o
among IN N
WP NNP i
RT NNP i
+ NNP i
NCHT NNP i
, , i
PO NNP i
RT NNP i
+ NNP i
NCHT NNP i
, , i
WP NNP i
RT NNP i
+ NNP i
AHT NNP i
, , N
and CC N
PO NNP i
RT NNP i
+ NNP i
AHT NNP i
( ( N
60 CD N
% NN N
v JJ N
44 CD N
% NN N
v JJ N
49 CD N
% NN N
v JJ N
50 CD N
% NN N
, , N
respectively RB N
; : N
P NNP N
=.008 NNP N
) ) N
. . N

No UH N
survival JJ o
advantage NN o
has VBZ N
yet RB N
been VBN N
seen VBN N
. . N

CONCLUSION NNP N
WP NNP i
RT NNP i
+ NNP i
NCHT NNP i
improves VBZ N
PFS NNP o
compared VBN N
with IN N
PO NNP i
RT NNP i
and CC N
NCHT NNP i
or CC N
PO NNP i
RT NNP i
and CC N
AHT NNP i
, , N
and CC N
compared VBN N
with IN N
WP NNP i
RT NNP i
+ NNP i
AHT NNP i
in IN N
patients NNS p
with IN p
a DT p
risk NN p
of IN p
LN NNP p
involvement NN p
of IN p
15 CD p
% NN p
. . p

-DOCSTART- -24101716- O O

The DT i
Autism NNP i
MEAL NNP i
Plan NN i
: : i
a DT N
parent-training JJ N
curriculum NN N
to TO N
manage VB N
eating JJ N
aversions NNS N
and CC N
low JJ N
intake NN N
among IN N
children NNS p
with IN p
autism NN p
. . p

Feeding VBG N
problems NNS N
represent VBP N
a DT N
frequent NN N
concern NN N
reported VBN N
by IN N
caregivers NNS p
of IN p
children NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
, , N
and CC N
growing VBG N
evidence NN N
suggests VBZ N
atypical JJ N
patterns NNS N
of IN N
intake NN N
may MD N
place VB N
this DT N
population NN N
at IN N
risk NN N
of IN N
nutritional JJ N
and/or NN N
related JJ N
medical JJ N
issues NNS N
, , N
including VBG N
chronic JJ N
vitamin NN N
and CC N
mineral JJ N
deficiencies NNS N
, , N
poor JJ N
bone NN N
growth NN N
, , N
and CC N
obesity NN N
. . N

This DT N
combination NN N
of IN N
factors NNS N
emphasizes VBZ N
a DT N
clear JJ N
need NN N
to TO N
identify VB N
and CC N
disseminate VB N
evidence-based JJ N
treatment NN N
of IN N
feeding VBG N
problems NNS N
associated VBN N
with IN N
autism NN N
spectrum NN N
disorders NNS N
. . N

Behavioral NNP N
intervention NN N
represents VBZ N
an DT N
effective JJ N
treatment NN N
for IN N
chronic JJ N
feeding NN N
concerns NNS N
in IN N
this DT N
population NN N
; : N
however RB N
, , N
evidence NN N
has VBZ N
largely RB N
been VBN N
established VBN N
with IN N
trained JJ N
therapists NNS N
working VBG N
in IN N
highly RB N
structured JJ N
settings NNS N
. . N

This DT N
pilot NN N
study NN N
seeks VBZ N
to TO N
fill VB N
this DT N
gap NN N
in IN N
the DT N
literature NN N
by IN N
describing VBG N
and CC N
evaluating VBG N
the DT N
Autism NNP i
MEAL NNP i
Plan NNP i
, , N
a DT N
behaviorally RB N
based VBN N
parent-training NN N
curriculum NN N
to TO N
address VB N
feeding VBG N
problems NNS N
associated VBN N
with IN N
autism NN N
spectrum NN N
disorders NNS N
. . N

We PRP N
assessed VBD N
the DT N
feasibility NN N
of IN N
the DT N
intervention NN N
in IN N
terms NNS N
of IN N
program NN N
content NN N
and CC N
study NN N
protocol NN N
( ( N
e.g JJ N
. . N

recruitment NN o
and CC o
retention NN o
of IN o
participants NNS o
, , o
assessment NN o
procedures NNS o
) ) o
, , N
as RB N
well RB N
as IN N
efficacy NN o
in IN N
terms NNS N
of IN N
changes NNS N
in IN N
feeding VBG N
behaviors NNS N
. . N

A DT N
total NN N
of IN N
10 CD p
families NNS p
participated VBN p
in IN p
the DT p
treatment NN p
condition NN p
, , N
and CC N
the DT N
program NN N
was VBD N
evaluated VBN N
using VBG N
a DT N
waitlist NN i
control NN i
design NN i
( ( N
n JJ N
= NNP N
9 CD N
) ) N
, , N
representing VBG N
the DT N
first JJ N
randomized-control NN N
study NN N
of IN N
a DT N
feeding VBG N
intervention NN N
in IN N
autism NN N
spectrum NN N
disorders NNS N
. . N

Results NNS N
provide VBP N
provisional JJ N
support NN N
regarding VBG N
the DT N
utility NN o
of IN o
the DT o
program NN o
, , N
including VBG N
high JJ o
social JJ o
validity NN o
, , o
parent NN o
perception NN o
of IN o
effectiveness NN o
, , o
and CC o
reduced JJ o
levels NNS o
of IN o
caregiver NN o
stress NN o
following VBG o
intervention NN o
. . o

Implications NNS N
, , N
limitations NNS N
, , N
and CC N
future JJ N
directions NNS N
for IN N
this DT N
line NN N
of IN N
research NN N
are VBP N
discussed VBN N
. . N

-DOCSTART- -10078672- O O

Behavioral NNP o
and CC o
physiological JJ o
effects NNS o
of IN N
remifentanil NN i
and CC i
alfentanil NN i
in IN N
healthy JJ p
volunteers NNS p
. . p

BACKGROUND IN N
The DT o
subjective JJ o
and CC o
psychomotor JJ o
effects NNS o
of IN N
remifentanil NNS i
have VBP N
not RB N
been VBN N
evaluated VBN N
. . N

Accordingly RB N
, , N
the DT N
authors NNS N
used VBD N
mood NN N
inventories NNS N
and CC N
psychomotor NN N
tests NNS N
to TO N
characterize VB N
the DT N
effects NNS N
of IN N
remifentanil NN i
in IN N
healthy JJ p
, , p
non-drug-abusing JJ p
volunteers NNS p
. . p

Alfentanil NNP N
was VBD N
used VBN N
as IN N
a DT N
comparator NN N
drug NN N
. . N

METHODS NNP N
Ten NNP p
healthy JJ p
volunteers NNS p
were VBD N
enrolled VBN N
in IN N
a DT N
randomized JJ N
, , N
double-blinded JJ N
, , N
placebo-controlled JJ i
, , N
crossover JJ N
trial NN N
in IN N
which WDT N
they PRP N
received VBD N
an DT N
infusion NN N
of IN N
saline NN i
, , i
remifentanil NN i
, , i
or CC i
alfentanil NN i
for IN i
120 CD i
min NN i
. . i

The DT N
age- JJ i
and CC i
weight-adjusted JJ i
infusions NNS i
( ( i
determined VBN i
with IN i
STANPUMP NNP i
, , i
a DT i
computer NN i
modeling VBG i
software NN i
package NN i
) ) i
were VBD N
given VBN N
to TO N
achieve VB N
three CD N
predicted VBN N
constant JJ N
plasma NN N
levels NNS N
for IN N
40 CD i
min NNS i
each DT i
of IN i
remifentanil NN i
( ( i
0.75 CD i
, , i
1.5 CD i
, , i
and CC i
3 CD i
ng/ml NN i
) ) i
and CC i
alfentanil NN i
( ( i
16 CD i
, , i
32 CD i
, , i
and CC i
64 CD i
ng/ml NN i
) ) i
. . i

Mood NN N
forms NNS N
and CC N
psychomotor NN N
tests NNS N
were VBD N
completed VBN N
, , N
and CC N
miosis NN N
was VBD N
assessed VBN N
, , N
during IN N
and CC N
after IN N
the DT N
infusions NNS N
. . N

In IN N
addition NN N
, , N
analgesia NN N
was VBD N
tested VBN N
at IN N
each DT N
dose JJ N
level NN N
using VBG N
a DT N
cold-pressor JJ N
test NN N
. . N

RESULTS NNP N
Remifentanil NNP i
had VBD N
prototypic VBN o
micro-like JJ o
opioid JJ o
subjective JJ o
effects NNS o
, , o
impaired JJ o
psychomotor NN o
performance NN o
, , o
and CC o
produced VBD o
analgesia NN o
. . o

Alfentanil NNP N
at IN N
the DT N
dose JJ N
range NN N
tested VBD N
had VBD N
more RBR N
mild JJ N
effects NNS N
on IN N
these DT N
measures NNS N
, , N
and CC N
the DT N
analgesia NN o
data NNS N
indicated VBD N
that IN N
a DT N
40:1 CD N
potency NN N
ratio NN N
, , N
rather RB N
than IN N
the DT N
20:1 CD N
ratio NN N
we PRP N
used VBD N
, , N
may MD N
exist VB N
between IN N
remifentanil NN N
and CC N
alfentanil NN N
. . N

A DT N
psychomotor NN N
test NN N
administered VBD N
60 CD N
min NN N
after IN N
the DT N
remifentanil NN N
infusion NN N
was VBD N
discontinued VBN N
showed VBD N
that IN N
the DT N
volunteers NNS N
were VBD N
still RB N
impaired VBN N
, , N
although IN N
they PRP N
reported VBD N
feeling VBG N
no DT N
drug NN N
effects NNS N
. . N

CONCLUSIONS VB N
The DT N
notion NN N
that IN N
the DT N
pharmacodynamic JJ o
effects NNS o
of IN N
remifentanil NN i
are VBP N
extremely RB N
short-lived JJ N
after IN N
the DT N
drug NN N
is VBZ N
no DT N
longer RB N
administered VBN N
must MD N
be VB N
questioned VBN N
given VBN N
our PRP$ N
findings NNS N
that IN N
psychomotor NN o
effects NNS o
were VBD N
still RB N
apparent JJ N
1 CD N
h NN N
after IN N
the DT N
infusion NN N
was VBD N
discontinued VBN N
. . N

-DOCSTART- -8391792- O O

Subcutaneous JJ N
low-molecular-weight JJ i
heparin NN i
compared VBN N
with IN N
continuous JJ N
intravenous JJ N
unfractionated JJ i
heparin NN i
in IN N
the DT N
treatment NN N
of IN N
proximal JJ p
deep JJ p
vein NN p
thrombosis NN p
. . p

BACKGROUND VB N
A DT N
low-molecular-weight JJ i
heparin NN i
, , i
enoxaparin JJ i
sodium NN i
, , N
has VBZ N
been VBN N
shown VBN N
to TO N
be VB N
effective JJ N
and CC N
safe JJ N
in IN N
preventing VBG N
deep JJ p
vein NN p
thrombosis NN p
both DT p
in IN p
general JJ p
surgery NN p
and CC p
in IN p
high-risk JJ p
orthopedic JJ p
surgery NN p
. . p

We PRP N
conducted VBD N
a DT N
controlled VBN N
, , N
randomized VBN N
trial NN N
with IN N
enoxaparin NN N
in IN N
the DT N
treatment NN N
of IN N
established VBN N
deep JJ N
vein NN N
thrombosis NN N
. . N

METHODS NNP N
In IN N
a DT N
multicenter NN N
trial NN N
, , N
we PRP N
compared VBN N
fixed-dose RB N
subcutaneous JJ N
enoxaparin NN i
, , N
given VBN N
twice RB N
daily RB N
, , N
with IN N
adjusted-dose JJ N
intravenous JJ N
unfractionated JJ i
heparin NN i
( ( i
UFH NNP i
) ) i
given VBN N
by IN N
continuous JJ N
intravenous JJ N
infusion NN N
for IN N
the DT N
initial JJ N
10 CD N
days NNS N
of IN N
treatment NN N
of IN N
patients NNS p
with IN p
proximal JJ p
vein NN p
thrombosis NN p
. . p

The DT N
primary JJ N
efficacy NN N
outcome NN N
was VBD N
the DT N
change NN o
of IN o
the DT o
size NN o
of IN o
the DT o
thrombus NN o
assessed VBN N
by IN N
repeated JJ N
venograms NNS N
between IN N
day NN N
0 CD N
and CC N
day NN N
10 CD N
. . N

The DT N
primary JJ N
analysis NN N
of IN N
safety NN N
was VBD N
based VBN N
on IN N
the DT N
incidence NN o
of IN o
major JJ o
bleeding VBG o
during IN N
10 CD N
days NNS N
of IN N
treatment NN N
. . N

RESULTS CC N
There EX p
were VBD p
67 CD p
patients NNS p
in IN p
each DT p
group NN p
. . p

Venographic NNP N
assessment NN N
of IN N
clot NN o
size NN o
evolution NN o
between IN N
day NN N
0 CD N
and CC N
day NN N
10 CD N
showed VBD N
a DT N
statistically RB N
significant JJ N
superiority NN N
( ( N
P NNP N
< NNP N
.002 NNP N
) ) N
of IN N
enoxaparin NN i
over IN N
the DT N
reference NN N
treatment NN N
with IN N
UFH NNP i
. . i

Moreover RB N
, , N
the DT N
incidence NN o
of IN o
overall JJ o
recurrent JJ o
thromboembolic JJ o
events NNS o
during IN N
10 CD N
days NNS N
of IN N
treatment NN N
was VBD N
significantly RB N
higher JJR N
( ( N
P NNP N
< NNP N
.002 NNP N
) ) N
in IN N
the DT N
UFH NNP i
group NN N
( ( N
seven CD N
of IN N
67 CD N
) ) N
than IN N
in IN N
the DT N
enoxaparin NN i
group NN N
( ( N
one CD N
of IN N
67 CD N
) ) N
. . N

There EX N
were VBD N
no DT N
serious JJ o
bleeding VBG o
complications NNS o
in IN N
either DT N
group NN N
. . N

CONCLUSIONS NNP N
Enoxaparin NNP i
is VBZ N
at IN N
least JJS N
as IN N
effective JJ N
and CC N
safe JJ N
as IN N
UFH NNP i
under IN N
the DT N
conditions NNS N
of IN N
this DT N
study NN N
. . N

Moreover RB N
, , N
it PRP N
is VBZ N
more RBR N
comfortable JJ N
for IN N
patients NNS N
and CC N
less JJR N
time-consuming NN N
for IN N
nurses NNS N
and CC N
laboratories NNS N
. . N

Thus RB N
, , N
our PRP$ N
study NN N
confirmed VBD N
, , N
with IN N
the DT N
use NN N
of IN N
enoxaparin NN i
, , N
other JJ N
observations NNS N
that IN N
low-molecular-weight JJ i
heparin NN i
provides VBZ N
a DT N
real JJ N
therapeutic JJ N
advance NN N
in IN N
the DT N
treatment NN N
of IN N
deep JJ p
vein NN p
thrombosis NN p
. . p

-DOCSTART- -23964752- O O

Efficacy NN N
and CC N
safety NN N
of IN N
diclofenac JJ i
diethylamine JJ i
1.16 CD N
% NN N
gel NN N
in IN N
acute JJ p
neck NN p
pain NN p
: : p
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
study NN N
. . N

BACKGROUND NNP N
Neck NNP N
pain NN N
( ( N
NP NNP N
) ) N
is VBZ N
a DT N
common JJ N
musculoskeletal JJ N
disorder NN N
in IN N
primary JJ N
care NN N
that WDT N
frequently RB N
causes VBZ N
discomfort NN N
. . N

Non-steroidal JJ N
anti-inflammatory JJ N
drugs NNS N
( ( N
NSAIDs NNP N
) ) N
may MD N
be VB N
used VBN N
to TO N
reduce VB N
neck NN N
pain NN N
and CC N
associated VBN N
inflammation NN N
and CC N
facilitate NN N
earlier RBR N
recovery NN N
. . N

Topical JJ i
diclofenac NN i
diethylamine NN i
( ( i
DDEA NNP i
) ) i
1.16 CD i
% NN i
gel NN i
is VBZ N
clinically RB N
proven VBN N
to TO N
be VB N
effective JJ N
and CC N
well RB N
tolerated VBN N
in IN N
acute NN N
and CC N
chronic JJ N
musculoskeletal NN N
conditions NNS N
, , N
but CC N
until IN N
now RB N
no DT N
clinical JJ N
data NNS N
existed VBD N
for IN N
its PRP$ N
use NN N
in IN N
acute JJ N
NP NNP N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
assess VB N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
DDEA NNP N
1.16 CD N
% NN N
gel NN N
compared VBN N
with IN N
placebo NN i
gel NN i
in IN N
acute JJ N
NP NNP N
. . N

METHODS NNP N
In IN N
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
study NN N
, , N
patients NNS p
with IN p
acute JJ p
NP NNP p
( ( p
n JJ p
= NNP p
72 CD p
) ) p
were VBD p
treated VBN N
with IN N
DDEA NNP N
1.16 CD N
% NN N
gel NN N
( ( N
2 CD N
g NN N
, , N
4x/day CD N
, , N
for IN N
5 CD N
days NNS N
) ) N
or CC N
placebo NN N
. . N

Efficacy NN N
assessments NNS N
included VBD o
pain-on-movement NN o
( ( o
POM NNP o
) ) o
, , o
pain-at-rest JJ o
( ( o
PAR NNP o
) ) o
, , o
functional JJ o
neck NN o
disability NN o
index NN o
( ( o
NDI NNP o
) ) o
and CC o
response NN o
to TO o
treatment NN o
( ( o
decrease NN o
in IN N
POM NNP N
by IN N
50 CD N
% NN N
after IN N
48 CD N
h NN N
) ) N
. . N

Adverse JJ N
events NNS N
( ( N
AEs NNP N
) ) N
were VBD N
recorded VBN N
throughout IN N
the DT N
study NN N
. . N

RESULTS VB N
The DT N
primary JJ N
outcome NN N
, , o
POM NNP o
at IN o
48 CD o
h NN o
, , o
was VBD N
statistically RB N
significantly RB N
lower JJR N
with IN N
DDEA NNP N
gel NN N
( ( N
19.5 CD N
mm NN N
) ) N
vs. FW N
placebo NN N
( ( N
56.9 CD N
mm NN N
) ) N
( ( N
p JJ N
< NNP N
0.0001 CD N
) ) N
, , N
representing VBG N
a DT N
clinically RB N
relevant JJ N
decrease NN N
from IN N
baseline NN N
( ( N
75 CD N
% NN N
vs. FW N
23 CD N
% NN N
, , N
respectively RB N
) ) N
. . N

All DT o
POM NNP o
scores NNS o
were VBD o
significantly RB N
lower JJR i
with IN i
DDEA NNP i
gel NN i
vs. FW N
placebo NN N
from IN N
1 CD N
h NN N
, , N
as IN N
were VBD N
PAR NNP N
and CC N
NDI NNP N
scores NNS N
from IN N
first JJ N
assessment NN N
( ( N
24 CD N
h NN N
) ) N
onwards NNS N
( ( N
all DT N
p VBP N
< $ N
0.0001 CD N
) ) N
. . o

Response NNP o
to TO o
treatment NN o
was VBD o
significantly RB o
higher JJR N
with IN i
DDEA NNP i
gel NN i
( ( N
94.4 CD N
% NN N
) ) N
vs. FW N
placebo NN N
( ( N
8.3 CD N
% NN N
) ) N
( ( N
p JJ N
< NNP N
0.0001 CD N
) ) N
. . N

There EX N
were VBD o
no DT o
AEs NNP o
with IN o
DDEA NNP N
gel NN N
. . N

CONCLUSIONS NNP N
DDEA NNP N
1.16 CD N
% NN N
gel NN N
, , N
which WDT N
is VBZ N
available JJ N
over-the-counter JJ o
, , o
was VBD o
effective JJ o
and CC o
well RB o
tolerated VBN o
in IN o
the DT o
treatment NN p
of IN p
acute JJ p
neck NN p
pain NN p
. . p

The DT p
tools NNS N
used VBD N
to TO N
assess VB N
efficacy NN N
suggest VBP N
that IN N
it PRP N
quickly RB N
reduced VBD N
neck NN o
pain NN o
and CC o
improved VBN o
neck NN o
function NN o
. . o

However RB N
, , N
questions NNS N
remain VBP N
regarding VBG N
the DT N
comparability NN N
and CC N
validity NN N
of IN N
such JJ N
tools NNS N
. . N

Further JJ N
studies NNS N
will MD N
help VB N
ascertain VB N
whether IN N
DDEA NNP N
1.16 CD N
% NN N
gel NN N
offers VBZ N
an DT N
alternative JJ N
treatment NN N
option NN N
in IN N
this DT N
common JJ N
, , N
often RB N
debilitating VBG N
condition NN N
. . N

TRIAL NNP N
REGISTRATION NNP N
ClinicalTrials.gov NNP N
identifier NN N
: : N
NCT01335724 NNP N
. . N

-DOCSTART- -384024- O O

Butorphanol NNP i
and CC i
meperidine NN i
compared VBN N
in IN N
patients NNS p
with IN p
acute JJ p
ureteral JJ p
colic NN p
. . p

Pain NNP N
relief NN N
was VBD N
evaluated VBN N
in IN N
81 CD p
patients NNS p
with IN p
acute JJ p
ureteral JJ p
colic NN p
and CC p
the DT p
confirmed JJ p
presence NN p
of IN p
a DT p
calculus NN p
. . p

A DT N
randomized JJ p
double-blind JJ p
comparison NN p
of IN p
intramuscular JJ p
2 CD p
and CC p
4 CD p
mg. NN p
butorphanol NN i
and CC i
80 CD p
mg. NNS p
meperidine NN i
was VBD p
used VBN p
. . p

Pain NNP o
intensity NN o
and CC N
pain NN o
relief NN o
were VBD N
evaluated VBN N
at IN N
half JJ N
hour NN N
and CC N
hourly JJ N
intervals NNS N
for IN N
4 CD N
hours NNS N
. . N

A DT N
2 CD N
mg. NN N
dose NN N
of IN N
butorphanol NN i
was VBD N
found VBN N
to TO N
be VB N
analgesically RB N
equivalent JJ N
to TO N
80 CD N
mg. NNS N
meperidine NN i
, , N
while IN N
a DT N
4 CD N
mg. NN N
dose NN N
of IN N
butorphanol NN i
was VBD N
found VBN N
to TO N
be VB N
more RBR N
effective JJ N
than IN N
80 CD N
mg. JJ N
meperidine NN i
and CC N
2 CD N
mg. NN N
butorphanol NN i
. . i

Each DT N
patient NN N
received VBD N
up RB N
to TO N
2 CD N
doses NNS N
of IN N
analgesic JJ N
medication NN N
when WRB N
necessary JJ N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
the DT N
incidence NN o
of IN o
side JJ o
effects NNS o
among IN N
treatments NNS N
. . N

One CD N
patient NN N
had VBD N
visual JJ o
hallucinations NNS o
after IN N
a DT N
2 CD N
mg. NN N
dose NN N
of IN N
butorphanol NN i
, , N
possibly RB N
owing VBG N
to TO N
its PRP$ N
antagonistic JJ N
activity NN N
to TO N
significant JJ N
narcotic JJ N
experience NN N
given VBN N
previously RB N
at IN N
another DT N
hospital NN N
. . N

There EX N
was VBD N
no DT N
other JJ N
evidence NN N
of IN N
toxicity NN o
with IN N
butorphanol NN i
. . i

It PRP N
was VBD N
found VBN N
to TO N
be VB N
a DT N
safe JJ o
, , o
effective JJ o
and CC o
wall RB o
tolerated JJ o
drug NN N
for IN N
the DT N
treatment NN N
of IN N
ureteral JJ N
colic NN N
and CC N
is VBZ N
recommended VBN N
in IN N
place NN N
of IN N
narcotics NNS N
. . N

-DOCSTART- -24988121- O O

Traumatic JJ p
brain NN p
injury-related JJ p
attention NN o
deficits NNS o
: : o
treatment NN N
outcomes NNS o
with IN N
lisdexamfetamine JJ i
dimesylate NN i
( ( i
Vyvanse NNP i
) ) i
. . i

BACKGROUND NNP N
AND NNP N
OBJECTIVES NNP N
Attention NNP N
deficits NNS N
are VBP N
often RB N
among IN N
the DT N
most RBS N
persistent JJ N
and CC N
debilitating VBG N
impairments NNS N
resulting VBG N
from IN N
traumatic JJ N
brain NN N
injury NN N
( ( N
TBI NNP N
) ) N
. . N

This DT N
study NN N
examined VBD N
the DT N
effects NNS N
of IN N
lisdexamfetamine JJ i
dimesylate NN i
( ( i
Vyvanse NNP i
) ) i
in IN N
treating VBG N
attention NN o
deficits NNS o
due JJ p
to TO p
moderate-to-severe JJ p
TBI NNP p
. . p

It PRP N
was VBD N
the DT N
first JJ N
study NN N
of IN N
lisdexamfetamine JJ i
dimesylate NN i
with IN N
this DT p
population NN p
and CC N
, , N
in IN N
fact NN N
, , N
was VBD N
the DT N
first JJ N
controlled VBN N
trial NN N
in IN N
this DT N
area NN N
examining VBG N
a DT N
stimulant JJ N
medication NN N
option NN N
other JJ N
than IN N
methylphenidate NN i
. . i

METHODS NNP N
This DT N
was VBD N
a DT N
12-week JJ N
, , N
randomized VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
, , N
cross-over JJ N
trial NN N
. . N

A DT p
total NN p
of IN p
22 CD p
rigorously RB p
selected VBN p
cases NNS p
were VBD p
enrolled VBN p
, , p
13 CD p
of IN p
whom WP p
completed VBD p
the DT p
trial NN p
. . p

They PRP p
were VBD p
16-42 JJ p
years NNS p
of IN p
age NN p
and CC p
had VBD p
newly RB p
acquired VBN p
attention NN o
deficits NNS o
persisting VBG p
for IN p
6-34 JJ p
months NNS p
post-injury NN p
. . p

They PRP p
were VBD N
assessed VBN N
on IN N
a DT N
broad JJ N
range NN N
of IN N
neuropsychological JJ o
and CC o
behavioural JJ o
measures NNS o
at IN N
baseline NN N
, , N
6-weeks JJ N
and CC N
at IN N
12-weeks JJ N
. . N

RESULTS NNP N
AND CC N
CONCLUSIONS NNP N
Positive NNP N
treatment NN N
effects NNS N
were VBD N
found VBN N
involving VBG N
selective JJ N
measures NNS N
of IN N
sustained JJ o
attention NN o
, , o
working VBG o
memory NN o
, , o
response NN o
speed NN o
stability NN o
and CC o
endurance NN o
and CC o
in IN o
aspects NNS o
of IN o
executive NN o
functioning NN o
. . o

No DT N
major JJ N
problems NNS N
with IN N
safety NN o
or CC o
tolerability NN o
were VBD N
observed VBN N
. . N

Some DT N
moderating VBG N
treatment NN N
effects NNS N
were VBD N
found VBN N
from IN N
a DT N
broad JJ N
range NN N
of IN N
pre-treatment JJ N
subject JJ N
characteristics NNS N
and CC N
injury NN N
variables NNS N
examined VBN N
. . N

Avenues NNS N
for IN N
further JJ N
research NN N
and CC N
treatment NN N
applications NNS N
in IN N
this DT N
area NN N
are VBP N
discussed VBN N
. . N

-DOCSTART- -3122275- O O

Effects NNS N
of IN N
misoprostol NN o
on IN N
human JJ p
circulation NN p
. . p

Prostaglandins NNP N
( ( N
PGs NNP N
) ) N
of IN N
the DT N
E-type NNP N
are VBP N
potent JJ N
vasodilators NNS N
in IN N
most JJS N
species NNS N
and CC N
in IN N
most JJS N
vascular JJ N
beds NNS N
. . N

However RB N
, , N
vasoconstrictor JJ N
effects NNS N
of IN N
PGEs NNP N
have VBP N
also RB N
been VBN N
noted VBN N
at IN N
selected VBN N
sites NNS N
. . N

This DT N
study NN N
examined VBD N
the DT N
effects NNS N
of IN N
misoprostol NN o
, , N
a DT N
PGE1 NNP N
analog NN N
with IN N
antiulcer NN N
activity NN N
, , N
on IN N
the DT N
human JJ N
cardiovascular NN N
system NN N
. . N

Twenty NNP p
healthy JJ p
subjects NNS p
participated VBN p
in IN N
this DT N
double-blind NN N
, , N
placebo-controlled JJ N
, , N
parallel JJ N
group NN N
study NN N
. . N

Following VBG N
a DT N
12 CD N
hour NN N
fast NN N
, , N
heart NN N
rate NN N
, , N
arterial JJ N
blood NN N
pressure NN N
, , N
light JJ N
reflex JJ N
plethysmography NN N
of IN N
the DT N
finger NN N
, , N
resting VBG N
blood NN N
flow NN N
volume NN N
in IN N
the DT N
lower JJR N
arm NN N
and CC N
leg NN N
and CC N
peripheral JJ o
vascular JJ o
resistance NN o
were VBD N
measured VBN N
at IN N
10 CD N
min NN N
. . N

intervals NNS N
for IN N
1 CD N
hour NN N
prior RB N
to TO N
drug NN N
administration NN N
, , N
to TO N
permit VB N
calculating VBG N
baseline NN N
values NNS N
. . N

Misoprostol NNP i
( ( i
400 CD i
mcg NN i
) ) i
or CC i
its PRP$ i
matching JJ i
placebo NN i
were VBD N
administered VBN N
orally RB N
, , N
and CC N
the DT N
measurements NNS N
were VBD N
repeated VBN N
at IN N
10 CD N
min NN N
. . N

intervals NNS N
over IN N
the DT N
next JJ N
2 CD N
hours NNS N
. . N

A DT N
decrease NN N
in IN N
leg NN o
blood NN o
flow NN o
volume NN o
and CC o
a DT o
corresponding JJ o
increase NN o
in IN o
leg JJ o
peripheral JJ o
vascular JJ o
resistance NN o
were VBD N
noted VBN N
in IN N
the DT N
misoprostol NN i
group NN N
. . N

A DT N
statistically RB N
significant JJ N
decrease NN N
in IN N
heart NN o
rate NN o
between IN N
the DT N
two CD N
treatment NN N
groups NNS N
was VBD N
also RB N
noted VBN N
. . N

These DT N
small JJ N
changes NNS N
were VBD N
not RB N
considered VBN N
to TO N
be VB N
of IN N
clinical JJ N
importance NN N
. . N

No DT N
adverse JJ o
experiences NNS o
were VBD N
reported VBN N
. . N

In IN N
conclusion NN N
, , N
a DT N
single JJ N
dose NN N
of IN N
misoprostol NN i
( ( N
400 CD N
mcg NN N
) ) N
has VBZ N
no DT N
clinically RB N
significant JJ N
vasoconstrictive JJ o
or CC o
vasodilative JJ o
properties NNS N
in IN N
man NN N
. . N

-DOCSTART- -23466656- O O

Neurophysiological JJ o
responses NNS o
to TO o
faces VBZ o
and CC o
gaze JJ o
direction NN o
differentiate NN N
children NNS p
with IN p
ASD NNP p
, , p
ADHD NNP p
and CC p
ASD+ADHD NNP p
. . p

Children NNP p
with IN p
autism NN p
spectrum NN p
disorder NN p
( ( p
ASD NNP p
) ) p
and CC p
attention NN p
deficit NN p
hyperactivity NN p
disorder NN p
( ( p
ADHD NNP p
) ) p
demonstrate VBP N
face NN o
processing NN o
abnormalities NNS o
that WDT N
may MD N
underlie VB N
social JJ N
impairment NN N
. . N

Despite IN N
substantial JJ N
overlap NN N
between IN N
ASD NNP N
and CC N
ADHD NNP N
, , N
ERP NNP o
markers NNS o
of IN o
face NN o
and CC o
gaze NN o
processing NN o
have VBP N
not RB N
been VBN N
directly RB N
compared VBN N
across IN N
pure NN N
and CC N
comorbid NN N
cases NNS N
. . N

Children NNP p
with IN p
ASD NNP p
( ( p
n=19 NN p
) ) p
, , p
ADHD NNP p
( ( p
n=18 NN p
) ) p
, , p
comorbid JJ p
ASD+ADHD NNP p
( ( p
n=29 NN p
) ) p
and CC p
typically RB p
developing VBG p
( ( p
TD NNP p
) ) p
controls NNS p
( ( p
n=26 NN p
) ) p
were VBD N
presented VBN N
with IN N
upright/inverted JJ i
faces VBZ i
with IN i
direct/averted VBN i
gaze NN i
, , N
with IN N
concurrent JJ N
recording NN N
of IN N
the DT N
P1 NNP N
and CC N
N170 NNP N
components NNS N
. . N

While IN N
the DT N
N170 NNP N
was VBD N
predominant VBN N
in IN N
the DT N
right NN N
hemisphere NN N
in IN N
TD NNP N
and CC N
ADHD NNP N
, , N
children NNS p
with IN p
ASD NNP p
( ( p
ASD/ASD+ADHD NNP p
) ) p
showed VBD N
a DT N
bilateral JJ N
distribution NN N
. . N

In IN N
addition NN N
, , N
children NNS p
with IN p
ASD NNP p
demonstrated VBD N
altered JJ N
response NN o
to TO o
gaze VB o
direction NN o
on IN N
P1 NNP N
latency NN N
and CC N
no DT N
sensitivity NN o
to TO o
gaze VB o
direction NN o
on IN N
midline-N170 JJ N
amplitude NN N
compared VBN N
to TO N
TD NNP N
and CC N
ADHD NNP N
. . N

In IN N
contrast NN N
, , N
children NNS p
with IN p
ADHD NNP p
( ( p
ADHD/ASD+ADHD NNP p
) ) p
exhibited VBD N
a DT N
reduced JJ N
face NN o
inversion NN o
effect NN o
on IN N
P1 NNP N
latency NN N
compared VBN N
to TO N
TD NNP N
and CC N
ASD NNP N
. . N

These DT N
findings NNS N
suggest VBP N
children NNS p
with IN p
ASD NNP p
have VBP N
specific JJ N
abnormalities NNS o
in IN o
gaze NN o
processing NN o
and CC o
altered JJ o
neural JJ o
specialisation NN o
, , N
whereas JJ N
children NNS p
with IN p
ADHD NNP p
show NN N
abnormalities NNS o
at IN N
early JJ N
visual JJ N
attention NN N
stages NNS N
. . N

Children NNP p
with IN p
ASD+ADHD NNP p
are VBP N
an DT N
additive JJ N
co-occurrence NN N
with IN N
deficits NNS N
of IN N
both DT N
disorders NNS N
. . N

Elucidating VBG N
the DT N
neural JJ N
basis NN N
of IN N
the DT N
overlap NN N
between IN N
ASD NNP N
and CC N
ADHD NNP N
is VBZ N
likely JJ N
to TO N
inform VB N
aetiological JJ N
investigation NN N
and CC N
clinical JJ N
assessment NN N
. . N

-DOCSTART- -20043831- O O

The DT N
effectiveness NN o
of IN N
physical JJ i
activity NN i
monitoring NN i
and CC i
distance NN i
counselling NN i
in IN N
an DT N
occupational JJ N
health NN N
setting NN N
-- : N
a DT N
research NN N
protocol NN N
for IN N
a DT N
randomised JJ N
controlled VBN N
trial NN N
( ( N
CoAct NNP N
) ) N
. . N

BACKGROUND IN N
The DT N
CoAct NNP N
( ( N
Cocreating NNP N
Activity NNP N
) ) N
study NN N
is VBZ N
investigating VBG N
a DT N
novel JJ N
lifestyle JJ i
intervention NN i
, , N
aimed VBN N
at IN N
the DT N
working VBG p
population NN p
, , N
with IN N
daily JJ N
activity NN N
monitoring NN N
and CC N
distance NN N
counselling NN N
via IN N
telephone NN N
and CC N
secure NN N
web NN N
messages NNS N
. . N

The DT N
main JJ N
purpose NN N
of IN N
this DT N
study NN N
is VBZ N
to TO N
evaluate VB N
the DT N
effectiveness NN o
of IN N
lifestyle JJ N
counselling VBG N
on IN N
the DT N
level NN N
of IN N
physical JJ o
activity NN o
in IN N
an DT N
occupational JJ N
health NN N
setting NN N
. . N

The DT N
purposes NNS N
include VBP N
also RB N
analysing VBG N
the DT N
potential JJ N
effects NNS N
of IN N
changes NNS N
in IN N
physical JJ N
activity NN N
on IN N
productivity NN o
at IN o
work NN o
and CC o
sickness JJ o
absence NN o
, , o
and CC o
healthcare NN o
costs NNS o
. . o

This DT N
article NN N
describes VBZ N
the DT N
design NN N
of IN N
the DT N
study NN N
and CC N
the DT N
participant NN N
flow NN N
until IN N
and CC N
including VBG N
randomization NN N
. . N

METHODS/DESIGN NNP N
CoAct NNP N
is VBZ N
a DT N
randomised JJ N
controlled VBN N
trial NN N
with IN N
two CD N
arms NNS N
: : N
a DT N
control NN i
group NN N
and CC N
intervention NN N
group NN N
with IN N
daily JJ i
activity NN i
monitoring NN i
and CC i
distance NN i
counselling NN i
. . i

The DT N
intervention NN N
focuses VBZ N
on IN N
lifestyle JJ N
modification NN N
and CC N
takes VBZ N
12 CD N
months NNS N
. . N

The DT N
study NN N
population NN N
consists VBZ N
of IN N
volunteers NNS p
from IN p
1100 CD p
eligible JJ p
employees NNS p
of IN p
a DT p
Finnish JJ p
insurance NN p
company NN p
. . p

The DT N
primary JJ N
outcomes NNS N
of IN N
this DT N
study NN N
are VBP N
change NN o
in IN o
physical JJ o
activity NN o
measured VBN o
in IN o
MET NNP o
minutes NNS o
per IN o
week NN o
, , o
work NN o
productivity NN o
and CC o
sickness NN o
absence NN o
, , o
and CC o
healthcare JJ o
utilisation NN o
. . o

Secondary JJ N
outcomes NNS N
include VBP N
various JJ o
physiological JJ o
measures NNS o
. . o

Cost-effectiveness JJ o
analysis NN N
will MD N
also RB N
be VB N
performed VBN N
. . N

The DT N
outcomes NNS N
will MD N
be VB N
measured VBN N
by IN N
questionnaires NNS o
at IN N
baseline NN N
, , N
after IN N
6 CD N
, , N
12 CD N
, , N
and CC N
24 CD N
months NNS N
, , N
and CC N
sickness JJ o
absence NN o
will MD N
be VB N
obtained VBN N
from IN N
the DT N
employer NN N
's POS N
registers NNS N
. . N

DISCUSSION NNP N
No NNP N
trials NNS N
are VBP N
yet RB N
available JJ N
that WDT N
have VBP N
evaluated VBN N
the DT N
effectiveness NN N
of IN N
daily JJ i
physical JJ i
activity NN i
monitoring NN i
and CC i
distance NN i
counselling NN i
in IN N
an DT N
occupational JJ N
health NN N
setting NN N
over IN N
a DT N
12 CD N
month NN N
period NN N
and CC N
no DT N
data NN N
on IN N
cost-effectiveness NN o
of IN N
such JJ N
intervention NN N
are VBP N
available JJ N
. . N

TRIAL NNP N
REGISTRATION NNP N
ClinicalTrials.gov NNP N
identifier NN N
: : N
NCT00994565 NNP N
. . N

-DOCSTART- -12816740- O O

Antiinflammatory JJ o
effects NNS o
of IN N
the DT N
phosphodiesterase-4 JJ i
inhibitor NN i
cilomilast NN i
( ( i
Ariflo NNP i
) ) i
in IN N
chronic JJ p
obstructive JJ p
pulmonary JJ p
disease NN p
. . p

Cilomilast NNP i
( ( i
Ariflo NNP i
) ) i
, , N
a DT N
new JJ N
oral JJ i
phosphodiesterase-4 JJ i
selective JJ i
inhibitor NN i
, , N
improves VBZ N
lung JJ o
function NN o
in IN N
chronic JJ N
obstructive JJ N
pulmonary JJ N
disease NN N
( ( N
COPD NNP N
) ) N
. . N

We PRP N
have VBP N
evaluated VBN N
its PRP$ N
antiinflammatory JJ o
effects NNS o
in IN N
59 CD p
patients NNS p
with IN p
COPD NNP p
randomized VBD p
to TO N
receive VB N
cilomilast NN i
, , N
15 CD N
mg NN N
two CD N
times NNS N
a DT N
day NN N
, , N
or CC N
placebo NN i
for IN N
12 CD N
weeks NNS N
. . N

Induced NNP o
sputum JJ o
differential NN o
cell NN o
counts NNS o
were VBD N
obtained VBN N
at IN N
baseline NN N
and CC N
at IN N
five CD N
further JJ N
visits NNS N
. . N

Interleukin-8 NNP o
and CC o
neutrophil JJ o
elastase NN o
were VBD N
measured VBN N
in IN N
sputum NN N
supernatant NN N
. . N

Bronchial JJ N
biopsies NNS N
obtained VBN N
at IN N
baseline NN N
and CC N
at IN N
Week NNP N
10 CD N
were VBD N
immunostained VBN N
and CC N
counted VBN N
for IN N
neutrophils NNS o
, , o
CD8+ NNP o
and CC o
CD4+ NNP o
T-lymphocyte NNP o
subsets NNS o
, , o
and CC o
CD68+ NNP o
macrophages NNS o
. . o

Cells NNP N
expressing VBG N
the DT N
genes NNS o
for IN o
interleukin-8 NN o
and CC o
tumor NN o
necrosis NN o
factor-alpha NN o
were VBD N
identified VBN N
by IN N
in IN N
situ JJ N
hybridization NN N
and CC N
quantified VBD N
. . N

Compared VBN N
with IN N
placebo NN i
, , N
analysis NN N
of IN N
variance NN N
( ( N
ANOVA NNP N
) ) N
of IN N
the DT N
change NN N
from IN N
baseline NN N
showed VBD N
that IN N
cilomilast NN i
did VBD N
not RB N
alter VB N
any DT N
sputum JJ o
endpoint NN o
or CC o
FEV1 NNP o
. . o

However RB N
, , N
bronchial JJ N
biopsies NNS N
demonstrated VBD N
that IN N
cilomilast NN i
treatment NN N
was VBD N
associated VBN N
with IN N
reductions NNS o
in IN o
CD8+ NNP o
( ( N
p JJ N
= VBZ N
0.001 CD N
; : N
ANOVA NNP N
) ) N
and CC N
CD68+ NNP o
cells NNS o
( ( N
p JJ N
< VBZ N
0.05 CD N
; : N
ANOVA NNP N
) ) N
. . N

In IN N
addition NN N
, , N
by IN N
Poisson NNP N
analysis NN N
, , N
comparison NN N
of IN N
cell NN N
counts NNS N
analyzed VBN N
as IN N
a DT N
ratio NN N
of IN N
active JJ N
to TO N
placebo VB N
demonstrated JJ N
reductions NNS o
of IN o
CD8+ NNP o
( ( N
48 CD N
% NN N
p NN N
< NNP N
0.01 CD N
) ) N
and CC N
CD68+ NNP o
( ( N
47 CD N
% NN N
p NN N
= NNP N
0.001 CD N
) ) N
cells NNS N
. . N

This DT N
is VBZ N
the DT N
first JJ N
demonstration NN N
of IN N
reduction NN N
by IN N
any DT N
agent NN N
of IN N
airway JJ o
tissue NN o
inflammatory NN o
cells NNS o
characteristic JJ N
of IN N
COPD NNP N
. . N

Phosphodiesterase-4 JJ i
inhibitors NNS i
represent VBP N
a DT N
promising JJ N
new JJ N
class NN N
of IN N
substances NNS N
for IN N
use NN N
in IN N
antiinflammatory JJ N
treatment NN N
of IN N
this DT N
disease NN N
. . N

-DOCSTART- -12538218- O O

A DT N
comparison NN N
of IN N
the DT N
upper JJ i
lip NN i
bite JJ i
test NN i
( ( i
a DT i
simple JJ i
new JJ i
technique NN i
) ) i
with IN i
modified VBN i
Mallampati NNP i
classification NN i
in IN N
predicting VBG N
difficulty NN N
in IN N
endotracheal JJ o
intubation NN o
: : o
a DT N
prospective JJ N
blinded VBN N
study NN N
. . N

We PRP N
explored VBD N
the DT N
possibility NN N
that IN N
a DT N
simple JJ N
and CC N
single JJ N
test NN N
could MD N
replace VB N
the DT N
modified JJ N
Mallampati NNP o
score NN o
for IN N
either CC N
a DT N
difficult JJ N
or CC N
an DT N
unaccomplished JJ N
tracheal NN o
intubation NN o
in IN N
an DT N
impending JJ o
hypoxic NN o
patient NN p
. . p

Three CD p
hundred VBD p
adult NN p
patients NNS p
were VBD p
enrolled VBN p
in IN p
this DT p
study NN p
. . p

They PRP N
were VBD N
subjected VBN N
to TO N
the DT N
following JJ N
assessments NNS N
: : N
1 CD N
) ) N
oropharyngeal NN i
class NN i
according VBG i
to TO i
the DT i
modified VBN i
Mallampati NNP i
criteria NNS i
; : i
2 CD N
) ) N
the DT i
new JJ i
, , i
upper JJ i
lip NN i
bite IN i
criteria-class NN i
I PRP i
= VBP i
lower JJR i
incisors NNS i
can MD i
bite VB i
the DT i
upper JJ i
lip NN i
above IN i
the DT i
vermilion NN i
line NN i
, , i
class NN i
II NNP i
= NNP i
lower JJR i
incisors NNS i
can MD i
bite VB i
the DT i
upper JJ i
lip NN i
below IN i
the DT i
vermilion NN i
line NN i
, , i
and CC i
class NN i
III NNP i
= NNP i
lower JJR i
incisors NNS i
can MD i
not RB i
bite VB i
the DT i
upper JJ i
lip NN i
; : i
and CC i
3 CD N
) ) N
laryngeal NN i
view NN i
grading VBG i
according VBG i
to TO i
Cormack NNP o
's POS o
criteria NNS o
. . o

The DT N
incidence NN o
of IN o
difficult JJ o
intubation NN o
was VBD N
5.7 CD N
% NN N
. . N

The DT i
upper JJ o
lip NN o
bite NN o
test NN o
showed VBD N
significantly RB N
higher JJR N
specificity NN o
and CC o
accuracy NN o
than IN N
the DT N
modified JJ i
Mallampati NNP o
test NN o
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

Comparisons NNS N
of IN N
sensitivity NN o
, , o
positive JJ o
and CC o
negative JJ o
predictive NN o
values NNS o
, , N
between IN N
the DT N
two CD N
tests NNS N
, , N
however RB N
, , N
did VBD N
not RB N
reveal VB N
any DT N
significant JJ N
differences NNS N
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
. . N

In IN N
conclusion NN N
, , N
the DT N
upper JJ N
lip NN N
bite JJ N
test NN N
is VBZ N
an DT N
acceptable JJ N
option NN N
for IN N
predicting VBG N
difficult JJ p
intubation NN p
as IN N
a DT N
simple NN N
, , N
single JJ N
test NN N
. . N

-DOCSTART- -21787048- O O

A DT N
communication-based JJ i
intervention NN i
for IN N
nonverbal JJ p
children NNS p
with IN N
autism NN N
: : N
what WP N
changes NNS N
? . N
Who WP N
benefits NNS N
? . N
OBJECTIVE IN N
This DT N
article NN N
examines VBZ N
the DT N
form NN N
and CC N
function NN N
of IN N
spontaneous JJ N
communication NN N
and CC N
outcome NN N
predictors NNS N
in IN N
nonverbal JJ p
children NNS p
with IN p
autism NN p
following VBG p
classroom-based JJ i
intervention NN i
( ( i
Picture NNP i
Exchange NNP i
Communication NNP i
System NNP i
[ NNP i
PECS NNP i
] NNP i
training NN i
) ) i
. . N

METHOD $ N
84 CD p
children NNS p
from IN p
15 CD p
schools NNS p
participated VBN p
in IN p
a DT p
randomized NN p
controlled VBN p
trial NN p
( ( N
RCT NNP N
) ) N
of IN N
PECS NNP N
( ( N
P. NNP N
Howlin NNP N
, , N
R. NNP N
K. NNP N
Gordon NNP N
, , N
G. NNP N
Pasco NNP N
, , N
A NNP N
. . N

Wade NNP N
, , N
& CC N
T. NNP N
Charman NNP N
, , N
2007 CD N
) ) N
. . N

They PRP p
were VBD p
aged VBN p
4-10 JJ p
years NNS p
( ( p
73 CD p
boys NNS p
) ) p
. . p

Primary JJ N
outcome JJ N
measure NN N
was VBD N
naturalistic JJ o
observation NN o
of IN o
communication NN o
in IN N
the DT N
classroom NN N
. . N

Multilevel NNP N
Poisson NNP N
regression NN N
was VBD N
used VBN N
to TO N
test VB N
for IN N
intervention NN o
effects NNS o
and CC o
outcome JJ o
predictors NNS o
. . o

RESULTS NNP N
Spontaneous JJ o
communication NN o
using VBG o
picture NN o
cards NNS o
, , o
speech NN o
, , o
or CC o
both DT o
increased VBN N
significantly RB N
following VBG N
training NN N
( ( N
rate NN N
ratio NN N
[ NNP N
RR NNP N
] NNP N
=1.90 NNP N
, , N
95 CD N
% NN N
CI NNP N
[ NNP N
1.46 CD N
, , N
2.48 CD N
] NN N
, , N
p NN N
< NNP N
.001 NNP N
; : N
RR NNP N
= VBZ N
1.77 CD N
, , N
95 CD N
% NN N
CI NNP N
[ NNP N
1.35 CD N
, , N
2.32 CD N
] NN N
, , N
p NN N
< NNP N
.001 NNP N
; : N
RR NNP N
= VBZ N
3.74 CD N
, , N
95 CD N
% NN N
CI NNP N
[ NNP N
2.19 CD N
, , N
6.37 CD N
] NN N
, , N
p NN N
< NNP N
.001 NNP N
, , N
respectively RB N
) ) N
. . N

Spontaneous JJ o
communication NN o
to TO o
request VB o
objects NNS o
significantly RB N
increased VBD N
( ( N
RR NNP N
= NNP N
2.17 CD N
, , N
95 CD N
% NN N
CI NNP N
[ NNP N
1.75 CD N
, , N
2.68 CD N
] NN N
, , N
p NN N
< NNP N
.001 NNP N
) ) N
, , N
but CC N
spontaneous JJ N
requesting NN N
for IN N
social JJ N
purposes NNS N
did VBD N
not RB N
( ( N
RR NNP N
= NNP N
1.34 CD N
, , N
95 CD N
% NN N
CI NNP N
[ NNP N
0.83 CD N
, , N
2.18 CD N
] NN N
, , N
p NN N
= NNP N
.237 NNP N
) ) N
. . N

Only RB N
the DT N
effect NN N
on IN N
spontaneous JJ o
speech NN o
persisted VBN N
by IN N
follow-up NN N
( ( N
9 CD N
months NNS N
later RB N
) ) N
. . N

Less CC N
severe JJ o
baseline NN o
autism NN o
symptomatology NN o
( ( o
lower JJR o
Autism NNP o
Diagnosis NNP o
Observation NNP o
Schedule NNP o
[ NNP o
ADOS NNP o
] NNP o
score NN o
; : o
C. NNP N
Lord NNP N
et VBZ N
al. RB N
, , N
2000 CD N
) ) N
was VBD N
associated VBN N
with IN N
greater JJR N
increase NN N
in IN N
spontaneous JJ o
speech NN o
( ( N
RR NNP N
= NNP N
0.90 CD N
, , N
95 CD N
% NN N
CI NNP N
[ NNP N
0.83 CD N
, , N
0.98 CD N
] NN N
, , N
p NN N
= NNP N
.011 NNP N
) ) N
and CC N
less RBR N
severe JJ o
baseline NN o
expressive JJ o
language NN o
impairment NN o
( ( N
lower JJR N
ADOS NNP N
item NN N
A1 NNP N
score NN N
) ) N
, , N
with IN N
larger JJR N
increases NNS N
in IN N
spontaneous JJ o
use NN o
of IN o
speech NN o
and CC o
pictures VBZ o
together RB o
( ( N
RR NNP N
= NNP N
0.62 CD N
, , N
95 CD N
% NN N
CI NNP N
[ NNP N
0.44 CD N
, , N
0.88 CD N
] NN N
, , N
p NN N
= NNP N
.008 NNP N
) ) N
. . N

CONCLUSION NNP N
Overall NNP N
, , N
PECS NNP N
appeared VBD N
to TO N
enhance VB N
children NNS N
's POS N
spontaneous JJ N
communication NN N
for IN N
instrumental JJ N
requesting VBG N
using VBG N
pictures NNS N
, , N
speech NN N
, , N
or CC N
a DT N
combination NN N
of IN N
both DT N
. . N

Some DT N
effects NNS N
of IN N
training NN N
were VBD N
moderated VBN N
by IN N
baseline NN N
factors NNS N
. . N

For IN N
example NN N
, , N
PECS NNP i
appears VBZ N
to TO N
have VB N
increased VBN N
spontaneous JJ N
speech NN N
in IN N
children NNS p
who WP p
could MD p
talk VB p
a DT N
little JJ N
at IN N
baseline NN N
. . N

-DOCSTART- -8434135- O O

Effects NNS N
of IN N
reducing VBG i
dietary JJ i
[ NN i
( ( i
Na+ NNP i
+ NNP i
K+ NNP i
) ) i
- : i
( ( i
Cl- JJ i
+ NNP i
SO4= NNP i
) ) i
] NN i
on IN N
the DT N
rate NN N
of IN N
calcium NN N
mobilisation NN N
by IN N
dairy NN p
cows NNS p
at IN p
parturition NN p
. . p

The DT N
effects NNS N
of IN N
feeding VBG N
diets NNS N
with IN N
different JJ N
milliequivalents NNS N
( ( N
meq NN N
) ) N
of IN N
dietary JJ N
[ NNP i
( ( i
Na+ NNP i
+ NNP i
K+ NNP i
) ) i
- : i
( ( i
Cl- JJ i
+ NNP i
SO4= NNP i
) ) i
] VBP i
to TO N
dairy VB p
cows NNS p
during IN p
the DT p
last JJ p
seven CD p
weeks NNS p
of IN p
pregnancy NN p
on IN N
their PRP$ N
acid-base JJ N
status NN N
and CC N
calcium NN N
mobilisation NN N
rate NN N
around IN N
parturition NN N
were VBD N
studied VBN N
. . N

Ten CD p
monozygotic JJ p
twin NN p
pairs NNS p
of IN p
pregnant JJ p
cows NNS p
( ( p
five CD p
pairs NNS p
of IN p
parity NN p
1 CD p
or CC p
2 CD p
, , p
and CC p
five CD p
pairs NNS p
of IN p
parity NN p
3 CD p
or CC p
more JJR p
) ) p
were VBD N
allocated VBN N
to TO N
two CD N
diets NNS N
which WDT N
were VBD N
formulated VBN N
to TO N
provide VB N
either RB N
-4 JJ i
meq NN i
( ( i
anion NN i
diet NN i
) ) i
or CC i
+572.5 JJ i
meq NN i
( ( i
cation NN i
diet NN i
) ) i
of IN i
[ NN i
( ( i
Na+ NNP i
+ NNP i
K+ NNP i
) ) i
- : i
( ( i
Cl- JJ i
+ NNP i
SO4= NNP i
) ) i
] VBD i
kg-1 JJ i
dietary JJ i
dry JJ i
matter NN i
( ( i
DM NNP i
) ) i
. . i

The DT N
daily JJ N
rations NNS N
consisted VBD N
of IN N
4 CD N
kg NNS N
grass NN i
hay NN i
and CC i
7 CD N
kg NN N
concentrates NNS i
. . i

Changes NNS N
in IN N
meq NN N
of IN N
dietary JJ o
[ NNP o
( ( o
Na+ NNP o
+ NNP o
K+ NNP o
) ) o
- : o
( ( o
Cl- JJ o
+ NNP o
SO4= NNP o
) ) o
] NN o
were VBD N
achieved VBN N
by IN N
adding VBG N
KCl NNP i
, , i
K2SO4 NNP i
and CC i
( ( i
NH4 NNP i
) ) i
2SO4 CD i
( ( i
anion NN i
diet NN i
) ) i
or CC i
K2CO3 NNP i
( ( i
cation NN i
diet NN i
) ) i
to TO N
basal VB N
concentrates NNS N
. . N

Plasma NNP o
calcium NN o
concentration NN o
and CC o
blood NN o
acid-base JJ o
parameters NNS o
were VBD N
not RB N
affected VBN N
by IN N
dietary JJ N
treatment NN N
. . N

However RB N
, , N
urinary JJ o
calcium NN o
excretion NN o
was VBD N
markedly RB N
higher JJR N
and CC N
urinary JJ o
pH NN o
and CC o
bicarbonate NN o
excretion NN o
significantly RB N
lower JJR N
in IN N
cows NNS p
fed VBP p
the DT p
anion NN i
diet NN i
than IN N
in IN N
cows NNS p
fed VBP p
the DT p
cation NN i
diet NN i
. . i

The DT N
responses NNS N
to TO N
hypocalcaemia VB N
induced VBN N
by IN N
an DT N
intravenous JJ N
infusion NN N
of IN N
EDTA NNP N
solution NN N
were VBD N
similar JJ N
in IN N
the DT N
cows NNS N
fed VBP N
either DT N
diet NN N
. . N

-DOCSTART- -23713303- O O

[ JJ N
Efficacy NNP N
observation NN N
on IN N
chronic JJ o
tension-type JJ o
headache NN o
treated VBN N
with IN N
acupuncture NN N
at IN N
galea NN N
tendon-muscle NN N
node NN N
] NNP N
. . N

OBJECTIVE NNP N
To TO N
explore VB N
the DT N
better JJR N
therapy NN N
for IN N
chronic JJ o
tension-type JJ o
headache NN o
( ( o
CTTH NNP o
) ) o
. . o

METHODS NNP N
Two CD p
hundred VBD p
and CC p
eighty-eight JJ p
cases NNS p
were VBD N
randomized VBN N
into IN N
a DT N
sticking VBG i
needling NN i
group NN i
( ( i
150 CD i
cases NNS i
) ) i
and CC i
an DT i
acupuncture NN i
group NN i
( ( N
138 CD N
cases NNS N
) ) N
. . N

In IN N
the DT N
sticking VBG i
needling NN i
group NN N
, , N
the DT i
manual JJ i
sticking NN i
needling NN i
technique NN i
was VBD N
adopted VBN N
to TO N
stimulate VB N
the DT N
galea NN N
tendon-muscle NN N
node NN N
. . N

In IN N
the DT N
acupuncture NN N
group NN N
, , N
the DT N
conventional JJ i
acupuncture NN i
therapy NN i
was VBD i
applied VBN i
to TO N
Baihui NNP N
( ( N
GV NNP N
20 CD N
) ) N
, , N
Sishencong NNP N
( ( N
EX-HN NNP N
1 CD N
) ) N
, , N
Fengchi NNP N
( ( N
GB NNP N
20 CD N
) ) N
, , N
Taiyang NNP N
( ( N
EX-HN NNP N
5 CD N
) ) N
, , N
Touwei NNP N
( ( N
ST NNP N
18 CD N
) ) N
, , N
Hegu NNP N
( ( N
LI NNP N
4 CD N
) ) N
, , N
etc FW N
. . N

The DT N
treatment NN N
was VBD N
given VBN N
once RB N
a DT N
day NN N
, , N
and CC N
30 CD N
days NNS N
made VBD N
one CD N
session NN N
. . N

After IN N
two CD N
sessions NNS N
of IN N
treatment NN N
and CC N
after IN N
three CD N
months NNS N
follow-up RB N
, , N
CTTH NNP o
score NN o
( ( o
including VBG o
the DT o
score NN o
of IN o
headache NN o
attack NN o
frequency NN o
and CC o
the DT o
score NN o
of IN o
headache NN o
severity NN o
) ) o
was VBD N
observed VBN N
and CC N
compared VBN N
before IN N
and CC N
after IN N
treatment NN N
separately RB N
. . N

The DT N
efficacy NN o
was VBD N
evaluated VBN N
in IN N
two CD N
groups NNS N
. . N

RESULTS NNP N
CTTH NNP o
score NN o
was VBD N
all DT N
reduced VBN N
after IN N
treatment NN N
in IN N
the DT N
two CD N
groups NNS N
( ( N
both DT N
P NNP N
< NNP N
0.01 CD N
) ) N
, , N
the DT N
score NN o
in IN o
the DT o
sticking VBG o
needling VBG o
group NN o
was VBD N
lower JJR N
than IN N
that DT N
in IN N
the DT N
acupuncture NN i
group NN N
( ( N
2.38 CD N
+/- JJ N
1.22 CD N
vs JJ N
4.16 CD N
+/- JJ N
2.54 CD N
, , N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

The DT N
effective JJ o
rate NN o
was VBD N
97.3 CD N
% NN N
( ( N
146/150 CD N
) ) N
in IN N
the DT N
sticking VBG N
needling NN N
group NN N
, , N
which WDT N
was VBD N
better JJR N
than IN N
88.4 CD N
% NN N
( ( N
122/138 CD N
) ) N
in IN N
the DT N
acupuncture NN i
group NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

CONCLUSION VB N
The DT N
manual JJ i
sticking NN i
needling NN i
technique NN i
at IN N
galea JJ N
tendon-muscle JJ N
node NN N
achieves VBZ N
the DT N
superior JJ N
results NNS N
of IN N
reducing VBG o
the DT o
pain NN o
attack NN o
frequency NN o
and CC o
severity NN o
of IN o
CTTH NNP o
as IN N
compared VBN N
with IN N
the DT N
acupuncture NN N
therapy NN N
of IN N
the DT N
routine JJ N
acupoint NN N
selection NN N
. . N

-DOCSTART- -3896455- O O

A DT N
randomized JJ N
comparative JJ N
trial NN N
of IN N
combined JJ N
versus NN N
alternating VBG N
therapy NN N
with IN N
cytostatic JJ N
drugs NNS N
and CC N
high-dose JJ N
medroxyprogesteron NN N
acetate NN N
in IN N
advanced JJ p
breast NN p
cancer NN p
. . p

A DT N
prospective JJ N
multicenter NN N
trial NN N
was VBD N
conducted VBN N
in IN N
155 CD p
consecutive JJ p
patients NNS p
with IN p
Stage NNP p
IV NNP p
breast NN p
cancer NN p
randomly RB p
allocated VBN p
to TO p
receive VB p
either DT p
( ( p
1 CD p
) ) p
vincristin NN i
( ( i
V NNP i
) ) i
1.2 CD p
mg/m2 NN p
( ( p
maximum JJ p
dose NN p
, , p
2 CD p
mg NN p
) ) p
, , p
Adriamycin NNP i
( ( i
A NNP i
) ) i
( ( i
doxorubicin NN i
) ) i
40 CD p
mg/m2 NN p
, , p
and CC i
cyclophosphamide NN i
( ( i
C NNP i
) ) i
500 CD p
mg/m2 NN p
, , p
all DT p
intravenously RB p
on IN p
day NN p
1 CD p
, , p
every DT p
4 CD p
weeks NNS p
, , p
in IN p
combination NN p
with IN p
medroxyprogesteron NN i
acetate NN i
( ( i
MPA NNP i
) ) i
600 CD p
mg NN p
orally RB p
on IN p
days NNS p
1 CD p
through IN p
14 CD p
, , p
500 CD p
mg NNS p
intramuscularly RB p
on IN p
days NNS p
1 CD p
through IN p
28 CD p
, , p
and CC p
twice RB p
weekly JJ p
afterwards NNS p
( ( p
combined VBN p
chemoendocrine NN p
approach NN p
) ) p
or CC p
( ( p
2 CD p
) ) p
the DT p
same JJ p
combination NN p
chemotherapy NN p
( ( p
VAC NNP p
) ) p
for IN p
three CD p
cycles NNS p
alternating VBG p
with IN p
MPA NNP p
in IN p
the DT p
above-mentioned JJ p
dosage NN p
during IN p
8 CD p
weeks NNS p
( ( p
alternating VBG p
chemoendocrine VB p
approach NN p
) ) p
. . N

Results NNP N
show VBP N
an DT N
overall JJ o
response NN o
rate NN o
of IN N
73 CD N
% NN N
with IN N
26 CD N
% NN N
complete JJ N
responses NNS N
in IN N
the DT N
combined JJ N
treatment NN N
arm NN N
, , N
whereas NNS N
in IN N
the DT N
alternating NN N
arm NN N
, , N
an DT N
overall JJ o
response NN o
rate NN o
of IN N
76 CD N
% NN N
with IN N
20 CD N
% NN N
complete JJ N
responses NNS N
was VBD N
observed VBN N
. . N

In IN N
patients NNS p
with IN p
more JJR p
than IN p
one CD p
metastatic JJ p
site NN p
, , N
response NN o
rate NN o
was VBD N
higher RBR N
in IN N
the DT N
combination NN N
treatment NN N
, , N
and CC N
only RB N
in IN N
this DT N
arm NN N
were VBD N
complete JJ N
responses NNS N
observed VBN N
in IN N
these DT N
patients NNS N
. . N

Although IN N
the DT N
median JJ o
duration NN o
of IN o
response NN o
was VBD o
long RB o
in IN N
both DT N
treatment NN N
arms NNS N
( ( N
combination NN N
, , N
19 CD N
months NNS N
versus IN N
alternating VBG N
, , N
21 CD N
months NNS N
) ) N
, , N
the DT N
median JJ N
overall JJ o
survival NN o
in IN N
both DT N
groups NNS N
was VBD N
not RB N
definitely RB N
prolonged VBN N
( ( N
22 CD N
versus NN N
24 CD N
months NNS N
, , N
respectively RB N
) ) N
. . N

However RB N
, , N
results NNS N
in IN N
subsets NNS N
of IN N
patients NNS N
suggest VBP N
that IN N
the DT N
alternating VBG N
chemoendocrine JJ N
approach NN N
may MD N
be VB N
better JJR N
for IN N
estrogen NN p
receptor NN p
( ( p
ER NNP p
) ) p
-negative JJ p
patients NNS p
, , N
for IN N
patients NNS p
younger JJR p
than IN p
51 CD p
years NNS p
of IN p
age NN p
, , N
and CC N
for IN N
patients NNS p
with IN p
a DT p
disease-free JJ p
interval NN p
of IN p
1 CD p
year NN p
or CC p
less JJR p
. . p

Patients NNS p
with IN p
these DT p
parameters NNS p
probably RB p
belong RB p
to TO p
the DT p
same JJ p
population NN p
. . p

It PRP N
is VBZ N
concluded VBN N
that IN N
combination NN o
of IN o
chemotherapy NN o
and CC o
high-dose JJ o
MPA NNP o
may MD o
be VB o
indicated VBN o
in IN o
ER-positive JJ o
patients NNS o
when WRB N
a DT N
clinical JJ N
response NN N
is VBZ N
urgently RB N
needed VBN N
. . N

In IN N
ER-negative JJ N
patients NNS N
, , N
the DT N
alternating VBG N
use NN N
of IN N
both DT N
treatment NN N
modalities VBZ N
deserves VBZ N
further JJ N
investigation NN N
. . N

-DOCSTART- -25229605- O O

Acute JJ N
effects NNS N
of IN N
static JJ i
active JJ i
or CC i
dynamic JJ i
active JJ i
stretching VBG i
on IN N
eccentric-exercise-induced JJ o
hamstring NN o
muscle NN o
damage NN o
. . o

OBJECTIVES UH N
To TO N
examine VB N
whether IN N
an DT N
acute NN N
bout NN N
of IN N
active JJ i
or CC i
dynamic JJ i
hamstring-stretching JJ i
exercises NNS i
would MD N
reduce VB N
the DT N
amount NN N
of IN N
muscle NN N
damage NN N
observed VBD N
after IN N
a DT N
strenuous JJ N
eccentric JJ N
task NN N
and CC N
to TO N
determine VB N
whether IN N
the DT N
stretching NN N
protocols VBZ N
elicit JJ N
similar JJ N
responses NNS N
. . N

DESIGN VB N
A DT N
randomized NN N
controlled VBD N
clinical JJ N
trial NN N
. . N

METHODS NNP N
Thirty-six NNP p
young JJ p
male NN p
students NNS p
performed VBD p
5 CD p
min NN p
of IN p
jogging NN i
as IN p
a DT p
warm-up JJ p
and CC p
were VBD p
allocated VBN p
to TO p
1 CD p
of IN p
3 CD p
groups NNS p
: : p
3 CD i
min NN i
of IN i
static JJ i
active JJ i
stretching NN i
( ( i
SAS NNP i
) ) i
, , i
3 CD i
min NN i
of IN i
dynamic JJ i
active JJ i
stretching NN i
( ( i
DAS NNP i
) ) i
, , i
or CC i
control NN i
( ( i
CON NNP i
) ) i
. . i

All DT N
subjects NNS p
performed VBN p
eccentric JJ i
exercise NN i
immediately RB p
after IN p
stretching VBG p
. . p

Heart NNP N
rate NN N
, , N
core NN N
temperature NN N
, , N
maximal JJ N
voluntary JJ N
isometric JJ N
contraction NN N
, , N
passive JJ N
hip NN N
flexion NN N
, , N
passive JJ N
hamstring NN N
stiffness NN N
( ( N
PHS NNP N
) ) N
, , N
plasma JJ N
creatine JJ N
kinase NN N
activity NN N
, , N
and CC N
myoglobin NNS N
were VBD N
recorded VBN N
at IN N
prestretching NN N
, , N
at IN N
poststretching NN N
, , N
and CC N
every DT N
day NN N
after IN N
the DT N
eccentric JJ N
exercises NNS N
for IN N
5 CD N
d. NN N
RESULTS NNP N
After IN N
stretching VBG i
, , N
the DT N
change NN o
in IN o
hip NN o
flexion NN o
was VBD N
significantly RB N
higher JJR N
in IN N
the DT N
SAS NNP i
( ( N
5? CD N
) ) N
and CC i
DAS NNP i
( ( N
10.8? CD N
) ) N
groups NNS N
than IN N
in IN N
the DT i
CON NNP i
( ( i
-4.1? NNP N
) ) N
group NN N
. . N

The DT N
change NN N
in IN N
PHS NNP o
was VBD o
significantly RB N
higher JJR N
in IN N
the DT N
DAS NNP i
( ( i
5.6 CD i
% NN N
) ) N
group NN N
than IN N
in IN N
the DT N
CON NNP i
( ( i
-5.7 NNP i
% NN N
) ) N
and CC N
SAS NNP N
( ( N
-6.7 NNP N
% NN N
) ) N
groups NNS N
. . N

Furthermore NNP o
, , o
changes NNS o
in IN o
muscle-damage NN o
markers NNS o
were VBD o
smaller JJR N
in IN N
the DT N
SAS NNP i
group NN i
than IN N
in IN N
the DT N
DAS NNP i
and CC i
CON NNP i
groups NNS i
. . N

CONCLUSIONS NNP N
Prior NNP N
active JJ N
stretching NN N
could MD N
be VB N
useful JJ N
for IN N
attenuating VBG N
the DT N
symptoms NNS N
of IN N
muscle NN N
damage NN N
after IN N
eccentric JJ N
exercise NN i
. . i

SAS NNP i
is VBZ i
recommended VBN N
over RP i
DAS NNP i
as IN i
a DT N
stretching VBG N
protocol NN N
in IN N
terms NNS N
of IN N
strength NN N
, , N
hamstring VBG N
range NN N
of IN N
motion NN N
, , N
and CC N
damage NN N
markers NNS N
. . N

-DOCSTART- -25842725- O O

1H CD N
nuclear JJ N
magnetic JJ N
resonance-based JJ N
metabolomic NN N
study NN N
on IN N
efficacy NN o
of IN N
Qingrehuatan NNP i
decoction NN i
against IN N
abundant JJ N
phlegm-heat JJ N
syndrome NN N
in IN N
young JJ p
adults NNS p
with IN p
essential JJ p
hypertension NN p
. . p

OBJECTIVE UH N
To TO N
observe VB N
the DT N
influence NN N
of IN N
Qingrehuatan NNP i
decoction NN i
( ( i
QRHT NNP i
) ) i
on IN N
serum NN o
metabolic NN o
profile NN o
in IN N
young JJ p
essential JJ p
hypertension NN p
( ( p
YEH NNP p
) ) p
patients NNS p
with IN p
abundant JJ p
phlegm-heat JJ p
syndrome NN p
and CC N
provide VB N
a DT N
basis NN N
for IN N
treatment NN N
with IN N
the DT N
decoction NN N
. . N

METHODS NNP N
Twelve NNP p
male NN p
YEH NNP p
patients NNS p
were VBD p
randomly RB p
selected VBN p
and CC p
serum JJ p
samples NNS p
were VBD p
collected VBN p
for IN p
examination NN p
before IN p
and CC p
after IN p
4 CD p
weeks NNS p
of IN p
the DT p
treatment NN p
with IN p
QRHT NNP i
. . i

Twelve NNP p
healthy JJ p
males NNS p
were VBD p
randomly RB p
selected VBN p
and CC p
their PRP$ p
serum NN p
samples NNS p
were VBD p
collected VBN p
as IN p
a DT p
control NN p
. . p

All DT N
serum NN N
samples NNS N
were VBD N
detected VBN N
using VBG N
metabolomic JJ N
technology NN N
with IN N
1H CD N
nuclear JJ N
magnetic JJ N
resonance NN N
. . N

Differences NNS N
in IN N
metabolites NNS N
were VBD N
studied VBN N
by IN N
principal JJ N
component NN N
analysis NN N
and CC N
partial JJ N
least JJS N
squares-discriminate JJ N
analysis NN N
, , N
which WDT N
produced VBD N
scores NNS N
and CC N
loadings NNS N
plots NNS N
. . N

RESULTS NNP N
After IN N
4 CD N
weeks NNS N
of IN N
treatment NN N
, , N
serum NN N
substances NNS N
could MD N
be VB N
distinguished VBN N
between IN N
the DT N
YEH NNP N
patients NNS N
with IN N
abundant JJ N
phlegm-heat JJ N
syndrome NN N
and CC N
the DT N
control NN N
patients NNS N
. . N

The DT N
specific JJ N
serum NN o
endog- JJ o
enous JJ o
metabolites NNS o
tended VBD N
to TO N
improve VB N
after IN N
the DT N
treatment NN N
. . N

QRHT CC i
can MD N
appropriately RB N
increase VB N
the DT N
levels NNS o
of IN o
glucose NN o
, , o
lactic JJ o
acid NN o
, , o
citric JJ o
acid NN o
, , o
high-density NN o
lipoprotein NN o
, , o
phosphatidylcholine NN o
, , o
glycerophosphate JJ o
choline NN o
, , o
hydroxybutyrate NN o
, , o
alanine NN o
, , o
and CC o
glutamate NN o
. . o

QRHT NNP i
could MD N
also RB N
decrease VB N
the DT N
levels NNS o
of IN o
low-density JJ o
lipoprotein/very JJ o
low-density NN o
lipoprotein NN o
, , o
lipids NNS o
, , o
N-acetyl NNP o
glycoprotein NN o
, , o
and CC o
O-acetyl NNP o
glycoprotein NN o
. . o

CONCLUSION NNP N
QRHT NNP N
can MD N
effectively RB N
ameliorate VB N
metabolic JJ o
disorders NNS o
in IN N
YEH NNP N
Patients NNPS N
with IN N
abundant JJ N
phlegm-heat JJ N
syndrome NN N
. . N

1H CD N
NMR-based JJ N
metabolomic JJ N
technology NN N
can MD N
provide VB N
an DT N
objective JJ N
basis NN N
for IN N
the DT N
treatment NN N
of IN N
YEH NNP p
patients NNS p
with IN p
abundant JJ p
phlegm-heat JJ p
syndrome NN p
using VBG N
QRHT NNP i
. . i

-DOCSTART- -19199847- O O

Development NNP N
of IN N
a DT N
telehealth NN i
intervention NN i
for IN N
head NN p
and CC p
neck NN p
cancer NN p
patients NNS p
. . p

Treatment NNP N
for IN N
head NN p
and CC p
neck NN p
cancer NN p
precipitates VBZ N
a DT N
myriad NN N
of IN N
distressing VBG N
symptoms NNS N
. . N

Patients NNS N
may MD N
be VB N
isolated VBN N
both DT N
physically RB N
and CC N
socially RB N
and CC N
may MD N
lack VB N
the DT N
self-efficacy NN N
to TO N
report VB N
problems NNS N
and CC N
participate VB N
as IN N
partners NNS N
in IN N
their PRP$ N
care NN N
. . N

The DT N
goal NN N
of IN N
this DT N
project NN N
was VBD N
to TO N
design VB N
a DT N
telehealth NN i
intervention NN i
to TO N
address VB N
such JJ N
isolation NN N
, , N
develop VB N
patient JJ N
self-efficacy NN N
, , N
and CC N
improve VB N
symptom JJ N
management NN N
during IN N
the DT N
treatment NN N
experience NN N
. . N

Participatory NNP N
action NN N
research NN N
and CC N
a DT N
review NN N
of IN N
the DT N
literature NN N
were VBD N
used VBN N
to TO N
develop VB N
electronically RB N
administered VBN N
symptom JJ N
management NN N
algorithms NN N
addressing VBG N
all DT N
major JJ N
symptoms NNS N
experienced VBN N
by IN N
patients NNS p
undergoing VBG p
treatment NN p
for IN p
head NN p
and CC p
neck NN p
cancers NNS p
. . p

Daily JJ N
questions NNS N
and CC N
related JJ N
messages NNS N
were VBD N
then RB N
programmed VBN N
into IN N
an DT N
easy-to-use JJ N
telehealth NN N
messaging NN N
device NN N
, , N
the DT N
Health NNP i
Buddy NNP i
( ( i
R NNP i
) ) i
. . N

Clinician JJ o
and CC o
patient JJ o
acceptance NN o
, , o
feasibility NN o
, , o
and CC o
technology NN o
issues NNS o
were VBD N
measured VBN N
. . N

Using VBG N
participatory JJ N
action NN N
research NN N
is VBZ N
an DT N
effective JJ N
means NNS N
for IN N
developing VBG N
electronic JJ N
algorithms NN N
acceptable JJ N
to TO N
both DT N
clinicians NNS N
and CC N
patients NNS N
. . N

The DT N
use NN N
of IN N
a DT N
simple JJ N
tele-messaging JJ N
device NN N
as IN N
an DT N
adjunct NN N
to TO N
symptom VB N
management NN N
is VBZ N
feasible JJ o
, , o
affordable JJ o
, , o
and CC o
acceptable JJ o
to TO N
patients NNS N
. . N

This DT N
telehealth NN i
intervention NN i
provides VBZ N
support NN N
and CC N
education NN N
to TO N
patients NNS p
undergoing VBG p
treatment NN p
for IN p
head NN p
and CC p
neck NN p
cancers NNS p
. . p

-DOCSTART- -21432861- O O

Quantification NN N
of IN N
cyproheptadine NN i
in IN p
human JJ p
plasma NN p
by IN N
high-performance NN N
liquid NN N
chromatography NN N
coupled VBD N
to TO N
electrospray VB N
tandem JJ N
mass NN N
spectrometry NN N
in IN N
a DT N
bioequivalence NN N
study NN N
. . N

A DT N
rapid JJ N
, , N
sensitive JJ N
and CC N
specific JJ N
method NN N
to TO N
quantify VB N
cyproheptadine NN i
in IN N
human JJ N
plasma NN N
using VBG N
amitriptyline NN N
as IN N
the DT N
internal JJ N
standard NN N
( ( N
IS NNP N
) ) N
is VBZ N
described VBN N
. . N

The DT N
analyte NN p
and CC p
the DT p
IS NNP p
were VBD N
extracted VBN N
from IN N
plasma NN N
by IN N
liquid-liquid JJ N
extraction NN N
using VBG N
a DT N
diethyl-ether/dichloromethane NN N
( ( N
70/30 CD N
; : N
v/v NN N
) ) N
solvent NN N
. . N

After IN N
removing VBG N
and CC N
drying VBG N
the DT N
organic JJ p
phase NN p
, , N
the DT N
extracts NNS N
were VBD N
reconstituted VBN N
with IN N
a DT N
fixed JJ N
volume NN N
of IN N
acetonitrile/water NN N
( ( N
50/50 CD N
v/v NN N
) ) N
+0.1 CD N
% NN N
of IN N
acetic JJ N
acid NN N
. . N

The DT N
extracts NNS N
were VBD N
analyzed VBN N
by IN N
high JJ N
performance NN N
liquid NN N
chromatography NN N
coupled VBD N
to TO N
electrospray VB N
tandem JJ N
mass NN N
spectrometry NN N
( ( N
LC-MS/MS NNP N
) ) N
. . N

Chromatography NNP i
was VBD N
performed VBN N
isocratically RB N
using VBG N
an DT N
Alltech NNP N
Prevail NNP N
C18 NNP N
5 CD N
?m NNP N
analytical JJ N
column NN N
, , N
( ( N
150 CD N
mm NN N
x VBD N
4.6 CD N
mm NNS N
I.D. NNP N
) ) N
. . N

The DT N
method NN N
had VBD N
a DT N
chromatographic JJ N
run NN N
time NN N
of IN N
4 CD N
min NNS N
and CC N
a DT N
linear JJ N
calibration NN N
curve NN N
ranging VBG N
from IN N
0.05 CD N
to TO N
10 CD N
ng/mL NNS N
( ( N
r2 VB N
> RB N
0.99 CD N
) ) N
. . N

The DT N
limit NN N
of IN N
quantification NN N
was VBD N
0.05 CD N
ng/mL RB N
. . N

This DT N
HPLC/MS/MS NNP N
procedure NN N
was VBD N
used VBN N
to TO N
assess VB N
the DT N
bioequivalence NN N
of IN N
cyproheptadine NN N
in IN N
two CD N
cyproheptadine NN N
+ NNS N
cobamamide VBP N
( ( N
4 CD N
mg NN N
+ VBD N
1 CD N
mg NN N
) ) N
tablet NN N
formulations NNS N
( ( N
Cobactin? NNP N
[ NNP N
cyproheptadine NN N
+ NNP N
cobamamide NN N
] NNP N
test NN N
formulation NN N
supplied VBN N
from IN N
Zambon NNP N
Laborat?rios NNP N
Farmac?uticos NNP N
Ltda NNP N
. . N

and CC N
Cobavital? NNP N
from IN N
Solvay NNP N
Farma NNP N
( ( N
standard JJ N
reference NN N
formulation NN N
) ) N
) ) N
. . N

A DT N
single JJ N
4 CD N
mg NN N
+ VBD N
1 CD N
mg NN N
[ NNP N
cyproheptadine NN N
+ NNP N
cobamamide NN N
] NNP N
dose NN N
of IN N
each DT N
formulation NN N
was VBD N
administered VBN N
to TO p
healthy JJ p
volunteers NNS p
. . p

The DT p
study NN p
was VBD N
conducted VBN N
using VBG N
an DT N
open JJ N
, , N
randomized VBN N
, , N
two-period JJ N
crossover NN N
design NN N
with IN N
a DT N
1-week JJ N
washout NN N
interval NN N
. . N

Since IN N
the DT o
90 CD o
% NN o
CI NNP o
for IN o
Cmax NNP o
and CC o
AUCs NNP o
ratios NNS o
were VBD N
all DT N
within IN N
the DT N
80-125 JJ N
% NN N
bioequivalence NN N
limit NN N
proposed VBN N
by IN N
the DT N
US NNP N
Food NNP N
and CC N
Drug NNP N
Administration NNP N
, , N
it PRP N
was VBD N
concluded VBN N
that IN N
the DT N
cyproheptadine JJ N
test NN N
formulation NN N
( ( N
Cobactin? NNP N
) ) N
is VBZ N
bioequivalent JJ N
to TO N
the DT N
Cobavital? NNP N
formulation NN N
for IN N
both DT N
the DT N
rate NN N
and CC N
the DT N
extent NN N
of IN N
absorption NN N
of IN i
cyproheptadine NN i
. . i

-DOCSTART- -16181530- O O

[ JJ N
Effect NNP N
of IN N
Yufeining VBG i
on IN N
induced JJ N
sputum JJ o
interleukin-8 NN o
in IN N
patients NNS p
with IN p
chronic JJ p
obstructive JJ p
pulmonary JJ p
disease NN p
at IN p
the DT p
stable JJ p
phase NN p
] NNP p
. . p

OBJECTIVE NNP N
To TO N
evaluate VB N
the DT N
effect NN N
of IN N
Yufeining NNP i
, , N
a DT N
traditional JJ N
Chinese JJ N
medicine NN N
, , N
on IN N
induced JJ o
sputum NN o
interleukin-8 JJ o
( ( o
IL-8 NNP o
) ) o
in IN N
patients NNS p
with IN p
chronic JJ p
obstructive JJ p
pulmonary JJ p
disease NN p
( ( p
COPD NNP p
) ) p
at IN p
the DT p
stable JJ p
phase NN p
. . p

METHODS NNP N
Thirty-six JJ p
patients NNS p
with IN p
COPD NNP p
were VBD N
divided VBN N
into IN N
trial NN N
group NN N
( ( N
18 CD N
cases NNS N
) ) N
and CC N
control NN N
group NN N
( ( N
18 CD N
cases NNS N
) ) N
randomly RB N
. . N

The DT N
trial NN N
group NN N
was VBD N
treated VBN N
with IN N
Yufeining VBG i
pills NNS i
taken VBN N
orally RB N
for IN N
half PDT N
a DT N
year NN N
; : N
the DT N
control NN i
group NN i
was VBD i
not RB i
given VBN i
any DT i
medicine NN i
. . i

Routine NNP N
lung NN o
function NN o
was VBD N
recorded VBN N
before IN N
and CC N
after IN N
treatment NN N
. . N

Total JJ o
cell NN o
count NN o
( ( o
TCC NNP o
) ) o
, , o
differential JJ o
cell NN o
counts NNS o
( ( o
DCCs NNP o
) ) o
and CC o
IL-8 NNP o
in IN o
induced JJ o
sputum NN o
were VBD N
determined VBN N
at IN N
the DT N
baseline NN N
and CC N
6 CD N
months NNS N
later RB N
. . N

RESULTS VB N
The DT N
indices NNS o
of IN o
lung NN o
function NN o
improved VBD N
significantly RB N
after IN N
6 CD N
months NNS N
' POS N
treatment NN N
in IN N
trial NN N
group NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
; : N
TCC NNP o
and CC o
absolute JJ o
neutrophil NN o
count NN o
decreased VBD N
significantly RB N
compared VBN N
with IN N
baseline NN N
in IN N
the DT N
trial NN N
group NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
; : N
Sputum NNP o
IL-8 NNP o
concentration NN o
dropped VBD N
significantly RB N
after IN N
6 CD N
months NNS N
' POS N
treatment NN N
, , N
from IN N
a DT N
mean NN N
of IN N
5.216 CD N
+/- JJ N
2.914 CD N
microg/L NN N
to TO N
4.222 CD N
+/- JJ N
2.140 CD N
microg/L NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

There EX N
were VBD N
insignificant JJ N
changes NNS N
in IN N
the DT N
parameters NNS o
in IN N
the DT N
control NN N
group NN N
between IN N
baseline NN N
and CC N
6 CD N
months NNS N
later RB N
. . N

CONCLUSION NNP N
Yufeining NNP N
could MD N
improve VB N
lung NN o
function NN o
, , N
decrease NN N
sputum NN o
TCC NNP o
, , o
absolute JJ o
neutrophil NN o
count NN o
and CC o
IL-8 NNP o
concentration NN o
, , N
and CC N
relieve VB N
airway NN o
inflammation NN o
in IN N
patients NNS p
with IN p
COPD NNP p
in IN p
the DT p
stable JJ p
phase NN p
. . p

-DOCSTART- -10348763- O O

Amphotericin NNP i
B NNP i
in IN p
children NNS p
with IN p
malignant JJ p
disease NN p
: : p
a DT N
comparison NN N
of IN N
the DT N
toxicities NNS N
and CC N
pharmacokinetics NNS N
of IN N
amphotericin NN i
B NNP i
administered VBN i
in IN i
dextrose JJ i
versus NN i
lipid JJ i
emulsion NN i
. . i

In IN N
a DT N
prospective JJ N
, , N
randomized JJ N
clinical JJ N
trial NN N
, , N
the DT N
toxicity NN N
of IN N
1 CD N
mg NN N
of IN N
amphotericin NN i
B NNP i
( ( i
AmB NNP i
) ) i
per IN N
kg NN N
of IN N
body NN N
weight JJ N
per IN N
day NN N
infused VBN N
in IN N
5 CD N
% NN N
dextrose NN i
was VBD N
compared VBN N
with IN N
that DT N
of IN N
AmB NNP i
infused VBD i
in IN i
lipid JJ i
emulsion NN i
in IN N
children NNS p
with IN p
malignant JJ p
disease NN p
. . p

In IN N
an DT N
analysis NN N
of IN N
82 CD p
children NNS p
who WP p
received VBD p
a DT p
full JJ p
course NN p
of IN p
6 CD p
days NNS p
or CC p
more JJR p
of IN p
AmB NNP i
( ( p
117 CD p
courses NNS p
) ) p
, , N
it PRP N
was VBD N
shown VBN N
that IN N
there EX N
were VBD N
significant JJ N
increases NNS N
in IN N
plasma JJ N
urea JJ N
and CC N
creatinine JJ N
concentrations NNS N
and CC N
in IN N
potassium NN N
requirement NN N
after IN N
6 CD N
days NNS N
of IN N
therapy NN N
with IN N
both DT N
AmB NNP i
infused VBN N
in IN N
dextrose NN i
and CC N
AmB NNP i
infused VBD N
in IN N
lipid JJ i
emulsion NN i
, , N
with IN N
there EX N
being VBG N
no DT N
difference NN N
between IN N
the DT N
two CD N
methods NNS N
of IN N
AmB NNP i
administration NN N
. . N

An DT N
intent-to-treat JJ N
comparison NN N
of IN N
the DT N
numbers NNS N
of IN N
courses NNS N
affected VBN N
by IN N
acute JJ N
toxicity NN N
( ( N
fever NN N
, , N
rigors NNS N
) ) N
and CC N
chronic JJ N
toxicity NN N
( ( N
nephrotoxicity NN N
) ) N
also RB N
indicated VBD N
that IN N
there EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
AmB NNP i
infused VBD i
in IN i
dextrose NN i
( ( N
78 CD N
courses NNS N
) ) N
and CC N
AmB NNP i
infused VBD i
in IN i
lipid JJ i
emulsion NN i
( ( N
84 CD N
courses NNS N
) ) N
. . N

The DT N
pharmacokinetics NNS o
of IN o
AmB NNP o
were VBD N
investigated VBN N
in IN N
20 CD N
children NNS N
who WP N
received VBD N
AmB NNP i
in IN i
dextrose NN i
and CC N
15 CD N
children NNS N
who WP N
received VBD N
AmB NNP i
in IN i
lipid JJ i
emulsion NN i
. . i

Blood NN N
samples NNS N
were VBD N
collected VBN N
up RB N
to TO N
24 CD N
h NN N
after IN N
administration NN N
of IN N
the DT N
first JJ N
dose NN N
, , N
and CC N
the DT N
concentration NN o
of IN o
AmB NNP o
in IN o
plasma NN o
was VBD N
analyzed VBN N
by IN N
a DT N
high-performance NN N
liquid NN N
chromatography NN N
assay NN N
. . N

The DT N
clearance NN o
( ( o
CL NNP o
) ) o
of IN o
AmB NNP o
in IN o
dextrose NN o
( ( N
0.039 CD N
+/- JJ N
0.016 CD N
liter NN N
. . N

h-1 NN N
. . N

kg-1 NN N
) ) N
was VBD N
significantly RB N
lower JJR N
( ( N
P NNP N
< NNP N
0.005 CD N
) ) N
than IN N
the DT N
CL NNP N
of IN N
AmB NNP i
in IN i
lipid JJ i
emulsion NN i
( ( N
0.062 CD N
+/- JJ N
0 CD N
. . N

024 CD N
liter NN N
. . N

h-1 NN N
. . N

kg-1 NN N
) ) N
. . N

The DT N
steady-state JJ o
volume NN o
of IN o
distribution NN o
for IN o
AmB NNP o
in IN N
dextrose NN N
( ( N
0.83 CD N
+/- JJ N
0.33 CD N
liter NN N
. . N

kg-1 NN N
) ) N
was VBD N
also RB N
significantly RB N
lower JJR N
( ( N
P NNP N
< NNP N
0.005 CD N
) ) N
than IN N
that DT N
for IN N
AmB NNP i
in IN i
lipid JJ i
emulsion NN i
( ( N
1.47 CD N
+/- JJ N
0.77 CD N
liter NN N
. . N

kg-1 NN N
) ) N
. . N

Although IN N
AmB NNP o
in IN o
lipid JJ o
emulsion NN o
is VBZ N
apparently RB N
cleared VBN N
faster RBR N
and CC N
distributes VBZ N
more RBR N
widely RB N
than IN N
AmB NNP o
in IN o
dextrose NN o
, , N
this DT N
study NN N
did VBD N
not RB N
reveal VB N
any DT N
significant JJ N
advantage NN N
with IN N
respect NN N
to TO N
safety NN o
and CC o
tolerance NN o
in IN N
the DT N
administration NN N
of IN N
AmB NNP i
in IN i
lipid JJ i
emulsion NN i
compared VBN N
to TO N
its PRP$ N
administration NN N
in IN N
dextrose NN i
in IN N
children NNS p
with IN p
malignant JJ p
disease NN p
. . p

-DOCSTART- -25481453- O O

Lifetime NNP N
history NN N
of IN N
heroin NN N
use NN N
is VBZ N
associated VBN N
with IN N
greater JJR N
drug NN N
severity NN N
among IN N
prescription NN p
opioid NN p
abusers NNS p
. . p

BACKGROUND NNP N
While IN N
research NN N
suggests VBZ N
primary JJ N
prescription NN N
opioid NN N
( ( N
PO NNP N
) ) N
abusers NNS N
may MD N
exhibit VB N
less JJR N
severe JJ N
demographic JJ N
and CC N
drug NN N
use NN N
characteristics NNS N
than IN N
primary JJ N
heroin NN N
abusers NNS N
, , N
less CC N
is VBZ N
known VBN N
about IN N
whether IN N
a DT N
lifetime JJ N
history NN N
of IN N
heroin NN N
use NN N
confers NNS N
greater JJR N
severity NN N
among IN N
PO NNP N
abusers NNS N
. . N

OBJECTIVE NN N
In IN N
this DT N
secondary JJ N
analysis NN N
, , N
we PRP N
examined VBD N
demographic JJ N
and CC N
drug NN N
use NN N
characteristics NNS N
as IN N
a DT N
function NN N
of IN N
lifetime NN N
heroin NN N
use NN N
among IN N
89 CD p
PO-dependent JJ p
adults NNS p
screened VBD p
for IN p
a DT p
trial NN p
evaluating VBG p
the DT p
relative JJ p
efficacy NN p
of IN p
buprenorphine NN p
taper NN p
durations NNS p
. . p

Exploratory NN N
analyses NNS N
also RB N
examined VBD N
contribution NN N
of IN N
lifetime NN N
heroin NN N
use NN N
to TO N
treatment NN N
response NN N
among IN N
a DT N
subset NN N
of IN N
participants NNS N
who WP N
received VBD N
a DT N
uniform JJ N
set NN N
of IN N
study NN N
procedures NNS N
. . N

METHODS NNP N
Baseline NNP N
characteristics NNS N
were VBD N
compared VBN N
between IN N
participants NNS p
reporting VBG p
lifetime NN p
heroin NN p
use NN p
?5 NNP p
( ( p
H NNP p
( ( p
+ NNP p
) ) p
; : p
n=41 CC p
) ) p
vs. FW p
< $ p
5 CD N
( ( p
H NNP p
( ( p
- : p
) ) p
; : p
n=48 CC p
) ) p
times NNS p
. . p

Treatment JJ N
response NN N
( ( N
i.e. FW N
, , N
illicit JJ i
opioid JJ i
abstinence NN i
and CC i
treatment NN N
retention NN N
at IN N
end NN N
of IN N
study NN N
) ) N
was VBD N
examined VBN N
in IN N
the DT N
subset NN N
of IN N
H NNP N
( ( N
+ NNP N
) ) N
and CC N
H NNP N
( ( N
- : N
) ) N
participants NNS N
randomized VBN N
to TO N
receive VB N
the DT N
4-week JJ N
taper NN N
condition NN N
( ( N
N=22 NNP N
) ) N
. . N

RESULTS NNP N
H NNP N
( ( N
+ NNP N
) ) N
participants NNS N
were VBD N
significantly RB N
older JJR N
and CC N
more RBR N
likely JJ N
to TO N
be VB N
male NN N
. . N

They PRP N
reported VBD N
longer JJR o
durations NNS o
of IN o
illicit NN o
opioid NN o
use NN o
, , o
greater JJR o
alcohol-related JJ o
problems NNS o
, , o
more JJR o
past-month JJ o
cocaine NN o
use NN o
, , o
greater JJR o
lifetime JJ o
IV NNP o
drug NN o
use NN o
, , o
and CC o
greater JJR o
lifetime NN o
use NN o
of IN o
cigarettes NNS o
, , o
amphetamines NNS o
and CC o
hallucinogens NNS o
. . o

H NNP N
( ( N
+ NNP N
) ) N
participants NNS N
also RB N
had VBD N
lower JJR N
scores NNS N
on IN N
the DT o
Positive NNP o
Symptom NNP o
Distress NNP o
and CC o
Depression NNP o
subscales NNS o
of IN o
the DT N
Brief NNP N
Symptom NNP N
Inventory NNP N
. . N

Finally RB N
, , N
there EX N
was VBD N
a DT N
trend NN N
toward IN N
poorer JJR N
treatment NN N
outcomes NNS N
among IN N
H NNP N
( ( N
+ NNP N
) ) N
participants NNS N
. . N

CONCLUSION VB N
A DT N
lifetime JJ N
history NN N
of IN N
heroin NN N
use NN N
may MD N
be VB N
associated VBN N
with IN N
elevated JJ N
drug NN N
severity NN N
and CC N
unique JJ N
treatment NN N
needs NNS N
among IN N
treatment-seeking JJ p
PO NNP p
abusers NNS p
. . p

-DOCSTART- -12394700- O O

Transurethral JJ i
prostate NN i
resection NN i
and CC N
bleeding NN N
: : N
a DT N
randomized JJ N
, , N
placebo NN i
controlled VBD N
trial NN N
of IN N
role NN N
of IN N
finasteride NN i
for IN N
decreasing VBG N
operative JJ N
blood NN N
loss NN N
. . N

PURPOSE NNP N
Bleeding NNP N
associated VBN N
with IN N
transurethral JJ N
prostate NN N
resection NN N
can MD N
often RB N
be VB N
significant JJ N
and CC N
lead JJ N
to TO N
increased VBN N
morbidity NN N
and CC N
occasionally RB N
mortality NN N
. . N

It PRP N
has VBZ N
been VBN N
shown VBN N
that IN N
finasteride NN i
decreases VBZ N
bleeding VBG N
in IN N
patients NNS p
with IN p
hematuria NNS p
of IN p
prostatic JJ p
origin NN p
. . p

We PRP N
hypothesized VBD N
that IN N
bleeding VBG N
in IN N
patients NNS p
undergoing JJ p
transurethral JJ p
prostate NN p
resection NN p
could MD N
be VB N
decreased VBN N
by IN N
giving VBG N
finasteride NN i
for IN N
2 CD N
weeks NNS N
before RB N
surgery NN N
. . N

MATERIALS NNP N
AND NNP N
METHODS NNP N
A NNP p
total JJ p
70 CD p
patients NNS p
scheduled VBN p
to TO p
undergo VB p
elective JJ p
transurethral JJ p
prostate NN p
resection NN p
were VBD p
randomized VBN p
to TO N
receive VB N
5 CD i
mg. NNS i
finasteride JJ i
daily RB i
or CC i
placebo VB i
for IN N
2 CD N
weeks NNS N
before RB N
surgery NN N
. . N

Serum NNP o
hemoglobin NN o
was VBD N
measured VBN N
before IN N
and CC N
after IN N
surgery NN N
, , N
and CC N
the DT N
following JJ N
day NN N
. . N

The DT N
volume NN o
of IN o
irrigation NN o
fluid NN o
used VBN N
and CC N
its PRP$ N
hemoglobin JJ N
concentration NN N
as RB N
well RB N
as IN N
resected VBN N
prostate NN N
weight NN N
were VBD N
recorded VBN N
. . N

RESULTS NNP N
Of IN N
the DT N
68 CD p
patients NNS p
who WP p
underwent JJ p
transurethral JJ p
prostate NN p
resection NN p
2 CD N
were VBD N
withdrawn VBN o
before RB N
surgery NN N
, , N
and CC N
so RB N
32 CD N
received VBD N
finasteride NN i
and CC N
36 CD N
received VBD N
placebo NN i
. . i

There EX N
was VBD N
significantly RB N
less JJR N
mean JJ o
blood NN o
loss NN o
in IN o
irrigation NN o
fluid NN o
in IN N
the DT N
finasteride NN i
group NN N
than IN N
in IN N
the DT N
control NN N
group NN N
( ( N
43.6 CD N
versus NN N
69.3 CD N
gm NN N
. . N

hemoglobin NN N
, , N
p NN N
= NNP N
0.011 CD N
) ) N
. . N

The DT N
mean JJ N
difference NN N
was VBD N
more RBR N
significant JJ N
when WRB N
blood NN o
loss NN o
per IN N
gm NN N
. . N

resected JJ N
prostate NN N
was VBD N
calculated VBN N
( ( N
2.65 CD N
versus NN N
4.65 CD N
gm NN N
. . N

hemoglobin NN N
per IN N
gm NN N
. . N

prostate NN N
, , N
p NN N
< NNP N
0.01 CD N
) ) N
. . N

CONCLUSIONS VB N
This DT N
study NN N
shows VBZ N
that IN N
finasteride NN i
given VBN N
for IN N
2 CD N
weeks NNS N
preoperatively RB N
decreases VBZ N
bleeding VBG o
in IN N
patients NNS p
undergoing JJ p
transurethral JJ p
prostate NN p
resection NN p
. . p

Further NNP N
study NN N
is VBZ N
required VBN N
to TO N
determine VB N
the DT N
optimal JJ N
timing NN N
and CC N
dose JJ N
duration NN N
to TO N
minimize VB N
blood NN o
loss NN o
and CC N
identify VB N
how WRB N
relevant JJ N
such JJ N
a DT N
decrease NN N
in IN N
bleeding NN N
is VBZ N
in IN N
clinical JJ N
practice NN N
. . N

-DOCSTART- -25515056- O O

Comparison NNP N
on IN N
therapeutic JJ N
effect NN o
of IN N
plasma JJ i
exchange NN i
and CC i
intravenous JJ i
immunoglobulin NN i
for IN N
Guillian-Barre NNP p
syndrome NN p
. . p

OBJECTIVES NNP N
To TO N
observe VB N
and CC N
compare VB N
the DT N
clinical JJ o
curative JJ o
effect NN o
of IN N
the DT N
plasma JJ i
exchange NN i
( ( i
PE NNP i
) ) i
and CC p
intravenous JJ i
immunoglobulin NN i
( ( i
IVIg NNP i
) ) i
for IN p
Guillian-Barre NNP p
Syndrome NNP p
( ( p
GBS NNP p
) ) p
. . p

METHODS NNP N
Overall NNP N
, , N
64 CD p
adult NN p
patients NNS p
with IN p
GBS NNP p
for IN p
PE NNP i
and CC p
IVIg NNP i
treatment NN p
, , p
respectively RB p
, , p
and CC p
nerve NN o
function NN o
were VBD N
observed VBN N
pre-treatment JJ N
and CC N
at IN N
1 CD N
week/2 NN N
weeks NNS N
after IN N
completion NN N
of IN N
treatment NN N
; : N
the DT N
blood NN N
immunoglobulin NN N
, , N
complement NN N
, , N
fibrinogen NN N
( ( N
Fib NNP N
) ) N
and CC N
monocyte JJ N
percentage NN N
( ( N
MON NNP N
% NN N
) ) N
were VBD N
detected VBN N
simultaneously RB N
. . N

RESULTS NNP N
After IN i
PE NNP i
treatment NN o
, , o
nerve NN o
function NN o
defect NN o
appeared VBD o
to TO N
improve VB N
better JJR N
than IN N
the DT N
IVIg NNP i
group NN i
and CC N
clinical JJ N
effect NN N
was VBD N
better JJR N
than IN N
the DT N
IVIg NNP i
group NN i
. . N

Treatment NNP o
effective JJ o
rates NNS o
of IN o
the DT N
two CD N
groups NNS N
after IN N
2 CD N
weeks NNS N
, , N
respectively RB N
, , N
are VBP N
96 CD N
and CC N
79 CD N
% NN i
. . i

PE NNP i
and CC i
IVIg NNP i
can MD N
significantly RB N
reduce VB N
the DT o
GBS NNP o
patients NNS o
' POS o
blood NN o
immunoglobulin NN o
IgG NNP o
, , o
IgA NNP o
, , o
IgM NNP o
, , o
C3 NNP o
and CC o
C4 NNP o
, , o
but CC o
these DT N
were VBD N
significantly RB N
lower JJR N
in IN N
the DT N
PE NNP i
group NN i
than IN N
in IN N
the DT N
IVIg NNP i
group NN N
. . N

Fib NNP o
and CC o
MON NNP o
% NN o
were VBD N
significantly RB N
lower JJR N
in IN N
the DT N
PE NNP i
group NN i
than IN N
in IN N
the DT N
IVIg NNP i
group NN N
. . N

CONCLUSION NNP i
Both NNP i
PE NNP i
and CC i
IVIg NNP i
have VBP N
a DT N
high JJ N
response NN N
as IN N
therapy NN N
and CC N
are VBP N
reasonable JJ N
therapeutic JJ N
options NNS N
for IN N
GBS NNP N
. . N

However RB i
, , i
PE NNP i
treatment NN i
has VBZ N
a DT N
more RBR N
significantly RB N
curative JJ N
effect NN N
, , N
as IN N
it PRP N
can MD N
effectively RB N
improve VB N
symptoms NNS N
and CC N
be VB N
helpful VBN N
in IN N
the DT N
early JJ N
rehabilitation NN p
of IN p
patients NNS p
. . p

-DOCSTART- -24146058- O O

Comparison NNP N
of IN N
meloxicam NN i
and CC i
a DT i
glucosamine-chondroitin JJ i
supplement NN i
in IN N
management NN N
of IN N
feline NN o
osteoarthritis NN o
. . o

A DT N
double-blind NN N
randomised VBN N
, , N
placebo-controlled JJ N
, , N
prospective JJ N
trial NN N
. . N

OBJECTIVE UH N
To TO N
compare VB N
the DT N
efficacy NN N
of IN N
meloxicam NN i
and CC i
a DT i
glucosamine-chondroitin JJ i
( ( i
Glu-Ch NNP i
) ) i
supplement NN i
in IN N
the DT N
management NN N
of IN N
feline NN o
osteoarthritis NN o
( ( o
OA NNP o
) ) o
. . N

METHODS NNP N
Prospective NNP N
, , N
blinded VBD N
, , N
randomized VBD N
clinical JJ N
trial NN N
. . N

Cats NNPS p
over IN p
eight CD p
years NNS p
of IN p
age NN p
with IN p
clinical JJ p
signs NNS p
of IN p
chronic JJ p
OA NNP p
were VBD p
assigned VBN p
to TO p
one CD p
of IN p
two CD p
groups NNS p
and CC N
Glu-Ch NNP i
or CC i
meloxicam NN i
was VBD N
administered VBN N
orally RB N
for IN N
70 CD N
days NNS N
, , N
followed VBN N
by IN N
a DT N
placebo NN i
until IN N
day NN N
98 CD N
. . N

Cats NNPS p
were VBD N
assessed VBN N
by IN N
a DT N
veterinarian NN N
on IN N
five CD N
occasions NNS N
and CC N
the DT N
owner NN N
completed VBD N
an DT N
assessment JJ N
form NN N
at IN N
the DT N
same JJ N
time NN N
. . N

RESULTS NNP N
Data NNP N
were VBD N
collected VBN N
from IN N
thirty NN N
cats NNS N
. . N

Pre-treatment JJ N
disease NN o
scores NNS o
were VBD N
significantly RB N
higher JJR N
in IN N
the DT N
meloxicam NN i
group NN N
for IN N
owner NN o
mobility NN o
( ( N
p=0.01 NN N
) ) N
and CC N
veterinary JJ o
lameness NN o
( ( N
p=0.02 NN N
) ) N
. . N

Owner NNP o
mobility NN o
scores NNS o
at IN N
day NN N
14 CD N
( ( N
p=0.01 NN N
) ) N
and CC N
day NN N
42 CD N
( ( N
p=0.002 NN N
) ) N
were VBD N
significantly RB N
improved VBN N
compared VBN N
to TO N
pre-treatment JJ N
scores NNS N
for IN N
the DT N
meloxicam NN i
group NN N
. . N

When WRB N
meloxicam NN i
and CC N
Glu-Ch NNP N
were VBD N
discontinued VBN N
and CC N
the DT N
placebo NN i
commenced VBD N
, , N
a DT N
significant JJ N
proportion NN N
of IN N
the DT N
meloxicam NN i
group NN N
showed VBD N
worsening NN N
of IN N
all PDT N
the DT N
owner-assessed JJ o
scores NNS o
between IN N
day NN N
70 CD N
and CC N
day NN N
98 CD N
, , N
when WRB N
compared VBN N
to TO N
the DT N
Glu-Ch NNP N
group NN N
( ( o
mobility NN o
p=0.01 NN N
; : N
activity NN o
p=0.02 NN N
; : N
temperament JJ o
p=0.04 NN N
; : N
lifestyle CC o
p=0.01 NN N
) ) N
. . N

CONCLUSIONS NNP N
Treatment NNP N
with IN N
meloxicam NN i
resulted VBN N
in IN N
a DT N
significant JJ N
improvement NN N
in IN N
mobility NN o
and CC o
activity NN o
levels NNS o
of IN N
cats NNS p
with IN N
OA NNP N
until IN N
the DT N
placebo NN i
was VBD N
introduced VBN N
. . N

A DT N
greater JJR N
proportion NN N
of IN N
cats NNS N
receiving VBG N
meloxicam NN i
medication NN N
showed VBD N
a DT N
significant JJ N
worsening NN N
of IN N
owner NN o
assessment NN o
scores VBZ o
once RB N
the DT N
placed NN N
was VBD N
introduced VBN N
, , N
when WRB N
compared VBN N
to TO N
the DT N
Glu-Ch NNP N
group NN N
. . N

-DOCSTART- -24393553- O O

Population NNP N
pharmacokinetic/pharmacodynamic JJ N
analysis NN N
of IN N
the DT N
DPP-4 NNP i
inhibitor NN i
linagliptin NN i
in IN N
Japanese JJ p
patients NNS p
with IN p
type JJ p
2 CD p
diabetes NNS p
mellitus RB p
. . p

OBJECTIVES NNP N
Linagliptin NNP i
is VBZ N
a DT N
novel JJ N
, , N
highly RB N
selective JJ N
and CC N
long JJ N
acting VBG N
DPP-4 NNP N
inhibitor NN N
for IN N
the DT N
treatment NN N
of IN N
type NN N
2 CD N
diabetes NNS N
mellitus FW N
( ( N
T2DM NNP N
) ) N
. . N

Linagliptin JJ i
exhibits VBZ N
non-linear JJ N
pharmacokinetics NNS N
( ( N
PK NNP N
) ) N
due JJ N
to TO N
saturable JJ N
binding NN N
to TO N
plasma VB N
and CC N
tissue VB N
DPP-4 NNP N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
characterize VB N
the DT N
PK NNP N
and CC N
PK/DPP-4 NNP N
inhibition NN N
relationship NN N
of IN N
linagliptin NN i
in IN N
Japanese JJ p
patients NNS p
with IN p
T2DM NNP p
using VBG N
a DT N
population NN N
PK/DPP-4 NNP N
model NN N
and CC N
to TO N
support VB N
the DT N
rationale NN N
for IN N
the DT N
therapeutic JJ N
dose NN N
in IN N
Japanese JJ N
patients NNS N
by IN N
simulation NN N
. . N

METHODS NNP N
Linagliptin NNP i
plasma NN N
concentration NN N
and CC N
DPP-4 NNP N
inhibition NN N
measurements NNS N
from IN N
a DT N
placebo-controlled JJ i
, , N
parallel JJ N
group NN N
multiple NN N
( ( N
28 CD N
days NNS N
) ) N
dose VBP N
trial NN N
that WDT N
included VBD N
36 CD p
T2DM NNP p
patients NNS p
( ( p
18 CD p
patients NNS p
each DT p
in IN p
2.5 CD p
mg NN p
and CC p
10 CD p
mg NNS p
dose JJ p
group NN p
) ) p
were VBD N
used VBN N
for IN N
analysis NN N
. . N

Modeling NNP N
was VBD N
performed VBN N
using VBG N
FOCE NNP N
INTERACTION NNP N
estimation NN N
method NN N
implemented VBN N
in IN N
NONMEM NNP N
V. NNP N
The DT N
linagliptin JJ N
plasma JJ N
concentration- NN N
and CC N
DPP-4 NNP N
inhibition- JJ N
time NN N
profiles NNS N
were VBD N
simulated VBN N
for IN N
Japanese JJ N
patients NNS N
receiving VBG N
5 CD N
mg JJ N
linagliptin NN i
once RB N
daily JJ N
by IN N
the DT N
model NN N
established VBN N
. . N

RESULTS NNP N
Nonlinear NNP N
PK NNP N
of IN N
linagliptin NN N
in IN N
T2DM NNP N
patients NNS N
were VBD N
well RB N
described VBN N
by IN N
a DT N
2-compartment JJ N
model NN N
assuming VBG N
concentration-dependent JJ N
binding NN N
to TO N
DPP-4 NNP N
in IN N
the DT N
central JJ N
and CC N
peripheral JJ N
compartment NN N
. . N

Plasma NNP o
DPP-4 NNP o
inhibition NN o
was VBD N
integrated VBN N
in IN N
the DT N
model NN N
by IN N
relating VBG N
the DT N
model-predicted JJ N
DPP-4 NNP N
occupancy NN N
with IN N
linagliptin JJ i
linearly JJ N
to TO N
DPP-4 JJ N
inhibition NN N
. . N

The DT N
simulation NN N
predicted VBD N
that IN N
for IN N
the DT N
5 CD N
mg NN N
dose NN N
group NN N
the DT N
trough JJ N
DPP-4 JJ o
inhibition NN o
at IN N
steady-state NN N
was VBD N
84.2 CD N
% NN N
, , N
which WDT N
is VBZ N
higher JJR N
than IN N
the DT N
target NN N
inhibition NN N
( ( N
?80 CD N
% NN N
) ) N
for IN N
an DT N
effective JJ N
dose NN N
of IN N
DPP-4 NNP N
inhibitor NN N
. . N

In IN N
2.5 CD N
mg NNS N
dose JJ N
group NN o
, , o
steady-state JJ o
DPP-4 NNP o
inhibition NN o
of IN o
> $ N
80 CD N
% NN N
was VBD N
not RB N
maintained VBN N
over IN N
24 CD N
hours NNS N
( ( N
observed VBN N
and CC N
simulated VBN N
) ) N
. . N

CONCLUSIONS VB N
The DT N
nonlinear JJ N
PK NNP N
of IN N
linagliptin NN i
and CC i
its PRP$ N
plasma JJ N
DPP-4 JJ N
inhibition NN N
in IN N
patients NNS N
were VBD N
well RB N
characterized VBN N
by IN N
a DT N
target-mediated JJ N
drug NN N
disposition NN N
model NN N
relating VBG N
DPP-4 NNP N
occupancy NN N
with IN N
linagliptin NN N
to TO N
DPP-4 NNP N
inhibition NN N
. . N

Simulations NNS N
of IN N
plasma JJ N
DPP-4 NNP N
inhibition NN N
suggest VBP N
that IN N
5 CD N
mg NNS N
linagliptin JJ i
once RB i
daily JJ N
is VBZ N
an DT N
appropriate JJ N
therapeutic JJ N
dose NN N
for IN N
Japanese JJ N
patients NNS N
with IN N
T2DM NNP N
. . N

-DOCSTART- -22495940- O O

Competitive JJ i
memory NN i
training NN i
( ( i
COMET NNP i
) ) i
for IN N
treating VBG N
low JJ o
self-esteem NNS o
in IN p
patients NNS p
with IN p
depressive JJ p
disorders NNS p
: : p
a DT N
randomized JJ N
clinical JJ N
trial NN N
. . N

BACKGROUND NNP N
Self-esteem NNP N
is VBZ N
a DT N
major JJ N
concern NN N
in IN N
mood NN N
disorders NNS N
. . N

Low JJ o
self-esteem NN o
is VBZ N
a DT N
symptom NN N
of IN N
depressive JJ N
disorders NNS N
and CC N
is VBZ N
considered VBN N
by IN N
some DT N
to TO N
be VB N
a DT N
predictor NN N
for IN N
relapse NN N
, , N
whereas JJ N
high JJ N
self-esteem NN N
seems VBZ N
to TO N
buffer VB N
against IN N
depression NN N
. . N

Recently RB N
, , N
Competitive NNP o
Memory NNP o
Training NNP o
( ( o
COMET NNP o
) ) o
has VBZ N
shown VBN N
to TO N
be VB N
effective JJ N
for IN N
the DT N
enhancement NN N
of IN N
self-esteem NN N
in IN N
several JJ N
psychopathological JJ N
conditions NNS N
. . N

The DT N
current JJ N
study NN N
assesses VBZ N
whether IN N
COMET NNP i
is VBZ N
also RB N
an DT N
effective JJ N
intervention NN N
for IN N
patients NNS N
with IN N
depressive JJ N
disorders NNS N
. . N

METHODS NNP N
Sixty-one JJ p
patients NNS p
with IN p
depressive JJ p
disorders NNS p
who WP p
were VBD p
already RB p
in IN p
therapy NN p
in IN p
an DT p
outpatient JJ p
mental JJ p
health NN p
institution NN p
were VBD N
randomly RB N
assigned VBN p
to TO N
either DT N
eight CD N
group NN N
sessions NNS N
of IN N
COMET NNP i
in IN i
addition NN i
to TO i
their PRP$ i
regular JJ i
therapy NN i
( ( i
COMET NNP i
+ NNP i
therapy NN i
as IN i
usual JJ i
[ NNP i
TAU NNP i
] NN i
: : i
the DT N
experimental JJ N
group NN N
) ) N
or CC N
to TO N
8 CD N
weeks NNS N
of IN i
ongoing VBG i
regular JJ i
therapy NN i
( ( i
TAU NNP i
only RB i
: : i
the DT N
control NN N
group NN N
) ) N
. . N

These DT N
latter JJ N
( ( N
control NN N
) ) N
patients NNS N
received VBD N
COMET NNP i
after IN N
their PRP$ N
TAU NNP i
only RB N
period NN N
. . N

All DT N
patients NNS N
in IN N
both DT N
groups NNS N
that WDT N
completed VBD N
COMET NNP i
were VBD N
contacted VBN N
3 CD N
and CC N
6 CD N
months NNS N
later RB N
to TO N
assess VB N
whether IN N
the DT N
effects NNS o
of IN o
COMET NNP o
had VBD N
remained VBN N
stable JJ N
. . N

RESULTS NNP N
Compared VBD N
to TO N
the DT N
patients NNS N
who WP N
received VBD N
TAU NNP i
only RB N
, , N
patients NNS N
in IN N
the DT N
COMET NNP i
+ NNP i
TAU NNP i
condition NN N
showed VBD N
significant JJ o
improvement NN o
with IN N
large JJ o
effect NN o
sizes VBZ o
on IN o
indices NNS o
of IN o
self-esteem JJ o
, , o
depression NN o
, , o
and CC o
depressive JJ o
rumination NN o
. . o

The DT N
therapeutic JJ o
effects NNS o
of IN N
COMET NNP i
+ NNP i
TAU NNP i
remained VBD N
stable JJ o
after IN N
3 CD N
and CC N
6 CD N
months NNS N
on IN N
all DT N
outcome NN N
measures NNS N
or CC N
improved VBN N
even RB N
further RBR N
. . N

CONCLUSION NNP N
COMET NNP i
for IN N
low JJ N
self-esteem JJ N
seems VBZ N
to TO N
be VB N
an DT N
efficacious JJ N
trans-diagnostic JJ N
intervention NN N
that WDT N
can MD N
relatively RB N
easily RB N
be VB N
added VBN N
to TO N
the DT N
regular JJ N
treatment NN N
of IN N
patients NNS N
with IN N
depressive JJ N
disorders NNS N
. . N

-DOCSTART- -26058489- O O

Pulsed VBN i
electromagnetic JJ i
fields NNS i
for IN N
postmenopausal NN p
osteoporosis NN p
and CC p
concomitant JJ p
lumbar NN p
osteoarthritis NN p
in IN p
southwest JJ p
China NNP p
using VBG N
proximal JJ o
femur NN o
bone NN o
mineral JJ o
density NN o
as IN N
the DT N
primary JJ N
endpoint NN N
: : N
study NN N
protocol NN N
for IN N
a DT N
randomized VBN N
controlled VBN N
trial NN N
. . N

BACKGROUND NNP N
Osteoporosis NNP N
( ( N
OP NNP N
) ) N
and CC N
osteoarthritis NN N
( ( N
OA NNP N
) ) N
are VBP N
prevalent JJ N
skeletal JJ N
disorders NNS N
among IN N
postmenopausal JJ p
women NNS p
. . p

Coexistence NN N
is VBZ N
common JJ N
especially RB N
that IN N
of IN N
postmenopausal NN N
osteoporosis NN N
( ( N
PMO NNP N
) ) N
and CC N
lumbar $ N
OA NNP N
. . N

An DT N
hypothesis NN N
has VBZ N
been VBN N
raised VBN N
that IN N
OP NNP N
and CC N
OA NNP N
might MD N
share NN N
the DT N
same JJ N
pathogenic JJ N
mechanism NN N
, , N
and CC N
pulsed VBD i
electromagnetic JJ i
fields NNS i
( ( i
PEMFs NNP i
) ) i
were VBD N
reported VBN N
to TO N
have VB N
anti-osteoporosis NN N
and CC N
anti-osteoarthritis NN N
properties NNS N
, , N
but CC N
this DT N
suggestion NN N
was VBD N
based VBN N
primarily RB N
on IN N
biomarker NN N
data NNS N
. . N

Therefore NNP N
, , N
whether IN N
these DT N
two CD N
effects NNS N
could MD N
take VB N
place NN N
simultaneously RB N
has VBZ N
not RB N
yet RB N
been VBN N
investigated VBN N
. . N

This DT N
randomized VBD N
controlled VBN N
trial NN N
( ( N
RCT NNP N
) ) N
is VBZ N
designed VBN N
to TO N
explore VB N
the DT N
effect NN N
of IN N
PEMFs NNP i
for IN N
PMO NNP N
and CC N
concomitant JJ N
lumbar NN N
OA NNP N
. . N

METHODS/DESIGN NNP N
The DT N
study NN N
will MD N
include VB N
PMO NNP p
patients NNS p
( ( p
postmenopausal JJ p
women NNS p
; : p
aged VBN p
between IN p
50 CD p
and CC p
70 CD p
years NNS p
; : p
have VBP p
been VBN p
postmenopausal VBN p
for IN p
at IN p
least JJS p
5 CD p
years NNS p
and CC p
diagnosed VBD p
with IN p
OP NNP p
using VBG p
proximal JJ p
femur JJ p
T-score NN p
) ) p
with IN p
concomitant JJ p
lumbar NN p
OA NNP p
( ( p
patients NNS p
with IN p
confounding VBG p
disorders NNS p
like IN p
diabetes NNS p
, , p
hypertension NN p
, , p
hyperlipidemia NN p
, , p
and CC p
previous JJ p
fracture NN p
history NN p
, , p
etcetera NN p
, , p
will MD p
be VB p
excluded VBN p
) ) p
will MD N
be VB N
randomly RB N
assigned VBN N
to TO N
two CD N
arms NNS N
: : N
PEMFs NNP i
group NN N
and CC N
sham NN i
PEMFs NNP i
group NN i
. . i

There EX N
will MD N
be VB N
25 CD p
participants NNS p
in IN p
each DT p
arm NN p
( ( p
50 CD p
in IN p
total JJ p
) ) p
and CC N
the DT N
outcome NN N
assessment NN N
, , N
including VBG N
the DT N
primary JJ N
endpoint NN N
( ( o
proximal JJ o
femur NN o
bone NN o
mineral JJ o
density NN o
) ) o
, , N
will MD N
be VB N
performed VBN N
at IN N
5 CD N
weeks NNS N
, , N
3 CD N
months NNS N
and CC N
6 CD N
months NNS N
after IN N
enrollment NN N
. . N

DISCUSSION NNP N
PMO NNP N
and CC N
lumbar NN N
OA NNP N
are VBP N
prominent JJ N
public JJ N
health NN N
problem NN N
, , N
especially RB N
for IN N
postmenopausal JJ p
women NNS p
. . p

We PRP N
hope VBP N
this DT N
RCT NNP N
will MD N
provide VB N
scientific JJ N
evidence NN N
to TO N
primary JJ N
care NN N
of IN N
the DT N
postmenopausal JJ N
women NNS N
regarding VBG N
the DT N
use NN N
of IN N
these DT N
nonpharmaceutical JJ N
, , N
noninvasive JJ N
modalities NNS N
, , N
PEMFs NNP i
, , N
in IN N
managing VBG N
PMO NNP N
and CC N
lumbar NN N
OA NNP N
. . N

TRIAL NNP N
REGISTRATION NNP N
Chinese NNP N
Clinical NNP N
Trial NNP N
Registry NNP N
: : N
ChiCTR-TRC-14005156 NNP N
( ( N
28 CD N
August NNP N
2014 CD N
) ) N
. . N

-DOCSTART- -10429005- O O

Why WRB N
the DT N
prone NN i
position NN i
is VBZ N
a DT N
risk NN N
factor NN N
for IN N
sudden JJ N
infant NN N
death NN N
syndrome NN N
. . N

INTRODUCTION NNP N
The DT N
laryngeal NN N
chemoreflex NN N
may MD N
explain VB N
why WRB N
prone NN N
sleeping NN N
increases VBZ N
the DT N
risk NN N
of IN N
sudden JJ N
infant NN N
death NN N
syndrome NN N
( ( N
SIDS NNP N
) ) N
. . N

Swallowing VBG N
and CC N
arousal NN N
are VBP N
crucial JJ N
to TO N
prevent VB N
laryngeal JJ N
chemoreflex JJ N
stimulation NN N
. . N

Our PRP$ N
aim NN N
was VBD N
to TO N
examine VB N
these DT N
reflexes NNS o
and CC o
breathing VBG o
responses NNS o
in IN N
healthy JJ p
neonates NNS p
after IN N
pharyngeal JJ N
infusion NN N
of IN N
water NN N
in IN N
the DT N
supine NN N
versus IN N
the DT N
prone NN N
position NN N
, , N
controlling VBG N
for IN N
sleep JJ N
state NN N
. . N

METHODS CC N
A DT N
total NN N
of IN N
10 CD p
term NN p
infants NNS p
were VBD N
recruited VBN N
after IN N
parental JJ N
consent NN N
and CC N
ethics NNS N
approval NN N
. . N

Polygraphic JJ N
recordings NNS N
included VBD N
sleep JJ o
state NN o
( ( o
active JJ o
and CC o
quiet JJ o
sleep NN o
by IN o
electroencephalogram NN o
, , o
eye NN o
movements NNS o
, , o
breathing NN o
, , o
and CC o
behavior NN o
) ) o
, , o
cardiorespiratory JJ o
measurements NNS o
( ( o
nasal JJ o
airflow NN o
, , o
chest VBP o
wall NN o
movements NNS o
, , o
heart NN o
rate NN o
, , o
and CC o
oxygen PRP o
saturation NN o
) ) o
, , o
swallowing VBG o
, , o
and CC o
esophageal JJ o
activity NN o
( ( o
solid JJ o
state NN o
pressure NN o
catheter NN o
) ) o
. . o

Initial JJ i
sleeping VBG i
position NN i
was VBD i
assigned VBN i
randomly RB i
. . i

Measurements NNS N
were VBD N
made VBN N
for IN N
1 CD i
minute NN i
before IN i
and CC i
after IN i
0.4 CD i
mL NN i
of IN i
water NN i
was VBD i
instilled VBN i
into IN i
the DT i
oropharynx NN i
. . i

To TO N
detect VB N
a DT N
30 CD N
% NN N
decrease NN N
in IN N
swallowing NN o
, , N
power NN N
analysis NN N
indicated VBD N
that IN N
> NNP N
/=10 NNP N
babies NNS N
were VBD N
required VBN N
. . N

Analysis NN N
, , N
blinded VBD N
to TO N
position NN N
, , N
was VBD N
made VBN N
using VBG N
nonparametric JJ N
statistics NNS N
. . N

RESULTS NNP N
Of IN N
the DT N
164 CD N
infusions NNS N
, , N
the DT N
most RBS N
commonly RB N
evoked VBD N
airway RB N
protective JJ N
responses NNS N
to TO N
pharyngeal VB N
infusion NN N
were VBD N
swallowing VBG o
( ( N
95 CD N
% NN N
) ) N
and CC N
arousal NN o
( ( N
54 CD N
% NN N
) ) N
. . N

After IN N
infusion NN N
in IN N
active JJ N
sleep NN N
, , N
there EX N
was VBD N
a DT N
significant JJ N
reduction NN N
in IN N
swallowing VBG o
and CC o
breathing VBG o
when WRB N
the DT N
prone NN N
position NN N
was VBD N
compared VBN N
with IN N
the DT N
supine JJ N
position NN N
( ( N
prone NN N
: : N
21.3 CD N
[ $ N
1.0 CD N
] NNP N
swallows/min NN o
and CC N
-9.6 NNP N
[ NNP N
2.1 CD N
] NNP N
breaths/min NN o
; : o
and CC N
supine VB N
: : N
32 CD N
( ( N
2.2 CD N
) ) N
and CC N
-2 NNP N
. . N

9 CD N
( ( N
1.5 CD N
) ) N
, , N
respectively RB N
) ) N
. . N

However RB N
, , N
there EX N
was VBD N
no DT N
difference NN N
in IN N
the DT N
occurrence NN N
of IN N
arousal NN o
after IN N
water NN N
infusion NN N
. . N

CONCLUSION NNP N
These DT N
data NNS N
suggest VBP N
that IN N
airway NN N
protection NN N
is VBZ N
compromised VBN N
in IN N
the DT N
prone NN N
sleeping VBG N
position NN N
during IN N
active JJ N
sleep NN N
, , N
even RB N
in IN N
healthy JJ N
infants NNS N
exposed VBN N
to TO N
minute VB N
pharyngeal JJ N
fluid JJ N
volumes NNS N
of IN N
0.4 CD N
mL NN N
. . N

This DT N
is VBZ N
because IN N
swallowing VBG o
rate NN o
is VBZ N
reduced VBN N
significantly RB N
, , N
and CC N
there EX N
is VBZ N
no DT N
compensatory JJ N
increase NN N
in IN N
arousal NN o
. . o

The DT N
reduction NN N
in IN N
airway RB o
protective JJ o
reflexes NNS o
when WRB N
in IN N
the DT N
prone NN N
position NN N
and CC N
in IN N
active JJ N
sleep NN N
may MD N
be VB N
the DT N
mechanism NN N
for IN N
the DT N
increased VBN N
risk NN N
of IN N
SIDS NNP N
in IN N
the DT N
prone NN N
position NN N
. . N

-DOCSTART- -23808817- O O

Patient JJ o
satisfaction NN o
with IN N
nutrition NN N
services NNS N
amongst JJ N
cancer NN p
patients NNS p
treated VBN p
with IN p
autologous JJ p
stem NN p
cell NN p
transplantation NN p
: : p
a DT N
comparison NN N
of IN N
usual JJ i
and CC N
extended JJ i
care NN i
. . i

BACKGROUND NNP N
This DT N
study NN N
aimed VBD N
to TO N
determine VB N
patient JJ N
satisfaction NN N
with IN N
clinical JJ N
nutrition NN i
services NNS i
delivered VBN N
by IN N
an DT N
accredited JJ N
practicing NN N
dietitian JJ N
amongst NN N
cancer NN p
patients NNS p
treated VBN p
with IN p
autologous JJ p
stem NN p
cell NN p
transplantation NN p
that WDT N
was VBD N
provided VBN N
with IN N
usual JJ i
and CC N
extended VBD i
care NN i
at IN N
100 CD N
days NNS N
post-transplantation NN N
. . N

METHODS JJ N
Patients NNPS N
were VBD N
randomised VBN N
to TO N
receive VB i
usual JJ i
nutrition NN i
care NN i
or CC i
extended VBN i
nutrition NN i
care NN i
during IN N
the DT N
course NN N
of IN N
their PRP$ N
stem NN N
cell NN N
transplantation NN N
. . N

After IN N
hospital JJ N
discharge NN N
, , N
usual JJ i
care NN i
patients NNS i
received VBD i
no DT i
further JJ i
nutrition NN i
support NN i
, , i
whereas RB i
extended VBN i
care NN i
patients NNS i
received VBD i
telephone NN i
dietary JJ i
counselling NN i
from IN i
the DT i
same JJ i
dietitian NN i
for IN i
up IN i
to TO i
100 CD i
days NNS i
post-transplantation NN i
. . i

The DT N
patient JJ N
satisfaction NN N
with IN N
clinical JJ N
nutrition NN N
service NN N
questionnaire NN N
was VBD N
completed VBN N
anonymously RB N
at IN N
100 CD N
days NNS N
post-transplantation NN N
. . N

Group NNP N
comparisons NNS N
were VBD N
made VBN N
using VBG N
independent JJ N
t-tests NNS N
. . N

RESULTS NNP p
Thirty-seven JJ p
patients NNS p
consented VBN p
to TO p
participate VB p
in IN p
the DT p
study NN p
( ( p
54 CD p
% NN p
male NN p
; : p
mean JJ p
age NN p
58.7 CD p
? . p
9.5 CD p
years NNS p
; : p
median JJ p
body NN p
mass NN p
index NN p
26.8 CD p
kg NN p
m NN p
( ( p
-2 NNP p
) ) p
, , p
range VBP p
16.4-47.6 JJ p
kg NN p
m NN p
( ( p
-2 NNP p
) ) p
) ) p
; : p
33 CD p
patients NNS p
completed VBD p
the DT p
study NN p
and CC p
28 CD p
patients NNS p
returned VBD p
the DT p
questionnaire NN p
( ( p
response NN p
rate NN p
= VBD p
85 CD p
% NN p
) ) p
. . o

All DT o
components NNS o
of IN o
the DT o
questionnaire NN o
were VBD o
rated VBN o
highly RB o
by IN N
both DT N
groups NNS N
; : N
there EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
the DT N
groups NNS N
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
. . N

Although IN N
not RB N
statistically RB N
significant JJ N
, , N
extended VBD N
care NN N
patients NNS N
who WP N
received VBD N
at IN N
least JJS N
three CD N
telephone NN N
calls VBZ N
rated VBN o
a DT o
higher JJR N
overall JJ N
satisfaction NN o
compared VBN o
to TO N
those DT N
who WP N
received VBD N
less JJR N
calls NNS N
; : N
this DT N
difference NN N
was VBD N
clinically RB N
important JJ N
( ( N
score JJ N
difference NN N
= NNP N
0.56 CD p
) ) p
. . p

CONCLUSIONS NNP p
Cancer NNP p
patients NNS p
treated VBD p
with IN p
autologous JJ p
stem NN p
cell NN p
transplantation NN p
were VBD N
satisfied VBN N
with IN i
usual JJ i
and CC i
extended JJ i
nutrition NN i
care NN i
. . i

Extended NNP i
care NN i
patients NNS i
who WP p
received VBD N
at IN N
least JJS N
three CD N
telephone NN N
calls VBZ N
after IN N
hospital NN N
discharge NN N
were VBD N
more JJR N
satisfied JJ N
than IN N
those DT N
with IN N
less JJR N
frequent JJ N
intervention NN N
. . N

Further JJ N
exploration NN N
regarding VBG N
the DT N
frequency NN N
and CC N
intensity NN N
of IN N
nutrition NN N
service NN N
is VBZ N
required VBN N
. . N

-DOCSTART- -3103932- O O

Chemotherapy NNP N
of IN N
advanced JJ p
gastric JJ p
carcinoma NN p
( ( p
stage JJ p
IV NNP p
) ) p
: : p
a DT N
randomized JJ N
study NN N
of IN N
FAM NNP i
versus IN N
5-FU JJ i
plus JJ i
BCNU NNP i
. . i

Forty-six JJ p
patients NNS p
with IN p
advanced JJ p
gastric JJ p
carcinoma NN p
( ( p
Stage NNP p
IV NNP p
) ) p
were VBD p
evaluated VBN p
in IN N
a DT N
prospective JJ N
randomized VBN N
comparison NN N
of IN N
two CD N
chemotherapy NN i
regimens NNS N
( ( i
FAM NNP i
versus IN i
5-FU JJ i
plus CC i
BCNU NNP i
) ) i
to TO N
identify VB N
therapeutic JJ N
activity NN N
. . N

Treatment NN N
groups NNS N
were VBD N
well RB N
balanced VBN N
with IN N
respect NN N
to TO N
known VBN N
prognostic JJ N
factors NNS N
. . N

Thirty-three JJ p
patients NNS p
had VBD p
measurable JJ p
disease NN p
and CC p
thirteen NN p
had VBD p
only RB p
microscopic JJ p
residual JJ p
disease NN p
in IN p
the DT p
resection NN p
margins NNS p
. . p

The DT N
overall JJ o
median JJ o
survival NN o
of IN N
the DT N
entire JJ N
group NN N
was VBD N
13.2 CD N
months NNS N
. . N

Two CD N
( ( N
6 CD N
% NN N
) ) N
patients NNS N
with IN N
measurable JJ N
disease NN N
reached VBD N
complete JJ o
response NN o
( ( o
CR NNP o
) ) o
, , N
1 CD N
( ( N
3 CD N
% NN N
) ) N
partial JJ o
response NN o
( ( o
PR NNP o
) ) o
, , N
12 CD N
( ( N
36 CD N
% NN N
) ) N
had VBD N
stable JJ o
disease NN o
( ( o
SD NNP o
) ) o
and CC N
18 CD N
( ( N
56 CD N
% NN N
) ) N
had VBD N
progressive JJ o
disease NN o
( ( o
PD NNP o
) ) o
. . o

The DT N
responders NNS N
had VBD N
not RB N
reached VBN N
the DT N
median JJ o
survival NN o
yet RB N
, , N
the DT N
patients NNS N
with IN N
SD NNP N
had VBD N
a DT N
median JJ N
survival NN o
of IN N
14.7 CD N
months NNS N
and CC N
the DT N
PD NNP N
9.5 CD N
months NNS N
. . N

In IN N
the DT N
FAM NNP i
arm NN N
there EX N
were VBD N
3 CD N
( ( N
18 CD N
% NN N
) ) N
responders NNS N
( ( N
2 CD N
CR NNP N
and CC N
1 CD N
PR NNP N
) ) N
, , N
7 CD N
( ( N
41 CD N
% NN N
) ) N
SD NNP N
and CC N
7 CD N
( ( N
41 CD N
% NN N
) ) N
PD NNP N
, , N
versus NN N
O NNP N
responders NNS N
, , N
5 CD N
( ( N
31 CD N
% NN N
) ) N
SD NNP N
and CC N
11 CD N
( ( N
69 CD N
% NN N
) ) N
PD NNP N
in IN N
the DT N
5-FU JJ N
plus CC N
BCNU NNP N
arm NN N
. . N

In IN N
the DT N
FAM NNP i
arm NN N
the DT N
median JJ o
survival NN o
was VBD N
15.7 CD N
months NNS N
versus IN N
9.9 CD N
months NNS N
in IN N
the DT N
other JJ N
therapeutic JJ N
arm NN N
. . N

The DT N
statistical JJ N
analysis NN N
indicated VBD N
that IN N
survival NN N
associated VBN N
with IN N
FAM NNP i
regimen NNS N
was VBD N
superior JJ N
to TO N
that DT N
reached VBN N
with IN N
the DT N
5-FU JJ i
plus CC i
BCNU JJ i
regimen NNS N
. . N

Thirteen JJ p
patients NNS p
with IN N
unmeasurable JJ N
disease NN N
had VBD N
a DT N
median JJ N
survival NN o
of IN N
15.9 CD N
months NNS N
. . N

-DOCSTART- -24104511- O O

Correlation NN N
of IN N
cognitive JJ N
and CC N
social JJ N
outcomes NNS N
among IN N
children NNS p
with IN p
autism NN p
spectrum NN p
disorder NN p
in IN N
a DT N
randomized JJ N
trial NN N
of IN N
behavioral JJ i
intervention NN i
. . i

Although IN N
social JJ N
impairments NNS N
are VBP N
considered VBN N
the DT N
hallmark NN N
deficit NN N
of IN N
autism NN N
, , N
many JJ N
behavioral JJ i
intervention NN i
studies NNS N
rely VBP N
on IN N
cognitive JJ N
functioning NN N
as IN N
a DT N
primary JJ N
outcome NN N
. . N

Fewer JJR N
studies NNS N
have VBP N
examined VBN N
whether IN N
changes NNS N
in IN N
cognition NN N
are VBP N
associated VBN N
with IN N
changes NNS N
in IN N
social JJ o
functioning NN o
. . o

This DT N
study NN N
examined VBD N
whether IN N
cognitive JJ N
gains NNS N
among IN N
192 CD p
students NNS p
from IN p
47 CD p
kindergarten-through-second-grade JJ p
autism NN p
support NN p
classrooms NNS p
participating VBG p
in IN p
a DT p
year-long JJ p
behavioral JJ i
intervention NN i
study NN p
were VBD N
associated VBN N
with IN N
gains NNS N
in IN N
social JJ N
functioning NN N
. . N

Children NNP p
's POS p
gains NNS N
in IN N
cognitive JJ o
ability NN o
were VBD N
modestly RB N
associated VBN N
with IN N
independent JJ o
assessors NNS o
' POS o
and CC o
teachers NNS o
' POS o
evaluations NNS o
of IN o
social JJ o
functioning NN o
but CC N
were VBD N
not RB N
associated VBN N
with IN N
changes NNS N
in IN N
parent NN o
ratings NNS o
. . o

Observed VBN N
social JJ o
gains NNS o
were VBD N
not RB N
commensurate JJ N
with IN N
gains NNS o
in IN o
cognition NN o
, , N
suggesting VBG N
the DT N
need NN N
both DT N
for IN N
interventions NNS i
that WDT N
directly RB N
target VBP N
social JJ N
functioning NN N
and CC N
relevant JJ N
field NN N
measures NNS N
of IN N
social JJ N
functioning NN N
. . N

-DOCSTART- -21846665- O O

Increasing VBG N
verbal JJ N
responsiveness NN N
in IN N
parents NNS p
of IN p
children NNS p
with IN p
autism NN p
: : p
a DT p
pilot NN N
study NN N
. . N

Correlational NNP N
studies NNS N
have VBP N
revealed VBN N
a DT N
positive JJ N
relationship NN N
between IN N
parent NN p
verbal JJ N
responsiveness NN N
and CC N
language NN N
outcomes NNS N
in IN N
children NNS p
with IN p
autism NN p
. . p

We PRP N
investigated VBD N
whether IN N
parents NNS p
of IN p
young JJ p
children NNS p
on IN p
the DT p
autism NN p
spectrum NN p
could MD N
learn VB N
and CC N
implement VB N
the DT N
specific JJ N
categories NNS N
of IN N
verbal JJ N
responsiveness NN N
that WDT N
have VBP N
been VBN N
suggested VBN N
to TO N
facilitate VB N
language NN N
development NN N
. . N

Parents NNS p
were VBD N
taught VBN N
to TO N
increase VB i
their PRP$ i
verbal JJ i
responsiveness NN i
in IN N
the DT N
context NN N
of IN N
a DT N
short-term JJ i
language NN i
intervention NN i
that WDT N
included VBD N
group NN i
parent NN i
education NN i
sessions NNS i
, , N
as RB N
well RB N
as IN N
individual JJ i
and CC i
small-group JJ i
coaching NN i
sessions NNS i
of IN i
parent-child JJ i
play NN i
interactions NNS i
. . i

Parents NNS p
in IN N
the DT N
treatment NN N
group NN N
increased VBD N
their PRP$ N
use NN N
of IN N
comments NNS N
that WDT N
: : N
described VBD N
their PRP$ N
child NN o
's POS o
focus NN o
of IN o
attention NN o
; : o
interpreted VBN N
or CC N
expanded VBN N
child JJ o
communication NN o
acts NNS o
; : o
and CC N
prompted VBD N
child JJ o
communication NN o
. . o

Preliminary JJ N
treatment NN N
effects NNS N
were VBD N
also RB N
noted VBN N
in IN N
children NNS o
's POS o
prompted VBN o
and CC o
spontaneous JJ o
communication NN o
. . o

These DT N
results NNS N
support VBP N
the DT N
use NN N
of IN N
parent-mediated JJ i
interventions NNS i
targeting VBG N
verbal JJ o
responsiveness NN o
to TO N
facilitate VB N
language NN o
development NN o
and CC o
communication NN o
in IN N
young JJ p
children NNS p
with IN p
autism NN p
. . p

-DOCSTART- -19577150- O O

Comparison NNP N
of IN N
arch NN N
dimension NN N
changes NNS N
in IN N
1-phase JJ N
vs JJ N
2-phase JJ N
treatment NN N
of IN N
Class NNP p
II NNP p
malocclusion NN p
. . p

INTRODUCTION NNP N
We PRP N
compared VBN N
arch JJ N
dimension NN N
changes NNS N
in IN N
1-phase JJ N
and CC N
2-phase JJ N
treatment NN N
of IN N
Class NNP p
II NNP p
malocclusion NN p
. . p

This DT N
was VBD N
a DT N
prospective JJ N
randomized VBN N
clinical JJ N
trial NN N
conducted VBN N
in IN N
the DT N
Department NNP p
of IN p
Orthodontics NNP p
at IN p
the DT p
University NNP p
of IN p
Florida NNP p
between IN p
1990 CD p
and CC p
2003 CD p
. . p

METHODS NNP N
During IN N
phase NN N
1 CD N
treatment NN N
, , N
86 CD p
subjects NNS p
were VBD p
treated VBN p
with IN p
a DT p
bionator NN i
, , p
93 CD p
were VBD p
treated VBN p
with IN p
headgear/biteplane NN i
, , N
and CC N
81 CD p
served VBD p
as IN p
the DT p
observation NN p
group NN p
. . p

For IN N
phase NN N
2 CD N
, , N
all DT N
subjects NNS N
were VBD N
then RB N
treated VBN N
with IN N
full JJ i
orthodontic JJ i
appliances NNS i
. . i

Arch VBP N
dimensions NNS N
were VBD N
followed VBN N
; : N
maxillary JJ N
and CC N
mandibular JJ N
alginate NN N
impressions NNS N
were VBD N
taken VBN N
at IN N
baseline NN N
, , N
end NN N
of IN N
early JJ N
Class NNP N
II NNP N
treatment NN N
or CC N
observation NN N
, , N
beginning VBG N
of IN N
fixed JJ N
appliance NN N
treatment NN N
, , N
end NN N
of IN N
orthodontic JJ N
treatment NN N
, , N
and CC N
approximately RB N
3 CD N
years NNS N
posttreatment NN N
. . N

Alginate NNP N
impressions NNS N
were VBD N
taken VBN N
of IN N
each DT N
dental JJ N
arch NN N
at IN N
each DT N
data NN N
collection NN N
point NN N
. . N

These DT N
were VBD N
poured VBN N
in IN N
orthodontic JJ N
stone NN N
, , N
trimmed VBN N
, , N
and CC N
photocopied VBD N
from IN N
the DT N
occlusal NN N
aspect NN N
. . N

These DT N
images NNS N
were VBD N
then RB N
scanned VBN N
and CC N
measured VBN N
. . N

RESULTS NNP N
Although IN N
differences NNS N
between IN N
the DT N
treatment NN N
groups NNS N
were VBD N
found VBN N
in IN N
both DT N
the DT N
maxillary NN N
and CC N
mandibular JJ N
arches NNS N
after IN N
phase NN N
1 CD N
, , N
these DT N
differences NNS N
were VBD N
no RB N
longer RBR N
evident JJ N
by IN N
the DT N
end NN N
of IN N
full JJ N
orthodontic JJ N
treatment NN N
or CC N
after IN N
posttreatment JJ N
retention NN N
. . N

CONCLUSIONS NNP N
There EX N
were VBD N
no DT N
differences NNS N
in IN N
arch NN o
dimensions NNS o
after IN N
1-phase JJ N
or CC N
2-phase JJ N
treatment NN N
of IN N
Class NNP N
II NNP N
malocclusion NN N
. . N

-DOCSTART- -18328868- O O

Randomized VBN N
, , N
controlled VBD N
trial NN N
of IN N
Behavioral NNP i
Family NNP i
Systems NNP i
Therapy NNP i
for IN N
Diabetes NNPS p
: : p
maintenance NN N
and CC N
generalization NN N
of IN N
effects NNS N
on IN N
parent-adolescent JJ N
communication NN N
. . N

We PRP N
report VBP N
a DT N
randomized JJ N
trial NN N
of IN N
a DT N
revised JJ N
Behavioral NNP i
Family NNP i
Systems NNP i
Therapy NNP i
for IN i
Diabetes NNP i
( ( i
BFST-D NNP i
) ) i
intervention NN i
. . N

Families NNS p
of IN p
104 CD p
adolescents NNS p
with IN p
diabetes NNS p
were VBD p
randomized VBN p
to TO N
standard VB i
care NN i
( ( i
SC NNP i
) ) i
or CC i
to TO i
6 CD i
months NNS i
of IN i
an DT i
educational JJ i
support NN i
group NN i
( ( i
ES NNP i
) ) i
or CC i
BFST-D. JJ i
Family NNP o
communication NN o
and CC o
problem-solving JJ o
skills NNS o
were VBD N
assessed VBN N
at IN N
0 CD N
, , N
6 CD N
, , N
12 CD N
, , N
and CC N
18 CD N
months NNS N
by IN N
independent JJ N
rating NN N
of IN N
videotaped JJ N
family NN N
problem-solving JJ N
discussions NNS N
. . N

BFST-D NNP i
improved VBD N
individual JJ N
communication NN o
of IN o
adolescents NNS o
and CC o
mothers NNS o
, , o
but CC o
not RB o
fathers NNS o
. . o

BFST-D NNP i
significantly RB N
improved VBD N
quality NN o
of IN o
family NN o
interaction NN o
compared VBN N
to TO N
SC NNP N
( ( N
10 CD N
of IN N
12 CD N
comparisons NNS N
) ) N
and CC N
ES NNP N
( ( N
6 CD N
of IN N
12 CD N
comparisons NNS N
) ) N
. . N

Changes NNS N
in IN N
family NN N
communication NN N
were VBD N
differentially RB N
associated VBN N
with IN N
changes NNS N
in IN N
glycemic JJ o
control NN o
, , o
adherence NN o
, , o
and CC o
family NN o
conflict NN o
. . o

BFST-D NNP i
improved VBD N
family NN o
communication NN o
and CC o
problem NN o
solving VBG o
relative JJ N
to TO N
SC NNP N
and CC N
modestly RB N
relative JJ N
to TO N
ES NNP N
. . N

-DOCSTART- -12496956- O O

Oxytocin NNP i
infusion NN i
reduces NNS N
repetitive JJ o
behaviors NNS o
in IN N
adults NNS p
with IN p
autistic JJ p
and CC p
Asperger NNP p
's POS p
disorders NNS p
. . p

Autism NNP N
is VBZ N
a DT N
neurodevelopmental JJ N
disorder NN N
characterized VBN N
by IN N
dysfunction NN N
in IN N
three CD N
core NN N
behavioral JJ N
domains NNS N
: : N
repetitive JJ o
behaviors NNS o
, , N
social JJ N
deficits NNS N
, , N
and CC N
language NN N
abnormalities NNS N
. . N

There EX N
is VBZ N
evidence NN N
that IN N
abnormalities NNS N
exist VBP N
in IN N
peptide NN N
systems NNS N
, , N
particularly RB N
the DT N
oxytocin NN N
system NN N
, , N
in IN N
autism NN p
spectrum NN p
patients NNS p
. . p

Furthermore NNP N
, , N
oxytocin NN N
and CC N
the DT N
closely RB N
related JJ N
peptide NN N
vasopressin NN N
are VBP N
known VBN N
to TO N
play VB N
a DT N
role NN N
in IN N
social JJ N
and CC N
repetitive JJ N
behaviors NNS N
. . N

This DT N
study NN N
examined VBD N
the DT N
impact NN N
of IN N
oxytocin NN i
on IN N
repetitive JJ o
behaviors NNS o
in IN N
15 CD p
adults NNS p
with IN p
autism NN p
or CC p
Asperger NNP p
's POS p
disorder NN p
via IN N
randomized VBN N
double-blind NN N
oxytocin NN i
and CC i
placebo NN i
challenges NNS N
. . N

The DT N
primary JJ N
outcome NN N
measure NN N
was VBD N
an DT N
instrument NN N
rating NN N
six CD o
repetitive JJ o
behaviors NNS o
: : o
need NN o
to TO o
know VB o
, , o
repeating VBG o
, , o
ordering VBG o
, , o
need NN o
to TO o
tell/ask VB o
, , o
self-injury NN o
, , o
and CC o
touching VBG o
. . o

Patients NNS N
with IN N
autism NN N
spectrum NN N
disorders NNS N
showed VBD N
a DT N
significant JJ N
reduction NN N
in IN N
repetitive JJ o
behaviors NNS o
following VBG N
oxytocin JJ N
infusion NN N
in IN N
comparison NN N
to TO N
placebo VB N
infusion NN N
. . N

Repetitive JJ o
behavior NN o
in IN N
autism NN N
spectrum NN N
disorders NNS N
may MD N
be VB N
related VBN N
to TO N
abnormalities NNS N
in IN N
the DT N
oxytocin NN N
system NN N
, , N
and CC N
may MD N
be VB N
partially RB N
ameliorated VBN N
by IN N
synthetic JJ N
oxytocin NN N
infusion NN N
. . N

-DOCSTART- -16908870- O O

A DT N
randomized JJ N
comparison NN N
of IN N
the DT N
effect NN N
of IN N
two CD N
prelinguistic JJ i
communication NN i
interventions NNS i
on IN N
the DT N
acquisition NN N
of IN N
spoken JJ N
communication NN N
in IN N
preschoolers NNS p
with IN p
ASD NNP p
. . p

PURPOSE NNP N
This DT N
randomized VBN N
group NN N
experiment NN N
compared VBN N
the DT N
efficacy NN N
of IN N
2 CD N
communication NN i
interventions NNS i
( ( i
Responsive JJ i
Education NN i
and CC i
Prelinguistic NNP i
Milieu NNP i
Teaching NNP i
[ NNP i
RPMT NNP i
] NNP i
and CC i
the DT i
Picture NNP i
Exchange NNP i
Communication NNP i
System NNP i
[ NNP i
PECS NNP i
] NNP i
) ) i
on IN N
spoken JJ N
communication NN N
in IN N
36 CD p
preschoolers NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
( ( p
ASD NNP p
) ) p
. . p

METHOD NNP N
Each DT N
treatment NN N
was VBD N
delivered VBN N
to TO N
children NNS N
for IN N
a DT N
maximum JJ N
total NN N
of IN N
24 CD N
hr NN N
over IN N
a DT N
6-month JJ N
period NN N
. . N

Spoken NNP N
communication NN N
was VBD N
assessed VBN N
in IN N
a DT N
rigorous JJ N
test NN N
of IN N
generalization NN N
at IN N
pretreatment NN N
, , N
posttreatment NN N
, , N
and CC N
6-month JJ N
follow-up JJ N
periods NNS N
. . N

RESULTS NNP N
PECS NNP o
was VBD o
more RBR o
successful JJ o
than IN o
RPMT NNP o
in IN o
increasing VBG o
the DT o
number NN o
of IN o
nonimitative JJ o
spoken JJ o
communication NN o
acts NNS o
and CC o
the DT o
number NN o
of IN o
different JJ o
nonimitative JJ o
words NNS o
used VBN o
at IN o
the DT o
posttreatment JJ o
period NN o
. . o

Considering VBG N
growth NN N
over IN N
all DT N
3 CD N
measurement NN N
periods NNS N
, , N
an DT N
exploratory NN N
analysis NN N
showed VBD N
that IN N
growth NN o
rate NN o
of IN o
the DT o
number NN o
of IN o
different JJ o
nonimitative JJ o
words NNS o
was VBD o
faster RBR o
in IN o
the DT o
PECS NNP o
group NN N
than IN N
in IN N
the DT N
RPMT NNP N
group NN N
for IN N
children NNS N
who WP N
began VBD N
treatment NN N
with IN N
relatively RB N
high JJ N
object JJ N
exploration NN N
. . N

In IN N
contrast NN N
, , N
analogous JJ o
slopes NNS o
were VBD N
steeper VBN N
in IN N
the DT N
RPMT NNP N
group NN N
than IN N
in IN N
the DT N
PECS NNP N
group NN N
for IN N
children NNS N
who WP N
began VBD N
treatment NN N
with IN N
relatively RB N
low JJ N
object JJ N
exploration NN N
. . N

-DOCSTART- -19965647- O O

The DT N
impact NN N
on IN N
outcome NN N
of IN N
the DT N
addition NN N
of IN N
all-trans NNS i
retinoic JJ i
acid NN i
to TO i
intensive JJ i
chemotherapy NN i
in IN N
younger JJR p
patients NNS p
with IN p
nonacute JJ p
promyelocytic JJ p
acute NN p
myeloid NN p
leukemia NN p
: : p
overall JJ N
results NNS N
and CC N
results NNS N
in IN N
genotypic JJ p
subgroups NNS p
defined VBN p
by IN p
mutations NNS p
in IN p
NPM1 NNP p
, , p
FLT3 NNP p
, , p
and CC p
CEBPA NNP p
. . p

We PRP N
investigated VBD N
the DT N
benefit NN N
of IN N
adding VBG N
all-trans JJ i
retinoic NN i
acid NN i
( ( i
ATRA NNP i
) ) i
to TO N
chemotherapy VB i
for IN p
younger JJR p
patients NNS p
with IN p
nonacute JJ p
promyelocytic JJ p
acute NN p
myeloid NN p
leukemia NN p
and CC p
high-risk JJ p
myelodysplastic JJ p
syndrome NN p
, , N
and CC N
considered VBD N
interactions NNS N
between IN N
treatment NN N
and CC N
molecular JJ N
markers NNS N
. . N

Overall NNP N
, , N
1075 CD p
patients NNS p
less RBR p
than IN p
60 CD p
years NNS p
of IN p
age NN p
were VBD N
randomized VBN N
to TO N
receive VB N
or CC N
not RB N
receive JJ N
ATRA NNP i
in IN N
addition NN N
to TO N
daunorubicin/Ara-C/thioguanine JJ i
chemotherapy NN i
with IN i
Ara-C NNP i
at IN i
standard NN i
or CC i
double JJ i
standard NN i
dose NN i
. . i

There EX N
were VBD N
data NNS N
on IN N
FLT3 NNP N
internal JJ N
tandem NN N
duplications NNS N
and CC N
NPM1 NNP N
mutations NNS N
( ( N
n JJ N
= NNP N
592 CD N
) ) N
, , N
CEBPA NNP N
mutations NNS N
( ( N
n JJ N
= NNP N
423 CD N
) ) N
, , N
and CC N
MN1 NNP N
expression NN N
( ( N
n JJ N
= NNP N
195 CD N
) ) N
. . N

The DT N
complete JJ o
remission NN o
rate NN o
was VBD N
68 CD N
% NN N
with IN N
complete JJ N
remission NN N
with IN N
incomplete JJ N
count NN N
recovery NN N
in IN N
an DT N
additional JJ N
16 CD N
% NN N
; : N
8-year JJ o
overall JJ o
survival NN o
was VBD N
32 CD N
% NN N
. . N

There EX N
was VBD N
no DT N
significant JJ N
treatment NN N
effect NN N
for IN N
any DT N
outcome NN N
, , N
with IN N
no DT N
significant JJ N
interactions NNS N
between IN N
treatment NN N
and CC N
demographics NNS N
, , N
or CC N
cytarabine JJ N
randomization NN N
. . N

Importantly RB N
, , N
there EX N
were VBD N
no DT N
interactions NNS N
by IN N
FLT3/internal NNP o
tandem NN o
duplications NNS o
, , o
NPM1 NNP o
, , o
or CC o
CEBPA NNP o
mutation NN o
. . o

There EX N
was VBD N
a DT N
suggestion NN N
that IN N
ATRA NNP i
reduced VBD N
relapse NN o
in IN N
patients NNS N
with IN N
lower JJR N
MN1 NNP N
levels NNS N
, , N
but CC N
no DT N
significant JJ N
effect NN N
on IN N
overall JJ o
survival NN o
. . o

Results NNS N
were VBD N
consistent JJ N
when WRB N
restricted VBN N
to TO N
patients NNS N
with IN N
normal JJ N
karyotype NN N
. . N

ATRA NNP i
has VBZ N
no DT N
overall JJ N
effect NN N
on IN N
treatment NN N
outcomes NNS N
in IN N
this DT N
group NN N
of IN N
patients NNS N
. . N

The DT N
study NN N
did VBD N
not RB N
identify VB N
any DT N
subgroup NN N
of IN N
patients NNS N
likely JJ N
to TO N
derive VB N
a DT N
significant JJ N
survival JJ N
benefit NN N
from IN N
the DT N
addition NN N
of IN N
ATRA NNP i
to TO i
chemotherapy VB i
. . i

-DOCSTART- -9205768- O O

Efficacy NN N
of IN N
ebrotidine NN i
and CC i
ranitidine NN i
combined VBN i
with IN i
amoxicillin NN i
and CC i
metronidazole NN i
in IN N
the DT N
eradication NN o
of IN N
Helicobacter NNP N
pylori NN N
in IN N
patients NNS p
with IN p
duodenal JJ p
ulcer NN p
. . p

This DT N
double-blind NN N
, , N
randomized VBN N
, , N
phase VB N
III NNP N
clinical JJ N
trial NN N
was VBD N
carried VBN N
out RP N
in IN N
two CD p
parallel JJ p
groups NNS p
to TO N
assess VB N
the DT N
efficacy NN N
of IN N
ebrotidine NN i
( ( i
N- JJ i
[ NN i
( ( i
E NNP i
) ) i
- : i
[ JJ i
[ JJ i
2- JJ i
[ NN i
[ NNP i
[ NNP i
2- JJ i
[ NNP i
( ( i
diaminomethylene NN i
) ) i
amino NN i
] JJ i
-4-thiazolyl NNP i
] NNP i
methyl NN i
] NNP i
thio NN i
] NNP i
ethyl VBZ i
] NNP i
amino NN i
] NNP i
methylene NN i
] NNP i
-4-bromo-benzenesulfonamide NNP i
, , i
CAS NNP i
100981-43-9 CD i
, , i
FI-3542 NNP i
) ) i
400 CD i
mg NN i
and CC i
ranitidine VB i
300 CD i
mg NN i
given VBN N
in IN N
single JJ N
evening NN N
dose NN N
, , N
combined VBN i
with IN i
amoxicillin JJ i
750 CD N
mg NN N
and CC N
metronidazole $ i
500 CD N
mg NN N
three CD N
times NNS N
daily RB N
for IN N
14 CD N
days NNS N
, , N
in IN N
the DT N
eradication NN o
of IN N
Helicobacter NNP N
pylori NN N
in IN N
patients NNS p
with IN p
duodenal JJ p
ulcer NN p
. . p

Thirty JJ p
patients NNS p
were VBD p
included VBN p
, , p
divided VBN p
into IN p
two CD p
groups NNS p
of IN p
15 CD p
, , p
to TO p
whom WP p
one CD p
of IN p
the DT p
study NN p
therapies NNS p
was VBD p
administered VBN p
based VBN p
on IN p
a DT p
randomization NN p
code NN p
. . p

Clinical JJ N
and CC N
endoscopic JJ N
controls NNS N
were VBD N
performed VBN N
4 CD N
, , N
6 CD N
and CC N
8 CD N
weeks NNS N
after IN N
the DT N
onset NN N
of IN N
the DT N
treatment NN N
. . N

No DT N
differences NNS N
were VBD N
seen VBN N
between IN N
the DT N
two CD N
treatment NN N
groups NNS N
with IN N
regard NN N
to TO N
demographic JJ o
parameters NNS o
and CC o
clinical JJ o
histories NNS o
. . o

They PRP N
were VBD N
both DT N
perfectly RB N
homogeneous JJ N
. . N

There EX N
were VBD N
no DT N
differences NNS N
between IN N
the DT N
eradication NN o
of IN N
both DT N
therapies NNS N
in IN N
both DT N
the DT N
antrum NN N
and CC N
gastric JJ N
body NN N
samples NNS N
( ( N
over IN N
80 CD N
% NN N
eradication NN N
) ) N
, , N
allowing VBG N
the DT N
results NNS N
to TO N
be VB N
classified VBN N
as IN N
satisfactory NN N
. . N

Moreover RB N
, , N
perfect JJ N
control NN N
was VBD N
achieved VBN N
through IN N
the DT N
study NN N
of IN N
clinical JJ o
symptoms NNS o
, , N
which WDT N
even RB N
disappeared VBD N
in IN N
some DT N
cases NNS N
. . N

There EX N
were VBD N
no DT N
differences NNS N
in IN N
the DT N
healing VBG o
rate NN o
of IN N
the DT N
duodenal JJ N
ulcer NN N
after IN N
four CD N
weeks NNS N
, , N
86.7 CD N
% NN N
being VBG N
achieved VBN N
for IN N
both DT N
groups NNS N
. . N

-DOCSTART- -12094254- O O

Overexpression NN N
of IN N
vascular JJ N
endothelial JJ N
growth NN N
factor NN N
( ( N
VEGF NNP N
) ) N
and CC N
its PRP$ N
cellular JJ N
receptor NN N
KDR NNP N
( ( N
VEGFR-2 NNP N
) ) N
in IN N
the DT N
bone NN p
marrow NN p
of IN p
patients NNS p
with IN p
acute JJ p
myeloid NN p
leukemia NN p
. . p

Vascular JJ N
endothelial JJ N
growth NN N
factor NN N
( ( N
VEGF NNP N
) ) N
and CC N
its PRP$ N
cellular JJ N
receptor NN N
VEGFR-2 NNP N
have VBP N
been VBN N
implicated VBN N
as IN N
the DT N
main JJ N
endothelial JJ N
pathway NN N
required VBN N
for IN N
tumor NN N
neovascularization NN N
. . N

However RB N
, , N
the DT N
importance NN N
of IN N
the DT N
VEGF/VEGFR-2 NNP N
system NN N
for IN N
angiogenesis NN N
in IN N
hematologic JJ N
malignancies NNS N
such JJ N
as IN N
AML NNP N
remains VBZ N
to TO N
be VB N
elucidated VBN N
. . N

In IN p
32 CD p
patients NNS p
with IN p
newly RB p
diagnosed VBN p
untreated JJ p
AML NNP p
, , N
we PRP N
observed VBD N
by IN N
immunohistochemical JJ i
analysis NN i
of IN i
bone NN i
marrow NN i
biopsies NNS i
significantly RB N
higher JJR N
levels NNS N
of IN N
VEGF NNP N
and CC N
VEGFR-2 NNP N
expression NN N
than IN N
in IN N
10 CD p
control NN p
patients NNS p
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

In IN N
contrast NN N
, , N
VEGFR-1 NNP N
staining NN N
levels NNS N
in IN N
AML NNP N
patients NNS N
were VBD N
in IN N
the DT N
same JJ N
range NN N
as IN N
in IN N
the DT N
controls NNS N
. . N

Expression NN o
of IN o
VEGF NNP o
and CC o
VEGFR-2 NNP o
was VBD N
significantly RB N
higher JJR N
in IN N
patients NNS N
with IN N
a DT N
high JJ N
degree NN N
of IN N
microvessel NN N
density NN N
compared VBN N
to TO N
those DT N
with IN N
a DT N
low JJ N
degree NN N
( ( N
VEGF NNP N
: : N
P NNP N
=0.024 NNP N
; : N
VEGFR-2 JJ N
: : N
P NNP N
=0.040 NNP N
) ) N
and CC N
correlated VBN N
well RB N
with IN N
bone NN N
marrow NN N
microvessel NN N
density NN N
( ( N
r NN N
( ( N
s PRP N
) ) N
=0.566 NN N
and CC N
0.609 CD N
, , N
respectively RB N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

Furthermore UH N
, , N
in IN N
patients NNS N
who WP N
achieved VBD N
a DT N
complete JJ N
remission NN o
following VBG N
induction NN i
chemotherapy VBD i
VEGFR-2 NNP o
staining NN o
levels NNS o
decreased VBN N
into IN N
the DT N
normal JJ N
range NN N
. . N

In IN N
conclusion NN N
, , N
our PRP$ N
results NNS N
provide VBP N
evidence NN N
for IN N
increased JJ N
expression NN N
of IN N
VEGF/VEGFR-2 NNP o
of IN o
leukemic JJ o
blasts NNS o
and CC N
correlation NN N
with IN N
angiogenesis NN N
in IN N
the DT N
bone NN N
marrow NN N
of IN N
AML NNP N
patients NNS N
. . N

Thus RB N
, , N
VEGF/VEGFR-2 NNP N
might MD N
constitute VB N
promising VBG N
targets NNS N
for IN N
antiangiogenic JJ i
and CC N
antileukemic JJ i
treatment NN i
strategies NNS N
in IN N
AML NNP N
. . N

-DOCSTART- -21931984- O O

Locomoting-to-reach NN i
: : i
information NN N
variables NNS N
and CC N
control NN N
strategies NNS N
for IN N
nested JJ N
actions NNS N
. . N

Locomoting-to-reach NNP i
is VBZ N
a DT N
basic JJ N
perception/action NN N
behavior NN N
that WDT N
requires VBZ N
visual JJ N
information NN N
for IN N
the DT N
control NN N
of IN N
both DT N
locomotion NN N
and CC N
reaching VBG N
components NNS N
. . N

We PRP N
investigated VBD N
the DT N
visual JJ N
information NN N
and CC N
the DT N
control NN N
strategies NNS N
used VBN N
to TO N
guide VB N
both PDT N
the DT N
head NN N
and CC N
the DT N
hand NN N
on IN N
approach NN N
to TO N
a DT N
target NN N
in IN N
a DT N
locomotion-to-reach JJ i
task NN i
. . i

In IN N
this DT N
study NN N
, , N
participants NNS p
were VBD p
required VBN p
to TO p
locomote VB i
in IN i
the DT i
dark NN i
to TO i
a DT i
lit NN i
target NN i
in IN i
three CD i
different JJ i
conditions NNS i
: : i
monocular JJ i
vision/target NN i
with IN i
image NN i
size NN i
, , i
binocular JJ i
vision/target NN i
with IN i
image NN i
size NN i
, , i
and CC i
binocular JJ i
vision/point-light JJ i
target NN i
( ( i
without IN i
image NN i
size NN i
) ) i
. . i

In IN N
task NN N
one CD N
, , N
participants NNS N
brought VBD N
their PRP$ N
eyes NNS N
to TO N
the DT N
target NN N
. . N

In IN N
task NN N
two CD N
, , N
participants NNS N
brought VBD N
their PRP$ N
outstretched JJ N
hand NN N
to TO N
the DT N
target NN N
. . N

Movement JJ o
trajectories NNS o
for IN N
both DT N
tasks NNS N
were VBD N
analyzed VBN N
. . N

Results NNP N
show VBP N
that IN N
participants NNS p
were VBD N
significantly RB N
more RBR N
accurate JJ o
when WRB o
binocular JJ o
information NN o
was VBD o
present JJ o
. . o

In IN N
both DT N
tasks NNS N
, , N
participants NNS N
were VBD N
found VBN N
to TO N
use VB N
a DT N
proportional JJ o
rate NN o
control NN o
strategy NN o
rather RB o
than IN o
a DT o
constant JJ o
? . o
strategy NN o
. . o

In IN N
the DT o
walk-to-reach NN o
task NN o
, , o
they PRP N
used VBD o
monocular JJ o
and/or NN o
binocular NN o
? . o
information NN o
to TO o
guide VB o
the DT o
head NN o
and CC o
then RB N
switched VBD N
to TO N
using VBG o
relative JJ o
disparity NN o
? . o
to TO o
guide VB o
the DT o
hand NN o
to TO o
final JJ o
target NN o
acquisition NN o
, , o
switching VBG o
when WRB N
the DT N
hand NN N
centric NN N
? . N
became VBD N
less JJR N
than IN N
the DT N
head NN N
centric JJ N
?. NNP N
Dynamical NNP N
models NNS N
of IN N
the DT N
information NN N
and CC N
control NN N
strategies NNS N
were VBD N
used VBN N
to TO N
perform VB o
simulations NNS o
that WDT o
were VBD N
found VBN N
to TO N
fit VB N
the DT N
data NN N
well RB N
. . N

The DT N
conclusion NN N
is VBZ N
that IN N
proportional JJ o
rate NN o
control NN o
is VBZ o
used VBN o
sequentially RB N
with IN N
head NN o
centric NN o
, , o
then RB o
hand-centric JJ o
?-based JJ o
information NN o
, , o
using VBG o
at IN N
each DT N
moment NN N
the DT o
? . o
with IN N
the DT N
smallest JJS N
value NN N
. . N

-DOCSTART- -6123810- O O

Clobazam NNP i
in IN N
catamenial JJ p
epilepsy NN p
. . p

A DT N
model NN N
for IN N
evaluating VBG N
anticonvulsants NNS N
. . N

The DT N
cyclical JJ N
exacerbations NNS N
of IN N
epilepsy NN N
( ( N
catamenial JJ N
epilepsy NN N
) ) N
were VBD N
used VBN N
to TO N
assess VB N
the DT N
antiepileptic JJ N
effect NN N
of IN N
a DT N
benzodiazepine NN i
, , i
clobazam NN i
. . i

Doses NNS N
of IN N
20 CD N
mg NN N
, , N
and CC N
in IN N
some DT N
cases NNS N
30 CD N
mg NN N
, , N
per IN N
day NN N
were VBD N
compared VBN N
with IN N
placebo NN i
over IN N
predetermined JJ N
ten-day JJ N
periods NNS N
in IN N
a DT N
double-blind JJ N
cross-over NN N
study NN N
. . N

The DT N
results NNS N
were VBD N
evaluated VBN N
by IN N
preference NN N
in IN N
a DT N
sequential JJ N
procedure NN N
. . N

In IN N
14 CD p
of IN p
18 CD p
patients NNS p
who WP p
received VBD p
both DT p
treatments NNS p
clobazam NN i
was VBD N
superior JJ N
to TO N
placebo VB i
, , N
and CC N
in IN N
4 CD N
patients NNS N
no DT N
preference NN N
was VBD N
established VBN N
. . N

Clobazam NNP i
completely RB N
prevented VBD N
seizures NNS o
in IN N
most JJS N
of IN N
the DT N
patients NNS N
, , N
and CC N
toxic JJ N
effects NNS N
were VBD N
of IN N
low JJ N
frequency NN o
and CC o
severity NN o
. . o

-DOCSTART- -5052446- O O

Sequential JJ i
radiotherapy NN i
and CC i
chemotherapy NN i
in IN N
the DT N
treatment NN N
of IN N
Hodgkin NNP p
's POS p
disease NN p
. . p

A NNP N
progress JJ o
report NN o
. . o

-DOCSTART- -25644584- O O

A DT N
feasibility NN N
study NN N
for IN N
a DT N
randomised JJ N
controlled JJ N
trial NN N
of IN N
treatment NN N
withdrawal NN N
in IN N
psoriatic JJ p
arthritis NN p
( ( N
REmoval NNP N
of IN N
treatment NN N
for IN N
patients NNS p
in IN N
REmission NNP N
in IN N
psoriatic JJ N
ArThritis NNP N
( ( N
RETREAT NNP N
( ( N
F NNP N
) ) N
) ) N
. . N

TNF NNP N
therapy NN N
is VBZ N
effective JJ N
for IN N
all DT N
aspects NNS N
of IN N
psoriatic JJ N
disease NN N
, , N
but CC N
these DT N
drugs NNS N
are VBP N
costly JJ N
and CC N
the DT N
long-term JJ N
effects NNS N
are VBP N
unknown JJ N
. . N

Further NNP N
, , N
methotrexate NN N
causes NNS N
concern NN N
with IN N
long-term JJ N
adverse JJ N
events NNS N
. . N

The DT N
purpose NN N
of IN N
this DT N
pilot NN N
study NN N
was VBD N
to TO N
test VB o
the DT o
feasibility NN o
of IN N
drug NN i
withdrawal NN i
from IN N
patients NNS p
with IN p
psoriatic JJ p
arthritis NN p
, , p
in IN p
stable JJ p
low JJ p
disease NN p
state NN p
. . p

We PRP N
examined VBD N
the DT N
availability NN o
of IN o
patients NNS o
, , o
their PRP$ o
willingness NN o
to TO o
participate VB o
, , o
study NN o
procedures NNS o
, , o
and CC o
the DT o
proportion NN o
of IN o
patients NNS o
in IN o
the DT o
withdrawal NN o
arm NN o
who WP o
relapsed VBD o
during IN N
the DT N
study NN N
. . N

Low JJ N
disease NN N
state NN N
was VBD N
defined VBN N
by IN N
minimal JJ N
disease NN N
activity NN N
criteria NNS N
( ( N
MDA NNP N
) ) N
, , N
and CC N
relapse NN N
by IN N
failure NN N
to TO N
achieve VB N
these DT N
criteria NNS N
. . N

Patients NNS N
in IN N
the DT N
withdrawal NN N
group NN N
underwent VBD N
a DT N
phased JJ i
withdrawal NN i
of IN i
medication NN i
where WRB N
the DT N
last JJ N
treatment NN N
added VBD N
was VBD N
the DT N
first JJ N
withdrawn NN i
. . i

Assessments NNS o
were VBD N
monthly RB N
for IN N
3 CD N
months NNS N
before IN N
study NN N
exit NN N
. . N

Seventy-two JJ p
patients NNS p
were VBD p
invited VBN p
to TO p
participate VB p
, , p
of IN p
which WDT p
57 CD p
were VBD p
found VBN p
to TO p
be VB p
eligible JJ p
. . p

Twenty-six NNP N
( ( N
36.1 CD N
% NN N
) ) N
subsequently RB N
attended VBD N
the DT N
screening JJ N
visit NN N
but CC N
9 CD N
failed VBD N
eligibility NN N
criteria NNS N
so RB N
that IN N
17 CD N
patients NNS N
( ( N
29.8 CD N
% NN N
of IN N
the DT N
57 CD N
eligible JJ N
patients NNS N
, , N
95 CD N
% NN N
confidence NN N
interval NN N
( ( N
CI NNP N
) ) N
18.4 CD N
, , N
43.4 CD N
% NN N
) ) N
were VBD N
randomised VBN N
at IN N
a DT N
ratio NN N
of IN N
2:1 CD N
in IN N
favour NN N
of IN N
the DT N
withdrawal NN i
arm NN i
( ( N
11 CD N
withdrawals NNS N
, , N
6 CD N
standard NN N
care NN N
) ) N
. . N

Six CD N
patients NNS N
experienced VBD N
a DT N
flare NN o
, , N
all DT N
of IN N
whom WP N
were VBD N
in IN N
the DT N
withdrawal NN i
arm NN i
( ( N
relapse JJ N
rate NN N
54.6 CD N
% NN N
, , N
95 CD N
% NN N
CI NNP N
23.4 CD N
, , N
83.3 CD N
% NN N
) ) N
. . N

Four CD N
of IN N
the DT N
flares NNS N
were VBD N
apparent JJ N
from IN N
visit NN N
3 CD N
( ( N
8 CD N
weeks NNS N
after IN N
starting VBG N
withdrawal NN i
) ) i
. . N

Given VBN N
the DT N
high JJ N
relapse NN o
rate NN o
, , N
an DT N
alternative JJ N
trial NN N
design NN N
of IN N
partial JJ N
treatment NN N
withdrawal NN N
, , N
possibly RB N
including VBG N
a DT N
patient JJ N
preference NN N
arm NN N
, , N
is VBZ N
recommended VBN N
. . N

-DOCSTART- -21793626- O O

Effect NN N
of IN N
ginseng NN i
extract JJ i
supplementation NN i
on IN N
testicular JJ o
functions NNS o
in IN N
diabetic JJ p
rats NNS p
. . p

OBJECTIVE IN N
It PRP N
was VBD N
aimed VBN N
to TO N
investigate VB N
the DT N
effect NN N
of IN N
standardized JJ N
ginseng NN i
extract NN i
on IN N
fertility NN o
parameters NNS o
in IN N
diabetic JJ p
rats NNS p
. . p

METHODS NNP N
Thirty NNP p
male NN p
rats NNS p
were VBD N
randomly RB N
allocated VBN N
into IN N
three CD N
groups NNS N
of IN N
10 CD N
rats NNS N
each DT N
: : N
1. CD N
controls NNS N
, , N
2. CD N
diabetes NNS N
( ( N
D NNP N
) ) N
and CC N
3. CD N
diabetes NNS N
+ JJ N
ginseng NN N
( ( N
DG NNP N
) ) N
. . N

The DT N
latter JJ N
two CD N
groups NNS N
were VBD N
rendered VBN N
diabetic JJ N
by IN N
i.p NN N
. . N

injection NN N
of IN N
streptozotocin NN i
( ( N
STZ NNP N
; : N
50 CD N
mg/kg NN N
) ) N
. . N

Standardized VBN i
ginseng NN i
extract NN i
( ( N
Dansk NNP N
Droge NNP N
A/S NNP N
, , N
Copenhagen NNP N
, , N
Denmark NNP N
) ) N
was VBD N
administered VBN N
per IN N
os NN N
( ( N
100 CD N
mg/kg RB N
BW NNP N
) ) N
by IN N
stomach NN N
tube NN N
daily RB N
for IN N
90 CD N
days NNS N
starting VBG N
one CD N
week NN N
after IN N
STZ NNP N
. . N

Ninety NNP N
days NNS N
post NN N
STZ VBP N
the DT N
rats NNS N
were VBD N
sacrificed VBN N
, , N
and CC N
testis NN o
, , o
epididymis NN o
, , o
prostate NN o
, , o
and CC o
seminal JJ o
vesicles NNS o
were VBD o
weighed VBN o
and CC o
subjected VBN o
to TO o
histological JJ o
examination NN o
. . o

In IN N
addition NN N
, , N
spermiogram NN o
, , o
testicular JJ o
enzyme NN o
markers NNS o
, , o
intratesticular JJ o
steroid JJ o
hormonal NN o
profile NN o
and CC o
testicular JJ o
antioxidant NN o
status NN o
were VBD N
estimated VBN N
. . N

RESULTS VB N
The DT N
administration NN N
of IN N
ginseng JJ i
extract NN i
resulted VBD N
in IN N
a DT N
significant JJ N
improvement NN N
of IN N
fertility NN o
parameters NNS o
and CC o
testicular JJ o
antioxidants NNS o
together RB o
with IN N
a DT N
decrease NN o
in IN o
malondialdehyde NN o
and CC o
testicular JJ o
pathological JJ o
signs NNS o
including VBG o
degenerative JJ o
changes NNS o
of IN o
the DT o
seminiferous JJ o
tubules NNS o
. . o

CONCLUSION NNP N
Ginseng NNP i
extract NN i
may MD N
be VB N
a DT N
beneficial JJ N
adjuvant NN N
therapy NN N
for IN N
diabetics NNS N
suffering VBG N
from IN N
infertility NN o
as IN N
a DT N
complication NN N
. . N

-DOCSTART- -25898050- O O

Effect NN N
of IN N
parent NN i
training NN i
vs NN i
parent NN i
education NN i
on IN N
behavioral JJ p
problems NNS p
in IN p
children NNS p
with IN p
autism NN p
spectrum NN p
disorder NN p
: : p
a DT N
randomized JJ N
clinical JJ N
trial NN N
. . N

IMPORTANCE NNP N
Disruptive NNP N
behavior NN N
is VBZ N
common JJ N
in IN N
children NNS p
with IN p
autism NN p
spectrum NN p
disorder NN p
. . p

Behavioral JJ N
interventions NNS N
are VBP N
used VBN N
to TO N
treat VB N
disruptive JJ N
behavior NN N
but CC N
have VBP N
not RB N
been VBN N
evaluated VBN N
in IN N
large-scale JJ N
randomized JJ N
trials NNS N
. . N

OBJECTIVE NNP N
To TO N
evaluate VB N
the DT N
efficacy NN N
of IN N
parent NN i
training NN i
for IN N
children NNS p
with IN p
autism NN p
spectrum NN p
disorder NN p
and CC p
disruptive JJ p
behavior NN p
. . p

DESIGN NNP N
, , N
SETTING NNP N
, , N
AND NNP N
PARTICIPANTS NNP N
This DT N
24-week JJ N
randomized JJ N
trial NN N
compared VBN N
parent NN i
training NN i
( ( i
n JJ i
= NNP i
89 CD i
) ) i
to TO i
parent VB i
education NN i
( ( i
n JJ i
= NNP p
91 CD p
) ) p
at IN p
6 CD p
centers NNS p
( ( p
Emory NNP p
University NNP p
, , p
Indiana NNP p
University NNP p
, , p
Ohio NNP p
State NNP p
University NNP p
, , p
University NNP p
of IN p
Pittsburgh NNP p
, , p
University NNP p
of IN p
Rochester NNP p
, , p
Yale NNP p
University NNP p
) ) p
. . p

We PRP p
screened VBD p
267 CD p
children NNS p
; : p
180 CD p
children NNS p
( ( p
aged VBN p
3-7 CD p
years NNS p
) ) p
with IN p
autism NN p
spectrum NN p
disorder NN p
and CC p
disruptive JJ p
behaviors NNS p
were VBD p
randomly RB p
assigned VBN p
( ( p
86 CD p
% NN p
white JJ p
, , p
88 CD p
% NN p
male NN p
) ) p
between IN p
September NNP p
2010 CD p
and CC p
February NNP p
2014 CD p
. . p

INTERVENTIONS NNP i
Parent NNP i
training NN i
( ( i
11 CD i
core NN i
, , i
2 CD i
optional JJ i
sessions NNS i
; : i
2 CD i
telephone NN i
boosters NNS i
; : i
2 CD i
home NN i
visits NNS i
) ) i
provided VBD N
specific JJ N
strategies NNS N
to TO N
manage VB N
disruptive JJ N
behavior NN N
. . i

Parent NN i
education NN i
( ( i
12 CD i
core NN i
sessions NNS i
, , i
1 CD i
home NN i
visit NN i
) ) i
provided VBN N
information NN N
about IN N
autism NN N
but CC N
no DT N
behavior JJ N
management NN N
strategies NNS N
. . N

MAIN NNP N
OUTCOMES NNP N
AND NNP N
MEASURES NNP N
Parents NNP o
rated VBD o
disruptive JJ o
behavior NN o
and CC o
noncompliance NN o
on IN o
co-primary JJ o
outcomes NNS o
: : o
the DT o
Aberrant NNP o
Behavior NNP o
Checklist-Irritability NNP o
subscale NN o
( ( o
range NN o
, , o
0-45 NN o
) ) o
and CC o
the DT o
Home NNP o
Situations NNP o
Questionnaire-Autism NNP o
Spectrum NNP o
Disorder NNP o
( ( o
range NN o
, , o
0-9 JJ o
) ) o
. . o

On IN N
both DT N
measures NNS N
, , N
higher JJR N
scores NNS N
indicate VBP N
greater JJR N
severity NN N
and CC N
a DT N
25 CD N
% NN N
reduction NN N
indicates VBZ N
clinical JJ N
improvement NN N
. . N

A DT N
clinician JJ N
blind NN N
to TO N
treatment NN N
assignment NN N
rated VBD N
the DT N
Improvement NNP N
scale NN N
of IN N
the DT N
Clinical NNP N
Global NNP N
Impression NNP N
( ( N
range NN N
, , N
1-7 JJ N
) ) N
, , N
a DT N
secondary JJ N
outcome NN N
, , N
with IN N
a DT N
positive JJ N
response NN N
less JJR N
than IN N
3 CD N
. . N

RESULTS NN N
At IN N
week NN N
24 CD N
, , N
the DT N
Aberrant NNP o
Behavior NNP o
Checklist-Irritability NNP o
subscale NN o
declined VBD o
47.7 CD N
% NN N
in IN N
parent NN i
training NN i
( ( i
from IN i
23.7 CD i
to TO N
12.4 CD N
) ) N
compared VBN N
with IN N
31.8 CD N
% NN N
for IN i
parent NN i
education NN i
( ( i
23.9 CD i
to TO i
16.3 CD N
) ) N
( ( N
treatment NN N
effect NN N
, , N
-3.9 NNP N
; : N
95 CD N
% NN N
CI NNP N
, , N
-6.2 NNP N
to TO N
-1.7 VB N
; : N
P NNP N
< NNP N
.001 NNP N
, , N
standardized VBD N
effect NN N
size NN N
= NNP N
0.62 CD N
) ) N
. . o

The DT o
Home NNP o
Situations NNP o
Questionnaire-Autism NNP o
Spectrum NNP o
Disorder NNP o
declined VBD o
55 CD N
% NN N
( ( N
from IN N
4.0 CD N
to TO N
1.8 CD N
) ) N
compared VBN N
with IN N
34.2 CD N
% NN N
in IN N
parent NN N
education NN N
( ( N
3.8 CD N
to TO N
2.5 CD N
) ) N
( ( N
treatment NN N
effect NN N
, , N
-0.7 NNP N
; : N
95 CD N
% NN N
CI NNP N
, , N
-1.1 NNP N
to TO N
-0.3 VB N
; : N
P NNP N
< NNP N
.001 NNP N
, , N
standardized VBD N
effect NN N
size NN N
= NNP N
0.45 CD N
) ) N
. . N

Neither CC N
measure NN N
met VBD N
the DT N
prespecified VBN N
minimal JJ N
clinically RB N
important JJ N
difference NN N
. . N

The DT N
proportions NNS N
with IN N
a DT N
positive JJ N
response NN N
on IN N
the DT N
Clinical JJ o
Global NNP o
Impression-Improvement NNP o
scale NN o
were VBD o
68.5 CD o
% NN o
for IN o
parent NN o
training NN N
vs JJ N
39.6 CD N
% NN N
for IN N
parent NN N
education NN N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

CONCLUSIONS NNP N
AND CC N
RELEVANCE NNP N
For IN p
children NNS p
with IN p
autism NN p
spectrum NN p
disorder NN p
, , p
a DT p
24-week JJ N
parent NN N
training NN N
program NN N
was VBD N
superior JJ i
to TO i
parent VB i
education NN i
for IN i
reducing VBG i
disruptive JJ N
behavior NN N
on IN N
parent-reported JJ N
outcomes NNS N
, , N
although IN N
the DT N
clinical JJ N
significance NN N
of IN N
the DT N
improvement NN N
is VBZ N
unclear JJ N
. . N

The DT N
rate NN N
of IN N
positive JJ N
response NN N
judged VBN N
by IN N
a DT N
blinded JJ N
clinician NN N
was VBD N
greater JJR i
for IN i
parent NN i
training NN i
vs NN i
parent NN i
education NN i
. . i

TRIAL NNP i
REGISTRATION NNP N
clinicaltrials.gov NN N
Identifier NNP N
: : N
NCT01233414 NN N
. . N

-DOCSTART- -2192505- O O

[ JJ i
Cisapride NNP i
for IN p
the DT p
treatment NN p
of IN p
irritable JJ p
stomach NN o
-- : o
results NNS o
of IN p
2 CD p
multicenter NN p
studies NNS p
] VBP p
. . N

-DOCSTART- -25040756- O O

The DT N
addition NN N
of IN N
tramadol NN i
to TO N
the DT N
standard NN N
of IN N
i.v NN N
. . N

acetaminophen NN i
and CC i
morphine NN i
infusion NN N
for IN N
postoperative JJ p
analgesia NN p
in IN p
neonates NNS p
offers NNS N
no DT N
clinical JJ N
benefit NN N
: : N
a DT N
randomized JJ N
placebo-controlled JJ i
trial NN N
. . N

BACKGROUND NNP N
Tramadol NNP i
is VBZ N
used VBN N
following VBG N
neonatal JJ p
cardiac JJ p
and CC p
general JJ p
surgery NN p
. . p

However RB N
, , N
its PRP$ N
ability NN N
to TO N
opioid-spare NN N
or CC N
facilitate NN N
earlier JJR N
extubation NN N
in IN N
postoperative JJ N
neonates NNS N
is VBZ N
unquantified JJ N
. . N

OBJECTIVE VB N
This DT N
randomized JJ N
placebo-controlled JJ N
trial NN N
aimed VBN N
to TO N
assess VB N
whether IN N
tramadol NN i
's POS i
addition NN N
to TO N
standard VB i
analgesia NN i
resulted VBD N
in IN N
earlier JJR N
extubation NN N
or CC N
reduced VBN N
analgesic/sedative JJ N
requirements NNS N
in IN N
postsurgical JJ p
neonates NNS p
. . p

METHODS NNP N
Neonates NNP p
born VBD p
?32 JJ p
weeks NNS p
postmenstrual JJ p
age NN p
received VBD p
either CC i
tramadol JJ i
[ NNP i
T NNP N
] VBD N
2 CD N
mg?kg NN N
( ( N
-1 JJ N
) ) N
or CC N
placebo JJ i
[ JJ i
P NNP i
] NNP N
6-hourly RB N
for IN N
up IN N
to TO N
5 CD N
days NNS p
postthoracoabdominal JJ p
surgery NN p
in IN p
addition NN N
to TO N
morphine VB i
( ( i
commenced VBN i
at IN N
20 CD N
mcg?kg NN N
( ( N
-1 NNP N
) ) N
?h NN N
( ( N
-1 NNP N
) ) N
) ) N
and CC N
6-hourly JJ N
i.v NN N
. . N

acetaminophen NN o
. . o

Time NN o
to TO o
extubation NN o
, , o
morphine NN o
and CC o
midazolam NN o
amounts NNS o
, , o
hourly RB o
pain NN o
scores NNS o
, , o
and CC o
seizure NN o
activity NN o
were VBD o
compared VBN N
using VBG N
an DT N
intention-to-treat JJ N
and CC N
per-protocol JJ N
analysis NN N
. . N

RESULTS NNP p
Seventy-one JJ p
neonates NNS p
participated VBD o
. . o

Median JJ o
survival JJ o
time NN o
to TO o
extubation NN o
was VBD o
similar JJ N
between IN N
the DT N
groups NNS N
( ( N
T NNP N
67 CD N
h NN N
[ JJ N
95 CD N
% NN N
CI NNP N
51 CD N
, , N
84 CD N
] NN N
vs NN N
P NNP N
52 CD N
h NN N
[ JJ N
95 CD N
% NN N
CI NNP N
43 CD N
, , N
65 CD N
] NN N
; : N
P NNP N
= NNP N
0.4 CD N
) ) N
, , N
and CC N
similar JJ N
numbers NNS N
were VBD N
extubated VBN N
by IN N
96 CD N
h NN N
( ( N
T NNP N
69 CD N
% NN N
vs NN N
P NNP N
77 CD N
% NN N
; : N
difference NN N
-8 CD N
% NN N
, , N
95 CD N
% NN N
CI NNP N
-28 NNP N
, , N
13 CD N
% NN N
) ) N
. . N

Morphine NNP N
and CC N
midazolam NN N
exposure NN N
was VBD N
similar JJ N
, , N
with IN N
low JJ o
pain NN o
scores NNS o
in IN o
both DT o
groups NNS N
( ( N
mean JJ N
percentage NN N
of IN N
time NN N
with IN N
a DT o
pain NN o
score NN o
> VBD o
5/20 CD o
during IN N
the DT N
5 CD N
days NNS N
: : N
T VB N
13 CD N
% NN N
vs NN N
P NNP N
11 CD N
% NN N
, , N
difference NN N
in IN N
means VBZ N
2.8 CD N
[ JJ N
95 CD N
% NN N
CI NNP N
-1.8 NNP N
, , N
7.6 CD N
] NN N
, , N
P NNP N
= NNP N
0.20 CD N
) ) N
. . N

Most JJS N
participants NNS N
had VBD N
normal JJ o
cranial JJ o
ultrasounds NNS o
( ( o
T NNP o
86 CD o
% NN N
vs NN N
P NNP N
86 CD N
% NN N
) ) N
; : N
no DT o
seizures NNS o
occurred VBD o
clinically RB N
or CC N
electroencephalographically RB N
. . N

CONCLUSION NNP N
Tramadol NNP N
's POS N
addition NN N
to TO N
standard VB N
analgesia NN N
in IN N
this DT N
small JJ N
group NN N
of IN p
postsurgical JJ p
neonates NNS p
did VBD p
not RB N
appear VB N
to TO N
have VB N
any DT N
positive JJ N
effect NN o
on IN o
time NN o
to TO o
extubation NN o
, , o
morphine NN o
or CC o
midazolam NN o
exposure NN o
, , o
or CC o
pain NN o
scores NNS o
. . o

This DT o
questions NNS N
the DT N
benefit NN N
of IN N
tramadol NN N
for IN N
postsurgical JJ N
neonates NNS N
. . N

Importantly RB N
, , N
no DT N
seizures NNS N
occurred VBD N
in IN N
these DT N
ill JJ N
neonates NNS N
who WP N
may MD N
potentially RB N
be VB N
at IN N
greater JJR N
risk NN N
of IN N
tramadol JJ N
toxicity NN N
compared VBN N
with IN N
adults NNS p
. . p

-DOCSTART- -14668075- O O

Bupropion NNP i
SR NNP i
and CC i
counseling VBG i
for IN i
smoking VBG i
cessation NN p
in IN N
actual JJ N
practice NN N
: : N
predictors NNS N
of IN N
outcome NN N
. . N

To TO N
date NN N
, , N
only RB N
one CD N
study NN N
has VBZ N
been VBN N
published VBN N
on IN N
individual JJ N
characteristics NNS N
associated VBN N
with IN N
outcome NN N
following VBG N
standard JJ i
treatment NN i
with IN i
bupropion NN i
SR NNP i
for IN N
smoking VBG N
cessation NN N
. . N

To TO N
investigate VB N
treatment NN N
outcome NN N
beyond IN N
the DT N
6-week JJ N
end-of-treatment JJ N
point NN N
, , N
the DT N
present JJ N
study NN N
examined VBD N
characteristics NNS N
associated VBN N
with IN N
more RBR N
clinically RB N
relevant JJ N
smoking NN N
endpoints NNS N
following VBG N
treatment NN N
with IN N
bupropion NN i
SR NNP i
in IN N
a DT N
large JJ N
health NN N
care NN N
system NN N
. . N

A DT N
total NN p
of IN p
1,524 CD p
smokers NNS p
( ( p
649 CD p
men NNS p
and CC p
875 CD p
women NNS p
) ) p
of IN p
average JJ p
age NN p
45.1 CD p
years NNS p
were VBD N
randomized VBN N
to TO N
receive VB N
one CD N
of IN N
four CD N
combinations NNS N
of IN N
bupropion NN i
SR NNP i
( ( N
150 CD N
or CC N
300 CD N
mg NN N
) ) N
and CC N
behavioral JJ i
counseling NN i
( ( i
tailored JJ i
mailings NNS i
or CC i
proactive JJ i
telephone NN i
counseling NN i
) ) i
and CC N
assessed VBN N
for IN N
point-prevalent JJ N
smoking NN N
status NN N
at IN N
3 CD N
and CC N
12 CD N
months NNS N
. . N

Multiple NNP N
logistic JJ N
regression NN N
analyses NNS N
of IN N
potential JJ N
risk NN N
factors NNS N
for IN N
12-month JJ N
point-prevalent JJ N
smoking NN N
and CC N
for IN N
persistent JJ N
smoking NN N
( ( N
point-prevalent JJ N
smoking NN N
at IN N
both DT N
follow-ups NNS N
) ) N
following VBG N
treatment NN N
were VBD N
conducted VBN N
for IN N
men NNS N
and CC N
women NNS N
combined VBN N
and CC N
separately RB N
. . N

Risk NN N
factors NNS N
for IN N
smoking NN N
at IN N
both DT N
endpoints NNS N
in IN N
the DT N
combined JJ N
sample NN N
included VBD N
treatment NN N
with IN N
tailored JJ N
mailings NNS N
, , N
female JJ N
gender NN N
, , N
younger JJR N
age NN N
, , N
higher JJR N
levels NNS N
of IN N
tobacco NN N
dependence NN N
, , N
shorter RB N
previous JJ N
quit NN N
attempts NNS N
, , N
previous JJ N
use NN N
of IN N
nicotine JJ N
replacement NN N
therapy NN N
, , N
and CC N
report NN N
of IN N
current JJ N
depressive JJ N
symptoms NNS N
or CC N
lifetime JJ N
depression NN N
. . N

Risk NN N
factors NNS N
for IN N
smoking VBG N
following VBG N
treatment NN N
identified VBN N
in IN N
women NNS N
only RB N
included VBD N
treatment NN N
with IN N
the DT N
lower JJR N
dose NN N
of IN N
bupropion NN i
SR NNP i
, , N
younger JJR N
age NN N
, , N
and CC N
higher JJR N
perceived VBD N
stress NN N
, , N
whereas VBP N
those DT N
that WDT N
were VBD N
unique JJ N
to TO N
men NNS N
included VBD N
the DT N
presence NN N
of IN N
lifetime JJ N
depression NN N
. . N

The DT N
results NNS N
are VBP N
discussed VBN N
in IN N
terms NNS N
of IN N
their PRP$ N
implications NNS N
for IN N
the DT o
need NN o
for IN o
more RBR o
effective JJ o
treatments NNS o
in IN N
general JJ N
, , N
and CC N
the DT N
role NN N
of IN N
individual JJ o
differences NNS o
in IN o
the DT o
likelihood NN o
of IN o
returning VBG o
to TO o
smoking VBG o
following VBG o
treatment NN o
for IN o
quitting VBG N
. . N

-DOCSTART- -22670827- O O

A DT N
randomised JJ N
comparison NN N
of IN N
the DT N
self-pressurised JJ N
air-QTM JJ N
intubating NN N
laryngeal JJ i
airway RB N
with IN N
the DT N
LMA NNP i
Unique? NNP i
in IN i
children NNS p
. . p

We PRP N
conducted VBD N
a DT N
randomised JJ N
trial NN N
comparing VBG N
the DT i
self-pressurised JJ i
air-Q? JJ i
intubating NN i
laryngeal NN i
airway RB i
( ( i
air-Q JJ i
SP NNP i
) ) i
with IN i
the DT i
LMA-Unique NNP i
in IN i
60 CD p
children NNS p
undergoing JJ p
surgery NN p
. . p

Outcomes CC p
measured VBN N
were VBD N
airway RB o
leak JJ o
pressure NN o
, , o
ease NN o
and CC o
time NN o
for IN o
insertion NN o
, , o
fibreoptic JJ o
examination NN o
, , o
incidence NN o
of IN o
gastric JJ o
insufflation NN o
and CC o
complications NNS o
. . o

Median JJ o
( ( N
IQR NNP N
[ NNP N
range NN o
] NNP o
) ) o
time NN o
to TO o
successful JJ o
device NN o
placement NN o
was VBD o
faster RBR N
with IN N
the DT N
air-Q JJ N
SP NNP N
( ( N
12 CD N
( ( N
10-15 JJ N
[ NNP N
5-18 CD N
] NNP N
) ) N
) ) N
s NN N
than IN N
with IN N
the DT N
LMA-Unique NNP N
( ( N
14 CD N
( ( N
12-17 JJ N
[ NNP N
6-22 NNP N
] NNP N
) ) N
s NN N
; : N
p=0.05 NN N
) ) N
. . N

There EX N
were VBD N
no DT N
statistically RB N
significant JJ N
differences NNS N
between IN N
the DT N
air-Q JJ N
SP NNP N
and CC N
LMA-Unique NNP N
in IN N
initial JJ o
airway NN o
leak NN o
pressures NNS o
( ( o
16 CD o
( ( N
14-18 JJ N
[ NNP N
10-29 CD N
] NNP N
) ) N
compared VBN N
with IN N
18 CD N
( ( N
15-20 JJ N
[ NNP N
10-30 CD N
] NNP N
) ) N
cmH2 NN N
O NNP N
, , N
p=0.12 NN N
) ) N
, , N
an DT N
airway NN o
leak NN o
pressures NNS o
at IN o
10 CD N
min NN N
( ( N
19 CD N
( ( N
16-22 JJ N
[ NNP N
12-30 CD N
] NNP N
) ) N
compared VBN N
with IN N
20 CD N
( ( N
16-22 JJ N
[ NNP N
10-30 CD N
] NNP N
) ) N
cmH2 NN N
O NNP N
, , N
p=0.81 NN o
) ) o
; : o
fibreoptic JJ o
position NN o
, , o
incidence NN o
of IN o
gastric JJ o
insufflation NN o
, , o
or CC o
complications NNS o
. . o

Both DT o
devices NNS N
provided VBD o
effective JJ o
ventilation NN o
without IN o
the DT o
need NN o
for IN o
airway JJ o
manipulation NN o
. . o

The DT o
air-Q JJ N
SP NNP N
is VBZ N
an DT N
alternative JJ N
to TO N
the DT N
LMA-Unique NNP N
should MD N
the DT N
clinician JJ N
prefer VBP N
a DT N
device NN N
not RB N
requiring VBG N
cuff NN N
monitoring NN N
during IN N
anaesthesia NN N
. . N

-DOCSTART- -23092665- O O

Is VBZ N
prophylactic JJ N
intravenous JJ N
administration NN N
of IN N
a DT N
proton NN i
pump NN i
inhibitor NN i
necessary JJ N
for IN N
perioperative JJ N
management NN N
of IN N
cardiac NN p
surgery NN p
? . N
BACKGROUND NNP N
Mortality NNP N
from IN N
gastrointestinal JJ N
( ( N
GI NNP N
) ) N
hemorrhage NN N
caused VBN N
by IN N
antiplatelet NN i
or CC i
anticoagulant JJ i
therapy NN i
( ( N
or CC N
both DT N
) ) N
is VBZ N
quite RB N
high JJ N
after IN N
cardiac JJ N
surgery NN N
. . N

We PRP N
previously RB N
reported VBD N
that IN N
proton NN i
pump NN i
inhibitor NN i
( ( i
PPI NNP i
) ) i
therapy NN i
is VBZ N
indispensable JJ N
in IN N
preventing VBG N
postoperative JJ N
GI NNP N
complications NNS N
. . N

PPIs NNS i
are VBP N
usually RB N
administered VBN N
intravenously RB N
immediately RB N
after IN N
surgery NN N
and CC N
subsequently RB N
by IN N
oral JJ N
formulations NNS N
. . N

We PRP N
conducted VBD N
a DT N
prospective JJ N
study NN N
to TO N
evaluate VB N
whether IN N
intravenous JJ N
PPI NNP i
followed VBN N
by IN N
oral JJ N
administration NN N
is VBZ N
more RBR N
efficient JJ N
as IN N
prophylaxis NN N
than IN N
oral-only JJ N
administration NN N
. . N

METHODS NNP N
AND CC N
RESULTS NNP N
We PRP N
enrolled VBD N
40 CD p
patients NNS p
scheduled VBN p
to TO p
undergo VB p
coronary JJ p
artery NN p
bypass NN p
grafting VBG p
with IN p
cardiopulmonary JJ p
bypass NN p
and CC N
randomly RB N
assigned VBD N
them PRP N
to TO N
receive VB i
oral JJ i
PPIs NNP i
alone RB i
( ( i
group NN i
1 CD i
) ) i
or CC i
intravenous JJ i
PPI NNP i
followed VBN i
by IN i
oral JJ i
administration NN i
( ( i
group NN i
2 CD i
) ) i
. . N

Postoperative JJ N
upper JJ N
GI NNP N
endoscopy NN N
evaluations NNS N
showed VBD N
no DT N
evidence NN N
of IN N
GI NNP o
bleeding NN o
. . o

Only RB N
gastritis NN o
, , o
esophagitis NN o
, , o
and CC o
hiatal JJ o
hernia NN o
were VBD N
observed VBN N
at IN N
similar JJ N
incidences NNS N
in IN N
the DT N
groups NNS N
. . N

Mean NNP o
hospital NN o
stays NNS o
were VBD N
also RB N
similar JJ N
, , N
but CC N
the DT N
cost NN o
of IN o
PPI NNP o
treatment NN o
was VBD N
significantly RB N
lower JJR N
in IN N
group NN N
1 CD N
. . N

CONCLUSION NNP N
No NNP N
additional JJ N
benefits NNS N
of IN N
intravenous JJ N
PPIs NNP N
over IN N
oral JJ N
formulations NNS N
were VBD N
demonstrated VBN N
. . N

Oral JJ N
PPIs NNP i
alone RB N
were VBD N
effective JJ N
and CC N
economical JJ N
as IN N
prophylaxis NN N
against IN N
GI NNP N
complications NNS N
. . N

Intravenous NNP N
PPIs NNP i
might MD N
be VB N
unnecessary JJ N
in IN N
selected VBN p
patients NNS p
after IN p
cardiac JJ p
surgery NN p
. . p

-DOCSTART- -2141713- O O

[ JJ N
Presentation NNP N
of IN N
a DT N
randomized JJ N
multicenter NN N
study NN N
protocol NN N
. . N

Evaluation NN N
of IN N
adjuvant JJ o
interferon NN o
effectiveness NN o
after IN N
radical JJ N
nephrectomy NN N
in IN N
kidney NN p
carcinoma NN p
with IN p
high JJ p
risk NN p
of IN p
relapse NN p
] NN p
. . N

-DOCSTART- -20152559- O O

A DT N
randomized JJ N
comparison NN N
of IN N
the DT N
Endeavor NNP i
zotarolimus-eluting JJ i
stent NN i
versus IN i
the DT i
TAXUS NNP i
paclitaxel-eluting JJ i
stent NN i
in IN N
de FW N
novo FW N
native JJ N
coronary JJ N
lesions NNS N
12-month JJ N
outcomes NNS N
from IN N
the DT N
ENDEAVOR NNP N
IV NNP N
trial NN N
. . N

OBJECTIVES CC N
The DT N
ENDEAVOR NNP N
IV NNP N
( ( N
Randomized NNP N
Comparison NNP N
of IN N
Zotarolimus-Eluting NNP i
and CC N
Paclitaxel-Eluting NNP i
Stents NNP i
in IN N
Patients NNP N
with IN N
Coronary NNP N
Artery NNP N
Disease NNP N
) ) N
trial NN N
evaluated VBD N
the DT N
safety NN o
and CC o
efficacy NN o
of IN N
the DT N
zotarolimus-eluting JJ i
stent NN i
( ( i
ZES NNP i
) ) i
compared VBN i
with IN i
the DT i
paclitaxel-eluting JJ i
stent NN i
( ( i
PES NNP i
) ) i
. . N

BACKGROUND NNP N
First-generation NNP N
drug-eluting NN N
stents NNS N
have VBP N
reduced VBN N
angiographic JJ N
and CC N
clinical JJ N
restenosis NN N
, , N
but CC N
long-term JJ N
safety NN N
remains VBZ N
controversial JJ N
. . N

A DT N
second-generation JJ i
drug-eluting JJ i
stent NN i
, , N
which WDT N
delivers VBZ N
zotarolimus NN i
, , N
a DT N
potent JJ N
antiproliferative JJ N
agent NN N
, , N
via IN N
a DT N
biocompatible JJ N
phosphorylcholine NN N
polymer NN N
on IN N
a DT N
cobalt JJ N
alloy NN N
thin-strut JJ N
stent NN N
has VBZ N
shown VBN N
promising JJ N
experimental JJ N
and CC N
early JJ N
clinical JJ N
results NNS N
. . N

METHODS NNP N
This DT N
is VBZ N
a DT N
prospective JJ N
, , N
randomized VBN N
( ( N
1:1 CD N
) ) N
, , N
single-blind JJ N
, , N
controlled JJ N
trial NN N
comparing VBG N
outcomes NNS N
of IN N
patients NNS p
with IN p
single JJ p
de FW p
novo FW p
coronary JJ p
lesions NNS p
treated VBN p
with IN p
ZES NNP p
or CC p
PES NNP p
. . p

The DT N
primary JJ o
end NN o
point NN o
was VBD o
noninferiority NN o
of IN o
9-month JJ o
target NN o
vessel JJ o
failure NN o
defined VBD o
as IN o
cardiac JJ o
death NN o
, , o
myocardial JJ o
infarction NN o
, , o
or CC o
target VB o
vessel JJ o
revascularization NN o
. . o

RESULTS NNP N
Among IN N
a DT N
total NN N
of IN N
1,548 CD p
patients NNS p
assigned VBN p
to TO p
ZES NNP i
( ( p
n JJ p
= NNP p
773 CD p
) ) p
or CC p
PES NNP p
( ( N
n JJ N
= NNP N
775 CD N
) ) N
, , N
at IN N
9 CD N
months NNS N
, , N
ZES NNP N
was VBD N
noninferior JJ N
to TO N
PES VB N
with IN N
rates NNS N
of IN N
target NN o
vessel JJ o
failure NN o
6.6 CD N
% NN N
versus IN N
7.1 CD N
% NN N
, , N
respectively RB N
( ( N
p NN N
( ( N
noninferiority NN N
) ) N
< NN N
or CC N
= VB N
0.001 CD N
) ) N
. . N

There EX N
were VBD N
fewer JJR N
periprocedural JJ o
myocardial JJ o
infarctions NNS o
with IN N
ZES NNP i
( ( N
0.5 CD N
% NN N
vs. FW N
2.2 CD N
% NN N
; : N
p CC N
= VB N
0.007 CD N
) ) N
, , N
whereas VBP N
at IN N
12 CD N
months NNS N
, , N
there EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
groups NNS N
in IN N
rates NNS N
of IN N
cardiac JJ o
death NN o
, , o
myocardial JJ o
infarction NN o
, , o
target NN o
vessel NN o
revascularization NN o
, , o
or CC o
stent JJ o
thrombosis NN o
. . o

Although IN N
incidence NN N
of IN N
8-month JJ N
binary JJ o
angiographic JJ o
in-segment JJ o
restenosis NN o
was VBD N
higher RBR N
in IN N
patients NNS N
treated VBN N
with IN N
ZES NNP i
versus NN N
PES NNP N
( ( N
15.3 CD N
% NN N
vs. FW N
10.4 CD N
% NN N
; : N
p CC N
= VB N
0.284 CD N
) ) N
, , N
rates NNS N
of IN N
12-month JJ N
target NN o
lesion NN o
revascularization NN o
were VBD N
similar JJ N
( ( N
4.5 CD N
% NN N
vs. FW N
3.2 CD N
% NN N
; : N
p CC N
= VB N
0.228 CD N
) ) N
, , N
especially RB N
in IN N
patients NNS N
without IN N
planned JJ N
angiographic JJ N
follow-up NN N
( ( N
3.6 CD N
% NN N
vs. FW N
3.2 CD N
% NN N
; : N
p CC N
= VB N
0.756 CD N
) ) N
. . N

CONCLUSIONS NNP N
These DT N
findings NNS N
demonstrate VBP N
that IN N
ZES NNP i
has VBZ N
similar JJ N
clinical JJ N
safety NN N
and CC N
efficacy NN N
compared VBN N
with IN N
PES NNP i
in IN N
simple JJ N
and CC N
medium JJ N
complexity NN N
single JJ N
de FW N
novo FW N
coronary JJ N
lesions NNS N
. . N

( ( N
ENDEAVOR NNP N
IV NNP N
Clinical NNP N
Trial NNP N
; : N
NCT00217269 NNP N
) ) N
. . N

-DOCSTART- -9652612- O O

Randomised VBN N
trial NN N
of IN N
laparoscopic NN i
versus NN i
open JJ i
cholecystectomy NN i
for IN N
acute NN p
and CC p
gangrenous JJ p
cholecystitis NN p
. . p

BACKGROUND NNP N
Laparoscopic NNP i
cholecystectomy NN i
( ( i
LC NNP i
) ) i
has VBZ N
become VBN N
the DT N
treatment NN N
of IN N
choice NN N
for IN N
elective JJ i
cholecystectomy NN i
, , N
but CC N
controversy NN N
persists NNS N
over IN N
use NN N
of IN N
this DT N
approach NN N
in IN N
the DT N
treatment NN N
of IN N
acute JJ p
cholecystitis NN p
. . p

We PRP N
undertook VBD N
a DT N
randomised JJ N
comparison NN N
of IN N
the DT N
safety NN N
and CC N
outcome NN N
of IN N
LC NNP i
and CC N
open JJ i
cholecystectomy NN i
( ( i
OC NNP i
) ) i
in IN N
patients NNS p
with IN p
acute JJ p
cholecystitis NN p
. . p

METHODS NNP N
63 CD p
of IN p
68 CD p
consecutive JJ p
patients NNS p
who WP p
met VBD p
criteria NNS p
for IN p
acute JJ p
cholecystitis NN p
were VBD p
randomly RB p
assigned VBN p
OC NNP i
( ( p
31 CD p
patients NNS p
) ) p
or CC p
LC NNP i
( ( p
32 CD p
patients NNS p
) ) p
. . p

The DT N
primary JJ N
endpoints NNS N
were VBD N
hospital JJ o
mortality NN o
and CC o
morbidity NN o
, , o
length NN o
of IN o
hospital NN o
stay NN o
, , o
and CC o
length NN o
of IN o
sick JJ o
leave VBP o
from IN o
work NN o
. . o

Analysis NN N
was VBD N
by IN N
intention NN N
to TO N
treat VB N
. . N

Suspected VBN o
bile-duct NN o
stones NNS o
were VBD N
investigated VBN N
by IN N
preoperative JJ N
endoscopic NN N
retrograde NN N
cholangiography NN N
( ( i
LC NNP i
group NN N
) ) N
or CC N
intraoperative JJ i
cholangiography NN i
( ( i
OC NNP i
group NN N
) ) N
. . N

FINDINGS PDT N
The DT N
two CD N
randomised VBD N
groups NNS N
were VBD N
similar JJ N
in IN N
demographic JJ N
, , N
physical JJ N
, , N
and CC N
clinical JJ N
characteristics NNS N
. . N

48 CD N
% NN N
of IN N
the DT N
patients NNS N
in IN N
the DT N
OC NNP i
group NN N
and CC N
59 CD N
% NN N
in IN N
the DT N
LC NNP i
group NN N
were VBD N
older JJR N
than IN N
60 CD N
years NNS N
. . N

13 CD N
patients NNS N
in IN N
each DT N
group NN N
had VBD N
gangrene NN o
or CC o
empyema NN o
, , N
and CC N
one CD N
in IN N
each DT N
group NN N
had VBD N
perforation NN o
of IN o
the DT o
gallbladder NN o
causing NN o
diffuse NN o
peritonitis NN o
. . o

Five CD N
( ( N
16 CD N
% NN N
) ) N
patients NNS N
in IN N
the DT N
LC NNP i
group NN N
required VBD N
conversion NN N
to TO N
OC NNP i
, , N
in IN N
most JJS N
because IN N
severe JJ o
inflammation NN o
distorted VBD N
the DT N
anatomy NN N
of IN N
Calot NNP N
's POS N
triangle NN N
. . N

There EX N
were VBD N
no DT N
deaths NNS o
or CC o
bile-duct NN o
lesions NNS o
in IN N
either DT N
group NN N
, , N
but CC N
the DT N
postoperative JJ o
complication NN o
rate NN N
was VBD N
significantly RB N
( ( N
p=0.0048 NN N
) ) N
higher JJR N
in IN N
the DT N
OC NNP i
than IN N
in IN N
the DT N
LC NNP i
group NN N
: : N
seven CD N
( ( N
23 CD N
% NN N
) ) N
patients NNS N
had VBD N
major JJ N
and CC N
six CD N
( ( N
19 CD N
% NN N
) ) N
minor NN o
complications NNS o
after IN N
OC NNP i
, , N
whereas IN N
only RB N
one CD N
( ( N
3 CD N
% NN N
) ) N
minor JJ N
complication NN N
occurred VBD N
after IN N
LC NNP i
. . i

The DT N
postoperative JJ o
hospital NN o
stay NN o
was VBD N
significantly RB N
shorter JJR N
in IN N
the DT N
LC NNP i
than IN N
the DT N
OC NNP i
group NN N
( ( N
median JJ N
4 CD N
[ JJ N
IQR NNP N
2-5 JJ N
] NNP N
vs NN N
6 CD N
[ JJ N
5-8 JJ N
] NNP N
days NNS N
; : N
p=0.0063 NN N
) ) N
. . N

Mean JJ o
length NN o
of IN o
sick JJ o
leave NN o
was VBD N
shorter RBR N
in IN N
the DT N
LC NNP i
group NN N
( ( N
13.9 CD N
vs RB N
30.1 CD N
days NNS N
; : N
95 CD N
% NN N
CI NNP N
for IN N
difference NN N
10.9-21.7 CD N
) ) N
. . N

INTERPRETATION NNP N
Even RB N
though IN N
LC NNP i
for IN N
acute NN N
and CC N
gangrenous JJ N
cholecystitis NN N
is VBZ N
technically RB N
demanding VBG N
, , N
in IN N
experienced JJ N
hands NNS N
it PRP N
is VBZ N
safe JJ o
and CC N
effective JJ o
. . o

It PRP N
does VBZ N
not RB N
increase VB N
the DT N
mortality NN o
rate NN o
, , N
and CC N
the DT N
morbidity NN o
rate NN o
seems VBZ N
to TO N
be VB N
even RB N
lower JJR N
than IN N
that DT N
in IN N
OC NNP i
. . i

However RB N
, , N
a DT N
moderately RB N
high JJ N
conversion NN N
rate NN N
must MD N
be VB N
accepted VBN N
. . N

-DOCSTART- -18555063- O O

Anxiety NN p
sensitivity NN p
as IN N
an DT N
incremental JJ N
predictor NN N
of IN N
later JJ p
anxiety NN p
symptoms NNS p
and CC p
syndromes NNS p
. . p

Although IN N
anxiety NN p
sensitivity NN p
( ( p
AS NNP p
) ) p
has VBZ N
been VBN N
shown VBN N
to TO N
predict VB N
anxiety NN p
symptoms NNS p
and CC p
panic NN p
, , N
this DT N
literature NN N
is VBZ N
limited VBN N
in IN N
regard NN N
to TO N
evaluating VBG N
AS NNP N
as IN N
an DT N
incremental JJ N
predictor NN N
of IN N
anxiety NN i
psychopathology NN i
relative VBP N
to TO N
other JJ N
established VBN N
risk NN N
factors NNS N
including VBG N
sex NN N
and CC N
negative JJ N
affect NN N
. . N

The DT N
present JJ N
report NN N
prospectively RB N
evaluated VBD N
whether IN N
AS NNP N
was VBD N
predictive NN N
of IN N
later JJ N
changes NNS N
in IN N
anxiety NN o
symptoms NNS o
after IN N
controlling VBG i
for IN i
potential JJ i
confounding NN i
factors NNS i
. . i

Consistent JJ N
with IN N
hypothesis NN N
, , N
AS NNP N
was VBD N
found VBN N
to TO N
be VB N
a DT N
significant JJ N
, , N
incremental JJ N
predictor NN N
of IN N
anxiety NN o
symptoms NNS o
over IN N
time NN N
, , N
even RB N
after IN N
controlling VBG N
for IN N
sex NN N
and CC N
negative JJ N
affectivity NN N
. . N

These DT N
data NNS N
provide VBP N
novel JJ N
evidence NN N
for IN N
the DT N
unique JJ N
association NN N
between IN N
AS NNP N
of IN N
the DT N
development NN N
of IN N
anxiety NN p
symptoms NNS p
. . p

-DOCSTART- -22678947- O O

The DT N
memory NN N
support NN N
system NN N
for IN N
mild JJ p
cognitive JJ p
impairment NN p
: : p
randomized JJ N
trial NN N
of IN N
a DT N
cognitive JJ i
rehabilitation NN i
intervention NN i
. . i

OBJECTIVE JJ N
Individuals NNS p
with IN p
amnestic JJ p
mild NNS p
cognitive JJ p
impairment NN p
( ( p
MCI NNP p
) ) p
have VBP N
few JJ N
empirically RB N
based VBN N
treatment NN N
options NNS N
for IN N
combating VBG N
their PRP$ N
memory NN o
loss NN o
. . o

This DT N
study NN N
sought VBD N
to TO N
examine VB N
the DT N
efficacy NN o
of IN N
a DT N
calendar/notebook NN i
rehabilitation NN i
intervention NN i
, , N
the DT N
memory NN o
support NN o
system NN o
( ( o
MSS NNP o
) ) o
, , N
for IN N
individuals NNS p
with IN p
amnestic JJ p
MCI NNP p
. . p

METHODS NNP N
Forty NNP p
individuals NNS p
with IN p
single JJ p
domain NN p
amnestic JJ i
MCI NNP i
and CC p
their PRP$ p
program NN p
partners NNS p
were VBD p
randomized VBN p
to TO N
receive VB N
the DT N
MSS NNP N
, , N
either RB N
with IN N
training NN N
or CC N
without IN N
( ( N
controls NNS N
) ) N
. . N

Measures NNS o
of IN o
adherence NN o
, , o
activities NNS o
of IN o
daily JJ o
living NN o
, , o
and CC o
emotional JJ o
impact NN o
were VBD N
completed VBN N
at IN N
the DT N
first JJ N
and CC N
last JJ N
intervention NN N
sessions NNS N
and CC N
again RB N
at IN N
8 CD N
weeks NNS N
and CC N
6 CD N
months NNS N
post VBN N
intervention NN N
. . N

RESULTS NNP N
Training NNP N
in IN N
use NN N
of IN N
a DT N
notebook/calendar NN N
system NN N
significantly RB N
improved VBN N
adherence NN o
over IN N
those DT N
who WP N
received VBD N
the DT N
calendars NNS N
but CC N
no DT N
training NN N
. . N

Functional NNP o
ability NN o
and CC o
memory NN o
self-efficacy NN o
significantly RB N
improved VBN N
for IN N
those DT N
who WP N
received VBD N
MSS NNP N
training NN N
. . N

Change NN o
in IN o
functional JJ o
ability NN o
remained VBD N
significantly RB N
better RBR N
in IN N
the DT N
intervention NN N
group NN N
than IN N
in IN N
the DT N
control NN N
group NN N
out IN N
to TO N
8-week JJ N
follow-up NN N
. . N

Care NNP N
partners NNS N
in IN N
the DT N
intervention NN N
group NN N
demonstrated VBD N
improved VBN N
mood NN o
by IN N
8-week JJ N
and CC N
6-month JJ N
follow-ups NNS N
, , N
whereas NNS N
control VBP N
care NN N
partners NNS N
reported VBD N
worse JJR N
caregiver NN o
burden NN o
by IN N
6-month JJ N
follow-up NN N
. . N

CONCLUSIONS NNP N
Memory NNP i
support NN i
system NN i
training NN i
resulted VBD N
in IN N
improvement NN N
in IN N
activities NNS o
of IN o
daily JJ o
living NN o
and CC o
sense NN o
of IN o
memory NN o
self-efficacy NN o
for IN N
individuals NNS N
with IN N
MCI NNP N
. . N

Although IN N
activities NNS N
of IN N
daily JJ N
living VBG N
benefits NNS N
were VBD N
maintained VBN N
out IN N
to TO N
8 CD N
weeks NNS N
post NN N
intervention NN N
, , N
future JJ N
inclusion NN N
of IN N
booster NN N
sessions NNS N
may MD N
help VB N
extend VB N
the DT N
therapeutic JJ N
effect NN N
out IN N
even RB N
further RBR N
. . N

Improved VBN o
mood NN o
of IN N
care NN N
partners NNS N
of IN N
trained JJ N
individuals NNS N
and CC N
worsening VBG o
sense NN o
of IN o
caregiver NN o
burden NN o
over IN N
time NN N
for IN N
partners NNS N
of IN N
untrained JJ N
individuals NNS N
further RBR N
support NN N
the DT N
efficacy NN N
of IN N
the DT N
MSS NNP N
for IN N
MCI NNP N
. . N

-DOCSTART- -12202662- O O

Randomized VBN N
comparative JJ N
study NN N
of IN N
tegafur/uracil NN i
and CC i
oral JJ i
leucovorin NN i
versus IN i
parenteral JJ i
fluorouracil NN i
and CC i
leucovorin NN i
in IN N
patients NNS p
with IN p
previously RB p
untreated VBN p
metastatic JJ p
colorectal NN p
cancer NN p
. . p

PURPOSE VB N
This DT N
phase NN N
III NNP N
study NN N
compared VBN N
the DT N
time NN o
to TO o
progression NN o
( ( o
TTP NNP o
) ) o
of IN N
an DT N
oral JJ N
regimen NNS N
of IN N
dihydropyrimidine JJ i
dehydrogenase NN i
inhibitory NN i
fluoropyrimidine NN i
composed VBN N
of IN N
a DT N
fixed JJ N
combination NN N
of IN N
tegafur NN i
and CC i
uracil NN i
in IN N
a DT N
1:4 CD N
molar JJ N
ratio NN N
( ( N
UFT NNP N
) ) N
and CC N
leucovorin $ i
( ( N
LV NNP N
) ) N
to TO N
intravenous JJ i
( ( i
IV NNP i
) ) i
fluorouracil NN i
( ( N
5-FU JJ N
) ) N
and CC i
LV NNP i
in IN N
previously RB p
untreated VBN p
metastatic JJ p
colorectal NN p
carcinoma NN p
( ( p
CRC NNP p
) ) p
patients NNS p
. . p

Secondary JJ N
end NN N
points NNS N
were VBD N
survival JJ o
, , o
tumor JJ o
response NN o
, , o
safety NN o
, , o
and CC o
quality NN o
of IN o
life NN o
. . o

PATIENTS NNP N
AND CC N
METHODS NNP N
Between NNP p
May NNP p
1996 CD p
and CC p
July NNP p
1997 CD p
, , p
380 CD p
patients NNS p
were VBD N
randomized VBN N
to TO N
receive VB N
either DT N
UFT NNP i
( ( N
300 CD N
mg/m NN N
( ( N
2 CD N
) ) N
/d NN N
) ) N
and CC N
LV NNP i
( ( N
90 CD N
mg/d NN N
) ) N
, , N
administered VBN N
for IN N
28 CD N
days NNS N
every DT N
35 CD N
days NNS N
, , N
or CC N
5-FU JJ i
( ( N
425 CD N
mg/m NN N
( ( N
2 CD N
) ) N
/d NN N
) ) N
and CC N
LV NNP i
( ( N
20 CD N
mg/m NN N
( ( N
2 CD N
) ) N
/d NN N
) ) N
, , N
given VBN N
IV NNP N
for IN N
5 CD N
days NNS N
every DT N
35 CD N
days NNS N
. . N

RESULTS NNP N
No NNP N
statistically RB N
significant JJ N
difference NN N
in IN N
TTP NNP o
was VBD N
observed VBN N
between IN N
treatments NNS N
. . N

With IN N
320 CD p
events NNS p
assessed VBN N
, , N
the DT N
median JJ N
TTP NNP o
was VBD N
3.4 CD N
months NNS N
( ( N
95 CD N
% NN N
Confidence NNP N
interval NN N
[ NNP N
CI NNP N
] NNP N
, , N
2.6 CD N
to TO N
3.8 CD N
) ) N
on IN N
UFT/LV NNP N
and CC N
3.3 CD N
months NNS N
( ( N
95 CD N
% NN N
CI NNP N
, , N
2.5 CD N
to TO N
3.7 CD N
) ) N
on IN N
5-FU/LV JJ N
( ( N
P NNP N
=.591 NNP N
, , N
stratified VBD N
log-rank JJ N
test NN N
) ) N
. . N

There EX N
were VBD N
no DT N
statistically RB N
significant JJ N
differences NNS N
in IN N
survival NN o
, , o
tumor NN o
response NN o
, , o
duration NN o
of IN o
response NN o
, , o
and CC o
time NN o
to TO o
response NN o
. . o

Substantial NNP N
safety NN o
benefits NNS o
were VBD N
observed VBN N
in IN N
patients NNS N
treated VBN N
with IN N
UFT/LV NNP N
. . N

They PRP N
experienced VBD N
significantly RB N
less JJR N
stomatitis/mucositis NN o
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
and CC N
myelosuppression NN o
, , N
resulting VBG N
in IN N
fewer JJR N
episodes NNS N
of IN N
febrile JJ o
neutropenia NN o
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
and CC N
less RBR N
documented JJ o
infection NN o
( ( N
P NNP N
=.04 NNP N
) ) N
. . N

Concomitant JJ N
medication NN N
usage NN N
was VBD N
significantly RB N
greater JJR N
on IN N
5-FU/LV JJ N
( ( N
P NNP N
=.010 NNP N
) ) N
. . N

With IN N
respect NN N
to TO N
quality NN o
of IN o
life NN o
, , N
after IN N
correcting VBG N
for IN N
baseline NN N
imbalances NNS N
, , N
there EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
treatments NNS N
for IN N
any DT N
scale NN N
, , N
except IN N
diarrhea NN o
. . o

CONCLUSION VB N
The DT N
oral JJ N
UFT/LV NNP N
regimen NNS N
failed VBD N
to TO N
achieve VB N
improved JJ N
TTP NNP o
; : o
however RB N
, , N
the DT N
study NN N
confirms VBZ N
significant JJ N
safety NN N
improvements NNS N
compared VBN N
with IN N
bolus JJ N
IV NNP N
5-FU/LV NN N
for IN N
the DT N
first-line JJ N
treatment NN N
of IN N
metastatic JJ N
CRC NNP N
. . N

-DOCSTART- -22382875- O O

Infrared NNP i
LED NNP i
irradiation NN i
applied VBD N
during IN N
high-intensity NN N
treadmill NN N
training VBG N
improves NNS N
maximal JJ o
exercise NN o
tolerance NN o
in IN N
postmenopausal JJ p
women NNS p
: : p
a DT N
6-month JJ N
longitudinal JJ N
study NN N
. . N

Reduced NNP N
aerobic JJ N
fitness NN N
is VBZ N
associated VBN N
with IN N
an DT N
increased VBN N
risk NN N
of IN N
cardiovascular JJ N
diseases NNS N
among IN N
the DT N
older JJR p
population NN p
. . p

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
investigate VB N
the DT N
effects NNS o
of IN N
LED NNP i
irradiation NN i
( ( N
850 CD N
nm RB N
) ) N
applied VBD N
during IN N
treadmill JJ N
training VBG N
on IN N
the DT N
maximal JJ o
exercise NN o
tolerance NN o
in IN N
postmenopausal JJ p
women NNS p
. . p

At IN N
the DT N
beginning NN N
of IN N
the DT N
study NN N
, , N
45 CD p
postmenopausal JJ p
women NNS p
were VBD N
assigned VBN N
randomly RB N
to TO N
three CD N
groups NNS N
, , N
and CC N
30 CD N
women NNS N
completed VBD N
the DT N
entire JJ N
6 CD N
months NNS N
of IN N
the DT N
study NN N
. . N

The DT N
groups NNS N
were VBD N
: : N
( ( i
1 CD i
) ) i
the DT i
LED NNP i
group NN i
( ( i
treadmill IN i
training VBG i
associated VBN i
with IN i
phototherapy NN i
, , i
n JJ i
= NNP i
10 CD i
) ) i
, , i
( ( i
2 CD i
) ) i
the DT i
exercise NN i
group NN i
( ( i
treadmill IN i
training NN i
, , i
n JJ i
= NNP i
10 CD i
) ) i
, , i
and CC i
( ( i
3 CD i
) ) i
the DT i
sedentary JJ i
group NN i
( ( i
neither DT i
physical JJ i
training NN i
nor CC i
phototherapy NN i
, , i
n JJ i
= NNP i
10 CD i
) ) i
. . i

The DT i
training NN i
was VBD N
performed VBN N
for IN N
45 CD N
min NN N
twice RB N
a DT N
week NN N
for IN N
6 CD N
months NNS N
at IN N
intensities NNS N
between IN N
85 CD N
% NN N
and CC N
90 CD N
% NN N
maximal JJ N
heart NN N
rate NN N
( ( N
HRmax NNP N
) ) N
. . N

The DT N
irradiation NN N
parameters NNS N
were VBD N
39 CD N
mW/cm NN N
( ( N
2 CD N
) ) N
, , N
45 CD N
min NN N
and CC N
108 CD N
J/cm NNP N
( ( N
2 CD N
) ) N
. . N

The DT N
cardiovascular JJ o
parameters NNS o
were VBD N
measured VBN N
at IN N
baseline NN N
and CC N
after IN N
6 CD N
months NNS N
. . N

As IN N
expected VBN N
, , N
no DT N
significant JJ N
differences NNS N
were VBD N
found VBN N
in IN N
the DT N
sedentary JJ N
group NN N
( ( N
p VB N
? . N
0.05 CD N
) ) N
. . N

The DT o
maximal JJ o
time NN o
of IN o
tolerance NN o
( ( o
Tlim NNP o
) ) o
, , o
metabolic JJ o
equivalents NNS o
( ( o
METs NNP o
) ) o
and CC o
Bruce NNP o
stage NN o
reached VBD o
significantly RB N
higher JJR N
values NNS N
in IN N
the DT i
LED NNP i
group NN N
and CC N
the DT N
exercise NN i
group NN N
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
. . N

Furthermore UH o
, , o
the DT o
HR NNP o
, , o
double JJ o
product NN o
and CC o
Borg NNP o
score NN o
at IN o
isotime NN o
were VBD N
significantly RB N
lower JJR N
in IN N
the DT N
LED NNP N
group NN N
and CC N
in IN N
the DT N
exercise NN N
group NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

However RB N
, , N
the DT o
time NN o
of IN o
recovery NN o
showed VBD o
a DT N
significant JJ N
decrease NN N
only RB N
in IN N
the DT N
LED NNP N
group NN N
( ( N
p JJ N
= NNP N
0.003 CD N
) ) N
. . N

Moreover RB N
, , N
the DT N
differences NNS o
between IN o
before IN o
and CC o
after IN o
training NN o
( ( o
delta JJ o
values NNS o
) ) o
for IN N
the DT o
Tlim NNP o
, , o
METs NNP o
and CC o
HR NNP o
at IN o
isotime NN N
were VBD N
greater JJR N
in IN N
the DT N
LED NNP N
group NN N
than IN N
in IN N
the DT N
exercise NN N
group NN N
with IN N
a DT N
significant JJ N
intergroup NN N
difference NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

Therefore RB i
, , i
the DT i
infrared JJ i
LED NNP i
irradiation NN i
during IN N
treadmill JJ N
training NN o
can MD o
improve VB o
maximal JJ o
performance NN o
and CC o
post-exercise JJ o
recovery NN o
in IN o
postmenopausal JJ o
women NNS p
. . p

-DOCSTART- -8450402- O O

Beta-carotene NNP i
in IN N
HIV NNP p
infection NN p
. . p

beta-Carotene NN i
has VBZ N
been VBN N
reported VBN N
to TO N
have VB N
an DT N
immunostimulatory JJ N
effect NN N
. . N

Recent JJ N
studies NNS N
suggest VBP N
that IN N
beta-carotene JJ i
supplementation NN i
can MD N
increase VB N
CD4 NNP o
counts NNS o
in IN N
HIV-infected JJ p
patients NNS p
. . p

Our PRP$ N
double-blind JJ N
, , N
placebo-controlled JJ i
clinical JJ N
trial NN N
was VBD N
designed VBN N
to TO N
test VB N
the DT N
efficacy NN N
of IN N
beta-carotene NN i
in IN N
raising VBG N
CD4 NNP N
counts NNS N
in IN N
HIV-infected JJ p
patients NNS p
. . p

Twenty-one CD p
HIV-seropositive JJ p
patients NNS p
were VBD N
randomized VBN N
to TO N
receive VB N
either DT N
beta-carotene NN i
, , i
180 CD i
mg/day NN i
or CC i
placebo NN i
for IN N
4 CD N
weeks NNS N
, , N
and CC N
then RB N
crossed VBD N
over IN N
to TO N
receive VB N
the DT N
alternative JJ N
treatment NN N
for IN N
the DT N
following JJ N
4 CD N
weeks NNS N
. . N

beta-Carotene NN N
resulted VBD N
in IN N
a DT N
statistically RB N
significant JJ N
increase NN N
in IN N
total JJ o
WBC NNP o
count NN o
( ( N
p JJ N
= NNP N
0.01 CD N
) ) N
, , N
% NN o
change NN o
in IN o
CD4 NNP o
count NN o
( ( N
p JJ N
= NNP N
0.02 CD N
) ) N
, , N
and CC N
% NN o
change NN o
in IN o
CD4/CD8 NNP o
ratios NNS o
( ( N
p JJ N
= NNP N
0.02 CD N
) ) N
compared VBN N
to TO N
placebo VB N
. . N

The DT N
absolute JJ o
CD4 NNP o
count NN o
, , o
absolute JJ o
CD4/CD8 NNP o
ratio NN o
, , o
and CC o
total JJ o
and CC o
B-lymphocytes NNP o
all DT N
increased VBN N
on IN N
carotene NN N
and CC N
fell VBD N
during IN N
placebo NN N
, , N
but CC N
these DT N
differences NNS N
did VBD N
not RB N
reach VB N
statistical JJ N
significance NN N
. . N

No DT N
toxicity NN o
was VBD N
observed VBN N
on IN N
either DT N
treatment NN N
. . N

beta-Carotene JJ N
appears VBZ N
to TO N
have VB N
an DT N
immunostimulatory JJ o
effect NN o
in IN N
HIV-infected JJ p
patients NNS p
. . p

Further JJ N
studies NNS N
are VBP N
needed VBN N
to TO N
demonstrate VB N
whether IN N
beta-carotene NN N
has VBZ N
a DT N
role NN N
as IN N
adjunct JJ N
therapy NN N
in IN N
treatment NN N
of IN N
HIV-infected JJ o
patients NNS o
. . o

-DOCSTART- -22001361- O O

Predictors NNS N
of IN N
recruited JJ N
melanoma NN p
families NNS p
into IN N
a DT N
behavioral JJ i
intervention NN i
project NN i
. . i

BACKGROUND NNP N
Examination NNP N
of IN N
families NNS p
represents VBZ N
an DT N
important JJ N
priority NN N
in IN N
health NN N
research NN N
. . N

In IN N
this DT N
paper NN N
we PRP N
report VBP o
on IN N
individual JJ o
and CC o
family-level JJ o
factors NNS o
associated VBN N
with IN N
enrollment NN N
in IN N
a DT N
cancer NN N
prevention NN N
research NN N
project NN N
. . N

We PRP N
approached VBD N
families NNS p
affected VBN p
by IN p
melanoma NN p
for IN N
possible JJ N
participation NN N
in IN N
a DT N
randomized NN N
controlled VBN N
trial NN N
of IN N
a DT N
web-based JJ i
communication NN i
and CC i
support NN i
intervention NN i
. . i

METHODS NNP N
We PRP N
recruited VBD N
three CD p
family NN p
members NNS p
per IN p
family NN p
for IN p
assessment NN p
- : p
the DT p
melanoma NN p
case NN p
, , p
a DT p
first-degree JJ p
relative NN p
( ( p
FDR NNP p
) ) p
, , p
and CC p
a DT p
relative NN p
who WP p
is VBZ p
a DT p
parent NN p
of IN p
a DT p
child JJ p
age NN p
18 CD p
or CC p
younger JJR p
. . p

Recruitment NNP N
involved VBD N
three CD N
steps NNS N
: : N
requesting VBG N
the DT N
physician NN N
's POS N
consent NN N
to TO N
approach VB N
the DT N
melanoma NN N
case NN N
, , N
approaching VBG N
the DT N
case NN N
to TO N
request VB N
their PRP$ N
participation NN N
and CC N
family NN N
contact NN N
information NN N
, , N
and CC N
they PRP N
approaching VBG N
the DT N
FDRs NNP N
and CC N
parents NNS N
. . N

RESULTS NNP N
Of IN N
the DT N
1380 CD p
families NNS p
approached VBD p
, , p
313 CD p
were VBD p
enrolled VBN p
, , p
263 CD p
were VBD p
excluded VBN p
because IN p
we PRP p
could MD p
not RB p
find VB p
or CC p
contact VB p
a DT p
family NN p
member NN p
( ( p
FDR CD p
or CC p
parent NN p
) ) p
, , p
331 CD p
did VBD p
not RB p
have VB p
eligible JJ p
family NN p
members NNS p
, , p
and CC p
473 CD p
refused VBD p
. . p

The DT N
most RBS N
frequently RB o
noted VBD N
reason NN N
for IN N
refusal NN o
was VBD N
being VBG N
too RB N
busy JJ N
or CC N
having VBG N
no DT N
time NN N
. . N

The DT N
primary JJ N
predictors NNS N
of IN N
participation NN o
for IN N
cases NNS N
( ( N
OR=1.6 NNP N
; : N
CI=1.01-2.51 NNP N
) ) N
and CC N
FDRs NNP N
( ( N
OR=2.15 NNP N
; : N
CI=1.11-4.13 NNP N
) ) N
included VBD N
higher JJR o
educational JJ o
attainment NN o
. . o

FDRs NNP N
were VBD N
more RBR N
likely JJ N
to TO N
enroll VB o
if IN N
they PRP N
were VBD N
female JJ o
( ( N
OR=1.77 NNP N
; : N
CI=1.1-.85 NNP N
) ) N
and CC N
parents NNS N
were VBD N
more RBR N
likely JJ N
to TO N
enroll VB o
if IN N
the DT N
case NN N
had VBD N
been VBN N
diagnosed VBN o
more RBR o
recently RB o
( ( N
OR=3.3 NNP N
; : N
CI=1.9-5.93 NNP N
) ) N
, , N
if IN N
the DT N
parent NN o
was VBD o
partnered VBN o
( ( N
OR=4.37 NNP N
; : N
CI=1.86-10.26 NNP N
) ) N
, , N
and CC N
if IN N
the DT N
parent NN o
lived VBD o
in IN o
the DT o
same JJ o
city NN o
as IN o
the DT o
case NN o
( ( N
OR=2.88 NNP N
; : N
CI=1.08-7.68 NNP N
) ) N
. . N

CONCLUSIONS VB N
The DT N
results NNS N
can MD N
provide VB N
information NN N
on IN N
potential JJ N
directions NNS N
for IN N
future JJ N
family NN N
recruitment NN N
. . N

-DOCSTART- -23980091- O O

Gefitinib NNP i
versus NN N
placebo NN i
in IN N
completely RB p
resected VBN p
non-small-cell JJ p
lung NN p
cancer NN p
: : p
results NNS N
of IN N
the DT N
NCIC NNP N
CTG NNP N
BR19 NNP N
study NN N
. . N

PURPOSE NNP N
Survival NNP N
of IN N
patients NNS p
with IN p
completely RB p
resected VBN p
non-small-cell JJ p
lung NN p
cancer NN p
( ( p
NSCLC NNP p
) ) p
is VBZ N
unsatisfactory JJ N
, , N
and CC N
in IN N
2002 CD N
, , N
the DT N
benefit NN N
of IN N
adjuvant JJ N
chemotherapy NN N
was VBD N
not RB N
established VBN N
. . N

This DT N
phase NN N
III NNP N
study NN N
assessed VBD N
the DT N
impact NN N
of IN N
postoperative JJ N
adjuvant JJ N
gefitinib NN i
on IN N
overall JJ o
survival NN o
( ( o
OS NNP o
) ) o
. . o

PATIENTS NNP N
AND CC N
METHODS NNP N
Patients NNPS p
with IN p
completely RB p
resected VBN p
( ( p
stage NN p
IB NNP p
, , p
II NNP p
, , p
or CC p
IIIA NNP p
) ) p
NSCLC NNP p
stratified VBN p
by IN p
stage NN p
, , p
histology NN p
, , p
sex NN p
, , p
postoperative JJ p
radiotherapy NN p
, , p
and CC p
chemotherapy NN p
were VBD N
randomly RB N
assigned VBN N
( ( N
1:1 CD N
) ) N
to TO N
receive VB N
gefitinib NN i
250 CD i
mg NN i
per IN i
day NN i
or CC i
placebo NN i
for IN N
2 CD N
years NNS N
. . N

Study NNP N
end VBP N
points NNS N
were VBD N
OS NNP o
, , o
disease-free JJ o
survival NN o
( ( o
DFS NNP o
) ) o
, , o
and CC o
toxicity NN o
. . o

RESULTS NNP N
As IN N
a DT N
result NN N
of IN N
early JJ N
closure NN N
, , N
503 CD p
of IN p
1,242 CD p
planned JJ p
patients NNS p
were VBD p
randomly RB p
assigned VBN p
( ( N
251 CD N
to TO N
gefitinib VB i
and CC N
252 CD N
to TO N
placebo VB i
) ) i
. . N

Baseline JJ N
factors NNS N
were VBD N
balanced VBN N
between IN N
the DT N
arms NNS N
. . N

With IN N
a DT N
median NN N
of IN N
4.7 CD N
years NNS N
of IN N
follow-up NN N
( ( N
range NN N
, , N
0.1 CD N
to TO N
6.3 CD N
years NNS N
) ) N
, , N
there EX N
was VBD N
no DT N
difference NN N
in IN N
OS NNP o
( ( N
hazard JJ N
ratio NN N
[ NNP N
HR NNP N
] NNP N
, , N
1.24 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
0.94 CD N
to TO N
1.64 CD N
; : N
P NNP N
= NNP N
.14 NNP N
) ) N
or CC N
DFS NNP o
( ( N
HR NNP N
, , N
1.22 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
0.93 CD N
to TO N
1.61 CD N
; : N
P NNP N
= NNP N
.15 NNP N
) ) N
between IN N
the DT N
arms NNS N
. . N

Exploratory JJ N
analyses NNS N
demonstrated VBD N
no DT N
DFS NNP o
( ( N
HR NNP N
, , N
1.28 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
0.92 CD N
to TO N
1.76 CD N
; : N
P NNP N
= NNP N
.14 NNP N
) ) N
or CC N
OS NNP o
benefit NN o
( ( N
HR NNP N
, , N
1.24 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
0.90 CD N
to TO N
1.71 CD N
; : N
P NNP N
= NNP N
.18 NNP N
) ) N
from IN N
gefitinib NN i
for IN N
344 CD p
patients NNS p
with IN p
epidermal JJ p
growth NN p
factor NN p
receptor NN p
( ( p
EGFR NNP p
) ) p
wild-type NN N
tumors NNS N
. . N

Similarly RB N
, , N
there EX N
was VBD N
no DT N
DFS NNP o
( ( N
HR NNP N
, , N
1.84 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
0.44 CD N
to TO N
7.73 CD N
; : N
P NNP N
= NNP N
.395 NNP N
) ) N
or CC N
OS NNP o
benefit NN N
( ( N
HR NNP N
, , N
3.16 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
0.61 CD N
to TO N
16.45 CD N
; : N
P NNP N
= NNP N
.15 NNP N
) ) N
from IN N
gefitinib NN i
for IN N
the DT N
15 CD N
patients NNS p
with IN N
EGFR NNP N
mutation-positive JJ N
tumors NNS N
. . N

Adverse JJ o
events NNS o
were VBD N
those DT N
expected VBN N
with IN N
an DT N
EGFR NNP N
inhibitor NN N
. . N

Serious JJ o
adverse JJ o
events NNS o
occurred VBD N
in IN N
? . N
5 CD N
% NN N
of IN N
patients NNS N
, , N
except IN o
infection NN o
, , o
fatigue NN o
, , o
and CC o
pain NN o
. . o

One CD N
patient NN N
in IN N
each DT N
arm NN N
had VBD o
fatal JJ o
pneumonitis NN o
. . o

CONCLUSION NNP N
Although IN N
the DT N
trial NN N
closed VBD N
prematurely RB N
and CC N
definitive JJ N
statements NNS N
regarding VBG N
the DT N
efficacy NN N
of IN N
adjuvant JJ i
gefitinib NN i
can MD i
not RB N
be VB N
made VBN N
, , N
these DT N
results NNS N
indicate VBP N
that IN N
it PRP N
is VBZ N
unlikely JJ N
to TO N
be VB N
of IN N
benefit NN N
. . N

-DOCSTART- -20447037- O O

Catheter-related JJ o
infections NNS o
via IN p
temporary JJ p
vascular JJ p
access NN p
catheters NNS N
: : N
a DT N
randomized JJ N
prospective JJ N
study NN N
. . N

Temporary NNP N
vascular JJ N
access NN N
catheters NNS N
( ( N
VACs NNP N
) ) N
are VBP N
important JJ N
devices NNS N
used VBN N
in IN N
acute JJ N
blood NN N
purification NN N
therapies NNS N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
whether IN N
a DT N
catheterization NN i
duration NN N
of IN N
2 CD N
weeks NNS N
increased VBD N
the DT N
risk NN o
of IN o
nosocomial JJ o
complications NNS o
when WRB N
compared VBN N
with IN N
a DT N
1-week JJ N
duration NN N
. . N

Fifty-six JJ p
patients NNS p
with IN p
90 CD p
double JJ p
lumen NNS p
VACs NNP p
were VBD p
randomly RB p
chosen VBN p
, , N
and CC N
received VBD N
either DT N
1- JJ N
or CC N
2-week JJ N
catheterizations NNS i
from IN N
operators NNS N
experienced VBN N
in IN N
the DT N
placement NN N
of IN N
such JJ N
catheters NNS N
at IN N
three CD N
sites NNS N
such JJ N
as IN N
the DT N
internal JJ N
jugular NN N
, , N
subclavian JJ N
, , N
or CC N
femoral JJ N
vein NN N
. . N

The DT N
characteristics NNS N
of IN N
the DT N
VACs NNP N
, , N
including VBG N
the DT N
sites NNS N
, , N
procedures NNS N
, , N
and CC N
lengths NNS N
, , N
were VBD N
similar JJ N
in IN N
both DT N
groups NNS N
. . N

No DT N
significant JJ N
difference NN N
in IN N
the DT N
rate NN o
of IN o
catheter NN o
colonization NN o
was VBD N
observed VBN N
between IN N
the DT N
groups NNS N
( ( N
14.6 CD N
% NN N
vs JJ N
26.2 CD N
% NN N
, , N
P NNP N
= NNP N
0.1371 CD N
) ) N
. . N

No DT N
significant JJ N
difference NN N
in IN N
the DT N
rate NN o
of IN o
catheter-related JJ o
bloodstream NN o
infections NNS o
was VBD N
observed VBN N
between IN N
the DT N
groups NNS N
( ( N
2.1 CD N
% NN N
vs JJ N
4.8 CD N
% NN N
, , N
P NNP N
= NNP N
0.5967 CD N
) ) N
. . N

Two-week JJ N
indwelling NN N
did VBD N
not RB N
increase VB N
the DT N
risk NN o
of IN o
infection NN o
compared VBN N
with IN N
1-week JJ N
indwelling NN N
at IN N
any DT N
of IN N
the DT N
sites NNS N
in IN N
critically RB p
ill JJ p
patients NNS p
. . p

-DOCSTART- -17467416- O O

Behavioral/psychoeducational NNP i
group NN i
training NN i
in IN N
therapy NN N
for IN N
overtaxed JJ o
men NNS o
. . o

-DOCSTART- -21148666- O O

Cost-effectiveness NN o
of IN N
ablation NN i
surgery NN i
in IN N
patients NNS p
with IN p
atrial JJ p
fibrillation NN p
undergoing VBG p
cardiac JJ p
surgery NN p
. . p

This DT N
study NN N
was VBD N
performed VBN N
to TO N
assess VB N
the DT N
cost-effectiveness NN N
of IN N
concomitant JJ N
ablation NN i
surgery NN i
( ( i
AS IN i
) ) i
compared VBN N
to TO N
regular VB N
cardiac JJ i
surgery NN i
in IN N
atrial JJ p
fibrillation NN p
( ( p
AF NNP p
) ) p
patients NNS p
over IN N
a DT N
one-year JJ N
follow-up NN N
. . N

Cost NN o
analysis NN o
was VBD N
performed VBN N
from IN N
a DT N
societal JJ N
perspective NN N
alongside IN N
a DT N
prospective JJ N
, , N
randomised JJ N
, , N
double-blinded JJ N
, , N
multicentre JJ N
trial NN N
. . N

One CD p
hundred CD p
and CC p
fifty JJ p
patients NNS p
with IN p
documented JJ p
AF NNP p
were VBD N
randomly RB i
assigned VBN i
to TO i
undergo VB i
cardiac JJ i
surgery NN i
with IN i
or CC i
without IN i
AS NNP i
. . i

One CD p
hundred CD p
and CC p
thirty-two JJ p
patients NNS p
were VBD p
included VBN p
in IN p
the DT p
cost-effectiveness NN i
study NN p
. . p

All DT o
costs NNS o
( ( o
medical JJ o
and CC o
non-medical JJ o
) ) o
were VBD N
measured VBN N
during IN N
follow-up JJ N
. . N

Costs NNS o
data NNS o
were VBD N
combined VBN N
with IN N
quality NN o
adjusted VBN o
life NN o
years NNS o
( ( N
QALYs NNP N
) ) N
to TO N
obtain VB N
the DT N
incremental JJ N
costs NNS N
per IN N
QALY NNP N
. . N

Total JJ o
costs NNS o
of IN N
the DT N
AS NNP i
group NN N
were VBD N
significantly RB N
higher JJR N
compared VBN N
to TO N
the DT N
regular JJ N
cardiac NN N
surgery NN N
group NN N
[ VBZ N
cost NN N
difference NN N
bootstrap NN N
: : N
?4,724 NN N
; : N
95 CD N
% NN N
uncertainty NN N
interval NN N
( ( N
UI NNP N
) ) N
, , N
?2,770-?6,678 JJ N
] NN N
. . N

The DT N
bootstrapped JJ N
difference NN o
in IN o
QALYs NNP o
was VBD N
not RB N
statistically RB N
significant JJ N
( ( N
0.06 CD N
; : N
95 CD N
% NN N
UI NN N
: : N
-0.024 NN N
to TO N
0.14 CD N
) ) N
. . N

The DT N
incremental JJ N
cost-effectiveness JJ N
ratio NN N
is VBZ N
?73,359 JJ N
per IN N
QALY NNP o
. . o

The DT o
acceptability NN N
curve NN N
showed VBD N
that IN N
, , N
even RB N
in IN N
the DT N
case NN N
of IN N
a DT N
maximum JJ N
threshold JJ N
value NN N
of IN N
?80,000 NNP N
per IN o
QALY NNP o
gained VBD N
, , N
the DT N
probability NN i
of IN i
AS NNP i
being VBG i
more RBR N
cost-effective JJ N
than IN N
regular JJ N
cardiac JJ N
surgery NN N
did VBD N
not RB N
reach VB N
beyond IN N
50 CD N
% NN N
. . N

Concluding VBG N
that DT N
concomitant NN i
AS IN i
in IN i
AF NNP i
is VBZ N
not RB N
cost-effective JJ N
after IN N
a DT N
one-year JJ N
follow-up NN N
compared VBN N
to TO N
regular VB N
cardiac JJ N
surgery NN N
. . N

-DOCSTART- -6354030- O O

Fat NNP N
embolism NN N
prophylaxis NN N
with IN N
corticosteroids NNS i
. . i

A DT N
prospective JJ N
study NN N
in IN N
high-risk JJ p
patients NNS p
. . p

The DT N
efficacy NN o
of IN N
corticosteroid JJ i
treatment NN N
in IN N
the DT N
prophylaxis NN N
of IN N
the DT N
fat JJ o
embolism NN o
syndrome NN o
was VBD N
evaluated VBN N
in IN N
a DT N
prospective JJ N
, , N
randomized VBN N
, , N
double-blind JJ N
study NN N
of IN N
high-risk JJ p
patients NNS p
with IN p
long-bone JJ p
fractures NNS p
. . p

Using VBG N
a DT N
set NN N
of IN N
objective JJ N
diagnostic JJ N
criteria NNS N
, , N
we PRP N
saw VBD N
a DT N
significant JJ N
difference NN N
in IN N
the DT N
incidence NN N
of IN N
the DT N
syndrome NN o
between IN N
corticosteroid- NN i
( ( p
0 CD p
of IN p
21 CD p
) ) p
and CC p
placebo-treated JJ i
patients NNS p
( ( p
9 CD p
of IN p
41 CD p
) ) p
( ( N
p NN N
less JJR N
than IN N
0.05 CD N
) ) N
. . N

There EX N
were VBD N
no DT N
complications NNS N
related VBN N
to TO N
corticosteroid VB i
treatment NN N
. . N

No DT N
routine JJ N
laboratory NN N
or CC N
physical JJ N
findings NNS N
reliably RB N
predicted VBD N
the DT N
development NN o
of IN o
the DT o
fat JJ o
embolism NN o
syndrome NN o
except IN N
petechial JJ o
rash NN o
, , N
which WDT N
occurred VBD N
only RB N
in IN N
5 CD N
placebo-treated JJ N
patients NNS N
who WP N
developed VBD N
the DT N
syndrome NN N
. . N

Complement JJ o
activation NN o
was VBD N
present JJ N
in IN N
all DT N
patients NNS N
studied VBN N
who WP N
had VBD N
the DT N
syndrome NN N
( ( N
5 CD N
of IN N
27 CD N
) ) N
but CC N
also RB N
in IN N
many JJ N
patients NNS N
who WP N
did VBD N
not RB N
meet VB N
our PRP$ N
diagnostic JJ N
criteria NNS N
, , N
suggesting VBG N
a DT N
multifactorial JJ N
cause NN N
. . N

These DT N
data NNS N
support NN N
the DT N
prophylactic JJ N
value NN N
of IN N
corticosteroid JJ i
treatment NN N
in IN N
patients NNS p
at IN p
high JJ p
risk NN p
for IN p
the DT p
fat JJ o
embolism NN o
syndrome NN o
, , N
particularly RB N
if IN N
several JJ N
unfavorable JJ N
predictors NNS N
are VBP N
present JJ N
. . N

-DOCSTART- -8838389- O O

Effect NN N
of IN N
practice NN N
on IN N
laterality NN N
in IN N
a DT N
mental JJ i
rotation NN i
task NN i
. . i

The DT N
purpose NN N
of IN N
the DT N
present JJ N
study NN N
was VBD N
to TO N
investigate VB N
the DT N
effect NN N
of IN N
practice NN i
on IN i
the DT i
lateralization NN i
of IN i
mental JJ i
rotation NN i
skills NNS i
. . i

Forty-six JJ p
females NNS p
and CC p
46 CD p
males NNS p
completed VBN N
four CD N
blocks NNS N
of IN N
64 CD N
trials NNS i
in IN i
a DT i
lateralized JJ i
mental JJ i
rotation NN i
task NN i
. . i

Results NNP N
revealed VBD N
a DT N
reduction NN N
in IN N
reaction NN o
time NN o
and CC N
error NN o
rate NN o
across IN N
blocks NNS N
, , N
thus RB N
demonstrating VBG N
a DT N
practice NN N
effect NN N
. . N

A DT N
shift NN N
from IN N
a DT N
right NN N
hemisphere RB N
advantage RB N
to TO N
a DT N
left NN N
hemisphere JJ N
advantage NN N
across IN N
blocks NNS N
of IN N
trials NNS N
was VBD N
also RB N
found VBN N
. . N

The DT N
results NNS N
are VBP N
discussed VBN N
in IN N
terms NNS N
of IN N
their PRP$ N
implication NN N
for IN N
hypotheses NNS N
linking VBG N
laterality NN N
and CC N
training NN N
. . N

Practical JJ N
implications NNS N
for IN N
laterality NN N
research NN N
are VBP N
also RB N
discussed VBN N
. . N

-DOCSTART- -15346745- O O

Comparison NNP N
of IN N
an DT N
allograft NN i
in IN N
an DT N
experimental JJ i
putty NN i
carrier NN i
and CC i
a DT i
bovine-derived JJ i
xenograft NN i
used VBN N
in IN N
ridge JJ N
preservation NN N
: : N
a DT N
clinical JJ N
and CC N
histologic JJ N
study NN N
in IN N
humans NNS p
. . p

PURPOSE VB N
The DT N
aim NN N
of IN N
this DT N
randomized VBN N
, , N
controlled VBN N
, , N
blinded VBD N
clinical JJ N
study NN N
was VBD N
to TO N
compare VB N
ridge JJ o
dimensions NNS o
and CC o
histologic JJ o
characteristics NNS o
of IN o
ridges NNS o
preserved VBN N
with IN N
2 CD N
different JJ N
graft NN i
materials NNS i
. . i

MATERIALS NNP N
AND CC N
METHODS NNP N
Twenty-four NNP p
subjects NNS p
, , p
each DT p
requiring VBG p
a DT p
nonmolar JJ p
extraction NN p
and CC p
delayed JJ p
implant NN p
placement NN p
, , N
were VBD N
randomly RB N
selected VBN N
to TO N
receive VB N
ridge NN i
preservation NN i
treatment NN i
with IN i
either DT i
an DT i
allograft NN i
in IN i
an DT i
experimental JJ i
putty NN i
carrier NN i
plus CC i
a DT i
calcium NN i
sulfate NN i
barrier NN i
( ( i
PUT NNP i
) ) i
or CC i
a DT i
bovine-derived JJ i
xenograft NN i
( ( i
BDX NNP i
) ) i
plus CC i
a DT i
collagen NN i
membrane NN i
. . i

Horizontal NNP o
and CC o
vertical JJ o
ridge NN o
dimensions NNS o
were VBD o
determined VBN o
using VBG o
a DT o
digital JJ o
caliper NN o
and CC o
a DT o
template NN o
. . o

At IN N
4 CD N
months NNS N
postextraction NN N
, , N
a DT N
trephine NN N
core NN N
was VBD N
obtained VBN N
for IN N
histologic JJ o
analysis NN o
. . o

RESULTS VB N
The DT N
average JJ N
ridge NN o
width NN o
decreased VBN N
by IN N
0.50 CD N
mm NN N
for IN N
both DT N
groups NNS N
( ( N
P NNP N
< NNP N
.05 NNP N
) ) N
. . N

The DT N
midbuccal JJ o
vertical JJ o
change NN o
for IN N
the DT N
PUT NNP N
group NN N
was VBD N
a DT N
loss NN N
of IN N
0.3+/-0.7 JJ N
mm NN N
versus IN N
a DT N
gain NN N
of IN N
0.7+/-1.2 JJ N
mm NN N
for IN N
the DT N
BDX NNP i
group NN N
, , N
a DT N
difference NN N
of IN N
1.0 CD N
mm NN N
( ( N
P NNP N
> NNP N
.05 NNP N
) ) N
. . N

Histologic NNP N
analysis NN N
revealed VBD N
vital JJ o
bone NN o
in IN N
the DT N
PUT NNP i
group NN N
of IN N
about RB N
61 CD N
% NN N
+/-9 JJ N
% NN N
versus IN N
26 CD N
% NN N
+/-20 JJ N
% NN N
for IN N
the DT N
BDX NNP i
group NN N
( ( N
P NNP N
< NNP N
.05 NNP N
) ) N
. . N

DISCUSSION NNP N
Greater NNP N
vital JJ o
bone NN o
fill NN o
in IN N
the DT N
PUT NNP i
group NN N
may MD N
be VB N
attributable JJ N
to TO N
earlier RBR N
and CC N
greater JJR N
vascular JJ N
invasion NN N
of IN N
the DT N
carrier NN N
material NN N
. . N

The DT N
putty JJ N
material NN N
was VBD N
characterized VBN N
by IN N
ease NN N
of IN N
handling VBG N
, , N
simple JJ N
placement NN N
, , N
and CC N
enhanced VBD N
graft NN N
particle NN N
containment NN N
. . N

CONCLUSIONS NNP N
Allograft NNP N
mixed VBD N
with IN N
an DT N
experimental JJ N
putty NN N
carrier NN N
produced VBD N
significantly RB N
more RBR N
vital JJ N
bone NN N
fill NN N
than IN N
did VBD N
the DT N
use NN N
of IN N
a DT N
xenograft NN i
with IN N
no DT N
carrier NN N
material NN N
. . N

Ridge NNP o
width NN o
and CC o
height JJ o
dimensions NNS o
were VBD N
similarly RB N
preserved VBN N
with IN N
both DT N
graft NN N
materials NNS N
. . N

-DOCSTART- -23511149- O O

Perioperative JJ o
myocardial JJ o
infarctions NNS o
are VBP N
common JJ N
and CC N
often RB N
unrecognized JJ N
in IN N
patients NNS p
undergoing VBG p
hip JJ p
fracture NN p
surgery NN p
. . p

BACKGROUND IN N
The DT N
aim NN N
of IN N
this DT N
prospective JJ N
cohort NN N
study NN N
was VBD N
to TO N
assess VB N
the DT N
incidence NN N
and CC N
characteristics NNS N
of IN N
acute JJ N
myocardial JJ N
infarction NN N
in IN N
patients NNS p
undergoing JJ p
surgery NN p
for IN p
acute JJ p
hip NN p
fracture NN p
. . p

METHODS NNP N
A NNP p
consecutive JJ p
cohort NN p
of IN p
patients NNS p
( ( p
n JJ p
= NN p
200 CD p
, , p
68 CD p
men NNS p
) ) p
referred VBD p
to TO p
acute VB i
surgical JJ i
correction NN i
of IN i
hip NN i
fracture NN i
was VBD p
studied VBN p
. . p

Troponin NNP i
T NNP i
( ( i
TnT NNP i
) ) i
measurements NNS i
and CC N
electrocardiographic JJ i
( ( i
ECG NNP i
) ) i
recordings NNS i
were VBD N
performed VBN N
at IN N
admission NN N
, , N
before IN N
operation NN N
, , N
and CC N
on IN N
the DT N
first JJ N
and CC N
2nd CD N
postoperative JJ N
days NNS N
, , N
which WDT N
were VBD N
used VBN N
for IN N
diagnosis NN N
. . N

RESULTS VB N
The DT p
age NN p
of IN p
the DT p
patients NNS p
ranged VBD p
from IN p
32 CD p
to TO p
98 CD p
years NNS p
( ( p
mean NN p
, , p
80.8 CD p
years NNS p
) ) p
, , p
and CC p
65 CD p
patients NNS p
had VBD p
a DT p
history NN p
of IN p
coronary JJ p
artery NN p
disease NN p
. . p

A DT N
significant JJ N
rise NN o
in IN o
TnT NNP o
as IN N
a DT N
sign NN N
of IN N
myocardial JJ o
infarction NN o
was VBD N
observed VBN N
in IN N
71 CD N
patients NNS N
( ( N
35.5 CD N
% NN N
) ) N
, , N
and CC N
25 CD N
of IN N
them PRP N
had VBD N
a DT N
TnT NNP o
elevation NN o
exceeding VBG N
five CD N
times NNS N
the DT N
upper JJ N
normal JJ N
limit NN N
. . N

TnT NNP o
elevation NN o
was VBD N
observed VBN N
in IN N
36 CD N
patients NNS N
( ( N
51 CD N
% NN N
) ) N
already RB N
before RB N
surgery NN N
. . N

Seven CD N
patients NNS N
( ( N
10 CD N
% NN N
) ) N
had VBD N
ST NNP o
elevation NN o
myocardial JJ o
infarction NN o
, , N
23 CD N
patients NNS N
( ( N
32 CD N
% NN N
) ) N
had VBD N
new JJ o
ST NNP o
depressions NNS o
, , N
and CC N
21 CD N
patients NNS N
( ( N
30 CD N
% NN N
) ) N
had VBD N
no DT N
new JJ N
ST NNP N
segment NN N
changes NNS N
in IN N
the DT N
serial JJ N
electrocardiographic JJ N
recordings NNS N
. . N

In IN N
40 CD N
patients NNS N
( ( N
56 CD N
% NN N
) ) N
, , N
the DT N
perioperative JJ N
myocardial JJ N
infarction NN N
was VBD N
the DT N
first JJ N
manifestation NN N
of IN N
coronary JJ N
artery NN N
disease NN N
. . N

Multivariate NNP N
logistic JJ N
regression NN N
revealed VBD N
that IN N
old JJ N
age NN N
( ( N
odds NNS N
ratio VBP N
[ CD N
OR NNP N
] NNP N
, , N
1.06 CD N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NNP N
, , N
1.02-1.10 JJ N
; : N
p VB N
= $ N
0.002 CD N
) ) N
, , N
earlier JJR N
revascularization NN N
( ( N
OR NNP N
, , N
3.29 CD N
; : N
95 CD N
% NN N
CI NNP N
1.12-9.73 CD N
; : N
p CC N
= VB N
0.03 CD N
) ) N
, , N
and CC N
heart NN N
failure NN N
( ( N
OR NNP N
, , N
2.42 CD N
; : N
95 CD N
% NN N
CI NNP N
1.04-5.61 CD N
; : N
p CC N
= VB N
0.04 CD N
) ) N
were VBD N
independent JJ N
predictors NNS N
of IN N
TnT NNP N
elevation NN N
. . N

Majority NNP o
of IN o
myocardial JJ o
infarctions NNS o
were VBD N
asymptomatic JJ N
or CC N
unrecognized JJ N
. . N

Evidence-based JJ o
medications NNS o
of IN N
myocardial JJ N
infarction NN N
were VBD N
seldom RB N
started VBN N
and CC N
cardiologist NN N
was VBD N
consulted VBN N
in IN N
12 CD N
patients NNS N
( ( N
16.9 CD N
% NN N
) ) N
. . N

CONCLUSION JJ N
Patients NNS N
with IN N
hip JJ N
fracture NN N
often RB N
develop VBZ N
asymptomatic JJ N
and CC N
clinically RB N
unrecognized JJ N
perioperative JJ N
myocardial JJ N
infarctions NNS N
. . N

Earlier JJR N
diagnosis NN N
and CC N
appropriate JJ N
treatment NN N
of IN N
cardiac JJ N
infarction NN N
may MD N
improve VB N
survival NN N
of IN N
hip NN N
fracture NN N
patients NNS N
. . N

LEVEL NNP N
OF IN N
EVIDENCE NNP N
Epidemiologic NNP N
study NN N
, , N
level NN N
III NNP N
. . N

-DOCSTART- -22616853- O O

Controlled-release NNP N
melatonin NN i
, , i
singly RB i
and CC i
combined VBN i
with IN i
cognitive JJ i
behavioural JJ i
therapy NN i
, , N
for IN N
persistent JJ p
insomnia NN o
in IN p
children NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
: : p
a DT N
randomized JJ N
placebo-controlled JJ N
trial NN N
. . N

Although IN N
melatonin NN i
and CC i
cognitive-behavioural JJ i
therapy NN i
have VBP N
shown VBN N
efficacy NN N
in IN N
treating VBG N
sleep JJ p
disorders NNS p
in IN p
children NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
, , N
little JJ N
is VBZ N
known VBN N
about IN N
their PRP$ N
relative NN N
or CC N
combined VBN N
efficacy NN N
. . N

One CD p
hundred CD p
and CC p
sixty JJ p
children NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
, , p
aged VBN p
4-10 CD p
years NNS p
, , p
suffering VBG p
from IN p
sleep JJ p
onset NN p
insomnia NN p
and CC p
impaired JJ p
sleep JJ p
maintenance NN p
, , N
were VBD N
assigned VBN N
randomly RB N
to TO N
either DT N
( ( N
1 CD N
) ) N
combination NN i
of IN i
controlled-release JJ i
melatonin NN i
and CC i
cognitive-behavioural JJ i
therapy NN i
; : i
( ( i
2 CD i
) ) i
controlled-release NN i
melatonin NN i
; : i
( ( i
3 CD i
) ) i
four CD i
sessions NNS i
of IN i
cognitive-behavioural JJ i
therapy NN i
; : i
or CC i
( ( i
4 CD i
) ) i
placebo FW i
drug NN i
treatment NN i
condition NN i
for IN N
12 CD N
weeks NNS N
in IN N
a DT N
1 CD N
: : N
1 CD N
: : N
1 CD N
: : N
1 CD N
ratio NN N
. . N

Children NNP N
were VBD N
studied VBN N
at IN N
baseline NN N
and CC N
after IN N
12 CD N
weeks NNS N
of IN N
treatment NN N
. . N

Treatment NNP N
response NN N
was VBD N
assessed VBN N
with IN N
1-week JJ N
actigraphic JJ N
monitoring NN N
, , N
sleep JJ N
diary NN N
and CC N
sleep JJ N
questionnaire NN N
. . N

Main NNP N
outcome NN N
measures NNS N
, , N
derived VBN N
actigraphically RB N
, , N
were VBD N
sleep JJ o
latency NN o
, , o
total JJ o
sleep JJ o
time NN o
, , o
wake VBP o
after IN o
sleep JJ o
onset NN o
and CC o
number NN o
of IN o
awakenings NNS o
. . o

The DT N
active JJ N
treatment NN N
groups NNS N
all DT N
resulted VBD N
in IN N
improvements NNS N
across IN N
all DT N
outcome NN N
measures NNS N
, , N
with IN N
moderate-to-large JJ N
effect NN N
sizes VBZ N
from IN N
baseline NN N
to TO N
a DT N
12-week JJ N
assessment NN N
. . N

Melatonin NNP i
treatment NN N
was VBD N
mainly RB N
effective JJ N
in IN N
reducing VBG N
insomnia NN o
symptoms NNS o
, , N
while IN N
cognitive-behavioural JJ i
therapy NN i
had VBD N
a DT N
light JJ N
positive JJ N
impact NN N
mainly RB N
on IN N
sleep JJ o
latency NN o
, , N
suggesting VBG N
that IN N
some DT N
behavioural JJ N
aspects NNS N
might MD N
play VB N
a DT N
role NN N
in IN N
determining VBG N
initial JJ o
insomnia NN o
. . o

The DT N
combination NN N
treatment NN N
group NN N
showed VBD N
a DT N
trend NN N
to TO N
outperform VB N
other JJ N
active JJ N
treatment NN N
groups NNS N
, , N
with IN N
fewer JJR N
dropouts NNS N
and CC N
a DT N
greater JJR N
proportion NN N
of IN N
treatment NN N
responders NNS N
achieving VBG N
clinically RB N
significant JJ N
changes NNS N
( ( N
63.38 CD N
% NN N
normative JJ N
sleep JJ N
efficiency NN N
criterion NN N
of IN N
> $ N
85 CD N
% NN N
and CC N
84.62 CD N
% NN N
, , N
sleep JJ N
onset NN N
latency NN N
< VBD N
30 CD N
min NN N
) ) N
. . N

This DT N
study NN N
demonstrates VBZ N
that IN N
adding VBG N
behavioural JJ i
intervention NN i
to TO N
melatonin VB i
treatment NN N
seems VBZ N
to TO N
result VB N
in IN N
a DT N
better JJR N
treatment NN N
response NN N
, , N
at IN N
least JJS N
in IN N
the DT N
short JJ N
term NN N
. . N

-DOCSTART- -2019772- O O

Vancomycin NNP i
added VBD N
to TO N
empirical JJ N
combination NN N
antibiotic JJ N
therapy NN N
for IN N
fever NN N
in IN N
granulocytopenic JJ p
cancer NN p
patients NNS p
. . p

European JJ N
Organization NNP N
for IN N
Research NNP N
and CC N
Treatment NNP N
of IN N
Cancer NNP N
( ( N
EORTC NNP N
) ) N
International NNP N
Antimicrobial NNP N
Therapy NNP N
Cooperative NNP N
Group NNP N
and CC N
the DT N
National NNP N
Cancer NNP N
Institute NNP N
of IN N
Canada-Clinical NNP N
Trials NNP N
Group NNP N
. . N

A NNP N
total NN N
of IN N
747 CD p
febrile JJ p
granulocytopenic JJ p
patients NNS p
with IN p
cancer NN p
were VBD N
randomized VBN N
to TO N
receive VB N
ceftazidime NN i
plus CC i
amikacin NN i
( ( i
CA NNP i
) ) i
with IN i
or CC i
without IN i
vancomycin NN i
( ( i
V NNP i
) ) i
as IN N
initial JJ N
empirical JJ N
therapy NN N
. . N

Single NNP N
gram-positive JJ N
bacteremias NN N
responded VBD N
in IN N
29 CD N
( ( N
43 CD N
% NN N
) ) N
of IN N
68 CD N
patients NNS N
treated VBN N
with IN N
CA NNP N
and CC N
in IN N
48 CD N
( ( N
72 CD N
% NN N
) ) N
of IN N
67 CD N
treated JJ N
with IN N
CAV NNP N
( ( N
P NNP N
= NNP N
.001 NNP N
) ) N
. . N

For IN N
single JJ N
gram-negative JJ N
bacteremias NN N
and CC N
clinically RB N
documented VBN N
and CC N
possible JJ N
infections NNS N
the DT N
response NN o
rates NNS o
of IN N
CA NNP N
and CC N
CAV NNP N
were VBD N
80 CD N
% NN N
and CC N
63 CD N
% NN N
( ( N
P NNP N
= NNP N
.17 NNP N
) ) N
, , N
55 CD N
% NN N
and CC N
75 CD N
% NN N
( ( N
P NNP N
= NNP N
.009 NNP N
) ) N
, , N
and CC N
74 CD N
% NN N
and CC N
81 CD N
% NN N
( ( N
P NNP N
= NNP N
.16 NNP N
) ) N
, , N
respectively RB N
. . N

However RB N
, , N
for IN N
patients NNS N
with IN N
gram-positive JJ N
bacteremia NN N
and CC N
for IN N
all DT N
other JJ N
patients NNS N
, , N
there EX N
were VBD N
no DT N
differences NNS N
by IN N
treatment NN N
regimens NNS N
in IN N
the DT N
proportion NN o
of IN o
febrile JJ o
patients NNS o
on IN N
each DT N
trial NN N
day NN N
( ( N
P NNP N
= NNP N
.85 NNP N
, , N
P NNP N
= NNP N
.82 NNP N
, , N
respectively RB N
) ) N
or CC N
in IN N
the DT N
duration NN o
of IN o
fever NN o
( ( N
P NNP N
= NNP N
.22 NNP N
, , N
P NNP N
= NNP N
.93 NNP N
, , N
respectively RB N
) ) N
. . N

Moreover RB N
, , N
no DT N
patient NN N
with IN N
gram-positive JJ N
bacteremia NN N
died VBD o
during IN N
the DT N
first JJ N
3 CD N
days NNS N
of IN N
true JJ N
empirical JJ N
therapy NN N
. . N

Antibiotic-associated JJ o
nephrotoxicity NN o
was VBD N
more RBR N
frequent JJ N
in IN N
patients NNS N
treated VBN N
with IN N
vancomycin NN N
( ( N
6 CD N
% NN N
vs. FW N
2 CD N
% NN N
, , N
P NNP N
= NNP N
.02 NNP N
) ) N
. . N

These DT N
results NNS N
do VBP N
not RB N
support VB N
the DT N
empirical JJ N
addition NN N
of IN N
vancomycin NN N
to TO N
initial JJ N
antibiotic JJ N
therapy NN N
in IN N
cancer NN p
patients NNS p
with IN p
fever NN p
and CC p
granulocytopenia NN p
. . p

-DOCSTART- -15193939- O O

Brain NNP o
activity NN o
correlates VBZ p
differentially RB p
with IN p
increasing VBG p
temporal JJ p
complexity NN p
of IN p
rhythms NN p
during IN p
initialisation NN p
, , p
synchronisation NN p
, , p
and CC p
continuation NN p
phases NNS p
of IN p
paced JJ i
finger NN i
tapping VBG i
. . i

Activity NN o
in IN o
parts NNS o
of IN o
the DT o
human JJ o
motor NN o
system NN o
has VBZ N
been VBN N
shown VBN N
to TO N
correlate VB N
with IN N
the DT N
complexity NN N
of IN N
performed JJ N
motor NN N
sequences NNS N
in IN N
terms NNS N
of IN N
the DT N
number NN N
of IN N
limbs NNS N
moved VBN N
, , N
number NN N
of IN N
movements NNS N
, , N
and CC N
number NN N
of IN N
trajectories NNS N
. . N

Here RB N
, , N
we PRP N
searched VBD N
for IN N
activity NN N
correlating VBG N
with IN N
temporal JJ N
complexity NN N
, , N
in IN N
terms NNS N
of IN N
the DT N
number NN N
of IN N
different JJ N
intervals NNS N
produced VBN N
in IN N
the DT N
sequence NN N
, , N
using VBG N
an DT N
overlearned JJ N
tapping NN N
task NN N
. . N

Our PRP$ N
task NN N
was VBD N
divided VBN N
into IN N
three CD N
phases NNS N
: : N
movement NN i
selection NN i
and CC i
initiation NN i
( ( i
initiate NN i
) ) i
, , i
synchronisation NN i
of IN i
finger NN i
tapping VBG i
with IN i
an DT i
external JJ i
auditory NN i
cue NN i
( ( i
synchronise NN i
) ) i
, , N
and CC N
continued VBD i
tapping VBG i
in IN i
absence NN i
of IN i
the DT i
auditory JJ i
pacer NN i
( ( N
continue NN N
) ) N
. . N

Comparisons NNS N
between IN N
synchronisation NN N
and CC N
continuation NN N
showed VBD N
a DT N
pattern NN N
in IN N
keeping VBG N
with IN N
prior JJ N
neuroimaging VBG N
studies NNS N
of IN N
paced JJ N
finger NN N
tapping VBG N
. . N

Thus RB N
, , N
activation NN o
of IN o
bilateral JJ o
SMA NNP o
and CC o
basal NN o
ganglia NN o
was VBD N
greater JJR N
in IN N
continuation NN i
tapping VBG N
than IN N
in IN N
synchronisation NN i
tapping NN N
. . N

Parametric JJ N
analysis NN N
revealed VBD N
activity NN o
correlating VBG o
with IN o
temporal JJ o
complexity NN o
during IN o
initiate NN o
in IN o
bilateral JJ o
supplementary JJ o
and CC o
pre-supplementary JJ o
motor NN o
cortex NN o
( ( o
SMA NNP o
and CC o
preSMA NN o
) ) o
, , o
rostral JJ o
dorsal NN o
premotor NN o
cortex NN o
( ( o
PMC NNP o
) ) o
, , o
basal JJ o
ganglia NN o
, , o
and CC o
dorsolateral JJ o
prefrontal NN o
cortex NN o
( ( o
DLPFC NNP o
) ) o
, , o
among IN o
other JJ o
areas NNS o
. . o

During IN N
synchronise NN N
, , N
correlated VBD o
activity NN o
was VBD N
observed VBN N
in IN N
bilateral JJ N
SMA NNP N
, , N
more RBR N
caudal JJ N
dorsal NN N
and CC N
ventral JJ N
PMC NNP N
, , N
right JJ N
DLPFC NNP N
and CC N
right JJ N
primary NN N
motor NN N
cortex NN N
. . N

No DT N
correlated JJ N
activity NN N
was VBD N
observed VBN N
during IN N
continue NN N
at IN N
P NNP N
< $ N
0.01 CD N
( ( N
corrected VBN N
, , N
cluster JJR N
level NN N
) ) N
, , N
though RB N
left VBD N
angular JJ N
gyrus NN N
was VBD N
active JJ N
at IN N
P NNP N
< NNP N
0.05 CD N
. . N

We PRP N
suggest VBP N
that IN N
the DT N
preSMA NN o
and CC o
rostral JJ o
dorsal NN o
PMC NNP o
activities NNS o
during IN N
initiate NN N
may MD N
be VB N
associated VBN N
with IN N
selection NN o
of IN o
timing VBG o
parameters NNS o
, , N
while IN N
activation NN N
in IN N
centromedial JJ N
prefrontal JJ N
cortex NN N
during IN N
both DT N
initiate JJ N
and CC N
synchronise NN N
may MD N
be VB N
associated VBN N
with IN N
temporal JJ o
error NN o
monitoring NN o
or CC o
correction NN o
. . o

The DT N
absence NN N
of IN N
activity NN o
significantly RB o
correlated VBN o
with IN o
temporal JJ o
complexity NN o
during IN N
continue JJ N
suggests NNS N
that IN N
, , N
once RB N
an DT N
overlearned VBN N
timed JJ N
movement NN N
sequence NN N
has VBZ N
been VBN N
selected VBN N
and CC N
initiated VBN N
, , N
there EX N
is VBZ N
no DT N
further JJ N
adjustment NN N
of IN N
the DT N
timing NN N
control NN N
processes VBZ N
related VBN N
to TO N
its PRP$ N
continued JJ N
production NN N
in IN N
absence NN N
of IN N
external JJ N
cues NNS N
. . N

-DOCSTART- -21918912- O O

Enhancing VBG N
the DT N
application NN N
and CC N
evaluation NN N
of IN N
a DT N
discrete JJ i
trial NN i
intervention NN i
package NN i
for IN N
eliciting VBG N
first JJ N
words NNS N
in IN N
preverbal JJ p
preschoolers NNS p
with IN p
ASD NNP p
. . p

This DT N
study NN N
evaluates VBZ N
the DT N
effectiveness NN N
of IN N
an DT N
intervention NN N
package NN N
including VBG N
a DT N
discrete JJ i
trial NN i
program NN i
( ( i
Rapid NNP i
Motor NNP i
Imitation NNP i
Antecedent NNP i
Training NNP i
( ( N
Tsiouri NNP N
and CC N
Greer NNP N
, , N
J NNP N
Behav NNP N
Educat NNP N
12:185-206 CD N
, , N
2003 CD N
) ) N
combined VBN i
with IN i
parent NN i
education NN i
for IN i
eliciting VBG N
first JJ N
words NNS N
in IN N
children NNS p
with IN p
ASD NNP p
who WP p
had VBD p
little JJ p
or CC p
no DT p
spoken JJ p
language NN p
. . p

Evaluation NN N
of IN N
the DT N
approach NN N
includes VBZ N
specific JJ N
intervention NN N
targets NNS N
and CC N
functional JJ o
spoken JJ o
language NN o
outcomes NNS o
( ( o
Tager-Flusberg NNP o
et FW o
al. NN o
, , N
J NNP o
Speech NNP o
Lang NNP o
Hear NNP o
Res NNP o
52:643-652 CD o
, , o
2009 CD o
) ) o
. . o

Results VB N
suggest JJS N
that IN N
RMIA NNP N
, , N
with IN N
parent NN N
training NN N
, , N
catalyzes VBZ N
development NN N
of IN N
verbal JJ o
imitation NN o
and CC o
production NN o
for IN N
some DT N
children NNS N
. . N

Three CD p
of IN p
five CD p
participants NNS p
acquired VBD N
word NN o
production NN o
within IN N
the DT N
DTT NNP N
framework NN N
and CC N
achieved VBD N
milestones NNS N
of IN N
early JJ o
functional JJ o
spoken NN o
language NN o
use NN o
( ( N
Tager-Flusberg NNP N
et FW N
al. NN N
, , N
J NNP N
Speech NNP N
Lang NNP N
Hear NNP N
Res NNP N
52:643-652 CD N
, , N
2009 CD N
) ) N
. . N

The DT N
implications NNS N
of IN N
these DT N
findings NNS N
for IN N
understanding VBG N
the DT N
role NN N
of IN N
discrete JJ N
trial NN N
approaches NNS N
to TO N
language NN N
intervention NN N
are VBP N
discussed VBN N
. . N

-DOCSTART- -20010551- O O

Divalproex NNP i
sodium NN i
vs NN i
placebo NN i
for IN N
the DT N
treatment NN N
of IN N
irritability NN o
in IN N
children NNS p
and CC p
adolescents NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
. . p

Autism NNP N
spectrum NN N
disorders NNS N
( ( N
ASDs NNP N
) ) N
are VBP N
neurodevelopmental JJ N
disorders NNS N
characterized VBN N
by IN N
social JJ N
and CC N
language NN N
deficits NNS N
and CC N
by IN N
repetitive JJ N
behaviors NNS N
and CC N
interests NNS N
. . N

Irritability/aggression NN N
is VBZ N
a DT N
significant JJ N
comorbid NN N
symptom NN N
in IN N
this DT N
population NN N
, , N
which WDT N
greatly RB N
impacts VBZ N
burden NN N
of IN N
care NN N
. . N

This DT N
study NN N
examined VBD N
the DT N
effect NN N
of IN N
divalproex NN i
sodium NN i
for IN N
irritability/aggression NN N
in IN N
children NNS p
and CC p
adolescents NNS p
with IN p
ASD NNP p
. . p

This DT N
was VBD N
a DT N
12-week JJ N
randomized NN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
trial NN N
. . N

All DT N
efficacy NN N
measures NNS N
were VBD N
obtained VBN N
by IN N
an DT N
independent JJ N
evaluator NN N
blinded VBD N
to TO N
randomization VB N
condition NN N
and CC N
side NN N
effects NNS N
. . N

A DT N
total NN p
of IN p
55 CD p
subjects NNS p
gavetheir JJ p
consent NN p
and CC p
27 CD p
were VBD p
randomized VBN p
in IN p
a DT p
1 CD p
: : p
1 CD p
manner NN p
( ( p
mean JJ p
age NN p
9.46+/-2.46 CD p
, , p
mean FW p
nonverbal JJ p
IQ NNP p
63.3+/-23.9 NN p
) ) p
. . p

Two CD N
subjects NNS N
from IN N
the DT N
active JJ N
group NN N
and CC N
one CD N
subject NN N
from IN N
the DT N
placebo NN i
group NN N
discontinued VBD N
the DT N
study NN N
because IN N
of IN N
either CC N
a DT N
lack NN N
of IN N
efficacy NN o
or CC N
side NN o
effects NNS o
( ( N
increased JJ N
irritability NN N
) ) N
. . N

Primary JJ N
outcome JJ N
measures NNS N
were VBD N
Aberrant NNP o
Behavior NNP o
Checklist-Irritability NNP o
subscale NN o
and CC o
Clinical JJ o
Global NNP o
Impression-Improvement NNP o
, , N
which WDT N
focused VBD N
on IN N
irritability NN N
. . N

Overall NNP N
, , N
62.5 CD N
% NN N
of IN N
divalproex JJ i
subjects NNS N
vs VBP N
9 CD N
% NN N
of IN N
placebo JJ i
subjects NNS N
were VBD N
responders NNS o
( ( N
CGI-irritability NN N
OR NNP N
: : N
16.7 CD N
, , N
Fisher NNP N
's POS N
exact JJ N
p=0.008 NN N
) ) N
. . N

A DT N
statistically RB N
significant JJ N
improvement NN N
was VBD N
also RB N
noted VBN N
on IN N
the DT N
ABC-Irritability NNP o
subscale NN o
( ( N
p=0.048 NN N
) ) N
. . N

There EX N
was VBD N
a DT N
trend NN N
for IN N
responders NNS N
to TO N
have VB N
higher JJR N
valproate NN o
blood NN o
levels NNS o
compared VBN N
with IN N
nonresponders NNS N
. . N

This DT N
study NN N
suggests VBZ N
the DT N
efficacy NN o
of IN N
divalproex NN i
for IN N
the DT N
treatment NN N
of IN N
irritability NN o
in IN N
children NNS N
and CC N
adolescents NNS N
with IN N
ASD NNP N
. . N

Larger NNP N
sample JJ N
follow-up JJ N
studies NNS N
are VBP N
warranted VBN N
. . N

-DOCSTART- -10575594- O O

Comparison NNP N
of IN N
antiresorptive JJ N
activities NNS N
of IN N
ipriflavone NN i
, , N
an DT N
isoflavone NN i
derivative NN i
, , N
and CC N
elcatonin NN i
, , N
an DT N
eel NN i
carbocalcitonin NN i
. . i

Thirty NNP p
postmenopausal JJ p
women NNS p
with IN p
reduced JJ p
bone NN p
mineral JJ p
density NN p
were VBD p
divided VBN p
randomly RB p
into IN p
two CD p
groups NNS p
based VBN p
on IN p
the DT p
chronological JJ p
sequence NN p
of IN p
their PRP$ p
first JJ p
visit NN p
to TO p
the DT p
Osteoporosis NNP p
Clinic NNP p
of IN p
Katsuragi NNP p
Hospital NNP p
. . p

Group NNP N
I PRP N
was VBD N
given VBN N
600 CD N
mg JJ N
ipriflavone NN i
orally RB N
daily JJ N
and CC N
group NN N
II NNP N
was VBD N
weekly RB N
injected VBN N
intramuscularly RB N
with IN N
20 CD N
units NNS N
elcatonin RB i
, , i
Asu1-7 NNP i
eel NN i
calcitonin NN i
( ( i
carbocalcitonin NN i
) ) i
. . i

Lumbar NNP o
spine NN o
BMD NNP o
was VBD N
measured VBN N
by IN N
dual-energy JJ i
X-ray JJ i
absorptiometry NN i
, , N
and CC N
trabecular JJ o
bone NN o
mineral JJ o
density NN o
at IN N
the DT N
distal JJ N
radius NN N
, , N
cortical JJ o
bone NN o
density NN o
, , N
and CC N
relative JJ o
cortical JJ o
volume NN o
at IN N
the DT N
radial JJ N
diaphysis NN N
by IN N
peripheral JJ N
computed VBN N
tomography NN N
before IN N
the DT N
beginning NN N
of IN N
the DT N
study NN N
and CC N
at IN N
the DT N
4th CD N
, , N
8th CD N
, , N
and CC N
12th CD N
month NN N
. . N

Markers NNS o
of IN o
bone NN o
metabolism NN o
-- : o
serum JJ o
total JJ o
alkaline NN o
phosphatase NN o
, , o
bone-specific JJ o
alkaline NN o
phosphatase NN o
, , o
tartrate-resistant JJ o
acid NN o
phosphatase NN o
, , o
osteocalcin NN o
, , o
intact JJ o
osteocalcin NN o
, , o
PICP NNP o
and CC o
ICTP NNP o
, , o
and CC o
urinary JJ o
pyridinoline NN o
, , o
deoxypyridinoline NN o
, , o
and CC o
calcium/creatinine NN o
( ( o
Ca/Cr NNP o
) ) o
-- : o
were VBD o
also RB N
measured VBN N
at IN N
the DT N
same JJ N
interval NN N
. . N

Plasma NNP o
parathyroid JJ o
hormone NN o
( ( o
PTH NNP o
) ) o
and CC o
calcitonin NN o
( ( o
CT NNP o
) ) o
were VBD N
measured VBN N
at IN N
the DT N
same JJ N
time NN N
. . N

Radial JJ o
trabecular JJ o
bone NN o
density NN o
showed VBD N
a DT N
significantly RB N
higher JJR N
rate NN N
of IN N
increase NN N
in IN N
group NN N
I PRP N
( ( i
ipriflavone VB i
group NN N
) ) N
than IN N
in IN N
group NN N
II NNP N
( ( N
elcatonin JJ N
group NN N
) ) N
at IN N
the DT N
4th CD N
month NN N
, , N
whereas JJ N
lumbar NN o
spine NN o
BMD NNP o
showed VBD N
more RBR N
pronounced JJ N
increase NN N
in IN N
the DT N
elcatonin NN N
group NN N
than IN N
in IN N
the DT N
ipriflavone NN i
group NN N
throughout IN N
the DT N
study NN N
period NN N
. . N

Bone NNP o
metabolism NN o
markers NNS o
tended VBD N
to TO N
decline VB N
in IN N
both DT N
groups NNS N
. . N

Total JJ o
and CC o
intact JJ o
osteocalcin NN o
showed VBD N
a DT N
significant JJ N
fall NN N
from IN N
the DT N
baseline NN N
throughout IN N
the DT N
study NN N
period NN N
only RB N
in IN N
the DT N
ipriflavone NN N
group NN N
. . N

Urine NNP o
pyridinoline NN o
and CC o
deoxypyridinoline NN o
showed VBD N
a DT N
significant JJ N
fall NN N
from IN N
the DT N
baseline NN N
at IN N
the DT N
12th CD N
month NN N
only RB N
in IN N
the DT N
ipriflavone NN N
group NN N
. . N

On IN N
comparing VBG N
bone NN N
gainers NNS N
with IN N
increase NN N
of IN N
lumbar JJ o
spine NN o
BMD NNP o
by IN N
2 CD N
% NN N
or CC N
more JJR N
with IN N
bone NN N
losers NNS N
with IN N
a DT N
decrease NN N
by IN N
2 CD N
% NN N
or CC N
more JJR N
, , N
only RB N
urine JJ o
Ca/Cr NNP o
was VBD N
significantly RB N
different JJ N
, , N
lower RBR N
in IN N
the DT N
former JJ N
than IN N
in IN N
the DT N
latter NN N
, , N
despite IN N
the DT N
general JJ N
tendency NN N
for IN N
bone NN N
resorption NN N
markers NNS N
to TO N
decrease VB N
in IN N
bone NN N
gainers NNS N
and CC N
to TO N
increase VB N
in IN N
bone JJ N
losers NNS N
. . N

-DOCSTART- -23688137- O O

Environmental JJ N
enrichment NN N
as IN N
an DT N
effective JJ N
treatment NN N
for IN N
autism NN o
: : o
a DT N
randomized NN N
controlled VBN N
trial NN N
. . N

Enriched NNP N
sensorimotor NN N
environments NNS N
enable JJ N
rodents NNS N
to TO N
compensate VB N
for IN N
a DT N
wide JJ N
range NN N
of IN N
neurological JJ N
challenges NNS N
, , N
including VBG N
those DT N
induced VBN N
in IN N
animal JJ N
models NNS N
of IN N
autism NN N
. . N

Given VBN N
the DT N
sensorimotor NN N
deficits NNS N
in IN N
most JJS N
children NNS p
with IN p
autism NN p
, , N
we PRP N
attempted VBD N
to TO N
translate VB N
that DT N
approach NN N
to TO N
their PRP$ N
treatment NN N
. . N

In IN N
a DT N
randomized NN N
controlled VBN N
trial NN N
, , N
3-12 JJ p
year-old JJ p
children NNS p
with IN p
autism NN p
were VBD N
assigned VBN N
to TO N
either VB N
a DT N
sensorimotor NN i
enrichment NN i
group NN i
, , N
which WDT N
received VBD N
daily RB N
olfactory/tactile JJ i
stimulation NN i
along IN i
with IN i
exercises NNS i
that WDT i
stimulated VBD i
other JJ i
paired JJ i
sensory JJ i
modalities NNS i
, , i
or CC i
to TO i
a DT i
control NN i
group NN i
. . i

We PRP N
administered VBD N
tests NNS N
of IN N
cognitive JJ N
performance NN N
and CC N
autism NN N
severity NN N
to TO N
both DT N
groups NNS N
at IN N
the DT N
initiation NN N
of IN N
the DT N
study NN N
and CC N
after IN N
6 CD N
months NNS N
. . N

Severity NNP o
of IN o
autism NN o
, , N
as IN N
assessed VBN N
with IN N
the DT N
Childhood NNP o
Autism NNP o
Rating NNP o
Scale NNP o
, , N
improved VBN N
significantly RB N
in IN N
the DT N
enriched JJ N
group NN N
compared VBN N
to TO N
controls NNS N
. . N

Indeed RB N
, , N
42 CD N
% NN N
of IN N
the DT N
enriched VBN N
group NN N
and CC N
only RB N
7 CD N
% NN N
of IN N
the DT N
control NN N
group NN N
had VBD N
what WP N
we PRP N
considered VBD N
to TO N
be VB N
a DT N
clinically RB N
significant JJ N
improvement NN N
of IN N
5 CD N
points NNS N
on IN N
that DT N
scale NN N
. . N

Sensorimotor NNP N
enrichment NN N
also RB N
produced VBD N
a DT N
clear JJ o
improvement NN o
in IN o
cognition NN o
, , N
as IN N
determined VBN N
by IN N
their PRP$ N
Leiter-R JJ N
Visualization NNP N
and CC N
Reasoning NNP N
scores NNS N
. . N

At IN N
6 CD N
months NNS N
, , N
the DT N
change NN N
in IN N
average JJ N
scores NNS N
for IN N
the DT N
enriched JJ N
group NN N
was VBD N
11.3 CD N
points NNS N
higher JJR N
than IN N
that DT N
for IN N
the DT N
control NN N
group NN N
. . N

Finally RB N
, , N
69 CD N
% NN N
of IN N
parents NNS N
in IN N
the DT N
enriched JJ N
group NN N
and CC N
31 CD N
% NN N
of IN N
parents NNS N
in IN N
the DT N
control NN N
group NN N
reported VBD N
improvement NN N
in IN N
their PRP$ N
child NN N
over IN N
the DT N
6-month JJ N
study NN N
. . N

Environmental JJ N
enrichment NN N
therefore RB N
appears VBZ N
to TO N
be VB N
effective JJ N
in IN N
ameliorating VBG o
some DT o
of IN o
the DT o
symptoms NNS o
of IN o
autism NN o
in IN N
children NNS N
. . N

-DOCSTART- -16915076- O O

Control NN N
of IN N
the DT N
lumbar NN N
neutral JJ N
zone NN N
decreases VBZ N
low JJ o
back RB o
pain NN o
and CC N
improves VBZ o
self-evaluated JJ o
work NN o
ability NN o
: : o
a DT N
12-month JJ N
randomized NN N
controlled VBD N
study NN N
. . N

STUDY NNP N
DESIGN NNP N
A NNP N
randomized NN N
controlled VBD N
study NN N
with IN N
12 CD N
months NNS N
intervention NN N
. . N

OBJECTIVE UH N
To TO N
study VB N
the DT N
effectiveness NN N
of IN N
a DT N
training NN i
intervention NN i
with IN i
emphases NNS i
on IN i
the DT i
control NN i
of IN i
lumbar JJ i
neutral JJ i
zone NN i
( ( N
NZ NNP N
) ) N
and CC N
behavior JJ i
modeling NN i
as IN N
secondary JJ N
prevention NN N
of IN N
low JJ o
back RB o
pain NN o
( ( o
LBP NNP o
) ) o
and CC o
disability NN o
. . o

SUMMARY NNP N
OF IN N
BACKGROUND NNP N
DATA NNP N
Improving NNP N
the DT N
control NN N
of IN N
lumbar NN N
NZ NNP N
and CC N
enhancing VBG N
muscle NN N
activation NN N
patterns NNS N
ensuring VBG N
spinal JJ N
stability NN N
have VBP N
been VBN N
proposed VBN N
as IN N
means NNS N
for IN N
secondary JJ N
prevention NN N
of IN N
LBP NNP o
and CC o
disability NN o
. . o

In IN N
addition NN N
, , N
cognitive JJ i
behavior NN i
interventions NNS i
have VBP N
been VBN N
shown VBN N
to TO N
lower VB N
the DT N
risk NN N
of IN N
recurrence NN o
of IN o
LBP NNP o
and CC o
long-term JJ o
disability NN o
. . o

METHODS NNP N
Middle-aged JJ p
working VBG p
men NNS p
with IN p
recent JJ p
LBP NNP p
but CC p
without IN p
severe JJ p
disability NN p
were VBD N
randomly RB N
allocated VBN N
to TO N
either VB N
a DT N
training NN i
( ( N
TG NNP N
, , N
n JJ N
= NNP N
52 CD N
) ) N
or CC N
control VB i
group NN i
( ( N
CG NNP N
, , N
n JJ N
= NNP N
54 CD N
) ) N
. . N

The DT N
aim NN N
was VBD N
to TO N
exercise VB N
twice RB N
a DT N
week NN N
for IN N
12 CD N
months NNS N
, , N
once RB N
guided VBN N
and CC N
once RB N
independently RB N
. . N

The DT N
outcome NN N
measures NNS N
were VBD N
the DT N
changes NNS o
in IN o
intensity NN o
of IN o
LBP NNP o
, , o
disability NN o
, , o
self-evaluated JJ o
future NN o
work NN o
ability NN o
, , o
and CC o
neuromuscular JJ o
fitness NN o
. . o

RESULTS VB N
The DT N
intensity NN o
of IN o
LBP NNP o
decreased VBD N
significantly RB N
more JJR N
( ( N
39 CD N
% NN N
) ) N
in IN N
the DT N
TG NNP N
than IN N
in IN N
CG NNP N
at IN N
12 CD N
months NNS N
. . N

The DT N
proportion NN o
of IN o
subjects NNS o
with IN o
negative JJ o
expectations NNS o
about IN o
their PRP$ o
future NN o
work NN o
ability NN o
decreased VBN N
in IN N
both DT N
groups NNS N
at IN N
6 CD N
and CC N
12 CD N
months NNS N
; : N
however RB N
, , N
the DT N
proportion NN N
was VBD N
significantly RB N
bigger JJR N
in IN N
TG NNP N
compared VBN N
with IN N
CG NNP N
( ( N
P NNP N
= NNP N
0.028 CD N
) ) N
. . N

There EX N
effects NNS N
on IN N
disability NN o
indexes NNS o
and CC o
fitness NN o
were VBD N
not RB N
statistically RB N
significant JJ N
. . N

CONCLUSIONS NNP N
Controlling NNP N
lumbar NN N
NZ NNP N
is VBZ N
a DT N
specific JJ N
form NN N
of IN N
exercise NN i
and CC i
daily JJ i
self-care NN i
with IN N
potential JJ N
for IN N
prevention NN N
of IN N
recurrent NN N
nonspecific JJ N
LBP NNP p
and CC p
disability NN p
among IN p
middle JJ p
aged VBN p
working VBG p
men NNS p
. . p

-DOCSTART- -19928389- O O

The DT N
effect NN o
of IN N
posture NN i
on IN N
Cheyne-Stokes NNP N
respirations NNS N
and CC N
hemodynamics NNS N
in IN N
patients NNS p
with IN p
heart NN p
failure NN p
. . p

STUDY NNP N
OBJECTIVES NNP N
Cheyne-Stokes NNP N
respirations NNS N
occur VBP N
in IN N
40 CD N
% NN N
of IN N
patients NNS p
with IN p
heart NN p
failure NN p
. . p

Orthopnea NNP N
is VBZ N
a DT N
cardinal JJ N
symptom NN N
of IN N
heart NN N
failure NN N
and CC N
may MD N
affect VB N
the DT N
patient NN N
's POS N
sleeping VBG N
angle NN N
. . N

The DT N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
assess VB o
the DT o
respiratory NN o
and CC o
hemodynamic JJ o
response NN o
to TO N
sleeping VBG i
angle NN i
in IN N
a DT N
group NN p
of IN p
subjects NNS p
with IN p
stable JJ p
heart NN p
failure NN p
. . p

DESIGN NNP N
Twenty-five JJ p
patients NNS p
underwent JJ N
overnight JJ N
polysomnography NN N
with IN N
simultaneous JJ N
and CC N
continuous JJ N
impedance NN N
cardiographic JJ N
monitoring NN N
. . N

Sleeping VBG o
polysomnographic JJ o
and CC o
impedance JJ o
cardiographic JJ o
data NNS o
were VBD N
recorded VBN N
. . N

SETTING VBG N
The DT N
study NN N
was VBD N
conducted VBN N
in IN N
a DT N
sleep JJ N
center NN N
. . N

PATIENTS VB N
All DT p
25 CD p
patients NNS p
had VBD p
clinically RB p
stable JJ p
heart NN p
failure NN p
and CC p
left VBD p
ventricular JJ p
ejection NN p
fractions NNS p
< VBP p
40 CD p
% NN p
. . p

INTERVENTIONS NNP N
The DT N
patients NNS N
slept VBD i
at IN i
0 CD i
degrees NNS i
, , i
15 CD i
degrees NNS i
, , i
30 CD i
degrees NNS i
, , i
and CC i
45 CD i
degrees NNS i
in IN i
random JJ i
order NN i
. . i

MEASUREMENTS NNS N
AND CC N
RESULTS NNP N
Seventeen NNP N
patients NNS N
had VBD N
Cheyne-Stokes NNP o
apneas NNS o
( ( N
index NN N
> RB N
5/h CD N
) ) N
and CC N
23 CD N
patients NNS N
had VBD N
hypopneas NNS o
( ( N
index NN N
> RB N
5/h CD N
) ) N
. . N

The DT N
hypopnea NN o
index NN o
showed VBD N
no DT N
response NN N
to TO N
sleeping VBG N
angle NN N
. . N

The DT N
Cheyne-Stokes NNP o
apnea NN o
index NN o
decreased VBD N
with IN N
increasing VBG N
sleeping VBG N
angle NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

This DT N
effect NN N
was VBD N
seen VBN N
only RB N
during IN N
supine JJ N
sleep NN N
and CC N
non-rapid JJ N
eye NN N
movement NN N
sleep NN N
and CC N
was VBD N
absent VBN N
in IN N
non-supine JJ N
sleep NN N
, , N
rapid JJ N
eye NN N
movement NN N
sleep NN N
, , N
and CC N
during IN N
periods NNS N
of IN N
wakefulness NN N
. . N

Thoracic NNP o
fluid NN o
content NN o
index NN o
and CC o
left VBD o
ventricular JJ o
hemodynamics NNS o
measured VBN N
by IN N
impedance NN N
cardiography NN N
showed VBD N
no DT N
response NN N
to TO N
sleeping VBG N
angle NN N
. . N

CONCLUSIONS NNP N
Changing VBG N
the DT N
heart NN N
failure NN N
patient NN N
's POS N
sleeping VBG N
angle NN N
from IN N
0 CD N
degrees NNS N
to TO N
45 CD N
degrees NNS N
results NNS N
in IN N
a DT N
significant JJ N
decrease NN N
in IN N
Cheyne-Stokes NNP N
apneas NN N
. . N

This DT N
decrease NN N
occurs VBZ N
on IN N
a DT N
constant JJ N
base NN N
of IN N
hypopneas NNS N
. . N

The DT N
changes NNS N
in IN N
Cheyne-Stokes NNP N
apneas NNS N
are VBP N
not RB N
related VBN N
to TO N
changes NNS N
in IN N
lung NN N
congestion NN N
and CC N
left VBD N
ventricular JJ N
hemodynamics NNS N
. . N

-DOCSTART- -19666626- O O

Ultrasonographic JJ i
tissue NN i
characterisation NN i
of IN N
human JJ N
Achilles NNP N
tendons NNS N
: : N
quantification NN N
of IN N
tendon NN N
structure NN N
through IN N
a DT N
novel JJ N
non-invasive JJ N
approach NN N
. . N

OBJECTIVE UH N
To TO N
assess VB N
whether IN N
three-dimensional JJ i
imaging NN i
of IN i
the DT i
Achilles NNP i
tendon NN i
by IN i
ultrasonographic JJ i
tissue NN i
characterisation NN i
( ( i
UTC NNP i
) ) i
can MD N
differentiate VB N
between IN N
symptomatic JJ N
and CC N
asymptomatic JJ N
tendons NNS N
. . N

DESIGN NNP N
Case-control NNP N
study NN N
. . N

SETTING NNP N
Sports NNP p
Medical NNP p
Department NNP p
of IN p
the DT p
Hague NNP p
Medical NNP p
Centre NNP p
. . p

PATIENTS NNP N
Twenty-six JJ p
tendons NNS p
from IN p
patients NNS p
with IN p
chronic JJ p
midportion NN p
Achilles NNP p
tendinopathy NN p
were VBD p
included VBN p
. . p

The DT N
matched JJ N
control NN N
group NN N
consisted VBD N
of IN N
26 CD p
asymptomatic JJ p
tendons NNS p
. . p

INTERVENTIONS NNP N
Symptomatic NNP i
and CC i
asymptomatic JJ i
tendons NNS i
were VBD i
scanned VBN i
using VBG i
the DT i
UTC NNP o
procedure NN o
. . o

One CD i
researcher NN i
performed VBD i
the DT i
ultrasonographic JJ o
data NNS i
collection NN i
. . i

These DT N
blinded VBN N
data NNS N
were VBD N
randomised VBN N
, , N
and CC N
outcome JJ N
measures NNS N
were VBD N
determined VBN N
by IN N
two CD N
independent JJ N
observers NNS N
. . N

MAIN NNP N
OUTCOME NNP N
MEASUREMENTS NNP N
The DT N
raw JJ N
ultrasonographic JJ N
images NNS N
were VBD N
analysed VBN N
with IN N
a DT N
custom-designed JJ N
algorithm NN N
that WDT N
quantifies VBZ N
the DT N
three-dimensional JJ o
stability NN o
of IN o
echo NN o
patterns NNS o
, , o
qua JJ o
intensity NN o
and CC o
distribution NN o
over IN o
contiguous JJ o
transverse JJ o
images NNS o
. . o

This DT N
three-dimensional JJ N
stability NN N
was VBD N
related VBN N
to TO N
tendon VB N
structure NN N
in IN N
previous JJ N
studies NNS N
. . N

UTC NNP N
categorises VBZ N
four CD N
different JJ N
echotypes NNS o
that WDT N
represent VBP N
( ( N
I PRP N
) ) N
highly RB o
stable JJ o
; : o
( ( N
II NNP N
) ) N
medium NN o
stable JJ o
; : o
( ( N
III NNP N
) ) N
highly RB o
variable JJ o
and CC N
( ( N
IV NNP N
) ) N
constantly RB o
low JJ o
intensity NN N
and CC N
variable JJ N
distribution NN N
. . N

The DT N
percentages NNS N
of IN N
echo-types NNS o
were VBD N
calculated VBN N
, , N
and CC N
the DT N
maximum JJ N
tendon NN o
thickness NN o
was VBD N
measured VBN N
. . N

Finally RB N
, , N
the DT N
inter-observer JJ N
reliability NN N
of IN N
UTC NNP i
was VBD N
determined VBN N
. . N

RESULTS NNP N
Symptomatic JJ N
tendons NNS N
showed VBD N
less JJR N
pixels NNS N
in IN N
echo-types JJ N
I PRP N
and CC N
II NNP N
than IN N
asymptomatic JJ N
tendons NNS N
( ( N
51.5 CD N
% NN N
vs JJ N
76.6 CD N
% NN N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
, , N
thus RB N
less JJR N
three-dimensional JJ N
stability NN N
of IN N
the DT N
echo JJ o
pattern NN o
. . o

The DT N
mean JJ N
maximum JJ N
tendon NN o
thickness NN o
was VBD N
9.2 CD N
mm NN N
in IN N
the DT N
symptomatic JJ N
group NN N
and CC N
6.8 CD N
mm NN N
in IN N
the DT N
asymptomatic JJ N
group NN N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
. . N

The DT N
Intraclass NNP o
Correlation NNP o
Coefficient NNP o
( ( N
ICC NNP N
) ) N
for IN N
the DT N
interobserver JJ N
reliability NN N
of IN N
determining VBG N
the DT N
echo-types JJ N
I+II NNP N
was VBD N
0.95 CD N
. . N

The DT N
ICC NNP N
for IN N
tendon NN o
thickness NN o
was VBD N
0.84 CD N
. . N

CONCLUSION NNP N
UTC NNP N
can MD N
quantitatively RB N
evaluate VB N
tendon NN N
structure NN N
and CC N
thereby RB N
discriminate VB N
symptomatic JJ N
and CC N
asymptomatic JJ N
tendons NNS N
. . N

As IN N
such JJ N
, , N
UTC NNP i
might MD N
be VB N
useful JJ N
to TO N
monitor VB N
treatment NN N
protocols NNS N
. . N

-DOCSTART- -2177746- O O

Behavioral JJ o
effects NNS o
of IN N
Org NNP i
2766 CD i
, , N
a DT N
synthetic JJ N
analog NN N
of IN N
the DT N
adrenocorticotrophic JJ N
hormone NN N
( ( N
4-9 JJ N
) ) N
, , N
in IN N
14 CD p
outpatient JJ p
autistic JJ p
children NNS p
. . p

Fourteen NNP p
children NNS p
( ( p
12 CD p
infantile NN p
autism NN p
full JJ p
syndrome NN p
present NN p
, , p
2 CD p
atypical JJ p
pervasive JJ p
developmental JJ p
disorder NN p
) ) p
between IN p
5 CD p
and CC p
13 CD p
years NNS p
of IN p
age NN p
participated VBN N
in IN N
a DT N
double-blind JJ N
placebo-controlled JJ N
cross-over JJ N
trial NN N
. . N

Each DT N
child NN N
received VBD N
20 CD i
mg NNS i
Org JJ i
2766 CD i
( ( i
synthetic JJ i
analog NN i
of IN i
ACTH NNP i
4-9 JJ i
) ) i
/day NN i
during IN i
4 CD i
weeks NNS i
, , i
or CC i
placebo NN i
in IN i
a DT i
randomly NN i
assigned VBN i
sequence NN i
. . i

Drug JJ o
effects NNS o
were VBD i
monitored VBN i
by IN i
ethological JJ o
playroom NN o
observation NN o
and CC i
by IN i
Aberrant NNP o
Behavior NNP o
Checklist NNP o
ratings NNS o
by IN i
parents NNS i
and CC i
teachers NNS i
. . i

Data NNP N
of IN N
the DT N
playroom NN N
observation NN N
pointed VBD N
to TO N
an DT N
activating VBG o
influence NN o
of IN N
Org NNP N
2766 CD N
, , N
as IN N
revealed VBN N
by IN N
a DT N
significant JJ N
decrease NN N
of IN N
stereotypic NN o
behavior NN o
and CC N
significant JJ N
increases NNS N
in IN N
change NN o
toys NNS o
, , o
locomote NN o
, , o
and CC o
talk NN o
. . o

Checklist JJ N
ratings NNS N
did VBD N
not RB N
show VB N
significant JJ N
changes NNS N
. . N

The DT N
clinical JJ N
implications NNS N
of IN N
these DT N
findings NNS N
are VBP N
discussed VBN N
. . N

-DOCSTART- -8467286- O O

Use NNP N
of IN N
granulocyte-macrophage JJ i
colony-stimulating JJ i
factor NN i
and CC N
erythropoietin NN i
in IN N
combination NN N
after IN p
autologous JJ i
marrow NN i
transplantation NN i
. . i

The DT N
toxicities NNS N
and CC N
possible JJ N
utility NN N
of IN N
the DT N
combination NN i
of IN i
recombinant JJ i
human JJ i
granulocyte-macrophage NN i
colony-stimulating NN i
factor NN i
( ( i
rhGM-CSF NN i
) ) i
and CC i
recombinant JJ i
human JJ i
erythropoietin NN i
( ( i
rHuEPO NN i
) ) i
given VBN N
after IN N
autologous JJ i
BMT NNP i
were VBD N
evaluated VBN N
in IN N
this DT N
pilot NN N
trial NN N
. . N

Eighteen JJ p
patients NNS p
received VBD N
the DT N
combination NN N
and CC N
were VBD N
compared VBN N
with IN N
six CD i
concurrent NN i
control NN i
and CC i
65 CD i
historical JJ i
control NN i
patients NNS i
treated VBN i
with IN i
rhGM-CSF JJ i
alone NN i
. . i

Patients NNS N
treated VBD N
with IN N
the DT N
combination NN N
tended VBD N
to TO N
have VB N
more RBR N
rapid JJ N
recovery NN o
to TO N
an DT N
absolute JJ o
neutrophil NN o
count NN o
of IN N
500 CD N
x NNS N
10 CD N
( ( N
6 CD N
) ) N
/l NN N
( ( N
median JJ N
= NN N
12.5 CD N
vs NN N
18 CD N
days NNS N
for IN N
concurrent NN N
and CC N
19 CD N
days NNS N
for IN N
historical JJ N
control NN N
patients NNS N
) ) N
. . N

There EX N
was VBD N
no DT N
apparent JJ N
impact NN N
on IN N
red JJ o
cell NN o
transfusion NN o
requirements NNS o
, , o
platelet JJ o
recovery NN o
or CC o
duration NN o
of IN o
hospitalization NN o
. . o

Patients NNS N
treated VBD N
in IN N
the DT N
current JJ N
study NN N
with IN N
rhGM-CSF JJ N
plus CC N
either CC N
rHuEPO NN N
or CC N
with IN N
placebo NN N
had VBD N
a DT N
higher JJR N
incidence NN o
of IN o
rash NN o
than IN N
seen VBN N
in IN N
our PRP$ N
historical JJ N
experience NN N
using VBG N
rhGM-CSF NN N
. . N

This DT N
difference NN N
may MD N
reflect VB N
changes NNS N
in IN N
the DT N
source NN N
of IN N
rhGM-CSF NN N
or CC N
in IN N
the DT N
infusion NN N
schedule NN N
. . N

Erythropoietin NN N
can MD N
be VB N
combined VBN N
safely RB N
with IN N
rhGM-CSF NN N
after IN N
autologous JJ N
transplantation NN N
. . N

Larger NNP N
controlled VBD N
trials NNS N
will MD N
be VB N
necessary JJ N
to TO N
detect VB N
possible JJ N
therapeutic JJ N
effects NNS N
. . N

-DOCSTART- -24384538- O O

Design NN N
and CC N
methods NNS N
of IN N
a DT N
double JJ N
blind NN N
randomized VBD N
placebo-controlled JJ i
trial NN N
of IN N
extended-release JJ i
naltrexone NN i
for IN N
alcohol NN p
dependent NN p
and CC p
hazardous JJ p
drinking NN p
prisoners NNS p
with IN p
HIV NNP p
who WP p
are VBP p
transitioning VBG p
to TO p
the DT p
community NN p
. . p

BACKGROUND NNP N
HIV-infected JJ p
prisoners NNS p
have VBP p
a DT p
high JJ p
prevalence NN p
of IN p
alcohol NN p
use NN p
disorders NNS p
and CC p
commonly RB p
relapse NN o
to TO o
alcohol VB o
soon RB p
after IN p
release NN p
to TO p
the DT p
community NN p
which WDT p
is VBZ p
linked VBN p
to TO p
high JJ p
morbidity NN p
, , p
poor JJ p
antiretroviral JJ p
therapy NN p
( ( p
ART NNP p
) ) p
adherence NN p
and CC p
increased VBD p
sexual JJ p
risk-taking JJ p
behaviors NNS p
. . p

Extended-release NNP i
naltrexone NN i
( ( i
XR-NTX JJ i
) ) i
effectively RB N
reduces VBZ N
relapse NN o
to TO o
alcohol VB o
in IN N
alcohol NN N
dependent JJ N
persons NNS N
, , N
yet CC N
it PRP N
remains VBZ N
unexamined JJ N
among IN N
criminal JJ N
justice NN N
system NN N
( ( N
CJS NNP N
) ) N
populations NNS N
transitioning VBG N
to TO N
the DT N
community NN N
. . N

METHODS VB N
A DT N
randomized JJ N
double-blind NN N
, , N
placebo-controlled JJ i
trial NN N
of IN N
XR-NTX NN i
to TO N
improve VB N
HIV NNP N
treatment NN N
outcomes NNS N
via IN N
reducing VBG N
relapse NN o
to TO o
alcohol VB o
use NN N
after IN N
prison NN N
release NN N
for IN N
HIV-infected NNP N
hazardous JJ N
drinking NN N
and CC N
alcohol NN p
dependent NN p
prisoners NNS p
is VBZ N
discussed VBN N
. . N

RESULTS NNP N
Acceptability NNP o
of IN N
study NN N
participation NN N
is VBZ N
high JJ N
with IN N
86 CD N
% NN N
of IN N
those DT N
referred VBN N
who WP N
met VBD N
eligibility NN N
criteria NNS N
and CC N
85 CD N
% NN N
of IN N
those DT N
who WP N
were VBD N
able JJ N
to TO N
receive VB N
injections NNS N
prior RB N
to TO N
release VB N
accepted JJ N
injections NNS N
, , N
yet RB N
important JJ N
implementation NN N
issues NNS N
are VBP N
identified VBN N
and CC N
addressed VBN N
during IN N
the DT N
study NN N
and CC N
are VBP N
discussed VBN N
in IN N
this DT N
paper NN N
. . N

CONCLUSION NNP N
Medication-assisted JJ N
therapies NNS N
for IN N
prevention NN N
of IN N
relapse NN N
to TO N
alcohol VB N
use NN N
for IN N
CJS NNP N
populations NNS N
transitioning VBG N
to TO N
the DT N
community NN N
, , N
especially RB N
for IN N
HIV-infected JJ p
patients NNS p
, , N
are VBP N
urgently RB N
needed VBN N
in IN N
order NN N
to TO N
reduce VB N
alcohol NN o
relapse NN o
after IN N
release NN N
and CC N
improve VB N
HIV NNP o
treatment NN o
outcomes NNS o
and CC N
contribute NN N
to TO N
improved VBN N
individual JJ o
and CC o
public JJ o
health NN o
. . o

-DOCSTART- -19660462- O O

Norfloxacin NNP i
modulates VBZ p
the DT p
inflammatory JJ p
response NN p
and CC p
directly RB p
affects VBZ p
neutrophils NNS p
in IN p
patients NNS p
with IN p
decompensated JJ p
cirrhosis NN p
. . p

BACKGROUND NNP N
& CC N
AIMS NNP N
Patients NNPS p
with IN p
cirrhosis NN p
undergoing VBG p
selective JJ p
intestinal JJ p
decontamination NN p
with IN p
norfloxacin JJ i
show NN N
a DT N
reduction NN N
in IN N
serum JJ N
cytokine NN N
levels NNS N
, , N
probably RB N
because IN N
of IN N
a DT N
combined JJ N
effect NN N
of IN N
norfloxacin NN i
on IN N
bowel NN N
flora NNS N
and CC N
neutrophils NNS N
. . N

METHODS NNP N
Thirty-one CD p
patients NNS p
with IN p
cirrhosis NN p
receiving VBG p
norfloxacin NN i
( ( p
400 CD p
mg/day NN p
) ) p
were VBD p
included VBN p
. . p

Blood NNP N
samples NNS N
were VBD N
collected VBN N
at IN N
0.5-4 JJ N
hours NNS N
( ( N
peak JJ N
samples NNS N
group NN N
, , N
n RB N
= VBZ N
47 CD N
) ) N
and CC N
at IN N
22-24 JJ N
hours NNS N
( ( N
trough IN N
samples NNS N
group NN N
, , N
n RB N
= VBZ N
84 CD N
) ) N
after IN N
dose NN N
. . N

Fifty-nine JJ p
ascitic JJ p
fluid NN p
samples NNS p
were VBD N
obtained VBN N
. . N

Single NNP N
doses NNS N
of IN N
norfloxacin NN i
and CC i
trimethoprim/sulfamethoxazole NN i
were VBD N
administered VBN N
to TO N
13 CD N
and CC N
5 CD N
patients NNS N
, , N
respectively RB N
, , N
( ( N
temporal JJ N
profile NN N
group NN N
) ) N
and CC N
samples NNS N
were VBD N
collected VBN N
at IN N
0 CD N
, , N
0.5 CD N
, , N
1 CD N
, , N
1.5 CD N
, , N
2 CD N
, , N
4 CD N
, , N
and CC N
24 CD N
hours NNS N
. . N

Norfloxacin NNP i
, , i
trimethoprim/sulfamethoxazole NN i
, , i
cytokines NNS i
, , i
nitric JJ i
oxide NN i
, , N
expression NN N
levels NNS N
of IN N
nuclear JJ N
factor NN N
( ( N
NF NNP N
) ) N
-kappaB NN N
and CC N
inhibitor NN N
of IN N
NF-kappaB NNP N
( ( N
IkB-alpha NNP N
) ) N
, , N
neutrophil JJ N
oxidative JJ N
burst NN N
, , N
and CC N
rate NN N
of IN N
apoptotic JJ N
events NNS N
were VBD N
determined VBN N
. . N

RESULTS NNP N
All NNP N
samples NNS N
were VBD N
bacterial JJ N
DNA NNP N
negative NN N
and CC N
had VBD N
no DT N
significant JJ N
levels NNS N
of IN N
lipopolysaccharide NN N
. . N

Serum NNP o
and CC o
ascitic JJ o
levels NNS o
of IN o
tumor NN o
necrosis NN o
factor-alpha JJ o
, , o
interferon-gamma JJ o
, , o
interleukin-12 JJ o
, , o
and CC o
nitric JJ o
oxide NN o
were VBD N
significantly RB N
lower JJR N
in IN N
peak NN N
than IN N
in IN N
trough JJ N
samples NNS N
. . N

A DT N
correlation NN N
was VBD N
present JJ N
between IN N
serum NN o
norfloxacins NNS o
concentrations NNS o
and CC o
tumor NN o
necrosis NN o
factor-alpha NN o
( ( N
r JJ N
= NNP N
-0.68 NNP N
; : N
P NNP N
< NNP N
.001 NNP N
) ) N
, , N
interferon-gamma JJ o
( ( N
r JJ N
= NNP N
-0.66 NNP N
; : N
P NNP N
< NNP N
.001 NNP N
) ) N
, , N
interleukin-12 JJ o
( ( N
r JJ N
= NNP N
-0.66 NNP N
; : N
P NNP N
< NNP N
.001 NNP N
) ) N
, , N
and CC N
nitric JJ o
oxide NN o
( ( N
r JJ N
= NNP N
-0.68 NNP N
; : N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

Serum NNP o
norfloxacin NN o
's POS o
highest JJS o
concentrations NNS o
( ( N
1 CD N
+/- JJ N
0.5 CD N
microg/mL NN N
) ) N
were VBD N
achieved VBN N
at IN N
1-2 JJ N
hours NNS N
and CC N
concurred VBN N
in IN N
time NN N
with IN N
the DT N
lower JJR N
levels NNS N
of IN N
cytokines NNS o
and CC o
nitric JJ o
oxide NN o
. . o

Intracellular NNP o
norfloxacin NN o
's POS o
highest JJS o
levels NNS o
( ( N
2 CD N
+/- JJ N
1 CD N
microg/mL/10 NN N
( ( N
7 CD N
) ) N
cells NNS N
) ) N
were VBD N
observed VBN N
at IN N
2 CD N
hours NNS N
and CC N
concurred VBN N
with IN N
a DT N
lower JJR N
NF-kappaB JJ N
expression NN N
, , N
a DT N
reduced JJ N
anion NN N
superoxide NN N
generation NN N
, , N
and CC N
apoptotic JJ N
rate NN N
in IN N
response NN N
to TO N
phorbol VB N
myristate JJ N
acetate NN N
. . N

Trimethoprim/sulfamethoxazole NNP i
did VBD N
not RB N
significantly RB N
modulate VB N
cytokine JJ o
expression NN o
. . o

CONCLUSIONS NNP N
Norfloxacin NNP i
but CC N
not RB N
trimethoprim/sulfamethoxazole JJ i
modulates NNS N
inflammatory JJ N
response NN N
and CC N
directly RB N
affects VBZ N
neutrophils NNS N
in IN N
patients NNS p
with IN p
cirrhosis NN p
. . p

-DOCSTART- -20484002- O O

Efficacy NN N
of IN N
TeachTown NNP N
: : N
Basics NNS i
computer-assisted JJ i
intervention NN i
for IN N
the DT N
Intensive NNP N
Comprehensive NNP N
Autism NNP N
Program NNP N
in IN N
Los NNP N
Angeles NNP N
Unified NNP N
School NNP N
District NNP N
. . N

Computer NNP i
Assisted NNP i
Instruction NNP i
( ( i
CAI NNP i
) ) i
has VBZ N
shown VBN N
increased VBN N
popularity NN N
recently RB N
and CC N
there EX N
are VBP N
many JJ N
studies NNS N
showing VBG N
promise NN N
for IN N
this DT N
approach NN N
for IN N
children NNS p
with IN p
Autism NNP p
Spectrum NNP p
Disorders NNP p
( ( p
ASD NNP p
) ) p
. . p

However RB N
, , N
there EX N
are VBP N
no DT N
between-subject JJ N
studies NNS N
to TO N
date NN N
assessing VBG N
the DT N
efficacy NN N
of IN N
CAI NNP i
with IN N
this DT N
population NN N
. . N

In IN N
this DT N
study NN N
, , N
47 CD p
preschool NN p
and CC p
K-1 JJ p
students NNS p
in IN p
ASD NNP p
classrooms NNS p
participated VBD p
from IN p
Los NNP p
Angeles NNP p
Unified NNP p
School NNP p
District NNP p
. . p

TeachTown NN i
: : i
Basics NNS i
, , i
a DT i
CAI NNP i
program NN i
which WDT i
also RB i
includes VBZ i
supplementary JJ i
off-computer NN i
activities NNS i
, , N
was VBD N
implemented VBN N
over IN N
3 CD N
months NNS N
for IN N
approximately RB N
20 CD N
minutes NNS N
per IN N
day NN N
on IN N
the DT N
computer NN i
and CC N
20 CD i
minutes NNS i
per IN i
day NN i
in IN i
supplementary JJ i
TeachTown NN i
: : i
Basics JJ i
activities NNS i
. . i

Compared VBN N
to TO N
the DT N
students NNS N
in IN N
the DT N
control NN N
group NN N
, , N
the DT N
TeachTown NNP N
: : N
Basics NNS N
students NNS N
showed VBD N
more RBR N
improvement NN N
overall JJ o
on IN o
language NN o
and CC o
cognitive JJ o
outcome NN o
measures NNS o
. . o

In IN N
addition NN N
, , N
students NNS N
who WP N
used VBD N
TeachTown NNP N
: : N
Basics NNS N
demonstrated VBD N
significant JJ N
progress NN o
overall NN o
in IN o
the DT o
software NN o
and CC N
those DT N
students NNS N
who WP N
used VBD N
the DT N
program NN N
for IN N
more JJR N
time NN N
demonstrated VBD o
larger JJR o
gains NNS o
within IN o
the DT o
software NN o
and CC o
in IN o
outcome JJ o
measures NNS o
. . o

Although IN N
not RB N
conclusive JJ N
, , N
these DT N
findings NNS N
offer VBP N
possibilities NNS N
for IN N
the DT N
use NN N
of IN N
CAI NNP i
for IN N
remediating VBG N
many JJ N
deficits NNS N
for IN N
children NNS p
with IN p
ASD NNP p
and CC p
other JJ p
special JJ p
needs NNS p
. . p

In IN N
addition NN N
, , N
CAI NNP i
may MD N
offer VB N
solutions NNS N
to TO N
schools NNS N
and CC N
parents NNS N
with IN N
insufficient JJ N
funds NNS N
for IN N
more RBR N
expensive JJ N
treatments NNS N
. . N

-DOCSTART- -23205521- O O

Exposure NN i
to TO i
the DT i
self-face NN i
facilitates VBZ i
identification NN o
of IN o
dynamic JJ o
facial JJ o
expressions NNS o
: : o
influences NNS N
on IN N
individual JJ N
differences NNS N
. . N

A DT N
growing VBG N
literature NN N
suggests VBZ N
that IN N
the DT N
self-face NN i
is VBZ N
involved VBN N
in IN N
processing VBG o
the DT o
facial JJ o
expressions NNS o
of IN N
others NNS N
. . N

The DT N
authors NNS N
experimentally RB N
activated VBD N
self-face JJ i
representations NNS i
to TO N
assess VB N
its PRP$ N
effects NNS N
on IN N
the DT N
recognition NN o
of IN o
dynamically RB o
emerging VBG o
facial JJ o
expressions NNS o
of IN o
others NNS o
. . o

They PRP N
exposed VBD N
participants NNS p
to TO N
videos NNS N
of IN N
either DT N
their PRP$ N
own JJ N
faces VBZ N
( ( i
self-face JJ i
prime NN i
) ) i
or CC i
faces VBZ i
of IN i
others NNS i
( ( i
nonself-face JJ i
prime NN i
) ) i
prior RB N
to TO N
a DT N
facial JJ N
expression NN N
judgment NN N
task NN N
. . N

Their PRP$ N
results NNS N
show VBP N
that IN N
experimentally RB N
activating VBG N
self-face JJ N
representations NNS N
results NNS N
in IN N
earlier JJR N
recognition NN o
of IN o
dynamically RB o
emerging VBG o
facial JJ o
expression NN o
. . o

As IN N
a DT N
group NN N
, , N
participants NNS p
in IN p
the DT p
self-face JJ p
prime JJ p
condition NN p
recognized VBD o
expressions NNS o
earlier RBR N
( ( N
when WRB N
less RBR N
affective JJ N
perceptual JJ N
information NN N
was VBD N
available JJ N
) ) N
compared VBN N
to TO N
participants NNS N
in IN N
the DT N
nonself-face JJ N
prime JJ N
condition NN N
. . N

There EX N
were VBD N
individual JJ N
differences NNS N
in IN N
performance NN N
, , N
such JJ N
that IN N
poorer JJR N
expression NN o
identification NN o
was VBD N
associated VBN N
with IN N
higher JJR p
autism NN p
traits NNS p
( ( N
in IN N
this DT N
neurocognitively RB p
healthy JJ p
sample NN p
) ) p
. . N

However RB N
, , N
when WRB N
randomized VBN N
into IN N
the DT N
self-face JJ N
prime JJ N
condition NN N
, , N
participants NNS p
with IN p
high JJ p
autism NN p
traits NNS p
performed VBN p
as RB p
well RB p
as IN p
those DT p
with IN p
low JJ p
autism NN p
traits NNS p
. . p

Taken VB N
together RB N
, , N
these DT N
data NNS N
suggest VBP N
that IN N
the DT N
ability NN o
to TO o
recognize VB o
facial JJ o
expressions NNS o
in IN N
others NNS N
is VBZ N
linked VBN N
with IN N
the DT N
internal JJ N
representations NNS N
of IN N
our PRP$ N
own JJ N
faces VBZ N
. . N

-DOCSTART- -15824212- O O

Simvastatin JJ i
blunts NNS N
endotoxin-induced JJ N
tissue NN N
factor NN N
in IN N
vivo NN N
. . N

BACKGROUND NNP N
Beyond NNP N
lipid JJ N
lowering NN N
, , N
various JJ N
antiinflammatory NN N
properties NNS N
have VBP N
been VBN N
ascribed VBN N
to TO N
statins NNS N
. . N

Moreover RB N
, , N
in IN N
vitro JJ N
studies NNS N
have VBP N
suggested VBN N
the DT N
presence NN N
of IN N
anticoagulant JJ N
effects NNS N
of IN N
3-hydroxy-3-methylglutaryl JJ N
coenzyme NN N
A NNP N
reductase NN N
inhibitors NNS N
, , N
as IN N
lipopolysaccharide NN N
( ( N
LPS NNP N
) ) N
-induced VBD N
monocyte JJ N
tissue NN N
factor NN N
( ( N
TF NNP N
) ) N
was VBD N
suppressed VBN N
. . N

In IN N
this DT N
study NN N
, , N
we PRP N
examined VBD N
the DT N
role NN N
of IN N
statins NNS i
in IN N
experimental JJ N
endotoxemia NN p
on IN N
inflammatory NN N
and CC N
procoagulant JJ N
responses NNS N
in IN N
vivo NN N
. . N

METHODS NNP N
AND CC N
RESULTS NNP N
In IN N
this DT N
double-blind NN N
, , N
placebo-controlled JJ i
, , N
parallel-group JJ N
study NN N
, , N
20 CD p
healthy JJ p
, , p
male JJ p
subjects NNS p
were VBD N
randomized VBN N
to TO N
receive VB N
either DT N
simvastatin NN i
( ( N
80 CD N
mg/d NN N
) ) N
or CC i
placebo NN i
for IN N
4 CD N
days NNS N
before RB N
intravenous JJ N
administration NN N
of IN N
LPS NNP N
( ( N
20 CD N
IU/kg NNP N
IV NNP N
) ) N
. . N

Plasma JJ o
high-sensitive JJ o
C-reactive JJ o
protein NN o
( ( o
hsCRP NN o
) ) o
, , o
monocyte JJ o
chemoattractant NN o
protein NN o
( ( o
MCP-1 NNP o
) ) o
, , o
sCD40L UH o
, , o
sCD40 JJ o
, , o
and CC o
prothrombin JJ o
fragment NN o
F1+2 NNP o
( ( o
F1.2 NNP o
) ) o
were VBD N
determined VBN N
by IN N
ELISAs NNP N
at IN N
baseline NN N
and CC N
at IN N
4 CD N
and CC N
8 CD N
hours NNS N
after IN N
LPS NNP N
administration NN N
. . N

Monocyte NNP o
TF NNP o
expression NN o
and CC o
monocyte-platelet NN o
aggregates NNS o
were VBD N
measured VBN N
by IN N
whole-blood NN N
flow NN N
cytometry NN N
over IN N
the DT N
same JJ N
time NN N
course NN N
. . N

The DT N
increases NNS N
in IN N
hsCRP NN o
and CC o
MCP-1 NNP o
, , N
both DT N
known JJ N
inducers NNS N
of IN N
TF NNP N
, , N
were VBD N
significantly RB N
suppressed VBN N
by IN N
statin NN N
treatment NN N
after IN N
LPS NNP N
challenge NN N
. . N

Statin NNP i
premedication NN N
blunted VBD N
the DT N
increase NN N
of IN N
monocyte JJ o
TF NNP o
expression NN o
in IN N
response NN N
to TO N
LPS NNP N
. . N

In IN N
parallel JJ N
, , N
endotoxin-induced JJ N
formation NN o
of IN o
F1.2 NNP o
was VBD N
significantly RB N
reduced VBN N
by IN N
simvastatin NN i
after IN N
4 CD N
and CC N
8 CD N
hours NNS N
. . N

LPS NNP N
infusion NN N
affected VBD N
neither CC N
the DT N
formation NN o
and CC o
activation NN o
of IN o
monocyte-platelet NN o
aggregates NNS o
nor CC N
plasma JJ o
levels NNS o
of IN o
sCD40 NN o
and CC o
sCD40L NN o
. . o

CONCLUSIONS NNP N
Simvastatin NNP i
suppresses VBZ N
the DT N
inflammatory JJ o
response NN o
to TO o
endotoxin VB o
and CC N
blunts NNS N
monocyte VBP o
TF NNP o
expression NN o
but CC N
does VBZ N
not RB N
affect VB N
platelet NN o
activation NN o
. . o

-DOCSTART- -25465111- O O

The DT N
durability NN N
of IN N
endovascular JJ i
coiling VBG i
versus NN i
neurosurgical JJ i
clipping NN i
of IN N
ruptured JJ p
cerebral JJ p
aneurysms NNS p
: : p
18 CD N
year NN N
follow-up NN N
of IN N
the DT N
UK NNP p
cohort NN p
of IN p
the DT p
International NNP p
Subarachnoid NNP p
Aneurysm NNP p
Trial NNP p
( ( p
ISAT NNP p
) ) p
. . p

BACKGROUND NNP N
Previous NNP N
analyses NNS N
of IN N
the DT N
International NNP p
Subarachnoid NNP p
Aneurysm NNP p
Trial NNP p
( ( p
ISAT NNP p
) ) p
cohort NN p
have VBP N
reported VBN N
on IN N
the DT N
risks NNS N
of IN N
recurrent NN N
subarachnoid JJ N
haemorrhage NN N
and CC N
death NN N
or CC N
dependency NN N
for IN N
a DT N
minimum NN N
of IN N
5 CD N
years NNS N
and CC N
up RB N
to TO N
a DT N
maximum NN N
of IN N
14 CD N
years NNS N
after IN N
treatment NN N
of IN N
a DT N
ruptured JJ N
intracranial JJ N
aneurysm NN N
with IN N
either DT N
neurosurgical JJ N
clipping NN N
or CC N
endovascular JJ N
coiling NN N
. . N

At IN N
1 CD N
year NN N
there RB N
was VBD N
a DT N
7 CD N
% NN N
absolute NN N
and CC N
a DT N
24 CD N
% NN N
relative JJ N
risk NN N
reduction NN N
of IN N
death NN o
and CC N
dependency NN o
in IN N
the DT N
coiling VBG N
group NN N
compared VBN N
with IN N
the DT N
clipping VBG N
group NN N
, , N
but CC N
the DT N
medium-term JJ N
results NNS N
showed VBD N
the DT N
increased VBN N
need NN N
for IN N
re-treatment NN o
of IN N
the DT N
target NN N
aneurysm NN N
in IN N
the DT N
patients NNS N
given VBN N
coiling VBG N
. . N

We PRP N
report VBP N
the DT N
long-term JJ N
follow-up NN N
of IN N
patients NNS N
in IN N
this DT N
UK NNP N
cohort NN N
. . N

METHODS NNP N
In IN N
ISAT NNP N
, , N
patients NNS p
were VBD p
randomly RB p
allocated VBN p
to TO p
either DT p
neurosurgical JJ i
clipping NN i
or CC p
endovascular JJ i
coiling NN i
after IN p
a DT p
subarachnoid JJ p
haemorrhage NN p
, , p
assuming VBG p
treatment NN p
equipoise NN p
, , p
between IN p
Sept NNP p
12 CD p
, , p
1994 CD p
, , p
and CC p
May NNP p
1 CD p
, , p
2002 CD p
. . p

We PRP N
followed VBD N
up RP N
1644 CD p
patients NNS p
in IN p
22 CD p
UK NNP p
neurosurgical JJ p
centres NNS p
for IN p
death NN p
and CC p
clinical JJ p
outcomes NNS p
for IN p
10?0-18?5 JJ p
years NNS p
. . p

We PRP N
assessed VBD o
dependency NN o
as IN o
self-reported JJ N
modified JJ o
Rankin NNP o
scale NN o
score NN o
obtained VBN o
through IN N
yearly RB N
questionnaires NNS N
. . N

Data NNP N
for IN o
recurrent NN o
aneurysms NNS o
and CC o
rebleeding VBG o
events NNS o
were VBD o
collected VBN N
from IN N
questionnaires NNS N
and CC N
from IN N
hospital NN N
and CC N
general JJ N
practitioner NN N
records NNS N
. . N

The DT N
Office NNP N
for IN N
National NNP N
Statistics NNPS N
supplied VBD N
data NNS N
on IN N
deaths NNS N
. . N

This DT N
study NN N
is VBZ N
registered VBN N
, , N
number NN N
ISRCTN49866681 NNP N
. . N

FINDINGS NNP N
At IN N
10 CD N
years NNS N
, , N
674 CD N
( ( N
83 CD N
% NN N
) ) N
of IN N
809 CD N
patients NNS N
allocated VBD N
endovascular JJ N
coiling NN N
and CC N
657 CD N
( ( N
79 CD N
% NN N
) ) N
of IN N
835 CD N
patients NNS N
allocated JJ N
neurosurgical JJ N
clipping NN N
were VBD N
alive JJ N
( ( N
odds NNS N
ratio VBP N
[ CD N
OR NNP N
] $ N
1?35 CD N
, , N
95 CD N
% NN N
CI NNP N
1?06-1?73 CD N
) ) N
. . N

Of IN N
1003 CD N
individuals NNS N
who WP N
returned VBD N
a DT N
questionnaire NN N
at IN N
10 CD N
years NNS N
, , N
435 CD N
( ( N
82 CD N
% NN N
) ) N
patients NNS N
treated VBN N
with IN N
endovascular JJ N
coiling NN N
and CC N
370 CD N
( ( N
78 CD N
% NN N
) ) N
patients NNS N
treated VBN N
with IN N
neurosurgical JJ i
clipping VBG i
were VBD i
independent JJ o
( ( o
modified JJ o
Rankin NNP N
scale NN N
score NN N
0-2 JJ N
; : N
OR CC N
1?25 CD N
; : N
95 CD N
% NN N
CI NNP N
0?92-1?71 NN N
) ) N
. . N

Patients NNS N
in IN N
the DT N
endovascular JJ N
treatment NN N
group NN N
were VBD N
more RBR N
likely JJ N
to TO o
be VB o
alive JJ o
and CC o
independent JJ o
at IN o
10 CD o
years NNS o
than IN o
were VBD N
patients NNS N
in IN N
the DT N
neurosurgery NN N
group NN N
( ( N
OR NNP N
1?34 CD N
, , N
95 CD N
% NN N
CI NNP N
1?07-1?67 CD N
) ) N
. . N

33 CD N
patients NNS N
had VBD o
a DT o
recurrent JJ o
subarachnoid JJ o
haemorrhage NN o
more JJR o
than IN o
1 CD N
year NN N
after IN N
their PRP$ N
initial JJ N
haemorrhage NN N
( ( N
17 CD N
from IN N
the DT N
target NN N
aneurysm NN N
) ) N
. . N

INTERPRETATION NNP N
Although IN N
rates NNS o
of IN o
increased JJ o
dependency NN o
alone RB N
did VBD N
not RB N
differ VB N
between IN N
groups NNS N
, , N
the DT N
probability NN o
of IN o
death NN o
or CC o
dependency NN o
was VBD N
significantly RB N
greater JJR N
in IN N
the DT N
neurosurgical JJ N
group NN N
than IN N
in IN N
the DT N
endovascular JJ o
group NN o
. . o

Rebleeding VBG o
was VBD N
more RBR N
likely JJ N
after IN N
endovascular JJ N
coiling NN N
than IN N
after IN N
neurosurgical JJ N
clipping NN N
, , N
but CC N
the DT N
risk NN N
was VBD N
small JJ N
and CC N
the DT N
probability NN N
of IN o
disability-free JJ o
survival NN o
was VBD o
significantly RB N
greater JJR N
in IN N
the DT N
endovascular NN N
group NN N
than IN N
in IN N
the DT N
neurosurgical JJ N
group NN N
at IN N
10 CD N
years NNS N
. . N

FUNDING NN N
UK NNP N
Medical NNP N
Research NNP N
Council NNP N
. . N

-DOCSTART- -12478408- O O

A DT N
randomized JJ N
prospective NN N
controlled VBN N
trial NN N
of IN N
oral JJ N
ganciclovir NN i
versus IN N
oral JJ N
valacyclovir NN i
for IN N
prophylaxis NN N
of IN N
cytomegalovirus NN o
disease NN o
after IN N
renal JJ p
transplantation NN p
. . p

Oral NNP N
ganciclovir NN i
and CC i
valacyclovir NN i
reduce VB N
the DT N
incidence NN N
of IN N
cytomegalovirus NN o
( ( o
CMV NNP o
) ) o
disease NN o
after IN p
renal JJ p
transplantation NN p
( ( p
RTx NNP p
) ) p
. . p

Our PRP$ N
study NN N
was VBD N
designed VBN N
to TO N
compare VB N
the DT N
efficacy NN o
, , o
costs NNS o
, , o
and CC o
safety NN o
of IN N
oral JJ N
ganciclovir NN i
and CC i
valacyclovir NN i
in IN N
the DT N
prophylaxis NN N
of IN N
CMV NNP N
disease NN N
over IN N
the DT N
first JJ N
6 CD N
months NNS N
after IN N
RTx NNP N
. . N

A NNP N
total NN p
of IN p
38 CD p
patients NNS p
was VBD p
randomized VBN p
to TO p
3-month JJ p
treatment NN p
with IN p
either DT p
oral JJ i
ganciclovir NN i
( ( p
1 CD p
g NN p
t.i.d. NN p
, , N
n=14 RB p
, , p
GAN NNP p
group NN p
) ) p
or CC p
oral JJ i
valacyclovir NN i
( ( p
2 CD p
g NN p
q.i.d. NN p
, , N
n=12 RB p
, , p
VAL NNP p
group NN p
) ) p
. . N

A DT N
third JJ N
group NN N
( ( N
C NNP N
, , N
n=12 NN N
) ) N
received VBD N
no DT i
prophylaxis NN i
. . i

The DT N
patients NNS N
were VBD N
monitored VBN N
by IN N
CMV-nested JJ N
PCR NNP N
in IN N
whole JJ N
blood NN N
. . N

No DT N
differences NNS N
were VBD N
found VBN N
between IN N
the DT N
groups NNS N
in IN N
their PRP$ N
demographic JJ N
characteristics NNS N
, , N
immunosuppressive JJ N
protocols NNS N
, , N
or CC N
donor NN N
and CC N
recipient NN N
CMV NNP N
serology NN N
. . N

Thirty-six CD N
out IN N
of IN N
38 CD N
( ( N
94.7 CD N
% NN N
) ) N
recipients NNS N
were VBD N
CMV-seropositive JJ o
. . o

Over IN N
the DT N
6-month JJ N
post-RTx JJ N
period NN N
, , N
there EX N
were VBD N
13 CD N
episodes NNS N
of IN N
CMV NNP o
disease NN N
in IN N
eight CD N
( ( N
66.7 CD N
% NN N
) ) N
patients NNS N
of IN N
the DT N
C NNP N
group NN N
compared VBN N
with IN N
none NN N
in IN N
the DT N
GAN NNP N
and CC N
VAL NNP N
groups NNS N
( ( N
P=0.0005 NNP N
, , N
GAN NNP N
vs NNP N
C NNP N
; : N
P=0.001 NNP N
, , N
VAL NNP N
vs NNP N
C NNP N
) ) N
. . N

The DT N
incidence NN o
of IN o
CMV NNP o
viremia NN o
was VBD N
30.8 CD N
% NN N
, , N
50.0 CD N
% NN N
, , N
and CC N
91.7 CD N
% NN N
in IN N
the DT N
GAN NNP N
, , N
VAL NNP N
, , N
and CC N
C NNP N
groups NNS N
, , N
respectively RB N
( ( N
P=0.004 NNP N
, , N
GAN NNP N
vs NNP N
C NNP N
; : N
P=0.07 NNP N
, , N
VAL NNP N
vs NNP N
C NNP N
; : N
P=NS NNP N
, , N
GAN NNP N
vs NNP N
VAL NNP N
) ) N
. . N

Treatment JJ o
failure NN o
( ( o
death NN o
, , o
graft NN o
loss NN o
, , o
CMV NNP o
disease NN o
, , o
or CC o
withdrawal NN o
from IN o
study NN o
) ) o
occurred VBD N
in IN N
14.3 CD N
% NN N
, , N
0 CD N
% NN N
and CC N
66.7 CD N
% NN N
in IN N
the DT N
GAN NNP N
, , N
VAL NNP N
, , N
and CC N
C NNP N
groups NNS N
, , N
respectively RB N
( ( N
P=0.014 NNP N
, , N
GAN NNP N
vs NNP N
C NNP N
; : N
P=0.001 NNP N
, , N
VAL NNP N
vs NNP N
C NNP N
; : N
P=NS NNP N
, , N
GAN NNP N
vs NNP N
VAL NNP N
) ) N
. . N

The DT N
average JJ o
CMV-associated JJ o
costs NNS o
per IN o
patient NN o
( ( N
in IN N
2001 CD N
euros NN N
) ) N
were VBD N
2,449+/-1,178 JJ N
, , N
2,485+/-581 JJ N
, , N
and CC N
4,259+/-4,616 JJ N
in IN N
the DT N
GAN NNP N
, , N
VAL NNP N
, , N
and CC N
C NNP N
groups NNS N
, , N
respectively RB N
. . N

Ganciclovir NNP N
and CC N
valacyclovir NN N
were VBD N
well RB o
tolerated VBN o
, , N
with IN N
ganciclovir JJ N
having VBG N
had VBD N
to TO N
be VB N
withdrawn VBN N
shortly RB N
in IN N
one CD N
patient NN N
only RB N
because IN N
of IN N
thrombocytopenia NN N
. . N

In IN N
conclusion NN N
, , N
oral JJ N
ganciclovir NN N
and CC N
valacyclovir NN N
are VBP N
equally RB o
safe JJ o
and CC o
effective JJ o
in IN N
the DT N
prophylaxis NN N
of IN N
CMV NNP N
disease NN N
after IN N
RTx NNP N
. . N

Both DT N
are VBP N
cost-effective JJ o
and CC N
help VB N
reduce VB N
CMV-associated JJ o
costs NNS o
by IN N
some DT N
40 CD N
% NN N
compared VBN N
with IN N
patients NNS N
without IN N
prophylaxis NN N
. . N

-DOCSTART- -7635420- O O

Synthesis NN N
of IN N
interleukin-1 JJ N
beta NN N
in IN N
primary JJ p
biliary JJ p
cirrhosis NN p
: : p
relationship NN N
to TO N
treatment NN N
with IN N
methotrexate NN i
or CC i
colchicine NN i
and CC N
disease NN N
progression NN N
. . N

Primary JJ p
biliary JJ p
cirrhosis NN p
( ( p
PBC NNP p
) ) p
is VBZ p
a DT p
chronic JJ p
, , p
progressive JJ p
, , p
cholestatic JJ p
liver NN p
disease NN p
. . p

Interleukin-1 JJ o
beta NN o
( ( o
IL-1 NNP o
beta NN o
) ) o
may MD N
play VB N
a DT N
role NN N
in IN N
the DT N
pathogenesis NN N
of IN N
PBC NNP N
by IN N
contributing VBG N
to TO N
altered VBN N
immune JJ N
function NN N
and CC N
fibrosis NN N
. . N

Colchicine NNP i
or CC i
methotrexate NN i
has VBZ N
some DT N
beneficial JJ N
effects NNS N
in IN N
the DT N
treatment NN N
of IN N
PBC NNP N
, , N
and CC N
also RB N
affects VBZ N
interleukin-1 JJ o
( ( o
IL-1 NNP o
) ) o
. . o

Therefore RB N
, , N
we PRP N
prospectively RB N
studied VBD N
the DT N
synthesis NN N
of IN N
IL-1 NNP o
beta NN o
by IN N
peripheral JJ N
blood NN N
mononuclear NN N
cells NNS N
( ( N
PBMC NNP N
) ) N
from IN p
42 CD p
patients NNS p
with IN p
PBC NNP p
entered VBD N
into IN N
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
double-dummy JJ N
controlled VBD N
trial NN N
of IN N
colchicine NN i
and CC i
methotrexate NN i
. . i

PBMC NNP N
obtained VBD N
at IN N
entry NN N
, , N
6 CD N
, , N
12 CD N
, , N
18 CD N
, , N
and CC N
24 CD N
months NNS N
were VBD N
stimulated VBN N
to TO N
produce VB N
IL-1 NNP N
beta NN N
with IN N
phytohemagglutinin NN N
( ( N
PHA NNP N
) ) N
, , N
lipopolysaccharide RB N
( ( N
LPS NNP N
) ) N
, , N
Staphylococcus NNP N
epidermidis NN N
, , N
recombinant JJ N
IL-2 NNP N
, , N
or CC N
mitochondrial JJ N
antigen NN N
. . N

Patients NNS N
in IN N
the DT N
two CD N
treatment NN N
groups NNS N
did VBD N
not RB N
differ VB N
at IN N
entry NN N
in IN N
biochemical JJ o
measures NNS o
or CC o
liver VB o
histological JJ o
stage NN o
. . o

Over IN N
24 CD N
months NNS N
in IN N
both DT N
groups NNS N
, , N
serum JJ o
bilirubin NN o
and CC o
histologic JJ o
stage NN o
remained VBD N
stable JJ N
and CC N
alkaline JJ o
phosphatase NN o
decreased VBN N
significantly RB N
. . N

For IN N
all DT N
patients NNS N
, , N
synthesis NN o
of IN o
IL-1 NNP o
beta NN o
increased VBD N
constitutively RB N
and CC N
in IN N
response NN N
to TO N
immune-mediated JJ N
stimulants NNS N
( ( N
PHA NNP N
, , N
IL-2 NNP N
, , N
and CC N
mitochondrial JJ N
antigen NN N
) ) N
but CC N
not RB N
the DT N
bacterial JJ N
stimulants NNS N
LPS NNP N
or CC N
S NNP N
epidermidis NN N
. . N

Compared VBN N
with IN N
levels NNS N
of IN N
IL-1 NNP N
beta NN N
at IN N
entry NN N
, , N
PHA NNP N
induced VBD N
increases NNS N
for IN N
patients NNS N
treated VBN N
with IN N
methotrexate NN N
( ( N
12 CD N
, , N
18 CD N
, , N
and CC N
24 CD N
months NNS N
) ) N
or CC N
colchicine NN N
( ( N
18 CD N
and CC N
24 CD N
months NNS N
) ) N
. . N

At IN N
24 CD N
months NNS N
, , N
IL-2-induced NNP o
IL-1 NNP o
beta NN o
synthesis NN o
was VBD N
increased VBN N
in IN N
patients NNS N
treated VBN N
with IN N
methotrexate NN i
, , N
whereas JJ N
S NNP o
epidermidis-induced JJ o
IL-1 NNP o
beta NN o
was VBD N
enhanced VBN N
in IN N
colchicine-treated JJ i
patients NNS N
. . N

Before IN N
treatment NN N
, , N
IL-1 NNP N
beta NN N
production NN N
did VBD N
not RB N
relate VB N
to TO N
severity NN N
of IN N
disease NN N
except IN N
in IN N
response NN N
to TO N
S NNP N
epidermidis NN N
. . N

( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
250 CD N
WORDS NNP N
) ) N
-DOCSTART- -26653722- O O

NSAID NNP i
Pretreatment NNP N
Inhibits NNP N
Prostaglandin NNP o
Release NNP o
in IN N
Femtosecond NNP i
Laser-Assisted NNP i
Cataract NNP i
Surgery NNP i
. . i

PURPOSE NNP N
To TO N
investigate VB N
whether IN N
short-term JJ N
nonsteroidal JJ i
anti-inflammatory JJ i
drug NN i
( ( i
NSAID NNP i
) ) i
pretreatment NN N
on IN N
the DT N
day NN N
of IN N
surgery NN N
inhibits NNS N
prostaglandin VBP o
release NN o
. . o

Previous JJ N
studies NNS N
detected VBN N
elevated JJ N
prostaglandin NN o
levels NNS o
after IN N
femtosecond NN i
laser NN i
treatment NN i
and CC N
identified VBD N
them PRP N
as IN N
a DT N
potential JJ N
mediator NN N
for IN N
laser-induced JJ N
miosis NN N
. . N

METHODS NNP N
Patients NNPS p
underwent JJ p
either CC p
image-guided JJ i
femtosecond NN i
laser NN i
cataract NN i
surgery NN i
or CC i
conventional JJ i
cataract NN i
surgery NN i
( ( p
n JJ p
= NNP p
75 CD p
) ) p
. . p

Half NN N
of IN N
the DT N
eyes NNS N
per IN N
group NN N
received VBD N
topical JJ i
NSAID NNP i
treatment NN i
on IN N
the DT N
day NN N
of IN N
surgery NN N
. . N

Aqueous JJ N
humor NN N
was VBD N
collected VBN N
from IN N
all DT p
patients NNS p
. . p

ELISA JJ N
measurements NNS N
were VBD N
performed VBN N
to TO N
detect VB N
aqueous JJ o
humor NN o
prostaglandin NN o
levels NNS o
. . o

RESULTS NNP N
Femtosecond NNP i
laser NNP i
cataract NN i
surgery NN i
led VBD N
to TO N
higher JJR N
prostaglandin NN o
levels NNS o
than IN N
conventional JJ i
cataract NN i
surgery NN i
( ( N
P NNP N
= NNP N
.007 NNP N
) ) N
. . N

In IN N
both DT N
groups NNS N
, , N
NSAID NNP i
pretreatment NN i
led VBD N
to TO N
reduced VBN N
prostaglandin NN o
release NN o
. . o

In IN N
the DT N
femtosecond NN p
laser NN p
group NN p
, , p
patients NNS p
pretreated VBD i
with IN i
NSAIDs NNP i
had VBD N
significantly RB N
lower JJR N
prostaglandin NN o
values NNS o
( ( N
65.3 CD N
? . N
13.2 CD N
pg/mL NN N
) ) N
than IN p
patients NNS i
not RB i
pretreated VBN i
with IN i
NSAIDs NNP i
( ( N
294.4 CD N
? . N
66.5 CD N
pg/mL NN N
) ) N
( ( N
P NNP N
= NNP N
.0009 NNP N
) ) N
. . N

CONCLUSIONS VB N
The DT N
short-term JJ i
NSAID NNP i
treatment NN i
prevented VBD o
prostaglandin JJ o
release NN o
in IN o
patients NNS p
treated VBN p
with IN i
image-guided JJ i
femtosecond NN i
laser NN i
. . i

Therefore RB N
, , N
it PRP N
has VBZ N
potential JJ N
to TO N
limit VB N
intraoperative JJ N
laser-induced JJ N
miosis NN N
. . N

-DOCSTART- -12437457- O O

A DT N
randomized JJ N
, , N
double-blind JJ N
, , N
vehicle-controlled JJ N
study NN N
to TO N
assess VB N
5 CD N
% NN N
imiquimod JJ i
cream NN i
for IN N
the DT N
treatment NN N
of IN p
multiple JJ o
actinic JJ o
keratoses NNS o
. . o

BACKGROUND NNP N
Actinic NNP o
keratoses NNS o
( ( o
AKs NNP o
) ) o
are VBP N
precancerous JJ N
epidermal JJ N
lesions NNS N
found VBD N
most JJS N
frequently RB N
on IN N
areas NNS N
of IN N
the DT N
skin NN N
exposed VBD N
to TO N
the DT N
sun NN N
. . N

Several JJ N
case NN N
studies NNS N
published VBN N
recently RB N
have VBP N
indicated VBN N
that IN N
5 CD N
% NN N
imiquimod JJ i
cream NN N
, , N
currently RB N
licensed VBN N
for IN N
the DT N
treatment NN N
of IN N
genital JJ N
warts NNS N
, , N
may MD N
be VB N
an DT N
effective JJ N
treatment NN N
for IN N
AK NNP N
. . N

OBJECTIVE NNP N
To TO N
assess VB N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
imiquimod NN N
for IN N
the DT N
treatment NN N
of IN N
AK NNP o
. . o

DESIGN NNP N
Patients NNPS N
in IN N
this DT N
randomized JJ N
, , N
double-blind JJ N
, , N
vehicle-controlled JJ N
study NN N
applied VBD N
5 CD i
% NN i
imiquimod JJ i
cream NN i
or CC i
vehicle NN i
to TO i
AK NNP o
lesions NNS o
3 CD i
times NNS i
per IN i
week NN i
for IN i
a DT i
maximum NN i
of IN i
12 CD i
weeks NNS i
or CC i
until IN i
lesions NNS i
had VBD i
resolved VBN i
. . i

In IN N
the DT N
event NN N
of IN N
an DT N
adverse JJ N
reaction NN N
, , N
application NN N
of IN N
imiquimod NN i
was VBD N
reduced VBN N
to TO N
1 CD N
or CC N
2 CD N
times NNS N
per IN N
week NN N
. . N

Rest JJS N
periods NNS N
were VBD N
also RB N
allowed VBN N
if IN N
necessary JJ N
. . N

SETTING VB N
A DT p
specialized JJ p
outpatient NN p
dermatology NN p
clinic NN p
within IN p
a DT p
state-funded JJ p
hospital NN p
in IN p
Germany NNP p
. . p

PATIENTS VB p
The DT p
study NN p
population NN p
was VBD p
aged VBN p
45 CD p
to TO p
85 CD p
years NNS p
. . p

Of IN p
52 CD p
patients NNS p
screened VBD p
, , p
36 CD p
men NNS p
and CC p
women NNS p
with IN p
AK NNP p
confirmed VBN p
by IN p
histological JJ p
diagnosis NN p
were VBD p
enrolled VBN p
. . p

Patients NNS p
were VBD p
excluded VBN p
from IN p
the DT p
study NN p
if IN p
they PRP p
did VBD p
not RB p
have VB p
a DT p
histological JJ p
diagnosis NN p
for IN p
AK NNP p
, , p
if IN p
they PRP p
were VBD p
older JJR p
than IN p
85 CD p
years NNS p
, , p
or CC p
if IN p
they PRP p
did VBD p
not RB p
comply VB p
with IN p
the DT p
protocol NN p
. . p

All DT p
patients NNS p
had VBD p
responded VBN p
to TO p
a DT p
notice NN p
asking VBG p
for IN p
volunteers NNS p
. . p

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
The DT N
number NN o
and CC o
appearance NN o
of IN o
lesions NNS o
were VBD N
evaluated VBN N
before RB N
, , N
during IN N
, , N
and CC N
after IN N
treatment NN N
. . N

All DT N
adverse JJ o
effects NNS o
were VBD N
recorded VBN N
. . N

RESULTS NNP N
Lesions NNP N
treated VBD N
with IN N
5 CD N
% NN N
imiquimod JJ i
cream NN i
were VBD N
clinically RB o
cleared VBN o
in IN N
21 CD N
( ( N
84 CD N
% NN N
) ) N
of IN N
25 CD N
patients NNS N
and CC N
partially RB o
cleared VBN o
in IN N
2 CD N
( ( N
8 CD N
% NN N
) ) N
. . N

Clearance NN o
was VBD N
histologically RB N
confirmed VBN N
2 CD N
weeks NNS N
after IN N
the DT N
last JJ N
application NN N
of IN N
imiquimod NN i
in IN N
all DT N
patients NNS N
clinically RB N
diagnosed VBN N
as IN N
lesion NN N
free NN N
. . N

Only RB N
10 CD N
% NN N
of IN N
patients NNS N
treated VBN N
with IN N
imiquimod NN i
were VBD N
clinically RB N
diagnosed VBN N
with IN N
recurrence NN N
1 CD N
year NN N
after IN N
treatment NN N
. . N

No DT N
reduction NN o
in IN o
the DT o
size NN o
or CC o
number NN o
of IN o
AK NNP o
lesions NNS o
was VBD N
observed VBN N
in IN N
vehicle-treated JJ N
patients NNS N
. . N

Adverse JJ N
effects NNS N
reported VBN N
by IN p
patients NNS p
treated VBN p
with IN p
imiquimod NN i
included VBD N
erythema NN o
, , o
edema NN o
, , o
induration NN o
, , o
vesicles NNS o
, , o
erosion NN o
, , o
ulceration NN o
, , o
excoriation NN o
, , o
and CC o
scabbing VBG o
. . o

However RB N
, , N
imiquimod NN i
was VBD N
well RB N
tolerated VBN o
since IN N
all DT N
patients NNS N
completed VBD N
the DT N
12-week JJ N
treatment NN N
. . N

Only RB N
a DT N
few JJ N
, , N
mild JJ N
adverse JJ N
reactions NNS N
to TO N
the DT N
vehicle NN N
cream NN N
were VBD N
reported VBN N
. . N

CONCLUSION NNP N
Application NNP N
of IN N
5 CD N
% NN N
imiquimod JJ i
cream NN i
for IN N
12 CD N
weeks NNS N
is VBZ N
an DT N
effective JJ N
and CC N
well-tolerated JJ N
treatment NN N
for IN N
AK NNP o
. . o

-DOCSTART- -17597498- O O

Improvement NN N
in IN N
sensory JJ N
impairment NN N
and CC N
social JJ N
interaction NN N
in IN N
young JJ p
children NNS p
with IN p
autism NN p
following VBG N
treatment NN N
with IN N
an DT N
original JJ i
Qigong NNP i
massage NN i
methodology NN i
. . i

In IN N
clinical JJ N
research NN N
, , N
sensory JJ N
impairment NN N
is VBZ N
considered VBN N
one CD N
of IN N
the DT N
core NN N
deficits NNS N
in IN N
autism NN N
and CC N
is VBZ N
associated VBN N
with IN N
impaired JJ N
socialization NN N
, , N
behavioral JJ N
disturbances NNS N
and CC N
bowel NN N
and CC N
sleep JJ N
problems NNS N
. . N

The DT N
effectiveness NN N
of IN N
the DT N
Cignolini NNP i
methodology NN i
, , i
an DT i
original JJ i
Qigong NNP i
massage NN i
methodology NN i
, , N
in IN N
treating VBG N
sensory JJ p
impairment NN p
in IN p
young JJ p
children NNS p
with IN N
autism NN N
was VBD N
evaluated VBN N
in IN N
a DT N
small JJ N
, , N
controlled VBN N
study NN N
. . N

Thirteen NNP p
children NNS p
with IN p
autism NN p
between IN p
the DT p
ages NNS p
of IN p
three CD p
and CC p
six CD p
received VBD N
daily JJ N
treatment NN N
according VBG N
to TO N
the DT N
methodology NN N
for IN N
5 CD N
months NNS N
. . N

Compared VBN N
with IN N
untreated JJ N
children NNS N
, , N
treated VBD N
children NNS N
experienced VBD N
significant JJ N
improvement NN N
of IN N
their PRP$ N
sensory JJ o
impairment NN o
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
, , N
and CC N
demonstrated VBD N
increased VBN N
social JJ o
skills NNS o
( ( N
p JJ N
< NNP N
0.04 CD N
) ) N
and CC N
basic JJ o
living NN o
skills NNS o
( ( N
p JJ N
< NNP N
0.02 CD N
) ) N
on IN N
standardized JJ N
measures NNS N
. . N

In IN N
addition NN N
, , N
all DT N
of IN N
the DT N
children NNS p
with IN p
bowel NN p
and CC p
sleep JJ p
abnormalities NNS p
demonstrated VBD N
improvement NN N
after IN N
treatment NN N
. . N

-DOCSTART- -18948032- O O

Two CD N
large JJ N
preoperative JJ N
doses NNS N
of IN N
erythropoietin NN i
do VBP N
not RB N
reduce VB N
the DT N
systemic JJ p
inflammatory NN p
response NN p
to TO p
cardiac VB p
surgery NN p
. . p

OBJECTIVES NNP N
Cardiac NNP N
surgery NN N
and CC N
cardiopulmonary JJ N
bypass NN N
( ( N
CPB NNP N
) ) N
induce VBP N
an DT N
inflammatory JJ N
reaction NN N
that WDT N
may MD N
lead VB N
to TO N
tissue VB N
injury NN N
. . N

Experimental JJ N
studies NNS N
suggest VBP N
that IN N
recombinant JJ i
human JJ i
erythropoietin NN i
( ( i
EPO NNP i
) ) i
independent JJ N
of IN N
its PRP$ N
erythropoietic JJ N
effect NN N
may MD N
be VB N
used VBN N
clinically RB N
as IN N
an DT N
anti-inflammatory JJ N
drug NN N
. . N

This DT N
study NN N
tested VBD N
the DT N
hypothesis NN N
that IN N
2 CD N
large JJ N
doses NNS N
of IN N
EPO NNP i
administered VBD N
shortly RB N
before IN N
CPB NNP N
ameliorate VBP N
the DT N
systemic JJ N
inflammatory NN N
response NN N
to TO N
CPB NNP N
. . N

DESIGN NNP N
AND NNP N
SETTING NNP N
A NNP N
prospective JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
and CC N
randomized JJ N
study NN N
at IN N
a DT N
single JJ N
tertiary NN N
care NN N
hospital NN N
. . N

PARTICIPANTS CC N
Patients NNS p
scheduled VBN p
for IN p
coronary JJ p
artery NN p
bypass NN p
graft NN p
surgery NN p
with IN p
CPB NNP p
. . p

INTERVENTIONS NNP N
EPO NNP i
( ( i
epoetin JJ i
alfa NN i
, , N
500 CD N
IU/kg NNP N
intravenously RB N
, , N
n JJ p
= NNP p
22 CD p
) ) p
or CC p
placebo NN i
( ( p
n JJ p
= NNP p
21 CD p
) ) p
was VBD N
administered VBN N
12 CD N
to TO N
18 CD N
hours NNS N
preoperatively RB N
and CC N
again RB N
at IN N
the DT N
induction NN N
of IN N
anesthesia NN N
. . N

MEASUREMENTS NNP N
AND CC N
MAIN NNP N
RESULTS NNP N
CPB NNP N
in IN N
both DT N
groups NNS N
greatly RB N
increased VBD N
plasma JJ o
concentrations NNS o
of IN o
tumor NN o
necrosis NN o
factor NN o
alpha NN o
( ( o
TNF-alpha NNP o
) ) o
, , o
interleukin FW o
( ( o
IL NNP o
) ) o
-1beta NN o
, , o
IL-1beta NNP o
receptor NN o
antagonist NN o
, , o
IL-6 NNP o
, , o
IL-10 NNP o
, , o
and CC o
N-terminal JJ o
probrain NN o
natriuretic JJ o
peptide NN o
( ( o
NT-proBNP NNP o
) ) o
. . o

Compared VBN N
with IN N
placebo NN i
, , i
EPO NNP i
at IN N
day NN N
3 CD N
after IN N
CPB NNP N
augmented VBD N
the DT N
TNF-alpha JJ o
response NN o
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
and CC N
at IN N
2 CD N
hours NNS N
after IN N
CPB NNP N
increased VBD N
NT-proBNP NNP o
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

Also RB N
, , N
EPO NNP i
tended VBD N
to TO N
enhance VB N
the DT N
CPB-induced JJ N
increase NN N
in IN N
IL-1beta NNP o
receptor NN o
antagonist NN o
( ( N
p JJ N
= NNP N
0.057 CD N
) ) N
. . N

Otherwise UH N
, , N
EPO NNP i
had VBD N
no DT N
effect NN N
on IN N
pro- NN o
and CC o
antiinflammatory NN o
mediators NNS o
compared VBN N
with IN N
placebo NN N
. . N

CONCLUSIONS NNP N
Two CD N
large JJ N
doses NNS N
of IN N
EPO NNP i
given VBN N
shortly RB N
before IN N
CPB NNP N
do VBP N
not RB N
reduce VB N
perioperative JJ o
release NN o
of IN o
inflammatory JJ o
cytokines NNS o
. . o

In IN N
contrast NN N
, , N
EPO NNP i
may MD N
augment VB N
the DT N
TNF-alpha NNP N
and CC N
NT-proBNP NNP N
response NN N
. . N

Although IN N
the DT N
long-term JJ N
clinical JJ N
impact NN N
remains VBZ N
unknown JJ N
, , N
the DT N
findings NNS N
do VBP N
not RB N
support VB N
use NN N
of IN N
EPO NNP i
as IN N
an DT N
anti-inflammatory JJ N
drug NN N
in IN N
patients NNS p
undergoing JJ p
cardiac JJ p
surgery NN p
. . p

-DOCSTART- -22325844- O O

Effect NN N
of IN N
HIV NNP N
infection NN N
on IN N
tolerability NN o
and CC o
bacteriologic JJ o
outcomes NNS o
of IN N
tuberculosis NN N
treatment NN N
. . N

SETTING NN N
Two CD N
international JJ N
, , N
multicenter JJ N
Phase NNP N
2 CD N
clinical JJ N
trials NNS N
examining VBG N
fluoroquinolone-containing JJ i
regimens NNS i
in IN N
adults NNS p
with IN p
smear-positive JJ p
pulmonary JJ p
tuberculosis NN p
( ( p
TB NNP p
) ) p
, , N
conducted VBN N
from IN N
July NNP N
2003 CD N
to TO N
March NNP N
2007 CD N
. . N

Both DT N
trials NNS N
enrolled VBD N
human JJ p
immunodeficiency NN p
virus NN p
( ( p
HIV NNP p
) ) p
infected VBD p
participants NNS p
who WP p
were VBD p
not RB p
receiving VBG p
antiretroviral JJ p
therapy NN p
( ( p
ART NNP p
) ) p
at IN p
TB NNP p
treatment NN p
initiation NN p
. . p

OBJECTIVE UH N
To TO N
assess VB N
the DT N
impact NN N
of IN N
HIV NNP N
infection NN N
on IN N
TB NNP N
treatment NN N
outcomes NNS N
in IN N
Phase NNP N
2 CD N
clinical JJ N
trials NNS N
. . N

DESIGN NNP N
Cross-protocol JJ i
analysis NN i
comparing VBG i
the DT i
safety NN o
, , o
tolerability NN o
and CC o
outcomes NNS o
of IN i
anti-tuberculosis NN i
treatment NN i
by IN i
HIV NNP i
status NN i
. . i

RESULTS NNP N
Of IN p
750 CD p
participants NNS p
who WP p
received VBD p
at IN p
least JJS p
one CD p
dose NN p
of IN p
study NN p
treatment NN p
, , p
123 CD p
( ( p
16 CD p
% NN p
) ) p
were VBD p
HIV-infected JJ p
. . p

Treatment JJ o
completion NN o
rates NNS o
were VBD N
similar JJ N
by IN N
HIV NNP N
status NN N
( ( N
81 CD N
% NN N
infected VBN N
vs. IN N
85 CD N
% NN N
non-infected JJ N
) ) N
, , N
as IN N
were VBD N
rates NNS N
of IN N
week NN N
8 CD N
culture NN N
conversion NN N
( ( N
66 CD N
% NN N
infected VBN N
vs. IN N
63 CD N
% NN N
non-infected JJ N
) ) N
, , N
and CC N
treatment NN N
failure NN N
( ( N
5 CD N
% NN N
infected VBN N
vs. IN N
3 CD N
% NN N
non-infected JJ N
) ) N
. . N

Among IN N
HIV-infected JJ p
participants NNS p
, , N
treatment NN o
failure NN o
detected VBD N
using VBG N
liquid JJ N
media NNS N
was VBD N
more RBR N
frequent JJ N
in IN N
those DT N
treated JJ N
thrice JJ N
weekly JJ N
( ( N
14 CD N
% NN N
thrice JJ N
weekly JJ N
vs. FW N
2 CD N
% NN N
daily RB N
, , N
P NNP N
= NNP N
0.03 CD N
) ) N
. . N

HIV-infected JJ p
participants NNS p
more RBR N
frequently RB N
experienced VBD N
an DT N
adverse JJ o
event NN o
during IN N
the DT N
intensive JJ N
phase NN N
treatment NN N
than IN N
non-HIV-infected JJ N
participants NNS N
( ( N
30 CD N
% NN N
vs. FW N
15 CD N
% NN N
, , N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

CONCLUSION NNP N
HIV-infected JJ p
persons NNS p
not RB N
receiving VBG N
ART NNP N
had VBD N
more RBR N
adverse JJ N
events NNS N
during IN N
the DT N
intensive JJ N
phase NN N
of IN N
anti-tuberculosis NN N
treatment NN N
, , N
but CC N
tolerated VBD o
treatment NN o
well RB o
. . o

Failure NN N
rates NNS N
were VBD N
higher JJR N
among IN N
HIV-infected JJ p
persons NNS p
treated VBN N
with IN N
thrice-weekly JJ N
intensive JJ N
phase NN N
therapy NN N
. . N

-DOCSTART- -20035541- O O

Randomized NNP N
clinical JJ N
trial NN N
of IN N
radiofrequency NN i
ablation NN i
or CC N
conventional JJ i
high JJ i
ligation NN i
and CC N
stripping VBG N
for IN N
great JJ p
saphenous JJ p
varicose NN p
veins NNS p
. . p

BACKGROUND NNP N
This DT N
randomized VBD N
clinical JJ N
trial NN N
compared VBN N
early JJ N
outcomes NNS N
after IN N
radiofrequency NN i
ablation NN i
( ( i
RFA NNP i
) ) i
and CC N
conventional JJ N
surgery NN N
for IN N
varicose JJ N
veins NNS N
. . N

METHODS NNP N
Consecutive JJ p
patients NNS p
with IN p
symptomatic JJ p
varicose NN p
veins NNS p
due JJ p
to TO p
isolated JJ p
great JJ p
saphenous JJ p
vein NN p
( ( p
GSV NNP p
) ) p
incompetence NN p
and CC p
suitable JJ p
for IN p
RFA NNP p
were VBD N
randomized VBN N
to TO N
either DT N
RFA NNP i
or CC N
conventional JJ N
surgery NN N
( ( N
saphenofemoral JJ N
disconnection NN N
and CC N
stripping NN N
) ) N
. . N

Clinical JJ o
, , o
radiological JJ o
and CC o
patient-based JJ o
outcomes NNS o
were VBD N
recorded VBN N
at IN N
1 CD N
and CC N
5 CD N
weeks NNS N
after IN N
intervention NN N
. . N

RESULTS NNP N
RFA NNP i
resulted VBD N
in IN N
successful JJ N
obliteration NN N
of IN N
the DT N
GSV NNP p
in IN p
all DT p
47 CD p
patients NNS p
. . p

Complete JJ o
above-knee JJ o
stripping NN o
was VBD N
unsuccessful JJ N
in IN N
seven CD N
of IN N
41 CD N
patients NNS N
. . N

RFA NNP N
took VBD N
longer JJR N
than IN N
conventional JJ N
surgery NN N
: : N
median JJ N
interquartile NN N
range NN N
76 CD N
( ( N
67-84 JJ N
) ) N
versus NN N
48 CD N
( ( N
39-54 CD N
) ) N
min NN N
; : N
P NNP N
< VBD N
0.001 CD N
. . N

Patients NNS N
returned VBD o
to TO o
their PRP$ o
normal JJ o
activities NNS o
significantly RB N
earlier RBR N
after IN N
RFA NNP i
( ( N
median JJ N
3 CD N
( ( N
2-5 CD N
) ) N
versus NN N
12.5 CD N
( ( N
4-21 JJ N
) ) N
days NNS N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

Postoperative JJ o
pain NN o
was VBD N
significantly RB N
less JJR N
after IN N
RFA NNP i
( ( N
median JJ N
score NN N
on IN N
visual JJ N
analogue NN N
scale NN N
1.70 CD N
( ( N
0.50-4.30 NN N
) ) N
versus NN N
4.0 CD N
( ( N
2.35-6.05 JJ N
) ) N
; : N
P NNP N
= NNP N
0.001 CD N
) ) N
. . N

Patient JJ o
satisfaction NN o
, , o
quality NN o
of IN o
life NN o
improvement NN o
and CC o
analgesic JJ o
requirements NNS o
significantly RB N
favoured VBD N
RFA NNP i
. . i

CONCLUSION NNP N
RFA NNP N
took VBD N
longer JJR N
to TO N
perform VB N
but CC N
resulted VBD N
in IN N
a DT N
significantly RB o
better RBR o
early RB o
outcome NN o
than IN N
conventional JJ N
surgery NN N
in IN N
suitable JJ N
patients NNS p
with IN p
great JJ p
saphenous JJ p
varicose NN p
veins NNS p
. . p

-DOCSTART- -11812696- O O

Small-dose JJ N
selective JJ N
spinal NN i
anesthesia NN i
for IN N
short-duration JJ N
outpatient JJ N
laparoscopy NN N
: : N
recovery NN N
characteristics NNS N
compared VBN N
with IN N
desflurane NN i
anesthesia NN i
. . i

UNLABELLED IN N
We PRP N
conducted VBD N
a DT N
randomized VBN N
controlled VBN N
trial NN N
to TO N
compare VB N
the DT N
recovery NN N
characteristics NNS N
of IN N
selective JJ i
spinal JJ i
anesthesia NN i
( ( i
SSA NNP i
) ) i
and CC N
desflurane JJ i
anesthesia NN i
( ( i
DES NNP i
) ) i
in IN N
outpatient JJ p
gynecological JJ i
laparoscopy NN i
. . i

Twenty NNP p
ASA NNP p
physical JJ p
status NN p
I PRP p
patients NNS p
undergoing VBG p
gynecological JJ p
laparoscopy NN p
were VBD N
randomized VBN N
to TO N
receive VB N
either DT N
SSA NNP i
with IN N
lidocaine JJ i
10 CD i
mg NN i
+ NNP i
sufentanil VBD i
10 CD i
microg NN i
or CC i
general JJ i
anesthesia NN i
with IN i
DES NNP i
and CC i
N NNP i
( ( i
2 CD i
) ) i
O. NNP i
Intraoperative NNP o
conditions NNS o
, , o
recovery NN o
times NNS o
, , o
postanesthesia JJ o
recovery NN o
scores NNS o
, , o
and CC o
postoperative JJ o
outcomes NNS o
were VBD N
recorded VBN N
. . N

Intraoperative JJ o
conditions NNS o
were VBD N
comparable JJ N
in IN N
both DT N
groups NNS N
. . N

All DT N
patients NNS p
in IN N
the DT N
SSA NNP i
group NN p
were VBD N
awake RB N
and CC N
oriented VBN N
at IN N
the DT N
end NN N
of IN N
surgery NN N
, , N
whereas JJ N
patients NNS N
in IN N
the DT N
DES NNP i
group NN N
required VBD N
7 CD N
+/- JJ N
2 CD N
min NN N
for IN N
extubation NN o
and CC o
orientation NN o
. . o

SSA NNP i
patients NNS N
had VBD N
a DT N
significantly RB N
shorter JJR o
time NN o
to TO o
straight VB o
leg NN o
raising VBG o
( ( N
3 CD N
+/- JJ N
1 CD N
min NN N
versus NN N
9 CD N
+/- JJ N
4 CD N
min NN N
; : N
P NNP N
< NNP N
0.0001 CD N
) ) N
and CC N
to TO N
ambulation NN o
( ( N
3 CD N
+/- JJ N
0.9 CD N
min NN N
versus NN N
59 CD N
+/- JJ N
16 CD N
min NN N
; : N
P NNP N
< NNP N
0.0001 CD N
) ) N
compared VBN N
with IN N
the DT N
DES NNP i
group NN N
. . N

SSA NNP i
patients NNS N
had VBD N
significantly RB N
less RBR N
postoperative JJ o
pain NN o
than IN N
DES NNP i
patients NNS N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

We PRP N
concluded VBD N
that IN N
SSA NNP N
was VBD N
an DT N
effective JJ o
alternative NN o
to TO N
DES NNP i
for IN N
outpatient JJ N
gynecological JJ N
laparoscopy NN N
. . N

IMPLICATIONS NNP N
This DT N
study NN N
compared VBN N
the DT N
use NN N
of IN N
a DT N
desflurane NN i
general JJ N
anesthetic JJ N
to TO N
a DT N
small-dose JJ N
spinal JJ N
anesthetic NN N
in IN N
ambulatory JJ N
gynecological JJ N
laparoscopy NN N
. . N

Using VBG N
the DT N
spinal JJ N
technique NN N
, , N
patients NNS N
can MD N
walk VB N
from IN N
the DT N
operating NN N
room NN N
table NN N
to TO N
a DT N
stretcher NN N
on IN N
completion NN N
of IN N
surgery NN N
. . N

Their PRP$ N
recovery NN o
time NN o
was VBD N
similar JJ N
to TO N
that DT N
of IN N
the DT N
desflurane NN i
group NN p
. . p

-DOCSTART- -12036809- O O

Do VB N
colonic JJ N
short-chain NN N
fatty JJ N
acids NNS N
contribute NN N
to TO N
the DT N
long-term JJ o
adaptation NN o
of IN o
blood NN o
lipids NNS o
in IN N
subjects NNS p
with IN p
type JJ p
2 CD p
diabetes NNS p
consuming VBG p
a DT p
high-fiber JJ i
diet NN i
? . N
BACKGROUND NNP N
We PRP N
recently RB N
obtained VBD N
evidence NN N
of IN N
long-term JJ o
adaptation NN o
of IN o
blood NN o
lipids NNS o
to TO N
changes NNS N
in IN N
intakes NNS N
of IN N
carbohydrate NN i
and CC i
fiber NN i
in IN N
subjects NNS p
with IN p
type JJ p
2 CD p
diabetes NNS p
. . p

OBJECTIVE IN N
We PRP N
determined VBD N
the DT N
effect NN N
of IN N
increased JJ i
carbohydrate NN i
and CC i
fiber NN i
intakes NNS i
on IN N
serum JJ o
short-chain JJ o
fatty JJ o
acids NNS o
( ( o
SCFAs NNP o
) ) o
and CC N
the DT N
relation NN o
between IN o
changes NNS o
in IN o
serum NN o
acetate NN o
and CC o
changes NNS o
in IN o
blood NN o
lipids NNS o
. . o

DESIGN NNP N
Subjects VBZ p
with IN p
type NN p
2 CD p
diabetes NNS p
( ( p
n JJ p
= NNP p
62 CD p
) ) p
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
approximately RB N
10 CD N
% NN N
of IN N
energy NN i
from IN i
low-fiber JJ i
breakfast NN i
cereal NN i
( ( i
LF NNP i
diet NN i
) ) i
, , i
high-fiber JJ i
breakfast NN i
cereal NN i
( ( i
HF NNP i
diet NN i
) ) i
, , i
or CC i
monounsaturated VBN i
fatty JJ i
acids NNS i
( ( i
MUFA NNP i
diet NN i
) ) i
for IN N
6 CD N
mo NNS N
. . N

RESULTS NNP N
Carbohydrate NNP o
intakes NNS o
were VBD N
higher JJR N
in IN N
the DT N
LF NNP N
and CC N
HF NNP N
groups NNS N
than IN N
in IN N
the DT N
MUFA NNP N
group NN N
( ( N
54 CD N
% NN N
compared VBN N
with IN N
43 CD N
% NN N
) ) N
, , N
and CC N
more JJR N
fiber NN N
was VBD N
consumed VBN N
by IN N
the DT N
HF NNP N
group NN N
( ( N
approximately RB N
50 CD N
g/d NNS N
) ) N
than IN N
by IN N
the DT N
LF NNP N
or CC N
MUFA NNP N
group NN N
( ( N
approximately RB N
23 CD N
g/d NN N
) ) N
. . N

Fasting VBG o
serum JJ o
SCFAs NNP o
did VBD N
not RB N
change VB N
significantly RB N
over IN N
the DT N
first JJ N
3 CD N
mo NN N
. . N

Between CC N
3 CD N
and CC N
6 CD N
mo NN N
, , N
serum JJ o
acetate NN o
tended VBD N
( ( N
NS NNP N
) ) N
to TO N
decrease VB N
in IN N
the DT N
LF NNP N
group NN N
( ( N
from IN N
69 CD N
+/- JJ N
4 CD N
to TO N
59 CD N
+/- JJ N
5 CD N
micromol/L NN N
) ) N
and CC N
increase VB N
in IN N
the DT N
HF NNP N
group NN N
( ( N
from IN N
100 CD N
+/- JJ N
18 CD N
to TO N
107 CD N
+/- JJ N
17 CD N
micromol/L NN N
) ) N
, , N
with IN N
no DT N
significant JJ N
change NN N
in IN N
the DT N
MUFA NNP N
group NN N
. . N

Serum NNP o
butyrate NN o
did VBD N
not RB N
change VB N
significantly RB N
in IN N
the DT N
LF NNP N
or CC N
MUFA NNP N
group NN N
but CC N
increased VBD N
in IN N
the DT N
HF NNP N
group NN N
( ( N
from IN N
2.5 CD N
+/- JJ N
0.5 CD N
to TO N
3.1 CD N
+/- JJ N
0.6 CD N
micromol/L NN N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

Changes NNS o
in IN o
serum NN o
acetate NN o
from IN N
0 CD N
to TO N
3 CD N
mo NNS N
were VBD N
not RB N
related VBN N
to TO N
changes NNS o
in IN o
lipids NNS o
. . o

However RB N
, , N
changes NNS o
in IN o
serum NN o
acetate NN o
from IN N
3 CD N
to TO N
6 CD N
mo NNS N
were VBD N
positively RB N
related VBN N
to TO N
changes NNS o
in IN o
the DT o
ratio NN o
of IN o
total JJ o
to TO o
HDL NNP o
cholesterol NN o
( ( N
P NNP N
= NNP N
0.041 CD N
) ) N
and CC N
in IN N
fasting NN N
( ( N
P NNP N
= NNP N
0.013 CD N
) ) N
and CC N
postprandial JJ o
( ( o
P NNP o
= NNP o
0.016 CD o
) ) o
triacylglycerols NNS o
. . o

CONCLUSIONS NNP N
In IN N
subjects NNS p
with IN p
type JJ p
2 CD p
diabetes NNS p
, , N
changes NNS N
in IN N
serum NN o
SCFAs NNP o
in IN N
response NN N
to TO N
changes NNS N
in IN N
carbohydrate NN o
and CC o
fiber NN o
intakes NNS o
took VBD N
many JJ N
months NNS N
to TO N
occur VB N
, , N
and CC N
the DT N
changes NNS N
in IN N
serum NN o
acetate NN o
were VBD N
significantly RB N
related VBN N
to TO N
the DT N
long-term JJ o
adaptive JJ o
changes NNS o
in IN o
blood NN o
lipids NNS o
. . o

-DOCSTART- -15294387- O O

An DT N
evaluation NN N
of IN N
an DT N
adaptive JJ i
automation NN i
system NN i
using VBG N
a DT N
cognitive JJ i
vigilance NN i
task NN i
. . i

The DT N
performance NN N
of IN N
an DT N
adaptive JJ i
automation NN i
system NN i
was VBD N
evaluated VBN N
using VBG N
a DT N
cognitive JJ N
vigilance NN N
task NN N
. . N

Participants NNS p
responded VBD N
to TO N
the DT N
presence NN N
of IN N
a DT N
green JJ i
K NNP i
in IN i
an DT i
array NN i
of IN i
two CD i
, , i
five CD i
, , i
or CC i
nine CD i
distractor NN i
stimuli NNS i
during IN i
a DT i
40-min JJ i
vigil NN i
. . i

The DT N
array NN N
with IN N
the DT N
target NN N
stimulus NN N
was VBD N
presented VBN N
once RB N
each DT N
minute NN N
. . N

Participants NNS p
EEG NNP i
was VBD N
recorded VBN N
and CC N
an DT N
engagement JJ o
index NN o
( ( N
EI NNP N
= VBZ N
20 CD N
x NN N
beta/ NN N
( ( N
alpha JJ N
+ NNP N
theta NN N
) ) N
) ) N
was VBD N
derived VBN N
. . N

In IN N
the DT N
negative JJ N
feedback NN N
condition NN N
, , N
increases VBZ N
in IN N
the DT N
EI NNP o
caused VBD o
the DT o
number NN o
of IN o
stimuli NNS o
in IN o
the DT o
array NN o
to TO o
decrease VB o
while IN N
decreases NNS o
in IN o
the DT o
EI NNP o
caused VBD o
the DT o
number NN o
of IN o
stimuli NNS o
to TO o
increase VB o
. . o

For IN N
the DT N
positive JJ N
feedback NN N
condition NN N
, , N
increases VBZ o
in IN o
the DT o
index NN o
caused VBD o
an DT o
increase NN o
in IN o
the DT o
array NN o
size NN o
( ( o
AS IN o
) ) o
while IN N
decreases NNS o
caused VBD o
a DT o
decrease NN o
in IN o
the DT o
array NN o
size NN o
. . o

Each DT N
experimental JJ N
participant NN p
had VBD p
a DT p
yoked VBN p
control NN p
partner NN p
who WP N
received VBD N
the DT N
same JJ N
pattern NN N
of IN N
changes NNS N
in IN N
array JJ N
irrespective NN N
of IN N
their PRP$ N
engagement JJ N
index NN N
. . N

A DT N
vigilance NN N
decrement NN N
was VBD N
seen VBN N
only RB N
for IN N
the DT N
positive JJ N
feedback NN N
, , N
experimental JJ p
group NN p
. . p

-DOCSTART- -21035047- O O

Stepwise NNP N
assessment JJ N
tool NN N
of IN N
operative JJ i
skills NNS i
( ( i
SATOS NNP i
) ) i
: : i
validity NN N
testing VBG N
on IN N
a DT N
porcine JJ i
training NN i
model NN i
of IN N
open JJ N
gastrectomy NN N
. . N

BACKGROUND IN N
The DT N
aim NN N
of IN N
this DT N
prospective JJ N
study NN N
was VBD N
to TO N
evaluate VB N
and CC N
compare VB N
operative JJ N
performance NN N
and CC N
technical JJ N
improvement NN N
of IN N
surgical JJ p
trainees NNS p
learning VBG p
open JJ p
gastrectomy NN p
using VBG N
an DT N
objective JJ N
structured JJ N
stepwise NN i
assessment JJ i
tool NN i
of IN i
operative JJ i
skills NNS i
( ( i
SATOS NNP i
) ) i
previously RB N
validated VBN N
for IN N
open JJ N
surgery NN N
. . N

STUDY NNP N
DESIGN NNP N
Thirty NNP p
residents NNS p
in IN p
general JJ p
surgery NN p
performed VBD p
2 CD p
open JJ i
partial JJ i
gastrectomy NN i
training VBG i
events NNS i
on IN p
a DT p
porcine JJ i
model NN i
. . i

Earlier JJR N
instruction NN N
was VBD N
provided VBN N
for IN N
the DT N
critical JJ N
operative JJ N
steps NNS N
, , N
with IN N
additional JJ N
intraoperative JJ N
instruction NN N
when WRB N
required VBN N
. . N

Performance NN N
was VBD N
assessed VBN N
by IN N
postgraduate JJ o
year NN o
( ( o
PGY NNP o
) ) o
according VBG o
to TO o
operative JJ o
time NN o
, , o
technical JJ o
skills NNS o
using VBG N
a DT N
23-step JJ o
objective NN o
structured VBD o
tool NN o
, , o
and CC o
error NN o
rate NN o
. . o

RESULTS CC N
There EX N
were VBD N
11 CD N
PGY-3 NNP N
, , N
11 CD N
PGY-4 NN N
, , N
and CC N
8 CD N
PGY-5 JJ N
residents NNS N
. . N

At IN N
the DT N
initial JJ N
assessment NN N
, , N
performance NN N
significantly RB N
differentiated VBD N
the DT N
3 CD N
PGY NNP N
grades NNS N
according VBG N
to TO N
technical JJ o
skills NNS o
and CC o
error NN o
rate NN o
. . o

At IN N
the DT N
second JJ N
assessment NN N
, , N
all DT N
3 CD N
PGY NNP N
classes NNS N
were VBD N
still RB N
significantly RB N
differentiable JJ N
by IN N
technical JJ o
skills NNS o
, , o
with IN o
no DT o
difference NN o
in IN o
error NN o
rate NN o
. . o

Comparing NNP N
performances NNS N
, , N
residents NNS N
improved VBD N
operative JJ o
time NN o
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
, , N
technical JJ o
skills NNS o
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
, , N
and CC N
error NN o
rate NN o
( ( N
p JJ N
= NNP N
0.019 CD N
) ) N
over IN N
the DT N
2 CD N
training NN N
events NNS N
. . N

CONCLUSIONS NNP N
SATOS NNP N
demonstrated VBD N
relevant JJ o
and CC o
accurate JJ o
objective JJ o
assessment NN o
of IN N
trainees NNS N
' POS N
operative JJ o
skills NNS o
and CC o
improvement NN o
for IN N
open JJ N
gastrectomy NN N
in IN N
a DT N
porcine JJ N
model NN N
. . N

This DT N
tool NN N
may MD N
be VB N
useful JJ N
to TO N
standardize VB N
instruction NN N
, , N
to TO N
expose VB N
weaknesses NNS N
of IN N
trainees NNS N
, , N
and CC N
to TO N
determine VB N
minimal JJ N
technical JJ N
standards NNS N
in IN N
residency NN N
programs NNS N
. . N

-DOCSTART- -24626980- O O

Short-term JJ N
speech-language NN N
intervention NN N
for IN N
children NNS p
with IN p
disorders NNS p
of IN p
the DT p
autism NN p
spectrum NN p
. . p

PURPOSE NNP N
To TO N
assess VB N
any DT N
changes NNS N
in IN N
the DT N
Functional NNP N
Communicative NNP N
Profile NNP N
( ( N
FCP NNP N
) ) N
and CC N
in IN N
the DT N
Social NNP N
Cognitive NNP N
Performance NNP N
( ( N
SCP NNP N
) ) N
of IN N
children NNS p
with IN p
Autism NNP p
Spectrum NNP p
Disorders NNP p
, , N
based VBN N
on IN N
two CD N
short JJ N
periods NNS N
of IN N
intervention NN N
. . N

METHODS NNP N
The DT N
study NN N
was VBD N
conducted VBN N
with IN N
21 CD p
children NNS p
with IN p
Autism NNP p
Spectrum NNP p
Disorder NNP p
diagnoses NNS p
, , N
randomly RB N
allocated VBN N
into IN N
two CD N
groups NNS N
, , N
who WP i
received VBD i
the DT i
same JJ i
short-term JJ i
intervention NN i
types NNS i
( ( i
6 CD i
weeks NNS i
with IN i
the DT i
mother NN i
and CC i
6 CD i
weeks NNS i
with IN i
the DT i
support NN i
of IN i
an DT i
educational JJ i
software NN i
program NN i
) ) i
. . i

The DT i
intervention NN i
process NN i
was VBD i
conducted VBN i
by IN i
speech-language JJ i
pathologists NNS i
who WP i
were VBD i
part NN i
of IN i
a DT i
graduate NN i
program NN i
in IN i
this DT i
area NN i
. . i

RESULTS NNP N
Samples NNP N
of IN N
15-minute JJ N
interaction NN N
sessions NNS N
between IN N
the DT N
child NN N
and CC N
speech-language JJ N
pathologist NN N
were VBD N
used VBN N
to TO N
assess VB N
the DT N
changes NNS N
in IN N
the DT N
FCP NNP N
and CC N
the DT N
SCP NNP N
. . N

The DT N
statistic JJ N
analysis NN N
pointed VBD N
out RP N
differences NNS N
only RB N
in IN N
Group NNP N
1 CD N
for IN N
the DT N
variables NNS N
percentage NN o
of IN o
communicative JJ o
space NN o
used VBN o
and CC o
use NN o
of IN o
the DT o
mediating NN o
object NN o
. . N

CONCLUSION NN N
With IN N
the DT N
intervention NN N
sessions NNS N
structured VBD N
over IN N
12 CD N
weeks NNS N
, , N
it PRP N
was VBD N
possible JJ N
to TO N
observe VB N
a DT N
few JJ N
changes NNS N
in IN N
the DT N
children NNS N
's POS N
FCP NNP N
and CC N
in IN N
the DT N
SCP NNP N
. . N

Therefore RB N
, , N
we PRP N
point VBP N
out RP N
the DT N
need NN N
for IN N
new JJ N
research NN N
studies NNS N
of IN N
longer JJR N
duration NN N
. . N

-DOCSTART- -11791023- O O

1999 CD N
WHO/ISH NNP N
Guidelines NNP N
applied VBD N
to TO N
a DT N
1999 CD p
MONICA NNP p
sample NN p
from IN p
northern JJ p
Sweden NNP p
. . p

BACKGROUND NNP N
Treating NNP N
hypertension NN N
with IN N
drugs NNS N
is VBZ N
so RB N
far RB N
the DT N
most RBS N
cost-effective JJ N
way NN N
to TO N
reduce VB N
this DT N
important JJ N
risk NN N
factor NN N
for IN N
cardiovascular JJ N
disease NN N
( ( N
CVD NNP N
) ) N
. . N

It PRP N
is VBZ N
, , N
however RB N
, , N
important JJ N
to TO N
determine VB N
absolute NN N
risk NN N
, , N
and CC N
thereby RB N
estimate VB N
indication NN N
for IN N
drug NN N
treatment NN N
, , N
in IN N
order NN N
to TO N
maintain VB N
a DT N
cost-effective JJ N
drug NN N
treatment NN N
. . N

WHO/ISH NNP N
Hypertension NNP N
Guidelines NNP N
from IN N
1999 CD N
propose NN N
a DT N
risk NN N
stratification NN N
for IN N
estimating VBG N
absolute NN N
risk NN N
for IN N
CVD NNP N
based VBN N
on IN N
blood NN N
pressure NN N
and CC N
additional JJ N
risk NN N
factors NNS N
, , N
target NN N
organ JJ N
damage NN N
( ( N
TOD NNP N
) ) N
and CC N
CVD NNP N
. . N

OBJECTIVES NNP N
We PRP N
studied VBD N
the DT N
consequences NNS N
of IN N
applying VBG N
the DT N
recent JJ N
WHO/ISH NNP i
risk NN i
stratification NN i
scheme NN i
to TO N
a DT N
MONICA NNP p
sample NN p
of IN p
6000 CD p
subjects NNS p
from IN p
a DT p
geographically RB p
defined VBN p
population NN p
in IN p
northern JJ p
Sweden NNP p
, , p
regarding VBG p
indications NNS p
for IN p
treatment NN p
, , p
target VB p
blood NN p
pressure NN p
and CC p
risk NN p
distribution NN p
. . p

METHODS NNP N
We PRP N
have VBP N
risk-classified JJ N
each DT N
of IN N
these DT N
patients NNS N
using VBG N
a DT N
computer NN i
program NN i
, , N
according VBG N
to TO N
the DT N
WHO/ISH NNP N
scheme NN N
. . N

Data NNP N
on IN N
TOD NNP N
were VBD N
not RB N
available JJ N
. . N

RESULTS NNP N
In IN N
all DT N
, , N
917 CD N
( ( N
15 CD N
% NN N
) ) N
had VBD N
drug-treated JJ p
hypertension NN p
. . p

Three-quarters NNS N
( ( N
n JJ N
= NNP N
737 CD N
) ) N
were VBD N
inadequately RB N
treated VBN N
, , N
with IN N
blood NN o
pressure NN o
levels NNS o
at IN N
or CC N
above VB N
140 CD N
or CC N
90 CD N
mmHg NN N
. . N

1773 CD N
( ( N
30 CD N
% NN N
of IN N
5997 CD N
) ) N
untreated JJ p
subjects NNS p
had VBD N
a DT N
blood NN N
pressure NN N
of IN N
140/90 CD N
or CC N
above RB N
; : N
16 CD N
% NN N
in IN N
the DT N
low- JJ p
, , N
62 CD N
% NN N
in IN N
the DT N
medium- NN p
, , N
8 CD N
% NN N
in IN N
the DT N
high- NN p
, , N
and CC N
14 CD N
% NN N
in IN N
the DT N
very-high-risk JJ p
group NN p
. . p

The DT N
corresponding JJ N
risk-group JJ N
pattern NN N
for IN N
the DT N
inadequately RB N
treated JJ N
hypertensives NNS N
( ( N
n JJ N
= NNP N
737 CD N
) ) N
was VBD N
5.5 CD N
, , N
48.3 CD N
, , N
11.1 CD N
and CC N
35.2 CD N
% NN N
, , N
respectively RB N
. . N

If IN N
we PRP N
shifted VBD N
the DT N
target NN N
blood NN N
pressure NN N
from IN N
below IN N
140/90 CD N
to TO N
below VB N
130/85 CD N
for IN N
drug-treated JJ N
subjects NNS N
under IN N
60 CD N
( ( N
n JJ N
= NNP N
278 CD N
) ) N
the DT N
number NN o
of IN o
inadequately RB o
treated JJ o
subjects NNS o
increased VBN N
by IN N
34 CD N
( ( N
12.2 CD N
% NN N
of IN N
278 CD N
) ) N
; : N
14 CD N
in IN N
the DT N
low-risk JJ N
group NN N
, , N
15 CD N
in IN N
the DT N
medium-risk JJ N
group NN N
, , N
and CC N
only RB N
five CD N
in IN N
the DT N
high- JJ N
or CC N
very-high-risk JJ N
groups NNS N
. . N

CONCLUSIONS NNP N
Only RB N
one-fifth NN N
of IN N
the DT N
drug-treated JJ N
hypertensives NNS N
were VBD N
well RB N
controlled VBN N
. . N

Moreover RB N
, , N
the DT N
incidence NN N
of IN N
newly RB o
detected VBN o
blood NN o
pressure NN o
elevation NN o
was VBD N
high JJ N
. . N

The DT N
majority NN N
of IN N
younger JJR N
subjects NNS N
with IN N
high JJ N
blood NN N
pressure NN N
had VBD N
low JJ N
risk NN N
, , N
but CC N
in IN N
those DT p
aged VBN p
45-54 CD p
this DT N
had VBD N
already RB N
risen VBN N
to TO N
a DT N
medium NN N
risk NN N
. . N

Changing VBG N
the DT N
target NN N
blood NN N
pressure NN N
to TO N
below IN N
130/85 CD N
, , N
for IN N
subjects NNS p
aged VBN p
below IN p
60 CD p
, , N
as IN N
recommended VBN N
by IN N
WHO/ISH NNP N
, , N
affects VBZ N
predominantly RB N
low- JJ N
and CC N
medium-risk JJ N
groups NNS N
. . N

-DOCSTART- -25670026- O O

Real-Time JJ N
Assessment NNP N
of IN N
the DT N
Effect NNP o
of IN o
Biofeedback NNP o
Therapy NNP o
with IN N
Migraine NNP N
: : N
A DT N
Pilot NNP N
Study NNP N
. . N

BACKGROUND NNP N
Biofeedback NNP i
therapy NN i
has VBZ N
been VBN N
reported VBN N
to TO N
be VB N
effective JJ N
in IN N
the DT N
treatment NN N
of IN N
migraine NN N
. . N

However RB N
, , N
previous JJ N
studies NNS N
have VBP N
assessed VBN N
its PRP$ N
effectiveness NN N
using VBG N
paper-and-pencil JJ N
diaries NNS N
, , N
which WDT N
are VBP N
not RB N
very RB N
reliable JJ N
. . N

PURPOSE VB N
The DT N
objective NN N
of IN N
the DT N
present JJ N
pilot NN N
study NN N
was VBD N
to TO N
investigate VB N
the DT N
feasibility NN N
of IN N
using VBG N
computerized JJ N
ecological JJ N
momentary JJ N
assessment NN N
( ( N
EMA NNP N
) ) N
for IN N
evaluating VBG o
the DT o
efficacy NN o
of IN o
BF NNP o
treatment NN o
for IN N
migraine NN N
in IN N
a DT N
randomized NN N
controlled VBN N
trial NN N
. . N

METHOD NNP N
The DT N
subjects NNS N
comprised VBD N
one CD p
male NN p
and CC p
26 CD p
female JJ p
patients NNS p
with IN p
migraine NN p
. . p

They PRP N
were VBD N
randomly RB N
assigned VBN N
to TO N
either DT N
biofeedback NN i
or CC N
wait-list JJ i
control NN i
groups NNS i
. . i

Patients NNS N
were VBD N
asked VBN N
to TO N
carry VB N
a DT N
palmtop-type JJ N
computer NN N
to TO N
record VB N
momentary NN N
symptoms NNS N
for IN N
4 CD N
weeks NNS N
before IN N
and CC N
after IN N
biofeedback NN i
treatment NN i
. . i

The DT N
primary JJ N
outcome NN N
measure NN N
was VBD N
headache JJ o
intensity NN o
. . o

The DT N
secondary JJ N
outcome NN N
measures NNS N
included VBD N
psychological JJ o
stress NN o
, , o
anxiety NN o
, , o
irritation NN o
, , o
headache-related JJ o
disability NN o
and CC o
the DT o
frequency NN o
( ( o
number NN o
of IN o
days NNS o
per IN o
month NN o
) ) o
of IN o
migraine NN o
attack NN o
and CC o
of IN o
headache NN o
of IN o
at IN o
least JJS o
moderate JJ o
intensity NN o
( ( N
pain NN N
rating NN N
?50 NN N
) ) N
. . N

RESULTS NNP o
Headache NNP o
intensity NN o
showed VBD o
significant JJ N
main JJ N
effects NNS N
of IN N
period NN N
( ( N
before IN N
vs. NN N
after IN N
therapy NN N
, , N
p NN N
= NNP N
0.02 CD N
) ) N
and CC N
group NN N
( ( N
biofeedback IN N
vs. FW N
control NN N
groups NNS N
, , N
p VBP N
= RB N
0.42 CD N
) ) N
and CC N
a DT N
significant JJ N
period NN N
? . N
group NN N
interaction NN N
( ( N
p JJ N
< NNP o
0.001 CD o
) ) o
. . o

Biofeedback NNP o
reduced VBD o
the DT o
duration NN o
of IN o
headaches NNS o
by IN o
1.9 CD o
days NNS N
, , N
and CC N
the DT o
frequency NN o
of IN o
days NNS o
when WRB o
headache NN o
intensity NN o
was VBD o
?50 VBN o
by IN N
2.4 CD N
times NNS N
. . N

In IN N
addition NN o
, , o
headache-related JJ o
disability NN o
, , o
psychological JJ o
stress NN o
, , o
depression NN o
, , o
anxiety NN o
, , o
and CC o
irritation NN o
were VBD o
significantly RB N
improved VBN N
. . N

CONCLUSION VB N
The DT N
present JJ N
study NN N
used VBN N
computerized VBN N
EMA NNP N
to TO N
show VB i
that DT i
biofeedback NN i
could MD i
improve VB o
the DT o
symptoms NNS o
of IN o
migraine NN o
, , o
including VBG o
psychological JJ o
stress NN o
and CC o
headache-related JJ o
disability NN o
. . o

-DOCSTART- -25087908- O O

The DT N
effects NNS N
of IN N
a DT N
course NN N
of IN N
intranasal JJ i
oxytocin NN i
on IN N
social JJ N
behaviors NNS N
in IN N
youth NN p
diagnosed VBN p
with IN p
autism NN p
spectrum NN p
disorders NNS p
: : p
a DT N
randomized NN N
controlled VBN N
trial NN N
. . N

BACKGROUND NNP N
There EX N
is VBZ N
increasing VBG N
interest NN N
in IN N
oxytocin NN i
as IN N
a DT N
therapeutic JJ N
to TO N
treat VB N
social JJ N
deficits NNS N
in IN N
autism NN p
spectrum NN p
disorders NNS p
( ( p
ASD NNP p
) ) p
. . p

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
investigate VB N
the DT N
efficacy NN N
of IN N
a DT N
course NN N
of IN N
oxytocin JJ i
nasal NN i
spray NN i
to TO N
improve VB N
social JJ N
behavior NN N
in IN N
youth NN p
with IN p
ASD NNP p
. . p

METHODS NNP N
In IN N
a DT N
double-blind JJ N
, , N
placebo-controlled JJ i
trial NN N
across IN N
two CD p
Australian JJ p
university NN p
sites NNS p
between IN p
February NNP p
2009 CD p
and CC p
January NNP p
2012 CD p
, , p
50 CD p
male NN p
participants NNS p
aged VBN p
between IN p
12 CD p
and CC p
18 CD p
years NNS p
, , p
with IN p
Autistic NNP p
or CC p
Asperger NNP p
's POS p
Disorder NNP p
, , N
were VBD N
randomized VBN N
to TO N
receive VB N
either DT N
oxytocin NN i
( ( N
n JJ N
= NNP N
26 CD N
) ) N
or CC i
placebo NN i
( ( N
n JJ N
= NNP N
24 CD N
) ) N
nasal NN i
sprays NNS i
( ( N
either CC N
18 CD N
or CC N
24 CD N
International NNP N
Units NNP N
) ) N
, , N
administered VBN N
twice-daily RB N
for IN N
8 CD N
weeks NNS N
. . N

Participants NNS N
were VBD N
assessed VBN N
at IN N
baseline NN N
, , N
after IN N
4- JJ N
and CC N
8-weeks CD N
of IN N
treatment NN N
, , N
and CC N
at IN N
3-month JJ N
follow-up NN N
. . N

Primary JJ N
outcomes NNS N
were VBD N
change NN N
in IN N
total JJ o
scores NNS o
on IN o
the DT o
caregiver-completed JJ o
Social NNP o
Responsiveness NNP o
Scale NNP o
and CC o
clinician-ratings NNS o
on IN o
the DT o
Clinical JJ o
Global NNP o
Impressions-Improvement NNP o
scale NN o
. . o

Secondary JJ N
assessments NNS N
included VBD N
caregiver NN o
reports NNS o
of IN o
repetitive JJ o
and CC o
other JJ o
developmental JJ o
behaviors NNS o
and CC o
social JJ o
cognition NN o
. . o

CLINICAL NNP N
TRIAL NNP N
REGISTRATION NNP N
Australian NNP N
New NNP N
Zealand NNP N
Clinical NNP N
Trials NNP N
Registry NNP N
www.anzctr.org.au VBD N
ACTRN12609000513213 NNP N
. . N

RESULTS NNP N
Participants NNPS N
who WP N
received VBD N
oxytocin RB N
showed VBN N
no DT N
benefit NN N
following VBG N
treatment NN N
on IN N
primary JJ N
or CC N
secondary JJ N
outcomes NNS N
. . N

However RB N
, , N
caregivers NNS N
who WP N
believed VBD N
their PRP$ N
children NNS N
received VBN N
oxytocin RB i
reported VBN N
greater JJR N
improvements NNS N
compared VBN N
to TO N
caregivers NNS N
who WP N
believed VBD N
their PRP$ N
child NN N
received VBD N
placebo NN i
. . i

Nasal NNP N
sprays NNS N
were VBD N
well RB N
tolerated VBN o
and CC N
there EX N
was VBD N
no DT N
evidence NN N
of IN N
increased JJ N
side NN o
effects NNS o
resulting VBG N
from IN N
oxytocin JJ i
administration NN N
. . N

CONCLUSIONS VB N
This DT N
is VBZ N
the DT N
first JJ N
evaluation NN N
of IN N
the DT N
efficacy NN N
for IN N
a DT N
course NN N
of IN N
oxytocin JJ i
treatment NN N
for IN N
youth NN N
with IN N
ASD NNP N
. . N

Although IN N
results NNS N
did VBD N
not RB N
suggest VB N
clinical JJ N
efficacy NN N
, , N
further JJ N
research NN N
is VBZ N
needed VBN N
to TO N
explore VB N
alternative JJ N
delivery NN N
methods NNS N
, , N
earlier JJR N
age NN N
of IN N
intervention NN N
, , N
and CC N
the DT N
influence NN N
of IN N
caregiver NN N
expectation NN N
on IN N
treatment NN N
response NN N
. . N

-DOCSTART- -25459500- O O

Exercise NN N
echocardiography NN N
demonstrates VBZ N
biventricular JJ N
systolic JJ N
dysfunction NN N
and CC N
reveals NNS N
decreased VBD N
left VBD N
ventricular JJ N
contractile NN N
reserve NN N
in IN N
children NNS p
after IN p
tetralogy NN p
of IN p
Fallot NNP p
repair NN p
. . p

BACKGROUND NNP N
Long-term NNP N
biventricular JJ N
systolic JJ N
performance NN N
is VBZ N
a DT N
key JJ N
determinant NN N
of IN N
clinical JJ N
outcomes NNS N
late RB N
after IN N
tetralogy NN i
of IN i
Fallot NNP i
( ( i
TOF NNP i
) ) i
repair NN i
. . i

A DT N
need NN N
exists VBZ N
for IN N
early JJ N
indices NNS N
of IN N
both DT N
left FW N
ventricular NN N
( ( N
LV NNP N
) ) N
and CC N
right JJ N
ventricular NN N
( ( N
RV NNP N
) ) N
compromise NN N
in IN N
this DT N
population NN N
. . N

METHODS NNP N
Twenty-nine JJ p
children NNS p
( ( p
age NN p
range NN p
, , p
5-18 CD p
years NNS p
) ) p
with IN p
repaired VBN p
TOF NNP p
and CC p
44 CD p
healthy JJ p
controls NNS p
were VBD N
prospectively RB N
evaluated VBN N
. . N

M-mode NNP i
and CC i
tissue NN i
Doppler NNP i
data NNS i
were VBD N
obtained VBN N
for IN N
each DT N
ventricle NN N
and CC N
the DT N
RV NNP N
outflow JJ N
tract NN N
at IN N
rest NN N
and CC N
during IN N
semisupine JJ i
bicycle NN i
exercise NN i
. . i

By IN N
making VBG N
measurements NNS N
of IN N
myocardial JJ N
acceleration NN N
during IN N
isovolumic JJ N
contraction NN N
during IN N
exercise NN N
, , N
at IN N
increasing VBG N
heart NN N
rates NNS N
, , N
LV NNP N
force-frequency NN N
curves NNS N
were VBD N
constructed VBN N
. . N

Patients NNS N
also RB N
underwent JJ N
cardiac JJ i
magnetic JJ i
resonance NN i
imaging NN i
, , i
cardiopulmonary JJ i
exercise NN i
testing NN i
, , i
and CC i
measurement NN i
of IN i
serum JJ i
neurohormonal JJ i
markers NNS i
. . i

RESULTS NNP N
Children NNP p
with IN p
repaired VBN p
TOF NNP p
had VBD N
dilated VBN N
right JJ N
ventricles NNS N
( ( N
RV NNP N
end-diastolic JJ N
volume NN N
index NN N
= VBD N
153 CD N
? . N
37.3 CD N
mL/m NN N
( ( N
2 CD N
) ) N
) ) N
but CC N
normal JJ N
ejection NN N
fractions NNS N
as IN N
measured VBN N
on IN N
magnetic JJ N
resonance NN N
imaging NN N
( ( N
LV NNP N
ejection NN N
fraction NN N
= VBD N
59.3 CD N
? . N
6.2 CD N
% NN N
, , N
RV NNP N
ejection NN N
fraction NN N
= VBD N
50.2 CD N
? . N
8.5 CD N
% NN N
) ) N
and CC N
normal JJ o
serum JJ o
neurohormonal JJ o
markers NNS o
. . o

Detailed VBN o
resting VBG N
echocardiography NN N
detected VBD o
abnormal JJ o
ventricular JJ o
function NN o
, , o
worst RB o
in IN N
the DT N
right JJ N
ventricle NN N
and CC N
RV NNP N
outflow IN N
tract NN N
. . N

Exercise NN N
exacerbated VBD N
these DT N
findings NNS N
and CC N
provoked VBD N
significant JJ N
decline NN N
in IN N
LV NNP o
indices NNS o
. . o

The DT o
LV NNP o
force-frequency NN o
curves NNS o
of IN o
patients NNS N
were VBD N
attenuated VBN N
, , N
with IN N
an DT N
early JJ N
plateau NN N
and CC N
inadequate JJ N
increase NN N
of IN N
isovolumic JJ N
contraction NN N
. . N

Correlations NNS N
were VBD N
seen VBN N
between IN N
peak JJ N
exercise NN N
LV NNP N
isovolumic JJ N
contraction NN N
and CC N
percentage NN N
predicted VBD o
peak JJ o
oxygen NN o
uptake NN o
( ( o
r JJ o
= NN N
0.51 CD N
, , N
P NNP N
= NNP N
.02 NNP N
) ) o
, , o
LV NNP o
and CC o
RV NNP o
ejection NN o
fractions NNS o
( ( o
r VB o
= RB N
0.41 CD N
, , N
P NNP N
= NNP N
.03 NNP N
) ) N
, , N
and CC N
RV NNP o
and CC o
LV NNP o
long-axis JJ o
fractional JJ o
shortening NN o
( ( o
r JJ o
= NN N
0.44 CD N
, , N
P NNP N
= NNP N
.02 NNP N
) ) N
. . N

CONCLUSIONS VB N
The DT N
postsurgical JJ N
pathophysiology NN N
of IN N
TOF NNP N
begins VBZ N
early JJ N
after IN N
repair NN N
. . N

At IN N
a DT N
time NN N
when WRB N
clinically RB N
well RB N
and CC N
while IN N
routine JJ N
indices NNS N
of IN N
heart NN N
function NN N
remain VBP N
normal JJ p
, , p
children NNS p
with IN p
repaired JJ p
TOF NNP p
exhibit NN p
RV NNP p
dilatation NN p
and CC p
subtle NN p
, , p
interlinked VBD p
biventricular JJ N
abnormalities NNS N
on IN N
resting VBG N
echocardiography NN i
. . i

Exercise NN i
echocardiography NN i
provides VBZ N
additional JJ N
information NN N
and CC N
reveals NNS N
abnormal JJ N
LV NNP N
excitation-contractile NN N
coupling VBG N
that WDT N
may MD N
be VB N
linked VBN N
to TO N
impaired JJ N
exercise NN N
capacity NN N
. . N

-DOCSTART- -9660035- O O

Zolmitriptan NNP i
( ( i
311C90 CD i
) ) i
does VBZ N
not RB N
interact VB N
with IN N
fluoxetine NN i
in IN N
healthy JJ p
volunteers NNS p
. . p

Zolmitriptan NNP i
( ( i
Zomig NNP i
, , i
formerly RB i
311C90 CD i
) ) i
is VBZ N
a DT N
selective JJ i
5-hydroxytryptamine JJ i
( ( i
5-HT JJ i
) ) i
1B/1D-receptor JJ i
agonist NN i
with IN N
central JJ N
and CC N
peripheral JJ N
activity NN N
for IN N
the DT N
acute JJ N
treatment NN N
of IN N
migraine NN N
. . N

This DT N
randomized JJ N
, , N
placebo-controlled JJ i
, , N
crossover NN N
study NN N
investigated VBD N
the DT N
effects NNS N
of IN N
fluoxetine JJ i
administration NN N
on IN N
the DT N
pharmacokinetics NNS o
and CC o
pharmacodynamics NNS o
of IN o
zolmitriptan NN o
. . o

Twenty CD p
volunteers NNS p
were VBD p
given VBN p
single JJ p
doses NNS p
of IN p
fluoxetine JJ i
20 CD i
mg NN i
or CC p
an DT p
identical JJ p
placebo NN i
daily RB p
for IN p
28 CD p
days NNS p
prior RB p
to TO p
receiving VBG p
a DT p
single JJ p
10 CD p
mg JJ p
oral JJ p
dose NN p
of IN p
zolmitriptan NN i
. . i

Sixteen JJ p
volunteers NNS p
completed VBD p
the DT p
two CD p
treatment NN p
phases NNS p
. . p

The DT N
pharmacokinetic JJ o
parameters NNS o
of IN o
zolmitriptan NN o
and CC o
its PRP$ o
metabolites NNS o
were VBD N
not RB N
significantly RB N
affected VBN N
by IN N
fluoxetine JJ i
pretreatment NN N
. . N

The DT N
pharmacodynamic JJ o
effects NNS o
of IN o
zolmitriptan NN o
were VBD N
also RB N
unaffected VBN N
by IN N
fluoxetine JJ i
pretreatment NN N
. . N

There EX N
were VBD N
small JJ N
, , N
clinically RB N
insignificant JJ N
increases NNS N
in IN N
blood NN o
pressure NN o
following VBG N
zolmitriptan NN i
which WDT N
were VBD N
unaltered VBN N
by IN N
fluoxetine NN i
. . i

Zolmitriptan NNP i
was VBD N
well RB o
tolerated VBN o
when WRB N
given VBN N
alone RB N
or CC N
concomitantly RB N
with IN N
fluoxetine NN i
. . i

These DT N
results NNS N
indicate VBP N
that IN N
there EX N
is VBZ N
no DT N
contraindication NN o
to TO N
the DT N
use NN N
of IN N
zolmitriptan NN i
in IN N
patients NNS p
treated VBN p
concurrently RB p
with IN p
selective JJ i
serotonin NNS i
reuptake VBP i
inhibitors NNS i
and CC N
that IN N
no DT N
adjustment NN N
of IN N
the DT N
zolmitriptan NN i
dose NN N
is VBZ N
required VBN N
in IN N
these DT N
circumstances NNS N
. . N

-DOCSTART- -17983307- O O

The DT N
value-congruence JJ N
model NN N
of IN N
memory NN o
for IN o
emotional JJ o
experiences NNS o
: : o
an DT N
explanation NN N
for IN N
cultural JJ p
differences NNS p
in IN p
emotional JJ p
self-reports NNS p
. . p

In IN N
3 CD N
studies NNS N
, , N
the DT N
authors NNS N
found VBD N
support NN N
for IN N
the DT N
value-congruence NN i
model NN i
that WDT N
accounts VBZ N
for IN N
cultural JJ N
variations NNS N
in IN N
memory NN o
for IN o
emotional JJ o
experiences NNS o
. . o

In IN N
Study NNP N
1 CD N
, , N
the DT N
authors NNS N
found VBD N
that IN N
in IN N
the DT N
made-in-the-U.S. JJ i
scenario NN i
condition NN N
, , N
European JJ p
Americans NNPS p
were VBD p
more JJR p
accurate JJ p
than IN p
were VBD p
Asian JJ p
Americans NNPS p
in IN N
their PRP$ N
retrospective JJ o
frequency NN o
judgments NNS o
of IN o
emotions NNS o
. . o

However RB N
, , N
in IN N
the DT N
made-in-Japan JJ i
scenario NN i
condition NN N
, , N
European JJ p
Americans NNPS p
were VBD N
less JJR N
accurate JJ N
than IN N
were VBD N
Asian JJ p
Americans NNPS p
. . p

In IN N
Study NNP N
2 CD N
, , N
the DT N
authors NNS N
demonstrated VBD N
that IN N
value NN N
orientation NN N
mediates VBZ N
the DT N
CulturexType NNP o
of IN o
Event NNP o
congruence NN o
effect NN o
. . o

In IN N
Study NNP N
3 CD N
( ( N
a DT N
daily RB i
event NN i
sampling VBG i
study NN i
) ) i
, , N
the DT N
authors NNS N
showed VBD N
that IN N
the DT N
congruence NN o
effect NN o
was VBD N
explained VBN N
by IN N
the DT N
importance NN N
of IN N
parental JJ N
approval NN N
. . N

In IN N
sum NN N
, , N
emotional JJ N
events NNS N
congruent NN N
with IN N
personal JJ o
values NNS o
remain VBP N
in IN N
memory NN N
longer NN N
and CC N
influence NN N
retrospective JJ o
frequency NN o
judgments NNS o
of IN o
emotion NN o
more JJR N
than IN N
do VB N
incongruent JJ N
events NNS N
. . N

-DOCSTART- -7891203- O O

Changes NNS N
in IN N
beta-carotene NN N
levels NNS N
by IN N
long-term JJ N
administration NN N
of IN N
natural JJ i
beta-carotene JJ i
derived VBN N
from IN N
Dunaliella NNP N
bardawil NN N
in IN N
humans NNS p
. . p

Long-term JJ N
administration NN N
of IN N
a DT N
beta-carotene JJ i
preparation NN i
derived VBN N
from IN N
Dunaliella NNP N
bardawil NN N
, , N
a DT N
beta-carotene-rich JJ i
algae NN i
, , N
was VBD N
studied VBN N
in IN N
healthy JJ p
young JJ p
male NN p
volunteers NNS p
. . p

The DT N
daily JJ N
administration NN N
of IN N
60 CD i
mg NN i
of IN i
the DT i
beta-carotene JJ i
preparation NN i
( ( N
30 CD N
mg NN N
of IN N
all-trans JJ N
beta-carotene NN N
and CC N
30 CD N
mg NN N
of IN N
9-cis JJ N
beta-carotene NN N
) ) N
was VBD N
performed VBN N
and CC N
beta-carotene JJ N
concentrations NNS N
were VBD N
determined VBN N
in IN N
the DT N
plasma NN o
, , o
red JJ o
blood NN o
cells NNS o
( ( o
RBC NNP o
) ) o
, , o
platelets NNS o
( ( o
PLT NNP o
) ) o
, , o
and CC o
mononuclear JJ o
cells NNS o
( ( o
MN NNP o
) ) o
. . o

The DT N
all-trans JJ o
beta-carotene JJ o
level NN o
increased VBD N
four- JJ N
, , N
two- JJ N
, , N
and CC N
threefold VBD N
the DT N
baseline NN N
in IN N
plasma NN o
, , o
PLT NNP o
, , o
and CC o
MN NNP o
, , N
respectively RB N
. . N

Basal NNP o
levels NNS o
of IN o
9-cis CD o
beta-carotene NN o
in IN o
plasma NN o
, , o
PLT NNP o
, , o
and CC o
MN NNP o
were VBD N
low JJ N
and CC N
found VBN N
as IN N
one-tenth JJ N
, , N
one-fifth JJ N
, , N
and CC N
one-fifth JJ N
of IN N
all-trans JJ N
beta-carotene NN N
, , N
which WDT N
increased VBD N
three- NN N
, , N
two- JJ N
, , N
and CC N
1.5-fold JJ N
the DT N
baseline NN N
, , N
respectively RB N
. . N

Plasma NNP o
and CC o
RBC NNP o
alpha-tocopherol NN o
levels NNS o
were VBD N
not RB N
changed VBN N
by IN N
the DT N
intake NN N
of IN N
beta-carotene NN N
. . N

No DT o
side NN o
effects NNS o
or CC o
toxicities NNS o
were VBD N
documented VBN N
in IN N
any DT N
of IN N
the DT N
subjects NNS N
during IN N
the DT N
administration NN N
period NN N
. . N

In IN N
conclusion NN N
, , N
the DT N
bioavailability NN N
of IN N
beta-carotene JJ N
derived VBN N
from IN N
Dunaliella NNP N
bardawil NN N
was VBD N
preferential JJ N
for IN N
all-trans JJ N
beta-carotene NN N
, , N
although IN N
a DT N
small JJ N
amount NN N
of IN N
the DT N
9-cis JJ N
form NN N
was VBD N
detected VBN N
in IN N
the DT N
plasma NN N
and CC N
blood NN N
cells NNS N
. . N

-DOCSTART- -24885551- O O

Efficacy NN o
and CC o
cost-effectiveness NN o
of IN N
an DT N
experimental JJ N
short-term JJ N
inpatient JJ i
Dialectical NNP i
Behavior NNP i
Therapy NNP i
( ( i
DBT NNP i
) ) i
program NN N
: : N
study NN N
protocol NN N
for IN N
a DT N
randomized VBN N
controlled VBN N
trial NN N
. . N

BACKGROUND NNP N
Borderline NNP p
Personality NNP p
Disorder NNP p
( ( p
BPD NNP p
) ) p
is VBZ N
a DT N
serious JJ N
psychiatric JJ N
condition NN N
associated VBN N
with IN N
substantial JJ N
mortality NN N
, , N
burden NN N
and CC N
public JJ N
health NN N
costs NNS N
. . N

DBT NNP N
is VBZ N
the DT N
treatment NN N
model NN N
with IN N
the DT N
largest JJS N
number NN N
of IN N
published VBN N
research NN N
articles VBZ N
showing VBG N
effectiveness NN N
. . N

However RB N
, , N
some DT N
patients NNS N
are VBP N
not RB N
sufficiently RB N
engaged VBN N
in IN N
outpatient JJ N
treatment NN N
while IN N
presenting VBG N
severe JJ N
parasuicidal JJ N
behavior NN N
, , N
making VBG N
hospitalization NN N
necessary JJ N
. . N

The DT N
Center NNP N
for IN N
Personality NNP N
Disorders NNP N
Jelgersma NNP N
developed VBD N
an DT N
intensive JJ N
12-week JJ N
inpatient NN N
DBT NNP N
program NN N
that IN N
( ( N
i NN N
) ) N
rapidly RB N
reduces VBZ N
core NN N
borderline NN N
symptoms NNS N
like IN N
suicidal JJ N
behavior NN N
, , N
( ( N
ii NN N
) ) N
minimizes VBZ N
the DT N
negative JJ N
effects NNS N
of IN N
an DT N
inpatient NN N
setting NN N
, , N
and CC N
( ( N
iii NN N
) ) N
enhances VBZ N
compliance NN N
with IN N
outpatient JJ N
treatment NN N
. . N

We PRP N
evaluate VBP N
the DT N
( ( o
cost- NN o
) ) o
effectiveness NN o
of IN N
this DT N
experimental JJ N
program NN N
. . N

METHODS/DESIGN NNP N
Seventy NNP p
patients NNS p
, , p
aged VBD p
18 CD p
to TO p
45 CD p
years NNS p
with IN p
a DT p
primary JJ p
diagnosis NN p
of IN p
BPD NNP p
, , p
showing VBG p
a DT p
chronic JJ p
pattern NN p
of IN p
parasuicidal JJ p
gestures NNS p
and/or IN p
reporting VBG p
high JJ p
degrees NNS p
of IN p
severity NN p
of IN p
other JJ p
borderline NN p
symptoms NNS p
, , p
are VBP p
randomly RB p
allocated VBN p
to TO p
the DT p
control NN p
and CC p
intervention NN p
groups NNS p
. . p

Subjects NNS p
in IN p
the DT p
control NN p
group NN p
receive VBP p
standard JJ i
outpatient NN i
DBT NNP i
, , i
provided VBD p
in IN p
one CD p
of IN p
three CD p
regular JJ p
mental JJ p
health NN p
settings NNS p
in IN p
GGZ NNP p
Rivierduinen NNP p
. . p

Subjects NNS p
in IN p
the DT p
intervention NN p
group NN p
receive VBP i
12 CD i
weeks NNS i
of IN i
intensified JJ i
inpatient NN i
DBT NNP i
plus CC i
six CD i
months NNS i
of IN i
standard JJ i
DBT NNP i
, , i
provided VBN p
in IN p
the DT p
Center NNP p
for IN p
Personality NNP p
Disorders NNP p
Jelgersma NNP p
. . p

The DT N
primary JJ N
outcome NN N
is VBZ N
the DT o
number NN o
of IN o
suicide JJ o
attempts/self-harming JJ o
acts NNS o
. . o

Secondary JJ N
outcomes NNS N
are VBP o
severity NN o
of IN o
other JJ o
borderline NN o
complaints NNS o
, , o
quality NN o
of IN o
life NN o
, , o
general JJ o
psychopathological NN o
symptoms NNS o
and CC o
health NN o
care NN o
utilization NN o
and CC o
productivity NN o
costs NNS o
. . o

Data NNS N
are VBP N
gathered VBN N
using VBG N
a DT N
prospective JJ N
, , N
two CD N
( ( N
group NN N
: : N
intervention NN N
and CC N
control NN N
) ) N
by IN N
five CD N
( ( N
time NN N
of IN N
measurement NN N
) ) N
repeated VBD N
measures NNS N
factorial JJ N
design.Participants NNS N
will MD N
complete VB N
three-monthly JJ N
outcome NN N
assessments NNS N
in IN N
the DT N
course NN N
of IN N
therapy NN N
: : N
at IN N
baseline NN N
, , N
and CC N
12 CD N
, , N
24 CD N
, , N
36 CD N
and CC N
52 CD N
weeks NNS N
after IN N
the DT N
start NN N
of IN N
the DT N
treatment NN N
. . N

The DT N
period NN N
of IN N
recruitment NN N
started VBN N
in IN N
March NNP N
2012 CD N
and CC N
the DT N
study NN N
will MD N
end VB N
in IN N
December NNP N
2014 CD N
. . N

DISCUSSION NNP p
Highly NNP p
suicidal JJ p
outpatient NN p
patients NNS p
can MD p
pose VB N
a DT N
dilemma NN N
for IN N
mental JJ N
health NN N
care NN N
professionals NNS N
. . N

Although IN N
hospitalization NN N
seems VBZ N
inevitable JJ N
under IN N
some DT N
circumstances NNS N
, , N
it PRP N
has VBZ N
proven VBN N
to TO N
be VB N
harmful JJ N
in IN N
its PRP$ N
own JJ N
right NN N
. . N

This DT N
paper NN N
outlines VBZ N
the DT N
background NN N
and CC N
methods NNS N
of IN N
a DT N
randomized JJ N
trial NN N
evaluating VBG N
the DT N
possible JJ N
surplus NN N
value NN N
of IN N
a DT N
short-term JJ N
inpatient NN N
DBT NNP N
program NN N
. . N

-DOCSTART- -11246578- O O

Work-related JJ p
stress NN p
and CC p
early JJ p
atherosclerosis NN p
. . p

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
examine VB N
the DT N
link NN N
between IN N
work-related JJ N
stress NN N
and CC N
early JJ p
atherosclerosis NN p
as IN N
measured VBN N
by IN N
common JJ N
carotid JJ N
artery JJ N
intima-media JJ N
thickness NN N
and CC N
focal JJ N
lesions NNS N
in IN N
the DT N
common JJ N
carotid NN N
artery NN N
and CC N
bifurcation NN N
. . N

Four CD p
hundred VBD p
sixty-seven JJ p
members NNS p
of IN p
an DT p
occupational JJ p
cohort NN p
( ( p
total JJ p
N NNP p
= NNP p
573 CD p
) ) p
were VBD p
examined VBN p
via IN p
questionnaires NNS i
and CC i
B-mode NNP i
ultrasound NN i
. . i

We PRP N
used VBD N
multiple JJ N
linear JJ N
and CC N
logistic JJ N
models NNS N
to TO N
regress VB N
lesion NN N
risk NN N
and CC N
intima-media JJ N
thickness NN N
on IN N
work-related JJ o
stress NN o
scores NNS o
from IN N
a DT N
questionnaire NN N
administered VBN N
at IN N
an DT N
18-month JJ N
follow-up JJ N
examination NN N
. . N

In IN N
an DT N
age-adjusted JJ N
model NN N
, , N
the DT N
prevalence NN o
of IN o
carotid JJ o
lesions NNS o
among IN N
men NNS N
scoring VBG N
in IN N
the DT N
highest JJS N
stress NN N
quintile NN N
was VBD N
36 CD N
% NN N
compared VBN N
with IN N
21 CD N
% NN N
among IN N
men NNS N
in IN N
the DT N
lowest JJS N
quintile NN N
. . N

We PRP N
also RB N
observed VBD N
an DT N
increase NN N
in IN N
intima-media JJ o
thickness NN o
in IN N
the DT N
highest JJS N
quintile JJ N
relative NN N
to TO N
the DT N
lowest JJS N
( ( N
difference NN N
= RB N
0.048 CD N
+/- JJ N
0.025 CD N
mm NN N
) ) N
among IN N
men NNS N
. . N

Among IN N
women NNS p
, , p
stress NN o
was VBD N
not RB N
related VBN N
to TO N
the DT N
prevalence NN o
of IN o
lesions NNS o
or CC o
intima-media JJ o
thickness NN o
. . o

These DT N
findings NNS N
suggest VBP N
that IN N
men NNS p
with IN p
greater JJR p
work-related JJ o
stress NN o
are VBP N
at IN N
increased VBN N
risk NN N
for IN N
atherosclerotic JJ o
disease NN o
. . o

Women NNP N
in IN N
this DT N
age NN N
group NN N
may MD N
be VB N
protected VBN N
from IN N
such JJ N
effects NNS N
, , N
or CC N
current JJ N
work-place JJ N
questionnaires NNS N
may MD N
not RB N
accurately RB N
assess JJ N
stress NN N
in IN N
women NNS N
. . N

-DOCSTART- -18836092- O O

A DT N
multifactorial JJ N
strategy NN N
of IN N
pain NN N
management NN N
is VBZ N
associated VBN N
with IN N
less JJR N
pain NN N
in IN N
scheduled JJ p
vaccination NN p
of IN N
children NNS p
. . p

A DT N
study NN N
realized VBN N
by IN N
family NN N
practitioners NNS N
in IN p
239 CD p
children NNS p
aged VBN p
4-12 CD p
years NNS p
old JJ p
. . p

BACKGROUND NNP N
AND CC N
AIMS NNP N
The DT N
multiplicity NN N
of IN N
vaccine JJ N
injections NNS N
during IN N
childhood NN N
leads NNS N
to TO N
iterative VB N
painful JJ N
and CC N
stressful JJ N
experiences NNS N
which WDT N
may MD N
lead VB N
in IN N
turn NN N
to TO N
anticipated VBN N
pain NN N
and CC N
then RB N
possibly RB N
to TO N
a DT N
true JJ N
needle JJ N
phobia NN N
. . N

We PRP N
aimed VBD N
at IN N
evaluating VBG N
a DT N
multifactorial JJ N
strategy NN N
of IN N
pain NN N
management NN N
combining VBG N
pharmacological JJ N
and CC N
non-pharmacological JJ N
approaches NNS N
during IN N
vaccination NN N
, , N
as IN N
compared VBN N
to TO N
usual JJ N
care NN N
, , N
in IN p
4- JJ p
to TO p
12-year-old JJ p
children NNS p
. . p

METHODS NNP N
In IN N
all DT N
, , N
239 CD p
children NNS p
were VBD p
enrolled VBN p
by IN p
25 CD p
family NN p
practitioners NNS p
in IN N
an DT N
open-label JJ N
study NN N
. . N

After IN N
a DT N
pseudo-randomization NN N
, , N
usual JJ i
pain NN i
management NN i
( ( i
n JJ i
= NNP i
132 CD i
) ) i
was VBD i
compared VBN i
to TO i
a DT i
multifactorial JJ i
strategy NN i
( ( i
n JJ i
= NNP i
107 CD i
) ) i
associating VBG i
preliminary JJ i
application NN i
of IN i
an DT i
anesthesic JJ i
patch NN i
, , i
preferential JJ i
use NN i
of IN i
specified JJ i
vaccines NNS i
, , i
child JJ i
education NN i
by IN i
the DT i
parents NNS i
and CC i
the DT i
doctor NN i
, , i
parental JJ i
accompaniment NN i
and CC i
child JJ i
distraction NN i
with IN i
soap NN i
bubbles NNS i
during IN i
the DT i
procedure NN i
. . i

The DT N
primary JJ N
outcome NN N
( ( N
i.e JJ N
. . N

child VB o
pain NN o
) ) o
was VBD N
assessed VBN N
with IN N
a DT N
self-report JJ o
scale NN o
named VBN o
visual JJ o
analog NN o
scale NN o
( ( o
VAS NNP o
) ) o
of IN o
pain NN o
. . o

RESULTS VB N
A DT N
significant JJ N
decrease NN N
in IN N
pain NN o
was VBD N
obtained VBN N
using VBG N
the DT N
multifactorial JJ N
strategy NN N
, , N
as IN N
assessed VBN N
by IN N
self-reported JJ N
VAS NNP N
( ( N
P NNP N
< NNP N
0.0001 CD N
) ) N
. . N

This DT N
was VBD N
confirmed VBN N
by IN N
another DT N
self-report JJ N
scale NN N
( ( N
the DT N
facial NN o
pain NN o
scale NN o
revised VBN N
: : N
P NNP N
= NNP N
0.005 CD N
) ) N
, , N
as RB N
well RB N
as IN N
with IN N
hetero-evaluations NNS N
by IN N
GPs NNP N
and CC N
parents NNS N
[ VBP o
Children NNP o
's POS o
Hospital NNP o
of IN o
Eastern NNP o
Ontario NNP o
Pain NNP o
Scale NNP o
: : o
P NNP N
= VBZ N
0.0007 CD N
; : N
GPs NNP N
VAS NNP N
( ( N
P NNP N
< NNP N
0.0001 CD N
) ) N
, , N
parents NNS o
VAS NNP o
( ( N
P NNP N
< NNP N
0.0001 CD N
) ) N
] NN N
, , N
which WDT N
were VBD N
secondary JJ N
outcome NN N
criteria NNS N
. . N

CONCLUSIONS VB N
This DT N
multifactorial JJ N
method NN N
significantly RB N
decreases VBZ N
vaccination NN N
pain NN o
in IN N
4- JJ p
to TO p
12-year-old JJ p
children NNS p
. . p

This DT N
strategy NN N
could MD N
make VB N
vaccines NNS N
more RBR N
acceptable JJ N
to TO N
children NNS p
and CC N
may MD N
improve VB N
child-doctor NN N
relationships NNS N
and CC N
contribute NN N
to TO N
a DT N
decrease NN N
in IN N
child JJ N
fear VBP N
about IN N
health NN N
care NN N
. . N

-DOCSTART- -21047593- O O

Lead-time NN N
in IN N
the DT N
European NNP N
Randomised VBD N
Study NNP N
of IN N
Screening NNP N
for IN N
Prostate NNP p
Cancer NNP p
. . p

BACKGROUND NNP N
Lead-time NNP N
is VBZ N
defined VBN N
as IN N
the DT N
time NN N
by IN N
which WDT N
screening VBG N
advances VBZ N
the DT N
diagnosis NN N
compared VBN N
with IN N
absence NN N
of IN N
screening VBG N
. . N

A DT N
sufficiently RB N
long JJ N
lead-time JJ N
needs NNS N
to TO N
be VB N
achieved VBN N
so RB N
that IN N
cancer NN N
can MD N
be VB N
detected VBN N
while IN N
still RB N
curable JJ N
. . N

A DT N
very RB N
short JJ N
lead-time NN N
may MD N
indicate VB N
poor JJ N
sensitivity NN N
of IN N
the DT N
screening JJ N
test NN N
, , N
while IN N
a DT N
very RB N
long JJ N
lead-time JJ N
suggests NNS N
overdiagnosis NN N
. . N

MATERIAL NNP N
AND NNP N
METHODS NNP N
In IN N
the DT N
first JJ N
screening NN N
round NN N
, , N
a DT p
total NN p
of IN p
56,294 CD p
men NNS p
aged VBN p
55-74 CD p
years NNS p
were VBD p
screened VBN p
with IN p
serum NN i
prostate NN i
specific JJ i
antigen NN i
( ( i
PSA NNP i
) ) i
in IN p
five CD p
countries NNS p
of IN p
the DT p
European NNP p
Randomised VBD p
Study NNP p
of IN p
Screening NNP p
for IN p
Prostate NNP p
Cancer NNP p
( ( p
ERSPC NNP p
) ) p
with IN p
an DT p
overall JJ p
detection NN p
rate NN p
( ( p
prevalence NN p
) ) p
of IN p
2.8 CD p
% NN p
( ( p
1972 CD p
prostate NN p
cancers NNS p
) ) p
. . p

Prostate NNP p
cancer NN p
incidence NN p
among IN p
92,142 CD p
men NNS p
randomly RB p
allocated VBN p
to TO p
the DT p
control NN p
arm NN p
of IN p
the DT p
trial NN p
was VBD p
also RB p
assessed VBN p
. . p

Lead-time NNP o
was VBD N
estimated VBN N
as IN N
the DT N
time NN N
required VBN N
to TO N
accumulate VB N
a DT N
similar JJ N
cumulative JJ N
risk NN N
of IN N
prostate NN N
cancer NN N
in IN N
the DT N
control NN N
arm NN N
to TO N
the DT N
detection NN N
rate NN N
in IN N
the DT N
intervention NN N
arm NN N
, , N
i.e NN N
. . N

from IN N
the DT N
ratio NN N
of IN N
detection NN N
rate NN N
( ( N
prevalence NN N
of IN N
screen-detected JJ N
cases NNS N
) ) N
and CC N
expected VBN N
incidence NN N
( ( N
cumulative JJ N
risk NN N
) ) N
. . N

RESULTS NNP N
Using VBG N
a DT N
serum JJ N
PSA NNP N
cut-off NN N
of IN N
4 CD N
ng/ml NNS N
, , N
the DT N
mean JJ o
lead-time NN o
in IN N
the DT N
whole NN N
study NN N
population NN N
was VBD N
estimated VBN N
as IN N
6.8 CD N
years NNS N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
( ( N
95 CD N
% NN N
CI NNP N
) ) N
7.9-8.4 NN N
) ) N
. . N

It PRP N
was VBD N
8 CD N
years NNS N
in IN N
The DT N
Netherlands NNP p
, , N
6 CD N
in IN N
Sweden NNP p
and CC p
Finland NNP p
, , N
5 CD N
in IN N
Italy NNP p
and CC N
4 CD N
in IN N
Belgium NNP p
. . p

The DT N
mean JJ o
lead-time NN o
was VBD N
similar JJ N
, , N
6-7 JJ N
years NNS N
, , N
at IN N
ages NNS N
50-64 CD N
years NNS N
, , N
but CC N
close RB N
to TO N
8 CD N
years NNS N
among IN N
men NNS N
aged VBN N
65-74 CD N
years NNS N
. . N

A DT N
lower JJR N
PSA NNP o
cut-off JJ o
level NN o
of IN N
3 CD N
ng/ml NNS N
used VBN N
in IN N
Sweden NNP N
and CC N
The DT N
Netherlands NNP N
prolonged VBD N
the DT N
mean JJ N
lead-time JJ N
by IN N
approximately RB N
1 CD N
year NN N
. . N

Lead-time NNP o
based VBN o
on IN o
advanced JJ o
prostate NN o
cancer NN o
only RB N
was VBD N
slightly RB N
shorter JJR N
, , N
mean JJ N
5.3 CD N
years NNS N
( ( N
95 CD N
% NN N
CI NNP N
4.6-6.0 CD N
) ) N
. . N

The DT N
lead-time NN o
for IN o
the DT o
second JJ o
screening NN o
round NN o
was VBD N
slightly RB N
shorter JJR N
than IN N
that DT N
for IN N
the DT N
first JJ N
( ( N
5.9 CD N
, , N
95 CD N
% NN N
CI NNP N
5.4-6.4 CD N
) ) N
, , N
reflecting VBG N
a DT N
similar JJ N
relation NN N
between IN N
detection NN N
rate NN N
and CC N
control NN N
group NN N
incidence NN N
. . N

CONCLUSION VB N
The DT N
lead-time NN N
for IN N
prostate NN N
cancer NN N
found VBD N
in IN N
ERSPC NNP N
substantially RB N
exceeded VBD N
that IN N
found NN N
for IN N
breast NN N
, , N
cervical JJ N
and CC N
colorectal JJ N
cancer NN N
screening NN N
. . N

One CD N
round NN N
of IN N
prostate NN N
cancer NN N
screening VBG N
can MD N
advance VB N
clinical JJ N
diagnosis NN N
by IN N
4-8 JJ N
years NNS N
. . N

Overdiagnosis NN N
or CC N
detection NN N
of IN N
non-progressive JJ N
tumours NNS N
may MD N
contribute VB N
substantially RB N
to TO N
the DT N
lead-time NN o
. . o

-DOCSTART- -20157845- O O

Can MD N
incentives VB i
undermine JJ N
intrinsic JJ o
motivation NN o
to TO N
participate VB N
in IN N
epidemiologic JJ N
surveys NNS N
? . N
Response JJ N
rates NNS N
to TO N
surveys NNS N
are VBP N
decreasing VBG N
. . N

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
use NN i
of IN i
lottery JJ i
tickets NNS i
as IN i
incentives NNS i
in IN N
an DT N
epidemiologic JJ p
control NN p
group NN p
. . p

A DT N
self-administered JJ p
questionnaire NN p
was VBD p
sent VBN p
to TO p
parents NNS p
in IN p
the DT p
municipality NN p
of IN p
Stockholm NNP p
, , p
Sweden NNP p
, , p
who WP p
were VBD p
to TO p
be VB p
used VBN p
as IN p
a DT p
control NN p
group NN p
in IN p
a DT p
study NN p
addressing VBG p
stress NN p
in IN p
parents NNS p
of IN p
children NNS p
with IN p
cancer NN p
. . p

A DT N
stratified JJ N
random JJ N
sample NN N
of IN N
450 CD p
parents NNS p
were VBD N
randomized VBN N
into IN N
three CD i
incentive JJ i
groups NNS i
: : i
( ( i
a DT i
) ) i
no DT i
incentive NN i
; : i
( ( i
b NN i
) ) i
a DT i
promised JJ i
incentive NN i
of IN i
one CD i
lottery NN i
ticket NN i
to TO i
be VB i
received VBN i
upon IN i
reply NN i
; : i
( ( i
c NN i
) ) i
a DT i
promised JJ i
incentive NN i
of IN i
one CD i
lottery NN i
ticket NN i
to TO i
be VB i
received VBN i
upon IN i
reply NN i
and CC i
an DT i
additional JJ i
lottery NN i
ticket NN i
upon IN i
reply NN i
within IN i
1 CD i
week NN i
. . i

The DT N
overall JJ N
response NN o
rate NN o
across IN N
the DT N
three CD N
groups NNS N
was VBD N
65.3 CD N
% NN N
. . N

The DT N
response NN o
rate NN o
was VBD N
highest JJS N
in IN N
the DT N
no DT i
incentive NN i
group NN i
( ( N
69.3 CD N
% NN N
) ) N
and CC N
lowest JJS N
in IN N
the DT N
one CD i
plus CC i
one CD i
lottery NN i
ticket NN i
group NN i
( ( N
62.0 CD N
% NN N
) ) N
. . N

In IN N
a DT N
survival JJ o
analysis NN o
, , N
the DT N
difference NN N
between IN N
the DT N
two CD N
response NN N
curves NNS N
was VBD N
significant JJ N
by IN N
the DT N
log-rank JJ N
test NN N
( ( N
P NNP N
= NNP N
0.04 CD N
) ) N
, , N
with IN N
the DT N
no DT N
incentive NN N
group NN N
having VBG N
a DT N
shorter JJR N
time NN N
to TO N
response NN N
than IN N
the DT N
incentive NN i
group NN i
. . i

Our PRP$ N
findings NNS N
suggest VBP N
that IN N
the DT N
use NN N
of IN N
lottery JJ i
tickets NNS i
as IN N
incentives NNS N
to TO N
increase VB o
participation NN o
in IN N
a DT N
mail NN o
questionnaire NN o
among IN N
parents NNS N
may MD N
be VB N
less RBR N
valuable JJ N
or CC N
even RB N
harmful JJ N
. . N

Incentives NNS i
may MD N
undermine VB N
motivation NN o
in IN N
studies NNS N
in IN N
which WDT N
the DT N
intrinsic JJ N
motivation NN N
of IN N
the DT N
respondents NNS p
is VBZ N
already RB N
high JJ N
. . N

-DOCSTART- -12567169- O O

Topical JJ N
imiquimod NN i
5 CD i
% NN i
cream NN i
as IN N
an DT N
effective JJ N
treatment NN N
for IN N
external JJ p
genital NN o
and CC o
perianal JJ o
warts NNS p
in IN p
different JJ p
patient JJ p
populations NNS p
. . p

BACKGROUND NNP N
Genital NNP N
infection NN N
with IN N
human JJ N
papillomavirus NN N
, , N
the DT N
cause NN N
of IN N
genital JJ N
warts NNS N
, , N
is VBZ N
one CD N
of IN N
the DT N
most RBS N
common JJ N
sexually RB N
transmitted JJ N
diseases NNS N
. . N

GOAL VB N
The DT N
aim NN N
of IN N
this DT N
analysis NN N
was VBD N
to TO N
determine VB N
whether IN N
patients NNS p
' POS p
demographic JJ p
variables NNS p
affect VBP N
the DT N
efficacy NN N
of IN N
imiquimod JJ i
5 CD i
% NN i
cream NN i
versus NN N
vehicle NN i
cream NN i
for IN N
the DT N
treatment NN N
of IN N
external JJ p
genital NN p
and CC p
perianal JJ p
warts NNS p
. . p

STUDY NNP N
DESIGN NNP N
Male NNP p
and CC p
female JJ p
immunocompetent NN p
patients NNS p
applied VBD N
imiquimod JJ i
5 CD i
% NN i
cream NN i
topically RB i
to TO N
external JJ N
genital JJ N
warts NNS N
3 CD N
times NNS N
a DT N
week NN N
until IN N
wart JJ N
clearance NN N
or CC N
for IN N
up IN N
to TO N
16 CD N
weeks NNS N
. . N

RESULTS NNP N
As IN N
previously RB N
published VBN N
, , N
the DT N
intent-to-treat NN o
( ( o
ITT NNP o
) ) o
clearance NN o
rate NN o
was VBD N
50 CD N
% NN N
( ( N
54/109 CD N
) ) N
in IN N
the DT N
imiquimod-treated JJ i
group NN N
and CC N
11 CD N
% NN N
( ( N
11/100 CD N
) ) N
in IN N
the DT N
vehicle-treated JJ i
group NN N
( ( N
P NNP N
< NNP N
0.0001 CD N
) ) N
. . N

The DT N
ITT NNP o
clearance NN o
rate NN o
in IN N
the DT N
imiquimod-treated JJ i
group NN N
was VBD N
higher JJR N
in IN N
females NNS N
( ( N
72 CD N
% NN N
) ) N
than IN N
in IN N
males NNS N
( ( N
33 CD N
% NN N
) ) N
. . N

We PRP N
have VBP N
examined VBN N
the DT N
clearance NN N
rates NNS N
for IN N
subgroups NNS p
based VBN p
on IN p
variables NNS o
of IN o
gender NN o
, , o
baseline JJ o
wart NN o
area NN o
, , o
duration NN o
of IN o
current JJ o
outbreak NN o
of IN o
warts NNS o
, , o
previous JJ o
wart NN o
treatment NN o
, , o
and CC o
tobacco NN o
use NN o
. . o

For IN N
each DT N
of IN N
these DT N
subgroups NNS N
, , N
imiquimod NN i
was VBD N
statistically RB N
more RBR N
effective JJ o
than IN N
vehicle NN i
in IN N
eradicating VBG o
external JJ o
genital NN o
and CC o
perianal JJ o
warts NNS o
. . o

CONCLUSION NNP N
Imiquimod NNP o
5 CD i
% NN i
cream NN i
is VBZ N
an DT N
effective JJ N
treatment NN N
for IN N
external JJ o
genital NN o
and CC o
perianal JJ o
warts NNS o
and CC N
provides VBZ N
a DT N
significant JJ N
benefit NN N
in IN N
comparison NN N
with IN N
vehicle NN i
cream NN i
, , N
independent JJ N
of IN N
gender NN N
, , N
initial JJ N
wart NN N
size NN N
, , N
duration NN N
of IN N
current JJ N
outbreak NN N
of IN N
warts NNS N
, , N
previous JJ N
wart NN o
treatment NN o
, , o
or CC o
tobacco NN o
use NN o
. . o

-DOCSTART- -10665129- O O

Bronchodilatory JJ o
responses NNS o
to TO N
formoterol VB i
, , i
ipratropium NN i
, , i
and CC i
their PRP$ i
combination NN i
in IN N
patients NNS p
with IN p
stable JJ p
COPD NNP p
. . p

We PRP N
studied VBD N
27 CD p
patients NNS p
with IN p
stable JJ p
chronic JJ p
obstuctive JJ p
pulmonary JJ p
disease NN p
( ( p
COPD NNP p
) ) p
in IN N
a DT N
randomised JJ N
, , N
single-blind JJ N
, , N
within-patient JJ N
, , N
placebo-controlled JJ i
clinical JJ N
study NN N
. . N

Each DT N
patient NN N
was VBD N
assigned VBN N
on IN N
six CD N
separate JJ N
days NNS N
to TO N
receive VB N
one CD N
of IN N
the DT N
following JJ N
drug NN N
regimens NNS N
in IN N
random JJ N
order NN N
: : N
A DT N
. . N

40 CD N
micrograms JJ N
ipratropium NN i
bromide NN i
( ( i
Atrovent NNP i
MDI NNP i
, , i
20 CD i
micrograms/puff NN i
) ) i
plus CC i
2 CD i
puffs NNS i
placebo NN i
; : i
B NNP N
. . N

12 CD N
micrograms NNS N
formoterol JJ i
fumarate NN i
( ( i
Foradil NNP i
MDI NNP i
, , i
12 CD i
micrograms/puff NN i
) ) i
plus CC i
3 CD i
puffs NNS i
placebo VBP i
; : i
C. NNP N
80 CD i
micrograms NNS i
ipratropium NN i
; : i
D. NNP i
24 CD i
micrograms NNS i
formoterol JJ i
plus CC i
2 CD i
puffs NNS i
placebo VBP i
; : i
E. NNP i
12 CD i
micrograms NNS i
formoterol JJ i
plus CC i
40 CD i
micrograms NNS i
ipratropium JJ i
plus CC i
1 CD i
puff NN i
placebo NN i
; : i
F. NNP N
4 CD i
puffs NNS i
placebo NN i
. . i

On IN N
each DT N
study NN N
day NN N
, , N
spirometric JJ o
indices NNS o
and CC o
vital JJ o
signs NNS o
were VBD N
measured VBN N
at IN N
5 CD N
, , N
10 CD N
, , N
15 CD N
and CC N
60 CD N
minutes NNS N
, , N
and CC N
hourly RB N
thereafter RB N
up IN N
to TO N
and CC N
including VBG N
12 CD N
hours NNS N
after IN N
study JJ N
drug NN N
administration NN N
. . N

Mean NNP o
peak JJ o
FEV1 NNP o
change NN o
( ( N
primary JJ N
endpoint NN N
) ) N
was VBD N
maximum JJ N
with IN N
the DT N
administration NN N
of IN N
the DT N
combination NN N
of IN N
ipratropium NN i
and CC i
formoterol NN i
( ( N
335.2 CD N
ml NN N
, , N
SE NNP N
24.6 CD N
) ) N
, , N
and CC N
it PRP N
differed VBD N
significantly RB N
from IN N
the DT N
observed JJ N
peak NN N
changes NNS N
following VBG N
single JJ N
administration NN N
of IN N
the DT N
two CD N
tested VBD N
doses NNS N
of IN N
ipratropium NN i
( ( N
p JJ N
< NN N
0.05 CD N
and CC N
p VB N
< JJ N
0.05 CD N
respectively RB N
) ) N
. . N

Safety NN o
and CC o
tolerability NN o
were VBD N
satisfactory JJ N
throughout IN N
the DT N
study NN N
. . N

-DOCSTART- -22092038- O O

Activator NNP i
protein-1 NN i
( ( i
AP-1 NNP i
) ) i
signalling VBG N
in IN N
human JJ p
atherosclerosis NN p
: : p
results NNS N
of IN N
a DT N
systematic JJ N
evaluation NN N
and CC N
intervention NN N
study NN N
. . N

Animal NNP N
studies NNS N
implicate VBP N
the DT N
AP-1 NNP i
( ( i
activator IN i
protein-1 NN i
) ) i
pro-inflammatory NN N
pathway NN N
as IN N
a DT N
promising NN N
target NN N
in IN N
the DT N
treatment NN N
of IN N
atherosclerotic JJ p
disease NN p
. . p

It PRP N
is VBZ N
, , N
however RB N
, , N
unclear JJ N
whether IN N
these DT N
observations NNS N
apply VBP N
to TO N
human JJ p
atherosclerosis NN p
. . p

Therefore IN N
we PRP N
evaluated VBD N
the DT N
profile NN N
of IN N
AP-1 NNP i
activation NN i
through IN N
histological JJ N
analysis NN N
and CC N
tested VBD N
the DT N
potential JJ N
benefit NN N
of IN N
AP-1 NNP i
inhibition NN i
in IN N
a DT N
clinical JJ N
trial NN N
. . N

AP-1 JJ i
activation NN i
was VBD N
quantified VBN N
by IN N
phospho-c-Jun JJ N
nuclear JJ N
translocation NN N
( ( N
immunohistochemistry NN N
) ) N
on IN N
a DT N
biobank NN p
of IN p
aortic JJ p
wall NN p
samples NNS p
from IN p
organ JJ p
donors NNS p
. . p

The DT N
effect NN N
of IN N
AP-1 NNP o
inhibition NN o
on IN N
vascular JJ N
parameters NNS N
was VBD N
tested VBN N
through IN N
a DT N
double JJ N
blind JJ N
placebo-controlled JJ N
cross-over NN N
study NN N
of IN N
28 CD i
days NNS i
doxycycline NN i
or CC i
placebo NN i
in IN p
patients NNS p
with IN p
symptomatic JJ p
peripheral JJ p
artery NN p
disease NN p
. . p

Vascular JJ o
function NN o
was VBD N
assessed VBN N
by IN N
brachial JJ N
dilation NN N
as RB N
well RB N
as IN N
by IN N
plasma NN N
samples NNS N
analysed VBN N
for IN N
hs-CRP NN N
( ( N
high-sensitivity JJ N
C-reactive NNP N
protein NN N
) ) N
, , N
IL-6 NNP N
( ( N
interleukin-6 NN N
) ) N
, , N
IL-8 NNP N
, , N
ICAM-1 NNP N
( ( N
intercellular JJ N
adhesion NN N
molecule-1 NN N
) ) N
, , N
vWF FW N
( ( N
von FW N
Willebrand NNP N
factor NN N
) ) N
, , N
MCP-1 NNP N
( ( N
monocyte JJ N
chemoattractant NN N
protein-1 NN N
) ) N
, , N
PAI-1 NNP N
( ( N
plasminogen JJ N
activator NN N
inhibitor-1 NN N
) ) N
and CC N
fibrinogen NN N
. . N

Histological JJ N
evaluation NN N
of IN N
human JJ o
atherosclerosis NN o
showed VBD N
minimal JJ o
AP-1 NNP o
activation NN o
in IN N
non-diseased JJ N
arterial JJ N
wall NN N
( ( N
i.e JJ N
. . N

vessel NN N
wall NN N
without IN N
any DT N
signs NNS N
of IN N
atherosclerotic JJ N
disease NN N
) ) N
. . N

A DT N
gradual JJ N
increase NN N
of IN o
AP-1 NNP o
activation NN o
was VBD N
found VBN N
in IN N
non-progressive JJ N
and CC N
progressive JJ N
phases NNS N
of IN N
atherosclerosis NN N
respectively RB N
( ( N
P NNP N
< NNP N
0.044 CD N
) ) N
. . N

No DT N
significant JJ N
difference NN N
was VBD N
found VBN N
between IN N
progressive JJ N
and CC o
vulnerable JJ o
lesions NNS N
. . N

The DT o
expression NN o
of IN o
phospho-c-Jun JJ o
diminished VBN N
as IN N
the DT N
lesion NN N
stabilized VBN N
( ( N
P NNP N
< NNP N
0.016 CD N
) ) N
and CC N
does VBZ N
not RB N
significantly RB N
differ VBP N
from IN N
the DT N
normal JJ N
aortic JJ N
wall NN N
( ( N
P NNP N
< NNP N
0.33 CD N
) ) N
. . N

Evaluation NN N
of IN N
the DT i
doxycycline NN i
intervention NN i
only RB N
revealed VBD N
a DT N
borderline-significant JJ N
reduction NN N
of IN o
circulating VBG o
hs-CRP JJ o
levels NNS o
( ( N
-0.51 NNP N
?g/ml NNP N
, , N
P=0.05 NNP N
) ) N
and CC N
did VBD N
not RB N
affect VB N
any DT N
of IN N
the DT N
other JJ o
markers NNS o
of IN o
systemic JJ o
inflammation NN o
and CC o
vascular JJ o
function NN o
. . o

Our PRP$ N
studies NNS N
do VBP N
not RB N
characterize VB i
AP-1 NNP i
as IN i
a DT N
therapeutic JJ N
target NN N
for IN p
progressive JJ p
human JJ p
atherosclerotic JJ p
disease NN p
. . p

-DOCSTART- -25282520- O O

Inhibition NN N
of IN N
PCSK9 NNP N
with IN N
evolocumab NN i
in IN N
homozygous JJ p
familial JJ p
hypercholesterolaemia NN p
( ( N
TESLA NNP N
Part NNP N
B NNP N
) ) N
: : N
a DT N
randomised JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
trial NN N
. . N

BACKGROUND NNP N
Homozygous NNP p
familial JJ p
hypercholesterolaemia NN p
is VBZ N
a DT N
rare JJ N
, , N
serious JJ N
disorder NN N
caused VBN N
by IN N
very RB N
low JJ N
or CC N
absent JJ N
plasma JJ N
clearance NN N
of IN N
LDL NNP N
, , N
substantially RB N
raised VBN N
LDL NNP N
cholesterol NN N
, , N
and CC N
accelerated VBD o
development NN o
of IN o
cardiovascular JJ o
disease NN o
. . o

Conventional JJ N
lipid-lowering JJ N
treatments NNS N
are VBP N
modestly RB N
effective JJ N
. . N

Evolocumab NNP i
, , N
a DT N
monoclonal JJ i
antibody NN i
to TO N
proprotein VB i
convertase NN i
subtilisin/kexin NN i
type NN i
9 CD i
( ( N
PCSK9 NNP N
) ) N
, , N
reduced VBD N
LDL NNP o
cholesterol NN o
by IN N
16 CD N
% NN N
in IN N
a DT N
pilot NN N
study NN N
. . N

We PRP N
now RB N
report VBP N
results NNS N
with IN N
evolocumab NN i
in IN N
a DT N
randomised JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
phase NN N
3 CD N
trial NN N
. . N

METHODS NNP N
This DT N
randomised VBD N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
phase NN N
3 CD N
trial NN N
was VBD N
undertaken VBN N
at IN N
17 CD N
sites NNS N
in IN N
ten JJ p
countries NNS p
in IN p
North NNP p
America NNP p
, , p
Europe NNP p
, , p
the DT p
Middle NNP p
East NNP p
, , p
and CC p
South NNP p
Africa NNP p
. . p

50 CD p
eligible JJ p
patients NNS p
( ( p
aged VBN p
?12 CD p
years NNS p
) ) p
with IN p
homozygous JJ p
familial JJ p
hypercholesterolaemia NN p
, , p
on IN p
stable JJ i
lipid-regulating JJ i
therapy NN i
for IN i
at IN p
least JJS p
4 CD p
weeks NNS p
, , p
and CC p
not RB p
receiving VBG p
lipoprotein JJ p
apheresis NN p
, , p
were VBD p
randomly RB p
allocated VBN p
by IN p
a DT p
computer-generated JJ p
randomisation NN p
sequence NN p
in IN p
a DT p
2:1 CD p
ratio NN p
to TO p
receive VB i
subcutaneous JJ i
evolocumab NNS i
420 CD i
mg NN i
or CC i
placebo NN i
every DT i
4 CD p
weeks NNS p
for IN p
12 CD p
weeks NNS p
. . p

Randomisation NN N
was VBD N
stratified VBN N
by IN N
LDL NNP N
cholesterol NN N
at IN N
screening VBG N
( ( N
< JJ N
11 CD N
mmol/L NN N
or CC N
?11 VB N
mmol/L NN N
) ) N
and CC N
implemented VBN N
by IN N
a DT N
computerised JJ i
interactive JJ i
voice-response NN i
system NN i
. . i

Patients NNS i
, , p
study NN p
personnel NNS p
, , p
and CC p
the DT p
funder NN p
were VBD p
masked VBN p
to TO p
treatment NN p
and CC p
to TO p
the DT p
efficacy NN p
results NNS p
by IN p
the DT p
central JJ p
laboratory NN p
not RB p
returning VBG p
LDL NNP p
cholesterol NN p
or CC p
any DT p
lipid JJ p
results NNS p
to TO p
the DT p
clinical JJ p
sites NNS p
after IN p
the DT p
baseline NN p
visit NN p
. . p

The DT p
primary JJ N
endpoint NN N
was VBD N
percentage NN N
change NN o
in IN o
ultracentrifugation NN o
LDL NNP o
cholesterol NN o
from IN o
baseline NN N
at IN N
week NN N
12 CD N
compared VBN N
with IN N
placebo NN N
, , N
analysed VBN N
by IN N
intention-to-treat NN N
. . N

This DT N
trial NN N
is VBZ N
registered VBN N
with IN N
ClinicalTrials.gov NNP N
, , N
number NN N
NCT01588496 NNP N
. . N

FINDINGS NNP N
Of IN N
the DT N
50 CD p
eligible JJ p
patients NNS p
randomly RB p
assigned VBN p
to TO p
the DT p
two CD p
treatment NN p
groups NNS p
, , p
49 CD p
actually RB p
received VBD p
the DT p
study NN p
drug NN p
and CC p
completed VBD p
the DT p
study NN p
( ( p
16 CD p
in IN p
the DT p
placebo NN i
group NN i
and CC p
33 CD p
in IN p
the DT p
evolocumab NN i
group NN i
) ) p
. . p

Compared VBN p
with IN N
placebo NN i
, , i
evolocumab VBP i
significantly RB i
reduced VBN o
ultracentrifugation NN o
LDL NNP o
cholesterol NN o
at IN o
12 CD N
weeks NNS N
by IN N
30?9 CD N
% NN N
( ( N
95 CD N
% NN N
CI NNP N
-43?9 NNP N
% NN N
to TO N
-18?0 CD N
% NN N
; : N
p CC N
< VB N
0?0001 CD o
) ) o
. . o

Treatment-emergent JJ o
adverse JJ o
events NNS o
occurred VBD N
in IN N
ten NN N
( ( N
63 CD N
% NN N
) ) N
of IN N
16 CD N
patients NNS N
in IN i
the DT i
placebo NN i
group NN N
and CC N
12 CD N
( ( N
36 CD N
% NN N
) ) N
of IN N
33 CD N
in IN N
the DT i
evolocumab NN i
group NN i
. . i

No DT N
serious JJ N
clinical JJ N
or CC N
laboratory JJ N
adverse JJ N
events NNS N
occurred VBD N
, , N
and CC N
no DT N
anti-evolocumab JJ o
antibody NN o
development NN o
was VBD o
detected VBN o
during IN N
the DT N
study NN N
. . N

INTERPRETATION NNP p
In IN p
patients NNS p
with IN p
homozygous JJ p
familial JJ p
hypercholesterolaemia NN p
receiving VBG p
stable JJ N
background IN N
lipid-lowering JJ N
treatment NN N
and CC N
not RB N
on IN N
apheresis NN i
, , i
evolocumab VBZ i
420 CD i
mg NN i
administered VBN N
every DT N
4 CD N
weeks NNS N
was VBD N
well RB N
tolerated VBN o
and CC o
significantly RB o
reduced VBN N
LDL NNP o
cholesterol NN o
compared VBN o
with IN i
placebo NN i
. . N

FUNDING NNP N
Amgen NNP N
Inc NNP N
. . N

-DOCSTART- -341733- O O

The DT N
effect NN N
of IN N
metronidazole NN i
on IN N
the DT N
incidence NN o
of IN o
postoperative JJ o
wound NN o
infection NN o
in IN p
elective JJ p
colon NN p
surgery NN p
. . p

A DT N
prospective JJ N
randomized VBN N
clinical JJ N
trial NN N
assessing VBG N
the DT N
relative JJ N
effectiveness NN N
of IN N
erythromycin-neomycin JJ i
and CC i
metronidazole-neomycin JJ i
as IN N
a DT N
preoperative JJ N
bowel NN N
preparation NN N
was VBD N
carried VBN N
out RP N
. . N

Bacteriologic NNP N
studies NNS N
of IN N
feces NNS N
and CC N
colon NN N
content NN N
revealed VBD N
no DT N
significant JJ N
difference NN N
in IN N
the DT N
reduction NN o
of IN o
aerobic JJ o
bacteria NNS o
between IN N
the DT N
two CD N
groups NNS N
. . N

There EX N
was VBD N
, , N
however RB N
, , N
a DT N
significantly RB N
greater JJR N
reduction NN o
in IN N
anaerobic JJ o
bacteria NNS o
in IN N
the DT N
feces NNS N
and CC N
colon NN N
contents NNS N
of IN N
patients NNS N
receiving VBG N
metronidazole NN N
. . N

Wound IN o
infection NN o
rate NN o
was VBD N
25 CD N
% NN N
in IN N
the DT N
erythromycin NN N
group NN N
, , N
and CC N
organisms NNS N
recovered VBN N
from IN N
the DT N
wound NN N
in IN N
all DT N
cases NNS N
were VBD N
fecal JJ N
in IN N
nature NN N
. . N

Two CD N
wound IN o
infections NNS o
occurred VBD N
in IN N
the DT N
metronidazole NN N
group NN N
( ( N
5 CD N
% NN N
) ) N
and CC N
in IN N
both DT N
cases NNS N
the DT N
organisms NNS N
recovered VBN N
were VBD N
staphylococci NNS o
of IN o
presumed JJ o
skin JJ o
origin NN o
. . o

These DT N
studies NNS N
suggest VBP N
that IN N
anaerobic JJ N
bacteria NNS N
are VBP N
the DT N
major JJ N
contributors NNS N
to TO N
wound VB o
infection NN o
after IN N
colon NN N
surgery NN N
and CC N
that IN N
their PRP$ N
specific JJ N
reduction NN N
is VBZ N
associated VBN N
with IN N
a DT N
lower JJR N
incidence NN N
of IN N
wound JJ o
infection NN o
. . o

-DOCSTART- -17201540- O O

Unpacking VBG N
attitude JJ p
certainty NN p
: : p
attitude NN N
clarity NN N
and CC N
attitude NN N
correctness NN N
. . N

Attitude NNP p
certainty NN p
has VBZ N
been VBN N
the DT N
subject NN N
of IN N
considerable JJ N
attention NN N
in IN N
the DT N
attitudes NNS N
and CC N
persuasion NN N
literature NN N
. . N

The DT N
present JJ N
research NN N
identifies VBZ N
2 CD N
aspects NNS N
of IN N
attitude NN p
certainty NN p
and CC N
provides VBZ N
evidence NN N
for IN N
the DT N
distinctness NN N
of IN N
the DT N
constructs NNS N
. . N

Specifically RB N
, , N
it PRP N
is VBZ N
proposed VBN N
that IN N
attitude JJ N
certainty NN N
can MD N
be VB N
conceptualized VBN N
, , N
and CC N
empirically RB N
separated VBN N
, , N
in IN N
terms NNS N
of IN N
attitude NN N
clarity NN N
( ( N
the DT N
subjective NN N
sense NN N
that WDT N
one CD N
knows VBZ N
what WP N
one CD N
's POS N
attitude NN N
is VBZ N
) ) N
and CC N
attitude JJ N
correctness NN N
( ( N
the DT N
subjective NN N
sense NN N
that IN N
one CD N
's POS N
attitude NN N
is VBZ N
correct JJ N
or CC N
valid JJ N
) ) N
. . N

Experiment JJ N
1 CD N
uses NNS N
factor NN p
analysis NN p
and CC p
correlational JJ p
data NNS p
to TO N
provide VB N
evidence NN N
for IN N
viewing VBG N
attitude JJ o
clarity NN o
and CC N
attitude NN o
correctness NN o
as IN N
separate JJ N
constructs NNS N
. . N

Experiments NNS N
2 CD N
and CC N
3 CD N
demonstrate NN N
that WDT N
attitude VBP o
clarity NN o
and CC o
attitude NN o
correctness NN o
can MD o
have VB o
distinct JJ o
antecedents NNS o
( ( o
repeated VBN o
expression NN o
and CC o
consensus NN o
feedback NN o
, , o
respectively RB o
) ) o
. . o

Experiment JJ N
4 CD N
reveals NNS N
that IN N
these DT N
constructs NNS N
each DT N
play VBP o
an DT o
independent JJ o
role NN o
in IN o
persuasion NN o
and CC o
resistance NN o
situations NNS o
. . o

As IN N
clarity NN o
and CC o
correctness JJ o
increase NN o
, , o
attitudes VBZ o
become VBP o
more RBR o
resistant JJ o
to TO N
counterattitudinal JJ N
persuasive JJ N
messages NNS N
. . N

These DT N
findings NNS N
are VBP N
discussed VBN N
in IN N
relation NN N
to TO N
the DT N
existing VBG p
attitude NN p
strength NN p
literature NN N
. . N

-DOCSTART- -10811665- O O

Outcome NN N
of IN N
CNS NNP N
disease NN N
at IN N
diagnosis NN N
in IN N
disseminated JJ p
small JJ p
noncleaved-cell JJ p
lymphoma NN p
and CC p
B-cell NNP p
leukemia NN p
: : p
a DT N
Children NNP p
's POS p
Cancer NNP p
Group NNP p
study NN p
. . p

PURPOSE NNP N
To TO N
examine VB N
the DT N
impact NN N
of IN N
initial JJ N
CNS NNP N
involvement NN N
on IN N
outcome NN N
and CC N
patterns NNS N
of IN N
failure NN N
in IN N
patients NNS p
with IN p
disseminated JJ p
small JJ p
noncleaved-cell JJ p
lymphoma NN p
and CC p
B-cell NNP p
leukemia NN p
who WP p
were VBD p
treated VBN p
in IN p
four CD i
successive JJ i
Children NNP i
's POS i
Cancer NNP i
Group NNP i
trials NNS i
. . i

PATIENTS NNP N
AND CC N
METHODS NNP N
Of IN N
462 CD p
patients NNS p
with IN p
disseminated JJ p
disease NN p
, , p
49 CD p
( ( p
10.6 CD p
% NN p
) ) p
had VBD p
CNS NNP p
disease NN p
at IN p
diagnosis NN p
( ( p
CNS+ NNP p
) ) p
. . p

CNS NNP N
disease NN N
included VBD N
meningeal JJ N
disease NN N
or CC N
CNS NNP N
parenchymal JJ N
masses NNS N
with IN N
or CC N
without IN N
cranial JJ N
neuropathies NNS N
( ( N
CSF+/Mass NNP N
; : N
CNPs NNP N
) ) N
in IN N
36 CD N
patients NNS N
and CC N
isolated JJ N
CNPs NNP N
in IN N
13 CD N
. . N

Of IN p
the DT p
CNS+ NNP p
patients NNS p
, , p
28 CD p
had VBD p
M2 NNP p
( ( p
5 CD p
% NN p
to TO p
25 CD p
% NN p
blasts NNS p
) ) p
or CC p
M3 NNP p
( ( p
> VB p
25 CD p
% NN p
blasts NNS p
) ) p
bone NN p
marrow JJ p
involvement NN p
. . p

All DT p
patients NNS p
received VBD p
protocol-based JJ i
systemic JJ i
and CC i
intrathecal JJ i
chemotherapy NN i
. . i

Thirty-six JJ N
patients NNS N
also RB N
received VBD N
CNS NNP i
irradiation NN i
. . i

RESULTS NNP N
Relapses NNPS o
occurred VBD N
in IN N
21 CD N
( ( N
43 CD N
% NN N
) ) N
of IN N
49 CD N
patients NNS N
, , N
predominantly RB N
in IN N
the DT N
CNS NNP N
( ( N
71 CD N
% NN N
) ) N
and CC N
bone NN N
marrow NN N
( ( N
52 CD N
% NN N
) ) N
. . N

The DT N
3-year JJ o
event-free JJ o
survival NN o
+/- JJ N
SE NNP N
for IN N
all DT N
patients NNS N
with IN N
CNS+ NNP N
disease NN N
was VBD N
45 CD N
% NN N
+/- JJ N
7 CD N
% NN N
. . N

Patients NNS N
with IN N
CSF+/Mass NNP N
had VBD N
a DT N
nominally RB N
higher JJR o
treatment NN o
failure NN o
rate NN o
compared VBN N
with IN N
patients NNS N
with IN N
CNS- NNP N
after IN N
adjusting VBG N
for IN N
marrow NN N
status NN N
and CC N
lactate VB N
dehydrogenase NN N
( ( N
LDH NNP N
) ) N
diagnosis NN N
, , N
with IN N
a DT N
relative JJ o
failure NN o
rate NN o
( ( o
RFR NNP o
) ) o
of IN N
1.52 CD N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NNP N
, , N
0.88 CD N
to TO N
2.6 CD N
; : N
P NNP N
=.15 NNP N
) ) N
. . N

In IN N
comparison NN N
, , N
the DT N
RFRs NNP o
for IN N
patients NNS N
with IN N
M2 NNP N
or CC N
M3 NNP N
marrow NN N
and CC N
for IN N
those DT N
with IN N
LDH NNP N
levels NNS N
greater JJR N
than IN N
500 CD N
IU/L NNP N
after IN N
adjusting VBG N
for IN N
CNS NNP o
disease NN o
were VBD N
1.4 CD N
( ( N
95 CD N
% NN N
CI NNP N
, , N
0.96 CD N
to TO N
2.0 CD N
; : N
P NNP N
=.029 NNP N
) ) N
and CC N
2.2 CD N
( ( N
95 CD N
% NN N
CI NNP N
, , N
1.5 CD N
to TO N
3.0 CD N
; : N
P NNP N
< NNP N
.001 NNP N
) ) N
, , N
respectively RB N
. . N

The DT N
RFR NNP o
for IN N
patients NNS N
with IN N
isolated JJ o
CNPs NNP o
was VBD N
0.87 CD N
( ( N
95 CD N
% NN N
CI NNP N
, , N
0.36 CD N
to TO N
2.1 CD N
; : N
P NNP N
=.76 NNP N
) ) N
. . N

CONCLUSION NNP N
We PRP N
conclude VBP N
that IN N
, , N
with IN N
the DT N
treatments NNS N
used VBN N
during IN N
the DT N
period NN N
covered VBN N
by IN N
these DT N
studies NNS N
, , N
the DT N
presence NN N
of IN N
CSF+/Mass NNP N
CNS NNP N
disease NN N
at IN N
diagnosis NN N
was VBD N
associated VBN N
with IN N
a DT N
nominally RB o
worse JJR o
outcome JJ o
independent JJ N
of IN N
initial JJ N
bone NN N
marrow NN N
status NN N
and CC N
LDH NNP N
level NN N
, , N
but CC N
the DT N
effect NN N
was VBD N
not RB N
statistically RB N
significant JJ N
. . N

-DOCSTART- -16904970- O O

Patient-reported JJ N
outcomes NNS o
after IN N
inguinal JJ i
herniorrhaphy NN i
. . i

BACKGROUND NNP N
Patient-reported JJ N
outcomes NNS o
( ( N
PRO NNP N
) ) N
reflect VBP N
the DT N
functional JJ N
outcomes NNS N
of IN N
inguinal JJ i
herniorrhaphy NN i
. . i

We PRP N
studied VBD N
the DT N
effect NN N
of IN N
hernia NN p
recurrence NN p
and CC p
complications NNS p
on IN p
PRO NNP p
for IN p
participants NNS p
in IN p
the DT p
Veterans NNP p
Affairs NNPS p
trial NN p
of IN p
Open NNP p
or CC p
Laparoscopic NNP p
Repair NNP p
of IN p
Inguinal NNP p
Hernia NNP p
. . p

METHODS NNP N
Analyzed NNP N
PRO NNP N
included VBD N
( ( N
1 CD N
) ) N
the DT N
Medical NNP N
Outcomes NNP N
Study NNP N
Short NNP N
Form NNP N
36 CD N
, , N
version NN N
2 CD N
, , N
( ( N
2 CD N
) ) N
the DT N
Surgical NNP N
Pain NNP N
Scale NNP N
, , N
( ( N
3 CD N
) ) N
the DT N
Activities NNPS N
Assessment NNP N
Scale NNP N
, , N
and CC N
( ( N
4 CD N
) ) N
patient NN N
satisfaction NN N
. . N

Recurrences NNS N
and CC N
complications NNS N
were VBD N
recorded VBN N
at IN N
follow-up JJ N
visits NNS N
. . N

Complications NNS N
were VBD N
categorized VBN N
by IN N
( ( N
1 CD N
) ) N
hematoma/seroma NN o
, , N
( ( N
2 CD N
) ) N
orchitis NN o
, , N
( ( N
3 CD N
) ) N
neuralgia NN o
, , N
and CC N
( ( N
4 CD N
) ) N
other JJ N
. . N

Univariate NNP N
and CC N
multivariable JJ N
regression NN N
analyses NNS N
identified VBD N
variables NNS N
significantly RB N
associated VBN N
with IN N
postoperative JJ N
PRO NNP N
. . N

RESULTS NNP N
Of IN N
the DT N
1603 CD p
patients NNS p
with IN p
PRO NNP p
data NNS p
, , p
105 CD p
had VBD p
a DT p
recurrence NN o
and CC p
342 CD p
had VBD p
a DT p
complication NN p
at IN p
2 CD p
years NNS p
. . p

Multivariable JJ N
analyses NNS N
showed VBD N
neuralgia JJ o
( ( N
P NNP N
< NNP N
.0005 NNP N
) ) N
adversely RB N
affected VBD N
all DT N
PRO NNP N
, , N
and CC N
recurrence NN N
( ( N
P NNP N
< NNP N
.05 NNP N
) ) N
affected VBD N
patient-reported JJ o
pain NN o
, , o
activity NN o
, , o
and CC o
satisfaction NN o
, , N
but CC N
not RB N
the DT N
score NN N
for IN N
the DT N
Medical NNP o
Outcomes NNP o
Study NNP o
Short NNP o
Form NNP o
3 CD o
. . o

Patients NNS N
with IN N
a DT N
recurrence NN N
after IN N
open JJ N
repair NN N
had VBD N
more RBR N
pain NN o
than IN N
those DT N
with IN N
a DT N
recurrence NN N
after IN N
laparoscopic JJ N
repair NN N
( ( N
P NNP N
= NNP N
.0001 NNP N
) ) N
. . N

Patients NNS N
with IN N
other JJ N
complications NNS N
after IN N
laparoscopic NN N
repair NN N
reported VBD N
more JJR N
pain NN o
and CC o
less JJR o
activity NN o
than IN N
those DT N
with IN N
other JJ N
complications NNS N
after IN N
open JJ N
repair NN N
( ( N
P NNP N
= NNP N
.003 NNP N
and CC N
P NNP N
= NNP N
.009 NNP N
, , N
respectively RB N
) ) N
. . N

CONCLUSIONS VB N
The DT N
effectiveness NN N
of IN N
inguinal JJ N
herniorrhaphy NN N
should MD N
be VB N
measured VBN N
by IN N
the DT N
rate NN N
of IN N
recurrence NN o
and CC o
neuralgia NN o
. . o

Postoperative JJ N
neuralgias NNS N
have VBP N
a DT N
deleterious JJ N
effect NN N
on IN N
all DT N
patient-reported JJ N
outcomes NNS N
. . N

-DOCSTART- -17702798- O O

Multitomographic JJ N
evaluation NN N
of IN N
the DT N
dental JJ o
effects NNS o
of IN N
two CD N
different JJ N
rapid JJ i
palatal JJ i
expansion NN i
appliances NNS i
. . i

Rapid NNP i
palatal JJ i
expansion NN i
( ( i
RPE NNP i
) ) i
is VBZ N
widely RB N
used VBN N
in IN N
the DT N
treatment NN N
of IN N
transverse JJ p
maxillary JJ p
deficiencies NNS p
. . p

Generally RB N
, , N
there EX N
are VBP N
two CD N
types NNS N
of IN N
RPE NNP i
appliances NNS i
: : i
banded VBN i
and CC i
bonded VBN i
expanders NNS i
. . i

The DT N
purpose NN N
of IN N
this DT N
prospective JJ N
study NN N
was VBD N
to TO N
compare VB N
the DT N
dental JJ o
effects NNS o
of IN N
banded JJ i
and CC i
bonded VBD i
appliances NNS i
. . i

The DT N
study NN N
consisted VBD N
of IN N
23 CD p
patients NNS p
( ( p
13 CD p
females NNS p
and CC p
10 CD p
males NNS p
) ) p
with IN p
a DT p
bilateral JJ p
maxillary JJ p
deficiency NN p
. . p

Twelve CD p
patients NNS p
( ( p
seven CD p
females NNS p
and CC p
five CD p
males NNS p
) ) p
with IN p
a DT p
mean JJ p
age NN p
of IN p
14.8 CD p
+/- JJ p
0.3 CD p
years NNS p
were VBD N
treated VBN N
with IN N
banded JJ i
RPE NNP i
and CC N
11 CD p
patients NNS p
( ( p
six CD p
females NNS p
and CC p
five CD p
males NNS p
) ) p
with IN p
a DT p
mean JJ p
age NN p
of IN p
15.1 CD p
+/- JJ p
0.7 CD p
years NNS p
with IN N
bonded JJ i
RPE NNP i
. . i

Multitomographic NNP N
radiographs NN N
were VBD N
taken VBN N
before RB N
( ( N
T0 NNP N
) ) N
and CC N
at IN N
the DT N
end NN N
( ( N
T1 NNP N
) ) N
of IN N
expansion NN N
while IN N
the DT N
patients NNS N
were VBD N
wearing VBG N
an DT N
acrylic JJ N
mandibular JJ N
appliance NN N
in IN N
which WDT N
ball JJ N
bearings NNS N
and CC N
bars NNS N
were VBD N
embedded VBN N
. . N

Statistical JJ N
analyses NNS N
of IN N
the DT N
measurements NNS N
at IN N
T0 NNP N
and CC N
T1 NNP N
were VBD N
undertaken VBN N
with IN N
a DT N
paired JJ N
t-test NN N
, , N
and CC N
the DT N
difference NN N
between IN N
the DT N
groups NNS N
assesed VBD N
with IN N
a DT N
Student NN N
's POS N
t-test NN N
. . N

In IN N
both DT N
groups NNS N
, , N
the DT N
angle NN o
between IN o
the DT o
radiographic JJ o
image NN o
of IN o
the DT o
bar NN o
and CC o
the DT o
axial JJ o
inclination NN o
of IN o
the DT o
upper JJ o
first JJ o
premolar NN o
and CC o
molar JJ o
teeth NN o
was VBD N
( ( N
5.34 CD N
and CC N
2.73 CD N
degrees NNS N
for IN N
the DT N
right JJ N
premolars NNS N
, , N
5.17 CD N
and CC N
2.28 CD N
degrees NNS N
for IN N
the DT N
left NN N
premolars VBZ N
, , N
11.83 CD N
and CC N
3.73 CD N
degrees NNS N
for IN N
the DT N
right JJ N
molars NNS N
, , N
and CC N
9.75 CD N
and CC N
5.64 CD N
degrees NNS N
for IN N
the DT N
left JJ N
molars NNS N
in IN N
the DT N
banded JJ N
and CC N
bonded VBD N
groups NNS N
, , N
respectively RB N
. . N

The DT N
distance NN o
from IN o
the DT o
vestibular JJ o
cortical JJ o
plate NN o
to TO o
the DT o
palatal JJ o
root NN o
of IN o
these DT o
teeth NNS o
( ( N
1.17 CD N
and CC N
1.23 CD N
mm NN N
for IN N
the DT N
right JJ N
premolars NNS N
, , N
2.46 CD N
and CC N
1.09 CD N
mm NN N
for IN N
the DT N
left NN N
premolars VBZ N
, , N
2.75 CD N
and CC N
0.64 CD N
mm NN N
for IN N
the DT N
right JJ N
molars NNS N
, , N
2.23 CD N
and CC N
0.96 CD N
mm NN N
for IN N
the DT N
left JJ N
molars NNS N
in IN N
the DT N
banded JJ N
and CC N
bonded VBD N
groups NNS N
, , N
respectively RB N
) ) N
increased VBN N
( ( N
both DT N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

These DT N
increases NNS N
indicated VBD N
buccal JJ o
tipping NN o
of IN N
the DT N
teeth NNS N
. . N

Comparison NNP N
of IN N
the DT N
two CD N
groups NNS N
showed VBD N
that IN N
tipping NN o
of IN o
the DT o
first JJ o
molar NN o
and CC o
premolar JJ o
teeth NNS o
in IN N
the DT N
banded JJ N
group NN N
was VBD N
significantly RB N
more JJR N
than IN N
in IN N
the DT N
bonded VBN N
group NN N
( ( N
P NNP N
< NNP N
0.01 CD N
and CC N
P NNP N
< NNP N
0.001 CD N
, , N
respectively RB N
) ) N
. . N

-DOCSTART- -12629094- O O

Final NNP o
height NN o
in IN o
girls NNS o
with IN p
turner NN p
syndrome NN p
after IN N
long-term JJ N
growth NN i
hormone NN i
treatment NN i
in IN N
three CD N
dosages NNS N
and CC N
low JJ N
dose NN N
estrogens NNS i
. . i

Although IN N
GH NNP i
treatment NN i
for IN N
short JJ N
stature NN N
in IN N
Turner NNP N
syndrome NN N
is VBZ N
an DT N
accepted JJ N
treatment NN N
in IN N
many JJ N
countries NNS N
, , N
which WDT N
GH NNP N
dosage NN N
to TO N
use VB N
and CC N
which WDT N
age NN N
to TO N
start VB N
puberty JJ N
induction NN N
are VBP N
issues NNS N
of IN N
debate NN N
. . N

This DT N
study NN N
shows VBZ N
final JJ o
height NN o
( ( o
FH NNP o
) ) o
in IN N
60 CD p
girls NNS p
with IN p
Turner NNP p
syndrome NN p
treated VBD p
in IN p
a DT p
randomized JJ p
dose-response JJ p
trial NN p
, , N
combining VBG i
GH NNP i
treatment NN i
with IN i
low JJ i
dose NN i
estrogens NNS i
at IN N
a DT N
relatively RB N
young JJ N
age NN N
. . N

Girls NNP p
were VBD N
randomly RB N
assigned VBN N
to TO N
group NN N
A NNP N
( ( N
4 CD N
IU/m NNP N
( ( N
2 CD N
) ) N
.d NN N
; : N
approximately RB N
0.045 CD N
mg/kg/d NN N
) ) N
, , N
group NN N
B NNP N
( ( N
first JJ N
year NN N
, , N
4 CD N
IU/m NNP N
( ( N
2 CD N
) ) N
.d NN N
; : N
thereafter RB N
6 CD N
IU/m NNP N
( ( N
2 CD N
) ) N
.d NN N
) ) N
, , N
or CC N
group NN N
C NNP N
( ( N
first JJ N
year NN N
, , N
4 CD N
IU/m NNP N
( ( N
2 CD N
) ) N
.d NN N
; : N
second JJ N
year NN N
, , N
6 CD N
IU/m NNP N
( ( N
2 CD N
) ) N
.d NN N
; : N
thereafter RB N
, , N
8 CD N
IU/m NNP N
( ( N
2 CD N
) ) N
.d NN N
) ) N
. . N

After IN N
a DT N
minimum NN N
of IN N
4 CD N
yr NN N
of IN N
GH NNP i
treatment NN i
, , N
at IN N
a DT N
mean JJ N
age NN N
of IN N
12.7 CD N
+/- JJ N
0.7 CD N
yr NNS N
, , N
low JJ N
dose RB N
micronized VBN i
17beta-estradiol CD i
was VBD N
given VBN N
orally RB N
. . N

After IN N
a DT N
mean JJ N
duration NN o
of IN o
GH NNP o
treatment NN o
of IN N
8.6 CD N
+/- JJ N
1.9 CD N
yr NN N
, , N
FH NNP N
was VBD N
reached VBN N
at IN N
a DT N
mean JJ N
age NN N
of IN N
15.8 CD N
+/- JJ N
0.9 CD N
yr. NN N
FH NNP o
, , N
expressed VBD N
in IN N
centimeters NNS N
or CC N
SD NNP N
score NN N
, , N
was VBD N
157.6 CD N
+/- JJ N
6.5 CD N
or CC N
-1.6 VB N
+/- JJ N
1.0 CD N
in IN N
group NN N
A NNP N
, , N
162.9 CD N
+/- JJ N
6.1 CD N
or CC N
-0.7 VB N
+/- JJ N
1.0 CD N
in IN N
group NN N
B NNP N
, , N
and CC N
163.6 CD N
+/- JJ N
6.0 CD N
or CC N
-0.6 VB N
+/- JJ N
1.0 CD N
in IN N
group NN N
C. NNP N
The DT N
difference NN N
in IN N
FH NNP o
in IN o
centimeters NNS o
, , N
corrected VBN N
for IN N
height NN N
SD NNP N
score NN N
and CC N
age NN N
at IN N
start NN N
of IN N
treatment NN N
, , N
was VBD N
significant JJ N
between IN N
groups NNS N
A NNP N
and CC N
B NNP N
[ NNP N
regression NN N
coefficient NN N
, , N
4.1 CD N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
( ( N
CI NNP N
) ) N
, , N
1.4 CD N
, , N
6.9 CD N
; : N
P NNP N
< VBD N
0.01 CD N
] NN N
, , N
and CC N
groups NNS N
A NNP N
and CC N
C NNP N
( ( N
coefficient NN N
, , N
5.0 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
2.3 CD N
, , N
7.7 CD N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
but CC N
not RB N
between IN N
groups NNS N
B NNP N
and CC N
C NNP N
( ( N
coefficient NN N
, , N
0.9 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
-1.8 NNP N
, , N
3.6 CD N
) ) N
. . N

Fifty NNP p
of IN p
the DT p
60 CD p
girls NNS p
( ( p
83 CD p
% NN p
) ) p
had VBD p
reached VBN p
a DT p
normal JJ o
FH NNP o
( ( p
FH NNP p
SD NNP p
score NN p
, , p
more JJR p
than IN p
-2 NN p
) ) p
. . N

After IN N
starting VBG N
estrogen NN i
treatment NN N
, , N
the DT N
decrease NN o
in IN o
height JJ o
velocity NN o
( ( o
HV NNP o
) ) o
changed VBD o
significantly RB o
to TO o
a DT o
stable JJ o
HV NNP o
, , N
without IN N
affecting VBG N
bone NN o
maturation NN o
( ( N
change NN N
in IN N
bone NN N
age/change NN N
in IN N
chronological JJ N
age NN N
) ) N
. . N

The DT N
following JJ N
variables NNS N
contributed VBD N
significantly RB N
to TO N
predicting VBG N
FH NNP o
SD NNP o
score NN o
: : o
GH NNP o
dose NN o
, , o
height VBD o
SD NNP o
score NN o
( ( N
ref JJ N
. . N

normal JJ N
girls NNS N
) ) N
, , N
chronological JJ o
age NN o
at IN o
start NN o
of IN o
treatment NN o
, , N
and CC N
HV NNP o
in IN N
the DT N
first JJ N
year NN N
of IN N
GH NNP N
treatment NN N
. . N

GH NNP i
treatment NN N
was VBD N
well RB o
tolerated VBN o
. . o

In IN N
conclusion NN N
, , N
GH NNP i
treatment NN N
leads VBZ N
to TO N
a DT N
normalization NN N
of IN N
FH NNP o
in IN N
most JJS N
girls NNS N
, , N
even RB N
when WRB N
puberty NN N
is VBZ N
induced VBN N
at IN N
a DT N
normal JJ N
pubertal JJ N
age NN N
. . N

The DT N
optimal JJ N
GH NNP i
dosage NN N
depends VBZ N
on IN N
height NN N
and CC N
age NN N
at IN N
the DT N
start NN N
of IN N
treatment NN N
and CC N
first JJ N
year NN N
HV NNP N
. . N

-DOCSTART- -26527417- O O

The DT N
ileal NN i
bile NN i
acid NN i
transporter NN i
inhibitor NN i
A4250 NNP i
decreases VBZ N
serum NN o
bile NN o
acids NNS o
by IN N
interrupting VBG N
the DT N
enterohepatic JJ N
circulation NN N
. . N

BACKGROUND NNP N
Reabsorption NNP N
of IN N
bile JJ N
acids NNS N
from IN N
the DT N
intestine NN N
by IN N
ileal NN N
bile NN N
acid NN N
transporter NN N
is VBZ N
pivotal JJ N
for IN N
the DT N
enterohepatic JJ N
circulation NN N
of IN N
BAs NNP N
and CC N
sterol JJ N
homoeostasis NN N
. . N

AIM NNP N
To TO N
assess VB N
tolerability NN o
and CC N
study NN N
, , N
bile JJ o
acid NN o
metabolism NN o
in IN N
a DT N
phase NN N
1 CD N
trial NN N
with IN N
the DT N
selective JJ N
ileal NN N
bile IN N
acid NN N
transporter NN N
inhibitor NN N
A4250 NNP N
. . N

METHODS NNP N
A DT N
randomised JJ N
double-blind NN N
, , N
single-ascending JJ N
dose NN N
( ( N
SAD NNP N
) ) N
and CC N
multiple-ascending-dose JJ N
study NN N
consisting VBG N
of IN N
five CD p
cohorts NNS p
comprising VBG p
40 CD p
individuals NNS p
with IN p
a DT p
single JJ p
administration NN p
of IN p
A4250 NNP i
( ( N
0.1 CD N
, , N
0.3 CD N
, , N
1 CD N
, , N
3 CD N
, , N
or CC N
10 CD N
mg NN N
) ) N
or CC i
placebo NN i
and CC p
three CD p
cohorts NNS p
comprising VBG p
24 CD p
individuals NNS p
with IN p
a DT p
1-week JJ p
administration NN p
of IN i
A4250 NNP i
( ( N
1 CD N
or CC N
3 CD N
mg NNS N
once RB N
daily RB N
or CC N
1.5 CD N
mg JJ N
twice RB N
daily RB N
) ) N
or CC N
placebo NN i
. . i

For IN i
the DT N
multiple-ascending-dose JJ N
study NN o
, , o
bile JJ o
acids NNS o
were VBD o
measured VBN N
by IN N
HPLC-MS NNP o
in IN o
plasma NN o
and CC o
faeces NNS o
, , o
and CC o
fibroblast JJ o
growth NN o
factor NN o
19 CD o
( ( o
FGF19 NNP o
) ) o
and CC o
7?-hydroxy-4-cholesten-3-one CD o
( ( o
C4 NNP o
) ) o
were VBD o
measured VBN N
in IN N
plasma NN N
. . N

RESULTS NNP o
No NNP o
serious JJ o
adverse JJ o
events NNS o
occurred VBD o
and CC N
all DT N
participants NNS N
finished VBD N
the DT N
trial NN N
per IN N
protocol NN N
. . N

At IN N
the DT N
end NN N
of IN N
the DT N
multiple-ascending-dose JJ N
study NN o
, , o
plasma JJ o
total NN o
bile JJ o
acids NNS o
and CC o
FGF19 NNP o
decreased VBN o
by IN N
47 CD N
% NN N
and CC N
76 CD N
% NN N
, , N
respectively RB N
, , N
at IN N
3 CD N
mg/day NN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
, , N
and CC N
by IN N
15 CD N
% NN N
and CC N
16 CD N
% NN N
, , N
respectively RB N
, , N
at IN N
1.5 CD N
mg JJ N
twice RB N
daily RB N
( ( N
P NNP N
< NNP N
0.05 CD o
) ) o
. . o

Plasma NNP o
C4 NNP o
and CC o
faecal JJ o
bile NN o
acids NNS o
increased VBD o
at IN N
all DT N
dose JJ N
regimens NNS N
, , N
by IN N
555 CD N
% NN N
, , N
664 CD N
% NN N
, , N
292 CD N
% NN N
and CC N
338 CD N
% NN N
, , N
421 CD N
% NN N
, , N
420 CD N
% NN N
, , N
respectively RB N
( ( N
P NNP N
< NNP N
0.01-0.05 NN N
) ) N
. . N

The DT N
primary JJ N
bile NN N
acids NNS N
cholic NN N
and CC N
chenodeoxycholic JJ N
acids NNS N
constituted VBD N
the DT N
majority NN N
of IN N
faecal JJ o
bile NN o
acids NNS o
in IN N
the DT N
A4250-treated JJ N
groups NNS N
. . N

CONCLUSIONS NNP N
A4250 NNP i
is VBZ i
well RB i
tolerated VBN N
. . N

By IN N
blocking VBG N
ileal NN i
bile NN i
acid NN i
transporter NN i
in IN N
the DT N
terminal NN N
ileum NN N
, , N
it PRP N
highly RB N
efficiently RB N
interrupts VBZ N
the DT o
enterohepatic JJ o
circulation NN o
of IN o
BAs NNP o
, , o
and CC o
should MD N
be VB N
of IN N
benefit NN N
to TO p
patients NNS p
with IN p
cholestatic JJ p
liver NN p
diseases NNS p
. . p

Clinical JJ p
Trial NNP N
registration NN N
EudraCT NNP N
2013-001175-21 CD N
. . N

-DOCSTART- -3998250- O O

Psychophysiological JJ o
outcome NN N
of IN N
behavioral JJ i
and CC i
pharmacological JJ i
treatments NNS i
of IN i
agoraphobia NN i
. . i

-DOCSTART- -25246602- O O

Fluticasone CD i
or CC N
montelukast VB i
in IN N
preschool NN p
wheeze NN p
: : p
a DT N
randomized NN N
controlled VBN N
trial NN N
. . N

INTRODUCTION NNP N
Approximately RB N
30 CD N
% NN N
of IN N
children NNS p
younger JJR p
than IN p
3 CD p
years NNS p
experience RB N
at IN N
least JJS N
1 CD N
episode NN N
of IN N
wheezing VBG N
. . N

Antiasthmatic JJ i
medication NN i
is VBZ N
routinely RB N
prescribed JJ N
, , N
but CC N
its PRP$ N
effectiveness NN N
remains VBZ N
unclear JJ N
. . N

Our PRP$ N
study NN N
was VBD N
aimed VBN N
to TO N
evaluate VB N
the DT N
effect NN N
of IN N
anti-inflammatory JJ i
treatment NN i
on IN N
frequency NN N
and CC N
severity NN N
of IN N
preschool NN o
wheeze NN o
episodes NNS o
( ( o
PWEs NNP o
) ) o
. . o

METHODS NNP N
Children NNP p
aged VBD p
6 CD p
to TO p
36 CD p
months NNS p
with IN p
the DT p
first JJ p
up RB p
to TO p
the DT p
third JJ p
PWE NNP p
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
montelukast NN i
, , i
fluticasone NN i
, , i
or CC i
no DT i
treatment NN i
for IN i
12 CD i
weeks NNS i
. . i

The DT N
outcome NN N
measures NNS N
were VBD N
the DT N
number NN o
of IN o
PWEs NNP o
, , o
the DT o
number NN o
of IN o
hospitalizations NNS o
due JJ o
to TO o
PWE NNP o
, , o
and CC o
the DT o
severity NN o
of IN o
respiratory NN o
symptoms NNS o
. . o

results NNS N
: : N
There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
outcome JJ N
measures NNS N
between IN N
the DT N
groups NNS N
. . N

However RB N
, , N
tobacco-exposed JJ N
children NNS N
treated VBN N
with IN N
fluticasone NN i
had VBD N
significantly RB N
fewer JJR N
PWEs NNP o
( ( N
P NNP N
= NNP N
.01 NNP N
) ) N
. . N

CONCLUSION NNP N
Neither NNP N
montelukast NN i
nor CC N
fluticasone NN i
has VBZ N
proven VBN N
effective JJ N
in IN N
the DT N
prevention NN N
of IN N
PWE NNP o
recurrence NN o
. . o

Children NNP p
of IN p
smoking VBG p
parents NNS p
may MD N
benefit VB N
from IN N
fluticasone NN i
treatment NN N
after IN N
PWE NNP N
. . N

This DT N
observation NN N
requires VBZ N
confirmation NN N
in IN N
larger JJR N
studies NNS N
. . N

-DOCSTART- -12233987- O O

Multimodal NNP N
evaluation NN N
of IN N
risperidone NN i
for IN N
destructive JJ N
behavior NN N
: : N
functional JJ o
analysis NN o
, , o
direct JJ o
observations NNS o
, , o
rating NN o
scales NNS o
, , o
and CC o
psychiatric JJ o
impressions NNS o
. . o

Risperidone NNP i
, , N
an DT N
atypical JJ N
neuroleptic NN N
, , N
has VBZ N
become VBN N
a DT N
popular JJ N
option NN N
for IN N
treating VBG N
destructive JJ N
behaviors NNS N
of IN N
persons NNS p
with IN p
developmental JJ p
disabilities NNS p
. . p

A DT N
few JJ N
studies NNS N
have VBP N
been VBN N
conducted VBN N
that IN N
evaluate VBP N
the DT N
effects NNS N
of IN N
risperidone NN i
on IN N
destructive JJ N
behavior NN N
; : N
however RB N
, , N
none NN N
of IN N
these DT N
studies NNS N
have VBP N
combined VBN N
objective JJ N
measures NNS N
with IN N
rating NN N
scales NNS N
to TO N
evaluate VB N
the DT N
effects NNS N
of IN N
risperidone NN i
on IN N
destructive JJ N
behavior NN N
across IN N
home NN N
and CC N
clinical JJ N
settings NNS N
. . N

This DT N
study NN N
evaluated VBD N
the DT N
wide JJ N
range NN N
of IN N
effects NNS N
of IN N
risperidone NN i
on IN N
destructive JJ N
behavior NN N
of IN N
2 CD p
persons NNS p
with IN p
developmental JJ p
disabilities NNS p
using VBG N
weekly JJ N
functional JJ o
analysis NN o
sessions NNS o
, , o
daily JJ o
observations NNS o
, , o
hourly RB o
home NN o
data NNS o
, , o
weekly JJ o
rating NN o
scales NNS o
, , o
and CC o
monthly JJ o
psychiatric JJ o
impressions NNS o
. . o

Results NNS N
indicate VBP N
that IN N
risperidone NN N
does VBZ N
decrease VB N
destructive JJ o
behavior NN o
and CC N
that IN N
, , N
for IN N
the DT N
most JJS N
part NN N
, , N
all DT N
of IN N
the DT N
various JJ N
measures NNS N
yielded VBD N
similar JJ N
results NNS N
. . N

-DOCSTART- -20084587- O O

[ JJ N
Evaluation NNP N
of IN N
Stepping NNP N
Stones NNP N
Triple NNP N
P NNP N
: : N
Interims NNP N
analysis NN N
of IN N
the DT N
Stepping-Stones-SPC-Multicentric NNP N
Study NNP N
] NNP N
. . N

Stepping VBG i
Stones JJ i
Triple NNP i
P NNP i
is VBZ N
a DT N
behavioural JJ N
parenting NN N
training NN N
for IN N
families NNS p
with IN p
a DT p
handicapped JJ p
child NN p
, , p
which WDT p
has VBZ p
already RB p
been VBN p
successfully RB p
evaluated VBN p
in IN p
its PRP$ p
country NN p
of IN p
origin NN p
, , p
Australia NNP p
. . p

Within IN N
a DT N
multicentric JJ N
study NN N
of IN N
several JJ p
Social NNP p
Pediatric NNP p
Centers NNP p
( ( p
SPCs NNP p
) ) p
and CC p
further JJ p
clinics/institutions NNS p
in IN p
Germany NNP p
, , N
it PRP N
has VBZ N
been VBN N
established VBN N
as IN N
a DT N
group NN i
parenting VBG i
training NN i
( ( p
3-7 JJ p
families NNS p
per IN p
training NN p
) ) p
. . N

Statistical JJ N
analysis NN N
proved VBD N
significant JJ N
effects NNS o
concerning VBG N
dysfunctional JJ o
parenting NN o
, , o
parental JJ o
stress NN o
and CC o
child VB o
behaviour NN o
problems NNS o
as RB N
well RB N
as IN N
little JJ o
side NN o
effects NNS o
and CC N
a DT N
positive JJ o
acceptance NN o
of IN N
stepping VBG N
stones NNS N
by IN N
the DT N
families NNS N
. . N

-DOCSTART- -22782459- O O

Celecoxib NNP i
as IN N
adjunctive JJ N
treatment NN N
to TO N
risperidone VB i
in IN N
children NNS p
with IN p
autistic JJ p
disorder NN p
: : p
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
trial NN N
. . N

RATIONAL JJ N
Autism NNP N
is VBZ N
associated VBN N
with IN N
activation NN N
of IN N
the DT N
inflammatory NN N
response NN N
system NN N
. . N

OBJECTIVE VB N
This DT N
study NN N
aims VBZ N
to TO N
assess VB N
the DT N
efficacy NN o
of IN N
a DT N
cyclooxygenase-2 JJ i
inhibitor NN i
, , i
celecoxib NN i
, , N
as IN N
adjunctive JJ N
therapy NN N
in IN N
the DT N
treatment NN N
of IN N
autism NN N
METHODS NNP N
In IN N
a DT N
10-week JJ N
randomized JJ N
double-blind JJ N
placebo-controlled JJ N
study NN N
, , N
40 CD p
outpatient JJ p
children NNS p
with IN p
a DT p
Diagnostic NNP p
and CC p
Statistical NNP p
Manual NNP p
of IN p
Mental NNP p
Disorders NNP p
, , p
fourth JJ p
edition NN p
, , p
text JJ p
revision NN p
clinical JJ p
diagnosis NN p
of IN p
autism NN p
were VBD N
randomly RB N
allocated VBN N
to TO N
celecoxib VB i
plus CC i
risperidone VB i
or CC i
placebo VB i
plus CC i
risperidone VB i
. . i

The DT N
dose NN N
of IN N
risperidone NN i
and CC N
celecoxib NN i
were VBD N
titrated VBN N
up RB N
to TO N
3 CD N
and CC N
300 CD N
mg/day NN N
, , N
respectively RB N
. . N

Patients NNS N
were VBD N
assessed VBN N
at IN N
baseline NN N
and CC N
after IN N
2 CD N
, , N
4 CD N
, , N
6 CD N
, , N
and CC N
10 CD N
weeks NNS N
of IN N
starting VBG N
medication NN N
using VBG N
the DT N
Aberrant NNP o
Behavior NNP o
Checklist-Community NNP o
( ( o
ABC-C NNP o
) ) o
Rating VBG o
Scale NNP o
. . o

Primary NNP N
outcome JJ N
measure NN N
was VBD N
the DT N
change NN o
in IN o
irritability NN o
subscale NN o
of IN o
ABC-C NNP o
. . o

RESULTS NNP N
Significant JJ N
time NN N
? . N
treatment NN N
interaction NN N
was VBD N
observed VBN o
for IN o
Irritability NNP o
( ( o
F NNP o
( ( o
1.658 CD N
, , N
63.021 CD N
) ) N
= NN N
13.580 CD N
, , N
P NNP N
< NNP N
0.001 CD N
) ) o
, , o
Lethargy/Social NNP o
Withdrawal NNP o
( ( o
F NNP N
( ( N
1.948 CD N
, , N
74.032 CD N
) ) N
= NN N
16.811 CD N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
and CC N
Stereotypic NNP o
Behavior NNP o
( ( N
F NNP N
( ( N
1.742 CD N
, , N
66.198 CD N
) ) N
= NN N
12.104 CD N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
but CC N
not RB N
for IN N
Hyperactivity/Noncompliance NNP o
( ( N
F NNP N
( ( N
2.564 CD N
, , N
97.424 CD N
) ) N
= NN N
1.469 CD N
, , N
P NNP N
= NNP N
0.232 CD N
) ) N
, , N
and CC o
Inappropriate NNP o
Speech NNP o
subscales NNS o
( ( N
F NNP N
( ( N
1.607 CD N
, , N
61.075 CD N
) ) N
= NN N
0.173 CD N
, , N
P NNP N
= NNP N
0.794 CD N
) ) N
. . N

By IN N
week NN N
10 CD N
, , N
patients NNS N
in IN N
the DT N
celecoxib NN i
group NN i
showed VBD N
significantly RB N
greater JJR N
improvement NN N
in IN N
the DT o
Irritability NNP o
( ( o
P NNP o
< NNP o
0.001 CD N
) ) N
, , N
Lethargy/Social NNP o
Withdrawal NNP o
( ( o
P NNP o
< NNP o
0.001 CD o
) ) o
, , o
and CC o
Stereotypic NNP o
Behavior NNP o
( ( N
P NNP N
< NNP N
0.00 CD N
) ) N
but CC o
not RB o
in IN o
Hyperactivity/Noncompliance NNP o
( ( o
P NNP o
= NNP o
0.202 CD o
) ) o
and CC o
Inappropriate NNP o
Speech NNP o
( ( o
P NNP o
= NNP o
0.802 CD o
) ) o
subscales NNS o
than IN i
the DT i
placebo NN i
group NN o
. . o

Complete JJ o
response NN o
was VBD o
achieved VBN o
by IN N
four CD N
( ( N
20 CD N
% NN N
) ) N
patients NNS N
in IN N
the DT i
placebo NN i
group NN i
and CC N
11 CD N
( ( N
55 CD N
% NN N
) ) N
patients NNS N
in IN N
the DT N
celecoxib NN N
group NN N
( ( N
? . N
( ( N
2 CD N
) ) N
( ( N
1 CD N
) ) N
= NN N
5.227 CD N
, , N
P NNP N
= NNP N
0.022 CD N
) ) N
. . N

Frequency NN N
of IN N
side NN o
effects NNS o
was VBD N
similar JJ N
between IN N
the DT N
two CD N
groups NNS N
. . N

CONCLUSIONS NNP N
Combination NNP N
of IN i
risperidone NN i
and CC i
celecoxib NN i
was VBD i
superior JJ N
to TO N
risperidone VB N
alone RB N
in IN N
treating VBG N
irritability NN o
, , o
social JJ o
withdrawal NN o
, , o
and CC o
stereotypy NN o
of IN o
children NNS o
with IN p
autism NN p
. . p

( ( N
Registration NNP N
, , N
www.irct.ir NN N
; : N
IRCT138711091556N2 NNP N
) ) N
. . N

-DOCSTART- -396063- O O

Haemodynamic NNP N
profile NN N
of IN N
angiotensin NN i
II NNP i
antagonism NN i
in IN N
essential JJ p
hypertensive JJ p
patients NNS p
. . p

1 CD N
. . N

The DT N
haemodynamic JJ N
response NN N
to TO N
antagonistic JJ i
( ( N
10 CD N
microgram RB N
min-1 JJ N
kg-1 NN N
) ) N
and CC N
agonistic JJ i
( ( N
40 CD N
microgram RB N
min-1 JJ N
kg-1 NN N
) ) N
doses VBZ N
of IN N
saralasin NN i
was VBD N
studied VBN N
in IN N
young JJ p
essential JJ p
hypertensive JJ p
patients NNS p
. . p

Blood NNP o
pressure NN o
behaviour NN o
alone RB N
was VBD N
thought VBN N
to TO N
be VB N
inadequate JJ N
to TO N
describe VB N
the DT N
response NN N
pattern NN N
. . N

2 CD N
. . N

Pre-saralasin JJ N
setting NN N
of IN N
the DT N
renin-angiotensin JJ i
axis NN i
was VBD N
varied VBN N
with IN N
salt JJ N
intake NN N
( ( N
15 CD N
and CC N
290 CD N
mmol NN N
of IN N
Na+/day NNP N
) ) N
each DT N
for IN N
10 CD N
days NNS N
. . N

This DT N
failed VBD N
to TO N
influence VB N
blood NN o
pressure NN o
or CC o
plasma NN o
volume NN o
. . o

3 CD N
. . N

Antagonist NN N
blockade NN N
after IN N
low JJ N
salt NN N
lowered VBD N
blood NN o
pressure NN o
in IN N
three CD N
patients NNS N
with IN N
the DT N
highest JJS N
plasma NN N
renin NN N
values NNS N
. . N

Cardiac NNP o
output NN o
rose VBD N
in IN N
two CD N
of IN N
these DT N
, , N
but CC N
it PRP N
dropped VBD N
in IN N
all DT N
others NNS N
. . N

4 CD N
. . N

Decreases NNS N
in IN N
cardiac JJ o
output NN o
occurred VBD N
with IN N
both DT N
doses NNS N
of IN N
saralasin NN N
and CC N
even RB N
with IN N
suppression NN N
of IN N
the DT N
renin-angiotensin JJ N
axis NN N
. . N

This DT N
response NN N
is VBZ N
therefore RB N
unlikely JJ N
to TO N
be VB N
due JJ N
to TO N
removal VB N
of IN N
myocardial JJ o
or CC o
venous JJ o
angiotensin NN o
effects NNS o
. . o

5 CD N
. . N

The DT N
renin-angiotensin JJ N
system NN N
played VBD N
a DT N
part NN N
in IN N
maintenance NN N
of IN N
blood NN o
pressure NN o
only RB N
with IN N
severe JJ N
salt NN N
restriction NN N
and CC N
in IN N
a DT N
small JJ N
proportion NN N
of IN N
cases NNS N
. . N

6 CD N
. . N

No DT N
heart NN o
rate NN o
effect NN o
was VBD N
seen VBN N
with IN N
sarcalasin NN N
. . N

7 CD N
. . N

Blood NN o
pressure NN o
and CC o
total JJ o
peripheral JJ o
resistance NN o
responses NNS o
were VBD N
dependent JJ N
on IN N
pre- NN N
( ( N
antagonist/agonist NN N
) ) N
setting NN N
, , N
but CC N
heart NN o
rate NN o
and CC N
cardiac JJ o
output NN o
were VBD N
not RB N
influenced VBN N
by IN N
this DT N
factor NN N
. . N

-DOCSTART- -8217692- O O

High JJ i
purity NN i
factor NN i
VIII NNP i
and CC N
immune JJ N
state NN N
in IN N
HIV NNP p
. . p

-DOCSTART- -7559252- O O

Effect NN N
of IN N
perception NN N
of IN N
mechanical JJ N
loading NN N
on IN N
human JJ o
respiratory NN o
pattern NN o
regulation NN N
. . N

We PRP N
applied VBD N
external JJ i
flow NN i
resistive NN i
( ( i
R NNP i
) ) i
and CC i
elastic JJ i
( ( i
E NNP i
) ) i
mechanical JJ i
loads NNS i
over IN N
the DT N
entire JJ N
respiratory NN N
cycle NN N
to TO N
five CD p
normal JJ p
subjects NNS p
by IN N
using VBG N
a DT N
pseudorandom NN N
loading VBG N
protocol NN N
. . N

Loads NNP N
ranged VBD N
in IN N
magnitude NN N
from IN N
imperceptible JJ i
( ( N
R0/E0 NNP N
) ) N
through IN N
just RB i
perceptible JJ i
( ( N
R1/E1 NNP N
) ) N
to TO N
large JJ i
( ( N
R2/E2 NNP N
) ) N
and CC N
resulted VBN N
in IN N
respiratory NN N
pattern NN N
responses NNS N
that WDT N
were VBD N
due JJ N
to TO N
reflex JJ N
responses NNS N
alone RB N
( ( N
R0/E0 NNP N
) ) N
or CC N
to TO N
a DT N
combination NN N
of IN N
reflex JJ N
responses NNS N
and CC N
behavioral JJ N
reactions NNS N
to TO N
the DT N
perception NN N
of IN N
impeded JJ N
breathing NN N
( ( N
R1/E1 NNP N
and CC N
R2/E2 NNP N
) ) N
. . N

Pattern NNP o
regulation NN o
dynamics NNS o
were VBD o
estimated VBN o
from IN o
the DT o
computed VBN o
impulse JJ o
responses NNS o
of IN o
tidal JJ o
volume NN o
and CC o
inspiratory NN o
and CC o
expiratory JJ o
durations NNS o
. . o

We PRP N
anticipated VBD N
that IN N
emergence NN N
of IN N
behavioral JJ N
contributions NNS N
would MD N
be VB N
marked VBN N
by IN N
increased JJ N
variability NN o
in IN o
response NN o
strategies NNS o
and CC N
by IN N
increased JJ N
nonlinearity NN o
in IN N
the DT N
observed JJ N
responses NNS N
. . N

Regarding VBG N
the DT N
immediate JJ N
pattern NN N
response NN N
to TO N
loading NN N
, , N
there EX N
was VBD N
a DT N
tendency NN N
for IN N
increased JJ N
qualitative JJ o
variation NN o
across NN N
subjects NNS N
as IN N
the DT N
load NN N
size NN N
increased VBD N
, , N
but CC N
the DT N
within-subject JJ N
variability NN N
( ( N
coefficient NN N
of IN N
variation NN N
) ) N
was VBD N
unaffected JJ N
. . N

We PRP N
found VBD N
no DT N
evidence NN N
for IN N
increased JJ N
nonlinearity NN N
as IN N
loads NNS N
became VBD N
perceptible JJ N
. . N

The DT N
emergence NN N
of IN N
behavioral JJ N
control NN N
in IN N
some DT N
instances NNS N
seemed VBD N
to TO N
be VB N
marked VBN N
by IN N
reduction NN N
of IN N
complexity NN N
of IN N
the DT N
impulse JJ N
response NN N
to TO N
one CD N
dominated VBN N
by IN N
the DT N
zeroth-order NN N
lag NN N
, , N
leading VBG N
to TO N
dynamically RB N
simpler VB N
responses NNS N
compared VBN N
to TO N
control VB N
. . N

-DOCSTART- -23249643- O O

The DT N
added JJ N
value NN N
of IN N
a DT N
brief JJ N
self-efficacy JJ o
coaching NN i
on IN N
the DT N
effectiveness NN N
of IN N
a DT N
12-week JJ N
physical JJ i
activity NN i
program NN i
. . i

BACKGROUND NNP N
Self-efficacy NNP o
has VBZ N
been VBN N
found VBN N
to TO N
be VB N
an DT N
important JJ N
precondition NN N
for IN N
behavioral JJ N
change NN N
in IN N
sedentary JJ p
people NNS p
. . p

The DT N
current JJ N
study NN N
examined VBD N
the DT N
effectiveness NN N
and CC N
added VBD N
value NN N
of IN N
including VBG N
a DT N
15-minute JJ N
self-efficacy NN N
coaching NN N
at IN p
the DT p
start NN p
of IN p
a DT p
12-week JJ p
lifestyle JJ i
physical JJ i
activity NN i
( ( i
PA NNP i
) ) i
program NN i
. . i

METHODS NNP N
Participants NNPS N
were VBD N
randomly RB i
assigned VBN i
to TO i
a DT i
standard-intervention NN i
group NN i
( ( i
without IN i
additional JJ i
self-efficacy NN i
coaching NN i
, , i
N NNP i
= NNP i
116 CD i
) ) i
or CC i
extra-intervention JJ i
group NN i
( ( i
with IN i
additional JJ i
self-efficacy NN i
coaching NN i
, , i
N NNP i
= NNP i
111 CD i
) ) i
. . i

Body NNP o
mass NN o
index NN o
( ( o
BMI NNP o
) ) o
, , o
cardiovascular JJ o
fitness NN o
, , o
self-reported JJ o
PA NNP o
, , o
and CC o
self-efficacy NN o
beliefs NNS o
were VBD i
assessed VBN i
at IN i
baseline NN i
and CC i
immediately RB i
after IN i
the DT i
intervention NN i
period NN i
. . i

Perceived VBD N
adherence NN N
to TO N
the DT N
PA NNP N
program NN N
was VBD N
assessed VBN N
postintervention NN N
. . N

RESULTS NNP N
At IN N
posttest JJS N
, , N
a DT N
significant JJ N
increase NN N
in IN N
cardiovascular JJ o
fitness NN o
and CC N
decrease NN N
in IN N
BMI NNP o
were VBD N
found VBN N
in IN N
both DT N
groups NNS N
. . N

Significant JJ N
intervention NN N
effects NNS N
emerged VBD N
on IN N
PA NNP o
behavior NN o
, , o
self-efficacy NN o
, , o
and CC o
program NN o
adherence NN o
, , N
in IN N
favor NN N
of IN N
the DT N
extra-intervention NN N
group NN N
. . N

Self-efficacy NN o
mediated VBD N
the DT N
intervention NN N
effect NN N
on IN N
program NN N
adherence NN N
whereas IN N
no DT N
evidence NN N
was VBD N
found VBN N
for IN N
its PRP$ N
role NN N
as IN N
mediator NN N
of IN N
PA NNP o
change NN N
. . N

CONCLUSIONS NNP N
Adding VBG N
a DT N
15-minute JJ N
self-efficacy NN N
coaching NN N
at IN N
the DT N
start NN N
of IN N
a DT N
lifestyle JJ i
PA NNP i
program NN i
is VBZ N
a DT N
promising JJ N
strategy NN N
to TO N
enhance VB N
the DT N
intervention NN N
effects NNS N
on IN N
PA NNP o
behavior NN o
, , o
self-efficacy JJ o
beliefs NN o
, , o
and CC o
program NN o
adherence NN o
. . o

However RB N
, , N
the DT N
role NN N
of IN N
self-efficacy NN N
as IN N
mediator NN N
of IN N
the DT N
intervention NN N
effect NN N
on IN N
in IN N
PA NNP N
was VBD N
not RB N
fully RB N
supported VBN N
. . N

-DOCSTART- -21412846- O O

Correlation NN N
of IN N
adenosinergic JJ N
activity NN N
with IN N
superior JJ o
efficacy NN o
of IN N
clozapine NN i
for IN N
treatment NN N
of IN N
chronic JJ p
schizophrenia NN p
: : p
a DT N
double JJ N
blind NN N
randomised VBD N
trial NN N
. . N

OBJECTIVE NN N
It PRP N
has VBZ N
been VBN N
proposed VBN N
that IN N
a DT N
deficit NN N
of IN N
adenosinergic JJ N
activity NN N
could MD N
contribute VB N
to TO N
the DT N
pathophysiology NN N
of IN N
schizophrenia NN N
. . N

The DT N
authors NNS N
undertook VBP N
this DT N
study NN N
to TO N
further RBR N
evaluate VB N
the DT N
level NN o
of IN o
adenosine JJ o
deaminase NN o
( ( o
ADA NNP o
) ) o
in IN N
patients NNS p
with IN p
chronic JJ p
schizophrenia NN p
treated VBN N
with IN N
monotherapy NN i
of IN i
haloperidol NN i
, , i
risperidone NN i
or CC i
clozapine NN i
and CC N
correlation NN N
between IN N
the DT N
ADA NNP o
level NN o
with IN N
response NN N
to TO N
treatment NN N
. . N

METHODS NNP N
The DT N
trial NN N
was VBD N
a DT N
prospective JJ N
, , N
8-week JJ N
, , N
double JJ N
blind NN N
study NN N
of IN N
parallel JJ N
groups NNS N
of IN N
patients NNS p
with IN p
chronic JJ p
schizophrenia NN p
. . p

Eligible JJ p
participants NNS p
in IN p
the DT p
study NN p
were VBD p
51 CD p
patients NNS p
with IN p
chronic JJ p
schizophrenia NN p
with IN p
ages NNS p
ranging VBG p
from IN p
20 CD p
to TO p
45 CD p
years NNS p
. . p

All DT p
participants NNS p
were VBD p
inpatients NNS p
, , p
in IN p
the DT p
active JJ p
phase NN p
of IN p
illness NN p
, , p
and CC p
met VBD p
DSM-IV-TR NNP p
criteria NNS p
for IN p
schizophrenia NN p
. . p

Patients NNS p
were VBD p
randomly RB p
allocated VBN p
( ( N
17 CD N
patients NNS N
in IN N
each DT N
group NN N
) ) N
to TO N
risperidone VB i
( ( N
6 CD N
mg/day NN N
) ) N
or CC N
haloperidol $ i
15 CD N
mg/day NN N
or CC N
clozapine NN i
( ( N
300 CD N
mg/day NN N
) ) N
. . N

Serum NNP o
ADA NNP o
activity NN o
was VBD N
measured VBN N
at IN N
baseline NN N
and CC N
week NN N
8 CD N
. . N

RESULTS VB N
The DT N
plasma JJ o
levels NNS o
of IN o
ADA NNP o
in IN N
patients NNS N
with IN N
chronic JJ N
schizophrenia NN N
who WP N
received VBD N
clozapine NN i
were VBD N
significantly RB N
higher JJR N
than IN N
patients NNS N
who WP N
received VBD N
haloperidol NN N
. . N

In IN N
addition NN N
, , N
response NN N
to TO N
treatment NN N
was VBD N
positively RB o
correlated VBN o
with IN N
plasma NN o
levels NNS o
of IN o
ADA NNP o
only RB N
in IN N
the DT N
clozapine NN i
group NN N
( ( N
r NN N
= VBZ N
0.46 CD N
and CC N
p VB N
= NNP N
0.04 CD N
) ) N
. . N

CONCLUSION VB N
The DT N
results NNS N
indicate VBP N
an DT o
increased JJ o
activity NN o
of IN o
the DT o
enzyme NN o
ADA NNP o
in IN o
the DT o
serum NN o
of IN o
schizophrenic JJ p
patients NNS p
being VBG p
treated VBN p
with IN i
clozapine NN i
and CC i
this DT i
increase NN N
may MD o
be VB o
correlated VBN i
with IN i
clozapine NN o
's POS o
superior JJ o
antipsychotic JJ o
efficacy NN o
. . o

-DOCSTART- -8639070- O O

The DT N
effects NNS N
of IN N
amantadine NN i
and CC N
pemoline NN i
on IN N
cognitive JJ p
functioning NN p
in IN N
multiple JJ N
sclerosis NN N
. . N

BACKGROUND NNP N
Amantadine NNP i
hydrochloride NN i
and CC N
pemoline NN i
, , N
both DT N
frequently RB N
used VBN N
to TO N
treat VB N
the DT N
fatigue NN N
of IN N
multiple JJ N
sclerosis NN N
( ( N
MS NNP N
) ) N
, , N
may MD N
also RB N
improve VB N
attention NN N
and CC N
other JJ N
cognitive JJ N
functions NNS N
in IN N
MS. NNP N
To TO N
our PRP$ N
knowledge NN N
, , N
these DT N
agents NNS N
have VBP N
never RB N
been VBN N
compared VBN N
in IN N
a DT N
placebo-controlled JJ N
trial NN N
of IN N
patients NNS p
with IN p
MS NNP p
. . p

OBJECTIVE NNP N
To TO N
evaluate VB N
the DT N
effects NNS N
of IN N
amantadine NN i
and CC i
pemoline NN i
on IN N
cognitive JJ N
functioning NN N
in IN N
MS. NNP N
METHODS NNP N
A NNP p
total NN p
of IN p
45 CD p
ambulatory JJ p
patients NNS p
with IN p
MS NNP p
and CC p
severe JJ p
fatigue NN p
were VBD N
treated VBN N
for IN N
6 CD N
weeks NNS N
with IN N
amantadine NN i
, , i
pemoline NN i
, , i
or CC i
placebo NN i
using VBG N
a DT N
parallel JJ N
group NN N
design NN N
. . N

They PRP N
underwent VBD N
comprehensive JJ N
neuropsychological JJ N
testing NN N
to TO N
determine VB N
treatment NN N
effects NNS N
on IN N
cognitive JJ N
functioning NN N
. . N

Primary JJ N
outcome JJ N
measures NNS N
were VBD N
tests NNS N
of IN N
attention NN N
( ( o
Digit NNP o
Span NNP o
, , o
Trail NNP o
Making NNP o
Test NNP o
, , o
and CC o
Symbol NNP o
Digit NNP o
Modalities NNP o
Test NNP o
) ) o
, , o
verbal JJ o
memory NN o
( ( o
Selective JJ o
Reminding NNP o
Test NNP o
) ) o
, , o
nonverbal JJ o
memory NN o
( ( o
Benton NNP o
Visual NNP o
Retention NNP o
Test NNP o
) ) o
, , o
and CC o
motor NN o
speed NN o
( ( o
Finger NNP o
Tapping NNP o
Test NNP o
) ) o
. . N

RESULTS NNP N
Fatigue NNP o
did VBD N
not RB N
significantly RB N
correlate VB N
with IN N
any DT N
of IN N
the DT N
neuropsychological JJ N
outcome NN N
measures NNS N
at IN N
baseline NN N
or CC N
after IN N
treatment NN N
. . N

All DT N
three CD N
treatment NN N
groups NNS N
improved VBN N
on IN N
tests NNS o
of IN o
attention NN o
( ( N
P NNP N
< NNP N
.003 NNP N
) ) N
, , N
verbal JJ o
memory NN o
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
, , N
and CC N
motor NN o
speed NN o
( ( N
P NNP N
< NNP N
.002 NNP N
) ) N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
amantadine NN N
, , N
pemoline NN N
, , N
and CC N
placebo NN N
. . N

CONCLUSIONS NNP N
Cognitive NNP N
functioning NN N
in IN N
MS NNP N
is VBZ N
independent JJ N
of IN N
fatigue NN N
. . N

Neither CC N
amantadine JJ i
nor CC N
pemoline JJ i
enhances NNS N
cognitive JJ N
performance NN N
in IN N
MS NNP N
compared VBN N
with IN N
placebo NN i
. . i

-DOCSTART- -11154142- O O

Unopposed VBN i
estrogen NN i
increases NNS N
total JJ N
plasma JJ N
factor NN N
VII NNP N
, , N
but CC N
not RB N
active JJ N
factor NN N
VII NNP N
-- : N
a DT N
short-term JJ N
placebo-controlled JJ i
study NN N
in IN N
healthy JJ p
postmenopausal NN p
women NNS p
. . p

Estrogen NNP i
therapy NN i
may MD N
increase VB N
the DT N
risk NN N
of IN N
arterial JJ N
thromboembolism NN N
, , N
at IN N
least JJS N
in IN N
the DT N
short JJ N
term NN N
. . N

In IN N
a DT N
randomized JJ N
, , N
double-blind JJ N
and CC N
placebo-controlled JJ N
study NN N
in IN N
25 CD p
healthy JJ p
postmenopausal NN p
women NNS p
( ( p
52.5 CD p
+/- JJ p
2.8 CD p
years NNS p
) ) p
, , N
we PRP N
therefore VBP N
examined VBD N
the DT N
short-term JJ N
effect NN N
of IN N
unopposed JJ i
estrogen NN i
on IN N
the DT N
fasting NN N
and CC N
fat-load-stimulated JJ N
plasma NN N
levels NNS N
of IN N
total JJ N
factor NN N
VII NNP N
versus NN N
active JJ N
factor NN N
VII NNP N
. . N

Plasma NNP o
total JJ o
factor NN o
VII NNP o
was VBD N
measured VBN N
by IN N
use NN N
of IN N
a DT N
chromogenic JJ N
assay NN N
; : N
plasma CC N
active JJ N
FVII NNP N
by IN N
a DT N
recently RB N
developed VBN N
method NN N
using VBG N
truncated JJ N
tissue NN N
factor NN N
. . N

As IN N
compared VBN N
to TO N
placebo VB i
, , N
8 CD N
weeks NNS N
of IN N
oral JJ i
17beta-estradiol JJ i
( ( N
2 CD N
mg NNS N
daily RB N
) ) N
increased VBD N
the DT N
mean NN o
fasting NN o
and CC o
postprandial JJ o
plasma NN o
levels NNS o
of IN o
total JJ o
factor NN o
VII NNP o
by IN N
17 CD N
and CC N
21 CD N
% NN N
points NNS N
, , N
respectively RB N
( ( N
both DT N
P NNP N
< NNP N
0.01 CD N
) ) N
, , N
but CC N
did VBD N
not RB N
affect VB N
the DT N
fasting NN o
and/or JJ o
postprandial JJ o
plasma NN o
levels NNS o
of IN o
active JJ o
factor NN o
VII NNP o
( ( N
mean JJ N
change NN N
both DT N
0.05 CD N
ng/mL NN N
; : N
P NNP N
> NNP N
0.35 CD N
) ) N
. . N

Furthermore UH N
, , N
the DT N
change NN o
in IN o
the DT o
fasting JJ o
level NN o
of IN o
total JJ o
factor NN o
VII NNP o
after IN N
therapy NN N
was VBD N
not RB N
associated VBN N
with IN N
the DT N
change NN o
in IN o
the DT o
fasting JJ o
level NN o
of IN o
active JJ o
factor NN o
VII NNP o
( ( N
r VB N
= RB N
0.27 CD N
; : N
P NNP N
= NNP N
0.21 CD N
) ) N
. . N

These DT N
findings NNS N
argue VBP N
against IN N
the DT N
idea NN N
that WDT N
elevated VBD N
levels NNS o
of IN o
total JJ o
factor NN o
VII NNP o
underlie VBZ N
an DT N
increased VBN N
risk NN o
of IN o
arterial JJ o
thromboembolism NN o
in IN N
postmenopausal JJ p
women NNS p
using VBG N
unopposed JJ i
estrogen NN i
replacement NN i
. . i

-DOCSTART- -12358251- O O

Tegaserod NNP i
, , i
a DT i
5-hydroxytryptamine JJ i
type NN i
4 CD i
receptor NN i
partial JJ i
agonist NN i
, , N
is VBZ N
devoid JJ N
of IN N
electrocardiographic JJ o
effects NNS o
. . o

OBJECTIVES NNP N
Certain NNP N
GI NNP i
prokinetic JJ i
agents NNS i
have VBP N
been VBN N
shown VBN N
to TO N
affect VB N
cardiac JJ N
repolarization NN N
, , N
which WDT N
may MD N
be VB N
associated VBN N
with IN N
life-threatening JJ N
arrhythmias NNS N
. . N

The DT N
selective JJ i
5-hydroxytryptamine JJ i
type NN i
4 CD i
receptor NN i
partial JJ i
agonist NN i
tegaserod NN i
is VBZ N
a DT N
novel JJ N
promotile NN N
agent NN N
developed VBD N
for IN N
the DT N
treatment NN N
of IN N
functional JJ N
motility NN N
disorders NNS N
such JJ N
as IN N
irritable JJ N
bowel NN N
syndrome NN N
( ( N
IBS NNP N
) ) N
. . N

The DT N
aim NN N
of IN N
the DT N
study NN N
was VBD N
to TO N
investigate VB N
the DT N
cardiac JJ o
safety NN o
profile NN o
of IN N
tegaserod NN i
through IN N
analysis NN N
of IN N
electrocardiographic JJ N
data NNS N
from IN N
clinical JJ N
studies NNS N
conducted VBN N
in IN N
patients NNS p
with IN p
IBS NNP p
and CC p
a DT p
study NN p
conducted VBN p
in IN p
healthy JJ p
male JJ p
subjects NNS p
. . p

METHODS NNP N
In IN N
three CD N
randomized NNS N
, , N
double JJ N
blind NN N
, , N
placebo-controlled JJ N
, , N
parallel JJ N
group NN N
clinical JJ N
studies NNS N
, , N
2516 CD p
IBS NNP p
patients NNS p
with IN p
symptoms NNS p
of IN p
abdominal JJ p
pain NN p
and CC p
constipation NN p
received VBD N
tegaserod JJ i
2 CD N
or CC N
6 CD N
mg JJ N
b.i.d NN N
. . N

( ( N
n JJ N
= NN N
1679 CD N
) ) N
or CC N
placebo NN i
( ( N
n JJ N
= NNP N
837 CD N
) ) N
for IN N
12 CD N
wk NN N
. . N

In IN p
an DT p
additional JJ p
study NN p
, , p
36 CD p
healthy JJ p
male NN p
subjects NNS p
received VBD p
iv NN p
. . p

single JJ p
doses NNS p
of IN p
tegaserod NN i
( ( p
0.8 CD p
mg NN p
to TO p
20 CD p
mg NN p
) ) p
or CC i
placebo NN i
. . i

Standard NNP N
12-lead JJ N
electrocardiograms NNS N
were VBD N
recorded VBN N
at IN N
baseline NN N
and CC N
during IN N
treatment NN N
. . N

Baseline NNP N
values NNS N
were VBD N
compared VBN N
with IN N
data NNS N
collected VBN N
during IN N
the DT N
treatment NN N
period NN N
. . N

RESULTS VB N
The DT N
proportion NN N
of IN N
patients NNS N
with IN N
prolongation NN o
of IN o
the DT o
QTc NNP o
interval NN o
was VBD N
the DT N
same JJ N
for IN N
placebo NN N
and CC N
tegaserod NN N
, , N
as IN N
was VBD N
the DT N
frequency NN o
of IN o
overall JJ o
electrocardiographic JJ o
abnormalities NNS o
. . o

No DT N
ventricular NN o
or CC o
supraventricular JJ o
tachycardia NN o
was VBD N
observed VBN N
. . N

Comparable JJ N
electrocardiographic JJ o
results NNS o
were VBD N
obtained VBN N
during IN N
placebo NN N
and CC N
tegaserod NN N
treatment NN N
. . N

In IN N
healthy JJ p
volunteers NNS p
, , N
tegaserod NN N
at IN N
i.v NN N
. . N

doses NNS N
resulting VBG N
in IN N
plasma NN o
concentrations NNS o
up IN N
to TO N
100 CD N
times NNS N
those DT N
measured VBN N
after IN N
therapeutic JJ N
doses NNS N
( ( N
6 CD N
mg NN N
b.i.d NN N
. . N

) ) N
did VBD N
not RB N
influence VB N
electrocardiographic JJ N
parameters NNS N
. . N

CONCLUSIONS NNP N
Tegaserod NNP N
is VBZ N
devoid JJ N
of IN N
electrocardiographic JJ o
effects NNS o
and CC N
is VBZ N
not RB N
expected VBN N
to TO N
adversely RB N
influence VB N
cardiac JJ o
function NN o
. . o

These DT N
data NNS N
confirm VBP N
preclinical JJ N
findings NNS N
. . N

-DOCSTART- -7429786- O O

Liquid JJ i
antacids NNS i
: : i
palatability NN N
and CC N
predictability NN N
study NN N
. . N

-DOCSTART- -9405728- O O

Biochemical JJ N
markers NNS N
as IN N
predictors NNS N
of IN N
bone JJ N
mineral JJ N
density NN N
changes NNS N
after IN p
GnRH NNP i
agonist NN i
treatment NN i
. . i

To TO N
evaluate VB N
bone NN N
biochemical JJ N
markers NNS N
as IN N
predictors NNS N
of IN N
the DT N
efficacy NN o
of IN N
a DT N
hormone NN i
replacement NN i
therapy NN i
( ( i
HRT NNP i
) ) i
, , N
we PRP N
studied VBD N
the DT N
bone NN N
changes NNS N
induced VBN N
by IN N
the DT N
cessation NN N
and CC N
return NN N
of IN N
ovarian JJ N
function NN N
in IN N
28 CD p
patients NNS p
treated VBD p
for IN p
6 CD p
months NNS p
with IN p
a DT p
GnRH NNP i
agonist NN i
. . i

This DT N
model NN N
reproduced VBD N
the DT N
effects NNS N
observed VBN N
in IN N
postmenopausal JJ p
women NNS p
with IN p
high JJ p
bone NN p
turnover NN p
treated VBN p
with IN p
HRT NNP p
. . p

At IN N
the DT N
end NN N
of IN N
the DT N
treatment NN N
, , N
Z NNP o
scores NNS o
were VBD N
1.8 CD N
+/- JJ N
0.3 CD N
for IN N
Crosslaps NNP N
( ( N
CTx NNP N
) ) N
and CC N
deoxypyridinoline NN N
( ( N
D-Pyr NNP N
) ) N
, , N
and CC N
1.1 CD N
+/- JJ N
0.2 CD N
for IN N
bone NN o
alkaline NN o
phosphatase NN o
( ( o
B-ALP NNP o
) ) o
and CC o
osteocalcin $ o
( ( o
OC NNP o
) ) o
. . o

This DT N
indicated VBD N
an DT N
imbalance NN o
in IN o
bone NN o
remodeling VBG o
with IN N
a DT N
high JJ o
bone NN o
resorption NN o
. . o

Bone NNP o
mineral JJ o
density NN o
( ( o
BMD NNP o
) ) o
fell VBD N
by IN N
4.2 CD N
+/- JJ N
2.5 CD N
% NN N
. . N

The DT N
changes NNS o
in IN o
BMD NNP o
between IN N
the DT N
6th CD N
and CC N
12th CD N
months NNS N
were VBD N
0 CD N
. . N

34 CD N
+/- JJ N
2.24 CD N
and CC N
-1.73 VB N
+/- JJ N
3.25 CD N
% NN N
at IN N
the DT N
lumbar NN o
spine NN o
and CC o
the DT o
femoral JJ o
neck NN o
, , N
respectively RB N
. . N

Biochemical JJ o
markers NNS o
except IN o
urinary JJ o
calcium NN o
and CC o
hydroxyproline NN o
measured VBN N
at IN N
6 CD N
months NNS N
were VBD N
positively RB N
correlated VBN N
with IN N
the DT N
BMD NNP o
changes NNS o
at IN o
the DT o
lumbar NN o
spine NN o
. . o

After IN N
the DT N
resumption NN N
of IN N
menstruation NN N
, , N
13 CD N
of IN N
28 CD N
women NNS N
displayed VBD N
positive JJ o
spine NN o
BMD NNP o
changes NNS o
between IN N
the DT N
6th CD N
and CC N
12th CD N
months NNS N
; : N
in IN N
this DT N
group NN N
, , N
bone RB o
biochemical JJ o
markers NNS o
measured VBD N
at IN N
6 CD N
months NNS N
were VBD N
significantly RB N
higher JJR N
( ( N
P NNP N
= NNP N
0.02 CD N
) ) N
. . N

Stepwise NNP N
regression NN N
analysis NN N
showed VBD N
that IN N
the DT N
association NN o
of IN o
B-ALP NNP o
and CC o
D-Pyr NNP o
measured VBD N
at IN N
6 CD N
months NNS N
explained VBD N
40 CD N
% NN N
of IN N
BMD NNP o
variance NN o
and CC N
the DT N
association NN o
of IN o
B-ALP NNP o
, , o
PTH NNP o
, , o
and CC o
estradiol RB o
56 CD N
% NN N
. . N

We PRP N
conclude VBP N
that IN N
measuring VBG N
individual JJ N
biochemical JJ o
bone NN o
markers NNS o
can MD N
help VB N
to TO N
predict VB N
the DT N
bone NN o
effect NN o
of IN N
an DT N
increase NN o
in IN N
the DT N
circulating NN N
estradiol NN N
in IN N
women NNS p
with IN p
ovarian JJ p
deficiency NN p
. . p

-DOCSTART- -9820191- O O

Basal NNP p
cell NN p
carcinoma NN p
of IN p
the DT p
face NN p
: : p
surgery NN i
or CC i
radiotherapy NN i
? . N
Results NNS N
of IN N
a DT N
randomized JJ N
study NN N
. . N

-DOCSTART- -5322596- O O

Incidence NN o
of IN o
candida NN o
in IN p
hospital JJ p
in-patients NNS p
and CC N
the DT N
effects NNS N
of IN N
antibiotic JJ i
therapy NN i
. . i

-DOCSTART- -7486842- O O

Comparison NNP N
of IN N
fluoxetine NN i
and CC i
placebo NN i
in IN N
the DT N
treatment NN N
of IN N
obesity NN o
. . o

Our PRP$ N
study NN N
aims VBZ N
at IN N
assessing VBG N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
fluoxetine NN i
as IN N
compared VBN N
with IN N
placebo NN i
in IN N
the DT N
treatment NN N
of IN N
obesity NN p
using VBG N
a DT N
double-blind JJ N
crossover NN N
design NN N
. . N

We PRP N
studied VBD N
42 CD p
obese JJ p
women NNS p
( ( p
body NN p
mass NN p
index NN p
35.9 CD p
+/- JJ p
5.3 CD p
kg/m2 NN p
) ) p
. . p

The DT N
obese JJ p
patients NNS p
were VBD N
randomized VBN N
to TO N
start VB N
treatment NN N
with IN N
fluoxetine NN i
( ( N
group NN N
A NNP N
) ) N
or CC N
placebo NN i
( ( N
group NN N
B NNP N
) ) N
for IN N
3 CD N
months NNS N
( ( N
period NN N
1 CD N
) ) N
. . N

After IN N
a DT N
1-month JJ N
washout NN N
period NN N
, , N
treatment NN N
was VBD N
crossed VBN N
for IN N
the DT N
following JJ N
3 CD N
months NNS N
( ( N
period NN N
2 CD N
) ) N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
weight JJ o
loss NN o
when WRB N
the DT N
patients NNS N
were VBD N
treated VBN N
with IN N
fluoxetine NN i
( ( N
group NN N
A NNP N
period NN N
1 CD N
and CC N
group NN N
B NNP N
period NN N
2 CD N
) ) N
as IN N
compared VBN N
with IN N
patients NNS N
treated VBN N
with IN N
placebo NN i
( ( N
group NN N
B NNP N
period NN N
1 CD N
and CC N
group NN N
A NNP N
period NN N
2 CD N
) ) N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
monthly JJ o
weight NN o
reduction NN o
during IN N
both DT N
treatments NNS N
. . N

In IN N
conclusion NN N
, , N
we PRP N
demonstrated VBD N
that IN N
serotoninergic JJ i
drugs NNS i
such JJ N
as IN N
fluoxetine JJ i
need VBP N
further JJ N
investigation NN N
before IN N
being VBG N
used VBN N
indiscriminately RB N
in IN N
obese JJ p
subjects NNS p
. . p

-DOCSTART- -484261- O O

A DT N
controlled VBN N
study NN N
of IN N
early JJ i
discharge NN i
after IN p
uncomplicated JJ p
myocardial JJ p
infarction NN p
. . p

Out IN N
of IN N
383 CD p
myocardial JJ p
infarction NN p
( ( p
MI NNP p
) ) p
patients NNS p
aged VBN p
below IN p
70 CD p
years NNS p
, , p
252 CD p
( ( p
66 CD p
% NN p
) ) p
were VBD p
judged VBN p
after IN p
the DT p
third JJ p
day NN p
in IN p
hospital NN p
to TO p
have VB p
had VBN p
uncomplicated VBN p
infarctions NNS p
. . p

These DT N
patients NNS N
were VBD N
allocated VBN N
at IN N
random NN N
to TO N
two CD N
groups NNS N
, , N
one CD i
of IN i
which WDT i
was VBD i
given VBN i
treatment NN i
for IN i
8 CD i
days NNS i
and CC i
the DT i
other JJ i
for IN i
15 CD i
days NNS i
. . i

No DT N
significant JJ N
differences NNS o
in IN o
mortality NN o
, , o
morbidity NN o
or CC o
incapacity NN o
for IN o
work NN o
could MD N
be VB N
detected VBN N
during IN N
the DT N
three-month JJ N
period NN N
of IN N
follow-up NN N
. . N

The DT N
findings NNS N
thus RB N
support VBP N
previous JJ N
conclusions NNS N
that WDT N
early RB i
discharge VBP i
from IN N
hospital NN N
after IN N
uncomplicated JJ N
MI NNP N
is VBZ N
not RB N
associated VBN N
with IN N
greater JJR N
risk NN N
for IN N
the DT N
patient NN N
than IN N
later RB N
discharge NN N
. . N

-DOCSTART- -9048274- O O

Temporal JJ N
variation NN N
in IN N
the DT N
effects NNS o
of IN N
ophthalmic JJ i
timolol NN i
on IN N
cardiovascular NN o
and CC o
respiratory JJ o
functions NNS o
in IN N
healthy JJ p
men NNS p
. . p

This DT N
study NN N
examined VBD N
the DT N
effects NNS N
of IN N
ophthalmic JJ i
timolol NN i
and CC N
time NN N
of IN N
administration NN N
on IN N
cardiovascular JJ o
and CC o
respiratory JJ o
functions NNS o
in IN N
healthy JJ p
young JJ p
male NN p
volunteers NNS p
. . p

Eight CD p
participants NNS p
( ( p
mean JJ p
age NN p
+/- JJ p
standard NN p
deviation NN p
, , p
22 CD p
+/- JJ p
0.9 CD p
years NNS p
) ) p
received VBD N
either CC N
50 CD N
microL NN N
of IN N
0.5 CD N
% NN N
timolol NN i
or CC N
placebo NN i
in IN N
the DT N
lower JJR N
conjunctival NN N
sacs NN N
of IN N
both DT N
eyes NNS N
in IN N
the DT N
morning NN N
or CC N
evening NN N
. . N

Intraocular JJ o
pressure NN o
, , o
blood NN o
pressure NN o
, , o
heart NN o
rate NN o
, , o
and CC o
respiratory JJ o
functions NNS o
, , o
including VBG o
percent NN o
forced VBD o
expiratory JJ o
volume NN o
in IN o
1 CD o
second JJ o
and CC o
peak JJ o
expiratory NN o
flow NN o
rate NN o
, , N
were VBD N
then RB N
measured VBN N
for IN N
3 CD N
hours NNS N
after IN N
drug NN N
administration NN N
. . N

Timolol NNP i
reduced VBD N
intraocular JJ o
pressure NN o
and CC o
cardiovascular JJ o
function NN o
at IN N
both DT N
administration NN N
times NNS N
. . N

However RB N
, , N
a DT N
timolol-induced JJ i
reduction NN N
in IN N
respiratory NN o
function NN o
was VBD N
observed VBN N
only RB N
in IN N
the DT N
evening NN N
: : N
percent NN o
forced VBD o
expiratory JJ o
volume NN o
in IN o
1 CD o
second JJ o
, , o
peak JJ o
expiratory NN o
flow NN o
rate NN o
, , o
and CC o
expiratory JJ o
flow NN o
rate NN o
at IN o
75 CD o
% NN o
vital JJ o
capacity NN o
were VBD N
reduced VBN N
by IN N
3 CD N
% NN N
, , N
7 CD N
% NN N
, , N
and CC N
12 CD N
% NN N
, , N
respectively RB N
, , N
3 CD N
hours NNS N
after IN N
administration NN N
. . N

These DT N
results NNS N
indicate VBP N
that IN N
ophthalmic JJ i
timolol NN i
reduces NNS N
cardiovascular JJ o
and CC o
respiratory JJ o
functions NNS o
in IN N
healthy JJ p
young JJ p
male JJ p
subjects NNS p
and CC N
that DT N
bronchial JJ o
sensitivity NN o
to TO N
timolol VB N
differs NNS N
between IN N
morning NN N
and CC N
evening NN N
. . N

-DOCSTART- -16125499- O O

Usefulness NN N
of IN N
temporal JJ N
changes NNS N
in IN N
neurohormones NNS i
as IN N
markers NNS N
of IN N
ventricular JJ N
remodeling NN N
and CC N
prognosis NN N
in IN N
patients NNS p
with IN p
left JJ p
ventricular JJ p
systolic JJ p
dysfunction NN p
and CC p
heart NN p
failure NN p
receiving VBG p
either CC p
candesartan NN i
or CC i
enalapril NN i
or CC i
both DT i
. . i

Although IN N
various JJ N
neurohormones NNS N
at IN N
initial JJ N
measurement NN N
confer NN N
prognostic JJ N
value NN N
in IN N
heart NN N
failure NN N
and CC N
correlate NN N
with IN N
the DT N
left NN o
ventricular JJ o
ejection NN o
fraction NN o
( ( o
EF NNP o
) ) o
and CC N
cardiac JJ o
volumes NNS o
, , N
the DT N
significance NN N
of IN N
their PRP$ N
temporal JJ N
changes NNS N
( ( N
Delta NNP N
) ) N
remains VBZ N
undetermined JJ N
. . N

This DT N
study NN N
examined VBD N
temporal JJ N
changes NNS o
in IN o
neurohormones NNS o
related VBN N
to TO N
cardiac VB N
remodeling NN N
and CC N
prognosis NN N
in IN N
patients NNS p
with IN p
systolic JJ p
dysfunction NN p
and CC p
heart NN p
failure NN p
receiving VBG p
therapeutic JJ p
inhibition NN p
of IN p
the DT p
renin-angiotensin-aldosterone NN p
system NN p
. . p

Temporal JJ o
changes NNS o
in IN o
plasma NN o
renin NN o
, , o
angiotensin-II JJ o
, , o
aldosterone NN o
, , o
epinephrine NN o
, , o
norepinephrine JJ o
, , o
B-type JJ o
natriuretic JJ o
peptide NN o
( ( o
BNP NNP o
) ) o
, , o
and CC o
N-terminal JJ o
atrial JJ o
natriuretic JJ o
peptide NN o
( ( o
NT-ANP NNP o
) ) o
in IN N
768 CD p
treated JJ p
patients NNS p
with IN p
heart NN p
failure NN p
measured VBN p
at IN p
baseline NN p
and CC N
17 CD N
and CC N
43 CD N
weeks NNS N
after IN N
randomization NN N
were VBD N
examined VBN N
for IN N
their PRP$ N
relations NNS N
with IN N
concurrent NN N
changes NNS N
in IN N
the DT N
EF NNP o
, , o
cardiac JJ o
volumes NNS o
, , o
and CC o
risk NN o
for IN o
subsequent JJ o
adverse JJ o
clinical JJ o
outcomes NNS o
. . o

Increasing VBG N
BNP NNP o
( ( N
p JJ N
< NNP N
0.0001 CD N
) ) N
and CC N
NT-ANP NNP o
( ( N
p JJ N
= NNP N
0.01 CD N
) ) N
over IN N
time NN N
were VBD N
associated VBN N
with IN N
a DT N
concurrent NN N
decreasing VBG N
EF NNP o
, , N
increasing VBG N
end-diastolic JJ o
volume NN o
( ( o
EDV NNP o
) ) o
, , N
and CC N
increasing VBG N
end-systolic JJ o
volume NN o
( ( N
ESV NNP N
; : N
all DT N
p VBP N
< $ N
0.0001 CD N
) ) N
. . N

In IN N
multivariable JJ N
analysis NN N
, , N
DeltaBNP NNP N
and CC N
DeltaNT-ANP NNP N
were VBD N
independent JJ N
predictors NNS N
of IN N
DeltaESV NNP N
and CC N
DeltaEDV NNP N
, , N
whereas JJ N
DeltaBNP NNP N
also RB N
predicted VBD N
DeltaEF NNP N
( ( N
all DT N
p VBP N
< $ N
0.0001 CD N
) ) N
. . N

Patients NNS N
who WP N
died VBD o
or CC o
experienced JJ o
heart NN o
failure NN o
hospitalization NN o
had VBD N
larger JJR N
antecedent NN N
increases NNS N
in IN N
NT-ANP NNP o
( ( N
+293.7 NNP N
vs RB N
-21.5 NNP N
pmol/ml NN N
, , N
p NN N
= NNP N
0.006 CD N
) ) N
and CC N
lesser JJR N
decreases NNS N
in IN N
norepinephrine NN o
( ( N
-22.3 JJ N
vs NN N
-48.5 NNP N
pg/ml NN N
, , N
p NN N
= NNP N
0.04 CD N
) ) N
. . N

Increasing VBG N
NT-ANP NNP o
( ( N
hazard JJ N
ratio NN N
[ NNP N
HR NNP N
] NNP N
3.45 CD N
, , N
p NN N
= NNP N
0.009 CD N
) ) N
and CC N
norepinephrine JJ N
( ( N
HR NNP N
2.04 CD N
, , N
p NN N
= NNP N
0.02 CD N
) ) N
over IN N
time NN N
independently RB N
predicted VBD N
increased VBN N
risk NN N
for IN N
subsequent JJ N
death NN o
or CC o
heart NN o
failure NN o
hospitalization NN o
. . o

In IN N
conclusion NN N
, , N
in IN N
treated JJ p
patients NNS p
with IN p
heart NN p
failure NN p
, , N
increasing VBG N
NT-ANP NNP N
and CC N
BNP NNP N
over IN N
time NN N
predict VBP N
a DT N
decreasing NN N
EF NNP o
and CC N
ventricular JJ o
dilatation NN o
, , N
while IN N
increasing VBG N
NT-ANP NNP N
and CC N
norepinephrine VB N
independently RB N
predict VBP N
greater JJR N
mortality NN o
and CC o
morbidity NN o
. . o

Serial JJ N
measurements NNS N
of IN N
these DT N
neurohormones NNS N
may MD N
serve VB N
as IN N
useful JJ N
surrogate JJ N
markers NNS N
of IN N
ventricular JJ o
remodeling NN o
and CC N
prognosticators NNS N
for IN N
clinical JJ N
risk NN N
stratification NN N
. . N

-DOCSTART- -5090759- O O

Psychiatric NNP i
treatment NN i
of IN N
eczema NN p
: : p
a DT N
controlled JJ N
trial NN N
. . N

Seventy-two JJ p
patients NNS p
with IN p
eczema NNS p
were VBD N
randomly RB N
allotted VBN N
to TO N
one CD N
of IN N
two CD N
treatment NN N
groups NNS N
: : N
A DT N
, , N
those DT N
receiving VBG N
dermatological JJ i
treatment NN i
only RB i
, , N
and CC N
B NNP N
, , N
those DT N
receiving VBG N
the DT N
same JJ i
dermatological JJ i
treatment NN i
plus CC i
psychiatric JJ i
treatment NN i
, , N
limited VBN N
where WRB N
possible JJ N
to TO N
four CD N
months NNS N
. . N

Cases NNS N
were VBD N
followed VBN N
up RP N
at IN N
six-monthly JJ N
dermatological JJ N
assessments NNS N
, , N
57 CD N
( ( N
79 CD N
% NN N
) ) N
for IN N
18 CD N
months NNS N
. . N

The DT N
findings NNS N
suggest VBP N
that IN N
in IN N
the DT N
presence NN o
of IN o
overt JJ o
emotional JJ o
disturbance NN o
, , N
of IN N
new JJ o
psychological JJ o
or CC o
psychophysiological JJ o
symptoms NNS o
preceding VBG o
the DT o
rash NN o
by IN N
up IN N
to TO N
a DT N
year NN N
, , N
and CC N
of IN N
high JJ o
motivation NN o
for IN N
it PRP N
, , N
brief JJ N
psychiatric JJ i
treatment NN i
improves VBZ o
the DT N
outcome NN N
in IN N
eczema NN o
( ( N
the DT N
proportion NN N
clear JJ N
at IN N
18 CD N
months NNS N
was VBD N
about IN N
doubled VBN N
) ) N
, , N
whereas NNS N
in IN N
their PRP$ N
absence NN N
such JJ N
treatment NN N
may MD N
worsen VB o
it PRP o
, , N
especially RB N
in IN N
the DT N
short JJ N
term NN N
. . N

-DOCSTART- -18704672- O O

Social JJ N
stories NNS N
: : N
mechanisms NNS N
of IN N
effectiveness NN N
in IN N
increasing VBG N
game NN i
play NN i
skills NNS i
in IN N
children NNS p
diagnosed VBN p
with IN p
autism NN p
spectrum NN p
disorder NN p
using VBG N
a DT N
pretest NN N
posttest NN N
repeated VBD N
measures NNS N
randomized VBN N
control NN N
group NN N
design NN N
. . N

An DT N
increasing VBG N
body NN N
of IN N
literature NN N
has VBZ N
indicated VBN N
that IN N
social JJ N
stories NNS N
are VBP N
an DT N
effective JJ N
way NN N
to TO N
teach VB N
individuals NNS p
diagnosed VBN p
with IN p
autism NN p
appropriate JJ N
social JJ N
behavior NN N
. . N

This DT N
study NN N
compared VBN N
two CD N
formats NNS N
of IN N
a DT N
social JJ i
story NN i
targeting VBG i
the DT i
improvement NN o
of IN o
social JJ o
skills NNS o
during IN i
game NN i
play NN i
using VBG N
a DT N
pretest NN N
posttest NN N
repeated VBD N
measures NNS N
randomized VBN N
control NN N
group NN N
design NN N
. . N

A DT N
total NN N
of IN N
45 CD p
children NNS p
diagnosed VBN p
with IN p
Autism NNP p
Spectrum NNP p
Disorder NNP p
( ( p
ASD NNP p
) ) p
ages VBZ p
7-14 CD p
were VBD N
randomly RB N
assigned VBN N
to TO N
standard VB N
, , N
directive JJ N
, , N
or CC N
control VB N
story NN N
conditions NNS N
. . N

Results NNS N
demonstrated VBD N
that IN N
the DT N
standard NN N
and CC N
directive JJ N
story NN N
formats NNS N
were VBD N
equally RB N
as IN N
effective JJ N
in IN N
eliciting VBG o
, , o
generalizing VBG o
and CC o
maintaining VBG o
the DT o
targeted VBN o
social JJ o
skills NNS o
in IN N
participants NNS N
who WP N
had VBD N
prior JJ N
game NN N
play NN N
experience NN N
and CC N
Verbal NNP o
Comprehension NNP o
Index NNP o
( ( o
VCI NNP o
) ) o
scores VBZ o
from IN o
the DT o
WISC-IV JJ o
intelligence NN o
test NN o
in IN N
the DT N
borderline NN N
range NN N
or CC N
above NN N
. . N

-DOCSTART- -26002536- O O

A DT N
Comparison NNP N
of IN N
Teaching NNP N
Modalities NNP N
and CC N
Fidelity NNP N
of IN N
Simulation NNP N
Levels NNP N
in IN N
Teaching NNP N
Resuscitation NNP N
Scenarios NNP N
. . N

INTRODUCTION NNP N
The DT N
purpose NN N
of IN N
our PRP$ N
study NN N
was VBD N
to TO N
examine VB N
the DT N
ability NN N
of IN N
novices NNS p
to TO N
learn VB N
selected VBN N
aspects NNS N
of IN N
Advanced NNP N
Cardiac NNP N
Life NNP N
Support NNP N
( ( N
ACLS NNP N
) ) N
in IN N
training VBG N
conditions NNS N
that WDT N
did VBD N
not RB N
incorporate VB N
simulation NN i
compared VBN N
to TO N
those DT N
that WDT N
contained VBD N
low- JJ i
and CC i
high-fidelity JJ i
simulation NN i
activities NNS N
. . N

We PRP N
sought VBD N
to TO N
determine VB N
at IN N
what WP N
level VBP N
additional JJ N
educational JJ N
opportunities NNS N
and CC N
simulation NN N
fidelity NN N
become VBP N
superfluous JJ N
with IN N
respect NN N
to TO N
learning VBG N
outcomes NNS N
. . N

METHODS NNP N
Totally RB p
39 CD p
medical JJ p
students NNS p
and CC p
physician JJ p
assistant NN p
students NNS p
were VBD N
randomly RB i
assigned VBN i
to TO i
4 CD i
training NN i
conditions NNS i
: : i
control NN i
( ( i
lecture NN i
only RB i
) ) i
, , i
video-based JJ i
didactic JJ i
instruction NN i
, , i
low- JJ i
, , i
and CC i
high-fidelity JJ i
simulation NN i
activities NNS i
. . i

Participants NNS N
were VBD N
assessed VBN N
using VBG N
a DT N
baseline NN N
written VBN N
pretest JJS o
of IN o
ACLS NNP o
knowledge NNP o
. . o

Following VBG i
this DT i
, , i
all DT i
participants NNS i
received VBD i
a DT i
lecture NN i
outlining VBG i
ACLS NNP i
science NN i
and CC i
algorithm JJ i
interpretation NN i
. . i

Participants NNS i
were VBD i
then RB i
trained VBN i
in IN i
specific JJ i
aspects NNS i
of IN i
ACLS NNP i
according VBG i
to TO i
their PRP$ i
assigned VBN i
instructional JJ i
condition NN i
. . i

After IN N
training NN N
, , N
each DT N
participant NN N
was VBD N
assessed VBN N
via IN N
a DT N
Megacode NNP o
performance NN o
examination NN o
and CC N
a DT N
written VBN o
posttest NN o
. . o

RESULTS NNP N
All NNP N
groups NNS N
performed VBD N
significantly RB N
better RBR N
on IN N
the DT N
written VBN N
posttest NN N
compared VBN N
with IN N
the DT N
pretest NN N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
; : N
however RB N
, , N
no DT N
groups NNS N
outperformed VBD N
any DT N
other JJ N
groups NNS N
. . N

On IN N
the DT N
Megacode NNP o
performance NN o
test NN o
, , N
the DT N
video-based JJ i
, , i
low- JJ i
, , i
and CC i
high-fidelity NN i
groups NNS i
performed VBD N
significantly RB N
better RBR N
than IN N
the DT N
control NN i
group NN i
( ( N
p JJ N
= NN N
0.028 CD N
, , N
p NN N
< VBD N
0.001 CD N
, , N
p NN N
= NNP N
0.019 CD N
) ) N
. . N

Equivalence NN N
testing VBG N
revealed VBD N
that IN N
the DT N
high-fidelity NN i
simulation NN i
condition NN N
was VBD N
statistically RB N
equivalent JJ N
to TO N
the DT N
video-based JJ i
and CC N
low-fidelity JJ i
simulation NN i
conditions NNS N
. . N

CONCLUSION NNP N
Video-based JJ i
and CC N
simulation-based JJ i
training NN N
is VBZ N
associated VBN N
with IN N
better JJR N
learning NN N
outcomes NNS N
when WRB N
compared VBN N
with IN N
traditional JJ N
didactic JJ N
lectures NNS N
only RB N
. . N

Video-based JJ i
, , i
low-fidelity NN i
, , i
and CC i
high-fidelity JJ i
simulation NN i
training VBG i
yield NN N
equivalent JJ N
outcomes NNS N
, , N
which WDT N
may MD N
indicate VB N
that IN N
high-fidelity NN N
simulation NN N
is VBZ N
superfluous JJ N
for IN N
the DT N
novice JJ p
trainee NN p
. . p

-DOCSTART- -20712132- O O

Glycerol NNP i
lidocaine NN i
eardrops NNS i
for IN N
the DT N
treatment NN N
of IN N
acute JJ o
abacterial JJ o
otitis NN o
externa NN o
. . o

Inflammations NNS N
of IN N
the DT N
external JJ N
auditory NN N
canal JJ N
number NN N
among IN N
the DT N
most RBS N
frequently RB N
occurring VBG N
ear-nose-throat NN N
diseases NNS N
. . N

For IN N
local JJ N
treatment NN N
, , N
substances NNS N
from IN N
various JJ N
groups NNS N
of IN N
active JJ N
ingredients NNS N
are VBP N
used VBN N
as IN N
combinations NNS N
and CC N
as IN N
single-agent JJ N
drugs NNS N
, , N
e.g NN N
. . N

antibiotics NNS i
, , i
glucocorticoids NNS i
or CC N
analgesics NNS i
[ VBP N
1 CD N
] NN N
. . N

In IN N
the DT N
case NN N
of IN N
acute NN N
otitis NN N
externa NN N
, , N
treatment NN N
measures NNS N
focus VBP N
on IN N
the DT N
reduction NN o
of IN o
pain NN o
and CC o
swelling NN o
. . o

The DT N
study NN N
described VBD N
here RB N
investigates VBZ N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
glycerol NN i
lidocaine NN i
eardrops VBZ i
for IN N
the DT N
treatment NN N
of IN N
acute JJ o
abacterial JJ o
otitis NN o
externa NN o
( ( N
CAS NNP N
No NNP N
. . N

for IN N
glycerol NN i
: : i
56-81-5 JJ N
, , N
lidocaine-HCl JJ i
: : i
73-78-9 JJ N
) ) N
. . N

In IN N
this DT N
double-blind NN N
, , N
three-arm NN N
study NN N
, , N
105 CD p
patients NNS p
diagnosed VBN p
with IN p
acute JJ p
abacterial JJ p
otitis NN p
externa NN p
were VBD p
included VBN p
and CC p
randomized VBN p
to TO N
receive VB N
either DT N
glycerol NN i
eardrops VBZ i
, , i
glycerol NN i
eardrops NNS i
with IN i
0.5 CD i
% NN i
lidocaine NN i
, , i
or CC i
glycerol NN i
eardrops NNS i
with IN i
2 CD i
% NN i
lidocaine NN i
for IN N
seven CD N
days NNS N
. . N

The DT N
primary JJ N
outcome NN N
parameter NN N
was VBD N
the DT N
change NN N
of IN N
the DT N
five CD N
typical JJ N
clinical NN N
symptoms NNS N
, , N
earache NN o
, , o
itching NN o
, , o
otorrhea NN o
, , o
hearing VBG o
impairment NN o
, , o
and CC o
clogged VBD o
ear NN o
at IN N
Visit NNP N
2 CD N
( ( N
Day NNP N
7 CD N
) ) N
based VBN N
on IN N
the DT N
initial JJ N
examination NN N
on IN N
Day NNP N
0 CD N
. . N

Both DT N
therapy NN N
groups NNS N
treated VBD N
with IN N
a DT N
combination NN N
of IN N
glycerol NN i
and CC i
lidocaine NN i
exhibited VBN N
definite JJ N
improvement NN N
in IN N
overall JJ o
symptoms NNS o
after IN N
seven CD N
days NNS N
. . N

This DT N
improvement NN N
differed VBD N
from IN N
the DT N
mild JJ o
reduction NN o
of IN o
symptoms NNS o
under IN N
treatment NN N
with IN N
glycerol NN N
eardrops NNS N
alone RB N
. . N

Overall JJ N
improvement NN N
of IN N
symptoms NNS N
, , N
expressed VBN N
by IN N
the DT N
area NN N
under IN N
the DT N
curve NN N
of IN N
the DT N
baseline-adjusted JJ o
symptom NN o
sum NN o
score NN o
, , N
yielded VBD N
a DT N
mean JJ N
value NN N
of IN N
10.95 CD N
( ( N
standard JJ N
deviation NN N
27.4 CD N
) ) N
for IN N
the DT N
morning NN N
survey NN N
of IN N
the DT N
groups NNS N
receiving VBG N
eardrops NNS N
containing VBG N
only RB N
glycerol NN N
; : N
in IN N
comparison NN N
, , N
for IN N
eardrops NNS N
containing VBG N
glycerol NN i
and CC N
2 CD N
% NN N
lidocaine NN i
it PRP N
was VBD N
15.71 CD N
( ( N
+/- JJ N
23.6 CD N
) ) N
and CC N
for IN N
glycerol NN i
with IN N
0.5 CD N
% NN N
lidocaine NN i
, , N
23.16 CD N
( ( N
+/- JJ N
19.4 CD N
) ) N
. . N

No UH o
severe JJ o
adverse JJ o
events NNS o
occurred VBD N
. . N

Five CD N
adverse JJ o
events NNS o
were VBD N
documented VBN N
during IN N
the DT N
clinical JJ N
investigation NN N
, , N
none NN N
of IN N
which WDT N
was VBD N
considered VBN N
by IN N
the DT N
investigators NNS N
to TO N
be VB N
related VBN N
to TO N
the DT N
study NN N
medication NN N
. . N

Local JJ N
therapy NN i
with IN i
glycerol NN i
lidocaine NN i
eardrops VBZ i
is VBZ N
a DT N
safe JJ o
, , o
and CC o
cost-effective JJ o
treatment NN N
for IN N
the DT N
widely RB N
spread JJ N
clinical JJ N
picture NN N
of IN N
acute JJ N
abacterial JJ N
otitis NN N
externa NN N
. . N

The DT N
advantage NN N
regarding VBG N
efficacy NN N
of IN N
this DT N
combination NN N
compared VBN N
with IN N
glycerol NN i
eardrops NNS N
must MD N
be VB N
demonstrated VBN N
in IN N
an DT N
adequately RB N
powered JJ N
clinical JJ N
trial NN N
. . N

-DOCSTART- -14699228- O O

The DT N
effect NN N
of IN N
use NN N
of IN N
pyridostigmine NN i
and CC N
requirement NN N
of IN N
vecuronium NN i
in IN N
patients NNS p
with IN p
myasthenia JJ p
gravis NN p
. . p

CONTEXT NNP N
Patients NNPS p
with IN p
myasthenia NNP p
gravis FW p
receive JJ p
pyridostigmine NN i
, , p
an DT p
anticholinesterase NN i
agent NN i
, , N
as IN N
a DT N
part NN N
of IN N
therapy NN N
. . N

These DT N
patients NNS N
demonstrate VBP N
a DT N
heightened JJ N
sensitivity NN N
towards IN N
non-depolarising JJ N
muscle NN N
relaxants NNS N
. . N

Continuing VBG N
pyridostigmine NN i
till IN N
the DT N
day NN N
of IN N
the DT N
surgery NN N
or CC N
omitting VBG N
it PRP N
on IN N
the DT N
night NN N
before IN N
surgery NN N
could MD N
provide VB N
variable JJ N
results NNS N
with IN N
regards NNS N
to TO N
the DT N
effect NN N
of IN N
vecuronium NN i
. . i

AIMS NNP N
Myographic NNP N
evaluation NN N
of IN N
a DT N
dose NN N
of IN N
vecuronium NN N
in IN N
patients NNS p
with IN p
myasthenia JJ p
gravis NN p
on IN p
pyridostigmine NN p
therapy NN p
. . p

SETTING NN N
AND CC N
DESIGN NNP N
A NNP N
randomised JJ N
, , N
double-blind JJ N
, , N
clinical JJ N
study NN N
conducted VBN N
in IN N
a DT N
teaching JJ N
hospital NN N
. . N

SUBJECTS NNP N
AND NNP N
METHODS NNP N
Medically NNP p
( ( i
oral JJ i
pyridostigmine NN i
) ) i
well-controlled JJ p
adult NN p
patients NNS p
with IN p
myasthenia JJ p
gravis NNS p
who WP p
were VBD p
posted VBN p
for IN p
thymectomy NN i
, , N
were VBD N
randomly RB N
divided VBN N
into IN N
two CD N
groups NNS N
. . N

Patients NNS N
in IN N
Group NNP N
1 CD N
received VBD N
their PRP$ N
last JJ N
dose NN N
of IN N
pyridostigmine NN i
on IN i
the DT i
night NN i
before IN i
surgery NN i
while IN N
those DT N
in IN N
Group NNP N
2 CD N
received VBD N
even RB N
the DT N
morning NN i
dose NN i
of IN i
the DT i
drug NN i
on IN i
the DT i
day NN i
of IN i
surgery NN i
. . i

Neostigmine NNP i
( ( N
1-2 JJ N
mg NN N
) ) N
intravenously RB N
was VBD N
used VBN N
as IN N
rescue JJ N
medication NN N
. . N

Vecuronium NNP i
( ( N
0.01 CD N
mg/kg NN N
) ) N
was VBD N
used VBN N
for IN N
intubation NN N
and CC N
muscle NN N
relaxation NN N
during IN N
trans-sternal JJ i
thymectomy NN i
and CC N
its PRP$ N
effect NN N
was VBD N
reversed VBN N
using VBG N
neostigmine NN N
and CC N
atropine NN N
. . N

RESULTS NNP N
Fourteen JJ p
patients NNS p
( ( N
7 CD N
in IN N
each DT N
group NN N
) ) N
belonging NN N
to TO N
both DT N
sexes NNS N
were VBD N
enrolled VBN N
in IN N
the DT N
study NN N
. . N

The DT N
intubating VBG N
dose NN N
of IN N
vecuronium NN N
showed VBD N
quicker JJR N
onset JJ o
time NN o
( ( N
155 CD N
sec NN N
or CC N
2.7 CD N
min NN N
approx NN N
. . N

) ) N
and CC N
peak JJ o
effect NN o
( ( N
99 CD N
% NN N
T1 NNP N
suppression NN N
) ) N
in IN N
patients NNS N
belonging VBG N
to TO N
Group NNP N
1 CD N
, , N
and CC N
3/7 CD N
( ( N
43 CD N
% NN N
) ) N
complained VBD N
of IN N
respiratory JJ N
discomfort NN N
while IN N
waiting VBG N
for IN N
surgery NN N
. . N

By IN N
giving VBG N
the DT N
morning NN N
dose NN N
of IN N
pyridostigmine NN i
( ( N
Group NNP N
2 CD N
) ) N
, , N
an DT N
identical JJ N
intubating NN N
dose NN N
of IN N
vecuronium NN i
showed VBD N
relative JJ o
resistance NN o
( ( N
peak JJ N
effect-97 NN N
% NN N
T1 NNP N
suppression NN N
) ) N
and CC N
delayed VBN o
onset NN o
time NN o
( ( N
198 CD N
sec NN N
approx. NN N
) ) N
. . N

However RB N
, , N
the DT N
reversal NN N
was VBD N
complete JJ N
at IN N
the DT N
end NN N
of IN N
surgery NN N
in IN N
both CC N
the DT N
regimens NNS N
. . N

CONCLUSIONS NNP N
Omission NNP N
of IN N
the DT N
pyridostigmine NN i
dose NN N
on IN N
the DT N
day NN N
of IN N
surgery NN N
predisposed VBN N
patients NNS N
with IN N
myasthenia JJ p
gravis NN p
to TO N
the DT N
possibility NN N
of IN N
respiratory JJ N
discomfort NN N
and CC N
sensitivity NN N
to TO N
vecuronium NN i
. . i

Continued VBN N
administration NN N
significantly RB N
prolonged VBD N
the DT N
onset JJ N
time NN N
of IN N
vecuronium NN i
and CC N
the DT N
patients NNS N
required VBD N
a DT N
higher JJR N
dose NN N
of IN N
vecuronium NN i
. . i

-DOCSTART- -7997384- O O

Effect NN N
of IN N
simultaneous JJ N
didanosine JJ i
administration NN N
on IN N
itraconazole JJ o
absorption NN o
in IN N
healthy JJ p
volunteers NNS p
. . p

STUDY NNP N
OBJECTIVE NNP N
To TO N
investigate VB N
the DT N
effect NN N
of IN N
simultaneously RB N
administered VBN N
didanosine NN i
( ( i
ddI NN i
) ) i
on IN N
the DT N
absorption NN N
of IN N
a DT N
single JJ N
dose NN N
of IN N
itraconazole NN i
. . i

DESIGN NNP N
Randomized NNP N
, , N
crossover NN N
, , N
unblinded JJ N
single-dose JJ N
pharmacokinetic JJ N
study NN N
in IN N
healthy JJ p
volunteers NNS p
. . p

Comparisons NNS N
of IN N
itraconazole JJ i
alone NN i
and CC N
itraconazole JJ i
with IN i
simultaneous JJ i
ddI NNS i
were VBD N
performed VBN N
on IN N
days NNS N
1 CD N
and CC N
15 CD N
. . N

SETTING VB N
A DT p
university NN p
medical JJ p
center NN p
. . p

PATIENTS VB N
Seven NNP p
healthy JJ p
men NNS p
and CC p
women NNS p
. . p

Six NNP p
subjects NNS p
( ( p
86 CD p
% NN p
) ) p
completed VBD p
the DT p
study NN p
; : p
one CD p
was VBD p
removed VBN p
due JJ p
to TO p
the DT p
development NN p
of IN p
a DT p
rash NN p
. . p

INTERVENTIONS NNP N
Volunteers NNPS N
received VBD N
a DT N
single JJ i
200-mg JJ i
oral JJ i
dose NN i
of IN i
itraconazole NN i
or CC i
itraconazole NN i
with IN i
concomitant JJ i
oral JJ i
ddI NN i
300 CD i
mg NN i
( ( i
two CD i
150-mg JJ i
tablets NNS i
) ) i
dispersed VBD N
in IN N
240 CD N
ml JJ N
water NN N
. . N

Each DT N
regimen NN N
was VBD N
separated VBN N
by IN N
a DT N
2-week JJ N
washout NN N
period NN N
. . N

Serum NNP N
samples NNS N
were VBD N
obtained VBN N
frequently RB N
for IN N
12 CD N
hours NNS N
after IN N
the DT N
dose NN N
. . N

MEASUREMENTS NNP N
AND CC N
MAIN NNP N
RESULTS NNP N
Concentrations NNP N
of IN N
itraconazole NN i
were VBD N
determined VBN N
using VBG N
a DT N
microbiologic JJ N
assay NN N
. . N

Individual JJ N
concentrations NNS N
in IN N
serum JJ o
versus NN o
time NN o
data NNS o
were VBD N
evaluated VBN N
by IN N
linear JJ N
regression NN N
analysis NN N
. . N

Peak NNP o
serum JJ o
concentration NN o
and CC o
time NN o
to TO o
peak VB o
were VBD N
determined VBN N
by IN N
visual JJ N
inspection NN N
of IN N
each DT N
individual NN N
's POS N
serum JJ N
concentration-time JJ N
curve NN N
. . N

A DT N
mean JJ o
+/- JJ o
SD NNP o
peak NN o
serum NN o
itraconazole JJ o
concentration NN o
of IN N
0.90 CD N
+/- JJ N
0.30 CD N
micrograms/ml NN N
was VBD N
observed VBN N
at IN N
3.0 CD N
+/- JJ N
0.7 CD N
hours NNS N
when WRB N
itraconazole NN N
was VBD N
administered VBN N
alone RB N
, , N
compared VBN N
with IN N
undetectable JJ N
levels NNS N
in IN N
all DT N
patients NNS N
during IN N
therapy NN N
with IN N
ddI NN N
. . N

CONCLUSIONS NNP N
Simultaneous NNP N
oral JJ i
administration NN i
of IN i
ddI NNS i
significantly RB N
decreases VBZ N
absorption NN o
of IN o
itraconazole NN o
. . o

These DT N
drugs NNS N
should MD N
not RB N
be VB N
administered VBN N
concurrently RB N
. . N

-DOCSTART- -6376144- O O

Treatment NN N
of IN N
adult NN p
asthma NN p
: : p
controlled VBN N
double-blind JJ N
clinical JJ N
trial NN N
of IN N
oxitropium NN i
bromide NN i
. . i

Sixteen NNP p
young JJ p
adult NN p
sufferers NNS p
from IN p
extrinsic JJ p
paroxysmal JJ p
asthma NN p
with IN p
pollen JJ p
hypersensitivity NN p
took VBD p
part NN p
in IN p
a DT p
therapeutic JJ p
trial NN p
of IN p
the DT p
synthetic JJ i
anticholinergic NN i
agent NN i
oxitropium NN i
bromide NN i
administered VBN p
by IN p
a DT p
metered VBN p
dose NN p
inhaler NN p
. . p

The DT N
study NN N
comprised VBD N
three CD N
3-week JJ N
periods NNS N
. . N

The DT N
first JJ N
, , N
run-in JJ N
period NN N
was VBD N
carried VBN N
out IN N
to TO N
confirm VB N
the DT N
ability NN N
of IN N
the DT N
patients NNS N
to TO N
maintain VB N
a DT N
daily JJ N
record NN N
of IN N
symptoms NNS N
. . N

During IN N
the DT N
second JJ N
and CC N
third JJ N
periods NNS N
, , N
the DT N
patient NN N
received VBD N
3 CD N
X NNP N
2 CD N
inhalations NNS N
of IN N
drug NN N
or CC N
placebo NN i
in IN N
a DT N
cross-over JJ N
design NN N
. . N

The DT N
medical JJ N
staff NN N
was VBD N
blind NN N
to TO N
the DT N
nature NN N
of IN N
the DT N
aerosol NN N
( ( i
drug NN i
or CC N
placebo NN i
) ) i
, , N
which WDT N
was VBD N
given VBN N
in IN N
random JJ N
order NN N
. . N

The DT N
run-in JJ N
clinical JJ N
score NN N
was VBD N
high JJ N
. . N

Asymptomatic JJ o
days NNS o
were VBD N
relatively RB N
infrequent JJ N
and CC N
daily JJ o
drug NN o
consumption NN o
was VBD N
high JJ N
. . N

Functional JJ N
studies NNS N
between IN N
the DT N
cross-over NN N
periods NNS N
showed VBD N
flow-rate JJ o
values NNS o
close RB N
to TO N
normal JJ N
, , N
with IN N
an DT N
increase NN N
in IN N
residual JJ o
volume NN o
and CC o
functional JJ o
residual JJ o
capacity NN o
. . o

During IN N
treatment NN N
either CC N
with IN N
placebo NN i
or CC N
oxitropium NN i
, , N
there EX N
was VBD N
a DT N
statistically RB N
significant JJ N
decrease NN o
in IN N
clinical JJ o
scores NNS o
. . o

Results NNS N
for IN N
oxitropium JJ i
bromide NN i
treatment NN i
were VBD N
significantly RB o
better JJR o
than IN N
the DT N
run-in JJ o
values NNS o
( ( N
p NN N
less JJR N
than IN N
0.005 CD N
) ) N
and CC N
the DT N
placebo NN i
period NN N
( ( N
p NN N
less JJR N
than IN N
0.02 CD N
) ) N
. . N

There EX N
was VBD N
no DT N
significant JJ N
change NN N
in IN N
non-trial JJ o
drug NN o
consumption NN o
. . o

Functional NNP N
values NNS N
showed VBD N
no DT N
difference NN N
in IN N
terms NNS N
of IN N
flow NN o
rate NN o
, , N
although IN N
oxitropium NN N
did VBD N
cause VB N
a DT N
significant JJ N
improvement NN N
in IN N
the DT N
RV/TLC NNP o
ratio NN o
( ( N
p NN N
less JJR N
than IN N
0.05 CD N
) ) N
. . N

No DT N
adverse JJ o
reactions NNS o
were VBD N
reported VBN N
. . N

-DOCSTART- -2232625- O O

The DT N
influence NN N
of IN N
penbutolol NN i
and CC N
placebo NN i
on IN N
blood NN N
sugar NN N
levels NNS N
and CC N
insulin NN N
consumption NN N
in IN N
the DT N
glucose-controlled JJ N
insulin NN N
infusion NN N
system NN N
( ( N
artificial JJ N
endocrine NN N
pancreas NNS N
) ) N
. . N

The DT N
aim NN N
of IN N
the DT N
study NN N
was VBD N
to TO N
investigate VB N
the DT N
influence NN N
of IN N
40 CD N
mg NN N
of IN N
the DT N
beta-blocker NN N
penbutolol NN i
( ( N
Betapressin NNP N
TM NNP N
; : N
Hoechst NNP N
Ltd. NNP N
, , N
Frankfurt/Main NNP N
) ) N
in IN N
comparison NN N
to TO N
placebo VB i
on IN N
the DT N
insulin NN N
consumption NN N
on IN N
the DT N
blood NN N
sugar NN N
profile NN N
in IN N
twelve JJ p
insulin-dependent JJ p
diabetes NNS p
( ( p
IDDM NNP p
) ) p
patients NNS p
. . p

The DT N
patients NNS N
were VBD N
treated VBN i
with IN i
penbutolol NN i
and CC i
placebo NN i
for IN i
a DT i
period NN i
of IN i
three CD i
days NNS i
, , i
and CC i
then RB i
were VBD i
examined VBN i
with IN i
the DT i
help NN i
of IN i
the DT i
glucose-controlled JJ i
insulin NN i
infusion NN i
system NN i
. . i

The DT N
blood NN o
sugar NN o
profile NN o
and CC o
insulin NN o
consumption NN o
over IN N
a DT N
24 CD N
hour NN N
period NN N
was VBD N
not RB N
affected VBN N
by IN N
either DT N
penbutolol NN N
or CC N
placebo NN N
, , N
nor CC N
could MD N
any DT N
changes NNS N
be VB N
measured VBN N
in IN N
these DT N
parameters NNS N
when WRB N
measured VBN N
after IN N
food NN N
intake NN N
. . N

After IN N
a DT N
submaximal JJ N
exercise NN N
load NN N
on IN N
the DT N
bicycle NN N
ergometer NN N
( ( N
1 CD N
watt NN N
per IN N
kg NN N
body NN N
weight VBD N
) ) N
following VBG N
an DT N
evening JJ N
meal NN N
, , N
no DT N
difference NN N
could MD N
be VB N
observed VBN N
between IN N
penbutolol NN N
and CC N
placebo NN N
in IN N
the DT N
above-mentioned JJ N
parameters NNS N
. . N

The DT N
same JJ N
was VBD N
also RB N
true JJ N
for IN N
hormonal JJ N
parameters NNS N
as IN N
STH NNP o
, , o
ACTH NNP o
, , o
cortisol NN o
, , o
and CC o
catecholamines NNS o
. . o

These DT N
findings NNS N
demonstrated VBD N
that IN N
medication NN N
of IN N
penbutolol NN N
over IN N
a DT N
three-day JJ N
period NN N
has VBZ N
no DT N
influence NN N
on IN N
the DT N
baseline NN N
blood NN N
sugar NN N
profile NN N
and CC N
insulin NN N
consumption NN N
or CC N
on IN N
insulin NN N
consumption NN N
after IN N
food NN N
intake NN N
during IN N
rest NN N
and CC N
physical JJ N
exercise NN N
. . N

-DOCSTART- -11450816- O O

Lamotrigine NNP i
therapy NN i
for IN N
autistic JJ p
disorder NN p
: : p
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
trial NN N
. . N

In IN N
autism NN N
, , N
glutamate NN N
may MD N
be VB N
increased VBN N
or CC N
its PRP$ N
receptors NNS N
up-regulated JJ N
as IN N
part NN N
of IN N
an DT N
excitotoxic JJ N
process NN N
that WDT N
damages NNS N
neural JJ N
networks NNS N
and CC N
subsequently RB N
contributes VBZ N
to TO N
behavioral VB N
and CC N
cognitive VB N
deficits NNS N
seen VBN N
in IN N
the DT N
disorder NN N
. . N

This DT N
was VBD N
a DT N
double-blind JJ N
, , N
placebo-controlled JJ N
, , N
parallel JJ N
group NN N
study NN N
of IN N
lamotrigine NN i
, , N
an DT N
agent NN N
that WDT N
modulates VBZ N
glutamate JJ N
release NN N
. . N

Twenty-eight JJ p
children NNS p
( ( p
27 CD p
boys NNS p
) ) p
ages VBZ p
3 CD p
to TO p
11 CD p
years NNS p
( ( p
M NNP p
= NNP p
5.8 CD p
) ) p
with IN p
a DT p
primary JJ p
diagnosis NN p
of IN p
autistic JJ p
disorder NN p
received VBD i
either CC i
placebo NN i
or CC i
lamotrigine JJ i
twice JJ i
daily RB i
. . i

In IN N
children NNS N
on IN N
lamotrigine NN i
, , i
the DT i
drug NN i
was VBD i
titrated VBN i
upward RB i
over IN i
8 CD i
weeks NNS i
to TO i
reach VB i
a DT i
mean JJ i
maintenance NN i
dose NN i
of IN i
5.0 CD i
mg/kg NNS i
per IN i
day NN i
. . i

This DT i
dose NN i
was VBD i
then RB i
maintained VBN i
for IN i
4 CD i
weeks NNS i
. . i

Following VBG i
maintenance NN i
evaluations NNS i
, , i
the DT i
drug NN i
was VBD i
tapered VBN i
down RB i
over RB i
2 CD i
weeks NNS i
. . i

The DT i
trial NN i
ended VBD i
with IN i
a DT i
4-week JJ i
drug-free JJ i
period NN i
. . i

Outcome NNP N
measures VBZ N
included VBD N
improvements NNS o
in IN o
severity NN o
and CC o
behavioral JJ o
features NNS o
of IN o
autistic JJ o
disorder NN o
( ( o
stereotypies NNS o
, , o
lethargy NN o
, , o
irritability NN o
, , o
hyperactivity NN o
, , o
emotional JJ o
reciprocity NN o
, , o
sharing VBG o
pleasures NNS o
) ) o
and CC o
improvements NNS o
in IN o
language NN o
and CC o
communication NN o
, , o
socialization NN o
, , o
and CC o
daily RB o
living VBG o
skills NNS o
noted VBD N
after IN N
12 CD N
weeks NNS N
( ( N
the DT N
end NN N
of IN N
a DT N
4-week JJ N
maintenance NN N
phase NN N
) ) N
. . N

We PRP N
did VBD N
not RB N
find VB N
any DT N
significant JJ N
differences NNS N
in IN N
improvements NNS N
between IN N
lamotrigine NN i
or CC i
placebo NN i
groups NNS N
on IN N
the DT N
Autism NNP o
Behavior NNP o
Checklist NNP o
, , o
the DT o
Aberrant NNP o
Behavior NNP o
Checklist NNP o
, , o
the DT o
Vineland NNP o
Adaptive NNP o
Behavior NNP o
scales NNS o
, , o
the DT o
PL-ADOS NNP o
, , o
or CC o
the DT o
CARS NNPS o
. . o

Parent NN o
rating NN o
scales NNS o
showed VBD N
marked JJ N
improvements NNS N
, , N
presumably RB N
due JJ N
to TO N
expectations NNS N
of IN N
benefits NNS N
. . N

-DOCSTART- -25451017- O O

A DT N
randomized JJ N
double-blind JJ N
placebo-controlled JJ N
clinical JJ N
trial NN N
of IN N
adjuvant JJ N
buspirone NN i
for IN N
irritability NN o
in IN p
autism NN p
. . p

BACKGROUND IN N
The DT N
brain NN N
serotonin NN N
level NN N
is VBZ N
decreased VBN N
in IN N
individuals NNS N
with IN N
autism NN N
. . N

Buspirone NNP N
is VBZ N
a DT N
5-HT JJ N
( ( N
1A CD N
) ) N
receptor NN N
agonist NN N
with IN N
antiaggressive JJ N
effects NNS N
increasing VBG N
prosocial JJ N
behaviors NNS N
. . N

METHODS NNP N
We PRP N
conducted VBD N
an DT N
8-week JJ N
randomized JJ N
double-blind JJ N
placebo-controlled JJ i
clinical JJ N
trial NN N
. . N

Participants NNS p
included VBD p
40 CD p
outpatient JJ p
children NNS p
and CC p
adolescents NNS p
with IN p
autism NN p
. . p

The DT N
patients NNS N
took VBD N
buspirone NN i
plus CC i
risperidone NN i
or CC i
risperidone NN i
plus CC i
placebo NN i
during IN N
8 CD N
weeks NNS N
. . N

The DT N
patients NNS N
were VBD N
assessed VBN N
at IN N
baseline NN N
, , N
week NN N
4 CD N
, , N
and CC N
week NN N
8 CD N
using VBG N
the DT N
Aberrant NNP N
Behavior NNP N
Checklist-Community NNP N
Rating NNP N
Scale NNP N
. . N

RESULTS NNP N
Eighteen JJ p
patients NNS p
in IN p
the DT p
placebo NN p
group NN p
and CC N
16 CD p
patients NNS p
in IN p
the DT p
buspirone NN p
group NN p
completed VBD N
this DT N
trial NN N
. . N

The DT N
mean JJ N
dose NN N
of IN N
buspirone NN N
was VBD N
6.7 CD N
( ( N
SD NNP N
2.7 CD N
) ) N
mg/day NN N
. . N

Irritability NNP o
subscale JJ o
score NN o
significantly RB N
decreased VBD N
during IN N
this DT N
trial NN N
in IN N
both DT N
groups NNS N
( ( N
buspirone NN N
group NN N
: : N
declined VBD N
from IN N
25.7 CD N
[ NNS N
SD NNP N
5.7 CD N
] NN N
to TO N
16.3 CD N
[ NNS N
SD NNP N
8.5 CD N
] NNP N
; : N
placebo CC N
group NN N
: : N
declined VBD N
from IN N
24.7 CD N
[ NNS N
SD NNP N
7.6 CD N
] NN N
to TO N
18.2 CD N
[ NNS N
SD NNP N
7.7 CD N
] NN N
) ) N
. . N

The DT N
Cohen NNP N
d NN N
effect NN N
size NN N
was VBD N
.45 NNP N
. . N

Thirteen NNP N
( ( N
81.2 CD N
% NN N
) ) N
of IN N
16 CD N
patients NNS N
in IN N
the DT N
buspirone NN N
group NN N
and CC N
7 CD N
( ( N
38.9 CD N
% NN N
) ) N
of IN N
18 CD N
patients NNS N
in IN N
the DT N
placebo NN N
group NN N
showed VBD N
a DT N
?30 NN N
% NN N
decline NN N
in IN N
irritability NN o
score NN o
. . o

The DT o
relative JJ o
risk NN o
for IN o
treatment NN N
was VBD N
2.1 CD N
. . N

There EX N
were VBD N
no DT N
serious JJ o
adverse JJ o
effects NNS o
. . o

The DT N
most RBS N
common JJ N
adverse JJ N
effects NNS N
in IN N
the DT i
buspirone NN i
group NN i
were VBD o
increased VBN o
appetite RB o
, , o
drowsiness NN o
, , o
and CC o
fatigue NN o
. . o

CONCLUSION VB N
This DT N
clinical JJ N
trial NN N
supports NNS N
that IN N
low JJ N
dose VB N
buspirone NN N
plus CC N
risperidone NN N
is VBZ N
more RBR N
effective JJ N
than IN N
risperidone NN N
plus CC N
placebo NN N
for IN N
treating VBG o
irritability NN o
in IN o
individuals NNS p
with IN p
autism NN p
. . p

-DOCSTART- -16137240- O O

Randomised VBN N
clinical JJ N
trial NN N
of IN N
physiotherapy NN i
after IN N
open JJ N
abdominal JJ N
surgery NN N
in IN N
high JJ p
risk NN p
patients NNS p
. . p

Postoperative NNP i
physiotherapy NN i
has VBZ N
been VBN N
shown VBN N
to TO N
reduce VB o
the DT o
incidence NN o
of IN N
postoperative JJ N
pulmonary JJ N
complications NNS N
after IN N
open JJ N
abdominal JJ N
surgery NN N
. . N

This DT N
study NN N
aimed VBD N
to TO N
determine VB N
if IN N
the DT N
addition NN N
of IN N
deep JJ i
breathing NN i
exercises NNS i
and CC N
secretion NN i
clearing NN i
techniques NNS i
to TO N
a DT N
standardised JJ i
physiotherapist-directed JJ i
program NN i
of IN N
early JJ N
mobilisation NN N
improved VBD N
clinical JJ N
outcomes NNS N
in IN N
patients NNS p
undergoing VBG p
open JJ p
abdominal JJ p
surgery NN p
. . p

Fifty-six JJ p
patients NNS p
undergoing VBG p
open JJ i
abdominal JJ i
surgery NN i
, , p
at IN p
high JJ p
risk NN p
of IN p
developing VBG p
postoperative JJ p
pulmonary JJ p
complications NNS p
, , N
were VBD N
randomised VBN i
before IN i
operation NN i
to TO i
an DT i
early JJ i
mobilisation-only JJ i
group NN i
or CC i
an DT i
early JJ i
mobilisation-plus-deep JJ i
breathing NN i
and CC i
coughing VBG i
group NN i
. . i

Mobility NNP o
duration NN o
, , o
frequency NN o
and CC o
intensity NN o
of IN o
breathing VBG o
interventions NNS o
were VBD i
quantified VBN i
for IN i
both DT i
groups NNS i
. . i

All DT i
outcomes NNS i
were VBD i
assessed VBN i
by IN i
a DT i
blinded JJ i
outcomes NN i
researcher NN i
using VBG i
a DT i
standardised JJ i
outcomes NNS i
measurement JJ i
tool NN i
developed VBD i
specifically RB i
for IN i
this DT i
population NN i
. . i

Outcomes CC o
included VBD o
incidence NN o
of IN o
clinically RB o
significant JJ o
postoperative JJ o
pulmonary JJ o
complications NNS o
, , o
fever RB o
, , o
length NN o
of IN o
stay NN o
, , o
and CC o
restoration NN o
of IN o
mobility NN o
. . o

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
groups NNS N
in IN N
mean JJ o
age NN o
, , o
anaesthetic JJ o
time NN o
, , o
perioperative JJ o
morbidity NN o
, , o
or CC o
postoperative JJ o
mobility NN o
. . o

Outcome NNP N
data NNS N
were VBD N
available JJ N
for IN N
89 CD N
% NN N
of IN N
enrolled JJ N
subjects NNS N
. . N

Overall JJ N
incidence NN N
of IN N
postoperative JJ o
pulmonary JJ o
complications NNS o
was VBD N
16 CD N
% NN N
. . N

The DT N
incidence NN N
of IN N
postoperative JJ o
pulmonary JJ o
complications NNS o
in IN N
the DT N
non-deep JJ N
breathing NN N
and CC N
coughing VBG N
group NN N
was VBD N
14 CD N
% NN N
, , N
and CC N
the DT N
incidence NN N
of IN N
postoperative JJ o
pulmonary JJ o
complications NNS o
in IN N
the DT N
deep JJ N
breathing NN N
and CC N
coughing VBG N
group NN N
was VBD N
17 CD N
% NN N
, , N
( ( N
absolute JJ N
risk NN N
reduction NN N
-3 NNP N
% NN N
, , N
95 CD N
% NN N
C1 NNP N
-22 NNP N
to TO N
19 CD N
% NN N
) ) N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
groups NNS N
in IN N
the DT N
incidence NN N
of IN N
fever NN o
, , o
physiotherapist JJ o
time NN o
, , o
or CC o
the DT o
number NN o
of IN o
treatments NNS o
. . o

This DT N
study NN N
suggests VBZ N
that IN N
, , N
in IN N
this DT N
clinical JJ N
setting NN N
, , N
the DT N
addition NN N
of IN N
deep JJ i
breathing NN i
and CC i
coughing NN i
exercises NNS i
to TO N
a DT N
physiotherapist-directed JJ N
program NN N
of IN N
early JJ N
mobilisation NN N
does VBZ N
not RB N
significantly RB N
reduce VB N
the DT N
incidence NN N
of IN N
clinically RB N
significant JJ N
postoperative JJ N
pulmonary JJ N
complications NNS N
in IN N
high JJ p
risk NN p
open JJ p
abdominal JJ p
surgery NN p
subjects NNS p
. . p

-DOCSTART- -16116055- O O

Impact NN N
of IN N
a DT N
single JJ N
intravenous JJ N
administration NN N
of IN N
nicorandil JJ i
before IN N
reperfusion NN N
in IN N
patients NNS p
with IN p
ST-segment-elevation NNP p
myocardial JJ p
infarction NN p
. . p

BACKGROUND NNP N
Intravenous NNP N
nicorandil NN i
, , N
a DT N
hybrid JJ N
compound NN N
of IN N
ATP-sensitive JJ N
potassium NN N
channel NN N
opener NN N
and CC N
nitric JJ N
oxide NN N
donor NN N
, , N
has VBZ N
been VBN N
reported VBN N
to TO N
ameliorate VB N
early JJ N
functional NN N
and CC N
clinical JJ N
problems NNS N
in IN N
patients NNS p
with IN p
acute JJ p
myocardial JJ p
infarction NN p
. . p

However RB N
, , N
its PRP$ N
effects NNS N
on IN N
the DT N
late JJ N
phase NN N
remain VBP N
unclear JJ N
. . N

METHODS NNP N
AND CC N
RESULTS NNP N
This DT N
follow-up JJ N
study NN N
to TO N
5 CD N
years NNS N
of IN N
a DT N
randomized JJ N
, , N
double-blinded JJ N
trial NN N
was VBD N
conducted VBN N
among IN N
368 CD p
patients NNS p
with IN p
first JJ p
ST-segment-elevation NNP p
myocardial JJ p
infarction NN p
undergoing VBG p
percutaneous JJ p
coronary JJ p
intervention NN p
( ( p
PCI NNP p
) ) p
. . p

They PRP N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
12 CD N
mg NN N
of IN N
nicorandil NN i
or CC i
a DT i
placebo NN i
intravenously RB N
just RB N
before IN N
reperfusion NN N
. . N

We PRP N
analyzed VBD N
incidence NN N
of IN N
cardiovascular JJ o
death NN o
or CC o
rehospitalization NN o
for IN N
congestive JJ o
heart NN o
failure NN o
after IN N
PCI NNP N
as RB N
well RB N
as IN N
various JJ N
aspects NNS N
of IN N
epicardial JJ N
flow NN N
and CC N
microvascular JJ N
function NN N
. . N

Mean JJ N
follow-up NN N
was VBD N
2.4 CD N
years NNS N
( ( N
SD NNP N
, , N
1.4 CD N
) ) N
. . N

A DT N
total NN N
of IN N
12 CD N
( ( N
6.5 CD N
% NN N
) ) N
patients NNS N
receiving VBG N
nicorandil JJ i
and CC N
30 CD N
( ( N
16.4 CD N
% NN N
) ) N
receiving NN N
placebo NN i
had VBD N
cardiovascular JJ o
death NN o
or CC o
hospital NN o
admission NN o
for IN o
congestive JJ o
heart NN o
failure NN o
( ( N
hazard JJ N
ratio NN N
, , N
0.39 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
0.20 CD N
to TO N
0.76 CD N
; : N
P=0.0058 NNP N
) ) N
. . N

Postprocedural NNP o
TIMI NNP o
3 CD o
flow NN o
was VBD N
obtained VBN N
in IN N
89.7 CD N
% NN N
of IN N
the DT N
nicorandil JJ i
group NN N
and CC N
in IN N
81.4 CD N
% NN N
of IN N
the DT N
placebo NN i
( ( N
hazard JJ N
ratio NN N
, , N
1.99 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
1.09 CD N
to TO N
3.65 CD N
; : N
P=0.025 NNP N
) ) N
. . N

Corrected VBN o
TIMI NNP o
frame NN o
count NN o
was VBD N
furthermore RB N
lower JJR N
in IN N
the DT N
nicorandil NN i
group NN N
( ( N
21.0+/-9.1 JJ N
versus NN N
25.1+/-14.1 CD N
; : N
P=0.0009 NNP N
) ) N
. . N

ST-segment JJ o
resolution NN o
> VBD o
50 CD o
% NN o
was VBD N
observed VBN N
in IN N
79.5 CD N
% NN N
and CC N
61.2 CD N
% NN N
of IN N
the DT N
nicorandil NN i
and CC N
placebo NN i
groups NNS N
, , N
respectively RB N
( ( N
hazard JJ N
ratio NN N
, , N
2.45 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
1.54 CD N
to TO N
3.90 CD N
; : N
P=0.0002 NNP N
) ) N
. . N

CONCLUSIONS VB N
The DT N
addition NN N
of IN N
intravenous JJ N
nicorandil NNS i
to TO N
PCI NNP N
leads VBZ N
to TO N
beneficial JJ N
clinical JJ o
outcomes NNS o
and CC N
prevents NNS N
cardiovascular JJ o
events NNS o
of IN o
long JJ o
duration NN o
and CC o
death NN o
in IN N
patients NNS p
with IN p
ST-segment-elevation NNP p
myocardial JJ p
infarction NN p
. . p

-DOCSTART- -24673076- O O

[ NN i
Encephalopathy NNP i
therapeutic JJ i
tongue NN i
acupoint NN i
apparatus NN i
( ( N
ETTAA NNP N
) ) N
for IN N
42 CD p
cases NNS p
of IN p
autism NN p
] NNP p
. . N

OBJECTIVE NNP N
To TO N
observe VB N
the DT N
efficacy NN o
of IN N
encephalopathy JJ i
therapeutic JJ i
tongue NN i
acupoint NN i
apparatus NN i
( ( i
ETTAA NNP i
) ) i
in IN N
the DT N
treatment NN N
of IN N
autism NN p
. . p

METHODS NNP N
Eighty-four JJ p
children NNS p
of IN p
autism NN p
were VBD p
randomly RB p
divided VBN p
into IN p
a DT p
tongue JJ i
acupuncture NN i
group NN p
( ( p
group NN p
A NNP p
) ) p
and CC p
a DT p
conventional JJ i
training NN i
group NN p
( ( p
group NN p
B NNP p
) ) p
, , p
42 CD p
cases NNS p
in IN p
each DT p
group NN p
. . p

The DT N
behavior JJ N
training NN N
and CC N
sensory JJ N
integration NN N
training NN N
were VBD N
carried VBN N
out RP N
in IN N
group NN N
B NNP N
and CC N
the DT N
ETTAA NNP N
was VBD N
added VBN N
in IN N
group NN N
A NNP N
. . N

The DT N
apparatus NN N
was VBD N
switched VBN N
on IN N
for IN N
20 CD N
min NN N
every DT N
time NN N
and CC N
3 CD N
times NNS N
a DT N
day NN N
. . N

Treatment NN N
of IN N
two CD N
months NNS N
were VBD N
carried VBN N
out RP N
in IN N
both DT N
groups NNS N
. . N

The DT N
score NN o
of IN o
childhood NN o
autism NN o
rating NN o
scale NN o
( ( o
CARS NNP o
) ) o
and CC N
clinical JJ o
efficacy NN o
in IN N
both DT N
groups NNS N
were VBD N
observed VBN N
before IN N
and CC N
after IN N
treatment NN N
. . N

RESULTS NNP N
After IN N
treatment NN N
, , N
the DT N
CARS NNPS o
in IN N
both DT N
groups NNS N
were VBD N
significantly RB N
reduced VBN N
( ( N
42.39 CD N
+/- JJ N
6.86 CD N
vs JJ N
32.15 CD N
+/- JJ N
5.12 CD N
, , N
P NNP N
< NNP N
0.001 CD N
; : N
44.58 CD N
+/- JJ N
6.76 CD N
vs JJ N
39.72 CD N
+/- JJ N
7.11 CD N
, , N
P NNP N
< NNP N
0.05 CD N
) ) N
, , N
which WDT N
was VBD N
more RBR N
significant JJ N
in IN N
group NN N
A NNP N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

The DT N
totally RB o
effective JJ o
rate NN o
in IN N
group NN N
A NNP N
[ RB N
90.5 CD N
% NN N
( ( N
38/42 CD N
) ) N
] NN N
was VBD N
superior JJ N
to TO N
that DT N
in IN N
group NN N
B NNP N
[ VBZ N
66.7 CD N
% NN N
( ( N
28/42 CD N
) ) N
, , N
P NNP N
< VBZ N
0.01 CD N
] NN N
. . N

CONCLUSION VB N
The DT N
clinical JJ o
efficacy NN o
in IN N
tongue JJ i
acupuncture NN i
group NN N
is VBZ N
apparently RB N
superior JJ N
to TO N
that DT N
in IN N
conventional JJ i
training NN i
group NN N
, , N
ETTAA NNP N
combined VBD N
with IN N
conventional JJ N
training NN N
have VBP N
a DT N
better JJR N
curative JJ o
effect NN o
in IN N
the DT N
treatment NN N
of IN N
autism NN p
. . p

-DOCSTART- -26882812- O O

The DT N
Effects NNPS N
of IN N
Valsartan NNP i
and CC N
Amlodipine NNP i
on IN N
the DT N
Levels NNP N
of IN N
Irisin NNP i
, , i
Adropin NNP i
, , i
and CC i
Perilipin NNP i
. . i

BACKGROUND NNP N
Hypertension NNP p
and CC p
obesity NN p
are VBP N
two CD N
major JJ N
threats NNS N
for IN N
public JJ N
health NN N
. . N

Up IN N
to TO N
the DT N
present JJ N
, , N
antihypertensive JJ N
medications NNS N
have VBP N
been VBN N
used VBN N
to TO N
lower VB N
blood NN N
pressure NN N
, , N
which WDT N
seem VBP N
to TO N
provide VB N
a DT N
better JJR N
life NN N
with IN N
lower JJR N
morbidity NN N
and CC N
mortality NN N
rates NNS N
. . N

Their PRP$ N
effect NN N
on IN N
etiopathogenesis NN N
of IN N
hypertension NN N
is VBZ N
now RB N
an DT N
area NN N
of IN N
developing VBG N
research NN N
. . N

The DT N
association NN N
between IN N
hypertension NN N
and CC N
obesity NN N
also RB N
suggests VBZ N
the DT N
link NN N
between IN N
antihypertensive JJ N
agents NNS N
and CC N
energy NN N
hemostasis NN N
. . N

We PRP N
aimed VBD N
to TO N
investigate VB N
the DT N
effects NNS N
of IN N
antihypertensive JJ N
treatment NN N
on IN N
the DT N
irisin NN N
, , N
adropin NN N
, , N
and CC N
perilipin NN N
levels NNS N
in IN N
patients NNS p
with IN p
essential JJ p
hypertension NN p
and CC N
to TO N
compare VB N
them PRP N
with IN N
healthy JJ p
volunteers NNS p
in IN N
terms NNS N
of IN N
their PRP$ N
effect NN N
on IN N
energy NN N
hemostasis NN N
. . N

METHODS NNP N
In IN N
total JJ N
, , N
85 CD p
newly RB p
diagnosed VBN p
patients NNS p
with IN p
untreated JJ p
essential JJ p
hypertension NN p
were VBD p
admitted VBN p
to TO p
the DT p
outpatient NN p
clinic NN p
. . p

Patients NNS N
were VBD N
randomized VBN N
to TO N
one CD N
of IN N
the DT N
following JJ N
treatment NN N
protocols NNS N
: : N
amlodipine NN i
or CC i
valsartan NN i
for IN N
a DT N
12 CD N
week NN N
period NN N
. . N

42 CD p
patients NNS p
were VBD p
randomized VBN p
into IN p
the DT p
valsartan NN i
group NN p
and CC p
43 CD p
patients NNS p
into IN p
the DT p
amlodipine NN i
group NN p
. . p

Serum NNP o
perilipin NN o
, , o
irisin NN o
, , o
and CC o
adropin NN o
levels NNS o
were VBD N
measured VBN N
before IN N
and CC N
after IN N
drug NN N
treatment NN N
by IN N
ELISA NNP i
kits NNS i
. . i

RESULTS NNP N
We PRP N
discovered VBD N
that IN N
the DT N
hypertensive JJ N
patients NNS N
have VBP N
lower JJR N
levels NNS o
of IN o
perilipin NN o
and CC N
higher JJR N
levels NNS o
of IN o
adropin NN o
compared VBN N
with IN N
the DT N
control NN N
group NN N
. . N

Both DT N
amlodipine JJ i
and CC N
valsartan NN i
increased VBD N
the DT N
levels NNS o
of IN o
perilipin NN o
, , o
irisin NN o
, , o
and CC o
adropin RB o
after IN N
12 CD N
weeks NNS N
of IN N
treatment NN N
. . N

CONCLUSIONS NNP N
In IN N
conclusion NN N
, , N
in IN N
regulating VBG N
energy NN N
balance NN N
, , N
perilipin NN N
, , N
irisin NN N
, , N
and CC N
adropin NN N
, , N
could MD N
be VB N
of IN N
pathogenic JJ N
importance NN N
in IN N
obesity-induced JJ p
hypertension NN p
. . p

Hence NNP N
, , N
ongoing VBG N
trials NNS N
need VBP N
to TO N
elucidate VB N
this DT N
mechanism NN N
. . N

-DOCSTART- -11323998- O O

Comparative JJ N
evaluation NN N
of IN N
calcium NN i
hydroxide NN i
and CC i
zinc NN i
oxide RB i
eugenol RB i
as IN N
root JJ o
canal JJ o
filling NN o
materials NNS o
for IN p
primary JJ p
molars NNS p
: : p
a DT N
clinical JJ N
and CC N
radiographic JJ N
study NN N
. . N

Calcium NNP i
hydroxide NN i
, , N
a DT N
material NN N
widely RB N
used VBN N
for IN N
the DT N
treatment NN N
of IN N
permanent JJ N
teeth NN N
has VBZ N
not RB N
been VBN N
used VBN N
frequently RB N
for IN N
pulpectomy NN N
in IN N
primary JJ N
teeth NNS N
. . N

A DT N
comparative JJ N
evaluation NN N
of IN N
calcium NN i
hydroxide NN i
and CC i
zinc NN i
oxide NN i
eugenol NN i
used VBN i
as IN i
root JJ o
canal JJ o
filling NN o
materials NNS o
in IN N
primary JJ p
molars NNS p
is VBZ N
presented VBN N
. . N

-DOCSTART- -23955236- O O

Successful JJ N
production NN o
of IN N
piglets NNS p
derived VBN N
from IN N
expanded JJ N
blastocysts NNS N
vitrified VBD N
using VBG N
a DT N
micro NN i
volume NN i
air NN i
cooling VBG i
method NN i
without IN N
direct JJ N
exposure NN N
to TO N
liquid VB N
nitrogen NN N
. . N

This DT N
study NN N
was VBD N
conducted VBN N
to TO N
clarify VB N
the DT N
feasibility NN N
of IN N
newly RB N
developed VBN N
vitrification NN N
techniques NNS N
for IN N
porcine NN p
embryos NN p
using VBG N
the DT N
micro NN i
volume NN i
air NN i
cooling VBG i
( ( i
MVAC NNP i
) ) i
method NN N
without IN N
direct JJ N
contact NN N
with IN N
liquid JJ N
nitrogen NN N
( ( N
LN? NNP N
) ) N
. . N

Expanded VBN N
blastocysts NNS N
were VBD N
vitrified VBN N
in IN N
a DT N
solution NN N
containing VBG i
6 CD i
M NNP i
ethylene NN i
glycol NN i
, , i
0.6 CD i
M NNP i
trehalose NN i
and CC i
2 CD i
% NN i
( ( i
wt/vol NN i
) ) i
polyethylene NN i
glycol NN i
in IN i
10 CD i
% NN i
HEPES-buffered JJ i
PZM-5 NNP i
. . i

The DT N
blastocysts NNS N
were VBD N
collected VBN N
from IN N
gilts NNS N
and CC N
vitrified VBD N
using VBG N
the DT i
new JJ i
device NN i
( ( i
MVAC NNP i
) ) i
or CC i
a DT i
Cryotop NNP i
( ( i
CT NNP i
) ) i
. . i

Blastocysts NNS N
were VBD N
stored VBN N
in IN N
LN? NNP N
for IN N
at IN N
least JJS N
1 CD N
month NN N
. . N

After IN N
warming VBG N
, , N
cryoprotective JJ N
agents NNS N
were VBD N
removed VBN N
using VBG N
a DT N
single JJ N
step NN N
. . o

Survival NN o
of IN o
the DT o
embryos NN o
was VBD o
assessed VBN N
by IN N
in IN N
vitro JJ N
culture NN N
( ( N
Experiment NNP N
1 CD N
) ) N
and CC N
by IN N
embryo NN N
transfer NN N
to TO N
recipients NNS N
( ( N
Experiment NNP N
2 CD N
) ) N
. . N

In IN N
Experiment JJ N
1 CD N
, , N
the DT N
embryos NN N
vitrified VBN N
by IN N
the DT N
MVAC NNP i
or CC i
CT NNP i
and CC N
fresh JJ N
embryos NN N
without IN N
vitrification NN N
( ( N
Control NNP N
) ) N
were VBD N
used VBN N
. . N

The DT N
survival JJ o
rates NNS o
of IN o
embryos NN o
in IN o
the DT N
MVAC NNP i
, , i
CT NNP i
and CC N
Control NNP N
groups NNS N
were VBD N
88.9 CD N
% NN N
( ( N
32/36 CD N
) ) N
, , N
91.7 CD N
% NN N
( ( N
33/36 CD N
) ) N
and CC N
100 CD N
% NN N
( ( N
34/34 CD N
) ) N
, , N
respectively RB N
, , N
after IN N
48 CD N
h JJ N
culture NN N
, , N
and CC N
the DT N
hatching VBG o
rates NNS o
of IN o
embryos NN o
after IN o
48 CD o
h JJ o
incubation NN o
were VBD o
69.4 CD N
% NN N
( ( N
25/36 CD N
) ) N
, , N
63.9 CD N
% NN N
( ( N
23/36 CD N
) ) N
and CC N
94.1 CD N
% NN N
( ( N
32/34 CD N
) ) N
, , N
respectively RB N
. . N

In IN N
Experiment JJ p
2 CD p
, , p
64 CD p
vitrified VBD p
embryos NN p
were VBD p
transferred VBN N
to TO N
5 CD N
recipient NN N
gilts NNS N
, , N
and CC N
8 CD o
healthy JJ o
piglets NNS o
were VBD o
produced VBN N
from IN N
3 CD N
recipients NNS N
in IN N
the DT N
MVAC NNP i
group NN i
. . N

Similarly RB p
, , p
66 CD p
vitrified VBD p
embryos NN p
were VBD p
transferred VBN N
to TO N
5 CD N
recipient NN N
gilts NNS N
, , N
and CC N
9 CD o
healthy JJ o
piglets NNS o
were VBD o
produced VBN N
from IN N
2 CD N
recipients NNS N
in IN N
the DT N
CT NNP i
group NN N
. . N

These DT N
results NNS N
indicated VBD N
that IN N
porcine NN p
expanded VBN p
blastocysts NNS p
can MD p
be VB N
cryopreserved VBN N
using VBG N
the DT N
MVAC NNP i
method NN i
without IN N
potential JJ N
pathogen NN N
contamination NN N
from IN N
LN? NNP N
. . N

-DOCSTART- -8884623- O O

Effects NNS N
of IN N
perioperative JJ N
indomethacin NN i
on IN N
intracranial JJ o
pressure NN o
, , o
cerebral JJ o
blood NN o
flow NN o
, , o
and CC o
cerebral JJ o
metabolism NN o
in IN p
patients NNS p
subjected VBN p
to TO p
craniotomy VB p
for IN p
cerebral JJ p
tumors NNS p
. . p

This DT N
study NN N
was VBD N
carried VBN N
out IN N
to TO N
evaluate VB N
the DT N
effects NNS o
of IN N
perioperative JJ N
indomethacin NN N
on IN o
intracranial JJ o
pressure NN o
( ( o
ICP NNP o
) ) o
, , o
cerebral JJ o
blood NN o
flow NN o
( ( o
CBF NNP o
) ) o
, , o
and CC o
cerebral JJ o
metabolism NN o
. . o

Twenty CD p
patients NNS p
subjected VBN p
to TO p
craniotomy VB p
for IN p
supratentorial JJ p
cerebral JJ p
tumors NNS p
were VBD N
anesthetized VBN i
with IN i
thiopental JJ i
, , i
fentanyl JJ i
, , i
nitrous JJ i
oxide NN i
, , i
and CC i
isoflurane NN i
. . i

A DT N
PaCO2 NNP N
level NN N
averaging VBG N
4.8 CD N
kPa NN N
( ( N
median JJ N
) ) N
was VBD N
achieved VBN N
. . N

The DT N
patients NNS N
were VBD N
randomized VBN p
to TO N
intravenous JJ i
indomethacin JJ i
50 CD i
mg NN i
or CC i
placebo NN i
administrated VBN i
after IN i
exposure NN i
of IN i
the DT i
dura NN i
. . i

ICP NNP o
was VBD i
measured VBN i
continuously RB i
subdurally RB i
with IN i
a DT i
22-gauge JJ i
canula NN i
connected VBN i
to TO i
a DT i
transducer NN i
. . i

CBF NNP o
and CC o
the DT o
arteriovenous JJ o
difference NN o
of IN o
oxygen NN o
( ( o
AVDO2 NNP o
) ) o
were VBD N
measured VBN N
twice RB N
, , N
before IN N
and CC N
after IN N
indomethacin/placebo JJ i
administration NN N
. . N

A DT N
significant JJ N
decrease NN N
in IN N
ICP NNP o
from IN N
6.5 CD N
to TO N
1.5 CD N
mm NNS N
Hg NNP N
( ( N
median JJ N
) ) N
was VBD N
found VBN N
after IN N
indomethacin JJ N
administration NN N
. . N

This DT N
decrease NN N
was VBD N
caused VBN N
by IN N
a DT N
significant JJ N
decrease NN N
in IN N
CBF NNP o
associated VBD N
with IN N
a DT N
significant JJ N
increase NN N
in IN N
AVDO2 NNP o
. . o

Indomethacin NNP N
did VBD N
not RB N
affect VB N
the DT N
cerebral JJ o
metabolic JJ o
rate NN o
of IN o
oxygen NN o
, , o
the DT o
arteriovenous JJ o
difference NN o
of IN o
lactate NN o
, , o
or CC o
the DT o
lactate/oxygen NN o
index NN o
, , N
suggesting VBG N
that IN N
indomethacin NN N
did VBD N
not RB N
provoke VB N
global JJ N
cerebral JJ N
ischemia NN N
. . N

In IN N
the DT N
indomethacin NN N
group NN N
, , N
dura NN o
was VBD N
sufficiently RB N
relaxed VBN N
in IN N
eight CD N
of IN N
nine CD N
patients NNS N
and CC N
dura NN o
was VBD N
opened VBN N
without IN N
the DT N
occurrence NN N
of IN N
cerebral JJ o
swelling VBG o
. . o

In IN N
one CD N
patient NN N
, , N
mannitol FW N
treatment NN N
was VBD N
necessary JJ N
to TO N
prevent VB N
dural JJ o
tightness NN o
. . o

In IN N
the DT N
placebo NN N
group NN N
, , N
mannitol RB N
supplemented VBN N
with IN N
hypocapnia NN N
was VBD N
applied VBN N
in IN N
five CD p
patients NNS p
. . p

These DT N
findings NNS N
suggest VBP N
that IN N
perioperative JJ N
treatment NN N
with IN N
indomethacin NN i
is VBZ N
an DT N
excellent JJ N
treatment NN N
of IN N
intracranial JJ N
hypertension NN N
during IN N
normocapnic JJ N
isoflurane NN N
anesthesia NN N
for IN N
craniotomy NN N
. . N

-DOCSTART- -23001240- O O

Iron NNP i
in IN N
relation NN N
to TO N
gastric JJ p
cancer NN p
in IN p
the DT N
Alpha-tocopherol NNP N
, , N
Beta-carotene NNP N
Cancer NNP N
Prevention NNP N
Study NNP N
. . N

BACKGROUND NNP N
Iron NNP i
is VBZ N
an DT N
essential JJ N
micronutrient NN N
that WDT N
can MD N
have VB N
carcinogenic JJ o
effects NNS o
when WRB N
at IN N
high JJ N
or CC N
low JJ N
concentrations NNS N
. . N

Previous JJ N
studies NNS N
of IN N
iron NN N
in IN N
relation NN N
to TO N
gastric JJ N
cancer NN N
have VBP N
not RB N
assessed VBN N
subtype-specific JJ N
relationships NNS N
. . N

We PRP N
used VBD N
the DT N
prospective JJ N
Alpha-Tocopherol NNP N
, , N
Beta-Carotene NNP N
( ( N
ATBC NNP N
) ) N
Cancer NNP N
Prevention NNP N
Study NNP N
to TO N
assess VB N
whether IN N
iron NN N
metrics NNS N
were VBD N
associated VBN N
with IN N
gastric JJ o
cardia NN o
cancer NN o
( ( o
GCC NNP o
) ) o
and CC o
gastric JJ o
noncardia NN o
cancer NN o
( ( o
GNCC NNP o
) ) o
. . o

METHODS NNP N
We PRP N
selected VBD N
341 CD p
incident JJ p
gastric JJ p
cancer NN p
cases NNS p
( ( p
86 CD p
cardia NN p
, , p
172 CD p
noncardia NN p
, , p
and CC p
83 CD p
nonspecified VBN p
) ) p
, , p
accrued VBN p
during IN p
22 CD p
years NNS p
of IN p
follow-up NN p
, , p
and CC p
341 CD p
individually RB p
matched VBN p
controls NNS p
. . p

We PRP N
measured VBD N
prediagnostic JJ N
serum NN N
iron NN N
, , N
ferritin NN N
, , N
unsaturated JJ N
iron NN N
binding NN N
capacity NN N
, , N
and CC N
C-reactive JJ N
protein NN N
. . N

Total JJ o
iron-binding JJ o
capacity NN o
( ( o
TIBC NNP o
) ) o
and CC N
transferrin JJ N
saturation NN N
were VBD N
estimated VBN N
from IN N
these DT N
metrics NNS N
. . N

Dietary NNP i
iron NN i
exposures NNS N
were VBD N
estimated VBN N
from IN N
a DT N
food NN N
frequency NN N
questionnaire NN N
. . N

Multivariable JJ N
logistic JJ N
regression NN N
was VBD N
used VBN N
for IN N
analysis NN N
. . N

RESULTS NNP N
Serum NNP o
iron NN o
metrics NNS o
were VBD N
not RB N
associated VBN N
with IN N
GCC NNP o
, , N
except IN N
for IN N
a DT N
potential JJ N
n NN N
-shaped VBD N
relationship NN N
with IN N
TIBC NNP N
( ( N
global JJ N
P NNP N
= NNP N
0.038 CD N
) ) N
. . N

GNCC NNP o
was VBD N
inversely RB N
associated VBN N
with IN N
serum NN o
ferritin NN o
( ( N
global JJ N
P NNP N
= NNP N
0.024 CD N
) ) N
, , N
serum JJ o
iron NN o
( ( N
global JJ N
P NNP N
= NNP N
0.060 CD N
) ) N
and CC N
, , N
possibly RB N
, , N
transferrin JJ o
saturation NN o
. . o

TIBC NNP o
appeared VBD N
to TO N
share NN N
a DT N
u NN N
-shaped VBD N
relationship NN N
with IN N
GNCC NNP o
( ( N
global JJ N
P NNP N
= NNP N
0.033 CD N
) ) N
. . N

Dietary NNP o
iron NN o
exposures NNS o
were VBD N
not RB N
associated VBN N
with IN N
either DT N
subsite NN N
. . N

Adjustment NN N
for IN N
Helicobacter NNP N
pylori NN N
and CC N
gastric JJ N
atrophy NN N
had VBD N
little JJ N
effect NN N
on IN N
observed JJ N
associations NNS N
. . N

CONCLUSIONS NNP N
We PRP N
found VBD N
little JJ N
evidence NN N
for IN N
the DT N
involvement NN N
of IN N
iron NN i
exposure NN N
in IN N
the DT N
pathogenesis NN o
of IN o
GCC NNP o
. . o

GNCC NNP o
was VBD N
associated VBN N
with IN N
an DT N
iron NN i
profile NN N
similar JJ N
to TO N
that DT N
of IN N
iron NN N
deficiency NN N
. . N

IMPACT NNP N
Our PRP$ N
findings NNS N
indicate VBP N
that IN N
inverse JJ N
associations NNS N
between IN N
iron NN N
metrics NNS N
and CC N
gastric JJ N
cancer NN N
are VBP N
driven VBN N
by IN N
associations NNS N
with IN N
GNCC NNP N
. . N

Further NNP N
elucidation NN N
of IN N
potential JJ N
mechanisms NN N
is VBZ N
warranted VBN N
. . N

-DOCSTART- -80115- O O

Anaphylactoid JJ o
reactions NNS o
and CC o
histamine NN o
release NN o
by IN N
plasma NN i
substitutes NNS i
: : i
a DT N
randomized NN N
controlled VBN N
trial NN N
in IN p
human JJ p
subjects NNS p
and CC p
in IN p
dogs NNS p
[ JJ N
proceedings NNS N
] NN N
. . N

-DOCSTART- -16377918- O O

Cross-over JJ N
trial NN N
of IN N
intensive JJ N
monotherapy NN N
with IN N
atorvastatin NN i
and CC N
combined VBN N
therapy NN N
with IN N
atorvastatin NN i
and CC N
colestimide NN i
for IN N
Japanese JJ p
familial JJ p
hypercholesterolemia NN p
. . p

BACKGROUND NNP N
In IN N
familial JJ p
hypercholesterolemia NN p
( ( p
FH NNP p
) ) p
, , N
low-density JJ o
lipoprotein-cholesterol NN o
( ( o
LDL-C NNP o
) ) o
-lowering VBG o
therapy NN N
is VBZ N
important JJ N
to TO N
avoid VB N
predisposition NN N
to TO N
coronary JJ N
artery NN N
disease NN N
. . N

This DT N
study NN N
investigated VBD N
the DT N
advantages NNS N
of IN N
combined JJ N
therapy NN N
with IN N
atorvastatin NN i
and CC N
colestimide NN i
vs NN N
intensive JJ N
monotherapy NN N
with IN N
atorvastatin NN i
. . i

METHODS NNP N
AND CC N
RESULTS NNP N
The DT N
trial NN N
used VBD N
a DT N
randomized JJ N
cross-over NN N
design NN N
consisting VBG N
of IN N
2 CD N
16-week JJ N
periods NNS N
of IN N
open-label JJ N
drug NN N
therapy NN N
. . N

Among IN N
the DT N
24 CD p
initial JJ p
patients NNS p
, , p
17 CD p
heterozygous JJ p
FH NNP p
patients NNS p
( ( p
age NN p
: : p
54.1 CD p
years NNS p
; : p
5 CD p
males NNS p
) ) p
were VBD N
enrolled VBN N
after IN i
20 CD i
mg/day JJ i
atorvastatin RB i
failed VBD i
to TO i
achieve VB i
their PRP$ i
target NN i
level NN i
. . i

The DT N
patients NNS N
received VBD N
20 CD N
mg/day JJ N
atorvastatin NN i
and CC N
3 CD N
g/day JJ N
colestimide NN i
or CC N
40 CD N
mg/day JJ N
atorvastatin NN i
. . i

Fifteen JJ p
patients NNS p
completed VBD p
the DT p
trial NN p
and CC N
their PRP$ N
LDL-C JJ o
reduced VBN N
from IN N
5.07 CD N
+/- JJ N
1.10 CD N
mmol/L NN N
to TO N
3.76 CD N
+/- JJ N
0.90 CD N
mmol/L NN N
with IN N
the DT N
combined JJ N
therapy NN N
and CC N
to TO N
3.81 CD N
+/- JJ N
0.50 CD N
mmol/L NN N
with IN N
the DT N
intensive JJ N
monotherapy NN N
. . N

Although IN N
the DT N
2 CD N
therapies NNS N
showed VBD N
comparable JJ N
mean JJ N
effects NNS N
for IN N
decreasing VBG N
LDL-C NNP o
, , N
similar JJ N
adverse JJ N
reaction NN N
and CC N
cost NN N
, , N
each DT N
therapy NN N
was VBD N
predominantly RB N
more RBR N
effective JJ N
in IN N
some DT N
patients NNS N
than IN N
in IN N
others NNS N
. . N

The DT N
triglyceride NN o
and CC o
high-density NN o
lipoprotein NNS o
cholesterol NN o
levels NNS o
were VBD N
similar JJ N
in IN N
both DT N
therapies NNS N
. . N

CONCLUSIONS NNP N
To TO N
achieve VB N
the DT N
therapeutic JJ N
target NN N
of IN N
LDL-C NNP o
level NN N
for IN N
refractory NN N
FH NNP N
, , N
the DT N
LDL-C-lowering JJ N
therapy NN N
selected VBN N
can MD N
be VB N
either RB N
intensive JJ N
monotherapy NN N
or CC N
combined VBN N
therapy NN N
as IN N
the DT N
next JJ N
to TO N
standard VB N
statin NN N
therapy NN N
. . N

-DOCSTART- -25744288- O O

Enhancing VBG N
the DT N
experience NN p
of IN p
carers NNS p
in IN p
the DT p
chemotherapy NN p
outpatient JJ p
setting NN p
: : p
an DT N
exploratory NN N
randomised VBD N
controlled VBN N
trial NN N
to TO N
test VB N
impact NN N
, , N
acceptability NN N
and CC N
feasibility NN N
of IN N
a DT N
complex JJ i
intervention NN i
co-designed VBN N
by IN N
carers NNS p
and CC p
staff NN p
. . p

PURPOSE NNP N
Supporting VBG N
someone NN N
through IN N
chemotherapy NN N
can MD N
be VB N
emotionally RB N
and CC N
physically RB N
demanding VBG N
. . N

However RB N
, , N
research NN N
has VBZ N
yet RB N
to TO N
establish VB N
the DT N
type NN N
of IN N
support NN N
carers NNS N
require VBP N
or CC N
the DT N
best JJS N
way NN N
to TO N
provide VB N
this DT N
. . N

This DT N
study NN N
tested VBD N
the DT N
feasibility NN N
and CC N
acceptability NN N
of IN N
a DT N
complex JJ N
intervention NN N
for IN N
carers NNS p
that WDT p
was VBD p
co-designed VBN p
by IN p
staff NN p
and CC p
carers NNS p
of IN p
patients NNS p
starting VBG p
chemotherapy NN i
. . i

METHODS NNP N
Forty-seven JJ p
carers NNS p
were VBD p
recruited VBN p
, , p
randomised VBN p
between IN p
the DT p
intervention NN i
( ( p
n JJ p
= NNP p
24 CD p
) ) p
and CC p
control NN i
( ( p
n JJ p
= NNP p
23 CD p
) ) p
groups NNS p
. . p

A DT N
questionnaire NN i
was VBD N
completed VBN N
pre- JJ N
and CC N
post-intervention JJ N
measuring NN N
knowledge NN N
of IN N
chemotherapy NN o
and CC N
its PRP$ N
side NN N
effects NNS N
, , N
experience NN N
of IN N
care NN N
, , N
satisfaction NN N
with IN N
outpatient NN N
services NNS N
, , N
coping VBG N
and CC N
emotional JJ N
wellbeing NN N
. . N

The DT N
intervention NN p
process NN p
was VBD N
evaluated VBN N
by IN N
carers NNS N
and CC N
healthcare NN N
professionals NNS N
( ( N
HCPs NNP N
) ) N
in IN N
focus NN p
groups NNS p
. . p

RESULTS NNP N
Recruitment NNP N
to TO N
the DT N
study NN N
was VBD N
unproblematic JJ N
and CC N
attrition NN N
from IN N
it PRP N
was VBD N
low JJ N
, , N
suggesting VBG N
the DT N
intervention NN N
and CC N
study NN N
processes NNS N
were VBD N
acceptable JJ N
to TO N
patients NNS N
and CC N
carers NNS N
. . N

Carers NNS N
in IN N
receipt NN N
of IN N
the DT N
'Take NNP N
Care NNP N
' POS N
intervention NN N
reported VBD N
statistically RB N
significantly RB N
better RBR N
understanding NN N
of IN N
symptoms NNS N
and CC N
side JJ N
effects NNS N
and CC N
their PRP$ N
information NN N
needs VBZ N
being VBG N
more RBR N
frequently RB N
met VBN N
than IN N
carers NNS N
in IN N
the DT N
control NN N
. . N

Confidence NN N
in IN N
coping VBG N
improved VBN N
between IN N
baseline NN N
and CC N
follow-up NN N
for IN N
the DT N
intervention NN N
group NN N
and CC N
declined VBD N
for IN N
the DT N
control NN N
although IN N
differences NNS N
were VBD N
insufficient JJ N
to TO N
achieve VB N
statistical JJ N
significance NN N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
the DT N
two CD N
groups NNS N
' POS N
emotional JJ N
wellbeing NN N
. . N

HCP NNP N
and CC N
carer NN N
focus NN N
groups NNS N
confirmed VBD N
the DT N
feasibility NN o
and CC o
acceptability NN o
of IN N
the DT N
intervention NN N
. . N

CONCLUSIONS VB N
The DT N
'Take NNP N
Care NNP N
' POS N
intervention NN N
proved VBD N
acceptable JJ N
to TO N
carers NNS p
and CC p
HCPs NNP p
and CC N
demonstrates VBZ N
considerable JJ N
promise NN N
and CC N
utility NN N
in IN N
practice NN N
. . N

Study NNP N
findings NNS N
support VBP N
the DT N
conduct NN N
of IN N
a DT N
fully RB N
powered VBN N
RCT NNP N
to TO N
determine VB N
the DT N
intervention NN N
's POS N
effectiveness NN N
and CC N
cost-effectiveness NN N
. . N

-DOCSTART- -9039228- O O

Marginal NNP N
zone NN N
B NNP N
cell NN N
lymphoma NN N
of IN N
the DT N
parotid JJ N
glands NNS N
: : N
results NNS N
of IN N
a DT N
randomised JJ N
trial NN N
comparing VBG N
radiotherapy NN i
to TO N
combined VBN i
therapy NN i
. . i

39 CD p
patients NNS p
with IN p
marginal JJ p
zone NN p
B NNP p
cell NN p
lymphoma NN p
( ( p
MZBCL NNP p
) ) p
of IN p
the DT p
parotid NN p
glands NNS p
( ( p
stages NNS p
I PRP p
or CC p
II NNP p
) ) p
were VBD p
studied VBN p
. . p

They PRP N
were VBD N
randomized VBN N
to TO N
be VB N
treated VBN N
with IN N
either DT N
radiotherapy NN i
alone RB i
( ( N
extended JJ N
fields NNS N
, , N
4500 CD N
cGy NN N
) ) N
or CC N
radiotherapy NN i
( ( i
the DT i
same JJ i
schedule NN i
) ) i
plus CC i
adjuvant JJ i
chemotherapy NN i
( ( i
cyclophosphamide NN i
, , i
vincristine NN i
and CC i
prednisone NN i
) ) i
. . i

The DT N
end NN o
points NNS o
were VBD N
survival JJ o
and CC o
time NN o
to TO o
treatment NN o
failure NN o
( ( o
TTF NNP o
) ) o
. . o

Patients NNPS N
who WP N
received VBD N
radiotherapy VB i
alone RB N
had VBD N
a DT N
complete JJ o
remission NN o
rate NN o
of IN N
100 CD N
% NN N
, , N
the DT N
TTF NNP o
was VBD N
90 CD N
% NN N
at IN N
5 CD N
years NNS N
and CC N
overall JJ o
survival NN o
at IN N
5 CD N
years NNS N
was VBD N
90 CD N
% NN N
with IN N
no DT N
statistical JJ N
difference NN N
when WRB N
compared VBN N
with IN N
patients NNS N
who WP N
received VBD N
combined JJ i
therapy NN i
[ NN N
100 CD N
, , N
80 CD N
and CC N
95 CD N
% NN N
, , N
respectively RB N
( ( N
P NNP N
= NNP N
0.5 CD N
) ) N
] NN N
. . N

Although IN N
adjuvant JJ i
chemotherapy NN i
was VBD N
well RB N
tolerated VBN o
, , N
the DT N
use NN N
of IN N
this DT N
therapeutic JJ N
approach NN N
in IN N
patients NNS N
with IN N
early JJ N
stage NN N
MZBCL NNP N
did VBD N
not RB N
offer VB N
any DT N
advantage NN N
over IN N
radiotherapy NN N
alone RB N
as IN N
the DT N
initial JJ N
treatment NN N
. . N

Until IN N
now RB N
, , N
radiotherapy NN i
was VBD N
considered VBN N
the DT N
treatment NN N
of IN N
choice NN N
in IN N
this DT N
clinical JJ N
setting NN N
of IN N
patients NNS N
. . N

-DOCSTART- -4448416- O O

Coagulation NNP i
factor NN i
concentrate NN i
in IN N
the DT N
treatment NN N
of IN N
the DT N
haemorrhagic JJ o
diathesis NN o
of IN p
fulminant JJ o
hepatic JJ o
failure NN o
. . o

To TO N
assess VB N
the DT N
value NN N
of IN N
clotting VBG i
factor NN i
concentrate NN i
infusions NNS i
in IN N
fulminant JJ p
hepatic JJ o
failure NN o
, , N
a DT N
controlled JJ N
trial NN N
was VBD N
performed VBN N
in IN N
which WDT N
nine CD p
patients NNS p
were VBD p
randomly RB p
allocated VBN p
to TO p
treatment NN p
with IN p
either DT p
concentrate NN i
alone RB i
or CC i
concentrate VB i
plus CC i
heparin VB i
. . i

The DT N
five CD N
patients NNS N
receiving VBG N
concentrate VB i
alone RB N
all DT N
died VBD o
, , N
with IN N
major JJ o
bleeding VBG o
as IN N
the DT N
direct JJ N
cause NN N
of IN N
death NN N
in IN N
three CD N
, , N
whereas NNS N
in IN N
the DT N
four CD N
receiving VBG N
heparin NN i
as RB N
well RB N
there EX N
was VBD N
only RB N
one CD N
instance NN N
of IN N
bleeding NN o
and CC N
one CD N
patient NN N
survived VBD o
. . o

Clinical JJ N
evidence NN N
of IN N
intravascular JJ o
coagulation NN o
appeared VBD N
in IN N
two CD N
patients NNS N
treated VBD N
with IN N
concentrate NN i
alone RB i
and CC N
the DT N
laboratory JJ N
evidence NN N
of IN N
this DT N
progressed VBN N
during IN N
the DT N
period NN N
of IN N
infusions NNS N
in IN N
all DT N
patients NNS N
in IN N
both DT N
treatment NN N
groups NNS N
, , N
although IN N
to TO N
a DT N
lesser JJR N
extent NN N
in IN N
those DT N
receiving VBG N
heparin NN i
. . i

Additional JJ N
evidence NN N
for IN N
intravascular JJ N
coagulation NN N
came VBD N
from IN N
the DT N
changes NNS N
observed VBN N
in IN N
factor NN o
VIII NNP o
levels NNS o
which WDT N
, , N
although IN N
initially RB N
high JJ N
in IN N
all DT N
patients NNS N
, , N
fell VBD N
subsequently RB N
, , N
particularly RB N
in IN N
those DT N
given VBN N
concentrate VBP i
alone RB N
. . N

There EX N
was VBD N
some DT N
improvement NN N
in IN N
the DT N
prothrombin NN o
ratio NN o
in IN N
both DT N
groups NNS N
of IN N
patients NNS N
but CC N
not RB N
complete JJ N
correction NN N
, , N
and CC N
serial JJ N
assays NNS N
of IN N
clotting VBG N
factors NNS N
showed VBD N
that IN N
although IN N
factor NN o
II NNP o
rose VBD N
to TO N
high JJ N
levels NNS N
during IN N
treatment NN N
, , N
factors NNS o
IX NNP o
and CC o
X NNP o
showed VBD N
little JJ N
response NN N
. . N

Thus RB N
, , N
the DT N
use NN N
of IN N
concentrate NN N
of IN N
factor NN o
IX NNP o
in IN N
this DT N
trial NN N
, , N
as RB N
well RB N
as IN N
potentiating VBG N
intravascular JJ o
coagulation NN o
, , N
was VBD N
inadequate JJ N
as IN N
replacement NN N
for IN N
the DT N
clotting NN N
factor NN N
deficiencies NNS N
. . N

-DOCSTART- -8519722- O O

0.1 CD N
% NN N
bupivacaine NN i
does VBZ N
not RB N
reduce VB N
the DT N
requirement NN N
for IN N
epidural JJ N
fentanyl NN N
infusion NN N
after IN p
major JJ p
abdominal JJ p
surgery NN p
. . p

BACKGROUND NNP N
AND NNP N
OBJECTIVES NNP N
Although IN N
local JJ N
anesthesia NN N
has VBZ N
been VBN N
demonstrated VBN N
to TO N
potentiate VB N
spinal JJ N
morphine NN N
analgesia NN N
in IN N
animal JJ N
studies NNS N
, , N
results NNS N
comparing VBG N
epidural JJ N
local JJ N
anesthesia/opioid NN N
mixtures NNS N
with IN N
opioid JJ N
alone NN N
are VBP N
contradictory JJ N
in IN N
clinical JJ N
studies NNS N
. . N

The DT N
hypothesis NN N
was VBD N
that IN N
, , N
although IN N
the DT N
concentration NN N
of IN N
bupivacaine NN i
( ( N
0.1 CD N
% NN N
) ) N
was VBD N
low JJ N
to TO N
minimize VB N
its PRP$ N
adverse JJ N
effects NNS N
, , N
if IN N
the DT N
infusion NN N
rate NN N
of IN N
a DT N
fentanyl/bupivacaine JJ i
solution NN N
was VBD N
closely RB N
adjusted VBN N
according VBG N
to TO N
need NN N
, , N
the DT N
presence NN N
bupivacaine NN N
would MD N
reduce VB N
the DT N
requirement NN N
for IN N
epidural JJ N
fentanyl NN N
. . N

METHODS NNP N
Forty NNP p
patients NNS p
were VBD N
randomly RB N
assigned VBN i
to TO i
receive VB i
either DT i
fentanyl NN i
( ( i
10 CD i
micrograms/mL NN i
) ) i
or CC i
a DT i
fentanyl/bupivacaine NN i
( ( i
0.1 CD i
% NN i
) ) i
mixture NN i
epidurally RB i
corresponding VBG i
to TO i
the DT i
dermatome NN i
of IN i
the DT i
surgical JJ i
incision NN i
in IN i
a DT i
double-blind JJ i
fashion NN i
for IN i
the DT i
first JJ i
18 CD i
hours NNS i
after IN i
major JJ i
abdominal JJ i
surgery NN i
. . i

The DT i
infusion NN i
was VBD i
titrated VBN i
for IN i
each DT i
patient NN i
to TO i
the DT i
rate NN i
required VBN i
for IN i
pain NN i
relief NN i
during IN i
forced VBN i
inspiration NN i
( ( i
pain NN i
score NN i
< NN i
or CC i
= $ i
2 CD i
, , i
maximum JJ i
10 CD i
) ) i
. . i

Pain NN N
scores NNS N
, , N
the DT N
fentanyl JJ N
doses NNS N
required VBN N
, , N
plasma JJ N
concentrations NNS N
of IN N
fentanyl NN N
at IN N
18 CD N
hours NNS N
, , N
and CC N
the DT N
incidence NN N
and CC N
severity NN N
of IN N
adverse JJ o
effects NNS o
were VBD N
recorded VBN N
. . N

RESULTS JJ N
Patients NNPS N
reported VBD N
similar JJ N
median JJ o
pain NN o
scores NNS o
and CC N
were VBD N
equally RB N
satisfied VBN N
with IN N
pain NN o
relief NN o
in IN N
both DT N
groups NNS N
. . N

The DT N
mean NN o
required VBN o
post-operative JJ o
fentanyl JJ o
infusion NN o
rate NN o
( ( N
57.7 CD N
+/- JJ N
19.5 CD N
micrograms/h NN N
) ) N
and CC N
the DT N
plasma NN o
concentrations NNS o
( ( N
0.84 CD N
+/- JJ N
0.36 CD N
ng/mL NN N
) ) N
in IN N
the DT N
fentanyl NN N
group NN N
were VBD N
comparable JJ N
to TO N
the DT N
infusion NN o
rate NN o
( ( N
54.4 CD N
+/- JJ N
19.2 CD N
micrograms/h NN N
) ) N
and CC N
the DT N
plasma NN o
concentrations NNS o
( ( N
0.86 CD N
+/- JJ N
0.36 CD N
ng/mL NN N
) ) N
in IN N
the DT N
fentanyl/bupivacaine NN N
group NN N
. . N

Respiratory NNP o
and CC o
cardiovascular JJ o
functions NNS o
were VBD N
preserved VBN N
, , N
and CC N
the DT N
incidence NN o
of IN o
nausea NN o
, , o
pruritus NN o
, , o
and CC o
periods NNS o
of IN o
drowsiness NN o
or CC o
sleep NN o
were VBD N
similar JJ N
in IN N
both DT N
groups NNS N
. . N

CONCLUSIONS NNP N
In IN N
low JJ N
concentrations NNS N
( ( N
0.1 CD N
% NN N
) ) N
, , N
bupivacaine NN i
did VBD N
not RB N
reduce VB N
the DT N
titrated JJ N
dose NN N
of IN N
epidural JJ N
fentanyl NN N
required VBN N
for IN N
adequate JJ N
pain NN N
relief NN N
during IN N
forced VBN N
inspiration NN N
after IN N
major JJ N
abdominal JJ N
surgery NN N
. . N

The DT N
incidence NN N
and CC N
severity NN N
of IN N
adverse JJ N
effects NNS N
were VBD N
also RB N
comparable JJ N
whether IN N
or CC N
not RB N
low-dose JJ N
bupivacaine NN i
infusion NN N
was VBD N
used VBN N
. . N

-DOCSTART- -10707032- O O

Treatment NN N
with IN N
metformin NN i
of IN N
non-diabetic JJ p
men NNS p
with IN p
hypertension NN p
, , p
hypertriglyceridaemia NN p
and CC p
central JJ p
fat JJ p
distribution NN p
: : p
the DT N
BIGPRO NNP N
1.2 CD N
trial NN N
. . N

BACKGROUND NNP N
In IN N
the DT N
BIGPRO NNP N
1 CD N
trial NN N
, , N
one CD N
year NN N
of IN N
treatment NN N
with IN N
metformin NN i
in IN N
non-diabetic JJ p
obese JJ p
subjects NNS p
with IN p
a DT p
central JJ p
fat JJ p
distribution NN p
had VBD N
no DT N
significant JJ N
effect NN N
on IN N
fasting VBG N
plasma JJ N
triglyceride JJ N
concentration NN N
or CC N
on IN N
blood NN N
pressure NN N
despite IN N
a DT N
decrease NN N
in IN N
weight NN N
, , N
fasting VBG N
plasma JJ N
insulin NN N
and CC N
glucose JJ N
concentrations NNS N
. . N

To TO N
re-evaluate VB N
the DT N
effect NN N
of IN N
metformin NN i
on IN N
fasting VBG N
triglyceride JJ N
concentration NN N
and CC N
on IN N
blood NN N
pressure NN N
, , N
the DT N
BIGPRO NNP N
1.2 CD N
trial NN N
included VBD N
non-diabetic JJ p
men NNS p
( ( p
n=168 NN p
) ) p
with IN p
a DT p
fasting VBG p
plasma NN p
triglyceride JJ p
concentration NN p
> NN p
or CC p
=1.7 NN p
and CC p
< NN p
or CC p
=6.5 NN p
mmol/l NN p
, , p
high JJ p
blood NN p
pressure NN p
( ( p
systolic JJ p
> NN p
or CC p
=140 NN p
and CC p
< NN p
or CC p
=180 VB p
and/or JJ p
diastolic JJ p
> NN p
or CC p
=90 NN p
and CC p
< NN p
or CC p
=105 NN p
mmHg NN p
, , p
or CC p
treatment NN p
for IN p
hypertension NN p
) ) p
and CC p
a DT p
waist-to-hip JJ p
ratio NN p
> NN p
or CC p
=0.95 NN p
. . p

METHODS NNP N
A DT N
randomised JJ N
double-blind JJ N
trial NN N
comparing VBG N
metformin NN i
treatment NN i
( ( i
850 CD i
mg RB i
bid NN i
) ) i
with IN i
placebo NN i
. . i

RESULTS NNP N
Metformin NNP i
had VBD N
no DT N
significant JJ N
effect NN N
either DT N
on IN N
blood NN o
pressure NN o
or CC o
plasma NN o
triglyceride JJ o
concentration NN o
. . o

In IN N
comparison NN N
with IN N
the DT N
placebo NN i
group NN N
, , N
fasting VBG o
plasma JJ o
insulin NN o
( ( N
p JJ N
< NNP N
0.04 CD N
) ) N
, , N
total JJ o
cholesterol NN o
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
and CC N
Apo NNP o
B NNP o
( ( N
p JJ N
< NNP N
0.008 CD N
) ) N
concentrations NNS o
decreased VBD N
more RBR N
in IN N
the DT N
metformin NN N
group NN N
in IN N
the DT N
BIGPRO NNP N
1 CD N
. . N

2 CD N
trial NN N
, , N
confirming VBG N
most JJS N
of IN N
the DT N
previous JJ N
results NNS N
of IN N
the DT N
BIGPRO NNP N
1 CD N
trial NN N
. . N

Tissue NNP o
plasminogen NN o
activator NN o
antigen NN o
concentration NN o
decreased VBN N
significantly RB N
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
only RB N
in IN N
the DT N
metformin NN i
group NN N
, , N
but CC N
this DT N
was VBD N
not RB N
significantly RB N
different JJ N
from IN N
the DT N
placebo NN i
group NN N
( ( N
p JJ N
< NNP N
0.12 CD N
) ) N
; : N
further RB N
, , N
there EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
the DT N
change NN N
in IN N
plasminogen NN N
activator NN N
inhibitor NN N
1 CD N
. . N

CONCLUSIONS VB N
The DT N
consistency NN N
of IN N
the DT N
two CD N
BIGPRO NNP N
trials NNS N
supports VBZ N
the DT N
conclusion NN N
that IN N
metformin VBZ i
affects NNS N
several JJ N
cardiovascular JJ N
risk NN N
factors NNS N
favourably RB N
in IN N
non-diabetic JJ p
subjects NNS p
with IN p
a DT p
central JJ p
fat JJ p
distribution NN p
. . p

-DOCSTART- -22369958- O O

Use NNP N
of IN N
a DT N
clay NN i
modeling VBG i
task NN i
to TO N
reduce VB N
chocolate NN o
craving NN o
. . o

Elaborated VBN N
Intrusion NNP N
theory NN N
( ( N
EI NNP N
theory NN N
; : N
Kavanagh NNP N
, , N
Andrade NNP N
, , N
& CC N
May NNP N
, , N
2005 CD N
) ) N
posits VBZ N
two CD N
main JJ N
cognitive JJ N
components NNS N
in IN N
craving NN o
: : o
associative JJ N
processes NNS N
that WDT N
lead VBP N
to TO N
intrusive VB N
thoughts NNS N
about IN N
the DT N
craved JJ N
substance NN N
or CC N
activity NN N
, , N
and CC N
elaborative JJ N
processes NNS N
supporting VBG N
mental JJ N
imagery NN N
of IN N
the DT N
substance NN N
or CC N
activity NN N
. . N

We PRP N
used VBD N
a DT N
novel JJ i
visuospatial JJ i
task NN i
to TO N
test VB N
the DT N
hypothesis NN N
that WDT N
visual JJ N
imagery NN N
plays VBZ N
a DT N
key JJ N
role NN N
in IN N
craving VBG o
. . o

Experiment NN N
1 CD N
showed VBD N
that IN N
spending VBG N
10 CD N
min JJ N
constructing VBG i
shapes NNS i
from IN i
modeling VBG i
clay NN i
( ( i
plasticine NN i
) ) i
reduced VBD N
participants NNS p
' POS p
craving VBG o
for IN o
chocolate NN o
compared VBN N
with IN N
spending NN N
10 CD N
min NN N
'letting VBG i
your PRP$ i
mind NN i
wander NN i
' POS i
. . i

Increasing VBG N
the DT N
load NN N
on IN N
verbal JJ N
working VBG N
memory NN N
using VBG N
a DT N
mental JJ N
arithmetic JJ N
task NN N
( ( N
counting VBG N
backwards NNS N
by IN N
threes NNS N
) ) N
did VBD N
not RB N
reduce VB N
craving VBG o
further RB N
. . N

Experiment JJ N
2 CD N
compared VBN N
effects NNS N
on IN N
craving NN o
of IN N
a DT N
simpler NN i
verbal JJ i
task NN i
( ( i
counting VBG i
by IN i
ones NNS i
) ) i
and CC i
clay NN i
modeling NN i
. . i

Clay NNP i
modeling VBG i
reduced VBN N
overall JJ o
craving NN o
strength NN o
and CC N
strength NN o
of IN o
craving VBG o
imagery NN o
, , N
and CC N
reduced VBD N
the DT N
frequency NN o
of IN o
thoughts NNS o
about IN o
chocolate NN o
. . o

The DT N
results NNS N
are VBP N
consistent JJ N
with IN N
EI NNP N
theory NN N
, , N
showing VBG N
that IN N
craving NN o
is VBZ N
reduced VBN N
by IN N
loading VBG N
the DT N
visuospatial JJ N
sketchpad NN N
of IN N
working VBG N
memory NN N
but CC N
not RB N
by IN N
loading VBG N
the DT N
phonological JJ N
loop NN N
. . N

Clay NNP i
modeling VBG i
might MD N
be VB N
a DT N
useful JJ N
self-help JJ N
tool NN N
to TO N
help VB N
manage VB N
craving VBG o
for IN p
chocolate NN p
, , p
snacks NNS p
and CC p
other JJ p
foods NNS p
. . p

-DOCSTART- -18849616- O O

Safety NN o
and CC o
immunogenicity NN o
of IN N
a DT N
cluster NN i
specific JJ i
immunotherapy NN i
in IN N
children NNS p
with IN p
bronchial JJ p
asthma NN p
and CC p
mite NN p
allergy NN p
. . p

BACKGROUND NNP N
Cluster NNP i
specific JJ i
immunotherapy NN i
( ( i
SIT NNP i
) ) i
is VBZ N
a DT N
modern JJ N
form NN N
of IN N
allergen NN N
immunotherapy NN N
allowing VBG N
safe JJ N
administration NN N
of IN N
high JJ N
allergen NN N
doses NNS N
in IN N
a DT N
short JJ N
time NN N
interval JJ N
compared VBN N
to TO N
classic JJ N
SIT NNP N
. . N

In IN N
the DT N
current JJ N
study NN N
, , N
we PRP N
investigated VBD N
the DT N
safety NN o
profile NN o
and CC o
immunological JJ o
effect NN o
of IN N
cluster NN N
SIT NNP N
in IN N
children NNS p
with IN p
allergic JJ p
asthma NNS p
due JJ p
to TO p
house NN p
dust NN p
mite NN p
allergy NN p
. . p

METHODS NNP N
A NNP N
total NN N
of IN N
34 CD p
children NNS p
( ( p
6-18 CD p
years NNS p
) ) p
with IN p
allergic JJ p
asthma NNS p
were VBD N
assigned VBN N
to TO N
cluster VB p
( ( p
n JJ p
= NNP p
22 CD p
) ) p
or CC N
classic JJ p
SIT NNP p
( ( p
n JJ p
= NNP p
12 CD p
) ) p
. . p

To TO N
achieve VB N
a DT N
maintenance NN N
dose NN N
of IN N
allergen NN N
extract NN N
, , N
cluster NN N
patients NNS N
received VBD N
14 CD i
injections NNS i
of IN i
house NN i
dust NN i
mite NN i
allergen NN i
within IN i
6 CD i
weeks NNS i
, , N
whereas IN N
the DT N
classic JJ i
SIT NNP i
group NN i
received VBD i
14 CD i
injections NNS i
within IN N
14 CD N
weeks NNS N
. . N

Safety NN o
was VBD N
monitored VBN N
by IN N
recording VBG N
adverse JJ N
events NNS N
. . N

Immunogenicity NNP o
was VBD N
measured VBN N
by IN N
specific JJ N
IgG NNP N
( ( N
Mite NNP N
) ) N
and CC N
IgG4 NNP N
( ( N
Mite NNP N
) ) N
, , N
by IN N
antibody-blocking JJ N
properties NNS N
on IN N
basophil NN N
activation NN N
, , N
and CC N
by IN N
the DT N
T NNP N
cell NN N
subset NN N
transcription NN N
factors NNS N
Foxp3 NNP N
, , N
T-bet NNP N
, , N
and CC N
GATA-3 NNP N
. . N

RESULTS NNP N
There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
local JJ o
and CC o
systemic JJ o
side NN o
effects NNS o
between IN N
the DT N
two CD N
groups NNS N
. . N

In IN N
the DT N
cluster NN N
group NN N
, , N
serum NN o
levels NNS o
of IN o
specific JJ o
IgG NNP o
( ( o
Mite NNP o
) ) o
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
and CC N
specific JJ o
IgG4 NNP o
( ( o
Mite NNP o
) ) o
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
significantly RB N
increased VBN N
after IN N
8 CD N
weeks NNS N
, , N
while IN N
it PRP N
took VBD N
12 CD N
weeks NNS N
in IN N
the DT N
classic JJ N
SIT NNP N
group NN N
. . N

These DT N
data NNS N
were VBD N
confirmed VBN N
by IN N
blocking VBG N
CD63 NNP o
expression NN o
as RB N
well RB N
as IN N
release NN N
of IN N
cysteinyl NN N
leukotrienes NNS N
after IN N
in IN N
vitro JJ N
basophil JJ N
stimulation NN N
. . N

No DT N
differences NNS N
in IN N
transcription NN o
factor NN o
expression NN o
were VBD N
found VBN N
in IN N
the DT N
two CD N
groups NNS N
. . N

CONCLUSION NNP N
Cluster NNP N
SIT NNP N
is VBZ N
safe JJ N
in IN N
children NNS p
. . p

Additionally RB N
, , N
our PRP$ N
data NNS N
demonstrated VBD N
an DT N
even RB N
more RBR N
rapid JJ N
induction NN o
of IN o
specific JJ o
immune JJ o
tolerance NN o
. . o

Cluster NNP N
SIT NNP N
is VBZ N
an DT N
attractive JJ N
alternative NN N
to TO N
conventional JJ N
up-dosing JJ N
schedules NNS N
with IN N
fewer JJR N
consultations NNS N
for IN N
the DT N
patients NNS N
. . N

-DOCSTART- -21434781- O O

Superior JJ N
fixation NN N
of IN N
pegged JJ i
trabecular JJ i
metal NN i
over IN N
screw-fixed JJ i
pegged JJ i
porous JJ i
titanium NN i
fiber NN i
mesh NN i
: : i
a DT N
randomized JJ N
clinical JJ N
RSA NNP N
study NN N
on IN N
cementless JJ N
tibial JJ N
components NNS N
. . N

BACKGROUND NNP N
AND CC N
PURPOSE NNP N
Lasting NNP N
stability NN o
of IN N
cementless NN N
implants NNS N
depends VBZ N
on IN N
osseointegration NN N
into IN N
the DT N
implant JJ N
surface NN N
, , N
and CC N
long-term JJ N
implant JJ N
fixation NN N
can MD N
be VB N
predicted VBN N
using VBG N
radiostereometric JJ N
analysis NN N
( ( N
RSA NNP N
) ) N
with IN N
short-term JJ N
follow-up JJ N
. . N

We PRP N
hypothesized VBD N
that IN N
there EX N
would MD N
be VB N
improved VBN N
fixation NN o
of IN N
high-porosity NN i
trabecular JJ i
metal NN i
( ( i
TM NNP i
) ) i
tibial JJ i
components NNS i
compared VBN N
to TO N
low-porosity JJ i
titanium NN i
pegged VBD i
porous JJ i
fiber-metal JJ i
( ( i
Ti NNP i
) ) i
polyethylene NN i
metal JJ i
backings NNS i
. . i

METHODS NNP N
In IN N
a DT N
prospective JJ N
, , N
parallel-group JJ N
, , N
randomized VBN N
unblinded JJ N
clinical JJ N
trial NN N
, , N
we PRP N
compared VBN N
cementless JJ i
tibial JJ i
components NNS i
in IN p
patients NNS p
aged VBN p
70 CD p
years NNS p
and CC p
younger JJR p
with IN p
osteoarthritis NN p
. . p

The DT N
pre-study JJ N
sample NN N
size NN N
calculation NN N
was VBD N
22 CD p
patients NNS p
per IN p
group NN p
. . p

25 CD i
TM NNP i
tibial JJ i
components NNS i
were VBD i
fixed VBN i
press-fit JJ i
by IN i
2 CD i
hexagonal JJ i
pegs NN i
( ( N
TM NNP N
group NN N
) ) N
and CC N
25 CD i
Ti NNP i
tibial JJ i
components NNS i
were VBD i
fixed VBN i
press-fit JJ i
and CC i
by IN i
4 CD i
supplemental JJ i
screws NNS i
( ( N
Ti NNP N
group NN N
) ) N
. . N

Stereo NNP N
radiographs NN N
for IN N
evaluation NN N
of IN N
absolute JJ N
component NN N
migration NN N
( ( N
primary JJ N
effect NN N
size NN N
) ) N
and CC N
single-direction JJ N
absolute NN N
component NN N
migration NN N
( ( N
secondary JJ N
effect NN N
size NN N
) ) N
were VBD N
obtained VBN N
within IN N
the DT N
first JJ N
postoperative JJ N
week NN N
and CC N
at IN N
6 CD N
weeks NNS N
, , N
6 CD N
months NNS N
, , N
1 CD N
year NN N
, , N
and CC N
2 CD N
years NNS N
. . N

American JJ o
Knee NNP o
Society NNP o
score NN o
was VBD N
used VBN N
for IN N
clinical JJ N
assessment NN N
preoperatively RB N
, , N
and CC N
at IN N
1 CD N
and CC N
2 CD N
years NNS N
. . N

RESULTS VB N
There EX N
were VBD N
no DT N
intraoperative JJ o
complications NNS o
, , o
and CC o
no DT o
postoperative JJ o
infections NNS o
or CC o
revisions NNS o
. . o

All DT p
patients NNS p
had VBD N
improved VBN o
function NN o
and CC o
regained VBD o
full JJ o
extension NN o
. . o

All DT N
tibial JJ N
components NNS N
migrated VBN o
initially RB N
. . N

Most JJS N
migration NN o
of IN o
the DT o
TM NNP o
components NNS o
( ( N
n JJ N
= NNP N
24 CD N
) ) N
occurred VBD N
within IN N
the DT N
first JJ N
3 CD N
months NNS N
after IN N
surgery NN N
whereas JJ N
migration NN N
of IN N
the DT N
Ti NNP i
components NNS i
( ( N
n JJ N
= NNP N
22 CD N
) ) N
appeared VBD N
to TO N
stabilize VB N
first RB N
after IN N
1 CD N
year NN N
. . N

The DT N
TM NNP i
components NNS i
migrated VBD N
less JJR N
than IN N
the DT N
Ti NNP i
components NNS i
at IN N
1 CD N
year NN N
( ( N
p JJ N
= NNP N
0.01 CD N
) ) N
and CC N
2 CD N
years NNS N
( ( N
p JJ N
= NNP N
0.004 CD N
) ) N
. . N

INTERPRETATION NNP N
We PRP N
conclude VBP N
that IN N
the DT N
mechanical JJ N
fixation NN N
of IN N
TM NNP i
tibial JJ i
components NNS i
is VBZ N
superior JJ N
to TO N
that DT N
of IN N
screw-fixed JJ N
Ti NNP i
tibial JJ i
components NNS i
. . N

We PRP N
expect VBP N
long-term JJ o
implant JJ o
survival NN o
to TO N
be VB N
better RB N
with IN N
the DT N
TM NNP i
tibial JJ i
component NN i
. . i

-DOCSTART- -16014845- O O

Tolerance NN o
and CC o
efficacy NN o
of IN N
combined JJ i
diethylcarbamazine NN i
and CC i
albendazole NN i
for IN N
treatment NN N
of IN N
Wuchereria NNP p
bancrofti NN p
and CC p
intestinal JJ p
helminth NN p
infections NNS p
in IN p
Haitian JJ p
children NNS p
. . p

This DT N
randomized JJ N
, , N
placebo-controlled JJ i
trial NN N
investigated VBD N
the DT N
tolerance NN N
, , N
efficacy NN N
, , N
and CC N
nutritional JJ N
benefit NN N
of IN N
combining VBG N
chemotherapeutic JJ i
treatment NN i
of IN N
intestinal JJ N
helminths NNS N
and CC N
lymphatic JJ N
filariasis NN N
. . N

Children NNP p
were VBD p
infected VBN p
with IN p
Ascaris NNP p
( ( p
30.7 CD p
% NN p
) ) p
, , p
Trichuris NNP p
( ( p
53.4 CD p
% NN p
) ) p
, , p
and CC p
hookworm NN p
( ( p
9.7 CD p
% NN p
) ) p
with IN p
69.9 CD p
% NN p
having VBG p
more JJR p
than IN p
one CD p
of IN p
these DT p
parasites NNS p
. . p

A DT N
total NN N
of IN N
15.8 CD N
% NN N
of IN N
the DT N
children NNS p
had VBD p
Wuchereria NNP p
bancrofti NN p
microfilariae NN p
. . p

Children NNP p
were VBD N
randomly RB N
assigned VBN N
treatment NN N
with IN N
placebo NN i
, , i
albendazole NN i
( ( i
ALB NNP i
) ) i
, , i
diethylcarbamazine NN i
( ( i
DEC NNP i
) ) i
, , i
or CC i
combined VBN i
therapy NN i
. . i

The DT o
combination NN o
of IN o
DEC/ALB NNP o
reduced VBD o
microfilarial JJ o
density NN o
compared VBN o
with IN o
placebo NN o
, , o
ALB NNP o
, , o
or CC o
DEC NNP o
( ( o
P NNP o
< NNP o
or CC o
= VB o
0.03 CD o
) ) o
. . o

Albendazole NNP o
and CC o
DEC/ALB NNP o
reduced VBD o
the DT o
prevalence NN o
of IN o
Ascaris NNP o
, , o
Trichuris NNP o
, , o
and CC o
hookworm RB o
more JJR o
than IN o
placebo NN o
or CC o
DEC NNP o
( ( o
P NNP o
< NNP o
or CC o
= VB o
0.03 CD o
) ) o
. . o

Among IN o
Trichuris-infected JJ o
children NNS o
, , o
those DT o
receiving VBG o
ALB NNP o
and CC o
DEC/ALB NNP o
demonstrated VBD o
greater JJR o
gains NNS o
in IN o
weight NN o
compared VBN o
with IN o
placebo NN o
( ( o
P NNP o
< NNP o
or CC o
= VB o
0.05 CD o
) ) o
. . o

Albendazole NNP o
and CC o
DEC/ALB NNP o
were VBD o
equally RB o
efficacious JJ o
in IN o
treating VBG o
intestinal JJ o
helminths NNS o
and CC o
for IN o
children NNS o
with IN o
W. NNP o
bancrofti NN o
microfilaremia NN o
, , o
DEC/ALB NNP o
was VBD o
more RBR o
effective JJ o
than IN o
DEC NNP o
, , o
with IN o
no DT o
increase NN o
in IN o
severity NN o
of IN o
adverse JJ o
reactions NNS o
. . o

-DOCSTART- -20023215- O O

Rituximab NNP i
plus CC i
concurrent JJ i
infusional JJ i
EPOCH NNP i
chemotherapy NN i
is VBZ N
highly RB N
effective JJ N
in IN p
HIV-associated JJ p
B-cell NNP p
non-Hodgkin JJ p
lymphoma NN p
. . p

Rituximab NNP N
plus CC N
intravenous JJ N
bolus NN N
chemotherapy NN N
is VBZ N
a DT N
standard JJ N
treatment NN N
for IN N
immunocompetent JJ p
patients NNS p
with IN p
B-cell NNP p
non-Hodgkin JJ p
lymphoma NN p
( ( p
NHL NNP p
) ) p
. . p

Some DT N
studies NNS N
have VBP N
suggested VBN N
that IN N
rituximab NN N
is VBZ N
associated VBN N
with IN N
excessive JJ o
toxicity NN o
in IN N
HIV-associated NNP N
NHL NNP N
, , N
and CC N
that IN N
infusional JJ N
chemotherapy NN N
may MD N
be VB N
more RBR N
effective JJ N
. . N

We PRP N
performed VBD N
a DT N
randomized JJ N
phase NN N
2 CD N
trial NN N
of IN N
rituximab NN i
( ( i
375 CD i
mg/m NN i
( ( i
2 CD i
) ) i
) ) i
given VBN i
either CC i
concurrently RB i
before IN i
each DT i
infusional JJ i
etoposide NN i
, , i
vincristine NN i
, , i
doxorubicin NN i
, , i
cyclophosphamide NN i
, , i
and CC i
prednisone NN i
( ( i
EPOCH NNP i
) ) i
chemotherapy NN i
cycle NN i
or CC i
sequentially RB i
( ( i
weekly JJ i
for IN i
6 CD i
weeks NNS i
) ) i
after IN i
completion NN i
of IN i
all DT i
chemotherapy NN i
in IN i
HIV-associated NNP i
NHL NNP i
. . i

EPOCH NNP i
consisted VBD N
of IN N
a DT N
96-hour JJ N
intravenous JJ N
infusion NN N
of IN N
etoposide NN i
, , i
doxorubicin NN i
, , i
and CC i
vincristine JJ i
plus CC i
oral JJ i
prednisone NN i
followed VBN N
by IN N
intravenous JJ N
bolus JJ N
cyclophosphamide NN i
given VBN N
every DT N
21 CD N
days NNS N
for IN N
4 CD N
to TO N
6 CD N
cycles NNS N
. . N

In IN N
the DT N
concurrent NN N
arm NN N
, , N
35 CD N
of IN N
48 CD p
evaluable JJ p
patients NNS p
( ( N
73 CD N
% NN N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
58 CD N
% NN N
-85 NNP N
% NN N
) ) N
had VBD N
a DT N
complete JJ o
response NN o
. . o

In IN N
the DT N
sequential JJ N
arm NN N
, , N
29 CD N
of IN N
53 CD p
evaluable JJ p
patients NNS p
( ( N
55 CD N
% NN N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
41 CD N
% NN N
-68 CD N
% NN N
) ) N
had VBD N
a DT N
complete JJ N
response NN N
. . N

The DT N
primary JJ N
efficacy NN N
endpoint NN N
was VBD N
met VBN N
for IN N
the DT N
concurrent NN N
arm NN N
only RB N
. . N

Toxicity NNP o
was VBD N
comparable JJ N
in IN N
the DT N
2 CD N
arms NNS N
, , N
although IN N
patients NNS N
with IN N
a DT N
baseline NN N
CD4 NNP o
count NN N
less JJR N
than IN N
50/microL CD N
had VBD N
a DT N
high JJ N
infectious JJ o
death NN o
rate NN o
in IN N
the DT N
concurrent NN N
arm NN N
. . N

We PRP N
conclude VBP N
that DT N
concurrent NN i
rituximab NN i
plus CC i
infusional JJ i
EPOCH NNP i
is VBZ N
an DT N
effective JJ N
regimen NNS N
for IN N
HIV-associated JJ p
lymphoma NN p
. . p

-DOCSTART- -12486433- O O

Comparison NNP N
of IN N
percutaneous JJ N
transmitral JJ N
commissurotomy NN N
with IN N
Inoue NNP N
balloon NN N
technique NN N
and CC N
metallic JJ N
commissurotomy NN N
: : N
immediate JJ N
and CC N
short-term JJ N
follow-up JJ N
results NNS N
of IN N
a DT N
randomized JJ N
study NN N
. . N

BACKGROUND NNP N
The DT N
Inoue NNP N
balloon NN N
technique NN N
for IN N
mitral JJ N
commissurotomy NN N
is VBZ N
well RB N
established VBN N
and CC N
carried VBN N
out RP N
worldwide NN N
. . N

Metallic NNP N
commissurotomy NN N
is VBZ N
reported VBN N
to TO N
be VB N
a DT N
cheaper JJR N
and CC N
effective JJ N
alternative NN N
to TO N
balloon VB N
mitral JJ N
commissurotomy NN N
. . N

METHODS NNP N
One CD p
hundred VBD p
patients NNS p
were VBD p
randomized VBN p
into IN p
2 CD p
groups NNS p
to TO p
undergo VB p
percutaneous JJ i
transmitral JJ i
commissurotomy NN i
( ( i
PTMC NNP i
) ) i
by IN p
means NNS i
of IN i
the DT i
Inoue NNP i
balloon NN i
technique NN i
( ( i
IBMC NNP i
, , i
n JJ i
= NNP i
49 CD i
) ) i
or CC i
metallic JJ i
commissurotomy NN i
( ( i
PMMC NNP i
, , i
n JJ i
= NNP i
51 CD i
) ) i
. . i

Patients NNS N
were VBD N
crossed VBN N
over IN N
to TO N
the DT N
other JJ N
technique NN i
when WRB N
the DT N
initial JJ N
technique NN N
was VBD N
a DT N
failure NN N
. . N

Success NN o
of IN o
valvotomy NN o
, , o
procedure-related JJ o
complications NNS o
, , o
and CC o
follow-up JJ o
events NNS o
of IN N
the DT N
2 CD N
techniques NNS N
were VBD N
compared VBN N
. . N

RESULTS NNP N
Basal NNP o
echocardiographic JJ o
and CC o
hemodynamic JJ o
data NNS o
were VBD N
similar JJ N
in IN N
both DT N
groups NNS N
. . N

Procedural NNP o
success NN o
was VBD N
similar JJ N
in IN N
both DT N
groups NNS N
: : N
45 CD N
of IN N
49 CD N
procedures NNS N
( ( N
91.8 CD N
% NN N
) ) N
in IN N
the DT N
IBMC NNP N
group NN N
, , N
compared VBN N
with IN N
46 CD N
of IN N
51 CD N
procedures NNS N
( ( N
90.18 CD N
% NN N
) ) N
in IN N
the DT N
PMMC NNP N
group NN N
( ( N
P NNP N
= NNP N
1.0 CD N
) ) N
. . N

Crossover NNP N
was VBD N
also RB N
comparable JJ N
, , N
with IN N
1 CD N
occurring VBG N
in IN N
the DT N
IBMC NNP N
group NN N
, , N
compared VBN N
with IN N
3 CD N
in IN N
the DT N
PMMC NNP N
group NN N
. . N

Complications NNS N
such JJ N
as IN N
cardiac JJ o
tamponade NN o
and CC o
mitral JJ o
regurgitation NN o
( ( N
requiring VBG N
or CC N
not RB N
requiring VBG N
mitral JJ N
valve FW N
replacement NN N
) ) N
were VBD N
similar JJ N
in IN N
both DT N
groups NNS N
, , N
with IN N
3 CD N
complications NNS N
in IN N
the DT N
IBMC NNP N
group NN N
, , N
compared VBN N
with IN N
4 CD N
complications NNS N
in IN N
the DT N
PMMC NNP N
group NN N
( ( N
P NNP N
=.29 NNP N
) ) N
. . N

After IN N
a DT N
follow-up JJ N
period NN N
of IN N
approximately RB N
4 CD N
months NNS N
, , N
both DT N
groups NNS N
had VBD N
similar JJ N
event NN N
rates NNS N
and CC N
comparable JJ N
hemodynamic JJ N
parameters NNS N
( ( N
P NNP N
= NNP N
not RB N
significant JJ N
) ) N
. . N

CONCLUSIONS NNP N
Both NNP N
IBMC NNP N
and CC N
PMMC NNP N
are VBP N
successful JJ N
means NNS N
of IN N
providing VBG N
relief NN N
from IN N
severe JJ p
mitral JJ p
stenosis NN p
with IN N
a DT N
gain NN N
in IN N
valve JJ N
area NN N
and CC N
reduction NN N
in IN N
transmitral JJ N
gradient NN N
. . N

Both DT N
techniques NNS N
have VBP N
similar JJ N
procedural JJ N
success NN N
, , N
complication NN N
rates NNS N
, , N
and CC N
follow-up JJ N
events NNS N
. . N

-DOCSTART- -1610994- O O

Effects NNS N
of IN N
halothane NN i
and CC N
isoflurane NN i
on IN N
transient JJ o
renal JJ o
dysfunction NN o
associated VBN N
with IN N
infrarenal JJ N
aortic JJ N
cross-clamping NN N
. . N

Aortic JJ N
cross-clamping NN N
for IN N
reconstructive JJ N
aortic JJ N
surgery NN N
is VBZ N
associated VBN N
with IN N
impairment NN N
of IN N
renal JJ o
function NN o
. . o

Halothane NNP i
or CC i
isoflurane NN i
was VBD N
used VBN N
to TO N
assess VB N
the DT N
influence NN N
of IN N
volatile JJ N
anesthesia NN N
on IN N
renal JJ o
hemodynamics NNS o
during IN N
aortic JJ N
surgery NN N
. . N

Nineteen JJ p
patients NNS p
with IN p
normal JJ p
preoperative JJ p
creatinine NN p
clearances NNS p
who WP p
were VBD p
scheduled VBN p
for IN p
reconstructive JJ p
aortic JJ p
surgery NN p
were VBD N
randomly RB N
divided VBN N
into IN N
two CD N
groups NNS N
: : N
halothane NN i
group NN i
( ( N
n JJ N
= NNP N
9 CD N
) ) N
and CC N
isoflurane JJ i
group NN i
( ( N
n JJ N
= NNP N
10 CD N
) ) N
. . N

Induction NN N
of IN N
anesthesia NN i
consisted VBN N
of IN N
midazolam NN i
, , i
fentanyl NN i
, , i
and CC i
pancuronium NN i
. . i

Anesthesia NNP i
was VBD N
maintained VBN N
with IN N
fentanyl NN i
and CC i
halothane NN i
or CC i
isoflurane NN i
in IN i
nitrous JJ i
oxide NN i
and CC i
oxygen NN i
( ( N
50/50 CD N
) ) N
. . N

Systemic JJ o
hemodynamics NNS o
were VBD N
similar JJ N
in IN N
both DT N
groups NNS N
throughout IN N
surgery NN N
. . N

Before IN N
aortic JJ N
cross-clamping NN N
, , N
effective JJ o
renal JJ o
plasma NN o
flow NN o
( ( o
ERPF NNP o
) ) o
( ( o
131I-hippuran JJ o
clearance NN o
) ) o
and CC o
glomerular JJ o
filtration NN o
rate NN o
( ( o
GFR NNP o
) ) o
( ( o
99Tc-DTPA JJ o
clearance NN o
) ) o
were VBD N
significantly RB N
lower JJR N
in IN N
the DT N
halothane NN N
group NN N
( ( N
118.4 CD N
+/- JJ N
25.6 CD N
and CC N
19.7 CD N
+/- JJ N
5.2 CD N
mL/min NN N
, , N
respectively RB N
) ) N
than IN N
in IN N
the DT N
isoflurane NN i
group NN N
( ( N
253.4 CD N
+/- JJ N
51.5 CD N
and CC N
44.9 CD N
+/- JJ N
8.4 CD N
mL/min NN N
) ) N
( ( N
P NNP N
less JJR N
than IN N
0.05 CD N
for IN N
both DT N
) ) N
. . N

During IN N
cross-clamping NN N
, , N
the DT N
renal JJ o
variables NNS o
were VBD N
not RB N
markedly RB N
affected VBN N
in IN N
either DT N
group NN N
and CC N
remained VBD N
higher JJR N
in IN N
the DT N
isoflurane-anesthetized JJ i
patients NNS N
( ( N
232.9 CD N
+/- JJ N
47.1 CD N
and CC N
49.5 CD N
+/- JJ N
1.2 CD N
mL/min NN N
for IN N
ERPF NNP N
and CC N
GFR NNP N
, , N
respectively RB N
) ) N
than IN N
in IN N
the DT N
halothane-anesthetized JJ i
patients NNS N
( ( N
132.4 CD N
+/- JJ N
31.6 CD N
and CC N
14.8 CD N
+/- JJ N
3.7 CD N
mL/min NN N
, , N
respectively RB N
) ) N
( ( N
P NNP N
less JJR N
than IN N
0.05 CD N
) ) N
. . N

After IN N
aortic JJ N
unclamping NN N
, , N
ERPF NNP o
increased VBD N
markedly RB N
in IN N
both DT N
groups NNS N
( ( N
467.8 CD N
+/- JJ N
122 CD N
and CC N
362.5 CD N
+/- JJ N
57.7 CD N
mL/min NN N
in IN N
the DT N
halothane NN N
and CC N
isoflurane NN N
groups NNS N
, , N
respectively RB N
) ) N
, , N
as IN N
did VBD N
GFR NNP o
( ( N
74.8 CD N
+/- JJ N
22 CD N
and CC N
71.8 CD N
+/- JJ N
13.1 CD N
mL/min NN N
, , N
respectively RB N
) ) N
. . N

These DT N
results NNS N
suggest VBP N
that IN N
anesthesia NN i
with IN N
halothane NN i
is VBZ N
associated VBN N
with IN N
transient JJ o
renal JJ o
vasoconstriction NN o
during IN N
abdominal JJ N
surgery NN N
. . N

In IN N
contrast NN N
, , N
aortic JJ N
cross-clamping NN N
during IN N
isoflurane NN N
anesthesia NN N
was VBD N
not RB N
associated VBN N
with IN N
renal JJ o
hemodynamic JJ o
impairment NN o
. . o

-DOCSTART- -7072873- O O

Memory NN i
aids NNS i
in IN N
longitudinal JJ N
health NN N
surveys NNS N
: : N
results NNS N
from IN N
a DT N
field NN N
experiment NN N
. . N

The DT N
use NN N
of IN N
memory NN i
aids NNS i
to TO N
improve VB N
respondent NN N
recall NN N
is VBZ N
becoming VBG N
increasingly RB N
popular JJ N
in IN N
health NN N
surveys NNS N
. . N

In IN N
a DT N
one-year JJ N
field NN N
experiment NN N
involving VBG N
over IN p
1,200 CD p
respondents NNS p
, , p
people NNS p
assigned VBD p
memory NN i
aids NNS i
reported VBD p
over IN p
50 CD p
per IN p
cent NN p
more JJR p
symptom JJ p
episodes NNS p
than IN p
those DT p
not RB p
assigned JJ p
memory NN p
aids NNS p
. . p

Differences NNS N
in IN N
reporting NN N
levels NNS N
were VBD N
particularly RB N
striking VBG N
during IN N
the DT N
first JJ N
six CD N
to TO N
12 CD N
weeks NNS N
of IN N
the DT N
survey NN N
, , N
for IN N
symptoms NNS N
related VBN N
to TO N
acute VB N
, , N
transitory NN N
illness NN N
, , N
and CC N
among IN N
minorities NNS N
and CC N
the DT N
lower JJR N
socioeconomic JJ N
groups NNS N
. . N

Respondents NNS N
assigned VBD N
memory NN i
aids NNS i
were VBD N
also RB N
more RBR N
likely JJ N
to TO N
report VB N
a DT N
doctor NN N
contact NN N
-- : N
especially RB N
during IN N
the DT N
fall/winter JJ N
months NNS N
. . N

Among IN N
respondent NN N
who WP N
used VBD N
their PRP$ N
memory NN i
aids NNS i
at IN N
least JJS N
once RB N
( ( N
N NNP N
= NNP N
252 CD N
) ) N
, , N
nearly RB N
35 CD N
per IN N
cent NN N
said VBD N
they PRP N
were VBD N
influenced VBN o
by IN o
the DT o
information NN o
recorded VBN o
in IN o
their PRP$ o
memory NN o
aids NNS o
, , N
and CC N
most JJS N
of IN N
those DT N
who WP N
were VBD N
influenced VBN N
said VBD N
that IN N
they PRP N
became VBD o
more RBR o
aware JJ o
of IN o
their PRP$ o
health NN o
. . o

Ten CD N
of IN N
these DT N
people NNS N
said VBD N
that IN N
they PRP N
became VBD N
more RBR o
worried JJ o
or CC o
depressed JJ o
because IN N
of IN N
the DT N
information NN N
recorded VBN N
in IN N
their PRP$ N
memory NN N
aids NNS N
. . N

This DT N
constitutes VBZ N
about IN N
a DT N
four CD N
per IN N
cent NN N
risk NN N
among IN N
those DT N
people NNS N
who WP N
reported VBD N
using VBG N
their PRP$ N
memory NN N
aids NNS N
at IN N
least JJS N
once RB N
. . N

There EX N
was VBD N
no DT N
evidence NN N
to TO N
suggest VB N
that IN N
the DT N
memory NN i
aids NNS i
influenced VBD N
perceptions NNS o
of IN o
health NN o
status NN o
. . o

-DOCSTART- -15735119- O O

Multi-institutional JJ N
randomized JJ N
phase NN N
II NNP N
trial NN N
of IN N
the DT N
epothilone NN i
B NNP i
analog NN i
ixabepilone NN i
( ( i
BMS-247550 NNP i
) ) i
with IN i
or CC i
without IN i
estramustine JJ i
phosphate NN i
in IN N
patients NNS p
with IN p
progressive JJ p
castrate NN p
metastatic JJ p
prostate NN p
cancer NN p
. . p

PURPOSE NNP N
To TO N
evaluate VB N
the DT N
antitumor NN o
activity NN o
and CC N
safety NN o
of IN N
the DT N
epothilone NN i
B NNP i
analog NN i
, , i
ixabepilone NN i
, , i
with IN i
or CC i
without IN i
estramustine JJ i
phosphate NN i
( ( i
EMP NNP i
) ) i
, , N
in IN N
chemotherapy-naive JJ p
patients NNS p
with IN p
progressive JJ p
castrate NN p
metastatic JJ p
prostate NN p
cancer NN p
. . p

PATIENTS NNP N
AND CC N
METHODS NNP N
Patients NNPS N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
ixabepilone NN i
( ( N
35 CD N
mg/m NN N
( ( N
2 CD N
) ) N
) ) N
by IN N
intravenous JJ i
infusion NN i
every DT i
3 CD i
weeks NNS i
with IN i
or CC i
without IN i
EMP NNP i
280 CD i
mg NN i
orally RB i
three CD N
times NNS N
daily RB N
on IN N
days NNS N
1 CD N
to TO N
5 CD N
. . N

RESULTS NN N
Between NNP p
December NNP p
2001 CD p
and CC p
October NNP p
2003 CD p
, , p
92 CD p
patients NNS p
were VBD p
enrolled VBN p
and CC p
randomly RB p
assigned VBN p
to TO N
treatment NN p
with IN p
ixabepilone NN i
alone RB i
( ( p
45 CD p
patients NNS p
) ) p
or CC p
in IN p
combination NN i
with IN i
EMP NNP i
( ( p
47 CD p
patients NNS p
) ) p
. . p

Grades $ o
3 CD o
and CC o
4 CD o
toxicities NNS o
experienced VBN N
by IN N
more JJR N
than IN N
5 CD N
% NN N
of IN N
patients NNS N
included VBN N
neutropenia RB o
( ( N
22 CD N
% NN N
) ) N
, , N
fatigue NN o
( ( N
9 CD N
% NN N
) ) N
, , N
and CC N
neuropathy JJ o
( ( N
13 CD N
% NN N
) ) N
on IN N
the DT N
ixabepilone NN o
arm NN o
, , o
and CC o
neutropenia NN o
( ( N
29 CD N
% NN N
) ) N
, , N
febrile JJ o
neutropenia NN o
( ( N
9 CD N
% NN N
) ) N
, , N
fatigue NN o
( ( N
9 CD N
% NN N
) ) N
, , N
neuropathy JJ o
( ( N
7 CD N
% NN N
) ) N
, , N
and CC N
thrombosis NN o
( ( N
6 CD N
% NN N
) ) N
on IN N
the DT N
ixabepilone NN N
+ NNP N
EMP NNP N
arm NN N
. . N

Post-treatment JJ N
declines NNS N
in IN N
prostate-specific JJ o
antigen NN o
of IN N
> NN N
or CC N
= VB N
50 CD N
% NN N
were VBD N
achieved VBN N
in IN N
21 CD N
of IN N
44 CD N
patients NNS N
( ( N
48 CD N
% NN N
; : N
95 CD N
% NN N
CI NNP N
, , N
33 CD N
% NN N
to TO N
64 CD N
% NN N
) ) N
on IN N
the DT N
ixabepilone NN N
arm NN N
, , N
and CC N
31 CD N
of IN N
45 CD N
patients NNS N
( ( N
69 CD N
% NN N
; : N
95 CD N
% NN N
CI NNP N
, , N
55 CD N
% NN N
to TO N
82 CD N
% NN N
) ) N
on IN N
the DT N
ixabepilone NN N
+ NNP N
EMP NNP N
arm NN N
. . N

In IN N
patients NNS N
with IN N
measurable JJ N
disease NN N
, , N
partial JJ o
responses NNS o
were VBD N
observed VBN N
in IN N
eight CD N
of IN N
25 CD N
patients NNS N
( ( N
32 CD N
% NN N
; : N
95 CD N
% NN N
CI NNP N
, , N
14 CD N
% NN N
to TO N
50 CD N
% NN N
) ) N
on IN N
the DT N
ixabepilone NN N
arm NN N
, , N
and CC N
11 CD N
of IN N
23 CD N
( ( N
48 CD N
% NN N
; : N
95 CD N
% NN N
CI NNP N
, , N
27 CD N
% NN N
to TO N
68 CD N
% NN N
) ) N
on IN N
the DT N
ixabepilone NN N
+ NNP N
EMP NNP N
arm NN N
. . N

Time NN o
to TO o
prostate-specific JJ o
antigen NN o
progression NN o
was VBD N
4.4 CD N
months NNS N
( ( N
95 CD N
% NN N
CI NNP N
, , N
3.1 CD N
to TO N
6.9 CD N
months NNS N
) ) N
on IN N
the DT N
ixabepilone-alone JJ N
arm NN N
and CC N
5.2 CD N
months NNS N
( ( N
95 CD N
% NN N
CI NNP N
, , N
4.5 CD N
to TO N
6.8 CD N
months NNS N
) ) N
on IN N
the DT N
combination NN N
arm NN N
. . N

CONCLUSION NNP N
Ixabepilone NNP i
, , N
with IN N
or CC N
without IN N
estramustine JJ i
phosphate NN i
, , N
is VBZ N
well RB o
tolerated VBN o
and CC N
has VBZ N
antitumor VBN o
activity NN o
in IN N
patients NNS p
with IN p
castrate JJ p
metastatic JJ p
prostate NN p
cancer NN p
. . p

-DOCSTART- -16948927- O O

Risperidone NN i
in IN N
children NNS p
with IN p
autism NN p
: : p
randomized VBN N
, , N
placebo-controlled JJ N
, , N
double-blind JJ N
study NN N
. . N

Some DT N
open-label JJ N
studies NNS N
suggest VBP N
that IN N
risperidone NN i
can MD N
be VB N
useful JJ N
in IN N
the DT N
treatment NN N
of IN N
certain JJ N
target NN N
symptoms NNS N
in IN N
children NNS p
with IN p
autism NN p
. . p

We PRP N
aimed VBD N
to TO N
study VB N
whether IN N
the DT N
use NN N
of IN N
risperidone NN i
in IN N
comparison NN N
with IN N
placebo NN i
improved VBN N
functioning NN N
in IN N
children NNS p
with IN p
autism NN p
with IN N
regard NN N
to TO N
behavior VB N
( ( N
aggressiveness NN N
, , N
hyperactivity NN N
, , N
irritability NN N
) ) N
, , N
social JJ N
and CC N
emotional JJ N
responsiveness NN N
, , N
and CC N
communication NN N
skills NNS N
. . N

We PRP N
conducted VBD N
a DT N
randomized VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
trial NN N
with IN N
40 CD p
consecutive JJ p
children NNS p
with IN p
autism NN p
, , p
whose WP$ p
ages NNS p
ranged VBD p
from IN p
2 CD p
to TO p
9 CD p
years NNS p
, , p
who WP p
were VBD p
receiving VBG p
either CC p
risperidone NN i
or CC i
placebo VB i
given VBN p
orally RB p
at IN p
a DT p
dose NN p
of IN p
1 CD p
mg/day NN p
for IN p
6 CD p
months NNS p
. . p

Autism NN N
symptoms NNS N
were VBD N
monitored VBN N
periodically RB N
. . N

The DT N
outcome NN N
variables NNS N
were VBD N
total JJ N
scores NNS N
on IN N
the DT N
Childhood NNP N
Autism NNP N
Rating NNP N
Scale NNP N
( ( N
CARS NNP N
) ) N
and CC N
the DT N
Children NNP N
's POS N
Global NNP N
Assessment NNP N
Scale NNP N
( ( N
CGAS NNP N
) ) N
after IN N
6 CD N
months NNS N
. . N

Of IN N
the DT N
40 CD p
children NNS p
enrolled VBD p
, , N
39 CD N
completed VBD N
the DT N
trial NN N
over IN N
a DT N
period NN N
of IN N
18 CD N
months NNS N
; : N
19 CD N
received VBD N
risperidone NN i
, , N
and CC N
20 CD N
received VBD N
placebo NN i
. . i

In IN N
the DT N
risperidone NN i
group NN N
, , N
12 CD N
of IN N
19 CD N
children NNS N
showed VBD N
improvement NN N
in IN N
the DT N
total JJ o
Childhood NNP o
Autism NNP o
Rating NNP o
Scale NNP o
score NN o
and CC N
17 CD N
of IN N
19 CD N
children NNS N
in IN N
the DT N
Children NNP o
's POS o
Global NNP o
Assessment NNP o
Scale NNP o
score NN o
compared VBN N
with IN N
0 CD N
of IN N
20 CD N
children NNS N
for IN N
the DT N
Childhood NNP o
Autism NNP o
Rating NNP o
Scale NNP o
score NN o
and CC N
2 CD N
of IN N
20 CD N
children NNS N
for IN N
the DT N
Children NNP o
's POS o
Global NNP o
Assessment NNP o
Scale NNP o
score NN o
in IN N
the DT N
placebo NN i
group NN N
( ( N
P NNP N
< NNP N
.001 NNP N
and CC N
P NNP N
= NNP N
.035 NNP N
, , N
respectively RB N
) ) N
. . N

Risperidone NNP i
also RB N
improved VBD N
social JJ o
responsiveness NN o
and CC o
nonverbal JJ o
communication NN o
and CC N
reduced VBD N
the DT N
symptoms NNS o
of IN o
hyperactivity NN o
and CC o
aggression NN o
. . o

Risperidone NN i
was VBD N
associated VBN N
with IN N
increased VBN N
appetite NN o
and CC o
a DT o
mild JJ o
weight NN o
gain NN o
, , o
mild JJ o
sedation NN o
in IN o
20 CD o
% NN o
, , o
and CC o
transient NN o
dyskinesias NN o
in IN N
three CD N
children NNS N
. . N

Risperidone NN i
improved VBD N
global JJ o
functioning NN o
and CC o
social JJ o
responsiveness NN o
while IN N
reducing VBG o
hyperactivity NN o
and CC o
aggression NN o
in IN N
children NNS p
with IN p
autism NN p
and CC N
was VBD N
well RB N
tolerated VBN N
. . N

-DOCSTART- -9855086- O O

Optimization NN N
of IN N
acid JJ N
suppression NN N
for IN N
patients NNS p
with IN p
peptic JJ p
ulcer NN p
bleeding NN p
: : p
an DT N
intragastric JJ N
pH-metry NN N
study NN N
with IN N
omeprazole NN i
. . i

OBJECTIVE UH N
To TO N
study VB N
whether IN N
an DT N
intravenous JJ N
infusion NN N
dose NN N
of IN N
omeprazole NN i
( ( N
80 CD N
mg NN N
+ VBD N
8 CD N
mg/h NN N
) ) N
during IN N
24 CD N
h NNS N
can MD N
be VB N
subsequently RB N
reduced VBN N
with IN N
maintained JJ N
effect NN N
. . N

Second NNP N
, , N
to TO N
study VB N
the DT N
effect NN N
of IN N
oral JJ N
omeprazole JJ i
20 CD N
mg NN N
given VBN N
once RB N
or CC N
twice RB N
daily RB N
up IN N
to TO N
day NN N
10 CD N
, , N
after IN N
cessation NN N
of IN N
a DT N
3-day JJ N
intravenous JJ N
infusion NN N
( ( N
80 CD N
mg NN N
+ VBD N
8 CD N
mg/h NN N
) ) N
. . N

DESIGN NNP N
Prospective NNP N
, , N
randomized VBD N
, , N
partly RB N
blinded VBD N
study NN N
. . N

METHODS NNP N
Twelve NNP p
Helicobacter NNP p
pylori NN p
( ( p
+ NNP p
) ) p
patients NNS p
and CC p
12 CD p
H. NNP p
pylori NN p
( ( p
- : p
) ) p
subjects NNS p
were VBD p
included VBN p
. . p

In IN N
part NN N
I PRP N
the DT N
patients NNS N
received VBD N
omeprazole JJ i
, , N
80 CD N
mg NN N
+ VBD N
8 CD N
mg/h NN N
, , N
during IN N
24 CD N
h NN N
followed VBN N
by IN N
8 CD N
, , N
4 CD N
or CC N
2 CD N
mg/h NN N
. . N

In IN N
part NN N
II NNP N
the DT N
subjects NNS N
received VBD N
80 CD N
mg NNS N
+ VBD N
8 CD N
mg/h NN N
during IN N
3 CD N
days NNS N
followed VBN N
by IN N
20 CD N
mg NNS N
omeprazole JJ i
orally RB N
, , N
once RB N
or CC N
twice JJ N
daily JJ N
until IN N
day NN N
10 CD N
. . N

Intragastric NNP o
pH NN o
was VBD N
measured VBN N
. . N

RESULTS NNP N
All NNP N
H. NNP N
pylori FW N
( ( N
+ NN N
) ) N
patients NNS N
showed VBD N
a DT N
rapid JJ N
increase NN N
of IN N
intragastric JJ o
pH NN o
with IN o
a DT o
mean JJ o
intragastric JJ o
pH NN o
of IN N
6.7 CD N
during IN N
the DT N
second JJ N
half NN N
of IN N
the DT N
first JJ N
day NN N
. . N

After IN N
the DT N
subsequent JJ N
dose NN N
reduction NN N
, , N
the DT N
mean JJ o
pH NN o
decreased VBD N
to TO N
6.1-6.2 JJ N
. . N

Patients NNPS N
continuing VBG N
on IN N
8 CD N
mg/h NN N
showed VBD N
the DT N
best JJS N
results NNS N
. . N

Likewise NNP N
, , N
all DT N
H. NNP N
pylori NN N
( ( N
- : N
) ) N
subjects VBZ N
showed VBD N
a DT N
rapid JJ N
and CC N
sustained JJ N
reduction NN N
of IN N
intragastric JJ o
acidity NN o
during IN N
the DT N
infusion NN N
. . N

Subsequent NNP N
dose JJ N
reduction NN N
to TO N
20 CD N
mg NNS N
once RB N
daily RB N
led VBN N
to TO N
a DT N
stable JJ N
fraction NN N
of IN N
time NN N
with IN N
pH JJ N
> JJ N
3 CD N
of IN N
72 CD N
% NN N
. . N

CONCLUSIONS NNP N
Omeprazole NNP i
given VBN N
as IN N
a DT N
continuous JJ N
infusion NN N
of IN N
80 CD N
mg NNS N
+ VBD N
8 CD N
mg/h NN N
for IN N
72 CD N
h NN N
followed VBN N
by IN N
omeprazole JJ i
20 CD N
mg NN N
once RB N
daily RB N
raised VBD N
the DT N
intragastric JJ o
pH NN o
to TO N
and CC N
above JJ N
levels NNS N
alleged VBN N
to TO N
allow VB N
haemostasis NN N
in IN N
patients NNS N
with IN N
peptic JJ p
ulcer NN p
bleeding NN p
and CC N
subsequent JJ N
healing NN N
of IN N
the DT N
ulcer NN N
. . N

-DOCSTART- -20431081- O O

Stroke NNP N
team NN N
remote NN N
evaluation NN N
using VBG N
a DT N
digital JJ N
observation NN N
camera NN N
in IN N
Arizona NNP p
: : p
the DT N
initial JJ N
mayo NN N
clinic JJ N
experience NN N
trial NN N
. . N

BACKGROUND NNP N
AND CC N
PURPOSE NNP N
Telemedicine NNP N
techniques NNS N
can MD N
be VB N
used VBN N
to TO N
address VB N
the DT N
rural-metropolitan JJ p
disparity NN N
in IN N
acute JJ N
stroke NN N
care NN N
. . N

The DT N
Stroke NNP N
Team NNP N
Remote NNP N
Evaluation NNP N
Using VBG N
a DT N
Digital NNP N
Observation NNP N
Camera NNP N
( ( N
STRokE NNP N
DOC NNP N
) ) N
trial NN N
reported VBD N
more RBR N
accurate JJ N
decision NN N
making NN N
for IN N
telemedicine JJ i
consultations NNS N
compared VBN N
with IN N
telephone-only JJ i
and CC N
that IN N
the DT N
California-based JJ N
research NN N
network NN N
facilitated VBD N
a DT N
high JJ N
rate NN N
of IN N
thrombolysis NN N
use NN N
, , N
improved VBN N
data NNS N
collection NN N
, , N
low JJ N
risk NN N
of IN N
complications NNS N
, , N
low JJ N
technical JJ N
complications NNS N
, , N
and CC N
favorable JJ N
assessment NN N
times NNS N
. . N

The DT N
main JJ N
objective NN N
of IN N
the DT N
STRokE NNP N
DOC NNP N
Arizona NNP N
TIME NNP N
( ( N
The DT N
Initial NNP N
Mayo NNP N
Clinic NNP N
Experience NNP N
) ) N
trial NN N
was VBD N
to TO N
determine VB N
the DT N
feasibility NN N
of IN N
establishing VBG N
, , N
de FW N
novo FW N
, , N
a DT N
single-hub JJ N
, , N
multirural JJ N
spoke VBD N
hospital JJ N
telestroke NN N
research NN N
network NN N
across IN N
a DT N
large JJ N
geographical JJ N
area NN N
in IN N
Arizona NNP N
by IN N
replicating VBG N
the DT N
STRokE NNP N
DOC NNP N
protocol NN N
. . N

METHODS NNP N
Methods NNP N
included VBD N
prospective JJ N
, , N
single-hub JJ N
, , N
2-spoke JJ N
, , N
randomized VBN N
, , N
blinded VBD N
, , N
controlled VBD N
trial NN N
of IN N
a DT N
2-way JJ N
, , N
site-independent JJ N
, , N
audiovisual JJ i
telemedicine NN i
system NN i
designed VBN i
for IN i
remote JJ i
examination NN i
of IN N
adult NN p
patients NNS p
with IN p
acute JJ p
stroke NN p
versus IN p
telephone NN i
consultation NN i
to TO i
assess VB i
eligibility NN i
for IN i
treatment NN i
with IN p
intravenous JJ i
thrombolysis NN i
. . i

The DT N
primary JJ N
outcome NN N
measure NN N
was VBD N
whether IN N
the DT N
decision NN o
to TO o
give VB o
thrombolysis NN o
was VBD o
correct JJ o
. . o

Secondary JJ N
outcomes NNS N
were VBD N
rate NN o
of IN o
thrombolytic JJ o
use NN o
, , o
90-day JJ o
functional JJ o
outcomes NNS o
, , o
incidence NN o
of IN o
intracerebral JJ o
hemorrhages NNS o
, , o
and CC o
technical JJ o
observations NNS o
. . o

RESULTS NN N
From IN p
December NNP p
2007 CD p
to TO p
October NNP p
2008 CD p
, , p
54 CD p
patients NNS p
were VBD p
assessed VBN p
, , N
27 CD N
of IN N
whom WP N
were VBD N
randomized VBN N
to TO N
each DT N
arm NN N
. . N

Mean JJ N
National NNP N
Institutes NNPS N
of IN N
Health NNP N
Stroke NNP N
Scale NNP N
score NN N
at IN N
presentation NN N
was VBD N
7.3 CD N
( ( N
SD NNP N
6.2 CD N
) ) N
points NNS N
. . N

No DT N
consultations NNS N
were VBD N
aborted VBN N
; : N
however RB N
, , N
technical JJ o
problems NNS o
( ( N
74 CD N
% NN N
) ) N
were VBD N
prevalent JJ N
in IN N
the DT N
telemedicine NN N
arm NN N
. . N

Overall JJ N
, , N
the DT N
correct JJ N
treatment NN o
decision NN o
was VBD N
established VBN N
in IN N
87 CD N
% NN N
of IN N
the DT N
consultations NNS N
. . N

Both DT N
modalities NNS N
, , N
telephone NN N
( ( N
89 CD N
% NN N
correct NN N
) ) N
and CC N
telemedicine NN N
( ( N
85 CD N
% NN N
correct NN N
) ) N
, , N
performed VBN N
well RB N
. . N

Intravenous JJ N
thrombolytic JJ i
treatment NN i
was VBD N
used VBN N
in IN N
30 CD N
% NN N
of IN N
the DT N
telemedicine NN N
and CC N
telephone NN N
consultations NNS N
. . N

Good JJ N
functional JJ o
outcomes NNS o
at IN N
90 CD N
days NNS N
were VBD N
not RB N
significantly RB N
different JJ N
. . N

There EX N
were VBD N
no DT N
statistically RB N
significant JJ N
differences NNS N
in IN N
mortality NN o
( ( N
4 CD N
% NN N
in IN N
telemedicine NN N
and CC N
11 CD N
% NN N
in IN N
telephone NN N
) ) N
or CC N
rates NNS o
of IN o
intracerebral JJ o
hemorrhage NN o
( ( N
4 CD N
% NN N
in IN N
telemedicine NN N
and CC N
0 CD N
% NN N
in IN N
telephone NN N
) ) N
. . N

CONCLUSIONS VB N
It PRP N
is VBZ N
feasible JJ N
to TO N
extend VB N
the DT N
original JJ N
STRokE NNP N
DOC NNP N
trial NN N
protocol NN N
to TO N
a DT N
new JJ N
state NN N
and CC N
establish VB N
an DT N
operational JJ N
single-hub NN N
, , N
multispoke VBD N
rural JJ N
hospital NN N
telestroke VBD N
research NN N
network NN N
in IN N
Arizona NNP N
. . N

The DT N
trial NN N
was VBD N
not RB N
designed VBN N
to TO N
have VB N
sufficient JJ N
power NN N
to TO N
detect VB N
a DT N
difference NN N
between IN N
the DT N
2 CD N
consultative JJ N
modes NNS N
: : N
telemedicine NN N
and CC N
telephone-only RB N
. . N

Whether CC N
by IN N
telemedicine NN N
or CC N
telephone NN N
consultative JJ N
modalities NNS N
, , N
there EX N
were VBD N
appropriate JJ N
treatment NN o
decisions NNS o
, , N
high JJ N
rates NNS N
of IN N
thrombolysis NN o
use NN o
, , N
improved VBN N
data NNS o
collection NN o
, , N
low JJ N
rates NNS o
of IN o
intracerebral JJ o
hemorrhage NN o
, , N
and CC N
equally RB N
favorable JJ N
time NN o
requirements NNS o
. . o

The DT N
learning VBG N
curve NN N
was VBD N
steep JJ N
for IN N
the DT N
hub NN N
and CC N
spoke VBD N
personnel NNS N
of IN N
the DT N
new JJ N
telestroke NN N
network NN N
, , N
as IN N
reflected VBN N
by IN N
frequent JJ N
technical JJ N
problems NNS N
. . N

Overall NNP N
, , N
the DT N
results NNS N
support VBD N
the DT N
effectiveness NN N
of IN N
highly RB N
organized VBN N
and CC N
structured VBN N
stroke NN N
telemedicine NN N
networks NNS N
for IN N
extending VBG N
expert JJ N
stroke NN N
care NN N
into IN N
rural JJ p
remote JJ p
communities NNS p
lacking VBG p
sufficient JJ p
neurological JJ p
expertise NN p
. . p

-DOCSTART- -3563413- O O

Fasting VBG N
and CC N
meal-stimulated JJ N
plasma NN N
levels NNS N
of IN N
neurotensin NN N
in IN N
obese JJ p
patients NNS p
after IN p
jejunoileal JJ i
bypass NN i
with IN p
3:1 CD p
or CC p
1:3 CD p
jejunoileal NN p
ratio NN p
. . p

The DT N
functional JJ N
role NN N
of IN N
the DT N
jejunum NN N
and CC N
ileum NN N
with IN N
regard NN N
to TO N
peripheral JJ N
plasma NN N
levels NNS N
of IN N
intact JJ N
neurotensin JJ N
and CC N
NH2-terminal JJ N
immunoreactivity NN N
of IN N
neurotensin NN N
was VBD N
studied VBN N
by IN N
using VBG N
jejunoileal JJ N
bypass NN N
as IN N
a DT N
model NN N
. . N

Plasma NNP N
levels NNS N
were VBD N
measured VBN N
by IN N
radioimmunoassay NN N
before IN N
and CC N
after IN N
jejunoileal JJ N
bypass NN N
randomized VBN N
to TO N
different JJ N
jejunoileal JJ N
ratios NNS N
. . N

Seven CD p
patients NNS p
were VBD p
studied VBN p
before IN p
bypass NN p
surgery NN p
and CC p
28 CD p
were VBD p
examined VBN p
after IN p
end-to-side JJ i
jejunoileal JJ i
bypass NN i
with IN i
50 CD i
cm NNS i
intestine NN i
in IN p
continuity NN p
and CC p
a DT p
3:1 CD p
or CC p
1:3 CD p
ratio NN p
between IN p
the DT p
length NN p
of IN p
the DT p
jejunal NN p
and CC p
ileal JJ p
segments NNS p
. . p

Fasting VBG o
levels NNS o
of IN o
intact JJ o
neurotensin NNS o
were VBD N
unchanged JJ N
by IN N
surgery NN N
, , N
whereas JJ N
levels NNS N
of IN N
NH2-terminal JJ o
immunoreactivity NN o
were VBD N
higher JJR N
in IN N
bypass NN N
patients NNS N
with IN N
a DT N
long JJ N
ileal NN N
segment NN N
( ( N
37.5 CD N
cm NN N
) ) N
than IN N
in IN N
unoperated JJ N
patients NNS N
and CC N
in IN N
those DT N
with IN N
a DT N
short JJ N
ileal NN N
segment NN N
( ( N
12.5 CD N
cm NN N
) ) N
. . N

Meal-stimulated JJ o
levels NNS o
of IN o
intact JJ o
neurotensin NNS o
were VBD N
higher JJR N
after IN N
1:3 CD N
than IN N
3:1 CD N
jejunoileal JJ N
bypass NN N
. . N

The DT N
levels NNS o
of IN o
NH2-terminal JJ o
immunoreactivity NN o
in IN N
patients NNS N
with IN N
a DT N
short JJ N
ileal NN N
segment NN N
and CC N
in IN N
controls NNS N
were VBD N
lower JJR N
than IN N
in IN N
patients NNS N
with IN N
a DT N
long JJ N
ileal NN N
segment NN N
. . N

The DT N
results NNS N
show VBP N
that IN N
postprandial JJ o
levels NNS o
of IN o
both DT o
intact JJ o
neurotensin NN o
and CC o
NH2-terminal JJ o
immunoreactivity NN o
are VBP N
related VBN N
to TO N
the DT N
length NN N
of IN N
the DT N
functioning NN N
ileum NN N
and CC N
that IN N
even RB N
a DT N
difference NN N
in IN N
length NN N
of IN N
25 CD N
cm NN N
is VBZ N
reflected VBN N
in IN N
the DT N
circulating NN N
levels NNS N
of IN N
neurotensin NN N
. . N

-DOCSTART- -17438178- O O

A DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
trial NN N
of IN N
pentoxifylline NN i
for IN N
the DT N
treatment NN N
of IN N
recurrent NN p
aphthous JJ p
stomatitis NN p
. . p

OBJECTIVE UH N
To TO N
evaluate VB N
pentoxifylline NN i
for IN N
the DT N
treatment NN N
of IN N
recurrent NN N
aphthous JJ N
stomatitis NN N
. . N

DESIGN VB N
A DT N
60-day JJ N
, , N
randomized VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
trial NN N
with IN N
a DT N
60-day JJ N
no DT N
treatment NN N
follow-up RB N
. . N

SETTING VBG N
An DT N
oral JJ N
medicine NN N
specialist NN N
referral JJ N
center NN N
in IN N
Manchester NNP N
. . N

PARTICIPANTS NNP N
Forty-nine JJ p
volunteers NNS p
who WP p
passed VBD p
the DT p
initial JJ p
assessment NN p
for IN p
recurrent NN p
aphthous JJ p
stomatitis NN p
entered VBD p
a DT p
pretrial JJ p
phase NN p
in IN p
which WDT p
their PRP$ p
eligibility NN p
for IN p
the DT p
trial NN p
phase NN p
of IN p
the DT p
study NN p
was VBD p
assessed VBN p
. . p

Sixteen JJ p
subjects NNS p
were VBD p
deemed VBN p
ineligible JJ p
, , N
and CC N
7 CD N
failed VBD N
to TO N
attend VB N
or CC N
withdrew VB N
. . N

The DT N
remaining VBG N
26 CD p
subjects NNS p
were VBD N
randomized VBN N
to TO N
placebo VB N
or CC N
treatment NN N
. . N

Six NNP N
subjects VBZ N
withdrew JJ N
because IN N
of IN N
adverse JJ N
effects NNS N
, , N
and CC N
1 CD N
was VBD N
unavailable JJ N
for IN N
follow-up NN N
. . N

INTERVENTION NNP N
Pentoxifylline NNP i
( ( N
also RB N
called VBN N
oxpentifylline NN N
) ) N
, , N
400 CD N
mg NN N
3 CD N
times NNS N
daily RB N
, , N
or CC N
matching VBG N
placebo NN i
. . i

MAIN NNP N
OUTCOME NNP N
MEASURE NNP N
A NNP N
reduction NN N
in IN N
the DT N
median JJ o
pain NN o
score NN o
, , o
ulcer JJ o
size NN o
, , o
number NN o
of IN o
ulcers NNS o
, , o
or CC o
total JJ o
number NN o
of IN o
ulcer JJ o
episodes NNS o
. . o

RESULTS JJ N
Patients NNPS N
taking VBG N
pentoxifylline NN i
had VBD N
less JJR o
pain NN o
and CC N
reported VBD N
smaller JJR o
and CC o
fewer JJR o
ulcers NNS o
compared VBN N
with IN N
baseline NN N
. . N

Patients NNS N
taking VBG N
placebo NN i
reported VBD N
no DT o
improvement NN o
in IN N
these DT N
variables NNS N
. . N

Patients NNS N
taking VBG N
pentoxifylline NN i
also RB N
reported VBD N
more RBR o
ulcer-free JJ o
days NNS o
than IN N
those DT N
taking VBG N
placebo NN i
. . i

However RB N
, , N
the DT N
differences NNS o
were VBD o
small JJ o
and CC N
, , N
with IN N
the DT N
exception NN o
of IN o
median JJ o
ulcer NN o
size NN o
( ( N
P NNP N
= NNP N
.05 NNP N
) ) N
, , N
did VBD o
not RB o
reach VB o
statistical JJ o
significance NN o
. . o

Adverse JJ o
effects NNS o
were VBD N
common JJ N
with IN N
pentoxifylline NN i
, , N
but CC N
not RB o
significantly RB o
different JJ o
from IN N
those DT N
experienced VBN N
by IN N
patients NNS N
taking VBG N
placebo NN i
. . i

CONCLUSIONS NNP N
Although IN N
pentoxifylline NN i
may MD N
have VB N
some DT N
benefit NN N
in IN N
the DT N
treatment NN N
of IN N
recurrent NN N
aphthous JJ N
stomatitis NN N
, , N
the DT N
benefit NN N
is VBZ N
limited VBN N
. . N

It PRP N
may MD N
have VB N
a DT N
role NN N
in IN N
the DT N
treatment NN N
of IN N
patients NNS N
unresponsive JJ N
to TO N
other JJ N
treatments NNS N
, , N
but CC N
can MD N
not RB N
yet RB N
be VB N
recommended VBN N
as IN N
a DT N
first-line JJ N
treatment NN N
. . N

-DOCSTART- -7526007- O O

Using VBG N
repeated JJ N
measures NNS N
of IN N
symptom NN N
score NN N
, , N
uroflowmetry NN N
and CC N
prostate NN N
specific JJ N
antigen NN N
in IN N
the DT N
clinical JJ N
management NN N
of IN N
prostate NN p
disease NN p
. . p

Benign NNP p
Prostatic NNP p
Hyperplasia NNP p
Treatment NNP N
Outcomes NNP N
Study NNP N
Group NNP N
. . N

Measurements NNS i
of IN i
American NNP o
Urological NNP o
Association NNP o
symptom VBD o
score RB o
, , o
peak JJ o
urine JJ o
flow NN o
rate NN o
and CC i
prostate NN o
specific JJ o
antigen NN o
( ( o
PSA NNP o
) ) o
are VBP i
often RB i
followed VBN i
over RP i
time NN i
in IN i
urological JJ i
management NN i
. . i

However RB N
, , N
their PRP$ N
interpretation NN N
is VBZ N
confounded VBN N
by IN N
within-patient JJ N
variability NN N
due JJ N
to TO N
chance NN N
. . N

Data NNP N
from IN N
2 CD N
clinical JJ N
trials NNS N
are VBP N
used VBN N
to TO N
examine VB N
the DT N
magnitude NN N
of IN N
this DT N
variation NN N
. . N

When WRB N
these DT N
measures NNS N
are VBP N
repeated VBN N
at IN N
a DT N
short JJ N
interval NN N
variation NN N
is VBZ N
modest JJ N
and CC N
might MD N
easily RB N
be VB N
misinterpreted VBN N
as IN N
a DT N
true JJ N
change NN N
in IN N
patient JJ N
condition NN N
. . N

For IN N
example NN N
, , N
approximately RB p
20 CD p
% NN p
of IN p
patients NNS p
might MD N
be VB N
expected VBN N
to TO N
have VB N
a DT N
chance NN N
increase NN N
or CC N
decrease NN N
in IN N
symptom NN N
score NN N
by IN N
at IN N
least JJS N
4.9 CD N
points NNS N
, , N
in IN N
peak JJ N
urine JJ N
flow NN N
rate NN N
by IN N
at IN N
least JJS N
4.1 CD N
ml NN N
. . N

per IN N
second NN N
or CC N
in IN N
PSA NNP N
by IN N
at IN N
least JJS N
1.6 CD N
ng./ml NN N
. . N

Clinicians NNS N
can MD N
use VB N
these DT N
data NNS N
to TO N
help VB N
interpret VB N
repeated JJ N
measures NNS N
of IN N
these DT N
variables NNS N
in IN N
patients NNS N
, , N
and CC N
can MD N
consider VB N
obtaining VBG N
paired JJ N
measurements NNS N
to TO N
decrease VB N
the DT N
effect NN N
of IN N
chance NN N
variation NN N
when WRB N
they PRP N
plan VBP N
on IN N
following VBG N
them PRP N
over IN N
time NN N
. . N

-DOCSTART- -375690- O O

Zinc NNP i
supplementation NN i
in IN N
alcoholic JJ p
cirrhosis NN p
. . p

A DT N
double-blind JJ N
clinical JJ N
trial NN N
. . N

A DT N
double-blind JJ N
clinical JJ N
trial NN N
with IN N
zinc NN i
sulfate NN i
, , N
0.2 CD N
g NN N
three CD N
times NNS N
daily RB N
, , N
and CC i
a DT i
placebo NN i
was VBD N
performed VBN N
in IN N
30 CD p
patients NNS p
with IN p
biopsy-proven JJ p
alcoholic JJ p
liver NN p
cirrhosis NN p
. . p

The DT N
disease NN N
was VBD N
in IN N
a DT N
stable JJ N
phase NN N
, , N
and CC N
none NN N
of IN N
the DT N
patients NNS N
showed VBD N
evidence NN N
of IN N
a DT N
decompensated VBN N
liver NN N
function NN N
. . N

Parameters NNS o
of IN o
liver NN o
function NN o
, , o
taste NN o
acuity NN o
, , o
dark JJ o
adaptation NN o
and CC o
of IN o
zinc NN o
and CC o
vitamin VB o
A DT o
metabolism NN o
were VBD N
followed VBN N
for IN N
six CD N
weeks NNS N
. . N

In IN N
the DT N
zinc-treated JJ N
group NN N
of IN N
16 CD N
patients NNS N
, , N
serum JJ o
zinc NN o
rose VBD N
from IN N
a DT N
normal JJ N
mean JJ N
value NN N
of IN N
13.3 CD N
to TO N
17.4 CD N
mumol/l NNS N
, , N
whereas IN N
the DT N
mean JJ o
serum NN o
vitamin VBZ o
A DT o
level NN o
remained VBD N
practically RB N
unaltered JJ N
within IN N
the DT N
normal JJ N
range NN N
, , N
1.89 CD N
at IN N
the DT N
entry NN N
and CC N
1.83 CD N
mumol/l NN N
at IN N
the DT N
end NN N
of IN N
the DT N
study NN N
. . N

Plasma NNP o
prothrombin NN o
and CC o
serum JJ o
alkaline JJ o
phosphatase NN o
levels NNS o
of IN N
the DT N
zinc NNP N
group NN N
increased VBD N
and CC N
serum JJ o
bilirubin NN o
and CC o
serum JJ o
carotene NN o
decreased VBN N
significantly RB N
. . N

The DT N
dark JJ o
adaptation NN o
did VBD N
not RB N
change NN N
, , N
but CC N
the DT N
taste NN o
function NN o
was VBD N
significantly RB N
improved VBN N
during IN N
zinc NN N
treatment NN N
. . N

The DT N
results NNS N
indicate VBP N
that IN N
zinc NN i
supplementation NN i
causes VBZ N
alleviation NN N
of IN N
certain JJ N
abnormalities NNS N
of IN N
cirrhotics NNS p
, , N
which WDT N
deserves VBZ N
further JJ N
attention NN N
. . N

-DOCSTART- -6344196- O O

The DT N
role NN N
of IN N
the DT N
MA-sensitive JJ N
leukocyte NN N
chemotaxis NN N
in IN N
rheumatoid JJ p
arthritis NN p
. . p

A DT N
randomized JJ N
double-blind JJ N
clinical JJ N
trial NN N
of IN N
griseofulvin NN i
treatment NN N
. . N

Polymorphonuclear JJ N
leukocyte NN N
( ( N
PMN NNP N
) ) N
chemotaxis NN N
is VBZ N
thought VBN N
to TO N
play VB N
an DT N
essential JJ N
role NN N
in IN N
the DT N
pathogenesis NN N
of IN N
rheumatoid JJ N
arthritis NN N
. . N

PMN NNP N
chemotaxis NN N
is VBZ N
in IN N
part NN N
sensitive NN N
to TO N
microtubule VB N
antagonists NNS N
( ( N
MAs NNP N
) ) N
, , N
e.g RB N
. . N

colchicine NN N
. . N

The DT N
antimycotic JJ N
antibiotic JJ N
griseofulvin NN i
inhibits VBZ N
the DT N
MA-sensitive JJ N
PMN NNP N
chemotaxis NN N
in IN N
vitro NN N
in IN N
concentrations NNS N
far RB N
below IN N
those DT N
obtained VBN N
in IN N
serum NN N
during IN N
antimycotic JJ i
therapy NN i
. . i

The DT N
role NN N
of IN N
the DT N
MA-sensitive JJ N
chemotaxis NN N
in IN N
rheumatoid JJ N
arthritis NN N
could MD N
thus RB N
be VB N
elucidated VBN N
by IN N
a DT N
clinical JJ N
trial NN N
of IN N
griseofulvin NN i
treatment NN N
. . N

Griseofulvin NNP i
( ( p
n JJ p
= NNP p
20 CD p
) ) p
was VBD N
tested VBN N
in IN N
a DT N
randomized JJ N
double-blind NN N
study NN N
versus IN N
placebo NN i
( ( p
m JJ p
= NNP p
19 CD p
) ) p
during IN N
one CD N
year NN N
in IN N
patients NNS p
with IN p
rheumatoid JJ p
arthritis NN p
of IN p
mild-moderate JJ p
activity NN p
. . p

No DT N
beneficial JJ o
effect NN o
of IN N
griseofulvin NN i
treatment NN N
was VBD N
noted VBN N
on IN o
clinical JJ o
symptoms NNS o
or CC o
laboratory JJ o
parameters NNS o
of IN N
rheumatoid JJ N
arthritis NN N
. . N

Moreover RB N
, , N
the DT N
placebo-treated JJ i
patients NNS N
showed VBD N
more RBR N
improvement NN o
than IN N
the DT N
griseofulvin-treated JJ i
patients NNS N
. . N

It PRP N
is VBZ N
therefore RB N
suggested VBN N
that IN N
the DT N
MA-sensitive JJ N
chemotaxis NN N
plays VBZ N
a DT N
reparative JJ N
role NN N
in IN N
the DT N
inflammatory JJ N
lesions NNS N
of IN N
rheumatoid JJ N
arthritis NN N
. . N

-DOCSTART- -22265360- O O

Effects NNS N
of IN N
risperidone NN i
and CC i
parent NN i
training NN i
on IN N
adaptive JJ N
functioning NN N
in IN N
children NNS p
with IN p
pervasive JJ p
developmental NN p
disorders NNS p
and CC p
serious JJ p
behavioral JJ p
problems NNS p
. . p

OBJECTIVE NNP N
Children NNP p
with IN p
Pervasive NNP p
Developmental NNP p
Disorders NNP p
( ( p
PDDs NNP p
) ) p
have VBP N
social JJ N
interaction NN N
deficits NNS N
, , N
delayed VBN N
communication NN N
, , N
and CC N
repetitive JJ N
behaviors NNS N
as RB N
well RB N
as IN N
impairments NNS N
in IN N
adaptive JJ N
functioning NN N
. . N

Many JJ N
children NNS N
actually RB N
show VBP N
a DT N
decline NN N
in IN N
adaptive JJ N
skills NNS N
compared VBN N
with IN N
age NN N
mates NNS N
over IN N
time NN N
. . N

METHOD VB N
This DT N
24-week JJ N
, , N
three-site JJ N
, , N
controlled VBD N
clinical JJ N
trial NN N
randomized VBD N
124 CD p
children NNS p
( ( p
4 CD p
through IN p
13 CD p
years NNS p
of IN p
age NN p
) ) p
with IN p
PDDs NNP p
and CC p
serious JJ p
behavioral JJ p
problems NNS p
to TO p
medication VB i
alone RB i
( ( p
MED NNP p
; : p
n CC p
= $ p
49 CD p
; : p
risperidone NN i
0.5 CD p
to TO p
3.5 CD p
mg/day NN p
; : p
if IN N
ineffective JJ N
, , N
switch VB N
to TO N
aripiprazole VB i
was VBD N
permitted VBN N
) ) N
or CC N
a DT N
combination NN i
of IN i
medication NN i
plus CC i
parent NN i
training NN i
( ( i
PT NNP i
) ) i
( ( N
COMB NNP N
; : N
n CC N
= VB N
75 CD N
) ) N
. . N

Parents NNS p
of IN p
children NNS p
in IN p
COMB NNP p
received VBD p
an DT p
average NN p
of IN p
11.4 CD p
PT NNP i
sessions NNS i
. . i

Standard NNP N
scores NNS N
and CC N
Age-Equivalent JJ N
scores NNS N
on IN N
Vineland NNP N
Adaptive NNP N
Behavior NNP N
Scales NNP N
were VBD N
the DT N
outcome NN N
measures NNS N
of IN N
primary JJ N
interest NN N
. . N

RESULTS NNP N
Seventeen JJ p
subjects NNS p
did VBD p
not RB p
have VB p
a DT p
post-randomization NN p
Vineland NNP p
assessment NN p
. . p

Thus RB N
, , N
we PRP N
used VBD N
a DT N
mixed JJ N
model NN N
with IN N
outcome NN N
conditioned VBN N
on IN N
the DT N
baseline NN N
Vineland NNP N
scores VBZ N
. . N

Both DT N
groups NNS N
showed VBD N
improvement NN N
over IN N
the DT N
24-week JJ N
trial NN N
on IN N
all DT N
Vineland NNP N
domains NNS N
. . N

Compared VBN N
with IN N
MED NNP N
, , N
Vineland NNP o
Socialization NNP o
and CC o
Adaptive NNP o
Composite NNP o
Standard NNP o
scores VBZ o
showed VBD N
greater JJR N
improvement NN N
in IN N
the DT N
COMB NNP N
group NN N
( ( N
p JJ N
= NNP N
.01 NNP N
and CC N
.05 NNP N
, , N
and CC N
effect NN N
sizes NNS N
= VBP N
0.35 CD N
and CC N
0.22 CD N
, , N
respectively RB N
) ) N
. . N

On IN N
Age NNP N
Equivalent NNP N
scores NNS N
, , N
Socialization NNP o
and CC o
Communication NNP o
domains NNS o
showed VBD N
greater JJR N
improvement NN N
in IN N
COMB NNP N
versus NN N
MED NNP N
( ( N
p JJ N
= NNP N
.03 NNP N
and CC N
0.05 CD N
, , N
and CC N
effect NN N
sizes NNS N
= VBP N
0.33 CD N
and CC N
0.14 CD N
, , N
respectively RB N
) ) N
. . N

Using VBG N
logistic JJ N
regression NN N
, , N
children NNS N
in IN N
the DT N
COMB NNP N
group NN N
were VBD N
twice RB N
as RB N
likely JJ N
to TO N
make VB N
at IN N
least JJS N
6 CD N
months NNS N
' POS N
gain NN N
( ( N
equal JJ N
to TO N
the DT N
passage NN N
of IN N
time NN N
) ) N
in IN N
the DT N
Vineland NNP o
Communication NNP o
Age NNP o
Equivalent NNP o
score NN o
compared VBN N
with IN N
MED NNP N
( ( N
p JJ N
= NNP N
.02 NNP N
) ) N
. . N

After IN N
controlling VBG N
for IN N
IQ NNP N
, , N
this DT N
difference NN N
was VBD N
no RB N
longer RBR N
significant JJ N
. . N

CONCLUSION NNP N
Reduction NNP N
of IN N
serious JJ N
maladaptive JJ N
behavior NN N
promotes NNS N
improvement NN N
in IN N
adaptive JJ N
behavior NN N
. . N

Medication NNP i
plus CC i
PT NNP i
shows VBZ N
modest JJ N
additional JJ N
benefit NN N
over IN N
medication NN i
alone RB i
. . i

Clinical JJ N
trial NN N
registration NN N
information-RUPP JJ N
PI NNP N
PDD NNP N
: : N
Drug NN N
and CC N
Behavioral NNP N
Therapy NNP N
for IN N
Children NNP p
With IN p
Pervasive NNP p
Developmental NNP p
Disorders NNP p
; : p
http NN N
: : N
//www.clinicaltrials.gov NN N
; : N
NCT00080145 NNP N
. . N

-DOCSTART- -18566204- O O

Best JJS N
evidence NN N
in IN N
critical JJ N
care NN N
medicine NN N
. . N

Steroids NNS i
to TO N
prevent VB N
post-extubation NN o
airway JJ o
obstruction NN o
in IN N
adult NN p
critically RB p
ill JJ p
patients NNS p
. . p

-DOCSTART- -3333530- O O

Predictors NNS N
of IN N
blood NN o
pressure NN o
change NN o
in IN N
a DT N
series NN N
of IN N
controlled JJ N
dietary JJ N
intervention NN N
studies NNS N
. . N

Three CD N
controlled VBD N
dietary JJ i
intervention NN i
studies NNS N
were VBD N
carried VBN N
out RP N
in IN N
1981-1983 JJ p
in IN p
North NNP p
Karelia NNP p
, , p
Finland NNP p
, , N
to TO N
asses VB N
the DT N
impact NN N
of IN N
dietary JJ N
fat JJ N
intake NN N
modification NN N
on IN N
blood NN o
pressure NN o
( ( o
BP NNP o
) ) o
. . o

All PDT N
these DT N
studies NNS N
involved VBD N
middle-aged JJ p
men NNS p
and CC p
women NNS p
in IN p
rural JJ p
or CC p
semirural JJ p
areas NNS p
and CC p
comprised VBD p
a DT p
baseline NN p
period NN p
, , p
a DT p
six CD p
week NN p
( ( p
or CC p
12 CD p
weeks NNS p
in IN p
the DT p
third JJ p
study NN p
) ) p
intervention NN p
period NN p
and CC p
a DT p
four CD p
to TO p
six CD p
week NN p
return NN p
to TO p
baseline VB p
. . p

During IN N
the DT N
intervention NN N
period NN N
the DT N
total JJ o
fat JJ o
intake NN o
was VBD N
reduced VBN N
from IN N
39 CD N
% NN N
to TO N
24 CD N
% NN N
of IN N
energy NN N
and CC N
the DT N
polyunsaturated/saturated VBN i
( ( i
P/S NNP i
) ) i
ratio NN i
increased VBD N
from IN N
0.2 CD N
to TO N
0.4-1.2 NN N
. . N

In IN N
all DT N
groups NNS N
energy NN N
intake NN N
was VBD N
kept VBN N
constant JJ N
. . N

For IN N
the DT N
present JJ N
report NN N
data NNS N
from IN N
the DT N
three CD N
studies NNS N
were VBD N
pooled VBN N
for IN N
a DT N
series NN N
of IN N
stepwise JJ N
regression NN N
analyses NNS N
to TO N
predict VB N
changes NNS N
in IN N
BP NNP o
with IN N
different JJ N
dietary JJ N
changes NNS N
. . N

For IN N
both DT N
systolic JJ o
( ( o
SBP NNP o
) ) o
and CC o
diastolic JJ o
( ( o
DBP NNP o
) ) o
blood NN o
pressure NN o
, , N
change NN N
in IN N
polyunsaturated JJ N
fatty JJ N
acid NNS N
intake NN N
was VBD N
the DT N
strongest JJS N
dietary JJ N
predictor NN N
of IN N
BP NNP o
change NN o
. . o

Changes NNS N
in IN N
body NN o
weight NN o
, , o
total JJ o
fat JJ o
intake NN o
, , o
urinary JJ o
sodium NN o
and CC o
potassium NN o
did VBD N
not RB N
have VB N
significant JJ N
predictive JJ N
power NN N
in IN N
any DT N
of IN N
the DT N
analyses NNS N
. . N

The DT N
findings NNS N
support VBP N
the DT N
hypothesis NN N
that IN N
modification NN N
of IN N
dietary JJ N
fat JJ N
intake NN N
is VBZ N
a DT N
significant JJ N
predictor NN N
of IN N
change NN N
in IN N
BP NNP o
. . o

-DOCSTART- -20875504- O O

Action NNP N
observation NN N
treatment NN N
improves VBZ N
recovery NN N
of IN N
postsurgical JJ p
orthopedic JJ p
patients NNS p
: : p
evidence NN N
for IN N
a DT N
top-down JJ N
effect NN N
? . N
OBJECTIVE UH N
To TO N
assess VB N
whether IN N
action NN i
observation NN i
treatment NN i
( ( i
AOT NNP i
) ) i
may MD N
also RB N
improve VB N
motor NN N
recovery NN N
in IN N
postsurgical JJ p
orthopedic JJ p
patients NNS p
, , N
in IN N
addition NN N
to TO N
conventional JJ N
physiotherapy NN N
. . N

DESIGN NNP N
Randomized NNP N
controlled VBD N
trial NN N
. . N

SETTING NNP N
Department NNP N
of IN N
rehabilitation NN N
. . N

PARTICIPANTS JJ N
Patients NNPS p
( ( p
N=60 NNP p
) ) p
admitted VBD p
to TO p
our PRP$ p
department NN p
postorthopedic NN p
surgery NN p
were VBD N
randomly RB N
assigned VBN N
to TO N
either VB N
a DT N
case NN N
( ( N
n=30 NN N
) ) N
or CC i
control NN i
( ( N
n=30 JJ N
) ) N
group NN i
. . i

Exclusion NN p
criteria NNS p
were VBD p
age NN p
18 CD p
years NNS p
or CC p
younger JJR p
and CC p
90 CD p
years NNS p
or CC p
older JJR p
, , p
Mini-Mental JJ p
State NNP p
Examination NNP p
score NN p
of IN p
21 CD p
of IN p
30 CD p
or CC p
lower JJR p
, , p
no DT p
ambulating VBG p
order NN p
, , p
advanced JJ p
vision NN p
impairment NN p
, , p
malignancy NN p
, , p
pneumonia NN p
, , p
or CC p
heart NN p
failure NN p
. . p

INTERVENTIONS NNP N
All NNP N
participants NNS N
underwent JJ N
conventional JJ p
physiotherapy NN p
. . p

In IN N
addition NN N
, , N
patients NNS N
in IN N
the DT N
case NN N
group NN N
were VBD N
asked VBN N
to TO N
observe VB i
video JJ i
clips NNS i
showing VBG i
daily JJ i
actions NNS i
and CC i
to TO i
imitate VB i
them PRP i
afterward RB i
. . i

Patients NNS N
in IN N
the DT N
control NN N
group NN N
were VBD N
asked VBN N
to TO N
observe VB i
video JJ i
clips NNS i
with IN i
no DT i
motor NN i
content NN i
and CC i
to TO i
execute VB i
the DT i
same JJ i
actions NNS i
as IN i
patients NNS i
in IN i
the DT i
case NN i
group NN i
afterward RB N
. . N

Participants NNS N
were VBD N
scored VBN N
on IN N
functional JJ N
scales NNS N
at IN N
baseline NN N
and CC N
after IN N
treatment NN N
by IN N
a DT N
physician NN N
blinded VBD N
to TO N
group NN N
assignment NN N
. . N

MAIN NNP N
OUTCOMES NNP N
MEASURES NNP N
Changes NNP o
in IN o
FIM NNP o
and CC o
Tinetti NNP o
scale NN o
scores NNS o
, , o
and CC o
dependence NN o
on IN o
walking VBG o
aids NNS o
. . o

RESULTS NNP N
At IN N
baseline NN N
, , N
groups NNS N
did VBD N
not RB N
differ VB N
in IN N
clinical JJ o
and CC o
functional JJ o
scale NN o
scores NNS o
. . o

After IN N
treatment NN N
, , N
patients NNS N
in IN N
the DT N
case NN N
group NN N
scored VBD N
better JJR N
than IN N
patients NNS N
in IN N
the DT N
control NN N
group NN N
( ( o
FIM NNP o
total NN o
score NN o
, , N
P=.02 NNP N
; : N
FIM NNP o
motor NN o
subscore NN o
, , N
P=.001 NNP N
; : N
Tinetti NNP o
scale NN o
score NN o
, , N
P=.04 NNP N
) ) N
; : N
patients NNS N
in IN N
the DT N
case NN N
group NN N
were VBD N
assigned VBN N
more RBR N
frequently RB o
to TO o
1 CD o
crutch NN o
( ( N
P=.01 NNP N
) ) N
. . N

CONCLUSIONS NNP N
In IN N
addition NN N
to TO N
conventional JJ N
physiotherapy NN N
, , N
AOT NNP N
is VBZ N
effective JJ N
in IN N
the DT N
rehabilitation NN N
of IN N
postsurgical JJ p
orthopedic JJ p
patients NNS p
. . p

The DT N
present JJ N
results NNS N
strongly RB N
support VB N
top-down JJ N
effects NNS N
of IN N
this DT N
treatment NN N
in IN N
motor NN N
recovery NN N
, , N
even RB N
in IN N
nonneurologic JJ p
patients NNS p
. . p

-DOCSTART- -25714521- O O

Long-term JJ o
functional JJ o
outcomes NNS o
and CC o
predictors NNS o
of IN o
shunt-dependent JJ o
hydrocephalus NN o
after IN p
treatment NN p
of IN p
ruptured JJ p
intracranial JJ p
aneurysms NN p
in IN N
the DT N
BRAT NNP N
trial NN N
: : N
revisiting VBG N
the DT N
clip NN N
vs NN N
coil NN N
debate NN N
. . N

BACKGROUND NNP N
Acute NNP p
hydrocephalus NN p
is VBZ N
a DT N
well-known JJ N
sequela NN N
of IN N
aneurysmal JJ N
subarachnoid JJ N
hemorrhage NN N
( ( N
SAH NNP N
) ) N
. . N

Controversy NNP N
exists VBZ N
about IN N
whether IN N
open JJ N
microsurgical JJ N
methods NNS N
serve VBP N
to TO N
reduce VB N
shunt NN o
dependency NN o
compared VBN N
with IN N
endovascular JJ N
techniques NNS N
. . N

OBJECTIVE NN N
To TO N
determine VB N
predictors NNS N
of IN N
shunt-dependent JJ o
hydrocephalus NN o
and CC o
functional JJ o
outcomes NNS o
after IN N
aneurysmal JJ N
SAH NNP N
. . N

METHODS NNP N
A NNP p
total NN p
of IN p
471 CD p
patients NNS p
who WP p
were VBD p
part NN p
of IN p
a DT p
prospective JJ p
, , p
randomized VBN p
, , p
controlled VBN p
trial NN p
from IN p
2003 CD p
to TO p
2007 CD p
were VBD p
retrospectively RB p
reviewed VBN p
. . p

All DT N
variables NNS N
including VBG N
demographic JJ o
data NNS o
, , o
medical JJ o
history NN o
, , o
treatment NN o
, , o
imaging NN o
, , o
and CC o
functional JJ o
outcomes NNS o
were VBD N
included VBN N
as IN N
part NN N
of IN N
the DT N
trial NN N
. . N

No DT N
additional JJ N
variables NNS N
were VBD N
retrospectively RB N
collected VBN N
. . N

RESULTS NNP N
Ultimately RB N
, , N
147 CD N
patients NNS N
( ( N
31.2 CD N
% NN N
) ) N
required VBD N
a DT N
ventriculoperitoneal JJ N
shunt NN N
( ( N
VPS NNP N
) ) N
in IN N
our PRP$ N
series NN N
. . N

Age NNP N
, , N
dissecting VBG N
aneurysm NN N
type NN N
, , N
ruptured VBD N
vertebrobasilar JJ N
aneurysm NN N
, , N
Fisher NNP N
grade NN N
, , N
Hunt NNP N
and CC N
Hess NNP N
grade NN N
, , N
admission NN N
intraventricular JJ N
hemorrhage NN N
, , N
admission NN N
intraparenchymal JJ N
hemorrhage NN N
, , N
blood NN N
in IN N
the DT N
fourth JJ N
ventricle NN N
on IN N
admission NN N
, , N
perioperative JJ N
ventriculostomy NN N
, , N
and CC N
hemicraniectomy NN N
were VBD N
significant JJ N
risk NN N
factors NNS N
( ( N
P NNP N
< NNP N
.05 NNP N
) ) N
associated VBN N
with IN N
shunt-dependent JJ o
hydrocephalus NN o
on IN N
univariate JJ N
analysis NN N
. . N

On IN N
multivariate NN N
analysis NN N
, , N
intraventricular JJ o
hemorrhage NN o
and CC o
intraparenchymal JJ o
hemorrhage NN o
were VBD N
independent JJ N
risk NN N
factors NNS N
for IN N
shunt NN o
dependency NN o
( ( N
P NNP N
< NNP N
.05 NNP N
) ) N
. . N

Clipping VBG i
vs JJ N
coiling VBG i
treatment NN N
was VBD N
not RB N
statistically RB N
associated VBN N
with IN N
VPS NNP N
after IN N
SAH NNP N
on IN N
both DT N
univariate JJ N
and CC N
multivariate JJ N
analyses NNS N
. . N

Patients NNS N
who WP N
did VBD N
not RB N
receive VB N
a DT N
VPS NNP N
at IN N
discharge NN N
had VBD N
higher JJR N
Glasgow NNP o
Outcome NNP o
Scale NNP o
and CC o
Barthel NNP o
Index NNP o
scores NNS o
and CC N
were VBD N
more RBR N
likely JJ N
to TO N
be VB N
functionally RB N
independent JJ N
and CC N
to TO N
return VB N
to TO N
work VB N
72 CD N
months NNS N
after IN N
surgery NN N
( ( N
P NNP N
< NNP N
.05 NNP N
) ) N
. . N

CONCLUSION NNP N
There EX N
is VBZ N
no DT N
difference NN N
in IN N
shunt NN o
dependency NN o
after IN N
SAH NNP N
among IN N
patients NNS p
treated VBN p
by IN p
endovascular JJ p
or CC p
microsurgical JJ p
means NNS p
. . p

Patients NNS N
in IN N
whom WP N
shunt-dependent JJ o
hydrocephalus NN o
does VBZ N
not RB N
develop VB N
after IN N
SAH NNP N
tend VBP N
to TO N
have VB N
improved VBN N
long-term JJ N
functional JJ N
outcomes NNS N
. . N

-DOCSTART- -15845130- O O

Outcome NN N
at IN N
7 CD N
years NNS N
of IN N
children NNS p
diagnosed VBN p
with IN p
autism NN p
at IN p
age NN p
2 CD p
: : p
predictive JJ N
validity NN N
of IN N
assessments NNS N
conducted VBN N
at IN N
2 CD p
and CC p
3 CD p
years NNS p
of IN p
age NN p
and CC N
pattern NN N
of IN N
symptom JJ N
change NN N
over IN N
time NN N
. . N

OBJECTIVE UH N
To TO N
examine VB N
the DT N
predictive JJ N
validity NN N
of IN N
symptom JJ o
severity NN o
, , o
cognitive JJ o
and CC o
language NN o
measures NNS o
taken VBN N
at IN N
ages NNS N
2 CD N
and CC N
3 CD N
years NNS N
to TO N
outcome VB N
at IN N
age NN N
7 CD N
in IN N
a DT N
sample NN p
of IN p
children NNS p
diagnosed VBN p
with IN p
autism NN p
at IN p
age NN p
2 CD p
. . p

METHOD NNP N
Twenty-six JJ p
children NNS p
diagnosed VBN p
with IN p
autism NN p
at IN p
age NN p
2 CD p
were VBD N
re-assessed VBN N
at IN N
ages NNS N
3 CD N
and CC N
7 CD N
years NNS N
. . N

At IN N
each DT N
age NN N
symptom JJ o
severity NN o
, , o
cognitive JJ o
and CC o
language NN o
assessments NNS o
were VBD N
completed VBN N
. . N

RESULTS VB N
The DT N
pattern NN N
of IN N
autistic JJ N
symptom NN N
severity NN N
varied VBN N
over IN N
time NN N
by IN N
domain NN N
. . N

Across IN N
time NN N
, , N
children NNS N
moved VBD N
across IN N
diagnostic JJ N
boundaries NNS N
both DT N
in IN N
terms NNS N
of IN N
clinical JJ N
diagnosis NN N
and CC N
in IN N
terms NNS N
of IN N
instrument NN N
diagnosis NN N
on IN N
the DT N
Autism NNP o
Diagnostic NNP o
Interview-Revised JJ o
( ( o
ADI-R NNP o
) ) o
. . N

On IN N
all DT N
measures NNS N
group NN N
variability NN N
in IN N
scores NNS N
increased VBN N
with IN N
age NN N
. . N

Although IN N
non-verbal JJ N
IQ NNP N
( ( N
NVIQ NNP N
) ) N
for IN N
the DT N
group NN N
as IN N
a DT N
whole NN N
was VBD N
stable JJ N
across IN N
the DT N
3 CD N
assessments NNS N
, , N
this DT N
masked VBD N
considerable JJ N
individual JJ N
instability NN N
. . N

Standard JJ N
assessments NNS N
at IN N
age NN N
2 CD N
did VBD N
not RB N
predict VB N
outcome NN N
at IN N
age NN N
7 CD N
even RB N
within IN N
the DT N
same JJ N
domain NN N
of IN N
functioning VBG N
. . N

In IN N
contrast NN N
, , N
standard JJ N
assessments NNS N
at IN N
age NN N
3 CD N
did VBD N
predict JJ N
outcome NN N
. . N

However RB N
, , N
a DT N
measure NN N
of IN N
rate NN o
of IN o
non-verbal JJ o
communicative JJ o
acts NNS o
taken VBN N
from IN N
an DT N
interactive JJ N
play-based JJ N
assessment NN N
at IN N
age NN N
2 CD N
was VBD N
significantly RB N
associated VBN N
with IN N
language NN o
, , o
communication NN o
and CC o
social JJ o
outcomes NNS o
at IN N
age NN N
7 CD N
. . N

CONCLUSIONS VB N
The DT N
trajectory NN N
of IN N
autism NN N
symptoms NNS N
over IN N
time NN N
differed VBN N
in IN N
different JJ N
domains NNS N
, , N
suggesting VBG N
that IN N
they PRP N
may MD N
be VB N
, , N
at IN N
least JJS N
in IN N
part NN N
, , N
separable JJ N
. . N

Variability NN N
in IN N
language NN o
, , o
NVIQ NNP o
and CC o
symptom JJ o
severity NN o
increased VBD N
over IN N
time NN N
. . N

Caution NN N
is VBZ N
required VBN N
when WRB N
interpreting VBG N
the DT N
findings NNS N
from IN N
assessments NNS N
of IN N
children NNS p
with IN p
autism NN p
at IN p
age NN p
2 CD p
years NNS p
. . p

At IN N
this DT N
age NN N
measures VBZ N
of IN N
rate NN N
of IN N
non-verbal JJ N
communication NN N
might MD N
be VB N
more RBR N
informative JJ N
than IN N
scores NNS N
on IN N
standard JJ N
psychometric NN N
tests NNS N
. . N

Predictive JJ N
validity NN N
of IN N
assessments NNS N
at IN N
age NN N
3 CD N
years NNS N
was VBD N
greater JJR N
. . N

-DOCSTART- -19284641- O O

Hyperbaric NNP N
treatment NN N
for IN N
children NNS p
with IN p
autism NN p
: : p
a DT N
multicenter NN N
, , N
randomized VBN N
, , N
double-blind NN N
, , N
controlled VBN N
trial NN N
. . N

BACKGROUND NNP N
Several NNP N
uncontrolled JJ N
studies NNS N
of IN N
hyperbaric JJ N
treatment NN N
in IN N
children NNS N
with IN N
autism NN N
have VBP N
reported VBN N
clinical JJ N
improvements NNS N
; : N
however RB N
, , N
this DT N
treatment NN N
has VBZ N
not RB N
been VBN N
evaluated VBN N
to TO N
date NN N
with IN N
a DT N
controlled VBN N
study NN N
. . N

We PRP N
performed VBD N
a DT N
multicenter NN N
, , N
randomized VBN N
, , N
double-blind NN N
, , N
controlled VBN N
trial NN N
to TO N
assess VB N
the DT N
efficacy NN o
of IN N
hyperbaric JJ N
treatment NN N
in IN N
children NNS N
with IN N
autism NN N
. . N

METHODS NNP N
62 CD p
children NNS p
with IN p
autism NN p
recruited VBN p
from IN p
6 CD p
centers NNS p
, , p
ages VBZ p
2-7 CD p
years NNS p
( ( p
mean JJ p
4.92 CD p
+/- JJ p
1.21 CD p
) ) p
, , N
were VBD N
randomly RB i
assigned VBN i
to TO i
40 CD i
hourly JJ i
treatments NNS i
of IN i
either DT i
hyperbaric JJ i
treatment NN i
at IN i
1.3 CD i
atmosphere NN i
( ( i
atm NN i
) ) i
and CC i
24 CD i
% NN i
oxygen NN i
( ( i
treatment NN i
group NN i
, , i
n RB i
= VBZ i
33 CD i
) ) i
or CC i
slightly RB i
pressurized JJ i
room NN i
air NN i
at IN i
1.03 CD i
atm NN i
and CC i
21 CD i
% NN i
oxygen NN i
( ( i
control NN i
group NN i
, , i
n RB i
= VBZ i
29 CD i
) ) i
. . i

Outcome NNP N
measures NNS N
included VBD N
Clinical NNP o
Global NNP o
Impression NNP o
( ( o
CGI NNP o
) ) o
scale NN o
, , o
Aberrant NNP o
Behavior NNP o
Checklist NNP o
( ( o
ABC NNP o
) ) o
, , o
and CC o
Autism NNP o
Treatment NNP o
Evaluation NNP o
Checklist NNP o
( ( o
ATEC NNP o
) ) o
. . o

RESULTS NNP N
After IN N
40 CD N
sessions NNS N
, , N
mean JJ N
physician JJ N
CGI NNP o
scores VBZ N
significantly RB N
improved VBN N
in IN N
the DT N
treatment NN N
group NN N
compared VBN N
to TO N
controls NNS N
in IN N
overall JJ o
functioning NN o
( ( N
p JJ N
= NNP N
0.0008 CD N
) ) N
, , N
receptive JJ o
language NN o
( ( N
p JJ N
< NNP N
0.0001 CD N
) ) N
, , N
social JJ o
interaction NN o
( ( N
p JJ N
= NNP N
0.0473 CD N
) ) N
, , N
and CC N
eye NN o
contact NN o
( ( N
p JJ N
= NNP N
0.0102 CD N
) ) N
; : N
9/30 CD N
children NNS N
( ( N
30 CD N
% NN N
) ) N
in IN N
the DT N
treatment NN N
group NN N
were VBD N
rated VBN N
as IN N
very RB N
much JJ N
improved VBN N
or CC N
much RB N
improved VBN N
compared VBN N
to TO N
2/26 CD N
( ( N
8 CD N
% NN N
) ) N
of IN N
controls NNS N
( ( N
p VB N
= RB N
0.0471 CD N
) ) N
; : N
24/30 CD N
( ( N
80 CD N
% NN N
) ) N
in IN N
the DT N
treatment NN N
group NN N
improved VBD N
compared VBN N
to TO N
10/26 CD N
( ( N
38 CD N
% NN N
) ) N
of IN N
controls NNS N
( ( N
p VB N
= RB N
0.0024 CD N
) ) N
. . N

Mean JJ N
parental JJ o
CGI NNP o
scores VBZ o
significantly RB N
improved VBN N
in IN N
the DT N
treatment NN N
group NN N
compared VBN N
to TO N
controls NNS N
in IN N
overall JJ o
functioning NN o
( ( N
p JJ N
= NNP N
0.0336 CD N
) ) N
, , N
receptive JJ o
language NN o
( ( N
p JJ N
= NNP N
0.0168 CD N
) ) N
, , N
and CC N
eye NN o
contact NN o
( ( N
p JJ N
= NNP N
0.0322 CD N
) ) N
. . N

On IN N
the DT N
ABC NNP o
, , N
significant JJ N
improvements NNS N
were VBD N
observed VBN N
in IN N
the DT N
treatment NN N
group NN N
in IN N
total JJ o
score NN o
, , o
irritability NN o
, , o
stereotypy NN o
, , o
hyperactivity NN o
, , o
and CC o
speech NN o
( ( N
p JJ N
< VBP N
0.03 CD N
for IN N
each DT N
) ) N
, , N
but CC N
not RB N
in IN N
the DT N
control NN N
group NN N
. . N

In IN N
the DT N
treatment NN N
group NN N
compared VBN N
to TO N
the DT N
control NN N
group NN N
, , N
mean JJ N
changes NNS N
on IN N
the DT N
ABC NNP o
total JJ o
score NN o
and CC o
subscales NNS o
were VBD N
similar JJ N
except IN N
a DT N
greater JJR N
number NN N
of IN N
children NNS N
improved VBN N
in IN N
irritability NN N
( ( N
p JJ N
= NNP N
0.0311 CD N
) ) N
. . N

On IN N
the DT N
ATEC NNP o
, , o
sensory/cognitive JJ o
awareness NN o
significantly RB N
improved VBN N
( ( N
p JJ N
= NNP N
0.0367 CD N
) ) N
in IN N
the DT N
treatment NN N
group NN N
compared VBN N
to TO N
the DT N
control NN N
group NN N
. . N

Post-hoc JJ N
analysis NN N
indicated VBD N
that IN N
children NNS N
over IN N
age NN N
5 CD N
and CC N
children NNS N
with IN N
lower JJR N
initial JJ N
autism NN N
severity NN N
had VBD N
the DT N
most RBS N
robust JJ N
improvements NNS N
. . N

Hyperbaric NNP N
treatment NN N
was VBD N
safe JJ N
and CC N
well-tolerated JJ N
. . N

CONCLUSION NNP N
Children NNP p
with IN p
autism NN p
who WP N
received VBD N
hyperbaric JJ N
treatment NN N
at IN N
1.3 CD N
atm NN N
and CC N
24 CD N
% NN N
oxygen NN N
for IN N
40 CD N
hourly JJ N
sessions NNS N
had VBD N
significant JJ N
improvements NNS N
in IN N
overall JJ o
functioning NN o
, , o
receptive JJ o
language NN o
, , o
social JJ o
interaction NN o
, , o
eye NN o
contact NN o
, , o
and CC o
sensory/cognitive JJ o
awareness NN o
compared VBN N
to TO N
children NNS N
who WP N
received VBD N
slightly RB N
pressurized VBN N
room NN N
air NN N
. . N

TRIAL NNP N
REGISTRATION NNP N
clinicaltrials.gov NN N
NCT00335790 NNP N
. . N

-DOCSTART- -9926538- O O

Network NNP N
support NN N
for IN N
drinking NN N
, , N
Alcoholics NNP N
Anonymous NNP N
and CC N
long-term JJ N
matching NN N
effects NNS N
. . N

AIMS NNP N
( ( N
1 CD N
) ) N
To TO N
examine VB N
the DT N
matching JJ N
hypothesis NN N
that WDT N
Twelve NNP i
Step NNP i
Facilitation NNP i
Therapy NNP i
( ( i
TSF NNP i
) ) i
is VBZ N
more RBR N
effective JJ N
than IN N
Motivational NNP i
Enhancement NNP i
Therapy NNP i
( ( i
MET NNP i
) ) i
for IN N
alcohol-dependent JJ p
clients NNS p
with IN N
networks NNS N
highly RB N
supportive JJ N
of IN N
drinking VBG N
3 CD N
years NNS N
following VBG N
treatment NN N
; : N
( ( N
2 CD N
) ) N
to TO N
test VB N
a DT N
causal NN N
chain NN N
providing VBG N
the DT N
rationale NN N
for IN N
this DT N
effect NN N
. . N

DESIGN NN N
Outpatients NNPS p
were VBD N
re-interviewed JJ N
3 CD N
years NNS N
following VBG N
treatment NN N
. . N

ANCOVAs NNP N
tested VBD N
the DT N
matching JJ N
hypothesis NN N
. . N

SETTING NN N
Outpatients NNS p
from IN p
five CD p
clinical JJ p
research NN p
units NNS p
distributed VBN p
across IN p
the DT p
United NNP p
States NNPS p
. . p

PARTICIPANTS NNP N
Eight NNP p
hundred VBD p
and CC p
six CD p
alcohol-dependent JJ p
clients NNS p
. . p

INTERVENTION JJ N
Clients NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
three CD N
12-week JJ N
, , N
manually-guided JJ i
, , i
individual JJ i
treatments NNS i
: : i
TSF NNP i
, , i
MET NNP i
or CC i
Cognitive NNP i
Behavioral NNP i
Coping NNP i
Skills NNP i
Therapy NNP i
( ( i
CBT NNP i
) ) i
. . i

MEASUREMENTS NNP N
Network NNP o
support NN o
for IN o
drinking VBG o
prior JJ o
to TO o
treatment NN o
, , o
Alcoholics NNP o
Anonymous NNP o
( ( o
AA NNP o
) ) o
involvement NN o
during IN o
and CC o
following VBG o
treatment NN o
, , o
percentage NN o
of IN o
days NNS o
abstinent JJ o
and CC o
drinks NNS o
per IN o
drinking NN o
day NN o
during IN o
months NNS o
37-39 JJ o
. . o

FINDINGS NNP N
( ( N
1 CD N
) ) N
The DT N
a DT N
priori JJ N
matching NN N
hypothesis NN N
that IN N
TSF NNP N
is VBZ N
more RBR N
effective JJ N
than IN N
MET NNP N
for IN N
clients NNS N
with IN N
networks NNS N
supportive NN N
of IN N
drinking NN N
was VBD N
supported VBN N
at IN N
the DT N
3 CD N
year NN N
follow-up NN N
; : N
( ( N
2 CD N
) ) N
AA NNP N
involvement NN N
was VBD N
a DT N
partial JJ N
mediator NN N
of IN N
this DT N
effect NN N
; : N
clients NNS N
with IN N
networks NNS N
supportive NN N
of IN N
drinking NN N
assigned VBN N
to TO N
TSF VB N
were VBD N
more RBR N
likely JJ N
to TO N
be VB N
involved VBN o
in IN o
AA NNP o
; : o
AA NNP o
involvement NN o
was VBD N
associated VBN N
with IN N
better JJR N
3-year JJ o
drinking NN o
outcomes NNS o
for IN N
such JJ N
clients NNS N
. . N

CONCLUSIONS NNP N
( ( N
1 CD N
) ) N
In IN N
the DT N
long-term JJ N
TSF NNP N
may MD N
be VB N
the DT N
treatment NN N
of IN N
choice NN N
for IN N
alcohol-dependent JJ N
clients NNS N
with IN N
networks NNS N
supportive NN N
of IN N
drinking NN N
; : N
( ( N
2 CD N
) ) N
involvement NN N
in IN N
AA NNP N
should MD N
be VB N
given VBN N
special JJ N
consideration NN N
for IN N
clients NNS N
with IN N
networks NNS N
supportive NN N
of IN N
drinking NN N
, , N
irrespective NN N
of IN N
the DT N
therapy NN N
they PRP N
will MD N
receive VB N
. . N

-DOCSTART- -6653648- O O

Diazoxide NNP i
and CC i
labetalol NN i
in IN N
acute JJ p
hypertension NN o
during IN N
haemodialysis NN N
. . N

The DT N
antihypertensive JJ N
effect NN N
of IN N
the DT N
peripheral JJ i
vasodilator NN i
diazoxide NN i
in IN N
13 CD p
patients NNS p
and CC p
the DT p
alpha-beta JJ i
adrenoceptor NN i
blocking VBG i
agent JJ i
labetalol NN i
in IN p
12 CD p
patients NNS p
were VBD p
compared VBN p
in IN p
46 CD p
severe JJ p
acute NN p
hypertensive JJ o
episodes NNS p
during IN p
haemodialysis NN p
. . p

A DT N
single JJ N
dose NN N
of IN N
diazoxide JJ i
150 CD i
mg NN i
or CC i
labetalol $ i
50 CD i
mg NN i
was VBD N
effective JJ N
in IN N
74 CD N
% NN N
and CC N
70 CD N
% NN N
of IN N
the DT N
hypertensive JJ o
episodes NNS N
, , N
respectively RB N
. . N

In IN N
the DT N
diazoxide-treated JJ i
patients NNS p
blood NN o
pressure NN o
fell VBD N
from IN N
192 CD N
+/- JJ N
3/115 CD N
+/- JJ N
4 CD N
mmHg NN N
to TO N
141 CD N
+/- JJ N
8/85 CD N
+/- JJ N
4 CD N
mmHg NN N
2 CD N
h NN N
after IN N
injection NN N
. . N

In IN N
7 CD N
hypertensive JJ o
episodes NNS N
a DT N
second JJ N
dose NN N
of IN N
diazoxide JJ i
150 CD N
mg NN N
was VBD N
given VBN N
60 CD N
+/- JJ N
11 CD N
min NN N
after IN N
the DT N
first JJ N
injection NN N
. . N

The DT N
reduction NN N
in IN N
mean JJ o
arterial JJ o
blood NN o
pressure NN o
at IN N
the DT N
end NN N
of IN N
haemodialysis NN N
was VBD N
21.5 CD N
+/- JJ N
2.6 CD N
% NN N
in IN N
patients NNS N
treated VBN N
with IN N
a DT N
single JJ N
dose NN N
and CC N
24.8 CD N
+/- JJ N
3.5 CD N
% NN N
in IN N
patients NNS N
treated VBN N
with IN N
the DT N
repeated VBN N
dose NN N
of IN N
diazoxide NN i
. . i

In IN N
the DT N
labetalol-treated JJ i
patients NNS p
blood NN o
pressure NN o
in IN N
17 CD N
instances NNS N
fell VBD N
from IN N
198 CD N
+/- JJ N
5/104 CD N
+/- JJ N
4 CD N
mmHg NN N
to TO N
143 CD N
+/- JJ N
7/89 CD N
+/- JJ N
5 CD N
mmHg NN N
180 CD N
min NN N
following VBG N
injection NN N
of IN N
labetalol $ i
50 CD N
mg NN N
. . N

In IN N
6 CD N
episodes NNS N
a DT N
second JJ N
dose NN N
labetalol VBD i
50 CD N
mg NN N
was VBD N
given VBN N
41 CD N
+/- JJ N
9 CD N
min NN N
after IN N
the DT N
first JJ N
injection NN N
. . N

At IN N
the DT N
end NN N
of IN N
haemodialysis NN N
the DT N
decrease NN N
in IN N
mean JJ o
arterial JJ o
blood NN o
pressure NN o
was VBD N
17.2 CD N
% NN N
in IN N
patients NNS N
treated VBN N
with IN N
a DT N
single JJ N
dose NN N
and CC N
18 CD N
+/- JJ N
5 CD N
% NN N
in IN N
patients NNS N
given VBN N
the DT N
repeated VBN N
dose NN N
of IN N
labetalol NN i
. . i

The DT N
reduction NN N
in IN N
blood NN o
pressure NN o
caused VBN N
by IN N
diazoxide NN i
was VBD N
slightly RB N
greater JJR N
than IN N
that DT N
due JJ N
to TO N
labetalol VB N
. . N

At IN N
the DT N
end NN N
of IN N
haemodialysis NN N
the DT N
percentage NN N
reduction NN N
in IN N
mean JJ N
arterial JJ N
blood NN N
pressure NN N
was VBD N
23 CD N
+/- JJ N
2 CD N
% NN N
in IN N
the DT N
diazoxide-treated JJ N
group NN N
and CC N
17 CD N
+/- JJ N
2 CD N
% NN N
after IN N
labetalol NN N
. . N

( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
250 CD N
WORDS NNP N
) ) N
-DOCSTART- -17942872- O O

Human NNP i
papillomavirus NN i
and CC N
Papanicolaou NNP i
tests NNS i
to TO N
screen VB N
for IN N
cervical JJ N
cancer NN N
. . N

BACKGROUND NNP N
Screening NNP N
for IN N
cervical JJ N
cancer NN N
based VBN N
on IN N
testing VBG N
for IN N
human JJ N
papillomavirus NN N
( ( N
HPV NNP N
) ) N
increases VBZ N
the DT N
sensitivity NN N
of IN N
detection NN N
of IN N
high-grade NN N
( ( N
grade JJ N
2 CD N
or CC N
3 CD N
) ) N
cervical JJ N
intraepithelial JJ N
neoplasia NN N
, , N
but CC N
whether IN N
this DT N
gain NN N
represents VBZ N
overdiagnosis NN N
or CC N
protection NN N
against IN N
future JJ N
high-grade JJ N
cervical JJ N
epithelial JJ N
neoplasia NN N
or CC N
cervical JJ N
cancer NN N
is VBZ N
unknown JJ N
. . N

METHODS NNP N
In IN p
a DT p
population-based JJ p
screening NN p
program NN p
in IN p
Sweden NNP p
, , p
12,527 CD p
women NNS p
32 CD p
to TO p
38 CD p
years NNS p
of IN p
age NN p
were VBD p
randomly RB p
assigned VBN p
at IN N
a DT N
1:1 CD N
ratio NN N
to TO N
have VB N
an DT N
HPV NNP i
test NN i
plus CC i
a DT i
Papanicolaou NNP i
( ( i
Pap NNP i
) ) i
test NN i
( ( i
intervention NN i
group NN i
) ) i
or CC N
a DT i
Pap JJ i
test NN i
alone RB i
( ( i
control VB i
group NN i
) ) i
. . i

Women NNS N
with IN N
a DT N
positive JJ N
HPV NNP i
test NN i
and CC N
a DT N
normal JJ N
Pap NNP i
test NN i
result NN N
were VBD N
offered VBN N
a DT N
second JJ N
HPV NNP i
test NN i
at IN N
least JJS N
1 CD N
year NN N
later RB N
, , N
and CC N
those DT N
who WP N
were VBD N
found VBN N
to TO N
be VB N
persistently RB N
infected VBN N
with IN N
the DT N
same JJ N
high-risk JJ N
type NN N
of IN N
HPV NNP N
were VBD N
then RB N
offered VBN N
colposcopy NN N
with IN N
cervical JJ N
biopsy NN N
. . N

A DT N
similar JJ N
number NN N
of IN N
double-blinded JJ o
Pap NNP o
smears NNS o
and CC o
colposcopies NNS o
with IN o
biopsy NN o
were VBD N
performed VBN N
in IN N
randomly RB N
selected VBN N
women NNS N
in IN N
the DT N
control NN N
group NN N
. . N

Comprehensive JJ N
registry NN N
data NNS N
were VBD N
used VBN N
to TO N
follow VB N
the DT N
women NNS N
for IN N
a DT N
mean NN N
of IN N
4.1 CD N
years NNS N
. . N

The DT N
relative JJ N
rates NNS o
of IN o
grade JJ o
2 CD o
or CC o
3 CD o
cervical JJ o
intraepithelial JJ o
neoplasia NN o
or CC o
cancer NN o
detected VBN o
at IN N
enrollment NN N
and CC N
at IN N
subsequent JJ N
screening VBG N
examinations NNS N
were VBD N
calculated VBN N
. . N

RESULTS NNP N
At IN N
enrollment NN N
, , N
the DT N
proportion NN N
of IN N
women NNS N
in IN N
the DT N
intervention NN i
group NN N
who WP N
were VBD N
found VBN N
to TO N
have VB N
lesions NNS o
of IN o
grade NN o
2 CD o
or CC o
3 CD o
cervical JJ o
intraepithelial JJ o
neoplasia NN o
or CC o
cancer NN o
was VBD N
51 CD N
% NN N
greater JJR N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NNP N
, , N
13 CD N
to TO N
102 CD N
) ) N
than IN N
the DT N
proportion NN N
of IN N
women NNS N
in IN N
the DT N
control NN i
group NN N
who WP N
were VBD N
found VBN N
to TO N
have VB N
such JJ N
lesions NNS N
. . N

At IN N
subsequent JJ N
screening VBG N
examinations NNS N
, , N
the DT N
proportion NN N
of IN N
women NNS N
in IN N
the DT N
intervention NN i
group NN N
who WP N
were VBD N
found VBN N
to TO N
have VB N
grade VBN N
2 CD o
or CC o
3 CD o
lesions NNS o
or CC o
cancer NN o
was VBD N
42 CD N
% NN N
less JJR N
( ( N
95 CD N
% NN N
CI NNP N
, , N
4 CD N
to TO N
64 CD N
) ) N
and CC N
the DT N
proportion NN N
with IN N
grade JJ N
3 CD N
lesions NNS N
or CC N
cancer NN N
was VBD N
47 CD N
% NN N
less JJR N
( ( N
95 CD N
% NN N
CI NNP N
, , N
2 CD N
to TO N
71 CD N
) ) N
than IN N
the DT N
proportions NNS N
of IN N
control NN i
women NNS N
who WP N
were VBD N
found VBN N
to TO N
have VB N
such JJ N
lesions NNS N
. . N

Women NNS N
with IN N
persistent JJ N
HPV NNP N
infection NN N
remained VBD N
at IN N
high JJ N
risk NN N
for IN N
grade JJ N
2 CD N
or CC N
3 CD N
lesions NNS N
or CC N
cancer NN N
after IN N
referral JJ N
for IN N
colposcopy NN N
. . N

CONCLUSIONS VB N
The DT N
addition NN N
of IN N
an DT N
HPV NNP i
test NN i
to TO N
the DT N
Pap NNP i
test NN i
to TO N
screen JJ N
women NNS p
in IN p
their PRP$ p
mid-30s NN p
for IN N
cervical JJ N
cancer NN N
reduces VBZ N
the DT N
incidence NN N
of IN N
grade NN N
2 CD N
or CC N
3 CD N
cervical JJ N
intraepithelial JJ N
neoplasia NN N
or CC N
cancer NN N
detected VBN N
by IN N
subsequent JJ N
screening NN N
examinations NNS N
. . N

( ( N
ClinicalTrials.gov NNP N
number NN N
, , N
NCT00479375 NNP N
[ NNP N
ClinicalTrials.gov NNP N
] NNP N
. . N

) ) N
. . N

-DOCSTART- -21543343- O O

A DT N
randomized JJ N
placebo-controlled JJ i
prevention NN N
trial NN N
of IN N
aspirin NN i
and/or NN i
resistant JJ i
starch NN i
in IN N
young JJ p
people NNS p
with IN p
familial JJ o
adenomatous JJ o
polyposis NN o
. . o

Evidence NN N
supporting VBG N
aspirin NNS i
and CC i
resistant JJ i
starch NN i
( ( i
RS NNP i
) ) i
for IN N
colorectal JJ p
cancer NN p
prevention NN N
comes VBZ N
from IN N
epidemiologic JJ N
and CC N
laboratory JJ N
studies NNS N
( ( i
aspirin NN i
and CC i
RS NNP i
) ) i
and CC N
randomized VBN N
controlled JJ N
clinical JJ N
trials NNS N
( ( i
aspirin NN i
) ) i
. . N

Familial NNP p
adenomatous JJ p
polyposis NN p
( ( p
FAP NNP p
) ) p
strikes VBZ N
young JJ N
people NNS N
and CC N
, , N
untreated JJ N
, , N
confers NNS N
virtually RB N
a DT N
100 CD N
% NN N
risk NN N
of IN N
colorectal JJ N
cancer NN N
and CC N
early JJ N
death NN N
. . N

We PRP N
conducted VBD N
an DT N
international JJ N
, , N
multicenter NN N
, , N
randomized VBN N
, , N
placebo-controlled JJ i
trial NN N
of IN N
aspirin NN i
( ( N
600 CD N
mg/d NN N
) ) N
and/or NN N
RS NNP i
( ( N
30 CD N
g/d NN N
) ) N
for IN N
from IN N
1 CD N
to TO N
12 CD N
years NNS N
to TO N
prevent VB N
disease NN N
progression NN N
in IN N
FAP NNP p
patients NNS p
from IN p
10 CD p
to TO p
21 CD p
years NNS p
of IN p
age NN p
. . p

In IN N
a DT N
2 CD N
? . N
2 CD N
factorial JJ N
design NN N
, , N
patients NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
the DT N
following VBG N
four CD N
study NN N
arms NNS i
: : i
aspirin NN i
plus CC i
RS NNP i
placebo NN i
; : i
RS NNP i
plus CC i
aspirin JJ i
placebo NN i
; : i
aspirin CC i
plus CC i
RS NNP i
; : i
RS NNP i
placebo NN i
plus CC i
aspirin JJ i
placebo NN i
; : i
they PRP N
were VBD N
followed VBN N
with IN N
standard JJ N
annual JJ N
clinical JJ N
examinations NNS N
including VBG N
endoscopy NN N
. . N

The DT o
primary JJ o
endpoint NN o
was VBD o
polyp JJ o
number NN o
in IN o
the DT o
rectum NN o
and CC o
sigmoid JJ o
colon NN o
( ( o
at IN o
the DT o
end NN o
of IN o
intervention NN o
) ) o
, , o
and CC o
the DT o
major JJ o
secondary JJ o
endpoint NN o
was VBD o
size NN o
of IN o
the DT o
largest JJS o
polyp NN o
. . o

A DT N
total NN p
of IN p
206 CD p
randomized JJ p
FAP NNP p
patients NNS p
commenced VBD p
intervention NN p
, , p
of IN p
whom WP p
133 CD p
had VBD p
at IN p
least JJS p
one CD p
follow-up JJ p
endoscopy NN p
and CC p
were VBD p
therefore RB p
included VBN p
in IN p
the DT p
primary JJ p
analysis NN p
. . p

Neither CC N
intervention NN N
significantly RB N
reduced VBN o
polyp NN o
count NN o
in IN o
the DT o
rectum NN o
and CC o
sigmoid JJ o
colon NN o
: : o
aspirin JJ N
relative JJ N
risk NN N
= VBP N
0.77 CD N
( ( N
95 CD N
% NN N
CI NNP N
, , N
0.54-1.10 NNP N
; : N
versus NN N
nonaspirin IN N
arms NNS N
) ) N
; : N
RS NNP N
relative VBP N
risk NN N
= VBP N
1.05 CD N
( ( N
95 CD N
% NN N
CI NNP N
, , N
0.73-1.49 NNP N
; : N
versus CD N
non-RS JJ N
arms NNS N
) ) N
. . N

There EX N
was VBD N
a DT N
trend NN N
toward IN N
a DT N
smaller JJR N
size NN N
of IN N
largest JJS N
polyp NN N
in IN N
patients NNS N
treated VBN N
with IN N
aspirin JJ N
versus NN N
nonaspirin NN N
-- : N
mean JJ N
3.8 CD N
mm NN N
versus NN N
5.5 CD N
mm NN N
for IN N
patients NNS N
treated JJ N
1 CD N
or CC N
more JJR N
years NNS N
( ( N
adjusted VBN N
P NNP N
= NNP N
0.09 CD N
) ) N
and CC N
mean $ N
3.0 CD N
mm NN N
versus NN N
6.0 CD N
mm NN N
for IN N
patients NNS N
treated VBD N
more JJR N
than IN N
1 CD N
year NN N
( ( N
P NNP N
= NNP N
0.02 CD N
) ) N
; : N
there EX N
were VBD N
similar JJ N
weaker JJR N
trends NNS N
with IN N
RS NNP N
versus IN N
non-RS JJ N
. . N

Exploratory NNP N
translational JJ N
endpoints NNS N
included VBD N
crypt JJ N
length NN N
( ( N
which WDT N
was VBD N
significantly RB N
shorter JJR N
in IN N
normal-appearing JJ N
mucosa NN N
in IN N
the DT N
RS NNP N
group NN N
over IN N
time NN N
) ) N
and CC N
laboratory JJ N
measures NNS N
of IN N
proliferation NN N
( ( N
including VBG N
Ki67 NNP N
) ) N
. . N

This DT N
clinical JJ N
trial NN N
is VBZ N
the DT N
largest JJS N
ever RB N
conducted VBN N
in IN N
the DT N
setting NN N
of IN N
FAP NNP N
and CC N
found VBD N
a DT N
trend NN N
of IN N
reduced JJ o
polyp NN o
load NN o
( ( N
number NN N
and CC N
size NN N
) ) N
with IN N
600 CD N
mg NNS N
of IN i
aspirin JJ i
daily JJ N
. . N

RS NNP N
had VBD N
no DT N
clinical JJ N
effect NN N
on IN o
adenomas NN o
. . o

-DOCSTART- -23857884- O O

CT NNP o
and CC o
MRI NNP o
measurements NNS o
of IN o
tibial JJ o
tubercle-trochlear JJ o
groove NN o
distances NNS o
are VBP N
not RB N
equivalent JJ N
in IN N
patients NNS p
with IN p
patellar JJ p
instability NN p
. . p

BACKGROUND NNP N
Tibial NNP o
tubercle-trochlear JJ o
groove NN o
distance NN o
( ( o
TT-TG NNP o
) ) o
is VBZ N
a DT N
commonly RB N
used VBN N
measurement NN N
for IN N
surgical JJ N
decision NN N
making NN N
in IN N
patients NNS p
with IN p
patellofemoral JJ p
malalignment NN p
and CC p
instability NN p
. . p

This DT N
measurement NN N
has VBZ N
historically RB N
been VBN N
performed VBN N
utilizing JJ N
axial JJ N
computed VBN N
tomography NN N
( ( N
CT NNP N
) ) N
. . N

More RBR N
recently RB N
, , N
magnetic JJ N
resonance NN N
imaging NN N
( ( N
MRI NNP N
) ) N
has VBZ N
been VBN N
proposed VBN N
as IN N
an DT N
equivalent JJ N
method NN N
, , N
but CC N
this DT N
has VBZ N
not RB N
yet RB N
been VBN N
fully RB N
validated VBN N
. . N

PURPOSE NNP N
To TO N
determine VB N
the DT N
reliability NN N
of IN N
TT-TG NNP o
distance NN o
measurements NNS o
on IN N
both DT N
MRI NNP N
and CC N
CT NNP N
and CC N
to TO N
determine VB N
whether IN N
the DT N
measurements NNS N
are VBP N
interchangeable JJ N
with IN N
one CD N
another DT N
. . N

STUDY NNP N
DESIGN NNP N
Cohort NNP N
study NN N
( ( N
diagnosis NN N
) ) N
; : N
Level NNP N
of IN N
evidence NN N
, , N
2 CD N
. . N

METHODS NNP N
All DT p
patients NNS p
with IN p
patellar JJ p
instability NN p
who WP p
underwent VBD p
both DT p
CT NNP i
and CC i
MRI NNP i
of IN p
the DT p
knee NN p
from IN p
2003 CD p
to TO p
2011 CD p
were VBD p
included VBN p
( ( p
n JJ p
= $ p
59 CD p
knees NNS p
in IN p
54 CD p
patients NNS p
) ) p
. . p

Two CD N
fellowship-trained JJ N
musculoskeletal JJ N
radiologists NNS N
measured VBD N
the DT N
TT-TG NNP o
distances NNS o
for IN N
each DT N
patient NN N
by IN N
CT NNP i
and CC i
MRI NNP i
in IN N
a DT N
randomized JJ N
, , N
blinded JJ N
fashion NN N
. . N

Interobserver NNP o
reliability NN o
was VBD N
calculated VBN N
between IN N
radiologists NNS N
for IN N
both DT N
imaging VBG N
modalities NNS N
, , N
and CC N
intermethod JJ o
reliability NN o
was VBD N
calculated VBN N
between IN N
the DT N
2 CD N
imaging NN N
modalities NNS N
. . N

The DT N
results NNS N
are VBP N
reported VBN N
using VBG N
intraclass NN N
correlation NN N
coefficients NNS N
( ( N
ICCs NNP N
) ) N
and CC N
Bland-Altman JJ N
analysis NN N
. . N

RESULTS VB N
The DT N
59 CD N
knees NNS N
had VBD N
a DT N
mean JJ N
TT-TG JJ o
distance NN o
of IN N
16.9 CD N
mm NN N
( ( N
range NN N
, , N
8.3-25.8 JJ N
mm NN N
) ) N
by IN N
CT NNP N
and CC N
14.7 CD N
mm NN N
( ( N
range NN N
, , N
1.5-25.1 JJ N
mm NN N
) ) N
by IN N
MRI NNP N
. . N

Interobserver NNP o
reliability NN o
between IN N
the DT N
radiologists NNS N
was VBD N
considered VBN N
excellent NN N
for IN N
both DT N
CT NNP i
and CC N
MRI NNP i
( ( N
ICC NNP N
= NNP N
0.777 CD N
and CC N
0.843 CD N
, , N
respectively RB N
) ) N
. . N

When WRB N
comparing VBG N
CT NNP N
to TO N
MRI NNP N
, , N
the DT N
ICC NNP o
was VBD N
considered VBN N
only RB N
fair JJ N
for IN N
each DT N
of IN N
the DT N
raters NNS N
( ( N
0.532 CD N
and CC N
0.539 CD N
) ) N
. . N

Eleven JJ N
patients NNS N
( ( N
19 CD N
% NN N
) ) N
had VBD N
a DT N
TT-TG JJ o
distance NN o
of IN N
?20 NNP N
mm NN N
on IN N
CT NNP N
preoperatively RB N
and CC N
underwent JJ o
distal JJ o
realignment NN o
by IN o
tibial JJ N
tubercle NN N
osteotomy NN N
. . N

In IN N
this DT N
surgical JJ N
subgroup NN N
, , N
the DT o
mean JJ o
TT-TG NNP o
distance NN o
was VBD o
22.5 CD N
mm NN N
( ( N
range NN N
, , N
19.8-25.8 JJ N
mm NN N
) ) N
by IN N
CT NNP N
and CC N
only RB N
18.7 CD N
mm NN N
( ( N
range NN N
, , N
14.4-22.8 JJ N
mm NN N
) ) N
by IN N
MRI NNP N
for IN N
a DT N
mean JJ N
difference NN N
of IN N
3.80 CD N
mm NN N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

CONCLUSION VB N
The DT o
TT-TG JJ o
distance NN o
can MD o
be VB N
measured VBN N
with IN N
excellent JJ o
interrater NN o
reliability NN o
on IN o
both DT N
MRI NNP N
and CC N
CT NNP N
; : N
however RB N
, , N
the DT N
values NNS N
derived VBN N
from IN N
these DT N
2 CD N
tests NNS N
may MD N
not RB N
be VB N
interchangeable JJ N
. . N

This DT N
observation NN N
should MD N
be VB N
taken VBN N
into IN N
consideration NN N
when WRB N
MRI NNP N
is VBZ N
used VBN N
for IN N
surgical JJ N
planning NN N
because IN N
MRI NNP N
may MD N
underestimate VB N
the DT o
TT-TG NNP o
distance NN o
when WRB o
compared VBN N
with IN N
CT NNP N
. . N

-DOCSTART- -9665186- O O

Improved VBN N
survival NN N
with IN N
early JJ i
intensification NN i
: : i
combined VBN N
results NNS N
from IN N
the DT N
Medical NNP N
Research NNP N
Council NNP N
childhood VBD N
ALL DT N
randomised VBN p
trials NNS p
, , N
UKALL NNP N
X NNP N
and CC N
UKALL NNP N
XI NNP N
. . N

Medical NNP N
Research NNP N
Council NNP N
Working NNP N
Party NNP N
on IN N
Childhood NNP N
Leukaemia NNP N
. . N

The DT N
Medical NNP N
Research NNP N
Council NNP N
( ( N
MRC NNP N
) ) N
United NNP N
Kingdom NNP N
trial NN N
for IN N
childhood NN p
acute NN p
lymphoblastic JJ p
leukaemia NN p
( ( p
UKALL NNP p
X NNP p
) ) p
randomised VBD p
patients NNS p
aged VBN p
0-14 CD p
years NNS p
inclusive JJ p
with IN p
an DT p
initial JJ p
white JJ p
blood NN p
count NN p
of IN p
less JJR p
than IN p
100 CD p
x JJ p
10 CD p
( ( p
9 CD p
) ) p
/l NN p
to TO p
receive VB p
an DT i
early JJ i
intensification NN i
block NN i
, , i
a DT i
late JJ i
intensification NN i
block NN i
, , i
both DT i
, , i
or CC i
neither RB i
. . i

The DT N
next JJ N
trial NN N
, , N
UKALL NNP p
XI NNP p
, , p
for IN p
children NNS p
aged VBN p
1-14 CD p
years NNS p
, , N
randomised VBD N
between IN N
different JJ i
central JJ i
nervous JJ i
system NN i
( ( i
CNS NNP i
) ) i
directed VBD i
therapies NNS i
. . i

At IN N
the DT N
beginning NN N
of IN N
the DT N
trial NN N
, , N
all DT p
patients NNS p
were VBD p
also RB p
randomised VBN p
between IN p
late JJ i
intensification NN i
alone RB i
and CC p
both DT i
early JJ i
plus NN i
late JJ i
blocks NNS i
. . i

The DT N
effects NNS N
of IN N
both DT N
the DT N
early JJ N
and CC N
the DT N
late JJ N
block NN N
in IN N
UKALL NNP N
X NNP N
alone RB N
have VBP N
been VBN N
reported VBN N
previously RB N
. . N

This DT N
paper NN N
examines VBZ N
the DT N
effect NN N
of IN N
the DT N
addition NN N
of IN N
the DT N
early JJ N
intensification NN N
block NN N
to TO N
treatment NN N
which WDT N
included VBD N
late JJ N
intensification NN N
, , N
combining VBG N
the DT N
data NN N
from IN N
UKALL NNP N
X NNP N
and CC N
the DT N
first JJ N
part NN N
of IN N
UKALL NNP N
XI NNP N
. . N

Early JJ N
intensification NN N
was VBD N
associated VBN N
with IN N
fewer JJR N
bone NN o
marrow NN o
relapses NNS o
and CC N
a DT N
reduction NN N
in IN N
the DT N
odds NNS N
of IN N
death NN o
of IN N
0.63 CD N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
: : N
0.46-0.87 JJ N
) ) N
. . N

Survival NN o
was VBD N
significantly RB N
improved VBN N
with IN N
an DT N
increase NN N
at IN N
5 CD N
years NNS N
of IN N
8 CD N
% NN N
, , N
from IN N
79 CD N
to TO N
87 CD N
% NN N
. . N

Following VBG N
this DT N
demonstration NN N
that WDT N
early JJ N
intensification NN N
improves VBZ N
survival NN N
, , N
the DT N
effect NN N
of IN N
a DT N
third JJ N
intensification NN N
block NN N
is VBZ N
under IN N
investigation NN N
. . N

-DOCSTART- -16200817- O O

Addition NN N
of IN N
fexofenadine NN i
to TO N
inhaled VB i
corticosteroid JJ i
therapy NN i
to TO N
reduce VB N
inflammatory JJ o
biomarkers NNS o
in IN p
atopic NN p
asthma NN p
. . p

BACKGROUND IN N
We PRP N
previously RB N
showed VBD N
that IN N
H1-antihistamines NNP N
may MD N
shift VB N
the DT N
PC20 NNP N
( ( N
provocation NN N
concentration NN N
that WDT N
caused VBD N
a DT N
decrease NN N
in IN N
forced JJ N
expiratory NN N
volume NN N
in IN N
1 CD N
second NN N
of IN N
20 CD N
% NN N
) ) N
threshold NN N
to TO N
adenosine VB N
monophosphate NN N
( ( N
AMP NNP N
) ) N
challenge NN N
but CC N
may MD N
paradoxically RB N
prolong VB N
recovery NN N
. . N

OBJECTIVES UH N
To TO N
measure VB N
AMP NNP N
recovery NN N
using VBG N
a DT N
constant JJ N
predetermined VBN N
AMP NNP N
PC20 NNP N
and CC N
to TO N
evaluate VB N
whether IN N
fexofenadine NN i
use NN N
confers NNS N
add-on JJ N
effects NNS N
to TO N
treatment NN N
with IN N
either DT N
fluticasone NN i
propionate NN i
alone RB N
or CC N
combined VBN i
fluticasone CD i
propionate-salmeterol NN i
. . i

METHODS NNP N
Fourteen NNP p
atopic NN p
patients NNS p
with IN p
mild-to-moderate JJ p
asthma NN p
( ( p
forced JJ p
expiratory NN p
volume NN p
in IN p
1 CD p
second NN p
of IN p
76 CD p
% NN p
) ) p
completed VBD N
a DT N
double-blind NN N
, , N
randomized VBN N
, , N
crossover NN N
study NN N
consisting VBG N
of IN N
3-week JJ N
treatment NN N
blocks NNS N
of IN N
either DT N
fluticasone JJ i
propionate-salmeterol NN i
, , N
250 CD N
microg NN N
twice RB N
daily RB N
, , N
or CC N
fluticasone JJ i
propionate NN i
alone RB i
, , N
250 CD N
microg NN N
twice RB N
daily RB N
, , N
in IN N
conjunction NN N
with IN N
either DT N
fexofenadine NN i
, , N
180 CD N
mg NN N
once RB N
daily JJ N
, , N
or CC N
matched VBD N
placebo NN i
. . i

Recovery NN o
after IN N
a DT N
predetermined JJ o
AMP NNP o
PC20 NNP o
challenge NN o
was VBD N
measured VBN N
( ( N
primary JJ N
outcome NN N
) ) N
, , N
along IN N
with IN N
exhaled JJ o
nitric JJ o
oxide NN o
levels NNS o
, , o
plasma NN o
eosinophil NN o
cationic JJ o
protein NN o
levels NNS o
, , o
peripheral JJ o
eosinophil NN o
counts NNS o
, , o
pulmonary JJ o
function NN o
, , o
diary JJ o
card NN o
outcomes NNS o
, , o
and CC o
quality NN o
of IN o
life NN o
( ( N
all DT N
secondary JJ N
outcomes NNS N
) ) N
. . N

RESULTS CC N
There EX N
were VBD N
no DT N
differences NNS N
in IN N
any DT N
of IN N
the DT N
primary JJ N
or CC N
secondary JJ N
outcomes NNS N
when WRB N
fexofenadine NN i
was VBD N
added VBN N
to TO N
treatment NN N
with IN N
either DT N
fluticasone JJ i
propionate-salmeterol NN i
or CC i
fluticasone NN i
propionate NN i
alone RB N
. . N

The DT N
mean NN N
AMP NNP N
recovery NN N
time NN N
was VBD N
25.0 CD N
vs NN N
23.4 CD N
minutes NNS N
for IN N
fexofenadine NN i
and CC N
placebo NN i
, , N
respectively RB N
, , N
as IN N
add-on JJ N
to TO N
fluticasone-salmeterol NN i
and CC N
22.5 CD N
vs NN N
23.9 CD N
minutes NNS N
, , N
respectively RB N
, , N
as IN N
add-on JJ N
to TO N
fluticasone VB i
alone RB N
. . N

CONCLUSION NNP N
Fexofenadine NNP i
did VBD N
not RB N
affect VB N
recovery NN N
to TO N
a DT N
fixed VBN N
dose NN N
of IN N
AMP NNP N
challenge NN N
or CC N
any DT N
other JJ N
surrogate JJ N
inflammatory NN N
markers NNS N
when WRB N
given VBN N
as IN N
add-on JJ N
therapy NN N
to TO N
corticosteroid-treatedatopic JJ p
asthmatic JJ p
patients NNS p
. . p

-DOCSTART- -24447434- O O

Phosphorylated VBN i
p-70S6K JJ i
predicts NNS N
tamoxifen JJ o
resistance NN o
in IN N
postmenopausal NN p
breast NN p
cancer NN p
patients NNS p
randomized VBD N
between IN N
adjuvant JJ N
tamoxifen NN i
versus IN N
no DT i
systemic JJ i
treatment NN i
. . i

INTRODUCTION NNP N
Activation NNP N
of IN N
the DT N
phosphatidylinositol-3-kinase NN i
( ( i
PI3K NNP i
) ) i
and/or VBD N
mitogen-activated JJ i
protein NN i
kinase NN i
( ( i
MAPK NNP i
) ) i
pathways VBZ N
results NNS N
in IN N
anti-estrogen JJ o
resistance NN o
in IN N
vitro NN N
, , N
but CC N
a DT N
biomarker NN N
with IN N
clinical JJ N
validity NN N
to TO N
predict VB N
intrinsic JJ N
resistance NN N
has VBZ N
not RB N
been VBN N
identified VBN N
. . N

In IN N
metastatic JJ p
breast NN p
cancer NN p
patients NNS p
with IN p
previous JJ p
exposure NN p
to TO p
endocrine VB i
therapy NN i
, , N
the DT N
addition NN N
of IN N
a DT N
mammalian JJ N
target NN N
of IN N
rapamycine NN i
( ( i
mTOR NN i
) ) i
inhibitor NN N
has VBZ N
been VBN N
shown VBN N
to TO N
be VB N
beneficial JJ N
. . N

Whether CC N
or CC N
not RB N
patients NNS N
on IN N
adjuvant JJ i
endocrine NN i
treatment NN i
might MD N
benefit VB N
from IN N
these DT N
drugs NNS N
is VBZ N
currently RB N
unclear JJ N
. . N

A DT N
biomarker NN N
that WDT N
predicts VBZ N
intrinsic JJ N
resistance NN N
could MD N
potentially RB N
be VB N
used VBN N
as IN N
companion NN N
diagnostic NN N
in IN N
this DT N
setting NN N
. . N

We PRP N
tested VBD N
the DT N
clinical JJ N
validity NN N
of IN N
different JJ N
downstream-activated JJ N
proteins NNS N
in IN N
the DT N
PI3K NNP N
and/or NN N
MAPK NNP N
pathways VBZ N
to TO N
predict VB N
intrinsic JJ o
tamoxifen NN o
resistance NN o
in IN N
postmenopausal NN N
primary JJ N
breast NN N
cancer NN N
patients NNS N
. . N

METHODS NNP N
We PRP N
recollected VBD N
primary JJ p
tumor NN p
tissue NN p
from IN p
patients NNS p
who WP p
participated VBD p
in IN p
a DT p
randomized JJ p
trial NN p
of IN p
adjuvant JJ i
tamoxifen NN i
( ( i
1-3 CD i
years NNS i
) ) i
versus NN i
observation NN i
. . i

After IN N
constructing VBG N
a DT N
tissue NN i
micro-array NN i
, , N
cores NNS N
from IN N
563 CD N
estrogen NN N
receptor NN N
? . N
positive JJ N
were VBD N
immunostained VBN N
for IN N
p-AKT NN N
( ( N
Thr308 NNP N
) ) N
, , N
p-AKT JJ N
( ( N
Ser473 NNP N
) ) N
, , N
p-mTOR JJ N
, , N
p-p706SK JJ N
and CC N
p-ERK1/2 JJ N
. . N

Cox NNP N
proportional JJ N
hazard NN N
models NNS N
for IN o
recurrence NN o
free JJ o
interval NN o
were VBD N
used VBN N
to TO N
assess VB o
hazard JJ o
ratios NNS o
and CC N
interactions NNS N
between IN N
these DT N
markers NNS N
and CC i
tamoxifen JJ i
treatment NN N
efficacy NN N
. . N

RESULTS JJ N
Interactions NNPS N
were VBD N
identified VBN N
between IN i
tamoxifen NNS i
and CC i
p-AKT NN i
( ( i
Thr308 NNP i
) ) i
, , i
p-mTOR JJ i
, , i
p-p70S6K JJ i
and CC i
p-ERK1/2 JJ i
. . i

Applying VBG N
a DT N
conservative JJ N
level NN N
of IN N
significance NN N
, , N
p-p70S6K NN i
remained VBD N
significantly RB N
associated VBN N
with IN o
tamoxifen JJ o
resistance NN o
. . o

Patients NNS N
with IN N
p-p70S6K JJ N
negative JJ N
tumors NNS N
derived VBD N
significant JJ N
benefit NN N
from IN i
tamoxifen NN i
( ( N
HR NNP N
0.24 CD N
, , N
P NNP N
< NNP N
0.0001 CD N
) ) N
, , N
while IN N
patients NNS N
whose WP$ N
tumor NN N
did VBD N
express JJ N
p-p70S6K NN N
did VBD N
not RB N
( ( N
HR NNP N
= NNP N
1.02 CD N
, , N
P NNP N
=0.95 NNP N
) ) N
, , N
P NNP N
for IN N
interaction NN N
0.004 CD N
. . N

In IN N
systemically RB N
untreated JJ N
breast NN N
cancer NN N
patients NNS N
, , N
p-p70S6K NN N
was VBD N
associated VBN N
with IN N
a DT N
decreased JJ N
risk NN o
for IN o
recurrence NN o
. . o

CONCLUSIONS JJ o
Patients NNPS p
whose WP$ p
tumor NN p
expresses VBZ p
p-p70S6K JJ p
, , p
as IN p
a DT p
marker NN p
of IN p
downstream NN p
PI3K NNP p
and/or NN p
MAPK NNP p
pathway NN p
activation NN p
, , p
have VBP p
a DT p
favorable JJ N
prognosis NN N
, , N
but CC N
do VBP N
not RB N
benefit VB N
from IN N
adjuvant JJ N
tamoxifen NN i
. . i

A DT i
potential JJ i
benefit NN N
from IN N
inhibitors NNS N
of IN N
the DT N
PI3K/Akt/mTOR NNP N
pathway NN N
in IN N
these DT N
patients NNS N
needs NNS N
to TO N
be VB N
further RB N
explored VBN N
. . N

-DOCSTART- -24085050- O O

Pimecrolimus NNP i
cream NN i
and CC N
Tacrolimus NNP i
ointment NN i
in IN N
the DT N
treatment NN N
of IN N
atopic JJ o
dermatitis NN o
: : o
a DT N
pilot NN N
study NN N
on IN N
patient JJ N
preference NN N
. . N

BACKGROUND NNP N
Pimecrolimus NNP i
cream VBZ N
1 CD N
% NN N
is VBZ N
approved VBN N
for IN N
mild NN p
to TO p
moderate VB p
atopic NN p
dermatitis NN p
in IN p
children NNS p
older JJR p
than IN p
two CD p
years NNS p
of IN p
age NN p
and CC p
adults NNS p
. . p

Tacrolimus NNP i
ointment JJ i
0.03 CD N
% NN N
is VBZ N
approved VBN N
for IN N
moderate JJ p
to TO p
severe VB p
atopic NN p
dermatitis NN p
in IN p
the DT p
patient JJ p
population NN p
between IN p
two CD p
to TO p
seventeen VB p
years NNS p
of IN p
age NN p
and CC N
Tacrolimus NNP i
0.1 CD i
% NN i
ointment NN i
for IN N
moderate JJ p
to TO p
severe VB p
atopic NN p
dermatitis NN p
in IN p
patients NNS p
18 CD p
years NNS p
of IN p
age NN p
and CC p
older JJR p
. . p

However RB N
, , N
beyond IN N
safety NN o
and CC o
efficacy NN o
, , N
the DT N
delivery NN N
system NN N
or CC N
vehicle NN N
used VBN N
in IN N
topical JJ N
treatment NN N
formulations NNS N
is VBZ N
equally RB N
important JJ N
in IN N
affecting VBG N
patient JJ o
satisfaction NN o
, , o
tolerability NN o
, , o
and CC o
subsequent JJ o
treatment NN o
compliance NN o
and CC N
hence RB N
clinical JJ o
resolution NN o
of IN N
active JJ N
disease NN N
. . N

-DOCSTART- -17762804- O O

Are NNP N
back RB i
supports VBZ i
plus CC i
education NN i
more RBR N
effective JJ N
than IN N
education NN i
alone RB i
in IN N
promoting VBG N
recovery NN p
from IN p
low JJ p
back RB p
pain NN p
? . N
: : N
Results NNS N
from IN N
a DT N
randomized JJ N
clinical JJ N
trial NN N
. . N

STUDY NNP N
DESIGN NNP N
Randomized NNP N
clinical JJ N
trial NN N
. . N

OBJECTIVES UH N
To TO N
evaluate VB N
the DT N
effectiveness NN N
of IN N
a DT N
back JJ i
support NN i
plus CC i
education NN i
versus IN N
education NN i
alone RB i
in IN N
promoting VBG N
recovery NN N
from IN N
a DT N
work-related JJ p
low JJ p
back RB p
disorder NN p
( ( p
WR-LBD NNP p
) ) p
while IN N
simultaneously RB N
considering VBG N
personal JJ N
, , N
health NN N
, , N
and CC N
occupational JJ N
factors NNS N
and CC N
the DT N
impact NN N
of IN N
occupational JJ N
factors NNS N
on IN N
recovery NN N
. . N

SUMMARY NNP N
OF IN N
BACKGROUND NNP N
DATA NNP N
No NNP N
randomized JJ N
studies NNS N
of IN N
active JJ p
industrial JJ p
workers NNS p
with IN p
low JJ p
back RB p
disorders NNS p
exist VBP N
regarding VBG N
the DT N
effectiveness NN N
of IN N
back JJ N
supports NNS N
plus CC N
education NN N
. . N

METHODS NNP N
A NNP N
total NN N
of IN N
433 CD p
actively RB p
employed VBN p
hourly RB p
union NN p
workers NNS p
who WP p
had VBD p
a DT p
recent JJ p
diagnosis NN p
of IN p
a DT p
WR-LBD JJ p
: : p
1 CD p
) ) p
those DT p
who WP p
wore VBP p
a DT i
specially RB i
designed VBN i
back RP i
support NN i
plus CC i
received JJ i
education NN i
on IN i
back JJ i
health NN i
; : i
and CC p
2 CD p
) ) p
those DT p
who WP p
received VBD p
education NN i
on IN i
back JJ i
health NN i
only RB i
. . i

Demographic NNP N
, , N
health NN N
, , N
medical JJ N
, , N
and CC N
occupational JJ N
factors NNS N
were VBD N
obtained VBN N
through IN N
interview NN N
or CC N
abstraction NN N
of IN N
computer NN N
files NNS N
; : N
individual JJ N
ergonomic JJ N
exposures NNS N
were VBD N
measured VBN N
with IN N
a DT N
lumbar NN N
motion NN N
monitor NN N
. . N

Outcomes CC N
evaluated VBD N
over IN N
a DT N
12-month JJ N
period NN N
included VBD N
: : N
self-reported JJ o
measures NNS o
of IN o
back RB o
pain NN o
, , o
back RB o
pain NN o
disability NN o
level NN o
, , o
physical JJ o
health NN o
, , o
mental JJ o
health NN o
, , o
and CC o
administrative JJ o
measures NNS o
of IN o
recurrence NN o
, , o
lost VBN o
work NN o
time NN o
, , o
and CC o
medical JJ o
care NN o
utilization NN o
. . o

RESULTS NNP N
There EX N
was VBD N
no DT N
difference NN N
between IN N
the DT N
study NN N
groups NNS N
with IN N
respect NN N
to TO N
mental VB o
or CC o
physical JJ o
health NN o
, , o
low JJ o
back RB o
pain NN o
, , o
back RB o
pain NN o
disability NN o
, , o
neurogenic JJ o
symptoms NNS o
, , o
lost VBN o
work NN o
time NN o
, , o
likelihood NN o
of IN o
recurrence NN o
of IN o
an DT o
episode NN o
of IN o
a DT o
back JJ o
disorder NN o
, , o
or CC o
other JJ o
administrative JJ o
measures NNS o
of IN o
healthcare JJ o
utilization NN o
or CC o
lost VBN o
work NN o
time NN o
. . o

However RB N
, , N
significant JJ N
decreases NNS N
in IN o
low JJ o
back RB o
pain NN o
, , o
low JJ o
back RB o
pain NN o
disability NN o
, , o
neurogenic JJ o
symptoms NNS o
, , o
and CC o
an DT o
increase NN o
in IN o
physical JJ o
health NN o
were VBD N
observed VBN N
over IN N
the DT N
12 CD N
months NNS N
of IN N
observation NN N
in IN N
both DT N
study NN N
groups NNS N
. . N

The DT N
only JJ N
occupational JJ N
variable NN N
found VBD N
to TO N
influence VB N
was VBD N
plant NN N
group NN N
whereby WRB N
service NN N
parts NNS N
operations NNS N
workers NNS N
in IN N
the DT N
back JJ N
support NN N
plus CC N
education NN N
group NN N
experienced VBD N
a DT N
lower JJR N
likelihood NN N
of IN N
WR-LBD NNP o
recurrence NN o
. . o

CONCLUSION NNP N
Although IN N
there EX N
was VBD N
no DT N
overall JJ N
effect NN N
on IN N
self-reported JJ N
recovery NN N
or CC N
administrative JJ N
measures NNS N
or CC N
lost VBN N
work NN N
time NN N
between IN N
the DT N
study NN N
groups NNS N
, , N
a DT N
back JJ i
support NN i
plus CC i
health NN i
education NN i
may MD N
have VB N
some DT N
value NN N
in IN N
preventing VBG N
recurrent JJ N
WR-LBD NNP N
in IN N
industrial JJ p
workers NNS p
who WP p
work VBP p
in IN p
psychosocial JJ p
environments NNS p
and CC p
perform VB p
manual JJ p
material NN p
handling VBG p
tasks NNS p
similar JJ p
to TO p
those DT p
found VBN p
in IN p
parts NNS p
distribution NN p
centers NNS p
. . p

-DOCSTART- -17579182- O O

Use NNP N
of IN N
a DT N
DNAemia NNP i
cut-off NN i
for IN N
monitoring VBG N
human JJ N
cytomegalovirus NN N
infection NN N
reduces VBZ N
the DT N
number NN o
of IN o
preemptively RB o
treated VBN o
children NNS o
and CC p
young JJ p
adults NNS p
receiving VBG p
hematopoietic JJ p
stem-cell JJ p
transplantation NN p
compared VBN N
with IN N
qualitative JJ i
pp65 NN i
antigenemia NN i
. . i

We PRP N
performed VBD N
a DT N
randomized JJ N
trial NN N
comparing VBG N
the DT N
use NN N
of IN N
quantitative JJ i
DNAemia NNP i
versus NN i
positive JJ i
antigenemia NN i
for IN N
starting VBG N
preemptive JJ N
antihuman NN N
cytomegalovirus NN N
( ( N
HCMV NNP N
) ) N
therapy NN N
in IN N
hematopoietic JJ p
stem-cell JJ p
transplantation NN p
( ( p
HSCT NNP p
) ) p
recipients NNS p
. . p

In IN N
the DT N
DNAemia NNP i
arm NN N
, , N
antiviral JJ i
therapy NN i
was VBD N
initiated VBN N
on IN N
reaching VBG N
a DT N
DNAemia NNP i
cut-off NN i
of IN N
10 CD N
000 CD N
DNA NNP N
copies/mL NN N
of IN N
whole JJ N
blood NN N
, , N
whereas NNS N
in IN N
the DT N
antigenemia NN N
arm NN N
, , N
therapy NN N
was VBD N
started VBN N
in IN N
the DT N
presence NN N
of IN N
a DT N
positive JJ i
antigenemia NN i
. . i

The DT N
aim NN N
of IN N
the DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
number NN N
of IN N
patients NNS N
treated VBN N
in IN N
the DT N
2 CD N
arms NNS N
. . N

On IN N
the DT N
whole NN N
, , N
178 CD p
patients NNS p
( ( p
89 CD p
in IN p
each DT p
arm NN p
) ) p
, , p
receiving VBG p
unmanipulated JJ i
HSCT NNP i
from IN p
either CC p
a DT p
relative NN p
or CC p
an DT p
unrelated JJ p
donor NN p
, , N
completed VBD N
the DT N
study NN N
. . N

Although IN N
the DT N
incidence NN N
of IN N
HCMV NNP o
infection NN o
was VBD N
comparable JJ N
in IN N
DNAemia NNP N
and CC N
antigenemia NN N
arms NNS N
( ( N
34 CD N
% NN N
vs JJ N
42 CD N
% NN N
, , N
respectively RB N
, , N
P NNP N
= NNP N
.259 NNP N
) ) N
, , N
the DT N
number NN o
of IN o
patients NNS o
treated VBN o
was VBD N
significantly RB N
lower JJR N
in IN N
the DT N
DNAemia NNP i
arm NN N
( ( N
18 CD N
% NN N
vs JJ N
31 CD N
% NN N
, , N
P NNP N
= NNP N
.026 NNP N
) ) N
. . N

No DT N
patient NN N
developed VBD N
HCMV NNP o
disease NN o
. . o

The DT N
use NN N
of IN N
a DT N
DNAemia NNP i
cut-off NN i
avoids NNS N
unnecessary JJ N
antiviral JJ i
treatment NN i
. . i

-DOCSTART- -22038501- O O

Standard NNP i
versus NN N
extended VBD i
lymphadenectomy NN i
in IN N
radical JJ N
pancreatoduodenectomy NN N
for IN N
ductal JJ N
adenocarcinoma NN N
of IN N
the DT N
head NN N
of IN N
the DT N
pancreas NNS N
: : N
long-term JJ N
results NNS N
of IN N
a DT N
Japanese JJ N
multicenter NN N
randomized VBD N
controlled VBN N
trial NN N
. . N

BACKGROUND IN N
The DT N
value NN N
of IN N
pancreatoduodenectomy NN N
( ( N
PD NNP N
) ) N
with IN N
extended VBN N
lymphadenectomy NN N
for IN N
pancreatic JJ N
cancer NN N
has VBZ N
been VBN N
evaluated VBN N
by IN N
many JJ N
retrospective JJ N
studies NNS N
and CC N
3 CD N
randomized VBN N
controlled VBN N
trials NNS N
( ( N
RCT NNP N
) ) N
. . N

However RB N
, , N
the DT N
protocols NNS N
used VBN N
and CC N
the DT N
results NNS N
found VBD N
in IN N
the DT N
3 CD N
RCTs NNP N
were VBD N
diverse JJ N
. . N

Therefore RB N
, , N
a DT N
multicenter NN N
RCT NNP N
was VBD N
proposed VBN N
in IN N
1998 CD N
to TO N
evaluate VB N
the DT N
primary JJ N
end NN N
point NN N
of IN N
long-term JJ N
survival NN N
and CC N
the DT N
secondary JJ N
end NN N
points NNS N
of IN N
morbidity NN N
, , N
mortality NN N
and CC N
quality NN N
of IN N
life NN N
of IN N
patients NNS p
undergoing VBG p
standard JJ i
versus NN p
extended VBD i
lymphadenectomy NN i
in IN p
radical JJ p
PD NNP p
for IN p
pancreatic JJ p
cancer NN p
. . N

METHODS NNP N
From IN N
March NNP p
2000 CD p
to TO p
May NNP p
2003 CD p
, , p
112 CD p
patients NNS p
with IN p
potentially RB p
curable JJ p
pancreatic JJ p
head NN p
cancer NN p
were VBD p
enrolled VBN p
and CC p
intraoperatively RB p
randomized VBN p
to TO p
a DT p
standard NN i
or CC i
extended JJ i
lymphadenectomy NN i
group NN i
. . i

No RB N
resected JJ N
patients NNS N
received VBD N
any DT N
adjuvant JJ N
treatments NNS N
. . N

RESULTS VB N
A DT p
hundred CD p
and CC p
one CD p
eligible JJ p
patients NNS p
were VBD p
analyzed VBN p
. . p

Demographic NNP p
and CC p
histopathological JJ p
characteristics NNS p
of IN p
the DT p
two CD p
groups NNS p
were VBD p
similar JJ p
. . p

The DT N
mean NN o
operating NN o
time NN o
, , o
intraoperative JJ o
blood NN o
loss NN o
and CC o
number NN o
of IN o
retrieved JJ o
lymph NN o
nodes NNS o
were VBD N
greater JJR N
in IN N
the DT N
extended JJ N
group NN N
, , N
but CC N
the DT N
other JJ N
operative JJ N
results NNS N
were VBD N
comparable JJ N
. . N

CONCLUSIONS NNP N
Although IN N
this DT N
multicenter NN N
RCT NNP N
was VBD N
conducted VBN N
in IN N
a DT N
strict JJ N
setting NN N
, , N
extended VBD i
lymphadenectomy NN i
in IN N
radical JJ N
PD NNP N
did VBD N
not RB N
benefit VB N
long-term JJ N
survival NN N
in IN N
patients NNS p
with IN p
resectable JJ p
pancreatic JJ p
head NN p
cancer NN p
and CC N
led VBD N
to TO N
levels NNS N
of IN N
morbidity NN N
, , N
mortality NN N
and CC N
quality NN N
of IN N
life NN N
comparable JJ N
to TO N
those DT N
found VBN N
after IN N
standard JJ i
lymphadenectomy NN i
. . i

-DOCSTART- -15528779- O O

Low-intensity NNP i
exercise NN i
and CC N
reduction NN N
of IN N
the DT o
risk NN o
for IN o
falls NNS o
among IN p
at-risk JJ p
elders NNS p
. . p

BACKGROUND NNP N
Among IN N
elderly JJ p
persons NNS p
, , N
falls VBZ o
account NN N
for IN N
87 CD N
% NN N
of IN N
all DT N
fractures NNS N
and CC N
are VBP N
contributing VBG N
factors NNS N
in IN N
many JJ N
nursing NN N
home NN N
admissions NNS N
. . N

This DT N
study NN N
evaluated VBD N
the DT N
effect NN N
of IN N
an DT N
easily RB N
implemented VBN N
, , N
low-intensity JJ i
exercise NN i
program NN i
on IN N
the DT N
incidence NN o
of IN o
falls NNS o
and CC p
the DT p
time NN o
to TO o
first VB o
fall NN o
among IN p
a DT p
clinically RB p
defined JJ p
population NN p
of IN p
elderly JJ p
men NNS p
and CC p
women NNS p
. . p

METHODS VB N
This DT N
community-based JJ N
, , N
randomized JJ N
trial NN N
compared VBN N
the DT N
exercise NN i
intervention NN i
with IN N
a DT N
no-intervention JJ i
control NN i
. . i

The DT p
participants NNS p
were VBD p
294 CD p
men NNS p
and CC p
women NNS p
, , p
aged VBD p
60 CD p
years NNS p
or CC p
older JJR p
, , p
who WP p
had VBD p
either CC p
a DT p
hospital JJ p
admission NN p
or CC p
bed NN p
rest NN p
for IN p
2 CD p
days NNS p
or CC p
more JJR p
within IN p
the DT p
previous JJ p
month NN p
. . p

Exercise NN i
participants NNS N
were VBD N
scheduled VBN N
to TO N
attend VB N
exercise NN i
sessions NNS i
lasting VBG N
45 CD N
minutes NNS N
, , N
including VBG N
warm-up JJ N
and CC N
cool-down JJ N
, , N
3 CD N
times NNS N
a DT N
week NN N
for IN N
8 CD N
weeks NNS N
( ( N
24 CD N
sessions NNS N
) ) N
. . N

Assessments NNS N
included VBD N
gait NN o
and CC o
balance NN o
measures NNS o
, , o
self-reported JJ o
physical JJ o
function NN o
, , N
the DT N
number NN o
of IN o
medications NNS o
being VBG o
taking VBG o
at IN o
baseline NN o
, , N
participant JJ N
age NN N
, , N
sex NN N
, , N
and CC N
history NN o
of IN o
falling VBG o
. . o

Falls NNS o
were VBD N
tracked VBN N
for IN N
1 CD N
year NN N
after IN N
each DT N
participant NN N
's POS N
baseline JJ N
assessment NN N
. . N

RESULTS VB N
29 CD N
% NN N
of IN N
the DT N
study NN N
participants NNS N
reported VBD N
a DT N
fall NN o
during IN N
the DT N
study NN N
period NN N
. . N

The DT N
effect NN N
of IN N
exercise NN i
in IN N
preventing VBG o
falls NNS o
varied VBN N
significantly RB N
by IN N
baseline JJ N
physical JJ N
function NN N
level NN N
( ( N
p JJ N
< NN N
or CC N
=.002 NN N
) ) N
. . N

The DT N
risk NN o
for IN o
falls NNS o
decreased VBN N
for IN N
exercise NN N
participants NNS N
with IN N
low JJ N
baseline NN N
physical JJ N
functioning NN N
( ( N
hazard JJ N
ratio NN N
, , N
.51 NN N
) ) N
but CC N
increased VBD N
for IN N
exercise NN N
participants NNS N
with IN N
high JJ N
baseline NN N
physical JJ N
functioning NN N
( ( N
hazard JJ N
ratio NN N
, , N
3.51 CD N
) ) N
. . N

CONCLUSIONS VB N
This DT N
easily RB N
implemented VBN N
, , N
low-intensity JJ i
exercise NN i
program NN i
appears VBZ N
to TO N
reduce VB N
the DT N
risk NN o
for IN o
falls NNS o
among IN p
elderly JJ p
men NNS p
and CC p
women NNS p
recovering VBG p
from IN p
recent JJ p
hospitalizations NNS p
, , p
bed VBD p
rest NN p
, , p
or CC p
both DT p
who WP p
have VBP p
low JJ p
levels NNS p
of IN p
physical JJ p
functioning NN p
. . p

-DOCSTART- -2015394- O O

Allogeneic NNP i
marrow NN i
transplantation NN i
in IN N
patients NNS p
with IN p
chronic JJ p
myeloid NN p
leukemia NN p
in IN p
the DT p
chronic JJ p
phase NN p
: : p
a DT N
randomized JJ N
trial NN N
of IN N
two CD N
irradiation NN N
regimens NNS N
. . N

A DT N
randomized JJ N
trial NN N
was VBD N
performed VBN N
to TO N
compare VB N
two CD N
regimens NNS N
of IN N
total JJ i
body NN i
irradiation NN i
in IN N
patients NNS p
with IN p
chronic JJ p
myeloid NN p
leukemia NN p
treated VBN p
by IN p
allogeneic JJ i
marrow NN i
transplantation NN i
while IN p
in IN p
the DT p
chronic JJ p
phase NN p
. . p

All DT N
patients NNS N
received VBD N
cyclophosphamide JJ i
120 CD N
mg/kg NN N
followed VBN N
by IN N
total JJ i
body NN i
irradiation NN i
and CC i
marrow NN i
from IN i
HLA-identical JJ i
siblings NNS i
. . i

Cyclosporine NNP i
and CC i
methotrexate NN i
were VBD N
used VBN N
for IN N
prophylaxis NN N
against IN N
acute JJ N
graft-versus-host JJ N
disease NN N
. . N

Fifty-seven JJ p
patients NNS p
were VBD N
randomized VBN N
to TO N
receive VB N
2.0 CD N
Gy NNP N
fractions NNS N
of IN N
irradiation NN i
daily NN N
for IN N
6 CD N
days NNS N
and CC N
59 CD N
were VBD N
randomized VBN N
to TO N
receive VB N
2.25 CD N
Gy NNP N
fractions NNS N
daily RB N
for IN N
7 CD N
days NNS N
. . N

The DT N
probabilities NNS o
of IN o
relapse NN o
at IN N
4 CD N
years NNS N
were VBD N
0.25 CD N
for IN N
the DT N
12.0 CD N
Gy NNP N
group NN N
and CC N
0.00 CD N
for IN N
the DT N
15.75 CD N
Gy NNP N
group NN N
( ( N
P NNP N
= NNP N
.008 NNP N
) ) N
. . N

The DT N
actuarial JJ o
probabilities NNS o
of IN o
survival NN o
and CC o
relapse-free JJ o
survival NN o
at IN N
4 CD N
years NNS N
were VBD N
0.60 CD N
and CC N
0.58 CD N
among IN N
the DT N
patients NNS N
who WP N
received VBD N
12.0 CD N
Gy NNP N
compared VBN N
with IN N
0.66 CD N
and CC N
0.66 CD N
for IN N
those DT N
who WP N
received VBD N
15.75 CD N
Gy NNP N
. . N

The DT N
4-year JJ o
probabilities NNS o
of IN o
transplant-related JJ o
mortality NN o
were VBD N
0.24 CD N
and CC N
0.34 CD N
respectively RB N
( ( N
P NNP N
= NNP N
.13 NNP N
) ) N
while IN N
the DT N
probability NN o
of IN o
moderate JJ o
to TO o
severe VB o
acute JJ o
graft-versus-host JJ o
disease NN o
was VBD N
0.33 CD N
for IN N
the DT N
12.0 CD N
Gy NNP N
group NN N
and CC N
0.44 CD N
for IN N
the DT N
15.75 CD N
Gy NNP N
group NN N
( ( N
P NNP N
= NNP N
.15 NNP N
) ) N
. . N

The DT N
lower JJR N
relapse NN o
probability NN o
in IN N
the DT N
patients NNS p
receiving VBG p
the DT p
higher JJR p
dose NN p
of IN p
total JJ i
body NN i
irradiation NN i
did VBD N
not RB N
result VB N
in IN N
improved JJ o
survival NN o
because IN N
mortality NN N
from IN N
causes VBZ N
other JJ N
than IN N
relapse NN N
was VBD N
increased VBN N
. . N

-DOCSTART- -15530681- O O

Influenza NNP N
and CC N
pneumococcal JJ N
vaccination NN i
as IN N
a DT N
model NN N
to TO N
assess VB N
C-reactive JJ N
protein NN N
response NN N
to TO N
mild VB p
inflammation NN p
. . p

This DT N
study NN N
was VBD N
set VBN N
up RP N
to TO N
examine VB N
whether IN N
an DT N
influenza JJ i
vaccine NN i
or CC i
an DT i
influenza JJ i
vaccine NN i
in IN i
combination NN i
with IN i
pneumococcal JJ i
vaccine NN i
can MD N
be VB N
used VBN N
as IN N
a DT N
model NN N
to TO N
study VB N
responses NNS N
to TO N
mild VB N
stimulation NN N
of IN N
the DT N
inflammatory NN N
system NN N
. . N

In IN N
this DT N
study NN N
, , N
19 CD p
subjects NNS p
received VBD p
the DT p
influenza JJ i
vaccine NN i
, , p
20 CD p
subjects NNS p
the DT p
combination NN p
of IN p
influenza NN i
and CC i
pneumococcal JJ i
vaccine NN i
. . i

CRP NNP o
and CC o
prothrombin VB o
fragment JJ o
1 CD o
and CC o
2 CD o
( ( o
F1+2 NNP o
) ) o
were VBD N
measured VBN N
at IN N
baseline NN N
, , N
and CC N
two CD N
times NNS N
after IN N
vaccination NN N
. . N

Influenza NNP i
vaccination NN i
increased VBD N
CRP NNP o
by IN N
0.20 CD N
mg/L NNS N
, , N
and CC N
influenza NN N
in IN N
combination NN N
with IN N
pneumococcal JJ i
vaccine NN i
increased VBN N
CRP NNP o
by IN N
0.60 CD N
mg/L NN N
. . N

F1+2 NNP o
increased VBD N
0.15 CD N
nmol/L NN N
after IN N
the DT N
combined JJ N
vaccination NN N
; : N
an DT N
increase NN N
in IN N
response NN o
to TO o
the DT o
influenza JJ o
vaccination NN o
was VBD N
not RB N
statistically RB N
significant JJ N
. . N

Our PRP$ N
findings NNS N
show VBP N
that IN N
the DT N
influenza JJ i
vaccine NN i
alone RB N
as RB N
well RB N
as IN N
the DT N
combination NN N
of IN N
the DT N
influenza NN i
and CC i
pneumococcal JJ i
vaccine NN i
increases VBZ N
CRP-levels NNP o
with IN N
a DT N
peak JJ N
2 CD N
days NNS N
after IN N
vaccination NN N
. . N

-DOCSTART- -19821888- O O

Comparison NNP N
of IN N
fluid NN N
types NNS N
for IN N
resuscitation NN N
after IN N
acute JJ o
blood NN o
loss NN o
in IN p
mallard NN p
ducks NNS p
( ( p
Anas NNP p
platyrhynchos NN p
) ) p
. . p

OBJECTIVE CC N
The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
the DT N
LD NNP N
( ( N
50 CD N
) ) N
for IN N
acute JJ p
blood NN p
loss NN p
in IN p
mallard NN p
ducks NNS p
( ( p
Anas NNP p
platyrhynchos NN p
) ) p
, , N
compare VBP N
the DT N
mortality NN N
rate NN N
among IN N
3 CD N
fluid JJ N
resuscitation NN N
groups NNS N
, , N
and CC N
determine VB N
the DT N
time NN N
required VBN N
for IN N
a DT N
regenerative JJ N
RBC NNP N
response NN N
. . N

DESIGN NNP N
Prospective NNP N
study NN N
. . N

SETTING NNP N
Medical NNP p
College NNP p
of IN p
Wisconsin NNP p
Research NNP p
facility NN p
. . p

ANIMALS NNP N
Eighteen NNP p
mallard NN p
ducks NNS p
were VBD N
included VBN N
for IN N
the DT N
LD NNP N
( ( N
50 CD N
) ) N
study NN N
and CC N
28 CD p
for IN N
the DT N
fluid NN i
resuscitation NN i
study NN N
. . N

INTERVENTIONS NNP N
Phlebotomy NNP i
was VBD N
performed VBN N
during IN N
both DT N
the DT N
LD NNP N
( ( N
50 CD N
) ) N
and CC N
fluid JJ i
resuscitation NN i
studies NNS N
. . N

Ducks NNS N
in IN N
the DT N
fluid NN N
resuscitation NN N
study NN N
received VBD N
a DT N
5 CD i
mL/kg NN i
intravenous JJ i
bolus NN i
of IN i
crystalloids NNS i
, , i
hetastarch NN i
( ( i
HES NNP i
) ) i
, , i
or CC i
a DT i
hemoglobin-based JJ i
oxygen-carrying JJ i
solution NN i
( ( i
HBOCS NNP i
) ) i
. . N

MEASUREMENTS NNP N
AND CC N
MAIN NNP N
RESULTS NNP N
The DT N
LD NNP N
( ( N
50 CD N
) ) N
for IN N
acute JJ o
blood NN o
loss NN o
was VBD N
60 CD N
% NN N
of IN N
total JJ o
blood NN o
volume NN o
. . o

This DT N
blood NN N
volume NN N
was VBD N
removed VBN N
in IN N
the DT N
fluid NN N
resuscitation NN N
study NN N
to TO N
create VB N
a DT N
model NN N
of IN N
acute JJ N
blood NN N
loss NN N
. . N

Following VBG N
fluid JJ N
administration NN N
, , N
6 CD N
birds NNS N
in IN N
the DT N
crystalloid NN N
group NN N
( ( N
66 CD N
% NN N
) ) N
, , N
4 CD N
birds NNS N
in IN N
the DT N
HES NNP N
group NN N
( ( N
40 CD N
% NN N
) ) N
, , N
and CC N
2 CD N
birds NNS N
in IN N
the DT N
HBOCS NNP N
group NN N
( ( N
20 CD N
% NN N
) ) N
died VBD N
. . N

No NNP N
statistical JJ N
difference NN N
in IN N
mortality NN o
rate NN o
was VBD N
seen VBN N
among IN N
the DT N
3 CD N
fluid NN N
resuscitation NN N
groups NNS N
. . N

Relative JJ N
polychromasia NN N
evaluated VBD N
post-phlebotomy JJ N
demonstrated JJ N
regeneration NN N
starting VBG N
at IN N
24 CD N
hours NNS N
and CC N
continuing VBG N
through IN N
48 CD N
hours NNS N
. . N

CONCLUSIONS VB N
The DT N
LD NNP N
( ( N
50 CD N
) ) N
for IN N
acute JJ o
blood NN o
loss NN o
in IN N
mallard NN p
ducks NNS p
was VBD N
60 CD N
% NN N
of IN N
their PRP$ N
total JJ N
blood NN N
volume NN N
. . N

Although IN N
no DT N
statistical JJ N
difference NN N
in IN N
mortality NN o
rate NN o
was VBD N
appreciated VBN N
among IN N
the DT N
3 CD N
fluid NN N
resuscitation NN N
groups NNS N
, , N
a DT N
trend NN N
of IN N
decreased JJ N
mortality NN o
rate NN o
was VBD N
observed VBN N
in IN N
the DT N
HBOCS NNP N
group NN N
. . N

An DT N
early JJ N
regenerative NN N
response NN N
was VBD N
apparent JJ N
following VBG N
acute JJ o
blood NN o
loss NN o
. . o

-DOCSTART- -1492408- O O

Effects NNS N
of IN N
a DT N
combination NN N
of IN N
evening VBG i
primrose JJ i
oil NN i
( ( i
gamma NN i
linolenic RB i
acid NN i
) ) i
and CC i
fish JJ i
oil NN i
( ( i
eicosapentaenoic JJ i
+ NNP i
docahexaenoic NN i
acid NN i
) ) i
versus NN i
magnesium NN i
, , i
and CC i
versus NN i
placebo NN i
in IN N
preventing VBG N
pre-eclampsia NN o
. . o

In IN N
a DT N
placebo NN i
controlled VBN N
, , N
partially RB N
double-blinded JJ N
, , N
clinical JJ N
trial NN N
, , N
a DT N
combination NN i
of IN i
evening VBG i
primrose JJ i
oil NN i
and CC i
fish JJ i
oil NN i
was VBD i
compared VBN i
to TO i
Magnesium NNP i
Oxide NNP i
, , i
and CC i
to TO i
a DT i
Placebo NNP i
in IN N
preventing VBG N
Pre-Eclampsia NNP o
of IN o
Pregnancy NNP o
. . o

All DT N
were VBD N
given VBN N
as IN N
nutritional JJ N
supplements NNS N
for IN N
six CD N
months NNS N
to TO N
a DT N
group NN p
of IN p
primiparous JJ p
and CC p
multiparous JJ p
pregnant JJ p
women NNS p
. . p

Some DT p
of IN p
these DT p
women NNS p
had VBD p
personal JJ p
or CC p
family NN p
histories NNS p
of IN p
hypertension NN p
( ( p
21 CD p
% NN p
) ) p
. . p

Only RB p
those DT p
patients NNS p
who WP p
received VBD p
prenatal JJ p
care NN p
at IN p
the DT p
Central NNP p
Maternity NNP p
Hospital NNP p
for IN p
Luanda NNP p
were VBD N
included VBN N
in IN N
the DT N
study NN N
. . N

Compared VBN N
to TO N
the DT N
Placebo NNP i
group NN N
( ( N
29 CD N
% NN N
) ) N
, , N
the DT N
group NN N
receiving VBG N
the DT N
mixture NN N
of IN N
evening VBG i
primrose JJ i
oil NN i
and CC N
fish JJ i
oil NN i
containing VBG N
Gamma-linolenic JJ i
acid NN i
( ( i
GLA NNP i
) ) i
, , i
Eicosapentaenoic NNP i
acid NN i
( ( i
EPA NNP i
) ) i
, , N
and CC N
Docosahexaenoic NNP i
acid NN i
( ( i
DHA NNP i
) ) i
had VBD N
a DT N
significantly RB N
lower JJR N
incidence NN o
of IN o
edema NN o
( ( N
13 CD N
% NN N
, , N
p NN N
= NNP N
0.004 CD N
) ) N
. . N

The DT N
group NN N
receiving VBG N
Magnesium NNP i
Oxide NNP i
had VBD N
statistically RB N
significant JJ N
fewer JJR N
subjects NNS N
who WP N
developed VBD N
hypertension NN o
of IN o
pregnancy NN o
. . o

There EX N
were VBD N
3 CD N
cases NNS N
of IN N
eclampsia NN o
, , N
all DT N
in IN N
the DT N
Placebo NNP i
group NN N
. . N

-DOCSTART- -25973096- O O

Comparison NNP N
of IN N
the DT N
neuroprotective JJ o
effects NNS o
and CC N
recovery NN o
profiles NNS o
of IN N
isoflurane NN i
, , i
sevoflurane NN i
and CC i
desflurane NN i
as IN N
neurosurgical JJ N
pre-conditioning NN N
on IN N
ischemia/reperfusion NN p
cerebral JJ p
injury NN p
. . p

BACKGROUND IN N
There EX N
are VBP N
a DT N
few JJ N
reports NNS N
regarding VBG N
the DT N
comparison NN N
of IN N
these DT N
anesthetic JJ N
agents NNS N
, , N
but CC N
previous JJ N
studies NNS N
mainly RB N
focus VBP N
on IN N
the DT N
veterinary JJ N
anesthesiology NN N
. . N

Less NNP N
attention NN N
has VBZ N
been VBN N
focused VBN N
comparing VBG N
the DT N
effectiveness NN N
of IN N
these DT N
inhalational JJ N
anesthetic JJ N
agents NNS N
in IN N
neurosurgery NN p
. . p

This DT N
lack NN N
of IN N
interest NN N
is VBZ N
regretful JJ N
particularly RB N
considering VBG N
the DT N
fact NN N
that IN N
anesthetics NNS N
during IN N
neurosurgery NN N
are VBP N
an DT N
issue NN N
of IN N
extreme JJ N
sensitivity NN N
and CC N
subtlety NN N
, , N
where WRB N
the DT N
cerebral JJ N
oxygenation NN N
process NN N
plays VBZ N
a DT N
significant JJ N
role NN N
in IN N
the DT N
neuroprotective JJ N
mechanisms NN N
. . N

OBJECTIVE CC N
The DT N
purpose NN N
of IN N
this DT N
retrospective JJ N
study NN N
is VBZ N
to TO N
contribute VB N
to TO N
the DT N
existing VBG N
knowledge NN N
of IN N
the DT N
comparative JJ N
studies NNS N
of IN N
the DT N
volatile JJ N
anesthetic JJ N
agents NNS N
such JJ N
as IN N
isoflurane NN i
, , i
sevoflurane NN i
and CC i
desflurane NN i
by IN N
evaluating VBG N
the DT N
maintenance NN N
and CC N
emergence NN N
characteristics NNS N
after IN N
volatile JJ N
anesthetics-induced JJ N
preconditioning NN N
with IN N
isoflurane NN i
, , i
sevoflurane NN i
or CC i
desflurane NN i
for IN N
inpatient JJ p
ischemia/reperfusion NN p
cerebral JJ p
injury NN p
during IN p
cerebral JJ p
or CC p
neural JJ p
surgeries NNS p
. . p

METHODS NNP N
The DT N
aim NN N
was VBD N
to TO N
investigate VB N
their PRP$ N
neuroprotective JJ N
mechanisms NNS N
and CC N
effects NNS o
by IN N
analyzing VBG N
and CC N
comparing VBG N
the DT N
superiority NN N
of IN N
each DT N
agent NN N
in IN N
a DT N
Chinese JJ p
patient NN p
population NN p
, , N
in IN N
terms NNS N
of IN N
faster NN N
emergence NN N
, , N
and CC N
early RB N
and CC N
intermediate JJ N
recovery NN N
. . N

The DT N
intraoperative JJ o
haemodynamic JJ o
profiles NNS o
and CC o
postoperative JJ o
adverse JJ o
effects NNS o
of IN N
these DT N
three CD N
agents NNS N
were VBD N
also RB N
systematically RB N
analyzed VBN N
. . N

RESULTS NNP N
We PRP N
found VBD N
that IN N
sevoflurane NN i
, , N
when WRB N
compared VBN N
with IN N
isoflurane NN i
and CC i
desflurane NN i
, , N
provided VBN N
anesthesia NN N
with IN N
similar JJ N
hemodynamic JJ N
stability NN N
but CC N
allowed VBN N
for IN N
a DT N
smoother NN N
, , N
more RBR N
rapid JJ N
emergence NN o
and CC N
better JJR N
quality NN o
of IN o
induction NN o
and CC o
recovery NN o
to TO N
surgical JJ p
patients NNS p
under IN p
clinical JJ p
conditions NNS p
, , N
particularly RB N
to TO N
those DT N
who WP N
were VBD N
experiencing VBG p
substantial JJ p
cerebral JJ p
vasodilation NN p
. . p

CONCLUSION NNP N
Sevoflurane NNP i
offers VBZ N
several JJ N
advantages NNS N
, , N
including VBG N
a DT N
relative JJ N
lack NN N
of IN N
airway JJ o
irritation NN o
, , N
a DT N
more RBR N
rapid JJ N
onset NN o
and CC o
recovery NN o
, , N
and CC N
greater JJR N
hemodynamic JJ o
stability NN o
than IN N
other JJ N
potent NN N
inhaled JJ N
agents NNS N
. . N

These DT N
properties NNS N
would MD N
appear VB N
to TO N
afford VB N
sevoflurane NN N
significant JJ N
clinical JJ N
potential NN N
. . N

-DOCSTART- -8333941- O O

Fusidic NNP N
acid VBZ N
prophylaxis NN N
before IN p
cataract JJ p
surgery NN p
: : p
patient JJ p
self-administration NN p
. . p

In IN N
a DT N
placebo-controlled JJ N
, , N
randomised JJ N
, , N
double-blind JJ N
clinical JJ N
trial NN N
, , N
the DT N
authors NNS N
evaluated VBD N
the DT N
efficacy NN N
of IN N
patient-administered JJ N
1 CD N
% NN N
fusidic JJ i
acid RB i
viscous JJ i
eye NN i
drops NNS i
in IN N
clearing VBG N
the DT N
commonest JJS N
organisms JJ N
causing VBG N
pseudophakic NN N
endophthalmitis NN N
( ( N
Staphylococcus NNP N
epidermidis RB N
and CC N
aureus RB N
) ) N
from IN N
the DT N
lids NNS N
and CC N
conjunctivae NN N
of IN N
79 CD p
patients NNS p
before IN p
cataract JJ p
surgery NN p
. . p

The DT N
treatment NN N
group NN N
self-administered JJ N
fusidic JJ i
acid NN i
viscous JJ N
eye NN N
drops VBZ N
four CD N
times NNS N
daily RB N
for IN N
seven CD N
days NNS N
before IN N
surgery NN N
; : N
the DT N
placebo NN N
group NN N
received VBD N
inert JJ i
ophthalmic JJ i
drops NNS i
. . i

Fellow NNP N
eyes NNS N
of IN N
both DT N
groups NNS N
remained VBD N
untreated JJ N
as IN N
a DT N
natural JJ N
control NN N
. . N

Lower JJR N
fornix NN N
and CC N
lid JJ N
margin NN N
cultures NNS N
were VBD N
taken VBN N
from IN N
both DT N
eyes NNS N
before IN N
and CC N
after IN N
treatment NN N
. . N

Before IN N
treatment NN N
, , N
there EX N
was VBD N
no DT N
statistical JJ N
difference NN N
in IN N
organism NN o
counts NNS o
between IN N
the DT N
groups NNS N
. . N

After IN N
treatment NN N
, , N
eyes NNS N
receiving VBG N
fusidic JJ i
acid NNS i
were VBD N
more RBR N
likely JJ N
to TO N
be VB N
free JJ N
of IN N
clinically RB N
relevant JJ N
Staphylococcus NNP N
spp NN N
. . N

than IN N
all DT N
pre-treatment JJ N
eyes NNS N
( ( N
for IN N
lids NNS N
, , N
P NNP N
< NNP N
0.001 CD N
; : N
conjunctivae NN N
, , N
P NNP N
= NNP N
0.02 CD N
) ) N
. . N

A DT N
highly RB N
significant JJ N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
number NN o
of IN o
lid JJ o
margins NNS o
were VBD N
rendered VBN N
'clinically RB N
clean JJ N
' '' N
( ( N
i.e. FW N
, , N
0-49 JJ N
organisms/swab NN N
) ) N
by IN N
fusidic JJ N
acid NN N
when WRB N
compared VBN N
with IN N
untreated JJ N
eyes NNS N
. . N

Treatment NNP N
also RB N
effectively RB N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
reduced VBD N
the DT N
numbers NNS o
of IN o
bacteria NNS o
isolated VBN o
from IN o
conjunctivae NN o
. . o

This DT N
study NN N
indicates VBZ N
that IN N
there EX N
is VBZ N
a DT N
highly RB N
significant JJ N
reduction NN N
of IN N
Staphylococcus NNP N
spp NN N
. . N

( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
non-Staphylococcus JJ N
spp NN N
. . N

( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
and CC N
attainment NN N
of IN N
sterile JJ N
eyes NNS N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
at IN N
operation NN N
gained VBN N
by IN N
patient JJ N
self-administration NN N
of IN N
1 CD N
% NN N
fusidic JJ N
acid RB N
four CD N
times NNS N
daily RB N
for IN N
seven CD N
days NNS N
before IN N
surgery NN N
. . N

-DOCSTART- -26388532- O O

Skin NNP N
antisepsis NN N
with IN N
chlorhexidine-alcohol JJ i
versus NN i
povidone NN i
iodine-alcohol NN i
, , N
with IN N
and CC N
without IN N
skin JJ N
scrubbing NN N
, , N
for IN N
prevention NN N
of IN N
intravascular-catheter-related JJ p
infection NN p
( ( N
CLEAN NNP N
) ) N
: : N
an DT N
open-label JJ N
, , N
multicentre NN N
, , N
randomised VBN N
, , N
controlled VBN N
, , N
two-by-two JJ N
factorial JJ N
trial NN N
. . N

BACKGROUND NNP N
Intravascular-catheter-related JJ N
infections NNS N
are VBP N
frequent JJ N
life-threatening JJ N
events NNS N
in IN N
health NN N
care NN N
, , N
but CC N
incidence NN N
can MD N
be VB N
decreased VBN N
by IN N
improvements NNS N
in IN N
the DT N
quality NN N
of IN N
care NN N
. . N

Optimisation NN N
of IN N
skin JJ N
antisepsis NN N
is VBZ N
essential JJ N
to TO N
prevent VB N
short-term JJ N
catheter-related JJ N
infections NNS N
. . N

We PRP N
hypothesised VBD N
that IN N
chlorhexidine-alcohol NN i
would MD N
be VB N
more RBR N
effective JJ N
than IN N
povidone RB i
iodine-alcohol NN i
as IN N
a DT N
skin JJ N
antiseptic NN N
to TO N
prevent VB N
intravascular-catheter-related JJ N
infections NNS N
. . N

METHODS NNP N
In IN N
this DT N
open-label JJ N
, , N
randomised VBD N
controlled VBN N
trial NN N
with IN N
a DT N
two-by-two JJ N
factorial JJ N
design NN N
, , N
we PRP N
enrolled VBD N
consecutive JJ p
adults NNS p
( ( p
age NN p
?18 CD p
years NNS p
) ) p
admitted VBD p
to TO p
one CD p
of IN p
11 CD p
French JJ p
intensive-care JJ p
units NNS p
and CC p
requiring VBG p
at IN p
least JJS p
one CD p
of IN p
central-venous JJ p
, , p
haemodialysis NN p
, , p
or CC p
arterial JJ p
catheters NNS i
. . i

Before IN i
catheter JJ i
insertion NN i
, , i
we PRP i
randomly VBP i
assigned VBN i
( ( i
1:1:1:1 CD i
) ) i
patients NNS i
via IN i
a DT i
secure JJ i
web-based JJ i
random-number JJ i
generator NN i
( ( i
permuted JJ i
blocks NNS i
of IN i
eight CD i
, , i
stratified VBN i
by IN i
centre NN i
) ) i
to TO i
have VB i
all DT i
intravascular JJ i
catheters NNS i
prepared VBD i
with IN i
2 CD i
% NN i
chlorhexidine-70 JJ i
% NN i
isopropyl NN i
alcohol NN i
( ( i
chlorhexidine-alcohol NN i
) ) i
or CC i
5 CD i
% NN i
povidone JJ i
iodine-69 JJ i
% NN i
ethanol NN i
( ( i
povidone JJ i
iodine-alcohol NN i
) ) i
, , i
with IN i
or CC i
without IN i
scrubbing VBG i
of IN i
the DT i
skin NN i
with IN i
detergent NN i
before IN i
antiseptic JJ i
application NN i
. . i

Physicians NNPS N
and CC N
nurses NNS N
were VBD N
not RB N
masked VBN N
to TO N
group NN N
assignment NN N
but CC N
microbiologists NNS N
and CC N
outcome JJ N
assessors NNS N
were VBD N
. . N

The DT N
primary JJ N
outcome NN N
was VBD N
the DT o
incidence NN o
of IN o
catheter-related JJ o
infections NNS o
with IN o
chlorhexidine-alcohol JJ i
versus NN i
povidone NN i
iodine-alcohol NN i
in IN i
the DT N
intention-to-treat JJ N
population NN N
. . N

This DT N
study NN N
is VBZ N
registered VBN N
with IN N
ClinicalTrials.gov NNP N
, , N
number NN N
NCT01629550 NNP N
and CC N
is VBZ N
closed VBN N
to TO N
new JJ N
participants NNS N
. . N

FINDINGS NNP p
Between NNP p
Oct NNP p
26 CD p
, , p
2012 CD p
, , p
and CC p
Feb NNP p
12 CD p
, , p
2014 CD p
, , p
2546 CD p
patients NNS p
were VBD p
eligible JJ p
to TO p
participate VB p
in IN p
the DT p
study NN p
. . p

We PRP N
randomly RB N
assigned VBD p
1181 CD p
patients NNS p
( ( p
2547 CD p
catheters NNS p
) ) p
to TO p
chlorhexidine-alcohol NN i
( ( i
594 CD N
patients NNS N
with IN N
scrubbing NN N
, , N
587 CD N
without IN N
) ) N
and CC N
1168 CD N
( ( N
2612 CD N
catheters NNS N
) ) N
to TO N
povidone VB i
iodine-alcohol NN i
( ( i
580 CD N
patients NNS N
with IN N
scrubbing NN N
, , N
588 CD N
without IN i
) ) i
. . i

Chlorhexidine-alcohol NN i
was VBD i
associated VBN N
with IN N
lower JJR o
incidence NN o
of IN o
catheter-related JJ o
infections NNS o
( ( o
0?28 CD N
vs RB N
1?77 CD N
per IN N
1000 CD N
catheter-days NNS N
with IN N
povidone JJ i
iodine-alcohol NN i
; : i
hazard CC i
ratio VB N
0?15 CD N
, , N
95 CD N
% NN N
CI NNP N
0?05-0?41 CD N
; : N
p=0?0002 NN N
) ) N
. . N

Scrubbing VBG N
was VBD N
not RB N
associated VBN N
with IN N
a DT N
significant JJ N
difference NN N
in IN N
catheter NN N
colonisation NN N
( ( N
p=0?3877 NN o
) ) o
. . o

No UH o
systemic JJ o
adverse JJ o
events NNS o
were VBD o
reported VBN N
, , N
but CC o
severe JJ o
skin NN o
reactions NNS o
occurred VBD o
more RBR N
frequently RB N
in IN N
those DT N
assigned VBN N
to TO i
chlorhexidine-alcohol NN i
( ( i
27 CD i
[ RB i
3 CD i
% NN i
] JJ i
patients NNS N
vs JJ N
seven CD N
[ $ N
1 CD N
% NN N
] NN N
with IN N
povidone JJ i
iodine-alcohol NN i
; : i
p=0?0017 CC i
) ) N
and CC N
led VBN N
to TO N
chlorhexidine VB N
discontinuation NN N
in IN N
two CD N
patients NNS N
. . N

INTERPRETATION NNP N
For IN N
skin JJ N
antisepsis NN N
, , o
chlorhexidine-alcohol NN o
provides VBZ i
greater JJR N
protection NN N
against IN N
short-term JJ N
catheter-related JJ N
infections NNS N
than IN N
does VBZ N
povidone VB i
iodine-alcohol NN i
and CC i
should MD i
be VB N
included VBN N
in IN N
all DT N
bundles NNS N
for IN N
prevention NN N
of IN N
intravascular JJ o
catheter-related JJ o
infections NNS o
. . o

FUNDING NN o
University NNP N
Hospital NNP N
of IN N
Poitiers NNP N
, , N
CareFusion NNP N
. . N

-DOCSTART- -2494948- O O

[ JJ i
Mitomycin NNP i
C NNP i
plus CC i
HCFU NNP i
adjuvant VBP N
chemotherapy NN N
for IN N
noncuratively RB N
resected VBN N
cases NNS N
of IN N
colorectal JJ N
carcinoma NN N
. . N

( ( N
Second JJ N
report NN N
) ) N
: : N
5-year JJ N
survival NN N
rate NN N
. . N

Cooperative NNP N
Study NNP N
Group NNP N
of IN N
Kyushu NNP N
and CC N
Chugoku NNP N
for IN N
HCFU NNP N
Adjuvant NNP N
Chemotherapy NNP N
] NNP N
. . N

In IN N
order NN N
to TO N
examine VB N
the DT N
efficacy NN N
of IN N
adjuvant JJ i
chemotherapy NN i
employing VBG N
mitomycin JJ i
C NNP i
( ( i
MMC NNP i
) ) i
and CC i
carmofur NN i
( ( i
HCFU NNP i
) ) i
for IN p
patients NNS p
with IN p
noncuratively RB p
resected VBN p
colorectal JJ p
carcinoma NN p
, , N
a DT N
cooperative JJ N
study NN N
was VBD N
performed VBN N
by IN N
54 CD p
institutions NNS p
in IN p
the DT p
Kyushu NNP p
and CC p
Chugoku NNP p
areas NNS p
of IN p
Japan NNP p
. . p

The DT p
criteria NNS p
for IN p
patient JJ p
selection NN p
were VBD p
as IN p
follows VBZ p
: : p
1 CD p
) ) p
Age NNP p
of IN p
75 CD p
years NNS p
or CC p
less JJR p
and CC p
not RB p
accompanied VBN p
by IN p
any DT p
serious JJ p
disease NN p
. . p

2 CD p
) ) p
Macroscopic NNP p
diagnosis NN p
as IN p
being VBG p
noncuratively RB p
resected VBN p
on IN p
completion NN p
of IN p
the DT p
surgical JJ p
procedure NN p
. . p

3 CD p
) ) p
Definitive JJ p
diagnosis NN p
of IN p
colorectal JJ p
carcinomas NN p
, , p
histologically RB p
. . p

4 CD p
) ) p
No DT p
synchronous JJ p
or CC p
metachronous JJ p
double JJ p
cancer NN p
. . p

The DT N
prospective JJ N
randomized NN N
controlled VBD N
study NN N
consisted VBN N
of IN N
two CD N
groups NNS N
. . N

In IN N
Group NNP N
A NNP N
, , N
the DT N
MMC NNP i
group NN p
received VBD N
bolus RB N
intravenous JJ N
injections NNS N
of IN N
20 CD N
mg NNS N
MMC NNP i
on IN N
the DT N
day NN N
of IN N
operation NN N
and CC N
10 CD N
mg NN N
the DT N
next JJ N
day NN N
, , N
followed VBN N
by IN N
10 CD N
mg NNS N
every DT N
4 CD N
weeks NNS N
until IN N
a DT N
total NN N
of IN N
100 CD N
mg NNS N
had VBD N
been VBN N
administered VBN N
. . N

In IN N
Group NNP N
B NNP N
, , N
the DT N
MMC NNP i
+ NNP i
HCFU NNP i
group NN i
received VBD N
the DT N
same JJ N
treatment NN N
in IN N
Group NNP N
A NNP N
, , N
but CC N
with IN N
the DT N
addition NN N
of IN N
600 CD N
mg/day NN N
of IN N
HCFU NNP i
from IN N
the DT N
second JJ N
week NN N
, , N
orally RB N
for IN N
at IN N
least JJS N
one CD N
year NN N
. . N

Concerning VBG N
the DT N
69-month JJ o
survival NN o
rate NN o
, , N
a DT N
better JJR N
result NN N
was VBD N
observed VBN N
in IN N
the DT N
MMC NNP i
+ NNP i
HCFU NNP i
group NN N
than IN N
in IN N
the DT N
MMC NNP i
only RB i
group NN N
( ( N
generalized VBN N
Wilcoxon NNP N
test NN N
: : N
p NN N
less JJR N
than IN N
0.05 CD N
) ) N
. . N

Significantly RB N
better JJR N
survival NN o
rates NNS o
were VBD N
obtained VBN N
in IN N
those DT N
cases NNS N
with IN N
disseminating VBG N
peritoneal JJ N
metastasis NN N
, , N
hepatic JJ N
metastasis NN N
and CC N
stage NN N
V NNP N
cancer NN N
in IN N
the DT N
MMC NNP i
+ NNP i
HCFU NNP i
group NN N
as IN N
when WRB N
compared VBN N
with IN N
the DT N
MMC NNP i
only RB N
group NN N
. . N

No DT o
significant JJ o
side NN o
effects NNS o
due JJ N
to TO N
the DT N
combined JJ N
administration NN N
of IN N
HCFU NNP i
were VBD N
recognized VBN N
. . N

The DT N
combined JJ N
administration NN N
of IN N
MMC NNP i
and CC N
HCFU NNP i
was VBD N
suggested VBN N
to TO N
be VB N
a DT N
safe JJ N
and CC N
effective JJ N
adjuvant NN N
chemotherapy NN N
for IN N
noncuratively RB N
resected VBN N
cases NNS N
of IN N
colorectal JJ N
carcinoma NN N
. . N

-DOCSTART- -19111789- O O

Financial JJ i
and CC i
quality-of-life JJ i
burden NN i
of IN N
dysfunctional JJ p
uterine JJ p
bleeding NN p
among IN p
women NNS p
agreeing VBG p
to TO p
obtain VB p
surgical JJ p
treatment NN p
. . p

PURPOSE NN N
In IN N
this DT N
study NN N
, , N
we PRP N
sought VBD N
to TO N
1 CD N
) ) N
describe NN N
elements NNS N
of IN N
the DT N
financial JJ i
and CC i
quality-of-life JJ i
burden NN i
of IN N
dysfunctional JJ p
uterine JJ p
bleeding NN p
( ( p
DUB NNP p
) ) p
from IN N
the DT N
perspective NN N
of IN p
women NNS p
who WP p
agreed VBD p
to TO p
obtain VB p
surgical JJ p
treatment NN p
; : p
2 CD N
) ) N
explore NN N
associations NNS N
between IN N
DUB NNP N
symptom NN N
characteristics NNS N
and CC N
the DT N
financial JJ i
and CC i
quality-of-life JJ i
burden NN i
; : i
3 CD N
) ) N
estimate VBP N
the DT N
annual JJ N
dollar NN N
value NN N
of IN N
the DT N
financial JJ N
burden NN N
; : N
and CC N
4 CD N
) ) N
estimate VBP N
the DT N
most RBS N
that DT N
could MD N
be VB N
spent VBN N
on IN N
surgery NN N
to TO N
eliminate VB N
DUB NNP N
symptoms NNS N
for IN N
which WDT N
medical JJ N
treatment NN N
has VBZ N
been VBN N
unsuccessful JJ N
that WDT N
would MD N
result VB N
in IN N
a DT N
$ $ N
50,000/quality-adjusted JJ N
life-year JJ N
incremental JJ N
cost-effectiveness NN N
ratio NN N
. . N

METHODS NNP N
We PRP p
collected VBD p
baseline NN i
data NNS i
on IN i
DUB NNP i
symptoms NNS i
and CC i
aspects NNS i
of IN i
the DT i
financial JJ i
and CC i
quality-of-life JJ i
burden NN i
for IN p
237 CD p
women NNS p
agreeing VBG p
to TO p
surgery VB p
for IN p
DUB NNP p
in IN p
a DT p
randomized JJ p
trial NN p
comparing VBG p
hysterectomy NN p
with IN p
endometrial JJ p
ablation NN p
. . p

Measures NNS N
included VBD N
out-of-pocket JJ o
pharmaceutical JJ o
expenditures NNS o
, , o
excess JJ o
expenditures NNS o
on IN o
pads NNS o
or CC o
tampons NNS o
, , o
the DT o
value NN o
of IN o
time NN o
missed VBN o
from IN o
paid VBN o
work NN o
and CC o
home NN o
management NN o
activities NNS o
, , o
and CC o
health NN o
utility NN o
. . o

We PRP N
used VBD N
chi2 NN N
and CC N
t NN N
tests NNS N
to TO N
assess VB N
the DT N
statistical JJ N
significance NN N
of IN N
associations NNS N
between IN N
DUB NNP N
characteristics NNS N
and CC N
the DT N
financial JJ i
and CC i
quality-of-life JJ i
burden NN i
. . i

The DT N
annual JJ N
financial JJ N
burden NN N
was VBD N
estimated VBN N
. . N

RESULTS NNP N
Pelvic NNP o
pain NN o
and CC o
cramps NNS o
were VBD o
associated VBN o
with IN o
activity NN o
limitations NNS o
and CC N
tiredness NN o
was VBD o
associated VBN o
with IN o
a DT o
lower JJR o
health NN o
utility NN o
. . o

Excess NNP o
pharmaceutical JJ o
and CC o
pad NN o
and CC o
tampon NN o
costs NNS o
were VBD N
$ $ N
333 CD N
per IN N
patient NN N
per IN N
year NN N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NNP N
, , N
$ $ N
263- JJ N
$ $ N
403 CD N
) ) N
. . N

Excess NNP N
paid VBD o
work NN o
and CC o
home NN o
management NN o
loss NN o
costs NNS o
were VBD N
$ $ N
2,291 CD N
per IN N
patient NN N
per IN N
year NN N
( ( N
95 CD N
% NN N
CI NNP N
, , N
$ $ N
1847- JJ N
$ $ N
2752 CD N
) ) N
. . N

Effective JJ o
surgical JJ o
treatment NN o
costing VBG N
$ $ N
40,000 CD N
would MD N
be VB N
cost-effective JJ o
compared VBN N
with IN N
unsuccessful JJ N
medical JJ N
treatment NN N
. . N

CONCLUSION NNP N
The DT N
financial JJ i
and CC i
quality-of-life JJ i
effects NNS i
of IN N
DUB NNP N
represent VBP N
a DT N
substantial JJ N
burden NN N
. . N

-DOCSTART- -2285871- O O

[ NN N
Does NNP N
urapidil VB i
attenuate VB N
the DT N
hypertensive JJ o
response NN o
to TO o
tracheal VB o
intubation NN o
at IN p
the DT p
time NN p
of IN p
general JJ p
anesthesia NN p
? . N
] NN N
. . N

-DOCSTART- -10902449- O O

[ RB N
Comparative NNP N
study NN N
between IN N
5 CD i
% NN i
prilocaine NN i
and CC N
2 CD i
% NN i
mepivacaine NN i
by IN N
the DT N
subarachnoid JJ N
route NN N
in IN N
transurethral JJ p
resections NNS p
] VBP p
. . N

OBJECTIVE NNP N
To TO N
compare VB N
the DT N
duration NN o
of IN N
spinal JJ N
block NN N
with IN N
5 CD i
% NN i
prilocaine NN i
and CC i
2 CD i
% NN i
mepivacaine NN i
in IN N
short JJ p
procedures NNS p
for IN p
transurethral JJ p
resection NN p
and CC N
to TO N
assess VB o
possible JJ o
complications NNS o
in IN N
the DT N
immediate JJ N
postoperative JJ N
period NN N
. . N

MATERIAL NNP N
AND NNP N
METHODS NNP N
Fifty-seven NNP p
patients NNS p
scheduled VBN p
for IN p
transurethral JJ p
resection NN p
of IN p
the DT p
prostate NN p
or CC p
a DT p
vesical JJ p
tumor NN p
. . p

Patients NNS p
were VBD p
ASA NNP p
I-III NNP p
, , p
over IN p
55 CD p
years NNS p
of IN p
age NN p
and CC N
randomly RB N
assigned VBN N
to TO N
two CD i
groups NNS i
to TO i
receive VB i
5 CD i
% NN i
prilocaine NN i
( ( i
1 CD i
mg/kg NN i
, , i
n JJ i
= NNP i
27 CD i
) ) i
or CC i
2 CD i
% NN i
mepivacaine NN i
( ( i
0.8 CD i
mg/kg NN i
, , i
n JJ i
= NNP i
30 CD i
) ) i
. . N

We PRP i
collected VBD i
data NNS i
on IN i
anesthetic JJ o
technique NN o
, , o
levels NNS o
of IN o
extension NN o
of IN o
motor NN o
and CC o
sensory JJ o
blockades NNS o
, , o
duration NN o
of IN o
blockades NNS o
and CC o
complications NNS o
within IN o
the DT o
first JJ o
24 CD o
hours NNS o
after IN i
surgery NN i
. . i

RESULTS NNP N
Demographic NNP N
data NNS N
, , N
ASA NNP N
classification NN N
and CC N
duration NN N
of IN N
surgery NN N
were VBD N
similar JJ N
in IN N
both DT N
groups NNS N
. . N

We PRP N
found VBD N
statistically RB N
significant JJ N
differences NNS N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
in IN N
duration NN o
of IN o
sensory JJ o
blockade NN o
( ( N
120.92 CD N
+/- JJ N
36.21 CD N
min NN N
with IN N
prilocaine NN i
and CC N
145.83 CD N
+/- JJ N
35.81 CD N
min NN N
with IN N
mepivacaine NN i
) ) i
and CC N
in IN N
motor NN o
blockade NN o
( ( N
106.29 CD N
+/- JJ N
38.16 CD N
min NN N
with IN N
prilocaine NN N
and CC N
133.16 CD N
+/- JJ N
42.21 CD N
min NN N
with IN N
mepivacaine NN N
) ) N
. . N

Five JJ N
cases NNS N
of IN N
hypotension NN o
and CC N
4 CD N
of IN N
bradycardia NN o
occurred VBN N
in IN N
each DT N
group NN N
and CC N
one CD N
patient NN N
in IN N
the DT N
mepivacaine NN N
group NN N
suffered VBD N
slight JJ N
postoperative JJ N
cephalea NN N
. . N

CONCLUSIONS NNP N
Both NNP N
local JJ N
anesthetics NNS N
offer VBP N
good JJ N
surgical JJ o
conditions NNS o
with IN N
hemodynamic JJ N
stability NN N
and CC N
few JJ N
complications NNS o
. . o

The DT N
duration NN N
of IN N
sensory NN o
and CC o
motor NN o
blockade NN o
is VBZ N
shorter JJR N
with IN N
prilocaine NN N
than IN N
with IN N
mepivacaine NN N
, , N
making VBG N
prilocaine NN N
more JJR N
appropriate JJ N
for IN N
short JJ N
interventions NNS N
. . N

-DOCSTART- -18795522- O O

Influence NN N
of IN N
occlusal JJ N
access NN N
on IN N
demineralized JJ o
dentin NN o
removal NN o
in IN N
the DT N
atraumatic JJ i
restorative JJ i
treatment NN i
( ( i
ART NNP i
) ) i
approach NN N
. . N

PURPOSE NNP N
To TO N
verify VB N
the DT N
influence NN N
of IN N
cavity NN N
access NN N
diameter NN N
on IN N
demineralized JJ o
dentin NN o
removal NN o
in IN N
the DT N
ART NNP i
approach NN N
. . N

METHODS $ N
40 CD p
non-carious JJ p
human JJ p
premolars NNS p
were VBD N
randomly RB N
divided VBN N
into IN N
four CD N
groups NNS N
. . N

The DT N
occlusal JJ N
surface NN N
was VBD N
ground NN N
flat JJ N
and CC N
the DT N
teeth NNS N
were VBD N
sectioned VBN N
mesio-distally RB N
. . N

The DT N
hemi-sections NNS N
were VBD N
reassembled VBN N
and CC N
occlusal JJ N
access NN N
preparations NNS N
were VBD N
carried VBN N
out RP N
using VBG N
ball-shaped JJ N
diamonds NNS N
. . N

The DT N
resulting VBG N
size NN N
of IN N
the DT N
occlusal NN N
opening NN N
was VBD N
1.0 CD N
mm NN N
, , N
1.4 CD N
mm NN N
, , N
1.6 CD N
mm NN N
and CC N
1.8 CD N
mm NN N
for IN N
Groups NNP N
A NNP N
, , N
B NNP N
, , N
C NNP N
, , N
and CC N
D NNP N
, , N
respectively RB N
. . N

Standardized VBN N
artificial JJ N
carious JJ N
lesions NNS N
were VBD N
created VBN N
and CC N
demineralized VBN N
dentin NN N
was VBD N
excavated VBN i
. . i

After IN N
excavation NN N
, , N
the DT N
cavities NNS N
were VBD N
analyzed VBN N
using VBG N
: : N
( ( N
a DT N
) ) N
the DT o
tactile NN o
method NN o
, , N
( ( N
b NN N
) ) N
caries-detection NN o
dye NN o
to TO o
stain VB o
demineralized JJ o
dentin NN o
, , N
as IN N
proposed VBN N
by IN N
Smales NNP N
& CC N
Fang NNP N
, , N
and CC N
( ( N
c NN N
) ) N
Demineralized NNP o
Tissue NNP o
Removal NNP o
index NN o
, , N
as IN N
proposed VBN N
in IN N
this DT N
study NN N
. . N

Statistical JJ N
analysis NN N
was VBD N
performed VBN N
using VBG N
Fisher NNP N
, , N
Spearman NNP N
correlation NN N
coefficient NN N
, , N
kappa NN N
, , N
Kruskal-Wallis NNP N
and CC N
Miller NNP N
tests NNS N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

RESULTS VB N
The DT N
three CD N
methods NNS N
of IN N
evaluation NN N
showed VBD N
no DT N
significant JJ N
difference NN N
between IN N
Groups NNP N
A NNP N
vs. NN N
B NNP N
, , N
and CC N
C NNP N
vs. FW N
D NNP N
, , N
while IN N
statistically RB N
significant JJ N
differences NNS N
were VBD N
observed VBN N
between IN N
Groups NNP N
A NNP N
vs. FW N
C NNP N
, , N
A NNP N
vs. NN N
D NNP N
, , N
B NNP N
vs. FW N
C NNP N
and CC N
B NNP N
vs. FW N
D. NNP N
Based VBD N
on IN N
the DT N
results NNS N
of IN N
this DT N
study NN N
, , N
the DT N
size NN N
of IN N
occlusal JJ N
access NN N
significantly RB N
affected VBD N
the DT N
efficacy NN o
of IN N
demineralized JJ o
tissue NN o
removal NN o
. . o

-DOCSTART- -3174738- O O

Mecamylamine NNP i
reduces VBZ N
some DT N
EEG NNP o
effects NNS o
of IN N
nicotine JJ p
chewing VBG p
gum NN p
in IN p
humans NNS p
. . p

Spontaneous JJ o
EEG NNP o
was VBD N
recorded VBN N
in IN N
nine CD p
cigarette NN p
smokers NNS p
who WP p
had VBD p
been VBN p
abstinent JJ p
from IN p
tobacco NN p
for IN p
12 CD p
hr NN p
. . p

Subjects NNS N
were VBD N
treated VBN N
with IN N
a DT N
capsule NN N
containing VBG N
either CC N
centrally RB i
acting VBG i
nicotine NN i
blocker NN i
, , i
mecamylamine NN i
( ( N
10 CD N
mg NN N
) ) N
, , N
or CC i
placebo NN i
. . i

At IN N
each DT N
of IN N
three CD N
60-min JJ N
intervals NNS N
after IN N
the DT N
capsule NN N
was VBD N
ingested VBN N
, , N
the DT N
subjects NNS N
chewed VBD N
two CD N
pieces NNS N
of IN N
gum NN N
containing VBG N
a DT N
total NN N
of IN N
0 CD N
, , N
4 CD N
or CC N
8 CD N
mg NN N
of IN N
nicotine NN N
. . N

Nicotine NNP i
and CC i
mecamylamine NN i
dose JJ N
combinations NNS N
were VBD N
randomized VBN N
across IN N
subjects NNS N
. . N

Two CD N
three-minute JJ N
periods NNS N
of IN N
spontaneous JJ o
EEG NNP o
were VBD N
recorded VBN N
before IN N
the DT N
capsule NN N
and CC N
before IN N
and CC N
after IN N
gum JJ N
chewing VBG N
from IN N
bipolar JJ N
electrode NN N
montages NNS N
at IN N
the DT N
following JJ N
positions NNS N
: : N
Cz-T5 JJ N
, , N
Cz-T6 NNP N
, , N
Cz-F7 NNP N
and CC N
Cz-F8 NNP N
. . N

During IN N
one CD N
period NN N
the DT N
subjects NNS N
relaxed VBN N
with IN N
eyes NNS N
closed VBD N
, , N
in IN N
the DT N
other JJ N
period NN N
they PRP N
performed VBD N
a DT N
math NN N
task NN N
with IN N
eyes NNS N
open JJ N
. . N

When WRB N
the DT N
drugs NNS N
were VBD N
given VBN N
individually RB N
, , N
mecamylamine NN i
decreased VBD N
beta JJ o
power NN o
and CC N
nicotine JJ N
gum NN N
( ( N
4 CD N
and CC N
8 CD N
mg NN N
) ) N
increased VBD N
alpha JJ o
frequency NN o
. . o

Mecamylamine NNP i
pretreatment NN N
prevented VBD N
the DT N
increase NN N
in IN N
alpha JJ o
frequency NN o
caused VBN N
by IN N
the DT N
4 CD N
mg NN N
gum NN N
dose NN N
but CC N
not RB N
the DT N
8 CD N
mg NN N
dose NN N
. . N

Alpha NNP o
power NN o
was VBD N
increased VBN N
by IN N
the DT N
8 CD N
mg NN N
gum NN N
dose NN N
and CC N
that IN N
increase NN N
was VBD N
prevented VBN N
by IN N
mecamylamine NN i
. . i

Self-reported JJ o
ratings NNS o
of IN N
the DT N
strength NN o
of IN N
the DT N
gum NN N
were VBD N
significantly RB N
diminished VBN N
by IN N
mecamylamine JJ N
pretreatment NN N
. . N

The DT N
data NNS N
are VBP N
consistent JJ N
with IN N
the DT N
results NNS N
of IN N
earlier JJR N
studies NNS N
which WDT N
indicate VBP N
that IN N
the DT N
effects NNS N
of IN N
tobacco NN N
administration NN N
and CC N
withdrawal NN N
are VBP N
mediated VBN N
by IN N
central JJ N
actions NNS N
of IN N
nicotine NN N
. . N

-DOCSTART- -8550361- O O

Long-term JJ N
efficacy NN N
of IN N
subcutaneous JJ i
sumatriptan NNS i
using VBG N
a DT N
novel JJ N
self-injector NN N
. . N

An DT N
open JJ N
, , N
multicenter NN N
study NN N
investigated VBD N
the DT N
long-term JJ N
efficacy NN N
, , N
tolerability NN N
, , N
and CC N
acceptability NN N
to TO N
patients NNS N
of IN N
subcutaneous JJ N
sumatriptan JJ i
6 CD N
mg NN N
, , N
administered VBN N
using VBG N
a DT N
novel NN N
cartridge NN N
system NN N
self-injector NN N
, , N
for IN p
the DT p
acute JJ p
treatment NN p
of IN p
migraine NN p
. . p

Eighty NNP p
patients NNS p
treated VBD p
all DT p
migraine NN p
attacks NNS p
for IN p
6 CD p
months NNS p
at IN p
home NN p
with IN p
a DT p
subcutaneous JJ p
injection NN i
of IN i
sumatriptan JJ i
6 CD i
mg. NN i
A NNP N
second JJ N
injection NN N
could MD N
be VB N
taken VBN N
after IN N
1 CD N
to TO N
24 CD N
hours NNS N
if IN N
relief NN N
was VBD N
inadequate JJ N
, , N
or CC N
if IN N
the DT N
headache NN o
recurred VBD N
, , N
and CC N
rescue NN N
medication NN N
could MD N
be VB N
taken VBN N
1 CD N
hour NN N
after IN N
the DT N
second JJ N
injection NN N
. . N

The DT N
primary JJ N
end NN N
point NN N
was VBD N
the DT N
percentage NN N
of IN N
attacks NNS N
in IN N
which WDT N
headache NN N
improved VBD N
from IN N
severe JJ N
or CC N
moderate JJ N
before IN N
treatment NN N
to TO N
mild VB N
or CC N
absent VB N
at IN N
1 CD N
hour NN N
after IN N
the DT N
first JJ N
injection NN N
. . N

A DT N
total NN N
of IN N
1566 CD p
attacks NNS p
were VBD p
treated VBN p
by IN p
the DT p
80 CD p
patients NNS p
and CC p
69 CD p
patients NNS p
completed VBD p
6 CD p
months NNS p
of IN p
treatment NN p
. . p

Headache NNP o
relief NN o
was VBD N
reported VBN N
1 CD N
hour NN N
after IN N
the DT N
first JJ N
injection NN N
in IN N
a DT N
mean NN N
of IN N
78 CD N
% NN N
of IN N
attacks NNS N
( ( N
83 CD N
% NN N
in IN N
the DT N
first JJ N
3 CD N
months NNS N
and CC N
76 CD N
% NN N
in IN N
the DT N
second JJ N
3 CD N
months NNS N
) ) N
. . N

A DT N
second JJ N
injection NN N
was VBD N
required VBN N
in IN N
a DT N
mean NN N
of IN N
40 CD N
% NN N
of IN N
attacks NNS N
, , N
and CC N
headache NN o
was VBD N
mild JJ N
or CC N
absent JJ N
1 CD N
hour NN N
after IN N
the DT N
second JJ N
injection NN N
in IN N
a DT N
mean NN N
of IN N
77 CD N
% NN N
of IN N
attacks NNS N
. . N

Rescue NNP o
medication NN o
was VBD N
required VBN N
after IN N
the DT N
second JJ N
injection NN N
in IN N
a DT N
mean NN N
of IN N
14 CD N
% NN N
of IN N
attacks NNS N
. . N

At IN N
the DT N
end NN N
of IN N
the DT N
study NN N
, , N
87 CD N
% NN N
of IN N
patients NNS N
said VBD N
that IN N
they PRP N
would MD N
take VB N
the DT N
medication NN N
again RB N
, , N
and CC N
at IN N
each DT N
clinic JJ N
visit NN N
over IN N
80 CD N
% NN N
said VBD N
that IN N
they PRP N
found VBD N
the DT N
injector NN N
easy NN N
to TO N
use VB N
. . N

Adverse JJ N
events NNS N
were VBD N
similar JJ N
to TO N
those DT N
reported VBN N
previously RB N
with IN N
sumatriptan NNS i
and CC N
were VBD N
mostly RB N
mild JJ N
to TO N
moderate VB N
in IN N
intensity NN N
, , N
short-lived JJ N
, , N
and CC N
resolved VBD N
spontaneously RB N
. . N

Subcutaneous JJ N
sumatriptan JJ i
6 CD N
mg NN N
is VBZ N
an DT N
effective JJ N
, , N
well RB N
tolerated VBN N
, , N
and CC N
well RB N
accepted VBN N
, , N
long-term JJ N
, , N
acute JJ N
treatment NN N
for IN N
migraine NN N
when WRB N
self-injected JJ N
by IN N
patients NNS p
using VBG p
the DT p
novel JJ p
self-injector NN p
. . p

-DOCSTART- -25022743- O O

Weighted VBN i
blankets NNS i
and CC N
sleep NN N
in IN N
autistic JJ p
children NNS p
-- : p
a DT p
randomized JJ N
controlled JJ N
trial NN N
. . N

OBJECTIVE UH N
To TO N
assess VB N
the DT N
effectiveness NN N
of IN N
a DT N
weighted-blanket JJ i
intervention NN i
in IN N
treating VBG N
severe JJ p
sleep NN p
problems NNS p
in IN p
children NNS p
with IN p
autism NN p
spectrum NN p
disorder NN p
( ( p
ASD NNP p
) ) p
. . p

METHODS NNP N
This DT N
phase NN N
III NNP N
trial NN N
was VBD N
a DT N
randomized JJ N
, , N
placebo-controlled JJ N
crossover NN N
design NN N
. . N

Participants NNS p
were VBD p
aged VBN p
between IN p
5 CD p
years NNS p
and CC p
16 CD p
years NNS p
10 CD p
months NNS p
, , p
with IN p
a DT p
confirmed JJ p
ASD NNP p
diagnosis NN p
and CC p
severe JJ p
sleep NN p
problems NNS p
, , p
refractory NN p
to TO p
community-based JJ p
interventions NNS p
. . p

The DT N
interventions NNS N
were VBD N
either RB N
a DT N
commercially RB i
available JJ i
weighted JJ i
blanket NN i
or CC i
otherwise RB i
identical JJ i
usual JJ i
weight NN i
blanket NN i
( ( N
control NN N
) ) N
, , N
introduced VBN N
at IN N
bedtime NN N
; : N
each DT N
was VBD N
used VBN N
for IN N
a DT N
2-week JJ N
period NN N
before IN N
crossover NN N
to TO N
the DT N
other JJ N
blanket NN N
. . N

Primary JJ N
outcome NN N
was VBD N
total JJ o
sleep JJ o
time NN o
( ( o
TST NNP o
) ) o
recorded VBN N
by IN N
actigraphy NN N
over IN N
each DT N
2-week JJ N
period NN N
. . N

Secondary JJ N
outcomes NNS N
included VBD N
actigraphically RB o
recorded VBN o
sleep-onset JJ o
latency NN o
, , o
sleep JJ o
efficiency NN o
, , o
assessments NNS o
of IN o
child NN o
behavior NN o
, , o
family NN o
functioning NN o
, , o
and CC o
adverse JJ o
events NNS o
. . o

Sleep NNP N
was VBD N
also RB N
measured VBN N
by IN N
using VBG N
parent-report JJ N
diaries NNS N
. . N

RESULTS NNP N
Seventy-three JJ p
children NNS p
were VBD p
randomized VBN p
and CC p
analysis NN p
conducted VBN p
on IN p
67 CD p
children NNS p
who WP p
completed VBD p
the DT p
study NN p
. . p

Using VBG N
objective JJ N
measures NNS N
, , N
the DT N
weighted JJ i
blanket NN i
, , N
compared VBN N
with IN N
the DT N
control NN i
blanket NN i
, , N
did VBD N
not RB N
increase VB N
TST NNP o
as IN N
measured VBN N
by IN N
actigraphy NN N
and CC N
adjusted VBN N
for IN N
baseline NN N
TST NNP N
. . N

There EX N
were VBD N
no DT N
group NN N
differences NNS N
in IN N
any DT N
other JJ N
objective NN o
or CC o
subjective JJ o
measure NN o
of IN o
sleep NN o
, , N
including VBG N
behavioral JJ N
outcomes NNS N
. . N

On IN N
subjective JJ N
preference NN N
measures NNS N
, , N
parents NNS N
and CC N
children NNS N
favored VBD N
the DT N
weighted JJ i
blanket NN i
. . i

CONCLUSIONS VB N
The DT N
use NN N
of IN N
a DT N
weighted JJ i
blanket NN i
did VBD N
not RB N
help VB N
children NNS p
with IN p
ASD NNP p
sleep NN N
for IN N
a DT N
longer JJR N
period NN N
of IN N
time NN N
, , N
fall VB N
asleep RB N
significantly RB N
faster RBR N
, , N
or CC N
wake VB N
less JJR N
often RB N
. . N

However RB N
, , N
the DT N
weighted JJ i
blanket NN i
was VBD N
favored VBN N
by IN N
children NNS N
and CC N
parents NNS N
, , N
and CC N
blankets NNS N
were VBD N
well RB o
tolerated VBN o
over IN N
this DT N
period NN N
. . N

-DOCSTART- -6756508- O O

Randomized NNP N
clinical JJ N
trial NN N
of IN N
tamoxifen JJ N
plus CC N
sequential JJ N
CMF NNP N
chemotherapy NN N
versus NN N
tamoxifen NN N
alone RB N
in IN N
postmenopausal JJ p
women NNS p
with IN p
advanced JJ p
breast NN p
cancer NN p
. . p

Eighty-eight JJ p
postmenopausal JJ p
women NNS p
with IN p
metastatic JJ p
breast NN p
cancer NN p
, , p
in IN p
whom WP p
estrogen NN p
receptors NNS p
( ( p
ER NNP p
) ) p
were VBD p
positive JJ p
or CC p
unknown JJ p
, , N
were VBD N
treated VBN N
on IN N
a DT N
controlled VBN N
trial NN N
to TO N
determine VB N
the DT N
effectiveness NN o
of IN N
tamoxifen NN i
and CC i
to TO i
assess VB i
the DT i
therapeutic JJ o
advantage NN o
of IN i
sequentially RB i
adding VBG i
low-dose JJ i
cyclophosphamide-methotrexate-5-fluorouracil NN i
( ( i
CMF NNP i
) ) i
chemotherapy NN i
in IN i
tamoxifen JJ i
responders NNS i
. . i

Patients NNS p
with IN p
known JJ p
ER NNP p
negative JJ p
status NN p
were VBD p
not RB p
studied VBN p
. . p

After IN N
the DT N
initial JJ N
12-week JJ N
treatment NN N
with IN N
tamoxifen NN i
alone RB i
, , N
60 CD N
% NN N
of IN N
ER NNP N
positive JJ N
patients NNS N
achieved VBD N
complete JJ o
or CC o
partial JJ o
response NN o
as IN N
did VBD N
35 CD N
% NN N
in IN N
whom WP N
ER NNP N
were VBD N
unknown JJ N
. . N

Response VB o
status NN o
further RB N
improved VBN N
in IN N
18 CD N
% NN N
randomized VBN N
to TO N
continue VB N
tamoxifen VB N
alone RB N
vs JJ N
31 CD N
% NN N
in IN N
whom WP N
CMF NNP N
was VBD N
added VBN N
to TO N
tamoxifen VB N
. . N

There EX N
were VBD N
no DT N
statistically RB N
significant JJ N
differences NNS N
in IN N
time NN N
to TO N
the DT N
development NN o
of IN o
progressive JJ o
disease NN o
or CC o
survival NN o
between IN N
the DT N
ER NNP N
positive JJ N
and CC N
ER NNP N
unknown JJ N
patients NNS N
or CC N
between IN N
the DT N
tamoxifen NN N
and CC N
tamoxifen JJ N
plus CC N
CMF JJ N
groups NNS N
. . N

We PRP N
conclude VBP N
that DT N
inability NN N
to TO N
determine VB N
ER NNP N
status NN N
should MD N
not RB N
prejudice VB N
against IN N
the DT N
use NN N
of IN N
tamoxifen NN N
in IN N
postmenopausal NN p
patients NNS p
with IN p
advanced JJ p
breast NN p
cancer NN p
. . p

No DT N
benefit NN N
has VBZ N
been VBN N
demonstrated VBN N
from IN N
the DT N
addition NN N
of IN N
CMF NNP N
chemotherapy NN N
in IN N
tamoxifen JJ N
responders NNS N
. . N

-DOCSTART- -25542620- O O

Crohn NNP N
's POS N
disease NN N
management NN N
after IN N
intestinal JJ N
resection NN N
: : N
a DT N
randomised JJ N
trial NN N
. . N

BACKGROUND NNP N
Most JJS N
patients NNS p
with IN p
Crohn NNP p
's POS p
disease NN p
need VBD N
an DT N
intestinal JJ N
resection NN N
, , N
but CC N
a DT N
majority NN N
will MD N
subsequently VB N
experience VB N
disease NN N
recurrence NN o
and CC N
require VB N
further JJ N
surgery NN N
. . N

This DT N
study NN N
aimed VBD N
to TO N
identify VB N
the DT N
optimal JJ N
strategy NN N
to TO N
prevent VB N
postoperative JJ N
disease NN N
recurrence NN N
. . N

METHODS NNP N
In IN N
this DT N
randomised JJ N
trial NN N
, , N
consecutive JJ p
patients NNS p
from IN p
17 CD p
centres NNS p
in IN p
Australia NNP p
and CC p
New NNP p
Zealand NNP p
undergoing JJ p
intestinal JJ i
resection NN i
of IN p
all DT p
macroscopic NNP p
Crohn NNP p
's POS p
disease NN p
, , p
with IN p
an DT p
endoscopically RB p
accessible JJ p
anastomosis NN p
, , p
received VBD p
3 CD p
months NNS p
of IN p
metronidazole JJ i
therapy NN p
. . p

Patients NNS p
at IN p
high JJ p
risk NN p
of IN p
recurrence NN p
also RB p
received VBD p
a DT p
thiopurine NN i
, , i
or CC i
adalimumab RB i
if IN p
they PRP p
were VBD p
intolerant JJ p
to TO p
thiopurines NNS p
. . p

Patients NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
parallel VB N
groups NNS N
: : N
colonoscopy NN i
at IN i
6 CD i
months NNS i
( ( i
active JJ i
care NN i
) ) i
or CC N
no DT i
colonoscopy NN i
( ( i
standard JJ i
care NN i
) ) i
. . i

We PRP N
used VBD N
computer-generated JJ N
block NN N
randomisation NN N
to TO N
allocate VB N
patients NNS N
in IN N
each DT N
centre NN N
to TO N
active JJ N
or CC N
standard JJ N
care NN N
in IN N
a DT N
2:1 CD N
ratio NN N
. . N

For IN N
endoscopic JJ o
recurrence NN o
( ( N
Rutgeerts NNP N
score RB N
?i2 VBD N
) ) N
at IN N
6 CD N
months NNS N
, , N
patients NNS N
stepped-up VBP N
to TO N
thiopurine VB N
, , N
fortnightly RB i
adalimumab VBZ i
with IN i
thiopurine NN i
, , i
or CC N
weekly JJ N
adalimumab NN N
. . N

The DT o
primary JJ o
endpoint NN o
was VBD o
endoscopic JJ o
recurrence NN o
at IN o
18 CD N
months NNS N
. . N

Patients NNS N
and CC N
treating VBG N
physicians NNS N
were VBD N
aware JJ N
of IN N
the DT N
patient NN N
's POS N
study NN N
group NN N
and CC N
treatment NN N
, , N
but CC N
central JJ N
reading NN N
of IN N
the DT N
endoscopic NN N
findings NNS N
was VBD N
undertaken JJ N
blind NN N
to TO N
the DT N
study NN N
group NN N
and CC N
treatment NN N
. . N

Analysis NN N
included VBD N
all DT N
patients NNS N
who WP N
received VBD N
at IN N
least JJS N
one CD N
dose NN N
of IN N
study JJ N
drug NN N
. . N

This DT N
trial NN N
is VBZ N
registered VBN N
with IN N
ClinicalTrials.gov NNP N
, , N
number NN N
NCT00989560 NNP N
. . N

FINDINGS NNP N
Between NNP N
Oct NNP N
13 CD N
, , N
2009 CD N
, , N
and CC N
Sept NNP N
28 CD N
, , N
2011 CD N
, , N
174 CD N
( ( N
83 CD N
% NN N
high JJ N
risk NN N
across IN N
both DT N
active JJ N
and CC N
standard JJ N
care NN N
groups NNS p
) ) p
patients NNS p
were VBD p
enrolled VBN N
and CC N
received VBN N
at IN N
least JJS N
one CD N
dose NN N
of IN N
study JJ N
drug NN N
. . N

Of IN N
122 CD p
patients NNS p
in IN p
the DT p
active JJ p
care NN p
group NN p
, , p
47 CD N
( ( N
39 CD N
% NN N
) ) N
stepped-up NN N
treatment NN N
. . N

At IN N
18 CD N
months NNS o
, , o
endoscopic FW o
recurrence NN o
occurred VBD o
in IN N
60 CD N
( ( N
49 CD N
% NN N
) ) N
patients NNS N
in IN N
the DT N
active JJ N
care NN N
group NN N
and CC N
35 CD N
( ( N
67 CD N
% NN N
) ) N
patients NNS N
in IN N
the DT N
standard NN N
care NN N
group NN N
( ( N
p=0.03 NN o
) ) o
. . o

Complete JJ o
mucosal NN o
normality NN o
was VBD o
maintained VBN N
in IN N
27 CD N
( ( N
22 CD N
% NN N
) ) N
of IN N
122 CD N
patients NNS N
in IN N
the DT N
active JJ N
care NN N
group NN N
versus IN N
four CD N
( ( N
8 CD N
% NN N
) ) N
in IN N
the DT N
standard NN N
care NN N
group NN N
( ( N
p=0.03 NN N
) ) N
. . N

In IN N
the DT N
active JJ N
care NN N
arm NN N
, , N
of IN N
those DT N
with IN N
6 CD N
months NNS o
recurrence NN o
who WP o
stepped VBD N
up RB N
treatment NN N
, , N
18 CD N
( ( N
38 CD N
% NN N
) ) N
of IN N
47 CD N
patients NNS N
were VBD N
in IN N
remission NN o
12 CD o
months NNS N
later RB N
; : N
conversely RB N
, , N
of IN N
those DT N
in IN N
remission NN N
at IN N
6 CD N
months NNS N
who WP N
did VBD N
not RB N
change VB N
therapy NN o
recurrence NN o
occurred VBD o
in IN N
31 CD N
( ( N
41 CD N
% NN N
) ) N
of IN N
75 CD N
patients NNS N
12 CD N
months NNS N
later RB N
. . N

Smoking NNP N
( ( N
odds NNS N
ratio VBP N
[ CD N
OR NNP N
] $ N
2.4 CD N
, , N
95 CD N
% NN N
CI NNP N
1.2-4.8 CD N
, , N
p=0.02 NN N
) ) N
and CC N
the DT N
presence NN N
of IN N
two CD N
or CC N
more JJR N
clinical JJ N
risk NN N
factors NNS N
including VBG N
smoking NN N
( ( N
OR CC N
2.8 CD N
, , N
95 CD N
% NN N
CI NNP N
1.01-7.7 CD N
, , N
p=0.05 NN N
) ) N
increased VBD N
the DT o
risk NN o
of IN o
endoscopic JJ o
recurrence NN o
. . o

The DT o
incidence NN o
and CC o
type NN o
of IN o
adverse JJ o
and CC o
severe JJ o
adverse JJ o
events NNS o
did VBD o
not RB N
differ VB N
significantly RB N
between IN N
patients NNS N
in IN N
the DT N
active JJ N
care NN N
and CC N
standard NN N
care NN N
groups NNS N
( ( N
100 CD N
[ RB N
82 CD N
% NN N
] NN N
of IN N
122 CD N
vs NNS N
45 CD N
[ JJ N
87 CD N
% NN N
] NN N
of IN N
52 CD N
; : N
p=0.51 NN N
) ) N
and CC N
( ( N
33 CD N
[ RB N
27 CD N
% NN N
] NN N
of IN N
122 CD N
vs NNS N
18 CD N
[ JJ N
35 CD N
% NN N
] NN N
of IN N
52 CD N
; : N
p=0.36 NN N
) ) N
, , N
respectively RB N
. . N

INTERPRETATION NNP N
Treatment NNP N
according VBG N
to TO N
clinical JJ o
risk NN o
of IN o
recurrence NN o
, , o
with IN N
early JJ N
colonoscopy NN N
and CC N
treatment NN N
step-up NN N
for IN N
recurrence NN N
, , N
is VBZ N
better JJR N
than IN N
conventional JJ N
drug NN N
therapy NN N
alone RB N
for IN N
prevention NN N
of IN N
postoperative JJ o
Crohn NNP o
's POS o
disease NN o
recurrence NN o
. . o

Selective JJ N
immune JJ N
suppression NN N
, , N
adjusted VBN N
for IN N
early JJ N
recurrence NN N
, , N
rather RB N
than IN N
routine VB N
use NN N
, , N
leads VBZ N
to TO N
disease VB o
control NN o
in IN o
most JJS N
patients NNS N
. . N

Clinical JJ N
risk NN N
factors NNS N
predict VBP o
recurrence NN o
, , o
but CC N
patients NNS N
at IN N
low JJ N
risk NN N
also RB N
need VBP o
monitoring VBG o
. . o

Early JJ o
remission NN o
does VBZ o
not RB N
preclude VB N
the DT N
need NN N
for IN N
ongoing VBG N
monitoring NN N
. . N

FUNDING NN N
AbbVie NNP N
, , N
Gutsy NNP N
Group NNP N
, , N
Gandel NNP N
Philanthropy NNP N
, , N
Angior NNP N
Foundation NNP N
, , N
Crohn NNP N
's POS N
Colitis NNP N
Australia NNP N
, , N
and CC N
the DT N
National NNP N
Health NNP N
and CC N
Medical NNP N
Research NNP N
Council NNP N
. . N

-DOCSTART- -7881703- O O

Absolute NNP N
bioavailability NN N
of IN N
a DT N
new JJ N
high JJ N
dose NN N
methylprednisolone NN i
tablet NN N
formulation NN N
. . N

This DT N
was VBD N
a DT N
single-blind JJ N
, , N
single-dose JJ N
, , N
randomized VBN N
crossover NN N
study NN N
to TO N
determine VB N
the DT N
absolute JJ o
bioavailability NN o
of IN N
Medrol NNP i
, , N
a DT N
new JJ N
high JJ N
dose NN N
( ( N
100 CD N
mg NN N
) ) N
methylprednisolone NN i
tablet NN N
product NN N
, , N
by IN N
comparing VBG N
it PRP N
with IN N
100 CD N
mg NNS N
methylprednisolone NN i
from IN N
an DT N
intravenous JJ N
formulation NN N
, , N
Solu-Medrol NNP i
. . i

Fourteen NNP p
healthy JJ p
, , p
non-smoking JJ p
, , p
Caucasian JJ p
male NN p
volunteers NNS p
took VBD N
part NN N
. . N

On IN N
treatment NN N
days NNS N
volunteers NNS N
remained VBD N
recumbent NN N
for IN N
4 CD N
hours NNS N
after IN N
drug NN N
administration NN N
, , N
with IN N
food NN N
and CC N
fluid NN N
intake VBP N
standardized VBN N
over IN N
this DT N
period NN N
. . N

Serial JJ N
blood NN N
samples NNS N
were VBD N
drawn VBN N
over IN N
a DT N
14-hour JJ N
period NN N
after IN N
drug NN N
administration NN N
. . N

Plasma NNP o
methylprednisolone NN o
concentrations NNS o
were VBD N
determined VBN N
by IN N
high JJ N
performance NN N
liquid NN N
chromatography NN N
. . N

The DT N
geometric JJ N
means NNS N
of IN N
AUCi.v NNP o
. . o

and CC o
AUCtablet NNP o
were VBD N
4,049 CD N
and CC N
3,334 CD N
ng.h/ml NN N
, , N
respectively RB N
. . N

The DT N
absolute JJ o
bioavailability NN o
of IN N
the DT N
tablet NN N
product NN N
was VBD N
82 CD N
% NN N
, , N
which WDT N
is VBZ N
in IN N
agreement NN N
with IN N
published VBN N
data NNS N
for IN N
other JJ N
oral JJ N
dosage NN N
forms NNS N
of IN N
methylprednisolone NN i
. . i

Volunteers NNS N
displayed VBD N
the DT N
expected VBN N
rise NN N
in IN N
peripheral JJ o
blood NN o
neutrophil NN o
count NN o
, , N
but CC N
no DT N
other JJ N
clinically RB o
relevant JJ o
changes NNS o
in IN o
hematology NN o
or CC o
clinical JJ o
chemistry NN o
were VBD N
observed VBN N
. . N

No DT N
adverse JJ o
drug NN o
reactions NNS o
were VBD N
recorded VBN N
. . N

It PRP N
is VBZ N
concluded VBN N
that IN N
the DT N
tablet NN N
product NN N
can MD N
be VB N
used VBN N
as IN N
a DT N
substitute NN N
for IN N
parenteral JJ N
methylprednisolone NN i
in IN N
situations NNS N
requiring VBG N
high-dose JJ N
therapy NN N
. . N

-DOCSTART- -18783079- O O

[ VB p
The DT p
CARESS-in-AMI NNP i
trial NN p
] NN p
. . N

-DOCSTART- -23578015- O O

Long-term JJ N
treatment NN N
with IN N
atomoxetine NN i
for IN N
attention-deficit/hyperactivity NN o
disorder NN o
symptoms NNS o
in IN p
children NNS p
and CC p
adolescents NNS p
with IN p
autism NN p
spectrum NN p
disorder NN p
: : p
an DT N
open-label JJ N
extension NN N
study NN N
. . N

OBJECTIVE CC N
The DT N
efficacy NN o
and CC o
tolerability NN o
of IN N
long-term JJ N
treatment NN N
with IN N
atomoxetine NN i
for IN N
symptoms NNS o
of IN o
attention-deficit/hyperactivity NN o
disorder NN o
( ( o
ADHD NNP o
) ) o
in IN N
children NNS p
with IN p
autism NN p
spectrum NN p
disorder NN p
( ( p
ASD NNP p
) ) p
has VBZ N
not RB N
been VBN N
established VBN N
. . N

METHODS NNP N
In IN N
this DT N
study NN N
, , N
88 CD p
patients NNS p
6-17 JJ p
years NNS p
of IN p
age NN p
, , p
with IN p
ADHD NNP p
and CC p
ASD NNP p
, , N
were VBD N
treated VBN N
with IN N
1.2 CD N
mg/kg/day JJ N
atomoxetine NN i
for IN N
20 CD N
weeks NNS N
as IN N
follow-up NN N
of IN N
an DT N
8 CD N
week NN N
double-blind JJ N
placebo-controlled JJ i
period NN N
. . N

Primary JJ N
endpoint NN N
was VBD N
the DT N
ADHD NNP o
Rating NNP o
Scale NNP o
( ( o
ADHD-RS NNP o
) ) o
. . o

RESULTS NNP N
After IN N
8 CD N
weeks NNS N
of IN N
initial JJ N
treatment NN N
, , N
the DT N
mean JJ o
total NN o
, , o
inattention NN o
, , o
and CC o
hyperactivity-impulsivity NN o
ADHD-RS NNP o
further RB N
decreased VBD o
significantly RB N
from IN N
34.9 CD N
to TO N
27.0 CD N
for IN N
the DT N
total JJ N
ADHD-RS NNP N
, , N
from IN N
18.3 CD N
to TO N
14.5 CD N
for IN N
the DT N
ADHD-RS NNP o
inattention NN o
subscale NN o
, , N
and CC N
from IN N
16.5 CD N
to TO N
12.6 CD N
for IN N
the DT N
hyperactivity-impulsivity JJ o
subscale NN o
. . o

Adverse JJ o
events NNS o
were VBD N
mild JJ N
and CC N
tended VBD N
to TO N
diminish VB N
over IN N
time NN N
during IN N
continued JJ N
treatment NN N
, , N
especially RB N
regarding VBG N
nausea NN o
and CC o
fatigue NN o
. . o

There EX N
were VBD N
no DT N
serious JJ o
adverse JJ o
events NNS o
. . o

CONCLUSIONS VB N
The DT N
results NNS N
of IN N
the DT N
present JJ N
analysis NN N
suggest NN N
that WDT N
continued VBD N
treatment NN N
with IN N
atomoxetine NN i
up RB N
to TO N
28 CD N
weeks NNS N
further RBR N
improve VB o
ADHD NNP o
symptoms NNS o
in IN N
children NNS p
and CC p
adolescents NNS p
with IN p
ASD NNP p
, , N
while IN N
adverse JJ o
events NNS o
tend VBP N
to TO N
subside VB N
. . N

Future JJ N
studies NNS N
investigating VBG N
the DT N
long-term JJ N
efficacy NN N
of IN N
atomoxetine NN i
in IN N
children NNS p
and CC p
adolescents NNS p
with IN p
ASD NNP p
should MD N
be VB N
randomized VBN N
and CC N
placebo VB N
controlled VBN N
. . N

This DT N
study NN N
has VBZ N
been VBN N
registered VBN N
in IN N
ClinicalTrials.gov NNP N
( ( N
www.clinicaltrials.gov NN N
) ) N
under IN N
registration NN N
number NN N
NCT00380692 NNP N
. . N

-DOCSTART- -24242260- O O

Testing VBG N
the DT N
efficacy NN N
of IN N
an DT N
HIV NNP o
stigma NN o
reduction NN o
intervention NN i
with IN N
medical JJ p
students NNS p
in IN p
Puerto NNP p
Rico NNP p
: : p
the DT N
SPACES NNP N
project NN N
. . N

INTRODUCTION NNP N
Stigma NNP o
associated VBD N
with IN N
HIV NNP N
has VBZ N
been VBN N
documented VBN N
as IN N
a DT N
barrier NN N
for IN N
accessing VBG N
quality NN N
health-related JJ N
services NNS N
. . N

When WRB N
the DT N
stigma NN N
manifests NNS N
in IN N
the DT N
health NN N
care NN N
setting VBG N
, , N
people NNS N
living VBG N
with IN N
HIV NNP N
receive VBP N
substandard NN N
services NNS N
or CC N
even RB N
be VB N
denied VBN N
care NN N
altogether RB N
. . N

Although IN N
the DT N
consequences NNS N
of IN N
HIV NNP o
stigma NN o
have VBP N
been VBN N
documented VBN N
extensively RB N
, , N
efforts NNS N
to TO N
reduce VB N
these DT N
negative JJ N
attitudes NNS N
have VBP N
been VBN N
scarce JJ N
. . N

Interventions NNS i
to TO i
reduce VB i
HIV NNP o
stigma NN o
should MD N
be VB N
implemented VBN N
as IN N
part NN N
of IN N
the DT N
formal JJ N
training NN N
of IN N
future JJ N
health NN N
care NN N
professionals NNS N
. . N

The DT N
interventions NNS N
that WDT N
have VBP N
been VBN N
tested VBN N
with IN N
health NN p
care NN p
professionals NNS p
and CC N
published VBN N
have VBP N
several JJ N
limitations NNS N
that WDT N
must MD N
be VB N
surpassed VBN N
( ( N
i.e NN N
. . N

lack NN N
of IN N
comparison NN N
groups NNS N
in IN N
research NN N
designs NNS N
and CC N
longitudinal JJ N
follow-up JJ N
data NNS N
) ) N
. . N

Furthermore UH N
, , N
Latino NNP p
health NN p
care NN p
professionals NNS p
have VBP N
been VBN N
absent JJ N
from IN N
these DT N
intervention NN N
efforts NNS N
even RB N
though IN N
the DT N
epidemic NN N
has VBZ N
affected VBN N
this DT N
population NN N
disproportionately RB N
. . N

METHODS NNP N
In IN N
this DT N
article NN N
, , N
we PRP N
describe VBP N
an DT N
intervention NN i
developed VBD i
to TO i
reduce VB i
HIV NNP o
stigma NN o
among IN i
medical JJ i
students NNS i
in IN i
Puerto NNP i
Rico NNP i
. . i

A NNP N
total NN N
of IN N
507 CD p
medical JJ p
students NNS p
were VBD N
randomly RB N
introduced VBN N
into IN N
our PRP$ N
intervention NN i
and CC i
control NN i
conditions NNS i
. . i

RESULTS VB N
The DT N
results NNS N
show VBP N
statistically RB N
significant JJ N
differences NNS N
between IN N
the DT N
intervention NN i
and CC N
control NN i
groups NNS N
; : N
intervention NN N
group NN N
participants NNS N
had VBD N
lower JJR o
HIV NNP o
stigma NN o
levels NNS o
than IN N
control NN N
participants NNS N
after IN N
the DT N
intervention NN N
. . N

In IN N
addition NN N
, , N
differences NNS N
in IN N
HIV NNP o
stigma NN o
levels NNS o
between IN N
the DT N
groups NNS N
were VBD N
sustained VBN N
for IN N
a DT N
12-month JJ N
period NN N
. . N

CONCLUSION VB N
The DT N
results NNS N
of IN N
our PRP$ N
study NN N
demonstrate VB N
the DT N
efficacy NN N
of IN N
the DT N
modes NNS N
of IN N
intervention NN N
developed VBN N
by IN N
us PRP N
and CC N
serve VB N
as IN N
a DT N
new JJ N
training NN N
tool NN N
for IN N
future JJ p
health NN p
care NN p
professionals NNS p
with IN N
regard NN N
to TO N
stigma VB o
reduction NN o
. . o

-DOCSTART- -25534295- O O

Carboplatin NNP i
and CC i
pegylated VBN i
liposomal JJ i
doxorubicin NN i
versus NN N
carboplatin NN i
and CC i
paclitaxel NN i
in IN N
very RB p
platinum-sensitive JJ p
ovarian JJ p
cancer NN p
patients NNS p
: : p
results NNS N
from IN N
a DT N
subset JJ p
analysis NN p
of IN p
the DT p
CALYPSO NNP p
phase NN p
III NNP p
trial NN p
. . p

AIM NNP N
To TO N
perform VB N
a DT N
subset JJ N
analysis NN N
of IN N
patients NNS p
with IN p
very RB p
platinum-sensitive JJ p
recurrent NN p
ovarian JJ p
cancer NN p
( ( p
ROC NNP p
) ) p
enrolled VBD p
in IN p
the DT p
phase NN p
III NNP p
CALYPSO NNP p
trial NN p
. . p

PATIENTS NNP N
AND CC N
METHODS NNP N
The DT p
international JJ p
non-inferiority JJ p
trial NN p
enrolled VBD p
women NNS p
with IN p
ROC NNP p
that WDT p
relapsed VBD p
> $ p
6 CD p
months NNS p
following VBG p
first- JJ p
or CC p
second-line JJ p
platinum- JJ i
and CC i
paclitaxel-based JJ i
therapies NNS i
. . i

Patients NNS N
were VBD N
randomised VBN N
to TO N
CD VB i
[ JJ i
carboplatin-pegylated JJ i
liposomal JJ i
doxorubicin NN i
( ( i
PLD NNP i
) ) i
] VBD i
or CC i
CP NNP i
( ( i
carboplatin-paclitaxel NN i
) ) i
and CC N
stratified VBN N
by IN N
treatment-free JJ N
interval NN N
( ( N
TFI NNP N
) ) N
. . N

In IN N
this DT N
analysis NN N
, , N
patients NNS p
with IN p
a DT p
TFI NNP p
> NNP p
24 CD p
months NNS p
were VBD N
analysed VBN N
separately RB N
for IN N
progression NN N
free JJ N
survival NN N
( ( N
PFS NNP N
) ) N
, , N
the DT N
primary JJ N
endpoint NN N
of IN N
CALYPSO NNP N
, , N
overall JJ N
survival NN N
( ( N
OS NNP N
) ) N
and CC N
safety NN N
. . N

RESULTS VB N
A DT p
total NN p
of IN p
259 CD p
very RB p
platinum-sensitive JJ p
patients NNS p
were VBD p
included VBN p
( ( p
n=131 UH p
, , p
CD NNP p
; : p
n=128 RB p
, , p
CP NNP p
) ) p
. . p

Median JJ o
PFS NNP o
was VBD N
12.0 CD N
months NNS N
for IN N
the DT N
CD NN i
arm NN N
and CC N
12.3 CD N
months NNS N
for IN N
CP NNP i
[ NNP N
HR=1.05 NNP N
( ( N
95 CD N
% NN N
CI NNP N
, , N
0.79-1.40 NNP N
) ) N
; : N
P=0.73 NNP N
for IN N
superiority NN N
] NNP N
and CC N
median JJ o
OS NNP o
was VBD N
40.2 CD N
months NNS N
for IN N
CD NN N
and CC N
43.9 CD N
for IN N
CP NNP N
[ NNP N
HR=1.18 NNP N
( ( N
95 CD N
% NN N
CI NNP N
0.85-1.63 NN N
) ) N
; : N
P=0.33 NNP N
for IN N
superiority NN N
] NNP N
. . N

Overall JJ N
response NN o
rates NNS o
were VBD N
42 CD N
% NN N
and CC N
38 CD N
% NN N
, , N
respectively RB N
( ( N
P=0.46 NNP N
) ) N
. . N

Toxicities NNPS o
were VBD N
more RBR N
common JJ N
with IN N
CP NNP i
versus NN N
CD NN i
, , N
including VBG N
grade NN o
3/4 CD o
neutropenia NN o
( ( N
40.8 CD N
% NN N
versus IN N
27.5 CD N
% NN N
; : N
P=0.025 NNP N
) ) N
, , N
nausea NN o
( ( N
4.8 CD N
% NN N
versus IN N
3.1 CD N
% NN N
; : N
P=0.47 NNP N
) ) N
, , N
allergic JJ o
reaction NN o
( ( N
8 CD N
% NN N
versus IN N
3.1 CD N
% NN N
; : N
P=0.082 NNP N
) ) N
sensory NN o
neuropathy JJ o
( ( N
4.8 CD N
% NN N
versus IN N
2.3 CD N
% NN N
; : N
P=0.27 NNP N
) ) N
and CC N
grade $ o
2 CD o
alopecia NN o
( ( N
88 CD N
% NN N
versus IN N
9.2 CD N
% NN N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

Grade $ o
3/4 CD o
thrombocytopenia NN o
( ( N
12.2 CD N
% NN N
versus IN N
3.2 CD N
% NN N
; : N
P=0.007 NNP N
) ) N
and CC N
mucositis NN o
( ( N
2.3 CD N
% NN N
versus IN N
0 CD N
% NN N
; : N
P=0.089 NNP N
) ) N
were VBD N
more RBR N
common JJ N
with IN N
CD NNP i
. . i

Grade VB o
3/4 CD o
hand-foot JJ o
syndrome NN o
occurred VBD N
rarely RB N
with IN N
CD NNP i
( ( N
3 CD N
patients NNS N
versus JJ N
0 CD N
in IN N
CP NNP N
arm NN N
; : N
P=0.089 NNP N
) ) N
. . N

CONCLUSION NNP N
CP NNP N
and CC N
CD NNP N
were VBD N
equally RB N
effective JJ N
treatment NN N
regimens NNS N
for IN N
patients NNS p
with IN p
very RB p
platinum-sensitive JJ p
ROC NNP p
. . p

The DT N
favourable JJ N
risk-benefit JJ N
profile NN N
suggests VBZ N
carboplatin-PLD NN i
as IN N
treatment NN N
of IN N
choice NN N
for IN N
these DT N
patients NNS N
. . N

-DOCSTART- -24925605- O O

Chocolate NNP i
frogs NNS i
do VBP N
not RB N
increase VB N
completion NN N
of IN N
parent NN N
survey NN N
: : N
randomised VBN N
study NN N
. . N

Four CD N
months NNS N
into IN N
a DT N
year-long JJ N
, , N
national JJ N
survey NN N
assessing VBG N
parents NNS N
' POS N
experiences NNS N
of IN N
a DT N
child NN N
's POS N
diagnosis NN N
of IN N
autism NN N
spectrum NN N
disorder NN N
, , N
our PRP$ N
response NN N
fraction NN N
was VBD N
only RB N
23 CD N
% NN N
. . N

We PRP N
aimed VBD N
to TO N
determine VB N
whether IN N
including VBG N
a DT N
chocolate NN i
incentive NN i
in IN N
the DT N
postal JJ N
survey NN N
would MD N
increase VB o
the DT o
response NN o
fraction NN o
. . o

Families NNS p
enrolled VBD p
between IN p
15 CD p
March NNP p
and CC p
25 CD p
May NNP p
2012 CD p
were VBD N
randomised VBN N
to TO N
receive VB N
a DT N
chocolate NN i
frog NN i
versus IN i
no DT i
chocolate NN i
frog NN i
. . i

Both DT p
groups NNS p
received VBD N
a DT N
written VBN i
reminder NN i
and CC N
replacement NN N
survey NN N
2 CD N
weeks NNS N
after IN N
the DT N
survey NN N
was VBD N
posted VBN N
and CC N
up RB N
to TO N
two CD N
telephone NN N
reminders NNS N
thereafter RB N
. . N

We PRP N
analysed VBD N
the DT N
effect NN o
of IN N
the DT N
incentive NN N
using VBG N
? . o
( ( o
2 CD o
) ) o
tests NNS o
for IN N
the DT N
categorical JJ N
response NN N
variable JJ N
and CC o
t-tests NNS o
for IN N
the DT N
continuous JJ N
reminder NN N
and CC N
length NN N
of IN N
response NN N
variables NNS N
at IN N
the DT N
end NN N
of IN N
( ( N
i NN N
) ) N
randomisation NN N
and CC N
( ( N
ii NN N
) ) N
the DT N
study NN N
( ( N
1 CD N
November NNP N
2012 CD p
) ) p
. . p

A DT p
total NN p
of IN p
137 CD p
families NNS p
were VBD p
randomised VBN N
in IN N
the DT N
6-week JJ N
period NN p
. . p

Parents NNS p
who WP p
received VBD p
an DT p
incentive NN p
were VBD p
more RBR p
likely JJ p
to TO p
return VB p
a DT p
completed VBN p
survey NN p
in IN p
the DT p
6 CD p
weeks NNS p
than IN p
those DT p
who WP p
did VBD p
not RB p
( ( p
21 CD p
% NN p
vs. FW p
6 CD p
% NN p
, , N
P NNP p
= NNP p
0.009 CD o
) ) o
. . o

This DT o
effect NN o
faded VBN N
by IN N
the DT N
end NN N
of IN N
the DT N
study NN N
( ( N
53 CD N
% NN N
vs. FW N
42 CD N
% NN N
, , N
P NNP N
= NNP N
0.4 CD N
) ) N
. . N

There EX N
were VBD N
no DT N
differences NNS N
between IN N
groups NNS N
at IN N
either DT N
follow-up NN N
in IN N
the DT N
number NN N
of IN N
reminders NNS N
that WDT N
parents NNS N
received VBD N
or CC N
the DT o
number NN o
of IN o
days NNS o
it PRP o
took VBD N
parents NNS N
to TO N
return VB N
the DT N
survey NN N
. . N

Including VBG N
a DT N
chocolate-based JJ i
incentive NN i
does VBZ N
not RB N
significantly RB o
increase VB o
response NN o
rate NN o
in IN o
a DT o
postal JJ N
survey NN N
over IN N
and CC N
above JJ N
standard NN N
reminder NN N
techniques NNS N
like IN N
posting VBG N
follow-up JJ N
survey NN N
packs NNS N
or CC N
phoning VBG N
families NNS N
. . N

-DOCSTART- -3220672- O O

Argon NNP i
laser NN i
trabeculoplasty NN i
in IN N
primary JJ p
open-angle JJ p
glaucoma NN p
-- : p
results NNS p
in IN N
black JJ p
Jamaican JJ p
population NN p
. . p

A DT N
controlled JJ N
, , N
randomised VBD N
, , N
prospective JJ N
trial NN N
of IN N
Argon NNP i
laser NN i
trabeculoplasty NN i
( ( i
ALT NNP i
) ) i
was VBD N
carried VBN N
out RP N
on IN N
48 CD p
eyes NNS p
of IN p
30 CD p
black JJ p
Jamaican JJ p
patients NNS p
with IN p
primary JJ p
open-angle JJ p
glaucoma NN p
. . p

All DT p
eyes NNS p
had VBD p
uncontrolled VBN p
intra-ocular JJ o
pressures NNS o
( ( p
greater JJR p
than IN p
or CC p
equal JJ p
to TO p
22 CD p
mm NNS p
Hg NNP p
) ) p
despite IN p
medical JJ p
therapy NN p
. . p

Treatment NN N
was VBD N
successful JJ N
in IN N
controlling VBG o
intraocular JJ o
pressure NN o
in IN N
68 CD N
% NN N
of IN N
eyes NNS N
after IN N
12 CD N
months NNS N
follow-up JJ N
( ( N
p JJ N
= NNP N
0.004 CD N
) ) N
. . N

The DT N
average JJ N
drop NN o
in IN o
intraocular JJ o
pressure NN o
attributable JJ N
to TO N
ALT NNP i
was VBD N
6.6 CD N
mmHg NN N
. . N

Argon NNP i
laser NN i
trabeculoplasty NN i
is VBZ N
an DT N
effective JJ N
adjunct NN N
in IN N
managing VBG N
to TO N
control VB N
intraocular JJ o
pressure NN o
in IN N
black JJ N
Jamaican NNP p
glaucoma NN p
patients NNS p
. . p

-DOCSTART- -8712652- O O

Comparison NNP N
of IN N
diclofenac JJ i
sodium NN i
and CC i
morphine NN i
sulphate NN i
for IN N
postoperative JJ o
analgesia NN o
after IN N
day NN N
case NN N
inguinal JJ p
hernia NN p
surgery NN p
. . p

Postoperative NNP o
pain NN o
may MD N
be VB N
a DT N
significant JJ N
reason NN N
for IN N
delayed JJ N
discharge NN N
from IN N
hospital NN N
, , N
increased VBN N
morbidity NN N
and CC N
reduced JJ N
patient JJ N
satisfaction NN N
with IN N
ambulatory JJ p
hernia NN p
surgery NN p
. . p

This DT N
study NN N
compared VBN N
two CD N
postoperative JJ p
oral JJ p
analgesic NN p
protocols NNS p
after IN p
day NN p
case NN p
inguinal JJ p
hernia NN p
repair NN p
; : p
30 CD i
mg NN i
morphine NN i
sulphate NN i
( ( i
MST NNP i
) ) i
and CC N
10 CD i
mg NNS i
metoclopramide RB i
every DT N
8 CD N
h NN N
for IN N
48 CD N
h NN N
or CC N
75 CD i
mg NNS i
diclofenac JJ i
twice RB N
daily RB N
for IN N
48 CD N
h. PDT N
The DT N
pain NN o
reported VBD o
in IN N
the DT N
MST NNP i
group NN N
was VBD N
significantly RB N
greater JJR N
on IN N
both DT N
the DT N
day NN N
of IN N
operation NN N
and CC N
the DT N
first JJ N
postoperative JJ N
day NN N
( ( N
P NNP N
< NNP N
0.05 CD N
, , N
Mann-Whitney NNP N
U NNP N
test NN N
) ) N
. . N

A DT N
significantly RB N
higher JJR N
proportion NN N
of IN N
patients NNS p
taking VBG p
MST NNP i
complained VBD N
of IN N
nausea NN o
on IN N
the DT N
day NN N
of IN N
operation NN N
and CC N
on IN N
the DT N
1st CD N
postoperative JJ N
day NN N
( ( N
P NNP N
< NNP N
0.05 CD N
, , N
chi RB N
2 CD N
) ) N
. . N

The DT N
time NN o
taken VBN o
to TO o
walk VB o
, , o
dress NN o
and CC o
leave VBP o
home NN o
alone RB o
were VBD N
achieved VBN N
in IN N
a DT N
significantly RB N
shorter JJR N
duration NN N
in IN N
patients NNS N
taking VBG N
diclofenac NN i
. . i

We PRP N
conclude VBP N
that IN N
diclofenac NN i
provides VBZ N
effective JJ N
analgesia NN o
, , N
has VBZ N
a DT N
more RBR N
acceptable JJ N
side-effect JJ N
profile NN N
than IN N
morphine JJ i
sulphate NN i
and CC N
is VBZ N
the DT N
treatment NN N
of IN N
choice NN N
after IN N
ambulatory NN N
hernia NN N
surgery NN N
. . N

-DOCSTART- -7810153- O O

The DT N
effect NN N
of IN N
cisapride NN i
on IN N
delayed JJ N
colonic JJ o
transit NN o
time NN o
in IN N
patients NNS p
with IN p
idiopathic JJ p
Parkinson NNP p
's POS p
disease NN p
. . p

Disorders NNS p
of IN p
autonomic JJ p
regulation NN p
are VBP N
common JJ N
in IN N
patients NNS p
with IN p
Parkinson NNP p
's POS p
disease NN p
( ( p
PD NNP p
) ) p
. . p

Patients NNS N
most RBS N
frequently RB N
complain VBP N
of IN N
dysphagia NN N
and CC N
therapy NN N
resistant JJ N
constipation NN N
, , N
as RB N
far RB N
as IN N
the DT N
gastrointestinal JJ N
tract NN N
is VBZ N
concerned VBN N
. . N

These DT N
symptoms NNS N
have VBP N
to TO N
be VB N
attributed VBN N
to TO N
a DT N
neuronal JJ N
degeneration NN N
. . N

In IN N
a DT N
pilot NN N
study NN N
we PRP N
therefore RB N
investigated VBD N
the DT N
effect NN N
of IN N
stimulation NN N
of IN N
the DT N
myenteric JJ N
plexus NN N
by IN N
cisapride NN i
. . i

11 CD p
women NNS p
and CC p
13 CD p
men NNS p
were VBD p
examined VBN p
, , p
the DT p
average JJ p
age NN p
was VBD p
67.3 CD p
years NNS p
, , p
the DT p
Webster NNP p
rating NN p
17 CD p
points NNS p
. . p

In IN N
2 CD N
out IN N
of IN N
24 CD N
patients NNS N
, , N
colonic JJ o
transit NN o
was VBD N
prolonged VBN N
up RB N
to TO N
the DT N
limit NN N
, , N
both DT N
with IN N
and CC N
without IN N
therapy NN N
. . N

The DT N
other JJ N
22 CD N
patients NNS N
showed VBD N
an DT N
acceleration NN o
in IN o
transit NN o
on IN N
response NN N
to TO N
cisapride VB i
. . i

On IN N
average JJ N
the DT N
colonic JJ o
transit NN o
of IN N
130 CD N
hours NNS N
was VBD N
reduced VBN N
to TO N
79 CD N
hours NNS N
. . N

This DT N
objective JJ N
improvement NN N
was VBD N
associated VBN N
with IN N
a DT N
subjective JJ N
improvement NN N
. . N

Central JJ N
side NN N
effects NNS N
or CC N
a DT N
worsening NN o
of IN o
Parkinsonian JJ o
symptoms NNS o
were VBD N
not RB N
found VBN N
. . N

We PRP N
conclude VBP N
that DT N
cisapride NN i
is VBZ N
effective JJ N
in IN N
the DT N
treatment NN N
of IN N
constipation NN p
in IN p
idiopathic JJ p
PD NNP p
. . p

-DOCSTART- -15492949- O O

Effect NN N
of IN N
gemfibrozil NN i
on IN N
change NN N
in IN N
renal JJ N
function NN N
in IN N
men NNS p
with IN p
moderate JJ p
chronic JJ p
renal JJ p
insufficiency NN p
and CC p
coronary JJ p
disease NN p
. . p

BACKGROUND NNP N
Limited NNP N
data NN N
suggest NN N
that IN N
low JJ N
levels NNS N
of IN N
serum JJ N
high-density NN N
lipoprotein NN N
cholesterol NN N
( ( N
HDL-C NNP N
) ) N
and CC N
high JJ N
levels NNS N
of IN N
triglyceride-rich JJ N
lipoproteins NNS N
may MD N
be VB N
associated VBN N
with IN N
more RBR N
rapid JJ N
rates NNS N
of IN N
kidney NN N
function NN N
loss NN N
in IN N
individuals NNS p
with IN p
chronic JJ p
renal JJ p
insufficiency NN p
( ( p
CRI NNP p
) ) p
. . p

Although IN N
fibric JJ N
acid NN N
derivatives NNS N
increase VBP N
serum JJ N
HDL-C NNP N
levels NNS N
and CC N
decrease VB N
triglyceride NN N
levels NNS N
, , N
their PRP$ N
effects NNS N
on IN N
renal JJ N
function NN N
are VBP N
largely RB N
unknown JJ N
. . N

We PRP N
conducted VBD N
this DT N
study NN N
to TO N
determine VB N
whether IN N
gemfibrozil NN i
reduced VBN N
rates NNS N
of IN N
renal JJ N
function NN N
loss NN N
in IN N
people NNS p
with IN p
moderate JJ p
CRI NNP p
. . p

METHODS NNP N
This DT N
was VBD N
a DT N
post NN N
hoc NN N
subgroup NN N
analysis NN N
in IN N
the DT N
Veterans NNP N
Affairs NNPS N
High-Density NNP N
Lipoprotein NNP N
Intervention NNP N
Trial NNP N
, , N
a DT N
randomized JJ N
double-blind JJ N
trial NN N
of IN N
gemfibrozil JJ i
versus NN i
placebo NN i
in IN N
2,531 CD p
men NNS p
with IN p
coronary JJ p
disease NN p
, , p
HDL-C NNP p
levels NNS p
of IN p
40 CD p
mg/dL NN p
or CC p
less JJR p
( ( p
< NN p
or CC p
=1.0 VB p
mmol/L NN p
) ) p
, , p
low-density JJ p
lipoprotein NN p
cholesterol NN p
levels NNS p
of IN p
140 CD p
mg/dL NN p
or CC p
less JJR p
( ( p
< NN p
or CC p
=3.6 VB p
mmol/L NN p
) ) p
, , p
and CC p
a DT p
range NN p
of IN p
triglyceride NN p
values NNS p
. . p

Moderate NNP N
CRI NNP N
is VBZ N
defined VBN N
as IN N
estimated VBN N
glomerular JJ N
filtration NN N
rate NN N
( ( N
GFR NNP N
) ) N
of IN N
30 CD N
to TO N
59.9 CD N
mL/min/1.73 NNS N
m2 NN N
at IN N
baseline NN N
. . N

Multivariate NNP N
regression NN N
was VBD N
used VBN N
to TO N
calculate VB N
rates NNS N
of IN N
decline NN N
in IN N
estimated VBN N
GFR NNP N
for IN N
individuals NNS N
administered VBN N
gemfibrozil NN i
or CC i
placebo NN i
, , N
controlling VBG N
for IN N
prospectively RB N
determined VBN N
potential JJ N
confounders NNS N
. . N

RESULTS NNP N
Change NNP o
in IN o
renal JJ o
function NN o
could MD N
be VB N
calculated VBN N
in IN N
1,981 CD p
individuals NNS p
, , p
of IN p
whom WP p
399 CD p
individuals NNS p
( ( p
20.2 CD p
% NN p
) ) p
were VBD p
eligible JJ p
for IN p
inclusion NN p
. . p

Among IN N
399 CD p
study NN p
subjects NNS p
, , N
the DT N
rate NN o
of IN o
change NN o
in IN o
renal JJ o
function NN o
in IN N
the DT N
gemfibrozil NN i
group NN N
during IN N
a DT N
median NN N
of IN N
61 CD N
months NNS N
was VBD N
not RB N
significantly RB N
different JJ N
from IN N
that DT N
in IN N
the DT N
placebo NN i
group NN N
( ( N
0.49 CD N
mL/min/1.73 NN N
m2/y NN N
faster RBR N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
0.09 CD N
slower JJR N
to TO N
1.09 CD N
faster NN N
; : N
P NNP N
= NNP N
0.10 CD N
) ) N
. . N

No UH N
clinically RB N
relevant JJ N
effect NN N
of IN N
gemfibrozil NN i
on IN N
renal JJ o
function NN o
was VBD N
observed VBN N
in IN N
groups NNS N
defined VBN N
by IN N
baseline NN o
lipid NN o
levels NNS o
, , o
kidney NN o
function NN o
, , o
diabetic JJ o
status NN o
, , o
or CC o
other JJ o
components NNS o
of IN o
the DT o
metabolic JJ o
syndrome NN o
. . o

The DT N
incidence NN N
of IN N
transient NN N
( ( N
10 CD N
% NN N
versus IN N
4 CD N
% NN N
; : N
P NNP N
= NNP N
0.01 CD N
) ) N
, , N
but CC N
not RB N
sustained VBN N
( ( N
9 CD N
% NN N
versus IN N
4 CD N
% NN N
; : N
P NNP N
= NNP N
0.07 CD N
) ) N
, , N
increases VBZ N
in IN N
serum JJ o
creatinine NN o
levels NNS o
of IN N
0.5 CD N
mg/dL NN N
or CC N
greater JJR N
( ( N
> CD N
or CC N
=44 VB N
micromol/L NN N
) ) N
was VBD N
significantly RB N
greater JJR N
in IN N
the DT N
gemfibrozil NN i
group NN N
. . N

However RB N
, , N
in IN N
5 CD N
subjects NNS N
with IN N
acute JJ N
increases NNS N
in IN N
serum JJ o
creatinine NN o
levels NNS o
, , o
serum NN o
creatine NN o
kinase NN o
levels NNS o
were VBD N
significantly RB N
elevated VBN N
as RB N
well RB N
, , N
suggesting VBG N
that IN N
myocyte JJ N
toxicity NN N
may MD N
have VB N
been VBN N
responsible JJ N
. . N

Even RB N
when WRB N
these DT N
individuals NNS N
were VBD N
excluded VBN N
, , N
no DT N
clinically RB N
significant JJ N
effect NN N
of IN N
gemfibrozil NN i
on IN N
kidney NN o
function NN o
was VBD N
observed VBN N
. . N

CONCLUSION NNP N
Gemfibrozil NNP i
does VBZ N
not RB N
appear VB N
to TO N
exert VB N
a DT N
clinically RB N
relevant JJ N
effect NN N
on IN N
rates NNS N
of IN N
kidney NN o
function NN o
loss NN N
in IN N
individuals NNS p
with IN p
moderate JJ p
CRI NNP p
, , p
low JJ p
HDL-C NNP p
levels NNS p
, , p
and CC p
concomitant JJ p
coronary JJ p
disease NN p
. . p

-DOCSTART- -18845704- O O

Medium NN i
chain NN i
triglyceride JJ i
oil NN i
consumption NN N
as IN N
part NN N
of IN N
a DT N
weight JJ N
loss NN N
diet NN N
does VBZ N
not RB N
lead VB N
to TO N
an DT N
adverse JJ N
metabolic NN N
profile NN N
when WRB N
compared VBN N
to TO N
olive JJ i
oil NN i
. . i

OBJECTIVE NNP N
Medium NNP i
chain NN i
triglyceride NN i
( ( i
MCT NNP i
) ) i
consumption NN N
may MD N
have VB N
a DT N
beneficial JJ N
impact NN N
on IN N
weight NN N
management NN N
, , N
however RB N
, , N
some DT N
studies NNS N
point VBP N
to TO N
a DT N
negative JJ N
impact NN N
of IN N
MCT NNP i
oil NN i
consumption NN N
on IN N
cardiovascular JJ N
disease NN N
risk NN N
. . N

This DT N
study NN N
examined VBD N
the DT N
effects NNS N
of IN N
MCT NNP i
oil NN i
consumption NN i
, , N
as IN N
part NN N
of IN N
a DT N
weight JJ N
loss NN N
diet NN N
, , N
on IN N
metabolic JJ N
risk NN N
profile NN N
compared VBN N
to TO N
olive JJ N
oil NN N
. . N

DESIGN NNP N
Thirty-one JJ p
men NNS p
and CC p
women NNS p
, , p
age NN p
19-50 JJ p
y NN p
and CC p
body NN p
mass NN p
index NN p
27-33 JJ p
kg/m NN p
( ( p
2 CD p
) ) p
, , N
completed VBD N
this DT N
randomized VBN N
, , N
controlled VBN N
, , N
16-week JJ N
weight JJ N
loss NN N
program NN N
. . N

Oils NNS N
were VBD N
consumed VBN N
at IN N
a DT N
level NN N
of IN N
approximately RB N
12 CD N
% NN N
of IN N
the DT N
subjects NNS N
' POS N
prescribed VBN N
energy NN N
intakes NNS N
in IN N
the DT N
form NN N
of IN N
muffins NNS N
and CC N
liquid JJ i
oil NN i
. . i

RESULTS NN N
After IN N
controlling VBG N
for IN N
body NN N
weight NN N
, , N
there EX N
was VBD N
a DT N
significant JJ N
effect NN N
of IN N
time NN N
on IN N
fasting VBG o
serum NN o
glucose NN o
( ( N
P NNP N
= NNP N
0.0177 CD N
) ) N
and CC N
total JJ o
cholesterol NN o
( ( N
P NNP N
= NNP N
0.0386 CD N
) ) N
concentrations NNS N
, , N
and CC N
on IN N
diastolic JJ o
blood NN o
pressure NN o
( ( N
P NNP N
= NNP N
0.0413 CD N
) ) N
, , N
with IN N
reductions NNS N
in IN N
these DT N
variables NNS N
occurring VBG N
over IN N
time NN N
; : N
there EX N
was VBD N
no DT N
time-by-diet JJ N
interaction NN N
for IN N
any DT N
of IN N
the DT N
parameters NNS N
studied VBN N
. . N

Two CD p
of IN p
the DT p
3 CD p
subjects NNS p
in IN p
the DT p
MCT NNP i
oil NN i
group NN p
with IN N
evidence NN N
of IN N
the DT N
metabolic JJ N
syndrome NN N
at IN N
baseline NN N
did VBD N
not RB N
have VB N
metabolic JJ N
syndrome VBN N
at IN N
endpoint NN N
. . N

In IN N
the DT N
olive JJ i
oil NN i
group NN N
, , N
6 CD p
subjects NNS p
had VBD p
the DT p
metabolic JJ p
syndrome NN p
at IN p
baseline NN p
; : p
2 CD p
subjects VBZ p
no RB p
longer RBR p
had VBD p
metabolic JJ p
syndrome NN p
at IN p
endpoint NN p
, , p
1 CD p
person NN p
developed VBD p
metabolic JJ p
syndrome NN p
, , p
and CC p
4 CD p
subjects NNS p
did VBD p
not RB p
have VB p
any DT p
change NN p
in IN p
their PRP$ p
metabolic JJ p
syndrome NN p
status NN p
. . p

CONCLUSIONS VB N
Our PRP$ N
results NNS N
suggest VBP N
that IN N
MCT NNP i
oil NN i
can MD N
be VB N
incorporated VBN N
into IN N
a DT N
weight JJ N
loss NN N
program NN N
without IN N
fear NN N
of IN N
adversely RB N
affecting VBG N
metabolic JJ N
risk NN N
factors NNS N
. . N

Distinction NN N
should MD N
be VB N
made VBN N
regarding VBG N
chain NN N
length NN N
when WRB N
it PRP N
comes VBZ N
to TO N
discussing VBG N
the DT N
effects NNS N
of IN N
saturated JJ N
fats NNS N
on IN N
metabolic JJ N
risk NN N
factors NNS N
. . N

-DOCSTART- -24930383- O O

Elevation NN N
of IN N
HDL-C NNP o
in IN N
response NN N
to TO N
statin VB i
treatment NN N
is VBZ N
involved VBN N
in IN N
the DT N
regression NN p
of IN p
carotid JJ p
atherosclerosis NN p
. . p

AIM NNP N
Atherosclerosis NNP N
is VBZ N
strongly RB N
associated VBN N
with IN N
an DT N
increased VBN N
mortality NN N
in IN N
subjects NNS p
with IN p
diabetes NNS p
. . p

The DT N
carotid JJ o
intima-media JJ o
thickness NN o
( ( o
IMT NNP o
) ) o
is VBZ N
commonly RB N
measured VBN N
as IN N
a DT N
surrogate NN N
marker NN N
for IN N
cardiovascular JJ N
risk NN N
. . N

Statins NNS N
are VBP N
well-established JJ N
protective JJ N
agents NNS N
against IN N
atherosclerosis NN N
and CC N
reportedly RB N
suppress JJ N
IMT NNP N
progression NN N
in IN N
subjects NNS N
with IN N
diabetes NNS N
. . N

To TO N
clarify VB N
the DT N
effects NNS N
of IN N
statins NNS N
on IN N
subclinical JJ N
atherosclerosis NN N
, , N
we PRP N
herein VBP N
investigated JJ N
changes NNS N
in IN N
the DT N
carotid NN N
IMT NNP N
and CC N
lipid JJ N
profiles NNS N
in IN N
a DT N
multi-center NN N
, , N
prospective JJ N
, , N
randomized JJ N
trial NN N
. . N

METHODS NNP N
Hypercholesterolemic NNP p
subjects VBZ p
with IN p
type NN p
2 CD p
diabetes NNS p
were VBD N
randomly RB N
assigned VBN N
to TO N
open-label JJ N
treatment NN N
with IN N
either DT N
pravastatin NN i
or CC i
pitavastatin NN i
. . i

The DT N
primary JJ N
endpoint NN N
of IN N
this DT N
study NN N
was VBD N
the DT N
IMT NNP o
change NN o
after IN N
36 CD N
months NNS N
of IN N
statin JJ i
treatment NN N
. . N

RESULTS VB N
A DT p
total NN p
of IN p
97 CD p
subjects NNS p
( ( p
51 CD p
pitavastatin NN i
; : i
46 CD p
pravastatin NN i
) ) i
completed VBD p
this DT p
36-month JJ p
study NN p
. . p

The DT N
LDL-C NNP o
decreased VBD N
significantly RB N
from IN N
163.4 CD N
? . N
27.9 CD N
mg/dl NN N
at IN N
baseline NN N
to TO N
100.4 CD N
? . N
19.6 CD N
mg/dl NN N
at IN N
36 CD N
months NNS N
in IN N
the DT N
pitavastatin NN N
group NN N
and CC N
from IN N
159.7 CD N
? . N
25.6 CD N
mg/dl NN N
to TO N
118.5 CD N
? . N
22.1 CD N
mg/dl NN N
in IN N
the DT N
pravastatin NN N
group NN N
. . N

The DT N
mean NN o
IMT NNP o
showed VBD N
moderate JJ N
regression NN N
in IN N
both CC N
the DT N
pitavastatin NN i
( ( i
-0.070 VB i
? . N
0.215 CD N
mm NN N
, , N
P NNP N
< NNP N
0.05 CD N
) ) N
and CC N
the DT i
pravastatin NN i
( ( i
-0.067 VB i
? . N
0.260 CD N
mm NN N
) ) N
group NN N
. . N

However RB N
, , N
there EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
the DT N
IMT NNP o
change NN o
between IN o
the DT N
two CD N
groups NNS N
. . N

When WRB N
the DT N
two CD N
groups NNS N
were VBD N
combined VBN N
, , N
the DT N
36-month JJ N
change NN N
in IN N
the DT N
mean JJ o
IMT NNP o
was VBD o
significantly RB N
associated VBN o
with IN o
HDL-C NNP o
change NN o
( ( o
r=-0.24 JJ o
, , N
P= NNP N
0.03 CD N
) ) N
. . N

Multiple JJ N
linear JJ N
regression NN N
analysis NN N
revealed VBD N
the DT N
change NN N
in IN o
HDL-C NNP o
to TO N
be VB N
an DT N
independent JJ N
variable JJ N
showing VBG N
a DT N
positive JJ N
correlation NN N
with IN N
the DT N
carotid NN N
IMT NNP N
reduction NN N
. . N

CONCLUSION NNP N
The DT N
administration NN N
of IN N
statins NNS N
for IN N
3 CD N
years NNS N
to TO N
subjects NNS N
with IN N
type JJ N
2 CD N
diabetes NNS N
resulted VBD N
in IN N
a DT N
significant JJ N
regression NN N
of IN N
the DT N
carotid NN o
IMT NNP o
. . o

An DT N
elevation NN N
of IN N
the DT N
plasma JJ o
HDL-C NNP o
with IN i
statin JJ i
treatment NN i
was VBD N
closely RB N
related VBN N
to TO N
a DT N
regression NN N
of IN N
atherosclerosis NN N
. . N

-DOCSTART- -2690913- O O

West NNP N
Midlands NNP N
Oncology NNP N
Association NNP N
trials NNS N
of IN N
adjuvant JJ i
chemotherapy NN i
in IN N
operable JJ p
breast NN p
cancer NN p
: : p
results NNS N
after IN N
a DT N
median JJ N
follow-up NN N
of IN N
7 CD N
years NNS N
. . N

I PRP N
. . N

Patients NNS p
with IN p
involved JJ p
axillary JJ p
lymph NN p
nodes NNS p
. . p

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
test VB N
the DT N
effectiveness NN N
of IN N
a DT N
regimen NNS i
of IN i
combination NN i
chemotherapy NN i
known VBN N
to TO N
be VB N
active JJ N
in IN N
advanced JJ N
breast NN N
cancer NN N
when WRB N
given VBN N
as IN N
an DT N
adjuvant JJ N
treatment NN N
after IN N
mastectomy NN N
. . N

A DT N
total NN N
of IN p
569 CD p
patients NNS p
with IN p
cancer NN p
of IN p
the DT p
breast NN p
and CC p
involvement NN p
of IN p
axillary JJ p
lymph NN p
nodes NNS p
were VBD p
randomised VBN p
, , p
after IN p
simple JJ i
mastectomy NN i
with IN i
axillary JJ i
sampling NN i
, , N
to TO N
receive VB N
either DT N
no DT i
adjuvant JJ i
treatment NN i
or CC i
intravenous JJ i
adriamycin NNS i
50 CD N
mg NN N
, , N
vincristine VBP i
1 CD N
mg NN N
, , N
cyclophosphamide RB i
250 CD N
mg NN N
, , N
methotrexate VB i
150 CD N
mg NN N
and CC N
fluorouracil NN i
250 CD N
mg NN N
( ( i
AVCMF NNP i
) ) i
every DT N
21 CD N
days NNS N
for IN N
eight CD N
cycles NNS N
. . N

Randomisation NN N
was VBD N
stratified VBN N
according VBG N
to TO N
menopausal NN N
status NN N
and CC N
tumour NN N
size NN N
. . N

Treatment NN N
was VBD N
started VBN N
within IN N
14 CD N
days NNS N
of IN N
surgery NN N
in IN N
94 CD N
% NN N
of IN N
patients NNS N
. . N

Eighty-eight JJ N
per IN N
cent NN N
of IN N
patients NNS N
received VBN N
at IN N
least JJS N
seven CD N
cycles NNS N
of IN N
chemotherapy NN N
with IN N
no DT N
dose JJ N
reduction NN N
. . N

The DT N
median JJ o
relapse-free JJ o
survival NN o
was VBD N
prolonged VBN N
by IN N
14 CD N
months NNS N
in IN N
patients NNS N
treated VBN N
with IN N
AVCMF NNP i
( ( N
chi2 JJ N
1 CD N
= JJ N
11.7 CD N
; : N
P NNP N
= NNP N
0.0006 CD N
) ) N
. . N

In IN N
the DT N
premenopausal NN p
group NN N
this DT N
period NN N
was VBD N
17 CD N
months NNS N
( ( N
chi2 JJ N
1 CD N
= JJ N
8.8 CD N
; : N
P NNP N
= NNP N
0.003 CD N
) ) N
compared VBN N
with IN N
8 CD N
months NNS N
in IN N
the DT N
post-menopausal JJ p
group NN N
( ( N
chi2 JJ N
1 CD N
= JJ N
3.3 CD N
; : N
P NNP N
= NNP N
0.07 CD N
) ) N
. . N

Neither CC N
overall JJ o
survival NN o
nor CC o
survival NN o
in IN N
these DT N
subgroups NNS N
was VBD N
significantly RB N
influenced VBN N
by IN N
treatment NN N
. . N

-DOCSTART- -8623941- O O

Processing VBG N
familiar JJ N
and CC N
unfamiliar JJ N
auditory NN N
stimuli NN N
during IN p
general JJ p
anesthesia NN p
. . p

We PRP N
tested VBD N
memory NN N
priming NN N
for IN N
auditory JJ i
stimuli NNS i
presented VBN N
during IN N
general JJ i
propofol-sufentanil JJ i
anesthesia NN i
in IN p
58 CD p
patients NNS p
undergoing JJ p
day-case JJ i
arthroscopic NN i
surgery NN i
. . i

Stimuli NNP i
were VBD i
presented VBN i
via IN i
headphones NNS i
and CC i
consisted VBN i
of IN i
common JJ i
facts NNS i
( ( p
Group NNP p
A NNP p
, , p
29 CD p
patients NNS p
) ) p
, , N
or CC i
familiar JJ i
or CC i
unfamiliar JJ i
full JJ i
names NNS i
of IN i
fictitious JJ i
people NNS i
( ( p
GRoup NNP p
B NNP p
, , p
29 CD p
patients NNS p
) ) p
. . p

Group NNP N
A NNP N
was VBD N
expected VBN N
to TO N
give VB N
more JJR N
correct JJ N
answers NNS N
to TO N
questions NNS N
about IN N
the DT N
common JJ N
facts NNS N
than IN N
Group NNP N
B NNP N
, , N
when WRB N
tested VBN N
postoperatively RB N
, , N
and CC N
Group NNP N
B NNP N
to TO N
attribute VB N
more JJR N
fame NN N
to TO N
presented VBN N
names NNS N
than IN N
Group NNP N
A NNP N
( ( N
famous JJ N
names RB N
test NN N
) ) N
. . N

Because IN N
the DT N
process NN N
for IN N
learning VBG N
new JJ N
or CC N
unfamiliar JJ N
stimuli NNS N
( ( N
elaboration NN N
) ) N
in IN N
particular JJ N
may MD N
be VB N
impaired VBN N
under IN p
general JJ p
anesthesia NN p
, , N
more JJR N
memory NN N
priming NN N
was VBD N
expected VBN N
for IN N
familiar JJ N
than IN N
for IN N
unfamiliar JJ N
material NN N
. . N

No DT N
significant JJ N
differences NNS N
were VBD N
demonstrated VBN N
between IN N
the DT N
two CD N
groups NNS N
in IN N
performance NN o
on IN o
common JJ o
facts NNS o
or CC N
in IN o
fame NN o
attributed VBN N
to TO N
the DT N
names NNS N
. . N

The DT N
amount NN o
of IN o
memory NN o
priming NN o
, , N
however RB N
, , N
was VBD N
positively RB o
related VBN o
to TO o
one CD o
of IN o
two CD o
measures NNS o
of IN N
preoperative JJ o
anxiety NN o
. . o

-DOCSTART- -16382035- O O

Albendazole JJ i
trial NN N
at IN N
15 CD N
or CC N
30 CD N
mg/kg/day NN N
for IN N
subarachnoid NN p
and CC p
intraventricular JJ p
cysticercosis NN p
. . p

Thirty-six JJ p
patients NNS p
with IN p
subarachnoid JJ p
and CC p
intraventricular JJ p
cysticercosis NN p
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
albendazole NN i
at IN N
15 CD N
or CC N
30 CD N
mg/kg/day JJ N
plus CC N
dexamethasone NN i
for IN N
8 CD N
days NNS N
. . N

Results NNS N
favored VBD N
a DT N
higher JJR N
dose NN N
, , N
with IN N
larger JJR o
cyst NN o
reduction NN o
on IN N
MRI NNP N
at IN N
90 CD N
and CC N
180 CD N
days NNS N
and CC N
higher JJR N
albendazole JJ o
sulfoxide NN o
levels NNS o
in IN o
plasma NN o
. . o

An DT N
albendazole JJ i
course NN N
at IN N
30 CD N
mg/kg/day NN N
combined VBN N
with IN N
corticosteroids NNS i
is VBZ N
safe JJ o
and CC o
more RBR o
effective JJ o
than IN N
the DT N
usual JJ N
dose NN N
. . N

A DT N
single JJ N
treatment NN N
was VBD N
insufficient JJ o
in IN N
intraventricular JJ N
and CC N
giant JJ N
cysts NNS N
. . N

-DOCSTART- -14970775- O O

Injection NN o
pain NN o
and CC o
postinjection NN o
pain NN o
of IN N
the DT N
palatal-anterior JJ p
superior JJ p
alveolar JJ p
injection NN p
, , N
administered VBN N
with IN N
the DT N
Wand NNP N
Plus NNP N
system NN N
, , N
comparing VBG N
2 CD N
% NN N
lidocaine NN i
with IN N
1:100,000 CD N
epinephrine NN i
to TO N
3 CD N
% NN N
mepivacaine NN i
. . i

PURPOSE VB N
The DT N
purpose NN N
of IN N
this DT N
prospective JJ N
, , N
randomized VBN N
, , N
double-blind JJ N
study NN N
was VBD N
to TO N
compare VB N
injection NN o
pain NN o
and CC o
postinjection NN o
pain NN o
of IN N
2 CD N
% NN N
lidocaine NN N
with IN N
1:100,000 CD N
epinephrine NN i
and CC N
3 CD N
% NN N
mepivacaine NN i
using VBG N
the DT N
computer-assisted JJ N
Wand NNP N
Plus NNP N
injection NN N
system NN N
to TO N
administer VB N
the DT N
palatal-anterior JJ N
superior JJ N
alveolar NN N
( ( N
P-ASA NNP N
) ) N
injection NN N
. . N

Additionally RB N
study NN N
was VBD N
done VBN N
to TO N
determine VB N
if IN N
the DT N
use NN N
of IN N
topical JJ i
anesthetic NN i
decreased VBD N
the DT N
pain NN o
of IN N
needle JJ N
insertion NN N
with IN N
the DT N
P-ASA NNP N
injection NN N
. . N

STUDY NNP N
DESIGN NNP N
Using VBG N
a DT N
crossover NN N
design NN N
, , N
40 CD p
subjects NNS p
randomly RB N
received VBD N
, , N
in IN N
a DT N
double-blind JJ N
manner NN N
, , N
P-ASA NNP i
injections NNS i
of IN i
1.4 CD i
mL NN i
of IN i
2 CD i
% NN i
lidocaine NN i
with IN N
1:100,000 CD i
epinephrine NN i
and CC i
1.4 CD i
mL NN i
of IN i
3 CD i
% NN i
mepivacaine NN i
, , N
at IN N
2 CD N
separate JJ N
appointments NNS N
. . N

The DT N
P-ASA JJ N
injection NN N
was VBD N
administered VBN N
, , N
utilizing VBG N
the DT N
Wand NNP N
Plus NNP N
system NN N
, , N
6 CD N
to TO N
10 CD N
mm NN N
into IN N
the DT N
incisive JJ N
canal NN N
located VBN N
lingual JJ N
to TO N
the DT N
central JJ N
incisors NNS N
. . N

The DT N
pain NN o
of IN o
needle JJ o
insertion NN o
, , o
needle JJ o
placement NN o
, , o
solution NN o
deposition NN o
and CC o
postinjection NN o
pain NN o
were VBD N
recorded VBN N
on IN N
a DT N
Heft-Parker NNP N
visual JJ N
analog NN N
scale NN N
for IN N
the DT N
2 CD N
P-ASA JJ N
injections NNS N
. . N

Eighty JJ N
injections NNS N
were VBD N
randomly RB N
administered VBN N
in IN N
the DT N
study NN N
, , N
40 CD N
using VBG N
topical JJ i
anesthetic JJ i
gel NN i
and CC N
40 CD N
using VBG N
a DT N
placebo NN i
gel NN i
. . i

RESULTS NNP N
For IN N
needle JJ N
insertion NN N
, , N
30 CD N
% NN N
of IN N
the DT N
subjects NNS N
reported VBN N
moderate/severe RB o
pain NN o
with IN N
the DT N
lidocaine JJ N
solution NN N
and CC N
43 CD N
% NN N
reported VBN N
moderate/severe RB o
pain NN o
with IN N
the DT N
mepivacaine JJ i
solution NN N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
( ( N
P NNP N
> NNP N
.05 NNP N
) ) N
between IN N
the DT N
topical JJ N
and CC N
placebo JJ i
groups NNS N
. . N

For IN N
needle JJ N
placement NN N
into IN N
the DT N
incisive JJ N
canal NN N
, , N
54 CD N
% NN N
of IN N
the DT N
subjects NNS N
reported VBN N
moderate/severe RB o
pain NN o
with IN N
the DT N
lidocaine JJ i
solution NN N
and CC N
58 CD N
% NN N
reported VBN N
moderate/severe RB o
pain NN o
with IN N
the DT N
mepivacaine JJ i
solution NN N
. . N

For IN N
anesthetic JJ N
solution NN N
deposition NN N
, , N
8 CD N
% NN N
of IN N
the DT N
subjects NNS N
reported VBN N
moderate JJ o
pain NN o
with IN N
the DT N
lidocaine JJ i
solution NN N
and CC N
12 CD N
% NN N
reported VBN N
moderate JJ o
pain NN o
with IN N
the DT N
mepivacaine JJ i
solution NN N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
( ( N
P NNP N
> NNP N
.05 NNP N
) ) N
between IN N
the DT N
lidocaine NN i
and CC N
mepivacaine JJ i
solutions NNS N
. . N

Regarding VBG N
postinjection NN o
pain NN o
, , N
when WRB N
anesthesia NN N
wore VBD N
off RP N
on IN N
the DT N
day NN N
of IN N
the DT N
injection NN N
, , N
20 CD N
% NN N
of IN N
the DT N
subjects NNS N
reported VBN N
moderate/severe RB o
pain NN o
with IN N
the DT N
lidocaine JJ i
solution NN N
and CC N
14 CD N
% NN N
reported VBN N
moderate/severe RB o
pain NN o
with IN N
the DT N
mepivacaine JJ i
solution NN N
. . N

Pain NNP o
ratings NNS o
decreased VBD N
over IN N
the DT N
next JJ N
3 CD N
days NNS N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
( ( N
P NNP N
> NNP N
.05 NNP N
) ) N
between IN N
the DT N
lidocaine NN i
and CC N
mepivacaine JJ i
solutions NNS N
. . N

Postinjection NNP N
, , N
12 CD N
% NN N
and CC N
18 CD N
% NN N
of IN N
the DT N
subjects NNS N
experienced VBD N
temporary JJ o
numbness/paresthesia NN o
of IN o
the DT o
incisive JJ o
papilla NN o
with IN N
the DT N
lidocaine NN i
and CC N
mepivacaine JJ i
solutions NNS N
, , N
respectively RB N
. . N

Twenty CD N
percent NN N
and CC N
28 CD N
% NN N
of IN N
the DT N
subjects NNS N
had VBD N
incisive JJ o
papilla NN o
swelling VBG o
or CC o
soreness NN o
with IN N
the DT N
lidocaine NN i
and CC N
mepivacaine JJ i
solutions NNS N
, , N
respectively RB N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
( ( N
P NNP N
> NNP N
.05 NNP N
) ) N
between IN N
the DT N
lidocaine NN i
and CC N
mepivacaine JJ i
solutions NNS N
. . N

CONCLUSIONS VB N
The DT N
P-ASA NNP N
injection NN N
of IN N
1.4 CD N
mL NN N
of IN N
2 CD N
% NN N
lidocaine NN i
with IN N
1:100,000 CD N
epinephrine NN i
or CC N
3 CD N
% NN N
mepivacaine NN i
, , N
administered VBN N
with IN N
the DT N
Wand NNP N
Plus NNP N
, , N
has VBZ N
the DT N
potential JJ N
to TO N
be VB N
a DT N
painful JJ N
injection NN N
. . N

The DT N
use NN N
of IN N
topical JJ N
anesthetic NN N
did VBD N
not RB N
significantly RB N
reduce VB N
pain NN o
of IN N
needle JJ N
insertion NN N
when WRB N
compared VBN N
to TO N
a DT N
placebo NN i
. . i

The DT N
incidence NN N
of IN N
postinjection NN o
pain NN o
, , o
temporary JJ o
numbness/paresthesia NN o
, , o
and CC o
incisive JJ o
papilla NN o
swelling VBG o
or CC o
soreness NN o
would MD N
indicate VB N
that IN N
some DT N
pain NN N
and CC N
problems NNS N
occur VBP N
with IN N
the DT N
P-ASA NNP N
technique NN N
, , N
regardless RB N
of IN N
whether IN N
2 CD N
% NN N
lidocaine NN i
with IN N
1:100,000 CD N
epinephrine NN i
or CC N
3 CD N
% NN N
mepivacaine NN i
is VBZ N
used VBN N
. . N

-DOCSTART- -16393740- O O

The DT N
impact NN N
of IN N
emotional JJ i
distress NN i
on IN N
HIV NNP o
risk NN o
reduction NN o
among IN p
women NNS p
. . p

This DT N
study NN N
evaluated VBD N
whether IN N
333 CD p
seronegative JJ p
African JJ p
American JJ p
female JJ p
drug NN p
users NNS p
( ( p
aged VBN p
18-59 CD p
years NNS p
) ) p
participating VBG p
in IN p
an DT p
HIV NNP i
intervention NN i
and CC p
with IN p
higher JJR p
levels NNS p
of IN p
emotional JJ p
distress NN p
, , p
specifically RB p
symptoms NNS p
of IN p
depression NN p
and CC p
anxiety NN p
, , N
reduced VBD N
HIV NNP N
risk NN N
behaviors NNS N
to TO N
a DT N
lesser JJR N
extent NN N
than IN N
those DT N
with IN N
lower JJR N
levels NNS N
of IN N
emotional JJ N
distress NN N
. . N

Participants NNS p
were VBD N
recruited VBN p
between IN p
June NNP p
1998 CD p
and CC p
January NNP p
2001 CD p
from IN p
inner-city NN p
Atlanta NNP p
( ( p
Georgia NNP p
, , p
U.S. NNP p
) ) p
neighborhoods NNS p
and CC N
were VBD N
randomly RB p
assigned VBN p
to TO p
one CD p
of IN p
two CD p
enhanced JJ i
gender-specific JJ i
and CC i
culturally RB i
specific JJ i
HIV NNP i
intervention NN i
conditions NNS p
or CC N
to TO N
the DT N
NIDA NNP N
standard JJ N
condition NN N
. . N

Participants NNS N
were VBD N
interviewed VBN N
at IN N
baseline NN N
, , N
post-intervention NN N
and CC N
at IN N
6-month JJ N
follow-up NN N
with IN N
a DT N
structured JJ i
questionnaire NN i
including VBG N
information NN N
on IN N
sociodemographics NNS N
, , N
sexual JJ N
and CC N
drug-using JJ N
behavior NN N
, , N
and CC N
psychosocial JJ N
characteristics NNS N
. . N

Despite IN N
a DT N
significant JJ N
decline NN N
in IN N
symptoms NNS N
of IN N
emotional JJ N
distress NN N
during IN N
the DT N
study NN N
period NN N
, , N
the DT N
women NNS N
in IN N
this DT N
sample NN N
reported VBD N
high JJ N
levels NNS N
of IN N
depressive NN o
and CC o
anxiety NN o
symptoms NNS o
at IN N
baseline NN N
and CC N
6-month JJ N
follow-up NN N
. . N

Higher JJR o
levels NNS o
of IN o
emotional JJ o
distress NN o
were VBD N
positively RB N
associated VBN N
with IN N
post-intervention NN o
sexual JJ o
and CC o
drug-taking JJ o
risk NN o
. . o

Women NNS N
in IN N
both DT N
enhanced JJ i
intervention NN i
conditions NNS i
reduced VBD N
their PRP$ N
sexual JJ o
and CC o
drug-taking JJ o
risks NNS o
more RBR N
than IN N
women NNS N
in IN N
the DT N
standard JJ i
intervention NN i
. . i

Those DT N
in IN N
the DT N
motivation NN i
intervention NN i
arm NN N
experienced VBD N
a DT N
greater JJR N
reduction NN N
in IN N
depressive JJ o
symptoms NNS o
, , N
accompanied VBN N
by IN N
a DT N
greater JJR N
reduction NN N
in IN N
sexual JJ o
risk NN o
behavior NN o
. . o

Findings NNS N
suggest VBP N
the DT N
need NN N
for IN N
effective JJ N
interventions NNS N
and CC N
mental JJ N
health NN N
resources NNS N
among IN N
subgroups NNS N
of IN N
high-risk JJ p
women NNS p
who WP p
may MD p
be VB p
most RBS p
resistant JJ p
to TO p
behavioral JJ p
change NN p
. . p

-DOCSTART- -6420374- O O

The DT N
effect NN N
of IN N
surgical JJ N
trauma NN N
and CC N
insulin NN i
on IN N
whole-body NN o
protein NN o
turnover NN o
in IN N
parenterally-fed JJ p
undernourished JJ p
patients NNS p
. . p

Ten CD p
undernourished JJ p
patients NNS p
receiving VBG p
total JJ p
parenteral JJ p
nutrition NN p
and CC p
undergoing JJ p
major JJ p
intestinal JJ p
surgery NN p
were VBD N
restarted VBN N
on IN N
intravenous JJ N
feeds NNS N
identical JJ N
to TO N
their PRP$ N
pre-operative JJ N
regimens NNS N
within IN N
24 CD N
h NNS N
of IN N
their PRP$ N
operation NN N
. . N

Five CD N
, , N
chosen VBN N
at IN N
random NN N
, , N
received VBD N
post-operatively RB N
1-2 JJ i
units NNS i
insulin/kg VBP i
body NN i
weight/24 JJ i
h NN i
with IN i
their PRP$ i
feed NN i
, , N
while IN N
the DT N
other JJ N
five CD N
received VBD i
the DT i
feed NN i
only RB i
. . i

Pre-operatively RB N
, , N
and CC N
2 CD N
h NN N
after IN N
commencing VBG N
their PRP$ N
post-operative JJ N
feeds NNS N
, , N
rates NNS o
of IN o
whole-body NN o
protein NN o
synthesis NN o
and CC o
breakdown NN o
were VBD N
measured VBN N
over IN N
a DT N
9-h JJ N
period NN N
following VBG N
intravenous JJ N
injection NN N
of IN N
a DT N
single JJ N
tracer NN N
dose NN N
of IN N
15N-glycine JJ i
by IN N
the DT N
ammonia NN N
and CC N
urea JJ N
end-product NN N
methods NNS N
. . N

During IN N
these DT N
9-h CD N
study NN N
periods NNS N
measurements NNS N
were VBD N
also RB N
made VBN N
of IN N
blood NN o
glucose NN o
, , o
plasma JJ o
insulin NN o
and CC o
glucagon NN o
, , o
urinary JJ o
ammonia NN o
, , o
nitrogen NN o
, , o
creatinine NN o
and CC o
3-methylhistidine JJ o
. . o

Blood NNP o
glucose NN o
and CC o
plasma JJ o
insulin NN o
and CC o
glucagon NN o
concentrations NNS o
rose VBD N
post-operatively RB N
whether IN N
or CC N
not RB N
insulin NN i
was VBD N
given VBN N
, , N
but CC N
the DT N
increment NN N
in IN N
insulin NN o
concentration NN o
was VBD N
significantly RB N
greater JJR N
when WRB N
insulin NN i
was VBD N
given VBN N
. . N

Apparent JJ o
nitrogen NN o
balance NN o
was VBD N
positive JJ N
pre-operatively RB N
and CC N
became VBD N
less RBR N
so RB N
post-operatively RB N
whether IN N
insulin NN i
was VBD N
given VBN N
or CC N
not RB N
. . N

Similarly RB N
, , N
post-operative JJ N
increments NNS N
in IN N
urinary JJ o
excretion NN o
of IN o
ammonia NN o
, , o
creatinine NN o
and CC o
3-methylhistidine JJ o
were VBD N
not RB N
altered VBN N
by IN N
addition NN N
of IN N
insulin NN i
. . i

Protein NNP o
turnover NN o
, , N
as IN N
estimated VBN N
by IN N
the DT N
ammonia JJ o
end-product NN o
method NN N
, , N
tended VBD N
to TO N
rise VB N
post-operatively RB N
, , N
but CC N
there EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
the DT N
increases NNS N
observed VBD N
with IN N
or CC N
without IN N
insulin NN i
. . i

The DT N
urea JJ N
end-product NN N
method NN N
suggested VBD N
that IN N
there EX N
was VBD N
no DT N
change NN N
in IN N
whole-body NN o
protein NN o
turnover NN o
after IN N
surgery NN N
, , N
whether IN N
or CC N
not RB N
insulin NN i
was VBD N
given VBN N
. . N

This DT N
study NN N
does VBZ N
not RB N
support VB N
the DT N
clinical JJ N
use NN N
of IN N
insulin NN o
as IN N
a DT N
means NN N
of IN N
modifying VBG N
protein JJ N
metabolic JJ N
losses NNS N
after IN N
major JJ p
surgery NN p
. . p

-DOCSTART- -25700292- O O

The DT N
nature NN N
of IN N
placebo NN i
response NN N
in IN N
clinical JJ N
studies NNS N
of IN N
major JJ p
depressive JJ p
disorder NN p
. . p

OBJECTIVE NNP N
To TO N
review VB N
factors NNS N
influencing VBG N
placebo NN i
response NN N
and CC N
clinical JJ N
trial NN N
outcome NN N
in IN N
depression NN p
, , N
and CC N
suggest VBP N
ways NNS N
to TO N
optimize VB N
trial NN N
success NN N
in IN N
mood NN N
disorders NNS N
. . N

DATA NNP N
SOURCES NNP N
PubMed NNP N
searches NNS N
were VBD N
conducted VBN N
by IN N
cross-referencing VBG N
the DT N
terms NNS N
depression NN N
, , N
depressive JJ N
with IN N
placebo NN i
, , N
clinical JJ N
trial NN N
, , N
and CC N
clinical JJ N
trials NNS N
for IN N
studies NNS p
published VBN p
in IN p
English NNP p
between IN p
1970 CD p
and CC p
September NNP p
2013 CD p
. . p

STUDY NNP N
SELECTION NNP N
Relevant NNP N
abstracts NNS N
were VBD N
identified VBN N
in IN N
PubMed NNP N
, , N
including VBG N
clinical JJ N
trials NNS N
, , N
quantitative JJ N
studies NNS N
, , N
and CC N
qualitative JJ N
research NN N
. . N

We PRP N
obtained VBD N
and CC N
reviewed VBD N
relevant JJ N
articles NNS N
and CC N
utilized VBD N
their PRP$ N
information NN N
to TO N
synthesize VB N
the DT N
present JJ N
review NN N
. . N

DATA NNP N
EXTRACTION NNP N
Included VBD N
articles NNS N
were VBD N
grouped VBN N
in IN N
the DT N
following JJ N
areas NNS N
of IN N
relevance NN N
: : N
( ( N
1 CD N
) ) N
biological JJ N
validity NN N
of IN N
illness NN N
, , N
( ( N
2 CD N
) ) N
baseline NN N
severity NN N
of IN N
illness NN N
, , N
( ( N
3 CD N
) ) N
chronicity NN N
of IN N
the DT N
index NN N
episode NN N
of IN N
depression NN N
, , N
( ( N
4 CD N
) ) N
age NN N
of IN N
participants NNS N
, , N
( ( N
5 CD N
) ) N
medical JJ N
and CC N
psychiatric JJ N
comorbidity NN N
, , N
( ( N
6 CD N
) ) N
probability NN N
of IN N
receiving VBG i
placebo NN i
, , N
( ( N
7 CD N
) ) N
use NN N
of IN N
prospective JJ N
treatment NN N
phases NNS N
( ( N
lead-in NN N
) ) N
( ( N
8 CD N
) ) N
dosing NN N
schedule NN N
, , N
( ( N
9 CD N
) ) N
trial NN N
duration NN N
, , N
( ( N
10 CD N
) ) N
frequency NN N
of IN N
follow-up JJ N
assessments NNS N
, , N
and CC N
( ( N
11 CD N
) ) N
study NN N
outcome JJ N
measure NN N
. . N

RESULTS NNP N
Several JJ N
key JJ N
elements NNS N
emerge VBP N
as RB N
critical JJ N
to TO N
the DT N
ultimate JJ N
success NN N
of IN N
a DT N
clinical JJ N
trial NN N
, , N
including VBG N
the DT N
probability NN o
of IN o
receiving VBG o
placebo NN o
, , o
study NN o
duration NN o
, , o
dosing VBG o
schedule NN o
, , o
visit NN o
frequency NN o
, , o
the DT o
use NN o
of IN o
blinded JJ o
lead-in JJ o
phases NNS o
, , o
the DT o
use NN o
of IN o
centralized JJ o
raters NNS o
, , o
illness JJ o
severity NN o
and CC o
duration NN o
, , o
and CC o
comorbid NN o
anxiety NN o
. . o

CONCLUSIONS NNP N
Our PRP$ N
increasing VBG N
understanding NN N
of IN N
the DT N
placebo NN i
response NN p
in IN p
clinical JJ p
trials NNS p
of IN N
major JJ p
depressive JJ p
disorder NN p
lends VBZ N
to TO N
a DT N
, , N
gradually RB N
, , N
more RBR N
predictable JJ N
phenomenon NN N
and CC N
, , N
hopefully RB N
, , N
to TO N
one CD N
that WDT N
becomes VBZ N
lesser JJR N
in IN N
magnitude NN N
and CC N
variability NN N
. . N

Several JJ N
elements NNS N
have VBP N
emerged VBN N
that WDT N
seem VBP N
to TO N
play VB N
a DT N
critical JJ N
role NN N
in IN N
trial NN N
success NN N
, , N
gradually RB N
reshaping VBG N
the DT N
design NN N
of IN N
clinical JJ N
, , N
translational JJ N
, , N
as RB N
well RB N
as IN N
mechanistic JJ N
studies NNS N
in IN N
depression NN N
. . N

-DOCSTART- -17194950- O O

Music NNP i
or CC i
guided VBN i
imagery NN i
for IN N
women NNS p
undergoing VBG p
colposcopy NN i
: : i
a DT N
randomized NN N
controlled VBN N
study NN N
of IN N
effects NNS N
on IN N
anxiety NN o
, , o
perceived VBD o
pain NN o
, , o
and CC o
patient JJ o
satisfaction NN o
. . o

OBJECTIVE IN N
It PRP N
was VBD N
hypothesized VBN N
that IN N
music NN i
or CC i
guided VBN i
imagery NN i
versus NN i
usual JJ i
care NN i
would MD N
result VB N
in IN N
less JJR N
anxiety NN o
and CC N
perceived VBD o
pain NN o
for IN N
colposcopy NN p
patients NNS p
. . p

MATERIALS NNP N
AND CC N
METHODS NNP N
Patients NNPS N
were VBD N
randomized VBN N
to TO N
music NN i
, , i
guided VBD i
imagery NN i
, , i
or CC i
usual JJ i
care NN i
after IN N
completing VBG N
a DT N
baseline NN i
questionnaire NN i
. . i

All DT N
patients NNS N
completed VBD N
a DT N
postprocedure NN i
questionnaire NN i
. . i

RESULTS NNP N
Study NNP p
participants NNS p
( ( p
N=170 NNP p
) ) p
had VBD p
a DT p
mean JJ p
age NN p
of IN p
28.4 CD p
years NNS p
( ( p
SD=9.6 NNP p
; : p
range VB p
18-60 JJ p
) ) p
and CC p
formed VBD p
a DT p
racially RB p
diverse JJ p
group NN p
. . p

Education/income NNP p
levels NNS p
were VBD p
low JJ p
. . p

No DT N
between-group JJ N
differences NNS N
were VBD N
found VBN N
for IN N
postprocedure NN o
anxiety NN o
or CC o
pain NN o
rating NN o
. . o

CONCLUSIONS NNP N
Mind-body JJ i
interventions NNS i
had VBD N
no DT N
statistically RB N
significant JJ N
impact NN N
on IN N
reported VBN N
anxiety NN o
, , o
perceived VBD o
pain NN o
, , o
or CC o
satisfaction NN o
with IN o
care NN o
, , N
even RB N
for IN N
those DT N
who WP N
anticipated VBD N
the DT N
most RBS N
pain NN N
or CC N
started VBN N
with IN N
high JJ N
anxiety NN N
. . N

-DOCSTART- -2890442- O O

Cardiovascular JJ N
effects NNS N
of IN N
non-depolarizing JJ i
neuromuscular JJ i
blockers NNS i
in IN N
patients NNS p
with IN p
aortic JJ p
valve NN p
disease NN p
. . p

To TO N
compare VB N
haemodynamic JJ N
responses NNS N
associated VBN N
with IN N
equipotent JJ N
doses NNS N
of IN N
neuromuscular JJ i
blockers NNS i
and CC N
high-dose JJ N
fentanyl NN i
( ( N
50 CD N
micrograms.kg-1 NN N
) ) N
, , N
40 CD p
patients NNS p
with IN p
aortic JJ p
valve NNS p
stenosis NN p
( ( p
AS IN p
) ) p
and CC p
20 CD p
patients NNS p
with IN p
aortic JJ p
insufficiency NN p
( ( p
AI NNP p
) ) p
were VBD N
randomized VBN N
to TO N
four CD N
study NN N
groups NNS N
to TO N
receive VB N
the DT N
following NN N
: : N
( ( N
1 CD N
) ) N
pancuronium NN i
0.12 CD i
mg.kg-1 NN i
, , i
( ( i
2 CD i
) ) i
vecuronium NN i
0.12 CD i
mg.kg-1 NN i
, , i
( ( i
3 CD i
) ) i
atracurium NN i
0.4 CD i
mg.kg-1 NN i
, , i
or CC i
( ( i
4 CD i
) ) i
pancuronium-metocurine NN i
mixture NN i
( ( N
0.4 CD N
mg NN N
+ VBD N
1.6 CD N
mg/ml NN N
) ) N
: : N
1 CD N
ml/10 NNS N
kg NN N
) ) N
. . N

Neuromuscular JJ i
blockers NNS i
were VBD N
injected VBN N
at IN N
the DT N
same JJ N
time NN N
with IN N
the DT N
fentanyl NN i
; : i
haemodynamics NNS N
were VBD N
recorded VBN N
with IN N
the DT N
patients NNS N
awake VBP N
( ( N
baseline NN N
) ) N
, , N
at IN N
two CD N
minutes NNS N
post-induction NN N
, , N
and CC N
at IN N
two CD N
and CC N
five CD N
minutes NNS N
after IN N
intubation NN N
. . N

In IN N
patients NNS N
with IN N
AS NNP N
, , N
pancuronium NN i
increased VBD N
heart NN o
rate NN o
more JJR N
than IN N
vecuronium NN i
or CC N
atracurium NN i
; : i
heart NN o
rates NNS o
were VBD N
also RB N
higher JJR o
with IN N
the DT N
pancuronium-metocurine JJ i
mixture NN i
than IN N
with IN N
vecuronium NN i
. . i

Although IN N
there EX N
were VBD N
no DT N
ECG NNP o
signs NNS o
of IN o
ischaemia NN o
, , N
one CD N
patient NN N
given VBN N
pancuronium NN N
developed VBD N
severe JJ o
hypotension NN o
associated VBN o
with IN o
tachycardia NN o
. . o

Reductions NNS N
in IN N
SVR NNP o
after IN N
atracurium NN N
allowed VBD N
small JJ N
but CC N
significant JJ N
( ( N
p NN N
less JJR N
than IN N
0.01 CD N
) ) N
decreases NNS N
in IN N
MAP NNP o
which WDT N
were VBD N
well RB o
tolerated VBN o
; : o
one CD N
patient NN N
, , N
however RB N
, , N
did VBD N
develop VB N
severe JJ o
hypotension NN o
. . o

Intubation NNP N
resulted VBD N
in IN N
significant JJ N
( ( N
p NN N
less JJR N
than IN N
0.01 CD N
) ) N
increases NNS N
in IN N
MAP NNP o
in IN N
the DT N
pancuronium-metocurine JJ i
mixture NN N
group NN N
. . N

Vecuronium NNP i
permitted VBD N
the DT N
most RBS N
stable JJ N
overall JJ o
haemodynamic JJ o
course NN o
at IN N
all DT N
measurement JJ N
times NNS N
. . N

In IN N
contrast NN N
, , N
patients NNS N
with IN N
AI NNP N
showed VBD N
stable JJ o
haemodynamics NNS o
after IN N
vecuronium NN i
, , i
pancuronium NN i
and CC N
the DT N
pancuronium-metocurine JJ i
mixture NN i
; : i
one CD N
patient NN N
became VBD N
tachycardic JJ o
following VBG N
vecuronium NN i
. . i

Atracurium NNP i
caused VBD N
unexplained JJ N
elevations NNS o
in IN o
diastolic JJ o
and CC o
mean JJ o
arterial NN o
pressures NNS o
which WDT N
were VBD N
significant JJ N
when WRB N
compared VBN N
to TO N
vecuronium VB i
( ( N
p NN N
less JJR N
than IN N
0.01 CD N
) ) N
. . N

These DT N
results NNS N
in IN N
increases NNS N
in IN N
PCWP NNP o
; : o
mean JJ o
PA NNP o
pressures NNS o
and CC o
CVP NNP o
were VBD N
also RB N
increased VBN o
. . o

These DT N
effects NNS N
of IN N
atracurium NN i
inpatients NNS N
with IN N
Al NNP N
need VBP N
further JJ N
evaluation NN N
. . N

-DOCSTART- -25726411- O O

A DT N
randomized VBN N
, , N
multicenter NN N
, , N
multivendor NN N
study NN N
of IN N
myocardial JJ N
perfusion NN N
imaging VBG N
with IN N
regadenoson NN i
CT NNP i
perfusion NN i
vs NN N
single JJ i
photon NN i
emission NN i
CT. NNP i
BACKGROUND NNP N
Myocardial NNP N
CT NNP N
perfusion NN N
( ( N
CTP NNP N
) ) N
is VBZ N
a DT N
promising JJ N
tool NN N
for IN N
the DT N
detection NN N
of IN N
myocardial JJ p
ischemia NN p
. . p

We PRP N
hypothesize VBP N
that IN N
regadenoson NN N
CTP NNP N
is VBZ N
noninferior JJ N
to TO N
regadenoson VB N
single JJ N
photon NN N
emission NN N
CT NNP N
( ( N
SPECT NNP N
) ) N
for IN N
detecting VBG N
or CC N
excluding VBG N
myocardial JJ p
ischemia NN p
. . p

METHODS NNP N
Patients NNPS p
( ( p
men NNS p
? . p
45 CD p
years NNS p
; : p
women NNS p
? . p
50 CD p
years NNS p
) ) p
with IN p
known VBN p
or CC p
suspected VBN p
coronary JJ p
artery NN p
disease NN p
( ( p
n JJ p
= NNP p
124 CD p
) ) p
were VBD p
randomized VBN N
to TO N
1 CD N
of IN N
2 CD N
diagnostic JJ N
sequences NNS i
: : i
rest NN i
and CC i
regadenoson NN i
SPECT NNP i
on IN i
day NN i
1 CD i
, , i
then RB i
regadenoson NN i
CTP NNP i
and CC i
rest VB i
CTP NNP i
( ( i
and CC i
coronary JJ i
CT NNP i
angiography NN i
[ NNP i
CTA NNP i
] NNP i
) ) i
( ( i
CTA NNP i
; : i
same JJ i
acquisition NN i
) ) i
on IN i
day NN i
2 CD i
or CC i
regadenoson VB i
CTP NNP i
and CC i
rest VB i
CTP NNP i
( ( i
and CC i
CTA NNP i
) ) i
on IN i
Day NNP i
1 CD i
, , i
then RB i
rest NN i
and CC i
regadenoson NN i
SPECT NNP i
on IN i
day NN i
2 CD i
. . i

Scanning VBG N
platforms NNS N
included VBD N
64- JJ N
, , N
128- JJ N
, , N
256- JJ N
, , N
and CC N
320-slice JJ N
systems NNS N
. . N

The DT N
primary JJ N
analysis NN N
examined VBD N
the DT N
agreement NN o
rate NN o
between IN o
CTP NNP o
and CC o
SPECT NNP o
for IN o
detecting VBG o
or CC o
excluding VBG o
reversible JJ o
ischemia NN o
in IN o
? . N
2 CD N
myocardial JJ N
segments NNS N
as IN N
assessed VBN N
by IN N
independent JJ N
, , N
blinded VBD N
readers NNS N
. . N

RESULTS NNP N
Complete NNP N
and CC N
interpretable JJ N
CTP NNP N
and CC N
SPECT NNP N
scans NNS N
were VBD N
obtained VBN p
for IN p
110 CD p
patients NNS i
. . i

Regadenoson NNP i
CTP NNP i
was VBD i
noninferior JJ N
to TO N
SPECT NNP N
for IN o
detecting VBG o
or CC o
excluding VBG o
reversible JJ o
ischemia NN o
with IN o
an DT N
agreement NN N
rate NN N
of IN N
0.87 CD N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NNP N
, , N
0.77-0.97 NNP N
) ) N
and CC N
sensitivity NN N
and CC N
specificity NN N
of IN N
0.90 CD N
( ( N
95 CD N
% NN N
CI NNP N
, , N
0.71-1.00 NNP N
) ) N
and CC N
0.84 CD N
( ( N
95 CD N
% NN N
CI NNP N
, , N
0.77-0.91 NNP N
) ) N
, , N
respectively RB o
. . o

The DT o
agreement NN o
rate NN o
for IN N
detecting VBG N
or CC N
excluding VBG o
? . o
1 CD o
fixed VBN o
defects NNS o
by IN N
regadenoson NN N
CTP NNP N
and CC N
SPECT NNP N
was VBD N
0.86 CD N
( ( N
95 CD N
% NN N
CI NNP N
, , N
0.74-0.98 NN N
) ) N
. . N

With IN N
SPECT NNP N
as IN N
the DT N
reference NN N
standard NN N
, , N
the DT N
diagnostic JJ N
accuracies NNS N
for IN N
detecting VBG N
or CC N
excluding VBG N
ischemia NN N
by IN N
regadenoson NN N
CTP NNP N
and CC N
CTA NNP N
alone RB N
were VBD N
0.85 CD N
( ( N
95 CD N
% NN N
CI NNP N
, , N
0.78-0.91 NNP N
) ) N
and CC N
0.69 CD N
( ( N
95 CD N
% NN N
CI NNP N
, , N
0.60-0.77 NNP N
) ) N
, , N
respectively RB N
. . N

CONCLUSIONS VB N
This DT N
study NN N
establishes VBZ N
the DT N
noninferiority NN i
of IN i
regadenoson NN i
CTP NNP i
to TO i
SPECT NNP i
for IN i
detecting VBG N
or CC N
excluding VBG p
myocardial JJ p
ischemia NN p
. . p

-DOCSTART- -16794570- O O

Modulation NN o
of IN o
human JJ o
motor NN o
cortex NN o
excitability NN o
by IN N
single JJ N
doses NNS N
of IN N
amantadine NN i
. . i

Amantadine-sulfate NNP i
has VBZ N
been VBN N
used VBN N
for IN N
several JJ N
decades NNS N
to TO N
treat VB N
acute JJ N
influenza NN p
A NNP p
, , p
Parkinson NNP p
's POS p
disease NN p
( ( p
PD NNP p
) ) p
, , p
and CC p
acute NN p
or CC p
chronic JJ p
drug-induced JJ p
dyskinesia NN p
. . p

Several JJ N
mechanisms NNS N
of IN N
actions NNS N
detected VBN N
in IN N
vivo/in JJ N
vitro JJ N
including VBG N
N-methyl-D-aspartate NNP o
( ( N
NMDA NNP N
) ) N
-receptor NN N
antagonism NN o
, , N
blockage NN N
of IN N
potassium NN N
channels NNS N
, , N
dopamine JJ N
receptor NN N
agonism NN N
, , N
enhancement NN N
of IN N
noradrenergic JJ N
release NN N
, , N
and CC N
anticholinergic JJ N
effects NNS N
have VBP N
been VBN N
described VBN N
. . N

We PRP N
used VBD N
transcranial JJ i
magnetic JJ i
stimulation NN i
( ( i
TMS NNP i
) ) i
to TO N
evaluate VB N
the DT N
effect NN N
of IN N
single JJ N
doses NNS N
of IN N
amantadine NN i
on IN N
human JJ N
motor NN N
cortex NN o
excitability NN N
in IN N
normal JJ p
subjects NNS p
. . p

Using VBG N
a DT N
double-blind JJ N
, , N
placebo-controlled JJ i
, , N
crossover NN N
study NN N
design NN N
, , N
motor NN N
thresholds NNS N
, , N
recruitment NN N
curves NNS N
, , N
cortical JJ N
stimulation-induced JJ N
silent JJ N
period NN N
( ( N
CSP NNP N
) ) N
, , N
short JJ N
intracortical JJ N
inhibition NN N
( ( N
ICI NNP N
) ) N
, , N
intracortical JJ N
facilitation NN N
( ( N
ICF NNP N
) ) N
, , N
and CC N
late JJ N
inhibition NN N
( ( N
L-ICI NNP N
) ) N
in IN N
14 CD p
healthy JJ p
subjects NNS p
were VBD N
investigated VBN N
after IN N
oral JJ i
doses NNS i
of IN i
50 CD i
and CC i
100 CD i
mg NNS i
amantadine VBP i
with IN i
single JJ i
and CC i
paired JJ i
pulse NN i
TMS NNP i
paradigms NN i
. . i

Spinal NNP o
cord NN o
excitability NN o
was VBD N
investigated VBN N
by IN N
distal JJ N
latencies NNS N
and CC N
M-amplitudes NNS o
of IN N
the DT N
abductor NN N
digiti NN N
minimi NN N
muscle NN N
. . N

After IN N
intake NN N
of IN N
amantadine NN i
, , N
a DT N
significant JJ N
dose-dependent JJ N
decrease NN N
of IN N
ICF NNP o
was VBD N
noticed VBN N
as RB N
well RB N
as IN N
a DT N
significant JJ N
increase NN N
of IN N
L-ICI NNP o
as IN N
compared VBN N
to TO N
placebo VB N
. . N

The DT N
effect NN N
on IN N
ICF NNP o
and CC N
L-ICI NNP o
significantly RB N
correlated VBD N
with IN N
amantadine JJ i
serum NN N
levels NNS N
. . N

ICI NNP o
was VBD N
slightly RB N
increased VBN N
after IN N
amantadine JJ i
intake NN N
, , N
but CC N
the DT N
effect NN N
failed VBD N
to TO N
be VB N
significant JJ N
. . N

Furthermore RB N
, , N
amantadine NN i
had VBD N
no DT N
significant JJ N
effects NNS N
on IN N
motor NN o
thresholds NNS o
, , o
MEP NNP o
recruitment NN o
curves NNS o
, , o
CSP NNP o
, , o
or CC o
peripheral JJ o
excitability NN o
. . o

In IN N
conclusion NN N
, , N
a DT N
low JJ N
dose NN N
of IN N
amantadine NN i
is VBZ N
sufficient JJ N
in IN N
modulating VBG o
human JJ o
motor NN o
cortex NN o
excitability NN o
. . o

The DT N
decrease NN N
of IN N
ICF NNP o
and CC N
increase NN N
of IN N
L-ICI NNP o
may MD N
reflect VB N
glutamatergic JJ N
modulation NN N
or CC N
a DT N
polysynaptic JJ N
interaction NN N
of IN N
glutamatergic NN N
and CC N
GABA-ergic JJ N
circuits NNS N
. . N

Although IN N
amantadine NN i
has VBZ N
several JJ N
mechanisms NNS N
of IN N
action NN N
, , N
the DT N
NMDA-receptor NNP N
antagonism NN N
seems VBZ N
to TO N
be VB N
the DT N
most RBS N
relevant JJ N
effect NN N
on IN N
cortical JJ o
excitability NN o
. . o

As IN N
L-ICI JJ o
can MD N
be VB N
influenced VBN N
by IN N
this DT N
type NN N
of IN N
drug NN N
, , N
it PRP N
may MD N
be VB N
an DT N
interesting JJ N
parameter NN N
for IN N
studies NNS N
of IN N
motor NN N
learning NN N
and CC N
use-dependent JJ N
plasticity NN N
. . N

-DOCSTART- -16249417- O O

Supplemental JJ i
perioperative JJ i
oxygen NN i
and CC N
the DT N
risk NN N
of IN N
surgical JJ o
wound NN o
infection NN o
: : o
a DT N
randomized NN N
controlled VBN N
trial NN N
. . N

CONTEXT NNP N
Supplemental NNP i
perioperative JJ i
oxygen NN i
has VBZ N
been VBN N
variously RB N
reported VBN N
to TO N
halve VB N
or CC N
double VB N
the DT N
risk NN N
of IN N
surgical JJ o
wound NN o
infection NN o
. . o

OBJECTIVE UH N
To TO N
test VB N
the DT N
hypothesis NN N
that IN N
supplemental JJ i
oxygen NN i
reduces NNS N
infection NN N
risk NN N
in IN N
patients NNS p
following VBG p
colorectal JJ p
surgery NN p
. . p

DESIGN NNP N
, , N
SETTING NNP N
, , N
AND NNP N
PATIENTS NNP N
A NNP N
double-blind NN N
, , N
randomized VBN N
controlled VBD N
trial NN N
of IN N
300 CD p
patients NNS p
aged VBD p
18 CD p
to TO p
80 CD p
years NNS p
who WP p
underwent VBP p
elective JJ p
colorectal NN p
surgery NN p
in IN p
14 CD p
Spanish JJ p
hospitals NNS p
from IN p
March NNP p
1 CD p
, , p
2003 CD p
, , p
to TO p
October NNP p
31 CD p
, , p
2004 CD p
. . p

Wound IN N
infections NNS N
were VBD N
diagnosed VBN N
by IN N
blinded JJ N
investigators NNS N
using VBG N
Centers NNPS N
for IN N
Disease NNP N
Control NNP N
and CC N
Prevention NNP N
criteria NNS N
. . N

Baseline NNP N
patient NN N
characteristics NNS N
, , N
anesthetic JJ N
treatment NN N
, , N
and CC N
potential JJ N
confounding NN N
factors NNS N
were VBD N
recorded VBN N
. . N

INTERVENTIONS JJ N
Patients NNPS N
were VBD N
randomly RB N
assigned VBN N
to TO N
either DT N
30 CD i
% NN i
or CC i
80 CD i
% NN i
fraction NN i
of IN i
inspired JJ i
oxygen NN i
( ( N
FIO2 NNP N
) ) N
intraoperatively RB N
and CC N
for IN N
6 CD N
hours NNS N
after IN N
surgery NN N
. . N

Anesthetic JJ N
treatment NN N
and CC N
antibiotic JJ N
administration NN N
were VBD N
standardized VBN N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Any NNP o
surgical JJ o
site NN o
infection NN o
( ( o
SSI NNP o
) ) o
; : o
secondary JJ N
outcomes NNS N
included VBD N
return NN o
of IN o
bowel NN o
function NN o
and CC o
ability NN o
to TO o
tolerate VB o
solid JJ o
food NN o
, , o
ambulation NN o
, , o
suture NN o
removal NN o
, , o
and CC o
duration NN o
of IN o
hospitalization NN o
. . o

RESULTS VB N
A DT N
total NN N
of IN N
143 CD N
patients NNS N
received VBD N
30 CD i
% NN i
perioperative JJ i
oxygen NN i
and CC N
148 CD N
received VBD N
80 CD i
% NN i
perioperative JJ i
oxygen NN i
. . i

Surgical JJ o
site NN o
infection NN o
occurred VBD N
in IN N
35 CD N
patients NNS N
( ( N
24.4 CD N
% NN N
) ) N
administered VBD N
30 CD N
% NN N
FIO2 NNP N
and CC N
in IN N
22 CD N
patients NNS N
( ( N
14.9 CD N
% NN N
) ) N
administered VBD N
80 CD N
% NN N
FIO2 NNP N
( ( N
P=.04 NNP N
) ) N
. . N

The DT N
risk NN o
of IN o
SSI NNP o
was VBD N
39 CD N
% NN N
lower JJR N
in IN N
the DT N
80 CD i
% NN i
FIO2 NNP i
group NN N
( ( N
relative JJ N
risk NN N
[ NNP N
RR NNP N
] NNP N
, , N
0.61 CD N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NNP N
, , N
0.38-0.98 NNP N
) ) N
vs VBD N
the DT N
30 CD i
% NN i
FIO2 NNP i
group NN N
. . N

After IN N
adjustment NN N
for IN N
important JJ N
covariates NNS N
, , N
the DT N
RR NNP N
of IN N
infection NN N
in IN N
patients NNS N
administered JJ N
supplemental JJ N
oxygen NN N
was VBD N
0.46 CD N
( ( N
95 CD N
% NN N
CI NNP N
, , N
0.22-0.95 NNP N
; : N
P NNP N
= NNP N
.04 NNP N
) ) N
. . N

None NN N
of IN N
the DT N
secondary JJ N
outcomes NNS N
varied VBD N
significantly RB N
between IN N
the DT N
2 CD N
treatment NN N
groups NNS N
. . N

CONCLUSIONS NNP N
Patients NNPS N
receiving VBG N
supplemental JJ i
inspired JJ i
oxygen NN i
had VBD N
a DT N
significant JJ N
reduction NN N
in IN N
the DT N
risk NN o
of IN o
wound JJ o
infection NN o
. . o

Supplemental JJ i
oxygen NN i
appears VBZ N
to TO N
be VB N
an DT N
effective JJ N
intervention NN N
to TO N
reduce VB N
SSI NNP o
in IN N
patients NNS p
undergoing VBG p
colon NN p
or CC p
rectal JJ p
surgery NN p
. . p

Trial JJ N
Registration NNP N
ClinicalTrials.gov NNP N
Identifier NNP N
: : N
NCT00235456 NN N
. . N

-DOCSTART- -11816482- O O

[ JJ N
Intravesical NNP N
instillation NN N
of IN N
doxorubicin NN i
or CC N
epirubicin NN i
for IN N
chemoprophylaxis NN N
of IN N
superficial JJ N
bladder NN N
cancer NN N
-- : N
the DT N
fifth JJ N
study NN N
of IN N
the DT N
Japanese JJ N
Urological JJ N
Cancer NNP N
Research NNP N
Group NNP N
for IN N
Adriamycin/Farumorubicin NNP N
] NNP N
. . N

A NNP p
total NN p
of IN p
465 CD p
patients NNS p
with IN p
primary JJ p
and CC p
multiple JJ p
or CC p
recurrent NN p
, , p
stages VBZ p
Ta NNP p
and CC p
T1 NNP p
superficial JJ p
bladder NN p
cancer NN p
were VBD N
included VBN N
in IN N
this DT N
randomized JJ N
multicenter NN N
trial NN N
to TO N
compare VB N
the DT N
prophylactic JJ N
effect NN N
by IN N
17 CD N
times NNS N
instillation NN N
of IN N
40 CD i
mg NNS i
doxorubicin VBD i
or CC i
40 CD i
mg NNS i
epirubicin VBP i
with IN i
no DT i
instillation NN i
after IN i
transurethral JJ i
resection NN i
of IN i
tumor NN i
( ( i
s NN i
) ) i
. . N

The DT N
primary JJ N
endpoint NN N
was VBD N
first JJ o
recurrence NN o
after IN N
transurethral JJ N
resection NN N
. . N

Endoscopic NNP o
examination NN o
as RB N
well RB N
as IN N
urinary JJ o
cytology NN o
was VBD N
performed VBN N
in IN N
each DT N
case NN N
every DT N
three CD N
months NNS N
. . N

It PRP N
became VBD N
evident JJ N
that IN N
the DT N
recurrence NN o
rate NN o
in IN N
the DT N
doxorubicin NN i
or CC N
epirubicin JJ i
instillation NN N
arm NN N
was VBD N
lower JJR N
that IN N
in IN N
the DT N
no DT N
instillation NN N
arm NN N
. . N

Toxicity NN o
was VBD N
mainly RB N
restricted VBN N
to TO N
bladder VB o
irritation NN o
in IN N
about RB N
10 CD N
% NN N
of IN N
patients NNS N
in IN N
each DT N
instillation NN N
arm NN N
. . N

-DOCSTART- -20708275- O O

Changes NNS N
in IN N
sleep JJ N
quality NN N
, , N
but CC N
not RB N
hormones VB N
predict JJ N
time NN N
to TO N
postpartum VB N
depression NN N
recurrence NN N
. . N

BACKGROUND NNP N
Poor NNP N
sleep JJ N
quality NN N
, , N
dysregulation NN N
of IN N
hormones NNS N
and CC N
increased VBD N
inflammatory JJ N
cytokines NNS N
are VBP N
all DT N
associated VBN N
with IN N
the DT N
risk NN N
for IN N
postpartum NN N
major JJ N
depression NN N
( ( N
PPMD NNP N
) ) N
. . N

We PRP N
evaluated VBD N
change NN N
over IN N
time NN N
in IN N
sleep JJ o
quality NN o
and CC N
hormones NNS o
during IN N
the DT N
first JJ N
17 CD N
weeks NNS N
postpartum RB N
, , N
as RB N
well RB N
as IN N
a DT N
single JJ N
cytokine NN N
measure NN N
, , N
and CC N
their PRP$ N
association NN N
with IN N
PPMD NNP N
recurrence NN N
. . N

METHODS JJ N
Participants NNS p
were VBD p
pregnant JJ p
women NNS p
( ( p
N=56 NNP p
) ) p
, , p
with IN p
past JJ p
histories NNS p
of IN p
MDD/PPMD NNP p
but CC p
not RB p
depressed VBN p
in IN p
their PRP$ p
current JJ p
pregnancy NN p
. . p

The DT N
Pittsburgh NNP o
Sleep NNP o
Quality NNP o
Index NNP o
( ( i
PSQI NNP i
) ) i
and CC N
blood NN i
samples NNS i
were VBD i
collected VBN i
8 CD N
times NNS N
during IN N
the DT N
first JJ N
17 CD N
weeks NNS N
postpartum NN N
. . N

Estradiol NNP o
, , o
prolactin NN o
and CC o
cortisol NN o
, , o
and CC o
a DT o
single JJ o
measure NN o
of IN o
IL-6 NNP o
were VBD N
assayed VBN N
. . N

Recurrence NN N
was VBD N
determined VBN N
by IN N
two CD N
consecutive JJ N
21-item JJ o
Hamilton NNP o
Rating NNP o
Scale NNP o
for IN o
Depression NNP o
( ( o
HRSD NNP o
) ) o
scores?15 NN o
and CC o
clinician JJ o
interview NN o
. . o

RESULTS NNP N
In IN N
the DT N
analyses NNS N
of IN N
time NN N
to TO N
PPMD NNP o
recurrence NN o
, , o
poor JJ o
sleep JJ o
quality NN o
, , o
but CC N
none NN N
of IN N
the DT N
hormones NNS N
, , N
was VBD N
associated VBN N
with IN o
PPMD NNP o
recurrence NN o
( ( o
p JJ N
< NNP N
.05 NNP N
) ) N
after IN N
controlling VBG N
for IN N
medication NN N
assignment NN N
. . N

With IN N
every DT N
one CD N
point NN N
increase NN N
in IN N
PSQI NNP N
scores NNS N
across IN N
time NN N
, , N
a DT N
woman NN N
's POS N
risk NN N
for IN N
recurrence NN N
increased VBN N
by IN N
approximately RB N
25 CD N
% NN N
There EX N
was VBD N
no DT N
significant JJ N
association NN N
between IN o
PSQI NNP o
scores NNS o
and CC o
IL-6 NNP o
concentrations NNS o
in IN N
early JJ N
postpartum NN N
( ( N
? . N
( ( N
2 CD N
) ) N
=0.98 NN N
, , N
p=.32 NN N
) ) N
. . N

CONCLUSIONS NNP N
Poor NNP N
sleep VBP N
quality NN N
across IN N
the DT N
first JJ N
17 CD N
weeks NNS N
post-delivery JJ N
increases NNS N
the DT N
risk NN N
for IN N
recurrent JJ N
PPMD NNP N
among IN p
women NNS p
with IN p
a DT p
history NN p
of IN p
MDD NNP p
. . p

Changes NNS p
in IN N
the DT N
hormonal JJ N
milieu NN N
were VBD N
not RB N
associated VBN N
with IN N
recurrence NN N
. . N

Further JJ N
exploration NN N
of IN N
the DT N
degree NN N
to TO N
which WDT N
poor JJ N
sleep NN N
contributes NNS N
to TO N
hormonal JJ N
and CC N
cytokine JJ N
dysregulation NN N
and CC N
how WRB N
they PRP N
are VBP N
involved VBN N
in IN N
the DT N
pathophysiology NN N
of IN N
PPMD NNP N
is VBZ N
warranted VBN N
. . N

-DOCSTART- -22712208- O O

[ NNP p
Medical NNP p
safety NN p
and CC p
staff NN p
mental JJ p
health NN p
] NNP p
. . N

Improvement NNP N
in IN N
patient JJ N
safety NN N
is VBZ N
a DT N
high-priority JJ N
issue NN N
of IN N
great JJ N
social JJ N
import NN N
. . N

Several JJ N
studies NNS N
have VBP N
reported VBN N
that IN N
most JJS N
adverse JJ N
events NNS N
are VBP N
due JJ N
to TO N
errors NNS N
of IN N
hospital JJ N
staff NN N
, , N
and CC N
emphasized VBD N
the DT N
necessity NN N
of IN N
promoting VBG N
countermeasures NNS N
against IN N
medical JJ N
errors NNS N
. . N

Root NNP N
cause NN N
analysis NN N
( ( N
RCA NNP N
) ) N
has VBZ N
been VBN N
implemented VBN N
to TO N
prevent VB N
such JJ N
errors NNS N
. . N

However RB N
, , N
the DT N
retrospective NN N
and CC N
qualitative JJ N
nature NN N
of IN N
RCA NNP N
is VBZ N
a DT N
limitation NN N
in IN N
scientific JJ N
analyses NNS N
examining VBG N
causal JJ N
relationships NNS N
. . N

We PRP N
showed VBD N
that IN N
prospective JJ N
design NN N
path NN N
analysis NN N
using VBG N
structural JJ i
equation NN i
modeling NN i
( ( i
SEM NNP i
) ) i
model NN N
for IN N
both DT N
direct JJ N
and CC N
indirect JJ N
effects NNS N
enabled VBD N
statistical JJ N
exploration NN N
of IN N
root NN N
causes NNS N
and CC N
estimation NN N
of IN N
their PRP$ N
impact NN N
on IN N
the DT N
outcome NN N
. . N

Our PRP$ N
findings NNS N
suggested VBD N
such JJ N
analysis NN N
to TO N
be VB N
useful JJ N
in IN N
devising VBG N
countermeasures NNS N
against IN N
medical JJ N
errors NNS N
. . N

The DT N
SEM NNP N
model NN N
constructed VBN N
in IN N
this DT N
study NN N
suggested VBD N
that IN N
one CD N
of IN N
the DT N
potential JJ N
root NN N
causes NNS N
was VBD N
sleep JJ o
disturbance NN o
. . o

We PRP N
conducted VBD N
a DT N
randomized VBN N
crossover NN N
study NN N
whether IN N
or CC N
not RB N
brief JJ N
bright JJ N
light NN N
( ( i
BL NNP i
) ) i
exposure NN N
on IN N
workday JJ N
mornings NNS N
can MD N
improve VB N
health NN N
, , N
performance NN N
and CC N
safety NN N
in IN N
nurses NNS p
with IN p
rapidly RB p
rotating VBG p
shifts NNS p
. . p

Significant JJ N
improvements NNS N
were VBD N
noted VBN N
in IN N
the DT N
BL NNP N
periods NNS N
compared VBN N
with IN N
the DT N
non-BL JJ N
periods NNS N
for IN N
self-assessed JJ o
sleepiness NN o
at IN N
10 CD N
: : N
00 CD N
on IN N
day-shift JJ N
days NNS N
, , N
self-assessment NN o
of IN o
night NN o
sleep NN o
for IN o
day-shift JJ o
days NNS o
and CC o
for IN o
fatigue NN o
. . o

Mean NNP o
response NN o
time NN o
evaluated VBN N
using VBG N
the DT N
psychomotor NN N
vigilance NN N
task NN N
test NN N
( ( N
PVT NNP N
) ) N
showed VBD N
significant JJ N
improvement NN N
in IN N
the DT N
BL NNP N
periods NNS N
compared VBN N
with IN N
the DT N
non-BL JJ N
periods NNS N
. . N

The DT N
frequency NN o
of IN o
perceived JJ o
adverse JJ o
events NNS o
and CC o
near JJ o
misses NNS o
was VBD N
also RB N
lower JJR N
in IN N
the DT N
BL NNP N
than IN N
in IN N
the DT N
non-BL JJ N
periods NNS N
, , N
but CC N
not RB N
significantly RB N
so RB N
, , N
possibly RB N
indicating VBG N
that IN N
the DT N
one-month JJ N
observation NN N
period NN N
was VBD N
too RB N
short JJ N
to TO N
achieve VB N
any DT N
significant JJ N
success NN N
. . N

Despite IN N
our PRP$ N
study NN N
's POS N
limitations NNS N
, , N
we PRP N
have VBP N
effectively RB N
demonstrated VBN N
the DT N
potential NN N
for IN N
preventing VBG N
medical JJ N
error NN N
risk NN N
among IN N
night-shift JJ p
workers NNS p
. . p

-DOCSTART- -20844187- O O

Maternal NNP i
dietary JJ i
counseling NN i
in IN N
the DT N
first JJ N
year NN N
of IN N
life NN N
is VBZ N
associated VBN N
with IN N
a DT N
higher JJR N
healthy JJ o
eating VBG o
index NN o
in IN N
childhood NN p
. . p

Food NNP N
preferences NNS N
are VBP N
established VBN N
in IN N
early JJ N
childhood NN N
and CC N
track NN N
later RB N
in IN N
life NN N
. . N

Therefore RB N
, , N
it PRP N
is VBZ N
important JJ N
to TO N
promote VB N
healthy JJ N
feeding NN N
practices NNS N
as RB N
early RB N
as IN N
possible JJ N
. . N

A DT N
randomized JJ N
field NN N
trial NN N
was VBD N
conducted VBN N
with IN N
500 CD p
mother-child JJ p
pairs NNS p
from IN p
a DT p
low-income JJ p
area NN p
of IN p
S?o NNP p
Leopoldo NNP p
, , p
State NNP p
of IN p
Rio NNP p
Grande NNP p
do VBP p
Sul NNP p
, , p
Brazil NNP p
, , p
to TO p
evaluate VB p
the DT p
impact NN p
of IN p
a DT p
nutritional JJ i
intervention NN i
in IN p
the DT p
first JJ p
year NN p
of IN p
life NN p
on IN p
the DT p
dietary JJ p
quality NN p
of IN p
3- JJ p
to TO p
4-y-old JJ p
children NNS p
. . p

Mother-child JJ N
pairs NNS N
were VBD N
randomized VBN N
either RB N
to TO i
intervention NN i
and CC i
control NN i
groups NNS N
and CC i
dietary JJ i
counseling NN i
was VBD N
provided VBN N
for IN N
mothers NNS N
in IN N
the DT N
intervention NN N
group NN N
during IN N
10 CD N
home NN N
visits NNS N
in IN N
the DT N
course NN N
of IN N
the DT N
first JJ N
year NN N
of IN N
life NN N
. . N

These DT N
visits NNS N
were VBD N
carried VBN N
out RP N
by IN N
fieldworkers NNS N
who WP i
counseled VBD i
the DT N
mothers NNS N
about IN N
the DT N
Ten NNP N
Steps NNP N
for IN N
Healthy NNP N
Feeding VBG N
from IN N
Birth NNP N
to TO N
Two CD N
Years NNS N
of IN N
Age NNP N
, , N
based VBN N
on IN N
the DT N
WHO NNP N
guidelines NNS N
. . N

Dietary JJ o
intake NN o
was VBD N
assessed VBN N
at IN N
3-4 JJ N
y NN N
of IN N
age NN N
for IN p
345 CD p
children NNS p
using VBG N
two CD N
24-h JJ N
food NN N
recalls NNS N
. . N

Overall JJ o
diet JJ o
quality NN o
was VBD N
determined VBN N
by IN N
the DT N
Healthy NNP N
Eating NNP N
Index NNP N
. . N

The DT o
prevalence NN o
of IN o
poor JJ o
diet NNS o
in IN N
the DT N
intervention NN N
group NN N
was VBD N
lower JJR N
compared VBN N
with IN N
the DT N
control NN N
group NN N
[ NNP N
relative NN N
risk NN N
( ( N
RR NNP N
) ) N
= VBZ N
0.30 CD N
; : N
95 CD N
% NN N
CI NNP N
= NNP N
0.13-0.71 NN N
) ) N
. . N

The DT N
number NN N
of IN N
children NNS N
who WP N
achieved VBD N
the DT o
75th CD o
percentile NN o
for IN o
the DT o
vegetable JJ o
and CC o
fruit JJ o
component NN o
score NN o
was VBD N
higher RBR N
in IN N
the DT N
intervention NN N
than IN N
in IN N
control NN N
group NN N
( ( N
RR NNP N
= NNP N
1.95 CD N
; : N
95 CD N
% NN N
CI NNP N
= NNP N
1.31-2.89 JJ N
and CC N
RR NNP N
= NNP N
1.49 CD N
; : N
95 CD N
% NN N
CI NNP N
= NNP N
1.07-2.07 CD N
, , N
respectively RB N
) ) N
. . N

Such JJ N
data NNS N
provide VBP N
evidence NN N
that IN i
dietary JJ i
counseling NN i
for IN N
mothers NNS N
during IN N
the DT N
first JJ N
year NN N
of IN N
life NN N
improves VBZ N
the DT o
overall JJ o
dietary JJ o
quality NN o
of IN p
children NNS p
in IN p
a DT p
low-income JJ p
population NN p
. . p

-DOCSTART- -20102444- O O

A DT N
comparative JJ N
study NN N
of IN N
the DT N
effects NNS N
of IN N
local JJ N
estrogen NN N
with IN N
or CC N
without IN N
local JJ N
testosterone NN i
on IN N
vulvovaginal JJ o
and CC o
sexual JJ o
dysfunction NN o
in IN p
postmenopausal JJ p
women NNS p
. . p

INTRODUCTION VB N
A DT N
significant JJ N
number NN N
of IN N
postmenopausal JJ p
women NNS p
suffer VBP N
from IN N
distressing VBG N
problems NNS N
because IN N
of IN N
urogenital JJ N
atrophy NN N
secondary JJ N
to TO N
the DT N
decline NN N
in IN N
circulating VBG N
estrogen NN N
levels NNS N
. . N

Treatment NN N
with IN N
topical JJ i
hormones NNS i
may MD N
provide VB N
relief NN N
in IN N
such JJ N
women NNS N
when WRB N
used VBN N
judiciously RB N
. . N

AIM NNP N
To TO N
study VB N
the DT N
effects NNS N
of IN N
local JJ N
estrogen NN N
with IN N
or CC N
without IN N
local JJ i
testosterone NN i
on IN N
urogenital JJ o
and CC o
sexual JJ o
health NN o
in IN N
postmenopausal JJ p
women NNS p
. . p

METHODS NNP N
Seventy-five JJ p
postmenopausal NN p
women NNS p
symptomatic JJ p
for IN p
urogenital JJ p
atrophy NN p
and CC p
sexual JJ p
dysfunction NN p
were VBD N
randomly RB N
divided VBN N
into IN N
two CD N
study NN N
groups NNS N
and CC N
one CD N
control NN N
group NN N
. . N

The DT N
women NNS N
in IN N
study NN N
group NN N
1 CD N
received VBD i
local JJ i
estrogen NN i
cream NN i
; : i
study CC i
group NN i
2 CD i
received VBD i
local JJ i
estrogen NN i
and CC i
testosterone NN i
cream NN i
; : i
the DT i
control NN i
group NN i
received VBD i
nonhormonal JJ i
lubricant JJ i
KY NNP i
gel NN i
for IN i
12 CD i
weeks NNS i
. . i

The DT N
urogenital JJ o
and CC o
sexuality NN o
score NN o
, , N
along IN N
with IN N
the DT N
vaginal JJ o
health NN o
index NN o
and CC o
the DT o
vaginal JJ o
maturation NN o
index NN o
( ( o
VMI NNP o
) ) o
, , N
was VBD N
calculated VBN N
at IN N
the DT N
beginning NN N
of IN N
therapy NN N
and CC N
12 CD N
weeks NNS N
later RB N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Changes NNP o
in IN o
the DT o
urogenital JJ o
and CC o
sexuality NN o
score NN o
along IN o
with IN o
vaginal JJ o
health NN o
index NN o
and CC o
VMI NNP o
. . o

RESULTS NNP N
After IN N
12 CD N
weeks NNS N
of IN N
therapy NN N
, , N
there EX N
was VBD N
a DT N
significant JJ N
improvement NN N
in IN N
all PDT N
the DT N
four CD N
study NN N
parameters NNS N
, , N
which WDT N
correlated VBD N
well RB N
with IN N
the DT N
improvement NN N
in IN N
symptoms NNS N
of IN N
urogenital JJ N
atrophy NN N
and CC N
sexual JJ N
dysfunction NN N
in IN N
both CC N
the DT N
study NN p
groups NNS p
as IN N
compared VBN N
with IN N
the DT N
control NN p
group NN p
. . p

Improvement NNP N
in IN N
sexuality NN o
score NN o
was VBD N
greatest JJS N
with IN N
combined JJ N
estrogen-androgen JJ N
therapy NN N
. . N

There EX N
were VBD N
no DT N
adverse JJ o
effects NNS o
and CC N
the DT N
therapies NNS N
were VBD N
well RB N
accepted VBN N
without IN N
any DT N
compliance NN N
issue NN N
. . N

CONCLUSION NNP N
Local NNP i
estrogen NN i
either CC N
alone RB N
or CC N
with IN N
androgen NN N
is VBZ N
highly RB N
effective JJ N
in IN N
relieving VBG N
symptoms NNS N
of IN N
urogenital JJ o
atrophy NN o
and CC N
in IN N
improving VBG o
sexual JJ o
function NN o
in IN N
symptomatic JJ p
postmenopausal NN p
women NNS p
. . p

-DOCSTART- -9316683- O O

Nimodipine NNP i
pharmacotherapeutic JJ N
adjuvant NN N
therapy NN N
for IN N
inpatient JJ p
treatment NN p
of IN p
cocaine NN p
dependence NN p
. . p

Recent JJ N
preclinical JJ N
studies NNS N
suggest VBP N
utility NN N
for IN N
voltage-sensitive JJ N
calcium NN N
channel NN N
blockers NNS N
( ( N
VSCCBs NNP N
) ) N
in IN N
the DT N
treatment NN N
of IN N
cocaine NN p
addiction NN p
. . p

The DT N
following JJ N
double-blind JJ N
placebo-controlled JJ i
study NN N
examined VBD N
the DT N
role NN N
of IN N
the DT N
VSCCB NNP N
nimodipine NN i
in IN N
attenuating VBG N
cocaine NN N
craving NN N
in IN N
66 CD p
recently RB p
abstinent JJ p
cocaine-dependent JJ p
patients NNS p
on IN p
an DT p
inpatient JJ p
substance NN p
abuse NN p
treatment NN p
unit NN p
utilizing VBG p
an DT p
intensive JJ p
12-step JJ p
milieu-oriented JJ p
psychosocial JJ p
therapy NN p
. . p

While IN N
the DT N
medication NN N
was VBD N
well RB N
tolerated VBN N
, , N
the DT N
dose NN N
of IN N
nimodipine NN i
used VBN N
in IN N
this DT N
study NN N
( ( N
90 CD N
mg NN N
q.d NN N
. . N

) ) N
was VBD N
not RB N
superior JJ N
to TO N
placebo VB i
in IN N
reducing VBG N
background NN N
or CC N
cue-induced JJ N
cocaine NN N
craving NN N
over IN N
the DT N
3 CD N
weeks NNS N
of IN N
the DT N
study NN N
. . N

There EX N
was VBD N
the DT N
suggestion NN N
that IN N
nimodipine NN i
might MD N
attenuate VB N
the DT N
severity NN N
of IN N
some DT N
cocaine-induced JJ N
brain NN N
deficits NNS N
, , N
as IN N
detected VBN N
by IN N
evaluation NN N
of IN N
smooth JJ o
pursuit NN o
eye NN o
movement NN o
function NN o
. . o

A DT N
rationale NN N
for IN N
evaluating VBG N
higher JJR N
doses NNS N
of IN N
nimodipine NN i
for IN N
the DT N
treatment NN N
of IN N
cocaine NN N
addiction NN N
is VBZ N
presented VBN N
. . N

As IN N
nimodipine NN i
might MD N
have VB N
anticraving VBG N
and CC N
mood-stabilizing JJ N
properties NNS N
and CC N
cardio- NN N
and CC N
neuroprotective JJ N
properties NNS N
in IN N
the DT N
face NN N
of IN N
cocaine NN N
intoxication NN N
and CC N
might MD N
possibly RB N
even RB N
reverse VB N
some DT N
cocaine-induced JJ N
brain NN N
deficits NNS N
, , N
further JJ N
investigation NN N
of IN N
the DT N
role NN N
of IN N
nimodipine NN i
( ( N
and CC N
other JJ N
VSCCBs NNP N
) ) N
in IN N
cocaine NN N
addiction NN N
appears VBZ N
an DT N
attractive JJ N
avenue NN N
of IN N
future JJ N
medication NN N
development NN N
. . N

-DOCSTART- -24101715- O O

Group NNP i
therapy NN i
for IN N
anxiety NN o
in IN N
children NNS p
with IN p
autism NN p
spectrum NN p
disorder NN p
. . p

AIM NNP N
To TO N
investigate VB N
the DT N
acceptability NN N
and CC N
feasibility NN N
of IN N
adapted VBN i
group NN i
therapy NN i
for IN N
anxiety NN N
in IN N
children NNS p
with IN p
autism NN p
spectrum NN p
disorder NN p
in IN N
a DT N
pilot NN N
randomised VBN N
controlled VBN N
trial NN N
. . N

METHOD VB N
A DT p
total NN p
of IN p
32 CD p
children NNS p
aged VBN p
9-13 CD p
years NNS p
were VBD N
randomised VBN N
to TO N
immediate VB i
or CC i
delayed VBN i
therapy NN i
using VBG N
the DT N
'Exploring VBG i
Feelings NNP i
' POS i
manual JJ N
( ( N
Attwood NNP N
, , N
2004 CD N
) ) N
. . N

Child NN p
and CC p
parent NN p
groups NNS p
were VBD N
run VBN N
in IN N
parallel NN N
, , N
for IN N
seven CD N
weekly JJ N
sessions NNS N
, , N
under IN N
the DT N
supervision NN N
of IN N
experienced JJ N
psychologists NNS N
. . N

The DT N
primary JJ N
blinded VBD N
outcome JJ N
measures NNS N
addressed VBD N
change NN N
in IN N
overall JJ o
functioning NN o
and CC N
in IN N
severity NN o
of IN o
the DT o
primary JJ o
anxiety NN o
diagnosis NN o
after IN N
3 CD N
months NNS N
. . N

RESULTS NNP N
Children NNP p
met VBD p
diagnostic JJ p
criteria NNS p
for IN p
1-6 JJ p
anxiety NN p
disorders NNS p
( ( p
median JJ p
3 CD p
) ) p
. . p

At IN N
end NN N
point NN N
, , N
both DT N
parents NNS N
and CC N
children NNS N
in IN N
the DT N
immediate JJ i
therapy NN i
group NN N
were VBD N
more RBR N
likely JJ N
to TO N
report VB N
a DT N
reduction NN o
in IN o
anxiety NN o
symptoms NNS o
. . o

Fidelity NNP o
of IN o
delivery NN o
of IN N
the DT N
group NN i
therapy NN i
was VBD N
high JJ o
, , N
and CC N
attendance NN o
was VBD N
91 CD N
% NN N
. . N

CONCLUSIONS NNP N
This DT N
pilot NN N
trial NN N
established VBD N
that IN N
children NNS N
and CC N
families NNS N
were VBD N
willing JJ N
to TO N
be VB N
recruited VBN N
and CC N
randomised VBN N
, , N
the DT N
outcome NN N
measures NNS N
were VBD N
acceptable JJ N
, , N
the DT N
format NN N
and CC N
content NN N
of IN N
the DT N
groups NNS N
were VBD N
feasible JJ N
within IN N
UK NNP p
child NN p
and CC p
adolescent JJ p
mental NN p
health NN p
services NNS p
, , N
the DT N
intervention NN N
was VBD N
appreciated VBN N
by IN N
families NNS N
and CC N
attrition NN N
was VBD N
very RB N
small JJ N
. . N

-DOCSTART- -27036056- O O

Internet-based JJ i
Mindfulness NNP i
Meditation NNP i
for IN N
Cognition NNP N
and CC N
Mood NNP o
in IN N
Older NNP p
Adults NNP p
: : p
A DT N
Pilot NNP N
Study NNP N
. . N

CONTEXT NNP N
Older NNP p
adults NNS p
are VBP N
at IN N
risk NN N
for IN N
greater JJR N
chronic JJ o
stress NN o
and CC N
cognitive JJ o
decline NN o
. . o

Training NN N
in IN N
mindfulness JJ i
meditation NN i
( ( i
MM NNP i
) ) i
may MD N
help VB N
reduce VB N
stress NN o
and CC N
, , N
thus RB N
, , N
cognitive JJ o
decline NN o
in IN N
older JJR N
adults NNS N
, , N
but CC N
little JJ N
research NN N
has VBZ N
explored VBN N
that IN N
hypothesis NN N
. . N

OBJECTIVE IN N
The DT N
current JJ N
study NN N
's POS N
primary JJ N
aim NN N
was VBD N
to TO N
evaluate VB N
the DT N
feasibility NN o
and CC o
acceptability NN o
for IN N
use NN N
by IN N
older JJR p
adults NNS p
of IN N
the DT N
Internet NNP i
Mindfulness NNP i
Meditation NNP i
Intervention NNP i
( ( i
IMMI NNP i
) ) i
, , N
a DT N
program NN N
that WDT N
had VBD N
been VBN N
developed VBN N
by IN N
the DT N
research NN N
team NN N
, , N
as RB N
well RB N
as IN N
of IN N
an DT N
Internet-based JJ N
health-and-wellness JJ N
education NN N
program NN N
, , N
the DT N
control NN N
. . N

The DT N
secondary JJ N
aim NN N
was VBD N
to TO N
collect VB N
preliminary JJ N
pre- NN N
and CC N
postintervention NN N
data NNS N
on IN N
mood NN o
and CC N
cognitive JJ o
function NN o
. . o

DESIGN VB N
The DT N
study NN N
was VBD N
a DT N
randomized JJ N
, , N
controlled VBN N
trial NN N
( ( N
RCT NNP N
) ) N
, , N
a DT N
pilot NN N
study NN N
, , N
with IN N
participants NNS p
randomized VBN N
either RB N
to TO N
the DT N
meditation NN i
group NN N
or CC N
the DT N
education NN i
group NN N
. . N

SETTING NN N
Participants NNS N
obtained VBD N
access NN N
to TO N
the DT N
programs NNS N
from IN N
their PRP$ N
homes NNS N
, , N
and CC N
the DT N
baseline NN N
and CC N
endpoint NN N
assessments NNS N
occurred VBD N
in IN N
their PRP$ N
homes NNS N
as RB N
well RB N
. . N

PARTICIPANTS NNP N
Older NNP p
adults NNS p
aged VBD p
65-90 JJ p
y NN p
were VBD p
recruited VBN p
from IN p
the DT p
Portland NNP p
, , p
OR NNP p
, , p
metropolitan JJ p
area NN p
. . p

Twenty-one CD p
people NNS p
enrolled VBN p
in IN p
the DT p
study NN p
. . p

INTERVENTION NNP N
Participants NNPS N
in IN N
both DT N
groups NNS N
took VBD N
part NN N
in IN N
a DT N
1-h JJ i
online NN i
session NN i
each DT i
week NN i
for IN i
6 CD i
wk NNS i
, , i
with IN i
30 CD i
min NNS i
of IN i
daily JJ i
home NN i
practice NN i
. . i

OUTCOME NNP N
MEASURES NNP N
Feasibility NNP o
and CC o
acceptability NN o
were VBD N
assessed VBN N
through IN N
measures NNS N
of IN N
adherence NN N
to TO N
the DT N
protocol NN N
and CC N
a DT N
client NN o
satisfaction NN o
questionnaire NN N
. . N

Mood NNP o
and CC o
cognitive JJ o
outcomes NNS o
were VBD N
also RB N
evaluated VBN N
before IN N
and CC N
after IN N
the DT N
interventions NNS N
. . N

RESULTS NNP N
Sixteen JJ p
participants NNS p
completed VBD N
the DT N
study NN N
, , N
8 CD N
in IN N
each DT N
group NN p
, , N
and CC N
5 CD p
dropped VBD N
out RP N
, , N
for IN N
a DT N
76 CD N
% NN N
completion NN N
rate NN N
. . N

Participants NNS p
' POS p
mean JJ N
age NN N
was VBD N
76.2 CD N
y NN N
; : N
88 CD N
% NN N
were VBD N
Caucasian JJ N
, , N
and CC N
50 CD N
% NN N
were VBD N
female JJ N
. . N

Acceptability NNP o
was VBD N
high JJ N
for IN N
the DT N
interventions NNS N
, , N
based VBN N
on IN N
above-average JJ N
scores NNS N
on IN N
the DT N
client NN N
satisfaction NN N
questionnaire NN N
. . N

The DT N
IMMI NNP i
participants NNS N
completed VBD N
( ( N
1 CD N
) ) N
4.25 CD N
? . N
2.4 CD N
sessions NNS N
, , N
with IN N
a DT N
range NN N
of IN N
0-6 NN N
; : N
( ( N
2 CD N
) ) N
604 CD N
? . N
506 CD N
home-practice NN N
minutes NNS N
, , N
with IN N
a DT N
range NN N
0-1432 NN N
; : N
and CC N
( ( N
3 CD N
) ) N
21.3 CD N
? . N
15.5 CD N
d NN N
of IN N
practice NN N
, , N
with IN N
a DT N
range NN N
of IN N
0-46 NN N
. . N

The DT N
education NN i
group NN i
completed VBD N
( ( N
1 CD N
) ) N
4.75 CD N
? . N
1.8 CD N
sessions NNS N
, , N
with IN N
a DT N
range NN N
of IN N
2-6 JJ N
; : N
( ( N
2 CD N
) ) N
873 CD N
? . N
395 CD N
home-practice NN N
minutes NNS N
, , N
with IN N
a DT N
range NN N
of IN N
327-1524 JJ N
; : N
and CC N
( ( N
3 CD N
) ) N
25.6 CD N
d NN N
of IN N
practice NN N
, , N
with IN N
a DT N
range NN N
of IN N
11-35 JJ N
. . N

The DT N
intervention NN N
and CC N
control NN N
formats NNS N
were VBD N
both DT N
feasible JJ N
, , N
and CC N
the DT N
control NN N
group NN N
was VBD N
appropriate JJ N
. . N

As IN N
expected VBN N
due JJ N
to TO N
the DT N
pilot JJ N
nature NN N
of IN N
the DT N
study NN N
, , N
no DT N
differences NNS N
existed VBD N
between IN N
groups NNS N
for IN N
the DT o
mood NN o
or CC o
cognitive JJ o
outcomes NNS o
. . o

CONCLUSIONS NNP o
Administering NNP N
interventions NNS N
via IN N
the DT N
Internet NNP N
to TO N
older VB N
adults NNS N
is VBZ N
feasible JJ N
. . N

The DT N
2 CD N
interventions NNS N
were VBD N
acceptable JJ N
to TO N
participants NNS N
and CC N
equal JJ N
with IN N
regard NN o
to TO o
perceived VBN o
credibility NN o
and CC o
acceptability NN o
. . o

Future JJ o
RCTs NNP N
are VBP N
planned VBN N
to TO N
evaluate VB N
the DT N
clinical JJ N
efficacy NN N
of IN N
the DT N
2 CD N
interventions NNS N
. . N

-DOCSTART- -1815520- O O

Pharmacokinetics NNS o
and CC o
relative JJ o
bioavailability NN o
of IN N
prajmalium NN i
bitartrate NN i
after IN N
single JJ N
oral JJ N
dosing NN N
. . N

Pharmacokinetics NNS o
and CC o
relative JJ o
bioavailability NN o
of IN N
the DT N
marketed JJ N
prajmalium NN i
bitartrate NN i
tablet NN i
( ( i
Neo-Gilurytmal JJ i
, , i
CAS NNP i
2589-47-1 CD i
) ) i
compared VBN i
to TO i
an DT i
oral JJ i
solution NN i
were VBD N
investigated VBN N
in IN N
an DT N
open JJ N
, , N
randomized VBN N
, , N
single-dose JJ N
two-fold JJ N
crossover NN N
study NN N
in IN N
20 CD p
healthy JJ p
male NN p
volunteers NNS p
. . p

One CD p
subject NN p
was VBD p
identified VBN p
to TO p
be VB p
a DT p
poor JJ o
metabolizer NN o
. . o

In IN N
the DT N
study NN N
population NN N
with IN N
normal JJ N
metabolic JJ N
status NN N
the DT N
two CD N
oral JJ N
formulations NNS N
proved VBD N
to TO N
be VB N
bioequivalent JJ N
with IN N
regard NN N
to TO N
the DT N
pharmacokinetic JJ o
parameters NNS o
Cmax NNP o
, , o
AUC NNP o
( ( o
0-Tlast NN o
) ) o
, , o
AUC NNP o
( ( o
0-infinity NN o
) ) o
and CC o
Ae NNP o
( ( o
24h CD o
) ) o
. . o

tmax NN o
was VBD N
prolonged VBN N
after IN N
administration NN N
of IN N
the DT N
tablets NNS N
. . N

The DT N
relative JJ o
bioavailability NN o
of IN N
prajmalium NN N
bitartrate NN N
from IN N
the DT N
tablet NN N
amounted VBD N
to TO N
112 CD N
% NN N
. . N

The DT N
poor JJ N
metabolizer NN N
demonstrated VBN N
in IN N
both DT N
oral JJ N
formulations NNS N
high JJ o
plasma NN o
concentrations NNS o
, , o
increased VBD o
AUCs NNP o
and CC o
prolonged VBD o
terminal JJ o
half-lives NNS o
as RB o
well RB o
as IN o
increased VBN o
renal JJ o
excretion NN o
of IN o
prajmalium NN o
bitartrate NN o
. . o

-DOCSTART- -8602105- O O

Concentration NN N
of IN N
inhaled JJ i
amiloride NN i
in IN N
cystic JJ p
fibrosis NN p
. . p

-DOCSTART- -25530107- O O

Effect NNP N
of IN N
low JJ N
versus NN N
high JJ N
dialysate NN N
sodium NN N
concentration NN N
on IN N
blood NN o
pressure NN o
and CC o
endothelial-derived JJ o
vasoregulators NNS o
during IN N
hemodialysis NN N
: : N
a DT N
randomized VBN N
crossover NN N
study NN N
. . N

BACKGROUND NNP N
Intradialytic NNP N
hypertension NN N
affects VBZ N
?15 CD N
% NN N
of IN N
hemodialysis NN N
patients NNS N
and CC N
is VBZ N
associated VBN N
with IN N
increased JJ N
morbidity NN N
and CC N
mortality NN N
. . N

While IN N
intradialytic JJ N
hypertension NN N
is VBZ N
associated VBN N
with IN N
increases NNS N
in IN N
endothelin NN N
1 CD N
relative NN N
to TO N
nitric JJ N
oxide NN N
( ( N
NO NNP N
) ) N
, , N
the DT N
cause NN N
of IN N
these DT N
imbalances NNS N
is VBZ N
unknown JJ N
. . N

In IN N
vitro JJ N
evidence NN N
suggests VBZ N
that IN N
altering VBG N
plasma JJ N
sodium NN N
levels NNS N
could MD N
affect VB o
endothelial-derived JJ o
vasoregulators NNS o
and CC o
blood NN o
pressure NN o
( ( o
BP NNP o
) ) o
. . o

Thus RB o
, , N
we PRP N
hypothesized VBD N
that IN N
compared VBN N
to TO N
high JJ N
dialysate NN N
sodium NN N
, , N
low JJ N
dialysate NN N
sodium NN N
concentration NN N
would MD N
lower VB o
endothelin VB o
1 CD o
levels NNS o
, , o
increase NN o
NO NNP o
release NN o
, , o
and CC o
reduce VB o
BP NNP o
. . N

STUDY NNP N
DESIGN NNP N
3-week JJ N
, , N
2-arm JJ N
, , N
randomized VBN N
, , N
crossover NN N
study NN N
. . N

SETTING NNP N
& CC N
PARTICIPANTS NNP p
16 CD p
patients NNS p
with IN p
intradialytic JJ p
hypertension NN p
. . p

INTERVENTION NNP i
Low NNP i
( ( i
5 CD i
mEq/L NN i
below IN i
serum JJ i
sodium NN i
) ) i
versus NN i
high JJ i
( ( i
5 CD i
mEq/L NNS i
above IN i
serum NN i
sodium NN i
) ) i
dialysate NN i
sodium NN i
concentration NN i
. . i

OUTCOMES NNP o
Endothelin NNP o
1 CD o
, , o
nitrite RB o
( ( o
NO2 NNP o
( ( o
- : o
) ) o
) ) o
, , o
and CC o
BP NNP o
. . o

MEASUREMENTS NNP o
Mixed JJ N
linear JJ N
regression NN N
was VBD N
used VBN N
to TO N
compare VB N
the DT N
effect NN N
of IN N
dialysate NN N
sodium NN N
( ( N
low JJ N
vs RB N
high JJ N
) ) N
and CC N
randomization NN N
arm NN N
( ( N
low-then-high JJ N
vs IN N
high-then-low JJ N
) ) N
on IN N
intradialytic JJ o
changes NNS o
in IN o
endothelin NN o
1 CD o
, , o
NO2 NNP o
( ( o
- : o
) ) o
, , o
and CC o
BP NNP o
values NNS o
. . o

RESULTS VB o
The DT N
average JJ o
systolic JJ o
BP NNP o
throughout IN N
all DT N
hemodialysis NN N
treatments NNS N
in IN N
a DT N
given VBN N
week NN N
was VBD N
lower JJR N
with IN N
low JJ N
dialysate NN N
sodium NN N
concentrations NNS N
compared VBN N
with IN N
treatments NNS N
with IN N
high JJ N
dialysate NN N
sodium NN N
concentrations NNS N
( ( N
parameter NN N
estimate NN N
, , N
-9.9 NNP N
[ VBD N
95 CD N
% NN N
CI NNP N
, , N
-13.3 NNP N
to TO N
-6.4 VB N
] NNP N
mm NNP N
Hg NNP N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

The DT o
average JJ o
change NN o
in IN o
systolic JJ o
BP NNP o
during IN o
hemodialysis NN o
also RB o
was VBD o
significantly RB N
lower JJR N
with IN N
low JJ N
vs NNS N
high JJ N
dialysate NN N
sodium NN N
concentrations NNS N
( ( N
parameter NN N
estimate NN N
, , N
-6.1 NNP N
[ VBD N
95 CD N
% NN N
CI NNP N
, , N
-9.0 NNP N
to TO N
-3.2 VB N
] NNP N
mm NNP N
Hg NNP N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN o
intradialytic JJ o
levels NNS o
of IN o
endothelin NN o
1 CD o
or CC o
NO2 NNP o
( ( o
- : o
) ) o
with IN N
low JJ N
vs NNS N
high JJ N
dialysate NN N
sodium NN N
concentrations NNS N
. . N

LIMITATIONS NNP N
Carryover NNP N
effects NNS N
limited VBD N
the DT N
power NN N
to TO N
detect VB N
significant JJ N
changes NNS N
in IN N
endothelial-derived JJ o
vasoregulators NNS o
, , o
and CC o
future JJ o
studies NNS N
will MD N
require VB N
parallel JJ N
trial NN N
designs NNS N
. . N

CONCLUSIONS NNP N
Low NNP N
dialysate NN N
sodium NN N
concentrations NNS N
significantly RB o
decreased VBD o
systolic JJ o
BP NNP o
and CC o
ameliorated VBN o
intradialytic JJ o
hypertension NN o
. . o

Longer JJR o
studies NNS o
are VBP N
needed VBN N
to TO N
determine VB N
the DT N
long-term JJ N
effects NNS N
of IN N
low JJ N
dialysate NN N
sodium NN N
concentrations NNS o
on IN o
BP NNP o
and CC o
clinical JJ N
outcomes NNS N
. . N

-DOCSTART- -26279130- O O

The DT N
VA NNP i
augmentation NN i
and CC i
switching NN i
treatments NNS i
for IN N
improving VBG N
depression NN N
outcomes NNS N
( ( N
VAST-D NNP N
) ) N
study NN N
: : N
Rationale NNP N
and CC N
design NN N
considerations NNS N
. . N

Because IN N
two-thirds NNS N
of IN N
patients NNS p
with IN p
Major JJ p
Depressive NNP p
Disorder NNP p
do VBP N
not RB N
achieve VB N
remission NN N
with IN N
their PRP$ N
first JJ N
antidepressant NN N
, , N
we PRP N
designed VBD N
a DT N
trial NN N
of IN N
three CD N
next-step JJ N
strategies NNS N
: : N
switching NN i
to TO i
another DT i
antidepressant NN i
( ( i
bupropion-SR JJ i
) ) i
or CC N
augmenting VBG i
the DT i
current JJ i
antidepressant NN i
with IN i
either DT i
another DT i
antidepressant NN i
( ( i
bupropion-SR JJ i
) ) i
or CC i
with IN i
an DT i
atypical JJ i
antipsychotic NN i
( ( i
aripiprazole JJ i
) ) i
. . i

The DT N
study NN N
will MD N
compare VB N
12-week JJ o
remission NN o
rates NNS o
and CC N
, , N
among IN N
those DT N
who WP N
have VBP N
at IN N
least JJS N
a DT N
partial JJ N
response NN N
, , N
relapse NN o
rates NNS o
for IN N
up IN N
to TO N
6 CD N
months NNS N
of IN N
additional JJ N
treatment NN N
. . N

We PRP N
review VBP N
seven CD N
key JJ N
efficacy/effectiveness JJ N
design NN N
decisions NNS N
in IN N
this DT N
mixed JJ N
efficacy-effectiveness JJ N
trial NN N
. . N

-DOCSTART- -24938562- O O

Effect NN N
of IN N
selumetinib NN i
vs NN N
chemotherapy NN i
on IN N
progression-free JJ N
survival NN N
in IN N
uveal JJ p
melanoma NN p
: : p
a DT N
randomized JJ N
clinical JJ N
trial NN N
. . N

IMPORTANCE NNP N
Uveal NNP N
melanoma NN N
is VBZ N
characterized VBN N
by IN N
mutations NNS N
in IN N
GNAQ NNP N
and CC N
GNA11 NNP N
, , N
resulting VBG N
in IN N
mitogen-activated JJ N
protein NN N
kinase VB N
pathway JJ N
activation NN N
. . N

OBJECTIVE UH N
To TO N
assess VB N
the DT N
efficacy NN N
of IN N
selumetinib NN i
, , N
a DT N
selective JJ N
, , N
non-adenosine JJ N
triphosphate NN N
competitive JJ N
inhibitor NN N
of IN N
MEK1 NNP N
and CC N
MEK2 NNP N
, , N
in IN N
uveal JJ p
melanoma NN p
. . p

DESIGN NNP N
, , N
SETTING NNP N
, , N
AND NNP N
PARTICIPANTS NNP N
Randomized NNP N
, , N
open-label NN N
, , N
phase NN N
2 CD N
clinical JJ N
trial NN N
comparing VBG N
selumetinib JJ i
vs NN N
chemotherapy NN i
conducted VBN N
from IN p
August NNP p
2010 CD p
through IN p
December NNP p
2013 CD p
among IN p
120 CD p
patients NNS p
with IN p
metastatic JJ p
uveal JJ p
melanoma NN p
at IN p
15 CD p
academic JJ p
oncology NN p
centers NNS p
in IN p
the DT p
United NNP p
States NNPS p
and CC p
Canada NNP p
. . p

INTERVENTIONS NNP N
One CD p
hundred VBD p
one CD p
patients NNS p
were VBD p
randomized VBN p
in IN p
a DT p
1:1 CD p
ratio NN p
to TO N
receive VB N
selumetinib NN i
, , N
75 CD N
mg NN N
orally RB N
twice RB N
daily RB N
on IN N
a DT N
continual JJ N
basis NN N
( ( N
n JJ N
= NNP N
50 CD N
) ) N
, , N
or CC N
chemotherapy NN i
( ( i
temozolomide JJ i
, , i
150 CD i
mg/m2 NNS N
orally RB N
daily RB N
for IN N
5 CD N
of IN N
every DT N
28 CD N
days NNS N
, , N
or CC N
dacarbazine NN i
, , i
1000 CD i
mg/m2 NN N
intravenously RB N
every DT N
21 CD N
days NNS N
[ NNP N
investigator NN N
choice NN N
] NNP N
; : N
n CC N
= VB N
51 CD N
) ) N
until IN N
disease NN N
progression NN N
, , N
death NN N
, , N
intolerable JJ N
adverse JJ N
effects NNS N
, , N
or CC N
withdrawal NN N
of IN N
consent NN N
. . N

After IN N
primary JJ N
outcome NN N
analysis NN N
, , p
19 CD p
patients NNS p
were VBD p
registered VBN p
and CC p
18 CD p
treated VBN p
with IN p
selumetinib NN p
without IN p
randomization NN p
to TO p
complete VB p
the DT p
planned VBN p
120-patient JJ p
enrollment NN p
. . p

Patients NNS p
in IN i
the DT i
chemotherapy NN i
group NN i
could MD i
receive VB N
selumetinib NN i
at IN i
the DT i
time NN N
of IN N
radiographic JJ N
progression NN N
. . N

MAIN NNP N
OUTCOMES NNP N
AND NNP N
MEASURES NNP N
Progression-free NNP o
survival NN o
, , o
the DT o
primary JJ o
end NN N
point NN N
, , N
was VBD N
assessed VBN N
as IN N
of IN N
April NNP N
22 CD N
, , N
2013 CD N
. . N

Additional JJ N
end NN N
points NNS N
, , N
including VBG o
overall JJ o
survival NN o
, , o
response NN o
rate NN o
, , o
and CC o
safety/toxicity NN o
, , o
were VBD o
assessed VBN o
as IN N
of IN N
December NNP N
31 CD N
, , N
2013 CD N
. . N

RESULTS VB N
Median JJ N
progression-free JJ N
survival NN N
among IN N
patients NNS N
randomized VBN i
to TO i
chemotherapy VB i
was VBD i
7 CD i
weeks NNS i
( ( N
95 CD N
% NN N
CI NNP N
, , N
4.3-8.4 JJ N
weeks NNS N
; : N
median JJ N
treatment NN N
duration NN N
, , N
8 CD N
weeks NNS N
; : N
interquartile JJ N
range NN N
[ NNP N
IQR NNP N
] NNP N
, , N
4.3-16 JJ N
weeks NNS N
) ) N
and CC N
among IN N
those DT N
randomized VBN i
to TO i
selumetinib VB i
was VBD i
15.9 CD i
weeks NNS N
( ( N
95 CD N
% NN N
CI NNP N
, , N
8.4-21.1 JJ N
weeks NNS N
; : N
median JJ N
treatment NN N
duration NN N
, , N
16.1 CD N
weeks NNS N
; : N
IQR NNP N
, , N
8.1-25.3 JJ N
weeks NNS N
) ) N
( ( N
hazard JJ N
ratio NN N
, , N
0.46 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
0.30-0.71 NNP N
; : N
P NNP N
< NNP N
.001 NNP N
) ) o
. . o

Median JJ o
overall JJ o
survival NN o
time NN o
was VBD o
9.1 CD o
months NNS N
( ( N
95 CD N
% NN N
CI NNP N
, , N
6.1-11.1 JJ N
months NNS N
) ) N
with IN N
chemotherapy NN N
and CC N
11.8 CD N
months NNS N
( ( N
95 CD N
% NN N
CI NNP N
, , N
9.8-15.7 JJ N
months NNS N
) ) N
with IN N
selumetinib NN i
( ( N
hazard JJ N
ratio NN N
, , N
0.66 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
0.41-1.06 NNP N
; : N
P NNP N
= NNP N
.09 NNP N
) ) N
. . N

No DT N
objective JJ N
responses NNS N
were VBD N
observed VBN N
with IN i
chemotherapy NN i
. . i

Forty-nine JJ i
percent NN N
of IN N
patients NNS N
treated VBN N
with IN i
selumetinib NN i
achieved VBN o
tumor NN o
regression NN o
, , o
with IN o
14 CD N
% NN N
achieving VBG N
an DT N
objective JJ N
radiographic JJ N
response NN N
to TO N
therapy VB N
. . N

Treatment-related JJ N
adverse JJ N
events NNS N
were VBD N
observed VBN N
in IN N
97 CD N
% NN N
of IN N
patients NNS N
treated VBN N
with IN N
selumetinib NN N
, , N
with IN N
37 CD N
% NN N
requiring VBG N
at IN N
least JJS N
1 CD N
dose JJ N
reduction NN N
. . N

CONCLUSIONS NNP N
AND CC N
RELEVANCE NNP N
In IN N
this DT N
hypothesis-generating JJ p
study NN p
of IN p
patients NNS p
with IN p
advanced JJ p
uveal JJ p
melanoma NN p
, , p
selumetinib NN N
compared VBN i
with IN i
chemotherapy NN i
resulted VBN i
in IN N
a DT N
modestly RB N
improved VBN N
progression-free JJ N
survival NN N
and CC N
response NN N
rate NN N
; : N
however RB N
, , N
no DT N
improvement NN N
in IN N
overall JJ N
survival NN N
was VBD N
observed VBN N
. . N

Improvement NN N
in IN N
clinical JJ N
outcomes NNS N
was VBD N
accompanied VBN N
by IN N
a DT N
high JJ N
rate NN N
of IN N
adverse JJ N
events NNS N
. . N

TRIAL NNP N
REGISTRATION NNP N
clinicaltrials.gov NN N
Identifier NNP N
: : N
NCT01143402 NN N
. . N

-DOCSTART- -21692873- O O

Effects NNS N
of IN N
dietary JJ i
pyridoxine NN i
on IN N
haemato-immunological JJ o
responses NNS o
of IN N
Labeo NNP p
rohita JJ p
fingerlings NNS p
reared VBD p
at IN p
higher JJR p
water NN p
temperature NN p
. . p

A DT N
sixty-day JJ N
feeding NN N
trial NN N
was VBD N
carried VBN N
out IN N
to TO N
elucidate VB N
the DT N
effect NN N
of IN N
dietary JJ i
pyridoxine NN i
( ( i
PN NNP i
) ) i
on IN N
hemato-immunological JJ o
parameters NNS o
in IN N
Labeo NNP p
rohita VBP p
fingerlings NNS p
exposed VBN p
to TO p
an DT p
elevated JJ p
temperature NN p
( ( p
ET NNP p
) ) p
of IN p
33 CD p
?C NNS p
. . p

Two CD p
hundred VBD p
and CC p
seventy JJ p
fingerlings NNS p
( ( p
6.71 CD p
? . p
0.32 CD p
g NN p
) ) p
were VBD p
randomly RB N
distributed VBN N
into IN i
six CD i
treatments NNS i
in IN i
triplicates NNS i
( ( i
15 CD N
fish/tank NN N
) ) N
. . N

Five CD i
iso-nitrogenous JJ i
( ( i
356.3 CD i
? . i
2.7 CD i
g/kg JJ i
crude NN i
protein NN i
) ) i
purified VBD i
diets NNS i
were VBD i
prepared VBN N
with IN N
graded JJ N
levels NNS N
( ( N
0 CD N
, , N
10 CD N
, , N
50 CD N
, , N
100 CD N
and CC N
200 CD N
mg/kg NNS N
diet JJ N
) ) N
of IN N
PN NNP N
. . N

Six NNP N
treatment NN N
groups NNS N
were VBD N
P10T26 NNP N
( ( N
10 CD N
mg NN N
PN NNP N
+ NNP N
ambient JJ N
temperature NN N
( ( N
26 CD N
?C NN N
) ) N
, , N
P0T33 NNP N
( ( N
0 CD N
mg NN N
PN NNP N
+ NNP N
ET NNP N
) ) N
, , N
P10T33 NNP N
( ( N
10 CD N
mg NN N
PN NNP N
+ NNP N
ET NNP N
) ) N
, , N
P50T33 NNP N
( ( N
50 CD N
mg NN N
PN NNP N
+ NNP N
ET NNP N
) ) N
, , N
P100T33 NNP N
( ( N
100 CD N
mg NN N
PN NNP N
+ NNP N
ET NNP N
) ) N
and CC N
P200T33 NNP N
( ( N
200 CD N
mg NN N
PN NNP N
+ NNP N
ET NNP N
) ) N
. . N

The DT N
responses NNS p
of IN p
L. NNP p
rohita JJ p
fingerlings NNS p
to TO p
dietary JJ N
PN NNP N
were VBD N
assessed VBN N
in IN N
terms NNS o
of IN o
growth NN o
and CC o
by IN N
analysing VBG N
some DT N
hemato-immunological JJ N
parameters NNS N
. . N

When WRB N
PN NNP i
supplementation NN i
increased VBD i
from IN N
10 CD N
to TO N
200 CD N
mg/kg NNS N
diet JJ N
, , N
a DT N
significant JJ N
improvement NN o
in IN o
weight JJ o
gain NN o
percentage NN o
was VBD o
observed VBN o
. . o

Erythrocyte NNP o
( ( o
RBC NNP o
) ) o
count NN o
, , o
leucocyte NN o
( ( o
WBC NNP o
) ) o
count NN o
, , o
haemoglobin NN o
content NN o
and CC o
respiratory JJ o
burst NN o
activity NN o
were VBD o
significantly RB N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
higher JJR N
in IN N
100 CD N
mg JJ i
PN/kg NNP i
diet-fed NN i
group NN i
than IN N
their PRP$ i
non-PN-fed JJ i
counterpart NN i
. . N

Also RB N
, , o
serum JJ o
albumin NN o
, , o
globulin NN o
and CC o
lysozyme JJ o
activity NN o
were VBD o
found VBN N
significantly RB N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
higher JJR N
in IN N
PN-fed NNP N
groups NNS N
. . N

The DT N
overall JJ N
results NNS N
indicated VBD N
that IN N
dietary JJ i
PN NNP i
supplementation NN i
at IN i
100 CD N
mg/kg NNS N
diet JJ N
may MD N
reverse VB N
the DT N
negative JJ N
effects NNS N
caused VBN N
by IN N
ET NNP N
and CC N
may MD N
protect VB N
the DT N
haemato-immunological JJ o
status NN o
of IN o
L. NNP p
rohita JJ p
fingerlings NNS p
reared VBD p
at IN p
higher JJR p
water NN p
temperature NN p
. . p

-DOCSTART- -2949396- O O

No DT N
effect NN N
of IN N
acetylsalicylic JJ i
acid NN i
on IN N
B-thromboglobulin NNP o
and CC o
platelet VB o
factor NN o
4 CD o
plasma NN o
levels NNS o
in IN N
patients NNS p
with IN p
transient JJ p
ischaemic JJ p
attacks NNS p
. . p

We PRP N
studied VBD N
the DT N
effect NN N
of IN N
acetylsalicylic JJ i
acid NN i
( ( i
ASA NNP i
) ) i
versus NN i
placebo NN i
on IN N
B-thromboglobulin NNP o
( ( o
B-TG NNP o
) ) o
and CC o
platelet JJ o
factor NN o
4 CD o
( ( o
PF4 NNP o
) ) o
plasma NN o
levels NNS o
and CC o
ADP-induced NNP o
platelet NN o
aggregation NN o
in IN N
25 CD p
male JJ p
patients NNS p
with IN p
transient JJ p
ischaemic JJ p
attacks NNS p
( ( p
TIA NNP p
) ) p
. . p

The DT N
patients NNS N
were VBD N
allocated VBN N
randomly RB N
to TO N
two CD N
groups NNS N
: : N
14 CD N
patients NNS N
received JJ N
oral JJ N
treatment NN N
with IN N
ASA NNP i
500 CD N
mg NN N
b.i.d NN N
. . N

for IN N
14 CD N
days NNS N
, , N
11 CD N
patients NNS N
placebo JJ i
b.i.d NN N
. . N

for IN N
the DT N
same JJ N
period NN N
. . N

B-TG NNP o
and CC o
PF4 NNP o
plasma NN o
levels NNS o
and CC o
ADP-induced NNP o
platelet NN o
aggregation NN o
were VBD N
determined VBN N
in IN N
basal NN N
conditions NNS N
, , N
and CC N
two CD N
hours NNS N
, , N
and CC N
seven CD N
and CC N
fourteen JJ N
days NNS N
after IN N
starting VBG N
with IN N
ASA NNP N
or CC N
placebo NN N
. . N

In IN p
addition NN p
, , p
the DT p
same JJ p
parameters NNS p
were VBD p
studied VBN p
in IN p
a DT p
group NN p
of IN p
20 CD p
healthy JJ p
males NNS p
of IN p
matched JJ p
age NN p
. . p

Basal NNP o
levels NNS o
of IN o
plasma JJ o
B-TG NNP o
and CC o
PF4 NNP o
and CC N
the DT N
maximal JJ N
amplitude NN o
of IN o
ADP-induced NNP o
platelet NN o
aggregation NN o
were VBD N
abnormally RB N
high JJ N
in IN N
TIA NNP N
patients NNS N
. . N

ASA NNP N
caused VBD N
a DT N
significant JJ N
reduction NN N
of IN N
B-TG NNP o
plasma NN o
levels NNS o
in IN N
TIA NNP N
patients NNS N
2 CD N
hours NNS N
after IN N
the DT N
first JJ N
administration NN N
, , N
but CC N
no DT N
effect NN N
was VBD N
observed VBN N
at IN N
the DT N
7th CD N
and CC N
14th CD N
day NN N
of IN N
treatment NN N
. . N

PF4 NNP o
plasma NN o
levels NNS o
were VBD N
unaffected VBN N
by IN N
ASA NNP N
treatment NN N
. . N

It PRP N
is VBZ N
concluded VBN N
that IN N
ASA NNP N
, , N
at IN N
the DT N
dose NN N
conventionally RB N
used VBN N
in IN N
clinical JJ N
trials NNS N
, , N
does VBZ N
not RB N
affect VB N
the DT N
release NN N
of IN N
two CD N
alpha-granule JJ N
proteins NNS N
. . N

-DOCSTART- -16454975- O O

XS0601 NN i
reduces VBZ N
the DT N
incidence NN N
of IN N
restenosis NN N
: : N
a DT N
prospective JJ N
study NN N
of IN N
335 CD p
patients NNS p
undergoing VBG p
percutaneous JJ p
coronary JJ p
intervention NN p
in IN p
China NNP p
. . p

BACKGROUND NNP N
XS0601 NNP i
, , N
consisting VBG N
of IN N
active JJ N
ingredients NNS N
( ( N
Chuangxiongol NNP N
and CC N
paeoniflorin NN N
) ) N
, , N
has VBZ N
been VBN N
shown VBN N
to TO N
inhibit VB N
arterial JJ N
neointimal JJ N
hyperplasia NN N
in IN N
animal JJ N
models NNS N
and CC N
in IN N
preliminary JJ N
human JJ N
studies NNS N
. . N

The DT N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
safety NN N
and CC N
efficacy NN N
of IN N
XS0601 NNP i
in IN N
preventing VBG N
restenosis NN N
following VBG N
percutaneous JJ i
coronary JJ i
intervention NN i
( ( N
PCI NNP N
) ) N
. . N

METHODS VB N
A DT N
multi-center NN N
, , N
randomized VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
trial NN N
was VBD N
conducted VBN N
. . N

A DT p
total NN p
of IN p
335 CD p
patients NNS p
were VBD p
randomized VBN p
into IN N
treatment NN N
with IN N
the DT N
oral JJ i
administration NN i
of IN i
XS0601 NNP i
, , i
or CC i
a DT i
placebo NN i
for IN N
6 CD N
months NNS N
after IN N
successful JJ N
PCI NNP N
. . N

Angiographic NNP N
follow-up NN N
was VBD N
scheduled VBN N
at IN N
6 CD N
months NNS N
, , N
and CC N
clinical JJ N
follow-ups NNS N
performed VBN N
at IN N
1 CD N
, , N
3 CD N
and CC N
6 CD N
months NNS N
after IN N
PCI NNP N
. . N

The DT N
primary JJ N
end NN N
point NN N
was VBD N
angiographic JJ o
restenosis NN o
. . o

The DT N
secondary JJ N
end NN N
points NNS N
were VBD N
the DT N
combined JJ o
incidence NN o
of IN o
death NN o
, , o
target NN o
lesion NN o
nonfatal JJ o
myocardial JJ o
infarction NN o
, , o
repeat NN o
angioplasty NN o
, , o
and CC o
coronary JJ o
artery NN o
bypass NN o
graft NN o
surgery NN o
. . o

RESULTS VB N
A DT p
total NN p
of IN p
308 CD p
patients NNS p
( ( p
91.9 CD p
% NN p
) ) p
completed VBD p
the DT p
study NN p
and CC p
145 CD p
cases NNS p
( ( p
47.1 CD p
% NN p
) ) p
received VBD p
angiographic JJ p
follow-up NN p
. . p

The DT N
restenosis NN o
rates NNS o
were VBD N
significantly RB N
reduced VBN N
in IN N
the DT N
XS0601 NNP i
group NN N
as IN N
compared VBN N
with IN N
the DT N
placebo NN i
group NN N
( ( N
26.0 CD N
% NN N
vs. FW N
47.2 CD N
% NN N
, , N
P NNP N
< NNP N
0.05 CD N
) ) N
, , N
and CC N
the DT N
minimum JJ o
lumen NNS o
diameter NN o
( ( o
MLD NNP o
) ) o
was VBD N
greater JJR N
[ NNP N
( ( N
2.08 CD N
+/- JJ N
0.89 CD N
) ) N
mm NN N
for IN N
XS0601 NNP i
vs. FW N
( ( N
1.73 CD N
+/- JJ N
0.94 CD N
) ) N
mm NN N
for IN N
placebo NN i
, , N
P NNP N
< VBZ N
0.05 CD N
] NN N
. . N

XS0601 NN i
also RB N
significantly RB N
reduced VBD N
the DT N
combined JJ o
incidence NN o
of IN o
major JJ o
adverse JJ o
cardiac NN o
event NN o
( ( N
10.4 CD N
% NN N
in IN N
the DT N
XS0601 NNP N
group NN N
vs. FW N
22.7 CD N
% NN N
in IN N
the DT N
placebo NN i
group NN N
, , N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

The DT N
incidence NN o
of IN o
recurrent JJ o
angina NN o
at IN N
3 CD N
and CC N
6 CD N
months NNS N
after IN N
PCI NNP N
was VBD N
also RB N
significantly RB N
reduced VBN N
in IN N
XS0601 NNP i
group NN N
( ( N
7.1 CD N
% NN N
and CC N
11.0 CD N
% NN N
) ) N
as IN N
compared VBN N
with IN N
those DT N
in IN N
placebo JJ i
group NN N
( ( N
19.5 CD N
% NN N
and CC N
42.9 CD N
% NN N
) ) N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

No DT N
significant JJ N
side NN N
effects NNS N
occurred VBD N
within IN N
the DT N
6-month JJ N
follow-up JJ N
period NN N
in IN N
the DT N
XS0601 NNP i
group NN N
. . N

CONCLUSION NNP N
Administration NNP N
of IN N
XS0601 NNP i
for IN N
6 CD N
months NNS N
is VBZ N
demonstrated VBN N
to TO N
be VB N
safe JJ N
and CC N
effective JJ N
in IN N
reducing VBG N
restenosis NN N
in IN N
post-PCI JJ p
patients NNS p
. . p

-DOCSTART- -17362495- O O

Immediately RB N
restored VBN N
, , N
single-tapered JJ N
implants NNS i
in IN p
the DT p
anterior JJ p
maxilla NN p
: : p
prosthodontic JJ N
and CC N
aesthetic JJ N
outcomes NNS N
after IN N
1 CD N
year NN N
. . N

BACKGROUND NNP N
Conventional NNP N
implant JJ N
protocols NNS N
advocate VBP N
a DT N
two-stage NN N
technique NN N
with IN N
a DT N
load-free JJ N
, , N
submerged VBD N
healing JJ N
period NN N
. . N

Recent JJ N
studies NNS N
suggest VBP N
that IN N
immediate JJ N
restoration NN N
of IN N
single JJ N
implants NNS N
may MD N
be VB N
a DT N
viable JJ N
treatment NN N
option NN N
. . N

PURPOSE VB N
The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
prosthodontic JJ o
and CC o
aesthetic JJ o
peri-implant JJ o
mucosal NN o
outcomes NNS N
of IN N
immediately RB p
restored VBN p
, , p
Southern JJ p
single-tapered JJ p
implants NNS i
in IN p
the DT p
anterior JJ p
maxilla NN p
after IN p
1 CD p
year NN p
. . p

MATERIALS NNP N
AND CC N
METHODS NNP N
Participants NNP p
( ( p
mean JJ p
age NN p
: : p
43.25 CD p
years NNS p
; : p
range NN p
: : p
23-71 JJ p
years NNS p
) ) p
satisfying VBG p
specified VBN p
inclusion NN p
criteria NNS p
were VBD N
randomly RB N
allocated VBN N
to TO N
conventional JJ N
two-stage JJ i
restoration NN i
( ( N
control NN N
group NN N
; : N
n=14 CC N
) ) N
and CC N
immediate JJ i
restoration NN i
groups NNS i
( ( N
test NN N
group NN N
; : N
n CC N
=14 NN N
) ) N
in IN N
a DT N
randomized NN N
controlled VBD N
clinical JJ N
trial NN N
. . N

Tapered VBN N
, , N
roughened-surface JJ N
Southern JJ N
implants NNS N
were VBD N
placed VBN N
using VBG N
a DT N
standardized JJ N
technique NN N
, , N
and CC N
implant JJ N
level NN N
bone NN N
impressions NNS N
were VBD N
made VBN N
. . N

Provisional JJ N
screw-retained JJ N
crowns NNS N
, , N
out IN N
of IN N
occlusion NN N
, , N
were VBD N
placed VBN N
at IN N
second-stage NN N
surgery NN N
after IN N
26 CD N
weeks NNS N
for IN N
the DT N
conventional JJ N
restoration NN N
group NN N
, , N
and CC N
within IN N
4 CD N
hours NNS N
of IN N
implant JJ N
placement NN N
for IN N
the DT N
immediate JJ N
restoration NN N
group NN N
. . N

Both DT N
groups NNS N
had VBD N
definitive JJ N
screw-retained JJ N
metal-ceramic JJ N
crowns NNS N
placed VBN N
in IN N
occlusion NN N
8 CD N
weeks NNS N
later RB N
. . N

Peri-implant JJ o
mucosal NN o
response NN o
and CC o
papilla NN o
index NN o
were VBD N
recorded VBN N
4 CD N
weeks NNS N
after IN N
definitive JJ N
crown JJ N
placement NN N
to TO N
allow VB N
for IN N
mucosal JJ N
maturation NN N
and CC N
at IN N
1 CD N
year NN N
. . N

Prosthodontic NNP o
and CC o
aesthetic JJ o
outcomes NNS N
were VBD N
assessed VBN N
using VBG N
established VBN N
criteria NNS N
. . N

RESULTS VB N
There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
within IN N
, , N
or CC N
between IN N
, , N
the DT N
control NN N
and CC N
test NN N
groups NNS N
for IN N
age NN o
, , o
gender NN o
, , o
bone NN o
quality NN o
or CC o
quantity NN o
, , o
implant JJ o
stability NN o
measurements NNS o
at IN o
surgery NN o
, , N
or CC N
implant JJ o
length NN o
. . o

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
the DT N
implant JJ o
success NN o
rate NN o
as IN N
determined VBN N
by IN N
radiographic JJ N
bone NN o
loss NN o
and CC N
stability NN N
tests NNS N
after IN N
1 CD N
year NN N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
prosthodontic JJ o
maintenance NN o
, , o
peri-implant JJ o
mucosal NN o
response NN o
, , o
and CC o
papilla NN o
index NN o
between IN N
the DT N
two CD N
groups NNS N
over IN N
1 CD N
year NN N
. . N

CONCLUSIONS NNP N
Tapered NNP N
, , N
roughened-surface JJ N
implants NNS N
immediately RB N
restored VBN N
with IN N
single JJ N
provisional JJ N
crowns NNS N
at IN N
surgery NN N
and CC N
definitive JJ N
crowns NNS N
8 CD N
weeks NNS N
later RB N
were VBD N
as IN N
prosthodontically RB N
and CC N
aesthetically RB N
successful JJ N
as IN N
conventionally RB N
restored VBN N
two-stage JJ N
implants NNS N
during IN N
the DT N
first JJ N
year NN N
of IN N
service NN N
. . N

Restoring VBG i
single JJ N
implants NNS N
immediately RB N
with IN N
screw-retained JJ N
crowns NNS N
is VBZ N
an DT N
efficient JJ N
procedure NN N
, , N
but CC N
the DT N
short-term JJ N
outcome NN N
is VBZ N
by IN N
no DT N
means NNS N
superior VBP N
to TO N
a DT N
conventional JJ N
two-stage JJ N
approach NN N
. . N

-DOCSTART- -10714690- O O

Combination NN N
cyclopentolate NN i
and CC N
phenylephrine NN i
for IN N
mydriasis NN N
in IN N
premature JJ p
infants NNS p
with IN p
heavily RB p
pigmented VBN p
irides NNS p
. . p

PURPOSE VB N
This DT N
study NN N
examined VBD N
whether IN N
safe JJ N
and CC N
effective JJ N
mydriasis NN N
can MD N
be VB N
achieved VBN N
in IN N
premature NN p
infants NNS p
with IN p
heavily RB p
pigmented VBN p
irides NNS p
using VBG N
combination NN N
cyclopentolate VB i
0.2 CD N
% NN N
and CC N
phenylephrine VB i
1 CD N
% NN N
eyedrops NNS N
. . N

METHODS NNP N
A NNP N
prospective JJ N
, , N
randomized VBN N
double-blind NN N
study NN N
was VBD N
performed VBN N
to TO N
compare VB N
combination NN N
cyclopentolate VB i
0.2 CD N
% NN N
and CC N
phenylephrine VB i
1 CD N
% NN N
eye-drops JJ N
with IN N
triple JJ N
instillation NN N
of IN N
tropicamide JJ i
0.5 CD N
% NN N
and CC N
phenylephrine VB i
2.5 CD N
% NN N
. . N

Twenty-eight JJ p
consecutive JJ p
babies NNS p
with IN p
dark JJ p
irides NNS p
and CC p
birthweight NN p
< NN p
1600 CD p
g NN p
referred VBD p
for IN p
screening VBG p
for IN p
retinopathy NN p
of IN p
prematurity NN p
comprised VBD p
the DT p
study NN p
population NN p
. . p

Infants NNS N
' POS N
eyes NNS N
were VBD N
randomly RB N
dilated VBN N
twice RB N
with IN N
both DT N
regimens NNS N
within IN N
a DT N
2-week JJ N
period NN N
. . N

Blood NNP o
pressure NN o
, , o
heart NN o
rate NN o
, , o
and CC o
pupil JJ o
size NN o
were VBD N
measured VBN N
. . N

RESULTS NNP N
Good JJ N
mydriasis NN N
was VBD N
achieved VBN N
in IN N
both DT N
groups NNS N
with IN N
no DT N
significant JJ N
differences NNS o
in IN o
pupil JJ o
size NN o
or CC o
blood NN o
pressure NN o
( ( o
systolic JJ o
, , o
diastolic JJ o
, , o
or CC o
mean VB o
arterial JJ o
pressures NNS o
) ) o
over IN N
starting VBG N
baseline JJ N
values NNS N
. . N

Pulse NNP o
rates NNS o
decelerated VBD N
below IN N
the DT N
baseline NN N
values NNS N
in IN N
both DT N
groups NNS N
, , N
but CC N
these DT N
differences NNS N
were VBD N
not RB N
large JJ N
. . N

CONCLUSION VB N
The DT N
single JJ N
combination NN N
eyedrop NN N
of IN N
cyclopentolate JJ N
0.2 CD N
% NN N
and CC N
phenylephrine VB N
1 CD N
% NN N
is VBZ N
as IN N
effective JJ N
and CC N
safe JJ N
a DT N
mydriatic JJ N
for IN N
infants NNS N
with IN N
dark JJ N
irides NNS N
as IN N
both DT N
tropicamide IN N
0.5 CD N
% NN N
and CC N
phenylephrine VB N
2.5 CD N
% NN N
. . N

-DOCSTART- -19054570- O O

Maintenance NN N
of IN N
response NN N
following VBG N
stabilization NN N
of IN N
mixed JJ N
index NN N
episodes NNS N
with IN N
olanzapine JJ i
monotherapy NN N
in IN N
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
study NN N
of IN N
bipolar JJ p
1 CD p
disorder NN p
. . p

BACKGROUND NNP N
In IN N
a DT N
population NN N
of IN N
patients NNS p
with IN p
manic JJ p
and CC p
mixed JJ p
mood NN p
episodes NNS p
, , N
olanzapine NN i
has VBZ N
proven VBN N
effective JJ N
in IN N
maintaining VBG N
response NN N
, , N
as IN N
compared VBN N
to TO N
placebo VB N
. . N

Whether IN N
this DT N
is VBZ N
true JJ N
for IN N
the DT N
subpopulation NN N
of IN N
patients NNS N
with IN N
a DT N
mixed JJ N
index NN N
episode NN N
is VBZ N
not RB N
known VBN N
. . N

METHODS NNP N
Post-hoc JJ N
analyses NNS N
were VBD N
conducted VBN N
on IN N
data NNS N
from IN N
patients NNS p
presenting VBG p
with IN p
a DT p
mixed JJ p
index NN p
episode NN p
who WP p
were VBD p
enrolled VBN p
in IN p
a DT p
larger JJR p
double-blind NN p
, , p
placebo-controlled JJ i
trial NN p
. . p

Patients NNS p
who WP p
met VBD p
remission NN p
criteria NNS p
at IN p
2 CD p
consecutive JJ p
weekly JJ p
visits NNS p
during IN p
6 CD p
to TO p
12 CD p
weeks NNS p
of IN p
open-label JJ p
olanzapine JJ i
treatment NN p
were VBD N
randomly RB N
assigned VBN N
to TO N
olanzapine VB i
or CC N
placebo VB i
treatment NN N
for IN N
48 CD N
weeks NNS N
. . N

The DT N
incidence NN N
of IN N
and CC N
time NN N
to TO N
symptomatic JJ o
relapse NN o
were VBD N
calculated VBN N
for IN N
any DT N
mood NN N
episode NN N
, , N
and CC N
for IN N
depressive JJ N
, , N
manic JJ N
, , N
hypo-manic JJ N
, , N
and CC N
mixed JJ N
mood NN N
episodes NNS N
. . N

RESULTS VB N
A DT N
total NN N
of IN N
121 CD p
of IN p
304 CD p
patients NNS p
( ( N
39.8 CD N
% NN N
) ) N
met VBD N
criteria NNS N
for IN N
symptomatic JJ o
remission NN o
in IN N
the DT N
open-label JJ N
treatment NN N
phase NN N
and CC N
were VBD N
randomly RB N
assigned VBN N
to TO N
olanzapine VB i
( ( N
n=76 NN N
) ) N
or CC N
placebo NN N
( ( N
n=45 JJ N
) ) N
. . N

Compared VBN N
to TO N
the DT N
placebo NN i
group NN N
, , N
the DT N
olanzapine NN i
group NN N
had VBD N
a DT N
lower JJR N
incidence NN N
of IN N
( ( N
59.2 CD N
% NN N
versus IN N
91.1 CD N
% NN N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
and CC N
a DT N
longer JJR N
time NN N
to TO N
( ( N
46 CD N
versus NN N
15 CD N
days NNS N
, , N
p VBP N
< RB N
0.001 CD N
) ) N
symptomatic JJ o
relapse NN o
of IN N
any DT N
kind NN N
. . N

Olanzapine-treated JJ i
patients NNS N
also RB N
experienced VBD N
longer JJR N
time NN o
to TO o
depressive VB o
symptomatic JJ o
relapse NN o
( ( N
85 CD N
versus NN N
22 CD N
days NNS N
, , N
p=0.001 NN N
) ) N
and CC N
manic JJ o
symptomatic JJ o
relapse NN o
( ( N
too RB N
few JJ N
relapses NNS N
to TO N
calculate VB N
versus NN N
42 CD N
days NNS N
, , N
p VBP N
< RB N
0.001 CD N
) ) N
than IN N
did VBD N
placebo-treated JJ N
patients NNS N
. . N

CONCLUSIONS NNP N
Compared NNP N
with IN N
placebo NN i
, , i
olanzapine JJ i
treatment NN N
was VBD N
associated VBN N
with IN N
longer JJR N
maintenance NN o
of IN o
response NN o
in IN N
patients NNS p
presenting VBG p
with IN p
a DT p
mixed JJ p
index NN p
episode NN p
of IN p
bipolar NN p
I PRP p
disorder VBP p
. . p

-DOCSTART- -18337049- O O

Nurse NNP o
and CC o
patient JJ o
communication NN o
profiles NNS o
in IN N
a DT N
home-based JJ p
telehealth NN p
intervention NN p
for IN N
heart NN N
failure NN N
management NN N
. . N

OBJECTIVE VB N
This DT N
study NN N
compared VBN N
differences NNS N
in IN N
nurse JJ o
and CC o
patient JJ o
communication NN o
profiles NNS o
between IN N
two CD N
telehealth NN N
modes NNS N
: : N
telephone NN i
and CC N
videophone NN i
, , N
and CC N
evaluated VBD N
longitudinal JJ o
changes NNS o
in IN o
communication NN o
, , o
nurse JJ o
perceptions NNS o
, , o
and CC o
patient JJ o
satisfaction NN o
. . o

METHODS NNP N
Subjects NNPS p
were VBD N
enrolled VBN N
in IN N
a DT N
randomized NN p
controlled VBD p
clinical JJ p
trial NN p
evaluating VBG N
a DT N
90-day JJ N
home-based JJ N
intervention NN N
for IN N
heart NN N
failure NN N
. . N

Telephone NNP i
( ( p
n=14 NN p
) ) p
and CC p
videophone NN i
( ( p
n=14 JJ p
) ) p
interactions NNS p
were VBD N
audio JJ N
taped VBN N
and CC N
analyzed VBN N
using VBG N
the DT N
Roter NNP o
Interaction NNP o
Analysis NNP o
System NNP o
. . o

RESULTS NNP N
Nurses NNPS p
were VBD N
more RBR N
likely JJ N
to TO N
use VB o
open-ended JJ o
questions NNS o
, , o
back-channel JJ o
responses NNS o
, , o
friendly JJ o
jokes NNS o
, , o
and CC o
checks NNS o
for IN o
understanding VBG o
on IN N
the DT N
telephone NN i
compared VBN N
to TO N
videophone VB i
. . i

Compliments NNS o
given VBN o
and CC o
partnership NN o
were VBD N
more JJR N
common JJ N
on IN N
the DT N
videophone NN N
. . N

Patients NNS p
were VBD N
more RBR N
likely JJ N
to TO N
give VB o
lifestyle JJ o
information NN o
and CC o
approval NN o
comments NNS o
on IN N
the DT N
telephone NN i
, , N
and CC N
used VBD N
more JJR N
closed-ended JJ o
questions NNS o
on IN N
the DT N
videophone NN i
. . i

Nurses CC o
perceptions NNS o
of IN o
the DT o
interactions NNS o
were VBD N
not RB N
different JJ N
between IN N
the DT N
telephone NN N
and CC N
videophone NN i
, , N
nor CC N
did VBD N
their PRP$ N
perceptions NNS o
change VBP N
significantly RB N
over IN N
the DT N
course NN N
of IN N
the DT N
intervention NN N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
patient JJ o
satisfaction NN o
between IN N
the DT N
telephone NN N
and CC N
videophone NN i
. . i

CONCLUSIONS VB N
The DT N
results NNS N
of IN N
this DT N
study NN N
did VBD N
not RB N
support VB N
use NN N
of IN N
a DT N
videophone NN i
over IN N
the DT N
telephone NN i
. . i

PRACTICE NNP N
IMPLICATIONS NNP N
It PRP N
is VBZ N
critical JJ N
to TO N
match VB N
technologies NNS N
to TO N
patient VB N
needs NNS N
and CC N
use VB N
the DT N
least JJS N
complex JJ N
technology NN N
possible JJ N
. . N

When WRB N
considering VBG N
use VBP N
a DT N
videophone NN i
, , N
health NN N
care NN N
providers NNS N
should MD N
critically RB N
examine VB N
the DT N
trade-offs NNS N
between IN N
additional JJ N
complexities NNS N
with IN N
the DT N
added JJ N
value NN N
of IN N
the DT N
visual JJ N
interaction NN N
. . N

-DOCSTART- -22306962- O O

Effect NN N
of IN N
acute NN i
exercise NN i
on IN N
executive NN o
function NN o
in IN N
children NNS p
with IN p
attention NN p
deficit NN p
hyperactivity NN p
disorder NN p
. . p

This DT N
study NN N
was VBD N
conducted VBN N
to TO N
determine VB N
the DT N
effect NN N
of IN N
acute NN i
aerobic JJ i
exercise NN i
on IN N
executive NN o
function NN o
in IN N
children NNS p
with IN p
attention NN p
deficit NN p
hyperactivity NN p
disorder NN p
( ( p
ADHD NNP p
) ) p
. . p

Forty NNP p
children NNS p
with IN p
ADHD NNP p
were VBD N
randomly RB N
assigned VBN N
into IN N
exercise NN N
or CC N
control NN N
groups NNS N
. . N

Participants NNS N
in IN N
the DT N
exercise NN N
group NN N
performed VBD N
a DT N
moderate JJ i
intensity NN i
aerobic JJ i
exercise NN i
for IN i
30 CD i
min NN i
, , N
whereas IN N
the DT N
control NN N
group NN N
watched VBD N
a DT N
running/exercise-related JJ i
video NN i
. . i

Neuropsychological JJ o
tasks NNS o
, , o
the DT o
Stroop NNP o
Test NNP o
and CC o
the DT o
Wisconsin NNP o
Card NNP o
Sorting NNP o
Test NNP o
( ( o
WCST NNP o
) ) o
, , N
were VBD N
assessed VBN N
before IN N
and CC N
after IN N
each DT N
treatment NN N
. . N

The DT N
results NNS N
indicated VBD N
that IN N
acute JJ N
exercise NN N
facilitated VBN N
performance NN N
in IN N
the DT N
Stroop NNP N
Test NNP N
, , N
particularly RB N
in IN N
the DT N
Stroop NNP o
Color-Word NNP o
condition NN o
. . o

Additionally RB N
, , N
children NNS N
in IN N
the DT N
exercise NN N
group NN N
demonstrated VBD N
improvement NN N
in IN N
specific JJ N
WCST NNP o
performances NNS o
in IN N
Non-perseverative JJ o
Errors NNS o
and CC o
Categories NNP o
Completed NNP o
, , N
whereas VBZ N
no DT N
influences NNS N
were VBD N
found VBN N
in IN N
those DT N
performances NNS N
in IN N
the DT N
control NN N
group NN N
. . N

Tentative JJ N
explanations NNS N
for IN N
the DT N
exercise NN N
effect NN N
postulate NN N
that WDT N
exercise NN N
allocates VBZ N
attention NN o
resources NNS N
, , N
influences VBZ N
the DT N
dorsolateral JJ o
prefrontal NN o
cortex NN o
, , N
and CC N
is VBZ N
implicated VBN N
in IN N
exercise-induced JJ o
dopamine NN o
release NN o
. . o

These DT N
findings NNS N
are VBP N
promising VBG N
and CC N
additional JJ N
investigations NNS N
to TO N
explore VB N
the DT N
efficacy NN o
of IN i
exercise NN i
on IN N
executive NN N
function NN N
in IN N
children NNS N
with IN N
ADHD NNP N
are VBP N
encouraged VBN N
. . N

-DOCSTART- -15965438- O O

Montelukast NNP i
treatment NN i
of IN N
moderate JJ N
to TO N
severe VB p
atopic NN p
dermatitis NN p
in IN p
adults NNS p
: : p
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
trial NN N
. . N

In IN N
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
4-week JJ N
trial NN N
, , N
59 CD p
patients NNS p
with IN p
moderate JJ p
to TO p
severe VB p
atopic NN p
dermatitis NN p
were VBD N
treated VBN N
orally RB N
with IN N
10 CD N
mg NN N
of IN N
the DT N
leukotriene JJ i
antagonist NN i
montelukast NN i
. . i

Forty-seven JJ p
patients NNS p
completed VBD p
the DT p
study NN p
. . p

No DT o
difference NN o
in IN o
efficacy NN o
was VBD N
seen VBN N
among IN N
patients NNS N
who WP N
received VBD N
montelukast NN i
and CC N
the DT N
group NN N
given VBN N
a DT N
placebo NN i
. . i

-DOCSTART- -12564610- O O

Long-term JJ N
use NN N
of IN N
Viozan NNP i
( ( i
sibenadet JJ i
HCl NNP i
) ) i
in IN N
patients NNS p
with IN p
chronic JJ p
obstructive JJ p
pulmonary JJ p
disease NN p
: : p
results NNS N
of IN N
a DT N
1-year JJ N
study NN N
. . N

Viozan NNP i
( ( i
sibenadet JJ i
HCl NNP i
, , i
AR-C68397AA NNP i
) ) i
is VBZ N
a DT N
novel JJ N
dual JJ N
D2 NNP N
dopamine NN N
receptor NN N
, , N
beta2-adrenoceptor JJ N
agonist NN N
that WDT N
has VBZ N
been VBN N
investigated VBN N
for IN N
efficacy NN N
in IN N
alleviating VBG N
the DT N
symptoms NNS N
of IN N
chronic JJ N
obstructive JJ N
pulmonary JJ N
disease NN N
( ( N
COPD NNP N
) ) N
. . N

The DT N
slowly RB N
progressive JJ N
nature NN N
of IN N
this DT N
disease NN N
means VBZ N
that IN N
patients NNS N
will MD N
require VB N
ongoing JJ N
therapeutic JJ N
management NN N
for IN N
many JJ N
years NNS N
, , N
or CC N
even RB N
decades NNS N
. . N

With IN N
such JJ N
long-term JJ N
treatment NN N
, , N
the DT N
safety NN N
profile NN N
of IN N
new JJ N
agents NNS N
will MD N
be VB N
of IN N
paramount JJ N
importance NN N
. . N

As IN N
part NN N
of IN N
the DT N
large-scale JJ N
assessment NN N
of IN N
sibenadet NN i
, , N
a DT N
12-month JJ N
safety NN N
study NN N
has VBZ N
been VBN N
conducted VBN N
. . N

Following VBG N
completion NN N
of IN N
a DT N
2-week JJ N
baseline NN N
period NN N
, , N
435 CD p
adults NNS p
with IN p
stable JJ p
, , p
symptomatic JJ p
, , p
smoking-related JJ p
COPD NNP p
were VBD p
randomized VBN p
to TO N
receive VB N
either RB N
500 CD i
microg NN i
sibenadet NN i
or CC i
placebo NN i
delivered VBN N
via IN N
pressurized VBN N
metered VBD N
dose JJ N
inhaler NN N
( ( N
pMDI NN N
) ) N
, , N
three CD N
times NNS N
daily RB N
for IN N
52 CD N
weeks NNS N
. . N

Sibenadet NNP i
therapy NN i
was VBD N
generally RB N
well RB o
tolerated VBN o
, , N
with IN N
the DT N
only JJ N
notable JJ o
differences NNS o
seen VBN N
in IN N
the DT N
incidence NN o
of IN o
tremor NN o
and CC o
taste NN o
of IN o
treatment NN o
( ( N
16.9 CD N
% NN N
vs. FW N
4.1 CD N
% NN N
and CC N
14.5 CD N
% NN N
vs. FW N
4.1 CD N
% NN N
in IN N
the DT N
sibenadet NN N
and CC N
placebo NN i
groups NNS N
respectively RB N
) ) N
. . N

There EX N
were VBD N
a DT N
total NN N
of IN N
79 CD p
patients NNS p
with IN p
serious JJ o
adverse JJ o
events NNS o
( ( p
SAEs NNP p
) ) p
, , p
43 CD p
( ( p
14.8 CD p
% NN p
) ) p
in IN p
the DT p
sibenadet NN p
pMDI NN p
group NN p
and CC p
36 CD p
( ( p
24.8 CD p
% NN p
) ) p
in IN p
the DT p
placebo NN i
group NN i
. . i

No DT N
clinically RB o
significant JJ o
abnormal JJ o
laboratory NN o
values NNS o
or CC N
overall JJ o
differences NNS o
between IN N
treatment NN N
groups NNS N
were VBD N
noted VBN N
. . N

Similarly RB N
, , N
there EX N
were VBD N
no DT o
clinically RB o
significant JJ o
differences NNS o
between IN N
the DT N
two CD N
treatment NN N
groups NNS N
for IN N
cardiac JJ o
variables NNS o
, , o
or CC o
in IN o
vital JJ o
signs NNS o
. . o

The DT N
secondary JJ o
variables NNS o
showed VBD N
no DT o
notable JJ o
differences NNS o
with IN N
respect NN N
to TO N
lung NN o
function NN o
, , o
exacerbations NNS o
or CC o
health-related JJ o
quality NN o
of IN o
life NN o
. . o

Due NNP N
to TO N
the DT N
effective JJ N
beta2-agonist NN N
properties NNS N
, , N
patients NNS N
in IN N
the DT N
sibenadet NN N
group NN N
did VBD N
, , N
however RB N
, , N
report NN N
reduced VBD o
rescue JJ o
medication NN o
usage NN o
at IN o
all DT o
timepoints NNS o
. . o

While IN N
the DT N
results NNS N
of IN N
this DT N
study NN N
show NN N
that IN N
, , N
overall JJ N
, , N
sibenadet JJ N
therapy NN N
was VBD N
well RB o
tolerated VBN o
, , N
the DT N
lack NN o
of IN o
sustained JJ o
benefit NN o
reported VBD N
in IN N
large-scale JJ o
clinical JJ o
efficacy NN o
studies NNS o
means VBZ N
that IN N
sibenadet NN N
development NN N
will MD N
not RB N
be VB N
continued VBN N
. . N

-DOCSTART- -8331682- O O

Low-dose JJ i
aspirin NN i
and CC N
incidence NN N
of IN N
colorectal JJ N
tumors NNS N
in IN N
a DT N
randomized JJ N
trial NN N
. . N

BACKGROUND NNP N
Laboratory NNP N
, , N
clinical JJ N
, , N
and CC N
epidemiologic JJ N
studies NNS N
have VBP N
recently RB N
suggested VBN N
that IN N
regular JJ N
use NN N
of IN N
aspirin NN i
can MD N
reduce VB N
colorectal JJ N
cancer NN N
incidence NN N
or CC N
mortality NN N
. . N

However RB N
, , N
observational JJ N
epidemiologic NN N
analyses NNS N
have VBP N
had VBN N
limited VBN N
opportunity NN N
to TO N
control VB N
for IN N
confounding VBG N
bias NN N
or CC N
to TO N
specify VB N
aspirin JJ i
doses NNS N
used VBN N
. . N

PURPOSE VB N
Our PRP$ N
purpose NN N
was VBD N
to TO N
examine VB N
the DT N
relationship NN N
between IN N
regular JJ N
use NN N
of IN N
low-dose JJ i
aspirin NN i
and CC N
incidence NN N
of IN N
invasive JJ N
and CC N
noninvasive JJ N
colorectal NN N
tumors NNS N
by IN N
utilizing VBG N
data NNS p
from IN p
the DT p
Physicians NNPS p
' POS p
Health NNP p
Study NNP p
, , N
a DT N
randomized VBN N
, , N
double-blinded JJ N
, , N
placebo-controlled JJ i
trial NN N
of IN N
aspirin NN i
and CC i
beta NN i
carotene NN i
. . i

We PRP N
also RB N
attempted VBD N
to TO N
determine VB N
whether IN N
invasive JJ N
cancers NNS N
among IN N
aspirin JJ i
users NNS p
were VBD N
associated VBN N
with IN N
rectal JJ N
bleeding NN N
and CC N
early JJ N
stage NN N
at IN N
diagnosis NN N
. . N

METHODS NNP N
The DT N
Physicians NNPS N
' POS N
Health NNP N
Study NNP N
includes VBZ N
22071 CD p
U.S. NNP p
male JJ p
physicians NNS p
. . p

The DT N
aspirin JJ p
arm NN p
was VBD N
terminated VBN N
in IN N
1988 CD N
after IN N
a DT N
mean JJ N
follow-up NN N
of IN N
5 CD N
years NNS N
. . N

Stage NN N
at IN N
diagnosis NN N
and CC N
signs NNS N
and/or VBP N
symptoms NNS N
during IN N
presentation NN N
were VBD N
abstracted VBN N
from IN N
medical JJ N
records NNS N
. . N

Cox NNP N
proportional JJ N
hazards NNS N
models NNS N
were VBD N
used VBN N
to TO N
estimate VB N
relative JJ o
risk NN o
( ( N
RR NNP N
) ) N
, , N
95 CD N
% NN N
confidence NN o
intervals NNS o
( ( N
CIs NNP N
) ) N
, , N
and CC N
the DT N
association NN N
between IN N
aspirin NN N
and CC N
bleeding NN N
. . N

Differences NNS N
between IN N
aspirin NN i
and CC i
placebo NN i
groups NNS N
in IN N
tumor NN N
risk NN N
over IN N
time NN N
were VBD N
visualized VBN N
with IN N
Kaplan-Meier NNP N
curves NNS N
. . N

We PRP N
assessed VBD N
the DT N
association NN N
between IN N
aspirin NN N
and CC N
stage NN N
at IN N
diagnosis NN N
with IN N
a DT N
Mann-Whitney NNP N
rank NN N
sum NN N
statistic NN N
for IN N
non-parametric JJ N
comparison NN N
of IN N
two CD N
ordinal JJ N
distributions NNS N
. . N

RESULTS VB N
The DT N
RR NNP N
of IN N
developing VBG N
colorectal JJ N
cancer NN N
for IN N
aspirin NNS N
compared VBN N
with IN N
placebo NN N
was VBD N
1.15 CD N
( ( N
95 CD N
% NN N
CI NNP N
= NNP N
0.80-1.65 NN N
) ) N
. . N

For IN N
in IN N
situ NN N
cancers NNS N
and CC N
polyps NNS N
, , N
the DT N
RR NNP N
was VBD N
0.86 CD N
( ( N
95 CD N
% NN N
CI NNP N
= NNP N
0.68-1.10 NN N
) ) N
. . N

There EX N
was VBD N
no DT N
significant JJ N
trend NN N
for IN N
decreasing VBG N
RR NNP o
by IN N
year NN N
of IN N
follow-up NN N
for IN N
invasive JJ N
cancers NNS N
( ( N
P NNP N
= NNP N
.09 NNP N
) ) N
or CC N
noninvasive JJ N
tumors NNS N
( ( N
P NNP N
= NNP N
.96 NNP N
) ) N
. . N

Aspirin NNP N
and CC N
placebo NN N
groups NNS N
did VBD N
not RB N
differ VB N
in IN N
stage NN N
or CC N
prevalence NN N
of IN N
rectal JJ o
bleeding NN o
at IN N
diagnosis NN N
. . N

CONCLUSIONS NNP N
Regular NNP N
aspirin NN i
use NN N
, , N
at IN N
a DT N
dose JJ N
adequate NN N
for IN N
preventing VBG N
myocardial JJ N
infarction NN N
, , N
was VBD N
not RB N
associated VBN N
with IN N
a DT N
substantial JJ N
reduction NN N
in IN N
the DT N
incidence NN N
of IN N
colorectal JJ o
cancer NN o
during IN N
5 CD N
years NNS N
of IN N
randomized JJ N
treatment NN N
and CC N
follow-up NN N
. . N

A DT N
small JJ N
decrease NN N
in IN N
polyps NNS N
in IN N
the DT N
aspirin NN N
group NN N
could MD N
not RB N
be VB N
reliably RB N
distinguished VBN N
from IN N
a DT N
chance NN N
association NN N
. . N

Our PRP$ N
results NNS N
suggest VBP N
that IN N
among IN N
low-dose JJ N
aspirin NN i
users NNS N
, , N
( ( N
a DT N
) ) N
colorectal NN N
cancer NN N
mortality NN N
is VBZ N
not RB N
likely JJ N
to TO N
be VB N
reduced VBN N
by IN N
earlier JJR N
detection NN N
and CC N
( ( N
b NN N
) ) N
incidence NN N
is VBZ N
not RB N
likely JJ N
to TO N
be VB N
increased VBN N
due JJ N
to TO N
aspirin-induced JJ N
gastrointestinal JJ N
bleeding NN N
. . N

IMPLICATIONS VBZ N
The DT N
potential NN N
for IN N
a DT N
benefit NN N
from IN N
higher JJR N
doses NNS N
of IN N
aspirin NN N
or CC N
longer JJR N
duration NN N
of IN N
use NN N
should MD N
be VB N
addressed VBN N
by IN N
more JJR N
detailed JJ N
observational JJ N
epidemiologic NN N
studies NNS N
and CC N
prevention NN N
trials NNS N
with IN N
longer JJR N
follow-up NN N
of IN N
randomized JJ N
participants NNS N
. . N

-DOCSTART- -345802- O O

Effects NNS N
of IN N
platelet NN i
suppressant NN i
, , i
anticoagulant JJ i
and CC i
fibrinolytic JJ i
therapy NN i
in IN N
patients NNS p
with IN p
recurrent JJ p
venous JJ p
thrombosis NN p
. . p

-DOCSTART- -3954130- O O

Response NN N
to TO N
tubular VB i
airway RP i
resistance NN i
in IN N
normal JJ p
subjects NNS p
and CC p
postoperative JJ p
patients NNS p
. . p

Critically NNP p
ill JJ p
patients NNS p
must MD N
often RB N
breathe VB N
spontaneously RB N
through IN N
an DT N
endotracheal JJ i
tube NN i
that WDT N
acts VBZ N
as IN N
a DT N
fixed JJ N
inspiratory NN N
and CC N
expiratory JJ N
tubular JJ N
airway NN N
resistor NN N
. . N

Although IN N
this DT N
practice NN N
is VBZ N
common JJ N
, , N
its PRP$ N
effect NN N
on IN N
the DT N
pattern NN N
of IN N
breathing NN N
is VBZ N
not RB N
known VBN N
. . N

The DT N
mean JJ N
breathing NN N
patterns NNS N
of IN N
seven CD p
normal JJ p
, , p
healthy JJ p
male NN p
subjects NNS p
and CC p
eight CD p
male NN p
patients NNS p
who WP p
had VBD p
undergone JJ p
upper JJ p
abdominal JJ p
surgery NN p
2-4 JJ p
days NNS p
previously RB p
were VBD N
studied VBN N
breathing VBG N
through IN N
a DT i
mouthpiece NN i
fitted VBN i
in IN i
random JJ i
order NN i
with IN i
a DT i
5 CD i
, , i
6 CD i
, , i
7 CD i
, , i
8 CD i
, , i
or CC i
15 CD i
mm NNS i
diameter NN i
( ( i
17 CD i
mm RB i
long RB i
) ) i
resistor NN i
. . i

These DT N
diameters NNS N
were VBD N
selected VBN N
because IN N
they PRP N
simulate VBP N
the DT N
pressure-flow JJ N
relationships NNS N
of IN N
adult NN N
endotracheal NN N
tubes NNS N
. . N

With IN N
the DT N
15 CD N
mm NN N
aperture NN N
, , N
the DT N
patients NNS N
had VBD N
a DT N
greater JJR N
breathing NN o
frequency NN o
( ( o
f NN o
) ) o
than IN N
did VBD N
the DT N
normal JJ N
subjects NNS N
( ( N
21 CD N
+/- JJ N
5 CD N
[ JJ N
SD NNP N
] NNP N
vs. IN N
14 CD N
+/- JJ N
4 CD N
breaths/min NN N
, , N
P NNP N
less JJR N
than IN N
0.01 CD N
) ) N
as RB N
well RB N
as IN N
a DT N
smaller JJR N
mean JJ o
tidal NN o
volume NN o
( ( o
VT NNP o
) ) o
. . o

In IN N
both DT N
groups NNS N
, , N
minute JJ o
ventilation NN o
( ( o
VE NNP o
) ) o
and CC o
f $ o
progressively RB N
decreased VBN N
as IN N
resistance NN N
was VBD N
increased VBN N
by IN N
decreasing VBG N
the DT N
aperture NN N
size NN N
from IN N
15 CD N
to TO N
16 CD N
mm NN N
. . N

In IN N
the DT N
normal JJ N
subjects NNS N
but CC N
not RB N
the DT N
patients NNS N
, , N
VT NNP o
also RB N
progressively RB N
decreased VBN N
. . N

When WRB N
the DT N
diameter NN N
was VBD N
decreased VBN N
from IN N
6 CD N
mm NNS N
to TO N
5 CD N
mm NN N
, , N
there EX N
were VBD N
increases NNS N
in IN N
VT NNP o
and CC N
decreases NNS N
in IN N
f NN o
that WDT N
were VBD N
more JJR N
marked VBN N
in IN N
the DT N
normal JJ N
subjects NNS N
. . N

In IN N
both DT N
groups NNS N
, , N
the DT N
changes NNS o
in IN o
VE NNP o
were VBD N
accompanied VBN N
by IN N
decreases NNS N
in IN N
mean NN N
and CC N
peak JJ o
inspiratory NN o
and CC o
expiratory NN o
flow NN o
rates NNS o
. . o

Throughout IN N
the DT N
study NN N
, , N
oxygen NN o
consumption NN o
( ( o
VO2 NNP o
) ) o
and CC o
carbon NN o
dioxide NN o
production NN o
( ( o
VCO2 NNP o
) ) o
did VBD N
not RB N
change VB N
. . N

This DT N
, , N
coupled VBN N
with IN N
the DT N
decreases NNS N
in IN N
VE NNP N
resulted VBD N
in IN N
decreases NNS N
in IN N
the DT N
ventilatory NN N
equivalents NNS N
to TO N
CO2 NNP N
and CC N
O2 NNP N
( ( N
VE/VCO2 NNP N
, , N
VE/VO2 NNP N
) ) N
. . N

( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
250 CD N
WORDS NNP N
) ) N
-DOCSTART- -24275895- O O

Neuropsychological JJ o
outcomes NNS o
after IN N
psychosocial JJ i
intervention NN i
for IN N
depression NN p
in IN p
Parkinson NNP p
's POS p
disease NN p
. . p

The DT N
authors NNS N
describe VBP N
neuropsychological JJ N
outcomes NNS N
in IN N
people NNS p
with IN p
Parkinson NNP p
's POS p
disease NN p
( ( p
PD NNP p
) ) p
after IN p
their PRP$ p
participation NN p
in IN p
an DT p
NIH-sponsored JJ p
, , p
randomized VBN p
, , p
controlled VBD p
trial NN p
of IN p
cognitive-behavioral JJ i
treatment NN i
for IN p
depression NN p
. . p

Improvements NNS o
in IN o
mood NN o
were VBD N
associated VBN N
with IN N
modest JJ o
gains NNS o
in IN o
verbal JJ o
memory NN o
and CC o
executive NN o
functioning NN o
over IN N
the DT N
10-week JJ N
treatment NN N
period NN N
and CC N
accounted VBD N
for IN N
greater JJR N
variance NN N
in IN N
neuropsychological JJ o
outcomes NNS o
at IN N
the DT N
end NN N
of IN N
treatment NN N
than IN N
other JJ N
known JJ N
correlates NNS N
of IN N
cognitive JJ o
functioning NN o
in IN N
PD NNP N
, , N
such JJ N
as IN N
disease NN N
severity NN N
, , N
age NN N
, , N
and CC N
education NN N
. . N

Baseline NNP o
working VBG o
memory NN o
and CC o
executive NN o
skills NNS o
were VBD N
also RB N
associated VBN N
with IN N
depression NN N
improvement NN N
over IN N
time NN N
. . N

-DOCSTART- -1459383- O O

The DT N
effects NNS N
of IN N
treatment NN N
of IN N
urinary JJ p
incontinence NN p
in IN N
general JJ N
practice NN N
. . N

A DT N
total NN p
of IN p
110 CD p
women NNS p
who WP p
had VBD p
reported VBN p
urinary JJ p
incontinence NN p
to TO p
their PRP$ p
general JJ p
practitioners NNS p
were VBD N
randomly RB N
assigned VBN N
to TO N
a DT N
treatment NN N
or CC N
control NN N
group NN N
. . N

Treatment NNP N
consisted VBD N
of IN N
pelvic JJ i
floor NN i
exercises NNS i
in IN N
the DT N
case NN N
of IN N
stress NN N
incontinence NN N
and CC N
bladder NN i
training NN i
in IN N
the DT N
case NN N
of IN N
urge JJ N
incontinence NN N
. . N

The DT N
results NNS N
were VBD N
measured VBN N
after IN N
3 CD N
and CC N
12 CD N
months NNS N
by IN N
a DT N
research NN N
assistant NN N
on IN N
the DT N
basis NN N
of IN N
a DT N
constructed JJ N
severity NN N
scale NN N
, , N
an DT N
incontinence NN N
diary NN N
, , N
and CC N
a DT N
comparison NN N
by IN N
the DT N
patients NNS N
themselves PRP N
of IN N
their PRP$ N
previous JJ N
and CC N
current JJ N
conditions NNS N
. . N

After IN N
3 CD N
months NNS N
the DT N
control NN N
group NN N
were VBD N
given VBN N
the DT N
same JJ N
treatment NN N
. . N

After IN N
a DT N
further JJ N
3 CD N
and CC N
12 CD N
months NNS N
, , N
they PRP N
were VBD N
assessed VBN N
in IN N
exactly RB N
the DT N
same JJ N
way NN N
as IN N
the DT N
treatment NN N
group NN N
. . N

After IN N
3 CD N
months NNS N
about IN N
60 CD N
% NN N
of IN N
the DT N
patients NNS N
were VBD N
either RB N
dry JJ o
or CC o
only RB o
mildly RB o
incontinent JJ o
; : o
the DT N
mean JJ o
number NN o
of IN o
wet JJ o
episodes NNS o
had VBD N
gone VBN N
down RB N
from IN N
20 CD N
to TO N
7 CD N
, , N
and CC N
74 CD N
% NN N
of IN N
the DT N
women NNS N
felt VBD N
improved JJ o
or CC o
cured VBN o
. . o

These DT N
results NNS N
were VBD N
later RB N
corroborated VBN N
by IN N
the DT N
control NN N
group NN N
. . N

After IN N
12 CD N
months NNS N
this DT N
successful JJ N
outcome NN N
was VBD N
improved VBN N
slightly RB N
further RBR N
. . N

It PRP N
may MD N
be VB N
concluded VBN N
that IN N
the DT N
majority NN N
of IN N
women NNS p
with IN p
incontinence NN p
can MD N
be VB N
successfully RB N
treated VBN o
by IN N
the DT N
general JJ N
practitioner NN N
. . N

The DT N
effect NN N
of IN N
this DT N
treatment NN N
continues VBZ N
after IN N
one CD N
year NN N
. . N

-DOCSTART- -18307223- O O

Closure NN N
of IN N
the DT N
femoral JJ N
artery NN N
after IN p
cardiac JJ p
catheterization NN p
: : p
a DT N
comparison NN N
of IN N
Angio-Seal NNP N
, , N
StarClose NNP N
, , N
and CC N
manual JJ N
compression NN N
. . N

OBJECTIVES NNP N
To TO N
compare VB N
Angio-Seal NNP i
( ( i
AS NNP i
) ) i
and CC i
StarClose NNP i
( ( i
SC NNP i
) ) i
and CC i
manual JJ i
compression NN i
( ( i
MC NNP i
) ) i
on IN N
efficacy NN o
of IN o
hemostasis NN o
, , o
complication NN o
rate NN o
, , o
safety NN o
of IN o
early JJ o
mobilization NN o
, , o
and CC o
patient JJ o
comfort NN o
. . o

BACKGROUND NNP N
Closure NNP N
of IN N
the DT N
femoral JJ N
artery NN N
after IN N
cardiac JJ N
catheterization NN N
can MD N
be VB N
obtained VBN N
through IN N
different JJ N
methods NNS N
. . N

Today NN N
, , N
physicians NNS N
can MD N
choose VB N
from IN N
a DT N
number NN N
of IN N
different JJ N
devices NNS N
to TO N
achieve VB N
arterial JJ N
closure NN N
. . N

METHODS NNP N
In IN i
a DT i
prospective JJ i
trial NN i
450 CD p
patients NNS p
were VBD i
randomized VBN i
to TO i
AS NNP i
, , i
SC NNP i
, , i
or CC i
MC NNP i
. . i

Patients NNS i
were VBD i
mobilized VBN i
1 CD i
to TO i
2 CD i
hr NN i
after IN i
device NN i
placement NN i
, , i
and CC i
6 CD i
hr NN i
after IN i
MC NNP i
. . i

Data NNP N
were VBD N
collected VBN N
during IN N
hospital JJ N
admission NN N
and CC N
by IN N
telephone NN N
at IN N
one CD N
month NN N
after IN N
hospital JJ N
discharge NN N
. . N

RESULTS JJ N
Devices NNPS N
were VBD N
used VBN N
in IN N
138/150 CD N
allocated JJ N
to TO N
AS NNP N
and CC N
124/150 CD N
allocated VBN N
to TO N
SC NNP N
patients NNS N
( ( N
92 CD N
% NN N
vs. FW N
83 CD N
% NN N
, , N
P NNP N
= NNP N
0.015 CD N
) ) N
Patients NNS N
with IN N
MC NNP N
experienced VBD N
more JJR N
pain NN o
during IN o
sheath NN o
removal NN o
than IN N
patients NNS N
receiving VBG N
a DT N
device NN N
, , N
and CC N
rated VBD N
their PRP$ N
period NN o
of IN o
bed NN o
rest NN o
as IN N
less RBR N
comfortable JJ N
. . N

Oozing VBG o
and CC o
need VB o
for IN o
pressure NN o
bandage NN o
at IN o
the DT o
puncture NN o
site NN o
were VBD N
observed VBN N
in IN N
37 CD N
AS IN N
patients NNS N
and CC N
57 CD N
SC NNP N
patients NNS N
( ( N
25 CD N
% NN N
vs. FW N
38 CD N
% NN N
, , N
P NNP N
= NNP N
0.002 CD N
) ) N
. . N

Hematoma NNP o
occurred VBD N
in IN N
15 CD N
AS IN N
patients NNS N
, , N
in IN N
17 CD N
SC NNP N
patients NNS N
, , N
and CC N
in IN N
14 CD N
MC NNP N
patients NNS N
( ( N
11 CD N
vs. FW N
14 CD N
vs. FW N
9 CD N
% NN N
, , N
ns NN N
) ) N
. . N

CONCLUSION NNP N
There EX N
is VBZ N
no DT N
difference NN N
in IN N
safety NN o
between IN N
the DT N
three CD N
methods NNS N
of IN N
arterial JJ N
closure NN N
. . N

SC NNP N
was VBD N
more RBR N
often RB N
not RB N
used VBN N
or CC N
successfully RB N
deployed VBN N
. . N

SC JJ N
patients NNS N
more RBR N
often RB N
had VBD N
continuing VBG N
oozing VBG o
. . o

On IN N
patient JJ o
comfort NN o
, , N
closure NN N
devices NNS N
performed VBD N
better JJR N
than IN N
MC NNP N
. . N

Early JJ N
ambulation NN N
in IN N
patients NNS N
with IN N
a DT N
closure NN N
device NN N
is VBZ N
safe JJ N
. . N

AS NNP N
is VBZ N
the DT N
preferred JJ N
method NN N
of IN N
arterial JJ N
closure NN N
after IN N
cardiac JJ N
catheterization NN N
. . N

-DOCSTART- -3315991- O O

Intravenous NNP N
lignocaine NN i
& CC N
haemodynamic JJ o
responses NNS o
to TO N
cystoscopy VB p
. . p

-DOCSTART- -24824660- O O

A DT N
trial NN N
of IN N
D-cycloserine NNP i
to TO N
treat VB N
stereotypies NNS N
in IN N
older JJR p
adolescents NNS p
and CC p
young JJ p
adults NNS p
with IN p
autism NN p
spectrum NN p
disorder NN p
. . p

OBJECTIVES CC N
Autism NNP N
spectrum NN N
disorders NNS N
( ( N
ASDs NNP N
) ) N
have VBP N
core VBN N
impairments NNS N
in IN N
social JJ N
communication NN N
as RB N
well RB N
as IN N
the DT N
presence NN N
of IN N
repetitive JJ N
, , N
stereotypic JJ N
behaviors NNS N
and CC N
restricted JJ N
interests NNS N
. . N

Older JJR N
adolescents NNS N
and CC N
young JJ N
adults NNS N
are VBP N
particularly RB N
impacted VBN N
by IN N
these DT N
deficits NNS N
. . N

Preclinical NNP N
data NN N
implicate NN N
glutamatergic JJ N
dysfunction NN N
in IN N
the DT N
pathophysiology NN N
of IN N
ASDs NNP N
. . N

D-Cycloserine NNP i
( ( i
DCS NNP i
) ) i
, , N
a DT N
partial JJ N
glycineB NN N
agonist NN N
at IN N
the DT N
N-methyl-D-aspartic JJ N
acid NN N
receptor NN N
site NN N
, , N
has VBZ N
been VBN N
shown VBN N
to TO N
improve VB N
sociability NN N
in IN N
mouse NN N
models NNS N
and CC N
a DT N
small JJ N
human NN N
study NN N
. . N

The DT N
sensitivity NN N
of IN N
the DT N
obligatory JJ N
glycineB JJ N
co-agonist NN N
binding VBG N
site NN N
may MD N
change VB N
with IN N
daily JJ N
administration NN N
of IN N
DCS NNP N
as IN N
a DT N
result NN N
of IN N
agonist-induced JJ N
desensitization NN N
. . N

The DT N
efficacy NN o
of IN N
a DT N
pulsed JJ N
once-weekly JJ N
administration NN N
versus IN N
daily JJ N
administration NN N
of IN N
DCS NNP N
was VBD N
compared VBN N
. . N

METHODS NNP N
Males NNP p
and CC p
females NNS p
, , p
ages VBZ p
14 CD p
to TO p
25 CD p
years NNS p
, , p
with IN p
a DT p
Diagnostic NNP p
and CC p
Statistical NNP p
Manual NNP p
of IN p
Mental NNP p
Disorders NNP p
, , p
Fourth NNP p
Edition NNP p
Text NNP p
Revision NNP p
diagnosis NN p
of IN p
an DT p
ASD NNP p
were VBD p
enrolled VBN p
in IN N
a DT N
double-blind NN N
, , N
randomized VBN N
10-week JJ N
trial NN N
consisting NN N
of IN N
8 CD N
weeks NNS N
of IN N
active JJ N
drug NN N
with IN N
either DT N
weekly JJ N
or CC N
daily JJ N
administration NN N
of IN N
50 CD N
mg NN N
of IN N
DCS NNP i
followed VBN N
by IN N
a DT N
2-week JJ N
follow-up JJ N
visit NN N
. . N

RESULTS NNP N
For IN N
the DT N
purposes NNS N
of IN N
this DT N
study NN N
, , N
no DT N
statistical JJ N
or CC N
clinical JJ N
differences NNS o
existed VBD N
between IN N
the DT N
2 CD N
dosage NN N
groups NNS N
on IN N
the DT N
Aberrant NNP o
Behavior NNP o
Checklist NNP o
subscale NN o
3 CD o
, , o
which WDT o
measures VBZ o
stereotypies/repetitive JJ o
movements NNS o
. . o

When WRB N
combining VBG N
groups NNS N
, , N
a DT N
statistically RB N
significant JJ N
decrease NN N
of IN N
37 CD N
% NN N
was VBD N
found VBN N
from IN N
baseline NN N
to TO N
week NN N
8 CD N
when WRB N
study NN N
drug NN N
was VBD N
completed VBN N
using VBG N
a DT N
linear JJ N
mixed JJ N
effects NNS N
model FW N
( ( N
P NNP N
= NNP N
0.003 CD N
) ) N
. . N

CONCLUSIONS NNP N
D-Cycloserine NNP i
was VBD N
shown VBN N
to TO N
be VB N
effective JJ N
in IN N
improving VBG N
stereotypic NN o
symptoms NNS o
in IN N
older JJR N
adolescents NNS N
and CC N
young JJ N
adults NNS N
with IN N
ASDs NNP N
measured VBN N
by IN N
the DT N
Aberrant NNP o
Behavior NNP o
Checklist NNP o
subscale VBD o
3 CD o
. . o

In IN N
addition NN N
, , N
DCS NNP i
was VBD N
safe JJ o
and CC o
well RB o
tolerated VBN o
. . o

-DOCSTART- -19264972- O O

Acute NNP N
and CC N
short-term JJ N
effects NNS N
of IN N
secondhand NN N
smoke NN N
on IN N
lung NN o
function NN o
and CC N
cytokine NN o
production NN o
. . o

RATIONALE VB N
The DT N
acute JJ N
effect NN N
of IN N
secondhand NN N
smoke NN N
( ( N
SHS NNP N
) ) N
on IN N
lung NN o
function NN o
and CC N
the DT N
duration NN N
of IN N
system NN o
disruption NN o
remain VBP N
unknown JJ N
. . N

OBJECTIVES NNP N
To TO N
assess VB N
the DT N
SHS NNP N
effects NNS N
and CC N
their PRP$ N
duration NN N
on IN N
lung NN o
function NN o
and CC N
inflammatory JJ o
markers NNS o
. . o

METHODS NNP N
In IN N
a DT N
randomized JJ N
single-blind NN N
crossover NN N
experiment NN N
data NNS N
were VBD N
obtained VBN N
from IN N
16 CD p
( ( p
8 CD p
women NNS p
) ) p
nonsmoking VBG p
adults NNS p
at IN N
baseline NN i
and CC i
at IN i
0 CD i
, , i
1 CD i
, , i
and CC i
3 CD i
hours NNS i
after IN i
a DT i
1-hour JJ i
SHS NNP i
exposure NN i
set VBN i
at IN i
bar/restaurant JJ i
SHS NNP i
levels NNS i
. . i

MEASUREMENTS NNP N
AND CC N
MAIN NNP N
RESULTS NNP N
Serum NNP o
and CC o
urine JJ o
cotinine NN o
, , o
lung NN o
function NN o
, , o
and CC o
cytokines NNS o
IL-4 NNP o
, , o
IL-5 NNP o
, , o
IL-6 NNP o
, , o
tumor NN o
necrosis NN o
factor NN o
( ( o
TNF NNP o
) ) o
-alpha NN o
, , o
and CC o
IFN-gamma NNP o
. . o

At IN N
0 CD N
hours NNS N
most RBS N
lung JJ o
function NN o
parameters NNS o
were VBD N
significantly RB N
reduced VBN N
( ( N
indicative JJ N
: : N
FEV NNP N
( ( N
1 CD N
) ) N
, , N
4.3 CD N
+/- JJ N
0.4 CD N
vs. FW N
3.8 CD N
+/- JJ N
0.3 CD N
L NNP N
; : N
FEV NNP N
( ( N
1 CD N
) ) N
/FVC NN N
, , N
0.9 CD N
+/- JJ N
0.1 CD N
vs. FW N
0.8 CD N
+/- JJ N
0.1 CD N
; : N
P NNP N
< NNP N
0.05 CD N
) ) N
but CC N
at IN N
3 CD N
hours NNS N
they PRP N
were VBD N
at IN N
baseline NN N
levels NNS N
. . N

In IN N
contrast NN N
, , N
cotinine NN o
( ( N
serum NN N
, , N
8.9 CD N
+/- JJ N
3.2 CD N
vs. FW N
35.5 CD N
+/- JJ N
10.2 CD N
ng JJ N
x NN N
ml NN N
( ( N
-1 NNP N
) ) N
) ) N
, , N
IL-4 NNP N
( ( N
41.3 CD N
+/- JJ N
5.8 CD N
vs. FW N
44.2 CD N
+/- JJ N
4.5 CD N
pg NN N
x NN N
ml NN N
( ( N
-1 NNP N
) ) N
) ) N
, , N
IL-5 NNP N
( ( N
36.1 CD N
+/- JJ N
3.2 CD N
vs. FW N
60.1 CD N
+/- JJ N
7.0 CD N
pg NN N
x NN N
ml NN N
( ( N
-1 NNP N
) ) N
) ) N
, , N
IL-6 NNP N
( ( N
2.5 CD N
+/- JJ N
0.3 CD N
vs. FW N
7.6 CD N
+/- JJ N
1.4 CD N
pg NN N
x NN N
ml NN N
( ( N
-1 NNP N
) ) N
) ) N
and CC N
IFN-gamma NNP o
( ( N
0.3 CD N
+/- JJ N
0.2 CD N
vs. FW N
0.6 CD N
+/- JJ N
0.2 CD N
IU NNP N
x NNP N
ml NN N
( ( N
-1 NNP N
) ) N
) ) N
at IN N
3 CD N
hours NNS N
were VBD N
higher JJR N
than IN N
at IN N
baseline NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

IL-4 JJ o
and CC o
TNF-alpha NNP o
increased VBD N
only RB N
in IN N
men NNS N
, , N
whereas IN N
IL-5 NNP o
, , o
IL-6 NNP o
, , o
and CC o
IFN-gamma NNP o
were VBD N
different JJ N
between IN N
sexes NNS N
after IN N
exposure NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

Regression NN N
analyses VBZ N
revealed JJ N
inverse JJ N
associations NNS N
of IN N
FEV NNP o
( ( o
1 CD o
) ) o
and CC N
FEV NNP o
( ( o
1 CD o
) ) o
/FVC NN o
ratio NN o
with IN N
IL-5 NNP o
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
in IN N
men NNS N
and CC N
with IN N
IL-5 NNP o
( ( N
P NNP N
= NNP N
0.01 CD N
) ) N
, , N
IL-6 NNP o
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
IFN-gamma NNP o
( ( N
P NNP N
= NNP N
0.034 CD N
) ) N
and CC N
serum JJ o
cotinine NN o
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
in IN N
women NNS N
. . N

CONCLUSIONS NNP N
We PRP N
conclude VBP N
that IN N
1 CD N
hour NN N
of IN N
SHS NNP N
exposure NN N
at IN N
bar/restaurant NN N
levels NNS N
is VBZ N
accompanied VBN N
by IN N
significant JJ N
decrements NNS o
on IN o
lung NN o
function NN o
and CC N
marked JJ N
increases NNS N
in IN N
inflammatory JJ o
cytokines NNS o
, , N
particularly RB N
in IN N
men NNS N
. . N

More RBR N
importantly RB N
, , N
whereas IN N
most JJS N
smoke-induced JJ N
effects NNS o
on IN o
lung NN o
function NN o
appear VBP N
to TO N
recede VB N
within IN N
60 CD N
minutes NNS N
, , N
inflammatory JJ o
cytokines NNS o
remain VBP N
elevated JJ N
for IN N
at IN N
least JJS N
3 CD N
hours NNS N
after IN N
exposure NN N
to TO N
SHS NNP N
. . N

-DOCSTART- -9572066- O O

Effect NN N
of IN N
L-carnitine NNP i
on IN N
myocardial JJ N
metabolism NN N
: : N
results NNS N
of IN N
a DT N
balanced JJ N
, , N
placebo-controlled JJ N
, , N
double-blind JJ N
study NN N
in IN N
patients NNS p
undergoing VBG p
open JJ p
heart NN p
surgery NN p
. . p

The DT N
effects NNS N
of IN N
L-carnitine NNP i
on IN N
cardiac JJ N
performance NN N
after IN N
open JJ N
heart NN N
surgery NN N
were VBD N
evaluated VBN N
in IN N
a DT N
balanced JJ N
, , N
placebo-controlled JJ i
, , N
double-blind JJ N
study NN N
in IN N
38 CD p
patients NNS p
. . p

Preoperative JJ N
haemodynamic JJ N
status NN N
was VBD N
good JJ N
in IN N
all DT N
of IN N
them PRP N
. . N

Seventeen JJ p
subjects NNS p
underwent JJ p
mitral JJ i
valve NN i
replacement NN i
and CC p
19 CD p
patients NNS p
coronary JJ i
artery JJ i
bypass NN i
grafting NN i
. . i

Five CD N
grams NNS N
L-carnitine JJ i
were VBD N
given VBN N
intravenously RB N
over IN N
2 CD N
h NNS N
, , N
twice RB N
daily RB N
for IN N
5 CD N
consecutive JJ N
days NNS N
; : N
moreover RB N
, , N
10 CD N
g JJ N
L-carnitine NNP i
in IN i
1500 CD i
ml NN i
cardioplegia NN i
were VBD N
administered VBN N
through IN N
the DT N
aortic JJ N
root NN N
after IN N
aortic JJ i
cross-clamping NN i
. . i

Surgery NN N
was VBD N
always RB N
planned VBN N
on IN N
treatment NN N
day NN N
3 CD N
. . N

The DT N
post-ischaemic JJ N
functional JJ N
recovery NN N
of IN N
the DT N
heart NN N
was VBD N
assessed VBN N
by IN N
clinical JJ N
parameters NNS N
, , N
as RB N
well RB N
as IN N
by IN N
biochemical JJ N
and CC N
ultrastructure JJ N
evaluations NNS N
on IN N
biopsy NN N
specimens NNS N
. . N

No DT N
differences NNS N
were VBD N
found VBN N
between IN N
the DT N
control NN N
and CC N
the DT N
treatment NN N
group NN N
with IN N
respect NN N
to TO N
all DT N
clinical JJ N
parameters NNS N
of IN N
cardiac JJ N
performance NN N
after IN N
cardiopulmonary JJ N
bypass NN N
. . N

At IN N
anaesthesia JJ N
induction NN N
, , N
serum JJ o
carnitine NN o
was VBD N
significantly RB N
increased VBN N
in IN N
treated JJ N
patients NNS N
, , N
but CC N
carnitine JJ o
concentrations NNS o
in IN N
the DT N
right JJ N
atrial JJ N
biopsy NN N
obtained VBN N
just RB N
before RB N
aortic JJ N
declamping NN N
were VBD N
similar JJ N
in IN N
the DT N
two CD N
groups NNS N
. . N

In IN N
patients NNS N
with IN N
mitral JJ N
valve FW N
replacement NN N
, , N
L-carnitine JJ i
therapy NN i
was VBD N
associated VBN N
with IN N
significantly RB N
higher JJR N
concentrations NNS N
of IN N
pyruvate NN o
, , o
ATP NNP o
and CC o
creatine JJ o
phosphate NN o
in IN N
papillary JJ N
muscle NN N
. . N

Glycogen NN o
levels NNS o
were VBD N
also RB N
higher JJR N
in IN N
the DT N
treated JJ N
group NN N
, , N
but CC N
the DT N
difference NN N
was VBD N
not RB N
statistically RB N
significant JJ N
. . N

Myocardial JJ N
ultrastructure NN N
on IN N
septal JJ N
biopsies NNS N
, , N
obtained VBD N
within IN N
5 CD N
min NN N
from IN N
weaning VBG N
from IN N
extracorporeal JJ N
circulation NN N
, , N
showed VBD N
better JJR N
preservation NN N
scores NNS N
for IN N
all DT N
considered VBN N
parameters NNS N
( ( o
nucleus NN o
, , o
sarcoplasmic JJ o
reticulum NN o
, , o
mitochondria NN o
and CC o
cellular JJ o
oedema NN o
) ) o
in IN N
the DT N
treated JJ N
subjects NNS N
, , N
although IN N
the DT N
difference NN N
reached VBD N
statistical JJ N
significance NN N
only RB N
for IN N
nuclei NN N
. . N

When WRB N
biochemical JJ N
and CC N
ultrastructural JJ N
data NNS N
are VBP N
considered VBN N
, , N
these DT N
findings NNS N
suggest VBP N
that IN N
L-carnitine NNP i
improves VBZ N
myocardial JJ o
metabolism NN o
. . o

However RB N
, , N
it PRP N
can MD N
not RB N
be VB N
concluded VBN N
that IN N
L-carnitine NNP N
provides VBZ N
an DT N
advantageous JJ o
support NN o
therapy NN o
for IN N
well-compensated JJ N
patients NNS p
requiring VBG p
cardiac JJ p
surgery NN p
. . p

In IN N
contrast NN N
, , N
the DT N
positive JJ N
effects NNS N
of IN N
L-carnitine NNP N
on IN N
cardiac JJ o
recovery NN o
after IN N
bypass NN N
might MD N
become VB N
clinically RB N
relevant JJ N
in IN N
the DT N
surgical JJ N
setting NN N
for IN N
haemodynamically RB p
compromised JJ p
patients NNS p
, , N
in IN N
which WDT N
further JJ N
investigations NNS N
are VBP N
required VBN N
. . N

-DOCSTART- -15612617- O O

Comparative JJ o
bioavailability NN o
of IN N
two CD N
formulations NNS N
of IN N
terbinafine NN i
. . i

Data NNS N
from IN N
a DT N
cross-over NN N
, , N
randomised VBN N
, , N
open-label JJ N
bioequivalence NN N
study NN N
in IN N
healthy JJ p
volunteers NNS p
. . p

An DT N
open-label JJ N
, , N
randomised JJ N
, , N
cross-over JJ N
single JJ N
dose NN N
study NN N
, , N
using VBG N
2 CD N
periods NNS N
x RB N
2 CD N
sequences NNS N
, , N
with IN N
a DT N
minimum JJ N
washout NN N
period NN N
of IN N
21 CD N
days NNS N
, , N
was VBD N
conducted VBN N
in IN N
order NN N
to TO N
assess VB N
the DT N
comparative JJ o
bioavailability NN o
of IN N
two CD N
formulations NNS N
of IN N
terbinafine NN i
( ( i
CAS NNP i
78628-80-5 NNP i
) ) i
250 CD N
mg JJ N
tablets NNS N
. . N

Plasma NNP o
samples NNS o
were VBD N
obtained VBN N
at IN N
baseline NN N
, , N
+0.333 NNP N
; : N
0.667 CD N
; : N
1.00 CD N
; : N
1.33 CD N
; : N
1.67 CD N
; : N
2.00 CD N
; : N
2.33 CD N
; : N
2.67 CD N
; : N
3.00 CD N
; : N
3.50 CD N
; : N
4.00 CD N
; : N
6.00 CD N
; : N
8.00 CD N
; : N
12.0 CD N
; : N
24.0 CD N
; : N
36.0 CD N
; : N
48.0 CD N
and CC N
72.0 CD N
h JJ N
post-administration NN N
. . N

Terbinafine NN o
levels NNS o
were VBD o
determined VBN o
by IN o
high JJ o
pressure NN o
liquid NN o
chromatography NN o
with IN o
tandem JJ o
mass NN o
detection NN o
( ( o
HPLC-MS/MS NNP o
) ) o
and CC N
the DT N
lower JJR N
limit NN N
of IN N
quantification NN N
was VBD N
set VBN N
at IN N
9.99 CD N
ng/mL NN N
. . N

The DT N
pharmacokinetic JJ o
parameters NNS o
used VBN N
for IN N
the DT N
bioequivalence NN o
assessment NN o
( ( o
AUClast NNP o
, , o
AUCinf NNP o
and CC o
Cmax NNP o
) ) o
were VBD N
determined VBN N
from IN N
the DT N
terbinafine JJ N
concentration NN N
data NNS N
using VBG N
non-compartmental JJ N
analysis NN N
. . N

Classical JJ o
90 CD o
% NN o
confidence NN o
intervals NNS o
( ( o
90CI CD o
) ) o
were VBD N
calculated VBN N
for IN N
the DT N
overall JJ N
sample NN N
, , N
and CC N
for IN N
males NNS p
and CC p
females NNS p
separately RB N
, , N
and CC N
gender NN N
effects NNS N
were VBD N
investigated VBN N
using VBG N
an DT N
appropriate JJ N
model NN N
. . N

The DT N
results NNS N
showed VBD N
that IN N
overall JJ N
classical JJ o
90CI CD o
were VBD N
96.08-105.40 CD N
% NN N
for IN N
AUCinf NNP N
, , N
95.68-105.33 CD N
for IN N
AUClast NNP o
and CC N
88.24-112.83 JJ N
for IN N
Cmax NNP o
, , N
that WDT N
is VBZ N
, , N
all DT N
within IN N
the DT N
predefined JJ N
ranges NNS N
for IN N
bioequivalence NN N
acceptance NN N
. . N

Separate JJ N
gender NN N
analysis NN N
showed VBD N
very RB N
similar JJ N
results NNS o
for IN N
males NNS p
and CC p
females NNS p
when WRB N
analysed VBN N
independently RB N
, , N
and CC N
no DT N
gender NN o
effects NNS o
were VBD N
detected VBN N
( ( N
p JJ N
> VBP N
0.05 CD N
for IN N
all DT N
of IN N
the DT N
tested JJ N
model NN N
effects NNS N
) ) N
. . N

It PRP N
may MD N
be VB N
therefore RB N
concluded VBD N
that IN N
the DT N
evaluated JJ N
formulations NNS N
are VBP N
bioequivalent JJ N
in IN N
terms NNS N
of IN N
rate NN N
and CC N
extent NN N
of IN N
absorption NN N
. . N

-DOCSTART- -17297382- O O

Safety NNP N
trial NN N
of IN N
the DT N
vaginal JJ i
microbicide NN i
cellulose NN i
sulfate NN i
gel NN i
in IN N
HIV-positive JJ p
men NNS p
. . p

OBJECTIVE NNP N
Cellulose NNP i
sulfate NN i
( ( i
CS NNP i
) ) i
is VBZ N
a DT N
promising JJ N
vaginal JJ N
microbicide NN N
. . N

Because IN N
men NNS p
will MD N
be VB N
exposed VBN N
to TO N
the DT N
microbicide NN N
when WRB N
engaging VBG N
in IN N
vaginal JJ N
intercourse NN N
, , N
safety NN o
and CC o
acceptability NN o
need VBP N
to TO N
be VB N
assessed VBN N
in IN N
men NNS p
. . p

DESIGN NN N
This DT N
randomized VBN N
double-blind NN N
phase NN N
I PRP N
study VBP N
assessed VBD N
the DT N
safety NN o
and CC o
acceptability NN o
of IN N
seven CD N
consecutive JJ N
daily JJ N
doses NNS N
of IN N
CS NNP i
versus NN N
KY NNP i
Jelly NNP i
in IN N
36 CD p
HIV-positive JJ p
men NNS p
. . p

RESULTS NNP N
No NNP N
new JJ o
or CC o
worsening NN o
of IN o
existing VBG o
genital JJ o
findings NNS o
were VBD N
observed VBN N
during IN N
the DT N
follow-up JJ N
examination NN N
. . N

Mild NNP o
genital JJ o
symptoms NNS o
were VBD N
reported VBN N
in IN N
42 CD N
% NN N
of IN N
CS NNP i
users NNS N
( ( o
itching VBG o
, , o
burning NN o
, , o
tingling VBG o
, , o
testicular JJ o
pain NN o
, , o
dysuria NN o
, , o
and CC o
warm NN o
or CC o
cold JJ o
feeling NN o
) ) o
and CC N
8 CD N
% NN N
of IN N
KY NNP i
Jelly NNP p
users NNS p
. . p

CONCLUSION NNP N
CS NNP i
gel NN N
applied VBD N
to TO N
the DT N
penis NN N
was VBD N
well RB N
tolerated VBN o
in IN N
this DT N
HIV-positive JJ p
male JJ p
population NN p
. . p

The DT N
itching NN o
and CC o
burning NN o
symptoms NNS N
were VBD N
not RB N
severe JJ N
and CC N
can MD N
be VB N
explained VBN N
by IN N
the DT N
preservative JJ N
benzyl NN N
alcohol NN N
present NN N
in IN N
the DT N
CS NNP i
gel NN N
. . N

-DOCSTART- -25542917- O O

Relationships NNS N
of IN N
PROP NNP N
Taste NNP N
Phenotype NNP N
, , N
Taste NNP N
Receptor NNP N
Genotype NNP N
, , N
and CC N
Oral NNP N
Nicotine NNP N
Replacement NNP N
Use NNP N
. . N

INTRODUCTION NNP N
Recommended VBD N
dosage NN N
of IN N
oral JJ N
nicotine JJ N
replacement NN N
therapy NN N
( ( N
NRT NNP N
) ) N
product NN N
is VBZ N
often RB N
not RB N
achieved VBN N
in IN N
smoking VBG N
cessation NN N
attempts NNS N
. . N

n-6-propylthiouracil NN N
( ( N
PROP NNP N
) ) N
bitter NN N
taste NN N
phenotype NN N
may MD N
be VB N
a DT N
potential JJ N
risk NN N
factor NN N
for IN N
non-adherence NN N
to TO N
oral JJ N
NRT NNP N
products NNS N
due JJ N
to TO N
their PRP$ N
bitter JJ N
taste NN N
. . N

There EX N
is VBZ N
limited JJ N
literature NN N
on IN N
this DT N
phenotype NN N
in IN N
the DT N
context NN N
of IN N
smoking NN N
and CC N
none NN N
in IN N
relation NN N
to TO N
oral JJ N
NRT NNP N
pharmacotherapy NN N
. . N

METHODS NNP N
The DT N
association NN N
of IN N
PROP NNP N
taste NN N
phenotype NN N
with IN N
NRT NNP N
usage NN N
and CC N
sensory JJ N
response NN N
to TO N
products NNS N
was VBD N
examined VBN N
. . N

In IN N
a DT N
cross-over JJ N
experimental JJ N
design NN N
, , N
120 CD p
participants NNS p
received VBD p
a DT p
1 CD i
week NN i
supply NN i
of IN i
nicotine JJ i
inhalers NNS i
and CC i
1 CD i
week NN i
of IN i
nicotine JJ i
lozenges NNS i
with IN N
random JJ N
assignment NN N
to TO N
order NN N
. . N

Mixed JJ N
effects NNS N
linear JJ N
model NN N
analyses NNS N
were VBD N
conducted VBN N
. . N

RESULTS NNP N
PROP NNP N
taste NN N
phenotype NN N
and CC N
taste NN N
receptor NN N
genotype NN N
were VBD N
not RB N
associated VBN N
with IN N
NRT NNP N
usage NN N
or CC N
sensory JJ N
response NN N
to TO N
NRT NNP N
, , N
after IN N
adjusting VBG N
for IN N
other JJ N
factors NNS N
. . N

However RB N
, , N
PROP NNP N
non-tasters NNS N
used VBD N
a DT N
higher JJR N
number NN o
of IN o
lozenges NNS o
per IN o
day NN o
( ( N
continuous JJ N
exposure NN N
) ) N
than IN N
nicotine JJ N
cartridges NNS N
( ( N
intermittent JJ N
exposure NN N
) ) N
. . N

Unexpectedly RB N
, , N
half NN N
of IN N
baseline JJ N
PROP NNP N
non-tasters NNS N
shifted VBD N
to TO N
taster VB N
phenotype JJ N
2 CD N
weeks NNS N
after IN N
smoking VBG N
cessation NN N
or CC N
reduction NN N
. . N

Menthol NNP p
cigarette NN p
smokers NNS p
identified VBD N
higher JJR o
NRT NNP o
strength NN o
of IN o
sensation NN o
scores NNS o
than IN N
nonmenthol JJ p
smokers NNS p
. . p

Taste NNP N
receptor NN N
genotype NN N
was VBD N
related VBN N
to TO N
PROP NNP N
taste NN N
phenotype NN N
( ( N
Kendall NNP N
? . N
= NNP N
.591 NNP N
, , N
p NN N
= NNP N
.0001 NNP N
) ) N
. . N

CONCLUSIONS VB N
A DT N
nonsignificant JJ N
relationship NN N
of IN N
PROP NNP N
phenotype NN N
and CC N
NRT NNP N
usage NN N
may MD N
be VB N
associated VBN N
with IN N
NRT NNP N
under-dosing JJ N
and CC N
limited JJ N
variance NN N
in IN N
the DT N
outcome NN N
variable NN N
. . N

PROP NNP N
non-tasters NNS N
' POS N
greater JJR N
use NN N
of IN N
lozenges NNS N
is VBZ N
consistent JJ N
with IN N
nicotine JJ N
exposure NN N
being VBG N
less RBR N
aversive JJ N
to TO N
non-tasters NNS N
. . N

Further NNP N
research NN N
of IN N
this DT N
and CC N
other JJ N
factors NNS N
impacting VBG N
NRT NNP N
usage NN N
are VBP N
warranted VBN N
to TO N
effectively RB N
inform VB N
smoking VBG N
cessation NN N
pharmacotherapy NN N
. . N

-DOCSTART- -12074271- O O

Double-blind JJ N
placebo-controlled JJ i
trial NN N
of IN N
aprindine NN i
and CC i
digoxin NN i
for IN N
the DT N
prevention NN o
of IN o
symptomatic JJ o
atrial JJ o
fibrillation NN o
. . o

A DT N
multicenter NN N
, , N
placebo-controlled JJ i
, , N
randomized VBN N
, , N
double-blind JJ N
trial NN N
compared VBN N
the DT N
preventive JJ o
effect NN o
of IN N
aprindine NN i
and CC i
digoxin NN i
on IN N
the DT N
recurrence NN o
of IN o
atrial JJ o
fibrillation NN o
( ( o
AF NNP o
) ) o
with IN N
placebo NN i
, , N
and CC N
also RB N
compare VBP N
the DT N
effectiveness NN o
of IN N
these DT N
2 CD N
drugs NNS N
in IN N
the DT N
prevention NN o
of IN o
AF NNP o
. . o

Patients NNS p
with IN p
symptomatic JJ p
paroxysmal NN p
or CC p
persistent JJ p
AF NNP p
who WP p
had VBD p
converted VBN p
to TO p
sinus VB p
rhythm NN p
( ( p
SR NNP p
) ) p
were VBD N
randomly RB N
assigned VBN N
aprindine NN i
( ( N
40 CD N
mg/day NN N
) ) N
, , N
digoxin NN i
( ( N
0.25 CD N
mg/day NN N
) ) N
or CC i
placebo NN i
and CC N
followed VBD N
up RP N
on IN N
an DT N
outpatient JJ N
basis NN N
every DT N
2 CD N
weeks NNS N
for IN N
6 CD N
months NNS N
. . N

Of IN p
the DT p
141 CD p
patients NNS p
from IN p
36 CD p
participating VBG p
centers NNS p
, , p
47 CD p
were VBD p
given VBN p
aprindine NN i
, , p
47 CD p
digoxin NN i
, , p
and CC p
47 CD p
were VBD p
on IN p
placebo NN i
. . i

After IN N
the DT N
6-month JJ N
follow-up NN N
, , N
the DT N
Kaplan-Meier NNP o
estimates NNS N
of IN N
the DT N
percentage NN N
of IN N
patients NNS N
remaining VBG N
free JJ N
of IN N
recurrent JJ o
symptomatic JJ o
AF NNP o
on IN N
aprindine NN i
, , i
digoxin NN i
and CC N
placebo NN i
were VBD N
33.3 CD N
% NN N
, , N
29.2 CD N
% NN N
and CC N
21.5 CD N
% NN N
, , N
respectively RB N
. . N

In IN N
patients NNS N
remaining VBG N
in IN N
SR NNP N
for IN N
15 CD N
days NNS N
after IN N
from IN N
the DT N
start NN N
of IN N
follow-up NN N
, , N
freedom NN o
from IN o
recurrence NN o
was VBD N
significantly RB N
more RBR N
prevalent JJ o
in IN N
the DT N
aprindine NN N
group NN N
than IN N
in IN N
the DT N
placebo NN i
group NN N
( ( N
p=0.0414 NN N
) ) N
, , N
but CC N
there EX N
was VBD N
no DT N
significant JJ o
difference NN o
between IN N
the DT N
digoxin NN N
and CC N
placebo NN N
groups NNS N
. . N

The DT N
rate NN o
of IN o
adverse JJ o
events NNS o
was VBD N
similar JJ N
in IN N
the DT N
3 CD N
groups NNS N
. . N

In IN N
conclusion NN N
, , N
neither CC N
aprindine JJ N
nor CC N
digoxin NN i
had VBD N
a DT N
significant JJ o
effect NN o
on IN N
preventing VBG o
relapse NN o
of IN o
symptomatic JJ o
AF NNP o
; : o
however RB N
, , N
recurrence NN o
of IN o
AF NNP o
occurred VBD N
later RBR o
with IN N
aprindine NN i
than IN N
with IN N
placebo NN i
or CC N
digoxin NN i
. . i

-DOCSTART- -9220179- O O

The DT N
benefit NN N
of IN N
low-dose JJ N
dopamine NN i
during IN N
vigorous JJ N
diuresis NN N
for IN N
congestive JJ p
heart NN p
failure NN p
associated VBN p
with IN p
renal JJ p
insufficiency NN p
: : p
does VBZ N
it PRP N
protect VB N
renal JJ N
function NN N
? . N
BACKGROUND NNP N
Low-dose NNP N
dopamine NN i
, , N
a DT N
renal JJ N
vasodilator NN N
, , N
has VBZ N
been VBN N
used VBN N
empirically RB N
to TO N
improve VB N
renal JJ N
function NN N
or CC N
outcome NN N
in IN N
critically RB p
ill JJ p
patients NNS p
with IN p
oliguria NNS p
or CC p
acute JJ p
renal JJ p
failure NN p
. . p

HYPOTHESIS NNP N
This DT N
study NN N
was VBD N
designed VBN N
to TO N
investigate VB N
the DT N
efficacy NN N
of IN N
low-dose JJ N
dopamine NN i
( ( N
2 CD N
micrograms/kg/min NN N
) ) N
as IN N
a DT N
renal-protective JJ N
agent NN N
during IN N
vigorous JJ N
diuresis NN N
for IN N
congestive JJ N
heart NN N
failure NN N
( ( N
CHF NNP N
) ) N
associated VBN N
with IN N
mild NN N
or CC N
moderate JJ N
renal JJ N
insufficiency NN N
. . N

METHODS NNP N
Of IN N
20 CD p
study NN p
patients NNS p
( ( p
mean JJ p
age NN p
74.3 CD p
+/- JJ p
15 CD p
years NNS p
) ) p
with IN p
severe JJ p
CHF NNP p
, , p
10 CD p
( ( p
Group NNP p
A NNP p
) ) p
were VBD N
randomized VBN N
to TO N
a DT N
treatment NN N
strategy NN N
of IN N
intravenous JJ N
bumetanide NN i
( ( N
1 CD N
mg NN N
b.i.d NN N
. . N

) ) N
alone RB N
and CC N
another DT N
10 CD N
( ( N
Group NNP N
B NNP N
) ) N
to TO N
low-dose JJ N
dopamine NN i
and CC N
a DT N
similar JJ N
diuretic JJ N
regimen NNS N
for IN N
a DT N
duration NN N
of IN N
5 CD N
days NNS N
or CC N
less JJR N
if IN N
clinical JJ N
edema NN N
remitted VBN N
. . N

RESULTS NNP N
Group NNP N
B NNP N
patients NNS N
showed VBD N
a DT N
significant JJ N
improvement NN N
in IN N
renal JJ o
function NN o
and CC o
urinary JJ o
output NN o
: : o
serum NN o
blood NN o
urea JJ o
nitrogen RB o
48.9 CD N
+/- JJ N
10.3 CD N
to TO N
32.1 CD N
+/- JJ N
14.4 CD N
mg/dl NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
; : N
serum JJ o
creatinine NN o
1.97 CD N
+/- JJ N
0.24 CD N
to TO N
1.49 CD N
+/- JJ N
0.39 CD N
mg/dl NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
; : N
creatinine JJ o
clearance NN o
35.6 CD N
+/- JJ N
11.6 CD N
to TO N
48.8 CD N
+/- JJ N
12.3 CD N
ml/min NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
; : N
and CC N
indexed JJ o
urinary JJ o
output NN o
0.56 CD N
+/- JJ N
0.16 CD N
to TO N
2.02 CD N
+/- JJ N
0.72 CD N
ml/kg/h NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

Group NNP N
A NNP N
patients NNS N
showed VBD N
a DT N
significant JJ N
increase NN N
in IN N
urinary JJ o
output NN o
but CC o
nonsignificant JJ o
renal JJ o
functional JJ o
deterioration NN o
. . o

CONCLUSION VB N
The DT N
renal-protective JJ N
effect NN N
of IN N
low-dose JJ N
dopamine NN i
in IN N
the DT N
setting NN N
of IN N
CHF NNP N
and CC N
vigorous JJ N
diuresis NN N
is VBZ N
supported VBN N
by IN N
this DT N
study NN N
. . N

-DOCSTART- -16859579- O O

Adjuvant NNP p
subcutaneous JJ p
interleukin-2 NN i
in IN p
patients NNS p
with IN p
resected JJ p
renal JJ p
cell NN p
carcinoma NN p
: : p
a DT N
pilot NN N
study NN N
. . N

BACKGROUND NNP N
A NNP N
pilot NN N
study NN N
was VBD N
conducted VBN N
to TO N
investigate VB N
the DT N
toxicity NN o
and CC o
tolerance NN o
to TO N
low-dose JJ N
subcutaneous JJ i
interleukin-2 NN i
( ( i
IL-2 NNP i
) ) i
for IN N
patients NNS p
with IN p
resected JJ p
renal JJ p
cell NN p
carcinoma NN p
( ( p
RCC NNP p
) ) p
at IN p
high JJ p
risk NN p
for IN p
recurrent JJ p
disease NN p
( ( p
TNM NNP p
stages VBZ p
III NNP p
and CC p
IV NNP p
resected VBD p
distant JJ p
metastases NNS p
) ) p
. . p

PATIENTS NNP N
AND CC N
METHODS NNP N
Patients NNPS p
with IN p
surgically RB p
resected VBN p
locally RB p
advanced JJ p
( ( p
T3-4 CD p
or CC p
N1-2 NNP p
) ) p
or CC p
metastatic JJ p
RCC NNP p
were VBD N
randomly RB N
assigned VBN N
to TO N
1 CD N
of IN N
4 CD N
treatment NN N
groups NNS N
that WDT N
received VBD N
different JJ N
dose NN N
levels NNS N
and CC N
schedules NNS N
of IN N
subcutaneous JJ N
IL-2 NNP i
as IN N
follows VBZ N
: : N
dose JJ N
level NN N
1 CD N
, , N
4 CD N
MIU/m2 NNP N
per IN N
day NN N
, , N
every DT N
other JJ N
week NN N
for IN N
24 CD N
weeks NNS N
( ( N
n JJ N
= NNP N
10 CD N
) ) N
; : N
dose JJ N
level NN N
2 CD N
, , N
8 CD N
MIU/m2 NNP N
per IN N
day NN N
, , N
every DT N
other JJ N
week NN N
for IN N
24 CD N
weeks NNS N
( ( N
n JJ N
= NNP N
9 CD N
) ) N
; : N
dose JJ N
level NN N
3 CD N
, , N
4 CD N
MIU/m2 NNP N
per IN N
day NN N
, , N
weeks NNS N
1-4 CD N
, , N
9-12 CD N
, , N
and CC N
17-20 JJ N
( ( N
n JJ N
= NNP N
11 CD N
) ) N
; : N
and CC N
dose VB N
level NN N
4 CD N
, , N
8 CD N
MIU/m2 NNP N
per IN N
day NN N
, , N
weeks NNS N
1-4 CD N
, , N
9-12 CD N
, , N
and CC N
17-20 JJ N
( ( N
n JJ N
= NNP N
10 CD N
) ) N
. . N

Interleukin-2 NN i
was VBD N
administered VBN N
in IN N
2 CD N
daily JJ N
doses NNS N
on IN N
days NNS N
1-5 CD N
of IN N
each DT N
week NN N
indicated VBN N
. . N

A DT N
dose JJ o
level NN o
was VBD N
considered VBN N
tolerable JJ o
if IN N
no DT N
more JJR N
than IN N
2 CD N
patients NNS N
experienced VBD N
grade JJ o
3/4 CD o
toxicity NN o
. . o

RESULTS JJ N
Forty-one JJ p
patients NNS p
were VBD p
entered VBN p
in IN p
the DT p
study NN p
and CC p
40 CD p
were VBD p
evaluable JJ p
for IN p
toxicity NN o
. . o

Therapy NN N
was VBD N
well RB N
tolerated VBN o
at IN N
all DT N
dose JJ N
levels NNS N
and CC N
schedules NNS N
, , N
with IN N
most JJS N
patients NNS N
( ( N
98 CD N
% NN N
) ) N
experiencing VBG N
mild-to-moderate JJ o
constitutional JJ o
symptoms NNS o
. . o

Grade VB o
3/4 CD o
toxicity NN o
was VBD N
seen VBN N
in IN N
8 CD N
patients NNS N
( ( N
20 CD N
% NN N
) ) N
. . N

Interleukin-2 NNP o
dose JJ o
reductions NNS o
were VBD N
required VBN N
in IN N
7 CD N
patients NNS N
, , N
and CC N
no DT N
patient NN N
discontinued VBN N
therapy RB N
secondary JJ N
to TO N
toxicity NN o
. . o

Of IN N
39 CD N
patients NNS N
evaluable JJ N
for IN N
efficacy NN N
, , N
31 CD N
have VBP N
experienced VBN N
relapse NN o
( ( N
79 CD N
% NN N
) ) N
, , N
and CC N
15 CD N
have VBP N
died VBN o
( ( N
38 CD N
% NN N
) ) N
. . N

Median JJ o
survival NN o
was VBD N
1.4 CD N
years NNS N
, , N
and CC N
the DT N
3-year JJ o
disease-free JJ o
survival NN o
rate NN o
was VBD N
33 CD N
% NN N
. . N

Median JJ o
overall JJ o
survival NN o
has VBZ N
not RB N
been VBN N
reached VBN N
; : N
however RB N
, , N
the DT N
3-year JJ o
survival NN o
rate NN o
was VBD N
70 CD N
% NN N
. . N

There EX N
was VBD N
no DT N
statistically RB N
significant JJ N
difference NN N
between IN N
any DT N
of IN N
the DT N
treatment NN N
arms NNS N
with IN N
respect NN N
to TO N
disease-free JJ o
survival NN o
or CC o
3-year JJ o
survival NN o
( ( N
P NNP N
> NNP N
0.54 CD N
and CC N
P NNP N
> NNP N
or= VBZ N
0.09 CD N
for IN N
all DT N
pairwise NN N
comparisons NNS N
) ) N
, , N
schedules NNS N
( ( N
dose VB N
level NN N
1/2 CD N
vs. IN N
3/4 CD N
; : N
P NNP N
= VBZ N
0.46 CD N
and CC N
P NNP N
= NNP N
0.5 CD N
) ) N
, , N
or CC N
dose NN N
of IN N
IL-2 NNP N
administered VBD N
( ( N
dose JJ N
level NN N
1/3 CD N
vs. IN N
2/4 CD N
; : N
P NNP N
= VBZ N
0.99 CD N
and CC N
P NNP N
= NNP N
0.1 CD N
) ) N
. . N

CONCLUSION NNP N
Subcutaneous NNP i
IL-2 NNP i
was VBD N
well RB N
tolerated VBN o
for IN N
6 CD N
months NNS N
in IN N
patients NNS p
with IN p
surgically RB p
resected VBN p
RCC NNP p
at IN p
high JJ p
risk NN p
of IN p
recurrence NN p
. . p

Future NNP N
adjuvant JJ N
trials NNS N
in IN N
this DT N
setting NN N
are VBP N
not RB N
likely JJ N
to TO N
include VB N
IL-2 NNP i
in IN N
view NN N
of IN N
the DT N
clinical JJ o
efficacy NN o
and CC o
favorable JJ o
toxicity NN o
profiles NNS N
of IN N
selected VBN N
multitargeted JJ N
kinase NN N
inhibitors NNS N
. . N

-DOCSTART- -19918712- O O

Effects NNS N
of IN N
topical JJ i
boswellic JJ i
acid NN i
on IN N
photo NN p
and CC p
age-damaged JJ p
skin NN p
: : p
clinical JJ o
, , o
biophysical JJ o
, , o
and CC o
echographic JJ o
evaluations NNS o
in IN N
a DT N
double-blind NN N
, , N
randomized VBN N
, , N
split-face JJ N
study NN N
. . N

Boswellic NNP i
acids NNS i
( ( i
BAs NNP i
) ) i
are VBP N
pentacyclic JJ N
triterpenes NNS N
with IN N
strong JJ N
anti-inflammatory JJ N
activity NN N
; : N
their PRP$ N
most RBS N
important JJ N
source NN N
is VBZ N
the DT N
extract NN N
of IN N
the DT N
gum NN N
resin NN N
of IN N
Boswellia NNP N
serrata NN N
, , N
a DT N
tropical JJ N
tree NN N
that WDT N
grows VBZ N
in IN N
India NNP N
and CC N
Africa NNP N
. . N

In IN N
the DT N
present JJ N
randomized VBN N
, , N
double-blind JJ N
, , N
split-face JJ N
, , N
comparative JJ N
study NN N
we PRP N
have VBP N
assessed VBN N
efficacy NN o
, , o
tolerability NN o
, , o
and CC o
safety NN o
of IN N
a DT N
base NN i
cream NN i
containing VBG i
0.5 CD i
% NN i
BAs NNP i
as IN N
compared VBN N
to TO N
the DT i
same JJ i
cream NN i
without IN i
these DT i
active JJ i
ingredients NNS i
in IN N
the DT N
treatment NN N
of IN N
clinical JJ N
manifestations NNS N
of IN N
photoaging NN p
of IN p
facial JJ p
skin NN p
. . p

Fifteen NNP p
female JJ p
volunteers NNS p
were VBD p
enrolled VBN p
; : p
they PRP N
applied VBD N
creams NNS N
once RB N
daily RB N
for IN N
30 CD N
days NNS N
. . N

At IN N
baseline NN N
, , N
at IN N
the DT N
end NN N
of IN N
the DT N
treatment NN N
, , N
and CC N
after IN N
a DT N
2-month JJ N
follow-up NN N
, , N
clinical JJ N
findings NNS N
were VBD N
assessed VBN N
according VBG N
to TO N
the DT N
Dover NNP o
classification NN o
scale NN o
for IN o
photoaging VBG o
and CC N
by IN N
biophysical JJ o
and CC o
ecographic JJ o
measurements NNS o
. . o

We PRP N
registered VBD N
a DT N
significant JJ N
improvement NN N
of IN N
tactile JJ o
roughness NN o
and CC o
fine JJ o
lines NNS o
in IN N
the DT N
half JJ N
side NN N
of IN N
the DT N
face NN N
treated VBD N
with IN N
BAs NNP i
; : i
noninvasive JJ N
instrumental JJ N
diagnostic JJ N
investigations NNS N
showed VBD N
an DT N
improvement NN N
of IN N
elasticity NN o
, , N
a DT N
decrease NN N
of IN N
sebum JJ o
excretion NN o
, , N
and CC N
a DT N
change NN N
of IN N
echographic JJ o
parameters NNS o
suggesting VBG N
a DT N
reshaping NN o
of IN o
dermal JJ o
tissue NN o
. . o

The DT N
treatment NN N
was VBD N
always RB N
well RB N
tolerated VBN o
without IN N
adverse JJ o
effects NNS o
. . o

The DT N
present JJ N
findings NNS N
seem VBP N
to TO N
indicate VB N
that IN N
the DT N
topical JJ N
application NN N
of IN N
BAs NNP i
may MD N
represent VB N
a DT N
suitable JJ N
treatment NN N
option NN N
for IN N
selected VBN N
features NNS N
of IN N
skin NN p
photoaging NN p
. . p

-DOCSTART- -24992750- O O

Comparison NNP N
of IN N
clinical JJ o
effectiveness NN o
of IN N
acupuncture NN i
and CC N
a DT N
Western JJ i
drug NN i
on IN N
allergic JJ p
rhinitis NN p
: : p
study NN N
protocol NN N
for IN N
a DT N
randomized VBN N
controlled VBN N
trial NN N
. . N

OBJECTIVE UH N
To TO N
compare VB N
the DT N
efficacy NN N
of IN N
an DT N
acupuncture NN i
regimen NN i
for IN N
persistent JJ p
allergic JJ p
rhinitis NN p
( ( p
PER NNP p
) ) p
, , N
aimed VBN N
at IN N
improving VBG N
a DT N
patient NN N
's POS N
mind NN N
or CC N
Shen NNP N
in IN N
Traditional NNP i
Chinese NNP i
Medicine NNP i
, , N
to TO N
that DT N
of IN N
a DT N
second-generation JJ i
Hi-receptor NNP i
antagonist NN i
, , i
cetirizine JJ i
hydrochloride NN i
. . i

METHODS NNP N
This DT N
multicenter NN p
, , p
randomized VBN p
, , p
controlled VBD p
clinical JJ p
trial NN p
on IN p
PER NNP p
will MD p
be VB p
conducted VBN p
at IN p
three CD p
institutions NNS p
in IN p
China NNP p
. . p

The DT N
total JJ N
study NN N
period NN N
will MD N
be VB N
9 CD N
weeks NNS N
. . N

After IN N
a DT N
1-week JJ N
preparatory NN N
screening VBG N
period NN N
, , N
240 CD p
eligible JJ p
participants NNS p
with IN p
PER NNP p
will MD N
be VB N
randomized VBN N
to TO N
receive VB N
acupuncture NN i
or CC i
pharmacotherapy NN i
( ( N
1:1 CD N
) ) N
for IN N
4 CD N
weeks NNS N
with IN N
a DT N
4-week JJ N
follow-up NN N
. . N

The DT N
primary JJ N
outcome NN N
will MD N
be VB N
changes NNS N
in IN N
7-day JJ o
average JJ o
total JJ o
nasal JJ o
symptom NN o
score NN o
. . o

Secondary JJ N
outcome NN N
measures NNS N
include VBP N
rhinoconjunctivitis JJ o
quality NN o
of IN o
life NN o
questionnaire NN o
score NN o
and CC o
total JJ o
non-nasal JJ o
symptom NN o
score NN o
. . o

RESULTS VB N
The DT N
presence NN N
and CC N
seriousness NN N
of IN N
psychological JJ N
and CC N
emotional JJ N
impairments NNS N
should MD N
be VB N
considered VBN N
in IN N
therapeutic JJ N
programs NNS N
for IN N
allergic JJ N
rhinitis NN N
. . N

No DT N
clinical JJ N
trial NN N
for IN N
treating VBG N
allergic JJ N
rhinitis NN N
via IN N
acupuncture NN i
regulation NN N
of IN N
psychological JJ N
and CC N
emotional JJ N
activities NNS N
has VBZ N
been VBN N
reported VBN N
. . N

CONCLUSION VB N
The DT N
findings NNS N
of IN N
the DT N
trial NN N
will MD N
allow VB N
us PRP N
to TO N
determine VB N
the DT N
effects NNS N
of IN N
the DT N
mind NN i
( ( i
Shen NNP i
) ) i
-regulation NN i
treatment NN i
approach NN N
. . N

We PRP N
will MD N
also RB N
be VB N
able JJ N
to TO N
confirm VB N
if IN N
the DT N
effects NNS N
of IN N
acupuncture NN i
are VBP N
equivalent JJ N
to TO N
those DT N
of IN N
the DT N
conventional JJ N
drug NN N
cetirizine NN i
hydrochloride NN i
. . i

-DOCSTART- -3859359- O O

Comparison NNP N
of IN N
maintenance NN i
treatment NN i
regimens NNS i
for IN N
first JJ N
central JJ p
nervous JJ p
system NN p
relapse NN p
in IN p
children NNS p
with IN p
acute JJ p
lymphocytic JJ p
leukemia NN p
. . p

A DT N
Pediatric NNP N
Oncology NNP N
Group NNP N
study NN N
. . N

Eighty-seven JJ p
children NNS p
with IN p
central JJ p
nervous JJ p
system NN p
( ( p
CNS NNP p
) ) p
leukemia NN p
were VBD N
randomized VBN N
to TO N
receive VB N
either DT i
induction NN i
intrathecal JJ i
chemotherapy NN i
( ( i
ITC NNP i
) ) i
and CC i
cranial JJ i
irradiation NN i
( ( i
CRT NNP i
) ) i
plus CC i
maintenance NN i
ITC NNP i
, , i
or CC i
induction NN i
ITC NNP i
and CC i
craniospinal JJ i
irradiation NN i
( ( i
CSpRT NNP i
) ) i
with IN i
no DT i
maintenance NN i
ITC NNP i
. . i

ITC NNP N
consisted VBD N
of IN N
six CD N
weekly JJ N
injections NNS N
of IN N
methotrexate NN i
, , i
hydrocortisone NN i
, , i
and CC i
arabinosylcytosine NN i
. . i

Also RB N
, , N
intensification NN i
of IN i
systemic JJ i
induction NN i
and CC i
maintenance NN i
chemotherapy NN i
was VBD N
given VBN N
. . N

CRT NNP i
+ NNP i
ITC NNP i
was VBD N
given VBN N
as IN N
CRT NNP i
, , N
2400 CD N
rad NN N
in IN N
12 CD N
fractions NNS N
followed VBN N
by IN N
ITC NNP i
maintenance NN N
bimonthly NN N
for IN N
2 CD N
years NNS N
. . N

Craniospinal JJ i
irradiation NN i
consisted VBD i
of IN i
CRT NNP i
+ NNP N
1400 CD N
rad NN N
in IN N
ten JJ N
fractions NNS N
to TO N
the DT N
spine NN N
. . N

Randomization NN N
was VBD N
stratified VBN N
according VBG N
to TO N
whether IN N
CNS NNP N
leukemia NN N
occurred VBD N
at IN N
initial JJ N
diagnosis NN N
of IN N
acute JJ N
lymphocytic JJ N
leukemia NN N
( ( N
ALL DT N
) ) N
( ( N
Stratum NNP N
I PRP N
, , N
15 CD N
patients NNS N
) ) N
, , N
during IN N
first JJ N
bone NN N
marrow NN N
( ( N
BM NNP N
) ) N
remission NN N
( ( N
Stratum NNP N
II NNP N
, , N
49 CD N
patients NNS N
) ) N
, , N
simultaneous JJ N
with IN N
first JJ N
BM NNP N
relapse NN N
( ( N
Stratum NNP N
III NNP N
, , N
12 CD N
patients NNS N
) ) N
, , N
or CC N
during IN N
second JJ N
BM NNP N
remission NN N
( ( N
Stratum NNP N
IV NNP N
, , N
11 CD N
patients NNS N
) ) N
. . N

The DT N
median JJ N
follow-up NN N
for IN N
patients NNS N
who WP N
remain VBP N
at IN N
risk NN N
is VBZ N
15 CD N
+ JJ N
months NNS N
. . N

Eight NNP N
children NNS N
( ( N
seven CD N
on IN N
CRT NNP N
+ NNP N
ITC NNP N
, , N
one CD N
on IN N
CSpRT NNP N
) ) N
developed VBD N
presumed VBN o
therapy RB o
related VBN o
encephalopathy NN o
. . o

In IN N
Stratum NNP N
II NNP N
, , N
16 CD N
of IN N
29 CD N
( ( N
55 CD N
% NN N
) ) N
patients NNS N
receiving VBG N
CRT NNP N
+ NNP N
ITC NNP N
experienced VBD N
adverse JJ o
events NNS o
: : o
3 CD N
deaths NNS o
during IN o
continuous JJ o
complete JJ o
remission NN o
( ( o
CCR NNP o
) ) o
and CC N
13 CD N
relapses NNS o
( ( N
2 CD N
CNS NNP N
, , N
1 CD N
CNS NNP N
+ NNP N
BM NNP N
, , N
1 CD N
BM NNP N
+ NNP N
testes VBZ N
, , N
and CC N
2 CD N
testes NNS N
) ) N
as IN N
compared VBN N
with IN N
only RB N
5 CD N
relapses NNS o
in IN N
20 CD N
( ( N
25 CD N
% NN N
) ) N
patients NNS N
on IN N
CSpRT NNP N
( ( N
1 CD N
CNS NNP N
, , N
1 CD N
CNS NNP N
+ NNP N
BM NNP N
, , N
1 CD N
BM NNP N
, , N
and CC N
2 CD N
testes NNS N
) ) N
. . N

The DT N
children NNS N
on IN N
both DT N
regimens NNS N
were VBD N
comparable JJ N
for IN N
sex NN N
, , N
race NN N
, , N
age NN N
at IN N
initial JJ N
ALL NNP N
diagnosis NN N
, , N
time NN o
from IN o
ALL NNP o
diagnosis NN o
to TO o
first JJ o
episode NN o
of IN o
CNS NNP o
leukemia NN o
, , o
systemic JJ o
therapy NN o
both DT o
before IN o
and CC o
after IN o
CNS NNP o
relapse NN o
, , o
and CC o
number NN o
of IN o
blasts NNS o
in IN o
the DT o
spinal JJ o
fluid NN o
at IN o
diagnosis NN o
of IN o
CNS NNP o
leukemia NN o
. . o

The DT N
conclusion NN N
is VBZ N
that IN N
children NNS N
with IN N
isolated JJ N
CNS NNP N
leukemia NN N
can MD N
achieve VB N
prolonged JJ o
survival NN o
with IN o
aggressive JJ o
therapy NN o
, , N
and CC N
that IN N
CSpRT NNP o
is VBZ o
possibly RB o
less RBR o
toxic JJ o
and CC N
more RBR N
likely JJ N
than IN N
is VBZ N
CRT NNP N
+ NNP N
ITC NNP N
to TO N
prevent VB N
subsequent JJ o
BM NNP o
and CC o
testicular JJ o
relapse NN o
( ( N
P NNP N
less JJR N
than IN N
0.02 CD N
) ) N
, , N
but CC N
not RB N
subsequent JJ N
CNS NNP o
relapse NN o
( ( N
P NNP N
= NNP N
0.7 CD N
) ) N
. . N

A DT N
possible JJ N
systemic JJ N
therapy NN N
effect NN N
of IN N
spinal JJ o
irradiation NN o
is VBZ N
postulated VBN N
to TO N
explain VB N
the DT N
superiority NN o
of IN o
CSpRT NNP o
. . o

-DOCSTART- -10690697- O O

Hip NNP i
protectors NNS i
improve VBP N
falls VBZ N
self-efficacy NN N
. . N

OBJECTIVES NNP N
To TO N
investigate VB N
the DT N
effect NN N
of IN N
use NN N
of IN N
external JJ i
hip NN i
protectors NNS i
on IN N
subjects NNS N
' POS N
fear NN N
of IN N
falling VBG N
and CC N
falls VBZ N
self-efficacy NN N
( ( N
belief NN N
in IN N
their PRP$ N
own JJ N
ability NN N
to TO N
avoid VB N
falling VBG N
) ) N
. . N

DESIGN NNP N
Randomized NNP N
controlled VBD N
trial NN N
. . N

SETTING CC N
Aged-care JJ p
health NN p
services NNS p
in IN p
Sydney NNP p
, , p
Australia NNP p
. . p

PARTICIPANTS NNP N
131 CD p
women NNS p
aged VBN p
75 CD p
years NNS p
or CC p
older JJR p
, , p
who WP p
had VBD p
two CD p
or CC p
more JJR p
falls NNS p
or CC p
one CD p
fall NN p
requiring VBG p
hospital JJ p
admission NN p
in IN p
the DT p
previous JJ p
year NN p
and CC p
who WP p
live VBP p
at IN p
home NN p
. . p

Sixty-one JJ p
subjects NNS p
were VBD p
in IN p
the DT p
intervention NN p
group NN p
and CC N
70 CD p
in IN p
the DT p
control NN i
group NN p
. . p

INTERVENTION NNP N
Use NNP N
of IN N
external JJ i
hip NN i
protectors NNS i
and CC i
encouragement NN i
to TO i
use VB i
the DT i
protectors NNS i
by IN i
an DT i
adherence NN i
nurse NN i
. . i

MEASUREMENTS CC N
At IN N
the DT N
time NN N
of IN N
enrolment NN N
into IN N
a DT N
wider NN N
study NN N
examining VBG N
the DT N
effect NN N
of IN N
hip NN i
protectors NNS i
on IN N
hip NN N
fractures NNS N
, , N
participants NNS p
recruited VBD p
at IN p
home NN p
completed VBD N
an DT N
assessment NN N
of IN N
fear NN o
of IN o
falling VBG o
and CC o
falls VBZ o
efficacy NN o
as IN N
measured VBN N
by IN N
the DT N
Falls NNP o
Efficacy NNP o
Scale NNP o
and CC o
the DT o
Modified NNP o
Falls NNP o
Efficacy NNP o
Scale NNP o
. . o

At IN N
4-month JJ N
follow-up NN N
, , N
these DT N
scales NNS N
were VBD N
readministered VBN N
by IN N
an DT N
observer NN N
who WP N
was VBD N
not RB N
aware JJ N
of IN N
the DT N
allocation NN N
of IN N
the DT N
participant NN N
to TO N
intervention NN N
or CC N
control NN N
groups NNS N
. . N

RESULTS NNP N
Fear NNP o
of IN o
falling VBG o
and CC o
falls VBZ o
self-efficacy NN o
, , N
as IN N
measured VBN N
by IN N
the DT N
Falls NNP o
Efficacy NNP o
and CC o
Modified NNP o
Falls NNP o
Efficacy NNP o
Scales NNP o
, , N
were VBD N
similar JJ N
at IN N
baseline NN N
in IN N
both DT N
groups NNS N
. . N

Fear NN o
of IN o
falling VBG o
was VBD N
present JJ N
at IN N
follow-up NN N
in IN N
43 CD N
% NN N
of IN N
subjects NNS N
using VBG N
hip NN N
protectors NNS N
and CC N
57 CD N
% NN N
of IN N
the DT N
control NN N
group NN N
( ( N
chi2 JJ N
= NN N
2.58 CD N
, , N
P NNP N
= NNP N
0.11 CD N
) ) N
. . N

Hip NNP i
protector NN i
users NNS N
had VBD N
greater JJR N
improvement NN N
in IN N
falls VBZ N
self-efficacy NN o
at IN N
follow-up JJ N
as IN N
measured VBN N
by IN N
the DT N
Falls NNP o
Efficacy NNP o
Scale NNP o
( ( N
t JJ N
= NN N
2.44 CD N
, , N
P NNP N
= NNP N
0.016 CD N
) ) N
and CC N
the DT N
Modified NNP o
Falls NNP o
Efficacy NNP o
Scale NNP o
( ( N
t JJ N
= NN N
2.08 CD N
, , N
P NNP N
= NNP N
0.039 CD N
) ) N
. . N

CONCLUSION NNP N
Hip NNP i
protectors NNS i
improve VBP N
falls VBZ N
self-efficacy NN N
. . N

As IN N
users NNS N
of IN N
hip NN i
protectors NNS i
feel VBP N
more RBR N
confident JJ N
that IN N
they PRP N
can MD N
complete VB N
tasks NNS N
safely RB N
, , N
they PRP N
may MD N
become VB N
more RBR N
physically RB N
active JJ N
and CC N
require VB N
less JJR N
assistance NN N
with IN N
activities NNS N
of IN N
daily JJ N
living NN N
. . N

-DOCSTART- -1608405- O O

Reactivation NN o
of IN o
unstable JJ o
angina NN o
after IN N
the DT N
discontinuation NN N
of IN N
heparin NN i
. . i

BACKGROUND NNP N
Heparin NNP i
is VBZ N
an DT N
effective JJ N
, , N
widely RB N
used VBN N
treatment NN N
for IN N
unstable JJ p
angina NNS p
. . p

Among IN N
patients NNS p
enrolled VBN N
in IN N
a DT N
double-blind NN N
, , N
randomized VBN N
, , N
placebo-controlled JJ i
trial NN i
comparing VBG N
intravenous JJ i
heparin NN i
, , i
aspirin NN i
, , i
both DT i
treatments NNS i
, , i
and CC i
neither RB i
during IN N
the DT N
acute JJ N
phase NN N
of IN N
unstable JJ N
angina NNS N
, , N
we PRP N
encountered VBD N
patients NNS N
in IN N
whom WP N
unstable JJ N
angina NN N
was VBD N
reactivated VBN N
after IN N
heparin NN i
was VBD N
discontinued VBN N
. . N

METHODS NNP N
The DT p
study NN p
population NN p
included VBD p
403 CD p
of IN p
the DT p
original JJ p
479 CD p
patients NNS p
in IN p
the DT p
trial NN p
who WP p
had VBD p
completed VBN p
six CD p
days NNS p
of IN p
blinded JJ p
therapy NN p
without IN p
refractory JJ p
angina NN p
or CC p
myocardial JJ p
infarction NN p
. . p

After IN N
the DT N
discontinuation NN N
of IN N
therapy NN N
, , N
clinical JJ o
events NNS o
, , o
including VBG o
reactivation NN o
of IN o
unstable JJ o
angina NN o
and CC o
myocardial JJ o
infarction NN o
occurring VBG o
within IN o
96 CD o
hours NNS o
after IN o
hospitalization NN o
, , N
were VBD N
closely RB N
monitored VBN N
. . N

RESULTS NNP N
Early JJ o
reactivation NN o
occurred VBD N
in IN N
14 CD N
of IN N
the DT N
107 CD N
patients NNS N
who WP N
received VBD N
heparin NN i
alone RB N
, , N
as IN N
compared VBN N
with IN N
only RB N
5 CD N
patients NNS N
in IN N
each DT N
of IN N
the DT N
other JJ N
three CD N
study NN N
groups NNS N
( ( N
P NNP N
less JJR N
than IN N
0.01 CD N
) ) N
. . N

These DT N
reactivations NNS o
required VBD N
urgent JJ N
intervention NN N
( ( N
thrombolysis NN N
, , N
angioplasty JJ N
, , N
or CC N
coronary-bypass NN N
surgery NN N
) ) N
in IN N
11 CD N
patients NNS N
treated VBN N
with IN N
heparin NN i
alone RB N
, , N
but CC N
in IN N
only RB N
2 CD N
patients NNS N
in IN N
the DT N
other JJ N
groups NNS N
combined VBN N
( ( N
P NNP N
less JJR N
than IN N
0.01 CD N
) ) N
. . N

Four CD N
of IN N
the DT N
six CD N
patients NNS N
who WP N
had VBD N
a DT N
myocardial JJ o
infarction NN o
during IN N
a DT N
reactivation NN N
of IN N
their PRP$ N
disease NN N
were VBD N
in IN N
the DT N
heparin NN N
group NN N
. . N

Reactivations NNS o
in IN N
this DT N
group NN N
occurred VBD N
in IN N
a DT N
cluster NN N
a DT N
mean NN N
( ( N
+/- JJ N
SD NNP N
) ) N
of IN N
9.5 CD N
+/- JJ N
5 CD N
hours NNS N
after IN N
the DT N
discontinuation NN N
of IN N
the DT N
study NN N
drug NN N
but CC N
were VBD N
randomly RB N
distributed VBN N
over IN N
the DT N
initial JJ N
96 CD N
hours NNS N
in IN N
the DT N
other JJ N
three CD N
groups NNS N
. . N

CONCLUSIONS NNP N
Although IN N
heparin NN i
is VBZ N
beneficial JJ N
in IN N
treating VBG N
unstable JJ N
angina NN N
, , N
the DT N
disease NN N
process NN N
may MD N
be VB N
reactivated VBN o
within IN N
hours NNS N
of IN N
the DT N
discontinuation NN N
of IN N
this DT N
drug NN N
. . N

Concomitant JJ N
therapy NN N
with IN N
aspirin NN N
may MD N
prevent VB N
this DT N
withdrawal NN N
phenomenon NN N
. . N

-DOCSTART- -1827602- O O

Chronology NN N
of IN N
panic NN N
and CC N
avoidance NN N
, , N
age NN p
of IN p
onset NN p
in IN p
panic JJ p
disorder NN p
, , N
and CC N
prediction NN N
of IN N
treatment NN N
response NN N
. . N

A DT N
report NN N
from IN N
the DT N
Cross-National JJ N
Collaborative NNP N
Panic NNP N
Study NNP N
. . N

The DT N
relevance NN N
of IN N
the DT N
chronology NN N
between IN N
panic JJ N
disorder NN N
and CC N
avoidance NN N
behavior NN N
and CC N
of IN N
an DT N
early JJ N
, , N
medium NN N
or CC N
late JJ N
onset NN N
of IN N
panic JJ N
disorder NN N
was VBD N
tested VBN N
. . N

Groups NNP p
from IN N
the DT p
sample NN p
of IN p
the DT p
cross-national JJ i
collaborative NN i
panic NN i
study NN i
( ( p
CNCPS NNP p
) ) p
were VBD N
compared VBN N
for IN N
differences NNS N
in IN N
basic JJ N
characteristics NNS N
and CC N
for IN N
the DT N
ability NN N
to TO N
predict VB N
treatment NN N
response NN N
. . N

Patients NNS p
who WP p
developed VBD p
avoidance NN o
behavior NN o
before IN p
the DT p
full JJ p
syndrome NN p
of IN p
panic JJ o
disorder NN o
had VBD N
less RBR N
often RB N
a DT N
full JJ N
agoraphobia NN o
but CC N
were VBD N
not RB N
different JJ N
in IN N
their PRP$ N
response NN N
to TO N
treatment NN i
. . i

Patients NNS p
with IN N
an DT N
early JJ o
onset NN o
of IN o
panic JJ o
disorder NN o
suffered VBD N
more RBR N
often RB N
from IN N
agoraphobia NNS o
. . o

The DT N
treatment NN o
response NN o
was VBD N
similar JJ o
in IN N
the DT N
groups NNS N
with IN N
early JJ o
, , o
medium NN o
or CC o
late JJ o
onset NN o
of IN o
panic JJ o
disorder NN o
. . o

Neither CC N
the DT N
chronology NN N
between IN N
panic JJ o
disorder NN o
and CC o
avoidance NN o
behavior NN o
nor CC N
the DT N
age NN o
of IN o
onset NN o
of IN o
panic JJ o
disorder NN o
predicted VBD N
outcome NN N
in IN N
short-term JJ i
treatment NN i
with IN i
alprazolam NN i
or CC i
imipramine NN i
. . i

-DOCSTART- -20865676- O O

The DT N
effect NN N
of IN N
L-arginine NNP i
and CC i
citrulline NN i
on IN N
endothelial JJ o
function NN o
in IN N
patients NNS p
in IN p
heart NN p
failure NN p
with IN p
preserved JJ p
ejection NN p
fraction NN p
. . p

BACKGROUND NNP N
To TO N
evaluate VB N
the DT N
effect NN N
of IN N
the DT N
amino JJ i
acids NNS i
L-arginine JJ i
and CC i
citrulline NN i
on IN N
endothelial JJ o
function NN o
in IN N
patients NNS p
in IN p
stable JJ p
diastolic NN p
and CC p
right JJ p
heart NN p
failure NN p
using VBG N
photoplethysmography NN N
. . N

METHODS NNP N
Thirty NNP p
patients NNS p
from IN p
the DT p
Heart NNP p
Failure NNP p
Clinic NNP p
of IN p
the DT p
Instituto NNP p
Nacional NNP p
de FW p
Ciencias NNP p
M?dicas NNP p
y NNP p
Nutrici?n NNP p
Salvador NNP p
Zubir?n NNP p
underwent JJ i
photoplethysmography NN i
using VBG i
the DT i
hyperemia NN i
technique NN o
. . o

Index NNP o
finger VBD o
flow NN o
was VBD o
assessed VBN N
at IN N
baseline NN N
and CC N
after IN N
ischemia NN N
every DT N
30 CD N
s NN N
by IN N
maximum JJ N
amplitude JJ N
time NN N
( ( N
MAT NNP N
) ) N
, , N
total JJ N
time NN N
of IN N
the DT N
curve NN N
( ( N
TT NNP N
) ) N
and CC N
the DT N
index NN N
of IN N
the DT N
two CD N
( ( N
MAT/TT NNP N
< VBZ N
30 CD N
= NNP N
normal JJ N
) ) N
before IN N
and CC N
after IN N
the DT N
administration NN N
of IN N
L-arginine NNP i
( ( i
8 CD i
g/day NN N
in IN N
two CD N
doses NNS N
, , N
n JJ N
= NNP N
15 CD N
) ) N
or CC N
citrulline NN i
( ( i
3 CD i
g/day NN N
in IN N
one CD N
dose NN N
, , N
n JJ N
= NNP N
15 CD N
) ) N
for IN N
60 CD N
days NNS N
in IN N
addition NN N
to TO N
optimal VB i
pharmacological JJ i
treatment NN i
. . i

RESULTS CC i
There EX N
were VBD N
no DT N
statistically RB N
significant JJ N
differences NNS N
between IN N
the DT N
two CD N
groups NNS N
at IN N
baseline NN N
. . N

After IN N
the DT N
intervention NN N
, , N
the DT N
MAT/TT NNP o
index NN o
of IN o
all DT N
patients NNS N
normalized VBN N
in IN N
each DT N
evaluation NN N
period NN N
with IN N
statistically RB N
significant JJ N
differences NNS N
. . N

Basal NNP i
L-arginine NNP i
group NN i
= VBD N
38.75 CD N
? . N
11.52 CD N
, , N
final JJ N
23.32 CD N
? . N
6.08 CD N
, , N
p NN N
= VBD N
0.007 CD N
and CC N
basal JJ N
citrulline NN i
group NN i
= VBD N
41.4 CD N
? . N
13.47 CD N
, , N
final JJ N
23.65 CD N
? . N
6.74 CD N
, , N
p NN N
= VBD N
0.007 CD N
at IN N
60-90 JJ N
s. JJ N
Post-ischemia NN i
: : i
basal NN i
L-arginine JJ i
36.60 CD i
? . N
11.51 CD N
, , N
final JJ N
18.81 CD N
? . N
15.13 CD N
, , N
p NN N
= VBD N
0.004 CD N
and CC N
basal JJ N
citrulline NN i
= NN i
49.51 CD i
? . N
15.17 CD N
, , N
final JJ N
27.13 CD N
? . N
7.87 CD N
, , N
p NN N
= VBD N
0.003 CD N
. . N

CONCLUSIONS VB N
The DT N
administration NN i
of IN i
L-arginine NNP i
and CC i
citrulline NN i
has VBZ N
a DT N
beneficial JJ N
effect NN o
on IN o
endothelial JJ o
function NN o
as IN o
shown VBN N
by IN N
the DT N
normalized JJ N
MAT/TT NNP N
index NN N
. . N

It PRP N
probably RB N
improves VBZ o
systemic JJ o
and CC o
pulmonary JJ o
hemodynamics NNS o
, , o
which WDT o
could MD o
help VB N
in IN N
the DT N
treatment NN N
of IN p
diastolic JJ p
heart NN p
failure NN p
. . p

-DOCSTART- -18512510- O O

Effect NN N
of IN N
adhesive JJ N
system NN N
type NN N
and CC N
tooth DT N
region NN N
on IN N
the DT N
bond NN N
strength NN N
to TO N
dentin VB N
. . N

PURPOSE VB N
This DT N
study NN N
evaluated VBD N
the DT N
bond NN N
strength NN N
of IN N
two CD N
etch-and-rinse JJ i
adhesive JJ i
systems NNS i
( ( N
two- JJ N
and CC N
three-step NN N
) ) N
and CC i
a DT i
self-etching JJ i
system NN i
to TO N
coronal VB o
and CC o
root VB o
canal JJ o
dentin NN o
. . o

MATERIALS NNP N
AND CC N
METHODS NNP N
The DT p
root NN p
canals NNS p
of IN p
30 CD p
human JJ p
incisors NNS p
and CC p
canines NNS p
were VBD N
instrumented VBN N
and CC N
prepared VBN N
with IN N
burs NNS N
. . N

The DT N
posts NNS i
used VBD i
for IN i
luting VBG i
were VBD i
duplicated VBN i
with IN i
dual JJ i
resin NN i
cement NN i
( ( i
Duo-link NNP i
) ) i
inside IN i
Aestheti NNP i
Plus NNP i
# # i
2 CD i
molds NNS i
. . i

Thus RB N
, , N
three CD N
groups NNS N
were VBD N
formed VBN N
( ( N
n JJ N
= NNP N
10 CD N
) ) N
according VBG N
to TO N
the DT N
adhesive JJ N
system NN N
employed VBN N
: : N
All-Bond JJ i
2 CD i
( ( i
TE3 NNP i
) ) i
+ VBP i
resin JJ i
cement NN i
post NN i
( ( i
rcp NN i
) ) i
+ VBZ i
Duo-link NNP i
( ( i
Dl NNP i
) ) i
; : i
One-Step JJ i
Plus NNP i
( ( i
TE2 NNP i
) ) i
+ VBP i
rcp JJ i
+ NNP i
Dl NNP i
; : i
Tyrian/One-Step JJ i
Plus NNP i
( ( i
SE NNP i
) ) i
+ VBP i
rcp JJ i
+ NNP i
Dl NNP i
. . i

Afterwards NNP N
, , N
8 CD N
transverse NN N
sections NNS N
( ( N
1.5 CD N
mm NN N
) ) N
were VBD N
cut VBN N
from IN N
4 CD N
mm NNS N
above IN N
the DT N
CEJ NNP N
up RB N
to TO N
4 CD N
mm NNS N
short JJ N
of IN N
the DT N
root NN N
canal JJ N
apex NN N
, , N
comprising VBG N
coronal JJ N
and CC N
root JJ N
canal JJ N
dentin NN N
. . N

The DT N
sections NNS N
were VBD N
submitted VBN N
to TO N
push-out JJ N
testing NN N
in IN N
a DT N
universal JJ N
testing VBG N
machine NN N
EMIC NNP N
( ( N
1 CD N
mm/min NN N
) ) N
. . N

Bond NNP o
strength NN o
data NNS o
were VBD o
analyzed VBN o
with IN o
two-way JJ o
repeated JJ o
measures NNS o
ANOVA NNP o
and CC o
Tukey NNP o
's POS o
test NN o
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

RESULTS VB N
The DT N
relationship NN o
between IN o
the DT o
adhesives NNS o
was VBD N
not RB N
the DT N
same JJ N
in IN N
the DT N
different JJ N
regions NNS N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

Comparison NNP N
of IN N
the DT N
means NNS N
achieved VBN N
with IN N
the DT N
adhesives NNS N
in IN N
each DT N
region NN N
( ( N
Tukey NNP N
; : N
p VBZ N
< $ N
0.05 CD N
) ) N
revealed VBD N
that IN N
TE3 NNP N
( ( N
mean JJ N
+/- JJ N
standard NN N
deviation NN N
: : N
5.22 CD N
+/- JJ N
1.70 CD N
) ) N
was VBD N
higher JJR N
than IN N
TE2 NNP N
( ( N
2.60 CD N
+/- JJ N
1.74 CD N
) ) N
and CC N
SE NNP N
( ( N
1.68 CD N
+/- JJ N
1.85 CD N
) ) N
. . N

CONCLUSION NNP N
Under IN N
the DT N
experimental JJ N
conditions NNS N
, , N
better JJR N
bonding VBG N
to TO N
dentin VB N
was VBD N
achieved VBN N
using VBG N
the DT N
three-step JJ N
etch-and-rinse JJ N
system NN N
, , N
especially RB N
in IN N
the DT N
coronal JJ N
region NN N
. . N

Therefore RB N
, , N
the DT N
traditional JJ N
etch-and-rinse JJ N
three-step NN N
adhesive JJ N
system NN N
seems VBZ N
to TO N
be VB N
the DT N
best JJS N
choice NN N
for IN N
teeth NN N
needing VBG N
adhesive JJ N
endodontic JJ N
restorations NNS N
. . N

-DOCSTART- -20587582- O O

Abnormal JJ N
cardiac JJ N
contractility NN N
in IN N
long-term JJ i
exogenous JJ i
subclinical JJ i
hyperthyroid NN i
patients NNS p
as IN N
demonstrated VBN N
by IN N
two-dimensional JJ N
echocardiography NN N
speckle NN N
tracking VBG N
imaging VBG N
. . N

BACKGROUND NNP N
Subclinical NNP N
hyperthyroidism NN N
is VBZ N
associated VBN N
with IN N
cardiovascular JJ o
morbidity NN o
. . o

Recent JJ N
advances NNS N
in IN N
echocardiography NN N
imaging NN N
have VBP N
allowed VBN N
sophisticated JJ N
evaluation NN N
of IN N
myocardial JJ o
tissue NN N
properties NNS N
. . N

OBJECTIVE NNP N
To TO N
investigate VB N
the DT N
myocardial JJ N
effects NNS N
of IN N
long-term JJ N
exogenous JJ i
subclinical JJ i
hyperthyroidism NN i
using VBG N
two-dimensional JJ i
speckle NN i
tracking VBG i
echocardiography NN i
imaging NN i
( ( i
2D-STE JJ i
) ) i
. . N

DESIGN NNP N
Prospective NNP N
, , N
single-blinded JJ N
, , N
placebo-controlled JJ N
randomized JJ N
trial NN N
of IN N
6 CD N
months NNS N
duration NN N
with IN N
two CD N
parallel JJ N
groups NNS N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
Totally NNP p
25 CD p
patients NNS p
with IN p
a DT p
history NN p
of IN p
differentiated JJ p
thyroid JJ p
carcinoma NN p
on IN p
long-term JJ p
TSH-suppressive JJ p
levothyroxine NN p
( ( p
l-T JJ p
( ( p
4 CD p
) ) p
) ) p
substitution NN p
were VBD N
randomized VBN N
to TO N
persistent JJ N
TSH-suppressive JJ i
l-T NN i
( ( i
4 CD i
) ) i
substitution NN i
( ( N
low-TSH JJ N
group NN N
) ) N
or CC N
restoration NN i
of IN i
euthyroidism NN i
. . i

Additionally RB p
40 CD p
euthyroid JJ p
controls NNS p
were VBD p
studied VBN p
. . p

RESULTS NNP N
( ( N
PROPOSAL NNP N
) ) N
: : N
At IN N
baseline NN N
, , N
the DT N
group NN N
of IN N
patients NNS N
showed VBD N
normal JJ o
left JJ o
ventricular NN o
( ( o
LV NNP o
) ) o
systolic JJ o
function NN o
but CC N
impaired JJ o
diastolic JJ o
function NN o
as IN N
assessed VBN N
with IN N
conventional JJ N
echocardiographic JJ N
parameters NNS N
. . N

Importantly RB N
, , N
2D-STE JJ N
analysis NN N
demonstrated VBD N
the DT N
presence NN N
of IN N
subclinical JJ o
LV NNP o
systolic NN o
and CC o
diastolic JJ o
dysfunction NN o
with IN N
impaired JJ o
circumferential NN o
and CC o
longitudinal JJ o
strain NN o
and CC o
strain NN o
rate NN o
at IN N
the DT N
isovolumic JJ N
relaxation NN N
time NN N
. . N

After IN N
restoration NN N
of IN N
euthyroidism NN N
, , N
a DT N
significant JJ N
improvement NN o
in IN o
LV NNP o
systolic NN o
and CC o
diastolic JJ o
function NN o
as IN N
assessed VBN N
with IN N
2D-STE JJ N
strain NN N
was VBD N
observed VBN N
. . N

CONCLUSION NNP N
Prolonged NNP i
subclinical JJ i
hyperthyroidism NN i
leads VBZ N
to TO N
systolic VB o
and CC o
diastolic JJ o
dysfunction NN o
, , N
which WDT N
is VBZ N
reversible JJ N
after IN N
restoration NN N
of IN N
euthyroidism NN N
. . N

2D-STE JJ N
is VBZ N
a DT N
more RBR N
sensitive JJ N
technique NN N
to TO N
evaluate VB N
subtle JJ N
changes NNS N
in IN N
LV NNP N
performance NN N
of IN N
these DT N
patients NNS N
. . N

-DOCSTART- -22039290- O O

Armodafinil NNP i
and CC i
modafinil NN i
in IN N
patients NNS p
with IN p
excessive JJ p
sleepiness NN p
associated VBN p
with IN p
shift NN p
work NN p
disorder NN p
: : p
a DT N
pharmacokinetic/pharmacodynamic JJ o
model NN N
for IN N
predicting VBG N
and CC N
comparing VBG N
their PRP$ N
concentration-effect JJ N
relationships NNS N
. . N

Armodafinil NNP i
, , N
the DT N
longer JJR N
lasting JJ N
R-isomer NNP N
of IN N
racemic JJ N
modafinil NN N
, , N
improves VBZ N
wakefulness NN o
in IN N
patients NNS p
with IN p
excessive JJ o
sleepiness NN o
associated VBN p
with IN p
shift NN o
work NN o
disorder NN o
( ( o
SWD NNP o
) ) o
. . p

Pharmacokinetic JJ N
studies NNS N
suggest VBP N
that IN N
armodafinil NN i
achieves VBZ N
higher JJR N
plasma NN o
concentrations NNS o
than IN N
modafinil NN N
late JJ N
in IN N
a DT N
dose JJ N
interval NN N
following VBG N
equal JJ N
oral JJ N
doses NNS N
. . N

Pooled VBN o
Multiple JJ o
Sleep NNP o
Latency NNP o
Test NNP o
( ( o
MSLT NNP o
) ) o
data NN N
from IN N
2 CD N
randomized NNS p
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
trials NNS N
in IN N
463 CD p
patients NNS p
with IN p
SWD NNP p
, , p
1 CD p
with IN p
armodafinil JJ i
150 CD i
mg/d NN i
and CC p
1 CD i
with IN i
modafinil NN i
200 CD i
mg/d NN i
( ( p
both DT p
administered VBN p
around IN p
2200 CD p
h NN p
before IN p
night NN p
shifts NNS p
) ) p
, , N
were VBD N
used VBN N
to TO N
build VB N
a DT N
pharmacokinetic/pharmacodynamic JJ o
model NN N
. . N

Predicted VBN N
plasma JJ o
drug NN o
concentrations NNS o
were VBD N
obtained VBN N
by IN N
developing VBG N
and CC N
applying VBG N
a DT N
population NN N
pharmacokinetic JJ o
model NN o
using VBG N
nonlinear JJ o
mixed-effects NNS o
modeling VBG o
. . o

Armodafinil $ N
200 CD N
mg NN N
produced VBD N
a DT N
plasma JJ o
concentration NN o
above IN N
the DT N
EC NNP N
( ( N
50 CD N
) ) N
( ( N
4.6 CD N
?g/mL NN N
) ) N
for IN N
9 CD N
hours NNS N
, , N
whereas NNS N
modafinil VBP N
200 CD N
mg NN N
did VBD N
not RB N
exceed VB N
the DT N
EC NNP N
( ( N
50 CD N
) ) N
. . N

Consequently RB N
, , N
armodafinil NN o
produced VBD N
greater JJR N
increases NNS N
in IN N
predicted JJ N
placebo-subtracted JJ o
MSLT NNP o
times NNS o
of IN N
0.5-1 JJ N
minute NN N
( ( N
up IN N
to TO N
10 CD N
hours NNS N
after IN N
dosing VBG N
) ) N
compared VBN N
with IN N
modafinil NN N
. . N

On IN N
a DT N
milligram-to-milligram JJ N
basis NN N
, , N
armodafinil RB N
200 CD N
mg NNS N
consistently RB o
increased VBD o
wakefulness RB o
more RBR N
than IN N
modafinil RB N
200 CD N
mg NNS N
, , N
including VBG N
times NNS N
late RB N
in IN N
the DT N
8-hour JJ N
shift NN N
. . N

-DOCSTART- -10986219- O O

Effect NN N
of IN N
L-ornithine-L-aspartate NNP i
on IN N
patients NNS p
with IN p
and CC p
without IN p
TIPS NNP p
undergoing VBG p
glutamine JJ p
challenge NN p
: : p
a DT N
double JJ N
blind NN N
, , N
placebo NN N
controlled VBD N
trial NN N
. . N

BACKGROUND NNP N
AND NNP N
AIM NNP N
An DT N
oral JJ N
glutamine NN N
load NN N
in IN N
cirrhotic JJ p
patients NNS p
awaiting VBG p
liver JJ p
transplantation NN p
was VBD N
shown VBN N
to TO N
cause VB N
a DT N
rise NN N
in IN N
blood NN o
ammonia NN o
and CC o
psychometric NN o
abnormalities NNS o
which WDT N
were VBD N
reversed VBN N
by IN N
hepatic JJ N
transplantation NN N
. . N

L-Ornithine-L-aspartate NNP i
( ( i
LOLA NNP i
) ) i
has VBZ N
been VBN N
shown VBN N
to TO N
reduce VB N
ammonia NN o
and CC o
improve VB o
psychometric JJ o
function NN o
in IN N
patients NNS p
with IN p
hepatic JJ p
encephalopathy NN p
. . p

The DT N
aim NN N
of IN N
the DT N
present JJ N
study NN N
was VBD N
to TO N
assess VB N
the DT N
effect NN N
of IN N
LOLA NNP i
in IN N
healthy JJ p
patients NNS p
with IN p
cirrhosis NN p
and CC p
no DT p
evidence NN p
of IN p
clinical JJ p
encephalopathy NN p
after IN N
challenging VBG N
the DT N
central JJ N
nervous JJ N
system NN N
by IN N
administration NN N
of IN N
oral JJ N
glutamine NN N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
Eight NNP p
cirrhotics NNS p
( ( p
Child NNP p
's POS p
B NNP p
or CC p
C NNP p
) ) p
without IN p
transjugular JJ p
intrahepatic JJ p
portosystemic JJ p
shunts NNS p
( ( p
TIPS NNP p
) ) p
and CC p
seven CD p
with IN p
TIPS NNP p
underwent JJ N
two CD N
oral JJ i
glutamine NN i
( ( i
20 CD i
g NN i
) ) i
challenges VBZ i
, , i
receiving VBG i
LOLA NNP i
( ( i
5 CD i
g RB i
intravenously RB i
) ) i
on IN N
one CD N
occasion NN N
and CC N
placebo NN i
on IN N
the DT N
other JJ N
in IN N
random JJ N
order NN N
. . N

Psychometric JJ N
tests NNS N
, , N
including VBG N
choice NN N
reaction NN N
time NN N
( ( N
CRT NNP N
) ) N
and CC N
number NN N
connection NN N
test NN N
, , N
were VBD N
performed VBN N
before IN N
and CC N
after IN N
glutamine NN N
, , N
together RB N
with IN N
electroencephalography NN N
and CC N
blood NN N
ammonia NN N
. . N

RESULTS NNP N
Mean NNP o
basal NN o
ammonia NN o
was VBD N
27 CD N
( ( N
SEM NNP N
5 CD N
) ) N
micromol/l NN N
in IN N
non-TIPS JJ N
and CC N
76 CD N
( ( N
10 CD N
) ) N
micromol/l NN N
in IN N
TIPS NNP N
patients NNS N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

Basal NNP o
CRT NNP o
2 CD o
was VBD N
0.643 CD N
( ( N
0.033 CD N
) ) N
s NN N
in IN N
non-TIPS JJ N
and CC N
0.825 CD N
( ( N
0.076 CD N
) ) N
s NN N
in IN N
TIPS NNP N
patients NNS N
( ( N
p JJ N
< NNP N
0.02 CD N
) ) N
. . N

In IN N
non-TIPS JJ N
patients NNS N
, , N
ammonia NNS o
increased VBD N
to TO N
36 CD N
( ( N
10 CD N
) ) N
micromol/l NN N
when WRB N
LOLA NNP i
was VBD N
administered VBN N
and CC N
to TO N
62 CD N
( ( N
13 CD N
) ) N
micromol/l NN N
with IN N
placebo NN N
( ( N
p JJ N
< NNP N
0.02 CD N
) ) N
. . N

There EX N
was VBD N
no DT N
alteration NN N
in IN N
psychometric JJ o
function NN o
in IN N
non-TIPS JJ N
patients NNS N
after IN N
glutamine NN N
when WRB N
LOLA NNP i
was VBD N
given VBN N
but CC N
when WRB N
placebo NN i
was VBD N
given VBN N
, , N
glutamine NN N
caused VBN N
prolongation NN N
of IN N
CRT NNP o
( ( N
p=0.02 NN N
) ) N
. . N

Glutamine NNP N
did VBD N
not RB N
affect VB N
psychometric JJ o
function NN o
in IN N
TIPS NNP N
patients NNS N
with IN N
or CC N
without IN N
LOLA NNP N
. . N

CONCLUSION NNP N
This DT N
study NN N
showed VBD N
that IN N
LOLA NNP i
ameliorated VBD N
the DT N
deleterious JJ N
psychometric JJ o
effects NNS o
of IN N
glutamine NN N
in IN N
Child NNP N
's POS N
grade NN N
B NNP N
and CC N
C NNP N
patients NNS p
with IN p
cirrhosis NN p
without IN p
TIPS NNP p
and CC N
supports VBZ N
its PRP$ N
use NN N
in IN N
clinical JJ N
practice NN N
in IN N
hepatic JJ N
encephalopathy NN N
. . N

-DOCSTART- -9672054- O O

A DT N
double-blind JJ N
, , N
placebo-controlled JJ N
study NN N
of IN N
risperidone NN i
in IN N
adults NNS p
with IN p
autistic JJ p
disorder NN p
and CC p
other JJ p
pervasive JJ p
developmental NN p
disorders NNS p
. . p

BACKGROUND NNP N
Neurobiological NNP N
research NN N
has VBZ N
implicated VBN N
the DT N
dopamine NN N
and CC N
serotonin JJ N
systems NNS N
in IN N
the DT N
pathogenesis NN N
of IN N
autism NN p
. . p

Open-label JJ N
reports NNS N
suggest VBP N
that IN N
the DT N
serotonin2A-dopamine JJ i
D2 NNP i
antagonist NN i
risperidone NN i
may MD N
be VB N
safe JJ N
and CC N
effective JJ N
in IN N
reducing VBG N
the DT N
interfering NN N
symptoms NNS N
of IN N
patients NNS p
with IN p
autism NN p
. . p

METHODS NNP N
Thirty-one CD p
adults NNS p
( ( p
age NN p
[ VBZ p
mean+/-SD JJ p
] NNP p
, , p
28.1+/-7.3 JJ p
years NNS p
) ) p
with IN p
autistic JJ p
disorder NN p
( ( p
n=17 JJ p
) ) p
or CC p
pervasive JJ p
developmental JJ p
disorder NN p
not RB p
otherwise RB p
specified VBN p
( ( p
n=14 JJ p
) ) p
participated VBD p
in IN p
a DT p
12-week JJ p
double-blind NN p
, , p
placebo-controlled JJ i
trial NN p
of IN p
risperidone NN i
. . i

Patients NNS N
treated VBD N
with IN N
placebo NN N
subsequently RB N
received VBD N
a DT N
12-week JJ N
open-label JJ N
trial NN N
of IN N
risperidone NN i
. . i

RESULTS NNP N
For IN N
persons NNS N
completing VBG N
the DT N
study NN N
, , N
8 CD N
( ( N
57 CD N
% NN N
) ) N
of IN N
14 CD N
patients NNS N
treated VBN N
with IN N
risperidone NN i
were VBD N
categorized VBN N
as IN N
responders NNS N
( ( N
daily JJ N
dose VB N
[ JJ N
mean+/-SD JJ N
] NN N
, , N
2.9+/-1.4 JJ N
mg NN N
) ) N
compared VBN N
with IN N
none NN N
of IN N
16 CD N
in IN N
the DT N
placebo NN i
group NN N
( ( N
P NNP N
< NNP N
.002 NNP N
) ) N
. . N

Risperidone NN i
was VBD N
superior JJ N
to TO N
placebo VB i
in IN N
reducing VBG N
repetitive JJ o
behavior NN o
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
, , N
aggression NN o
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
, , N
anxiety NN o
or CC o
nervousness NN o
( ( o
P NNP o
< NNP o
.02 NNP o
) ) o
, , o
depression NN o
( ( o
P NNP o
< NNP o
.03 NNP o
) ) o
, , o
irritability NN o
( ( o
P NNP o
< NNP o
.01 NNP o
) ) o
, , N
and CC N
the DT N
overall JJ o
behavioral JJ o
symptoms NNS o
of IN o
autism NN o
( ( N
P NNP N
< NNP N
.02 NNP N
) ) N
. . N

Objective NNP N
, , N
measurable JJ N
change NN N
in IN N
social JJ o
behavior NN o
and CC o
language NN o
did VBD N
not RB N
occur VB N
. . N

Nine NNP N
( ( N
60 CD N
% NN N
) ) N
of IN N
15 CD N
patients NNS N
who WP N
received VBD N
treatment NN N
with IN N
open-label JJ N
risperidone NN N
following VBG N
the DT N
double-blind JJ N
placebo NN i
phase NN N
responded VBD N
. . N

Other JJ N
than IN N
mild JJ o
, , o
transient JJ o
sedation NN o
, , N
risperidone NN N
was VBD N
well RB N
tolerated VBN o
, , N
with IN N
no DT N
evidence NN N
of IN N
extrapyramidal JJ o
effects NNS o
, , o
cardiac JJ o
events NNS o
, , o
or CC o
seizures NNS o
. . o

CONCLUSION NNP N
Risperidone NNP i
is VBZ N
more RBR N
effective JJ N
than IN N
placebo NN i
in IN N
the DT N
short-term JJ N
treatment NN N
of IN N
symptoms NNS N
of IN N
autism NN p
in IN p
adults NNS p
. . p

-DOCSTART- -23959380- O O

Infant NNP N
distress NN N
and CC N
development NN N
of IN N
functional JJ N
gastrointestinal JJ N
disorders NNS N
in IN N
childhood NN N
: : N
is VBZ N
there EX N
a DT N
connection NN N
? . N
-DOCSTART- -23815478- O O

Perceptual JJ o
learning NN o
of IN o
speech NN o
under IN N
optimal JJ N
and CC N
adverse JJ N
conditions NNS N
. . N

Humans NNS p
have VBP N
a DT N
remarkable JJ N
ability NN N
to TO N
understand VB N
spoken JJ N
language NN N
despite IN N
the DT N
large JJ N
amount NN N
of IN N
variability NN N
in IN N
speech NN N
. . N

Previous JJ N
research NN N
has VBZ N
shown VBN N
that IN N
listeners NNS N
can MD N
use VB N
lexical JJ i
information NN i
to TO N
guide VB N
their PRP$ N
interpretation NN N
of IN N
atypical JJ N
sounds NNS N
in IN N
speech NN N
( ( N
Norris NNP N
, , N
McQueen NNP N
, , N
& CC N
Cutler NNP N
, , N
2003 CD N
) ) N
. . N

This DT N
kind NN N
of IN N
lexically RB i
induced VBN i
perceptual JJ o
learning NN o
enables NNS N
people NNS p
to TO N
adjust VB N
to TO N
the DT N
variations NNS N
in IN N
utterances NNS N
due JJ N
to TO N
talker-specific JJ N
characteristics NNS N
, , N
such JJ N
as IN N
individual JJ N
identity NN N
and CC N
dialect NN N
. . N

The DT N
current JJ N
study NN N
investigated VBD N
perceptual JJ o
learning NN o
in IN N
two CD N
optimal JJ N
conditions NNS N
: : N
conversational JJ i
speech NN i
( ( i
Experiment NNP i
1 CD N
) ) N
versus NN N
clear JJ i
speech NN i
( ( N
Experiment NNP N
2 CD N
) ) N
, , N
and CC N
three CD N
adverse JJ N
conditions NNS N
: : N
noise NN i
( ( N
Experiment NNP N
3a CD N
) ) N
versus NN N
two CD i
cognitive JJ i
loads NNS i
( ( N
Experiments NNS N
4a CD N
and CC N
4b CD N
) ) N
. . N

Perceptual JJ o
learning NN o
occurred VBD N
in IN N
the DT N
two CD N
optimal JJ i
conditions NNS i
and CC N
in IN N
the DT N
two CD N
cognitive JJ i
load NN i
conditions NNS i
, , N
but CC N
not RB N
in IN N
the DT N
noise NN i
condition NN i
. . i

Furthermore NNP N
, , N
perceptual JJ o
learning NN o
occurred VBD N
only RB N
in IN N
the DT N
first JJ N
of IN N
two CD N
sessions NNS N
for IN N
each DT N
participant NN N
, , N
and CC N
only RB N
for IN N
atypical JJ N
/s/ NNP N
sounds NNS N
and CC N
not RB N
for IN N
atypical JJ N
/f/ NNP N
sounds VBZ N
. . N

This DT N
pattern NN N
of IN N
learning NN N
and CC N
nonlearning NN N
reflects VBZ N
a DT N
balance NN N
between IN N
flexibility NN N
and CC N
stability NN N
that IN N
the DT N
speech NN N
system NN N
must MD N
have VB N
to TO N
deal VB N
with IN N
speech NN N
variability NN N
in IN N
the DT N
diverse JJ N
conditions NNS N
that IN N
speech NN N
is VBZ N
encountered VBN N
. . N

-DOCSTART- -17700649- O O

Should MD N
snacks NNS i
be VB N
recommended VBN N
in IN N
obesity NN p
treatment NN p
? . N
A DT N
1-year JJ N
randomized JJ N
clinical JJ N
trial NN N
. . N

OBJECTIVE UH N
To TO N
study VB N
the DT N
effect NN N
to TO N
recommend VB N
no DT i
snacks NNS i
vs VBP i
three CD i
snacks NNS i
per IN N
day NN N
on IN N
1-year JJ N
weight JJ N
loss NN N
. . N

The DT N
hypothesis NN N
was VBD N
that IN N
it PRP N
is VBZ N
easier JJR N
to TO N
control VB N
energy NN N
intake NN N
and CC N
lose VB N
weight NN N
if IN N
snacks NNS N
in IN N
between IN N
meals NNS N
are VBP N
omitted VBN N
. . N

SUBJECTS/METHOD NNP N
In IN N
total JJ N
140 CD p
patients NNS p
( ( p
36 CD p
men NNS p
, , p
104 CD p
women NNS p
) ) p
, , p
aged VBN p
18-60 CD p
years NNS p
and CC p
body NN p
mass NN p
index NN p
> VBD p
30 CD p
kg/m NN p
( ( p
2 CD p
) ) p
were VBD p
randomized VBN p
and CC p
93 CD p
patients NNS p
( ( p
27 CD p
men NNS p
, , p
66 CD p
women NNS p
) ) p
completed VBD p
the DT p
study NN p
. . p

A DT N
1-year JJ N
randomized JJ N
intervention NN N
trial NN N
was VBD N
conducted VBN N
with IN N
two CD N
treatment NN N
arms NNS N
with IN N
different JJ N
eating VBG N
frequencies NNS N
; : N
3 CD i
meals/day NN i
( ( i
3M CD i
) ) i
or CC N
3 CD i
meals NNS i
and CC i
3 CD i
snacks/day NN i
( ( N
3+3M CD N
) ) N
. . N

The DT N
patients NNS N
received VBD N
regular JJ N
and CC N
individualized JJ N
counseling NN N
by IN N
dieticians NNS N
. . N

Information NN o
on IN o
eating NN o
patterns NNS o
, , o
dietary JJ o
intake NN o
, , o
weight NN o
and CC o
metabolic JJ o
variables NNS o
was VBD N
collected VBN N
at IN N
baseline NN N
and CC N
after IN N
1 CD N
year NN N
. . N

RESULTS NNP N
Over IN N
1 CD N
year NN N
the DT N
3M CD i
group NN N
reported VBD N
a DT N
decrease NN N
in IN N
the DT N
number NN o
of IN o
snacks NNS o
whereas VBP N
the DT N
3+3M CD i
group NN N
reported VBD N
an DT N
increase NN N
( ( N
-1.1 JJ N
vs NN N
+0.4 NN N
snacks/day NN N
, , N
respectively RB N
, , N
P NNP N
< NNP N
0.0001 CD N
) ) N
. . N

Both DT N
groups NNS N
decreased VBD N
energy NN o
intake NN o
and CC N
E NNP o
% NN o
( ( o
energy NN o
percent NN o
) ) o
fat NN o
and CC N
increased VBD N
E NNP o
% NN o
protein NN o
and CC o
fiber VB o
intake NN o
but CC N
there EX N
was VBD N
no DT N
differences NNS N
between IN N
the DT N
groups NNS N
. . N

Both DT N
groups NNS N
lost VBD o
weight NN o
, , N
but CC N
there EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
weight JJ o
loss NN o
after IN N
1 CD N
year NN N
of IN N
treatment NN N
( ( i
3M CD i
vs RB N
3+3M=-4.1+/-6.1 JJ i
vs NN N
-5.9+/-9.4 NNP N
kg NN N
; : N
P=0.31 NNP N
) ) N
. . N

Changes NNS N
in IN N
metabolic JJ o
variables NNS o
did VBD N
not RB N
differ VB N
between IN N
the DT N
groups NNS N
, , N
except IN N
for IN N
high-density NN o
lipoprotein NN o
that WDT N
increased VBD N
in IN N
the DT N
3M CD i
group NN N
but CC N
not RB N
in IN N
3+3M CD i
group NN N
( ( N
P NNP N
< VBZ N
0.033 CD N
for IN N
group NN N
difference NN N
) ) N
. . N

CONCLUSION NNP N
Recommending VBG N
snacks NNS N
or CC N
not RB N
between IN N
meals NNS N
does VBZ N
not RB N
influence VB N
1-year JJ o
weight NN o
loss NN o
. . o

-DOCSTART- -19644973- O O

Randomized NNP N
clinical JJ N
trial NN N
comparing VBG N
laparoscopic NN i
and CC N
open JJ i
surgery NN i
in IN N
patients NNS p
with IN p
rectal JJ p
cancer NN p
. . p

BACKGROUND IN N
The DT N
laparoscopic NN i
treatment NN i
of IN N
rectal JJ N
cancer NN N
is VBZ N
controversial JJ N
. . N

This DT N
study NN N
compared VBN N
surgical JJ N
outcomes NNS N
after IN N
laparoscopic NN i
and CC N
open JJ N
approaches NNS N
for IN N
mid NN p
and CC p
low JJ p
rectal NN p
cancers NNS p
. . p

METHODS NNP N
Some DT p
204 CD p
patients NNS p
with IN p
mid NNS p
and CC p
low JJ p
rectal NN p
adenocarcinomas NN p
were VBD p
allocated VBN p
randomly RB p
to TO p
open VB i
( ( p
103 CD p
) ) p
or CC i
laparoscopic NN i
( ( i
101 CD i
) ) i
surgery NN i
. . i

The DT N
surgical JJ N
team NN N
was VBD N
the DT N
same JJ N
for IN N
both DT N
procedures NNS N
. . N

Most JJS p
patients NNS p
had VBD p
stage NN p
II NNP p
or CC p
III NNP p
disease NN p
, , N
and CC N
received VBD N
neoadjuvant JJ i
therapy NN i
with IN N
oral JJ i
capecitabine NN i
and CC i
50-54 JJ i
Gy NNP i
external JJ i
beam NN i
radiotherapy NN i
. . i

RESULTS NNP N
Sphincter-preserving JJ i
surgery NN i
was VBD N
performed VBN N
in IN N
78.6 CD N
and CC N
76.2 CD N
per IN N
cent NN N
of IN N
patients NNS N
in IN N
the DT N
open JJ i
and CC N
laparoscopic JJ N
groups NNS N
respectively RB N
. . N

Blood NNP o
loss NN o
was VBD N
significantly RB N
greater JJR N
for IN N
open JJ i
surgery NN i
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
and CC N
operating VBG o
time NN o
was VBD N
significantly RB N
greater JJR N
for IN N
laparoscopic NN i
surgery NN i
( ( N
P NNP N
= NNP N
0.020 CD N
) ) N
, , N
and CC N
return NN N
to TO N
diet VB N
and CC N
hospital VB o
stay NN o
were VBD N
longer JJR N
for IN N
open JJ i
surgery NN i
. . i

Complication NN o
rates NNS o
, , o
and CC o
involvement NN o
of IN o
circumferential JJ o
and CC o
radial JJ o
margins NNS o
were VBD N
similar JJ N
for IN N
both DT N
procedures NNS N
, , N
but CC N
the DT N
number NN N
of IN N
isolated JJ N
lymph NN N
nodes NNS N
was VBD N
greater JJR N
in IN N
the DT N
laparoscopic NN i
group NN N
( ( N
mean JJ N
13.63 CD N
versus NN N
11.57 CD N
; : N
P NNP N
= NNP N
0.026 CD N
) ) N
. . N

There EX N
were VBD N
no DT N
differences NNS N
in IN N
local JJ o
recurrence NN o
, , o
disease-free JJ o
or CC o
overall JJ o
survival NN o
. . o

CONCLUSION NNP N
Laparoscopic NNP i
surgery NN i
for IN N
rectal JJ N
cancer NN N
has VBZ N
a DT N
similar JJ N
complication NN N
rate NN N
to TO N
open VB i
surgery NN i
, , N
with IN N
less JJR N
blood NN o
loss NN o
, , N
rapid JJ N
intestinal JJ o
recovery NN o
, , N
shorter JJR N
hospital NN o
stay NN o
, , N
and CC N
no DT N
compromise NN N
of IN N
oncological JJ o
outcomes NNS o
. . o

-DOCSTART- -17069545- O O

Neuropsychological JJ N
effects NNS N
of IN N
risperidone NN i
in IN N
children NNS p
with IN p
pervasive JJ p
developmental JJ p
disorders NNS p
: : p
a DT N
blinded JJ N
discontinuation NN N
study NN N
. . N

OBJECTIVE NNP N
Little NNP N
is VBZ N
known VBN N
about IN N
the DT N
neuropsychological JJ N
effects NNS N
of IN N
risperidone NN i
in IN N
children NNS p
with IN p
pervasive JJ p
developmental NN p
disorders NNS p
. . p

METHOD NNP N
Twenty-four JJ p
children NNS p
( ( p
aged VBN p
5-17 CD p
years NNS p
) ) p
with IN p
pervasive JJ p
developmental NN p
disorders NNS p
and CC p
co-morbid JJ p
disruptive JJ p
behavior NN p
who WP p
responded VBD p
favorably RB p
to TO p
open-label JJ p
treatment NN p
with IN p
risperidone NN i
as IN p
part NN p
of IN p
a DT p
previously RB p
described VBN p
controlled VBN p
discontinuation NN p
study NN p
completed VBD N
two CD i
different JJ i
computerized JJ i
attention NN i
tasks NNS i
at IN i
baseline NN i
, , i
weeks NNS i
4 CD i
, , i
8 CD i
, , i
and CC i
24 CD i
of IN i
open-label JJ i
treatment NN i
, , i
and CC i
, , i
at IN i
8 CD i
weeks NNS i
after IN i
random JJ i
assignment NN i
to TO i
either DT i
placebo NN i
or CC i
risperidone NN i
. . i

The DT N
primary JJ N
efficacy NN N
measures NNS N
were VBD N
response NN o
latencies NNS o
to TO N
visually RB N
presented VBN N
stimuli JJ N
requiring VBG N
two CD N
different JJ N
types NNS N
of IN N
attention-controlled JJ o
processing NN o
, , o
i.e. FW o
, , N
focused VBD o
and CC o
divided VBD o
attention NN o
. . o

RESULTS VB N
About IN N
half NN N
of IN N
the DT N
clinical JJ N
responders NNS N
did VBD N
not RB N
produce VB N
valid JJ o
performance NN o
measures NNS o
. . o

These DT N
could MD N
be VB N
shown VBN N
to TO N
be VB N
of IN N
younger JJR N
mental JJ N
age NN N
and CC N
less RBR N
adaptive JJ N
as IN N
measured VBN N
by IN N
the DT N
Vineland NNP o
Behavior NNP o
Scales NNP o
. . o

For IN N
the DT N
valid JJ N
task NN N
performers NNS N
divided VBD N
attention NN N
( ( o
serial JJ o
search NN o
in IN o
working VBG o
memory NN o
) ) o
was VBD N
shown VBN N
to TO N
regress VB N
in IN N
the DT N
placebo NN N
group NN N
( ( N
n JJ N
= NNP N
7 CD N
) ) N
, , N
while IN N
in IN N
the DT N
risperidone NN N
group NN N
( ( N
n JJ N
= NNP N
7 CD N
) ) N
there EX N
was VBD N
further JJ N
improvement NN N
. . N

No DT N
such JJ N
group NN N
difference NN N
was VBD N
found VBN N
for IN N
focused JJ N
attention NN N
. . N

CONCLUSIONS VB N
The DT N
study NN N
suggests VBZ N
a DT N
beneficial JJ N
effect NN N
of IN N
risperidone NN i
after IN N
several JJ N
months NNS N
of IN N
treatment NN N
, , N
enhancing VBG N
divided VBN N
attention NN N
in IN N
children NNS p
with IN p
pervasive JJ p
developmental NN p
disorders NNS p
. . p

-DOCSTART- -9327193- O O

An DT N
open JJ N
, , N
parallel JJ N
group NN N
comparison NN N
of IN N
quinapril NN i
and CC i
captopril NN i
, , N
when WRB N
added VBN N
to TO N
diuretic JJ i
therapy NN i
, , N
in IN N
the DT N
treatment NN N
of IN N
elderly JJ p
patients NNS p
with IN p
heart NN p
failure NN p
. . p

This DT N
study NN N
aimed VBD N
to TO N
compare VB N
the DT N
efficacy NN o
, , o
tolerability NN o
and CC o
first-dose JJ o
blood-pressure JJ o
response NN o
of IN N
once-daily JJ N
quinapril NN i
and CC N
twice-daily JJ N
captopril NN i
when WRB N
added VBD N
to TO N
diuretic JJ i
therapy NN i
in IN N
elderly JJ p
patients NNS p
with IN p
heart NN p
failure NN p
. . p

The DT N
study NN N
was VBD N
performed VBN N
at IN p
a DT p
single JJ p
centre NN p
as IN N
an DT N
open JJ N
randomised VBD N
parallel-group NN N
study NN N
, , N
patients NNS p
being VBG p
selected VBN p
for IN p
inclusion NN p
from IN p
the DT p
outpatient JJ p
population NN p
. . p

Following VBG N
a DT N
starting VBG N
dose NN N
of IN N
either CC N
2.5 CD N
mg JJ N
once-daily RB N
quinapril NN i
, , N
or CC N
6.25 CD N
mg JJ N
twice-daily JJ N
captopril NN i
, , N
patients NNS N
were VBD N
reviewed VBN N
at IN N
two-weekly JJ N
intervals NNS N
, , N
and CC N
following VBG N
clinical JJ N
assessment NN N
a DT N
decision NN N
was VBD N
made VBN N
either DT N
to TO N
titrate VB N
up RP N
to TO N
the DT N
next JJ N
medication NN N
stage NN N
or CC N
to TO N
enter VB N
the DT N
patient NN N
into IN N
the DT N
16-week JJ N
maintenance NN N
phase NN N
. . N

Efficacy NN o
was VBD N
assessed VBN o
using VBG N
a DT N
six-minute JJ o
walking NN o
test NN o
, , o
the DT o
New NNP o
York NNP o
Heart NNP o
Association NNP o
( ( o
NYHA NNP o
) ) o
class NN o
, , o
a DT o
functional JJ o
lifescale NN o
( ( o
FLS NNP o
) ) o
questionnaire NN o
and CC o
the DT o
cardiothoracic NN o
ratio NN o
( ( o
CTR NNP o
) ) o
-at NN o
study NN o
entry NN o
and CC o
at IN o
the DT o
end NN o
of IN o
the DT o
maintenance NN o
phase NN o
. . o

Blood NNP o
pressure NN o
was VBD N
measured VBN N
for IN N
5 CD N
h JJ N
post-first-dose JJ N
of IN N
medication NN N
. . N

Sixty-one CD p
patients NNS p
were VBD N
randomised VBN N
to TO N
treatment NN N
: : N
30 CD N
to TO N
quinapril VB i
and CC N
31 CD N
to TO N
captopril VB i
. . i

Following VBG N
withdrawals NNS N
, , N
data NNS N
from IN N
36 CD N
patients NNS N
( ( N
20 CD N
on IN N
quinapril NN i
, , N
16 CD N
on IN N
captopril NN i
) ) i
were VBD N
available JJ N
for IN N
analysis NN N
. . N

The DT N
distance NN o
walked VBD o
during IN o
the DT o
six-minute JJ o
walking NN o
test NN o
improved VBN o
in IN N
both DT N
groups NNS N
; : N
the DT N
difference NN N
between IN N
the DT N
treatment NN N
groups NNS N
was VBD N
not RB N
statistically RB o
significant JJ o
. . o

There EX N
were VBD N
no DT N
significant JJ o
changes NNS o
in IN N
the DT N
FLS NNP o
or CC o
CTR NNP o
. . o

An DT N
analysis NN N
of IN N
change NN N
in IN N
the DT N
NYHA NNP N
status NN N
from IN N
study NN N
entry NN N
to TO N
study VB N
end NN N
showed VBD N
a DT N
statistically RB o
significant JJ o
difference NN o
between IN N
the DT N
two CD N
groups NNS N
( ( N
p JJ N
= NNP N
0.02 CD N
) ) N
in IN N
favour NN N
of IN N
quinapril NN i
. . i

Five CD N
patients NNS N
in IN N
each DT N
group NN N
experienced VBD N
hypotension NN o
during IN N
the DT N
5 CD N
h NN N
following VBG N
the DT N
first JJ N
dose NN N
of IN N
medication NN N
. . N

This DT N
study NN N
has VBZ N
shown VBN N
heart NN N
failure NN N
to TO N
be VB N
as RB N
well RB N
controlled VBN N
by IN N
once-daily JJ N
quinapril NN i
as IN N
by IN N
twice-daily JJ N
captopril NN i
, , N
with IN N
comparable JJ N
effects NNS N
on IN N
first-dose JJ o
blood-pressure JJ o
response NN o
. . o

-DOCSTART- -6522132- O O

Effects NNS N
of IN N
antihypertensive JJ i
drugs NNS N
on IN N
cognitive JJ o
function NN o
in IN N
adolescents NNS p
. . p

The DT N
effects NNS N
of IN N
clonidine NN i
and CC N
hydrochlorothiazide NN i
on IN N
cognitive JJ o
function NN o
were VBD N
studied VBN N
in IN N
hypertensive JJ p
adolescents NNS p
requiring VBG p
pharmacologic JJ p
therapy NN p
for IN p
blood NN p
pressure NN p
control NN p
. . p

Twenty-four JJ p
adolescents NNS p
with IN p
persistent JJ p
blood NN o
pressure NN o
elevation NN p
( ( p
greater JJR p
than IN p
95th CD p
% NN p
) ) p
on IN p
placebo NN i
were VBD N
randomized VBN N
double JJ N
blind NN N
to TO N
clonidine VB i
or CC i
hydrochlorothiazide VB i
treatment NN N
. . N

A DT N
battery NN N
of IN N
cognitive JJ o
tests NNS o
were VBD N
performed VBN N
during IN N
the DT N
placebo NN N
phase NN N
and CC N
after IN N
16 CD N
weeks NNS N
of IN N
active JJ N
therapy NN N
. . N

Antihypertensive JJ i
therapy NN i
resulted VBD N
in IN N
significant JJ N
blood NN o
pressure NN o
reduction NN o
( ( N
p NN N
less JJR N
than IN N
.01 NN N
) ) N
. . N

A DT N
slight JJ N
interactive JJ N
effect NN N
was VBD N
observed VBN N
in IN N
arithmetic JJ o
performance NN o
( ( N
p NN N
less JJR N
than IN N
.05 NN N
) ) N
. . N

All DT N
other JJ N
parameters NNS N
of IN N
cognitive JJ o
function NN o
were VBD N
not RB N
affected VBN N
by IN N
either DT N
treatment NN N
. . N

-DOCSTART- -17244100- O O

Can MD N
patient VB i
coaching VBG i
reduce VB N
racial/ethnic JJ N
disparities NNS N
in IN N
cancer NN N
pain NN N
control NN N
? . N
Secondary JJ N
analysis NN N
of IN N
a DT N
randomized VBN N
controlled VBN N
trial NN N
. . N

PURPOSE NNP N
Minority NNP p
patients NNS p
with IN p
cancer NN p
experience NN N
worse JJR N
control NN N
of IN N
their PRP$ N
pain NN N
than IN N
do VBP N
their PRP$ N
white JJ N
counterparts NNS N
. . N

This DT N
disparity NN N
may MD N
, , N
in IN N
part NN N
, , N
reflect VBP N
more JJR N
miscommunication NN N
between IN N
minority NN p
patients NNS p
and CC N
their PRP$ N
physicians NNS N
. . N

Therefore RB N
, , N
we PRP N
examined VBD N
whether IN N
patient NN i
coaching NN i
could MD N
reduce VB N
disparities NNS o
in IN o
pain NN o
control NN o
in IN N
a DT N
secondary JJ N
analysis NN N
of IN N
a DT N
randomized VBN N
controlled VBN N
trial NN N
. . N

METHODS NNP N
Sixty-seven JJ p
English-speaking NNP p
adult NN p
cancer NN p
outpatients NNS p
, , p
including VBG p
15 CD p
minorities NNS p
, , p
with IN p
moderate JJ p
pain NN p
over IN p
the DT p
prior JJ p
2 CD p
weeks NNS p
were VBD N
randomly RB N
assigned VBN N
to TO N
the DT N
experimental NN N
( ( N
N NNP N
= NNP N
34 CD N
) ) N
or CC N
control VB N
group NN N
( ( N
N NNP N
= NNP N
33 CD N
) ) N
. . N

Experimental JJ N
patients NNS N
received VBD N
a DT N
20-minute JJ i
individualized JJ i
education NN i
and CC i
coaching VBG i
session NN i
to TO i
increase VB i
knowledge NN i
of IN i
pain NN i
self-management JJ i
, , i
to TO i
redress VB i
personal JJ i
misconceptions NNS i
about IN i
pain NN i
treatment NN i
, , i
and CC i
to TO i
rehearse VB i
an DT i
individually RB i
scripted VBN i
patient-physician JJ i
dialog NN i
about IN i
pain NN o
control NN o
. . o

The DT N
control NN N
group NN N
received VBD i
standardized JJ i
information NN i
on IN i
controlling VBG i
pain NN i
. . i

Data NNP N
on IN N
average NN o
pain NN o
( ( N
0-10 JJ N
scale NN N
) ) N
were VBD N
collected VBN N
at IN N
enrollment NN N
and CC N
2-week JJ N
follow-up NN N
. . N

RESULTS NNP N
At IN N
enrollment NN N
, , N
minority NN p
patients NNS p
had VBD N
significantly RB N
more RBR N
pain NN o
than IN N
their PRP$ N
white JJ N
counterparts NNS N
( ( N
6.0 CD N
vs NN N
5.0 CD N
, , N
P NNP N
= NNP N
0.05 CD N
) ) N
. . N

At IN N
follow-up JJ N
, , N
minorities NNS N
in IN N
the DT N
control NN N
group NN N
continued VBD N
to TO N
have VB N
more JJR N
pain NN o
( ( N
6.4 CD N
vs NN N
4.7 CD N
, , N
P NNP N
= NNP N
0.01 CD N
) ) N
, , N
whereas RB N
in IN N
the DT N
experimental JJ N
group NN N
, , N
disparities NNS N
were VBD N
eliminated VBN N
( ( N
4.0 CD N
vs NN N
4.3 CD N
, , N
P NNP N
= NNP N
0.71 CD N
) ) N
. . N

The DT N
effect NN N
of IN N
the DT N
intervention NN N
on IN N
reducing VBG N
disparities NNS N
was VBD N
significant JJ N
( ( N
P NNP N
= NNP N
0.04 CD N
) ) N
. . N

CONCLUSIONS NNP N
Patient NNP i
coaching VBG i
offers NNS N
promise RB N
as IN N
a DT N
means NN N
of IN N
reducing VBG N
racial/ethnic JJ o
disparities NNS o
in IN o
pain NN o
control NN o
. . o

Larger NNP N
studies NNS N
are VBP N
needed VBN N
to TO N
validate VB N
these DT N
findings NNS N
and CC N
to TO N
explore VB N
possible JJ N
mechanisms NNS N
. . N

-DOCSTART- -7211918- O O

Heparin NNP i
therapy NN i
in IN N
venous JJ p
thromboembolism NN p
. . p

Patients NNS p
with IN p
pulmonary JJ p
embolism NN p
or CC p
deep JJ p
venous JJ p
thrombosis NN p
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
either DT N
intermittent NN i
or CC i
continuous JJ i
intravenous JJ i
heparin NN i
therapy NN i
. . i

In IN N
patients NNS p
with IN p
an DT p
enhanced JJ p
risk NN p
of IN p
bleeding NN o
, , N
major JJ N
bleeding NN N
was VBD N
significantly RB N
more JJR N
common JJ N
during IN N
the DT N
intermittent NN N
use NN N
of IN N
heparin NN N
; : N
in IN N
patients NNS p
without IN p
these DT p
risk NN p
factors NNS p
, , N
hemorrhage NN o
occurred VBD N
with IN N
equal JJ N
frequency NN N
during IN N
intermittent NN N
and CC N
continuous JJ i
heparin NN i
therapy NN i
. . i

Recurrent JJ o
thromboembolism NN o
was VBD N
seen VBN N
significantly RB N
more RBR N
often RB N
in IN N
patients NNS p
receiving VBG p
continuous JJ p
heparin NN p
therapy NN p
. . p

Controlling VBG N
the DT N
dose NN N
of IN N
heparin NN N
with IN N
coagulation NN N
tests NNS N
resulted VBD N
in IN N
the DT N
administration NN N
of IN N
significantly RB N
larger JJR N
daily JJ N
doses NNS N
of IN N
heparin NN N
with IN N
intermittent JJ N
injections NNS N
than IN N
with IN N
continuous JJ N
infusion NN N
. . N

Therefore RB N
, , N
the DT N
bleeding VBG N
complications NNS N
of IN N
intermittent JJ N
heparin NN N
therapy NN N
could MD N
have VB N
been VBN N
due JJ N
to TO N
the DT N
higher JJR N
dose NN N
, , N
and CC N
the DT N
recurrences NNS N
associated VBN N
with IN N
continuous JJ N
heparin NNS N
therapy NN N
may MD N
have VB N
resulted VBN N
from IN N
lower JJR N
doses NNS N
rather RB N
than IN N
from IN N
differences NNS N
in IN N
the DT N
method NN N
of IN N
administration NN N
. . N

In IN N
a DT N
small JJ N
trial NN N
, , N
arbitrary JJ N
lower JJR N
doses NNS N
of IN N
heparin NN N
given VBN N
intermittently RB N
similar JJ N
to TO N
the DT N
doses NNS N
of IN N
heparin NN N
given VBN N
continuously RB N
resulted VBN N
in IN N
fewer JJR N
bleeding NN o
complications NNS o
and CC N
more JJR N
recurrences NNS o
. . o

In IN N
patients NNS p
without IN p
risk NN p
factors NNS p
for IN p
bleeding NN p
, , N
the DT N
intermittent JJ N
administration NN i
of IN i
heparin NN i
in IN N
the DT N
higher JJR N
dose NN N
is VBZ N
preferable JJ N
because IN N
of IN N
fewer JJR N
recurrences NNS N
and CC N
no DT N
increase NN N
in IN N
hemorrhagic JJ o
complications NNS o
. . o

In IN N
patients NNS p
with IN p
a DT p
high JJ p
risk NN p
of IN p
bleeding NN p
, , N
conventional JJ i
doses NNS i
of IN i
heparin NN i
given VBN N
continuously RB N
can MD N
reduce VB N
the DT N
rate NN o
of IN o
hemorrhagic JJ o
complications NNS o
but CC N
will MD N
result VB N
in IN N
more JJR N
recurrences NNS N
. . N

-DOCSTART- -14616133- O O

Mometasone NNP i
furoate NN i
nasal NN i
spray NN i
improves VBZ N
olfactory JJ o
performance NN o
in IN o
seasonal JJ o
allergic JJ o
rhinitis NN o
. . o

-DOCSTART- -10414756- O O

Moderate-intensity NNP i
exercise NN i
training NN i
with IN N
elements NNS N
of IN N
step NN N
aerobics NNS N
in IN N
patients NNS p
with IN p
severe JJ p
chronic JJ p
heart NN p
failure NN p
. . p

OBJECTIVE NN N
To TO N
evaluate VB N
whether IN N
a DT N
specific JJ N
program NN N
of IN N
moderate-intensity JJ i
step NN i
aerobics NNS i
training NN i
may MD N
be VB N
sufficient JJ N
to TO N
improve VB N
the DT N
exercise NN N
tolerance NN N
of IN N
patients NNS p
with IN p
severe JJ p
chronic JJ p
heart NN p
failure NN p
. . p

PATIENTS VB N
Twenty-six JJ p
patients NNS p
( ( p
22 CD p
men NNS p
, , p
4 CD p
women NNS p
; : p
mean VB p
+/- JJ p
SD NNP p
age NN p
, , p
54 CD p
+/- JJ p
9yrs CD p
) ) p
with IN p
a DT p
history NN p
of IN p
severe JJ p
chronic JJ p
heart NN p
failure NN p
( ( p
left JJ p
ventricular JJ p
ejection NN p
fraction NN p
of IN p
18 CD p
% NN p
+/- JJ p
8 CD p
% NN p
) ) p
. . p

STUDY NNP N
DESIGN NNP N
Prospective NNP N
, , N
randomized VBD N
, , N
controlled VBD N
trial NN N
. . N

Patients NNS N
were VBD N
randomized VBN N
into IN N
exercise NN N
and CC N
control NN N
groups NNS N
. . N

All DT N
patients NNS N
underwent VBD N
a DT N
clinical JJ N
examination NN N
and CC N
a DT N
ramp NN N
pattern JJ N
cycle NN N
exercise NN N
test NN N
before IN N
and CC N
after IN N
the DT N
observation NN N
period NN N
. . N

The DT N
exercise NN N
group NN N
underwent VBD N
a DT N
moderate-intensity NN i
( ( i
50 CD i
% NN i
of IN i
peak NN i
oxygen NN i
uptake NN i
) ) i
12-week JJ i
training NN i
program NN i
, , i
progressing VBG i
to TO i
100 CD i
minutes NNS i
per IN i
week NN i
of IN i
step NN i
aerobics NNS i
and CC i
50 CD i
minutes NNS i
per IN i
week NN i
of IN i
cycling NN i
. . i

The DT N
control NN N
group NN N
did VBD N
not RB N
perform VB i
a DT i
training NN i
program NN i
. . i

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Peak NNP o
oxygen NN o
uptake NN o
, , o
peak JJ o
workload NN o
, , o
percent NN o
of IN o
predicted JJ o
power NN o
ability NN o
. . o

RESULTS NNP N
Significant JJ N
increases NNS N
in IN N
peak NN o
oxygen NN o
uptake NN o
( ( N
15 CD N
+/- JJ N
3.4 CD N
to TO N
18.5 CD N
+/- JJ N
2.9mL/kg/min CD N
; : N
p NN N
= NNP N
.001 NNP N
) ) N
, , N
peak JJ o
workload NN o
( ( N
77 CD N
+/- JJ N
26 CD N
to TO N
99 CD N
+/- JJ N
31 CD N
watts NN N
; : N
p CC N
= NNP N
.000 NNP N
) ) N
, , N
and CC N
percent NN o
of IN o
predicted JJ o
power NN o
ability NN o
( ( N
43 CD N
% NN N
+/- JJ N
10 CD N
% NN N
to TO N
56 CD N
% NN N
+/- JJ N
13 CD N
% NN N
; : N
p CC N
= NNP N
.000 NNP N
) ) N
were VBD N
observed VBN N
in IN N
the DT N
exercise NN N
group NN N
. . N

No DT N
significant JJ N
changes NNS o
in IN N
baseline NN N
parameters NNS N
occurred VBD N
in IN N
the DT N
control NN N
group NN N
. . N

There EX N
were VBD N
no DT N
critical JJ N
changes NNS N
in IN N
heart NN o
rate NN o
or CC o
blood NN o
pressure NN o
in IN N
either DT N
group NN N
. . N

CONCLUSION NNP N
Moderate-intensity NNP N
step NN N
aerobics NNS N
training VBG N
significantly RB N
increases VBZ N
peak JJ o
oxygen NN o
uptake NN o
and CC N
peak JJ o
workloads NNS o
in IN N
patients NNS p
with IN p
severe JJ p
chronic JJ p
heart NN p
failure NN p
. . p

-DOCSTART- -19996335- O O

The DT N
6 CD N
minute NN N
walk NN N
in IN N
idiopathic JJ N
pulmonary JJ N
fibrosis NN N
: : N
longitudinal JJ N
changes NNS N
and CC N
minimum JJ N
important JJ N
difference NN N
. . N

RATIONALE VB N
The DT N
response NN N
characteristics NNS N
of IN N
the DT N
6 CD i
minute NN i
walk NN i
test NN i
( ( i
6MWT CD i
) ) i
in IN N
studies NNS N
of IN N
idiopathic JJ p
pulmonary JJ p
fibrosis NN p
( ( p
IPF NNP p
) ) p
are VBP N
only RB N
poorly RB N
understood JJ N
, , N
and CC N
the DT N
change NN N
in IN N
walk NN N
distance NN N
that WDT N
constitutes VBZ N
the DT N
minimum JJ N
important JJ N
difference NN N
( ( N
MID NNP N
) ) N
over IN N
time NN N
is VBZ N
unknown JJ N
. . N

OBJECTIVES NNP N
To TO N
examine VB N
changes NNS N
over IN N
time NN o
in IN o
distance NN o
walked VBD o
( ( N
ie NN N
, , N
6MWD CD N
) ) N
during IN N
the DT N
6MWT CD i
and CC N
to TO N
estimate VB N
the DT N
change NN N
in IN N
distance NN N
that WDT N
constitutes VBZ N
the DT N
MID NNP N
in IN N
patients NNS p
with IN p
IPF NNP p
. . p

METHODS NNP N
Data NNP N
from IN N
a DT N
recently RB N
completed VBN N
trial NN N
that WDT N
included VBD N
subjects NNS p
with IN p
IPF NNP p
who WP p
completed VBD p
the DT p
6MWT CD i
, , p
Saint NNP p
George NNP p
's POS p
Respiratory NNP p
Questionnaire NNP p
( ( p
SGRQ NNP p
) ) p
and CC p
forced VBN p
vital JJ p
capacity NN p
( ( p
FVC NNP p
) ) p
at IN N
6 CD N
and CC N
12 CD N
months NNS N
were VBD N
used VBN N
to TO N
examine VB N
longitudinal JJ N
changes NNS N
in IN N
6MWD CD N
. . N

Both DT N
anchor- JJ N
and CC N
distribution-based JJ N
approaches NNS N
as RB N
well RB N
as IN N
linear JJ N
regression NN N
analyses NNS N
were VBD N
used VBN N
to TO N
determine VB N
the DT N
MID NNP N
for IN N
6MWD CD N
. . N

The DT N
SGRQ NNP o
Total NNP o
score NN o
and CC o
FVC NNP o
were VBD N
used VBN N
as IN N
clinical JJ N
anchors NNS N
. . N

MAIN NNP N
RESULTS NNP N
Among IN N
123 CD p
subjects NNS p
alive JJ p
and CC p
able JJ p
to TO p
complete VB p
the DT p
6MWT CD p
at IN p
both DT p
follow-up JJ p
time NN p
points NNS p
, , N
6MWD CD o
did VBD N
not RB N
change VB N
significantly RB N
over IN N
time NN N
( ( N
378.1 CD N
m NN N
at IN N
baseline NN N
vs NN N
376.8 CD N
m NN N
at IN N
6 CD N
months NNS N
vs RB N
361.3 CD N
m NN N
at IN N
12 CD N
months NNS N
, , N
p=0.5 NN N
) ) N
. . N

The DT N
point NN N
estimate NN N
for IN N
the DT N
6MWD CD o
MID NNP o
was VBD N
28 CD N
m NN N
with IN N
a DT N
range NN N
of IN N
10.8-58.5 JJ N
m. JJ N
CONCLUSION NNP N
In IN N
a DT N
group NN N
of IN N
patients NNS p
with IN p
IPF NNP p
with IN p
moderate JJ p
physiological JJ p
impairment NN p
, , N
for IN N
those DT N
alive JJ N
and CC N
able JJ N
to TO N
complete VB N
a DT N
6MWT CD N
, , N
6MWD CD o
does VBZ N
not RB N
change VB N
over IN N
12 CD N
months NNS N
. . N

At IN N
the DT N
population NN N
level NN N
, , N
the DT N
MID NNP N
for IN N
6MWD CD o
appears VBZ N
to TO N
be VB N
approximately RB N
28 CD N
m. NNS N
Further NNP N
investigation NN N
using VBG N
other JJ N
anchors NNS N
and CC N
derivation NN N
methods NNS N
is VBZ N
required VBN N
to TO N
refine VB N
estimates NNS N
of IN N
the DT N
MID NNP N
for IN N
6MWD CD N
in IN N
this DT N
patient JJ p
population NN p
. . p

-DOCSTART- -2699786- O O

[ JJ i
Cannulation NNP i
of IN i
the DT i
internal JJ i
jugular NN i
vein NN i
using VBG i
2 CD i
ultrasonic JJ i
technics NNS i
. . i

A DT N
comparative NN N
controlled VBN N
study NN N
] NN N
. . N

The DT N
internal JJ N
jugular NN N
vein NN N
( ( N
IJV NNP N
) ) N
is VBZ N
a DT N
common JJ N
access NN N
route NN N
to TO N
the DT N
central JJ N
venous JJ N
system NN N
. . N

Anatomical JJ N
landmarks NNS N
( ( N
group NN N
I PRP N
) ) N
are VBP N
normally RB N
used VBN N
for IN N
localization NN N
of IN N
the DT N
IJV NNP N
. . N

We PRP N
have VBP N
compared VBN N
this DT N
method NN N
with IN N
two CD N
other JJ N
methods NNS N
based VBN N
on IN N
ultrasonic JJ N
waves NNS N
to TO N
identify VB N
the DT N
IJV NNP N
and CC N
the DT N
carotid NN N
artery NN N
( ( N
CA NNP N
) ) N
( ( N
even RB N
in IN N
atypical JJ N
positions NNS N
) ) N
. . N

We PRP N
employed VBD N
an DT i
ultrasound JJ i
Doppler NNP i
device NN i
in IN i
group NN i
II NNP i
and CC i
a DT i
real-time JJ i
ultrasonograph NN i
in IN i
group NN i
III NNP i
. . i

Central NNP i
venous JJ i
catheters NNS i
were VBD i
placed VBN i
into IN i
the DT i
right JJ i
IJV NNP i
by IN i
the DT i
Seldinger NNP i
technique NN i
. . i

The DT N
IJV NNP o
could MD o
be VB o
located VBN o
in IN N
all DT N
patients NNS N
with IN N
both DT N
ultrasound JJ N
methods NNS N
, , N
but CC N
the DT N
course NN o
of IN o
the DT o
IJV NNP o
could MD N
only RB N
be VB N
identified VBN N
by IN N
ultrasonography NN N
. . N

For IN N
this DT N
reason NN N
, , N
the DT N
direction NN N
of IN N
the DT N
IJV NNP N
was VBD N
classified VBN N
as IN N
typical JJ N
in IN N
80 CD N
% NN N
of IN N
group NN N
I PRP N
, , N
in IN N
85 CD N
% NN N
of IN N
group NN N
II NNP N
, , N
but CC N
in IN N
only RB N
45 CD N
% NN N
of IN N
group NN N
III NNP N
. . N

No NNP N
intergroup NN N
differences NNS N
were VBD N
found VBN N
with IN N
respect NN N
to TO N
the DT N
number NN o
of IN o
punctures NNS o
( ( N
mean JJ N
value NN N
1.6 CD N
+/- JJ N
0.83 CD N
) ) N
and CC N
the DT N
incidence NN o
of IN o
complications NNS o
. . o

The DT N
time NN o
required VBN o
to TO o
locate VB o
the DT o
site NN o
and CC N
direction NN o
of IN o
puncture NN o
increased VBN N
with IN N
technical JJ N
sophistication NN N
. . N

There EX N
was VBD N
, , N
however RB N
, , N
no DT N
difference NN N
in IN N
the DT N
total JJ o
time NN o
for IN o
catheter NN o
placement NN o
, , N
because IN N
puncture NN N
was VBD N
performed VBN N
faster RB N
when WRB N
aided VBN N
by IN N
sonography NN N
. . N

In IN N
four CD N
patients NNS N
in IN N
groups NNS N
I PRP N
and CC N
II NNP N
, , N
in IN N
whom WP N
attempts NNS N
to TO N
puncture VB N
the DT N
IJV NNP N
had VBD N
not RB N
been VBN N
successful JJ N
, , N
this DT N
could MD N
subsequently RB N
be VB N
achieved VBN N
with IN N
ultrasonographic JJ N
aid NN N
. . N

One CD N
patient NN N
( ( N
group NN N
I PRP N
) ) N
displayed VBD N
a DT N
hematoma NN o
following VBG N
inadvertent JJ N
puncture NN N
of IN N
the DT N
CA NNP N
. . N

In IN N
one CD N
patient NN N
in IN N
group NN N
II NNP N
the DT N
IJV NNP N
and CC N
CA NNP N
could MD N
not RB N
be VB N
distinguished VBN N
as IN N
one CD N
was VBD N
overlying VBG N
the DT N
other JJ N
. . N

The DT N
echocamera NN N
provided VBD N
improved JJ N
localization NN N
of IN N
the DT N
IJV NNP N
and CC N
the DT N
CA NNP N
in IN N
comparison NN N
with IN N
the DT N
Doppler NNP N
ultrasound NN N
. . N

( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
250 CD N
WORDS NNP N
) ) N
-DOCSTART- -16492716- O O

Perceptual JJ o
wind-up NN o
in IN N
the DT N
human JJ p
oesophagus NN p
is VBZ N
enhanced VBN N
by IN N
central JJ N
sensitisation NN N
. . N

BACKGROUND NNP N
Oesophageal NNP N
acid JJ N
infusion NN N
induces NNS N
enhanced VBD N
pain NN N
hypersensitivity NN N
in IN N
non-acid JJ N
exposed JJ N
upper JJ N
oesophagus NN N
( ( N
secondary JJ N
hyperalgesia NN N
) ) N
in IN N
patients NNS N
with IN N
non-cardiac JJ N
chest NN N
pain NN N
, , N
thus RB N
suggesting VBG N
central JJ N
sensitisation NN N
contributes NNS N
to TO N
visceral JJ N
pain NN N
hypersensitivity NN N
in IN N
functional JJ N
gut NN N
disorders NNS N
( ( N
FGD NNP N
) ) N
. . N

Perceptual JJ N
wind-up JJ N
( ( N
increased JJ N
pain NN N
perception NN N
to TO N
constant JJ N
intensity NN N
sensory NN N
stimuli NN N
at IN N
frequencies NNS N
> VBP N
or=0.3 JJ N
Hz NNP N
) ) N
is VBZ N
used VBN N
as IN N
a DT N
proxy NN N
for IN N
central JJ N
sensitisation NN N
to TO N
investigate VB N
pain NN N
syndromes NNS N
where WRB N
pain NN N
hypersensitivity NN N
is VBZ N
important JJ N
( ( N
for IN N
example NN N
, , N
fibromyalgia NN N
) ) N
. . N

AIMS $ N
Wind-up JJ N
in IN N
central JJ N
sensitisation NN N
induced VBD N
human JJ N
visceral JJ N
pain NN N
hypersensitivity NN N
has VBZ N
not RB N
been VBN N
explored VBN N
. . N

We PRP N
hypothesised VBD N
that IN N
if IN N
wind-up NN N
is VBZ N
a DT N
proxy NN N
for IN N
central JJ N
sensitisation NN N
induced VBD N
human JJ N
visceral JJ N
pain NN N
hypersensitivity NN N
, , N
then RB N
oesophageal JJ N
wind-up NN N
should MD N
be VB N
enhanced VBN N
by IN N
secondary JJ N
hyperalgesia NN N
. . N

METHODS NNP N
In IN N
eight CD p
healthy JJ p
volunteers NNS p
( ( p
seven CD p
males NNS p
; : p
mean JJ p
age NN p
32 CD p
years NNS p
) ) p
, , N
perception NN N
at IN N
pain NN N
threshold NN N
to TO N
a DT N
train NN N
of IN N
20 CD N
electrical JJ i
stimuli NNS i
applied VBN N
to TO N
the DT N
hand NN N
and CC N
upper JJ N
oesophagus NN N
( ( N
UO NNP N
) ) N
at IN N
either DT N
0.1 CD i
Hz NNP i
( ( N
control NN N
) ) N
or CC N
2 CD i
Hz NNP i
was VBD N
determined VBN N
before IN N
and CC N
one CD N
hour NN N
after IN N
a DT N
30 CD N
minute NN N
lower JJR N
oesophageal NN N
acid JJ N
infusion NN N
. . N

RESULTS NNP N
Wind-up JJ o
occurred VBD N
only RB N
with IN N
the DT N
2 CD i
Hz NNP i
train NN N
in IN N
the DT N
UO NNP N
and CC N
hand NN N
( ( N
both DT N
p=0.01 NN N
) ) N
. . N

Following VBG N
acid JJ N
infusion NN N
, , N
pain VBP o
threshold JJ o
decreased VBN o
( ( N
17 CD N
( ( N
4 CD N
) ) N
% NN N
; : N
p=0.01 NN N
) ) N
in IN N
the DT N
UO NNP N
, , N
suggesting VBG N
the DT N
presence NN N
of IN N
secondary JJ N
hyperalgesia NN N
. . N

Wind-up UH o
to TO o
the DT o
2 CD o
Hz NNP o
train NN o
increased VBD N
in IN N
the DT N
UO NNP o
( ( N
wind-up JJ N
ratio NN N
1.4 CD N
( ( N
0.1 CD N
) ) N
to TO N
1.6 CD N
( ( N
0.1 CD N
) ) N
; : N
p=0.03 NN N
) ) N
but CC N
not RB N
in IN N
the DT N
hand NN N
( ( N
wind-up JJ N
ratio NN N
1.3 CD N
( ( N
0.1 CD N
) ) N
and CC N
1.3 CD N
( ( N
0.1 CD N
) ) N
; : N
p=0.3 NN N
) ) N
CONCLUSION NNP N
Enhanced NNP N
wind-up NN N
after IN N
secondary JJ N
oesophageal NN N
hyperalgesia NN N
suggests VBZ N
that IN N
visceral JJ N
pain NN N
hypersensitivity NN N
induced VBN N
by IN N
central JJ N
sensitisation NN N
results NNS N
from IN N
increased JJ N
central JJ N
neuronal JJ N
excitability NN N
. . N

Wind-up JJ N
may MD N
offer VB N
new JJ N
opportunities NNS N
to TO N
investigate VB N
the DT N
contribution NN N
of IN N
central JJ N
neuronal JJ N
changes NNS N
to TO N
symptoms NNS N
in IN N
FGD NNP N
. . N

-DOCSTART- -19646778- O O

A DT N
prospective JJ N
randomized VBN N
trial NN N
of IN N
topical JJ N
pimecrolimus NN i
for IN N
cetuximab-associated JJ p
acnelike JJ p
eruption NN p
. . p

BACKGROUND NNP N
Clinical NNP N
trials NNS N
addressing VBG N
the DT N
acneiform NN N
rash NN N
associated VBN N
with IN N
epidermal JJ N
growth NN N
factor NN N
receptor NN N
inhibitors NNS N
are VBP N
lacking VBG N
. . N

OBJECTIVE IN N
We PRP N
evaluated VBD N
the DT N
ability NN N
of IN N
topical JJ N
pimecrolimus NN i
to TO N
reduce VB N
the DT N
severity NN N
of IN N
cetuximab-related JJ p
facial JJ p
rash NN p
. . p

METHODS NNP N
In IN p
all DT p
, , p
24 CD p
patients NNS p
with IN p
metastatic JJ p
colorectal JJ p
cancer NN p
with IN p
cetuximab JJ p
facial JJ p
rash NN p
received VBD N
twice RB N
daily JJ N
pimecrolimus NNS i
application NN N
for IN N
5 CD N
weeks NNS N
to TO N
half NN N
of IN N
the DT N
face NN N
. . N

At IN N
baseline NN N
, , N
week NN N
2 CD N
, , N
and CC N
week NN N
5 CD N
, , N
a DT N
dermatologist NN N
performed VBN N
facial JJ N
lesion NN N
counts NNS N
, , N
patients NNS N
reported VBD N
perceived JJ N
severity NN N
of IN N
rash-related JJ N
symptoms NNS N
, , N
and CC N
standardized VBD N
facial JJ N
photographs NN N
were VBD N
obtained VBN N
for IN N
blinded JJ N
evaluation NN N
of IN N
global JJ N
rash NN N
severity NN N
. . N

RESULTS NNP N
Treatment NNP N
sides NNS N
had VBD N
greater JJR N
decrease NN N
in IN N
lesion NN o
counts NNS o
than IN N
observation NN N
sides NNS N
of IN N
face NN N
at IN N
weeks NNS N
2 CD N
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
and CC N
5 CD N
( ( N
P NNP N
= NNP N
.02 NNP N
) ) N
. . N

However RB N
, , N
there EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
patients NNS N
' POS N
assessment NN N
of IN N
symptoms NNS N
and CC N
in IN N
review NN N
of IN N
facial JJ N
photographs NN N
for IN N
rash NN o
severity NN o
between IN N
treatment NN N
and CC N
observation NN N
sides NNS N
. . N

LIMITATIONS VB N
This DT N
study NN N
was VBD N
not RB N
placebo JJ N
controlled VBN N
. . N

CONCLUSIONS NNP N
Pimecrolimus NNP i
application NN N
did VBD N
not RB N
translate VB N
into IN N
clinically RB N
meaningful JJ N
benefit NN N
for IN N
patients NNS p
with IN p
cetuximab-related JJ p
facial JJ p
rash NN p
. . p

-DOCSTART- -22987897- O O

A DT N
randomised JJ N
group NN N
comparison NN N
controlled VBD N
trial NN N
of IN N
'preschoolers NNS p
with IN p
autism NN p
' '' p
: : p
a DT N
parent NN i
education NN i
and CC i
skills NNS i
training VBG i
intervention NN i
for IN N
young JJ p
children NNS p
with IN p
autistic JJ p
disorder NN p
. . p

AIM NNP N
To TO N
determine VB N
the DT N
effect NN N
of IN N
parent NN i
education NN i
on IN i
adaptive JJ o
behaviour NN o
, , o
autism NN o
symptoms NNS o
and CC o
cognitive/language NN o
skills NNS o
of IN N
young JJ p
children NNS p
with IN p
autistic JJ p
disorder NN p
. . p

METHOD NNP N
A NNP N
randomised VBD N
group NN N
comparison NN N
design NN N
involving VBG N
a DT N
parent NN i
education NN i
and CC i
counselling VBG i
intervention NN i
and CC i
a DT i
parent NN i
education NN i
and CC i
behaviour JJ i
management NN i
intervention NN i
to TO i
control VB i
for IN i
parent NN i
skills NNS i
training NN i
and CC i
a DT i
control NN i
sample NN i
. . i

Two CD p
rural JJ p
and CC p
two CD p
metropolitan JJ p
regions NNS p
were VBD p
randomly RB p
allocated VBN p
to TO p
intervention NN i
groups NNS i
( ( p
n JJ p
= NNP p
70 CD p
) ) p
or CC i
control NN i
( ( p
n JJ p
= NNP p
35 CD p
) ) p
. . p

Parents NNS p
from IN p
autism NN p
assessment NN p
services NNS p
in IN p
the DT p
intervention NN p
regions NNS p
were VBD N
randomly RB N
allocated VBN N
to TO N
parent VB i
education NN i
and CC i
behaviour JJ i
management NN i
( ( N
n JJ N
= NNP N
35 CD N
) ) N
or CC i
parent JJ i
education NN i
and CC i
counselling NN i
( ( N
n JJ N
= NNP N
35 CD N
) ) N
. . N

RESULTS JJ N
Parent JJ N
education NN N
and CC N
behaviour VB N
management NN N
resulted VBD N
in IN N
significant JJ N
improvement NN N
in IN N
adaptive JJ o
behaviour NN o
and CC o
autism NN o
symptoms NNS o
at IN N
6 CD N
months NNS N
follow-up RB N
for IN N
children NNS N
with IN N
greater JJR N
delays NNS N
in IN N
adaptive JJ o
behaviour NN o
. . o

Parent NN N
education NN N
and CC N
behaviour JJ N
management NN N
was VBD N
superior JJ N
to TO N
parent VB N
education NN N
and CC N
counselling NN N
. . N

We PRP N
conclude VBP N
that IN N
a DT N
20-week JJ N
parent NN N
education NN N
programme NN N
including VBG N
skills NNS N
training VBG N
for IN N
parents NNS p
of IN p
young JJ p
children NNS p
with IN p
autistic JJ p
disorder NN p
provides VBZ N
significant JJ N
improvements NNS N
in IN N
child JJ o
adaptive JJ o
behaviour NN o
and CC o
symptoms NNS o
of IN o
autism NN o
for IN N
low-functioning JJ p
children NNS p
. . p

-DOCSTART- -26665290- O O

Clinical JJ N
Study NNP N
to TO N
Assess VB N
the DT N
Stain NNP o
Removal NNP o
Effectiveness NNP o
of IN N
a DT N
Tooth NNP i
Whitening NNP i
Regimen NNP i
with IN i
Added NNP i
Whitening NNP i
Booster NNP i
. . i

OBJECTIVE NNP N
This DT N
randomized VBN N
, , N
controlled VBD N
clinical JJ N
trial NN N
was VBD N
conducted VBN N
to TO N
assess VB N
the DT N
extrinsic JJ o
stain NN o
reduction NN o
achieved VBN N
by IN N
brushing VBG N
with IN N
a DT N
whitening NN N
dentifrice NN N
and CC N
powered VBD N
toothbrush NN N
, , N
and CC N
to TO N
determine VB N
whether IN N
the DT N
addition NN N
of IN N
a DT N
whitening NN N
booster NN N
paste NN N
to TO N
this DT N
regimen NNS N
would MD N
enhance VB N
its PRP$ N
stain NN o
reducing VBG o
effectiveness NN o
. . o

METHODS NNP N
Sixty NNP p
qualifying VBG p
subjects NNS p
were VBD p
randomly RB p
assigned VBN p
either RB N
to TO N
Regimen NNP N
One NNP N
, , N
a DT i
whitening NN i
dentifrice NN i
( ( N
Arm NNP N
& CC N
Hammer NNP N
Truly NNP N
Radiant NNP N
[ NNP N
TR NNP N
] NNP N
toothpaste NN N
] NN N
and CC N
powered VBD i
toothbrush NN i
( ( N
Arm NNP N
& CC N
Hammer NNP N
Truly NNP N
Radiant NNP N
[ NNP N
TR NNP N
] NNP N
Extra NNP N
Whitening NNP N
Spinbrush NNP N
) ) N
; : N
Regimen NNP N
Two CD N
, , N
the DT i
dentifrice NN i
and CC i
powered VBD i
toothbrush NN i
with IN i
the DT i
addition NN i
of IN i
a DT i
whitening JJ i
booster NN i
; : i
or CC N
Regimen NNP N
Three NNP N
, , N
a DT N
negative JJ i
control NN i
( ( i
Colgate NNP i
Cavity NNP i
Protection NNP i
toothpaste NN i
and CC i
an DT i
ADA NNP i
standard NN i
manual JJ i
brush NN i
) ) i
. . N

They PRP N
were VBD N
instructed VBN N
in IN N
the DT N
use NN N
of IN N
their PRP$ N
assigned VBN N
products NNS N
and CC N
then RB N
brushed VBD N
unsupervised JJ N
at IN N
home NN N
for IN N
two CD N
minutes NNS N
, , N
twice RB N
daily RB N
, , N
for IN N
14 CD N
days NNS N
. . N

Extrinsic JJ o
tooth NN o
stain NN N
was VBD N
assessed VBN N
at IN N
baseline NN N
and CC N
after IN N
two CD N
, , N
five CD N
, , N
and CC N
14 CD N
days NNS N
using VBG N
a DT N
Modified NNP o
Lobene NNP o
Stain NNP o
Index NNP o
( ( o
MLSI NNP o
) ) o
with IN N
Lobene NNP N
inclusion NN N
criteria NNS N
of IN N
? . N
1.5 CD N
. . N

RESULTS VB N
All DT N
three CD N
treatment NN N
groups NNS N
had VBD N
statistically RB N
significant JJ N
( ( N
p JJ N
< NNP N
0.0001 CD o
) ) o
mean NN o
total JJ o
MLSI NNP o
reductions NNS o
from IN o
baseline NN N
at IN N
each DT N
time NN N
point NN N
, , N
in IN N
a DT N
time-dependent JJ N
manner NN N
. . N

Day NNP N
14 CD N
reductions NNS N
were VBD N
22.2 CD N
% NN N
for IN N
Colgate NNP N
Cavity NNP N
Protection NNP N
, , N
29.1 CD N
% NN N
for IN N
Regimen NNP N
One NNP N
, , N
and CC N
34.4 CD N
% NN N
for IN N
Regimen NNP N
Two CD o
. . o

Reductions NNS o
for IN o
Regimen NNP N
One CD N
and CC N
Regimen NNP N
Two CD N
were VBD N
significantly RB N
greater JJR N
compared VBN N
to TO N
Regimen NNP N
Three NNP N
, , N
the DT N
negative JJ N
control NN N
, , N
at IN N
each DT N
time NN N
period NN N
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
, , N
and CC N
those DT N
for IN N
Regimen NNP N
Two CD N
were VBD N
significantly RB N
greater JJR N
compared VBN N
to TO N
Regimen NNP N
One NNP N
on IN N
days NNS N
2 CD N
and CC N
14 CD N
( ( N
p NN N
< RB N
0.05 CD N
) ) N
and CC N
directionally RB N
more RBR N
effective JJ N
on IN N
day NN N
5 CD N
( ( N
p NN N
= RB N
0.0673 CD N
) ) N
. . N

CONCLUSION VB N
The DT i
combination NN i
of IN i
Truly NNP i
Radiant NNP i
toothpaste NN i
and CC i
Truly NNP i
Radiant NNP i
Spinbrush NNP i
provides VBZ o
safe JJ o
and CC o
effective JJ o
stain NN o
removal NN o
that WDT o
can MD N
be VB N
further RB N
enhanced VBN N
by IN N
the DT N
addition NN N
of IN N
the DT N
whitening NN N
booster NN N
. . N

-DOCSTART- -10901647- O O

Transesophageal NNP i
echocardiography NN i
in IN N
quantification NN N
of IN N
emboli NN N
during IN N
femoral JJ N
nailing NN N
: : N
reamed VBN i
versus NN N
unreamed JJ i
techniques NNS N
. . N

We PRP N
quantified VBD N
the DT N
embolic JJ N
load NN N
to TO N
the DT N
lungs NNS N
created VBN N
with IN N
two CD N
different JJ N
techniques NNS N
of IN N
femoral JJ i
nailing NN i
. . i

Eleven JJ p
patients NNS p
with IN p
12 CD p
traumatic JJ p
femur NN p
fractures NNS p
were VBD N
randomized VBN N
to TO N
reamed VB i
( ( N
7 CD N
fractures NNS N
) ) N
and CC N
unreamed JJ i
( ( N
5 CD N
fractures NNS N
) ) N
groups NNS N
. . N

Intramedullary JJ N
nailing NN N
was VBD N
with IN N
the DT N
AO/ASIF* NNP N
universal NN N
reamed VBD i
or CC N
unreamed JJ i
nail NN i
. . i

Transesophageal NNP i
echocardiography NN i
( ( i
TEE NNP i
) ) i
was VBD N
used VBN N
to TO N
evaluate VB N
the DT N
quantity NN o
and CC o
quality NN o
of IN o
emboli NN o
generated VBN o
by IN o
nailing VBG o
. . o

Data NNS N
were VBD N
analyzed VBN N
using VBG N
software NN N
that WDT N
digitized VBD N
the DT N
TEE NNP N
images NNS N
and CC N
quantified VBD N
the DT N
area NN N
of IN N
embolic JJ N
particles NNS N
in IN N
each DT N
frame NN N
. . N

The DT N
duration NN N
of IN N
each DT N
level NN N
of IN N
embolic JJ N
phenomena NNS N
( ( N
zero CD N
, , N
moderate JJ N
, , N
severe JJ N
) ) N
was VBD N
used VBN N
to TO N
determine VB N
total JJ N
embolic JJ N
load NN N
with IN N
various JJ N
steps NNS N
( ( N
fracture NN N
manipulation NN N
, , N
proximal JJ N
portal JJ N
opening NN N
, , N
reaming NN N
, , N
and CC N
nail JJ N
passage NN N
) ) N
. . N

Manual JJ N
grading NN N
of IN N
emboli NN o
correlated VBN N
highly RB o
with IN N
software NN N
quantification NN N
. . N

Our PRP$ N
data NNS N
confirm VBP N
the DT N
presence NN N
and CC N
similarity NN N
of IN N
emboli JJ o
generation NN o
with IN o
both DT o
methods NNS o
of IN o
intramedullary JJ o
nailing NN o
. . o

Unreamed NNP o
nails NNS o
do VBP N
not RB N
protect VB N
the DT N
patient NN N
from IN N
pulmonary JJ N
embolization NN N
of IN N
marrow NN N
contents NNS N
. . N

-DOCSTART- -24559095- O O

Decreased VBN N
expression NN o
of IN o
Yes-associated JJ o
protein NN o
is VBZ N
associated VBN N
with IN N
outcome NN N
in IN N
the DT N
luminal NN p
A NNP p
breast NN p
cancer NN p
subgroup NN p
and CC N
with IN N
an DT N
impaired JJ N
tamoxifen NN i
response NN N
. . N

BACKGROUND NNP N
Yes-associated JJ o
protein NN o
( ( o
YAP1 NNP o
) ) o
is VBZ N
frequently RB N
reported VBN N
to TO N
function NN N
as IN N
an DT N
oncogene NN N
in IN N
many JJ N
types NNS N
of IN N
cancer NN N
, , N
but CC N
in IN N
breast JJ N
cancer NN N
results NNS N
remain VBP N
controversial JJ N
. . N

We PRP N
set VBD N
out RP N
to TO N
clarify VB N
the DT N
role NN N
of IN N
YAP1 NNP o
in IN N
breast NN N
cancer NN N
by IN N
examining VBG N
gene NN N
and CC N
protein JJ N
expression NN N
in IN N
subgroups NNS N
of IN N
patient JJ N
material NN N
and CC N
by IN N
downregulating VBG N
YAP1 NNP N
in IN N
vitro NN N
and CC N
studying VBG N
its PRP$ N
role NN N
in IN N
response NN N
to TO N
the DT N
widely RB N
used VBN N
anti-estrogen NN N
tamoxifen NN i
. . i

METHODS NNP N
YAP1 NNP o
protein NN o
intensity NN o
was VBD N
scored VBN N
as IN N
absent NN N
, , N
weak JJ N
, , N
intermediate JJ N
or CC N
strong JJ N
in IN N
two CD p
primary JJ p
breast NN p
cancer NN p
cohorts NNS p
( ( p
n JJ p
= NN p
144 CD p
and CC p
n JJ p
= NNP p
564 CD p
) ) p
and CC p
mRNA JJ o
expression NN o
of IN o
YAP1 NNP o
was VBD p
evaluated VBN p
in IN p
a DT p
gene NN p
expression NN p
dataset NN p
( ( p
n JJ p
= NN p
1107 CD p
) ) p
. . N

Recurrence-free JJ o
survival NN o
was VBD N
analysed VBN N
using VBG N
the DT N
log-rank JJ N
test NN N
and CC N
Cox NNP N
multivariate VBP N
analysis NN N
was VBD N
used VBN N
to TO N
test VB N
for IN N
independence NN N
. . N

WST-1 JJ i
assay NN i
was VBD N
employed VBN N
to TO N
measure VB N
cell NN o
viability NN o
and CC N
a DT N
luciferase NN o
ERE NNP o
( ( N
estrogen JJ N
responsive JJ N
element NN N
) ) N
construct NN N
was VBD N
used VBN N
to TO N
study VB N
the DT N
effect NN N
of IN N
tamoxifen NN i
, , N
following VBG N
downregulation NN N
of IN N
YAP1 NNP N
using VBG N
siRNAs NN N
. . N

RESULTS NNP N
In IN N
the DT N
ER+ NNP p
( ( p
Estrogen NNP p
Receptor NNP p
? . p
positive JJ p
) ) p
subgroup NN p
of IN N
the DT N
randomised JJ N
cohort NN N
, , N
YAP1 NNP o
expression NN o
was VBD N
inversely RB N
correlated VBN N
to TO N
histological JJ N
grade NN N
and CC N
proliferation NN N
( ( N
p JJ N
= NN N
0.001 CD N
and CC N
p VB N
= JJ N
0.016 CD N
, , N
respectively RB N
) ) N
whereas NNS N
in IN N
the DT p
ER- NNP p
( ( p
Estrogen NNP p
Receptor NNP p
? . p
negative JJ p
) ) p
subgroup NN o
YAP1 NNP o
expression NN o
correlated VBD o
positively RB N
to TO N
proliferation NN N
( ( N
p JJ N
= NNP N
0.005 CD N
) ) N
. . N

Notably RB N
, , N
low JJ o
YAP1 NNP o
mRNA NN o
was VBD o
independently RB N
associated VBN N
with IN N
decreased JJ o
recurrence-free JJ o
survival NN o
in IN o
the DT N
gene NN N
expression NN N
dataset NN N
, , N
specifically RB N
for IN N
the DT N
luminal JJ N
A NNP N
subgroup NN N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
which WDT N
includes VBZ N
low JJ N
proliferating VBG N
tumours NN N
of IN N
lower JJR N
grade NN N
, , N
usually RB N
associated VBN N
with IN N
a DT N
good JJ N
prognosis NN N
. . N

This DT N
subgroup NN N
specificity NN N
led VBD N
us PRP N
to TO N
hypothesize VB N
that IN o
YAP1 NNP o
may MD o
be VB N
important JJ N
for IN N
response NN N
to TO N
endocrine VB N
therapies NNS N
, , N
such JJ N
as IN N
tamoxifen NN i
, , i
extensively RB N
used VBN N
for IN N
luminal JJ N
A NNP N
breast NN N
cancers NNS N
. . N

In IN N
a DT N
tamoxifen NN i
randomised VBN i
patient JJ N
material NN N
, , N
absent JJ o
YAP1 NNP o
protein NN o
expression NN o
was VBD o
associated VBN N
with IN N
impaired JJ o
tamoxifen NN o
response NN o
which WDT o
was VBD N
significant JJ N
upon IN N
interaction NN N
analysis NN N
( ( N
p JJ N
= NNP N
0.042 CD N
) ) N
. . N

YAP1 CC N
downregulation NN N
resulted VBD N
in IN N
increased JJ o
progesterone NN o
receptor NN o
( ( o
PgR NNP o
) ) o
expression NN o
and CC o
a DT N
delayed NN N
and CC N
weaker JJR i
tamoxifen NN i
in IN i
support NN N
of IN N
the DT N
clinical JJ N
data NNS N
. . N

CONCLUSIONS NNP N
Decreased VBD o
YAP1 NNP o
expression NN o
is VBZ o
an DT N
independent JJ N
prognostic JJ N
factor NN N
for IN N
recurrence NN N
in IN N
the DT N
less RBR N
aggressive JJ p
luminal NN p
A NNP p
breast NN p
cancer NN p
subgroup NN p
, , p
likely RB N
due JJ N
to TO N
the DT N
decreased VBN i
tamoxifen NN i
sensitivity NN i
conferred VBN N
by IN N
YAP1 NNP N
downregulation NN N
. . N

-DOCSTART- -16527796- O O

Nasotracheal JJ i
intubation NN i
under IN i
curve-tipped JJ i
suction NN i
catheter NN i
guidance NN N
reduces NNS N
epistaxis VBP p
. . p

BACKGROUND NNP N
Nasotracheal NNP i
intubation NN i
( ( i
NTI NNP i
) ) i
has VBZ N
greater JJR N
potential JJ N
for IN N
trauma NN N
of IN N
nasopharyngeal NN N
mucosa NN N
than IN N
orotracheal JJ N
intubation NN N
. . N

The DT N
present JJ N
study NN N
investigated VBD N
the DT N
success NN o
rate NN o
of IN N
NTI NNP N
and CC N
frequency NN N
of IN N
nasal JJ N
bleeding VBG N
using VBG N
a DT N
curve-tipped JJ i
suction NN i
catheter NN i
( ( i
CTSC NNP i
) ) i
to TO i
guide VB N
nasotracheal JJ N
tube JJ N
advancement NN N
. . N

METHODS NNP N
Subjects NNPS p
comprised VBD p
131 CD p
adult NN p
patients NNS p
who WP p
under-went JJ p
NTI NNP i
. . i

Subjects NNS p
were VBD p
randomly RB p
divided VBN p
into IN p
two CD p
groups NNS p
: : p
a DT p
) ) p
NTI NNP i
under IN i
CTSC NNP i
guidance NN i
( ( i
G NNP i
[ NNP i
+ NNP i
] NNP i
group NN i
) ) i
. . N

The DT N
CTSC NNP N
( ( N
14 CD N
Fr NNP N
) ) N
was VBD N
first RB N
inserted VBN N
through IN N
the DT N
tracheal NN N
tube NN N
, , N
with IN N
the DT N
tip NN N
of IN N
the DT N
CTSC NNP N
emerging VBG N
from IN N
the DT N
distal JJ N
end NN N
of IN N
the DT N
tube NN N
. . N

The DT N
curved JJ N
tip NN N
was VBD N
directed VBN N
ventrally RB N
. . N

Both DT N
tracheal JJ N
tube NN N
and CC N
CTSC NNP N
were VBD N
advanced VBN N
together RB N
through IN N
the DT N
nasopharynx NN N
; : N
b NN N
) ) N
NTI NN i
without IN i
CTSC NNP i
guidance NN i
( ( N
G NNP N
[ NNP N
- : N
] NN N
group NN N
) ) N
. . N

The DT N
tracheal NN N
tube NN N
was VBD N
advanced VBN N
into IN N
the DT N
nasal JJ N
cavity NN N
and CC N
passed VBD N
into IN N
the DT N
pharynx NN N
without IN N
CTSC NNP N
guidance NN N
. . N

The DT N
time NN o
required VBN o
to TO o
pass VB o
the DT o
endotracheal NN o
tube NN o
through IN o
the DT o
nasal JJ o
cavity NN o
( ( o
nasal JJ o
passage NN o
time NN o
) ) o
, , o
success NN o
rate NN o
of IN o
nasal JJ o
passage NN o
with IN o
nasotracheal JJ o
tube NN o
, , o
and CC o
the DT o
incidence NN o
and CC o
severity NN o
of IN o
nasal JJ o
bleeding VBG o
were VBD N
compared VBN N
. . N

RESULTS NNP N
Success NNP o
rate NN o
for IN o
nasal JJ o
passage NN o
was VBD N
100 CD N
% NN N
in IN N
the DT N
G NNP N
( ( N
+ NNP N
) ) N
group NN N
( ( N
62/62 CD N
) ) N
and CC N
82.6 CD N
% NN N
in IN N
the DT N
G NNP N
( ( N
- : N
) ) N
group NN N
( ( N
57/69 CD N
; : N
P NNP N
= NNP N
0.0006 CD N
) ) N
. . N

Frequency NN o
of IN o
nasal JJ o
bleeding NN o
was VBD N
significantly RB N
lower JJR N
in IN N
the DT N
G NNP N
( ( N
+ NNP N
) ) N
group NN N
( ( N
21/62 CD N
, , N
33.9 CD N
% NN N
) ) N
than IN N
in IN N
the DT N
G NNP N
( ( N
- : N
) ) N
group NN N
( ( N
37/69 CD N
, , N
53.6 CD N
% NN N
; : N
P NNP N
= NNP N
0.023 CD N
) ) N
. . N

Severity NN o
of IN o
nasal JJ o
bleeding NN o
was VBD N
also RB N
significantly RB N
lower JJR N
in IN N
the DT N
G NNP N
( ( N
+ NNP N
) ) N
group NN N
than IN N
in IN N
the DT N
G NNP N
( ( N
- : N
) ) N
group NN N
( ( N
P NNP N
= NNP N
0.030 CD N
) ) N
. . N

CONCLUSIONS NNP N
Nasotracheal NNP i
intubation NN i
under IN i
CTSC NNP i
guidance NN i
increases VBZ N
the DT N
success NN o
rate NN o
of IN N
airway NN N
instrumentation NN N
, , N
and CC N
also RB N
reduces VBZ N
the DT N
incidence NN o
and CC o
severity NN o
of IN N
epistaxis NN p
. . p

-DOCSTART- -24684165- O O

Triple JJ i
combination NN i
as IN i
adjuvant JJ i
to TO i
cryotherapy VB i
in IN N
the DT N
treatment NN o
of IN o
solar JJ o
lentigines NNS o
: : o
investigator-blinded JJ N
, , N
randomized JJ N
clinical JJ N
trial NN N
. . N

BACKGROUND NNP N
Post-inflammatory JJ N
hyperpigmentation NN o
is VBZ N
a DT N
frequent JJ N
concern NN N
when WRB N
treating VBG N
solar JJ o
lentigines NNS o
. . o

OBJECTIVES NNP N
To TO N
assess VB N
the DT N
safety NN o
and CC o
efficacy NN o
of IN N
a DT N
triple JJ i
combination NN i
cream NN i
with IN i
fluocinolone NN i
acetonide RB i
0.01 CD N
% NN N
, , N
hydroquinone CD i
4 CD N
% NN N
and CC N
tretinoin VB i
0.05 CD N
% NN N
as IN N
adjuvant NN N
to TO N
cryotherapy VB N
in IN N
the DT N
treatment NN o
of IN o
solar JJ o
lentigines NNS o
in IN N
hands NNS N
dorsum JJ N
, , N
and CC N
in IN N
the DT N
prevention NN o
of IN o
post-inflammatory JJ o
hyperpigmentation NN o
after IN N
cryotherapy NN N
. . N

METHODS NNP N
This DT p
prospective JJ p
, , p
randomized VBN p
, , p
controlled VBN p
, , p
investigator-blinded JJ p
, , p
single-centre JJ p
study NN p
enrolled VBD p
50 CD p
patients NNS p
. . p

Twenty-five JJ p
patients NNS p
received VBD N
a DT N
2-week JJ i
daily JJ i
triple NN i
combination NN i
cream NN i
plus CC i
sunscreen JJ i
pre-treatment JJ i
and CC N
25 CD p
received VBD p
sunscreen JJ i
alone RB i
. . i

After IN N
that DT N
, , N
cryotherapy NN i
was VBD N
performed VBN N
in IN N
all DT N
patients NNS N
followed VBN N
by IN N
a DT N
3-week JJ N
recovery NN N
period NN N
. . N

After IN N
this DT N
period NN N
, , N
patients NNS N
received VBD N
the DT N
same JJ N
initial JJ N
treatment NN N
and CC N
were VBD N
followed VBN N
up RP N
for IN N
8 CD N
weeks NNS N
. . N

Melanin NNP o
and CC o
erythema JJ o
levels NNS o
of IN N
a DT N
target NN N
and CC N
a DT N
control NN N
lentigo NN N
were VBD N
objectively RB N
measured VBN N
using VBG N
a DT N
narrowband NN N
reflectance NN N
spectrophotometer NN N
. . N

Lentigines NNP o
count NN o
, , o
colour VBP o
homogeneity NN o
and CC o
global JJ o
improvement NN o
were VBD N
also RB N
assessed VBN N
. . N

RESULTS VB N
The DT o
number NN o
of IN o
solar JJ o
lentigines NNS o
reduced VBN N
in IN N
the DT N
first JJ N
2 CD N
weeks NNS N
only RB N
in IN N
patients NNS N
who WP N
used VBD N
the DT N
triple JJ N
combination NN N
25 CD N
? . N
7 CD N
vs. IN N
22 CD N
? . N
8 CD N
( ( N
P NNP N
< NNP N
0.0001 CD N
) ) N
, , N
and CC N
reduced VBD N
at IN N
the DT N
end NN N
of IN N
the DT N
study NN N
for IN N
both DT N
groups NNS N
( ( N
P NNP N
< NNP N
0.0001 CD o
) ) o
. . o

The DT o
melanin NN o
levels NNS o
also RB o
reduced VBN N
in IN N
the DT N
first JJ N
2 CD N
weeks NNS N
only RB N
in IN N
patients NNS N
who WP N
used VBD N
the DT N
triple JJ N
combination NN N
297 CD N
? . N
69 CD N
vs. IN N
273 CD N
? . N
66 CD N
( ( N
P NNP N
< NNP N
0.0001 CD N
) ) N
and CC N
reduced VBN N
at IN N
the DT N
end NN N
of IN N
the DT N
study NN N
for IN N
both DT N
groups NNS N
( ( N
P NNP N
< NNP N
0.0001 CD N
) ) N
. . N

Erythema NNP o
and CC o
residual JJ o
blisters NNS o
from IN o
cryotherapy NN o
were VBD o
the DT N
reported VBN o
adverse JJ o
reactions NNS o
. . o

CONCLUSION NNP o
Triple NNP N
combination NN N
cream NN N
can MD N
be VB N
used VBN N
to TO N
enhance VB N
the DT N
resolution NN o
of IN o
solar JJ o
lentigines NNS o
, , o
and CC o
to TO N
significantly RB N
reduce VB N
melanin NN o
levels NNS o
and CC o
lentigines NNS o
count NN o
, , o
improving VBG o
treatment NN o
results NNS o
. . o

It PRP o
was VBD o
well-tolerated JJ o
and CC N
did VBD N
not RB N
increase VB N
the DT N
occurrence NN N
of IN N
neither DT o
erythema NN o
nor CC o
other JJ o
side-effects NNS o
after IN N
the DT N
cryotherapy NN N
. . N

-DOCSTART- -24138011- O O

Aripiprazole NNP i
treatment NN N
of IN N
irritability NN N
associated VBN N
with IN N
autistic JJ p
disorder NN p
and CC N
the DT N
relationship NN N
between IN N
prior JJ N
antipsychotic JJ N
exposure NN N
, , N
adverse JJ N
events NNS N
, , N
and CC N
weight VBD N
change NN N
. . N

OBJECTIVE IN N
The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
impact NN N
of IN N
prior JJ N
antipsychotic JJ N
exposure NN N
( ( N
PAE NNP N
) ) N
on IN N
safety NN o
and CC o
tolerability NN o
outcomes NNS o
in IN N
pediatric JJ p
subjects NNS p
receiving VBG p
aripiprazole JJ p
treatment NN p
. . p

METHODS NNP N
This DT N
study NN N
was VBD N
a DT N
post-hoc JJ N
analysis NN N
of IN N
pooled VBN N
data NNS N
from IN N
two CD N
8-week JJ N
, , N
double-blind JJ N
, , N
randomized VBN N
, , N
placebo-controlled JJ i
studies NNS N
evaluating VBG N
aripiprazole NN i
for IN N
the DT N
treatment NN N
of IN N
irritability NN N
in IN N
pediatric JJ p
subjects NNS p
with IN p
autistic JJ p
disorder NN p
, , p
aged VBN p
6-17 CD p
years NNS p
. . p

Subjects NNS p
were VBD p
stratified VBN p
by IN p
PAE NNP p
; : p
adverse JJ N
events NNS N
( ( N
AEs NNP N
) ) N
, , N
and CC N
changes NNS N
in IN N
weight NN N
, , N
and CC N
metabolic JJ N
measures NNS N
were VBD N
evaluated VBN N
. . N

For IN N
subjects NNS N
receiving VBG N
aripiprazole NN N
, , N
regardless RB N
of IN N
PAE NNP N
, , N
baseline NN N
weight NN N
, , N
age NN N
, , N
gender NN N
, , N
and CC N
symptom JJ N
severity NN N
were VBD N
evaluated VBN N
in IN N
a DT N
regression NN N
model NN N
predicting VBG N
body NN N
weight JJ N
change NN N
. . N

RESULTS NNP N
Of IN N
316 CD p
randomized JJ p
subjects NNS p
, , p
259 CD p
( ( p
82.0 CD p
% NN p
) ) p
were VBD p
antipsychotic JJ p
na?ve NN p
( ( p
AN NNP p
) ) p
and CC p
57 CD p
( ( p
18.0 CD p
% NN p
) ) p
had VBD p
a DT p
PAE NNP p
. . p

Aripiprazole-treated NNP N
AN NNP N
subjects NNS N
were VBD N
more RBR N
likely JJ N
than IN N
PAE NNP N
subjects NNS N
to TO N
report VB N
somnolence NN N
( ( N
11.9 CD N
% NN N
vs. FW N
2.8 CD N
% NN N
) ) N
, , N
sedation NN N
( ( N
22.7 CD N
% NN N
vs. FW N
11.1 CD N
% NN N
) ) N
, , N
or CC N
fatigue NN N
( ( N
17.0 CD N
% NN N
vs. FW N
13.9 CD N
% NN N
) ) N
. . N

Rates NNS o
of IN o
extrapyramidal JJ o
disorder NN o
and CC o
drooling NN o
, , o
but CC o
not RB o
akathisia VB o
or CC o
tremor VB o
, , o
were VBD N
marginally RB N
higher JJR N
in IN N
AN NNP N
subjects NNS N
. . N

Overall NNP N
, , N
10.8 CD N
% NN N
of IN N
aripiprazole-treated JJ N
AN NNP N
subjects NNS N
had VBD N
at IN N
least JJS N
one CD N
AE NNP N
leading VBG N
to TO N
discontinuation NN N
compared VBN N
with IN N
8.3 CD N
% NN N
of IN N
aripiprazole-treated JJ N
PAE NNP N
subjects NNS N
. . N

AN NNP N
subjects VBZ N
receiving VBG N
aripiprazole NN N
had VBD N
a DT N
larger JJR N
change NN N
in IN N
weight NN N
from IN N
baseline NN N
to TO N
endpoint VB N
compared VBN N
with IN N
those DT N
receiving VBG N
placebo NN N
( ( N
1.9 CD N
vs. FW N
0.7 CD N
kg NN N
; : N
treatment NN N
difference NN N
1.2 CD N
kg NN N
, , N
95 CD N
% NN N
CI NNP N
: : N
0.5 CD N
, , N
1.9 CD N
) ) N
than IN N
PAE NNP N
subjects NNS N
receiving VBG N
aripiprazole JJ N
compared VBN N
with IN N
subjects NNS N
receiving VBG N
placebo NN N
( ( N
0.4 CD N
vs. FW N
-0.4 NNP N
kg NN N
; : N
treatment NN N
difference NN N
0.9 CD N
kg NN N
, , N
95 CD N
% NN N
CI NNP N
: : N
-0.6 NN N
, , N
2.4 CD N
) ) N
. . N

Regression NN N
analysis NN N
identified VBD N
that IN p
younger JJR p
subjects NNS p
with IN p
higher JJR p
baseline NN p
weight VBD p
z-score NN N
were VBD N
at IN N
highest JJS N
risk NN N
for IN N
weight JJ N
gain NN N
. . N

There EX N
were VBD N
no DT N
significant JJ N
changes NNS N
in IN o
metabolic JJ o
measures NNS o
compared VBN N
with IN N
placebo NN N
in IN N
either DT N
group NN N
. . N

CONCLUSIONS NNP o
Weight NNP o
gain NN o
was VBD N
more RBR N
pronounced JJ N
in IN N
AN NNP N
subjects NNS N
and CC N
more RBR N
likely JJ N
to TO N
occur VB N
in IN p
younger JJR p
subjects NNS p
with IN p
a DT p
higher JJR p
baseline NN p
weight VBD p
z-score RB p
. . p

AN JJ N
subjects NNS N
were VBD N
more RBR N
likely JJ N
to TO N
experience VB N
AEs NNP N
related VBN N
to TO N
somnolence NN N
. . N

However RB N
, , N
based VBN N
on IN N
discontinuations NNS N
rates NNS N
from IN N
AEs NNP N
, , N
overall JJ o
tolerability NN o
was VBD N
good JJ N
for IN N
both DT N
AN NNP N
and CC N
PAE NNP N
groups NNS N
. . N

CLINICAL NNP N
TRIAL NNP N
REGISTRATION NNP N
Study NNP N
of IN N
aripiprazole NN N
in IN N
the DT N
treatment NN N
of IN p
children NNS p
and CC p
adolescents NNS p
with IN p
autistic JJ p
disorder NN p
. . p

Registry NN N
: : N
www.clinicaltrials.gov NN N
. . N

Identifiers NNS N
: : N
NCT00332241 NNP N
and CC N
NCT00337571 NNP N
. . N

-DOCSTART- -23257173- O O

Simvastatin NNP i
reduces VBZ N
sympathetic JJ N
outflow NN N
and CC N
augments NNS N
endothelium-independent JJ N
dilation NN N
in IN N
non-hyperlipidaemic JJ p
primary JJ p
hypertension NN p
. . p

OBJECTIVES NNP N
Previous JJ N
reports NNS N
, , N
involving VBG N
hypercholesterolaemic JJ p
hypertensive JJ p
subjects NNS p
, , N
that IN N
statins VBZ N
reduce VB N
muscle NN N
sympathetic JJ N
nerve NN N
activity NN N
( ( N
MSNA NNP N
) ) N
did VBD N
not RB N
investigate VB N
potential JJ N
neural JJ N
sites NNS N
of IN N
such JJ N
sympathoinhibition NN N
or CC N
determine VB N
its PRP$ N
consequences NNS N
for IN N
endothelial JJ N
function NN N
or CC N
insulin NN N
resistance NN N
. . N

This DT N
study NN N
of IN N
hypertensive JJ p
subjects NNS p
with IN p
lower JJR p
plasma NN p
cholesterol NN p
tested VBD N
the DT N
hypotheses NNS N
that WDT N
lipophilic JJ N
simvastatin NN i
would MD N
attenuate VB N
resting VBG N
sympathoexcitation NN N
and CC N
augment NN N
baroreflex JJ N
modulation NN N
of IN N
MSNA NNP N
and CC N
heart NN N
rate NN N
( ( N
HR NNP N
) ) N
, , N
flow-mediated JJ N
vasodilation NN N
and CC N
insulin NN N
sensitivity NN N
. . N

DESIGN NNP N
Prospective NNP N
, , N
randomised VBD N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
crossover NN N
study NN N
. . N

SETTING NNP N
Academic NNP N
hospital-based JJ N
study NN N
. . N

PATIENTS NNP N
Fourteen JJ p
non-hyperlipidaemic JJ p
primary JJ p
hypertensive JJ p
subjects NNS p
( ( p
10 CD p
men NNS p
; : p
overall JJ p
mean?SD NN p
age NN p
58?12 CD p
years NNS p
) ) p
. . p

INTERVENTIONS NNP N
Four NNP N
weeks NNS N
of IN N
simvastatin NN i
( ( i
80 CD i
mg/day NN i
) ) i
or CC i
placebo NN i
. . i

MAIN NNP N
OUTCOME NNP N
MEASURES NNP o
Resting NNP o
blood NN o
pressure NN o
( ( o
BP NNP o
) ) o
, , o
HR NNP o
, , o
MSNA NNP o
, , o
spontaneous JJ o
arterial JJ o
baroreflex NN o
MSNA NNP o
and CC o
HR NNP o
modulation NN o
, , o
endothelium-dependent JJ o
and CC o
endothelium-independent JJ o
vasodilation NN o
, , o
and CC o
the DT o
homoeostatic JJ o
model NN o
assessment NN o
of IN o
insulin NN o
resistance NN o
( ( o
HOMA-IR NNP o
) ) o
. . o

RESULTS NNP i
Simvastatin NNP i
lowered VBD o
MSNA NNP o
burst JJ o
frequency NN o
( ( o
from IN N
32?12 CD N
to TO N
25?9 CD N
bursts/min NN N
) ) N
and CC N
MSNA NNP o
burst NN o
incidence NN o
( ( o
from IN o
55?23 CD N
% NN N
to TO N
43?17 CD N
% NN N
; : N
all DT N
p VBP N
< $ N
0.01 CD N
) ) N
without IN N
affecting VBG o
BP NNP o
, , o
HR NNP o
, , o
baroreflex JJ o
modulation NN o
of IN o
either DT o
MSNA NNP o
or CC o
HR NNP o
, , o
or CC o
HR NNP o
variability NN o
( ( o
all DT o
p VBP N
> $ N
0.05 CD N
) ) o
. . o

Plasma NNP o
glucose NN o
, , o
insulin NN o
, , o
HOMA-IR NNP o
and CC o
endothelium-dependent JJ o
vasodilation NN o
( ( o
all DT o
p VBP N
> $ N
0.05 CD N
) ) N
were VBD N
unchanged JJ N
, , N
whereas JJ o
endothelium-independent JJ o
vasodilation NN o
increased VBD o
( ( N
7.1?3.8 CD N
% NN N
to TO N
9.7?3.9 CD N
% NN N
, , N
n=13 RB N
; : N
p VB N
< $ N
0.01 CD N
) ) N
. . N

The DT N
fall NN N
in IN N
MSNA NNP o
was VBD N
unrelated JJ N
to TO N
the DT N
decrease NN N
in IN o
low-density NN o
lipoprotein NN o
cholesterol NN o
( ( o
r=0.41 NN o
, , N
p=0.14 NN N
) ) N
. . N

CONCLUSIONS NNP N
These DT N
findings NNS N
are VBP N
consistent JJ N
with IN N
the DT N
concept NN N
that IN N
, , N
in IN N
non-hyperlipidaemic JJ p
subjects NNS p
with IN p
primary JJ p
hypertension NN p
, , p
simvastatin JJ p
causes VBZ N
a DT N
cholesterol-independent JJ N
reduction NN N
in IN N
an DT N
elevated JJ N
central JJ N
set-point NN N
for IN N
MSNA NNP N
, , N
without IN N
affecting VBG N
arterial JJ N
baroreflex JJ N
modulation NN N
of IN N
either DT N
MSNA NNP N
or CC N
HR NNP N
. . N

There EX N
may MD N
be VB N
less JJR N
neurogenic JJ N
constraint NN N
on IN N
endothelium-independent JJ N
vasodilation NN N
as IN N
a DT N
consequence NN N
. . N

-DOCSTART- -16435344- O O

Randomized VBN N
, , N
placebo-controlled JJ i
, , N
double-blind JJ N
clinical JJ N
trial NN N
evaluating VBG N
the DT N
treatment NN N
of IN N
plantar NN p
fasciitis NN p
with IN N
an DT N
extracoporeal NN i
shockwave NN i
therapy NN i
( ( i
ESWT NNP i
) ) i
device NN i
: : i
a DT N
North JJ p
American JJ p
confirmatory NN p
study NN p
. . p

Despite IN N
numerous JJ N
publications NNS N
and CC N
clinical JJ N
trials NNS N
, , N
the DT N
results NNS N
of IN N
treatment NN N
of IN N
recalcitrant JJ p
chronic JJ p
plantar NN p
fasciitis NN p
with IN N
extracorporeal JJ i
shockwave JJ i
therapy NN i
( ( i
ESWT NNP i
) ) i
still RB N
remain VBP N
equivocal JJ N
as IN N
to TO N
whether IN N
or CC N
not RB N
this DT N
treatment NN N
provides VBZ N
relief NN o
from IN N
the DT o
pain NN o
associated VBN N
with IN N
this DT N
condition NN N
. . N

The DT N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
whether IN N
extracorporeal NN N
shock NN N
wave VBP N
therapy NN N
can MD N
safely RB o
and CC o
effectively RB o
relieve VB o
the DT o
pain NN o
associated VBN N
with IN N
chronic JJ N
plantar NN N
fasciitis NN N
compared VBN N
to TO N
placebo VB N
treatment NN N
, , N
as IN N
demonstrated VBN N
by IN N
pain NN N
with IN N
walking NN N
in IN N
the DT N
morning NN N
. . N

This DT N
was VBD N
set VBN N
in IN N
a DT N
multicenter NN N
, , N
randomized VBN N
, , N
placebo-controlled JJ N
, , N
double-blind JJ N
, , N
confirmatory JJ N
clinical JJ N
study NN N
undertaken VBN N
in IN N
four CD p
outpatient NN p
orthopedic NN p
clinics NNS p
. . p

The DT p
patients NNS p
, , p
114 CD p
adult NN p
subjects NNS p
with IN p
chronic JJ p
plantar NN p
fasciitis NN p
, , p
recalcitrant JJ p
to TO p
conservative JJ p
therapies NNS p
for IN p
at IN p
least JJS p
6 CD p
months NNS p
, , N
were VBD N
randomized VBN N
to TO N
two CD N
groups NNS N
. . N

Treatment NNP N
consisted VBD N
of IN N
approximately RB N
3,800 CD i
total JJ i
shock NN i
waves NNS i
( ( N
+/-10 JJ N
) ) N
reaching VBG N
an DT N
approximated JJ N
total NN N
energy NN N
delivery NN N
of IN N
1,300 CD N
mJ/mm NN N
( ( N
2 CD N
) ) N
( ( N
ED+ NNP N
) ) N
in IN N
a DT N
single JJ N
session NN N
versus IN N
placebo NN i
treatment NN i
. . i

This DT N
study NN N
demonstrated VBD N
a DT N
statistically RB N
significant JJ N
difference NN N
between IN N
treatment NN N
groups NNS N
in IN N
the DT N
change NN N
from IN N
baseline NN N
to TO N
3 CD N
months NNS N
in IN N
the DT N
primary JJ N
efficacy NN N
outcome NN N
of IN N
pain NN o
during IN N
the DT o
first JJ o
few JJ o
minutes NNS o
of IN o
walking VBG o
measured VBN N
by IN N
a DT N
visual JJ o
analog NN o
scale NN o
. . o

There EX N
was VBD N
also RB N
a DT N
statistically RB N
significant JJ N
difference NN N
between IN N
treatments NNS N
in IN N
the DT N
number NN N
of IN N
participants NNS N
whose WP$ N
changes NNS N
in IN N
Visual NNP o
Analog NNP o
Scale NNP o
scores VBZ o
met VBD N
the DT N
study NN N
definition NN N
of IN N
success NN N
at IN N
both DT N
6 CD N
weeks NNS N
and CC N
3 CD N
months NNS N
posttreatment NN N
; : N
and CC N
between IN N
treatment NN N
groups NNS N
in IN N
the DT N
change NN N
from IN N
baseline NN N
to TO N
3 CD N
months NNS N
posttreatment NN N
in IN N
the DT N
Roles NNP o
and CC o
Maudsley NNP o
Score NNP o
. . o

The DT N
results NNS N
of IN N
this DT N
study NN N
confirm VBP N
that IN N
ESWT NNP i
administered VBD N
with IN N
the DT N
Dornier NNP N
Epos NNP N
Ultra NNP N
is VBZ N
a DT N
safe JJ o
and CC N
effective JJ o
treatment NN N
for IN N
recalcitrant JJ N
plantar NN N
fasciitis NN N
. . N

-DOCSTART- -1835223- O O

Intravenous JJ i
or CC i
intramuscular JJ i
teicoplanin NN i
once RB N
daily JJ N
for IN N
skin NN o
and CC o
soft-tissue JJ o
infections NNS o
. . o

Teicoplanin NNP i
is VBZ N
a DT N
new JJ N
glycopeptide NN N
antibiotic JJ N
with IN N
potent JJ N
activity NN N
against IN N
gram-positive JJ N
bacteria NNS N
and CC N
pharmacokinetics NNS N
that WDT N
allow VBP N
once RB N
daily JJ N
administration NN N
. . N

To TO N
study VB N
the DT N
efficacy NN o
and CC o
safety NN o
of IN N
teicoplanin NN i
for IN N
skin NN N
and CC N
soft-tissue NN N
infections NNS N
, , N
75 CD p
patients NNS p
received VBD p
teicoplanin JJ i
intravenously RB i
( ( i
38 CD i
) ) i
or CC i
intramuscularly RB i
( ( p
37 CD p
, , p
of IN p
which WDT p
16 CD p
were VBD p
outpatients NNS p
) ) p
. . N

Of IN N
62 CD p
clinically RB p
evaluable JJ p
patients NNS p
, , N
97 CD N
percent NN N
of IN N
teicoplanin NN i
iv NN N
and CC N
93 CD N
percent NN N
of IN N
teicoplanin NN i
im NN N
patients NNS N
were VBD N
cured VBN N
or CC N
improved VBN N
. . N

All DT N
teicoplanin JJ i
iv NN N
patients NNS N
and CC N
64 CD N
percent NN N
of IN N
teicoplanin NN i
im NN N
patients NNS N
were VBD N
cured VBN o
microbiologically RB o
at IN N
24-48 JJ N
hours NNS N
posttherapy NN N
. . N

Persistence NN N
of IN N
organisms NNS N
frequently RB N
was VBD N
associated VBN N
with IN N
skin JJ o
ulcers NNS o
or CC o
abscess JJ o
cavities NNS o
and CC N
usually RB N
had VBD N
no DT N
bearing NN N
on IN N
clinical JJ N
outcome NN N
. . N

Possible JJ N
adverse JJ o
clinical JJ o
and CC o
laboratory JJ o
reactions NNS o
caused VBN N
by IN N
teicoplanin NN i
occurred VBD N
in IN N
4 CD N
of IN N
38 CD N
teicoplanin JJ N
iv NN N
patients NNS N
( ( N
11 CD N
percent NN N
) ) N
and CC N
in IN N
8 CD N
of IN N
37 CD N
teicoplanin JJ i
im NN N
patients NNS N
( ( N
22 CD N
percent NN N
) ) N
. . N

Reactions NNPS N
were VBD N
mild JJ o
and CC N
resolved VBN N
with IN N
discontinuation NN N
of IN N
teicoplanin NN i
in IN N
most JJS N
cases NNS N
. . N

In IN N
this DT N
study NN N
, , N
teicoplanin NN N
appeared VBD N
to TO N
be VB N
safe JJ o
, , o
efficacious JJ o
, , o
and CC o
convenient NN o
for IN N
both DT N
hospital JJ N
staff NN N
and CC N
patients NNS N
, , N
and CC N
potentially RB N
cost-effective JJ o
for IN N
the DT N
treatment NN N
of IN N
skin NN N
and CC N
soft-tissue JJ N
infections NNS N
. . N

In IN N
particular JJ N
, , N
teicoplanin JJ i
appears VBZ N
to TO N
be VB N
appropriate JJ N
for IN N
outpatient JJ N
parenteral JJ N
therapy NN N
. . N

-DOCSTART- -11422660- O O

Nicotine NNP i
infusion NN N
acutely RB N
impairs JJ N
insulin NN N
sensitivity NN N
in IN N
type NN p
2 CD p
diabetic JJ p
patients NNS p
but CC N
not RB N
in IN N
healthy JJ N
subjects NNS N
. . N

OBJECTIVES IN N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
examine VB N
if IN N
an DT N
acute JJ N
nicotine NN i
infusion NN N
alters NNS N
insulin VBP N
sensitivity NN N
to TO N
a DT N
similar JJ N
degree NN N
in IN N
type NN N
2 CD N
diabetic JJ N
patients NNS N
as IN N
in IN N
healthy JJ N
control NN N
subjects NNS N
. . N

DESIGN NNP N
. . N

Double-blind NNP N
, , N
cross-over NN N
, , N
placebo-controlled JJ i
, , N
randomized JJ N
experimental NN N
study NN N
. . N

Nicotine NNP i
0.3 CD N
microg NN N
kg-1 JJ N
min NN N
( ( N
-1 JJ N
) ) N
or CC i
NaCl NNP i
was VBD i
infused VBN i
( ( N
2 CD N
h NN N
) ) N
during IN N
a DT N
euglycaemic JJ N
hyperinsulinaemic NN N
clamp NN N
( ( N
4 CD N
h NN N
) ) N
to TO N
assess VB N
insulin JJ N
sensitivity NN N
. . N

SETTING NNP N
University NNP N
research NN N
laboratory NN N
. . N

SUBJECTS NNP N
Six NNP p
male NN p
and CC p
female JJ p
type NN p
2 CD p
diabetic JJ p
patients NNS p
[ JJ p
DM2 NNP p
; : p
age NN p
54 CD p
+/- JJ p
10 CD p
( ( p
mean JJ p
+/- NNP p
SD NNP p
) ) p
years NNS p
; : p
body NN p
mass NN p
index NN p
( ( p
BMI NNP p
) ) p
25.6 CD p
+/- JJ p
2.9 CD p
kg NN p
m NN p
( ( p
-2 NNP p
) ) p
] NN p
treated VBN p
with IN p
diet JJ p
or CC p
one CD p
oral JJ p
hypoglycaemic JJ p
agent NN p
and CC p
six CD p
age- JJ p
and CC p
BMI-matched JJ p
control NN p
subjects NNS p
( ( p
Ctr NNP p
) ) p
. . p

MAIN NNP N
OUTCOME NNP N
MEASURE NNP N
Insulin NNP o
sensitivity NN o
( ( o
rate NN o
of IN o
glucose JJ o
infusion NN o
per IN o
kg NN o
fat JJ o
free JJ o
body NN o
mass NN o
and CC o
minute NN o
) ) o
, , o
nicotine JJ o
and CC o
free JJ o
fatty NN o
acid NN o
( ( o
FFA NNP o
) ) o
levels NNS o
, , o
pulse NN o
rate NN o
and CC o
blood NN o
pressure NN o
. . o

RESULTS VB N
The DT N
infusions NNS N
produced VBD N
similar JJ N
nicotine NN N
levels NNS N
in IN N
both DT N
groups NNS N
. . N

In IN N
the DT N
absence NN N
of IN N
nicotine NN i
, , N
DM2 NNP N
were VBD N
more JJR N
insulin NN o
resistant NN o
than IN N
Ctr NNP N
( ( N
6.7 CD N
+/- JJ N
0.4 CD N
vs. FW N
10.9 CD N
+/- JJ N
0.3 CD N
mg JJ N
kg-1 JJ N
LBM NNP N
min NN N
( ( N
-1 NNP N
) ) N
, , N
respectively RB N
; : N
P NNP N
< NNP N
0.0001 CD N
) ) N
. . N

This DT N
insulin NN o
resistance NN o
was VBD N
further RBR N
aggravated VBN N
by IN N
the DT N
nicotine JJ N
infusion NN N
in IN N
DM2 NNP N
but CC N
not RB N
in IN N
Ctr NNP N
( ( N
4.6 CD N
+/- JJ N
0.3 CD N
vs. FW N
10.9 CD N
+/- JJ N
0.3 CD N
mg NN N
kg NN N
( ( N
-1 NNP N
) ) N
LBM NNP N
min NN N
( ( N
-1 NNP N
) ) N
; : N
P NNP N
< NNP N
0.0001 CD N
) ) N
. . N

Only RB N
minor JJ N
differences NNS N
were VBD N
seen VBN N
in IN N
FFA NNP o
levels NNS o
, , o
pulse NN o
rates NNS o
and CC o
blood NN o
pressure NN o
. . o

CONCLUSIONS NN N
At IN N
this DT N
low JJ N
infusion NN N
rate NN N
, , N
nicotine NN i
aggravated VBD N
the DT N
insulin NN o
resistance NN o
in IN N
DM2 NNP N
but CC N
not RB N
in IN N
Ctr NNP N
. . N

This DT N
finding NN N
may MD N
be VB N
because IN N
of IN N
the DT N
( ( N
dysmetabolic JJ N
) ) N
diabetic JJ N
state NN N
per IN N
se NN N
or CC N
to TO N
an DT N
increased VBN N
sensitivity NN N
to TO N
environmental JJ N
factors NNS N
associated VBN N
with IN N
a DT N
genetic JJ N
predisposition NN N
for IN N
type NN N
2 CD N
diabetes NNS N
. . N

These DT N
results NNS N
show VBP N
that IN N
diabetic JJ N
subjects NNS N
are VBP N
particularly RB N
susceptible JJ N
to TO N
the DT N
detrimental JJ N
effects NNS N
of IN N
nicotine NN i
. . N

-DOCSTART- -15302308- O O

Gonadotropin-releasing VBG i
hormone NN i
agonist NN i
with IN p
or CC p
without IN p
raloxifene NN i
: : i
effects NNS N
on IN N
cognition NN o
, , o
mood NN o
, , o
and CC o
quality NN o
of IN o
life NN o
. . o

-DOCSTART- -17941914- O O

Maternal JJ N
breast-milk NN N
and CC N
intestinal JJ N
bifidobacteria NNS N
guide VBP N
the DT N
compositional JJ N
development NN N
of IN N
the DT N
Bifidobacterium NNP N
microbiota NN N
in IN N
infants NNS p
at IN p
risk NN p
of IN p
allergic JJ p
disease NN p
. . p

BACKGROUND IN N
The DT N
sources NNS N
and CC N
the DT N
impact NN N
of IN N
maternal JJ N
bacteria NNS N
on IN N
the DT N
initial JJ N
inoculum NN N
of IN N
the DT N
intestinal JJ N
microflora NN N
of IN N
newborn JJ N
infants NNS N
remain VBP N
elusive JJ N
. . N

OBJECTIVE NN N
To TO N
assess VB N
the DT N
association NN N
between IN N
maternal JJ N
breast-milk NN N
and CC N
fecal JJ N
bifidobacteria NN N
and CC N
infants NNS N
' POS N
fecal JJ N
bifidobacteria NN N
. . N

METHODS NNP N
Sixty-one JJ p
mother-infant JJ p
pairs NNS p
were VBD p
included VBN p
, , p
special JJ p
emphasis NN p
being VBG p
placed VBN p
on IN p
the DT p
maternal JJ p
allergic NN p
status NN p
. . p

Bifidobacteria NNP o
were VBD o
analysed VBN o
by IN i
a DT i
direct JJ i
PCR NNP i
method NN i
in IN i
fecal JJ i
samples NNS i
from IN i
mothers NNS i
at IN N
30-35 JJ N
weeks NNS N
of IN N
gestation NN N
and CC N
from IN N
infants NNS N
at IN N
1 CD N
month NN N
of IN N
age NN N
and CC N
from IN N
breast-milk JJ i
samples NNS i
1 CD i
month NN i
post-partum NN i
. . i

RESULTS NNP N
Fecal NNP N
Bifidobacterium NNP N
adolescentis NN N
and CC N
Bifidobacterium NNP N
bifidum NN N
colonization NN N
frequencies NNS N
and CC N
counts NNS N
among IN N
mother-infant JJ N
pairs NNS N
correlated VBN N
significantly RB N
( ( N
P=0.005 NNP N
and CC N
0.02 CD N
for IN N
frequencies NNS N
, , N
respectively RB N
, , N
and CC N
P=0.002 NNP N
and CC N
0.01 CD N
for IN N
counts NNS N
, , N
respectively RB N
) ) N
. . N

Only JJ N
infants NNS p
of IN p
allergic NN p
, , p
atopic NN p
mothers NNS p
were VBD N
colonized VBN N
with IN N
B. NNP N
adolescentis NN N
. . N

Each DT N
of IN N
the DT N
breast-milk NN N
samples NNS N
contained VBN N
bifidobacteria NNS N
[ NNP N
median JJ N
1.4 CD N
x JJ N
10 CD N
( ( N
3 CD N
) ) N
bacterial JJ N
cells/mL NN N
; : N
interquartile JJ N
range NN N
( ( N
IQR NNP N
) ) N
48.7-3.8 CD N
x $ N
10 CD N
( ( N
3 CD N
) ) N
] NN N
. . N

Bifidobacterium NNP o
longum NN o
was VBD N
the DT N
most RBS N
frequently RB N
detected VBN N
species NNS N
in IN N
breast-milk NN N
. . N

Allergic NNP p
mothers NNS p
had VBD N
significantly RB N
lower JJR N
amounts NNS N
of IN N
bifidobacteria NN o
in IN N
breast-milk NN N
compared VBN N
with IN N
non-allergic JJ N
mothers NNS N
[ VBP N
median JJ N
1.3 CD N
x JJ N
10 CD N
( ( N
3 CD N
) ) N
bacterial NN N
cells/mL NN N
( ( N
IQR NNP N
22.4-3.0 CD N
x NNP N
10 CD N
( ( N
3 CD N
) ) N
) ) N
vs. FW N
5.6 CD N
x $ N
10 CD N
( ( N
3 CD N
) ) N
bacterial NN N
cells/mL NN N
( ( N
1.8 CD N
x RB N
10 CD N
( ( N
3 CD N
) ) N
-1.8 NN N
x $ N
10 CD N
( ( N
4 CD N
) ) N
) ) N
, , N
respectively RB N
, , N
( ( N
P=0.004 NNP N
) ) N
] NN N
, , N
and CC N
their PRP$ N
infants NNS N
had VBD N
concurrently RB N
lower JJR N
counts NNS N
of IN N
bifidobacteria NN o
in IN o
feces NNS o
[ VBP N
3.9 CD N
x JJ N
10 CD N
( ( N
8 CD N
) ) N
bacterial NN N
cells/g NN N
( ( N
IQR NNP N
6.5 CD N
x NN N
10 CD N
( ( N
6 CD N
) ) N
-1.5 NN N
x $ N
10 CD N
( ( N
9 CD N
) ) N
) ) N
in IN N
infants NNS N
of IN N
allergic JJ N
mothers NNS N
, , N
vs. FW N
2.5 CD N
x $ N
10 CD N
( ( N
9 CD N
) ) N
bacterial NN N
cells/g NN N
( ( N
6.5 CD N
x RB N
10 CD N
( ( N
8 CD N
) ) N
-3.2 NN N
x $ N
10 CD N
( ( N
10 CD N
) ) N
) ) N
in IN N
infants NNS N
of IN N
non-allergic JJ N
mothers NNS N
, , N
P=0.013 NNP N
] NNP N
. . N

CONCLUSIONS NNP N
Breast-milk NNP N
contains VBZ N
significant JJ N
numbers NNS N
of IN N
bifidobacteria NN N
and CC N
the DT N
maternal JJ N
allergic NN N
status NN N
further RBR N
deranges VBZ N
the DT N
counts NNS N
of IN N
bifidobacteria NN N
in IN N
breast-milk NN N
. . N

Maternal NNP N
fecal JJ N
and CC N
breast-milk JJ N
bifidobacterial JJ N
counts NNS N
impacted VBN N
on IN N
the DT N
infants NNS N
' POS N
fecal JJ N
Bifidobacterium NN N
levels NNS N
. . N

Breast-milk NNP N
bacteria NN N
should MD N
thus RB N
be VB N
considered VBN N
an DT N
important JJ N
source NN N
of IN N
bacteria NNS N
in IN N
the DT N
establishment NN N
of IN N
infantile JJ N
intestinal JJ N
microbiota NN N
. . N

-DOCSTART- -18449445- O O

Immunoenhanced NNP i
enteral JJ i
nutrition NN i
formulas NNS i
in IN N
head NN p
and CC p
neck NN p
cancer NN p
surgery NN p
: : p
a DT N
prospective JJ N
, , N
randomized JJ N
clinical JJ N
trial NN N
. . N

INTRODUCTION NNP N
Significant NNP N
malnutrition NN N
exists VBZ N
in IN N
a DT N
high JJ N
percentage NN N
of IN N
patients NNS p
with IN p
head NN p
and CC p
neck NN p
cancer NN p
. . p

Malnutrition NNP N
is VBZ N
associated VBN N
with IN N
defects NNS N
in IN N
immune JJ N
function NN N
that WDT N
may MD N
impair VB N
the DT N
host NN N
response NN N
to TO N
malignancy NN N
. . N

Malnutrition NNP N
and CC N
immunosupression NN N
make VBP N
patients NNS N
highly RB N
susceptible JJ N
to TO N
postoperative JJ N
infections NNS N
and CC N
complications NNS N
. . N

OBJECTIVES NNP N
Compare NNP N
two CD N
immunoenhanced VBD i
enteral JJ i
nutritions NNS i
with IN N
a DT N
control NN N
diet NN N
, , N
and CC N
evaluate VB N
the DT N
effect NN N
in IN N
postoperative JJ o
infections NNS o
, , o
length NN o
of IN o
stay NN o
and CC o
inflammatory JJ o
markers NNS o
. . o

PATIENTS VB N
A DT p
population NN p
of IN p
44 CD p
patients NNS p
with IN p
oral JJ p
and CC p
laryngeal JJ p
cancer NN p
was VBD p
enrolled VBN p
in IN p
a DT p
randomized JJ p
trial NN p
. . p

At IN N
surgery NN N
, , N
patients NNS N
were VBD N
randomly RB N
allocated VBN N
to TO N
three CD N
groups NNS N
: : N
( ( N
group NN N
I PRP N
) ) N
; : N
patients NNS N
receiving VBG N
an DT N
arginine-enhanced JJ i
formula NN i
( ( N
group NN N
II NNP N
) ) N
; : N
patients NNS N
receiving VBG N
a DT N
standard JJ i
polymeric NN i
formula NN i
, , N
and CC N
( ( N
group NN N
III NNP N
) ) N
patients NNS N
receiving VBG N
an DT N
arginine NN i
, , i
RNA NNP i
and CC i
omega-3 JJ i
fatty JJ i
acids NNS i
enhanced VBD i
formula NN i
, , N
in IN N
an DT N
isonitrogenous JJ N
way NN N
. . N

RESULTS VB N
The DT N
duration NN o
of IN o
enteral JJ o
nutrition NN o
in IN N
the DT N
three CD N
groups NNS N
was VBD N
similar JJ N
with IN N
an DT N
average JJ N
duration NN N
of IN N
14,5 CD N
+/- JJ N
8 CD N
days NNS N
. . N

The DT N
length NN o
of IN o
postoperative JJ o
stay NN o
was VBD N
similar JJ N
, , N
with IN N
an DT N
average NN N
of IN N
19,8 CD N
+/- JJ N
8,5 CD N
days NNS N
. . N

Wound JJ o
infections NNS o
and CC o
general JJ o
infections NNS o
were VBD N
more RBR N
frequent JJ N
in IN N
the DT N
control NN N
group NN N
. . N

Fistula NNP o
rates NNS o
were VBD N
not RB N
improved VBN N
in IN N
the DT N
enhanced JJ N
diet JJ N
groups NNS N
. . N

No DT N
significant JJ N
intergroup NN N
differences NNS N
in IN N
the DT N
trend NN N
of IN N
the DT N
two CD o
plasma NN o
proteins NNS o
( ( o
albumin NN o
, , o
transferrin NN o
) ) o
, , o
lymphocytes VBZ o
, , o
weight NN o
, , o
IL-6 NNP o
, , o
CPR NNP o
and CC o
TNFalpha NNP o
were VBD N
detected VBN N
. . N

The DT N
control NN N
group NN N
showed VBD N
the DT N
highest JJS N
levels NNS N
of IN N
TNFalpha NNP o
at IN N
the DT N
fourteenth JJ N
postoperative JJ N
day NN N
. . N

Gastrointestinal JJ o
tolerance NN o
and CC o
diarrhoea NN o
rate NN o
were VBD N
similar JJ N
in IN N
all PDT N
the DT N
patients NNS N
. . N

CONCLUSIONS NNP N
Immunoenhanced NNP i
enteral JJ i
nutrition NN i
formulas NNS i
improved VBD N
the DT N
infection NN o
rate NN o
in IN N
the DT N
postoperative NN N
of IN N
head NN p
and CC p
neck NN p
cancer NN p
patients NNS p
. . p

In IN N
the DT N
fistula NN o
rates NNS o
, , N
we PRP N
observed VBD N
that DT N
technical JJ N
problems NNS N
and CC N
nutritional JJ N
status NN N
might MD N
have VB N
played VBN N
an DT N
equally RB N
important JJ N
role NN N
, , N
and CC N
therefore RB N
the DT N
positive JJ N
effect NN N
of IN N
immunonutrition NN N
in IN N
this DT N
parameter NN N
might MD N
have VB N
been VBN N
overestimated VBN N
. . N

-DOCSTART- -10390407- O O

Comparison NNP N
of IN N
the DT N
relative JJ N
efficacy NN o
of IN N
formoterol NN N
and CC N
salmeterol NN N
in IN N
asthmatic JJ p
patients NNS p
. . p

Studies NNS N
performed VBD N
on IN N
airway NN N
smooth JJ N
muscle NN N
in IN N
vitro NNS N
have VBP N
indicated VBN N
that IN N
salmeterol NN N
is VBZ N
a DT N
partial JJ N
agonist NN N
on IN N
the DT N
beta2-receptor NN N
in IN N
comparison NN N
to TO N
formoterol VB N
. . N

In IN N
the DT N
present JJ N
study NN N
we PRP N
evaluated VBD N
whether IN N
these DT N
pharmacological JJ N
differences NNS N
between IN N
salmeterol NN N
and CC N
formoterol NN N
also RB N
are VBP N
applicable JJ N
to TO N
asthmatic JJ p
patients NNS p
. . p

The DT N
protective JJ N
effects NNS N
by IN N
increasing VBG N
cumulative JJ N
doses NNS N
of IN N
formoterol NN i
( ( N
12 CD N
, , N
60 CD N
, , N
120 CD N
micrograms NNS N
) ) N
and CC N
salmeterol NN i
( ( N
50 CD N
, , N
250 CD N
, , N
500 CD N
micrograms NNS N
) ) N
on IN N
methacholine-induced JJ N
bronchoconstriction NN N
were VBD N
evaluated VBN N
in IN N
a DT N
double-blind NN N
, , N
crossover NN N
, , N
placebo-controlled JJ N
design NN N
. . N

Patients NNS p
were VBD N
regularly RB i
treated VBN i
with IN i
salbutamol JJ i
200 CD i
micrograms NNS i
twice RB i
daily RB i
during IN i
the DT i
study NN i
period NN i
, , i
to TO i
avoid VB i
variability NN i
in IN i
beta2-adrenoceptor JJ o
tolerance NN o
. . o

S-potassium NN o
, , o
heart NN o
rate NN o
corrected VBD o
Q-T NNP o
interval NN o
( ( o
Q-Tc NNP o
) ) o
, , o
and CC o
tremor NN o
score NN o
were VBD i
followed VBN i
as IN i
measures NNS i
of IN i
systemic JJ i
effects NNS i
. . i

Formoterol NNP i
dose-dependently RB N
protected VBD N
against IN N
methacholine NN i
responsiveness NN i
( ( i
4.6 CD i
doubling VBG i
doses NNS i
after IN i
120 CD i
micrograms NNS i
) ) i
. . N

Salmeterol NNP N
, , N
however RB N
, , N
showed VBD N
a DT N
flatter JJ N
dose-response JJ N
curve NN N
, , N
and CC N
a DT N
significantly RB N
weaker JJR N
maximal JJ N
protective JJ N
effect NN N
( ( N
2.8 CD N
doubling VBG N
doses NNS N
after IN N
250 CD N
micrograms NNS N
) ) N
. . N

Formoterol NNP N
caused VBD N
a DT N
significantly RB N
higher JJR N
tremor NN o
score NN o
and CC N
a DT N
larger JJR N
drop NN N
in IN N
S-potassium NNP o
than IN N
salmeterol NN N
at IN N
the DT N
highest JJS N
doses NNS N
. . N

These DT N
data NNS N
show VBP N
that IN N
salmeterol NN N
is VBZ N
a DT N
partial JJ N
agonist NN N
on IN N
the DT N
beta2-receptor NN N
in IN N
relation NN N
to TO N
formoterol VB N
in IN N
human JJ N
airways NNS N
in IN N
vivo NN N
. . N

Further JJ N
studies NNS N
are VBP N
required VBN N
to TO N
document VB N
the DT N
clinical JJ N
consequences NNS N
of IN N
this DT N
finding NN N
, , N
for IN N
example NN N
in IN N
severe JJ p
asthmatic JJ p
patients NNS p
. . p

-DOCSTART- -24914426- O O

Antibacterial JJ o
effects NNS o
of IN N
fluoride JJ N
varnish JJ N
compared VBN N
with IN N
chlorhexidine JJ N
plus CC N
fluoride JJ N
in IN N
disabled JJ p
children NNS p
. . p

PURPOSE NNP N
To TO N
evaluate VB N
the DT N
effects NNS N
of IN N
fluoride JJ N
varnish JJ N
vs NN N
a DT N
combination NN N
of IN N
chlorhexidine-thymol JJ N
varnish JJ N
plus CC N
a DT N
gel NN N
containing VBG N
chlorhexidine NN N
and CC N
fluoride NN N
on IN N
oral JJ N
hygiene NN N
and CC N
caries NNS N
prevention NN N
in IN N
disabled JJ p
children NNS p
. . p

MATERIALS NNP N
AND CC N
METHODS NNP N
Ninety NNP p
patients NNS p
aged VBN p
3-17 CD p
years NNS p
who WP p
were VBD p
treated VBN p
under IN p
general JJ p
anaesthesia NN p
were VBD N
randomly RB N
assigned VBN N
into IN N
three CD N
groups NNS N
as IN N
follows VBZ N
: : N
group NN N
1 CD N
: : N
Fluor NNP i
Protector NNP i
( ( i
0.1 CD i
% NN i
fluoride JJ i
varnish NN i
) ) i
; : i
group NN i
2 CD i
: : i
Cervitec JJ i
Plus NNP i
( ( i
1 CD i
% NN i
chlorhexidine- JJ i
1 CD i
% NN i
thymol JJ i
varnish NN i
) ) i
+ VBZ i
Cervitec JJ i
Gel NNP i
( ( i
0.2 CD i
% NN i
chlorhexidine-0.2 JJ i
% NN i
sodium NN i
fluoride NN i
) ) i
; : i
group NN i
3 CD i
: : i
control NN i
( ( i
toothbrushing VBG i
only RB N
) ) N
. . N

Mutans NNPS o
streptococci NN o
( ( o
MS NNP o
) ) o
and CC o
lactobacilli $ o
( ( o
LB NNP o
) ) o
levels NNS o
, , o
visible JJ o
plaque NN o
index NN o
( ( o
VPI NNP o
) ) o
and CC o
gingival JJ o
bleeding NN o
index NN o
( ( o
GBI NNP o
) ) o
were VBD N
evaluated VBN N
at IN N
four CD N
stages NNS N
: : N
T0 NNP N
, , N
before IN N
general JJ N
anaesthesia NN N
; : N
T1 NNP N
, , N
one CD N
month NN N
after IN N
treatment NN N
; : N
T2 NNP N
, , N
six CD N
months NNS N
after IN N
treatment NN N
; : N
T3 NNP N
, , N
twelve JJ N
months NNS N
after IN N
treatment NN N
. . N

The DT N
data NNS N
were VBD N
evaluated VBN N
using VBG N
Kruskal-Wallis NNP o
and CC o
Mann-Whitney NNP o
U-tests NNS o
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

RESULTS NNP N
Groups NNP N
1 CD N
and CC N
2 CD N
showed VBD N
significantly RB o
lower JJR o
scores NNS o
than IN N
group NN N
3 CD N
for IN N
all DT N
parameters NNS N
at IN N
T1 NNP N
and CC N
T2 NNP N
. . N

No NNP o
statistically RB o
significant JJ o
difference NN o
was VBD N
detected VBN N
among IN N
any DT N
of IN N
the DT N
the DT N
groups NNS N
at IN N
T3 NNP N
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
. . N

CONCLUSION VB N
The DT N
use NN N
of IN N
materials NNS N
that WDT N
include VBP N
both DT N
fluoride JJ N
and CC N
chlorhexidine NN N
as IN N
routine JJ N
treatment NN N
of IN N
children NNS p
with IN p
disability NN p
may MD N
increase VB N
the DT N
success NN o
of IN o
restorations NNS o
by IN o
improving VBG o
oral JJ o
hygiene NN o
, , o
reduce VB o
the DT o
need NN o
for IN o
future JJ o
restorative JJ o
treatments NNS o
and CC o
thus RB o
the DT o
need NN o
for IN o
general JJ o
anaesthesia NN o
. . o

-DOCSTART- -21661164- O O

[ JJ i
Diabetic NNP i
retinopathy NN i
candesartan NN i
trial NN N
] NN N
. . N

-DOCSTART- -23715565- O O

Prospective JJ N
investigation NN N
of IN N
body NN N
mass NN N
index NN N
, , N
colorectal JJ o
adenoma NN o
, , N
and CC N
colorectal JJ o
cancer NN o
in IN N
the DT N
prostate NN N
, , N
lung NN N
, , N
colorectal NN N
, , N
and CC N
ovarian JJ N
cancer NN N
screening VBG N
trial NN N
. . N

PURPOSE NNP N
Obesity NNP N
has VBZ N
consistently RB N
been VBN N
linked VBN N
to TO N
an DT N
increased VBN N
risk NN o
of IN o
colorectal JJ o
cancer NN o
, , N
particularly RB N
among IN N
men NNS N
. . N

Whether NNP N
body NN N
mass NN N
index NN N
( ( N
BMI NNP N
) ) N
differentially RB N
influences VBZ N
the DT N
risk NN N
across IN N
the DT N
stages NNS N
of IN N
colorectal JJ N
cancer NN N
development NN N
remains VBZ N
unclear JJ N
. . N

We PRP N
evaluated VBD N
the DT N
associations NNS N
of IN N
BMI NNP N
with IN N
colorectal JJ o
adenoma NN o
incidence NN o
, , o
adenoma JJ o
recurrence NN o
, , o
and CC o
cancer NN o
in IN N
the DT N
context NN N
of IN N
a DT N
large JJ N
screening VBG N
trial NN N
, , N
in IN N
which WDT N
cases NNS N
and CC N
controls NNS N
had VBD N
an DT N
equal JJ N
chance NN N
for IN N
disease JJ N
detection NN N
. . N

METHODS NNP N
We PRP N
prospectively RB N
evaluated VBD N
the DT N
association NN N
between IN N
baseline NN p
BMI NNP p
and CC p
the DT p
risk NN p
of IN p
incident JJ o
distal JJ o
adenoma NN o
( ( p
1,213 CD p
cases NNS p
) ) p
, , p
recurrent JJ o
adenoma NN o
( ( p
752 CD p
cases NNS p
) ) p
, , p
and CC p
incident JJ o
colorectal NN o
cancer NN o
( ( p
966 CD p
cases NNS p
) ) p
among IN p
men NNS p
and CC p
women NNS p
, , p
ages VBZ p
55 CD p
to TO p
74 CD p
years NNS p
, , p
randomly RB p
assigned VBN p
to TO p
receive VB p
flexible JJ i
sigmoidoscopy NN i
screening NN i
as IN p
part NN p
of IN p
the DT p
Prostate NNP p
, , p
Lung NNP p
, , p
Colorectal NNP p
, , p
and CC p
Ovarian JJ p
Cancer NNP p
Screening NNP p
Trial NNP p
. . p

We PRP N
calculated VBD N
odds NNS o
ratios NNS o
( ( o
ORs NNP o
) ) o
and CC o
95 CD o
% NN o
CIs NNP o
for IN N
adenoma NN o
incidence NN o
and CC o
recurrence NN o
, , N
and CC N
hazard JJ o
ratios NNS o
( ( o
HRs NNP o
) ) o
and CC N
95 CD o
% NN o
CIs NNP o
for IN N
colorectal JJ o
cancer NN o
incidence NN o
, , N
using VBG N
multivariable-adjusted JJ N
models NNS N
. . N

RESULTS NNP N
Compared VBD N
with IN N
normal-weight JJ N
men NNS N
( ( N
18.5 CD N
to TO N
24.9 CD N
kg/m NNS N
( ( N
2 CD N
) ) N
) ) N
, , N
obese JJ N
men NNS N
( ( N
? . N
30 CD N
kg/m NN N
( ( N
2 CD N
) ) N
) ) N
had VBD N
significantly RB N
higher JJR o
risk NN o
of IN o
incident JJ o
adenoma NN o
( ( o
OR NNP N
, , N
1.32 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
1.06 CD N
to TO N
1.65 CD N
) ) N
and CC o
colorectal JJ o
cancer NN o
( ( o
HR NNP N
, , N
1.48 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
1.16 CD N
to TO N
1.89 CD N
) ) N
and CC N
a DT N
borderline NN N
increased VBN N
risk NN N
of IN N
recurrent NN o
adenoma NN o
( ( o
OR NNP N
, , N
1.50 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
0.98 CD N
to TO N
2.30 CD N
) ) N
. . N

No UH N
associations NNS N
were VBD N
observed VBN N
for IN N
either DT o
adenoma NN o
or CC o
cancer NN o
in IN o
women NNS N
. . N

CONCLUSION NNP N
Data NNP N
from IN N
this DT N
large JJ N
prospective JJ N
study NN N
suggest VBP N
that IN N
obesity NN N
is VBZ N
important JJ N
throughout IN N
the DT N
natural JJ N
history NN N
of IN N
colorectal JJ o
cancer NN o
, , o
at IN N
least JJS N
in IN N
men NNS N
, , N
and CC o
colorectal JJ o
cancer NN o
prevention NN o
efforts NNS N
should MD N
encourage VB N
the DT N
achievement NN N
and CC N
maintenance NN N
of IN N
a DT N
healthy JJ N
body NN N
weight NN N
in IN N
addition NN N
to TO N
regular JJ N
screenings NNS N
. . N

-DOCSTART- -3926042- O O

Relief NN N
of IN N
pain NN o
by IN N
infusion NN N
of IN N
morphine NN i
after IN N
operation NN N
: : N
does VBZ N
tolerance VB o
develop VB N
? . N
To TO N
see VB N
whether IN N
continuous JJ N
intravenous JJ N
infusion NN N
of IN N
opiates NNS N
provides VBZ N
more RBR N
effective JJ N
postoperative JJ o
relief NN o
of IN o
pain NN o
than IN N
conventional JJ N
intramuscular JJ N
injection NN N
these DT N
regimens NNS N
were VBD N
compared VBN N
in IN N
a DT N
prospective JJ N
double NN N
blind IN N
trial NN N
. . N

Thirty NN p
patients NNS p
undergoing VBG p
elective JJ p
cholecystectomy NN p
were VBD p
allocated VBN p
randomly RB N
to TO N
receive VB N
an DT N
infusion NN N
of IN N
morphine NN i
or CC N
an DT N
infusion NN N
of IN N
placebo NN i
( ( N
control VB N
group NN N
) ) N
for IN N
24 CD N
hours NNS N
. . N

Both DT N
groups NNS N
were VBD N
allowed VBN N
supplementary JJ N
morphine NN i
boluses NNS N
as IN N
requested JJ N
. . N

During IN N
the DT N
first JJ N
48 CD N
hours NNS N
after IN N
operation NN N
the DT N
degree NN o
of IN o
pain NN o
was VBD N
almost RB N
identical JJ N
between IN N
the DT N
groups NNS N
. . N

Surprisingly RB N
, , N
the DT N
group NN N
that WDT N
was VBD N
given VBN N
the DT N
infusion NN N
of IN N
morphine NN N
received VBN N
as IN N
much JJ N
supplementary JJ N
morphine NN i
as IN N
the DT N
control NN N
group NN N
during IN N
the DT N
first JJ N
24 CD N
hours NNS N
and CC N
appreciably RB N
more RBR N
during IN N
the DT N
24 CD N
hours NNS N
after IN N
the DT N
infusion NN N
had VBD N
been VBN N
withdrawn VBN N
. . N

Nausea NN o
and CC o
vomiting NN o
were VBD N
more RBR N
prevalent JJ N
among IN N
the DT N
patients NNS N
given VBN N
the DT N
infusion NN N
of IN N
morphine NN i
. . i

These DT N
results NNS N
suggest VBP N
that IN N
continuous JJ N
infusion NN N
of IN N
morphine NN i
may MD N
be VB N
an DT N
inferior JJ N
regimen NNS N
to TO N
intermittent VB N
bolus JJ N
administration NN N
in IN N
the DT N
relief NN o
of IN o
postoperative JJ o
pain NN o
. . o

This DT N
may MD N
be VB N
explained VBN N
by IN N
the DT N
development NN N
of IN N
tolerance NN o
in IN N
patients NNS p
who WP p
received VBD p
the DT p
infusion NN p
of IN p
morphine NN i
. . i

-DOCSTART- -14521638- O O

Randomized VBN N
controlled JJ N
trial NN N
of IN N
education NN N
and CC N
feedback NN N
for IN N
implementation NN N
of IN N
guidelines NNS N
for IN N
acute NN N
low JJ N
back RB N
pain NN N
. . N

OBJECTIVE CC N
The DT N
effect NN N
of IN N
clinical JJ N
guidelines NNS N
on IN N
resource NN N
utilization NN N
for IN N
complex JJ N
conditions NNS N
with IN N
substantial JJ N
barriers NNS N
to TO N
clinician JJ N
behavior NN N
change NN N
has VBZ N
not RB N
been VBN N
well RB N
studied VBN N
. . N

We PRP N
report VBP N
the DT N
impact NN N
of IN N
a DT N
multifaceted JJ i
guideline NN i
implementation NN i
intervention NN i
on IN N
primary JJ p
care NN p
clinician JJ p
utilization NN N
of IN N
radiologic NN N
and CC N
specialty NN N
services NNS N
for IN N
the DT N
care NN N
of IN N
acute NN N
low JJ N
back RB N
pain NN N
. . N

DESIGN NNP N
Physician JJ p
groups NNS p
were VBD N
randomized VBN N
to TO N
receive VB N
guideline JJ i
education NN i
and CC i
individual JJ i
feedback NN i
, , i
supporting VBG i
patient JJ i
education NN i
materials NNS i
, , i
both DT i
, , N
or CC N
neither RB i
. . i

The DT N
impact NN N
on IN N
guideline NN N
adherence NN N
and CC N
resource NN N
utilization NN N
was VBD N
evaluated VBN N
during IN N
the DT N
12-month JJ N
period NN N
before IN N
and CC N
after IN N
implementation NN N
. . N

PARTICIPANTS NNP N
Fourteen NNP p
physician JJ p
groups NNS p
with IN p
120 CD p
primary JJ p
care NN p
physician NN p
and CC p
associate JJ p
practitioners NNS p
from IN p
2 CD p
group NN p
model NN p
HMO NNP p
practices NNS p
. . p

INTERVENTIONS NNP N
Guideline NNP i
implementation NN i
utilized VBD N
an DT N
education/audit/feedback NN N
model NN N
with IN N
local JJ N
peer NN N
opinion NN N
leaders NNS N
. . N

The DT N
patient JJ i
education NN i
component NN i
included VBD i
written VBN i
and CC i
videotaped VBN i
materials NNS i
on IN i
the DT i
care NN i
of IN i
low JJ i
back RB i
pain NN i
. . i

MAIN NNP N
RESULTS NNP N
The DT N
clinician JJ i
intervention NN i
was VBD N
associated VBN N
with IN N
an DT N
absolute JJ N
increase NN N
in IN N
guideline-consistent JJ o
behavior NN o
of IN N
5.4 CD N
% NN N
in IN N
the DT N
intervention NN N
group NN N
versus VBD N
a DT N
decline NN N
of IN N
2.7 CD N
% NN N
in IN N
the DT N
control NN N
group NN N
( ( N
P NNP N
=.04 NNP N
) ) N
. . N

The DT N
patient JJ N
education NN N
intervention NN N
produced VBD N
no DT N
significant JJ N
change NN N
in IN N
guideline-consistent JJ o
behavior NN o
, , N
but CC N
was VBD N
poorly RB N
adopted VBN N
. . N

Patient JJ N
characteristics NNS N
including VBG N
duration NN o
of IN o
pain NN o
, , o
prior JJ o
history NN o
of IN o
low JJ o
back RB o
pain NN o
, , o
and CC o
number NN o
of IN o
visits NNS o
during IN N
the DT N
illness JJ N
episode NN N
were VBD N
strong JJ N
predictors NNS N
of IN N
service NN N
utilization NN N
and CC N
guideline-consistent JJ N
behavior NN N
. . N

CONCLUSIONS NNP N
Implementation NNP N
of IN N
an DT N
education NN N
and CC N
feedback-supported JJ N
acute NN N
low JJ N
back RB N
pain NN N
care NN N
guideline NN N
for IN N
primary JJ p
care NN p
clinicians NNS p
was VBD N
associated VBN N
with IN N
an DT N
increase NN N
in IN N
guideline-consistent JJ N
behavior NN N
. . N

Patient JJ N
education NN N
materials NNS N
did VBD N
not RB N
enhance VB N
guideline NN N
effectiveness NN N
. . N

Implementation NNP N
barriers NNS N
could MD N
limit VB N
the DT N
utility NN N
of IN N
this DT N
approach NN N
in IN N
usual JJ p
care NN p
settings NNS p
. . p

-DOCSTART- -24874588- O O

Effects NNS o
of IN o
surfactant NN o
on IN N
biofilm NN N
formation NN N
on IN N
silicone NN i
nasal NN i
splints NNS i
. . i

Biofilms NNS i
are VBP N
sessile JJ N
communities NNS N
of IN N
bacteria NNS N
embedded VBN N
in IN N
self-produced JJ N
extracellular JJ N
polysaccharide NN N
matrix NN N
and CC N
are VBP N
considered VBN N
to TO N
be VB N
responsible JJ N
for IN N
bacterial JJ N
infections NNS N
in IN N
humans NNS p
. . p

Topical NNP N
surfactant NN N
use NN N
on IN N
silicone NN N
nasal JJ N
splints NNS N
may MD N
have VB N
a DT N
preventive JJ N
effect NN N
on IN N
biofilm NN o
formation NN o
. . o

The DT N
objective NN N
of IN N
this DT N
study NN N
is VBZ N
to TO N
investigate VB N
the DT N
effect NN N
of IN N
surfactant-containing JJ N
nasal JJ N
solutions NNS N
on IN N
biofilm NN o
formation NN o
over IN N
the DT N
surface NN N
of IN N
silicone NN o
nasal JJ o
splints NNS o
. . o

Forty CD p
patients NNS p
were VBD p
randomized VBN p
after IN p
septoplasty NN i
to TO N
receive VB N
surfactant-containing JJ i
saline JJ i
solution NN i
( ( i
group NN i
1 CD N
) ) N
or CC N
saline VB i
without IN i
surfactant JJ i
( ( N
group NN N
2 CD N
) ) N
. . N

At IN N
the DT N
postoperative JJ N
48th CD N
, , N
72th CD N
and CC N
96th CD N
hours NNS N
, , N
pieces NNS N
of IN N
splint NN N
samples NNS N
were VBD N
taken VBN N
and CC N
prepared VBN N
for IN N
scanning VBG o
electron NN o
microscopic NN o
evaluation NN o
. . o

Biofilm NNP o
formation NN o
was VBD N
observed VBN N
in IN N
3 CD N
, , N
6 CD N
and CC N
14 CD N
of IN N
20 CD N
samples NNS N
in IN N
group NN N
1 CD N
( ( N
surfactant NN N
used VBN N
) ) N
and CC N
3 CD N
, , N
14 CD N
and CC N
20 CD N
of IN N
20 CD N
samples NNS N
in IN N
group NN N
2 CD N
( ( N
control NN N
) ) N
at IN N
48th CD N
, , N
72th CD N
and CC N
96th CD N
hours NNS N
, , N
respectively RB N
. . N

Biofilm NNP o
formation NN o
incidences NNS N
of IN N
groups NNS N
at IN N
48th CD N
hour NN N
were VBD N
similar JJ N
( ( N
p JJ N
> NNP N
0.05 CD N
) ) N
, , N
whereas IN N
it PRP N
was VBD N
significantly RB N
lower JJR N
at IN N
group NN N
1 CD N
regarding VBG N
72th CD N
and CC N
96th CD N
hours NNS N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

Surfactant-containing JJ i
nasal JJ i
solutions NNS i
have VBP N
an DT N
inhibitory JJ N
effect NN N
on IN N
biofilm NN o
formation NN o
over IN N
the DT N
surface NN N
of IN N
silicone NN N
nasal JJ N
splints NNS N
especially RB N
after IN N
48 CD N
h. JJ N
Surfactant-containing JJ i
nasal JJ i
solutions NNS i
may MD N
have VB N
an DT N
important JJ N
role NN N
in IN N
nasal JJ o
septal JJ o
dressing NN o
in IN N
the DT N
future NN N
. . N

-DOCSTART- -17723125- O O

Fondaparinux NNP i
combined VBD i
with IN i
intermittent JJ i
pneumatic JJ i
compression NN i
vs. FW N
intermittent JJ i
pneumatic JJ i
compression NN i
alone RB i
for IN N
prevention NN N
of IN N
venous JJ o
thromboembolism NN o
after IN p
abdominal JJ p
surgery NN p
: : p
a DT N
randomized JJ N
, , N
double-blind JJ N
comparison NN N
. . N

BACKGROUND VB N
The DT N
benefit NN N
of IN N
combined JJ N
mechanical JJ N
and CC N
pharmacologic JJ N
methods NNS N
for IN N
venous JJ o
thromboembolism NN o
prevention NN N
after IN p
abdominal JJ p
surgery NN p
has VBZ N
not RB N
been VBN N
clearly RB N
established VBN N
. . N

OBJECTIVES NNP N
To TO N
compare VB N
the DT N
efficacy NN o
and CC N
safety NN o
of IN N
fondaparinux NN i
in IN i
conjunction NN i
with IN i
intermittent JJ i
pneumatic JJ i
compression NN i
vs. FW N
intermittent JJ i
pneumatic JJ i
compression NN i
alone RB i
in IN N
this DT N
context NN N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
This DT N
was VBD N
a DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
superiority NN N
trial NN N
. . N

Patients NNS p
aged VBN p
at IN p
least JJS p
40 CD p
years NNS p
undergoing JJ p
abdominal JJ p
surgery NN p
were VBD N
randomized VBN N
to TO N
receive VB N
either DT N
fondaparinux JJ i
2.5 CD N
mg NN N
or CC N
placebo NN i
s.c. NN N
for IN N
5-9 JJ N
days NNS N
, , N
starting VBG N
6-8 JJ N
h NN N
postoperatively RB N
. . N

All DT N
patients NNS N
received VBD N
intermittent JJ i
pneumatic JJ i
compression NN i
. . i

The DT N
primary JJ N
efficacy NN N
outcome NN N
was VBD N
venous JJ o
thromboembolism NN o
up RB o
to TO o
day NN o
10 CD o
. . o

The DT N
main JJ N
safety NN N
outcomes NNS N
were VBD N
major JJ o
bleeding NN o
and CC o
all-cause JJ o
mortality NN o
. . o

Follow-up NNP N
lasted VBD N
32 CD N
days NNS N
. . N

RESULTS NNP N
Of IN N
the DT N
1309 CD p
patients NNS p
randomized VBN N
, , N
842 CD N
( ( N
64.3 CD N
% NN N
) ) N
were VBD N
evaluable JJ N
for IN N
efficacy NN N
. . N

The DT N
venous JJ o
thromboembolism NN o
rate NN o
was VBD N
1.7 CD N
% NN N
( ( N
7/424 CD N
) ) N
in IN N
the DT N
fondaparinux-treated JJ i
patients NNS p
and CC N
5.3 CD N
% NN N
( ( N
22/418 CD N
) ) N
in IN N
the DT N
placebo-treated JJ i
patients NNS p
( ( N
odds NNS N
ratio VBP N
reduction NN N
69.8 CD N
% NN N
; : N
95 CD N
% NN N
confidence NN N
interval JJ N
27.9-87.3 JJ N
; : N
P NNP N
= NNP N
0.004 CD N
) ) N
. . N

Fondaparinux NNP i
significantly RB N
reduced VBD N
the DT N
proximal JJ o
deep JJ o
vein NN o
thrombosis NN o
rate NN o
from IN N
1.7 CD N
% NN N
( ( N
7/417 CD N
) ) N
to TO N
0.2 CD N
% NN N
( ( N
1/424 CD N
; : N
P NNP N
= NNP N
0.037 CD N
) ) N
. . N

Major JJ o
bleeds NNS o
occurred VBD N
in IN N
1.6 CD N
% NN N
( ( N
10/635 CD N
) ) N
and CC N
0.2 CD N
% NN N
( ( N
1/650 CD N
) ) N
of IN N
fondaparinux-treated JJ i
and CC N
placebo-treated JJ i
patients NNS N
, , N
respectively RB N
( ( N
P NNP N
= NNP N
0.006 CD N
) ) N
, , N
none NN N
being VBG N
fatal JJ N
or CC N
involving VBG N
a DT N
critical JJ N
organ NN N
. . N

By IN N
day NN N
32 CD N
, , N
eight CD N
patients NNS N
( ( N
1.3 CD N
% NN N
) ) N
receiving NN N
fondaparinux NN i
and CC N
five CD N
( ( N
0.8 CD N
% NN N
) ) N
receiving NN N
placebo NN i
had VBD N
died VBN o
. . o

CONCLUSIONS NNP N
In IN N
patients NNS p
undergoing JJ p
abdominal JJ p
surgery NN p
and CC p
receiving VBG p
intermittent JJ i
pneumatic JJ i
compression NN i
, , i
fondaparinux VBP i
2.5 CD N
mg NN N
reduced VBD N
the DT N
venous JJ o
thromboembolism NN o
rate NN o
by IN N
69.8 CD N
% NN N
as IN N
compared VBN N
to TO N
pneumatic JJ i
compression NN i
alone RB i
, , N
with IN N
a DT N
low JJ o
bleeding NN o
risk NN o
as IN N
compared VBN N
to TO N
placebo VB i
. . i

-DOCSTART- -24830566- O O

Caudal NNP i
epidural JJ i
analgesia NN i
using VBG N
lidocaine JJ i
alone RB i
or CC N
in IN N
combination NN i
with IN i
ketamine NN i
in IN N
dromedary JJ p
camels NNS p
Camelus NNP p
dromedarius NN p
. . p

This DT N
study NN N
was VBD N
performed VBN N
to TO N
investigate VB N
the DT N
analgesic JJ o
effect NN o
of IN N
lidocaine NN i
and CC i
a DT i
combination NN i
of IN i
lidocaine NN i
and CC i
ketamine NN i
following VBG N
epidural JJ N
administration NN N
in IN N
dromedary JJ p
camels NNS p
. . p

Ten CD p
12-18-month-old JJ p
camels NNS p
were VBD N
randomly RB N
divided VBN N
into IN N
two CD N
equal JJ N
groups NNS N
. . N

In IN N
group NN N
L NNP N
, , N
the DT N
animals NNS N
received VBD N
2 CD N
% NN N
lidocaine NN i
( ( N
0.22 CD N
mg/kg NN N
) ) N
and CC N
in IN N
group NN N
LK NNP N
the DT N
animals NNS N
received VBD N
a DT N
mixture NN N
of IN N
10 CD N
% NN N
ketamine NN i
( ( N
1 CD N
mg/kg NN N
) ) N
and CC N
2 CD N
% NN N
lidocaine NN i
( ( N
0.22 CD N
mg/kg NN N
) ) N
administered VBD N
into IN N
the DT N
first JJ N
intercoccygeal NN N
( ( N
Co1-Co2 NNP N
) ) N
epidural JJ N
space NN N
while IN N
standing VBG N
. . N

Onset NNP o
time NN o
and CC o
duration NN o
of IN o
caudal JJ o
analgesia NN o
, , o
sedation NN o
level NN o
and CC o
ataxia NN o
were VBD N
recorded VBN N
after IN N
drug NN N
administration NN N
. . N

Data NNS N
were VBD N
analysed VBN N
by IN N
U NNP N
Mann-Whitney NNP N
tests NNS N
and CC N
significance NN N
was VBD N
taken VBN N
as IN N
p NN N
& CC N
lt NN N
; : N
0.05 CD N
. . N

The DT N
results NNS N
showed VBD N
that IN N
epidural JJ i
lidocaine NN i
and CC N
co-administration NN N
of IN N
lidocaine NN i
and CC i
ketamine VB i
produced VBN N
complete JJ o
analgesia NN o
in IN o
the DT o
tail NN o
, , o
anus NN o
and CC o
perineum NN o
. . o

Epidural JJ N
administration NN N
of IN N
the DT N
lidocaine-ketamine JJ i
mixture NN i
resulted VBD N
in IN N
mild NN o
to TO o
moderate VB o
sedation NN o
, , N
whilst VBP N
the DT N
animals NNS N
that WDT N
received VBD N
epidural JJ i
lidocaine NN i
alone RB N
were VBD N
alert JJ o
and CC o
nervous JJ o
during IN N
the DT N
study NN N
. . N

Ataxia NNP o
was VBD N
observed VBN N
in IN N
all DT N
test NN N
subjects NNS N
and CC N
was VBD N
slightly RB N
more JJR N
severe JJ N
in IN N
camels NNS N
that WDT N
received VBD N
the DT N
lidocaine-ketamine JJ i
mixture NN i
. . i

It PRP N
was VBD N
concluded VBN N
that IN N
epidural JJ N
administration NN N
of IN N
lidocaine JJ i
plus CC i
ketamine JJ i
resulted VBN N
in IN N
longer JJR N
caudal NN N
analgesia NN o
in IN N
standing VBG p
conscious JJ p
dromedary JJ p
camels NNS p
compared VBN N
with IN N
the DT N
effect NN N
of IN N
administering VBG N
lidocaine JJ i
alone RB N
. . N

-DOCSTART- -18453793- O O

Predictive JJ N
validity NN N
of IN N
a DT N
medication NN N
adherence NN N
measure NN N
in IN N
an DT N
outpatient JJ p
setting NN p
. . p

This DT N
study NN N
examines VBZ N
the DT N
psychometric JJ N
properties NNS N
and CC N
tests VBZ N
the DT N
concurrent NN N
and CC N
predictive JJ N
validity NN N
of IN N
a DT N
structured JJ i
, , i
self-reported JJ i
medication NN i
adherence NN i
measure NN i
in IN N
patients NNS p
with IN p
hypertension NN p
. . p

The DT N
authors NNS N
also RB N
assessed VBD N
various JJ N
psychosocial JJ o
determinants NNS o
of IN o
adherence NN o
, , N
such JJ N
as IN N
knowledge NN o
, , o
social JJ o
support NN o
, , o
satisfaction NN o
with IN o
care NN o
, , N
and CC N
complexity NN o
of IN o
the DT o
medical JJ o
regimen NNS o
. . o

A DT p
total NN p
of IN p
1367 CD p
patients NNS p
participated VBN p
in IN p
the DT p
study NN p
; : p
mean JJ p
age NN p
was VBD p
52.5 CD p
years NNS p
, , p
40.8 CD p
% NN p
were VBD p
male JJ p
, , p
76.5 CD p
% NN p
were VBD p
black JJ p
, , p
50.8 CD p
% NN p
graduated VBN p
from IN p
high JJ p
school NN p
, , p
26 CD p
% NN p
were VBD p
married VBN p
, , p
and CC p
54.1 CD p
% NN p
had VBD p
income NN p
< NNP p
$ $ p
5,000 CD p
. . p

The DT N
8-item JJ N
medication NN i
adherence NN i
scale NN N
was VBD N
reliable JJ N
( ( N
alpha=.83 NN N
) ) N
and CC N
significantly RB N
associated VBN N
with IN N
blood NN o
pressure NN o
control NN o
( ( N
P NNP N
< NNP N
.05 NNP N
) ) N
. . N

Using VBG N
a DT N
cutpoint NN N
of IN N
< $ N
6 CD N
, , N
the DT N
sensitivity NN N
of IN N
the DT N
measure NN N
to TO N
identify VB N
patients NNS N
with IN N
poor JJ N
blood NN o
pressure NN o
control NN o
was VBD N
estimated VBN N
to TO N
be VB N
93 CD N
% NN N
, , N
and CC N
the DT N
specificity NN N
was VBD N
53 CD N
% NN N
. . N

The DT N
medication NN N
adherence NN N
measure NN N
proved VBD N
to TO N
be VB N
reliable JJ N
, , N
with IN N
good JJ N
concurrent NN N
and CC N
predictive JJ N
validity NN N
in IN N
primarily RB p
low-income JJ p
, , p
minority NN p
patients NNS p
with IN p
hypertension NN p
and CC N
might MD N
function VB N
as IN N
a DT N
screening VBG N
tool NN N
in IN N
outpatient JJ p
settings NNS p
with IN N
other JJ N
patient NN p
groups NNS p
. . p

-DOCSTART- -22565413- O O

Internet-based JJ i
program NN i
for IN N
coping VBG N
with IN N
cancer NN N
: : N
a DT N
randomized NN N
controlled VBN N
trial NN N
with IN N
hematologic JJ p
cancer NN p
patients NNS p
. . p

OBJECTIVE NNP N
Psychosocial NNP N
patient NN N
care NN N
in IN N
oncology NN N
is VBZ N
no DT N
longer RB N
limited VBN N
to TO N
the DT N
inpatient NN N
setting NN N
. . N

Outpatient NNP N
services NNS N
are VBP N
in IN N
demand NN N
. . N

Internet-based JJ i
interventions NNS i
could MD N
aid VB N
in IN N
optimizing VBG N
service NN N
delivery NN N
across IN N
disciplines NNS N
. . N

The DT N
effectiveness NN N
of IN N
an DT N
Internet-based JJ N
program NN N
for IN N
hematologic JJ p
cancer NN p
patients NNS p
was VBD N
tested VBN N
in IN N
a DT N
randomized NN N
controlled VBN N
trial NN N
under IN N
field NN N
experimental JJ N
conditions NNS N
. . N

METHODS VB N
A DT N
4-week JJ i
cognitive-behavioral JJ i
program NN i
for IN i
coping VBG i
with IN N
cancer NN N
was VBD N
offered VBN N
to TO N
hematologic VB p
cancer NN p
patients NNS p
online VBP p
. . p

One CD p
hundred VBD p
eighty-six JJ p
registrants NNS p
were VBD N
randomly RB N
assigned VBN N
to TO N
an DT N
intervention NN i
group NN i
( ( N
n JJ N
= NNP N
105 CD N
) ) N
or CC N
a DT N
waiting JJ i
list NN i
( ( N
n JJ N
= NNP N
81 CD N
) ) N
. . N

The DT N
outcome NN N
measures NNS N
, , N
'mental JJ o
adjustment NN o
' POS o
( ( o
MAC NNP o
) ) o
and CC o
'psychological JJ o
distress NN o
' POS o
( ( o
BSI NNP o
) ) o
, , N
were VBD N
assessed VBN N
at IN N
registration NN N
and CC N
after IN N
4 CD N
weeks NNS N
. . N

Patient JJ o
satisfaction NN o
was VBD N
assessed VBN N
( ( N
ZUF-8 NNP N
) ) N
, , N
and CC N
complete-cases NNS N
and CC N
intention-to-treat JJ N
analyses NNS N
were VBD N
performed VBN N
. . N

RESULTS NNP N
At IN N
registration NN N
, , N
the DT N
majority NN N
of IN N
participants NNS N
displayed VBN N
clinically RB N
significant JJ N
distress NN N
( ( o
BSI NNP o
) ) o
and CC N
lacked JJ N
alternative JJ N
access NN N
concerning VBG N
psychosocial JJ N
care NN N
. . N

One CD p
hundred VBD p
eleven JJ p
patients NNS p
filled VBN N
out RP N
the DT N
post NN N
questionnaire NN N
at IN N
4 CD N
weeks NNS N
. . N

In IN N
contrast NN N
to TO N
the DT N
waiting VBG N
list NN N
, , N
the DT N
intervention NN N
group NN N
displayed VBD N
a DT N
significant JJ N
increase NN N
in IN N
fighting VBG o
spirit NN o
( ( N
d JJ N
= VBZ N
0.42 CD N
; : N
CI NNP N
95 CD N
% NN N
, , N
0.04 CD N
to TO N
0.80 CD N
) ) N
. . N

The DT N
effect NN N
was VBD N
confirmed VBN N
by IN N
intention-to-treat NN N
analysis NN N
( ( N
d JJ N
= VBZ N
0.33 CD N
; : N
CI NNP N
95 CD N
% NN N
, , N
0.04 CD N
to TO N
0.62 CD N
) ) N
. . N

Otherwise NNP N
, , N
no DT N
effects NNS N
were VBD N
observed VBN N
. . N

Patient JJ o
satisfaction NN o
with IN N
the DT N
program NN N
was VBD N
high JJ N
. . N

CONCLUSION VB N
The DT N
results NNS N
demonstrate VBP N
the DT N
potential JJ N
efficacy NN N
of IN N
Internet-based JJ N
programs NNS N
while IN N
highlighting VBG N
their PRP$ N
limitations NNS N
. . N

Future NNP N
research NN N
is VBZ N
needed VBN N
to TO N
clarify VB N
and CC N
optimize VB N
efficacy NN N
, , N
taking VBG N
different JJ N
program NN N
components NNS N
and CC N
patient JJ N
characteristics NNS N
into IN N
particular JJ N
consideration NN N
. . N

-DOCSTART- -25619686- O O

Three-Arm NNP N
Randomized NNP N
Phase NNP N
III NNP N
Trial NNP N
: : N
Quality NN N
Aloe NNP i
and CC i
Placebo NNP i
Cream NNP N
Versus NNP N
Powder NNP i
as IN N
Skin NNP N
Treatment NNP N
During IN N
Breast NNP p
Cancer NNP p
Radiation NNP p
Therapy NNP p
. . p

BACKGROUND NNP N
The DT N
efficacy NN N
of IN N
aloe JJ i
extract NN i
in IN N
reducing VBG N
radiation-induced JJ o
skin JJ o
injury NN o
is VBZ N
controversial JJ N
. . N

The DT N
purpose NN N
of IN N
the DT N
present JJ N
3-arm JJ N
randomized VBN N
trial NN N
was VBD N
to TO N
test VB N
the DT N
efficacy NN N
of IN N
quality-tested JJ N
aloe NN N
extract NN N
in IN N
reducing VBG N
the DT N
severity NN N
of IN N
radiation-induced JJ N
skin JJ N
injury NN N
and CC N
, , N
secondarily RB N
, , N
to TO N
examine VB N
the DT N
effect NN N
of IN N
a DT N
moist NN i
cream NN i
versus IN N
a DT N
dry JJ i
powder NN i
skin NN i
care NN i
regimen NNS i
. . i

MATERIALS NNP N
AND NNP N
METHODS NNP N
A NNP p
total NN p
of IN p
248 CD p
patients NNS p
with IN p
breast JJ p
cancer NN p
were VBD N
randomized VBN N
to TO N
powder VB i
, , i
aloe VB i
cream NN i
, , N
or CC N
placebo NN i
cream NN i
. . i

Acute NNP o
skin JJ o
toxicity NN o
was VBD N
scored VBN N
weekly JJ N
and CC N
after IN N
treatment NN N
at IN N
weeks NNS N
1 CD N
, , N
2 CD N
, , N
and CC N
4 CD N
using VBG N
a DT N
modified VBN N
10-point JJ N
Catterall NNP N
scale NN N
. . N

The DT N
patients NNS N
scored VBD N
their PRP$ N
symptom JJ N
severity NN N
using VBG N
a DT N
6-point JJ N
Likert NNP N
scale NN N
and CC N
kept VBD N
an DT N
acute JJ N
phase NN N
diary NN N
. . N

RESULTS VB N
The DT N
aloe JJ N
formulation NN N
did VBD N
not RB N
reduce VB o
acute JJ o
skin NN o
toxicity NN o
or CC o
symptom JJ o
severity NN o
. . o

Patients NNS p
with IN N
a DT N
greater JJR N
body NN N
mass NN N
index NN N
were VBD N
more RBR N
likely JJ N
to TO N
develop VB o
acute JJ o
skin NN o
toxicity NN o
. . o

A DT N
similar JJ N
pattern NN N
of IN N
increased VBN N
skin NN o
reaction NN o
toxicity NN o
occurred VBD N
with IN N
both DT N
study NN N
creams NNS N
compared VBN N
with IN N
the DT N
dry JJ N
powder NN N
regimen NNS N
. . N

CONCLUSION NNP N
No NNP N
evidence NN N
was VBD N
found VBN N
to TO N
support VB N
prophylactic JJ N
application NN N
of IN N
quality NN N
aloe VBP i
extract NN i
or CC N
cream NN N
to TO N
improve VB N
the DT N
symptoms NNS N
or CC N
reduce VB N
the DT N
skin NN o
reaction NN o
severity NN o
. . o

Our PRP$ N
results NNS N
support VB N
a DT N
dry JJ N
skin NN N
care NN N
regimen NNS N
of IN N
powder NN N
during IN N
radiation NN N
therapy NN N
. . N

-DOCSTART- -25456370- O O

Everolimus NNP i
for IN N
subependymal JJ N
giant NN N
cell NN N
astrocytoma NN N
in IN N
patients NNS p
with IN p
tuberous JJ p
sclerosis NN p
complex NN p
: : p
2-year JJ N
open-label JJ N
extension NN N
of IN N
the DT N
randomised JJ N
EXIST-1 NNP N
study NN N
. . N

BACKGROUND NNP N
In IN N
the DT N
EXIST-1 NNP N
trial NN N
, , N
initiated VBN N
on IN N
Aug NNP N
10 CD N
, , N
2009 CD N
, , N
more JJR N
than IN N
35 CD N
% NN N
of IN N
patients NNS p
with IN p
subependymal JJ p
giant NN p
cell NN p
astrocytoma NN p
( ( p
SEGA NNP p
) ) p
associated VBN p
with IN p
tuberous JJ p
sclerosis NN p
complex NN p
had VBD N
at IN N
least JJS N
50 CD N
% NN N
reduction NN N
in IN N
SEGA NNP N
volume NN N
after IN N
9?6 CD N
months NNS N
of IN N
treatment NN N
with IN N
everolimus NN N
. . N

In IN N
this DT N
Article NNP N
, , N
we PRP N
report VBP N
interim JJ N
data NNS p
( ( p
up IN p
to TO p
Jan NNP p
11 CD p
, , p
2013 CD p
) ) p
to TO N
support VB N
longer-term JJ N
tolerability NN N
and CC N
efficacy NN N
of IN i
everolimus NN i
from IN N
the DT N
continuing VBG N
4-year JJ N
extension NN N
phase NN N
of IN N
EXIST-1 NNP N
. . N

METHODS NNP N
We PRP N
assessed VBD N
data NNS N
from IN N
a DT N
prospective JJ N
, , N
open-label JJ N
extension NN N
of IN N
a DT N
multicentre NN N
, , N
phase NN N
3 CD N
, , N
randomised VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
study NN N
in IN p
patients NNS p
with IN p
tuberous JJ p
sclerosis NN p
complex NN p
who WP p
had VBD p
SEGA NNP p
that WDT p
was VBD p
growing VBG p
and CC p
needed VBN p
treatment NN p
. . p

In IN N
this DT N
extension NN N
study NN N
, , N
we PRP N
included VBD p
all DT p
patients NNS p
who WP p
had VBD p
been VBN p
assigned VBN i
everolimus RBR i
during IN p
the DT p
double-blind NN p
, , p
randomised VBD p
phase NN p
of IN p
the DT p
trial NN p
and CC p
those DT p
patients NNS p
who WP p
crossed VBD p
over IN p
from IN p
the DT i
placebo NN i
group NN p
to TO p
receive VB i
everolimus NN i
during IN p
the DT p
randomised JJ p
phase NN p
or CC p
at IN p
the DT p
start NN p
of IN p
the DT p
extension NN p
phase NN p
. . p

All DT N
patients NNS N
received VBD N
oral JJ i
everolimus NN i
at IN N
a DT N
starting VBG N
dose NN N
of IN N
4?5 CD N
mg/m NN N
( ( N
2 CD N
) ) N
per IN N
day NN i
. . i

Everolimus NNP i
dose NN i
was VBD N
subsequently RB N
adjusted VBN N
subject NN N
to TO N
tolerability NN N
to TO N
attain VB o
blood NN o
trough IN o
concentrations NNS o
of IN o
5-15 JJ N
ng/mL NN N
. . N

An DT N
independent JJ N
central JJ N
radiology NN N
review NN N
team NN N
assessed VBD N
SEGA NNP N
response NN N
( ( N
at IN N
least JJS N
a DT N
50 CD N
% NN N
reduction NN N
from IN N
baseline NN N
in IN N
total JJ N
volume NN N
of IN N
all DT N
target NN N
SEGAs NNP N
; : N
the DT N
primary JJ N
endpoint NN N
) ) N
by IN N
MRI NNP N
at IN N
12 CD N
, , N
24 CD N
, , N
and CC N
48 CD N
weeks NNS N
, , N
then RB N
every DT N
year NN N
thereafter RB N
in IN N
all DT N
patients NNS N
who WP N
received VBD N
at IN N
least JJS N
one CD N
dose NN N
of IN N
everolimus NN N
. . N

This DT N
study NN N
was VBD N
registered VBN N
with IN N
ClinicalTrials.gov NNP N
, , N
number NN N
NCT00789828 NNP N
. . N

FINDINGS NNP N
Of IN N
the DT p
original JJ p
117 CD p
randomly RB p
assigned VBN p
patients NNS p
, , p
111 CD p
were VBD p
given VBN p
everolimus NNS p
between IN p
Aug NNP p
20 CD p
, , p
2009 CD p
, , p
and CC p
Jan NNP p
11 CD p
, , p
2013 CD p
( ( p
date NN N
of IN N
data NNS N
cutoff NN N
) ) N
; : N
we PRP N
included VBD N
these DT N
patients NNS N
in IN N
our PRP$ N
longer-term JJ N
analysis NN N
. . N

Median JJ N
duration NN N
of IN N
everolimus NN N
exposure NN N
was VBD N
29?3 CD N
months NNS N
( ( N
IQR NNP N
19?4-33?8 CD N
) ) N
. . N

Median JJ N
follow-up NN N
was VBD N
28?3 CD N
months NNS N
( ( N
IQR NNP N
19?3-33?0 CD N
) ) N
. . N

54 CD N
( ( N
49 CD N
% NN N
) ) N
patients NNS N
had VBD N
a DT N
response NN N
of IN N
50 CD N
% NN N
or CC N
greater JJR N
reduction NN o
in IN o
SEGA NNP o
volume NN o
( ( N
95 CD N
% NN N
CI NNP N
39?0-58?3 CD o
) ) o
, , o
and CC o
duration NN o
of IN o
response NN o
was VBD N
between IN N
2?1 CD N
and CC N
31?1 CD N
months NNS N
( ( N
median JJ N
not RB N
reached VBN N
) ) N
. . o

SEGA JJ o
volume NN o
was VBD N
reduced VBN N
by IN N
50 CD N
% NN N
or CC N
more JJR N
in IN N
39 CD N
( ( N
37 CD N
% NN N
) ) N
of IN N
105 CD N
patients NNS N
at IN N
24 CD N
weeks NNS N
, , N
48 CD N
( ( N
46 CD N
% NN N
) ) N
of IN N
104 CD N
patients NNS N
at IN N
48 CD N
weeks NNS N
, , N
36 CD N
( ( N
47 CD N
% NN N
) ) N
of IN N
76 CD N
patients NNS N
at IN N
96 CD N
weeks NNS N
, , N
and CC N
11 CD N
( ( N
38 CD N
% NN N
) ) N
of IN N
29 CD N
patients NNS N
at IN N
144 CD N
weeks NNS N
. . o

Stomatitis NNP o
( ( N
48 CD N
[ RB N
43 CD N
% NN N
] JJ N
patients NNS N
) ) N
and CC o
mouth JJ o
ulceration NN o
( ( N
33 CD N
[ RB N
30 CD N
% NN N
] JJ N
patients NNS N
) ) N
were VBD N
the DT N
most RBS N
frequent JJ N
treatment-related JJ N
adverse JJ N
events NNS o
; : o
infections NNS o
were VBD N
the DT N
most RBS N
commonly RB N
reported VBD N
treatment-related JJ N
serious JJ N
adverse JJ N
event NN N
, , N
occurring VBG N
in IN N
15 CD N
( ( N
14 CD N
% NN N
) ) N
patients NNS N
. . N

35 CD N
( ( N
32 CD N
% NN N
) ) N
patients NNS N
reported VBD N
treatment-related JJ N
grade NN N
3 CD N
or CC N
4 CD N
adverse JJ o
events NNS o
, , o
the DT o
most RBS N
common JJ N
of IN N
which WDT N
were VBD o
stomatitis NN o
( ( N
nine CD N
[ RB N
8 CD N
% NN N
] NN N
) ) N
and CC o
pneumonia NN o
( ( o
nine CD N
[ RB N
8 CD N
% NN N
] NN N
) ) N
. . N

18 CD N
( ( N
16 CD N
% NN N
) ) N
patients NNS N
had VBD N
treatment-related JJ o
serious JJ o
adverse JJ o
events NNS o
. . o

Six NNP o
( ( N
5 CD N
% NN N
) ) N
patients NNS N
withdrew VBD N
because IN o
of IN o
adverse JJ o
events NNS o
. . o

INTERPRETATION NNP o
These DT N
results NNS N
support VBD N
the DT N
longer-term JJ N
use NN N
of IN N
everolimus NN N
in IN p
patients NNS p
who WP p
have VBP p
few JJ p
treatment NN p
options NNS p
and CC p
who WP p
need VBP p
continued VBN p
treatment NN p
for IN p
tuberous JJ p
sclerosis NN p
complex NN p
and CC p
its PRP$ N
varied JJ N
manifestations NNS o
. . o

Reduction NN o
or CC o
stabilisation NN o
of IN o
tumour JJ o
volume NN o
with IN o
everolimus NN i
will MD N
hopefully RB N
provide VB N
long-term JJ N
clinical JJ N
benefit NN N
in IN N
patients NNS N
with IN N
SEGA NNP N
. . N

FUNDING NN N
Novartis NN N
Pharmaceuticals NNP N
. . N

-DOCSTART- -24076133- O O

Local JJ o
contextual JJ o
processing NN o
in IN N
major JJ N
depressive JJ N
disorder NN N
. . N

OBJECTIVE CC N
The DT N
study NN N
investigated VBD N
local JJ o
contextual JJ o
processing NN o
in IN N
patients NNS p
with IN p
major JJ p
depressive JJ p
disorder NN p
( ( p
MDD NNP p
) ) p
. . p

This DT N
was VBD N
defined VBN N
as IN N
the DT N
ability NN N
to TO N
utilize VB N
predictive JJ N
contextual JJ N
information NN N
to TO N
facilitate VB N
detection NN N
of IN N
predictable JJ N
versus NN N
random JJ N
targets NNS N
. . N

METHOD NNP N
We PRP N
recorded VBD N
EEG NNP i
in IN N
15 CD p
MDD NNP p
patients NNS p
and CC p
14 CD p
age-matched JJ p
controls NNS p
. . p

Recording VBG i
blocks NNS i
consisted VBN i
of IN i
targets NNS i
preceded VBN i
by IN i
randomized JJ i
sequences NNS i
of IN i
standards NNS i
and CC i
by IN i
sequences NNS i
of IN i
standards NNS i
that WDT i
included VBD i
a DT i
predictive JJ i
sequence NN i
signaling VBG i
the DT i
occurrence NN i
of IN i
a DT i
subsequent JJ i
target NN i
event NN i
. . i

RESULTS NNP N
Both NNP N
MDD NNP p
patients NNS p
and CC p
age-matched JJ p
controls NNS p
demonstrated VBD N
a DT N
significant JJ o
reaction NN o
time NN o
( ( o
RT NNP o
) ) o
and CC o
P3b NNP o
latency NN o
differences NNS o
between IN N
predicted VBN N
and CC N
random JJ N
targets NNS N
. . N

However RB N
, , N
patients NNS N
demonstrated VBD N
a DT N
specific JJ o
prolongation NN o
of IN N
these DT N
measures NNS N
during IN N
processing NN N
of IN N
predicted JJ N
targets NNS N
, , N
as RB N
well RB N
as IN N
an DT N
attenuation NN o
of IN o
P3b NNP o
amplitudes NNS o
for IN N
the DT N
predictive JJ N
sequence NN N
. . N

In IN N
addition NN N
, , N
patients NNS N
target VBP N
N1 NNP o
amplitudes NNS o
were VBD o
attenuated VBN o
compared VBN N
with IN N
controls NNS i
. . i

CONCLUSION NNP N
MDD NNP p
patients NNS p
were VBD N
able JJ N
to TO N
utilize VB o
predictive JJ o
context NN o
in IN N
order NN N
to TO N
facilitate VB N
processing NN N
of IN N
deterministic JJ N
targets NNS N
, , N
however RB N
, , N
this DT N
ability NN o
was VBD o
limited VBN o
compared VBN N
to TO N
controls NNS N
, , N
as IN N
demonstrated VBN N
by IN N
context-dependent JJ N
P3b NNP N
deficits NNS N
. . N

SIGNIFICANCE NNP N
These DT N
findings NNS N
suggest VBP N
that IN N
patients NNS N
with IN N
major JJ N
depression NN N
have VBP N
altered VBN o
processing NN o
of IN o
local JJ o
contextual JJ o
processing NN o
. . o

-DOCSTART- -9469367- O O

Comparison NNP N
of IN N
single-dose JJ N
oral JJ N
granisetron NN i
versus NN N
intravenous JJ N
ondansetron NN i
in IN N
the DT N
prevention NN N
of IN N
nausea NN o
and CC o
vomiting NN o
induced VBN o
by IN o
moderately RB o
emetogenic JJ o
chemotherapy NN o
: : o
a DT N
multicenter NN N
, , N
double-blind NN N
, , N
randomized VBN N
parallel NN N
study NN N
. . N

PURPOSE VB N
The DT N
antiemetic JJ N
effectiveness NN N
and CC N
safety NN N
of IN N
single-dose JJ N
oral JJ N
granisetron NN i
were VBD N
compared VBN N
with IN N
intravenous JJ N
( ( N
I.V NNP N
. . N

) ) N
ondansetron NN i
in IN N
chemotherapy-naive JJ p
patients NNS p
who WP p
received VBD p
moderately RB i
emetogenic JJ i
chemotherapy NN i
. . i

PATIENTS NNP N
AND CC N
METHODS NNP N
In IN N
this DT N
double-blind NN N
, , N
parallel-group NN p
study NN p
, , p
patients NNS p
naive VBP p
to TO p
emetogenic VB i
chemotherapy NN i
( ( p
N NNP p
= NNP p
1,085 CD p
) ) p
who WP p
were VBD p
scheduled VBN p
to TO p
receive VB p
cyclophosphamide- NN i
( ( i
500 CD i
to TO i
1,200 CD i
mg/m2 NN i
) ) i
or CC i
carboplatin NN i
( ( p
> CD p
or CC p
= VB p
300 CD p
mg/m2 NN p
) ) p
based VBN p
chemotherapy NN p
, , N
were VBD N
randomized VBN N
to TO N
receive VB N
either DT N
oral JJ N
granisetron NN i
( ( N
n JJ N
= NNP N
542 CD N
) ) N
or CC N
I.V NNP N
. . N

ondansetron NN i
( ( N
n JJ N
= NNP N
543 CD N
) ) N
. . N

Efficacy NN N
assessments NNS N
included VBD N
the DT N
proportion NN N
of IN N
patients NNS N
in IN N
each DT N
treatment NN i
group NN i
with IN N
total JJ N
control NN i
over IN N
the DT N
24 CD N
and CC N
48 CD N
hours NNS N
following VBG N
chemotherapy NN i
initiation NN N
, , N
as RB N
well RB N
as IN N
incidence NN N
and CC N
severity NN N
of IN N
nausea NN o
and CC o
emesis NN o
and CC N
use NN N
of IN N
antiemetic JJ N
rescue NN N
medication NN N
. . N

Prophylactic JJ i
corticosteroids NNS i
were VBD i
allowed VBN i
. . i

Safety NNP N
assessment NN N
was VBD N
based VBN N
on IN N
patients NNS N
' POS N
reports NNS N
of IN N
adverse JJ N
experiences NNS N
. . N

RESULTS NNP N
Approximately RB N
80 CD N
% NN N
of IN N
patients NNS N
received VBN N
prophylactic JJ i
corticosteroids NNS i
. . i

Single-dose JJ N
oral JJ N
granisetron NN i
( ( N
2 CD N
mg NN N
) ) N
and CC N
I.V NNP N
. . N

ondansetron NN i
( ( N
32 CD N
mg NN N
) ) N
resulted VBD N
in IN N
equivalent JJ N
levels NNS N
of IN N
total JJ o
emetic JJ o
control NN o
during IN N
the DT N
first JJ N
48 CD N
hours NNS N
after IN N
chemotherapy NN i
. . i

The DT N
proportion NN o
of IN o
nausea- JJ o
and CC o
emesis-free JJ o
patients NNS o
at IN N
24 CD N
and CC N
48 CD N
hours NNS N
were VBD N
also RB N
approximately RB N
equivalent JJ N
. . N

The DT N
most RBS N
commonly RB N
reported VBD N
adverse JJ N
experiences NNS N
were VBD N
headache NN o
, , o
asthenia NN o
, , o
and CC o
constipation NN o
. . o

More JJR N
patients NNS N
who WP N
received VBD N
ondonsetron JJR i
than IN N
granisetron NN i
reported VBN N
dizziness NN o
( ( N
9.6 CD N
% NN N
v JJ N
5.4 CD N
% NN N
, , N
respectively RB N
; : N
P NNP N
= NNP N
.011 NNP N
) ) N
and CC N
abnormal JJ o
vision NN o
( ( N
4.2 CD N
% NN N
v JJ N
0.6 CD N
% NN N
, , N
respectively RB N
; : N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

CONCLUSION VB N
A DT N
single JJ N
oral JJ N
dose NN N
of IN N
granisetron NN i
( ( N
2 CD N
mg NN N
) ) N
resulted VBD N
in IN N
equivalent JJ N
levels NNS N
of IN N
antiemetic JJ o
protection NN o
as IN N
I.V NNP N
. . N

ondansetron NN i
( ( N
32 CD N
mg NN N
) ) N
. . N

Both DT N
agents NNS N
were VBD N
well RB N
tolerated VBN N
, , N
although IN N
more JJR N
dizziness NN o
and CC o
abnormal JJ o
vision NN o
were VBD N
reported VBN N
with IN N
ondansetron NN i
. . i

Because IN N
the DT N
two CD N
antiemetic JJ N
regimens NNS N
exhibited VBD N
equivalent JJ N
efficacies NNS N
, , N
additional JJ N
factors NNS N
such JJ N
as IN N
convenience NN N
and CC N
cost NN N
of IN N
therapy NN N
should MD N
be VB N
considered VBN N
. . N

-DOCSTART- -9601831- O O

Transcutaneous JJ i
electrical JJ i
nerve NN i
stimulation NN i
in IN N
the DT N
treatment NN N
of IN N
myofascial JJ N
pain NN N
dysfunction NN N
. . N

The DT N
effect NN N
of IN N
transcutaneous JJ i
electrical JJ i
nerve NN i
stimulation NN i
( ( i
TENS NNP i
) ) i
plus CC i
conservative JJ i
therapy NN i
( ( i
ibuprofen JJ i
, , i
bite JJ i
plate NN i
, , i
self-physiotherapy NN i
) ) i
on IN N
myofascial JJ p
pain NN p
dysfunction NN p
( ( p
MPD NNP p
) ) p
was VBD N
determined VBN N
. . N

A DT N
single-blind JJ N
trial NN N
as IN N
done VBN N
in IN N
10 CD p
patients NNS p
with IN p
MPD NNP p
with IN p
subthreshold JJ i
TENS NNP i
( ( p
frequency NN p
35 CD p
Hz NNP p
, , p
pulse RB p
width VBZ p
100 CD p
milliseconds NNS p
, , p
modulation NN p
50 CD p
% NN p
) ) p
compared VBN p
with IN p
sham NN i
TENS NNP i
at IN p
8 CD p
visits NNS p
over IN p
14 CD p
weeks NNS p
. . p

Pain NNP o
was VBD N
assessed VBN N
on IN N
a DT N
visual JJ o
analogue NN o
scale NN o
before IN N
and CC N
after IN N
TENS NNP i
at IN N
each DT N
visit NN N
and CC N
the DT N
data NNS N
were VBD N
analysed VBN N
with IN N
the DT N
analysis NN N
of IN N
variance NN N
( ( N
ANOVA NNP N
) ) N
for IN N
repeated VBN N
measures NNS N
. . N

A DT N
highly RB N
significant JJ N
effect NN N
was VBD N
seen VBN N
for IN N
time NN o
( ( N
F NNP N
= NNP N
4.80 CD N
, , N
P NNP N
= NNP N
0.0003 CD N
) ) N
but CC N
not RB N
for IN N
TENS NNP i
. . i

Subthreshold NNP i
TENS NNP i
did VBD N
not RB N
increase VB N
the DT N
symptom JJ N
relief NN N
produced VBN N
by IN N
conservative JJ N
treatment NN N
with IN N
the DT N
protocol NN N
used VBN N
. . N

-DOCSTART- -2245435- O O

[ NN i
Simvastatin NNP i
versus NN i
gemfibrozil NN i
in IN N
the DT N
treatment NN N
of IN N
primary JJ p
hypercholesterolemia NN p
in IN p
hypertensive JJ p
patients NNS p
treated VBN p
with IN p
hydrochlorothiazide JJ i
] NN i
. . N

Recent JJ N
pharmacological JJ N
studies NNS N
confirmed VBD N
the DT N
role NN N
of IN N
hypercholesterolemia NN N
in IN N
the DT N
pathogenesis NN N
of IN N
coronary JJ N
atherosclerosis NN N
. . N

A DT N
10 CD N
% NN N
reduction NN N
in IN N
cholesterol NN N
levels NNS N
can MD N
reduce VB N
the DT N
risk NN N
of IN N
coronary JJ N
heart NN N
disease NN N
by IN N
15 CD N
% NN N
. . N

However RB N
many JJ N
hypercholesterolemic JJ p
patients NNS p
often RB N
suffer VBP N
from IN N
arterial JJ N
hypertension NN N
and CC N
drugs NNS N
such JJ N
as IN N
thiazide JJ i
diuretics NNS i
cause VBP N
an DT N
imbalance NN N
in IN N
lipid JJ N
metabolism NN N
. . N

The DT N
efficacy NN o
and CC o
the DT o
tolerability NN o
of IN N
simvastatin NN i
( ( N
a DT N
inhibitor NN N
of IN N
HGM-CoA NNP N
reductase NN N
) ) N
with IN N
that DT N
of IN N
gemfibrozil NN i
( ( N
a DT N
fibric NN N
acid NN N
derivative NN N
, , N
which WDT N
can MD N
reduce VB N
the DT N
VLDL NNP N
level NN N
) ) N
were VBD N
compared VBN N
in IN N
a DT N
placebo-controlled JJ i
study NN N
in IN N
2 CD N
groups NNS N
of IN N
patients NNS p
with IN p
primary JJ p
hypercholesterolemia NN p
and CC p
mild-to-moderate JJ p
essential JJ p
hypertension NN p
treated VBN p
with IN p
hydrochlorothiazide NN p
. . p

After IN p
10 CD p
weeks NNS p
standard JJ i
hypolipidemic JJ i
diet NN i
and CC i
hydrochlorothiazide NN i
( ( p
25 CD p
mg RB p
od NN p
) ) p
therapy NN p
, , p
30 CD p
patients NNS p
whose WP$ p
cholesterol NN o
levels NNS o
were VBD p
still RB p
greater JJR p
than IN p
or CC p
equal JJ p
to TO p
250 CD p
mg/100 NNS p
ml NN p
and CC p
whose WP$ p
diastolic JJ o
blood NN o
pressure NN p
was VBD p
less JJR p
than IN p
95 CD p
mmHg NNS p
were VBD N
randomized VBN N
to TO N
one CD N
of IN N
the DT N
following JJ N
treatments NNS N
: : N
simvastatin NN i
, , N
20 CD N
mg NN N
od NN N
, , N
gemfibrozil NN i
, , N
600 CD N
mg NN N
bid NN N
or CC i
placebo NN i
, , N
while IN N
continuing VBG N
dietetic JJ N
and CC N
diuretic JJ N
treatment NN N
. . N

After IN N
24 CD N
weeks NNS N
treatment NN N
, , N
simvastatin NN i
induced VBD N
a DT N
37 CD N
% NN N
reduction NN N
in IN N
cholesterol NN o
plasma NN o
levels NNS o
, , N
a DT N
9 CD N
% NN N
increase NN N
of IN N
HDL NNP o
and CC N
a DT N
16 CD N
% NN N
reduction NN N
of IN N
LDL NNP o
. . o

APO-A1 NNP o
showed VBD N
a DT N
4 CD N
% NN N
increase NN N
, , N
while IN N
APO-B NNP N
showed VBD N
a DT N
3 CD N
% NN N
reduction NN N
. . N

Gemfibrozil NNP i
induced VBD N
a DT N
20 CD N
% NN N
reduction NN N
in IN N
plasma NN o
triglycerides NNS o
and CC N
a DT N
13 CD N
% NN N
decrease NN N
in IN N
plasma NN o
cholesterol NN o
, , N
with IN N
a DT N
significant JJ N
19 CD N
% NN N
increase NN N
in IN N
HDL NNP o
and CC N
a DT N
11 CD N
% NN N
reduction NN N
in IN N
LDL NNP o
. . o

No NNP N
significant JJ N
variations NNS N
in IN N
any DT N
of IN N
the DT N
lipid JJ N
parameters NNS N
monitored VBD N
were VBD N
observed VBN N
in IN N
the DT N
placebo NN i
group NN N
. . N

Treatment NN N
with IN N
simvastatin NN i
or CC N
gemfibrozil NN i
in IN N
hypertensive JJ N
patients NNS N
in IN N
hydrochlorothiazide JJ i
monotherapy NN N
can MD N
reduce VB N
total JJ o
cholesterol NN o
and CC o
LDL-cholesterol NNP o
plasma NN o
levels NNS o
, , N
while IN N
significantly RB N
increasing VBG N
HDL NNP o
plasma NN o
levels NNS o
compared VBN N
to TO N
placebo VB N
. . N

Simvastatin NNP i
, , N
however RB N
, , N
resulted VBD N
more RBR N
efficient JJ N
than IN N
gemfibrozil NN i
on IN N
total JJ o
cholesterol NN o
or CC o
cholesterol NN o
fractions NNS o
. . o

-DOCSTART- -3108794- O O

Antibiotic JJ i
prophylaxis NN i
in IN N
high-risk JJ p
head NN p
and CC p
neck NN p
surgery NN p
: : p
one-day JJ i
vs. IN N
five-day JJ i
therapy NN i
. . i

Patients NNS p
who WP p
undergo VBP p
major JJ p
contaminated VBN p
surgery NN p
of IN p
the DT p
head NN p
and CC p
neck NN p
benefit NN N
from IN N
perioperative JJ N
antibiotic JJ i
prophylaxis NN i
. . i

This DT N
study NN N
was VBD N
developed VBN N
to TO N
determine VB N
if IN N
5 CD N
days NNS N
of IN N
antibiotic JJ o
administration NN o
would MD N
be VB N
more RBR N
effective JJ N
than IN N
1 CD N
day NN N
. . N

A DT N
multi-institutional JJ N
prospective JJ N
randomized VBN N
double-blind NN N
study NN N
was VBD N
designed VBN N
. . N

Patients NNS p
who WP p
were VBD p
identified VBN p
as IN p
requiring VBG p
pedicled VBD p
flap JJ p
reconstruction NN p
were VBD p
potential JJ p
candidates NNS p
for IN p
the DT p
study NN p
. . p

Later NNP N
, , N
patients NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
cefoperazone NN i
sodium NN i
for IN N
either DT N
24 CD i
hours NNS i
or CC i
120 CD i
hours NNS i
. . i

In IN N
each DT N
case NN N
, , N
the DT N
drug NN N
was VBD N
administered VBN N
intravenously RB N
, , N
beginning VBG N
1 CD N
to TO N
2 CD N
hours NNS N
preoperatively RB N
and CC N
continued VBD N
for IN N
the DT N
prescribed JJ N
period NN N
. . N

One CD p
hundred VBD p
nine CD p
patients NNS p
were VBD p
evaluable JJ p
. . p

Fifty-three JJ N
patients NNS N
were VBD N
assigned VBN N
to TO N
1 CD N
day NN N
of IN N
perioperative JJ N
prophylaxis NN N
. . N

Wound NNP o
infection NN o
developed VBD N
in IN N
ten JJ N
patients NNS N
( ( N
18.9 CD N
% NN N
) ) N
. . N

Fifty-six JJ N
patients NNS N
were VBD N
assigned VBN N
to TO N
5 CD N
days NNS N
of IN N
perioperative JJ i
antibiotic JJ i
prophylaxis NN i
. . i

Wound NNP o
infection NN o
developed VBD N
in IN N
14 CD N
( ( N
25 CD N
% NN N
) ) N
of IN N
these DT N
patients NNS N
( ( N
P NNP N
greater JJR N
than IN N
.05 NN N
) ) N
. . N

These DT N
data NNS N
suggest VBP N
that IN N
no DT N
beneficial JJ N
effect NN N
from IN N
administration NN N
of IN N
antibiotics NNS i
for IN N
longer JJR N
than IN N
24 CD N
hours NNS N
postoperatively RB N
can MD N
be VB N
achieved VBN N
in IN N
patients NNS N
who WP N
undergo VBP N
myocutaneous JJ N
flap JJ N
reconstruction NN N
. . N

-DOCSTART- -10539493- O O

The DT N
impact NN N
of IN N
schizophrenic JJ p
patient NN p
functionality NN N
on IN N
service NN o
utilization NN o
and CC o
cost NN o
. . o

Based VBN N
on IN N
a DT N
presentation NN N
by IN N
Sandra NNP N
L. NNP N
Tunis NNP N
, , N
PhD NNP N
. . N

With IN N
the DT N
advent NN N
of IN N
atypical JJ N
agents NNS N
in IN N
the DT N
treatment NN N
of IN N
schizophrenia NN N
, , N
physicians NNS N
and CC N
policy NN N
makers NNS N
must MD N
consider VB N
the DT N
costs NNS N
that WDT N
may MD N
accompany VB N
greater JJR N
clinical JJ N
efficacy NN N
. . N

Analyses VBZ N
reveal NN N
that WDT N
olanzapine NN i
shows VBZ N
a DT N
greater JJR N
clinical JJ o
cost NN o
effectiveness NN o
, , N
as RB N
well RB N
as IN N
a DT N
greater JJR N
functional JJ o
cost NN o
effectiveness NN o
, , N
than IN N
haloperidol NN i
, , N
and CC N
that IN N
functional JJ o
outcomes NNS o
, , N
in IN N
particular JJ N
, , N
show VBP N
promise NN N
as IN N
important JJ N
measures NNS N
of IN N
effectiveness NN N
. . N

Functional JJ N
outcomes NNS N
can MD N
help VB N
differentiate VB N
medications NNS N
and CC N
can MD N
be VB N
used VBN N
to TO N
help VB N
demonstrate VB N
the DT N
cost NN o
effectiveness NN o
of IN N
atypical JJ N
agents NNS N
. . N

Mental NNP o
health NN o
and CC o
physical JJ o
health NN o
functioning NN o
, , o
as RB o
well RB o
as IN o
work NN o
status NN o
, , N
are VBP N
all DT N
measures NNS N
of IN N
functioning VBG N
that WDT N
have VBP N
been VBN N
used VBN N
to TO N
evaluate VB N
treatment NN N
strategies NNS N
. . N

When WRB N
comparing VBG N
olanzapine NN i
with IN N
haloperidol NN i
, , N
cost NN o
savings NNS o
are VBP N
seen VBN N
throughout IN N
the DT N
treatment NN N
period NN N
( ( N
1 CD N
year NN N
) ) N
, , N
with IN N
physical JJ o
functioning VBG o
most JJS N
highly RB N
affected VBN N
over IN N
time NN N
. . N

Functional JJ o
outcomes NNS o
can MD N
therefore VB N
serve VB N
2 CD N
purposes NNS N
: : N
to TO N
enhance VB N
compliance NN N
by IN N
improving VBG N
health-related JJ o
quality NN o
of IN o
life NN o
and CC N
to TO N
assist VB N
in IN N
making VBG N
both DT N
treatment NN N
and CC N
formulary JJ N
decisions NNS N
. . N

-DOCSTART- -24201232- O O

Double-blind NNP N
, , N
placebo-controlled JJ i
trial NN N
of IN N
risperidone NN i
plus CC i
amantadine NN i
in IN N
children NNS p
with IN p
autism NN p
: : p
a DT N
10-week JJ N
randomized NN N
study NN N
. . N

OBJECTIVE NNP N
This DT N
study NN N
aimed VBD N
to TO N
investigate VB N
the DT N
effect NN N
of IN N
adding VBG N
amantadine NN i
to TO i
risperidone VB i
for IN N
treatment NN N
of IN N
autism NN N
. . N

METHODS NNP N
Forty NNP p
outpatients NNS p
aged VBD p
4 CD p
to12 NN p
years NNS p
, , p
who WP p
were VBD p
diagnosed VBN p
with IN p
autism NN p
spectrum NN p
disorders NNS p
based VBN p
on IN p
the DT p
Diagnostic NNP p
and CC p
Statistical NNP p
Manual NNP p
of IN p
Mental NNP p
Disorders NNP p
, , p
Fourth NNP p
Edition NNP p
, , p
Text NNP p
Revision NNP p
criteria NNS p
, , N
were VBD N
assigned VBN N
to TO N
this DT N
double-blind JJ N
clinical JJ N
trial NN N
. . N

The DT N
subjects NNS N
were VBD N
divided VBN N
randomly RB N
into IN N
2 CD N
groups NNS N
. . N

One CD N
group NN N
received VBD N
risperidone JJ i
plus CC i
amantadine JJ i
, , i
and CC i
the DT i
other JJ i
group NN i
received VBD i
risperidone JJ i
plus CC i
placebo NN i
. . i

The DT N
dose NN N
of IN N
risperidone NN N
was VBD N
titrated VBN N
between IN N
1 CD N
and CC N
2.0 CD N
mg/d NN N
, , N
and CC N
the DT N
dose NN N
of IN N
amantadine NN i
was VBD N
100 CD N
or CC N
150 CD N
mg/d NNS N
for IN N
patients NNS N
less JJR N
than IN N
30 CD N
kg NN N
or CC N
more JJR N
than IN N
30 CD N
kg NNS N
, , N
respectively RB N
. . N

The DT N
patients NNS N
were VBD N
assessed VBN N
using VBG N
the DT N
Aberrant NNP o
Behavioral NNP o
Checklist-Community NNP o
( ( o
ABC-C NNP o
) ) o
and CC o
adverse JJ o
effects NNS o
checklist NN o
as RB N
well RB N
as IN N
clinical JJ o
global JJ o
impression-improvement NN o
( ( o
CGI-I NNP o
) ) o
at2 VBZ N
checkpoints NNS N
of IN N
5-week JJ N
intervals NNS N
after IN N
the DT N
baseline NN N
. . N

Informed NNP N
consentwas NN N
obtained VBN N
from IN N
the DT N
parents NNS N
of IN N
each DT N
participant NN N
. . N

RESULTS NNP N
Among IN N
ABC-C NNP o
subscales NNS o
, , o
Hyperactivity NNP o
and CC o
Irritability NNP o
showed VBD N
significantly RB N
greater JJR N
reduction NN N
in IN N
the DT N
amantadine NN N
group NN N
than IN N
the DT N
placebo NN N
group NN N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
adverse JJ o
effects NNS o
between IN N
the DT N
2 CD N
groups NNS N
. . N

The DT N
CGI-I JJ o
scores NNS o
show VBP N
significant JJ N
improvement NN N
in IN N
the DT N
amantadine NN i
group NN N
compared VBN N
to TO N
the DT N
placebo NN N
group NN N
. . N

CONCLUSIONS VB N
The DT N
present JJ N
study NN N
suggests VBZ N
that IN N
amantadine NN i
may MD N
be VB N
a DT N
potential JJ N
adjunctive JJ N
treatment NN N
strategy NN N
for IN N
autism NN N
and CC N
it PRP N
was VBD N
generally RB N
well RB N
tolerated VBN N
. . N

-DOCSTART- -22631032- O O

Evaluation NN o
of IN N
the DT N
pharmacodynamics NNS N
of IN N
acetylsalicylic JJ N
acid NN N
81 CD N
mg NN N
with IN N
or CC N
without IN N
esomeprazole JJ N
20 CD N
mg NN N
in IN N
healthy JJ p
volunteers NNS p
. . p

BACKGROUND IN N
The DT N
absence NN N
of IN N
a DT N
pharmacokinetic JJ o
interaction NN o
between IN N
the DT N
proton NN N
pump NN N
inhibitor NN N
esomeprazole NN N
( ( N
40 CD N
mg NN N
) ) N
and CC N
acetylsalicylic JJ N
acid NN N
( ( N
aspirin JJ N
, , N
ASA NNP N
; : N
325 CD N
mg NN N
) ) N
has VBZ N
previously RB N
been VBN N
established VBN N
. . N

OBJECTIVE VB N
This DT N
study NN N
set VBD N
out RP N
to TO N
investigate VB N
the DT N
potential NN N
for IN N
pharmacodynamic JJ o
interaction NN o
between IN N
low-dose JJ N
ASA NNP N
and CC N
esomeprazole VB N
in IN N
healthy JJ p
volunteers NNS p
, , N
by IN N
measuring VBG N
ASA NNP N
antiplatelet NN o
activity NN o
. . o

STUDY NNP N
DESIGN NNP N
This DT N
was VBD N
a DT N
single-center JJ N
, , N
open-label JJ N
, , N
two-period JJ N
, , N
randomized VBN N
crossover NN N
study NN N
. . N

PARTICIPANTS NNP N
Healthy NNP p
male NN p
and CC p
female JJ p
volunteers NNS p
aged VBN p
18-75 CD p
years NNS p
were VBD p
included VBN p
. . p

All DT i
volunteers NNS i
received VBD i
ASA NNP i
81 CD i
mg NN i
once RB i
daily JJ i
for IN i
5 CD i
days NNS i
prior RB i
to TO i
the DT i
study NN i
( ( i
pre-screen JJ i
) ) i
. . i

Subjects NNS p
were VBD p
eligible JJ p
for IN p
inclusion NN p
if IN p
they PRP p
had VBD p
aspirin VBN o
reactivity NN o
units NNS o
( ( o
ARU NNP o
, , o
as IN o
measured VBN o
by IN o
the DT o
VerifyNow NNP o
ASA NNP o
assay VBP o
) ) o
of IN p
< $ p
550 CD p
on IN p
Day NNP p
6 CD p
. . p

INTERVENTION NN N
After IN i
pre-screening NN i
and CC i
a DT i
washout JJ i
period NN i
of IN i
at IN i
least JJS i
14 CD i
days NNS i
, , i
eligible JJ i
volunteers NNS i
received VBD i
ASA NNP i
81 CD i
mg NN i
with IN i
or CC i
without IN i
esomeprazole JJ i
20 CD i
mg NN i
once RB i
daily JJ i
for IN i
5 CD i
days NNS i
in IN i
randomized JJ i
order NN i
, , i
with IN i
a DT i
14-day JJ i
washout NN i
between IN i
treatments NNS i
. . i

MAIN NNP N
OUTCOME NNP N
MEASURE NNP N
The DT N
main JJ N
outcome NN N
measure NN N
was VBD N
the DT N
antiplatelet NN o
activity NN o
of IN o
ASA NNP o
, , o
as IN o
assessed VBN o
by IN o
ARU NNP o
ratio NN o
relative NN o
to TO o
baseline VB o
in IN o
the DT o
VerifyNow NNP o
ASA NNP o
assay VBP o
; : o
suppression NN o
of IN o
serum NN o
thromboxane NN o
B NNP o
( ( o
2 CD o
) ) o
( ( o
TXB NNP o
( ( o
2 CD o
) ) o
) ) o
was VBD N
a DT N
secondary JJ N
endpoint NN N
. . N

Statistical JJ N
comparisons NNS N
were VBD N
made VBN N
using VBG N
linear JJ N
mixed JJ N
models NNS N
. . N

RESULTS VB N
A DT p
total NN p
of IN p
29 CD p
volunteers NNS p
( ( p
19 CD p
aged VBN p
?50 CD p
years NNS p
; : p
8 CD p
women NNS p
; : p
21 CD p
men NNS p
) ) p
were VBD p
evaluable JJ p
for IN p
pharmacodynamic JJ N
analysis NN N
( ( N
per IN N
protocol NN N
) ) N
. . N

All DT N
volunteers NNS N
on IN N
both DT N
treatments NNS N
achieved VBN o
ARU NNP o
< $ o
550 CD N
at IN N
Day NNP N
6 CD N
. . N

The DT N
geometric JJ N
mean NN N
ratio NN N
of IN N
Day NNP N
6 CD N
to TO N
Day NNP N
1 CD N
( ( N
baseline NN o
) ) o
platelet NN o
aggregation NN o
was VBD o
0.70 CD N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NNP N
0.68 CD N
, , N
0.72 CD N
) ) N
with IN N
ASA NNP N
alone RB N
and CC N
0.71 CD N
( ( N
95 CD N
% NN N
CI NNP N
0.69 CD N
, , N
0.74 CD N
) ) N
with IN N
ASA NNP N
+ NNP N
esomeprazole NN N
. . N

The DT N
ratio NN N
of IN N
platelet NN o
aggregation NN o
( ( o
ASA NNP N
+ NNP N
esomeprazole/ASA NN N
) ) N
was VBD N
1.02 CD N
( ( N
95 CD N
% NN N
CI NNP N
0.99 CD N
, , N
1.05 CD N
) ) N
. . N

ASA NNP N
administered VBD N
alone RB N
or CC N
with IN N
esomeprazole JJ N
reduced VBN o
serum NN o
TXB NNP o
( ( o
2 CD o
) ) o
by IN o
more JJR N
than IN N
99.5 CD N
% NN N
. . N

The DT N
ratio NN N
of IN N
suppression NN N
of IN N
serum NN o
TXB NNP o
( ( o
2 CD o
) ) o
levels NNS o
( ( o
ASA NNP N
+ NNP N
esomeprazole/ASA NN N
) ) N
was VBD N
1.06 CD N
( ( N
95 CD N
% NN N
CI NNP N
0.88 CD N
, , N
1.29 CD N
) ) N
. . N

The DT N
combination NN N
of IN N
ASA NNP N
and CC N
esomeprazole NN N
was VBD N
well RB o
tolerated VBN o
. . o

CONCLUSION NNP N
No NNP N
pharmacodynamic JJ o
interaction NN o
between IN o
low-dose JJ N
ASA NNP N
and CC N
esomeprazole NN N
was VBD N
found VBN N
with IN N
regard NN N
to TO N
platelet VB o
function NN o
. . o

TRIAL NNP N
REGISTRATION NNP N
Registered NNP N
at IN N
ClinicalTrials NNP N
. . N

gov NN N
as IN N
NCT01199328 NNP N
. . N

-DOCSTART- -8570879- O O

Lung NNP N
function NN N
measurement NN N
in IN N
general JJ N
practice NN N
: : N
a DT N
comparison NN N
of IN N
the DT N
Escort NNP i
spirometer NN i
with IN N
the DT N
Micromed NNP i
turbine NN i
spirometer NN i
and CC N
the DT N
mini-Wright JJ i
peak NN i
flow NN i
meter NN i
. . i

It PRP N
is VBZ N
important JJ N
that IN N
new JJ N
types NNS N
of IN N
spirometer NN i
for IN N
widespread JJ N
clinical JJ N
use NN N
are VBP N
pragmatically RB N
evaluated VBN N
in IN N
primary JJ N
care NN N
. . N

This DT N
study NN N
compared VBN N
measurements NNS N
taken VBN N
by IN N
a DT N
new JJ i
portable JJ i
Fleisch NNP i
pneumotachograph NN i
spirometer NN i
( ( i
known VBN i
as IN i
the DT i
Escort NNP i
) ) i
with IN N
those DT N
of IN N
the DT N
commonly NN N
used VBN N
mini-Wright JJ i
peak NN i
flow NN i
meter NN i
and CC N
the DT N
Micromed NNP i
Pocket NNP i
turbine NN i
spirometer NN i
. . i

A NNP N
pragmatic JJ N
study NN N
was VBD N
conducted VBN N
in IN N
two CD N
phases NNS N
during IN p
routine JJ p
surgeries NNS p
at IN N
Aldermoor NNP N
Health NNP N
Centre NNP N
, , N
Southampton NNP N
. . N

Phase NNP N
I PRP N
compared VBN N
the DT N
new JJ i
spirometer NN i
with IN N
the DT N
mini-Wright JJ i
peak NN i
flow NN i
meter NN i
and CC N
Phase NNP N
2 CD N
compared VBN N
the DT N
new JJ i
spirometer NN i
and CC N
the DT N
turbine NN i
spirometer NN i
. . i

One CD p
hundred VBD p
patients NNS p
aged VBN p
5-88 CD p
years NNS p
( ( p
56 CD p
patients NNS p
with IN p
a DT p
history NN p
of IN p
chronic JJ p
respiratory NN p
complaints NNS p
and CC p
44 CD p
patients NNS p
without IN p
) ) p
entered VBD p
Phase NNP p
1 CD p
, , p
and CC p
100 CD p
patients NNS p
aged VBN p
6-82 JJ p
years NNS p
( ( p
62 CD p
patients NNS p
with IN p
a DT p
history NN p
of IN p
chronic JJ p
respiratory NN p
complaints NNS p
and CC p
38 CD p
patients NNS p
without IN p
) ) p
entered VBD p
Phase NNP p
2 CD p
. . p

Each DT N
patient NN N
contributed VBD N
only RB N
once RB N
to TO N
each DT N
phase NN N
, , N
but CC N
some DT N
entered VBD N
both DT N
phases NNS N
on IN N
separate JJ N
occasions NNS N
. . N

Ninety-five JJ N
percent NN N
limits NNS N
of IN N
agreement NN N
( ( N
mean JJ N
+/- NNP N
SD NNP N
) ) N
were VBD N
wide JJ N
for IN N
all DT N
comparisons NNS N
. . N

Graphical JJ o
plots NNS o
revealed VBD N
trends NNS N
towards IN N
higher JJR N
Escort NN o
values NNS o
as IN N
mean NN N
values NNS N
rose VBD N
compared VBN N
with IN N
both DT N
mini-Wright JJ i
and CC N
turbine JJ i
readings NNS N
for IN N
peak JJ o
expiratory JJ o
flow NN o
rate NN o
and CC o
forced VBD o
expiratory JJ o
volume NN o
in IN o
one CD o
second NN o
. . o

Possible JJ N
over-reading NN N
of IN N
peak JJ o
expiratory JJ o
flow NN o
rate NN o
with IN N
the DT N
mini-Wright JJ i
meter NN i
at IN N
low JJ N
mean NN N
values NNS N
was VBD N
also RB N
seen VBN N
. . N

Readings NNS N
taken VBN N
with IN N
these DT N
different JJ N
types NNS N
of IN N
meter NN N
can MD N
not RB N
be VB N
interchanged VBN N
with IN N
confidence NN N
in IN N
clinical JJ N
practice NN N
. . N

The DT N
clinical JJ N
significance NN N
of IN N
the DT N
theoretically RB N
more RBR N
accurate JJ N
measures NNS o
of IN o
lung NN o
function NN o
produced VBN N
with IN N
the DT N
new JJ i
meter NN i
, , N
and CC N
indeed RB N
of IN N
spirometry NN N
itself PRP N
, , N
needs VBZ N
further JJ N
investigation NN N
. . N

-DOCSTART- -7705531- O O

Expectant JJ i
management NN i
of IN N
functional JJ p
ovarian JJ p
cysts NNS p
: : p
an DT N
alternative NN N
to TO N
hormonal JJ i
therapy NN i
. . i

OBJECTIVE IN N
We PRP N
studied VBD N
whether IN N
the DT N
administration NN N
of IN N
oral JJ i
contraceptives NNS i
facilitates VBZ N
the DT N
disappearance NN N
of IN N
spontaneously RB N
formed VBN p
functional JJ p
ovarian JJ p
cysts NNS p
. . p

METHODS NNP N
Eighty NNP p
patients NNS p
in IN p
whom WP p
ultrasonography NN p
revealed VBD p
unilateral JJ p
, , p
mobile JJ p
, , p
unilocular JJ p
, , p
thin-walled JJ p
ovarian JJ p
cysts NNS p
without IN p
internal JJ p
echoes NNS p
and CC p
greater JJR p
than IN p
30 CD p
mm NNS p
but CC p
not RB p
exceeding VBG p
60 CD p
mm NN p
in IN p
diameter NN p
were VBD p
enrolled VBN p
into IN p
the DT p
study NN p
. . p

Patients NNS N
were VBD N
randomized VBN N
by IN N
stratification NN N
to TO N
receive VB N
a DT N
low-dose JJ i
monophasic NN i
pill NN i
, , i
a DT i
high-dose JJ i
monophasic NN i
pill NN i
, , i
a DT i
multiphasic JJ i
pill NN i
or CC i
no DT i
therapy NN i
. . i

Patients NNS N
were VBD N
re-evaluated JJ N
after IN N
5 CD N
weeks NNS N
of IN N
therapy NN N
and CC N
at IN N
the DT N
end NN N
of IN N
therapy NN N
( ( N
10 CD N
weeks NNS N
) ) N
. . N

RESULTS VB N
The DT N
mean JJ o
ages NNS o
and CC o
the DT o
mean JJ o
cyst NN o
diameters NNS o
of IN N
the DT N
patients NNS N
for IN N
each DT N
group NN N
were VBD N
not RB N
significantly RB N
different JJ N
. . N

We PRP N
did VBD N
not RB N
find VB N
a DT N
significant JJ N
effect NN N
of IN N
oral JJ N
contraceptive JJ N
administration NN N
on IN N
the DT N
disappearance NN o
rate NN o
of IN o
functional JJ o
ovarian JJ o
cysts NNS o
over IN N
that DT N
of IN N
expectant JJ N
management NN N
. . N

CONCLUSION NNP N
We PRP N
conclude VBP N
that IN N
oral JJ i
contraceptive JJ i
therapy NN N
even RB N
with IN N
multiphasic JJ N
pills NNS N
is VBZ N
very RB N
effective JJ N
in IN N
the DT N
management NN N
of IN N
functional JJ o
ovarian JJ o
cysts NNS o
but CC N
expectant JJ N
management NN N
achieves NNS N
similar JJ N
success NN N
rates NNS N
and CC N
may MD N
be VB N
a DT N
good JJ N
alternative NN N
to TO N
oral JJ i
contraceptive JJ i
therapy NN i
. . i

-DOCSTART- -7889896- O O

Long-stay JJ i
versus NN N
short-stay JJ i
hospital NN i
treatment NN i
of IN N
children NNS p
suffering VBG p
from IN p
severe JJ p
protein-energy JJ p
malnutrition NN p
. . p

OBJECTIVE UH N
To TO N
contrast VB N
early JJ i
discharge NN i
versus NN N
attempted VBD i
full JJ i
nutritional JJ i
rehabilitation NN i
in IN N
hospital NN p
of IN p
children NNS p
suffering VBG p
from IN p
severe JJ p
protein-energy JJ p
malnutrition NN p
( ( p
PEM NNP p
) ) p
. . p

DESIGN NNP N
Field NNP N
experiment NN N
, , N
two-way JJ N
analysis NN N
of IN N
variance NN N
with IN N
one CD N
between IN N
group NN p
( ( i
short- JJ i
versus IN i
long-stay NN i
) ) i
and CC p
one CD p
repeated VBN p
measures NNS p
factor NN p
( ( p
admission NN p
, , p
then RB p
12 CD p
, , p
18 CD p
, , p
24 CD p
, , p
30 CD p
and CC p
36 CD p
months NNS p
post-admission NN p
) ) p
. . N

Covariates NNPS N
introduced VBD N
. . N

SETTING NNP p
Primary NNP p
health NN p
care NN p
, , p
Kingston NNP p
, , p
Jamaica NNP p
. . p

SUBJECTS NNP p
n JJ p
= NNP p
81 CD p
; : p
mean JJ p
age NN p
11 CD p
months NNS p
; : p
79 CD p
contribute VBP p
longitudinal JJ p
data NNS p
; : p
44 CD p
every DT p
measurement NN p
. . p

INTERVENTIONS NNP N
When WRB N
concurrent NN N
illnesses NNS N
had VBD N
been VBN N
treated VBN N
and CC N
normal JJ N
feeding VBG N
re-established JJ N
( ( N
weight JJ N
gain NN N
5 CD N
g/kg.day-1 NN N
) ) N
, , N
subjects NNS N
were VBD N
randomly RB N
allocated VBN N
to TO N
short-stay NN i
( ( i
SS NNP i
) ) i
or CC i
long-stay JJ i
( ( i
LS NNP i
) ) i
group NN i
. . i

LS NNP i
retained VBD i
in IN i
hospital NN i
for IN i
full JJ i
nutritional JJ i
rehabilitation NN i
mean VB N
40 CD N
days NNS N
) ) N
. . N

SS NNP i
discharged VBD i
immediately RB i
( ( N
mean JJ N
18 CD N
days NNS N
) ) N
for IN i
standard JJ i
Health NNP i
Service NNP i
care NN i
at IN i
home NN i
for IN N
6 CD N
months NNS N
plus CC i
high-energy JJ i
supplement NN i
( ( N
3.31 CD N
MJ NNP N
with IN N
20.6 CD N
g NNS N
protein JJ N
daily JJ N
) ) N
for IN N
first JJ N
3 CD N
months NNS N
. . N

After IN N
discharge NN N
LS NNP i
received VBD N
6 CD N
months NNS N
home NN N
care NN N
, , N
but CC N
without IN N
supplementation NN N
. . N

RESULTS NNP N
Significant NNP N
advantages VBZ N
for IN N
LS NNP N
group NN N
on IN N
NCHS NNP o
weight NN o
& CC o
length NN o
for IN o
age NN o
at IN o
discharge NN o
, , N
and CC N
at IN N
12 CD N
, , N
18 CD N
, , N
24 CD N
and CC N
for IN N
length NN N
also RB N
30 CD N
months NNS N
( ( N
P NNP N
< VBZ N
0.05 CD N
to TO N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

Weight NNP o
advantage NN o
peaked VBD N
at IN N
12 CD N
and CC N
18 CD N
months NNS N
, , N
length NN N
later RB N
at IN N
18 CD N
and CC N
24 CD N
months NNS N
. . N

CONCLUSIONS NNP N
Contrary NNP N
to TO N
earlier VB N
reports NNS N
, , N
full JJ N
nutritional JJ N
rehabilitation NN N
can MD N
be VB N
achieved VBN N
in IN N
hospital NN N
for IN N
children NNS N
suffering VBG N
from IN N
PEM NNP N
. . N

Although IN N
in IN N
the DT N
long-term JJ N
both DT N
groups NNS N
move VBP N
towards NNS N
expected VBN N
levels NNS N
in IN N
their PRP$ N
home NN N
community NN N
, , N
a DT N
significant JJ N
advantage NN N
maintained VBD N
for IN N
approximately RB N
2 CD N
years NNS N
is VBZ N
developmentally RB N
advantageous JJ N
during IN N
the DT N
critical JJ N
time NN N
after IN N
weaning VBG N
. . N

-DOCSTART- -10832772- O O

Secretin NNP N
and CC N
autism NN N
: : N
a DT N
two-part JJ N
clinical JJ N
investigation NN N
. . N

Recent JJ N
anecdotal JJ N
reports NNS N
have VBP N
touted VBN N
the DT N
gastrointestinal NN N
( ( N
GI NNP N
) ) N
hormone NN N
secretin NN i
as IN N
a DT N
treatment NN N
modality NN N
for IN N
autism NN N
, , N
though IN N
there EX N
is VBZ N
little JJ N
clinical JJ N
evidence NN N
or CC N
literature NN N
to TO N
support VB N
its PRP$ N
viability NN N
. . N

We PRP N
undertook VBD N
a DT N
two-part JJ N
clinical JJ N
trial NN N
to TO N
investigate VB N
these DT N
claims NNS N
. . N

Fifty-six JJ p
patients NNS p
( ( p
49 CD p
boys NNS p
, , p
7 CD p
girls NNS p
, , p
mean JJ p
age NN p
= VBD p
6.4 CD p
years NNS p
, , p
SD NNP p
= NNP p
2.7 CD p
) ) p
enrolled VBN p
in IN p
an DT p
open-label JJ p
trial NN p
of IN p
secretin NN i
, , p
during IN p
which WDT p
they PRP p
received VBD p
one CD p
injection NN p
of IN p
the DT p
hormone NN p
( ( p
2 CD p
IU/kg NNP p
) ) p
. . p

All DT N
subjects NNS N
were VBD N
evaluated VBN N
by IN N
their PRP$ N
parents NNS N
at IN N
baseline NN N
and CC N
follow-up JJ N
visits NNS N
( ( N
3-6 JJ N
weeks NNS N
later RB N
, , N
M NNP N
= NNP N
3.7 CD N
, , N
SD NNP N
= VBZ N
1.4 CD N
weeks NNS N
) ) N
with IN N
Childhood NNP o
Autism NNP o
Rating NNP o
Scales NNP o
( ( o
CARS NNP o
) ) o
. . N

Thirty-four JJ p
patients NNS p
were VBD p
labeled VBN p
with IN p
Pervasive NNP p
Developmental NNP p
Disorder NNP p
Not RB p
Otherwise NNP p
Specified NNP p
, , p
and CC p
22 CD p
met VBD p
diagnostic JJ p
criteria NNS p
for IN p
Autistic JJ p
Disorder NNP p
. . p

Forty-five JJ p
patients NNS p
were VBD p
concurrently RB p
on IN p
other JJ p
drug NN p
treatments NNS p
. . p

At IN N
follow-up NN N
, , N
some DT N
reported VBD N
minimal JJ N
but CC N
potentially RB N
significant JJ N
improvements NNS N
including VBG N
changes NNS o
in IN o
GI NNP o
symptoms NNS o
, , o
expressive JJ o
and/or NN o
receptive JJ o
language NN o
function NN o
, , o
and CC o
improved JJ o
awareness NN o
and CC o
social JJ o
interactions NNS o
. . o

No DT N
adverse JJ o
effects NNS o
were VBD N
reported VBN N
or CC N
observed VBN N
. . N

Subsequently NNP N
, , N
17 CD N
of IN N
the DT N
most RBS N
responsive JJ N
patients NNS N
from IN N
Study NNP N
1 CD N
began VBD N
a DT N
double-blind JJ N
trial NN N
that WDT N
also RB N
included VBD N
8 CD N
newly RB N
enrolled VBN N
patients NNS N
. . N

Patients NNS N
in IN N
this DT N
second JJ N
study NN N
were VBD N
alternatively RB N
entered VBN N
into IN N
one CD N
of IN N
two CD N
groups NNS N
and CC N
received VBD N
injections NNS N
of IN N
secretin NN i
or CC i
placebo NN i
with IN N
crossover NN N
at IN N
4 CD N
weeks NNS N
. . N

Patients NNS p
from IN p
Study NNP p
1 CD p
entered VBD p
into IN p
Study NNP p
2 CD p
at IN p
an DT p
average NN p
of IN p
6.5 CD p
( ( p
SD NNP p
= NNP p
0.8 CD p
) ) p
weeks NNS p
after IN p
beginning VBG p
Study NNP p
1 CD p
. . p

Results NNS N
of IN N
both DT N
inquiries NNS N
indicate VBP N
that IN N
although IN N
treatment NN N
with IN N
secretin NN i
was VBD N
reported VBN N
to TO N
cause VB N
transient JJ o
changes NNS o
in IN o
speech NN o
and CC o
behavior NN o
in IN N
some DT N
children NNS N
, , N
overall JJ N
it PRP N
produced VBD N
few JJ N
clinically RB N
meaningful JJ N
changes NNS N
when WRB N
compared VBN N
to TO N
children NNS N
given VBN N
placebo JJ i
injections NNS N
. . N

-DOCSTART- -9512218- O O

Treatment NN N
of IN N
hyperinsulinaemia NN N
in IN N
polycystic JJ N
ovary JJ N
syndrome NN N
? . N
-DOCSTART- -22011217- O O

Skin NNP o
improvement NN o
with IN N
two CD N
different JJ N
oestroprogestins NNS i
in IN N
patients NNS p
affected VBN p
by IN p
acne NN p
and CC p
polycystic JJ p
ovary JJ p
syndrome NN p
: : p
clinical JJ N
and CC N
instrumental JJ N
evaluation NN N
. . N

BACKGROUND NNP N
Despite IN N
it PRP N
is VBZ N
accepted VBN N
that IN N
acne NN N
is VBZ N
mostly RB N
caused VBN N
by IN N
an DT N
hyper-responsiveness NN N
of IN N
the DT N
pilo-sebaceous JJ N
unit NN N
to TO N
normal JJ N
circulating VBG N
androgen NN N
hormones NNS N
, , N
in IN N
a DT N
few JJ p
patients NNS p
, , p
especially RB p
women NNS p
, , N
acneic JJ N
lesions NNS N
can MD N
be VB N
associated VBN N
with IN N
increased JJ N
serum NN o
androgen NN o
levels NNS o
( ( N
hyperandrogenism NN N
) ) N
, , N
of IN N
which WDT N
polycystic JJ N
ovary JJ N
syndrome NN N
( ( N
PCOS NNP N
) ) N
is VBZ N
the DT N
most RBS N
common JJ N
cause NN N
. . N

In IN p
women NNS p
with IN p
acne NN p
and CC p
proven JJ p
PCOS NNP p
therapy NN p
with IN p
estroprogestins NNS i
( ( i
EPs NNP i
) ) i
can MD N
be VB N
an DT N
excellent JJ N
option NN N
. . N

OBJECTIVE IN N
The DT N
aim NN N
of IN N
the DT N
study NN N
was VBD N
to TO N
assess VB N
the DT N
effects NNS N
of IN N
two CD i
estroprogestins NNS i
( ( i
EPs NNP i
) ) i
, , i
ethinyl-estradiol JJ i
( ( i
EE NNP i
) ) i
30 CD i
mcg/drospirenone NN i
( ( i
DRSP NNP i
) ) i
3 CD i
mg NN i
, , i
and CC i
ethinyl-estradiol NN i
( ( i
EE NNP i
) ) i
30 CD i
mcg/chlormadinone NN i
acetate NN i
( ( i
CMA NNP i
) ) i
2 CD i
mg NN i
, , N
both DT N
on IN N
increased VBN N
serum NN o
androgen NN o
levels NNS o
and CC N
on IN N
several JJ N
skin NN o
parameters NNS o
in IN N
women NNS p
affected VBN p
by IN p
mild NN p
to TO p
severe VB p
acne NN p
and CC p
polycystic JJ p
ovary JJ p
syndrome NN p
( ( p
PCOS NNP p
) ) p
. . p

METHODS NNP N
Fifty-nine JJ p
women NNS p
were VBD p
randomized VBN p
to TO N
receive VB N
EE/DRSP NNP i
( ( N
n JJ N
= NNP N
32 CD N
) ) N
or CC N
EE/CMA NNP i
( ( N
n JJ N
= NNP N
27 CD N
) ) N
for IN N
six CD N
months NNS N
. . N

Evaluation NN N
of IN N
serum NN o
androgen NN o
levels NNS o
, , o
grading NN o
of IN o
acne NN o
and CC o
hirsutism NN o
( ( N
respectively RB N
with IN N
Pillsbury NNP N
and CC N
Ferriman-Gallwey NNP N
score NN N
) ) N
and CC N
non-invasive JJ o
assessment NN o
of IN o
skin JJ o
hydration NN o
, , o
transepidermal JJ o
water NN o
loss NN o
( ( o
TEWL NNP o
) ) o
and CC o
skin JJ o
homogeneity NN o
were VBD N
performed VBN N
at IN N
baseline NN N
, , N
at IN N
3 CD N
and CC N
6 CD N
months NNS N
( ( N
end NN N
of IN N
treatment NN N
) ) N
. . N

RESULTS NNP N
Both DT N
treatments NNS N
were VBD N
well RB N
tolerated VBN N
and CC N
showed VBD N
a DT N
significant JJ N
improvement NN N
of IN N
skin NN o
and CC o
hormonal JJ o
parameters NNS o
, , N
although IN N
EE/DRSP NNP i
showed VBD N
a DT N
more RBR N
potent JJ N
effect NN N
on IN N
acne NN o
and CC o
seborrhea NN o
. . o

CONCLUSIONS NNP N
Estroprogestins NNP i
represent VBP N
an DT N
effective JJ o
and CC o
safe JJ o
treatment NN o
in IN N
women NNS p
with IN p
acne NN p
and CC N
polycystic JJ N
ovary JJ N
syndrome NN N
( ( N
PCOS NNP N
) ) N
. . N

Nevertheless RB N
, , N
the DT N
combination NN N
EE NNP i
30 CD i
mcg/DRSP NN i
3 CD i
mg NN i
appears VBZ N
to TO N
be VB N
a DT N
more RBR N
potent JJ o
therapeutic JJ o
option NN o
. . o

-DOCSTART- -11981066- O O

Effect NN N
of IN N
cerivastatin NN i
on IN N
proteinuria NNS N
and CC N
urinary JJ N
podocytes NNS N
in IN N
patients NNS p
with IN p
chronic JJ p
glomerulonephritis NN p
. . p

BACKGROUND IN N
We PRP N
previously RB N
reported VBD N
urinary JJ N
podocytes NNS N
to TO N
be VB N
a DT N
marker NN N
of IN N
glomerular JJ N
injury NN N
. . N

The DT N
aim NN N
of IN N
the DT N
present JJ N
study NN N
was VBD N
to TO N
determine VB N
whether IN N
cerivastatin NN i
, , N
a DT N
newly RB N
developed VBN N
, , N
potent JJ N
synthetic JJ N
statin NN N
, , N
affects VBZ N
proteinuria NNS N
and CC N
urinary JJ N
podocyte NN N
excretion NN N
in IN N
patients NNS p
with IN p
chronic JJ p
glomerulonephritis NN p
( ( p
CGN NNP p
) ) p
. . N

METHODS NNP N
We PRP N
randomly VBP N
assigned VBD N
40 CD p
normotensive JJ p
hypercholesterolemic JJ p
patients NNS p
with IN p
CGN NNP p
to TO N
receive VB N
either DT N
cerivastatin NN i
0.15 CD N
mg/day NN N
( ( N
n=20 JJ N
) ) N
or CC N
placebo NN i
( ( N
n=20 JJ N
) ) N
. . N

Subjects NNS p
comprised VBD p
24 CD p
men NNS p
and CC p
16 CD p
women NNS p
, , p
with IN p
a DT p
mean JJ p
age NN p
of IN p
40.8+/-14.4 JJ p
years NNS p
; : p
27 CD p
had VBD p
IgA NNP p
nephropathy JJ p
and CC p
13 CD p
had VBD p
non-IgA JJ p
proliferative JJ p
glomerulonephritis NN p
. . p

Treatment NN N
was VBD N
continued VBN N
for IN N
6 CD N
months NNS N
. . N

Plasma NNP o
total JJ o
cholesterol NN o
, , o
HDL-cholesterol NNP o
, , o
LDL-cholesterol NNP o
and CC o
triglycerides NNS o
, , o
urinary JJ o
protein NN o
excretion NN o
and CC o
the DT o
number NN o
of IN o
podocytes NNS o
were VBD N
measured VBN N
before IN N
treatment NN N
and CC N
at IN N
3 CD N
and CC N
6 CD N
months NNS N
after IN N
treatment NN N
. . N

RESULTS NNP N
After IN N
6 CD N
months NNS N
, , N
a DT N
significant JJ N
reduction NN N
in IN N
total JJ o
cholesterol NN o
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
LDL-cholesterol NNP o
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
and CC N
triglycerides NNS o
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
, , N
and CC N
a DT N
significant JJ N
increase NN o
in IN o
HDL-cholesterol NNP o
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
were VBD N
observed VBN N
in IN N
the DT N
group NN N
treated VBD N
with IN N
cerivastatin NN i
. . i

Urinary JJ o
protein NN o
excretion NN o
decreased VBN N
from IN N
1.8+/-0.6 JJ N
to TO N
0.8+/-0.4 JJ N
g/day NN N
, , N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
in IN N
this DT N
group NN N
, , N
and CC N
urinary JJ o
podocyte NN o
excretion NN o
decreased VBN N
from IN N
1.6+/-0.6 JJ N
to TO N
0.9+/-0.4 JJ N
cells/ml NN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

However RB N
, , N
placebo NN i
showed VBD N
little JJ N
effect NN N
on IN N
these DT N
lipid JJ o
levels NNS o
, , o
urinary JJ o
protein NN o
excretion NN o
and CC o
urinary JJ o
podocyte NN o
excretion NN o
. . o

The DT N
differences NNS N
between IN N
the DT N
cerivastatin NN N
group NN N
and CC N
the DT N
placebo NN N
group NN N
were VBD N
significant JJ N
( ( N
cholesterol NN N
, , N
P NNP N
< NNP N
0.001 CD N
; : N
LDL-cholesterol NNP o
, , N
P NNP N
< NNP N
0.001 CD N
; : N
triglycerides NNS o
, , N
P NNP N
< NNP N
0.05 CD N
; : N
HDL-cholesterol NNP o
, , N
P NNP N
< NNP N
0.001 CD N
; : N
urinary JJ o
protein NN o
, , N
P NNP N
< NNP N
0.01 CD N
; : N
and CC N
urinary JJ o
podocytes NNS o
, , N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

CONCLUSION NNP N
Statins NNP N
such JJ N
as IN N
cerivastatin NN N
may MD N
be VB N
beneficial JJ N
for IN N
restoration NN N
of IN N
injured JJ N
podocytes NNS N
in IN N
patients NNS p
with IN p
CGN NNP p
and CC p
hypercholesterolaemia NN p
. . p

-DOCSTART- -16940738- O O

A DT N
double-blind JJ N
randomized NN N
controlled VBD N
trial NN N
of IN N
oral JJ N
misoprostol NN i
and CC N
intramuscular JJ N
syntometrine NN N
in IN N
the DT N
management NN N
of IN N
the DT N
third JJ p
stage NN p
of IN p
labor NN p
. . p

BACKGROUND IN N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
oral JJ N
misoprostol NN N
400 CD N
mug NN N
with IN N
intramuscular JJ N
syntometrine NN N
in IN N
the DT N
management NN N
of IN N
the DT N
third JJ N
stage NN N
of IN N
labor NN N
. . N

MATERIAL NNP N
AND CC N
METHODS NNP N
This DT N
was VBD N
a DT N
double-blind JJ N
randomized NN N
controlled VBD N
trial NN N
conducted VBN N
in IN N
a DT N
tertiary JJ N
care NN N
hospital NN N
. . N

Three CD p
hundred VBD p
and CC p
fifty-five JJ p
women NNS p
randomized VBN N
to TO N
receive VB N
either DT N
oral JJ i
misoprostol NN i
400 CD i
mug NN i
or CC i
intramuscular JJ i
syntometrine NN i
in IN N
the DT N
third JJ p
stage NN p
of IN p
labor NN p
were VBD N
studied VBN N
. . N

The DT N
change NN N
in IN N
hemoglobin JJ o
level NN o
from IN N
before IN N
to TO N
48 CD N
h NN N
after IN N
delivery NN N
, , N
use NN N
of IN N
additional JJ N
oxytocics NNS N
and CC N
treatment NN N
related JJ N
side NN N
effects NNS N
were VBD N
the DT N
main JJ N
outcome NN N
measures NNS N
. . N

RESULTS NNP N
There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
the DT N
two CD N
groups NNS N
in IN N
terms NNS N
of IN N
the DT N
change NN N
in IN N
hemoglobin JJ o
level NN o
and CC o
mean JJ o
blood NN o
loss NN o
. . o

The DT N
incidence NN N
of IN N
shivering NN o
was VBD N
significantly RB N
higher JJR N
in IN N
the DT N
misoprostol NN i
group NN N
whilst VBD N
that IN N
of IN N
vomiting NN N
was VBD N
significantly RB N
higher JJR N
in IN N
the DT N
syntometrine NN i
group NN N
. . N

There EX N
were VBD N
no DT N
differences NNS N
in IN N
the DT N
incidence NN N
of IN N
nausea NN o
, , o
headache NN o
, , o
diarrhea NN o
and CC o
pyrexia NN o
between IN N
the DT N
two CD N
groups NNS N
. . N

CONCLUSION NNP N
Orally RB N
administered VBD N
misoprostol NN i
at IN N
a DT N
dose NN N
of IN N
400 CD N
mug NN N
is VBZ N
an DT N
acceptable JJ N
alternative NN N
in IN N
preventing VBG N
post-partum JJ N
blood NN o
loss NN o
, , N
as IN N
measured VBN N
by IN N
the DT N
peri-partum JJ N
change NN N
in IN N
hemoglobin JJ o
level NN o
and CC N
was VBD N
not RB N
associated VBN N
with IN N
an DT N
increased JJ N
incidence NN N
of IN N
side NN N
effects NNS N
. . N

-DOCSTART- -16644334- O O

Antiarrhythmic NNP N
efficacy NN N
of IN N
azimilide NN i
in IN N
patients NNS p
with IN p
atrial JJ p
fibrillation NN p
. . p

Maintenance NN N
of IN N
sinus NN N
rhythm NN N
after IN p
conversion NN p
to TO p
sinus VB p
rhythm NN p
. . p

BACKGROUND NNP N
Azimilide NNP i
dihydrochloride NN i
( ( N
azimilide IN N
) ) N
is VBZ N
an DT N
investigational JJ N
antiarrhythmic JJ N
drug NN N
that WDT N
has VBZ N
been VBN N
tested VBN N
in IN N
patients NNS N
with IN N
a DT N
variety NN N
of IN N
arrhythmias NN N
. . N

In IN N
patients NNS p
with IN p
atrial JJ p
fibrillation NN p
, , N
it PRP N
has VBZ N
shown VBN N
excellent JJ N
efficacy NN N
in IN N
some DT N
previous JJ N
trials NNS N
and CC N
minimal JJ N
efficacy NN N
in IN N
others NNS N
. . N

METHODS NNP N
Patients NNPS p
who WP p
had VBD p
symptomatic JJ p
atrial JJ p
fibrillation NN p
for IN p
> $ p
48 CD p
hours NNS p
but CC p
< $ p
6 CD p
months NNS p
were VBD p
eligible JJ p
for IN N
this DT N
multicenter NN N
, , N
randomized VBN N
, , N
placebo-controlled JJ N
clinical JJ N
trial NN N
. . N

Patients NNS p
were VBD p
admitted VBN p
to TO p
a DT p
hospital NN p
and CC N
randomly RB p
assigned VBN p
to TO p
receive VB p
either DT p
azimilide JJ i
125 CD i
mg NN i
or CC i
a DT i
matched JJ i
placebo NN i
twice RB i
daily RB i
for IN i
3 CD i
days NNS i
and CC i
then RB i
once RB i
daily JJ i
. . i

Patients NNS p
who WP p
were VBD p
in IN p
sinus NN p
rhythm NN p
spontaneously RB p
or CC p
had VBD p
sinus VBN p
rhythm NNS p
restored VBN p
by IN p
electric JJ p
cardioversion NN p
on IN p
day NN p
4 CD p
were VBD p
discharged VBN p
from IN p
the DT p
hospital NN p
. . p

Recurrence NN o
of IN o
atrial JJ o
fibrillation NN o
was VBD N
documented VBN N
by IN N
electrocardiogram NN i
. . i

In IN N
the DT N
primary JJ N
efficacy NN N
analysis NN N
, , N
time NN N
to TO N
recurrence VB N
in IN N
the DT N
2 CD N
treatment NN N
groups NNS N
was VBD N
compared VBN N
with IN N
the DT N
log-rank JJ N
test NN N
in IN N
the DT N
subgroup NN N
of IN N
patients NNS p
with IN p
structural JJ p
heart NN p
disease NN p
. . p

Safety NNP N
was VBD N
assessed VBN N
as IN N
deaths NNS o
, , o
adverse JJ o
events NNS o
, , o
and CC o
serious JJ o
adverse JJ o
events NNS o
. . o

RESULTS VB N
A DT N
total NN N
of IN N
446 CD p
patients NNS p
were VBD p
randomized VBN p
in IN p
the DT p
study NN p
; : p
314 CD p
were VBD p
in IN p
the DT p
subgroup NN p
with IN p
structural JJ p
heart NN p
disease NN p
. . p

The DT N
median JJ o
time NN o
to TO o
arrhythmia VB o
recurrence NN o
in IN N
both DT N
treatment NN N
groups NNS N
with IN N
structural JJ N
heart NN N
disease NN N
was VBD N
13 CD N
days NNS N
, , N
and CC N
the DT N
difference NN N
between IN N
treatments NNS N
was VBD N
not RB N
significant JJ N
( ( N
P NNP N
= NNP N
.4596 NNP N
, , N
n JJ N
= NNP N
314 CD N
) ) N
. . N

The DT N
relative JJ o
risk NN o
for IN o
recurrence NN o
( ( N
placebo NN N
: : N
azimilide NN N
) ) N
was VBD N
1.104 CD N
( ( N
95 CD N
% NN N
CI NNP N
0.849-1.436 NN N
) ) N
. . N

There EX N
was VBD N
1 CD N
death NN o
in IN N
the DT N
placebo NN N
group NN N
and CC N
3 CD N
in IN N
the DT N
azimilide NN N
group NN N
. . N

CONCLUSIONS NNP N
Azimilide NNP i
did VBD N
not RB N
demonstrate VB N
clinically RB N
important JJ N
or CC N
statistically RB N
significant JJ N
efficacy NN N
in IN N
reducing VBG N
the DT N
risk NN N
for IN N
arrhythmia JJ N
recurrence NN N
in IN N
patients NNS p
with IN p
structural JJ p
heart NN p
disease NN p
who WP p
were VBD p
in IN p
atrial JJ p
fibrillation NN p
and CC p
converted VBD p
to TO p
sinus VB p
rhythm NN p
. . p

-DOCSTART- -24065423- O O

The DT N
effect NN N
of IN N
leukocyte NN i
reduction NN i
filters NNS i
on IN N
inflammatory NN N
mediator NN N
release NN N
during IN N
coronary JJ N
artery NN N
bypass NN N
grafting NN N
. . N

BACKGROUND NNP N
Extracorporeal NNP N
circulation NN N
used VBN N
during IN N
coronary JJ N
artery NN N
bypass NN N
grafting VBG N
triggers NNS N
systemic JJ N
inflammatory JJ N
response NN N
with IN N
neutrophil JJ N
activation NN N
which WDT N
adversely RB N
affects VBZ N
ischaemic/reperfused JJ N
myocardium NN N
. . N

One CD N
method NN N
of IN N
myocardial JJ N
protection NN N
during IN N
cardiac JJ N
surgery NN N
is VBZ N
the DT N
use NN N
of IN N
blood NN N
cardioplegia NN N
. . N

Its PRP$ N
protective JJ N
effect NN N
is VBZ N
related VBN N
to TO N
cardiac VB N
cooling NN N
and CC N
metabolism NN N
reduction NN N
, , N
oxygen VBP N
supply NN N
from IN N
erythrocytes NNS N
, , N
and CC N
reactive JJ N
oxygen NN N
species NNS N
scavenging VBG N
. . N

However RB N
, , N
blood NN N
cardioplegia NN N
is VBZ N
also RB N
associated VBN N
with IN N
myocardial JJ N
damage NN N
induced VBN N
by IN N
undesirable JJ N
morphotic JJ N
blood NN N
elements NNS N
. . N

AIM NNP N
To TO N
evaluate VB N
the DT N
effect NN N
of IN N
the DT N
use NN N
of IN N
leukocyte JJ i
reduction NN i
filters NNS i
on IN N
the DT N
activity NN N
of IN N
polymorphonuclear NN N
neutrophils NNS N
( ( N
PMN NNP N
) ) N
in IN N
patients NNS p
undergoing VBG p
surgical JJ p
myocardial JJ p
revascularisation NN p
. . p

PMN NNP N
activity NN N
was VBD N
evaluated VBN N
based VBN N
on IN N
measurements NNS N
of IN N
plasma JJ N
activity NN N
of IN N
granulocyte NN N
enzymes NNS N
, , N
lysozyme NN N
and CC N
beta-glucuronidase NN N
. . N

METHODS NNP N
We PRP N
studied VBD N
40 CD p
patients NNS p
who WP p
underwent VBP p
myocardial JJ p
revascularisation NN p
using VBG p
extracorporeal JJ i
circulation NN i
. . i

Patients NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
two CD N
equal JJ N
groups NNS N
: : N
in IN N
Group NNP N
I PRP N
, , N
blood VBD i
cardioplegia NN i
was VBD i
administered VBN i
using VBG i
leukocyte JJ i
reduction NN i
filters NNS i
, , N
and CC N
in IN N
Group NNP N
II NNP N
, , N
leukocyte JJ i
reduction NN i
filters NNS i
were VBD i
not RB i
used VBN i
for IN i
blood NN i
cardioplegia NN i
. . i

Measurements NNS N
were VBD N
performed VBN N
in IN N
plasma NN N
of IN N
arterial JJ N
and CC N
coronary JJ N
sinus NN N
blood NN N
samples NNS N
collected VBD N
before IN N
aortic JJ N
clamping NN N
, , N
immediately RB N
after IN N
unclamping VBG N
, , N
and CC N
after IN N
25 CD N
min NN N
of IN N
reperfusion NN N
. . N

In IN N
addition NN N
, , N
blood NN N
cardioplegic JJ N
solution NN N
samples NNS N
were VBD N
collected VBN N
in IN N
Group NNP N
I PRP N
from IN N
the DT N
lines NNS N
proximal NN N
and CC N
distal NN N
to TO N
the DT N
filter NN N
during IN N
first JJ N
and CC N
last JJ N
administration NN N
. . N

Plasma NNP o
levels NNS o
of IN o
lysozyme NN o
and CC o
beta-glucuronidase NN o
were VBD N
determined VBN N
using VBG N
previously RB N
described VBN N
methods NNS N
. . N

RESULTS NNP N
We PRP N
found VBD N
a DT N
significant JJ N
decrease NN N
in IN N
PMN NNP o
count NN o
in IN N
filtered JJ N
blood NN o
cardioplegic JJ o
solution NN o
during IN N
its PRP$ N
first JJ N
administration NN N
( ( N
0.27 CD N
? . N
0.07 CD N
G/L NNP N
) ) N
compared VBN N
to TO N
samples NNS N
collected VBN N
before IN N
filter JJ N
passage NN N
( ( N
1.73 CD N
? . N
0.049 CD N
G/L NNP N
) ) N
. . N

Also RB N
during IN N
last JJ N
administration NN o
, , o
PMN NNP o
count NN o
in IN o
filtered JJ o
blood NN o
cardioplegic JJ o
solution NN o
was VBD o
decreased VBN N
compared VBN N
to TO N
samples NNS N
collected VBN N
before IN N
filter JJ N
passage NN N
( ( N
0.66 CD N
? . N
0.35 CD N
G/L NNP N
vs. FW N
3.64 CD N
? . N
1.14 CD N
G/L NNP N
, , N
respectively RB N
) ) N
. . N

Significantly RB N
lower JJR N
( ( N
p JJ N
< NNP N
0.02 CD N
) ) o
plasma VB o
beta-glucuronidase JJ o
levels NNS o
were VBD o
found VBN N
in IN N
arterial JJ N
blood NN N
samples NNS N
in IN N
Group NNP N
I PRP N
compared VBN N
to TO N
Group NNP N
II NNP N
( ( N
5.59 CD N
? . N
1.63 CD N
?g/mL NN N
immediately RB N
after IN N
aortic JJ N
unclamping NN N
and CC N
6.59 CD N
? . N
1.98 CD N
?g/mL NN N
after IN N
25 CD N
min NN N
of IN N
reperfusion NN N
in IN N
Group NNP N
I PRP N
vs. VBP N
10.19 CD N
? . N
2.66 CD N
and CC N
12.83 CD N
? . N
1.88 CD N
?g/mL NN N
, , N
respectively RB N
, , N
in IN N
Group NNP N
II NNP N
) ) N
. . N

Beta-glucuronidase JJ o
levels NNS o
in IN o
coronary JJ o
sinus NN o
blood NN o
samples NNS o
collected VBN o
after IN N
aortic JJ N
unclamping NN N
and CC N
at IN N
the DT N
end NN N
of IN N
reperfusion NN N
were VBD N
significantly RB N
higher JJR N
in IN N
Group NNP N
II NNP N
compared VBN N
to TO N
Group NNP N
I PRP N
( ( N
p JJ N
< NNP N
0.04 CD N
) ) N
. . N

In IN N
Group NNP N
I PRP N
, , N
plasma FW o
lysozyme NN o
levels NNS o
in IN o
arterial JJ N
and CC N
venous JJ N
blood NN N
samples NNS N
did VBD N
not RB N
show VB N
significant JJ N
changes NNS N
during IN N
the DT N
surgery NN N
. . N

In IN N
contrast NN N
, , o
plasma VBP o
lysozyme JJ o
level NN o
in IN o
coronary JJ o
sinus NN N
blood NN N
samples NNS N
at IN N
the DT N
end NN N
of IN N
reperfusion NN N
in IN N
Group NNP N
II NNP N
was VBD N
significantly RB N
higher JJR N
compared VBN N
to TO N
that DT N
in IN N
pre-clamping JJ N
samples NNS N
( ( N
p JJ N
< NNP N
0.014 CD N
) ) N
. . N

CONCLUSIONS NN N
With IN N
the DT N
use NN N
of IN N
leukocyte JJ i
reduction NN i
filters NNS i
, , i
we PRP i
found VBD N
significantly RB N
lower JJR N
beta-glucuronidase NN N
levels NNS N
in IN N
arterial JJ N
and CC N
coronary JJ N
sinus NN N
blood NN N
samples NNS N
. . N

These DT N
findings NNS N
seem VBP N
to TO N
confirm VB N
reduced VBN N
PMN NNP N
activation NN N
and/or NN N
reduced VBD N
myocardial JJ N
infiltration NN N
by IN N
activated JJ N
PMN NNP N
. . N

Plasma NNP N
levels NNS N
of IN N
lysozyme NN N
, , N
a DT N
characteristic JJ N
product NN N
of IN N
PMN NNP N
degranulation NN N
, , N
did VBD N
not RB N
show VB N
significant JJ N
differences NNS N
between IN N
the DT N
study NN N
groups NNS N
. . N

-DOCSTART- -6988462- O O

A DT N
comparative JJ N
trial NN N
of IN N
liver NN N
biopsy NN i
needles NNS N
. . N

A DT N
sheathed JJ i
needle NN i
( ( N
Tru-Cut NNP N
) ) N
was VBD N
compared VBN N
with IN N
a DT N
suction NN i
biopsy NN i
needle NN i
( ( i
Menghini NNP i
) ) i
in IN N
a DT N
randomised JJ N
prospective JJ N
trial NN N
over IN N
18 CD N
months NNS N
to TO N
determine VB N
whether IN N
the DT N
former JJ N
offered VBD N
any DT N
special JJ N
advantages NNS N
in IN N
routine JJ i
percutaneous JJ i
liver NN i
biopsy NN i
. . i

Seventy-seven JJ p
consecutive JJ p
biopsies NNS i
were VBD N
performed VBN N
by IN N
a DT p
single JJ p
operator NN p
. . p

Although IN N
biopsy JJ N
fragmentation NN N
was VBD N
commoner NN N
with IN N
the DT N
suction NN i
needle NN i
, , N
the DT N
length NN N
and CC N
volume NN N
of IN N
the DT N
largest JJS N
core NN N
obtained VBN N
was VBD N
similar JJ N
to TO N
results NNS N
with IN N
the DT N
sheathed JJ i
needle NN i
. . i

Cytology NNP N
provided VBD N
useful JJ N
additional JJ N
information NN N
with IN N
the DT N
Menghini NNP i
technique NN i
. . i

The DT N
suction NN i
needle NN i
was VBD N
repeatedly RB o
reusable JJ o
and CC o
considerably RB o
cheaper JJR o
than IN N
the DT N
sheathed JJ i
needle NN i
, , N
which WDT N
may MD N
be VB N
used VBN N
once RB N
only RB N
. . N

-DOCSTART- -22692116- O O

The DT N
effects NNS o
of IN N
different JJ N
intensities NNS N
and CC N
durations NNS N
of IN N
the DT N
general JJ i
warm-up NN i
on IN o
leg JJ o
press NN o
1RM CD o
. . o

The DT N
precision NN N
of IN N
maximum JJ N
strength NN N
assessments NNS N
( ( N
1 CD N
repetition NN N
maximum NN N
; : N
1RM CD N
) ) N
is VBZ N
important JJ N
to TO N
evaluate VB N
the DT N
functional JJ N
capacity NN N
and CC N
to TO N
prescribe VB N
and CC N
monitor VB N
the DT N
training NN N
load NN N
. . N

Several JJ N
factors NNS N
can MD N
affect VB N
the DT N
precision NN N
of IN N
1RM CD N
tests NNS N
, , N
including VBG N
the DT N
warm-up JJ N
procedure NN N
. . N

General NNP N
and CC N
specific JJ N
warm-up JJ N
routines NNS N
are VBP N
recommended VBN N
to TO N
enhance VB N
performance NN N
. . N

The DT N
effects NNS N
of IN N
a DT N
specific JJ N
warm-up NN N
have VBP N
already RB N
been VBN N
acknowledged VBN N
in IN N
improving VBG N
performance NN N
. . N

However RB N
, , N
the DT N
effects NNS N
of IN N
a DT N
general JJ i
warm-up NN i
( ( i
GWU NNP i
) ) i
are VBP N
unclear JJ N
but CC N
seem VBP N
to TO N
depend VB N
on IN N
its PRP$ N
ability NN N
to TO N
increase VB N
muscle NN N
temperature NN N
while IN N
avoiding VBG N
fatigue NN N
. . N

Furthermore NNP N
, , N
temperature NN N
elevation NN N
is VBZ N
dependent JJ N
on IN N
both DT N
the DT N
duration NN N
and CC N
the DT N
intensity NN N
of IN N
the DT N
activity NN N
, , N
which WDT N
may MD N
eventually RB N
affect VB N
1RM CD N
performance NN N
. . N

The DT N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
investigate VB N
the DT N
effect NN o
of IN N
different JJ N
intensities NNS N
and CC N
durations NNS N
of IN N
GWU NNP N
on IN N
1RM CD N
performance NN N
. . N

Sixteen JJ p
strength-trained JJ p
men NNS p
were VBD N
tested VBN N
for IN N
1RM CD o
leg NN o
press NN o
after IN N
4 CD N
GWU NNP N
conditions NNS N
after IN N
specific JJ N
warm-up NN N
: : N
short JJ N
duration NN N
and CC N
low JJ N
intensity NN N
( ( N
SDLI NNP N
; : N
i.e. NN N
, , N
5 CD N
minutes NNS N
at IN N
40 CD N
% NN N
V NNP N
[ NNP N
Combining NNP N
Dot NNP N
Above NNP N
] NNP N
O2max NNP N
) ) N
, , N
long JJ N
duration NN N
and CC N
low JJ N
intensity NN N
( ( N
LDLI NNP N
; : N
i.e. NN N
, , N
15 CD N
minutes NNS N
at IN N
40 CD N
% NN N
V NNP N
[ NNP N
Combining NNP N
Dot NNP N
Above NNP N
] NNP N
O2max NNP N
) ) N
, , N
short JJ N
duration NN N
and CC N
moderate JJ N
intensity NN N
( ( N
SDMI NNP N
; : N
i.e. NN N
, , N
5 CD N
minutes NNS N
at IN N
70 CD N
% NN N
V NNP N
[ NNP N
Combining NNP N
Dot NNP N
Above NNP N
] NNP N
O2max NNP N
) ) N
, , N
long JJ N
duration NN N
and CC N
moderate JJ N
intensity NN N
( ( N
LDMI NNP N
; : N
i.e. NN N
, , N
15 CD N
minutes NNS N
at IN N
70 CD N
% NN N
V NNP N
[ NNP N
Combining NNP N
Dot NNP N
Above NNP N
] NNP N
O2max NNP N
) ) N
, , N
and CC N
the DT N
control NN N
( ( N
CTRL NNP N
) ) N
no-GWU JJ N
condition NN N
. . N

Leg NNP o
press NN o
1RM CD o
values NNS o
were VBD o
higher JJR o
( ( N
on IN N
average NN N
3 CD N
% NN N
) ) N
when WRB N
subjects NNS N
performed VBN N
LDLI NNP N
( ( N
367.8 CD N
? . N
70.1 CD N
kg NN N
; : N
p CC N
= VB N
0.01 CD N
) ) N
, , N
compared VBN N
with IN N
the DT N
other JJ N
4 CD N
conditions NNS N
. . N

After IN N
the DT N
LDMI NNP N
condition NN N
, , N
1RM CD o
values NNS o
were VBD o
lower JJR o
( ( N
on IN N
average NN N
-4 CD N
% NN N
) ) N
than IN N
in IN N
the DT N
other JJ N
4 CD N
conditions NNS N
( ( N
345.6 CD N
? . N
70.5 CD N
kg NN N
; : N
p CC N
= VB N
0.01 CD N
) ) N
. . N

There EX N
were VBD o
no DT o
differences NNS o
between IN o
SDMI NNP o
, , o
SDLI NNP o
, , o
and CC o
CTRL NNP o
( ( o
359.4 CD N
? . N
69.2 CD N
kg NN N
, , N
359.1 CD N
? . N
69.3 CD N
kg NN N
, , N
and CC N
359.4 CD N
? . N
70.4 CD N
kg NN N
, , N
respectively RB N
; : N
p VB N
= $ N
0.99 CD N
) ) N
. . N

According VBG N
to TO N
our PRP$ N
results NNS N
, , N
long-duration JJ N
low-intensity JJ N
general JJ N
warm-up NN N
seems VBZ N
be VB N
appropriately RB N
to TO N
improve VB N
1RM CD N
performance NN p
in IN p
strength-trained JJ p
individuals NNS p
. . p

-DOCSTART- -25659828- O O

Effects NNS N
of IN N
adjunctive JJ N
zonisamide NN i
treatment NN N
on IN N
weight NN o
and CC o
body NN o
mass NN o
index NN o
in IN N
children NNS p
with IN p
partial JJ p
epilepsy NN p
. . p

BACKGROUND NNP N
Zonisamide NNP i
has VBZ N
been VBN N
associated VBN N
with IN N
weight JJ o
loss NN p
in IN p
children NNS p
and CC N
adults NNS N
. . N

AIMS NNP N
OF IN N
THE NNP N
STUDY NNP N
To TO N
assess VB N
the DT N
effects NNS N
of IN N
adjunctive JJ N
zonisamide NN i
on IN N
weight NN o
and CC o
body NN o
mass NN o
index NN o
( ( o
BMI NNP o
) ) o
in IN N
children NNS p
with IN p
partial JJ p
epilepsy NN p
. . p

METHODS NNP N
A DT N
subanalysis NN N
was VBD N
conducted VBN N
of IN N
a DT N
Phase NNP N
III NNP N
trial NN N
and CC N
extension NN N
study NN N
, , N
in IN N
which WDT N
children NNS p
with IN p
partial JJ p
epilepsy NN p
received VBD N
adjunctive JJ i
zonisamide NN i
( ( i
target NN i
dose RB i
8 CD i
mg/kg/day NN i
; : i
maximum JJ i
500 CD i
mg/day NN i
) ) i
. . N

Changes NNS N
in IN N
weight NN o
were VBD N
correlated VBN N
with IN N
skeletal JJ N
development NN N
and CC N
sexual JJ N
maturation NN N
. . N

RESULTS NNP N
Overall NNP N
, , N
179 CD p
children NNS p
( ( p
93 CD p
male NN p
, , p
86 CD p
female NN p
; : p
age NN p
6-18 CD p
years NNS p
) ) p
received VBD N
zonisamide NN i
( ( N
mean JJ N
duration NN N
370.6 CD N
days NNS N
) ) N
. . N

Weight NNP o
loss NN o
? . o
5 CD o
% NN o
was VBD o
reported VBN N
for IN N
64 CD N
of IN N
179 CD N
( ( N
35.8 CD i
% NN i
) ) i
zonisamide-treated JJ i
children NNS i
. . N

Of IN N
these DT N
, , N
46.9 CD N
% NN N
were VBD o
overweight/obese JJ o
at IN o
study NN N
entry NN N
, , N
compared VBN N
with IN N
23.4 CD N
% NN N
at IN N
study JJ N
end NN N
( ( N
P NNP N
= NNP N
0.0007 CD N
) ) N
; : N
48.4 CD N
% NN N
had VBD N
normal JJ o
weight NN o
at IN o
study NN N
entry NN N
, , N
compared VBN N
with IN N
65.6 CD N
% NN N
at IN N
study JJ N
end NN N
( ( N
P NNP N
= NNP N
0.03 CD N
) ) N
. . N

Three CD N
patients NNS N
were VBD o
underweight JJ o
at IN o
study NN N
entry NN N
, , N
and CC N
four CD N
more JJR N
became VBD o
underweight JJ o
by IN o
study JJ N
end NN N
. . N

No DT N
consistent JJ N
correlations NNS N
between IN o
weight JJ o
loss NN o
and CC o
skeletal JJ o
development NN o
or CC o
sexual JJ o
maturation NN o
were VBD o
observed VBN N
. . N

CONCLUSIONS NNP N
Approximately RB N
one-third NN N
of IN N
children NNS N
treated VBN N
with IN i
zonisamide NN i
experienced VBN o
? . o
5 CD o
% NN o
weight JJ o
loss NN o
. . o

Weight NNP o
loss NN o
was VBD p
most RBS N
apparent JJ N
in IN N
children NNS N
with IN N
high JJ N
baseline NN N
BMI NNP N
values NNS N
and CC N
did VBD N
not RB N
appear VB N
to TO N
be VB N
associated VBN N
with IN N
any DT N
consistent JJ N
effects NNS N
on IN N
growth NN N
and CC N
development NN N
. . N

-DOCSTART- -15955950- O O

TENS NNP i
for IN N
the DT N
treatment NN N
of IN N
writer NN p
's POS p
cramp NN p
dystonia NN p
: : p
a DT N
randomized JJ N
, , N
placebo-controlled JJ i
study NN N
. . N

Manipulation NNP N
of IN N
afferent NN N
inputs NNS N
may MD N
temporarily RB N
modulate VB N
dystonic JJ N
spasms NNS N
. . N

Ten CD p
patients NNS p
with IN p
writer NN p
's POS p
cramp NN p
were VBD N
enrolled VBN N
in IN N
a DT N
double-blind NN N
, , N
randomized VBN N
, , N
crossover NN N
study NN N
in IN N
which WDT N
the DT N
effects NNS N
of IN N
transcutaneous JJ i
electrical JJ i
stimulation NN i
( ( i
TENS NNP i
) ) i
and CC i
placebo JJ i
treatment NN N
were VBD N
compared VBN N
. . N

Patients NNS N
were VBD N
evaluated VBN N
using VBG N
four CD N
measures NNS o
of IN o
dystonic JJ o
impairment NN o
. . o

The DT N
TENS NNP i
group NN N
showed VBD N
a DT N
significant JJ o
improvement NN o
that WDT N
persisted VBD N
for IN N
3 CD N
weeks NNS N
in IN N
three CD N
of IN N
the DT N
four CD N
measures NNS N
. . N

-DOCSTART- -21860188- O O

Effect NN N
of IN N
prophylactic JJ i
amiodarone NN i
in IN N
patients NNS p
with IN p
rheumatic JJ p
valve NNS p
disease NN p
undergoing VBG p
valve JJ p
replacement NN p
surgery NN p
. . p

The DT N
study NN N
was VBD N
carried VBN N
out IN N
to TO N
evaluate VB N
the DT N
effect NN N
of IN N
prophylactic JJ N
single-dose JJ N
intravenous JJ N
amiodarone NN i
in IN N
patients NNS p
undergoing VBG p
valve JJ p
replacement NN p
surgery NN p
. . p

Maintenance NN N
of IN N
sinus NN N
rhythm NN N
is VBZ N
better JJR N
than IN N
maintenance NN N
of IN N
fixed JJ N
ventricular JJ N
rate NN N
in IN N
atrial JJ N
fibrillation NN N
( ( N
AF NNP N
) ) N
especially RB N
in IN N
the DT N
presence NN N
of IN N
irritable JJ N
left NN N
or CC N
right JJ N
atrium NN N
because IN N
of IN N
enlargement NN N
. . N

Fifty-six JJ p
patients NNS p
with IN p
valvular JJ p
heart NN p
disease NN p
with IN p
or CC p
without IN p
AF NNP p
were VBD p
randomly RB p
divided VBN p
into IN N
two CD N
groups NNS N
. . N

Group NNP N
I PRP N
or CC N
the DT N
amiodarone NN i
group NN i
( ( N
n=28 NN N
) ) N
received VBD N
amiodarone NN i
( ( N
3 CD N
mg/kg NN N
in IN N
100 CD N
ml NNS N
normal JJ N
saline NN N
) ) N
and CC N
group NN N
II NNP N
or CC N
the DT N
control NN i
group NN N
received VBD N
same JJ N
volume NN N
of IN N
normal JJ i
saline NN i
. . i

The DT N
standardized JJ N
protocol NN N
for IN N
cardiopulmonary JJ N
bypass NN N
was VBD N
maintained VBN N
for IN N
all PDT N
the DT N
patients NNS N
. . N

AF NNP o
occurred VBD N
in IN N
7.14 CD N
% NN N
patients NNS N
in IN N
group NN N
I PRP N
, , N
and CC N
in IN N
group NN N
II NNP N
, , N
28.57 CD N
% NN N
( ( N
P=0.035 NNP N
) ) N
; : N
ventricular JJ o
tachycardia/fibrillation NN o
was VBD N
observed VBN N
in IN N
21.43 CD N
% NN N
patients NNS N
in IN N
group NN N
I PRP N
and CC N
46.43 CD N
% NN N
patients NNS N
in IN N
group NN N
II NNP N
( ( N
P=0.089 NNP N
) ) N
after IN N
release NN N
of IN N
aortic JJ N
clamp NN N
. . N

Most JJS N
of IN N
the DT N
patients NNS N
in IN N
group NN N
I PRP N
( ( N
92.86 CD N
% NN N
) ) N
maintained VBD N
sinus JJ o
rhythm NN o
without IN o
cardioversion NN o
or CC o
defibrillation NN o
after IN N
release NN N
of IN N
aortic JJ N
cross NN N
clamp NN N
( ( N
P=0.002 NNP N
) ) N
. . N

Defibrillation NN o
or CC o
cardio NN o
version NN o
was VBD N
needed VBN N
in IN N
7.14 CD N
% NN N
patients NNS N
in IN N
group NN N
I PRP N
and CC N
28.57 CD N
% NN N
patients NNS N
in IN N
group NN N
II NNP N
( ( N
P=0.078 NNP N
) ) N
. . N

A DT N
single JJ N
prophylactic JJ N
intraoperative NN N
dose NN N
of IN N
intravenous JJ N
amiodarone NN i
decreased VBD N
post NN o
bypass NN o
arrhythmia NN o
in IN N
this DT N
study NN N
in IN N
comparison NN N
to TO N
the DT N
control NN N
group NN N
. . N

Single NNP N
dose NN N
of IN N
intraoperative JJ N
amiodarone NN i
may MD N
be VB N
used VBN N
to TO N
decrease VB N
postoperative JJ N
arrhythmia NN N
in IN N
open JJ N
heart NN N
surgery NN N
. . N

-DOCSTART- -21366734- O O

Which JJ N
women NNS N
default NN N
from IN N
follow-up JJ N
cervical JJ N
cytology NN N
tests NNS N
? . N
A DT N
cohort NN N
study NN N
within IN N
the DT N
TOMBOLA NNP N
trial NN N
. . N

OBJECTIVE UH N
To TO N
identify VB N
factors NNS N
associated VBN N
with IN N
default NN N
from IN N
follow-up JJ o
cervical JJ o
cytology NN o
tests NNS o
. . o

METHODS NNP N
A NNP N
cohort NN N
study NN N
was VBD N
conducted VBN N
involving VBG N
2166 CD p
women NNS p
, , p
aged VBD p
20-59 JJ p
, , p
with IN p
recent JJ p
low-grade JJ p
cervical JJ p
cytology NN p
taken VBN p
within IN p
the DT p
NHS NNP i
Cervical NNP i
Screening NNP i
Programmes NNP i
in IN p
Scotland NNP p
and CC p
England NNP p
, , p
and CC p
managed VBN p
by IN p
6-monthly JJ p
cytology NN p
in IN p
primary JJ p
care NN p
. . p

For IN N
the DT N
first JJ N
( ( N
6-month JJ N
) ) N
and CC N
second JJ N
( ( N
12-month JJ N
) ) N
surveillance NN N
cytology NN N
tests NNS N
separately RB N
, , N
women NNS N
were VBD N
categorized VBN N
as IN N
'on-time JJ i
attendees NNS i
' POS i
( ( i
attended JJ i
?6 NNP i
months NNS i
of IN i
test NN i
being VBG i
due JJ i
) ) i
, , i
'late '' i
attendees NNS i
' POS i
( ( i
attended VBD i
greater JJR i
than IN i
6 CD i
months NNS i
after IN i
test NN i
was VBD i
due JJ i
) ) i
or CC i
'non-attendees NNS i
' POS i
( ( i
failed VBN i
to TO i
attend VB o
) ) o
. . o

Multivariate NNP o
odds JJ o
ratios NNS o
( ( o
ORs NNP N
) ) N
were VBD N
computed VBN N
for IN N
factors NNS N
associated VBN N
with IN o
late JJ o
and CC o
non-attendance JJ o
. . o

RESULTS NNP N
For IN N
the DT N
first JJ N
surveillance NN N
test NN o
, , o
risk NN o
of IN o
non-attendance NN o
was VBD o
significantly RB N
higher JJR N
in IN N
younger JJR p
women NNS p
, , p
those DT p
without IN p
post-secondary JJ p
education NN p
, , p
and CC p
non-users NNS p
of IN p
prescribed JJ p
contraception NN p
. . p

Factors NNS N
significantly RB N
associated VBN N
with IN o
late JJ o
attendance NN o
for IN o
the DT N
first JJ N
test NN N
were VBD N
the DT N
same JJ N
as IN N
for IN N
non-attendance NN N
, , N
plus CC N
current JJ N
smoking NN N
and CC N
having VBG N
children NNS N
. . N

The DT N
most RBS N
important JJ N
predictor NN N
of IN N
non-attendance NN o
for IN o
the DT N
second JJ N
surveillance NN N
test NN N
was VBD N
late JJ N
attendance NN N
for IN N
the DT N
first JJ N
test NN N
( ( N
OR NNP N
= VBZ N
9.65 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
6.60-16.62 JJ o
) ) o
. . o

Non-attendance NN o
for IN o
the DT N
second JJ N
test NN N
was VBD N
also RB N
significantly RB N
higher JJR N
among IN p
women NNS p
who WP p
were VBD p
younger JJR p
, , p
smokers NNS p
and CC p
had VBD p
negative JJ p
cytology NN p
on IN p
the DT N
first JJ N
surveillance NN N
test NN o
. . o

Late JJ o
attendance NN o
for IN o
the DT N
second JJ N
surveillance NN N
test NN N
was VBD N
higher RBR N
in IN N
women NNS p
who WP p
were VBD p
younger JJR p
, , p
smokers NNS p
, , p
had VBD p
children NNS p
and CC p
attended VBD p
late RB p
for IN p
the DT N
first JJ N
test NN N
. . N

CONCLUSIONS NNP N
Women NNP N
at IN N
highest JJS N
risk NN N
of IN N
default NN N
from IN N
follow-up JJ N
cytology NN N
tend NN N
to TO N
be VB N
young JJ p
, , p
smoke NN p
, , p
lack NN p
post-secondary JJ p
education NN p
, , p
and CC p
have VBP p
defaulted VBN p
from IN p
a DT p
previous JJ p
surveillance NN p
appointment NN p
. . p

Tackling VBG N
default NN N
will MD N
require VB N
development NN N
of IN N
targeted JJ N
strategies NNS N
to TO N
encourage VB N
attendance NN N
and CC N
research NN N
to TO N
better JJR N
understand VB N
the DT N
reasons NNS N
underpinning VBG N
default NN N
. . N

-DOCSTART- -2764265- O O

[ RB N
Preventive NNP N
use NN N
of IN N
Pentaglobin NNP i
in IN N
intensive JJ N
care NN N
treatment NN N
of IN N
trauma NN p
patients NNS p
] VBP p
. . N

Basing VBG N
on IN N
50 CD p
posttraumatic JJ p
intensive-care JJ p
patients NNS p
with IN p
medium NN p
grade NN p
lesions NNS p
( ( p
ISS NNP p
criteria NNS p
) ) p
, , p
the DT p
prophylactic JJ N
effect NN N
of IN N
an DT N
intravenously RB N
applicable JJ N
IgM NNP N
preparation NN N
( ( i
Pentaglobin NNP i
) ) i
against IN N
nosocomial JJ N
infections NNS o
was VBD N
investigated VBN N
. . N

The DT N
prophylaxis NN N
group NN N
received VBD N
on IN N
the DT N
3rd CD N
, , N
4th CD N
and CC N
5th CD N
day NN N
a DT N
daily JJ N
dose NN N
of IN N
10 CD N
g NNS N
each DT N
. . N

At IN N
the DT N
same JJ N
times VBZ N
the DT N
controls NNS N
were VBD N
given VBN N
12.5 CD i
g JJ i
human JJ i
albumin NN i
each DT N
. . N

Whereas IN N
no DT N
difference NN N
was VBD N
seen VBN N
between IN N
both DT N
groups NNS N
regarding VBG N
the DT N
definitive JJ N
outcome NN N
of IN N
the DT N
treatment NN N
, , N
the DT N
prophylaxis NN N
group NN N
clearly RB N
showed VBD N
fewer JJR N
infection NN o
pointers NNS o
during IN N
the DT N
clinical JJ N
course NN N
. . N

In IN N
particular JJ N
, , N
the DT N
incidence NN o
and CC o
magnitude NN o
of IN o
febrile JJ o
temperatures NNS o
were VBD N
significantly RB N
lower JJR N
between IN N
the DT N
4th CD N
and CC N
8th CD N
days NNS N
of IN N
treatment NN N
. . N

Our PRP$ N
results NNS N
indicate VBP N
, , N
however RB N
, , N
that IN N
the DT N
prophylactic JJ N
use NN N
those DT N
patients NNS p
who WP p
are VBP p
at IN p
particularly RB p
high JJ p
infection NN p
exposure NN p
risk NN p
, , p
e.g NN p
. . p

through IN p
reintervention NN o
surgery NN o
, , o
haemorrhage NN o
complications NNS o
or CC o
extensive JJ o
diagnostic JJ o
interventions NNS o
. . o

-DOCSTART- -12551867- O O

Acute NNP i
intravenous JJ i
L-arginine JJ i
infusion NN i
decreases VBZ N
endothelin-1 JJ o
levels NNS o
and CC N
improves VBZ N
endothelial JJ o
function NN o
in IN N
patients NNS p
with IN p
angina JJ p
pectoris NN p
and CC p
normal JJ p
coronary JJ p
arteriograms NNS p
: : p
correlation NN N
with IN N
asymmetric JJ N
dimethylarginine NN o
levels NNS o
. . o

BACKGROUND NNP N
We PRP N
tested VBD N
the DT N
hypothesis NN N
that WDT N
asymmetric JJ o
dimethylarginine NN o
( ( o
ADMA NNP o
) ) o
levels NNS o
could MD N
be VB N
elevated VBN N
and CC N
influence VB N
endothelin-1 JJ o
and CC i
nitric JJ o
oxide NN o
release NN o
and CC o
action NN o
in IN N
patients NNS p
with IN p
cardiac JJ p
syndrome NN p
X NNP p
( ( p
CSX NNP p
) ) p
. . p

In IN N
addition NN N
, , N
we PRP N
evaluated VBD N
whether IN N
an DT N
intravenous JJ N
infusion NN N
of IN N
L-arginine NNP i
would MD N
improve VB N
endothelial JJ o
function NN o
in IN N
these DT N
subjects NNS N
. . N

METHODS NNP N
AND CC N
RESULTS NNP N
Nine NNP p
patients NNS p
with IN p
CSX NNP p
and CC p
14 CD p
control NN p
subjects NNS p
underwent VBD p
a DT p
continuous JJ p
infusion NN p
of IN p
L-arginine NNP i
( ( i
0.125 CD i
g/min NN i
) ) i
or CC i
saline NN i
for IN p
120 CD p
minutes NNS p
. . p

Sixty NNP N
minutes NNS N
after IN N
L-arginine NNP i
or CC i
saline JJ i
infusions NNS i
, , N
an DT N
intravenous JJ N
insulin NN i
bolus NN N
( ( N
0.1 CD N
U/kg NNP N
) ) N
combined VBD N
with IN N
a DT N
euglycemic JJ i
clamp NN i
was VBD N
performed VBN N
. . N

Basal NNP o
ADMA NNP o
and CC o
endothelin-1 JJ o
levels NNS o
were VBD N
higher JJR N
in IN N
patients NNS p
with IN p
CSX NNP p
than IN N
in IN N
controls NNS p
. . p

At IN N
the DT N
end NN N
of IN N
the DT N
first JJ N
hour NN N
of IN N
infusion NN N
, , N
compared VBN N
with IN N
saline NN i
, , i
L-arginine JJ i
infusion NN N
increased VBD N
basal JJ o
forearm NN o
blood NN o
flow NN o
, , o
nitrite JJ o
and CC o
nitrate JJ o
( ( o
NOx NNP o
) ) o
, , o
and CC o
forearm NN o
cGMP NN o
release NN o
and CC N
decreased VBD N
endothelin-1 NN o
. . o

After IN N
insulin NN N
bolus NN N
, , N
during IN N
saline NN N
, , N
insulin-induced JJ o
NOx NNP o
, , o
endothelin-1 JJ o
, , o
and CC o
forearm NN o
cGMP NN o
release NN o
was VBD N
almost RB N
abolished VBN N
. . N

Conversely RB N
, , N
L-arginine NNP N
restored VBD N
a DT N
physiological JJ N
profile NN N
of IN N
all DT N
endothelial JJ o
variables NNS o
compared VBN N
with IN N
control NN N
subjects NNS N
. . N

In IN N
control NN N
subjects NNS N
, , N
compared VBN N
with IN N
saline JJ i
infusion NN i
, , i
L-arginine JJ i
infusion NN i
did VBD N
not RB N
modify VB N
any DT N
parameter NN N
. . N

ADMA NNP o
levels NNS o
were VBD N
positively RB N
correlated VBN N
with IN N
basal JJ N
endothelin-1 JJ o
levels NNS o
and CC N
negatively RB N
correlated VBN N
with IN N
insulin-induced JJ o
incremental JJ o
levels NNS o
of IN o
NOx NNP o
and CC o
forearm NN o
cGMP NN o
release NN o
. . o

CONCLUSIONS NNP N
Plasma NNP o
ADMA NNP o
levels NNS o
are VBP N
increased VBN N
in IN N
patients NNS p
with IN p
CSX NNP p
, , N
and CC N
they PRP N
are VBP N
correlated VBN N
with IN N
increases NNS N
in IN N
endothelin-1 JJ o
and CC N
reductions NNS N
in IN N
insulin-induced JJ N
increments NNS N
in IN N
plasma NN o
NOx NNP o
and CC o
cGMP NN o
, , N
effects NNS N
that WDT N
are VBP N
reversed VBN N
by IN N
intravenous JJ N
L-arginine NNP N
. . N

These DT N
data NNS N
suggest VBP N
that IN N
increased VBD N
ADMA NNP o
levels NNS o
play VBP N
a DT N
role NN N
in IN N
the DT N
abnormal JJ N
vascular JJ N
reactivity NN N
that WDT N
is VBZ N
observed VBN N
in IN N
patients NNS N
with IN N
CSX NNP p
. . p

-DOCSTART- -19564877- O O

A DT N
randomized JJ N
double-blind JJ N
placebo-controlled JJ i
study NN N
of IN N
the DT N
long-term JJ N
efficacy NN N
and CC N
safety NN N
of IN N
diethylpropion NN i
in IN N
the DT N
treatment NN N
of IN N
obese JJ p
subjects NNS p
. . p

OBJECTIVE NNP N
To TO N
evaluate VB N
the DT N
efficacy NN N
of IN N
diethylpropion NN i
on IN N
a DT N
long-term JJ N
basis NN N
, , N
with IN N
emphasis NN N
in IN N
cardiovascular JJ N
and CC N
psychiatric JJ N
safety NN N
aspects NNS N
. . N

DESIGN NNP N
Randomized NNP N
, , N
double-blind NN N
, , N
placebo-controlled JJ N
trial NN N
. . N

MEASUREMENTS NNP N
Following VBG N
a DT N
2-week JJ N
screening NN N
period NN N
, , N
69 CD p
obese JJ p
healthy JJ p
adults NNS p
received VBD p
a DT p
hypocaloric JJ i
diet NN i
and CC N
were VBD N
randomized VBN N
to TO N
diethylpropion VB i
50 CD i
mg NNS i
BID NNP i
( ( N
n=37 NN N
) ) N
or CC N
placebo NN i
( ( N
n=32 JJ N
) ) N
for IN N
6 CD N
months NNS N
. . N

After IN N
this DT N
period NN N
, , N
all DT N
participants NNS N
received VBN N
diethylpropion NN i
in IN N
an DT N
open-label JJ N
extension NN N
for IN N
an DT N
additional JJ N
6 CD N
months NNS N
. . N

The DT N
primary JJ N
outcome NN N
was VBD N
percentage NN o
change NN o
in IN o
body NN o
weight NN o
. . o

Electrocardiogram NNP o
( ( o
ECG NNP o
) ) o
, , o
echocardiography NN o
and CC o
clinical JJ o
chemistry NN o
were VBD N
performed VBN N
at IN N
baseline NN N
and CC N
every DT N
6 CD N
months NNS N
. . N

Psychiatric NNP o
evaluation NN o
and CC o
application NN o
of IN o
Hamilton NNP o
rating NN o
scales NNS o
for IN o
depression NN o
and CC o
anxiety NN o
were VBD N
also RB N
performed VBN N
by IN N
experienced JJ N
psychiatrists NNS N
at IN N
baseline NN N
and CC N
every DT N
3 CD N
months NNS N
. . N

RESULTS NNP N
After IN N
6 CD N
months NNS N
, , N
the DT N
diethylpropion NN N
group NN N
lost VBD N
an DT N
average NN N
of IN N
9.8 CD N
% NN N
( ( N
s.d NN N
. . N

6.9 CD N
% NN N
) ) N
of IN N
initial JJ N
body NN o
weight VBD o
vs RB N
3.2 CD N
% NN N
( ( N
3.7 CD N
% NN N
) ) N
in IN N
the DT N
placebo NN i
group NN N
( ( N
P NNP N
< NNP N
0.0001 CD N
) ) N
. . N

From IN N
baseline NN N
to TO N
month NN N
12 CD N
, , N
the DT N
mean JJ o
weight NN o
loss NN o
produced VBN N
by IN N
diethylpropion NN N
was VBD N
10.6 CD N
% NN N
( ( N
8.3 CD N
% NN N
) ) N
. . N

Participants NNS N
in IN N
the DT N
placebo NN i
group NN N
who WP N
were VBD N
switched VBN N
to TO N
diethylpropion NN i
after IN N
6 CD N
months NNS N
lost VBN N
an DT N
average NN N
of IN N
7.0 CD N
% NN N
( ( N
7.7 CD N
% NN N
) ) N
of IN N
initial JJ o
body NN o
weight NN o
. . o

The DT N
difference NN N
between IN N
groups NNS N
at IN N
month NN N
12 CD N
was VBD N
not RB N
significant JJ N
( ( N
P=0.07 NNP N
) ) N
. . N

No DT N
differences NNS N
in IN N
blood NN o
pressure NN o
, , o
pulse JJ o
rate NN o
, , o
ECG NNP o
and CC o
psychiatric JJ o
evaluation NN o
were VBD N
observed VBN N
. . N

Dry NNP o
mouth NN o
and CC o
insomnia NN o
were VBD N
the DT N
most RBS N
frequent JJ N
adverse JJ N
events NNS N
. . N

CONCLUSION NNP N
Diethylpropion NNP i
plus CC N
diet JJ N
produced VBN N
sustained VBN N
and CC N
clinically RB N
significant JJ N
weight JJ o
loss NN o
over IN N
1 CD N
year NN N
. . N

It PRP N
seems VBZ N
to TO N
be VB N
safe JJ N
in IN N
relation NN N
to TO N
cardiovascular VB N
and CC N
psychiatric JJ N
aspects NNS N
in IN N
a DT N
well-selected JJ p
population NN p
. . p

-DOCSTART- -16686565- O O

Effect NN N
of IN N
step NN i
aerobics NNS i
training VBG i
on IN N
anaerobic JJ N
performance NN N
of IN N
men NNS p
and CC p
women NNS p
. . p

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
investigate VB N
the DT N
effects NNS N
of IN N
10 CD N
weeks NNS N
of IN N
step NN i
aerobics NNS i
training VBG i
on IN N
anaerobic JJ N
performance NN N
of IN N
men NNS p
and CC p
women NNS p
. . p

College-age JJ p
volunteers NNS p
( ( p
64 CD p
women NNS p
and CC p
54 CD p
men NNS p
) ) p
were VBD N
divided VBN N
into IN N
step NN i
aerobics NNS i
( ( N
33 CD N
women NNS N
, , N
27 CD N
men NNS N
) ) N
and CC N
control NN i
( ( N
31 CD N
women NNS N
, , N
27 CD N
men NNS N
) ) N
groups NNS N
. . N

Before IN N
and CC N
after IN N
the DT N
10-week JJ N
period NN N
, , N
the DT N
subjects NNS N
' POS N
body NN N
composition NN N
, , N
muscular JJ N
strength NN N
, , N
Wingate NNP N
anaerobic JJ N
performance NN N
, , N
and CC N
vertical JJ N
jump NN N
anaerobic JJ N
performance NN N
were VBD N
determined VBN N
. . N

The DT N
step NN i
aerobics NNS i
group NN N
participated VBD N
in IN N
step NN i
aerobics NNS i
sessions NNS N
of IN N
50 CD N
minutes NNS N
per IN N
day NN N
, , N
3 CD N
days NNS N
per IN N
week NN N
for IN N
10 CD N
weeks NNS N
, , N
at IN N
60-80 CD N
% NN N
of IN N
their PRP$ N
heart NN N
rate NN N
reserve NN N
. . N

Results NNS N
of IN N
2 CD N
x JJ N
2 CD N
analysis NN N
of IN N
covariance NN N
with IN N
repeated JJ N
measures NNS N
indicated VBD N
significant JJ o
sex NN o
differences NNS o
in IN o
percentage NN o
body NN o
fat NN o
, , o
lean JJ o
body NN o
mass NN o
, , o
muscular JJ o
strength NN o
, , o
and CC o
in IN o
all DT o
of IN o
the DT o
measured JJ o
indices NNS o
of IN o
the DT o
Wingate NNP o
Anaerobic NNP o
Test NNP o
. . o

The DT N
step NN o
aerobics NNS o
group NN o
showed VBD o
significant JJ o
improvement NN o
only RB o
in IN o
mean JJ o
power NN o
relative NN o
to TO o
body NN o
weight JJ o
compared VBN o
with IN o
the DT o
control NN o
group NN o
and CC o
women NNS o
showed VBD o
significant JJ o
improvement NN o
only RB o
in IN o
anaerobic JJ o
power NN o
of IN o
vertical JJ o
jump NN o
when WRB o
compared VBN o
with IN o
men NNS o
. . o

It PRP N
can MD N
be VB N
concluded VBN N
that IN N
10 CD N
weeks NNS N
of IN N
step NN o
aerobics NNS o
was VBD o
not RB o
effective JJ o
in IN o
improving VBG o
all DT o
of IN o
the DT o
measured VBN o
anaerobic JJ o
indices NNS o
in IN o
men NNS o
and CC o
women NNS o
. . o

-DOCSTART- -17624203- O O

Efficacy NN o
and CC o
safety NN o
of IN N
sildenafil NN i
in IN N
Asian JJ p
males NNS p
with IN p
erectile JJ p
dysfunction NN p
and CC p
cardiovascular JJ p
risk NN p
. . p

OBJECTIVE NNP N
Assess NNP N
the DT N
effectiveness NN N
of IN N
sildenafil NN i
in IN N
Asian JJ p
males NNS p
with IN p
erectile JJ p
dysfunction NN p
( ( p
ED NNP p
) ) p
and CC p
one CD p
or CC p
more JJR p
of IN p
the DT p
co-morbidities NNS p
, , p
mild-to-moderate JJ p
hypertension NN p
, , p
dyslipidemia NN p
, , p
and CC p
diabetes NNS p
. . p

MATERIAL NNP N
AND NNP N
METHOD NNP N
A NNP N
six-week JJ N
, , N
double-blind JJ N
, , N
randomized VBN N
, , N
placebo-controlled JJ i
, , N
multicenter NN N
study NN N
was VBD N
carried VBN N
out RP N
in IN N
Thailand NNP N
, , N
Malaysia NNP N
and CC N
Singapore NNP N
. . N

One CD p
hundred CD p
and CC p
fifty VB p
five CD p
male JJ p
subjects NNS p
were VBD N
randomized VBN N
( ( N
2:1 CD N
) ) N
to TO N
sildenafil VB i
( ( N
n JJ N
= NNP N
104 CD N
) ) N
or CC N
placebo NN i
( ( N
n JJ N
= NNP N
51 CD N
) ) N
. . N

Sildenafil NNP i
was VBD N
started VBN N
at IN N
50 CD N
mg NN N
and CC N
increased VBD N
( ( N
100 CD N
mg NN N
) ) N
or CC N
decreased VBN N
( ( N
25 CD N
mg NN N
) ) N
at IN N
week NN N
2 CD N
if IN N
necessary JJ N
. . N

RESULTS VB N
On IN N
the DT N
primary JJ N
efficacy NN N
endpoint NN N
, , N
sildenafil-treated JJ i
subjects NNS N
had VBD N
significantly RB N
better JJR N
scores NNS o
on IN N
the DT N
International NNP o
Index NNP o
of IN o
Erectile NNP o
Function NNP o
( ( o
IIEF NNP o
) ) o
questions NNS o
3 CD o
and CC o
4 CD o
than IN N
placebo NN N
( ( N
p JJ N
< NN N
0.001 CD N
, , N
both DT N
questions NNS N
) ) N
. . N

When WRB N
accumulated VBN N
into IN N
IIEF NNP N
domains NNS N
, , N
all DT N
five CD N
domains NNS N
were VBD N
significant JJ N
in IN N
favor NN N
of IN N
sildenafil NN N
. . N

In IN N
addition NN N
, , N
sildenafil-treated JJ i
subjects NNS N
were VBD N
more RBR N
satisfied JJ o
with IN N
treatment NN N
and CC N
had VBD N
a DT N
higher JJR N
intercourse JJ o
success NN o
rate NN o
. . o

The DT N
majority NN N
of IN N
adverse JJ N
events NNS N
were VBD N
mild VBN N
in IN N
severity NN o
; : o
the DT N
most RBS N
commonly RB N
reported VBD N
treatment-related JJ N
events NNS N
were VBD N
dizziness NN o
( ( N
7.7 CD N
% NN N
) ) N
and CC N
tinnitus NN o
( ( N
2.9 CD N
% NN N
) ) N
. . N

CONCLUSION NNP N
Sildenafil NNP N
( ( N
25 CD N
, , N
50 CD N
, , N
and CC N
100 CD N
mg NN N
) ) N
was VBD N
found VBN N
to TO N
be VB N
an DT N
effective JJ N
, , N
safe JJ N
, , N
and CC N
well-tolerated JJ N
treatment NN N
for IN N
ED NNP N
in IN N
the DT N
present JJ N
study NN N
population NN N
of IN N
Thai NNP N
, , N
Malaysian NNP N
, , N
and CC N
Singaporean NNP N
males NNS N
who WP N
also RB N
had VBD N
increased VBN N
cardiovascular JJ N
risk NN N
-DOCSTART- -16173223- O O

Comparison NNP N
of IN N
the DT N
effectiveness NN o
of IN N
oral JJ N
diazepam NN i
and CC i
midazolam NN i
for IN N
the DT N
sedation NN o
of IN p
autistic JJ p
patients NNS p
during IN p
dental JJ p
treatment NN p
. . p

PURPOSE VB N
This DT N
study NN N
was VBD N
undertaken VBN N
to TO N
compare VB N
the DT N
effectiveness NN o
of IN N
oral JJ N
diazepam NN i
and CC i
midazolam NN i
in IN N
sedating VBG p
autistic JJ p
patients NNS p
during IN p
dental JJ p
treatment NN p
. . p

METHODS NNP N
The DT N
treatment NN N
regimen NNS N
consisted VBD N
of IN N
nitrous JJ i
oxide/oxygen NN i
inhalation NN i
in IN N
conjunction NN N
with IN N
oral JJ i
administration NN i
of IN i
either DT i
diazepam NN i
0.3 CD i
mg/kg NN i
or CC i
midazolam VB i
0.5 CD i
mg/kg NN i
in IN N
a DT N
cross-over JJ N
design NN N
study NN N
of IN N
13 CD p
subjects NNS p
aged VBD p
5.8 CD p
to TO p
14.7 CD p
years NNS p
. . p

A DT N
drug NN N
was VBD N
classified VBN N
as IN N
being VBG N
effective JJ o
when WRB N
over RB N
70 CD N
% NN N
of IN N
the DT N
patients NNS N
taking VBG N
the DT N
drug NN N
were VBD N
judged VBN N
as IN N
success NN N
in IN N
all DT N
3 CD N
behavioral JJ N
criteria NNS N
: : N
( ( N
1 CD N
) ) N
sleeping NN N
; : N
( ( N
2 CD N
) ) N
body NN N
movement NN N
; : N
and CC N
( ( N
3 CD N
) ) N
crying NN N
behaviors NNS N
. . N

The DT N
study NN N
was VBD N
observed VBN N
by IN N
an DT N
independent JJ N
clinician NN N
with IN N
an DT N
intraexaminer NN N
reliability NN N
of IN N
88 CD N
% NN N
. . N

RESULTS NNP N
For IN N
sleeping VBG o
behavior NN o
, , N
midazolam NN N
was VBD N
found VBN N
to TO N
be VB N
significantly RB o
more RBR o
effective JJ o
than IN N
diazepam RB N
as IN N
the DT N
duration NN N
of IN N
stimulation NN N
increased VBN N
( ( N
P NNP N
< NNP N
.05 NNP N
) ) N
. . N

For IN N
the DT N
movement NN o
and CC o
crying NN o
behaviors NNS o
, , N
midazolam NN N
also RB N
proved VBD N
to TO N
be VB N
significantly RB o
more RBR o
effective JJ o
from IN N
the DT N
start NN N
of IN N
treatment NN N
through IN N
the DT N
35- JJ N
and CC N
40-min JJ N
markers NNS N
, , N
respectively RB N
( ( N
P NNP N
< NNP N
.05 NNP N
) ) N
. . N

For IN N
the DT N
remainder NN o
of IN o
treatment NN o
, , N
however RB N
, , N
there EX N
was VBD N
no DT o
statistically RB o
significant JJ o
difference NN o
in IN N
these DT N
behaviors NNS N
between IN N
the DT N
trials NNS N
( ( N
P NNP N
> NNP N
.05 NNP N
) ) N
. . N

Diazepam NNP N
and CC N
midazolam NNS N
were VBD N
rated VBN N
as IN N
77 CD N
% NN N
and CC N
100 CD N
% NN N
successful JJ o
, , N
according VBG N
to TO N
the DT N
overall JJ N
behavior NN o
evaluation NN o
criteria NNS N
( ( N
P=.02 NNP N
) ) N
. . N

CONCLUSIONS NNP N
Both NNP N
diazepam NN N
and CC N
midazolam NN N
were VBD N
shown VBN N
to TO N
be VB N
effective JJ o
sedative JJ N
agents NNS N
, , N
successfully RB N
and CC N
safely RB N
used VBN N
to TO N
sedate VB N
autistic JJ p
patients NNS p
for IN N
dental JJ N
treatment NN N
. . N

Midazolam NNP N
was VBD N
significantly RB N
more RBR N
effective JJ N
than IN N
diazepam NN N
in IN N
those DT N
portions NNS N
of IN N
the DT N
procedure NN N
with IN N
increased JJ N
stimulation NN N
. . N

-DOCSTART- -6885201- O O

Pharmacokinetics NNS N
of IN N
naproxen NN i
after IN N
oral JJ N
administration NN N
of IN N
two CD N
tablet NN N
formulations NNS N
in IN N
healthy JJ p
volunteers NNS p
. . p

The DT N
pharmacokinetics NNS N
of IN N
two CD N
naproxen JJ i
tablet NN N
formulations NNS N
were VBD N
compared VBN N
after IN N
oral JJ N
administration NN N
. . N

The DT N
250-mg JJ i
naproxen JJ i
tablets NNS i
, , N
tablet NN N
I PRP N
from IN N
AFI NNP N
, , N
Oslo NNP N
, , N
Norway NNP N
, , N
and CC N
tablet NN N
II NNP N
Naprosyn NNP N
, , N
Astra-Syntex NNP N
, , N
were VBD N
taken VBN N
by IN N
12 CD p
healthy JJ p
volunteers NNS p
in IN N
a DT N
randomized JJ N
two-period NN N
crossover NN N
study NN N
. . N

Plasma NNP N
levels NNS N
of IN N
naproxen NN i
were VBD N
measured VBN N
by IN N
a DT N
sensitive JJ o
and CC o
specific JJ o
HPLC NNP o
method NN o
. . o

The DT N
data NNS N
were VBD N
analyzed VBN N
by IN N
means NNS N
of IN N
two-way JJ N
analysis NN N
of IN N
variance NN N
to TO N
test VB N
for IN N
significant JJ N
differences NNS N
between IN N
tablet NN N
formulation NN N
and CC N
differences NNS N
between IN N
the DT N
first JJ N
and CC N
second JJ N
trial NN N
periods NNS N
. . N

Rapid JJ o
absorption NN o
, , N
with IN N
most JJS N
Cmax NNP o
values NNS o
from IN N
50-60 JJ N
micrograms/ml NN N
reached VBD N
within IN N
1.5-3 JJ N
h NN N
, , N
was VBD N
found VBN N
for IN N
both DT N
tablet JJ N
formulations NNS N
. . N

No DT N
significant JJ o
difference NN o
was VBD N
found VBN N
in IN N
the DT N
rate NN o
and CC o
extent NN o
of IN o
absorption NN o
between IN N
the DT N
two CD N
formulations NNS N
: : N
the DT N
relative JJ N
bioavailability NN o
of IN N
tablet NN N
I PRP N
compared VBN N
to TO N
tablet VB N
II NNP N
was VBD N
1.05 CD N
+/- JJ N
0.21 CD N
( ( N
mean JJ N
+/- NNP N
SD NNP N
) ) N
. . N

The DT N
naproxen JJ o
concentration NN o
2 CD N
h NN N
after IN N
ingestion NN N
and CC N
the DT N
Cmax NNP N
were VBD N
higher JJR N
on IN N
the DT N
second JJ N
occasion NN N
, , N
regardless RB N
of IN N
preparation NN N
, , N
suggesting VBG N
that IN N
the DT N
subjects NNS N
were VBD N
clinically RB o
different JJ o
on IN N
the DT N
two CD N
occasions NNS N
. . N

-DOCSTART- -21990307- O O

Phase NNP N
II NNP N
study NN N
of IN N
the DT N
effects NNS N
of IN N
ginger NN i
root NN i
extract NN i
on IN N
eicosanoids NNS N
in IN N
colon NN N
mucosa NN N
in IN N
people NNS p
at IN p
normal JJ p
risk NN p
for IN p
colorectal JJ p
cancer NN p
. . p

Inhibitors NNS N
of IN N
COX NNP N
indicate VBP N
that IN N
upregulation NN N
of IN N
inflammatory JJ N
eicosanoids NNS N
produced VBN N
by IN N
COX NNP N
, , N
and CC N
in IN N
particular JJ N
prostaglandin NN N
E NNP N
( ( N
2 CD N
) ) N
( ( N
PGE NNP N
( ( N
2 CD N
) ) N
) ) N
, , N
are VBP N
early JJ N
events NNS N
in IN N
the DT N
development NN N
of IN N
colorectal JJ N
cancer NN N
( ( N
CRC NNP N
) ) N
. . N

Ginger NNP N
has VBZ N
shown VBN N
downregulation NN N
of IN N
COX NNP N
in IN N
vitro NN N
and CC N
decreased JJ N
incidence/multiplicity NN N
of IN N
adenomas NN N
in IN N
rats NNS N
. . N

This DT N
study NN N
was VBD N
conducted VBN N
to TO N
determine VB N
if IN N
2.0 CD N
g/d NN N
of IN N
ginger NN i
could MD N
decrease VB N
the DT N
levels NNS N
of IN N
PGE NNP o
( ( o
2 CD o
) ) o
, , o
13-hydroxy-octadecadienoic JJ o
acids NNS o
, , o
and CC o
5- JJ o
, , o
12- JJ o
, , o
and CC o
15-hydroxyeicosatetraenoic JJ o
acid NN o
( ( o
5- JJ o
, , o
12- JJ o
, , o
and CC o
15-HETE JJ o
) ) o
, , N
in IN N
the DT N
colon NN N
mucosa NN N
of IN N
healthy JJ p
volunteers NNS p
. . p

To TO N
investigate VB N
this DT N
aim NN N
, , N
we PRP N
randomized VBD N
30 CD p
subjects NNS p
to TO N
2.0 CD i
g/d NN i
ginger NN i
or CC i
placebo NN i
for IN i
28 CD i
days NNS i
. . i

Flexible JJ o
sigmoidoscopy NN o
at IN N
baseline NN N
and CC N
day NN N
28 CD N
was VBD N
used VBN N
to TO N
obtain VB N
colon NN N
biopsies NNS N
. . N

A DT N
liquid JJ i
chromatography NN i
mass NN i
spectrometry NN i
method NN i
was VBD N
used VBN N
to TO N
determine VB N
eicosanoid JJ o
levels NNS o
in IN N
the DT N
biopsies NNS N
, , N
and CC N
levels NNS N
were VBD N
expressed VBN N
per IN N
protein NN N
or CC N
per IN N
free JJ N
arachidonic JJ N
acid NN N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
mean JJ o
percent NN o
change NN o
between IN N
baseline NN N
and CC N
day NN N
28 CD N
for IN N
any DT N
of IN N
the DT N
eicosanoids NNS o
, , N
when WRB N
normalized VBN N
to TO N
protein VB N
. . N

There EX N
was VBD N
a DT N
significant JJ N
decrease NN N
in IN N
mean JJ o
percent NN o
change NN o
in IN o
PGE NNP o
( ( o
2 CD o
) ) o
( ( N
P NNP N
= NNP N
0.05 CD N
) ) N
and CC N
5-HETE JJ o
( ( N
P NNP N
= NNP N
0.04 CD N
) ) N
, , N
and CC N
a DT N
trend NN N
toward IN N
significant JJ N
decreases NNS N
in IN N
12-HETE JJ o
( ( N
P NNP N
= NNP N
0.09 CD N
) ) N
and CC N
15-HETE JJ o
( ( N
P NNP N
= NNP N
0.06 CD N
) ) N
normalized VBN N
to TO N
free VB o
arachidonic JJ o
acid NN o
. . o

There EX N
was VBD N
no DT N
difference NN N
between IN N
the DT N
groups NNS N
in IN N
terms NNS N
of IN N
total JJ o
adverse JJ o
events NNS o
P NNP N
= NNP N
0.55 CD N
) ) N
. . N

On IN N
the DT N
basis NN N
of IN N
these DT N
results NNS N
, , N
it PRP N
seems VBZ N
that IN N
ginger NN N
has VBZ N
the DT N
potential JJ N
to TO N
decrease VB N
eicosanoid JJ o
levels NNS o
, , N
perhaps RB N
by IN N
inhibiting VBG N
their PRP$ N
synthesis NN N
from IN N
arachidonic JJ N
acid NN N
. . N

Ginger NNP i
also RB N
seemed VBD N
to TO N
be VB N
tolerable JJ o
and CC o
safe JJ o
. . o

Further JJ N
investigation NN N
in IN N
people NNS N
at IN N
high JJ N
risk NN N
for IN N
CRC NNP N
seems VBZ N
warranted VBN N
. . N

-DOCSTART- -22648717- O O

Oral JJ N
magnesium NN i
supplementation NN i
in IN N
children NNS p
with IN p
cystic JJ p
fibrosis NN p
improves VBZ N
clinical JJ o
and CC o
functional JJ o
variables NNS o
: : o
a DT N
double-blind NN N
, , N
randomized VBN N
, , N
placebo-controlled JJ N
crossover NN N
trial NN N
. . N

BACKGROUND NNP N
Magnesium NNP N
is VBZ N
one CD N
of IN N
the DT N
most RBS N
important JJ N
minerals NNS N
in IN N
the DT N
body NN N
. . N

Although IN N
some DT N
studies NNS N
reported VBD N
that IN N
patients NNS N
with IN N
cystic JJ N
fibrosis NN N
( ( N
CF NNP N
) ) N
lack NN N
magnesium NN N
, , N
no DT N
international JJ N
study NN N
has VBZ N
assessed VBN N
the DT N
importance NN N
of IN N
oral JJ N
magnesium NN N
supplementation NN N
in IN N
CF NNP N
patients NNS N
. . N

OBJECTIVE IN N
We PRP N
prospectively RB N
investigated VBD N
the DT N
long-term JJ N
effect NN N
of IN N
oral JJ N
magnesium NN i
supplementation NN N
on IN N
respiratory JJ o
muscle NN o
strength NN o
by IN N
using VBG N
manuvacuometry NN N
and CC N
the DT N
Shwachman-Kulczycki NNP o
( ( o
SK NNP o
) ) o
score NN o
among IN N
children NNS p
and CC p
adolescents NNS p
with IN p
CF NNP p
. . p

DESIGN NNP N
This DT N
double-blind NN N
, , N
randomized VBN N
, , N
placebo-controlled JJ N
crossover NN N
study NN N
included VBD N
44 CD p
CF NNP p
patients NNS p
( ( p
aged VBN p
7-19 CD p
y NN p
; : p
20 CD p
males NNS p
) ) p
who WP p
were VBD p
randomly RB p
assigned VBN p
to TO p
receive VB p
magnesium NN i
( ( p
n JJ p
= VBZ p
22 CD p
; : p
300 CD p
mg/d NN p
) ) p
or CC p
placebo NN i
( ( p
n JJ p
= NNP p
22 CD p
) ) p
for IN p
8 CD p
wk NN p
with IN p
a DT p
4-wk JJ p
washout NN p
period NN p
between IN p
trials NNS p
. . p

All DT N
patients NNS N
were VBD N
undergoing JJ N
conventional JJ N
treatment NN N
of IN N
CF NNP N
. . N

The DT N
experimental JJ N
protocol NN N
included VBD N
clinical JJ N
evaluation NN N
, , N
assessment NN N
of IN N
urinary JJ N
concentration NN N
of IN N
magnesium NN N
, , N
and CC N
manuvacuometric JJ N
measurements NNS N
[ VBP o
maximal JJ o
inspiratory JJ o
pressure NN o
( ( o
MIP NNP o
) ) o
and CC N
maximal JJ o
expiratory NN o
pressure NN o
( ( o
MEP NNP o
) ) o
] NN o
. . N

MIP NNP o
was VBD N
the DT N
primary JJ N
outcome NN N
. . N

RESULTS NNP N
Urinary JJ o
magnesium NN o
increased VBD N
after IN N
the DT N
administration NN N
of IN N
magnesium NN N
( ( N
change NN N
: : N
36.38 CD N
mg/d NN N
after IN N
magnesium NN N
compared VBN N
with IN N
0.72 CD N
mg/d NNS N
after IN N
placebo NN N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

Moreover RB N
, , N
MIP NNP o
and CC o
MEP NNP o
significantly RB N
improved VBD N
only RB N
after IN N
magnesium NN i
administration NN N
( ( N
change NN N
in IN N
MIP NNP N
: : N
11 CD N
% NN N
predicted VBN N
after IN N
magnesium NN N
compared VBN N
with IN N
0.5 CD N
% NN N
predicted VBN N
after IN N
placebo NN N
; : N
change NN N
in IN N
MEP NNP N
: : N
11.9 CD N
% NN N
predicted VBN N
after IN N
magnesium NN N
compared VBN N
with IN N
0.8 CD N
% NN N
predicted VBN N
after IN N
placebo NN N
; : N
P NNP N
< VBZ N
0.001 CD N
for IN N
both DT N
) ) N
. . N

Magnesium NNP N
administration NN N
had VBD N
a DT N
beneficial JJ N
effect NN N
on IN N
clinical JJ N
variables NNS N
assessed VBN N
by IN N
the DT N
SK NNP o
score NN o
( ( N
change NN N
: : N
4.48 CD N
points NNS N
after IN N
magnesium NN N
compared VBN N
with IN N
-1.30 NNP N
points NNS N
after IN N
placebo NN N
; : N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

CONCLUSION NNP N
Oral NNP N
magnesium NN i
supplementation NN N
helped VBD N
improve VB N
both DT N
the DT N
SK NNP o
score NN o
and CC o
respiratory JJ o
muscle NN o
strength NN o
in IN N
pediatric JJ N
patients NNS N
with IN N
CF NNP N
. . N

-DOCSTART- -3353525- O O

[ VB N
The DT N
effect NN N
of IN N
thoracic JJ i
peridural JJ i
analgesia NN i
on IN N
the DT N
cortisol NN o
and CC o
glucose JJ o
response NN o
in IN N
surgery NN p
of IN p
the DT p
abdominal JJ p
aorta NN p
] NNP p
. . N

UNLABELLED NN N
It PRP N
has VBZ N
been VBN N
shown VBN N
that IN N
the DT N
stress NN N
response NN N
to TO N
lower JJR p
abdominal JJ p
surgery NN p
can MD N
be VB N
inhibited VBN N
by IN N
epidural JJ i
analgesia NN i
( ( i
EA NNP i
) ) i
. . i

But CC N
EA NNP N
seems VBZ N
to TO N
have VB N
little JJ N
influence NN N
on IN N
the DT N
stress NN N
reaction NN N
to TO N
major JJ N
abdominal JJ N
surgery NN N
. . N

The DT N
purpose NN N
of IN N
our PRP$ N
study NN N
was VBD N
to TO N
find VB N
out RP N
whether IN N
EA NNP N
is VBZ N
able JJ N
to TO N
diminish VB N
the DT N
cortisol NN o
and CC o
glucose JJ o
response NN o
to TO N
major JJ p
transabdominal JJ p
surgery NN p
. . p

METHODS NNP N
31 CD p
patients NNS p
undergoing JJ p
elective JJ p
surgery NN p
of IN p
the DT p
abdominal JJ p
aorta NN p
were VBD N
subdivided VBN N
at IN N
random NN N
into IN N
3 CD N
different JJ N
anaesthesia NN N
groups NNS N
: : N
1. CD N
halothane NN i
anesthesia NN i
, , N
2. CD N
neuroleptanalgesia NN i
( ( i
NLA NNP i
) ) i
and CC N
3. CD N
thoracic NNS i
EA NNP i
with IN i
bupivacaine NN i
( ( i
0.5 CD i
% NN i
) ) i
in IN N
combination NN i
with IN i
a DT i
light JJ i
general JJ i
anesthesia NN i
. . i

Some DT N
patients NNS N
of IN N
each DT N
group NN N
received VBD N
an DT N
intravenous JJ N
infusion NN N
of IN N
5 CD N
% NN N
glucose NN N
. . N

Blood NN N
samples NNS N
were VBD N
drawn VBN N
before IN N
anesthesia NN N
, , N
after IN N
intubation NN N
, , N
5 CD N
times NNS N
during IN N
surgery NN N
and CC N
at IN N
the DT N
end NN N
of IN N
the DT N
operation NN N
and CC N
were VBD N
analysed VBN N
for IN N
cortisol NN N
and CC N
glucose NN N
. . N

During IN N
the DT N
early JJ N
postoperative JJ N
period NN N
, , N
1 CD N
, , N
2 CD N
and CC N
24 CD N
h NN N
after IN N
surgery NN N
, , N
only RB N
cortisol NN o
was VBD N
measured VBN N
. . N

RESULTS NNP N
Only RB N
the DT N
glucose JJ o
levels NNS o
of IN N
patients NNS N
who WP N
received VBD N
no DT N
carbohydrate-containing JJ N
infusion NN N
fluids NNS N
were VBD N
used VBN N
for IN N
evaluation NN N
of IN N
the DT N
stress NN N
response NN N
. . N

In IN N
the DT N
halothane NN N
group NN N
, , N
there EX N
was VBD N
a DT N
significant JJ N
increase NN N
of IN N
the DT N
mean JJ o
cortisol NN o
and CC o
glucose NN o
levels NNS o
after IN N
the DT N
start NN N
of IN N
surgery NN N
. . N

No DT N
intraoperative JJ N
elevations NNS N
of IN N
blood NN o
glucose NN o
and CC o
cortisol NN o
were VBD N
seen VBN N
in IN N
the DT N
EA NNP N
group NN N
. . N

Patients NNS N
of IN N
the DT N
NLA NNP N
group NN N
showed VBD N
no DT N
hyperglycaemia NN N
and CC N
only RB N
mild JJ N
elevations NNS N
of IN N
the DT N
cortisol NN N
levels NNS N
during IN N
the DT N
intraoperative JJ N
period NN N
. . N

( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
250 CD N
WORDS NNP N
) ) N
-DOCSTART- -16691061- O O

Safety NN N
and CC N
acceptability NN N
of IN N
cellulose JJ i
sulfate NN i
as IN N
a DT N
vaginal JJ N
microbicide NN N
in IN N
HIV-infected JJ p
women NNS p
. . p

OBJECTIVES NNP N
Few JJ N
studies NNS N
of IN N
topical JJ N
microbicides NNS N
have VBP N
assessed VBN N
their PRP$ N
safety NN o
in IN o
HIV-infected JJ o
women NNS o
. . o

We PRP N
conducted VBD N
this DT N
study NN N
to TO N
evaluate VB N
the DT N
safety NN o
and CC o
acceptability NN o
of IN N
6 CD N
% NN N
cellulose JJ i
sulfate NN i
( ( i
CS NNP i
) ) i
gel NN N
as IN N
a DT N
vaginal JJ N
microbicide NN N
in IN p
sexually RB p
abstinent JJ p
and CC p
active JJ p
HIV-infected JJ p
women NNS p
. . p

METHODS NNP N
Fifty-nine JJ p
HIV-infected JJ p
women NNS p
were VBD N
enrolled VBN N
in IN N
a DT N
randomized JJ N
double-blind JJ N
placebo-controlled JJ i
study NN N
comparing VBG N
6 CD N
% NN N
CS NNP i
to TO i
placebo VB i
gel NNS i
used VBN N
for IN N
14 CD N
days NNS N
. . N

Sexually NNP p
abstinent JJ p
women NNS p
applied VBD N
gel JJ N
once RB N
or CC N
twice JJ N
daily JJ N
and CC N
sexually RB N
active JJ N
women NNS N
used VBN N
gel JJ N
once RB N
daily JJ N
. . N

RESULTS NNP N
CS NNP N
gel NN N
was VBD N
safe JJ N
with IN N
no DT N
reported VBN N
severe RB o
or CC o
life-threatening JJ o
adverse JJ o
events NNS o
( ( o
AE NNP o
) ) o
. . o

Thirty-nine NNP N
( ( N
66 CD N
% NN N
) ) N
of IN N
the DT N
participants NNS N
experienced VBD N
urogenital JJ o
AE NNP o
judged VBD N
as IN N
probably RB N
or CC N
possibly RB N
related VBN N
to TO N
gel VB N
. . N

The DT N
majority NN N
( ( N
51 CD N
% NN N
) ) N
of IN N
these DT N
participants NNS N
reported VBD N
only RB N
mild JJ o
events NNS o
. . o

Fewer JJR N
women NNS N
( ( N
62 CD N
% NN N
) ) N
who WP N
used VBD N
CS NNP N
experienced VBD N
urogenital JJ o
AE NNP o
than IN N
those DT N
assigned VBN N
to TO N
placebo VB i
gel NN N
( ( N
70 CD N
% NN N
) ) N
( ( N
P NNP N
= NNP N
0.59 CD N
) ) N
. . N

Eleven NNP N
( ( N
19 CD N
% NN N
) ) N
women NNS N
experienced VBD N
intermenstrual JJ o
bleeding NN o
judged VBD N
to TO N
be VB N
probably RB N
or CC N
possibly RB N
related VBN N
to TO N
gel VB N
use NN N
( ( N
four CD N
in IN N
the DT N
CS NNP N
and CC N
seven CD N
in IN N
the DT N
placebo NN N
gel NN N
group NN N
) ) N
. . N

There EX N
was VBD N
no DT N
increase NN N
in IN N
AE NNP o
by IN N
frequency NN N
of IN N
gel NN N
use NN N
or CC N
sexual JJ N
activity NN N
with IN N
the DT N
exception NN N
of IN N
abdominal/pelvic NN o
pain NN o
which WDT N
was VBD N
noted VBN N
more RBR N
frequently RB N
with IN N
twice RB N
daily JJ N
use NN N
among IN N
sexually RB N
abstinent JJ N
women NNS N
. . N

Women NNS N
and CC N
men NNS N
found VBD N
the DT N
gel NN N
highly RB N
acceptable JJ N
. . N

CONCLUSIONS VB N
This DT N
Phase NNP N
I PRP N
study VBP N
demonstrated VBD N
that IN N
CS NNP i
vaginal JJ i
gel NN i
was VBD N
safe JJ o
, , o
well RB o
tolerated VBN o
and CC o
acceptable JJ o
by IN N
HIV-infected JJ p
women NNS p
and CC p
their PRP$ p
male JJ p
partners NNS p
. . p

Thus RB N
, , N
further JJ N
development NN N
of IN N
CS NNP N
is VBZ N
warranted VBN N
as IN N
a DT N
potential JJ N
method NN N
to TO N
prevent VB N
HIV NNP o
transmission NN o
and CC o
acquisition NN o
. . o

-DOCSTART- -6403021- O O

Comparison NNP N
of IN N
tocainide NN i
and CC i
prajmalium NN i
bitartrate NN i
for IN N
the DT N
treatment NN N
of IN N
ventricular JJ p
arrhythmias NN p
. . p

The DT N
antiarrhythmic JJ N
efficacy NN o
of IN N
tocainide NN i
, , N
a DT N
new JJ N
antiarrhythmic JJ N
substance NN N
, , N
has VBZ N
been VBN N
compared VBN N
with IN N
that DT N
of IN N
prajmalium NN i
bitartrate NN i
, , N
a DT N
drug NN N
in IN N
clinical JJ N
use NN N
for IN N
many JJ N
years NNS N
in IN N
the DT N
German JJ p
speaking NN p
countries NNS p
. . p

The DT N
investigation NN N
was VBD N
performed VBN N
as IN N
a DT N
double-blind JJ N
cross-over NN N
study NN N
in IN N
20 CD p
patients NNS p
with IN p
ventricular JJ p
arrhythmias NNS p
( ( p
VA NNP p
) ) p
of IN p
various JJ p
origin NN p
. . p

The DT N
efficacy NN N
was VBD N
assessed VBN N
by IN N
serial JJ N
Holter NNP o
monitoring NN o
. . o

Plasma NN o
levels NNS o
were VBD N
measured VBN N
to TO N
study VB N
the DT N
dose-effect JJ N
relationship NN N
. . N

Applying VBG N
to TO N
the DT N
criterion NN N
of IN N
a DT N
reduction NN o
of IN o
VA NNP o
of IN N
more JJR N
than IN N
75 CD N
% NN N
or CC N
an DT N
improvement NN N
according VBG N
to TO N
the DT N
Lown NNP o
grading VBG o
8 CD N
pts NNS N
. . N

under IN N
tocainide NN N
and CC N
7 CD N
under IN N
prajmalium NN i
bitartrate NN i
were VBD N
responders NNS N
. . N

Side JJ o
effects NNS o
were VBD N
few JJ N
and CC N
under IN N
tocainide NN N
only RB N
2 CD N
pts NNS N
. . N

had VBD N
to TO N
discontinue VB N
the DT N
therapy NN N
. . N

From IN N
the DT N
present JJ N
findings NNS N
tocainide NN i
and CC N
prajmalium NN i
bitartrate NN i
have VBP N
the DT N
same JJ N
efficient JJ N
antiarrhythmic JJ o
effects NNS o
in IN N
the DT N
majority NN N
of IN N
patients NNS N
. . N

-DOCSTART- -14758586- O O

Comparison NNP N
study NN N
of IN N
venlafaxine NN i
and CC i
paroxetine NN i
for IN N
the DT N
treatment NN N
of IN N
depression NN o
in IN p
elderly JJ p
Chinese JJ p
inpatients NNS p
. . p

-DOCSTART- -23127528- O O

Monitoring NN N
of IN N
CA19-9 NNP N
and CC N
SPan-1 NNP N
can MD N
facilitate VB N
the DT N
earlier JJR N
confirmation NN N
of IN N
progressing VBG N
pancreatic JJ N
cancer NN N
during IN N
chemotherapy NN N
. . N

BACKGROUND NNP N
Measurement NNP N
of IN N
objective JJ o
response NN o
to TO o
chemotherapy VB o
using VBG o
imaging VBG o
modalities NNS o
is VBZ N
sometimes RB N
difficult JJ N
in IN N
pancreatic JJ p
cancer NN p
( ( p
PC NN p
) ) p
. . p

We PRP N
aimed VBD N
to TO N
verify VB N
whether IN N
monitoring NN N
of IN N
serum JJ o
tumor NN o
markers NNS o
( ( o
TMs NNP o
) ) o
, , o
namely RB o
carcinoembryonic JJ o
antigen NN o
, , o
CA19-9 NNP o
, , o
DUPAN-2 NNP o
, , o
SPan-1 NNP o
, , N
can MD N
facilitate VB N
earlier JJR N
confirmation NN N
of IN N
treatment NN N
failure NN N
. . N

METHODS NNP N
Monitoring NNP o
of IN o
serum NN o
TMs NNP o
and CC o
computed VBN o
tomography NN o
were VBD i
performed VBN i
every DT i
4 CD i
weeks NNS i
until IN i
progression NN i
of IN i
disease NN i
in IN N
90 CD p
patients NNS p
with IN p
PC NNP p
undergoing VBG p
gemcitabine JJ p
therapy NN p
. . p

In IN N
Group NNP N
A NNP N
( ( N
January NNP N
2006-October NNP N
2007 CD N
) ) N
, , N
we PRP i
analyzed VBD i
the DT i
fluctuation NN o
rates NNS o
of IN o
TMs NNP o
with IN i
high JJ i
pretreatment NN i
positive JJ i
rates NNS i
, , i
and CC i
defined VBD i
the DT i
criteria NNS i
of IN i
progressive JJ i
disease NN i
under IN i
TM NNP i
monitoring NN i
( ( i
TM-PD NNP i
) ) i
. . i

In IN N
Group NNP N
B NNP N
( ( N
November NNP N
2007-October JJ N
2008 CD N
) ) N
, , N
we PRP i
calculated VBD i
the DT i
time NN o
to TO o
progression NN o
( ( o
TTP NNP o
) ) o
under IN i
this DT i
TM-PD NNP i
criteria NNS i
, , i
which WDT i
was VBD i
compared VBN i
with IN i
the DT i
TTP NNP i
under IN i
the DT i
RECIST NNP i
criteria NNS i
. . i

RESULTS NNP N
CA19-9 JJ N
and CC N
SPan-1 NNP N
had VBD N
the DT N
highest JJS N
pretreatment JJ N
positive JJ N
rates NNS N
: : N
83 CD N
% NN N
and CC N
90 CD N
% NN N
, , N
respectively RB N
. . N

In IN N
Group NNP N
A NNP N
( ( N
CA19-9 NNP N
, , N
n JJ N
= VBP N
38 CD N
; : N
SPan-1 NNP N
, , N
n JJ N
= NNP N
36 CD N
) ) N
, , N
TM-PD JJ N
criteria NNS N
were VBD N
defined VBN N
as IN N
follows VBZ o
: : o
fluctuation NN o
rates NNS o
were VBD o
?25 CD N
% NN N
for IN N
a DT N
month NN N
or CC N
?10 CD N
% NN N
for IN N
2 CD N
consecutive JJ N
months NNS N
in IN N
CA19-9 NNP N
, , N
and CC N
?10 CD N
% NN N
for IN N
a DT N
month NN N
in IN N
SPan-1 NNP N
. . N

In IN N
Group NNP N
B NNP N
( ( N
CA19-9 NNP N
, , N
n JJ N
= VBP N
18 CD N
; : N
SPan-1 NNP N
, , N
n JJ N
= NNP N
17 CD N
) ) N
, , N
under IN N
these DT N
criteria NNS N
, , N
one-month JJ N
earlier JJR o
confirmation NN o
of IN o
treatment NN o
failure NN o
was VBD o
feasible JJ o
in IN N
61 CD N
% NN N
by IN N
CA19-9 NNP N
and CC N
59 CD N
% NN N
by IN N
SPan-1 NNP N
. . N

Furthermore NNP N
, , N
the DT N
combination NN N
could MD N
facilitate VB N
this DT N
determination NN N
in IN N
72 CD N
% NN N
( ( N
35/49 CD N
) ) N
, , N
significantly RB N
better JJR N
than IN N
CA19-9 NNP N
alone RB N
( ( N
P NNP N
= NNP N
0.004 CD N
) ) N
. . N

CONCLUSION NNP N
Monitoring NNP N
of IN N
serum JJ N
CA19-9 NNP N
and CC N
SPan-1 NNP N
is VBZ N
helpful JJ N
for IN N
earlier JJR N
confirmation NN N
of IN N
treatment NN N
failure NN N
during IN N
gemcitabine JJ N
therapy NN N
in IN N
PC NN N
. . N

-DOCSTART- -8930174- O O

Differential JJ N
effects NNS N
of IN N
angiotensin NN i
converting VBG i
enzyme JJ i
inhibitors NNS i
on IN N
the DT N
vasodepressor NN N
and CC N
prostacyclin NN N
responses NNS N
to TO N
bradykinin VB i
. . i

Angiotensin NNP i
converting VBG i
enzyme NN i
( ( i
ACE NNP i
) ) i
inhibitors NNS N
block VBP N
degradation NN N
of IN N
bradykinin NN N
and CC N
bradykinin NN N
stimulates NNS N
prostacyclin VBP N
production NN N
. . N

ACE NNP i
inhibitors NNS N
are VBP N
reported VBN N
to TO N
increase VB N
prostaglandins NNS N
. . N

Therefore RB N
, , N
we PRP N
set VBP N
out RP N
to TO N
determine VB N
1 CD N
) ) N
the DT N
contribution NN N
of IN N
prostacyclin NN N
to TO N
the DT N
bradykinin-mediated JJ N
vasodepressor NN N
effects NNS N
of IN N
ACE NNP i
inhibitors NNS i
, , N
2 CD N
) ) N
whether IN N
ACE NNP i
inhibitors NNS i
alter VBP N
the DT N
effect NN N
of IN N
bradykinin NN N
on IN N
prostacyclin NN N
, , N
and CC N
3 CD N
) ) N
whether IN N
the DT N
effects NNS N
of IN N
ACE NNP i
inhibitors NNS i
on IN N
bradykinin NN N
and CC N
prostaglandins NNS N
are VBP N
class NN N
effects NNS N
or CC N
dependent NN N
on IN N
ACE NNP i
inhibitor NN N
structure NN N
. . N

To TO N
address VB N
these DT N
questions NNS N
, , N
we PRP N
compared VBN N
the DT N
effects NNS N
of IN N
captopril NN i
, , i
quinapril NN i
and CC i
placebo NN i
on IN N
blood NN N
pressure NN N
, , N
urinary JJ N
excretion NN N
of IN N
2,3-dinor-6-keto-PGF1 JJ N
alpha NN N
, , N
and CC N
the DT N
vasodepressor NN N
response NN N
to TO N
i.v VB N
. . N

bradykinin NN i
in IN N
21 CD p
salt-replete JJ p
normal-to-high JJ p
renin NN p
hypertensive JJ p
patients NNS p
. . p

Captopril NNP i
and CC i
quinapril JJ i
doses NNS N
were VBD N
titrated VBN N
to TO N
lower VB N
pressure NN N
similarly RB N
. . N

Captopril NNP i
, , N
but CC N
not RB N
quinapril JJ N
, , N
increased JJ N
excretion NN N
of IN N
prostacyclin NN o
metabolite NN o
( ( N
217 CD N
+/- JJ N
50 CD N
vs. FW N
135 CD N
+/- JJ N
21 CD N
pg/mg NN N
Cr NNP N
base NN N
line NN N
, , N
P NNP N
< NNP N
.05 NNP N
) ) N
. . N

Both DT N
ACE NNP i
inhibitors NNS N
dramatically RB N
, , N
equally RB N
potentiated VBD N
the DT N
vasodepressor NN o
response NN o
to TO N
bradykinin NN N
; : N
the DT N
bradykinin NN N
dose NN N
required VBN N
to TO N
decrease VB N
mean JJ o
arterial JJ o
pressure NN o
15 CD N
mm NN N
Hg NNP N
or CC N
increase VB N
pulse JJ N
20 CD N
bpm NN N
was VBD N
50-fold JJ N
lower JJR N
in IN N
ACEI-treated NNP i
than IN N
in IN N
placebo-treated JJ i
subjects NNS N
( ( N
10 CD N
+/- JJ N
0 CD N
and CC N
12.1 CD N
+/- JJ N
2.1 CD N
ng/kg/min NN N
in IN N
captopril NN i
and CC N
quinapril NN i
groups NNS N
vs. VBP N
567 CD N
+/- JJ N
109 CD N
ng/kg/min NN N
in IN N
the DT N
placebo NN i
group NN N
; : N
P NNP N
< NNP N
.005 NNP N
) ) N
. . N

ACE NNP i
inhibition NN N
significantly RB N
attenuated VBD N
the DT N
prostacyclin NN o
response NN o
to TO o
bradykinin VB o
at IN N
any DT N
given VBN N
level NN N
of IN N
hypotensive JJ N
response NN N
. . N

Indomethacin NNP i
abolished VBD N
the DT N
prostacyclin NN o
response NN o
to TO N
bradykinin VB N
but CC N
did VBD N
not RB N
alter VB N
the DT N
vasodepressor NN o
response NN o
. . o

These DT N
data NNS N
demonstrate NN N
that IN N
ACE NNP i
inhibitors NNS N
potentiate VBP N
bradykinin-mediated JJ N
vasodepression NN N
through IN N
a DT N
prostaglandin-independent JJ N
mechanism NN N
. . N

They PRP N
suggest VBP N
that IN N
although IN N
ACE NNP i
inhibitors NNS N
increase VBP N
prostaglandins NNS N
by IN N
increasing VBG N
bradykinin NN N
, , N
ACE NNP i
inhibitors NNS N
may MD N
attenuate VB N
prostaglandin NN N
production NN N
through IN N
a DT N
second JJ N
bradykinin-independent JJ N
mechanism NN N
. . N

-DOCSTART- -17152183- O O

Cognitive-behavioural JJ i
stress NN i
management NN i
with IN N
HIV-positive JJ p
homosexual JJ p
men NNS p
: : p
mechanisms NNS N
of IN N
sustained JJ N
reductions NNS o
in IN o
depressive JJ o
symptoms NNS o
. . o

BACKGROUND IN N
We PRP N
examined VBD N
the DT N
sustained JJ N
efficacy NN N
of IN N
a DT N
group-based JJ i
cognitive-behavioural JJ i
stress NN i
management NN i
( ( i
CBSM NNP i
) ) i
intervention NN i
in IN N
comparison NN N
to TO N
a DT N
modified VBN N
wait-list NN i
control NN i
condition NN i
on IN N
measures NNS N
of IN N
mood NN o
, , o
coping VBG o
and CC o
social JJ o
support NN o
in IN N
mildly RB p
symptomatic JJ p
HIV-positive JJ p
homosexual JJ p
and CC p
bisexual JJ p
men NNS p
. . p

Participants NNS p
were VBD p
recruited VBN p
largely RB p
during IN p
the DT p
era NN p
prior RB p
to TO p
highly RB p
active JJ p
antiretroviral JJ p
therapy NN p
( ( p
HAART NNP p
; : p
1992-1997 JJ p
) ) p
. . p

METHODS NNP N
Men NNPS p
were VBD N
randomized VBN N
to TO N
either VB N
a DT N
10-week JJ N
, , N
group-based JJ N
CBSM NNP i
intervention NN i
( ( N
n JJ N
= NNP N
83 CD N
) ) N
or CC N
a DT p
psychoeducational JJ i
seminar NN i
group NN i
( ( p
n JJ p
= NNP p
46 CD p
) ) p
. . p

All DT N
participants NNS N
completed VBD N
a DT N
battery NN i
of IN i
psychosocial JJ o
questionnaires NNS o
administered VBN i
by IN i
a DT i
research NN i
assistant NN i
at IN i
baseline NN i
, , i
immediately RB i
following VBG i
the DT i
10-week JJ i
CBSM NNP i
intervention NN i
period NN i
, , i
and CC i
at IN i
a DT i
6-month JJ i
follow-up NN i
. . i

RESULTS NNP N
Men NNP p
in IN p
the DT p
CBSM NNP p
group NN p
maintained VBD N
previously RB N
observed VBN N
effects NNS N
on IN N
depressive NN o
symptoms NNS o
and CC o
perceived VBD o
social JJ o
support NN o
. . o

These DT N
sustained JJ N
effects NNS N
of IN N
CBSM NNP N
on IN N
depressive JJ N
symptoms NNS N
were VBD N
mediated VBN N
by IN N
10-week JJ o
increases NNS o
in IN o
cognitive JJ o
coping NN o
( ( N
i.e JJ N
. . N

positive JJ N
reframing NN N
) ) N
. . N

DISCUSSION NNP N
CBSM NNP N
appears VBZ N
to TO N
be VB N
a DT N
potentially RB N
efficacious JJ N
treatment NN N
that WDT N
reduces VBZ N
and CC N
maintains NNS N
lower JJR N
levels NNS N
of IN N
depressive NN N
symptoms NNS N
and CC N
enhances VBZ N
social JJ N
support NN N
in IN N
HIV-positive JJ p
homosexual JJ p
and CC p
bisexual JJ p
men NNS p
. . p

In IN N
particular JJ N
, , N
changes NNS o
in IN o
positive JJ o
reframing NN o
during IN N
the DT N
10-week JJ N
intervention NN N
period NN N
remain VBP N
a DT N
crucial JJ N
factor NN N
contributing VBG N
to TO N
sustained VBN N
reductions NNS o
in IN o
depressive JJ o
symptoms NNS o
. . N

-DOCSTART- -25907208- O O

Effect NN o
of IN o
cooling VBG o
proparacaine JJ i
0.5 CD i
% NN i
eye NN i
drops NNS i
on IN p
patient NN o
's POS o
comfort NN o
during IN p
instillation NN p
. . p

-DOCSTART- -24375082- O O

Effect NN N
of IN N
camel NN i
milk NN i
on IN N
thymus NN N
and CC N
activation-regulated JJ N
chemokine NN N
in IN N
autistic JJ p
children NNS p
: : p
double-blind NN N
study NN N
. . N

BACKGROUND NNP N
This DT N
study NN N
aimed VBD N
to TO N
investigate VB N
the DT N
role NN N
of IN N
the DT N
effectiveness NN N
of IN N
camel NN i
milk NN i
( ( i
CM NNP i
) ) i
( ( i
raw JJ i
and CC i
boiled VBN i
) ) i
on IN N
thymus NN o
and CC o
activation-regulated JJ o
chemokine NN o
( ( o
TARC NNP o
) ) o
serum NN o
levels NNS o
and CC N
childhood NN o
autism NN o
rating NN o
scale NN o
( ( o
CARS NNP o
) ) o
score NN o
in IN N
subjects NNS p
with IN p
autism NN p
and CC N
compared VBN N
to TO N
placebo VB i
group NN i
( ( i
cow JJ i
milk NN i
) ) i
. . N

METHODS NNP N
Forty-five JJ p
subjects NNS p
diagnosed VBN p
with IN p
autism NN p
were VBD p
randomly RB p
assigned VBN p
to TO p
receive VB p
boiled VBN i
CM NNP i
for IN i
group NN i
I PRP i
( ( p
n JJ p
= NNP p
15 CD p
) ) p
, , p
raw JJ i
CM NNP i
for IN i
group NN i
II NNP i
( ( p
n JJ p
= NNP p
15 CD p
) ) p
, , p
and CC p
placebo NN i
for IN i
group NN i
III NNP i
( ( p
n JJ p
= NNP p
15 CD p
) ) p
for IN p
2 CD p
wk NN p
. . p

Measures NNS N
included VBD N
changes NNS N
in IN N
professionally RB N
completed VBN N
CARS NNP o
score NN o
and CC o
blood NN o
samples NNS o
for IN o
TARC NNP o
serum NN o
level NN o
were VBD N
taken VBN N
before RB N
and CC N
after IN N
milk NN N
consumption NN N
of IN N
500 CD N
ml NNS N
per IN N
day NN N
in IN N
children NNS N
's POS N
regular JJ N
daily JJ N
diet NN N
. . N

RESULTS VB N
The DT o
serum NN o
levels NNS o
of IN o
TARC NNP o
decreased VBD o
significantly RB N
( ( N
P NNP N
= NNP N
0.004 CD N
) ) N
in IN N
boiled VBN N
CM NNP N
and CC N
in IN N
raw JJ N
CM NNP N
group NN N
( ( N
P NNP N
= NNP N
0.01 CD N
) ) N
too RB N
, , N
but CC N
no DT N
effect NN N
was VBD N
observed VBN N
( ( N
P NNP N
= NNP N
0.68 CD N
) ) N
in IN N
placebo NN N
group NN N
. . N

Furthermore RB N
, , N
significant JJ N
improvements NNS N
were VBD N
observed VBN N
in IN N
CARS NNP o
score NN o
( ( o
P NNP N
= NNP N
0.04 CD N
) ) N
in IN N
raw JJ N
CM NNP N
group NN N
only RB N
. . N

There EX N
were VBD N
no DT N
significant JJ N
relationships NNS N
between IN N
the DT o
serum NN o
of IN o
TARC NNP o
level NN o
and CC o
the DT o
CARS NNP o
score NN o
, , o
age NN o
, , o
or CC o
gender VB o
for IN o
any DT N
group NN N
. . N

CONCLUSION NNP N
CM NNP N
administered VBD N
for IN N
2 CD N
wk NNS N
significantly RB N
improved VBN N
clinical JJ N
measurements NNS N
of IN N
autism NN N
severity NN N
and CC N
decreased VBD o
serum JJR o
level NN o
of IN o
TARC NNP o
in IN o
autistic JJ p
children NNS p
, , p
but CC N
subsequent JJ N
studies NNS N
are VBP N
recommended VBN N
. . N

-DOCSTART- -22951426- O O

A DT N
prospective JJ N
, , N
randomized VBN N
, , N
double JJ N
dummy NN N
, , N
placebo-controlled JJ N
trial NN N
of IN N
oral JJ N
cefditoren NNS i
pivoxil VBP i
400mg CD N
once RB N
daily JJ N
as IN N
switch NN N
therapy NN N
after IN N
intravenous JJ N
ceftriaxone NN N
in IN N
the DT N
treatment NN N
of IN N
acute JJ N
pyelonephritis NN N
. . N

OBJECTIVES NNP N
To TO N
compare VB N
the DT N
clinical JJ N
and CC N
bacteriological JJ o
effectiveness NN o
of IN N
intravenous JJ N
( ( N
IV NNP N
) ) N
ceftriaxone NN i
followed VBN N
by IN N
oral JJ N
cefditoren NNS i
pivoxil VBP i
or CC N
IV NNP i
ceftriaxone NN i
for IN N
acute JJ N
pyelonephritis NN N
. . N

METHODS NNP N
A NNP N
prospective JJ N
randomized VBN N
controlled JJ N
trial NN N
of IN N
patients NNS p
with IN p
a DT p
presumptive JJ p
diagnosis NN p
of IN p
acute JJ p
pyelonephritis NN p
was VBD N
performed VBN N
. . N

Daily JJ N
2g CD i
IV NNP i
ceftriaxone NN i
was VBD N
initially RB N
given VBN N
to TO N
all DT N
patients NNS p
. . p

After IN N
day NN N
3 CD N
, , N
patients NNS p
who WP p
satisfied VBD p
the DT p
criteria NNS p
for IN p
switch NN p
therapy NN p
were VBD N
randomized VBN N
to TO N
either DT N
group NN p
A NNP p
( ( i
IV NNP i
ceftriaxone NN i
) ) i
or CC N
group NN i
B NNP i
( ( i
oral JJ i
cefditoren NNS i
pivoxil VBP i
400mg CD i
once RB N
daily JJ N
) ) N
. . N

RESULTS JJ N
Eighty-two JJ p
patients NNS p
were VBD p
enrolled VBN p
; : p
41 CD p
( ( p
50 CD p
% NN p
) ) p
patients NNS p
in IN p
group NN p
A NNP p
and CC p
41 CD p
( ( p
50 CD p
% NN p
) ) p
patients NNS p
in IN p
group NN p
B NNP p
were VBD p
evaluated VBN p
. . p

There EX N
was VBD N
no DT N
statistically RB N
significant JJ N
difference NN N
in IN N
baseline NN o
characteristics NNS o
between IN N
the DT N
two CD N
groups NNS N
. . N

Clinical JJ o
cure NN o
was VBD N
observed VBN N
in IN N
39 CD N
of IN N
41 CD N
( ( N
95.1 CD N
% NN N
) ) N
patients NNS N
in IN N
group NN N
A NNP N
and CC N
41 CD N
of IN N
41 CD N
( ( N
100 CD N
% NN N
) ) N
patients NNS N
in IN N
group NN N
B NNP N
( ( N
p=0.15 NN N
, , N
95 CD N
% NN N
confidence NN N
interval NN N
( ( N
CI NNP N
) ) N
-0.12 VBP N
to TO N
0.02 CD N
) ) N
. . N

Urine NNP o
bacteriological JJ o
eradication NN o
was VBD N
found VBN N
in IN N
63.4 CD N
% NN N
in IN N
group NN N
A NNP N
and CC N
60 CD N
% NN N
in IN N
group NN N
B NNP N
( ( N
p=0.75 NN N
, , N
95 CD N
% NN N
CI NNP N
-0.18 NNP N
to TO N
0.25 CD N
) ) N
. . N

There EX N
was VBD N
no DT N
statistically RB N
significant JJ N
difference NN N
in IN N
adverse JJ o
effects NNS o
between IN N
the DT N
two CD N
treatment NN N
groups NNS N
. . N

CONCLUSION NNP N
These DT N
data NNS N
suggest VBP N
that IN N
IV NNP N
ceftriaxone NN i
followed VBN N
by IN N
oral JJ N
cefditoren NNS i
pivoxil NN i
is VBZ N
highly RB N
effective JJ o
and CC N
well-tolerated JJ o
for IN N
the DT N
treatment NN N
of IN N
acute JJ N
pyelonephritis NN N
, , N
even RB N
for IN N
uropathogens NNS N
with IN N
a DT N
high JJ N
proportion NN N
of IN N
quinolone-resistant JJ N
strains NNS N
. . N

-DOCSTART- -20221773- O O

The DT N
limit NN N
to TO N
exercise VB N
tolerance NN N
in IN N
humans NNS p
: : p
mind NN N
over IN N
muscle NN N
? . N
In IN N
exercise NN N
physiology NN N
, , N
it PRP N
has VBZ N
been VBN N
traditionally RB N
assumed VBN N
that IN N
high-intensity NN i
aerobic JJ i
exercise NN i
stops NNS N
at IN N
the DT N
point NN N
commonly RB N
called VBD N
exhaustion NN N
because IN N
fatigued VBN N
subjects NNS N
are VBP N
no RB N
longer RBR N
able JJ N
to TO N
generate VB N
the DT N
power NN N
output NN N
required VBN N
by IN N
the DT N
task NN N
despite IN N
their PRP$ N
maximal JJ N
voluntary JJ N
effort NN N
. . N

We PRP N
tested VBD N
the DT N
validity NN N
of IN N
this DT N
assumption NN N
by IN N
measuring VBG N
maximal JJ o
voluntary JJ o
cycling VBG o
power NN o
before IN N
( ( N
mean JJ N
+/- JJ N
SD NNP N
, , N
1,075 CD N
+/- JJ N
214 CD N
W NNP N
) ) N
and CC N
immediately RB N
after IN N
( ( N
731 CD N
+/- JJ N
206 CD N
W NNP N
) ) N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
exhaustive VBP i
cycling VBG i
exercise NN i
at IN N
242 CD N
+/- JJ N
24 CD N
W NNP N
( ( N
80 CD N
% NN N
of IN N
peak NN N
aerobic JJ N
power NN N
measured VBN N
during IN N
a DT N
preliminary JJ N
incremental NN N
exercise NN N
test NN N
) ) N
in IN N
ten JJ p
fit JJ p
male NN p
human JJ p
subjects NNS p
. . p

Perceived NNP o
exertion NN o
during IN N
exhaustive JJ i
cycling NN i
exercise NN i
was VBD N
strongly RB N
correlated VBN N
( ( N
r JJ N
= NNP N
-0.82 NNP N
, , N
P NNP N
= NNP N
0.003 CD N
) ) N
with IN N
time NN o
to TO o
exhaustion NN o
( ( N
10.5 CD N
+/- JJ N
2.1 CD N
min NN N
) ) N
. . N

These DT N
results NNS N
challenge VBP N
the DT N
long-standing JJ N
assumption NN N
that IN N
muscle NN N
fatigue NN N
causes VBZ N
exhaustion NN N
during IN N
high-intensity NN N
aerobic JJ N
exercise NN N
, , N
and CC N
suggest VBP N
that IN N
exercise NN N
tolerance NN N
in IN N
highly RB N
motivated JJ N
subjects NNS N
is VBZ N
ultimately RB N
limited VBN N
by IN N
perception NN N
of IN N
effort NN N
. . N

-DOCSTART- -24061784- O O

Baseline NNP N
factors NNS N
predicting VBG N
placebo NN i
response NN N
to TO N
treatment NN N
in IN N
children NNS p
and CC p
adolescents NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
: : p
a DT N
multisite JJ N
randomized JJ N
clinical JJ N
trial NN N
. . N

IMPORTANCE VBZ N
The DT N
finding NN N
of IN N
factors NNS N
that WDT N
differentially RB N
predict VBP N
the DT N
likelihood NN N
of IN N
response NN N
to TO N
placebo VB N
over IN N
that DT N
of IN N
an DT N
active JJ N
drug NN N
could MD N
have VB N
a DT N
significant JJ N
impact NN N
on IN N
study NN N
design NN N
in IN N
this DT N
population NN N
. . N

OBJECTIVE UH N
To TO N
identify VB N
possible JJ N
nonspecific NN N
, , N
baseline JJ N
predictors NNS N
of IN N
response NN o
to TO o
intervention NN o
in IN N
a DT N
large JJ N
randomized JJ N
clinical JJ N
trial NN N
of IN N
children NNS p
and CC p
adolescents NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
. . p

DESIGN NNP N
, , N
SETTING NNP N
, , N
AND NNP N
PARTICIPANTS NNP N
Randomized NNP N
clinical JJ N
trial NN N
of IN N
citalopram NN i
hydrobromide NN i
for IN N
children NNS p
and CC p
adolescents NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
and CC p
prominent JJ p
repetitive JJ p
behavior NN p
. . p

Baseline NNP N
data NN N
at IN N
study NN N
entry NN N
were VBD N
examined VBN N
with IN N
respect NN N
to TO N
final JJ N
outcome NN N
to TO N
determine VB N
if IN N
response NN N
predictors NNS N
could MD N
be VB N
identified VBN N
. . N

A DT N
total NN N
of IN N
149 CD p
children NNS p
and CC p
adolescents NNS p
5 CD p
to TO p
17 CD p
years NNS p
of IN p
age NN p
( ( p
mean JJ p
[ NNP p
SD NNP p
] NNP p
age NN p
, , p
9.4 CD p
[ NN p
3.1 CD p
] CD p
years NNS p
) ) p
from IN p
6 CD p
academic JJ p
centers NNS p
were VBD N
randomly RB N
assigned VBN N
to TO N
citalopram VB i
( ( N
n JJ N
= NNP N
73 CD N
) ) N
or CC N
placebo NN i
( ( N
n JJ N
= NNP N
76 CD N
) ) N
. . N

Participants NNS p
had VBD p
autistic JJ p
disorder NN p
, , p
Asperger NNP p
syndrome NN p
, , p
or CC p
pervasive JJ p
developmental JJ p
disorder NN p
, , p
not RB p
otherwise RB p
specified VBN p
; : p
had VBD p
illness JJ p
severity NN p
ratings NNS p
that WDT p
were VBD p
moderate JJ p
or CC p
more JJR p
than IN p
moderate VB p
on IN p
the DT p
Clinical JJ p
Global NNP p
Impression-Severity NNP p
scale NN p
; : p
and CC p
scored VBD p
moderate JJ p
or CC p
more JJR p
than IN p
moderate VB p
on IN p
compulsive JJ p
behaviors NNS p
measured VBN p
with IN p
the DT p
modified JJ p
Children NNP p
's POS p
Yale-Brown JJ p
Obsessive-Compulsive JJ p
Scale NNP p
. . p

INTERVENTIONS NNP N
Twelve NNP N
weeks NNS N
of IN N
treatment NN N
with IN N
citalopram NN i
( ( N
10 CD N
mg/5 RB N
mL NN N
) ) N
or CC N
placebo NN i
. . i

The DT N
mean NN N
( ( N
SD NNP N
) ) N
maximum VBD N
dose NN N
of IN N
citalopram NN N
was VBD N
16.5 CD N
( ( N
6.5 CD N
) ) N
mg NN N
by IN N
mouth JJ N
daily JJ N
( ( N
maximum JJ N
dose NN N
, , N
20 CD N
mg/d NN N
) ) N
. . N

MAIN NNP N
OUTCOMES NNP N
AND NNP N
MEASURES NNP N
A NNP N
positive JJ N
response NN N
was VBD N
defined VBN N
as IN N
having VBG N
a DT N
score NN N
of IN N
at IN N
least JJS N
much JJ N
improved VBN N
on IN N
the DT N
Clinical JJ o
Global NNP o
Impression-Improvement NNP o
scale NN o
at IN N
week NN N
12 CD N
. . N

Baseline NNP N
measures VBZ N
included VBN N
demographic JJ N
( ( N
sex NN N
, , N
age NN N
, , N
weight NN N
, , N
and CC N
pubertal JJ N
status NN N
) ) N
, , N
clinical JJ N
, , N
and CC N
family NN N
measures NNS N
. . N

Clinical JJ N
variables NNS N
included VBD N
baseline NN N
illness NN N
severity NN N
ratings NNS N
( ( o
the DT o
Aberrant NNP o
Behavior NNP o
Checklist NNP o
, , o
the DT o
Child NNP o
and CC o
Adolescent NNP o
Symptom NNP o
Inventory NNP o
, , o
the DT o
Vineland NNP o
Adaptive NNP o
Behavior NNP o
Scales NNP o
, , o
the DT o
Repetitive JJ o
Behavior NNP o
Scale-Revised JJ o
, , o
and CC o
the DT o
Children NNP o
's POS o
Yale-Brown JJ o
Obsessive-Compulsive JJ o
Scale NNP o
) ) o
. . N

Family JJ N
measures NNS N
included VBD N
the DT N
Caregiver NNP o
Strain NNP o
Questionnaire NNP o
. . o

RESULTS NNP N
Several JJ N
baseline JJ N
predictors NNS N
of IN N
response NN N
were VBD N
identified VBN N
, , N
and CC N
a DT N
principal JJ N
component NN N
analysis NN N
yielded VBD N
3 CD N
composite JJ N
measures NNS N
( ( o
disruptive JJ o
behavior NN o
, , o
autism/mood NN o
, , o
and CC o
caregiver RB o
strain NN o
) ) o
that WDT N
significantly RB N
predicted VBD N
response NN N
at IN N
week NN N
12 CD N
. . N

Specifically RB N
, , N
participants NNS N
in IN N
the DT N
placebo NN N
group NN N
were VBD N
significantly RB N
less RBR N
likely JJ N
than IN N
participants NNS N
in IN N
the DT N
citalopram NN N
group NN N
to TO N
respond VB N
at IN N
week NN N
12 CD N
if IN N
they PRP N
entered VBD N
the DT N
study NN N
more RBR N
symptomatic JJ N
on IN N
each DT N
of IN N
the DT N
3 CD N
composite JJ N
measures NNS N
, , N
and CC N
they PRP N
were VBD N
at IN N
least JJS N
2 CD N
times NNS N
less RBR N
likely JJ N
to TO N
be VB N
responders NNS N
. . N

CONCLUSIONS NNP N
AND CC N
RELEVANCE NNP N
This DT N
analysis NN N
suggests VBZ N
strategies NNS N
that WDT N
may MD N
be VB N
useful JJ N
in IN N
anticipating VBG N
and CC N
potentially RB N
mitigating VBG N
the DT N
nonspecific JJ N
response NN N
in IN N
randomized JJ N
clinical JJ N
trials NNS N
of IN N
children NNS p
and CC p
adolescents NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
. . p

TRIAL NNP N
REGISTRATION NNP N
clinicaltrials.gov NN N
Identifier NNP N
: : N
NCT00086645 NN N
. . N

-DOCSTART- -23185761- O O

[ JJ o
Therapeutic NNP o
efficacy NN o
of IN N
youdujing VBG i
preparation NN i
in IN N
treating VBG N
cervical JJ p
high-risk JJ p
human JJ p
papilloma NN p
virus NN p
infection NN p
patients NNS p
] VBP p
. . N

OBJECTIVE NNP N
To TO N
study VB N
the DT N
clinical JJ N
efficacy NN N
and CC N
mechanisms NN N
of IN N
Youdujing NNP i
( ( i
YDJ NNP i
) ) i
preparation NN i
in IN N
treating VBG N
the DT N
cervical JJ p
high-risk JJ p
human JJ p
papilloma NN p
virus NN p
( ( p
HR-HPV NNP p
) ) p
infection NN p
. . p

METHODS NNP N
Totally RB p
HR-HPV NNP p
infection NN p
70 CD p
patients NNS p
were VBD N
assigned VBN N
to TO N
the DT N
treatment NN i
group NN N
and CC N
the DT N
control NN i
group NN N
using VBG N
random JJ N
single JJ N
blind NN N
method NN N
, , N
35 CD N
cases NNS N
in IN N
each DT N
group NN N
. . N

YDJ NNP i
external JJ i
lotion NN i
and CC i
YDJ NNP i
cream NN i
were VBD N
applied VBN N
to TO N
patients NNS N
in IN N
the DT N
treatment NN N
group NN N
, , N
while IN N
normal JJ i
saline NN i
was VBD N
applied VBN N
for IN N
those DT N
in IN N
the DT N
control NN i
group NN N
. . N

HR-HPV NNP o
DNA NNP o
detection NN o
was VBD N
performed VBN N
by IN N
the DT N
end NN N
of IN N
the DT N
1st CD N
menstruation NN N
after IN N
3 CD N
menstrual JJ N
cycles NNS N
. . N

The DT N
cervical JJ N
biopsy NN N
and CC N
cervical JJ N
smear NN N
were VBD N
performed VBN N
using VBG N
vaginoscope NN N
before IN N
and CC N
after IN N
treatment NN N
. . N

The DT N
mRNA JJ o
expression NN o
of IN o
human JJ o
telomerase NN o
reverse NN o
transcriptase NN o
( ( o
hTERT NN o
) ) o
was VBD N
detected VBN N
from IN N
fresh JJ N
tissues NNS N
of IN N
the DT N
cervical JJ N
lesion NN N
. . N

RESULTS VB N
The DT N
total JJ o
effective JJ o
rate NN o
was VBD N
96.6 CD N
% NN N
in IN N
the DT N
treatment NN N
group NN N
, , N
higher JJR N
than IN N
that DT N
of IN N
the DT N
control NN N
group NN N
( ( N
70.00 CD N
% NN N
, , N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

Before IN N
treatment NN N
there EX N
was VBD N
no DT N
statistical JJ N
difference NN N
in IN N
the DT N
pathological JJ o
results NNS o
of IN o
the DT o
cervix NN o
and CC N
the DT N
mRNA JJ o
expression NN o
of IN o
hTERT NN o
between IN N
the DT N
two CD N
groups NNS N
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
. . N

The DT N
mRNA JJ o
expression NN o
of IN o
hTERT NN o
decreased VBN N
in IN N
the DT N
two CD N
groups NNS N
after IN N
treatment NN N
, , N
showing VBG N
statistical JJ N
difference NN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

Better JJR N
effects NNS N
on IN N
the DT N
pathological JJ N
results NNS N
of IN N
the DT N
cervix NN o
and CC N
the DT N
mRNA JJ o
expression NN o
of IN o
hTERT NN o
were VBD N
obtained VBN N
in IN N
the DT N
treatment NN N
group NN N
after IN N
treatment NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

CONCLUSION NNP N
YDJ NNP i
played VBD N
a DT N
role NN N
in IN N
clearing VBG N
HR-HPV NNP o
infection NN o
and CC N
reversing VBG N
the DT N
cervical JJ o
precancerous JJ o
changes NNS o
possibly RB N
through IN N
down-regulating NN N
the DT N
mRNA JJ N
expression NN N
of IN N
hTERT NN N
and CC N
lowering VBG N
the DT N
telomerase NN N
activation NN N
. . N

-DOCSTART- -9657576- O O

Effects NNS N
of IN N
formoterol NN i
, , i
salmeterol NN i
or CC i
oxitropium NN i
bromide NN i
on IN N
airway NN o
responses NNS o
to TO o
salbutamol VB o
in IN N
COPD NNP p
. . p

We PRP N
examined VBD N
whether IN N
a DT N
pretreatment NN N
with IN N
formoterol NN i
, , i
oxitropium NN i
bromide NN i
, , i
or CC i
salmeterol NN i
might MD N
modify VB N
the DT N
dose-response JJ o
curves NNS o
to TO o
inhaled VB o
salbutamol NN o
in IN N
patients NNS p
with IN p
stable JJ p
and CC p
partially RB p
reversible JJ p
chronic JJ p
obstructive JJ p
pulmonary JJ p
disease NN p
( ( p
COPD NNP p
) ) p
. . p

Sixteen JJ p
outpatients NNS p
with IN p
partially RB p
reversible JJ p
, , p
stable JJ p
COPD NNP p
received VBD i
24 CD i
microg NNS i
formoterol NN i
, , i
50 CD i
microg NN i
salmeterol NN i
, , i
200 CD i
microg NN i
oxitropium NN i
bromide NN i
, , i
or CC i
placebo VB i
on IN i
four CD i
non-consecutive JJ i
days NNS i
. . i

Spirometric JJ i
testing NN i
was VBD N
performed VBN N
immediately RB N
before IN N
inhalation NN N
of IN N
treatment NN N
and CC N
after IN N
2 CD N
h. VBD N
A DT N
dose-response JJ o
curve NN o
to TO o
inhaled VB o
salbutamol NN o
was VBD N
then RB N
constructed VBN i
using VBG i
doses NNS i
of IN i
100 CD i
, , i
100 CD i
, , i
200 CD i
microg NN i
and CC i
400 CD i
microg NN i
-- : i
that WDT i
is VBZ i
, , i
a DT i
total JJ i
cumulative JJ i
dose NN i
of IN i
800 CD i
microg NN i
. . i

Dose JJ N
increments NNS N
were VBD N
given VBN N
at IN N
20 CD N
min NN N
intervals NNS N
with IN N
measurements NNS N
being VBG N
made VBD N
15 CD N
min NNS N
after IN N
each DT N
dose NN N
. . N

Formoterol NNP i
, , i
salmeterol NN i
, , N
or CC N
oxitropium NN i
bromide RB i
elicited VBD N
a DT N
significant JJ N
increase NN N
in IN N
forced JJ o
expiratory NN o
volume NN o
in IN o
one CD o
second NN o
( ( o
FEV1 NNP o
) ) o
compared VBN N
with IN N
placebo NN i
( ( N
mean JJ N
differences NNS N
( ( N
L NNP N
) ) N
= VBD N
placebo $ i
0.05 CD N
; : N
formoterol NN i
0.34 CD N
; : N
salmeterol NN i
0.27 CD N
; : N
oxitropium NN i
bromide IN i
0.23 CD N
) ) N
. . N

Dose-dependent JJ N
increases NNS N
in IN N
FEV1 NNP o
were VBD N
seen VBN N
( ( N
mean JJ N
values NNS N
( ( N
L NNP N
) ) N
before IN N
salbutamol NN N
and CC N
after IN N
a DT N
cumulative JJ N
dose NN N
of IN N
100 CD N
, , N
200 CD N
, , N
400 CD N
, , N
and CC N
800 CD N
microg NN N
= NN N
placebo NN i
: : i
1.06 CD N
, , N
1.28 CD N
, , N
1.35 CD N
, , N
1.39 CD N
, , N
1.41 CD N
; : N
formoterol NN i
: : i
1.33 CD N
, , N
1.37 CD N
, , N
1.41 CD N
, , N
1.44 CD N
, , N
1.44 CD N
; : N
salmeterol NN i
: : i
1.30 CD N
, , N
1.33 CD N
, , N
1.36 CD N
, , N
1.39 CD N
, , N
1.42 CD N
; : N
oxitropium JJ i
bromide NN i
: : i
1.27 CD N
, , N
1.34 CD N
, , N
1.37 CD N
, , N
1.41 CD N
, , N
1.40 CD N
) ) N
. . N

Statistical JJ N
analysis NN N
revealed VBD N
no DT N
significant JJ N
differences NNS N
in IN N
FEV1 NNP o
and CC o
forced VBD o
vital JJ o
capacity NN o
( ( o
FVC NNP o
) ) o
responses VBZ o
to TO N
salbutamol VB N
after IN N
therapy NN N
with IN N
formoterol NN i
, , i
salmeterol NN i
, , i
or CC i
oxitropium NN i
bromide NN i
compared VBN N
with IN N
placebo NN i
. . i

This DT N
study NN N
clearly RB N
shows VBZ N
that IN N
a DT N
pretreatment NN N
with IN N
a DT N
conventional JJ N
dose NN N
of IN N
formoterol NN i
, , i
salmeterol NN i
, , i
or CC i
oxitropium JJ i
bromide NN i
does VBZ N
not RB N
preclude VB N
the DT N
possibility NN N
of IN N
inducing VBG N
a DT N
further JJ N
bronchodilation NN o
with IN N
salbutamol NN i
in IN N
patients NNS p
suffering VBG p
from IN p
partially RB p
reversible JJ p
chronic JJ p
obstructive JJ p
pulmonary JJ p
disease NN p
. . p

-DOCSTART- -3528402- O O

A DT N
randomized JJ N
comparison NN N
of IN N
tamoxifen NN i
with IN N
surgical JJ i
oophorectomy NN i
in IN N
premenopausal NN p
patients NNS p
with IN p
advanced JJ p
breast NN p
cancer NN p
. . p

We PRP N
randomized VBD N
122 CD p
premenopausal JJ p
women NNS p
to TO N
receive VB N
tamoxifen NN i
or CC N
to TO N
undergo VB i
a DT i
surgical JJ i
oophorectomy NN i
. . i

Of IN N
54 CD p
evaluable JJ p
women NNS p
treated VBN p
with IN p
tamoxifen NN i
, , p
24 CD p
% NN p
had VBD p
an DT p
objective JJ o
response NN o
, , p
as IN p
compared VBN p
with IN p
21 CD p
% NN p
of IN p
53 CD p
women NNS p
having VBG p
an DT p
oophorectomy NN i
. . i

The DT N
median JJ o
duration NN o
of IN o
response NN o
for IN N
tamoxifen NN i
( ( N
20 CD N
months NNS N
) ) N
was VBD N
longer JJR N
than IN N
that DT N
for IN N
surgical JJ i
oophorectomy NN i
( ( N
7 CD N
months NNS N
) ) N
, , N
but CC N
this DT N
did VBD N
not RB N
achieve VB N
statistical JJ N
significance NN N
( ( N
P NNP N
= NNP N
.056 NNP N
) ) N
. . N

Overall JJ o
median JJ o
survival NN o
was VBD N
15 CD N
months NNS N
for IN N
58 CD p
patients NNS p
receiving VBG N
tamoxifen NN N
and CC N
25 CD N
months NNS N
for IN N
53 CD N
patients NNS N
undergoing JJ N
oophorectomy JJ N
( ( N
P NNP N
= NNP N
.18 NNP N
) ) N
. . N

Toxicity NN o
was VBD N
greater JJR N
in IN N
those DT N
undergoing JJ N
oophorectomy NN N
, , N
though IN N
both DT o
treatments NNS o
were VBD o
well RB o
tolerated VBN o
. . o

In IN N
those DT N
premenopausal JJ p
women NNS p
for IN N
whom WP N
hormonal JJ N
therapy NN N
is VBZ N
indicated VBN N
, , N
tamoxifen EX i
is VBZ N
a DT N
suitable JJ N
alternative NN N
to TO N
surgical JJ i
oophorectomy NN i
. . i

-DOCSTART- -22510874- O O

Osteopontin NNP i
is VBZ N
a DT N
prognostic JJ N
factor NN N
for IN N
survival NN o
of IN N
acute JJ p
myeloid JJ p
leukemia NN p
patients NNS p
. . p

Osteopontin NNP o
( ( o
OPN NNP o
) ) o
is VBZ N
a DT N
glycoprotein NN N
that WDT N
is VBZ N
secreted VBN N
by IN N
osteoblasts NNS N
and CC N
hematopoietic JJ N
cells NNS N
. . N

OPN NNP i
suppresses VBZ N
the DT N
proliferation NN N
of IN N
hematopoietic JJ N
stem NN N
cells NNS N
in IN N
vitro NN N
and CC N
may MD N
regulate VB N
the DT N
hematopoietic JJ N
stem NN N
cell NN N
pool NN N
. . N

Increased VBN N
serum NN N
OPN NNP N
concentrations NNS N
occur VBP N
in IN N
chronic JJ N
myeloid NN N
leukemia NN N
, , N
multiple JJ N
myeloma NN N
, , N
and CC N
acute JJ N
myeloid NN N
leukemia NN N
( ( N
AML NNP N
) ) N
. . N

In IN N
the DT N
present JJ N
study NN N
, , N
we PRP N
analyzed VBD N
the DT N
prognostic JJ N
impact NN N
of IN N
OPN NNP N
in IN N
AML NNP N
by IN N
investigating VBG N
the DT N
expression NN o
and CC o
relevance NN o
of IN o
OPN NNP o
in IN N
newly RB p
diagnosed VBN p
AML NNP p
patients NNS p
from IN p
2 CD p
large JJ p
study NN p
groups NNS p
( ( p
the DT p
German JJ p
AML NNP p
Cooperative NNP p
Group NNP p
and CC p
the DT p
Dutch-Belgian JJ p
Hematology NNP p
Oncology NNP p
Cooperative NNP p
group NN p
) ) p
. . p

IHC NNP o
( ( N
n JJ N
= NNP N
84 CD N
) ) N
, , N
ELISAs NNP o
of IN o
blood/BM NN o
sera NN o
( ( N
n JJ N
= NNP N
41 CD N
) ) N
, , N
and CC N
microarray NN o
data NNS o
for IN o
mRNA NN o
levels NNS o
( ( N
n JJ N
= NNP N
261 CD N
) ) N
were VBD N
performed VBN N
. . N

Expression NN o
of IN o
OPN NNP o
protein NN o
was VBD N
increased VBN N
in IN N
AML NNP N
patients NNS N
both DT N
in IN N
BM NNP N
blasts NNS N
( ( i
IHC NNP i
) ) i
and CC N
in IN N
BM NNP N
serum NN N
( ( i
ELISA NNP i
) ) i
compared VBN N
with IN N
healthy JJ N
controls NNS N
. . N

Patients NNS N
expressing VBG N
high JJ N
levels NNS o
of IN o
OPN NNP o
within IN o
the DT o
BM NNP o
( ( N
IHC NNP N
) ) N
experienced VBD N
shortened VBN N
overall JJ o
survival NN o
( ( N
OS NNP N
; : N
P NNP N
= NNP N
.025 NNP N
) ) N
. . N

Multivariate NNP N
analysis NN N
identified VBD N
karyotype NN o
, , o
blast JJ o
clearance NN o
( ( N
day NN N
16 CD N
) ) N
, , N
and CC N
the DT N
level NN o
of IN o
OPN NNP o
expression NN o
as IN N
independent JJ N
prognostic JJ N
factors NNS N
for IN N
OS NNP o
. . o

This DT N
prompted VBD N
us PRP N
to TO N
analyze VB N
microarray NN N
data NNS N
from IN N
261 CD p
patients NNS p
from IN p
a DT p
third JJ p
cohort NN p
. . p

The DT N
analysis NN N
confirmed VBD N
OPN NNP N
as IN N
a DT N
prognostic JJ N
marker NN N
. . N

In IN N
summary JJ N
, , N
high JJ N
OPN NNP o
mRNA NN o
expression NN o
indicated VBD N
decreased JJ N
event-free JJ o
survival NN o
( ( N
P NNP N
= NNP N
.0002 NNP N
) ) N
and CC N
OS NNP N
( ( N
P NNP N
= NNP N
.001 NNP N
) ) N
. . N

The DT N
prognostic JJ N
role NN N
of IN N
OPN NNP i
was VBD N
most RBS N
prominent JJ N
in IN N
intermediate-risk JJ N
AML NNP N
. . N

These DT N
data NNS N
provide VBP N
evidence NN N
that IN N
OPN NNP o
expression NN o
is VBZ N
an DT N
independent JJ N
prognostic JJ N
factor NN N
in IN N
AML NNP N
. . N

-DOCSTART- -19682342- O O

Large-dose JJ N
intravenous JJ N
ferric NNS i
carboxymaltose VBP i
injection NN i
for IN N
iron NN p
deficiency NN p
anemia NN p
in IN p
heavy JJ p
uterine JJ p
bleeding NN p
: : p
a DT N
randomized NN N
, , N
controlled VBN N
trial NN N
. . N

BACKGROUND VB N
The DT N
objective NN N
was VBD N
to TO N
evaluate VB N
efficacy NN N
and CC N
safety NN N
of IN N
rapid JJ N
, , N
large-dose JJ i
intravenous JJ i
( ( i
IV NNP i
) ) i
administration NN i
of IN i
ferric JJ i
carboxymaltose NN i
compared VBN N
to TO N
oral JJ i
iron NN i
in IN N
correcting VBG N
iron NN N
deficiency NN N
anemia NN N
due JJ N
to TO N
heavy JJ N
uterine JJ N
bleeding NN N
. . N

STUDY NNP N
DESIGN NNP N
AND NNP N
METHODS NNP N
In IN N
a DT N
randomized NN N
, , N
controlled VBN N
trial NN N
, , N
477 CD p
women NNS p
with IN p
anemia NN p
, , p
iron NN p
deficiency NN p
, , p
and CC p
heavy JJ p
uterine JJ p
bleeding NN p
were VBD p
assigned VBN p
to TO N
receive VB N
either DT N
IV NNP i
ferric NN i
carboxymaltose NN i
( ( N
< JJ N
or=1000 NN N
mg NN N
over IN N
15 CD N
min NNS N
, , N
repeated VBD N
weekly JJ N
to TO N
achieve VB N
a DT N
total JJ N
calculated JJ N
replacement NN N
dose NN N
) ) N
or CC N
325 CD N
mg NN N
of IN i
ferrous JJ i
sulfate NN i
( ( N
65 CD N
mg NN N
elemental JJ N
iron NN N
) ) N
prescribed VBD N
orally RB N
thrice JJ N
daily RB N
for IN N
6 CD N
weeks NNS N
. . N

RESULTS NNP N
Compared VBD N
to TO N
those DT N
assigned VBN N
to TO N
ferrous JJ i
sulfate NN i
, , N
more JJR N
patients NNS N
assigned VBD N
to TO N
ferric VB i
carboxymaltose NN i
responded VBN N
with IN N
a DT N
hemoglobin NN o
( ( o
Hb NNP o
) ) o
increase NN N
of IN N
2.0 CD N
g/dL NN N
or CC N
more JJR N
( ( N
82 CD N
% NN N
vs. FW N
62 CD N
% NN N
, , N
95 CD N
% NN N
confidence NN N
interval NN N
for IN N
treatment NN N
difference NN N
12.2-28.3 CD N
, , N
p VBZ N
< NNP N
0.001 CD N
) ) N
, , N
more JJR N
achieved VBD N
a DT N
3.0 CD N
g/dL NN N
or CC N
more JJR N
increase NN N
( ( N
53 CD N
% NN N
vs. FW N
36 CD N
% NN N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
, , N
and CC N
more JJR N
achieved JJ N
correction NN o
( ( N
Hb NNP N
> NNP N
or= VBD N
12 CD N
g/dL NN N
) ) N
of IN N
anemia NN N
( ( N
73 CD N
% NN N
vs. FW N
50 CD N
% NN N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
. . N

Patients NNS N
treated VBD N
with IN N
ferric JJ i
carboxymaltose NN i
compared VBN N
to TO N
those DT N
prescribed VBN N
ferrous JJ i
sulfate NN i
reported VBD N
greater JJR N
gains NNS N
in IN N
vitality NN o
and CC o
physical JJ o
function NN o
and CC o
experienced JJ o
greater JJR o
improvement NN o
in IN o
symptoms NNS o
of IN o
fatigue NN o
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

There EX N
were VBD N
no DT N
serious JJ o
adverse JJ o
drug NN o
events NNS o
. . o

CONCLUSIONS NNP N
In IN N
patients NNS p
with IN p
iron NN p
deficiency NN p
anemia NN p
due JJ p
to TO p
heavy JJ p
uterine JJ p
bleeding NN p
, , N
rapid JJ N
IV NNP N
administration NN N
of IN N
large JJ N
doses NNS N
of IN N
a DT N
new JJ i
iron NN i
agent NN i
, , i
ferric JJ i
carboxymaltose NN i
, , N
is VBZ N
more RBR N
effective JJ N
than IN N
oral JJ i
iron NN i
therapy NN i
in IN N
correcting VBG o
anemia NN o
, , o
replenishing VBG o
iron NN o
stores NNS o
, , o
and CC o
improving VBG o
quality NN o
of IN o
life NN o
. . o

-DOCSTART- -6146112- O O

Comparison NNP N
between IN N
the DT N
central JJ N
effects NNS N
of IN N
camazepam NN i
and CC i
temazepam NN i
. . i

Computerized JJ N
analysis NN N
of IN N
sleep JJ N
recordings NNS N
. . N

The DT N
effects NNS N
of IN N
acute JJ N
administration NN N
per IN N
os NN N
of IN N
30 CD N
mg NNS N
camazepam NN i
and CC N
the DT N
same JJ N
dose NN N
of IN N
temazepam NN i
, , N
were VBD N
compared VBN N
with IN N
placebo NN i
in IN N
8 CD p
young JJ p
male NN p
volunteers NNS p
, , p
fully RB p
adapted VBN p
to TO p
the DT p
laboratory NN p
environment NN p
by IN p
6 CD p
nights NNS p
of IN p
adaptation NN p
. . p

The DT N
study NN N
was VBD N
double-blind JJ N
, , N
in IN N
a DT N
random NN N
order NN N
, , N
10 CD N
days NNS N
separating VBG N
each DT N
session NN N
. . N

Spectral JJ N
analysis NN N
was VBD N
performed VBN N
on IN N
the DT N
all-night JJ N
records NNS N
( ( N
1-min JJ N
epochs NN N
) ) N
, , N
and CC N
the DT N
relative JJ N
power NN N
of IN N
six CD N
frequency NN N
bands NNS N
calculated VBN N
. . N

Concerning VBG N
sleep JJ o
parameters NNS o
, , N
temazepam NN i
induces NNS N
a DT N
statistically RB N
significant JJ N
reduction NN N
of IN N
: : N
phase NN N
shifts NNS N
; : N
number NN N
of IN N
awakenings NNS N
; : N
percent JJ N
duration NN N
of IN N
sleep JJ N
stages NNS N
I PRP N
and CC N
IV NNP N
. . N

A NNP N
significant JJ N
increase NN N
of IN N
the DT N
percent NN o
duration NN o
of IN o
stage NN o
II NNP o
and CC o
sleep JJ o
efficiency NN o
was VBD N
also RB N
found VBN N
. . N

Camazepam NNP o
shows VBZ o
modification NN o
, , o
with IN o
the DT o
same JJ o
trend NN o
, , o
but CC o
not RB o
reaching VBG o
statistical JJ o
significance NN o
. . N

Concerning VBG N
spectral JJ N
analysis NN N
, , N
temazepam NN o
induces NNS N
a DT N
light JJ N
increase NN N
of IN N
the DT N
relative JJ N
power NN N
of IN N
the DT N
slowest JJS N
frequencies NNS N
, , N
paralleled VBN N
by IN N
an DT N
increase NN N
of IN N
the DT N
fast JJ N
bands NNS N
, , N
while IN N
major JJ N
effects NNS N
are VBP N
found VBN N
on IN N
the DT N
characteristic JJ N
periodicity NN N
of IN N
delta NN N
activities NNS N
, , N
which WDT N
appear VBP N
disrupted VBN N
by IN N
the DT N
drug NN N
. . N

These DT N
effects NNS N
are VBP N
not RB N
evident JJ N
with IN N
camazepam NN i
, , N
which WDT N
does VBZ N
not RB N
seem VB N
to TO N
distort VB N
the DT N
normal JJ N
sleep JJ N
pattern NN N
. . N

-DOCSTART- -15541087- O O

Pimecrolimus NNP i
cream VBZ i
1 CD N
% NN N
vs. FW N
betamethasone CD i
17-valerate JJ i
0.1 CD N
% NN N
cream NN N
in IN N
the DT N
treatment NN N
of IN N
seborrhoeic JJ N
dermatitis NN N
. . N

A DT N
randomized JJ N
open-label JJ N
clinical JJ N
trial NN N
. . N

BACKGROUND NNP N
Seborrhoeic NNP N
dermatitis NN N
is VBZ N
a DT N
chronic JJ N
inflammatory NN N
disease NN N
with IN N
remissions NNS N
and CC N
exacerbations NNS N
, , N
characterized VBN N
by IN N
erythema NN N
, , N
scaling VBG N
and CC N
pruritus JJ N
primarily RB N
on IN N
the DT N
face NN N
, , N
scalp NN N
and CC N
chest NN N
. . N

Corticosteroids NNP N
and CC N
antifungals NNS N
are VBP N
the DT N
mainstay NN N
of IN N
therapy NN N
. . N

However RB N
, , N
chronic JJ N
use NN N
of IN N
corticosteroids NNS N
is VBZ N
associated VBN N
with IN N
side-effects NNS N
such JJ N
as IN N
skin JJ N
atrophy NN N
and CC N
telangiectasia NN N
. . N

Pimecrolimus NNP i
, , N
an DT N
inhibitor NN N
of IN N
calcineurin NN N
, , N
has VBZ N
been VBN N
used VBN N
successfully RB N
in IN N
one CD N
patient NN N
with IN N
seborrhoeic JJ N
dermatitis NN N
. . N

OBJECTIVES CC N
The DT N
objective NN N
of IN N
this DT N
randomized VBN N
open-label JJ N
clinical JJ N
trial NN N
was VBD N
to TO N
compare VB N
the DT N
efficacy NN o
and CC o
tolerability NN o
of IN N
pimecrolimus NN i
in IN N
comparison NN N
with IN N
a DT N
potent NN N
corticosteroid NN i
( ( i
betamethasone CD i
17-valerate NN i
) ) i
in IN N
the DT N
treatment NN N
of IN N
seborrhoeic JJ N
dermatitis NN N
. . N

METHODS NNP N
Twenty NNP p
patients NNS p
with IN p
seborrhoeic JJ p
dermatitis NN p
were VBD p
included VBN p
in IN p
this DT p
study NN p
, , p
11 CD p
patients NNS p
in IN p
the DT p
pimecrolimus JJ i
1 CD i
% NN i
cream NN i
group NN i
and CC p
nine CD p
patients NNS p
in IN p
the DT p
betamethasone NN i
17-valerate JJ i
0.1 CD i
% NN i
cream NN i
group NN i
. . i

Patients NNS N
were VBD N
instructed VBN N
to TO N
use VB N
a DT N
thin JJ N
layer NN N
of IN N
the DT N
study NN N
products NNS N
twice RB N
daily RB N
at IN N
the DT N
lesional JJ N
area NN N
and CC N
to TO N
discontinue VB N
treatment NN N
as RB N
soon RB N
as IN N
symptoms NNS N
were VBD N
absent JJ N
. . N

Clinical JJ N
measures NNS N
assessed VBN N
were VBD N
erythema RB o
, , o
scaling VBG o
and CC o
pruritus NN o
which WDT N
were VBD N
evaluated VBN N
using VBG N
a DT N
four-point JJ N
scale NN N
( ( N
0-3 JJ N
) ) N
. . N

RESULTS NNP N
Both NNP N
pimecrolimus FW i
and CC N
betamethasone NN i
were VBD N
highly RB N
effective JJ o
in IN N
the DT N
treatment NN N
of IN N
seborrhoeic JJ N
dermatitis NN N
. . N

Betamethasone NNP i
reduced VBD N
all DT N
three CD N
parameters NNS N
, , N
erythema NN o
, , o
scaling VBG o
and CC o
pruritus NN o
, , N
faster JJR N
than IN N
pimecrolimus NN i
, , N
but CC N
the DT N
differences NNS N
in IN N
reduction NN N
were VBD N
not RB N
statistically RB N
significant JJ N
. . N

Relapses NNS o
were VBD N
observed VBN N
more RBR N
frequently RB N
and CC N
were VBD N
more JJR N
severe JJ N
with IN N
betamethasone NN i
than IN N
with IN N
pimecrolimus NN i
. . i

Moreover RB N
, , N
pruritus NN o
was VBD N
not RB N
observed VBN N
after IN N
discontinuation NN N
of IN N
treatment NN N
from IN N
day NN N
15 CD N
and CC N
beyond IN N
in IN N
the DT N
pimecrolimus NN i
group NN N
, , N
whereas IN N
it PRP N
was VBD N
reported VBN N
in IN N
most JJS N
patients NNS N
of IN N
the DT N
betamethasone NN i
group NN N
. . N

This DT N
difference NN N
was VBD N
statistically RB N
significant JJ N
. . N

CONCLUSIONS VB N
It PRP N
appears VBZ N
that IN N
pimecrolimus NN i
, , N
a DT N
nonsteroidal JJ N
topical JJ N
treatment NN N
, , N
may MD N
be VB N
an DT N
excellent JJ N
alternative JJ N
therapeutic JJ N
modality NN N
for IN N
treating VBG N
seborrhoeic JJ N
dermatitis NN N
. . N

-DOCSTART- -2881132- O O

Antibiotic JJ N
elimination NN N
of IN N
group-B JJ N
streptococci NN N
in IN N
urine NN N
in IN N
prevention NN N
of IN N
preterm JJ o
labour NN o
. . o

The DT N
presence NN N
of IN N
group-B JJ N
streptococci NN N
in IN N
the DT N
urine NN N
of IN N
pregnant JJ p
women NNS p
seems VBZ N
to TO N
be VB N
associated VBN N
with IN N
preterm JJ N
labour NN N
. . N

Urine JJ N
samples NNS N
from IN N
4122 CD p
women NNS p
at IN p
27-31 JJ p
weeks NNS p
' POS p
gestation NN p
were VBD N
examined VBN N
for IN N
bacteria NNS N
. . N

Group-B JJ N
streptococci NN N
were VBD N
found VBN N
in IN N
the DT N
urine NN N
of IN N
69 CD p
women NNS p
. . p

In IN N
a DT N
double-blind NN N
, , N
controlled VBD N
study NN N
these DT N
patients NNS N
were VBD N
given VBN N
either CC N
penicillin NN i
( ( N
10 CD N
( ( N
6 CD N
) ) N
IU NNP N
three CD N
times NNS N
daily RB N
for IN N
6 CD N
days NNS N
; : N
37 CD N
patients NNS N
) ) N
or CC N
placebo NN i
( ( N
32 CD N
patients NNS N
) ) N
. . N

The DT N
rates NNS N
of IN N
primary JJ o
rupture NN o
of IN o
the DT o
membranes NNS o
( ( N
11 CD N
% NN N
v JJ N
53 CD N
% NN N
; : N
p CC N
less JJR N
than IN N
0.001 CD N
) ) N
and CC N
preterm VB o
labour NN o
( ( N
5.4 CD N
% NN N
v JJ N
38 CD N
% NN N
; : N
p CC N
less JJR N
than IN N
0.002 CD N
) ) N
were VBD N
significantly RB N
lower JJR N
in IN N
the DT N
penicillin NN i
group NN N
than IN N
in IN N
the DT N
placebo NN i
group NN N
. . N

These DT N
results NNS N
suggest VBP N
that IN N
treatment NN N
and CC N
follow-up NN N
to TO N
prevent VB N
recolonisation NN N
in IN N
pregnant JJ p
women NNS p
with IN p
group-B JJ p
streptococci NN p
in IN p
the DT p
urine NN p
may MD N
reduce VB N
the DT N
frequency NN o
of IN o
preterm JJ o
labour NN o
in IN N
these DT N
patients NNS N
. . N

-DOCSTART- -21424566- O O

A DT N
simplified JJ N
approach NN N
to TO N
virtual JJ i
colonoscopy NN i
using VBG i
different JJ i
intestinal JJ i
preparations NNS i
: : i
preliminary JJ N
experience NN N
with IN N
regard NN N
to TO N
quality NN N
, , N
accuracy NN N
and CC N
patient JJ N
acceptability NN N
. . N

PURPOSE VB N
The DT N
authors NNS N
assessed VBD N
the DT N
quality NN N
, , N
diagnostic JJ N
accuracy NN N
and CC N
patient JJ N
acceptability NN N
of IN N
computed VBN i
tomography NN i
( ( i
CT NNP i
) ) i
colonography NN i
performed VBD N
using VBG N
a DT N
simplified JJ N
bowel NN N
preparation NN N
and CC N
software NN N
for IN N
post-processing JJ N
digital JJ N
elimination NN N
of IN N
stool NN N
and CC N
fluid NN N
data NNS N
from IN N
images NNS N
compared VBN N
with IN N
the DT N
examination NN N
obtained VBN N
with IN N
conventional JJ N
preparation NN N
. . N

MATERIALS NNP N
AND CC N
METHODS NNP N
Two CD p
groups NNS p
of IN p
40 CD p
consecutive JJ p
asymptomatic JJ p
patients NNS p
aged VBN p
between IN p
48 CD p
and CC p
72 CD p
years NNS p
underwent JJ p
CT NNP i
colonography NN i
. . i

In IN N
group NN N
A NNP N
, , N
the DT N
CT NNP i
scan NN i
was VBD i
performed VBN i
with IN i
conventional JJ i
bowel NN i
preparation NN i
( ( N
a DT N
full JJ N
cathartic NN N
dose NN N
and CC N
oral JJ N
contrast NN N
medium NN N
to TO N
tag VB N
any DT N
residue NN N
in IN N
the DT N
3 CD N
days NNS N
preceding VBG N
the DT N
study NN N
) ) N
. . N

In IN N
the DT N
second JJ N
group NN N
, , N
CT NNP i
colonography NN i
was VBD i
performed VBN i
after IN i
a DT i
reduced JJ i
bowel NN i
preparation NN i
, , N
with IN N
the DT N
oral JJ N
contrast NN N
medium NN N
for IN N
residue JJ N
tagging VBG N
being VBG N
administered VBN N
only RB N
on IN N
the DT N
day NN N
of IN N
the DT N
investigation NN N
. . N

Examination NNP o
quality NN o
, , o
diagnostic JJ o
performance NN o
and CC o
patient JJ o
acceptability NN o
( ( o
rated VBN o
with IN o
a DT o
self-completed JJ o
questionnaire NN o
) ) o
in IN N
the DT N
two CD N
groups NNS N
of IN N
patients NNS N
were VBD N
compared VBN N
by IN N
using VBG N
the DT N
McNemar NNP N
test NN N
. . N

RESULTS NNP N
No NNP N
significant JJ N
difference NN N
was VBD N
obtained VBN N
with IN N
regard NN N
to TO N
examination NN o
quality NN o
( ( N
180 CD N
vs. FW N
165 CD N
segments NNS N
free JJ N
from IN N
stools NNS N
and CC N
fluid NN N
, , N
p NN N
> NNP N
0.05 CD N
) ) N
and CC N
overall JJ o
diagnostic JJ o
accuracy NN o
( ( N
16/17 CD N
colonic JJ N
polyps NNS N
detected VBN N
in IN N
group NN N
A NNP N
and CC N
12/13 CD N
in IN N
group NN N
B NNP N
, , N
p NN N
> NNP N
0.05 CD N
) ) N
. . N

The DT N
questionnaires NNS N
revealed VBD N
a DT N
greater JJR N
acceptability NN N
of IN N
the DT N
reduced JJ i
bowel NN o
preparation NN o
compared VBN N
with IN N
the DT N
standard JJ i
procedure NN i
( ( N
p=0.01 NN N
) ) N
. . N

CONCLUSIONS NNP N
In IN N
asymptomatic JJ N
patients NNS N
, , N
the DT N
use NN N
of IN N
software NN N
for IN N
post-processing JJ N
digital JJ N
elimination NN N
of IN N
residue NN N
from IN N
images NNS N
in IN N
conjunction NN N
with IN N
reduced JJ i
bowel NN i
preparation NN i
does VBZ N
not RB N
reduce VB N
examination NN o
quality NN o
or CC N
diagnostic JJ o
performance NN o
when WRB N
compared VBN N
with IN N
the DT N
conventional JJ i
CT NNP i
colonography NN i
technique NN i
and CC N
is VBZ N
more RBR N
acceptable JJ o
to TO N
and CC N
better RB N
tolerated VBN o
by IN N
the DT N
patient NN N
. . N

-DOCSTART- -21822762- O O

Predictors NNS N
and CC N
moderators NNS N
of IN N
parent NN N
training NN N
efficacy NN N
in IN N
a DT N
sample NN p
of IN p
children NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
and CC p
serious JJ p
behavioral JJ p
problems NNS p
. . p

The DT N
Research NNP N
Units NNP N
on IN N
Pediatric NNP N
Psychopharmacology NNP N
-- : N
Autism NNP N
Network NNP N
reported VBD N
additional JJ N
benefit NN N
when WRB N
adding VBG i
parent NN i
training NN i
( ( i
PT NNP i
) ) i
to TO i
antipsychotic JJ i
medication NN i
in IN N
children NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
and CC p
serious JJ p
behavior NN p
problems NNS p
. . p

The DT N
intent-to-treat JJ N
analyses NNS N
were VBD N
rerun VBN N
with IN N
putative JJ N
predictors NNS N
and CC N
moderators NNS N
. . N

The DT N
Home NNP o
Situations NNP o
Questionnaire NNP o
( ( o
HSQ NNP o
) ) o
and CC o
the DT o
Hyperactivity/Noncompliance NNP o
subscale NN o
of IN o
the DT o
Aberrant NNP o
Behavior NNP o
Checklist NNP o
were VBD i
used VBN i
as IN i
outcome JJ i
measures NNS i
. . i

Candidate NNP N
predictors NNS N
and CC N
moderators NNS N
included VBD N
21 CD N
demographics NNS N
and CC N
baseline JJ N
measures NNS N
of IN N
behavior NN N
. . N

Higher JJR N
baseline NN N
HSQ NNP o
scores NNS o
predicted VBD N
greater JJR N
improvement NN N
on IN N
the DT N
HSQ NNP N
regardless NN N
of IN N
treatment NN N
assignment NN N
, , N
but CC N
no DT N
other JJ N
predictors NNS N
of IN N
outcome NN N
were VBD N
observed VBN N
. . N

None NN N
of IN N
the DT N
variables NNS N
measured VBN N
in IN N
this DT N
study NN N
moderated VBD N
response NN N
to TO N
PT NNP N
. . N

Antipsychotic JJ i
medication NN i
plus CC i
PT NNP i
appears VBZ N
to TO N
be VB N
equally RB N
effective JJ N
for IN N
children NNS p
with IN p
a DT p
wide JJ p
range NN p
of IN p
demographic JJ p
and CC p
behavioral JJ p
characteristics NNS p
. . p

-DOCSTART- -18054932- O O

Effectiveness NN N
of IN N
cetrorelix NN i
for IN N
the DT N
prevention NN N
of IN N
premature NN o
luteinizing VBG o
hormone NN o
surge NN o
during IN N
controlled JJ N
ovarian JJ N
stimulation NN N
using VBG N
letrozole JJ N
and CC N
gonadotropins NNS N
: : N
a DT N
randomized JJ N
trial NN N
. . N

OBJECTIVE UH N
To TO N
evaluate VB N
the DT N
effectiveness NN N
of IN N
a DT N
GnRH NNP N
antagonist NN N
in IN N
preventing VBG N
premature NN o
LH NNP o
surge NN o
under IN N
a DT N
letrozole NN N
and CC N
gonadotropin NN N
protocol NN N
. . N

DESIGN NNP N
Prospective NNP N
, , N
randomized VBD N
clinical JJ N
trial NN N
. . N

SETTING VB N
A DT N
teaching JJ N
hospital NN N
and CC N
tertiary JJ N
medical JJ N
center NN N
. . N

PATIENT NNP N
( ( N
S NNP N
) ) N
Sixty-one CD p
patients NNS p
were VBD N
randomly RB N
assigned VBN N
into IN N
two CD i
letrozole JJ i
and CC i
gonadotropin-treated JJ i
groups NNS N
. . N

These DT N
were VBD N
distinguished VBN N
by IN N
the DT N
absence NN i
( ( i
group NN i
I PRP i
) ) i
or CC i
presence NN i
( ( i
group NN i
II NNP i
) ) i
of IN i
supplementation NN i
with IN i
0.25 CD i
mg NNS i
of IN i
cetrorelix NN i
. . i

INTERVENTION NNP N
( ( N
S NNP N
) ) N
Controlled VBD N
ovarian JJ N
stimulation NN N
with IN N
letrozole JJ i
and CC i
gonadotropins NNS i
, , i
cetrorelix NN i
and CC N
intrauterine JJ N
insemination NN N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURE NNP N
( ( N
S NNP N
) ) N
Rate NNP o
of IN o
premature NN o
LH NNP o
surge NN o
. . o

RESULT NNP N
( ( N
S NNP N
) ) N
Compared NNP N
with IN N
group NN N
I PRP N
, , N
the DT N
rate NN o
of IN o
premature NN o
LH NNP o
surge NN o
was VBD N
statistically RB N
significantly RB N
lower JJR N
for IN N
group NN N
II NNP N
( ( N
43.4 CD N
% NN N
[ CC N
13/30 CD N
] NN N
vs. FW N
19.4 CD N
% NN N
[ CC N
6/31 CD N
] NN N
) ) N
, , N
but CC N
the DT N
amount NN o
of IN o
gonadotropins NNS o
used VBN N
was VBD N
statistically RB N
significantly RB N
higher JJR N
( ( N
817.5 CD N
+/- JJ N
28.5 CD N
vs. FW N
907.5 CD N
+/- JJ N
27.3 CD N
IU NNP N
) ) N
. . N

Patients NNS N
with IN N
premature JJ o
LH NNP o
surge NN o
had VBD N
a DT N
statistically RB N
significantly RB N
lower JJR N
pregnancy NN o
rate NN o
( ( N
21.4 CD N
% NN N
[ CC N
9/42 CD N
] NN N
vs. FW N
0 CD N
[ $ N
0/18 CD N
] NNP N
) ) N
relative VBP N
to TO N
their PRP$ N
unaffected JJ N
counterparts NNS N
. . N

CONCLUSION NNP N
( ( N
S NNP N
) ) N
A NNP N
flexible JJ N
protocol NN N
of IN N
0.25 CD N
mg NN N
of IN N
cetrorelix NN i
for IN N
IUI NNP N
cycles NNS N
appears VBZ N
to TO N
suppress VB N
the DT N
rate NN N
of IN N
premature NN o
LH NNP o
surge NN o
during IN N
ovarian JJ N
stimulation NN N
with IN N
letrozole JJ N
and CC N
gonadotropins NNS N
. . N

However RB N
, , N
the DT N
incidence NN N
of IN N
premature NN o
LH NNP o
surge NN o
remains VBZ N
too RB N
high JJ N
, , N
and CC N
modification NN N
will MD N
be VB N
necessary JJ N
before IN N
the DT N
application NN N
of IN N
cetrorelix NN N
to TO N
IVF NNP N
treatment NN N
. . N

-DOCSTART- -21809679- O O

[ NN p
Use NNP p
of IN p
Tachocomb NNP i
for IN p
prevention NN p
of IN p
postoperative JJ p
lymphatic JJ o
leaks NNS o
in IN p
the DT p
abdomen NNS p
] VBP p
. . N

-DOCSTART- -19109542- O O

Modified VBN i
constraint-induced JJ i
therapy NN i
combined VBN N
with IN N
mental JJ i
practice NN i
: : i
thinking NN N
through IN N
better JJR N
motor NN N
outcomes NNS N
. . N

BACKGROUND NNP N
AND CC N
PURPOSE NNP N
Modified NNP i
constraint-induced JJ i
therapy NN i
( ( i
mCIT NN i
) ) i
is VBZ N
an DT N
outpatient JJ N
therapy NN N
encouraging VBG N
repetitive JJ N
, , N
task-specific JJ N
practice NN N
with IN N
the DT N
affected JJ N
arm NN N
. . N

mCIT NN i
has VBZ N
shown VBN N
efficacy NN o
in IN N
all DT N
stages NNS N
poststroke VBP N
. . N

Given VBN N
its PRP$ N
efficacy NN N
when WRB N
combined VBN N
with IN N
other JJ N
therapy NN N
regimens NNS N
, , N
the DT N
current JJ N
study NN N
examined VBD N
the DT N
efficacy NN o
of IN N
mental JJ i
practice NN i
when WRB N
combined VBN N
with IN N
mCIT JJ i
versus NN N
mCIT NN i
only RB i
using VBG N
randomized VBN N
, , N
controlled VBN N
methods NNS N
. . N

METHOD NNP N
Ten CD p
patients NNS p
with IN p
chronic JJ p
stroke NN p
( ( p
7 CD p
males NNS p
; : p
mean JJ p
age NN p
, , p
61.4+/-3.02 JJ p
years NNS p
; : p
age NN p
range NN p
, , p
48 CD p
to TO p
79 CD p
years NNS p
; : p
mean JJ p
time NN p
since IN p
stroke NN p
, , p
28.5 CD p
months NNS p
; : p
range NN p
, , p
13 CD p
to TO p
42 CD p
months NNS p
) ) p
exhibiting VBG p
stable JJ p
, , p
affected JJ p
arm NN p
motor NN p
deficits NNS p
were VBD N
administered VBN N
mCIT NN i
, , N
consisting VBG N
of IN N
: : N
( ( N
1 CD N
) ) N
structured VBD N
therapy NN N
emphasizing VBG N
affected JJ N
arm NN N
use NN N
in IN N
functional JJ N
activities NNS N
3 CD N
days/week NN N
for IN N
10 CD N
weeks NNS N
; : N
and CC N
( ( N
2 CD N
) ) N
less RBR N
affected JJ N
arm NN N
restraint NN N
5 CD N
days/week NN N
for IN N
5 CD N
hours NNS N
. . N

Both DT N
of IN N
these DT N
components NNS N
were VBD N
administered VBN N
during IN N
a DT N
10-week JJ N
period NN N
. . N

Subjects NNS N
randomly RB N
assigned VBN N
to TO N
the DT N
mCIT+mental JJ i
practice NN i
experimental JJ N
condition NN N
also RB N
received VBD N
30-minute JJ N
mental JJ N
practice NN N
sessions NNS N
provided VBD N
directly RB N
after IN N
therapy NN N
sessions NNS N
. . N

These DT N
mental JJ i
practice NN i
sessions NNS N
required VBN N
daily RB N
cognitive JJ N
rehearsal NN N
of IN N
the DT N
activities NNS N
of IN N
daily JJ N
living NN N
practiced VBD N
during IN N
mCIT JJ i
clinical JJ N
sessions NNS N
. . N

RESULTS NNP N
No NNP N
pre-existing JJ N
differences NNS N
were VBD N
found VBN N
between IN N
groups NNS N
on IN N
any DT N
demographic JJ N
variable NN N
or CC N
movement NN N
scale NN N
. . N

All DT N
subjects NNS N
exhibited VBN N
marked JJ N
reductions NNS N
in IN N
affected JJ o
arm NN o
impairment NN o
and CC o
functional JJ o
limitation NN o
. . o

However RB N
, , N
subjects NNS N
in IN N
the DT N
mCIT+mental JJ i
practice NN i
group NN N
exhibited VBD N
significantly RB N
larger JJR N
changes NNS N
on IN N
both DT N
movement NN o
measures NNS o
after IN N
intervention NN N
: : N
Action NNP N
Research NNP N
Arm NNP N
Test NNP N
, , N
+15.4-point JJ N
change NN N
versus IN N
+8.4-point JJ N
change NN N
for IN N
mCIT NN i
only RB i
subjects VBZ N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
; : N
Fugl-Meyer NNP N
, , N
+7.8-point JJ N
change NN N
versus IN N
+4.1-point JJ N
change NN N
for IN N
the DT N
mCIT NN i
only RB i
subjects VBZ N
( ( N
P=0.01 NNP N
) ) N
. . N

These DT N
changes NNS N
were VBD N
sustained VBN N
3 CD N
months NNS N
after IN N
intervention NN N
. . N

CONCLUSIONS NNP N
mCIT NN i
remains VBZ N
a DT N
promising JJ N
motor NN N
intervention NN N
. . N

However RB N
, , N
its PRP$ N
efficacy NN o
appears VBZ N
to TO N
be VB N
enhanced VBN N
by IN N
use NN N
of IN N
mental JJ i
practice NN i
provided VBD N
directly RB N
after IN N
mCIT JJ i
clinical JJ N
sessions NNS N
. . N

-DOCSTART- -1818543- O O

A DT N
randomised JJ N
double-blind JJ N
trial NN N
of IN N
cyclosporin NN i
and CC i
azathioprine NN i
in IN N
refractory NN p
rheumatoid NN p
arthritis NN p
. . p

Fifty-two JJ p
patients NNS p
with IN p
severe JJ p
rheumatoid NN p
arthritis NN p
( ( p
RA NNP p
) ) p
from IN p
four CD p
Australian JJ p
centres NNS p
were VBD N
randomised VBN N
to TO N
receive VB i
cyclosporin NN i
A NNP i
( ( i
CSA NNP i
) ) i
( ( i
n JJ i
= NNP i
25 CD i
) ) i
or CC i
azathioprine NN i
( ( i
AZA NNP i
) ) i
( ( i
n JJ i
= NNP i
27 CD i
) ) i
for IN i
six CD i
months NNS i
. . i

Initial JJ N
mean JJ N
doses NNS N
of IN N
CSA NNP i
and CC N
AZA NNP i
were VBD N
4.2 CD N
mg/kg NNS N
and CC N
1.7 CD N
mg/kg NN N
respectively RB N
. . N

The DT N
mean JJ N
doses NNS N
of IN N
CSA NNP i
and CC N
AZA NNP i
at IN N
six CD N
months NNS N
were VBD N
3.4 CD N
mg/kg NNS N
and CC N
1.9 CD N
mg/kg NN N
. . N

Assessments NNS N
of IN N
side-effects NNS N
and CC N
outcomes NNS N
of IN N
benefit NN N
were VBD N
made VBN N
monthly RB N
by IN N
independent JJ N
, , N
blinded VBD N
observers NNS N
. . N

Both DT N
treatment NN N
groups NNS N
exhibited VBD N
statistically RB N
significant JJ N
improvement NN N
in IN N
standard JJ N
outcome NN N
parameters NNS N
when WRB N
compared VBN N
with IN N
baseline NN N
values NNS N
. . N

However RB N
, , N
there EX N
were VBD N
no DT N
statistically RB N
significant JJ N
differences NNS N
in IN N
these DT N
parameters NNS N
between IN N
the DT N
two CD N
groups NNS N
. . N

There EX N
was VBD N
a DT N
mean JJ N
increase NN N
in IN N
serum JJ o
creatinine NN o
concentration NN o
associated VBN N
with IN N
CSA NNP N
; : N
no DT N
persons NNS N
were VBD N
withdrawn VBN N
from IN N
the DT N
study NN N
for IN N
this DT N
reason NN N
. . N

Seven NNP p
CSA NNP i
recipients NNS p
( ( o
three CD o
gastrointestinal NN o
symptoms NNS o
, , o
two CD o
neurological JJ o
symptoms NNS o
, , o
two CD o
other JJ o
) ) o
and CC p
12 CD p
AZA NNP i
recipients NNS p
( ( o
six CD o
gastrointestinal NN o
symptoms NNS o
, , o
four CD o
inefficacy NN o
, , o
two CD o
other JJ o
) ) o
withdrew VBD o
from IN p
treatment NN p
prematurely RB p
. . p

Seven NNP N
CSA NNP i
recipients NNS N
became VBD N
hypertensive JJ o
and CC N
four CD N
required VBN N
anti-hypertensive JJ o
therapy NN o
. . o

Adverse JJ N
events NNS N
not RB N
requiring VBG N
cessation NN N
of IN N
therapy NN N
were VBD N
more JJR N
commonly JJ N
seen VBN N
among IN N
CSA JJ i
patients NNS N
. . N

In IN N
this DT N
group NN N
of IN N
severely RB p
affected JJ p
patients NNS p
with IN p
RA NNP p
both DT N
cyclosporin NN i
and CC N
azathioprine NN i
were VBD N
effective JJ N
therapies NNS N
. . N

CSA NNP o
toxicities NNS o
were VBD N
predictable JJ N
and CC N
manageable JJ N
but CC N
required VBD N
close JJ N
monitoring NN N
. . N

-DOCSTART- -10889804- O O

The DT N
Finnish JJ p
Diabetes NNP p
Prevention NNP N
Study NNP N
. . N

The DT N
aim NN N
of IN N
the DT N
Finnish NNP p
Diabetes NNP p
Prevention NNP N
Study NNP N
is VBZ N
to TO N
assess VB N
the DT N
efficacy NN o
of IN N
an DT N
intensive JJ i
diet-exercise NN i
programme NN i
in IN N
preventing VBG N
or CC N
delaying VBG N
type JJ o
2 CD o
diabetes NNS o
in IN p
individuals NNS p
with IN p
impaired JJ p
glucose JJ p
tolerance NN p
( ( p
IGT NNP p
) ) p
and CC N
to TO N
evaluate VB N
the DT N
effect NN N
of IN N
the DT N
programme NN N
on IN N
the DT N
risk NN N
factors NNS N
of IN N
atherosclerotic JJ N
vascular NN N
diseases NNS N
and CC N
the DT N
incidence NN N
of IN N
cardiovascular JJ N
events NNS N
. . N

In IN N
this DT N
ongoing JJ N
study NN N
, , N
a DT p
total NN p
of IN p
523 CD p
overweight JJ p
subjects NNS p
with IN p
IGT NNP p
based VBN p
on IN p
two CD p
oral JJ p
glucose JJ p
tolerance NN p
tests NNS p
were VBD N
randomized VBN N
to TO N
either DT N
an DT N
intervention NN p
group NN p
or CC N
a DT N
control NN p
group NN p
. . p

The DT N
main JJ N
measure NN N
in IN N
the DT N
intervention NN N
group NN N
is VBZ N
individual JJ o
dietary JJ o
advice NN o
aimed VBN N
at IN N
reducing VBG i
weight NN i
and CC i
intake NN i
of IN i
saturated JJ i
fat NN i
and CC i
increasing VBG i
intake NN i
of IN i
dietary JJ i
fibre NN i
. . i

The DT N
intervention NN N
subjects NNS N
are VBP N
individually RB N
guided VBN N
to TO N
increase VB o
their PRP$ o
level NN o
of IN o
physical JJ o
activity NN o
. . o

The DT N
control NN i
group NN i
receives VBZ i
general JJ i
information NN i
about IN i
the DT i
benefits NNS i
of IN i
weight NN i
reduction NN i
, , i
physical JJ i
activity NN i
and CC i
healthy JJ i
diet NN i
in IN i
the DT i
prevention NN i
of IN i
diabetes NNS i
. . i

A DT N
pilot NN N
study NN N
began VBD N
in IN N
1993 CD N
, , N
and CC N
recruitment NN N
ended VBN N
in IN N
1998 CD N
. . N

By IN N
the DT N
end NN N
of IN N
April NNP N
1999 CD N
there EX N
were VBD N
65 CD N
new JJ N
cases NNS N
of IN N
diabetes NNS N
, , N
34 CD N
drop-outs NNS N
and CC N
one CD N
death NN o
. . o

The DT N
weight NN o
reduction NN o
was VBD N
greater JJR N
( ( N
-4.6 NNP N
kg NN N
) ) N
at IN N
1 CD N
year NN N
in IN N
the DT N
intervention NN N
group NN N
( ( N
n JJ N
= NNP N
152 CD N
) ) N
than IN N
in IN N
the DT N
control NN N
group NN N
( ( N
n JJ N
= NN N
143 CD N
, , N
-0.9 NNP N
kg NNP N
, , N
P NNP N
< NNP N
0.0001 CD N
) ) N
, , N
and CC N
this DT N
difference NN N
was VBD N
sustained VBN N
in IN N
the DT N
second JJ N
year NN N
of IN N
follow-up NN N
. . N

At IN N
1 CD N
year NN N
43.4 CD N
% NN N
and CC N
at IN N
2 CD N
years NNS N
41.8 CD N
% NN N
of IN N
the DT N
intervention NN N
subjects NNS N
had VBD N
achieved VBN N
a DT N
weight JJ o
reduction NN o
of IN N
at IN N
least JJS N
5 CD N
kg NNS N
, , N
while IN N
the DT N
corresponding JJ N
figures NNS N
for IN N
the DT N
control NN N
subjects VBZ N
were VBD N
14.0 CD N
and CC N
12.0 CD N
% NN N
( ( N
P NNP N
< VBZ N
0.001 CD N
between IN N
the DT N
groups NNS N
) ) N
. . N

At IN N
1 CD N
year NN N
the DT N
intervention NN N
group NN N
showed VBD N
significantly RB N
greater JJR o
reductions NNS o
in IN N
2 CD o
h NN o
glucose NN o
, , o
fasting VBG o
and CC o
2 CD o
h NN o
insulin NN o
, , o
systolic JJ o
and CC o
diastolic JJ o
blood NN o
pressure NN o
, , o
and CC o
serum NN o
triglycerides NNS o
. . o

Most JJS N
of IN N
the DT N
beneficial JJ N
changes NNS N
in IN N
cardiovascular JJ o
risk NN o
factors NNS o
were VBD N
sustained VBN N
for IN N
2 CD N
years NNS N
. . N

These DT N
interim JJ N
results NNS N
of IN N
the DT N
ongoing JJ N
Finnish JJ N
Diabetes NNP N
Prevention NNP N
Study NNP N
demonstrate VB N
the DT N
efficacy NN o
and CC o
feasibility NN o
of IN N
the DT N
lifestyle JJ N
intervention NN N
programme NN N
. . N

-DOCSTART- -8657237- O O

Comparison NNP N
of IN N
coronary JJ i
bypass NN i
surgery NN i
with IN N
angioplasty NN i
in IN N
patients NNS p
with IN p
multivessel JJ p
disease NN p
. . p

The DT N
Bypass NNP N
Angioplasty NNP N
Revascularization NNP N
Investigation NNP N
( ( N
BARI NNP N
) ) N
Investigators NNPS N
. . N

BACKGROUND NNP N
Coronary-artery JJ i
bypass NN i
grafting NN i
( ( i
CABG NNP i
) ) i
and CC N
percutaneous JJ i
transluminal JJ i
coronary NN i
angioplasty NN i
( ( i
PTCA NNP i
) ) i
are VBP N
alternative JJ N
methods NNS N
of IN N
revascularization NN N
in IN N
patients NNS p
with IN p
coronary JJ p
artery NN p
disease NN p
. . p

We PRP N
tested VBD N
the DT N
hypothesis NN N
that IN N
in IN N
selected JJ N
patients NNS p
with IN p
multivessel JJ p
disease NN p
suitable JJ p
for IN p
treatment NN p
with IN p
either DT p
procedure NN p
, , N
an DT N
initial JJ N
strategy NN N
of IN N
PTCA NNP N
does VBZ N
not RB N
result VB N
in IN N
a DT N
poorer JJR N
five-year JJ N
clinical JJ o
outcome NN o
than IN N
CABG NNP N
. . N

METHODS NNP N
Patients NNPS p
with IN p
multivessel JJ p
disease NN p
were VBD p
randomly RB p
assigned VBN p
to TO p
an DT p
initial JJ p
treatment NN p
strategy NN p
of IN p
CABG NNP p
( ( p
n JJ p
= NNP p
914 CD p
) ) p
or CC p
PTCA NNP p
( ( p
n JJ p
= NNP p
915 CD p
) ) p
and CC N
were VBD N
followed VBN N
for IN N
an DT N
average NN N
of IN N
5.4 CD N
years NNS N
. . N

Analysis NN N
of IN N
outcome JJ N
events NNS N
was VBD N
performed VBN N
according VBG N
to TO N
the DT N
intention NN N
to TO N
treat VB N
. . N

RESULTS VB N
The DT N
respective JJ N
in-hospital JJ N
event NN N
rates NNS N
for IN N
CABG NNP N
and CC N
PTCA NNP N
were VBD N
1.3 CD N
percent NN N
and CC N
1.1 CD N
percent NN N
for IN N
mortality NN o
, , N
4.6 CD N
percent NN N
and CC N
2.1 CD N
percent NN N
for IN N
Q-wave NNP o
myocardial JJ o
infarction NN o
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
, , N
and CC N
0.8 CD N
percent NN N
and CC N
0.2 CD N
percent NN N
for IN N
stroke NN o
. . o

The DT N
five-year JJ o
survival NN o
rate NN o
was VBD N
89.3 CD N
percent NN N
for IN N
those DT N
assigned VBN N
to TO N
CABG NNP N
and CC N
86.3 CD N
percent NN N
for IN N
those DT N
assigned VBN N
to TO N
PTCA NNP N
( ( N
P NNP N
= NNP N
0.19 CD N
; : N
95 CD N
percent NN N
confidence NN N
interval NN N
of IN N
the DT N
difference NN N
in IN N
survival NN N
, , N
-0.2 JJ N
percent NN N
to TO N
6.0 CD N
percent NN N
) ) N
. . N

The DT N
respective JJ o
five-year JJ o
survival NN o
rates NNS o
free VBP o
from IN o
Q-wave NNP o
myocardial JJ o
infarction NN o
were VBD N
80.4 CD N
percent NN N
and CC N
78.7 CD N
percent NN N
. . N

By IN N
five CD N
years NNS N
after IN N
study NN N
entry NN N
, , N
8 CD N
percent NN N
of IN N
the DT N
patients NNS N
assigned VBD N
to TO N
CABG NNP N
had VBD N
undergone JJ N
additional JJ N
revascularization NN o
procedures NNS o
, , N
as IN N
compared VBN N
with IN N
54 CD N
percent NN N
of IN N
those DT N
assigned VBN N
to TO N
PTCA NNP N
; : N
69 CD N
percent NN N
of IN N
those DT N
assigned VBN N
to TO N
PTCA NNP N
did VBD N
not RB N
subsequently RB N
undergo JJ N
CABG NNP N
. . N

Among IN p
diabetic JJ p
patients NNS p
who WP p
were VBD p
being VBG p
treated VBN p
with IN p
insulin NN p
or CC p
oral JJ p
hypoglycemic JJ p
agents NNS p
at IN p
base NN p
line NN p
, , N
a DT N
subgroup NN N
not RB N
specified VBN N
by IN N
the DT N
protocol NN N
, , N
five-year JJ o
survival NN o
was VBD N
80.6 CD N
percent NN N
for IN N
the DT N
CABG NNP N
group NN N
as IN N
compared VBN N
with IN N
65.5 CD N
percent NN N
for IN N
the DT N
PTCA NNP N
group NN N
( ( N
P NNP N
= NNP N
0.003 CD N
) ) N
. . N

CONCLUSIONS NNP N
As IN N
compared VBN N
with IN N
CABG NNP i
, , N
an DT N
initial JJ N
strategy NN N
of IN N
PTCA NNP i
did VBD N
not RB N
significantly RB N
compromise VB N
five-year JJ o
survival NN o
in IN N
patients NNS p
with IN p
multivessel JJ p
disease NN p
, , N
although IN N
subsequent JJ o
revascularization NN o
was VBD N
required VBN N
more RBR N
often RB N
with IN N
this DT N
strategy NN N
. . N

For IN N
treated JJ p
diabetics NNS p
, , N
five-year JJ o
survival NN o
was VBD N
significantly RB N
better JJR N
after IN N
CABG NNP i
than IN N
after IN N
PTCA NNP i
. . i

-DOCSTART- -7595712- O O

Cisplatin NNP i
plus CC i
etoposide JJ i
with IN i
and CC i
without IN i
ifosfamide NN i
in IN N
extensive JJ p
small-cell NN p
lung NN p
cancer NN p
: : p
a DT N
Hoosier NNP N
Oncology NNP N
Group NNP N
study NN N
. . N

PURPOSE NNP N
To TO N
determine VB N
whether IN N
the DT N
addition NN N
of IN N
ifosfamide NN i
to TO i
cisplatin VB i
plus JJ i
etoposide JJ i
improves VBZ N
the DT N
response NN o
rate NN o
, , o
time NN o
to TO o
disease VB o
progression NN o
, , o
or CC o
overall JJ o
survival NN o
in IN N
previously RB p
untreated JJ p
patients NNS p
with IN p
extensive-stage JJ p
small-cell JJ p
carcinoma NN p
of IN p
the DT p
lung NN p
( ( p
SCLC NNP p
) ) p
. . p

PATIENTS NNP N
AND CC N
METHODS NNP N
Patients NNPS p
with IN p
extensive JJ p
SCLC NNP p
with IN p
a DT p
Karnofsky NNP p
performance NN p
score NN p
( ( p
KPS NNP p
) ) p
> VBD p
or CC p
= $ p
50 CD p
and CC p
adequate JJ p
renal JJ p
function NN p
and CC p
bone NN p
marrow NN p
reserve NN p
were VBD p
eligible JJ p
. . p

Patients NNS p
with IN p
CNS NNP p
metastases NNS p
were VBD p
eligible JJ p
and CC N
received JJ N
concurrent JJ N
whole-brain JJ N
radiotherapy NN N
. . N

Patients NNS N
were VBD N
randomized VBN N
to TO N
receive VB N
cisplatin NN i
( ( N
20 CD N
mg/m2 NN N
) ) N
plus CC N
etoposide JJ i
( ( N
100 CD N
mg/m2 NN N
) ) N
( ( N
VP NNP N
) ) N
both DT N
given VBN N
intravenously RB N
( ( N
i.v JJ N
. . N

) ) N
on IN N
days NNS N
1 CD N
to TO N
4 CD N
or CC N
cisplatin NN i
( ( N
20 CD N
mg/m2 NN N
) ) N
, , N
ifosfamide RB i
( ( N
1.2 CD N
g/m2 NN N
) ) N
, , N
and CC N
etoposide RB i
( ( N
75 CD N
mg/m2 NN N
) ) N
( ( N
VIP NNP N
) ) N
all DT N
given VBN N
i.v NNS N
. . N

on IN N
days NNS N
1 CD N
to TO N
4 CD N
. . N

Cycles NNS N
were VBD N
repeated VBN N
every DT N
3 CD N
weeks NNS N
for IN N
four CD N
cycles NNS N
. . N

RESULTS NNP N
From NNP p
May NNP p
1989 CD p
through IN p
March NNP p
1993 CD p
, , p
171 CD p
patients NNS p
were VBD p
randomized VBN p
( ( p
84 CD p
to TO p
VP NNP p
and CC p
87 CD p
to TO p
VIP NNP p
) ) p
. . p

The DT N
median JJ N
follow-up JJ N
duration NN N
is VBZ N
26 CD N
months NNS N
. . N

All DT p
patients NNS p
were VBD p
assessable JJ p
for IN p
survival NN o
; : o
163 CD p
were VBD p
fully RB p
assessable JJ o
for IN o
response NN o
and CC p
162 CD p
for IN p
toxicity NN o
. . o

Myelosuppression NN o
was VBD N
greater JJR o
with IN N
VIP NNP N
. . N

Objective JJ o
responses NNS o
were VBD N
observed VBN N
in IN N
55 CD N
of IN N
82 CD N
( ( N
67 CD N
% NN N
) ) N
and CC N
59 CD N
of IN N
81 CD N
( ( N
73 CD N
% NN N
) ) N
assessable JJ N
patients NNS N
treated VBN N
with IN N
VP NNP N
and CC N
VIP NNP N
, , N
respectively RB N
( ( N
difference NN N
not RB N
significant JJ N
) ) N
. . N

The DT N
difference NN N
in IN N
the DT N
median JJ o
time NN o
to TO o
progression NN o
was VBD N
statistically RB N
different JJ N
( ( N
P NNP N
= NNP N
.039 NNP N
) ) N
. . N

The DT N
median JJ o
survival NN o
times NNS o
on IN N
VP NNP N
and CC N
VIP NNP N
were VBD N
7.3 CD N
months NNS N
and CC N
9.0 CD N
months NNS N
, , N
respectively RB N
( ( N
P NNP N
= NNP N
.045 NNP N
for IN N
survival JJ N
curves NNS N
by IN N
stratified JJ N
log-rank JJ N
test NN N
) ) N
with IN N
2-year JJ o
survival JJ o
rates NNS o
of IN N
5 CD N
% NN N
versus IN N
13 CD N
% NN N
, , N
respectively RB N
. . N

CONCLUSION NNP N
VIP NNP N
combination NN N
chemotherapy NN N
is VBZ N
associated VBN N
with IN N
an DT N
improved JJ N
time NN o
to TO o
progression NN o
and CC o
overall JJ o
survival NN o
over IN N
VP NNP N
therapy NN N
in IN N
patients NNS p
with IN p
extensive JJ p
SCLC NNP p
. . p

-DOCSTART- -17198705- O O

Principal JJ N
findings NNS N
from IN N
a DT N
multicenter NN p
trial NN p
investigating VBG N
the DT N
safety NN N
of IN N
follicular-fluid JJ i
meiosis-activating JJ i
sterol NN i
for IN N
in IN N
vitro JJ N
maturation NN N
of IN N
human JJ N
cumulus-enclosed JJ N
oocytes NNS N
. . N

OBJECTIVE NNP N
To TO N
evaluate VB N
the DT N
safety NN N
of IN N
applying VBG N
follicular-fluid JJ i
meiosis-activating JJ i
sterol NN i
( ( i
FF-MAS NNP i
) ) i
in IN N
vitro NN N
to TO N
immature VB N
human JJ N
oocytes NNS N
. . N

DESIGN NNP N
Phase NNP N
I PRP N
bicenter VBP N
, , N
randomized VBN N
, , N
parallel-group JJ N
, , N
controlled VBN N
, , N
partially RB N
blinded VBN N
trial NN N
. . N

SETTING CC N
Third-level JJ p
referral JJ p
academic JJ p
centers NNS p
, , N
including VBG N
reproductive JJ N
biology NN N
and CC N
genetics NNS N
laboratories NNS N
. . N

PATIENTS NNP N
Endocrinologically NNP p
normal JJ p
women NNS p
with IN p
a DT p
medical JJ p
indication NN p
for IN p
IVF NNP p
or CC p
intracytoplasmic JJ p
sperm JJ p
injection NN p
, , p
or CC p
healthy JJ p
volunteers NNS p
. . p

INTERVENTION NNP N
( ( N
S NNP N
) ) N
Subjects NNPS N
were VBD N
randomized VBN N
at IN N
a DT N
ratio NN N
1 CD N
to TO N
6 CD N
into IN N
either DT i
conventional JJ i
GnRH-agonist JJ i
and CC i
recombinant JJ i
FSH NNP i
stimulation NN i
( ( i
IVO NNP i
) ) i
for IN i
oocyte NN i
retrieval NN i
, , i
or CC i
minimally RB i
stimulated VBN i
in IN i
vitro JJ i
maturation NN i
( ( i
IVM NNP i
) ) i
with IN i
the DT i
use NN i
of IN i
recombinant JJ i
FSH NNP i
. . i

Retrieved VBN N
immature NN N
oocyte NN N
cumulus NN N
complexes NNS N
were VBD N
cultured VBN N
for IN N
30 CD N
or CC N
36 CD N
hours NNS N
in IN N
one CD N
of IN N
six CD N
IVM NNP i
culture NN i
conditions NNS i
containing VBG i
FF-MAS NNP i
( ( N
range NN N
, , N
0.1-20 JJ N
microM NN N
) ) N
. . N

Polar JJ N
body-extruded JJ N
oocytes NNS N
from IN N
the DT N
IVO NNP N
and CC N
IVM NNP N
groups NNS N
were VBD N
processed VBN N
for IN N
chromosomal JJ N
analysis NN N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURE NNP N
( ( N
S NNP N
) ) N
The DT N
primary JJ N
endpoint NN N
was VBD N
the DT N
incidence NN o
of IN o
metaphase NN o
II NNP o
stage NN o
oocytes NNS o
with IN o
numeric JJ o
chromosomal JJ o
abnormalities NNS o
, , N
using VBG N
full JJ N
( ( N
spectral JJ N
karyotyping NN N
) ) N
or CC N
partial JJ N
( ( N
fluorescent JJ N
in IN N
situ JJ N
hybridization NN N
with IN N
seven CD N
probes NNS N
) ) N
karyotyping VBG N
or CC N
Giemsa NNP N
count NN N
. . N

A DT N
secondary JJ N
objective NN N
was VBD N
to TO N
document VB N
the DT N
frequency NN o
of IN o
metaphase NN o
II NNP o
oocytes VBZ o
after IN N
IVM NNP N
with IN N
FF-MAS NNP N
supplements NNS N
. . N

RESULT NNP N
( ( N
S NNP N
) ) N
Oocyte NNP N
cumulus NN N
complexes NNS N
obtained VBN N
from IN N
the DT N
IVO NNP N
( ( N
mean NN N
, , N
8.9 CD N
) ) N
and CC N
IVM NNP N
( ( N
mean NN N
, , N
6.2 CD N
) ) N
groups NNS N
had VBD N
equal JJ o
maturation NN o
rates NNS o
. . o

Compared VBN N
to TO N
IVO NNP N
, , N
exposure NN N
of IN N
germinal-vesicle NN N
oocytes NNS N
for IN N
a DT N
maturation NN N
period NN N
of IN N
30 CD N
hours NNS N
did VBD N
not RB N
increase VB N
aneuploidy NN o
. . o

An DT N
exposure JJ N
period NN N
of IN N
36 CD N
hours NNS N
doubled VBD N
the DT N
aneuploidy NN o
rate NN o
, , N
but CC N
this DT N
was VBD N
significant JJ N
only RB N
for IN N
the DT N
20-muM JJ N
dose NN N
of IN N
FF-MAS NNP i
. . i

CONCLUSION NNP N
Inclusion NNP N
of IN N
1-10 JJ N
microM JJ i
FF-MAS NNP i
in IN N
a DT N
30-hour JJ N
IVM NNP N
protocol NN N
is VBZ N
safe JJ N
. . N

-DOCSTART- -19779715- O O

Phase NNP N
III NNP N
, , N
randomised VBD N
, , N
multicentre JJ N
trial NN N
of IN N
maintenance NN N
immunotherapy NN i
with IN N
low-dose JJ N
interleukin-2 JJ i
and CC i
interferon-alpha JJ i
for IN N
metastatic JJ p
renal NN p
cell NN p
cancer NN p
. . p

This DT N
is VBZ N
the DT N
first JJ N
phase NN N
III NNP N
randomised VBD N
trial NN N
to TO N
evaluate VB N
maintenance NN N
immunotherapy NN N
in IN N
metastatic JJ p
renal NN p
cell NN p
cancer NN p
( ( N
mRCC NN N
) ) N
. . N

Patients NNS p
were VBD N
randomised VBN N
to TO N
receive VB N
treatment NN N
with IN N
a DT N
4-week JJ N
cycle NN N
of IN N
subcutaneous JJ i
low JJ i
doses NNS i
IL-2 NNP i
+ NNP i
IFN NNP i
in IN N
months NNS N
1 CD N
, , N
3 CD N
and CC N
5 CD N
, , N
and CC N
then RB N
every DT N
3 CD N
months NNS N
until IN N
the DT N
first JJ N
documented JJ N
disease NN N
progression NN N
( ( N
arm NN N
A NNP N
, , N
suspension NN N
) ) N
, , N
or CC N
the DT N
same JJ N
regimen NNS N
, , N
with IN N
chronic JJ N
maintenance NN N
of IN N
immunotherapy NN N
, , N
regardless RB N
of IN N
tumour JJ N
response NN N
, , N
until IN N
death NN N
or CC N
intolerable JJ N
toxicity NN N
( ( N
arm NN N
B NNP N
, , N
maintenance NN N
) ) N
. . N

The DT N
primary JJ N
endpoint NN N
was VBD N
overall JJ o
survival NN o
( ( o
OS NNP o
) ) o
; : o
secondary JJ N
endpoints NNS N
were VBD N
time NN o
from IN o
first JJ o
progression NN o
to TO o
death NN o
( ( o
TFPTD NNP o
) ) o
and CC o
tolerability NN o
. . o

One CD p
hundred CD p
and CC p
eighty-three JJ p
patients NNS p
were VBD p
enrolled VBN p
between IN p
January NNP p
1998 CD p
and CC p
November NNP p
2003 CD p
. . p

After IN N
a DT N
median JJ N
follow-up NN N
of IN N
53.9 CD N
months NNS N
, , N
response NN o
rate NN o
, , o
median JJ o
OS NNP o
and CC o
median JJ o
TFPTD NNP o
were VBD N
14.7 CD N
% NN N
( ( N
6.3 CD N
% NN N
CR NNP N
) ) N
versus VBP N
11.3 CD N
% NN N
( ( N
5.5 CD N
% NN N
CR NNP N
) ) N
, , N
14 CD N
versus NN N
14 CD N
months NNS N
, , N
6 CD N
versus NN N
5 CD N
months NNS N
, , N
in IN N
arms NNS N
A NNP N
and CC N
B NNP N
, , N
respectively RB N
with IN N
no DT N
significant JJ N
differences NNS N
between IN N
the DT N
groups NNS N
. . N

Cox NNP N
regression NN N
analysis NN N
showed VBD N
that IN N
the DT N
use NN N
of IN N
chemotherapy NN i
after IN N
first JJ N
progression NN N
( ( N
HR NNP N
0.54 CD N
; : N
95 CD N
% NN N
CI NNP N
0.35-0.86 CD N
; : N
p CC N
= VB N
0.008 CD N
) ) N
, , N
PS NNP N
= VBZ N
0 CD N
( ( N
HR NNP N
0.53 CD N
; : N
95 CD N
% NN N
CI NNP N
0.35-0.81 CD N
; : N
p CC N
= VB N
0.001 CD N
) ) N
and CC N
female JJ N
gender NN N
( ( N
HR NNP N
0.63 CD N
; : N
95 CD N
% NN N
CI NNP N
0.41-0.98 CD N
; : N
p CC N
= VB N
0.038 CD N
) ) N
were VBD N
significantly RB N
associated VBN N
with IN N
a DT N
longer RBR N
TFPTD NNP o
; : o
treatment NN N
arm NN N
was VBD N
not RB N
significant JJ N
( ( N
HR NNP N
0.88 CD N
; : N
95 CD N
% NN N
CI NNP N
0.60-1.31 CD N
; : N
p CC N
= VB N
0.54 CD N
) ) N
. . N

Toxicity NN o
was VBD N
mainly RB N
limited JJ N
to TO N
WHO NNP N
grades VBZ N
1 CD N
or CC N
2 CD N
. . N

Chronic JJ i
maintenance NN i
immunotherapy NN i
after IN N
disease NN N
progression NN N
is VBZ N
feasible JJ N
, , N
but CC N
does VBZ N
not RB N
significantly RB N
increase VB N
OS NNP o
or CC N
the DT N
TFPTD NNP o
. . o

-DOCSTART- -12185505- O O

Combined VBN N
therapy NN N
in IN N
the DT N
treatment NN N
of IN N
primary JJ p
mediastinal JJ p
B-cell NNP p
lymphoma NN p
: : p
conventional JJ N
versus NN N
escalated VBD N
chemotherapy NN N
. . N

Treatment NN N
of IN N
patients NNS p
with IN p
primary JJ p
mediastinal JJ p
B-cell NNP p
lymphoma NN p
( ( p
PMBCL NNP p
) ) p
remains VBZ N
controversial JJ N
. . N

We PRP N
started VBD N
a DT N
controlled JJ N
clinical JJ N
trial NN N
to TO N
evaluate VB N
the DT N
efficacy NN o
and CC o
toxicity NN o
of IN N
a DT N
conventional JJ N
versus NN N
more RBR N
intensive JJ N
regimen NNS N
of IN N
combined JJ N
chemotherapy NN N
followed VBN N
by IN N
radiotherapy NN N
to TO N
the DT N
mediastinum NN N
with IN N
the DT N
mantle NN N
technique NN N
. . N

From IN p
1989 CD p
to TO p
1997 CD p
, , p
68 CD p
patients NNS p
diagnosed VBN p
with IN p
previously RB p
untreated VBN p
PMBCL NNP p
, , p
aged VBD p
18-65 CD p
years NNS p
and CC p
negative JJ p
for IN p
immunodeficiency NN p
virus NN p
test NN p
, , N
were VBD N
considered VBN N
candidates NNS N
to TO N
receive VB N
either DT i
conventional JJ i
chemotherapy NN i
with IN i
CEOP-Bleo NNP i
( ( i
cyclophosphamide VB i
750 CD i
mg/m NN i
( ( i
2 CD i
) ) i
, , i
vincristine JJ i
1.4 CD i
mg/m NN i
( ( i
2 CD i
) ) i
, , i
prednisone RB i
40 CD i
mg/m NN i
( ( i
2 CD i
) ) i
, , i
epirubicin $ i
70 CD i
mg/m NN i
( ( i
2 CD i
) ) i
, , i
and CC i
bleomycin $ i
10 CD i
mg/m NN i
( ( i
2 CD i
) ) i
) ) i
or CC i
mega JJ i
CEOP-Bleo NNP i
( ( i
cyclophosphamide JJ i
1000 CD i
mg/m NN i
( ( i
2 CD i
) ) i
, , i
epirubicin $ i
120 CD i
mg/m NN i
( ( i
2 CD i
) ) i
, , i
vincristine NN i
, , i
prednisone NN i
, , i
and CC i
bleomycin NN i
at IN i
the DT i
same JJ i
doses NNS i
) ) i
every DT i
21 CD i
days NNS i
for IN i
six CD i
cycles NNS i
, , i
followed VBN i
by IN i
radiotherapy NN i
to TO i
the DT i
mediastinum NN i
with IN i
the DT i
mantle NN i
technique NN i
( ( i
35-45 JJ i
Gy NNP i
, , i
mean VBP i
38 CD i
Gy NNP i
) ) i
. . i

Complete JJ o
response NN o
( ( o
CR NNP o
) ) o
rates NNS o
were VBD N
not RB N
statistically RB N
different JJ N
: : N
64 CD N
% NN N
[ CC N
95 CD N
percent NN N
confidence NN o
interval NN o
( ( o
CI NNP o
) ) o
: : o
58 CD N
percent NN N
to TO N
70 CD N
percent NN N
] NN N
for IN N
conventional JJ N
arm NN N
vs NN N
81 CD N
percent NN N
( ( N
95 CD N
CI NN N
: : N
77-86 JJ N
percent NN N
) ) N
in IN N
the DT N
intensive JJ N
group NN N
( ( N
p=0.2 NN N
) ) N
. . N

However RB N
, , N
failure-free JJ o
survival NN o
( ( o
FFS NNP o
) ) o
and CC o
overall JJ o
survival NN o
( ( o
OS NNP o
) ) o
had VBD o
statistical JJ o
differences NNS o
. . o

At IN N
5 CD N
years NNS N
, , N
actuarial JJ o
FFS NNP o
for IN N
patients NNS N
treated VBN N
with IN N
conventional JJ N
chemotherapy NN N
was VBD N
51 CD N
percent NN N
( ( N
95 CD N
percent NN N
CI NN N
: : N
44-59 JJ N
percent NN N
) ) N
compared VBN N
to TO N
70 CD N
percent NN N
( ( N
95 CD N
percent NN N
CI NN N
: : N
65-76 JJ N
percent NN N
) ) N
in IN N
the DT N
intensive JJ N
arm NN N
( ( N
p JJ N
> NNP N
0.01 CD N
) ) N
. . N

OS CC o
rates NNS o
were VBD N
also RB N
different JJ N
: : N
54 CD N
percent NN N
( ( N
95 CD N
percent NN N
CI NN N
: : N
48-57 JJ N
percent NN N
) ) N
vs VBZ N
70 CD N
percent NN N
( ( N
95 CD N
percent NN N
CI NN N
: : N
65-76 JJ N
percent NN N
) ) N
, , N
respectively RB N
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
. . N

Toxicity NN o
was VBD N
mild JJ N
and CC N
no DT N
therapy-related JJ o
deaths NNS o
were VBD N
observed VBN N
. . N

At IN N
a DT N
median JJ N
follow-up NN N
of IN N
7.3 CD N
years NNS N
, , N
no DT N
second JJ N
neoplasia NN o
or CC o
acute NN o
leukemia NN o
has VBZ N
been VBN N
observed VBN N
. . N

The DT o
international JJ o
prognostic JJ o
index NN o
was VBD N
not RB N
useful JJ N
to TO N
define VB N
clinical JJ N
risk NN N
in IN N
this DT N
selected VBN N
group NN N
of IN N
patients NNS N
. . N

Multivariate NNP N
analysis NN N
identified VBN N
pleural JJ o
and CC o
pericardial JJ o
effusion NN o
and CC o
chemotherapy NN o
regimen NNS o
as IN N
prognostic JJ N
factors NNS N
influencing VBG N
FFS NNP o
and CC o
OS NNP o
. . o

We PRP N
feel VBP N
that IN N
patients NNS p
with IN p
PMBCL NNP p
should MD N
be VB N
treated VBN N
with IN N
more RBR N
intensive JJ N
, , N
but CC N
not RB N
myeloablative JJ N
chemotherapy NN N
, , N
followed VBN N
by IN N
adjuvant JJ N
radiotherapy NN N
to TO N
achieve VB N
an DT N
improvement NN N
in IN N
outcome NN N
in IN N
this DT N
setting NN N
of IN N
patients NNS N
. . N

Patients NNS N
with IN N
pleural JJ N
or CC N
pericardial JJ N
effusion NN N
are VBP N
considered VBN N
at IN N
high JJ N
risk NN N
for IN N
failure NN N
with IN N
the DT N
actual JJ N
programs NNS N
of IN N
treatment NN N
and CC N
probably RB N
will MD N
be VB N
considered VBN N
for IN N
experimental JJ N
therapeutic JJ N
approaches NNS N
. . N

-DOCSTART- -7707405- O O

Prophylactic JJ i
cranial JJ i
irradiation NN i
for IN N
patients NNS N
with IN N
small-cell JJ p
lung NN p
cancer NN p
in IN p
complete JJ p
remission NN p
. . p

BACKGROUND NNP N
Prophylactic NNP i
cranial JJ i
irradiation NN i
in IN N
patients NNS p
with IN p
small-cell JJ p
lung NN p
cancer NN p
decreases VBZ N
the DT N
overall JJ N
rate NN o
of IN o
brain NN o
metastases NNS o
without IN N
an DT N
effect NN N
on IN N
overall JJ o
survival NN o
. . o

It PRP N
has VBZ N
been VBN N
suggested VBN N
that IN N
this DT N
treatment NN N
may MD N
increase VB N
neuropsychological JJ o
syndromes NNS o
and CC o
brain NN o
abnormalities NNS o
indicated VBN N
by IN N
computed JJ N
tomography NN N
scans NNS N
. . N

However RB N
, , N
other JJ N
retrospective JJ N
data NNS N
suggested VBD N
a DT N
beneficial JJ N
effect NN N
on IN N
overall JJ N
survival NN N
for IN N
patients NNS p
in IN p
complete JJ p
remission NN p
. . p

PURPOSE VB N
Our PRP$ N
purpose NN N
was VBD N
to TO N
evaluate VB N
the DT N
effects NNS N
of IN N
prophylactic JJ i
cranial JJ i
irradiation NN i
on IN N
brain NN o
metastasis NN o
, , o
overall JJ o
survival NN o
, , N
and CC N
late-occurring JJ o
toxic NN o
effects NNS o
in IN N
patients NNS p
with IN p
small-cell JJ p
lung NN p
cancer NN p
in IN p
complete JJ p
remission NN p
. . p

METHODS NNP N
We PRP N
conducted VBD N
a DT N
prospective JJ N
study NN N
of IN N
300 CD p
patients NNS p
who WP p
had VBD p
small-cell NN p
lung NN p
cancer NN p
that WDT p
was VBD p
in IN p
complete JJ p
remission NN p
. . p

The DT N
patients NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
either RB N
prophylactic JJ i
cranial JJ i
irradiation NN i
delivering VBG N
24 CD N
Gy NNP N
in IN N
eight CD N
fractions NNS N
during IN N
12 CD N
days NNS N
( ( N
treatment NN N
group NN N
) ) N
or CC N
no DT i
prophylactic JJ i
cranial JJ i
irradiation NN i
( ( i
control VB i
group NN i
) ) i
. . i

A DT N
neuropsychological JJ N
examination NN N
and CC N
a DT N
computed JJ N
tomography NN N
scan NN N
of IN N
the DT N
brain NN N
were VBD N
performed VBN N
at IN N
the DT N
time NN N
of IN N
random JJ N
assignment NN N
and CC N
repeatedly RB N
assessed VBD N
at IN N
6 CD N
, , N
18 CD N
, , N
30 CD N
, , N
and CC N
48 CD N
months NNS N
. . N

Patterns NNP N
of IN N
failure NN N
were VBD N
analyzed VBN N
according VBG N
to TO N
total JJ N
event NN N
rates NNS N
and CC N
also RB N
according VBG N
to TO N
an DT N
isolated VBN N
first JJ N
site NN N
of IN N
relapse NN N
, , N
using VBG N
a DT N
competing-risk JJ N
approach NN N
. . N

RESULTS NNP N
Two CD p
hundred VBD p
ninety-four JJ p
patients NNS p
who WP p
did VBD p
not RB p
have VB p
brain NN p
metastases NNS p
at IN N
the DT N
time NN N
of IN N
random JJ N
assignment NN N
were VBD N
analyzed VBN N
. . N

The DT N
2-year JJ o
cumulative JJ o
rate NN o
of IN o
brain NN o
metastasis NN o
as IN N
an DT N
isolated JJ N
first JJ N
site NN N
of IN N
relapse NN o
was VBD N
45 CD N
% NN N
in IN N
the DT N
control NN N
group NN N
and CC N
19 CD N
% NN N
in IN N
the DT N
treatment NN N
group NN N
( ( N
P NNP N
< VBZ N
10 CD N
( ( N
-6 NNP N
) ) N
) ) N
. . N

The DT N
total JJ o
2-year JJ o
rate NN o
of IN o
brain NN o
metastasis NN o
was VBD N
67 CD N
% NN N
and CC N
40 CD N
% NN N
, , N
respectively RB N
( ( N
relative JJ N
risk NN N
= VBD N
0.35 CD N
; : N
P NNP N
< VBZ N
10 CD N
( ( N
-13 NNP N
) ) N
) ) N
. . N

The DT N
2-year JJ o
overall JJ o
survival NN o
rate NN o
was VBD N
21.5 CD N
% NN N
in IN N
the DT N
control NN N
group NN N
and CC N
29 CD N
% NN N
in IN N
the DT N
treatment NN N
group NN N
( ( N
relative JJ N
risk NN N
= VBD N
0.83 CD N
; : N
P NNP N
= NNP N
.14 NNP N
) ) N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
the DT N
two CD N
groups NNS N
in IN N
terms NNS N
of IN N
neuropsychological JJ o
function NN o
or CC o
abnormalities NNS o
indicated VBN N
by IN N
computed JJ N
tomography NN N
brain NN N
scans NNS N
. . N

CONCLUSIONS NNP N
Prophylactic NNP i
cranial JJ i
irradiation NN i
given VBN N
to TO N
patients NNS p
with IN p
small-cell JJ p
lung NN p
cancer NN p
in IN p
complete JJ p
remission NN p
decreases VBZ N
the DT N
risk NN N
of IN N
brain NN N
metastasis NN N
threefold VBD N
without IN N
a DT N
significant JJ N
increase NN N
in IN N
complications NNS N
. . N

A DT N
possible JJ N
beneficial JJ N
effect NN N
on IN N
overall JJ N
survival NN N
should MD N
be VB N
tested VBN N
with IN N
a DT N
higher JJR N
statistical JJ N
power NN N
. . N

IMPLICATIONS VBZ N
The DT N
results NNS N
of IN N
the DT N
trial NN N
favor NN N
, , N
at IN N
present JJ N
, , N
the DT N
indication NN N
of IN N
prophylactic JJ N
cranial JJ N
irradiation NN N
for IN N
patients NNS p
who WP p
are VBP p
in IN p
complete JJ p
remission NN p
. . p

A NNP N
longer JJR N
follow-up NN N
and CC N
confirmatory NN N
trials NNS N
are VBP N
needed VBN N
to TO N
fully RB N
assess VB N
late-occurring JJ N
toxic JJ N
effects NNS N
. . N

The DT N
possible JJ N
effect NN N
on IN N
overall JJ o
survival NN o
needs NNS N
to TO N
be VB N
evaluated VBN N
with IN N
a DT N
larger JJR N
number NN N
of IN N
patients NNS p
in IN p
complete JJ p
remission NN p
, , N
and CC N
a DT N
meta-analysis NN N
of IN N
similar JJ N
trials NNS N
is VBZ N
recommended VBN N
. . N

-DOCSTART- -23306077- O O

Translating VBG N
the DT N
Dietary NNP i
Approaches NNP i
to TO i
Stop VB i
Hypertension NNP i
( ( i
DASH NNP i
) ) i
diet NN i
for IN N
use NN N
in IN N
underresourced JJ p
, , p
urban JJ p
African JJ p
American JJ p
communities NNS p
, , p
2010 CD p
. . p

INTRODUCTION NNP N
Randomized NNP N
trials NNS N
have VBP N
demonstrated VBN N
the DT N
effectiveness NN N
of IN N
the DT N
Dietary NNP i
Approaches NNP i
to TO i
Stop VB i
Hypertension NNP i
( ( i
DASH NNP i
) ) i
program NN N
for IN N
lowering VBG N
blood NN o
pressure NN o
; : o
however RB N
, , N
program NN N
participation NN N
has VBZ N
been VBN N
limited VBN N
in IN N
some DT N
populations NNS N
. . N

The DT N
objective NN N
of IN N
this DT N
pilot NN N
study NN N
was VBD N
to TO N
test VB N
the DT N
feasibility NN N
of IN N
using VBG N
a DT N
culturally RB N
modified VBN N
version NN N
of IN N
DASH NNP i
among IN N
African JJ p
Americans NNPS p
in IN p
an DT p
underresourced JJ p
community NN p
. . p

METHODS NNP N
This DT N
randomized VBD N
controlled VBN N
pilot NN N
study NN N
recruited VBD N
African JJ p
Americans NNPS p
in IN p
2 CD p
North NNP p
Carolina NNP p
neighborhoods NNS p
who WP p
had VBD p
high JJ p
blood NN p
pressure NN p
and CC p
used VBD p
fewer JJR p
than IN p
3 CD p
antihypertension NN p
medications NNS p
. . p

We PRP N
offered VBD N
2 CD N
individual JJ i
and CC i
9 CD N
group NN i
DASH NNP i
sessions NNS i
to TO N
intervention NN N
participants NNS N
and CC N
1 CD i
individual JJ i
session NN i
and CC i
printed VBD i
DASH NNP i
educational JJ i
materials NNS i
to TO i
control VB i
participants NNS i
. . i

We PRP N
collected VBD N
data NNS N
at IN N
baseline NN N
( ( N
March NNP N
2010 CD N
) ) N
and CC N
12 CD N
weeks NNS N
( ( N
June NNP N
2010 CD N
) ) N
. . N

RESULTS NNP N
Of IN p
152 CD p
potential JJ p
participants NNS p
, , p
25 CD p
were VBD p
randomly RB p
assigned VBN p
to TO p
either CC p
the DT p
intervention NN i
( ( p
n JJ p
= NNP p
14 CD p
) ) p
or CC p
the DT p
control NN i
( ( p
n JJ p
= NNP p
11 CD p
) ) p
group NN p
; : p
22 CD p
were VBD p
women NNS p
, , p
and CC p
21 CD p
were VBD p
educated VBN p
beyond IN p
high JJ p
school NN p
. . p

At IN p
baseline NN p
, , p
mean JJ o
blood NN o
pressure NN o
was VBD p
130/78 CD p
mm JJ p
Hg NNP p
; : p
19 CD p
participants NNS p
used VBN p
antihypertension NN p
medications NNS p
, , p
and CC p
mean VB p
body NN o
mass NN o
index NN o
was VBD p
35.9 CD p
kg/m NN p
( ( p
2 CD p
) ) p
. . p

Intervention NN N
participants NNS N
attended VBD N
7 CD N
of IN N
9 CD N
group NN N
sessions NNS N
on IN N
average NN N
. . N

After IN N
12 CD N
weeks NNS N
, , N
we PRP N
observed VBD N
significant JJ N
increases NNS N
in IN N
fruit NN o
and CC o
vegetable JJ o
consumption NN o
and CC N
increases NNS N
in IN N
participants NNS o
' POS o
confidence NN o
in IN o
their PRP$ o
ability NN o
to TO o
reduce VB o
salt NN o
and CC o
fat JJ o
consumption NN o
and CC o
eat NN o
healthier NN o
snacks NNS o
in IN N
intervention NN N
compared VBN N
with IN N
control NN N
participants NNS N
. . N

We PRP N
found VBD N
no DT N
significant JJ N
decreases NNS N
in IN N
blood NN o
pressure NN o
. . o

CONCLUSION NNP N
Implementation NNP N
of IN N
a DT N
culturally RB N
modified VBN N
, , N
community-based JJ i
DASH NNP i
intervention NN i
was VBD N
feasible JJ N
in IN N
our PRP$ N
small JJ p
sample NN p
of IN p
African JJ p
Americans NNPS p
, , p
which WDT p
included VBD p
people NNS p
being VBG p
treated VBN p
for IN p
high JJ p
blood NN o
pressure NN o
. . o

Future JJ N
studies NNS N
should MD N
evaluate VB N
the DT N
long-term JJ N
effect NN N
of IN N
this DT N
program NN N
in IN N
a DT N
larger JJR N
sample NN N
. . N

-DOCSTART- -21667200- O O

Design NN N
and CC N
subject JJ N
characteristics NNS N
in IN N
the DT N
federally-funded JJ N
citalopram NN i
trial NN N
in IN N
children NNS p
with IN p
pervasive JJ p
developmental NN p
disorders NNS p
. . p

The DT N
Studies NNPS N
to TO N
Advance NNP N
Autism NNP N
Research NNP N
and CC N
Treatment NNP N
Network NNP N
conducted VBD N
a DT N
randomized JJ N
trial NN N
with IN N
citalopram NN i
in IN N
children NNS p
with IN p
Pervasive NNP p
developmental NN p
disorders NNS p
( ( p
PDDs NNP p
) ) p
. . p

We PRP N
present VBD N
the DT N
rationale NN N
, , N
design NN N
and CC N
sample JJ N
characteristics NNS N
of IN N
the DT N
citalopram JJ i
trial NN N
. . N

Subjects NNS p
( ( p
128 CD p
boys NNS p
, , p
21 CD p
girls NNS p
) ) p
had VBD p
a DT p
mean JJ p
age NN p
of IN p
9.3 CD p
( ( p
?3.12 NN p
) ) p
years NNS p
; : p
132 CD p
( ( p
88.6 CD p
% NN p
) ) p
were VBD p
diagnosed VBN p
with IN p
autistic JJ p
disorder NN p
( ( p
4.7 CD p
% NN p
with IN p
Asperger NNP p
's POS p
Disorder NNP p
; : p
6.7 CD p
% NN p
with IN p
PDD-not NNP p
otherwise RB p
specified VBD p
) ) p
. . p

Less JJR p
than IN p
half NN p
of IN p
the DT p
subjects NNS p
were VBD o
intellectually RB o
disabled VBN o
; : o
117 CD p
( ( p
78.5 CD p
% NN p
) ) p
were VBD p
rated VBN p
Moderate NNP p
or CC p
Marked VBN p
on IN p
the DT o
Clinical NNP o
Global NNP o
Impression NNP o
for IN o
Severity NNP o
. . o

Study NNP N
measures NNS N
were VBD N
similar JJ N
to TO N
previous JJ N
Research NNP N
Units NNP N
on IN N
Pediatric NNP N
Psychopharmacology NNP N
trials NNS N
. . N

Subjects NNS p
in IN p
this DT p
trial NN p
were VBD p
slightly RB p
older JJR p
and CC p
more RBR p
likely JJ p
to TO p
have VB p
complaints NNS p
of IN o
repetitive JJ o
behavior NN o
than IN N
participants NNS N
in IN N
RUPP NNP N
trials NNS N
. . N

-DOCSTART- -17426001- O O

[ JJ N
Comparison NNP N
of IN N
three CD N
analgesic JJ N
methods NNS N
for IN N
postoperative JJ p
pain NN p
relief NN N
and CC N
their PRP$ N
effects NNS N
on IN N
plasma JJ o
interleukin-6 JJ o
concentration NN o
following VBG N
radical JJ p
surgery NN p
for IN p
gastric JJ p
carcinoma NN p
] NNP p
. . N

OBJECTIVE NNP N
To TO N
compare VB N
the DT N
efficacy NN N
of IN N
preemptive JJ i
epidural JJ i
analgesia NN i
combined VBN i
with IN i
postoperative JJ i
epidural JJ i
analgesia NN i
, , i
postoperative JJ i
epidural JJ i
analgesia NN i
alone RB i
and CC N
intravenous JJ i
analgesia NN i
for IN N
postoperative JJ o
pain NN o
relief NN o
and CC N
their PRP$ N
effects NNS N
on IN N
plasma JJ o
interleukin-6 JJ o
( ( o
IL-6 NNP o
) ) o
concentration NN o
following VBG N
radical JJ p
surgery NN p
for IN p
gastric JJ p
carcinoma NN p
. . p

METHODS NNP N
Sixty-six JJ p
patients NNS p
with IN p
gastric JJ p
carcinoma NN p
scheduled VBN p
for IN p
gastrectomy NN p
were VBD N
randomly RB N
divided VBN N
into IN N
3 CD N
groups NNS N
, , N
namely RB N
group NN N
P NNP N
( ( N
n=22 NN N
) ) N
, , N
group NN N
E NNP N
( ( N
n=22 NN N
) ) N
and CC N
group NN N
V NNP N
( ( N
n=22 NN N
) ) N
, , N
to TO N
receive VB N
preemptive JJ i
epidural JJ i
analgesia NN i
combined VBN i
with IN i
postoperative JJ i
epidural JJ i
analgesia NN i
, , i
exclusive JJ i
postoperative JJ i
epidural JJ i
analgesia NN i
, , i
and CC i
exclusive JJ i
postoperative NN i
intravenous JJ i
analgesia NN i
, , N
respectively RB N
. . N

Hemodynamic NNP o
data NNS o
were VBD N
recorded VBN N
for IN N
all PDT N
the DT N
patients NNS N
during IN N
the DT N
operation NN N
, , N
and CC N
visual JJ o
analogue NN o
scale NN o
( ( o
VAS NNP o
) ) o
was VBD N
used VBN N
to TO N
assess VB N
the DT N
pain NN o
intensity NN o
at IN N
4 CD N
, , N
8 CD N
, , N
16 CD N
, , N
24 CD N
, , N
48 CD N
and CC N
72 CD N
h NN N
after IN N
surgery NN N
. . N

Plasma NNP o
IL-6 JJ o
concentration NN o
was VBD N
determined VBN N
before IN N
surgery NN N
and CC N
at IN N
24 CD N
, , N
48 CD N
, , N
72 CD N
h NN N
after IN N
surgery NN N
. . N

RESULTS NNP N
No NNP N
significant JJ N
changes NNS N
occurred VBD N
in IN N
the DT N
hemodynamics NNS N
during IN N
the DT N
preoperative JJ N
periods NNS N
. . N

VAS NNP o
and CC o
IL-6 NNP o
were VBD N
lower JJR N
in IN N
group NN N
P NNP N
than IN N
in IN N
group NN N
E NNP N
and CC N
V NNP N
, , N
and CC N
group NN N
E NNP N
had VBD N
lower JJR N
measurement NN N
than IN N
group NN N
V NNP N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

CONCLUSION NNP N
Preemptive NNP N
epidural JJ N
analgesia NN N
combined VBN N
with IN N
postoperative JJ N
epidural JJ N
analgesia NN N
provides VBZ N
more RBR N
satisfactory JJ N
pain NN o
relief NN o
and CC N
more RBR N
effectively RB N
prevents VBZ N
IL-6 JJ o
increment NN o
than IN N
exclusive JJ N
epidural JJ N
analgesia NN N
or CC N
intravenous JJ N
analgesia NN N
after IN p
gastrectomy NN p
for IN p
gastric JJ p
carcinoma NN p
. . p

-DOCSTART- -11029568- O O

Epidural JJ i
fentanyl-bupivacaine JJ i
compared VBN N
with IN N
clonidine-bupivacaine NN i
for IN N
analgesia NN p
in IN p
labour NN p
. . p

Alpha-adrenergic JJ N
agonists NNS N
produce VBP N
pain NN o
relief NN o
through IN N
an DT N
opioid JJ N
independent JJ N
mechanism NN N
and CC N
may MD N
be VB N
alternatives NNS N
to TO N
opioids NNS N
for IN N
combination NN N
with IN N
local JJ N
anaesthetics NNS N
for IN N
analgesia NN N
during IN p
labour NN p
. . p

We PRP p
studied VBD p
41 CD p
pregnant JJ p
women NNS p
. . p

Epidural JJ N
block NN N
was VBD N
performed VBN N
with IN N
75 CD N
microg NNS N
clonidine NN i
( ( N
n JJ N
= NNP N
20 CD N
) ) N
or CC N
50 CD i
microg NNS i
fentanyl NN i
( ( N
n JJ N
= NNP N
21 CD N
) ) N
combined VBN i
with IN i
0.125 CD i
% NN i
bupivacaine NN i
( ( N
10 CD N
mL NN N
) ) N
. . N

Maternal JJ o
vital JJ o
parameters NNS o
were VBD N
measured VBN N
. . N

Analgesia NNP o
was VBD N
evaluated VBN N
using VBG N
a DT N
visual JJ N
analogue NN N
scale NN N
( ( N
VAS NNP N
) ) N
; : N
sedation NN o
was VBD N
scored VBN N
using VBG N
a DT N
five-point JJ N
scale NN N
. . N

There EX N
were VBD N
no DT N
differences NNS N
in IN N
maternal JJ o
vital JJ o
parameters NNS o
, , o
fetal JJ o
heart NN o
rate NN o
( ( o
FHR NNP o
) ) o
or CC o
Apgar NNP o
scores NNS o
between IN N
the DT N
groups NNS N
. . N

Analgesia NNP o
lasted VBD N
longer RBR N
in IN N
the DT N
bupivacaine-clonidine JJ i
group NN N
( ( N
139.4 CD N
+/- JJ N
31 CD N
min NN N
) ) N
compared VBN N
with IN N
the DT N
bupivacaine-fentanyl JJ i
group NN N
( ( N
127.9 CD N
+/- JJ N
48 CD N
min NN N
) ) N
( ( N
P NNP N
= NNP N
0.42 CD N
) ) N
. . N

Additional JJ o
analgesic JJ o
requirement NN o
was VBD N
more RBR N
often RB N
in IN N
the DT N
fentanyl-bupivacaine JJ i
group NN N
and CC N
total JJ N
bupivacaine NN N
requirement NN N
was VBD N
less RBR N
in IN N
the DT N
clonidine-bupivacaine JJ i
group NN N
( ( N
22.5 CD N
+/- JJ N
12.5 CD N
mg NN N
vs. FW N
30.9 CD N
+/- JJ N
12.8 CD N
mg NN N
) ) N
( ( N
P NNP N
= NNP N
0.04 CD N
) ) N
. . N

This DT N
small JJ N
study NN N
confirms VBZ N
that IN N
this DT N
combination NN N
of IN N
bupivacaine NN i
and CC N
clonidine NN i
provides VBZ N
satisfactory JJ o
analgesia NN o
for IN N
first-stage JJ N
labour NN N
, , N
and CC N
of IN N
longer JJR N
duration NN o
than IN N
bupivacaine-fentanyl NN i
. . i

-DOCSTART- -1527133- O O

The DT N
A-V NNP i
Impulse NNP i
System NNP i
reduces VBZ N
deep-vein JJ p
thrombosis NN p
and CC p
swelling NN p
after IN p
hemiarthroplasty NN p
for IN p
hip NN p
fracture NN p
. . p

We PRP N
performed VBD N
a DT N
prospective JJ N
randomised VBN N
controlled JJ N
trial NN N
of IN N
the DT N
A-V NNP i
Impulse NNP i
System NNP i
in IN N
82 CD p
patients NNS p
treated VBN p
by IN p
hemiarthroplasty NN p
for IN p
subcapital JJ p
fracture NN p
of IN p
the DT p
femoral JJ p
neck NN p
. . p

The DT N
incidence NN N
of IN N
proximal JJ N
deep-vein JJ N
thrombosis NN N
as IN N
assessed VBN N
by IN N
Doppler NNP i
ultrasonography NN i
was VBD N
23 CD N
% NN N
in IN N
the DT N
control NN N
group NN N
and CC N
0 CD N
% NN N
in IN N
those DT N
using VBG N
the DT N
device NN N
( ( N
p NN N
less JJR N
than IN N
0.01 CD N
) ) N
. . N

Calf NNP N
and CC N
thigh JJ N
circumferences NNS N
were VBD N
measured VBN N
in IN N
both DT N
groups NNS N
at IN N
seven CD N
to TO N
ten VB N
days NNS N
after IN N
operation NN N
. . N

In IN N
the DT N
treatment NN N
group NN N
there EX N
was VBD N
a DT N
mean JJ o
relative JJ o
reduction NN o
of IN o
postoperative JJ o
swelling NN o
of IN o
the DT o
thigh NN o
by IN N
3.27 CD N
cm NN N
( ( N
p NN N
less JJR N
than IN N
0.001 CD N
) ) N
and CC N
of IN N
the DT N
calf NN N
by IN N
1.55 CD N
cm NN N
( ( N
p NN N
less JJR N
than IN N
0.001 CD N
) ) N
. . N

The DT N
A-V NNP N
Impulse NNP N
System NNP N
appears VBZ N
to TO N
be VB N
a DT N
safe JJ o
and CC N
effective JJ N
method NN N
of IN N
reducing VBG N
the DT N
incidence NN o
of IN o
proximal JJ o
deep-vein JJ o
thrombosis NN o
, , o
and CC o
of IN o
postoperative JJ o
swelling NN o
. . o

-DOCSTART- -20061873- O O

Evidence NN N
for IN N
poorer JJR N
outcome NN N
in IN N
patients NNS p
with IN p
severe JJ p
negative JJ p
trauma-related JJ p
cognitions NNS p
receiving VBG N
prolonged JJ i
exposure NN i
plus CC N
cognitive JJ i
restructuring NN i
: : i
implications NNS N
for IN N
treatment NN N
matching NN N
in IN N
posttraumatic JJ N
stress NN N
disorder NN N
. . N

In IN N
the DT N
current JJ N
article NN N
, , N
we PRP N
address VBP N
the DT N
existing VBG N
assumption NN N
in IN N
the DT N
literature NN N
on IN N
cognitive JJ i
behavioral JJ i
treatment NN i
of IN N
PTSD NNP N
that IN N
patients NNS p
with IN p
severe JJ p
negative JJ p
trauma-related JJ p
cognitions NNS p
would MD N
benefit VB N
more RBR N
from IN N
a DT N
treatment NN N
package NN N
that WDT N
includes VBZ N
exposure NN i
and CC i
cognitive JJ i
techniques NNS i
compared VBN N
with IN N
a DT N
treatment NN N
that WDT N
includes VBZ N
exposure NN i
only RB i
. . i

To TO N
test VB N
this DT N
assumption NN N
, , N
54 CD p
PTSD NN p
patients NNS p
were VBD N
randomized VBN N
to TO N
prolonged VB i
exposure NN i
therapy NN i
or CC i
prolonged JJ i
exposure NN i
therapy NN i
plus CC i
cognitive JJ i
restructuring NN i
. . i

Contrary NNP N
to TO N
expectations NNS N
, , N
findings NNS N
revealed VBD N
that IN N
patients NNS N
characterized VBN N
by IN N
more JJR N
severe JJ N
pretreatment NN N
trauma-related JJ N
cognitions NNS N
( ( N
and CC N
more RBR N
severe JJ N
pretreatment NN N
PTSD NNP N
symptoms NNS N
) ) N
fared VBD N
slightly RB N
worse JJR N
in IN N
treatment NN N
combining NN N
exposure NN i
and CC i
cognitive JJ i
restructuring NN i
. . i

However RB N
, , N
there EX N
was VBD N
no DT N
relationship NN N
between IN N
pre- NN N
and CC N
post-treatment JJ o
measures NNS o
of IN o
negative JJ o
cognitions NNS o
and CC o
PTSD NNP o
symptoms NNS o
in IN N
the DT N
exposure NN i
alone RB i
group NN N
. . N

The DT N
implications NNS N
of IN N
these DT N
findings NNS N
for IN N
examining VBG N
Person NNP N
X NNP N
Treatment NNP N
interactions NNS N
and CC N
the DT N
efficacy NN o
of IN N
combining VBG N
treatments NNS N
for IN N
PTSD NNP N
are VBP N
discussed VBN N
. . N

-DOCSTART- -20010618- O O

Effectiveness NN N
of IN N
initiating VBG N
treatment NN N
with IN N
valsartan/hydrochlorothiazide NN i
in IN N
patients NNS p
with IN p
stage-1 JJ p
or CC p
stage-2 JJ p
hypertension NN p
. . p

This DT N
prospective JJ N
, , N
6-week JJ N
, , N
multicenter NN N
, , N
double-blind NN N
study NN N
examined VBD N
the DT N
benefits NNS N
of IN N
initiating VBG N
treatment NN N
with IN N
combination NN N
valsartan/hydrochlorothiazide NN i
( ( i
HCTZ NNP i
) ) i
compared VBN N
with IN N
initial JJ N
valsartan NNS N
monotherapy NN N
for IN N
648 CD p
patients NNS p
with IN p
stage-1 JJ p
or CC p
stage-2 JJ p
hypertension NN p
( ( p
age=52.6+/-10 JJ p
years NNS p
; : p
54 CD p
% NN p
male NN p
; : p
baseline VB p
blood NN p
pressure NN p
( ( p
BP NNP p
) ) p
=161/98 VBP p
mm JJ p
Hg NNP p
, , p
32 CD p
% NN p
stage NN p
1 CD p
) ) p
. . p

Patients NNS N
were VBD N
randomized VBN N
to TO N
valsartan VB i
80 CD i
mg NN i
( ( i
V-low NNP i
) ) i
, , i
valsartan $ i
160 CD i
mg NN i
( ( i
V-high NNP i
) ) i
or CC i
valsartan/HCTZ $ i
160/12.5 CD i
mg NN i
( ( i
V/HCTZ NNP i
) ) i
, , i
and CC i
electively RB i
titrated VBN i
after IN i
weeks NNS i
2 CD i
and CC i
4 CD i
to TO i
the DT i
next JJ i
dosage NN i
level NN i
( ( i
maximum JJ i
dose NN i
valsartan/HCTZ NN i
160/25 CD i
mg NN i
) ) i
if IN i
BP NNP i
remained VBD i
> JJ i
140/90 CD i
mm NN i
Hg NNP i
. . i

At IN N
end NN N
of IN N
the DT N
study NN N
, , N
patients NNS N
initiated VBN N
with IN N
V/HCTZ NNP i
required VBD N
less JJR o
titration JJ o
steps NNS o
compared VBN N
with IN N
the DT N
initial JJ N
valsartan NN N
monotherapy NN N
groups NNS N
( ( N
63 CD N
vs RB N
86 CD N
% NN N
required VBN N
titration NN N
by IN N
study JJ N
end NN N
, , N
respectively RB N
) ) N
and CC N
reached VBD N
the DT N
target NN N
BP NNP o
goal NN o
of IN N
< $ N
140/90 CD N
mm NN N
Hg NNP N
in IN N
a DT N
shorter JJ N
period NN N
of IN N
time NN N
( ( N
2.8 CD N
weeks NNS N
) ) N
( ( N
P NNP N
< NNP N
0.0001 CD N
) ) N
vs NN N
V-low NNP N
( ( N
4.3 CD N
weeks NNS N
) ) N
and CC N
V-high NNP N
( ( N
3.9 CD N
weeks NNS N
) ) N
. . N

Initial JJ N
combination NN N
therapy NN N
was VBD N
also RB N
associated VBN N
with IN N
higher JJR N
BP NNP o
control NN o
rates NNS o
and CC N
greater JJR N
reductions NNS o
in IN o
both DT o
systolic JJ o
and CC o
diastolic JJ o
BP NNP o
from IN N
baseline NN N
( ( N
63 CD N
% NN N
, , N
-27.7+/-13/-15.1+/-8 NNP N
mm NNP N
Hg NNP N
) ) N
compared VBN N
with IN N
V-low NNP N
( ( N
46 CD N
% NN N
, , N
-21.2+/-13/-11.4+/-8 NNP N
mm NNP N
Hg NNP N
, , N
P NNP N
< NNP N
0.0001 CD N
) ) N
or CC N
V-high NNP N
( ( N
51 CD N
% NN N
, , N
-24.0+/-13/-12.0+/-10 NNP N
mm NNP N
Hg NNP N
, , N
P NNP N
< NNP N
0.01 CD N
) ) N
. . N

Overall JJ N
and CC N
drug-related JJ o
AEs NNP o
were VBD N
mild JJ N
to TO N
moderate VB N
and CC N
were VBD N
similar JJ N
between IN N
V/HCTZ NNP i
( ( N
53.1 CD N
and CC N
14.1 CD N
% NN N
, , N
respectively RB N
) ) N
and CC N
the DT N
two CD N
monotherapy NN N
groups NNS N
, , N
V-low NNP N
( ( N
50.5 CD N
and CC N
13.8 CD N
% NN N
) ) N
and CC N
V-high NNP N
( ( N
50.7 CD N
and CC N
11.8 CD N
% NN N
) ) N
. . N

In IN N
conclusion NN N
, , N
initiating VBG N
therapy NN N
with IN N
a DT N
combination NN N
of IN N
valsartan NN i
and CC N
low-dose JJ N
HCTZ NNP i
results NNS N
in IN N
early JJ o
, , o
improved JJ o
BP NNP o
efficacy NN o
with IN N
similar JJ N
tolerability NN o
as IN N
compared VBN N
with IN N
starting VBG N
treatment NN N
with IN N
a DT N
low JJ N
or CC N
higher JJR N
dose NN N
of IN N
valsartan NN i
for IN N
patients NNS p
with IN p
stage-1 JJ p
and CC p
stage-2 JJ p
hypertension NN p
. . p

-DOCSTART- -8656171- O O

Effectiveness NN N
of IN N
erythromycin NN i
in IN N
the DT N
treatment NN N
of IN N
acute JJ p
bronchitis NN p
. . p

BACKGROUND NNP N
Clinical NNP N
trials NNS N
have VBP N
not RB N
shown VBN N
a DT N
consistent JJ N
benefit NN N
of IN N
treating VBG N
bronchitis NN N
with IN N
antibiotics NNS N
. . N

Many JJ N
physicians NNS N
, , N
however RB N
, , N
treat VB N
acute JJ N
bronchitis NN N
with IN N
antibiotics NNS N
because IN N
of IN N
the DT N
possibility NN N
of IN N
Mycoplasma NNP N
pneumoniae NN N
or CC N
other JJ N
pathogens NNS N
. . N

The DT N
objectives NNS N
of IN N
this DT N
study NN N
were VBD N
to TO N
determine VB N
the DT N
effectiveness NN N
of IN N
erythromycin JJ i
treatment NN N
in IN N
patients NNS p
with IN p
acute JJ p
bronchitis NN p
and CC N
to TO N
determine VB N
whether IN N
a DT N
newly RB N
developed VBN N
rapid JJ N
M NNP N
pneumoniae NN N
antibody NN N
test NN N
is VBZ N
useful JJ N
in IN N
predicting VBG N
which WDT N
patients NNS N
will MD N
respond VB N
to TO N
therapy VB N
. . N

METHODS NNP N
We PRP N
conducted VBD N
a DT N
randomized VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
clinical JJ N
trial NN N
at IN N
three CD p
primary JJ p
care NN p
centers NNS p
in IN p
North NNP p
Carolina NNP p
. . p

A DT N
convenience NN N
sample NN N
of IN N
140 CD p
patients NNS p
presenting VBG p
with IN p
acute JJ p
bronchitis NN p
were VBD p
tested VBN p
for IN p
M NNP p
pneumoniae NN p
, , p
91 CD p
of IN p
whom WP p
were VBD p
treated VBN p
with IN N
either DT N
erythromycin JJ i
250 CD i
mg RB i
four CD i
times NNS i
daily RB i
for IN i
10 CD i
days NNS i
or CC i
an DT i
identical-appearing JJ i
placebo NN i
. . i

RESULTS JJ N
Patients NNS N
treated VBN N
with IN N
erythromycin NN i
missed VBD N
an DT N
average NN N
of IN N
only JJ N
0.81 CD N
+/- JJ N
1.1 CD N
days NNS o
of IN o
work NN o
compared VBN N
with IN N
2.16 CD N
+/- JJ N
3.2 CD N
days NNS N
for IN N
placebo-treated JJ i
patients NNS N
( ( N
P NNP N
< NNP N
.02 NNP N
) ) N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
cough NN o
, , o
use NN o
of IN o
cough JJ o
medicine NN o
, , o
general JJ o
feeling NN o
of IN o
well-being NN o
, , o
or CC o
chest JJS o
congestion NN o
between IN N
the DT N
erythromycin NN i
and CC N
placebo NN i
groups NNS N
. . N

Twenty-five JJ N
percent NN N
of IN N
the DT N
patients NNS N
tested VBD N
positive JJ N
for IN N
M NNP N
pneumoniae NN N
. . N

There EX N
were VBD N
no DT N
differences NNS N
in IN N
response NN N
to TO N
erythromycin VB i
based VBN N
on IN N
whether IN N
the DT N
patient NN N
had VBD N
a DT N
positive JJ N
test NN N
for IN N
M NNP N
pneumoniae NN N
. . N

CONCLUSIONS NNP N
Erythromycin NNP i
is VBZ N
effective JJ N
in IN N
significantly RB N
reducing VBG N
lost VBN N
time NN N
from IN N
work NN N
, , N
but CC N
it PRP N
is VBZ N
not RB N
effective JJ N
in IN N
reducing VBG N
cough NN N
or CC N
other JJ N
symptoms NNS N
in IN N
patients NNS p
with IN p
acute JJ p
bronchitis NN p
, , N
regardless RB N
of IN N
the DT N
outcome NN N
of IN N
the DT N
M NNP N
pneumoniae NN N
antibody NN N
test NN N
. . N

-DOCSTART- -17491486- O O

Treatment NN i
of IN i
periodontal JJ i
disease NN i
and CC p
the DT p
risk NN p
of IN p
preterm JJ o
birth NN o
. . o

-DOCSTART- -8156515- O O

Antifungal NNP N
prophylaxis NN N
during IN N
remission NN p
induction NN p
therapy NN p
for IN p
acute JJ p
leukemia NN p
fluconazole JJ N
versus NN i
intravenous JJ i
amphotericin NN i
B NNP i
. . i

BACKGROUND NNP N
Fungal NNP N
infection NN N
is VBZ N
a DT N
frequent JJ N
and CC N
often RB N
fatal JJ N
complication NN N
in IN N
patients NNS p
undergoing JJ p
remission NN p
induction NN p
therapy NN p
for IN p
acute JJ p
leukemia NN p
. . p

Although IN N
candidiasis NN N
is VBZ N
the DT N
most RBS N
common JJ N
infection NN N
, , N
mold JJ N
infections NNS N
are VBP N
increasing VBG N
in IN N
frequency NN N
. . N

Fluconazole NNP i
( ( i
FLU NNP i
) ) i
is VBZ N
a DT N
new JJ N
antifungal JJ N
agent NN N
that WDT N
has VBZ N
been VBN N
used VBN N
successfully RB N
to TO N
treat VB N
Candida NNP N
infections NNS N
and CC N
has VBZ N
modest JJ N
activity NN N
against IN N
aspergillosis NN N
in IN N
animal JJ N
models NNS N
. . N

Subtherapeutic JJ N
doses NNS N
of IN N
amphotericin NN i
B NNP i
( ( i
AMB NNP i
) ) i
have VBP N
been VBN N
considered VBN N
effective JJ N
as IN N
prophylaxis NN N
in IN N
these DT N
patients NNS N
. . N

This DT N
study NN N
was VBD N
designed VBN N
to TO N
compare VB N
the DT N
efficacy NN o
and CC o
toxicity NN o
of IN N
these DT N
agents NNS N
as IN N
antifungal JJ N
prophylaxis NN N
. . N

METHODS NNP N
Adults NNP p
with IN p
acute JJ p
leukemia NN p
undergoing VBG p
remission NN p
induction NN p
chemotherapy NN p
randomly NN N
were VBD N
assigned VBN N
to TO N
receive VB i
antifungal JJ i
prophylaxis NN i
with IN i
AMB NNP i
( ( i
0.5 CD i
mg/kg NN i
three CD i
times NNS i
weekly JJ i
) ) i
or CC i
FLU NNP i
( ( i
400 CD i
mg NNS i
daily RB i
) ) i
. . i

Trimethoprim-sulfamethoxazole NN i
was VBD i
administered VBN i
as IN i
an DT i
antibacterial JJ i
prophylaxis NN i
. . i

Prophylaxis NNP i
was VBD i
continued VBN i
until IN i
the DT i
patient NN i
achieved VBD i
complete JJ i
remission NN i
or CC i
was VBD i
treated VBN i
for IN i
8 CD i
weeks NNS i
without IN i
antileukemic JJ i
response NN i
. . i

Prophylaxis NNP N
was VBD N
discontinued VBN N
if IN N
the DT N
patient NN N
experienced VBD N
a DT N
possible JJ N
or CC N
proven JJ N
fungal JJ N
infection NN N
or CC N
a DT N
serious JJ N
toxicity NN N
. . N

RESULTS NNP N
Overall NNP N
, , N
58 CD N
% NN N
of IN N
the DT N
36 CD p
patients NNS p
assigned VBN N
to TO N
AMB NNP i
successfully RB N
completed VBD N
prophylaxis NNS N
compared VBN N
with IN N
80 CD N
% NN N
of IN N
the DT N
41 CD p
patients NNS p
assigned VBN N
to TO N
FLU NNP i
( ( N
< NNP N
0.05 CD N
) ) N
. . N

Proven NNP o
, , o
probable JJ o
, , o
or CC o
possible JJ o
fungal JJ o
infections NNS o
occurred VBD N
in IN N
31 CD N
% NN N
and CC N
17 CD N
% NN N
of IN N
the DT N
patients NNS N
, , N
respectively RB N
. . N

The DT N
risk NN N
of IN N
discontinuing VBG N
prophylaxis NN N
due JJ N
to TO N
fungal JJ o
infection NN o
or CC N
toxicity NN o
increased VBN N
with IN N
time NN N
in IN N
the DT N
study NN N
and CC N
was VBD N
significantly RB N
greater JJR N
for IN N
AMB NNP N
( ( N
P NNP N
= NNP N
0.02 CD N
) ) N
. . N

CONCLUSIONS NN N
At IN N
the DT N
dose NN N
used VBN N
in IN N
this DT N
study NN N
, , N
AMB NNP i
was VBD N
no DT N
more RBR N
effective JJ o
and CC N
was VBD N
more JJR N
toxic JJ o
than IN N
FLU NNP i
for IN N
prophylaxis NN N
of IN N
fungal JJ o
infections NNS o
in IN N
patients NNS p
undergoing JJ p
remission NN p
induction NN p
chemotherapy NN p
for IN p
acute JJ p
leukemia NN p
. . p

-DOCSTART- -9398110- O O

The DT N
effects NNS N
of IN N
the DT N
angiotensin-converting JJ i
enzyme NN i
inhibitor NN i
imidapril NN i
on IN N
plasma NN N
plasminogen NN N
activator NN N
inhibitor NN N
activity NN N
in IN N
patients NNS p
with IN p
acute JJ p
myocardial JJ p
infarction NN p
. . p

This DT N
study NN N
sought VBD N
to TO N
determine VB N
whether IN N
early JJ N
treatment NN N
with IN N
angiotensin-converting JJ i
enzyme NN i
( ( i
ACE NNP i
) ) i
inhibitors NNS i
in IN N
patients NNS N
with IN N
acute JJ N
myocardial JJ N
infarction NN N
( ( N
AMI NNP N
) ) N
is VBZ N
useful JJ N
for IN N
the DT N
improvement NN N
of IN N
fibrinolytic JJ o
function NN o
, , N
as RB N
well RB N
as IN N
left VBN o
ventricular JJ o
function NN o
. . o

This DT N
study NN N
was VBD N
designed VBN N
to TO N
examine VB N
the DT N
levels NNS N
of IN N
plasma NN o
plasminogen NN o
activator NN o
inhibitor NN o
( ( o
PAI NNP o
) ) o
activity NN o
and CC N
serum JJ o
ACE NNP o
activity NN o
during IN N
the DT N
course NN N
of IN N
2 CD N
weeks NNS N
in IN N
40 CD p
patients NNS p
with IN p
AMI NNP p
within IN p
12 CD p
hours NNS p
after IN p
the DT p
onset NN p
of IN p
the DT p
symptom NN p
and CC p
who WP p
randomly VBP p
received VBN p
early JJ p
treatment NN p
with IN p
either CC p
the DT p
ACE NNP i
inhibitor NN i
imidapril NN i
or CC i
a DT i
placebo NN i
( ( p
20 CD p
patients NNS p
in IN p
the DT p
imidapril NN p
group NN p
and CC p
20 CD p
in IN p
the DT p
placebo NN p
group NN p
) ) p
. . p

The DT N
levels NNS o
of IN o
serum JJ o
ACE NNP o
activity NN o
in IN N
the DT N
imidapril NN i
group NN N
decreased VBD N
significantly RB N
( ( N
p JJ N
< NNP N
0.01 CD N
) ) N
8 CD N
hours NNS N
after IN N
the DT N
administration NN N
of IN N
imidapril NN i
, , N
and CC N
the DT N
levels NNS N
24 CD N
hours NNS N
after IN N
administration NN N
were VBD N
significantly RB N
lower JJR N
than IN N
those DT N
in IN N
the DT N
placebo NN i
group NN N
( ( N
3.6 CD N
+/- JJ N
0.6 CD N
IU/L NNP N
vs VBD N
7.4 CD N
+/- JJ N
0.8 CD N
IU/L NNP N
; : N
p VBZ N
< $ N
0.001 CD N
) ) N
. . N

The DT N
plasma JJ o
PAI NNP o
activity NN o
increased VBD N
gradually RB N
to TO N
peak VB N
levels NNS N
16 CD N
hours NNS N
after IN N
the DT N
administration NN N
of IN N
imidapril NN N
and CC N
placebo NN N
. . N

The DT N
levels NNS N
in IN N
the DT N
placebo NN N
group NN N
decreased VBD N
gradually RB N
but CC N
remained VBD N
high JJ N
during IN N
the DT N
study NN N
period NN N
. . N

On IN N
the DT N
other JJ N
hand NN N
, , N
the DT N
levels NNS o
of IN o
PAI NNP o
activity NN o
in IN N
the DT N
imidapril NN i
group NN N
decreased VBD N
rapidly RB N
and CC N
those DT N
48 CD N
hours NNS N
after IN N
administration NN N
were VBD N
significantly RB N
lower JJR N
than IN N
those DT N
in IN N
the DT N
placebo NN i
group NN N
( ( N
7.9 CD N
+/- JJ N
1.9 CD N
IU/ml NNP N
vs VBD N
18.4 CD N
+/- JJ N
3.5 CD N
IU/ml NNP N
; : N
p VBZ N
< $ N
0.01 CD N
) ) N
. . N

The DT N
levels NNS o
of IN o
left JJ o
ventricular JJ o
ejection NN o
fraction NN o
about IN N
2 CD N
weeks NNS N
after IN N
admission NN N
were VBD N
significantly RB N
higher JJR N
in IN N
the DT N
imidapril NN N
group NN N
than IN N
in IN N
the DT N
placebo NN i
group NN N
( ( N
65.9 CD N
% NN N
+/- JJ N
2.5 CD N
% NN N
vs JJ N
49.1 CD N
% NN N
+/- JJ N
4.4 CD N
% NN N
; : N
p CC N
< VB N
0.01 CD N
) ) N
. . N

This DT N
study NN N
showed VBD N
that IN N
imidapril NN i
, , N
an DT N
ACE NNP N
inhibitor NN N
, , N
might MD N
be VB N
useful JJ N
for IN N
the DT N
improvement NN N
of IN N
fibrinolytic JJ o
function NN o
and CC N
left VBD o
ventricular JJ o
function NN o
in IN N
the DT N
acute JJ N
phase NN N
of IN N
myocardial JJ N
infarction NN N
. . N

-DOCSTART- -15283485- O O

Long-term JJ o
quality NN o
of IN o
life NN o
measures NNS N
after IN N
functional JJ N
endoscopic NN N
sinus NN N
surgery NN N
. . N

BACKGROUND NNP N
Chronic NNP p
rhinosinusitis NN p
( ( p
CRS NNP p
) ) p
is VBZ N
a DT N
common JJ N
disease NN N
that WDT N
has VBZ N
a DT N
significant JJ N
impact NN N
on IN N
quality NN o
of IN o
life NN o
( ( N
QOL NNP N
) ) N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
longer-term JJ N
effects NNS N
of IN N
combined JJ N
medical JJ N
and CC N
surgical JJ i
therapy NN i
for IN i
CRS NNP i
on IN N
overall JJ N
health NN N
status NN N
and CC N
QOL NNP N
. . N

METHODS NNP N
We PRP N
used VBD N
a DT N
prospective JJ N
study NN N
that WDT N
utilized VBD N
the DT N
Short-Form NNP i
36 CD i
Survey NNP i
at IN N
baseline JJ i
presentation NN i
and CC N
at IN N
a DT N
mean JJ i
time NN i
of IN i
3 CD i
years NNS i
post-functional JJ i
endoscopic NN i
sinus NN i
surgery NN i
to TO N
assess VB N
the DT N
general JJ N
health NN N
status NN N
of IN N
patients NNS p
who WP p
presented VBD p
for IN p
their PRP$ p
initial JJ p
visitfrom NN p
1996 CD p
to TO p
1998 CD p
. . p

Of IN N
the DT N
200 CD p
randomly RB p
selected VBN p
patients NNS p
, , N
150 CD N
respondents NNS N
completed VBN N
follow-up JJ N
surveys NNS N
( ( N
a DT N
75 CD N
% NN N
response NN N
rate NN N
) ) N
. . N

RESULTS JJ N
Eighty-nine JJ p
( ( p
59.3 CD p
% NN p
) ) p
women NNS p
and CC p
61 CD p
( ( p
40.7 CD p
% NN p
) ) p
men NNS p
were VBD N
included VBN N
in IN N
the DT N
study NN N
. . N

Baseline NNP o
QOL NNP o
scores NNS o
indicated VBD N
significant JJ N
differences NNS N
between IN N
patients NNS p
with IN p
CRS NNP p
and CC N
published VBN N
norms NNS N
in IN N
6/8 CD N
subscale JJ N
parameters NNS N
( ( o
role NN o
physical NN o
, , o
bodily RB o
pain NN o
, , o
general JJ o
health NN o
, , o
social JJ o
function NN o
, , o
vitality NN o
, , o
and CC o
mental JJ o
health NN o
) ) o
. . N

Significant JJ N
improvement NN N
in IN N
all DT N
six CD N
categories NNS N
was VBD N
maintained VBN N
at IN N
the DT N
end NN N
of IN N
the DT N
study NN N
period NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
with IN N
QOL NNP o
scores NNS o
within IN N
limits NNS N
of IN N
published VBN N
norms NNS N
for IN N
the DT N
general JJ N
population NN N
. . N

CONCLUSION NNP N
Our PRP$ N
data NNS N
indicate VBP N
that IN N
functional JJ i
endoscopic NN i
sinus NN i
surgery NN i
, , N
combined VBN N
with IN N
appropriate JJ N
postoperative JJ N
care NN N
, , N
is VBZ N
effective JJ N
at IN N
maintaining VBG N
a DT N
significant JJ N
improvement NN N
in IN N
the DT N
overall JJ N
general JJ N
health NN N
status NN N
of IN N
patients NNS N
for IN N
at IN N
least JJS N
3 CD N
years NNS N
after IN N
surgical JJ N
intervention NN N
and CC N
that IN N
the DT N
overall JJ N
scores NNS N
return VBP N
to TO N
a DT N
range NN N
of IN N
normative JJ N
values NNS N
for IN N
the DT N
general JJ N
population NN N
. . N

-DOCSTART- -16540862- O O

A DT N
randomized JJ N
trial NN N
of IN N
chiropractic JJ i
and CC i
medical JJ i
care NN i
for IN N
patients NNS p
with IN p
low JJ o
back RB o
pain NN o
: : o
eighteen-month JJ N
follow-up JJ N
outcomes NNS N
from IN N
the DT N
UCLA NNP N
low JJ N
back RB N
pain NN N
study NN N
. . N

STUDY NNP N
DESIGN NNP N
Randomized NNP N
clinical JJ N
trial NN N
. . N

OBJECTIVES UH N
To TO N
compare VB N
the DT N
long-term JJ N
effectiveness NN N
of IN N
medical JJ i
and CC i
chiropractic JJ i
care NN i
for IN i
low JJ i
back RB i
pain NN i
in IN p
managed VBN p
care NN p
and CC N
to TO N
assess VB N
the DT N
effectiveness NN N
of IN N
physical JJ i
therapy NN i
and CC N
modalities NNS N
among IN N
patients NNS p
receiving VBG p
medical JJ i
or CC i
chiropractic JJ i
care NN i
. . i

SUMMARY NNP N
OF IN N
BACKGROUND NNP N
DATA NNP N
Evidence NNP N
comparing VBG N
the DT N
long-term JJ N
relative JJ N
effectiveness NN N
of IN N
common JJ N
treatment NN N
strategies NNS N
offered VBD N
to TO N
low VB p
back RB p
pain NN p
patients NNS p
in IN N
managed VBN N
care NN N
is VBZ N
lacking VBG N
. . N

METHODS NNP N
A NNP p
total NN p
of IN p
681 CD p
low JJ p
back RB p
pain NN p
patients NNS p
presenting VBG p
to TO p
a DT p
managed-care JJ p
facility NN p
were VBD N
randomized VBN N
to TO N
chiropractic VB i
with IN i
or CC i
without IN i
physical JJ i
modalities NNS i
, , i
or CC i
medical JJ i
care NN i
with IN i
or CC i
without IN i
physical JJ i
therapy NN i
, , N
and CC N
followed VBD N
for IN N
18 CD N
months NNS N
. . N

The DT N
primary JJ N
outcome NN N
variables NNS N
are VBP N
low JJ o
back RB o
pain NN o
intensity NN o
, , o
disability NN o
, , o
and CC o
complete JJ o
remission NN o
. . o

The DT N
secondary JJ N
outcome NN N
is VBZ N
participants NNS o
' POS o
perception NN o
of IN o
improvement NN o
in IN o
low JJ o
back RB o
symptoms NNS o
. . o

RESULTS NNP N
Of IN N
the DT N
681 CD p
patients NNS p
, , p
610 CD p
( ( p
89.6 CD p
% NN p
) ) p
were VBD p
followed VBN p
through IN p
18 CD p
months NNS p
. . p

Among IN N
participants NNS N
not RB N
assigned VBN N
to TO N
receive VB N
physical JJ N
therapy NN N
or CC N
modalities NNS N
, , N
the DT N
estimated JJ N
improvements NNS N
in IN N
pain NN o
and CC o
disability NN o
and CC N
18-month JJ N
risk NN o
of IN o
complete JJ o
remission NN o
were VBD N
a DT N
little JJ N
greater JJR N
in IN N
the DT N
chiropractic JJ N
group NN N
than IN N
in IN N
the DT N
medical JJ N
group NN N
( ( N
adjusted VBN N
RR NNP N
of IN N
remission NN N
= NNP N
1.29 CD N
; : N
95 CD N
% NN N
CI NNP N
= NNP N
0.80-2.07 NN N
) ) N
. . N

Among IN N
participants NNS N
assigned VBN N
to TO N
medical JJ N
care NN N
, , N
mean JJ o
changes NNS o
in IN o
pain NN o
and CC o
disability NN o
and CC o
risk NN o
of IN o
remission NN o
were VBD N
larger JJR N
in IN N
patients NNS N
assigned VBN N
to TO N
receive VB N
physical JJ i
therapy NN i
( ( N
adjusted VBN N
RR NNP N
= NNP N
1.69 CD N
; : N
95 CD N
% NN N
CI NNP N
= NNP N
1.08-2.66 JJ N
) ) N
. . N

Among IN N
those DT N
assigned VBN N
to TO N
chiropractic JJ i
care NN i
, , N
however RB N
, , N
assignment NN N
to TO N
methods NNS N
was VBD N
not RB N
associated VBN N
with IN N
improvement NN N
or CC N
remission NN N
( ( N
adjusted VBN N
RR NNP N
= NNP N
0.98 CD N
; : N
95 CD N
% NN N
CI NNP N
= NNP N
0.62-1.55 NN N
) ) N
. . N

Compared VBN N
with IN N
medical JJ N
care NN N
only RB N
patients NNS N
, , N
chiropractic JJ i
and CC N
physical JJ N
therapy NN N
patients NNS N
were VBD N
much RB N
more RBR N
likely JJ N
to TO N
perceive VB N
improvement NN N
in IN N
their PRP$ N
low JJ N
back RB N
symptoms NNS N
. . N

However RB N
, , N
less JJR N
than IN N
20 CD N
% NN N
of IN N
all DT N
patients NNS N
were VBD N
pain-free JJ o
at IN N
18 CD N
months NNS N
. . N

CONCLUSIONS NNP N
Differences NNPS N
in IN N
outcomes NNS N
between IN N
medical JJ i
and CC i
chiropractic JJ i
care NN i
without IN N
physical JJ N
therapy NN N
or CC N
modalities NNS N
are VBP N
not RB N
clinically RB N
meaningful JJ N
, , N
although IN N
chiropractic JJ N
may MD N
result VB N
in IN N
a DT N
greater JJR N
likelihood NN N
of IN N
perceived JJ N
improvement NN N
, , N
perhaps RB N
reflecting VBG N
satisfaction NN N
or CC N
lack NN N
of IN N
blinding NN N
. . N

Physical JJ i
therapy NN i
may MD N
be VB N
more RBR N
effective JJ N
than IN N
medical JJ N
care NN N
alone RB N
for IN N
some DT N
patients NNS N
, , N
while IN N
physical JJ N
modalities NNS N
appear VBP N
to TO N
have VB N
no DT N
benefit NN N
in IN N
chiropractic JJ N
care NN N
. . N

-DOCSTART- -25284194- O O

Selenium NNP i
Treatment NNP i
and CC i
Chagasic NNP i
Cardiopathy NNP i
( ( i
STCC NNP i
) ) i
: : i
study NN N
protocol NN N
for IN N
a DT N
double-blind JJ N
randomized NN N
controlled VBD N
trial NN N
. . N

BACKGROUND NNP N
Heart NNP N
disease NN N
progression NN N
occurs VBZ N
in IN N
30 CD N
% NN N
of IN N
patients NNS N
with IN N
chronic JJ N
Trypanosoma NNP N
cruzi NN N
infection NN N
. . N

Supplementation NN N
with IN N
selenium NN N
( ( N
Se NNP N
) ) N
in IN N
animal JJ N
model NN N
of IN N
T. NNP N
cruzi NN N
infection NN N
produced VBD N
promising JJ N
results NNS N
. . N

There EX N
is VBZ N
evidence NN N
that IN N
patients NNS p
with IN p
Chagas NNP p
heart NN p
disease NN p
have VBP N
lower JJR N
Se NNP N
levels NNS N
than IN N
healthy JJ N
individuals NNS N
and CC N
patients NNS N
with IN N
T. NNP N
cruzi NN N
infection NN N
without IN N
of IN N
cardiac JJ N
disease NN N
. . N

The DT N
aim NN N
of IN N
this DT N
investigation NN N
is VBZ N
to TO N
estimate VB N
the DT N
effect NN N
of IN N
Se NNP i
treatment NN i
on IN N
prevention NN N
of IN N
heart NN N
disease NN N
progression NN N
in IN N
patients NNS p
with IN p
chagasic JJ p
cardiopathy NN p
. . p

METHODS NNP N
The DT N
Selenium NNP N
Treatment NNP N
and CC N
Chagasic NNP N
Cardiopathy NNP N
trial NN N
is VBZ N
a DT N
superiority NN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
, , N
randomized JJ N
clinical JJ N
trial NN N
. . N

The DT N
eligibility NN N
criteria NNS N
are VBP N
as IN N
follows VBZ N
: : N
( ( p
1 CD p
) ) p
a DT p
Chagas NNP p
disease NN p
diagnosis NN p
confirmed VBN p
by IN p
serology NN p
; : p
( ( p
2 CD p
) ) p
segmental NN p
, , p
mild NN p
or CC p
moderate VB p
global JJ p
left NN p
ventricular JJ p
systolic JJ p
dysfunction NN p
; : p
and CC p
( ( p
3 CD p
) ) p
age NN p
between IN p
18 CD p
and CC p
65 CD p
years NNS p
. . p

The DT N
exclusion NN p
criteria NNS p
are VBP p
as IN p
follows VBZ p
: : p
( ( p
1 CD p
) ) p
pregnancy NN p
, , p
( ( p
2 CD p
) ) p
diabetes VBZ p
mellitus NN p
, , p
( ( p
3 CD p
) ) p
tobacco NN p
use NN p
, , p
( ( p
4 CD p
) ) p
alcohol NN p
abuse NN p
, , p
( ( p
5 CD p
) ) p
evidence NN p
of IN p
nonchagasic JJ p
heart NN p
disease NN p
, , p
( ( p
6 CD p
) ) p
depression NN p
, , p
( ( p
7 CD p
) ) p
dysphagia NN p
with IN p
evidence NN p
of IN p
food NN p
residues NNS p
in IN p
the DT p
esophagus NN p
, , p
( ( p
8 CD p
) ) p
dysphagia NN p
with IN p
weight JJ p
loss NN p
higher JJR p
than IN p
15 CD p
% NN p
of IN p
usual JJ p
weight NN p
in IN p
the DT p
last JJ p
four CD p
months NNS p
and/or RB p
( ( p
9 CD p
) ) p
conditions NNS p
that WDT p
may MD p
result VB p
in IN p
low JJ p
protocol NN p
adherence NN p
. . p

The DT N
intervention NN N
will MD N
be VB N
100 CD i
?g NNP i
of IN i
sodium NN i
selenite NN i
once RB i
daily JJ i
for IN i
365 CD i
consecutive JJ i
days NNS i
compared VBN i
to TO i
placebo VB i
. . i

The DT N
following VBG N
are VBP N
the DT N
primary JJ N
outcomes NNS N
to TO N
be VB N
measured VBN o
: : o
( ( o
1 CD o
) ) o
the DT o
trajectories NNS o
of IN o
the DT o
left NN o
ventricular JJ o
ejection NN o
fraction NN o
in IN o
the DT o
follow-up JJ o
period NN o
; : o
( ( o
2 CD o
) ) o
reduction NN o
of IN o
heart NN o
disease NN o
progression NN o
rates NNS o
, , o
with IN o
progression NN o
defined VBN o
as IN o
a DT o
10 CD o
% NN o
decrease NN o
in IN o
left JJ o
ventricular JJ o
ejection NN o
fraction NN o
; : o
and CC o
( ( o
3 CD o
) ) o
rate NN o
of IN o
hospital NN o
admissions NNS o
attributable JJ o
to TO o
dysrhythmia VB o
, , o
heart NN o
failure NN o
or CC o
stroke NN o
due JJ o
to TO o
Chagas NNP o
disease NN o
. . o

One CD N
hundred VBD N
thirty NN N
patients NNS N
will MD N
be VB N
randomly RB N
allocated VBN N
into IN N
either CC N
the DT N
intervention NN N
or CC N
placebo NN N
group NN N
at IN N
a DT N
ratio NN N
of IN N
1:1 CD N
. . N

The DT N
sequence NN N
allocation NN N
concealment NN N
and CC N
blinding NN N
were VBD N
planned VBN N
to TO N
be VB N
conducted VBN N
with IN N
the DT N
strategy NN N
of IN N
numbered JJ N
boxes NNS N
. . N

Both DT N
patients NNS N
and CC N
health-care JJ N
providers NNS N
will MD N
remain VB N
blinded JJ N
to TO N
the DT N
intervention NN N
groups NNS N
during IN N
the DT N
5 CD N
years NNS N
of IN N
follow-up NN N
. . N

DISCUSSION NNP N
If IN N
Se NNP N
treatment NN N
reduces VBZ N
the DT o
progression NN o
of IN o
Chagas NNP o
cardiopathy NN o
, , o
the DT N
inclusion NN N
of IN N
this DT N
micronutrient NN N
in IN N
the DT N
daily JJ N
diet NN N
can MD N
improve VB N
the DT N
therapeutic JJ N
regimen NNS N
for IN N
this DT N
neglected JJ N
tropical JJ N
disease NN N
at IN N
low JJ N
cost NN N
. . N

TRIAL NNP N
REGISTRATION NNP N
Clinical NNP N
Trials.gov NNP N
ID NNP N
: : N
NCT00875173 NNP N
( ( N
registered VBD N
20 CD N
October NNP N
20 CD N
2008 CD N
) ) N
. . N

-DOCSTART- -25015354- O O

Safety NNP N
assessment NN N
of IN N
docosahexaenoic NN i
acid NN i
in IN N
X-linked JJ p
retinitis NN p
pigmentosa NN p
: : p
the DT N
4-year JJ N
DHAX NNP N
trial NN N
. . N

PURPOSE NNP N
Docosahexaenoic NNP N
acid NN N
( ( N
DHA NNP N
) ) N
continues VBZ N
to TO N
be VB N
evaluated VBN N
and CC N
recommended VBN N
as IN N
treatment NN N
and CC N
prophylaxis NN N
for IN N
various JJ N
diseases NNS N
. . N

We PRP N
recently RB N
assessed VBD N
efficacy NN N
of IN N
high-dose JJ N
DHA NNP N
supplementation NN N
to TO N
slow VB N
vision NN o
loss NN o
in IN N
patients NNS p
with IN p
X-linked JJ p
retinitis NN p
pigmentosa NN p
( ( p
XLRP NNP p
) ) p
in IN N
a DT N
randomized JJ N
clinical JJ N
trial NN N
. . N

Because IN N
DHA NNP N
is VBZ N
a DT N
highly RB N
unsaturated JJ N
fatty JJ N
acid NN N
, , N
it PRP N
could MD N
serve VB N
as IN N
a DT N
target NN N
for IN N
free-radical JJ N
induced JJ N
oxidation NN N
, , N
resulting VBG N
in IN N
increased VBN N
oxidative JJ N
stress NN N
. . N

Biosafety NNP o
was VBD N
monitored VBN N
during IN N
the DT N
4-year JJ N
trial NN N
to TO N
determine VB N
whether IN N
DHA NNP N
supplementation NN N
was VBD N
associated VBN N
with IN N
identifiable JJ N
risks NNS N
. . N

METHODS NNP N
Males NNP p
( ( p
n JJ p
= VBZ p
78 CD p
; : p
7-31 CD p
years NNS p
) ) p
meeting NN p
entry NN p
criteria NNS p
were VBD p
enrolled VBN p
. . p

The DT N
modified JJ N
intent-to-treat JJ N
cohort NN N
( ( N
DHA NNP N
= NNP N
33 CD N
; : N
placebo NN i
= VBZ N
27 CD N
) ) N
adhered VBD N
to TO N
the DT N
protocol NN N
? . N
1 CD N
year NN N
. . N

Participants NNS N
were VBD N
randomized VBN N
to TO N
an DT N
oral JJ N
dose NN N
of IN N
30 CD i
mg/kg/d NNS i
DHA NNP i
or CC i
placebo VB i
plus CC i
a DT N
daily JJ N
multivitamin NN N
. . N

Comprehensive NNP N
metabolic JJ N
analyses NNS N
were VBD N
assessed VBN N
for IN N
group NN N
differences NNS N
. . N

Treatment-emergent JJ o
adverse JJ o
events NNS o
including VBG o
blood NN o
chemistry NN o
metabolites NNS o
were VBD o
recorded VBN N
. . N

RESULTS VBN N
By IN N
year NN N
4 CD N
, , N
supplementation NN o
elevated VBD o
plasma NN o
and CC o
red JJ o
blood NN o
cell-DHA JJ o
4.4- JJ o
and CC o
3.6-fold JJ N
, , N
respectively RB N
, , N
compared VBN N
with IN N
the DT N
placebo NN N
group NN N
( ( N
P NNP N
< NNP N
0.00001 CD N
) ) N
. . N

Over IN N
the DT N
trial NN N
duration NN N
, , N
no DT N
significant JJ N
differences NNS N
between IN N
DHA NNP N
and CC N
placebo NN N
groups NNS N
were VBD N
found VBN N
for IN o
vitamin NN o
A NNP o
, , o
vitamin NN o
E NNP o
, , o
platelet NN o
aggregation NN o
, , o
antioxidant JJ o
activity NN o
, , o
lipoprotein NN o
cholesterol NN o
, , o
or CC o
oxidized VBN o
LDL NNP o
levels NNS o
( ( o
all DT N
P NNP N
> NNP N
0.14 CD o
) ) o
. . o

Adverse JJ o
events NNS o
were VBD o
transient JJ N
and CC o
not RB o
considered VBN o
severe JJ o
( ( o
e.g. JJ N
, , N
gastrointestinal JJ o
[ NN o
GI NNP o
] NNP o
irritability NN o
, , o
blood NN o
chemistry NN o
alterations NNS o
) ) o
. . o

One CD N
participant NN N
was VBD N
unable JJ N
to TO N
tolerate VB o
persistent JJ o
GI NNP o
discomfort NN o
. . o

CONCLUSIONS NNP N
Long-term NNP N
, , N
high-dose JJ N
DHA NNP N
supplementation NN N
to TO N
patients NNS p
with IN p
XLRP NNP p
was VBD p
associated VBN N
with IN o
limited JJ o
safety NN o
risks NNS o
in IN o
this DT N
4-year JJ N
trial NN N
. . N

Nevertheless NNP o
, , o
GI NNP o
symptoms NNS o
should MD o
be VB N
monitored VBN N
in IN N
all DT N
patients NNS N
taking VBG N
high JJ N
dose JJ N
DHA NNP N
especially RB N
those DT N
with IN N
personal JJ N
or CC N
family NN N
history NN N
of IN N
GI NNP N
disturbances NNS N
. . N

( ( N
ClinicalTrials.gov NNP N
number NN N
, , N
NCT00100230 NNP N
. . N

) ) N
. . N

-DOCSTART- -25102328- O O

A DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
pilot NN N
study NN N
of IN N
naltrexone NN i
to TO N
counteract VB N
antipsychotic-associated JJ o
weight JJ o
gain NN o
: : o
proof NN N
of IN N
concept NN N
. . N

Patients NNS p
with IN p
schizophrenia JJ p
experience NN N
higher JJR N
rates NNS N
of IN N
obesity NN N
as RB N
well RB N
as IN N
related JJ N
morbidity NN N
and CC N
mortality NN N
than IN N
the DT N
general JJ N
population NN N
does VBZ N
. . N

Women VB p
with IN p
schizophrenia NN p
are VBP N
at IN N
particular JJ N
risk NN N
for IN N
antipsychotic-associated JJ o
weight NN o
gain NN o
, , o
obesity NN o
, , o
and CC o
related JJ o
medical JJ o
disorders NNS o
such JJ N
as IN N
diabetes NNS o
and CC N
cardiovascular JJ o
disease NN o
. . o

Given NNP N
preclinical JJ N
studies NNS N
revealing VBG N
the DT N
role NN N
of IN N
the DT N
endogenous JJ N
opioid JJ N
systems NNS N
in IN N
human JJ N
appetite NN N
and CC N
the DT N
potential NN N
of IN N
antipsychotic JJ N
medications NNS N
to TO N
interfere VB N
with IN N
this DT N
system NN N
, , N
we PRP N
hypothesized VBD N
that IN N
opioid JJ N
antagonists NNS N
may MD N
be VB N
beneficial JJ N
in IN N
arresting VBG N
antipsychotic-associated JJ o
weight NN o
gain NN o
and CC N
promoting VBG N
further JJ N
weight JJ o
loss NN o
in IN N
women NNS N
with IN N
schizophrenia NN N
. . N

In IN N
the DT N
present JJ N
study NN N
, , N
24 CD p
overweight JJ p
women NNS p
with IN p
a DT p
diagnosis NN p
of IN p
schizophrenia NN p
or CC p
schizoaffective JJ p
disorder NN p
were VBD N
randomized VBN N
to TO N
placebo VB i
or CC i
naltrexone VB i
( ( i
NTX NNP i
) ) i
25 CD N
mg/d NN N
for IN N
8 CD N
weeks NNS N
. . N

The DT N
primary JJ N
outcome NN N
measure NN N
was VBD N
a DT N
change NN o
in IN o
body NN o
weight NN o
from IN o
baseline NN o
. . o

The DT N
patients NNS N
in IN N
the DT N
NTX NNP N
group NN N
had VBD N
significant JJ o
weight JJ o
loss NN o
( ( N
-3.40 JJ N
kg NN N
) ) N
compared VBN N
with IN N
weight JJ o
gain NN o
( ( N
+1.37 NNP N
kg NN N
) ) N
in IN N
the DT N
patients NNS N
in IN N
the DT N
placebo NN N
group NN N
. . N

Mainly RB N
, , N
nondiabetic JJ N
subjects NNS N
lost VBN o
weight NN o
in IN N
the DT N
NTX NNP N
arm NN N
. . N

These DT N
data NNS N
support NN N
the DT N
need NN N
to TO N
further VB N
investigate VB N
the DT N
role NN N
of IN N
D2 NNP N
blockade NN N
in IN N
reducing VBG N
food NN o
reward-based JJ o
overeating NN o
. . o

A NNP N
larger JJR N
study NN N
addressing VBG N
the DT N
weaknesses NNS N
of IN N
this DT N
pilot NN N
study NN N
is VBZ N
currently RB N
underway JJ N
. . N

-DOCSTART- -21664757- O O

Positive JJ N
impact NN N
of IN N
crisis NN i
resource NN i
management NN i
training NN i
on IN N
no-flow JJ N
time NN N
and CC N
team NN N
member NN N
verbalisations NNS N
during IN N
simulated JJ i
cardiopulmonary JJ i
resuscitation NN i
: : i
a DT N
randomised JJ N
controlled VBN N
trial NN N
. . N

OBJECTIVES UH N
To TO N
evaluate VB N
the DT N
impact NN N
of IN N
video-based JJ i
interactive JJ i
crisis NN i
resource NN i
management NN i
( ( i
CRM NNP i
) ) i
training VBG i
on IN N
no-flow JJ o
time NN o
( ( o
NFT NNP o
) ) o
and CC N
on IN N
proportions NNS N
of IN N
team NN o
member NN o
verbalisations NNS o
( ( o
TMV NNP o
) ) o
during IN N
simulated VBN i
cardiopulmonary JJ i
resuscitation NN i
( ( i
CPR NNP i
) ) i
. . N

Further UH N
, , N
to TO N
investigate VB N
the DT N
link NN N
between IN N
team NN N
leader NN N
verbalisation NN N
accuracy NN N
and CC N
NFT NNP N
. . N

METHODS NNP N
The DT N
randomised VBN N
controlled VBD N
study NN N
was VBD N
embedded VBN N
in IN N
the DT N
obligatory NN N
advanced VBD N
life NN N
support NN N
( ( N
ALS NNP N
) ) N
course NN N
for IN N
final-year JJ p
medical JJ p
students NNS p
. . p

Students NNS p
( ( p
176 CD p
; : p
25.35?1.03 CD p
years NNS p
, , p
63 CD p
% NN p
female NN p
) ) p
were VBD N
alphabetically RB N
assigned VBN N
to TO p
44 CD p
four-person JJ p
teams NNS p
that WDT N
were VBD N
then RB N
randomly RB N
( ( N
computer-generated JJ N
) ) N
assigned VBN N
to TO N
either DT i
CRM NNP i
intervention NN i
( ( N
n=26 JJ N
) ) N
, , N
receiving VBG i
interactive JJ i
video-based JJ i
CRM-training NN i
, , i
or CC i
to TO i
control VB i
intervention NN i
( ( i
n=18 JJ i
) ) i
, , i
receiving VBG i
an DT i
additional JJ i
ALS-training NN i
. . i

Primary JJ N
outcomes NNS N
were VBD o
NFT NNP o
and CC o
proportions NNS o
of IN o
TMV NNP o
, , o
which WDT N
were VBD N
subdivided VBN N
into IN N
eight CD N
categories NNS N
: : N
four CD N
team NN N
leader NN N
verbalisations NNS N
( ( N
TLV NNP N
) ) N
with IN N
different JJ N
accuracy NN N
levels NNS N
and CC N
four CD N
follower JJR N
verbalisation NN N
categories NNS N
( ( N
FV NNP N
) ) N
. . N

Measurements NNS N
were VBD N
made VBN N
of IN p
all DT p
groups NNS p
administering VBG p
simulated JJ p
adult NN p
CPR NNP p
. . p

RESULTS NNP o
NFT NNP o
rates NNS o
were VBD N
significantly RB N
lower JJR N
in IN N
the DT N
CRM-training NNP N
group NN N
( ( N
31.4?6.1 CD N
% NN N
vs. FW N
36.3?6.6 CD N
% NN N
, , N
p=0.014 NN N
) ) N
. . N

Proportions NNS N
of IN N
all DT N
TLV NNP o
categories NNS o
were VBD N
higher JJR N
in IN N
the DT N
CRM-training NNP N
group NN N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
. . N

Differences NNS N
in IN N
FV NNP N
were VBD N
only RB N
found VBN N
for IN N
one CD N
category NN N
( ( N
unsolicited JJ N
information NN N
) ) N
( ( N
p=0.012 NN N
) ) N
. . N

The DT N
highest JJS o
correlation NN o
with IN o
NFT NNP o
was VBD o
found VBN N
for IN N
high JJ o
accuracy NN o
TLV NNP o
( ( o
direct JJ o
orders NNS N
) ) N
( ( N
p=0.06 NN N
) ) N
. . N

CONCLUSIONS VB N
The DT N
inclusion NN N
of IN N
CRM NNP i
training NN i
in IN i
undergraduate JJ N
medical JJ N
education NN N
reduces NNS N
NFT NNP N
in IN N
simulated JJ i
CPR NNP i
and CC i
improves VBZ N
TLV NNP N
proportions NNS N
during IN i
simulated JJ i
CPR NNP i
. . i

Further NNP i
research NN N
will MD N
test VB N
how WRB N
these DT N
results NNS N
translate VBP N
into IN N
clinical JJ N
performance NN N
and CC N
patient JJ N
outcome NN N
. . N

-DOCSTART- -10637238- O O

Comparison NNP N
of IN N
chemotherapy NN i
with IN i
chemohormonal JJ i
therapy NN i
as IN N
first-line JJ N
therapy NN N
for IN N
metastatic JJ p
, , p
hormone-sensitive JJ p
breast NN p
cancer NN p
: : p
An DT p
Eastern JJ p
Cooperative NNP p
Oncology NNP p
Group NNP p
study NN p
. . p

PURPOSE NNP N
Although IN N
hormonal JJ N
therapy NN N
represents VBZ N
standard JJ N
therapy NN N
for IN N
metastatic JJ N
hormone-sensitive JJ N
disease NN N
, , N
many JJ N
patients NNS N
receive VBP N
initial JJ N
chemotherapy NN i
because IN N
of IN N
the DT N
location NN N
, , N
bulk NN N
, , N
or CC N
aggressiveness NN N
of IN N
their PRP$ N
disease NN N
. . N

It PRP N
is VBZ N
uncertain JJ N
whether IN N
simultaneous JJ i
hormonal JJ i
therapy NN i
provides VBZ N
additional JJ N
benefit NN N
compared VBN N
with IN N
chemotherapy NN N
alone RB N
. . N

Eastern JJ N
Cooperative NNP N
Oncology NNP N
Group NNP N
trial NN N
E3186 NNP N
was VBD N
initiated VBN N
to TO N
explore VB N
this DT N
question NN N
. . N

PATIENTS NN N
AND CC N
METHODS NNP N
Between NNP p
January NNP p
1988 CD p
and CC p
December NNP p
1992 CD p
, , p
231 CD p
patients NNS p
with IN p
estrogen JJ p
receptor NN p
( ( p
ER NNP p
) ) p
-positive CD p
or CC p
ER-unknown JJ p
metastatic JJ p
breast NN p
cancer NN p
were VBD N
randomized VBN N
to TO N
receive VB N
either DT N
chemotherapy NN i
( ( i
cyclophosphamide NN i
, , i
doxorubicin NN i
, , i
and CC i
fluorouracil RB i
?CAF NNP i
) ) i
or CC i
chemohormonal JJ i
therapy NN i
( ( i
CAF NNP i
plus CC i
tamoxifen NN i
and CC i
Halotestin NNP i
?fluoxymesterone NN i
; : i
Pharmacia-Upjohn NNP i
, , i
Kalamazoo NNP i
, , i
MI NNP i
?CAFTH NNP i
) ) i
as IN i
front-line JJ i
therapy NN i
for IN i
metastatic JJ N
breast NN N
cancer NN N
. . N

Patients NNS N
who WP N
experienced VBD N
a DT N
complete JJ N
response NN N
to TO N
induction NN N
therapy NN N
either CC N
received VBD N
or CC N
did VBD N
not RB N
receive JJ N
maintenance NN N
cyclophosphamide NN N
, , N
methotrexate NN N
, , N
fluorouracil NN N
, , N
prednisone NN N
, , N
and CC N
TH NNP N
as IN N
a DT N
secondary JJ N
randomization NN N
. . N

RESULTS VB N
The DT N
response NN o
rates NNS o
( ( o
complete JJ o
response NN o
and CC o
partial JJ o
response NN o
) ) o
of IN o
patients NNS N
who WP N
received VBD N
CAF NNP N
and CC N
CAFTH NNP N
were VBD N
similar JJ N
( ( N
69.2 CD N
% NN N
v JJ N
68.9 CD N
% NN N
, , N
respectively RB N
; : N
P NNP N
=.99 NNP o
) ) o
. . o

Time NN o
to TO o
treatment NN o
failure NN o
( ( o
TTF NNP o
) ) o
was VBD o
slightly RB N
longer JJR N
for IN N
patients NNS N
who WP N
received VBD N
chemohormonal JJ N
therapy NN N
compared VBN N
with IN N
chemotherapy NN N
alone RB N
patients NNS N
( ( N
13.4 CD N
months NNS N
v RB N
10.3 CD N
months NNS N
, , N
respectively RB N
; : N
P NNP N
=.087 NNP N
) ) N
, , N
and CC N
TTF NNP o
was VBD o
significantly RB N
longer RBR N
in IN N
ER-positive JJ N
compared VBN N
with IN N
ER-negative JJ N
patients NNS N
( ( N
17.4 CD N
months NNS N
v RB N
10.3 CD N
months NNS N
, , N
respectively RB N
; : N
P NNP N
=.048 NNP N
) ) N
. . N

However RB N
, , N
ER NNP N
status NN N
had VBD N
no DT N
effect NN N
on IN N
overall JJ o
survival NN o
( ( o
30.0 CD o
months NNS N
for IN N
CAF NNP N
v FW N
29.3 CD N
months NNS N
for IN N
CAFTH NNP N
) ) N
. . N

CONCLUSION NNP N
In IN N
patients NNS N
with IN N
potentially RB N
hormone-sensitive JJ N
metastatic JJ N
breast NN N
cancer NN i
, , i
chemohormonal JJ i
therapy NN i
prolongs NNS i
TTF NNP N
for IN N
ER-positive JJ N
patients NNS N
without IN N
improving VBG N
overall JJ N
survival NN N
. . N

-DOCSTART- -24564346- O O

Are NNP N
'leaky NNP o
gut NN o
' '' o
and CC N
behavior RB o
associated VBN N
with IN N
gluten NNS i
and CC i
dairy NN i
containing VBG N
diet NN N
in IN N
children NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
? . N
OBJECTIVES NNP N
Studies NNPS N
have VBP N
suggested VBN N
a DT N
link NN N
between IN N
diet JJ N
and CC N
behavior NN o
in IN N
children NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
( ( p
ASDs NNP p
) ) p
. . p

Parental JJ N
reports NNS N
of IN N
behavioral JJ N
changes NNS N
upon IN N
exposure NN N
to TO N
gluten VB N
and/or JJ N
casein NN N
are VBP N
common JJ N
in IN N
clinical JJ N
practice NN N
. . N

An DT N
association NN N
between IN N
diet JJ N
type NN N
, , N
intestinal JJ o
permeability NN o
( ( o
IP NNP o
) ) o
( ( o
'leaky JJ o
gut NN o
' '' o
) ) o
, , N
and CC N
behavior NN o
has VBZ N
been VBN N
long RB N
proposed VBN N
but CC N
not RB N
substantiated VBN N
. . N

We PRP N
explored VBD N
this DT N
possible JJ N
association NN N
in IN N
this DT N
trial NN N
. . N

METHODS NNP N
This DT N
randomized JJ N
double-blind NN N
, , N
placebo-controlled JJ N
study NN N
explored VBD N
the DT N
effects NNS N
of IN N
gluten NNS i
and CC i
milk NN i
on IN N
IP NNP N
and CC N
behavior NN N
in IN N
children NNS p
with IN p
ASDs NNP p
over IN N
a DT N
period NN N
of IN N
4 CD N
weeks NNS N
. . N

IP NNP i
assessed VBN i
by IN i
lactulose NN o
: : o
mannitol NN o
( ( o
L/M NNP o
) ) o
sugar NN o
permeability NN o
test NN o
and CC i
behavior NN i
assessed VBN i
by IN i
the DT i
Aberrant NNP o
Behavior NNP o
Checklist NNP o
and CC o
Conners NNP o
Parent NNP o
Rating NNP o
were VBD N
measured VBN N
. . N

Gastrointestinal NNP o
symptoms NNS o
in IN N
both DT N
groups NNS N
were VBD N
also RB N
monitored VBN N
. . N

RESULTS NNP N
Neither CC N
the DT N
L/M NNP o
ratio NN o
nor CC o
behavioral JJ o
scores NNS o
were VBD N
different JJ N
between IN N
groups NNS N
exposed VBN N
to TO N
gluten/dairy VB N
or CC N
placebo VB N
. . N

The DT N
changes NNS N
observed VBN N
were VBD N
noted VBN N
to TO N
be VB N
small JJ N
and CC N
not RB N
clinically RB N
significant JJ N
. . N

DISCUSSION NNP N
Our PRP$ N
study NN N
although IN N
underpowered JJ N
to TO N
show VB N
small JJ N
differences NNS N
does VBZ N
not RB N
support VB N
an DT N
association NN N
between IN N
dietary JJ N
gluten/milk NN N
, , N
IP NNP o
, , N
and CC N
behavioral JJ o
changes NNS o
in IN N
subjects NNS p
with IN p
ASD NNP p
. . p

-DOCSTART- -19807791- O O

Mediterranean NNP i
diet NN i
and CC i
high JJ i
dietary JJ i
acid NN i
load NN i
associated VBN N
with IN N
mixed JJ i
nuts NNS i
: : i
effect NN o
on IN N
bone NN o
metabolism NN o
in IN N
elderly JJ p
subjects NNS p
. . p

OBJECTIVES NNP N
To TO N
analyze VB N
the DT N
effect NN N
of IN N
differing VBG N
diet NN N
on IN N
the DT N
acid JJ N
load NN N
content NN N
on IN N
bone NN o
metabolism NN o
. . o

DESIGN NNP N
Multicentric NNP N
, , N
randomized VBD N
, , N
single-blind JJ N
, , N
parallel-group JJ N
clinical JJ N
trial NN N
. . N

SETTING NN N
Outpatient JJ p
clinics NNS p
. . p

PARTICIPANTS VB N
Two CD p
hundred CD p
thirty-eight JJ p
elderly JJ p
men NNS p
and CC p
women NNS p
aged VBD p
60 CD p
to TO p
80 CD p
at IN p
high JJ p
risk NN p
for IN p
cardiovascular JJ p
disease NN p
were VBD N
randomly RB N
assigned VBN N
to TO N
three CD N
interventional JJ N
groups NNS N
: : N
a DT N
recommended JJ i
low-fat JJ i
diet NN i
( ( i
control VB i
diet JJ i
group NN i
) ) i
, , i
a DT i
Mediterranean NNP i
diet NN i
supplemented VBD i
with IN i
virgin JJ i
olive JJ i
oil NN i
, , i
or CC i
a DT i
Mediterranean NNP i
diet NN i
supplemented VBD i
with IN i
mixed JJ i
nuts NNS i
. . i

MEASUREMENTS NNP N
Main NNP N
outcomes NNS N
were VBD N
12-month JJ N
changes NNS N
from IN N
baseline NN N
in IN N
bone NN o
formation NN o
and CC o
resorption NN o
markers NNS o
and CC o
bone NN o
mass NN o
measured VBD o
according VBG N
to TO N
quantitative JJ N
ultrasound JJ N
scanning NN N
. . N

RESULTS VB N
The DT N
baseline NN N
data NNS N
on IN N
the DT N
anthropometric NN o
, , o
bone NN o
densitometry NN o
, , o
and CC o
biochemical JJ o
variables NNS o
did VBD N
not RB N
differ VB N
between IN N
the DT N
three CD p
groups NNS p
. . p

Dietary NNP o
potential JJ o
renal JJ o
acid NN o
load NN o
( ( o
PRAL NNP o
) ) o
and CC o
daily JJ o
net NN o
endogenous JJ o
acid NN o
production NN o
( ( o
NEAP NNP o
) ) o
at IN N
baseline NN N
did VBD N
not RB N
differ VB N
between IN N
groups NNS N
. . N

After IN N
intervention NN N
, , N
subjects NNS p
allocated VBD N
to TO N
the DT N
Mediterranean NNP i
diet NN i
with IN i
mixed JJ i
nuts NNS i
had VBD N
a DT N
significant JJ N
increase NN N
of IN N
PRAL NNP o
and CC o
NEAP NNP o
. . o

In IN N
comparison NN N
, , N
subjects NNS N
in IN N
the DT N
Mediterranean NNP i
diet NN i
with IN i
nuts NNS i
group NN p
had VBD N
higher JJR N
parathyroid NN o
hormone NN o
( ( o
PTH NNP o
) ) o
levels NNS o
( ( N
2.63 CD N
, , N
95 CD N
% NN N
confidence NN N
interval NN N
( ( N
CI NNP N
) ) N
=-1.01-6.35 NN N
, , N
P=.02 NNP N
) ) N
and CC N
a DT N
nonsignificantly RB N
higher JJR N
( ( N
0.31 CD N
, , N
95 CD N
% NN N
CI=-0.13-0.74 NNP N
, , N
P=.14 NNP N
) ) N
urine VBP o
free JJ o
deoxypyridoxine NN o
: : o
creatinine NN o
ratio NN o
, , N
a DT N
marker NN N
of IN N
bone NN N
resorption NN N
, , N
than IN N
the DT N
control NN N
group NN p
and CC N
the DT N
Mediterranean NNP N
diet NN N
with IN N
virgin JJ N
olive JJ N
oil NN N
group NN p
. . p

CONCLUSION VB N
A DT N
Mediterranean NNP i
dietary JJ i
pattern NN i
associated VBN N
with IN N
a DT N
high JJ N
dietary JJ N
acid NN N
load NN N
derived VBN N
from IN N
consumption NN N
of IN N
mixed JJ N
nuts NNS N
does VBZ N
not RB N
seem VB N
to TO N
have VB N
a DT N
much RB N
greater JJR N
effect NN N
on IN N
bone NN o
metabolism NN o
biomarkers NNS o
, , N
with IN N
the DT N
exception NN N
of IN N
PTH NNP o
levels NNS o
, , N
than IN N
a DT N
Mediterranean NNP i
diet NN i
without IN i
mixed JJ i
nuts NNS i
or CC i
a DT i
control NN i
diet NN i
in IN N
elderly JJ p
subjects NNS p
. . p

-DOCSTART- -17929164- O O

A DT N
double-blind JJ N
placebo NN i
controlled VBD N
trial NN N
of IN N
piracetam NN i
added VBN N
to TO N
risperidone VB i
in IN N
patients NNS p
with IN p
autistic JJ p
disorder NN p
. . p

It PRP N
has VBZ N
been VBN N
reported VBN N
that IN N
autism NN N
is VBZ N
a DT N
hypoglutamatergic JJ N
disorder NN N
. . N

Therefore RB N
, , N
it PRP N
was VBD N
of IN N
interest NN N
to TO N
assess VB N
the DT N
efficacy NN o
of IN N
piracetam NN i
, , N
a DT N
positive JJ N
modulator NN N
of IN N
AMPA-sensitive JJ N
glutamate NN N
receptors NNS N
in IN N
autistic JJ N
disorder NN N
. . N

About IN p
40 CD p
children NNS p
between IN p
the DT p
ages NNS p
three CD p
and CC p
11 CD p
years NNS p
( ( p
inclusive JJ p
) ) p
with IN p
a DT p
DSM NNP p
IV NNP p
clinical JJ p
diagnosis NN p
of IN p
autism NN p
and CC p
who WP p
were VBD p
outpatients NNS p
from IN p
a DT p
specialty NN p
clinic NN p
for IN p
children NNS p
were VBD p
recruited VBN p
. . p

The DT N
children NNS p
presented VBN p
with IN p
a DT p
chief JJ p
complaint NN p
of IN p
severely RB p
disruptive JJ p
symptoms NNS p
related VBN p
to TO p
autistic JJ p
disorder NN p
. . p

Patients NNS N
were VBD N
randomly RB N
allocated VBN N
to TO N
piracetam VB i
+ NNP i
risperidone NN i
( ( i
Group NNP i
A NNP i
) ) i
or CC i
placebo JJ i
+ NN i
risperidone NN i
( ( N
Group NNP N
B NNP N
) ) N
for IN N
a DT N
10-week JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
study NN N
. . N

The DT N
dose NN N
of IN N
risperidone NN i
was VBD N
titrated VBN N
up RB N
to TO N
2 CD N
mg/day NN N
for IN N
children NNS N
between IN N
10 CD N
and CC N
40 CD N
kg NN N
and CC N
3 CD N
mg/day NN N
for IN N
children NNS N
weighting VBG N
above IN N
40 CD N
kg NN N
. . N

The DT N
dose NN N
of IN N
piracetam NN i
was VBD N
titrated VBN N
up RB N
to TO N
800 CD N
mg/day NN N
. . N

Patients NNS N
were VBD N
assessed VBN N
at IN N
baseline NN N
and CC N
after IN N
2 CD N
, , N
4 CD N
, , N
6 CD N
, , N
8 CD N
and CC N
10 CD N
weeks NNS N
of IN N
starting VBG N
medication NN N
. . N

The DT N
measure NN N
of IN N
the DT N
outcome NN N
was VBD N
the DT N
Aberrant NNP o
Behavior NNP o
Checklist-Community NNP o
( ( o
ABC-C NNP o
) ) o
Rating VBG o
Scale NNP o
( ( o
total JJ o
score NN o
) ) o
. . o

The DT N
ABC-C JJ o
Rating NNP o
Scale NNP o
scores VBZ o
improved VBN N
with IN N
piracetam NN N
. . N

The DT N
difference NN N
between IN N
the DT N
two CD N
protocols NNS N
was VBD N
significant JJ N
as IN N
indicated VBN N
by IN N
the DT N
effect NN N
of IN N
group NN N
, , N
the DT N
between IN N
subjects NNS N
factor NN N
( ( N
F NNP N
= NNP N
5.85 CD N
, , N
d.f NN N
. . N

= CC N
1 CD N
, , N
P NNP N
= NNP N
0.02 CD N
) ) N
. . N

The DT N
changes NNS N
at IN N
the DT N
endpoint NN N
compared VBN N
with IN N
baseline NN N
were VBD N
: : N
-11.90 JJ N
+/- JJ N
3.79 CD N
( ( N
mean JJ N
+/- NNP N
SD NNP N
) ) N
and CC N
-5.15 JJ N
+/- JJ N
3.04 CD N
for IN N
group NN N
A NNP N
and CC N
B NNP N
respectively RB N
. . N

A DT N
significant JJ N
difference NN N
was VBD N
observed VBN N
on IN N
the DT N
change NN N
in IN N
scores NNS o
in IN o
the DT o
ABC-C NNP o
Rating NNP o
Scale NNP o
in IN N
week NN N
10 CD N
compared VBN N
with IN N
baseline NN N
in IN N
the DT N
two CD N
groups NNS N
( ( N
t JJ N
= NN N
6.017 CD N
, , N
d.f NN N
. . N

= CC N
38 CD N
, , N
P NNP N
< NNP N
0.0001 CD N
) ) N
. . N

The DT N
results NNS N
suggest VBP N
that IN N
a DT N
combination NN N
of IN N
atypical JJ N
antipsychotic JJ N
medications NNS N
and CC N
a DT N
glutamate JJ N
agent NN N
such JJ N
as IN N
piracetam NNS N
, , N
might MD N
have VB N
increase VBN N
synergistic JJ N
effects NNS N
in IN N
the DT N
treatment NN N
of IN N
autism NN N
. . N

-DOCSTART- -17853393- O O

Severe NNP N
enteropathy NN N
among IN N
patients NNS p
with IN p
stage NN p
II/III NNP p
colon NN p
cancer NN p
treated VBN N
on IN N
a DT N
randomized JJ N
trial NN N
of IN N
bolus JJ i
5-fluorouracil/leucovorin JJ i
plus CC i
or CC i
minus CC i
oxaliplatin NN i
: : i
a DT N
prospective JJ N
analysis NN N
. . N

BACKGROUND NNP N
Cases NNP N
of IN N
severe JJ N
gastrointestinal JJ N
toxicity NN N
were VBD N
monitored VBN N
prospectively RB N
during IN N
NSABP NNP N
C-07 NNP N
, , N
a DT N
randomized JJ N
clinical JJ N
trial NN N
of IN N
adjuvant JJ N
therapy NN N
for IN N
patients NNS p
with IN p
stage NN p
II/III NNP p
colon NN p
cancer NN p
. . p

METHODS NNP N
Patients NNPS N
were VBD N
treated VBN N
with IN N
weekly JJ N
bolus NN i
5-fluorouracil JJ i
( ( i
5-FU JJ i
) ) i
and CC i
leucovorin $ i
( ( N
FL NNP N
; : N
Roswell NNP N
Park NNP N
Regimen NNP N
) ) N
or CC N
the DT N
same JJ i
regimen NNS i
plus CC i
oxaliplatin NN i
( ( i
FLOX NNP i
) ) i
. . i

RESULTS NNP N
Of IN N
1857 CD p
patients NNS p
, , p
79 CD p
( ( p
4.3 CD p
% NN p
) ) p
developed VBD p
a DT p
syndrome NN o
of IN o
bowel NN o
wall NN o
injury NN o
( ( o
BWI NNP o
, , o
small JJ o
or CC o
large JJ o
) ) o
characterized VBN p
by IN p
hospitalization NN p
for IN p
the DT p
management NN p
of IN p
severe JJ o
diarrhea NN o
or CC o
dehydration NN o
and CC o
radiographic JJ o
or CC o
endoscopic JJ o
evidence NN o
of IN o
bowel NN o
wall NN o
thickening NN o
or CC o
ulceration NN o
. . o

Fifty-one CD N
( ( N
64.6 CD N
% NN N
) ) N
of IN N
these DT N
adverse JJ o
events NNS o
occurred VBD N
in IN N
patients NNS N
treated VBN N
with IN N
FLOX NNP i
and CC N
28 CD N
( ( N
35.4 CD N
% NN N
) ) N
in IN N
those DT N
treated VBN N
with IN N
FL NNP N
( ( N
P NNP N
< NNP N
.01 NNP N
) ) N
. . N

Enteric JJ o
sepsis NN o
( ( o
ES NNP o
) ) o
, , N
characterized VBN N
by IN N
grade NN o
3 CD o
or CC o
greater JJR o
diarrhea NN o
and CC o
grade VBD o
4 CD o
neutropenia NN o
with IN o
or CC o
without IN o
proven JJ o
bacteremia NN o
occurred VBD N
in IN N
22 CD N
patients NNS N
treated VBN N
with IN N
FLOX NNP i
, , N
versus NN N
8 CD N
in IN N
those DT N
treated VBN N
with IN N
FL NNP i
( ( N
P NNP N
= NNP N
.01 NNP N
) ) N
. . N

Patients NNPS N
> JJ N
60 CD N
years NNS N
were VBD N
at IN N
higher JJR o
risk NN o
for IN o
BWI NNP o
after IN N
treatment NN N
with IN N
FLOX NNP i
( ( N
6.7 CD N
% NN N
) ) N
versus NN N
treatment NN N
with IN N
FL NNP i
( ( N
2.9 CD N
% NN N
, , N
P NNP N
< NNP N
.01 NNP N
) ) N
. . N

Female JJ N
patients NNS N
had VBD N
a DT N
higher JJR o
incidence NN o
of IN o
BWI NNP o
with IN N
FLOX NNP i
( ( N
9.1 CD N
% NN N
) ) N
than IN N
with IN N
FL NNP N
( ( N
3.9 CD N
% NN N
, , N
P NNP N
< NNP N
.01 NNP N
) ) N
. . N

Severe JJ o
gastrointestinal JJ o
toxicity NN o
usually RB N
occurred VBD N
during IN N
the DT N
third JJ N
or CC N
fourth JJ N
week NN N
on IN N
the DT N
first JJ N
cycle NN N
of IN N
therapy NN N
, , N
required VBN N
hospitalization NN N
, , N
and CC N
was VBD N
managed VBN N
with IN N
fluids NNS N
, , N
antidiarrheals NNS N
, , N
and CC N
antibiotics NNS N
. . N

There EX N
were VBD N
5 CD N
deaths NNS o
( ( N
0.3 CD N
% NN N
) ) N
due JJ N
to TO N
enteropathy VB N
, , N
2 CD N
related VBN N
to TO N
ES NNP N
and CC N
3 CD N
related VBN N
to TO N
both DT N
BWI NNP N
and CC N
ES NNP N
. . N

Seventy-one CD N
percent NN N
of IN N
patients NNS N
resumed VBN N
treatment NN N
with IN N
FL NNP i
after IN N
recovery NN N
. . N

CONCLUSIONS NNP N
Patients NNPS N
treated VBD N
with IN N
adjuvant JJ N
FL NNP i
should MD N
be VB N
closely RB N
monitored VBN N
for IN N
diarrhea NN o
and CC N
aggressively RB N
managed VBN N
, , N
especially RB N
if IN N
oxaliplatin VBN N
has VBZ N
been VBN N
added VBN N
to TO N
the DT N
regimen NNS N
. . N

Society NN N
. . N

-DOCSTART- -7595068- O O

Effect NN N
of IN N
fats NNS i
high JJ N
in IN N
individual JJ N
saturated VBD N
fatty JJ N
acids NNS N
on IN N
plasma NN o
lipoprotein NN o
[ VBZ o
a DT o
] NN o
levels NNS o
in IN N
young JJ p
healthy JJ p
men NNS p
. . p

Plasma NNP o
lipoprotein VBZ o
[ VBZ o
a DT o
] NN o
( ( o
Lp NNP o
[ VBZ o
a DT o
] NN o
) ) o
is VBZ N
associated VBN N
with IN N
atherogenesis NN N
and CC N
thrombogenesis NN N
. . N

We PRP N
examined VBD N
how WRB N
plasma JJ N
Lp NNP N
[ VBZ N
a DT N
] NN N
in IN N
healthy JJ N
young JJ N
men NNS N
was VBD N
affected VBN N
by IN N
fats NNS i
high JJ i
in IN i
stearic JJ i
( ( i
C18 NNP i
) ) i
, , i
palmitic JJ i
( ( i
C16 NNP i
) ) i
, , i
and CC i
lauric+myristic JJ i
( ( i
C12+ NNP i
C14 NNP i
) ) i
acid NN i
( ( p
experiment JJ p
I PRP p
, , p
15 CD p
subjects NNS p
) ) p
, , N
and CC i
by IN i
fats NNS i
high JJ i
in IN i
myristic JJ i
( ( i
C14 NNP i
) ) i
and CC i
palmitic JJ i
( ( i
C16 NNP i
) ) i
acid NN i
( ( i
experiment JJ i
II NNP p
, , p
12 CD p
subjects NNS p
) ) p
. . N

Strictly RB i
controlled VBN i
isocaloric JJ i
diets NNS i
with IN N
36 CD N
% NN N
of IN N
energy NN N
from IN N
test NN N
fats NNS N
were VBD N
served VBN N
in IN N
random JJ N
order NN N
for IN N
3 CD N
weeks NNS N
separated VBN N
by IN N
wash-out JJ N
period NN N
( ( N
s JJ N
) ) N
. . N

Diets NNS i
high JJ i
in IN i
C18 NNP i
gave VBD N
significantly RB N
higher JJR N
levels NNS o
of IN o
Lp NNP o
[ NNP o
a DT o
] NNP o
( ( N
51 CD N
( ( N
12-560 JJ N
) ) N
mg/L NN N
) ) N
than IN N
diets NNS i
high JJ i
in IN i
C16 NNP i
( ( N
38 CD N
( ( N
12-533 JJ N
mg/L NN N
) ) N
( ( N
P NNP N
= NNP N
0.020 CD N
) ) N
and CC N
C12 NNP N
+ NNP N
C14 NNP N
( ( N
34 CD N
( ( N
12-534 JJ N
) ) N
mg/L NN N
) ) N
( ( N
P NNP N
= NNP N
0.002 CD N
) ) N
. . N

These DT N
differences NNS o
were VBD N
observed VBN N
in IN N
several JJ N
of IN N
the DT N
subjects NNS N
in IN N
experiment NN N
I PRP N
. . N

In IN N
experiment JJ N
II NNP N
we PRP N
saw VBD N
no DT N
difference NN N
in IN N
plasma NN o
Lp NNP o
[ VBZ o
a DT o
] NN o
after IN N
diets NNS N
high JJ N
in IN N
C16 NNP N
and CC N
C14 NNP N
. . N

Our PRP$ N
observations NNS N
suggest VBP N
that IN N
a DT N
fat JJ N
high NN N
in IN N
stearic JJ N
acid NN N
might MD N
affect VB N
Lp NNP o
[ VB o
a DT o
] NN o
in IN N
a DT N
different JJ N
way NN N
than IN N
fats NNS N
high JJ N
in IN N
palmitic JJ N
and CC N
myristic+lauric JJ N
acid NN N
. . N

Lp NNP o
[ VBD o
a DT o
] JJ o
concentrations NNS o
were VBD N
not RB N
associate JJ N
with IN N
changes NNS N
in IN N
tissue-plasminogen NN o
activator NN o
( ( o
t-PA JJ o
) ) o
activity NN o
, , o
factor NN o
VII NNP o
coagualant NN o
activity NN o
, , N
or CC N
plasma NN o
LDL NNP o
cholesterol NN o
. . o

-DOCSTART- -3207656- O O

Surgery NN N
of IN N
aphakic JJ p
retinal JJ p
detachment NN p
. . p

In IN N
a DT N
prospective JJ N
study NN N
84 CD p
patients NNS p
with IN p
aphakic JJ p
retinal JJ p
detachment NN p
were VBD p
treated VBN p
either RB p
by IN p
local JJ i
scleral JJ i
buckling VBG i
alone RB i
or CC i
combined VBN i
with IN i
an DT i
encirclement NN i
. . i

The DT N
rate NN o
of IN o
surgical JJ o
reattachment NN o
of IN o
the DT o
retina NN o
was VBD N
found VBN N
to TO N
be VB N
similar JJ N
with IN N
either DT N
technique NN N
over IN N
a DT N
minimum JJ N
follow-up JJ N
period NN N
of IN N
one CD N
year NN N
. . N

Simplicity NNP N
and CC N
a DT N
low JJ N
incidence NN N
of IN N
serious JJ N
complications NNS N
of IN N
the DT N
local JJ N
procedure NN N
merit NN N
its PRP$ N
application NN N
as IN N
the DT N
initial JJ N
method NN N
of IN N
repairing VBG N
aphakic JJ N
detachments NNS N
. . N

-DOCSTART- -8735490- O O

Accuracy NN N
of IN N
pelvic JJ p
radiotherapy NN i
: : i
prospective JJ N
analysis NN N
of IN N
90 CD p
patients NNS p
in IN N
a DT N
randomised JJ N
trial NN N
of IN N
blocked VBN N
versus FW N
standard JJ N
radiotherapy NN N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
assess VB N
the DT N
accuracy NN o
of IN N
pelvic JJ N
radiotherapy NN i
during IN N
a DT N
trial NN N
of IN N
blocked JJ N
radiotherapy NN N
at IN N
the DT N
Royal NNP N
Marsden NNP N
Hospital NNP N
, , N
UK NNP p
. . p

Prospective JJ N
evaluation NN N
was VBD N
performed VBN N
on IN N
90 CD p
patients NNS p
receiving VBG p
CT NNP i
planned VBD i
pelvic JJ i
radiotherapy NN i
using VBG p
weekly JJ p
anterior-posterior JJ p
and CC p
lateral JJ p
portal JJ p
films NNS p
. . p

Field NNP o
placement JJ o
errors NNS o
( ( o
FPEs NNP o
) ) o
were VBD N
calculated VBN N
by IN N
comparing VBG N
field NN N
centres NNS N
of IN N
each DT N
film NN N
with IN N
a DT N
designated JJ N
point NN N
of IN N
interest NN N
. . N

Data NNP N
was VBD N
evaluated VBN N
to TO N
calculate VB N
the DT N
overall JJ o
treatment NN o
simulator NN o
differences NNS o
, , o
the DT o
number NN o
of IN o
error JJ o
free JJ o
treatments NNS o
, , o
and CC o
mean VB o
treatment-simulator JJ o
position NN o
and CC N
to TO N
evaluate VB o
the DT o
role NN o
of IN o
systematic JJ o
versus NN o
random JJ o
errors NNS o
. . o

Age NNP o
, , o
weight NN o
, , o
disease NN o
site NN o
, , o
position NN o
of IN o
treatment NN o
, , o
fractionation NN o
, , o
blocked VBD o
versus JJ o
conventional JJ o
techniques NNS o
were VBD N
assessed VBN N
for IN N
their PRP$ N
effect NN N
on IN N
treatment NN N
accuracy NN N
. . N

The DT N
mean JJ o
absolute NN o
error NN o
between IN N
treatment NN N
and CC N
simulator NN N
films NNS N
was VBD N
anterior JJ N
right-left NN N
( ( N
ARL NNP N
) ) N
0.25 CD N
cm NN N
, , N
anterior JJ N
superior-inferior JJ N
( ( N
ASI NNP N
) ) N
0.32 CD N
cm NN N
, , N
lateral JJ N
anterior-posterior JJ N
( ( N
LAP NNP N
) ) N
0.42 CD N
cm NN N
, , N
and CC N
lateral JJ N
superior-inferior JJ N
( ( N
LSI NNP N
) ) N
0.28 CD N
cm NN N
. . N

On IN N
average JJ N
the DT N
field NN N
centre NN N
was VBD N
displaced VBN N
by IN N
0.66 CD N
cm NN N
( ( N
standard JJ N
deviation NN N
, , N
S.D NNP N
. . N

= VB N
0.34 CD N
) ) N
from IN N
that DT N
intended VBN N
. . N

On IN N
each DT N
treatment NN N
day NN N
29 CD N
% NN N
of IN N
anterior JJ N
films NNS N
and CC N
45 CD N
% NN N
of IN N
lateral JJ N
films NNS N
had VBD N
at IN N
least JJS N
one CD N
0.5 CD N
cm NN N
error NN N
. . N

Overall JJ N
59 CD N
% NN N
of IN N
treatments NNS N
had VBD N
at IN N
least JJS N
one CD N
0.5 CD N
cm NN N
error NN N
and CC N
9 CD N
% NN N
a DT N
1.0 CD N
cm NN N
error NN N
. . N

The DT N
field NN N
centre NN N
was VBD N
more JJR N
than IN N
0.5 CD N
cm NN N
from IN N
the DT N
position NN N
intended VBN N
in IN N
66 CD N
% NN N
of IN N
treatments NNS N
and CC N
over IN N
1 CD N
cm NNS N
for IN N
14 CD N
% NN N
of IN N
treatments NNS N
. . N

Analysis NN N
of IN N
variance NN N
showed VBD N
that IN N
both DT N
random NN N
and CC N
systematic JJ N
errors NNS N
occurred VBD N
in IN N
all DT N
directions NNS N
. . N

Though IN N
random JJ N
errors NNS N
were VBD N
of IN N
similar JJ N
magnitude NN N
in IN N
all DT N
direction NN N
( ( N
variance NN N
sigma NN N
2 CD N
= JJ N
0.06-0.09 JJ N
cm2 NN N
) ) N
; : N
systematic JJ N
errors NNS N
showed VBD N
a DT N
4-fold JJ N
variation NN N
being VBG N
greatest JJS N
in IN N
the DT N
LAP NNP N
direction NN N
( ( N
sigma JJ N
2 CD N
= JJ N
0.19 CD N
cm2 NN N
) ) N
and CC N
least JJS N
the DT N
ARL NNP N
direction NN N
( ( N
sigma JJ N
2 CD N
= JJ N
0.048 CD N
cm2 NN N
) ) N
. . N

No DT N
factor NN N
consistently RB N
predicted VBN N
for IN N
worse JJR N
outcome NN N
in IN N
all DT N
directions NNS N
. . N

Hypofractionated VBN N
treatments NNS N
were VBD N
less JJR N
accurate JJ o
in IN N
the DT N
LSI NNP N
direction NN N
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
. . N

Systematic JJ o
errors NNS o
were VBD N
associated VBN N
in IN N
the DT N
ARL NNP N
direction NN N
with IN N
hypofractionation NN N
( ( N
P NNP N
< NNP N
0.01 CD N
) ) N
and CC N
, , N
in IN N
the DT N
LSI NNP N
direction NN N
with IN N
weight NN N
( ( N
P NNP N
< NNP N
0.03 CD N
) ) N
and CC N
age NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

We PRP N
conclude VBP N
that DT N
significant JJ N
random NN N
and CC N
systematic JJ N
errors NNS N
can MD N
occur VB N
during IN N
pelvic JJ N
radiotherapy NN i
especially RB N
in IN N
the DT N
LAP NNP N
direction NN N
. . N

These DT N
results NNS N
suggest VBP N
that IN N
in IN N
the DT N
absence NN N
of IN N
a DT N
customised JJ N
immobilisation NN N
device NN N
, , N
to TO N
cover VB N
95 CD N
% NN N
of IN N
errors NNS N
, , N
margins NNS N
of IN N
0.6 CD N
cm NN N
for IN N
RL NNP N
and CC N
SI NNP N
directions NNS N
and CC N
0.9 CD N
cm NN N
for IN N
AP NNP N
direction NN N
should MD N
be VB N
allowed VBN N
between IN N
the DT N
planning NN N
and CC N
clinical JJ N
target NN N
volumes NNS N
. . N

However RB N
, , N
ideally RB N
, , N
each DT N
centre NN N
should MD N
determine VB N
their PRP$ N
own JJ N
margin NN N
requirements NNS N
according VBG N
to TO N
local JJ N
clinical JJ N
practice NN N
. . N

-DOCSTART- -15464783- O O

Effects NNS N
of IN N
finasteride NN i
on IN N
the DT N
morphology NN o
of IN o
polycystic JJ o
ovaries NNS o
. . o

-DOCSTART- -18343039- O O

Testosterone NN i
and CC N
gonadotropins NNS i
but CC N
not RB N
estrogen RB N
associated VBN N
with IN N
spatial JJ o
ability NN o
in IN N
women NNS p
suffering VBG p
from IN p
schizophrenia NN p
: : p
a DT N
double-blind NN N
, , N
placebo-controlled JJ i
study NN N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
investigate VB N
the DT N
association NN N
between IN N
estrogen NN o
and CC N
spatial JJ o
ability NN o
tasks NNS N
in IN N
women NNS p
suffering VBG p
from IN p
schizophrenia NN p
. . p

For IN N
this DT N
purpose NN N
, , N
a DT N
placebo-controlled JJ i
, , N
double-blind JJ N
, , N
three-time JJ N
cross-over NN N
study NN N
using VBG N
17beta-estradiol JJ i
combined VBN i
with IN i
norethisterone JJ i
acetate NN i
for IN N
replacement NN i
therapy NN i
and CC N
as IN N
an DT N
adjunct NN N
to TO N
a DT N
naturalistic JJ N
maintenance NN N
antipsychotic JJ i
treatment NN i
was VBD N
carried VBN N
out RP N
over IN N
a DT N
period NN N
of IN N
8 CD N
months NNS N
. . N

Nineteen JJ p
women NNS p
( ( p
mean JJ p
age=38.0 NN p
years NNS p
, , p
SD=9.9 NNP p
years NNS p
) ) p
with IN p
schizophrenia NN p
hospitalized VBN p
for IN p
the DT p
first JJ p
time NN p
or CC p
repeatedly RB p
were VBD N
included VBN N
in IN N
the DT N
study NN N
. . N

Sex NNP o
hormones VBZ o
- : o
17beta-estradiol JJ o
, , o
luteinizing VBG o
hormone NN o
( ( o
LH NNP o
) ) o
, , o
follicle-stimulating JJ o
hormone NN o
( ( o
FSH NNP o
) ) o
, , o
prolactin NN o
, , o
testosterone NN o
, , o
and CC o
dehydroepiandrosterone NN o
sulfate NN o
- : N
were VBD N
measured VBN N
and CC N
the DT N
patients NNS N
completed VBD N
a DT N
neuropsychological JJ N
test NN N
in IN N
the DT N
last JJ N
two CD N
active JJ N
drug NN N
and/or NN N
placebo NN N
phases NNS N
. . N

Three CD N
different JJ N
spatial JJ N
ability NN N
tasks NNS N
- : N
spatial JJ o
orientation NN o
, , o
spatial JJ o
visualization NN o
, , o
and CC o
flexibility NN o
of IN o
closure NN o
- : N
were VBD N
measured VBN N
by IN N
a DT N
paper-and-pencil JJ N
test NN N
. . N

No DT N
association NN N
between IN N
estrogen NN o
and CC N
spatial JJ o
ability NN o
was VBD N
found VBN N
; : N
however RB N
, , N
in IN N
an DT N
additional JJ N
exploratory NN N
data NNS N
analysis NN N
, , N
high JJ o
levels NNS o
of IN o
testosterone NN o
, , o
LH NNP o
, , o
and CC o
FSH NNP o
correlated VBD N
significantly RB N
with IN N
performance NN N
in IN N
the DT N
flexibility NN o
of IN o
closure NN o
task NN N
. . N

This DT N
is VBZ N
the DT N
very RB N
first JJ N
study NN N
, , N
based VBN N
on IN N
estrogen NN i
intervention NN N
instead RB N
of IN N
physiological JJ N
hormone NN N
changes NNS N
, , N
to TO N
examine VB N
the DT N
association NN N
between IN N
estrogen NN o
and CC N
spatial JJ o
ability NN o
in IN N
women NNS p
with IN p
schizophrenia NN p
. . p

-DOCSTART- -19910076- O O

First-line JJ i
cisplatin NN i
with IN i
docetaxel NN i
or CC i
vinorelbine NN i
in IN N
patients NNS p
with IN p
advanced JJ p
non-small-cell JJ p
lung NN p
cancer NN p
: : p
a DT N
quality NN p
of IN p
life NN p
directed VBN p
phase NN p
II NNP p
randomized VBD p
trial NN p
of IN p
Gruppo NNP p
Oncologico NNP p
Italia NNP p
Meridionale NNP p
. . p

BACKGROUND NNP N
Quality NNP o
of IN o
life NN o
( ( o
QoL NNP o
) ) o
has VBZ N
gained VBN N
greater JJR N
importance NN N
in IN N
the DT N
management NN N
of IN N
metastatic JJ p
non-small-cell JJ p
lung NN p
cancer NN p
due JJ N
to TO N
the DT N
palliative JJ N
nature NN N
of IN N
treatment NN N
. . N

Docetaxel NNP i
( ( i
DCT NNP i
) ) i
and CC i
cisplatin NN i
( ( i
CDDP NNP i
) ) i
doublet NN i
has VBZ N
been VBN N
reported VBN N
to TO N
be VB N
associated VBN N
to TO N
a DT N
better JJR N
QoL NNP N
than IN N
the DT N
weekly JJ N
vinorelbine NN i
( ( i
VNR NNP i
) ) i
and CC i
CDDP NNP i
regimen NNS N
. . N

Recently RB N
a DT N
newer NN N
more RBR N
tolerated JJ N
schedule NN N
of IN N
the DT N
VNR/CDDP NNP i
regimen NN N
has VBZ N
been VBN N
published VBN N
and CC N
is VBZ N
widely RB N
employed VBN N
in IN N
medical JJ N
practice NN N
. . N

The DT N
impact NN N
of IN N
these DT N
regimens NNS N
on IN N
patients NNS N
' POS N
QoL NNP N
as RB N
well RB N
as IN N
symptoms NNS o
control NN o
and CC o
type NN o
and CC N
grading VBG N
chemo-related JJ N
side-effects NNS o
has VBZ N
been VBN N
compared VBN N
prospectically RB N
. . N

METHODS NNP N
Patients NNPS p
received VBD N
CDDP NNP i
75 CD i
mg/m NN i
( ( i
2 CD i
) ) i
plus CC i
DCT NNP i
75 CD i
mg/m NN i
( ( i
2 CD i
) ) i
on IN N
day NN N
1 CD N
every DT N
weeks NNS N
( ( N
arm IN N
A NNP N
) ) N
or CC N
CDDP $ i
80 CD i
mg/m NN i
( ( i
2 CD i
) ) i
on IN i
day NN i
1 CD i
plus CC i
VNR NNP i
30 CD i
mg/m NN i
( ( i
2 CD i
) ) i
day NN N
1 CD N
and CC N
8 CD N
every DT N
3 CD N
weeks NNS N
( ( N
arm NN N
B NNP N
) ) N
. . N

G-CSF NNP i
and/or JJ i
EPO NNP i
were VBD N
employed VBN N
as IN N
needed VBN N
. . N

Health-related JJ o
QoL NNP o
was VBD N
assessed VBN N
at IN N
entry NN N
and CC N
after IN N
every DT N
cycle NN N
by IN N
the DT N
EORTC-QLQ-C30 NNP N
and CC N
LC13 NNP o
questionnaires NNS o
, , o
toxicity NN o
by IN N
the DT N
NCI-NCCN NNP N
CTC NNP N
vs NN N
2 CD N
, , N
and CC N
intent-to-treat JJ N
objective JJ o
response NN o
by IN N
the DT N
Recist NNP N
criteria NNS N
. . N

RESULTS VB N
The DT N
QoL NNP o
questionnaires NNS o
were VBD N
completed VBN N
by IN N
37 CD p
pts NNS p
( ( p
88 CD p
% NN p
) ) p
in IN p
the DT p
DCT/CDDP NNP i
arm NN p
and CC N
39 CD p
pts NNS p
( ( p
87 CD p
% NN p
) ) p
in IN p
the DT p
VNR/CDDP NNP i
one NN p
. . p

Baseline JJ N
mean JJ N
scores NNS N
and CC N
rates NNS N
at IN N
which WDT N
pts NNS N
failed VBD N
to TO N
complete VB N
QoL NNP N
assessment NN N
were VBD N
similar JJ N
in IN N
the DT N
two CD N
arms NNS N
. . N

Global NNP o
health NN o
status NN o
of IN N
the DT N
EORTC NNP o
QLQ-C30 NNP o
scale NN o
and CC N
specific JJ o
symptoms NNS o
control NN o
( ( N
LC13 NNP N
module NN N
) ) N
improved VBD N
during IN N
treatment NN N
without IN N
any DT N
statistically RB N
significant JJ N
difference NN N
between IN N
the DT N
two CD N
arms NNS N
. . N

Emotional JJ o
functioning NN o
remained VBD N
stable JJ N
in IN N
both DT N
groups NNS N
during IN N
treatment NN N
, , N
whereas JJ N
physical JJ o
and CC o
role NN o
improved VBN N
slightly RB N
. . N

In IN N
the DT N
DCT/CDDP NNP i
arm NN N
14 CD N
pts NNS N
( ( N
33 CD N
% NN N
; : N
95 CD N
% NN N
CL NNP N
24-40 CD N
% NN N
) ) N
had VBD N
PR NNP N
, , N
and CC N
10 CD N
( ( N
24 CD N
% NN N
) ) N
SD NNP N
for IN N
a DT N
57 CD N
% NN N
TGCR NNP N
. . N

In IN N
the DT N
VNR/CDDP NNP i
arm NN N
12 CD N
pts NNS N
( ( N
27 CD N
% NN N
) ) N
achieved VBD N
PR NNP o
, , N
18 CD N
( ( N
41 CD N
% NN N
) ) N
SD VBZ N
a DT N
68 CD N
% NN N
TGCR NNP N
. . N

Differences NNS N
were VBD N
not RB N
statistically RB N
significant JJ N
. . N

Median JJ o
time-to-progression NN o
was VBD N
4.2 CD N
months NNS N
in IN N
the DT N
DCT/CDDP NNP i
arm NN N
and CC N
4.5 CD N
months NNS N
in IN N
the DT N
VNR/CDDP NNP i
one CD N
, , N
and CC N
median JJ o
overall JJ o
survival NN o
was VBD N
12.1 CD N
( ( N
range VB N
1-26+ JJ N
months NNS N
) ) N
and CC N
12.5 CD N
months NNS N
( ( N
range VB N
1-28+ JJ N
months NNS N
) ) N
for IN N
DCT/CDDP NNP i
and CC N
VNR/CDDP NNP i
arms NNS N
, , N
respectively RB N
. . N

Febrile NNP o
neutropenia JJ o
rate NN o
was VBD N
higher RBR N
in IN N
the DT N
VNR/CDDP NNP i
arm NN N
( ( N
p=0.02 NN N
) ) N
as RB N
well RB N
as IN N
G3-4 NNP N
anemia NN o
( ( N
p=0.005 NN N
) ) N
and CC N
G-CSF/EPO NNP N
use NN N
( ( N
p=0.019 NN N
) ) N
. . N

CONCLUSIONS NNP N
Global NNP o
and CC o
specific JJ o
health-related JJ o
QoL NNP o
data NNS N
similar JJ N
in IN N
both DT N
treatment NN N
groups NNS N
with IN N
no DT N
statistically RB N
significant JJ N
difference NN N
. . N

Efficacy NN o
measures NNS o
, , o
overall JJ o
response NN o
rate NN o
, , o
time-to-progression NN o
and CC o
overall JJ o
survival NN o
were VBD N
equivalent JJ N
in IN N
both DT N
arms NNS N
. . N

However RB N
, , N
severe JJ o
anemia NN o
and CC o
febrile JJ o
neutropenia NN o
are VBP N
statistically RB N
more RBR N
frequent JJ N
in IN N
the DT N
VNR/CDDP NNP i
arm NN N
than IN N
in IN N
the DT N
DCT/CDDP NNP i
one NN N
. . N

These DT N
data NNS N
should MD N
be VB N
considered VBN N
in IN N
treatment NN N
decision-making NN N
for IN N
pts NNS p
with IN p
advanced JJ p
non-small-cell JJ p
lung NN p
cancer NN p
and CC N
for IN N
the DT N
design NN N
of IN N
future JJ N
trials NNS N
with IN N
chemotherapy NN N
plus CC N
biologics NNS N
. . N

-DOCSTART- -18572078- O O

Effect NN N
of IN N
laquinimod NN i
on IN N
MRI-monitored JJ o
disease NN o
activity NN o
in IN N
patients NNS p
with IN p
relapsing-remitting JJ p
multiple JJ p
sclerosis NN p
: : p
a DT p
multicentre NN p
, , N
randomised VBN N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
phase NN N
IIb NNP N
study NN N
. . N

BACKGROUND VB N
A DT N
24-week JJ N
phase NN N
II NNP N
trial NN N
has VBZ N
shown VBN N
that IN N
0.3 CD N
mg NN N
of IN N
laquinimod JJ i
given VBN N
daily JJ N
to TO N
patients NNS p
with IN p
relapsing-remitting JJ p
multiple JJ p
sclerosis NN p
was VBD N
well RB N
tolerated VBN N
and CC N
reduced VBN N
the DT N
formation NN N
of IN N
active JJ o
lesions NNS o
. . o

We PRP N
assessed VBD N
the DT N
effect NN N
of IN N
oral JJ N
daily JJ N
0.3 CD N
and CC N
0.6 CD N
mg NN N
laquinimod NN i
on IN N
MRI-monitored JJ o
disease NN o
activity NN N
in IN N
a DT N
36-week JJ N
double-blind NN N
, , N
placebo-controlled JJ N
phase NN N
IIb NNP N
study NN N
. . N

METHODS NNP N
The DT p
study NN p
was VBD p
done VBN p
in IN p
51 CD p
centres NNS p
in IN p
nine CD p
countries NNS p
. . p

Inclusion NN p
criteria NNS p
were VBD p
one CD p
or CC p
more JJR p
relapses NNS p
in IN p
the DT p
year NN p
before IN p
entry NN p
and CC p
at IN p
least JJS p
one CD p
gadolinium NN o
enhancing NN o
( ( o
GdE NNP o
) ) o
lesion NN o
on IN p
screening VBG p
MRI NNP p
. . p

Of IN p
720 CD p
patients NNS p
screened VBD p
, , p
306 CD p
eligible JJ p
patients NNS p
were VBD p
enrolled VBN p
. . p

Patients NNS p
, , p
aged VBN p
18-50 CD p
years NNS p
, , N
were VBD N
randomly RB N
assigned VBN N
to TO N
placebo VB i
( ( N
n=102 NN N
) ) N
, , N
laquinimod $ i
0.3 CD N
mg NN N
a DT N
day NN N
( ( N
n=98 NN N
) ) N
, , N
or CC N
0.6 CD N
mg NNS N
a DT N
day NN N
( ( N
n=106 JJ N
) ) N
. . N

Brain NNP o
MRI NNP o
scans NNS o
and CC o
clinical JJ o
assessments NNS o
were VBD N
done VBN N
at IN N
week NN N
-4 NN N
, , N
baseline NN N
, , N
and CC N
monthly RB N
from IN N
week NN N
12 CD N
to TO N
week NN N
36 CD N
. . N

The DT N
primary JJ N
outcome NN N
was VBD N
the DT N
cumulative JJ o
number NN o
of IN o
GdE NNP o
lesions NNS o
at IN N
weeks NNS N
24 CD N
, , N
28 CD N
, , N
32 CD N
, , N
and CC N
36 CD N
. . N

The DT N
principal JJ N
analysis NN N
of IN N
the DT N
primary JJ N
endpoint NN N
was VBD N
done VBN N
on IN N
the DT N
intention-to-treat JJ N
cohort NN N
. . N

This DT N
study NN N
is VBZ N
registered VBN N
with IN N
ClinicalTrials.gov NNP N
, , N
number NN N
NCT00349193 NNP N
. . N

FINDINGS NNP N
Compared NNP N
with IN N
placebo NN N
, , N
treatment NN N
with IN N
laquinimod JJ N
0.6 CD N
mg JJ N
per IN N
day NN N
showed VBD N
a DT N
40.4 CD N
% NN N
reduction NN N
of IN N
the DT N
baseline NN N
adjusted VBN N
mean JJ N
cumulative JJ o
number NN o
of IN o
GdE NNP o
lesions NNS o
per IN o
scan NN o
on IN N
the DT N
last JJ N
four CD N
scans NNS N
( ( N
simple JJ N
means VBZ N
4.2 CD N
[ NN N
SD NNP N
9.2 CD N
] NNP N
vs NN N
2.6 CD N
[ NN N
5.3 CD N
] NN N
, , N
p=0.0048 NN N
) ) N
; : N
treatment NN N
with IN N
0.3 CD N
mg NNS N
per IN N
day NN N
showed VBD N
no DT N
significant JJ N
effects NNS N
( ( N
3.9 CD N
[ RB N
5.5 CD N
] JJ N
vs NN N
placebo NN N
, , N
p=0.6740 NN N
) ) N
. . N

Both DT N
doses NNS N
of IN N
laquinimod NN N
were VBD N
well RB N
tolerated VBN N
, , N
with IN N
some DT N
transient NN N
and CC N
dose-dependent JJ N
increases NNS N
in IN N
liver NN o
enzymes NNS o
. . o

A DT N
case NN N
of IN N
Budd-Chiari NNP o
syndrome-ie NN o
, , N
a DT N
thrombotic JJ o
venous JJ o
outflow JJ o
obstruction NN o
of IN o
the DT o
liver-occurred JJ o
after IN N
1 CD N
month NN N
of IN N
exposure NN N
in IN N
a DT N
patient NN N
with IN N
underlying JJ N
hypercoagulability NN N
who WP N
received VBD N
0.6 CD N
mg NN N
laquinimod NN N
. . N

Anticoagulant NNP N
treatment NN N
resulted VBD N
in IN N
a DT N
decline NN N
of IN N
liver NN o
enzymes NNS o
to TO N
normal JJ N
without IN N
any DT N
clinical JJ N
signs NNS N
of IN N
hepatic JJ o
decompensation NN o
. . o

INTERPRETATION NNP N
In IN p
patients NNS p
with IN p
relapsing-remitting JJ p
multiple JJ p
sclerosis NN p
, , N
0.6 CD N
mg NNS N
per IN N
day NN N
laquinimod NN N
significantly RB N
reduced VBN N
MRI-measured JJ o
disease NN o
activity NN o
and CC N
was VBD N
well RB N
tolerated VBN N
. . N

-DOCSTART- -15068403- O O

Cyproheptadine NN i
in IN N
the DT N
treatment NN N
of IN N
autistic JJ p
disorder NN p
: : p
a DT N
double-blind JJ N
placebo-controlled JJ i
trial NN N
. . N

OBJECTIVE CC N
Autism NNP N
is VBZ N
a DT N
childhood-onset JJ N
disorder NN N
of IN N
unknown JJ N
, , N
possibly RB N
of IN N
multiple JJ N
aetiologies NNS N
. . N

The DT N
core NN N
symptoms NNS N
of IN N
autism NN N
are VBP N
abnormalities NNS N
in IN N
social JJ N
interaction NN N
, , N
communication NN N
and CC N
behaviour NN N
. . N

The DT N
involvement NN N
of IN N
neurotransmitters NNS N
such JJ N
as IN N
5-HT JJ N
has VBZ N
been VBN N
suggested VBN N
in IN N
neuropsychiatric JJ N
disorders NNS N
and CC N
particularly RB N
in IN N
autistic JJ N
disorder NN N
. . N

Increased VBN N
platelet NN N
5-HT JJ N
levels NNS N
were VBD N
found VBN N
in IN N
40 CD N
% NN N
of IN N
the DT N
autistic JJ N
population NN N
, , N
suggesting VBG N
that IN N
hyperserotonaemia NN N
may MD N
be VB N
a DT N
pathologic JJ N
factor NN N
in IN N
infantile JJ p
autism NN p
. . p

Therefore RB N
, , N
it PRP N
is VBZ N
of IN N
interest NN N
to TO N
assess VB N
the DT N
efficacy NN N
of IN N
cyproheptadine NN i
, , i
a DT i
5-HT2 JJ i
antagonist NN i
in IN N
the DT N
treatment NN N
of IN N
autistic JJ N
disorder NN N
. . N

In IN N
this DT N
8-week JJ N
double-blind NN N
, , N
placebo-controlled JJ i
trial NN N
, , N
we PRP N
assessed VBD N
the DT N
effects NNS N
of IN N
cyproheptadine NN i
plus CC i
haloperidol NN i
in IN N
the DT N
treatment NN N
of IN N
autistic JJ N
disorder NN N
. . N

METHODS NNP N
Children NNP p
between IN p
the DT p
ages NNS p
3 CD p
and CC p
11 CD p
years NNS p
( ( p
inclusive JJ p
) ) p
with IN p
a DT p
DSM NNP p
IV NNP p
clinical JJ p
diagnosis NN p
of IN p
autism NN p
and CC p
who WP p
were VBD p
outpatients NNS p
from IN p
a DT p
specialty NN p
clinic NN p
for IN p
children NNS p
at IN p
Roozbeh NNP p
Psychiatric NNP p
Teaching NNP p
Hospital NNP p
were VBD p
recruited VBN p
. . p

The DT N
children NNS p
presented VBN p
with IN p
a DT p
chief JJ p
complaint NN p
of IN p
severely RB p
disruptive JJ p
symptoms NNS p
related VBN p
to TO p
autistic JJ p
disorder NN p
. . p

Patients NNS N
were VBD N
randomly RB N
allocated VBN N
to TO N
cyproheptadine VB i
+ NNP i
haloperidol NN i
( ( N
Group NNP N
A NNP N
) ) N
or CC N
haloperidol JJ i
+ JJ i
placebo NN i
( ( N
Group NNP N
B NNP N
) ) N
for IN N
an DT N
8-week JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
study NN N
. . N

The DT N
dose NN N
of IN N
haloperidol NN i
and CC i
cyproheptadine NN i
was VBD N
titrated VBN N
up RB N
to TO N
0.05 CD N
and CC N
0.2 CD N
mg/kg/day NN N
respectively RB N
. . N

Patients NNS N
were VBD N
assessed VBN N
by IN N
a DT N
third-year JJ N
resident NN N
of IN N
psychiatry NN N
at IN N
baseline NN N
and CC N
after IN N
2 CD N
, , N
4 CD N
, , N
6 CD N
and CC N
8 CD N
weeks NNS N
of IN N
starting VBG N
medication NN N
. . N

The DT N
primary JJ N
measure NN N
of IN N
the DT N
outcome NN N
was VBD N
the DT N
Aberrant NNP o
Behaviour NNP o
Checklist-Community NNP o
( ( o
ABC-C NNP o
) ) o
and CC N
the DT N
secondary JJ N
measure NN N
of IN N
the DT N
outcome NN N
was VBD N
the DT N
Childhood NNP o
Autism NNP o
Rating NNP o
Scale NNP o
( ( o
relating VBG o
to TO o
people NNS o
and CC o
verbal JJ o
communication NN o
) ) o
. . N

Side JJ N
effects NNS N
and CC N
extrapyramidal NN N
symptoms NNS N
were VBD N
systematically RB N
recorded VBN N
throughout IN N
the DT N
study NN N
and CC N
were VBD N
assessed VBN N
using VBG N
a DT N
checklist NN N
and CC N
the DT N
Extrapyramidal NNP N
Symptoms NNP N
Rating NNP N
Scale NNP N
, , N
administered VBN N
by IN N
a DT N
resident NN N
of IN N
psychiatry NN N
during IN N
weeks NNS N
1 CD N
, , N
2 CD N
, , N
4 CD N
, , N
6 CD N
and CC N
8 CD N
. . N

RESULTS VB N
The DT N
ABC-C NNP o
and CC o
the DT o
Childhood NNP o
Autism NNP o
Rating NNP o
Scale NNP o
scores VBZ o
improved VBN N
with IN N
cyproheptadine NN i
. . i

The DT N
behaviour NN o
of IN N
the DT N
two CD N
treatments NNS N
was VBD N
not RB N
homogeneous JJ N
across IN N
time NN N
( ( N
groups-by-time JJ N
interaction NN N
, , N
Greenhouse-Geisser NNP N
correction NN N
; : N
F NNP N
= VBZ N
7.30 CD N
, , N
d.f NN N
. . N

= CC N
1.68 CD N
, , N
P NNP N
= NNP N
0.002 CD N
; : N
F NNP N
= VBZ N
8.21 CD N
, , N
d.f NN N
. . N

= CC N
1.19 CD N
, , N
P NNP N
= VBZ N
0.004 CD N
respectively RB N
) ) N
. . N

The DT N
difference NN N
between IN N
the DT N
two CD N
treatments NNS N
was VBD N
significant JJ N
as IN N
indicated VBN N
by IN N
the DT N
effect NN N
of IN N
group NN N
, , N
and CC N
the DT N
between-subjects NNS N
factor NN N
( ( N
F NNP N
= NNP N
4.17 CD N
, , N
d.f NN N
. . N

= CC N
1 CD N
, , N
P NNP N
= NNP N
0.048 CD N
; : N
F NNP N
= VBZ N
4.29 CD N
, , N
d.f NN N
. . N

= CC N
1 CD N
, , N
P NNP N
= VBZ N
0.045 CD N
respectively RB N
) ) N
. . N

No DT N
significant JJ N
difference NN N
was VBD N
observed VBN N
between IN N
the DT N
two CD N
groups NNS N
in IN N
terms NNS N
of IN N
extrapyramidal NN o
symptoms NNS o
( ( N
P NNP N
= NNP N
0.23 CD N
) ) N
. . N

The DT N
difference NN N
between IN N
the DT N
two CD N
groups NNS N
in IN N
the DT N
frequency NN o
of IN o
side NN o
effects NNS o
was VBD N
not RB N
significant JJ N
. . N

CONCLUSION VB N
The DT N
results NNS N
suggest VBP N
that IN N
the DT N
combination NN N
of IN N
cyproheptadine NN i
with IN i
a DT i
conventional JJ i
antipsychotic JJ i
may MD N
be VB N
superior JJ N
to TO N
conventional JJ i
antipsychotic JJ i
alone NN i
for IN N
children NNS p
with IN p
autistic JJ p
disorder NN p
. . p

However RB N
the DT N
results NNS N
need VBP N
confirmation NN N
by IN N
a DT N
larger JJR N
randomized VBN N
controlled VBN N
trial NN N
. . N

-DOCSTART- -8237838- O O

Veterans NNS p
Affairs VBP p
congestive JJ p
heart NN p
failure NN p
antiarrhythmic JJ N
trial NN N
. . N

CHF NNP N
STAT NNP N
Investigators NNP N
. . N

This DT N
is VBZ N
a DT N
prospective JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
trial NN N
to TO N
determine VB N
the DT N
effect NN N
of IN N
antiarrhythmic JJ N
drug NN N
therapy NN N
on IN N
mortality NN o
in IN N
patients NNS p
with IN p
congestive JJ p
heart NN p
failure NN p
and CC p
ventricular JJ p
arrhythmia NN p
. . p

Patients NNS N
will MD N
be VB N
assigned VBN N
to TO N
receive VB N
either CC N
amiodarone VB i
or CC i
placebo VB i
. . i

Eligible JJ p
patients NNS p
include VBP p
those DT p
with IN p
ischemic JJ p
and CC p
nonischemic JJ p
congestive JJ p
heart NN p
failure NN p
and CC p
with IN p
> NNP p
or CC p
= $ p
10 CD p
ventricular JJ p
premature NN p
beats NNS p
per IN p
hour NN p
. . p

All DT p
patients NNS p
must MD p
have VB p
shortness NN p
of IN p
breath NN p
with IN p
minimal JJ p
exertion NN p
or CC p
paroxysmal JJ p
nocturnal JJ p
dyspnea NN p
, , p
a DT p
left JJ p
ventricular JJ p
internal JJ p
dimension NN p
( ( p
LVIDd NNP p
) ) p
by IN p
echocardiogram NN p
of IN p
> NN p
or CC p
= $ p
55 CD p
mm NN p
or CC p
a DT p
cardiothoracic JJ p
ratio NN p
of IN p
> $ p
0.5 CD p
and CC p
an DT p
ejection NN p
fraction NN p
of IN p
< NN p
or CC p
= VB p
40 CD p
% NN p
. . p

All DT N
patients NNS N
will MD N
receive VB N
vasodilator NN N
therapy NN N
, , N
unless IN N
they PRP N
find VBP N
it PRP N
intolerable JJ N
. . N

Patients NNS p
will MD p
be VB p
entered VBN p
into IN p
the DT p
study NN p
for IN p
2.5 CD p
years NNS p
and CC p
followed VBD p
for IN p
an DT p
additional JJ p
2 CD p
years NNS p
. . p

Drug NNP N
therapy NN N
will MD N
be VB N
continued VBN N
for IN N
all DT N
patients NNS N
throughout IN N
the DT N
entire JJ N
study NN N
unless IN N
adverse JJ N
reactions NNS N
occur VBP N
that IN N
necessitate JJ N
individualized JJ N
treatment NN N
. . N

The DT N
expectation NN N
is VBZ N
that IN N
674 CD p
patients NNS p
will MD p
be VB p
entered VBN p
into IN p
the DT p
study NN p
from IN p
25 CD p
participating VBG p
centers NNS p
. . p

This DT N
sample JJ N
size NN N
will MD N
allow VB N
for IN N
the DT N
detection NN N
of IN N
a DT N
33 CD N
% NN N
decrease NN N
in IN N
2-year JJ o
mortality NN o
( ( N
20 CD N
% NN N
vs JJ N
30 CD N
% NN N
) ) N
in IN N
the DT N
treated JJ N
patients NNS N
compared VBN N
with IN N
those DT N
in IN N
the DT N
placebo NN N
group NN N
, , N
with IN N
a DT N
power NN N
of IN N
0.90 CD N
and CC N
a DT N
2-sided JJ N
alpha JJ N
level NN N
of IN N
0.05 CD N
. . N

Intermittent JJ N
Holter NNP N
monitoring NN N
, , N
radionuclide JJ N
ventriculograms NN N
, , N
pulmonary JJ N
function NN N
tests NNS N
, , N
echocardiograms NNS N
, , N
and CC N
blood NN N
tests NNS N
, , N
including VBG N
arterial JJ N
blood NN N
gases NNS N
, , N
will MD N
be VB N
required VBN N
for IN N
each DT N
patient NN N
. . N

( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
250 CD N
WORDS NNP N
) ) N
-DOCSTART- -17377092- O O

A DT N
comparison NN N
of IN N
laser-assisted JJ i
drug NN i
delivery NN i
at IN N
two CD N
output NN N
energies NNS N
for IN N
enhancing VBG p
the DT p
delivery NN o
of IN o
topically RB o
applied VBN o
LMX-4 NNP o
cream NN o
prior RB p
to TO p
venipuncture NN i
. . i

BACKGROUND NNP N
Laser-assisted JJ i
drug NN i
delivery NN i
( ( i
LAD NNP i
) ) i
has VBZ N
the DT N
potential NN N
for IN N
facilitating VBG N
topical JJ o
anesthesia NN o
with IN o
reduced JJ o
onset JJ o
time NN o
. . o

METHODS NNP N
In IN N
this DT N
randomized JJ N
, , N
double-blind JJ N
, , N
crossover NN N
study NN N
we PRP N
compared VBN N
the DT N
efficacy NN N
and CC N
adverse JJ N
event NN N
profile NN N
of IN N
LAD NNP i
for IN i
topical JJ i
anesthesia NN i
before IN p
venipuncture NN i
using VBG N
two CD N
output NN N
energies NNS N
( ( N
2.0 CD N
and CC N
3.5 CD N
J/cm2 NNP N
) ) N
. . N

RESULTS JJ N
Mean NNP o
Visual NNP o
Analog NNP o
Scale NNP o
pain NN o
scores NNS o
were VBD N
not RB N
statistically RB N
different JJ N
( ( N
P NNP N
= NNP N
0.57 CD N
) ) N
between IN N
the DT N
low-energy JJ N
( ( N
mean JJ N
= NNP N
6.7 CD N
) ) N
and CC N
high-energy JJ N
( ( N
mean JJ N
= NNP N
8.1 CD N
) ) N
lasers NNS N
. . N

CONCLUSIONS NNP N
LAD NNP i
at IN N
an DT N
energy NN N
of IN N
2.0 CD N
J/cm2 NNP N
( ( N
570 CD N
mJ NN N
) ) N
is VBZ N
as IN N
effective JJ N
, , N
with IN N
similar JJ N
adverse JJ o
events NNS o
, , N
as IN N
an DT N
energy NN N
of IN N
3.5 CD N
J/cm2 NNP N
( ( N
1000 CD N
mJ NN N
) ) N
in IN N
facilitating VBG N
topical JJ N
anesthesia NN N
. . N

-DOCSTART- -1342906- O O

Topical JJ i
anti-inflammatory JJ i
drugs NNS i
in IN N
the DT N
treatment NN N
of IN N
allergic JJ p
pollinosic JJ p
conjunctivitis NN p
: : p
a DT N
comparative JJ N
double-blind NN N
study NN N
. . N

Anti-inflammatory JJ N
drugs NNS N
, , N
i.e NN N
. . N

glucocorticosteroids NNS i
and CC i
NSAIDs NNP i
( ( i
nonsteroidal JJ i
anti-inflammatory NN i
drugs NNS i
) ) i
, , N
are VBP N
often RB N
included VBN N
in IN N
the DT N
treatment NN N
of IN N
allergic JJ p
conjunctivitis NN p
. . p

The DT N
present JJ N
study NN N
compares VBZ N
the DT N
clinical JJ N
efficacy NN o
and CC o
safety NN o
of IN N
topical JJ N
hydrocortisone NN i
, , i
acetylsalicylic JJ i
acid NN i
( ( i
ASA NNP i
) ) i
and CC i
piroxicam $ i
compared VBN N
to TO N
placebo VB i
. . i

The DT N
trial NN N
, , N
designed VBN N
as IN N
a DT N
double-blind NN N
, , N
randomized VBN N
and CC N
parallel-group JJ N
treatment NN N
, , N
was VBD N
carried VBN N
out RP N
in IN N
a DT N
group NN N
of IN N
40 CD p
patients NNS p
suffering VBG p
from IN p
seasonal JJ p
allergic JJ p
conjunctivitis NN p
due JJ p
to TO p
Parietaria NNP p
pollen NN p
, , p
during IN p
the DT p
pollen NN p
season NN p
( ( p
June-July NNP p
, , p
1990 CD p
) ) p
. . p

Patients NNS N
received VBD N
hydrocortisone RB i
0.1 CD i
% NN i
solution NN i
, , i
ASA NNP i
1 CD i
% NN i
solution NN i
, , i
piroxicam VB i
0.5 CD i
% NN i
solution NN i
or CC i
placebo NN i
as IN N
eye NN N
drops NNS N
, , N
all DT N
one CD N
drop NN N
in IN N
each DT N
eye NN N
q.i.d NN N
. . N

for IN N
14 CD N
days NNS N
. . N

The DT N
symptoms NNS N
were VBD N
evaluated VBN N
at IN N
baseline NN N
and CC N
at IN N
the DT N
end NN N
of IN N
treatment NN N
by IN N
the DT N
clinician NN N
and CC N
by IN N
patients NNS N
on IN N
a DT N
diary JJ N
card NN N
. . N

The DT N
hydrocortisone NN N
group NN N
showed VBD N
a DT N
rapid JJ N
and CC N
significant JJ N
improvement NN N
during IN N
the DT N
first JJ N
week NN N
of IN N
treatment NN N
, , N
while IN N
ASA NNP N
and CC N
piroxicam NN N
reduced VBD N
symptomatology NN o
during IN N
the DT N
second JJ N
week NN N
of IN N
treatment NN N
; : N
this DT N
difference NN N
was VBD N
statistically RB N
significant JJ N
. . N

At IN N
the DT N
end NN N
of IN N
the DT N
trial NN N
, , N
the DT N
active JJ N
drugs NNS N
were VBD N
comparable JJ N
with IN N
regard NN N
to TO N
clinical JJ o
efficacy NN o
. . o

A DT N
statistically RB N
significant JJ N
difference NN N
was VBD N
observed VBN N
between IN N
the DT N
active JJ N
drugs NNS N
and CC N
placebo NN N
, , N
while IN N
no DT N
statistically RB N
significant JJ N
difference NN N
was VBD N
observed VBN N
among IN N
the DT N
three CD N
drugs NNS N
. . N

No DT N
serious JJ o
side-effects NNS o
were VBD N
observed VBN N
. . N

The DT N
results NNS N
demonstrate VBP N
the DT N
clinical JJ N
efficacy NN N
of IN N
anti-inflammatory JJ N
drugs NNS N
in IN N
the DT N
treatment NN N
of IN N
pollen-induced JJ N
allergic JJ N
conjunctivitis NN N
; : N
they PRP N
also RB N
suggest VBP N
the DT N
use NN N
of IN N
NSAIDs NNP N
in IN N
long-term JJ N
treatment NN N
, , N
as IN N
their PRP$ N
efficacy NN N
has VBZ N
been VBN N
shown VBN N
to TO N
be VB N
closely RB N
comparable JJ N
to TO N
that DT N
of IN N
steroids NNS N
, , N
while IN N
avoiding VBG N
the DT N
well-known JJ N
side-effects NNS N
of IN N
the DT N
latter NN N
in IN N
prolonged JJ N
treatment NN N
. . N

-DOCSTART- -9513236- O O

Histopathologic NNP o
changes NNS o
of IN o
the DT o
eyelid JJ o
skin NN o
following VBG p
trichloroacetic JJ i
acid JJ i
chemical NN i
peel NN i
. . i

The DT N
use NN N
of IN N
trichloroacetic JJ i
acid NN i
( ( i
TCA NNP i
) ) i
as IN N
a DT N
periorbital NN N
and CC N
eyelid JJ N
peel NN N
for IN N
skin JJ N
rejuvenation NN N
is VBZ N
gaining VBG N
significant JJ N
acceptance NN N
among IN N
oculoplastic JJ N
surgeons NNS N
, , N
dermatologists NNS N
, , N
and CC N
other JJ N
surgery NN N
groups NNS N
. . N

In IN N
spite NN N
of IN N
the DT N
current JJ N
enthusiasm NN N
, , N
there EX N
remain VBP N
potentially RB N
serious JJ N
complications NNS N
resulting VBG N
from IN N
any DT N
periorbital JJ N
peel NN N
. . N

Cases NNS N
of IN N
cicatricial JJ N
ectropion NN N
have VBP N
been VBN N
reported VBN N
in IN N
phenol-peeled JJ p
patients NNS p
, , N
and CC N
lower JJR N
eyelid JJ N
ectropion NN N
has VBZ N
reportedly RB N
occurred VBN N
in IN N
patients NNS p
undergoing JJ p
deep JJ p
eyelid NN p
peel NN p
in IN p
conjunction NN p
with IN p
a DT p
blepharoplasty NN i
( ( N
1,2 CD N
) ) N
. . N

To TO N
avoid VB N
this DT N
complication NN N
, , N
it PRP N
is VBZ N
necessary JJ N
to TO N
better RBR N
understand VB N
the DT N
depth NN N
of IN N
the DT N
wound NN N
produced VBN N
by IN N
different JJ N
strengths NNS N
and CC N
combinations NNS N
of IN N
peeling VBG N
agents NNS N
applied VBN N
to TO N
living VBG N
eyelid JJ N
tissue NN N
and CC N
, , N
more RBR N
important JJ N
, , N
to TO N
determine VB N
the DT N
concentrations NNS N
of IN N
TCA NNP i
that WDT N
are VBP N
likely JJ N
to TO N
lead VB N
to TO N
cicatricial JJ N
ectropion NN N
when WRB N
applied VBN N
in IN N
a DT N
consistent JJ N
fashion NN N
. . N

We PRP N
chose VBD N
upper-eyelid JJ N
skin NN N
because IN N
it PRP N
is VBZ N
easier JJR N
to TO N
obtain VB N
for IN N
histopathologic NN N
study NN N
than IN N
lower-eyelid JJ N
skin NN N
and CC N
, , N
in IN N
our PRP$ N
experience NN N
, , N
is VBZ N
more RBR N
sensitive JJ N
to TO N
hypertrophic JJ N
changes NNS N
after IN N
chemical NN N
peeling NN N
or CC N
carbon NN N
dioxide IN N
laser NN N
resurfacing NN N
. . N

We PRP N
applied VBD N
TCA NNP i
to TO N
the DT N
preseptal JJ N
skin NN N
of IN N
10 CD p
patients NNS p
48 CD N
h NN N
before IN N
standard JJ p
upper-eyelid JJ p
blepharoplasty NN p
. . p

The DT N
acid NN N
was VBD N
applied VBN N
to TO N
produce VB N
a DT N
frost NN N
, , N
using VBG N
varying VBG N
concentrations NNS N
of IN N
acid NN N
, , N
ranging VBG N
from IN N
20 CD N
to TO N
50 CD N
% NN N
. . N

The DT N
treated JJ N
skin NN N
removed VBN N
at IN N
the DT N
time NN N
of IN N
blepharoplasty NN N
was VBD N
reviewed VBN N
in IN N
a DT N
masked JJ N
fashion NN N
by IN N
a DT N
dermatopathologist NN N
to TO N
determine VB N
the DT N
depth NN N
of IN N
necrosis NN N
. . N

We PRP N
found VBD N
that IN N
superficial JJ o
peels NNS o
with IN o
necrosis NN o
involving VBG N
30 CD N
% NN N
of IN N
the DT N
epidermis NN N
were VBD N
produced VBN N
by IN N
the DT N
lowest-concentration JJ N
combination NN N
of IN N
TCA NNP i
applied VBD o
( ( N
20 CD N
% NN N
followed VBN N
by IN N
0 CD N
% NN N
) ) N
. . N

As IN N
the DT N
strength NN o
increased VBD o
, , N
so RB N
did VBD N
the DT N
depth NN N
of IN N
peel NN N
. . N

The DT N
combination NN N
of IN N
50 CD N
% NN N
followed VBN N
by IN N
a DT N
second JJ N
application NN N
of IN N
50 CD N
% NN N
produced VBD N
the DT N
deepest JJS o
peel NN o
, , N
with IN N
necrosis NN N
into IN N
the DT N
papillary JJ N
dermis NN N
. . N

This DT N
finding NN N
would MD N
indicate VB N
that IN N
the DT N
chance NN N
of IN N
developing VBG N
cicatricial JJ N
ectropion NN N
with IN N
any DT N
of IN N
the DT N
tested JJ N
combinations NNS N
of IN N
TCA NNP i
should MD N
be VB N
very RB N
remote JJ N
. . N

-DOCSTART- -25080906- O O

[ JJ N
Effect NNP N
of IN N
zero-balanced JJ i
ultrafiltration NN i
and CC i
modified VBN i
ultrafiltration NN i
on IN N
pulmonary JJ N
function NN N
after IN p
cardiac JJ p
surgery NN p
in IN p
infants NNS p
] NNP p
. . N

OBJECTIVE NNP N
To TO N
determine VB N
the DT N
protective JJ N
effect NN N
of IN N
zero-balanced JJ i
ultrafiltration NN i
and CC i
modified VBN i
ultrafiltration NN i
on IN N
infants NNS p
' POS p
pulmonary JJ p
function NN p
after IN p
cardiac JJ p
surgery NN p
. . p

METHODS NNP N
Sixty NNP p
infants NNS p
with IN p
congenital JJ p
heart NN p
diseases NNS p
were VBD N
randomly RB N
divided VBN N
into IN N
3 CD i
groups NNS i
: : i
a DT i
zero-balanced JJ i
ultrafiltration NN i
group NN i
( ( i
Z NNP i
group NN i
) ) i
, , i
a DT i
modified JJ i
ultrafiltration NN i
group NN i
( ( i
M NNP i
group NN i
) ) i
and CC i
a DT i
zero-balanced JJ i
ultrafiltration NN i
with IN i
modified JJ i
ultrafiltration NN i
group NN i
( ( i
Z+M NNP i
group NN i
) ) i
. . N

Oxygenation NNP o
index NN o
( ( o
OI NNP o
) ) o
, , o
difference NN o
of IN o
alveoli-arterial JJ o
oxygen NN o
pressure NN o
( ( o
P NNP o
( ( o
A-? NNP o
) ) o
O2 NNP o
) ) o
, , o
static JJ o
lung NN o
compliance NN o
( ( o
Cstat NNP o
) ) o
, , o
and CC o
airway RB o
resistance NN o
( ( o
Raw NNP o
) ) o
were VBD o
measured VBN o
before IN i
caridopulmonary JJ i
bypass NN i
( ( i
CPB NNP i
, , i
T1 NNP i
) ) i
, , i
20 CD i
minutes NNS i
after IN i
the DT i
CPB NNP i
( ( i
T2 NNP i
) ) i
, , i
2 CD i
h NN i
after IN i
the DT i
operation NN i
( ( i
T3 NNP i
) ) i
, , i
6 CD i
h NN i
after IN i
the DT i
operation NN i
( ( i
T4 NNP i
) ) i
and CC i
12 CD i
h NN i
after IN i
the DT i
operation NN i
( ( i
T5 NNP i
) ) i
. . i

The DT o
time NN o
of IN o
mechanical JJ o
ventilation NN o
was VBD N
also RB N
monitored VBN N
. . N

RESULTS NNP N
After IN N
the DT o
CPB NNP o
, , o
OI NNP o
and CC o
Cstat NNP o
in IN N
all DT N
groups NNS N
decreased VBD N
significantly RB N
, , N
while IN o
Raw NNP o
and CC o
P NNP o
( ( o
A-? NNP o
) ) o
O2 NNP o
increased VBD o
significantly RB N
. . N

At IN N
T3 NNP o
, , o
T4 NNP o
and CC o
T5 NNP o
, , o
OI NNP o
and CC o
Cstat NNP o
in IN o
the DT N
Z+M NNP N
group NN N
were VBD N
significantly RB N
higher JJR N
than IN N
those DT N
in IN N
the DT N
Z NNP N
group NN N
and CC N
the DT N
M NNP N
group NN N
( ( N
P NNP N
< NNP o
0.05 CD o
) ) o
, , o
Raw NNP o
and CC o
P NNP o
( ( o
A-? NNP o
) ) o
O2 NNP o
in IN o
the DT N
Z+M NNP N
group NN N
were VBD N
significantly RB N
lower JJR N
than IN N
those DT N
in IN N
the DT N
Z NNP N
group NN N
and CC N
the DT N
M NNP N
group NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

The DT N
ventilation NN o
time NN o
in IN o
the DT N
Z+M NNP N
group NN N
was VBD N
significantly RB N
shorter JJR N
than IN N
that DT N
in IN N
the DT N
Z NNP N
group NN N
and CC N
the DT N
M NNP N
group NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

CONCLUSION NNP i
Zero-balanced JJ i
ultrafiltration NN i
and CC i
modified JJ i
ultrafiltration NN i
can MD i
effectively RB N
promote VB N
the DT N
pulmonary JJ N
function NN N
after IN N
cardiac JJ N
surgery NN N
in IN N
infants NNS N
. . N

-DOCSTART- -8917026- O O

Ranitidine NNP N
improves VBZ N
lymphocyte JJ N
function NN N
after IN N
severe JJ p
head NN p
injury NN p
: : p
results NNS N
of IN N
a DT N
randomized JJ N
, , N
double-blind JJ N
study NN N
. . N

OBJECTIVE NNP N
To TO N
study VB N
the DT N
immunomodulatory JJ N
effect NN N
of IN N
the DT N
histamine NN N
receptor NN N
antagonist NN N
, , N
ranitidine NN N
, , N
in IN N
patients NNS p
admitted VBN p
to TO p
the DT p
intensive JJ p
care NN p
unit NN p
after IN p
severe JJ p
head NN p
injury NN p
. . p

DESIGN NNP N
Randomized NNP N
, , N
prospective JJ N
, , N
double-blind JJ N
study NN N
. . N

SETTING NNP N
Surgical NNP N
intensive JJ N
care NN N
unit NN N
of IN N
a DT N
university NN p
Level NNP p
I PRP p
trauma VBP p
center NN p
. . p

PATIENTS NNP N
Twenty NNP p
patients NNS p
admitted VBD p
with IN p
a DT p
Glasgow NNP p
Coma NNP p
Scale NNP p
score NN p
of IN p
< $ p
10 CD p
who WP N
were VBD N
enrolled VBN N
as IN N
part NN N
of IN N
a DT N
prospective JJ N
, , N
multicenter JJ N
trial NN N
to TO N
assess VB N
the DT N
impact NN N
of IN N
multiple JJ N
risk NN N
factors NNS N
and CC N
ranitidine VB N
prophylaxis NN N
on IN N
the DT N
development NN N
of IN N
stress-related JJ N
upper JJ N
gastrointestinal NN N
bleeding NN N
. . N

INTERVENTIONS NNP N
Continuous NNP i
infusion NN i
of IN i
ranitidine NN i
at IN i
6.25 CD i
mg/hr NN i
( ( i
n JJ i
= NNP i
9 CD i
) ) i
or CC i
placebo NN i
( ( i
n JJ i
= NNP i
11 CD i
) ) i
for IN i
a DT i
maximum NN i
of IN i
5 CD i
days NNS i
. . i

MEASUREMENTS NNP N
AND CC N
MAIN NNP N
RESULTS NNP N
Before IN N
the DT N
patients NNS N
were VBD N
enrolled VBN N
in IN N
the DT N
study NN N
and CC N
on IN N
completion NN N
of IN N
treatment NN N
, , N
lymphocyte JJ o
cell-surface NN o
antigen NN o
expression NN o
was VBD N
determined VBN N
by IN N
flow JJ N
cytometry NN N
( ( N
n JJ N
= $ N
14 CD N
patients NNS N
) ) N
; : N
mitogen-stimulated JJ o
interferon-gamma JJ o
and CC o
interleukin-2 JJ o
production NN o
were VBD N
measured VBN N
by IN N
enzyme-linked JJ N
immunosorbent NN N
assay NN N
( ( N
n JJ N
= $ N
19 CD N
patients NNS N
) ) N
. . N

Treatment NN N
with IN N
ranitidine NN i
, , N
but CC N
not RB N
placebo VB i
, , N
was VBD N
associated VBN N
with IN N
a DT N
significant JJ N
increase NN N
in IN N
CD4+ NNP o
lymphocytes NNS o
( ( N
33 CD N
% NN N
to TO N
49 CD N
% NN N
; : N
p CC N
< NNP N
.05 NNP N
) ) N
and CC N
a DT N
significant JJ N
decrease NN N
in IN N
CD8+ NNP o
lymphocytes NNS o
( ( N
41 CD N
% NN N
to TO N
27 CD N
% NN N
; : N
p CC N
< NNP N
.05 NNP N
) ) N
. . N

Also RB N
, , N
the DT N
mitogen-stimulated JJ o
interferon-gamma JJ o
production NN o
increased VBD N
from IN N
121 CD N
to TO N
269 CD N
pg/mL NN N
( ( N
p JJ N
< NNP N
.05 NNP N
) ) N
in IN N
patients NNS N
treated VBN N
with IN N
ranitidine NN i
, , N
but CC N
not RB N
in IN N
patients NNS N
treated VBN N
with IN N
placebo NN i
. . i

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
interleukin-2 JJ o
production NN o
or CC o
circulating VBG o
B-cell NNP o
concentrations NNS o
between IN N
both DT N
groups NNS N
. . N

CONCLUSION NNP N
This DT N
study NN N
demonstrates VBZ N
an DT N
immunostimulatory JJ N
effect NN N
of IN N
the DT N
histamine-2-receptor JJ N
antagonist NN N
, , N
ranitidine NN N
, , N
both DT N
at IN N
the DT N
cellular JJ N
and CC N
mediator NN N
levels NNS N
in IN N
patients NNS p
after IN p
head JJ p
injury NN p
. . p

-DOCSTART- -18417969- O O

Testing VBG N
three CD N
different JJ N
cancer NN N
genetics NNS N
registry VBP N
recruitment JJ N
methods NNS N
with IN N
Hispanic JJ p
cancer NN p
patients NNS p
and CC p
their PRP$ p
family NN p
members NNS p
previously RB p
registered VBN p
in IN p
local JJ p
cancer NN p
registries NNS p
in IN p
Texas NNP p
. . p

OBJECTIVE NN N
To TO N
increase VB N
accrual JJ N
among IN N
Hispanics NNPS p
to TO p
the DT p
Cancer NNP p
Genetics NNP p
Network NNP p
national JJ p
cancer NN p
genetics NNS p
registry NN p
. . p

METHODS NNP N
Drawing VBG N
from IN N
South NNP p
Texas NNP p
cancer NN p
registries NNS p
, , p
444 CD p
Hispanic JJ p
men NNS p
and CC p
women NNS p
were VBD p
randomly RB p
assigned VBN p
to TO N
one CD N
of IN N
three CD N
experimental JJ N
conditions NNS N
: : N
standard JJ i
direct-mailed JJ i
procedures NNS i
( ( i
X1 NNP i
) ) i
, , i
X1 NNP i
plus CC i
culturally RB i
tailored JJ i
materials NNS i
( ( i
X2 NNP i
) ) i
, , N
and CC N
X2 NNP i
plus CC i
interpersonal JJ i
phone NN i
contact NN i
( ( i
X3 NNP i
) ) i
. . N

Participants NNS N
were VBD N
also RB N
surveyed VBN N
about IN N
the DT N
effectiveness NN N
of IN N
the DT N
education NN N
materials NNS N
and CC N
the DT N
phone NN N
contact NN N
. . N

A DT N
refusal NN N
survey NN N
was VBD N
provided VBN N
for IN N
those DT N
who WP N
declined VBD N
to TO N
join VB N
the DT N
study NN N
. . N

RESULTS VB N
A DT N
total NN N
of IN N
154 CD p
individuals NNS p
joined VBD p
the DT p
Cancer NNP p
Genetics NNP p
Network NNP p
. . p

The DT N
X3 JJ o
condition NN o
yielded VBD o
the DT o
greatest JJS o
accrual JJ o
( ( N
43.2 CD N
% NN N
) ) N
compared VBN N
to TO N
X1 NNP N
( ( N
30.9 CD N
% NN N
) ) N
and CC N
X2 NNP N
( ( N
29.9 CD N
% NN N
; : N
p CC N
< VB N
0.05 CD N
) ) N
. . N

Tailored VBN N
materials NNS N
appeared VBD N
to TO N
have VB N
no DT N
effect NN N
but CC N
were VBD N
highly RB N
regarded VBN N
. . N

The DT N
main JJ N
reasons NNS N
for IN N
not RB N
participating VBG N
were VBD N
a DT N
lack NN o
of IN o
interest NN o
and CC o
time NN o
requirements NNS o
. . o

CONCLUSION NNP N
Interpersonal NNP i
communication NN i
can MD N
have VB N
a DT N
powerful JJ N
effect NN N
on IN N
recruitment NN N
. . N

However RB N
, , N
more JJR N
research NN N
is VBZ N
needed VBN N
to TO N
determine VB N
the DT N
cost-efficacy NN N
of IN N
more JJR N
labor-intensive JJ N
approaches NNS N
to TO N
registry VB N
accrual JJ N
. . N

-DOCSTART- -7761011- O O

[ RB N
Postoperative JJ N
analgesia NN N
: : N
peridural JJ i
morphine NN i
versus NN N
sublingual JJ i
buprenorphine NN i
. . i

Comparative NNP N
clinical JJ N
study NN N
] NNP N
. . N

The DT N
authors NNS N
herein VBP N
present JJ N
their PRP$ N
personal JJ N
series NN N
on IN N
the DT N
clinical JJ N
evaluation NN N
of IN N
the DT N
analgesic JJ N
efficacy NN N
of IN N
2 CD N
opiodes NNS N
, , N
peridural JJ i
morphine NN i
hydrochloride NN i
( ( i
0.5 CD i
mg/kg NN i
) ) i
administered VBD N
to TO N
group NN p
A NNP p
patients NNS p
, , N
and CC N
sublingual JJ i
buprenorphine NN i
( ( i
0.4 CD i
mg NN i
) ) i
administered VBD N
to TO N
group NN p
B NNP p
patients NNS p
in IN N
the DT N
management NN N
of IN N
post-operative JJ N
pain NN N
in IN N
major JJ N
abdominal JJ N
surgery NN N
. . N

The DT N
study NN N
was VBD N
conducted VBN N
on IN N
44 CD p
patients NNS p
, , p
both DT p
male NN p
and CC p
female NN p
, , p
classified VBD p
as IN p
ASA NNP p
II NNP p
and CC p
III NNP p
. . p

Statistical JJ N
analysis NN N
of IN N
cardiovascular JJ o
parameters NNS o
( ( o
BP NNP o
and CC o
cardiac JJ o
frequency NN o
) ) o
, , o
respiratory JJ o
frequency NN o
and CC o
pain NN o
score NN o
showed VBD N
an DT N
overlapping JJ N
progression NN N
among IN N
the DT N
two CD N
groups NNS N
. . N

Spontaneous JJ o
pain NN o
decreased VBD N
significantly RB N
to TO N
zero CD N
at IN N
T6 NNP N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
. . N

However RB N
, , N
the DT N
necessity NN N
to TO N
administer VB N
buprenorphine NN i
more RBR N
frequently RB N
after IN N
the DT N
sixth JJ N
hour NN N
and CC N
the DT N
consequent JJ N
increase NN N
in IN N
side JJ o
effects NNS o
, , N
lead VBP N
us PRP N
to TO N
believe VB N
that IN N
the DT N
method NN N
used VBN N
for IN N
group NN p
A NNP p
patients NNS p
is VBZ N
more RBR N
advantageous JJ N
. . N

-DOCSTART- -16257339- O O

Gefitinib NNP i
plus CC i
best JJS i
supportive JJ i
care NN i
in IN N
previously RB p
treated VBN p
patients NNS p
with IN p
refractory JJ p
advanced JJ p
non-small-cell JJ p
lung NN p
cancer NN p
: : p
results NNS N
from IN N
a DT N
randomised VBN N
, , N
placebo-controlled JJ N
, , N
multicentre JJ N
study NN N
( ( N
Iressa NNP N
Survival NNP N
Evaluation NNP N
in IN N
Lung NNP N
Cancer NNP N
) ) N
. . N

BACKGROUND VB N
This DT N
placebo-controlled JJ i
phase NN N
III NNP N
study NN N
investigated VBD N
the DT N
effect NN o
on IN o
survival NN o
of IN N
gefitinib NN i
as IN N
second-line JJ N
or CC N
third-line JJ N
treatment NN N
for IN N
patients NNS p
with IN p
locally RB p
advanced JJ p
or CC p
metastatic JJ p
non-small-cell JJ p
lung NN p
cancer NN p
. . p

METHODS NNP N
1692 CD p
patients NNS p
who WP p
were VBD p
refractory JJ p
to TO p
or CC p
intolerant VB p
of IN p
their PRP$ p
latest JJS p
chemotherapy NN i
regimen NNS p
were VBD N
randomly RB N
assigned VBN N
in IN N
a DT N
ratio NN N
of IN N
two CD N
to TO N
one CD N
either DT N
gefitinib NN i
( ( i
250 CD i
mg/day NN i
) ) i
or CC i
placebo NN i
, , i
plus CC i
best JJS i
supportive JJ i
care NN i
. . i

The DT N
primary JJ N
endpoint NN N
was VBD N
survival VBN o
in IN N
the DT N
overall JJ N
population NN N
of IN N
patients NNS N
and CC N
those DT N
with IN N
adenocarcinoma NN N
. . N

The DT N
primary JJ N
analysis NN N
of IN N
the DT N
population NN N
for IN N
survival NN o
was VBD N
by IN N
intention NN N
to TO N
treat VB N
. . N

This DT N
study NN N
has VBZ N
been VBN N
submitted VBN N
for IN N
registration NN N
with IN N
ClinicalTrials.gov NNP N
, , N
number NN N
1839IL/709 CD N
. . N

FINDINGS JJ N
1129 CD p
patients NNS p
were VBD p
assigned VBN p
gefitinib NNS p
and CC p
563 CD p
placebo NN p
. . p

At IN N
median JJ N
follow-up NN N
of IN N
7.2 CD N
months NNS N
, , N
median JJ o
survival NN o
did VBD N
not RB N
differ VB N
significantly RB N
between IN N
the DT N
groups NNS N
in IN N
the DT N
overall JJ N
population NN N
( ( N
5.6 CD N
months NNS N
for IN N
gefitinib NN N
and CC N
5.1 CD N
months NNS N
for IN N
placebo NN N
; : N
hazard CC N
ratio VB N
0.89 CD N
[ JJ N
95 CD N
% NN N
CI NNP N
0.77-1.02 CD N
] NNP N
, , N
p=0.087 NN N
) ) N
or CC N
among IN N
the DT N
812 CD p
patients NNS p
with IN p
adenocarcinoma NN p
( ( N
6.3 CD N
months NNS N
vs RB N
5.4 CD N
months NNS N
; : N
0.84 CD N
[ IN N
0.68-1.03 JJ N
] NN N
, , N
p=0.089 NN N
) ) N
. . N

Preplanned VBN N
subgroup NN N
analyses VBZ N
showed VBN N
significantly RB N
longer RBR N
survival NN o
in IN N
the DT N
gefitinib NN N
group NN N
than IN N
the DT N
placebo NN N
group NN N
for IN N
never-smokers NNS p
( ( N
n=375 NN N
; : N
0.67 CD N
[ IN N
0.49-0.92 JJ N
] NN N
, , N
p=0.012 NN N
; : N
median JJ o
survival NN o
8.9 CD N
vs NN N
6.1 CD N
months NNS N
) ) N
and CC N
patients NNS N
of IN N
Asian JJ p
origin NN p
( ( N
n=342 JJ N
; : N
0.66 CD N
[ IN N
0.48-0.91 JJ N
] NN N
, , N
p=0.01 NN N
; : N
median JJ o
survival NN o
9.5 CD N
vs NN N
5.5 CD N
months NNS N
) ) N
. . N

Gefitinib NNP N
was VBD N
well RB N
tolerated VBN o
, , N
as IN N
in IN N
previous JJ N
studies NNS N
. . N

INTERPRETATION NNP N
Treatment NNP N
with IN N
gefitinib NN i
was VBD N
not RB N
associated VBN N
with IN N
significant JJ N
improvement NN N
in IN N
survival NN o
in IN N
either DT N
coprimary JJ N
population NN N
. . N

There EX N
was VBD N
pronounced JJ N
heterogeneity NN N
in IN N
survival JJ o
outcomes NNS N
between IN N
groups NNS N
of IN N
patients NNS N
, , N
with IN N
some DT N
evidence NN N
of IN N
benefit NN N
among IN N
never-smokers NNS p
and CC p
patients NNS p
of IN p
Asian JJ p
origin NN p
. . p

-DOCSTART- -16600723- O O

Clinical JJ N
usefulness NN N
of IN N
serum NN i
prostate NN i
specific JJ i
antigen NN i
for IN N
the DT N
detection NN N
of IN N
prostate NN p
cancer NN p
is VBZ N
preserved VBN N
in IN N
men NNS p
receiving VBG p
the DT p
dual JJ i
5alpha-reductase JJ i
inhibitor NN i
dutasteride NN i
. . i

PURPOSE NNP N
We PRP N
determined VBD N
whether IN N
the DT N
decrease NN N
in IN N
serum NN N
PSA NNP N
seen VBN N
with IN N
5alpha-reductase JJ i
inhibitors NNS i
affects VBZ N
the DT N
clinical JJ N
usefulness NN N
of IN N
PSA NNP N
for IN N
prostate NN N
cancer NN N
screening VBG N
using VBG N
data NNS N
from IN N
2 CD N
dutasteride JJ N
benign JJ N
prostatic JJ N
hyperplasia NN N
studies NNS N
. . N

MATERIALS NNP N
AND NNP N
METHODS NNP N
A NNP p
total NN p
of IN p
2,802 CD p
men NNS p
50 CD p
years NNS p
or CC p
older JJR p
with IN p
a DT p
clinical JJ p
diagnosis NN p
of IN p
benign JJ p
prostatic JJ p
hyperplasia NN p
, , p
no DT p
history NN p
of IN p
prostate NN p
cancer NN p
, , p
PSA NNP p
1.5 CD p
to TO p
10 CD p
ng/ml NNS p
, , p
prostate NN p
volume NN p
30 CD p
cc NN p
or CC p
greater JJR p
, , p
an DT p
American NNP p
Urological NNP p
Association NNP p
symptom VBD p
score NN p
of IN p
12 CD p
or CC p
greater JJR p
and CC p
peak JJ p
urinary JJ p
flow NN p
rate NN p
15 CD p
ml NN p
per IN p
second NN p
or CC p
less JJR p
were VBD p
randomized VBN p
to TO p
0.5 CD i
mg NNS i
dutasteride JJ i
daily RB i
or CC i
matching VBG i
placebo NN i
for IN N
24 CD N
months NNS N
. . N

Increases NNS N
in IN N
PSA NNP N
from IN N
baseline NN N
and CC N
the DT N
maximum JJ N
increase NN N
from IN N
nadir JJ N
to TO N
month NN N
24 CD N
were VBD N
compared VBN N
between IN N
the DT N
groups NNS N
and CC N
analyzed VBN N
by IN N
prostate NN N
cancer NN N
status NN N
, , N
as IN N
determined VBN N
by IN N
PSA NNP N
driven JJ N
biopsy NN N
and CC N
an DT N
advised JJ N
cutoff NN N
of IN N
more JJR N
than IN N
4 CD N
ng/ml NNS N
after IN N
doubling VBG N
to TO N
correct VB N
for IN N
dutasteride JJ i
treatment NN N
with IN N
sensitivity NN N
and CC N
specificity NN N
calculated VBN N
for IN N
each DT N
. . N

RESULTS NNP N
In IN N
placebo NN i
treated VBN N
men NNS N
without IN N
prostate NN N
cancer NN N
there EX N
was VBD N
an DT N
8.3 CD N
% NN N
median JJ o
increase NN o
in IN o
PSA NNP o
at IN o
month NN o
24 CD o
compared VBN N
with IN N
-59.5 CD N
% NN N
in IN N
those DT N
who WP N
received VBD N
dutasteride RB i
, , N
using VBG N
doubled VBD N
values NNS N
to TO N
correct VB N
for IN N
dutasteride JJ i
treatment NN N
. . N

In IN N
those DT N
with IN N
prostate JJ N
cancer NN N
these DT N
changes NNS N
were VBD N
23.8 CD N
% NN N
and CC N
-37.2 CD N
% NN N
, , N
respectively RB N
. . N

Using VBG o
the DT o
upper JJ o
PSA NNP o
limit NN o
of IN o
4 CD o
ng/ml JJ o
sensitivity NN o
for IN N
prostate NN N
cancer NN N
in IN N
men NNS N
receiving VBG N
dutasteride NN i
vs NN i
placebo NN i
was VBD N
0.737 CD N
vs NN N
0.804 CD N
, , N
while IN N
specificity NN o
was VBD N
0.671 CD N
vs JJ N
0.578 CD N
. . N

Using VBG o
a DT o
PSA NNP o
increase NN o
from IN o
nadir NN o
of IN o
0.8 CD o
ng/ml IN o
the DT N
sensitivity NN o
of IN N
dutasteride NN i
was VBD N
0.548 CD N
and CC N
its PRP$ N
specificity NN o
was VBD N
0.795 CD N
. . N

CONCLUSIONS VB N
A DT N
doubling JJ N
factor NN N
is VBZ N
effective JJ N
for IN N
maintaining VBG N
the DT N
sensitivity NN N
and CC N
specificity NN N
of IN N
PSA NNP o
for IN N
prostate NN N
cancer NN N
detection NN N
in IN N
men NNS N
on IN N
dutasteride NN i
. . i

Increases VBZ N
in IN N
serum NN o
PSA NNP o
in IN N
men NNS N
receiving VBG N
dutasteride NN i
should MD N
be VB N
considered VBN N
suspicious JJ N
and CC N
serial JJ N
PSA NNP o
measurements NNS N
should MD N
be VB N
used VBN N
to TO N
evaluate VB N
changes NNS N
from IN N
nadir NN N
. . N

-DOCSTART- -21902704- O O

Effects NNS o
of IN N
three CD N
oral JJ N
analgesics NNS i
on IN N
postoperative JJ N
pain NN N
following VBG N
root JJ N
canal JJ N
preparation NN N
: : N
a DT N
controlled JJ N
clinical JJ N
trial NN N
. . N

AIM NNP N
To TO N
compare VB N
the DT N
effects NNS N
of IN N
single JJ N
doses NNS N
of IN N
three CD N
oral JJ N
medications NNS N
on IN N
postoperative JJ N
pain NN o
following VBG N
instrumentation NN N
of IN N
root NN N
canals NNS N
in IN N
teeth NN N
with IN N
irreversible JJ N
pulpitis NN N
. . N

METHODOLOGY NNP N
In IN N
this DT N
double-blind JJ N
clinical JJ N
trial NN N
, , N
100 CD p
patients NNS p
who WP p
had VBD p
anterior CC p
or CC p
premolar JJ p
teeth NNS p
with IN p
irreversible JJ p
pulpitis NN p
without IN p
any DT p
signs NNS p
and CC p
symptoms NNS p
of IN p
acute NN p
or CC p
chronic JJ p
apical JJ p
periodontitis NN p
and CC p
moderate VB p
to TO p
severe VB p
pain NN p
were VBD N
divided VBN N
by IN N
balanced JJ N
block NN N
random NN N
allocation NN N
into IN N
four CD N
groups NNS N
of IN N
25 CD N
each DT N
, , N
a DT N
control NN i
group NN i
receiving VBG i
a DT i
placebo NN i
medication NN i
, , i
and CC i
three CD i
experimental JJ i
groups NNS i
receiving VBG i
a DT i
single JJ i
dose NN i
of IN i
either DT i
Tramadol NNP i
( ( i
100 CD i
mg NN i
) ) i
, , i
Novafen NNP i
( ( i
325 CD i
mg NN i
of IN i
paracetamol NN i
, , i
200 CD i
mg NN i
ibuprofen NN i
and CC i
40 CD i
mg NNS i
caffeine VBP i
anhydrous JJ i
) ) i
or CC i
Naproxen NNP i
( ( i
500 CD i
mg NN i
) ) i
immediately RB i
after IN i
the DT i
first JJ i
appointment NN i
where WRB i
the DT i
pulp NN i
was VBD i
removed VBN i
, , i
and CC i
the DT i
canals NNS i
were VBD i
fully RB i
prepared VBN i
. . i

The DT o
intensity NN o
of IN o
pain NN o
was VBD o
scored VBN o
based VBN o
on IN o
10-point JJ o
VAS NNP o
before IN o
and CC o
after IN o
treatment NN o
for IN o
up IN o
to TO o
24 CD o
h NN o
postoperatively RB o
. . o

Data NNS o
were VBD o
submitted VBN o
to TO o
repeated VBN o
analysis NN o
of IN o
variance NN o
. . N

RESULTS NNP N
At IN N
the DT N
6 CD N
, , N
12 CD N
and CC N
24 CD N
h NNS N
postoperative JJ N
intervals NNS N
after IN N
drug NN N
administration NN N
, , o
the DT o
intensity NN o
of IN o
pain NN o
was VBD o
significantly RB o
lower JJR N
in IN N
the DT N
experimental NN N
groups NNS N
than IN N
in IN N
the DT i
placebo NN i
group NN i
( ( N
P NNP N
< NNP N
0.01 CD i
) ) i
. . i

Tramadol NNP i
was VBD i
significantly RB i
less RBR N
effective JJ N
( ( N
P NNP N
< NNP N
0.05 CD i
) ) i
than IN i
Naproxen NNP i
, , i
and CC i
Novafen NNP i
that WDT N
were VBD N
similar JJ N
to TO N
each DT N
other JJ N
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
. . N

CONCLUSION VB N
A DT N
single JJ N
oral JJ N
dose NN i
of IN i
Naproxen NNP i
, , i
Novafen NNP i
and CC i
Tramadol NNP i
taken VBN i
immediately RB N
after IN N
treatment NN N
reduced VBD N
postoperative JJ N
pain NN N
following VBG N
pulpectomy NN N
and CC N
root JJ N
canal JJ N
preparation NN N
of IN N
teeth NNS N
with IN N
irreversible JJ N
pulpitis NN N
. . N

-DOCSTART- -3739807- O O

Abstinence NN i
or CC i
controlled VBN i
drinking NN i
in IN N
clinical JJ N
practice NN N
: : N
indications NNS N
at IN N
initial JJ N
assessment NN N
. . N

Previous JJ N
research NN N
has VBZ N
suggested VBN N
two CD N
leading JJ N
hypotheses NNS N
concerning VBG N
which WDT N
excessive JJ p
drinkers NNS p
can MD N
re-establish VB N
control NN N
: : N
one CD N
based VBN N
upon IN N
level NN N
of IN N
dependence NN N
, , N
the DT N
other JJ N
upon IN N
the DT N
client NN N
's POS N
personal JJ N
persuasion NN N
. . N

Using VBG N
initial JJ N
assessment NN N
data NNS N
from IN N
46 CD p
clients NNS p
of IN p
a DT p
clinical JJ p
psychology NN p
alcohol NN p
problems NNS p
service NN p
( ( p
30 CD p
men NNS p
, , p
16 CD p
women NNS p
) ) p
, , N
an DT N
attempt NN N
was VBD N
made VBN N
to TO N
operationalize VB N
the DT N
concepts NNS N
of IN N
dependence NN i
and CC N
personal JJ i
persuasion NN i
using VBG N
a DT N
variety NN N
of IN N
indicators NNS N
of IN N
each DT N
. . N

Although IN N
SADQ NNP o
scores NNS o
and CC o
Rand NNP o
definite VBP o
alcoholism NN o
were VBD N
in IN N
general JJ N
agreement NN N
, , N
there EX N
were VBD N
a DT N
number NN N
of IN N
borderline JJ N
instances NNS N
and CC N
cases NNS N
of IN N
disagreement NN N
, , N
and CC N
neither DT N
was VBD N
in IN N
good JJ N
agreement NN N
with IN N
estimates NNS N
of IN N
problem NN N
duration NN N
, , N
nor CC N
with IN N
reports NNS N
of IN N
recent JJ N
or CC N
earlier RBR N
attainment NN N
of IN N
abstinence NN i
or CC N
control NN i
. . i

Indicators NNS N
of IN N
personal JJ o
persuasion NN o
were VBD N
more RBR N
consistent JJ N
. . N

Those DT p
with IN p
dependence NN i
indicators NNS o
for IN o
abstinence NN o
tended VBD N
to TO N
prefer VB N
abstinence NN i
as IN N
a DT N
goal NN N
, , N
but CC N
there EX N
were VBD N
many JJ N
departures NNS N
from IN N
this DT N
pattern NN N
particularly RB N
for IN N
women NNS N
. . N

It PRP N
is VBZ N
concluded VBN N
that IN N
in IN N
clinical JJ N
practice NN N
it PRP N
will MD N
be VB N
very RB N
difficult JJ N
to TO N
make VB N
a DT N
clear JJ N
cut NN N
recommendation NN N
about IN N
treatment NN N
goal NN N
at IN N
initial JJ N
assessment NN N
except IN N
in IN N
a DT N
few JJ N
cases NNS N
. . N

-DOCSTART- -19092729- O O

A DT N
randomized JJ N
comparison NN N
of IN N
parecoxib/valdecoxib NN i
and CC N
placebo NN i
for IN N
the DT N
prevention NN N
of IN N
cystoid JJ N
macular NN N
edema NN N
after IN N
scleral JJ p
buckling NN p
surgery NN p
. . p

AIMS NNP N
To TO N
assess VB N
the DT N
impact NN N
of IN N
valdecoxib NN i
on IN N
the DT N
incidence NN N
of IN N
macular JJ N
edema NN N
, , N
after IN N
scleral JJ N
buckling NN N
surgery NN N
. . N

METHODS NNP N
Prospective NNP N
randomized VBD N
double JJ N
masked JJ N
placebo NN i
controlled VBD N
study NN N
. . N

Patients NNS p
undergoing VBG p
scleral JJ p
buckle NN p
surgery NN p
over IN p
18 CD p
months NNS p
were VBD N
recruited VBN N
and CC N
randomized VBN N
to TO N
receive VB N
either DT N
oral JJ i
valdecoxib NN i
or CC i
placebo NN i
. . i

Patients NNS N
also RB N
received VBD N
two CD N
doses NNS N
of IN N
either DT N
parecoxib NN i
( ( i
pro-drug JJ i
of IN i
valdecoxib NN i
) ) i
intravenously RB i
40 CD N
mg NNS N
6 CD N
hourly RB N
day NN N
one CD N
postoperative NN N
or CC N
identical JJ i
placebo NN i
injection NN i
Patients NNP N
underwent JJ N
retinal JJ N
examination NN N
, , N
optical JJ N
coherence NN N
tomography NN N
and CC N
retinal JJ N
thickness NN N
analyzer NN N
scan NN N
of IN N
the DT N
macula NN N
preoperatively RB N
, , N
and CC N
at IN N
2 CD N
and CC N
6 CD N
weeks NNS N
postoperatively RB N
. . N

Outcome NNP N
measures NNS N
were VBD N
the DT N
incidence NN N
of IN N
macular JJ o
edema NN o
, , o
retinal JJ o
thickness NN o
, , o
visual JJ o
acuity NN o
, , o
contrast NN o
sensitivity NN o
and CC o
presence NN o
of IN o
persistent JJ o
subretinal JJ o
fluid NN o
. . o

RESULTS NNP N
Interim NNP N
analysis NN N
was VBD N
performed VBN N
with IN N
116 CD p
patients NNS p
were VBD p
recruited VBN p
, , p
58 CD p
to TO p
each DT p
treatment NN p
arm NN p
. . p

The DT N
incidence NN o
of IN o
macular JJ o
edema NN o
in IN N
all DT N
patients NNS N
was VBD N
5 CD N
% NN N
at IN N
visit NN N
1 CD N
and CC N
2.2 CD N
% NN N
at IN N
visit NN N
2 CD N
postoperatively RB N
. . N

This DT N
incidence NN N
was VBD N
much RB o
lower JJR o
than IN N
the DT N
expected JJ N
incidence NN N
used VBN N
in IN N
the DT N
power NN N
calculation NN N
to TO N
determine VB N
study NN N
size NN N
. . N

It PRP N
was VBD N
therefore RB N
apparent JJ N
that IN N
a DT N
much RB N
larger JJR N
study NN N
population NN N
would MD N
be VB N
required VBN N
to TO N
test VB N
for IN N
an DT N
effect NN N
and CC N
that IN N
this DT N
was VBD N
not RB N
achievable JJ N
within IN N
the DT N
study NN N
time NN N
period NN N
. . N

The DT N
study NN N
was VBD N
therefore RB N
terminated VBN N
early RB N
. . N

There EX N
was VBD N
no DT N
evidence NN N
of IN N
a DT N
difference NN N
between IN N
COX NNP N
2 CD N
inhibitor NN N
and CC N
placebo NN N
groups NNS N
in IN N
the DT N
incidence NN o
of IN o
edema NN o
, , o
retinal JJ o
thickness NN o
or CC o
visual JJ o
outcome NN o
. . o

The DT N
presence NN o
of IN o
residual JJ o
subretinal JJ o
fluid NN o
at IN o
the DT o
macula NN o
was VBD N
significantly RB N
reduced VBN N
by IN N
COX NNP N
2 CD N
inhibitor NN N
treatment NN N
. . N

CONCLUSIONS VB N
The DT N
rate NN N
of IN N
cystoid NN N
macular NN N
edema NN N
after IN N
scleral JJ N
buckling NN N
surgery NN N
is VBZ N
low JJ N
and CC N
is VBZ N
not RB N
influenced VBN N
by IN N
prophylactic JJ N
use NN N
of IN N
valdecoxib NN i
. . i

The DT N
rate NN N
of IN N
residual JJ N
subretinal JJ N
fluid NN N
was VBD N
reduced VBN N
by IN N
COX NNP N
2 CD N
inhibitor NN N
treatment NN N
. . N

Enhanced NNP N
antiinflammatory NN N
therapy NN N
has VBZ N
the DT N
potential NN N
to TO N
improve VB N
outcomes NNS N
in IN N
scleral JJ N
buckling NN N
surgery NN N
. . N

-DOCSTART- -24679062- O O

Aspirin NNP i
in IN N
patients NNS p
undergoing JJ p
noncardiac JJ p
surgery NN p
. . p

BACKGROUND NNP N
There EX N
is VBZ N
substantial JJ N
variability NN N
in IN N
the DT N
perioperative JJ N
administration NN N
of IN N
aspirin NNS i
in IN N
patients NNS p
undergoing JJ p
noncardiac JJ p
surgery NN p
, , N
both DT N
among IN N
patients NNS p
who WP p
are VBP p
already RB p
on IN p
an DT p
aspirin JJ i
regimen NNS p
and CC p
among IN p
those DT p
who WP p
are VBP p
not RB p
. . p

METHODS NNP N
Using VBG N
a DT N
2-by-2 JJ N
factorial JJ N
trial NN N
design NN N
, , N
we PRP N
randomly VBP N
assigned VBD N
10,010 CD p
patients NNS p
who WP p
were VBD p
preparing VBG p
to TO p
undergo VB p
noncardiac JJ p
surgery NN p
and CC p
were VBD p
at IN p
risk NN p
for IN p
vascular JJ p
complications NNS p
to TO N
receive VB N
aspirin NN i
or CC i
placebo NN i
and CC i
clonidine NN i
or CC i
placebo NN i
. . i

The DT N
results NNS N
of IN N
the DT N
aspirin JJ i
trial NN N
are VBP N
reported VBN N
here RB N
. . N

The DT N
patients NNS N
were VBD N
stratified VBN N
according VBG N
to TO N
whether IN N
they PRP N
had VBD N
not RB N
been VBN N
taking VBG N
aspirin NN i
before IN N
the DT N
study NN N
( ( N
initiation NN N
stratum NN N
, , N
with IN N
5628 CD N
patients NNS N
) ) N
or CC N
they PRP N
were VBD N
already RB N
on IN N
an DT N
aspirin JJ i
regimen NNS N
( ( N
continuation NN N
stratum NN N
, , N
with IN N
4382 CD N
patients NNS N
) ) N
. . N

Patients NNS N
started VBD N
taking VBG N
aspirin NN i
( ( N
at IN N
a DT N
dose NN N
of IN N
200 CD N
mg NN N
) ) N
or CC N
placebo VB i
just RB N
before RB N
surgery NN N
and CC N
continued VBD N
it PRP N
daily RB N
( ( N
at IN N
a DT N
dose NN N
of IN N
100 CD N
mg NNS N
) ) N
for IN N
30 CD N
days NNS N
in IN N
the DT N
initiation NN N
stratum NN N
and CC N
for IN N
7 CD N
days NNS N
in IN N
the DT N
continuation NN N
stratum NN N
, , N
after IN N
which WDT N
patients NNS N
resumed VBD N
their PRP$ N
regular JJ N
aspirin JJ i
regimen NNS N
. . N

The DT N
primary JJ N
outcome NN N
was VBD N
a DT N
composite JJ o
of IN o
death NN o
or CC o
nonfatal JJ o
myocardial JJ o
infarction NN o
at IN o
30 CD o
days NNS o
. . o

RESULTS VB N
The DT N
primary JJ o
outcome NN o
occurred VBD N
in IN N
351 CD N
of IN N
4998 CD N
patients NNS N
( ( N
7.0 CD N
% NN N
) ) N
in IN N
the DT N
aspirin NN i
group NN N
and CC N
in IN N
355 CD N
of IN N
5012 CD N
patients NNS N
( ( N
7.1 CD N
% NN N
) ) N
in IN N
the DT N
placebo NN i
group NN N
( ( N
hazard JJ N
ratio NN N
in IN N
the DT N
aspirin NN N
group NN N
, , N
0.99 CD N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NNP N
, , N
0.86 CD N
to TO N
1.15 CD N
; : N
P=0.92 NNP N
) ) N
. . N

Major JJ o
bleeding NN o
was VBD N
more RBR N
common JJ N
in IN N
the DT N
aspirin NN N
group NN N
than IN N
in IN N
the DT N
placebo NN i
group NN N
( ( N
230 CD N
patients NNS N
[ JJ N
4.6 CD N
% NN N
] NNP N
vs. IN N
188 CD N
patients NNS N
[ JJ N
3.8 CD N
% NN N
] NN N
; : N
hazard CC N
ratio NN N
, , N
1.23 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
1.01 CD N
, , N
to TO N
1.49 CD N
; : N
P=0.04 NNP N
) ) N
. . N

The DT N
primary JJ N
and CC N
secondary JJ N
outcome NN N
results NNS N
were VBD N
similar JJ N
in IN N
the DT N
two CD N
aspirin NN i
strata NNS N
. . N

CONCLUSIONS NNP N
Administration NNP N
of IN N
aspirin NN i
before IN N
surgery NN N
and CC N
throughout IN N
the DT N
early JJ N
postsurgical JJ N
period NN N
had VBD N
no DT N
significant JJ N
effect NN N
on IN N
the DT N
rate NN o
of IN o
a DT o
composite NN o
of IN o
death NN o
or CC o
nonfatal JJ o
myocardial JJ o
infarction NN o
but CC N
increased VBD N
the DT N
risk NN o
of IN o
major JJ o
bleeding NN o
. . o

( ( N
Funded VBN N
by IN N
the DT N
Canadian NNP N
Institutes NNPS N
of IN N
Health NNP N
Research NNP N
and CC N
others NNS N
; : N
POISE-2 NNP N
ClinicalTrials.gov NNP N
number NN N
, , N
NCT01082874 NNP N
. . N

) ) N
. . N

-DOCSTART- -2936772- O O

Comparative JJ N
efficacy NN N
of IN N
oral JJ i
erythromycin FW i
versus FW i
oral JJ i
tetracycline NN i
in IN N
the DT N
treatment NN N
of IN N
acne JJ o
vulgaris NN o
. . o

A DT N
double-blind JJ N
study NN N
. . N

The DT N
efficacy NN o
of IN N
erythromycin JJ o
base NN o
( ( o
E-Mycin JJ o
tablets NNS o
, , o
333 CD o
mg NN o
) ) o
and CC N
the DT N
efficacy NN o
of IN N
tetracycline JJ o
hydrochloride NN o
( ( N
Panmycin NNP N
tablets NNS N
) ) N
were VBD N
compared VBN N
in IN N
this DT N
double-blind NN N
, , N
randomized VBN N
study NN N
. . N

Two CD p
hundred VBD p
patients NNS p
with IN p
moderate JJ p
to TO p
moderately RB p
severe JJ p
acne NNS p
vulgaris NNS p
were VBD N
randomly RB N
assigned VBN N
to TO N
the DT N
study NN N
. . N

One CD N
hundred VBD N
patients NNS N
received VBD N
1 CD i
gm NN i
of IN i
erythromycin JJ i
base NN i
by IN N
mouth JJ N
per IN N
day NN N
for IN N
4 CD N
weeks NNS N
, , N
followed VBN N
by IN N
333 CD N
mg/day NN N
for IN N
8 CD N
weeks NNS N
, , N
plus CC N
placebo NN i
for IN i
tetracycline NN i
. . i

The DT N
second JJ N
group NN N
of IN N
patients NNS N
received VBD N
1 CD N
gm NN N
of IN N
tetracycline NN i
by IN N
mouth JJ N
per IN N
day NN N
for IN N
4 CD N
weeks NNS N
, , N
followed VBN N
by IN N
500 CD N
mg/day NN N
for IN N
8 CD N
weeks NNS N
, , N
plus CC N
placebo NN i
for IN i
erythromycin NN i
. . i

Both DT N
drugs NNS N
reduced VBD N
acne JJ o
severity NN o
to TO N
the DT N
same JJ N
extent NN N
. . N

Pustules NNP o
, , o
papules NNS o
, , o
and CC o
open JJ o
comedo NN o
counts NNS o
decreased VBN N
significantly RB N
over IN N
the DT N
12-week JJ N
period NN N
. . N

Seventy-seven JJ N
percent NN N
of IN N
the DT N
erythromycin-treated JJ N
patients NNS N
and CC N
89 CD N
% NN N
of IN N
the DT N
tetracycline-treated JJ N
patients NNS N
stated VBD N
that IN N
their PRP$ N
acne NN o
was VBD N
markedly RB N
improved VBN N
or CC N
improved VBN N
by IN N
week NN N
12 CD N
. . N

Most JJS N
of IN N
the DT N
side NN N
effects NNS N
in IN N
patients NNS N
treated VBN N
with IN N
erythromycin NNS N
were VBD N
gastrointestinal JJ o
symptoms NNS o
. . o

Among IN N
the DT N
side NN N
effects NNS N
in IN N
patients NNS N
treated VBN N
with IN N
tetracycline NN N
were VBD N
Candida NNP o
vaginitis NN o
in IN N
one CD N
patient NN N
and CC N
pseudotumor NN o
cerebri NN o
in IN N
one CD N
patient NN N
. . N

-DOCSTART- -11978262- O O

Oat NNP i
ingestion NN i
reduces VBZ N
systolic JJ N
and CC N
diastolic JJ N
blood NN N
pressure NN N
in IN N
patients NNS p
with IN p
mild JJ p
or CC p
borderline JJ p
hypertension NN p
: : p
a DT N
pilot NN N
trial NN N
. . N

OBJECTIVES IN N
We PRP N
assessed VBD N
the DT N
short-term JJ N
antihypertensive JJ N
effects NNS N
of IN N
soluble JJ i
fiber-rich JJ i
whole JJ i
oat NN i
cereals NNS i
when WRB N
added VBN N
to TO N
a DT N
standard JJ N
American JJ N
diet NN N
. . N

In IN N
addition NN N
, , N
multiple JJ N
assessments NNS N
of IN N
insulin NN N
sensitivity NN N
were VBD N
conducted VBN N
. . N

STUDY NNP N
DESIGN NNP N
This DT N
was VBD N
a DT N
randomized JJ N
, , N
controlled VBN N
, , N
parallel-group JJ N
pilot NN N
study NN N
designed VBN N
to TO N
compare VB N
an DT N
oat NN i
cereal NN i
group NN i
( ( i
standardized VBN i
to TO i
5.52 CD i
g/day JJ i
beta-glucan JJ i
) ) i
to TO i
a DT i
low-fiber JJ i
cereal NN i
control NN i
group NN i
( ( i
less JJR i
than IN i
1.0 CD i
g/day JJ i
total JJ i
fiber NN i
) ) i
over IN i
6 CD i
weeks NNS i
. . i

POPULATION VB N
A DT p
total NN p
of IN p
18 CD p
hypertensive JJ p
and CC p
hyperinsulinemic JJ p
( ( p
= JJ p
10 CD p
U/mL NNP p
or CC p
more JJR p
) ) p
men NNS p
and CC p
women NNS p
completed VBD p
the DT p
trial NN p
. . p

OUTCOMES NNP N
MEASURED NNP N
Primary NNP N
study NN N
outcomes NNS N
were VBD N
changes NNS N
in IN N
systolic JJ o
blood NN o
pressure NN o
( ( o
SBP NNP o
) ) o
and CC o
diastolic JJ o
blood NN o
pressure NN o
( ( o
DBP NNP o
) ) o
. . o

Secondary JJ N
outcomes NNS N
included VBD N
blood NN o
lipid NN o
, , o
fasting VBG o
glucose NN o
, , o
and CC o
insulin NN o
levels NNS o
and CC o
side NN o
effects NNS o
related VBN o
to TO o
elevated VBN o
blood NN o
pressure NN o
and CC o
increased VBD o
dietary JJ o
fiber NN o
intake NN o
. . o

RESULTS VB N
The DT N
oat NN N
cereal NN N
group NN N
experienced VBD N
a DT N
7.5 CD N
mm NN N
Hg NNP N
reduction NN N
in IN N
SBP NNP o
( ( N
P NNP N
& CC N
lt.01 NN N
) ) N
and CC N
a DT N
5.5 CD N
mm NN N
Hg NNP N
reduction NN N
in IN N
DBP NNP o
( ( N
P NNP N
& CC N
lt.02 NN N
) ) N
, , N
while IN N
there EX N
was VBD N
virtually RB N
no DT N
change NN N
in IN N
either DT N
SBP NNP N
or CC N
DBP NNP N
in IN N
the DT N
control NN N
group NN N
. . N

In IN N
the DT N
oat NN N
cereal NN N
group NN N
, , N
a DT N
trend NN N
was VBD N
observed VBN N
for IN N
a DT N
lower JJR N
total JJ o
insulin NN o
response NN o
to TO N
a DT N
glucose JJ N
load NN N
, , N
suggesting VBG N
improved VBN N
insulin JJ N
sensitivity NN N
. . N

However RB N
, , N
this DT N
could MD N
not RB N
be VB N
confirmed VBN N
using VBG N
estimates NNS N
from IN N
the DT N
Bergman NNP N
Minimal NNP N
Model NNP N
, , N
perhaps RB N
because IN N
of IN N
our PRP$ N
small JJ N
sample NN N
size NN N
. . N

The DT N
oats NNS N
group NN N
experienced VBD N
a DT N
significant JJ N
reduction NN N
in IN N
both DT N
total JJ o
cholesterol NN o
( ( N
9 CD N
% NN N
) ) N
and CC N
low-density JJ o
lipoprotein NN o
cholesterol NN o
( ( N
14 CD N
% NN N
) ) N
. . N

CONCLUSIONS VB N
The DT N
addition NN N
of IN N
oat NN i
cereals NNS i
to TO N
the DT N
normal JJ N
diet NN N
of IN N
patients NNS p
with IN p
hypertension NN p
significantly RB N
reduces VBZ N
both DT N
SBP NNP o
and CC o
DBP NNP o
. . o

Soluble JJ i
fiber-rich JJ i
whole JJ i
oats NNS i
may MD N
be VB N
an DT N
effective JJ N
dietary JJ N
therapy NN N
in IN N
the DT N
prevention NN N
and CC N
adjunct JJ N
treatment NN N
of IN N
hypertension NN N
. . N

-DOCSTART- -15895329- O O

Effects NNS N
of IN N
home NN i
strength NN i
training NN i
and CC i
stretching VBG i
versus NN i
stretching VBG i
alone RB i
after IN p
lumbar JJ p
disk NN p
surgery NN p
: : p
a DT N
randomized JJ N
study NN N
with IN N
a DT N
1-year JJ N
follow-up NN N
. . N

OBJECTIVE UH N
To TO N
assess VB N
the DT N
adherence NN N
to TO N
and CC N
effects NNS N
of IN N
a DT N
12-month JJ N
combined JJ i
strength NN i
and CC i
stretching NN i
home NN i
exercise NN i
regimen NNS i
versus IN i
stretching VBG i
alone RB i
, , N
on IN N
patient JJ p
outcome NN p
after IN p
lumbar NN p
disk NN p
surgery NN p
. . p

DESIGN NNP N
Randomized NNP N
controlled VBD N
trial NN N
. . N

SETTING NN N
Departments NNS p
of IN p
physical JJ p
medicine NN p
and CC p
rehabilitation NN p
and CC p
orthopedics NNS p
at IN p
a DT p
Finnish JJ p
hospital NN p
. . p

PARTICIPANTS JJ N
Patients NNPS p
( ( p
N=126 NNP p
) ) p
were VBD p
randomized VBN p
into IN N
either CC N
a DT N
combined JJ i
strength NN i
training NN i
and CC i
stretching VBG i
group NN i
( ( N
STG NNP N
, , N
n=65 NN N
) ) N
or CC N
a DT N
control NN i
group NN i
( ( N
CG NNP N
, , N
n=61 NN N
) ) N
. . N

INTERVENTION NNP N
The DT N
STG NNP N
was VBD N
instructed VBN N
to TO N
perform VB N
strength NN i
training NN i
and CC N
both DT N
the DT N
STG NNP N
and CC N
CG NNP N
were VBD N
instructed VBN N
in IN N
the DT N
same JJ N
stretching NN i
and CC i
stabilization NN i
exercises NNS i
for IN N
12 CD N
months NNS N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Pain NNP N
on IN N
the DT N
visual JJ o
analog NN o
scale NN o
( ( o
VAS NNP o
) ) o
, , o
the DT o
Oswestry NNP o
and CC o
the DT o
Million NNP o
disability NN o
indexes NNS o
, , o
isometric JJ o
and CC o
dynamic JJ o
trunk NN o
muscle NN o
strength NN o
, , o
mobility NN o
in IN o
the DT o
lumbar NN o
spine NN o
, , o
and CC o
straight-leg JJ o
raising NN o
were VBD N
measured VBN N
. . N

RESULTS VB N
The DT N
trial NN N
was VBD N
completed VBN N
by IN N
71 CD N
% NN N
and CC N
77 CD N
% NN N
of IN N
the DT N
patients NNS N
from IN N
the DT N
STG NNP N
and CC N
the DT N
CG NNP N
, , N
respectively RB N
. . N

The DT N
mean JJ o
strength NN o
training NN o
frequency NN o
decreased VBD N
from IN N
1.5 CD N
to TO N
0.6 CD N
times NNS N
a DT N
week NN N
in IN N
the DT N
STG NNP N
during IN N
the DT N
intervention NN N
. . N

The DT N
mean JJ o
stretching NN o
frequency NN o
decreased VBD N
from IN N
3.7 CD N
to TO N
1.6 CD N
times NNS N
a DT N
week NN N
in IN N
both DT N
groups NNS N
. . N

Median JJ o
back RB o
and CC o
leg NN o
pain NN o
varied VBD N
between IN N
17 CD N
and CC N
23 CD N
mm NN N
( ( N
VAS NNP N
) ) N
, , N
and CC N
the DT N
Million NNP o
and CC o
Oswestry NNP o
indices NNS o
varied VBD N
between IN N
14 CD N
and CC N
23 CD N
points NNS N
2 CD N
months NNS N
postoperatively RB N
. . N

No DT N
statistically RB N
significant JJ N
changes NNS N
took VBD N
place NN N
in IN N
these DT N
outcome NN N
measures NNS N
during IN N
the DT N
12-month JJ N
follow-up NN N
in IN N
both DT N
groups NNS N
. . N

The DT N
changes NNS N
in IN N
isometric JJ o
trunk NN o
extension NN o
favored VBD N
the DT N
STG NNP N
( ( N
P NNP N
=.016 NNP N
) ) N
during IN N
the DT N
first JJ N
2 CD N
months NNS N
. . N

However RB N
, , N
during IN N
the DT N
whole JJ N
12-month JJ N
training NN N
period NN N
, , N
both DT N
dynamic JJ o
and CC o
isometric JJ o
back NN o
extension NN o
and CC o
flexion NN o
strength NN o
, , N
as RB N
well RB N
as IN N
mobility NN o
of IN o
the DT o
spine NN o
and CC o
repetitive JJ o
squat-test JJ o
results NNS o
, , N
improved VBN N
significantly RB N
in IN N
both DT N
groups NNS N
, , N
and CC N
no DT N
differences NNS N
were VBD N
found VBN N
in IN N
any DT N
of IN N
the DT N
physical JJ o
function NN o
parameters NNS o
between IN N
the DT N
STG NNP N
and CC N
CG NNP N
. . N

CONCLUSIONS NNP N
At IN N
the DT N
12-month JJ N
follow-up NN N
, , N
no DT N
statistically RB N
significant JJ N
changes NNS N
were VBD N
found VBN N
in IN N
the DT N
physical JJ o
function NN o
, , o
pain NN o
, , o
or CC o
disability NN o
measures NNS o
between IN N
the DT N
groups NNS N
. . N

In IN N
the DT N
STG NNP N
, , N
training VBG N
adherence NN N
with IN N
regard NN N
to TO N
training NN N
frequency NN N
and CC N
intensity NN N
remained VBD N
too RB N
low JJ N
to TO N
lead VB N
to TO N
specific JJ N
training-induced JJ N
adaptations NNS N
in IN N
the DT N
neuromuscular JJ N
system NN N
. . N

Progressive JJ N
loading NN N
, , N
supervision NN N
of IN N
training NN N
, , N
and CC N
psychosocial JJ N
support NN N
is VBZ N
needed VBN N
in IN N
long-term JJ N
rehabilitation NN N
programs NNS N
to TO N
maintain VB N
patient JJ N
motivation NN N
. . N

-DOCSTART- -15816106- O O

The DT N
influence NN N
of IN N
epidermal JJ i
growth NN i
factor NN i
receptor NN i
and CC N
tumor NN N
differentiation NN N
on IN N
the DT N
response NN N
to TO N
accelerated VBN N
radiotherapy NN N
of IN N
squamous JJ p
cell NN p
carcinomas NN p
of IN p
the DT p
head NN p
and CC p
neck NN p
in IN N
the DT N
randomized JJ N
DAHANCA NNP N
6 CD N
and CC N
7 CD N
study NN N
. . N

BACKGROUND NNP N
AND NNP N
PURPOSE NNP N
Reduction NNP N
of IN N
the DT N
overall JJ N
treatment NN N
time NN N
of IN N
radiotherapy NN N
has VBZ N
increased VBN N
locoregional JJ o
control NN o
and CC N
disease NN o
specific JJ o
survival NN o
in IN N
squamous JJ p
cell NN p
carcinomas NN p
of IN p
the DT p
head NN p
and CC p
neck NN p
( ( p
HNSCC NNP p
) ) p
, , N
but CC N
the DT N
response NN N
is VBZ N
heterogeneous JJ N
. . N

EGFr NNP N
is VBZ N
often RB N
overexpressed VBN N
in IN N
HNSCC NNP N
and CC N
has VBZ N
been VBN N
related VBN N
to TO N
the DT N
repopulation NN N
taking VBG N
place NN N
during IN N
radiotherapy NN N
. . N

The DT N
aim NN N
of IN N
the DT N
current JJ N
study NN N
was VBD N
to TO N
address VB N
the DT N
influence NN o
of IN o
EGFr NNP o
and CC N
histopathological JJ o
differentiation NN o
when WRB N
the DT N
overall JJ o
treatment NN o
time NN o
of IN o
radiotherapy NN o
was VBD N
moderately RB N
reduced VBN N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
Eight NNP p
hundred VBD p
and CC p
three CD p
patients NNS p
with IN p
representative JJ p
pretreatment NN p
tissue NN p
samples NNS p
from IN p
the DT p
randomized VBN p
DAHANCA NNP p
6 CD p
and CC p
7 CD p
study NN p
of IN p
5 CD p
vs. FW p
6 CD p
fx/wk NN p
of IN p
radiotherapy NN i
. . i

EGFr NNP N
was VBD N
visualized VBN N
using VBG N
immunohistochemistry NN N
and CC N
separated VBN N
into IN N
high JJ N
and CC N
low JJ N
expression NN N
before IN N
correlation NN N
with IN N
clinical JJ N
data NNS N
. . N

RESULTS NNP N
Tumors NNPS N
with IN N
high JJ N
EGFr NNP N
( ( N
84 CD N
% NN N
) ) N
responded VBD o
better RBR N
to TO N
moderately RB N
accelerated JJ N
radiotherapy NN N
, , N
than IN N
carcinomas NNS N
with IN N
low JJ N
EGFr NNP N
, , N
using VBG N
locoregional JJ N
control NN N
as IN N
endpoint NN N
and CC N
a DT N
similar JJ N
pattern NN N
was VBD N
seen VBN N
, , N
stratifying VBG N
by IN N
well/moderate NN N
vs. FW N
poor JJ N
tumor NN o
differentiation NN o
. . o

Therefore RB N
, , N
a DT N
combined JJ N
parameter NN N
was VBD N
constructed VBN N
showing VBG N
a DT N
more RBR N
prominent JJ o
separation NN o
of IN o
response NN o
: : o
tumors NNS N
with IN N
high JJ N
EGFr NNP N
and CC N
well/moderate JJ N
differentiation NN o
did VBD N
benefit VB N
from IN N
moderate JJ N
acceleration NN N
of IN N
treatment NN N
regarding VBG N
locoregional JJ N
control NN N
, , N
HR NNP N
0.54 CD N
( ( N
0.37-0.78 NN N
) ) N
, , N
whereas NNS N
such JJ N
an DT N
effect NN N
was VBD N
not RB N
seen VBN N
in IN N
tumors NNS N
with IN N
low JJ N
EGFr NNP N
and/or NN N
poor JJ N
differentiation NN N
, , N
HR NNP N
0.8 CD N
( ( N
0.51-1.25 NN N
) ) N
. . N

These DT N
results NNS N
reflected VBD N
the DT N
disease NN o
specific JJ o
survival NN o
as IN N
well RB N
and CC N
were VBD N
confirmed VBN N
in IN N
multivariable JJ N
analyses NNS N
. . N

CONCLUSIONS NNP N
Moderately RB N
accelerated JJ N
fractionation NN N
is VBZ N
superior JJ o
to TO o
conventional JJ o
treatment NN o
in IN N
HNSCC NNP N
but CC N
the DT N
response NN o
is VBZ N
heterogeneous JJ N
and CC N
may MD N
be VB N
predicted VBN N
by IN N
high JJ N
expression NN o
of IN o
EGFr NNP o
and CC N
well/moderate JJ N
tumor NN o
differentiation NN o
. . o

-DOCSTART- -11379334- O O

Efficacy NN o
and CC o
tolerability NN o
of IN N
antibiotics NNS i
in IN N
patients NNS p
undergoing VBG p
H. NNP p
pylori JJ p
eradication NN p
. . p

BACKGROUND/AIMS NNP N
Helicobacter NNP N
pylori NN N
( ( N
H. NNP N
pylori NN N
) ) N
infection NN N
is VBZ N
one CD N
of IN N
the DT N
most RBS N
common JJ N
gastrointestinal JJ N
diseases NNS N
. . N

An DT N
increasing VBG N
number NN N
of IN N
people NNS N
undergo JJ N
different JJ N
treatment NN N
options NNS N
. . N

Unfortunately RB N
, , N
H. NNP N
pylori FW N
therapy NN N
may MD N
be VB N
troublesome JJ N
for IN N
drug NN N
side NN N
effects NNS N
and CC N
inefficacious JJ N
for IN N
resistance NN N
to TO N
antibiotics NNS i
. . i

METHODOLOGY NNP N
One CD p
hundred CD p
and CC p
ninety-three JJ p
( ( p
193 CD p
) ) p
H. NNP p
pylori-positive JJ p
patients NNS p
were VBD N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
the DT N
following JJ N
7-day JJ N
treatments NNS N
: : N
Group NNP p
A NNP p
( ( p
N NNP p
= NNP p
64 CD p
) ) p
: : p
amoxicillin NN i
, , i
clarithromycin NN i
and CC i
rabeprazole NN i
; : i
Group NNP p
B NNP p
( ( p
N NNP p
= NNP p
64 CD p
) ) p
: : p
tinidazole NN i
, , i
clarithromycin NN i
and CC i
ranitidine NN i
bismuth NN i
citrate NN i
; : i
Group NNP p
C NNP p
( ( p
N NNP p
= NNP p
65 CD p
) ) p
: : p
tinidazole NN i
, , i
clarithromycin NN i
and CC i
rabeprazole JJ i
Eradication NNP N
was VBD N
assessed VBN N
by IN N
13C-Urea JJ N
Breath NNP N
Test NNP N
6-8 JJ N
weeks NNS N
after IN N
the DT N
end NN N
of IN N
the DT N
therapy NN N
. . N

Not-eradicated JJ N
patients NNS N
underwent VBD N
a DT N
second JJ N
cycle NN N
with IN N
tinidazole NN i
, , i
tetracycline NN i
, , i
bismuth NN i
and CC i
rabeprazole NN i
. . i

All DT p
patients NNS p
were VBD N
asked VBN N
to TO N
complete VB N
a DT N
validated JJ N
questionnaire NN N
regarding VBG N
presence NN N
and CC N
intensity NN N
of IN N
drug NN N
side NN N
effects NNS N
. . N

RESULTS NNP N
One CD p
hundred CD p
and CC p
eighty-eight JJ p
out IN p
of IN p
the DT p
193 CD p
H. NNP p
pylori-positive JJ p
patients NNS p
( ( p
96 CD p
% NN p
) ) p
completed VBD p
therapy NN p
. . p

No DT N
significant JJ N
difference NN N
in IN N
eradication NN o
rates NNS o
was VBD N
observed VBN N
among IN N
the DT N
three CD N
groups NNS N
both DT N
in IN N
intention NN N
to TO N
treat VB N
analysis NN N
and CC N
in IN N
per IN N
protocol NN N
analysis NN N
. . N

No DT N
significant JJ N
difference NN N
in IN N
incidence NN o
of IN o
side NN o
effects NNS o
occurred VBD N
among IN N
groups NNS N
after IN N
the DT N
first-line JJ N
regimens NNS N
: : N
48 CD N
% NN N
in IN N
group NN N
A NNP N
, , N
44 CD N
% NN N
in IN N
group NN N
B NNP N
and CC N
46 CD N
% NN N
in IN N
group NN N
C. NNP N
Twenty-two NNP N
out IN N
of IN N
the DT N
193 CD p
enrolled JJ p
subjects NNS p
( ( N
11 CD N
% NN N
) ) N
were VBD N
not RB N
eradicated VBN o
after IN N
the DT N
first-line JJ N
therapy NN N
. . N

Among IN N
them PRP N
, , N
86 CD N
% NN N
were VBD N
successfully RB N
eradicated VBN o
by IN N
the DT N
tinidazole NN i
, , i
tetracycline NN i
, , i
bismuth NN i
and CC N
rabeprazole JJ i
therapy NN N
. . N

Moreover RB N
, , N
during IN N
quadruple JJ N
therapy NN N
, , N
a DT N
higher JJR N
prevalence NN o
and CC o
intensity NN o
of IN o
side NN o
effects NNS o
than IN N
in IN N
each DT N
one CD N
of IN N
the DT N
groups NNS N
submitted VBD N
to TO N
the DT N
first-line JJ N
triple JJ N
therapy NN N
was VBD N
observed VBN N
. . N

CONCLUSIONS VB N
This DT N
study NN N
shows VBZ N
that IN N
triple JJ i
rabeprazole-based JJ i
eradicating NN i
regimens NNS i
are VBP N
effective JJ o
and CC o
safe JJ o
. . o

Incidence NN N
of IN N
side NN o
effects NNS o
seems VBZ N
low JJ N
and CC N
similar JJ N
in IN N
different JJ N
three-drug JJ N
regimens NNS N
used VBN N
. . N

Quadruple JJ i
therapy NN i
, , N
which WDT N
appear VBP N
highly RB N
efficacious JJ N
as IN N
a DT N
second JJ N
line NN N
therapy NN N
, , N
is VBZ N
associated VBN N
with IN N
a DT N
significantly RB N
higher JJR N
incidence NN N
of IN N
side NN N
effects NNS N
when WRB N
compared VBN N
to TO N
first-line JJ N
treatment NN N
. . N

-DOCSTART- -15947531- O O

Effect NN N
of IN N
Orlistat NNP i
in IN N
obese JJ p
patients NNS p
with IN p
heart NN p
failure NN p
: : p
a DT N
pilot NN N
study NN N
. . N

Heart NNP N
failure NN N
is VBZ N
the DT N
leading VBG N
cause NN N
of IN N
hospitalization NN N
. . N

Obesity NNP N
is VBZ N
increasingly RB N
common JJ N
and CC N
is VBZ N
a DT N
major JJ N
public JJ N
health NN N
problem NN N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
is VBZ N
to TO N
assess VB N
whether IN N
obese JJ p
patients NNS p
with IN p
heart NN p
failure NN p
can MD N
benefit VB N
from IN N
losing VBG N
weight NN N
via IN N
an DT N
orlistat-assisted JJ i
diet NN i
. . i

This DT N
randomized JJ N
clinical JJ N
trial NN N
included VBD N
obese JJ p
patients NNS p
with IN p
ejection NN p
fractions NNS p
< VBP p
or CC p
=40 CD p
% NN p
. . p

Orlistat NNP i
and CC i
diet JJ i
counseling NN i
were VBD i
compared VBN i
with IN i
diet JJ i
counseling VBG i
alone RB i
. . i

Twenty-one JJ p
consecutive JJ p
obese JJ p
patients NNS p
with IN p
heart NN p
failure NN p
were VBD p
recruited VBN p
. . p

Significant JJ N
improvement NN N
in IN N
6-minute JJ o
walk NN o
test NN o
( ( N
45.8 CD N
m NN N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
5.2-86.4 JJ N
m NN N
; : N
p=0.031 NN N
) ) N
, , N
functional JJ o
class NN o
( ( N
-0.6+/-0.5 UH N
, , N
p=0.014 NN N
) ) N
, , N
weight JJ o
loss NN o
( ( N
-8.55 JJ N
kg NN N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
-13.0 NN N
to TO N
-4.1 VB N
kg NN N
; : N
p CC N
< VB N
0.001 CD N
) ) N
and CC N
also RB N
significant JJ N
decreases NNS N
in IN N
total JJ o
cholesterol NN o
( ( N
p=0.017 NN N
) ) N
, , N
low-density JJ o
lipoprotein NN o
cholesterol NN o
( ( N
p=0.03 NN N
) ) N
, , N
and CC N
triglycerides NNS o
( ( N
p=0.036 NN N
) ) N
were VBD N
observed VBN N
in IN N
the DT N
orlistat NN N
group NN N
. . N

Orlistat CC i
can MD N
promote VB N
significant JJ N
weight JJ o
loss NN o
and CC o
symptoms NNS o
of IN o
relief NN o
in IN N
obese JJ N
patients NNS N
with IN N
heart NN N
failure NN N
, , N
as IN N
measured VBN N
by IN N
6-minute JJ N
walk NN N
test NN N
and CC N
functional JJ N
capacity NN N
. . N

The DT N
lipid JJ N
profile NN N
improved VBN N
. . N

Orlistat NNP i
was VBD N
safe JJ N
and CC N
well RB N
tolerated VBN N
. . N

-DOCSTART- -25047312- O O

Intramuscular JJ i
compared VBN i
to TO i
intravenous JJ i
midazolam NN i
for IN N
paediatric JJ N
sedation NN N
: : N
A DT N
study NN N
on IN N
cardiopulmonary JJ N
safety NN N
and CC N
effectiveness NN N
. . N

BACKGROUND NNP N
Sedation NNP N
in IN N
children NNS p
remains VBZ N
a DT N
controversial JJ N
issue NN N
in IN N
emergency NN N
departments NNS N
( ( N
ED NNP N
) ) N
. . N

Midazolam NNP i
, , N
as IN N
a DT N
benzodiazepine NN i
is VBZ N
widely RB N
used VBN N
for IN N
procedural JJ N
sedation NN N
among IN N
paediatrics NNS N
. . N

We PRP N
compared VBN N
the DT N
effectiveness NN N
and CC N
safety NN N
of IN N
two CD N
forms NNS N
of IN N
midazolam JJ i
prescription NN i
; : i
intramuscular JJ i
( ( i
IM NNP i
) ) i
and CC i
intravenous JJ i
( ( i
IV NNP i
) ) i
. . i

PATIENTS NNP N
AND CC N
METHODS NNP N
A NNP N
cohort NN N
study NN N
was VBD N
conducted VBN N
on IN N
two CD p
matched JJ p
groups NNS p
of IN p
30 CD p
children NNS p
referred VBD p
to TO p
our PRP$ p
ED NNP p
between IN p
2010 CD p
and CC p
2011 CD p
. . p

The DT N
first JJ N
group NN N
received VBD N
IM NNP i
midazolam NNP i
( ( N
0.3 CD N
mg/kg NN N
) ) N
and CC N
the DT N
second JJ N
group NN N
received VBD N
IV NNP i
midazolam NNP i
( ( N
0.15 CD N
mg/kg NN N
) ) N
for IN N
sedation NN N
. . N

For IN N
evaluating VBG N
effectiveness NN o
, , o
sedation NN o
, , o
irritation NN o
and CC o
cooperation NN o
score NN o
were VBD N
followed VBN N
every DT N
15 CD N
min NN N
for IN N
60 CD N
min NNS N
and CC N
for IN N
safety NN o
assessment NN o
, , o
vital JJ o
signs NNS o
and CC o
O NNP o
2 CD o
saturation NN o
were VBD N
observed VBN N
. . N

RESULTS JJ N
Mean JJ p
age NN p
was VBD p
6.18 CD p
? . p
2.88 CD p
years NNS p
and CC p
31 CD p
patients NNS p
( ( p
51.7 CD p
% NN p
) ) p
were VBD p
male JJ p
. . p

All DT N
patients NNS N
were VBD o
sedated VBN o
completely RB N
after IN N
using VBG N
first RB N
dose RB N
. . N

There EX N
was VBD N
an DT o
overall JJ o
complication NN o
rate NN o
of IN N
68.3 CD N
% NN N
. . N

35 CD N
( ( N
58.3 CD N
% NN N
) ) N
patients NNS N
presented VBN o
euphoria RB o
as IN N
the DT N
most RBS N
common JJ N
complication NN N
, , N
but CC N
there EX N
was VBD N
no DT N
statistical JJ N
difference NN N
between IN N
the DT N
two CD N
groups NNS N
( ( N
P NNP N
= NNP N
0.396 CD N
) ) N
. . N

Cases NNPS N
who WP N
received VBD i
IV NNP i
midazolam NN i
became VBD o
sedated JJ o
faster RBR N
than IN N
those DT N
received VBN i
IM NNP i
midazolam NN i
( ( N
P NNP N
> NNP N
0.001 CD N
) ) N
. . N

The DT N
vital JJ N
signs NNS N
including VBG o
heart NN o
rate NN o
, , o
respiratory NN o
rate NN o
, , o
systolic JJ o
blood NN o
pressure NN o
and CC o
O NNP o
2 CD o
saturation NN o
changed VBD N
significantly RB N
between IN N
and CC N
within IN N
groups NNS N
during IN N
the DT N
sedation NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

CONCLUSION NNP N
Both DT N
forms NNS N
of IN i
midazolam NN i
, , i
IM NNP i
and CC i
IV NNP i
, , i
are VBP o
effective JJ o
and CC o
safe JJ o
for IN N
paediatric JJ N
sedation NN N
in IN N
ED NNP N
. . N

Although IN N
the DT N
sedative JJ N
with IN N
IV NNP N
form NN N
might MD N
appear VB N
sooner NN N
, , N
IM NNP N
form NN N
of IN i
midazolam NN i
can MD N
be VB N
effectively RB N
used VBN N
in IN N
patient NN N
with IN N
limited JJ N
IV NNP N
access NN N
. . N

Patients NNS N
are VBP N
better JJR N
to TO N
observe VB N
closely RB N
for IN N
psychological JJ N
side-effects NNS N
. . N

-DOCSTART- -1621668- O O

Antipyretic JJ o
efficacy NN o
of IN N
ibuprofen JJ i
vs NN N
acetaminophen NN i
. . i

OBJECTIVE UH N
To TO N
compare VB N
the DT N
antipyretic JJ o
efficacy NN o
of IN N
ibuprofen NN i
, , i
placebo NN i
, , N
and CC N
acetaminophen NN i
. . i

DESIGN NNP N
Double-dummy NNP N
, , N
double-blind NN N
, , N
randomized VBN N
, , N
placebo-controlled JJ i
trial NN N
. . N

SETTING NN N
Emergency NNP N
department NN N
and CC N
inpatient JJ N
units NNS N
of IN N
a DT N
large JJ N
, , N
metropolitan JJ p
, , p
university-based JJ p
, , p
children NNS p
's POS p
hospital NN p
in IN p
Michigan NNP p
. . p

PARTICIPANTS NNP N
37 CD p
otherwise RB p
healthy JJ p
children NNS p
aged VBD p
2 CD p
to TO p
12 CD p
years NNS p
with IN p
acute NN p
, , p
intercurrent NN p
, , p
febrile JJ p
illness NN p
. . p

INTERVENTIONS NNP N
Each DT N
child NN p
was VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
a DT N
single JJ N
dose NN N
of IN N
acetaminophen NN i
( ( N
10 CD N
mg/kg NN N
) ) N
, , N
ibuprofen NN i
( ( N
7.5 CD N
or CC N
10 CD N
mg/kg NN N
) ) N
, , N
or CC N
placebo NN i
. . i

MEASUREMENTS/MAIN NNP N
RESULTS NNP N
Oral NNP o
temperature NN o
was VBD N
measured VBN N
before IN N
dosing NN N
, , N
30 CD N
minutes NNS N
after IN N
dosing VBG N
, , N
and CC N
hourly RB N
thereafter RB N
for IN N
8 CD N
hours NNS N
after IN N
the DT N
dose NN N
. . N

Patients NNS N
were VBD N
monitored VBN N
for IN N
adverse JJ o
effects NNS o
during IN N
the DT N
study NN N
and CC N
24 CD N
hours NNS N
after IN N
administration NN N
of IN N
the DT N
assigned JJ N
drug NN N
. . N

All DT N
three CD N
active JJ N
treatments NNS N
produced VBD N
significant JJ N
antipyresis NN o
compared VBN N
with IN N
placebo NN i
. . i

Ibuprofen NNP i
provided VBD N
greater JJR N
temperature NN o
decrement NN o
and CC N
longer JJR N
duration NN o
of IN o
antipyresis NN o
than IN N
acetaminophen NN i
when WRB N
the DT N
two CD N
drugs NNS N
were VBD N
administered VBN N
in IN N
approximately RB N
equal JJ N
doses NNS N
. . N

No DT N
adverse JJ o
effects NNS o
were VBD N
observed VBN N
in IN N
any DT N
treatment NN N
group NN N
. . N

CONCLUSION NNP N
Ibuprofen NNP i
is VBZ N
a DT N
potent JJ N
antipyretic JJ o
agent NN N
and CC N
is VBZ N
a DT N
safe JJ o
alternative NN N
for IN N
the DT N
selected VBN N
febrile NN p
child NN p
who WP N
may MD N
benefit VB N
from IN N
antipyretic JJ N
medication NN N
but CC N
who WP N
either DT N
can MD N
not RB N
take VB N
or CC N
does VBZ N
not RB N
achieve VB N
satisfactory JJ N
antipyresis NN o
with IN N
acetaminophen NN i
. . i

-DOCSTART- -23944980- O O

Bedside IN N
ultrasound-guided JJ i
celiac NN i
plexus NN i
neurolysis NN i
in IN N
upper JJ p
abdominal JJ p
cancer NN p
patients NNS p
: : p
a DT N
randomized JJ N
, , N
prospective JJ N
study NN N
for IN N
comparison NN N
of IN N
percutaneous JJ N
bilateral JJ i
paramedian JJ i
vs. FW N
unilateral JJ i
paramedian JJ i
needle-insertion NN i
technique NN i
. . i

INTRODUCTION NNP N
Percutaneous NNP i
anterior JJ i
abdominal JJ i
ultrasound NN i
guidance NN i
for IN N
performing VBG N
celiac JJ N
plexus NN N
neurolysis NN N
is VBZ N
a DT N
relatively RB N
new JJ N
but CC N
more RBR N
economical JJ N
, , N
less RBR N
time-consuming JJ N
, , N
more RBR N
comfortable JJ N
bedside NN N
technique NN N
for IN N
interventional JJ N
pain NN N
management NN N
. . N

Paucity NN N
of IN N
studies NNS N
evaluating VBG N
the DT N
efficacy NN N
of IN N
single-site JJ N
vs. FW N
double-site JJ N
injections NNS N
at IN N
celiac JJ N
trunk NN N
for IN N
ultrasound-guided JJ i
celiac NN i
plexus NN i
neurolysis NN i
( ( i
USCPN NNP i
) ) i
prompted VBD N
us PRP N
to TO N
conduct VB N
a DT N
prospective JJ N
, , N
randomized VBN N
, , N
single-blind JJ N
clinical JJ N
trial NN N
to TO N
compare VB N
USCPN NNP i
using VBG N
bilateral JJ i
paramedian NN i
( ( i
double JJ i
needle NN i
) ) i
technique NN i
with IN N
unilateral JJ i
paramedian NN i
( ( i
single JJ i
needle NN i
) ) i
technique NN i
. . i

METHODS NNP N
Sixty NNP p
patients NNS p
aged VBD p
18 CD p
years NNS p
or CC p
older JJR p
with IN p
unresectable JJ p
upper JJ p
abdominal JJ p
cancers NNS p
were VBD N
randomized VBN N
into IN N
two CD N
groups NNS N
to TO N
receive VB N
USCPN NNP N
. . N

A DT N
20-mL JJ N
mixture NN N
of IN N
50 CD N
% NN N
ethanol NN i
with IN N
0.25 CD N
% NN N
bupivacaine NN i
was VBD N
injected VBN N
either RB N
unilaterally RB i
( ( N
20 CD N
mL?1 RB N
site NN N
) ) N
or CC i
bilaterally RB i
( ( N
10 CD N
mL?2 NN N
sites NNS N
) ) N
depending VBG N
on IN N
the DT N
randomization NN N
group NN N
. . N

Subjects NNS N
were VBD N
assessed VBN N
for IN N
the DT o
pain NN o
relief NN o
using VBG o
Numerical NNP N
rating NN N
scale NN N
( ( N
NRS NNP N
) ) N
to TO N
assess VB N
their PRP$ N
pain NN N
relief NN N
. . N

RESULTS NNP N
Baseline NNP N
parameters NNS N
being VBG N
comparable JJ N
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
, , N
the DT N
site NN N
of IN N
drug NN N
injections NNS N
( ( N
single JJ N
or CC N
double JJ N
needle NN N
) ) N
had VBD N
no DT N
bearing NN N
on IN N
the DT N
onset NN N
of IN N
pain NN o
relief NN o
and CC o
patient JJ o
satisfaction NN o
scores NNS o
( ( o
P NNP N
> NNP N
0.05 CD o
) ) o
. . o

Pain VB o
relief NN o
during IN o
follow-up JJ N
visits NNS N
was VBD N
comparable JJ N
between IN N
the DT N
two CD N
groups NNS N
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
. . N

The DT N
discomfort NN N
score NN N
correlated VBD N
well RB N
with IN N
the DT o
pain NN o
relief NN o
scoring VBG o
without IN N
any DT N
significant JJ N
difference NN N
between IN N
the DT N
two CD N
groups NNS N
except IN N
in IN N
the DT N
last JJ N
visit NN N
( ( N
at IN N
3 CD N
month NN N
) ) N
. . N

Incidences NNS N
of IN N
the DT N
complications NNS N
were VBD N
comparable JJ N
in IN N
the DT N
two CD N
groups NNS N
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
. . N

CONCLUSION NNP i
Ultrasound-guided JJ i
celiac NN i
plexus NN i
neurolysis NN i
using VBG i
unilateral JJ i
paramedian NN i
( ( i
single JJ i
needle NN i
) ) i
needle-insertion NN i
technique NN i
is VBZ i
comparable JJ N
with IN i
bilateral JJ i
paramedian NN i
( ( i
double JJ i
needle NN i
) ) i
needle-insertion NN i
technique NN i
with IN i
regard NN N
to TO N
pain VB o
relief NN o
and CC o
side NN o
effects NNS o
. . o

-DOCSTART- -11068835- O O

Magnetic JJ N
resonance NN N
angiography NN N
for IN N
monitoring VBG N
prophylactic JJ N
endoscopic NN N
treatment NN N
of IN N
high JJ N
risk NN N
esophageal NN N
varices NNS N
. . N

BACKGROUND NNP N
AND NNP N
STUDY NNP N
AIMS NNP N
Endoscopic NNP i
injection NN i
sclerotherapy NN i
( ( i
EIS NNP i
) ) i
and CC i
endoscopic $ i
variceal JJ i
ligation NN i
( ( i
EVL NNP i
) ) i
are VBP N
used VBN N
worldwide RB N
as IN N
the DT N
treatment NN N
for IN N
esophageal JJ N
varices NNS N
. . N

We PRP N
evaluated VBD N
portal JJ N
hemodynamics NNS N
using VBG N
magnetic JJ N
resonance NN N
angiography NN N
( ( N
MRA NNP N
) ) N
in IN N
these DT N
two CD N
forms NNS N
of IN N
treatment NN N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
The DT N
study NN N
was VBD N
carried VBN N
out RP N
in IN N
50 CD p
cirrhotic JJ p
patients NNS p
. . p

MRA NNP N
was VBD N
performed VBN N
to TO N
identify VB N
the DT N
hepatofugal JJ N
supply NN N
vein NN N
selectively RB N
for IN N
esophageal JJ p
varices NNS p
. . p

Those DT N
who WP N
showed VBD N
a DT N
positive JJ N
MR NNP N
angiogram NN N
for IN N
the DT N
supply NN N
vein NN N
were VBD N
randomly RB N
allocated VBN N
to TO N
one CD N
of IN N
two CD N
groups NNS N
, , N
using VBG N
the DT N
sealed VBN N
envelope NN N
method NN N
, , N
and CC N
underwent JJ N
either CC N
EIS NNP i
or CC N
EVL NNP i
. . i

On IN N
the DT N
other JJ N
hand NN N
, , N
those DT N
with IN N
a DT N
negative JJ N
angiogram NN N
received VBD N
only RB N
EVL NNP N
. . N

EIS NNP i
was VBD N
done VBN N
to TO N
embolize VB N
esophageal JJ N
varices NNS N
as RB N
well RB N
as IN N
their PRP$ N
feeders NNS N
by IN N
intravariceal JJ N
injection NN N
of IN N
sclerosant JJ N
under IN N
fluoroscopic JJ N
guidance NN N
. . N

RESULTS VB N
A NNP N
positive JJ N
MR NNP N
angiogram NN N
of IN N
the DT N
hepatofugal NN N
left VBD N
gastric JJ N
vein NN N
as IN N
the DT N
supply NN N
vein NN N
was VBD N
observed VBN N
in IN N
41 CD p
patients NNS p
. . p

Nine CD p
patients NNS p
showed VBD p
negative JJ p
MRA NNP p
results NNS p
. . p

Among IN N
those DT N
with IN N
positive JJ N
angiograms NNS N
, , N
the DT N
rate NN o
of IN o
eradication NN o
of IN o
the DT o
left NN o
gastric JJ o
vein NN o
was VBD N
higher RBR N
in IN N
the DT N
EIS-treated NNP N
group NN N
than IN N
in IN N
the DT N
EVL NNP N
treated VBD N
group NN N
( ( N
50 CD N
% NN N
vs. FW N
8.6 CD N
% NN N
) ) N
. . N

After IN N
either DT N
treatment NN N
, , N
the DT N
recurrence-free JJ o
rate NN o
for IN o
high JJ o
risk NN o
esophageal NN o
varices NNS o
was VBD N
higher RBR N
in IN N
patients NNS N
with IN N
complete JJ N
eradication NN N
of IN N
the DT N
left NN N
gastric NN N
vein NN N
than IN N
in IN N
those DT N
without IN N
( ( N
88 CD N
% NN N
vs. FW N
35 CD N
% NN N
) ) N
. . N

In IN N
patients NNS N
with IN N
negative JJ N
angiogram NN N
results NNS N
, , N
who WP N
only RB N
underwent JJ N
EVL NNP N
, , N
high JJ N
risk NN o
esophageal NN o
varices NNS o
did VBD N
not RB N
reappear VB N
over IN N
a DT N
long JJ N
period NN N
. . N

CONCLUSION NNP N
MRA NNP N
is VBZ N
useful JJ N
for IN N
evaluating VBG N
portal JJ N
hemodynamics NNS N
. . N

With IN N
the DT N
aim NN N
of IN N
avoiding VBG N
recurrence NN N
of IN N
esophageal JJ N
varices NNS N
, , N
EIS NNP N
was VBD N
suitable JJ N
for IN N
patients NNS N
who WP N
had VBD N
a DT N
hepatofugal JJ N
supply NN N
vein NN N
for IN N
the DT N
varices NNS N
because IN N
recurrence NN N
could MD N
be VB N
prevented VBN N
by IN N
embolization NN N
of IN N
the DT N
supply NN N
vein NN N
. . N

EVL NNP N
may MD N
be VB N
expected VBN N
to TO N
be VB N
efficacious JJ N
in IN N
patients NNS N
where WRB N
no DT N
image NN N
of IN N
a DT N
hepatofugal JJ N
supply NN N
vein NN N
is VBZ N
found VBN N
on IN N
MRA NNP N
. . N

-DOCSTART- -4346973- O O

Dipyrone NN i
for IN N
treatment NN N
of IN N
post-operative JJ o
pain NN o
. . o

-DOCSTART- -8210973- O O

Erythrocyte NNP o
deformability NN o
, , o
endothelin NN o
levels NNS o
, , o
and CC o
renal JJ o
function NN o
in IN N
cyclosporin-treated JJ i
renal JJ p
transplant NN p
recipients NNS p
: : p
effects NNS N
of IN N
intervention NN N
with IN N
fish JJ i
oil NN i
and CC N
corn NN i
oil NN i
. . i

Twenty NNP p
nine CD p
stable JJ p
renal JJ p
transplant NN p
recipients NNS p
, , p
10 CD p
receiving VBG p
cyclosporin NN i
, , i
10 CD i
cyclosporin-prednisolone NN i
and CC i
nine CD i
azathioprine-prednisolone NN i
were VBD N
supplemented VBN N
in IN N
a DT N
double JJ N
blind JJ N
randomization NN N
cross-over NN N
study NN N
with IN N
fish JJ i
oil NN i
and CC N
corn NN i
oil NN i
for IN N
a DT N
period NN N
of IN N
4 CD N
months NNS N
each DT N
. . N

Erythrocyte NNP o
deformability NN o
was VBD N
reduced VBN N
in IN N
the DT N
cyclosporin-treated JJ i
patients NNS N
and CC N
returned VBN N
to TO N
normal JJ N
values NNS N
after IN N
supplementation NN N
of IN N
either DT N
oil NN i
. . i

The DT N
oil NN N
supplementation NN N
resulted VBD N
in IN N
an DT N
increased VBN N
polyunsaturated JJ o
fatty JJ o
acid NN o
content NN o
in IN N
the DT N
plasma NN N
phospholipids NNS N
. . N

An DT N
increased JJ N
erythrocyte NN N
membrane NN N
polyunsaturated VBD N
fatty JJ N
acid JJ N
content NN N
might MD N
correct VB N
the DT N
lower JJR N
erythrocyte NN N
deformability NN N
in IN N
cyclosporin NN i
treated VBD N
patients NNS N
. . N

Therefore RB N
, , N
it PRP N
is VBZ N
probable JJ N
that IN N
these DT N
changes NNS N
are VBP N
membrane-related JJ N
. . N

The DT N
oil NN i
supplementation NN N
had VBD N
no DT N
effect NN N
on IN N
glomerular JJ o
filtration NN o
rate NN o
, , o
effective JJ o
renal JJ o
plasma NN o
flow NN o
, , o
filtration NN o
fraction NN o
or CC o
blood NN o
pressure NN o
, , N
which WDT N
does VBZ N
not RB N
exclude VB N
effects NNS N
of IN N
the DT N
cyclosporin-induced JJ N
rigidified JJ N
erythrocytes NNS N
in IN N
the DT N
acute JJ N
phase NN N
of IN N
renal JJ N
transplantation NN N
. . N

Decreased VBN N
erythrocyte JJ o
deformability NN o
could MD N
play VB N
a DT N
role NN N
in IN N
the DT N
cyclosporin-induced JJ i
deterioration NN N
of IN N
renal JJ N
haemodynamics NNS N
. . N

This DT N
may MD N
enhance VB N
the DT N
effects NNS N
of IN N
endothelin NN N
, , N
as IN N
these DT N
patients NNS N
also RB N
had VBD N
elevated VBN N
endothelin NN N
levels NNS N
. . N

-DOCSTART- -19681862- O O

A DT N
randomized VBN N
controlled JJ N
trial NN N
of IN N
R-salbutamol NNP i
for IN N
topical JJ N
treatment NN N
of IN N
discoid JJ p
lupus NN p
erythematosus NN p
. . p

BACKGROUND NNP N
In IN N
a DT N
recent JJ N
open JJ N
pilot NN N
trial NN N
, , N
R-salbutamol NNP i
sulphate NN i
, , N
a DT N
well-known JJ N
molecule NN N
with IN N
anti-inflammatory JJ N
effects NNS N
, , N
was VBD N
tested VBN N
successfully RB N
on IN N
patients NNS p
with IN p
therapy-resistant JJ p
discoid NN p
lupus NN p
erythematosus NN p
( ( p
DLE NNP p
) ) p
. . p

OBJECTIVES UH N
To TO N
compare VB N
the DT N
efficacy NN N
and CC N
safety NN N
of IN N
R-salbutamol NNP i
cream NN i
0.5 CD N
% NN N
vs. FW i
placebo NN i
on IN N
DLE NNP N
lesions NNS N
in IN N
a DT N
multicentre NN N
, , N
double-blinded JJ N
, , N
randomized VBN N
, , N
placebo-controlled JJ N
phase NN N
II NNP N
trial NN N
. . N

METHODS NNP N
Thirty-seven JJ p
patients NNS p
with IN p
at IN p
least JJS p
one CD p
newly RB p
developed VBN p
DLE NNP p
lesion NN p
were VBD N
randomized VBN i
- : i
19 CD i
to TO i
the DT i
R-salbutamol NNP i
cream NN i
0.5 CD i
% NN i
and CC i
18 CD i
to TO i
placebo VB i
- : i
and CC i
treated JJ i
twice RB i
daily RB i
for IN i
8 CD i
weeks NNS i
. . i

Efficacy NN o
was VBD N
evaluated VBN N
through IN N
scores NNS o
of IN o
erythema NN o
, , o
scaling/hypertrophy NN o
and CC o
induration NN o
as RB o
well RB o
as IN o
pain NN o
and CC o
itching NN o
; : o
general JJ o
improvement NN o
scored VBN o
by IN o
the DT o
investigator NN o
and CC o
global JJ o
improvement NN o
scored VBN o
by IN o
patients NNS o
' POS o
assessment NN o
were VBD o
also RB o
evaluated VBN o
. . o

RESULTS VB N
The DT N
mean JJ N
area NN N
under IN N
the DT N
curve NN N
of IN N
improvement NN N
for IN N
scaling/hypertrophy NN o
, , o
pain NN o
, , o
itching NN o
and CC o
global JJ o
patient NN o
assessment NN o
was VBD N
significantly RB N
better JJR N
for IN N
the DT N
actively RB N
treated JJ N
patients NNS N
as IN N
compared VBN N
with IN N
placebo NN i
( ( N
scaling/hypertrophy NN N
, , N
P NNP N
= NNP N
0.0262 CD N
; : N
pain NN N
, , N
P NNP N
= NNP N
0.0238 CD N
; : N
itching NN N
, , N
P NNP N
= NNP N
0.0135 CD N
; : N
global JJ N
patient NN N
assessment NN N
, , N
P NNP N
= NNP N
0.045 CD N
) ) N
. . N

Moreover RB N
, , N
the DT N
percentage NN N
of IN N
patients NNS N
without IN N
induration NN o
was VBD N
significantly RB N
higher JJR N
in IN N
the DT N
active JJ N
group NN N
compared VBN N
with IN N
the DT N
placebo NN N
group NN N
( ( N
P NNP N
= NNP N
0.013 CD N
) ) N
, , N
and CC N
a DT N
statistically RB N
significantly RB N
greater JJR N
decrease NN N
in IN N
the DT N
size NN o
of IN o
the DT o
lesional JJ o
area NN o
was VBD N
also RB N
seen VBN N
in IN N
the DT N
overall JJ N
analysis NN N
of IN N
the DT N
R-salbutamol-treated JJ N
patients NNS N
( ( N
P NNP N
= NNP N
0.0197 CD N
) ) N
. . N

No DT N
serious JJ o
adverse JJ o
events NNS o
were VBD N
reported VBN N
. . N

CONCLUSIONS NNP N
Application NNP N
of IN N
R-salbutamol NNP N
cream NN N
0.5 CD N
% NN N
was VBD N
safe JJ N
and CC N
well RB N
tolerated VBN N
. . N

Statistically NNP N
significant JJ N
effects NNS N
were VBD N
seen VBN N
on IN N
scaling/hypertrophy NN N
, , N
induration NN N
, , N
pain NN N
and CC N
itching NN N
as RB N
well RB N
as IN N
patient NN N
global JJ N
assessment NN N
, , N
suggesting VBG N
that IN N
R-salbutamol NNP N
could MD N
be VB N
a DT N
promising JJ N
new JJ N
topical JJ N
therapy NN N
alternative NN N
for IN N
DLE NNP N
. . N

-DOCSTART- -4938245- O O

Persistent JJ p
phenothiazine NN p
dyskinesia NN p
treated VBN N
with IN N
tetrabenazine NN i
. . i

Six CD p
patients NNS p
with IN p
persistent JJ p
phenothiazine NN p
dyskinesia NN p
were VBD N
treated VBN N
in IN N
a DT N
double-blind NN N
controlled VBN N
trial NN N
with IN N
tetrabenazine JJ i
100 CD i
mg NN i
in IN i
divided JJ i
dosage NN i
. . i

In IN N
three CD N
patients NNS N
the DT N
abnormal JJ N
movements NNS N
were VBD N
abolished VBN N
and CC N
in IN N
two CD N
others NNS N
there EX N
was VBD N
some DT N
improvement NN N
, , N
but CC N
this DT N
was VBD N
no DT N
greater JJR N
than IN N
that DT N
achieved VBN N
with IN N
the DT N
diazepam NN i
control NN N
. . N

Tetrabenazine NNP i
may MD N
be VB N
useful JJ N
in IN N
the DT N
treatment NN N
of IN N
some DT N
patients NNS N
with IN N
persistent JJ N
phenothiazine NN N
dyskinesia NN N
. . N

-DOCSTART- -1396108- O O

Buprenorphine NNP i
alone RB N
and CC N
in IN N
combination NN N
with IN N
naloxone NN i
in IN N
non-dependent JJ p
humans NNS p
. . p

This DT N
study NN N
evaluated VBD N
the DT N
effects NNS N
of IN N
concurrent NN N
naloxone NN i
on IN N
the DT N
opioid JJ o
agonist JJ o
effects NNS o
of IN N
buprenorphine NN i
, , N
a DT N
mixed JJ N
agonist-antagonist JJ N
marketed VBN N
as IN N
an DT N
analgesic JJ N
and CC N
under IN N
development NN N
as IN N
a DT N
treatment NN N
for IN N
drug NN N
abuse NN N
. . N

In IN N
a DT N
residential JJ N
laboratory NN N
seven CD p
non-physically-dependent JJ p
opioid JJ p
abuser NN p
volunteers NNS p
received VBD N
intramuscular JJ N
buprenorphine NN i
( ( N
0.4 CD N
mg NN N
or CC N
0.8 CD N
mg/70 NNS N
kg NN N
) ) N
alone RB N
and CC N
in IN N
combination NN N
with IN N
naloxone NN i
( ( N
0.4 CD N
mg NN N
or CC N
0.8 CD N
mg/70 NNS N
kg NN N
) ) N
versus NN N
placebo NN i
. . i

Buprenorphine NNP i
produced VBD N
dose-related JJ N
opioid JJ N
agonist NN N
effects NNS N
on IN N
physiological JJ o
and CC o
subjective JJ o
measures NNS o
. . o

Concurrent NNP N
naloxone RB i
attenuated VBD N
the DT o
opioid JJ o
agonist JJ o
effects NNS o
of IN N
buprenorphine NN i
. . i

Thus RB N
, , N
a DT N
combination NN N
product NN N
of IN N
buprenorphine NN i
and CC N
naloxone NN N
may MD N
have VB N
lower JJR N
abuse NN o
liability NN o
than IN N
buprenorphine VB i
alone JJ N
. . N

-DOCSTART- -17324094- O O

Do VB N
cervical JJ N
cancer NN N
screening VBG N
rates NNS N
increase VBP N
in IN N
association NN N
with IN N
an DT N
intervention NN N
designed VBN N
to TO N
increase VB N
mammography NN N
usage NN N
? . N
OBJECTIVES UH N
To TO N
assess VB N
cervical JJ o
cancer NN o
screening VBG o
behaviors NNS o
among IN N
underserved JJ p
women NNS p
participating VBG p
in IN p
an DT p
intervention NN p
designed VBN p
to TO p
increase VB p
mammography NN p
use NN p
. . p

METHODS NNP N
This DT N
was VBD N
a DT N
randomized JJ N
trial NN N
of IN N
897 CD p
women NNS p
from IN p
three CD p
racial JJ p
groups NNS p
( ( p
white JJ p
, , p
African JJ p
American NNP p
, , p
Native JJ p
American NNP p
) ) p
living NN p
in IN p
a DT p
rural JJ p
county NN p
in IN p
North NNP p
Carolina NNP p
. . p

Baseline NNP N
and CC N
followup JJ N
surveys NNS N
were VBD N
completed VBN N
by IN N
815 CD p
women NNS p
; : p
775 CD p
women NNS p
provided VBD p
data NNS p
to TO N
be VB N
included VBN N
in IN N
these DT N
analyses NNS N
. . N

The DT N
intervention NN N
group NN N
received VBD N
an DT N
educational JJ i
program NN i
focused VBN i
on IN i
mammography NN i
delivered VBN i
by IN i
a DT i
lay NN i
health NN i
advisor NN i
, , N
and CC N
the DT N
control NN N
group NN N
received VBD N
a DT N
physician JJ i
letter/brochure NN i
focusing VBG i
on IN i
Pap NNP i
tests NNS i
. . i

RESULTS NNP N
Women NNP N
in IN N
both CC N
the DT N
intervention NN N
( ( N
OR NNP N
1.70 CD N
; : N
1.31 CD N
, , N
2.21 CD N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
and CC N
control NN N
groups NNS N
( ( N
OR NNP N
1.38 CD N
; : N
1.04 CD N
, , N
1.82 CD N
, , N
p NN N
= NNP N
0.025 CD N
) ) N
significantly RB N
increased VBD N
cervical JJ o
cancer NN o
screening VBG o
rates NNS o
within IN N
risk NN N
appropriate JJ N
guidelines NNS N
. . N

No DT N
differences NNS N
by IN N
racial JJ N
group NN N
were VBD N
documented VBN N
. . N

Women NNP N
categorized VBD N
in IN N
the DT N
high-risk JJ N
group NN N
for IN N
developing VBG N
cervical JJ N
cancer NN N
( ( N
> $ N
2 CD N
sexual JJ N
partners NNS N
, , N
age NN N
< VBD N
18 CD N
years NNS N
at IN N
first JJ N
sexual JJ N
intercourse NN N
, , N
smoker NN N
; : N
treated VBN N
for IN N
sexually RB N
transmitted VBN N
disease NN N
[ NNP N
STD NNP N
] NNP N
or CC N
partner NN N
with IN N
treated JJ N
STD NNP N
) ) N
significantly RB N
( ( N
OR NNP N
1.88 CD N
; : N
1.54 CD N
, , N
2.28 CD N
, , N
p NN N
< NNP N
0.001 CD N
) ) N
increased VBD o
Pap NNP o
test NN o
completion NN o
. . o

However RB N
, , N
a DT N
nonsignificant JJ o
increase NN o
( ( N
OR NNP N
1.25 CD N
; : N
0.87 CD N
, , N
1.79 CD N
, , N
p NN N
= NNP N
0.221 CD N
) ) N
in IN N
Pap NNP o
test NN o
completion NN o
was VBD N
demonstrated VBN N
in IN N
women NNS N
categorized VBN N
as IN N
low JJ N
risk NN N
for IN N
cervical JJ N
cancer NN N
. . N

CONCLUSIONS VB N
This DT N
study NN N
suggests VBZ N
that IN N
women NNS N
in IN N
an DT N
intensive JJ i
behavioral JJ i
intervention NN i
designed VBN i
to TO i
increase VB i
mammography NN i
use NN i
may MD N
also RB N
increase VB N
Pap NNP o
test JJS o
completion NN o
, , N
similar JJ N
to TO N
a DT N
minimal JJ N
intervention NN N
focused VBD N
only RB N
on IN N
increasing VBG N
Pap NNP o
test NN o
completion NN o
. . o

These DT N
results NNS N
have VBP N
implications NNS N
for IN N
the DT N
design NN N
and CC N
evaluation NN N
of IN N
behavioral JJ N
intervention NN N
studies NNS N
. . N

-DOCSTART- -3300426- O O

Nitrous JJ i
oxide NN i
does VBZ N
not RB N
increase VB N
the DT N
incidence NN N
of IN N
nausea NN p
and CC p
vomiting NN p
after IN p
isoflurane NN p
anesthesia NN p
. . p

A DT N
total NN N
of IN N
110 CD p
patients NNS p
undergoing JJ p
elective JJ p
abdominal JJ p
hysterectomy NN p
were VBD p
anesthetized VBN p
in IN p
random JJ p
order NN p
with IN N
either DT N
isoflurane NN i
in IN i
nitrous JJ i
oxide NN i
and CC i
oxygen NN i
or CC i
isoflurane NN i
in IN i
air NN i
and CC i
oxygen NN i
. . i

Fentanyl NNP i
was VBD N
used VBN N
as IN N
an DT N
adjunct NN N
to TO N
isoflurane VB N
in IN N
all DT p
patients NNS p
, , N
0.05 CD N
mg NN N
every DT N
45 CD N
min NN N
. . N

No DT N
difference NN N
was VBD N
found VBN N
between IN N
the DT N
two CD N
anesthetic JJ N
techniques NNS N
in IN N
the DT N
incidence NN o
of IN o
nausea NN o
, , o
vomiting VBG o
, , o
or CC o
both DT o
during IN N
the DT N
first JJ N
24 CD N
hr NN N
after IN N
operation NN N
. . N

The DT N
overall JJ N
incidence NN o
was VBD N
62 CD N
and CC N
67 CD N
% NN N
for IN N
air-O2 JJ N
and CC N
N2O-O2 JJ N
groups NNS N
, , N
respectively RB N
. . N

Patients NNS N
who WP N
had VBD N
had VBN N
nausea NN o
or CC o
vomiting NN o
after IN N
previous JJ N
anesthetics NNS N
had VBD N
nausea NN o
or CC o
vomiting VBG o
significantly RB N
more RBR N
frequently RB N
than IN N
patients NNS N
who WP N
did VBD N
not RB N
. . N

It PRP N
is VBZ N
concluded VBN N
that IN N
nitrous JJ i
oxide NN i
does VBZ N
not RB N
contribute VB N
to TO N
the DT N
occurrence NN N
of IN N
nausea NN o
or CC o
vomiting NN o
after IN N
isoflurane NN N
anesthesia NN N
for IN N
gynecologic JJ N
laparotomies NNS N
. . N

-DOCSTART- -16223394- O O

A DT N
comparison NN N
of IN N
two CD N
double-injection NN N
techniques NNS N
for IN N
peribulbar NN p
block NN p
analgesia NN p
: : p
infero-temporal JJ i
plus CC i
supero-medial JJ i
vs. FW i
infero-temporal JJ i
plus CC i
medial-percaruncular JJ i
. . i

BACKGROUND NNP N
Combinations NNPS N
of IN N
infero-temporal JJ N
and CC N
either DT N
supero-nasal JJ i
( ( i
'inferior-superior JJ i
' '' i
) ) i
or CC N
medial JJ i
percaruncular NN i
( ( i
'inferior-medial JJ i
' '' i
) ) i
injections NNS N
are VBP N
popular JJ N
double-injection NN N
techniques NNS N
for IN N
establishing VBG N
peribulbar NN N
block NN N
analgesia NN N
. . N

This DT N
study NN N
compared VBN N
the DT N
efficacy NN N
of IN N
these DT N
two CD N
techniques NNS N
in IN N
achieving VBG N
ocular JJ N
and CC N
lid JJ N
akinesia NN N
. . N

METHODS NNP N
One CD p
hundred VBD p
patients NNS p
were VBD p
randomized VBN p
to TO N
receive VB N
inferior-superior JJ i
or CC i
inferior-medial JJ i
injections NNS i
in IN N
a DT N
study NN N
in IN N
which WDT N
injectate NN N
, , N
injectate NN N
volumes NNS N
, , N
5-min JJ N
ocular JJ i
akinesia NN i
scoring NN N
( ( N
0-8 JJ N
) ) N
, , N
lid JJ i
scoring NN i
( ( N
0-2 JJ N
) ) N
and CC N
supplemental JJ N
injection NN N
protocols NNS N
were VBD N
standardized VBN N
. . N

The DT N
numbers NNS N
of IN N
supplemental JJ N
injections NNS N
required VBN N
at IN N
each DT N
observation NN N
period NN N
and CC N
the DT N
total JJ N
volume NN N
of IN N
injectate NN N
required VBN N
to TO N
produce VB N
ocular JJ N
and CC N
lid JJ N
akinesia NN N
were VBD N
compared VBN N
. . N

RESULTS VB N
The DT N
two CD N
test NN N
groups NNS N
were VBD N
demographically RB N
similar JJ N
. . N

The DT N
inferior-medial JJ N
combination NN N
achieved VBN N
greater JJR N
ocular JJ o
akinesia NN o
than IN N
the DT N
inferior-superior JJ N
combination NN N
5 CD N
min NN N
after IN N
the DT N
initial JJ N
injections NNS N
( ( N
mean JJ N
score RB N
+/- JJ N
standard JJ N
deviation NN N
of IN N
1.74 CD N
+/- JJ N
1.86 CD N
vs. FW N
2.66 CD N
+/- JJ N
2.39 CD N
; : N
P NNP N
< NNP N
0.05 CD N
) ) N
, , N
with IN N
a DT N
reduced JJ N
requirement NN N
for IN N
supplementary JJ N
injections NNS N
( ( N
3 CD N
vs. FW N
23 CD N
supplementary JJ N
injections NNS N
; : N
P NNP N
< NNP N
0.025 CD N
) ) N
. . N

The DT N
inferior-superior JJ N
technique NN N
achieved VBN N
greater JJR N
lid JJ o
akinesia NN o
at IN N
5 CD N
min NN N
than IN N
the DT N
inferior-medial JJ N
technique NN N
( ( N
mean JJ N
score RB N
+/- JJ N
standard JJ N
deviation NN N
of IN N
0.7 CD N
+/- JJ N
0.9 CD N
vs. FW N
0.3 CD N
+/- JJ N
0.58 CD N
; : N
P NNP N
< NNP N
0.005 CD N
) ) N
. . N

A DT N
medial JJ o
subconjunctival NN o
hemorrhage NN o
occurred VBD N
in IN N
one CD N
patient NN N
in IN N
the DT N
inferior-medial JJ N
group NN N
. . N

CONCLUSION NNP N
Compared NNP N
with IN N
the DT N
inferior-superior JJ N
technique NN N
, , N
the DT N
inferior-medial JJ N
combination NN N
achieved VBD N
more RBR N
rapid JJ o
ocular JJ o
akinesia NN o
with IN N
less JJR N
need NN N
for IN N
supplementation NN N
, , N
but CC N
induced VBD N
less RBR N
efficient JJ N
lid JJ N
akinesia NN N
and CC N
had VBD N
a DT N
propensity NN N
to TO N
cause VB N
iatrogenic JJ o
subconjunctival JJ o
hemorrhage NN o
. . o

The DT N
latter JJ N
complication NN N
is VBZ N
considered VBN N
by IN N
our PRP$ N
surgeons NNS N
to TO N
be VB N
a DT N
contraindication NN N
to TO N
the DT N
inferior-medial JJ N
technique NN N
in IN N
patients NNS p
undergoing VBG p
trabeculectomy NN p
. . p

-DOCSTART- -15377466- O O

Treatment NN N
of IN N
severe JJ N
aplastic JJ N
anemia NN N
with IN N
antilymphocyte JJ i
globulin NN i
, , i
cyclosporine NN i
and CC i
two CD i
different JJ i
granulocyte NNS i
colony-stimulating JJ i
factor NN i
regimens NNS i
: : i
a DT N
GITMO NNP N
prospective JJ N
randomized VBN N
study NN N
. . N

BACKGROUND NNP N
AND NNP N
OBJECTIVES NNP N
In IN N
a DT N
previous JJ N
study NN N
we PRP N
showed VBD N
that IN N
patients NNS p
with IN p
severe JJ p
aplastic JJ p
anemia NN p
( ( p
SAA NNP p
) ) p
treated VBD i
with IN i
anti-lymphocyte JJ i
globulin NN i
( ( i
ALG NNP i
) ) i
, , i
cyclosporin NN i
( ( i
CyA NNP i
) ) i
and CC i
granulocyte JJ i
colony-stimulating JJ i
factor NN i
( ( i
G-CSF NNP i
) ) i
5 CD i
micro NN i
g/kg/day NN i
had VBD N
an DT N
encouraging JJ N
outcome NN o
. . o

However RB N
, , N
failure NN o
to TO o
respond VB o
, , o
delayed JJ o
responses NNS o
, , o
partial JJ o
responses NNS o
, , o
relapses NNS o
and CC N
early JJ o
deaths NNS o
remain VBP N
significant JJ N
problems NNS N
. . N

The DT N
aim NN N
of IN N
the DT N
present JJ N
study NN N
was VBD N
to TO N
test VB N
whether IN N
a DT N
higher JJR i
dose NN i
of IN i
G-CSF NNP i
( ( i
10 CD i
micro NNS i
g/kg/day NN i
) ) i
would MD N
reduce VB o
these DT o
complications NNS o
. . o

DESIGN NNP N
AND CC N
METHODS NNP N
This DT N
was VBD N
a DT N
multicenter NN p
prospective JJ p
trial NN p
in IN p
77 CD p
SAA NNP p
patients NNS p
treated VBD p
with IN p
horse NN i
ALG NNP i
( ( i
15 CD i
mg/kg/day RB i
day1-5 NN i
) ) i
and CC i
CyA NNP i
( ( i
5 CD i
mg/kg/day RB i
day NN i
1-180 JJ i
) ) i
. . i

Patients NNS p
were VBD p
randomized VBN p
to TO N
receive VB i
G-CSF NNP i
5 CD i
micro NN i
g/kg/day NN i
( ( i
n=38 JJ i
, , i
group NN i
A NNP i
) ) i
or CC i
10 CD i
micro NNS i
g/kg/day NN i
( ( i
n=39 JJ i
, , i
group NN i
B NNP i
) ) i
from IN i
day NN i
+1 CD i
to TO i
day NN i
+30 NNP i
. . i

All DT i
patients NNS i
then RB i
received VBD i
G-CSF NNP i
5 CD i
micro NN i
g/kg/day NN i
from IN i
day NN i
+31 CD i
to TO i
day NN i
+90 NNP i
. . i

The DT N
primary JJ N
end NN N
point NN N
of IN N
this DT N
study NN N
was VBD N
response NN o
at IN N
day NN N
+120 NNP N
. . N

Secondary JJ N
end NN N
points NNS N
were VBD N
early JJ o
deaths NNS o
, , o
blood NN o
counts NNS o
at IN N
day NN N
+120 NNP N
, , N
and CC N
survival NN o
. . o

RESULTS NNP N
At IN N
day NN N
+120 JJ N
responses NNS o
were VBD N
classified VBN N
as IN N
absent NN o
, , o
partial JJ o
, , N
and CC N
complete JJ o
in IN N
12 CD N
, , N
22 CD N
, , N
and CC N
4 CD N
patients NNS N
in IN N
group NN N
A NNP N
and CC N
in IN N
23 CD N
, , N
7 CD N
, , N
and CC N
9 CD N
patients NNS N
in IN N
group NN N
B NNP N
( ( N
p=0.001 NN N
) ) N
. . N

At IN N
last JJ N
follow-up JJ N
these DT N
figures NNS N
were VBD N
respectively RB N
9 CD N
, , N
12 CD N
, , N
and CC N
17 CD N
vs NN N
19 CD N
, , N
2 CD N
, , N
and CC N
18 CD N
( ( N
p=0.004 NN N
) ) N
. . N

Thirteen JJ p
patients NNS p
( ( p
5 CD p
in IN p
group NN p
A NNP p
and CC p
8 CD p
in IN p
group NN p
B NNP p
) ) p
died VBD o
before IN N
day NN N
120 CD N
( ( N
p=0.3 NN N
) ) N
. . N

Median JJ N
peripheral JJ o
blood NN o
counts NNS o
on IN N
day NN N
120 CD N
were VBD N
comparable JJ N
in IN N
the DT N
two CD N
groups NNS N
: : N
Hb NNP N
10.5 CD N
and CC N
9.5 CD N
g/dL NN N
in IN N
group NN N
A NNP N
and CC N
B NNP N
, , N
respectively RB N
( ( N
p=0.6 NN N
) ) N
, , N
Neutrophil NNP o
counts VBZ o
were VBD N
2.4 CD N
vs NNS N
1.9x10 CD N
( ( N
9 CD N
) ) N
/L NN N
in IN N
groups NNS N
A NNP N
and CC N
B NNP N
( ( N
p=0.4 NN N
) ) N
and CC N
platelet NN o
counts NNS o
were VBD N
, , N
respectively RB N
, , N
42 CD N
vs NN N
36x10 CD N
( ( N
9 CD N
) ) N
/L NN N
( ( N
p=0.3 NN N
) ) N
. . N

The DT N
actuarial JJ o
survival NN o
at IN N
4 CD N
years NNS N
is VBZ N
72 CD N
% NN N
in IN N
group NN N
A NNP N
and CC N
67 CD N
% NN N
in IN N
group NN N
B NNP N
( ( N
p=0.3 NN N
) ) N
. . N

INTERPRETATION NNP N
AND CC N
CONCLUSIONS NNP N
Increasing VBG N
the DT N
dose NN N
of IN N
G-CSF NNP i
does VBZ N
not RB N
appear VB N
to TO N
reduce VB o
early JJ o
deaths NNS o
, , N
does VBZ N
not RB N
improve VB N
peripheral JJ o
blood NN o
counts NNS o
nor CC N
survival NN o
, , N
and CC N
may MD N
reduce VB N
the DT N
response NN o
rate NN o
in IN N
patients NNS p
with IN p
SAA NNP p
receiving VBG p
ALG NNP i
and CC i
CyA NNP i
. . i

-DOCSTART- -10463847- O O

Delineation NN N
of IN N
cryptogenic JJ N
Lennox-Gastaut NNP N
syndrome NN N
and CC N
myoclonic JJ N
astatic JJ N
epilepsy NN N
using VBG N
multiple JJ i
correspondence NN i
analysis NN i
. . i

PURPOSE NNP N
To TO N
distinguish VB N
various JJ N
types NNS N
of IN N
childhood NN p
severe JJ p
cryptogenic/idiopathic NN p
generalised VBD p
epilepsy NN p
on IN N
the DT N
basis NN N
of IN N
reproducible JJ N
diagnostic JJ N
criteria NNS N
, , N
using VBG N
multiple JJ i
correspondence NN i
analysis NN i
( ( i
MCA NNP i
) ) i
. . i

METHODS NNP N
We PRP N
applied VBD N
MCA NNP N
to TO N
a DT N
series NN N
of IN N
72 CD p
children NNS p
with IN p
no DT p
evidence NN p
of IN p
brain NN p
damage NN p
, , p
starting VBG p
epilepsy NN p
between IN p
1 CD p
and CC p
10 CD p
years NNS p
, , p
with IN p
two CD p
or CC p
more JJR p
types NNS p
of IN p
generalised JJ p
seizures NNS p
. . p

We PRP N
excluded VBD p
patients NNS p
with IN p
infantile JJ p
spasms NNS p
or CC p
typical JJ p
absences NNS p
. . p

MCA NNP i
was VBD N
performed VBN N
on IN N
all DT N
clinical JJ N
and CC N
EEG NNP N
parameters NNS N
, , N
first RB N
throughout IN N
follow-up NN N
, , N
then RB N
restricted VBD N
to TO N
the DT N
first JJ N
year NN N
of IN N
the DT N
disease NN N
. . N

RESULTS VB N
When WRB N
including VBG N
all DT N
follow-up JJ N
variables NNS N
, , N
there EX N
were VBD N
three CD N
groups NNS N
: : N
( ( N
1 CD N
) ) N
Thirty-seven CD N
children NNS N
with IN N
male JJ N
predominance NN N
, , N
familial JJ N
history NN N
of IN N
epilepsy NN N
, , N
simple JJ N
febrile JJ N
convulsions NNS N
, , N
massive JJ N
myoclonus NN N
, , N
tonic-clonic JJ N
fits NNS N
. . N

Outcome NNP N
was VBD N
favourable JJ N
, , N
with IN N
no DT o
seizures NNS o
and CC o
mildly RB o
affected VBD o
cognitive JJ o
functions NNS o
. . o

Interictal NNP N
EEG NNP i
showed VBD N
short JJ o
sequences NNS o
of IN o
irregular JJ o
3-Hz JJ o
spike-waves NNS o
. . o

( ( N
2 CD N
) ) N
In IN N
18 CD N
children NNS N
, , N
clinical JJ o
characteristics NNS o
were VBD N
similar JJ N
to TO N
those DT N
of IN N
the DT N
first JJ N
group NN N
at IN N
the DT N
early JJ N
stage NN N
, , N
but CC N
95 CD N
% NN N
exhibited VBD N
myoclonic JJ o
status NN o
and CC o
vibratory NN o
tonic JJ o
seizures NNS o
, , o
with IN o
persisting VBG o
seizures NNS o
on IN N
follow-up NN N
. . N

EEG NNP N
showed VBD N
long JJ o
sequences NNS o
of IN o
generalised JJ o
irregular JJ o
spike NN o
and CC o
slow JJ o
waves NNS o
. . o

Those DT N
two CD N
groups NNS N
meet VBD N
the DT N
characteristics NNS N
of IN N
childhood NN N
onset VBN N
myoclonic-astatic JJ N
epilepsy NN N
( ( N
MAE NNP N
) ) N
with IN N
respectively RB N
, , N
favourable JJ N
and CC N
unfavourable JJ N
outcome NN N
. . N

( ( N
3 CD N
) ) N
Eleven NNP N
children NNS N
had VBD N
later RBR N
onset VBN N
, , N
atypical JJ o
absences NNS o
, , o
tonic JJ o
and CC o
partial JJ o
seizures NNS o
, , N
and CC N
no DT N
myoclonus NN N
, , N
or CC N
vibratory NN N
tonic JJ N
seizures NNS N
. . N

All DT N
had VBD N
mental JJ o
retardation NN o
and CC o
persisting NN o
seizures NNS o
. . o

EEG NNP N
showed VBD N
long JJ o
sequences NNS o
of IN o
slow JJ o
spike-wave JJ o
activity NN o
and CC o
half PDT o
the DT o
patients NNS o
had VBD o
spike VBN o
and CC o
slow JJ o
wave NN o
foci NN o
. . o

These DT N
patients NNS N
met VBD N
the DT N
major JJ N
characteristics NNS N
of IN N
Lennox-Gastaut NNP N
syndrome NN N
. . N

Initial JJ N
parameters NNS N
failed VBD N
to TO N
distinguish VB N
the DT N
first JJ N
two CD N
groups NNS N
, , N
but CC N
Lennox-Gastaut NNP N
syndrome NN N
( ( N
the DT N
third JJ N
group NN N
) ) N
was VBD N
distinct VBN N
from IN N
both DT N
groups NNS N
of IN N
myoclonic JJ N
astatic JJ N
epilepsy NN N
from IN N
the DT N
onset NN N
. . N

Within IN N
MAE NNP N
groups NNS N
combined VBD N
, , N
clinical JJ N
and CC N
EEG NNP N
risk NN N
factors NNS N
for IN N
mental JJ N
retardation NN N
could MD N
be VB N
identified VBN N
. . N

CONCLUSION VB N
It PRP N
is VBZ N
possible JJ N
to TO N
validate VB N
statistically RB N
the DT N
distinction NN N
between IN N
discrete JJ N
epileptic JJ N
syndromes NNS N
. . N

Myoclonic NNP N
astatic JJ N
epilepsy NN N
is VBZ N
therefore RB N
distinct JJ N
from IN N
Lennox-Gastaut NNP N
syndrome NN N
, , N
and CC N
the DT N
distinction NN N
appears VBZ N
from IN N
the DT N
first JJ N
year NN N
of IN N
the DT N
disorder NN N
. . N

-DOCSTART- -9581739- O O

Comparison NNP N
of IN N
single- JJ i
and CC i
dual-coil JJ i
active JJ i
pectoral JJ i
defibrillation NN i
lead NN i
systems NNS i
. . i

OBJECTIVES IN N
The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
defibrillation NN N
thresholds NNS N
with IN N
lead JJ N
systems NNS N
consisting VBG N
of IN N
an DT N
active JJ N
left JJ N
pectoral JJ N
electrode NN N
and CC N
either DT N
single JJ i
or CC N
dual JJ i
transvenous JJ i
coils NNS i
. . i

BACKGROUND NNP N
Lead NNP N
systems NNS N
that WDT N
include VBP N
an DT N
active JJ N
pectoral JJ N
pulse NN N
generator NN N
reduce VB N
defibrillation NN N
thresholds NNS N
and CC N
permit VBP N
transvenous JJ N
defibrillation NN N
in IN N
nearly RB N
all DT N
patients NNS N
. . N

A DT N
further JJ N
improvement NN N
in IN N
defibrillation NN o
efficacy NN o
is VBZ N
desirable JJ N
to TO N
allow VB N
for IN N
smaller JJR N
pulse NN N
generators NNS N
with IN N
a DT N
reduced VBN N
maximal NN N
output NN N
. . N

METHODS NNP N
This DT N
prospective JJ N
study NN N
was VBD N
performed VBN N
in IN N
50 CD p
consecutive JJ p
patients NNS p
. . p

Each DT p
patient NN p
was VBD N
evaluated VBN N
with IN N
two CD N
lead JJ i
configurations NNS i
with IN N
the DT N
order NN N
of IN N
testing VBG N
randomized VBN N
. . N

Shocks NNS N
were VBD N
delivered VBN N
between IN N
the DT N
right JJ N
ventricular NN N
coil NN N
and CC N
either DT N
an DT N
active JJ N
can MD N
alone RB N
( ( i
single JJ i
coil NN i
) ) i
or CC N
an DT N
active JJ N
can MD N
with IN N
the DT N
proximal JJ N
atrial JJ N
coil NN N
( ( i
dual JJ i
coil NN i
) ) i
. . N

The DT N
right JJ N
ventricular NN N
coil NN N
was VBD N
the DT N
cathode NN N
for IN N
the DT N
first JJ N
phase NN N
of IN N
the DT N
biphasic JJ N
defibrillation NN N
waveform NN N
. . N

RESULTS NNP N
Delivered NNP o
energy NN o
at IN N
the DT N
defibrillation NN o
threshold NN o
was VBD N
10.1+/-5.0 JJ N
J NNP N
for IN N
the DT N
single-coil JJ i
configuration NN N
and CC N
8.7+/-4.0 JJ N
J NNP N
for IN N
the DT N
dual-coil JJ i
configuration NN N
( ( N
p JJ N
< NNP N
0.02 CD N
) ) N
. . N

Moreover RB N
, , N
98 CD p
% NN p
of IN p
patients NNS p
had VBD p
low JJ p
( ( p
< JJ p
15 CD p
J NNP p
) ) p
thresholds VBZ o
with IN N
the DT N
dual-coil JJ i
lead NN p
system NN p
, , N
compared VBN N
with IN N
88 CD p
% NN p
of IN p
patients NNS p
with IN p
the DT p
single-coil JJ i
configuration NN p
( ( N
p=0.05 NN N
) ) N
. . N

Leading VBG o
edge NN o
voltage NN o
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
and CC N
shock NN o
impedance NN o
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
were VBD N
also RB N
decreased VBN N
with IN N
the DT N
dual-coil NN i
configuration NN N
, , N
although IN N
peak JJ o
current JJ o
was VBD N
increased VBN N
( ( N
p JJ N
< NNP N
0.001 CD N
) ) N
. . N

CONCLUSIONS VB N
A DT N
dual-coil NN i
, , N
active JJ N
pectoral JJ N
lead NN N
system NN N
reduces VBZ N
defibrillation NN o
energy NN o
requirements NNS o
compared VBN N
with IN N
a DT N
single-coil NN i
, , N
unipolar JJ N
configuration NN N
. . N

-DOCSTART- -26317618- O O

High JJ N
Platelet NNP N
Reactivity NNP N
in IN N
Patients NNP p
with IN p
Acute NNP p
Coronary NNP p
Syndromes NNP p
Undergoing NNP p
Percutaneous NNP p
Coronary NNP p
Intervention NN p
: : p
Randomised VBN N
Controlled NNP N
Trial NNP N
Comparing NNP N
Prasugrel NNP N
and CC N
Clopidogrel NNP N
. . N

BACKGROUND NNP N
Prasugrel NNP N
is VBZ N
more RBR N
effective JJ N
than IN N
clopidogrel NN N
in IN N
reducing VBG N
platelet NN N
aggregation NN N
in IN N
acute JJ p
coronary JJ p
syndromes NNS p
. . p

Data NNP N
available JJ N
on IN N
prasugrel NN N
reloading NN N
in IN N
clopidogrel NN N
treated VBD N
patients NNS N
with IN N
high JJ N
residual JJ N
platelet NN N
reactivity NN N
( ( N
HRPR NNP N
) ) N
i.e NN N
. . N

poor JJ N
responders NNS N
, , N
is VBZ N
limited VBN N
. . N

OBJECTIVES UH N
To TO N
determine VB N
the DT N
effects NNS N
of IN N
prasugrel NN i
loading VBG N
on IN N
platelet NN N
function NN N
in IN N
patients NNS p
on IN p
clopidogrel NN i
and CC p
high JJ p
platelet NN p
reactivity NN p
undergoing VBG p
percutaneous JJ i
coronary JJ i
intervention NN i
for IN p
acute JJ p
coronary JJ p
syndrome NN p
( ( p
ACS NNP p
) ) p
. . p

PATIENTS JJ N
Patients NNS p
with IN p
ACS NNP p
on IN N
clopidogrel NN i
who WP N
were VBD N
scheduled VBN N
for IN N
PCI NNP i
found VBD N
to TO N
have VB N
a DT N
platelet NN N
reactivity NN N
?40 NNP N
AUC NNP N
with IN N
the DT N
Multiplate NNP N
Analyzer NNP N
, , N
i.e NN N
. . N

poor JJ N
responders NNS N
were VBD N
randomised VBN N
to TO N
prasugrel VB i
( ( i
60 CD N
mg NN N
loading NN N
and CC N
10 CD N
mg JJ N
maintenance NN N
dose NN N
) ) N
or CC N
clopidogrel NN i
( ( i
600 CD N
mg NN N
reloading NN N
and CC N
150 CD N
mg JJ N
maintenance NN N
dose NN N
) ) N
. . N

The DT N
primary JJ N
outcome NN N
measure NN N
was VBD o
proportion NN o
of IN o
patients NNS o
with IN o
platelet JJ o
reactivity NN o
< VBP o
40 CD o
AUC NNP o
4 CD N
hours NNS N
after IN N
loading VBG N
with IN N
study NN N
medication NN N
, , N
and CC N
also RB N
at IN N
one CD N
hour NN N
( ( N
secondary JJ N
outcome NN p
) ) p
. . p

44 CD p
patients NNS p
were VBD p
enrolled VBN p
and CC p
the DT N
study NN N
was VBD N
terminated VBN N
early RB N
as IN N
clopidogrel NN N
use NN N
decreased VBD N
sharply RB N
due JJ N
to TO N
introduction NN N
of IN N
newer JJR N
P2Y12 NNP N
inhibitors NNS N
. . N

RESULTS NNP N
At IN N
4 CD N
hours NNS N
after IN N
study NN N
medication NN N
100 CD N
% NN N
of IN N
patients NNS N
treated VBN N
with IN N
prasugrel NN N
compared VBN N
to TO N
91 CD N
% NN N
of IN N
those DT N
treated VBN N
with IN N
clopidogrel NN N
had VBD o
platelet VBN o
reactivity NN o
< VBZ o
40 CD o
AUC NNP o
( ( o
p JJ N
= NNP N
0.49 CD N
) ) N
, , N
while IN N
at IN N
1 CD N
hour NN N
the DT N
proportions NNS N
were VBD N
95 CD N
% NN N
and CC N
64 CD N
% NN N
respectively RB N
( ( N
p JJ N
= NNP N
0.02 CD o
) ) o
. . o

Mean JJ o
platelet NN o
reactivity NN o
at IN o
4 CD N
and CC N
1 CD N
hours NNS N
after IN N
study NN N
medication NN N
in IN N
prasugrel NN N
and CC N
clopidogrel NN N
groups NNS N
respectively RB N
were VBD N
12 CD N
versus NN N
22 CD N
( ( N
p NN N
= RB N
0.005 CD N
) ) N
and CC N
19 CD N
versus NN N
34 CD N
( ( N
p NN N
= RB N
0.01 CD N
) ) N
respectively RB N
. . N

CONCLUSIONS NNP N
Routine NNP N
platelet NN N
function NN N
testing VBG N
identifies NNS N
patients NNS N
with IN N
high JJ o
residual JJ o
platelet NN o
reactivity NN o
( ( o
poor JJ N
responders NNS N
) ) N
on IN N
clopidogrel NN N
. . N

A DT N
strategy NN N
of IN N
prasugrel NN N
rather RB N
than IN N
clopidogrel VB N
reloading VBG N
results NNS N
in IN N
earlier JJR N
and CC N
more RBR N
sustained JJ N
suppression NN N
of IN N
platelet NN N
reactivity NN N
. . N

Future JJ N
trials NNS N
need VBP N
to TO N
identify VB N
if IN N
this DT N
translates VBZ N
into IN N
clinical JJ N
benefit NN N
. . N

TRIAL NNP N
REGISTRATION NNP N
ClinicalTrials.gov NNP N
NCT01339026 NNP N
. . N

-DOCSTART- -341946- O O

Placebo-controlled JJ i
double-blind JJ p
trial NN p
of IN p
mianserin NN i
hydrochloride NN i
. . i

-DOCSTART- -12031821- O O

Improved VBN N
fibrinolysis NN N
after IN N
1-year JJ N
treatment NN N
with IN N
HMG NNP i
CoA NNP i
reductase NN i
inhibitors NNS i
in IN N
patients NNS p
with IN p
coronary JJ p
heart NN p
disease NN p
. . p

The DT N
study NN N
was VBD N
aimed VBN N
to TO N
investigate VB N
the DT N
effect NN N
of IN N
two CD N
different JJ N
statins NNS i
on IN N
the DT N
levels NNS N
of IN N
haemostatic JJ N
variables NNS N
reflecting VBG N
procoagulant NN N
and CC N
fibrinolytic JJ N
activity NN N
in IN N
patients NNS p
with IN p
coronary JJ p
heart NN p
disease NN p
( ( p
CHD NNP p
) ) p
, , N
with IN N
the DT N
hypothesis NN N
that WDT N
statins VBZ i
might MD N
beneficially RB N
modify VB N
these DT N
levels NNS N
. . N

Fifty-eight JJ p
patients NNS p
were VBD N
randomized VBN N
to TO N
treatment NN N
with IN N
atorvastatin NN i
( ( N
n=28 JJ N
) ) N
or CC N
simvastatin NN i
( ( N
n=30 JJ N
) ) N
for IN N
1 CD N
year NN N
. . N

The DT N
starting VBG N
dose NN N
in IN N
both DT N
groups NNS N
was VBD N
20 CD N
mg/day NN N
. . N

Fasting VBG o
blood NN o
samples NNS o
were VBD N
collected VBN N
before IN N
and CC N
after IN N
12-month JJ N
treatment NN N
for IN N
determinations NNS N
of IN N
fibrinogen NN o
, , o
prothrombin JJ o
fragment NN o
1+2 CD o
( ( o
F1+2 NNP o
) ) o
, , o
plasma JJ o
D-dimer NNP o
, , o
soluble JJ o
tissue NN o
factor NN o
, , o
tissue NN o
plasminogen NN o
activator NN o
( ( o
tPA NN o
) ) o
antigen NN o
, , o
tPA NN o
activity NN o
, , o
plasminogen NN o
activator NN o
inhibitor JJ o
type-1 JJ o
activity NN o
( ( o
PAI-1 NNP o
activity NN o
) ) o
and CC o
serum JJ o
D-dimer NNP o
as IN o
a DT o
global JJ o
test NN o
of IN o
fibrinolytic JJ o
activity NN o
. . o

In IN N
the DT N
total JJ N
population NN N
, , N
improved VBN o
fibrinolytic JJ o
activity NN o
was VBD N
observed VBN N
after IN N
1 CD N
year NN N
with IN N
increased JJ o
levels NNS o
of IN N
serum NN o
D-dimer NNP o
( ( N
P=.001 NNP N
) ) N
and CC N
tPA JJ o
activity NN o
( ( N
P=.024 NNP N
) ) N
and CC N
a DT N
reduction NN o
in IN o
tPA NN o
antigen NN o
( ( N
P=.048 NNP N
) ) N
. . N

No DT N
statistically RB N
significant JJ N
changes NNS N
were VBD N
observed VBN N
in IN N
any DT N
of IN N
the DT N
measured JJ N
coagulation NN N
variables NNS N
. . N

Separately RB N
examined VBD N
, , N
an DT N
improved JJ N
fibrinolytic JJ N
profile NN N
was VBD N
seen VBN N
in IN N
the DT N
atorvastatin NN i
group NN N
with IN N
a DT N
significant JJ o
increase NN o
in IN o
serum JJ o
D-dimer NNP o
( ( N
P=.005 NNP N
) ) N
, , N
a DT N
borderline JJ o
increase NN o
in IN o
tPA JJ o
activity NN o
( ( N
P=.083 NNP N
) ) N
and CC N
a DT N
borderline NN o
reduction NN o
in IN o
tPA NN o
antigen NN o
( ( N
P=.069 NNP N
) ) N
. . N

Within IN N
the DT N
simvastatin NN i
group NN N
, , N
a DT N
reduction NN o
in IN o
prothrombin NN o
F1+2 NNP o
was VBD N
observed VBN N
( ( N
P=.038 NNP N
) ) N
. . N

The DT N
differences NNS N
in IN N
changes NNS N
between IN N
the DT N
groups NNS N
were VBD N
statistically RB N
significant JJ N
only RB N
for IN N
global JJ o
fibrinolysis NN o
( ( N
serum JJ N
D-dimer NNP N
, , N
P=.046 NNP N
) ) N
. . N

In IN N
conclusion NN N
, , N
an DT N
improved JJ N
fibrinolytic JJ o
profile NN o
was VBD N
observed VBN N
after IN N
statin NN i
treatment NN N
, , N
most RBS N
pronounced JJ N
with IN N
atorvastatin NN i
. . i

The DT N
results NNS N
indicate VBP N
that IN N
the DT N
drugs NNS N
promote VBP N
a DT N
profibrinolytic JJ N
profile NN N
, , N
and CC N
may MD N
in IN N
part NN N
explain VBP N
the DT N
benefit NN N
of IN N
statin NN i
treatment NN N
rendered VBN N
in IN N
the DT N
prevention NN N
of IN N
CHD NNP N
. . N

-DOCSTART- -3825543- O O

Parietal NNP o
cell NN o
density NN o
in IN N
duodenal JJ p
ulcer NN p
patients NNS p
after IN p
short-term JJ p
treatment NN p
with IN p
cimetidine NN i
and CC i
antacids NNS i
. . i

In IN N
a DT N
prospective JJ N
study NN N
, , N
20 CD p
patients NNS p
with IN p
endoscopically RB p
proven JJ p
duodenal JJ p
ulcers NNS p
were VBD N
randomised VBN N
to TO N
be VB N
treated VBN N
with IN N
cimetidine NN i
1 CD i
g JJ i
daily JJ i
or CC i
with IN i
antacids NNS i
350 CD i
mmol JJ i
daily RB i
. . i

The DT N
duration NN N
of IN N
treatment NN N
was VBD N
30 CD N
days NNS N
, , N
but CC N
this DT N
was VBD N
extended VBN N
to TO N
three CD N
months NNS N
in IN N
3 CD N
patients NNS N
in IN N
the DT N
cimetidine NN i
group NN N
and CC N
4 CD N
patients NNS N
in IN N
the DT N
antacid NN i
group NN N
. . N

A DT N
morphological JJ N
study NN N
of IN N
biopsies NNS N
taken VBN N
via IN N
a DT N
gastroscope NN N
from IN N
the DT N
corpus NN N
mucosa NN N
showed VBD N
no DT N
change NN N
in IN N
mucosal NN o
height NN o
, , o
parietal JJ o
cell NN o
density NN o
per IN o
unit NN o
volume NN o
or CC o
changes NNS o
in IN o
cellular JJ o
infiltration NN o
after IN N
30 CD N
and CC N
90 CD N
days NNS N
treatment NN N
in IN N
the DT N
two CD N
groups NNS N
. . N

Neither CC N
H-2 JJ i
receptor NN i
blockers NNS i
nor CC N
antacids NNS i
alter NN N
mucosal NN o
height VBD o
or CC o
parietal JJ o
cell NN o
density NN o
. . o

Treatment NNP N
was VBD N
not RB N
found VBN N
to TO N
induce VB N
gastritic JJ o
changes NNS o
in IN N
the DT N
mucosa NN N
. . N

-DOCSTART- -2682347- O O

Auditory NNP N
evoked VBD N
potential JJ N
modifications NNS N
according VBG N
to TO N
clinical JJ N
and CC N
biochemical JJ N
responsiveness NN N
to TO N
fenfluramine VB i
treatment NN i
in IN N
children NNS p
with IN p
autistic JJ p
behavior NN p
. . p

Evoked JJ N
potentials NNS N
to TO N
auditory JJ N
stimulations NNS N
varying VBG N
in IN N
intensity NN N
were VBD N
studied VBN N
in IN N
13 CD p
children NNS p
with IN p
autistic JJ p
behavior NN p
treated VBN p
with IN p
fenfluramine NN i
. . i

Modifications NNS o
of IN o
both DT o
amplitude JJ o
and CC o
single-trial JJ o
potential JJ o
variability NN o
were VBD N
considered VBN N
according VBG N
to TO N
the DT N
clinical JJ N
and CC N
biochemical JJ N
responsiveness NN N
to TO N
this DT N
drug NN N
. . N

Six NNP p
children NNS p
( ( p
responders NNS p
) ) p
were VBD N
clinically RB N
improved VBN N
by IN N
the DT N
treatment NN N
. . N

Electrophysiological JJ N
data NNS N
were VBD N
affected JJ N
according VBG N
to TO N
the DT N
clinical JJ N
and CC N
biochemical JJ N
responsiveness NN N
to TO N
fenfluramine VB i
: : i
the DT N
auditory NN o
evoked VBD o
potential JJ o
amplitude NN o
increased VBN N
, , N
and CC N
the DT N
single-trial JJ o
potential JJ o
variability NN o
decreased VBN N
at IN N
each DT N
intensity NN N
level NN N
only RB N
in IN N
responders NNS N
whose WP$ N
dopaminergic JJ o
metabolism NN o
was VBD N
significantly RB N
modified VBN N
by IN N
fenfluramine JJ N
treatment NN N
. . N

No DT N
modification NN N
was VBD N
found VBN N
in IN N
nonresponders NNS N
. . N

Both DT N
biochemical JJ N
and CC N
electrophysiological JJ N
results NNS N
argued VBD N
for IN N
an DT N
amphetamine-like JJ N
action NN N
of IN N
fenfluramine NN i
in IN N
those DT N
autistic JJ N
children NNS N
whose WP$ N
attention NN N
deficits NNS N
are VBP N
associated VBN N
with IN N
motor NN N
disturbances NNS N
including VBG N
hyperactivity NN N
. . N

-DOCSTART- -24685085- O O

[ RB N
Prophylactic NNP N
use NN N
of IN N
low JJ i
molecular JJ i
weight NN i
heparin NN i
in IN N
combination NN N
with IN N
graduated JJ i
compression NN i
stockings NNS i
in IN N
post-operative JJ p
patients NNS p
with IN p
gynecologic JJ p
cancer NN p
] NNP p
. . N

OBJECTIVE CC N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
efficacy NN N
of IN N
low JJ i
molecular JJ i
weight NN i
heparin NN i
( ( i
LMWH NNP i
) ) i
combined VBD i
with IN i
graduated JJ i
compression NN i
stockings NNS i
( ( i
GCS NNP i
) ) i
with IN N
GCS NNP i
alone RB i
as IN N
prophylactic JJ o
measures NNS o
for IN o
venous JJ o
thromboembolism NN o
( ( o
VTE NNP o
) ) o
in IN N
post-operative JJ p
patients NNS p
with IN p
gynecologic JJ p
cancer NN p
. . p

METHODS NNP N
Patients NNPS p
diagnosed VBD p
with IN p
gynecologic JJ p
cancer NN p
undergoing VBG p
primary JJ p
major JJ p
surgery NN p
between IN p
2010 CD p
and CC p
2011 CD p
in IN p
our PRP$ p
institute NN p
were VBD p
randomized VBN p
to TO N
receive VB N
LMWH+GCS NNP i
or CC N
GCS NNP i
as IN N
VTE NNP N
prophylaxis IN N
post-operatively RB N
. . N

RESULTS NNP N
Altogether RB p
247 CD p
patients NNS p
were VBD p
enrolled VBN p
. . p

The DT N
incidence NN o
of IN o
VTE NNP o
in IN N
patients NNS N
treated VBN N
with IN N
LMWH NNP i
+ NNP i
GCS NNP i
was VBD N
significantly RB N
lower JJR N
than IN N
that DT N
in IN N
patients NNS N
using VBG N
GCS NNP i
alone RB N
( ( N
0.8 CD N
% NN N
Vs. NNP N
8.1 CD N
% NN N
, , N
P NNP N
= NNP N
0.01 CD N
) ) N
. . N

There EX N
were VBD N
no DT N
severe JJ o
bleeding VBG o
complications NNS o
in IN N
the DT N
patients NNS N
with IN N
prophylactic JJ N
use NN N
of IN N
LMWH NNP i
and CC N
the DT N
occurrence NN o
rate NN o
of IN o
wound NN o
dehiscence NN o
was VBD N
comparable JJ N
between IN N
the DT N
two CD N
groups NNS N
( ( N
P NNP N
> NNP N
0.05 CD N
) ) N
. . N

Multivariable JJ N
logistic JJ N
regression NN N
analysis NN N
revealed VBD N
that IN N
age NN N
over IN N
60 CD N
years NNS N
( ( N
P NNP N
= NNP N
0.015 CD N
) ) N
, , N
duration NN N
of IN N
operation NN N
over IN N
3 CD N
hours NNS N
( ( N
P NNP N
= NNP N
0.04 CD N
) ) N
and CC N
without IN N
prophylactic JJ N
use NN N
of IN N
LMWH NNP i
( ( N
P NNP N
= NNP N
0.02 CD N
) ) N
were VBD N
independent JJ N
risk NN N
factors NNS N
for IN N
VTE NNP N
. . N

CONCLUSIONS NNP N
Dual NNP N
prophylaxis NN N
with IN N
LMWH NNP i
and CC i
GCS NNP i
should MD N
be VB N
recommended VBN N
for IN N
gynecologic JJ N
cancer NN N
patients NNS N
undergoing VBG N
major JJ N
surgery NN N
for IN N
its PRP$ N
better JJR N
efficacy NN o
than IN N
GCS NNP i
. . i

Prophylactic NNP N
use NN N
of IN N
LMWH NNP i
is VBZ N
safe JJ N
and CC N
convenient JJ N
. . N

Patients NNS N
with IN N
older JJR N
age NN N
and CC N
prolonged JJ N
operation NN N
time NN N
are VBP N
at IN N
highest JJS N
risk NN N
of IN N
developing VBG N
VTE NNP o
post-operatively RB o
. . o

-DOCSTART- -12954577- O O

Randomized VBN N
, , N
double-blind JJ N
, , N
multicenter JJ N
trial NN N
comparing VBG N
two CD N
doses NNS N
of IN N
arzoxifene NN i
( ( i
LY353381 NNP i
) ) i
in IN N
hormone-sensitive JJ p
advanced JJ p
or CC p
metastatic JJ p
breast NN p
cancer NN p
patients NNS p
. . p

BACKGROUND NNP N
This DT N
randomized VBN N
, , N
double-blind JJ N
, , N
phase NN N
II NNP N
study NN N
assessed VBD N
two CD N
doses NNS N
of IN N
the DT N
selective JJ i
estrogen NN i
receptor NN i
modulator NN i
arzoxifene NN i
in IN N
women NNS p
with IN p
advanced JJ p
breast NN p
cancer NN p
. . p

The DT N
primary JJ N
end NN N
point NN N
was VBD N
to TO N
choose VB N
the DT N
best JJS N
of IN N
two CD N
doses NNS N
of IN N
arzoxifene NN i
based VBN N
on IN N
the DT N
response NN o
rate NN o
or CC o
the DT o
clinical JJ o
benefit NN o
rate NN o
( ( o
CBR NNP o
) ) o
. . o

Pharmacokinetics NNPS o
and CC o
toxicities NNS o
were VBD N
also RB N
assessed VBN N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
Ninety-two NNP p
patients NNS p
with IN p
advanced JJ p
breast NN p
cancer NN p
received VBD i
arzoxifene JJ i
20 CD i
or CC i
50 CD i
mg/day NN i
. . i

Tumor NNP o
response NN o
was VBD i
assessed VBN i
using VBG i
World NNP i
Health NNP i
Organization NNP i
criteria NNS i
. . i

Toxicities NNS o
were VBD i
graded VBN i
according VBG i
to TO i
the DT i
National NNP i
Cancer NNP i
Institute NNP i
Common NNP i
Toxicity NNP i
Criteria NNP i
( ( i
NCI-CTC NNP i
) ) i
system NN i
. . i

Pharmacokinetic JJ o
data NNS o
were VBD N
analyzed VBN N
using VBG N
the DT N
NONMEM NNP N
software NN N
program NN N
( ( N
GloboMax NNP N
, , N
Hanover NNP N
, , N
MD NNP N
, , N
USA NNP N
) ) N
. . N

RESULTS JJ N
Response JJ o
rates NNS o
in IN N
the DT N
20 CD N
mg NN N
arm NN N
were VBD N
numerically RB N
higher JJR N
than IN N
the DT N
50-mg JJ N
arm NN N
according VBG N
to TO N
the DT N
investigator NN N
( ( N
40.5 CD N
% NN N
versus IN N
36.4 CD N
% NN N
) ) N
and CC N
the DT N
independent JJ N
review NN N
panel NN N
( ( N
42.9 CD N
% NN N
versus IN N
27.3 CD N
% NN N
) ) N
. . N

CBR NNP o
was VBD N
higher RBR N
in IN N
the DT N
20 CD N
mg NN N
arm NN N
according VBG N
to TO N
the DT N
investigator NN N
( ( N
64.3 CD N
% NN N
versus IN N
61.4 CD N
% NN N
) ) N
and CC N
the DT N
independent JJ N
review NN N
panel NN N
( ( N
59.5 CD N
% NN N
versus IN N
47.7 CD N
% NN N
) ) N
. . N

Arzoxifene NNP i
was VBD N
well RB N
tolerated VBN N
. . N

There EX N
were VBD N
no DT N
study NN N
drug-related JJ o
deaths NNS o
. . o

Mean NNP N
observed VBD N
steady-state JJ o
plasma JJ o
concentrations NNS o
of IN N
arzoxifene NN i
were VBD N
3.62 CD N
and CC N
7.48 CD N
ng/ml NN N
for IN N
the DT N
20 CD N
and CC N
50 CD N
mg NN N
doses NNS N
, , N
respectively RB N
. . N

CONCLUSIONS VB N
There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
in IN N
efficacy NN o
or CC N
safety NN o
between IN N
20 CD N
and CC N
50 CD N
mg NN N
of IN N
arzoxifene NN i
. . i

Accordingly RB N
, , N
arzoxifene VBZ i
20 CD N
mg/day NN N
was VBD N
selected VBN N
for IN N
further JJ N
study NN N
in IN N
patients NNS N
with IN N
breast JJ N
cancer NN N
. . N

-DOCSTART- -2590611- O O

Differential JJ N
effect NN N
of IN N
aspirin NN i
on IN N
thromboxane NN o
and CC o
prostaglandin JJ o
biosynthesis NN o
in IN p
man NN p
. . p

1 CD N
. . N

Effects NNS N
of IN N
a DT N
single JJ N
intravenous JJ N
dose NN N
of IN N
aspirin NN i
( ( N
600 CD N
mg NN N
) ) N
on IN N
bradykinin-stimulated JJ o
prostaglandin NN o
( ( o
PG NNP o
) ) o
and CC o
on IN o
thromboxane NN o
( ( o
TX NNP o
) ) o
biosynthesis NN o
were VBD N
determined VBN N
in IN N
nine CD p
healthy JJ p
male NN p
volunteers NNS p
. . p

Plasma NNP N
concentrations NNS N
of IN N
6-oxo-PGF1 JJ N
alpha NN N
and CC N
13,14-dihydro-15-oxo-PGF2 JJ N
alpha NN N
were VBD N
measured VBN N
in IN N
samples NNS N
obtained VBN N
during IN N
repeated JJ N
10 CD N
min NN N
intravenous JJ N
infusions NNS N
of IN N
bradykinin NN N
before IN N
and CC N
up RB N
to TO N
6 CD N
h NN N
after IN N
the DT N
dose NN N
of IN N
aspirin NN i
. . i

TXB2 NNP o
was VBD o
measured VBN o
in IN o
serum NN o
from IN N
blood NN N
allowed VBN N
to TO N
clot VB N
at IN N
37 CD N
degrees NNS N
C. NNP N
2 CD N
. . N

Aspirin NNP o
inhibited VBD o
bradykinin NN o
stimulated VBN o
PG NNP o
and CC N
platelet VB N
TX NNP N
biosynthesis NN N
0.5 CD N
h NN N
after IN N
the DT N
dose NN N
. . N

Serum NNP o
TXB2 NNP o
remained VBD o
low JJ o
, , N
whereas JJ N
PG NNP o
synthesis NN o
recovered VBD o
within IN N
6 CD N
h. JJ N
3 CD N
. . N

Effects NNS N
of IN N
intravenous JJ i
sodium NN i
salicylate NN i
( ( N
600 CD N
mg NN N
) ) N
were VBD N
studied VBN N
identically RB N
in IN N
eight CD N
subjects NNS N
. . N

Prostanoid NNP o
biosynthesis NN o
was VBD N
not RB N
inhibited VBN N
. . N

4 CD N
. . N

Biosynthesis NN o
of IN o
prostacyclin NN o
and CC o
TXA2 NNP o
under IN N
basal NN N
conditions NNS N
was VBD N
studied VBN N
in IN N
eight CD N
subjects NNS N
by IN N
measuring VBG o
2,3-dinor-6-oxo-PGF1 JJ o
alpha NN o
and CC o
2,3-dinor-TXB2 JJ o
in IN N
hourly JJ N
urine JJ N
samples NNS N
obtained VBN N
during IN N
and CC N
after IN N
intravenous JJ N
infusion NN i
of IN i
aspirin NN i
and CC N
, , N
on IN N
a DT N
separate JJ N
occasion NN N
, , N
of IN N
vehicle NN N
. . N

5 CD N
. . N

Aspirin NNP i
infusion NN i
reduced VBD o
urinary JJ o
excretion NN o
of IN N
both DT N
metabolites NNS N
greater JJR N
than IN N
90 CD N
% NN N
, , N
but CC N
excretion NN N
of IN N
2,3-dinor-6-oxo-PGF1 JJ o
alpha NN o
recovered VBD o
more RBR o
rapidly RB o
than IN N
did VBD N
that IN N
of IN N
2,3-dinor-TXB2 JJ N
. . N

6 CD N
. . N

We PRP N
conclude VBP N
that DT N
cyclo-oxygenase NN N
is VBZ N
rapidly RB o
synthesised VBN o
in IN o
bradykinin-responsive JJ o
tissues NNS o
in IN N
vivo NN N
and CC N
that IN N
this DT N
reflects VBZ N
similarly RB N
rapid JJ N
enzyme JJ N
biosynthesis NN N
in IN N
tissues NNS N
that WDT N
produce VBP N
PGI2 NNP N
under IN N
basal NN N
conditions NNS N
. . N

-DOCSTART- -12169964- O O

Primary JJ i
deep JJ i
sclerectomy NN i
versus IN N
primary JJ i
deep JJ i
sclerectomy NN i
with IN i
the DT i
use NN i
of IN i
mitomycin NN i
C NNP i
in IN N
primary JJ p
open-angle JJ p
glaucoma NN p
. . p

PURPOSE NNP N
To TO N
prospectively RB N
study VB N
and CC N
compare VB N
the DT N
effectiveness NN o
and CC N
the DT N
safety NN o
of IN N
primary JJ N
deep JJ N
sclerectomy NN N
with IN N
and CC N
without IN N
the DT N
use NN N
of IN N
mitomycin NN N
C NNP N
in IN N
eyes NNS p
with IN p
open-angle JJ p
glaucoma NN p
. . p

PATIENTS NNP N
AND CC N
METHODS NNP N
A NNP p
total NN p
of IN p
90 CD p
eyes NNS p
of IN p
90 CD p
patients NNS p
with IN p
primary JJ p
open-angle JJ p
glaucoma NN p
or CC p
pseudoexfoliative JJ p
glaucoma NN p
underwent JJ p
deep JJ p
sclerectomy NN p
. . p

Patients NNS N
were VBD N
enrolled VBN N
consecutively RB N
and CC N
assigned VBD N
randomly RB N
to TO N
undergo VB N
deep JJ i
sclerectomy NN i
without IN i
the DT i
use NN i
of IN i
mitomycin NN i
C NNP i
( ( i
DS NNP i
group NN i
) ) i
and CC i
deep JJ i
sclerectomy NN i
with IN i
the DT i
application NN i
of IN i
mitomycin NN i
C NNP i
( ( i
DSMMC NNP i
group NN i
) ) i
in IN N
a DT N
concentration NN N
of IN N
0.2 CD N
mg/mL NN N
for IN N
2.5 CD N
minutes NNS N
, , N
before IN N
the DT N
superficial JJ N
scleral JJ N
flap NN N
formation NN N
. . N

RESULTS VB N
The DT N
intraocular JJ o
pressure NN o
was VBD N
significantly RB N
decreased VBN N
by IN N
7.13 CD N
mm NNS N
Hg NNP N
or CC N
27.59 CD N
% NN N
in IN N
the DT N
DS NNP N
group NN N
and CC N
by IN N
11.68 CD N
mm NNS N
Hg NNP N
or CC N
42.25 CD N
% NN N
in IN N
the DT N
DSMMC NNP N
group NN N
at IN N
the DT N
end NN N
of IN N
the DT N
follow-up JJ N
period NN N
. . N

The DT N
intraocular JJ o
pressure NN o
reduction NN o
in IN N
the DT N
DSMMC NNP N
group NN N
was VBD N
statistically RB N
significant JJ N
when WRB N
compared VBN N
with IN N
that DT N
in IN N
the DT N
DS NNP N
group NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

The DT N
complete JJ N
( ( N
IOP NNP N
< VBZ N
22 CD N
mm NN N
Hg NNP N
without IN N
medication NN N
) ) N
and CC N
qualified VBN N
( ( N
IOP NNP N
< VBZ N
22 CD N
mm NN N
Hg NNP N
with IN N
or CC N
without IN N
medication NN N
) ) N
success NN o
rates NNS o
at IN N
the DT N
end NN N
of IN N
the DT N
follow-up JJ N
period NN N
were VBD N
42.5 CD N
% NN N
and CC N
72.5 CD N
% NN N
in IN N
the DT N
DS NNP N
group NN N
and CC N
50 CD N
% NN N
and CC N
95 CD N
% NN N
in IN N
the DT N
DSMMC NNP N
group NN N
. . N

The DT N
qualified JJ o
success NN o
rate NN o
in IN N
the DT N
DSMMC NNP N
group NN N
was VBD N
statistically RB N
significant JJ N
when WRB N
compared VBN N
with IN N
that DT N
in IN N
the DT N
DS NNP N
group NN N
. . N

Differences NNS N
in IN N
complications NNS N
( ( o
choroidal JJ o
detachment NN o
, , o
hyphema NN o
, , o
leakage NN o
) ) o
seen VBN N
between IN N
the DT N
two CD N
groups NNS N
were VBD N
statistically RB N
nonsignificant JJ N
. . N

A DT N
hemorrhagic JJ o
detachment NN o
of IN o
the DT o
Descemet NNP o
membrane NN o
was VBD N
observed VBN N
in IN N
one CD N
eye NN N
in IN N
the DT N
DSMMC NNP N
group NN N
. . N

CONCLUSIONS NNP N
The DT N
use NN N
of IN N
intraoperative JJ N
mitomycin NN N
C NNP N
during IN N
deep JJ N
sclerectomy NN N
significantly RB N
reduced VBD N
the DT N
postoperative JJ N
IOP NNP N
and CC N
increased VBD N
the DT N
success NN N
rate NN N
of IN N
the DT N
procedure NN N
. . N

-DOCSTART- -15810908- O O

B-domain NNP i
deleted VBD i
recombinant JJ i
factor NN i
VIII NNP i
preparations NNS i
are VBP N
bioequivalent JJ N
to TO N
a DT N
monoclonal JJ N
antibody NN N
purified VBD N
plasma-derived JJ N
factor NN N
VIII NNP N
concentrate NN N
: : N
a DT N
randomized JJ N
, , N
three-way JJ N
crossover NN N
study NN N
. . N

BACKGROUND NNP N
Deletion NNP N
of IN N
the DT N
B-domain NNP N
of IN N
recombinant JJ N
blood NN N
coagulation NN N
factor NN N
VIII NNP N
( ( N
BDDrFVIII NNP N
) ) N
increases VBZ N
the DT N
manufacturing VBG N
yield NN N
of IN N
the DT N
product NN N
but CC N
does VBZ N
not RB N
impair VB N
in IN N
vitro NN N
or CC N
in IN N
vivo JJ N
functionality NN N
. . N

BDDrFVIII NNP N
( ( N
ReFacto NNP N
) ) N
has VBZ N
been VBN N
developed VBN N
with IN N
the DT N
additional JJ N
benefit NN N
of IN N
being VBG N
formulated VBN N
without IN N
human JJ N
albumin NN N
. . N

OBJECTIVE CC N
The DT N
primary JJ N
objective NN N
of IN N
this DT N
three-way JJ N
crossover-design NN N
study NN N
was VBD N
to TO N
compare VB N
the DT N
pharmacokinetic JJ p
( ( p
PK NNP p
) ) p
parameters NNS N
of IN N
two CD N
BDDrFVIII NNP i
formulations NNS i
( ( i
one CD i
reconstituted VBN i
with IN i
5 CD i
mL NNS i
of IN i
sterile JJ i
water NN i
, , i
the DT i
other JJ i
reconstituted VBD i
with IN i
4 CD i
mL NNS i
sodium JJ i
chloride RB i
0.9 CD i
% NN i
USP NNP i
) ) i
with IN N
those DT N
of IN N
a DT N
plasma-derived JJ N
, , N
full-length JJ i
FVIII NNP i
preparation NN i
( ( i
Hemofil NNP i
M NNP i
) ) i
in IN p
patients NNS p
with IN p
haemophilia PDT p
A DT p
to TO N
determine VB N
bioequivalence NN N
. . N

METHODS VB N
A NNP N
series NN p
of IN p
blood NN o
samples NNS o
were VBD p
collected VBN p
over IN p
a DT p
period NN p
of IN p
48 CD p
h NN p
after IN p
i.v NN p
. . p

administration NN p
of IN p
each DT p
of IN p
the DT p
FVIII NNP i
preparations NNS i
. . i

Plasma NNP o
FVIII NNP o
activity NN o
was VBD N
determined VBN N
using VBG N
a DT N
validated JJ N
chromogenic JJ N
substrate NN N
assay NN N
. . N

Plasma NNP o
FVIII NNP o
activity NN o
vs. FW N
time NN o
curves NNS o
was VBD N
characterized VBN N
for IN N
a DT N
standard JJ N
set NN N
of IN N
PK NNP N
parameter NN N
estimates NNS N
. . N

Two CD N
parameter NN N
estimates NNS N
, , N
the DT N
maximum JJ o
plasma JJ o
concentration NN o
( ( o
Cmax NNP o
) ) o
and CC o
the DT o
area NN o
under IN o
plasma JJ o
concentration NN o
vs. FW o
time NN o
curves NNS o
( ( o
AUCs NNP o
) ) o
, , N
were VBD N
used VBN N
to TO N
evaluate VB N
bioequivalence NN N
. . N

The DT N
two CD N
preparations NNS N
were VBD N
considered VBN N
bioequivalent NN N
if IN N
the DT N
90 CD N
% NN N
confidence NN N
intervals NNS N
for IN N
the DT N
ratio NN o
of IN o
geometric JJ o
means NNS o
for IN o
Cmax NNP o
and CC o
AUCs NNP o
fell VBD N
within IN N
the DT N
bioequivalence NN N
window NN N
of IN N
80 CD N
% NN N
to TO N
125 CD N
% NN N
. . N

RESULTS/CONCLUSION NNP N
Results NNP N
show VBP N
that IN N
each DT N
BDDrFVIII NNP i
formulation NN i
is VBZ N
bioequivalent JJ o
to TO N
Hemofil NNP N
M NNP N
and CC N
the DT N
two CD N
formulations NNS N
of IN N
BDDrFVIII NNP N
are VBP N
bioequivalent JJ N
to TO N
each DT N
other JJ N
. . N

-DOCSTART- -11789002- O O

[ NN i
Statins VBZ i
in IN N
the DT N
treatment NN N
of IN N
patients NNS p
with IN p
arterial JJ p
occlusive JJ p
disease NN p
of IN p
the DT p
lower JJR p
extremities NNS p
] VBP p
. . N

In IN N
patients NNS p
with IN p
advanced JJ p
atherosclerosis NN p
manifested VBN p
by IN p
arterial JJ p
occlusion NN p
in IN p
the DT p
lower JJR p
extremities NNS p
without IN p
a DT p
baseline NN p
blood NN p
lipid JJ p
disorder NN p
statin NN i
treatment NN i
caused VBD N
improvement NN N
of IN N
the DT N
efficiency NN o
, , o
i.e NN o
. . o

prolongation NN o
of IN o
the DT o
claudication NN o
interval NN o
, , N
while IN N
in IN N
a DT N
comparable JJ p
control NN p
group NN p
without IN p
statins VBZ p
the DT N
efficiency NN N
deteriorated VBD N
further RBR N
. . N

In IN N
patients NNS p
with IN p
arterial JJ p
occlusion NN p
of IN p
the DT p
lower JJR p
extremities NNS p
with IN p
baseline NN p
dyslipidaemia NN p
statin NN i
treatment NN i
proved VBD N
protective JJ o
, , o
i.e JJ o
. . o

at IN o
least JJS o
it PRP o
retarded VBD o
the DT o
patients NNS o
' POS o
complaints NNS o
. . o

The DT N
authors NNS N
recorded VBD N
improvement NN N
of IN N
the DT o
prooxidation NN o
state NN o
which WDT N
followed VBD N
after IN N
the DT N
dynamics NNS N
of IN N
improvement NN N
of IN N
the DT N
impaired JJ N
blood NN o
lipid JJ o
spectrum NN o
. . o

The DT N
results NNS N
admit VBP N
a DT N
possible JJ N
part NN N
played VBN N
by IN N
the DT N
pleiotropic NN N
effect NN N
of IN N
statins NNS N
. . N

-DOCSTART- -15548759- O O

Folate NN N
levels NNS N
determine VBP N
effect NN N
of IN N
antioxidant JJ i
supplementation NN i
on IN N
micronuclei NN o
in IN N
subjects NNS p
with IN p
cardiovascular JJ p
risk NN p
. . p

We PRP N
have VBP N
investigated VBN N
the DT N
effect NN N
of IN N
modest JJ N
supplementation NN i
with IN i
alpha-tocopherol NN i
( ( N
100 CD N
mg/day NN N
) ) N
, , N
beta-carotene JJ i
( ( N
6 CD N
mg/day NN N
) ) N
, , N
vitamin FW i
C NNP i
( ( N
100 CD N
mg/day NN N
) ) N
and CC N
selenium NN i
( ( N
50 CD N
microg/day NN N
) ) N
on IN N
oxidative JJ N
stress NN N
and CC N
chromosomal JJ N
damage NN N
, , N
and CC N
the DT N
influence NN N
of IN N
methylenetetrahydrofolate NN N
reductase NN N
( ( N
MTHFR NNP N
) ) N
genotype NN N
on IN N
these DT N
end-points NNS N
. . N

Subjects NNS N
were VBD N
two CD p
groups NNS p
of IN p
middle-aged JJ p
men NNS p
differing VBG p
in IN p
cardiovascular JJ p
risk NN p
; : p
46 CD p
survivors NNS p
of IN p
myocardial JJ p
infarction NN p
before IN p
age NN p
50 CD p
and CC p
60 CD p
healthy JJ p
controls NNS p
. . p

They PRP N
were VBD N
randomly RB N
divided VBN N
into IN N
equal JJ N
groups NNS N
to TO N
receive VB N
antioxidants NNS i
or CC N
placebo NN i
for IN N
12 CD N
weeks NNS N
. . N

Twenty-eight JJ p
patients NNS p
and CC p
58 CD p
controls NNS p
completed VBD p
the DT p
intervention NN p
. . N

Micronucleus NNP o
levels NNS o
in IN o
peripheral JJ o
lymphocytes NNS o
and CC o
changes NNS o
seen VBN o
after IN o
intervention NN o
were VBD o
studied VBN o
in IN o
relation NN o
to TO o
the DT o
MTHFR NNP o
C677T NNP o
genotype NN o
, , o
basal JJ o
homocysteine NN o
and CC o
plasma JJ o
folate NN o
levels NNS o
. . o

Ferric NNP o
reducing VBG o
ability NN o
of IN o
plasma NN o
and CC o
concentration NN o
of IN o
malondialdehyde NNS o
were VBD o
measured VBN o
to TO o
assess VB o
the DT o
antioxidant JJ o
effect NN o
of IN o
supplementation NN o
. . o

There EX N
was VBD N
no DT N
association NN N
of IN N
micronuclei NN N
with IN N
folate NN N
, , N
homocysteine NN N
or CC N
malondialdehyde NN N
levels NNS N
before IN N
supplementation NN N
. . N

Micronucleus NNP o
frequencies NNS o
and CC o
plasma JJ o
folate NN o
levels NNS o
did VBD N
not RB N
vary JJ N
significantly RB N
with IN N
MTHFR NNP N
genotype NN N
. . N

Homocysteine NNP o
levels NNS o
in IN N
subjects NNS p
with IN p
the DT p
TT NNP p
variant NN p
genotype NN p
were VBD N
significantly RB N
higher JJR N
compared VBN N
with IN N
CT NNP N
or CC N
CC NNP N
( ( N
P NNP N
= NNP N
0.001 CD N
) ) N
, , N
especially RB N
in IN N
subjects NNS p
with IN p
low JJ p
folate NN p
( ( N
P NNP N
= NNP N
0.012 CD N
) ) N
. . N

In IN N
the DT N
placebo NN N
control NN N
group NN N
an DT N
increase NN N
in IN N
micronuclei NN o
( ( N
P NNP N
= NNP N
0.04 CD N
) ) N
was VBD N
detected VBN N
at IN N
the DT N
end NN N
of IN N
the DT N
intervention NN N
period NN N
. . N

This DT N
effect NN N
was VBD N
not RB N
seen VBN N
in IN N
the DT N
supplemented JJ N
group NN N
. . N

In IN N
antioxidant-supplemented JJ N
myocardial JJ p
infarction NN p
survivors NNS p
we PRP N
found VBD N
an DT N
increase NN N
in IN N
the DT N
ferric JJ o
reducing VBG o
ability NN o
of IN o
plasma NN o
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
and CC N
a DT N
decrease NN o
in IN o
malondialdehyde NN o
( ( N
P NNP N
= NNP N
0.001 CD N
) ) N
. . N

Micronucleus NNP o
frequency NN o
showed VBD N
a DT N
decrease NN N
, , N
strongest JJS N
in IN N
subjects NNS p
with IN p
normal JJ p
folate NN p
levels NNS p
( ( N
P NNP N
= NNP N
0.015 CD N
) ) N
. . N

In IN N
subjects NNS p
with IN p
low JJ p
folate NN p
levels NNS p
, , N
a DT N
high JJ N
correlation NN N
was VBD N
found VBN N
between IN N
micronuclei NN o
after IN N
supplementation NN N
and CC N
homocysteine NN N
, , N
both DT N
before IN N
( ( N
r NN N
= VBZ N
0.979 CD N
, , N
P NNP N
= NNP N
0.002 CD N
) ) N
and CC N
after IN N
supplementation NN N
( ( N
r JJ N
= NN N
0.922 CD N
, , N
P NNP N
= NNP N
0.009 CD N
) ) N
. . N

Thus RB N
, , N
folate JJ N
deficiency NN N
may MD N
amplify VB N
the DT N
effect NN N
of IN N
other JJ N
risk NN N
factors NNS N
such JJ N
as IN N
elevated JJ N
homocysteine NN N
levels NNS N
or CC N
variant JJ N
MTHFR NNP N
genotype NN N
, , N
as RB N
well RB N
as IN N
influencing VBG N
the DT N
ability NN N
of IN N
antioxidant JJ i
supplementation NN i
to TO N
protect VB N
against IN N
genetic JJ N
damage NN N
. . N

-DOCSTART- -21072224- O O

Trachoma NNP N
prevalence NN N
and CC N
associated VBN N
risk NN N
factors NNS N
in IN N
the DT p
gambia NN p
and CC p
Tanzania NNP p
: : p
baseline NN N
results NNS N
of IN N
a DT N
cluster NN N
randomised VBN N
controlled VBN N
trial NN N
. . N

BACKGROUND NNP N
Blinding NNP N
trachoma NN N
, , N
caused VBN N
by IN N
ocular JJ N
infection NN N
with IN N
Chlamydia NNP N
trachomatis NN N
, , N
is VBZ N
targeted VBN N
for IN N
global JJ N
elimination NN N
by IN N
2020 CD N
. . N

Knowledge NNP N
of IN N
risk NN N
factors NNS N
can MD N
help VB N
target VB N
control JJ N
interventions NNS N
. . N

METHODOLOGY/PRINCIPAL NNP N
FINDINGS NNP N
As IN N
part NN N
of IN N
a DT N
cluster NN N
randomised VBN N
controlled VBN N
trial NN N
, , N
we PRP N
assessed VBD o
the DT o
baseline NN o
prevalence NN o
of IN o
, , o
and CC o
risk NN o
factors NNS o
for IN o
, , N
active JJ N
trachoma NN o
and CC N
ocular JJ o
C. NNP o
trachomatis NN o
infection NN o
in IN N
randomly RB p
selected VBN p
children NNS p
aged VBN p
0-5 CD p
years NNS p
from IN p
48 CD p
Gambian JJ p
and CC p
36 CD p
Tanzanian JJ p
communities NNS p
. . p

Both DT i
children NNS i
's POS i
eyes NNS i
were VBD i
examined VBN i
according VBG N
to TO N
the DT N
World NNP o
Health NNP o
Organization NNP o
( ( o
WHO NNP o
) ) o
simplified VBD o
grading VBG o
system NN o
, , N
and CC N
an DT i
ocular JJ o
swab NN o
was VBD i
taken VBN i
from IN i
each DT i
child NN i
's POS i
right JJ i
eye NN i
and CC i
processed VBN i
by IN i
Amplicor NNP o
polymerase NN o
chain NN o
reaction NN o
to TO i
test VB i
for IN i
the DT i
presence NN i
of IN i
C. NNP i
trachomatis NN i
DNA NNP i
. . i

Prevalence NN N
of IN N
active JJ N
trachoma NN N
was VBD N
6.7 CD N
% NN N
( ( N
335/5033 CD N
) ) N
in IN N
The DT p
Gambia NNP p
and CC N
32.3 CD N
% NN N
( ( N
1008/3122 CD N
) ) N
in IN N
Tanzania NNP p
. . p

The DT N
countries NNS N
' POS N
corresponding VBG N
Amplicor NNP o
positive JJ o
prevalences NNS o
were VBD N
0.8 CD N
% NN N
and CC N
21.9 CD N
% NN N
. . N

After IN N
adjustment NN N
, , N
risk NN N
factors NNS N
for IN N
follicular JJ N
trachoma NN N
( ( N
TF NNP N
) ) N
in IN N
both DT N
countries NNS N
were VBD N
ocular JJ o
or CC o
nasal JJ o
discharge NN o
, , N
a DT N
low JJ o
level NN o
of IN o
household NN o
head NN o
education NN o
, , N
and CC N
being VBG N
aged VBN o
? . o
1 CD o
year NN o
. . o

Additional NNP N
risk NN N
factors NNS N
in IN N
Tanzania NNP p
were VBD o
flies NNS o
on IN o
the DT o
child NN o
's POS o
face NN o
, , o
being VBG o
Amplicor NNP o
positive JJ o
, , o
and CC o
crowding NN o
( ( o
the DT N
number NN N
of IN N
children NNS N
per IN N
household NN N
) ) N
. . N

The DT N
risk NN N
factors NNS N
for IN N
being VBG o
Amplicor NNP o
positive JJ o
in IN o
Tanzania NNP p
were VBD p
similar JJ N
to TO N
those DT N
for IN N
TF NNP N
, , N
with IN N
the DT N
exclusion NN N
of IN N
flies NNS N
and CC N
crowding VBG N
. . N

In IN N
The DT p
Gambia NNP p
, , p
only RB o
ocular JJ o
discharge NN o
was VBD o
associated VBN N
with IN N
being VBG o
Amplicor NNP o
positive JJ o
. . o

CONCLUSIONS/SIGNIFICANCE NNP N
These DT N
results NNS N
indicate VBP N
that IN N
although IN N
the DT N
prevalence NN N
of IN N
active JJ N
trachoma NN N
and CC o
Amplicor NNP o
positives NNS o
were VBD o
very RB N
different JJ N
between IN N
the DT N
two CD N
countries NNS N
, , N
the DT N
risk NN N
factors NNS N
for IN N
active JJ N
trachoma NN N
were VBD N
similar JJ N
but CC N
those DT N
for IN N
being VBG o
Amplicor NNP o
positive JJ o
were VBD o
different JJ N
. . N

The DT N
lack NN N
of IN N
an DT N
association NN N
between IN N
being VBG N
Amplicor NNP N
positive JJ N
and CC N
TF NNP N
in IN N
The DT p
Gambia NNP p
highlights VBZ p
the DT N
poor JJ N
correlation NN N
between IN N
the DT N
presence NN N
of IN N
trachoma JJ o
clinical JJ o
signs NNS o
and CC o
evidence NN o
of IN o
C. NNP o
trachomatis NN o
infection NN o
in IN o
this DT N
setting NN N
. . N

Only RB o
ocular JJ o
discharge NN o
was VBD o
associated VBN N
with IN N
evidence NN N
of IN N
C. NNP N
trachomatis NN N
DNA NN N
in IN N
The DT p
Gambia NNP p
, , p
suggesting VBG N
that IN N
at IN N
this DT N
low JJ N
endemicity NN N
, , N
this DT N
may MD N
be VB N
the DT N
most RBS N
important JJ N
risk NN N
factor NN N
. . N

TRIAL NNP N
REGISTRATION NNP N
ClinicalTrials.gov NNP N
NCT00792922 NNP N
. . N

-DOCSTART- -6151482- O O

Statistical JJ N
aspects NNS N
of IN N
early JJ N
termination NN N
in IN N
the DT N
beta-blocker JJ N
heart NN N
attack NN N
trial NN N
. . N

The DT N
Beta-Blocker NNP N
Heart NNP N
Attack NNP N
Trial NNP N
was VBD N
a DT N
randomized JJ N
double JJ N
blind NN N
controlled VBD N
trial NN N
comparing VBG N
propranolol NN i
with IN i
placebo NN i
in IN N
3837 CD p
patients NNS p
with IN p
a DT p
recent JJ p
myocardial JJ p
infarction NN p
. . p

The DT N
trial NN N
was VBD N
terminated VBN N
on IN N
recommendation NN N
of IN N
the DT N
Policy NNP N
and CC N
Data NNP N
Monitoring NNP N
Board NNP N
9 CD N
months NNS N
before IN N
the DT N
scheduled JJ N
closing NN N
date NN N
. . N

The DT N
propranolol NN i
group NN N
, , N
at IN N
the DT N
time NN N
of IN N
the DT N
decision NN N
, , N
had VBD N
a DT N
26 CD N
% NN N
lower JJR N
mortality NN o
( ( N
z JJ N
= NNP N
2.82 CD N
) ) N
. . N

Many JJ N
issues NNS N
were VBD N
considered VBN N
in IN N
this DT N
decision NN N
. . N

These DT N
included VBD N
the DT N
magnitude NN N
of IN N
the DT N
overall JJ N
results NNS N
; : N
consistency NN N
of IN N
results NNS N
across IN N
subgroups NNS N
, , N
clinical JJ N
centers NNS N
, , N
and CC N
cause NN N
of IN N
death NN N
; : N
and CC N
completeness NN N
of IN N
follow-up JJ N
. . N

Two CD N
basic JJ N
statistical JJ N
methods NNS N
were VBD N
used VBN N
in IN N
declaring VBG N
the DT N
overall JJ o
mortality NN o
results NNS N
significant JJ N
. . N

The DT N
first JJ N
method NN N
evaluated VBD N
the DT N
current JJ N
survival NN o
data NNS o
taking VBG N
into IN N
account NN N
the DT N
issue NN N
of IN N
repeated VBN N
significance NN N
testing VBG N
. . N

The DT N
second JJ N
method NN N
evaluated VBD N
whether IN N
the DT N
observed JJ N
trend NN N
was VBD N
so RB N
impressive JJ N
that IN N
the DT N
conclusion NN N
was VBD N
unlikely JJ N
to TO N
change VB N
even RB N
if IN N
the DT N
trial NN N
should MD N
continue VB N
to TO N
the DT N
scheduled JJ N
end NN N
. . N

These DT N
two CD N
methods NNS N
, , N
as RB N
well RB N
as IN N
other JJ N
considerations NNS N
led VBN N
to TO N
the DT N
recommendation NN N
to TO N
discontinue VB N
the DT N
trial NN N
. . N

-DOCSTART- -22015462- O O

The DT N
competition NN N
between IN N
enamel NN N
and CC N
dentin NN N
adhesion NN N
within IN N
a DT N
cavity NN N
: : N
an DT N
in IN p
vitro JJ p
evaluation NN p
of IN p
class NN p
V NNP p
restorations NNS p
. . p

To TO N
gain VB N
more JJR N
insight NN N
into IN N
the DT N
consequences NNS N
of IN N
curing VBG N
contraction NN N
within IN N
the DT N
tooth JJ N
cavity NN N
, , N
we PRP N
assessed VBD N
the DT N
margin NN N
behavior NN N
of IN N
12 CD p
contemporary JJ p
restorative JJ p
systems NNS p
in IN p
class NN p
V NNP p
restorations NNS p
with IN p
margins NNS p
located VBN p
on IN p
enamel NN p
and CC p
dentin NN p
after IN p
mechanical JJ p
loading NN p
and CC p
water NN p
storage NN p
. . p

Mixed JJ p
class NN p
V NNP p
cavities NNS p
were VBD p
prepared VBN p
on IN p
extracted JJ p
human JJ p
molars NNS p
and CC p
restored VBD p
using VBG p
five CD i
etch NN i
and CC i
rinse NN i
and CC p
seven CD i
self-etch JJ i
adhesive JJ i
systems NNS i
with IN p
their PRP$ p
corresponding NN p
composites NNS p
. . p

Marginal JJ N
adaptation NN N
was VBD N
evaluated VBN N
by IN N
using VBG N
a DT N
computer-assisted JJ N
quantitative JJ N
marginal JJ N
analysis NN N
in IN N
a DT N
scanning NN i
electron NN i
microscope NN i
( ( N
SEM NNP N
) ) N
on IN N
epoxy JJ N
replicas NN N
before IN N
, , N
after IN N
thermal JJ N
and CC N
mechanical JJ N
stressing NN N
and CC N
after IN N
1 CD N
year NN N
of IN N
water NN N
storage NN N
. . N

The DT N
interactions NNS N
of IN N
testing VBG N
conditions NNS N
, , N
adhesive-composite JJ N
combination NN N
and CC N
tooth JJ N
substrate NN N
with IN N
marginal JJ N
adaptation NN N
were VBD N
evaluated VBN N
by IN N
two-way JJ N
ANOVA NNP N
. . N

Fatigue NNP o
, , o
stress NN o
and CC o
storage NN o
conditions NNS o
had VBD N
significant JJ N
effects NNS N
on IN N
the DT N
marginal JJ o
adaptation NN o
. . o

Only RB N
two CD N
groups NNS N
( ( N
Optibond NNP N
FL NNP N
and CC N
G NNP N
Bond NNP N
) ) N
presented VBD N
equal JJ N
percentages NNS N
of IN N
marginal JJ o
adaptation NN o
on IN o
enamel NN o
and CC o
dentin NN o
; : o
in IN N
the DT N
other JJ N
groups NNS N
, , N
the DT N
rate NN o
of IN o
degradation NN o
was VBD N
product NN N
dependent NN N
. . N

All DT N
materials NNS N
tested VBN N
showed VBD N
a DT N
distinct JJ N
behavior NN N
on IN N
enamel NN o
and CC o
dentin NN o
. . o

In IN N
addition NN N
to TO N
mechanical JJ N
resistance NN N
and CC N
long-term JJ N
stability NN N
, , N
differences NNS N
within IN N
materials NNS N
also RB N
exist VBP N
in IN N
their PRP$ N
ability NN N
to TO N
simultaneously RB o
bond NN o
to TO o
enamel VB o
and CC o
dentin VB o
. . o

-DOCSTART- -9777717- O O

Evaluation NN N
of IN N
the DT N
safety NN o
, , o
immunogenicity NN o
, , o
and CC o
pharmacokinetic JJ o
profile NN o
of IN N
a DT N
new JJ i
, , i
highly RB i
purified VBN i
, , i
heat-treated JJ i
equine NN i
rabies NNS i
immunoglobulin VBP i
, , N
administered VBD N
either CC N
alone RB N
or CC N
in IN N
association NN N
with IN N
a DT N
purified JJ N
, , N
Vero-cell NNP i
rabies VBZ i
vaccine NN i
. . i

A DT N
clinical JJ N
evaluation NN N
of IN N
a DT N
new JJ i
, , i
purified JJ i
, , i
heat-treated JJ i
equine NN i
rabies NNS i
immunoglobulin VBP i
( ( i
PHT-Erig NNP i
) ) i
, , i
F NNP i
( ( i
ab IN i
' POS i
) ) i
2 CD i
preparation NN i
, , N
was VBD N
carried VBN N
out RP N
in IN N
Thailand NNP p
and CC N
in IN N
the DT N
Philippines-two JJ p
countries NNS N
where WRB N
rabies NNS N
is VBZ N
endemic JJ N
. . N

An DT N
initial JJ N
prospective NN N
, , N
randomised VBN N
, , N
controlled VBN N
trial NN N
( ( N
Study NNP N
1 CD N
) ) N
, , N
compared VBN N
the DT N
safety NN o
and CC o
pharmacokinetics NNS o
( ( o
serum JJ o
concentrations NNS o
of IN o
rabies NNS o
antibodies NNS o
) ) o
after IN N
administration NN N
either DT N
of IN N
PHT-Erig NNP i
or CC N
of IN N
a DT i
commercially-available JJ i
, , i
equine JJ i
rabies NNS i
immune VBP i
globulin NN i
( ( i
Erig NNP i
PMC NNP i
) ) i
. . i

A DT N
second JJ N
trial NN N
( ( N
Study NNP N
2 CD N
) ) N
simulated VBD N
post-exposure JJ N
rabies NNS N
prophylaxis VBN N
by IN N
using VBG N
a DT N
reference NN N
cell NN N
culture NN N
vaccine NN N
, , N
the DT i
purified JJ i
Vero-cell NNP i
rabies NNS i
vaccine NN i
( ( i
PVRV NNP i
) ) i
, , N
administered VBN N
in IN N
association NN N
with IN N
either DT i
Erig NNP i
PMC NNP i
or CC i
PHT-Erig NNP i
. . i

In IN N
Study NNP N
1 CD N
, , N
27 CD p
healthy JJ p
, , p
Thai NNP p
adults NNS p
received VBD p
a DT p
40 CD p
IU NNP p
kg NN p
( ( p
-1 NNP p
) ) p
dose NN p
of IN p
either DT p
Erig NNP i
PMC NNP i
( ( p
n JJ p
= NNP p
12 CD p
) ) p
or CC p
PHT-Erig NNP i
( ( p
n JJ p
= NNP p
15 CD p
) ) p
via IN p
the DT p
intramuscular NN p
( ( p
i.m JJ p
. . p

) ) p
route NN p
; : p
half NN N
of IN N
the DT N
dose NN N
was VBD N
injected VBN N
into IN N
the DT N
deltoid JJ N
area NN N
and CC N
the DT N
other JJ N
half NN N
into IN N
the DT N
buttocks NNS N
. . N

Serum NNP N
for IN N
rabies NNS N
antibody JJ N
determination NN N
and CC N
F NNP N
( ( N
ab IN N
' POS N
) ) N
2 CD N
concentration NN N
was VBD N
collected VBN N
at IN N
hours NNS N
( ( N
H NNP N
) ) N
0 CD N
, , N
6 CD N
and CC N
12 CD N
, , N
and CC N
on IN N
day NN N
( ( N
D NNP N
) ) N
2 CD N
, , N
3 CD N
, , N
4 CD N
, , N
6 CD N
, , N
8 CD N
, , N
10 CD N
, , N
12 CD N
and CC N
15 CD N
. . N

Both DT N
products NNS N
were VBD N
safe JJ N
, , N
with IN N
no DT N
serious JJ N
adverse JJ N
events NNS N
, , N
and CC N
in IN N
particular JJ N
, , N
no DT N
anaphylactic JJ N
reactions NNS N
or CC N
serum NN N
sickness NN N
was VBD N
reported VBN N
. . N

A DT N
statistical JJ N
comparison NN N
of IN N
the DT N
pharmacokinetic JJ o
parameters NNS o
did VBD N
not RB N
demonstrate VB N
bioequivalence NN N
of IN N
the DT N
two CD N
products NNS N
. . N

Nonetheless RB N
, , N
the DT N
relative JJ o
bioavailability NN o
of IN N
93 CD N
% NN N
and CC N
the DT N
similar JJ N
absorption NN o
rates NNS o
suggest VBP N
the DT N
pharmacokinetic JJ N
profiles NNS N
of IN N
Erig NNP N
and CC N
PHT-Erig NNP N
are VBP N
similar JJ N
. . N

The DT N
antibody NN o
level NN o
in IN N
either DT N
group NN N
were VBD N
low JJ N
throughout IN N
the DT N
15-day JJ N
study NN N
period NN N
. . N

The DT N
geometric JJ o
mean NN o
titer NN o
( ( o
GMT NNP o
) ) o
values NNS o
ranged VBD N
from IN N
group NN N
0.027-0.117 CD N
IU NNP N
ml NN N
( ( N
-1 NN N
) ) N
in IN N
the DT N
Erig NNP N
group NN N
and CC N
from IN N
0.029 CD N
to TO N
0.072 CD N
IU NNP N
ml NN N
( ( N
-1 NN N
) ) N
in IN N
the DT N
PHT-Erig NNP N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
the DT N
evolution NN o
of IN o
GMT NNP o
values NNS o
for IN N
the DT N
two CD N
groups NNS N
. . N

In IN N
Study NNP N
2 CD N
, , N
71 CD p
healthy JJ p
volunteers NNS p
received VBD N
40 CD N
IU NNP N
kg NN N
( ( N
-1 JJ N
) ) N
via IN N
the DT N
intramuscular JJ N
route NN N
of IN N
either DT N
Erig NNP N
PMC NNP N
( ( N
n JJ N
= NNP N
36 CD N
) ) N
or CC N
PHT-Erig NNP N
( ( N
n JJ N
= NNP N
35 CD N
) ) N
on IN N
D0 NNP N
, , N
in IN N
association NN N
with IN N
five CD N
doses NNS N
of IN N
PVRV NNP N
on IN N
D0 NNP N
, , N
D3 NNP N
, , N
D7 NNP N
, , N
D14 NNP N
and CC N
D28 NNP N
. . N

The DT N
safety NN o
evaluation NN o
was VBD N
performed VBN N
during IN N
the DT N
28-day JJ N
follow-up NN N
and CC N
serum NN o
samples NNS o
for IN o
anti-rabies NNS o
antibody JJ o
titration NN o
were VBD N
collected VBN N
on IN N
D0 NNP N
( ( N
before IN N
injection NN N
) ) N
D3 NNP N
, , N
D7 NNP N
, , N
D14 NNP N
and CC N
D28 NNP N
. . N

No NNP N
serious JJ o
reactions NNS o
were VBD N
reported VBN N
in IN N
either DT N
group NN N
. . N

In IN N
particular JJ N
, , N
no DT N
immediate JJ o
( ( o
anaphylactic JJ o
type NN o
) ) o
or CC o
delayed VBN o
( ( o
serum JJ o
sickness NN o
) ) o
allergic NN o
reactions NNS o
were VBD N
observed VBN N
. . N

Over IN N
the DT N
28-day JJ N
follow-up JJ N
period NN N
, , N
GMT NNP o
profiles NNS o
of IN N
the DT N
two CD N
groups NNS N
were VBD N
statistically RB N
equivalent JJ N
. . N

On IN N
D14 NNP N
, , N
100 CD N
% NN N
of IN N
the DT N
subjects NNS N
had VBD N
protective JJ o
antibody NN o
titers NNS o
( ( N
anti-rabies JJ N
antibodies NNS N
> VBP N
or CC N
= VBP N
0.5 CD N
IU NNP N
ml NN N
( ( N
-1 NNP N
) ) N
, , N
which WDT N
is VBZ N
the DT N
WHO-recommended JJ N
level NN N
of IN N
seroconversion NN N
) ) N
, , N
and CC N
Erig NNP N
PMC NNP N
and CC N
PHT-Erig NNP N
were VBD N
indistinguishable JJ N
according VBG N
to TO N
the DT N
clinical JJ N
definition NN N
chosen VBN N
. . N

On IN N
D28 NNP N
, , N
the DT N
GMT NNP o
values NNS o
were VBD N
33.2 CD N
IU NNP N
ml NN N
( ( N
-1 NN N
) ) N
( ( N
95 CD N
% NN N
CI NNP N
, , N
23.8-46.1 JJ N
IU NNP N
ml NN N
( ( N
-1 NNP N
) ) N
) ) N
in IN N
the DT N
Erig NNP N
PMC/PVRV NNP N
group NN N
and CC N
31.4 CD N
IU NNP N
ml NN N
( ( N
-1 NN N
) ) N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
CI NNP N
, , N
23.4-42.2 JJ N
IU NNP N
ml NN N
( ( N
-1 NNP N
) ) N
) ) N
in IN N
the DT N
PHT-Erig/PVRV NNP N
group NN N
, , N
showing VBG N
evidence NN N
of IN N
adequate JJ N
vaccine-induced JJ N
antibody NN o
responses NNS o
in IN N
both DT N
groups NNS N
. . N

The DT N
increased JJ N
purity NN N
, , N
the DT N
heat-treatment JJ N
step NN N
introduced VBN N
in IN N
the DT N
manufacturing NN N
process NN N
of IN N
PHT-Erig NNP N
, , N
and CC N
the DT N
good JJ N
clinical JJ N
results NNS N
substantiate VBP N
the DT N
use NN N
of IN N
this DT N
new JJ N
generation NN N
, , N
purified JJ N
equine NN N
F NNP N
( ( N
ab IN N
' POS N
) ) N
2 CD N
preparation NN N
in IN N
the DT N
post-exposure JJ N
prophylaxis NN N
of IN N
rabies NNS N
. . N

-DOCSTART- -20973712- O O

Line-item JJ N
analysis NN N
of IN N
the DT N
Aberrant NNP N
Behavior NNP N
Checklist NNP N
: : N
results NNS N
from IN N
two CD p
studies NNS p
of IN p
aripiprazole NN i
in IN p
the DT p
treatment NN p
of IN p
irritability NN p
associated VBN p
with IN p
autistic JJ p
disorder NN p
. . p

OBJECTIVES CC N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
efficacy NN N
of IN N
aripiprazole NN i
in IN N
the DT N
treatment NN N
of IN N
discrete JJ N
symptoms NNS N
of IN N
irritability NN N
associated VBN N
with IN N
autistic JJ N
disorder NN N
, , N
as RB N
well RB N
as IN N
other JJ N
symptoms NNS N
captured VBN N
on IN N
the DT N
Aberrant NNP N
Behavior NNP N
Checklist NNP N
( ( N
ABC NNP N
) ) N
. . N

METHODS NNP N
This DT N
was VBD N
a DT N
post NN N
hoc NN N
analysis NN N
of IN N
data NNS N
from IN N
two CD p
8-week JJ p
, , p
randomized VBN p
, , p
double-blind JJ p
, , p
multicenter JJ p
trials NNS p
to TO N
evaluate VB N
the DT N
efficacy NN N
of IN N
aripiprazole NN i
dosed VBN i
flexibly RB i
( ( N
2-15 JJ N
mg/day NN N
, , N
n=47 NN N
) ) N
or CC N
fixed VBN N
( ( N
5 CD N
, , N
10 CD N
, , N
or CC N
15 CD N
mg/day NN N
, , N
n JJ N
= NNP N
166 CD N
) ) N
versus NN N
placebo NN i
( ( N
flexibly RB N
dosed VBN N
, , N
n JJ N
= VBP N
51 CD N
; : N
fixed VBN N
dose NN N
, , N
n JJ N
= NNP N
52 CD N
) ) N
. . N

The DT N
effects NNS N
of IN N
treatment NN N
on IN N
the DT N
58 CD N
ABC NNP N
items NNS N
were VBD N
evaluated VBN N
. . N

RESULTS NNP N
Statistically NNP N
significantly RB N
greater JJR N
improvement NN N
was VBD N
seen VBN N
with IN N
aripiprazole JJ i
versus NN i
placebo NN i
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
for IN N
all DT N
arms NNS N
in IN N
both DT N
trials NNS N
on IN N
the DT N
ABC-Irritability NNP o
total JJ o
subscale NN o
score NN o
and CC o
on IN o
the DT o
following JJ o
individual JJ o
ABC-Irritability NNP o
items NNS o
: : o
Mood NNP o
changes NNS o
quickly RB o
, , o
cries/screams NNS o
inappropriately RB o
, , o
and CC o
stamps JJ o
feet/bangs NNS o
objects NNS o
. . o

Several JJ N
additional JJ N
items NNS N
measuring VBG N
tantrum-like JJ o
behaviors NNS o
improved VBN N
in IN N
the DT N
flexibly RB N
dosed VBN N
trial NN N
and CC N
at IN N
least JJS N
one CD N
arm NN N
of IN N
the DT N
fixed-dose JJ N
trial NN N
( ( N
p JJ N
< NNP N
0.05 CD N
) ) N
. . N

Measures NNS o
of IN o
self-injurious JJ o
behavior NN o
, , N
which WDT N
had VBD N
low JJ N
baseline NN N
values NNS N
, , N
demonstrated VBD N
numerical JJ N
, , N
but CC N
not RB N
statistically RB N
significant JJ N
, , N
improvement NN N
in IN N
both DT N
trials NNS N
. . N

Statistically RB N
significantly RB N
greater JJR N
improvement NN N
in IN N
ABC NNP o
Stereotypic NNP o
Behavior NNP o
and CC o
Hyperactivity NNP o
total JJ o
subscale NN o
scores NNS o
was VBD N
also RB N
consistent JJ N
across IN N
all DT N
arms NNS N
in IN N
both DT N
trials NNS N
. . N

In IN N
particular JJ N
, , N
there EX N
was VBD N
a DT N
cluster NN N
of IN N
items NNS N
related VBN N
to TO N
hyperkinesis VB o
that WDT N
were VBD N
consistently RB N
sensitive JJ N
to TO N
treatment NN N
. . N

CONCLUSIONS NNP N
Aripiprazole NNP i
is VBZ N
efficacious JJ N
in IN N
the DT N
treatment NN N
of IN N
irritability NN N
in IN N
children NNS p
and CC p
adolescents NNS p
with IN p
autistic JJ p
disorder NN p
, , N
particularly RB N
with IN N
respect NN N
to TO N
symptoms NNS N
associated VBN N
with IN N
tantrum JJ N
behavior NN N
. . N

-DOCSTART- -1996926- O O

Repeatability NN N
and CC N
protocol JJ N
comparability NN N
of IN N
presyncopal JJ i
symptom NN p
limited VBD i
lower JJR i
body NN i
negative JJ i
pressure NN i
exposures NNS p
. . p

Data NNS N
on IN N
repeatability NN N
and CC N
comparability NN N
of IN N
different JJ N
presyncopal JJ i
symptom-limited JJ i
lower JJR i
body NN i
negative JJ i
pressure NN i
( ( i
PSL-LBNP NNP i
) ) i
exposure NN i
protocols NNS i
, , N
while IN N
scarce NN N
, , N
are VBP N
critical JJ N
to TO N
the DT N
interpretation NN N
of IN N
studies NNS N
using VBG N
PSL-LBNP NNP i
methods NNS N
. . N

To TO N
investigate VB N
if IN N
PSL-LBNP JJ N
tolerance NN N
, , N
heart NN N
rate NN N
, , N
and CC N
blood NN N
pressure NN N
were VBD N
repeatable JJ N
, , N
11 CD p
subjects NNS p
were VBD p
exposed VBN p
to TO p
4 CD p
PSL-LBNP JJ i
tests NNS i
; : i
each DT N
test NN N
occurring VBG N
at IN N
the DT N
same JJ N
time NN N
of IN N
day NN N
, , N
separated VBN N
by IN N
at IN N
least JJS N
72 CD N
h NN N
, , N
and CC N
using VBG N
the DT N
same JJ N
protocol NN N
. . N

No DT N
significant JJ N
differences NNS N
were VBD N
found VBN N
in IN N
either CC N
the DT N
heart NN o
rate NN o
or CC o
blood NN o
pressure NN o
responses VBZ o
to TO N
the DT N
PSL-LBNP NNP i
or CC N
the DT N
tolerance NN o
indices NNS o
( ( N
cumulative JJ N
stress NN N
index NN N
; : N
maximum JJ N
negative JJ N
pressure NN N
tolerated VBN N
; : N
and CC N
duration NN N
of IN N
negative JJ N
pressure NN N
exposure NN N
) ) N
. . N

To TO N
study VB N
the DT N
comparability NN N
of IN N
different JJ N
PSL-LBNP NNP i
protocols NNS N
, , N
nine CD p
subjects NNS p
were VBD N
exposed VBN N
randomly RB N
to TO N
five CD N
PSL-LBNP JJ i
tests NNS i
using VBG N
protocols NNS N
that WDT N
varied VBD N
in IN N
stage NN N
duration NN N
but CC N
not RB N
pressure NN N
profile NN N
. . N

The DT N
protocols NNS N
had VBD N
1- CD N
, , N
3- CD N
, , N
5- JJ N
, , N
7- JJ N
, , N
or CC N
9-min JJ N
stage NN N
durations NNS N
. . N

These DT N
PSL-LBNP JJ i
exposures NNS N
were VBD N
conducted VBN N
at IN N
the DT N
same JJ N
time NN N
of IN N
day NN N
and CC N
separated VBN N
by IN N
at IN N
least JJS N
72 CD N
h. NN N
While IN N
no DT N
differences NNS N
were VBD N
noted VBN N
in IN N
either CC N
the DT N
response NN N
pattern NN N
or CC N
magnitude NN N
of IN N
heart NN o
rate NN o
or CC o
blood NN o
pressure NN o
to TO N
the DT N
differing NN N
protocols NNS N
, , N
the DT N
cumulative JJ o
stress NN o
index NN o
and CC o
the DT o
duration NN o
of IN o
negative JJ o
pressure NN o
exposure NN o
varied VBD N
proportionally RB N
with IN N
the DT N
length NN N
of IN N
the DT N
stage NN N
durations NNS N
. . N

With IN N
the DT N
exception NN N
of IN N
the DT N
1-min JJ N
protocol NN N
, , N
the DT N
maximum JJ N
negative JJ N
pressure NN N
tolerated VBD N
did VBD N
not RB N
vary JJ N
regardless NN N
of IN N
the DT N
protocol NN N
used VBN N
. . N

( ( N
ABSTRACT NNP N
TRUNCATED NNP N
AT NNP N
250 CD N
WORDS NNP N
) ) N
-DOCSTART- -17009630- O O

Studies NNS N
on IN N
leptin NN o
and CC o
leptin NN o
receptor NN o
gene NN o
expression NN o
in IN N
myometrium NN p
and CC p
uterine JJ p
myomas NN p
of IN p
gnRH JJ i
analogue-treated JJ i
women NNS p
. . p

AIM NNP N
To TO N
test VB N
if IN N
treatment NN N
with IN N
GnRH NNP i
analogue NN i
, , N
which WDT N
leads VBZ N
to TO N
a DT N
significant JJ N
reduction NN N
in IN N
myoma NN o
volume NN o
, , o
changes NNS o
expression NN o
of IN o
leptin NN o
genes NNS o
and CC o
gene NN o
coding VBG o
leptin JJ o
receptor NN o
isoforms NNS o
in IN N
uterine JJ N
myomas NN N
and CC N
in IN N
the DT N
surrounding NN N
unaltered JJ N
myometrium NN N
. . N

METHODS NNP N
Using VBG N
RT-PCR NNP N
, , N
expression NN N
of IN N
leptin NN N
genes NNS N
and CC N
leptin NN N
receptor NN N
genes NNS N
was VBD N
studied VBN N
in IN N
myomas NN N
and CC N
in IN N
the DT N
surrounding VBG N
myometrium NN N
in IN N
women NNS p
with IN p
uterine JJ p
myomas NN p
, , p
untreated VBD p
or CC p
treated VBN p
with IN p
GnRH NNP i
analogue NN i
. . i

In IN N
the DT N
randomly RB N
selected VBN N
cases NNS N
presence NN N
of IN N
leptin NN N
protein NN N
and CC N
of IN N
leptin JJ N
receptor NN N
proteins NNS N
was VBD N
examined VBN N
also RB N
by IN N
Western JJ N
blotting NN N
. . N

RESULTS NNP N
Expression NNP o
of IN o
leptin NN o
genes NNS o
was VBD N
demonstrated VBN N
both DT N
in IN N
myomas NN N
and CC N
in IN N
the DT N
surrounding VBG N
myometrium NN N
, , N
and CC N
a DT N
similar JJ N
pattern NN N
of IN N
expression NN N
was VBD N
found VBN N
for IN N
leptin JJ N
receptor NN N
isoforms NNS N
. . N

The DT N
results NNS N
of IN N
RT-PCR NNP N
were VBD N
confirmed VBN N
by IN N
Western JJ N
blotting NN N
, , N
which WDT N
documented VBD N
the DT N
identical JJ N
distribution NN N
of IN N
leptin NN o
proteins NNS o
and CC o
leptin JJ o
receptor NN o
proteins NNS o
in IN N
studied JJ N
tissues NNS N
. . N

Treatment NN N
with IN N
GnRH NNP i
analogue NN i
had VBD N
no DT N
effect NN o
on IN N
the DT N
expression NN o
pattern NN o
of IN N
studied VBN N
genes NNS N
. . N

CONCLUSION NNP N
The DT N
results NNS N
of IN N
the DT N
present JJ N
study NN N
on IN N
the DT N
administration NN N
of IN N
GnRH NNP i
analogue NN i
to TO N
females NNS p
with IN p
myomas NN p
suggest VBP N
that IN N
no DT N
direct JJ N
or CC N
immediate JJ N
inter-relationship JJ N
exists NNS N
between IN N
expression NN N
of IN N
leptin NN o
genes NNS o
in IN N
uterine JJ N
myomas NN N
on IN N
one CD N
hand NN N
and CC N
estrogen NN N
, , N
progesterone NN N
and CC N
leptin NN N
levels NNS N
in IN N
the DT N
blood NN N
on IN N
the DT N
other JJ N
. . N

Expression NN N
seems VBZ N
to TO N
be VB N
of IN N
a DT N
more RBR N
durable JJ N
nature NN N
but CC N
factors NNS N
that WDT N
induce VBP N
such JJ N
expression NN N
remain VBP N
unknown JJ N
. . N

-DOCSTART- -12585821- O O

The DT N
development NN N
and CC N
evaluation NN N
of IN N
a DT N
computer-based JJ i
program NN i
to TO N
test VB N
and CC N
to TO N
teach VB N
the DT N
recognition NN N
of IN N
facial JJ o
affect NN o
. . o

Autism NNP N
is VBZ N
a DT N
chronic JJ N
pervasive JJ N
neurodevelopmental JJ N
disorder NN N
characterized VBN N
by IN N
the DT N
early JJ N
onset NN N
of IN N
social JJ N
and CC N
communicative JJ N
impairments NNS N
as RB N
well RB N
as IN N
restricted VBN N
, , N
ritualized VBN N
, , N
stereotypic JJ N
behavior NN N
. . N

The DT N
endophenotype NN N
of IN N
autism NN N
includes VBZ N
neuropsychological JJ N
deficits NNS N
, , N
for IN N
instance NN N
a DT N
lack NN N
of IN N
Theory NNP N
of IN N
Mind NNP N
and CC N
problems NNS N
recognizing VBG N
facial JJ N
affect NN N
. . N

In IN N
this DT N
study NN N
, , N
we PRP N
report VBP N
the DT N
development NN N
and CC N
evaluation NN N
of IN N
a DT N
computer-based JJ i
program NN i
to TO N
teach VB N
and CC N
test VB N
the DT N
ability NN N
to TO N
identify VB N
basic JJ o
facially RB o
expressed VBN o
emotions NNS o
. . o

10 CD p
adolescent NN p
or CC p
adult NN p
subjects NNS p
with IN p
high-functioning JJ p
autism NN p
or CC p
Asperger-syndrome NNP p
were VBD p
included VBN p
in IN p
the DT p
investigation NN p
. . p

A DT N
priori FW N
the DT N
facial JJ N
affect NN N
recognition NN N
test NN N
had VBD N
shown VBN N
good JJ N
psychometric NN N
properties NNS N
in IN N
a DT N
normative JJ N
sample NN N
( ( N
internal JJ N
consistency NN N
: : N
rtt=.91-.95 NN N
; : N
retest JJS N
reliability NN N
: : N
rtt=.89-.92 NN N
) ) N
. . N

In IN N
a DT N
prepost NN N
design NN N
, , N
one CD N
half NN N
of IN N
the DT N
sample NN N
was VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
computer NN i
treatment NN i
while IN N
the DT N
other JJ N
half NN N
of IN N
the DT N
sample NN N
served VBD N
as IN N
control NN N
group NN N
. . N

The DT N
training NN N
was VBD N
conducted VBN N
for IN N
five CD N
weeks NNS N
, , N
consisting VBG N
of IN N
two CD N
hours NNS N
training VBG N
a DT N
week NN N
. . N

The DT N
trained JJ N
individuals NNS N
improved VBN N
significantly RB N
on IN N
the DT N
affect JJ o
recognition NN o
task NN o
, , N
but CC N
not RB N
on IN N
any DT N
other JJ N
measure NN N
. . N

Results VB N
support NN N
the DT N
usefulness NN N
of IN N
the DT N
program NN N
to TO N
teach VB o
the DT o
detection NN o
of IN o
facial JJ o
affect NN o
. . o

However RB N
, , N
the DT N
improvement NN N
found VBD N
is VBZ N
limited VBN N
to TO N
a DT N
circumscribed JJ N
area NN N
of IN N
social-communicative JJ N
function NN N
and CC N
generalization NN N
is VBZ N
not RB N
ensured VBN N
. . N

-DOCSTART- -11752031- O O

Controlled VBN N
prospective JJ N
trial NN N
of IN N
prednisolone NN i
and CC i
cytotoxics NNS i
in IN N
progressive JJ p
IgA NNP p
nephropathy NN p
. . p

In IN N
a DT N
single-center JJ N
, , N
multiple-referral JJ N
source NN N
study NN N
, , N
38 CD p
patients NNS p
with IN p
progressive JJ p
IgA NNP p
nephropathy NN p
and CC p
controlled VBN p
hypertension NN p
were VBD N
randomized VBN N
to TO N
treatment NN N
with IN N
prednisolone NN i
and CC i
cytotoxic NN i
agents NNS i
, , N
to TO N
therapy VB N
with IN N
low-dose JJ i
cyclophosphamide NN i
then RB i
azathioprine VB i
, , i
and CC i
to TO i
control VB i
groups NNS i
. . i

The DT N
follow-up JJ N
period NN N
lasted VBD N
2 CD N
to TO N
6 CD N
yr. JJ N
Renal NNP N
survival NN N
, , N
as IN N
assessed VBN N
by IN N
Kaplan-Meier NNP N
analysis NN N
annually RB N
to TO N
5 CD N
yr NN N
, , N
showed VBD N
significant JJ N
preservation NN N
of IN N
function NN N
from IN N
3 CD N
yr NN N
in IN N
the DT N
treatment NN N
group NN N
and CC N
82 CD N
, , N
82 CD N
, , N
72 CD N
, , N
and CC N
72 CD N
% NN N
for IN N
2 CD N
, , N
3 CD N
, , N
4 CD N
, , N
and CC N
5 CD N
yr NN N
, , N
respectively RB N
, , N
compared VBN N
with IN N
68 CD N
, , N
47 CD N
, , N
26 CD N
, , N
and CC N
6 CD N
% NN N
in IN N
controls NNS N
. . N

Rate NNP N
of IN N
loss NN o
of IN o
renal JJ o
function NN o
, , N
evaluated VBN N
objectively RB N
by IN N
least-squares JJ o
analyses NNS o
of IN o
reciprocal JJ o
serum NN o
creatinine NN o
, , N
was VBD N
reduced-and NN N
in IN N
one-third NN N
of IN N
the DT N
patients NNS N
, , N
arrested-during JJ N
immunosuppressive JJ N
treatment NN N
. . N

Proteinuria NNP o
, , p
present NN p
in IN p
all DT p
patients NNS p
at IN p
the DT p
time NN p
of IN p
entry NN p
into IN p
the DT p
trial NN p
, , N
was VBD N
reduced VBN N
by IN N
treatment NN N
from IN N
12 CD N
mo NN N
, , N
compared VBN N
with IN N
pretreatment NN o
levels NNS o
or CC o
controls NNS o
; : o
erythrocyturia NN o
was VBD N
reduced VBN N
from IN N
6 CD N
mo NN N
. . N

Histologic NNP o
activity NN o
and CC o
chronicity NN o
indexes NNS o
were VBD N
determined VBN N
in IN N
renal JJ N
biopsies NNS N
performed VBN N
at IN N
trial NN N
entry NN N
. . N

Multivariate NNP o
analysis NN o
demonstrated VBD N
that IN N
mesangial JJ o
cell NN o
proliferation NN o
and CC o
matrix NN o
scores NNS o
were VBD N
highest JJS N
in IN N
those DT N
patients NNS N
with IN N
more RBR N
rapidly RB N
progressive JJ N
disease NN N
. . N

No DT N
morphologic JJ o
variable NN o
or CC o
residual JJ o
renal JJ o
function NN o
predicted VBD N
response NN N
to TO N
immunosuppressive JJ N
therapy NN N
at IN N
entry NN N
. . N

Mean NNP o
arterial JJ o
pressures NNS o
did VBD N
not RB N
differ VB N
significantly RB N
between IN N
treatment NN N
and CC N
control NN N
groups NNS N
. . N

There EX N
was VBD N
thus RB N
no DT N
explanation NN N
other JJ N
than IN N
treatment NN N
for IN N
the DT N
improved JJ N
outcome NN N
in IN N
patients NNS N
who WP N
received VBD N
immunosuppressive JJ N
therapy NN N
. . N

Morbidity NNP o
attributable JJ N
to TO N
treatment NN N
or CC N
to TO N
renal JJ o
failure NN o
occurred VBD N
in IN N
both DT N
groups NNS N
; : N
an DT N
audit NN N
showed VBD N
that IN N
benefits NNS o
of IN o
therapy NN o
outweighed VBN N
expected VBD N
or CC N
minor JJ N
side NN N
effects NNS N
of IN N
drugs NNS N
in IN N
this DT N
population NN N
at IN N
risk NN N
of IN N
end-stage JJ N
renal JJ N
failure NN N
. . N

Patients NNS p
selected VBN p
for IN p
moderately RB p
progressive JJ o
IgA NNP o
nephropathy JJ o
benefit NN N
from IN N
treatment NN N
with IN N
prednisolone NN i
and CC N
cytotoxic NN i
agents NNS i
; : i
results NNS N
are VBP N
consistent JJ N
with IN N
modulation NN o
of IN o
systemic JJ o
immune JJ o
response NN o
or CC o
nephritic JJ o
injury NN o
, , N
thus RB N
explaining VBG N
improved VBN N
outcome NN N
, , N
and CC N
indicate VBP N
that IN N
this DT N
therapy NN N
has VBZ N
an DT N
acceptably RB N
low JJ N
risk NN N
of IN N
side NN o
effects NNS o
. . o

-DOCSTART- -19535468- O O

Emotional NNP o
, , o
motivational JJ o
and CC o
interpersonal JJ o
responsiveness NN o
of IN N
children NNS p
with IN p
autism NN p
in IN N
improvisational JJ i
music NN i
therapy NN i
. . i

Through IN N
behavioural JJ N
analysis NN N
, , N
this DT N
study NN N
investigated VBD N
the DT N
social-motivational JJ N
aspects NNS N
of IN N
musical JJ i
interaction NN i
between IN N
the DT N
child NN p
and CC N
the DT N
therapist NN N
in IN N
improvisational JJ i
music NN i
therapy NN i
by IN N
measuring VBG N
emotional JJ N
, , N
motivational JJ N
and CC N
interpersonal JJ N
responsiveness NN p
in IN p
children NNS p
with IN p
autism NN p
during IN p
joint JJ p
engagement NN p
episodes NNS p
. . p

The DT N
randomized NN N
controlled VBD N
study NN N
( ( p
n JJ p
= NNP p
10 CD p
) ) p
employed VBD N
a DT N
single JJ N
subject NN N
comparison NN N
design NN N
in IN N
two CD N
different JJ N
conditions NNS N
, , N
improvisational JJ i
music NN i
therapy NN i
and CC i
toy NN i
play NN i
sessions NNS i
, , i
and CC i
DVD NNP i
analysis NN i
of IN i
sessions NNS i
. . i

Improvisational JJ i
music NN i
therapy NN i
produced VBD N
markedly RB N
more RBR N
and CC N
longer JJR N
events NNS o
of IN o
'joy NNP o
' POS o
, , o
'emotional JJ o
synchronicity NN o
' POS o
and CC o
'initiation NN o
of IN o
engagement NN o
' '' o
behaviours NNS o
in IN N
the DT N
children NNS N
than IN N
toy NN i
play NN i
sessions NNS i
. . i

In IN N
response NN N
to TO N
the DT N
therapist NN N
's POS N
interpersonal JJ N
demands NNS N
, , N
'compliant NNP o
( ( o
positive JJ o
) ) o
responses NNS o
' POS o
were VBD N
observed VBN N
more RBR N
in IN N
music NN N
therapy NN N
than IN N
in IN N
toy JJ N
play NN N
sessions NNS N
, , N
and CC N
'no POS o
responses NNS o
' POS o
were VBD N
twice RB N
as RB N
frequent JJ N
in IN N
toy JJ N
play NN N
sessions NNS N
as IN N
in IN N
music NN i
therapy NN i
. . i

The DT N
results NNS N
of IN N
this DT N
exploratory NN N
study NN N
found VBD N
significant JJ N
evidence NN N
supporting VBG N
the DT N
value NN N
of IN N
music NN i
therapy NN i
in IN N
promoting VBG N
social JJ o
, , o
emotional JJ o
and CC o
motivational JJ o
development NN o
in IN N
children NNS p
with IN p
autism NN p
. . p

-DOCSTART- -7593098- O O

Quantifying VBG N
the DT N
extent NN N
of IN N
osteonecrosis NN p
of IN p
the DT p
femoral JJ p
head NN p
. . p

A DT N
new JJ N
method NN N
using VBG N
MRI NNP i
. . i

In IN N
a DT N
randomised JJ N
trial NN N
comparing VBG N
core NN N
decompression NN N
with IN N
conservative JJ N
treatment NN N
we PRP N
tested VBD N
the DT N
hypothesis NN N
that IN N
the DT N
extent NN N
of IN N
necrosis NN N
at IN N
the DT N
initial JJ N
MRI NNP i
predicts VBZ N
the DT N
subsequent JJ N
risk NN N
of IN N
collapse NN N
of IN N
the DT N
femoral JJ N
head NN N
. . N

After IN N
the DT N
initial JJ N
clinical JJ N
evaluation NN N
, , N
including VBG N
plain NN i
radiography NN i
and CC N
MRI NNP i
, , N
37 CD p
hips NNS p
with IN p
early-stage JJ p
osteonecrosis NN p
( ( p
ON NNP p
) ) p
in IN p
33 CD p
patients NNS p
were VBD p
randomly RB p
assigned VBN p
to TO N
a DT N
core-decompression NN i
group NN i
or CC i
a DT i
conservatively-treated JJ i
group NN i
. . i

All DT N
were VBD N
followed VBN N
regularly RB N
by IN N
clinical JJ N
evaluation NN N
, , N
plain VBP i
radiography NN i
and CC N
MRI NNP i
at IN N
intervals NNS N
of IN N
three CD N
months NNS N
. . N

The DT N
extent NN N
of IN N
ON NNP N
was VBD N
estimated VBN N
on IN N
the DT N
basis NN N
of IN N
abnormal JJ N
signal JJ N
intensity NN N
in IN N
the DT N
weight-bearing JJ N
portion NN N
of IN N
the DT N
femoral JJ N
head NN N
as IN N
determined VBN N
from IN N
a DT N
combination NN N
of IN N
coronal JJ N
and CC N
sagittal JJ N
MRIs NNP N
. . N

The DT N
arc NN N
of IN N
the DT N
necrotic JJ N
portion NN N
in IN N
the DT N
mid-coronal JJ N
image NN N
( ( N
A DT N
) ) N
and CC N
that IN N
in IN N
the DT N
mid-sagittal JJ N
image NN N
( ( N
B NNP N
) ) N
were VBD N
used VBN N
to TO N
quantify VB N
the DT N
extent NN N
of IN N
necrosis NN N
by IN N
the DT N
formula NN N
: : N
( ( N
A/180 NNP N
) ) N
x NN N
( ( N
B/180 NNP N
) ) N
x VBD N
100 CD N
. . N

There EX N
was VBD N
a DT N
strong JJ N
correlation NN N
between IN N
this DT N
index NN o
and CC o
the DT o
risk NN o
of IN o
collapse NN o
before IN N
and CC N
after IN N
adjustment NN N
for IN N
age NN N
, , N
gender NN N
, , N
stage NN N
and CC N
treatment NN N
group NN N
. . N

We PRP N
conclude VBP N
that IN N
the DT N
extent NN o
of IN o
the DT o
necrotic JJ o
portion NN o
ascertain NN N
by IN N
this DT N
method NN N
is VBZ N
a DT N
major JJ N
predictor NN N
of IN N
future JJ N
collapse NN N
. . N

We PRP N
propose VBP N
a DT N
systematic JJ N
method NN N
of IN N
determining VBG N
the DT N
index NN N
of IN N
the DT N
necrotic JJ o
portion NN o
which WDT N
may MD N
be VB N
clinically RB N
useful JJ N
in IN N
the DT N
management NN N
of IN N
early-stage NN p
ON NNP o
of IN p
the DT p
femoral JJ p
head NN p
. . p

-DOCSTART- -15915547- O O

Enhancement NN o
of IN o
blood NN o
glucose NN o
lowering VBG o
effect NN o
of IN N
a DT N
sulfonylurea NN i
when WRB N
coadministered VBN N
with IN N
an DT N
ACE NNP i
inhibitor NN i
: : i
results NNS N
of IN N
a DT N
glucose-clamp JJ N
study NN N
. . N

BACKGROUND NNP N
To TO N
investigate VB N
if IN N
coadministration NN N
of IN N
enalapril NN i
alters NNS N
the DT N
metabolic JJ N
effect NN N
of IN N
glibenclamide NN i
by IN N
employing VBG N
an DT N
euglycemic JJ N
glucose-clamp NN N
technique NN N
in IN N
healthy JJ p
volunteers NNS p
. . p

METHODS VB N
A DT N
double-blind JJ N
crossover NN N
study NN N
with IN N
nine CD p
healthy JJ p
normotensive JJ p
volunteers NNS p
( ( p
age NN p
27 CD p
+/- JJ p
3 CD p
y NN p
, , p
BMI NNP p
23.3 CD p
+/- JJ p
2.0 CD p
kg NN p
m NN p
( ( p
-2 NNP p
) ) p
; : p
mean JJ p
+/- JJ p
SD NNP p
) ) p
-randomly RB p
assigned VBN N
to TO N
a DT N
3-day JJ N
treatment NN N
of IN N
either CC N
5 CD i
mg NN i
enalapril NN i
or CC i
placebo NN i
. . i

In IN N
the DT N
morning NN N
of IN N
the DT N
fourth JJ N
day NN N
, , N
volunteers NNS N
orally RB N
received VBD N
3.5 CD N
mg NNS N
glibenclamide RB i
together RB N
with IN N
either DT N
10 CD N
mg NN N
enalapril NN i
or CC i
placebo NN i
. . i

Blood NNP o
glucose JJ o
levels NNS o
of IN N
volunteers NNS N
were VBD N
allowed VBN N
to TO N
fall VB N
by IN N
10 CD N
% NN N
from IN N
fasting NN N
levels NNS N
and CC N
were VBD N
kept VBN N
constant JJ N
thereafter NN N
by IN N
employing VBG N
a DT N
Biostator-based JJ i
euglycemic JJ i
glucose NN i
clamp NN i
. . i

RESULTS NNP N
Coadministration NNP N
of IN N
enalapril-compared JJ i
with IN N
placebo-resulted JJ i
in IN N
a DT N
temporarily RB N
higher JJR N
metabolic JJ o
effect NN o
of IN o
glibenclamide NN o
( ( N
AUC NNP N
GIR NNP N
( ( N
0-120 NNP N
) ) N
229 CD N
+/- JJ N
173 CD N
vs JJ N
137 CD N
+/- JJ N
44 CD N
mg NN N
kg NN N
( ( N
-1 NNP N
) ) N
, , N
p JJ N
< VBP N
0.01 CD N
; : N
mean JJ N
+/- JJ N
SD NNP N
) ) N
, , N
which WDT N
lasted VBD N
from IN N
120 CD N
min NNS N
to TO N
240 CD N
min NNS N
after IN N
enalapril DT i
administration NN N
. . N

In IN N
parallel NN N
, , N
the DT N
maximal JJ o
metabolic JJ o
effect NN o
of IN o
glibenclamide NN o
tended VBD N
to TO N
be VB N
higher JJR N
with IN N
enalapril NN i
( ( N
GIR NNP N
( ( N
max NN N
) ) N
5.2 CD N
+/- JJ N
1.9 CD N
vs JJ N
4.1 CD N
+/- JJ N
1.3 CD N
mg NN N
kg NN N
( ( N
-1 NNP N
) ) N
min NN N
( ( N
-1 NNP N
) ) N
; : N
p CC N
= VB N
0.19 CD N
) ) N
. . N

However RB N
, , N
the DT N
total JJ o
metabolic JJ o
effect NN o
of IN o
glibenclamide NN o
was VBD N
almost RB N
identical JJ N
between IN N
volunteers NNS N
taking VBG N
enalapril NN i
or CC i
placebo NN i
( ( N
AUC NNP N
GIR NNP N
( ( N
0-600 CD N
) ) N
1267 CD N
+/- JJ N
334 CD N
vs JJ N
1286 CD N
+/- JJ N
249 CD N
mg NN N
kg NN N
( ( N
-1 NNP N
) ) N
, , N
ns RB N
) ) N
. . N

In IN N
contrast NN N
, , N
serum JJ o
insulin NN o
levels NNS o
, , o
C-peptide NNP o
levels NNS o
, , o
and CC o
serum JJ o
glibenclamide NN o
profiles NNS o
were VBD N
not RB N
significantly RB N
different JJ N
between IN N
enalapril NN i
and CC i
placebo NN i
. . i

CONCLUSIONS VB N
The DT N
results NNS N
of IN N
this DT N
study NN N
may MD N
explain VB N
the DT N
higher JJR N
incidence NN N
of IN N
hypoglycemic JJ o
episodes NNS o
observed VBN N
in IN N
patients NNS N
with IN N
type JJ N
2 CD N
diabetes NNS N
when WRB N
taking VBG N
ACE NNP i
inhibitors NNS i
together RB N
with IN N
sulfonylureas NNS i
or CC N
insulin NN i
. . i

ACE NNP i
inhibitors NNS i
may MD N
cause VB N
a DT N
temporary JJ N
increase NN N
of IN N
the DT N
insulin NN o
sensitivity NN o
, , N
which WDT N
leads VBZ N
to TO N
an DT N
increased VBN o
risk NN o
of IN o
hypoglycemia NN o
under IN N
these DT N
conditions NNS N
. . N

-DOCSTART- -2834996- O O

Intranasal NNP i
recombinant JJ i
alfa-2b JJ i
interferon NN i
treatment NN o
of IN N
naturally RB o
occurring VBG o
common JJ o
colds NNS o
. . o

In IN N
a DT N
double-blind JJ N
, , N
placebo-controlled JJ N
study NN N
, , N
patients NNS p
with IN p
naturally RB p
occurring VBG p
common JJ p
colds NNS p
of IN p
less JJR p
than IN p
or CC p
equal JJ p
to TO p
48 CD p
h NNS p
duration NN p
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
nasal JJ N
sprays NNS N
of IN N
recombinant JJ i
alfa-2b JJ i
interferon NN i
at IN N
10 CD N
or CC N
20 CD N
MU/day NNPS N
or CC N
placebo VB i
four CD N
times NNS N
per IN N
day NN N
for IN N
5 CD N
days NNS N
. . N

The DT N
10-MU JJ p
( ( p
n JJ p
= NNP p
74 CD p
) ) p
, , p
20-MU JJ p
( ( p
n JJ p
= NNP p
74 CD p
) ) p
, , p
and CC p
placebo NN i
( ( p
n JJ p
= NNP p
72 CD p
) ) p
groups NNS p
had VBD N
comparable JJ N
frequencies NNS N
of IN N
documented JJ N
rhinovirus NN N
colds NNS N
( ( N
50 CD N
to TO N
65 CD N
% NN N
) ) N
and CC N
mean JJ o
durations NNS o
of IN o
pretreatment NN o
symptoms NNS o
( ( N
26 CD N
to TO N
27 CD N
h NN N
) ) N
. . N

The DT N
median JJ o
duration NN o
of IN o
colds NNS o
tended VBD N
to TO N
be VB N
longer RBR N
in IN N
the DT N
20-MU JJ N
group NN N
( ( N
10 CD N
days NNS N
) ) N
than IN N
the DT N
10-MU JJ N
group NN N
( ( N
8 CD N
days NNS N
) ) N
or CC N
placebo VBN i
group NN N
( ( N
8 CD N
days NNS N
) ) N
( ( N
P NNP N
= NNP N
0.06 CD N
) ) N
. . N

In IN N
those DT N
with IN N
proven JJ N
rhinovirus NN N
colds NNS N
treated VBD N
within IN N
24 CD N
h NN N
, , N
the DT N
median JJ o
duration NN o
was VBD N
significantly RB N
longer RBR N
in IN N
the DT N
20-MU JJ N
group NN N
( ( N
9 CD N
days NNS N
) ) N
than IN N
in IN N
the DT N
placebo NN i
group NN N
( ( N
6 CD N
days NNS N
) ) N
. . N

No DT N
differences NNS N
favoring VBG N
interferon NN N
treatment NN N
were VBD N
found VBN N
in IN N
respiratory JJ o
symptom JJ o
scores NNS o
or CC o
resolution NN o
of IN o
specific JJ o
symptoms NNS o
. . o

On IN N
days NNS N
5 CD N
and CC N
7 CD N
, , N
nasal JJ i
washings NNS i
from IN N
compliant JJ N
subjects NNS N
with IN N
proven JJ N
rhinovirus NN N
colds NNS N
yielded VBD N
rhinoviruses NNS N
more RBR N
often RB N
in IN N
placebo NN i
( ( N
47 CD N
and CC N
48 CD N
% NN N
, , N
respectively RB N
) ) N
than IN N
in IN N
interferon NN i
( ( N
15 CD N
and CC N
16 CD N
% NN N
, , N
respectively RB N
) ) N
recipients NNS N
( ( N
P NNP N
less JJR N
than IN N
0.02 CD N
) ) N
, , N
but CC N
no DT N
differences NNS N
in IN N
new JJ N
respiratory NN o
illness JJ o
occurrence NN o
were VBD N
observed VBN N
in IN N
household NN N
contacts NNS N
. . N

Interferon NNP i
recipients NNS N
had VBD N
significantly RB N
higher JJR N
frequencies NNS N
of IN N
blood NN o
in IN o
nasal JJ o
mucus NN o
( ( N
16 CD N
to TO N
18 CD N
% NN N
) ) N
than IN N
did VBD N
placebo VB i
recipients NNS N
( ( N
4 CD N
% NN N
) ) N
during IN N
treatment NN N
. . N

Antibiotics NNS o
for IN N
presumed JJ N
secondary JJ N
infections NNS N
were VBD N
given VBN N
more RBR N
often RB N
in IN N
the DT N
20-MU JJ N
group NN N
( ( N
11 CD N
% NN N
) ) N
than IN N
in IN N
the DT N
placebo NN i
group NN N
( ( N
0 CD N
% NN N
) ) N
( ( N
P NNP N
less JJR N
than IN N
0.01 CD N
) ) N
. . N

Nasal NNP N
sprays NNS N
of IN N
recombinant JJ i
alfa-2b JJ i
interferon NN i
were VBD N
not RB N
an DT N
effective JJ o
treatment NN o
for IN o
natural JJ o
colds NNS o
and CC N
were VBD N
associated VBN N
with IN N
toxicity NN o
. . o

-DOCSTART- -14655885- O O

Extracorporeal NNP i
shock NN i
wave NN i
therapy NN i
( ( i
ESWT NNP i
) ) i
in IN N
patients NNS p
with IN p
chronic JJ p
proximal JJ p
plantar NN p
fasciitis NN p
: : p
a DT N
2-year JJ N
follow-up NN N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
effect NN N
of IN N
extracorporeal NN i
shock NN i
wave VBP i
therapy NN i
( ( N
ESWT NNP N
) ) N
in IN N
patients NNS N
with IN N
chronically RB p
painful JJ p
proximal JJ p
plantar NN p
fasciitis NN p
with IN N
a DT N
further JJ N
conventional JJ N
conservative JJ N
treatment NN N
. . N

Forty-seven JJ p
patients NNS p
( ( p
49 CD p
feet NNS p
) ) p
with IN p
a DT p
previously RB p
unsuccessful JJ p
nonsurgical JJ p
treatment NN p
of IN p
at IN p
least JJS p
6 CD p
months NNS p
were VBD p
randomized VBN p
to TO p
two CD p
groups NNS p
. . p

Heel NNP i
cups NNS i
had VBD N
to TO N
be VB N
worn VBN N
throughout IN N
the DT N
study NN N
. . N

Group NNP p
1 CD p
( ( p
25 CD p
heels NNS p
) ) p
was VBD N
treated VBN N
immediately RB N
with IN N
three CD N
sessions NNS N
of IN N
ESWT NNP i
( ( i
3000 CD i
shock NN i
waves/session NN i
of IN i
0.2 CD i
mJ/mm2 NN i
) ) i
at IN i
weekly JJ i
intervals NNS i
. . i

The DT N
patients NNS N
of IN N
group NN p
2 CD p
( ( p
24 CD p
heels NNS p
) ) p
continued VBD N
nonsurgical JJ i
treatment NN i
( ( i
iontophoresis NN i
with IN i
diclofenac NN i
and CC i
an DT i
oral JJ i
nonsteroidal JJ i
anti-inflammatory JJ i
drug NN i
) ) i
for IN N
12 CD N
weeks NNS N
. . N

After IN N
this DT N
period NN N
they PRP N
were VBD N
treated VBN N
using VBG N
the DT N
protocol NN N
of IN N
group NN N
1 CD N
. . N

No DT N
significant JJ N
difference NN N
of IN N
pain NN o
and CC o
walking NN o
time NN o
after IN N
further JJ N
nonsurgical JJ N
treatment NN N
( ( N
3 CD N
months NNS N
) ) N
was VBD N
seen VBN N
in IN N
group NN N
2 CD N
. . N

At IN N
12 CD N
weeks NNS N
after IN N
ESWT NNP N
, , N
the DT N
pain NN o
estimation NN o
on IN o
the DT o
visual JJ o
analogue NN o
scale NN o
( ( o
VAS NNP o
) ) o
for IN o
activities NNS o
of IN o
daily JJ o
living NN o
diminished VBN N
significantly RB N
by IN N
62.9 CD N
% NN N
in IN N
group NN N
1 CD N
and CC N
by IN N
63.0 CD N
% NN N
in IN N
group NN N
2 CD N
. . N

The DT N
comfortable JJ o
walking NN o
time NN o
had VBD N
increased VBN N
significantly RB N
in IN N
both DT N
groups NNS N
. . N

Two CD N
years NNS N
after IN N
ESWT NNP N
, , N
pain NN o
during IN o
activities NNS o
of IN o
daily JJ o
living NN o
decreased VBN N
by IN N
94 CD N
% NN N
in IN N
group NN N
1 CD N
and CC N
by IN N
90 CD N
% NN N
in IN N
group NN N
2 CD N
on IN N
the DT N
VAS NNP N
and CC N
the DT N
comfortable JJ o
walking NN o
time NN o
had VBD N
increased VBN N
significantly RB N
in IN N
both DT N
groups NNS N
. . N

-DOCSTART- -23021480- O O

Effects NNS N
of IN N
a DT N
brief JJ i
Early JJ i
Start NNP i
Denver NNP i
model NN i
( ( i
ESDM NNP i
) ) i
-based VBD i
parent NN i
intervention NN i
on IN i
toddlers NNS i
at IN p
risk NN p
for IN p
autism NN p
spectrum NN p
disorders NNS p
: : p
a DT N
randomized NN N
controlled VBN N
trial NN N
. . N

OBJECTIVE VB N
This DT N
study NN N
was VBD N
carried VBN N
out IN N
to TO N
examine VB N
the DT N
efficacy NN N
of IN N
a DT N
12-week JJ N
, , N
low-intensity JJ i
( ( i
1-hour/wk CD i
of IN i
therapist JJ i
contact NN i
) ) i
, , i
parent-delivered JJ i
intervention NN i
for IN i
toddlers NNS i
at IN p
risk NN p
for IN p
autism NN p
spectrum NN p
disorders NNS p
( ( p
ASD NNP p
) ) p
aged VBD p
14 CD p
to TO p
24 CD p
months NNS p
and CC p
their PRP$ p
families NNS p
. . p

METHOD NNP N
A NNP N
randomized VBD N
controlled VBN N
trial NN N
involving VBG N
98 CD p
children NNS p
and CC p
families NNS p
was VBD N
carried VBN N
out RP N
in IN N
three CD N
different JJ N
sites NNS N
investigating VBG N
the DT N
efficacy NN o
of IN N
a DT N
parent NN N
delivery NN N
of IN N
the DT N
Early JJ i
Start NNP i
Denver NNP i
model NN i
( ( i
P-ESDM NNP i
) ) i
, , N
which WDT N
fosters VBZ N
parental JJ N
use NN N
of IN N
a DT N
child-centered JJ N
responsive JJ N
interaction NN N
style NN N
that WDT N
embeds VBZ N
many JJ N
teaching VBG N
opportunities NNS N
into IN N
play NN N
, , N
compared VBN i
to TO i
community NN i
treatment NN i
as IN i
usual JJ i
. . i

Assessments NNS N
were VBD N
completed VBN N
at IN N
baseline NN N
and CC N
12 CD N
weeks NNS N
later RB N
, , N
immediately RB N
after IN N
the DT N
end NN N
of IN N
parent NN N
coaching NN N
sessions NNS N
. . N

RESULTS NNP N
There EX N
was VBD N
no DT o
effect NN o
of IN N
group NN N
assignment NN N
on IN N
parent-child JJ N
interaction NN N
characteristics NNS N
or CC N
on IN N
any DT N
child JJ N
outcomes NNS N
. . N

Both DT N
groups NNS N
of IN N
parents NNS N
improved VBN N
interaction NN o
skills NNS o
, , N
and CC N
both DT N
groups NNS N
of IN N
children NNS N
demonstrated JJ o
progress NN o
. . o

Parents NNS i
receiving VBG i
P-ESDM NNP i
demonstrated VBD N
significantly RB N
stronger JJR o
working VBG o
alliances NNS o
with IN N
their PRP$ N
therapists NNS o
than IN N
did VBD N
the DT N
community NN N
group NN N
. . N

Children NNP N
in IN N
the DT N
community NN N
group NN N
received VBD N
significantly RB N
more JJR N
intervention NN o
hours NNS o
than IN N
those DT N
in IN N
the DT N
P-ESDM NNP i
group NN N
. . N

For IN N
the DT N
group NN N
as IN N
a DT N
whole NN N
, , N
both DT N
younger JJR N
child NN N
age NN N
at IN N
the DT N
start NN N
of IN N
intervention NN N
and CC N
a DT N
greater JJR N
number NN o
of IN o
intervention NN o
hours NNS o
were VBD N
positively RB N
related VBN N
to TO N
the DT N
degree NN N
of IN N
improvement NN N
in IN N
children NNS N
's POS N
behavior NN N
for IN N
most JJS N
variables NNS N
. . N

CONCLUSIONS NNP N
Parent-implemented JJ i
intervention NN i
studies NNS i
for IN N
early JJ N
ASD NNP N
thus RB N
far RB N
have VBP N
not RB N
demonstrated VBN N
the DT N
large JJ N
effects NNS N
seen VBN N
in IN N
intensive-treatment JJ N
studies NNS N
. . N

Evidence NN N
that IN N
both DT N
younger JJR N
age NN N
and CC N
more JJR N
intervention NN N
hours NNS N
positively RB N
affect VBP N
developmental JJ N
rates NNS N
has VBZ N
implications NNS N
for IN N
clinical JJ N
practice NN N
, , N
service NN N
delivery NN N
, , N
and CC N
public JJ N
policy NN N
. . N

-DOCSTART- -1562431- O O

Slotted VBN i
versus IN i
non-slotted JJ i
locked JJ i
intramedullary JJ i
nailing NN i
for IN N
femoral JJ N
shaft NN N
fractures NNS N
. . N

Experimentally RB N
, , N
two CD i
slotted VBD i
nails NNS i
, , i
the DT i
Grosse-Kempf NNP i
nail NN i
and CC i
the DT i
AO/ASIF NNP i
universal JJ i
femoral JJ i
nail NN i
, , N
were VBD N
compared VBN N
to TO N
the DT N
non-slotted JJ i
Grosse-Kempf NNP i
nail NN i
and CC i
control NN i
bone NN i
using VBG N
a DT N
cadaver JJ i
femoral JJ i
osteotomy NN i
. . i

The DT N
stiffnesses NNS o
and CC o
strengths NNS o
of IN o
the DT o
osteotomies NNS o
fixed VBN o
with IN N
slotted JJ i
nails NNS i
in IN N
10-30 JJ N
degrees NNS N
torsion NN N
were VBD N
6-8 CD N
% NN N
and CC N
the DT N
values NNS N
of IN N
non-slotted JJ N
nails NNS N
40 CD N
% NN N
of IN N
control NN N
bone NN N
. . N

The DT N
maximal JJ o
moments NNS o
were VBD N
14-18 CD N
% NN N
and CC N
48 CD N
% NN N
, , N
respectively RB N
. . N

In IN N
the DT N
clinical JJ N
range NN N
of IN N
torsion NN N
, , N
the DT N
implant-bone JJ o
construct NN o
never RB N
failed VBD N
or CC N
was VBD N
deformed VBN N
. . N

Clinically NNP N
, , N
46 CD p
femoral JJ p
shaft NN p
fractures NNS p
were VBD p
randomized VBN p
to TO p
treatment NN p
with IN p
Gross-Kempf NNP i
nails NNS i
, , p
24 CD p
with IN p
slotted VBN i
nails NNS i
and CC p
22 CD p
with IN p
non-slotted JJ i
nails NNS i
. . i

Four CD N
complications NNS o
in IN N
the DT N
slotted JJ N
nail NN N
group NN N
and CC N
three CD N
in IN N
the DT N
non-slotted JJ N
nail NN N
group NN N
were VBD N
considered VBN N
to TO N
be VB N
independent JJ N
of IN N
the DT N
choice NN N
of IN N
nail NN N
and CC N
did VBD N
not RB N
affect VB N
the DT N
end NN N
result NN N
. . N

Three CD N
splinterings NNS o
of IN o
the DT o
distal JJ o
fragment NN o
, , N
one CD N
resulting NN N
in IN N
a DT N
change NN o
of IN o
the DT o
osteosynthesis NN o
implant NN o
to TO N
a DT N
condylar JJ N
plate NN N
, , N
were VBD N
considered VBN N
to TO N
result VB N
from IN N
the DT N
high JJ N
stiffness NN N
of IN N
the DT N
non-slotted JJ N
nail NN N
. . N

Osteosynthesis NN N
of IN N
femoral JJ N
shaft NN N
fractures NNS N
using VBG N
slotted VBN N
nails NNS N
has VBZ N
not RB N
resulted VBN N
in IN N
healing VBG N
disturbances NNS N
, , N
which WDT N
could MD N
be VB N
accounted VBN N
for IN N
by IN N
the DT N
high JJ N
torsional JJ N
elasticity NN N
of IN N
the DT N
nail NN N
; : N
there RB N
seems VBZ N
to TO N
be VB N
no DT N
indication NN N
for IN N
high-stiffness NN N
nails NNS N
in IN N
femoral JJ p
fractures NNS p
. . p

-DOCSTART- -12058842- O O

Brief JJ N
report NN N
: : N
imitation NN i
effects NNS N
on IN N
children NNS p
with IN p
autism NN p
. . p

Twenty NNP p
children NNS p
with IN p
autism NN p
( ( p
mean JJ p
age NN p
, , p
5 CD p
years NNS p
) ) p
were VBD p
recruited VBN p
for IN p
the DT p
study NN p
from IN p
a DT p
school NN p
for IN p
children NNS p
with IN p
autism NN p
. . p

The DT N
children NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
an DT N
imitation NN i
( ( p
n JJ p
= NNP p
10 CD p
) ) p
or CC p
contingently RB i
responsive JJ i
( ( p
n JJ p
= NNP p
10 CD p
) ) p
interaction NN N
group NN N
based VBN N
on IN N
a DT N
stratification NN N
table NN N
for IN N
gender NN N
and CC N
developmental NN N
and CC N
chronological JJ N
age NN N
. . N

The DT N
sessions NNS N
consisted VBD N
of IN N
four CD N
phases NNS N
, , N
with IN N
each DT N
phase NN N
lasting VBG N
3 CD N
minutes NNS N
. . N

In IN N
the DT N
first JJ N
phase NN N
, , N
the DT N
child NN N
walked VBD N
into IN N
a DT N
room NN N
that WDT N
was VBD N
furnished VBN N
with IN N
a DT N
sofa NN N
, , N
a DT N
table NN N
, , N
chairs NNS N
, , N
and CC N
two CD N
sets NNS N
of IN N
identical JJ N
toys NN N
. . N

An DT N
adult NN N
was VBD N
in IN N
the DT N
room NN N
sitting VBG N
very RB N
still RB N
like IN N
a DT N
statue NN N
( ( N
first JJ N
still-face JJ N
condition NN N
) ) N
. . N

In IN N
the DT N
second JJ N
phase NN N
, , N
the DT N
adult NN N
either RB N
imitated VBD N
the DT N
child NN N
or CC N
was VBD N
contingently RB i
responsive JJ i
to TO N
the DT N
child NN N
. . N

In IN N
the DT N
third JJ N
phase NN N
, , N
the DT N
adult NN N
sat VBD N
still RB N
again RB N
( ( N
second JJ N
still-face JJ N
condition NN N
) ) N
, , N
and CC N
in IN N
the DT N
fourth JJ N
phase NN N
, , N
the DT N
adult NN N
engaged VBN N
in IN N
a DT N
spontaneous JJ N
interaction NN N
. . N

During IN N
the DT N
third JJ N
phase NN N
( ( N
the DT N
second JJ N
still-face JJ N
condition NN N
) ) N
, , N
the DT N
children NNS N
in IN N
the DT N
imitation NN i
group NN N
spent VBD o
less JJR o
time NN o
in IN N
gross JJ N
motor NN N
activity NN N
and CC N
more JJR o
time NN o
touching VBG o
the DT o
adult NN o
, , N
as IN N
if IN N
attempting VBG N
to TO N
initiate VB N
an DT N
interaction NN N
. . N

The DT N
contingency NN i
condition NN N
appeared VBD N
to TO N
be VB N
a DT N
more RBR o
effective JJ o
way NN N
to TO N
facilitate VB N
a DT N
distal JJ o
social JJ o
behavior NN o
( ( o
attention NN o
) ) o
, , N
whereas IN N
the DT N
imitative JJ i
condition NN N
was VBD N
a DT N
more RBR o
effective JJ o
way NN N
to TO N
facilitate VB N
a DT N
proximal JJ o
social JJ o
behavior NN o
( ( o
touching VBG o
) ) o
. . o

-DOCSTART- -7857500- O O

Hypericum NNP i
treatment NN i
of IN N
mild JJ p
depressions NNS p
with IN p
somatic JJ p
symptoms NNS p
. . p

In IN N
a DT N
randomized JJ N
, , N
placebo-controlled JJ i
, , N
double-blind JJ N
study NN N
, , N
39 CD p
patients NNS p
with IN p
depression NN p
with IN p
somatic JJ p
symptoms NNS p
were VBD N
treated VBN N
with IN N
hypericum JJ i
extract JJ i
LI NNP i
160 CD i
. . i

The DT N
therapy NN N
lasted VBD N
for IN N
4 CD N
weeks NNS N
; : N
the DT N
dosage NN N
was VBD N
300 CD N
mg NN N
three CD N
times NNS N
daily RB N
. . N

At IN N
the DT N
onset NN N
of IN N
the DT N
study NN N
as RB N
well RB N
as IN N
after IN N
2 CD N
and CC N
4 CD N
weeks NNS N
, , N
the DT N
following JJ N
criteria NNS N
were VBD N
analyzed VBN N
: : N
HAMD NNP N
, , N
B-L NNP N
, , N
CGI NNP N
, , N
and CC N
vegetative JJ N
symptoms NNS N
. . N

The DT N
results NNS N
show VBP N
a DT N
significant JJ o
improvement NN o
in IN N
the DT N
active JJ N
treatment NN N
group NN N
at IN N
the DT N
5 CD N
% NN N
level NN N
as IN N
compared VBN N
to TO N
placebo VB N
. . N

Seventy NNP N
percent NN N
of IN N
the DT N
patients NNS N
treated VBN N
with IN N
LI NNP N
160 CD N
were VBD N
free JJ o
of IN o
symptoms NNS o
after IN N
4 CD N
weeks NNS N
. . N

Typical JJ N
symptoms NNS N
of IN N
the DT N
depression NN N
such JJ N
as IN N
lack NN o
of IN o
activity NN o
, , o
tiredness NN o
, , o
fatigue NN o
, , o
and CC o
disturbed JJ o
sleep NN o
, , N
were VBD N
especially RB N
responsive JJ N
. . N

In IN N
no DT o
case NN N
were VBD N
any DT N
undesirable JJ o
side NN o
effects NNS o
observed VBD N
. . N

-DOCSTART- -2679258- O O

Prospective JJ N
trial NN N
of IN N
timing NN N
of IN N
bacillus NN i
Calmette-Gu?rin NNP i
vaccination NN i
in IN p
Canadian JJ p
Cree NNP p
infants NNS p
. . p

We PRP N
studied VBD p
184 CD p
Cree NNP p
Indian JJ p
infants NNS p
in IN N
randomized VBN N
, , N
prospective JJ N
fashion NN N
to TO N
assess VB N
the DT N
effect NN N
of IN N
age NN N
on IN o
lymphocyte JJ o
sensitization NN o
to TO N
purified VB N
protein JJ N
derivative JJ N
( ( N
PPD NNP N
) ) N
before IN N
and CC N
after IN N
and CC N
without IN i
bacillus JJ i
Calmette-Gu?rin NNP i
( ( i
BCG NNP i
) ) i
vaccination NN o
. . o

Lymphocyte JJ o
responses NNS o
to TO o
PPD NNP N
, , N
Candida NNP N
, , N
and CC N
streptokinase NN N
were VBD N
measured VBN N
at IN N
birth NN N
and CC N
at IN N
intervals NNS N
later RB N
. . N

The DT N
mean JJ N
response NN N
of IN N
paired JJ N
values NNS N
from IN p
26 CD p
infants NNS p
without IN p
BCG NNP p
vaccination NN p
rose VBD p
for IN p
the DT N
PPD NNP N
stimulation NN N
index NN N
( ( N
SI NNP N
) ) N
from IN N
2.7 CD N
at IN N
birth NN N
to TO N
3.9 CD N
before IN N
2 CD N
yr NN N
of IN N
age NN N
. . N

The DT N
SI NNP N
for IN N
both DT N
Candida NNP N
and CC N
streptokinase VB N
for IN N
this DT N
group NN N
of IN N
infants NNS N
rose VBD N
significantly RB N
in IN N
the DT N
first JJ N
2 CD N
yr NN N
( ( N
p NN N
less JJR N
than IN N
0.05 CD N
) ) N
. . N

In IN N
66 CD p
infants NNS p
who WP p
received VBD i
BCG NNP i
in IN i
the DT p
first JJ p
7 CD p
days NNS p
of IN p
life NN p
, , p
the DT o
PPD-SI NNP o
rose VBD o
from IN N
3.1 CD N
to TO N
35.3 CD N
( ( N
p NN N
less JJR N
than IN N
0.001 CD N
) ) N
. . N

In IN N
17 CD N
infants NNS N
who WP N
received VBD N
the DT N
vaccine NN N
later RB N
but CC N
before IN N
9 CD N
months NNS N
, , N
it PRP N
rose VBD N
from IN N
3.1 CD N
at IN N
birth NN N
to TO N
24.9 CD N
, , N
and CC N
in IN N
14 CD N
who WP N
received VBD N
it PRP N
between IN N
9 CD N
months NNS N
and CC N
2 CD N
yr NN N
, , N
it PRP N
rose VBD N
from IN N
2.2 CD N
to TO N
52.9 CD N
. . N

The DT o
lymphocyte JJ o
responses NNS o
to TO o
PPD NNP N
after IN i
BCG NNP i
in IN i
these DT N
two CD N
groups NNS N
were VBD N
significantly RB N
different JJ N
( ( N
p NN N
less JJR N
than IN N
0.05 CD N
) ) N
. . N

There EX N
was VBD N
no DT N
evidence NN N
in IN N
the DT N
older JJR N
infants NNS N
that IN N
a DT N
raised VBN o
PPD-SI NN o
before IN o
BCG NNP N
vaccination NN N
affected VBD o
lymphocyte JJ o
sensitization NN o
by IN o
the DT N
vaccine NN N
. . N

We PRP N
conclude VBP N
that IN N
increasing VBG N
the DT N
age NN N
at IN N
vaccination NN N
with IN i
BCG NNP i
from IN i
birth NN N
to TO N
more JJR N
than IN N
9 CD N
months NNS N
enhances NNS o
immunologic JJ o
sensitization NN o
to TO o
PPD NNP N
significantly RB N
in IN N
this DT N
population NN N
. . N

-DOCSTART- -2891940- O O

Mexiletine NNP i
for IN N
treatment NN N
of IN N
chronic JJ N
painful JJ N
diabetic JJ N
neuropathy NN N
. . N

Sixteen NNP p
of IN p
nineteen JJ p
patients NNS p
completed VBD p
a DT p
randomised JJ p
double-blind NN p
crossover NN p
trial NN p
to TO p
assess VB p
the DT p
effect NN p
of IN p
oral JJ i
mexiletine NN i
( ( i
10 CD i
mg/kg NNS i
bodyweight JJ i
daily RB i
) ) i
on IN i
the DT i
symptoms NNS i
and CC i
signs NNS i
of IN i
chronic JJ i
painful JJ i
diabetic JJ i
neuropathy NN i
. . i

The DT p
median JJ p
age NN p
of IN p
the DT p
sixteen JJ p
patients NNS p
was VBD p
50 CD p
years NNS p
( ( p
range VB p
30-64 NNP p
) ) p
. . p

Assessment NN N
with IN N
a DT N
five-item JJ o
clinical JJ o
symptom NN o
scale NN o
showed VBD N
significant JJ N
improvement NN N
during IN N
the DT N
mexiletine NN N
phase NN N
compared VBN N
with IN N
the DT N
placebo NN i
phase NN N
. . N

Pain NN o
was VBD N
reduced VBN N
during IN N
mexiletine NN i
but CC N
not RB N
during IN N
placebo NN i
, , N
as IN N
assessed VBN N
by IN N
a DT N
visual JJ N
analogue NN N
rating NN N
scale NN N
. . N

Mexiletine NNP i
treatment NN N
had VBD N
no DT N
effect NN N
on IN N
tendon NN o
reflexes NNS o
, , o
vibration NN o
threshold NN o
levels NNS o
, , o
beat-to-beat JJ o
variation NN o
in IN o
heart NN o
rate NN o
during IN o
deep JJ o
breathing NN o
, , o
and CC o
postural JJ o
blood NN o
pressure NN o
response NN o
. . o

Mild JJ o
side-effects NNS o
were VBD N
seen VBN N
in IN N
three CD N
of IN N
the DT N
sixteen JJ N
patients NNS N
during IN N
mexiletine JJ N
treatment NN N
. . N

-DOCSTART- -7015093- O O

[ JJ N
Prevention NNP N
of IN N
stress NN p
ulcers NNS p
with IN N
synthetic JJ i
depot NN i
secretin NN i
] NN i
. . N

The DT N
pathogenesis NN N
of IN N
stress NN p
ulcers NNS p
is VBZ N
still RB N
far RB N
from IN N
being VBG N
understood NN N
. . N

It PRP N
is VBZ N
reported VBN N
about IN N
a DT N
synthetic JJ i
secretin NN i
( ( i
Hoe $ i
069 CD i
+ NNP i
depot FW i
component NN i
) ) i
given VBN N
prophylactically RB N
to TO N
100 CD p
patients NNS p
postoperatively RB p
. . p

It PRP N
eliminated VBD o
or CC o
ameliorated VBD o
stress JJ o
ulcers NNS o
. . o

The DT N
result NN N
, , N
confirmed VBN N
by IN N
gastroscopy NN N
, , N
demonstrates VBZ N
the DT N
treatment NN i
with IN i
secretin JJ i
plus CC i
depot JJ i
component NN i
as IN N
a DT N
highly RB N
recommendable JJ N
prophylaxis NN N
in IN N
the DT N
postsurgical JJ N
intensive JJ N
care NN N
treatment NN N
. . N

-DOCSTART- -1922868- O O

[ JJ N
Efficacy NNP N
of IN N
immunomodulating VBG i
treatment NN i
in IN N
patients NNS p
with IN p
different JJ p
degrees NNS p
of IN p
immunosuppression NN p
] NNP p
. . N

Immunodepression NNP N
is VBZ N
a DT N
common JJ N
condition NN N
in IN N
patients NNS N
undergoing JJ N
elective JJ N
operations NNS N
and CC N
it PRP N
constitutes VBZ N
a DT N
high JJ N
risk NN N
for IN N
the DT N
onset NN N
of IN N
postoperative JJ N
infective JJ N
complications NNS N
. . N

The DT N
use NN N
of IN N
immunomodulatory NN i
drugs NNS i
has VBZ N
proved VBN N
useful JJ N
in IN N
the DT N
prophylaxis NN N
of IN N
these DT N
complications NNS N
, , N
although IN N
the DT N
precise JJ N
indications NNS N
for IN N
each DT N
drug NN N
have VBP N
not RB N
yet RB N
been VBN N
clearly RB N
codified VBN N
. . N

The DT N
present JJ N
study NN N
aimed VBN N
to TO N
assess VB N
the DT N
effects NNS N
of IN N
thymostimulin NN i
in IN N
patients NNS p
with IN p
different JJ p
degrees NNS p
of IN p
immunodepression NN p
, , N
by IN N
evaluating VBG N
both PDT N
the DT N
incidence NN o
of IN o
postoperative JJ o
infections NNS o
and CC N
the DT N
changes NNS o
induced VBN o
in IN N
various JJ N
immunological JJ o
parameters NNS o
. . o

The DT N
results NNS N
obtained VBD N
indicated JJ N
that IN N
those DT N
subjects NNS N
with IN N
the DT N
highest JJS N
degree NN N
of IN N
immunodepression NN N
( ( N
hypo-anergic JJ N
) ) N
benefited VBD N
most JJS N
from IN N
drug NN i
therapy NN i
in IN N
comparison NN N
to TO N
those DT N
with IN N
a DT N
lesser JJR N
degree NN N
of IN N
immunodepression NN N
( ( N
relatively RB N
hypo-ergic NN N
) ) N
. . N

The DT N
advantages NNS N
were VBD N
evident JJ N
in IN N
hypo-anergic JJ N
subjects NNS N
both DT N
with IN N
regard NN N
to TO N
the DT N
frequency NN o
of IN o
early JJ o
postoperative JJ o
infections NNS o
, , N
and CC N
with IN N
regard NN N
to TO N
immunological JJ o
parameters NNS o
. . o

On IN N
the DT N
other JJ N
hand NN N
, , N
in IN N
relatively RB N
hypo-ergic JJ N
subjects NNS N
, , N
benefits NNS N
were VBD N
limited VBN N
to TO N
the DT N
improvement NN N
of IN N
some DT N
immunological JJ o
parameters NNS o
. . o

In IN N
our PRP$ N
opinion NN N
, , N
the DT N
use NN N
of IN N
thymostimulin NN i
is VBZ N
of IN N
particular JJ N
use NN N
only RB N
in IN N
those DT N
subjects NNS N
with IN N
marked JJ N
immunodepression NN N
since IN N
the DT N
incidence NN N
of IN N
post-operative JJ o
sepsis NN o
is VBZ N
highest JJS N
in IN N
this DT N
group NN N
. . N

-DOCSTART- -8530236- O O

Laparoscopic NNP p
hysterectomy NN p
: : p
is VBZ N
dissecting VBG i
the DT i
ureter NN i
necessary JJ N
? . N
Laparoscopic NNP i
hysterectomy NN i
has VBZ N
been VBN N
first RB N
reported VBN N
by IN N
Reich NNP N
et CC N
al NN N
. . N

in IN N
1989 CD N
, , N
which WDT N
confirmed VBD N
the DT N
possibility NN N
of IN N
laparoscopic JJ N
hysterectomy NN N
being VBG N
employed VBN N
as IN N
a DT N
replacement NN N
of IN N
the DT N
vast JJ N
majority NN N
of IN N
traditional JJ N
abdominal JJ N
hysterectomies NNS N
. . N

There EX N
are VBP N
three CD N
critical JJ N
points NNS N
in IN N
laparoscopic JJ N
hysterectomy NN N
. . N

The DT N
most RBS N
important JJ N
critical JJ N
point NN N
is VBZ N
to TO N
identify VB N
uterine JJ N
arteries NNS N
from IN N
the DT N
ureter NN N
in IN N
the DT N
paracervical JJ N
area NN N
. . N

Several JJ N
ureteral JJ o
injuries NNS o
at IN N
operative JJ N
laparoscopy NN N
have VBP N
been VBN N
reported VBN N
. . N

We PRP N
performed VBD N
two CD p
hundred CD p
and CC p
thirty VB p
laparoscopic JJ i
hysterectomies NNS i
during IN p
the DT p
period NN p
from IN p
March NNP p
1991 CD p
to TO p
October NNP p
1993 CD p
. . p

Sixty CD p
patients NNS p
were VBD p
later RB p
included VBN p
in IN p
this DT p
study NN p
. . p

Thirty NNP N
of IN N
these DT N
applied VBN N
the DT N
technique NN N
of IN N
dissecting VBG i
the DT i
ureter NN i
at IN N
the DT N
initiation NN N
of IN N
laparoscopic JJ N
hysterectomy NN N
. . N

Most JJS N
of IN N
the DT N
patients NNS N
were VBD N
discharged VBN N
on IN N
the DT N
second JJ N
postoperative JJ N
day NN N
. . N

Although IN N
dissecting VBG i
the DT i
ureter NN i
at IN N
the DT N
beginning NN N
of IN N
the DT N
operation NN N
did VBD N
not RB N
produce VB N
a DT N
significant JJ N
discrepancy NN o
in IN N
operation NN o
time NN o
, , o
blood NN o
loss NN o
, , o
hospitalization NN o
day NN o
and CC o
ureter JJ o
injury NN o
when WRB N
compared VBN N
with IN N
the DT N
control NN N
group NN N
, , N
the DT N
uterine JJ N
arteries NNS N
, , N
however RB N
, , N
may MD N
be VB N
confidently RB N
desiccated VBN N
once RB N
the DT N
path NN N
of IN N
the DT N
ureter NN N
near IN N
the DT N
uterosacral JJ N
ligament NN N
is VBZ N
identified VBN N
. . N

-DOCSTART- -1728202- O O

Granulocyte-macrophage JJ i
colony-stimulating JJ i
factor NN i
( ( i
GM-CSF NNP i
) ) i
as IN N
adjunct JJ N
therapy NN N
in IN N
relapsed JJ p
Hodgkin NNP p
disease NN p
. . p

OBJECTIVE UH N
To TO N
determine VB N
the DT N
clinical JJ N
and CC N
economic JJ N
effects NNS N
of IN N
granulocyte JJ i
macrophage NN i
colony-stimulating JJ i
factor NN i
( ( i
GM-CSF NNP i
) ) i
as IN N
adjunct JJ N
therapy NN N
in IN N
relapsed JJ p
or CC p
refractory JJ p
Hodgkin NNP p
disease NN p
. . p

DESIGN VB N
A DT N
randomized JJ N
, , N
double-blind JJ N
, , N
phase JJ N
III NNP N
clinical JJ N
trial NN N
. . N

SETTING VB N
A DT N
tertiary JJ p
referral NN p
center NN p
. . p

PATIENTS VB N
Twenty-four JJ p
patients NNS p
( ( p
twelve NN p
of IN p
whom WP p
were VBD p
controls NNS p
) ) p
treated VBN p
with IN p
high-dose JJ i
chemotherapy NN i
and CC p
autologous JJ i
bone NN i
marrow NN i
transplantation NN i
. . i

MAIN NNP N
RESULTS VBD N
The DT N
12 CD N
patients NNS N
treated VBN N
with IN N
GM-CSF NNP i
, , N
when WRB N
compared VBN N
with IN N
placebo NN i
recipients NNS N
, , N
had VBD N
shorter JJR N
periods NNS o
of IN o
neutropenia NN o
( ( N
median JJ N
duration NN N
of IN N
an DT N
absolute JJ N
neutrophil NN N
count NN N
of IN N
less JJR N
than IN N
1000 CD N
cells/mm3 NN N
, , N
16 CD N
days NNS N
compared VBN N
with IN N
27 CD N
days NNS N
; : N
P NNP N
= NNP N
0.02 CD N
) ) N
, , N
shorter JJR o
periods NNS o
of IN o
platelet-transfusion NN o
dependency NN o
( ( N
median JJ N
duration NN N
, , N
13.5 CD N
days NNS N
compared VBN N
with IN N
21 CD N
days NNS N
; : N
P NNP N
= NNP N
0.03 CD N
) ) N
, , N
and CC N
shorter JJR o
hospitalizations NNS o
( ( N
median JJ N
hospital NN N
stay NN N
, , N
32 CD N
days NNS N
compared VBN N
with IN N
40.5 CD N
days NNS N
; : N
P NNP N
= NNP N
0.004 CD N
) ) N
. . N

Other JJ N
clinical JJ N
outcomes NNS N
, , N
such JJ N
as IN N
frequency NN o
and CC o
severity NN o
of IN o
toxicities NNS o
, , o
development NN o
of IN o
pneumonia NN o
or CC o
infection NN o
, , o
in-hospital JJ o
death NN o
, , o
and CC o
response NN o
rate NN o
were VBD N
similar JJ N
in IN N
the DT N
two CD N
groups NNS N
. . N

Actuarial JJ N
long-term JJ o
disease-free JJ o
survival NN o
was VBD N
64 CD N
% NN N
for IN N
patients NNS N
treated VBN N
with IN N
GM-CSF NNP i
and CC N
58 CD N
% NN N
for IN N
patients NNS N
who WP N
received VBD N
placebo NN i
after IN N
32 CD N
months NNS N
of IN N
follow-up NN N
( ( N
P NNP N
= NNP N
0.15 CD N
) ) N
. . N

The DT N
group NN N
treated VBD N
with IN N
GM-CSF NNP i
had VBD N
lower JJR o
total NN o
charges NNS o
after IN o
infusion NN o
of IN o
autologous JJ o
marrow NN o
than IN N
the DT N
placebo NN i
group NN N
( ( N
median JJ N
in-hospital NN N
charges NNS N
, , N
$ $ N
39,800 CD N
compared VBN N
with IN N
$ $ N
62,500 CD N
; : N
P NNP N
= NNP N
0.005 CD N
) ) N
because IN N
of IN N
lower JJR o
post-infusion NN o
charges NNS o
for IN N
room NN N
and CC N
board NN N
, , N
antibiotic JJ N
therapy NN N
, , N
transfusions NNS N
, , N
laboratory NN N
tests NNS N
, , N
and CC N
physical JJ N
therapy NN N
visits NNS N
. . N

CONCLUSIONS NNP N
Administration NNP N
of IN N
GM-CSF NNP i
was VBD N
associated VBN N
with IN N
acceleration NN o
of IN o
myeloid NN o
and CC o
platelet NN o
recovery NN o
and CC N
was VBD N
cost VBN o
effective JJ o
in IN N
the DT N
treatment NN N
of IN N
patients NNS p
with IN p
relapsed JJ p
Hodgkin NNP p
disease NN p
who WP p
received VBD p
intensive JJ p
chemotherapy NN p
. . p

-DOCSTART- -8798245- O O

Relation NN N
of IN N
total JJ N
homocysteine NN i
and CC N
lipid JJ i
levels NNS i
in IN N
children NNS p
to TO N
premature VB N
cardiovascular JJ N
death NN N
in IN N
male JJ p
relatives NNS p
. . p

We PRP N
assessed VBD N
the DT N
relative JJ o
importance NN o
of IN N
lipid JJ o
, , o
apo JJ o
B NNP o
, , o
lipoprotein NN o
( ( o
a DT o
) ) o
[ NN o
Lp NNP o
( ( o
a DT o
) ) o
] NN o
, , o
and CC o
total JJ o
homocysteine NN o
( ( o
tHcy NN o
) ) o
levels NNS o
in IN N
children NNS p
in IN N
relation NN N
to TO N
premature VB N
cardiovascular JJ N
disease NN N
in IN N
family NN p
members NNS p
. . p

Parents NNS p
of IN p
381 CD p
girls NNS p
and CC p
375 CD p
boys NNS p
age NN p
8-12 JJ p
y NN p
completed VBN p
family NN i
history NN i
questionnaires NNS i
. . i

Nonfasting VBG o
serum JJ o
lipid JJ o
and CC o
lipoproteins NNS o
and CC o
plasma NN o
tHcy NN o
and CC o
cysteine NN o
levels NNS o
were VBD N
measured VBN N
in IN N
the DT N
children NNS N
. . N

Serum NNP o
folate NN o
and CC o
vitamin NN o
B12 NNP o
levels NNS o
were VBD N
determined VBN N
in IN N
a DT N
random JJ N
subsample NN N
of IN N
23 CD N
% NN N
of IN N
the DT N
children NNS N
, , N
who WP N
participated VBD N
in IN N
a DT N
food NN N
frequency NN N
interview NN N
. . N

Children NNP N
whose WP$ N
parents NNS N
reported VBD N
hypercholesterolemia NN N
had VBD N
higher JJR N
total JJ o
and CC o
non-HDL JJ o
cholesterol NN o
and CC o
apo NN o
B NNP o
levels NNS o
than IN N
the DT N
rest NN N
, , N
but CC N
these DT N
levels NNS N
were VBD N
not RB N
associated VBN N
with IN N
cardiovascular JJ N
disease NN N
. . N

tHcy NN o
levels NNS o
were VBD N
similar JJ N
in IN N
girls NNS N
and CC N
boys NNS N
. . N

tHcy NN o
was VBD N
higher RBR N
in IN N
children NNS p
whose WP$ N
father NN N
, , N
grandfather NN N
, , N
or CC N
uncle NN N
died VBN N
at IN N
age NN N
< NN N
or CC N
= $ N
55 CD N
y NN N
of IN N
myocardial JJ N
infarction NN N
or CC N
sudden JJ N
cardiac JJ N
arrest NN N
( ( N
n JJ N
= NNP N
42 CD N
) ) N
than IN N
in IN N
control NN N
children NNS N
[ VBP N
5.92 CD N
mumol/L NN N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NNP N
of IN N
5.47-6.36 NNP N
) ) N
versus NN N
5.25 CD N
mumol/L NN N
( ( N
95 CD N
% NN N
CI NNP N
, , N
5.16-5.34 JJ N
) ) N
] NN N
, , N
also RB N
after IN N
adjustment NN N
for IN N
socioeconomic JJ N
group NN N
. . N

Intake NNP o
and CC o
serum NN o
levels NNS o
of IN o
vitamin NN o
B12 NNP o
and CC o
folate NN o
were VBD N
within IN N
recommended VBN N
or CC N
reference NN N
ranges NNS N
. . N

In IN N
a DT N
stepwise NN N
multiple JJ N
regression NN N
analysis NN N
, , N
serum NN o
folate NN o
( ( o
negative JJ o
correlation NN o
) ) o
, , o
plasma JJ o
creatinine NN o
, , o
and CC o
sugar RB o
intake VB o
as IN N
percent NN N
of IN N
dietary JJ N
energy NN N
( ( N
positive JJ N
correlations NNS N
) ) N
were VBD N
significantly RB N
associated VBN N
with IN N
tHcy NN o
( ( N
multiple JJ N
r NN N
= NN N
0.44 CD N
, , N
adjusted VBN N
r2 NN N
= VBZ N
18 CD N
% NN N
; : N
95 CD N
% NN N
CI NNP N
, , N
5-30 JJ N
% NN N
) ) N
. . N

Our PRP$ N
data NNS N
show VBP N
that IN N
a DT N
modest JJ N
elevation NN N
in IN N
tHcy NN o
in IN N
children NNS N
was VBD N
related VBN N
to TO N
premature VB o
cardiovascular JJ o
death NN o
in IN N
their PRP$ N
male NN N
relatives NNS N
and CC N
may MD N
partly RB N
account VB N
for IN N
the DT N
contribution NN N
of IN N
family NN N
history NN N
to TO N
risk NN N
of IN N
cardiovascular JJ N
disease NN N
. . N

tHcy NN o
may MD N
be VB N
modifiable JJ N
through IN N
the DT N
diet NN N
, , N
even RB N
in IN N
children NNS N
with IN N
apparently RB N
adequate JJ N
vitamin JJ N
nutriture NN N
. . N

-DOCSTART- -25760553- O O

A DT N
possible JJ N
link NN N
between IN N
early JJ N
probiotic JJ i
intervention NN i
and CC N
the DT N
risk NN o
of IN o
neuropsychiatric JJ o
disorders NNS o
later RB p
in IN p
childhood NN p
: : p
a DT N
randomized JJ N
trial NN N
. . N

BACKGROUND NNP N
Recent NNP N
experimental JJ N
evidence NN N
suggests VBZ N
that IN N
gut NN N
microbiota NN N
may MD N
alter VB N
function NN N
within IN N
the DT N
nervous JJ N
system NN N
providing VBG N
new JJ N
insight NN N
on IN N
the DT N
mechanism NN N
of IN N
neuropsychiatric JJ N
disorders NNS N
. . N

METHODS NNP N
Seventy-five JJ p
infants NNS p
who WP p
were VBD p
randomized VBN p
to TO p
receive VB p
Lactobacillus NNP i
rhamnosus NN i
GG NNP i
( ( i
ATCC NNP i
53103 CD i
) ) i
or CC i
placebo NN i
during IN p
the DT p
first JJ p
6 CD p
mo NN p
of IN p
life NN p
were VBD p
followed-up JJ p
for IN p
13 CD p
y NN p
. . p

Gut NNP o
microbiota NN o
was VBD N
assessed VBN N
at IN N
the DT N
age NN N
of IN N
3 CD N
wk NN N
, , N
3 CD N
, , N
6 CD N
, , N
12 CD N
, , N
18 CD N
, , N
24 CD N
mo NN N
, , N
and CC N
13 CD N
y NN N
using VBG i
fluorescein NN i
in IN i
situ JJ i
hybridization NN i
( ( i
FISH NNP N
) ) N
and CC N
qPCR $ N
, , N
and CC N
indirectly RB N
by IN N
determining VBG N
the DT o
blood NN o
group NN o
secretor NN o
type NN o
at IN o
the DT N
age NN N
of IN N
13 CD N
y NN N
. . N

The DT N
diagnoses NNS N
of IN N
attention NN o
deficit NN o
hyperactivity NN o
disorder NN o
( ( o
ADHD NNP o
) ) o
and CC o
Asperger NNP o
syndrome VBP o
( ( o
AS IN o
) ) o
by IN o
a DT N
child JJ N
neurologist NN N
or CC N
psychiatrist NN N
were VBD N
based VBN N
on IN N
ICD-10 NNP N
diagnostic JJ N
criteria NNS N
. . N

RESULTS NN N
At IN N
the DT N
age NN N
of IN N
13 CD N
y NNS N
, , N
ADHD NNP o
or CC o
AS NNP o
was VBD o
diagnosed VBN N
in IN N
6/35 CD N
( ( N
17.1 CD N
% NN N
) ) N
children NNS N
in IN N
the DT N
placebo NN N
and CC N
none NN N
in IN N
the DT N
probiotic JJ N
group NN N
( ( N
P NNP N
= NNP N
0.008 CD N
) ) N
. . N

The DT o
mean NN o
( ( o
SD NNP o
) ) o
numbers NNS o
of IN o
Bifidobacterium NNP o
species NNS o
bacteria VBP o
in IN o
feces NNS o
during IN o
the DT o
first JJ o
6 CD o
mo NN o
of IN o
life NN o
was VBD o
lower JJR N
in IN N
affected JJ N
children NNS N
8.26 CD N
( ( N
1.24 CD N
) ) N
log NN N
cells/g NN N
than IN N
in IN N
healthy JJ N
children NNS N
9.12 CD N
( ( N
0.64 CD N
) ) N
log NN N
cells/g NN N
; : N
P NNP N
= VBD N
0.03 CD N
. . N

CONCLUSION NNP i
Probiotic NNP i
supplementation NN i
early RB i
in IN N
life NN N
may MD N
reduce VB N
the DT o
risk NN o
of IN o
neuropsychiatric JJ o
disorder NN o
development NN o
later RB o
in IN p
childhood NN p
possible JJ p
by IN N
mechanisms NNS N
not RB N
limited VBN N
to TO N
gut VB N
microbiota JJ N
composition NN N
. . N

-DOCSTART- -11041498- O O

An DT N
evaluation NN N
of IN N
chemical JJ N
arthrodesis NN N
of IN N
the DT N
proximal JJ p
interphalangeal NN p
joint NN p
in IN p
the DT p
horse NN p
by IN N
using VBG N
monoiodoacetate NN i
. . i

The DT N
use NN N
of IN N
monoiodoacetate NN i
( ( i
MIA NNP i
) ) i
for IN N
arthrodesis NN N
of IN N
the DT N
proximal JJ N
interphalangeal NN N
joint NN N
( ( N
PIJ NNP N
) ) N
and CC N
the DT N
effect NN N
of IN N
exercise NN N
on IN N
the DT N
degree NN N
of IN N
fusion NN N
were VBD N
investigated VBN N
. . N

Eight JJ p
horses NNS p
received VBD N
3 CD N
injections NNS N
( ( N
Weeks NNP N
0 CD N
, , N
3 CD N
, , N
6 CD N
) ) N
of IN N
MIA NNP i
( ( N
2 CD N
mL NN N
; : N
60 CD N
mg/mL NN N
) ) N
into IN N
the DT N
right NN N
or CC N
left VBD N
front JJ N
PIJ NNP N
. . N

Peri-operatively RB N
, , N
the DT N
horses NNS N
received VBD N
phenylbutazone NN i
, , i
butorphanol NN i
, , i
and CC i
abaxial JJ i
sesamoidean NN i
nerve NN i
blocks NNS i
to TO N
relieve VB N
pain NN N
. . N

During IN N
the DT N
study NN N
, , N
the DT N
horses NNS N
were VBD N
monitored VBN N
for IN N
general JJ N
health NN N
, , N
lameness NN N
, , N
and CC N
swelling VBG N
around IN N
the DT N
injection NN N
area NN N
. . N

Radiographs NNP N
were VBD N
taken VBN N
biweekly RB N
to TO N
evaluate VB N
bony NN N
fusion NN N
. . N

Horses NNS N
were VBD N
randomly RB N
divided VBN N
into IN N
non-exercised JJ i
and CC N
exercised JJ i
groups NNS N
. . N

Exercise NNP i
consisted VBD N
of IN N
20 CD N
minutes NNS N
of IN N
trotting VBG N
on IN N
a DT N
treadmill NN N
( ( N
4 CD N
m/s NN N
) ) N
, , N
3 CD N
days NNS N
per IN N
week NN N
for IN N
13 CD N
weeks NNS N
. . N

The DT N
horses NNS N
were VBD N
euthanized VBN N
at IN N
24 CD N
weeks NNS N
. . N

Slab NNP N
sections NNS N
of IN N
the DT N
PIJ NNP N
were VBD N
evaluated VBN N
grossly RB N
and CC N
radiographically RB N
for IN N
bony NN N
fusion NN N
. . N

Histologic JJ N
examinations NNS N
were VBD N
performed VBN N
to TO N
evaluate VB N
articular JJ N
cartilage NN N
. . N

Three CD N
horses NNS N
were VBD N
excluded VBN N
from IN N
the DT N
study NN N
after IN N
developing VBG N
soft JJ N
tissue NN N
necrosis NN N
around IN N
the DT N
injection NN N
site NN N
, , N
septic JJ N
arthritis NN N
, , N
and CC N
necrotic JJ N
tendinitis NN N
. . N

The DT N
remaining VBG N
horses NNS N
remained VBD N
healthy JJ N
, , N
developed VBD N
a DT N
grade NN N
1 CD N
to TO N
4 CD N
lameness NN N
with IN N
minimal JJ N
to TO N
severe VB N
swelling VBG N
in IN N
the DT N
PIJ NNP N
region NN N
. . N

All DT o
5 CD o
horses NNS o
showed VBD o
radiographic JJ o
evidence NN o
of IN o
bony NN o
fusion NN o
, , o
however RB o
, , o
no DT o
fusion NN o
was VBD o
present JJ o
when WRB o
injected JJ o
joints NNS o
were VBD o
examined VBN o
on IN o
postmortem NN o
examination NN o
. . o

Histologic NNP o
examination NN o
revealed VBD o
thinning NN o
of IN o
the DT o
cartilage NN o
, , o
diffuse VBP o
necrosis NN o
of IN o
chondrocytes NNS o
, , o
with IN o
the DT o
calcified JJ o
zone NN o
intact JJ o
. . o

Subjectively RB o
, , o
exercise NN o
did VBD o
not RB o
influence VB o
the DT o
degree NN o
of IN o
cartilage NN o
destruction NN o
. . o

Based VBN o
on IN o
this DT o
study NN o
, , o
chemical JJ o
arthrodesis NN o
can MD o
not RB o
be VB o
advocated VBN o
in IN o
clinical JJ o
cases NNS o
because IN o
of IN o
the DT o
high JJ o
complication NN o
rate NN o
and CC o
lack NN o
of IN o
bony NN o
fusion NN o
. . o

-DOCSTART- -22221670- O O

Randomised VBN N
controlled JJ N
trial NN N
of IN N
improvisational JJ i
music NN i
therapy NN i
's POS i
effectiveness NN o
for IN N
children NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
( ( N
TIME-A NNP N
) ) N
: : N
study NN N
protocol NN N
. . N

BACKGROUND NNP N
Previous NNP N
research NN N
has VBZ N
suggested VBN N
that IN N
music NN i
therapy NN i
may MD N
facilitate VB N
skills NNS o
in IN N
areas NNS N
typically RB N
affected VBN N
by IN N
autism NN p
spectrum NN p
disorders NNS p
such JJ N
as IN N
social JJ o
interaction NN o
and CC o
communication NN o
. . o

However RB N
, , N
generalisability NN N
of IN N
previous JJ N
findings NNS N
has VBZ N
been VBN N
restricted VBN N
, , N
as IN N
studies NNS N
were VBD N
limited VBN N
in IN N
either DT N
methodological JJ N
accuracy NN N
or CC N
the DT N
clinical JJ N
relevance NN N
of IN N
their PRP$ N
approach NN N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
is VBZ N
to TO N
determine VB N
effects NNS N
of IN N
improvisational JJ i
music NN i
therapy NN i
on IN N
social JJ o
communication NN o
skills NNS o
of IN N
children NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
. . p

An DT N
additional JJ N
aim NN N
of IN N
the DT N
study NN N
is VBZ N
to TO N
examine VB N
if IN N
variation NN N
in IN N
dose NN N
of IN N
treatment NN N
( ( N
i.e. FW N
, , N
number NN N
of IN N
music NN i
therapy NN i
sessions NNS N
per IN N
week NN N
) ) N
affects VBZ N
outcome NN o
of IN o
therapy NN o
, , N
and CC N
to TO N
determine VB N
cost-effectiveness NN o
. . o

METHODS/DESIGN NNP N
Children NNP p
aged VBD p
between IN p
4 CD p
; : p
0 CD p
and CC p
6 CD p
; : p
11 CD p
years NNS p
who WP p
are VBP p
diagnosed VBN p
with IN p
autism NN p
spectrum NN p
disorder NN p
will MD N
be VB N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
three CD N
conditions NNS N
. . N

Parents NNS p
of IN p
all DT p
participants NNS p
will MD N
receive VB N
three CD i
sessions NNS i
of IN i
parent NN i
counselling NN i
( ( N
at IN N
0 CD N
, , N
2 CD N
, , N
and CC N
5 CD N
months NNS N
) ) N
. . N

In IN N
addition NN N
, , N
children NNS N
randomised VBD N
to TO N
the DT N
two CD N
intervention NN N
groups NNS N
will MD N
be VB N
offered VBN N
individual JJ i
, , i
improvisational JJ i
music NN i
therapy NN i
over IN N
a DT N
period NN N
of IN N
five CD N
months NNS N
, , N
either RB N
one CD N
session NN N
( ( N
low-intensity NN N
) ) N
or CC N
three CD N
sessions NNS N
( ( N
high-intensity NN N
) ) N
per IN N
week NN N
. . N

Generalised JJ N
effects NNS N
of IN N
music NN i
therapy NN i
will MD N
be VB N
measured VBN N
using VBG N
standardised JJ o
scales NNS o
completed VBN N
by IN N
blinded JJ N
assessors NNS N
( ( o
Autism NNP o
Diagnostic NNP o
Observation NNP o
Schedule NNP o
, , o
ADOS NNP o
) ) o
and CC o
parents NNS o
( ( o
Social NNP o
Responsiveness NNP o
Scale NNP o
, , o
SRS NNP o
) ) o
before IN N
and CC N
2 CD N
, , N
5 CD N
, , N
and CC N
12 CD N
months NNS N
after IN N
randomisation NN N
. . N

Cost NNP o
effectiveness NN o
will MD N
be VB N
calculated VBN N
as IN N
man NN N
years NNS N
. . N

A DT N
group NN N
sequential JJ N
design NN N
with IN N
first JJ N
interim JJ N
look NN N
at IN N
N NNP N
= NNP N
235 CD N
will MD N
ensure VB N
both DT N
power NN N
and CC N
efficiency NN N
. . N

DISCUSSION NNP N
Responding VBG N
to TO N
the DT N
need NN N
for IN N
more RBR N
rigorously RB N
designed VBN N
trials NNS N
examining VBG N
the DT N
effectiveness NN N
of IN N
music NN i
therapy NN i
in IN N
autism NN p
spectrum NN p
disorders NNS p
, , N
this DT N
pragmatic JJ N
trial NN N
sets NNS N
out RP N
to TO N
generate VB N
findings NNS N
that WDT N
will MD N
be VB N
well RB N
generalisable JJ N
to TO N
clinical JJ N
practice NN N
. . N

Addressing VBG N
the DT N
issue NN N
of IN N
dose JJ N
variation NN N
, , N
this DT N
study NN N
's POS N
results NNS N
will MD N
also RB N
provide VB N
information NN N
on IN N
the DT N
relevance NN N
of IN N
session NN o
frequency NN o
for IN N
therapy NN o
outcome NN o
. . o

TRIAL NNP N
REGISTRATION NNP N
Current NNP N
Controlled NNP N
Trials NNP N
ISRCTN78923965 NNP N
. . N

-DOCSTART- -24526141- O O

Non-contrast-enhanced JJ i
4D CD i
MR NNP i
angiography NN i
with IN N
STAR NNP N
spin NN N
labeling NN N
and CC N
variable JJ N
flip NN N
angle NN N
sampling NN N
: : N
a DT N
feasibility NN N
study NN N
for IN N
the DT N
assessment NN N
of IN N
Dural NNP p
Arteriovenous NNP p
Fistula NNP p
. . p

INTRODUCTION NNP N
This DT N
study NN N
aimed VBD N
to TO N
evaluate VB N
the DT N
feasibility NN N
of IN N
non-contrast-enhanced JJ N
4D CD N
magnetic JJ N
resonance NN N
angiography NN N
( ( N
NCE NNP N
4D CD N
MRA NNP N
) ) N
with IN N
signal JJ N
targeting VBG N
with IN N
alternative JJ N
radiofrequency NN N
( ( N
STAR NNP N
) ) N
spin NN N
labeling NN N
and CC N
variable JJ N
flip NN N
angle NN N
( ( N
VFA NNP N
) ) N
sampling NN N
in IN N
the DT N
assessment NN N
of IN N
dural JJ p
arteriovenous JJ p
fistula NN p
( ( p
DAVF NNP p
) ) p
in IN p
the DT p
transverse NN p
sinus NN p
. . p

METHODS NNP N
Nine NNP p
patients NNS p
underwent JJ p
NCE NNP i
4D CD i
MRA NNP i
for IN N
the DT N
evaluation NN N
of IN N
DAVF NNP N
in IN N
the DT N
transverse NN N
sinus NN N
at IN N
3 CD N
T. NNP N
One CD N
patient NN N
was VBD N
examined VBN N
twice RB N
, , N
once RB N
before IN N
and CC N
once RB N
after IN N
the DT N
interventional JJ N
treatment NN N
. . N

All DT p
patients NNS p
also RB p
underwent JJ i
digital JJ i
subtraction NN i
angiography NN i
( ( p
DSA NNP p
) ) p
and/or VBD i
contrast-enhanced JJ i
magnetic JJ i
resonance NN i
angiography NN i
( ( N
CEMRA NNP N
) ) N
. . N

For IN N
the DT N
acquisition NN N
of IN N
NCE NNP N
4D CD N
MRA NNP N
, , N
a DT N
STAR NNP N
spin NN N
tagging VBG N
method NN N
was VBD N
used VBN N
, , N
and CC N
a DT N
VFA NNP N
sampling NN N
was VBD N
applied VBN N
in IN N
the DT N
data NNS N
readout NN N
module NN N
instead RB N
of IN N
a DT N
constant JJ N
flip NN N
angle NN N
. . N

Two CD N
readers NNS N
evaluated VBD N
the DT N
NCE NNP N
4D CD N
MRA NNP N
data NNS N
for IN N
the DT N
diagnosis NN N
of IN N
DAVF NNP N
and CC N
its PRP$ N
type NN N
with IN N
consensus NN N
. . N

The DT N
results NNS N
were VBD N
compared VBN N
with IN N
those DT N
from IN N
DSA NNP N
and/or NN N
CEMRA NNP N
. . N

RESULTS NNP N
All NNP N
patients NNS o
underwent JJ o
NCE NNP i
4D CD i
MRA NNP o
without IN o
any DT o
difficulty NN o
. . o

Among IN p
seven CD p
patients NNS p
with IN p
patent NN p
DAVFs NNP p
, , p
all DT N
cases NNS N
showed VBD N
an DT o
early JJ o
visualization NN o
of IN o
the DT o
transverse JJ o
sinus NN o
on IN i
NCE NNP i
4D CD i
MRA NNP i
. . i

Except IN N
for IN N
one CD N
case NN N
, , N
the DT N
type NN N
of IN N
DAVF NNP N
of IN i
NCE NNP i
4D CD i
MRA NNP i
was VBD N
agreed VBN N
with IN N
that DT N
of IN N
reference NN N
standard NN N
study NN N
. . N

Cortical NNP o
venous JJ o
reflux NN o
( ( o
CVR NNP o
) ) o
was VBD N
demonstrated VBN N
in IN N
two CD N
cases NNS N
out IN N
of IN p
three CD p
patients NNS p
with IN p
CVR NNP p
. . p

CONCLUSION NNP N
NCE NNP N
4D CD N
MRA NNP N
with IN N
STAR NNP N
tagging VBG N
and CC N
VFA NNP N
sampling NN N
is VBZ N
technically RB N
and CC N
clinically RB N
feasible JJ N
and CC N
represents VBZ N
a DT N
promising NN N
technique NN N
for IN N
assessment NN N
of IN N
DAVF NNP N
in IN N
the DT N
transverse NN N
sinus NN N
. . N

Further NNP N
technical JJ N
developments NNS N
should MD N
aim VB N
at IN N
improvements NNS N
of IN N
spatial JJ N
and CC N
temporal JJ N
coverage NN N
. . N

-DOCSTART- -16197624- O O

Safety NN o
and CC N
efficacy NN o
of IN N
irinotecan JJ i
plus CC i
high-dose JJ i
leucovorin NN i
and CC N
intravenous JJ N
bolus JJ N
5-fluorouracil JJ i
for IN N
metastatic JJ p
colorectal JJ p
cancer NN p
: : p
pooled VBN N
analysis NN N
of IN N
two CD N
consecutive JJ N
southern JJ p
Italy NNP p
cooperative JJ p
oncology NN p
group NN p
trials NNS p
. . p

BACKGROUND VB N
A DT N
biweekly JJ N
regimen NN N
of IN N
irinotecan JJ i
200 CD N
mg/m2 NN N
on IN N
day NN N
1 CD N
and CC N
levo-leucovorin JJ i
( ( i
LV NNP i
) ) i
250 CD N
mg/m2 JJ N
plus CC N
5-fluorouracil JJ i
( ( i
5-FU JJ i
) ) i
850 CD N
mg/m2 NN N
via IN N
intravenous JJ N
bolus NNS N
on IN N
day NN N
2 CD N
was VBD N
assessed VBN N
in IN N
2 CD N
consecutive JJ N
randomized VBN N
trials NNS N
in IN N
metastatic JJ p
colorectal NN p
cancer NN p
( ( p
CRC NNP p
) ) p
. . p

PATIENTS NNP N
AND CC N
METHODS NNP N
Individual NNP N
data NN N
of IN N
254 CD p
patients NNS p
were VBD N
merged VBN N
, , N
and CC N
baseline NN N
features NNS N
potentially RB N
affecting VBG N
overall JJ o
response NN o
rate NN o
( ( o
ORR NNP o
) ) o
, , o
progression-free JJ o
survival NN o
( ( o
PFS NNP o
) ) o
, , o
overall JJ o
survival NN o
( ( o
OS NNP o
) ) o
, , o
and CC o
occurrence NN o
of IN o
severe JJ o
toxicity NN o
were VBD N
analyzed VBN N
by IN N
univariate JJ N
and CC N
multivariate JJ N
analyses NNS N
. . N

RESULTS NNP N
In IN N
the DT N
pooled JJ N
series NN N
, , N
ORR NNP o
was VBD N
33 CD N
% NN N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NNP N
, , N
27 CD N
% NN N
-39 NNP N
% NN N
) ) N
. . N

Liver-only JJ N
disease NN N
( ( N
47 CD N
% NN N
vs. FW N
25 CD N
% NN N
; : N
P=0.0012 NNP N
) ) N
and CC N
absence NN N
of IN N
previous JJ N
weight JJ N
loss NN N
( ( N
38 CD N
% NN N
vs. FW N
20 CD N
% NN N
; : N
P=0.0189 NNP N
) ) N
were VBD N
significantly RB N
associated VBN N
with IN N
a DT N
higher JJR N
ORR NN N
on IN N
the DT N
multivariate NN N
analysis NN N
. . N

Absence NN N
of IN N
weight JJ o
loss NN o
( ( N
hazard JJ N
ratio NN N
, , N
1.40 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
1.02-1.93 JJ N
; : N
P=0.0377 NNP N
) ) N
was VBD N
significantly RB N
associated VBN N
with IN N
a DT N
longer RBR N
PFS NNP N
( ( N
7.5 CD N
months NNS N
vs. IN N
6 CD N
months NNS N
) ) N
. . N

Median JJ o
OS NNP o
was VBD N
15.1 CD N
months NNS N
( ( N
95 CD N
% NN N
CI NNP N
, , N
13.5-16.6 JJ N
months NNS N
) ) N
. . N

Primary JJ N
surgery NN N
, , N
good JJ N
performance NN N
status NN N
( ( N
PS NNP N
) ) N
, , N
only RB N
one CD N
metastatic JJ N
site NN N
, , N
and CC N
oxaliplatin-based JJ N
second-line JJ N
treatment NN N
independently RB N
predicted VBD N
a DT N
longer RBR o
OS NNP o
. . o

Grade VB o
4 CD o
neutropenia NN o
was VBD N
significantly RB N
associated VBN N
with IN N
a DT N
PS NNP N
> NNP N
or=1 NN N
, , N
whereas JJ N
risk NN N
of IN N
grade NN N
> NNP N
or=3 NN N
diarrhea NN o
was VBD N
directly RB N
related VBN N
to TO N
age NN N
and CC N
previous JJ N
weight NN N
loss NN N
. . N

CONCLUSION JJ N
Patients NNS N
with IN N
no DT N
weight JJ N
loss NN N
and/or NN N
preserved VBD N
PS NNP N
and CC N
with IN N
a DT N
limited JJ N
disease NN N
extent NN N
appeared VBD N
to TO N
obtain VB N
the DT N
greatest JJS N
benefit NN N
from IN N
our PRP$ N
irinotecan/5-FU/LV JJ i
regimen NNS N
, , N
with IN N
acceptable JJ N
toxicity NN N
. . N

Notably RB N
, , N
the DT N
regimen NNS N
was VBD N
effective JJ N
and CC N
well RB N
tolerated VBN N
by IN N
elderly JJ p
patients NNS p
. . p

This DT N
regimen NN N
may MD N
represent VB N
the DT N
rationale NN N
for IN N
assessing VBG N
the DT N
addition NN N
of IN N
novel JJ N
antiangiogenic JJ N
drugs NNS N
to TO N
the DT N
treatment NN N
of IN N
metastatic JJ N
CRC NNP N
. . N

-DOCSTART- -24424141- O O

A DT N
comparison NN N
of IN N
the DT N
effectiveness NN N
of IN N
treating VBG N
those DT p
with IN p
and CC p
without IN p
the DT p
complications NNS p
of IN p
superficial JJ p
venous JJ p
insufficiency NN p
. . p

OBJECTIVE UH N
To TO N
test VB N
the DT N
hypothesis NN N
that IN N
patients NNS p
with IN p
soft JJ p
tissue NN p
changes NNS p
related VBN p
to TO p
superficial JJ o
venous JJ o
insufficiency NN o
( ( p
SVI NNP p
) ) p
have VBP N
greater JJR N
benefits NNS N
from IN N
treatment NN N
than IN N
those DT p
with IN p
only RB p
symptomatic JJ p
varicose NN p
veins NNS p
. . p

BACKGROUND VB N
A NNP N
commonly RB N
held VBD N
view NN N
is VBZ N
that IN N
SVI NNP p
is VBZ N
only RB N
a DT N
minor JJ N
ailment NN N
, , N
yet RB N
randomized VBN N
clinical JJ N
trials NNS N
( ( N
RCTs NNP N
) ) N
show VBP N
that IN N
treatment NN N
improves VBZ N
quality NN o
of IN o
life NN o
( ( o
QoL NNP o
) ) o
and CC N
is VBZ N
cost-effective JJ N
. . N

In IN N
an DT N
effort NN N
to TO N
curb VB N
the DT N
treatment NN N
costs NNS N
of IN N
this DT N
common JJ N
disorder NN N
, , N
rationing VBG N
is VBZ N
applied VBN N
in IN N
many JJ N
health NN N
care NN N
systems NNS N
, , N
often RB N
limiting VBG N
the DT N
reimbursement NN N
of IN N
treatment NN N
to TO N
those DT N
with IN N
soft JJ N
tissue NN N
changes NNS N
. . N

METHODS NNP N
This DT N
cohort NN N
study NN N
draws VBZ N
its PRP$ N
data NN N
from IN N
an DT N
interventional JJ i
RCT NNP i
. . i

After IN N
informed JJ N
consent NN N
, , N
consecutive JJ p
patients NNS p
with IN p
symptomatic JJ p
unilateral JJ p
SVI NNP p
were VBD N
randomized VBN N
to TO N
receive VB i
surgical JJ o
ligation NN o
and CC o
stripping NN o
or CC o
endovenous JJ o
laser NN o
ablation NN o
. . o

This DT N
analysis NN N
differentially RB N
studies NNS N
the DT N
outcomes NNS N
of IN N
patients NNS p
with IN p
simple JJ p
varicose JJ p
veins NNS p
( ( p
C2 NNP p
: : p
n JJ p
= NNP p
191 CD p
) ) p
and CC p
soft JJ p
tissue NN p
complications NNS p
( ( p
C3-4 JJ p
: : p
n JJ p
= NNP p
76 CD p
) ) p
. . p

Effectiveness NNP N
outcomes RB N
measured VBD N
up RB N
to TO N
1 CD N
year NN N
included VBD N
the DT N
following NN N
: : N
Qol NNP o
[ NNP o
short JJ o
form NN o
36 CD o
( ( o
SF36 NNP o
) ) o
, , o
EuroQol NNP o
, , o
and CC o
the DT o
Aberdeen NNP o
Varicose NNP o
Veins NNP o
Questionnaire NNP o
] NNP o
, , o
clinical JJ o
recurrence NN o
, , N
and CC N
the DT N
need NN N
for IN N
secondary JJ N
procedures NNS N
. . N

Multivariable JJ N
regression NN N
analysis NN N
was VBD N
used VBN N
to TO N
control VB N
for IN N
potential JJ N
confounding NN N
factors NNS N
. . N

RESULTS NNP N
Both NNP N
groups NNS N
saw VBD N
significant JJ N
improvements NNS N
in IN N
QoL NNP o
. . o

All DT N
improvements NNS N
were VBD N
equal JJ N
between IN N
groups NNS N
apart RB N
from IN N
the DT N
SF36 NNP N
domain NN N
of IN N
Bodily NNP o
Pain NNP N
, , N
where WRB N
C2 NNP N
saw VBD N
an DT N
improvement NN N
of IN N
12.8 CD N
[ JJ N
95 CD N
% NN N
confidence NN N
interval NN N
( ( N
CI NNP N
) ) N
: : N
4.8-20.8 JJ N
] NN N
points NNS N
over IN N
C3-4 JJ N
participants NNS N
( ( N
P NNP N
= NNP N
0.002 CD N
) ) N
, , N
who WP N
also RB N
suffered VBD N
more JJR N
recurrence NN N
[ NNP N
odds NNS N
ratio NN N
( ( N
OR NNP N
) ) N
= VBZ N
2.7 CD N
, , N
95 CD N
% NN N
CI NNP N
: : N
1.2-6.1 JJ N
, , N
P NNP N
= VBZ N
0.022 CD N
] NN N
and CC N
required VBD N
more JJR N
secondary JJ N
procedures NNS N
( ( N
OR NNP N
= VBZ N
4.4 CD N
, , N
95 CD N
% NN N
CI NNP N
: : N
1.2-16.3 JJ N
, , N
P NNP N
= NNP N
0.028 CD N
) ) N
. . N

CONCLUSIONS VB N
This DT N
study NN N
suggests VBZ N
that IN N
rationing VBG N
by IN N
clinical JJ N
severity NN N
contradicts VBZ N
the DT N
evidence NN N
. . N

Delaying VBG N
treatment NN N
until IN N
the DT N
development NN N
of IN N
skin JJ N
damage NN N
leads VBZ N
to TO N
a DT N
degree NN N
of IN N
irreversible JJ N
morbidity NN N
and CC N
greater JJR N
recurrence NN N
. . N

TRIAL NNP N
REGISTRATION NNP N
NCT00759434 NNP N
Clinicaltrials.gov NNP N
. . N

-DOCSTART- -21098003- O O

Plasma NNP N
pH NN N
does VBZ N
not RB N
influence VB N
the DT N
cerebral JJ p
metabolic JJ p
ratio NN p
during IN p
maximal JJ p
whole JJ p
body NN p
exercise NN p
. . p

Exercise NN N
lowers VBZ N
the DT N
cerebral JJ N
metabolic JJ N
ratio NN N
of IN N
O2 NNP N
to TO N
carbohydrate VB N
( ( N
glucose+1/2 JJ N
lactate NN N
) ) N
and CC N
metabolic JJ N
acidosis NN N
appears VBZ N
to TO N
promote VB o
cerebral JJ o
lactate JJ o
uptake NN o
. . o

However RB N
, , N
the DT N
influence NN N
of IN N
pH NN N
on IN N
cerebral JJ N
lactate JJ N
uptake NN N
and CC N
, , N
in IN N
turn NN N
, , N
on IN N
the DT N
cerebral JJ N
metabolic JJ N
ratio NN N
during IN N
exercise NN N
is VBZ N
not RB N
known VBN N
. . N

Sodium NN i
bicarbonate NN i
( ( i
Bicarb NNP i
, , i
1 CD i
M NNP i
; : i
350-500 CD i
ml NN i
) ) i
or CC i
an DT i
equal JJ i
volume NN i
of IN i
normal JJ i
saline NN i
( ( i
Sal NNP i
) ) i
was VBD i
infused VBN i
intravenously RB i
at IN i
a DT i
constant JJ i
rate NN i
during IN i
a DT i
'2000 CD i
m NN i
' '' i
maximal JJ i
ergometer NN i
row NN i
in IN N
six CD p
male JJ p
oarsmen NNS p
( ( p
23?2 CD p
years NNS p
; : p
mean?S.D. NN p
) ) p
. . p

During IN N
the DT N
Sal NNP N
trial NN o
, , o
pH NN o
decreased VBD o
from IN N
7.41?0.01 CD N
at IN N
rest NN N
to TO N
7.02?0.02 CD N
but CC N
only RB N
to TO N
7.36?0.02 CD N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
during IN N
the DT N
Bicarb NNP N
trial NN N
. . o

Arterial JJ o
lactate NN o
increased VBD o
to TO N
21.4?0.8 CD N
and CC N
32.7?2.3 CD N
mM NN N
during IN N
the DT N
Sal NNP N
and CC N
Bicarb NNP N
trials NNS N
, , N
respectively RB N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

Also RB N
, , N
the DT o
arterial-jugular JJ o
venous JJ o
lactate NN o
difference NN o
increased VBD N
from-0.03?0.01 JJ N
mM NN N
at IN N
rest NN N
to TO N
3.2?0.9 CD N
mM NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
and CC N
3.4?1.4 CD N
mM NN N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
following VBG N
the DT N
Sal NNP N
and CC N
Bicarb NNP N
trials NNS N
, , N
respectively RB N
. . N

Accordingly RB o
, , o
the DT o
cerebral JJ o
metabolic NN o
ratio NN o
decreased VBD o
equally RB N
during IN N
the DT N
Sal NNP N
and CC N
Bicarb NNP N
trials NNS N
: : N
from IN N
5.8?0.6 CD N
at IN N
rest NN N
to TO N
1.7?0.1 CD N
and CC N
1.8?0.2 CD N
, , N
respectively RB N
. . N

The DT o
enlarged JJ o
blood-buffering NN o
capacity NN o
after IN o
infusion NN i
of IN i
Bicarb NNP i
eliminated VBD o
metabolic JJ o
acidosis NN o
during IN o
maximal JJ N
exercise NN N
but CC N
that DT N
did VBD N
not RB N
affect VB N
the DT o
cerebral JJ o
lactate NN o
uptake NN o
and CC o
, , o
therefore RB N
, , N
the DT N
decrease NN N
in IN N
the DT o
cerebral JJ o
metabolic NN o
ratio NN o
. . o

-DOCSTART- -17365975- O O

The DT N
NORwegian JJ N
study NN N
on IN N
DIstrict NNP N
treatment NN N
of IN N
ST-elevation NNP p
myocardial JJ p
infarction NN p
( ( N
NORDISTEMI NNP N
) ) N
. . N

OBJECTIVES NNP N
Thrombolysis NNP N
is VBZ N
the DT N
treatment NN N
of IN N
choice NN N
for IN N
patients NNS p
with IN p
ST-elevation NNP p
myocardial JJ p
infarction NN p
( ( p
STEMI NNP p
) ) p
living NN p
in IN p
rural JJ p
areas NNS p
with IN p
long JJ p
transfer NN p
delays NNS p
to TO p
percutaneous JJ p
coronary JJ p
intervention NN p
( ( p
PCI NNP p
) ) p
. . p

This DT N
trial NN N
compares VBZ N
two CD N
different JJ N
strategies NNS N
following VBG N
thrombolysis NN N
: : N
to TO N
transfer VB N
all DT N
patients NNS N
for IN N
immediate JJ N
coronary JJ N
angiography NN N
and CC N
intervention NN N
, , N
or CC N
to TO N
manage VB N
the DT N
patients NNS N
more RBR N
conservatively RB N
. . N

DESIGN VB N
The DT p
NORwegian JJ p
study NN p
on IN p
DIstrict NNP p
treatment NN p
of IN p
STEMI NNP p
( ( p
NORDISTEMI NNP p
) ) p
is VBZ N
an DT N
open JJ N
, , N
prospective JJ N
, , N
randomized VBD i
controlled VBN i
trial NN i
in IN i
patients NNS i
with IN i
STEMI NNP i
of IN i
less JJR i
than IN i
6 CD i
hours NNS i
of IN i
duration NN i
and CC i
more JJR i
than IN i
90 CD i
minutes NNS i
expected VBD i
time NN i
delay NN i
to TO i
PCI NNP i
. . i

A NNP p
total NN p
of IN p
266 CD p
patients NNS p
will MD N
receive VB i
full-dose JJ i
thrombolysis NN i
, , i
preferably RB i
pre-hospital JJ i
, , i
and CC i
then RB i
be VB i
randomized VBN i
to TO i
either DT i
strategy NN i
. . i

Our PRP$ N
primary JJ N
endpoint NN N
is VBZ N
the DT N
one CD N
year NN N
combined VBN o
incidence NN o
of IN o
death NN o
, , o
reinfarction NN o
, , o
stroke VBD o
or CC o
new JJ o
myocardial JJ o
ischaemia NN o
. . o

The DT N
study NN N
is VBZ N
registered VBN N
with IN N
ClinicalTrials.gov NNP N
, , N
number NN N
NCT00161005 NNP N
. . N

RESULTS VBN N
By IN N
April NNP p
2006 CD p
, , p
109 CD p
patients NNS p
have VBP N
been VBN N
randomized VBN N
. . N

Thrombolysis NN N
has VBZ N
been VBN N
given VBN N
pre-hospital JJ N
to TO N
52 CD N
% NN N
of IN N
patients NNS N
. . N

The DT N
median JJ N
transport NN N
distance NN N
from IN N
first JJ N
medical JJ N
contact NN N
to TO N
catheterization NN N
laboratory NN N
was VBD N
155 CD N
km NN N
( ( N
range JJ N
90-396 CD N
km NN N
) ) N
. . N

Results NNS N
of IN N
the DT N
study NN N
are VBP N
expected VBN N
in IN N
2008 CD N
. . N

-DOCSTART- -20100962- O O

Pazopanib NNP i
in IN N
locally RB p
advanced JJ p
or CC p
metastatic JJ p
renal NN p
cell NN p
carcinoma NN p
: : p
results NNS N
of IN N
a DT N
randomized JJ N
phase NN N
III NNP N
trial NN N
. . N

PURPOSE NNP N
Pazopanib NNP i
is VBZ N
an DT N
oral JJ i
angiogenesis NN i
inhibitor NN i
targeting VBG N
vascular JJ N
endothelial JJ N
growth NN N
factor NN N
receptor NN N
, , N
platelet-derived JJ N
growth NN N
factor NN N
receptor NN N
, , N
and CC N
c-Kit NN N
. . N

This DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
phase NN N
III NNP N
study NN N
evaluated VBD N
efficacy NN N
and CC N
safety NN N
of IN N
pazopanib JJ i
monotherapy NN i
in IN N
treatment-naive JJ p
and CC p
cytokine-pretreated JJ i
patients NNS p
with IN p
advanced JJ p
renal JJ p
cell NN p
carcinoma NN p
( ( p
RCC NNP p
) ) p
. . p

PATIENTS NNP N
AND CC N
METHODS NNP N
Adult NNP p
patients NNS p
with IN p
measurable JJ p
, , p
locally RB p
advanced JJ p
, , p
and/or JJ p
metastatic JJ p
RCC NNP p
were VBD N
randomly RB N
assigned VBN N
2:1 CD N
to TO N
receive VB i
oral JJ i
pazopanib NN i
or CC i
placebo NN i
. . i

The DT N
primary JJ N
end NN N
point NN N
was VBD N
progression-free JJ o
survival NN o
( ( o
PFS NNP o
) ) o
. . o

Secondary JJ N
end NN N
points NNS N
included VBD N
overall JJ o
survival NN o
, , o
tumor NN o
response NN o
rate NN o
( ( o
Response NNP o
Evaluation NNP o
Criteria NNP o
in IN o
Solid NNP o
Tumors NNP o
) ) o
, , o
and CC o
safety NN o
. . o

Radiographic JJ N
assessments NNS N
of IN N
tumors NNS N
were VBD N
independently RB N
reviewed VBN N
. . N

Results NNS N
Of IN p
435 CD p
patients NNS p
enrolled VBD p
, , p
233 CD p
were VBD p
treatment NN p
naive JJ p
( ( p
54 CD p
% NN p
) ) p
and CC p
202 CD p
were VBD p
cytokine NN p
pretreated VBN p
( ( p
46 CD p
% NN p
) ) p
. . p

PFS NNP o
was VBD N
significantly RB N
prolonged VBN N
with IN N
pazopanib NNS i
compared VBN N
with IN N
placebo NN i
in IN N
the DT N
overall JJ N
study NN N
population NN N
( ( N
median JJ N
, , N
PFS NNP N
9.2 CD N
v NN N
4.2 CD N
months NNS N
; : N
hazard PRP$ N
ratio NN N
[ NNP N
HR NNP N
] NNP N
, , N
0.46 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
0.34 CD N
to TO N
0.62 CD N
; : N
P NNP N
< NNP N
.0001 NNP N
) ) N
, , N
the DT N
treatment-naive JJ i
subpopulation NN N
( ( N
median JJ N
PFS NNP N
11.1 CD N
v NN N
2.8 CD N
months NNS N
; : N
HR NNP N
, , N
0.40 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
0.27 CD N
to TO N
0.60 CD N
; : N
P NNP N
< NNP N
.0001 NNP N
) ) N
, , N
and CC N
the DT N
cytokine-pretreated JJ N
subpopulation NN N
( ( N
median JJ N
PFS NNP N
, , N
7.4 CD N
v NN N
4.2 CD N
months NNS N
; : N
HR NNP N
, , N
0.54 CD N
; : N
95 CD N
% NN N
CI NNP N
, , N
0.35 CD N
to TO N
0.84 CD N
; : N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

The DT N
objective JJ o
response NN o
rate NN o
was VBD N
30 CD N
% NN N
with IN N
pazopanib NN i
compared VBN N
with IN N
3 CD N
% NN N
with IN N
placebo NN i
( ( N
P NNP N
< NNP N
.001 NNP N
) ) N
. . N

The DT N
median JJ o
duration NN o
of IN o
response NN o
was VBD N
longer JJR N
than IN N
1 CD N
year NN N
. . N

The DT N
most RBS N
common JJ N
adverse JJ N
events NNS N
were VBD N
diarrhea RB o
, , o
hypertension NN o
, , o
hair NN o
color NN o
changes NNS o
, , o
nausea NN o
, , o
anorexia NN o
, , o
and CC o
vomiting VBG o
. . o

There EX N
was VBD N
no DT N
evidence NN N
of IN N
clinically RB N
important JJ N
differences NNS N
in IN N
quality NN N
of IN N
life NN N
for IN N
pazopanib JJ i
versus NN i
placebo NN i
. . i

CONCLUSION NNP N
Pazopanib NNP i
demonstrated VBD N
significant JJ N
improvement NN N
in IN N
PFS NNP N
and CC N
tumor NN N
response NN N
compared VBN N
with IN N
placebo NN i
in IN N
treatment-naive JJ p
and CC p
cytokine-pretreated JJ i
patients NNS p
with IN p
advanced JJ p
and/or NNS p
metastatic JJ p
RCC NNP p
. . p

-DOCSTART- -17387189- O O

Middle NNP o
cerebral JJ o
arterial JJ o
blood NN o
flow NN o
velocity NN o
and CC o
hemodynamics NNS o
in IN N
heart NN N
surgery NN N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
effects NNS N
of IN N
propofol NN i
, , i
isoflurane NN i
, , i
and CC i
sevoflurane NN i
on IN N
middle JJ o
cerebral JJ o
arterial JJ o
blood NN o
flow NN o
velocity NN o
during IN N
open JJ p
heart NN p
surgery NN p
, , N
and CC N
the DT N
relationship NN N
between IN N
these DT N
effects NNS N
and CC N
hemodynamic JJ N
parameters NNS N
. . N

Fifty-two JJ p
patients NNS p
undergoing VBG p
coronary JJ p
artery NN p
bypass NN p
on IN p
cardiopulmonary JJ p
bypass NN p
were VBD N
divided VBN N
randomly RB N
into IN N
3 CD N
groups NNS N
: : N
the DT N
first JJ N
group NN i
received VBD i
100 CD i
microg NNS i
x JJ i
kg NN i
( ( i
-1 NNP i
) ) i
x VBP i
min NN i
( ( i
-1 NNP i
) ) i
propofol NN i
, , i
the DT i
other JJ i
groups NNS i
received VBD i
one CD i
minimum NN i
alveolar JJ i
concentration NN i
of IN i
sevoflurane NN i
or CC i
isoflurane NN i
for IN i
anesthesia JJ i
maintenance NN i
. . i

Middle NNP o
cerebral JJ o
arterial JJ o
blood NN o
flow NN o
velocities NNS o
were VBD N
measured VBN N
by IN N
transcranial JJ N
Doppler NNP N
, , N
and CC N
hemodynamics NNS o
were VBD N
measured VBN N
by IN N
the DT N
thermodilution NN N
technique NN N
. . N

Middle NNP o
cerebral JJ o
arterial JJ o
blood NN o
flow NN o
velocities NNS o
decreased VBN N
significantly RB N
after IN N
administration NN N
of IN N
isoflurane NN N
and CC N
propofol NN N
, , N
but CC N
there EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
the DT N
groups NNS N
. . N

After IN N
weaning VBG N
from IN N
cardiopulmonary JJ N
bypass NN N
, , N
cerebral JJ o
blood NN o
flow NN o
increased VBD o
and CC N
came VBD N
close RB N
to TO N
the DT N
value NN N
after IN N
induction NN N
in IN N
all DT N
groups NNS N
. . N

The DT N
pulsatility NN o
index NN o
and CC o
resistivity NN o
index NN o
increased VBD N
significantly RB N
only RB N
after IN N
the DT N
propofol NN N
infusion NN N
, , N
but CC N
there EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
the DT N
groups NNS N
. . N

-DOCSTART- -16083628- O O

[ JJ N
Treatment NNP N
of IN N
hyperhomocysteinemia NN N
and CC N
endothelial JJ N
dysfunction NN N
in IN N
renal-transplant JJ p
recipients NNS p
with IN N
vitamin NN N
B NNP N
] NNP N
. . N

OBJECTIVE NNP N
To TO N
study VB N
the DT N
effect NN o
of IN N
vitamin NN N
B NNP N
on IN N
treatment NN N
of IN N
hyperhomocysteinemia NN N
and CC N
endothelial JJ N
dysfunction NN N
in IN N
renal-transplant JJ p
recipients NNS p
. . p

METHODS NNP N
Thirty-six NNP p
stable JJ p
hyperhomocysteinemic JJ p
renal-transplant JJ p
recipients NNS p
were VBD N
randomly RB i
assigned VBN i
to TO i
vitamin VB i
treatment NN i
( ( i
group NN i
A NNP i
, , i
n JJ i
= NN i
18 CD i
, , i
folic JJ i
acid VBP i
5 CD i
mg/d NN i
, , i
vitamin NN i
B NNP i
( ( i
6 CD i
) ) i
50 CD i
mg/d NN i
, , i
B NNP i
( ( i
12 CD i
) ) i
1000 CD i
microg/d NN i
) ) i
or CC i
controlled VBN i
group NN i
( ( i
group NN i
B NNP i
, , i
n JJ i
= NNP i
18 CD i
) ) i
for IN i
6 CD i
months NNS i
. . i

All DT i
subjects NNS i
underwent JJ i
assessment NN i
of IN i
levels NNS o
for IN o
creatinine NN o
, , o
creatinine JJ o
clearance NN o
, , o
average JJ o
pressure NN o
, , o
total JJ o
cholesterol NN o
, , o
triglyceride NN o
and CC o
fasting JJ o
homocysteine NN o
. . o

Endothelial JJ o
function NN o
was VBD N
evaluated VBN N
using VBG N
high-resolution NN N
vascular JJ N
ultrasound NN N
. . N

RESULTS VB N
The DT N
levels NNS N
of IN N
homocysteine NN N
markedly RB N
decreased VBD N
in IN N
group NN N
A NNP N
[ NNP N
( ( N
13 CD N
+/- JJ N
4 CD N
) ) N
micromol/L NN N
vs NN N
( ( N
20 CD N
+/- JJ N
5 CD N
) ) N
micromol/L NN N
, , N
t EX N
= JJ N
5.3 CD N
, , N
P NNP N
< VBZ N
0.01 CD N
] NN N
after IN N
treatment NN N
, , N
whereas IN N
no DT N
significant JJ N
changes NNS N
were VBD N
observed VBN N
in IN N
group NN N
B NNP N
. . N

In IN N
group NN N
A NNP N
, , N
endothelium NN N
dependent JJ N
[ NNP N
( ( N
12 CD N
+/- JJ N
5 CD N
) ) N
% NN N
vs NN N
( ( N
9 CD N
+/- JJ N
5 CD N
) ) N
% NN N
, , N
t JJ N
= NN N
2.9 CD N
, , N
P NNP N
< VBZ N
0.01 CD N
] NN N
and CC N
independent JJ N
[ NNP N
( ( N
18 CD N
+/- JJ N
4 CD N
) ) N
% NN N
vs NN N
( ( N
12 CD N
+/- JJ N
5 CD N
) ) N
% NN N
, , N
t JJ N
= NN N
3.4 CD N
, , N
P NNP N
< VBZ N
0.01 CD N
] JJ N
vasodilatation NN o
responses NNS o
significantly RB N
increased VBD N
after IN N
treatment NN N
, , N
no DT N
significant JJ N
changes NNS N
were VBD N
observed VBN N
in IN N
group NN N
B. NNP N
Endothelium NNP N
dependent NN N
[ NNP N
( ( N
9 CD N
+/- JJ N
6 CD N
) ) N
% NN N
, , N
t JJ N
= NN N
2.8 CD N
, , N
P NNP N
< VBZ N
0.01 CD N
] NN N
and CC N
independent JJ N
[ NNP N
( ( N
12 CD N
+/- JJ N
5 CD N
) ) N
% NN N
, , N
t JJ N
= NN N
3.5 CD N
, , N
P NNP N
< VBZ N
0.01 CD N
] JJ N
vasodilatation NN o
responses NNS o
of IN N
group NN N
A NNP N
were VBD N
significantly RB N
lower JJR N
than IN N
that DT N
of IN N
group NN N
B NNP N
after IN N
treatment NN N
. . N

CONCLUSIONS NNP N
Vitamin NNP N
B NNP N
supplementation NN N
can MD N
reduce VB N
the DT N
levels NNS N
of IN N
homocysteine NN N
and CC N
improve VB N
the DT N
endothelial JJ N
function NN N
in IN N
hyperhomocysteinemic JJ p
renal-transplant JJ p
recipients NNS p
. . p

-DOCSTART- -7679164- O O

Angiotensin-converting JJ i
enzyme JJ i
inhibition NN i
does VBZ N
not RB N
suppress VB N
plasma NN N
angiotensin NN N
II NNP N
increase NN N
during IN N
exercise NN p
in IN p
humans NNS p
. . p

Physical JJ N
effort NN N
stimulates VBZ N
the DT N
reninangiotensin NN N
system NN N
( ( N
RAS NNP N
) ) N
. . N

We PRP N
studied VBD N
the DT N
effect NN N
of IN N
an DT N
angiotensin-converting JJ i
enzyme NN i
inhibitor NN i
( ( i
ACE NNP i
inhibitor NN i
) ) i
in IN N
a DT N
double-blind JJ N
placebo-controlled JJ N
study NN N
, , N
on IN N
eight CD p
volunteers NNS p
undergoing VBG p
physical JJ p
stress NN p
on IN p
an DT p
ergometric JJ p
bicycle NN p
. . p

The DT N
effects NNS N
of IN N
captopril NN i
( ( N
C NNP N
) ) N
( ( N
50 CD N
mg NN N
, , N
three CD N
times NNS N
daily RB N
for IN N
3 CD N
days NNS N
) ) N
on IN N
arterial JJ o
pressure NN o
( ( o
AP NNP o
) ) o
, , o
O2 NNP o
consumption NN o
( ( o
VO2 NNP o
) ) o
, , o
variations NNS o
in IN o
auricular JJ o
natriuretic JJ o
factor NN o
( ( o
ANF NNP o
) ) o
, , o
renin NN o
, , o
angiotensin NN o
II NNP o
( ( o
AII NNP o
) ) o
plasma NN o
levels NNS o
, , o
as RB o
well RB o
as IN o
glomerular JJ o
filtration NN o
rate NN o
( ( o
GFR NNP o
) ) o
and CC o
microalbuminuria $ o
( ( o
MA NNP o
) ) o
were VBD N
evaluated VBN N
. . N

The DT N
different JJ N
parameters NNS N
were VBD N
compared VBN N
by IN N
analysis NN N
of IN N
variance NN N
( ( N
ANOVA NNP N
) ) N
. . N

The DT N
pressure NN N
profile NN N
and CC N
VO2 NNP N
were VBD N
not RB N
modified VBN N
by IN N
ACE NNP i
inhibitor NN i
. . i

Exercise NN N
stimulates VBZ N
release NN N
of IN N
renin NN N
; : N
this DT N
action NN N
was VBD N
greater JJR N
with IN N
captopril JJ i
administration NN N
( ( N
treatment NN N
effect NN N
: : N
p NN N
< VBZ N
10 CD N
( ( N
-4 NN N
) ) N
, , N
indicating VBG N
blockade NN N
of IN N
the DT N
RAS NNP N
. . N

This DT N
inhibition NN N
was VBD N
incomplete JJ N
because IN N
AII NNP N
levels NNS N
increased VBD N
markedly RB N
when WRB N
captopril NN i
was VBD N
given VBN N
( ( N
no DT N
treatment NN N
effect NN N
: : N
p NN N
< VBZ N
0.37 CD N
) ) N
. . N

Finally RB N
, , N
ACE NNP i
inhibitor NN i
resulted VBD N
in IN N
decreased JJ N
GFR NNP o
( ( N
p JJ N
= $ N
115 CD N
+/- JJ N
5.8 CD N
ml/mn-1 NN N
, , N
C NNP N
= VBD N
91.1 CD N
+/- JJ N
4 CD N
, , N
p NN N
< NNP N
0.05 CD N
) ) N
with IN N
exercise NN N
without IN N
modification NN N
of IN N
MA NNP N
. . N

ACE NNP i
inhibitor JJ i
administration NN i
does VBZ N
not RB N
modify VB N
the DT N
physical JJ N
performance NN N
of IN N
nonathletic JJ N
subjects NNS N
; : N
AII NNP N
is VBZ N
significantly RB N
increased VBN N
with IN N
exercise NN N
despite IN N
captopril JJ N
treatment NN N
; : N
ACE NNP i
inhibitor NN i
decreases VBZ N
GFR NNP o
significantly RB N
but CC N
does VBZ N
not RB N
influence VB N
MA NNP N
with IN N
prolonged JJ N
physical JJ N
effort NN N
. . N

-DOCSTART- -24886549- O O

Impact NN N
of IN N
additional JJ i
counselling NN i
sessions NNS i
through IN i
phone NN i
calls NNS i
on IN N
smoking VBG o
cessation NN o
outcomes NNS o
among IN N
smokers NNS p
in IN p
Penang NNP p
State NNP p
, , p
Malaysia NNP p
. . p

BACKGROUND NNP N
Studies NNPS N
all DT N
over IN N
the DT N
world NN N
reported VBD N
that IN N
smoking VBG N
relapses NNS N
occur VBP N
during IN N
the DT N
first JJ N
two CD N
weeks NNS N
after IN N
a DT N
quit NN N
date NN N
. . N

The DT N
current JJ N
study NN N
aimed VBD N
to TO N
assess VB N
the DT N
impact NN N
of IN N
the DT N
additional JJ i
phone NN i
calls VBZ i
counselling VBG i
during IN N
the DT N
first JJ N
month NN N
on IN N
the DT N
abstinence NN o
rate NN o
at IN N
3 CD N
and CC N
6 CD N
months NNS N
after IN N
quit NN N
date NN N
among IN p
smokers NNS p
in IN p
Penang NNP p
, , p
Malaysia NNP p
. . p

METHODS NNP p
The DT p
study NN p
was VBD p
conducted VBN p
at IN p
Quit NNP p
Smoking NNP p
Clinic NNP p
of IN p
two CD p
major JJ p
hospitals NNS p
in IN p
Penang NNP p
, , p
Malaysia NNP p
. . p

All PDT p
the DT p
eligible JJ p
smokers NNS p
who WP p
attended VBD p
the DT p
clinics NNS p
between IN p
February NNP p
1st CD p
and CC p
October NNP p
31st CD p
2012 CD p
were VBD p
invited VBN p
. . p

Participants NNS N
were VBD N
randomly RB N
assigned VBN N
by IN N
using VBG N
urn JJ N
design NN N
method NN N
either DT N
to TO i
receive VB i
the DT i
usual JJ i
care NN i
that WDT i
followed VBD i
in IN i
the DT i
clinics NNS i
( ( i
control NN i
) ) i
or CC i
the DT i
usual JJ i
care NN i
procedure NN i
plus CC i
extra JJ i
counselling NN i
sessions NNS i
through IN i
phone NN i
calls NNS i
during IN i
the DT i
first JJ i
month NN i
of IN i
quit NN i
attempt NN i
( ( i
intervention NN i
) ) i
. . i

RESULTS JJ p
Participants NNS p
in IN p
our PRP$ p
cohort NN p
smoked VBD p
about IN p
14 CD p
cigarettes NNS p
per IN p
day NN p
on IN p
average NN p
( ( p
mean JJ p
= NN p
13.78 CD p
? . p
7.0 CD p
) ) p
. . p

At IN p
3 CD p
months NNS p
, , N
control NN N
group NN N
was VBD N
less RBR N
likely JJ N
to TO o
quit VB o
smoking NN o
compared VBN o
to TO N
intervention VB N
group NN N
( ( N
36.9 CD N
% NN N
vs. FW N
46.7 CD N
% NN N
, , N
verified VBD N
smoking NN N
status NN N
) ) N
but CC N
this DT N
did VBD N
not RB N
reach VB N
statistical JJ N
significance NN N
( ( N
OR NNP N
= VBZ N
0.669 CD N
; : N
95 CD N
% NN N
CI NNP N
= NNP N
0.395-1.133 NN N
, , N
P NNP N
= NNP N
0.86 CD N
) ) N
. . N

However RB N
, , N
at IN N
6 CD N
months NNS N
, , N
71.7 CD N
% NN N
of IN N
the DT N
intervention NN N
group NN N
were VBD N
successfully RB N
quit JJ o
smoking NN o
( ( o
bio-chemically RB o
verified VBN o
) ) o
compared VBN o
to TO o
48.6 CD o
% NN N
of IN N
the DT N
control NN N
group NN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

The DT N
control NN N
group NN N
were VBD N
significantly RB N
less RBR N
likely JJ N
to TO N
quit VB o
smoking NN o
( ( N
OR NNP N
= VBZ N
0.375 CD N
; : N
95 CD N
% NN N
CI NNP N
= NNP N
0.217-0.645 NN N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

CONCLUSIONS NNP i
Smoking NNP i
cessation NN i
intervention NN i
consisting VBG i
of IN i
phone NN i
calls NNS i
counselling VBG i
delivered VBN i
during IN N
the DT N
first JJ N
month NN N
of IN N
quit NN N
attempt NN N
revealed VBD N
significantly RB N
higher JJR N
abstinence NN N
rates NNS N
compared VBN N
with IN N
a DT N
standard NN N
care NN N
approach NN N
. . N

Therefore RB N
, , N
the DT N
additional JJ i
counselling NN i
in IN N
the DT N
first JJ N
few JJ N
weeks NNS N
after IN N
stop JJ N
smoking NN N
is VBZ N
a DT N
promising JJ N
treatment NN N
strategy NN N
that WDT N
should MD N
be VB N
evaluated VBN N
further RB N
. . N

TRIAL NNP N
REGISTRATION NNP N
TCTR20140504001 NNP N
. . N

-DOCSTART- -2871744- O O

Propranolol NNP i
in IN N
acute JJ p
myocardial JJ p
infarction NN p
: : p
the DT N
MILIS NNP N
experience NN N
. . N

The DT N
results NNS N
of IN N
the DT N
propranolol NN i
limb NN N
of IN N
the DT N
Multicenter NNP N
Investigation NNP N
of IN N
the DT N
Limitation NNP N
of IN N
Infarct NNP N
Size NNP N
are VBP N
reviewed VBN N
. . N

A DT p
total NN p
of IN p
269 CD p
patients NNS p
, , p
who WP p
presented VBD p
with IN p
symptoms NNS p
and CC p
electrocardiographic JJ p
signs NNS p
suggesting VBG p
acute JJ p
myocardial JJ p
infarction NN p
were VBD p
randomized VBN p
to TO p
acute VB p
intravenous JJ p
and CC p
subsequent JJ p
oral JJ p
therapy NN p
with IN p
propranolol NN i
( ( p
n JJ p
= NNP p
134 CD p
) ) p
or CC i
placebo NN i
( ( p
n JJ p
= NNP p
135 CD p
) ) p
. . p

Eligibility NN N
for IN N
acute JJ N
beta-blocker NN N
therapy NN N
was VBD N
determined VBN N
on IN N
the DT N
basis NN N
of IN N
readily RB N
available JJ N
, , N
noninvasive JJ N
tests NNS N
. . N

Therapy NN N
was VBD N
started VBN N
at IN N
an DT N
average JJ N
time NN N
of IN N
8.5 CD N
hours NNS N
after IN N
onset NN N
of IN N
symptoms NNS N
. . N

The DT N
full JJ N
induction NN N
dose NN N
of IN N
intravenous JJ N
propranolol NN i
( ( N
0.1 CD N
mg/kg NN N
) ) N
was VBD N
tolerated VBN N
by IN N
90 CD N
% NN N
of IN N
treated JJ N
patients NNS N
, , N
and CC N
oral JJ N
maintenance NN N
therapy NN N
was VBD N
being VBG N
continued VBN N
in IN N
82 CD N
% NN N
of IN N
treated JJ N
patients NNS N
on IN N
the DT N
second JJ N
hospital NN N
day NN N
. . N

There EX N
was VBD N
a DT N
significant JJ N
reduction NN N
in IN N
heart NN o
rate NN o
throughout IN N
maintenance NN N
therapy NN N
with IN N
propranolol NN N
, , N
which WDT N
continued VBD N
through IN N
the DT N
tenth JJ N
hospital NN N
day NN N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
the DT N
incidence NN o
of IN o
congestive JJ o
heart NN o
failure NN o
between IN N
propranolol- JJ i
and CC N
placebo-treated JJ i
groups NNS N
. . N

There EX N
was VBD N
also RB N
no DT N
significant JJ N
difference NN N
between IN N
the DT N
2 CD N
groups NNS N
in IN N
infarct JJ o
size NN o
estimated VBN N
by IN N
measurement NN N
of IN N
serum JJ o
CK-MB NNP o
, , o
planimetry NN o
of IN o
infarct JJ o
area NN o
on IN o
technetium NN o
pyrophosphate NN o
myocardial JJ o
scintigrams NNS o
or CC o
R-wave JJ o
measurements NNS o
in IN N
patients NNS N
with IN N
transmural JJ N
anterior NNS N
and CC N
inferior JJ N
infarcts NNS N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
mortality NN o
between IN N
the DT N
2 CD N
groups NNS N
during IN N
an DT N
average NN N
of IN N
36 CD N
months NNS N
' POS N
follow-up NN N
. . N

Although IN N
propranolol NN i
can MD N
be VB N
administered VBN N
safely RB N
to TO N
patients NNS p
with IN p
acute JJ p
myocardial JJ p
infarction NN p
who WP N
are VBP N
selected VBN N
on IN N
the DT N
basis NN N
of IN N
simple JJ N
clinical JJ N
criteria NNS N
, , N
there EX N
is VBZ N
no DT N
evidence NN N
of IN N
reduction NN N
of IN N
infarct NN o
size NN o
when WRB N
beta NN N
blockade NN N
is VBZ N
begun VBN N
8.5 CD N
hours NNS N
after IN N
the DT N
onset NN N
of IN N
symptoms NNS N
. . N

-DOCSTART- -11545629- O O

Penetration NN N
of IN N
ofloxacin NN i
and CC i
ciprofloxacin NN i
into IN N
the DT N
aqueous JJ N
humor NN N
of IN N
eyes NNS p
with IN p
functioning VBG p
filtering VBG p
blebs NN p
: : p
a DT N
randomized JJ N
trial NN N
. . N

OBJECTIVE NN N
To TO N
determine VB N
concentrations NNS N
of IN N
ofloxacin NN N
and CC N
ciprofloxacin NN N
hydrochloride NN N
in IN N
aqueous JJ N
humor NN N
after IN N
topical JJ N
or CC N
combined VBN N
topical JJ N
and CC N
oral JJ N
administration NN N
in IN N
eyes NNS p
with IN p
filtering VBG p
blebs NN p
. . p

DESIGN VB N
A DT N
prospective JJ N
, , N
investigator-masked JJ N
, , N
randomized VBN N
, , N
controlled VBD N
comparative JJ N
study NN N
involving VBG N
36 CD p
eyes NNS p
of IN p
34 CD p
patients NNS p
with IN p
functioning VBG p
filtering VBG p
blebs NNS p
who WP p
were VBD p
to TO p
undergo VB p
cataract NN p
surgery NN p
. . p

Treatment NN N
groups NNS N
received VBD N
either RB N
topical JJ i
ofloxacin NN i
or CC i
topical JJ i
ciprofloxacin NN i
( ( N
instillation NN N
of IN N
0.3 CD N
% NN N
ophthalmic JJ N
solution NN N
every DT N
30 CD N
minutes NNS N
for IN N
4 CD N
hours NNS N
before IN N
surgery NN i
) ) i
, , N
or CC N
a DT N
combined JJ N
topical JJ N
plus CC N
oral JJ N
regimen NNS N
( ( i
ciprofloxacin JJ i
hydrochloride NN i
, , i
four CD i
100-mg JJ i
tablets NNS i
, , i
or CC i
ofloxacin RB i
, , i
one CD i
400-mg JJ i
tablet NN i
, , N
administered VBN N
24-26 JJ N
, , N
12-14 JJ N
, , N
and CC N
2 CD N
hours NNS N
preceding VBG N
surgery NN i
) ) i
. . N

The DT N
main JJ N
outcome NN N
measure NN N
was VBD N
antibiotic JJ o
concentration NN o
measured VBN N
by IN N
chromatographic JJ N
separation NN N
and CC N
mass NN N
spectrometry NN N
of IN N
aqueous JJ N
samples NNS N
obtained VBN N
during IN N
surgery NN N
. . N

RESULTS NNP N
Topical NNP N
antibiotic JJ N
treatment NN N
yielded VBN N
mean JJ N
concentrations NNS o
of IN o
ofloxacin NN o
, , N
0.75 CD N
microg/mL NN N
, , N
and CC N
ciprofloxacin NN i
, , N
0.21 CD N
microg/mL NN N
, , N
in IN N
aqueous JJ N
. . N

With IN N
combined JJ N
topical JJ N
and CC N
oral JJ N
therapy NN N
, , N
significantly RB N
more JJR N
ofloxacin NN N
was VBD N
measured VBN N
than IN N
ciprofloxacin NN N
( ( N
3.84 CD N
microg/mL NN N
vs NN N
0.35 CD N
microg/mL NN N
[ NNP N
P NNP N
< NNP N
.001 NNP N
] NNP N
) ) N
. . N

The DT N
combination NN N
regimen NNS N
produced VBD N
significantly RB N
greater JJR o
ofloxacin NN o
levels NNS o
than IN N
did VBD N
topical JJ N
therapy NN N
alone RB N
( ( N
P NNP N
=.007 NNP N
) ) N
. . N

CONCLUSIONS NNP N
Ofloxacin NNP N
penetrates VBZ N
better JJR N
than IN N
ciprofloxacin NN o
into IN N
the DT N
aqueous JJ N
of IN N
eyes NNS N
with IN N
filtering VBG N
blebs NNS N
, , N
particularly RB N
after IN N
combined VBN N
topical JJ N
and CC N
oral JJ N
administration NN N
, , N
by IN N
which WDT N
ofloxacin NN N
reaches VBZ N
more JJR N
than IN N
a DT N
10-fold JJ N
greater JJR N
concentration NN N
than IN N
does VBZ N
ciprofloxacin VB N
. . N

Combined VBN N
topical JJ i
and CC i
oral JJ i
therapy NN i
with IN i
ofloxacin NN i
may MD N
be VB N
beneficial JJ N
in IN N
the DT N
treatment NN N
of IN N
bleb-associated JJ N
infections NNS N
. . N

-DOCSTART- -22502844- O O

Kata NNP i
techniques NNS i
training VBG i
consistently RB N
decreases VBZ N
stereotypy NN N
in IN N
children NNS p
with IN p
autism NN p
spectrum NN p
disorder NN p
. . p

The DT N
effects NNS N
of IN N
14 CD N
weeks NNS N
of IN N
Kata NNP i
techniques NNS i
training VBG i
on IN N
stereotypic JJ N
behaviors NNS N
of IN N
children NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
( ( p
ASD NNP p
) ) p
were VBD N
investigated VBN N
. . N

The DT N
study NN N
included VBD N
30 CD p
eligible JJ p
( ( p
diagnosed JJ p
ASD NNP p
, , p
school NN p
age NN p
) ) p
children NNS p
with IN p
ages NNS p
ranging VBG p
from IN p
5 CD p
to TO p
16 CD p
years NNS p
whom WP N
they PRP N
assigned VBD N
to TO N
an DT N
exercise NN N
( ( N
n=15 JJ N
) ) N
or CC N
a DT N
no-exercise JJ i
control NN i
group NN i
( ( N
n=15 RB N
) ) N
. . N

Participants NNS N
of IN N
the DT N
exercise NN N
group NN N
received VBD N
Kata NNP i
techniques NNS i
instruction VBP i
four CD N
times NNS N
per IN N
week NN N
for IN N
14 CD N
weeks NNS N
( ( N
56 CD N
sessions NNS N
) ) N
. . N

Stereotypy NNP i
was VBD N
assessed VBN N
at IN N
baseline NN N
( ( N
pre-intervention NN N
) ) N
, , N
week NN N
14 CD N
( ( N
post-intervention NN N
) ) N
, , N
and CC N
at IN N
one CD N
month NN N
follow VB N
up RP N
in IN N
both DT N
groups NNS N
. . N

Results NNS N
showed VBD N
that IN N
Kata NNP N
techniques NNS N
training VBG N
significantly RB N
reduced VBN o
stereotypy NN o
in IN o
the DT o
exercise NN o
group NN o
. . o

Following VBG N
participation NN N
in IN N
Kata NNP N
techniques NNS N
training NN N
, , N
stereotypy NN o
decreased VBN o
from IN o
baseline NN o
levels NNS o
by IN N
a DT N
M NNP N
of IN N
42.54 CD N
% NN N
across IN N
participants NNS N
. . N

Interestingly NNP N
, , N
after IN N
30 CD N
days NNS N
of IN N
no DT N
practice NN N
, , N
stereotypy NN o
in IN o
the DT o
exercise NN o
group NN o
remained VBD o
significantly RB o
decreased VBN o
compared VBN N
to TO N
pre-intervention NN N
time NN N
. . N

The DT N
participants NNS N
of IN N
the DT N
control NN N
group NN N
did VBD N
not RB N
show VB N
significant JJ N
changes NNS N
in IN N
the DT N
stereotypy NN o
. . o

Teaching VBG N
martial JJ N
arts NNS N
techniques NNS N
to TO N
children NNS p
with IN p
ASD NNP p
for IN N
a DT N
long JJ N
period NN N
of IN N
time NN N
consistently RB N
decreased VBN N
their PRP$ N
stereotypic NN N
behaviors NNS N
. . N

-DOCSTART- -19801029- O O

Comparison NNP N
of IN N
the DT N
effect NN N
of IN N
intra-arterial JJ i
versus NN N
intravenous JJ i
heparin NN i
on IN N
radial JJ p
artery NN p
occlusion NN p
after IN p
transradial JJ p
catheterization NN p
. . p

Radial JJ N
artery NN N
occlusion NN N
( ( N
RAO NNP N
) ) N
is VBZ N
an DT N
infrequent NN N
, , N
asymptomatic JJ N
, , N
complication NN N
of IN N
transradial JJ N
catheterization NN N
and CC N
probably RB N
1 CD N
of IN N
the DT N
few JJ N
. . N

Intravenous JJ N
heparin NN N
and CC N
patent NN N
hemostasis NN N
lower RBR N
its PRP$ N
incidence NN N
. . N

A DT N
possible JJ N
local JJ N
effect NN N
of IN N
intra-arterially RB N
administered VBN N
heparin NN i
during IN N
transradial JJ N
procedures NNS N
has VBZ N
not RB N
been VBN N
evaluated VBN N
. . N

We PRP N
studied VBD N
500 CD p
consecutive JJ p
patients NNS p
randomized VBN i
to TO i
an DT i
intravenous JJ i
group NN i
( ( i
n JJ i
= NNP i
250 CD i
) ) i
, , i
receiving VBG i
50 CD i
U/kg NNP i
of IN i
unfractionated JJ i
heparin NN i
( ( i
maximal JJ i
dose VBP i
5,000 CD i
U NNP i
) ) i
intravenously RB i
, , i
and CC i
an DT i
intra-arterial JJ i
group NN i
( ( i
n JJ i
= NNP i
250 CD i
) ) i
receiving VBG i
the DT i
same JJ i
dose JJ i
intra-arterially RB i
. . i

All DT N
patients NNS N
received VBD N
a DT N
vasodilator NN i
cocktail NN i
intra-arterially RB i
and CC i
underwent JJ i
cardiac JJ i
catheterization NN i
using VBG i
a DT i
5F CD i
introducer NN i
sheath NN i
and CC i
catheters NNS i
. . i

The DT N
activated JJ o
clotting NN o
time NN o
was VBD N
measured VBN N
at IN N
the DT N
end NN N
of IN N
the DT N
procedure NN N
. . N

All DT N
patients NNS N
received VBD N
hemostasis NN N
with IN N
a DT N
radial JJ N
compression NN N
device NN N
( ( N
TR NNP N
Band NNP N
) ) N
, , N
applied VBN N
after IN N
sheath NN N
removal NN N
, , N
for IN N
2 CD N
hours NNS N
. . N

A DT N
plethysmographic JJ o
evaluation NN o
for IN o
RAO NNP o
was VBD N
performed VBN N
at IN N
24 CD N
hours NNS N
and CC N
30 CD N
days NNS N
after IN N
the DT N
procedure NN N
. . N

Early JJ o
RAO NNP o
occurred VBD N
in IN N
5.6 CD N
% NN N
( ( N
n JJ N
= NNP N
14 CD N
) ) N
of IN N
the DT N
intravenous JJ N
group NN N
and CC N
6 CD N
% NN N
( ( N
n JJ N
= NNP N
15 CD N
) ) N
of IN N
the DT N
intra-arterial JJ N
group NN N
. . N

The DT N
difference NN N
was VBD N
not RB N
statistically RB N
significant JJ N
( ( N
chi-square JJ N
= NN N
0.037 CD N
, , N
p NN N
> NNP N
0.8 CD N
) ) N
. . N

Chronic NNP o
RAO NNP o
occurred VBD N
in IN N
3.2 CD N
% NN N
, , N
( ( N
n JJ N
= NNP N
8 CD N
) ) N
of IN N
the DT N
intravenous JJ N
group NN N
compared VBN N
to TO N
4 CD N
% NN N
( ( N
n JJ N
= NNP N
10 CD N
) ) N
of IN N
the DT N
intra-arterial JJ N
group NN N
. . N

The DT N
difference NN N
was VBD N
not RB N
statistically RB N
significant JJ N
( ( N
chi-square JJ N
= NN N
0.231 CD N
, , N
p NN N
> NNP N
0.6 CD N
) ) N
. . N

The DT N
activated JJ o
clotting NN o
time NN o
was VBD N
211 CD N
+/- JJ N
16 CD N
seconds NNS N
in IN N
the DT N
intravenous JJ N
group NN N
and CC N
213 CD N
+/- JJ N
17 CD N
seconds NNS N
in IN N
the DT N
intra-arterial JJ N
group NN N
, , N
a DT N
statistically RB N
insignificant JJ N
difference NN N
( ( N
t JJ N
= NNP N
-1.095 NNP N
, , N
p NN N
> NNP N
0.2 CD N
) ) N
. . N

In IN N
conclusion NN N
, , N
intra-arterial JJ N
and CC N
intravenous JJ N
heparin NNS N
administration NN N
provide VBP N
comparable JJ N
efficacy NN N
in IN N
preventing VBG N
RAO NNP N
, , N
favoring VBG N
a DT N
probable JJ N
systemically RB N
mediated VBD N
mechanism NN N
of IN N
action NN N
, , N
rather RB N
than IN N
a DT N
local JJ N
effect NN N
. . N

-DOCSTART- -7527453- O O

Comparison NNP o
of IN N
autologous JJ N
bone NN N
marrow NN N
transplantation NN N
with IN N
sequential JJ N
chemotherapy NN N
for IN N
intermediate-grade JJ p
and CC p
high-grade JJ p
non-Hodgkin NN p
's POS p
lymphoma NN p
in IN p
first JJ p
complete JJ o
remission NN o
: : o
a DT p
study NN p
of IN p
464 CD p
patients NNS p
. . p

Groupe NNP N
d'Etude NN N
des NNS N
Lymphomes NNP N
de IN N
l'Adulte FW N
. . N

PURPOSE NNP N
Intensive NNP N
chemotherapy NN N
followed VBN N
by IN N
autotransplantation NN N
has VBZ N
given VBN N
promising VBG N
results NNS N
in IN N
partially RB N
responding VBG N
or CC N
sensitive JJ N
relapsed JJ N
patients NNS p
with IN p
aggressive JJ p
non-Hodgkin NN p
's POS p
lymphoma NN p
. . p

In IN N
1987 CD N
, , N
we PRP N
designed VBD N
a DT N
randomized VBN N
study NN N
to TO N
evaluate VB N
the DT N
potential JJ N
benefit NN o
of IN N
a DT N
high-dose JJ i
regimen NN i
containing VBG i
cyclophosphamide NN i
, , i
carmustine NN i
, , i
and CC i
etoposide RB i
( ( i
CBV NNP i
) ) i
followed VBN i
by IN i
autotransplantation NN i
over IN i
a DT i
consolidative JJ i
sequential JJ i
chemotherapy NN i
( ( i
ifosfamide JJ i
, , i
etoposide RB i
, , i
asparaginase NN i
, , i
and CC i
cytarabine NN i
) ) i
in IN N
patients NNS N
in IN N
first JJ N
complete JJ N
remission NN N
with IN N
intermediate- JJ p
and CC p
high-grade JJ p
non-Hodgkin NN p
's POS p
lymphoma NN p
. . p

PATIENTS NNP N
AND CC N
METHODS NNP N
Patients NNPS p
were VBD p
younger JJR p
than IN p
55 CD p
years NNS p
and CC p
had VBD p
at IN p
least JJS p
one CD p
adverse JJ p
prognostic JJ p
factor NN p
. . p

Induction NNP N
treatment NN N
was VBD N
that IN N
of IN N
the DT N
LNH84 NNP N
protocol NN N
with IN N
an DT N
open JJ N
randomization NN N
on IN N
the DT N
anthracycline NN i
. . i

Patients NNS N
in IN N
complete JJ o
remission NN o
were VBD N
further JJ N
randomly RB N
assigned VBN N
to TO N
receive VB N
either DT N
consolidation NN N
procedure NN N
. . N

RESULTS NNP N
After IN N
induction NN N
treatment NN N
, , N
464 CD p
patients NNS p
were VBD N
assessable JJ N
for IN N
the DT N
consolidation NN N
phase NN N
. . N

With IN N
a DT N
median JJ N
follow-up JJ N
duration NN N
of IN N
28 CD N
months NNS N
, , N
the DT N
3-year JJ o
disease-free JJ o
survival NN o
rate NN o
was VBD N
52 CD N
% NN N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
45 CD N
% NN N
to TO N
59 CD N
% NN N
) ) N
in IN N
the DT N
sequential JJ N
chemotherapy NN N
arm NN N
and CC N
59 CD N
% NN N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
52 CD N
% NN N
to TO N
66 CD N
% NN N
) ) N
in IN N
the DT N
autologous JJ N
transplant NN N
arm NN N
( ( N
P NNP N
= NNP N
.46 NNP N
, , N
relative JJ N
risk NN N
= NNP N
0.90 CD N
) ) N
. . N

The DT N
3-year JJ o
survival NN o
rate NN o
did VBD N
not RB N
differ VB N
between IN N
sequential JJ N
chemotherapy NN N
and CC N
autotransplantation NN N
, , N
at IN N
71 CD N
% NN N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
64 CD N
% NN N
to TO N
78 CD N
% NN N
) ) N
and CC N
69 CD N
% NN N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
62 CD N
% NN N
to TO N
76 CD N
% NN N
) ) N
, , N
respectively RB N
( ( N
P NNP N
= NNP N
.60 NNP N
, , N
relative JJ N
risk NN N
= NNP N
1.11 CD N
) ) N
. . N

CONCLUSION NNP N
For IN N
such JJ N
a DT N
subset NN N
of IN N
patients NNS N
, , N
consolidation NN N
with IN N
the DT N
CBV NNP N
regimen NNS N
followed VBN N
by IN N
autologous JJ N
bone NN N
marrow NN N
transplantation NN N
is VBZ N
not RB N
superior JJ o
to TO N
sequential JJ N
chemotherapy NN N
. . N

-DOCSTART- -11191952- O O

[ JJ N
Diphtheria NNP N
antitoxin NN N
level NN N
2 CD N
years NNS N
after IN N
booster NN i
vaccination NN i
] NNP i
. . N

In IN N
a DT N
prospective JJ N
, , N
controlled VBN N
, , N
randomized VBN N
, , N
multicenter RBR N
study VBP N
the DT N
immunogenicity NN N
of IN N
a DT N
single JJ N
( ( N
day NN N
0 CD N
) ) N
and CC N
two CD N
( ( N
day NN N
0 CD N
, , N
28 CD N
) ) N
booster NN i
vaccination NN i
against IN i
diphtheria NN i
were VBD N
compared VBN N
in IN N
subjects NNS p
who WP p
had VBD p
received VBN p
their PRP$ p
last JJ p
diphtheria NN i
vaccination NN i
more JJR p
than IN p
10 CD p
years NNS p
ago RB p
. . p

Both DT N
short-term JJ N
and CC N
long-term JJ N
immunogenicity NN N
was VBD N
assessed VBN N
by IN N
determining VBG N
diphtheria NN o
antitoxin NN o
levels NNS o
four CD N
weeks NNS N
after IN N
vaccination NN i
and CC N
after IN N
one CD N
and CC N
two CD N
years NNS N
. . N

102 CD p
subjects NNS p
received VBD p
the DT p
first JJ i
booster NN i
vaccination NN i
, , i
and CC i
83 CD i
were VBD i
vaccinated VBN i
twice RB i
. . i

Prior NNP N
to TO N
the DT N
first JJ N
vaccination NN N
27 CD p
% NN p
of IN p
the DT p
subjects NNS p
had VBD N
a DT N
diphtheria NN o
antitoxin NN o
level NN o
below IN N
0.01 CD N
I.U./ml NNP N
; : N
after IN N
the DT N
first JJ N
booster NN N
only RB N
5 CD N
% NN N
were VBD N
unprotected VBN N
. . N

The DT N
second JJ N
booster NN i
did VBD N
not RB N
show VB N
a DT N
significant JJ N
effect NN N
, , N
however RB N
, , N
in IN N
1 CD N
of IN N
the DT N
5 CD N
subjects NNS N
who WP N
were VBD N
still RB N
unprotected VBN N
after IN N
the DT N
first JJ N
booster NN N
the DT N
second JJ N
elicited VBD N
an DT N
antitoxin JJ o
level NN o
of IN N
more JJR N
than IN N
0.01 CD N
I.U./ml NNP N
. . N

After IN N
one CD N
and CC N
two CD N
years NNS N
7 CD p
% NN p
and CC p
8 CD p
% NN p
of IN p
the DT p
subjects NNS p
had VBD N
diphtheria VBN o
antitoxin JJ o
level NN o
below IN N
0.01 CD N
I.U./ml NNP N
. . N

A NNP N
serological JJ N
effect NN N
of IN N
a DT N
second JJ N
booster NN i
vaccination NN i
four CD N
weeks NNS N
after IN N
the DT N
first JJ N
one NN N
could MD N
not RB N
be VB N
demonstrated VBN N
neither RB N
after IN N
one CD N
nor CC N
after IN N
two CD N
years NNS N
. . N

-DOCSTART- -2454375- O O

Pharmacokinetics NNS N
and CC N
disposition NN N
of IN N
carvedilol NN i
in IN p
humans NNS p
. . p

Pharmacokinetics NNS o
of IN N
carvedilol NN i
( ( N
C NNP N
) ) N
have VBP N
been VBN N
studied VBN N
in IN N
healthy JJ p
volunteers NNS p
after IN p
a DT p
single JJ p
i.v NN p
. . p

and CC p
oral JJ p
administration NN p
, , N
and CC N
the DT N
metabolic JJ N
disposition NN N
after IN N
oral JJ N
administration NN N
of IN N
14C-labeled JJ i
drug NN i
. . i

C NNP N
demonstrates VBZ N
dose-linear JJ N
behavior NN N
. . N

The DT N
absolute JJ N
bioavailability NN N
reaches VBZ N
24 CD N
% NN N
probably RB N
due JJ N
to TO N
a DT N
first-pass JJ N
effect NN N
. . N

After IN N
a DT N
50 CD N
mg JJ N
oral JJ N
dose NN N
, , N
maximum JJ N
concentrations NNS N
of IN N
66 CD N
micrograms/l NNS N
are VBP N
achieved VBN N
within IN N
1.2 CD N
h. JJ N
C NNP N
is VBZ N
extensively RB N
distributed VBN N
to TO N
the DT N
tissues NNS N
( ( N
Vz NNP N
= VBZ N
132 CD N
l NN N
) ) N
and CC N
eliminated VBN N
primarily RB N
by IN N
hepatic JJ N
metabolism NN N
( ( N
total JJ N
clearance NN N
590 CD N
ml/min NN N
, , N
renal JJ N
clearance NN N
4 CD N
ml/min NN N
) ) N
. . N

Because IN N
of IN N
the DT N
longer RBR N
half-life NN N
of IN N
6.4 CD N
h NN N
after IN N
oral JJ N
administration NN N
in IN N
contrast NN N
to TO N
2.4 CD N
h NN N
after IN N
i.v NN N
. . N

administration NN N
, , N
C NNP N
is VBZ N
assumed VBN N
to TO N
be VB N
absorption JJ N
dependent JJ N
since IN N
no DT N
sustained-release JJ N
formulation NN N
was VBD N
used VBN N
. . N

The DT N
half-life NN o
of IN N
radioactivity NN N
in IN N
plasma NN N
is VBZ N
39 CD N
h NN N
; : N
16 CD N
% NN N
of IN N
C NNP N
is VBZ N
excreted VBN N
in IN N
urine NN N
in IN N
the DT N
form NN N
of IN N
metabolites NNS N
and CC N
only RB N
0.3 CD N
% NN N
unchanged JJ N
. . N

The DT N
urinary JJ N
metabolites NNS N
consist VBP N
of IN N
carvedilol NN N
glucuronide NN N
( ( N
5.2 CD N
% NN N
of IN N
the DT N
dose NN N
) ) N
, , N
cleavage JJ N
products NNS N
of IN N
the DT N
beta-blocking JJ N
side NN N
chain NN N
( ( N
2.1 CD N
% NN N
) ) N
, , N
and CC N
ring-hydroxylated JJ N
forms NNS N
( ( N
2.9 CD N
% NN N
) ) N
. . N

Sixty NNP N
percent NN N
of IN N
the DT N
dose NN N
is VBZ N
recovered VBN N
in IN N
the DT N
feces NNS N
. . N

A DT N
demethylated JJ N
product NN N
of IN N
C NNP N
exhibits VBZ N
only RB N
minor JJ N
beta-blocking JJ o
activity NN o
. . o

This DT N
metabolite NN o
is VBZ N
detected VBN N
in IN N
plasma NN N
in IN N
concentrations NNS N
ten VBP N
times NNS N
lower JJR N
than IN N
the DT N
parent NN N
compound NN N
. . N

-DOCSTART- -16239862- O O

Long-term JJ N
effects NNS N
of IN N
risperidone NN i
in IN N
children NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
: : p
a DT N
placebo NN i
discontinuation NN N
study NN N
. . N

OBJECTIVE IN N
The DT N
short-term JJ N
benefit NN N
of IN N
risperidone NN i
in IN N
ameliorating VBG N
severe JJ o
disruptive JJ o
behavior NN o
in IN N
pediatric JJ p
patients NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
is VBZ N
well RB N
established VBN N
; : N
however RB N
, , N
only RB N
one CD N
placebo-controlled JJ i
, , N
long-term JJ N
study NN N
of IN N
efficacy NN N
is VBZ N
available JJ N
. . N

METHOD NNP N
Thirty-six JJ p
children NNS p
with IN p
an DT p
autism NN p
spectrum NN p
disorder NN p
( ( p
5-17 JJ p
years NNS p
old JJ p
) ) p
accompanied VBN p
by IN p
severe JJ p
tantrums NNS p
, , p
aggression NN p
, , p
or CC p
self-injurious JJ p
behavior NN p
, , N
started VBD N
8-week JJ N
open-label JJ N
treatment NN N
with IN N
risperidone NN i
. . i

Responders NNP N
( ( N
n JJ N
= NNP N
26 CD N
) ) N
continued VBD N
treatment NN N
for IN N
another DT N
16 CD N
weeks NNS N
, , N
followed VBN N
by IN N
a DT N
double-blind JJ N
discontinuation NN N
( ( N
n JJ N
= VBZ N
24 CD N
; : N
two CD N
patients NNS N
discontinued VBN N
treatment NN N
because IN N
of IN N
weight JJ N
gain NN N
) ) N
consisting NN N
of IN N
either CC N
3 CD N
weeks NNS N
of IN N
taper NN N
and CC N
5 CD N
weeks NNS N
of IN N
placebo NN i
only RB N
or CC N
continuing VBG N
use NN N
of IN N
risperidone NN i
. . i

Relapse NNP N
was VBD N
defined VBN N
as IN N
a DT N
significant JJ N
deterioration NN N
of IN N
symptoms NNS N
based VBN N
on IN N
clinical JJ N
judgment NN N
and CC N
a DT N
parent NN N
questionnaire NN N
. . N

RESULTS NNP N
Risperidone NNP i
was VBD N
superior JJ N
to TO N
placebo VB i
in IN N
preventing VBG N
relapse NN o
: : o
this DT N
occurred VBD N
in IN N
3 CD N
of IN N
12 CD N
patients NNS N
continuing VBG N
on IN N
risperidone NN N
versus NN N
8 CD N
of IN N
12 CD N
who WP N
switched VBD N
to TO N
placebo VB N
( ( N
p JJ N
= NNP N
.049 NNP N
) ) N
. . N

Weight NNP o
gain NN o
, , o
increased VBD o
appetite RB o
, , o
anxiety NN o
, , o
and CC o
fatigue NN o
were VBD N
the DT N
most RBS N
frequently RB N
reported VBN N
side NN N
effects NNS N
. . N

CONCLUSIONS VB N
This DT N
study NN N
indicates VBZ N
the DT N
effectiveness NN N
of IN N
risperidone NN N
during IN N
a DT N
period NN N
of IN N
several JJ N
months NNS N
, , N
reducing VBG N
disruptive JJ o
behavior NN o
in IN N
about IN N
half NN N
of IN N
the DT N
children NNS p
with IN p
autism NN p
spectrum NN p
disorders NNS p
. . p

The DT N
results NNS N
provide VBP N
a DT N
rationale NN N
for IN N
the DT N
continuing VBG N
use NN N
of IN N
risperidone NN i
beyond IN N
6 CD N
months NNS N
, , N
although IN N
considerable JJ N
weight JJ o
gain NN o
can MD N
limit VB N
the DT N
use NN N
of IN N
this DT N
agent NN N
. . N

-DOCSTART- -15260182- O O

Effects NNS N
of IN N
two-month JJ i
vocal JJ i
exercising NN i
with IN N
and CC N
without IN N
spectral JJ i
biofeedback NN i
on IN N
student NN p
actors NNS p
' POS p
speaking NN N
voice NN N
. . N

Twelve NNP p
student NN p
actors NNS p
( ( p
6 CD p
males NNS p
, , p
6 CD p
females NNS p
) ) p
were VBD N
given VBN N
voice NN i
training VBG i
for IN N
two CD N
months NNS N
. . N

Randomly NNP N
selected VBD N
, , N
half NN N
of IN N
the DT N
students NNS p
( ( p
3 CD p
males NNS p
, , p
3 CD p
females NNS p
) ) p
was VBD N
trained VBN N
in IN N
the DT N
traditional JJ i
way NN i
, , N
while IN N
the DT N
other JJ N
half NN N
was VBD N
given VBN N
biofeedback RP N
with IN N
real-time JJ N
spectrum NN N
analysis NN N
. . N

The DT N
aim NN N
was VBD N
a DT N
ringing JJ o
voice NN o
quality NN o
with IN o
strong JJ o
overtones NNS o
at IN o
3-5 JJ o
kHz NN o
. . o

Text NNP N
samples VBZ N
read VBP N
at IN N
different JJ N
loudness NN N
levels NNS N
were VBD N
recorded VBN N
before IN N
and CC N
after IN N
training NN N
. . N

Fundamental JJ o
frequency NN o
( ( o
F0 NNP o
) ) o
, , o
sound JJ o
pressure NN o
level NN o
( ( o
SPL NNP o
) ) o
and CC o
long-term-average JJ o
spectrum NN o
( ( o
LTAS NNP o
) ) o
analyses NNS o
were VBD N
made VBN N
. . N

Voice NNP o
quality NN o
was VBD N
evaluated VBN N
by IN N
two CD N
voice NN N
trainers NNS N
. . N

Sound NNP o
energy NN o
at IN o
3-5 JJ o
kHz NNS o
increased VBN o
by IN o
3-4 JJ o
dB NN o
( ( N
1.5-14.5 JJ N
dB NN N
) ) N
across IN N
groups NNS N
after IN N
training VBG N
. . N

This DT N
change NN N
, , N
which WDT N
was VBD N
slightly RB N
larger JJR N
for IN N
the DT N
biofeedback NN N
( ( N
BF NNP N
) ) N
group NN N
, , N
did VBD N
not RB N
correlate VB N
with IN N
SPL NNP o
. . o

F0 NNP o
increased VBD o
slightly RB o
in IN N
the DT N
BF NNP N
group NN N
and CC N
decreased VBN o
in IN N
the DT N
control NN N
group NN N
. . N

The DT N
relative JJ o
dB NN o
level NN o
of IN o
fundamental JJ o
decreased VBN N
significantly RB N
more RBR N
in IN N
the DT N
BF NNP N
group NN N
probably RB N
suggesting VBG N
a DT N
tighter JJR N
adduction NN N
. . N

Voice NNP o
quality NN o
improved VBN N
in IN N
both DT N
groups NNS N
. . N

Visual JJ N
feedback NN N
seems VBZ N
to TO N
add VB N
some DT N
efficacy NN o
in IN N
voice NN N
training NN N
. . N

However RB N
, , N
there EX N
is VBZ N
a DT N
danger NN N
of IN N
hyperfunctional JJ N
voice NN N
production NN N
if IN N
other JJ N
sensory JJ N
feedback NN N
is VBZ N
neglected VBN N
. . N

-DOCSTART- -10757579- O O

Ropivacaine-clonidine JJ i
combination NN i
for IN N
caudal NN p
blockade NN p
in IN p
children NNS p
. . p

BACKGROUND NNP N
Adding NNP N
clonidine NN i
to TO N
weak JJ i
ropivacaine JJ i
solutions NNS i
( ( N
< VB N
0.2 CD N
% NN N
) ) N
could MD N
potentially RB N
enhance VB o
analgesia NN o
as RB N
well RB N
as IN N
further JJ N
reduce VB o
the DT o
risk NN o
for IN o
unwanted JJ o
motor NN o
blockade NN o
. . o

The DT N
aim NN N
of IN N
the DT N
present JJ N
study NN N
was VBD N
to TO N
compare VB N
the DT N
postoperative JJ N
pain-relieving JJ o
quality NN o
of IN N
a DT N
ropivacaine JJ i
0.1 CD i
% NN i
-clonidine JJ i
mixture NN i
to TO N
that DT N
of IN N
plain NN i
ropivacaine VBP i
0.2 CD N
% NN N
following VBG N
caudal JJ p
administration NN p
in IN p
children NNS p
. . p

METHODS NNP N
In IN N
a DT N
prospective JJ N
, , N
observer-blinded JJ N
fashion NN N
, , N
40 CD p
ASA NNP p
1 CD p
paediatric JJ p
patients NNS p
undergoing VBG p
subumbilical JJ p
surgery NN p
were VBD N
randomly RB i
allocated VBN i
to TO i
receive VB i
a DT i
caudal JJ i
injection NN i
of IN i
either DT i
plain NN i
ropivacaine VBP i
0.2 CD i
% NN i
( ( i
1 CD i
ml/kg NN i
) ) i
( ( i
R0.2 NNP i
) ) i
or CC i
a DT i
mixture NN i
of IN i
ropivacaine JJ i
0.1 CD i
% NN i
with IN i
clonidine JJ i
2 CD i
microg/kg NN i
( ( i
1 CD i
ml/kg NN i
) ) i
( ( i
R0.1C NNP i
) ) i
. . N

Objective JJ o
pain NN o
scale NN o
score NN o
and CC o
need NN o
for IN o
supplemental JJ o
analgesia NN o
were VBD i
used VBN i
to TO i
evaluate VB i
analgesia NN i
during IN i
the DT i
first JJ i
24 CD i
h NN i
postoperatively RB i
. . i

Residual JJ o
postoperative JJ o
sedation NN o
was VBD i
also RB i
assessed VBN i
. . i

RESULTS VB N
A DT N
significantly RB N
higher JJR N
number NN N
of IN N
patients NNS N
in IN N
the DT N
R0.1C NNP N
group NN N
( ( N
18/20 CD N
) ) N
could MD N
be VB N
managed VBN N
without IN N
supplemental JJ o
analgesia NN o
during IN N
the DT N
first JJ N
24 CD N
h NN N
postoperatively RB N
compared VBN N
to TO N
the DT N
R0.2 NNP N
group NN N
( ( N
11/20 CD N
) ) N
( ( N
P=0.034 NNP N
) ) N
. . N

Both CC N
the DT N
degree NN o
and CC o
the DT o
duration NN o
of IN o
postoperative JJ o
sedation NN o
was VBD N
similar JJ N
in IN N
both DT N
groups NNS N
. . N

No DT N
signs NNS N
of IN N
postoperative JJ o
motor NN o
blockade NN o
were VBD N
observed VBN N
. . N

CONCLUSIONS VB N
The DT N
combination NN N
of IN N
clonidine NN i
( ( i
2 CD i
microg/kg NN i
) ) i
and CC i
ropivacaine VB i
0.1 CD i
% NN i
is VBZ N
associated VBN N
with IN N
an DT N
improved JJ o
quality NN o
of IN o
postoperative JJ o
analgesia NN o
compared VBN N
to TO N
plain VB i
0.2 CD i
% NN i
ropivacaine NN i
. . i

The DT N
improved JJ o
analgesic JJ o
quality NN o
of IN N
the DT N
clonidine-ropivacaine JJ N
mixture NN N
is VBZ N
achieved VBN N
without IN N
causing VBG N
any DT N
significant JJ N
degree NN N
of IN N
postoperative JJ N
sedation NN N
. . N

-DOCSTART- -24799074- O O

Development NNP N
and CC N
in IN N
vitro/in JJ N
vivo JJ N
evaluation NN N
of IN N
immediate JJ N
release NN N
perindopril NN i
tablets NNS i
. . i

Perindopril NNP i
erbumine NN i
( ( i
PE NNP i
) ) i
is VBZ N
a DT N
BCS NNP N
( ( N
Biopharmaceutics NNPS N
Classification NNP N
System NNP N
) ) N
class NN N
3 CD N
drug NN N
with IN N
high JJ N
solubility NN N
and CC N
low JJ N
permeability NN N
. . N

It PRP N
is VBZ N
an DT N
inhibitor NN N
of IN N
the DT N
enzyme NN N
that WDT N
converts VBZ N
angiotensin NN N
I PRP N
( ( N
Angiotensin NNP N
Converting NNP N
Enzyme NNP N
, , N
ACE NNP N
) ) N
into IN N
angiotensin NN N
II NNP N
as RB N
well RB N
as IN N
causing VBG N
the DT N
degradation NN N
of IN N
the DT N
vasodilator NN N
bradykinin NN N
into IN N
an DT N
inactive JJ N
heptapeptide NN N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
develop VB N
an DT N
alternative JJ N
drug NN N
product NN N
by IN N
using VBG N
a DT N
different JJ N
salt NN N
of IN N
perindopril NN i
and CC N
to TO N
evaluate VB N
the DT N
bioequivalence NN N
between IN N
PE NNP N
, , N
not RB N
still RB N
licensed VBN N
, , N
and CC N
perindopril JJ N
arginine NN N
( ( N
PA NNP N
) ) N
, , N
licensed VBD N
in IN N
many JJ N
countries NNS N
, , N
and CC N
to TO N
prepare VB N
PE NNP N
tablets NNS N
by IN N
using VBG N
direct JJ N
compression NN N
method NN N
. . N

Many JJ N
different JJ N
formulations NNS N
were VBD N
prepared VBN N
, , N
among IN N
which WDT N
F3-coded NNP i
formulation NN i
was VBD N
only RB N
selected VBN N
due JJ N
to TO N
releasing VBG N
of IN N
98.03 CD N
% NN N
active JJ N
substance NN N
at IN N
45th CD N
minute NN N
. . N

Bioequivalence NNP N
study NN N
was VBD N
planned VBN N
as IN N
a DT N
cross-designed JJ N
, , N
randomized VBN N
, , N
open-labeled JJ N
, , N
single-dose JJ N
, , N
single-center JJ N
study NN N
and CC N
conducted VBN p
in IN p
24 CD p
male NN p
healthy JJ p
volunteers NNS p
via IN p
peroral JJ p
route NN p
. . p

The DT N
results NNS N
of IN N
bioequivalence NN N
study NN N
were VBD N
evaluated VBN N
for IN N
Perindopril NNP i
and CC i
Perindoprilat NNP i
according VBG N
to TO N
Cmax NNP o
, , o
tmax NN o
and CC o
AUC NNP o
criteria NNS o
. . o

The DT N
geometric JJ o
mean JJ o
ratios NNS o
( ( N
90 CD N
% NN N
CI NNP N
) ) N
of IN N
perindopril NN i
and CC i
perindoprilat NN i
followed VBD N
test NN N
and CC N
reference NN N
drug NN N
were VBD N
calculated VBN N
for IN N
AUC0-t NNP o
and CC N
Cmax NNP o
, , N
105.946 CD N
% NN N
( ( N
100.218-112.002 CD N
% NN N
) ) N
and CC N
110.437 CD N
% NN N
( ( N
102.534-118.948 CD N
% NN N
) ) N
; : N
109.542 CD N
% NN N
( ( N
98.364-121.992 CD N
% NN N
) ) N
and CC N
115.729 CD N
% NN N
( ( N
101.031-132.565 CD N
% NN N
) ) N
, , N
respectively RB N
. . N

The DT N
90 CD N
% NN N
confidence NN N
intervals NNS N
of IN N
them PRP N
were VBD N
found VBN N
within IN N
the DT N
standard JJ N
bioequivalence NN o
range NN o
( ( N
80-125 CD N
% NN N
) ) N
. . N

-DOCSTART- -10078673- O O

Comparison NNP N
of IN N
three CD N
solutions NNS N
of IN N
ropivacaine/fentanyl NN i
for IN N
postoperative JJ p
patient-controlled JJ p
epidural JJ p
analgesia NN p
. . p

BACKGROUND NNP N
Ropivacaine NNP i
, , N
0.2 CD N
% NN N
, , N
is VBZ N
a DT N
new JJ N
local JJ N
anesthetic JJ N
approved VBN N
for IN N
epidural JJ N
analgesia NN N
. . N

The DT N
addition NN N
of IN N
4 CD N
microg/ml NNS N
fentanyl JJ i
improves NNS N
analgesia VBP N
from IN N
epidural JJ N
ropivacaine NN N
. . N

Use NNP N
of IN N
a DT N
lower JJR N
concentration NN N
of IN N
ropivacaine-fentanyl NN i
may MD N
further VB N
improve VB N
analgesia NN o
or CC N
decrease JJ N
side NN o
effects NNS o
. . o

METHODS NNP N
Thirty NNP p
patients NNS p
undergoing VBG p
lower JJR p
abdominal JJ p
surgery NN p
were VBD p
randomized VBN p
in IN N
a DT N
double-blinded JJ N
manner NN N
to TO N
receive VB N
one CD N
of IN N
three CD N
solutions NNS N
: : N
0.2 CD i
% NN i
ropivacaine-4 JJ i
microg NN i
fentanyl VBD i
0.1 CD i
% NN i
ropivacaine-2 JJ i
microg NN i
fentanyl NN i
, , i
or CC i
0.05 CD i
% NN i
ropivacaine-1 JJ i
microg NN i
fentanyl NN i
for IN N
patient-controlled JJ N
epidural JJ N
analgesia NN N
after IN N
standardized VBN N
combined JJ N
epidural JJ N
and CC N
general JJ N
anesthesia NN N
. . N

Patient-controlled JJ N
epidural JJ N
analgesia NN N
settings NNS N
and CC N
adjustments NNS N
for IN N
the DT N
three CD N
solutions NNS N
were VBD N
standardized VBN N
to TO N
deliver VB N
equivalent JJ N
drug NN N
doses NNS N
. . N

Pain NN o
scores NNS o
( ( o
rest NN o
, , o
cough NN o
, , o
and CC o
ambulation NN o
) ) o
, , o
side JJ o
effects NNS o
( ( o
nausea NN o
, , o
pruritus NN o
, , o
sedation NN o
, , o
motor NN o
block NN o
, , o
hypotension NN o
, , o
and CC o
orthostasis NN o
) ) o
, , o
and CC o
patient-controlled JJ o
epidural JJ o
analgesia NN o
consumption NN o
were VBD N
measured VBN N
for IN N
48 CD N
h. JJ N
RESULTS NNP N
All NNP N
three CD N
solutions NNS N
produced VBD N
equivalent JJ N
analgesia NN N
. . N

Motor NNP o
block NN o
was VBD N
significantly RB N
more JJR N
common JJ N
( ( N
30 CD N
vs. FW N
0 CD N
% NN N
) ) N
and CC N
more JJR N
intense JJ N
with IN N
the DT N
0.2 CD N
% NN N
ropivacaine-4 JJ i
microg NN N
fentanyl JJ N
solution NN N
. . N

Other JJ N
side NN N
effects NNS N
were VBD N
equivalent JJ N
between IN N
solutions NNS N
and CC N
mild NN N
in IN N
severity NN o
. . o

A DT N
significantly RB N
smaller JJR N
volume NN N
of IN N
0.2 CD N
% NN N
ropivacaine-4 JJ o
microg NN o
fentanyl JJ o
solution NN o
was VBD N
used VBN N
, , N
whereas IN N
the DT N
0.1 CD N
% NN N
ropivacaine-2 JJ i
microg NN N
fentanyl NN N
group NN N
used VBD N
a DT N
significantly RB N
greater JJR N
amount NN N
of IN N
ropivacaine NN o
and CC o
fentanyl NN o
. . o

CONCLUSIONS NNP N
Lesser NNP N
concentrations NNS N
of IN N
ropivacaine NN i
and CC N
fentanyl JJ i
provide NN N
comparable JJ N
analgesia NN o
with IN N
less JJR N
motor NN o
block NN o
despite IN N
the DT N
use NN N
of IN N
similar JJ N
amounts NNS N
of IN N
ropivacaine NN N
and CC N
fentanyl NN N
. . N

This DT N
finding NN N
suggests VBZ N
that IN N
concentration NN N
of IN N
local JJ N
anesthetic JJ N
solution NN N
at IN N
low JJ N
doses NNS N
is VBZ N
a DT N
primary JJ N
determinant NN o
of IN o
motor NN o
block NN o
with IN N
patient-controlled JJ N
epidural JJ N
analgesia NN N
after IN N
lower JJR N
abdominal JJ N
surgery NN N
. . N

-DOCSTART- -8540453- O O

Effect NN N
of IN N
dietary JJ N
supplementation NN N
with IN N
n-3 JJ N
fatty JJ N
acids NNS N
on IN N
coronary JJ p
artery NN p
bypass NN p
graft NN p
patency NN p
. . p

Epidemiologic NNP N
and CC N
experimental JJ N
data NNS N
suggest VBP N
that IN N
a DT N
high JJ N
dietary JJ N
intake NN N
of IN N
long-chain JJ N
polyunsaturated JJ N
n-3 JJ i
fatty JJ i
acids NNS i
may MD N
reduce VB N
the DT N
risk NN N
of IN N
atherothrombotic JJ N
disease NN N
. . N

In IN N
a DT N
randomized NN N
, , N
controlled VBD N
study NN N
, , N
610 CD p
patients NNS p
undergoing JJ p
coronary JJ p
artery NN p
bypass NN p
grafting VBG p
were VBD N
assigned VBN N
either RB N
to TO N
a DT N
fish JJ i
oil NN i
group NN i
, , i
receiving VBG i
4 CD i
g/day NN i
of IN i
fish JJ i
oil NN i
concentrate NN i
, , i
or CC i
to TO i
a DT i
control NN i
group NN i
. . i

All DT p
patients NNS p
received VBD p
antithrombotic JJ i
treatment NN i
, , i
either CC i
aspirin NN i
or CC i
warfarin NN i
. . i

Their PRP$ N
diet JJ N
and CC N
serum JJ N
phospholipid JJ N
fatty JJ N
acid NN N
profiles NNS N
were VBD N
monitored VBN N
. . N

The DT N
primary JJ N
end NN N
point NN N
was VBD N
1-year JJ N
graft NN o
patency NN o
, , N
which WDT N
was VBD N
assessed VBN N
by IN N
angiography NN N
in IN N
95 CD N
% NN N
of IN N
patients NNS N
. . N

Vein NNP o
graft JJ o
occlusion NN o
rates NNS o
per IN o
distal JJ o
anastomoses NNS o
were VBD N
27 CD N
% NN N
in IN N
the DT N
fish JJ i
oil NN i
group NN N
and CC N
33 CD N
% NN N
in IN N
the DT N
control NN N
group NN N
( ( N
odds NNS N
ratio VBP N
0.77 CD N
, , N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
0.60 CD N
to TO N
0.99 CD N
, , N
p NN N
= NNP N
0.034 CD N
) ) N
. . N

In IN N
the DT N
fish JJ i
oil NN i
group NN N
, , N
43 CD N
% NN N
of IN N
the DT N
patients NNS N
had VBD N
> VBN o
or CC o
= $ o
1 CD o
occluded VBN o
vein NN o
graft NN o
( ( o
s PRP o
) ) o
compared VBN N
with IN N
51 CD N
% NN N
in IN N
the DT N
control NN N
group NN N
( ( N
odds NNS N
ratio VBP N
0.72 CD N
, , N
95 CD N
% NN N
confidence NN N
interval NN N
, , N
0.51 CD N
to TO N
1.01 CD N
, , N
p NN N
= NNP N
0.05 CD N
) ) N
. . N

Moreover RB N
, , N
in IN N
the DT N
entire JJ N
patient NN N
group NN N
, , N
there EX N
was VBD N
a DT N
significant JJ N
trend NN N
to TO N
fewer JJR N
patients NNS N
with IN N
vein JJ N
graft NN N
occlusions NNS N
with IN N
increasing VBG N
relative JJ N
change NN N
in IN N
serum JJ o
phospholipid JJ o
n-3 JJ o
fatty JJ o
acids NNS o
during IN N
the DT N
study NN N
period NN N
( ( N
p NN N
for IN N
linear JJ N
trend NN N
= VBZ N
0.0037 CD N
) ) N
. . N

Thus RB N
, , N
in IN N
patients NNS p
undergoing VBG p
coronary JJ p
artery NN p
bypass NN p
grafting NN p
, , N
dietary JJ N
supplementation NN N
with IN N
n-3 JJ i
fatty JJ i
acids NNS i
reduced VBD N
the DT N
incidence NN N
of IN N
vein NN N
graft NN N
occlusion NN N
, , N
and CC N
an DT N
inverse JJ N
relation NN N
between IN N
relative JJ N
change NN N
in IN N
serum JJ o
phospholipid JJ o
n-3 JJ o
fatty JJ o
acids NNS o
and CC o
vein NN o
graft NN o
occlusions NNS o
was VBD N
observed VBN N
. . N

-DOCSTART- -18665413- O O

Effects NNS N
of IN N
fatty NN i
and CC i
lean JJ i
fish JJ i
intake NN i
on IN N
blood NN o
pressure NN o
in IN N
subjects NNS p
with IN p
coronary JJ p
heart NN p
disease NN p
using VBG p
multiple JJ p
medications NNS p
. . p

BACKGROUND NNP N
Intake NNP N
of IN N
fish JJ N
and CC N
long-chain JJ N
n-3 JJ N
fatty NN N
acids NNS N
has VBZ N
been VBN N
of IN N
wide JJ N
interest NN N
due JJ N
to TO N
their PRP$ N
beneficial JJ N
effects NNS N
on IN N
cardiovascular JJ N
risk NN N
factors NNS N
and CC N
lower JJR N
coronary JJ p
heart NN p
disease NN p
( ( p
CHD NNP p
) ) p
risk NN N
. . N

AIM NNP N
OF IN N
THE NNP N
STUDY NNP N
The DT N
aim NN N
of IN N
this DT N
pilot NN N
study NN N
was VBD N
to TO N
examine VB N
the DT N
effects NNS N
of IN N
fatty JJ i
fish NN i
and CC N
lean JJ i
( ( i
white JJ i
) ) i
fish NN i
on IN N
fatty JJ o
acid JJ o
composition NN o
of IN o
serum NN o
lipids NNS o
and CC N
cardiovascular JJ o
risk NN o
factors NNS o
in IN N
subjects NNS p
with IN p
CHD NNP p
using VBG p
multiple JJ p
drugs NNS p
for IN p
this DT p
condition NN p
. . p

METHODS NNP N
The DT N
study NN N
was VBD N
an DT N
8-week JJ N
controlled NN N
, , N
parallel JJ N
intervention NN N
. . N

Inclusion NNP p
criteria NNS p
were VBD p
myocardial JJ p
infarction NN p
or CC p
unstable JJ p
ischemic JJ p
attack NN p
, , p
age NN p
under IN p
70 CD p
years NNS p
, , p
use NN p
of IN p
betablockers NNS p
and CC p
presence NN p
of IN p
sinus NN p
rhythm NN p
. . p

The DT N
subjects NNS N
were VBD N
randomized VBN N
to TO N
one CD N
of IN N
the DT N
following JJ N
groups NNS N
: : N
4 CD i
meals/week NN i
fatty JJ i
fish NN i
( ( i
n JJ i
= NNP i
11 CD i
) ) i
, , i
4 CD i
meals/week JJ i
lean JJ i
fish NN i
( ( i
n JJ i
= NNP i
12 CD i
) ) i
and CC i
control VB i
diet JJ i
including VBG i
lean JJ i
meat NN i
( ( i
n JJ i
= NNP i
10 CD i
) ) i
. . i

RESULTS VB N
The DT N
mean JJ N
( ( N
+/-SD JJ N
) ) N
of IN N
reported VBN N
fish JJ N
meals NNS N
per IN N
week NN N
was VBD N
4.3 CD N
+/- JJ N
0.4 CD N
, , N
4.7 CD N
+/- JJ N
1.1 CD N
and CC N
0.6 CD N
+/- JJ N
0.4 CD N
in IN N
the DT N
groups NNS N
, , N
respectively RB N
. . N

The DT N
proportions NNS o
of IN o
eicosapentaenoic NN o
and CC o
docosahexaenoic JJ o
acids NNS o
in IN o
serum JJ o
lipids NNS o
increased VBD N
in IN N
the DT N
fatty JJ N
fish NN N
group NN N
only RB N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

Systolic NNP o
and CC o
diastolic JJ o
blood NN o
pressure NN o
levels NNS N
decreased VBN N
in IN N
the DT N
lean JJ N
fish NN N
group NN N
( ( N
0 CD N
vs. FW N
8 CD N
week NN N
: : N
3.5 CD N
+/- JJ N
3.2 CD N
and CC N
4.6 CD N
+/- JJ N
3.6 CD N
% NN N
, , N
respectively RB N
, , N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

Serum NNP o
total JJ o
triglyceride JJ o
concentration NN o
did VBD N
not RB N
significantly RB N
change VBP N
. . N

HDL NNP o
cholesterol NN o
concentration NN o
change NN N
differed VBD N
among IN N
groups NNS N
but CC N
without IN N
significant JJ N
post NN N
hoc NN N
differences NNS N
. . N

Apolipoprotein NNP o
A-1 JJ o
concentration NN o
decreased VBN N
in IN N
the DT N
control NN N
group NN N
( ( N
0 CD N
vs. FW N
8 CD N
week NN N
, , N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

Coagulation NN o
factors NNS o
, , o
25-hydroxy JJ o
vitamin NN o
D NNP o
, , o
and CC o
heart NN o
rate NN o
variability NN o
( ( o
24 CD o
h RB o
Holter NNP o
) ) o
did VBD N
not RB N
change VB N
among IN N
the DT N
groups NNS N
. . N

CONCLUSIONS NNP N
Our PRP$ N
results NNS N
suggest VBP N
that IN N
intake NN N
of IN N
lean JJ i
fish NN i
at IN N
least JJS N
four CD N
times NNS N
per IN N
week NN N
could MD N
reduce VB N
blood NN N
pressure NN N
levels NNS N
in IN N
CHD NNP p
patients NNS p
. . p

-DOCSTART- -2023746- O O

Aminocaproic NNP i
acid VBZ i
versus FW N
prednisone NN i
for IN N
the DT N
treatment NN N
of IN N
traumatic JJ p
hyphema NN p
. . p

A DT N
randomized JJ N
clinical JJ N
trial NN N
. . N

One CD p
hundred VBD p
twelve NN p
patients NNS p
who WP p
sustained VBD p
hyphema NN p
after IN p
blunt NN p
trauma NN p
were VBD p
enrolled VBN p
in IN N
a DT N
double-blind JJ N
randomized JJ N
clinical JJ N
trial NN N
to TO N
determine VB N
the DT N
relative JJ N
efficacies NNS N
of IN N
aminocaproic JJ i
acid NN i
( ( i
Amicar NNP i
) ) i
and CC N
systemic JJ i
prednisone NN i
for IN N
reducing VBG N
the DT N
rate NN o
of IN o
secondary JJ o
hemorrhage NN o
. . o

Fifty-six JJ N
patients NNS N
received VBD N
an DT N
oral JJ i
dosage NN i
of IN i
50 CD i
mg/kg NN i
of IN i
aminocaproic JJ i
acid NN i
every DT N
4 CD N
hours NNS N
for IN N
5 CD N
days NNS N
, , N
up RB N
to TO N
a DT N
maximum NN N
of IN N
30 CD N
g JJ N
daily JJ N
, , N
and CC N
56 CD N
patients NNS N
received VBD N
an DT N
oral JJ i
dosage NN i
of IN i
40 CD i
mg NN i
of IN i
prednisone JJ i
daily JJ i
( ( N
adjusted VBN N
for IN N
weight NN N
) ) N
in IN N
two CD N
divided JJ N
doses NNS N
. . N

Placebo NNP i
pills NNS N
and CC N
liquids NNS N
were VBD N
given VBN N
to TO N
each DT N
patient NN N
to TO N
mask VB N
the DT N
treatment NN N
schedules NNS N
. . N

There EX N
were VBD N
no DT N
statistically RB N
significant JJ N
differences NNS N
between IN N
the DT N
patient NN N
populations NNS N
for IN N
any DT N
demographic JJ N
or CC N
clinical JJ N
characteristic NN N
( ( N
e.g. JJ N
, , N
visual JJ o
acuity NN o
, , o
intraocular JJ o
pressure NN o
[ NNP o
IOP NNP o
] NNP o
, , o
initial JJ o
hyphema NN o
size NN o
) ) o
measured VBN N
in IN N
the DT N
study NN N
. . N

Blacks NNS p
comprised VBD p
53 CD p
% NN p
of IN p
the DT p
study NN p
population NN p
, , p
and CC p
the DT p
mean JJ p
age NN p
of IN p
the DT p
patients NNS p
was VBD p
23.5 CD p
years NNS p
. . p

Four CD N
patients NNS N
in IN N
each DT N
of IN N
the DT N
treatment NN N
groups NNS N
experienced VBD N
a DT N
secondary JJ o
hemorrhage NN o
; : o
the DT N
rebleed NN o
rate NN o
was VBD N
7.1 CD N
% NN N
in IN N
each DT N
group NN N
. . N

-DOCSTART- -11106679- O O

Chemoprevention NN N
of IN N
gastric JJ N
dysplasia NN N
: : N
randomized JJ N
trial NN N
of IN N
antioxidant JJ i
supplements NNS i
and CC i
anti-helicobacter JJ i
pylori NN i
therapy NN i
. . i

BACKGROUND NNP N
Previous NNP N
research NN N
has VBZ N
identified VBN N
a DT N
high JJ N
risk NN N
of IN N
gastric JJ N
carcinoma NN N
as RB N
well RB N
as IN N
a DT N
high JJ N
prevalence NN N
of IN N
cancer NN N
precursor NN N
lesions NNS N
in IN N
rural JJ p
populations NNS p
living VBG p
in IN p
the DT p
province NN p
of IN p
Nari?o NNP p
, , p
Colombia NNP p
, , p
in IN p
the DT p
Andes NNP p
Mountains NNP p
. . p

METHODS NNP N
A NNP N
randomized NN N
, , N
controlled VBN N
chemoprevention NN N
trial NN N
was VBD N
conducted VBN N
in IN p
subjects NNS p
with IN p
confirmed JJ p
histologic JJ p
diagnoses NNS p
of IN p
multifocal JJ p
nonmetaplastic JJ p
atrophy NN p
and/or IN p
intestinal JJ p
metaplasia NN p
, , p
two CD p
precancerous JJ p
lesions NNS p
. . p

Individuals NNS N
were VBD N
assigned VBN N
to TO i
receive VB i
anti-Helicobacter JJ i
pylori NN i
triple JJ i
therapy NN i
and/or NN i
dietary JJ i
supplementation NN i
with IN i
ascorbic JJ i
acid NN i
, , i
beta-carotene JJ i
, , i
or CC i
their PRP$ i
corresponding JJ i
placebos NN i
. . i

Gastric NNP o
biopsy NN o
specimens VBZ o
taken VBN i
at IN i
baseline NN i
were VBD i
compared VBN i
with IN i
those DT i
taken VBN i
at IN i
72 CD i
months NNS i
. . i

Relative JJ N
risks NNS N
of IN o
progression NN o
, , o
no DT o
change NN o
, , o
and CC o
regression NN o
from IN N
multifocal JJ N
nonmetaplastic JJ N
atrophy NN N
and CC N
intestinal JJ N
metaplasia NN N
were VBD N
analyzed VBN N
with IN N
multivariate NN N
polytomous JJ N
logistic JJ N
regression NN N
models NNS N
to TO N
estimate VB N
treatment NN N
effects NNS N
. . N

All DT N
statistical JJ N
tests NNS N
were VBD N
two-sided JJ N
. . N

RESULTS VB N
All DT N
three CD N
basic JJ N
interventions NNS N
resulted VBD N
in IN N
statistically RB N
significant JJ N
increases NNS N
in IN N
the DT o
rates NNS o
of IN o
regression NN o
: : o
Relative JJ N
risks NNS N
were VBD N
4.8 CD N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NNP N
= NNP N
1.6-14.2 JJ N
) ) N
for IN N
anti-H. JJ N
pylori NN N
treatment NN N
, , N
5 CD N
. . N

1 CD N
( ( N
95 CD N
% NN N
CI NNP N
= NNP N
1.7-15.0 JJ N
) ) N
for IN i
beta-carotene JJ i
treatment NN N
, , N
and CC N
5.0 CD N
( ( N
95 CD N
% NN N
CI NNP N
= NNP N
1.7-14.4 JJ N
) ) N
for IN i
ascorbic JJ i
acid JJ i
treatment NN N
in IN N
subjects NNS N
with IN N
atrophy NN N
. . N

Corresponding VBG N
relative JJ o
risks NNS o
of IN o
regression NN o
in IN N
subjects NNS N
with IN N
intestinal JJ N
metaplasia NNS N
were VBD N
3.1 CD N
( ( N
95 CD N
% NN N
CI NNP N
= NNP N
1.0-9.3 JJ N
) ) N
, , N
3.4 CD N
( ( N
95 CD N
% NN N
CI NNP N
= NNP N
1.1-9.8 JJ N
) ) N
, , N
and CC N
3.3 CD N
( ( N
95 CD N
% NN N
CI NNP N
= NNP N
1.1-9.5 JJ N
) ) N
. . N

Combinations NNS N
of IN N
treatments NNS N
did VBD N
not RB N
statistically RB N
significantly RB N
increase VB N
the DT o
regression NN o
rates NNS o
. . o

Curing VBG N
the DT N
H. NNP N
pylori NN N
infection NN N
( ( N
which WDT N
occurred VBD N
in IN N
74 CD N
% NN N
of IN N
the DT N
treated JJ N
subjects NNS N
) ) N
produced VBD N
a DT N
marked JJ N
and CC N
statistically RB N
significant JJ N
increase NN N
in IN N
the DT o
rate NN o
of IN o
regression NN o
of IN N
the DT N
precursor NN N
lesions NNS N
( ( N
relative JJ N
risks NNS N
= VBP N
8.7 CD N
[ JJ N
95 CD N
% NN N
CI NNP N
= NNP N
2.7-28.2 JJ N
] NN N
for IN p
subjects NNS p
with IN p
atrophy NN p
and CC N
5.4 CD N
[ JJ N
95 CD N
% NN N
CI NNP N
= NNP N
1.7-17.6 JJ N
] NN N
for IN p
subjects NNS p
with IN p
intestinal JJ p
metaplasia NN p
) ) p
. . p

CONCLUSIONS NNP N
In IN N
the DT p
very RB p
high-risk JJ p
population NN p
studied VBN N
, , N
effective JJ N
anti-H. JJ N
pylori NN N
treatment NN N
and CC N
dietary JJ N
supplementation NN N
with IN N
antioxidant JJ N
micronutrients NNS N
may MD N
interfere VB N
with IN N
the DT N
precancerous JJ N
process NN N
, , N
mostly RB N
by IN N
increasing VBG N
the DT N
rate NN N
of IN o
regression NN o
of IN N
cancer NN N
precursor NN N
lesions NNS N
, , N
and CC N
may MD N
be VB N
an DT N
effective JJ N
strategy NN N
to TO N
prevent VB N
gastric JJ N
carcinoma NN N
. . N

-DOCSTART- -6123343- O O

An DT N
assessment NN N
of IN N
beta-adrenoceptor NN p
blockade NN p
in IN p
man NN p
by IN p
prizidilol JJ i
hydrochloride NN i
. . i

1 CD N
Prizidilol NNP i
hydrochloride NN i
( ( N
SK NNP N
& CC N
F NNP N
92657 CD N
) ) N
is VBZ N
a DT N
new JJ N
compound NN N
which WDT N
causes VBZ N
both DT N
arteriolar JJ N
dilatation NN N
and CC N
beta-adrenoceptor NN o
blockade NN o
. . o

The DT N
effect NN N
of IN N
a DT N
single JJ N
oral JJ N
dose NN N
on IN N
the DT N
responses NNS N
of IN N
heart NN N
rate NN N
and CC N
blood NN N
pressure NN N
to TO N
isoprenaline VB N
infusion NN N
has VBZ N
been VBN N
studied VBN N
in IN N
healthy JJ p
volunteers NNS p
. . p

2 CD N
Isoprenaline JJ i
heart NN o
rate NN o
dose-response JJ o
curves NNS o
showed VBD N
parallel JJ N
shifts NNS N
to TO N
the DT N
right NN N
after IN N
oral JJ N
prizidilol NN i
, , N
indicating VBG N
antagonism NN N
by IN N
this DT N
compound NN N
at IN N
beta-adrenoceptors NNS N
in IN N
the DT N
heart NN N
. . N

3 CD N
Isoprenaline NNP N
dose-response JJ N
curves NNS N
for IN N
decreases NNS N
in IN N
diastolic JJ o
blood NN o
pressure NN o
also RB N
showed VBD N
shifts NNS N
to TO N
the DT N
right NN N
after IN N
oral JJ N
prizidilol NN i
, , N
providing VBG N
evidence NN N
of IN N
beta-adrenoceptor NN N
antagonism NN N
by IN N
this DT N
drug NN N
in IN N
peripheral JJ N
resistance NN N
vessels NNS N
. . N

4 CD N
The DT N
peak JJ N
effect NN N
of IN N
a DT N
40 CD N
mg NN N
dose NN N
of IN N
propranolol NN i
was VBD N
greater JJR N
than IN N
that DT N
of IN N
a DT N
200 CD N
mg NN N
dose NN N
of IN N
prizidilol NN i
but CC N
both DT N
drugs NNS N
caused VBD N
persistent JJ N
beta-adrenoceptor NN o
blockade NN o
for IN N
at IN N
least JJS N
7 CD N
h NN N
after IN N
ingestion NN N
. . N

-DOCSTART- -20536364- O O

Standard NNP N
versus NN N
newer NN N
antibacterial JJ N
agents NNS N
in IN N
the DT N
treatment NN N
of IN N
severe JJ p
acute JJ p
exacerbation NN p
of IN p
chronic JJ p
obstructive JJ p
pulmonary JJ p
disease NN p
: : p
a DT N
randomized JJ N
trial NN N
of IN N
trimethoprim-sulfamethoxazole JJ i
versus NN N
ciprofloxacin NN N
. . N

BACKGROUND NNP N
. . N

Although IN N
the DT N
use NN N
of IN N
antibiotics NNS N
in IN N
the DT N
treatment NN N
of IN N
acute JJ N
exacerbation NN N
of IN N
chronic JJ p
obstructive JJ p
pulmonary JJ p
disease NN p
( ( p
COPD NNP p
) ) p
is VBZ N
largely RB N
accepted VBN N
, , N
controversy NN N
remains VBZ N
regarding VBG N
whether IN N
the DT N
choice NN N
of IN N
antibiotic JJ N
has VBZ N
any DT N
impact NN N
on IN N
outcome NN N
. . N

Our PRP$ N
aim NN N
was VBD N
to TO N
compare VB N
the DT N
effects NNS N
of IN N
the DT N
combination NN N
of IN N
trimethoprim JJ i
and CC i
sulfamethoxazole JJ i
and CC N
ciprofloxacin NN N
in IN N
patients NNS p
treated VBN p
for IN p
severe JJ p
COPD NNP p
exacerbation NN p
requiring VBG p
mechanical JJ p
ventilation NN p
. . p

METHODS NNP N
. . N

In IN N
a DT N
randomized JJ N
, , N
double-blind JJ N
trial NN N
, , N
we PRP N
included VBD N
170 CD p
patients NNS p
with IN p
an DT p
acute JJ p
exacerbation NN p
of IN p
COPD NNP p
requiring VBG p
mechanical JJ p
ventilation NN p
. . p

Enrolled JJ N
patients NNS N
received VBN N
trimethoprim-sulfamethoxazole JJ i
( ( N
n JJ N
= NNP N
85 CD N
) ) N
or CC N
ciprofloxacin NN i
( ( N
n JJ N
= NNP N
85 CD N
) ) N
for IN N
10 CD N
days NNS N
. . N

Main NNP N
outcomes NNS N
were VBD N
hospital JJ o
death NN o
and CC N
need NN o
for IN o
an DT o
additional JJ o
course NN o
of IN o
antibiotics NNS o
. . o

Secondary JJ N
outcomes NNS N
were VBD N
duration NN o
of IN o
mechanical JJ o
ventilation NN o
, , o
length NN o
of IN o
hospital NN o
stay NN o
, , o
and CC o
exacerbation-free JJ o
interval NN o
. . o

RESULTS NNP N
. . N

Combined NNP N
hospital JJ o
death NN o
and CC o
additional JJ o
antibiotic JJ o
prescription NN o
rates NNS o
were VBD N
similar JJ N
in IN N
the DT N
2 CD N
groups NNS N
( ( N
16.4 CD N
% NN N
vs JJ N
15.3 CD N
% NN N
for IN N
trimethoprim-sulfamethoxazole JJ N
group NN N
vs NN N
ciprofloxacin NN N
group NN N
; : N
difference NN N
, , N
1.1 CD N
% NN N
; : N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NNP N
-9.8 NNP N
% NN N
to TO N
12.0 CD N
% NN N
; : N
P NNP N
= NNP N
.832 NNP N
) ) N
. . N

Hospital NNP o
death NN o
occurred VBD N
in IN N
7 CD N
patients NNS N
( ( N
8.2 CD N
% NN N
) ) N
receiving VBG N
trimethoprim-sulfamethoxazole JJ i
and CC N
8 CD N
patients NNS N
( ( N
9.4 CD N
% NN N
) ) N
receiving NN N
ciprofloxacin NN N
( ( N
difference NN N
, , N
-1.2 CD N
% NN N
; : N
95 CD N
% NN N
CI NNP N
, , N
-9.7 NNP N
to TO N
7.3 CD N
; : N
P NNP N
= NNP N
.90 NNP N
) ) N
. . N

The DT N
need NN o
for IN o
an DT o
additional JJ o
antibiotic JJ o
course NN o
was VBD N
observed VBN N
in IN N
8 CD N
patients NNS N
in IN N
the DT N
trimethoprim-sulfamethoxazole JJ i
group NN N
and CC N
5 CD N
patients NNS N
in IN N
the DT N
ciprofloxacin NN N
group NN N
( ( N
difference NN N
, , N
2.3 CD N
% NN N
; : N
95 CD N
% NN N
CI NNP N
, , N
-5.4 NNP N
to TO N
10.0 CD N
; : N
P NNP N
= NNP N
.549 NNP N
) ) N
. . N

The DT N
mean JJ o
exacerbation-free JJ o
interval NN o
( ( N
+/- JJ N
standard NN N
deviation NN N
) ) N
was VBD N
similar JJ N
in IN N
both DT N
treatment NN N
groups NNS N
( ( N
83 CD N
+/- JJ N
25 CD N
vs JJ N
79 CD N
+/- JJ N
22 CD N
for IN N
the DT N
trimethoprim-sulfamethoxazole JJ i
group NN N
vs NN N
ciprofloxacin NN N
group NN N
; : N
difference NN N
, , N
4 CD N
days NNS N
; : N
95 CD N
% NN N
CI NNP N
, , N
-15 NNP N
to TO N
19 CD N
days NNS N
; : N
P NNP N
= NNP N
.41 NNP N
) ) N
. . N

Duration NN o
of IN o
mechanical JJ o
ventilation NN o
and CC o
hospital NN o
stay NN o
was VBD N
not RB N
significantly RB N
different JJ N
between IN N
the DT N
2 CD N
groups NNS N
. . N

CONCLUSIONS NNP N
. . N

In IN N
patients NNS p
with IN p
acute JJ p
exacerbation NN p
of IN p
COPD NNP p
requiring VBG p
mechanical JJ p
ventilation NN p
, , N
efficacy NN o
of IN N
trimethoprim-sulfamethoxazole NN i
was VBD N
not RB N
inferior JJ N
to TO N
ciprofloxacin VB N
. . N

Trial JJ N
registration NN N
. . N

ClinicalTrials.gov NNP N
identifier NN N
: : N
NCT00791505 NNP N
. . N

-DOCSTART- -24732169- O O

Effect NN N
of IN N
a DT N
mixed JJ i
kinesio JJ i
taping-compression NN i
technique NN i
on IN N
quality NN o
of IN o
life NN o
and CC N
clinical JJ o
and CC N
gait JJ o
parameters NNS o
in IN N
postmenopausal JJ p
women NNS p
with IN p
chronic JJ p
venous JJ p
insufficiency NN p
: : p
double-blinded JJ N
, , N
randomized VBN N
controlled VBN N
trial NN N
. . N

OBJECTIVE UH N
To TO N
investigate VB N
the DT N
short-term JJ N
effect NN N
of IN N
a DT N
mixed JJ N
Kinesio NNP i
taping NN i
( ( N
KT NNP N
) ) N
model NN N
on IN N
range NN o
of IN o
ankle JJ o
motion NN o
( ( o
ROAM NNP o
) ) o
, , o
gait NN o
, , o
pain NN o
, , o
perimeter NN o
of IN o
lower JJR o
limbs NN o
, , o
and CC o
quality NN o
of IN o
life NN o
in IN N
postmenopausal JJ p
women NNS p
with IN p
chronic JJ p
venous JJ p
insufficiency NN p
( ( p
CVI NNP p
) ) p
. . p

DESIGN NNP N
Double-blinded JJ N
, , N
randomized VBN N
controlled VBN N
trial NN N
. . N

SETTING NNP N
Clinical JJ N
setting NN N
. . N

PARTICIPANTS NNP N
Consecutive JJ p
postmenopausal NN p
women NNS p
( ( p
N=130 NNP p
; : p
mean JJ p
age NN p
? . p
SD NNP p
, , p
65.44?14.7y CD p
) ) p
with IN p
mild JJ p
CVI NNP p
. . p

No NNP N
participant NN N
withdrew VBD N
because IN N
of IN N
adverse JJ N
effects NNS N
. . N

INTERVENTION NN N
Participants NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
either DT N
( ( N
1 CD N
) ) i
an DT i
experimental JJ i
group NN i
to TO i
receive VB i
a DT i
mixed JJ i
KT-compression NNP i
treatment NN i
following VBG i
KT NNP i
recommendations NNS i
for IN i
gastrocnemius JJ i
muscle NN i
enhancement NN i
and CC i
functional JJ i
correction NN i
of IN i
the DT i
ankle NN i
, , i
and CC i
adding VBG i
2 CD i
tapes NNS i
to TO i
simulate VB i
traditional JJ i
compression NN i
bandages NNS i
( ( i
no DT i
KT NNP i
guidelines NNS i
) ) i
; : i
or CC i
( ( i
2 CD i
) ) i
a DT i
placebo NN i
control NN i
group NN i
for IN i
sham NN i
KT NNP i
. . i

Both DT N
interventions NNS N
were VBD N
performed VBN N
3 CD N
times NNS N
a DT N
week NN N
during IN N
a DT N
4-week JJ N
period NN N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP o
ROAM NNP o
, , o
gait NN o
, , o
pain NN o
, , o
perimeter NN o
of IN o
right NN o
and CC o
left VBD o
lower JJR o
limb NN o
, , o
and CC o
quality NN o
of IN o
life NN o
were VBD o
assessed VBN N
at IN N
baseline NN N
and CC N
48 CD N
hours NNS N
posttreatment NN N
. . N

RESULTS NNP o
Quality NNP o
of IN o
life NN o
was VBD o
better RBR N
in IN N
the DT N
intervention NN N
group NN N
by IN N
a DT N
mean NN N
of IN N
8.76 CD N
points NNS N
( ( N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NNP N
, , N
4.96-12.55 JJ N
) ) N
. . N

The DT N
experimental JJ N
group NN N
also RB N
showed VBD N
significant JJ N
pre-/posttreatment JJ N
improvements NNS N
in IN N
both DT o
lower JJR o
limbs NN o
in IN o
gait JJ o
dorsiflexion NN o
ROAM NNP o
( ( o
95 CD N
% NN N
CI NNP N
, , N
1.02-2.49 JJ o
) ) o
, , o
cadence NN o
( ( o
95 CD N
% NN N
CI NNP N
, , N
3.45-1.47 NNP o
) ) o
, , o
stride JJ o
length NN o
( ( o
95 CD N
% NN N
CI NNP N
, , N
21.48-10.83 JJ o
) ) o
, , o
step JJ o
length NN o
( ( o
95 CD N
% NN N
CI NNP N
, , N
1.68-6.61 JJ o
) ) o
, , o
stance NN o
phase NN o
( ( o
95 CD N
% NN N
CI NNP N
, , N
61-107 JJ N
) ) N
, , N
and CC o
foot NN o
( ( o
95 CD N
% NN N
CI NNP N
, , N
.56-.92 NNP N
) ) N
and CC o
malleolus $ o
( ( o
95 CD N
% NN N
CI NNP N
, , N
1.15-1.63 JJ o
) ) o
circumference NN o
. . o

None NN N
of IN N
these DT N
variables NNS N
were VBD N
significantly RB N
modified VBN N
in IN N
the DT N
placebo NN N
group NN N
. . N

Both DT N
groups NNS N
reported VBD N
a DT N
significant JJ N
reduction NN N
in IN N
pain NN o
. . o

CONCLUSIONS NNP o
Ankle NNP o
dorsiflexion NN o
during IN o
gait NN o
, , o
walking VBG o
parameters NNS o
, , o
peripheral JJ o
edema NN o
, , o
venous JJ o
pain NN o
, , o
and CC o
quality NN o
of IN o
life NN o
remain VBP o
improved VBN N
in IN N
patients NNS N
with IN N
CVI NNP N
at IN N
1 CD N
month NN N
after IN i
mixed JJ i
KT-compression NNP i
therapy NN i
. . i

KT NNP N
may MD N
have VB N
a DT N
placebo NN i
effect NN i
on IN N
pain NN N
perception NN N
. . N

-DOCSTART- -12182253- O O

A DT N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ N
comparison NN N
of IN N
the DT N
analgesic JJ o
efficacy NN o
, , o
onset NN o
of IN o
action NN o
, , N
and CC N
tolerability NN o
of IN N
ibuprofen JJ i
arginate NN i
and CC N
ibuprofen NN i
in IN N
postoperative JJ p
dental NN p
pain NN p
. . p

BACKGROUND NNP N
Because IN N
of IN N
its PRP$ N
enhanced JJ N
pharmacokinetic JJ o
characteristics NNS o
, , N
ibuprofen JJ i
arginate NN i
might MD N
be VB N
expected VBN N
to TO N
provide VB N
faster JJR N
pain NN o
relief NN o
than IN N
standard JJ i
ibuprofen JJ i
formulations NNS N
in IN N
patients NNS p
experiencing VBG p
acute JJ p
pain NN p
. . p

OBJECTIVE CC N
This DT N
study NN N
assessed VBD N
the DT N
analgesic JJ o
efficacy NN o
, , o
speed NN o
of IN o
onset NN o
, , o
and CC o
tolerability NN o
of IN N
ibuprofen JJ N
arginate NN N
compared VBN N
with IN N
a DT N
commercially RB N
available JJ N
form NN N
of IN N
ibuprofen NN N
in IN N
patients NNS p
with IN p
postoperative JJ p
dental NN p
pain NN p
. . p

METHODS NNP N
Patients NNPS N
were VBD N
randomized VBN N
to TO N
receive VB N
ibuprofen JJ i
arginate NN i
200 CD i
or CC i
400 CD i
mg NN i
, , i
ibuprofen JJ i
200 CD i
or CC i
400 CD i
mg NN i
, , i
or CC i
placebo NN i
in IN N
this DT N
multicenter NN N
, , N
double-blind JJ N
, , N
double-dummy JJ N
, , N
parallel-group JJ N
trial NN N
. . N

Patients NNS N
were VBD N
observed VBN N
for IN N
6 CD N
hours NNS N
after IN N
administration NN N
of IN N
a DT N
single JJ N
dose NN N
of IN N
study NN N
medication NN N
. . N

A DT N
repeated-dose JJ N
, , N
open-label JJ N
phase NN N
followed VBD N
. . N

Pain NNP o
intensity NN o
and CC o
pain NN o
relief NN o
were VBD N
measured VBN N
using VBG N
traditional JJ N
verbal JJ o
descriptor NN o
scales NNS o
; : o
onset VBN o
of IN o
analgesia NN o
was VBD N
assessed VBN N
using VBG N
2 CD N
stopwatches NNS N
to TO N
measure VB N
the DT N
time NN o
to TO o
achievement NN o
of IN o
specific JJ o
pain NN o
relief NN o
criteria NNS N
. . N

RESULTS VB N
A DT p
total NN p
of IN p
498 CD p
patients NNS p
( ( p
219 CD p
men NNS p
, , p
279 CD p
women NNS p
; : p
mean JJ p
age NN p
, , p
21.5 CD p
years NNS p
) ) p
participated VBD p
in IN p
this DT p
study NN p
. . p

Baseline NNP o
pain NN o
was VBD N
moderate JJ N
in IN N
388 CD N
patients NNS N
( ( N
78 CD N
% NN N
) ) N
and CC N
severe JJ N
in IN N
110 CD N
patients NNS N
( ( N
22 CD N
% NN N
) ) N
. . N

Meaningful JJ N
pain NN o
relief NN o
was VBD N
reached VBN N
after IN N
a DT N
median NN N
of IN N
29 CD N
and CC N
28 CD N
minutes NNS N
with IN N
ibuprofen JJ i
arginate NN i
200 CD N
and CC N
400 CD N
mg NN N
, , N
respectively RB N
, , N
and CC N
after IN N
52 CD N
and CC N
44 CD N
minutes NNS N
with IN N
ibuprofen JJ i
200 CD N
and CC N
400 CD N
mg NN N
, , N
respectively RB N
( ( N
all DT N
, , N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

The DT N
percentages NNS N
of IN N
patients NNS N
who WP N
achieved VBD N
meaningful JJ N
pain NN o
relief NN o
within IN N
the DT N
first JJ N
hour NN N
after IN N
treatment NN N
were VBD N
77.6 CD N
% NN N
and CC N
83.7 CD N
% NN N
for IN N
ibuprofen JJ i
arginate NN i
200 CD N
and CC N
400 CD N
mg NN N
, , N
respectively RB N
, , N
61.0 CD N
% NN N
and CC N
63.0 CD N
% NN N
for IN N
ibuprofen JJ i
200 CD N
and CC N
400 CD N
mg NN N
, , N
respectively RB N
, , N
and CC N
39.8 CD N
% NN N
for IN N
placebo NN N
. . N

The DT N
differences NNS N
between IN N
ibuprofen JJ N
arginate NN N
and CC N
ibuprofen NN N
were VBD N
statistically RB N
significant JJ N
( ( N
both DT N
doses NNS N
, , N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

Significantly RB N
greater JJR N
numbers NNS N
of IN N
patients NNS N
achieved VBN N
meaningful JJ N
pain NN o
relief NN o
with IN N
ibuprofen JJ i
arginate NN i
400 CD N
mg NN N
compared VBN N
with IN N
placebo NN i
from IN N
20 CD N
minutes NNS N
through IN N
6 CD N
hours NNS N
and CC N
with IN N
ibuprofen JJ N
arginate NN N
200 CD N
mg NN N
from IN N
30 CD N
minutes NNS N
through IN N
6 CD N
hours NNS N
( ( N
P NNP N
< NNP N
0.05 CD N
) ) N
. . N

Compared VBN N
with IN N
placebo NN N
, , N
a DT N
greater JJR N
number NN N
of IN N
patients NNS N
achieved VBN N
meaningful JJ N
pain NN o
relief NN o
with IN N
ibuprofen JJ i
400 CD N
mg NN N
from IN N
45 CD N
minutes NNS N
through IN N
6 CD N
hours NNS N
; : N
with IN N
ibuprofen NN N
200 CD N
mg. NN N
the DT N
corresponding JJ N
interval NN N
was VBD N
from IN N
I PRP N
through IN N
6 CD N
hours NNS N
. . N

After IN N
the DT N
first JJ N
hour NN N
, , N
pain NN o
reduction NN o
was VBD N
similar JJ N
for IN N
the DT N
similar JJ N
doses NNS N
of IN N
the DT N
2 CD N
ibuprofen JJ i
preparations NNS N
. . N

Median JJ o
remedication NN o
times NNS o
with IN N
both DT N
doses NNS N
of IN N
ibuprofen JJ i
arginate NN i
were VBD N
similar JJ N
to TO N
those DT N
with IN N
both DT N
doses NNS N
of IN N
ibuprofen NN N
, , N
ranging VBG N
from IN N
4.0 CD N
to TO N
5.2 CD N
hours NNS N
. . N

Adverse-event JJ o
profiles NNS o
were VBD N
similar JJ N
between IN N
the DT N
2 CD N
active JJ N
medications NNS N
. . N

CONCLUSIONS NNP N
Ibuprofen NNP i
arginate NN i
was VBD N
effective JJ N
in IN N
this DT N
population NN N
of IN N
patients NNS N
experiencing VBG N
moderate JJ N
to TO N
severe VB N
pain NN N
after IN N
surgical JJ N
extraction NN N
of IN N
> NN N
or CC N
= $ N
1 CD N
impacted JJ N
third JJ N
molar NN N
, , N
with IN N
16 CD N
to TO N
24 CD N
minutes NNS N
' POS N
faster NN N
time NN N
to TO N
meaningful VB N
pain NN o
relief NN o
than IN N
with IN N
ibuprofen NN N
. . N

The DT N
2 CD N
formulations NNS N
had VBD N
similar JJ N
tolerability NN o
profiles NNS o
. . o

-DOCSTART- -24433230- O O

Goodstart NN N
: : N
a DT N
cluster NN N
randomised VBD N
effectiveness JJ o
trial NN N
of IN N
an DT N
integrated VBN i
, , i
community-based JJ i
package NN i
for IN i
maternal JJ i
and CC i
newborn JJ i
care NN i
, , i
with IN i
prevention NN i
of IN i
mother-to-child JJ i
transmission NN i
of IN i
HIV NNP i
in IN p
a DT p
South JJ p
African JJ p
township NN p
. . p

BACKGROUND NNP N
Progress NNP N
towards NNS N
MDG4 NNP N
for IN N
child NN N
survival NN N
in IN N
South NNP N
Africa NNP N
requires VBZ N
effective JJ N
prevention NN N
of IN N
mother-to-child JJ N
transmission NN N
( ( N
PMTCT NNP N
) ) N
of IN N
HIV NNP N
including VBG N
increasing VBG N
exclusive JJ N
breastfeeding NN N
, , N
as RB N
well RB N
as IN N
a DT N
new JJ N
focus NN N
on IN N
reducing VBG N
neonatal JJ N
deaths NNS N
. . N

This DT N
necessitates VBZ N
increased JJ N
focus NN N
on IN N
the DT N
pregnancy NN N
and CC N
early JJ N
post-natal JJ N
periods NNS N
, , N
developing VBG N
and CC N
scaling VBG N
up RP N
appropriate JJ N
models NNS N
of IN N
community-based JJ N
care NN N
, , N
especially RB N
to TO N
reach VB N
the DT N
peri-urban JJ p
poor JJ p
. . p

METHODS NNP N
We PRP N
used VBD N
a DT N
randomised JJ N
controlled VBN N
trial NN N
with IN N
30 CD p
clusters NNS p
( ( p
15 CD p
in IN p
each DT p
arm NN p
) ) p
to TO p
evaluate VB p
an DT p
integrated VBN i
, , i
scalable JJ i
package NN i
providing VBG i
two CD i
pregnancy NN i
visits NNS i
and CC i
five CD i
post-natal JJ i
home NN i
visits NNS i
delivered VBN i
by IN i
community NN i
health NN i
workers NNS i
in IN p
Umlazi NNP p
, , p
Durban NNP p
, , p
South NNP p
Africa NNP p
. . p

Primary NNP N
outcomes NNS N
were VBD N
exclusive JJ o
and CC o
appropriate JJ o
infant NN o
feeding NN o
at IN o
12 CD o
weeks NNS o
post-natally RB o
and CC o
HIV-free JJ o
infant NN o
survival NN o
. . o

RESULTS NNP N
At IN N
12 CD p
weeks NNS p
of IN p
infant JJ p
age NN p
, , N
the DT N
intervention NN N
was VBD N
effective JJ N
in IN N
almost RB N
doubling VBG N
the DT N
rate NN o
of IN o
exclusive JJ o
breastfeeding NN o
( ( N
risk NN N
ratio VBP N
1.92 CD N
; : N
95 CD N
% NN N
CI NNP N
: : N
1.59-2.33 JJ N
) ) N
and CC N
increasing VBG N
infant JJ o
weight NN o
and CC o
length-for-age JJ o
z-scores NNS o
( ( N
weight JJ N
difference NN N
0.09 CD N
; : N
95 CD N
% NN N
CI NNP N
: : N
0.00-0.18 JJ N
, , N
length JJ N
difference NN N
0.11 CD N
; : N
95 CD N
% NN N
CI NNP N
: : N
0.03-0.19 NN N
) ) N
. . N

No DT N
difference NN N
was VBD N
seen VBN N
between IN N
study NN N
arms NNS N
in IN N
HIV-free JJ o
survival NN o
. . o

Women NNS N
in IN N
the DT N
intervention NN N
arm NN N
were VBD N
also RB N
more RBR N
likely JJ N
to TO N
take VB o
their PRP$ o
infant NN o
to TO o
the DT o
clinic NN o
within IN o
the DT o
first JJ o
week NN o
of IN o
life NN o
( ( N
risk NN N
ratio VBP N
1.10 CD N
; : N
95 CD N
% NN N
CI NNP N
: : N
1.04-1.18 JJ N
) ) N
. . N

CONCLUSIONS VB N
The DT N
trial NN N
coincided VBD N
with IN N
national JJ N
scale NN N
up IN N
of IN N
ARVs NNP N
for IN N
PMTCT NNP N
, , N
and CC N
this DT N
could MD N
have VB N
diluted VBN N
the DT N
effect NN N
of IN N
the DT N
intervention NN N
on IN N
HIV-free NNP o
survival NN o
. . o

We PRP N
have VBP N
demonstrated VBN N
that IN N
implementation NN N
of IN N
a DT N
pro-poor JJ N
integrated JJ N
PMTCT NNP N
and CC N
maternal JJ N
, , N
neonatal JJ N
and CC N
child JJ N
health NN N
home NN N
visiting VBG N
model NN N
is VBZ N
feasible JJ N
and CC N
effective JJ N
. . N

This DT N
trial NN N
could MD N
inform VB N
national JJ N
primary NN N
healthcare NN N
reengineering VBG N
strategies NNS N
in IN N
favour NN N
of IN N
home NN N
visits NNS N
. . N

The DT N
dose JJ N
effect NN N
on IN N
exclusive JJ N
breastfeeding NN N
is VBZ N
notable JJ N
as IN N
improving VBG N
exclusive JJ N
breastfeeding NN N
has VBZ N
been VBN N
resistant JJ N
to TO N
change VB N
in IN N
other JJ N
studies NNS N
targeting VBG N
urban JJ N
poor JJ N
families NNS N
. . N

-DOCSTART- -24998293- O O

Quality NN o
of IN o
life NN o
and CC o
fatigue NN o
of IN N
patients NNS p
with IN p
spinal JJ p
bone NN p
metastases NNS p
under IN p
combined VBN p
treatment NN p
with IN p
resistance NN i
training NN i
and CC i
radiation NN i
therapy- NN i
a DT N
randomized VBN N
pilot NN N
trial NN N
. . N

BACKGROUND VB N
The DT N
aim NN N
of IN N
this DT N
trial NN N
was VBD N
to TO N
compare VB N
the DT N
effects NNS N
of IN N
resistance NN i
training NN i
versus IN i
passive JJ i
physical JJ i
therapy NN i
on IN N
quality NN o
of IN o
life NN o
( ( o
QoL NNP o
) ) o
, , o
fatigue NN o
, , o
and CC o
emotional JJ o
distress NN o
outcomes NNS N
during IN N
radiation NN N
therapy NN N
in IN N
patients NNS p
with IN p
spinal JJ p
bone NN p
metastases NNS p
under IN p
radiotherapy NN i
( ( i
RT NNP i
) ) i
. . i

METHODS NNP N
In IN N
this DT N
randomized JJ N
trial NN N
, , N
60 CD p
patients NNS p
were VBD p
treated VBN p
from IN p
September NNP p
2011 CD p
until IN p
March NNP p
2013 CD p
into IN N
one CD N
of IN N
the DT N
two CD N
groups NNS N
: : N
isometric JJ i
resistance NN i
training NN i
or CC i
physical JJ i
therapy NN i
with IN N
thirty JJ N
patients NNS N
in IN N
each DT N
group NN N
during IN N
RT NNP i
. . i

EORTC NNP o
QLQ-BM22 NNP o
, , o
EORTC NNP o
QLQ-FA13 NNP o
, , N
and CC N
FBK-R10 NNP o
were VBD N
assessed VBN N
at IN N
baseline NN N
, , N
three CD N
months NNS N
, , N
and CC N
six CD N
months NNS N
after IN N
RT NNP i
. . i

RESULTS NNP N
Psychosocial JJ N
aspects NNS N
in IN N
resistance NN i
training NN i
group NN N
( ( N
Arm NNP N
A NNP N
) ) N
were VBD N
significantly RB N
improved VBN N
after IN N
three CD N
( ( N
p VB N
= RB N
0.001 CD N
) ) N
and CC N
six CD N
months NNS N
( ( N
p JJ N
= NNP N
0.010 CD N
) ) N
. . N

Other JJ N
rated JJ N
items NNS N
of IN N
the DT o
QLQ-BM22 NNP o
painful JJ o
site NN o
, , o
and CC o
pain NN N
characteristics NNS o
were VBD o
without IN o
significant JJ N
differences NNS o
. . o

Functional JJ o
interference NN N
showed VBD N
a DT N
positive JJ N
trend NN N
after IN N
six CD N
months NNS N
( ( N
p JJ N
= NNP N
0.081 CD N
) ) N
. . N

After IN N
six CD N
months NNS N
, , N
physical JJ o
fatigue NN o
( ( o
p JJ o
= NNP N
0.013 CD N
) ) N
, , N
and CC o
interference NN o
with IN o
daily JJ o
life NN o
( ( N
p JJ N
= NNP N
0.006 CD N
) ) N
according VBG N
to TO N
the DT N
QLQ-FA13 NNP N
assessment NN N
improved VBN N
in IN N
Arm NNP N
A NNP N
significantly RB N
. . N

Emotional JJ o
distress NN o
was VBD N
in IN N
Arm NNP N
A NNP N
lower JJR N
after IN N
six CD N
months NNS N
( ( N
p JJ N
= NNP N
0.016 CD N
) ) N
. . N

The DT N
Cohen NNP N
's POS N
effect NN N
size NN N
confirmed VBD N
the DT N
clinically NN N
significant JJ N
improvement NN N
of IN N
these DT N
findings NNS N
. . N

CONCLUSIONS NNP N
In IN N
this DT N
group NN p
of IN p
patients NNS p
we PRP N
were VBD N
able JJ N
to TO N
show VB N
that DT i
guided VBD i
isometric JJ i
resistance NN i
training NN i
of IN i
the DT i
paravertebral JJ i
muscles NNS i
can MD o
improve VB o
functional JJ o
capacity NN o
, , o
reduce VB o
fatigue NN o
and CC o
thereby NN o
enhance NN o
QoL NNP o
over IN N
a DT N
6-months JJ N
period NN N
in IN N
patients NNS N
with IN N
stable JJ N
spinal JJ N
metastases NNS N
. . N

The DT N
results NNS N
offer VBP N
a DT N
rationale NN N
for IN N
future JJ N
large JJ N
controlled VBN N
investigations NNS N
to TO N
confirm VB N
these DT N
findings NNS N
. . N

TRIAL NNP N
REGISTRATION NNP N
Clinical NNP N
trial NN N
identifier NN N
NCT01409720 NNP N
. . N

-DOCSTART- -24666361- O O

Predictors NNS N
of IN N
local JJ N
adverse JJ N
effects NNS N
caused VBN N
by IN N
topical JJ N
tretinoin NN i
cream NN N
0?1 CD N
% NN N
in IN N
the DT p
Veterans NNP p
Affairs NNP p
Topical NNP p
Tretinoin NNP p
Chemoprevention NNP p
trial NN p
. . p

BACKGROUND NNP N
Topical NNP i
tretinoin NN i
is VBZ N
commonly RB N
prescribed VBN N
, , N
but CC N
its PRP$ N
frequent JJ N
adverse JJ N
effects NNS N
are VBP N
barriers NNS N
to TO N
use VB N
. . N

Predictors NNS N
of IN N
resistance NN N
or CC N
susceptibility NN N
to TO N
retinoid VB N
irritation NN N
are VBP N
not RB N
known VBN N
. . N

OBJECTIVE UH N
To TO N
identify VB N
baseline JJ N
patient NN N
characteristics NNS N
associated VBN N
with IN N
adverse JJ N
effects NNS N
of IN N
topical JJ N
tretinoin NN N
. . N

METHODS NNP p
This DT p
cohort NN p
study NN p
used VBN p
data NNS p
collected VBD p
from IN p
324 CD p
participants NNS p
in IN p
the DT p
Veterans NNP p
Affairs NNP p
Topical NNP p
Tretinoin NNP p
Chemoprevention NNP p
trial NN p
who WP p
were VBD p
randomized VBN p
to TO p
apply VB i
tretinoin JJ i
cream NN i
on IN i
the DT i
face NN i
and CC i
ears NNS i
. . i

Univariate NNP N
and CC N
multivariate VB N
logistic JJ N
regression NN N
models NNS N
were VBD N
used VBN N
to TO N
examine VB N
the DT N
associations NNS N
between IN N
baseline NN N
characteristics NNS N
and CC N
local JJ N
adverse JJ N
effects NNS N
. . N

RESULTS NNP N
One CD N
hundred CD N
and CC N
ninety-seven JJ N
patients NNS N
( ( N
61 CD N
% NN N
of IN N
those DT N
randomized VBN N
to TO N
tretinoin VB N
) ) N
reported VBD o
local JJ o
adverse JJ o
effects NNS o
within IN N
6 CD N
months NNS N
. . N

Clinical JJ N
signs NNS N
of IN o
severe JJ o
photodamage NN o
at IN N
baseline NN N
[ NNP N
odds NNS N
ratio NN N
( ( N
OR NNP N
) ) N
0?15 CD N
, , N
95 CD N
% NN N
confidence NN N
interval NN N
( ( N
CI NNP N
) ) N
0?04-0?54 NN N
] NN N
and CC N
history NN o
of IN o
acne NN o
( ( o
OR CC o
0?46 CD N
, , N
95 CD N
% NN N
CI NNP N
0?27-0?77 NN N
) ) N
were VBD N
associated VBN N
with IN N
a DT N
decreased JJ N
risk NN N
of IN N
adverse JJ o
effects NNS o
to TO o
tretinoin VB o
. . N

The DT N
use NN N
of IN N
other JJ N
topical JJ N
medications NNS N
at IN N
enrolment NN N
( ( N
OR CC N
1?88 CD N
, , N
95 CD N
% NN N
CI NNP N
1?15-3?08 CD N
) ) N
predicted VBD N
an DT N
increase NN N
in IN o
adverse JJ o
effects NNS o
. . o

CONCLUSIONS NNP N
In IN N
this DT N
study NN N
population NN N
, , N
the DT N
common JJ N
indications NNS N
of IN N
topical JJ N
tretinoin NN N
treatment NN N
were VBD N
associated VBN N
with IN N
lower JJR N
risks NNS o
of IN o
adverse JJ o
effects NNS o
. . o

The DT N
concurrent NN N
use NN N
of IN N
other JJ N
topical JJ N
medications NNS N
may MD N
worsen VB N
irritation NN N
caused VBN N
by IN N
tretinoin NN N
. . N

-DOCSTART- -25082565- O O

Randomized VBN N
open-label JJ N
non-comparative JJ N
multicenter NN N
phase NN N
II NNP N
trial NN N
of IN N
sequential JJ N
erlotinib NN i
and CC i
docetaxel NN i
versus NN i
docetaxel NN i
alone RB i
in IN N
patients NNS p
with IN p
non-small-cell JJ p
lung NN p
cancer NN p
after IN p
failure NN p
of IN p
first-line JJ p
chemotherapy NN p
: : p
GFPC NNP N
10.02 CD N
study NN N
. . N

BACKGROUND NNP N
Concomitant NNP i
administration NN i
of IN i
erlotinib NN i
with IN i
standard JJ i
chemotherapy NN i
does VBZ N
not RB N
appear VB N
to TO N
improve VB N
survival NN o
among IN N
patients NNS p
with IN p
non-small-cell JJ p
lung NN p
cancer NN p
( ( p
NSCLC NNP p
) ) p
, , N
but CC N
preliminary JJ N
studies NNS N
suggest VBP N
that IN N
sequential JJ N
administration NN N
might MD N
be VB N
effective JJ N
. . N

OBJECTIVE NNP N
To TO N
assess VB N
the DT N
efficacy NN o
and CC o
tolerability NN o
of IN N
second-line JJ N
sequential JJ N
administration NN N
of IN N
erlotinib NN i
and CC i
docetaxel NN i
in IN N
advanced JJ N
NSCLC NNP N
. . N

METHODS NNP N
In IN N
an DT N
open-label JJ N
phase NN N
II NNP N
trial NN N
, , N
patients NNS p
with IN p
advanced JJ p
NSCLC NNP p
, , p
EGFR NNP p
wild-type NN p
or CC p
unknown JJ p
, , p
PS NNP p
0-2 CD p
, , p
in IN p
whom WP p
initial JJ p
cisplatin-based JJ p
chemotherapy NN p
had VBD p
failed VBN p
were VBD N
randomized VBN N
to TO N
sequential JJ i
erlotinib NN i
150 CD i
mg/d NN i
( ( i
day NN i
2-16 CD i
) ) i
+docetaxel NN i
( ( i
75 CD i
mg/m NN i
( ( i
2 CD i
) ) i
d1 NN i
) ) i
( ( i
arm JJ i
ED NNP i
) ) i
or CC i
docetaxel NN i
( ( i
75 CD i
mg/m NN i
( ( i
2 CD i
) ) i
d1 NN i
) ) i
alone RB i
( ( N
arm JJ N
D NNP N
) ) N
( ( N
21-day JJ N
cycle NN N
) ) N
. . N

The DT N
primary JJ N
endpoint NN N
was VBD N
the DT N
progression-free JJ o
survival NN o
rate NN o
at IN N
15 CD N
weeks NNS N
( ( N
PFS NNP N
15 CD N
) ) N
. . N

Secondary JJ N
endpoints NNS N
included VBD N
PFS NNP o
, , o
overall JJ o
survival NN o
( ( o
OS NNP o
) ) o
, , o
the DT o
overall JJ o
response NN o
rate NN o
( ( o
ORR NNP o
) ) o
and CC o
tolerability NN o
. . o

Based VBN N
on IN N
a DT N
Simon NNP N
optimal JJ N
two-stage NN N
design NN N
, , N
the DT N
ED NNP i
strategy NN N
was VBD N
rejected VBN N
if IN N
the DT N
primary JJ N
endpoint NN N
was VBD N
below IN N
33/66 CD N
patients NNS N
at IN N
the DT N
end NN N
of IN N
the DT N
two CD N
Simon NNP N
stages NNS N
. . N

RESULTS VB N
147 CD p
patients NNS p
were VBD p
randomized VBN p
( ( p
median JJ p
age NN p
: : p
60?8 CD p
years NNS p
, , p
PS NNP p
0/1/2 CD p
: : p
44/83/20 CD p
patients NNS p
; : p
males NNS p
: : p
78 CD p
% NN p
) ) p
. . p

The DT i
ED NNP i
strategy NN N
was VBD N
rejected VBN N
, , N
with IN N
only RB N
18 CD N
of IN N
73 CD N
patients NNS N
achieving VBG o
PFS15 NNP o
in IN o
arm NN o
ED NN o
at IN N
the DT N
end NN N
of IN N
stage NN N
2 CD N
and CC N
17 CD N
of IN N
74 CD N
patients NNS N
in IN N
arm JJ N
D. NNP N
In IN N
arms NNS i
ED NNP i
and CC i
D NNP i
, , i
respectively RB N
, , N
median JJ o
PFS NNP o
was VBD N
2.2 CD N
and CC N
2.5 CD N
months NNS N
and CC o
median JJ o
OS NNP o
was VBD N
6.5 CD N
and CC N
8.3 CD N
months NNS N
. . N

CONCLUSION NNP i
Sequential NNP i
erlotinib NN i
and CC i
docetaxel NN i
was VBD N
not RB N
more RBR o
effective JJ o
than IN i
docetaxel RB i
alone JJ i
as IN N
second-line JJ N
treatment NN N
for IN N
advanced JJ N
NSCLC NNP N
with IN N
wild-type JJ N
or CC N
unknown JJ o
EGFR NNP o
status NN o
. . o

-DOCSTART- -526820- O O

A DT N
tube NN i
spacer NN i
to TO N
improve VB N
inhalation NN o
of IN o
drugs NNS o
from IN N
pressurised VBN N
aerosols NNS N
. . N

-DOCSTART- -2493733- O O

Intravenous JJ i
flecainide NN i
versus NN i
verapamil NN i
for IN N
acute JJ N
conversion NN N
of IN N
paroxysmal JJ p
atrial JJ p
fibrillation NN p
or CC p
flutter NN p
to TO p
sinus VB p
rhythm NN p
. . p

In IN N
a DT N
single-blind JJ N
randomized NN N
study NN N
, , N
the DT N
efficacy NN o
of IN N
intravenous JJ i
flecainide NN i
( ( N
2 CD N
mg/kg/10 NN N
minutes NNS N
) ) N
versus VBP i
verapamil NN i
( ( N
10 CD N
mg/1 RB N
minute NN N
) ) N
was VBD N
assessed VBN N
in IN N
40 CD p
patients NNS p
with IN p
paroxysmal JJ p
atrial JJ p
fibrillation NN p
( ( p
AF NNP p
) ) p
or CC p
atrial JJ p
flutter NN p
( ( p
AFI NNP p
) ) p
. . p

The DT N
treatment NN N
was VBD N
considered VBN N
successful JJ N
if IN N
sinus JJ o
rhythm NN o
occurred VBD N
within IN N
1 CD N
hour NN N
. . N

Of IN N
20 CD p
patients NNS p
receiving VBG p
flecainide RB i
, , p
14 CD p
of IN p
17 CD p
( ( p
82 CD p
% NN p
) ) p
with IN p
AF NNP p
converted VBD p
to TO p
sinus VB p
rhythm NN p
, , p
but CC p
in IN p
3 CD p
patients NNS p
with IN p
AFI NNP p
flecainide NN i
failed VBD p
. . p

All DT N
patients NNS N
treated VBN N
with IN N
verapamil NN i
( ( N
17 CD N
AF NNP N
, , N
3 CD N
AFI NNP N
) ) N
showed VBD N
lower JJR o
ventricular NN o
rates NNS o
after IN N
1 CD N
hour NN N
; : N
however RB N
, , N
only RB N
1 CD N
( ( N
6 CD N
% NN N
) ) N
with IN N
AF NNP N
converted VBD N
to TO N
sinus VB N
rhythm NN N
and CC N
1 CD N
( ( N
6 CD N
% NN N
) ) N
converted VBD N
to TO N
AFI NNP N
. . N

Patients NNS N
who WP N
did VBD N
not RB N
convert VB N
to TO N
sinus VB N
rhythm NN N
after IN N
treatment NN N
with IN N
verapamil NNS i
were VBD N
treated VBN N
with IN N
flecainide NN i
and CC N
observed VBD N
for IN N
another DT N
hour NN N
. . N

After IN N
the DT N
change NN N
to TO N
flecainide VB N
, , N
9 CD N
of IN N
15 CD N
patients NNS N
( ( N
60 CD N
% NN N
) ) N
with IN N
AF NNP N
still RB N
converted VBD o
. . o

Thus NNP N
, , N
23 CD N
of IN N
32 CD N
patients NNS N
( ( N
72 CD N
% NN N
) ) N
with IN N
AF NNP N
and CC N
none NN N
of IN N
7 CD N
with IN N
AFI NNP N
converted VBD N
to TO N
sinus VB o
rhythm NN o
after IN N
treatment NN N
with IN N
flecainide NN N
. . N

Conversion NN o
to TO o
sinus VB o
rhythm NN o
was VBD N
achieved VBN N
in IN N
19 CD N
of IN N
22 CD N
patients NNS N
( ( N
86 CD N
% NN N
) ) N
when WRB N
AF NNP N
lasted VBD N
less JJR N
than IN N
24 CD N
hours NNS N
and CC N
in IN N
4 CD N
of IN N
10 CD N
( ( N
40 CD N
% NN N
) ) N
when WRB N
the DT N
arrhythmia NN N
lasted VBD N
greater JJR N
than IN N
24 CD N
hours NNS N
. . N

Transient JJ o
adverse JJ o
effects NNS o
were VBD N
noted VBN N
in IN N
10 CD N
patients NNS N
( ( N
26 CD N
% NN N
) ) N
after IN N
flecainide NN N
. . N

In IN N
summary JJ N
, , N
flecainide EX i
is VBZ N
an DT N
effective JJ o
and CC o
safe JJ o
drug NN o
for IN N
conversion NN N
of IN N
paroxysmal JJ N
AF NNP N
to TO N
sinus VB N
rhythm NN N
, , N
but CC N
ineffective JJ N
for IN N
AFI NNP o
. . o

Verapamil NNP i
appears VBZ N
to TO N
be VB N
of IN N
no DT N
use NN N
for IN N
conversion NN o
of IN o
AF NNP o
or CC o
AFI NNP o
to TO N
sinus VB N
rhythm NN N
. . N

-DOCSTART- -24107284- O O

Enhanced NNP N
vascular JJ N
endothelial JJ N
growth NN N
factor NN N
and CC N
inflammatory JJ N
cytokine NN N
removal NN N
with IN N
online JJ N
hemodiafiltration NN N
over IN N
high-flux JJ N
hemodialysis NN N
in IN N
sepsis-related JJ p
acute JJ p
kidney NN p
injury NN p
patients NNS p
. . p

Hypercytokinemia NNP N
plays VBZ N
a DT N
central JJ N
role NN N
in IN N
pathogenesis NN N
and CC N
is VBZ N
related VBN N
to TO N
the DT N
high JJ N
mortality NN N
in IN N
sepsis-related JJ p
acute JJ p
kidney NN p
injury NN p
( ( p
AKI NNP p
) ) p
. . p

Besides IN N
the DT N
established VBN N
cytokines NNS N
, , N
vascular JJ N
endothelial JJ N
growth NN N
factor NN N
( ( N
VEGF NNP N
) ) N
is VBZ N
demonstrated VBN N
as IN N
an DT N
important JJ N
factor NN N
in IN N
enhancing VBG N
vascular JJ N
leakage NN N
in IN N
sepsis NN N
. . N

This DT N
prospective JJ N
randomized JJ N
trial NN N
was VBD N
conducted VBN N
to TO N
compare VB N
the DT N
efficacy NN N
of IN N
cytokine NN i
removal NN i
between IN i
online JJ i
hemodiafiltration NN i
( ( i
HDF NNP i
) ) i
, , i
which WDT i
combines VBZ i
convective NN i
and CC i
diffusive JJ i
solute NN i
removal NN i
, , i
and CC i
high-flux JJ i
hemodialysis NN i
( ( i
HD NNP i
) ) i
. . N

Twenty-eight JJ p
sepsis-related JJ p
AKI NNP p
patients NNS p
were VBD p
included VBN p
and CC p
randomized VBN p
into IN p
online JJ i
HDF NNP i
and CC i
high-flux JJ i
HD NNP i
. . i

The DT N
percentages NNS N
of IN N
the DT N
reduction NN o
ratio NN o
in IN o
plasma JJ o
cytokines NNS o
were VBD N
measured VBN N
as IN N
primary JJ N
outcomes NNS N
. . N

Other JJ o
clinical JJ o
parameters NNS o
were VBD N
determined VBN N
as IN N
secondary JJ N
outcomes NNS N
. . N

When WRB N
compared VBN N
with IN N
high-flux JJ N
HD NNP N
, , N
online JJ N
HDF NNP N
provided VBD N
significantly RB N
greater JJR N
percentages NNS N
of IN N
the DT N
reduction NN o
ratio NN o
in IN o
plasma JJ o
cytokine NN o
levels NNS o
, , N
including VBG N
VEGF NNP o
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
, , N
IL-6 NNP N
( ( N
P NNP N
= NNP N
0.001 CD o
) ) o
, , o
IL-8 NNP o
( ( o
P NNP N
= NNP N
0.021 CD o
) ) o
, , o
IL-10 NNP o
( ( o
P NNP o
= NNP o
0.011 CD N
) ) N
, , N
and CC o
tumor NN o
necrosis NN o
factor-? NN o
( ( o
P NNP o
= NNP o
0.029 CD o
) ) N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS o
in IN o
intradialytic JJ o
blood NN o
pressures NNS o
. . o

Online NNP o
HDF NNP N
revealed VBD N
better RBR o
renal JJ o
recovery NN o
and CC o
shorter JJR o
length NN o
of IN o
hospitalization NN o
than IN o
high-flux JJ o
HD NNP o
. . o

In IN o
conclusion NN N
, , N
online JJ N
HDF NNP N
in IN N
sepsis-related JJ N
AKI NNP N
could MD N
provide VB N
significantly RB N
better JJR N
removal NN o
of IN o
VEGF NNP o
and CC o
other JJ o
cytokines NNS o
and CC N
these DT N
were VBD N
associated VBN N
with IN N
better JJR o
renal NN o
outcome NN o
than IN N
high-flux JJ N
HD NNP N
. . N

Thus NNP N
, , N
online JJ N
HDF NNP N
would MD N
offer VB N
a DT N
potential JJ N
role NN N
in IN N
hypercytokinemic JJ N
state NN p
in IN p
sepsis-related JJ p
AKI NNP p
. . p

-DOCSTART- -24920862- O O

Variations NNS N
in IN N
EEG NNP o
discharges NNS o
predict VBP N
ADHD NNP N
severity NN N
within IN N
individual JJ p
Smith-Lemli-Opitz JJ p
patients NNS p
. . p

OBJECTIVE IN N
We PRP N
sought VBD N
to TO N
examine VB N
the DT N
prevalence NN N
of IN N
EEG NNP N
abnormalities NNS N
in IN N
Smith-Lemli-Opitz NNP p
syndrome NN p
( ( p
SLOS NNP p
) ) p
as RB N
well RB N
as IN N
the DT N
relationship NN N
between IN N
interictal JJ N
epileptiform NN N
discharges NNS N
( ( N
IEDs NNP N
) ) N
and CC N
within-subject JJ N
variations NNS N
in IN N
attentional JJ N
symptom NN N
severity NN N
. . N

METHODS NNP N
In IN N
the DT N
context NN N
of IN N
a DT N
clinical JJ N
trial NN N
for IN N
SLOS NNP N
, , N
we PRP N
performed VBD N
cross-sectional JJ N
and CC N
repeated-measure JJ N
observational JJ N
studies NNS N
of IN N
the DT N
relationship NN N
between IN N
EEG NNP i
findings NNS N
and CC N
cognitive/behavioral JJ N
factors NNS N
on IN N
23 CD p
children NNS p
( ( p
aged VBN p
4-17 CD p
years NNS p
) ) p
. . p

EEGs NNP i
were VBD N
reviewed VBN N
for IN N
clinical JJ N
abnormalities NNS N
, , N
including VBG N
IEDs NNP N
, , N
by IN N
readers NNS N
blinded VBD N
to TO N
participants NNS N
' POS N
behavioral NN N
symptoms NNS N
. . N

Between-group JJ N
differences NNS N
in IN N
baseline JJ N
characteristics NNS N
of IN N
participants NNS N
with IN N
and CC N
without IN N
IEDs NNP N
were VBD N
analyzed VBN N
. . N

Within-subject JJ N
analyses NNS N
examined VBD N
the DT N
association NN N
between IN N
the DT N
presence NN N
of IN N
IEDs NNP N
and CC N
changes NNS N
in IN N
attention-deficit/hyperactivity NN o
disorder NN o
( ( o
ADHD NNP o
) ) o
symptoms NNS o
. . o

RESULTS NNP N
Of IN N
85 CD N
EEGs NNP N
, , N
43 CD N
( ( N
51 CD N
% NN N
) ) N
were VBD N
abnormal JJ o
, , N
predominantly RB N
because IN N
of IN N
IEDs NNP N
. . N

Only RB N
one CD N
subject NN N
had VBD N
documented VBN N
clinical JJ o
seizures NNS o
. . o

IEDs NNP N
clustered VBD N
in IN N
13 CD p
subjects NNS p
( ( p
57 CD p
% NN p
) ) p
, , p
whereas $ p
9 CD p
subjects NNS p
( ( p
39 CD p
% NN p
) ) p
had VBD p
EEGs NNP p
consistently RB p
free JJ p
of IN p
IEDs NNP p
. . p

While IN N
there EX N
were VBD N
no DT N
significant JJ N
group NN N
differences NNS N
in IN N
sex NN o
, , o
age NN o
, , o
intellectual JJ o
disability NN o
, , o
language NN o
level NN o
, , o
or CC o
baseline VB o
ADHD NNP o
symptoms NNS o
, , o
autistic JJ o
symptoms NNS o
tended VBD N
to TO N
be VB N
more RBR N
prevalent JJ N
in IN N
the DT N
IED NNP N
group NN N
( ( N
according VBG N
to TO N
Autism NNP o
Diagnostic NNP o
Observation NNP o
Schedule-2 NNP o
criteria NNS o
) ) o
. . N

Within JJ N
individuals NNS N
, , N
the DT N
presence NN N
of IN N
IEDs NNP N
on IN N
a DT N
particular JJ N
EEG NNP N
predicted VBD N
, , N
on IN N
average NN N
, , N
a DT N
27 CD N
% NN N
increase NN N
in IN N
ADHD NNP o
symptom NN o
severity NN o
. . o

CONCLUSIONS NNP N
Epileptiform NNP N
discharges NNS N
are VBP N
common JJ N
in IN N
SLOS NNP N
, , N
despite IN N
a DT N
relatively RB N
low JJ N
prevalence NN N
of IN N
epilepsy NN N
. . N

Fluctuations NNS N
in IN N
the DT N
presence NN N
of IN N
epileptiform NN N
discharges NNS N
within IN N
individual JJ N
children NNS N
with IN N
a DT N
developmental JJ N
disability NN N
syndrome NN N
may MD N
be VB N
associated VBN N
with IN N
fluctuations NNS N
in IN N
ADHD NNP N
symptomatology NN N
, , N
even RB N
in IN N
the DT N
absence NN N
of IN N
clinical JJ N
seizures NNS N
. . N

-DOCSTART- -24768960- O O

To TO N
excise VB i
or CC i
ablate VB i
endometriosis NN p
? . N
A DT N
prospective JJ N
randomized VBN N
double-blinded JJ N
trial NN N
after IN N
5-year JJ N
follow-up NN N
. . N

STUDY NNP N
OBJECTIVE NNP N
To TO N
compare VB N
reduction NN N
of IN N
pain NN N
after IN N
laparoscopy NN N
for IN N
ablation NN i
or CC N
excision NN i
of IN N
endometriosis NN N
. . N

DESIGN NNP N
Prospective NNP N
, , N
randomized VBD N
, , N
double-blind JJ N
study NN N
( ( N
Canadian JJ N
Task NNP N
Force NNP N
classification NN N
I PRP N
) ) N
. . N

SETTING CC N
Endometriosis NNP p
and CC p
pelvic JJ p
pain NN p
clinic NN p
at IN p
a DT p
university NN p
teaching VBG p
hospital NN p
. . p

PATIENTS NNP N
Women NNP p
of IN p
reproductive JJ p
age NN p
with IN p
pelvic JJ p
pain NN p
and CC p
visually RB p
proved JJ p
endometriosis NN p
. . p

INTERVENTIONS NNP N
Subjects NNPS N
completed VBD N
a DT N
questionnaire NN i
rating NN i
various JJ N
kinds NNS N
of IN N
pain NN N
using VBG N
visual JJ N
analog NN N
scales NNS N
( ( N
VAS NNP N
) ) N
. . N

After IN N
visual JJ N
identification NN N
subjects NNS N
were VBD N
randomized VBN N
to TO N
treatment NN N
via IN N
ablation NN i
or CC i
excision NN i
by IN N
supervised JJ N
training NN N
gynecologists NNS N
as IN N
primary JJ N
surgeons NNS N
. . N

Follow-up JJ N
questionnaires NNS N
documented VBN N
pain NN o
levels NNS o
every DT N
3 CD N
months NNS N
for IN N
1 CD N
year NN N
and CC N
then RB N
every DT N
6 CD N
months NNS N
for IN N
5 CD N
years NNS N
. . N

MEASUREMENTS NNP N
AND CC N
MAIN NNP N
RESULTS NNP N
Change NNP o
in IN o
pain NN o
VAS NNP o
scores VBZ o
during IN N
5 CD N
years NNS N
after IN N
the DT N
operation NN N
and CC N
rates NNS o
of IN o
pregnancy NN o
, , o
repeat NN o
surgery NN o
, , o
and CC o
use NN o
of IN o
hormone NN o
therapy NN o
were VBD N
evaluated VBN N
. . N

There EX N
was VBD N
a DT N
reduction NN N
in IN N
all DT N
pain NN o
scores NNS o
over IN N
the DT N
5-year JJ N
follow-up NN N
in IN N
both DT N
treatment NN N
groups NNS N
. . N

A DT N
significantly RB N
greater JJR N
reduction NN N
in IN N
dyspareunia NN o
VAS NNP o
scores NNS o
was VBD N
observed VBN N
in IN N
the DT N
excision NN N
group NN N
at IN N
5 CD N
years NNS N
( ( N
p JJ N
= NN N
.03 NN N
at IN N
univariate JJ N
analysis NN N
, , N
and CC N
p NN N
= NN N
.007 NN N
at IN N
multivariate JJ N
analysis NN N
) ) N
. . N

More JJR N
women NNS N
in IN N
the DT N
ablation NN N
group NN N
continued VBD N
to TO N
receive VB N
medical JJ o
treatment NN o
of IN o
endometriosis NN o
at IN N
5 CD N
years NNS N
( ( N
p JJ N
= NNP N
.004 NNP N
) ) N
. . N

CONCLUSIONS NNP N
Surgical NNP N
treatment NN N
of IN N
endometriosis NN N
provides VBZ N
symptom JJ N
reduction NN N
for IN N
up IN N
to TO N
5 CD N
years NNS N
. . N

In IN N
some DT N
limited JJ N
areas NNS N
such JJ N
as IN N
deep JJ N
dyspareunia NN N
, , N
excision NN i
is VBZ N
more RBR N
effective JJ N
than IN N
ablation NN i
. . i

-DOCSTART- -23775967- O O

Randomized VBN N
controlled JJ N
trial NN N
of IN N
entecavir NN i
prophylaxis NN i
for IN N
rituximab-associated JJ N
hepatitis NN N
B NNP N
virus NN N
reactivation NN N
in IN N
patients NNS p
with IN p
lymphoma NN p
and CC p
resolved VBD p
hepatitis NN p
B NNP p
. . p

PURPOSE NNP N
The DT N
role NN N
of IN N
antiviral JJ i
prophylaxis NN i
in IN N
preventing VBG N
hepatitis NN N
B NNP N
virus NN N
( ( N
HBV NNP N
) ) N
reactivation NN N
before IN N
rituximab-based JJ i
chemotherapy NN i
in IN N
patients NNS p
with IN p
lymphoma NN p
and CC p
resolved VBD p
hepatitis NN p
B NNP p
is VBZ N
unclear JJ N
. . N

PATIENTS NNP N
AND CC N
METHODS NNP N
Eighty NNP p
patients NNS p
with IN p
CD20 NNP p
( ( p
+ NNP p
) ) p
lymphoma NN p
and CC p
resolved VBD p
hepatitis NN p
B NNP p
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
either RB N
prophylactic JJ i
entecavir NN i
( ( i
ETV NNP i
) ) i
before IN i
chemotherapy NN i
to TO i
3 CD i
months NNS i
after IN i
completing VBG i
chemotherapy NN i
( ( i
ETV NNP i
prophylactic JJ i
group NN i
, , i
n RB i
= VBZ i
41 CD i
) ) i
or CC i
to TO i
receive VB i
therapeutic JJ i
ETV NNP i
at IN i
the DT i
time NN i
of IN i
HBV NNP i
reactivation NN i
and CC i
hepatitis NN i
B NNP i
surface NN i
antigen NN i
( ( i
HBsAg NNP i
) ) i
reverse NN i
seroconversion NN i
since IN i
chemotherapy NN i
( ( i
control NN i
group NN i
, , i
n RB i
= VBZ i
39 CD i
) ) i
. . i

RESULTS JJ N
Fifty-eight JJ p
patients NNS p
( ( N
72.5 CD N
% NN N
) ) N
were VBD N
positive JJ N
for IN N
hepatitis NN N
B NNP N
surface NN N
antibody NN N
, , N
and CC N
HBV NNP N
DNA NNP N
was VBD N
undetectable JJ N
in IN N
50 CD N
patients NNS N
( ( N
62.5 CD N
% NN N
) ) N
. . N

During IN N
a DT N
mean JJ N
18-month JJ N
follow-up JJ N
period NN N
, , N
one CD p
patient NN p
( ( N
2.4 CD N
% NN N
) ) N
in IN N
the DT N
ETV NNP i
prophylactic JJ N
group NN N
and CC N
seven CD p
patients NNS p
( ( N
17.9 CD N
% NN N
) ) N
in IN N
the DT N
control NN N
group NN N
developed VBD N
HBV NNP N
reactivation NN N
( ( N
P NNP N
= NNP N
.027 NNP N
) ) N
. . N

The DT N
cumulative JJ o
HBV NNP o
reactivation NN o
rates NNS o
at IN N
months NNS N
6 CD N
, , N
12 CD N
, , N
and CC N
18 CD N
after IN N
chemotherapy NN N
were VBD N
8 CD N
% NN N
, , N
11.2 CD N
% NN N
, , N
and CC N
25.9 CD N
% NN N
, , N
respectively RB N
, , N
in IN N
the DT N
control NN p
group NN p
, , N
and CC N
0 CD N
% NN N
, , N
0 CD N
% NN N
, , N
and CC N
4.3 CD N
% NN N
in IN N
the DT N
ETV NNP N
prophylactic JJ N
group NN N
( ( N
P NNP N
= NNP N
.019 NNP N
) ) N
. . N

Four CD p
patients NNS p
( ( N
50 CD N
% NN N
) ) N
in IN N
the DT N
control NN N
group NN N
had VBD N
HBsAg NNP o
reverse NN o
seroconversion NN o
after IN N
HBV NNP N
reactivation NN N
. . N

The DT N
cumulative JJ o
HBsAg NNP o
reverse NN o
seroconversion NN o
rates NNS o
at IN N
months NNS N
6 CD N
, , N
12 CD N
, , N
and CC N
18 CD N
since IN N
chemotherapy NN N
were VBD N
0 CD N
% NN N
, , N
6.4 CD N
% NN N
, , N
and CC N
16.3 CD N
% NN N
in IN N
the DT N
control NN p
group NN p
, , N
respectively RB N
, , N
which WDT N
were VBD N
significantly RB N
higher JJR N
than IN N
those DT N
in IN N
the DT N
ETV NNP N
prophylactic JJ N
group NN N
( ( N
P NNP N
= NNP N
.032 NNP N
) ) N
. . N

Patients NNS N
with IN N
detectable JJ N
or CC N
undetectable JJ N
viral JJ N
load NN N
could MD N
develop VB N
HBV NNP o
reactivation NN o
and CC o
HBsAg NNP o
reverse NN o
seroconversion NN o
. . o

CONCLUSION NNP N
Undetectable JJ N
HBV NNP N
viral JJ N
load NN N
before IN N
chemotherapy NN N
did VBD N
not RB N
confer VB N
reactivation-free JJ N
status NN N
. . N

Antiviral NNP i
prophylaxis NN i
can MD N
potentially RB N
prevent VB N
rituximab-associated JJ N
HBV NNP N
reactivation NN N
in IN N
patients NNS p
with IN p
lymphoma NN p
and CC p
resolved VBD p
hepatitis NN p
B NNP p
. . p

-DOCSTART- -21040167- O O

Pre-transplant JJ N
pharmacokinetic JJ N
profiling NN N
and CC N
tacrolimus NN o
requirements NNS o
post-transplant JJ o
. . o

AIM NNP N
To TO N
determine VB N
the DT N
proportion NN N
of IN N
patients NNS p
achieving VBG p
tacrolimus JJ o
whole-blood JJ o
concentrations NNS o
of IN p
?10 NNP p
ng/mL NN p
within IN p
3 CD p
days NNS p
of IN p
kidney NN p
transplantation NN p
, , p
after IN p
randomization NN p
either RB p
to TO p
standard VB i
dosing VBG i
( ( i
control VB i
group NN i
) ) i
or CC i
post-transplantation NN i
dosing NN i
guided VBN i
by IN p
a DT p
2-hour JJ p
( ( p
C NNP p
( ( p
2 CD p
) ) p
) ) p
level NN p
following VBG p
a DT p
preoperative JJ i
tacrolimus NN i
dose NN i
( ( p
T2 NNP p
group NN p
) ) p
. . p

METHODS NNP N
The DT N
first JJ i
postoperative JJ i
tacrolimus NN i
dose NN i
was VBD i
given VBN N
either RB N
according VBG N
to TO N
standard NN N
care NN N
( ( N
control VB N
group NN N
) ) N
or CC N
0.15 CD N
mg/kg JJ N
b.d NN N
. . N

if IN N
the DT N
pre-transplant JJ N
C NNP N
( ( N
2 CD N
) ) N
level NN N
was VBD N
?20 JJ N
ng/mL RB N
, , N
0.1 CD N
mg/kg NN N
b.d NN N
. . N

if IN N
the DT N
C NNP N
( ( N
2 CD N
) ) N
level NN N
was VBD N
21-59 JJ N
ng/mL NN N
or CC N
0.05 CD N
mg/kg JJ N
b.d NN N
. . N

if IN N
the DT N
C NNP N
( ( N
2 CD N
) ) N
level NN N
was VBD N
?60 JJ N
ng/mL NN N
( ( N
T2 NNP N
group NN N
) ) N
. . N

Subsequent JJ N
dosing NN N
in IN N
both DT N
groups NNS N
was VBD N
based VBN N
upon IN i
tacrolimus JJ i
trough IN i
level NN N
monitoring NN p
. . p

Participants NNS p
received VBD p
concomitant JJ p
mycophenolate NN p
mofetil NN p
and CC p
steroids NNS p
. . p

RESULTS NNP p
Ninety NNP p
patients NNS p
were VBD p
recruited VBN p
, , p
of IN p
which WDT p
84 CD p
were VBD p
included VBN p
in IN p
the DT p
analysis NN p
( ( p
control NN p
group NN p
n=43 VBD p
; : p
T2 NNP p
group NN p
n=41 NN p
) ) p
. . N

There EX N
was VBD N
no DT N
difference NN N
in IN N
the DT N
proportion NN o
of IN o
subjects NNS o
achieving VBG o
tacrolimus JJ o
trough NN o
levels NNS o
?10 VBP o
ng/mL RB o
( ( N
82.9 CD N
% NN N
Control NNP N
vs VBZ N
93.0 CD N
% NN N
T2 NNP N
; : N
P=0.19 NNP N
) ) N
or CC N
between IN N
10 CD N
and CC N
15 CD N
ng/mL NN N
( ( N
41.5 CD N
% NN N
Control NNP N
vs VBZ N
41.9 CD N
% NN N
T2 NNP N
; : N
P=0.97 NNP N
) ) N
at IN N
day NN N
3 CD N
post NN N
transplant NN N
. . N

The DT N
T2 NNP N
group NN N
achieved VBD N
tacrolimus RB o
trough JJ o
levels NNS o
of IN o
?10 NNP o
ng/mL FW o
significantly RB o
faster RBR N
than IN N
the DT N
control NN N
group NN N
( ( N
100 CD N
% NN N
achievement NN N
in IN N
14 CD N
days NNS N
( ( N
Control NNP N
) ) N
versus VBP N
4 CD N
days NNS N
( ( N
T2 NNP N
) ) N
; : N
P=0.01 NNP N
) ) N
. . N

CONCLUSION NNP N
Performing VBG N
a DT N
pre-transplant JJ i
tacrolimus NN i
C NNP i
( ( i
2 CD i
) ) i
does VBZ i
not RB N
significantly RB N
increase VB N
the DT o
high JJ o
proportion NN o
of IN o
subjects NNS o
achieving VBG o
10 CD o
ng/mL JJ o
tacrolimus NN o
concentrations NNS o
by IN o
day NN o
3 CD o
using VBG N
routine JJ N
protocols NNS N
. . N

However RB N
, , N
compared VBN N
with IN N
standard JJ N
care NN N
, , N
performing VBG N
a DT N
pre-transplant JJ i
tacrolimus NN i
C NNP i
( ( i
2 CD i
) ) i
does VBZ i
lead JJ N
to TO N
patients NNS N
achieving VBG N
a DT o
whole-blood JJ o
concentration NN o
of IN o
?10 NNP o
ng/mL JJ o
sooner NN N
. . N

-DOCSTART- -19805710- O O

Randomized NNP N
clinical JJ N
trial NN N
of IN N
behavioral JJ N
intervention NN N
and CC N
nutrition NN N
education NN N
to TO N
improve VB N
caloric JJ N
intake NN N
and CC N
weight NN N
in IN N
children NNS p
with IN p
cystic JJ p
fibrosis NN p
. . p

OBJECTIVE UH N
To TO N
evaluate VB N
the DT N
efficacy NN N
of IN N
a DT N
behavioral JJ N
plus CC N
nutrition JJ N
education NN N
intervention NN N
, , N
Be NNP N
In IN N
CHARGE NNP N
! . N
, , N
compared VBN N
with IN N
that DT N
of IN N
a DT N
nutrition NN N
education NN N
intervention NN N
alone RB N
on IN N
caloric JJ o
intake NN o
and CC N
weight JJ o
gain NN o
in IN N
children NNS p
with IN p
cystic JJ p
fibrosis NN p
and CC p
pancreatic JJ p
insufficiency NN p
. . p

DESIGN NNP N
Randomized NNP N
controlled VBD N
trial NN N
. . N

SETTING NNP N
Cystic JJ p
fibrosis NN p
centers NNS p
in IN p
the DT p
eastern JJ p
, , p
midwestern JJ p
, , p
and CC p
southern JJ p
United NNP p
States NNPS p
. . p

PARTICIPANTS VB N
Seventy-nine JJ p
children NNS p
aged VBD p
4 CD p
to TO p
12 CD p
years NNS p
below IN p
the DT p
40th CD p
percentile NN p
for IN p
weight NN p
for IN p
age NN p
were VBD p
recruited VBN p
. . p

Sixty-seven JJ N
completed VBD N
the DT N
intervention NN N
and CC N
59 CD N
completed VBD N
a DT N
24-month JJ N
follow-up JJ N
assessment NN N
. . N

INTERVENTION NNP N
Comparison NNP N
of IN N
a DT N
behavioral JJ i
plus CC i
nutrition JJ i
education NN i
intervention NN i
with IN i
a DT i
nutrition NN i
education NN i
intervention NN i
alone RB i
. . i

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Primary NNP N
outcomes NNS N
were VBD N
changes NNS N
from IN N
pretreatment NN N
to TO N
posttreatment VB N
in IN N
caloric JJ o
intake NN o
and CC o
weight JJ o
gain NN o
. . o

Secondary JJ N
outcomes NNS N
were VBD N
changes NNS N
from IN N
pretreatment NN N
to TO N
posttreatment VB N
in IN N
percentage NN o
of IN o
the DT o
estimated VBN o
energy NN o
requirement NN o
and CC o
body NN o
mass NN o
index NN o
z VBD o
score NN o
. . o

These DT N
outcomes NNS N
were VBD N
also RB N
examined VBN N
24 CD N
months NNS N
posttreatment NN N
. . N

RESULTS NNP N
After IN N
treatment NN N
, , N
the DT N
behavioral JJ N
plus CC N
nutrition JJ N
education NN N
intervention NN N
as IN N
compared VBN N
with IN N
the DT N
nutrition NN N
education NN N
intervention NN N
alone RB N
had VBD N
a DT N
statistically RB N
greater JJR N
average JJ N
increase NN N
on IN N
the DT N
primary JJ N
and CC N
secondary JJ N
outcomes NNS N
of IN N
caloric JJ o
intake NN o
( ( N
mean JJ N
, , N
872 CD N
vs NN N
489 CD N
cal/d NN N
, , N
respectively RB N
) ) N
, , N
percentage NN o
of IN o
the DT o
estimated VBN o
energy NN o
requirement NN o
( ( N
mean JJ N
, , N
148 CD N
% NN N
vs JJ N
127 CD N
% NN N
, , N
respectively RB N
) ) N
, , N
weight JJ o
gain NN o
( ( N
mean JJ N
, , N
1.47 CD N
vs NN N
0.92 CD N
kg NN N
, , N
respectively RB N
) ) N
, , N
and CC N
body NN o
mass NN o
index NN o
z NN o
score NN o
( ( N
0.38 CD N
vs NN N
0.18 CD N
, , N
respectively RB N
) ) N
. . N

At IN N
the DT N
24-month JJ N
follow-up NN N
, , N
children NNS N
in IN N
both DT N
conditions NNS N
maintained VBD N
an DT N
estimated VBN N
energy NN o
requirement NN o
of IN N
around IN N
120 CD N
% NN N
and CC N
did VBD N
not RB N
significantly RB N
differ VB N
on IN N
any DT N
outcomes NNS N
. . N

CONCLUSIONS VB N
A DT N
behavioral JJ N
plus CC N
nutrition JJ N
education NN N
intervention NN N
was VBD N
more RBR N
effective JJ N
than IN N
a DT N
nutrition JJ N
education NN N
intervention NN N
alone RB N
at IN N
increasing VBG N
dietary JJ N
intake NN N
and CC N
weight NN N
over IN N
a DT N
9-week JJ N
period NN N
. . N

However RB N
, , N
across IN N
the DT N
24-month JJ N
follow-up NN N
, , N
both DT N
treatments NNS N
achieved VBD N
similar JJ N
outcomes NNS N
. . N

Trial JJ N
Registration NNP N
clinicaltrials.gov NN N
Identifier NNP N
: : N
NCT00006169 NN N
. . N

-DOCSTART- -23528101- O O

Randomized VBN N
, , N
controlled VBN N
, , N
parallel-group JJ N
trial NN N
of IN N
routine JJ i
prophylaxis NN i
vs. IN i
on-demand JJ i
treatment NN i
with IN i
sucrose-formulated JJ i
recombinant JJ i
factor NN i
VIII NNP i
in IN p
adults NNS p
with IN p
severe JJ p
hemophilia NN p
A NNP p
( ( p
SPINART NNP p
) ) p
. . p

BACKGROUND IN N
The DT N
benefits NNS N
of IN N
routine JJ i
prophylaxis NN i
vs. IN i
on-demand JJ i
treatment NN i
with IN i
factor NN i
VIII NNP i
products NNS i
have VBP i
not RB N
been VBN N
evaluated VBN N
in IN N
controlled JJ N
clinical JJ N
trials NNS N
in IN N
older JJR p
patients NNS p
with IN p
hemophilia PDT p
A NNP p
. . N

OBJECTIVES NNP N
To TO N
report VB N
results NNS N
from IN N
a DT N
preplanned JJ N
analysis NN N
of IN N
data NNS N
from IN N
the DT N
first JJ N
year NN N
of IN N
the DT N
3-year JJ N
SPINART NNP N
study NN N
, , N
which WDT N
compares VBZ N
routine JJ N
prophylaxis NN N
with IN N
on-demand JJ N
treatment NN N
with IN i
sucrose-formulated JJ i
recombinant JJ i
FVIII NNP i
( ( i
rFVIII-FS NN i
) ) i
. . i

PATIENTS/METHODS NNP N
SPINART NNP N
is VBZ N
an DT N
open-label JJ N
, , N
randomized VBN N
, , N
controlled VBN N
, , N
parallel-group NN N
, , N
multinational JJ N
trial NN p
. . p

Males NNS p
aged VBN p
12-50 CD p
years NNS p
with IN p
severe JJ p
hemophilia NN p
A NNP p
, , p
? . p
150 CD p
days NNS p
of IN p
exposure NN p
to TO p
FVIII NNP p
, , p
no DT p
FVIII NNP p
inhibitors NNS p
, , p
no DT p
prophylaxis NN p
for IN p
> $ p
12 CD p
consecutive JJ p
months NNS p
in IN p
the DT p
past JJ p
5 CD p
years NNS p
and CC p
6-24 JJ p
bleeding NN p
episodes NNS p
in IN p
the DT p
preceding VBG p
6 CD p
months NNS p
were VBD p
randomized VBN N
1 CD N
: : N
1 CD N
to TO N
rFVIII-FS JJ i
prophylaxis NN i
( ( i
25 CD i
IU NNP i
kg NN i
( ( i
-1 NNP i
) ) i
, , i
three CD i
times NNS i
weekly JJ i
) ) i
or CC i
on-demand JJ i
treatment NN i
. . i

The DT i
primary JJ N
efficacy NN N
endpoint NN o
, , o
number NN o
of IN o
total JJ o
bleeding VBG o
episodes NNS o
in IN o
the DT N
intent-to-treat JJ N
population NN N
, , N
was VBD N
analyzed VBN N
after IN N
the DT N
last JJ N
patient NN N
had VBD N
completed VBN N
1 CD N
year NN N
of IN N
follow-up NN N
. . N

A DT N
negative JJ N
binomial JJ N
model NN N
was VBD N
used VBN N
for IN N
the DT N
primary JJ N
endpoint NN N
analysis NN N
; : N
analysis NN N
of IN N
variance NN N
was VBD N
used VBN N
for IN N
confirmatory JJ N
analysis NN N
of IN N
annualized JJ N
bleeding NN N
rates NNS N
. . N

RESULTS NNP p
Eighty-four JJ p
patients NNS p
were VBD p
enrolled VBN p
and CC p
analyzed VBN p
( ( p
n JJ p
= $ p
42 CD p
per IN p
group NN p
; : p
mean JJ p
age NN p
, , p
30.6 CD p
years NNS p
; : p
median JJ p
treatment NN p
duration NN p
, , p
1.7 CD p
years NNS p
) ) p
. . p

The DT p
median JJ N
number NN N
of IN N
total JJ o
bleeding NN o
episodes NNS o
and CC o
total JJ o
bleeding NN o
episodes NNS o
per IN N
year NN N
were VBD N
significantly RB N
lower JJR N
with IN N
prophylaxis NN N
than IN N
with IN N
on-demand JJ N
treatment NN N
( ( N
total JJ N
, , N
0 CD N
vs. FW N
54.5 CD N
; : N
total JJ N
per IN N
year NN N
, , N
0 CD N
vs. FW N
27.9 CD N
; : N
both DT N
P NNP N
< NNP N
0.0001 CD N
) ) N
. . N

No DT N
treatment-related JJ N
adverse JJ N
events NNS N
occurred VBD N
, , N
and CC N
no DT N
patients NNS N
developed VBD N
FVIII NNP N
inhibitors NNS N
. . N

CONCLUSIONS NNP N
Routine NNP N
prophylaxis NN N
with IN N
rFVIII-FS JJ i
leads NNS i
to TO N
a DT N
significant JJ N
reduction NN N
in IN N
bleeding VBG N
as IN N
compared VBN N
with IN N
on-demand JJ N
treatment NN N
. . N

Adverse JJ N
events NNS N
were VBD N
consistent JJ N
with IN N
the DT N
established VBN i
rFVIII-FS NN i
safety NN i
profile NN N
. . N

-DOCSTART- -4037540- O O

Differential JJ o
inhibition NN o
of IN o
bronchoconstriction NN o
by IN N
the DT N
calcium NN i
channel NN i
blockers NNS i
, , i
verapamil NN i
and CC i
nifedipine NN i
. . i

Recent JJ N
studies NNS N
have VBP N
demonstrated VBN N
that IN N
the DT N
calcium NN i
channel NN i
blocking VBG i
agents NNS i
can MD N
inhibit VB N
experimentally RB o
induced JJ o
bronchoconstriction NN o
in IN N
asthmatics NNS p
, , N
but CC N
their PRP$ N
protective JJ N
action NN N
has VBZ N
been VBN N
variable JJ N
. . N

To TO N
clarify VB N
the DT N
influence NN N
of IN N
stimulus NN N
intensity NN N
and CC N
choice NN N
of IN N
calcium NN N
blocker NN N
on IN N
these DT N
reported VBN N
differences NNS N
in IN N
outcome NN N
, , N
we PRP N
performed VBD N
noncumulative JJ N
thermal JJ N
stimulus-response JJ N
curves NNS N
using VBG N
isocapnic JJ N
hyperventilation NN N
of IN N
cold JJ N
air NN N
in IN N
8 CD p
asthmatics NNS p
. . p

Subjects NNS p
received VBD N
pretreatment JJ N
with IN N
orally RB N
administered VBN N
nifedipine NN i
( ( N
20 CD N
mg NN N
) ) N
, , N
intravenously RB N
administered VBN N
verapamil NN i
( ( N
10 CD N
mg NN N
bolus NN N
followed VBN N
by IN N
a DT N
continuous JJ N
infusion NN N
) ) N
, , N
or CC N
appropriate JJ N
placebos NNS i
in IN N
a DT N
randomized JJ N
, , N
double-blind JJ N
fashion NN N
. . N

Verapamil NNP N
afforded VBD N
no DT N
consistent JJ N
protection NN N
against IN N
the DT N
thermal JJ N
challenges NNS N
, , N
whereas NNS N
nifedipine VBP N
significantly RB N
blunted VBN N
the DT N
bronchoconstrictor NN o
response NN o
to TO o
stimuli NNS o
of IN o
low JJ o
( ( N
p NN N
less JJR N
than IN N
0.02 CD N
) ) N
and CC N
middle JJ o
( ( N
p NN N
less JJR N
than IN N
0.03 CD N
) ) N
intensity NN N
. . N

At IN N
the DT N
highest JJS N
thermal JJ N
burden NN N
, , N
the DT N
effect NN o
of IN o
nifedipine NN o
was VBD N
inconsistent JJ N
and CC N
not RB N
significantly RB N
different JJ N
from IN N
that DT N
of IN N
placebo NN i
. . i

These DT N
results NNS N
indicate VBP N
that IN N
the DT N
protection NN o
from IN o
bronchoconstriction NN o
afforded VBN N
by IN N
the DT N
calcium NN i
channel NN i
blockers NNS i
depends VBZ N
on IN N
the DT N
choice NN N
of IN N
agent NN N
and CC N
the DT N
intensity NN N
of IN N
the DT N
bronchoconstricting NN N
stimulus NN N
, , N
and CC N
they PRP N
raise VBP N
the DT N
possibility NN N
that IN N
the DT N
contribution NN N
of IN N
transmembrane NN N
calcium NN N
ion NN N
influx NN N
to TO N
the DT N
pathogenesis NN N
of IN N
bronchoconstriction NN N
may MD N
vary VB N
according VBG N
to TO N
stimulus JJ N
intensity NN N
. . N

-DOCSTART- -17408924- O O

Single-dose JJ i
and CC i
multi-dose JJ i
clindamycin NN i
therapy NN i
fails VBZ N
to TO N
demonstrate VB N
efficacy NN N
in IN N
preventing VBG N
infectious JJ N
and CC N
inflammatory JJ N
complications NNS N
in IN N
third JJ p
molar JJ p
surgery NN p
. . p

The DT N
goal NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
efficacy NN N
of IN N
single- JJ i
and CC i
multi-dose JJ i
( ( i
5-day JJ i
) ) i
clindamycin NN i
therapy NN i
for IN N
the DT N
prevention NN N
of IN N
inflammatory JJ N
complications NNS N
in IN N
patients NNS p
undergoing VBG p
lower JJR p
third JJ p
molar JJ p
surgical JJ p
extraction NN p
with IN p
bone NN p
removal NN p
. . p

Patients NNS p
who WP N
qualified VBD N
for IN N
the DT N
prospective JJ N
, , N
randomized VBN N
, , N
double-masked JJ N
, , N
placebo-controlled JJ i
trial NN N
were VBD N
randomly RB N
divided VBN N
into IN N
three CD N
groups NNS N
: : N
( ( N
1 CD N
) ) N
single JJ i
dose NN i
of IN i
oral JJ i
clindamycin NN i
administered VBN i
preoperatively RB i
( ( N
single-dose JJ N
group NN N
) ) N
; : N
( ( N
2 CD N
) ) N
clindamycin NN i
administered VBD i
preoperatively RB i
with IN i
continued JJ i
therapy NN i
for IN i
5 CD i
days NNS i
( ( N
5-day JJ N
group NN N
) ) N
; : N
and CC N
( ( N
3 CD N
) ) N
a DT N
placebo NN i
group NN N
. . N

The DT N
following JJ N
parameters NNS N
were VBD N
evaluated VBN N
on IN N
the DT N
first JJ N
, , N
second JJ N
and CC N
seventh JJ N
days NNS N
postsurgery NN N
: : N
trismus NN o
, , o
facial JJ o
swelling NN o
, , o
body NN o
temperature NN o
, , o
lymphadenopathy JJ o
, , o
alveolar JJ o
osteitis NN o
and CC o
subjective JJ o
pain NN o
sensations NNS o
. . o

There EX p
were VBD p
86 CD p
patients NNS p
( ( p
31 CD p
in IN p
the DT p
single-dose JJ p
group NN p
, , p
28 CD p
in IN p
the DT p
5-day JJ p
group NN p
and CC p
27 CD p
in IN p
the DT p
placebo NN i
group NN p
) ) p
enrolled VBD p
in IN p
the DT p
study NN p
. . p

There EX N
were VBD N
no DT N
statistically RB N
significant JJ N
differences NNS N
in IN N
postoperative JJ o
inflammatory JJ o
complications NNS o
in IN N
patients NNS N
during IN N
the DT N
first JJ N
and CC N
second JJ N
days NNS N
postsurgery NN N
. . N

A DT N
statistically RB N
significant JJ N
variation NN o
in IN N
body NN o
temperature NN o
was VBD N
reported VBN N
on IN N
the DT N
seventh JJ N
day NN N
. . N

Analysis NN N
of IN N
the DT N
postoperative JJ o
analgesic JJ o
intake NN o
did VBD N
not RB N
show VB N
statistically RB N
significant JJ N
differences NNS N
between IN N
examined VBN N
groups NNS N
. . N

Clindamycin NNP i
applied VBD N
in IN N
a DT N
single JJ N
preoperative NN N
dose NN N
of IN N
600 CD N
mg NN N
with IN N
or CC N
without IN N
subsequent JJ N
5-day JJ N
therapy NN N
does VBZ N
not RB N
demonstrate VB N
efficacy NN o
in IN N
prophylaxis NN N
for IN N
postoperative JJ N
inflammatory NN N
complications NNS N
after IN N
third JJ N
molar JJ N
surgery NN N
. . N

-DOCSTART- -23929781- O O

Anemia NNP N
and CC N
associated VBN N
clinical JJ N
outcomes NNS N
in IN N
patients NNS p
with IN p
heart NN p
failure NN p
due JJ p
to TO p
reduced VB p
left JJ p
ventricular JJ p
systolic JJ p
function NN p
. . p

BACKGROUND NNP N
Anemia NNP N
is VBZ N
associated VBN N
with IN N
decreased JJ N
functional JJ N
capacity NN N
, , N
reduced VBD N
quality NN N
of IN N
life NN N
, , N
and CC N
worsened VBD N
outcomes NNS N
among IN N
patients NNS p
with IN p
heart NN p
failure NN p
( ( p
HF NNP p
) ) p
due JJ p
to TO p
reduced VB p
left JJ p
ventricular JJ p
ejection NN p
fraction NN p
( ( p
HFREF NNP p
) ) p
. . p

We PRP N
sought VBD N
to TO N
evaluate VB N
the DT N
independent JJ N
effect NN N
of IN N
anemia NN N
on IN N
clinical JJ N
outcomes NNS N
among IN N
those DT p
with IN p
HFREF NNP p
. . p

HYPOTHESIS NNP N
Anemia NNP N
is VBZ N
associated VBN N
with IN N
cardiovascular JJ N
events NNS N
in IN N
patients NNS p
with IN p
heart NN p
failure NN p
. . p

METHODS PDT N
The DT N
HF-ACTION NNP N
trial NN N
was VBD N
a DT N
prospective JJ N
, , N
randomized JJ N
trial NN N
of IN N
exercise NN i
therapy NN i
vs NN i
usual JJ i
care NN i
in IN N
2331 CD p
patients NNS p
with IN p
HFREF NNP p
. . p

Patients NNS p
with IN p
New NNP p
York NNP p
Heart NNP p
Association NNP p
class NN p
II NNP p
to TO p
IV NNP p
HF NNP p
and CC p
left VBD p
ventricular JJ p
ejection NN p
fractions NNS p
of IN p
? . p
35 CD p
% NN p
were VBD p
recruited VBN o
. . o

Hemoglobin NNP o
( ( o
Hb NNP o
) ) o
was VBD o
measured VBN N
up RB N
to TO N
1 CD N
year NN N
prior RB N
to TO N
entry NN N
and CC N
was VBD N
stratified VBN N
by IN N
quintile NN o
. . o

Anemia NNP o
was VBD o
defined VBN N
as IN N
baseline NN p
Hb NNP p
< VBZ p
13 CD p
g/dL NN p
and CC p
< $ p
12 CD p
g/dL NN p
in IN p
men NNS p
and CC p
women NNS p
, , p
respectively RB o
. . o

Hemoglobin NNP o
was VBD o
assessed VBN N
in IN N
2 CD N
models NNS N
: : N
a DT N
global JJ N
prediction NN N
model NN N
that WDT N
had VBD N
been VBN N
previously RB N
developed VBN N
, , N
and CC N
a DT N
modified JJ N
model NN N
including VBG N
variables NNS N
associated VBN N
with IN N
anemia NN N
and CC N
the DT N
studied JJ N
outcomes NNS N
. . N

RESULTS NNP o
Hemoglobin NNP o
was VBD o
available JJ N
at IN N
baseline NN N
in IN N
1763 CD p
subjects NNS p
( ( p
76 CD p
% NN p
of IN p
total JJ p
study NN p
population NN p
) ) p
; : p
their PRP$ p
median JJ p
age NN p
was VBD p
59.0 CD p
years NNS p
, , p
73 CD p
% NN p
were VBD p
male JJ p
, , p
and CC p
62 CD p
% NN p
were VBD p
Caucasian JJ p
. . p

The DT N
prevalence NN N
of IN N
anemia NN N
was VBD N
515/1763 CD N
( ( N
29 CD N
% NN N
) ) N
. . N

Older JJR N
age NN N
, , N
female JJ N
sex NN N
, , N
African JJ N
American NNP N
race NN N
, , N
diabetes VBZ N
, , N
hypertension NN N
, , N
and CC N
lower JJR N
estimated VBN N
glomerular JJ N
filtration NN N
rates NNS N
were VBD N
all DT N
more RBR N
frequent JJ N
in IN N
lower JJR N
Hb NNP N
quintiles NNS N
. . N

Over IN N
a DT N
median JJ N
follow-up NN N
of IN N
30 CD N
months NNS N
, , N
the DT N
primary JJ N
outcome NN N
of IN N
all-cause JJ o
mortality NN o
or CC o
all-cause JJ o
hospitalization NN o
occurred VBD o
in IN N
78 CD N
% NN N
of IN N
those DT N
with IN N
anemia NN N
and CC N
64 CD N
% NN N
in IN N
those DT N
without IN N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

The DT N
secondary JJ N
outcomes NNS N
of IN N
all-cause JJ o
mortality NN o
alone RB o
, , o
cardiovascular JJ o
( ( o
CV NNP o
) ) o
mortality NN o
or CC o
CV NNP o
hospitalization NN o
, , o
and CC o
CV NNP o
mortality NN o
or CC o
HF NNP o
hospitalization NN o
occurred VBD o
in IN N
23 CD N
% NN N
vs JJ N
15 CD N
% NN N
, , N
67 CD N
% NN N
vs JJ N
54 CD N
% NN N
, , N
and CC N
44 CD N
vs NNS N
29 CD N
% NN N
, , N
respectively RB N
( ( N
P NNP N
< NNP N
0.001 CD o
) ) o
. . o

Heart NNP o
failure NN o
hospitalizations NNS o
occurred VBD o
in IN N
36 CD N
% NN N
vs JJ N
22 CD N
% NN N
, , N
and CC o
urgent JJ o
outpatient NN o
visits NNS o
for IN o
HF NNP o
exacerbations NNS o
occurred VBD o
in IN N
67 CD N
% NN N
and CC N
55 CD N
% NN N
, , N
respectively RB N
( ( N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

For IN N
the DT N
global JJ N
model NN N
, , N
there EX N
was VBD N
an DT N
association NN N
observed VBD N
for IN N
anemia NN N
and CC o
all-cause JJ o
mortality NN o
or CC o
hospitalization NN o
( ( o
adjusted VBN N
hazard RB N
ratio JJ N
[ NNP N
HR NNP N
] NN N
: : N
1.15 CD N
, , N
95 CD N
% NN N
confidence NN N
interval NN N
[ NNP N
CI NNP N
] NN N
: : N
1.01-1.32 JJ N
, , N
P NNP N
= NNP N
0.04 CD N
) ) N
, , N
but CC N
other JJ N
outcomes NNS N
were VBD N
not RB N
significant JJ N
at IN N
P NNP N
< NNP N
0.05 CD N
. . N

In IN N
the DT N
modified JJ N
model NN N
, , N
the DT N
adjusted JJ o
HR NNP o
for IN o
anemia NN N
and CC N
the DT N
primary JJ N
outcome NN N
of IN N
all-cause JJ N
mortality NN N
or CC N
all-cause JJ N
hospitalization NN N
was VBD N
1.25 CD N
( ( N
95 CD N
% NN N
CI NNP N
: : N
1.10-1.42 JJ N
, , N
P NNP N
< NNP N
0.001 CD N
) ) N
. . N

There EX N
were VBD N
independent JJ N
associations NNS N
between IN o
anemia NN o
and CC o
all-cause JJ o
death NN o
( ( o
HR NNP N
: : N
1.11 CD N
, , N
95 CD N
% NN N
CI NNP N
: : N
0.87-1.42 JJ N
, , N
P NNP N
= NNP N
0.38 CD o
) ) o
, , o
CV NNP o
death NN o
or CC o
CV NNP o
hospitalization NN o
( ( o
HR NNP N
: : N
1.16 CD N
, , N
95 CD N
% NN N
CI NNP N
: : N
1.01-1.33 JJ N
, , N
P NNP N
= NNP N
0.035 CD N
) ) N
, , N
and CC N
CV NNP N
death NN N
and CC o
HF NNP o
hospitalization NN o
( ( o
HR NNP N
: : N
1.27 CD N
, , N
95 CD N
% NN N
CI NNP N
: : N
1.06-1.51 JJ N
, , N
P NNP N
= NNP N
0.008 CD N
) ) N
. . N

CONCLUSIONS NNP N
Anemia NNP N
modestly RB N
is VBZ N
associated VBN N
with IN N
increased JJ N
rates NNS N
of IN N
death NN N
, , N
hospitalization NN N
, , N
and CC N
HF NNP N
exacerbation NN N
in IN N
patients NNS p
with IN p
chronic JJ p
HFREF NNP p
. . p

After IN N
adjusting VBG N
for IN N
other JJ N
important JJ N
covariates NNS N
, , N
anemia NN N
is VBZ N
independently RB N
associated VBN N
with IN N
an DT N
excess JJ N
hazard NN N
for IN N
all-cause JJ N
mortality NN N
and CC N
all-cause JJ N
hospitalization NN N
. . N

Anemia NNP N
is VBZ N
also RB N
associated VBN N
with IN N
combinations NNS N
of IN N
CV NNP N
death NN N
and CC N
CV/HF NNP N
hospitalizations NNS N
as IN N
composite JJ N
endpoints NNS N
. . N

-DOCSTART- -22732975- O O

Lactobacillus NNP i
plantarum NN i
CECT7315 NNP i
and CC i
CECT7316 NNP i
stimulate VBP N
immunoglobulin NN o
production NN o
after IN N
influenza JJ i
vaccination NN i
in IN p
elderly JJ p
. . p

OBJECTIVE IN N
The DT N
effectiveness NN N
of IN N
influenza JJ i
vaccination NN i
in IN N
preventing VBG N
illness NN N
is VBZ N
lower RBR N
in IN N
the DT N
elderly JJ N
; : N
this DT N
is VBZ N
why WRB N
the DT N
ability NN N
of IN N
Lactobacillus NNP i
plantarum NN i
CECT NNP i
7315/7316 CD i
to TO N
stimulate VB o
the DT o
response NN o
to TO o
influenza VB o
vaccination NN o
in IN p
elderly JJ p
was VBD N
evaluated VBN N
. . N

RESEARCH NNP N
METHODS NNP N
AND NNP N
PROCEDURES NNP N
A NNP N
randomized JJ N
, , N
double-blind JJ N
, , N
placebo-controlled JJ i
human JJ N
trial NN N
including VBG N
60 CD p
institutionalized JJ p
volunteers NNS p
aged VBN p
65-85 CD p
years NNS p
was VBD N
performed VBN N
. . N

All PDT N
the DT N
volunteers NNS N
were VBD N
vaccinated VBN N
with IN N
a DT N
trivalent JJ i
influenza NN i
vaccine NN i
( ( i
A/Wisconsin/67/2005 NNP i
NYMC NNP i
X-161B NNP i
( ( i
H3N2 NNP i
) ) i
, , i
A/Solomon NNP i
Islands/3/2006 NNP i
( ( i
H1N1 NNP i
) ) i
and CC i
B/Malaysia/2506/2004 NNP i
) ) i
for IN N
the DT N
Spanish JJ N
vaccine NN N
campaign NN N
2006/2007 CD N
. . N

The DT N
consumption NN N
of IN N
the DT N
probiotic JJ N
began VBD N
between IN N
three CD N
and CC N
four CD N
months NNS N
after IN N
the DT N
vaccination NN N
. . N

Volunteers NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
three CD N
following VBG N
groups NNS N
: : N
group NN N
A NNP N
( ( N
receiving VBG N
5*10 CD N
( ( N
9 CD N
) ) N
cfu/day NN N
of IN N
L. NNP i
plantarum NN i
CECT NNP i
7315/7316 CD i
in IN N
20 CD N
g NN N
powdered VBD N
skim JJ N
milk NN N
) ) N
, , N
group NN N
B NNP N
( ( N
receiving VBG N
5*10 CD N
( ( N
8 CD N
) ) N
cfu/day NN N
of IN N
L. NNP i
plantarum NN i
CECT NNP i
7315/7316 CD i
in IN N
20 CD N
g NN N
powdered VBD N
skim JJ N
milk NN N
) ) N
and CC N
group NN N
C NNP N
or CC N
placebo NN i
( ( N
20 CD N
g NN N
powered VBN i
skim JJ i
milk NN i
) ) i
. . i

The DT N
participants NNS N
consumed VBD N
the DT N
probiotic JJ N
during IN N
3 CD N
months NNS N
. . N

RESULTS VB N
The DT N
consumption NN N
of IN N
L. NNP i
plantarum NN i
CECT NNP i
7315/7316 CD i
during IN N
3 CD N
months NNS N
after IN N
influenza JJ i
vaccination NN i
increased VBD N
the DT N
levels NNS o
of IN o
influenza-specific JJ o
IgA NNP o
and CC o
IgG NNP o
antibodies NNS o
. . o

Moreover RB N
, , N
a DT N
trend NN N
towards IN N
an DT N
increase NN N
in IN N
influenza-specific JJ o
IgM NNP o
antibodies NNS o
was VBD N
also RB N
observed VBN N
. . N

CONCLUSION NNP N
L. NNP i
plantarum NN i
CECT7315/7316 NNP i
has VBZ N
an DT N
immunostimulating JJ N
effect NN N
and CC N
could MD N
be VB N
used VBN N
to TO N
improve VB N
the DT N
response NN N
to TO N
influenza VB i
vaccination NN i
in IN N
elderly JJ N
. . N

-DOCSTART- -3183852- O O

Heparin NNP i
plus CC i
dipyridamole NN i
in IN N
childhood NN p
hemolytic-uremic JJ p
syndrome NN p
: : p
a DT N
prospective JJ N
, , N
randomized VBN N
study NN N
. . N

From IN N
1976 CD p
to TO p
1985 CD p
, , p
a DT p
total NN p
of IN p
58 CD p
infants NNS p
and CC p
children NNS p
with IN p
the DT p
hemolytic-uremic JJ p
syndrome NN p
were VBD N
randomly RB N
assigned VBN N
to TO N
treatment NN N
either RB N
with IN N
heparin NN i
and CC i
dipyridamole NN i
or CC i
with IN i
supportive JJ i
management NN i
only RB i
. . i

In IN N
the DT N
treatment NN N
group NN N
, , N
two CD N
patients NNS N
died VBD N
in IN N
the DT N
early JJ N
weeks NNS N
of IN N
the DT N
disease NN N
. . N

Analysis NN N
of IN N
clinical JJ N
and CC N
laboratory NN N
data NNS N
showed VBD N
no DT N
significant JJ N
difference NN N
between IN N
either DT N
group NN N
of IN N
patients NNS N
as IN N
to TO N
the DT N
evolution NN N
of IN N
their PRP$ N
illness NN N
except IN N
for IN N
a DT N
significantly RB N
higher JJR N
incidence NN o
of IN o
anuria NNS o
and CC N
a DT N
significantly RB N
faster RBR o
recovery NN o
from IN o
hypertension NN o
in IN N
the DT N
treated JJ N
group NN N
. . N

Renal NNP N
biopsy NN N
studies NNS N
showed VBD N
no DT N
differences NNS N
between IN N
the DT N
two CD N
groups NNS N
in IN N
terms NNS N
of IN N
incidence NN o
and CC o
severity NN o
of IN o
the DT o
histologic JJ o
lesions NNS o
. . o

The DT N
long-term JJ N
data NNS N
on IN N
blood NN o
pressure NN o
and CC o
creatinine JJ o
clearance NN o
values NNS o
in IN N
the DT N
survivors NNS N
were VBD N
similar JJ N
in IN N
both DT N
groups NNS N
. . N

This DT N
study NN N
indicates VBZ N
that IN N
treatment NN i
with IN i
heparin NN o
and CC o
dipyridamole NN o
has VBZ N
no DT N
benefit NN o
over IN o
symptomatic JJ o
therapy NN o
alone RB N
in IN N
the DT N
typical JJ N
form NN N
of IN N
childhood NN p
hemolytic-uremic JJ p
syndrome NN p
. . p

-DOCSTART- -7036799- O O

Lidocaine NNP i
and CC N
bupivacaine NN i
mixtures NNS N
for IN N
epidural JJ N
blockade NN N
. . N

In IN N
a DT N
prospective JJ N
double-blind NN N
clinical JJ N
study NN N
, , N
single-dose JJ N
lumbar NN N
epidural JJ N
blockade NN N
was VBD N
instituted VBN N
in IN N
60 CD p
healthy JJ p
patients NNS p
undergoing VBG p
lower JJR p
abdominal JJ p
surgery NN p
. . p

Patients NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
five CD N
groups NNS N
. . N

Each DT N
group NN N
received VBD N
treatment NN N
with IN N
a DT N
different JJ N
local JJ N
anesthetic JJ N
solution NN N
containing VBG N
1:200,000 CD N
epinephrine NN i
. . i

Local JJ N
anesthetic JJ N
solutions NNS N
used VBN N
were VBD N
0.5 CD i
per IN i
cent NN i
bupivacaine NN i
HCl NNP i
, , i
2 CD i
per IN i
cent NN i
lidocaine NN i
HCl NNP i
, , i
and CC i
lidocaine-bupivacaine JJ i
mixtures NNS i
in IN N
the DT N
ratios NNS N
of IN N
1:3 CD N
, , N
1:1 CD N
or CC N
3:1 CD N
by IN N
volume NN N
. . N

Onset NNP o
and CC o
complete JJ o
spread NN o
of IN o
sensory JJ o
blockade NN o
were VBD N
similar JJ N
in IN N
all DT N
five CD N
groups NNS N
. . N

Time NNP N
to TO N
regression VB N
to TO N
two CD N
segments NNS N
of IN N
partial JJ N
and CC N
complete JJ N
sensory NN N
blockade NN N
was VBD N
positively RB N
correlated VBN N
( ( N
P NNP N
less JJR N
than IN N
0.05 CD N
) ) N
with IN N
increasing VBG N
dose NN N
of IN N
bupivacaine NN i
in IN N
the DT N
solutions NNS N
and CC N
ranged VBD N
from IN N
84 CD N
min NN N
( ( N
partial JJ N
) ) N
and CC N
70 CD N
min NN N
( ( N
complete JJ N
) ) N
for IN N
lidocaine NN i
, , N
to TO N
128 CD N
min NN N
( ( N
partial JJ N
) ) N
and CC N
101 CD N
min NN N
( ( N
complete JJ N
) ) N
for IN N
bupivacaine NN i
. . i

Using VBG N
skin JJ N
temperature NN N
as IN N
a DT N
criterion NN N
of IN N
sympathetic JJ N
blockade NN N
, , N
all DT N
three CD N
mixtures NNS N
demonstrated VBD N
a DT N
duration NN o
of IN o
action NN o
intermediate NN N
between IN N
the DT N
two CD N
single JJ N
drugs NNS N
, , N
lidocaine NN N
( ( N
124 CD N
+/- JJ N
13 CD N
min NN N
) ) N
and CC N
bupivacaine NN i
( ( N
286 CD N
+/- JJ N
32 CD N
min NN N
) ) N
. . N

Onset NNP o
of IN o
complete JJ o
motor NN o
blockade NN o
was VBD N
fastest JJS N
and CC N
the DT N
degree NN o
of IN o
motor NN o
blockade NN o
was VBD N
most RBS N
profound JJ N
with IN N
the DT N
mixture NN N
containing VBG N
equal JJ N
proportions NNS N
of IN N
lidocaine NN i
and CC N
bupivacaine NN i
. . i

Pharmacokinetics NNS N
of IN N
individual JJ N
drugs NNS N
were VBD N
unaltered VBN N
in IN N
any DT N
of IN N
the DT N
mixtures NNS N
. . N

-DOCSTART- -17140502- O O

The DT N
use NN N
of IN N
the DT N
Antenatal NNP i
Psychosocial NNP i
Health NNP i
Assessment NNP i
( ( i
ALPHA NNP i
) ) i
tool NN i
in IN N
the DT N
detection NN N
of IN N
psychosocial JJ o
risk NN o
factors NNS o
for IN N
postpartum JJ N
depression NN N
: : N
a DT N
randomized NN N
controlled VBN N
trial NN N
. . N

OBJECTIVE CC N
Eliciting VBG N
known VBN N
risk NN o
factors NNS o
for IN o
postpartum NN o
depression NN o
( ( N
PPD NNP N
) ) N
during IN N
pregnancy NN N
may MD N
enable VB N
primary JJ N
health NN N
care NN N
providers NNS N
to TO N
identify VB N
women NNS N
at IN N
increased JJ N
risk NN N
of IN N
becoming VBG N
depressed VBN N
. . N

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
examine VB N
how WRB N
well RB N
the DT N
Antenatal NNP i
Psychosocial NNP i
Health NNP i
Assessment NNP i
( ( i
ALPHA NNP i
) ) i
form NN N
identified VBN N
antenatal JJ N
risk NN N
factors NNS N
for IN N
PPD NNP N
, , N
compared VBN N
with IN N
routine JJ N
care NN N
, , N
in IN N
a DT N
sample NN N
of IN N
pregnant JJ p
women NNS p
. . p

METHODS VB N
A DT N
randomized NN N
controlled VBD N
trial NN N
was VBD N
conducted VBN N
to TO N
assess VB N
the DT N
effectiveness NN o
of IN o
the DT o
ALPHA NNP o
form NN N
in IN N
detecting VBG N
antenatal JJ N
risk NN N
factors NNS N
associated VBN N
with IN N
the DT N
adverse JJ N
postpartum NN N
outcomes NNS N
of IN N
postpartum NN o
depression NN o
, , o
intimate NN o
partner NN o
violence NN o
, , o
child NN o
abuse NN o
, , o
and CC o
couple JJ o
dysfunction NN o
. . o

The DT p
participants NNS p
were VBD p
primary JJ p
antenatal JJ p
care NN p
providers NNS p
-- : p
family NN p
physicians NNS p
, , p
obstetricians NNS p
, , p
and CC p
midwives NNS p
-- : p
from IN p
four CD p
diverse NN p
communities NNS p
in IN p
Ontario NNP p
. . p

These DT N
providers NNS N
were VBD N
matched VBN i
and CC i
then RB i
randomly RB i
allocated VBN i
into IN i
the DT i
intervention NN i
group NN i
, , i
who WP i
used VBD i
the DT i
ALPHA NNP i
form NN i
, , i
or CC i
into IN i
the DT i
control NN i
group NN i
, , i
who WP i
administered VBD i
usual JJ i
care NN i
. . i

In IN p
total JJ p
, , p
227 CD p
pregnant JJ p
women NNS p
were VBD p
recruited VBN p
: : p
98 CD p
in IN p
the DT p
ALPHA NNP i
group NN p
and CC p
129 CD p
in IN p
the DT p
control NN p
group NN p
. . p

The DT N
data NN N
presented VBN N
in IN N
this DT N
paper NN N
are VBP N
from IN N
a DT N
secondary JJ N
analysis NN N
focusing VBG N
on IN N
PPD NNP N
as IN N
the DT N
outcome NN N
. . N

RESULTS JJ N
Providers NNPS N
randomized VBD N
to TO N
the DT N
ALPHA NNP N
group NN N
identified VBD N
a DT N
statistically RB N
significantly RB N
higher JJR N
proportion NN N
of IN N
women NNS N
with IN N
antenatal JJ o
psychosocial JJ o
risk NN o
factors NNS o
for IN o
PPD NNP o
( ( N
36 CD N
% NN N
vs. FW N
26 CD N
% NN N
) ) N
and CC N
a DT N
significantly RB N
higher JJR N
number NN N
of IN N
risk NN o
factors NNS o
per IN N
woman NN N
compared VBN N
with IN N
the DT N
control NN N
group NN N
( ( N
mean JJ N
2.1 CD N
vs.1.8 NN N
) ) N
( ( N
z JJ N
= NNP N
-1.96 NNP N
, , N
P NNP N
= NNP N
0.05 CD N
) ) N
. . N

Providers NNS N
in IN N
the DT N
ALPHA NNP N
group NN N
also RB N
identified VBD N
significantly RB N
more JJR N
women NNS N
having VBG N
a DT N
previous JJ o
history NN o
of IN o
depression NN o
( ( N
16 CD N
% NN N
vs. FW N
6 CD N
% NN N
) ) N
( ( N
chi2 JJ N
= NN N
5.243 CD N
, , N
df NN N
= VBD N
1 CD N
, , N
P NNP N
= NNP N
0.03 CD N
) ) N
and CC N
[ $ o
having VBG o
] NNP o
witnessed VBD o
or CC o
experienced JJ o
abuse NN o
as IN o
a DT o
child NN o
( ( N
17 CD N
% NN N
vs. FW N
3 CD N
% NN N
) ) N
( ( N
chi2 JJ N
= NN N
12.488 CD N
, , N
df NN N
= VBD N
1 CD N
, , N
P NNP N
= NNP N
0.0005 CD N
) ) N
, , N
which WDT N
are VBP N
both DT N
established VBN N
risk NN N
factors NNS N
for IN N
PPD NNP o
. . o

CONCLUSION NNP N
The DT N
ALPHA NNP i
provides VBZ N
a DT N
systematic JJ N
means NNS N
of IN N
eliciting VBG N
antenatal JJ N
psychosocial JJ N
risk NN N
factors NNS N
for IN N
PPD NNP N
for IN N
primary JJ N
care NN N
providers NNS N
, , N
and CC N
it PRP N
may MD N
be VB N
particularly RB N
useful JJ N
for IN N
raising VBG N
and CC N
discussing VBG N
sensitive JJ N
issues NNS N
. . N

The DT N
detection NN N
of IN N
depressive JJ o
symptomatology NN o
during IN N
pregnancy NN N
remains VBZ N
problematic JJ N
, , N
however RB N
, , N
and CC N
detection NN N
may MD N
be VB N
improved VBN N
by IN N
administering VBG N
a DT N
simple JJ N
standardized JJ N
measure NN N
of IN N
depressive JJ N
symptomatology NN N
during IN N
routine JJ N
antenatal JJ N
care NN N
. . N

-DOCSTART- -8873520- O O

The DT N
tension-free JJ i
hernioplasty NN i
in IN N
a DT N
randomized JJ N
trial NN N
. . N

BACKGROUND VB N
The DT N
tension-free JJ i
hernioplasty NN i
as IN N
introduced VBN N
by IN N
Lichtenstein NNP N
has VBZ N
gained VBN N
increasing VBG N
acceptance NN N
during IN N
the DT N
last JJ N
decade NN N
although IN N
the DT N
technique NN N
has VBZ N
not RB N
been VBN N
evaluated VBN N
in IN N
a DT N
randomized JJ N
trial NN N
. . N

METHODS NNP N
This DT N
randomized VBN N
study NN N
compares VBZ N
the DT N
2-year JJ N
follow-up JJ N
results NNS N
after IN N
102 CD p
tension-free JJ i
hernioplasties NNS i
with IN i
implantation NN i
of IN i
a DT i
prolene NN i
mesh NN i
in IN i
all DT i
groin NN i
hernias VBD i
to TO p
53 CD p
Cooper NNP i
ligament NN i
repairs NNS i
in IN i
direct JJ i
hernias NN i
and CC p
53 CD p
abdominal JJ i
ring NN i
repairs NNS i
in IN i
indirect JJ i
hernias NN i
. . i

RESULTS NNP N
After IN N
tension-free JJ i
repairs NNS i
five CD N
hernias NNS o
recurred VBN o
( ( N
5 CD N
% NN N
) ) N
, , N
and CC N
after IN N
either DT N
Cooper NNP i
ligament NN i
or CC i
abdominal JJ i
ring NN i
repair NN i
, , N
16 CD N
recurrences NNS o
were VBD N
found VBN N
( ( N
15 CD N
% NN N
) ) N
( ( N
P NNP N
= NNP N
0.025 CD N
) ) N
. . N

No UH N
indirect JJ o
hernias NN o
recurred VBD o
after IN N
a DT N
tension-free JJ i
repair NN i
; : i
2 CD N
recurred VBD N
after IN N
abdominal JJ i
ring NN i
repair NN i
( ( N
4 CD N
% NN N
; : N
NS NNP N
) ) N
. . N

The DT N
recurrence NN o
rate NN o
after IN o
tension-free JJ o
repairs NNS o
for IN o
primary JJ o
direct JJ o
inguinal JJ o
hernias NN o
was VBD N
7 CD N
% NN N
as IN N
compared VBN N
with IN N
30 CD N
% NN N
after IN N
Cooper NNP i
ligament NN i
repair NN i
( ( N
P NNP N
= NNP N
0.0081 CD N
) ) N
. . N

No DT N
difference NN N
in IN N
complication NN o
rate NN o
between IN N
the DT N
tested JJ N
methods NNS N
was VBD N
found VBN N
. . N

CONCLUSION JJ N
Recurrence NNP o
rate NN o
is VBZ N
reduced VBN N
to TO N
one-third JJ N
after IN N
tension-free JJ i
herniotomies NNS i
as IN N
compared VBN N
with IN N
the DT N
conventionel NN i
herniotomies NNS i
without IN N
increase NN N
in IN N
complication NN o
rate NN o
. . o

-DOCSTART- -10986363- O O

Superior JJ N
modulation NN N
of IN N
activation NN N
levels NNS N
of IN N
stimulus JJ N
representations NNS N
does VBZ N
not RB N
underlie JJ N
superior JJ N
discrimination NN N
in IN N
autism NN p
. . p

The DT N
performance NN N
of IN N
children NNS p
with IN p
and CC p
without IN p
autism NN p
was VBD N
compared VBN N
in IN N
object-based JJ i
positive JJ i
and CC i
negative JJ i
priming NN i
tasks NNS i
within IN N
a DT N
visual JJ i
search NN i
procedure NN i
. . i

Object-based JJ N
positive JJ o
and CC o
negative JJ o
priming NN o
effects NNS o
were VBD N
found VBN N
in IN N
both DT N
groups NNS N
of IN N
children NNS N
. . N

This DT N
result NN N
provides VBZ N
the DT N
first JJ N
evidence NN N
for IN N
the DT N
activation NN N
of IN N
object-based JJ o
representations NNS o
during IN N
visual JJ i
search NN i
task NN i
performance NN i
and CC N
further JJ N
supports NNS N
the DT N
notion NN N
that IN N
both DT N
excitatory NN o
and CC o
inhibitory JJ o
guidance NN o
mechanisms NNS o
are VBP N
involved VBN N
in IN N
target NN N
location NN N
in IN N
visual JJ N
search NN N
. . N

The DT p
children NNS p
with IN p
autism NN p
were VBD N
overall JJ N
better JJR N
than IN N
the DT N
typically RB N
developing VBG N
children NNS N
at IN N
visual JJ o
search NN o
, , N
thus RB N
replicating VBG N
demonstrations NNS N
of IN N
superior JJ N
discrimination NN N
in IN N
autism NN N
. . N

Furthermore RB N
, , N
there EX N
was VBD N
no DT N
difference NN N
between IN N
the DT N
magnitude NN N
of IN N
the DT N
positive JJ N
nor CC N
the DT N
negative JJ N
priming NN o
effects NNS o
of IN N
the DT N
groups NNS N
. . N

This DT N
finding NN N
suggests VBZ N
that IN N
excitatory NN o
and CC o
inhibitory NN o
control NN o
operate NN o
comparably RB o
in IN N
autism NN N
and CC N
normal JJ o
development NN o
. . o

These DT N
results NNS N
are VBP N
discussed VBN N
in IN N
the DT N
light NN N
of IN N
the DT N
superior JJ N
ability NN N
of IN N
individuals NNS p
with IN p
autism NN p
to TO N
discriminate VB N
between IN N
items NNS N
. . N

More RBR N
specifically RB N
, , N
it PRP N
is VBZ N
argued VBN N
that IN N
superior JJ N
discrimination NN N
in IN N
autism NN N
does VBZ N
not RB N
result VB N
from IN N
enhanced VBN N
top-down JJ N
excitatory NN N
and CC N
inhibitory NN N
control NN N
. . N

-DOCSTART- -10482855- O O

Inhibition NN o
of IN o
the DT o
seasonal JJ o
IgE NNP o
increase NN p
to TO p
Dactylis NNP p
glomerata NNS p
by IN N
daily JJ i
sodium NN i
chloride NN i
nasal-sinus JJ i
irrigation NN i
during IN N
the DT N
grass NN N
pollen NN N
season NN N
. . N

-DOCSTART- -21048092- O O

Dopexamine NNP i
has VBZ N
no DT N
additional JJ N
benefit NN N
in IN N
high-risk JJ p
patients NNS p
receiving VBG p
goal-directed JJ i
fluid NN i
therapy NN i
undergoing VBG i
major JJ i
abdominal JJ i
surgery NN i
. . i

BACKGROUND NNP N
Dopexamine NNP i
has VBZ N
been VBN N
shown VBN N
to TO N
reduce VB N
both DT N
mortality NN o
and CC o
morbidity NN o
in IN N
major JJ N
surgery NN N
when WRB N
it PRP N
is VBZ N
used VBN N
as IN N
part NN N
of IN N
a DT N
protocol NN N
to TO N
increase VB N
oxygen NN N
delivery NN N
in IN N
the DT N
perioperative JJ N
period NN N
. . N

A DT N
European JJ N
multicenter NN N
study NN N
has VBZ N
examined VBN N
the DT N
use NN N
of IN N
dopexamine NN i
in IN N
patients NNS p
undergoing VBG p
major JJ i
abdominal JJ i
surgery NN i
, , N
showing VBG N
a DT N
trend NN N
toward IN N
improved VBN o
survival NN o
and CC o
reduced JJ o
complications NNS o
in IN N
high-risk JJ N
patients NNS N
when WRB N
receiving VBG N
low-dose JJ i
dopexamine NN i
( ( N
0.5 CD N
?g NN N
? . N
kg NN N
( ( N
-1 NN N
) ) N
? . N
min NN N
( ( N
-1 NNP N
) ) N
) ) N
. . N

A DT N
reduced JJ N
oxygen NN N
uptake NN N
at IN N
the DT N
anaerobic JJ N
threshold NN N
( ( N
AT NNP N
) ) N
has VBZ N
been VBN N
shown VBN N
to TO N
confer VB N
a DT N
significant JJ N
risk NN N
of IN N
mortality NN N
in IN N
patients NNS p
undergoing VBG i
major JJ i
abdominal JJ i
surgery NN i
and CC i
allows VBZ N
objective JJ N
identification NN N
of IN N
a DT N
high-risk JJ N
operative JJ N
group NN N
. . N

In IN N
this DT N
study NN N
, , N
we PRP N
assessed VBD N
the DT N
effects NNS N
of IN N
low-dose JJ i
dopexamine NN i
on IN i
morbidity NN N
after IN i
major JJ i
abdominal JJ i
surgery NN i
in IN i
patients NNS p
who WP p
were VBD p
at IN p
increased VBN p
risk NN p
by IN p
virtue NN p
of IN p
a DT p
reduced VBN p
AT NNP p
. . N

METHODS NNP p
Patients NNPS p
undergoing VBG p
elective JJ p
major JJ i
colorectal NN i
or CC i
urological JJ i
surgery NN i
who WP i
had VBD p
an DT p
AT NNP p
of IN p
< NNP p
11 CD p
mL NN p
? . p
kg NN p
( ( p
-1 NN p
) ) p
? . p
min NN p
( ( p
-1 JJ p
) ) p
or CC p
an DT p
AT NNP p
of IN p
11 CD p
to TO p
14 CD p
mL NNS p
? . p
kg NN p
( ( p
-1 NN p
) ) p
? . p
min NN p
( ( p
-1 NNP p
) ) p
with IN p
a DT p
history NN p
of IN p
ischemic JJ p
heart NN p
disease NN p
were VBD p
recruited VBN p
. . p

Before IN p
surgery NN N
, , N
a DT N
radial JJ N
arterial JJ N
cannula NN N
was VBD N
placed VBN N
and CC N
attached VBN N
to TO N
an DT N
Edwards NNP N
Lifesciences NNP N
FloTrac/Vigileo NNP N
system NN N
for IN N
measuring VBG N
cardiac JJ N
output NN N
. . N

Patients NNS N
were VBD N
given VBN N
a DT N
250-mL JJ N
bolus NN N
of IN i
Voluven NNP i
( ( i
6 CD i
% NN i
hydroxyethyl NN i
starch NN i
130/0.4 CD i
in IN i
0.9 CD i
% NN i
sodium NN i
chloride NN i
) ) i
until IN i
the DT N
stroke NN N
volume NN N
no RB N
longer RBR N
increased VBN N
by IN N
10 CD N
% NN N
, , N
then RB N
received VBD N
either CC N
dopexamine NN i
( ( i
0.5 CD i
?g NN i
? . N
kg NN N
( ( N
-1 NN N
) ) N
? . N
min NN N
( ( N
-1 NNP N
) ) N
) ) N
or CC i
saline VB i
0.9 CD N
% NN N
for IN N
24 CD N
hours NNS N
. . N

During IN N
surgery NN i
, , i
fluid NN N
boluses NNS N
of IN N
Voluven NNP i
were VBD i
given VBN N
if IN N
the DT N
stroke NN N
volume NN N
variation NN N
was VBD N
> JJ N
10 CD N
% NN N
. . N

No DT N
crystalloid NN N
was VBD N
given VBN N
during IN N
surgery NN N
. . N

A DT N
standardized JJ N
postoperative JJ N
fluid NN N
regime NN N
with IN i
Hartmann NNP i
solution NN i
was VBD N
prescribed VBN N
at IN N
1.5 CD N
mL NN N
? . N
kg NN N
( ( N
-1 NN N
) ) N
? . N
h NN N
( ( N
-1 NNP N
) ) N
for IN N
24 CD N
hours NNS N
. . N

The DT N
primary JJ N
outcome NN N
measure NN N
was VBD N
postoperative JJ o
morbidity NN o
measured VBN o
by IN N
the DT N
Postoperative NNP N
Morbidity NNP N
Survey NNP N
. . N

RESULTS NNP p
One CD p
hundred VBD p
twenty-four JJ p
patients NNS p
were VBD p
recruited VBN p
over IN p
a DT p
23-month JJ p
period NN p
. . p

The DT p
incidence NN o
of IN o
morbidity NN o
as IN o
measured VBN N
by IN N
the DT N
Postoperative NNP N
Morbidity NNP N
Survey NNP N
on IN N
day NN N
5 CD N
was VBD N
55 CD N
% NN N
in IN N
the DT i
control NN i
group NN i
versus VBD i
47 CD N
% NN N
in IN i
the DT i
dopexamine NN i
group NN N
( ( N
P NNP N
= NNP N
0.14 CD N
) ) N
. . N

There EX N
was VBD N
no DT N
significant JJ N
reduction NN N
in IN N
morbidity NN o
on IN o
any DT N
measured JJ N
postoperative JJ o
day NN o
. . o

Complication NN o
rates NNS o
, , o
mortality NN o
, , o
and CC o
hospital JJ o
length NN o
of IN o
stay NN o
were VBD o
similar JJ N
between IN N
the DT N
2 CD N
groups NNS N
; : N
however RB N
, , N
administration NN i
of IN i
dopexamine NN i
was VBD N
associated VBN N
with IN N
earlier JJR N
return NN o
of IN o
tolerating VBG o
an DT N
enteral JJ N
diet NN N
. . N

CONCLUSION NN N
With IN N
the DT N
effective JJ N
use NN i
of IN i
goal-directed JJ i
fluid NN i
therapy NN i
in IN i
elective JJ p
surgical JJ p
patients NNS p
, , p
the DT p
routine JJ N
use NN N
of IN i
dopexamine NN i
does VBZ N
not RB N
confer VB N
an DT N
additional JJ N
clinical JJ N
benefit NN N
. . N

-DOCSTART- -2276106- O O

Effects NNS N
of IN N
telephone NN i
call NN i
interventions NNS i
on IN N
patients NNS p
' POS p
well-being NN p
in IN p
a DT p
radiation NN p
therapy NN p
department NN p
. . p

This DT N
study NN N
examined VBD N
the DT N
effects NNS N
of IN N
telephone NN i
call NN i
interventions NNS i
by IN N
a DT N
collaborative JJ N
team NN N
on IN N
patients NNS p
' POS p
well-being JJ p
. . p

Fifty-five JJ p
subjects NNS p
undergoing VBG p
radiation NN p
therapy NN p
for IN p
cure NN p
and CC p
who WP p
were VBD p
able JJ p
to TO p
communicate VB p
by IN p
telephone NN p
comprised VBD p
the DT p
sample NN p
. . p

Subjects NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
a DT N
control NN i
group NN i
, , i
who WP i
received VBD i
the DT i
usual JJ i
care NN i
or CC i
to TO i
an DT i
experimental JJ i
group NN i
, , i
who WP i
received VBD i
a DT i
weekly JJ i
telephone NN i
call NN i
intervention NN i
in IN i
addition NN i
to TO i
the DT i
usual JJ i
care NN i
. . i

Speilberger NNP o
's POS o
State NNP o
Trait NNP o
Inventory NNP o
, , o
the DT o
Side NNP o
Effects NNP o
Profile NNP o
, , o
and CC o
the DT o
Coping NNP o
Strategies NNP o
Profile NNP o
were VBD N
used VBN N
along IN N
with IN N
a DT N
telephone NN N
survey NN N
to TO N
collect VB N
data NNS N
. . N

Analysis NN N
of IN N
the DT N
data NN N
showed VBD N
no DT N
significant JJ N
differences NNS N
between IN N
groups NNS N
in IN N
anxiety NN o
, , o
severity NN o
of IN o
side NN o
effects NNS o
, , o
helpfulness NN o
of IN o
self-care JJ o
strategies NNS o
, , o
and CC o
coping VBG o
strategies NNS o
. . o

However RB N
, , N
the DT N
survey NN N
indicated VBD N
that IN N
the DT N
telephone NN N
calls VBZ N
were VBD N
clinically RB o
significant JJ o
and CC N
provided VBD N
a DT N
mechanism NN N
for IN N
demonstrating VBG N
that IN N
the DT N
health NN N
care NN N
professionals NNS N
cared VBD N
about IN N
their PRP$ N
patients NNS N
and CC N
provided VBD N
an DT N
opportunity NN N
for IN N
patients NNS N
to TO N
talk VB N
about IN N
their PRP$ N
concerns NNS N
. . N

The DT N
investigators NNS N
believe VBP N
that IN N
collaboration NN N
, , N
caring NN N
, , N
and CC N
communication NN N
are VBP N
the DT N
essence NN N
of IN N
exemplary JJ N
health NN N
care NN N
. . N

-DOCSTART- -8305277- O O

MR NNP N
imaging NN N
of IN N
pituitary JJ p
region NN p
lesions NNS p
with IN N
gadodiamide JJ i
injection NN N
. . N

Twelve CD p
patients NNS p
with IN p
known VBN p
or CC p
suspected VBN p
pituitary JJ p
lesions NNS p
underwent JJ N
MR NNP i
imaging VBG i
with IN N
gadodiamide JJ i
injection NN i
at IN N
a DT N
dose NN N
of IN N
0.1 CD N
( ( N
n JJ N
= NNP N
5 CD N
) ) N
or CC N
0.3 CD N
( ( N
n JJ N
= NNP N
7 CD N
) ) N
mM/kg NN N
. . N

Six CD p
of IN p
the DT p
patients NNS p
were VBD N
also RB N
studied VBN N
with IN N
0.1 CD i
mM/kg NNS i
gadopentetate JJ i
dimeglumine NN i
. . i

Consistent JJ N
with IN N
previous JJ N
reports NNS N
gadodiamide NN i
injection NN N
was VBD N
found VBN N
to TO N
be VB N
a DT N
safe JJ o
and CC o
effective JJ o
contrast NN N
medium NN N
for IN N
MR NNP N
imaging NN N
of IN N
the DT N
pituitary JJ N
region NN N
. . N

No DT N
additional JJ N
diagnostic JJ N
information NN N
was VBD N
obtained VBN N
using VBG N
0.3 CD N
mM/kg JJ N
gadodiamide NN i
injection NN N
compared VBN N
to TO N
0.1 CD N
mM/kg NNS N
gadopentate JJ N
dimeglumine NN N
in IN N
the DT N
same JJ N
patients NNS N
. . N

The DT N
high JJ N
dose NN N
( ( N
0.3 CD N
mM/kg NN N
) ) N
gadodiamide NN i
injection NN N
in IN N
7 CD N
patients NNS N
did VBD N
not RB N
shorten VB o
the DT o
T2 NNP o
value NN o
sufficiently RB o
to TO N
overwhelm VB N
the DT N
T1 NNP o
shortening NN o
and CC o
leave VBP o
pathologic JJ o
lesions NNS o
hypointense VBP o
compared VBN N
to TO N
precontrast VB N
studies NNS N
. . N

With IN N
the DT N
comparable JJ N
relaxivities NNS N
of IN N
gadodiamide JJ i
injection NN N
and CC N
gadopentetate NN i
dimeglumine NN i
, , N
similarities NNS N
in IN N
results NNS N
have VBP N
to TO N
be VB N
expected VBN N
when WRB N
using VBG N
these DT N
media NNS N
for IN N
MR NNP N
image NN N
enhancement NN N
. . N

-DOCSTART- -10190267- O O

Rett NNP p
syndrome NN p
: : p
randomized VBN N
controlled VBD N
trial NN N
of IN N
L-carnitine NNP i
. . i

Rett NNP N
syndrome NN N
is VBZ N
a DT N
severe JJ N
neurodevelopmental JJ N
disorder NN N
of IN N
unknown JJ N
etiology NN N
, , N
occurring VBG N
almost RB N
exclusively RB N
in IN N
female JJ p
patients NNS p
. . p

The DT N
etiology NN N
and CC N
functional JJ N
significance NN N
of IN N
plasma JJ N
carnitine NN N
deficiency NN N
seen VBN N
in IN N
some DT N
patients NNS N
with IN N
Rett NNP N
syndrome NN N
is VBZ N
unknown JJ N
. . N

To TO N
investigate VB N
whether IN N
L-carnitine JJ i
might MD N
be VB N
of IN N
benefit NN N
in IN N
Rett NNP N
syndrome NN N
, , N
a DT N
randomized VBN N
, , N
placebo-controlled JJ i
, , N
double-blind JJ N
crossover NN N
trial NN N
of IN N
L-carnitine NNP i
has VBZ N
been VBN N
completed VBN N
in IN N
35 CD p
subjects NNS p
. . p

Eight-week JJ N
treatment NN N
phases NNS N
were VBD N
completed VBN N
for IN N
both DT N
a DT N
placebo NN i
and CC i
L-carnitine NNP i
. . i

Outcome NNP N
was VBD N
measured VBN N
by IN N
parents/caregivers NNS N
and CC N
at IN N
medical JJ N
follow-up NN N
using VBG N
three CD N
established VBN N
tools NNS N
: : N
the DT o
Rett NNP o
Syndrome NNP o
Motor NNP o
Behavioral NNP o
Assessment NNP o
, , o
the DT o
Hand NNP o
Apraxia NNP o
Scale NNP o
, , o
and CC o
the DT o
Patient NNP o
Well-Being NNP o
Index NNP o
. . o

Analysis NNP N
comparing VBG N
change NN N
between IN N
baseline NN N
and CC N
week NN N
8 CD N
of IN N
treatment NN N
for IN N
L-carnitine NNP i
and CC N
the DT N
placebo NN i
showed VBD N
that IN N
both DT N
parents/caregivers NNS N
and CC N
medical JJ N
follow-up NN N
detected JJ N
improvements NNS N
in IN N
the DT N
subjects NNS N
' POS N
well-being NN o
. . o

In IN N
addition NN N
, , N
medical JJ N
review NN N
showed VBD N
an DT N
improvement NN N
on IN N
the DT N
Hand NNP o
Apraxia NNP o
Scale NNP o
for IN N
a DT N
higher JJR N
proportion NN N
of IN N
girls NNS N
on IN N
L-carnitine NNP N
. . N

Identification NN N
of IN N
predictors NNS N
of IN N
clinical JJ N
improvement NN N
has VBZ N
been VBN N
limited VBN N
by IN N
the DT N
power NN N
of IN N
the DT N
study NN N
. . N

These DT N
findings NNS N
suggest VBP N
that IN N
L-carnitine NNP i
is VBZ N
of IN N
benefit NN N
in IN N
some DT N
patients NNS p
with IN p
Rett NNP p
syndrome NN p
. . p

While IN N
L-carnitine NNP i
did VBD N
not RB N
lead VB N
to TO N
major JJ N
functional JJ N
changes NNS N
in IN N
ability NN N
, , N
the DT N
type NN N
of IN N
changes NNS N
reported VBN N
could MD N
still RB N
have VB N
a DT N
substantial JJ N
impact NN N
on IN N
the DT N
girls NNS N
and CC N
their PRP$ N
families NNS N
. . N

Information NN N
is VBZ N
still RB N
needed VBN N
, , N
however RB N
, , N
to TO N
determine VB N
if IN N
only RB N
subgroups NNS N
of IN N
girls NNS N
with IN N
the DT N
disorder NN N
are VBP N
responsive JJ N
to TO N
L-carnitine NNP i
and CC N
the DT N
appropriate JJ N
duration NN N
of IN N
therapy NN N
. . N

-DOCSTART- -3098997- O O

Effects NNS N
of IN N
resistive JJ i
exercise NN i
on IN N
skeletal JJ N
muscle NN N
in IN N
marrow NN p
transplant NN p
recipients NNS p
receiving VBG p
total JJ p
parenteral JJ p
nutrition NN p
. . p

Skeletal JJ o
muscle NN o
protein NN o
loss NN o
occurs VBZ N
during IN N
marrow JJ N
transplantation NN N
despite IN N
total JJ N
parenteral JJ N
nutrition NN N
. . N

To TO N
determine VB N
if IN N
muscle NN o
atrophy NN o
could MD N
be VB N
minimized VBN N
with IN N
exercise NN i
therapy NN i
, , N
30 CD p
patients NNS p
undergoing JJ p
marrow JJ p
transplantation NN p
for IN p
acute NN p
leukemia NN p
completed VBD N
a DT N
prospective JJ N
randomized VBN N
trial NN N
to TO N
receive VB N
: : N
( ( N
1 CD N
) ) N
no DT i
therapy NN i
( ( i
controls NNS i
) ) i
, , i
( ( i
2 CD i
) ) i
physical JJ i
therapy NN i
thrice NN i
weekly RB i
( ( i
PT3 NNP i
) ) i
, , i
or CC i
( ( i
3 CD i
) ) i
physical JJ i
therapy NN i
five CD i
times NNS i
weekly JJ i
( ( N
PT5 NNP N
) ) N
. . N

Patients NNS N
were VBD N
studied VBN N
through IN N
35 CD N
days NNS N
posttransplant NN N
. . N

Muscle NNP o
protein NN o
status NN o
and CC o
turnover NN o
was VBD N
assessed VBN N
by IN N
weekly JJ o
nitrogen NN o
balance NN o
, , o
and CC o
creatinine NN o
and CC o
3-methylhistidine JJ o
excretion NN o
. . o

Results NNS N
favored VBD N
a DT N
muscle NN N
protein-sparing JJ N
effect NN N
of IN N
exercise NN i
, , N
as IN N
a DT N
significant JJ N
decrease NN N
in IN N
creatinine JJ o
excretion NN o
in IN N
controls NNS N
only RB N
suggested VBD N
muscle NN o
protein NN o
loss NN o
associated VBN N
with IN N
inactivity NN N
. . N

Changes NNS N
in IN N
arm NN o
muscle NN o
area NN o
correlated VBN N
with IN N
energy NN N
, , N
but CC N
not RB N
protein JJ N
intake NN N
. . N

Large JJ N
individual JJ N
variation NN N
, , N
inadequate JJ N
nutritional JJ N
support NN N
and CC N
differences NNS N
in IN N
admission NN N
arm NN N
muscle NN N
area NN N
may MD N
have VB N
clouded VBN N
these DT N
results NNS N
. . N

-DOCSTART- -9864127- O O

The DT N
tolerability NN N
of IN N
lactated JJ i
Ringer NNP i
's POS i
solution NN i
and CC N
BSS NNP i
plus CC i
for IN N
ocular JJ N
irrigation NN N
with IN N
and CC N
without IN N
the DT N
Morgan NNP N
therapeutic JJ N
lens NNS N
. . N

OBJECTIVE NNP N
To TO N
evaluate VB N
two CD N
solutions NNS N
, , N
lactated VBD i
Ringer NNP i
's POS i
( ( i
LR NNP i
) ) i
and CC i
a DT i
balanced JJ i
salt NN i
solution NN i
( ( N
BSS NNP N
Plus NNP N
, , N
Alcon NNP N
Laboratories NNPS N
, , N
Ft. NNP N
Worth NNP N
, , N
TX NNP N
) ) N
, , N
compared VBN N
with IN N
normal JJ N
saline JJ i
solution NN i
( ( i
NSS NNP i
) ) i
, , N
for IN N
ocular JJ N
irrigation NN N
in IN N
healthy JJ p
adult NN p
volunteers NNS p
with IN p
and CC p
without IN p
the DT p
Morgan NNP p
therapeutic JJ p
lens NNS p
( ( p
MTL NNP p
) ) p
. . p

METHODS NNP N
This DT N
was VBD N
a DT N
prospective JJ N
, , N
double-blind JJ N
, , N
randomized JJ N
study NN N
of IN N
healthy JJ p
volunteers NNS p
who WP p
were VBD p
at IN p
least JJS p
18 CD p
years NNS p
of IN p
age NN p
. . p

Exclusion NN N
criteria NNS N
included VBD N
the DT N
use NN N
of IN N
analgesics NNS N
within IN N
four CD N
hours NNS N
of IN N
the DT N
study NN N
. . N

A NNP N
complete JJ N
ophthalmologic JJ N
examination NN N
was VBD N
performed VBN N
at IN N
baseline NN N
and CC N
at IN N
the DT N
completion NN N
of IN N
the DT N
study NN N
. . N

Following VBG N
randomization NN N
and CC N
prior RB N
to TO N
any DT N
intervention NN N
, , N
baseline JJ N
discomfort NN o
scores NNS o
were VBD N
obtained VBN N
by IN N
means NNS N
of IN N
a DT N
verbally RB N
administered VBN N
, , N
horizontal JJ N
, , N
100-mm JJ N
, , N
unnumbered JJ N
analog NN N
discomfort NN N
scale NN N
. . N

Both DT p
eyes NNS i
of IN i
each DT i
volunteer NN i
were VBD i
irrigated VBN i
simultaneously RB i
for IN i
15 CD i
minutes NNS i
, , N
with IN N
additional JJ N
discomfort NN o
scores NNS o
being VBG N
recorded VBN N
every DT N
5 CD N
minutes NNS N
using VBG N
the DT N
same JJ N
100-mm JJ N
, , N
unnumbered JJ o
analog NN o
discomfort NN o
scale NN o
. . o

A DT N
global JJ N
evaluation NN N
to TO N
assess VB N
the DT N
method NN N
of IN N
irrigation NN N
and CC N
the DT N
solutions NNS N
used VBN N
for IN N
irrigation NN N
was VBD N
completed VBN N
by IN N
both DT N
the DT N
physician NN N
blinded VBD N
to TO N
the DT N
treatment NN p
groups NNS p
and CC p
the DT p
volunteers NNS p
. . p

The DT p
volunteers NNS p
were VBD N
continuously RB N
monitored VBN N
for IN N
any DT N
adverse JJ o
effects NNS o
resulting VBG N
from IN N
the DT N
irrigation NN N
solutions NNS N
or CC N
MTL NNP N
. . N

RESULTS NNP N
Sixty-three JJ p
volunteers NNS p
were VBD p
recruited VBN p
into IN p
the DT p
study NN p
, , p
with IN p
61 CD p
entered VBN p
in IN p
the DT p
final JJ p
analysis NN p
. . p

Age NNP N
and CC N
gender NN N
were VBD N
balanced VBN N
within IN N
each DT N
group NN N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
discomfort NN o
scores NNS o
between IN N
the DT N
two CD N
groups NNS N
; : N
however RB N
, , N
all DT N
discomfort NN o
scores NNS o
decreased VBN N
over IN N
time NN N
( ( N
p JJ N
= NNP N
0.008 CD N
) ) N
. . N

A DT N
lens-solution JJ N
interaction NN N
was VBD N
identified VBN N
, , N
with IN N
LR NNP N
being VBG N
the DT N
most RBS N
tolerated JJ o
when WRB N
administered VBN N
with IN N
the DT N
MTL NNP N
. . N

A NNP N
statistically RB N
higher JJR N
ocular JJ o
pH NN o
difference NN o
was VBD N
seen VBN N
between IN N
the DT N
pre- NN N
and CC N
postirrigation NN N
readings NNS N
for IN N
the DT N
control NN N
eye NN N
in IN N
volunteers NNS N
irrigated VBN N
with IN N
MTL NNP N
( ( N
p JJ N
= NNP N
0.046 CD N
) ) N
. . N

Analysis NN N
of IN N
the DT N
global JJ N
evaluations NNS N
for IN N
each DT N
group NN N
revealed VBD N
no DT N
difference NN N
in IN N
the DT N
distributions NNS N
of IN N
physician JJ o
and CC o
volunteer JJ o
scores NNS o
. . o

No DT N
adverse JJ o
event NN o
was VBD N
reported VBN N
in IN N
either DT N
group NN N
. . N

CONCLUSION NNP N
There EX N
does VBZ N
not RB N
appear VB N
to TO N
be VB N
any DT N
difference NN N
in IN N
discomfort NN o
scores NNS o
between IN N
the DT N
ocular JJ N
irrigation NN N
fluids NNS N
when WRB N
used VBN N
without IN N
the DT N
MTL NNP N
. . N

Overall NNP N
, , N
the DT N
use NN N
of IN N
the DT N
MTL NNP N
appears VBZ N
well RB N
tolerated VBN N
by IN N
healthy JJ N
, , N
adult JJ N
volunteers NNS N
. . N

However RB N
, , N
there EX N
does VBZ N
appear VB N
to TO N
be VB N
a DT N
significant JJ N
lens-solution JJ o
effect NN o
on IN N
volunteers NNS N
' POS N
discomfort NN N
scores NNS N
, , N
with IN N
LR NNP N
having VBG N
significantly RB N
lower JJR N
discomfort NN N
scores NNS N
when WRB N
used VBN N
for IN N
ocular JJ N
irrigation NN N
with IN N
the DT N
MTL NNP N
. . N

The DT N
authors NNS N
conclude VBP N
that IN N
the DT N
use NN N
of IN N
the DT N
MTL NNP N
for IN N
ocular JJ N
irrigation NN N
is VBZ N
well RB N
tolerated VBN N
and CC N
recommend VB N
using VBG N
LR NNP N
as IN N
the DT N
irrigation NN N
solution NN N
for IN N
maximal JJ N
patient NN N
comfort NN N
. . N

-DOCSTART- -19169898- O O

Netilmicin NNP i
in IN N
the DT N
neonate NN p
: : p
pharmacokinetic JJ N
analysis NN N
and CC N
influence NN N
of IN N
parenteral JJ i
nutrition NN i
. . i

OBJECTIVE CC N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
investigate VB N
the DT N
impact NN N
of IN N
parenteral JJ N
nutrition NN N
on IN N
netilmicin JJ i
pharmacokinetics NNS o
in IN N
critically RB p
ill JJ p
neonates NNS p
during IN p
the DT p
first JJ p
week NN p
of IN p
life NN p
. . p

METHOD NNP N
A NNP N
total NN N
of IN N
200 CD p
neonates NNS p
( ( p
gestational JJ p
ages NNS p
26.4-41 JJ p
weeks NNS p
) ) p
treated VBD p
with IN p
netilmicin JJ i
( ( i
4-5 JJ i
mg/kg NN i
in IN i
extended JJ i
dosing NN i
intervals NNS i
) ) i
for IN p
postnatal JJ p
sepsis NN p
in IN p
the DT p
first JJ p
week NN p
of IN p
life NN p
received VBD N
either CC N
fluid JJ i
therapy NN i
or CC N
parenteral JJ i
nutrition NN i
. . i

Netilmicin NNP N
peak NN N
and CC N
trough JJ N
serum NN N
concentrations NNS N
were VBD N
monitored VBN N
and CC N
netilmicin JJ N
pharmacokinetic JJ N
parameters NNS N
were VBD N
compared VBN N
with IN N
and CC N
without IN N
parenteral JJ N
nutrition NN N
. . N

RESULTS CC N
There EX N
were VBD N
no DT N
statistically RB N
significant JJ N
differences NNS N
between IN N
the DT N
pharmacokinetic JJ o
parameters NNS o
of IN o
netilmicin NN o
( ( o
volume NN o
of IN o
distribution NN o
, , o
elimination NN o
half-life NN o
, , o
clearance NN o
) ) o
in IN N
critically RB p
ill JJ p
neonates NNS p
> VBP p
32 CD p
weeks NNS p
during IN N
the DT N
first JJ N
week NN N
of IN N
life NN N
that WDT N
received VBD N
either DT N
fluid JJ i
therapy NN i
or CC N
parenteral JJ i
nutrition NN i
. . i

For IN N
neonates NNS p
< VBP p
32 CD p
weeks NNS p
this DT N
comparison NN N
was VBD N
not RB N
feasible JJ N
as IN N
the DT N
majority NN N
were VBD N
parenterally RB N
fed VBN N
. . N

CONCLUSION NNP N
Provision NNP N
of IN N
parenteral JJ i
nutrition NN i
( ( N
versus JJ N
fluid NN N
therapy NN N
) ) N
in IN N
critically RB p
ill JJ p
neonates NNS p
> VBP p
32 CD p
weeks NNS p
did VBD N
not RB N
significantly RB N
affect JJ N
netilmicin JJ o
pharmacokinetics NNS o
and CC N
therefore RB N
does VBZ N
not RB N
require VB N
modification NN N
of IN N
recommended JJ N
netilmicin JJ N
dosage NN N
regimens NNS N
. . N

